-DOCSTART- -X- O O

Need NN N
for IN N
insulin NN i
therapy NN i
in IN N
type NN p
II NNP p
diabetes VBZ p
mellitus NN p
. . p

A DT N
randomized JJ N
trial NN N
. . N

To TO p
identify VB p
patients NNS p
with IN p
type JJ p
II NNP p
diabetes VBZ p
mellitus NN p
for IN p
whom WP p
insulin NN i
therapy NN i
is VBZ p
most RBS p
beneficial JJ p
, , p
we PRP p
conducted VBD p
a DT p
randomized VBN p
controlled VBN p
trial NN p
in IN p
the DT p
general JJ p
medicine NN p
clinic NN p
of IN p
a DT p
university NN p
hospital NN p
. . p

Asymptomatic NNP p
, , p
obese JJ p
, , p
insulin-treated JJ p
patients NNS p
were VBD N
given VBN N
diet JJ i
and CC i
diabetes VBZ i
education NN i
and CC N
, , N
in IN N
half NN N
of IN N
these DT N
patients NNS N
, , N
insulin JJ i
therapy NN i
was VBD i
withdrawn VBN i
. . i

Over IN N
six CD N
months NNS N
, , N
patients NNS N
developing VBG N
hyperglycemic JJ o
symptoms NNS o
or CC o
acetonemia NN o
were VBD N
counted VBN N
as IN N
study NN N
failures NNS N
. . N

Failure NN o
criteria NNS o
developed VBD N
in IN N
13 CD N
of IN N
25 CD p
insulin-withdrawal JJ p
patients NNS p
, , N
at IN N
a DT N
median NN N
of IN N
four CD N
weeks NNS N
after IN N
withdrawal NN N
, , N
compared VBN N
with IN N
two CD N
of IN N
24 CD p
control NN p
subjects NNS p
. . p

Elevated VBN o
stimulated VBD o
glucose JJ o
levels NNS o
predicted VBD N
the DT N
need NN N
for IN N
insulin JJ N
therapy NN N
. . N

Hyperglycemia NNP o
worsened VBD N
in IN N
insulin-withdrawal JJ N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
study JJ N
failure NN N
criteria NNS N
, , N
but CC N
it PRP N
improved VBD N
in IN N
control NN N
patients NNS N
. . N

Study NNP N
patients NNS N
were VBD N
insulin JJ N
deficient NN N
as IN N
shown VBN N
by IN N
low JJ N
baseline NN o
C NNP o
peptide NN o
values NNS o
( ( o
0.43 CD o
+/- JJ N
0.05 CD N
nmol/L NN N
) ) N
. . N

The DT N
prompt JJ N
metabolic JJ N
decompensation NN N
precipitated VBN N
by IN N
insulin NN N
withdrawal NN N
suggests VBZ N
that IN N
insulin-deficient JJ N
patients NNS N
may MD N
benefit VB N
from IN N
insulin NN N
therapy NN N
and CC N
may MD N
need VB N
it PRP N
to TO N
prevent VB N
symptomatic JJ o
hyperglycemia NN o
. . o

-DOCSTART- -X- O O

Short-term JJ N
effects NNS N
of IN N
prednisolone NN i
and CC i
dexamethasone NN i
on IN N
circulating VBG o
concentrations NNS o
of IN o
leptin NN o
and CC o
sex NN o
hormone-binding JJ o
globulin NN o
in IN N
children NNS p
being VBG p
treated VBN p
for IN p
acute JJ p
lymphoblastic JJ p
leukaemia NN p
. . p

OBJECTIVE NNP N
Disturbances NNPS N
in IN N
body NN N
weight JJ N
regulation NN N
are VBP N
often RB N
encountered VBN N
during IN N
glucocorticoid JJ i
treatment NN i
and CC N
are VBP N
associated VBN N
with IN N
increased JJ N
insulin NN N
resistance NN N
and CC N
truncal JJ N
fat NN N
accumulation NN N
. . N

Children NNP p
were VBD p
investigated VBN p
who WP p
were VBD p
receiving VBG p
glucocorticoid JJ i
treatment NN i
for IN p
acute JJ p
lymphoblastic JJ p
leukaemia NN p
( ( p
ALL DT p
) ) p
. . p

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
prednisolone VB i
or CC i
dexamethasone VB i
as IN N
part NN N
of IN N
induction NN N
of IN N
remission NN N
. . N

This DT N
randomization NN N
process NN N
provided VBD N
a DT N
suitable JJ N
opportunity NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
these DT N
two CD N
administered VBD N
steroid NN N
on IN N
surrogate JJ N
markers NNS N
of IN N
adipocyte NN N
activity NN N
( ( N
leptin NN N
) ) N
and CC N
hyperinsulinaemia/insulin JJ N
resistance NN N
( ( N
SHBG NNP N
) ) N
. . N

DESIGN NNP N
AND CC N
PATIENTS NNP N
Prospective NNP N
study NN N
over IN N
16 CD N
weeks NNS N
of IN N
children NNS p
randomized VBN N
to TO N
receive VB N
prednisolone NN i
( ( i
40 CD i
mg/m2 NN i
) ) i
or CC i
dexamethasone NN i
( ( i
6.5 CD i
mg/m2 NN i
) ) i
as IN i
part NN i
of IN i
the DT i
MRC-ALL97/99 NNP i
induction NN i
chemotherapy NN i
for IN i
ALL NNP i
. . i

Nineteen NNP p
children NNS p
( ( p
8 CD p
male NN p
, , p
11 CD p
female NN p
) ) p
with IN p
a DT p
median JJ p
age NN p
5.9 CD p
years NNS p
( ( p
range VB p
2.6-13 CD p
years NNS p
) ) p
were VBD p
recruited VBN p
into IN p
the DT p
study NN p
. . p

Main NNP N
outcome JJ N
measures NNS N
were VBD N
body JJ o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
serum JJ o
leptin NN o
and CC o
sex NN o
hormone NN o
binding VBG o
globulin NN o
( ( o
SHBG NNP o
) ) o
. . o

RESULTS NNP N
Glucocorticoid NNP N
administration NN N
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
increases NNS N
in IN N
BMI NNP o
, , o
leptin NN o
( ( o
corrected VBN o
for IN o
BMI NNP o
) ) o
and CC o
the DT o
leptin NN o
: : o
SHBG NNP o
ratio NN o
and CC o
lowering NN o
of IN o
SHBG NNP o
. . o

Dose NNP N
for IN N
dose NN N
, , N
dexamethasone NN i
was VBD N
significantly RB N
more RBR N
potent JJ N
than IN N
prednisolone NN i
in IN N
altering VBG N
these DT N
parameters NNS N
. . N

CONCLUSIONS NNP N
Short-term JJ N
glucocorticoid NN N
treatment NN N
has VBZ N
significant JJ N
effects NNS N
on IN N
BMI NNP N
, , N
leptin NN N
and CC N
SHBG NNP N
. . N

The DT N
leptin NN N
: : N
SHBG NNP N
ratio NN N
increase NN N
indicates VBZ N
that IN N
this DT N
may MD N
be VB N
a DT N
novel JJ N
and CC N
sensitive JJ N
biochemical JJ N
marker NN N
of IN N
metabolic JJ N
change NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
glucocorticoid JJ i
treatment NN i
regimens NNS i
should MD N
be VB N
kept VBN N
as RB N
short JJ N
as IN N
possible JJ N
to TO N
avoid VB N
possible JJ N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
increased JJ N
adiposity NN N
and CC N
insulin NN N
resistance NN N
. . N

-DOCSTART- -X- O O

Safety NN o
of IN N
ferumoxytol NN i
in IN N
patients NNS p
with IN p
anemia NN p
and CC p
CKD NNP p
. . p

BACKGROUND NNP N
Iron NNP N
deficiency NN N
anemia NN N
is VBZ N
a DT N
common JJ N
complication NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
. . p

Currently NNP N
available JJ N
intravenous JJ N
( ( N
IV NNP N
) ) N
iron NN i
replacement NN i
therapies NNS i
have VBP N
either DT N
inconvenient JJ N
regimens NNS N
of IN N
administration NN N
or CC N
adverse JJ N
event NN N
profiles NNS N
that WDT N
limit VBP N
their PRP$ N
utility NN N
in IN N
the DT N
outpatient JJ p
setting NN N
. . N

Ferumoxytol NNP i
is VBZ N
a DT N
novel NN N
, , N
semisynthetic JJ N
, , N
carbohydrate-coated JJ N
, , N
superparamagnetic JJ N
iron NN N
oxide NN N
nanoparticle NN N
that WDT N
is VBZ N
administered VBN N
IV NNP N
as IN N
an DT N
injection NN N
. . N

The DT N
main JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
safety NN o
of IN N
ferumoxytol NN i
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
CKD NNP p
stages VBZ p
1 CD p
to TO p
5 CD p
and CC p
5D CD p
. . p

STUDY NNP N
DESIGN NNP N
Phase NNP N
3 CD N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
, , N
multicenter NN N
study NN N
of IN N
a DT N
single JJ N
510-mg JJ N
dose NN N
of IN N
ferumoxytol JJ i
versus NN i
saline NN i
as IN i
placebo NN i
. . i

SETTING NNP N
& CC N
PARTICIPANTS NNP N
750 CD p
patients NNS p
with IN p
CKD NNP p
stages VBZ p
1 CD p
to TO p
5 CD p
and CC p
5D CD p
. . p

INTERVENTION NNP N
An DT N
IV NNP i
injection NN i
of IN N
either CC N
17 CD N
mL NN N
of IN N
ferumoxytol NN i
or CC i
saline NN i
placebo NN i
over IN N
17 CD N
seconds NNS N
on IN N
day NN N
0 CD N
and CC N
the DT N
alternate NN N
agent NN N
on IN N
day NN N
7 CD N
. . N

OUTCOMES NNP N
& CC N
MEASUREMENTS NNP N
Descriptive NNP N
comparison NN N
of IN N
adverse JJ o
events NNS o
, , o
laboratory NN o
tests NNS o
, , o
and CC o
vital JJ o
signs NNS o
. . o

RESULTS NNP N
Of IN N
750 CD p
randomly NNS p
assigned VBD p
patients NNS p
with IN p
CKD NNP p
, , p
60 CD p
% NN p
were VBD p
not RB p
on IN p
dialysis NN i
therapy NN i
. . i

713 CD p
patients NNS p
received VBD p
ferumoxytol JJ i
, , p
and CC p
711 CD p
received VBD p
placebo NN i
. . i

There EX N
were VBD N
420 CD p
adverse JJ o
events NNS o
reported VBD p
; : p
242 CD p
in IN p
152 CD p
patients NNS p
( ( p
21.3 CD p
% NN p
) ) p
with IN p
ferumoxytol NN p
and CC p
178 CD p
in IN p
119 CD p
patients NNS p
( ( p
16.7 CD p
% NN p
) ) p
with IN p
placebo NN i
. . i

The DT N
incidence NN o
of IN o
related JJ o
adverse JJ o
events NNS o
was VBD N
5.2 CD N
% NN N
with IN N
ferumoxytol NN i
and CC N
4.5 CD N
% NN N
with IN N
placebo NN i
. . i

The DT N
most RBS N
common JJ N
related JJ N
adverse JJ o
events NNS o
after IN N
each DT N
treatment NN N
included VBD N
symptoms NNS o
related VBN N
to TO N
the DT N
injection/infusion NN o
site NN o
, , o
dizziness NN o
, , o
pruritus NN o
, , o
headache NN o
, , o
fatigue NN o
, , o
and CC o
nausea NN o
. . o

Serious JJ o
adverse JJ o
events NNS o
occurred VBD N
in IN N
21 CD N
patients NNS N
( ( N
2.9 CD N
% NN N
) ) N
after IN N
ferumoxytol NN i
and CC N
13 CD N
patients NNS N
( ( N
1.8 CD N
% NN N
) ) N
after IN N
placebo NN i
. . i

Serious JJ o
related JJ o
adverse JJ o
events NNS o
were VBD N
observed VBN N
in IN N
1 CD N
patient NN N
( ( N
0.1 CD N
% NN N
) ) N
after IN N
each DT N
treatment NN N
. . N

There EX N
was VBD N
no DT N
meaningful JJ N
decrease NN N
in IN N
blood NN o
pressure NN o
after IN N
administration NN N
of IN N
ferumoxytol NN i
or CC i
placebo NN i
. . i

LIMITATIONS NNP N
Follow-up NNP N
was VBD N
7 CD N
days NNS N
after IN N
each DT N
study NN N
treatment NN N
. . N

CONCLUSIONS NNP N
Ferumoxytol NNP i
is VBZ N
well RB N
tolerated VBN o
and CC N
has VBZ N
a DT N
safety NN o
profile NN o
similar JJ N
to TO N
placebo VB i
in IN N
anemic JJ p
patients NNS p
with IN p
CKD NNP p
stages VBZ p
1 CD p
to TO p
5 CD p
and CC p
5D CD p
. . p

-DOCSTART- -X- O O

[ JJ N
Efficacy NNP N
of IN N
naftopidil NN i
in IN N
patients NNS p
with IN p
overactive JJ p
bladder NN p
associated VBN p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
: : p
prospective JJ N
randomized NN N
controlled VBD N
study NN N
to TO N
compare VB N
differences NNS N
in IN N
efficacy NN N
between IN N
morning NN N
and CC N
evening VBG N
medication NN N
] NNP N
. . N

A NNP N
total NN p
of IN p
100 CD p
patients NNS p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
and CC p
overactive JJ p
bladder NN p
( ( p
OAB NNP p
) ) p
symptoms NNS p
( ( p
BPH/OAB NNP p
) ) p
, , p
enrolled VBN p
between IN p
June NNP p
2006 CD p
to TO p
March NNP p
2008 CD p
, , N
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD N
groups NNS N
of IN N
morning NN N
medication NN N
( ( N
M NNP N
) ) N
and CC N
evening VBG N
medication NN N
( ( N
E NNP N
) ) N
groups NNS N
, , N
then RB i
50 CD i
mg NN i
of IN i
naftopidil NN i
was VBD i
given VBN i
once RB i
a DT i
day NN i
after IN i
breakfast NN i
or CC i
supper NN i
for IN i
8 CD i
weeks NNS i
. . i

Data NNS N
were VBD N
available JJ N
for IN N
efficacy NN N
analysis NN N
on IN N
80 CD N
patients NNS N
( ( N
M NNP N
group NN N
; : N
43 CD N
, , N
E NNP N
group NN N
; : N
37 CD N
) ) N
. . N

Naftopidil NNP i
significantly RB N
improved VBD N
the DT N
overall JJ o
international JJ o
prostatic JJ o
symptom NN o
score NN o
; : N
from IN N
19.2?7.9 CD N
to TO N
11.7?5.8 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
19.4?6.4 CD N
to TO N
12.3?6.8 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
QOL NNP N
score NN N
from IN N
4.9?0.8 CD N
to TO N
3.2?1.4 CD N
in IN N
the DT N
M NNP N
group NN N
and CC N
from IN N
5.0?0.8 CD N
to TO N
3.6?1.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD o
) ) o
, , o
and CC o
OAB NNP o
symptom VBD o
score NN o
from IN o
7.8?2.6 CD N
to TO N
5.0?2.5 CD N
in IN N
the DT N
M NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
from IN N
8.6?2.9 CD N
to TO N
5.8? CD N
3.3 CD N
in IN N
the DT N
E NNP N
group NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
adverse JJ o
effects NNS o
between IN o
the DT N
M NNP N
group NN N
( ( N
6.1 CD N
% NN N
) ) N
and CC N
E NNP N
group NN N
( ( N
2.2 CD N
% NN N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
naftopidil JJ N
improves NNS o
storage NN o
symptoms NNS o
as RB o
well RB o
as IN o
voiding VBG o
symptoms NNS o
regardless RB o
of IN N
timing NN N
of IN N
administration NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
topical JJ N
azithromycin NN i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
posterior JJ p
blepharitis NN p
. . p

INTRODUCTION NNP N
Azithromycin NNP i
, , N
a DT N
broad-spectrum JJ N
antibiotic JJ N
with IN N
potent JJ N
anti-inflammatory JJ N
activities NNS N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
effectively RB N
treat VB N
blepharitis NN o
, , p
an DT p
inflammatory JJ p
disease NN p
of IN p
the DT p
eyelid JJ p
with IN p
abnormal JJ p
eyelid JJ p
flora NN p
as IN p
an DT p
etiologic JJ p
determinant NN p
. . p

The DT N
present JJ N
study NN N
compared VBN N
the DT N
efficacy NN o
of IN N
topical JJ N
azithromycin NN i
ophthalmic JJ N
solution NN N
1 CD N
% NN N
( ( N
AzaSite NNP N
; : N
Inspire NNP N
Pharmaceuticals NNP N
, , N
Inc NNP N
, , N
NC NNP N
, , N
USA NNP N
) ) N
combined VBD N
with IN N
warm JJ N
compresses NNS N
( ( N
azithromycin JJ N
group NN N
) ) N
to TO N
warm JJ N
compresses NNS N
alone RB N
( ( N
compress JJ N
group NN N
) ) N
in IN N
patients NNS N
with IN N
posterior JJ N
blepharitis NN N
. . N

METHODS NNP N
Twenty-one CD p
patients NNS p
diagnosed VBN p
with IN p
posterior JJ p
blepharitis NN p
were VBD N
randomized VBN N
in IN N
an DT N
open-label JJ N
study NN N
to TO N
receive VB N
either DT N
azithromycin NN i
plus CC i
warm JJ i
compresses NNS i
( ( N
10 CD N
patients NNS N
) ) N
, , N
or CC N
compresses VBZ N
alone RB N
( ( N
11 CD N
patients NNS N
) ) N
. . N

All DT N
patients NNS N
were VBD N
instructed VBN N
to TO N
apply VB N
compresses NNS N
to TO N
each DT N
eye NN N
for IN N
5-10 JJ N
minutes NNS N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Each DT N
eye NN N
in IN N
the DT N
azithromycin NN i
group NN N
also RB N
received VBD N
azithromycin JJ N
solution NN N
( ( N
1 CD N
drop NN N
) ) N
twice RB N
daily RB N
for IN N
the DT N
first JJ N
2 CD N
days NNS N
followed VBN N
by IN N
once RB N
daily JJ N
for IN N
the DT N
next JJ N
12 CD N
days NNS N
. . N

Patients NNS N
were VBD N
evaluated VBN N
at IN N
study NN N
initiation NN N
( ( N
visit IN N
1 CD N
) ) N
and CC N
at IN N
end NN N
of IN N
treatment NN N
( ( N
visit IN N
2 CD N
) ) N
for IN N
the DT N
severity NN N
of IN N
five CD N
clinical JJ N
signs NNS N
: : N
eyelid JJ o
debris NN o
, , o
eyelid JJ o
redness NN o
, , o
eyelid JJ o
swelling NN o
, , o
meibomian JJ o
gland NN o
( ( o
MG NNP o
) ) o
plugging NN o
, , o
and CC o
the DT o
quality NN o
of IN o
MG NNP o
secretion NN o
. . o

At IN N
visit NN N
2 CD N
, , N
patients NNS N
also RB N
rated VBD N
their PRP$ N
degree NN N
of IN N
overall JJ o
symptomatic JJ o
relief NN o
. . o

RESULTS NNP N
Twenty NNP p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

At IN N
visit NN N
2 CD N
, , N
patients NNS N
in IN N
the DT N
azithromycin NN i
group NN N
demonstrated VBD N
significant JJ o
improvements NNS o
in IN N
MG NNP o
plugging NN o
, , o
MG NNP o
secretions NNS o
, , o
and CC o
eyelid JJ o
redness NN o
as IN N
compared VBN N
with IN N
the DT N
compress NN N
group NN N
. . N

In IN N
the DT N
azithromycin NN i
group NN N
, , N
MG NNP o
plugging VBG o
resolved VBN N
completely RB N
in IN N
three CD N
patients NNS N
and CC N
MG NNP o
secretion NN o
returned VBD o
to TO o
normal JJ o
in IN N
two CD N
patients NNS N
; : N
no DT N
such JJ N
results NNS N
were VBD N
seen VBN N
in IN N
the DT N
compress NN N
group NN N
. . N

Furthermore RB N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
patients NNS N
in IN N
the DT N
azithromycin NN N
group NN N
rated VBD N
overall JJ o
symptomatic JJ o
relief NN o
as IN N
excellent NN N
or CC N
good JJ N
. . N

Visual JJ o
acuity NN o
measurements NNS o
and CC o
biomicroscopic JJ o
evaluation NN o
revealed VBD N
no DT o
ocular JJ o
safety NN o
issues NNS o
. . o

CONCLUSION NNP N
Azithromycin NNP i
ophthalmic JJ N
solution NN N
in IN N
combination NN N
with IN N
warm JJ N
compresses NNS N
provided VBD N
a DT N
significantly RB o
greater JJR o
clinical JJ o
benefit NN o
than IN N
warm JJ N
compresses NNS N
alone RB N
in IN N
treating VBG N
the DT N
signs NNS o
and CC o
symptoms NNS o
of IN o
posterior JJ o
blepharitis NN o
. . o

-DOCSTART- -X- O O

A DT N
30-month JJ N
longitudinal JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
some DT N
oral JJ i
hygiene NN i
measures NNS i
on IN N
Streptococcus NNP o
mutans NNS o
and CC o
approximal JJ o
dental JJ o
caries NNS o
. . o

The DT N
effects NNS N
of IN N
some DT N
oral JJ i
hygiene NN i
measures NNS i
on IN N
Streptococcus NNP o
mutants NNS o
and CC p
approximal JJ o
dental JJ o
caries NNS o
were VBD N
evaluated VBN N
. . N

One CD p
hundred CD p
and CC p
eighty-seven JJ p
13-year-old JJ p
individuals NNS p
with IN p
high JJ p
levels NNS p
of IN p
salivary JJ p
S. NNP o
mutans NNS o
( ( p
greater JJR p
than IN p
10 CD p
( ( p
6 CD p
) ) p
/mL NN p
) ) p
were VBD p
selected VBN p
. . p

They PRP N
were VBD N
randomly RB N
distributed VBN N
into IN N
three CD N
groups NNS N
. . N

Group NNP N
I PRP N
initially RB N
received VBD N
professional JJ i
mechanical JJ i
tooth-cleaning NN i
, , i
tongue-scraping NN i
, , i
chlorhexidine NN i
treatment NN i
, , i
and CC i
oral JJ i
hygiene NN i
instructions NNS i
concentrated VBD N
on IN N
the DT N
approximal JJ N
surfaces NNS N
most RBS N
colonized VBN N
by IN N
S. NNP N
mutans NNS N
. . N

The DT N
treatment NN N
was VBD N
given VBN N
four CD N
times NNS N
with IN N
intervals NNS N
of IN N
two CD N
days NNS N
, , N
followed VBN N
by IN N
one CD N
single JJ N
treatment NN N
every DT N
six CD N
months NNS N
throughout IN N
the DT N
experimental JJ N
period NN N
. . N

The DT N
initial JJ N
treatment NN N
period NN N
for IN N
group NN N
II NNP N
, , N
also RB N
consisting VBG N
of IN N
four CD N
visits NNS N
, , N
included VBD N
the DT N
same JJ N
oral JJ i
hygiene NN i
instructions NNS i
as IN N
for IN N
group NN N
I PRP N
. . N

The DT N
instructions NNS N
were VBD N
repeated VBN N
every DT N
six CD N
months NNS N
. . N

Group NNP N
III NNP N
was VBD N
maintained VBN N
in IN N
the DT N
preventive JJ i
program NN i
provided VBN i
by IN i
the DT i
local JJ i
Dental NNP i
Health NNP i
Office NNP i
, , N
based VBN N
on IN N
mechanical JJ i
plaque NN i
control NN i
and CC N
topical JJ i
use NN i
of IN i
fluorides NNS i
and CC i
chlorhexidine NN i
at IN N
individualized JJ N
intervals NNS N
. . N

Group NNP N
I PRP N
showed VBD N
a DT N
significant JJ N
immediate JJ N
reduction NN N
of IN N
S. NNP o
mutans NNS o
in IN o
saliva NN o
as RB N
well RB N
as IN N
an DT N
approximal JJ N
tooth NN N
surfaces NNS N
. . N

After IN N
six CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
among IN N
the DT N
three CD N
groups NNS N
regarding VBG N
these DT N
variables NNS N
. . N

Compared VBN N
with IN N
baseline NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
of IN N
S. NNP o
mutans NNS o
in IN N
all DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
caries NNS o
progression NN o
among IN N
the DT N
three CD N
groups NNS N
. . N

However RB N
, , N
the DT N
selected VBN N
high-risk JJ N
individuals NNS N
in IN N
group NN N
I PRP N
developed VBD N
0.25 CD N
new JJ N
manifest NN N
caries NNS N
lesions NNS N
approximally/year VBP N
, , N
compared VBN N
with IN N
0.27 CD N
for IN N
all DT N
children NNS N
of IN N
the DT N
same JJ N
age NN N
group NN N
in IN N
the DT N
area NN N
. . N

Seventeen JJ N
individuals NNS N
had VBD N
approximal JJ N
surfaces NNS N
with IN N
consistently RB N
high JJ N
or CC N
consistently RB N
low JJ N
S. NNP o
mutans NN o
levels NNS o
. . o

Forty-six CD N
percent NN N
of IN N
the DT N
surfaces NNS N
with IN N
high JJ N
values NNS N
developed VBD N
new JJ o
or CC o
progressive JJ o
caries NNS o
, , N
compared VBN N
with IN N
2 CD N
% NN N
of IN N
the DT N
surfaces NNS N
with IN N
low JJ N
values NNS N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
efficacy NN N
of IN N
donepezil NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
: : p
neuropsychological JJ N
measures NNS N
. . N

OBJECTIVE NNP N
There EX N
has VBZ N
been VBN N
recent JJ N
interest NN N
in IN N
the DT N
use NN N
of IN N
cognitive JJ i
enhancing VBG i
drugs NNS i
, , N
such JJ N
as IN N
cholinesterase NN i
inhibitors NNS i
, , N
as IN N
a DT N
possible JJ N
treatment NN N
for IN N
executive NN o
functioning NN o
( ( N
EF NNP N
) ) N
deficits NNS N
in IN N
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
tolerability NN o
, , o
safety NN o
, , o
and CC o
efficacy NN o
of IN N
donepezil NN N
on IN N
EF NNP N
in IN N
a DT N
sample NN p
of IN p
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

METHOD NNP N
Thirty-four JJ p
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
( ( p
age NN p
range NN p
8-17 CD p
years NNS p
; : p
IQ NNP p
> NNP p
75 CD p
) ) p
were VBD p
enrolled VBN p
in IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
donepezil NN i
( ( i
doses NNS i
of IN i
5 CD i
and CC i
10 CD i
mg NN i
) ) i
, , i
followed VBN i
by IN i
a DT i
10-week JJ i
open JJ i
label NN i
trial NN i
for IN i
placebo NN i
nonresponders NNS i
. . i

RESULTS VB N
The DT N
effect NN N
of IN N
donepezil NN i
treatment NN i
on IN N
EF NNP N
was VBD N
examined VBN N
. . N

Despite IN N
improvement NN N
on IN N
a DT N
number NN N
of IN N
EF NNP o
measures NNS o
, , o
no DT N
statistically RB N
significant JJ N
between-group JJ N
differences NNS N
were VBD N
found VBN N
( ( N
with IN N
gains NNS N
observed VBN N
for IN N
both DT N
the DT N
placebo NN N
and CC N
donepezil NN N
groups NNS N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
suggest VBP N
that IN N
short-term JJ N
treatment NN N
with IN N
donepezil NN N
may MD N
have VB N
limited VBN N
impact NN N
on IN N
cognitive JJ N
functioning NN N
in IN N
ASD NNP N
. . N

Future NNP N
controlled VBD N
trials NNS N
may MD N
need VB N
to TO N
consider VB N
a DT N
longer RBR N
treatment NN N
period NN N
to TO N
detect VB N
significant JJ N
gains NNS N
on IN N
EF NNP N
measures NNS N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
mental JJ N
health NN N
problems NNS N
and CC N
negative JJ N
caregiving NN N
experiences NNS N
in IN N
carers NNS p
of IN p
adolescents NNS p
with IN p
bulimia NN p
nervosa NN p
. . p

OBJECTIVE CC N
This DT N
exploratory NN N
study NN N
focuses VBZ N
on IN N
the DT N
mental JJ i
health NN i
( ( i
MH NNP i
) ) i
and CC i
caregiving VBG i
experience NN i
of IN i
carers NNS i
of IN i
adolescents NNS i
with IN p
Bulimia NNP p
Nervosa NNP p
( ( p
BN NNP p
) ) p
/Eating VBG p
Disorder NNP p
not RB p
otherwise RB p
specified VBN p
( ( p
EDNOS NNP p
) ) p
, , N
aiming VBG N
to TO N
determine VB N
: : N
levels NNS N
of IN N
MH NNP N
problems NNS N
in IN N
carers NNS N
and CC N
if IN N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
predicts NNS N
carer VBP N
MH NNP N
status NN N
and CC N
which WDT N
factors NNS N
predict VBP N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
. . N

METHOD NNP N
Hundred NNP p
and CC p
twelve VB p
carers NNS p
and CC p
68 CD p
adolescents NNS p
with IN p
BN/EDNOS NNP p
completed VBD p
self-report JJ i
measures NNS i
( ( i
General NNP i
Health NNP i
Questionnaire NNP i
, , i
Experience NNP i
of IN i
Caregiving NNP i
Inventory NNP i
, , i
Level NNP i
of IN i
Expressed JJ i
Emotion NNP i
, , i
Self-report NNP i
Family NNP i
Inventory NNP i
, , i
Inventory NNP i
of IN i
Interpersonal NNP i
Problems NNP i
) ) i
. . i

RESULTS NNP N
Over IN N
half NN N
of IN N
the DT N
carers NNS N
reported VBD N
some DT N
MH NNP o
problems NNS o
and CC N
a DT N
minority NN N
( ( N
5.4 CD N
% NN N
) ) N
were VBD N
experiencing VBG N
considerable JJ N
difficulties NNS N
. . N

A DT o
negative JJ o
experience NN o
of IN o
caregiving VBG o
predicted VBN N
carer NN N
MH NNP N
status NN N
. . N

Higher JJR o
weekly JJ o
contact NN o
hours NNS o
and CC o
patient JJ o
ratings NNS o
of IN o
expressed VBN o
emotion NN o
( ( o
EE NNP o
) ) o
predicted VBD N
a DT N
negative JJ N
experience NN N
of IN N
caregiving VBG N
. . N

CONCLUSIONS NNP N
Interventions NNPS i
focusing VBG i
on IN i
reducing VBG i
EE NNP o
and CC i
contact NN o
hours NNS o
could MD N
prove VB N
beneficial JJ N
for IN N
both DT N
patient NN p
and CC N
caregiver NN p
outcomes NNS N
. . N

-DOCSTART- -X- O O

Right RB N
ventricular JJ N
function NN N
during IN N
high-frequency JJ i
oscillatory JJ i
ventilation NN i
in IN N
adults NNS p
with IN p
acute JJ p
respiratory NN p
distress NN p
syndrome NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
mean JJ N
airway JJ N
pressure NN N
under IN N
high-frequency NN i
oscillatory NN i
ventilation NN i
on IN N
right JJ N
ventricular JJ N
function NN N
. . N

DESIGN NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Intensive NNP N
care NN N
unit NN N
of IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

PATIENTS NNP N
Sixteen NNP p
consecutive JJ p
patients NNS p
within IN p
the DT p
first JJ p
48 CD p
hrs NN p
of IN p
mainly RB p
pulmonary JJ p
acute NN p
respiratory NN p
distress JJ p
syndrome NN p
. . p

INTERVENTIONS NNP N
After IN N
a DT N
6-hr-period JJ N
of IN N
protective JJ i
conventional JJ i
mechanical JJ i
ventilation NN i
, , N
patients NNS N
were VBD N
submitted VBN N
to TO N
three CD i
1-hr JJ i
periods NNS i
of IN i
high-frequency NN i
oscillatory NN i
ventilation NN i
( ( N
+5 JJ N
, , N
+10 NNP N
, , N
+15 NNP N
) ) N
in IN N
a DT N
randomized JJ N
order NN N
, , N
with IN N
a DT N
mean JJ N
airway NN N
pressure NN N
level NN N
determined VBN N
by IN N
adding VBG N
5 CD i
, , i
10 CD i
, , i
or CC i
15 CD i
cm NNS i
H2O NNP i
to TO N
the DT N
mean JJ N
airway NN N
pressure NN N
recorded VBN N
during IN N
conventional JJ N
mechanical JJ N
ventilation NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Mean NNP o
airway JJ o
pressure NN o
was VBD N
18?3 CD N
cm JJ N
H2O NNP N
during IN i
conventional JJ i
mechanical JJ i
ventilation NN i
and CC N
was VBD N
increased VBN N
until IN N
33?3 CD N
cm NNS N
H2O NNP N
at IN N
high-frequency NN i
oscillatory NN i
ventilation+15 NN o
. . o

Right NNP o
ventricular JJ o
function NN o
was VBD o
assessed VBN N
using VBG o
transesophageal JJ o
echocardiography NN o
. . o

During IN i
conventional JJ i
mechanical JJ i
ventilation NN i
, , i
nine CD N
patients NNS N
presented VBD N
a DT N
right JJ o
ventricular NN o
dysfunction NN o
( ( o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
ratio NN N
> NNP N
0.6 CD N
) ) N
of IN N
whom WP N
four CD N
patients NNS N
had VBD N
a DT N
right JJ o
ventricular NN o
failure NN o
( ( o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
ratio NN i
> NNP i
0.9 CD i
) ) i
. . i

High-frequency NNP i
oscillatory JJ i
ventilation+10 NN i
and CC i
+15 VB N
further RB o
worsened VBN o
right JJ o
ventricular NN o
function NN o
, , o
resulting VBG N
in IN N
about IN N
a DT N
40 CD N
% NN N
increase NN N
in IN N
right JJ o
ventricular JJ o
end-diastolic JJ o
area/left NN o
ventricular JJ o
end-diastolic JJ o
area NN o
ratio NN o
and CC o
a DT N
30 CD N
% NN N
increase NN N
in IN N
end-diastolic JJ o
eccentricity NN o
index NN o
when WRB o
compared VBN N
with IN i
conventional JJ i
mechanical JJ i
ventilation NN i
or CC i
high-frequency NN i
oscillatory NN i
ventilation+5 NN i
periods NNS i
. . N

At IN N
high-frequency JJ N
oscillatory NN N
ventilation+15 NN N
, , N
15 CD N
patients NNS N
had VBD o
right JJ o
ventricular JJ o
dysfunction NN o
and CC o
nine CD N
had VBD o
right JJ o
ventricular JJ o
failure NN o
. . o

High-frequency NNP N
oscillatory JJ N
ventilation NN N
did VBD N
not RB o
improve VB o
oxygenation NN o
whatever IN o
the DT N
mean JJ N
airway NN N
pressure NN N
level NN N
. . N

A DT N
significant JJ N
redistribution NN N
of IN N
tidal JJ N
variation NN N
to TO N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lung NN N
was VBD N
observed VBN N
on IN N
electrical JJ N
impedance NN N
tomography NN N
measurements NNS N
when WRB o
increasing VBG o
mean VB o
airway JJ o
pressure NN o
. . o

However RB N
, , N
this DT N
redistribution NN N
was VBD N
not RB N
observed VBN N
in IN N
patients NNS N
who WP N
presented VBD N
a DT N
worsening NN o
of IN o
right JJ o
ventricular JJ o
function NN o
( ( o
right JJ N
ventricular NN N
end-diastolic JJ N
area/left NN N
ventricular JJ N
end-diastolic JJ N
area NN N
increase NN N
> VBD N
40 CD N
% NN N
) ) N
at IN N
high-frequency NN i
oscillatory NN i
ventilation+15 NN i
. . i

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
mainly RB p
pulmonary JJ p
acute NN p
respiratory NN p
distress NN p
syndrome NN p
, , p
using VBG N
high JJ N
mean JJ N
airway NN N
pressure NN N
under IN i
high-frequency NN i
oscillatory JJ i
ventilation NN i
can MD o
worsen VB o
right JJ o
ventricular NN o
function NN o
when WRB o
compared VBN N
with IN i
protective JJ i
conventional JJ i
mechanical JJ i
ventilation NN i
, , i
notably RB N
in IN N
patients NNS N
in IN N
whom WP N
high-frequency NN N
oscillatory NN N
ventilation NN N
produced VBD N
less JJR N
alveolar JJ N
recruitment NN N
of IN N
the DT N
posterior JJ N
parts NNS N
of IN N
the DT N
lungs NNS N
. . N

This DT N
study NN N
highlights VBZ N
the DT N
interest NN N
of IN N
monitoring VBG N
right JJ N
ventricular JJ N
function NN N
during IN i
high-frequency JJ i
oscillatory JJ i
ventilation NN i
. . i

-DOCSTART- -X- O O

The DT N
instruction NN N
to TO N
refrain VB i
from IN i
blinking VBG i
affects NNS N
auditory JJ o
P3 NNP o
and CC o
N1 NNP o
amplitudes NNS o
. . o

Often NNP N
subjects VBZ N
have VBP N
been VBN N
instructed VBN N
to TO N
refrain VB i
from IN i
blinking VBG i
lest JJS N
their PRP$ N
evoked JJ N
EEG NNP N
potentials NNS N
should MD N
be VB N
distorted VBN N
. . N

We PRP N
studied VBD N
whether IN N
these DT N
very RB N
instructions NNS N
have VBP N
any DT N
impact NN N
on IN N
P3 NNP o
amplitude NN o
. . o

Two CD N
tones NNS N
were VBD N
presented VBN N
in IN N
random JJ N
order NN N
, , N
and CC N
subjects NNS N
had VBD N
to TO N
count VB N
the DT N
high-pitched JJ N
tones NNS N
. . N

Half PDT p
the DT p
subjects NNS p
were VBD p
instructed VBN i
not RB i
to TO i
blink VB i
, , N
whereas IN N
this DT N
instruction NN N
was VBD N
omitted VBN N
for IN N
the DT N
other JJ N
subjects NNS N
. . N

Target NNP N
tones NNS N
evoked VBD N
larger JJR N
P3s NNP o
than IN N
non-targets NNS N
in IN N
the DT N
latter JJ N
group NN N
but CC N
not RB N
in IN N
the DT N
former JJ N
, , N
in IN N
particular JJ N
not RB N
in IN N
those DT N
subjects NNS N
that WDT N
actually RB N
blinked VBD N
rarely RB N
. . N

The DT N
groups NNS N
also RB N
differed VBN N
in IN N
their PRP$ N
N1 NNP o
amplitudes NNS o
. . o

These DT N
findings NNS N
might MD N
be VB N
relevant JJ N
to TO N
P3 NNP N
studies NNS N
working VBG N
with IN N
patients NNS N
and CC N
controls NNS N
: : N
the DT N
harder NN N
some DT N
frequently RB N
blinking JJ N
subjects NNS N
try VBP N
to TO N
refrain VB N
from IN N
blinking NN N
, , N
the DT N
smaller JJR N
might MD N
become VB N
their PRP$ N
P3 NNP o
amplitudes NNS o
. . o

Omitting VBG N
the DT N
instruction NN N
and CC N
using VBG N
off-line JJ N
blink NN N
subtraction NN N
procedures NNS N
seems VBZ N
a DT N
viable JJ N
alternative NN N
. . N

This DT N
study NN N
was VBD N
actually RB N
motivated VBN N
by IN N
discrepant JJ N
findings NNS N
on IN N
the DT N
effects NNS o
of IN o
the DT o
preceding VBG o
tone NN o
sequence NN o
on IN o
P3 NNP o
. . o

These DT N
discrepancies NNS N
could MD N
be VB N
largely RB N
resolved VBN N
by IN N
the DT N
instructional JJ N
variable NN N
, , N
in IN N
conjunction NN N
with IN N
different JJ N
tone NN o
intensities NNS o
. . o

It PRP N
is VBZ N
suggested VBN N
that IN N
subjects NNS i
who WP i
are VBP i
discouraged VBN i
from IN i
blinking VBG i
try NN N
to TO N
protect VB N
themselves PRP N
against IN N
the DT N
arousing JJ N
effects NNS N
of IN N
stimuli NN N
. . N

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
a DT N
psychological JJ i
intervention NN i
on IN N
quality NN o
of IN o
life NN o
in IN N
non-metastatic JJ p
breast NN p
cancer NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
psychological JJ i
intervention NN i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
quality NN o
of IN o
life NN o
and CC o
behaviour NN o
of IN N
women NNS p
diagnosed VBN p
with IN p
breast NN p
cancer NN p
. . p

36 CD p
consecutive JJ p
patients NNS p
with IN p
non-metastatic JJ p
breast NN p
cancer NN p
assigned VBD p
to TO p
surgery VB p
and CC p
systemic VB p
chemotherapy NN p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
psychological JJ i
intervention NN i
( ( i
weekly JJ i
cognitive VBP i
individual JJ i
psychotherapy NN i
and CC i
bimonthly JJ i
family NN i
counselling VBG i
) ) i
or CC N
standard JJ i
follow-up NN i
. . i

Personality NNP o
( ( o
16-PF JJ o
and CC o
IIQ NNP o
) ) o
, , o
quality NN o
of IN o
life NN o
( ( o
FLIC NNP o
) ) o
, , o
and CC o
depression NN o
( ( o
BDI NNP o
) ) o
scores NNS o
were VBD N
the DT N
endpoints NNS N
for IN N
this DT N
study NN N
, , N
and CC N
the DT N
questionnaires NNS N
were VBD N
completed VBN N
by IN N
the DT N
patients NNS N
at IN N
diagnosis NN N
, , N
and CC N
up RB N
to TO N
9 CD N
months NNS N
after IN N
diagnosis NN N
. . N

Cognitive JJ N
psychotherapy NN N
and CC N
family NN N
counselling NN N
improved VBD N
both DT N
depression NN o
and CC o
quality NN o
of IN o
life NN o
indexes NNS o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Better NNP N
emotional JJ o
coping NN o
behaviours NNS o
were VBD N
also RB N
revealed VBN N
by IN N
some DT N
changes NNS N
in IN N
personality NN N
traits NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

-DOCSTART- -X- O O

[ JJ N
European JJ N
topic NN N
: : N
liver NN i
surgery NN i
II NNP i
-- : i
regional JJ i
chemotherapy NN i
] NN i
. . N

The DT N
most RBS N
important JJ N
methods NNS N
of IN N
regional JJ i
chemotherapy NN i
are VBP N
exemplified VBN N
by IN N
657 CD p
cases NNS p
of IN p
primary JJ p
and CC p
secondary JJ p
liver NN p
only RB p
malignancies VBZ p
. . p

I PRP N
. . N

Adjuvant JJ i
portal JJ i
therapy NN i
of IN i
the DT i
liver NN i
with IN i
resection NN i
of IN i
the DT i
colorectal JJ i
primary JJ i
malignancy NN i
seems VBZ N
to TO N
be VB N
advantageous JJ N
for IN N
advanced JJ N
tumors NNS N
. . N

II NNP N
. . N

It PRP N
is VBZ N
still RB N
unresolved JJ N
whether IN N
survival NN o
is VBZ N
prolonged VBN N
by IN N
adjuvant JJ N
treatment NN N
of IN N
the DT N
liver NN N
following VBG N
curative JJ i
resection NN i
of IN i
colorectal JJ i
liver NN i
metastases NNS i
. . i

III NNP N
. . N

The DT N
median JJ o
survival NN o
time NN o
( ( o
FUDR NNP o
, , o
pump NN o
) ) o
is VBZ N
17 CD N
months NNS N
for IN N
palliative JJ i
local JJ i
chemotherapy NN i
of IN N
unresectable JJ p
colorectal JJ p
liver NN p
metastases NNS p
. . p

IV NNP N
. . N

Primary NNP N
non-resectable JJ N
liver NN N
malignancies NNS N
show VBP N
the DT N
best JJS N
results NNS N
after IN N
chemoembolisation NN N
( ( N
Frankfurt NNP N
method NN N
) ) N
. . N

-DOCSTART- -X- O O

Long-term JJ N
growth NN N
hormone NN N
treatment NN N
in IN N
growth NN p
hormone NN p
deficient NN p
adults NNS p
. . p

Growth NNP i
hormone NN i
treatment NN i
in IN N
GH-deficient NNP p
adults NNS p
has VBZ N
proved VBN N
beneficial JJ N
in IN N
recent JJ N
short-term JJ N
trials NNS N
, , N
but CC N
long-term JJ N
results NNS N
have VBP N
not RB N
yet RB N
been VBN N
reported VBN N
. . N

Thirteen JJ p
GH-deficient JJ p
adults NNS p
( ( p
4 CD p
females NNS p
, , p
9 CD p
males NNS p
; : p
mean FW p
( ( p
SEM NNP p
) ) p
age NN p
26.4 CD p
( ( p
1.7 CD p
) ) p
years NNS p
) ) p
, , N
who WP N
had VBD N
completed VBN N
4 CD N
months NNS N
of IN N
GH NNP i
therapy NN i
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ i
cross-over NN N
study NN N
were VBD N
followed VBN N
, , N
for IN N
further JJ N
16.1 CD N
( ( N
0.8 CD N
) ) N
months NNS N
of IN N
uninterrupted JJ N
GH NNP i
therapy NN i
in IN N
an DT N
open JJ N
design NN N
. . N

A DT N
significant JJ N
mean JJ N
increase NN N
of IN N
1.3 CD N
cm NN N
in IN N
linear JJ o
height NN o
was VBD N
recorded VBN N
, , N
whereas IN N
body NN o
mass NN o
index NN o
remained VBD N
unchanged JJ N
. . N

Mean JJ o
muscle NN o
volume NN o
of IN o
the DT o
thigh NN o
, , o
estimated VBN o
by IN o
computerised JJ o
tomography NN o
, , N
increased VBD N
significantly RB N
compared VBN N
with IN N
that DT N
of IN N
the DT N
initial JJ N
placebo NN i
period NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
a DT N
slight JJ N
decrease NN N
was VBD N
recorded VBN N
in IN N
adipose JJ o
tissue NN o
volume NN o
of IN o
the DT o
thigh NN o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
and CC N
subscapular JJ o
skinfold NN o
thickness NN o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
. . N

Still RB N
, , N
the DT N
muscle NN o
to TO o
fat VB o
ratio NN o
of IN o
the DT o
thigh NN o
was VBD N
significantly RB N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ p
subjects NNS p
( ( N
72.6/27.4 CD N
vs RB N
77.9/22.1 CD N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
mean JJ o
isometric JJ o
strength NN o
of IN o
the DT o
quadriceps JJ o
muscles NNS o
increased VBD o
significantly RB N
during IN N
long-term JJ N
GH NNP N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
but CC N
remained VBD N
lower JJR N
compared VBN N
with IN N
that DT N
of IN N
normal JJ N
subjects NNS N
( ( N
1.66 CD N
( ( N
0.10 CD N
) ) N
vs NN N
2.13 CD N
( ( N
0.11 CD N
) ) N
Nm/kg NNP N
body NN N
weight NN N
) ) N
. . N

Exercise NN o
capacity NN o
performed VBN o
on IN o
a DT o
bicycle NN o
ergometer NN o
increased VBD N
significantly RB N
after IN N
long-term JJ N
therapy NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
, , N
but CC N
still RB N
did VBD N
not RB N
reach VB N
the DT N
values NNS N
seen VBN N
in IN N
normal JJ N
subjects NNS N
( ( N
22.5 CD N
( ( N
3.4 CD N
) ) N
vs NN N
37.4 CD N
( ( N
4.2 CD N
) ) N
watt.min.kg-1 NN N
. . N

No DT N
adverse JJ o
reactions NNS o
were VBD N
recorded VBN N
during IN N
long-term JJ N
therapy NN N
and CC N
hemoglobin NN o
A1c NNP o
remained VBD N
unchanged JJ N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
long-term JJ N
GH NNP N
replacement NN N
therapy NN N
in IN N
GH-deficient NNP N
adults NNS N
has VBZ N
beneficial JJ N
effects NNS N
on IN N
several JJ N
physiological JJ N
features NNS N
which WDT N
are VBP N
subnormal JJ N
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Isoniazid NNP i
prophylaxis NN N
for IN N
tuberculosis NN p
in IN p
HIV NNP p
infection NN p
: : p
a DT N
meta-analysis NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
isoniazid NN i
for IN N
the DT N
prevention NN N
of IN N
tuberculosis NN N
in IN N
tuberculin JJ p
skin JJ p
test-positive JJ p
and CC p
negative JJ p
individuals NNS p
with IN p
HIV NNP p
infection NN p
. . p

DESIGN NNP N
Meta-analysis NN N
of IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

SETTING NNP N
Seven NNP p
trials NNS p
from IN p
Mexico NNP p
, , p
Haiti NNP p
, , p
the DT p
United NNP p
States NNPS p
, , p
Zambia NNP p
, , p
Uganda NNP p
and CC p
Kenya NNP p
. . p

PATIENTS NNP N
Individuals NNP p
free JJ p
from IN p
tuberculosis NN p
, , p
2367 CD p
persons NNS p
in IN p
the DT p
intervention NN p
and CC p
2162 CD p
in IN p
the DT p
control NN p
groups NNS p
. . p

INTERVENTION NNP N
Comparison NNP o
of IN o
isoniazid NN o
with IN o
placebo NN o
or CC o
no DT o
prophylaxis NN o
. . o

METHODS NNP N
A NNP N
systematic JJ N
search NN N
of IN N
the DT N
literature NN N
was VBD N
carried VBN N
out IN N
from IN N
1985 CD N
to TO N
October NNP N
1997 CD N
for IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
isoniazid JJ i
prophylaxis NN p
in IN p
HIV-infected JJ p
persons NNS p
. . p

Two CD N
reviewers NNS N
evaluated VBD N
the DT N
relevance NN N
of IN N
each DT N
candidate NN N
study NN N
and CC N
the DT N
validity NN N
of IN N
eligible JJ N
trials NNS N
. . N

Studies NNS N
were VBD N
pooled VBN N
using VBG N
a DT N
random JJ N
effect NN N
model NN N
, , N
conducting VBG N
secondary JJ N
analyses NNS N
for IN N
tuberculin JJ N
skin JJ N
test-positive JJ N
and CC N
negative JJ N
persons NNS N
. . N

RESULTS JJ N
Mean JJ N
follow-up NN N
in IN N
trials NNS N
varied VBD N
between IN N
0.4 CD N
and CC N
3.2 CD N
years NNS N
. . N

Pooling VBG N
all DT N
seven CD N
trials NNS N
, , N
a DT N
risk NN o
ratio NN o
was VBD N
found VBN N
for IN N
persons NNS N
treated VBN N
with IN N
isoniazid NN i
for IN N
developing VBG N
tuberculosis NN N
of IN N
0.58 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
0.43-0.80 JJ N
] NN N
and CC N
0.94 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.83-1.07 NNP N
) ) N
for IN N
death NN o
. . o

In IN N
groups NNS N
of IN N
tuberculin JJ N
skin JJ N
test-positive JJ N
and CC N
negative JJ N
persons NNS N
, , N
the DT N
risk NN o
ratio NN o
of IN o
tuberculosis NN o
was VBD N
0.40 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.24-0.65 NNP N
) ) N
and CC N
0.84 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.54-1.30 NNP N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN o
in IN o
the DT o
effectiveness NN o
of IN N
isoniazid JJ i
versus NN N
placebo NN i
between IN N
these DT N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.03 CD N
, , N
for IN N
the DT N
difference NN N
of IN N
summary JJ N
estimates NNS N
) ) N
. . N

Consistency NN N
of IN N
results NNS N
was VBD N
found VBN N
across IN N
trials NNS N
( ( N
P NNP N
> NNP N
0.10 CD N
, , N
heterogeneity NN N
value NN N
) ) N
for IN N
all DT N
comparisons NNS N
. . N

CONCLUSIONS NNP N
Prophylaxis NNP N
with IN N
isoniazid JJ i
reduces NNS N
the DT N
risk NN N
of IN N
tuberculosis NN N
in IN N
persons NNS p
with IN p
HIV NNP p
infection NN p
. . p

The DT N
effect NN N
is VBZ N
restricted VBN p
to TO p
tuberculin VB p
skin JJ p
test-positive JJ p
persons NNS p
. . p

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
1- JJ N
and CC N
3-minute JJ N
lockout NN N
periods NNS N
during IN N
patient-controlled JJ p
sedation NN p
with IN p
midazolam NN i
. . i

PURPOSE VB N
The DT N
maximum JJ N
effect NN N
of IN N
midazolam NN i
injected VBN N
intravenously RB N
occurs VBZ N
in IN N
about IN N
3 CD N
minutes NNS N
. . N

Patient-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
of IN N
midazolam NN i
at IN N
3-minute JJ N
intervals NNS N
provides VBZ N
comparable JJ N
conditions NNS N
to TO N
that DT N
of IN N
doctor-controlled JJ N
sedation NN N
carried VBD N
out RP N
with IN N
1-mg JJ N
increments NNS N
at IN N
1-minute JJ N
intervals NNS N
, , N
except IN N
for IN N
the DT N
longer JJR N
duration NN N
taken VBN N
for IN N
the DT N
patients NNS N
to TO N
achieve VB N
satisfactory JJ N
sedation NN N
prior RB N
to TO N
surgery NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
how WRB N
safe JJ N
it PRP N
would MD N
be VB N
to TO N
shorten VB N
the DT N
interval NN N
of IN N
increments NNS N
of IN N
midazolam NN i
to TO N
1 CD N
minute NN N
in IN N
patient-controlled JJ i
sedation NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
randomized VBN N
crossover NN N
study NN N
, , N
26 CD p
patients NNS p
undergoing JJ p
bilateral JJ p
lower JJR p
third JJ p
molar JJ p
surgery NN p
at IN p
two CD p
visits NNS p
had VBD N
patient-controlled JJ N
sedation NN N
with IN N
1 CD N
mg NNS N
midazolam JJ i
increments NNS N
at IN N
1-minute JJ i
or CC N
3-minute JJ i
intervals NNS i
at IN N
one CD N
visit NN N
and CC N
the DT N
alternative NN N
at IN N
the DT N
other JJ N
visit NN N
. . N

RESULTS VB N
The DT N
time NN N
taken VBN N
for IN N
patients NNS N
to TO N
achieve VB N
a DT N
degree NN o
of IN o
sedation NN o
that IN N
they PRP N
thought VBD N
was VBD N
sufficient JJ N
to TO N
tolerate VB N
the DT N
surgery NN N
was VBD N
significantly RB N
longer RBR N
when WRB N
the DT N
increment NN N
interval NN N
was VBD N
3 CD N
minutes NNS N
( ( N
t JJ N
= NNP N
-4.8 NNP N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Both DT N
techniques NNS N
provided VBD N
good JJ N
operating NN o
conditions NNS o
, , N
stable JJ N
vital JJ o
signs NNS o
, , N
mild NN N
to TO N
moderate VB N
sedation NN N
, , N
without IN N
loss NN o
of IN o
verbal JJ o
contact NN o
. . o

CONCLUSION VB N
A DT N
significant JJ N
majority NN N
preferred VBD N
the DT N
sedation NN N
technique NN N
with IN N
1-minute JJ N
increment NN N
intervals NNS N
( ( N
chi VB N
2 CD N
= JJ N
4.6 CD N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Green JJ i
banana-supplemented JJ i
diet NN i
in IN N
the DT N
home NN N
management NN N
of IN N
acute NN o
and CC o
prolonged JJ o
diarrhoea NN o
in IN o
children NNS o
: : o
a DT p
community-based JJ p
trial NN p
in IN p
rural JJ p
Bangladesh NNP p
. . p

SUMMARY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
green JJ i
banana NN i
in IN N
the DT N
home NN N
management NN N
of IN N
acute NN o
( ( p
< JJ p
7 CD p
days NNS p
) ) p
or CC p
prolonged VBN o
( ( p
? . p
7 CD p
days NNS o
) ) o
diarrhoea VBP o
at IN o
the DT N
community NN N
level NN N
. . N

METHODS NNP N
A NNP N
cluster NN N
randomized VBD N
field NN N
trial NN N
was VBD N
conducted VBN N
among IN p
2968 CD p
Bangladeshi NNP p
rural JJ p
children NNS p
6-36 JJ p
months NNS p
old JJ p
. . p

Wards NNP N
( ( N
villages NNS N
) ) N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
a DT N
standard JJ i
care NN i
group NN i
or CC i
a DT i
standard JJ i
care NN i
plus CC i
green JJ i
banana NN i
group NN i
where WRB i
mothers NNS N
were VBD N
instructed VBN N
to TO N
add VB i
cooked JJ i
green JJ i
banana NN i
to TO i
the DT N
diets NNS N
of IN N
diarrhoeal JJ p
children NNS p
. . p

Through IN N
a DT N
village-based JJ N
surveillance NN N
system NN o
, , o
diarrhoeal JJ o
morbidity NN o
data NNS o
( ( o
severity NN o
, , o
duration NN o
, , o
compliance NN o
) ) o
were VBD o
collected VBN N
for IN N
14 CD N
days NNS N
. . N

Treatment JJ N
effects NNS N
were VBD N
determined VBN N
by IN N
analysing VBG o
cumulative JJ o
probability NN o
of IN o
cure NN o
by IN o
testing VBG o
Cox NNP o
proportional JJ o
hazards NNS o
models NNS o
and CC o
relative JJ o
risk NN o
( ( o
RR NNP N
) ) N
. . N

RESULTS VB N
The DT o
cumulative JJ o
probability NN o
of IN o
cure NN o
was VBD o
significantly RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
different JJ N
in IN N
children NNS N
receiving VBG N
GB NNP N
for IN N
both DT o
acute JJ o
[ NNP o
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
= VBZ N
0.63 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.56-0.67 NN N
) ) N
] NN N
and CC o
prolonged VBD o
diarrhoea NNS o
[ NNP o
HR NNP N
= VBZ N
0.38 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
0.26-0.59 NN N
) ) N
] NN N
. . N

The DT o
recovery NN o
rates NNS o
of IN o
children NNS o
with IN o
acute JJ o
diarrhoea NN o
receiving VBG o
GB NNP N
( ( N
vs. FW N
control NN N
) ) N
were VBD N
significantly RB N
more JJR N
by IN N
day NN N
3 CD N
: : N
79.9 CD N
% NN N
vs NN N
. . N

53.3 CD N
% NN N
[ NN N
( ( N
RR NNP N
) ) N
= VBD N
0.47 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.41-0.55 JJ N
] NN N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
day NN N
7 CD N
: : N
96.6 CD N
% NN N
vs NN N
. . N

89.1 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.32 CD N
; : N
0.22-0.46 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Children NNP N
with IN N
prolonged JJ N
diarrhoea NN N
receiving VBG i
green JJ i
banana NN i
had VBD i
significantly RB N
higher JJR o
recovery NN o
rates NNS o
by IN o
day NN N
10 CD N
: : N
79.8 CD N
% NN N
vs NN N
. . N

51.9 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.42 CD N
; : N
0.23-0.73 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
day NN N
14 CD N
: : N
93.6 CD N
% NN N
vs NN N
. . N

67.2 CD N
% NN N
( ( N
RR NNP N
= NNP N
0.22 CD N
; : N
0.08-0.54 JJ N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
green JJ i
banana-supplemented JJ i
diet NN o
hastened VBD o
recovery NN o
of IN o
acute NN p
and CC p
prolonged VBD p
childhood NN p
diarrhoea NN p
managed VBD p
at IN N
home NN N
in IN N
rural JJ N
Bangladesh NNP N
. . N

-DOCSTART- -X- O O

Brief JJ N
report NN N
: : N
effect NN N
of IN N
a DT N
focused JJ i
imitation NN i
intervention NN i
on IN N
social JJ o
functioning NN o
in IN N
children NNS p
with IN p
autism NN p
. . p

Imitation NNP N
is VBZ N
an DT N
early JJ N
skill NN N
thought VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
social JJ N
development NN N
, , N
leading VBG N
some DT N
to TO N
suggest VB N
that IN N
teaching VBG N
imitation NN N
to TO N
children NNS p
with IN p
autism NN p
should MD N
lead VB N
to TO N
improvements NNS N
in IN N
social JJ o
functioning NN o
. . o

This DT N
study NN N
used VBD N
a DT N
randomized JJ N
controlled VBN N
trial NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
focused JJ i
imitation NN i
intervention NN i
on IN N
initiation NN N
of IN N
joint JJ o
attention NN o
and CC o
social-emotional JJ o
functioning NN o
in IN N
27 CD p
young JJ p
children NNS p
with IN p
autism NN p
. . p

Results NNS N
indicated VBD N
the DT N
treatment NN N
group NN N
made VBD N
significantly RB N
more RBR N
gains NNS N
in IN N
joint JJ o
attention NN o
initiations NNS o
at IN N
post-treatment JJ N
and CC N
follow-up JJ N
and CC N
social-emotional JJ o
functioning NN o
at IN N
follow-up NN N
than IN N
the DT N
control NN N
group NN N
. . N

Although IN N
gains NNS o
in IN o
social JJ o
functioning NN o
were VBD N
associated VBN N
with IN N
treatment NN N
, , N
a DT N
mediation NN N
analysis NN N
did VBD N
not RB N
support VB N
imitation NN i
as IN N
the DT N
mechanism NN N
of IN N
action NN N
. . N

These DT N
findings NNS N
suggest VBP N
the DT N
intervention NN N
improves VBZ N
social JJ o
functioning NN o
in IN o
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
synthetic JJ i
appeasing VBG i
pheromone NN i
on IN N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS p
. . p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
effects NNS N
of IN N
a DT N
synthetic JJ i
, , i
dog-appeasing JJ i
pheromone NN i
( ( i
sDAP NN i
) ) i
on IN N
the DT N
behavioral JJ N
, , N
neuroendocrine JJ N
, , N
immune JJ N
, , N
and CC N
acute-phase JJ N
perioperative JJ N
stress NN N
responses NNS N
in IN N
dogs NNS p
undergoing VBG p
elective JJ p
orchiectomy NN p
or CC p
ovariohysterectomy NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

ANIMALS $ N
46 CD p
dogs NNS p
housed VBN p
in IN p
animal NN p
shelters NNS p
and CC p
undergoing VBG p
elective JJ p
orchiectomy NN p
or CC p
ovariohysterectomy NN p
. . p

PROCEDURES NNP N
Intensive NNP N
care NN N
unit NN N
cages NNS N
were VBD N
sprayed VBN N
with IN N
sDAP JJ i
solution NN i
or CC i
sham NN i
treated VBN i
with IN i
the DT i
carrier NN i
used VBN i
in IN i
the DT i
solution NN i
20 CD i
minutes NNS i
prior RB i
to TO i
use VB i
. . i

Dogs NNS N
( ( N
n JJ N
= NN N
24 CD N
and CC N
22 CD N
in IN N
the DT N
sDAP NN i
and CC N
sham JJ i
treatment NN i
exposure NN N
groups NNS N
, , N
respectively RB N
) ) N
were VBD N
placed VBN N
in IN N
treated JJ N
cages NNS N
for IN N
30 CD N
minutes NNS N
before IN N
and CC N
after IN N
surgery NN N
. . N

Indicators NNS N
of IN N
stress NN N
( ( N
ie NN N
, , N
alterations NNS N
in IN N
behavioral JJ o
, , o
neuroendocrine JJ o
, , o
immune JJ o
, , o
and CC o
acute-phase JJ o
responses NNS o
) ) o
were VBD N
evaluated VBN N
perioperatively RB N
. . N

Behavioral JJ o
response NN o
variables NNS o
, , o
salivary JJ o
cortisol NN o
concentration NN o
, , o
WBC NNP o
count NN o
, , o
and CC o
serum JJ o
concentrations NNS o
of IN o
glucose NN o
, , o
prolactin NN o
, , o
haptoglobin NN o
, , o
and CC o
C-reactive JJ o
protein NN o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Behavioral NNP o
response NN o
variables NNS o
and CC o
serum NN o
prolactin NN o
concentration NN o
were VBD N
influenced VBN N
by IN N
sDAP NN N
exposure NN N
. . N

Dogs NNS N
exposed VBD N
to TO N
sDAP VB N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
alertness NN o
and CC o
visual JJ o
exploration NN o
behaviors NNS o
after IN N
surgery NN N
than IN N
were VBD N
dogs NNS N
exposed VBN N
to TO N
sham VB N
treatment NN N
. . N

Decreases VBZ N
in IN N
serum NN o
prolactin NN o
concentrations NNS o
in IN N
response NN N
to TO N
perioperative JJ N
stress NN N
were VBD N
significantly RB N
smaller JJR N
in IN N
dogs NNS N
exposed VBN N
to TO N
sDAP VB N
, , N
compared VBN N
with IN N
findings NNS N
in IN N
dogs NNS N
exposed VBN N
to TO N
the DT N
sham NN N
treatment NN N
. . N

Variables NNS N
examined VBD N
to TO N
evaluate VB N
the DT N
hypothalamic-pituitary-adrenal JJ N
axis NN N
, , N
immune JJ N
system NN N
, , N
and CC N
acute-phase JJ N
responses NNS N
were VBD N
unaffected VBN N
by IN N
treatment NN N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
sDAP NN N
appeared VBD N
to TO N
affect VB N
behavioral JJ o
and CC o
neuroendocrine JJ o
perioperative JJ o
stress NN o
responses NNS o
by IN N
modification NN N
of IN N
lactotropic JJ N
axis NN N
activity NN N
. . N

Use NN N
of IN N
sDAP NN i
in IN N
a DT N
clinical JJ N
setting NN N
may MD N
improve VB N
the DT N
recovery NN o
and CC N
welfare NN N
of IN N
dogs NNS p
undergoing VBG p
surgery NN p
. . p

-DOCSTART- -X- O O

Virtual JJ i
reality NN i
intervention NN i
for IN N
older JJR p
women NNS p
with IN p
breast NN p
cancer NN p
. . p

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
virtual JJ i
reality NN i
distraction NN i
intervention NN i
on IN N
chemotherapy-related JJ p
symptom NN o
distress NN o
levels NNS p
in IN p
16 CD p
women NNS p
aged VBD p
50 CD p
and CC p
older JJR p
. . p

A DT N
cross-over JJ N
design NN N
was VBD N
used VBN N
to TO N
answer VB N
the DT N
following JJ N
research NN N
questions NNS N
: : N
( ( N
1 CD N
) ) N
Is VBZ N
virtual JJ N
reality NN N
an DT N
effective JJ N
distraction NN N
intervention NN N
for IN N
reducing VBG N
chemotherapy-related JJ N
symptom NN N
distress NN N
levels NNS N
in IN N
older JJR p
women NNS p
with IN p
breast NN p
cancer NN p
? . N
( ( N
2 CD N
) ) N
Does NNP N
virtual JJ i
reality NN i
have VBP N
a DT N
lasting JJ N
effect NN N
? . N
Chemotherapy NN N
treatments NNS N
are VBP N
intensive JJ N
and CC N
difficult JJ N
to TO N
endure VB N
. . N

One CD N
way NN N
to TO N
cope VB N
with IN N
chemotherapy-related JJ N
symptom NN N
distress NN N
is VBZ N
through IN N
the DT N
use NN N
of IN N
distraction NN N
. . N

For IN N
this DT N
study NN N
, , N
a DT i
head-mounted JJ i
display NN i
( ( i
Sony NNP i
PC NNP i
Glasstron NNP i
PLM NNP i
- : i
S700 NN i
) ) i
was VBD i
used VBN i
to TO i
display VB i
encompassing VBG i
images NNS i
and CC i
block NN i
competing VBG i
stimuli NNS i
during IN i
chemotherapy JJ i
infusions NNS i
. . i

The DT N
Symptom NNP o
Distress NNP o
Scale NNP o
( ( o
SDS NNP o
) ) o
, , o
Revised VBN o
Piper NNP o
Fatigue NNP o
Scale NNP o
( ( o
PFS NNP o
) ) o
, , o
and CC o
the DT o
State NNP o
Anxiety NNP o
Inventory NNP o
( ( o
SAI NNP o
) ) o
were VBD i
used VBN i
to TO i
measure VB i
symptom JJ i
distress NN i
. . i

For IN N
two CD N
matched JJ N
chemotherapy NN N
treatments NNS N
, , N
one CD N
pre-test NN N
and CC N
two CD N
post-test JJ N
measures NNS N
were VBD N
employed VBN N
. . N

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
VR NNP i
distraction NN i
intervention NN i
during IN i
one CD i
chemotherapy NN i
treatment NN i
and CC i
received VBD i
no DT i
distraction NN i
intervention NN i
( ( i
control VB i
condition NN i
) ) i
during IN i
an DT i
alternate JJ i
chemotherapy NN i
treatment NN i
. . i

Analysis NN N
using VBG N
paired VBN N
t-tests NNS N
demonstrated VBD N
a DT N
significant JJ N
decrease NN o
in IN N
the DT N
SAI NNP o
( ( N
p JJ N
= NNP N
0.10 CD N
) ) N
scores NNS N
immediately RB N
following VBG N
chemotherapy NN N
treatments NNS N
when WRB N
participants NNS N
used VBD N
VR NNP N
. . N

No NNP N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
SDS NNP o
or CC o
PFS NNP o
values NNS o
. . o

There EX N
was VBD N
a DT N
consistent JJ N
trend NN N
toward IN N
improved VBN o
symptoms NNS o
on IN N
all DT N
measures NNS N
48 CD N
h NN N
following VBG N
completion NN N
of IN N
chemotherapy NN N
. . N

Evaluation NN N
of IN N
the DT N
intervention NN N
indicated VBD N
that IN N
women NNS p
thought VBD N
the DT N
head NN N
mounted VBD N
device NN N
was VBD N
easy JJ N
to TO N
use VB N
, , N
they PRP N
experienced VBD N
no DT N
cybersickness NN o
, , N
and CC N
100 CD N
% NN N
would MD N
use VB N
VR NNP N
again RB N
. . N

-DOCSTART- -X- O O

Primary JJ N
prophylaxis NN N
with IN N
pyrimethamine NN i
for IN N
toxoplasmic JJ N
encephalitis NN N
in IN N
patients NNS p
with IN p
advanced JJ p
human JJ p
immunodeficiency NN p
virus NN p
disease NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

Terry NNP N
Beirn NNP N
Community NNP N
Programs NNP N
for IN N
Clinical NNP N
Research NNP N
on IN N
AIDS NNP N
. . N

Pyrimethamine NNP i
, , N
25 CD N
mg NN N
thrice NN N
weekly RB N
, , N
was VBD N
evaluated VBN N
as IN N
primary JJ N
prophylaxis NN N
for IN N
toxoplasmic JJ N
encephalitis NN N
( ( N
TE NNP N
) ) N
in IN N
a DT N
double-blind NN N
, , N
randomized VBD N
clinical JJ N
trial NN N
in IN N
patients NNS p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
disease NN p
, , p
absolute JJ p
CD4 NNP p
lymphocyte NN p
count NN p
of IN p
< $ p
200/microL CD p
( ( p
or CC p
prior RB p
AIDS-defining NNP p
opportunistic JJ p
infection NN p
) ) p
, , p
and CC p
the DT p
presence NN p
of IN p
serum NN p
IgG NNP p
to TO p
Toxoplasma NNP p
gondii NN p
. . p

Leucovorin NNP i
was VBD N
coadministered VBN N
only RB N
for IN N
hematologic JJ N
toxicity NN N
. . N

There EX N
was VBD N
a DT N
significantly RB N
higher JJR N
death NN o
rate NN o
among IN N
patients NNS N
receiving VBG N
pyrimethamine NN i
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
2.5 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.3-4.8 JJ N
; : N
P NNP N
= NNP N
.006 NNP N
) ) N
, , N
even RB N
after IN N
adjusting VBG N
for IN N
factors NNS N
predictive CD N
of IN N
survival NN N
. . N

The DT N
TE NNP o
event NN o
rate NN o
was VBD N
low JJ N
in IN N
both DT N
treatment NN N
groups NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

Only RB N
1 CD N
of IN N
218 CD p
patients NNS p
taking VBG p
trimethoprim-sulfamethoxazole JJ i
but CC N
7 CD N
of IN N
117 CD p
taking VBG p
aerosolized JJ i
pentamidine NN i
for IN N
prophylaxis NN N
against IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
developed VBD N
TE NNP N
( ( N
adjusted VBN N
RR NNP N
for IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
group NN N
, , N
0.16 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.01-1.79 NNP N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
. . N

Thus RB N
, , N
for IN N
HIV-infected JJ p
patients NNS p
receiving VBG N
trimethoprim-sulfamethoxazole JJ i
, , N
additional JJ N
prophylaxis NN N
for IN N
TE NNP N
appears VBZ N
unnecessary JJ N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
maintenance NN i
treatment NN i
regimens NNS i
for IN N
first JJ N
central JJ p
nervous JJ p
system NN p
relapse NN p
in IN p
children NNS p
with IN p
acute JJ p
lymphocytic JJ p
leukemia NN p
. . p

A DT N
Pediatric NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

Eighty-seven JJ p
children NNS p
with IN p
central JJ p
nervous JJ p
system NN p
( ( p
CNS NNP p
) ) p
leukemia NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT i
induction NN i
intrathecal JJ i
chemotherapy NN i
( ( i
ITC NNP i
) ) i
and CC i
cranial JJ i
irradiation NN i
( ( i
CRT NNP i
) ) i
plus CC i
maintenance NN i
ITC NNP i
, , i
or CC i
induction NN i
ITC NNP i
and CC i
craniospinal JJ i
irradiation NN i
( ( i
CSpRT NNP i
) ) i
with IN i
no DT i
maintenance NN i
ITC NNP i
. . i

ITC NNP N
consisted VBD N
of IN N
six CD N
weekly JJ N
injections NNS N
of IN N
methotrexate NN i
, , i
hydrocortisone NN i
, , i
and CC i
arabinosylcytosine NN i
. . i

Also RB N
, , N
intensification NN i
of IN i
systemic JJ i
induction NN i
and CC i
maintenance NN i
chemotherapy NN i
was VBD N
given VBN N
. . N

CRT NNP i
+ NNP i
ITC NNP i
was VBD N
given VBN N
as IN N
CRT NNP i
, , N
2400 CD N
rad NN N
in IN N
12 CD N
fractions NNS N
followed VBN N
by IN N
ITC NNP i
maintenance NN N
bimonthly NN N
for IN N
2 CD N
years NNS N
. . N

Craniospinal JJ i
irradiation NN i
consisted VBD i
of IN i
CRT NNP i
+ NNP N
1400 CD N
rad NN N
in IN N
ten JJ N
fractions NNS N
to TO N
the DT N
spine NN N
. . N

Randomization NN N
was VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
CNS NNP N
leukemia NN N
occurred VBD N
at IN N
initial JJ N
diagnosis NN N
of IN N
acute JJ N
lymphocytic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
( ( N
Stratum NNP N
I PRP N
, , N
15 CD N
patients NNS N
) ) N
, , N
during IN N
first JJ N
bone NN N
marrow NN N
( ( N
BM NNP N
) ) N
remission NN N
( ( N
Stratum NNP N
II NNP N
, , N
49 CD N
patients NNS N
) ) N
, , N
simultaneous JJ N
with IN N
first JJ N
BM NNP N
relapse NN N
( ( N
Stratum NNP N
III NNP N
, , N
12 CD N
patients NNS N
) ) N
, , N
or CC N
during IN N
second JJ N
BM NNP N
remission NN N
( ( N
Stratum NNP N
IV NNP N
, , N
11 CD N
patients NNS N
) ) N
. . N

The DT N
median JJ N
follow-up NN N
for IN N
patients NNS N
who WP N
remain VBP N
at IN N
risk NN N
is VBZ N
15 CD N
+ JJ N
months NNS N
. . N

Eight NNP N
children NNS N
( ( N
seven CD N
on IN N
CRT NNP N
+ NNP N
ITC NNP N
, , N
one CD N
on IN N
CSpRT NNP N
) ) N
developed VBD N
presumed VBN o
therapy RB o
related VBN o
encephalopathy NN o
. . o

In IN N
Stratum NNP N
II NNP N
, , N
16 CD N
of IN N
29 CD N
( ( N
55 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
CRT NNP N
+ NNP N
ITC NNP N
experienced VBD N
adverse JJ o
events NNS o
: : o
3 CD N
deaths NNS o
during IN o
continuous JJ o
complete JJ o
remission NN o
( ( o
CCR NNP o
) ) o
and CC N
13 CD N
relapses NNS o
( ( N
2 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
+ NNP N
testes VBZ N
, , N
and CC N
2 CD N
testes NNS N
) ) N
as IN N
compared VBN N
with IN N
only RB N
5 CD N
relapses NNS o
in IN N
20 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
on IN N
CSpRT NNP N
( ( N
1 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
, , N
and CC N
2 CD N
testes NNS N
) ) N
. . N

The DT N
children NNS N
on IN N
both DT N
regimens NNS N
were VBD N
comparable JJ N
for IN N
sex NN N
, , N
race NN N
, , N
age NN N
at IN N
initial JJ N
ALL NNP N
diagnosis NN N
, , N
time NN o
from IN o
ALL NNP o
diagnosis NN o
to TO o
first JJ o
episode NN o
of IN o
CNS NNP o
leukemia NN o
, , o
systemic JJ o
therapy NN o
both DT o
before IN o
and CC o
after IN o
CNS NNP o
relapse NN o
, , o
and CC o
number NN o
of IN o
blasts NNS o
in IN o
the DT o
spinal JJ o
fluid NN o
at IN o
diagnosis NN o
of IN o
CNS NNP o
leukemia NN o
. . o

The DT N
conclusion NN N
is VBZ N
that IN N
children NNS N
with IN N
isolated JJ N
CNS NNP N
leukemia NN N
can MD N
achieve VB N
prolonged JJ o
survival NN o
with IN o
aggressive JJ o
therapy NN o
, , N
and CC N
that IN N
CSpRT NNP o
is VBZ o
possibly RB o
less RBR o
toxic JJ o
and CC N
more RBR N
likely JJ N
than IN N
is VBZ N
CRT NNP N
+ NNP N
ITC NNP N
to TO N
prevent VB N
subsequent JJ o
BM NNP o
and CC o
testicular JJ o
relapse NN o
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
not RB N
subsequent JJ N
CNS NNP o
relapse NN o
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
. . N

A DT N
possible JJ N
systemic JJ N
therapy NN N
effect NN N
of IN N
spinal JJ o
irradiation NN o
is VBZ N
postulated VBN N
to TO N
explain VB N
the DT N
superiority NN o
of IN o
CSpRT NNP o
. . o

-DOCSTART- -X- O O

Hypnosis NNP i
treatment NN i
for IN N
severe JJ o
irritable JJ o
bowel NN o
syndrome NN o
: : o
investigation NN N
of IN N
mechanism NN N
and CC N
effects NNS N
on IN N
symptoms NNS N
. . N

Hypnosis NNP i
improves VBZ N
irritable JJ o
bowel NN o
syndrome NN o
( ( N
IBS NNP N
) ) N
, , N
but CC N
the DT N
mechanism NN N
is VBZ N
unknown JJ N
. . N

Possible JJ N
physiological JJ N
and CC N
psychological JJ N
mechanisms NNS N
were VBD N
investigated VBN N
in IN N
two CD N
studies NNS N
. . N

Patients NNS p
with IN p
severe JJ p
irritable JJ p
bowel NN p
syndrome NN p
received VBD N
seven CD N
biweekly JJ i
hypnosis NN i
sessions NNS i
and CC i
used VBD i
hypnosis NN i
audiotapes NNS i
at IN N
home NN N
. . N

Rectal JJ N
pain NN N
thresholds NNS N
and CC N
smooth JJ N
muscle NN N
tone NN N
were VBD N
measured VBN N
with IN N
a DT N
barostat NN N
before IN N
and CC N
after IN N
treatment NN N
in IN N
18 CD p
patients NNS p
( ( p
study VB p
I PRP p
) ) p
, , N
and CC N
treatment NN N
changes NNS N
in IN N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
skin JJ N
conductance NN N
, , N
finger NN N
temperature NN N
, , N
and CC N
forehead JJ N
electromyographic JJ N
activity NN N
were VBD N
assessed VBN N
in IN N
24 CD p
patients NNS p
( ( p
study VB p
II NNP p
) ) p
. . p

Somatization NN N
, , N
anxiety NN N
, , N
and CC N
depression NN N
were VBD N
also RB N
measured VBN N
. . N

All DT o
central JJ o
IBS NNP o
symptoms NNS o
improved VBN N
substantially RB N
from IN N
treatment NN N
in IN N
both DT N
studies NNS N
. . N

Rectal JJ o
pain NN o
thresholds NNS o
, , o
rectal JJ o
smooth JJ o
muscle NN o
tone NN o
, , o
and CC o
autonomic JJ o
functioning NN o
( ( o
except IN o
sweat NN o
gland VBP o
reactivity NN o
) ) o
were VBD N
unaffected VBN N
by IN N
hypnosis NN N
treatment NN N
. . N

However RB N
, , N
somatization NN o
and CC o
psychological JJ o
distress NN o
showed VBD N
large JJ N
decreases NNS N
. . N

In IN N
conclusion NN N
, , N
hypnosis NN i
improves NNS N
IBS NNP o
symptoms NNS o
through IN N
reductions NNS N
in IN N
psychological JJ o
distress NN o
and CC o
somatization NN o
. . o

Improvements NNS N
were VBD N
unrelated JJ N
to TO N
changes NNS N
in IN N
the DT N
physiological JJ N
parameters NNS N
measured VBD N
. . N

-DOCSTART- -X- O O

Direct JJ N
and CC N
indirect JJ N
effects NNS N
of IN N
interdental JJ i
hygiene NN i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

Many JJ N
randomized VBD N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
in IN N
dental JJ N
research NN N
test NN N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
more JJR N
than IN N
one CD N
outcome NN N
variable NN N
. . N

Univariate NNP N
methods NNS N
, , N
such JJ N
as IN N
the DT N
t JJ N
test NN N
or CC N
analysis NN N
of IN N
covariance NN N
, , N
can MD N
not RB N
evaluate VB N
the DT N
efficacy NN N
of IN N
interventions NNS N
on IN N
multiple JJ N
outcomes NNS N
simultaneously RB N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
use VB N
structural JJ i
equation NN i
modeling NN i
( ( N
SEM NNP N
) ) N
to TO N
re-analyze VB N
a DT N
RCT NNP N
, , N
comparing VBG N
the DT N
effects NNS N
of IN N
pre-curved JJ i
interdental JJ i
brushes NNS i
and CC i
flossing VBG i
on IN N
probing VBG N
pocket NN N
depth NN N
( ( N
PPD NNP N
) ) N
, , N
plaque JJ N
indices NNS N
, , N
and CC N
bleeding VBG N
on IN N
probing VBG N
( ( N
BOP NNP N
) ) N
measured VBD N
at IN N
baseline NN N
, , N
intermediate NN N
, , N
and CC N
final JJ N
examinations NNS N
. . N

Results NNS N
of IN N
SEM NNP N
showed VBD N
that IN N
the DT N
observed JJ N
greater JJR o
reduction NN o
in IN o
PPD NNP o
and CC o
BOP NNP o
in IN N
persons NNS p
using VBG p
interdental JJ p
brushing NN p
than IN p
in IN p
those DT p
flossing NN p
is VBZ N
due JJ N
mainly RB N
to TO N
the DT N
greater JJR N
efficiency NN o
in IN o
plaque NN o
removal NN o
with IN N
the DT N
interdental JJ N
brushes NNS N
( ( N
indirect JJ N
effect NN N
) ) N
rather RB N
than IN N
to TO N
the DT N
compression NN N
of IN N
the DT N
interdental JJ N
papillae NN N
( ( N
direct JJ N
effect NN N
) ) N
. . N

In IN N
contrast NN N
, , N
smokers NNS p
showed VBD N
less JJR N
BOP NNP o
at IN N
baseline NN N
but CC N
also RB N
less RBR N
improvement NN N
in IN N
BOP NNP o
through IN N
direct JJ N
effects NNS N
. . N

-DOCSTART- -X- O O

Menopausal NNP o
quality NN o
of IN o
life NN o
: : o
RCT NNP i
of IN i
yoga NN i
, , i
exercise NN i
, , i
and CC i
omega-3 JJ i
supplements NNS i
. . i

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
3 CD i
nonhormonal JJ i
therapies NNS i
for IN N
the DT N
improvement NN N
of IN N
menopause-related JJ o
quality NN o
of IN o
life NN o
in IN N
women NNS p
with IN p
vasomotor NN p
symptoms NNS p
. . p

STUDY NNP N
DESIGN NNP N
We PRP N
conducted VBD N
a DT N
12-week JJ N
3 CD N
? . N
2 CD N
randomized VBD N
, , N
controlled VBD N
, , N
factorial JJ N
design NN N
trial NN N
. . N

Peri- NN p
and CC p
postmenopausal JJ p
women NNS p
, , p
40-62 JJ p
years NNS p
old JJ p
, , p
were VBD N
assigned VBN N
randomly RB N
to TO i
yoga VB i
( ( N
n JJ N
= NNP N
107 CD N
) ) N
, , N
exercise NN i
( ( N
n JJ N
= NNP N
106 CD N
) ) N
, , N
or CC i
usual JJ i
activity NN i
( ( N
n JJ N
= NNP N
142 CD N
) ) N
and CC N
also RB N
assigned VBD N
randomly RB N
to TO N
a DT N
double-blind JJ N
comparison NN N
of IN i
omega-3 JJ i
( ( N
n JJ N
= NNP N
177 CD i
) ) i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
178 CD N
) ) N
capsules NNS N
. . N

We PRP N
performed VBD N
the DT N
following JJ N
interventions NNS N
: : N
( ( N
1 CD i
) ) i
weekly JJ i
90-minute CD i
yoga NN i
classes NNS i
with IN i
daily JJ i
at-home JJ i
practice NN i
, , i
( ( i
2 CD i
) ) i
individualized VBN i
facility-based JJ i
aerobic JJ i
exercise NN i
training NN i
3 CD i
times/week NN i
, , i
and CC N
( ( N
3 CD N
) ) N
0.615 CD N
g JJ N
omega-3 JJ i
supplement NN i
, , i
3 CD N
times/day NN N
. . N

The DT N
outcomes NNS N
were VBD N
assessed VBN N
with IN N
the DT N
following JJ N
scores NNS o
: : o
Menopausal NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
MENQOL NNP o
) ) o
total NN o
and CC o
domain NN o
( ( o
vasomotor NN o
symptoms NNS o
, , o
psychosocial JJ o
, , o
physical JJ o
and CC o
sexual JJ o
) ) o
. . o

RESULTS NNP p
Among IN p
355 CD p
randomly NNS p
assigned VBN p
women NNS p
who WP p
average VBP p
age NN p
was VBD p
54.7 CD p
years NNS p
, , p
338 CD p
women NNS p
( ( p
95 CD p
% NN p
) ) p
completed VBD p
12-week JJ p
assessments NNS p
. . p

Mean NNP o
baseline NN o
vasomotor NN o
symptoms JJ o
frequency NN o
was VBD N
7.6/day CD N
, , N
and CC N
the DT o
mean JJ o
baseline NN o
total JJ o
MENQOL NNP o
score NN o
was VBD N
3.8 CD N
( ( N
range NN N
, , N
1-8 CD N
from IN N
better JJR N
to TO N
worse VB N
) ) N
with IN N
no DT N
between-group JJ N
differences NNS N
. . N

For IN i
yoga NN i
compared VBN N
to TO N
usual JJ N
activity NN N
, , N
baseline NN N
to TO N
12-week JJ N
improvements NNS N
were VBD N
seen VBN N
for IN o
MENQOL NNP o
total JJ N
-0.3 NNP N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-0.6 VBP N
to TO N
0 CD N
; : N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
vasomotor NN o
symptom NN o
domain NN o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
, , N
and CC o
sexuality NN o
domain NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
scores VBZ N
. . N

For IN N
women NNS N
who WP N
underwent VBP i
exercise NN i
and CC i
omega-3 JJ i
therapy NN i
compared VBN N
with IN N
control NN N
subjects NNS N
, , N
improvements NNS N
in IN N
baseline NN N
to TO N
12-week JJ N
total JJ o
MENQOL NNP o
scores NNS o
were VBD N
not RB N
observed VBN N
. . N

Exercise NN N
showed VBD N
benefit NN N
in IN N
the DT o
MENQOL NNP o
physical JJ o
domain NN o
score NN o
at IN N
12 CD N
weeks NNS N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION NNP N
All NNP N
women NNS N
become VBP N
menopausal JJ N
, , N
and CC N
many JJ N
of IN N
them PRP N
seek VBP N
medical JJ N
advice NN N
on IN N
ways NNS N
to TO N
improve VB o
quality NN o
of IN o
life NN o
; : o
little JJ N
evidence-based JJ N
information NN N
exists NNS N
. . N

We PRP N
found VBD N
that IN N
, , N
among IN p
healthy JJ p
sedentary JJ p
menopausal NN p
women NNS p
, , p
yoga NN i
appears VBZ N
to TO N
improve VB o
menopausal NN o
quality NN o
of IN o
life NN o
; : o
the DT N
clinical JJ N
significance NN N
of IN N
our PRP$ N
finding NN N
is VBZ N
uncertain JJ N
because IN N
of IN N
the DT N
modest JJ N
effect NN N
. . N

-DOCSTART- -X- O O

Environmental JJ N
enrichment NN N
as IN N
an DT N
effective JJ N
treatment NN N
for IN N
autism NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Enriched NNP N
sensorimotor NN N
environments NNS N
enable JJ N
rodents NNS N
to TO N
compensate VB N
for IN N
a DT N
wide JJ N
range NN N
of IN N
neurological JJ N
challenges NNS N
, , N
including VBG N
those DT N
induced VBN N
in IN N
animal JJ N
models NNS N
of IN N
autism NN N
. . N

Given VBN N
the DT N
sensorimotor NN N
deficits NNS N
in IN N
most JJS N
children NNS p
with IN p
autism NN p
, , N
we PRP N
attempted VBD N
to TO N
translate VB N
that DT N
approach NN N
to TO N
their PRP$ N
treatment NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
3-12 JJ p
year-old JJ p
children NNS p
with IN p
autism NN p
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
sensorimotor NN i
enrichment NN i
group NN i
, , N
which WDT N
received VBD N
daily RB N
olfactory/tactile JJ i
stimulation NN i
along IN i
with IN i
exercises NNS i
that WDT i
stimulated VBD i
other JJ i
paired JJ i
sensory JJ i
modalities NNS i
, , i
or CC i
to TO i
a DT i
control NN i
group NN i
. . i

We PRP N
administered VBD N
tests NNS N
of IN N
cognitive JJ N
performance NN N
and CC N
autism NN N
severity NN N
to TO N
both DT N
groups NNS N
at IN N
the DT N
initiation NN N
of IN N
the DT N
study NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

Severity NNP o
of IN o
autism NN o
, , N
as IN N
assessed VBN N
with IN N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , N
improved VBN N
significantly RB N
in IN N
the DT N
enriched JJ N
group NN N
compared VBN N
to TO N
controls NNS N
. . N

Indeed RB N
, , N
42 CD N
% NN N
of IN N
the DT N
enriched VBN N
group NN N
and CC N
only RB N
7 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
had VBD N
what WP N
we PRP N
considered VBD N
to TO N
be VB N
a DT N
clinically RB N
significant JJ N
improvement NN N
of IN N
5 CD N
points NNS N
on IN N
that DT N
scale NN N
. . N

Sensorimotor NNP N
enrichment NN N
also RB N
produced VBD N
a DT N
clear JJ o
improvement NN o
in IN o
cognition NN o
, , N
as IN N
determined VBN N
by IN N
their PRP$ N
Leiter-R JJ N
Visualization NNP N
and CC N
Reasoning NNP N
scores NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
change NN N
in IN N
average JJ N
scores NNS N
for IN N
the DT N
enriched JJ N
group NN N
was VBD N
11.3 CD N
points NNS N
higher JJR N
than IN N
that DT N
for IN N
the DT N
control NN N
group NN N
. . N

Finally RB N
, , N
69 CD N
% NN N
of IN N
parents NNS N
in IN N
the DT N
enriched JJ N
group NN N
and CC N
31 CD N
% NN N
of IN N
parents NNS N
in IN N
the DT N
control NN N
group NN N
reported VBD N
improvement NN N
in IN N
their PRP$ N
child NN N
over IN N
the DT N
6-month JJ N
study NN N
. . N

Environmental JJ N
enrichment NN N
therefore RB N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
ameliorating VBG o
some DT o
of IN o
the DT o
symptoms NNS o
of IN o
autism NN o
in IN N
children NNS N
. . N

-DOCSTART- -X- O O

Divalproex NNP i
sodium NN i
vs. FW i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
behaviours NNS o
in IN N
autism NN p
spectrum NN p
disorder NN p
. . p

Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
impairment NN N
in IN N
three CD N
core NN N
symptom NN N
domains NNS N
: : N
socialization NN N
, , N
communication NN N
, , N
and CC N
repetitive/stereotyped VBD N
behaviours NNS N
. . N

Other JJ N
associated JJ N
symptom NN N
domains NNS N
are VBP N
also RB N
affected JJ N
including VBG N
impulsivity/aggression NN N
, , N
self-injury NN N
, , N
anxiety NN N
, , N
and CC N
mood NN N
lability NN N
. . N

Divalproex NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
efficacy NN N
in IN N
treating VBG N
epilepsy NN N
, , N
bipolar JJ N
disorder NN N
, , N
mood NN N
lability NN N
, , N
and CC N
impulsive JJ N
aggression NN N
. . N

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
use NN N
of IN N
divalproex NN i
in IN N
the DT N
treatment NN N
of IN N
repetitive JJ o
, , o
compulsive-like JJ o
symptoms NNS o
of IN o
autism NN o
spectrum NN o
disorder NN o
( ( o
ASD NNP o
) ) o
. . o

Thirteen JJ p
individuals NNS p
with IN p
ASD NNP p
participated VBD N
in IN N
an DT N
8-wk JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
divalproex NN i
sodium NN i
vs. FW i
placebo NN i
. . i

There EX N
was VBD N
a DT N
significant JJ N
group NN N
difference NN N
on IN N
improvement NN N
in IN N
repetitive JJ o
behaviours NNS o
as IN N
measured VBN N
by IN N
the DT N
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive NNP o
Compulsive NNP o
Scale NNP o
( ( o
C-YBOCS NNP o
) ) o
( ( N
p=0.037 NN N
) ) N
and CC N
a DT N
large JJ N
effect NN N
size NN N
( ( N
d=1.616 NN N
) ) N
. . N

This DT N
study NN N
provides VBZ N
preliminary JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
divalproex NN i
in IN N
treating VBG N
repetitive JJ o
behaviours NNS o
in IN N
ASD NNP p
. . p

Further NNP N
research NN N
is VBZ N
needed VBN N
to TO N
evaluate VB N
the DT N
specificity NN N
and CC N
mechanism NN N
of IN N
action NN N
of IN N
these DT N
findings NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBD N
trial NN N
of IN N
lumbar NN N
interlaminar JJ N
epidural JJ N
injections NNS N
in IN N
central JJ p
spinal JJ p
stenosis NN p
: : p
2-year JJ N
follow-up NN N
. . N

BACKGROUND NNP N
While IN N
low JJ N
back RB N
pain NN N
is VBZ N
the DT N
number NN N
one CD N
cause NN N
of IN N
disability NN N
in IN N
the DT N
United NNP N
States NNPS N
, , N
lumbar VBP p
spinal JJ p
stenosis NN p
along IN N
with IN N
intervertebral JJ N
disc NN N
herniation NN N
and CC N
degenerative JJ N
spondylolisthesis NN N
is VBZ N
one CD N
of IN N
the DT N
3 CD N
most JJS N
common JJ N
diagnosis NN N
of IN N
low JJ N
back RB N
and CC N
leg NN N
pain NN N
for IN N
which WDT N
surgery NN N
is VBZ N
performed VBN N
. . N

Numerous JJ N
modalities NNS N
of IN N
treatments NNS N
including VBG N
drug NN N
therapy NN N
and CC N
complex JJ N
surgical JJ N
fusions NNS N
have VBP N
been VBN N
recommended VBN N
for IN N
treatment NN N
of IN N
central JJ N
spinal JJ N
stenosis NN N
. . N

Epidural JJ i
injections NNS i
are VBP N
one CD N
of IN N
the DT N
commonly NN N
performed VBD N
nonsurgical JJ N
interventions NNS N
in IN N
managing VBG N
central JJ N
spinal JJ N
stenosis NN N
; : N
however RB N
, , N
there EX N
has VBZ N
been VBN N
paucity NN N
of IN N
literature NN N
in IN N
reference NN N
to TO N
efficacy NN N
of IN N
epidural JJ i
injections NNS i
in IN N
managing VBG N
central JJ N
spinal JJ N
stenosis NN N
with IN N
lumbar NN i
interlaminar JJ i
epidural JJ i
injections NNS i
. . i

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
active JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
Private JJ N
interventional JJ N
pain NN N
management NN N
practice NN N
and CC N
specialty NN N
referral JJ N
center NN N
in IN N
the DT N
United NNP p
States NNPS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
lumbar NN i
interlaminar JJ i
epidural JJ i
injections NNS i
with IN i
or CC i
without IN i
steroids NNS i
in IN N
providing VBG N
effective JJ N
and CC N
long-lasting JJ N
pain NN N
relief NN N
with IN N
improvement NN N
in IN N
functional JJ N
status NN N
for IN N
the DT N
management NN N
of IN N
chronic NN N
low JJ N
back RB N
and CC N
lower JJR N
extremity NN N
pain NN N
related VBN N
to TO N
lumbar VB N
central JJ N
spinal JJ N
stenosis NN N
. . N

METHODS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
active-control JJ N
trial NN N
was VBD N
designed VBN N
with IN N
the DT N
inclusion NN N
of IN N
120 CD p
patients NNS p
assigned VBN p
to TO p
2 CD p
groups NNS p
. . p

Group NNP N
I PRP N
patients NNS N
received VBD N
lumbar JJ i
interlaminar JJ i
epidural JJ i
injections NNS i
of IN i
local JJ i
anesthetic JJ i
( ( i
lidocaine JJ i
0.5 CD i
% NN i
) ) i
6 CD i
mL NN i
, , N
whereas WP N
Group NNP i
II NNP i
received VBD i
lumbar JJ i
interlaminar JJ i
epidural JJ i
injections NNS i
with IN i
local JJ i
anesthetic NN i
( ( i
lidocaine JJ i
0.5 CD i
% NN i
) ) i
5 CD i
mL NN i
mixed JJ i
with IN i
1 CD i
mL NNS i
of IN i
steroids NNS i
and CC i
6 CD i
mg NN i
of IN i
betamethasone NN i
. . i

OUTCOMES NNP N
ASSESSMENT NNP N
Outcomes NNP N
were VBD N
assessed VBN N
utilizing VBG N
the DT N
numeric JJ o
pain NN o
rating NN o
scale NN o
( ( o
NRS NNP o
) ) o
and CC o
Oswestry NNP o
Disability NNP o
Index NNP o
( ( o
ODI NNP o
) ) o
at IN N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
post VBN N
treatment NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
significant JJ N
improvement NN N
, , N
defined VBD N
as IN N
50 CD o
% NN o
improvement NN o
in IN o
pain NN o
and CC o
disability NN o
scores NNS o
. . o

RESULTS NNP N
Significant JJ o
relief NN o
and CC o
functional JJ o
status NN o
improvement NN o
was VBD N
seen VBN N
in IN N
72 CD N
% NN N
and CC N
73 CD N
% NN N
of IN N
patients NNS N
in IN N
Groups NNP N
I PRP N
and CC N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
considering VBG N
all DT N
participants NNS N
; : N
however RB N
, , N
this DT N
was VBD N
84 CD N
% NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
successful JJ N
group NN N
. . N

Overall JJ o
significant JJ o
improvement NN o
was VBD N
achieved VBN N
for IN N
65.7 CD N
? . N
37.3 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
and CC N
68.9 CD N
? . N
37.7 CD N
weeks NNS N
in IN N
Group NNP N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
when WRB N
all DT N
participants NNS N
were VBD N
considered VBN N
; : N
whereas NNS N
, , N
this DT N
was VBD N
77 CD N
? . N
27.8 CD N
weeks NNS N
and CC N
77.9 CD N
? . N
30.2 CD N
weeks NNS N
when WRB N
they PRP N
were VBD N
separated VBN N
into IN N
successful JJ N
categories NNS N
. . N

The DT N
average JJ o
number NN o
of IN o
procedures NNS o
per IN o
patient NN N
was VBD N
5 CD N
to TO N
6 CD N
in IN N
both DT N
groups NNS N
. . N

LIMITATIONS NNP N
Limitations NNPS N
of IN N
this DT N
trial NN N
include VBP N
lack NN N
of IN N
placebo NN N
control NN N
group NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
multiple JJ N
procedures NNS N
over IN N
a DT N
period NN N
of IN N
2 CD N
years NNS N
. . N

CONCLUSION NNP i
Lumbar NNP i
interlaminar JJ i
epidural JJ i
injections NNS i
of IN i
local JJ i
anesthetic JJ i
with IN i
or CC N
without IN N
steroids NNS N
provide VBP N
relief NN N
in IN N
a DT N
significant JJ N
proportion NN N
of IN N
patients NNS N
with IN N
lumbar JJ p
central JJ p
spinal JJ p
stenosis NN p
. . p

CLINICAL NNP p
TRIAL NNP N
NCT00681447 NNP N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
arbutamine NN i
and CC N
exercise NN i
echocardiography NN i
in IN N
diagnosing VBG p
myocardial JJ p
ischemia NN p
. . p

Arbutamine NNP i
is VBZ N
a DT N
new JJ N
catecholamine NN N
designed VBN N
for IN N
use NN N
as IN N
a DT N
pharmacologic JJ N
stress NN N
agent NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
sensitivity NN N
of IN N
arbutamine NN i
with IN N
symptom-limited JJ i
exercise NN i
to TO N
induce VB N
echocardiographic JJ o
signs NNS o
of IN o
ischemia NN o
. . o

Arbutamine NNP i
was VBD N
administered VBN N
by IN N
a DT N
computerized JJ N
closed-loop NN N
delivery NN N
system NN N
that WDT N
controls VBZ N
the DT N
infusion NN N
rate NN N
of IN N
arbutamine NN i
toward IN N
a DT N
predefined JJ N
rate NN N
of IN N
heart NN N
rate NN N
increase NN N
and CC N
maximum JJ N
heart NN N
rate NN N
limit NN N
. . N

Beta NNP N
blockers NNS N
were VBD N
stopped VBN N
> CD N
or CC N
= VB N
48 CD N
hours NNS N
before IN N
both DT N
tests NNS N
. . N

Stress NN N
was VBD N
stopped VBN N
for IN N
intolerable JJ N
symptoms NNS N
, , N
or CC N
clinical JJ N
, , N
electrocardiographic JJ N
or CC N
echocardiographic JJ N
signs NNS N
of IN N
ischemia NN N
( ( N
new JJ N
or CC N
worsening VBG N
wall JJ N
motion NN N
abnormality NN N
) ) N
, , N
target VB N
heart NN N
rate NN N
( ( N
> CD N
or CC N
= VB N
85 CD N
% NN N
age NN N
predicted VBD N
maximum JJ N
heart NN N
rate NN N
) ) N
, , N
or CC N
plateau NN N
of IN N
heart NN N
rate NN N
response NN N
. . N

Thirty-seven JJ p
patients NNS p
were VBD p
entered VBN p
into IN p
the DT p
study NN p
( ( p
35 CD p
arbutamine NN i
and CC p
exercise NN i
, , p
1 CD p
arbutamine NN i
only RB p
, , p
1 CD p
exercise NN i
only RB p
) ) p
, , p
of IN p
which WDT p
30 CD p
had VBD p
angiographic JJ p
evidence NN p
of IN p
coronary JJ p
artery NN p
disease NN p
( ( p
> CD p
or CC p
= VB p
50 CD p
% NN p
lumen NNS p
diameter RB p
narrowing VBG p
) ) p
. . p

Rate-pressure JJ o
product NN o
increased VBN N
significantly RB N
in IN N
response NN N
to TO N
both DT N
stress JJ N
modalities NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
was VBD N
significantly RB N
greater JJR N
with IN N
exercise NN N
( ( N
11,308 CD N
+/- JJ N
2,443 CD N
) ) N
than IN N
with IN N
arbutamine NN N
( ( N
9,486 CD N
+/- JJ N
2,479 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
time NN o
to TO o
maximum VB o
heart NN o
rate NN o
was VBD N
longer RBR N
during IN N
arbutamine JJ i
stress NN N
echocardiography NN N
than IN N
during IN N
exercise NN i
testing NN N
( ( N
17.3 CD N
+/- JJ N
9.4 CD N
versus NN N
9.3 CD N
+/- JJ N
4.2 CD N
minutes NNS N
, , N
respectively RB N
, , N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
more JJR N
patients NNS N
with IN N
interpretable JJ N
echo NN N
data NNS N
for IN N
arbutamine NN i
( ( N
82 CD N
% NN N
) ) N
than IN N
for IN N
exercise NN i
( ( N
67 CD N
% NN N
) ) N
. . N

Sensitivity NN o
for IN o
recognition NN o
of IN o
myocardial JJ o
ischemia NN o
was VBD N
94 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
70 CD N
% NN N
to TO N
100 CD N
% NN N
) ) N
and CC N
88 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
62 CD N
% NN N
to TO N
98 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

The DT N
most RBS N
frequent JJ N
adverse JJ o
events NNS o
during IN N
arbutamine NN i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
were VBD N
dyspnea VBN o
( ( N
5.6 CD N
% NN N
) ) N
and CC N
tremor NN o
( ( N
5.6 CD N
% NN N
) ) N
. . N

Two CD N
arbutamine JJ i
stress NN N
tests NNS N
were VBD N
discontinued VBN N
due JJ N
to TO N
arrhythmias VB o
: : o
1 CD N
patient NN N
had VBD N
premature JJ o
atrial JJ o
and CC o
ventricular JJ o
beats NNS o
, , N
and CC N
the DT N
other JJ N
had VBD N
premature JJ o
atrial JJ o
contractions NNS o
and CC o
atrial JJ o
fibrillation NN o
. . o

Arrhythmias NNP o
were VBD o
well RB o
tolerated VBN o
and CC o
resolved VBN o
without IN N
sequelae NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
sensitivity NN N
of IN N
arbutamine NN i
to TO N
induce VB N
echocardiographic JJ o
signs NNS o
of IN o
ischemia NN o
was VBD N
similar JJ N
to TO N
that DT N
of IN N
exercise NN i
despite IN N
a DT N
lower JJR N
rate-pressure NN o
product NN o
. . o

Arbutamine NNP i
was VBD N
well RB o
tolerated JJ o
and CC o
provides VBZ o
a DT o
reliable JJ o
alternative NN o
to TO o
exercise VB o
echocardiography NN o
. . o

-DOCSTART- -X- O O

RCT NNP N
of IN N
a DT N
manualized JJ N
social JJ i
treatment NN i
for IN N
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
RCT NNP N
examined VBD N
the DT N
efficacy NN N
of IN N
a DT N
manualized VBN i
social JJ i
intervention NN i
for IN N
children NNS p
with IN p
HFASDs NNP p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
or CC N
wait-list JJ i
conditions NNS i
. . i

Treatment NNP i
included VBD N
instruction NN i
and CC i
therapeutic JJ i
activities NNS i
targeting VBG i
social JJ i
skills NNS i
, , i
face-emotion NN i
recognition NN i
, , i
interest NN i
expansion NN i
, , i
and CC i
interpretation NN i
of IN i
non-literal JJ i
language NN i
. . i

A DT N
response-cost JJ N
program NN N
was VBD N
applied VBN N
to TO N
reduce VB N
problem NN N
behaviors NNS N
and CC N
foster JJ N
skills NNS N
acquisition NN N
. . N

Significant NNP N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
five CD o
of IN o
seven CD o
primary JJ o
outcome JJ o
measures NNS o
( ( o
parent NN o
ratings NNS o
and CC o
direct JJ o
child NN o
measures NNS o
) ) o
. . N

Secondary JJ N
measures NNS N
based VBN N
on IN N
staff NN o
ratings NNS o
( ( N
treatment NN N
group NN N
only RB N
) ) N
corroborated VBD N
gains NNS N
reported VBN N
by IN N
parents NNS N
. . N

High JJ N
levels NNS N
of IN N
parent NN o
, , o
child NN o
and CC o
staff NN o
satisfaction NN o
were VBD N
reported VBN N
, , N
along IN N
with IN N
high JJ N
levels NNS N
of IN N
treatment NN o
fidelity NN o
. . o

Standardized JJ N
effect NN N
size NN N
estimates NNS N
were VBD N
primarily RB N
in IN N
the DT N
medium NN N
and CC N
large JJ N
ranges NNS N
and CC N
favored VBD N
the DT N
treatment NN N
group NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
three CD N
solutions NNS N
of IN N
ropivacaine/fentanyl NN i
for IN N
postoperative JJ p
patient-controlled JJ p
epidural JJ p
analgesia NN p
. . p

BACKGROUND NNP N
Ropivacaine NNP i
, , N
0.2 CD N
% NN N
, , N
is VBZ N
a DT N
new JJ N
local JJ N
anesthetic JJ N
approved VBN N
for IN N
epidural JJ N
analgesia NN N
. . N

The DT N
addition NN N
of IN N
4 CD N
microg/ml NNS N
fentanyl JJ i
improves NNS N
analgesia VBP N
from IN N
epidural JJ N
ropivacaine NN N
. . N

Use NNP N
of IN N
a DT N
lower JJR N
concentration NN N
of IN N
ropivacaine-fentanyl NN i
may MD N
further VB N
improve VB N
analgesia NN o
or CC N
decrease JJ N
side NN o
effects NNS o
. . o

METHODS NNP N
Thirty NNP p
patients NNS p
undergoing VBG p
lower JJR p
abdominal JJ p
surgery NN p
were VBD p
randomized VBN p
in IN N
a DT N
double-blinded JJ N
manner NN N
to TO N
receive VB N
one CD N
of IN N
three CD N
solutions NNS N
: : N
0.2 CD i
% NN i
ropivacaine-4 JJ i
microg NN i
fentanyl VBD i
0.1 CD i
% NN i
ropivacaine-2 JJ i
microg NN i
fentanyl NN i
, , i
or CC i
0.05 CD i
% NN i
ropivacaine-1 JJ i
microg NN i
fentanyl NN i
for IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
after IN N
standardized VBN N
combined JJ N
epidural JJ N
and CC N
general JJ N
anesthesia NN N
. . N

Patient-controlled JJ N
epidural JJ N
analgesia NN N
settings NNS N
and CC N
adjustments NNS N
for IN N
the DT N
three CD N
solutions NNS N
were VBD N
standardized VBN N
to TO N
deliver VB N
equivalent JJ N
drug NN N
doses NNS N
. . N

Pain NN o
scores NNS o
( ( o
rest NN o
, , o
cough NN o
, , o
and CC o
ambulation NN o
) ) o
, , o
side JJ o
effects NNS o
( ( o
nausea NN o
, , o
pruritus NN o
, , o
sedation NN o
, , o
motor NN o
block NN o
, , o
hypotension NN o
, , o
and CC o
orthostasis NN o
) ) o
, , o
and CC o
patient-controlled JJ o
epidural JJ o
analgesia NN o
consumption NN o
were VBD N
measured VBN N
for IN N
48 CD N
h. JJ N
RESULTS NNP N
All NNP N
three CD N
solutions NNS N
produced VBD N
equivalent JJ N
analgesia NN N
. . N

Motor NNP o
block NN o
was VBD N
significantly RB N
more JJR N
common JJ N
( ( N
30 CD N
vs. FW N
0 CD N
% NN N
) ) N
and CC N
more JJR N
intense JJ N
with IN N
the DT N
0.2 CD N
% NN N
ropivacaine-4 JJ i
microg NN N
fentanyl JJ N
solution NN N
. . N

Other JJ N
side NN N
effects NNS N
were VBD N
equivalent JJ N
between IN N
solutions NNS N
and CC N
mild NN N
in IN N
severity NN o
. . o

A DT N
significantly RB N
smaller JJR N
volume NN N
of IN N
0.2 CD N
% NN N
ropivacaine-4 JJ o
microg NN o
fentanyl JJ o
solution NN o
was VBD N
used VBN N
, , N
whereas IN N
the DT N
0.1 CD N
% NN N
ropivacaine-2 JJ i
microg NN N
fentanyl NN N
group NN N
used VBD N
a DT N
significantly RB N
greater JJR N
amount NN N
of IN N
ropivacaine NN o
and CC o
fentanyl NN o
. . o

CONCLUSIONS NNP N
Lesser NNP N
concentrations NNS N
of IN N
ropivacaine NN i
and CC N
fentanyl JJ i
provide NN N
comparable JJ N
analgesia NN o
with IN N
less JJR N
motor NN o
block NN o
despite IN N
the DT N
use NN N
of IN N
similar JJ N
amounts NNS N
of IN N
ropivacaine NN N
and CC N
fentanyl NN N
. . N

This DT N
finding NN N
suggests VBZ N
that IN N
concentration NN N
of IN N
local JJ N
anesthetic JJ N
solution NN N
at IN N
low JJ N
doses NNS N
is VBZ N
a DT N
primary JJ N
determinant NN o
of IN o
motor NN o
block NN o
with IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
after IN N
lower JJR N
abdominal JJ N
surgery NN N
. . N

-DOCSTART- -X- O O

Behavioral NNP o
and CC o
physiological JJ o
effects NNS o
of IN N
remifentanil NN i
and CC i
alfentanil NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

BACKGROUND IN N
The DT o
subjective JJ o
and CC o
psychomotor JJ o
effects NNS o
of IN N
remifentanil NNS i
have VBP N
not RB N
been VBN N
evaluated VBN N
. . N

Accordingly RB N
, , N
the DT N
authors NNS N
used VBD N
mood NN N
inventories NNS N
and CC N
psychomotor NN N
tests NNS N
to TO N
characterize VB N
the DT N
effects NNS N
of IN N
remifentanil NN i
in IN N
healthy JJ p
, , p
non-drug-abusing JJ p
volunteers NNS p
. . p

Alfentanil NNP N
was VBD N
used VBN N
as IN N
a DT N
comparator NN N
drug NN N
. . N

METHODS NNP N
Ten NNP p
healthy JJ p
volunteers NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
, , N
crossover JJ N
trial NN N
in IN N
which WDT N
they PRP N
received VBD N
an DT N
infusion NN N
of IN N
saline NN i
, , i
remifentanil NN i
, , i
or CC i
alfentanil NN i
for IN i
120 CD i
min NN i
. . i

The DT N
age- JJ i
and CC i
weight-adjusted JJ i
infusions NNS i
( ( i
determined VBN i
with IN i
STANPUMP NNP i
, , i
a DT i
computer NN i
modeling VBG i
software NN i
package NN i
) ) i
were VBD N
given VBN N
to TO N
achieve VB N
three CD N
predicted VBN N
constant JJ N
plasma NN N
levels NNS N
for IN N
40 CD i
min NNS i
each DT i
of IN i
remifentanil NN i
( ( i
0.75 CD i
, , i
1.5 CD i
, , i
and CC i
3 CD i
ng/ml NN i
) ) i
and CC i
alfentanil NN i
( ( i
16 CD i
, , i
32 CD i
, , i
and CC i
64 CD i
ng/ml NN i
) ) i
. . i

Mood NN N
forms NNS N
and CC N
psychomotor NN N
tests NNS N
were VBD N
completed VBN N
, , N
and CC N
miosis NN N
was VBD N
assessed VBN N
, , N
during IN N
and CC N
after IN N
the DT N
infusions NNS N
. . N

In IN N
addition NN N
, , N
analgesia NN N
was VBD N
tested VBN N
at IN N
each DT N
dose JJ N
level NN N
using VBG N
a DT N
cold-pressor JJ N
test NN N
. . N

RESULTS NNP N
Remifentanil NNP i
had VBD N
prototypic VBN o
micro-like JJ o
opioid JJ o
subjective JJ o
effects NNS o
, , o
impaired JJ o
psychomotor NN o
performance NN o
, , o
and CC o
produced VBD o
analgesia NN o
. . o

Alfentanil NNP N
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ N
effects NNS N
on IN N
these DT N
measures NNS N
, , N
and CC N
the DT N
analgesia NN o
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
, , N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
, , N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS N
were VBD N
still RB N
impaired VBN N
, , N
although IN N
they PRP N
reported VBD N
feeling VBG N
no DT N
drug NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ o
effects NNS o
of IN N
remifentanil NN i
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN o
effects NNS o
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

-DOCSTART- -X- O O

Dexamethasone NNP i
effectively RB N
reduces VBZ N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
a DT N
general JJ p
surgical JJ p
adult NN p
patient JJ p
population NN p
. . p

BACKGROUND NNP N
Postoperative NNP N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
is VBZ N
still RB N
a DT N
common JJ N
and CC N
major JJ N
complication NN N
for IN N
surgical JJ p
patients NNS p
, , N
which WDT N
may MD N
delay VB N
post-anesthetic JJ N
care NN N
unit NN N
discharge NN N
, , N
prolong JJ N
hospital NN N
stay NN N
and CC N
thus RB N
increase VB N
the DT N
cost NN N
of IN N
hospitalization NN N
. . N

It PRP N
is VBZ N
understood JJ N
that IN N
PONV NNP N
is VBZ N
a DT N
multi-factorial JJ N
outcome NN N
and CC N
occurs VBZ N
more RBR N
often RB N
with IN N
general JJ N
anesthesia NN N
than IN N
with IN N
other JJ N
anesthetic JJ N
methods NNS N
. . N

Prophylactic JJ N
administration NN N
of IN N
antihistamines NNS N
, , N
antidopaminergics NNS N
, , N
anticholinergics NNS N
, , N
phenothiazines NNS N
, , N
serotonin JJ N
antagonist NN N
, , N
steroids NNS N
and CC N
even RB N
acupuncture NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
. . N

However RB N
, , N
expenses NNS N
and CC N
side JJ N
effects NNS N
of IN N
these DT N
agents NNS N
have VBP N
also RB N
been VBN N
a DT N
concern NN N
for IN N
clinical JJ N
doctors NNS N
. . N

The DT N
aim NN N
for IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
find VB N
an DT N
agent NN N
that WDT N
is VBZ N
cost RBS N
effective JJ N
and CC N
side JJ N
effect NN N
free JJ N
( ( N
or CC N
at IN N
least JJS N
with IN N
a DT N
low JJ N
incidence NN N
of IN N
side JJ N
effects NNS N
) ) N
for IN N
the DT N
prevention NN N
of IN N
PONV NNP N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
700 CD p
adult NN p
surgical JJ p
patients NNS p
who WP p
planned VBD p
to TO p
have VB p
surgery NN p
under IN p
general JJ p
anesthesia NN p
were VBD N
enrolled VBN N
in IN N
this DT N
double-blinded JJ N
, , N
randomized JJ N
and CC N
placebo-controlled JJ i
study NN N
. . N

Group NNP N
P NNP N
received VBD N
the DT N
placebo NN i
( ( N
0.9 CD N
% NN N
normal JJ i
saline JJ i
2 CD N
ml NN N
) ) N
and CC N
Group NNP N
D NNP N
received VBD N
10 CD N
mg NNS N
dexamethasone RB i
intravenously RB N
right JJ N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
. . N

RESULTS NNP N
We PRP N
found VBD N
that IN N
during IN N
the DT N
postoperative JJ N
period NN N
of IN N
1-8 JJ N
h NN N
, , N
patients NNS N
in IN N
Group NNP N
D NNP N
reported VBD N
a DT N
lower JJR N
incidence NN N
of IN N
PONV NNP o
( ( N
24 CD N
% NN N
) ) N
than IN N
those DT N
in IN N
Group NNP N
P NNP N
( ( N
39 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
in IN N
Group NNP N
D NNP N
also RB N
requested VBD N
less JJR N
rescue JJ N
anti-emetic JJ N
( ( N
17 CD N
% NN N
) ) N
than IN N
those DT N
in IN N
Group NNP N
P NNP N
( ( N
30 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
same JJ N
phenomenon NN N
was VBD N
also RB N
noted VBN N
in IN N
the DT N
8-to-24-hour JJ N
interval NN N
( ( N
PONV NNP N
4 CD N
% NN N
vs. FW N
12 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
and CC N
rescue VB N
anti-emetic JJ N
3 CD N
% NN N
vs. FW N
9 CD N
% NN N
, , N
p NN N
< VBD N
0.05 CD N
in IN N
Group NNP N
D NNP N
vs. FW N
Group NNP N
P NNP N
, , N
respectively RB N
. . N

) ) N
CONCLUSIONS IN N
We PRP N
conclude VBP N
that IN N
the DT N
prophylactic JJ N
intravenous JJ N
administration NN N
of IN N
10 CD N
mg NNS N
dexamethasone VBP N
immediately RB N
before IN N
the DT N
induction NN N
of IN N
anesthesia NN N
is VBZ N
effective JJ N
in IN N
preventing VBG N
PONV NNP N
in IN N
the DT N
general JJ p
surgical JJ p
adult NN p
patient JJ p
population NN p
. . p

-DOCSTART- -X- O O

Science NN N
to TO N
practice NN N
in IN N
underserved JJ N
communities NNS N
: : N
the DT N
effectiveness NN o
of IN N
school NN i
mental JJ i
health NN i
programming NN i
. . i

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
treatment NN i
program NN i
comprised VBN i
of IN i
several JJ i
components NNS i
based VBN i
on IN i
evidence-based JJ i
treatments NNS i
( ( i
EBTs NNP i
) ) i
for IN i
disruptive JJ i
behavior NN i
problems NNS i
delivered VBN N
to TO N
youth VB p
participating VBG p
in IN p
a DT p
school NN p
mental JJ p
health NN p
program NN p
in IN p
an DT p
underserved JJ p
community NN p
in IN p
the DT p
Appalachian JJ p
region NN p
. . p

Participants NNS N
were VBD N
117 CD p
children NNS p
in IN p
kindergarten VBN p
through IN p
6th CD p
grade NN p
including VBG p
91 CD p
children NNS p
( ( p
78 CD p
% NN p
male NN p
) ) p
from IN p
5 CD p
schools NNS p
who WP p
were VBD p
consecutively RB p
referred VBN p
to TO p
the DT p
intervention NN i
program NN i
and CC p
26 CD p
children NNS p
( ( p
73 CD p
% NN p
male NN p
) ) p
from IN p
3 CD p
schools NNS p
in IN p
which WDT p
program NN p
implementation NN p
was VBD p
delayed VBN p
for IN p
1 CD p
year NN p
. . p

Treatment NNP N
outcome NN N
was VBD N
measured VBN N
via IN N
parent NN o
and CC o
teacher JJ o
ratings NNS o
of IN o
child NN o
symptoms NNS o
and CC o
functioning VBG o
. . o

The DT N
treatment NN N
condition NN N
resulted VBD N
in IN N
significant JJ N
reduction NN N
in IN N
hyperactivity/impulsivity NN o
and CC o
early JJ o
aggressive JJ o
and CC o
delinquent JJ o
behavior NN o
, , o
as RB o
well RB o
as IN o
significant JJ o
improvement NN o
in IN o
several JJ o
other JJ o
functional JJ o
domains NNS o
. . o

Results VB N
suggest JJS N
that IN N
EBTs NNP i
can MD N
retain VB N
their PRP$ N
effectiveness NN o
when WRB N
transported VBN N
to TO N
a DT N
community NN N
context NN N
. . N

-DOCSTART- -X- O O

Chromium NNP i
Supplementation NNP i
and CC N
the DT N
Effects NNS N
on IN N
Metabolic NNP o
Status NNP o
in IN N
Women NNP p
with IN p
Polycystic NNP p
Ovary NNP p
Syndrome NNP p
: : p
A DT N
Randomized NNP N
, , N
Double-Blind NNP N
, , N
Placebo-Controlled JJ N
Trial NNP N
. . N

BACKGROUND NNP N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
beneficial JJ N
effects NNS N
of IN N
chromium NN i
intake NN N
on IN N
markers NNS N
of IN N
insulin NN o
metabolism NN o
and CC N
lipid JJ o
profiles NNS o
in IN N
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
, , N
64 CD p
women NNS p
with IN p
PCOS NNP p
were VBD p
randomized VBN p
to TO N
receive VB N
200 CD i
?g NNP i
chromium NN i
picolinate NN i
supplements NNS i
( ( i
n JJ i
= NNP i
32 CD i
) ) i
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
32 CD N
) ) N
for IN N
8 CD N
weeks NNS N
. . N

Fasting VBG o
blood NN o
samples NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
8 CD N
weeks NNS N
after IN N
the DT N
intervention NN N
to TO N
quantify VB N
markers NNS N
of IN N
insulin NN N
metabolism NN N
and CC N
lipid JJ N
concentrations NNS N
. . N

RESULTS NNP i
Chromium NNP i
supplementation NN N
in IN N
women NNS N
with IN N
PCOS NNP N
resulted VBD N
in IN N
significant JJ N
decreases NNS N
in IN o
serum JJ o
insulin NN o
levels NNS o
( ( N
-3.6 VB N
? . N
7.4 CD N
vs. IN N
+3.6 NN N
? . N
6.2 CD N
?IU/ml NN N
, , N
p NN N
< NNP N
0.001 CD o
) ) o
, , o
homeostasis JJ o
model NN o
of IN o
assessment-insulin JJ o
resistance NN o
( ( o
HOMA-IR NNP o
; : N
-0.8 NNP N
? . N
1.6 CD N
vs. IN N
+0.9 NN N
? . N
1.5 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , o
homeostatic JJ o
model NN o
assessment-beta NN o
cell NN o
function NN o
( ( o
HOMA-B NNP o
; : N
-15.5 NNP N
? . N
32.3 CD N
vs. IN N
+13.6 NN N
? . N
23.1 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
a DT N
significant JJ N
increase NN N
in IN o
quantitative JJ o
insulin NN o
sensitivity NN o
check NN o
index NN o
( ( o
QUICKI NNP o
) ) o
score NN o
( ( o
+0.02 VB N
? . N
0.03 CD N
vs. IN N
-0.008 NN N
? . N
0.02 CD N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
compared VBN N
with IN i
the DT i
placebo NN i
. . i

In IN N
addition NN N
, , N
a DT N
trend NN N
toward IN N
a DT N
significant JJ N
effect NN N
of IN N
chromium NN i
supplementation NN N
on IN N
decreasing VBG N
serum NN o
triglycerides NNS o
( ( o
-12.4 VB o
? . o
74.4 CD N
vs. IN N
+15.2 NN N
? . N
32.4 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
very RB N
low-density JJ o
lipoprotein-cholesterol NN o
( ( o
-2.5 VB o
? . o
14.9 CD o
vs. IN N
+3.0 NN N
? . N
6.5 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
and CC N
cholesterol NN o
concentrations NNS o
( ( o
-8.6 VB o
? . o
21.9 CD o
vs. IN N
+0.7 NN N
? . N
22.4 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.09 CD N
) ) N
was VBD N
seen VBN N
. . N

CONCLUSIONS NNP N
Eight NNP i
weeks NNS i
of IN i
chromium JJ i
supplementation NN i
among IN p
PCOS NNP p
women NNS p
had VBD p
favorable JJ N
effects NNS o
on IN o
markers NNS o
of IN o
insulin NN o
metabolism NN o
. . o

-DOCSTART- -X- O O

Family RB i
economic JJ i
empowerment NN i
and CC N
mental JJ N
health NN N
among IN N
AIDS-affected JJ p
children NNS p
living VBG p
in IN p
AIDS-impacted JJ p
communities NNS p
: : p
evidence NN N
from IN N
a DT N
randomised JJ N
evaluation NN N
in IN N
southwestern JJ p
Uganda NNP p
. . p

OBJECTIVE CC N
The DT N
authors NNS N
examine VBP N
whether IN N
an DT N
innovative JJ N
family NN i
economic JJ i
empowerment NN i
intervention NN N
addresses VBZ N
mental JJ N
health NN N
functioning NN N
of IN N
AIDS-affected JJ p
children NNS p
in IN p
communities NNS p
heavily RB p
impacted VBN p
by IN p
HIV/AIDS NNP p
in IN p
Uganda NNP p
. . p

METHODS NNP N
A NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
consisting VBG N
of IN N
two CD N
study NN N
arms NNS N
, , N
a DT p
treatment NN i
condition NN i
( ( p
n=179 JJ p
) ) p
and CC p
a DT p
control NN i
condition NN i
( ( p
n=118 JJ p
) ) p
, , N
was VBD N
used VBN N
to TO N
examine VB N
the DT N
impact NN N
of IN N
the DT N
family NN i
economic JJ i
empowerment NN i
intervention NN i
on IN N
children NNS N
's POS N
levels NNS N
of IN N
hopelessness NN N
and CC N
depression NN N
. . N

The DT N
intervention NN N
comprised VBD N
matched JJ i
children NNS i
savings NNS i
accounts NNS i
, , i
financial JJ i
management NN i
workshops NNS i
and CC i
mentorship NN i
. . i

Data NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
12 CD N
months NNS N
post-intervention NN N
. . N

RESULTS NNP N
Using VBG N
multivariate JJ N
analysis NN N
with IN N
several JJ N
socioeconomic JJ N
controls NNS N
, , N
the DT N
authors NNS N
find VBP N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
condition NN N
( ( N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
significant JJ N
improvement NN N
in IN N
their PRP$ N
mental JJ o
health NN o
functioning NN o
. . o

Specifically RB N
, , N
the DT N
intervention NN N
reduces VBZ N
hopelessness NN o
and CC o
depression NN o
levels NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
children NNS N
in IN N
the DT N
control NN i
condition NN N
( ( N
not RB N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
no DT N
changes NNS N
on IN N
both DT N
measures NNS N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
children NNS p
with IN p
poor JJ p
mental JJ p
health NN p
functioning VBG p
living NN p
in IN p
communities NNS p
affected VBN p
by IN p
HIV/AIDS NNP p
may MD N
benefit VB N
from IN N
innovative JJ N
family NN N
economic JJ N
empowerment NN N
interventions NNS N
. . N

As IN N
measures NNS N
of IN N
mental JJ N
health NN N
functioning NN N
, , N
both DT N
hopelessness NN o
and CC o
depression NN o
have VBP N
long-term JJ N
negative JJ N
psychosocial NN N
and CC N
developmental JJ N
impacts NNS N
on IN N
children NNS N
. . N

These DT N
findings NNS N
have VBP N
implications NNS N
for IN N
public JJ N
health NN N
programmes NNS N
intended VBN N
for IN N
long-term JJ N
care NN N
and CC N
support NN N
of IN N
children NNS p
living VBG p
in IN p
resource JJ p
poor JJ p
AIDS-impacted JJ p
communities NNS p
. . p

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
of IN N
LEAP NNP i
, , i
TEACCH NNP i
and CC N
non-model-specific JJ i
special JJ i
education NN i
programs NNS i
for IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

LEAP NNP i
and CC i
TEACCH NNP i
represent VBP N
two CD N
comprehensive JJ N
treatment NN N
models NNS N
( ( N
CTMs NNP N
) ) N
that WDT N
have VBP N
been VBN N
widely RB N
used VBN N
across IN N
several JJ N
decades NNS N
to TO N
educate VB N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
quasi-experimental JJ N
study NN N
was VBD N
to TO N
compare VB N
high JJ i
fidelity NN i
LEAP NNP i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
and CC i
TEACCH NNP i
( ( i
n JJ N
= NNP N
25 CD N
) ) N
classrooms NNS N
to TO N
each DT N
other JJ N
and CC N
a DT N
control NN N
condition NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
, , N
in IN N
which WDT N
teachers NNS p
in IN p
high JJ p
quality NN p
special JJ p
education NN p
programs NNS p
used VBD p
non-model-specific JJ N
practices NNS N
. . N

A DT N
total NN N
of IN p
198 CD p
children NNS p
were VBD p
included VBN N
in IN N
data NNS N
analysis NN N
. . N

Across IN N
conditions NNS o
, , o
children NNS o
's POS o
performances NNS o
improved VBN o
over IN N
time NN N
. . N

This DT N
study NN N
raises VBZ N
issues NNS N
of IN N
the DT N
replication NN N
of IN N
effects NNS N
for IN N
CTMs NNP N
, , N
and CC N
whether IN N
having VBG N
access NN N
to TO N
a DT N
high JJ N
quality NN i
special JJ i
education NN i
program NN i
is VBZ i
as RB i
beneficial JJ N
as IN N
access NN N
to TO N
a DT N
specific JJ N
CTM NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
prophylactic JJ i
amiodarone NN i
in IN N
patients NNS p
with IN p
rheumatic JJ p
valve NNS p
disease NN p
undergoing VBG p
valve JJ p
replacement NN p
surgery NN p
. . p

The DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prophylactic JJ N
single-dose JJ N
intravenous JJ N
amiodarone NN i
in IN N
patients NNS p
undergoing VBG p
valve JJ p
replacement NN p
surgery NN p
. . p

Maintenance NN N
of IN N
sinus NN N
rhythm NN N
is VBZ N
better JJR N
than IN N
maintenance NN N
of IN N
fixed JJ N
ventricular JJ N
rate NN N
in IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
especially RB N
in IN N
the DT N
presence NN N
of IN N
irritable JJ N
left NN N
or CC N
right JJ N
atrium NN N
because IN N
of IN N
enlargement NN N
. . N

Fifty-six JJ p
patients NNS p
with IN p
valvular JJ p
heart NN p
disease NN p
with IN p
or CC p
without IN p
AF NNP p
were VBD p
randomly RB p
divided VBN p
into IN N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
or CC N
the DT N
amiodarone NN i
group NN i
( ( N
n=28 NN N
) ) N
received VBD N
amiodarone NN i
( ( N
3 CD N
mg/kg NN N
in IN N
100 CD N
ml NNS N
normal JJ N
saline NN N
) ) N
and CC N
group NN N
II NNP N
or CC N
the DT N
control NN i
group NN N
received VBD N
same JJ N
volume NN N
of IN N
normal JJ i
saline NN i
. . i

The DT N
standardized JJ N
protocol NN N
for IN N
cardiopulmonary JJ N
bypass NN N
was VBD N
maintained VBN N
for IN N
all PDT N
the DT N
patients NNS N
. . N

AF NNP o
occurred VBD N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
, , N
and CC N
in IN N
group NN N
II NNP N
, , N
28.57 CD N
% NN N
( ( N
P=0.035 NNP N
) ) N
; : N
ventricular JJ o
tachycardia/fibrillation NN o
was VBD N
observed VBN N
in IN N
21.43 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
46.43 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.089 NNP N
) ) N
after IN N
release NN N
of IN N
aortic JJ N
clamp NN N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
92.86 CD N
% NN N
) ) N
maintained VBD N
sinus JJ o
rhythm NN o
without IN o
cardioversion NN o
or CC o
defibrillation NN o
after IN N
release NN N
of IN N
aortic JJ N
cross NN N
clamp NN N
( ( N
P=0.002 NNP N
) ) N
. . N

Defibrillation NN o
or CC o
cardio NN o
version NN o
was VBD N
needed VBN N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
28.57 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.078 NNP N
) ) N
. . N

A DT N
single JJ N
prophylactic JJ N
intraoperative NN N
dose NN N
of IN N
intravenous JJ N
amiodarone NN i
decreased VBD N
post NN o
bypass NN o
arrhythmia NN o
in IN N
this DT N
study NN N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

Single NNP N
dose NN N
of IN N
intraoperative JJ N
amiodarone NN i
may MD N
be VB N
used VBN N
to TO N
decrease VB N
postoperative JJ N
arrhythmia NN N
in IN N
open JJ N
heart NN N
surgery NN N
. . N

-DOCSTART- -X- O O

Vitamin NNP i
D NNP i
supplementation NN i
ameliorates VBZ N
hypoinsulinemia NN o
and CC o
hyperglycemia NN o
in IN N
static JJ p
magnetic JJ p
field-exposed JJ p
rat NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
vitamin NN i
D NNP i
supplementation NN i
on IN N
glucose NN o
and CC o
lipid JJ o
metabolism NN o
in IN N
static JJ p
magnetic JJ p
field NN p
( ( p
SMF NNP p
) ) p
-exposed VBD p
rats NNS p
. . p

Rats NNS p
exposed VBD N
to TO N
SMF NNP N
( ( N
128 CD N
mT NN N
; : N
1 CD N
h/day NN N
) ) N
during IN N
5 CD N
consecutive JJ N
days NNS N
showed VBD N
an DT N
increase NN N
in IN N
plasma JJ o
glucose JJ o
level NN o
and CC o
a DT o
decrease NN o
in IN o
plasma JJ o
insulin NN o
concentration NN o
. . o

By IN N
contrast NN N
, , N
the DT N
same JJ N
treatment NN N
failed VBD N
to TO N
alter VB N
body NN o
weight NN o
and CC o
plasmatic JJ o
total NN o
cholesterol NN o
, , o
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
-cholesterol NN o
, , o
low-density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
-cholesterol NN o
, , o
and CC o
triglyceride NN o
levels NNS o
. . o

Interestingly RB N
, , N
supplementation NN N
with IN N
vitamin NN i
D NNP i
( ( N
1,600 CD N
IU/100 NNP N
g NN N
, , N
per IN N
os NN N
) ) N
corrected VBD N
and CC N
restored VBD N
glycemia NN o
and CC o
insulinemia NN o
in IN N
SMF-exposed JJ p
rats NNS p
. . p

The DT N
same JJ N
treatment NN N
had VBD N
no DT N
effects NNS N
on IN N
lipid JJ o
metabolism NN o
. . o

-DOCSTART- -X- O O

A DT N
parent-mediated JJ i
intervention NN i
that WDT N
targets VBZ N
responsive JJ N
parental JJ N
behaviors NNS N
increases VBZ N
attachment JJ o
behaviors NNS o
in IN N
children NNS p
with IN p
ASD NNP p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

The DT N
current JJ N
study NN N
is VBZ N
a DT N
randomized JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
efficacy NN N
of IN N
Focused JJ i
Playtime NNP i
Intervention NNP i
( ( i
FPI NNP i
) ) i
in IN N
a DT N
sample NN N
of IN N
70 CD p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

This DT N
parent-mediated JJ N
intervention NN N
has VBZ N
previously RB N
been VBN N
shown VBN N
to TO N
significantly RB N
increase VB N
responsive JJ N
parental JJ N
communication NN N
( ( N
Siller NNP N
et RB N
al RB N
. . N

in IN N
J NNP N
Autism NNP N
Dev NNP N
Disord NNP N
43:540-555 CD N
, , N
2013a CD N
) ) N
. . N

The DT N
current JJ N
analyses NNS N
focus VBP N
on IN N
children NNS N
's POS N
attachment NN o
related VBN o
outcomes NNS o
. . o

Results NNS N
revealed VBD N
that IN N
children NNS N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
FPI NNP i
showed VBD N
bigger JJR N
increases NNS N
in IN N
attachment-related JJ o
behaviors NNS o
, , N
compared VBN N
to TO N
children NNS N
assigned VBN N
to TO N
the DT N
control NN N
condition NN N
. . N

Significant JJ N
treatment NN N
effects NNS N
of IN N
FPI NNP i
were VBD N
found VBN N
for IN N
both DT N
an DT N
observational JJ N
measure NN N
of IN N
attachment-related JJ o
behaviors NNS o
elicited VBD N
during IN N
a DT N
brief JJ N
separation-reunion JJ N
episode NN N
and CC N
a DT N
questionnaire JJ N
measure NN N
evaluating VBG N
parental JJ o
perceptions NNS o
of IN o
child JJ o
attachment NN o
. . o

The DT N
theoretical JJ N
and CC N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Who WP N
is VBZ N
at IN N
low JJ N
risk NN N
for IN N
cardiovascular JJ N
disease NN N
? . N
An DT N
assessment NN N
of IN N
different JJ N
definitions NNS N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
little JJ N
information NN N
regarding VBG N
the DT N
determinants NNS N
and CC N
trends NNS N
of IN N
the DT N
prevalence NN N
of IN N
low JJ o
cardiovascular JJ o
risk NN o
factor NN o
( ( N
RF NNP N
) ) N
profile NN N
in IN N
the DT N
general JJ p
population NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
prevalence NN o
and CC o
trends NNS o
of IN o
low JJ o
RF NNP o
profile NN o
in IN N
the DT N
Swiss JJ p
population NN p
according VBG N
to TO N
different JJ N
definitions NNS N
. . N

METHODS NNP N
Population-based JJ i
cross-sectional JJ i
studies NNS i
conducted VBN p
in IN p
1984-1986 JJ p
( ( p
N=3300 NNP p
) ) p
, , p
1988-1989 JJ p
( ( p
N=3331 NNP p
) ) p
, , p
1992-1993 JJ p
( ( p
N=3133 NNP p
) ) p
and CC p
2003-2006 JJ p
( ( p
N=6170 NNP p
) ) p
and CC p
restricted VBN p
to TO p
age NN p
group NN p
35-75 CD p
years NNS p
. . p

Seven RB i
different JJ i
definitions NNS i
of IN i
low JJ i
RF NNP i
profile NN i
were VBD N
used VBN N
to TO N
assess VB N
determinants NNS N
, , N
while IN N
two CD N
definitions NNS N
were VBD N
used VBN N
to TO N
assess VB N
trends NNS N
. . N

RESULTS NNP N
Prevalence NNP N
of IN N
low JJ o
RF NNP o
profile NN o
varied VBD N
between IN N
6.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
5.9-7.1 JJ N
) ) N
and CC N
9.7 CD N
% NN N
( ( N
9.0-10.5 CD N
) ) N
depending VBG N
on IN N
the DT N
definition NN N
used VBN N
. . N

This DT N
prevalence NN N
was VBD N
higher JJR N
than IN N
in IN N
other JJ N
countries NNS N
. . N

Irrespective NNP N
of IN N
the DT N
definition NN N
used VBN N
, , N
the DT N
prevalence NN N
of IN N
low JJ o
RF NNP o
profile NN o
was VBD N
higher RBR N
in IN N
women NNS N
and CC N
in IN N
physically RB N
active JJ N
participants NNS N
, , N
and CC N
decreased VBD N
with IN N
increasing VBG N
age NN N
or CC N
in IN N
the DT N
presence NN N
of IN N
a DT N
family NN N
history NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Using VBG N
one CD N
definition NN N
, , N
the DT N
prevalence NN N
of IN N
low JJ N
RF NNP o
profile NN o
increased VBD N
from IN N
3.8 CD N
% NN N
( ( N
3.1-4.5 JJ N
) ) N
in IN N
1984-1986 JJ N
to TO N
6.7 CD N
% NN N
( ( N
6.1-7.3 JJ N
) ) N
in IN N
2003-2006 JJ N
; : N
using VBG N
another DT N
definition NN N
, , N
the DT N
results NNS N
were VBD N
5.9 CD N
% NN N
( ( N
5.1-6.8 JJ N
) ) N
and CC N
9.7 CD N
% NN N
( ( N
9.0-10.5 CD N
) ) N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Switzerland NNP N
is VBZ N
characterized VBN N
by IN N
a DT N
high JJ N
and CC N
increasing VBG N
prevalence NN N
of IN N
low JJ N
RF NNP N
profile NN N
within IN N
the DT N
age NN p
group NN p
35 CD p
to TO p
75 CD p
, , N
irrespective NN N
of IN N
the DT N
criteria NNS N
used VBN N
. . N

This DT N
high JJ N
prevalence NN N
might MD N
partly RB N
explain VB N
the DT N
low JJ N
and CC N
decreasing VBG o
trend NN o
in IN o
cardiovascular JJ o
mortality NN o
rates NNS o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
quality NN o
of IN o
life NN o
, , o
work NN o
productivity NN o
and CC N
medical JJ o
resource NN o
utilization NN o
of IN N
peginterferon NN i
alpha NN i
2a CD i
vs IN N
the DT N
combination NN N
of IN N
interferon NN i
alpha NN i
2b CD i
plus CC i
ribavirin VB i
as IN N
initial JJ N
treatment NN N
in IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C. NNP N
The DT N
on-treatment JJ N
impact NN N
of IN N
interferon-based JJ N
therapies NNS N
on IN N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
, , o
work NN o
productivity NN o
, , o
and CC o
medical JJ o
resource NN o
utilization NN o
has VBZ N
not RB N
been VBN N
systematically RB N
studied VBN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
treatment NN N
with IN N
peginterferon NN i
alpha NN i
( ( i
pegIFNalpha NN i
) ) i
2a CD i
monotherapy NN i
and CC N
the DT N
combination NN i
of IN i
interferon NN i
alpha NN i
( ( i
IFNalpha NNP i
) ) i
2b CD i
plus CC i
ribavirin NN i
( ( i
RBV NNP i
) ) i
on IN N
health-related JJ o
QOL NNP o
, , o
work NN o
productivity NN o
and CC o
resource NN o
utilization NN o
. . o

A DT N
total NN N
of IN N
412 CD p
patients NNS p
with IN p
hepatitis NN p
C NNP p
infection NN p
were VBD N
randomized VBN N
to TO N
open-label JJ i
treatment NN i
with IN i
either DT i
pegIFNalpha NN i
2a CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
or CC i
IFNalpha $ i
2b/RBV CD i
( ( i
n JJ i
= NNP i
206 CD i
) ) i
. . i

PegIFNalpha $ i
2a CD i
was VBD N
administered VBN N
subcutaneously RB N
at IN N
a DT N
dose NN N
of IN N
180 CD N
microg NN N
once RB N
weekly JJ N
for IN N
48 CD N
weeks NNS N
; : N
and CC N
IFNalpha $ i
2b/RBV CD i
at IN N
doses NNS N
of IN N
3 CD N
MU NNP N
thrice JJ N
weekly RB N
subcutaneously RB N
and CC N
1000-1200 JJ N
mg/day NN N
orally RB N
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
SF-36 NNP o
Health NNP o
Survey NNP o
Questionnaire NNP o
and CC o
additional JJ o
generic NN o
and CC o
specific JJ o
scales NNS o
. . o

During IN N
treatment NN N
, , N
for IN N
all DT N
SF-36 NNP N
summary NN N
and CC N
Hepatitis NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
HQLQ NNP o
) ) o
-specific NN o
scales NNS o
, , N
the DT N
pegIFNalpha NN i
2a CD i
group NN N
experienced VBD N
less JJR N
impairment JJ N
than IN N
did VBD N
the DT N
IFNalpha NNP i
2b/RBV CD i
patients NNS N
. . N

The DT N
between-treatment JJ N
differences NNS N
were VBD N
significant JJ N
for IN N
many JJ N
of IN N
the DT N
scores NNS N
particularly RB N
in IN N
the DT N
first JJ N
24 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Across IN N
all DT N
measures NNS N
of IN N
work NN N
functioning NN N
and CC N
productivity NN N
at IN N
each DT N
visit NN N
, , N
patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
treatment NN N
showed VBD N
less RBR N
impairment JJ o
relative NN N
to TO N
the DT N
group NN N
treated VBD N
with IN N
IFNalpha NNP i
2b/RBV CD i
. . i

Hence NNP N
treatment NN N
with IN N
pegIFNalpha JJ i
2a CD i
relative JJ N
to TO N
IFNalpha NNP i
2b/RBV CD i
minimizes VBZ N
the DT N
adverse JJ N
impact NN N
of IN N
therapy NN N
on IN N
health-related JJ o
QOL NNP o
. . o

Patients NNS N
randomized VBD N
to TO N
pegIFNalpha VB i
2a CD i
had VBD N
improved VBN N
work NN o
productivity NN o
, , o
less JJR o
activity NN o
impairment NN o
, , o
decreased VBD o
need NN o
for IN o
prescription NN o
drugs NNS o
to TO o
treat VB o
adverse JJ o
effects NNS o
, , o
and CC o
better JJR o
adherence NN o
to TO o
therapy NN o
. . o

-DOCSTART- -X- O O

Anecortave NNP i
acetate NN i
treatment NN i
for IN N
retinal JJ p
angiomatous JJ p
proliferation NN p
: : p
a DT N
pilot NN N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
anecortave JJ i
acetate JJ i
treatment NN i
of IN N
retinal JJ p
angiomatous JJ p
proliferation NN p
( ( p
RAP NNP p
) ) p
, , N
a DT N
neovascular JJ N
form NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
, , N
with IN N
specific JJ N
regard NN N
to TO N
inhibition NN o
of IN o
neovascularization NN o
and CC o
maintenance NN o
of IN o
vision NN o
. . o

METHODS NNP N
Thirty-four JJ p
patients NNS p
with IN p
RAP NNP p
with IN p
any DT p
stage NN p
of IN p
neovascularization NN p
were VBD N
randomized VBN N
1:1:1 CD N
for IN N
treatment NN N
with IN N
three CD N
different JJ N
quantities NNS N
( ( N
30 CD N
mg NN N
, , N
15 CD N
mg NN N
, , N
3 CD N
mg NN N
) ) N
of IN N
anecortave NN i
acetate NN i
sterile JJ i
suspension NN i
for IN i
juxtascleral JJ i
administration NN i
. . i

Best-corrected JJ o
visual JJ o
acuity NN o
( ( o
Early JJ o
Treatment NNP o
Diabetic NNP o
Retinopathy NNP o
Study NNP o
chart NN o
) ) o
, , o
intraocular JJ o
pressure NN o
measurement NN o
, , o
biomicroscopy NN o
, , o
funduscopy NN o
, , o
digital JJ o
fluorescein NN o
, , o
and CC o
indocyanine NN o
green JJ o
angiography NN o
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

A DT N
6-month JJ N
retreatment NN N
interval NN N
was VBD N
established VBN N
for IN N
this DT N
study NN N
with IN N
a DT N
follow-up NN N
of IN N
12 CD N
months NNS N
. . N

In IN N
selected JJ N
patients NNS N
optical JJ N
coherence NN N
tomography NN N
was VBD N
performed VBN N
. . N

The DT N
outcomes NNS N
were VBD N
mean JJ o
changes NNS o
in IN o
visual JJ o
acuity NN o
and CC o
lesion NN o
size NN o
at IN o
1 CD o
year NN o
. . o

RESULTS VB N
The DT N
detachment NN o
of IN o
the DT o
neurosensory JJ o
retina NN o
and CC o
retinal JJ o
pigment NN o
epithelium NN o
improved VBN N
in IN N
all DT N
eyes NNS N
, , N
but CC N
all DT N
neovascular JJ o
lesions NNS o
increased VBD o
in IN o
size NN o
. . o

Vision NNP o
loss NN o
occurred VBD N
in IN N
the DT N
majority NN N
of IN N
study NN N
eyes NNS N
( ( N
22 CD N
out IN N
of IN N
34 CD N
eyes NNS N
, , N
64.7 CD N
% NN N
) ) N
independent JJ N
of IN N
the DT N
concentration NN N
administered VBD N
. . N

CONCLUSION NNP N
The DT N
results NNS N
suggest VBP N
that IN N
a DT N
posterior JJ N
juxtascleral JJ N
injection NN N
of IN N
anecortave JJ i
acetate NN i
reduces NNS N
capillary JJ o
permeability NN o
in IN N
patients NNS p
with IN p
RAP NNP p
. . p

However RB N
, , N
in IN N
spite NN N
of IN N
improvement NN N
of IN N
the DT N
exudation NN N
there EX N
is VBZ N
a DT N
progression NN N
of IN N
neovascularization NN o
and CC N
a DT N
significant JJ o
loss NN o
of IN o
vision NN o
in IN N
all PDT N
these DT N
patients NNS N
. . N

Like IN N
other JJ N
monotherapeutic JJ N
methods NNS N
used VBN N
to TO N
treat VB N
this DT N
variant NN N
of IN N
neovascular JJ N
age-related JJ N
macular JJ N
degeneration NN N
, , N
anecortave VBP i
acetate JJ i
alone RB N
does VBZ N
not RB N
appear VB N
to TO N
benefit VB N
these DT N
patients NNS N
. . N

Future JJ N
studies NNS N
should MD N
investigate VB N
a DT N
combination NN N
form NN N
of IN N
therapy NN N
. . N

-DOCSTART- -X- O O

Clinical JJ i
hypnosis NN i
versus NN i
cognitive JJ i
behavioral JJ i
training NN i
for IN N
pain NN o
management NN o
with IN N
pediatric JJ p
cancer NN p
patients NNS p
undergoing VBG p
bone NN p
marrow NN p
aspirations NNS p
. . p

A DT N
randomized JJ N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
clinical JJ i
hypnosis NN i
versus NN i
cognitive JJ i
behavioral NN i
( ( i
CB NNP i
) ) i
coping VBG i
skills NNS i
training VBG i
in IN N
alleviating VBG N
the DT N
pain NN o
and CC o
distress NN o
of IN N
30 CD p
pediatric JJ p
cancer NN p
patients NNS p
( ( p
age NN p
5 CD p
to TO p
15 CD p
years NNS p
) ) p
undergoing VBG p
bone NN p
marrow NN p
aspirations NNS p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
hypnosis NN i
, , i
a DT i
package NN i
of IN i
CB NNP i
coping VBG i
skills NNS i
, , i
and CC i
no DT i
intervention NN i
. . i

Patients NNS N
who WP N
received VBD N
either CC N
hypnosis NN N
or CC N
CB NNP N
reported VBD N
less JJR N
pain NN o
and CC o
pain-related JJ o
anxiety NN o
than IN N
did VBD N
control VB N
patients NNS N
and CC N
less JJR N
pain NN o
and CC o
anxiety NN o
than IN N
at IN N
their PRP$ N
own JJ N
baseline NN N
. . N

Hypnosis NNP N
and CC N
CB NNP N
were VBD N
similarly RB N
effective JJ N
in IN N
the DT N
relief NN o
of IN o
pain NN o
. . o

Results NNP N
also RB N
indicated VBD N
that IN N
children NNS N
reported VBD N
more RBR N
anxiety NN o
and CC N
exhibited VBD N
more RBR N
behavioral JJ o
distress NN o
in IN N
the DT N
CB NNP N
group NN N
than IN N
in IN N
the DT N
hypnosis NN N
group NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
hypnosis NN N
and CC N
CB NNP N
coping VBG N
skills NNS N
are VBP N
effective JJ o
in IN N
preparing VBG o
pediatric JJ p
oncology NN p
patients NNS p
for IN N
bone NN N
marrow NN N
aspiration NN N
. . N

-DOCSTART- -X- O O

MDM2 NNP N
and CC N
Ki-67 NNP N
predict NN N
for IN N
distant JJ o
metastasis NN o
and CC o
mortality NN o
in IN N
men NNS p
treated VBN p
with IN p
radiotherapy NN i
and CC p
androgen NN i
deprivation NN i
for IN p
prostate JJ p
cancer NN p
: : p
RTOG NNP N
92-02 CD N
. . N

PURPOSE NNP N
MDM2 NNP N
regulates VBZ N
p53 NN N
, , N
which WDT N
controls VBZ N
cell NN N
cycle NN N
arrest NN N
and CC N
apoptosis NN N
. . N

Both DT N
proteins NNS N
, , N
along IN N
with IN N
Ki-67 NNP N
, , N
which WDT N
is VBZ N
an DT N
established VBN N
strong JJ N
determinant NN N
of IN N
metastasis NN N
, , N
have VBP N
shown VBN N
promise NN N
in IN N
predicting VBG N
the DT N
outcome NN N
of IN N
men NNS N
treated VBN N
with IN N
radiation NN i
therapy NN i
( ( i
RT NNP i
) ) i
with IN i
or CC i
without IN i
short-term JJ i
androgen NN i
deprivation NN i
( ( i
STAD NNP i
) ) i
. . i

This DT N
report NN N
compares VBZ N
the DT N
utility NN N
of IN N
abnormal JJ N
expression NN N
of IN N
these DT N
biomarkers NNS N
in IN N
estimating VBG N
progression NN N
in IN N
a DT N
cohort NN N
of IN N
men NNS N
treated VBN N
on IN N
RTOG NNP N
92-02 CD N
. . N

PATIENTS NNPS N
AND CC N
METHODS NNP N
Adequate NNP N
tissue NN N
for IN N
immunohistochemistry NN N
was VBD N
available JJ N
for IN N
p53 NN N
, , N
Ki-67 NNP N
, , N
and CC N
MDM2 NNP N
analyses NNS N
in IN N
478 CD p
patient JJ p
cases NNS p
. . p

The DT N
percentage NN N
of IN N
tumor NN o
nuclei NN o
staining VBG o
positive JJ o
( ( N
PSP NNP N
) ) N
was VBD N
quantified VBN N
manually RB N
or CC N
by IN N
image NN N
analysis NN N
, , N
and CC N
the DT N
per-sample JJ o
mean JJ o
intensity NN o
score NN o
( ( o
MIS NNP o
) ) o
was VBD N
quantified VBN N
by IN N
image NN N
analysis NN N
. . N

Cox NNP N
regression NN N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
overall JJ o
mortality NN o
( ( o
OM NNP o
) ) o
, , N
and CC N
Fine NNP N
and CC N
Gray NNP N
's POS N
regressions NNS N
were VBD N
applied VBN N
to TO N
the DT N
end NN N
points NNS N
of IN N
distant JJ o
metastasis NN o
( ( o
DM NNP o
) ) o
and CC o
cause-specific JJ o
mortality NN o
( ( o
CSM NNP o
) ) o
. . o

Results NNS N
In IN N
multivariate JJ N
analyses NNS N
that WDT N
adjusted VBD N
for IN N
all DT N
markers NNS N
and CC N
treatment NN N
covariates NNS N
, , N
MDM2 NNP o
overexpression NN o
was VBD N
significantly RB N
related VBN N
to TO N
DM NNP o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
and CC N
OM NNP N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
and CC N
Ki-67 NNP o
overexpression NN o
was VBD N
significantly RB N
related VBN N
to TO N
DM NNP o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
CSM NNP o
( ( N
P NNP N
= NNP N
.0007 NNP N
) ) N
, , N
and CC N
OM NNP o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

P53 NNP o
overexpression NN o
was VBD N
significantly RB N
related VBN N
to TO N
OM NNP o
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

When WRB N
considered VBN N
in IN N
combination NN N
, , N
the DT N
overexpression NN o
of IN o
both DT o
Ki-67 NNP o
and CC o
MDM2 NNP o
at IN N
high JJ N
levels NNS N
was VBD N
associated VBN N
with IN N
significantly RB o
increased VBN o
failure NN o
rates NNS o
for IN N
all DT N
end NN N
points NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
for IN N
DM NNP N
, , N
CSM NNP N
, , N
and CC N
OM NNP N
) ) N
. . N

CONCLUSION NNP N
Combined VBD N
MDM2 NNP o
and CC o
Ki-67 NNP o
expression NN o
levels NNS o
were VBD N
independently RB N
related VBN N
to TO N
distant JJ o
metastasis NN o
and CC o
mortality NN o
and CC N
, , N
if IN N
validated VBN N
, , N
could MD N
be VB N
considered VBN N
for IN N
risk NN N
stratification NN N
of IN N
patients NNS p
with IN p
prostate JJ p
cancer NN p
in IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN i
and CC i
calcium NN i
supplementation NN i
on IN N
arterial JJ o
blood NN o
pressure NN o
and CC o
sodium NN o
metabolism NN o
in IN N
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
potassium NN i
and CC i
calcium NN i
supplementation NN i
in IN N
table JJ N
salt NN N
on IN N
reduction NN N
of IN N
arterial JJ o
blood NN o
pressure NN o
and CC o
sodium NN o
metabolism NN o
in IN N
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
. . p

METHODS CC N
A DT N
single JJ N
blind NN N
placebo-controlled JJ i
trial NN N
was VBD N
carried VBN N
out RP N
for IN N
two CD N
years NNS N
in IN N
220 CD p
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
, , p
aged VBD p
18 CD p
- : p
22 CD p
years NNS p
, , p
who WP p
were VBD p
randomly RB p
divided VBN p
into IN p
supplementary JJ p
group NN p
( ( p
n JJ p
= NNP p
110 CD p
) ) p
and CC p
control NN p
group NN p
( ( p
n JJ p
= NNP p
110 CD p
) ) p
. . p

Each DT p
of IN p
the DT p
subjects NNS p
in IN p
the DT p
supplementary JJ p
group NN p
and CC p
their PRP$ p
family NN p
members NNS p
was VBD N
given VBN N
10 CD i
mmol NN i
of IN i
potassium NN i
and CC i
10 CD i
mmol NN i
of IN i
calcium NN i
mixed VBN i
in IN i
their PRP$ i
table JJ i
salt JJ i
daily RB N
for IN N
24 CD N
months NNS N
. . N

RESULTS NNP N
Night NNP o
urinary JJ o
sodium NN o
and CC o
potassium JJ o
excretion NN o
increased VBD N
( ( N
urinary JJ N
Na NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
urinary JJ N
K NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
blood NN o
pressure NN o
lowered VBN o
by IN N
5.3 CD N
mm NNS N
Hg/1.8 NNP N
mm NN N
Hg NNP N
in IN N
average NN N
from IN N
the DT N
baseline NN N
in IN N
the DT N
supplementary JJ N
group NN N
two CD N
years NNS N
after IN N
potassium NN i
and CC i
calcium NN i
supplementation NN i
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
control NN N
group NN N
increased VBN N
by IN N
( ( N
1.3/1.7 CD N
) ) N
mm NN N
Hg NNP N
. . N

CONCLUSIONS NNP N
Adequate NNP N
supplement NN i
of IN i
potassium NN i
and CC i
calcium NN i
in IN N
daily JJ N
table JJ N
salt NN N
intake NN N
was VBD N
an DT N
effective JJ N
way NN N
to TO N
prevent VB N
form NN o
hypertension NN o
and CC N
could MD N
promote VB N
their PRP$ N
urinary JJ o
sodium NN o
excretion NN o
and CC o
reduction NN o
of IN o
arterial JJ o
blood NN o
pressure NN o
in IN N
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
self-administered JJ i
vaginal JJ i
misoprostol NN i
versus NN N
placebo NN i
for IN N
cervical JJ N
ripening VBG N
prior JJ N
to TO N
operative JJ N
hysteroscopy NN N
using VBG N
a DT N
sequential JJ N
trial NN N
design NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
impact NN N
of IN N
1000-microgram JJ N
self-administered JJ i
vaginal JJ i
misoprostol NN i
versus IN N
self-administered JJ i
vaginal JJ i
placebo NN i
at IN N
home NN N
on IN N
preoperative JJ N
cervical JJ N
ripening NN N
in IN N
both DT N
premenopausal NN p
and CC p
postmenopausal JJ p
women NNS p
prior RB p
to TO p
outpatient VB p
resectoscopy NN p
. . p

DESIGN NNP N
Randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
sequential JJ N
trial NN N
. . N

SETTING NN N
Norwegian JJ p
university NN p
teaching VBG p
hospital NN p
. . p

SAMPLE NNP N
Premenopausal NNP p
and CC p
postmenopausal JJ p
women NNS p
referred VBD p
to TO p
outpatient VB p
resectoscopy NN p
. . p

METHODS NNP N
The DT N
women NNS N
were VBD N
randomised VBN N
to TO N
either DT N
1000 CD N
micrograms NNS N
of IN N
self-administered JJ i
vaginal JJ i
misoprostol NN i
or CC N
self-administered JJ i
vaginal JJ i
placebo NN i
the DT N
evening NN N
before IN N
outpatient JJ N
resectoscopy NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Preoperative NNP o
cervical JJ o
dilatation NN o
, , o
acceptability NN o
and CC o
complications NNS o
. . o

RESULTS NNP N
( ( N
a DT N
) ) N
Intraoperative JJ N
findings NNS N
and CC N
distribution NN N
of IN o
cervical JJ o
dilatation NN o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
median JJ o
( ( o
range NN o
) ) o
or CC o
n JJ o
( ( o
% NN o
) ) o
. . o

( ( N
b NN N
) ) N
Acceptability NN o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
completely RB N
acceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
; : N
fairly RB N
acceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
; : N
fairly RB N
unacceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
and CC N
completely RB N
unacceptable JJ N
, , N
n JJ N
( ( N
% NN N
) ) N
. . N

( ( N
c NN N
) ) N
Pain NN o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Pain NNP o
was VBD N
measured VBN N
with IN N
a DT N
visual JJ N
analogue NN N
scale NN N
score NN N
, , N
scale JJ N
ranges NNS N
from IN N
0 CD N
( ( N
no DT N
pain NN N
) ) N
to TO N
10 CD N
( ( N
unbearable JJ N
pain NN N
) ) N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
median JJ N
( ( N
range NN N
) ) N
. . N

( ( N
d NN N
) ) N
Occurrence NN o
of IN o
adverse JJ o
effects NNS o
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Values NNS N
are VBP N
given VBN N
as IN N
n JJ N
( ( N
% NN N
) ) N
. . N

( ( N
e NN N
) ) N
Complications NNPS o
, , N
given VBN N
as IN N
n JJ N
( ( N
% NN N
) ) N
. . N

-DOCSTART- -X- O O

A DT N
first-in-man JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
feasibility NN o
of IN N
autologous JJ i
delipidated VBN i
high-density NN i
lipoprotein NN i
plasma NN i
infusions NNS i
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
. . p

OBJECTIVES CC N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
serial JJ i
autologous JJ i
infusions NNS i
of IN i
selective JJ i
high-density NN i
lipoprotein NN i
( ( i
HDL NNP i
) ) i
delipidated VBD i
plasma NN i
are VBP N
feasible JJ o
and CC N
well RB N
tolerated VBN o
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
( ( p
ACS NNP p
) ) p
. . p

BACKGROUND NNP N
Low NNP N
HDL NNP N
is VBZ N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Plasma NNP N
selective JJ N
delipidation NN N
converts NNS N
alphaHDL VBP N
to TO N
prebeta-like JJ N
HDL NNP N
, , N
the DT N
most RBS N
effective JJ N
form NN N
of IN N
HDL NNP N
for IN N
lipid JJ N
removal NN N
from IN N
arterial JJ N
plaques NNS N
. . N

METHODS NNP N
ACS NNP p
patients NNS p
undergoing VBG p
cardiac JJ p
catheterization NN p
with IN p
> NNP p
or=1 VBP p
nonobstructive JJ p
native JJ p
coronary JJ p
artery NN p
atheroma NN p
were VBD N
randomized VBN N
to TO N
either DT N
7 CD N
weekly JJ N
HDL NNP i
selective NN i
delipidated VBD i
or CC i
control VB i
plasma JJ i
apheresis/reinfusions NNS i
. . i

Patients NNS N
underwent JJ N
intravascular JJ o
ultrasound NN o
( ( o
IVUS NNP o
) ) o
evaluation NN o
of IN N
the DT N
target NN N
vessel NN N
during IN N
the DT N
catheterization NN N
for IN N
ACS NNP N
and CC N
up RB N
to TO N
14 CD N
days NNS N
following VBG N
the DT N
final JJ N
apheresis/reinfusion NN i
session NN N
. . N

2-D JJ N
gel JJ N
electrophoresis NN N
of IN N
delipidated JJ N
plasmas NN N
established VBN N
successful JJ N
conversion NN N
of IN N
alphaHDL NN N
to TO N
prebeta-like JJ N
HDL NNP N
. . N

The DT N
trial NN N
was VBD N
complete JJ N
with IN N
28 CD p
patients NNS p
randomized VBN N
. . N

RESULTS NNP N
All DT N
reinfusion NN N
sessions NNS N
were VBD N
tolerated VBN o
well RB N
by IN N
all DT N
patients NNS N
. . N

The DT N
levels NNS o
of IN o
prebeta-like JJ o
HDL NNP o
and CC o
alphaHDL NN o
in IN N
the DT N
delipidated JJ N
plasma NN N
converted VBD N
from IN N
5.6 CD N
% NN N
to TO N
79.1 CD N
% NN N
and CC N
92.8 CD N
% NN N
to TO N
20.9 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
IVUS NNP N
data NNS N
demonstrated VBD N
a DT N
numeric JJ N
trend NN N
toward IN N
regression NN N
in IN N
the DT N
total JJ N
atheroma NN o
volume NN o
of IN N
-12.18 JJ N
+/- JJ N
36.75 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
delipidated JJ N
group NN N
versus VBD N
an DT N
increase NN N
of IN N
total JJ o
atheroma JJ o
volume NN o
of IN N
2.80 CD N
+/- JJ N
21.25 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.268 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN p
ACS NNP p
patients NNS p
, , N
serial JJ N
autologous JJ N
infusions NNS N
of IN N
selective JJ i
HDL NNP i
delipidated VBD i
plasma NNS i
are VBP N
clinically RB o
feasible JJ o
and CC N
well RB N
tolerated VBN o
. . o

This DT N
therapy NN N
may MD N
offer VB N
a DT N
novel JJ N
adjunct JJ N
treatment NN N
for IN N
patients NNS p
presenting VBG p
with IN p
ACS NNP p
. . p

Further NNP N
study NN N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
its PRP$ N
ability NN N
to TO N
reduce VB N
clinical JJ o
cardiovascular JJ o
events NNS o
. . o

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
surgical JJ N
trauma NN N
and CC N
insulin NN i
on IN N
whole-body NN o
protein NN o
turnover NN o
in IN N
parenterally-fed JJ p
undernourished JJ p
patients NNS p
. . p

Ten CD p
undernourished JJ p
patients NNS p
receiving VBG p
total JJ p
parenteral JJ p
nutrition NN p
and CC p
undergoing JJ p
major JJ p
intestinal JJ p
surgery NN p
were VBD N
restarted VBN N
on IN N
intravenous JJ N
feeds NNS N
identical JJ N
to TO N
their PRP$ N
pre-operative JJ N
regimens NNS N
within IN N
24 CD N
h NNS N
of IN N
their PRP$ N
operation NN N
. . N

Five CD N
, , N
chosen VBN N
at IN N
random NN N
, , N
received VBD N
post-operatively RB N
1-2 JJ i
units NNS i
insulin/kg VBP i
body NN i
weight/24 JJ i
h NN i
with IN i
their PRP$ i
feed NN i
, , N
while IN N
the DT N
other JJ N
five CD N
received VBD i
the DT i
feed NN i
only RB i
. . i

Pre-operatively RB N
, , N
and CC N
2 CD N
h NN N
after IN N
commencing VBG N
their PRP$ N
post-operative JJ N
feeds NNS N
, , N
rates NNS o
of IN o
whole-body NN o
protein NN o
synthesis NN o
and CC o
breakdown NN o
were VBD N
measured VBN N
over IN N
a DT N
9-h JJ N
period NN N
following VBG N
intravenous JJ N
injection NN N
of IN N
a DT N
single JJ N
tracer NN N
dose NN N
of IN N
15N-glycine JJ i
by IN N
the DT N
ammonia NN N
and CC N
urea JJ N
end-product NN N
methods NNS N
. . N

During IN N
these DT N
9-h CD N
study NN N
periods NNS N
measurements NNS N
were VBD N
also RB N
made VBN N
of IN N
blood NN o
glucose NN o
, , o
plasma JJ o
insulin NN o
and CC o
glucagon NN o
, , o
urinary JJ o
ammonia NN o
, , o
nitrogen NN o
, , o
creatinine NN o
and CC o
3-methylhistidine JJ o
. . o

Blood NNP o
glucose NN o
and CC o
plasma JJ o
insulin NN o
and CC o
glucagon NN o
concentrations NNS o
rose VBD N
post-operatively RB N
whether IN N
or CC N
not RB N
insulin NN i
was VBD N
given VBN N
, , N
but CC N
the DT N
increment NN N
in IN N
insulin NN o
concentration NN o
was VBD N
significantly RB N
greater JJR N
when WRB N
insulin NN i
was VBD N
given VBN N
. . N

Apparent JJ o
nitrogen NN o
balance NN o
was VBD N
positive JJ N
pre-operatively RB N
and CC N
became VBD N
less RBR N
so RB N
post-operatively RB N
whether IN N
insulin NN i
was VBD N
given VBN N
or CC N
not RB N
. . N

Similarly RB N
, , N
post-operative JJ N
increments NNS N
in IN N
urinary JJ o
excretion NN o
of IN o
ammonia NN o
, , o
creatinine NN o
and CC o
3-methylhistidine JJ o
were VBD N
not RB N
altered VBN N
by IN N
addition NN N
of IN N
insulin NN i
. . i

Protein NNP o
turnover NN o
, , N
as IN N
estimated VBN N
by IN N
the DT N
ammonia JJ o
end-product NN o
method NN N
, , N
tended VBD N
to TO N
rise VB N
post-operatively RB N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
increases NNS N
observed VBD N
with IN N
or CC N
without IN N
insulin NN i
. . i

The DT N
urea JJ N
end-product NN N
method NN N
suggested VBD N
that IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
whole-body NN o
protein NN o
turnover NN o
after IN N
surgery NN N
, , N
whether IN N
or CC N
not RB N
insulin NN i
was VBD N
given VBN N
. . N

This DT N
study NN N
does VBZ N
not RB N
support VB N
the DT N
clinical JJ N
use NN N
of IN N
insulin NN o
as IN N
a DT N
means NN N
of IN N
modifying VBG N
protein JJ N
metabolic JJ N
losses NNS N
after IN N
major JJ p
surgery NN p
. . p

-DOCSTART- -X- O O

Approval JJ N
summary NN N
: : N
imatinib JJ i
mesylate NN o
in IN N
the DT N
treatment NN N
of IN N
metastatic JJ p
and/or NN p
unresectable JJ p
malignant JJ p
gastrointestinal JJ o
stromal JJ o
tumors NNS o
. . o

The DT N
purpose NN N
of IN N
the DT N
present JJ N
application NN N
was VBD N
to TO N
fulfill VB N
a DT N
postmarketing NN N
commitment NN N
to TO N
provide VB N
long-term JJ N
efficacy NN N
and CC N
safety NN N
data NNS N
on IN N
treatment NN N
with IN N
imatinib JJ o
mesylate NN o
( ( N
Gleevec NNP N
; : N
Novartis NNP N
Pharmaceuticals NNP N
, , N
East NNP N
Hanover NNP N
, , N
NJ NNP N
) ) N
in IN N
patients NNS p
with IN p
CD117 NNP p
( ( p
+ NNP p
) ) p
unresectable JJ p
and/or JJ p
metastatic JJ p
malignant JJ p
gastrointestinal JJ p
stromal NN p
tumors NNS p
( ( p
GISTs NNP p
) ) p
. . p

In IN N
addition NN N
, , N
this DT N
application NN N
also RB N
provides VBZ N
evidence NN N
to TO N
support VB N
a DT N
change NN N
in IN N
the DT N
label NN N
to TO N
allow VB N
for IN N
an DT N
escalation NN N
of IN N
imatinib NN o
dosing VBG N
to TO N
800 CD N
mg/day NN N
for IN N
patients NNS p
with IN p
progressive JJ p
disease NN p
on IN p
a DT p
lower JJR p
dose NN p
. . p

Two CD N
open-label JJ N
, , N
controlled VBN N
, , N
multicenter NN N
, , N
intergroup NN N
, , N
international JJ N
, , N
randomized JJ N
phase NN N
III NNP N
studies NNS N
were VBD N
submitted VBN N
-- : N
one CD N
conducted VBN N
by IN N
the DT N
European JJ p
Organization NNP p
for IN p
Research NNP p
and CC p
Treatment NNP p
of IN p
Cancer NNP o
( ( p
n JJ p
= NNP p
946 CD p
) ) p
and CC p
the DT p
other JJ p
by IN p
the DT p
Southwest NNP p
Oncology NNP o
Group NNP p
( ( p
n JJ p
= NNP p
746 CD p
) ) p
. . p

These DT N
studies NNS N
compared VBN N
400 CD N
mg/day NN N
of IN N
imatinib NN o
with IN N
800 CD N
mg/day NN N
of IN N
imatinib NN o
. . o

A DT N
combined JJ N
analysis NN N
of IN N
the DT N
two CD N
studies NNS N
was VBD N
prospectively RB N
defined VBN N
and CC N
agreed VBN N
to TO N
by IN N
both DT N
groups NNS N
. . N

Both DT N
protocols NNS N
allowed VBD N
patients NNS N
randomized VBN N
to TO N
the DT N
400-mg/day JJ N
imatinib NN i
arm NN N
to TO N
cross VB N
over IN N
to TO N
800 CD N
mg/day NN N
imatinib NN o
at IN N
progression NN N
. . N

Objective JJ N
responses NNS N
were VBD N
achieved VBN N
in IN N
> JJ N
50 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
either CC N
imatinib JJ o
dose NN N
. . N

The DT N
median JJ N
progression-free JJ o
survival NN o
time NN o
was VBD N
approximately RB N
20 CD N
months NNS N
and CC N
the DT N
median JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
time NN N
was VBD N
approximately RB N
49 CD N
months NNS N
. . N

In IN N
the DT N
combined JJ N
analysis NN N
, , N
347 CD N
patients NNS N
crossed VBN N
over IN N
to TO N
800 CD N
mg/day NN N
imatinib NN i
at IN N
the DT N
time NN N
of IN N
progression NN N
. . N

The DT N
median JJ o
OS NNP o
time NN N
after IN N
crossover NN N
was VBD N
14.3 CD N
months NNS N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
fluid JJ N
retention NN N
, , N
nausea NN o
, , o
fatigue NN o
, , o
skin JJ o
rash NN o
, , o
gastrointestinal JJ o
complaints NNS o
, , o
and CC o
myalgia NN o
. . o

The DT N
most RBS N
common JJ N
laboratory NN N
abnormality NN o
was VBD o
anemia VBN o
. . o

Most JJS N
often RB N
the DT N
AEs NNP o
were VBD N
of IN N
mild-to-moderate JJ N
severity NN N
. . N

Fluid NNP N
retention NN N
events NNS N
and CC N
skin JJ N
rash NN N
were VBD N
numerically RB N
reported VBN N
more RBR N
often RB N
in IN N
the DT N
800-mg/day JJ N
treatment NN N
cohort NN N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
acarbose NN i
on IN N
additional JJ N
insulin NN i
therapy NN i
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
late JJ p
failure NN p
of IN p
sulphonylurea JJ p
therapy NN p
. . p

AIM VB N
The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
acarbose NN i
on IN N
insulin NN o
requirements NNS o
and CC N
glycaemic JJ o
control NN o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
receiving VBG p
exogenous JJ p
insulin NN i
due JJ p
to TO p
secondary JJ p
failure NN p
of IN p
maximum NN p
dose JJ p
sulphonylurea JJ p
therapy NN p
. . p

METHODS VB N
A DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
was VBD N
performed VBN N
in IN N
48 CD p
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
late-term JJ p
failure NN p
following VBG p
at IN p
least JJS p
3 CD p
years NNS p
of IN p
sulphonylurea JJ i
therapy NN p
requiring VBG p
additional JJ p
insulin NN i
therapy NN p
to TO p
determine VB p
the DT p
impact NN p
of IN p
acarbose NN i
on IN p
glycaemic JJ p
control NN p
and CC p
insulin NN p
requirements NNS p
. . p

The DT N
primary JJ N
end NN N
points NNS N
were VBD N
glycaemic JJ o
response NN o
rate NN o
( ( N
responders NNS N
being VBG N
predefined VBN N
as IN N
patients NNS N
who WP N
achieve VBP N
a DT N
decrease NN N
in IN N
HbA1c NNP N
to TO N
less JJR N
than IN N
8 CD N
% NN N
or CC N
a DT N
reduction NN N
by IN N
at IN N
least JJS N
15 CD N
% NN N
as IN N
compared VBN N
to TO N
the DT N
baseline NN N
values NNS N
) ) N
and CC N
the DT N
daily JJ o
insulin NN o
dose NN o
at IN N
6 CD N
months NNS N
. . N

Secondary JJ N
parameters NNS N
assessed VBD N
included VBN N
postprandial JJ o
changes NNS o
in IN o
blood NN o
glucose NN o
, , o
serum JJ o
insulin NN o
and CC o
C-peptide NNP o
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS CC N
There EX N
were VBD N
significantly RB N
more JJR N
responders NNS N
in IN N
the DT N
acarbose-treated JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
20/24 CD N
patients NNS N
vs. FW N
10/19 CD N
patients NNS N
; : N
p VB N
< $ N
0.05 CD N
) ) N
. . N

The DT N
mean JJ o
daily JJ o
insulin NN o
dose NN o
after IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
was VBD N
16.4 CD N
+/- JJ N
10.1 CD N
IU NNP N
in IN N
the DT N
acarbose JJ i
group NN N
and CC N
22.4 CD N
+/- JJ N
12.2 CD N
IU NNP N
in IN N
the DT N
placebo NN i
group NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

; : N
p JJ N
< NNP N
0.07 CD N
) ) N
. . N

Postprandial JJ o
increases NNS o
in IN o
blood NN o
glucose NN o
, , o
insulin NN o
and CC o
C-peptide NNP o
were VBD N
consistently RB N
lower JJR N
in IN N
the DT N
acarbose-treated JJ N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

For IN N
example NN N
, , N
the DT N
mean JJ o
increase NN o
in IN o
2-h JJ o
postprandial JJ o
serum NN o
insulin NN o
remained VBD N
almost RB N
unchanged JJ N
in IN N
the DT N
acarbose JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
of IN N
treatment NN N
compared VBN N
to TO N
an DT N
increase NN N
to TO N
43 CD N
+/- JJ N
29 CD N
microU/ml NN N
( ( N
mean JJ N
+/- JJ N
s.d NN N
. . N

) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
for IN N
the DT N
placebo NN i
group NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
the DT N
addition NN N
of IN N
acarbose NN i
to TO N
sulphonylurea/insulin VB i
combination NN i
therapy NN i
can MD N
improve VB N
glycaemic JJ o
control NN o
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
. . p

Acarbose NNP i
may MD N
also RB N
reduce VB N
insulin NN o
resistance NN o
and CC o
hyperinsulinaemia NN o
. . o

-DOCSTART- -X- O O

Efficacy NN N
of IN N
intravenous JJ N
granisetron NN i
to TO N
control VB N
nausea NN N
and CC N
vomiting VBG N
during IN N
multiple JJ N
cycles NNS N
of IN N
cisplatin-based JJ i
chemotherapy NN i
. . i

The DT N
safety NN N
and CC N
efficacy NN N
of IN N
granisetron NN i
( ( N
10 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
) ) N
were VBD N
evaluated VBN N
during IN N
a DT N
second JJ N
( ( N
n JJ N
= NNP N
393 CD N
) ) N
and CC N
third JJ N
( ( N
n JJ N
= NNP N
200 CD N
) ) N
cycle NN N
of IN N
chemotherapy NN N
in IN N
this DT N
multicenter NN p
, , p
double-blind NN p
, , p
randomized VBN p
, , p
parallel-group JJ p
study NN p
. . p

Granisetron NNP i
was VBD N
administered VBN N
as IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
before IN N
the DT N
start NN N
of IN N
cisplatin NN i
chemotherapy NN i
( ( p
> CD p
or CC p
= VB p
60 CD p
mg/m2 NN p
) ) p
. . p

Total JJ o
control NN o
( ( o
no DT o
vomiting NN o
, , o
no DT o
retching NN o
, , o
no DT o
nausea NN o
, , o
and CC o
no DT o
use NN o
of IN o
antiemetic JJ o
rescue NN o
medication NN o
) ) o
after IN o
the DT o
first JJ o
24 CD o
hr NN o
following VBG N
chemotherapy NN i
was VBD N
achieved VBN N
in IN N
40 CD p
% NN p
and CC p
49 CD p
% NN p
of IN p
patients NNS p
in IN p
Cycles NNP p
2 CD p
and CC p
3 CD p
, , p
respectively RB p
, , p
for IN p
the DT p
10 CD p
micrograms/kg NN p
group NN p
, , p
and CC p
in IN p
42 CD p
% NN p
and CC p
38 CD p
% NN p
of IN p
patients NNS p
in IN p
Cycles NNP p
2 CD p
and CC p
3 CD p
, , p
respectively RB p
, , p
for IN p
the DT p
40 CD p
micrograms/kg NN p
group NN p
. . p

Both DT N
dose JJ o
levels NNS o
of IN o
granisetron NN o
were VBD N
well RB N
tolerated VBN o
. . o

The DT N
results NNS N
demonstrate VBP N
comparable JJ N
efficacy NN N
between IN N
the DT N
10 CD N
micrograms/kg NN N
and CC N
40 CD N
micrograms/kg NN N
doses NNS N
of IN N
granisetron NN i
in IN N
preventing VBG N
nausea NN o
and CC o
vomiting VBG o
during IN N
repeat NN N
cycles NNS N
of IN N
high-dose JJ p
cisplatin-based JJ i
chemotherapy NN i
. . i

The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
granisetron VBZ i
10 CD N
micrograms/kg NN N
is VBZ N
safe JJ N
and CC N
well RB N
tolerated VBN N
, , N
and CC N
remains VBZ N
effective JJ N
with IN N
repeat NN N
cycle NN N
use NN N
. . N

-DOCSTART- -X- O O

Chumnguh NNP N
thleum NN N
: : N
understanding JJ N
liver NN p
illness NN p
and CC p
hepatitis NN p
B NNP p
among IN p
Cambodian JJ p
immigrants NNS p
. . p

Cambodian JJ p
immigrants NNS p
are VBP N
over IN N
25 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
evidence NN N
of IN N
chronic JJ N
hepatitis NN N
B NNP N
infection NN N
than IN N
the DT N
general JJ N
US NNP N
population NN N
. . N

Carriers NNS N
of IN N
HBV NNP N
are VBP N
over IN N
100 CD N
times NNS N
more RBR N
likely JJ N
to TO N
develop VB N
liver RB N
cancer NN N
than IN N
non-carriers NNS N
. . N

Liver NNP N
cancer NN N
incidence NN N
is VBZ N
the DT N
second JJ N
leading JJ N
cancer NN N
for IN N
Cambodian JJ p
men NNS p
and CC p
the DT p
sixth JJ p
for IN p
Cambodian JJ p
women NNS p
. . p

Despite IN N
this DT N
, , N
this DT N
underserved JJ p
population NN p
has VBZ N
received VBN N
very RB N
little JJ N
attention NN N
from IN N
health NN N
disparities NNS N
researchers NNS N
. . N

Culturally NNP N
and CC N
linguistically RB N
appropriate JJ N
interventions NNS N
are VBP N
necessary JJ N
to TO N
increase VB N
hepatitis NN o
B NNP o
knowledge NN o
, , o
serologic JJ o
testing NN o
, , N
and CC N
vaccination NN o
among IN N
Cambodian JJ N
Americans NNPS N
. . N

Eight NNP i
group NN i
interviews NNS i
were VBD N
held VBN N
with IN N
Cambodian JJ p
American JJ p
men NNS p
( ( p
48 CD p
) ) p
and CC p
women NNS p
( ( p
49 CD p
) ) p
. . p

Focus NNP N
group NN N
discussion NN N
revealed VBD N
unanticipated JJ N
information NN N
about IN N
sociocultural JJ o
influences NNS o
on IN N
participants NNS o
' POS o
understanding VBG o
about IN o
hepatitis NN o
B NNP o
transmission NN o
, , o
disease NN o
course NN o
, , o
and CC o
prevention NN o
and CC o
treatment NN o
informed VBN N
by IN N
humoral JJ N
theories NNS N
underlying VBG N
Khmer NNP N
medicine NN N
, , N
by IN N
biomedicine NN N
, , N
and CC N
by IN N
migration NN N
experiences NNS N
. . N

Our PRP$ N
findings NNS N
reveal VBP N
the DT N
value NN N
of IN N
qualitative JJ N
exploration NN N
to TO N
providing VBG N
cultural JJ N
context NN N
to TO N
biomedical JJ N
information NN N
-- : N
a DT N
formula NN N
for IN N
effective JJ N
health NN N
promotion NN N
and CC N
practice NN N
. . N

-DOCSTART- -X- O O

Chlorhexidine-based JJ i
antiseptic JJ i
solution NN i
vs IN N
alcohol-based JJ i
povidone-iodine NN i
for IN N
central JJ N
venous JJ N
catheter NN N
care NN N
. . N

BACKGROUND NNP N
Although IN N
chlorhexidine-based JJ i
solutions NNS i
and CC N
alcohol-based JJ i
povidone-iodine NN i
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
efficient JJ N
than IN N
aqueous JJ N
povidone-iodine NN N
for IN N
skin JJ N
disinfection NN N
at IN N
catheter NN p
insertion NN p
sites NNS p
, , N
their PRP$ N
abilities NNS N
to TO N
reduce VB N
catheter-related JJ o
infection NN o
have VBP N
never RB N
been VBN N
compared VBN N
. . N

METHODS NNP N
Consecutively RB p
scheduled VBD p
central JJ p
venous JJ p
catheters NNS p
inserted VBN p
into IN p
jugular NN p
or CC p
subclavian JJ p
veins NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
be VB N
disinfected VBN N
with IN N
5 CD i
% NN i
povidone-iodine NN i
in IN i
70 CD i
% NN i
ethanol NN i
or CC i
with IN i
a DT i
combination NN i
of IN i
0.25 CD i
% NN i
chlorhexidine NN i
gluconate NN i
, , i
0.025 CD i
% NN i
benzalkonium NN i
chloride NN i
, , i
and CC i
4 CD i
% NN i
benzylic JJ i
alcohol NN i
. . i

Solutions NNS N
were VBD N
used VBN N
for IN N
skin JJ N
disinfection NN N
before IN N
catheter NN N
insertion NN N
( ( N
2 CD N
consecutive JJ N
30-second JJ N
applications NNS N
separated VBN N
by IN N
a DT N
period NN N
sufficiently RB N
long RB N
to TO N
allow VB N
for IN N
dryness NN N
) ) N
and CC N
then RB N
as IN N
single JJ N
applications NNS N
during IN N
subsequent JJ N
dressing NN N
changes NNS N
( ( N
every DT N
72 CD N
hours NNS N
, , N
or CC N
earlier RB N
if IN N
soiled VBN N
or CC N
wet VBN N
) ) N
. . N

RESULTS NNP N
Of IN N
538 CD p
catheters NNS p
randomized VBD p
, , p
481 CD p
( ( p
89.4 CD p
% NN p
) ) p
produced VBD p
evaluable JJ p
culture NN o
results NNS o
. . o

Compared VBN N
with IN N
povidone-iodine NN i
, , N
the DT N
chlorhexidine-based JJ i
solution NN i
was VBD N
associated VBN N
with IN N
a DT N
50 CD N
% NN N
decrease NN N
in IN N
the DT N
incidence NN o
of IN o
catheter NN o
colonization NN o
( ( N
11.6 CD N
% NN N
vs JJ N
22.2 CD N
% NN N
[ JJ N
P NNP N
= NNP N
.002 NNP N
] NNP N
; : N
incidence NN o
density NN o
, , N
9.7 CD N
vs NN N
18.3 CD N
per IN N
1000 CD N
catheter-days NN N
) ) N
and CC N
with IN N
a DT N
trend NN N
toward IN N
lower JJR N
rates NNS N
of IN N
catheter-related JJ o
bloodstream NN o
infection NN o
( ( N
1.7 CD N
% NN N
vs JJ N
4.2 CD N
% NN N
[ JJ N
P NNP N
= NNP N
.09 NNP N
] NNP N
; : N
incidence NN o
density NN o
, , N
1.4 CD N
vs NN N
3.4 CD N
per IN N
1000 CD N
catheter-days NN N
) ) N
. . N

Independent JJ N
risk NN N
factors NNS N
for IN N
catheter NN o
colonization NN o
were VBD N
catheter JJ N
insertion NN N
into IN N
the DT N
jugular JJ N
vein NN N
( ( N
adjusted VBN N
relative NN N
risk NN N
, , N
2.01 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.24-3.24 JJ N
) ) N
and CC N
use NN N
of IN N
povidone-iodine NN i
( ( N
adjusted VBN N
relative NN N
risk NN N
, , N
1.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.18-2.96 JJ N
) ) N
. . N

CONCLUSION NNP N
Chlorhexidine-based JJ i
solutions NNS i
should MD N
be VB N
considered VBN N
as IN N
a DT N
replacement NN N
for IN N
povidone-iodine NN i
( ( i
including VBG i
alcohol-based VBN i
) ) i
formulations NNS i
in IN N
efforts NNS N
to TO N
prevent VB N
catheter-related JJ o
infection NN o
. . o

-DOCSTART- -X- O O

Psychosocial JJ i
nursing NN i
therapy NN i
following VBG p
sudden JJ p
cardiac JJ p
arrest NN p
: : p
impact NN N
on IN N
two-year JJ o
survival NN o
. . o

BACKGROUND NNP N
Although IN N
psychosocial JJ i
therapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
mortality NN o
after IN N
myocardial JJ N
infarction NN N
, , N
it PRP N
is VBZ N
unknown JJ N
whether IN N
the DT N
benefits NNS N
of IN N
psychosocial JJ i
therapy NN i
on IN N
mortality NN o
reduction NN o
extend VBP N
to TO N
out-of-hospital JJ N
sudden JJ N
cardiac NN N
arrest NN N
, , N
a DT N
main JJ N
cause NN N
of IN N
cardiovascular JJ o
mortality NN o
. . o

OBJECTIVE NNP N
Describe NNP N
efficacy NN N
of IN N
psychosocial JJ i
therapy NN i
on IN N
two-year JJ N
cardiovascular JJ o
mortality NN o
in IN N
sudden JJ p
cardiac JJ p
arrest NN p
survivors NNS p
. . p

METHOD NNP N
Survivors NNPS p
of IN p
out-of-hospital JJ p
ventricular JJ p
fibrillation NN p
or CC p
asystole NN p
( ( p
N NNP p
= NNP p
129 CD p
) ) p
, , p
documented VBN p
by IN p
electrocardiograms NNS p
from IN p
registries NNS p
of IN p
a DT p
citywide NN p
Medic NNP p
One NNP p
unit NN p
and CC p
two CD p
countywide NN p
emergency NN p
units NNS p
, , N
were VBD N
randomized VBN N
into IN N
a DT N
two CD N
group NN N
, , N
experimental JJ N
, , N
longitudinal JJ N
design NN N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
11 CD N
individual JJ N
sessions NNS N
, , N
implementing VBG N
three CD N
components NNS N
: : N
physiologic JJ N
relaxation NN N
with IN N
biofeedback NN N
training NN N
focused VBD N
on IN N
altering VBG N
autonomic JJ N
tone NN N
; : N
cognitive JJ i
behavioral JJ i
therapy NN i
aimed VBN N
at IN N
self-management JJ N
and CC N
coping VBG N
strategies NNS N
for IN N
depression NN N
, , N
anxiety NN N
, , N
and CC N
anger NN N
; : N
and CC N
cardiovascular JJ N
health NN N
education NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
cardiovascular JJ o
mortality NN o
. . o

RESULTS NNP N
Risk NNP o
of IN o
cardiovascular JJ o
death NN o
was VBD N
significantly RB N
reduced VBN N
86 CD N
% NN N
by IN N
psychosocial JJ N
therapy NN N
, , N
p NN N
= NNP N
.03 NNP N
. . N

Six NNP N
of IN N
the DT N
seven CD N
cardiovascular JJ o
deaths NNS o
in IN N
the DT N
control NN N
group NN N
were VBD N
caused VBN N
by IN N
ventricular JJ N
arrhythmias NN N
. . N

The DT o
cardiovascular JJ o
death NN o
in IN N
the DT N
therapy NN N
group NN N
was VBD N
due JJ N
to TO N
stroke VB N
. . N

Controlling VBG N
for IN N
depression NN o
, , o
previous JJ o
myocardial JJ o
infarction NN o
, , o
low JJ o
ejection NN o
fraction NN o
, , o
decreased JJ o
heart NN o
rate NN o
variability NN o
, , o
and CC o
ventricular JJ o
ectopic NN o
beats NNS o
had VBD N
little JJ N
impact NN N
on IN N
estimated VBN N
treatment NN N
effect NN N
. . N

The DT N
risk NN o
of IN o
all-cause JJ o
mortality NN o
was VBD N
reduced VBN N
by IN N
62 CD N
% NN N
in IN N
the DT N
therapy NN N
group NN N
, , N
p VBP N
= JJ N
.13 NNP N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
three CD N
deaths NNS o
in IN N
the DT N
therapy NN N
group NN N
and CC N
eight CD N
deaths NNS o
in IN N
the DT N
control NN i
group NN N
. . N

CONCLUSIONS NNP N
Psychosocial NNP i
therapy NN i
significantly RB N
reduced VBD N
the DT N
risk NN N
of IN N
cardiovascular JJ o
death NN o
in IN N
sudden JJ p
cardiac JJ p
arrest NN p
survivors NNS p
. . p

-DOCSTART- -X- O O

Action NNP N
observation NN N
treatment NN N
improves VBZ N
recovery NN N
of IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
: : p
evidence NN N
for IN N
a DT N
top-down JJ N
effect NN N
? . N
OBJECTIVE UH N
To TO N
assess VB N
whether IN N
action NN i
observation NN i
treatment NN i
( ( i
AOT NNP i
) ) i
may MD N
also RB N
improve VB N
motor NN N
recovery NN N
in IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
, , N
in IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Department NNP N
of IN N
rehabilitation NN N
. . N

PARTICIPANTS JJ N
Patients NNPS p
( ( p
N=60 NNP p
) ) p
admitted VBD p
to TO p
our PRP$ p
department NN p
postorthopedic NN p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
case NN N
( ( N
n=30 NN N
) ) N
or CC i
control NN i
( ( N
n=30 JJ N
) ) N
group NN i
. . i

Exclusion NN p
criteria NNS p
were VBD p
age NN p
18 CD p
years NNS p
or CC p
younger JJR p
and CC p
90 CD p
years NNS p
or CC p
older JJR p
, , p
Mini-Mental JJ p
State NNP p
Examination NNP p
score NN p
of IN p
21 CD p
of IN p
30 CD p
or CC p
lower JJR p
, , p
no DT p
ambulating VBG p
order NN p
, , p
advanced JJ p
vision NN p
impairment NN p
, , p
malignancy NN p
, , p
pneumonia NN p
, , p
or CC p
heart NN p
failure NN p
. . p

INTERVENTIONS NNP N
All NNP N
participants NNS N
underwent JJ N
conventional JJ p
physiotherapy NN p
. . p

In IN N
addition NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB i
video JJ i
clips NNS i
showing VBG i
daily JJ i
actions NNS i
and CC i
to TO i
imitate VB i
them PRP i
afterward RB i
. . i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB i
video JJ i
clips NNS i
with IN i
no DT i
motor NN i
content NN i
and CC i
to TO i
execute VB i
the DT i
same JJ i
actions NNS i
as IN i
patients NNS i
in IN i
the DT i
case NN i
group NN i
afterward RB N
. . N

Participants NNS N
were VBD N
scored VBN N
on IN N
functional JJ N
scales NNS N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
by IN N
a DT N
physician NN N
blinded VBD N
to TO N
group NN N
assignment NN N
. . N

MAIN NNP N
OUTCOMES NNP N
MEASURES NNP N
Changes NNP o
in IN o
FIM NNP o
and CC o
Tinetti NNP o
scale NN o
scores NNS o
, , o
and CC o
dependence NN o
on IN o
walking VBG o
aids NNS o
. . o

RESULTS NNP N
At IN N
baseline NN N
, , N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
clinical JJ o
and CC o
functional JJ o
scale NN o
scores NNS o
. . o

After IN N
treatment NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
scored VBD N
better JJR N
than IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( o
FIM NNP o
total NN o
score NN o
, , N
P=.02 NNP N
; : N
FIM NNP o
motor NN o
subscore NN o
, , N
P=.001 NNP N
; : N
Tinetti NNP o
scale NN o
score NN o
, , N
P=.04 NNP N
) ) N
; : N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
assigned VBN N
more RBR N
frequently RB o
to TO o
1 CD o
crutch NN o
( ( N
P=.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
, , N
AOT NNP N
is VBZ N
effective JJ N
in IN N
the DT N
rehabilitation NN N
of IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
. . p

The DT N
present JJ N
results NNS N
strongly RB N
support VB N
top-down JJ N
effects NNS N
of IN N
this DT N
treatment NN N
in IN N
motor NN N
recovery NN N
, , N
even RB N
in IN N
nonneurologic JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
external JJ i
beam NN i
radiotherapy NN i
versus NN N
cryoablation NN i
in IN N
patients NNS p
with IN p
localized JJ p
prostate NN p
cancer NN p
: : p
quality NN N
of IN N
life NN N
outcomes NNS N
. . N

BACKGROUND VB N
A DT N
recent JJ N
randomized JJ N
trial NN N
to TO N
compare VB N
external JJ i
beam NN i
radiation NN i
therapy NN i
( ( i
EBRT NNP i
) ) i
to TO N
cryoablation NN N
for IN N
localized JJ N
disease NN N
showed VBD N
cryoablation NN N
to TO N
be VB N
noninferior JJ N
to TO N
external JJ i
beam NN i
EBRT NNP i
in IN N
disease NN N
progression NN N
and CC N
overall JJ N
and CC N
disease-specific JJ N
survival NN N
. . N

We PRP N
report VBP N
on IN N
the DT N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
outcomes VBZ N
for IN N
this DT N
trial NN N
. . N

METHODS NN N
From IN p
December NNP p
1997 CD p
through IN p
February NNP p
2003 CD p
, , p
244 CD p
men NNS p
with IN p
newly RB p
diagnosed VBN p
localized JJ p
prostate NN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
cryoablation NN i
or CC i
EBRT NNP i
( ( N
median JJ N
dose NN N
68 CD N
Gy NNP N
) ) N
. . N

All DT N
patients NNS N
received VBD N
neoadjuvant JJ i
antiandrogen NN i
therapy NN N
. . N

Patients NNS N
completed VBD N
the DT N
EORTC NNP N
QLQ NNP N
C30 NNP N
and CC N
the DT N
Prostate NNP N
Cancer NNP N
Index NNP N
( ( N
PCI NNP N
) ) N
before IN N
treatment NN N
and CC N
at IN N
1.5 CD N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
24 CD N
, , N
and CC N
36 CD N
months NNS N
post-treatment JJ N
. . N

RESULTS NNP N
Regardless NNP N
of IN N
treatment NN N
arm NN N
, , N
participants NNS N
reported VBD N
high JJ N
levels NNS N
of IN N
QOL NNP o
with IN N
few JJ N
exceptions NNS N
. . N

cryoablation NN o
was VBD N
associated VBN N
with IN N
more RBR N
acute JJ o
urinary JJ o
dysfunction NN o
( ( N
mean JJ N
PCI NNP N
urinary JJ N
function NN N
cryoablation=69.4 NN N
; : N
mean JJ N
EBRT=90.7 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
which WDT N
resolved VBD N
over IN N
time NN N
. . N

No DT o
late JJ o
arising NN o
QOL NNP o
issues NNS o
were VBD N
observed VBN N
. . N

Both DT N
EBRT NNP i
and CC N
cryoablation NN i
participants NNS N
reported VBD N
decreases NNS o
in IN o
sexual JJ o
function NN o
at IN N
3 CD N
months NNS N
with IN N
the DT N
cryoablation NN N
patients NNS N
reporting VBG N
poorer NN N
functioning NN N
( ( N
mean JJ N
cryoablation=7.2 NN N
: : N
mean JJ N
EBRT=32.9 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Mean JJ o
sexual JJ o
function NN o
score NN o
was VBD N
15 CD N
points NNS N
lower JJR N
at IN N
3 CD N
years NNS N
for IN N
the DT N
cryoablation NN i
group NN N
and CC N
13 CD N
% NN N
more JJR N
of IN N
the DT N
cryoablation NN i
men NNS N
said VBD N
that IN N
sexuality NN N
was VBD N
a DT N
moderate JJ N
or CC N
big JJ N
problem NN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
no DT N
long-term JJ N
QOL NNP o
advantage NN N
for IN N
either DT N
treatment NN N
was VBD N
apparent JJ N
with IN N
the DT N
exception NN N
of IN N
poorer JJR N
sexual JJ o
function NN o
reported VBN N
by IN N
those DT N
treated VBN N
with IN N
cryoablation NN i
. . i

Men NN N
who WP N
wish VBZ N
to TO N
increase VB N
their PRP$ N
odds NNS N
of IN N
retaining VBG N
sexual JJ o
function NN o
might MD N
be VB N
counseled VBN N
to TO N
choose VB N
EBRT NNP i
over IN N
cryoablation NN i
. . i

-DOCSTART- -X- O O

Deleterious JJ N
effects NNS N
of IN N
low-dose JJ i
oestrogen NN i
therapy NN i
on IN N
coronary JJ N
status NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
. . p

The DT N
effects NNS N
of IN N
oestrogen NN i
therapy NN i
and CC N
of IN N
orchidectomy NN i
on IN N
coronary JJ N
status NN N
, , N
as IN N
reflected VBN N
by IN N
exercise NN N
ECG-testing NN N
before IN N
and CC N
after IN N
one CD N
year NN N
of IN N
treatment NN N
, , N
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
study NN N
of IN N
patients NNS p
( ( p
N NNP p
= NNP p
100 CD p
) ) p
with IN p
prostatic JJ p
cancer NN p
. . p

Oestrogen NNP i
was VBD N
given VBN N
as IN N
polyestradiol NN i
phosphate NN i
80 CD N
mg NN N
i.m NN N
. . N

per IN N
month NN N
in IN N
combination NN N
with IN N
150 CD i
micrograms NNS i
ethinylestradiol JJ i
p.o NN N
. . N

per IN N
day NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
inter-group JJ N
differences NNS N
in IN N
conventional JJ N
risk NN N
factors NNS N
or CC N
in IN N
pre-treatment JJ N
exercise NN N
test NN N
results NNS N
. . N

Twelve NNP N
months NNS N
after IN N
the DT N
start NN N
of IN N
therapy NN N
the DT N
oestrogen NN N
group NN N
showed VBD N
a DT N
significantly RB N
greater JJR N
depression NN N
of IN N
the DT N
ST-segment NNP N
during IN N
maximal JJ N
exercise NN N
in IN N
leads NNS N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
compared VBN N
with IN N
the DT N
pre-treatment JJ N
depression NN N
. . N

Twenty-five JJ N
per IN N
cent NN N
( ( N
N NNP N
= NNP N
13 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
suffered VBD N
cardiovascular JJ o
complications NNS o
during IN N
the DT N
year NN N
of IN N
therapy NN N
, , N
whereas JJ N
no DT N
such JJ N
complications NNS N
were VBD N
observed VBN N
in IN N
the DT N
orchidectomy NN N
group NN N
. . N

However RB N
, , N
even RB N
the DT N
patients NNS N
in IN N
the DT N
oestrogen NN N
group NN N
who WP N
had VBD N
not RB N
suffered VBN N
cardiovascular JJ o
complications NNS o
had VBD N
significantly RB N
greater JJR N
depressions NNS o
of IN o
the DT o
ST-segment NNP o
during IN N
exercise NN N
both DT N
in IN N
lead NN N
CH2 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.0005 CD N
) ) N
and CC N
in IN N
CH5 NNP N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
change NN N
in IN N
the DT N
ST-segment JJ o
level NN o
in IN N
the DT N
orchidectomy NN N
group NN N
twelve VBD N
months NNS N
after IN N
surgery NN N
. . N

In IN N
summary JJ N
, , N
we PRP N
found VBD N
evidence NN N
of IN N
an DT N
induction NN N
of IN N
myocardial JJ o
ischaemia NN o
during IN N
treatment NN N
with IN N
exogenous JJ i
oestrogens NNS i
at IN N
low JJ N
dosage NN N
in IN N
patients NNS p
with IN p
prostatic JJ p
cancer NN p
. . p

This DT N
deleterious JJ N
effect NN N
of IN N
oestrogen NN i
on IN N
the DT N
coronary JJ N
status NN N
argues NNS N
against IN N
oestrogen NN N
therapy NN N
, , N
since IN N
oestrogen NN i
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
beneficial JJ N
than IN N
orchidectomy NN N
against IN N
prostatic JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O

Early JJ N
combination NN N
disease-modifying JJ N
antirheumatic JJ i
drug NN i
therapy NN i
and CC N
tight JJ N
disease NN N
control NN N
improve VB N
long-term JJ o
radiologic JJ o
outcome NN o
in IN N
patients NNS p
with IN p
early JJ p
rheumatoid NN p
arthritis NN p
: : p
the DT N
11-year JJ N
results NNS N
of IN N
the DT N
Finnish NNP N
Rheumatoid NNP N
Arthritis NNP N
Combination NNP N
Therapy NNP N
trial NN N
. . N

INTRODUCTION NNP N
Early NNP N
treatment NN N
of IN N
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
has VBZ N
been VBN N
shown VBN N
to TO N
retard VB N
the DT N
development NN o
of IN o
joint JJ o
damage NN o
for IN N
a DT N
period NN N
of IN N
up IN N
to TO N
5 CD N
years NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB o
the DT o
radiologic JJ o
progression NN o
beyond IN N
that DT N
time NN N
in IN N
patients NNS p
with IN p
early JJ p
RA NNP p
initially RB p
treated VBD p
with IN p
a DT p
combination NN p
of IN p
three CD i
disease-modifying JJ i
antirheumatic JJ i
drugs NNS i
( ( i
DMARDs NNP i
) ) i
or CC p
a DT p
single JJ i
DMARD NNP i
. . i

METHODS NNP N
A NNP N
cohort NN N
of IN N
199 CD p
patients NNS p
with IN p
early JJ p
active JJ p
RA NNP p
were VBD N
initially RB N
randomized VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
combination NN i
of IN i
methotrexate NN i
, , i
sulfasalazine NN i
, , i
and CC i
hydroxychloroquine NN i
with IN i
prednisolone NN i
( ( i
FIN-RACo NNP i
) ) i
, , i
or CC i
treatment NN i
with IN i
a DT i
single JJ i
DMARD NNP i
( ( i
initially RB i
, , i
sulfasalazine NN i
) ) i
with IN i
or CC i
without IN i
prednisolone NN i
( ( i
SINGLE NNP i
) ) i
. . i

After IN N
2 CD N
years NNS N
, , N
the DT N
drug-treatment JJ N
strategy NN N
became VBD N
unrestricted JJ N
, , N
but CC N
still RB N
targeted VBN N
remission NN N
. . N

The DT N
radiographs NN o
of IN N
hands NNS N
and CC N
feet NNS N
were VBD N
analyzed VBN o
by IN o
using VBG o
the DT o
Larsen NNP o
score NN o
at IN N
baseline NN N
, , N
2 CD N
, , N
5 CD N
, , N
and CC N
11 CD N
years NNS N
, , N
and CC N
the DT N
radiographs NN N
of IN N
large JJ N
joints NNS N
, , N
at IN N
11 CD N
years NNS N
. . N

RESULTS VB N
Sixty-five JJ N
patients NNS N
in IN N
the DT N
FIN-RACo NNP i
and CC N
65 CD N
in IN N
the DT N
SINGLE NNP i
group NN N
had VBD N
radiographs NN N
of IN N
hands NNS N
and CC N
feet NNS N
available JJ N
at IN N
baseline NN N
and CC N
at IN N
11 CD N
years NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
to TO N
11 CD N
years NNS N
in IN N
Larsen NNP o
score NN o
was VBD N
17 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
12 CD N
to TO N
26 CD N
) ) N
in IN N
the DT N
FIN-RACo NNP i
group NN N
and CC N
27 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
22 CD N
to TO N
33 CD N
) ) N
in IN N
the DT N
SINGLE NNP i
group NN N
( ( N
P=0.037 NNP N
) ) N
. . N

In IN N
total JJ N
, , N
87 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
74 CD N
to TO N
94 CD N
) ) N
and CC N
72 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
58 CD N
to TO N
84 CD N
) ) N
of IN N
the DT N
patients NNS N
in IN N
the DT N
FIN-RACo NNP N
and CC N
the DT N
SINGLE NNP N
treatment NN N
arms NNS N
, , N
respectively RB N
, , N
had VBD N
no DT N
erosive JJ o
changes NNS o
in IN N
large JJ N
joints NNS N
at IN N
11 CD N
years NNS N
. . N

CONCLUSIONS NNP N
Targeting VBG N
to TO N
remission NN N
with IN N
tight JJ N
clinical JJ N
controls NNS N
results NNS N
in IN N
low JJ N
radiologic JJ o
progression NN o
in IN N
most JJS N
RA JJ p
patients NNS p
. . p

Patients NNS N
treated VBD N
initially RB N
with IN N
a DT N
combination NN i
of IN i
DMARDs NNP i
have VBP N
less RBR N
long-term JJ o
radiologic NN o
damage NN o
than IN N
do VBP N
those DT N
treated VBN N
initially RB N
with IN N
DMARD NNP i
monotherapy NN i
. . i

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN18445519 NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
acupuncture NN i
combined VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
granules NNS i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
observe VB N
clinical JJ N
therapeutic JJ o
effect NN o
of IN N
acupuncture NN i
combined VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
for IN N
treatment NN N
of IN N
Alzheimer NNP N
's POS N
disease NN N
and CC N
its PRP$ N
effects NNS N
on IN N
intelligence NN o
, , o
daily JJ o
life NN o
and CC o
social JJ o
activity NN o
ability NN o
. . o

METHODS NNP N
Eighty-four JJ p
cases NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
, , p
28 CD p
cases NNS p
in IN p
each DT p
group NN p
. . p

The DT N
combined JJ N
acupuncture NN i
and CC N
medication NN N
group NN N
was VBD N
treated VBN N
with IN N
acupuncture NN i
at IN N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Dazhui NNP N
( ( N
GV NNP N
14 CD N
) ) N
, , N
Guanyuan NNP N
( ( N
CV NNP N
4 CD N
) ) N
, , N
etc FW N
. . N

and CC N
oral JJ N
administration NN N
of IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
; : i
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
treated VBN N
with IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
, , N
and CC N
the DT N
western JJ i
medicine NN i
group NN i
with IN N
oral JJ N
administration NN N
of IN N
Aricept NNP i
. . i

The DT N
scores NNS o
for IN o
the DT o
Mini-Mental JJ o
State NNP o
Examination NNP o
( ( o
MMSE NNP o
) ) o
, , o
Ability NNP o
of IN o
Daily NNP o
Life NNP o
( ( o
ADL NNP o
) ) o
and CC o
the DT o
therapeutic JJ o
effects NNS o
were VBD N
assessed VBN N
and CC N
compared VBN N
before IN N
treatment NN N
and CC N
after IN N
treatment NN N
for IN N
12 CD N
weeks NNS N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
scores NNS N
for IN N
MMSE NNP o
and CC o
ADL NNP o
were VBD N
improved VBN N
in IN N
the DT N
combined JJ i
acupuncture NN i
and CC i
medication NN i
group NN N
, , N
the DT N
Chinese JJ i
herb NN i
group NN N
and CC N
the DT N
western JJ i
medicine NN i
group NN N
, , N
which WDT N
were VBD N
better RBR N
in IN N
the DT N
combined JJ N
acupuncture NN i
and CC i
medication NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
total JJ o
effective JJ o
rate NN o
of IN N
85.7 CD N
% NN N
in IN N
the DT N
combined JJ i
acupuncture NN i
and CC i
medication NN i
group NN N
was VBD N
better JJR N
than IN N
71.4 CD N
% NN N
in IN N
the DT N
Chinese JJ N
herb NN N
group NN N
and CC N
67.9 CD N
% NN N
in IN N
the DT N
western JJ N
medicine NN N
group NN N
. . N

CONCLUSION NNP N
Acupuncture NNP i
combined VBN i
with IN i
Yizhi NNP i
Jiannao NNP i
Granules NNP i
has VBZ N
a DT N
significant JJ N
therapeutic JJ o
effect NN o
on IN N
Alzheimer NNP N
's POS N
disease NN N
, , N
which WDT N
is VBZ N
better JJR N
than IN N
that DT N
of IN N
Yizhi NNP i
Jiannao NNP i
Granules NNP i
or CC N
Aricept NNP i
. . i

-DOCSTART- -X- O O

[ JJ p
Branch NNP p
atheromatous JJ p
disease NN p
: : p
prognosis NN N
and CC N
management NN N
. . N

The DT N
SPS3 NNP i
experience NN N
] NN N
. . N

-DOCSTART- -X- O O

Comparative NNP N
dose NN N
efficacy NN o
study NN N
of IN N
atorvastatin JJ i
versus NN N
simvastatin NN i
, , i
pravastatin NN i
, , i
lovastatin NN i
, , i
and CC i
fluvastatin NN i
in IN N
patients NNS p
with IN p
hypercholesterolemia NN p
( ( N
the DT N
CURVES NNP N
study NN N
) ) N
The DT N
objective NN N
of IN N
this DT N
multicenter NN p
, , N
randomized VBN N
, , N
open-label JJ N
, , N
parallel-group JJ N
, , N
8-week JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
comparative JJ N
dose JJ N
efficacy NN N
of IN N
the DT N
3-hydroxy-3-methylglutaryl JJ i
coenzyme NN i
A NNP i
( ( i
HMG-CoA NNP i
) ) i
reductase NN i
inhibitor NN i
atorvastatin VBD i
10 CD i
, , i
20 CD i
, , i
40 CD i
, , i
and CC i
80 CD i
mg NNS i
compared VBN i
with IN i
simvastatin NN i
10 CD i
, , i
20 CD i
, , i
and CC i
40 CD i
mg NN i
, , i
pravastatin NN i
10 CD i
, , i
20 CD i
, , i
and CC i
40 CD i
mg NN i
, , i
lovastatin VBZ i
20 CD i
, , i
40 CD i
, , i
and CC i
80 CD i
mg NN i
, , i
and CC i
fluvastatin $ i
20 CD i
and CC i
40 CD i
mg. NN i
Investigators NNS N
enrolled VBD N
534 CD p
hypercholesterolemic JJ p
patients NNS p
( ( p
low-density JJ p
lipoprotein NN p
[ NNP p
LDL NNP p
] NNP p
cholesterol NN p
> NN p
or CC p
= $ p
160 CD p
mg/dl NN p
[ VBD p
4.2 CD p
mmol/L NN p
] NN p
and CC p
triglycerides NNS p
< VBP p
or CC p
= VBP p
400 CD p
mg/dl NN p
[ VBD p
4.5 CD p
mmol/L NNS p
] RB p
) ) p
. . p

The DT N
efficacy JJ N
end NN N
points NNS N
were VBD N
mean JJ N
percent NN N
change NN N
in IN N
plasma NN o
LDL NNP o
cholesterol NN o
( ( o
primary JJ o
) ) o
, , o
total JJ o
cholesterol NN o
, , o
triglycerides NNS o
, , o
and CC o
high-density NN o
lipoprotein NN o
cholesterol NN o
concentrations NNS o
from IN N
baseline NN N
to TO N
the DT N
end NN N
of IN N
treatment NN N
( ( N
week NN N
8 CD N
) ) N
. . N

Atorvastatin $ i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
produced VBN N
greater JJR N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.01 CD N
) ) N
reductions NNS N
in IN N
LDL NNP o
cholesterol NN o
, , N
-38 CD N
% NN N
, , N
-46 CD N
% NN N
, , N
and CC N
-51 NNP N
% NN N
, , N
respectively RB N
, , N
than IN N
the DT N
milligram JJ N
equivalent JJ N
doses NNS N
of IN N
simvastatin NN i
, , i
pravastatin NN i
, , i
lovastatin NN i
, , N
and CC N
fluvastatin NN i
. . i

Atorvastatin $ i
10 CD N
mg NN N
produced VBN N
LDL NNP o
cholesterol NN o
reductions NNS N
comparable JJ N
to TO N
or CC N
greater JJR N
than IN N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.02 CD N
) ) N
simvastatin NN i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
, , N
pravastatin NN i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
, , N
lovastatin CC i
20 CD N
and CC N
40 CD N
mg NN N
, , N
and CC N
fluvastatin $ i
20 CD N
and CC N
40 CD N
mg. NN N
Atorvastatin NNP i
10 CD N
, , N
20 CD N
, , N
and CC N
40 CD N
mg NN N
produced VBN N
greater JJR N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.01 CD N
) ) N
reductions NNS N
in IN N
total JJ o
cholesterol NN o
than IN N
the DT N
milligram JJ N
equivalent JJ N
doses NNS N
of IN N
simvastatin NN i
, , i
pravastatin NN i
, , i
lovastatin NN i
, , N
and CC N
fluvastatin NN i
. . i

All DT N
reductase NN N
inhibitors NNS N
studied VBD N
had VBD N
similar JJ N
tolerability NN o
. . o

There EX N
were VBD N
no DT N
incidences NNS N
of IN N
persistent JJ N
elevations NNS N
in IN N
serum NN o
transaminases NNS o
or CC o
myositis NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
music NN i
therapy NN i
group NN i
intervention NN i
on IN N
enhancing VBG N
social JJ o
skills NNS o
in IN N
children NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
Research NNP N
indicates VBZ N
that IN N
music NN i
therapy NN i
can MD N
improve VB N
social JJ N
behaviors NNS N
and CC N
joint JJ N
attention NN N
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
; : p
however RB N
, , N
more JJR N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
interventions NNS N
for IN N
social JJ o
skills NNS o
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
impact NN N
of IN N
group NN N
music NN N
therapy NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
music NN i
therapy NN i
group NN N
intervention NN N
on IN N
eye NN o
gaze NN o
, , o
joint JJ o
attention NN o
, , o
and CC o
communication NN o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

METHOD NNP N
Seventeen NNP p
children NNS p
, , p
ages VBZ p
6 CD p
to TO p
9 CD p
, , p
with IN p
a DT p
diagnosis NN p
of IN p
ASD NNP p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
music NN i
therapy NN i
group NN i
( ( i
MTG NNP i
) ) i
or CC p
the DT p
no-music JJ i
social JJ i
skills NNS i
group NN i
( ( i
SSG NNP i
) ) i
. . i

Children NNP N
participated VBD N
in IN N
ten JJ N
50-minute JJ N
group NN N
sessions NNS N
over IN N
a DT N
period NN N
of IN N
5 CD N
weeks NNS N
. . N

All DT N
group NN N
sessions NNS N
were VBD N
designed VBN N
to TO N
target VB N
social JJ N
skills NNS N
. . N

The DT N
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
the DT o
Autism NNP o
Treatment NNP o
Evaluation NNP o
Checklist NNP o
( ( o
ATEC NNP o
) ) o
, , o
and CC o
video JJ o
analysis NN o
of IN o
sessions NNS o
were VBD N
used VBN N
to TO N
evaluate VB N
changes NNS N
in IN N
social JJ N
behavior NN N
. . N

RESULTS CC N
There EX N
were VBD N
significant JJ N
between-group JJ N
differences NNS N
for IN N
joint JJ o
attention NN o
with IN o
peers NNS o
and CC o
eye NN o
gaze NN o
towards NNS o
persons NNS o
, , N
with IN N
participants NNS N
in IN N
the DT N
MTG NNP N
demonstrating NN N
greater JJR N
gains NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group NN N
differences NNS N
for IN N
initiation NN o
of IN o
communication NN o
, , o
response NN o
to TO o
communication NN o
, , o
or CC o
social JJ o
withdraw/behaviors NNS o
. . o

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
time NN N
and CC N
group NN N
for IN N
SRS NNP o
scores NNS o
, , N
with IN N
improvements NNS N
for IN N
the DT N
MTG NNP N
but CC N
not RB N
the DT N
SSG NNP N
. . N

Scores NNS o
on IN o
the DT o
ATEC NNP o
did VBD N
not RB N
differ VB N
over IN N
time NN N
between IN N
the DT N
MTG NNP i
and CC N
SSG NNP N
. . N

CONCLUSIONS NNP N
The DT N
results NNS N
of IN N
this DT N
study NN N
support VB N
further JJ N
research NN N
on IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
group NN N
interventions NNS N
for IN N
social JJ o
skills NNS o
in IN N
children NNS p
with IN p
ASD NNP p
. . p

Statistical JJ N
results NNS N
demonstrate VBP N
initial JJ N
support NN N
for IN N
the DT N
use NN N
of IN N
music NN N
therapy NN N
social JJ N
groups NNS N
to TO N
develop VB N
joint JJ o
attention NN o
. . o

-DOCSTART- -X- O O

Reputation NNP N
management NN N
: : N
evidence NN N
for IN N
ability NN N
but CC N
reduced JJ N
propensity NN o
in IN N
autism NN p
. . p

Previous JJ N
research NN N
has VBZ N
reported VBN N
that IN N
autistic JJ p
adults NNS p
do VBP N
not RB N
manage VB N
their PRP$ N
reputation NN N
, , N
purportedly RB N
due JJ N
to TO N
problems NNS N
with IN N
theory NN N
of IN N
mind NN N
[ NNP N
Izuma NNP N
, , N
Matsumoto NNP o
, , N
Camerer NNP N
, , N
& CC N
Adolphs NNP o
] NNP o
. . N

The DT N
current JJ N
study NN N
aimed VBD N
to TO N
test VB i
alternative JJ i
explanations NNS i
for IN N
this DT N
apparent JJ N
lack NN N
of IN N
reputation NN N
management NN N
. . N

Twenty NNP p
typical JJ p
and CC p
19 CD p
autistic JJ p
adults NNS p
donated VBD i
to TO i
charity NN i
and CC i
to TO i
a DT i
person NN i
, , p
both DT p
when WRB p
alone RB p
and CC N
when WRB N
observed VBN N
. . N

In IN N
an DT N
additional JJ N
manipulation NN N
, , N
for IN N
half NN N
of IN N
the DT N
participants NNS N
, , N
the DT N
observer NN N
was VBD N
also RB N
the DT N
recipient NN N
of IN N
their PRP$ N
donations NNS N
, , N
and CC N
participants NNS N
were VBD N
told VBN N
that IN N
this DT N
observer NN N
would MD N
subsequently RB N
have VB N
the DT N
opportunity NN N
to TO N
donate VB i
to TO N
them PRP N
( ( N
motivation NN N
condition NN N
) ) N
. . N

This DT N
manipulation NN N
was VBD N
designed VBN N
to TO N
encourage VB N
an DT N
expectation NN N
of IN N
a DT N
reciprocal JJ N
tit-for-tat NN o
strategy NN N
in IN N
the DT N
participant NN N
, , N
which WDT N
may MD N
motivate VB N
participants NNS N
to TO N
change VB N
their PRP$ N
behavior NN N
to TO N
receive VB N
more JJR N
donations NNS N
. . N

The DT N
remaining VBG N
participants NNS N
were VBD N
told VBN N
that IN N
the DT N
person NN N
watching NN N
was VBD N
just RB N
observing VBG N
the DT N
procedure NN N
( ( N
no DT N
motivation NN N
condition NN N
) ) N
. . N

Our PRP$ N
results NNS N
replicated VBD N
Izuma NNP o
et CC N
al NN N
. . N

's POS N
finding VBG N
that IN p
autistic JJ p
adults NNS p
did VBD p
not RB o
donate VB o
more JJR o
to TO o
charity NN o
when WRB o
observed VBN N
. . N

Yet CC N
, , N
in IN N
the DT N
motivation NN N
condition NN N
, , N
both DT N
typical JJ N
and CC N
autistic JJ N
adults NNS i
donated VBD i
significantly RB i
more RBR N
to TO N
the DT N
observer NN N
when WRB N
watched VBN N
, , N
although IN N
this DT N
effect NN N
was VBD N
significantly RB N
attenuated VBN N
in IN N
autistic JJ p
individuals NNS p
. . p

Results NNS N
indicate VBP N
that IN N
, , N
while IN p
individuals NNS p
with IN p
autism NN p
may MD p
have VB N
the DT N
ability NN N
to TO N
think VB N
about IN N
reputation NN N
, , N
a DT N
reduced JJ N
expectation NN N
of IN N
reciprocal JJ N
behavior NN N
from IN N
others NNS N
may MD N
reduce VB N
the DT N
degree NN N
to TO N
which WDT N
they PRP o
engage VBP o
in IN o
reputation NN N
management NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
recombinant JJ i
alpha JJ i
2b-interferon JJ i
with IN i
or CC i
without IN i
indomethacin NNS i
in IN N
patients NNS p
with IN p
metastatic JJ p
malignant JJ p
melanoma NN p
. . p

alpha-Interferon NN i
has VBZ N
antitumor VBN N
activity NN N
in IN N
a DT N
variety NN N
of IN N
malignancies NNS N
but CC N
is VBZ N
frequently RB N
associated VBN N
with IN N
unacceptable JJ N
toxic JJ o
side-effects NNS o
. . o

The DT N
routine JJ N
use NN N
of IN N
agents NNS N
potentially RB N
capable JJ N
of IN N
reducing VBG N
these DT N
side-effects NNS N
has VBZ N
not RB N
been VBN N
recommended VBN N
out IN N
of IN N
concern NN N
for IN N
possible JJ N
reductions NNS N
in IN N
the DT N
therapeutic JJ N
activity NN N
of IN N
interferon NN N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
alpha-interferon JJ N
given VBN N
with IN N
or CC N
without IN N
indomethacin JJ i
to TO N
patients NNS p
with IN p
malignant JJ p
melanoma NN p
to TO N
determine VB N
what WP N
effect NN N
, , N
if IN N
any DT N
, , N
indomethacin NN i
might MD N
have VB N
on IN N
the DT N
toxic NN o
, , o
immunomodulatory NN o
, , o
and CC o
therapeutic JJ o
properties NNS o
of IN N
interferon NN N
in IN N
this DT N
disease NN N
. . N

53 CD p
patients NNS p
were VBD p
stratified VBN p
according VBG p
to TO p
performance NN p
status NN p
and CC N
randomized VBN N
to TO N
receive VB N
alpha JJ i
2b-interferon CD i
, , N
20 CD N
million CD N
units NNS N
per IN N
m2 NN N
i.v. NN N
, , N
5 CD N
days NNS N
per IN N
week NN N
for IN N
4 CD N
weeks NNS N
followed VBN N
by IN N
10 CD N
million CD N
units NNS N
per IN N
m2 NN N
s.c. NN N
three CD N
times NNS N
per IN N
week NN N
, , N
either RB N
with IN N
or CC N
without IN N
indomethacin NN i
, , N
25 CD N
mg NN N
orally RB N
three CD N
times NNS N
a DT N
day NN N
. . N

The DT N
overall JJ o
major JJ o
response NN o
rate NN o
was VBD N
13 CD N
% NN N
( ( N
three CD N
complete JJ N
responders NNS N
and CC N
three CD N
partial JJ N
responders NNS N
among IN N
47 CD N
evaluable JJ N
patients NNS N
) ) N
and CC N
was VBD N
the DT N
same JJ N
on IN N
both DT N
arms NNS N
. . N

The DT N
mean JJ o
maximal JJ o
temperature NN o
elevation NN o
induced VBN N
by IN N
interferon NN N
was VBD N
significantly RB N
reduced VBN N
( ( N
from IN N
102.1 CD N
to TO N
100.7 CD N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
by IN N
indomethacin NN i
, , N
but CC N
the DT N
incidence NN o
and CC o
severity NN o
of IN o
interferon-related JJ o
fatigue NN o
, , o
reduction NN o
in IN o
performance NN o
status NN o
, , o
headache NN o
, , o
depression NN o
, , o
confusion NN o
, , o
elevations NNS o
in IN o
liver JJ o
function NN o
tests NNS o
, , o
and CC o
myelosuppression NN o
were VBD N
no DT N
different JJ N
in IN N
either DT N
arm NN N
of IN N
the DT N
study NN N
. . N

Indomethacin NNP i
did VBD N
not RB N
reduce VB N
the DT N
frequency NN o
of IN o
dose JJ o
reductions NNS o
for IN o
toxic JJ o
side-effects NNS o
and CC N
did VBD N
not RB N
permit VB N
the DT N
administration NN o
of IN o
higher JJR o
interferon NN o
doses NNS o
. . o

Peripheral NNP o
blood VBD o
natural JJ o
killer NN o
activity NN o
was VBD N
significantly RB N
enhanced VBN N
in IN N
patients NNS N
during IN N
maintenance NN N
therapy NN N
whether IN N
or CC N
not RB N
they PRP N
received VBD N
indomethacin NN N
. . N

Indomethacin NNP i
appeared VBD N
to TO N
inhibit VB N
augmentation NN o
of IN o
natural JJ o
killer NN o
activity NN o
during IN N
high JJ N
dose JJ N
induction NN N
therapy NN N
. . N

Immunological JJ o
changes NNS o
did VBD N
not RB N
correlate VB N
with IN N
response NN N
status NN N
. . N

We PRP N
conclude VBP N
that IN N
indomethacin NN N
can MD N
reduce VB N
the DT N
fever NN o
associated VBN N
with IN N
interferon NN N
therapy NN N
in IN N
patients NNS p
with IN p
malignant JJ p
melanoma NN p
without IN N
interfering VBG N
with IN N
its PRP$ N
therapeutic JJ o
or CC o
chronic JJ o
immunomodulatory NN o
activities NNS o
. . o

Since IN N
fever NN o
is VBZ N
rarely RB N
the DT N
dose-limiting JJ N
toxicity NN N
of IN N
interferon NN N
, , N
indomethacin NN i
is VBZ N
of IN N
marginal JJ N
benefit NN N
to TO N
patients NNS p
with IN p
malignant JJ p
melanoma NN p
receiving VBG N
interferon NN N
at IN N
the DT N
doses NNS N
outlined VBN N
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

LNH-84 JJ N
regimen NNS N
: : N
a DT N
multicenter NN N
study NN N
of IN N
intensive JJ N
chemotherapy NN N
in IN N
737 CD p
patients NNS p
with IN p
aggressive JJ p
malignant JJ p
lymphoma NN p
. . p

From IN p
July NNP p
1984 CD p
to TO p
September NNP p
1987 CD p
, , p
737 CD p
patients NNS p
with IN p
aggressive JJ p
malignant JJ p
lymphoma NN p
( ( p
ML NNP p
) ) p
were VBD N
treated VBN N
by IN N
an DT N
intensive JJ i
regimen NNS i
( ( i
LNH-84 NNP i
) ) i
comprising VBG N
three CD i
or CC i
four CD i
courses NNS i
of IN i
doxorubicin NN i
, , i
75 CD i
mg/m2 NN i
; : i
cyclophosphamide NN i
, , i
1,200 CD i
mg/m2 NN i
; : i
vindesine NN i
, , i
2 CD i
mg/m2 NN i
x NN i
2 CD i
; : i
bleomycin NN i
, , i
10 CD i
mg NN i
x NN i
2 CD i
; : i
and CC i
prednisolone NN i
, , i
60 CD i
mg/m2 NN i
x NN i
5 CD i
( ( i
ACVB NNP i
) ) i
, , i
consolidation NN i
with IN i
high-dose JJ i
methotrexate NN i
, , i
ifosfamide NN i
, , i
etoposide RB i
, , i
asparaginase NN i
, , i
and CC i
cytarabine NN i
, , i
and CC i
a DT i
randomized VBN i
late JJ i
intensification NN i
with IN i
two CD i
courses NNS i
of IN i
cytarabine NN i
, , i
cyclophosphamide NN i
, , i
teniposide NN i
, , i
bleomycin NN i
, , i
and CC i
prednisone NN i
( ( i
AraCVmB NNP i
) ) i
. . i

Four CD p
hundred VBD p
forty-two JJ p
patients NNS p
had VBD N
intermediate-grade JJ N
ML NNP N
, , N
221 CD N
highgrade NN N
ML NNP N
, , N
and CC N
74 CD N
unclassified JJ N
ML NNP N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
had VBD N
advanced JJ N
disease NN N
: : N
stage NN N
IIE NNP N
( ( N
23 CD N
% NN N
) ) N
, , N
III NNP N
( ( N
13 CD N
% NN N
) ) N
, , N
or CC N
IV NNP N
( ( N
47 CD N
% NN N
) ) N
; : N
38 CD N
% NN N
disseminated JJ N
nodes NNS N
; : N
38 CD N
% NN N
two CD N
or CC N
more JJR N
extranodal JJ N
sites NNS N
; : N
and CC N
41 CD N
% NN N
a DT N
tumoral JJ N
mass NN N
greater JJR N
than IN N
10 CD N
cm NN N
. . N

Five CD N
hundred VBD N
fifty-three JJ N
patients NNS N
( ( N
75 CD N
% NN N
) ) N
went VBD N
into IN N
complete JJ o
remission NN o
( ( o
CR NNP o
) ) o
, , N
63 CD N
( ( N
9 CD N
% NN N
) ) N
into IN N
partial JJ o
remission NN o
, , N
62 CD N
( ( N
8 CD N
% NN N
) ) N
failed VBD o
to TO o
respond VB o
, , N
and CC N
59 CD N
( ( N
8 CD N
% NN N
) ) N
died VBD o
during IN N
ACVB NNP N
courses NNS N
, , N
17 CD N
of IN N
them PRP N
from IN N
progression NN N
of IN N
the DT N
disease NN N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
23 CD N
months NNS N
, , N
the DT N
estimated VBN N
2-year JJ N
overall JJ o
survival NN o
time NN o
to TO o
failure NN o
( ( o
TTF NNP o
) ) o
, , N
and CC N
time NN o
to TO o
relapse VB o
( ( o
TTR NNP o
) ) o
survival NN o
are VBP N
67 CD N
% NN N
, , N
56 CD N
% NN N
, , N
and CC N
67 CD N
% NN N
, , N
respectively RB N
. . N

Patients NNS N
receiving VBG N
a DT N
late JJ N
intensification NN N
had VBD N
the DT N
same JJ N
relapse NN o
rate NN o
as IN N
the DT N
other JJ N
patients NNS N
. . N

A DT N
persistent JJ o
fibronecrotic JJ o
mass NN o
was VBD N
found VBN N
in IN N
150 CD N
patients NNS N
( ( N
20 CD N
% NN N
) ) N
and CC N
did VBD N
not RB N
influence VB N
the DT N
relapse NN o
rate NN o
. . o

Toxicity NNP o
was VBD N
mainly RB N
neutropenia JJ o
and CC N
infection NN o
during IN N
the DT N
ACVB NNP N
courses NNS N
, , N
with IN N
40 CD N
patients NNS N
( ( N
5 CD N
% NN N
) ) N
dying VBG o
from IN o
septic JJ o
complications NNS o
while IN N
responding VBG N
to TO N
treatment NN N
. . N

Fifty-three JJ N
percent NN N
of IN N
the DT N
patients NNS N
had VBD N
a DT N
neutropenia NN o
less JJR N
than IN N
0.500 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
, , N
58 CD N
% NN N
fever NN N
( ( N
6 CD N
% NN N
grade JJ N
4 CD N
) ) N
, , N
and CC N
49 CD N
% NN N
a DT N
documented JJ o
infection NN o
( ( N
8 CD N
% NN N
grade JJ N
4 CD N
) ) N
. . N

These DT N
results NNS N
obtained VBD N
with IN N
the DT N
LNH-84 JJ N
regimen NNS N
demonstrate VBP N
that IN N
this DT N
therapeutic JJ N
scheme NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
aggressive JJ N
ML NNP N
. . N

-DOCSTART- -X- O O

The DT N
aging VBG N
motor NN N
system NN N
as IN N
a DT N
model NN N
for IN N
plastic JJ N
changes NNS N
of IN N
GABA-mediated NNP N
intracortical JJ N
inhibition NN N
and CC N
their PRP$ N
behavioral JJ N
relevance NN N
. . N

Since IN N
GABAA-mediated JJ N
intracortical JJ N
inhibition NN N
has VBZ N
been VBN N
shown VBN N
to TO N
underlie VB N
plastic NN N
changes NNS N
throughout IN N
the DT N
lifespan NN N
from IN N
development NN N
to TO N
aging VBG N
, , N
here RB N
, , N
the DT N
aging VBG N
motor NN N
system NN N
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
analyze VB N
the DT N
interdependence NN N
of IN N
plastic JJ N
alterations NNS N
within IN N
the DT N
inhibitory JJ N
motorcortical JJ N
network NN N
and CC N
level NN N
of IN N
behavioral JJ N
performance NN N
. . N

Double-pulse JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
dpTMS NN i
) ) i
was VBD i
used VBN i
to TO i
examine VB i
inhibition NN i
by IN i
means NNS i
of IN i
short-interval JJ i
intracortical JJ i
inhibition NN i
( ( i
SICI NNP i
) ) i
of IN i
the DT i
contralateral JJ i
primary JJ i
motor NN i
cortex NN i
in IN N
a DT N
sample NN N
of IN N
64 CD p
healthy JJ p
right-handed JJ p
human JJ p
subjects NNS p
covering VBG p
a DT p
wide JJ p
range NN p
of IN p
the DT p
adult NN p
lifespan NN p
( ( p
age NN p
range NN p
20-88 CD p
years NNS p
, , p
mean VB p
47.6 CD p
? . p
20.7 CD p
, , p
34 CD p
female NN p
) ) p
. . p

SICI NNP o
was VBD N
evaluated VBN N
during IN N
resting VBG N
state NN N
and CC N
in IN N
an DT N
event-related JJ N
condition NN N
during IN N
movement NN N
preparation NN N
in IN N
a DT N
visually RB N
triggered VBN N
simple JJ N
reaction NN N
time NN N
task NN N
. . N

In IN N
a DT N
subgroup NN N
( ( N
N NNP N
= NNP N
23 CD N
) ) N
, , N
manual JJ o
motor NN o
performance NN o
was VBD N
tested VBN N
with IN N
tasks NNS N
of IN N
graded VBN N
dexterous JJ N
demand NN N
. . N

Weak JJ o
resting-state JJ o
inhibition NN o
was VBD N
associated VBN N
with IN N
an DT N
overall JJ N
lower JJR N
manual JJ N
motor NN N
performance NN N
. . N

Better RBR o
event-related JJ o
modulation NN o
of IN o
inhibition NN o
correlated VBN N
with IN N
better JJR N
performance NN N
in IN N
more RBR N
demanding JJ N
tasks NNS N
, , N
in IN N
which WDT N
fast RB N
alternating VBG N
activation NN N
of IN N
cortical JJ N
representations NNS N
are VBP N
necessary JJ N
. . N

Declining VBG o
resting-state JJ o
inhibition NN o
was VBD N
associated VBN N
with IN N
weakened JJ N
event-related JJ N
modulation NN N
of IN N
inhibition NN N
. . N

Therefore NN N
, , N
reduced VBD o
resting-state JJ o
inhibition NN N
might MD N
lead VB N
to TO N
a DT N
subsequent JJ N
loss NN N
of IN N
modulatory JJ N
capacity NN N
, , N
possibly RB N
reflecting VBG N
malfunctioning VBG N
precision NN N
in IN N
GABAAergic NNP N
neurotransmission NN N
; : N
the DT N
consequence NN N
is VBZ N
an DT N
inevitable JJ N
decline NN N
in IN N
motor NN N
function NN N
. . N

-DOCSTART- -X- O O

Pouch JJ i
versus NN i
esophagojejunostomy NN o
after IN N
total JJ p
gastrectomy NN o
: : o
a DT p
randomized JJ p
clinical JJ p
trial NN p
. . p

-DOCSTART- -X- O O

Long JJ N
term NN N
follow VBP N
up IN N
of IN N
patients NNS p
treated VBN p
for IN p
Helicobacter NNP o
pylori JJ o
infection NN o
. . o

BACKGROUND NNP N
Helicobacter NNP N
pylori POS N
infection NN N
induces NNS N
progressive JJ N
inflammatory JJ o
changes NNS o
in IN N
the DT N
gastric JJ N
mucosa NN N
that WDT N
may MD N
lead VB N
to TO N
gastric JJ N
cancer NN N
. . N

Understanding VBG N
long JJ N
term NN N
effects NNS N
resulting VBG N
from IN N
the DT N
cure NN N
of IN N
this DT N
infection NN N
is VBZ N
needed VBN N
to TO N
design VB N
cancer NN N
prevention NN N
strategies NNS N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
795 CD p
adults NNS p
with IN p
preneoplastic JJ p
gastric JJ p
lesions NNS p
was VBD p
randomised VBN p
to TO p
receive VB i
anti-H JJ i
pylori NN i
treatment NN i
and/or JJ i
antioxidants NNS i
. . i

At IN N
the DT N
end NN N
of IN N
six CD N
years NNS N
of IN N
intervention NN N
, , N
those DT N
who WP N
did VBD N
not RB N
receive VB N
anti-H JJ N
pylori NN N
treatment NN N
were VBD N
offered VBN N
it PRP N
. . N

Gastric JJ N
biopsies NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
years NNS N
. . N

A DT N
histopathology NN o
score NN o
was VBD N
utilised VBN N
to TO N
document VB N
changes NNS N
in IN N
gastric JJ o
lesions NNS o
. . o

Non-linear JJ N
mixed JJ N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
cumulative JJ N
effect NN N
of IN N
H NNP N
pylori JJ N
clearance NN N
on IN N
histopathology NN o
scores NNS o
adjusted VBN N
for IN N
follow VB N
up RP N
time NN N
, , N
interventions NNS N
, , N
and CC N
confounders NNS N
. . N

RESULTS NNP N
Ninety NNP p
seven CD p
per IN p
cent NN p
of IN p
subjects NNS p
were VBD p
H NNP o
pylori JJ o
positive JJ p
at IN p
baseline NN p
, , p
and CC p
53 CD p
% NN p
were VBD p
positive JJ p
at IN p
12 CD p
years NNS p
. . p

Subjects NNS N
accumulated JJ N
1703 CD N
person NN N
years NNS N
free JJ o
of IN o
infection NN o
. . o

A DT N
multivariate NN N
model NN N
showed VBD N
a DT N
significant JJ N
regression NN o
in IN o
histopathology NN o
score NN o
as IN N
a DT N
function NN N
of IN N
the DT N
square NN N
of IN N
H NNP o
pylori FW o
negative JJ o
time NN o
. . o

Subjects NNS N
who WP N
were VBD N
H NNP o
pylori JJ o
negative JJ N
had VBD N
14.8 CD N
% NN N
more JJR N
regression NN o
and CC N
13.7 CD N
% NN N
less JJR N
progression NN o
than IN N
patients NNS N
who WP N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
healing NN o
of IN o
gastric JJ o
lesions NNS o
occurred VBD N
more RBR N
rapidly RB N
as IN N
years NNS o
free JJ o
of IN o
infection NN o
accumulated VBN N
, , N
and CC N
was VBD N
more RBR N
pronounced JJ N
in IN N
less RBR N
advanced JJ N
lesions NNS N
. . N

CONCLUSIONS NNP N
Preneoplastic NNP o
gastric JJ o
lesions NNS o
regress NN N
at IN N
a DT N
rate NN N
equal JJ N
to TO N
the DT N
square NN N
of IN N
time NN N
in IN N
patients NNS N
rendered JJ N
free JJ N
of IN N
H NNP N
pylori JJ N
infection NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
patients NNS p
with IN p
preneoplastic JJ p
gastric JJ p
lesions NNS p
should MD N
be VB N
treated VBN N
and CC N
cured VBN N
of IN N
their PRP$ N
H NNP o
pylori NN o
infection NN o
. . o

-DOCSTART- -X- O O

Aztreonam NNP i
versus NN i
gentamicin NN i
for IN N
short-term JJ N
prophylaxis NN N
in IN N
biliary JJ p
and CC p
gastric JJ p
surgery NN p
. . p

Short-term NNP N
antibiotic JJ N
prophylaxis NN N
was VBD N
studied VBN N
in IN N
80 CD p
patients NNS p
undergoing JJ p
biliary JJ p
or CC p
gastric JJ p
surgery NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
g NN N
of IN N
aztreonam NN i
or CC N
80 CD N
mg NN N
of IN N
gentamicin NN i
intravenously RB N
30 CD N
minutes NNS N
before IN N
surgery NN N
and CC N
8 CD N
and CC N
16 CD N
hours NNS N
after IN N
surgery NN N
. . N

Of IN N
samples NNS N
taken VBN N
from IN N
the DT N
abdominal JJ N
cavity NN N
for IN N
bacteriologic NN N
study NN N
, , N
53 CD N
% NN N
were VBD N
culture NN N
positive JJ N
. . N

Wound IN o
infections NNS o
developed VBN N
in IN N
two CD N
( ( N
4.5 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
receiving VBG N
aztreonam NN i
and CC N
in IN N
seven CD N
( ( N
19.4 CD N
% NN N
) ) N
of IN N
36 CD N
patients NNS N
treated VBN N
with IN N
gentamicin NN i
. . i

Staphylococcus NNP o
epidermidis NN o
and CC o
Enterobacter NNP o
species NNS o
were VBD N
isolated VBN N
from IN N
sites NNS N
of IN N
wound JJ o
infection NN o
in IN N
the DT N
aztreonam JJ i
group NN N
; : N
Escherichia NNP N
coli NNS N
( ( N
two CD N
isolates NNS N
) ) N
, , N
Pseudomonas NNP N
aeruginosa NN N
( ( N
two CD N
isolates NNS N
) ) N
, , N
Enterobacter NNP o
species NNS o
, , o
Klebsiella NNP o
species NNS o
, , o
Enterococcus NNP o
faecalis NN o
, , o
and CC o
Aeromonas NNP o
hydrophila NN o
were VBD N
isolated VBN N
from IN N
the DT N
gentamicin NN N
group NN N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
aztreonam NN i
is VBZ N
safe JJ o
and CC o
effective JJ o
for IN N
the DT N
prevention NN N
of IN N
infections NNS N
following VBG N
biliary JJ p
and CC p
gastric JJ p
surgery NN p
. . p

-DOCSTART- -X- O O

Feasibility NNP N
study NN N
of IN N
the DT N
effects NNS o
of IN N
art NN N
as IN N
a DT N
creative JJ N
engagement NN N
intervention NN N
during IN N
stroke NN N
rehabilitation NN N
on IN N
improvement NN N
of IN N
psychosocial JJ o
outcomes NNS o
: : o
study NN N
protocol NN N
for IN N
a DT N
single JJ N
blind NN N
randomized VBD N
controlled VBN N
trial NN N
: : N
the DT N
ACES NNP N
study NN N
. . N

BACKGROUND NNP N
Benefits NNP N
of IN N
art NN N
participation NN N
after IN N
stroke NN N
are VBP N
becoming VBG N
increasingly RB N
recognized VBN N
. . N

Qualitative JJ N
studies NNS N
suggest VBP N
that IN N
participation NN N
in IN N
visual JJ N
arts NNS N
creative JJ N
engagement JJ N
interventions NNS N
( ( N
CEIs NNP N
) ) N
during IN N
rehabilitation NN N
after IN N
stroke NN N
may MD N
improve VB N
mood NN o
, , o
self-esteem JJ o
, , o
hope NN o
and CC N
some DT N
aspects NNS N
of IN N
physical JJ N
recovery NN N
. . N

This DT N
study NN N
examines VBZ N
the DT N
feasibility NN N
of IN N
undertaking VBG N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
CEI NNP N
delivered VBN N
by IN N
artists NNS N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
to TO N
test VB N
effectiveness NN N
. . N

METHODS/DESIGN NNP N
This DT N
trial NN N
is VBZ N
a DT N
two CD N
arm NN N
, , N
single-blind NN N
, , N
randomized VBN N
controlled VBN N
feasibility NN N
trial NN N
within IN N
in-patient JJ N
stroke NN N
rehabilitation NN N
. . N

We PRP N
will MD N
recruit VB N
80 CD p
patients NNS p
receiving VBG i
stroke NN i
rehabilitation NN i
in IN i
two CD i
stroke VBD i
units NNS i
in IN i
a DT i
health NN i
board NN i
area NN i
of IN i
Scotland NNP i
( ( i
40 CD i
patients NNS i
in IN i
each DT i
arm NN i
) ) i
. . i

Intervention NNP i
arm NN i
participants NNS i
will MD i
receive VB i
a DT i
visual-arts NNS i
based VBN i
CEI NNP i
facilitated VBN i
by IN i
experienced JJ i
artists NNS i
. . i

Artists NNS i
will MD i
follow VB i
an DT i
intervention NN i
protocol NN i
with IN i
specific JJ i
components NNS i
that WDT i
enable VBP i
participants NNS i
to TO i
set VB i
, , i
achieve VB i
and CC i
review VB i
artistic JJ i
goals NNS i
. . i

Participants NNS i
will MD i
receive VB i
up RP i
to TO i
eight CD i
intervention NN i
sessions NNS i
, , i
four CD i
within IN i
a DT i
group NN i
and CC i
four CD i
one-to-one NN i
with IN i
the DT i
artist NN i
. . i

Control NNP N
group NN N
participants NNS N
will MD N
receive VB N
usual JJ N
care NN N
only.Data JJ N
collection NN N
will MD N
occur VB N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
three-month JJ N
follow-up NN N
. . N

Stroke-related JJ o
health NN o
status NN o
is VBZ N
the DT N
primary JJ N
outcome NN N
; : N
mood NN o
, , o
self-esteem JJ o
, , o
self-efficacy JJ o
, , o
perceived JJ o
recovery NN o
control NN o
and CC o
hope NN o
are VBP o
secondary JJ o
outcomes NNS N
. . N

Semi-structured JJ N
interviews NNS N
will MD N
be VB N
conducted VBN N
with IN N
purposively RB N
selected VBN N
patients NNS N
, , N
artists NNS N
and CC N
healthcare JJ N
staff NN N
to TO N
elicit VB o
views NNS o
and CC o
experiences NNS o
of IN N
the DT N
intervention NN N
and CC N
feasibility NN o
and CC o
acceptability NN o
of IN N
trial NN N
processes NNS N
. . N

Recruitment JJ o
rates NNS o
, , o
retention NN o
rates NNS o
and CC o
patient JJ o
preference NN o
for IN o
art JJ o
participation NN o
will MD N
also RB N
be VB N
collected VBN N
. . N

Data NNP N
will MD N
indicate VB N
, , N
with IN N
confidence NN N
intervals NNS N
, , N
the DT N
proportion NN N
of IN N
patients NNS N
choosing VBG N
or CC N
refusing VBG N
participation NN N
in IN N
the DT N
CEI NNP N
and CC N
will MD N
allow VB N
calculation NN N
of IN N
recruitment NN o
rates NNS o
for IN N
a DT N
future JJ N
definitive JJ N
trial NN N
. . N

Summary NNP N
data NNS N
will MD N
indicate VB N
potential JJ N
variability NN N
, , N
magnitude NN N
and CC N
direction NN N
of IN N
difference NN N
between IN N
groups NNS N
. . N

Findings NNS N
will MD N
inform VB N
sample JJ N
size NN N
calculations NNS N
for IN N
a DT N
definitive JJ N
trial NN N
. . N

Thematic JJ N
analysis NN N
of IN N
qualitative JJ N
data NNS N
will MD N
be VB N
managed VBN N
using VBG N
the DT N
Framework NNP N
Approach NNP N
. . N

Framework NNP N
is VBZ N
an DT N
analytical JJ N
approach NN N
for IN N
qualitative JJ N
data NNS N
, , N
commonly RB N
used VBN N
in IN N
policy NN N
and CC N
medical JJ N
research NN N
. . N

DISCUSSION NNP N
If IN N
shown VBN N
to TO N
demonstrate VB N
effects NNS N
, , N
this DT N
intervention NN N
has VBZ N
the DT N
potential JJ N
to TO N
address VB N
aspects NNS N
of IN N
stroke NN N
recovery NN N
previously RB N
. . N

Not RB N
routinely RB N
addressed VBN N
in IN N
rehabilitation NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Registered NNP N
with IN N
Clinical NNP N
Trials.Gov NNP N
: : N
NCT02085226 NN N
on IN N
6th CD N
March NNP N
2014 CD N
. . N

-DOCSTART- -X- O O

Early JJ i
educational JJ i
intervention NN i
for IN N
very RB p
low JJ p
birth NN p
weight NN p
infants NNS p
: : p
results NNS N
from IN N
the DT N
Infant NNP i
Health NNP i
and CC i
Development NNP i
Program NNP i
. . i

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
early JJ i
educational JJ i
intervention NN i
after IN N
discharge NN N
from IN N
the DT N
hospital NN N
on IN N
the DT N
health NN N
and CC N
developmental JJ N
status NN N
of IN N
very RB p
low JJ p
birth NN p
weight NN p
( ( p
< CD p
or CC p
= VB p
1500 CD p
gm NN p
) ) p
infants NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
trial NN N
, , N
with IN N
post NN N
hoc NN N
analysis NN N
. . N

SETTING NN N
Eight NNP p
sites NNS p
, , p
heterogeneous JJ p
for IN p
sociodemographic JJ p
and CC p
health NN p
care NN p
use NN p
. . p

PARTICIPANTS NN N
Infants NNS p
( ( p
N NNP p
= NNP p
280 CD p
) ) p
born VBN p
weighing VBG p
< NN p
or CC p
= NN p
1500 CD p
gm NN p
and CC p
selected VBN p
for IN p
the DT p
Infant NNP p
Health NNP p
and CC p
Development NNP p
Program NNP p
. . p

Eligibility NNP N
was VBD N
limited VBN N
primarily RB N
by IN N
geographic JJ p
distance NN p
from IN p
the DT p
day NN p
care NN p
center NN p
. . p

One CD N
third WDT N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
intervention NN N
( ( N
INT NNP N
) ) N
group NN N
and CC N
two CD N
thirds NNS N
to TO N
follow-up JJ i
only RB i
. . i

INTERVENTIONS NNP N
All NNP N
children NNS N
received VBD N
intensive JJ i
pediatric NNS i
and CC i
developmental JJ i
surveillance NN i
. . i

The DT N
INT NNP N
group NN N
received VBD i
home NN i
visits NNS i
and CC i
center-based JJ i
educational JJ i
interventions NNS i
until IN N
36 CD p
months NNS p
of IN p
age NN p
( ( p
corrected VBN p
for IN p
gestational JJ p
age NN p
when WRB p
final JJ p
assessments NNS p
were VBD p
completed VBN p
) ) p
. . p

OUTCOMES NNP N
Cognitive NNP o
development NN o
( ( o
Stanford-Binet JJ o
Intelligence NNP o
Scale NNP o
) ) o
, , o
behavioral JJ o
competence NN o
( ( o
Achebach NNP o
Child NNP o
Behavior NNP o
Checklist NNP o
) ) o
, , o
and CC o
health NN o
status NN o
( ( o
indexes NNS o
summarizing VBG o
reported VBD o
morbidity NN o
, , o
the DT o
Functional NNP o
Status NNP o
II NNP o
( ( o
R NNP o
) ) o
Scale NNP o
, , o
and CC o
General NNP o
Health NNP o
Ratings NNP o
Index NNP o
) ) o
. . N

RESULTS NNP N
Cognitive NNP o
development NN o
scores NNS o
were VBD N
7.2 CD N
points NNS N
higher JJR N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
in IN N
the DT N
INT NNP N
group NN N
, , N
after IN N
adjustment NN N
for IN N
baseline NN N
differences NNS N
in IN N
site NN N
, , N
sociodemographic JJ N
characteristics NNS N
, , N
and CC N
neonatal JJ o
morbidity NN o
, , N
and CC N
were VBD N
9.4 CD N
points NNS N
higher JJR N
( ( N
p JJ N
< NNP N
0.0003 CD N
) ) N
when WRB N
the DT N
29 CD N
children NNS N
with IN N
significant JJ N
cerebral JJ N
palsy NN N
were VBD N
removed VBN N
. . N

No DT N
differences NNS N
in IN N
behavior NN o
, , o
serious JJ o
morbidity NN o
, , o
functional JJ o
status NN o
, , o
or CC o
health NN o
rating NN o
were VBD N
found VBN N
overall RB N
. . N

The DT N
infants NNS N
in IN N
the DT N
INT NNP N
group NN N
who WP N
weighted VBD N
< NNP N
or CC N
= VB N
1000 CD N
gm NN N
at IN N
birth NN N
had VBD N
significantly RB N
lower JJR o
behavior NN o
problem NN o
scores NNS o
but CC N
no DT N
differences NNS N
on IN N
other JJ N
outcomes NNS N
. . N

All DT N
children NNS N
in IN N
the DT N
INT NNP N
group NN N
had VBD N
slightly RB N
higher JJR N
rates NNS o
of IN o
less JJR o
serious JJ o
morbidity NN o
. . o

CONCLUSION VB N
The DT N
advantage NN N
conferred VBN N
by IN N
being VBG N
in IN N
the DT N
INT NNP N
group NN N
, , N
as IN N
previously RB N
reported VBN N
for IN N
heavier JJR N
infants NNS N
, , N
extends VBZ N
to TO N
very RB p
low JJ p
birth NN p
weight NN p
children NNS p
, , N
supporting VBG N
the DT N
use NN N
of IN N
early JJ N
intervention NN N
in IN N
this DT N
group NN N
. . N

-DOCSTART- -X- O O

Abstinence NNP o
incentive NN o
effects NNS o
in IN N
a DT N
short-term JJ N
outpatient JJ N
detoxification NN N
program NN N
. . N

Despite IN N
being VBG N
widely RB N
available JJ N
, , N
outpatient JJ N
detoxification NN N
has VBZ N
limited VBN N
efficacy NN N
as IN N
a DT N
stand-alone JJ N
treatment NN N
. . N

This DT N
study NN N
examined VBD N
whether IN N
abstinence-contingent JJ i
incentives NNS i
would MD N
improve VB N
outcomes NNS N
for IN N
patients NNS p
entering VBG p
outpatient JJ p
opiate JJ o
detoxification NN o
. . o

Participants NNS p
( ( p
N NNP p
= NNP p
211 CD p
) ) p
received VBD N
a DT N
100 CD N
US NNP N
dollars NNS N
voucher RB N
on IN N
the DT N
last JJ N
day NN N
of IN N
detoxification NN i
either CC N
contingent NN N
on IN N
opiate NN N
and CC N
cocaine NN N
abstinence NN N
or CC N
noncontingently RB N
. . N

Urine JJ N
samples NNS N
were VBD N
collected VBN N
at IN N
intake NN N
, , N
on IN N
Wednesday NNP N
, , N
Friday NNP N
( ( N
the DT N
last JJ N
day NN N
of IN N
detoxification NN N
) ) N
, , N
and CC N
the DT N
following JJ N
Monday NNP N
. . N

Among IN N
contingent-voucher JJ i
participants NNS N
, , N
31 CD N
% NN N
were VBD N
drug-free JJ o
on IN N
Friday NNP N
compared VBN N
with IN N
18 CD N
% NN N
of IN N
noncontingent NN N
controls NNS N
( ( N
Z NNP N
= NNP N
2.4 CD N
, , N
p NN N
< NNP N
.05 NNP N
) ) N
. . N

Few JJ N
( ( N
12-13 CD N
% NN N
) ) N
participants NNS N
tested VBN N
negative JJ o
on IN N
Monday NNP N
. . N

Results NNP N
support VBD N
the DT N
ability NN N
of IN N
vouchers NNS N
to TO N
produce VB N
modest JJ o
improvements NNS o
in IN o
abstinence NN o
initiation NN o
rates NNS o
during IN N
brief JJ N
detoxification NN N
but CC N
suggest VBP N
that IN N
additional JJ N
interventions NNS N
are VBP N
needed VBN N
to TO N
sustain VB N
improvements NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
weight JJ i
reduction NN i
interventions NNS i
by IN N
community NN N
pharmacists NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
a DT N
meal JJ i
replacement NN i
( ( i
MR NNP i
) ) i
program NN i
with IN i
a DT i
conventional JJ i
reduced-calorie JJ i
diet NN i
( ( i
RCD NNP i
) ) i
for IN N
weight NN o
management NN o
using VBG N
the DT N
pharmacy NN i
as IN i
the DT i
setting NN i
and CC i
the DT i
pharmacist NN i
as IN i
the DT i
point NN i
of IN i
contact NN i
for IN i
dietary JJ i
advice NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
open-label JJ N
trial NN N
. . N

SETTING NN N
Travis NNP p
Pharmacy NNP p
in IN p
Shenandoah NNP p
, , p
Iowa NNP p
. . p

PATIENTS NNP N
Ninety-five JJ p
patients NNS p
from IN p
southwestern JJ p
iowa NN p
and CC p
southeastern JJ p
Nebraska NNP p
were VBD N
enrolled VBN N
, , N
of IN N
whom WP N
88 CD p
were VBD p
considered VBN p
eligible JJ p
for IN p
comparison NN p
( ( p
by IN p
continuing VBG p
through IN p
week NN p
2 CD p
of IN p
the DT p
study NN p
) ) p
. . p

INTERVENTION JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
an DT N
MR NNP i
plan NN N
or CC N
a DT N
traditional JJ N
RCD NNP i
plan NN N
. . N

Patients NNS N
were VBD N
followed VBN N
for IN N
a DT N
3-month JJ N
period NN N
of IN N
active JJ N
weight JJ N
loss NN N
and CC N
a DT N
10-week JJ N
period NN N
of IN N
weight JJ N
maintenance NN N
. . N

Patients NNS N
returned VBD N
every DT N
3 CD N
weeks NNS N
for IN N
follow-up NN N
with IN N
the DT N
pharmacist NN N
, , N
for IN N
a DT N
total NN N
of IN N
13 CD N
visits NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Weight NNP o
changes NNS o
. . o

RESULTS NNP N
During IN N
the DT N
active JJ N
weight NN N
loss NN N
phase NN N
, , N
the DT N
MR NNP p
( ( p
n JJ p
= NNP p
45 CD p
) ) p
and CC p
RCD NNP p
( ( p
n JJ p
= NNP p
43 CD p
) ) p
groups NNS N
lost VBD N
a DT N
significant JJ o
amount NN o
of IN o
weight NN o
, , N
although IN N
no DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
groups NNS N
( ( N
mean JJ N
+/- JJ N
standard NN N
error NN N
= VBZ N
4.90 CD N
+/- JJ N
0.30 CD N
kg NN N
MR NNP N
versus NN N
4.30 CD N
+/- JJ N
0.30 CD N
kg NN N
RCD NNP N
; : N
P NNP N
= NNP N
.16 NNP N
) ) N
. . N

In IN N
the DT N
weight NN N
maintenance NN N
phase NN N
, , N
the DT N
MR NNP N
group NN N
lost VBD N
0.70 CD N
+/- JJ N
0.40 CD N
kg NN N
and CC N
the DT N
RCD NNP N
group NN N
lost VBD N
0.90 CD N
+/- JJ N
0.40 CD N
kg NN N
( ( N
P NNP N
= NNP N
.60 NNP N
) ) N
. . N

Significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
waist JJ o
circumference NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
and CC o
triglyceride NN o
levels NNS o
. . o

No DT N
significant JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
high-density NN o
lipoprotein NN o
cholesterol NN o
or CC o
low-density NN o
lipoprotein NNS o
cholesterol NN o
levels NNS o
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
Successful NNP N
weight VBD o
management NN o
can MD N
be VB N
achieved VBN N
in IN N
a DT N
pharmacy NN N
setting NN N
. . N

Both DT N
MR NNP i
and CC i
RCD NNP i
programs NNS N
were VBD N
effective JJ N
. . N

-DOCSTART- -X- O O

Gonadotropin-releasing VBG i
hormone NN i
agonist NN i
with IN p
or CC p
without IN p
raloxifene NN i
: : i
effects NNS N
on IN N
cognition NN o
, , o
mood NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -X- O O

Activation NN N
and CC N
intermuscular JJ N
coherence NN N
of IN N
distal JJ N
arm NN N
muscles NNS N
during IN N
proximal JJ N
muscle NN N
contraction NN N
. . N

In IN N
the DT N
human JJ N
upper JJ N
extremity NN N
( ( N
UE NNP N
) ) N
, , N
unintended JJ N
effects NNS N
of IN N
proximal JJ N
muscle NN N
activation NN N
on IN N
muscles NNS N
controlling VBG N
the DT N
hand NN N
could MD N
be VB N
an DT N
important JJ N
aspect NN N
of IN N
motor NN N
control NN N
due JJ N
to TO N
the DT N
necessary JJ N
coordination NN N
of IN N
distal NN N
and CC N
proximal JJ N
segments NNS N
during IN N
functional JJ N
activities NNS N
. . N

This DT N
study NN N
aimed VBD N
to TO N
elucidate VB N
the DT N
effects NNS N
of IN N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
on IN N
the DT N
coordination NN N
between IN N
hand NN N
muscles NNS N
performing VBG N
a DT N
grip NN N
task NN N
. . N

Eleven NNP p
healthy JJ p
subjects NNS p
performed VBN N
precision NN i
grip NN i
tasks NNS i
while IN i
a DT i
constant JJ i
extension NN i
or CC i
flexion NN i
moment NN i
was VBD i
applied VBN i
to TO i
their PRP$ i
elbow NN i
joints NNS i
, , N
inducing VBG N
a DT N
sustained VBN N
submaximal JJ N
contraction NN N
of IN N
elbow NN N
muscles NNS N
to TO N
counter VB N
the DT N
applied JJ N
torque NN N
. . N

Activation NNP N
of IN N
four CD N
hand NN N
muscles NNS N
was VBD N
measured VBN N
during IN N
each DT N
task NN N
condition NN N
using VBG N
surface NN i
electromyography NN i
( ( i
EMG NNP i
) ) i
. . i

When WRB N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
was VBD N
induced VBN N
, , N
significant JJ N
changes NNS N
in IN N
the DT N
activation NN o
levels NNS o
of IN o
the DT o
hand NN o
muscles NNS o
were VBD N
observed VBN N
, , N
with IN N
greater JJR N
effects NNS N
on IN N
the DT N
extrinsic JJ N
finger NN N
extensor NN N
( ( N
23.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.003 CD N
) ) N
than IN N
extrinsic JJ N
finger NN N
flexor NN N
( ( N
14.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
; : N
p CC N
= VB N
0.130 CD N
) ) N
. . N

Elbow NNP o
muscle NN o
activation NN o
also RB N
induced VBD N
involuntary JJ N
changes NNS N
in IN N
the DT N
intrinsic JJ o
thumb NN o
flexor NN o
activation NN o
( ( N
44.6 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.005 CD N
) ) N
. . N

EMG-EMG JJ N
coherence NN N
analyses NNS N
revealed VBD N
that IN N
elbow JJ o
muscle NN o
activation NN o
significantly RB N
reduced VBD N
intermuscular JJ o
coherence NN o
between IN o
distal JJ o
muscle NN o
pairs NNS o
, , N
with IN N
its PRP$ N
greatest JJS N
effects NNS N
on IN N
coherence NN N
in IN N
the DT N
?-band NN N
( ( N
13-25 JJ N
Hz NNP N
) ) N
( ( N
average NN N
of IN N
17 CD N
% NN N
decrease NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
provide VBP N
evidence NN N
for IN N
involuntary JJ N
, , N
muscle-specific JJ N
interactions NNS N
between IN N
distal NN N
and CC N
proximal JJ N
UE NNP N
muscles NNS N
, , N
which WDT N
may MD N
contribute VB N
to TO N
UE NNP N
motor NN N
performance NN N
in IN N
health NN N
and CC N
disease NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
antipsychotic JJ i
drugs NNS i
on IN N
cortical JJ o
thickness NN o
. . o

A DT N
randomized JJ N
controlled VBN N
one-year JJ N
follow-up NN N
study NN N
of IN N
haloperidol NN i
, , i
risperidone NN i
and CC i
olanzapine NN i
. . i

BACKGROUND NNP N
Imaging NNP N
evidence NN N
indicates VBZ N
that IN N
brain NN N
alterations NNS N
are VBP N
primary JJ N
to TO N
the DT N
full-blown JJ N
onset NN N
of IN N
schizophrenia NN N
and CC N
seem VBP N
to TO N
progress VB N
across IN N
time NN N
. . N

The DT N
potential JJ N
effects NNS o
of IN o
antipsychotic JJ o
medication NN o
on IN N
brain NN N
structure NN N
represent VBP N
a DT N
key JJ N
factor NN N
in IN N
understanding VBG N
brain NN N
changes NNS N
in IN N
psychosis NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
low JJ N
doses NNS N
of IN N
haloperidol NN i
, , i
risperidone NN i
and CC i
olanzapine NN i
on IN N
cortical JJ o
thickness NN o
. . o

METHOD NNP N
We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
risperidone NN i
( ( p
N=16 NNP p
) ) p
, , p
olanzapine JJ i
( ( p
N=18 NNP p
) ) p
and CC p
low JJ p
doses NNS p
of IN p
haloperidol NN i
( ( p
N=18 NNP p
) ) p
in IN N
cortical JJ o
thickness NN o
changes NNS N
during IN N
1-year JJ N
follow-up JJ N
period NN N
in IN N
a DT N
large JJ p
and CC p
heterogeneous JJ p
sample NN p
of IN p
schizophrenia NN p
spectrum NN p
patients NNS p
. . p

The DT N
relationship NN N
between IN N
cortical JJ o
thickness NN o
changes NNS o
and CC N
clinical JJ o
and CC o
cognitive JJ o
outcome NN o
was VBD N
also RB N
assessed VBN N
. . N

A DT N
group NN p
of IN p
45 CD p
healthy JJ p
volunteers NNS p
was VBD p
also RB p
longitudinally RB p
evaluated VBN p
. . p

Magnetic JJ N
resonance NN N
imaging VBG N
brain NN N
scans NNS N
( ( N
1.5T CD N
) ) N
were VBD N
obtained VBN N
and CC N
images NNS N
were VBD N
analyzed VBN N
by IN N
using VBG N
BRAINS2 NNP N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
time NN N
( ( N
F NNP N
( ( N
1,47 CD N
) ) N
< NN N
1.66 CD N
; : N
P NNP N
> NNP N
0.204 CD N
) ) N
, , N
treatment NN N
group NN N
( ( N
F NNP N
( ( N
2,47 CD N
) ) N
< NN N
1.47 CD N
; : N
P NNP N
> NNP N
0.242 CD N
) ) N
or CC N
group-by-time JJ N
interaction NN N
( ( N
F NNP N
( ( N
2,47 CD N
) ) N
< NN N
1.82 CD N
; : N
P NNP N
> NNP N
0.174 CD N
) ) N
for IN N
any DT N
of IN N
the DT N
cortical JJ o
thickness NN o
variables NNS o
. . o

When WRB N
the DT N
group NN N
of IN N
healthy JJ N
controls NNS N
was VBD N
included VBN N
in IN N
the DT N
analyses NNS N
, , N
it PRP N
is VBZ N
of IN N
note NN N
that IN N
group-by-time JJ N
interaction NN N
showed VBD N
a DT N
significant JJ N
result NN N
for IN N
the DT N
frontal JJ N
lobe NN N
at IN N
trend NN N
level NN N
( ( N
F NNP N
( ( N
3,81 CD N
) ) N
=2.686 NN N
; : N
P=0.052 NNP N
) ) N
. . N

After IN N
the DT N
Bonferroni NNP N
adjustment NN N
for IN N
multiple JJ N
comparisons NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
associations NNS N
between IN N
changes NNS o
in IN o
cortical JJ o
thickness NN o
and CC N
clinical JJ o
and CC o
cognitive JJ o
outcome NN o
. . o

CONCLUSIONS NNP N
Low NNP N
doses NNS N
of IN N
haloperidol NN i
, , i
risperidone NN i
, , i
and CC i
olanzapine NN i
seem VBP N
to TO N
equally RB N
affect VB N
gray JJ o
matter NN o
cortical JJ o
thickness NN o
, , o
overall JJ o
and CC o
lobes JJ o
, , N
at IN N
the DT N
medium-term NN N
( ( N
1 CD N
year NN N
) ) N
. . N

The DT N
clinical JJ N
effectiveness NN N
of IN N
treatments NNS N
was VBD N
not RB N
significantly RB N
related VBN N
to TO N
changes NNS N
in IN N
cortical JJ o
thickness NN o
. . o

-DOCSTART- -X- O O

A DT N
cost-benefit JJ o
comparison NN N
of IN N
intensive JJ i
diabetes NNS i
management NN i
with IN i
implantable JJ i
pumps NNS i
versus IN N
multiple JJ i
subcutaneous JJ i
injections NNS i
in IN N
patients NNS p
with IN p
type NN p
I PRP p
diabetes VBZ p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
if IN N
intraperitoneal JJ i
( ( i
IP NNP i
) ) i
insulin NN i
infusion NN i
via IN i
programmable JJ i
implantable JJ i
pumps NNS i
is VBZ N
a DT N
potential JJ N
alternative NN N
to TO N
subcutaneous JJ i
( ( i
SC NNP i
) ) i
insulin NN i
via IN i
multiple JJ i
injections NNS i
. . i

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
We PRP N
compared VBN N
the DT N
cost-benefits NNS o
of IN N
the DT N
two CD N
methods NNS N
using VBG N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
6-month JJ N
, , N
crossover JJ N
design NN N
in IN N
10 CD p
adult NN p
type NN p
I PRP p
diabetic JJ p
patients NNS p
. . p

RESULTS NNP N
When WRB N
judged VBN N
on IN N
the DT N
last JJ N
month NN N
of IN N
IP NNP N
versus NN N
SC NNP N
periods NNS N
in IN N
the DT N
nine CD N
patients NNS N
who WP N
completed VBD N
the DT N
study NN N
, , N
metabolic JJ o
data NN o
showed VBD N
better JJR N
glycemic JJ o
control NN o
( ( N
HbA1c NNP N
: : N
7.2 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
8.5 CD N
+/- JJ N
0.7 CD N
% NN N
SC NNP N
, , N
mean JJ N
+/- JJ N
SE NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
reduced VBN o
glycemic JJ o
fluctuations NNS o
( ( N
SD NNP N
of IN N
capillary JJ N
glucose JJ N
values NNS N
: : N
3.4 CD N
+/- JJ N
0.2 CD N
IP NNP N
vs. FW N
4.6 CD N
+/- JJ N
0.2 CD N
mM NN N
SC NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
fewer JJR N
mild JJ o
hypoglycemic JJ o
events NNS o
( ( N
5.7 CD N
+/- JJ N
2.0 CD N
IP NNP N
vs. FW N
10.0 CD N
+/- JJ N
3.1 CD N
events/month JJ N
SC NNP N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Quality NN o
of IN o
life NN o
, , o
judged VBN o
by IN o
Diabetes NNP o
Control NNP o
and CC o
Complications NNP o
Trial NNP o
questionnaires NNS o
, , N
was VBD N
unaffected VBN N
by IN N
pump NN i
therapy NN N
. . N

Direct JJ o
costs NNS o
, , o
including VBG o
pump JJ o
acquisition NN o
, , o
implantation NN o
, , o
and CC o
follow-up NN o
, , N
were VBD N
2.6-fold JJ N
higher JJR N
with IN N
IP NNP N
than IN N
with IN N
SC NNP N
delivery NN N
. . N

CONCLUSIONS VB N
The DT N
implantable JJ i
pump NN i
is VBZ N
more RBR o
effective JJ o
in IN N
the DT N
short JJ N
term NN N
, , N
equally RB N
accepted VBN o
, , N
but CC N
more RBR N
costly JJ o
than IN N
multiple JJ i
injections NNS i
and CC N
should MD N
be VB N
limited VBN N
to TO N
patients NNS N
with IN N
unsatisfactory JJ N
glycemic JJ o
control NN o
despite IN N
intensive JJ N
diabetes NNS N
management NN N
with IN N
SC NNP N
insulin NN N
. . N

In IN N
addition NN N
, , N
longer-term JJ N
, , N
larger-scale JJ N
, , N
and CC N
comparative JJ N
evaluation NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -X- O O

The DT N
efficacy NN N
of IN N
melatonin NN i
for IN N
sleep JJ N
problems NNS N
in IN N
children NNS N
with IN N
autism NN N
, , N
fragile JJ N
X NNP N
syndrome NN N
, , N
or CC N
autism NN N
and CC N
fragile JJ N
X NNP N
syndrome NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
melatonin NN i
on IN p
sleep NN p
problems NNS p
in IN p
children NNS p
with IN N
autistic JJ N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
and CC N
fragile JJ N
X NNP N
syndrome NN N
( ( N
FXS NNP N
) ) N
. . N

METHODS VB N
A DT N
4-week JJ N
, , N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
design NN N
was VBD N
conducted VBN N
following VBG N
a DT N
1-week JJ N
baseline NN N
period NN N
. . N

Either CC N
melatonin NN i
, , N
3 CD N
mg NN N
, , N
or CC N
placebo NN i
was VBD N
given VBN N
to TO N
participants NNS p
for IN p
2 CD p
weeks NNS p
and CC N
then RB N
alternated VBD N
for IN N
another DT N
2 CD N
weeks NNS N
. . N

Sleep JJ o
variables NNS o
, , N
including VBG N
sleep JJ o
duration NN o
, , o
sleep-onset JJ o
time NN o
, , o
sleep-onset JJ o
latency NN o
time NN o
, , o
and CC o
the DT o
number NN o
of IN o
night NN o
awakenings NNS o
, , N
were VBD N
recorded VBN N
using VBG N
an DT N
Actiwatch NN N
and CC N
from IN N
sleep JJ N
diaries NNS N
completed VBN N
by IN N
parents NNS N
. . N

All DT p
participants NNS p
had VBD N
been VBN N
thoroughly RB N
assessed VBN N
for IN N
ASD NNP N
and CC N
also RB N
had VBD N
DNA NNP N
testing VBG N
for IN N
the DT N
diagnosis NN N
of IN N
FXS NNP N
. . N

RESULTS NNP N
Data NNP N
were VBD N
successfully RB N
obtained VBN N
from IN N
the DT N
12 CD p
of IN p
18 CD p
subjects NNS p
who WP p
completed VBD p
the DT p
study NN p
( ( p
11 CD p
males NNS p
, , p
age NN p
range NN p
2 CD p
to TO p
15.25 CD p
years NNS p
, , p
mean JJ p
5.47 CD p
, , p
SD NNP p
3.6 CD p
) ) p
. . p

Five CD p
participants NNS p
met VBD N
diagnostic JJ N
criteria NNS N
for IN N
ASD NNP N
, , N
3 CD N
for IN N
FXS NNP N
alone RB N
, , N
3 CD N
for IN N
FXS NNP N
and CC N
ASD NNP N
, , N
and CC N
1 CD N
for IN N
fragile JJ N
X NNP N
premutation NN N
. . N

Eight CD p
out IN p
of IN p
12 CD p
had VBD p
melatonin VBN i
first RB p
. . N

The DT N
conclusions NNS N
from IN N
a DT N
nonparametric JJ N
repeated-measures NNS N
technique NN N
indicate VBP N
that IN N
mean JJ o
night NN o
sleep NN o
duration NN o
was VBD N
longer RBR N
on IN N
melatonin NN i
than IN N
placebo NN i
by IN N
21 CD N
minutes NNS N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
, , N
mean JJ o
sleep-onset JJ o
latency NN o
was VBD N
shorter JJR N
by IN N
28 CD N
minutes NNS N
( ( N
p JJ N
= NNP N
.0001 NNP N
) ) N
, , N
and CC N
mean VB o
sleep-onset JJ o
time NN o
was VBD N
earlier RB N
by IN N
42 CD N
minutes NNS N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
support VBD N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
melatonin NN i
treatment NN N
for IN N
sleep JJ N
problems NNS N
in IN N
children NNS N
with IN N
ASD NNP N
and CC N
FXS NNP N
. . N

-DOCSTART- -X- O O

Humoral NNP p
immunity NN p
after IN p
kidney NN p
transplantation NN p
: : p
impact NN N
of IN N
two CD N
randomized JJ N
immunosuppressive JJ N
protocols NNS N
. . N

BACKGROUND NNP N
Controlling NNP N
alloimmune JJ N
humoral JJ N
response NN N
is VBZ N
a DT N
challenge NN N
in IN N
transplantation NN N
. . N

Few JJ N
studies NNS N
have VBP N
evaluated VBN N
the DT N
impact NN N
of IN N
maintenance NN N
immunosuppression NN N
on IN N
blood NN N
humoral JJ N
parameters NNS N
. . N

MATERIAL/METHODS NNP N
We PRP N
performed VBD N
a DT N
post-hoc JJ N
analysis NN N
on IN N
307 CD p
kidney NN p
transplant NN p
recipients NNS p
included VBD p
in IN p
a DT p
prospective JJ p
randomized VBN p
trial NN p
comparing VBG p
tacrolimus/mycophenolate NN i
mofetil NN i
( ( i
Tac/MMF NNP i
) ) i
vs. FW i
cyclosporine/azathioprine NN i
( ( i
CsA/AZA NNP i
) ) i
, , N
both DT N
used VBN N
with IN N
antithymocyte JJ i
globulin NN i
induction NN i
and CC N
steroids NNS i
. . i

Humoral JJ N
parameters NNS N
were VBD N
analyzed VBN N
at IN N
D0 NNP N
, , N
D15 NNP N
, , N
and CC N
M12 NNP N
. . N

RESULTS NNP N
IgG NNP o
, , o
IgA NNP o
, , o
and CC o
IgM NNP o
levels NNS o
decreased VBN N
significantly RB N
as RB N
soon RB N
as IN N
D15 NNP N
in IN N
both DT N
groups NNS N
( ( N
?35 CD N
% NN N
, , N
?26 CD N
% NN N
, , N
and CC N
?35 CD N
% NN N
respectively RB N
, , N
vs. FW N
D0 NNP N
) ) N
. . N

At IN N
M12 NNP N
, , N
although IN o
peripheral JJ o
B-cell NNP o
counts NNS o
did VBD o
not RB o
differ VB N
between IN N
the DT N
groups NNS N
, , N
Tac/MMF NNP N
regimen NN N
was VBD N
associated VBN N
with IN N
lower JJR N
IgG NNP N
, , N
IgA NNP N
, , N
and CC N
IgM NNP N
levels NNS N
than IN N
CsA/AZA NNP N
( ( N
?5.9 CD N
% NN N
, , N
?14.6 CD N
% NN N
, , N
and CC N
?34 NNP N
% NN N
, , N
respectively RB N
) ) o
. . o

Hypogammaglobulinemia NNP o
at IN o
D15 NNP o
was VBD o
not RB N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN o
of IN o
infections NNS o
during IN N
the DT N
first JJ N
year NN N
. . N

The DT o
proportion NN o
of IN o
HLA-sensitized JJ o
patients NNS o
decreased VBN o
in IN N
the DT N
Tac/MMF NNP N
group NN N
( ( N
15.9 CD N
% NN N
at IN N
D0 NNP N
and CC N
6.7 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.02 NN N
) ) N
and CC N
remained VBD N
stable JJ N
in IN N
the DT N
CsA/AZA NNP N
group NN N
( ( N
10.3 CD N
% NN N
at IN N
D0 NNP N
and CC N
8.9 CD N
% NN N
at IN N
M12 NNP N
, , N
p=0.5 NN N
) ) N
. . N

More JJR N
patients NNS N
sensitized VBN N
at IN N
baseline NN N
became VBD N
non-sensitized JJ N
at IN N
M12 NNP N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
humoral JJ N
immunosuppression NN N
is VBZ N
better RBR N
with IN N
Tac/MMF NNP N
than IN N
with IN N
CsA/AZA NNP N
during IN N
the DT N
first JJ N
year NN N
of IN N
kidney NN N
transplantation NN N
. . N

-DOCSTART- -X- O O

Evidence NN N
for IN N
poorer JJR N
outcome NN N
in IN N
patients NNS p
with IN p
severe JJ p
negative JJ p
trauma-related JJ p
cognitions NNS p
receiving VBG N
prolonged JJ i
exposure NN i
plus CC N
cognitive JJ i
restructuring NN i
: : i
implications NNS N
for IN N
treatment NN N
matching NN N
in IN N
posttraumatic JJ N
stress NN N
disorder NN N
. . N

In IN N
the DT N
current JJ N
article NN N
, , N
we PRP N
address VBP N
the DT N
existing VBG N
assumption NN N
in IN N
the DT N
literature NN N
on IN N
cognitive JJ i
behavioral JJ i
treatment NN i
of IN N
PTSD NNP N
that IN N
patients NNS p
with IN p
severe JJ p
negative JJ p
trauma-related JJ p
cognitions NNS p
would MD N
benefit VB N
more RBR N
from IN N
a DT N
treatment NN N
package NN N
that WDT N
includes VBZ N
exposure NN i
and CC i
cognitive JJ i
techniques NNS i
compared VBN N
with IN N
a DT N
treatment NN N
that WDT N
includes VBZ N
exposure NN i
only RB i
. . i

To TO N
test VB N
this DT N
assumption NN N
, , N
54 CD p
PTSD NN p
patients NNS p
were VBD N
randomized VBN N
to TO N
prolonged VB i
exposure NN i
therapy NN i
or CC i
prolonged JJ i
exposure NN i
therapy NN i
plus CC i
cognitive JJ i
restructuring NN i
. . i

Contrary NNP N
to TO N
expectations NNS N
, , N
findings NNS N
revealed VBD N
that IN N
patients NNS N
characterized VBN N
by IN N
more JJR N
severe JJ N
pretreatment NN N
trauma-related JJ N
cognitions NNS N
( ( N
and CC N
more RBR N
severe JJ N
pretreatment NN N
PTSD NNP N
symptoms NNS N
) ) N
fared VBD N
slightly RB N
worse JJR N
in IN N
treatment NN N
combining NN N
exposure NN i
and CC i
cognitive JJ i
restructuring NN i
. . i

However RB N
, , N
there EX N
was VBD N
no DT N
relationship NN N
between IN N
pre- NN N
and CC N
post-treatment JJ o
measures NNS o
of IN o
negative JJ o
cognitions NNS o
and CC o
PTSD NNP o
symptoms NNS o
in IN N
the DT N
exposure NN i
alone RB i
group NN N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
examining VBG N
Person NNP N
X NNP N
Treatment NNP N
interactions NNS N
and CC N
the DT N
efficacy NN o
of IN N
combining VBG N
treatments NNS N
for IN N
PTSD NNP N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Lack NN N
of IN N
antihistamine NN N
properties NNS N
of IN N
single JJ N
dose JJ N
cinnarizine NN i
in IN N
man NN p
. . p

A DT N
simple JJ N
way NN N
to TO N
study VB N
a DT N
histamine JJ N
antagonist NN N
in IN N
man NN p
is VBZ N
to TO N
observe VB N
the DT N
effect NN N
it PRP N
has VBZ N
on IN N
the DT N
magnitude NN N
of IN N
the DT N
skin JJ N
reaction NN N
to TO N
intradermal JJ N
histamine NN i
. . i

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
antihistamine JJ N
activity NN N
of IN N
single JJ N
oral JJ N
doses NNS N
of IN N
75 CD N
mg NNS N
cinnarizine VBP i
using VBG i
75 CD N
mg JJ N
diphenhydramine NN i
as IN i
control NN i
, , N
both DT N
being VBG N
compared VBN N
to TO N
placebo VB i
. . i

The DT N
study NN N
was VBD N
performed VBN N
with IN N
two CD p
groups NNS p
of IN p
5 CD p
healthy JJ p
subjects NNS p
, , p
each DT p
group NN p
receiving VBG p
one CD p
of IN p
the DT p
active JJ p
treatments NNS p
or CC p
placebo NN i
randomly RB p
under IN p
blind JJ p
conditions NNS p
. . p

All DT N
subjects NNS N
received VBN N
intradermal JJ N
injections NNS N
on IN N
the DT N
forearm NN N
of IN N
a DT N
0.05 CD N
ml NN N
saline JJ i
solution NN i
containing VBG N
5 CD N
micrograms NNS N
of IN N
histamine NN i
before IN N
and CC N
at IN N
different JJ N
times NNS N
after IN N
drug NN N
intake NN N
. . N

The DT N
histamine-induced JJ N
wheal JJ N
area NN N
was VBD N
measured VBN N
and CC N
, , N
after IN N
drug NN N
administration NN N
, , N
the DT N
percent NN N
decrease NN N
of IN N
the DT N
wheal JJ o
area NN o
was VBD N
calculated VBN N
. . N

Results NNS N
showed VBD N
that IN N
diphenhydramine NN o
produced VBD o
a DT o
significant JJ o
inhibition NN o
of IN o
the DT o
histamine-induced JJ o
wheal NN o
size NN o
at IN N
1.5 CD N
h NN N
which WDT N
lasted VBD N
up RB N
to TO N
4 CD N
h NNS N
after IN N
drug NN N
administration NN N
, , N
reaching VBG N
maximum JJ N
inhibition NN N
at IN N
2.5 CD N
h. NN N
After IN N
cinnarizine NN i
treatment NN N
no DT o
significant JJ o
decrease NN o
of IN o
the DT o
histamine-induced JJ o
wheal JJ o
area NN o
was VBD o
observed VBN o
at IN o
any DT o
time NN o
. . o

-DOCSTART- -X- O O

Auditory NNP o
signal JJ o
detection NN o
in IN N
paranoid NN p
and CC p
nonparanoid JJ p
schizophrenics NNS p
. . p

-DOCSTART- -X- O O

Dose NNP N
dependent JJ N
pharmacokinetics NNS N
of IN N
theophylline NN i
: : i
Michaelis-Menten JJ N
parameters NNS N
for IN N
its PRP$ N
major JJ N
metabolic JJ N
pathways NNS N
. . N

Dose NNP N
Dependency NNP N
for IN N
pharmacokinetics NNS N
of IN N
theophylline NN i
and CC N
the DT N
formation NN N
of IN N
its PRP$ N
major JJ N
metabolites NNS N
, , N
3-methylxanthine JJ N
( ( N
3-MX JJ N
) ) N
; : N
1-methyluric JJ N
acid NN N
( ( N
1-MU JJ N
) ) N
; : N
1,3-dimethyluric JJ N
acid NN N
( ( N
DMU NNP N
) ) N
, , N
were VBD N
examined VBN N
by IN N
administering VBG N
three CD N
single JJ N
oral JJ N
doses NNS N
( ( N
250 CD N
, , N
375 CD N
, , N
500 CD N
mg NN N
) ) N
of IN N
theophylline NN i
to TO N
six CD p
healthy JJ p
adult NN p
volunteers NNS p
. . p

The DT N
serum NN N
and CC N
urine JJ N
concentrations NNS N
of IN N
theophylline NN i
and CC N
the DT N
metabolites NNS N
in IN N
serum NN N
and CC N
urine NN N
were VBD N
determined VBN N
by IN N
high-performance NN N
liquid NN N
chromatography NN N
. . N

Total JJ o
clearance NN o
of IN N
theophylline NN i
decreased VBN N
and CC N
its PRP$ N
half JJ N
life NN N
increased VBD N
over IN N
the DT N
range NN N
of IN N
doses NNS N
administered VBN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
dose NN N
related JJ N
decrease NN N
in IN N
the DT N
fractional JJ N
recovery NN N
of IN N
3-MX JJ N
and CC N
1-MU JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
dose NN N
related JJ N
increase NN N
in IN N
fractional JJ o
excretion NN o
of IN o
DMU NNP o
and CC N
unchanged JJ N
theophylline NN N
( ( N
p JJ N
< NN N
0.01 CD N
and CC N
p VB N
< JJ N
0.001 CD N
respectively RB N
) ) N
. . N

No DT N
significant JJ N
dose NN N
related VBN N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
renal JJ o
clearance NN o
of IN o
3-MX JJ o
, , o
1-MU JJ o
and CC o
DMU NNP o
, , N
indicating VBG N
linear JJ N
urinary JJ N
excretion NN N
kinetics NNS N
of IN N
the DT N
metabolites NNS N
. . N

Theophylline NNP o
metabolic JJ o
clearance NN o
to TO o
3-MX JJ o
as RB N
well RB N
as IN N
to TO N
1-MU CD N
decreased VBN N
with IN N
increasing VBG N
dose NN N
but CC N
clearance NN N
to TO N
DMU NNP N
remained VBD N
unnaffected JJ N
by IN N
the DT N
size NN N
of IN N
dose NN N
. . N

The DT N
individual JJ N
Michaelis-Menten NNP o
parameters NNS o
Km NNP o
and CC o
Vmax NNP o
were VBD N
estimated VBN N
for IN N
six CD p
subjects NNS p
receiving VBG N
three CD N
different JJ N
single JJ N
doses NNS N
. . N

The DT N
Km NNP o
values NNS o
for IN o
theophylline JJ o
metabolism NN o
to TO o
3-MX JJ o
, , o
1-MU JJ o
and CC o
DMU NNP o
were VBD N
2.4+/-0.6 JJ N
, , N
5.1+/-1.8+/- JJ N
and CC N
112.3+/-36.8 JJ N
mg/L NN N
respectively RB N
and CC N
the DT N
Vmax NNP o
values NNS o
were VBD N
3.5+/-0.7 JJ N
, , N
7.5+/-2.6 JJ N
and CC N
112.3+/-36.8 JJ N
mg/hr NN N
respectively RB N
. . N

The DT N
Km NNP o
values NNS o
for IN o
the DT o
N-demethylation NNP o
pathways NNS o
( ( o
3MX CD o
and CC o
1-MU JJ o
) ) o
were VBD N
lower JJR N
corresponding VBG N
to TO N
therapeutic JJ N
serum NN N
concentrations NNS N
of IN N
drug NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
elimination NN N
kinetics NNS N
of IN N
theophylline NN i
is VBZ N
nonlinear JJ N
in IN N
the DT N
human NN N
in IN N
the DT N
therapeutic JJ N
range NN N
of IN N
serum JJ o
concenntrations NNS o
and CC N
can MD N
be VB N
explained VBN N
by IN N
saturable JJ N
formation NN N
kinetics NNS N
of IN N
3-MX JJ N
and CC N
1-MU JJ N
. . N

In IN N
contrast NN N
to TO N
previous JJ N
studies NNS N
we PRP N
did VBD N
n't RB N
find VB N
obvious JJ N
indication NN N
for IN N
nonlinear JJ N
formation NN N
of IN N
DMU NNP N
at IN N
therapeutic JJ N
concentration NN N
range NN N
. . N

-DOCSTART- -X- O O

Morphological JJ N
onset NN N
and CC N
early JJ N
diagnosis NN N
in IN N
apical JJ p
hypertrophic JJ p
cardiomyopathy NN p
: : p
a DT N
long JJ N
term NN N
analysis NN N
with IN N
nuclear JJ i
magnetic JJ i
resonance NN i
imaging NN i
. . i

OBJECTIVES VB N
A DT N
long-term JJ N
follow-up NN N
study NN N
with IN N
nuclear JJ i
magnetic JJ i
resonance NN i
( ( i
NMR NNP i
) ) i
imaging NN i
was VBD N
undertaken VBN N
to TO N
detect VB N
the DT N
morphological JJ N
onset NN N
and CC N
to TO N
establish VB N
the DT N
early JJ N
diagnosis NN N
in IN N
apical JJ N
hypertrophic JJ N
cardiomyopathy NN N
( ( N
HCM NNP N
) ) N
. . N

BACKGROUND VB N
A DT N
spadelike JJ N
configuration NN N
on IN N
left JJ o
ventriculogram NN o
( ( o
LVG NNP o
) ) o
is VBZ N
regarded VBN N
as IN N
a DT N
diagnostic JJ N
criterion NN N
for IN N
the DT N
classical JJ N
apical JJ N
HCM NNP N
. . N

There EX N
also RB N
exists VBZ N
a DT N
segmented JJ o
hypertrophy NN o
at IN o
the DT o
apical JJ o
level NN o
without IN N
indicating VBG N
the DT N
spadelike NN N
features NNS N
( ( N
a DT N
nonspade NN N
configuration NN N
) ) N
. . N

To TO N
detect VB N
the DT N
hypertrophied JJ N
myocardium NN N
of IN N
the DT N
nonspade JJ N
configuration NN N
, , N
circumferential JJ N
scrutiny NN N
of IN N
the DT N
apex NN N
is VBZ N
required VBN N
. . N

Although IN N
both DT N
configurations NNS N
can MD N
be VB N
underlying JJ N
causes NNS N
of IN N
giant JJ N
negative JJ N
T NNP N
waves NNS N
, , N
etiological JJ N
relationship NN N
between IN N
the DT N
two CD N
is VBZ N
not RB N
clarified VBN N
. . N

METHODS NNP N
The DT N
criteria NN N
for IN N
the DT N
spadelike NN N
configuration NN N
defined VBN N
on IN N
left JJ N
ventricular JJ N
short-axis JJ N
NMR NNP i
images NNS i
were VBD N
as IN N
follows VBZ N
: : N
( ( N
apical JJ N
maximal NN N
thickness NN N
> NN N
or CC N
= $ N
15 CD N
mm NN N
) ) N
, , N
( ( N
apical JJ N
anterior NN N
thickness NN N
over IN N
basal JJ N
anterior JJ N
thickness NN N
> NN N
or CC N
= VB N
1.3 CD N
) ) N
and CC N
( ( N
apical JJ N
posterior NN N
thickness NN N
over IN N
basal JJ N
posterior JJ N
thickness NN N
> NN N
or CC N
=1.3 NN N
) ) N
. . N

Thirteen JJ p
patients NNS p
who WP p
had VBD p
predominant JJ p
hypertrophy NN p
( ( p
> CD p
or CC p
= VB p
15 CD p
mm NN p
) ) p
at IN p
the DT p
apical JJ p
level NN p
without IN p
the DT p
spadelike NN p
configuration NN p
underwent JJ p
NMR NNP i
imaging VBG i
twice RB i
before RB i
and CC i
after IN i
54+/-10 JJ i
months NNS i
' POS i
follow-up NN i
. . i

RESULTS NNP N
Apical NNP o
hypertrophy NN o
that WDT N
had VBD N
been VBN N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
in IN N
four CD N
, , N
the DT N
anterior-lateral JJ N
wall NN N
in IN N
two CD N
, , N
and CC N
the DT N
septal-anterior JJ N
wall NN N
in IN N
one CD N
developed NN N
to TO N
become VB N
circumferential JJ o
hypertrophy NN o
that WDT N
fulfilled VBD N
the DT N
criteria NNS N
for IN N
the DT N
spadelike NN N
configuration NN N
after IN N
the DT N
follow-up JJ N
period NN N
. . N

CONCLUSIONS VB N
The DT N
spadelike NN N
configuration NN N
can MD N
begin VB N
with IN N
the DT N
nonspade JJ N
configuration NN N
and CC N
therefore NN N
, , N
both DT N
can MD N
constitute VB N
a DT N
single JJ N
disease NN N
entity NN N
of IN N
apical JJ N
HCM NNP N
. . N

The DT N
early JJ N
diagnosis NN N
of IN N
apical JJ o
HCM NNP o
can MD N
be VB N
achieved VBN N
by IN N
identifying VBG N
the DT N
hypertrophy NN o
frequently RB N
confined VBN N
to TO N
the DT N
lateral JJ N
wall NN N
at IN N
the DT N
apical JJ N
level NN N
. . N

-DOCSTART- -X- O O

Involvement NN N
of IN N
cholecystokininA NN N
receptors NNS N
in IN N
transient NN N
lower JJR N
esophageal NN N
sphincter NN N
relaxations NNS N
triggered VBN N
by IN N
gastric JJ N
distension NN N
. . N

OBJECTIVE CC N
Transient NNP o
lower JJR o
esophageal NN o
sphincter NN o
relaxations NNS o
( ( o
TLESRs NNP o
) ) o
are VBP N
the DT N
main JJ N
mechanism NN N
underlying VBG N
gastroesophageal JJ N
reflux NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
loxiglumide NN N
, , N
a DT N
specific JJ N
cholecystokininA NN N
( ( N
CCKA NNP N
) ) N
-receptor NN N
antagonist NN N
, , N
on IN N
the DT N
occurrence NN N
of IN N
TLESRs NNP N
evoked VBN N
by IN N
gastric JJ N
distension NN N
. . N

METHODS NNP N
Eight NNP p
healthy JJ p
subjects NNS p
underwent JJ p
esophageal JJ p
manometry NN p
using VBG p
a DT p
10-lumen JJ i
sleeve NN i
assembly NN i
during IN i
placebo NN i
or CC i
loxiglumide NN i
( ( p
10 CD p
mg/kg/h NN p
) ) p
in IN p
a DT N
randomized JJ N
double-blind JJ N
order NN N
. . N

Gastric NNP N
distension NN N
was VBD N
induced VBN N
by IN N
inflation NN i
of IN i
400 CD i
ml NN i
of IN i
air NN i
. . i

RESULTS VB N
Basal NNP o
lower JJR o
esophageal NN o
pressure NN o
( ( o
LESP NNP o
) ) o
and CC o
swallow-induced JJ o
relaxation NN o
were VBD N
not RB N
affected VBN N
by IN N
loxiglumide NN N
. . N

Loxiglumide NNP N
significantly RB N
reduced VBD N
the DT N
number NN N
of IN N
TLESRs NNP o
, , N
from IN N
11.5 CD N
( ( N
5.8-18.3 JJ N
) ) N
to TO N
6.0 CD N
( ( N
3.3-14.3 JJ N
) ) N
during IN N
the DT N
total JJ N
recording JJ N
period NN N
of IN N
1 CD N
h NN N
, , N
and CC N
from IN N
5.5 CD N
( ( N
4.25-7.5 JJ N
) ) N
to TO N
2.0 CD N
( ( N
0.5-6.8 JJ N
) ) N
during IN N
the DT N
first JJ N
15 CD N
min NN N
. . N

The DT N
number NN o
of IN o
common JJ o
cavities NNS o
was VBD N
significantly RB N
decreased VBN N
by IN N
loxiglumide NN N
, , N
from IN N
8.0 CD N
( ( N
4.0-20.0 JJ N
) ) N
to TO N
5.0 CD N
( ( N
2.0-7.8 JJ N
) ) N
. . N

TLESRs NNP o
represented VBD N
the DT N
main JJ N
mechanism NN N
( ( N
60 CD N
% NN N
during IN N
placebo NN N
, , N
74 CD N
% NN N
during IN N
loxiglumide NN N
) ) N
underlying VBG N
common JJ N
cavities NNS N
, , N
followed VBN N
by IN N
swallow-induced JJ N
relaxation NN N
. . N

CONCLUSIONS NNP N
Loxiglumide NNP N
significantly RB N
reduces VBZ N
the DT N
number NN N
of IN N
TLESRs NNP o
triggered VBN N
by IN N
gastric JJ N
distension NN N
without IN N
interfering VBG N
with IN N
swallow-related JJ N
relaxation NN N
of IN N
the DT N
lower JJR N
esophageal NN N
sphincter NN N
, , N
suggesting VBG N
the DT N
involvement NN N
of IN N
CCKA NNP N
receptors NNS N
in IN N
the DT N
reflex JJ N
pathway NN N
mediating VBG N
TLESRs NNP N
. . N

-DOCSTART- -X- O O

Domperidone NN i
, , i
metoclopramide NN i
, , i
and CC i
placebo NN i
. . i

All DT N
give JJ N
symptomatic JJ o
improvement NN o
in IN o
gastroesophageal JJ o
reflux NN o
. . o

A DT N
double-blind JJ N
crossover NN N
study NN N
was VBD N
conducted VBN N
of IN N
two CD N
gastric JJ i
prokinetic JJ i
drugs NNS i
in IN N
23 CD p
patients NNS p
with IN p
gastroesophageal JJ p
reflux NN p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
on IN N
the DT N
basis NN N
of IN N
a DT N
dual-isotope JJ N
mixed-meal JJ N
study NN N
of IN N
their PRP$ N
gastric JJ N
emptying NN N
( ( N
GE NNP N
) ) N
. . N

Group NNP p
I PRP p
had VBD N
normal JJ N
GE NNP N
and CC N
group NN N
II NNP N
delayed VBD N
GE NNP N
. . N

Nine NNP N
gastrointestinal JJ N
symptoms NNS N
were VBD N
assessed VBN N
for IN N
frequency NN N
and CC N
severity NN N
before IN N
treatment NN N
. . N

The DT N
trial NN N
had VBD N
three CD N
1-month JJ N
treatment NN N
periods NNS N
using VBG N
metoclopramide RB i
10 CD N
mg NN N
q.i.d. NN N
, , N
domperidone NN i
20 CD N
mg NN N
q.i.d. NN N
, , N
or CC i
placebo NN i
on IN N
a DT N
random JJ N
basis NN N
. . N

Symptoms NNS N
were VBD N
reassessed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
month NN N
. . N

Taken NNP N
as IN N
a DT N
whole NN N
, , N
the DT N
group NN N
showed VBD N
a DT N
significant JJ N
symptomatic JJ o
response NN o
in IN N
all DT N
three CD N
treatment NN N
periods NNS N
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
, , N
but CC N
patients NNS p
with IN p
delayed JJ p
or CC p
normal JJ p
GE NNP p
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
their PRP$ N
symptomatic JJ N
response NN N
. . N

Eleven JJ N
patients NNS N
complained VBD N
of IN N
side NN o
effects NNS o
with IN N
metoclopramide NN i
and CC N
three CD N
stopped VBD N
therapy NN N
before IN N
the DT N
1-month JJ N
course NN N
was VBD N
completed VBN N
. . N

Two CD N
patients NNS N
described JJ N
side JJ N
effects NNS N
with IN N
domperidone NN i
, , N
including VBG N
one CD N
woman NN N
with IN N
galactorrhea NN o
after IN N
36 CD N
h NN N
of IN N
treatment NN N
. . N

Three CD N
patients NNS N
on IN N
placebo NN i
also RB N
complained VBD N
of IN N
important JJ o
side NN o
effects NNS o
. . o

We PRP N
conclude VBP N
that IN N
a DT N
significant JJ N
placebo NN N
effect NN N
is VBZ N
present JJ N
in IN N
the DT N
treatment NN N
of IN N
gastroesophageal JJ N
reflux NN N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
demonstrated VBN N
in IN N
symptomatic JJ o
improvement NN o
between IN N
placebo NN i
, , i
domperidone NN i
, , N
and CC N
metoclopramide RB i
in IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Exposure NN N
reduced VBN N
agoraphobia NNS N
but CC N
not RB N
panic JJ N
, , N
and CC N
cognitive JJ i
therapy NN i
reduced VBD N
panic JJ N
but CC N
not RB N
agoraphobia RB N
. . N

Earlier JJR N
studies NNS N
showed VBD N
that IN N
cognitive JJ i
therapy NN i
has VBZ N
anti-panic JJ N
effects NNS N
and CC N
exposure NN N
has VBZ N
anti-agoraphobic JJ N
effects NNS N
while IN N
other JJ N
studies NNS N
suggest VBP N
that IN N
agoraphobia NN N
is VBZ N
a DT N
secondary JJ N
complication NN N
of IN N
panic JJ N
disorder NN N
. . N

It PRP N
was VBD N
therefore RB N
hypothesized VBN N
that IN N
cognitive JJ i
therapy NN i
not RB N
only RB N
reduces VBZ N
panic NN N
but CC N
also RB N
agoraphobia JJ N
and CC N
that IN N
it PRP N
potentiates VBZ N
the DT N
effects NNS N
of IN N
exposure NN N
in IN N
vivo NN N
. . N

Two CD p
groups NNS p
of IN p
12 CD p
severe JJ p
agoraphobics NNS p
were VBD p
treated VBN p
with IN N
4 CD N
sessions NNS N
of IN N
cognitive JJ i
therapy NN i
followed VBN i
by IN i
8 CD i
sessions NNS i
of IN i
cognitive JJ i
therapy NN i
combined VBN i
with IN i
in IN i
vivo NN i
exposure NN i
. . i

The DT N
other JJ N
12 CD p
received VBD p
4 CD i
sessions NNS i
of IN i
'associative JJ i
therapy NN i
' '' i
, , N
a DT N
presumably RB N
inert JJ N
treatment NN N
that WDT N
controls VBZ N
for IN N
therapist NN N
attention NN N
, , N
followed VBN N
by IN N
8 CD N
sessions NNS N
of IN N
in IN N
vivo NN N
exposure NN N
that WDT N
was VBD N
framed VBN N
in IN N
common JJ N
behavioral JJ N
terms NNS N
. . N

The DT N
initial JJ N
cognitive JJ N
therapy NN N
produced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
panic JJ o
frequency NN o
, , N
while IN N
associative JJ N
therapy NN N
did VBD N
not RB N
affect VB N
panic NN N
. . N

Neither CC N
cognitive JJ i
therapy NN i
alone RB N
, , N
nor CC N
associate JJ i
therapy NN i
alone RB N
significantly RB N
reduced VBN N
depression NN o
, , o
state NN o
or CC o
trait NN o
anxiety NN o
, , o
self-rated JJ o
agoraphobia NN o
or CC o
behavioral JJ o
avoidance NN o
. . o

After IN N
adding VBG N
exposure NN N
however RB N
, , N
these DT N
parameters NNS N
were VBD N
clearly RB N
and CC N
significantly RB N
reduced VBN N
. . N

Cognitive JJ i
therapy NN i
did VBD N
not RB N
potentiate VB N
exposure NN N
effects NNS N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
chronic JJ i
aerobic JJ i
exercise NN i
and CC i
progressive JJ i
relaxation NN i
on IN N
motor NN N
performance NN N
and CC N
affect NN N
following VBG N
acute JJ N
stress NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
10-week JJ N
aerobic JJ i
exercise NN i
and CC i
progressive JJ i
relaxation NN i
training VBG N
program NN N
on IN N
somatic JJ N
, , N
emotional JJ N
, , N
and CC N
behavioral JJ N
responses NNS N
to TO N
acute VB N
stress NN N
, , N
as IN N
determined VBN N
by IN N
quality NN N
of IN N
motor NN N
performance NN N
and CC N
affect NN N
, , N
were VBD N
examined VBN N
. . N

The DT N
participants NNS N
consisted VBD N
of IN N
60 CD p
unfit JJ p
male NN p
university NN p
undergraduate JJ p
students NNS p
with IN p
no DT p
previous JJ p
training NN p
in IN p
stress JJ p
management NN p
who WP N
were VBD N
randomly RB N
and CC N
evenly RB N
assigned VBD N
to TO N
engage VB N
in IN N
one CD i
of IN i
four CD i
treatments NNS i
over IN i
10 CD i
weeks NNS i
: : i
( ( i
a DT i
) ) i
moderate NN i
aerobic JJ i
exercise NN i
, , i
( ( i
b NN i
) ) i
progressive NN i
relaxation NN i
, , i
( ( i
c NN i
) ) i
a DT i
placebo NN i
group NN i
that WDT i
engaged VBD i
in IN i
group NN i
discussion NN i
but CC i
did VBD i
experience VB i
acute NN i
stress NN i
, , i
and CC i
( ( i
d NN i
) ) i
a DT i
nonintervention NN i
control NN i
group NN i
that WDT i
did VBD i
not RB i
experience VB i
stress NN i
while IN i
performing VBG i
the DT i
motor NN i
task NN i
. . i

Acute NNP N
stress NN N
consisted VBD N
of IN N
losing VBG N
against IN N
a DT N
competitor NN N
of IN N
the DT N
opposite JJ N
sex NN N
on IN N
the DT N
criterion NN N
motor NN N
task NN N
while IN N
receiving VBG N
unpleasant JJ N
information NN N
about IN N
their PRP$ N
performance NN N
over IN N
30 CD N
preintervention NN N
and CC N
30 CD N
postintervention NN N
trials NNS N
. . N

Analyses NNS N
indicated VBD N
that IN N
aerobic JJ N
exercisers NNS N
, , N
in IN N
comparisons NNS N
with IN N
the DT N
other JJ N
groups NNS N
, , N
responded VBD N
to TO N
acute VB o
stress NN o
with IN N
more RBR N
positive JJ N
affect NN N
, , N
lower JJR o
stressor NN o
task JJ o
heart NN o
rate NN o
, , o
reduced VBN o
systolic JJ o
( ( o
but CC o
not RB o
diastolic JJ o
) ) o
blood NN o
pressure NN o
, , N
and CC N
superior JJ N
motor NN o
performance NN o
. . o

Progressive JJ N
relaxation NN N
markedly RB N
reduced VBD N
systolic JJ o
blood NN o
pressure NN o
but CC N
did VBD N
not RB N
favorably RB N
influence JJ N
performance NN N
or CC N
affect VB N
in IN N
response NN N
to TO N
acute VB o
stress NN o
. . o

Placebo NNP N
and CC N
control NN N
groups NNS N
were VBD N
statistically RB N
similar JJ N
on IN N
all DT N
measures NNS N
. . N

The DT N
findings NNS N
indicated VBD N
support NN N
for IN N
the DT N
use NN N
of IN N
chronic JJ N
aerobic JJ N
exercise NN N
as IN N
a DT N
strategy NN N
for IN N
improved JJ N
coping NN N
with IN N
acute JJ N
stress NN N
. . N

-DOCSTART- -X- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
ranibizumab NN i
with IN i
and CC i
without IN i
ketorolac NN i
eyedrops NNS i
for IN N
exudative JJ o
age-related JJ o
macular JJ o
degeneration NN o
. . o

AIMS NNP N
To TO N
evaluate VB N
whether IN N
ketorolac NN i
eyedrops NNS i
and CC N
ranibizumab VB i
intravitreal JJ i
injections NNS i
would MD N
provide VB N
additional JJ N
benefit NN N
over IN N
ranibizumab NN i
alone RB N
in IN N
the DT N
treatment NN N
of IN N
choroidal JJ p
neovascularisation NN p
( ( p
CNV NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
pilot NN N
study NN N
of IN N
eyes NNS p
with IN p
new-onset JJ p
CNV NNP p
. . p

A NNP N
total NN p
of IN p
56 CD p
patients NNS p
were VBD p
enrolled VBN p
consecutively RB N
and CC N
randomised VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
to TO N
receive VB N
combination NN N
treatment NN N
with IN N
intravitreal JJ i
ranibizumab NN i
and CC i
topical JJ i
ketorolac NN i
( ( N
group NN N
1 CD N
) ) N
or CC N
ranibizumab VB i
alone RB i
( ( N
group NN N
2 CD N
) ) N
. . N

All DT N
patients NNS N
received VBN N
monthly JJ N
0.5-mg JJ N
ranibizumab NN i
intravitreal NN i
injections NNS i
for IN N
3 CD N
months NNS N
, , N
after IN N
which WDT N
monthly JJ N
injections NNS N
were VBD N
administered VBN N
in IN N
accordance NN N
with IN N
the DT N
standard NN N
of IN N
care NN N
. . N

Group NNP N
1 CD N
patients NNS N
also RB N
self-administered JJ N
one CD N
drop NN N
of IN N
ketorolac NN i
three CD N
times NNS N
a DT N
day NN N
for IN N
6 CD N
months NNS N
. . N

All DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
both DT N
groups NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
best-corrected JJ o
visual JJ o
acuity NN o
( ( N
both DT N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
two CD N
treatments NNS N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
the DT N
number NN o
of IN o
ranibizumab JJ o
injections NNS o
required VBN o
. . o

However RB N
, , N
the DT N
mean JJ N
6-month JJ o
change NN o
in IN o
central JJ o
macular JJ o
thickness NN o
( ( o
CMT NNP o
) ) o
in IN N
the DT N
combination NN N
group NN N
was VBD N
-124 VBN N
?m NNP N
( ( N
-29.7 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
while IN N
in IN N
the DT i
ranibizumab-only JJ i
group NN N
, , N
the DT N
change NN N
was VBD N
-86.9 JJ N
?m NNP N
( ( N
-19.5 CD N
% NN N
; : N
p=0.001 CC N
) ) N
; : N
thus RB N
, , N
the DT i
combination NN i
treatment NN i
resulted VBD i
in IN N
a DT N
greater JJR N
reduction NN N
( ( N
p=0.003 NN N
) ) N
. . N

The DT i
combination NN i
treatment NN i
had VBD i
no DT N
adverse JJ o
effects NNS o
. . o

CONCLUSIONS VB N
This DT N
pilot NN N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
prospectively RB N
investigate VB N
the DT o
efficacy NN o
and CC o
safety NN o
of IN o
a DT N
combination NN N
of IN N
0.45 CD i
% NN i
ketorolac NN i
eyedrops VBZ i
three CD i
times NNS N
a DT N
day NN N
and CC i
intravitreal VB i
ranibizumab JJ i
injections NNS i
in IN i
patients NNS p
with IN p
CNV NNP p
, , p
and CC N
suggests VBZ N
that DT N
topical JJ i
ketorolac NN i
supplements VBZ i
the DT N
activity NN N
of IN N
intravitreal NN i
ranibizumab NN i
in IN i
reducing VBG o
CMT NNP o
in IN o
CNV NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
sport-tinted JJ i
contact NN i
lenses NNS i
for IN N
contrast NN N
enhancement NN N
on IN N
retinal JJ N
straylight NN N
measurements NNS N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
tinted JJ i
contact NN i
lenses NNS i
( ( i
CL NNP i
) ) i
designed VBN N
for IN N
outdoor JJ N
sports NNS N
activity NN N
on IN N
the DT N
psychometric JJ N
determination NN N
of IN N
retinal JJ N
straylight NN N
using VBG N
the DT N
compensation NN N
comparison NN N
method NN N
. . N

METHODS NNP N
Thirteen NNP p
emmetropic JJ p
subjects NNS p
were VBD N
randomly RB N
fitted VBN N
with IN N
two CD i
different JJ i
tinted VBN i
Nike NNP i
Maxsight NNP i
( ( i
Bausch NNP i
& CC i
Lomb NNP i
, , i
Rochester NNP i
, , i
NY NNP i
, , i
USA NNP i
) ) i
CL NNP i
in IN i
one CD i
eye NN i
, , i
while IN i
the DT i
contralateral JJ i
eye NN i
was VBD i
fitted VBN i
with IN i
a DT i
clear JJ i
lens NNS i
made VBN i
of IN i
the DT i
same JJ i
material NN i
( ( i
Optima NNP i
38 CD i
, , i
Bausch NNP i
& CC i
Lomb NNP i
) ) i
. . i

Three CD N
valid JJ N
straylight NN o
measurements NNS o
were VBD N
taken VBN N
on IN N
each DT N
eye NN N
before IN N
and CC N
a DT N
few JJ N
minutes NNS N
after IN N
lens JJ N
insertion NN N
, , N
when WRB N
lens VBZ N
stabilization NN N
had VBD N
occurred VBN N
. . N

RESULTS VB N
The DT N
subjects NNS N
' POS N
mean NN o
straylight NN o
values NNS o
were VBD N
0.90 CD N
+/- JJ N
0.09 CD N
at IN N
baseline NN N
and CC N
0.95 CD N
+/- JJ N
0.10 CD N
with IN N
the DT N
clear JJ N
Optima NNP N
38 CD N
CL NNP N
. . N

Straylight NNP o
values NNS o
were VBD N
0.97 CD N
+/- JJ N
0.10 CD N
and CC N
1.0 CD N
+/- JJ N
0.10 CD N
log JJ N
units NNS N
with IN N
the DT N
amber NN N
and CC N
grey-green JJ N
tinted JJ N
CL NNP N
, , N
respectively RB N
. . N

Differences NNS N
in IN N
straylight NN o
between IN N
baseline NN N
( ( N
without IN N
CL NNP N
) ) N
and CC N
with IN N
the DT N
clear JJ N
CL NNP N
in IN N
place NN N
were VBD N
neither RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.066 CD N
) ) N
nor CC N
was VBD N
there EX N
a DT N
significant JJ N
difference NN N
between IN N
baseline NN N
and CC N
the DT N
amber NN N
CL NNP N
( ( N
p JJ N
= NNP N
0.052 CD N
) ) N
. . N

However RB N
, , N
the DT N
grey-green JJ N
CL NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
from IN N
baseline NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
. . N

Differences NNS N
in IN N
straylight NN N
with IN N
the DT N
clear JJ N
CL NNP N
compared VBN N
with IN N
the DT N
grey-green JJ N
CL NNP N
were VBD N
also RB N
statistically RB N
different JJ N
from IN N
zero NN N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
showing VBG N
an DT N
increased VBN N
straylight NN o
value NN o
for IN N
the DT N
tinted JJ N
CL NNP N
. . N

These DT N
differences NNS N
were VBD N
variable JJ N
, , N
but CC N
consistent JJ N
for IN N
each DT N
subject NN N
, , N
thus RB N
those DT N
showing VBG N
higher JJR N
or CC N
lower JJR N
changes NNS N
with IN N
one CD N
tinted JJ N
lens VBZ N
tended VBN N
to TO N
show VB N
the DT N
same JJ N
trend NN N
with IN N
the DT N
second JJ N
lens NNS N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.736 CD N
) ) N
. . N

CONCLUSIONS NNP N
Despite IN N
increases NNS N
having VBG N
been VBN N
found VBN N
in IN N
straylight JJ N
values NNS N
with IN N
tinted VBN N
contact NN N
lenses NNS N
, , N
those DT N
changes NNS N
are VBP N
not RB N
likely JJ N
to TO N
induce VB N
clinically RB N
significant JJ N
changes NNS N
in IN N
visual JJ N
function NN N
under IN N
photopic NN N
conditions NNS N
, , N
even RB N
for IN N
the DT N
grey-green JJ N
CL NNP N
, , N
which WDT N
seems VBZ N
to TO N
increase VB N
straylight JJ N
values NNS N
more RBR N
significantly RB N
than IN N
the DT N
amber JJ N
CL NNP N
. . N

This DT N
difference NN N
between IN N
the DT N
tinted JJ N
CL NNP N
could MD N
suggest VB N
a DT N
wavelength JJ N
dependence NN N
of IN N
straylight NN N
values NNS N
, , N
although IN N
this DT N
should MD N
be VB N
investigated VBN N
further JJ N
by IN N
controlling VBG N
for IN N
pupil NN N
size NN N
and CC N
subjects NNS N
' POS N
pigmentation NN N
, , N
as RB N
well RB N
as IN N
by IN N
using VBG N
neutral JJ N
density NN N
filters NNS N
. . N

-DOCSTART- -X- O O

Joint NNP N
study NN N
of IN N
extracranial JJ N
arterial JJ N
occlusion NN N
. . N

VI NNP N
. . N

Racial JJ N
differences NNS N
in IN N
hospitalized JJ p
patients NNS p
with IN p
ischemic JJ p
stroke NN p
. . p

-DOCSTART- -X- O O

Long-term JJ o
results NNS o
of IN N
the DT N
MRC NNP i
AML10 NNP i
trial NN p
. . p

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
of IN N
the DT N
effect NN o
of IN N
indomethacin NN i
in IN N
uremic JJ o
pericarditis NN o
. . o

To TO N
determine VB N
the DT N
impact NN N
of IN N
indomethacin NN i
on IN N
the DT N
course NN N
of IN N
uremic JJ N
pericarditis NN N
we PRP N
performed VBD N
a DT N
prospective JJ N
, , N
double JJ N
blind NN N
study NN N
in IN N
which WDT N
24 CD p
patients NNS p
with IN p
endstage NN p
chronic JJ p
renal JJ p
failure NN p
and CC p
pericarditis NN p
randomly RB p
received VBD p
indomethacin JJ i
, , p
25 CD p
mg NN p
four CD p
times NNS p
daily RB p
, , p
( ( p
11 CD p
patients NNS p
) ) p
or CC p
a DT p
placebo NN i
( ( p
13 CD p
patients NNS p
) ) p
for IN N
a DT N
3-week JJ N
period NN N
. . N

All DT N
patients NNS p
received VBN p
peritoneal JJ p
or CC p
hemodialysis NN p
treatment NN p
concurrently RB p
with IN N
the DT N
study NN N
drug NN N
. . N

In IN N
contrast NN N
to TO N
the DT N
placebo NN i
, , i
indomethacin NN i
produced VBD N
an DT N
immediate JJ N
and CC N
sustained JJ N
reduction NN o
of IN o
fever NN o
in IN N
all DT N
but CC N
one CD N
patient NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
indomethacin NN i
had VBD N
no DT N
effect NN N
on IN N
the DT N
duration NN o
of IN o
chest NN o
pain NN o
( ( N
mean JJ N
days NNS N
+/- JJ N
SE NNP N
: : N
placebo NN i
1.4 CD N
+/- JJ N
0.6 CD N
, , N
indomethacin JJ i
5.5 CD N
+/- JJ N
3.3 CD N
) ) N
, , N
duration NN N
of IN N
pericardial JJ o
friction NN o
rub NN o
( ( N
placebo JJ N
10.3 CD N
+/- JJ N
1.7 CD N
, , N
indomethacin JJ i
16.0 CD N
+/- JJ N
3.8 CD N
) ) N
, , N
or CC N
on IN N
the DT N
amount NN N
of IN N
pericardial JJ o
effusion NN o
. . o

Further NNP N
, , N
indomethacin NN N
did VBD N
not RB N
diminish VB N
the DT N
need NN o
for IN o
invasive JJ o
surgical JJ o
procedures NNS o
for IN o
relief NN o
of IN o
tamponade NN o
( ( N
three CD N
of IN N
13 CD N
placebo NN N
patients NNS N
, , N
two CD N
of IN N
11 CD N
indomethacin JJ N
patients NNS N
) ) N
or CC N
result NN N
in IN N
decreased JJ N
mortality NN o
rate NN o
. . o

Death NNP o
( ( N
not RB N
due RB N
to TO N
pericarditis NN N
) ) N
occurred VBD N
in IN N
two CD N
patients NNS N
treated VBN N
with IN N
indomethacin NN N
and CC N
one CD N
patient NN N
who WP N
received VBD N
the DT N
placebo NN i
. . i

In IN N
our PRP$ N
patients NNS N
pericarditis VBP N
encompassed VBD N
a DT N
wide JJ N
spectrum NN N
ranging VBG N
from IN N
a DT N
mild JJ o
illness NN o
of IN o
several JJ o
days NNS o
duration NN o
to TO N
a DT N
painful JJ o
and CC o
debilitating JJ o
disease NN o
lasting JJ o
weeks NNS o
and CC N
requiring VBG N
surgical JJ o
intervention NN o
. . o

Although IN N
the DT N
size NN N
of IN N
our PRP$ N
population NN N
prohibits VBZ N
definitive JJ N
conclusions NNS N
, , N
it PRP N
would MD N
appear VB N
that IN N
, , N
except IN N
for IN N
fever NN N
, , N
the DT N
manifestations NNS N
and CC N
natural JJ N
history NN N
of IN N
this DT N
illness NN o
are VBP N
unaffected VBN N
by IN N
indomethacin NN i
. . i

-DOCSTART- -X- O O

Can MD N
HMG NNP i
Co-A NNP i
reductase NN i
inhibitors NNS i
( ( i
statins NNS i
) ) i
slow VBP N
the DT N
progression NN N
of IN N
age-related JJ p
macular JJ p
degeneration NN p
? . N
The DT N
age-related JJ N
maculopathy NN N
statin NN N
study NN N
( ( N
ARMSS NNP N
) ) N
. . N

Age-related JJ p
macular JJ p
degeneration NN p
( ( p
AMD NNP p
) ) p
is VBZ N
responsible JJ N
for IN N
the DT N
majority NN N
of IN N
visual JJ N
impairment NN N
in IN N
the DT N
Western JJ N
world NN N
. . N

The DT N
role NN N
of IN N
cholesterol-lowering JJ N
medications NNS N
, , N
HMG NNP i
Co-A NNP i
reductase NN i
inhibitors NNS i
or CC i
statins NNS i
, , N
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
or CC N
of IN N
delaying VBG N
its PRP$ N
progression NN N
has VBZ N
not RB N
been VBN N
fully RB N
investigated VBN N
. . N

A DT N
3-year JJ N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
40 CD i
mg NN i
simvastatin NN i
per IN i
day NN i
compared VBN i
to TO i
placebo VB i
in IN N
subjects NNS p
at IN p
high JJ p
risk NN p
of IN p
AMD NNP p
progression NN p
is VBZ N
described VBN N
. . N

This DT N
paper NN N
outlines VBZ N
the DT N
primary JJ N
aims NNS N
of IN N
the DT N
Age-Related NNP N
Maculopathy NNP N
Statin NNP N
Study NNP N
( ( N
ARMSS NNP N
) ) N
, , N
and CC N
the DT N
methodology NN N
involved VBN N
. . N

Standardized NNP N
clinical JJ N
grading NN N
of IN N
macular JJ N
photographs NN N
and CC N
comparison NN N
of IN N
serial JJ N
macular JJ N
digital NN N
photographs NN N
, , N
using VBG N
the DT N
International NNP N
grading NN N
scheme NN N
, , N
form VB N
the DT N
basis NN N
for IN N
assessment NN N
of IN N
primary JJ N
study NN N
outcomes NNS N
. . N

In IN N
addition NN N
, , N
macular JJ N
function NN N
is VBZ N
assessed VBN N
at IN N
each DT N
visit NN N
with IN N
detailed JJ N
psychophysical JJ N
measurements NNS N
of IN N
rod NN N
and CC N
cone NN N
function NN N
. . N

Information NN N
collected VBN N
in IN N
this DT N
study NN N
will MD N
assist VB N
in IN N
the DT N
assessment NN N
of IN N
the DT N
potential JJ N
value NN N
of IN N
HMG NNP i
Co-A NNP i
reductase NN i
inhibitors NNS i
( ( i
statins NNS i
) ) i
in IN N
reducing VBG N
the DT N
risk NN N
of IN N
AMD NNP N
progression NN N
. . N

-DOCSTART- -X- O O

Modest JJS N
visceral JJ N
fat NN i
gain NN i
causes VBZ N
endothelial JJ p
dysfunction NN p
in IN p
healthy JJ p
humans NNS p
. . p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
fat JJ N
gain NN N
and CC N
its PRP$ N
distribution NN N
on IN N
endothelial JJ o
function NN o
in IN p
lean JJ p
healthy JJ p
humans NNS p
. . p

BACKGROUND NNP N
Endothelial NNP o
dysfunction NN o
has VBZ N
been VBN N
identified VBN N
as IN N
an DT N
independent JJ N
predictor NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

Whether NNP N
fat JJ i
gain NN i
impairs NNS N
endothelial JJ o
function NN o
is VBZ N
unknown JJ N
. . N

METHODS VB N
A DT N
randomized NN N
controlled VBD N
study NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
fat JJ i
gain NN i
on IN N
endothelial JJ N
function NN N
. . N

Forty-three JJ p
normal-weight JJ p
healthy JJ p
volunteers NNS p
were VBD p
recruited VBN p
( ( p
mean JJ p
age NN p
29 CD p
years NNS p
; : p
18 CD p
women NNS p
) ) p
. . p

Subjects NNS p
were VBD N
assigned VBN N
to TO N
gain VB i
weight NN i
( ( N
approximately RB N
4 CD N
kg NNS N
) ) N
( ( N
n=35 JJ N
) ) N
or CC N
to TO N
maintain VB i
weight NN i
( ( N
n=8 JJ N
) ) N
. . N

Endothelial JJ o
function NN o
( ( o
brachial JJ o
artery NN o
flow-mediated JJ o
dilation NN o
[ NNP o
FMD NNP o
] NNP o
) ) o
was VBD N
measured VBN N
at IN N
baseline NN N
, , N
after IN N
fat JJ N
gain NN N
( ( N
8 CD N
weeks NNS N
) ) N
, , N
and CC N
after IN N
weight JJ N
loss NN N
( ( N
16 CD N
weeks NNS N
) ) N
for IN N
fat JJ N
gainers NNS N
and CC N
at IN N
baseline NN N
and CC N
follow-up NN N
( ( N
8 CD N
weeks NNS N
) ) N
for IN N
weight NN N
maintainers NNS N
. . N

Body NNP N
composition NN N
was VBD N
measured VBN N
by IN N
dual-energy JJ N
X-ray JJ N
absorptiometry NN N
and CC N
abdominal JJ N
computed JJ N
tomographic JJ N
scans NNS N
. . N

RESULTS NNP N
After IN N
an DT N
average JJ N
weight JJ N
gain NN N
of IN N
4.1 CD N
kg NN N
, , N
fat JJ N
gainers NNS N
significantly RB N
increased VBD N
their PRP$ N
total JJ o
, , o
visceral JJ o
, , o
and CC o
subcutaneous JJ o
fat NN o
. . o

Blood NNP o
pressure NN o
and CC o
overnight JJ o
polysomnography NN o
did VBD N
not RB N
change NN N
after IN N
fat JJ N
gain NN N
or CC N
loss NN N
. . N

FMD NNP o
remained VBD N
unchanged JJ N
in IN N
weight JJ N
maintainers NNS N
. . N

FMD NNP o
decreased VBD N
in IN N
fat JJ N
gainers NNS N
( ( N
9.1+/-3 CD N
% NN N
vs. FW N
7.8+/-3.2 CD N
% NN N
, , N
p=0.003 NN N
) ) N
but CC N
recovered VBD N
to TO N
baseline VB N
when WRB N
subjects NNS N
shed VBD N
the DT N
gained JJ N
weight NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
correlation NN N
between IN N
the DT N
decrease NN N
in IN N
FMD NNP o
and CC N
the DT N
increase NN N
in IN N
visceral JJ o
fat JJ o
gain NN o
( ( N
rho=-0.42 JJ N
, , N
p=0.004 NN N
) ) N
, , N
but CC N
not RB N
with IN N
subcutaneous JJ o
fat JJ o
gain NN o
( ( N
rho=-0.22 JJ N
, , N
p=0.15 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
normal-weight JJ p
healthy JJ p
young JJ p
subjects NNS p
, , N
modest JJ N
fat JJ i
gain NN i
results NNS N
in IN N
impaired JJ N
endothelial JJ o
function NN o
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
changes NNS N
in IN N
blood NN o
pressure NN o
. . o

Endothelial JJ o
function NN o
recovers NNS N
after IN N
weight JJ N
loss NN N
. . N

Increased VBN N
visceral JJ o
rather RB o
than IN o
subcutaneous JJ o
fat JJ o
predicts NNS N
endothelial JJ o
dysfunction NN o
. . o

( ( N
Fat JJ N
Gain NNP N
and CC N
Cardiovascular NNP N
Disease NNP N
Mechanisms NNP N
; : N
NCT00589498 NNP N
) ) N
. . N

-DOCSTART- -X- O O

The DT N
prophylactic JJ o
effect NN o
of IN N
valproate NN i
on IN N
glyceryltrinitrate NN o
induced VBN o
migraine NN o
. . o

In IN N
this DT N
study NN N
the DT N
human JJ N
glyceryltrinitrate NN N
( ( N
GTN NNP N
) ) N
model NN N
of IN N
migraine NN N
was VBD N
for IN N
the DT N
first JJ N
time NN N
used VBN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
prophylactic JJ i
drug NN i
. . i

We PRP N
chose VBD N
to TO N
test VB N
valproate NN i
due JJ N
to TO N
its PRP$ N
well RB N
documented JJ N
effect NN N
as IN N
a DT N
migraine JJ i
prophylactic JJ i
drug NN i
. . i

Efficacy NN o
of IN N
this DT N
compound NN N
would MD N
support VB N
the DT N
usefulness NN N
of IN N
the DT N
model NN N
in IN N
prophylactic JJ N
antimigraine JJ N
drug NN N
development NN N
. . N

Twelve CD p
patients NNS p
with IN p
migraine NN p
without IN p
aura NN p
were VBD p
included VBN p
in IN p
a DT p
randomized JJ p
double JJ p
blind NN p
crossover NN p
study NN p
. . p

Valproate VB i
1000 CD N
mg NN N
or CC i
placebo NN i
was VBD N
given VBN N
daily RB N
, , N
each DT N
for IN N
a DT N
minimum NN N
of IN N
13 CD N
days NNS N
. . N

On IN N
the DT N
last JJ N
treatment NN N
day NN N
of IN N
each DT N
arm NN N
a DT N
20 CD N
min NN N
intravenous JJ N
infusion NN N
of IN N
GTN NNP i
( ( N
0.25 CD N
microg/kg/min NN N
) ) N
was VBD N
given VBN N
. . N

Headache NNP o
was VBD N
registered VBN N
for IN N
12 CD N
h NN N
after IN N
the DT N
infusion NN N
and CC N
headache NN o
intensity NN o
was VBD N
scored VBN N
on IN N
a DT N
scale NN N
from IN N
0 CD N
to TO N
10 CD N
. . N

Fulfillment NN N
of IN N
IHS NNP N
criteria NNS N
was VBD N
recorded VBN N
for IN N
24 CD N
h. PDT N
The DT N
middle JJ o
cerebral JJ o
arteries NNS o
were VBD N
evaluated VBN N
by IN N
transcranial JJ o
Doppler NNP o
and CC N
the DT N
diameter NN o
of IN o
the DT o
superficial JJ o
temporal JJ o
and CC o
radial JJ o
arteries NNS o
were VBD N
measured VBN N
with IN N
high JJ o
frequency NN o
ultrasound NN o
. . o

GTN NNP o
evoked VBD o
migraine JJ o
fulfilling NN o
IHS NNP o
criteria NNS o
1.1 CD N
in IN N
6 CD N
patients NNS N
after IN N
placebo NN i
and CC N
in IN N
2 CD N
patients NNS N
after IN N
valproate NN i
( ( N
P NNP N
= NNP N
0.125 CD N
) ) N
. . N

Including VBG N
additionally RB N
3 CD N
patients NNS N
on IN N
placebo NN i
and CC N
1 CD N
patient NN N
on IN N
valproate NN i
who WP N
felt VBD N
they PRP N
had VBD N
suffered VBN N
a DT N
migraine JJ o
attack NN o
, , N
but CC N
who WP N
had VBD N
as IN N
associated VBN o
symptoms NNS o
only RB N
photophobia VBP o
or CC N
phonophobia VBP o
, , N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
of IN o
patients NNS o
with IN o
induced JJ o
migraine NN o
after IN N
valproate NN i
was VBD N
seen VBN N
( ( N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

Median JJ o
peak NN o
headache NN o
intensity NN o
was VBD N
1 CD N
( ( N
range VB N
0-9 NN N
) ) N
after IN N
valproate NN i
compared VBN N
to TO N
4.5 CD N
( ( N
range VB N
0-8 NN N
) ) N
after IN N
placebo NN i
( ( N
P NNP N
= NNP N
0.120 CD N
) ) N
. . N

Pretreatment NN N
with IN N
valproate NN i
as IN N
compared VBN N
to TO N
placebo VB i
reduced VBN N
the DT N
velocity NN o
in IN N
both DT N
middle JJ o
cerebral NN o
arteries NNS o
after IN N
GTN NNP N
( ( N
left VBN N
P NNP N
= NNP N
0.021 CD N
, , N
right JJ N
P NNP N
= NNP N
0.031 CD N
) ) N
. . N

No DT N
effect NN N
of IN N
valproate NN i
was VBD N
seen VBN N
in IN N
the DT N
diameter NN o
of IN o
the DT o
superficial JJ o
temporal JJ o
artery NN o
( ( N
P NNP N
= NNP N
0.781 CD N
) ) N
or CC N
the DT N
radial JJ o
artery NN o
( ( N
P NNP N
= NNP N
0.367 CD N
) ) N
before IN N
or CC N
after IN N
GTN NNP N
. . N

The DT N
study NN N
indicates VBZ N
that IN N
a DT N
prophylactic JJ N
effect NN N
of IN N
valproate NN i
may MD N
be VB N
demonstrated VBN N
using VBG N
the DT N
GTN NNP o
human JJ o
migraine NN o
model NN i
. . i

Although IN N
, , N
all DT N
headache NN o
parameters NNS o
were VBD N
reduced VBN N
after IN N
valproate NN i
compared VBN N
to TO N
placebo VB i
, , N
only RB N
one CD N
parameter NN N
was VBD N
statistically RB N
significantly RB N
reduced VBN N
probably RB N
because IN N
of IN N
the DT N
small JJ N
number NN N
of IN N
patients NNS N
. . N

The DT N
size NN N
of IN N
the DT N
effect NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
valproate NN N
in IN N
clinical JJ N
trials NNS N
. . N

The DT i
GTN NNP i
model NN i
may MD N
therefore RB N
be VB N
a DT N
valid JJ N
tool NN N
for IN N
testing VBG N
new JJ N
prophylactic JJ N
antimigraine NN N
drugs NNS N
. . N

-DOCSTART- -X- O O

Transurethral JJ i
prostate NN i
resection NN i
and CC N
bleeding NN N
: : N
a DT N
randomized JJ N
, , N
placebo NN i
controlled VBD N
trial NN N
of IN N
role NN N
of IN N
finasteride NN i
for IN N
decreasing VBG N
operative JJ N
blood NN N
loss NN N
. . N

PURPOSE NNP N
Bleeding NNP N
associated VBN N
with IN N
transurethral JJ N
prostate NN N
resection NN N
can MD N
often RB N
be VB N
significant JJ N
and CC N
lead JJ N
to TO N
increased VBN N
morbidity NN N
and CC N
occasionally RB N
mortality NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
finasteride NN i
decreases VBZ N
bleeding VBG N
in IN N
patients NNS p
with IN p
hematuria NNS p
of IN p
prostatic JJ p
origin NN p
. . p

We PRP N
hypothesized VBD N
that IN N
bleeding VBG N
in IN N
patients NNS p
undergoing JJ p
transurethral JJ p
prostate NN p
resection NN p
could MD N
be VB N
decreased VBN N
by IN N
giving VBG N
finasteride NN i
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total JJ p
70 CD p
patients NNS p
scheduled VBN p
to TO p
undergo VB p
elective JJ p
transurethral JJ p
prostate NN p
resection NN p
were VBD p
randomized VBN p
to TO N
receive VB N
5 CD i
mg. NNS i
finasteride JJ i
daily RB i
or CC i
placebo VB i
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

Serum NNP o
hemoglobin NN o
was VBD N
measured VBN N
before IN N
and CC N
after IN N
surgery NN N
, , N
and CC N
the DT N
following JJ N
day NN N
. . N

The DT N
volume NN o
of IN o
irrigation NN o
fluid NN o
used VBN N
and CC N
its PRP$ N
hemoglobin JJ N
concentration NN N
as RB N
well RB N
as IN N
resected VBN N
prostate NN N
weight NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
68 CD p
patients NNS p
who WP p
underwent JJ p
transurethral JJ p
prostate NN p
resection NN p
2 CD N
were VBD N
withdrawn VBN o
before RB N
surgery NN N
, , N
and CC N
so RB N
32 CD N
received VBD N
finasteride NN i
and CC N
36 CD N
received VBD N
placebo NN i
. . i

There EX N
was VBD N
significantly RB N
less JJR N
mean JJ o
blood NN o
loss NN o
in IN o
irrigation NN o
fluid NN o
in IN N
the DT N
finasteride NN i
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
43.6 CD N
versus NN N
69.3 CD N
gm NN N
. . N

hemoglobin NN N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
mean JJ N
difference NN N
was VBD N
more RBR N
significant JJ N
when WRB N
blood NN o
loss NN o
per IN N
gm NN N
. . N

resected JJ N
prostate NN N
was VBD N
calculated VBN N
( ( N
2.65 CD N
versus NN N
4.65 CD N
gm NN N
. . N

hemoglobin NN N
per IN N
gm NN N
. . N

prostate NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
finasteride NN i
given VBN N
for IN N
2 CD N
weeks NNS N
preoperatively RB N
decreases VBZ N
bleeding VBG o
in IN N
patients NNS p
undergoing JJ p
transurethral JJ p
prostate NN p
resection NN p
. . p

Further NNP N
study NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
and CC N
dose JJ N
duration NN N
to TO N
minimize VB N
blood NN o
loss NN o
and CC N
identify VB N
how WRB N
relevant JJ N
such JJ N
a DT N
decrease NN N
in IN N
bleeding NN N
is VBZ N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

N-acetylcysteine NNP i
as IN N
an DT N
adjunctive JJ i
therapy NN i
to TO N
risperidone VB i
for IN N
treatment NN N
of IN N
irritability NN N
in IN p
autism NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
efficacy NN N
and CC N
safety NN N
. . N

OBJECTIVES NNP N
According VBG N
to TO N
the DT N
proposed VBN N
interference NN N
of IN N
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
with IN N
pathophysiologic JJ N
processes NNS N
of IN N
autistic JJ N
disorders NNS N
( ( N
ADs NNP N
) ) N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT o
effectiveness NN o
and CC o
safety NN o
of IN N
NAC NNP i
as IN N
an DT N
adjunct NN N
to TO N
risperidone VB i
in IN N
the DT N
treatment NN N
of IN N
ADs NNP N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
trial NN N
. . N

METHODS NNP N
The DT N
participants NNS p
were VBD p
referred VBN p
outpatients NNS p
between IN p
4 CD p
and CC p
12 CD p
years NNS p
of IN p
age NN p
with IN p
the DT p
diagnosis NN p
of IN p
ADs NNP p
and CC p
a DT p
score NN p
of IN p
more JJR p
than IN p
12 CD p
on IN p
Aberrant JJ o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Irritability NNP o
subscale NN o
score NN o
. . o

The DT N
participants NNS N
were VBD N
randomized VBN N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ i
plus CC i
NAC NNP i
, , N
and CC N
the DT N
other JJ N
group NN N
received VBD N
risperidone JJ i
plus CC i
placebo NN i
. . i

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
NAC NNP i
was VBD N
600 CD N
to TO N
900 CD N
mg/d NN N
. . N

The DT N
main JJ N
outcome NN N
was VBD N
mean JJ o
decrease NN o
in IN o
the DT o
ABC-C NNP o
irritability NN o
subscale NN o
score NN o
from IN N
baseline NN N
at IN N
5 CD N
and CC N
10 CD N
weeks NNS N
. . N

Changes NNS o
in IN o
other JJ o
subscales NNS o
were VBD N
considered VBN N
as IN N
secondary JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
Forty NNP p
patients NNS p
completed VBD p
the DT p
10-week JJ p
trial NN p
. . p

Baseline NNP N
characteristics NNS N
including VBG N
age NN o
, , o
sex NN o
and CC o
body NN o
weight NN o
, , N
as RB N
well RB N
as IN N
baseline NN o
scores NNS o
in IN N
5 CD N
subscales NNS o
did VBD N
not RB N
demonstrate VB N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Repeated-measures NNS N
analysis NN N
showed VBD N
significant JJ N
effect NN o
for IN N
time NN N
? . N
treatment NN N
interaction NN N
in IN o
irritability NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC o
hyperactivity/noncompliance NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
subscales NNS N
. . N

By IN N
week NN N
10 CD N
, , N
the DT i
NAC NNP i
group NN N
showed VBD N
significantly RB N
more JJR o
reduction NN o
in IN o
irritability NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC o
hyperactivity/noncompliance NN o
( ( N
P NNP N
= NNP N
0.01 CD o
) ) o
subscales NNS o
scores NNS o
. . o

CONCLUSIONS NNP i
N-acetylcysteine JJ i
can MD N
be VB N
considered VBN N
as IN N
an DT N
adjuvant JJ N
therapy NN N
for IN N
ADs NNP N
with IN N
beneficial JJ o
therapeutic JJ o
outcomes NNS o
. . o

-DOCSTART- -X- O O

Levosulpiride NNP i
in IN N
functional JJ p
dyspepsia NN p
: : p
a DT N
multicentric JJ N
, , N
double-blind JJ N
, , N
controlled JJ N
trial NN N
. . N

Abnormalities NNS N
in IN N
gastrointestinal JJ N
motility NN N
have VBP N
been VBN N
reported VBN N
in IN N
a DT N
substantial JJ N
proportion NN N
of IN N
patients NNS p
with IN p
functional JJ p
dyspepsia NN p
, , p
supporting VBG p
the DT p
use NN p
of IN p
prokinetic JJ i
drugs NNS i
for IN p
treatment NN p
of IN p
dyspeptic JJ p
symptoms NNS p
. . p

To TO N
evaluate VB N
efficacy NN o
and CC o
safety NN o
of IN N
levosulpiride NN i
in IN N
short-term JJ N
treatment NN N
, , N
1298 CD p
patients NNS p
were VBD p
enrolled VBN p
in IN p
a DT p
double-blind JJ p
multicentric NN p
study NN p
carried VBD p
out IN p
in IN p
45 CD p
Italian JJ p
Gastroenterology NNP p
Departments NNP p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
levosulpiride NN i
( ( N
25 CD N
mg RB N
tid NN N
) ) N
, , N
domperidone NN i
( ( N
10 CD N
mg RB N
tid NN N
) ) N
, , N
metoclopramide RB i
( ( N
10 CD N
mg RB N
tid NN N
) ) N
or CC N
placebo NN i
( ( N
1 CD N
tablet NN N
tid NN N
) ) N
for IN N
4 CD N
weeks NNS N
. . N

Patients NNS p
were VBD p
selected VBN p
on IN p
the DT p
basis NN p
of IN p
: : p
a DT p
) ) p
occurrence NN p
in IN p
the DT p
last JJ p
4 CD p
weeks NNS p
of IN p
at IN p
least JJS p
5/10 CD p
selected VBN p
symptoms NNS p
( ( o
anorexia NN o
, , o
nausea NN o
, , o
vomiting VBG o
, , o
upper JJ o
abdominal JJ o
pain NN o
, , o
postprandial JJ o
bloating NN o
, , o
abdominal JJ o
fullness NN o
, , o
early JJ o
satiety NN o
, , o
belching NN o
, , o
heartburn NN o
, , o
regurgitation NN o
) ) o
, , p
severity NN p
of IN p
which WDT p
should MD p
reach/exceed VB p
a DT p
total JJ p
score NN p
of IN p
8 CD p
, , p
as IN p
assessed VBN p
by IN p
a DT p
specific JJ p
scale NN p
ranging VBG p
from IN p
0 CD p
( ( p
absent NN p
) ) p
to TO p
3 CD p
( ( p
severe JJ p
) ) p
; : p
b VBN p
) ) p
normal JJ p
results NNS p
of IN p
routine JJ p
biochemical NN p
, , p
ultrasound NN p
and CC p
endoscopic JJ p
examinations NNS p
. . p

In IN N
addition NN N
, , N
each DT N
patient NN N
subjectively RB N
evaluated VBD N
efficacy NN o
of IN N
treatment NN N
by IN N
a DT N
visual JJ N
analogue NN N
scale NN N
. . N

Significant JJ N
improvement NN N
was VBD N
recorded VBN N
for IN N
all DT N
symptoms NNS N
at IN N
days NNS N
10 CD N
and CC N
28 CD N
in IN N
all DT N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
levosulpiride NN i
was VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
superior NN N
to TO N
domperidone VB i
, , i
metoclopramide NN i
and CC N
placebo VB i
both DT N
in IN N
the DT N
overall JJ N
clinical JJ N
improvement NN N
scale NN N
as RB N
well RB N
as IN N
in IN N
a DT N
subgroup NN N
of IN N
symptoms NNS N
( ( o
postprandial JJ o
bloating NN o
, , o
epigastric JJ o
pain NN o
, , o
heartburn NN o
) ) o
. . N

Active JJ i
treatments NNS i
and CC N
placebo NNS i
were VBD N
comparable JJ N
as RB N
far RB N
as IN N
concerns NNS N
occurrence IN N
of IN N
side-effects NNS N
( ( N
12-20 CD N
% NN N
) ) N
including VBG N
galactorrhoea NN o
, , o
breast NN o
tenderness NN o
and CC o
menstrual JJ o
changes NNS o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
phosphorus-restricted JJ i
diet JJ i
and CC i
phosphate-binding JJ i
therapy NN i
on IN N
outcomes NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
. . p

BACKGROUND NNP N
Phosphorus NNP N
is VBZ N
associated VBN N
with IN N
mortality NN N
in IN N
patients NNS p
with IN p
chronic JJ p
kidney NN p
disease NN p
( ( p
CKD NNP p
) ) p
not RB p
on IN p
dialysis NN p
, , N
possibly RB N
through IN N
phosphorus-dependent JJ N
vascular JJ N
calcification NN N
. . N

Although IN N
a DT N
phosphorus-restricted JJ i
diet JJ i
reduces NNS N
serum VBP N
phosphorus NN N
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
it PRP N
reduces VBZ N
vascular JJ N
calcification NN N
progression NN N
in IN N
CKD NNP N
. . N

This DT N
study NN N
evaluated VBD N
whether IN N
a DT N
combined JJ i
strategy NN i
of IN i
phosphorus-restricted JJ i
diet JJ i
and CC i
phosphate-binding JJ i
therapy NN i
can MD N
reduce VB N
the DT N
risk NN o
of IN o
all-cause JJ o
mortality NN o
and/or JJ o
dialysis NN o
initiation NN o
by IN N
attenuating VBG N
coronary JJ o
artery NN o
calcification NN o
( ( o
CAC NNP o
) ) o
progression NN o
in IN N
non-dialysis JJ p
CKD NNP p
patients NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
analysis NN N
of IN N
a DT N
subgroup NN p
of IN p
patients NNS p
from IN p
a DT p
study NN p
that WDT p
evaluated VBD p
the DT p
impact NN p
of IN p
two CD p
phosphorus NN p
binder NN p
regimens NNS p
on IN p
hard JJ p
outcomes NNS p
in IN p
CKD NNP p
. . p

Patients NNS p
( ( p
n JJ p
= NNP p
113 CD p
) ) p
with IN p
stage NN p
3-4 JJ p
CKD NNP p
and CC p
evidence NN p
of IN p
CAC NNP p
on IN p
a DT p
phosphorus-restricted JJ i
diet NN i
were VBD i
randomized VBN N
to TO N
receive VB N
either DT i
calcium NN i
carbonate NN i
or CC i
sevelamer NN i
added VBN i
to TO N
their PRP$ i
phosphorus-restricted JJ i
diet NN i
. . i

End-points NNS N
were VBD o
death NN o
for IN o
any DT o
cause NN o
and CC o
initiation NN o
of IN o
dialysis NN o
. . o

Patients NNS N
were VBD N
monitored VBN N
to TO N
the DT N
first JJ N
event NN N
or CC N
to TO N
conclusion NN N
of IN N
the DT N
36-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
treatment NN N
with IN i
calcium NN i
carbonate NN i
was VBD i
associated VBN N
with IN o
increased JJ o
CAC NNP o
progression NN o
and CC o
occurrence NN o
of IN o
all-cause JJ o
mortality NN o
, , o
dialysis NN o
initiation NN o
, , o
and CC o
the DT o
composite JJ o
end-point NN o
. . o

After IN N
adjustment NN N
for IN N
confounders NNS i
, , i
sevelamer NN i
use NN i
was VBD N
the DT N
only JJ N
independent JJ N
predictive JJ N
factor NN N
of IN N
reduced JJ o
risk NN o
of IN o
each DT o
endpoint NN o
but CC o
only RB N
if IN N
CAC NNP o
progression NN o
was VBD o
either CC N
absent JJ N
or CC N
moderate JJ o
. . o

Accelerated VBN o
progression NN o
( ( o
annual JJ N
CAC NNP N
increase NN N
> VBD N
75th CD N
percentile NN N
of IN N
the DT N
study NN N
cohort NN N
) ) N
increased VBD N
the DT o
risk NN o
of IN o
all-cause JJ o
mortality NN o
and CC o
composite JJ o
end-point NN o
( ( o
p JJ N
= NNP N
0.01 CD N
) ) N
independently RB N
of IN N
the DT N
use NN N
of IN N
sevelamer NN N
. . N

CONCLUSIONS VB N
A DT N
significant JJ N
reduction NN o
in IN o
all-cause JJ o
mortality NN o
, , o
dialysis NN o
initiation NN o
, , o
and CC o
composite JJ o
end-point NN o
risk NN o
was VBD o
achieved VBN N
by IN N
combining VBG i
phosphorus-restricted JJ i
diet JJ i
and CC i
sevelamer JJ i
in IN i
non-dialysis JJ N
CKD NNP N
patients NNS p
with IN p
absent NN N
or CC N
moderate VB N
but CC N
not RB N
accelerated JJ o
CAC NNP o
progression NN o
. . o

Future JJ o
studies NNS N
should MD N
investigate VB N
the DT N
role NN N
of IN N
serum NN N
phosphorus NN N
, , N
the DT N
usefulness NN N
of IN N
a DT N
phosphorus-restricted JJ N
diet NN N
, , N
and CC N
the DT N
appropriateness NN N
of IN N
current JJ N
normal JJ N
ranges NNS N
of IN N
serum NN N
phosphorus NN N
concentration NN N
in IN N
relation NN N
to TO N
events NNS N
in IN N
non-dialyzed JJ N
CKD NNP N
patients NNS N
. . N

-DOCSTART- -X- O O

Injection NNP i
sclerotherapy NN i
versus NN i
electrocoagulation NN i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ p
haemorrhoids NNS p
. . p

OBJECTIVE NNP N
To TO N
study VB N
the DT N
symptomatology NN N
of IN N
early JJ p
hemorrhoids NNS p
and CC N
to TO N
compare VB N
injection NN i
sclerotherapy NN i
( ( i
IS NNP i
) ) i
with IN i
electrocoagulation NN i
( ( i
EC NNP i
) ) i
in IN N
the DT N
management NN N
outcome NN N
of IN N
early JJ N
haemorrhoids NNS N
with IN N
respect NN N
to TO N
pain VB o
during IN o
the DT o
procedure NN o
, , o
reduction NN o
in IN o
bleeding VBG o
per IN o
rectum NN o
, , N
and CC N
overall JJ o
patient NN o
satisfaction NN o
score NN o
. . o

METHODS NNP N
A NNP N
total NN N
of IN N
102 CD p
patients NNS p
were VBD p
included VBN p
in IN N
this DT N
experimental JJ N
study NN N
at IN p
the DT p
POF NNP p
Hospital NNP p
, , p
Wah NNP p
Cantt NNP p
from IN p
October NNP p
2004 CD p
to TO p
June NNP p
2005 CD p
. . p

A DT N
detailed JJ N
history NN N
was VBD N
taken VBN N
and CC N
proctoscopic JJ N
examination NN N
was VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
then RB N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
Lottery NNP N
method NN N
) ) N
. . N

One CD N
group NN N
was VBD N
subjected VBN N
to TO N
EC NNP N
and CC N
the DT N
other JJ N
to TO N
IS NNP N
. . N

In IN N
the DT N
EC NNP N
, , N
using VBG N
the DT N
EC NNP N
machine NN N
( ( N
Wieda NNP N
, , N
China NNP N
) ) N
, , N
direct JJ N
current JJ N
of IN N
10-20 JJ N
mA NN N
was VBD N
applied VBN N
in IN N
the DT N
submucosal JJ N
plane NN N
of IN N
each DT N
pile NN N
core NN N
for IN N
5-7 JJ N
minutes NNS N
. . N

In IN N
the DT N
IS NNP N
1-2 JJ N
ml NN N
of IN N
5 CD N
% NN N
phenol NN i
in IN i
almond NN i
oil NN i
was VBD N
injected VBN N
in IN N
the DT N
same JJ N
plane NN N
in IN N
each DT N
pile NN N
core NN N
. . N

Pain NN o
during IN o
the DT o
procedure NN o
, , o
reduction NN o
in IN o
bleeding VBG o
per IN o
rectum NN o
and CC o
overall JJ o
patient NN o
satisfaction NN o
, , N
were VBD N
studied VBN N
as IN N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
The DT p
mean JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
44 CD p
years NNS p
, , p
86 CD p
were VBD p
males NNS p
and CC p
16 CD p
were VBD p
females NNS p
. . p

Two CD N
thirds NNS N
of IN N
the DT N
patients NNS N
were VBD N
having VBG N
symptoms NNS N
for IN N
more JJR N
than IN N
6 CD N
months NNS N
. . N

A DT N
third JJ N
of IN N
patients NNS N
had VBD N
associated VBN N
local JJ o
pain NN o
while IN N
another DT N
third JJ N
had VBD N
associated VBN N
mucous JJ o
discharge NN o
. . o

Chronic JJ o
constipation NN o
was VBD N
present JJ N
in IN N
81 CD N
% NN N
patients NNS N
. . N

Only RB N
24.5 CD p
% NN p
of IN p
the DT p
patients NNS p
had VBD p
a DT p
positive JJ p
family NN p
history NN p
of IN p
haemorrhoids NNS p
. . p

Patients NNS N
in IN N
the DT N
electrocoagulation NN N
( ( N
EC NNP N
) ) N
group NN N
experienced VBD N
more JJR N
pain NN o
during IN o
the DT o
procedure NN o
than IN N
the DT N
injection NN N
sclerotherapy NN i
( ( i
IS NNP i
) ) i
group NN N
( ( N
P NNP N
< NNP N
0.000 CD N
) ) N
, , N
but CC N
EC NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
IS NNP N
in IN N
terms NNS N
of IN N
reducing VBG N
the DT N
bleeding NN o
per IN o
rectum NN o
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
and CC N
also RB N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
were VBD N
fully RB o
satisfied VBN o
with IN N
EC NNP N
than IN N
with IN N
IS NNP N
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

CONCLUSION NNP N
EC NNP N
, , N
although IN N
more RBR N
painful JJ o
, , N
is VBZ N
a DT N
safe JJ o
, , N
more RBR N
effective JJ o
and CC N
a DT N
highly RB o
satisfying JJ o
procedure NN N
for IN N
treating VBG N
early JJ N
hemorrhoids NNS N
. . N

-DOCSTART- -X- O O

Induction NNP i
chemotherapy NN i
in IN N
head NN p
and CC p
neck NN p
cancer NN p
: : p
results NNS N
of IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

Between IN p
December NNP p
1982 CD p
and CC p
October NNP p
1986 CD p
, , p
131 CD p
patients NNS p
with IN p
stage JJ p
II-III-IV NNP p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
oropharynx NN p
or CC p
oral JJ p
cavity NN p
were VBD N
randomized VBN N
to TO N
induction VB i
chemotherapy NN i
, , i
consisting VBG i
of IN i
bleomycin NN i
( ( i
10 CD i
mg/m2/day NN i
in IN i
continuous JJ i
infusion NN i
from IN i
day NN i
1 CD i
to TO i
day NN i
5 CD i
) ) i
, , i
methotrexate NN i
( ( i
120 CD i
mg/m2 NN i
on IN i
day NN i
2 CD i
) ) i
followed VBN i
by IN i
folinic JJ i
acid NN i
, , i
5-fluorouracil JJ i
( ( i
5 CD i
FU NNP i
) ) i
( ( i
600 CD i
mg/m2 NN i
on IN i
day NN i
2 CD i
) ) i
, , i
and CC i
cisplatin NN i
( ( i
120 CD i
mg/m2 NN i
on IN i
day NN i
4 CD i
) ) i
every DT i
4 CD i
weeks NNS i
for IN i
a DT i
total NN i
of IN i
three CD i
cycles NNS i
followed VBN i
by IN i
definitive JJ i
locoregional JJ i
treatment NN i
versus IN i
locoregional JJ i
treatment NN i
alone RB i
. . i

The DT N
modalities NNS N
of IN N
definitive JJ N
treatment NN N
( ( i
radiotherapy JJ i
+/- JJ i
surgery NN i
) ) i
were VBD N
chosen VBN N
prior RB N
to TO N
randomization NN N
. . N

A DT p
total NN p
of IN p
116 CD p
patients NNS p
were VBD p
evaluable JJ p
. . p

Of IN N
55 CD N
patients NNS N
in IN N
the DT N
chemotherapy NN i
arm NN N
, , N
four CD N
( ( N
7 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
( ( N
CR NNP N
) ) N
and CC N
23 CD N
( ( N
42 CD N
% NN N
) ) N
a DT N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
following VBG N
the DT N
induction NN N
regimen NNS N
. . N

At IN N
the DT N
completion NN N
of IN N
locoregional JJ N
treatment NN N
, , N
76 CD N
% NN N
( ( N
42 CD N
of IN N
55 CD N
) ) N
of IN N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
were VBD N
in IN N
CR NNP N
compared VBN N
to TO N
89 CD N
% NN N
( ( N
54 CD N
of IN N
61 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
survival NN o
, , o
cause-specific JJ o
survival NN o
, , o
and CC o
pattern NN o
of IN o
relapse NN o
between IN N
both DT N
groups NNS N
. . N

The DT N
median JJ o
survival NN o
was VBD N
22 CD N
months NNS N
in IN N
the DT N
chemotherapy NN N
group NN N
and CC N
29 CD N
months NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Responders NNS N
to TO N
chemotherapy VB N
did VBD N
not RB N
fare VB N
better JJR N
than IN N
nonresponders NNS N
. . N

Chemotherapy-related JJ o
toxicities NNS o
were VBD N
few JJ N
and CC N
most JJS N
of IN N
them PRP N
related VBN N
to TO N
cisplatin VB N
which WDT N
was VBD N
reduced VBN N
to TO N
100 CD N
mg/m2 NN N
for IN N
35 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ N
deaths NNS o
and CC N
, , N
in IN N
the DT N
experimental JJ N
arm NN N
of IN N
the DT N
trial NN N
, , N
no DT N
increased VBN N
morbidity NN o
from IN N
locoregional JJ N
treatment NN N
. . N

This DT N
induction NN N
regimen NN N
does VBZ N
not RB N
offer VB N
any DT N
advantages NNS N
over IN N
standard JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Central JJ N
5-HT4 JJ N
receptor NN N
binding NN N
as IN N
biomarker NN N
of IN N
serotonergic JJ N
tonus NN N
in IN N
humans NNS p
: : p
a DT N
[ $ N
11C CD N
] NNP N
SB207145 NNP N
PET NNP N
study NN N
. . N

Identification NNP N
of IN N
a DT N
biomarker NN N
that WDT N
can MD N
inform VB N
on IN N
extracellular JJ N
serotonin NN N
( ( N
5-HT JJ N
) ) N
levels NNS N
in IN N
the DT N
brains NNS N
of IN N
living NN p
humans NNS p
would MD N
enable VB N
greater JJR N
understanding NN N
of IN N
the DT N
way NN N
brain NN N
circuits NNS N
are VBP N
modulated VBN N
by IN N
serotonergic JJ N
neurotransmission NN N
. . N

Substantial JJ N
evidence NN N
from IN N
studies NNS N
in IN N
animals NNS N
and CC N
humans NNS N
indicates VBZ N
an DT N
inverse NN N
relationship NN N
between IN N
central JJ N
5-HT JJ N
tonus NN N
and CC N
5-HT JJ N
type NN N
4 CD N
receptor NN N
( ( N
5-HT4R JJ N
) ) N
density NN N
, , N
suggesting VBG N
that IN N
5-HT4R JJ N
receptor NN N
density NN N
may MD N
be VB N
a DT N
biomarker NN N
marker NN N
for IN N
5-HT JJ N
tonus NN N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
whether IN N
a DT N
3-week JJ N
administration NN N
of IN N
a DT N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
, , N
expected VBN N
to TO N
increase VB N
brain NN N
5-HT JJ N
levels NNS N
, , N
is VBZ N
associated VBN N
with IN N
a DT N
decline NN N
in IN N
brain NN N
5-HT4R JJ N
binding NN N
. . N

A DT p
total NN p
of IN p
35 CD p
healthy JJ p
men NNS p
were VBD p
studied VBN p
in IN N
a DT N
placebo-controlled JJ i
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
. . N

Participants NNS N
were VBD N
assigned VBN N
to TO N
receive VB N
3 CD N
weeks NNS N
of IN N
oral JJ i
dosing VBG i
with IN i
placebo NN i
or CC i
fluoxetine NN i
, , i
40 CD i
mg NNS i
per IN i
day NN i
. . i

Brain VB o
5-HT4R JJ o
binding NN o
was VBD N
quantified VBN N
at IN N
baseline NN N
and CC N
at IN N
follow-up JJ N
with IN N
[ NNP i
( ( i
11 CD i
) ) i
C NNP i
] NNP i
SB207145 NNP i
positron NN o
emission NN o
tomography NN o
( ( o
PET NNP o
) ) o
. . o

Three CD N
weeks NNS N
of IN N
intervention NN N
with IN N
fluoxetine NN N
was VBD N
associated VBN N
with IN N
a DT N
5.2 CD N
% NN N
reduction NN N
in IN N
brain NN o
5-HT4R JJ o
binding NN o
( ( N
P=0.017 NNP N
) ) N
, , N
whereas JJ N
placebo NN N
intervention NN N
did VBD N
not RB N
change VB N
5-HT4R JJ N
binding NN N
( ( N
P=0.52 NNP N
) ) N
. . N

Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
a DT N
model NN N
, , N
wherein VBP N
the DT N
5-HT4R JJ o
density NN o
adjusts VBZ N
to TO N
changes NNS N
in IN N
the DT N
extracellular JJ N
5-HT JJ N
tonus NN N
. . N

Our PRP$ N
data NNS N
demonstrate NN N
for IN N
the DT N
first JJ N
time NN N
in IN N
humans NNS p
that IN N
the DT N
imaging NN N
of IN N
central JJ N
5-HT4R JJ N
binding NN N
may MD N
be VB N
used VBN N
as IN N
an DT N
in IN N
vivo NN N
biomarker NN N
of IN N
the DT N
central JJ N
5-HT JJ N
tonus NN N
. . N

-DOCSTART- -X- O O

Metformin NNP i
does VBZ N
not RB N
enhance VB N
ovulation NN N
induction NN N
in IN N
clomiphene NN p
resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
in IN N
clinical JJ N
practice NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
metformin NN i
pretreatment NN i
has VBZ N
beneficial JJ o
effects NNS o
in IN N
clomiphene NN p
resistant JJ p
infertile JJ p
women NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
in IN p
an DT p
infertility NN p
clinic NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
placebo NN N
controlled VBD N
double-blind NN N
crossover NN N
study NN N
of IN N
3 CD N
months NNS N
metformin RB i
( ( N
1500 CD N
mg IN N
day-1 NN i
) ) i
/placebo NN i
, , N
followed VBN N
by IN N
3 CD N
months NNS N
metformin/placebo VBN i
together RB i
with IN i
clomiphene NN i
( ( N
50-100 JJ N
mg NN N
for IN N
5 CD N
days NNS N
) ) N
for IN N
three CD N
cycles NNS N
in IN N
clomiphene NN p
resistant JJ p
women NNS p
with IN p
PCOS NNP p
. . p

The DT N
primary JJ N
outcomes NNS N
were VBD N
restoration NN o
of IN o
spontaneous JJ o
menses NNS o
, , o
ovulation NN o
induction NN o
( ( o
spontaneous JJ o
or CC o
clomiphene NN o
induced VBN o
) ) o
and CC o
pregnancy NN o
. . o

Secondary JJ o
endpoints NNS o
were VBD N
changes NNS N
in IN N
biochemical JJ N
parameters NNS N
related VBN N
to TO N
androgens NNS N
and CC N
insulin NN N
. . N

RESULTS NNP N
Twelve NNP p
women NNS p
completed VBD p
the DT p
metformin NN i
arm NN p
and CC p
14 CD p
the DT p
placebo NN i
arm NN p
. . p

Spontaneous JJ o
menstruation NN o
resumed VBD N
in IN N
five CD N
metformin NNS i
treated VBD N
patients NNS N
and CC N
in IN N
six CD N
placebo NN i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

No NNP N
women NNS N
given VBN N
metformin NNS N
spontaneously RB o
ovulated VBD o
, , N
although IN N
one CD N
patient NN N
given VBN N
placebo NN i
did VBD N
, , N
P=0.30 NNP N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
efficacy NN o
of IN o
clomiphene NN o
between IN N
the DT N
two CD N
groups NNS N
with IN N
ovulation NN o
being VBG o
induced VBN o
in IN N
five CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
metformin NN i
treated VBN N
women NNS N
and CC N
four CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
placebo NN i
treated VBN N
women NNS N
, , N
P=0.63 NNP N
. . N

Pregnancy NN o
occurred VBD N
in IN N
three CD N
( ( N
out IN N
of IN N
12 CD N
) ) N
women NNS N
given VBN N
metformin NNS i
and CC N
two CD N
( ( N
out IN N
of IN N
14 CD N
) ) N
women NNS N
given VBN N
placebo NNS i
, , N
P=0.59 NNP N
. . N

CONCLUSIONS NNP N
Metformin NNP i
is VBZ N
not RB N
always RB N
beneficial JJ N
when WRB N
given VBN N
to TO N
clomiphene VB p
resistant JJ p
infertile JJ p
women NNS p
with IN p
PCOS NNP p
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

Allopurinol NNP i
use NN N
yields NNS N
potentially RB N
beneficial JJ N
effects NNS N
on IN N
inflammatory JJ N
indices NNS N
in IN N
those DT p
with IN p
recent JJ p
ischemic JJ p
stroke NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Elevated NNP N
serum NN N
uric JJ N
acid NN N
level NN N
is VBZ N
associated VBN N
with IN N
poor JJ N
outcome NN N
and CC N
increased VBD N
risk NN N
of IN N
recurrent NN N
events NNS N
after IN N
stroke NN N
. . N

The DT N
xanthine JJ N
oxidase NN N
inhibitor NN N
allopurinol NN i
lowers NNS N
uric JJ N
acid NN N
but CC N
also RB N
attenuates VBZ N
expression NN N
of IN N
inflammatory JJ N
adhesion NN N
molecules NNS N
in IN N
murine NN N
models NNS N
, , N
reduces NNS N
oxidative VBP N
stress NN N
in IN N
the DT N
vasculature NN N
, , N
and CC N
improves VBZ N
endothelial JJ N
function NN N
. . N

We PRP N
sought VBD N
to TO N
investigate VB N
whether IN N
allopurinol JJ i
alters NNS N
expression NN N
of IN N
inflammatory NN N
markers NNS N
after IN N
acute JJ N
ischemic JJ N
stroke NN N
. . N

METHODS NNP N
We PRP N
performed VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
investigate VB N
the DT N
safety NN N
, , N
tolerability NN N
, , N
and CC N
effect NN N
of IN N
6 CD i
weeks NNS i
' POS i
treatment NN i
with IN i
high- NN i
( ( i
300 CD i
mg NN i
once RB i
a DT i
day NN i
) ) i
or CC i
low- JJ i
( ( i
100 CD i
mg NN i
once RB i
a DT i
day NN i
) ) i
dose NN i
allopurinol NN i
on IN N
levels NNS N
of IN N
uric JJ N
acid NN N
and CC N
circulating VBG N
inflammatory JJ N
markers NNS N
after IN N
ischemic JJ N
stroke NN N
. . N

RESULTS NNP N
We PRP N
enrolled VBD N
50 CD p
patients NNS p
with IN p
acute JJ p
ischemic JJ p
stroke NN p
( ( p
17 CD p
, , p
17 CD p
, , p
and CC p
16 CD p
in IN p
the DT p
high JJ p
, , p
low JJ p
, , p
and CC p
placebo NN i
groups NNS p
, , p
respectively RB p
) ) p
. . N

Mean NNP p
( ( p
+/-SD NNP p
) ) p
age NN p
was VBD p
70 CD p
( ( p
+/-13 JJ p
) ) p
years NNS p
. . p

Groups NNP N
had VBD N
similar JJ N
characteristics NNS N
at IN N
baseline NN N
. . N

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ N
events NNS N
. . N

Uric NNP o
acid NN o
levels NNS o
were VBD N
significantly RB N
reduced VBN N
at IN N
both DT N
7 CD N
days NNS N
and CC N
6 CD N
weeks NNS N
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
by IN N
0.14 CD N
mmol/L NNS N
at IN N
6 CD N
weeks NNS N
, , N
P=0.002 NNP N
) ) N
. . N

Intercellular JJ o
adhesion NN o
molecule-1 JJ o
concentration NN o
( ( N
ng/mL JJ N
) ) N
rose VBD N
by IN N
51.2 CD N
in IN N
the DT N
placebo NN N
group NN N
, , N
rose VBD N
slightly RB N
( ( N
by IN N
10.6 CD N
) ) N
in IN N
the DT N
low-dose JJ N
allopurinol NN i
group NN N
, , N
but CC N
fell VBD N
in IN N
the DT N
high-dose JJ N
group NN N
( ( N
by IN N
2.6 CD N
; : N
difference NN N
between IN N
groups NNS N
P=0.012 NNP N
, , N
Kruskal-Wallis NNP N
test NN N
) ) N
. . N

CONCLUSIONS NNP N
Allopurinol NNP i
treatment NN N
is VBZ N
well RB N
tolerated VBN N
and CC N
attenuates VBZ N
the DT N
rise NN N
in IN N
intercellular JJ N
adhesion NN N
molecule-1 NN N
levels NNS N
seen VBN N
after IN N
stroke NN N
. . N

Uric JJ N
acid NN N
levels NNS N
were VBD N
lowered VBN N
with IN N
high JJ N
doses NNS N
. . N

These DT N
findings NNS N
support NN N
further JJ N
evaluation NN N
of IN N
allopurinol NN i
as IN N
a DT N
preventive JJ N
measure NN N
after IN N
stroke NN N
. . N

-DOCSTART- -X- O O

Screening VBG i
, , i
brief JJ i
intervention NN i
, , i
and CC i
referral JJ i
to TO i
treatment NN i
( ( i
SBIRT NNP i
) ) i
in IN N
a DT N
Polish JJ p
emergency NN p
department NN p
: : p
three-month JJ N
outcomes NNS N
of IN N
a DT N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
A DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
screening NN i
, , i
brief JJ i
intervention NN i
, , i
and CC i
referral JJ i
to TO i
treatment NN i
( ( i
SBIRT NNP i
) ) i
for IN N
drinking NN p
and CC p
related JJ p
problems NNS p
among IN p
at-risk JJ p
and CC p
dependent JJ p
drinkers NNS p
was VBD N
conducted VBN N
in IN N
an DT N
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
in IN p
Sosnowiec NNP p
, , p
Poland NNP p
, , p
among IN p
patients NNS p
ages VBZ p
18 CD p
years NNS p
and CC p
older JJR p
. . p

METHOD NNP N
Data NNP p
were VBD p
collected VBN p
over IN p
a DT p
23-week JJ p
period NN p
, , p
from IN p
4:00 CD p
PM NNP p
to TO p
midnight VB p
, , N
and CC N
resulted VBD N
in IN N
446 CD p
patients NNS p
being VBG p
recruited VBN p
into IN p
the DT p
study NN p
( ( p
90 CD p
% NN p
of IN p
those DT p
who WP p
screened VBD p
positive JJ p
) ) p
and CC N
randomized VBN N
to TO N
three CD N
conditions NNS N
following VBG N
a DT N
two-stage JJ N
process NN N
: : N
screened VBN i
only RB i
( ( N
n JJ N
= NNP N
147 CD N
) ) N
, , N
assessed VBN i
( ( N
n JJ N
= NNP N
152 CD N
) ) N
, , N
and CC N
received VBN i
intervention NN i
( ( N
n JJ N
= NNP N
147 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
assessment NN i
( ( N
85 CD N
% NN N
) ) N
and CC N
intervention NN i
( ( N
83 CD N
% NN N
) ) N
conditions NNS N
were VBD N
blindly RB N
reassessed VBN N
at IN N
3 CD N
months NNS N
via IN N
a DT N
telephone NN N
interview NN N
. . N

RESULTS NNP N
At IN N
3-month JJ N
follow-up NN N
, , N
both DT N
groups NNS N
showed VBD N
significant JJ N
decreases NNS N
in IN N
the DT N
proportion NN N
who WP N
were VBD N
positive JJ N
for IN N
at-risk JJ N
drinking NN N
, , N
the DT N
primary JJ N
outcome NN N
variable NN N
. . N

Both DT N
groups NNS N
also RB N
showed VBD N
significant JJ N
decreases NNS N
in IN N
drinking NN o
days NNS o
per IN o
week NN o
, , o
drinks NNS o
per IN o
drinking NN o
day NN o
, , o
maximum JJ o
drinks NNS o
per IN o
occasion NN o
, , o
and CC o
negative JJ o
consequences NNS o
of IN o
drinking NN o
. . o

Using VBG N
analysis NN N
of IN N
covariance NN N
to TO N
control VB N
for IN N
baseline NN N
measures NNS N
and CC N
demographic JJ N
characteristics NNS N
, , N
no DT N
difference NN N
in IN N
outcome JJ N
measures NNS N
was VBD N
found VBN N
between IN N
intervention NN i
and CC N
assessment JJ i
conditions NNS N
. . N

Subgroup NNP N
analysis NN N
found VBD N
some DT N
significant JJ N
interactions NNS N
between IN N
intervention NN i
and CC N
secondary JJ N
outcomes NNS N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
main JJ N
findings NNS N
were VBD N
similar JJ N
to TO N
those DT N
from IN N
other JJ N
brief-intervention NN N
studies NNS N
in IN N
Western JJ N
cultures NNS N
, , N
findings NNS N
here RB N
also RB N
suggest VBP N
that IN N
intervention NN N
may MD N
have VB N
differential JJ N
benefits NNS N
for IN N
specific JJ N
subgroups NNS N
of IN N
patients NNS N
in IN N
the DT N
ED NNP N
, , N
an DT N
area NN N
of IN N
research NN N
that WDT N
may MD N
warrant VB N
additional JJ N
study NN N
of IN N
brief JJ N
intervention NN N
in IN N
the DT N
ED NNP N
setting NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
oral JJ N
sirolimus NN N
for IN N
restenosis NN o
prevention NN N
in IN N
patients NNS p
with IN p
in-stent JJ p
restenosis NN p
: : p
the DT N
Oral NNP N
Sirolimus NNP i
to TO N
Inhibit NNP N
Recurrent NNP N
In-stent JJ N
Stenosis NNP N
( ( N
OSIRIS NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
interventional JJ N
cardiology NN N
, , N
including VBG N
the DT N
introduction NN N
of IN N
drug-eluting JJ N
stents NNS N
for IN N
de FW N
novo FW N
coronary JJ N
lesions NNS N
, , N
the DT N
treatment NN N
of IN N
in-stent JJ N
restenosis NN N
( ( N
ISR NNP N
) ) N
remains VBZ N
a DT N
challenging JJ N
clinical JJ N
issue NN N
. . N

Given VBN N
the DT N
efficacy NN N
of IN N
systemic JJ N
sirolimus JJ N
administration NN N
to TO N
prevent VB N
neointimal JJ o
hyperplasia NN o
in IN N
animal JJ N
models NNS N
and CC N
to TO N
halt VB N
and CC N
even RB N
reverse VB N
the DT N
progression NN N
of IN N
allograft NN N
vasculopathy NN N
, , N
the DT N
aim NN N
of IN N
the DT N
present JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
10-day JJ N
oral JJ N
sirolimus NN N
treatment NN N
with IN N
2 CD N
different JJ N
loading VBG N
regimens NNS N
for IN N
the DT N
prevention NN N
of IN N
recurrent JJ N
restenosis NN N
in IN N
patients NNS p
with IN p
ISR NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Three NNP p
hundred VBD p
symptomatic JJ p
patients NNS p
with IN p
ISR NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
treatment NN N
arms NNS N
: : N
placebo NN i
or CC i
usual-dose JJ i
or CC i
high-dose JJ i
sirolimus NN i
. . i

Patients NNS N
received VBD N
a DT N
cumulative JJ N
loading NN N
dose NN N
of IN N
0 CD N
, , N
8 CD N
, , N
or CC N
24 CD N
mg NN N
of IN N
sirolimus JJ N
2 CD N
days NNS N
before IN N
and CC N
the DT N
day NN N
of IN N
repeat NN N
intervention NN N
followed VBN N
by IN N
maintenance NN N
therapy NN N
of IN N
2 CD N
mg/d NN N
for IN N
7 CD N
days NNS N
. . N

Angiographic JJ o
restenosis NN o
at IN o
6-month JJ o
angiography NN o
was VBD N
the DT N
primary JJ N
end NN N
point NN N
of IN N
the DT N
study NN N
. . N

Restenosis NNP o
was VBD N
significantly RB N
reduced VBN N
from IN N
42.2 CD N
% NN N
to TO N
38.6 CD N
% NN N
and CC N
to TO N
22.1 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
sirolimus NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.005 NNP N
) ) N
. . N

Similarly RB N
, , N
the DT N
need NN o
for IN o
target NN o
vessel JJ o
revascularization NN o
was VBD N
reduced VBN N
from IN N
25.5 CD N
% NN N
to TO N
24.2 CD N
% NN N
and CC N
to TO N
15.2 CD N
% NN N
in IN N
the DT N
placebo NN N
, , N
usual-dose JJ N
, , N
and CC N
high-dose JJ N
groups NNS N
, , N
respectively RB N
( ( N
P=0.08 NNP N
) ) N
. . N

The DT o
sirolimus JJ o
blood NN o
concentration NN o
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
correlated VBD N
significantly RB N
with IN N
the DT N
late JJ N
lumen NNS N
loss NN N
at IN N
follow-up JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS N
with IN N
ISR NNP N
, , N
an DT N
oral JJ N
adjunctive JJ N
sirolimus NN N
treatment NN N
with IN N
an DT N
intensified JJ N
loading NN N
regimen NNS N
before IN N
coronary JJ N
intervention NN N
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
angiographic JJ o
parameters NNS o
of IN o
restenosis NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
pravastatin NN i
on IN N
cardiovascular JJ o
events NNS o
in IN N
women NNS p
after IN p
myocardial JJ p
infarction NN p
: : p
the DT N
cholesterol NN N
and CC N
recurrent JJ N
events NNS N
( ( N
CARE NNP N
) ) N
trial NN N
. . N

OBJECTIVES IN N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
pravastatin NN i
on IN N
recurrent NN o
cardiovascular JJ o
events NNS o
in IN N
women NNS p
with IN p
average JJ p
cholesterol NN p
levels NNS p
after IN p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
. . p

BACKGROUND NNP N
Little JJ N
information NN N
is VBZ N
available JJ N
on IN N
the DT N
effectiveness NN N
of IN N
lipid JJ N
lowering VBG N
in IN N
secondary JJ N
prevention NN N
of IN N
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
in IN p
women NNS p
; : p
in IN p
particular JJ p
, , p
those DT p
with IN p
CHD NNP p
and CC p
average JJ p
cholesterol NN p
levels NNS p
. . p

METHODS NNP N
In IN N
the DT N
Cholesterol NNP N
and CC N
Recurrent NNP N
Events NNP N
( ( N
CARE NNP N
) ) N
trial NN N
, , N
576 CD p
postmenopausal NN p
women NNS p
, , p
between IN p
3 CD p
and CC p
20 CD p
months NNS p
after IN p
MI NNP p
, , p
with IN p
a DT p
total JJ p
cholesterol NN p
level NN p
< VBD p
240 CD p
mg/dl NN p
and CC p
a DT p
low JJ p
density NN p
lipoprotein NN p
cholesterol NN p
level NN p
115 CD p
to TO p
174 CD p
mg/dl NNS p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
pravastatin NN i
40 CD i
mg/day NN i
or CC N
matching VBG N
placebo NN i
for IN N
a DT N
median JJ N
follow-up JJ N
period NN N
of IN N
5 CD N
years NNS N
. . N

The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
combined VBN o
coronary JJ o
events NNS o
( ( o
coronary JJ o
death NN o
, , o
nonfatal JJ o
MI NNP o
, , o
percutaneous JJ o
transluminal JJ o
coronary NN o
angioplasty NN o
[ NNP o
PTCA NNP o
] NNP o
or CC o
coronary JJ o
artery NN o
bypass NN o
graft NN o
surgery NN o
[ NNP o
CABG NNP o
] NNP o
) ) o
, , o
the DT o
primary JJ o
trial NN o
end NN o
point NN o
( ( o
coronary JJ o
death NN o
or CC o
nonfatal JJ o
MI NNP o
) ) o
and CC o
stroke NN o
. . o

RESULTS NNP N
Women NNP N
treated VBD N
with IN N
pravastatin NN N
had VBD N
a DT N
risk NN o
reduction NN o
of IN N
43 CD N
% NN N
for IN N
the DT N
primary JJ N
end NN N
point NN N
( ( N
p JJ N
= NNP N
0.035 CD N
) ) N
, , N
46 CD N
% NN N
for IN N
combined JJ N
coronary JJ N
events NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
, , N
48 CD N
% NN N
for IN N
PTCA NNP N
( ( N
p JJ N
= NNP N
0.025 CD N
) ) N
, , N
40 CD N
% NN N
for IN N
CABG NNP N
( ( N
p JJ N
= NNP N
0.14 CD N
) ) N
and CC N
56 CD N
% NN N
for IN N
stroke NN N
( ( N
p JJ N
= NNP N
0.07 CD N
) ) N
. . N

The DT p
3,583 CD p
men NNS p
in IN p
the DT p
CARE NNP p
trial NN p
also RB N
showed VBD N
a DT N
reduction NN N
in IN N
risk NN o
, , N
but CC N
the DT N
magnitude NN N
tended VBD N
to TO N
be VB N
less JJR N
. . N

Pravastatin NNP i
improved VBD N
plasma JJ o
lipids NNS o
similarly RB N
in IN N
men NNS p
and CC p
women NNS p
. . p

There EX N
were VBD N
no DT N
differences NNS N
in IN N
risk NN o
of IN o
coronary JJ o
events NNS o
in IN N
the DT N
placebo NN N
group NN N
between IN N
men NNS N
and CC N
women NNS N
. . N

Minor JJ N
differences NNS N
between IN N
men NNS N
and CC N
women NNS N
were VBD N
present JJ N
in IN N
baseline NN N
characteristics NNS N
and CC N
treatment NN N
for IN N
MI NNP N
, , N
in IN N
general JJ N
, , N
conferring VBG N
a DT N
higher JJR N
risk NN N
status NN N
and CC N
a DT N
lower JJR N
incidence NN N
of IN N
CABG NNP o
in IN N
the DT N
women NNS N
. . N

CONCLUSIONS NNP N
Pravastatin NNP i
led VBD N
to TO N
significant JJ N
early JJ N
reduction NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
cardiovascular JJ o
events NNS o
in IN N
post-MI JJ p
women NNS p
with IN p
average JJ p
cholesterol NN p
levels NNS p
. . p

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
fenretinide NN i
in IN N
superficial JJ p
bladder NN p
cancer NN p
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
as IN N
an DT N
intermediate JJ N
end NN N
point NN N
. . N

Retinoids NNS N
have VBP N
shown VBN N
a DT N
potential JJ N
activity NN N
in IN N
preventing VBG N
tumor NN N
recurrence NN N
in IN N
superficial JJ p
bladder NN p
cancer NN p
. . p

We PRP N
assessed VBD N
the DT N
activity NN N
of IN N
the DT N
synthetic JJ i
retinoid NN i
fenretinide NN i
in IN N
superficial JJ N
bladder NN N
cancer NN N
using VBG N
DNA NNP N
flow JJ N
cytometry NN N
and CC N
conventional JJ N
cytology NN N
as IN N
surrogate JJ N
biomarkers NNS N
. . N

A DT N
total NN p
of IN p
99 CD p
subjects NNS p
with IN p
resected JJ p
superficial JJ p
bladder NN p
cancer NN p
( ( p
pTa NN p
, , p
pT1 NN p
) ) p
were VBD N
randomized VBN N
to TO N
either DT N
fenretinide NN i
( ( i
200 CD i
mg NNS i
day NN i
p.o NN i
. . i

for IN i
24 CD i
months NNS i
) ) i
or CC i
no DT i
intervention NN i
. . i

Cystoscopy NNP N
and CC N
bladder NN N
washing NN N
for IN N
DNA NNP N
flow NN N
cytometry NN N
end NN N
points NNS N
( ( N
proportion NN N
of IN N
DNA NNP N
aneuploid JJ N
histograms NN N
, , N
hyperdiploid JJ N
fraction NN N
, , N
and CC N
percentage NN N
of IN N
apoptotic JJ N
cells NNS N
) ) N
and CC N
proportion NN N
of IN N
abnormal JJ o
cytological JJ o
examinations NNS o
were VBD N
repeated VBN N
every DT N
4 CD N
months NNS N
for IN N
up IN N
to TO N
36 CD N
months NNS N
. . N

The DT N
primary JJ N
study NN N
end NN N
point NN N
was VBD N
the DT N
proportion NN o
of IN o
DNA NNP o
aneuploid JJ o
histograms NNS o
after IN N
12 CD N
months NNS N
. . N

This DT N
figure NN N
was VBD N
48.9 CD N
% NN N
in IN N
the DT N
fenretinide JJ i
arm NN N
and CC N
41.9 CD N
% NN N
in IN N
the DT N
control NN N
arm NN N
( ( N
odds NNS N
ratio NN N
, , N
1.16 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.44-3.07 JJ N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
any DT N
other JJ N
response NN o
biomarker NN o
between IN N
the DT N
two CD N
groups NNS N
up RB N
to TO N
36 CD N
months NNS N
, , N
nor CC N
was VBD N
any DT N
biomarker NN N
able JJ N
to TO N
predict VB N
recurrence NN N
risk NN N
. . N

Recurrence-free JJ o
survival NN o
was VBD N
comparable JJ N
between IN N
the DT N
arms NNS N
( ( N
27 CD N
events NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus NN N
21 CD N
in IN N
the DT N
control NN N
arm NN N
; : N
P NNP N
= NNP N
0.36 CD N
) ) N
. . N

Twelve NNP N
subjects VBZ N
in IN N
the DT N
fenretinide JJ N
arm NN N
complained VBD N
of IN N
diminished JJ N
dark NN o
adaptability NN o
, , N
and CC N
nine CD N
subjects NNS N
in IN N
the DT N
fenretinide JJ N
arm NN N
versus IN N
one CD N
control NN N
subject NN N
had VBD N
mild JJ o
dermatological JJ o
alterations NNS o
. . o

We PRP N
conclude VBP N
that DT N
fenretinide NN N
showed VBD N
a DT N
lack NN N
of IN N
effect NN N
on IN N
the DT N
DNA NNP N
content NN o
distribution NN o
and CC N
the DT N
morphology NN o
of IN o
urothelial JJ o
cells NNS o
obtained VBN N
in IN N
serial JJ N
bladder NN N
washings NNS N
. . N

Recurrence-free JJ o
survival NN o
was VBD N
comparable JJ N
between IN N
groups NNS N
. . N

Because IN N
our PRP$ N
data NNS N
are VBP N
hampered VBN N
by IN N
the DT N
lack NN N
of IN N
predictivity NN N
of IN N
the DT N
selected VBN N
biomarkers NNS N
, , N
additional JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
assess VB N
the DT N
activity NN N
of IN N
fenretinide NN N
in IN N
preventing VBG N
bladder NN p
cancer NN p
. . p

-DOCSTART- -X- O O

Baseline NNP N
distribution NN N
of IN N
participants NNS p
with IN p
depression NN p
and CC p
impaired JJ p
quality NN p
of IN p
life NN p
in IN N
the DT N
Treatment NNP N
of IN N
Preserved NNP N
Cardiac NNP N
Function NNP N
Heart NNP N
Failure NNP N
with IN N
an DT N
Aldosterone NNP N
Antagonist NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Previous NNP N
studies NNS N
have VBP N
demonstrated VBN N
the DT N
psychosocial JJ N
effect NN N
of IN N
heart NN N
failure NN N
in IN N
patients NNS p
with IN p
reduced JJ p
ejection NN p
fraction NN p
. . p

However RB N
, , N
the DT N
effects NNS N
on IN N
patients NNS N
with IN N
preserved JJ N
ejection NN N
fraction NN N
have VBP N
not RB N
yet RB N
been VBN N
elucidated VBN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
the DT N
baseline NN N
characteristics NNS N
of IN N
participants NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
as IN N
it PRP N
relates VBZ N
to TO N
impaired JJ N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
and CC N
depression NN N
, , N
identify JJ N
predictors NNS N
of IN N
poor JJ N
QOL NNP N
and CC N
depression NN N
, , N
and CC N
determine VB N
the DT N
correlation NN N
between IN N
QOL NNP N
and CC N
depression NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Among IN N
patients NNS p
enrolled VBN p
in IN p
the DT p
Treatment NNP p
of IN p
Preserved NNP p
Cardiac NNP p
Function NNP p
Heart NNP p
Failure NNP p
With IN p
an DT p
Aldosterone NNP i
Antagonist NNP i
Trial NNP i
( ( i
TOPCAT NNP i
) ) i
, , p
3400 CD p
patients NNS p
completed VBD p
the DT p
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
, , p
3395 CD p
patients NNS p
completed VBN p
European JJ o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
, , p
and CC p
1431 CD p
patients NNS p
in IN p
United NNP p
States NNPS p
and CC p
Canada NNP p
completed VBD p
the DT p
Patient NNP o
Health NNP o
Questionnaire-9 NNP o
. . o

The DT N
mean JJ N
summary JJ N
score NN N
on IN N
the DT N
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
was VBD N
54.8 CD N
, , N
and CC N
on IN N
European JJ o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
, , N
it PRP N
was VBD N
60.3 CD N
; : N
27 CD N
% NN N
of IN N
patients NNS N
had VBD N
moderate JJ N
to TO N
severe JJ N
depression NN N
. . N

Factors NNS N
associated VBD N
with IN N
better JJR N
Kansas NNP o
City NNP o
Cardiomyopathy NNP o
Questionnaire NNP o
and CC o
European NNP o
QOL NNP o
5D CD o
Visual NNP o
Analog NNP o
Scale NNP o
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
were VBD N
American JJ N
region NN N
, , N
older JJR N
age NN N
, , N
no DT N
history NN N
of IN N
angina JJ N
pectoris NN N
or CC N
asthma NN N
, , N
no DT N
use NN N
of IN N
hypoglycemic JJ N
agent NN N
, , N
more JJR N
activity NN N
level NN N
, , N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
. . N

Factors NNS N
associated VBD N
with IN N
depression NN N
via IN N
multiple JJ N
logistic JJ N
regression NN N
analysis NN N
included VBD N
younger JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
comorbid NN N
angina NN N
, , N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
, , N
use NN N
of IN N
a DT N
hypoglycemic JJ N
agent NN N
, , N
lower JJR N
activity NN N
level NN N
, , N
higher JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
class NN N
, , N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
use NN N
. . N

There EX N
were VBD N
significant JJ N
correlations NNS N
between IN N
each DT N
of IN N
the DT N
QOL NNP o
scores NNS o
and CC o
depression NN o
. . o

CONCLUSIONS JJ N
Patients NNS p
with IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
, , p
who WP p
were VBD p
younger JJR p
had VBD p
higher JJR p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
or CC p
comorbid NN p
angina NNS p
pectoris NN p
, , p
had VBD p
lower JJR p
activity NN p
levels NNS p
, , p
lived VBD p
in IN p
Eastern NNP p
Europe NNP p
or CC p
were VBD p
taking VBG p
hypoglycemic JJ p
agents NNS p
, , N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
impaired VBN p
QOL NNP p
and CC p
depression NN p
. . p

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
http NN N
: : N
//www.clinicaltrials.gov NN N
. . N

Unique NNP N
identifier NN N
: : N
NCT00094302 NNP N
. . N

-DOCSTART- -X- O O

Penetration NN o
and CC o
accumulation NN o
of IN N
moxifloxacin NN i
in IN N
uterine JJ N
tissue NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
moxifloxacin NN i
penetrates VBZ N
the DT N
uterine JJ N
tissue NN N
and CC N
accumulates NNS N
at IN N
levels NNS N
sufficient JJ N
to TO N
eradicate VB o
the DT o
major JJ o
pathogens NNS o
causing VBG N
pelvic JJ p
inflammatory JJ p
disease NN p
( ( p
PID NNP p
) ) p
. . p

METHOD NNP N
In IN N
a DT N
prospective JJ N
, , N
multicenter NN N
, , N
open-label JJ N
, , N
parallel-group JJ N
study NN N
we PRP N
determined VBD N
the DT N
concentration NN N
of IN N
moxifloxacin NN N
in IN N
plasma NN N
and CC N
uterine JJ N
tissue NN N
after IN N
a DT N
single JJ N
, , N
400-mg JJ i
intravenous JJ i
dose NN i
of IN i
moxifloxacin NN i
. . i

Study NN N
participants NNS N
were VBD N
randomized VBN N
for IN N
time NN N
of IN N
tissue NN N
sampling NN N
, , N
which WDT N
was VBD N
performed VBN N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
7 CD N
, , N
or CC N
24 CD N
hours NNS N
following VBG N
the DT N
moxifloxacin JJ i
infusion NN N
. . N

RESULTS NNP N
Of IN N
43 CD p
participants NNS p
, , p
40 CD p
were VBD p
randomized VBN p
to TO p
tissue VB p
sampling VBG p
. . p

Moxifloxacin NNP o
accumulated VBD o
in IN o
uterine JJ o
tissue NN o
and CC o
concentrations NNS o
were VBD N
highest JJS N
1 CD N
hour NN N
after IN N
infusion NN N
in IN N
both DT N
plasma NN N
and CC N
tissue NN N
. . N

Tissue NN o
to TO o
plasma VB o
ratios NNS o
remained VBD N
between IN N
1.7 CD N
and CC N
2.1 CD N
for IN N
24 CD N
hours NNS N
. . N

Moxifloxacin NNP N
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
well RB o
tolerated VBN o
. . o

CONCLUSION NNP N
Based VBD N
on IN N
known VBN N
minimum JJ N
inhibitory JJ N
concentration NN N
data NNS N
, , N
the DT N
uterine JJ o
tissue NN o
concentrations NNS o
of IN N
moxifloxacin NN N
achieved VBN N
over IN N
24 CD N
hours NNS N
would MD N
be VB N
sufficient JJ N
to TO N
eradicate VB N
the DT N
range NN N
of IN N
bacterial JJ N
pathogens NNS N
responsible JJ N
for IN N
PID NNP p
. . p

-DOCSTART- -X- O O

Sublingual JJ N
administration NN N
of IN N
micronized JJ i
estradiol NN i
and CC i
progesterone NN i
, , N
with IN N
and CC N
without IN N
micronized VBN i
testosterone NN i
: : i
effect NN N
on IN N
biochemical JJ p
markers NNS p
of IN p
bone NN o
metabolism NN p
and CC o
bone JJ o
mineral JJ o
density NN o
. . o

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
evaluate VB N
the DT N
relative JJ N
efficacy NN N
of IN N
the DT N
sublingual JJ N
administration NN N
of IN N
micronized JJ i
estradiol NN i
( ( i
E2 NNP i
) ) i
, , i
progesterone NN i
( ( i
P4 NNP i
) ) i
, , i
and CC i
testosterone NN i
( ( i
T NNP i
) ) i
on IN N
bone NN p
mineral JJ p
density NN p
and CC p
biochemical JJ p
markers NNS p
of IN p
bone NN p
metabolism NN p
. . p

DESIGN NN N
In IN N
this DT N
double-blind NN N
, , N
prospective JJ N
study NN N
, , N
postmenopausal JJ p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD p
treatment NN p
groups NNS p
: : p
hysterectomized VBN p
women NNS p
were VBD N
assigned VBN N
to TO N
either DT N
1 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
or CC N
2 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN i
T NNP i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

Women NNS p
with IN p
intact JJ p
uteri NNS p
were VBD N
assigned VBN N
to TO N
either DT N
3 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ N
micronized VBN i
P4 NNP i
( ( N
100 CD N
mg NN N
) ) N
or CC N
4 CD N
) ) N
micronized VBN i
E2 NNP i
( ( N
0.5 CD N
mg NN N
) ) N
+ VBZ i
micronized VBN i
P4 NNP i
( ( N
100 CD N
mcg NN N
) ) N
+ VBZ i
micronized VBN i
T NNP i
( ( N
1.25 CD N
mg NN N
) ) N
. . N

For IN N
the DT N
purpose NN N
of IN N
this DT N
study NN N
, , N
the DT N
four CD N
treatment NN N
groups NNS N
were VBD N
combined VBN N
into IN N
two CD N
groups NNS N
for IN N
all DT N
comparisons NNS N
. . N

The DT N
E2 NNP i
and CC N
E2+P4 NNP i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP p
alone RB p
group NN p
( ( p
n=30 NN p
) ) p
, , N
and CC N
the DT N
E2+T NNP i
and CC N
E2+P4+T NNP i
groups NNS N
were VBD N
combined VBN N
into IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN p
( ( p
n=27 RB p
) ) p
. . p

Hormones NNPS N
were VBD N
administered VBN N
sublingually RB N
as IN N
a DT N
single JJ N
tablet NN N
twice RB N
a DT N
day NN N
for IN N
12 CD N
months NNS N
. . N

Bone NNP o
mineral JJ o
density NN o
was VBD N
measured VBN N
in IN N
the DT N
anterior-posterior JJ N
lumbar NN N
spine NN N
and CC N
total JJ N
left JJ N
hip NN N
via IN N
dual JJ N
energy NN N
x-ray JJ N
absorptiometry NN N
. . N

Bone NNP o
metabolism NN o
was VBD N
assessed VBN N
via IN N
serum JJ N
bone-specific JJ N
alkaline NN N
phosphatase NN N
and CC N
urinary JJ N
deoxypyridinoline NN N
and CC N
cross-linked JJ N
N-telopeptide NNP N
of IN N
type NN N
I PRP N
collagen VBP N
, , N
both DT N
normalized VBN N
to TO N
creatinine VB N
. . N

Data NNP N
were VBD N
analyzed VBN N
via IN N
a DT N
repeated JJ N
measures NNS N
analysis NN N
of IN N
variance NN N
and CC N
a DT N
Student NN N
's POS N
t JJ N
test NN N
( ( N
alpha=0.05 NN N
) ) N
. . N

RESULTS VB N
The DT p
subjects NNS p
were VBD p
of IN p
similar JJ p
age NN p
( ( p
54.0 CD p
+/- JJ p
0.8 CD p
years NNS p
) ) p
, , p
height VBD p
( ( p
64.0 CD p
+/- JJ p
0.3 CD p
in IN p
) ) p
, , p
weight VBD p
( ( p
157.6 CD p
+/- JJ p
4.2 CD p
lb NN p
) ) p
, , p
and CC p
had VBD p
similar JJ p
baseline NN p
follicle-stimulating NN p
hormone NN p
( ( p
66.4 CD p
+/- JJ p
3.2 CD p
mIU/L NN p
) ) p
, , p
E2 NNP p
( ( p
26.4 CD p
+/- JJ p
1.5 CD p
pg/ml NN p
) ) p
, , p
P4 NNP p
( ( p
0.3 CD p
+/- JJ p
0.1 CD p
ng/ml NN p
) ) p
, , p
total JJ p
T NNP p
( ( p
19.0 CD p
+/- JJ p
1.5 CD p
ng/dL NN p
) ) p
, , p
and CC p
bioavailable JJ p
T NNP p
( ( p
3.7 CD p
+/- JJ p
0.3 CD p
ng/dL NN p
) ) p
levels NNS p
. . p

During IN N
therapy NN N
, , N
serum NN N
levels NNS N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
each DT N
hormone NN N
. . N

Bone NNP o
mineral JJ o
density NN o
and CC o
bone NN o
markers NNS o
at IN N
baseline NN N
were VBD N
similar JJ N
for IN N
each DT N
treatment NN N
group NN N
. . N

Bone-specific JJ o
alkaline JJ o
phosphatase NN o
decreased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
-14.3 JJ N
+/- JJ N
4.1 CD N
% NN N
in IN N
the DT N
HRT NNP i
alone RB N
group NN N
and CC N
by IN N
-8.2 NNP N
+/- JJ N
4.6 CD N
% NN N
in IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN N
. . N

Deoxypyridinoline NNP N
levels NNS o
decreased VBN N
significantly RB N
in IN N
the DT N
HRT NNP i
alone RB i
and CC N
HRT NNP i
+ NNP i
T NNP i
groups NNS N
, , N
- : N
14.4 CD N
+/- JJ N
6.8 CD N
% NN N
and CC N
-26.9 JJ N
+/- JJ N
7.6 CD N
% NN N
, , N
respectively RB N
. . N

Significant JJ N
reductions NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
cross-linked JJ o
N-telopeptide NNP o
of IN o
type NN o
I PRP o
collagen VBP o
were VBD N
also RB N
observed VBN N
in IN N
both DT N
groups NNS N
, , N
-24.4 VBD N
+/- JJ N
6.5 CD N
% NN N
and CC N
-39.5 JJ N
+/- JJ N
8.6 CD N
% NN N
, , N
respectively RB N
. . N

Bone NNP o
mineral JJ o
density NN o
in IN o
the DT o
lumbar NN o
spine NN o
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
by IN N
+2.2 JJ N
+/- JJ N
0.5 CD N
% NN N
the DT N
HRT NNP i
alone RB i
group NN N
and CC N
by IN N
+ JJ N
1.8 CD N
+/- JJ N
0.6 CD N
% NN N
in IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN N
. . N

Total JJ o
hip NN o
bone NN o
mineral JJ o
density NN o
was VBD N
maintained VBN N
in IN N
the DT N
HRT NNP i
alone RB i
group NN N
( ( N
+0.4 JJ N
+/- JJ N
0.4 CD N
% NN N
) ) N
and CC N
increased VBN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
HRT NNP i
+ NNP i
T NNP i
group NN N
( ( N
+ JJ N
1.8 CD N
+/- JJ N
0.5 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Sublingual NNP N
micronized VBD N
HRT NNP i
favorably RB N
decreases VBZ N
serum NN o
and CC o
urine JJ o
markers NNS o
of IN o
bone NN o
metabolism NN o
, , N
prevents VBZ N
bone JJ o
loss NN o
, , N
and CC N
results NNS N
in IN N
a DT N
slight JJ N
increase NN N
in IN N
spine NN o
and CC o
hip NN o
bone NN o
mineral JJ o
density NN o
. . o

Although IN N
the DT N
addition NN N
of IN N
testosterone NN N
to TO N
HRT NNP i
for IN N
1 CD N
year NN N
did VBD N
not RB N
result VB N
in IN N
added JJ N
benefit NN N
to TO N
the DT N
spine NN o
bone NN o
mineral JJ o
density NN o
, , N
it PRP N
did VBD N
result VB N
in IN N
a DT N
significant JJ N
increase NN N
in IN N
hip NN o
bone NN o
mineral JJ o
density NN o
. . o

Longer JJR N
duration NN N
of IN N
therapy NN N
may MD N
have VB N
further JJR N
improved VBN N
these DT N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Transitions NNS N
during IN N
effective JJ N
treatment NN N
for IN N
cocaine-abusing JJ p
homeless JJ p
persons NNS p
: : p
establishing VBG N
abstinence NN N
, , N
lapse NN N
, , N
and CC N
relapse NN N
, , N
and CC N
reestablishing VBG N
abstinence NN N
. . N

Data NNS N
are VBP N
reported VBN N
on IN N
drug NN N
use NN N
among IN N
cocaine-dependent JJ p
homeless NN p
persons NNS p
who WP p
participated VBD p
in IN p
a DT p
clinical JJ p
trial NN p
that WDT p
compared VBN p
day NN i
treatment NN i
only RB i
( ( p
DT NNP p
, , p
n JJ p
= NNP p
69 CD p
) ) p
with IN p
day NN i
treatment NN i
plus CC i
abstinent-contingent JJ i
housing NN i
and CC i
work NN i
( ( p
DT+ NNP p
, , p
n JJ p
= NNP p
72 CD p
) ) p
. . p

Drug NNP o
use NN o
was VBD o
measured VBN o
with IN o
multiple JJ o
weekly JJ o
urine NN o
toxicologies NNS o
. . o

Compared VBN N
with IN N
DT NNP N
participants NNS N
, , N
more JJR N
DT+ JJ N
participants NNS N
established VBN N
abstinence NN o
, , o
maintained VBD o
abstinence NN o
for IN o
longer JJR o
durations NNS o
, , N
were VBD N
marginally RB N
significantly RB N
more RBR N
likely JJ N
to TO N
lapse VB o
, , N
and CC N
significantly RB N
less RBR N
likely JJ N
to TO N
relapse VB o
. . o

Of IN N
all DT N
participants NNS N
who WP N
established VBD N
abstinence NN N
and CC N
then RB N
relapsed VBD N
, , N
DT+ NNP N
participants NNS N
relapsed VBD N
later RB N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
reestablish VB o
abstinence NN o
. . o

These DT N
analyses NNS N
yield VBP N
information NN N
on IN N
the DT N
processes NNS N
involved VBN N
in IN N
the DT N
manner NN N
in IN N
which WDT N
drug NN N
use NN N
changes NNS N
as IN N
a DT N
result NN N
of IN N
abstinent-contingent JJ i
housing NN i
and CC i
work NN i
. . i

-DOCSTART- -X- O O

Olanzapine NNP i
versus NN i
haloperidol NN i
in IN N
children NNS p
with IN p
autistic JJ o
disorder NN o
: : o
an DT N
open JJ N
pilot NN N
study NN N
. . N

OBJECTIVES NNP N
Conventional NNP N
neuroleptics NNS i
ameliorate VBP N
symptoms NNS N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
; : p
however RB N
, , N
they PRP N
are VBP N
known VBN N
to TO N
cause VB N
dyskinesias NN N
. . N

Atypical JJ i
neuroleptics NNS i
, , N
including VBG N
olanzapine NN N
, , N
may MD N
have VB N
less JJR N
risk NN N
for IN N
dyskinesia NN N
, , N
but CC N
their PRP$ N
efficacy NN N
in IN N
autistic JJ N
disorder NN N
is VBZ N
not RB N
established VBN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
safety NN N
and CC N
effectiveness NN N
of IN N
open-label JJ N
olanzapine NN i
as IN N
a DT N
treatment NN N
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
by IN N
using VBG N
haloperidol NN i
as IN N
a DT N
standard JJ N
comparator NN N
treatment NN N
. . N

METHOD NNP N
In IN N
a DT N
parallel JJ p
groups NNS p
design NN p
, , p
12 CD p
children NNS p
with IN p
DSM-IV NNP p
autistic JJ p
disorder NN p
( ( p
mean JJ p
age NN p
7.8+/-2.1 CD p
years NNS p
) ) p
were VBD p
randomized VBN p
to TO N
6 CD N
weeks NNS N
of IN N
open JJ i
treatment NN i
with IN i
olanzapine NN i
or CC i
haloperidol NN i
. . i

Mean NNP N
final JJ N
dosages NNS N
were VBD N
7.9+/-2.5 JJ N
mg/day NN N
for IN N
olanzapine NN i
and CC N
1.4+/-0.7 JJ N
mg/day NN N
for IN N
haloperidol NN i
. . i

Outcome NNP N
measures NNS N
included VBD N
the DT N
Clinical NNP o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
and CC o
the DT o
Children NNP o
's POS o
Psychiatric NNP o
Rating NNP o
Scale NNP o
( ( o
CPRS NNP o
) ) o
. . o

RESULTS NNP N
Both NNP N
groups NNS N
had VBD N
symptom VBN o
reduction NN o
. . o

Five CD N
of IN N
six CD N
in IN N
the DT N
olanzapine NN i
group NN N
and CC N
three CD N
of IN N
six CD N
in IN N
the DT N
haloperidol NN i
group NN N
were VBD N
rated VBN N
as IN N
responders NNS N
according VBG N
to TO N
the DT N
CGI NNP o
Improvement NNP N
item NN N
. . N

Subjects NNS N
showed VBD N
improvement NN N
on IN N
the DT N
CPRS NNP o
Autism NNP o
Factor NNP o
( ( N
F1,9 NNP N
= NNP N
24.4 CD N
, , N
p NN N
= NNP N
.0008 NNP N
) ) N
. . N

Side JJ N
effects NNS N
included VBD N
drowsiness NN o
and CC o
weight JJ o
gain NN o
. . o

CONCLUSIONS VB N
The DT N
findings NNS N
suggest VBP N
that IN N
olanzapine NN i
is VBZ N
a DT N
promising JJ N
treatment NN o
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Further JJ N
placebo-controlled JJ N
and CC N
long-term JJ N
studies NNS N
of IN N
olanzapine NN i
in IN N
autistic JJ N
disorder NN N
are VBP N
required VBN N
. . N

-DOCSTART- -X- O O

Combination NNP N
hydrocodone NN i
and CC i
ibuprofen JJ i
versus NN N
combination NN N
codeine NN i
and CC i
acetaminophen NN i
for IN N
the DT N
treatment NN p
of IN p
chronic JJ p
pain NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
combination NN N
hydrocodone NN i
7.5 CD N
mg NN N
and CC N
ibuprofen $ i
200 CD N
mg NN N
with IN N
that DT N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC N
acetaminophen $ i
300 CD N
mg NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
pain NN N
. . N

BACKGROUND NNP N
Hydrocodone NNP i
7.5 CD N
mg NN N
with IN N
ibuprofen JJ i
200 CD N
mg NN N
is VBZ N
the DT N
only JJ N
approved VBD N
fixed-dose JJ N
combination NN N
analgesic IN N
containing VBG N
an DT N
opioid NN N
and CC N
ibuprofen NN N
. . N

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
repeated-dose JJ N
, , N
active-comparator JJ N
, , N
4-week JJ N
, , N
multicenter NN N
study NN N
, , N
469 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
1-tablet JJ N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
or CC N
2-tablet JJ N
( ( N
n JJ N
= NNP N
153 CD N
) ) N
dose NN N
of IN N
combination NN i
hydrocodone NN i
7.5 CD i
mg NN i
and CC i
ibuprofen $ i
200 CD i
mg NN i
( ( N
HI1 NNP N
and CC N
HI2 NNP N
, , N
respectively RB N
) ) N
or CC N
a DT N
2-tablet JJ i
dose NN i
of IN N
combination NN N
codeine NN i
30 CD i
mg NN i
and CC i
acetaminophen $ i
300 CD i
mg NN i
( ( N
CA NNP N
, , N
n RB N
= VBZ N
160 CD N
) ) N
, , N
the DT N
active JJ N
comparator NN N
, , N
every DT N
6 CD N
to TO N
8 CD N
hours NNS N
as IN N
needed VBN N
for IN N
pain NN N
. . N

Efficacy NN N
was VBD N
measured VBN N
through IN N
pain NN o
relief NN o
scores NNS o
, , o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
study NN o
medication NN o
, , o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
supplemental JJ o
analgesics NNS o
, , o
number NN o
of IN o
patients NNS o
who WP o
discontinued VBD o
therapy NN o
due JJ o
to TO o
an DT o
unsatisfactory JJ o
analgesic JJ o
response NN o
, , N
and CC N
global JJ N
assessment NN N
scores NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
469 CD p
patients NNS p
, , p
255 CD p
( ( p
54.4 CD p
% NN p
) ) p
were VBD p
female JJ p
and CC p
214 CD p
( ( p
45.6 CD p
% NN p
) ) p
were VBD p
male JJ p
. . p

The DT N
mean JJ p
age NN p
was VBD p
51.1 CD p
years NNS p
. . p

Types NNS p
of IN p
chronic NN p
pain NN p
included VBD p
back RB p
( ( p
214 CD p
; : p
45.6 CD p
% NN p
) ) p
, , p
arthritic JJ p
( ( p
145 CD p
; : p
30.9 CD p
% NN p
) ) p
, , p
other JJ p
musculoskeletal NN p
( ( p
65 CD p
; : p
13.9 CD p
% NN p
) ) p
, , p
cancer NN p
( ( p
6 CD p
; : p
1.3 CD p
% NN p
) ) p
, , p
diabetic JJ p
neuropathic NN p
( ( p
3 CD p
; : p
0.6 CD p
% NN p
) ) p
, , p
postherpetic JJ p
neuralgic NN p
( ( p
5 CD p
; : p
1.1 CD p
% NN p
) ) p
, , p
other JJ p
neurologic NN p
( ( p
21 CD p
; : p
4.5 CD p
% NN p
) ) p
, , p
and CC p
other JJ p
unclassified JJ p
chronic JJ p
pain NN p
( ( p
10 CD p
; : p
2.1 CD p
% NN p
) ) p
. . N

During IN N
the DT N
48 CD N
hours NNS N
prior RB N
to TO N
the DT N
study NN N
, , N
351 CD N
( ( N
74.8 CD N
% NN N
) ) N
patients NNS N
had VBD N
been VBN N
treated VBN N
with IN N
opioid JJ N
or CC N
opioid-nonopioid JJ N
combination NN N
analgesics NNS N
. . N

The DT N
overall JJ o
mean JJ o
daily JJ o
pain NN o
relief NN o
score NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.25+/-0.89 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
1.98+/-0.87 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
1.85+/-0.96 JJ N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
overall JJ o
mean JJ o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
study NN o
medication NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2.94+/-0.99 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
3.23+/-0.76 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.036 CD N
) ) N
or CC N
the DT N
CA NNP N
group NN N
( ( N
3.26+/-0.75 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

The DT N
overall JJ o
mean JJ o
number NN o
of IN o
daily JJ o
doses NNS o
of IN o
supplemental JJ o
analgesics NNS o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
0.24+/-0.49 CD N
) ) N
than IN N
in IN N
the DT N
HI1 NNP N
group NN N
( ( N
0.34+/-0.58 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.021 CD N
) ) N
or CC N
CA NNP N
group NN N
( ( N
0.49+/-0.85 JJ N
) ) N
( ( N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

The DT N
number NN o
of IN o
patients NNS o
who WP o
discontinued VBD o
treatment NN o
due JJ o
to TO o
an DT o
unsatisfactory JJ o
analgesic JJ o
response NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
HI2 NNP N
group NN N
( ( N
2 CD N
; : N
1.3 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
CA NNP N
group NN N
( ( N
12 CD N
; : N
7.5 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

HI2 NNP N
was VBD N
more RBR N
effective JJ N
than IN N
HI1 NNP N
and CC N
CA NNP N
as IN N
measured VBN N
by IN N
pain NN o
relief NN o
scores NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
< VBZ N
0.001 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
, , N
and CC N
week NN N
3 CD N
( ( N
P NNP N
= VBZ N
0.008 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ o
doses NNS o
of IN o
study NN o
medication NN o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.019 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.011 CD N
vs NN N
CA NNP N
) ) N
; : N
daily JJ o
doses NNS o
of IN o
supplemental JJ o
analgesics NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.010 CD N
vs NN N
HI1 NNP N
and CC N
CA NNP N
) ) N
; : N
and CC N
global JJ o
assessment NN o
scores NNS o
for IN N
week NN N
1 CD N
( ( N
P NNP N
= VBZ N
0.018 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
week NN N
2 CD N
( ( N
P NNP N
= VBZ N
0.005 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
< NNP N
0.001 CD N
vs NN N
CA NNP N
) ) N
, , N
and CC N
week NN N
4 CD N
( ( N
P NNP N
= VBZ N
0.013 CD N
vs NN N
HI1 NNP N
and CC N
P NNP N
= NNP N
0.023 CD N
vs NN N
CA NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
HI1 NNP i
and CC N
CA NNP i
in IN N
any DT N
efficacy NN o
variable JJ N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
number NN o
of IN o
patients NNS o
experiencing VBG o
adverse JJ o
events NNS o
in IN N
the DT N
HI2 NNP N
( ( N
127 CD N
; : N
83 CD N
% NN N
) ) N
, , N
HI1 NNP i
( ( N
124 CD N
; : N
79.5 CD N
% NN N
) ) N
, , N
and CC N
CA NNP i
( ( N
129 CD N
; : N
80.6 CD N
% NN N
) ) N
groups NNS N
. . N

However RB N
, , N
the DT N
mean JJ o
number NN o
of IN o
patients NNS o
who WP o
discontinued VBD o
treatment NN o
due JJ o
to TO o
adverse JJ o
events NNS o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
HI2 NNP i
group NN N
( ( N
40 CD N
; : N
26.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
HI1 NNP i
group NN N
( ( N
23 CD N
; : N
14.7 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
hydrocodone NN i
7.5 CD N
mg NN N
and CC i
ibuprofen $ i
200 CD N
mg NN N
may MD N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
1-tablet JJ N
doses NNS N
of IN N
this DT N
combination NN N
or CC N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC i
acetaminophen $ i
300 CD N
mg NN N
. . N

Moreover RB N
, , N
1-tablet JJ N
doses NNS N
of IN N
combination NN i
hydrocodone NN i
7.5 CD i
mg NN i
and CC i
ibuprofen $ i
200 CD N
mg NN N
may MD N
be VB N
as RB N
effective JJ N
as IN N
2-tablet JJ N
doses NNS N
of IN N
combination NN N
codeine NN i
30 CD N
mg NN N
and CC i
acetaminophen $ i
300 CD N
mg NN N
. . N

-DOCSTART- -X- O O

Adriamycin NNP i
and CC i
chlorambucil VB i
versus NN i
adriamycin NN i
and CC i
thiabendazole NN i
in IN N
the DT N
treatment NN N
of IN N
extensive JJ o
, , o
non-small JJ o
cell NN o
carcinoma NN o
of IN o
the DT o
lung NN o
: : o
a DT p
Southwest NNP p
Oncology NNP p
Group NNP p
pilot NN N
study NN N
. . N

-DOCSTART- -X- O O

Final JJ N
Report NNP N
of IN N
the DT N
Intergroup NNP N
Randomized NNP N
Study NNP N
of IN N
Combined NNP i
Androgen-Deprivation NNP i
Therapy NNP i
Plus NNP i
Radiotherapy NNP i
Versus NNP i
Androgen-Deprivation NNP i
Therapy NNP i
Alone NNP i
in IN N
Locally NNP N
Advanced NNP N
Prostate NNP N
Cancer NNP N
. . N

PURPOSE NNP N
We PRP N
have VBP N
previously RB N
reported VBN N
that IN N
radiotherapy NN i
( ( i
RT NNP i
) ) i
added VBD N
to TO N
androgen-deprivation JJ i
therapy NN i
( ( i
ADT NNP i
) ) i
improves VBZ N
survival JJ N
in IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

Here RB N
, , N
we PRP N
report VBP N
the DT N
prespecified JJ N
final JJ N
analysis NN N
of IN N
this DT N
randomized JJ N
trial NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
NCIC NNP p
Clinical NNP p
Trials NNP p
Group NNP p
PR.3/Medical NNP p
Research NNP p
Council NNP p
PR07/Intergroup NNP p
T94-0110 NNP p
was VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

Patients NNS p
with IN p
T3-4 NNP p
, , p
N0/Nx NNP p
, , p
M0 NNP p
prostate NN p
cancer NN p
or CC p
T1-2 JJ p
disease NN p
with IN p
either DT p
prostate-specific JJ p
antigen NN p
( ( p
PSA NNP p
) ) p
of IN p
more JJR p
than IN p
40 CD p
?g/L NN p
or CC p
PSA NNP p
of IN p
20 CD p
to TO p
40 CD p
?g/L NNS p
plus CC p
Gleason NNP p
score NN p
of IN p
8 CD p
to TO p
10 CD p
were VBD p
randomly RB N
assigned VBN N
to TO N
lifelong VB i
ADT NNP i
alone RB i
or CC N
to TO N
ADT+RT NNP i
. . i

The DT i
RT NNP i
dose NN i
was VBD N
64 CD N
to TO N
69 CD N
Gy NNP N
in IN N
35 CD N
to TO N
39 CD N
fractions NNS N
to TO N
the DT N
prostate NN N
and CC N
pelvis NN N
or CC N
prostate VB N
alone RB o
. . o

Overall JJ o
survival NN o
was VBD o
compared VBN N
using VBG N
a DT N
log-rank JJ N
test NN N
stratified VBD N
for IN N
prespecified JJ N
variables NNS N
. . N

RESULTS NNP p
One CD p
thousand CD p
two CD p
hundred VBD p
five CD p
patients NNS p
were VBD p
randomly RB N
assigned VBN N
between IN N
1995 CD N
and CC N
2005 CD N
, , N
602 CD N
to TO N
ADT NNP i
alone RB i
and CC N
603 CD N
to TO N
ADT+RT NNP i
. . i

At IN N
a DT N
median JJ N
follow-up JJ N
time NN N
of IN N
8 CD N
years NNS N
, , N
465 CD N
patients NNS N
had VBD N
died VBN N
, , N
including VBG N
199 CD N
patients NNS N
from IN N
prostate JJ N
cancer NN o
. . o

Overall JJ o
survival NN o
was VBD o
significantly RB N
improved VBN N
in IN N
the DT N
patients NNS N
allocated VBD N
to TO N
ADT+RT NNP i
( ( i
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.70 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.57 CD N
to TO N
0.85 CD N
; : N
P NNP N
< NNP N
.001 NNP o
) ) o
. . o

Deaths NNS o
from IN o
prostate NN o
cancer NN o
were VBD o
significantly RB N
reduced VBN N
by IN N
the DT N
addition NN N
of IN N
RT NNP i
to TO i
ADT NNP i
( ( i
HR NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.61 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Patients NNS N
on IN N
ADT+RT NNP i
reported VBD i
a DT N
higher JJR o
frequency NN o
of IN o
adverse JJ o
events NNS o
related VBN o
to TO o
bowel VB o
toxicity NN o
, , o
but CC N
only RB N
two CD N
of IN N
589 CD N
patients NNS N
had VBD o
grade VBN o
3 CD o
or CC o
greater JJR o
diarrhea NN o
at IN o
24 CD N
months NNS N
after IN i
RT NNP i
. . i

CONCLUSION NNP N
This DT N
analysis NN N
demonstrates VBZ N
that IN N
the DT N
previously RB N
reported VBN N
benefit NN N
in IN N
survival NN o
is VBZ o
maintained VBN N
at IN N
a DT N
median JJ N
follow-up NN N
of IN N
8 CD N
years NNS N
and CC N
firmly RB N
establishes VBZ N
the DT N
role NN N
of IN N
RT NNP i
in IN i
the DT N
treatment NN N
of IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
phytonadione NN i
for IN N
excessive JJ o
anticoagulation NN o
. . o

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
managing VBG N
excessive JJ N
anticoagulation NN N
in IN N
the DT N
absence NN N
of IN N
bleeding NN N
by IN N
either DT N
omitting VBG N
warfarin JJ N
therapy NN N
alone RB N
or CC N
administering VBG N
oral JJ N
phytonadione NN i
in IN N
addition NN N
to TO N
omitting VBG N
warfarin JJ N
therapy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
. . N

SETTING NNP N
Clinical JJ N
pharmacy NN N
anticoagulation NN N
service NN N
in IN N
a DT N
group NN N
model NN N
health NN N
maintenance NN N
organization NN N
. . N

SUBJECTS NNP N
Thirty NNP p
nonbleeding VBG p
patients NNS p
with IN p
international JJ p
normalized JJ p
ratios NNS p
( ( p
INRs NNP p
) ) p
ranging VBG p
from IN p
6.0-10.0 JJ p
. . p

INTERVENTIONS JJ N
Patients NNPS p
were VBD p
randomized VBN p
to TO p
receive VB p
either CC p
a DT p
single JJ i
oral JJ i
dose NN i
of IN i
phytonadione NN i
2.5 CD i
mg NN i
or CC i
placebo NN i
. . i

Both DT N
groups NNS N
omitted VBD i
warfarin JJ i
doses NNS i
until IN i
the DT i
INR NNP i
became VBD i
less RBR i
than IN i
or CC i
equal JJ i
to TO i
4.0 CD i
. . i

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
The DT N
mean NN o
calculated VBD o
time NN o
to TO o
reach VB o
an DT o
INR NNP o
of IN o
4.0 CD o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
placebo NN N
than IN N
the DT N
phytonadione NN N
group NN N
( ( N
2.6 CD N
vs RB N
1.4 CD N
days NNS N
, , N
p=0.006 NN N
) ) N
. . N

Overcorrection NN o
of IN o
anticoagulation NN o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
patients NNS N
receiving VBG N
phytonadione NN N
. . N

Overt NNP o
warfarin VBD o
resistance NN o
was VBD N
not RB N
observed VBN N
in IN N
either DT N
group NN N
after IN N
reinitiating VBG N
warfarin JJ N
therapy NN N
. . N

No DT N
major JJ o
bleeding NN o
or CC o
thromboembolic JJ o
complications NNS o
occurred VBD N
, , N
and CC N
minor JJ N
bleeding NN o
episodes NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
The DT N
addition NN N
of IN N
oral JJ N
phytonadione NN N
2.5 CD N
mg NN N
reduced VBD N
the DT N
time NN N
to TO N
achieve VB N
an DT N
INR NNP N
of IN N
4.0 CD N
by IN N
approximately RB N
1 CD N
day NN N
compared VBN N
with IN N
omitting VBG N
warfarin JJ N
therapy NN N
alone RB N
. . N

Adverse JJ N
events NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Both DT N
strategies NNS N
were VBD N
effective JJ N
in IN N
managing VBG N
asymptomatic JJ p
patients NNS p
with IN p
INRs NNP p
of IN p
6.0-10.0 NNP p
. . p

Oral NNP N
phytonadione NN N
may MD N
be VB N
most RBS N
appropriate JJ N
for IN N
patients NNS p
at IN p
high JJ p
risk NN p
for IN p
bleeding VBG p
in IN p
whom WP p
the DT p
benefit NN p
of IN p
prompt JJ p
INR NNP o
reduction NN o
would MD p
outweigh VB p
the DT p
thromboembolic JJ p
risk NN p
associated VBN p
with IN p
INR NNP o
overcorrection NN o
. . o

-DOCSTART- -X- O O

Complementary JJ N
feeding NN N
with IN N
fortified JJ N
spread NN N
and CC N
incidence NN N
of IN N
severe JJ o
stunting VBG o
in IN N
6- JJ p
to TO p
18-month-old JJ p
rural JJ p
Malawians NNPS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
growth NN o
and CC N
incidence NN N
of IN N
malnutrition NN o
in IN N
infants NNS p
receiving VBG p
long-term JJ p
dietary JJ p
supplementation NN p
with IN p
ready-to-use NN p
fortified VBN i
spread NN i
( ( i
FS NNP i
) ) i
or CC p
micronutrient-fortified JJ i
maize-soy JJ i
flour NN i
( ( i
likuni JJ i
phala NN i
[ NNP p
LP NNP p
] NNP p
) ) p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
, , N
single-blind JJ N
trial NN N
. . N

SETTING NNP N
Rural JJ N
Malawi NNP N
. . N

PARTICIPANTS VB N
A DT p
total NN p
of IN p
182 CD p
six-month-old JJ p
infants NNS p
. . p

INTERVENTION NN N
Participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
1 CD N
year NN N
of IN N
daily JJ N
supplementation NN N
with IN N
71 CD N
g NN N
of IN N
LP NNP i
( ( N
282 CD N
kcal NN N
) ) N
, , N
50 CD N
g NN N
of IN N
FS NNP i
( ( N
FS50 NNP N
) ) N
( ( N
256 CD N
kcal NN N
) ) N
, , N
or CC N
25 CD N
g NN N
of IN N
FS NNP i
( ( i
FS25 NNP i
) ) i
( ( N
130 CD N
[ RB N
corrected VBN N
] NNP N
kcal JJ N
) ) N
. . N

OUTCOME NNP N
MEASURES NNP N
Weight NNP o
and CC o
length NN o
gains NNS o
and CC o
the DT o
incidences NNS o
of IN o
severe JJ o
stunting NN o
, , o
underweight JJ o
, , o
and CC o
wasting VBG o
. . o

RESULTS NNP N
Mean NNP o
weight NN o
and CC o
length NN o
gains NNS o
in IN N
the DT N
LP NNP i
, , N
FS50 NNP N
, , N
and CC N
FS25 NNP N
groups NNS N
were VBD N
2.37 CD N
, , N
2.47 CD N
, , N
and CC N
2.37 CD N
kg NN N
( ( N
P NNP N
= NNP N
.66 NNP N
) ) N
and CC N
12.7 CD N
, , N
13.5 CD N
, , N
and CC N
13.2 CD N
cm NN N
( ( N
P NNP N
= NNP N
.23 NNP N
) ) N
, , N
respectively RB N
. . N

In IN N
the DT N
same JJ N
groups NNS N
, , N
the DT N
cumulative JJ N
12-month JJ N
incidence NN N
of IN N
severe JJ o
stunting NN o
was VBD N
13.3 CD N
% NN N
, , N
0.0 CD N
% NN N
, , N
and CC N
3.5 CD N
% NN N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
of IN N
severe JJ N
underweight NN o
was VBD N
15.0 CD N
% NN N
, , N
22.5 CD N
% NN N
, , N
and CC N
16.9 CD N
% NN N
( ( N
P NNP N
= NNP N
.71 NNP N
) ) N
, , N
and CC N
of IN N
severe JJ o
wasting NN o
was VBD N
1.8 CD N
% NN N
, , N
1.9 CD N
% NN N
, , N
and CC N
1.8 CD N
% NN N
( ( N
P NNP N
> NNP N
.99 NNP N
) ) N
. . N

Compared VBN N
with IN N
LP-supplemented JJ i
infants NNS N
, , N
those DT N
given VBN N
FS50 NNP N
gained VBD N
a DT N
mean NN N
of IN N
100 CD N
g NNS N
more JJR N
weight NN o
and CC N
0.8 CD N
cm NN N
more JJR N
length NN o
. . o

There EX N
was VBD N
a DT N
significant JJ N
interaction NN N
between IN N
baseline NN N
length NN N
and CC N
intervention NN N
( ( N
P NNP N
= NNP N
.04 NNP N
) ) N
; : N
in IN N
children NNS N
with IN N
below-median JJ N
length NN N
at IN N
enrollment NN N
, , N
those DT N
given VBN N
FS50 NNP N
gained VBD N
a DT N
mean NN N
of IN N
1.9 CD N
cm NNS N
more JJR N
than IN N
individuals NNS N
receiving VBG N
LP NNP i
. . i

CONCLUSION NNP N
One-year-long JJ N
complementary JJ N
feeding NN N
with IN N
FS NNP i
does VBZ N
not RB N
have VB N
a DT N
significantly RB N
larger JJR N
effect NN N
than IN N
LP NNP i
on IN N
mean JJ o
weight NN o
gain NN o
in IN N
all DT N
infants NNS N
, , N
but CC N
it PRP N
is VBZ N
likely JJ N
to TO N
boost VB N
linear JJ o
growth NN o
in IN N
the DT N
most RBS N
disadvantaged JJ N
individuals NNS N
and CC N
, , N
hence RB N
, , N
decrease VB N
the DT N
incidence NN o
of IN o
severe JJ o
stunting NN o
. . o

-DOCSTART- -X- O O

Independent NNP N
prognostic JJ N
information NN N
provided VBN N
by IN N
sphygmomanometrically RB i
determined VBN i
pulse JJ o
pressure NN o
and CC i
mean JJ i
arterial JJ o
pressure NN o
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
relationship NN N
of IN N
baseline NN N
pulse JJ N
pressure NN N
and CC N
mean JJ N
arterial JJ N
pressure NN N
to TO N
mortality NN N
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

BACKGROUND NNP N
Increased VBD N
conduit NN N
vessel NN N
stiffness NN N
increases VBZ N
pulse JJ N
pressure NN N
and CC N
pulsatile NN N
load NN N
, , N
potentially RB N
contributing VBG N
to TO N
adverse VB N
outcomes NNS N
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

METHODS NNP N
Pulse NNP N
and CC N
mean VB N
arterial JJ N
pressure NN N
were VBD N
analyzed VBN N
for IN N
their PRP$ N
effect NN N
on IN N
mortality NN o
, , N
adjusting VBG N
for IN N
other JJ N
modifiers NNS N
of IN N
risk NN N
, , N
using VBG N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
analysis NN N
of IN N
data NNS N
collected VBN N
from IN N
6,781 CD p
patients NNS p
randomized VBN p
into IN p
the DT p
Studies NNPS p
of IN p
Left NNP p
Ventricular NNP p
Dysfunction NNP p
trials NNS p
. . p

RESULTS NNP N
Pulse NNP o
and CC o
mean VB o
arterial JJ o
pressure NN o
were VBD N
related VBN N
positively RB N
to TO N
each DT N
other JJ N
, , N
age NN N
, , N
ejection NN N
fraction NN N
and CC N
prevalence NN N
of IN N
diabetes NNS N
and CC N
hypertension NN N
and CC N
inversely RB N
to TO N
prior VB N
myocardial JJ N
infarction NN N
and CC N
beta-adrenergic JJ N
blocking NN N
agent NN N
use NN N
. . N

Higher JJR o
pulse JJ o
pressure NN o
was VBD N
associated VBN N
with IN N
increased JJ N
prevalence NN N
of IN N
female JJ N
gender NN N
, , N
greater JJR N
calcium NN i
channel NN i
blocking VBG i
agent NN i
, , i
digoxin NN i
and CC N
diuretic JJ i
use NN N
, , N
lower JJR N
heart NN N
rate NN N
and CC N
a DT N
higher JJR N
rate NN N
of IN N
reported VBN N
smoking NN N
history NN N
. . N

Higher JJR o
mean JJ o
arterial JJ o
pressure NN o
was VBD N
associated VBN N
with IN N
higher JJR N
heart NN N
rate NN N
, , N
lower JJR N
calcium NN i
channel NN i
blocker NN i
and CC N
digoxin NN i
use NN N
and CC N
lower JJR N
New NNP N
York NNP N
Heart NNP N
Association NNP N
functional JJ N
class NN N
. . N

Over IN N
a DT N
61-month JJ N
follow-up JJ N
1,582 CD N
deaths NNS o
( ( N
1,397 CD N
cardiovascular NN N
) ) N
occurred VBD N
. . N

In IN N
a DT N
multivariate NN N
analysis NN N
adjusting VBG N
for IN N
the DT N
above JJ N
covariates NNS N
and CC N
treatment NN N
assignment NN N
, , N
higher JJR N
pulse JJ o
pressure NN o
remained VBD N
an DT N
independent JJ N
predictor NN N
of IN N
total JJ o
and CC o
cardiovascular JJ o
mortality NN o
( ( N
total JJ N
mortality NN N
relative NN N
risk NN N
, , N
1.05 CD N
per IN N
10 CD N
mm NN N
Hg NNP N
increment NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.01 CD N
to TO N
1.10 CD N
; : N
p NN N
= VBZ N
0.02 CD N
) ) N
. . N

Mean JJ o
arterial JJ o
pressure NN o
was VBD N
inversely RB N
related VBN N
to TO N
total JJ o
and CC o
cardiovascular JJ o
mortality NN o
( ( N
total JJ N
mortality NN N
relative NN N
risk NN N
, , N
0.89 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.85 CD N
to TO N
0.94 CD N
; : N
p NN N
< VBZ N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
One CD N
noninvasive JJ i
blood NN i
pressure NN i
measurement NN i
provides VBZ N
two CD N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
survival NN o
. . o

Increased VBD o
conduit NN o
vessel NN o
stiffness NN o
, , N
as IN N
assessed VBN N
by IN N
pulse JJ N
pressure NN N
, , N
may MD N
contribute VB N
to TO N
increased VBN N
mortality NN o
in IN N
patients NNS N
with IN N
left JJ N
ventricular JJ N
dysfunction NN N
, , N
independent JJ N
of IN N
mean JJ N
arterial JJ N
pressure NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
Selaginella NNP i
combined VBD N
with IN N
radiotherapy NN i
on IN N
nasopharyngeal JJ p
carcinoma NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
Chinese JJ N
herbal JJ N
medicine NN N
Selaginella-induced NNP N
radiosensitization NN N
of IN N
terminal JJ p
nasopharyngeal JJ p
carcinoma NN p
( ( p
NPC NNP p
) ) p
. . p

METHODS NNP N
Totally RB N
180 CD p
patients NNS p
with IN p
NPC NNP p
were VBD N
divided VBN N
equally RB N
into IN N
3 CD N
groups NNS N
with IN N
the DT N
same JJ N
radiotherapeutic JJ N
protocols NNS N
. . N

The DT N
patients NNS N
in IN N
group NN i
A NNP i
received VBD i
radiotherapy NN i
alone RB i
, , i
those DT i
in IN i
group NN i
B NNP i
were VBD i
given VBN i
daily JJ i
Selaginella NNP i
( ( i
30 CD i
g NN i
) ) i
prepared VBD i
into IN i
50 CD i
ml JJ i
decoction NN i
during IN i
the DT i
entire JJ i
course NN i
of IN i
radiotherapy NN i
, , N
and CC N
those DT N
in IN N
group NN i
C NNP i
had VBD i
Selaginella NNP i
30 CD i
g JJ i
daily RB i
in IN i
the DT i
late JJ i
course NN i
of IN i
radiotherapy NN i
. . i

RESULTS VB N
The DT N
complete JJ o
remission NN o
rate NN o
of IN o
nasopharyngeal JJ o
primary JJ o
lesions NNS o
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
in IN N
group NN N
A NNP N
, , N
with IN N
also RB N
significantly RB N
higher JJR N
complete JJ N
remission NN o
rates NNS o
of IN o
the DT o
cervical JJ o
lymph NN o
nodes NNS o
. . o

The DT N
acute JJ o
toxicity NN o
of IN o
the DT o
skin NN o
and CC o
mucous JJ o
membrane NN o
was VBD N
milder RBR N
in IN N
the DT N
latter JJ N
two CD N
groups NNS N
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
significant JJ N
. . N

CONCLUSION NNP N
Selaginella NNP i
may MD N
induce VB N
radiosensitization NN N
for IN N
terminal JJ p
NPC NNP p
and CC N
does VBZ N
not RB N
increase VB N
the DT N
acute JJ N
toxicity NN N
of IN N
radiotherapy NN N
. . N

-DOCSTART- -X- O O

The DT N
role NN N
of IN N
routinely RB N
given VBN N
hyoscine-N-butylbromide NN i
in IN N
colonoscopy NN p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
Hyoscine-N-butylbromide NNP i
( ( i
HBB NNP i
) ) i
has VBZ N
been VBN N
proposed VBN N
to TO N
ease VB N
colonoscopy NN N
and CC N
improve VB N
mucosal NN N
visualization NN N
, , N
yet RB N
the DT N
results NNS N
from IN N
previous JJ N
studies NNS N
are VBP N
conflicting VBG N
. . N

In IN N
our PRP$ N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
study NN N
we PRP N
aimed VBD N
at IN N
evaluating VBG N
whether IN N
routine JJ N
administration NN N
of IN N
HBB NNP i
, , N
before IN N
and CC N
during IN N
colonoscopy NN N
, , N
ease VB o
the DT o
procedure NN o
or CC o
increase VB o
the DT o
detection NN o
rate NN o
for IN o
polyps NNS o
. . o

MATERIAL NNP N
AND CC N
METHODS NNP N
One CD p
hundred VBD p
fifty JJ p
outpatients NNS p
scheduled VBN p
for IN p
an DT p
elective JJ p
colonoscopy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
intravenous JJ N
injections NNS N
of IN N
either DT N
10 CD N
mg JJ N
hyoscine-N-butylbromide NN i
or CC i
saline NN i
before IN i
insertion NN N
and CC N
at IN N
cecum NN N
. . N

Patient JJ o
tolerance NN o
and CC o
technical JJ o
ease NN o
of IN o
colonoscopy NN o
were VBD N
evaluated VBN N
by IN N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
. . N

Procedure NN o
times NNS o
were VBD N
recorded VBN N
. . N

Number NNP o
of IN o
detected JJ o
polyps NNS o
per IN o
patient NN o
was VBD N
evaluated VBN N
as RB N
well RB N
. . N

Heart NNP o
rate NN o
was VBD N
monitored VBN N
with IN N
a DT N
pulse JJ N
oximetry NN N
. . N

RESULTS NNP N
HBB NNP i
did VBD N
not RB N
improve VB N
patient NN o
tolerance NN o
or CC o
technically RB o
ease VB o
the DT o
procedure NN o
as IN N
evaluated VBN N
by IN N
VAS NNP N
. . N

However RB N
, , N
HBB NNP i
led VBD N
to TO N
faster VB N
ileal JJ o
intubation NN o
( ( N
1.5 CD N
vs RB N
2.0 CD N
min NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
shorter JJR N
total JJ o
procedure NN o
time NN o
( ( N
22.0 CD N
vs RB N
24.0 CD N
min NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
HBB NNP i
also RB N
needed VBD N
less RBR N
often RB N
external JJ o
abdominal JJ o
pressure NN o
( ( N
48.6 CD N
vs RB N
66.7 CD N
% NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
. . N

HBB NNP i
did VBD N
not RB N
improve VB N
polyp JJ o
detection NN o
rate NN o
( ( N
0.89 CD N
vs NN N
0.91 CD N
, , N
p NN N
= NNP N
0.90 CD N
) ) N
. . N

HBB NNP i
induced VBD N
a DT N
significant JJ N
rise NN N
in IN N
heart NN o
rate NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
more RBR N
often RB N
tachycardia NNP o
( ( N
17.6 CD N
vs RB N
0 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Routine NNP N
administration NN N
of IN N
HBB NNP i
before IN N
and CC N
during IN N
colonoscopy NN N
yields NNS N
only RB N
limited VBD N
improvement NN N
in IN N
the DT N
technical JJ o
performance NN o
of IN o
the DT o
examination NN o
compromised VBN N
by IN N
high JJ N
incidence NN N
of IN N
tachycardia NN o
. . o

-DOCSTART- -X- O O

Treatment NN N
of IN N
recurrent NN p
chronic JJ p
hyperplastic JJ p
sinusitis NN p
with IN p
nasal JJ p
polyposis NN p
. . p

OBJECTIVE UH N
To TO N
demonstrate VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
intranasal JJ N
furosemide NN i
, , N
an DT N
inhibitor NN N
of IN N
the DT N
sodium NN N
chloride NN N
cotransporter NN N
channel NN N
at IN N
the DT N
basolateral JJ N
surface NN N
of IN N
the DT N
respiratory JJ N
epithelial JJ N
cell NN N
, , N
vs VBZ N
no DT i
therapeutic JJ i
intervention NN i
vs NN N
intranasal NN N
mometasone NN i
furoate NN i
, , i
a DT i
corticosteroid NN i
, , N
in IN N
preventing VBG N
relapses NNS N
of IN N
chronic JJ N
hyperplastic JJ N
sinusitis NN N
with IN N
nasal JJ N
polyposis NN N
. . N

DESIGN NNP N
Randomized NNP N
prospective NN N
controlled VBD N
study NN N
. . N

Patients NNS N
were VBD N
examined VBN N
every DT N
6 CD N
months NNS N
during IN N
follow-up NN N
( ( N
range NN N
, , N
1-9 JJ N
years NNS N
) ) N
. . N

PATIENTS VB N
One CD p
hundred JJ p
seventy NN p
patients NNS p
with IN p
bilateral JJ p
obstructive CD p
or CC p
minimally RB p
obstructive JJ p
chronic JJ p
hyperplastic JJ p
sinusitis NN p
with IN p
nasal JJ p
polyposis NN p
. . p

INTERVENTION NNP N
All DT p
patients NNS p
were VBD p
surgically RB p
treated VBN p
in IN p
the DT p
ENT NNP p
Department NNP p
, , p
University NNP p
of IN p
Siena NNP p
Medical NNP p
School NNP p
. . p

One CD p
month NN p
after IN p
surgery NN p
, , N
group NN N
1 CD p
patients NNS p
( ( N
n JJ N
= NNP N
97 CD N
) ) N
started VBD N
treatment NN i
with IN i
intranasal JJ i
furosemide NN i
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
40 CD N
) ) N
received VBD i
no DT i
therapeutic JJ i
treatment NN i
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
33 CD N
) ) N
were VBD N
treated VBN i
with IN i
mometasone NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Clinical NNP o
and CC o
instrumental JJ o
evaluation NN o
of IN o
postoperative JJ o
outcomes NNS o
. . o

RESULTS NNP N
Seventeen NNP N
( ( N
17.5 CD N
% NN N
) ) N
of IN N
97 CD N
patients NNS N
in IN N
group NN N
1 CD N
, , N
12 CD N
( ( N
30.0 CD N
% NN N
) ) N
of IN N
40 CD N
patients NNS N
in IN N
group NN N
2 CD N
, , N
and CC N
8 CD N
( ( N
24.2 CD N
% NN N
) ) N
of IN N
33 CD N
patients NNS N
in IN N
group NN N
3 CD N
experienced VBD N
nasal JJ o
polyposis NN o
relapses NNS o
. . o

We PRP N
noted VBD N
a DT N
prevalence NN N
of IN N
early-stage JJ o
relapse NN o
in IN N
patients NNS p
treated VBN p
with IN p
furosemide NN i
or CC p
mometasone NN i
, , N
whereas JJ N
patients NNS p
who WP p
did VBD p
not RB p
receive VB p
any DT p
treatment NN p
experienced VBD N
more JJR N
severe JJ N
grades NNS o
of IN o
chronic JJ o
hyperplastic JJ o
sinusitis NN o
with IN o
nasal JJ o
polyposis NN o
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
intranasal NN N
furosemide JJ i
represents VBZ N
a DT N
valid JJ N
therapeutic JJ N
treatment NN N
in IN N
the DT N
prevention NN N
of IN N
chronic JJ p
hyperplastic JJ p
sinusitis NN p
with IN p
nasal JJ p
polyposis NN p
. . p

-DOCSTART- -X- O O

A DT p
limited JJ p
sampling NN p
method NN p
for IN p
the DT p
estimation NN o
of IN o
flunarizine JJ o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
and CC o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
. . o

A DT N
limited JJ N
sampling NN N
model NN N
has VBZ N
been VBN N
developed VBN N
for IN N
flunarizine NN N
following VBG N
a DT N
30 CD N
mg JJ N
oral JJ N
dose NN N
in IN N
epileptic JJ p
patients NNS p
who WP p
were VBD i
receiving VBG i
phenytoin NN i
or CC i
carbamazepine NN i
or CC i
both DT i
, , i
to TO i
estimate VB o
the DT o
area NN o
under IN o
the DT o
curve NN o
( ( o
AUC NNP o
) ) o
and CC o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
. . o

The DT N
model NN N
was VBD N
developed VBN N
using VBG N
training VBG N
data NNS N
sets NNS N
from IN N
30 CD p
, , p
20 CD p
, , p
15 CD p
, , p
or CC p
10 CD p
patients NNS p
at IN p
one CD p
or CC p
two CD p
time NN p
points NNS p
. . p

The DT N
equations NNS N
describing VBG N
the DT N
models NNS N
for IN N
AUC NNP N
using VBG N
two CD N
time NN N
points NNS N
( ( N
3 CD N
and CC N
24h CD N
) ) N
and CC N
Cmax NNP N
for IN N
the DT N
training NN N
data NNS N
set NN N
of IN N
30 CD N
subjects NNS N
were VBD N
AUCpredicted NNP N
= NNP N
11.1 CD N
C3h NNP N
+ VBD N
121.4 CD N
C24h NNP N
- : N
157 CD N
( ( N
r NN N
= RB N
0.80 CD N
) ) N
Cmax NNP N
( ( N
predicted VBN N
) ) N
= $ N
0.036 CD N
AUC NNP N
+ $ N
42.9 CD N
( ( N
r NN N
= RB N
0.74 CD N
) ) N
The DT N
model NN N
was VBD N
validated VBN N
on IN N
64 CD p
patients NNS p
who WP N
received VBD N
flunarizine JJ N
orally RB N
. . N

The DT N
model NN N
provided VBD N
reasonably RB N
good JJ N
estimates NNS o
for IN o
both DT o
AUC NNP o
and CC o
Cmax NNP o
. . o

The DT N
mean NN o
predicted VBD o
AUC NNP o
of IN o
flunarizine NN o
was VBD N
1230 CD N
+/- JJ N
717 CD N
ng JJ N
h NN N
mL-1 NN N
, , N
whereas IN N
the DT N
observed JJ o
AUC NNP o
was VBD N
1203 CD N
+/- JJ N
900 CD N
ng JJ N
h JJ N
mL-1 NN N
. . N

The DT N
bias NN o
of IN o
the DT o
prediction NN o
was VBD N
2 CD N
% NN N
and CC N
precision NN N
was VBD N
28 CD N
% NN N
. . N

The DT N
mean NN N
predicted VBD o
Cmax NNP o
of IN o
flunarizine NN o
was VBD N
86 CD N
+/- JJ N
32 CD N
ng JJ N
mL-1 NN N
as IN N
compared VBN N
to TO N
an DT N
observed JJ o
mean NN o
Cmax NNP o
of IN N
90 CD N
+/- JJ N
42 CD N
ng JJ N
mL-1 NN N
. . N

The DT N
bias NN o
and CC o
precision NN o
of IN o
the DT o
prediction NN o
were VBD N
4 CD N
% NN N
and CC N
24 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
method NN N
described VBD N
here RB N
may MD N
be VB N
used VBN N
to TO N
estimate VB N
AUC NNP N
and CC N
Cmax NNP N
for IN N
flunarizine NN N
without IN N
detailed JJ N
pharmacokinetic JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

Barriers NNS N
to TO N
hypertension NN N
care NN N
and CC N
control NN N
in IN N
young JJ p
urban JJ p
black JJ p
men NNS p
. . p

Barriers NNS N
to TO N
high JJ o
blood NN o
pressure NN o
( ( N
HBP NNP N
) ) N
care NN N
and CC N
control NN N
have VBP N
been VBN N
reported VBN N
in IN N
the DT N
literature NN N
for IN N
> $ N
30 CD N
years NNS N
. . N

Few JJ N
reports NNS N
on IN N
barriers NNS N
, , N
however RB N
, , N
have VBP N
focused VBN N
on IN N
the DT N
young JJ p
black JJ p
man NN p
with IN p
HBP NNP p
, , N
the DT N
age/sex/race NN N
group NN N
with IN N
the DT N
highest JJS N
rates NNS N
of IN N
early JJ N
severe JJ N
and CC N
complicated JJ N
HBP NNP N
and CC N
the DT N
lowest JJS N
rates NNS N
of IN N
awareness NN N
, , N
treatment NN N
, , N
and CC N
control NN N
. . N

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
comprehensive JJ N
care NN N
for IN N
hypertensive JJ p
young JJ p
urban JJ p
black JJ p
men NNS p
, , N
factors NNS N
potentially RB N
associated VBN N
with IN N
care NN N
and CC N
control NN N
were VBD N
assessed VBN N
at IN N
baseline NN N
for IN N
the DT N
309 CD p
enrolled VBD p
men NNS p
. . p

A DT p
majority NN p
of IN p
the DT p
men NNS p
encountered VBD p
a DT p
variety NN p
of IN p
barriers NNS p
including VBG p
economic JJ p
, , p
social JJ p
, , p
and CC p
lifestyle JJ p
obstacles NNS p
to TO p
adequate VB p
BP NNP p
care NN p
and CC p
control NN p
, , p
including VBG p
no DT o
current JJ o
HBP NNP o
care NN o
( ( p
49 CD p
% NN p
) ) p
, , p
risk NN o
of IN o
alcoholism NN o
( ( p
62 CD p
% NN p
) ) p
, , p
use NN o
of IN o
illicit NN o
drugs NNS o
( ( p
45 CD p
% NN p
) ) p
, , p
social JJ o
isolation NN o
( ( p
47 CD p
% NN p
) ) p
, , p
unemployment NN o
( ( p
40 CD p
% NN p
) ) p
, , p
and CC p
lack NN o
of IN o
health NN o
insurance NN o
( ( p
51 CD p
% NN p
) ) p
. . p

Having VBG o
health NN o
insurance NN o
( ( N
odds NNS N
ratio VBP N
= JJ N
7.20 CD N
, , N
P NNP N
= NNP N
.00 NNP N
) ) N
and CC N
a DT N
negative JJ o
urine JJ o
drug NN o
screen NN o
( ( N
odds NNS N
ratio VBP N
= JJ N
.56 NNP N
, , N
P NNP N
= NNP N
.04 NNP N
) ) N
were VBD N
significant JJ N
predictors NNS N
of IN N
being VBG N
in IN N
HBP NNP N
care NN N
. . N

Low JJ o
alcoholism NN o
risk NN o
and CC o
employment NN o
were VBD N
identified VBN N
as IN N
significant JJ N
predictors NNS N
of IN N
compliance NN N
with IN N
HBP NNP N
medication-taking JJ N
behavior NN N
. . N

Men NNP p
currently RB p
using VBG o
illicit JJ o
drugs NNS o
were VBD N
2.64 CD N
times NNS N
less RBR N
likely JJ N
to TO N
have VB N
controlled VBN o
BP NNP o
compared VBN N
with IN N
their PRP$ N
counterparts NNS p
who WP p
did VBD p
not RB p
use VB p
illicit JJ p
drugs NNS p
, , N
and CC N
men NNS p
currently RB p
taking VBG o
HBP NNP o
medication NN o
were VBD N
63 CD N
times NNS N
more RBR N
likely JJ N
have VBP N
controlled VBN o
BP NNP o
compared VBN N
with IN N
men NNS p
not RB p
taking VBG p
HBP NNP p
medication NN p
. . p

Comprehensive JJ i
interventions NNS i
are VBP N
needed VBN N
to TO N
address VB N
socioeconomic JJ N
and CC N
lifestyle JJ N
issues NNS N
as RB N
well RB N
as IN N
other JJ N
barriers NNS N
to TO N
care VB N
and CC N
treatment NN N
, , N
if IN N
HBP NNP N
care NN N
is VBZ N
to TO N
be VB N
salient JJ N
and CC N
effective JJ N
in IN N
this DT N
high JJ p
risk NN p
group NN p
. . p

-DOCSTART- -X- O O

Topical JJ i
treatment NN i
of IN N
alopecia NN N
areata NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
previously RB N
that IN N
alopecia JJ N
areata NNS N
can MD N
be VB N
treated VBN N
with IN N
dinitrochlorobenzene NN i
( ( i
DNCB NNP i
) ) i
and CC N
other JJ N
contact NN i
allergens NNS i
. . i

Whether IN N
these DT N
agents NNS N
work NN N
by IN N
inducing VBG N
immunologic JJ N
stimulation NN N
or CC N
simply RB N
a DT N
nonspecific JJ N
inflammatory NN N
reaction NN N
has VBZ N
not RB N
been VBN N
definitively RB N
demonstrated VBN N
. . N

To TO N
test VB N
the DT N
relative JJ N
importance NN N
of IN N
these DT N
two CD N
mechanisms NNS N
, , N
we PRP N
have VBP N
randomly RB N
studied VBN N
22 CD p
patients NNS p
with IN p
alopecia JJ p
areata NNS p
to TO p
whom WP p
either DT p
DNCB NNP i
or CC i
croton VB i
oil NN i
was VBD p
applied VBN p
topically RB p
. . p

Sixty-three JJ N
percent NN N
of IN N
patients NNS N
without IN N
spontaneous JJ N
regrowth NN o
of IN o
hair NN o
regrew NNS o
hair NN o
after IN N
DNCB NNP N
application NN N
. . N

None NN o
of IN N
those DT N
treated VBN N
with IN N
croton NN i
oil NN i
regrew VBD o
hair NN o
when WRB N
treated VBN N
later RB N
with IN N
DNCB NNP i
. . i

Therefore NNP N
, , N
a DT N
proved JJ N
contact NN N
allergen NN N
was VBD N
shown VBN N
to TO N
be VB N
required VBN N
for IN N
therapeutic JJ N
success NN N
. . N

Patient JJ o
acceptance NN o
of IN N
the DT N
induced JJ N
contact NN N
dermatitis NN N
was VBD N
excellent JJ N
. . N

In IN N
light NN N
of IN N
recent JJ N
data NNS N
on IN N
the DT N
mutagenicity NN N
of IN N
DNCB NNP i
to TO N
bacteria NNS N
, , N
other JJ N
contact NN N
allergens NNS N
for IN N
topical JJ N
immunotherapy NN N
are VBP N
being VBG N
sought VBN N
. . N

-DOCSTART- -X- O O

Healthcare NN N
costs NNS N
around IN N
the DT N
time NN N
of IN N
smoking VBG N
cessation NN N
. . N

BACKGROUND IN N
The DT N
Affordable NNP N
Care NNP N
Act NNP N
mandates VBZ N
that IN N
new JJ N
insurance NN N
plans NNS N
cover VBP N
smoking-cessation NN i
therapy NN i
without IN N
cost-sharing NN N
. . N

Previous JJ N
cost NN N
difference NN N
estimates NNS N
, , N
which WDT N
show VBP N
a DT N
spike NN N
around IN N
the DT N
time NN N
of IN N
cessation NN N
, , N
suggest VBP N
premiums NNS N
might MD N
rise VB N
as IN N
a DT N
result NN N
of IN N
covering VBG N
these DT N
services NNS N
. . N

PURPOSE VB N
The DT N
goal NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
test VB N
( ( N
1 CD N
) ) N
whether IN N
individuals NNS p
in IN p
an DT p
RCT NNP p
of IN p
pharmacotherapy NN i
and CC p
counseling VBG i
for IN p
smoking VBG p
cessation NN p
differed VBN N
in IN N
their PRP$ N
healthcare NN N
costs VBZ N
around IN N
the DT N
cessation NN N
period NN N
, , N
and CC N
( ( N
2 CD N
) ) N
whether IN N
the DT N
healthcare NN N
costs NNS N
of IN N
those DT N
in IN N
the DT N
trial NN N
who WP N
successfully RB N
quit VBP N
were VBD N
different JJ N
from IN N
a DT N
matched JJ N
sample NN N
of IN N
smokers NNS N
in IN N
the DT N
community NN N
. . N

METHODS NNP N
Generalized NNP i
linear JJ i
regression NN i
models NNS i
were VBD i
used VBN i
to TO i
analyze VB i
healthcare NN o
cost NN o
data NNS o
on IN i
individuals NNS i
enrolled VBN i
in IN i
a DT i
comparative JJ i
effectiveness NN i
trial NN i
of IN i
cessation NN i
therapies NNS i
between IN p
October NNP p
2005 CD p
and CC p
May NNP p
2007 CD p
( ( p
1346 CD p
total NN p
participants NNS p
; : p
1338 CD p
with IN p
requisite JJ p
data NNS p
for IN p
further JJ p
analysis NN p
) ) p
. . p

Cost NN o
differences NNS o
for IN N
the DT N
period NN N
preceding NN N
and CC N
subsequent JJ N
to TO N
the DT N
cessation NN N
attempt NN N
were VBD N
assessed VBN N
by IN N
trial NN N
participants NNS N
' POS N
12-month JJ N
sustained VBD N
quit NN N
status NN N
. . N

Healthcare NNP o
cost NN o
differences NNS o
between IN N
sustained VBN N
quitters NNS N
and CC N
a DT N
sample NN N
of IN N
community-dwelling JJ N
smokers NNS N
, , N
matched VBD N
to TO N
these DT N
quitters NNS N
on IN N
the DT N
basis NN N
of IN N
health NN N
services NNS N
use VBP N
around IN N
the DT N
time NN N
trial NN N
participant NN N
enrolled VBN N
and CC N
by IN N
demographics NNS N
, , N
were VBD N
also RB N
examined VBN N
. . N

Data NNS N
were VBD N
analyzed VBN N
in IN N
2011 CD N
. . N

RESULTS VB N
All DT N
three CD N
groups NNS N
had VBD N
a DT N
spike NN N
in IN N
cost NN N
associated VBN N
with IN N
the DT N
index NN N
clinic JJ N
visit NN N
. . N

Regression NNP N
results NNS N
revealed VBD N
little JJ N
difference NN N
in IN N
healthcare NN o
costs NNS o
by IN N
quit NN N
status NN N
for IN N
trial NN N
participants NNS N
until IN N
the DT N
sixth JJ N
quarter NN N
post-quit NN N
. . N

By IN N
that DT N
quarter NN N
, , N
continuous JJ N
sustained VBD N
quitters NNS N
cost VBD o
$ $ N
541 CD N
( ( N
p NN N
< RB N
0.001 CD N
) ) N
less JJR N
than IN N
continuing VBG N
smokers NNS N
. . N

Continuous JJ N
sustained VBD N
quitters NNS N
cost NN o
less JJR N
than IN N
their PRP$ N
matched JJ N
community- JJ N
dwelling VBG N
smokers NNS N
in IN N
almost RB N
every DT N
quarter NN N
observed VBN N
. . N

The DT N
cost NN N
difference NN N
ranged VBD N
from IN N
$ $ N
270 CD N
( ( N
p=0.01 NN N
) ) N
during IN N
the DT N
quarter NN N
of IN N
quit NN N
, , N
to TO N
$ $ N
490 CD N
( ( N
p NN N
< RB N
0.01 CD N
) ) N
in IN N
the DT N
6th CD N
quarter NN N
after IN N
quitting VBG N
. . N

CONCLUSIONS VB N
The DT N
inclusion NN N
of IN N
smoking-cessation JJ i
therapy NN i
does VBZ N
not RB N
appear VB N
to TO N
raise VB N
short-term JJ o
healthcare NN o
costs NNS o
. . o

By IN N
the DT N
sixth JJ N
quarter NN N
post-quit NN N
, , N
sustained VBN N
quitters NNS N
were VBD N
less RBR N
costly JJ N
than IN N
trial NN N
participants NNS N
who WP N
continued VBD N
smoking NN N
. . N

-DOCSTART- -X- O O

Fixed-dose JJ N
combination NN N
of IN N
AR-13324 NNP i
and CC i
latanoprost NN i
: : i
a DT N
double-masked JJ N
, , N
28-day JJ N
, , N
randomised VBN N
, , N
controlled VBN N
study NN N
in IN N
patients NNS p
with IN p
open-angle JJ p
glaucoma NN p
or CC p
ocular JJ p
hypertension NN p
. . p

BACKGROUND/AIMS NNP N
To TO N
evaluate VB N
the DT N
ocular JJ N
hypotensive JJ N
efficacy NN o
of IN N
fixed-dose JJ N
combinations NNS N
of IN N
the DT N
Rho NNP i
kinase NN i
inhibitor NN i
and CC i
norepinephrine JJ i
transport NN i
inhibitor NN i
AR-13324 NNP i
( ( N
0.01 CD N
% NN N
and CC N
0.02 CD N
% NN N
) ) N
and CC N
latanoprost $ i
( ( N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
) ) N
relative VBP N
to TO N
the DT N
active JJ N
components NNS N
AR-13324 JJ i
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
, , N
used VBN N
bilaterally RB N
at IN N
night NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
double-masked JJ N
, , N
randomised VBN N
, , N
parallel JJ N
comparison NN N
study NN N
in IN N
patients NNS p
with IN p
open-angle JJ p
glaucoma NN p
or CC p
ocular JJ p
hypertension NN p
. . p

After IN N
washout NN N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
four CD N
treatment NN N
arms NNS N
and CC N
treated VBD N
for IN N
28 CD N
days NNS N
. . N

The DT N
primary JJ N
efficacy NN N
variable NN N
was VBD o
mean JJ o
diurnal JJ o
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
at IN o
day NN N
29 CD N
. . N

RESULTS NN N
We PRP N
randomised VBD p
298 CD p
patients NNS p
, , p
of IN p
whom WP p
292 CD p
( ( p
98 CD p
% NN p
) ) p
completed VBD p
the DT p
study NN p
. . p

Mean NNP o
unmedicated VBD o
diurnal JJ o
IOPs NNP o
( ( o
study VB N
eye NN N
) ) N
was VBD N
25.1 CD N
, , N
25.1 CD N
, , N
26.0 CD N
and CC N
25.4 CD N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN N
and CC N
AR-13324 JJ N
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

On IN N
day NN N
29 CD N
, , N
mean JJ o
diurnal JJ o
IOP NNP o
decreased VBD o
to TO N
17.3 CD N
, , N
16.5 CD N
, , N
18.4 CD N
and CC N
19.1 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

For IN N
the DT N
primary JJ o
efficacy NN o
variable NN o
of IN N
mean JJ o
diurnal JJ o
IOP NNP o
at IN o
day NN N
29 CD N
, , N
PG324 NNP N
0.02 CD N
% NN N
met VBD N
the DT N
criterion NN N
for IN N
statistical JJ N
superiority NN N
relative NN N
to TO N
both DT N
latanoprost FW N
and CC N
AR-13324 NNP N
0.02 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
providing VBG N
additional JJ N
IOP NNP N
lowering NN N
of IN N
1.9 CD N
and CC N
2.6 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
. . N

PG324 VB N
0.01 CD N
% NN N
also RB N
met VBD N
the DT N
criterion NN N
for IN N
superiority NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ N
event NN N
was VBD N
conjunctival JJ o
hyperaemia NN o
with IN o
an DT o
incidence NN o
of IN N
41 CD N
% NN N
( ( N
30/73 CD N
) ) N
, , N
40 CD N
% NN N
( ( N
29/73 CD N
) ) N
, , N
14 CD N
% NN N
( ( N
10/73 CD N
) ) N
and CC N
40 CD N
% NN N
( ( N
31/78 CD N
) ) N
in IN N
the DT N
PG324 NNP N
0.01 CD N
% NN N
, , N
PG324 NNP N
0.02 CD N
% NN N
, , N
latanoprost NN i
and CC i
AR-13324 JJ i
0.02 CD N
% NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
short-term JJ N
study NN N
, , N
the DT N
fixed-dose JJ N
combination NN i
of IN i
AR-13324 NNP i
0.02 CD N
% NN N
and CC N
latanoprost $ N
0.005 CD N
% NN N
in IN N
PG324 NNP N
Ophthalmic NNP N
Solution NNP N
provides VBZ N
clinically RB N
and CC N
statistically RB o
superior JJ o
ocular JJ o
hypotensive JJ o
efficacy NN o
relative JJ N
to TO N
its PRP$ N
individual JJ N
active JJ N
components NNS N
at IN N
the DT N
same JJ N
concentrations NNS N
. . N

The DT N
only JJ N
safety NN o
finding NN o
of IN N
note NN N
was VBD N
transient JJ N
asymptomatic JJ N
conjunctival NN N
hyperaemia NN N
which WDT N
was VBD N
typically RB N
of IN N
mild JJ N
severity NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT02207491 NNP N
. . N

-DOCSTART- -X- O O

Blood NNP o
purification NN o
for IN N
critical JJ N
care NN N
medicine NN N
: : N
endotoxin NN N
adsorption NN N
. . N

Many JJ N
kinds NNS N
of IN N
blood NN i
purifying VBG i
technologies NNS i
have VBP N
been VBN N
applied VBN N
to TO N
the DT N
treatment NN N
of IN N
critically RB p
ill JJ p
patients NNS p
since IN N
1979 CD N
when WRB N
plasma JJ N
exchange NN N
with IN N
hollow-fiber JJ N
membranes NNS N
was VBD N
developed VBN N
. . N

These DT N
technologies NNS N
have VBP N
been VBN N
applied VBN N
not RB N
only RB N
to TO N
the DT N
removal NN N
of IN N
toxic JJ N
substances NNS N
, , N
but CC N
also RB N
to TO N
the DT N
treatment NN N
of IN N
objective JJ N
diseases NNS N
and CC N
the DT N
removal NN N
of IN N
the DT N
factors NNS N
relating VBG N
to TO N
the DT N
associated VBN N
inflammation NN N
. . N

This DT N
article NN N
summarizes VBZ N
these DT N
methods NNS N
and CC N
their PRP$ N
efficacies NNS N
for IN N
critically RB p
ill JJ p
patients NNS p
, , p
especially RB p
those DT p
with IN p
severe JJ p
sepsis NN p
. . p

Attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
remove VB N
endotoxin NN N
, , N
the DT N
main JJ N
cause NN N
of IN N
sepsis NN N
, , N
from IN N
the DT N
circulation NN N
using VBG N
polymyxin NN i
B NNP i
immobilized VBD i
fiber NN i
, , i
charcoal NN i
hemoperfusion NN i
, , N
and CC N
plasma NN i
or CC i
whole JJ i
blood NN i
exchange NN i
. . i

Attempts NNS N
have VBP N
also RB N
been VBN N
made VBN N
to TO N
remove VB N
proinflammatory NN N
cytokines NNS N
, , N
eicosanoides NNS N
, , N
and CC N
coagulative JJ N
factors NNS N
from IN N
the DT N
circulation NN N
in IN N
the DT N
human JJ N
body NN N
. . N

Continuous JJ N
hemofiltration NN N
or CC N
hemodiafiltration NN N
is VBZ N
the DT N
representative JJ N
technology NN N
. . N

The DT N
efficacy NN o
of IN N
these DT N
methods NNS N
has VBZ N
been VBN N
established VBN N
, , N
but CC N
several JJ N
issues NNS N
remain VBP N
unresolved JJ N
. . N

All DT N
methods NNS N
of IN N
the DT N
treatment NN N
of IN N
severe JJ N
sepsis NN N
are VBP N
discussed VBN N
with IN N
reference NN N
to TO N
treatment NN N
indications NNS o
, , o
efficacy NN o
, , N
and CC N
outcome JJ o
parameters NNS o
. . o

In IN N
particular JJ N
, , N
the DT N
clinical JJ N
results NNS N
of IN N
endotoxin JJ N
removal NN N
with IN N
polymyxin NN i
B NNP i
immobilized JJ i
fiber NN i
are VBP N
summarized VBN N
in IN N
this DT N
article NN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
valproate NN i
for IN N
aggression NN N
in IN N
youth NN p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
study VB N
valproate JJ i
efficacy NN N
and CC N
safety NN N
for IN N
aggression NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
( ( p
PDD NNP p
) ) p
. . p

METHODS NNP N
In IN N
this DT N
prospective JJ N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
, , N
30 CD p
subjects NNS p
( ( p
20 CD p
boys NNS p
, , p
10 CD p
girls NNS p
) ) p
6-20 CD p
years NNS p
of IN p
age NN p
with IN p
PDD NNP p
and CC p
significant JJ p
aggression NN p
were VBD p
randomized VBN p
and CC N
received VBN N
treatment NN N
with IN N
valproate NN i
( ( i
VPA NNP i
) ) i
or CC N
placebo NN i
( ( i
PBO NNP i
) ) i
for IN N
8 CD N
weeks NNS N
as IN N
outpatients NNS p
. . p

Mean NNP o
VPA NNP o
trough IN o
blood NN o
levels NNS o
were VBD N
75.5 CD N
mcg/mL NNS N
at IN N
week NN N
4 CD N
and CC N
77.8 CD N
mcg/mL NN N
at IN N
week NN N
8 CD N
. . N

RESULTS VB N
No DT N
treatment NN N
difference NN N
was VBD N
observed VBN N
statistically RB N
between IN N
VPA NNP i
and CC N
PBO NNP i
groups NNS N
. . N

The DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
-- : o
Community NNP o
Scale NNP o
( ( o
ABC-C NNP o
) ) o
Irritability NNP o
subscale NN o
was VBD N
the DT N
primary JJ N
outcome NN N
measure NN N
( ( N
p JJ N
= NNP N
0.65 CD N
) ) N
, , N
and CC N
CGI NNP o
-- : o
Improvement NNP o
( ( N
p JJ N
= NNP N
0.16 CD N
) ) N
and CC N
OAS NNP o
( ( N
p JJ N
= NNP N
0.96 CD N
) ) N
were VBD N
secondary JJ N
outcome NN N
measures NNS N
. . N

Increased VBN o
appetite NN o
and CC o
skin NN o
rash NN o
were VBD N
significant JJ N
side NN N
effects NNS N
. . N

Only RB N
1 CD N
subject NN N
was VBD N
dropped VBN N
from IN N
the DT N
study NN N
owing VBG N
to TO N
side VB N
effects NNS N
, , N
notably RB N
a DT N
spreading NN o
skin NN o
rash NN o
, , N
which WDT N
then RB N
resolved VBD N
spontaneously RB N
. . N

Two CD N
subjects NNS N
receiving VBG N
VPA NNP i
developed VBD N
increased VBN N
serum NN o
ammonia NN o
levels NNS o
, , N
one CD N
with IN N
an DT N
associated JJ N
parent NN N
report NN N
of IN N
slurred JJ o
speech NN o
and CC o
mild JJ o
cognitive JJ o
slowing NN o
. . o

Poststudy NNP N
, , N
of IN N
16 CD N
VPA NNP i
and CC N
PBO NNP i
subjects NNS N
receiving VBG N
VPA NNP i
, , N
10 CD N
subjects NNS N
demonstrated VBD N
sustained JJ o
response NN o
, , N
4 CD N
of IN N
whom WP N
later RB N
attempted VBN N
taper NN N
, , N
with IN N
significant JJ N
relapse NN o
of IN o
aggression NN o
. . o

CONCLUSION VB N
The DT N
present JJ N
negative JJ N
findings NNS N
can MD N
not RB N
be VB N
viewed VBN N
as IN N
conclusive JJ N
, , N
partly RB N
owing VBG N
to TO N
the DT N
large JJ N
placebo NN i
response NN N
, , N
subject JJ N
heterogeneity NN N
, , N
and CC N
size NN N
of IN N
the DT N
groups NNS N
. . N

Larger JJR N
studies NNS N
are VBP N
needed VBN N
to TO N
expand VB N
upon IN N
these DT N
findings NNS N
. . N

-DOCSTART- -X- O O

Brief JJ N
Report NNP N
: : N
social JJ o
disability NN o
in IN p
autism NN p
spectrum NN p
disorder NN p
: : p
results NNS N
from IN N
Research NNP p
Units NNP p
on IN p
Pediatric NNP p
Psychopharmacology NNP p
( ( p
RUPP NNP p
) ) p
Autism NNP p
Network NNP p
trials NNS p
. . p

There EX N
is VBZ N
growing VBG N
interest NN N
in IN N
measuring VBG N
social JJ o
disability NN o
as IN N
a DT N
core NN N
element NN N
of IN N
autism NN p
spectrum NN p
disorders NNS p
in IN N
medication NN N
trials NNS N
. . N

We PRP N
conducted VBD N
a DT N
secondary JJ N
analysis NN N
on IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Social NNP o
Withdrawal NNP o
subscale JJ o
using VBG N
data NNS p
from IN p
two CD p
federally-funded JJ p
, , p
multi-site JJ p
, , p
randomized JJ p
trials NNS p
with IN p
risperidone NN i
. . i

Study NNP p
1 CD p
included VBD p
52 CD p
subjects NNS p
assigned VBN p
to TO p
placebo VB i
and CC p
49 CD p
subjects NNS p
to TO p
risperidone VB i
under IN p
double-blind JJ p
conditions NNS p
. . p

Study NNP p
2 CD p
included VBD p
49 CD p
subjects NNS p
assigned VBN p
to TO p
risperidone VB i
only RB i
and CC p
75 CD p
subjects NNS p
assigned VBN p
to TO p
risperidone VB i
plus JJ i
parent NN i
training NN i
. . i

After IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
, , N
all DT N
active JJ N
treatments NNS N
were VBD N
superior JJ N
to TO N
placebo VB N
( ( N
effect NN N
sizes VBZ N
ranging VBG N
from IN N
0.42 CD N
to TO N
0.65 CD N
) ) N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
the DT N
Social NNP N
Withdrawal NNP N
subscale NN N
may MD N
be VB N
a DT N
useful JJ N
measure NN N
of IN N
social JJ o
disability NN o
in IN N
acute JJ N
treatment NN N
trials NNS N
. . N

-DOCSTART- -X- O O

Phonophoresis NNP i
versus NN N
topical JJ N
application NN N
of IN N
ketoprofen NN i
: : i
comparison NN N
between IN N
tissue NN N
and CC N
plasma NN N
levels NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Over IN N
the DT N
last JJ N
few JJ N
decades NNS N
, , N
application NN N
of IN N
ultrasound NN N
has VBZ N
been VBN N
attempted VBN N
to TO N
enhance VB N
transdermal JJ N
transport NN N
of IN N
several JJ N
drugs NNS N
, , N
a DT N
method NN N
referred VBD N
to TO N
as IN N
phonophoresis NN N
. . N

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
ultrasound NN N
on IN N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
in IN N
humans NNS N
and CC N
to TO N
compare VB N
the DT N
concentrations NNS N
found VBD N
after IN N
continuous JJ N
and CC N
pulsed JJ N
application NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Twenty-six NNP p
patients NNS p
with IN p
knee NN p
disorders NNS p
requiring VBG p
arthroscopy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

Just NNP N
before IN N
surgery NN N
, , N
phonophoresis NN i
of IN i
a DT i
ketoprofen NN i
gel NN i
( ( N
Fastum NNP N
gel NN N
) ) N
was VBD N
given VBN N
to TO N
group NN N
A NNP N
using VBG N
continuous JJ i
ultrasound NN i
( ( N
1 CD N
MHz NNP N
, , N
1.5 CD N
W/cm2 NNP N
, , N
for IN N
5 CD N
minutes NNS N
) ) N
. . N

Group NNP N
B NNP N
received VBD N
the DT N
same JJ N
treatment NN N
but CC N
with IN N
pulsed JJ i
ultrasound NN i
( ( N
100 CD N
Hz NNP N
, , N
20 CD N
% NN N
duty NN N
cycle NN N
) ) N
. . N

Group NNP N
C NNP N
received VBD N
5 CD N
minutes NNS N
of IN N
sham NN i
ultrasound NN i
with IN i
the DT i
ketoprofen NN i
gel NN i
. . i

The DT N
ultrasound JJ N
head NN N
was VBD N
moved VBN N
over IN N
a DT N
10-cm2 JJ N
area NN N
using VBG N
small JJ N
, , N
continuous JJ N
, , N
circular JJ N
movements NNS N
. . N

Biopsies NNS N
of IN N
adipose JJ N
tissue NN N
and CC N
synovial JJ N
tissue NN N
were VBD N
taken VBN N
during IN N
surgery NN N
to TO N
evaluate VB o
the DT o
local JJ o
penetration NN o
of IN o
the DT o
drug NN o
. . o

Blood NN N
samples NNS N
also RB N
were VBD N
collected VBN N
to TO N
determine VB o
whether IN o
ketoprofen NN o
entered VBD o
the DT o
systemic JJ o
circulation NN o
. . o

RESULTS VB N
The DT N
concentration NN o
of IN o
ketoprofen NN o
in IN N
plasma NN N
was VBD N
negligible JJ N
in IN N
all DT N
3 CD N
groups NNS N
. . N

The DT N
concentration NN o
of IN o
ketoprofen NN o
in IN N
synovial JJ N
tissue NN N
differed VBD N
from IN N
that IN N
in IN N
fat JJ N
tissue NN N
. . N

A DT N
difference NN N
in IN N
concentration NN o
of IN o
ketoprofen NN o
in IN N
synovial JJ N
tissue NN N
was VBD N
found VBN N
between IN N
group NN N
C NNP N
and CC N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

The DT N
concentration NN o
of IN o
ketoprofen NN o
in IN o
fat JJ o
tissue NN o
and CC o
synovial JJ o
tissue NN o
was VBD N
consistently RB N
higher JJR N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

DISCUSSION NNP N
AND CC N
CONCLUSION NNP N
This DT N
study NN N
confirms VBZ N
that IN N
phonophoresis NN N
of IN N
ketoprofen NN N
allows VBZ N
the DT N
attainment NN N
of IN N
higher JJR N
local JJ N
concentrations NNS N
, , N
whereas JJ N
systemic JJ N
exposure NN N
is VBZ N
lower JJR N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
, , N
in IN N
contrast NN N
to TO N
sham VB N
phonopheresis NN N
, , N
ultrasound NN N
can MD N
increase VB N
the DT N
transdermal JJ N
delivery NN N
of IN N
ketoprofen NN N
. . N

-DOCSTART- -X- O O

Hepatectomy NNP i
Versus NNP i
Hepatectomy NNP i
With IN i
Lymphadenectomy NNP i
in IN N
Hepatocellular NNP N
Carcinoma NNP N
: : N
A DT N
Prospective NNP N
, , N
Randomized NNP N
Controlled NNP N
Clinical NNP N
Trial NNP N
. . N

GOALS NNP N
AND CC N
BACKGROUND NNP N
The DT N
role NN N
of IN N
preventive JJ N
lymphadenectomy NN N
has VBZ N
not RB N
yet RB N
been VBN N
determined VBN N
for IN N
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
patients NNS p
. . p

We PRP N
designed VBD N
a DT N
study NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
hepatectomy NN i
combined VBN i
with IN i
preventive JJ i
lymphadenectomy NN i
on IN N
HCC NNP p
patients NNS p
. . p

STUDY NNP N
Patients NNPS N
were VBD N
randomly RB N
divided VBN N
into IN N
group NN N
A NNP N
( ( i
treated VBN i
with IN i
hepatectomy JJ i
alone RB i
) ) i
and CC N
group NN N
B NNP N
( ( i
underwent JJ i
hepatectomy NN i
combined VBN i
with IN i
lymphadenectomy NN i
) ) i
. . N

The DT N
postoperative JJ N
complications NNS N
and CC N
oncologic JJ o
prognoses NNS o
were VBD N
analyzed VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
85 CD p
patients NNS p
enrolled VBD p
into IN p
this DT p
study NN p
, , p
79 CD p
cases NNS p
( ( p
38 CD p
in IN p
group NN p
A NNP p
and CC p
41 CD p
in IN p
group NN p
B NNP p
) ) p
were VBD N
pathologically RB p
confirmed VBN p
to TO p
have VB p
HCC NNP p
and CC N
received VBD N
curative JJ N
resection NN N
. . N

One CD N
hundred CD N
and CC N
sixteen JJ N
lymph NN N
nodes NNS N
were VBD N
dissected VBN N
and CC N
evaluated VBN N
as IN N
negative JJ N
by IN N
the DT N
pathologist NN N
. . N

The DT N
12- JJ N
, , N
36- JJ N
, , N
and CC N
60-month JJ N
disease-free JJ o
survival NN o
rates NNS o
of IN N
group NN N
A NNP N
were VBD N
81.6 CD N
% NN N
, , N
68.4 CD N
% NN N
, , N
and CC N
63.2 CD N
% NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
78.0 CD N
% NN N
, , N
65.9 CD N
% NN N
, , N
and CC N
63.4 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
group NN N
B NNP N
. . N

The DT N
12- JJ N
, , N
36- JJ N
, , N
and CC N
60-month JJ N
overall JJ o
survival NN o
rates NNS o
in IN N
group NN N
A NNP N
were VBD N
94.7 CD N
% NN N
, , N
78.9 CD N
% NN N
, , N
and CC N
65.8 CD N
% NN N
, , N
respectively RB N
, , N
whereas IN N
they PRP N
were VBD N
87.8 CD N
% NN N
, , N
78.0 CD N
% NN N
, , N
and CC N
70.7 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
group NN N
B NNP N
. . N

The DT N
differences NNS N
in IN N
the DT N
disease-free JJ o
survival NN o
and CC o
overall JJ o
survival NN o
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
according VBG N
to TO N
the DT N
log-rank JJ N
test NN N
( ( N
P=0.811 NNP N
and CC N
P=0.881 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
difference NN N
in IN N
the DT N
surgical JJ o
complication NN o
rate NN o
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
47.4 CD N
% NN N
vs. FW N
36.6 CD N
% NN N
, , N
P=0.332 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
hepatectomy NN i
combined VBN i
with IN i
regional JJ i
lymphadenectomy NN i
is VBZ N
a DT N
safe JJ N
procedure NN N
, , N
preventive JJ N
lymphadenectomy NN N
may MD N
not RB N
decrease VB N
the DT N
rate NN N
of IN N
tumor NN N
recurrence NN o
nor CC N
improve VB N
the DT N
prognosis NN o
in IN N
early-stage JJ p
HCC NNP p
patients NNS p
. . p

-DOCSTART- -X- O O

The DT N
need NN N
for IN N
chemotherapy NN i
after IN N
prolonged JJ p
complete JJ p
remission NN p
in IN p
acute JJ p
leukemia NN p
of IN p
childhood NN p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
7-day JJ i
and CC i
14-day JJ i
proton NN i
pump IN i
inhibitor-containing JJ i
triple JJ i
therapy NN i
for IN N
Helicobacter NNP o
pylori JJ o
eradication NN o
: : o
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN N
rate NN N
in IN N
Korea NNP p
. . p

BACKGROUND NNP N
AND CC N
AIMS NNP N
Although IN N
triple JJ i
combination NN i
therapy NN i
containing VBG N
a DT i
proton NN i
pump NN i
inhibitor NN i
( ( i
PPI NNP i
) ) i
and CC N
two CD i
antibiotics NNS i
is VBZ N
considered VBN N
as IN N
a DT N
standard JJ N
regimen NN N
for IN N
the DT N
first-line JJ N
anti-Helicobacter JJ N
pylori NN N
treatment NN N
, , N
there EX N
are VBP N
still RB N
debates NNS N
on IN N
the DT N
ideal JJ N
duration NN N
of IN N
treatment NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS o
of IN N
7-day JJ i
and CC i
14-day JJ i
PPI-containing JJ i
triple NN i
therapy NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
study NN N
was VBD N
performed VBN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
prospective JJ N
manner NN N
. . N

After IN p
upper JJ i
gastrointestinal JJ i
endoscopy NN i
, , p
H. NNP p
pylori-infected JJ p
patients NNS p
with IN p
a DT p
gastric JJ p
ulcer NN p
and/or VBZ p
a DT p
duodenal JJ p
ulcer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
PAC7 NNP i
group NN N
( ( i
omeprazole JJ i
20 CD i
mg NN i
or CC i
equivalent JJ i
dose NN i
of IN i
other JJ i
PPIs NNP i
, , i
amoxicillin NN i
1000 CD i
mg NN i
, , i
and CC i
clarithromycin VBZ i
500 CD i
mg NN i
twice RB i
daily RB i
for IN i
7 CD i
days NNS i
) ) i
or CC N
to TO N
a DT N
PAC14 NNP i
group NN N
( ( i
the DT i
same JJ i
regimen NN i
as IN i
the DT i
PAC7 NNP i
group NN i
but CC i
for IN i
14 CD i
days NNS i
) ) i
. . N

H. NNP N
pylori NN N
status NN N
was VBD N
evaluated VBN N
by IN N
( ( o
13 CD o
) ) o
C NNP o
urea JJ o
breath NN o
test NN N
5 CD N
weeks NNS N
after IN N
anti-ulcer JJ N
treatment NN N
completion NN N
. . N

RESULTS VB N
A DT N
total NN p
of IN p
598 CD p
patients NNS p
were VBD p
enrolled VBN p
; : p
337 CD N
were VBD N
randomized VBN N
to TO N
the DT N
PAC7 NNP i
group NN N
and CC N
261 CD N
to TO N
the DT N
PAC14 NNP i
group NN N
. . N

The DT N
two CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
baseline NN N
characteristics NNS N
. . N

The DT N
eradication NN N
rates NNS N
of IN N
the DT N
PAC7 NNP i
group NN N
were VBD N
not RB N
inferior JJ N
to TO N
those DT N
of IN N
the DT N
PAC14 NNP i
group NN N
in IN N
both DT N
intention-to-treat JJ N
analysis NN N
( ( N
71.2 CD N
% NN N
vs. FW N
75.5 CD N
% NN N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
83.6 CD N
% NN N
vs. FW N
86.6 CD N
% NN N
) ) N
. . N

Incidences NNS N
of IN N
adverse JJ o
events NNS o
were VBD N
comparable JJ N
. . N

CONCLUSIONS NNP N
Although IN N
the DT N
7-day JJ i
PPI-containing JJ i
triple JJ i
anti-H. JJ i
pylori NN i
therapy NN i
is VBZ N
not RB N
inferior JJ N
to TO N
the DT N
14-day JJ i
therapy NN N
, , N
neither CC N
treatment NN N
duration NN N
provides VBZ N
acceptable JJ N
eradication NN o
rate NN o
reaching VBG N
90 CD N
% NN N
in IN N
per-protocol JJ N
analysis NN N
. . N

New NNP N
combination NN N
regimen NNS N
with IN N
higher JJR N
efficacy NN N
should MD N
be VB N
developed VBN N
as IN N
a DT N
first-line JJ N
eradication NN N
therapy NN N
for IN N
H. NNP p
pylori NN p
in IN p
Korea NNP p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
menopausal NN N
symptoms NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
adjuvant JJ N
therapy NN N
with IN N
either DT N
exemestane NN i
or CC i
tamoxifen NN i
in IN N
early JJ p
breast NN p
cancer NN p
: : p
report NN N
of IN N
a DT N
Tamoxifen NNP N
Exemestane NNP N
Adjuvant NNP N
Multicenter NNP N
trial NN N
substudy NN N
. . N

PURPOSE NNP N
Hormonal NNP N
breast NN N
cancer NN N
treatment NN N
increases NNS N
menopausal VBP o
symptoms NNS o
in IN N
women NNS p
. . p

This DT N
study NN N
investigated VBD N
differences NNS N
between IN N
the DT N
symptoms NNS N
associated VBN N
with IN N
either DT N
adjuvant JJ i
tamoxifen NN i
or CC i
exemestane NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Ten NNP N
common JJ N
symptoms NNS N
were VBD N
assessed VBN N
by IN N
self-report JJ N
questionnaire NN N
administered VBD N
to TO N
1,614 CD p
consecutive JJ p
patients NNS p
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
a DT N
double-blind NN N
, , N
randomized VBN N
trial NN N
of IN N
postmenopausal JJ p
women NNS p
with IN p
early JJ p
hormone NN p
receptor-positive JJ p
breast NN p
cancer NN p
. . p

Symptoms NNS N
were VBD N
categorized VBN N
as IN N
none NN N
, , N
mild NN N
, , N
moderate JJ N
, , N
or CC N
severe RB N
. . N

A DT N
hot JJ o
flash NN o
score NN o
was VBD N
calculated VBN N
at IN N
each DT N
time NN N
point NN N
. . N

Symptoms NNS N
were VBD N
analyzed VBN N
by IN N
repeated-measures NNS N
analysis NN N
of IN N
variance NN N
. . N

Each DT N
time NN N
period NN N
was VBD N
tested VBN N
repeatedly RB N
against IN N
the DT N
baseline NN N
; : N
an DT N
overall JJ N
P NNP N
value NN N
was VBD N
assigned VBN N
for IN N
each DT N
reported VBN N
symptom NN N
. . N

RESULTS NNP N
Compliance NNP N
was VBD N
excellent JJ N
, , N
with IN N
7,286 CD N
questionnaires NNS N
analyzed VBN N
. . N

Baseline NNP o
symptom JJ o
prevalence NN N
ranged VBD N
from IN N
2 CD N
% NN N
( ( N
vaginal JJ N
bleeding NN N
) ) N
to TO N
60 CD N
% NN N
to TO N
70 CD N
% NN N
( ( o
bone/muscle NN o
aches NNS o
and CC o
low JJ o
energy NN o
) ) o
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
vaginal JJ o
bleeding NN o
, , o
mood NN o
alteration NN o
, , o
or CC o
low JJ o
energy NN o
. . o

Patients NNS p
receiving VBG p
tamoxifen NN p
had VBD N
significantly RB N
more RBR N
vaginal JJ o
discharge NN o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

Exemestane NN N
patients NNS N
reported VBD N
more RBR N
bone/muscle NN o
aches NNS o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
vaginal JJ o
dryness NN o
( ( N
P NNP N
= NNP N
.0004 NNP N
) ) N
, , N
and CC N
difficulty NN o
sleeping NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
hot JJ o
flash NN o
score NN o
peaked VBD N
at IN N
3 CD N
months NNS N
and CC N
decreased JJ N
thereafter NN N
. . N

At IN N
12 CD N
months NNS N
, , N
patients NNS N
receiving VBG N
tamoxifen NN N
had VBD N
a DT N
significantly RB N
higher JJR N
mean JJ o
hot JJ o
flash NN o
score NN o
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
with IN N
daily JJ N
hot JJ o
flashes NNS o
increasing VBG N
from IN N
baseline NN N
by IN N
33 CD N
% NN N
compared VBN N
with IN N
a DT N
7 CD N
% NN N
increase NN N
from IN N
baseline NN N
with IN N
exemestane NN N
. . N

CONCLUSION NNP N
At IN N
12 CD N
months NNS N
, , N
exemestane NN N
was VBD N
associated VBN N
with IN N
fewer JJR N
hot JJ o
flashes NNS o
and CC N
less JJR N
vaginal JJ o
discharge NN o
than IN N
tamoxifen NN N
, , N
but CC N
with IN N
more JJR N
vaginal JJ o
dryness NN o
, , o
bone/muscle NN o
aches NNS o
, , o
and CC o
difficulty NN o
sleeping NN o
. . o

Symptoms NNS N
were VBD N
common JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Validation NN N
of IN N
an DT N
FFQ NNP N
for IN N
evaluation NN N
of IN N
EPA NNP o
and CC o
DHA NNP o
intake VBP o
. . o

OBJECTIVE NNP N
To TO N
validate VB N
an DT N
FFQ NNP N
for IN N
the DT N
assessment NN N
of IN N
dietary JJ N
EPA NNP o
and CC o
DHA NNP o
against IN N
their PRP$ N
relative JJ o
concentrations NNS o
in IN o
red JJ o
blood NN o
cells NNS o
( ( o
RBC NNP o
) ) o
. . o

DESIGN NNP N
Cross-sectional JJ N
analysis NN N
of IN N
baseline NN N
data NNS N
. . N

Intakes NNS N
of IN N
marine NN i
food NN i
products NNS i
and CC N
EPA NNP i
and CC N
DHA NNP i
were VBD N
estimated VBN N
by IN N
FFQ NNP N
on IN N
the DT N
basis NN N
of IN N
consumption NN N
of IN N
marine NN i
food NN i
products NNS i
in IN N
the DT N
last JJ N
month NN N
. . N

Fatty NNP N
acid JJ N
composition NN N
of IN N
RBC NNP N
membranes NNS N
was VBD N
quantified VBN N
by IN N
GC NNP N
. . N

SETTING NNP N
Saint-Fran?ois JJ p
d'Assise NN p
Hospital NNP p
, , p
Qu?bec NNP p
, , p
Canada NNP p
. . p

SUBJECTS NNP N
A NNP N
total NN N
of IN N
sixty-five JJ p
middle-aged JJ p
women NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
clinical JJ p
trial NN p
. . p

RESULTS NNP N
Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN o
intake NN o
of IN o
EPA NNP o
, , o
DHA NNP o
and CC o
EPA NNP o
+ NNP o
DHA NNP o
and CC o
their PRP$ N
corresponding JJ o
concentration NN o
in IN o
RBC NNP o
was VBD o
0.46 CD N
, , N
0.40 CD N
and CC N
0.42 CD N
, , N
respectively RB N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
of IN N
EPA+DHA NNP o
intake NN o
and CC o
RBC NNP o
EPA NNP o
+ NNP o
DHA NNP o
concentration NN o
indicated VBD o
positive JJ N
and CC N
significant JJ N
correlations NNS N
for IN N
oily RB N
fish JJ N
( ( N
beta JJ N
= NN N
0.44 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16 CD N
, , N
0.72 CD N
, , N
P NNP N
= NNP N
0.0027 CD N
) ) N
, , N
total JJ N
fish NN N
( ( N
beta JJ N
= NN N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.19 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0005 CD N
) ) N
and CC i
marine VB i
food NN i
products NNS i
( ( i
beta NN N
= RB N
0.42 CD N
, , N
95 CD N
% NN N
CI NNP N
0.20 CD N
, , N
0.64 CD N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
. . N

No UH N
other JJ N
marine VB N
food NN N
products NNS N
significantly RB N
predicted VBD o
RBC NNP o
EPA NNP o
+ NNP o
DHA NNP o
concentration NN o
. . o

CONCLUSIONS NNP N
Although IN N
the DT N
present JJ N
validation NN N
study NN N
was VBD N
undertaken VBN N
among IN p
middle-aged JJ p
women NNS p
with IN p
low JJ p
consumption NN p
of IN p
marine NN p
food NN p
products NNS p
( ( p
< $ p
3 CD p
servings/week NN p
) ) p
, , p
our PRP$ N
FFQ NNP N
provided VBD N
estimates NNS N
of IN N
EPA NNP o
and CC o
DHA NNP o
intakes NNS o
that WDT o
correlated VBD N
fairly RB N
well RB N
with IN N
their PRP$ o
RBC NNP o
concentrations NNS o
. . o

However RB N
, , N
the DT N
absence NN N
of IN N
correlations NNS N
between IN o
EPA NNP o
+ NNP o
DHA NNP o
intakes NNS o
from IN o
different JJ N
marine NN N
species NNS N
suggests VBZ N
that IN N
a DT N
minimum JJ i
EPA NNP i
+ NNP i
DHA NNP i
intake NN i
is VBZ N
necessary JJ N
to TO N
observe VB N
a DT N
relationship NN N
with IN o
RBC NNP o
EPA NNP o
+ NNP o
DHA NNP o
concentrations NNS o
. . o

-DOCSTART- -X- O O

Automatic JJ p
detection NN p
of IN p
red JJ p
lesions NNS p
in IN p
digital JJ p
color NN p
fundus NN p
photographs NN p
. . p

The DT N
robust JJ N
detection NN i
of IN i
red JJ o
lesions NNS o
in IN i
digital JJ i
color NN i
fundus NN i
photographs NN i
is VBZ N
a DT N
critical JJ N
step NN N
in IN N
the DT N
development NN N
of IN N
automated JJ N
screening VBG N
systems NNS N
for IN N
diabetic JJ p
retinopathy NN p
. . p

In IN N
this DT N
paper NN N
, , N
a DT N
novel NN i
red JJ i
lesion NN i
detection NN i
method NN i
is VBZ N
presented VBN N
based VBN N
on IN N
a DT N
hybrid JJ N
approach NN N
, , N
combining VBG N
prior JJ N
works NNS N
by IN N
Spencer NNP N
et CC N
al NN N
. . N

( ( N
1996 CD N
) ) N
and CC N
Frame NNP N
et NNP N
al NN N
. . N

( ( N
1998 CD N
) ) N
with IN N
two CD N
important JJ N
new JJ N
contributions NNS N
. . N

The DT N
first JJ N
contribution NN N
is VBZ N
a DT N
new JJ N
red JJ i
lesion NN i
candidate NN i
detection NN i
system NN i
based VBN N
on IN N
pixel JJ N
classification NN N
. . N

Using VBG N
this DT N
technique NN N
, , N
vasculature NN o
and CC o
red JJ o
lesions NNS o
are VBP N
separated VBN N
from IN N
the DT N
background NN N
of IN N
the DT N
image NN N
. . N

After IN N
removal NN N
of IN N
the DT N
connected JJ N
vasculature NN N
the DT N
remaining VBG N
objects NNS N
are VBP N
considered VBN N
possible JJ N
red JJ N
lesions NNS N
. . N

Second NNP N
, , N
an DT N
extensive JJ N
number NN N
of IN N
new JJ N
features NNS N
are VBP N
added VBN N
to TO N
those DT N
proposed VBN N
by IN N
Spencer-Frame NNP N
. . N

The DT N
detected JJ N
candidate NN N
objects NNS N
are VBP N
classified VBN N
using VBG N
all DT N
features NNS N
and CC N
a DT N
k-nearest JJ N
neighbor NN N
classifier NN N
. . N

An DT N
extensive JJ N
evaluation NN N
was VBD N
performed VBN N
on IN N
a DT N
test NN N
set NN N
composed VBN N
of IN N
images NNS N
representative NN N
of IN N
those DT N
normally RB N
found VBN N
in IN N
a DT N
screening NN N
set NN N
. . N

When WRB N
determining VBG N
whether IN N
an DT N
image NN N
contains VBZ N
red JJ o
lesions NNS o
the DT N
system NN N
achieves VBZ N
a DT N
sensitivity NN o
of IN N
100 CD N
% NN N
at IN N
a DT N
specificity NN N
of IN N
87 CD N
% NN N
. . N

The DT N
method NN N
is VBZ N
compared VBN N
with IN N
several JJ N
different JJ N
automatic JJ N
systems NNS N
and CC N
is VBZ N
shown VBN N
to TO N
outperform VB N
them PRP N
all DT N
. . N

Performance NNP o
is VBZ N
close RB N
to TO N
that DT N
of IN N
a DT N
human JJ N
expert NN N
examining VBG N
the DT N
images NNS N
for IN N
the DT N
presence NN N
of IN N
red JJ N
lesions NNS N
. . N

-DOCSTART- -X- O O

Tailored NNP i
, , i
iterative JJ i
, , i
printed JJ i
dietary JJ i
feedback NN i
is VBZ N
as RB N
effective JJ N
as IN N
group NN N
education NN N
in IN N
improving VBG N
dietary JJ N
behaviours NNS N
: : N
results NNS N
from IN N
a DT N
randomised VBN N
control NN N
trial NN N
in IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
. . p

BACKGROUND NNP N
Tailored NNP N
nutrition NN N
interventions NNS N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
non-tailored JJ N
materials NNS N
in IN N
changing VBG N
dietary JJ N
behaviours NNS N
, , N
particularly RB N
fat JJ N
intake NN N
and CC N
fruit NN N
and CC N
vegetable JJ N
intake NN N
. . N

But CC N
further JJ N
research NN N
examining VBG N
efficacy NN N
of IN N
tailored JJ N
nutrition NN N
education NN N
in IN N
comparison NN N
to TO N
other JJ N
nutrition JJ N
education NN N
methods NNS N
and CC N
across IN N
a DT N
wider NN N
range NN N
of IN N
dietary JJ N
behaviours NNS N
is VBZ N
needed VBN N
. . N

The DT p
Stages NNPS p
to TO p
Healthy NNP p
Eating NNP p
Patterns NNP p
Study NNP p
( ( p
STEPs NNP p
) ) p
was VBD N
an DT N
intervention NN N
study NN N
, , N
in IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
, , N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
delivered VBN N
by IN N
mail NN N
in IN N
improving VBG N
short-term JJ N
dietary JJ N
behaviour NN N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ N
fat NN N
, , N
fruit NN N
, , N
vegetable JJ N
and CC N
grain NN N
and CC N
cereal NN N
intake NN N
. . N

METHODS NNP N
STEPs NNP N
was VBD N
a DT N
3-month JJ N
randomised VBN N
controlled VBN N
trial NN N
with IN N
a DT N
pre NN N
and CC N
post-test JJ N
design NN N
. . N

There EX N
were VBD N
three CD N
experimental JJ N
conditions NNS N
: : N
1 CD N
) ) N
tailored VBN i
, , i
iterative JJ i
, , i
printed JJ i
dietary JJ i
feedback NN i
( ( i
TF NNP i
) ) i
with IN N
three CD N
instalments NNS N
mail-delivered JJ N
over IN N
a DT N
3-month JJ N
period NN N
that WDT N
were VBD N
re-tailored VBN N
to TO N
most RBS N
recent JJ N
assessment NN N
of IN N
dietary JJ N
intake NN N
, , N
intention NN N
to TO N
change VB N
and CC N
assessment NN N
of IN N
self-adequacy NN N
of IN N
dietary JJ N
intake NN N
. . N

Tailoring VBG N
for IN N
dietary JJ N
intake NN N
was VBD N
performed VBN N
on IN N
data NNS N
from IN N
a DT N
validated JJ N
63-item JJ N
combination NN N
FFQ NNP N
designed VBN N
for IN N
the DT N
purpose JJ N
2 CD N
) ) N
small JJ N
group NN N
nutrition NN i
education NN i
sessions NNS i
( ( N
GE NNP N
) ) N
: : N
consisting NN N
of IN N
two CD N
90-minute JJ N
dietitian-led JJ N
small JJ N
group NN N
nutrition NN N
education NN N
sessions NNS N
and CC N
3 CD N
) ) N
and CC N
a DT N
wait-listed JJ N
control NN N
( ( N
C NNP N
) ) N
group NN N
who WP N
completed VBD N
the DT N
dietary JJ i
measures NNS i
and CC i
socio-demographic JJ i
questionnaires NNS i
at IN N
baseline NN N
and CC N
3-months JJ N
later NN N
. . N

Dietary NNP N
outcome NN N
measures NNS N
in IN N
the DT N
areas NNS N
of IN N
saturated JJ o
fat JJ o
intake NN o
( ( o
g NN o
) ) o
, , N
and CC N
the DT N
intake NN o
of IN o
fruit NN o
( ( o
serves NNS o
) ) o
, , o
vegetables NNS o
( ( o
serves NNS o
) ) o
, , o
grain NN o
and CC o
cereals NNS o
as IN N
total JJ o
and CC o
wholegrain NN o
( ( o
serves NNS o
) ) o
were VBD N
collected VBN N
using VBG N
7-day JJ N
estimated VBN N
dietary JJ N
records NNS N
. . N

Descriptive JJ N
statistics NNS N
, , N
paired VBD N
t-tests NNS N
and CC N
general JJ N
linear JJ N
models NNS N
adjusted VBN N
for IN N
baseline NN N
dietary JJ N
intake NN N
, , N
age NN N
and CC N
gender NN N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
effectiveness NN N
of IN N
different JJ N
nutrition NN N
interventions NNS N
. . N

RESULTS VB N
The DT N
TF NNP i
group NN N
reported VBD N
a DT N
significantly RB N
greater JJR N
increase NN N
in IN N
fruit JJ o
intake NN o
( ( N
0.3 CD N
serves/d NN N
P NNP N
= NNP N
0.031 CD N
) ) N
in IN N
comparison NN N
to TO N
GE NNP N
and CC N
the DT N
C NNP N
group NN N
. . N

All DT N
three CD N
intervention NN N
groups NNS N
showed VBD N
a DT N
reduction NN N
in IN N
total JJ o
saturated JJ o
fat JJ o
intake NN o
. . o

GE NNP N
also RB N
had VBD N
a DT N
within-group JJ N
increase NN N
in IN N
mean JJ o
vegetable JJ o
intake NN o
after IN N
3 CD N
months NNS N
, , N
but CC N
this DT N
increase NN N
was VBD N
not RB N
different JJ N
from IN N
changes NNS N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
printed VBN N
, , N
tailored VBN N
, , N
iterative JJ N
dietary JJ N
feedback NN N
was VBD N
more RBR N
effective JJ N
than IN N
small JJ N
group NN N
nutrition NN N
education NN N
in IN N
improving VBG N
the DT N
short-term JJ N
fruit NN N
intake VB N
behaviour NN N
, , N
and CC N
as IN N
effective JJ N
in IN N
improving VBG N
saturated VBN N
fat JJ N
intake NN N
of IN N
middle-aged JJ p
adults NNS p
with IN p
cardiovascular JJ p
risk NN p
factors NNS p
. . p

This DT N
showed VBD N
that IN N
a DT N
low-level JJ N
dietary JJ N
intervention NN N
could MD N
achieve VB N
modest JJ N
dietary JJ N
behaviour NN N
changes NNS N
that WDT N
are VBP N
of IN N
public JJ N
health NN N
significance NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
modified VBN i
eggs NNS i
and CC i
an DT i
egg-yolk NN i
based VBN i
beverage NN i
on IN p
serum NN o
lutein NN o
and CC o
zeaxanthin JJ o
concentrations NNS o
and CC N
macular JJ N
pigment NN N
optical JJ N
density NN N
: : N
results NNS N
from IN N
a DT N
randomized JJ N
trial NN N
. . N

UNLABELLED CC N
Increasing VBG N
evidence NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
lutein NN N
and CC N
zeaxanthin NN N
on IN N
the DT N
progression NN N
of IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
lutein NN i
or CC i
zeaxanthin NN i
enriched VBN i
eggs NNS i
or CC i
a DT i
lutein JJ i
enriched VBN i
egg-yolk NN i
based VBN i
buttermilk NN i
beverage NN i
on IN N
serum NN o
lutein NN o
and CC o
zeaxanthin JJ o
concentrations NNS o
and CC N
macular JJ N
pigment NN N
levels NNS N
. . N

Naturally RB i
enriched VBN i
eggs NNS i
were VBD N
made VBN N
by IN N
increasing VBG N
the DT N
levels NNS N
of IN N
the DT N
xanthophylls NNP N
lutein NN N
and CC N
zeaxanthin NN i
in IN N
the DT N
feed NN N
given VBN N
to TO N
laying VBG N
hens NNS N
. . N

One CD p
hundred VBD p
healthy JJ p
volunteers NNS p
were VBD p
recruited VBN p
and CC p
randomized VBN p
into IN p
5 CD p
groups NNS p
for IN p
90 CD p
days NNS p
. . p

Group NNP N
one CD N
added VBD N
one CD i
normal JJ i
egg NN i
to TO i
their PRP$ i
daily JJ i
diet NNS i
and CC N
group NN i
two CD i
received VBD i
a DT i
lutein NN i
enriched VBD i
egg-yolk NN i
based VBN i
beverage NN i
. . i

Group NNP N
three CD N
added VBD N
one CD i
lutein NN i
enriched VBD i
egg NN i
and CC N
group NN i
four CD i
one CD i
zeaxanthin NN i
enriched VBD i
egg NN i
to TO i
their PRP$ i
diet JJ i
. . i

Group NNP N
five CD N
was VBD N
the DT N
control NN i
group NN i
and CC i
individuals NNS i
in IN i
this DT i
group NN i
did VBD i
not RB i
modify VB i
their PRP$ i
daily JJ i
diet NN i
. . i

Serum NNP o
lutein NN o
and CC o
zeaxanthin JJ o
concentrations NNS o
and CC N
macular JJ o
pigment NN o
densities NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
day NN N
45 CD N
and CC N
day NN N
90 CD N
. . N

Macular JJ o
pigment NN o
density NN o
was VBD N
measured VBN N
by IN N
heterochromatic JJ N
flicker NN N
photometry NN N
. . N

Serum NNP o
lutein JJ o
concentration NN o
in IN N
the DT N
lutein NN N
enriched VBD N
egg NN N
and CC N
egg NN N
yolk-based JJ N
beverage NN N
groups NNS N
increased VBD N
significantly RB N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
76 CD N
% NN N
and CC N
77 CD N
% NN N
) ) N
. . N

A DT N
strong JJ N
increase NN N
in IN N
the DT N
serum NN o
zeaxanthin NN o
concentration NN o
was VBD N
observed VBN N
in IN N
individuals NNS N
receiving VBG N
zeaxanthin NN i
enriched VBN i
eggs NNS i
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
430 CD N
% NN N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
in IN N
macular JJ o
pigment NN o
density NN o
in IN N
the DT N
various JJ N
groups NNS N
tested VBN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
daily JJ N
consumption NN N
of IN N
lutein NN i
or CC i
zeaxanthin NN i
enriched VBN i
egg NN i
yolks NNS i
as RB N
well RB N
as IN N
an DT N
egg NN i
yolk-based JJ i
beverage NN i
show NN N
increases VBZ N
in IN N
serum NN o
lutein NN o
and CC o
zeaxanthin NN o
levels NNS o
that WDT N
are VBP N
comparable JJ N
with IN N
a DT N
daily JJ N
use NN N
of IN N
5 CD N
mg NN N
supplements NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00527553 NNP N
. . N

-DOCSTART- -X- O O

Magnocellular JJ i
visual JJ i
evoked VBN N
potential JJ N
delay NN N
with IN N
high JJ p
autism NN p
spectrum JJ p
quotient NN p
yields NNS N
a DT N
neural JJ N
mechanism NN N
for IN N
altered JJ o
perception NN o
. . o

Everyone NN N
has VBZ N
autistic JJ N
characteristics NNS N
to TO N
a DT N
greater JJR N
or CC N
lesser JJR N
degree NN N
, , N
encapsulated VBN N
in IN N
the DT N
Autism NNP o
Spectrum NNP o
Quotient NNP o
, , N
a DT N
scale NN N
that WDT N
measures VBZ N
the DT N
degree NN N
to TO N
which WDT N
an DT N
adult NN p
of IN p
normal JJ p
intelligence NN p
displays NNS N
traits NNS N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Recent JJ N
psychophysical JJ N
analyses NNS N
of IN N
autism NN N
spectrum NN N
disorders NNS N
point VBP N
to TO N
superior VB N
local JJ N
processing NN N
, , N
and CC N
impaired VBD N
or CC N
ignored VBN N
global JJ N
and CC N
contextual JJ N
processing NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
whether IN N
low- JJ i
and CC p
high-scoring JJ i
individuals NNS i
on IN i
the DT i
Autism NNP i
Spectrum NNP i
Quotient NNP i
differ NN N
on IN N
a DT N
measure NN N
of IN N
local JJ o
and CC o
global JJ o
processing NN o
, , i
motion NN i
processing NN i
and CC i
visual JJ i
pathway NN i
integrity NN i
. . i

Fifteen NNP p
low-scoring JJ p
individuals NNS p
and CC p
14 CD p
high-scoring JJ p
individuals NNS p
derived VBN p
from IN p
a DT p
normal JJ p
population NN p
participated VBD p
in IN p
the DT p
study NN p
. . p

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
initial JJ N
cortical JJ o
response NN o
to TO N
the DT N
magnocellular JJ N
afferents NNS N
is VBZ N
weaker JJR N
at IN N
low JJ N
contrast NN N
in IN N
the DT N
high JJ N
autistic JJ N
tendency NN N
group NN N
and CC N
that IN N
a DT N
second-order JJ N
response NN N
, , N
reflecting VBG N
magnocellular JJ N
activity NN N
, , N
demonstrated VBD N
a DT o
delay NN o
for IN N
high JJ N
versus NN N
low JJ N
scorers NNS N
when WRB N
the DT N
parvocellular JJ N
pathway NN N
was VBD N
also RB N
active JJ N
in IN N
response NN N
to TO N
a DT N
high JJ N
contrast NN N
stimulus NN N
. . N

High-scoring JJ N
individuals NNS N
also RB N
demonstrated VBD N
difficulty NN N
in IN N
identifying VBG o
the DT o
global JJ o
components NNS o
of IN N
locally RB N
salient JJ N
hierarchical JJ N
Navon NNP N
figures NNS N
. . N

Furthermore RB N
, , N
cross-validated JJ N
discriminant NN N
analysis NN N
, , N
using VBG N
four CD N
physiologically RB N
and CC N
three CD N
psychophysically RB N
derived JJ N
parameters NNS N
, , N
correctly RB N
classified VBD N
83 CD N
% NN N
of IN N
individuals NNS N
who WP N
scored VBD N
either CC N
high JJ N
or CC N
low JJ N
on IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
. . N

These DT N
findings NNS N
in IN N
the DT N
group NN N
scoring VBG N
high JJ N
on IN N
the DT N
Autism NNP p
Spectrum NNP p
Quotient NNP p
indicate VBP N
that IN N
a DT N
delay NN N
in IN N
primary JJ N
visual/prestriate JJ N
cortical JJ N
processing NN N
of IN N
magnocellular JJ N
input NN N
diminishes VBZ N
the DT N
advantage NN N
of IN N
its PRP$ N
early JJ N
arrival NN N
to TO N
primary JJ N
visual JJ N
cortex NN N
. . N

This DT N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
impaired JJ o
global JJ o
visual JJ o
perception NN o
, , N
predicting VBG N
with IN N
high JJ N
accuracy NN N
behavioural JJ o
tendencies NNS o
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

It PRP N
has VBZ N
been VBN N
proposed VBN N
that IN N
perceptual JJ N
impairment NN N
in IN N
autism NN N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
dysfunction NN N
of IN N
horizontal JJ N
connections NNS N
within IN N
early JJ N
visual JJ N
areas NNS N
, , N
presumably RB N
parvocellular JJ N
in IN N
nature NN N
. . N

However RB N
, , N
the DT N
timing NN N
of IN N
such JJ N
form NN N
processing NN N
aberrations NNS N
is VBZ N
much RB N
later RBR N
than IN N
the DT N
timing NN N
of IN N
abnormal JJ N
magnocellular JJ N
visual JJ N
processing NN N
measured VBN N
directly RB N
here RB N
. . N

Thus VB N
it PRP N
is VBZ N
proposed VBN N
that IN N
a DT N
magnocellular JJ N
processing NN N
delay NN N
decreases VBZ N
the DT N
ability NN N
of IN N
autistic JJ p
individuals NNS p
to TO N
benefit VB N
perceptually RB N
from IN N
feedback NN N
normally RB N
associated VBN N
with IN N
the DT N
magnocellular JJ N
advantage NN N
. . N

-DOCSTART- -X- O O

A DT N
high JJ N
intake NN N
of IN N
trans NNS i
fatty JJ i
acids NNS i
has VBZ N
little JJ N
effect NN N
on IN N
markers NNS o
of IN o
inflammation NN o
and CC o
oxidative JJ o
stress NN o
in IN N
humans NNS p
. . p

Consumption NN i
of IN i
industrial JJ i
trans NNS i
fatty JJ i
acids NNS i
( ( i
iTFA NN i
) ) i
increases VBZ N
LDL NNP N
cholesterol NN N
, , N
decreases VBZ N
HDL NNP N
cholesterol NN N
, , N
and CC N
is VBZ N
strongly RB N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

However RB N
, , N
changes NNS N
in IN N
circulating VBG N
cholesterol NN N
can MD N
not RB N
explain VB N
the DT N
entire JJ N
effect NN N
. . N

Therefore RB N
, , N
we PRP N
studied VBD N
whether IN N
iTFA NN i
and CC N
conjugated VBD i
linoleic JJ i
acid NN i
( ( i
CLA NNP i
) ) i
affect VBP N
markers NNS o
of IN o
inflammation NN o
and CC o
oxidative JJ o
stress NN o
. . o

Sixty-one CD p
healthy JJ p
adults NNS p
consumed VBD p
each DT p
of IN p
3 CD p
diets NNS i
for IN p
3 CD p
wk NN p
, , N
in IN N
random JJ N
order NN N
. . N

Diets NNS N
were VBD N
identical JJ N
except IN N
for IN N
7 CD N
% NN N
of IN N
energy NN N
provided VBN N
by IN N
oleic JJ i
acid NN i
( ( i
control VB i
diet NN i
) ) i
, , i
iTFA JJ i
, , i
or CC i
CLA NNP i
. . i

At IN N
the DT N
end NN N
of IN N
the DT N
3 CD N
wk NN N
, , N
we PRP N
measured VBD N
plasma JJ o
inflammatory JJ o
markers NNS o
IL-6 NNP o
, , o
C-reactive NNP o
protein NN o
, , o
tumor NN o
necrosis NN o
factor NN o
receptors NNS o
I PRP o
and CC o
II NNP o
( ( o
TNF-RI NNP o
and CC o
-RII NNP o
) ) o
, , o
monocyte JJ o
chemotactic JJ o
protein-1 NN o
and CC o
E-selectin NNP o
, , o
and CC o
urinary JJ o
8-iso-PGF NN o
( ( o
2? CD o
) ) o
, , o
a DT o
marker NN o
of IN o
lipid JJ o
peroxidation NN o
. . o

Consumption NN N
of IN i
iTFA NN i
caused VBD N
4 CD N
% NN N
lower JJR o
TNF-RI NNP o
concentrations NNS o
and CC N
6 CD N
% NN N
higher JJR o
E-selectin JJ o
concentrations NNS o
compared VBN N
with IN N
oleic JJ N
acid NN N
( ( N
control NN N
) ) N
and CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
other JJ o
inflammatory JJ o
markers NNS o
. . o

CLA NNP N
did VBD N
not RB N
significantly RB N
affect JJ o
inflammatory NN o
markers NNS o
. . o

The DT o
urine JJ o
concentration NN o
of IN o
8-iso-PGF JJ o
( ( o
2? CD o
) ) o
[ NN o
geometric JJ N
mean NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
] NN N
was VBD N
greater JJR N
after IN N
the DT N
iTFA NN N
[ VBZ N
0.54 CD N
( ( N
0.48 CD N
, , N
0.60 CD N
) ) N
nmol/mmol FW N
creatinine NN N
] NN N
and CC N
the DT N
CLA NNP N
[ NNP N
1.2 CD N
( ( N
1.1 CD N
, , N
1.3 CD N
) ) N
nmol/mmol FW N
creatinine NN N
] NNP N
diet VBZ N
periods NNS N
than IN N
after IN N
the DT N
control NN N
period NN N
[ VBD N
0.45 CD N
( ( N
0.41 CD N
, , N
0.50 CD N
) ) N
nmol/mmol FW N
creatinine NN N
; : N
P NNP N
< VBD N
0.05 CD N
] NN N
. . N

In IN N
conclusion NN N
, , N
high JJ N
intakes NNS N
of IN N
iTFA NN i
and CC i
CLA NNP i
did VBD i
not RB N
substantially RB N
affect JJ o
plasma NN o
concentrations NNS o
of IN o
inflammatory JJ o
markers NNS o
, , o
but CC N
they PRP N
increased VBD N
the DT o
urine JJ o
8-iso-PGF JJ o
( ( o
2? CD o
) ) o
concentration NN o
. . o

However RB o
, , N
it PRP N
is VBZ N
unlikely JJ N
this DT N
plays VBZ N
a DT N
major JJ N
role NN N
in IN N
the DT N
mechanism NN N
by IN N
which WDT i
iTFA JJ i
increase NN i
the DT N
risk NN N
of IN N
CVD NNP N
. . N

However RB N
, , N
more JJR N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
understand VB N
the DT N
implications NNS N
of IN N
these DT N
findings NNS N
. . N

-DOCSTART- -X- O O

Wheelchair NNP i
skills VBZ i
training NN i
to TO N
improve VB N
confidence NN o
with IN N
using VBG N
a DT N
manual JJ N
wheelchair NN N
among IN N
older JJR p
adults NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
wheelchair NN i
skills NNS i
training VBG i
on IN N
confidence NN o
in IN N
older JJR p
adults NNS p
who WP p
are VBP p
inexperienced VBN p
wheelchair JJ p
users NNS p
. . p

DESIGN NNP N
Parallel NNP N
group NN N
, , N
single-blind JJ N
randomized VBD N
controlled JJ N
trial NN N
. . N

SETTING NNP N
Research NNP N
laboratory NN N
in IN N
a DT N
rehabilitation NN N
hospital NN N
. . N

PARTICIPANTS JJ N
Participants NNS p
( ( p
N=20 NNP p
) ) p
who WP p
were VBD p
community-living JJ p
older JJR p
adults NNS p
at IN p
least JJS p
65 CD p
years NNS p
old JJ p
( ( p
mean JJ p
age NN p
, , p
70y CD p
) ) p
, , p
50 CD p
% NN p
women NNS p
, , p
and CC p
who WP p
had VBD p
no DT p
experience NN p
of IN p
using VBG p
a DT p
wheelchair NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
an DT N
intervention NN N
( ( N
n=10 JJ N
) ) N
or CC N
control NN N
( ( N
n=10 JJ N
) ) N
group NN N
. . N

INTERVENTIONS VBZ N
The DT N
intervention NN N
group NN N
received VBD N
two CD i
1-hour JJ i
training NN i
sessions NNS i
that WDT i
followed VBD i
the DT i
Wheelchair NNP i
Skills NNP i
Training NNP i
Program NNP i
( ( i
WSTP NNP i
) ) i
protocol NN i
. . i

The DT N
control NN N
group NN N
received VBD N
a DT N
single JJ i
socialization NN i
contact NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
Wheelchair NNP o
Use NNP o
Confidence NNP o
Scale-Manual JJ o
( ( o
WheelCon-M NNP o
) ) o
was VBD N
used VBN N
to TO N
evaluate VB o
confidence NN o
with IN N
using VBG N
a DT N
manual JJ N
wheelchair NN N
. . N

The DT N
WheelCon-M NNP N
is VBZ N
a DT N
self-report JJ N
questionnaire NN N
that WDT N
comprises VBZ N
65 CD N
items NNS N
in IN N
6 CD N
conceptual JJ N
areas NNS N
. . N

RESULTS VB N
A DT N
1-way JJ N
between-groups JJ N
analysis NN N
of IN N
covariance NN N
revealed VBD N
a DT N
significant JJ o
difference NN o
in IN N
postintervention NN o
WheelCon-M JJ o
scores NNS o
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
( ( N
F1,17=10.9 NNP N
, , N
P=.004 NNP N
) ) N
after IN N
controlling VBG N
for IN N
baseline JJ N
WheelCon-M JJ N
scores NNS N
. . N

A DT N
large JJ N
effect NN o
size NN o
was VBD N
also RB N
observed VBN N
( ( N
partial JJ N
? . N
( ( N
2 CD N
) ) N
=.39 NN N
) ) N
. . N

Secondary JJ N
analyses NNS N
revealed VBD N
that IN N
the DT N
WSTP NNP N
had VBD N
greater JJR o
effects NNS o
on IN o
confidence NN o
in IN o
areas NNS o
related VBN o
to TO o
maneuvering VBG o
around IN o
the DT o
physical JJ o
environment NN o
, , o
knowledge NN o
and CC o
problem NN o
solving NN o
, , o
advocacy NN o
, , o
and CC o
managing VBG o
emotions NNS o
than IN o
in IN o
areas NNS o
related VBN o
to TO o
performing VBG o
activities NNS o
and CC o
behaving VBG o
in IN o
social JJ o
situations NNS o
. . o

CONCLUSION NNP N
Two CD N
1-hour JJ N
WSTP NNP N
sessions NNS N
improve VBP o
confidence NN o
with IN o
using VBG o
a DT o
manual JJ o
wheelchair NN o
among IN p
older JJR p
adults NNS p
who WP p
are VBP p
inexperienced VBN p
wheelchair JJ p
users NNS p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
cognitive-behavioral JJ i
therapy NN i
on IN N
anxiety NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
a DT N
16-week JJ N
Cognitive-Behavioral JJ i
Therapy NNP i
( ( i
CBT NNP i
) ) i
program NN i
and CC i
a DT i
Social NNP i
Recreational NNP i
( ( i
SR NNP i
) ) i
program NN i
on IN N
anxiety NN N
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Seventy JJ p
children NNS p
( ( p
9-16 CD p
years NNS p
old JJ p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
the DT N
programs NNS N
( ( N
n FW N
( ( i
CBT NNP i
) ) i
= VBZ N
36 CD N
; : N
n NNS N
( ( N
SR NNP N
) ) N
= VBP N
34 CD N
) ) N
. . N

Measures NNS N
on IN N
child NN N
's POS N
anxiety NN N
using VBG N
the DT N
Spence NNP o
Child NNP o
Anxiety NNP o
Scale NNP o
-- : o
Child NNP o
( ( o
SCAS-C NNP o
) ) o
and CC N
the DT N
Clinical JJ o
Global NNP o
Impression-Severity NNP o
scale NN o
( ( o
CGI NNP o
-- : o
S NNP o
) ) o
were VBD N
administered VBN N
at IN N
pre- JJ N
, , N
post-treatment JJ N
, , N
and CC N
follow-ups NNS N
( ( N
3- CD N
and CC N
6-month JJ N
) ) N
. . N

Children NNP N
in IN N
both DT N
programs NNS N
showed VBD N
significantly RB N
lower JJR N
levels NNS N
of IN N
generalized VBN o
anxiety NN o
and CC o
total JJ o
anxiety NN o
symptoms NNS o
at IN N
6-month JJ N
follow-up NN N
on IN N
SCAS-C. NNP N
Clinician NNP N
ratings NNS N
on IN N
the DT N
CGI-S NNP o
demonstrated VBD N
an DT N
increase NN N
in IN N
the DT N
percentage NN N
of IN N
participants NNS N
rated VBN N
as IN N
Normal NNP N
and CC N
Borderline NNP N
for IN N
both DT N
programs NNS N
. . N

Findings NNS N
from IN N
the DT N
present JJ N
study NN N
suggest JJS N
factors NNS N
such JJ N
as IN N
regular JJ i
sessions NNS i
in IN i
a DT i
structured JJ i
setting NN i
, , i
consistent JJ i
therapists NNS i
, , i
social JJ i
exposure NN i
and CC N
the DT N
use NN N
of IN N
autism-friendly JJ i
strategies NNS i
are VBP N
important JJ N
components NNS N
of IN N
an DT N
effective JJ N
framework NN N
in IN N
the DT N
management NN N
of IN N
anxiety NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
single-dose JJ i
versus NN N
conventional-dose JJ i
antibiotic JJ i
treatment NN i
of IN N
bacteriuria NN p
in IN p
elderly JJ p
women NNS p
. . p

The DT N
efficacy NN N
of IN N
single-dose JJ i
antibiotic JJ i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
bacteriuria NN p
in IN p
a DT p
group NN p
of IN p
non-catheterized JJ p
elderly JJ p
women NNS p
was VBD N
compared VBN N
with IN N
that DT N
of IN N
conventional JJ i
7-10 JJ i
day NN i
courses NNS i
of IN i
antibiotic JJ i
therapy NN i
. . i

Thirty-one JJ p
women NNS p
received VBD p
single-dose JJ i
treatment NN i
and CC p
22 CD p
conventional-dose JJ i
treatment NN i
. . i

The DT N
cure NN o
rates NNS o
at IN N
1 CD N
and CC N
6 CD N
weeks NNS N
for IN N
the DT N
single-dose JJ N
treatments NNS N
were VBD N
52 CD N
% NN N
and CC N
38 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
the DT N
cure NN o
rates NNS o
for IN N
the DT N
conventional-dose JJ N
treatments NNS N
at IN N
1 CD N
and CC N
6 CD N
weeks NNS N
were VBD N
59 CD N
% NN N
and CC N
52 CD N
% NN N
, , N
respectively RB N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
there EX N
may MD N
be VB N
a DT N
place NN N
for IN N
the DT N
use NN N
of IN N
single-dose JJ i
antibiotic JJ i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
selected VBN p
elderly JJ p
women NNS p
with IN p
bacteriuria NN p
, , N
but CC N
larger JJR N
studies NNS N
are VBP N
needed VBN N
. . N

-DOCSTART- -X- O O

Anticholinergic NNP i
drugs NNS i
: : i
effects NNS N
on IN N
oxygen NN o
consumption NN o
and CC o
energy NN o
expenditure NN o
. . o

Premedication NN N
has VBZ N
been VBN N
shown VBN N
to TO N
affect VB N
both DT N
oxygen NN o
consumption NN o
( ( N
VO2 NNP N
) ) N
and CC N
energy NN o
expenditure NN o
( ( N
EE NNP N
) ) N
. . N

The DT N
metabolic JJ N
responses NNS N
to TO N
anticholinergic VB N
drugs NNS N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

In IN N
this DT N
study NN N
the DT N
effects NNS N
of IN N
anticholinergic JJ i
drugs NNS i
on IN N
VO2 NNP N
and CC N
EE NNP N
( ( N
calculated VBN N
from IN N
the DT N
measured VBN N
rates NNS N
of IN N
VO2 NNP N
and CC N
carbon NN N
dioxide NN N
production NN N
[ NNP N
VCO2 NNP N
] NN N
: : N
EE NNP N
[ NNP N
kcal/d NNP N
] NNP N
= VBD N
3.581 CD N
x NNP N
VO2 NNP N
[ NNP N
L/d NNP N
] NNP N
+ VBD N
1.448 CD N
x NNP N
VCO2 NNP N
[ NNP N
L/d NNP N
] NNP N
- : N
32.4 CD N
) ) N
were VBD N
measured VBN N
in IN N
six CD p
healthy JJ p
female NN p
volunteers NNS p
. . p

They PRP N
were VBD N
given VBN N
intramuscular JJ N
atropine NN i
( ( N
15 CD N
micrograms/kg NN N
) ) N
, , N
glycopyrrolate NN i
( ( N
8 CD N
micrograms/kg NN N
) ) N
, , N
scopolamine NN i
( ( N
8 CD N
micrograms/kg NN N
) ) N
, , N
and CC i
placebo NN i
in IN N
a DT N
random JJ N
double-blind JJ N
cross-over NN N
design NN N
. . N

The DT N
consecutive JJ N
sessions NNS N
were VBD N
at IN N
least JJS N
1 CD N
wk JJ N
apart RB N
for IN N
each DT N
subject NN N
. . N

VO2 NNP o
and CC o
EE NNP o
were VBD N
measured VBN N
using VBG N
an DT N
indirect JJ N
calorimetry NN N
( ( N
Deltatrac NNP N
) ) N
. . N

Cardiovascular JJ o
responses NNS o
were VBD N
assessed VBN N
using VBG N
standard JJ N
noninvasive JJ N
monitoring NN N
. . N

Plasma NNP o
drug NN o
concentrations NNS o
were VBD N
analyzed VBN N
using VBG N
a DT N
sensitive JJ N
modification NN N
of IN N
radioreceptor NN N
assay NN N
. . N

Subjective JJ N
responses NNS N
were VBD N
measured VBN N
with IN N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
. . N

Atropine NNP i
and CC N
glycopyrrolate NN i
induced VBD N
a DT N
significant JJ N
increase NN N
in IN N
heart NN o
rate NN o
with IN N
a DT N
simultaneous JJ N
decrease NN N
in IN N
pressure NN o
rate NN o
quotient NN o
( ( o
PRQ NNP o
) ) o
, , N
while IN N
scopolamine NN N
caused VBD N
a DT N
significant JJ N
decrease NN N
in IN N
heart NN o
rate NN o
with IN N
a DT N
simultaneous JJ N
increase NN o
in IN o
PRQ NNP o
. . o

Scopolamine NNP i
significantly RB N
decreased VBD N
both DT N
VO2 NNP o
and CC o
EE NNP o
, , N
whereas JJ N
glycopyrrolate NN i
increased VBD N
VO2 NNP o
. . o

Atropine NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
metabolic JJ o
variables NNS o
. . o

Only RB N
scopolamine NN N
induced JJ N
sedation NN o
in IN N
this DT N
study NN N
. . N

In IN N
conclusion NN N
, , N
atropine NN i
, , i
glycopyrrolate NN i
, , N
and CC N
scopolamine NN i
differ NN N
not RB N
only RB N
in IN N
their PRP$ N
cardiovascular NN N
and CC N
central JJ N
nervous JJ N
system NN N
effects NNS N
, , N
but CC N
also RB N
in IN N
their PRP$ N
effects NNS N
on IN N
metabolism NN N
. . N

-DOCSTART- -X- O O

Nepafenac NNP i
for IN N
epiretinal JJ p
membrane NN p
surgery NN p
. . p

-DOCSTART- -X- O O

Anaphylactoid JJ o
reactions NNS o
and CC o
histamine NN o
release NN o
by IN N
plasma NN i
substitutes NNS i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN p
human JJ p
subjects NNS p
and CC p
in IN p
dogs NNS p
[ JJ N
proceedings NNS N
] NN N
. . N

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
of IN N
early JJ i
discharge NN i
after IN p
uncomplicated JJ p
myocardial JJ p
infarction NN p
. . p

Out IN N
of IN N
383 CD p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
patients NNS p
aged VBN p
below IN p
70 CD p
years NNS p
, , p
252 CD p
( ( p
66 CD p
% NN p
) ) p
were VBD p
judged VBN p
after IN p
the DT p
third JJ p
day NN p
in IN p
hospital NN p
to TO p
have VB p
had VBN p
uncomplicated VBN p
infarctions NNS p
. . p

These DT N
patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
, , N
one CD i
of IN i
which WDT i
was VBD i
given VBN i
treatment NN i
for IN i
8 CD i
days NNS i
and CC i
the DT i
other JJ i
for IN i
15 CD i
days NNS i
. . i

No DT N
significant JJ N
differences NNS o
in IN o
mortality NN o
, , o
morbidity NN o
or CC o
incapacity NN o
for IN o
work NN o
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

The DT N
findings NNS N
thus RB N
support VBP N
previous JJ N
conclusions NNS N
that WDT N
early RB i
discharge VBP i
from IN N
hospital NN N
after IN N
uncomplicated JJ N
MI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
greater JJR N
risk NN N
for IN N
the DT N
patient NN N
than IN N
later RB N
discharge NN N
. . N

-DOCSTART- -X- O O

Prior JJ p
experience NN p
with IN p
a DT p
pain NN p
stimulus NN p
as IN N
a DT N
predictor NN N
of IN N
placebo NN N
analgesia NN o
. . o

Placebo NNP i
effects NNS N
are VBP N
important JJ N
in IN N
pain NN o
reduction NN o
, , N
but CC N
the DT N
effects NNS N
are VBP N
inconsistent JJ N
. . N

Prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
may MD N
moderate VB N
placebo NN N
analgesia NN o
. . o

The DT N
current JJ N
study NN N
tests VBZ N
the DT N
effect NN N
of IN N
prior JJ N
experience NN N
with IN N
a DT N
pain NN N
stimulus NN N
on IN N
placebo NN o
analgesia NN o
during IN N
a DT N
laboratory NN N
pain NN N
task NN N
. . N

Healthy NNP p
normotensive JJ p
undergraduates NNS p
( ( p
66 CD p
women NNS p
, , p
68 CD p
men NNS p
) ) p
who WP p
either DT p
did VBD p
or CC p
did VBD p
not RB p
report VB p
prior JJ p
experience NN p
with IN p
pain NN o
from IN p
submerging VBG p
a DT p
limb NN p
in IN p
cold JJ p
water NN p
were VBD p
enrolled VBN p
. . p

In IN N
the DT N
laboratory NN N
, , N
an DT N
experimenter NN N
applied VBD N
an DT N
inert NN N
, , N
medicinal-smelling JJ i
cream NN i
to TO N
participants NNS N
' POS N
non-dominant JJ N
hand NN N
. . N

Participants NNS N
randomized VBD N
to TO N
the DT N
no-expectation JJ N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN i
was VBD i
a DT i
hand NN i
cleanser NN i
. . i

Participants NNS N
randomized VBD N
to TO N
the DT N
placebo NN i
expectation NN N
group NN N
were VBD N
told VBN N
that IN N
the DT N
cream NN i
would MD N
reduce VB N
the DT N
pain NN o
associated VBN N
with IN N
the DT N
cold JJ i
pressor NN i
task NN i
. . i

Participants NNS N
then RB N
completed VBD N
the DT N
cold JJ i
pressor NN i
task NN i
and CC N
reported VBD N
their PRP$ N
pain NN o
on IN N
the DT N
short JJ N
form NN N
of IN N
the DT N
McGill NNP o
Pain NNP o
Questionnaire NNP o
. . o

Analysis NN N
of IN N
variance NN N
revealed VBD N
a DT N
main JJ N
effect NN N
of IN N
expectation NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
in IN N
the DT N
placebo NN N
expectation NN N
group NN N
reported VBD N
less JJR o
pain NN o
. . o

An DT N
interaction NN N
was VBD N
also RB N
found VBN N
between IN N
expectation NN N
and CC N
prior JJ N
experience NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
, , N
such JJ N
that IN N
participants NNS N
with IN N
prior JJ N
experience NN N
with IN N
pain NN o
from IN o
cold JJ N
water NN N
immersion NN N
showed VBD N
no DT N
difference NN o
in IN o
pain NN o
reports NNS o
between IN o
expectation NN N
groups NNS N
. . N

In IN N
a DT N
pain NN N
context NN p
, , p
prior JJ p
experience NN p
with IN p
the DT p
pain NN p
stimulus NN p
may MD p
prevent VB i
a DT i
placebo JJ i
expectation NN i
from IN N
reducing VBG N
the DT N
experience NN o
of IN o
pain NN o
. . o

-DOCSTART- -X- O O

Prehydration NNP N
alone RB N
is VBZ N
sufficient JJ N
to TO N
prevent VB N
contrast-induced JJ N
nephropathy JJ N
after IN N
day-only JJ p
angiography NN p
procedures NNS p
-- : p
a DT p
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Contrast NNP N
agents NNS N
used VBN N
in IN N
angiography NN N
procedures NNS N
for IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
are VBP N
known VBN N
to TO N
cause VB N
contrast-induced JJ N
nephropathy NN N
( ( N
CIN NNP N
) ) N
, , N
which WDT N
may MD N
be VB N
partially RB N
due JJ N
to TO N
the DT N
production NN N
of IN N
nephrotoxic JJ N
oxygen-free JJ N
radicals NNS N
. . N

It PRP N
is VBZ N
uncertain JJ N
whether IN N
administration NN N
of IN N
intravenous JJ i
( ( i
IV NNP i
) ) i
anti-oxidant NN i
, , i
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
, , N
can MD N
prevent VB N
reduction NN N
in IN N
renal JJ N
function NN N
and CC N
whether IN N
this DT N
is VBZ N
a DT N
cost-effective JJ N
approach NN N
. . N

METHODS NNP N
Sixty-five JJ p
day-only JJ p
patients NNS p
with IN p
renal JJ p
impairment NN p
( ( p
mean JJ p
serum NN p
creatinine NN p
concentration NN p
0.16+/-0.03 NNP p
mmol/l NN p
) ) p
due JJ p
to TO p
undergo JJ p
coronary JJ p
or CC p
peripheral JJ p
angiography NN p
and/or NN p
stenting VBG p
were VBD N
randomly RB N
assigned VBN N
to TO N
IV NNP i
NAC NNP i
300 CD i
or CC i
600 CD i
mg NNS N
immediately RB N
before IN N
and CC N
after IN N
the DT N
procedure NN N
or CC N
IV NNP N
fluid VBP N
alone RB N
. . N

RESULTS NNP N
Of IN N
the DT N
60 CD p
patients NNS p
with IN p
complete JJ p
data NNS p
, , N
none NN N
had VBD N
acute VBN N
CIN NNP N
( ( N
increase NN N
in IN N
serum JJ N
creatinine NN N
concentration NN N
> NN N
or CC N
= $ N
0.044 CD N
mmol/l NN N
, , N
48 CD N
h NN N
after IN N
administration NN N
of IN N
contrast NN N
agent NN N
) ) N
. . N

Eight CD N
patients NNS N
( ( N
13 CD N
% NN N
) ) N
have VBP N
demonstrated VBN N
an DT N
increase NN N
in IN N
their PRP$ N
serum NN o
creatinine NN o
concentration NN o
> NN N
or CC N
= $ N
0.044 CD N
mmol/l JJ N
30 CD N
days NNS N
after IN N
administration NN N
of IN N
contrast NN N
agent NN N
: : N
2/19 CD N
( ( N
11 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
2/21 CD N
( ( N
10 CD N
% NN N
) ) N
in IN N
the DT N
600 CD N
mg NN N
NAC NNP N
group NN N
and CC N
4/20 CD N
( ( N
20 CD N
% NN N
) ) N
the DT N
300 CD N
mg NN N
NAC NNP N
group NN N
( ( N
p JJ N
= NNP N
0.66 CD N
) ) N
. . N

The DT N
mean JJ o
volumes NNS o
of IN o
contrast NN o
agent NN o
used VBN N
and CC N
prehydration NN N
given VBN N
for IN N
each DT N
of IN N
the DT N
three CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.83 CD N
) ) N
. . N

There EX N
was VBD N
significant JJ N
improvement NN N
in IN N
creatinine JJ o
clearance NN o
within IN N
each DT N
group NN N
from IN N
baseline NN N
to TO N
30 CD N
days NNS N
( ( N
p JJ N
< NN N
or CC N
= VB N
0.03 CD N
) ) N
, , N
but CC N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
at IN N
48 CD N
h NN N
and CC N
30 CD N
days NNS N
( ( N
p JJ N
> NN N
or CC N
= VB N
0.43 CD N
) ) N
. . N

Considering VBG N
the DT N
cost NN N
of IN N
NAC NNP N
and CC N
its PRP$ N
administration NN N
, , N
we PRP N
estimate VBP N
that IN N
this DT N
would MD N
translate VB N
to TO N
a DT N
saving NN o
of IN N
dollar NN N
26,637 CD N
per IN N
annum NN N
. . N

CONCLUSION NNP N
For IN N
day-stay JJ p
patients NNS p
with IN p
mild-to-moderate JJ p
chronic JJ p
renal JJ p
impairment NN p
undergoing VBG p
angiography NN p
and/or NN p
intervention NN p
, , N
prehydration NN N
alone RB N
is VBZ N
less RBR N
complicated JJ N
and CC N
more RBR N
cost-effective JJ N
than IN N
a DT N
combination NN N
of IN N
IV NNP N
NAC NNP i
( ( N
at IN N
doses NNS N
used VBN N
) ) N
and CC N
hydration NN N
. . N

-DOCSTART- -X- O O

Supplementation NN N
with IN N
n3 JJ i
fatty JJ i
acid NN i
ethyl NN i
esters NNS i
increases VBZ N
large JJ N
and CC N
small JJ N
artery NN N
elasticity NN o
in IN N
obese JJ p
adults NNS p
on IN p
a DT p
weight JJ p
loss NN p
diet NN p
. . p

Increased VBN N
arterial JJ N
stiffness NN N
is VBZ N
associated VBN N
with IN N
enhanced JJ N
risk NN N
of IN N
cardiovascular JJ p
disease NN p
in IN p
obese JJ p
individuals NNS p
. . p

Whether NNP N
n3 JJ i
fatty RB i
acid JJ i
ethyl NN i
ester NN i
( ( i
FAEE NNP i
) ) i
supplementation NN i
improves VBZ N
arterial JJ N
stiffness NN N
in IN N
obese JJ p
participants NNS p
on IN p
a DT p
weight JJ p
loss NN p
diet NN p
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
carry VB N
out RP N
a DT N
12-wk JJ N
randomized NN N
, , N
single-blind JJ N
trial NN N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
25 CD p
% NN p
energy NN i
deficit NN i
weight VBD i
loss NN i
diet NN i
alone RB i
( ( i
WL NNP i
) ) i
( ( p
n JJ p
= NNP p
12 CD p
) ) p
or CC N
WL NNP i
plus CC i
4 CD i
g/d NN i
Omacor NNP i
( ( i
46 CD i
% NN i
EPA NNP i
and CC i
38 CD i
% NN i
DHA NNP i
) ) i
supplementation NN i
( ( i
WL+FAEE NNP i
) ) i
( ( p
n JJ p
= NNP p
13 CD p
) ) p
on IN N
arterial JJ N
elasticity NN N
in IN N
obese JJ p
adults NNS p
. . p

Large NNP o
( ( o
C1 NNP o
) ) o
and CC o
small JJ o
artery NN o
elasticity NN o
( ( o
C2 NNP o
) ) o
were VBD N
measured VBN N
by IN N
pulse JJ N
contour NN N
analysis NN N
of IN N
the DT N
radial JJ N
artery NN N
. . N

WL NNP N
alone RB N
reduced VBD o
( ( N
P NNP N
< VBZ N
0.05 CD N
in IN N
all DT N
) ) N
body NN o
weight NN o
( ( N
-3 CD N
% NN N
) ) N
, , N
waist JJ o
circumference NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ o
( ( N
-3 CD N
% NN N
) ) N
and CC N
diastolic JJ o
( ( N
-3 CD N
% NN N
) ) N
blood NN o
pressures NNS o
, , o
cardiac JJ o
output NN o
( ( o
-4 CD o
% NN o
) ) o
, , o
plasma JJ o
TG NNP o
concentration NN o
( ( N
-25 CD N
% NN N
) ) N
, , N
and CC N
the DT N
homeostasis NN o
model NN o
assessment NN o
( ( o
HOMA NNP o
) ) o
score NN o
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased VBD o
plasma NN o
HDL NNP o
cholesterol NN o
( ( N
+9 CD N
% NN N
) ) N
and CC N
adiponectin NN o
( ( N
+18 CD N
% NN N
) ) N
concentrations NNS o
. . o

However RB N
, , N
WL NNP i
alone RB N
did VBD N
not RB N
alter VB N
C1 NNP N
and CC N
C2 NNP N
. . N

The DT N
WL+FAEE NNP i
intervention NN i
significantly RB o
reduced VBN o
body NN o
weight NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
waist JJ o
circumference NN o
( ( N
-4 CD N
% NN N
) ) N
, , N
systolic JJ o
( ( N
-8 CD N
% NN N
) ) N
and CC N
diastolic JJ o
( ( N
-5 CD N
% NN N
) ) N
blood NN o
pressures NNS o
, , o
pulse JJ o
pressure NN o
( ( N
-5 CD N
% NN N
) ) N
, , N
heart NN o
rate NN o
( ( N
-8 CD N
% NN N
) ) N
, , N
plasma JJ o
TG NNP o
concentration NN o
( ( N
-36 CD N
% NN N
) ) N
, , N
and CC N
HOMA NNP o
score NN o
( ( N
-12 CD N
% NN N
) ) N
and CC N
increased JJ o
stroke NN o
volume NN o
( ( N
+3 CD N
% NN N
) ) N
, , N
plasma JJ o
HDL NNP o
cholesterol NN o
( ( N
+6 CD N
% NN N
) ) N
and CC N
adiponectin JJ o
concentrations NNS o
( ( N
+28 CD N
% NN N
) ) N
, , N
and CC N
C1 NNP o
( ( N
+20 NNP N
% NN N
) ) N
and CC N
C2 NNP o
( ( N
+22 NNP N
% NN N
) ) N
artery NN o
elasticity NN o
. . o

The DT N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
plasma NN o
TGs NNP o
, , o
C1 NNP o
, , o
and CC o
C2 NNP o
were VBD N
significantly RB o
greater JJR o
in IN N
the DT N
WL+FAEE NNP i
group NN N
than IN N
in IN N
the DT N
WL NNP i
group NN N
. . N

Supplementation NN N
with IN N
n3 JJ i
FAEEs NNP i
improves VBZ N
C1 NNP o
and CC o
C2 NNP o
independently RB N
of IN N
weight JJ o
loss NN o
in IN N
obese JJ p
adults NNS p
. . p

-DOCSTART- -X- O O

Aerobic NNP i
and CC i
strength NN i
training NN i
reduces NNS N
adiposity NN o
in IN N
overweight JJ p
Latina NNP p
adolescents NNS p
. . p

PURPOSE NNP N
To TO N
date NN N
, , N
no DT N
study NN N
has VBZ N
examined VBN N
the DT N
synergistic JJ N
effects NNS N
of IN N
a DT N
nutrition NN i
and CC N
combination NN i
of IN i
aerobic JJ i
and CC i
strength NN i
training NN i
( ( i
CAST NNP i
) ) i
on IN N
both DT N
adiposity NN o
and CC o
metabolic JJ o
parameters NNS o
in IN N
overweight JJ p
Latina NNP p
adolescent NN p
females NNS p
. . p

The DT N
goal NN N
was VBD N
to TO N
assess VB N
if IN N
a DT N
16-wk JJ N
nutrition NN i
plus CC N
CAST NNP i
pilot NN N
study NN N
had VBD N
stronger JJR N
effects NNS N
on IN N
reducing VBG N
adiposity NN o
and CC N
on IN N
improving VBG N
glucose/insulin NN o
indices NNS o
compared VBN N
with IN N
control NN N
( ( N
C NNP N
) ) N
, , N
nutrition NN i
only RB i
( ( N
N NNP N
) ) N
, , N
and CC N
a DT N
nutrition NN i
plus CC N
strength NN i
training NN i
( ( N
N NNP N
+ NNP N
ST NNP N
) ) N
groups NNS N
. . N

METHODS NNP N
In IN N
a DT N
16-wk JJ N
randomized JJ N
trial NN N
, , N
41 CD p
overweight JJ p
Latina NNP p
girls NNS p
( ( p
15.2 CD p
+/- JJ p
1.1 CD p
yr NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
C NNP i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
N NNP i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
, , N
N NNP i
+ NNP i
ST NNP i
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
or CC N
N NNP i
+ NNP i
CAST NNP i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

All DT N
intervention NN N
groups NNS N
received VBD N
modified JJ i
carbohydrate NN i
nutrition NN i
classes NNS i
( ( N
once RB N
a DT N
week NN N
) ) N
, , N
whereas IN N
the DT N
N NNP i
+ NNP i
ST NNP i
also RB N
received VBD i
strength NN i
training NN i
( ( N
twice RB N
a DT N
week NN N
) ) N
and CC N
the DT N
N NNP i
+ NNP i
CAST NNP i
received VBD N
a DT i
combination NN i
of IN i
strength NN i
and CC i
aerobic JJ i
training NN i
( ( N
twice RB N
a DT N
week NN N
) ) N
. . N

The DT N
following VBG N
were VBD N
measured VBN N
before IN N
and CC N
after IN N
intervention NN N
: : N
strength NN o
by IN N
one CD N
repetition NN N
maximum NN N
, , N
physical JJ o
activity NN o
by IN o
the DT o
7-d JJ o
accelerometry NN o
and CC N
the DT N
3-d JJ o
physical JJ o
activity NN o
recall NN o
, , o
dietary JJ o
intake NN o
by IN o
3-d JJ o
records NNS o
, , o
body NN o
composition NN o
by IN N
dual-energy JJ N
x-ray JJ N
absorptiometry NN N
( ( N
DEXA NNP N
) ) N
, , N
glucose/insulin JJ o
indices NNS o
by IN N
oral JJ N
glucose JJ N
tolerance NN N
test NN N
, , N
and CC N
intravenous JJ o
glucose JJ o
tolerance NN o
test NN o
with IN N
minimal JJ N
modeling NN N
. . N

Across IN N
intervention NN N
group NN N
, , N
effects NNS N
were VBD N
tested VBN N
using VBG N
ANCOVA NNP N
with IN N
post NN N
hoc NN N
pairwise NN N
comparisons NNS N
. . N

RESULTS VB N
There EX N
were VBD N
significant JJ N
overall JJ N
intervention NN N
effects NNS N
for IN N
all DT N
adiposity NN o
measures NNS o
( ( o
weight NN o
, , o
body NN o
mass NN o
index NN o
[ NNP o
BMI NNP o
] NNP o
, , o
BMI NNP o
z-scores NNS o
, , o
and CC o
DEXA NNP o
total VBP o
body NN o
fat NN o
) ) o
, , N
with IN N
a DT N
decrease NN N
of IN N
3 CD N
% NN N
in IN N
the DT N
N NNP i
+ NNP i
CAST NNP i
group NN N
compared VBN N
with IN N
a DT N
3 CD N
% NN N
increase NN N
in IN N
the DT N
N NNP i
+ NNP i
ST NNP i
group NN N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
an DT N
intervention NN N
effect NN N
for IN N
fasting VBG o
glucose NN o
with IN N
the DT N
N NNP i
group NN N
increasing VBG N
by IN N
3 CD N
% NN N
and CC N
the DT N
N NNP i
+ NNP i
CAST NNP i
group NN N
decreasing VBG N
by IN N
4 CD N
% NN N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
CAST NNP i
was VBD N
more RBR N
effective JJ N
than IN N
nutrition NN i
alone RB N
or CC N
nutrition JJ i
plus CC N
strength NN i
training NN i
for IN N
reducing VBG N
multiple JJ o
adiposity NN o
outcomes NNS o
and CC o
fasting VBG o
glucose NN o
in IN N
overweight JJ p
Latina NNP p
girls NNS p
. . p

However RB N
, , N
further JJ N
research NN N
investigating NN N
and CC N
identifying VBG N
intervention NN N
approaches NNS N
that WDT N
improve VBP N
both DT N
adiposity NN o
and CC o
insulin NN o
indices NNS o
, , N
particularly RB N
in IN N
high-risk JJ N
populations NNS N
, , N
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomised JJ N
open JJ N
multicentre NN N
comparative JJ N
trial NN N
of IN N
lamotrigine NN i
and CC i
carbamazepine NN i
as IN N
monotherapy NN N
in IN N
patients NNS p
with IN p
newly RB p
diagnosed VBN p
or CC p
recurrent JJ p
epilepsy NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
lamotrigine NN i
and CC i
carbamazepine NN i
as IN N
monotherapy NN N
in IN N
patients NNS p
with IN p
untreated JJ p
, , p
newly RB p
diagnosed VBN p
or CC p
recurrent JJ p
partial JJ p
and/or NN p
generalised VBD p
tonic-clonic JJ p
seizures NNS p
, , N
were VBD N
compared VBN N
in IN N
a DT N
randomised JJ N
, , N
open JJ N
, , N
multicentre JJ N
study NN N
. . N

Patients NNS N
received VBD N
24 CD N
weeks NNS N
' POS N
treatment NN N
with IN N
oral JJ i
lamotrigine NN i
100 CD i
mg NN i
( ( i
LTG NNP i
100 CD i
, , i
n RB i
= VBZ i
115 CD i
) ) i
or CC i
200 CD i
mg NN i
( ( i
LTG NNP i
200 CD i
, , i
n RB i
= VBZ i
111 CD i
) ) i
or CC i
carbamazepine $ i
600 CD i
mg NN i
( ( i
CBZ NNP i
600 CD N
, , N
n RB N
= VBZ N
117 CD N
) ) N
. . N

Efficacy NN o
measurements NNS o
were VBD N
comparable JJ N
between IN N
the DT N
three CD N
treatment NN N
groups NNS N
, , N
although IN N
the DT N
higher JJR N
lamotrigine NN i
dose NN N
was VBD N
possibly RB N
most RBS N
effective JJ N
, , N
with IN N
60.4 CD N
% NN N
completing VBG N
seizure NN N
free JJ N
compared VBN N
with IN N
51.3 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
54.7 CD N
% NN N
( ( N
CBZ NNP N
600 CD N
) ) N
. . N

Both DT N
dosage NN N
regimens NNS N
of IN N
lamotrigine NN i
were VBD N
well RB N
tolerated VBN o
. . o

More JJR N
patients NNS p
on IN p
CBZ NNP i
600 CD p
reported VBD N
adverse JJ o
experiences NNS o
, , N
66 CD N
% NN N
versus IN N
53 CD N
% NN N
( ( i
LTG NNP i
100 CD N
) ) N
and CC N
58 CD N
% NN N
( ( i
LTG NNP i
200 CD N
) ) N
, , N
and CC N
of IN N
these DT N
a DT N
greater JJR N
proportion NN N
were VBD N
attributed VBN N
to TO N
CBZ NNP i
600 CD N
treatment NN N
, , N
53 CD N
% NN N
versus IN N
23 CD N
% NN N
( ( N
LTG NNP N
100 CD N
) ) N
and CC N
28 CD N
% NN N
( ( N
LTG NNP N
200 CD N
) ) N
. . N

Similarly RB N
, , N
a DT N
greater JJR N
proportion NN N
of IN N
the DT N
CBZ NNP i
600 CD N
group NN N
required VBD N
a DT N
change NN N
in IN N
dose NN N
, , N
47 CD N
% NN N
versus IN N
20 CD N
% NN N
( ( i
LTG NNP i
100 CD N
) ) N
and CC N
17 CD N
% NN N
( ( i
LTG NNP i
200 CD N
) ) N
or CC N
withdrew $ N
completely RB N
due JJ N
to TO N
adverse JJ o
experiences NNS o
, , N
10.3 CD N
% NN N
versus IN N
4.3 CD N
% NN N
( ( i
LTG NNP i
100 CD N
) ) N
and CC N
4.5 CD N
% NN N
( ( i
LTG NNP i
200 CD N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
experience NN o
leading VBG N
to TO N
withdrawal VB N
was VBD N
rash NN o
, , N
with IN N
approximately RB N
double JJ N
the DT N
proportion NN N
of IN N
reports NNS N
occurring VBG N
in IN N
patients NNS N
on IN N
CBZ NNP i
600 CD N
( ( N
5.1 CD N
% NN N
) ) N
compared VBN N
with IN N
lamotrigine NN i
( ( N
1.7 CD N
% NN N
on IN N
LTG NNP i
100 CD N
and CC N
2.7 CD N
% NN N
on IN N
LTG NNP i
200 CD N
) ) N
. . N

Overall JJ N
lamotrigine NN i
appeared VBD N
equally RB N
effective JJ N
but CC N
better RB N
tolerated VBD N
compared VBN N
with IN N
carbamazepine NN i
. . i

-DOCSTART- -X- O O

Unpacking VBG N
attitude JJ p
certainty NN p
: : p
attitude NN N
clarity NN N
and CC N
attitude NN N
correctness NN N
. . N

Attitude NNP p
certainty NN p
has VBZ N
been VBN N
the DT N
subject NN N
of IN N
considerable JJ N
attention NN N
in IN N
the DT N
attitudes NNS N
and CC N
persuasion NN N
literature NN N
. . N

The DT N
present JJ N
research NN N
identifies VBZ N
2 CD N
aspects NNS N
of IN N
attitude NN p
certainty NN p
and CC N
provides VBZ N
evidence NN N
for IN N
the DT N
distinctness NN N
of IN N
the DT N
constructs NNS N
. . N

Specifically RB N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
attitude JJ N
certainty NN N
can MD N
be VB N
conceptualized VBN N
, , N
and CC N
empirically RB N
separated VBN N
, , N
in IN N
terms NNS N
of IN N
attitude NN N
clarity NN N
( ( N
the DT N
subjective NN N
sense NN N
that WDT N
one CD N
knows VBZ N
what WP N
one CD N
's POS N
attitude NN N
is VBZ N
) ) N
and CC N
attitude JJ N
correctness NN N
( ( N
the DT N
subjective NN N
sense NN N
that IN N
one CD N
's POS N
attitude NN N
is VBZ N
correct JJ N
or CC N
valid JJ N
) ) N
. . N

Experiment JJ N
1 CD N
uses NNS N
factor NN p
analysis NN p
and CC p
correlational JJ p
data NNS p
to TO N
provide VB N
evidence NN N
for IN N
viewing VBG N
attitude JJ o
clarity NN o
and CC N
attitude NN o
correctness NN o
as IN N
separate JJ N
constructs NNS N
. . N

Experiments NNS N
2 CD N
and CC N
3 CD N
demonstrate NN N
that WDT N
attitude VBP o
clarity NN o
and CC o
attitude NN o
correctness NN o
can MD o
have VB o
distinct JJ o
antecedents NNS o
( ( o
repeated VBN o
expression NN o
and CC o
consensus NN o
feedback NN o
, , o
respectively RB o
) ) o
. . o

Experiment JJ N
4 CD N
reveals NNS N
that IN N
these DT N
constructs NNS N
each DT N
play VBP o
an DT o
independent JJ o
role NN o
in IN o
persuasion NN o
and CC o
resistance NN o
situations NNS o
. . o

As IN N
clarity NN o
and CC o
correctness JJ o
increase NN o
, , o
attitudes VBZ o
become VBP o
more RBR o
resistant JJ o
to TO N
counterattitudinal JJ N
persuasive JJ N
messages NNS N
. . N

These DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
relation NN N
to TO N
the DT N
existing VBG p
attitude NN p
strength NN p
literature NN N
. . N

-DOCSTART- -X- O O

Benefits NNS N
of IN N
adding VBG N
fluticasone NN i
propionate/salmeterol NN i
to TO N
tiotropium VB i
in IN N
moderate JJ p
to TO p
severe VB p
COPD NNP p
. . p

BACKGROUND NNP N
Combining NNP N
maintenance NN N
medications NNS N
with IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
may MD N
improve VB N
outcomes NNS N
in IN N
COPD NNP N
. . N

In IN N
this DT N
study NN N
we PRP N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
fluticasone/salmeterol NN i
( ( i
FSC NNP i
) ) i
( ( N
250/50 CD N
mcg NN N
twice RB N
daily RB N
) ) N
when WRB N
added VBN N
to TO i
tiotropium VB i
( ( N
18 CD N
mcg NN N
once RB N
daily RB i
) ) i
( ( i
TIO NNP N
) ) N
in IN N
subjects NNS p
with IN p
symptomatic JJ p
moderate NN p
to TO p
severe VB p
COPD NNP p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
24-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel JJ N
group NN N
, , N
multi-center NN N
study NN p
. . p

Subjects VBZ p
40 CD p
years NNS p
or CC p
older JJR p
with IN p
cigarette NN p
smoking VBG p
history NN p
?10 JJ p
pack-years NNS p
and CC p
with IN p
the DT p
diagnosis NN p
of IN p
COPD NNP p
and CC p
post-bronchodilator NN p
FEV NNP p
( ( p
1 CD p
) ) p
?40 NN p
to TO p
? . p
80 CD p
% NN p
of IN p
predicted VBN p
normal JJ p
and CC p
FEV NNP p
( ( p
1 CD p
) ) p
/FVC NN p
of IN p
?0.70 NN p
were VBD p
enrolled VBN p
. . p

Following VBG N
a DT N
4-week JJ N
treatment NN N
with IN N
open-label JJ N
TIO NNP i
18 CD i
mcg NN i
once RB N
daily JJ N
, , N
subjects NNS N
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
fashion NN N
to TO N
either VB N
the DT N
addition NN N
of IN N
FSC NNP N
250/50 CD N
DISKUS NNP N
twice RB N
daily RB N
or CC N
matching VBG N
placebo NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD o
AM NNP o
pre-dose JJ o
FEV NNP o
( ( o
1 CD o
) ) o
and CC o
secondary JJ N
endpoints NNS N
included VBD N
other JJ o
measures NNS o
of IN o
lung NN o
function NN o
, , o
rescue NN o
albuterol NN o
use NN o
, , o
health NN o
status NN o
and CC o
exacerbations NNS o
. . o

RESULTS VB o
The DT o
addition NN N
of IN N
FSC NNP i
to TO i
TIO NNP N
significantly RB o
improved VBD o
lung JJ o
function NN o
indices NNS o
including VBG o
AM NNP o
pre-dose JJ o
FEV NNP o
( ( o
1 CD o
) ) o
, , o
2 CD o
h NN o
post-dose JJ o
FEV NNP o
( ( o
1 CD o
) ) o
, , o
AM NNP o
pre-dose JJ o
FVC NNP o
, , o
2 CD o
h NN o
post-dose JJ o
FVC NNP o
and CC o
AM NNP o
pre-dose JJ o
IC NNP o
compared VBN N
with IN N
TIO NNP N
alone RB N
. . N

Furthermore RB N
, , N
this DT N
combination NN N
was VBD N
superior JJ N
to TO N
TIO VB N
alone RB N
in IN N
reducing VBG o
rescue NN o
albuterol NN o
use NN o
. . o

However RB o
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS o
in IN o
health NN o
status NN o
or CC o
COPD NNP o
exacerbations NNS o
. . o

The DT o
incidence NN o
of IN N
adverse JJ o
events NNS o
was VBD o
similar JJ o
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
FSC NNP p
to TO p
subjects NNS p
with IN p
COPD NNP p
treated VBD p
with IN N
TIO NNP N
significantly RB N
improves VBZ o
lung JJ o
function NN o
without IN o
increasing VBG N
the DT o
risk NN o
of IN o
adverse JJ o
events NNS o
. . N

NCT00784550 NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
daily JJ N
etidronate NN i
on IN N
the DT N
osteolysis NN N
of IN N
multiple JJ N
myeloma NN N
. . N

Progressive NNP N
bone NN N
disease NN N
in IN N
multiple JJ N
myeloma NN N
frequently RB N
leads VBZ N
to TO N
osteolysis VB N
, , N
bone NN N
resorption NN N
, , N
pathologic JJ N
fractures NNS N
, , N
vertebral JJ N
compression NN N
, , N
and CC N
hypercalcemia NN N
. . N

We PRP N
conducted VBD N
a DT N
double-blind NN N
study NN N
in IN N
173 CD p
newly RB p
diagnosed VBN p
multiple JJ p
myeloma NN p
patients NNS p
of IN p
etidronate JJ p
disodium NN p
( ( p
EHDP NNP p
) ) p
, , p
a DT p
diphosphonate NN p
compound NN p
that WDT p
reduces VBZ p
bone NN p
resorption NN p
by IN p
inhibiting VBG p
osteoclastic JJ p
activity NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ i
EHDP NNP i
5 CD i
mg/kg/d NN i
or CC i
placebo NN i
until IN N
death NN N
or CC N
discontinuation NN N
due JJ N
to TO N
intolerance VB N
or CC N
refusal VB N
. . N

The DT N
extent NN N
of IN N
vertebral JJ N
deformity NN N
was VBD N
measured VBN N
by IN N
a DT N
vertebral JJ N
index NN N
as RB N
well RB N
as IN N
height NN N
. . N

The DT N
frequency NN o
of IN o
pathologic JJ o
fractures NNS o
, , o
hypercalcemia NN o
, , o
and CC o
bone NN o
pain NN o
was VBD N
regularly RB N
assessed VBN N
, , N
as RB N
well RB N
as IN N
size NN N
and CC N
number NN N
of IN N
osteolytic JJ N
lesions NNS N
. . N

All DT N
patients NNS N
received VBD N
melphalan JJ i
and CC N
prednisone JJ i
daily JJ N
for IN N
4 CD N
days NNS N
every DT N
4 CD N
weeks NNS N
as IN N
the DT N
primary JJ N
chemotherapy NN N
for IN N
their PRP$ N
disease NN N
. . N

Although IN N
the DT N
repeated JJ N
measures NNS N
analysis NN N
showed VBD N
a DT N
significant JJ N
height JJ o
loss NN o
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
treatment NN N
arms NNS N
( ( N
P NNP N
= NNP N
.98 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
bone NN o
pain NN o
, , o
episodes NNS o
of IN o
hypercalcemia NN o
, , o
or CC o
development NN o
of IN o
pathologic JJ o
fractures NNS o
. . o

Patients NNS p
on IN p
EHDP NNP i
showed VBD N
less JJR N
deterioration NN o
in IN o
their PRP$ o
vertebral JJ o
index NN o
, , N
but CC N
this DT N
difference NN N
only RB N
approached VBD N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
.07 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
EHDP NNP i
therapy NN N
used VBN N
in IN N
this DT N
dosage NN N
schedule NN N
does VBZ N
not RB N
have VB N
a DT N
clinically RB N
significant JJ N
impact NN N
in IN N
multiple JJ N
myeloma NN N
. . N

-DOCSTART- -X- O O

Bevacizumab NNP i
compared VBN N
with IN N
macular JJ i
laser NN i
grid JJ i
photocoagulation NN i
for IN N
cystoid JJ p
macular JJ p
edema NN p
in IN p
branch JJ p
retinal JJ p
vein NN p
occlusion NN p
. . p

INTRODUCTION NNP N
To TO N
evaluate VB N
the DT N
outcome NN N
of IN N
cystoid JJ N
macular JJ N
edema NN N
treated VBN N
with IN N
intravitreal JJ i
injections NNS i
of IN i
bevacizumab NN i
and CC i
macular JJ i
grid NN i
laser NN i
photocoagulation NN i
( ( i
GLP NNP i
) ) i
, , N
in IN N
patients NNS p
with IN p
perfused JJ p
branch NN p
retinal JJ p
vein NN p
occlusion NN p
. . p

METHODS NNP N
Thirty NNP p
eyes NNS p
of IN p
30 CD p
consecutive JJ p
patients NNS p
with IN p
cystoid JJ p
macular JJ p
edema NN p
secondary JJ p
to TO p
nonischemic JJ p
branch NN p
retinal JJ p
vein NN p
occlusion NN p
were VBD p
assigned VBN p
to TO N
either DT N
GLP NNP i
group NN i
or CC N
to TO N
intravitreal VB i
bevacizumab NN i
( ( i
IB NNP i
) ) i
group NN N
. . N

Complete NNP o
ophthalmologic JJ o
examinations NNS o
were VBD N
performed VBN N
just RB N
before IN N
GLP NNP i
and CC N
IB NNP i
injection NN N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
treatment NN N
. . N

Changes NNS N
in IN N
logarithm NN o
of IN o
minimum JJ o
angle NN o
of IN o
resolution NN o
( ( o
logMAR JJ o
) ) o
best-corrected JJ o
visual JJ o
acuity NN o
( ( o
BCVA NNP o
) ) o
, , o
central JJ o
macular JJ o
thickness NN o
( ( o
CMT NNP o
) ) o
shown VBN o
by IN o
optical JJ o
coherence NN o
tomography-3 NN o
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Baseline NNP o
BCVA NNP o
( ( o
logMAR NN o
) ) o
and CC o
CMT NNP o
were VBD N
, , N
respectively RB N
, , N
0.89 CD N
+/- JJ N
0.13 CD N
and CC N
650 CD N
+/- JJ N
140 CD N
microm NN N
for IN N
the DT N
GLP NNP i
group NN N
, , N
0.87 CD N
+/- JJ N
0.16 CD N
and CC N
690 CD N
+/- JJ N
120 CD N
microm NN N
for IN N
the DT N
IB NNP i
group NN N
. . N

After IN N
the DT N
treatment NN N
, , N
at IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
in IN N
the DT N
GLP NNP i
group NN N
, , N
BCVA NNP o
had VBD N
improved VBN N
by IN N
0.19 CD N
, , N
0.22 CD N
, , N
0.21 CD N
, , N
and CC N
0.20 CD N
logMAR NN N
, , N
CMT NNP o
had VBD N
decreased VBN N
by IN N
40 CD N
% NN N
, , N
41.3 CD N
% NN N
, , N
40.5 CD N
% NN N
, , N
and CC N
42 CD N
% NN N
. . N

In IN N
the DT N
IB NNP i
group NN N
, , N
BCVA NNP o
had VBD N
improved VBN N
by IN N
0.31 CD N
, , N
0.32 CD N
, , N
0.30 CD N
, , N
and CC N
0.31 CD N
logMAR NN o
and CC N
CMT NNP o
had VBD N
decreased VBN N
by IN N
59.5 CD N
% NN N
, , N
59 CD N
% NN N
, , N
60 CD N
% NN N
, , N
and CC N
60.3 CD N
% NN N
. . N

The DT N
group NN N
receiving VBG N
bevacizumab NN i
had VBD N
better JJR N
BCVA NNP o
and CC N
lower JJR N
CMT NNP o
values NNS N
at IN N
all DT N
time NN N
points NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Intravitreal NNP N
bevacizumab NN i
injection NN N
improves VBZ N
BCVA NNP o
and CC N
reduces NNS N
CMT NNP o
more JJR N
than IN N
GLP NNP N
. . N

Intravitreal NNP N
bevacizumab JJ i
injection NN N
was VBD N
well RB N
tolerated VBN N
and CC N
could MD N
be VB N
used VBN N
as IN N
primary JJ N
treatment NN N
in IN N
patients NNS N
with IN N
cystoid JJ N
macular JJ N
edema NN N
secondary JJ N
to TO N
perfused VBN N
branch NN N
retinal JJ N
vein NN N
occlusion NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
total JJ N
enteral JJ N
nutrition NN N
on IN N
the DT N
short-term JJ o
outcome NN o
of IN N
severely RB o
malnourished VBN o
cirrhotics NNS o
. . o

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

Thirty-five JJ p
severely RB p
malnourished VBN p
cirrhotic JJ p
patients NNS p
were VBD N
randomized VBN i
to TO i
receive VB i
either DT i
enteral-tube JJ i
feeding NN i
as IN i
the DT i
sole JJ i
nutritional JJ i
support NN i
( ( i
n JJ i
= NNP i
16 CD i
) ) i
or CC i
an DT i
isocaloric JJ i
, , i
isonitrogenous JJ i
, , i
low-sodium JJ i
standard JJ i
oral JJ i
diet NN i
( ( i
n JJ i
= NNP i
19 CD i
) ) i
. . N

Both DT p
groups NNS p
were VBD p
homogeneous JJ p
regarding VBG p
age NN p
, , p
sex NN p
distribution NN p
, , p
etiology NN p
of IN p
liver JJ p
cirrhosis NN p
, , p
history NN p
of IN p
previous JJ p
complications NNS p
, , p
clinical JJ p
status NN p
, , p
liver RB p
and CC p
renal JJ p
function NN p
, , p
modified VBD p
Child NNP p
's POS p
score NN p
, , p
and CC p
nutritional JJ p
status NN p
at IN p
admission NN p
. . p

The DT N
enteral JJ i
formula NN i
diet NN i
was VBD i
energy NN i
dense NN i
, , i
containing VBG i
40 CD i
mmol NN i
Na/day NNP i
, , i
whole JJ i
protein NN i
plus CC i
branched-chain JJ i
amino NN i
acids NNS i
, , i
medium- JJ i
and CC i
long-chain JJ i
triglycerides NNS i
, , i
and CC i
maltodextrin NN i
. . i

It PRP i
supplied VBD i
2115 CD i
kcal/day NN i
. . i

The DT i
amount NN i
of IN i
vitamins NNS i
and CC i
trace NN i
elements NNS i
was VBD i
at IN i
the DT i
upper JJ i
limit NN i
of IN i
the DT i
recommended JJ i
dietary JJ i
allowances NNS i
. . i

The DT i
orally RB i
fed JJ i
patients NNS i
were VBD i
encouraged VBN i
to TO i
eat VB i
all DT i
meals NNS i
served VBD i
. . i

Total JJ o
enteral JJ o
nutrition NN o
was VBD N
well RB N
tolerated VBN o
without IN N
major JJ N
complications NNS N
. . N

Serum NNP o
albumin NN o
and CC o
Child NNP o
's POS o
score NN o
improved VBD N
in IN N
the DT N
enterally RB N
fed JJ N
patients NNS N
but CC N
not RB N
in IN N
controls NNS N
. . N

Mortality NNP o
rate NN o
while IN o
in IN o
the DT o
hospital NN o
was VBD N
lower JJR N
in IN N
patients NNS N
on IN N
enteral JJ N
feeding NN N
than IN N
in IN N
controls NNS N
( ( N
12 CD N
% NN N
vs JJ N
47 CD N
% NN N
) ) N
. . N

These DT N
results NNS N
show VBP N
that IN N
total JJ N
enteral JJ N
nutrition NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
the DT N
short-term JJ o
clinical JJ o
outcome NN o
in IN N
severely RB p
malnourished JJ p
cirrhotics NNS p
. . p

-DOCSTART- -X- O O

Emotional JJ o
reactivity NN o
to TO N
social JJ N
rejection NN N
and CC N
negative JJ N
evaluation NN N
among IN N
persons NNS p
with IN p
borderline JJ p
personality NN p
features NNS p
. . p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
emotional JJ o
reactivity NN o
of IN N
persons NNS p
with IN p
heightened JJ p
borderline NN p
personality NN p
( ( p
BP NNP p
) ) p
features VBZ p
to TO N
social JJ N
rejection NN N
and CC N
negative JJ N
evaluation NN N
in IN N
the DT N
laboratory NN N
. . N

Individuals NNS p
with IN p
high JJ p
levels NNS p
of IN p
BP NNP p
features NNS p
( ( p
n JJ p
= NNP p
30 CD p
) ) p
and CC p
controls NNS p
with IN p
low JJ p
levels NNS p
of IN p
BP NNP p
features NNS p
( ( p
n JJ p
= NNP p
44 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
condition NN i
involving VBG i
negative JJ i
evaluation NN i
based VBN i
on IN i
writing NN o
( ( i
negative JJ i
evaluation/academic NN i
) ) i
, , i
or CC i
a DT i
condition NN i
involving VBG i
negative JJ i
evaluation NN i
based VBN i
on IN i
personal JJ o
characteristics NNS o
as RB i
well RB i
as IN i
social JJ o
rejection NN o
( ( o
negative JJ o
evaluation/social JJ o
rejection NN o
) ) o
. . o

Hypothesis $ N
1 CD N
was VBD N
that IN N
high-BP JJ p
individuals NNS p
, , N
but CC N
not RB N
low-BP JJ p
controls NNS p
, , N
would MD N
show VB N
greater JJR N
emotional JJ o
reactivity NN o
to TO N
the DT N
negative JJ i
evaluation/social JJ i
rejection NN i
stressor NN i
, , N
compared VBN N
with IN N
the DT N
negative JJ i
evaluation/academic JJ i
( ( i
writing VBG i
) ) i
stressor NN i
. . i

Hypothesis $ N
2 CD N
was VBD N
that IN N
high-BP JJ p
individuals NNS p
would MD N
specifically RB N
show VB N
greater JJR N
reactivity NN o
of IN o
shame- JJ o
and CC o
anger-related JJ o
emotions NNS o
to TO N
the DT N
negative JJ i
evaluation/social JJ i
rejection NN i
stressor NN i
compared VBN N
with IN N
the DT N
negative JJ i
evaluation/academic JJ i
stressor NN i
. . i

Findings NNS N
indicated VBD N
that IN N
high-BP JJ p
individuals NNS p
showed VBD N
heightened VBN o
emotional JJ o
reactivity NN o
to TO N
the DT N
social JJ i
rejection NN i
stressor NN i
but CC N
not RB N
to TO N
the DT N
negative JJ i
evaluation NN i
stressor NN i
, , N
but CC N
the DT N
opposite JJ N
pattern NN N
occurred VBD N
for IN N
controls NNS N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
evidence NN N
for IN N
heightened JJ o
reactivity NN o
of IN o
irritability NN o
, , o
distress NN o
, , o
and CC o
shame NN o
for IN N
the DT N
high-BP JJ N
group NN N
, , N
specifically RB N
in IN N
the DT N
social JJ N
rejection NN N
condition NN N
. . N

-DOCSTART- -X- O O

Nutrient JJ N
retention NN N
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ p
infant NN p
formulas NN p
. . p

Our PRP$ N
purpose NN N
was VBD N
to TO N
compare VB o
nitrogen NN o
, , o
mineral NN o
, , o
and CC o
zinc NN o
balance NN o
in IN N
preterm JJ p
infants NNS p
fed VBN p
standard JJ i
infant NN i
formulas NNS i
, , i
Similac NNP i
With IN i
Iron NNP i
and CC i
Similac NNP i
With IN i
Whey NNP i
+ NNP i
Iron NNP i
. . i

Nitrogen NNP o
and CC o
magnesium NN o
balances NNS o
were VBD N
similar JJ N
during IN N
both DT N
feeds NNS N
, , N
and CC N
met VBD N
estimated VBN N
fetal JJ N
requirements NNS N
. . N

Infants NNS N
absorbed VBD N
and CC N
retained VBD N
( ( N
milligrams FW N
per IN N
kilogram FW N
per IN N
day NN N
) ) N
more JJR N
calcium NN o
, , o
phosphorus NN o
, , o
and CC o
zinc NN o
when WRB N
fed VBN N
Similac NNP i
With IN i
Iron NNP i
. . i

However RB N
, , N
retention NN o
of IN o
calcium NN o
, , o
phosphorus NN o
( ( o
both DT o
formulas NN o
) ) o
, , o
and CC o
zinc NN o
( ( N
Similac NNP N
With IN N
Whey NNP N
+ NNP N
Iron NNP N
) ) N
was VBD N
inadequate JJ N
to TO N
meet VB N
estimated JJ N
fetal JJ N
requirements NNS N
. . N

These DT N
findings NNS N
are VBP N
important JJ N
in IN N
the DT N
rapidly RB p
growing VBG p
preterm JJ p
infant NN p
, , N
who WP N
is VBZ N
already RB N
at IN N
risk NN N
for IN N
the DT N
development NN N
of IN N
rickets NNS N
and CC N
zinc NN N
deficiency NN N
and CC N
may MD N
be VB N
fed VBN N
either DT N
formula NN N
on IN N
discharge NN N
from IN N
the DT N
newborn JJ N
nursery NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
sclerotherapy NN i
with IN N
staple JJ i
transection NN i
of IN i
the DT i
esophagus NN i
for IN N
the DT N
emergency NN N
control NN o
of IN o
bleeding VBG o
from IN p
esophageal JJ p
varices NNS p
. . p

We PRP N
compared VBN N
two CD N
procedures NNS N
for IN N
the DT N
emergency NN N
treatment NN N
of IN N
bleeding VBG o
esophageal JJ p
varices NNS p
in IN p
patients NNS p
who WP p
did VBD p
not RB p
respond VB p
to TO p
blood VB p
transfusion NN p
and CC p
vasoactive JJ p
drugs NNS p
. . p

We PRP N
randomly VBP N
assigned VBD N
101 CD p
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
and CC p
bleeding VBG p
esophageal JJ p
varices NNS p
to TO N
undergo VB i
either DT i
emergency NN i
sclerotherapy NN i
( ( i
n JJ i
= NNP i
50 CD i
) ) i
or CC i
staple JJ i
transection NN i
of IN i
the DT i
esophagus NN i
( ( i
n JJ i
= NNP i
51 CD i
) ) i
. . N

Four CD N
patients NNS N
assigned VBN N
to TO N
sclerotherapy VB i
and CC N
12 CD N
assigned VBN N
to TO N
staple VB N
transection NN N
did VBD N
not RB N
actually RB N
undergo VBP N
those DT N
procedures NNS N
, , N
but CC N
all DT N
analyses NNS N
were VBD N
made VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

Total JJ o
mortality NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
; : N
the DT N
relative JJ o
risk NN o
of IN o
death NN o
for IN N
staple JJ N
transection NN N
as IN N
compared VBN N
with IN N
sclerotherapy NN N
was VBD N
0.88 CD N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.54 CD N
) ) N
. . N

Mortality NN o
at IN N
six CD N
weeks NNS N
was VBD N
44 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB i
and CC N
35 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
. . N

Complication NN o
rates NNS o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

An DT N
interval NN o
of IN o
five CD o
days NNS o
without IN o
bleeding NN o
was VBD N
achieved VBN N
in IN N
88 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
and CC N
in IN N
62 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB i
after IN N
a DT N
single JJ N
injection NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
82 CD N
percent NN N
after IN N
three CD N
injections NNS N
. . N

In IN N
only RB N
2 CD N
of IN N
the DT N
11 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
sclerotherapy NN i
injection NN N
was VBD N
bleeding VBG o
controlled VBN o
for IN N
more JJR N
than IN N
five CD N
days NNS N
, , N
and CC N
9 CD N
died VBD N
. . N

We PRP N
conclude VBP N
that IN N
staple JJ N
transection NN N
of IN N
the DT N
esophagus NN N
is VBZ N
as RB o
safe JJ o
as IN o
sclerotherapy NN o
for IN N
the DT N
emergency NN o
treatment NN o
of IN o
bleeding VBG o
esophageal JJ N
varices NNS N
and CC N
that IN N
it PRP N
is VBZ N
more RBR N
effective JJ N
than IN N
a DT N
single JJ N
sclerotherapy NN i
procedure NN N
. . N

We PRP N
currently RB N
recommend VBP N
surgery NN N
after IN N
two CD N
injection NN N
treatments NNS N
have VBP N
failed VBN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
recombinant JJ i
adenovirus-p53 NN i
combined VBN i
with IN i
radiotherapy NN i
on IN N
long-term JJ o
prognosis NN o
of IN o
advanced JJ o
nasopharyngeal JJ o
carcinoma NN o
. . o

PURPOSE NNP N
To TO N
centrally RB N
assess VB N
the DT N
safety NN o
, , o
efficacy NN o
, , o
and CC o
6-year JJ o
follow-up NN o
of IN N
recombinant JJ i
adenovirus-p53 JJ i
( ( i
rAd-p53 NN i
) ) i
combined VBN i
with IN i
radiotherapy NN i
( ( i
RT NNP i
) ) i
for IN N
patients NNS p
with IN p
nasopharyngeal JJ p
carcinoma NN p
( ( p
NPC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
randomized VBD N
controlled VBN N
clinical JJ N
study NN N
on IN N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
in IN N
42 CD p
patients NNS p
with IN p
NPC NNP p
was VBD p
compared VBN p
with IN p
a DT p
control NN p
group NN p
of IN p
40 CD p
patients NNS p
with IN p
NPC NNP p
treated VBD p
with IN p
RT NNP i
alone RB i
. . i

In IN N
the DT N
group NN N
receiving VBG N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
, , i
rAd-p53 NN i
was VBD N
intratumorally RB N
injected VBN N
once RB N
a DT N
week NN N
for IN N
8 CD N
weeks NNS N
. . N

Concurrent NNP N
RT NNP N
( ( N
70 CD N
Gy NNP N
in IN N
35 CD N
fractions NNS N
) ) N
was VBD N
given VBN N
to TO N
the DT N
nasopharyngeal JJ N
tumor NN N
and CC N
neck NN N
lymph NN N
node NN N
. . N

Patients NNS N
and CC N
tumors NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ o
events NNS o
and CC o
responses NNS o
. . o

RESULTS NNP N
rAd-p53-specific JJ o
p53 NN o
mRNA NN o
was VBD N
detected VBN N
in IN N
postinjection NN N
of IN N
rAd-p53 JJ N
biopsies NNS N
from IN N
16 CD N
( ( N
94.1 CD N
% NN N
) ) N
of IN N
17 CD N
patients NNS N
. . N

Upregulation NN N
of IN N
p21/WAF1 NN o
and CC o
Bax NNP o
and CC N
downregulation NN N
of IN N
vascular JJ o
endothelial JJ o
growth NN o
factor NN o
were VBD N
observed VBN N
in IN N
postinjection NN N
tumor NN N
biopsy NN N
. . N

Complete JJ o
response NN o
rate NN o
in IN N
the DT N
group NN N
receiving VBG N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
was VBD N
observed VBN N
at IN N
2.73 CD N
times NNS N
that WDT N
of IN N
the DT N
group NN N
receiving VBG N
RT NNP i
alone RB i
( ( N
66.7 CD N
% NN N
v JJ N
24.4 CD N
% NN N
) ) N
. . N

Six-year JJ N
follow-up JJ N
data NN N
showed VBD N
that IN N
rAd-p53 JJ i
significantly RB N
increased VBD N
the DT N
5-year JJ o
locoregional JJ o
tumor NN o
control NN o
rate NN o
by IN N
25.3 CD N
% NN N
for IN N
patients NNS p
with IN p
NPC NNP p
treated VBD N
with IN N
irradiation NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
. . N

The DT N
5-year JJ o
overall JJ o
survival NN o
rate NN o
and CC o
5-year JJ o
disease-free JJ o
survival NN o
rate NN o
of IN N
the DT N
group NN N
receiving VBG N
rAd-p53 NN i
combined VBN i
with IN i
RT NNP i
were VBD N
7.5 CD N
% NN N
( ( N
P NNP N
= NNP N
.34 NNP N
) ) N
and CC N
11.7 CD N
% NN N
( ( N
P NNP N
= NNP N
.21 NNP N
) ) N
higher JJR N
than IN N
those DT N
of IN N
the DT N
group NN N
receiving VBG N
RT NNP i
alone RB i
. . i

No DT N
dose-limiting JJ o
toxicity NN o
or CC o
adverse JJ o
events NNS o
appeared VBD N
, , N
except IN N
for IN N
transient NN o
fever NN o
after IN N
rAd-p53 JJ i
administration NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS p
with IN p
NPC NNP p
, , N
rAd-p53 NN i
was VBD N
safe JJ o
and CC o
biologically RB o
active JJ o
. . o

Our PRP$ N
results NNS N
indicated VBD N
that IN N
rAd-p53 JJ i
improves NNS N
radiotherapeutic JJ o
tumor NN o
control NN o
and CC o
survival JJ o
rate NN o
in IN N
patients NNS p
with IN p
NPC NNP p
. . p

-DOCSTART- -X- O O

Small NN N
but CC N
important JJ N
errors NNS N
in IN N
cardiovascular JJ N
risk NN N
calculation NN N
by IN N
practice NN p
nurses NNS p
: : p
a DT N
cross-sectional JJ N
study NN N
in IN N
randomised JJ N
trial NN N
setting NN N
. . N

BACKGROUND NNP N
Practice NNP p
nurses NNS p
play VBP N
an DT N
increasingly RB N
important JJ N
role NN N
in IN N
the DT N
prevention NN N
of IN N
cardiovascular JJ N
diseases NNS N
but CC N
we PRP N
do VBP N
not RB N
have VB N
evidence NN N
about IN N
the DT N
accuracy NN o
of IN N
their PRP$ N
cardiovascular JJ N
risk NN N
assessments NNS N
during IN N
real JJ N
practice NN N
consultations NNS N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
how WRB N
nurses NNS p
perform VBP N
with IN N
regard NN N
to TO N
absolute VB N
10-year JJ N
cardiovascular JJ o
risk NN o
assessment NN o
in IN N
actual JJ N
practice NN N
. . N

DESIGN NNP N
Cross-sectional JJ N
study NN N
. . N

SETTING NN N
This DT p
study NN p
was VBD p
nested VBN p
in IN p
the DT p
IMPALA NNP p
study NN p
, , p
a DT p
clustered VBN p
randomised VBN p
controlled VBN p
trial NN p
involving VBG p
24 CD p
general JJ p
practices NNS p
in IN p
The DT p
Netherlands NNP p
. . p

PARTICIPANTS VB N
24 CD p
practice NN p
nurses NNS p
, , p
trained VBN p
in IN p
10-year JJ p
cardiovascular JJ p
risk NN p
assessment NN p
, , N
calculated VBD N
the DT N
risk NN N
of IN N
a DT N
total NN N
of IN N
421 CD p
patients NNS p
without IN p
established VBN p
cardiovascular JJ p
diseases NNS p
but CC p
eligible JJ p
for IN p
cardiovascular JJ o
risk NN o
assessment NN o
. . o

METHODS NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
accuracy NN o
of IN o
risk NN o
assessments NNS o
, , N
defined VBN N
as IN N
( ( N
1 CD N
) ) N
the DT N
difference NN o
between IN o
the DT o
10-year JJ o
cardiovascular JJ o
risk NN o
percentage NN o
calculated VBN o
by IN o
nurses NNS o
and CC o
an DT o
independent JJ o
assessor NN o
, , N
and CC N
( ( N
2 CD N
) ) N
the DT o
agreement NN o
between IN o
the DT o
treatment NN o
categories NNS o
assigned VBN o
by IN o
the DT o
nurses NNS o
( ( o
low JJ o
, , o
moderate JJ o
or CC o
high JJ o
risk NN o
) ) o
and CC o
those DT o
assigned VBN o
by IN o
the DT o
independent JJ o
assessor NN o
. . o

RESULTS VB N
Thirty-one NNP N
( ( N
7.4 CD N
% NN N
) ) N
of IN N
the DT N
calculated JJ N
risk NN N
percentages NNS N
differed VBN N
by IN N
more JJR N
than IN N
our PRP$ N
preset NN N
limits NNS N
, , N
25 CD N
( ( N
81 CD N
% NN N
) ) N
being VBG N
underestimations NNS N
. . N

Elderly JJ p
patients NNS p
( ( N
OR NNP N
1.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-1.1 CD N
) ) N
, , N
male JJ p
patients NNS p
( ( p
vs. FW p
female NN p
OR NNP N
3.1 CD N
, , N
95 CD N
% NN N
CI NNP N
1.2-7.3 CD N
) ) N
, , N
and CC N
smoking NN p
patients NNS p
( ( p
vs. IN p
non-smoking NN p
OR NNP N
3.8 CD N
, , N
95 CD N
% NN N
CI NNP N
1.7-8.9 CD N
) ) N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
their PRP$ N
cardiovascular JJ o
risk NN o
miscalculated VBD o
. . o

Ten NNP p
( ( p
28 CD p
% NN p
) ) p
of IN p
the DT p
36 CD p
patients NNS p
who WP p
should MD p
be VB p
assigned VBN p
to TO p
the DT p
high-risk JJ p
treatment NN p
category NN p
according VBG N
to TO N
the DT N
independent JJ N
calculation NN N
, , N
were VBD N
missed VBN N
as IN N
high-risk JJ N
patients NNS N
by IN N
the DT N
practice NN N
nurses NNS N
. . N

CONCLUSIONS VB N
The DT N
overall JJ N
standard NN N
of IN N
accuracy NN N
of IN N
cardiovascular JJ i
risk NN i
assessment NN i
by IN N
trained JJ p
practice NN p
nurses NNS p
in IN p
actual JJ p
practice NN p
is VBZ N
high JJ N
. . N

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
high-risk JJ N
patients NNS N
were VBD N
misclassified VBN N
, , N
with IN N
the DT N
probability NN N
that IN N
it PRP N
led VBD N
to TO N
missed VBN N
opportunities NNS N
for IN N
risk-reducing JJ N
interventions NNS N
. . N

As IN N
cardiovascular JJ N
risk NN N
assessments NNS N
are VBP N
frequently RB N
done VBN N
by IN N
nurses NNS p
in IN p
general JJ p
practice NN p
, , N
further JJ N
specific JJ N
training NN N
should MD N
be VB N
considered VBN N
to TO N
prevent VB N
undertreatment NN N
. . N

-DOCSTART- -X- O O

Development NNP N
of IN N
an DT N
adaptive JJ i
low-pass NN i
filtered VBD i
speech JJ i
test NN i
for IN N
the DT N
identification NN N
of IN N
auditory NN o
processing NN o
disorders NNS o
. . o

OBJECTIVE CC N
One CD N
type NN N
of IN N
test NN N
commonly RB N
used VBD N
to TO N
examine VB N
auditory JJ p
processing NN p
disorders NNS p
( ( p
APD NNP p
) ) p
is VBZ N
the DT N
low-pass NN i
filtered VBD i
speech JJ i
test NN i
( ( N
LPFST NNP N
) ) N
, , N
of IN N
which WDT N
there EX N
are VBP N
various JJ N
versions NNS N
. . N

In IN N
LPFSTs NNP N
, , N
a DT N
monaural JJ N
, , N
low-redundancy JJ N
speech NN N
sample NN N
is VBZ N
distorted VBN N
by IN N
using VBG N
filtering VBG N
to TO N
modify VB N
its PRP$ N
frequency NN N
content NN N
. . N

Due JJ N
to TO N
the DT N
richness NN N
of IN N
the DT N
neural JJ N
pathways NNS N
in IN N
the DT N
auditory NN N
system NN N
and CC N
the DT N
redundancy NN N
of IN N
acoustic JJ N
information NN N
in IN N
spoken JJ N
language NN N
, , N
a DT N
normal JJ N
listener NN N
is VBZ N
able JJ N
to TO N
recognize VB N
speech NN N
even RB N
when WRB N
parts NNS N
of IN N
the DT N
signal NN N
are VBP N
missing VBG N
, , N
whereas IN N
this DT N
ability NN N
is VBZ N
often RB N
impaired VBN N
in IN N
listeners NNS p
with IN p
APD NNP p
. . p

One CD N
limitation NN N
of IN N
the DT N
various JJ N
versions NNS N
of IN N
the DT N
LPFST NNP i
is VBZ N
that IN N
they PRP N
are VBP N
carried VBN N
out IN N
using VBG N
a DT N
constant JJ N
level NN N
of IN N
low-pass JJ N
filtering NN N
( ( N
e.g NN N
. . N

a DT N
fixed JJ N
1kHz CD N
corner NN N
frequency NN N
) ) N
which WDT N
makes VBZ N
them PRP N
prone VB N
to TO N
ceiling NN N
and CC N
floor NN N
effects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
counter VB N
these DT N
effects NNS N
by IN N
modifying VBG N
the DT N
LPFST NNP N
using VBG N
a DT N
computer-based JJ N
adaptive JJ N
procedure NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
performance NN N
of IN N
normal-hearing JJ p
participants NNS p
of IN p
varying VBG p
ages NNS p
on IN N
the DT N
test NN N
. . N

METHODS NNP N
In IN N
this DT N
preliminary JJ N
study NN N
, , N
33 CD p
adults NNS p
and CC p
30 CD p
children NNS p
( ( p
aged VBN p
8-11 CD p
years NNS p
) ) p
with IN p
no DT p
known JJ p
history NN p
of IN p
listening VBG p
difficulties NNS p
were VBD N
tested VBN N
. . N

The DT i
University NNP i
of IN i
Canterbury NNP i
Adaptive NNP i
Speech NNP i
Test NNP i
( ( i
UCAST NNP i
) ) i
platform NN i
was VBD i
used VBN i
to TO i
administer VB i
a DT i
four-alternative JJ i
forced-choice JJ i
adaptive JJ i
test NN i
that WDT i
altered VBD i
a DT i
low-pass JJ i
filter NN i
( ( i
LPF NNP i
) ) i
to TO i
track VB i
the DT i
corner NN i
frequency NN i
at IN i
which WDT i
participants NNS i
correctly RB i
identified VBN i
a DT i
certain JJ i
percentage NN i
of IN i
the DT i
word NN i
stimuli NN i
. . i

RESULTS NNP N
Findings NNP N
on IN N
the DT N
University NNP o
of IN o
Canterbury NNP o
Adaptive NNP o
Speech NNP o
Test-Filtered NNP o
Words NNP o
( ( o
UCAST-FW NNP o
) ) o
indicated VBD N
a DT N
significant JJ o
maturational JJ o
effect NN o
. . o

Adult NN p
participants NNS p
performed VBD N
significantly RB N
better RBR N
on IN N
the DT N
UCAST-FW NNP o
in IN N
comparison NN N
to TO N
the DT N
child NN p
participants NNS p
. . p

The DT N
UCAST-FW JJ i
test NN N
was VBD N
reliable JJ N
over IN N
repeated JJ N
administrations NNS N
. . N

CONCLUSIONS NNP N
An DT N
adaptive JJ N
low-pass NN N
filtered VBD N
speech JJ N
test NN N
such JJ N
as IN N
the DT N
UCAST-FW NNP o
is VBZ N
sensitive JJ N
to TO N
maturational JJ o
changes NNS o
in IN o
auditory NN o
processing NN o
ability NN o
. . o

-DOCSTART- -X- O O

Wavefront-guided JJ i
versus NN i
standard NN i
LASIK NNP i
enhancement NN i
for IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
efficacy NN o
, , o
safety NN o
, , o
predictability NN o
, , o
stability NN o
, , o
and CC o
changes NNS o
in IN o
higher-order NN o
aberrations NNS o
( ( o
HOAs NNP o
) ) o
and CC N
contrast JJ o
sensitivity NN o
( ( o
CS NNP o
) ) o
after IN N
wavefront-guided JJ i
and CC i
standard JJ i
LASIK NNP i
enhancement NN i
for IN N
the DT N
correction NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
comparative JJ N
clinical JJ N
study NN N
. . N

PARTICIPANTS NNP N
Twenty NNP p
eyes NNS p
of IN p
20 CD p
consecutive JJ p
patients NNS p
( ( p
spherical JJ p
equivalent NN p
[ NNP p
SE NNP p
] NNP p
, , p
-2.01+/-1.36 NNP p
diopters NNS p
[ NNP p
D NNP p
] NNP p
) ) p
treated VBD p
with IN p
wavefront-guided JJ i
Zyoptix NNP i
Ablation NNP i
Refinement NNP i
software NN i
( ( i
ZAR NNP i
) ) i
LASIK NNP i
and CC p
20 CD p
eyes NNS p
of IN p
20 CD p
consecutive JJ p
patients NNS p
( ( p
SE NNP p
, , p
-1.81+/-1.21 NNP p
D NNP p
) ) p
treated VBD p
with IN p
standard JJ i
Planoscan NNP i
LASIK NNP i
, , p
both DT p
for IN p
residual JJ p
refractive JJ p
error NN p
enhancement NN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Efficacy NNP o
, , o
safety NN o
, , o
predictability NN o
, , o
stability NN o
, , o
HOAs NNP o
, , o
and CC o
CS NNP o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
enhancement NN N
at IN N
6 CD N
months NNS N
' POS N
follow-up NN N
. . N

METHODS NNP N
Uncorrected VBD o
visual JJ o
acuity NN o
( ( o
UCVA NNP o
) ) o
, , o
best-corrected JJ o
visual JJ o
acuity NN o
( ( o
BCVA NNP o
) ) o
, , o
manifest JJS o
refraction NN o
, , o
CS NNP o
by IN o
means NNS o
of IN o
the DT o
Functional NNP o
Acuity NNP o
Contrast NNP o
Test NNP o
, , o
and CC o
HOAs NNP o
by IN o
means NNS o
of IN o
Zywave NNP o
aberrometry NN o
were VBD N
evaluated VBN N
preoperatively RB N
and CC N
6 CD N
months NNS N
after IN N
retreatment NN N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
postoperatively RB N
, , N
UCVA NNP o
was VBD N
20/25 CD N
or CC N
better JJR N
in IN N
100 CD N
% NN N
of IN N
the DT N
eyes NNS N
. . N

Efficacy NN o
indexes NNS o
were VBD N
1.09 CD N
for IN N
ZAR NNP i
patients NNS N
and CC N
0.95 CD N
for IN N
Planoscan JJ i
patients NNS N
. . N

No DT o
eyes NNS o
lost VBN o
> CD N
or CC N
=1 JJ N
line NN N
of IN N
BCVA NNP o
; : o
in IN N
the DT N
ZAR NNP i
group NN N
, , N
2 CD N
eyes NNS N
gained VBD o
1 CD N
line NN N
and CC N
6 CD N
eyes NNS N
gained VBN o
> CD N
or CC N
=2 JJ N
lines NNS N
; : N
in IN N
the DT N
Planoscan NNP i
group NN N
, , N
3 CD N
eyes NNS N
gained VBD N
1 CD N
line NN N
. . N

The DT N
ZAR NNP i
group NN N
showed VBD N
a DT N
percentage NN N
of IN N
eyes NNS N
( ( N
94.4 CD N
% NN N
) ) N
within IN N
the DT N
0.5-D JJ N
range NN N
in IN N
SE NNP N
higher JJR N
than IN N
that DT N
shown VBN N
by IN N
the DT N
Planoscan NNP i
group NN N
( ( N
88.8 CD N
% NN N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
HOA NNP o
root NN o
mean NN o
square NN o
( ( o
RMS NNP o
) ) o
increased VBD N
on IN N
average NN N
by IN N
a DT N
factor NN N
of IN N
1.44 CD N
for IN N
the DT N
Planoscan NNP i
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

No UH N
change NN N
or CC N
reduction NN o
in IN o
HOA NNP o
RMS NNP o
was VBD N
found VBN N
in IN N
the DT N
ZAR NNP i
group NN N
( ( N
factor NN N
of IN N
0.96 CD N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

Contrast NNP o
sensitivity NN o
was VBD N
reduced VBN N
in IN N
the DT N
Planoscan NNP i
group NN N
only RB N
at IN N
the DT N
highest JJS N
spatial JJ N
frequency NN N
( ( N
18 CD N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN o
of IN o
CS NNP o
as IN o
a DT o
function NN o
of IN o
HOA NNP o
increase NN o
for IN N
the DT N
Planoscan NNP i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No UH N
changes NNS N
were VBD N
observed VBN N
for IN N
the DT N
ZAR NNP i
group NN N
at IN N
any DT N
spatial JJ o
frequency NN o
( ( N
1.5-18 JJ N
cycles NNS N
per IN N
degree NN N
; : N
P NNP N
> NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
Wavefront-guided JJ i
LASIK NNP i
using VBG N
the DT N
ZAR NNP N
algorithm NN N
is VBZ N
an DT N
effective JJ N
and CC N
safe JJ N
procedure NN N
for IN N
treatment NN N
of IN N
residual JJ N
refractive JJ N
errors NNS N
. . N

Wavefront-guided JJ i
LASIK NNP i
does VBZ N
not RB N
increase VB N
HOAs NNP N
and CC N
does VBZ N
not RB N
modify VB N
CS NNP N
compared VBN N
with IN N
preoperative JJ N
values NNS N
. . N

Wavefront-guided JJ i
LASIK NNP i
seems VBZ N
to TO N
be VB N
better JJR N
than IN N
standard JJ N
LASIK NNP i
for IN N
retreatments NNS N
. . N

-DOCSTART- -X- O O

Diet-Related JJ N
Colorectal NNP N
Cancer NNP N
Prevention NNP N
Beliefs NNP N
and CC N
Dietary NNP i
Intakes NNP i
in IN N
an DT N
Urban JJ p
Minority NNP p
Population NNP p
. . p

In IN N
the DT N
United NNP p
States NNPS p
, , N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
is VBZ N
the DT N
third JJ N
leading JJ N
cause NN N
of IN N
cancer-related JJ N
death NN N
and CC N
third JJ N
most RBS N
commonly RB N
diagnosed JJ N
cancer NN N
among IN N
adults NNS N
. . N

This DT N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
diet-related JJ o
beliefs NNS o
for IN o
colorectal JJ o
cancer NN o
prevention NN o
and CC o
dietary JJ o
intake NN o
among IN N
an DT N
urban JJ p
, , p
predominantly RB p
Black NNP p
population NN p
( ( p
n JJ p
= NNP p
169 CD p
) ) p
. . p

More JJR N
than IN N
two-thirds NNS N
reported VBN N
diet-related JJ N
CRC NNP N
prevention NN N
beliefs NN N
. . N

Those DT N
with IN N
diet-related JJ i
CRC NNP N
prevention NN N
beliefs NNS N
had VBD N
healthier JJR N
intakes NNS o
for IN o
dietary JJ o
fiber NN o
( ( N
p JJ N
= NNP N
.005 NNP N
) ) N
, , N
fruit NN o
, , o
vegetable NN o
, , o
bean NN o
( ( N
p JJ N
= NNP N
.027 NNP N
) ) N
, , N
red JJ o
meat NN o
( ( N
p JJ N
= NNP N
.032 NNP N
) ) N
, , N
vitamin FW o
C NNP o
( ( N
p JJ N
= NNP N
.039 NNP N
) ) N
, , N
and CC N
cholesterol NN o
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
. . N

Most JJS N
people NNS N
may MD N
already RB N
have VB N
diet-related JJ i
CRC NNP i
prevention NN i
beliefs NN i
and CC N
having VBG N
them PRP N
is VBZ N
associated VBN N
with IN N
a DT N
more RBR N
healthful JJ o
dietary JJ o
intake NN o
. . o

-DOCSTART- -X- O O

Endobronchial JJ N
ultrasonography-guided JJ N
transbronchial JJ i
needle JJ i
aspiration NN i
increases VBZ N
the DT N
diagnostic JJ o
yield NN o
of IN N
peripheral JJ p
pulmonary JJ p
lesions NNS p
: : p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
diagnostic JJ o
yield NN o
of IN N
endobronchial JJ i
ultrasonography NN i
( ( i
EBUS NNP i
) ) i
-guided VBD i
transbronchial JJ i
needle JJ i
aspiration NN i
( ( i
TBNA NNP i
) ) i
for IN N
peripheral JJ N
pulmonary JJ N
lesions NNS N
( ( N
PPLs NNP N
) ) N
has VBZ N
not RB N
been VBN N
evaluated VBN N
. . N

The DT N
diagnostic JJ N
impact NN N
of IN N
TBNA NNP N
when WRB N
the DT N
EBUS NNP N
probe NN N
is VBZ N
adjacent JJ N
to TO N
lesions NNS N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

DESIGN VB N
A DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
two CD p
patients NNS p
with IN p
PPLs NNP p
and CC p
positive JJ p
EBUS NNP p
findings NNS p
were VBD p
enrolled VBN p
. . p

They PRP N
were VBD N
randomly RB N
classified VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
the DT N
EBUS NNP N
conventional JJ N
diagnostic JJ N
procedures NNS N
( ( N
CDPs NNP N
) ) N
group NN N
( ( N
103 CD N
patients NNS N
) ) N
, , N
both DT N
transbronchial JJ i
biopsy NN i
( ( N
TBB NNP N
) ) N
and CC N
bronchial JJ N
washing NN N
( ( N
BW NNP N
) ) N
were VBD N
performed VBN N
. . N

In IN N
the DT N
EBUS-TBNA JJ N
plus CC N
CDPs NNP N
group NN N
( ( N
99 CD N
patients NNS N
) ) N
, , N
TBNA NNP N
, , N
TBB NNP N
, , N
and CC N
BW NNP N
were VBD N
performed VBN N
. . N

The DT N
diagnostic JJ o
yield NN o
in IN N
each DT N
group NN N
was VBD N
compared VBN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
182 CD p
patients NNS p
( ( p
94 CD p
in IN p
the DT p
EBUS NNP p
CDPs NNP p
group NN p
and CC p
88 CD p
in IN p
the DT p
EBUS-TBNA JJ p
plus CC p
CDPs NNP p
group NN p
) ) p
were VBD p
analyzed VBN p
. . p

The DT N
yield NN o
in IN o
the DT o
EBUS-TBNA JJ o
plus CC N
CDPs NNP N
group NN N
( ( N
78.4 CD N
% NN N
) ) N
was VBD N
significantly RB N
higher JJR N
than IN N
the DT N
EBUS NNP N
CDPs NNP N
group NN N
( ( N
60.6 CD N
% NN N
, , N
p NN N
= NNP N
0.015 CD N
) ) N
. . N

Cases NNS N
in IN N
which WDT N
the DT N
EBUS NNP N
probe NN N
was VBD N
located VBN N
within IN N
the DT N
lesions NNS N
had VBD N
a DT N
significantly RB N
higher RBR o
diagnostic JJ o
yield NN o
( ( N
78.3 CD N
% NN N
) ) N
than IN N
when WRB N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
them PRP N
( ( N
47.2 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Concerning VBG N
the DT N
three CD N
different JJ N
techniques NNS N
, , N
TBNA NNP N
showed VBD N
the DT N
highest JJS o
diagnostic JJ o
yield NN o
( ( N
62.5 CD N
% NN N
) ) N
in IN N
comparison NN N
to TO N
TBB NNP N
( ( N
48.9 CD N
% NN N
) ) N
and CC N
to TO N
BW NNP N
( ( N
19.8 CD N
% NN N
) ) N
. . N

The DT N
diagnostic JJ o
yield NN o
of IN o
TBNA NNP o
remained VBD N
unchanged JJ N
even RB N
when WRB N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
the DT N
lesions NNS N
( ( N
p JJ N
= NNP N
0.89 CD N
) ) N
. . N

No DT N
additional JJ N
adverse JJ o
effects NNS o
were VBD N
observed VBN N
in IN N
the DT N
EBUS-TBNA JJ N
plus CC N
CDPs NNP N
group NN N
. . N

CONCLUSIONS NNP N
Applying NNP N
TBNA NNP N
to TO N
EBUS-guided NNP N
CDPs NNP N
further RBR N
increased VBD N
the DT N
diagnostic JJ o
yield NN o
of IN N
PPLs NNP N
without IN N
additional JJ N
risk NN N
. . N

The DT N
diagnostic JJ o
advantage NN o
of IN N
TBNA NNP N
became VBD N
more RBR N
obvious JJ N
if IN N
the DT N
EBUS NNP N
probe NN N
was VBD N
adjacent JJ N
to TO N
the DT N
lesions NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
Identifier NNP N
: : N
NCT00626587 NN N
. . N

-DOCSTART- -X- O O

Controlled VBN N
trial NN N
of IN N
induction NN N
of IN N
labor NN o
by IN N
vaginal JJ N
suppositories NNS i
containing VBG N
prostaglandin NN i
E2 NNP i
. . i

A NNP N
group NN N
of IN N
84 CD p
women NNS p
at IN p
39-43 JJ p
weeks NNS p
of IN p
pregnancy NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
blind JJ N
trial NN N
of IN N
induction NN N
of IN N
labor NN o
with IN N
vaginal JJ N
suppositories NNS i
containing VBG N
inert JJ i
material NN i
or CC N
either CC N
0.2 CD N
mg NN N
or CC N
0.4 CD N
mg NN N
of IN N
prostaglandin NN i
E2 NNP i
. . i

The DT N
suppositories NNS N
were VBD N
self-administered JJ N
every DT N
two CD N
hours NNS N
during IN N
waking VBG N
hours NNS N
on IN N
two CD N
successive JJ N
days NNS N
until IN N
labor NN N
started VBD N
or CC N
15 CD N
had VBD N
been VBN N
used VBN N
. . N

Side-effects NNS N
were VBD N
absent JJ N
. . N

Labor NN o
was VBD o
established VBN o
within IN N
48 CD N
hr NN N
of IN N
insertion NN N
of IN N
the DT N
first JJ N
suppository NN N
in IN N
9.3 CD N
% NN N
of IN N
control NN N
patients NNS N
, , N
65.4 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
0.2 CD N
mg NNS N
PGE2 NNP i
and CC N
85.7 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
0.4 CD N
mg NNS N
PGE2 NNP i
. . i

The DT N
mean JJ o
Apgar NNP o
scores NNS o
in IN N
the DT N
three CD N
groups NNS N
were VBD N
the DT N
same JJ N
. . N

The DT N
mean JJ o
total NN o
dose NN o
of IN o
PGE2 NNP o
were VBD N
2.0 CD N
mg NN N
( ( N
0.2 CD N
mg NNS N
group NN N
) ) N
and CC N
2.3 CD N
mg NN N
( ( N
0.4 CD N
mg NNS N
group NN N
) ) N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
vaginal JJ o
PGE2 NNP o
is VBZ N
an DT N
effective JJ N
and CC N
acceptable JJ N
method NN o
of IN o
inducing VBG o
labor NN o
at IN o
term NN o
. . o

-DOCSTART- -X- O O

Epidural JJ i
fentanyl-bupivacaine JJ i
compared VBN N
with IN N
clonidine-bupivacaine NN i
for IN N
analgesia NN p
in IN p
labour NN p
. . p

Alpha-adrenergic JJ N
agonists NNS N
produce VBP N
pain NN o
relief NN o
through IN N
an DT N
opioid JJ N
independent JJ N
mechanism NN N
and CC N
may MD N
be VB N
alternatives NNS N
to TO N
opioids NNS N
for IN N
combination NN N
with IN N
local JJ N
anaesthetics NNS N
for IN N
analgesia NN N
during IN p
labour NN p
. . p

We PRP p
studied VBD p
41 CD p
pregnant JJ p
women NNS p
. . p

Epidural JJ N
block NN N
was VBD N
performed VBN N
with IN N
75 CD N
microg NNS N
clonidine NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
50 CD i
microg NNS i
fentanyl NN i
( ( N
n JJ N
= NNP N
21 CD N
) ) N
combined VBN i
with IN i
0.125 CD i
% NN i
bupivacaine NN i
( ( N
10 CD N
mL NN N
) ) N
. . N

Maternal JJ o
vital JJ o
parameters NNS o
were VBD N
measured VBN N
. . N

Analgesia NNP o
was VBD N
evaluated VBN N
using VBG N
a DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
; : N
sedation NN o
was VBD N
scored VBN N
using VBG N
a DT N
five-point JJ N
scale NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
maternal JJ o
vital JJ o
parameters NNS o
, , o
fetal JJ o
heart NN o
rate NN o
( ( o
FHR NNP o
) ) o
or CC o
Apgar NNP o
scores NNS o
between IN N
the DT N
groups NNS N
. . N

Analgesia NNP o
lasted VBD N
longer RBR N
in IN N
the DT N
bupivacaine-clonidine JJ i
group NN N
( ( N
139.4 CD N
+/- JJ N
31 CD N
min NN N
) ) N
compared VBN N
with IN N
the DT N
bupivacaine-fentanyl JJ i
group NN N
( ( N
127.9 CD N
+/- JJ N
48 CD N
min NN N
) ) N
( ( N
P NNP N
= NNP N
0.42 CD N
) ) N
. . N

Additional JJ o
analgesic JJ o
requirement NN o
was VBD N
more RBR N
often RB N
in IN N
the DT N
fentanyl-bupivacaine JJ i
group NN N
and CC N
total JJ N
bupivacaine NN N
requirement NN N
was VBD N
less RBR N
in IN N
the DT N
clonidine-bupivacaine JJ i
group NN N
( ( N
22.5 CD N
+/- JJ N
12.5 CD N
mg NN N
vs. FW N
30.9 CD N
+/- JJ N
12.8 CD N
mg NN N
) ) N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

This DT N
small JJ N
study NN N
confirms VBZ N
that IN N
this DT N
combination NN N
of IN N
bupivacaine NN i
and CC N
clonidine NN i
provides VBZ N
satisfactory JJ o
analgesia NN o
for IN N
first-stage JJ N
labour NN N
, , N
and CC N
of IN N
longer JJR N
duration NN o
than IN N
bupivacaine-fentanyl NN i
. . i

-DOCSTART- -X- O O

Safety NN o
and CC o
efficacy NN o
of IN N
oral JJ N
DMSA NNP i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
part NN N
B NNP N
- : N
behavioral JJ N
results NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
oral JJ i
dimercapto NN i
succinic JJ i
acid NN i
( ( i
DMSA NNP i
) ) i
therapy NN i
on IN N
the DT N
behavioural JJ N
symptoms NNS N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
ages VBZ p
3-8 JJ p
years NNS p
. . p

METHODS NNP N
Phase NNP p
1 CD p
involved VBD p
65 CD p
children NNS p
with IN p
ASD NNP p
who WP p
received VBD p
one CD p
round NN p
of IN p
DMSA NNP p
( ( p
3 CD p
days NNS p
) ) p
. . p

Participants NNS p
who WP p
had VBD p
high JJ p
urinary JJ p
excretion NN p
of IN p
toxic JJ p
metals NNS p
were VBD p
selected VBN p
to TO p
continue VB p
on IN p
to TO p
phase VB p
2 CD p
. . p

In IN N
phase NN p
2 CD p
, , p
49 CD p
participants NNS p
were VBD p
randomly RB p
assigned VBN p
in IN p
a DT p
double-blind JJ p
design NN p
to TO p
receive VB p
an DT p
additional JJ p
6 CD i
rounds NNS i
of IN i
either DT i
DMSA NNP i
or CC i
placebo NN i
. . i

RESULTS VB N
The DT N
groups NNS N
receiving VBG N
one CD N
round NN N
and CC N
seven CD N
rounds NNS N
of IN N
DMSA NNP i
had VBD N
significant JJ N
improvements NNS N
on IN N
all PDT N
the DT N
assessment JJ N
measures NNS N
. . N

For IN N
the DT N
seven CD N
round NN N
group NN N
, , N
the DT N
degree NN N
of IN N
improvement NN o
on IN N
the DT N
assessment NN o
measures NNS o
could MD N
be VB N
partially RB N
explained VBN N
by IN N
a DT N
regression NN N
analysis NN N
based VBN N
on IN N
excretion NN o
of IN o
toxic JJ o
metals NNS o
and CC o
changes NNS o
in IN o
glutathione NN o
( ( N
adjusted VBN N
R2 NNP N
of IN N
0.28-0.75 NNP N
, , N
p NN N
< VBD N
0.02 CD N
in IN N
all DT N
cases NNS N
) ) N
. . N

One CD N
round NN N
of IN N
DMSA NNP N
had VBD N
nearly RB N
the DT N
same JJ N
benefit NN N
as IN N
seven CD N
rounds NNS N
. . N

The DT N
assessment JJ N
measures NNS N
correlated VBN N
reasonably RB N
with IN N
one CD N
another DT N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
( ( N
r JJ N
= NNP N
0.60-0.87 NN N
) ) N
and CC N
even RB N
better JJR N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
r JJ N
= NNP N
0.63-0.94 NN N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
both DT N
one CD N
and CC N
seven CD N
rounds NNS N
of IN N
DMSA NNP i
therapy NN N
seems VBZ N
to TO N
be VB N
reasonably RB N
safe JJ o
in IN N
children NNS p
with IN p
ASD NNP p
who WP p
have VBP p
high JJ p
urinary JJ p
excretion NN p
of IN p
toxic JJ p
metals NNS p
, , N
and CC N
possibly RB N
helpful JJ N
in IN N
reducing VBG N
some DT N
of IN N
the DT N
symptoms NNS N
of IN N
autism NN N
in IN N
those DT N
children NNS N
. . N

-DOCSTART- -X- O O

The DT N
placebo NN i
effect NN o
. . o

Drug NNP N
trial NN N
considerations NNS N
. . N

-DOCSTART- -X- O O

Cisplatin NNP i
, , i
epirubicin NN i
, , i
leucovorin NN i
and CC i
5-fluorouracil JJ i
( ( i
PELF NNP i
) ) i
is VBZ N
more RBR N
active JJ N
than IN N
5-fluorouracil JJ i
, , i
doxorubicin JJ i
and CC i
methotrexate NN i
( ( i
FAMTX NNP i
) ) i
in IN N
advanced JJ p
gastric JJ p
carcinoma NN p
. . p

BACKGROUND NNP N
5-Fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
, , i
doxorubicin NN i
and CC i
methotrexate NN i
( ( i
FAMTX NNP i
) ) i
and CC i
cisplatin NN i
, , i
epirubicin NN i
, , i
leucovorin NN i
and CC i
5-FU JJ i
( ( i
PELF NNP i
) ) i
have VBP N
both DT N
been VBN N
reported VBN N
to TO N
be VB N
superior JJ N
to TO N
the DT N
combination NN N
5-FU JJ N
, , N
doxorubicin JJ N
and CC N
mitomycin JJ N
C NNP N
( ( N
FAM NNP N
) ) N
in IN N
advanced JJ p
gastric JJ p
carcinoma NN p
. . N

On IN N
the DT N
basis NN N
of IN N
the DT N
presence NN N
and CC N
dose JJ N
intensity NN N
of IN N
the DT N
included JJ N
agents NNS N
, , N
we PRP N
hypothesised VBD N
that IN N
PELF NNP N
would MD N
be VB N
superior JJ N
to TO N
FAMTX NNP i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Two CD p
hundred VBD p
patients NNS p
with IN p
untreated JJ p
advanced JJ p
gastric JJ p
carcinoma NN p
were VBD N
randomised VBN N
to TO N
receive VB N
PELF NNP i
or CC i
FAMTX NNP i
for IN N
a DT N
maximum NN N
of IN N
six CD N
cycles NNS N
or CC N
until IN N
disease JJ N
progression NN N
. . N

RESULTS VB N
The DT N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
rates NNS o
to TO N
PELF NNP N
and CC N
FAMTX NNP i
were VBD N
, , N
respectively RB N
, , N
13 CD N
% NN N
[ JJ N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
6 CD N
% NN N
to TO N
20 CD N
% NN N
] NN N
and CC N
2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0 CD N
% NN N
to TO N
5 CD N
% NN N
; : N
P NNP N
= NNP N
0.003 CD N
) ) N
, , N
and CC N
the DT N
objective JJ o
response NN o
rates NNS o
[ VBP N
CR NNP N
plus CC N
partial JJ o
response NN o
( ( N
PR NNP N
) ) N
rates NNS N
] VBP N
39 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
29 CD N
% NN N
to TO N
49 CD N
% NN N
) ) N
and CC N
22 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
13 CD N
% NN N
to TO N
30 CD N
% NN N
; : N
P NNP N
= NNP N
0.009 CD N
) ) N
, , N
thus RB N
significantly RB N
favouring VBG N
the DT N
PELF NNP N
combination NN N
. . N

The DT N
survival NN o
rates NNS o
after IN N
12 CD N
months NNS N
( ( N
30.8 CD N
% NN N
versus IN N
22.4 CD N
% NN N
) ) N
and CC N
24 CD N
months NNS N
( ( N
15.7 CD N
% NN N
versus IN N
9.5 CD N
% NN N
) ) N
were VBD N
also RB N
higher JJR N
among IN N
patients NNS N
receiving VBG N
PELF NNP N
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

The DT N
toxicities NNS o
were VBD N
qualitatively RB N
different JJ N
but CC N
quantitatively RB N
similar JJ N
. . N

Both DT N
regimens VBZ N
seem VBP N
to TO N
be VB N
feasible JJ N
provided VBN N
that IN N
careful JJ N
patient JJ N
monitoring NN N
is VBZ N
assured VBN N
. . N

CONCLUSIONS NNP N
PELF NNP i
is VBZ N
significantly RB N
more RBR N
active JJ N
than IN N
FAMTX NNP i
and CC N
deserves VBZ N
further JJ N
research NN N
in IN N
the DT N
adjuvant JJ N
setting NN N
. . N

-DOCSTART- -X- O O

Omega-3 JJ i
fatty JJ i
acids NNS i
supplementation NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
double-blind JJ N
randomized NN N
, , N
placebo-controlled JJ i
pilot NN N
study NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
evidence NN N
that IN N
fatty JJ N
acid JJ N
deficiencies NNS N
or CC N
imbalances NNS N
may MD N
contribute VB N
to TO N
childhood VB p
neurodevelopmental JJ p
disorders NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
6-week JJ N
pilot NN N
trial NN N
investigating VBG N
the DT N
effects NNS N
of IN N
1.5 CD i
g/d NN i
of IN i
omega-3 JJ i
fatty JJ i
acids NNS i
( ( i
.84 JJ i
g/d NN i
eicosapentaenoic NN i
acid NN i
, , i
.7 NNP i
g/d NN i
docosahexaenoic NN i
acid NN i
) ) i
supplementation NN i
in IN N
13 CD p
children NNS p
( ( p
aged VBN p
5 CD p
to TO p
17 CD p
years NNS p
) ) p
with IN p
autistic JJ p
disorders NNS p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
. . p

The DT N
outcome NN N
measure NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
at IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
We PRP N
observed VBD N
an DT N
advantage NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
compared VBN N
with IN N
placebo NN i
for IN N
hyperactivity NN o
and CC o
stereotypy NN o
, , N
each DT N
with IN N
a DT N
large JJ N
effect NN N
size NN N
. . N

Repeated-measures NNS N
ANOVA NNP N
indicated VBD N
a DT N
trend NN N
toward IN N
superiority NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
over IN N
placebo NN N
for IN N
hyperactivity NN o
. . o

No DT N
clinically RB N
relevant JJ N
adverse JJ o
effects NNS o
were VBD N
elicited VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS VBZ N
The DT N
results NNS N
of IN N
this DT N
study NN N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
omega-3 JJ i
fatty JJ i
acids NNS i
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -X- O O

Variations NNS N
in IN N
EEG NNP o
discharges NNS o
predict VBP N
ADHD NNP N
severity NN N
within IN N
individual JJ p
Smith-Lemli-Opitz JJ p
patients NNS p
. . p

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
examine VB N
the DT N
prevalence NN N
of IN N
EEG NNP N
abnormalities NNS N
in IN N
Smith-Lemli-Opitz NNP p
syndrome NN p
( ( p
SLOS NNP p
) ) p
as RB N
well RB N
as IN N
the DT N
relationship NN N
between IN N
interictal JJ N
epileptiform NN N
discharges NNS N
( ( N
IEDs NNP N
) ) N
and CC N
within-subject JJ N
variations NNS N
in IN N
attentional JJ N
symptom NN N
severity NN N
. . N

METHODS NNP N
In IN N
the DT N
context NN N
of IN N
a DT N
clinical JJ N
trial NN N
for IN N
SLOS NNP N
, , N
we PRP N
performed VBD N
cross-sectional JJ N
and CC N
repeated-measure JJ N
observational JJ N
studies NNS N
of IN N
the DT N
relationship NN N
between IN N
EEG NNP i
findings NNS N
and CC N
cognitive/behavioral JJ N
factors NNS N
on IN N
23 CD p
children NNS p
( ( p
aged VBN p
4-17 CD p
years NNS p
) ) p
. . p

EEGs NNP i
were VBD N
reviewed VBN N
for IN N
clinical JJ N
abnormalities NNS N
, , N
including VBG N
IEDs NNP N
, , N
by IN N
readers NNS N
blinded VBD N
to TO N
participants NNS N
' POS N
behavioral NN N
symptoms NNS N
. . N

Between-group JJ N
differences NNS N
in IN N
baseline JJ N
characteristics NNS N
of IN N
participants NNS N
with IN N
and CC N
without IN N
IEDs NNP N
were VBD N
analyzed VBN N
. . N

Within-subject JJ N
analyses NNS N
examined VBD N
the DT N
association NN N
between IN N
the DT N
presence NN N
of IN N
IEDs NNP N
and CC N
changes NNS N
in IN N
attention-deficit/hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
symptoms NNS o
. . o

RESULTS NNP N
Of IN N
85 CD N
EEGs NNP N
, , N
43 CD N
( ( N
51 CD N
% NN N
) ) N
were VBD N
abnormal JJ o
, , N
predominantly RB N
because IN N
of IN N
IEDs NNP N
. . N

Only RB N
one CD N
subject NN N
had VBD N
documented VBN N
clinical JJ o
seizures NNS o
. . o

IEDs NNP N
clustered VBD N
in IN N
13 CD p
subjects NNS p
( ( p
57 CD p
% NN p
) ) p
, , p
whereas $ p
9 CD p
subjects NNS p
( ( p
39 CD p
% NN p
) ) p
had VBD p
EEGs NNP p
consistently RB p
free JJ p
of IN p
IEDs NNP p
. . p

While IN N
there EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
in IN N
sex NN o
, , o
age NN o
, , o
intellectual JJ o
disability NN o
, , o
language NN o
level NN o
, , o
or CC o
baseline VB o
ADHD NNP o
symptoms NNS o
, , o
autistic JJ o
symptoms NNS o
tended VBD N
to TO N
be VB N
more RBR N
prevalent JJ N
in IN N
the DT N
IED NNP N
group NN N
( ( N
according VBG N
to TO N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule-2 NNP o
criteria NNS o
) ) o
. . N

Within JJ N
individuals NNS N
, , N
the DT N
presence NN N
of IN N
IEDs NNP N
on IN N
a DT N
particular JJ N
EEG NNP N
predicted VBD N
, , N
on IN N
average NN N
, , N
a DT N
27 CD N
% NN N
increase NN N
in IN N
ADHD NNP o
symptom NN o
severity NN o
. . o

CONCLUSIONS NNP N
Epileptiform NNP N
discharges NNS N
are VBP N
common JJ N
in IN N
SLOS NNP N
, , N
despite IN N
a DT N
relatively RB N
low JJ N
prevalence NN N
of IN N
epilepsy NN N
. . N

Fluctuations NNS N
in IN N
the DT N
presence NN N
of IN N
epileptiform NN N
discharges NNS N
within IN N
individual JJ N
children NNS N
with IN N
a DT N
developmental JJ N
disability NN N
syndrome NN N
may MD N
be VB N
associated VBN N
with IN N
fluctuations NNS N
in IN N
ADHD NNP N
symptomatology NN N
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
clinical JJ N
seizures NNS N
. . N

-DOCSTART- -X- O O

A DT N
placebo-controlled JJ i
, , N
randomized JJ N
clinical JJ N
trial NN N
using VBG N
testosterone NN i
undecanoate NN i
with IN i
injectable JJ i
norethisterone JJ i
enanthate NN i
: : i
effect NN N
on IN N
anthropometric NN p
, , p
metabolic JJ p
and CC p
biochemical JJ p
parameters NNS p
. . p

Testosterone CD N
administered VBD N
alone RB N
or CC N
in IN N
combination NN N
with IN N
progestogens NNS N
in IN N
male JJ N
contraception NN N
induces NNS N
reversible JJ N
oligo-azoospermia JJ N
, , N
but CC N
its PRP$ N
effects NNS N
on IN N
body NN N
composition NN N
and CC N
metabolism NN N
are VBP N
less RBR N
known JJ N
. . N

We PRP N
analysed VBD p
anthropometric JJ p
and CC p
metabolic JJ p
parameters NNS p
in IN p
five CD p
groups NNS p
of IN p
10 CD p
males NNS p
: : p
four CD p
receiving VBG p
testosterone NN i
undecanoate NN i
( ( N
TU NNP N
: : N
1000 CD N
mg NN N
) ) N
plus CC i
norethisterone JJ i
enanthate NN i
( ( N
NETE NNP N
: : N
200 CD N
mg NN N
) ) N
at IN N
different JJ N
intervals NNS N
( ( N
every DT N
8 CD N
weeks NNS N
: : N
NETE-8 JJ N
; : N
every DT N
12 CD N
weeks NNS N
: : N
NETE-12 NN N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12 JJ N
; : N
every DT N
6 CD N
weeks NNS N
for IN N
12 CD N
weeks NNS N
and CC N
then RB N
TU NNP i
plus CC i
placebo JJ i
every DT N
12 CD N
weeks NNS N
: : N
NETE-6/12/0 NNP N
) ) N
and CC N
one CD N
placebo NN i
( ( N
NETE-0/0 NNP N
) ) N
for IN N
a DT N
total NN N
of IN N
48 CD N
weeks NNS N
. . N

Body NNP o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
and CC o
waist JJ o
circumference NN o
did VBD o
not RB o
change VB o
in IN N
any DT N
groups NNS N
except IN N
for IN N
the DT N
NETE-8 NNP N
in IN N
which WDT N
BMI NNP o
increased VBD o
significantly RB o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
. . N

Lean JJ o
body NN o
mass NN o
( ( o
MAMC NNP o
or CC o
AMA NNP o
) ) o
increased VBD o
significantly RB o
in IN N
the DT N
highest JJS N
hormonal JJ N
dose NN N
groups NNS N
( ( N
p JJ N
= NN N
0.04 CD N
, , N
NETE-6/12 NNP N
; : N
p VBZ N
= $ N
0.004 CD N
, , N
NETE-8 NNP N
) ) N
. . N

No UH N
differences NNS N
were VBD N
observed VBN N
in IN N
glucose JJ o
levels NNS o
, , o
insulin NN o
sensitivity NN o
index NN o
and CC o
lipid JJ o
profile NN o
as RB N
well RB N
as IN N
in IN N
biochemical JJ o
and CC o
cell NN o
count NN o
parameters NNS o
in IN N
any DT N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
NETE NNP N
and CC N
TU NNP N
for IN N
48 CD N
weeks NNS N
were VBD N
not RB N
accompanied VBN N
by IN N
any DT N
metabolic JJ o
changes NNS o
and CC o
any DT o
adverse JJ o
effects NNS o
. . o

The DT N
weight JJ o
gain NN o
of IN N
the DT N
highest JJS N
NETE JJ N
plus CC N
TU JJ N
dosage NN N
was VBD N
mainly RB N
because IN N
of IN N
gain NN N
in IN N
muscle NN N
mass NN N
. . N

-DOCSTART- -X- O O

Intraperitoneal NNP N
application NN N
of IN N
bupivacaine NN i
plus CC N
morphine NN i
for IN N
pain NN o
relief NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Intraperitoneal NNP N
administration NN N
of IN N
a DT N
local JJ N
anaesthetic NN N
in IN N
combination NN N
with IN N
an DT N
opioid NN i
, , N
for IN N
the DT N
relief NN N
of IN N
postoperative JJ o
pain NN o
, , N
has VBZ N
already RB N
been VBN N
reported VBN N
except IN N
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

This DT N
study NN N
was VBD N
aimed VBN N
at IN N
assessing VBG N
the DT N
analgesic JJ N
effect NN N
of IN N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
bupivacaine NN i
and CC i
morphine NN i
in IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
. . p

METHODS NNP N
At IN N
the DT N
end NN N
of IN N
laparoscopic JJ N
cholecystectomy NN N
, , N
in IN N
a DT N
double-blind NN N
, , N
randomized JJ N
manner NN N
, , N
one CD N
of IN N
the DT N
following JJ N
injections NNS N
was VBD N
given VBN N
intraperitoneally RB N
. . N

There EX N
were VBD N
30 CD p
patients NNS p
in IN p
each DT p
group NN p
: : p
Group NNP N
1 CD N
, , N
physiological JJ i
saline NN i
30 CD N
mL NN N
; : N
Group NNP N
2 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
; : N
Group NNP N
3 CD N
, , N
bupivacaine VBP i
0.25 CD N
% NN N
30 CD N
mL NN N
plus CC i
morphine JJ i
2 CD N
mg NN N
. . N

In IN N
addition NN N
, , N
Group NNP N
2 CD N
received VBD N
2 CD N
mg NNS N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
morphine NN i
in IN N
2 CD N
mL NNS N
saline NN i
, , N
and CC N
Groups NNP N
1 CD N
and CC N
3 CD N
, , N
2 CD N
mL NN N
saline NN i
intravenously RB N
. . N

Patients NNS N
' POS N
postoperative JJ o
pain NN o
was VBD N
evaluated VBN N
using VBG N
a DT N
visual JJ o
analogue NN o
scale NN o
and CC N
a DT N
verbal JJ o
rating NN o
score NN o
. . o

The DT N
postoperative JJ N
analgesic JJ N
requirement NN N
was VBD N
assessed VBN N
by IN N
the DT N
total JJ N
dose NN N
of IN N
metamizol NN o
administered VBN N
by IN N
an DT N
i.v NN N
. . N

patient-controlled JJ o
analgesia NN o
( ( o
PCA NNP o
) ) o
device NN N
. . N

Pain NNP o
, , o
vital JJ o
signs NNS o
, , o
supplemental JJ o
analgesic JJ o
consumption NN o
and CC o
side-effects NNS o
were VBD N
recorded VBN N
for IN N
all DT N
patients NNS N
for IN N
24 CD N
h. JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
three CD N
groups NNS N
regarding VBG N
pain NN o
scores NNS o
( ( N
at IN N
rest NN N
and CC N
coughing VBG N
) ) N
during IN N
the DT N
study NN N
except IN N
in IN N
the DT N
first JJ N
2 CD N
h NN N
, , N
when WRB N
scores NNS N
were VBD N
lower JJR N
for IN N
patients NNS N
receiving VBG N
intraperitoneal JJ N
bupivacaine NN i
plus CC N
i.v NN N
. . N

morphine NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Supplemental JJ o
consumption NN o
of IN o
metamizol NN o
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
Group NNP N
3 CD N
than IN N
in IN N
Group NNP N
1 CD N
during IN N
the DT N
first JJ N
6 CD N
h NN N
after IN N
surgery NN N
. . N

However RB N
, , N
the DT N
cumulative JJ o
doses NNS o
of IN N
metamizol NN N
were VBD N
also RB N
lower JJR N
in IN N
Group NNP N
2 CD N
than IN N
in IN N
Groups NNP N
1 CD N
and CC N
3 CD N
over IN N
the DT N
entire JJ N
study NN N
( ( N
2025 CD N
+/- NN N
1044 CD N
mg NN N
vs. FW N
4925 CD N
+/- JJ N
1238 CD N
and CC N
4125 CD N
+/- JJ N
1276mg CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
, , N
the DT N
intraperitoneal JJ N
administration NN N
of IN N
morphine JJ i
plus CC N
bupivacaine JJ i
0.25 CD N
% NN N
reduced VBD N
the DT N
analgesic JJ o
requirements NNS o
during IN N
the DT N
first JJ N
6 CD N
postoperative JJ N
hours NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
intraperitoneal JJ N
bupivacaine JJ i
0.25 CD N
% NN N
and CC N
i.v NN N
. . N

morphine NN i
was VBD N
more RBR N
effective JJ N
for IN N
treatment NN N
of IN N
pain NN o
after IN N
laparoscopic JJ p
cholecystectomy NN p
. . p

-DOCSTART- -X- O O

First-line JJ i
cisplatin NN i
with IN i
docetaxel NN i
or CC i
vinorelbine NN i
in IN N
patients NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
: : p
a DT N
quality NN p
of IN p
life NN p
directed VBN p
phase NN p
II NNP p
randomized VBD p
trial NN p
of IN p
Gruppo NNP p
Oncologico NNP p
Italia NNP p
Meridionale NNP p
. . p

BACKGROUND NNP N
Quality NNP o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
has VBZ N
gained VBN N
greater JJR N
importance NN N
in IN N
the DT N
management NN N
of IN N
metastatic JJ p
non-small-cell JJ p
lung NN p
cancer NN p
due JJ N
to TO N
the DT N
palliative JJ N
nature NN N
of IN N
treatment NN N
. . N

Docetaxel NNP i
( ( i
DCT NNP i
) ) i
and CC i
cisplatin NN i
( ( i
CDDP NNP i
) ) i
doublet NN i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
associated VBN N
to TO N
a DT N
better JJR N
QoL NNP N
than IN N
the DT N
weekly JJ N
vinorelbine NN i
( ( i
VNR NNP i
) ) i
and CC i
CDDP NNP i
regimen NNS N
. . N

Recently RB N
a DT N
newer NN N
more RBR N
tolerated JJ N
schedule NN N
of IN N
the DT N
VNR/CDDP NNP i
regimen NN N
has VBZ N
been VBN N
published VBN N
and CC N
is VBZ N
widely RB N
employed VBN N
in IN N
medical JJ N
practice NN N
. . N

The DT N
impact NN N
of IN N
these DT N
regimens NNS N
on IN N
patients NNS N
' POS N
QoL NNP N
as RB N
well RB N
as IN N
symptoms NNS o
control NN o
and CC o
type NN o
and CC N
grading VBG N
chemo-related JJ N
side-effects NNS o
has VBZ N
been VBN N
compared VBN N
prospectically RB N
. . N

METHODS NNP N
Patients NNPS p
received VBD N
CDDP NNP i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
plus CC i
DCT NNP i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
on IN N
day NN N
1 CD N
every DT N
weeks NNS N
( ( N
arm IN N
A NNP N
) ) N
or CC N
CDDP $ i
80 CD i
mg/m NN i
( ( i
2 CD i
) ) i
on IN i
day NN i
1 CD i
plus CC i
VNR NNP i
30 CD i
mg/m NN i
( ( i
2 CD i
) ) i
day NN N
1 CD N
and CC N
8 CD N
every DT N
3 CD N
weeks NNS N
( ( N
arm NN N
B NNP N
) ) N
. . N

G-CSF NNP i
and/or JJ i
EPO NNP i
were VBD N
employed VBN N
as IN N
needed VBN N
. . N

Health-related JJ o
QoL NNP o
was VBD N
assessed VBN N
at IN N
entry NN N
and CC N
after IN N
every DT N
cycle NN N
by IN N
the DT N
EORTC-QLQ-C30 NNP N
and CC N
LC13 NNP o
questionnaires NNS o
, , o
toxicity NN o
by IN N
the DT N
NCI-NCCN NNP N
CTC NNP N
vs NN N
2 CD N
, , N
and CC N
intent-to-treat JJ N
objective JJ o
response NN o
by IN N
the DT N
Recist NNP N
criteria NNS N
. . N

RESULTS VB N
The DT N
QoL NNP o
questionnaires NNS o
were VBD N
completed VBN N
by IN N
37 CD p
pts NNS p
( ( p
88 CD p
% NN p
) ) p
in IN p
the DT p
DCT/CDDP NNP i
arm NN p
and CC N
39 CD p
pts NNS p
( ( p
87 CD p
% NN p
) ) p
in IN p
the DT p
VNR/CDDP NNP i
one NN p
. . p

Baseline JJ N
mean JJ N
scores NNS N
and CC N
rates NNS N
at IN N
which WDT N
pts NNS N
failed VBD N
to TO N
complete VB N
QoL NNP N
assessment NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
arms NNS N
. . N

Global NNP o
health NN o
status NN o
of IN N
the DT N
EORTC NNP o
QLQ-C30 NNP o
scale NN o
and CC N
specific JJ o
symptoms NNS o
control NN o
( ( N
LC13 NNP N
module NN N
) ) N
improved VBD N
during IN N
treatment NN N
without IN N
any DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
arms NNS N
. . N

Emotional JJ o
functioning NN o
remained VBD N
stable JJ N
in IN N
both DT N
groups NNS N
during IN N
treatment NN N
, , N
whereas JJ N
physical JJ o
and CC o
role NN o
improved VBN N
slightly RB N
. . N

In IN N
the DT N
DCT/CDDP NNP i
arm NN N
14 CD N
pts NNS N
( ( N
33 CD N
% NN N
; : N
95 CD N
% NN N
CL NNP N
24-40 CD N
% NN N
) ) N
had VBD N
PR NNP N
, , N
and CC N
10 CD N
( ( N
24 CD N
% NN N
) ) N
SD NNP N
for IN N
a DT N
57 CD N
% NN N
TGCR NNP N
. . N

In IN N
the DT N
VNR/CDDP NNP i
arm NN N
12 CD N
pts NNS N
( ( N
27 CD N
% NN N
) ) N
achieved VBD N
PR NNP o
, , N
18 CD N
( ( N
41 CD N
% NN N
) ) N
SD VBZ N
a DT N
68 CD N
% NN N
TGCR NNP N
. . N

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ o
time-to-progression NN o
was VBD N
4.2 CD N
months NNS N
in IN N
the DT N
DCT/CDDP NNP i
arm NN N
and CC N
4.5 CD N
months NNS N
in IN N
the DT N
VNR/CDDP NNP i
one CD N
, , N
and CC N
median JJ o
overall JJ o
survival NN o
was VBD N
12.1 CD N
( ( N
range VB N
1-26+ JJ N
months NNS N
) ) N
and CC N
12.5 CD N
months NNS N
( ( N
range VB N
1-28+ JJ N
months NNS N
) ) N
for IN N
DCT/CDDP NNP i
and CC N
VNR/CDDP NNP i
arms NNS N
, , N
respectively RB N
. . N

Febrile NNP o
neutropenia JJ o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
VNR/CDDP NNP i
arm NN N
( ( N
p=0.02 NN N
) ) N
as RB N
well RB N
as IN N
G3-4 NNP N
anemia NN o
( ( N
p=0.005 NN N
) ) N
and CC N
G-CSF/EPO NNP N
use NN N
( ( N
p=0.019 NN N
) ) N
. . N

CONCLUSIONS NNP N
Global NNP o
and CC o
specific JJ o
health-related JJ o
QoL NNP o
data NNS N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
with IN N
no DT N
statistically RB N
significant JJ N
difference NN N
. . N

Efficacy NN o
measures NNS o
, , o
overall JJ o
response NN o
rate NN o
, , o
time-to-progression NN o
and CC o
overall JJ o
survival NN o
were VBD N
equivalent JJ N
in IN N
both DT N
arms NNS N
. . N

However RB N
, , N
severe JJ o
anemia NN o
and CC o
febrile JJ o
neutropenia NN o
are VBP N
statistically RB N
more RBR N
frequent JJ N
in IN N
the DT N
VNR/CDDP NNP i
arm NN N
than IN N
in IN N
the DT N
DCT/CDDP NNP i
one NN N
. . N

These DT N
data NNS N
should MD N
be VB N
considered VBN N
in IN N
treatment NN N
decision-making NN N
for IN N
pts NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
and CC N
for IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
with IN N
chemotherapy NN N
plus CC N
biologics NNS N
. . N

-DOCSTART- -X- O O

Can MD N
incentives VB i
undermine JJ N
intrinsic JJ o
motivation NN o
to TO N
participate VB N
in IN N
epidemiologic JJ N
surveys NNS N
? . N
Response JJ N
rates NNS N
to TO N
surveys NNS N
are VBP N
decreasing VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
use NN i
of IN i
lottery JJ i
tickets NNS i
as IN i
incentives NNS i
in IN N
an DT N
epidemiologic JJ p
control NN p
group NN p
. . p

A DT N
self-administered JJ p
questionnaire NN p
was VBD p
sent VBN p
to TO p
parents NNS p
in IN p
the DT p
municipality NN p
of IN p
Stockholm NNP p
, , p
Sweden NNP p
, , p
who WP p
were VBD p
to TO p
be VB p
used VBN p
as IN p
a DT p
control NN p
group NN p
in IN p
a DT p
study NN p
addressing VBG p
stress NN p
in IN p
parents NNS p
of IN p
children NNS p
with IN p
cancer NN p
. . p

A DT N
stratified JJ N
random JJ N
sample NN N
of IN N
450 CD p
parents NNS p
were VBD N
randomized VBN N
into IN N
three CD i
incentive JJ i
groups NNS i
: : i
( ( i
a DT i
) ) i
no DT i
incentive NN i
; : i
( ( i
b NN i
) ) i
a DT i
promised JJ i
incentive NN i
of IN i
one CD i
lottery NN i
ticket NN i
to TO i
be VB i
received VBN i
upon IN i
reply NN i
; : i
( ( i
c NN i
) ) i
a DT i
promised JJ i
incentive NN i
of IN i
one CD i
lottery NN i
ticket NN i
to TO i
be VB i
received VBN i
upon IN i
reply NN i
and CC i
an DT i
additional JJ i
lottery NN i
ticket NN i
upon IN i
reply NN i
within IN i
1 CD i
week NN i
. . i

The DT N
overall JJ N
response NN o
rate NN o
across IN N
the DT N
three CD N
groups NNS N
was VBD N
65.3 CD N
% NN N
. . N

The DT N
response NN o
rate NN o
was VBD N
highest JJS N
in IN N
the DT N
no DT i
incentive NN i
group NN i
( ( N
69.3 CD N
% NN N
) ) N
and CC N
lowest JJS N
in IN N
the DT N
one CD i
plus CC i
one CD i
lottery NN i
ticket NN i
group NN i
( ( N
62.0 CD N
% NN N
) ) N
. . N

In IN N
a DT N
survival JJ o
analysis NN o
, , N
the DT N
difference NN N
between IN N
the DT N
two CD N
response NN N
curves NNS N
was VBD N
significant JJ N
by IN N
the DT N
log-rank JJ N
test NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
with IN N
the DT N
no DT N
incentive NN N
group NN N
having VBG N
a DT N
shorter JJR N
time NN N
to TO N
response NN N
than IN N
the DT N
incentive NN i
group NN i
. . i

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
lottery JJ i
tickets NNS i
as IN N
incentives NNS N
to TO N
increase VB o
participation NN o
in IN N
a DT N
mail NN o
questionnaire NN o
among IN N
parents NNS N
may MD N
be VB N
less RBR N
valuable JJ N
or CC N
even RB N
harmful JJ N
. . N

Incentives NNS i
may MD N
undermine VB N
motivation NN o
in IN N
studies NNS N
in IN N
which WDT N
the DT N
intrinsic JJ N
motivation NN N
of IN N
the DT N
respondents NNS p
is VBZ N
already RB N
high JJ N
. . N

-DOCSTART- -X- O O

Augmented VBN i
soft JJ i
tissue NN i
mobilization NN i
vs IN N
natural JJ i
history NN i
in IN N
the DT N
treatment NN N
of IN N
lateral JJ N
epicondylitis NN N
: : N
a DT N
pilot NN N
study NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
augmented JJ i
soft JJ i
tissue NN i
mobilization NN i
( ( N
ASTM NNP N
) ) N
on IN N
the DT N
treatment NN N
of IN N
lateral JJ N
epicondylitis NN N
. . N

METHODS NNP N
This DT N
randomized VBD N
clinical JJ N
study NN N
assessed VBD N
27 CD p
subjects NNS p
( ( p
12 CD p
men NNS p
and CC p
15 CD p
women NNS p
) ) p
with IN p
lateral JJ p
epicondylitis NN p
and CC N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD p
groups NNS p
. . p

The DT i
experimental JJ i
group NN i
( ( i
n JJ i
= NNP i
15 CD i
) ) i
received VBD i
ASTM NNP i
twice RB i
a DT i
week NN i
for IN i
5 CD i
weeks NNS i
. . i

The DT i
subjects NNS i
of IN i
the DT i
control NN i
group NN i
( ( i
n JJ i
= NNP i
12 CD i
) ) i
received VBN i
advice NN i
on IN i
the DT i
natural JJ i
evolution NN i
of IN i
lateral JJ i
epicondylitis NN i
, , i
computer NN i
ergonomics NNS i
, , i
and CC i
stretching VBG i
exercises NNS i
. . i

Patient-rated JJ i
outcome NN i
was VBD i
assessed VBN i
at IN i
baseline NN i
and CC i
after IN i
6 CD i
weeks NNS i
and CC i
3 CD i
months NNS i
using VBG i
a DT i
visual JJ i
analog NN i
scale NN i
and CC i
the DT i
Patient-Rated JJ i
Tennis NNP i
Elbow NNP i
Evaluation NNP i
. . i

The DT N
function NN N
was VBD N
assessed VBN N
using VBG N
the DT N
pain-free JJ o
grip NN o
strength NN o
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
improvements NNS o
in IN o
pain-free JJ o
grip NN o
strength NN o
, , o
visual JJ o
analog NN o
scale NN o
, , o
and CC o
Patient-Rated JJ o
Tennis NNP o
Elbow NNP o
Evaluation NNP o
. . o

Sample NNP N
size NN N
for IN N
larger JJR N
future NN N
randomized VBD N
clinical JJ N
trial NN N
was VBD N
116 CD N
participants NNS N
. . N

CONCLUSION VB N
A NNP N
larger JJR N
study NN N
investigating VBG N
the DT N
same JJ N
hypothesis NN N
is VBZ N
warranted VBN N
to TO N
detect VB N
difference NN N
in IN N
the DT N
effects NNS N
of IN N
these DT N
treatments NNS N
strategies NNS N
. . N

The DT N
study NN N
design NN N
is VBZ N
feasible JJ N
, , N
and CC N
minor JJ N
improvements NNS N
will MD N
help VB N
to TO N
minimize VB N
the DT N
potential JJ N
bias NN N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
a DT N
controlled VBN i
heated VBN i
breathing VBG i
tube NN i
humidifier NN i
on IN N
sleep JJ o
quality NN o
during IN N
CPAP NNP i
therapy NN i
in IN p
a DT p
cool JJ p
sleeping NN p
environment NN p
. . p

There EX N
are VBP N
conflicting VBG N
data NNS N
on IN N
the DT N
effect NN N
of IN N
adding VBG N
a DT N
heated VBN i
humidifier NN i
to TO N
nasal RB N
continuous JJ i
positive JJ i
airway NN i
pressure NN i
( ( i
CPAP NNP i
) ) i
therapy NN i
for IN N
patients NNS p
with IN p
obstructive JJ p
sleep JJ p
apnoea NN p
syndrome NN p
( ( p
OSAS NNP p
) ) p
. . p

The DT N
effects NNS N
of IN N
heated JJ N
humidification NN N
on IN N
sleep JJ o
quality NN o
and CC o
treatment NN o
side-effects NNS o
for IN N
patients NNS N
who WP N
prefer VBP N
a DT N
cold JJ N
bedroom NN N
environment NN N
have VBP N
not RB N
been VBN N
studied VBN N
. . N

A DT N
randomised JJ N
, , N
controlled VBD N
crossover RB N
trial NN N
involving VBG N
19 CD p
patients NNS p
with IN p
a DT p
first-ever JJ p
diagnosis NN p
of IN p
OSAS NNP p
measured VBD N
the DT N
effect NN N
of IN N
conventional JJ i
heated JJ i
humidification NN i
added VBD i
to TO i
CPAP NNP i
compared VBN N
with IN N
a DT N
controlled VBN i
heated VBN i
breathing VBG i
tube NN i
humidifier NN i
( ( i
ThermoSmart NNP i
( ( i
R NNP i
) ) i
; : i
Fisher NNP N
and CC N
Paykel NNP N
Healthcare NNP N
, , N
Auckland NNP N
, , N
New NNP N
Zealand NNP N
) ) N
on IN N
sleep JJ o
quality NN o
. . o

During IN N
the DT N
night NN N
in IN N
the DT N
sleep JJ N
laboratory NN N
at IN N
a DT N
mean JJ N
room NN N
temperature NN N
of IN N
14 CD N
degrees NNS N
C NNP N
, , N
less JJR N
condensation NN o
formed VBN N
with IN N
the DT N
controlled VBN i
heated VBD i
breathing VBG i
tube NN i
humidifier NN i
( ( N
1.9 CD N
mL NN N
versus NN N
35.3 CD N
mL NN N
) ) N
in IN N
the DT N
delivery NN N
system NN N
. . N

In IN N
addition NN N
, , N
the DT N
total JJ o
sleep JJ o
time NN o
, , o
time NN o
spent VBN o
in IN o
sleep JJ o
stages NNS o
3 CD o
and CC o
4 CD o
, , o
and CC o
rapid JJ o
eye NN o
movement NN o
sleep JJ o
phases NNS o
were VBD N
significantly RB N
longer RBR N
and CC N
the DT N
overall JJ o
side-effect JJ o
score NN o
was VBD N
lower JJR N
than IN N
with IN N
conventional JJ N
heated JJ N
humidification NN N
. . N

Patients NNS N
on IN N
nasal JJ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
desiring VBG N
a DT N
cool JJ N
bedroom NN N
temperature NN N
could MD N
benefit VB N
from IN N
controlled VBN i
heated VBN i
breathing VBG i
tube JJ i
humidification NN i
technology NN i
( ( N
with IN N
inputs NNS N
from IN N
ambient JJ N
temperature NN N
, , N
set VBN N
pressure NN N
and CC N
flow NN N
) ) N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
the DT N
electrothermal JJ i
bipolar JJ i
vessel NN i
system NN i
( ( i
EBVS NNP i
) ) i
in IN N
laparoscopic JJ N
adrenalectomy NN N
: : N
a DT N
prospective JJ N
study NN N
. . N

BACKGROUND NNP N
Since IN N
laparoscopic NN p
adrenalectomy NN p
( ( p
LA NNP p
) ) p
has VBZ N
been VBN N
adopted VBN N
as IN N
the DT N
gold JJ N
standard NN N
for IN N
the DT N
treatment NN N
of IN N
adrenal JJ N
diseases NNS N
, , N
the DT N
development NN N
of IN N
technology NN N
for IN N
vascular JJ N
control NN N
and CC N
dissection NN N
manoeuvres NNS N
, , N
amongst VBZ N
other JJ N
things NNS N
, , N
may MD N
play VB N
a DT N
pivotal JJ N
role NN N
in IN N
its PRP$ N
further JJ N
improvement NN N
. . N

We PRP N
report VBP N
our PRP$ N
experience NN N
with IN N
the DT N
electrothermal JJ i
bipolar JJ i
vessel NN i
sealing NN i
( ( i
EBVS NNP i
) ) i
device NN N
for IN N
LA NNP N
. . N

METHODS NNP N
From IN p
January NNP p
2004 CD p
to TO p
January NNP p
2006 CD p
, , p
50 CD p
patients NNS p
( ( p
pts NNS p
) ) p
undergoing VBG p
LA NNP p
were VBD N
selected VBN N
and CC N
randomized VBN N
for IN N
use NN N
of IN N
the DT N
EBVS NNP i
( ( i
25 CD i
pts NNS i
, , i
group NN i
A NNP i
) ) i
versus IN i
the DT i
UltraSonic NNP i
Shears NNP i
( ( i
USS NNP i
) ) i
device NN i
( ( N
25 CD N
pts NNS N
, , N
group NN N
B NNP N
) ) N
. . N

Age NNP N
, , N
sex NN N
, , N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
, , N
previous JJ N
surgery NN N
and CC N
associated VBN N
diseases NNS N
were VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
main JJ N
surgical JJ N
parameters NNS N
collected VBN N
for IN N
each DT N
patient NN N
( ( N
pt NN N
) ) N
concerned VBD N
operative JJ N
time NN N
, , N
major JJ N
and CC N
minor JJ N
complications NNS N
, , N
conversion NN N
rate NN N
, , N
blood NN N
loss NN N
, , N
hospital JJ N
stay NN N
and CC N
histology NN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT o
mortality NN o
in IN N
either DT N
group NN N
. . N

The DT N
right JJ N
adrenalectomy NN N
mean VB o
operative JJ o
time NN o
( ( o
OpT NNP o
) ) o
was VBD N
51.8 CD N
mins NNS N
( ( N
range VB N
40-90 JJ N
mins NNS N
) ) N
and CC N
68.6 CD N
mins NNS N
( ( N
range VB N
50-130 NNP N
mins NNS N
) ) N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

The DT N
left JJ o
adrenalectomy JJ o
mean JJ o
OpT NNP o
was VBD N
72.2 CD N
mins NNS N
( ( N
range VB N
55-100 NNP N
mins NNS N
) ) N
and CC N
94 CD N
mins NNS N
( ( N
range VB N
65-140 NNP N
mins NNS N
) ) N
for IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
mean JJ o
blood NN o
loss NN o
was VBD N
83 CD N
ml NN N
( ( N
group NN N
A NNP N
) ) N
and CC N
210 CD N
ml NN N
( ( N
group NN N
B NNP N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Complications NNS N
were VBD N
not RB N
different JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
mean JJ o
hospital NN o
stay NN o
was VBD N
2.9 CD N
and CC N
3.1 CD N
days NNS N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P NNP N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
EBVS NNP N
in IN N
LA NNP N
may MD N
provide VB N
a DT N
significantly RB N
short JJ o
operating NN o
time NN o
and CC o
blood NN o
loss NN o
. . o

-DOCSTART- -X- O O

Untoward NNP N
effects NNS N
of IN N
fenfluramine NN i
in IN N
autistic JJ p
children NNS p
. . p

Several JJ N
recent JJ N
studies NNS N
have VBP N
described VBN N
the DT N
benefits NNS N
of IN N
fenfluramine NN i
for IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
infantile JJ p
autism NN p
. . p

No DT N
large JJ N
surveys NNS N
of IN N
side JJ N
effects NNS N
of IN N
this DT N
drug NN N
have VBP N
been VBN N
reported VBN N
in IN N
autistic JJ p
children NNS p
. . p

To TO N
evaluate VB N
the DT N
untoward JJ N
effects NNS N
of IN N
fenfluramine NN i
in IN N
children NNS p
with IN p
autism NN p
, , p
12 CD p
subjects NNS p
were VBD N
systematically RB N
studied VBN N
. . N

Medication NNP N
was VBD N
administered VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
. . N

Parents NNS N
were VBD N
trained VBN N
in IN N
monitoring VBG N
untoward JJ N
effects NNS N
. . N

These DT N
observations NNS N
were VBD N
compiled VBN N
in IN N
detailed JJ N
daily JJ N
notes NNS N
. . N

In IN p
addition NN p
, , p
four CD p
cases NNS p
describing VBG p
unusual JJ p
effects NNS p
found VBN p
in IN p
a DT p
sample NN p
of IN p
170 CD p
patients NNS p
treated VBN p
with IN p
fenfluramine NN i
are VBP p
also RB p
reported VBN p
. . p

In IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
listlessness NN N
, , N
food NN o
refusal NN o
, , o
and CC o
stomach NN o
upset NN o
were VBD N
frequently RB N
seen VBN N
. . N

A DT N
different JJ N
pattern NN N
of IN N
untoward JJ o
effects NNS o
was VBD N
seen VBN N
in IN N
the DT N
final JJ N
14 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Irritability NNP o
, , o
agitation NN o
, , o
and CC o
crying VBG o
along RB o
with IN o
continued VBN o
food NN o
refusal NN o
were VBD N
noted VBN N
. . N

The DT N
subjects NNS N
lost VBD N
2.1 CD N
% NN N
of IN N
body NN o
weight NN o
during IN N
active JJ N
drug NN N
phase NN N
, , N
but CC N
there RB N
was VBD N
a DT N
rebound NN o
weight NN o
gain NN o
during IN N
the DT N
subsequent JJ N
placebo NN i
phase NN N
. . N

A DT N
thorough JJ N
understanding NN N
of IN N
fenfluramine NN i
's POS i
side NN N
effects NNS N
and CC N
adverse JJ N
reactions NNS N
is VBZ N
necessary JJ N
so RB N
as IN N
to TO N
differentiate VB N
them PRP N
from IN N
the DT N
multiple NN N
symptoms NNS N
inherent NN N
in IN N
the DT N
syndrome NN N
of IN N
autism NN p
. . p

-DOCSTART- -X- O O

Impact NN N
of IN N
different JJ N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
receptor NN N
inhibitors NNS N
among IN N
diabetic JJ p
patients NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
: : p
: : N
Do VB N
Tirofiban NNP N
and CC N
ReoPro NNP N
Give NNP N
Similar NNP N
Efficacy NNP N
Outcomes NNP N
Trial NNP N
( ( N
TARGET NNP N
) ) N
1-year JJ N
follow-up NN N
. . N

BACKGROUND IN N
The DT N
platelet NN N
glycoprotein NN N
IIb/IIIa NNP N
receptor NN N
inhibitor NN N
abciximab NN N
, , N
a DT N
monoclonal JJ N
antibody NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
early JJ N
and CC N
late JJ N
outcomes NNS N
among IN N
diabetic JJ p
patients NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

It PRP N
is VBZ N
unknown JJ N
whether IN N
small-molecule JJ N
agents NNS N
confer VBP N
similar JJ N
benefits NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
In IN p
18 CD p
countries NNS p
, , p
4809 CD p
patients NNS p
undergoing VBG p
PCI NNP p
with IN p
stent JJ p
implantation NN p
were VBD N
randomized VBN N
to TO N
tirofiban VB i
or CC i
abciximab VB i
. . i

At IN N
the DT N
time NN N
of IN N
enrollment NN N
, , N
patients NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
diabetes NNS N
status NN N
. . N

As IN N
compared VBN N
with IN N
non-diabetic JJ N
patients NNS N
, , N
patients NNS N
with IN N
diabetes NNS N
( ( N
n=1117 NN N
) ) N
showed VBD N
similar JJ N
30-day JJ N
ischemic JJ N
outcomes NNS N
, , N
an DT N
increased JJ N
incidence NN o
of IN o
any DT o
target NN o
vessel NN o
revascularization NN o
( ( o
TVR NNP o
) ) o
at IN N
6 CD N
months NNS N
( ( N
10.3 CD N
% NN N
versus IN N
7.8 CD N
% NN N
; : N
P= NNP N
0.008 CD N
) ) N
, , N
and CC N
a DT N
trend NN N
toward IN N
higher JJR o
1-year JJ o
mortality NN o
( ( N
2.5 CD N
% NN N
versus IN N
1.6 CD N
% NN N
; : N
P=0.056 NNP N
) ) N
. . N

Among IN N
diabetic JJ N
patients NNS N
randomized VBN N
to TO N
tirofiban VB N
( ( N
n=560 NN N
) ) N
, , N
the DT N
incidence NN o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
( ( o
MI NNP o
) ) o
, , o
or CC o
urgent JJ o
TVR NNP o
at IN N
30 CD N
days NNS N
was VBD N
6.2 CD N
% NN N
, , N
and CC N
among IN N
those DT N
randomized VBN N
to TO N
abciximab VB N
( ( N
n=557 NN N
) ) N
it PRP N
was VBD N
5.4 CD N
% NN N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1.16 CD N
; : N
P=0.540 NNP N
) ) N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
composite NN N
of IN N
death NN o
, , o
MI NNP o
, , o
or CC o
any DT o
TVR NNP o
occurred VBD N
in IN N
15.7 CD N
% NN N
and CC N
in IN N
16.9 CD N
% NN N
of IN N
tirofiban NN N
and CC N
abciximab NN N
patients NNS N
, , N
respectively RB N
( ( N
HR NNP N
0.93 CD N
; : N
P=0.610 NNP N
) ) N
. . N

Any DT N
TVR NNP o
occurred VBD N
in IN N
9.5 CD N
% NN N
and CC N
11.1 CD N
% NN N
, , N
respectively RB N
( ( N
HR NNP N
0.84 CD N
; : N
P= NNP N
0.366 CD N
) ) N
. . N

The DT N
1-year JJ o
mortality NN o
was VBD N
2.1 CD N
% NN N
in IN N
the DT N
tirofiban NN N
group NN N
and CC N
2.9 CD N
% NN N
in IN N
the DT N
abciximab NN N
group NN N
( ( N
HR NNP N
0.74 CD N
; : N
P= NNP N
0.436 CD N
) ) N
. . N

CONCLUSIONS NNP N
Among IN N
diabetic JJ p
patients NNS p
undergoing VBG p
PCI NNP p
, , N
tirofiban NN N
and CC N
abciximab NN N
were VBD N
associated VBN N
with IN N
comparable JJ N
event NN N
rates NNS N
, , N
including VBG N
similar JJ N
rates NNS N
of IN N
6-month JJ N
TVR NNP N
and CC N
1-year JJ N
mortality NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
non-glycoprotein JJ N
IIb/IIIa NNP N
properties NNS N
of IN N
abciximab NNS N
do VBP N
not RB N
translate VB N
into IN N
a DT N
discernible JJ N
long-term JJ N
clinical JJ N
benefit NN N
among IN N
diabetic JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

Locomoting-to-reach NN i
: : i
information NN N
variables NNS N
and CC N
control NN N
strategies NNS N
for IN N
nested JJ N
actions NNS N
. . N

Locomoting-to-reach NNP i
is VBZ N
a DT N
basic JJ N
perception/action NN N
behavior NN N
that WDT N
requires VBZ N
visual JJ N
information NN N
for IN N
the DT N
control NN N
of IN N
both DT N
locomotion NN N
and CC N
reaching VBG N
components NNS N
. . N

We PRP N
investigated VBD N
the DT N
visual JJ N
information NN N
and CC N
the DT N
control NN N
strategies NNS N
used VBN N
to TO N
guide VB N
both PDT N
the DT N
head NN N
and CC N
the DT N
hand NN N
on IN N
approach NN N
to TO N
a DT N
target NN N
in IN N
a DT N
locomotion-to-reach JJ i
task NN i
. . i

In IN N
this DT N
study NN N
, , N
participants NNS p
were VBD p
required VBN p
to TO p
locomote VB i
in IN i
the DT i
dark NN i
to TO i
a DT i
lit NN i
target NN i
in IN i
three CD i
different JJ i
conditions NNS i
: : i
monocular JJ i
vision/target NN i
with IN i
image NN i
size NN i
, , i
binocular JJ i
vision/target NN i
with IN i
image NN i
size NN i
, , i
and CC i
binocular JJ i
vision/point-light JJ i
target NN i
( ( i
without IN i
image NN i
size NN i
) ) i
. . i

In IN N
task NN N
one CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
eyes NNS N
to TO N
the DT N
target NN N
. . N

In IN N
task NN N
two CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
outstretched JJ N
hand NN N
to TO N
the DT N
target NN N
. . N

Movement JJ o
trajectories NNS o
for IN N
both DT N
tasks NNS N
were VBD N
analyzed VBN N
. . N

Results NNP N
show VBP N
that IN N
participants NNS p
were VBD N
significantly RB N
more RBR N
accurate JJ o
when WRB o
binocular JJ o
information NN o
was VBD o
present JJ o
. . o

In IN N
both DT N
tasks NNS N
, , N
participants NNS N
were VBD N
found VBN N
to TO N
use VB N
a DT N
proportional JJ o
rate NN o
control NN o
strategy NN o
rather RB o
than IN o
a DT o
constant JJ o
? . o
strategy NN o
. . o

In IN N
the DT o
walk-to-reach NN o
task NN o
, , o
they PRP N
used VBD o
monocular JJ o
and/or NN o
binocular NN o
? . o
information NN o
to TO o
guide VB o
the DT o
head NN o
and CC o
then RB N
switched VBD N
to TO N
using VBG o
relative JJ o
disparity NN o
? . o
to TO o
guide VB o
the DT o
hand NN o
to TO o
final JJ o
target NN o
acquisition NN o
, , o
switching VBG o
when WRB N
the DT N
hand NN N
centric NN N
? . N
became VBD N
less JJR N
than IN N
the DT N
head NN N
centric JJ N
?. NNP N
Dynamical NNP N
models NNS N
of IN N
the DT N
information NN N
and CC N
control NN N
strategies NNS N
were VBD N
used VBN N
to TO N
perform VB o
simulations NNS o
that WDT o
were VBD N
found VBN N
to TO N
fit VB N
the DT N
data NN N
well RB N
. . N

The DT N
conclusion NN N
is VBZ N
that IN N
proportional JJ o
rate NN o
control NN o
is VBZ o
used VBN o
sequentially RB N
with IN N
head NN o
centric NN o
, , o
then RB o
hand-centric JJ o
?-based JJ o
information NN o
, , o
using VBG o
at IN N
each DT N
moment NN N
the DT o
? . o
with IN N
the DT N
smallest JJS N
value NN N
. . N

-DOCSTART- -X- O O

Implementing VBG N
a DT N
simplified JJ i
neonatal JJ i
resuscitation NN i
protocol-helping JJ i
babies NNS p
breathe VBP p
at IN p
birth NN p
( ( N
HBB NNP N
) ) N
- : N
at IN N
a DT N
tertiary JJ N
level NN N
hospital NN N
in IN N
Nepal NNP p
for IN N
an DT N
increased JJ N
perinatal NN o
survival NN o
. . o

BACKGROUND NNP N
Reducing NNP N
neonatal JJ o
death NN o
has VBZ N
been VBN N
an DT N
emerging VBG N
challenge NN N
in IN N
low JJ p
and CC p
middle JJ p
income NN p
countries NNS p
in IN N
the DT N
past JJ N
decade NN N
. . N

The DT N
development NN N
of IN N
the DT N
low JJ N
cost NN N
interventions NNS N
and CC N
their PRP$ N
effective JJ N
delivery NN N
are VBP N
needed VBN N
to TO N
reduce VB N
deaths NNS o
from IN N
birth NN N
asphyxia NN N
. . N

This DT N
study NN N
will MD N
assess VB N
the DT N
impact NN N
of IN N
a DT N
simplified JJ i
neonatal JJ i
resuscitation NN i
protocol NN i
provided VBN N
by IN N
Helping VBG N
Babies NNS N
Breathe NNP N
( ( N
HBB NNP N
) ) N
at IN N
a DT N
tertiary JJ p
hospital NN p
in IN p
Nepal NNP p
. . p

Perinatal NNP N
outcomes NNS N
and CC N
performance NN N
of IN N
skilled JJ p
birth NN p
attendants NNS p
on IN N
management NN o
of IN o
intrapartum-related JJ o
neonatal JJ o
hypoxia NN o
will MD N
be VB N
the DT N
main JJ N
measurements NNS N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
be VB N
carried VBN N
out RP N
at IN N
a DT N
tertiary JJ p
level NN p
maternity NN p
hospital NN p
in IN p
Nepal NNP p
. . p

A DT N
prospective JJ N
cohort-study NN N
will MD N
include VB N
a DT N
six-month JJ N
baseline NN N
a DT N
six CD N
month NN N
intervention NN N
period NN N
and CC N
a DT N
three-month JJ N
post NN N
intervention NN N
period NN N
. . N

A DT N
quality NN N
improvement NN N
process NN N
cycle NN N
will MD N
introduce VB N
the DT N
neonatal JJ N
resuscitation NN N
protocol NN N
. . N

A DT N
surveillance NN N
system NN N
, , N
including VBG N
CCD NNP i
cameras NNS i
and CC i
pulse JJ i
oximeters NNS i
, , N
will MD N
be VB N
set VBN N
up RP N
to TO N
evaluate VB N
the DT N
intervention NN N
. . N

DISCUSSION NNP N
Along IN N
with IN N
a DT N
technique NN N
to TO N
improve VB N
health NN o
workers NNS o
performance NN o
on IN N
the DT N
protocol NN N
, , N
the DT N
study NN N
will MD N
generate VB N
evidence NN N
on IN N
the DT N
research NN N
gap NN N
on IN N
the DT N
effectiveness NN N
of IN N
the DT N
simplified JJ N
neonatal JJ N
resuscitation NN N
protocol NN N
on IN N
intrapartum NN o
outcome NN o
and CC o
early JJ o
neonatal JJ o
survival NN o
. . o

This DT N
will MD N
generate VB N
a DT N
global JJ N
interest NN N
and CC N
inform NN N
policymaking NN N
in IN N
relation NN N
to TO N
delivery NN N
care NN N
in IN N
all DT N
income NN N
settings NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN97846009 NNP N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
clinical JJ N
trial NN N
comparison NN N
between IN N
pivotal JJ i
response NN i
treatment NN i
( ( i
PRT NNP i
) ) i
and CC i
structured VBN i
applied JJ i
behavior NN i
analysis NN i
( ( i
ABA NNP i
) ) i
intervention NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

Accumulating VBG N
studies NNS N
are VBP N
documenting VBG N
specific JJ N
motivational JJ N
variables NNS N
that IN N
, , N
when WRB N
combined VBN N
into IN N
a DT N
naturalistic JJ i
teaching NN i
paradigm NN i
, , N
can MD N
positively RB N
influence VB N
the DT N
effectiveness NN N
of IN N
interventions NNS N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
two CD N
applied JJ i
behavior NN i
analysis NN i
( ( i
ABA NNP i
) ) i
intervention NN i
procedures NNS i
, , i
a DT i
naturalistic JJ i
approach NN i
, , i
pivotal JJ i
response NN i
treatment NN i
( ( i
PRT NNP i
) ) i
with IN i
a DT i
structured JJ i
ABA NNP i
approach NN i
in IN N
a DT N
school NN N
setting NN N
. . N

A DT N
randomized JJ N
clinical JJ N
trial NN N
design NN N
using VBG N
two CD p
groups NNS p
of IN p
children NNS p
, , p
matched VBD p
according VBG p
to TO p
age NN p
, , p
sex NN p
and CC p
mean JJ p
length NN p
of IN p
utterance NN p
was VBD N
used VBN N
to TO N
compare VB N
the DT N
interventions NNS N
. . N

The DT N
data NN N
showed VBD N
that IN N
the DT N
PRT NNP i
approach NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
in IN N
improving VBG o
targeted VBN o
and CC o
untargeted JJ o
areas NNS o
after IN N
3 CD N
months NNS N
of IN N
intervention NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
variables NNS N
that WDT N
produce VBP N
more JJR N
rapid JJ N
improvements NNS N
in IN N
communication NN N
for IN N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

Direct JJ N
evidence NN N
for IN N
spinal JJ N
cord NN N
involvement NN N
in IN N
placebo NN N
analgesia NN N
. . N

Placebo NNP N
analgesia NN N
is VBZ N
a DT N
prime JJ N
example NN N
of IN N
the DT N
impact NN N
that WDT N
psychological JJ N
factors NNS N
have VBP N
on IN N
pain NN N
perception NN N
. . N

We PRP N
used VBD N
functional JJ i
magnetic JJ i
resonance NN i
imaging NN i
of IN N
the DT N
human JJ N
spinal JJ N
cord NN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
placebo VBZ N
analgesia JJ N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
nociceptive JJ p
processing NN p
in IN p
the DT p
spinal JJ p
cord NN p
. . p

In IN N
line NN N
with IN N
behavioral JJ N
data NNS N
that WDT N
show VBP N
decreased VBN p
pain NN o
responses NNS o
under IN p
placebo NN p
, , N
pain-related JJ o
activity NN o
in IN N
the DT N
spinal JJ N
cord NN N
is VBZ N
strongly RB N
reduced VBN N
under IN N
placebo NN N
. . N

These DT N
results NNS N
provide VBP N
direct JJ N
evidence NN N
for IN N
spinal JJ N
inhibition NN N
as IN N
one CD N
mechanism NN N
of IN N
placebo NN N
analgesia NN N
and CC N
highlight NN N
that WDT N
psychological JJ N
factors NNS N
can MD N
act VB N
on IN N
the DT N
earliest JJS N
stages NNS N
of IN N
pain NN N
processing NN N
in IN N
the DT N
central JJ N
nervous JJ N
system NN N
. . N

-DOCSTART- -X- O O

The DT N
effectiveness NN N
of IN N
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
training NN i
for IN N
teachers NNS p
of IN p
children NNS p
with IN p
autism NN p
: : p
a DT N
pragmatic JJ N
, , N
group NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
expert JJ N
training NN N
and CC N
consultancy NN N
for IN N
teachers NNS p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
in IN N
the DT N
use NN N
of IN N
the DT N
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
( ( i
PECS NNP i
) ) i
. . i

METHOD NNP N
DESIGN NNP N
Group NNP N
randomised VBD N
, , N
controlled VBN N
trial NN N
( ( N
3 CD N
groups NNS N
: : N
immediate JJ N
treatment NN N
, , N
delayed VBN N
treatment NN N
, , N
no DT N
treatment NN N
) ) N
. . N

PARTICIPANTS $ N
84 CD p
elementary JJ p
school NN p
children NNS p
, , p
mean JJ p
age NN p
6.8 CD p
years NNS p
. . p

TREATMENT VB N
A DT i
2-day JJ i
PECS NNP i
workshop NN i
for IN i
teachers NNS i
plus CC i
6 CD i
half-day JJ i
, , i
school-based JJ i
training NN i
sessions NNS i
with IN i
expert JJ i
consultants NNS i
over IN i
5 CD i
months NNS i
. . i

OUTCOME NNP N
MEASURES NNP N
Rates NNPS N
of IN N
: : N
communicative JJ o
initiations NNS o
, , o
use NN o
of IN o
PECS NNP o
, , o
and CC o
speech NN o
in IN o
the DT o
classroom NN o
; : o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule-Generic NNP o
( ( o
ADOS-G NNP o
) ) o
domain NN o
scores NNS o
for IN o
Communication NNP o
and CC o
Reciprocal NNP o
Social NNP o
Interaction NNP o
; : o
scores NNS o
on IN o
formal JJ o
language NN o
tests NNS o
. . o

RESULTS NNP N
Controlling VBG N
for IN N
baseline NN N
age NN N
, , N
developmental JJ o
quotient NN o
( ( o
DQ NNP o
) ) o
and CC o
language NN o
; : o
rates NNS o
of IN o
initiations NNS o
and CC o
PECS NNP o
usage NN o
increased VBD N
significantly RB N
immediately RB N
post-treatment JJ N
( ( N
Odds NNP N
Ratio NNP N
( ( N
OR NNP N
) ) N
of IN N
being VBG N
in IN N
a DT N
higher JJR N
ordinal JJ N
rate NN N
category NN N
2.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
1.22-6.09 JJ N
, , N
p JJ N
< NNP N
.05 NNP N
and CC N
OR NNP N
3.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.75-8.68 CD N
) ) N
, , N
p JJ N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
. . N

There EX N
were VBD N
no DT N
increases NNS N
in IN N
frequency NN o
of IN o
speech NN o
, , o
or CC o
improvements NNS o
in IN o
ADOS-G NNP o
ratings NNS o
or CC o
language NN o
test NN o
scores NNS o
. . o

CONCLUSIONS VB N
The DT N
results NNS N
indicate VBP N
modest JJ N
effectiveness NN N
of IN N
PECS NNP i
teacher NN i
training/consultancy NN i
. . i

Rates NNS N
of IN N
pupils NNS N
' POS N
initiations NNS N
and CC N
use NN N
of IN N
symbols NNS N
in IN N
the DT N
classroom NN N
increased VBD N
, , N
although IN N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
improvement NN N
in IN N
other JJ N
areas NNS N
of IN N
communication NN N
. . N

TREATMENT NNP N
effects NNS N
were VBD N
not RB N
maintained VBN N
once RB N
active JJ N
intervention NN N
ceased VBD N
. . N

-DOCSTART- -X- O O

Long JJ N
term NN N
response NN N
to TO N
therapy NN N
of IN N
chronic JJ p
anti-HBe-positive JJ p
hepatitis NN p
B NNP p
is VBZ N
poor JJ N
independent JJ N
of IN N
type NN N
and CC N
schedule NN N
of IN N
interferon NN N
. . N

OBJECTIVE CC N
The DT N
response NN o
rate NN o
to TO o
alpha VB o
interferon NN o
( ( o
IFN NNP o
) ) o
of IN N
chronic JJ N
anti-HBe-positive JJ N
hepatitis NN N
B NNP N
is VBZ N
variable JJ N
. . N

We PRP N
studied VBD N
whether IN N
type NN N
, , N
dose NN N
, , N
and CC N
schedule NN N
of IN N
IFN NNP i
, , N
and CC N
type NN N
and CC N
frequency NN N
of IN N
posttreatment NN N
monitoring NN N
, , N
influence VB N
the DT N
response NN N
rate NN N
. . N

METHODS NNP N
Seventy-two JJ p
consecutive JJ p
anti-HBe-positive JJ p
chronic NN p
hepatitis NN p
B NNP p
patients NNS p
( ( p
59 CD p
male NN p
and CC p
13 CD p
female NN p
, , p
median JJ p
age NN p
41 CD p
yr NN p
) ) p
stratified VBN p
by IN p
sex NN p
and CC p
histology NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
treatment NN N
arms NNS N
. . N

Twenty-seven JJ N
patients NNS N
( ( N
A DT N
) ) N
received VBD N
10 CD N
million CD N
units NNS N
alpha-N1 JJ i
IFN NNP i
i.m NN i
. . i

t.w NN N
. . N

for IN N
24 CD N
wk NN N
( ( N
total JJ N
dose NN N
: : N
720 CD N
million CD N
units NNS N
) ) N
; : N
21 CD N
( ( N
B NNP N
) ) N
received VBD N
9 CD N
million CD N
units NNS N
alpha-2a JJ i
IFN NNP i
i.m NN i
. . i

t.w NN N
. . N

for IN N
4 CD N
wk NN N
, , N
followed VBN N
by IN N
18 CD N
million CD N
units NNS N
for IN N
12 CD N
wk NN N
and CC N
9 CD N
million CD N
units NNS N
for IN N
8 CD N
wk NN N
( ( N
972 CD N
million CD N
units NNS N
) ) N
; : N
24 CD N
( ( N
C NNP N
) ) N
received VBD N
2 CD i
alpha-2a JJ i
IFN NNP i
courses NNS i
( ( N
9 CD N
million CD N
units NNS N
i.m RB N
. . N

t.w NN N
. . N

for IN N
16 CD N
and CC N
12 CD N
wk NN N
separated VBN N
by IN N
a DT N
6-month JJ N
interval NN N
[ $ N
756 CD N
million CD N
units NNS N
] NNP N
) ) N
. . N

Primary JJ N
response NN N
was VBD N
defined VBN N
by IN N
normal JJ o
ALT NNP o
and CC o
serum VB o
HBV-DNA NNP o
levels NNS o
below IN N
10 CD N
pg/ml NN N
at IN N
the DT N
end NN N
of IN N
therapy NN N
and CC N
sustained VBN N
response NN N
by IN N
normal JJ o
ALT NNP o
( ( N
tested VBN N
monthly RB N
) ) N
, , N
undetectable JJ o
HBV-DNA NN o
and CC N
IgM NNP N
anti-HBc NN N
( ( N
< JJ N
7 CD N
I.U NNP N
. . N

Paul NNP N
Ehrlich NNP N
Institute NNP N
) ) N
( ( N
tested VBN N
every DT N
3 CD N
months NNS N
) ) N
during IN N
the DT N
posttreatment JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
the DT N
end NN N
of IN N
treatment NN N
, , N
12 CD N
, , N
8 CD N
, , N
and CC N
13 CD N
patients NNS N
from IN N
groups NNS N
A NNP N
, , N
B NNP N
, , N
and CC N
C NNP N
, , N
respectively RB N
, , N
were VBD N
responders NNS N
. . N

At IN N
the DT N
18-month JJ N
follow-up JJ N
, , N
two CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
only RB N
one CD N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
maintained VBD N
the DT N
response NN o
. . o

Overall NNP N
, , N
after IN N
34 CD N
months NNS N
( ( N
median JJ N
posttreatment NN N
follow-up NN N
) ) N
, , N
three CD N
patients NNS N
were VBD N
long JJ N
term NN N
responders NNS N
, , N
whereas NNS N
three CD N
showed VBD N
a DT N
sustained VBN N
remission NN o
after IN N
relapse NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN o
of IN o
long JJ o
term NN o
response NN o
to TO N
interferon VB N
of IN N
anti-HBe-positive JJ N
chronic JJ N
hepatitis NN N
B NNP N
is VBZ N
poor JJ N
, , N
independent JJ N
of IN N
IFN NNP N
type NN N
, , N
dose VB N
, , N
or CC N
schedule NN N
; : N
the DT N
more RBR N
stringent JJ N
the DT N
monitoring NN N
, , N
the DT N
higher JJR N
the DT N
relapse NN N
rate NN N
. . N

-DOCSTART- -X- O O

Recommending VBG N
self-paced JJ i
exercise NN i
among IN N
overweight JJ p
and CC p
obese JJ p
adults NNS p
: : p
a DT N
randomized JJ N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
National NNP N
guidelines NNS N
call NN N
for IN N
exercise NN N
of IN N
at IN N
least JJS N
moderate JJ N
intensity NN N
; : N
however RB N
, , N
recommending VBG N
self-paced JJ i
exercise NN i
may MD N
lead VB N
to TO N
better JJR N
adherence NN o
, , N
particularly RB N
among IN N
overweight JJ p
and CC p
obese JJ p
adults NNS p
. . p

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
proof-of-concept NN N
for IN N
recommending VBG N
self-paced JJ N
exercise NN N
among IN N
overweight JJ N
adults NNS N
. . N

METHODS NNP N
Fifty-nine NNP p
healthy JJ p
, , p
low-active JJ p
( ( p
exercise NN p
< VBZ p
60 CD p
min/week NN p
) ) p
, , p
overweight JJ p
( ( p
body JJ p
mass NN p
index NN p
25.0-39.9 JJ p
) ) p
adults NNS p
( ( p
18-65 JJ p
) ) p
received VBD N
a DT N
6-month JJ i
print-based JJ i
exercise NN i
promotion NN i
program NN i
with IN i
the DT i
goal NN i
of IN i
walking VBG i
30-60 JJ i
min/day NN i
. . i

Participants NNS N
were VBD N
surreptitiously RB N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
recommendation NN i
for IN i
either DT i
self-paced JJ i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
or CC i
moderate JJ i
( ( i
64-76 JJ i
% NN N
maximum JJ N
heart NN N
rate NN N
; : N
n CC N
= VB N
29 CD N
) ) N
intensity NN i
exercise NN i
. . i

All DT p
participants NNS p
used VBN p
electronic JJ p
diaries NNS p
and CC p
heart NN p
rate NN p
monitors NNS p
to TO p
track VB o
exercise NN o
frequency NN o
, , o
duration NN o
, , o
and CC o
intensity NN o
. . o

RESULTS VB N
The DT N
self-paced JJ N
condition NN N
reported VBD N
more RBR o
minutes/week NNS o
of IN o
walking NN o
( ( N
f JJ N
( ( N
2 CD N
) ) N
= NN N
0.17 CD N
, , N
p NN N
= NNP N
0.045 CD N
) ) N
and CC N
a DT N
trend NN N
toward IN N
greater JJR o
exercise-related JJ o
energy NN o
expenditure/week NN o
( ( o
f JJ N
( ( N
2 CD N
) ) N
= NN N
0.12 CD N
, , N
p NN N
= NNP N
0.243 CD N
) ) N
, , N
corresponding VBG N
to TO N
approximately RB N
26 CD N
additional JJ N
minutes/week NN N
and CC N
83 CD N
additional JJ N
kilocalories/week NN N
over IN N
6 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Explicit NNP N
recommendation NN N
for IN N
self-paced JJ i
exercise NN i
may MD i
improve VB o
adherence NN o
to TO o
exercise VB o
programs NNS o
among IN o
overweight JJ p
and CC p
obese JJ p
adults NNS p
. . N

-DOCSTART- -X- O O

Ambulatory NNP i
phlebectomy NN i
versus NN N
compression NN i
sclerotherapy NN i
: : i
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
no DT N
randomized VBN N
controlled VBN N
trial NN N
has VBZ N
assessed VBN N
the DT N
effects NNS N
of IN N
either DT N
compression NN i
sclerotherapy NN i
or CC N
ambulatory JJ i
phlebectomy NN i
, , N
both DT N
techniques NNS N
are VBP N
used VBN N
to TO N
treat VB N
varicose JJ N
veins NNS N
worldwide RB N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
compare VB N
recurrence NN N
rates NNS N
of IN N
varicose JJ N
veins NNS N
and CC N
complications NNS N
after IN N
compression NN i
sclerotherapy NN i
and CC N
ambulatory JJ i
phlebectomy NN i
. . i

METHODS NNP N
From IN N
September NNP p
1996 CD p
to TO p
October NNP p
1998 CD p
, , p
we PRP p
randomly RB p
allocated VBD p
49 CD p
legs NNS p
to TO p
compression VB i
sclerotherapy NN i
and CC p
49 CD p
legs NNS p
to TO p
ambulatory JJ i
phlebectomy NN i
. . i

Our PRP$ N
primary JJ N
outcome NN N
parameters NNS N
were VBD N
as IN N
follows VBZ N
: : N
recurrence NN N
rates NNS N
at IN N
1 CD N
and CC N
2 CD N
years NNS N
and CC N
complications NNS N
related VBN N
to TO N
therapy VB N
. . N

Eighty-two JJ p
patients NNS p
were VBD p
included VBN p
, , p
of IN p
whom WP p
16 CD p
were VBD p
included VBN p
with IN p
both DT p
of IN p
their PRP$ p
legs NNS p
. . p

The DT p
number NN p
of IN p
treated JJ p
legs NN p
was VBD p
therefore RB p
98 CD p
, , N
but CC N
two CD p
patients NNS p
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

RESULTS VB N
One CD o
year NN o
recurrence NN o
amounted VBD N
to TO N
1 CD N
out IN N
of IN N
48 CD N
for IN N
phlebectomy NN i
and CC N
12 CD N
out IN N
of IN N
48 CD N
for IN N
compression NN i
sclerotherapy NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
at IN N
2 CD N
years NNS N
, , N
six CD N
additional JJ N
recurrences NNS o
were VBD N
found VBN N
, , N
but CC N
then RB N
solely RB N
for IN N
compression NN i
sclerotherapy NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significant JJ N
differences NNS N
in IN N
complications NNS N
occurring VBG N
more RBR N
in IN N
phlebectomy NN N
than IN N
in IN N
compression NN i
sclerotherapy NN i
therapy NN N
were VBD N
blisters NNS o
, , o
teleangiectatic JJ o
matting NN o
, , o
scar NN o
formation NN o
, , o
and CC o
bruising VBG o
from IN o
bandaging VBG o
. . o

CONCLUSION NNP N
Our PRP$ N
results NNS N
show VBP N
that IN N
ambulatory JJ i
phlebectomy NN i
is VBZ N
an DT N
effective JJ N
therapy NN N
for IN N
varicose JJ N
veins NNS N
of IN N
the DT N
leg NN N
. . N

Recurrence NN N
rates NNS N
are VBP N
significantly RB N
lower JJR N
than IN N
for IN N
compression NN i
sclerotherapy NN i
therapy NN i
. . i

If IN N
varicose JJ N
veins NNS N
persist VBP N
4 CD N
weeks NNS N
after IN N
compression NN i
sclerotherapy NN i
, , N
it PRP N
can MD N
be VB N
argued VBN N
that IN N
to TO N
reduce VB N
the DT N
risk NN N
of IN N
future JJ N
recurrence NN N
ambulatory JJ i
phlebectomy NN i
should MD N
be VB N
considered VBN N
as IN N
the DT N
better JJR N
treatment NN N
option NN N
. . N

-DOCSTART- -X- O O

Pretreatment NN N
and CC N
co-administration NN N
of IN N
oral JJ i
anti-diabetic JJ i
agent NN i
with IN N
clomiphene JJ i
citrate NN i
or CC N
rFSH NN i
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

AIM IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
explore VB N
the DT N
result NN N
of IN N
pretreatment NN N
and CC N
concomitant NN N
use NN N
of IN N
metformin NN i
with IN N
clomiphene JJ i
citrate NN i
( ( i
CC NNP i
) ) i
and CC N
rFSH NN i
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
done VBN N
in IN N
the DT N
Dhaka NNP p
Medical NNP p
College NNP p
and CC p
Hospital NNP p
and CC p
the DT p
Infertility NNP p
Care NNP p
and CC p
Research NNP p
Centre NNP p
, , p
Dhaka NNP p
, , p
Bangladesh NNP p
. . p

A NNP N
total NN N
of IN N
165 CD p
infertile JJ p
patients NNS p
with IN p
CC-resistant JJ p
PCOS NNP p
who WP p
attended VBD p
for IN p
treatment NN p
were VBD p
the DT p
target NN p
population NN p
for IN p
this DT p
study NN p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
groups NNS N
A DT N
and CC N
B NNP N
were VBD N
given VBN N
metformin NNS i
and CC N
group NN N
C NNP N
was VBD N
the DT N
control NN i
. . i

Along IN N
with IN N
metformin NN i
, , N
group NN N
A NNP N
received VBD N
CC NNP i
and CC N
group NN N
B NNP N
received VBD N
rFSH NN i
. . i

Group NNP N
C NNP N
was VBD N
treated VBN N
with IN N
only RB N
rFSH NN i
. . i

Metformin NNP i
was VBD N
given VBN N
1500 CD N
mg JJ N
daily JJ N
for IN N
4 CD N
weeks NNS N
. . N

Afterwards NNS i
CC NNP i
or CC i
rFSH VB i
were VBD i
added VBN N
for IN N
induction NN N
of IN N
ovulation NN N
along IN N
with IN i
metformin NN i
. . i

Six NNP N
ovulatory JJ N
cycles NNS N
were VBD N
assessed VBN N
. . N

Treatment NNP N
was VBD N
terminated VBN N
when WRB N
there EX N
was VBD N
no DT N
response NN N
with IN N
maximum JJ N
dose NN N
of IN N
CC NNP i
and CC i
rFSH NN i
or CC i
after IN N
six CD N
ovulatory JJ N
cycles NNS N
without IN N
pregnancy NN N
or CC N
after IN N
achieving VBG N
pregnancy NN N
. . N

A DT N
P-value NNP N
of IN N
< NNP N
0.5 CD N
was VBD N
considered VBN N
as IN N
significant JJ N
. . N

RESULTS NNP o
Ovulation NNP o
( ( o
89.09 CD N
% NN N
) ) N
and CC o
pregnancy NN o
( ( o
54.55 CD N
% NN N
) ) N
rates NNS N
were VBD N
higher JJR N
in IN N
group NN N
B. NNP N
Ovulation NNP o
( ( o
74.55 CD N
% NN N
) ) N
and CC o
pregnancy NN o
( ( o
29.09 CD N
% NN N
) ) N
rates NNS N
were VBD N
also RB N
satisfactory JJ N
in IN N
group NN N
C NNP N
but CC N
a DT N
dose NN N
of IN N
rFSH JJ i
requirement NN i
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

In IN N
group NN N
A NNP N
, , N
both DT N
ovulation NN o
and CC o
pregnancy NN o
rate NN o
were VBD N
much RB N
lower JJR N
than IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
27.27 CD N
% NN N
and CC N
12.73 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
metformin NN i
increases VBZ i
the DT N
response NN N
of IN N
ovulation-inducing JJ N
agents NNS N
and CC N
can MD N
be VB N
used VBN N
safely RB N
in IN p
PCOS NNP p
. . p

-DOCSTART- -X- O O

Torasemide NNP i
versus NN N
furosemide NN i
in IN N
cirrhosis NN p
: : p
a DT N
long-term JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
clinical JJ N
study NN N
. . N

The DT N
effects NNS N
of IN N
long-term JJ N
therapy NN N
( ( N
70 CD N
days NNS N
) ) N
with IN N
torasemide NN i
( ( N
20 CD N
mg/day NN N
) ) N
, , N
a DT N
new JJ N
loop NN N
diuretic JJ N
, , N
were VBD N
compared VBN N
with IN N
those DT N
of IN N
furosemide NN i
( ( N
50 CD N
mg/day NN N
) ) N
in IN N
a DT N
randomized JJ N
double-blind JJ N
trial NN N
. . N

Both DT N
drugs NNS N
were VBD N
administered VBN N
in IN N
association NN N
with IN N
spironolactone NN i
( ( N
200 CD N
mg/day NN N
) ) N
in IN N
28 CD p
nonazotemic JJ p
cirrhotic JJ p
patients NNS p
with IN p
controlled JJ p
ascites NNS p
. . p

The DT N
treatments NNS N
did VBD N
not RB N
modify VB N
creatinine JJ o
clearance NN o
and CC N
exhibited VBD N
a DT N
similar JJ N
effect NN N
on IN N
body NN o
weight NN o
, , o
urinary JJ o
volume NN o
, , N
and CC N
fractional JJ o
excretion NN o
of IN o
uric JJ o
acid NN o
, , o
sodium NN o
, , o
and CC o
chloride NN o
. . o

The DT N
effect NN N
of IN N
torasemide NN i
on IN N
fractional JJ o
potassium NN o
excretion NN o
was VBD N
lower JJR N
than IN N
that DT N
of IN N
furosemide NN i
. . i

Torasemide VB i
showed VBD N
higher JJR N
sparing VBG o
effect NN o
than IN N
furosemide NN i
on IN N
calcium NN o
, , o
inorganic JJ o
phosphate NN o
, , o
and CC o
magnesium NN o
excretion NN o
and CC N
stronger JJR N
action NN N
on IN N
free JJ o
water NN o
clearance NN o
. . o

No DT N
changes NNS N
in IN N
serum NN o
parameters NNS o
were VBD N
induced VBN N
by IN N
either DT N
treatment NN N
. . N

Two CD N
episodes NNS N
of IN N
hepatic JJ o
encephalopathy NN o
occurred VBD N
in IN N
the DT N
torasemide NN i
group NN N
. . N

In IN N
view NN N
of IN N
its PRP$ N
effects NNS o
on IN o
sodium NN o
and CC o
water NN o
excretion NN o
and CC N
on IN o
other JJ o
urinary JJ o
parameters NNS o
, , N
torasemide NN i
can MD N
represent VB N
an DT N
alternative JJ N
tool NN N
for IN N
the DT N
long-term JJ N
treatment NN N
of IN N
ascites NNS p
. . p

-DOCSTART- -X- O O

Lung NNP p
cancer NN p
diagnosis NN p
and CC N
staging VBG N
with IN N
endobronchial JJ i
ultrasound-guided JJ i
transbronchial JJ i
needle JJ i
aspiration NN i
compared VBN N
with IN N
conventional JJ N
approaches NNS N
: : N
an DT N
open-label JJ N
, , N
pragmatic JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
diagnosis NN N
and CC N
staging NN N
of IN N
lung NN N
cancer NN N
is VBZ N
an DT N
important JJ N
process NN N
that IN N
identifies VBZ N
treatment NN N
options NNS N
and CC N
guides NNS N
disease JJ N
prognosis NN N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
endobronchial JJ i
ultrasound-guided JJ i
transbronchial JJ i
needle JJ i
aspiration NN i
as IN N
an DT N
initial JJ N
investigation NN N
technique NN N
for IN N
patients NNS p
with IN p
suspected JJ p
lung NN p
cancer NN p
. . p

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
multicentre NN N
, , N
pragmatic JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
, , N
we PRP N
recruited VBD p
patients NNS p
who WP p
had VBD p
undergone NN p
a DT p
CT NNP p
scan JJ p
and CC p
had VBD p
suspected VBN p
stage NN p
I PRP p
to TO p
IIIA NNP p
lung NN p
cancer NN p
, , p
from IN p
six CD p
UK NNP p
centres NNS p
and CC N
randomly RB N
assigned VBD N
them PRP N
to TO N
either DT N
endobronchial JJ i
ultrasound-guided JJ i
transbronchial JJ i
needle JJ i
aspiration NN i
( ( N
EBUS-TBNA NNP N
) ) N
or CC N
conventional JJ i
diagnosis NN i
and CC i
staging NN i
( ( N
CDS NNP N
) ) N
, , N
for IN N
further JJ N
investigation NN N
and CC N
staging NN N
. . N

If IN N
a DT N
target NN N
node NN N
could MD N
not RB N
be VB N
accessed VBN N
by IN N
EBUS-TBNA NNP N
, , N
then RB N
endoscopic VBZ i
ultrasound-guided JJ i
fine JJ i
needle JJ i
aspiration NN i
( ( N
EUS-FNA NNP N
) ) N
was VBD N
allowed VBN N
as IN N
an DT N
alternative JJ N
procedure NN N
. . N

Randomisation NN N
was VBD N
stratified VBN N
according VBG N
to TO N
the DT N
presence NN N
of IN N
mediastinal JJ N
lymph NN N
nodes NNS N
measuring VBG N
1 CD N
cm NN N
or CC N
more RBR N
in IN N
the DT N
short JJ N
axis NN N
and CC N
by IN N
recruiting VBG N
centre NN N
. . N

We PRP N
used VBD N
a DT N
telephone NN N
randomisation NN N
method NN N
with IN N
permuted JJ N
blocks NNS N
of IN N
four CD N
generated VBN N
by IN N
a DT N
computer NN N
. . N

Because IN N
of IN N
the DT N
nature NN N
of IN N
the DT N
intervention NN N
, , N
masking VBG N
of IN N
participants NNS N
and CC N
consenting VBG N
investigators NNS N
was VBD N
not RB N
possible JJ N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-to-treatment JJ o
decision NN o
after IN N
completion NN N
of IN N
the DT N
diagnostic JJ N
and CC N
staging JJ N
investigations NNS N
and CC N
analysis NN N
was VBD N
by IN N
intention-to-diagnose JJ N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00652769 NNP N
. . N

FINDINGS NNP N
Between NNP N
June NNP N
10 CD N
, , N
2008 CD N
, , N
and CC N
July NNP N
4 CD N
, , N
2011 CD N
, , N
we PRP N
randomly RB p
allocated VBD p
133 CD p
patients NNS p
to TO p
treatment NN p
: : p
66 CD p
to TO p
EBUS-TBNA NNP p
and CC p
67 CD p
to TO p
CDS NNP p
( ( N
one CD N
later RB N
withdrew JJ N
consent NN N
) ) N
. . N

Two CD N
patients NNS N
from IN N
the DT N
EBUS-TBNA NNP N
group NN N
underwent JJ N
EUS-FNA NNP N
. . N

The DT N
median JJ o
time NN o
to TO o
treatment NN o
decision NN o
was VBD N
shorter JJR N
with IN N
EBUS-TBNA NNP N
( ( N
14 CD N
days NNS N
; : N
95 CD N
% NN N
CI NNP N
14-15 CD N
) ) N
than IN N
with IN N
CDS NNP N
( ( N
29 CD N
days NNS N
; : N
23-35 JJ N
) ) N
resulting VBG N
in IN N
a DT N
hazard NN N
ratio NN N
of IN N
1?98 CD N
, , N
( ( N
1?39-2?82 JJ N
, , N
p JJ N
< NNP N
0?0001 CD N
) ) N
. . N

One CD N
patient NN N
in IN N
each DT N
group NN N
had VBD N
a DT o
pneumothorax NN o
from IN o
a DT N
CT-guided JJ N
biopsy NN N
sample NN N
; : N
the DT N
patient NN N
from IN N
the DT N
CDS NNP N
group NN o
needed VBD o
intercostal JJ o
drainage NN o
and CC o
was VBD N
admitted VBN N
to TO N
hospital VB N
. . N

INTERPRETATION NNP i
Transbronchial NNP i
needle JJ i
aspiration NN i
guided VBN i
by IN i
endobronchial JJ i
ultrasound NN i
should MD i
be VB N
considered VBN N
as IN N
the DT N
initial JJ N
investigation NN N
for IN N
patients NNS p
with IN p
suspected JJ p
lung NN p
cancer NN p
, , p
because IN p
it PRP N
reduces VBZ N
the DT N
time NN N
to TO N
treatment NN N
decision NN N
compared VBN N
with IN N
conventional JJ N
diagnosis NN N
and CC N
staging VBG N
techniques NNS N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
. . N

-DOCSTART- -X- O O

Gemcitabine NNP i
and CC N
split-dose JJ N
paclitaxel NN i
or CC N
docetaxel NN i
in IN N
metastatic JJ N
breast NN N
cancer NN N
: : N
a DT N
randomised JJ N
phase NN N
II NNP N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
activity NN o
and CC o
toxicity NN o
of IN N
split-dose JJ i
paclitaxel NN i
or CC i
docetaxel NN i
in IN i
combination NN i
with IN i
gemcitabine NN i
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
( ( p
MBC NNP p
) ) p
who WP p
had VBD p
previously RB p
received VBN p
anthracyclines NNS p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN p
of IN p
210 CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatment NN N
arms NNS N
: : N
gemcitabine NN i
1,250 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
paclitaxel VB i
175 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
3-h JJ i
infusion NN i
on IN i
Day NNP i
1 CD i
( ( i
GP1 NNP i
) ) i
; : i
gemcitabine $ i
1,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
paclitaxel VB i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
1-h JJ i
infusion NN i
on IN i
Days NNP i
1 CD i
and CC i
8 CD i
( ( i
GP2 NNP i
) ) i
; : i
gemcitabine $ i
1,000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
Days VBZ i
1 CD i
and CC i
8 CD i
and CC i
docetaxel VB i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
as IN i
a DT i
1-h JJ i
infusion NN i
on IN i
Days NNP i
1 CD i
and CC i
8 CD i
( ( i
GD NNP i
) ) i
. . N

Cycles NNS N
were VBD N
repeated VBN N
every DT N
3 CD N
weeks NNS N
. . N

RESULTS NNP N
For IN N
the DT N
204 CD p
patients NNS p
evaluable JJ p
for IN p
response NN p
assessment NN p
, , p
the DT p
response NN o
rates NNS o
were VBD p
48.6 CD p
% NN p
for IN p
GP1 NNP p
, , p
52.2 CD p
% NN p
for IN p
GP2 NNP p
, , p
and CC p
52.3 CD p
% NN p
for IN p
GD NNP p
. . p

Median JJ o
response NN o
duration NN o
, , o
time NN o
to TO o
treatment NN o
failure NN o
, , o
and CC o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
were VBD N
similar JJ N
in IN N
each DT N
arm NN N
. . N

Median JJ o
TTP NNP o
for IN N
GP1 NNP N
, , N
GP2 NNP N
and CC N
GD NNP N
was VBD N
7.5 CD N
, , N
7.0 CD N
and CC N
7.4 CD N
months NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
208 CD p
patients NNS p
evaluable JJ p
for IN p
safety NN o
, , N
the DT N
most RBS N
common JJ N
grade NN N
3/4 CD N
toxicity NN o
for IN N
each DT N
regimen NN N
was VBD N
neutropaenia RB o
, , N
with IN N
64 CD N
% NN N
, , N
57 CD N
% NN N
, , N
and CC N
68 CD N
% NN N
for IN N
GP1 NNP N
, , N
GP2 NNP N
, , N
and CC N
GD NNP N
, , N
respectively RB N
. . N

Grade VB N
4 CD N
neutropaenia NN o
, , N
grade VBD N
3/4 CD N
anaemia NN o
, , o
febrile JJ o
neutropaenia NN o
, , o
and CC o
diarrhoea NNS o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
docetaxel NN N
arm NN N
, , N
as IN N
was VBD N
the DT N
use NN N
of IN N
intravenous JJ N
antibiotics NNS N
and CC N
blood NN N
transfusions NNS N
. . N

CONCLUSION VB N
The DT N
study NN N
confirmed VBD N
the DT N
high JJ N
activity NN N
of IN N
gemcitabine-taxane JJ i
combinations NNS i
in IN N
MBC NNP N
. . N

Split-dose JJ N
paclitaxel NN i
had VBD N
similar JJ N
activity NN o
and CC N
toxicity NN o
to TO N
the DT N
3-weekly JJ N
administration NN N
. . N

The DT N
split-dose JJ N
docetaxel NN i
regimen NNS N
had VBD N
similar JJ N
activity NN o
to TO N
the DT N
paclitaxel NN i
combinations NNS i
though IN N
associated VBN N
with IN N
higher JJR N
toxicity NN o
. . o

-DOCSTART- -X- O O

Virtual JJ i
reality NN i
for IN N
acute NN N
pain NN N
reduction NN N
in IN N
adolescents NNS p
undergoing VBG p
burn NN p
wound NN p
care NN p
: : p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Effective NNP N
pain NN i
management NN i
remains VBZ N
a DT N
challenge NN N
for IN N
adolescents NNS p
during IN p
conscious JJ p
burn NN p
wound NN p
care NN p
procedures NNS p
. . p

Virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
shows VBZ N
promise NN N
as IN N
a DT N
non-pharmacological JJ N
adjunct NN N
in IN N
reducing VBG N
pain NN N
. . N

AIMS VB N
This DT N
study NN N
assessed VBD N
off-the-shelf JJ i
VR NNP i
for IN N
( ( N
1 CD N
) ) N
its PRP$ N
effect NN N
on IN N
reducing VBG N
acute JJ N
pain NN N
intensity NN N
during IN N
adolescent JJ N
burn NN N
wound NN N
care NN N
, , N
and CC N
( ( N
2 CD N
) ) N
its PRP$ N
clinical JJ N
utility NN N
in IN N
a DT N
busy JJ N
hospital NN N
setting NN N
. . N

METHODS NNP N
Forty-one CD p
adolescents NNS p
( ( p
11-17 CD p
years NNS p
) ) p
participated VBD N
in IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

Acute NNP N
pain NN N
outcomes NNS N
including VBG N
adolescent JJ N
self-report NN N
, , N
nursing VBG N
staff NN N
behavioral JJ N
observation NN N
, , N
caregiver NN N
observation NN N
and CC N
physiological JJ N
measures NNS N
were VBD N
collected VBN N
. . N

Length NNP N
of IN N
procedure NN N
times NNS N
and CC N
adolescent JJ N
reactions NNS N
were VBD N
also RB N
recorded VBN N
to TO N
inform VB N
clinical JJ N
utility NN N
. . N

RESULTS NNP N
Nursing JJ N
staff NN N
reported VBD N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
pain NN o
scores NNS o
during IN N
dressing VBG N
removal NN N
, , N
and CC N
significantly RB N
less JJR N
rescue JJ o
doses NNS o
of IN o
Entonox NNP o
given VBN N
to TO N
those DT N
receiving VBG N
VR NNP i
, , N
compared VBN N
to TO N
those DT N
receiving VBG N
standard JJ N
distraction NN N
. . N

For IN N
all DT N
other JJ N
pain NN N
outcomes NNS N
and CC N
length NN N
of IN N
treatment NN N
, , N
there EX N
was VBD N
a DT N
trend NN N
for IN N
lower JJR N
pain NN o
scores NNS o
and CC o
treatment NN o
times NNS o
for IN N
those DT N
receiving VBG N
VR NNP i
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSION NNP N
Despite IN N
only RB N
minimal JJ N
pain NN N
reduction NN N
achieved VBD N
using VBG N
off-the-shelf JJ N
VR NNP i
, , N
other JJ N
results NNS N
from IN N
this DT N
trial NN N
and CC N
previous JJ N
research NN N
on IN N
younger JJR N
children NNS N
with IN N
burns NNS N
suggest VBP N
a DT N
customized JJ N
, , N
adolescent JJ N
and CC N
hospital JJ N
friendly JJ N
device NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
pain NN N
reduction NN N
. . N

-DOCSTART- -X- O O

Parenteral NNP i
amino NN i
acid NN i
and CC N
metabolic JJ N
acidosis NN N
in IN N
premature JJ p
infants NNS p
. . p

BACKGROUND NNP N
Aggressive NNP i
parenteral JJ i
nutrition NN i
( ( i
PN NNP i
) ) i
including VBG i
amino JJ i
acids NNS i
is VBZ N
recommended VBN N
for IN N
low-birth-weight JJ p
infants NNS p
to TO N
prevent VB N
energy NN N
and CC N
protein NN N
deficit NN N
. . N

Their PRP$ N
impact NN N
on IN N
acid-base JJ N
homeostasis NN N
has VBZ N
not RB N
been VBN N
examined VBN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
impact NN N
of IN N
dose NN N
and CC N
duration NN N
of IN N
parenteral JJ i
amino NN i
acids NNS i
, , i
with IN i
cysteine NN i
, , N
on IN N
acid-base JJ N
parameters NNS N
in IN N
122 CD p
low-birth-weight JJ p
infants NNS p
. . p

Premature NN p
infants NNS p
< VBP p
or=32 JJ p
weeks NNS p
, , p
< NNP p
or=1850 MD p
g VB p
, , p
and CC p
receiving VBG p
parenteral JJ i
amino NN i
acids NNS i
at IN p
1.5 CD p
g/kg/d NN p
for IN p
an DT p
extended JJ p
period NN p
( ( p
> JJ p
24 CD p
hours NNS p
) ) p
, , p
or CC p
3 CD p
g/kg/d NN p
for IN p
a DT p
short JJ p
( ( p
5 CD p
hour NN p
) ) p
, , p
extended VBD p
( ( p
24 CD p
hour NN p
) ) p
, , p
or CC p
prolonged VBN p
( ( p
3-5 JJ p
days NNS p
) ) p
duration NN p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Data NNS N
were VBD N
obtained VBN N
at IN N
age NN N
0-3 JJ N
days NNS N
( ( N
n JJ N
= NNP N
43 CD N
) ) N
or CC N
, , N
when WRB N
clinically RB N
stable JJ N
, , N
age NN N
3-5 JJ N
days NNS N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

Data NNS N
from IN N
30 CD p
infants NNS p
, , p
matched VBN p
for IN p
birth NN p
weight NN p
and CC p
gestational JJ p
age NN p
, , p
receiving VBG p
PN NNP i
during IN p
the DT p
first JJ p
5 CD p
days NNS p
after IN p
birth NN p
were VBD N
also RB N
obtained VBN N
. . N

Acidosis NNP N
was VBD N
defined VBN N
as IN N
pH NN N
< $ N
7.25 CD N
. . N

RESULTS JJ N
Acidosis NNP o
was VBD N
evident JJ N
in IN N
all DT N
infants NNS N
between IN N
2 CD N
and CC N
5 CD N
days NNS N
after IN N
birth NN N
. . N

Infants NNS p
with IN p
large JJ p
patent NN p
ductus NN p
arteriosus NN p
( ( p
PDA NNP p
) ) p
exhibited VBD N
significantly RB N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
lower JJR o
pH NN o
early RB N
, , N
had VBD N
higher JJR N
blood NN o
urea JJ o
nitrogen NN o
levels NNS o
( ( N
26 CD N
+/- JJ N
9 CD N
vs NN N
18 CD N
+ NN N
8 CD N
mg/dL NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
, , N
and CC N
had VBD N
greater JJR o
weight JJ o
loss NN o
( ( N
approximately RB N
17 CD N
% NN N
of IN N
birth NN N
weight NN N
) ) N
when WRB N
compared VBN N
with IN N
infants NNS N
without IN N
PDA NNP N
. . N

Gestational NNP o
age NN o
, , o
weight JJ o
loss NN o
, , o
and CC o
patent NN o
ductus NN o
arteriosus NN o
accounted VBD N
for IN N
65 CD N
% NN N
of IN N
variance NN N
in IN N
acidosis NN N
. . N

CONCLUSIONS NNP N
Low-birth-weight JJ p
infants NNS p
develop VB N
metabolic JJ N
acidosis NN N
between IN N
2 CD N
and CC N
5 CD N
days NNS N
after IN N
birth NN N
, , N
irrespective NN N
of IN N
dose NN N
and CC N
duration NN N
of IN N
parenteral JJ i
amino NN i
acid JJ i
administration NN i
. . i

Careful JJ N
management NN N
of IN N
parenteral JJ i
fluids NNS i
and CC N
comorbidities NNS N
may MD N
lower VB N
the DT N
incidence NN N
of IN N
acidosis NN N
and CC N
promote NN N
protein NN N
accretion NN N
. . N

-DOCSTART- -X- O O

An DT N
exploratory NN N
, , N
pragmatic JJ N
, , N
cluster NN N
randomised VBD N
trial NN N
of IN N
practice NN i
nurse JJ i
training NN i
in IN p
the DT p
use NN p
of IN p
asthma JJ p
action NN p
plans NNS p
. . p

INTRODUCTION NNP N
To TO N
investigate VB N
the DT N
feasibility NN o
of IN N
improving VBG N
asthma JJ N
management NN N
- : N
in IN N
particular JJ N
, , N
the DT N
implementation NN N
of IN N
individualised JJ i
asthma JJ i
action NN i
plans NNS i
( ( i
AAPs NNP i
) ) i
for IN N
poorly-controlled JJ p
adult NN p
asthma NN p
patients NNS p
- : N
by IN N
providing VBG N
training NN N
in IN N
asthma-focused JJ N
clinical JJ N
and CC N
communication NN N
skills NNS N
for IN N
practice NN N
nurses NNS p
who WP p
deliver VBP p
asthma JJ p
clinics NNS p
. . p

METHODS NNP N
A NNP N
pragmatic JJ N
, , N
cluster NN N
randomised VBD N
trial NN N
with IN N
an DT N
intervention NN N
( ( N
an DT N
interactive JJ N
seminar NN N
) ) N
delivered VBD N
at IN N
practice NN N
level NN N
( ( p
n=13 JJ p
practices NNS p
; : p
6=intervention CD p
, , p
7=control CD p
) ) p
. . N

The DT N
impact NN N
of IN N
the DT N
intervention NN N
was VBD N
assessed VBN N
against IN N
patient JJ o
outcomes NNS o
: : o
routinely RB o
available JJ o
asthma JJ o
outcome NN o
measures NNS o
( ( o
beta2-agonist JJ o
prescription NN o
rate NN o
and CC o
number NN o
of IN o
oral JJ o
steroid NN o
courses NNS o
) ) o
for IN N
asthma NN p
patients NNS p
identified VBN p
as IN p
being VBG p
poorly-controlled JJ p
from IN p
practice NN p
records NNS p
; : p
and CC N
questionnaire VB o
data NNS o
- : o
Mini NNP o
Asthma NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
AQLQ NNP o
) ) o
and CC o
the DT o
Asthma NNP o
Control NNP o
Questionnaire NNP o
( ( o
ACQ NNP o
) ) o
- : N
from IN N
a DT N
subset NN N
of IN N
consenting VBG N
patients NNS N
. . N

Data NNP N
was VBD N
collected VBN N
at IN N
baseline NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

ANALYSISs NN N
: : N
Routine NNP N
data NN N
was VBD N
analysed VBN N
for IN N
629 CD p
patients NNS p
. . p

236 CD p
( ( p
37 CD p
% NN p
) ) p
of IN p
these DT p
patients NNS p
consented VBD p
to TO p
provide VB p
questionnaire NN p
data NNS p
at IN N
baseline NN N
, , N
with IN N
75 CD N
% NN N
returning VBG N
questionnaires NNS N
at IN N
follow-up NN N
. . N

After IN N
adjustment NN N
for IN N
baseline NN N
and CC N
practice NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
at IN N
followup NN N
between IN N
intervention NN N
and CC N
control NN N
practices NNS N
on IN N
the DT N
Mini NNP o
AQLQ NNP o
only RB N
( ( N
p=0.03 NN N
) ) N
. . N

Estimates NNS N
for IN N
subsequent JJ N
sample NN N
sizes NNS N
to TO N
inform VB N
future JJ N
trials NNS N
of IN N
asthma JJ N
training NN N
were VBD N
identified VBN N
. . N

CONCLUSION NNP N
Training NNP N
designed VBD N
to TO N
support VB N
practice NN p
nurses NNS p
in IN N
implementing VBG N
individualised JJ N
AAPs NNP N
impacted VBD N
on IN N
one CD N
patient NN N
outcome NN N
only RB N
. . N

This DT N
disappointing JJ N
outcome NN N
may MD N
have VB N
been VBN N
due JJ N
to TO N
many JJ N
different JJ N
factors NNS N
such JJ N
as IN N
outcome JJ N
measure NN N
limitations NNS N
, , N
data NNS N
collection NN N
problems NNS N
, , N
and CC N
underestimating VBG N
the DT N
complexity NN N
of IN N
supporting VBG N
practice NN p
nurses NNS p
in IN N
behaviour JJ N
change NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
light-cured JJ N
filled VBN N
sealant NN N
on IN N
shear JJ N
bond NN N
strength NN N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
a DT N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
. . N

INTRODUCTION NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
highly RB N
filled VBN N
light-cured JJ i
sealant NN i
( ( i
HFLCS NNP i
) ) i
on IN N
the DT N
shear JJ N
bond NN N
strength NN N
and CC N
bond NN N
failure NN N
site NN N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
resin-modified JJ N
glass NN N
ionomer NN N
cement NN N
( ( N
RMGIC NNP N
) ) N
. . N

METHODS NNP N
Eighty NNP p
freshly RB p
extracted VBD p
maxillary JJ p
premolars NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
4 CD p
groups NNS p
( ( p
20 CD p
in IN p
each DT p
group NN p
) ) p
. . p

In IN N
all DT N
groups NNS N
, , N
the DT N
teeth NNS p
were VBD N
etched VBN N
with IN N
37 CD i
% NN i
phosphoric JJ i
acid NN i
for IN i
20 CD i
seconds NNS i
, , i
and CC i
RMGIC NNP i
( ( i
Fuji NNP i
Ortho NNP i
LC NNP i
, , i
GC NNP i
Europe NNP i
, , i
Leuven NNP i
, , i
Belgium NNP i
) ) i
was VBD N
used VBN N
for IN N
bracket NN N
bonding NN N
. . N

In IN N
groups NNS N
1 CD N
and CC N
3 CD N
, , N
the DT N
brackets NNS N
were VBD N
bonded VBN N
directly RB N
to TO N
etched VB N
enamel JJ N
surfaces NNS N
; : N
in IN N
groups NNS N
2 CD N
and CC N
4 CD N
, , N
the DT N
etched JJ N
enamel NN N
was VBD N
covered VBN N
with IN N
HFLCS NNP i
( ( i
Pro NNP i
Seal NNP i
, , i
Reliance NNP i
Orthodontic NNP i
Products NNP i
, , i
Itasca NNP i
, , i
Ill NNP i
) ) i
. . i

Groups $ N
1 CD N
and CC N
2 CD N
received VBD N
metal JJ i
brackets NNS i
, , N
and CC N
groups NNS N
3 CD N
and CC N
4 CD N
had VBD N
ceramic JJ i
brackets NNS i
. . i

The DT N
specimens NNS N
were VBD N
stored VBN N
in IN N
distilled JJ N
water NN N
at IN N
room NN N
temperature NN N
for IN N
24 CD N
hours NNS N
and CC N
subsequently RB N
tested VBN N
in IN N
shear JJ N
mode NN N
with IN N
a DT N
universal JJ N
testing NN N
machine NN N
. . N

After IN N
debonding VBG N
, , N
the DT N
teeth NNS N
and CC N
the DT N
brackets NNS N
were VBD N
examined VBN N
under IN N
a DT N
stereomicroscope NN N
( ( N
model JJ N
SMZ-1B NNP N
, , N
Nikon NNP N
, , N
Osaka NNP N
, , N
Japan NNP N
) ) N
at IN N
20-times JJ N
magnification NN N
to TO N
assess VB N
the DT N
residual JJ N
adhesive NN N
on IN N
the DT N
tooth NN N
surfaces NNS N
. . N

RESULTS NNP N
Interaction NNP N
between IN N
HFLCS NNP N
and CC N
bracket NN N
type NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
. . N

Pretreatment NN N
with IN N
HFLCS NNP o
did VBD o
not RB o
cause VB o
a DT o
statistically RB o
significant JJ o
change NN o
in IN o
the DT o
shear JJ o
bond NN o
values NNS o
of IN o
either DT o
metal NN o
or CC o
ceramic JJ o
brackets NNS o
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Shear JJ o
bond NN o
values NNS o
of IN o
the DT o
ceramic JJ o
brackets NNS o
were VBD N
higher JJR N
than IN N
those DT N
of IN N
the DT N
metal JJ N
brackets NNS N
independent JJ N
of IN N
HFLCS NNP N
application NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
bond NN o
failure NN o
modes VBZ o
in IN N
the DT N
4 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
HFLCS NNP N
application NN N
on IN N
enamel NN N
etched VBN N
with IN N
37 CD N
% NN N
phosphoric JJ N
acid NN N
did VBD N
not RB N
affect VB N
the DT N
bond NN o
strength NN o
values NNS o
and CC N
the DT N
bond NN o
failure NN o
modes NNS o
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
RMGIC NNP N
. . N

RESULTS NNP N
Interaction NNP N
between IN N
HFLCS NNP N
and CC N
bracket NN N
type NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
. . N

Pretreatment NN N
with IN N
HFLCS NNP N
did VBD N
not RB N
cause VB N
a DT N
statistically RB N
significant JJ N
change NN N
in IN N
the DT N
shear JJ o
bond NN o
values NNS o
of IN o
either DT o
metal NN o
or CC o
ceramic JJ o
brackets NNS o
( ( N
P NNP N
= NNP N
0.38 CD N
) ) N
. . N

Shear JJ o
bond NN o
values NNS o
of IN o
the DT o
ceramic JJ o
brackets NNS o
were VBD N
higher JJR N
than IN N
those DT N
of IN N
the DT N
metal JJ N
brackets NNS N
independent JJ N
of IN N
HFLCS NNP N
application NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
bond NN N
failure NN N
modes VBZ N
in IN N
the DT N
4 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
HFLCS NNP N
application NN N
on IN N
enamel NN N
etched VBN N
with IN N
37 CD N
% NN N
phosphoric JJ N
acid NN N
did VBD N
not RB N
affect VB N
the DT N
bond NN N
strength NN N
values NNS N
and CC N
the DT N
bond NN N
failure NN N
modes NNS N
of IN N
metal NN N
and CC N
ceramic JJ N
brackets NNS N
bonded VBN N
with IN N
RMGIC NNP N
. . N

-DOCSTART- -X- O O

Selected VBN N
polymorphisms NNS N
of IN N
GSTP1 NNP N
and CC N
TERT NNP N
were VBD N
associated VBN N
with IN N
glioma NN p
risk NN p
in IN p
Han NNP p
Chinese NNP p
. . p

BACKGROUND NNP N
Current NNP N
evidence NN N
suggests VBZ N
that IN N
a DT N
majority NN N
of IN N
the DT N
inherited JJ N
risks NNS N
play VBP N
a DT N
major JJ N
role NN N
in IN N
glioma JJ p
susceptibility NN p
, , N
and CC N
glioma NN N
is VBZ N
due JJ N
to TO N
the DT N
co-inheritance NN N
of IN N
multiple JJ N
low-risk JJ N
variants NNS N
. . N

These DT N
variants NNS N
can MD N
be VB N
identified VBN N
through IN N
association NN N
studies NNS N
including VBG N
such JJ N
as IN N
genome-wide JJ N
association NN N
studies NNS N
( ( N
GWAS NNP N
) ) N
, , N
which WDT N
has VBZ N
led VBN N
the DT N
glioma NN N
epidemiology NN N
researchers NNS N
to TO N
focus VB N
on IN N
identifying VBG N
potential JJ N
disease-causing JJ N
factors NNS N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
and CC N
validated VBD N
10 CD p
tag NN p
single JJ p
nucleotide JJ p
polymorphisms NN p
( ( p
tSNPs NN p
) ) p
in IN p
seven CD p
genes NNS p
associated VBN p
with IN p
glioma NN p
susceptibility NN p
in IN p
a DT p
Han NNP p
Chinese NNP p
population NN p
, , p
including VBG p
301 CD p
glioma NN p
cases NNS p
and CC p
302 CD p
controls NNS p
, , p
using VBG p
a DT p
multiplexed JJ i
single JJ i
nucleotide NN i
polymorphism NN i
( ( i
SNP NNP i
) ) i
MassEXTEND NNP i
assay NN i
. . i

We PRP N
ascertained VBD N
the DT N
genotypic NN N
frequencies NNS N
for IN N
each DT N
tSNP NN N
in IN N
control NN N
subjects NNS N
were VBD N
within IN N
Hardy-Weinberg NNP N
equilibrium NN N
( ( N
HWE NNP N
) ) N
using VBG N
an DT N
exact JJ N
test NN N
, , N
and CC N
then RB N
compared VBN N
the DT N
genotype NN N
and CC N
allele JJ N
frequencies NNS N
of IN N
glioma NN N
patients NNS N
and CC N
control NN N
subjects NNS N
using VBG N
the DT N
?2 JJ N
test NN N
. . N

We PRP N
then RB N
applied VBD N
three CD N
genetic JJ N
models NNS N
( ( N
dominant JJ N
, , N
recessive JJ N
, , N
and CC N
additive JJ N
) ) N
using VBG N
PLINK NNP N
software NN N
to TO N
assess VB N
the DT N
association NN N
of IN N
each DT N
tSNP NN N
with IN N
glioma NN N
risk NN N
. . N

RESULTS NNP N
We PRP N
identified VBD N
two CD N
tSNPs NN N
to TO N
be VB N
associated VBN N
with IN o
glioma NN o
susceptibility NN o
( ( N
rs1695 NN N
, , N
GSTP1 NNP N
, , N
P NNP N
= NNP N
0.019 CD N
; : N
rs2853676 NN N
, , N
TERT NNP N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
, , N
which WDT N
we PRP N
confirmed VBD N
using VBG N
dominant NN N
and CC N
additive JJ N
model NN N
analyses NNS N
. . N

The DT N
genotype NN N
& CC N
ldquo NN N
; : N
GA NNP N
& CC N
rdquo NN N
; : N
for IN N
rs1695 NN N
was VBD N
recognized VBN N
to TO N
be VB N
a DT N
protective JJ N
genotype NN N
for IN o
glioma NN o
( ( N
OR NNP N
, , N
0.67 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.47-0.96 NNP N
; : N
P NNP N
= NNP N
0.027 CD N
) ) N
, , N
while IN N
the DT N
genotype NN N
& CC N
ldquo NN N
; : N
AG NNP N
& CC N
rdquo NN N
; : N
for IN N
rs2853676 NN N
was VBD N
shown VBN N
to TO N
be VB N
a DT N
risk NN N
genotype NN N
for IN o
glioma NN o
( ( N
OR NNP N
, , N
1.50 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.05-2.15 JJ N
; : N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
, , N
and CC N
those DT N
from IN N
previous JJ N
studies NNS N
, , N
suggest VBP N
potential JJ N
genetic JJ N
contributes NNS N
for IN N
GSTP1 NNP N
and CC N
TERT NNP N
in IN N
glioma NN N
development NN N
. . N

-DOCSTART- -X- O O

A DT N
placebo-controlled JJ i
trial NN N
of IN N
maintenance NN N
therapy NN N
with IN N
fluconazole JJ i
after IN p
treatment NN p
of IN p
cryptococcal JJ p
meningitis NN p
in IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
. . p

California NNP N
Collaborative NNP N
Treatment NNP N
Group NNP N
. . N

BACKGROUND NNP N
AND NNP N
METHODS NNP N
In IN N
patients NNS p
with IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
( ( p
AIDS NNP p
) ) p
, , N
the DT N
rate NN N
of IN N
relapse NN N
after IN N
primary JJ N
treatment NN N
for IN N
cryptococcal JJ N
meningitis NN N
remains VBZ N
high JJ N
. . N

We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
double-blind JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
maintenance NN N
therapy NN N
with IN N
fluconazole NN N
. . N

At IN N
entry NN N
into IN N
the DT N
study NN N
, , N
all DT p
participants NNS p
had VBD p
sterile JJ p
cultures NNS p
of IN p
cerebrospinal JJ p
fluid NN p
, , p
blood NN p
, , p
and CC p
urine JJ p
after IN p
following VBG p
a DT p
standardized JJ p
course NN p
of IN p
therapy NN p
for IN p
culture-proved JJ p
cryptococcal JJ p
meningitis NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
take VB N
either DT N
fluconazole NN i
or CC i
placebo NN i
as IN N
maintenance NN N
therapy NN N
. . N

The DT N
dose NN N
of IN N
fluconazole NN i
was VBD N
100 CD N
mg JJ N
daily RB N
in IN N
the DT N
first JJ N
phase NN N
of IN N
study NN N
and CC N
200 CD N
mg NNS N
daily RB N
in IN N
the DT N
second JJ N
phase NN N
. . N

RESULTS NNP N
Of IN p
84 CD p
patients NNS p
initially RB p
enrolled VBD p
, , p
16 CD p
( ( p
19 CD p
percent NN p
) ) p
were VBD p
found VBN p
to TO p
have VB p
silent JJ p
, , p
persistent JJ p
infection NN p
on IN p
the DT p
basis NN p
of IN p
cultures NNS p
that WDT p
became VBD p
positive JJ p
after IN p
entry NN p
into IN p
the DT p
study NN p
; : p
7 CD p
other JJ p
patients NNS p
were VBD p
lost VBN p
to TO p
follow-up NNS p
shortly RB p
after IN p
entry NN p
. . N

Of IN N
the DT N
remaining VBG p
61 CD p
patients NNS p
, , N
10 CD N
of IN N
27 CD N
assigned VBN N
to TO N
placebo VB i
( ( N
37 CD N
percent NN N
) ) N
and CC N
1 CD N
of IN N
34 CD N
assigned VBN N
to TO N
fluconazole VB i
( ( N
3 CD N
percent NN N
) ) N
had VBD N
a DT N
recurrence NN o
of IN o
cryptococcal JJ o
infection NN o
at IN o
any DT o
site NN o
( ( N
difference NN N
in IN N
risk NN N
, , N
34 CD N
percent NN N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
15 CD N
to TO N
53 CD N
) ) N
. . N

Of IN N
the DT N
11 CD N
recurrent NN N
infections NNS N
, , N
7 CD N
were VBD N
detected VBN N
in IN N
urine NN N
obtained VBN N
after IN N
prostatic JJ N
massage NN N
. . N

There EX N
were VBD N
four CD N
recurrent NN o
meningeal NN o
infections NNS o
in IN N
the DT N
patients NNS N
taking VBG N
placebo NN i
, , N
but CC N
none NN N
in IN N
those DT N
taking VBG N
fluconazole JJ i
( ( N
mean JJ N
duration NN N
of IN N
follow-up NN N
, , N
164 CD N
days NNS N
) ) N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

In IN N
multivariate NN N
analyses NNS N
, , N
the DT N
best JJS N
predictors NNS N
of IN N
recurrence-free JJ o
survival NN o
were VBD N
fluconazole JJ i
treatment NN i
( ( N
P NNP N
= NNP N
0.02 CD N
; : N
relative JJ N
hazard NN N
, , N
13.2 CD N
) ) N
, , N
a DT N
lower JJR N
serum NN N
cryptococcal-antigen NN N
titer NN N
( ( N
P NNP N
= NNP N
0.05 CD N
; : N
relative JJ N
hazard NN N
, , N
1.2 CD N
) ) N
, , N
and CC N
more JJR N
prolonged JJ N
primary JJ N
therapy NN N
with IN N
flucytosine NN N
( ( N
P NNP N
= NNP N
0.09 CD N
; : N
relative JJ N
hazard NN N
, , N
1.1 CD N
) ) N
. . N

Survival NNP o
and CC o
toxicity NN o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
maintenance-treatment JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
AIDS NNP p
, , N
silent JJ N
persistent JJ N
infection NN N
is VBZ N
common JJ N
after IN N
clinically RB N
successful JJ N
treatment NN N
for IN N
cryptococcal JJ N
meningitis NN N
. . N

Maintenance NNP N
therapy NN N
with IN N
fluconazole NN i
is VBZ N
highly RB N
effective JJ N
in IN N
preventing VBG N
recurrent JJ N
cryptococcal JJ N
infection NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
evolutional JJ o
process NN o
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
in IN N
different JJ N
language NN i
therapeutic JJ i
interventions NNS i
. . i

PURPOSE NNP N
To TO N
analyze VB N
and CC N
compare VB N
the DT o
extension NN o
and CC o
the DT o
speed NN o
of IN o
the DT o
evolutional JJ o
process NN o
of IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
in IN N
direct JJ i
and CC i
indirect JJ i
interventions NNS i
as IN N
opposed VBN N
to TO N
only RB N
indirect VB N
intervention NN N
. . N

METHODS NNP N
The DT N
design NN N
of IN N
this DT N
study NN N
is VBZ N
a DT N
clinical JJ N
trial NN N
. . N

The DT N
sample NN N
was VBD N
composed VBN N
of IN N
11 CD p
children NNS p
diagnosed VBN p
with IN p
Autism NNP p
( ( p
n=6 NN p
) ) p
and CC p
Asperger NNP p
syndrome VBP p
( ( p
n=5 NN p
) ) p
by IN p
a DT p
multidisciplinary JJ p
team NN p
, , p
that WDT p
attended VBD p
specialized JJ p
speech-language JJ p
pathology NN p
therapy NN p
at IN p
the DT p
institution NN p
were VBD p
the DT p
study NN p
was VBD p
carried VBN p
out RP p
. . p

These DT N
children NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
Therapy NNP i
Group NNP i
( ( i
TG NNP i
) ) i
- : i
composed VBN i
by IN i
six CD i
subjects NNS i
receiving VBG i
both DT i
direct JJ i
and CC i
indirect JJ i
intervention NN i
; : i
and CC i
Orientation NNP i
Group NNP i
( ( i
OG NNP i
) ) i
- : i
constituted VBN i
by IN i
five CD i
subjects NNS i
receiving VBG i
exclusively RB i
indirect JJ i
intervention NN i
. . i

It PRP N
was VBD N
used VBN N
the DT N
Autism NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
to TO i
interview NN i
the DT i
mothers NNS i
, , i
and CC i
the DT i
Sample NNP o
of IN o
Vocal NNP o
Behavior NNP o
( ( o
SVB NNP o
) ) o
, , i
in IN i
three CD i
occasions NNS i
: : i
at IN i
the DT i
beginning NN i
of IN i
the DT i
intervention NN i
process NN i
( ( i
time NN i
0 CD i
) ) i
, , i
six CD i
months NNS i
later RB i
( ( i
time NN i
1 CD i
) ) i
and CC i
12 CD i
months NNS i
later RB i
( ( i
time NN i
2 CD i
) ) i
. . i

RESULTS VB N
It PRP N
was VBD N
observed VBN N
greater JJR N
speed NN o
and CC o
extension NN o
in IN o
the DT o
evolutional JJ o
process NN o
of IN N
the DT N
TG NNP N
Group NNP N
, , N
both DT N
in IN N
the DT N
analysis NN N
of IN N
the DT N
Autism NNP o
Behavior NNP o
Checklist NNP o
( ( o
total JJ o
and CC o
partial JJ o
scores NNS o
) ) o
and CC N
the DT N
Sample NNP o
of IN o
Vocal NNP o
Behavior NNP o
, , N
especially RB N
in IN N
the DT N
item NN N
Full NNP N
Language NNP N
. . N

The DT N
performance NN N
of IN N
children NNS p
with IN p
Asperger NNP p
syndrome NN p
was VBD N
considered VBN N
more RBR N
positive JJ N
when WRB N
compared VBN N
to TO N
that DT N
of IN N
children NNS p
with IN p
autism NN p
. . p

There EX N
was VBD N
greater JJR N
evolution NN o
in IN N
younger JJR N
children NNS N
and CC N
with IN N
normal JJ N
, , N
mild JJ N
, , N
and CC N
moderate JJ N
adaptive JJ o
functioning NN o
. . o

CONCLUSION VB N
The DT N
tendency NN N
towards NNS N
better RBR N
performance NN o
of IN N
the DT N
children NNS N
attending VBG N
direct JJ i
and CC i
indirect JJ i
intervention NN i
showed VBD N
that IN N
this DT N
association NN N
is VBZ N
fundamental JJ N
in IN N
the DT N
therapeutic JJ N
process NN N
of IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
vacuum-compression NN o
therapy NN o
on IN N
healing NN N
of IN N
diabetic JJ o
foot NN o
ulcers NNS o
: : o
randomized VBN N
controlled JJ N
trial NN N
. . N

A DT N
single-blind JJ N
, , N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
vacuum-compression NN o
therapy NN o
( ( o
VCT NNP o
) ) o
for IN N
the DT N
healing NN N
of IN N
diabetic JJ o
foot NN o
ulcers NNS o
. . o

Eighteen NNP p
diabetic JJ p
patients NNS p
with IN p
foot JJ o
ulcers NNS o
were VBD p
recruited VBN p
through IN p
simple JJ p
nonprobability NN p
sampling VBG p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
experimental JJ N
or CC N
a DT N
control NN i
group NN N
. . N

Before IN N
and CC N
after IN N
intervention NN N
, , N
the DT N
foot NN o
ulcer JJ o
surface NN o
area NN o
was VBD N
estimated VBN N
stereologically RB N
, , N
based VBN N
on IN N
Cavalieri NNP N
's POS N
principle NN N
. . N

The DT N
experimental JJ N
group NN N
was VBD N
treated VBN N
with IN N
VCT NNP o
in IN i
addition NN i
to TO i
conventional JJ o
therapy NN o
for IN N
10 CD N
sessions NNS N
. . N

The DT N
control NN N
group NN N
received VBD N
only RB N
conventional JJ o
therapy NN o
, , i
including VBG i
debridement NN o
, , o
blood NN o
glucose NNS o
control NN o
agents NNS o
, , o
systemic JJ o
antibiotics NNS o
, , o
wound IN o
cleaning VBG o
with IN o
normal JJ o
saline NN o
, , o
offloading VBG o
( ( o
pressure NN o
relief NN o
) ) o
, , i
and CC i
daily RB o
wound JJ o
dressings NNS o
. . o

The DT N
mean JJ N
foot NN o
ulcer JJ o
surface NN o
area NN o
decreased VBD N
from IN N
46.88 CD N
+/- JJ N
9.28 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
35.09 CD N
+/- JJ N
4.09 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
and CC N
from IN N
46.62 CD N
+/- JJ N
10.03 CD N
mm NN N
( ( N
2 CD N
) ) N
to TO N
42.89 CD N
+/- JJ N
8.1 CD N
mm NN N
( ( N
2 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
the DT N
experimental JJ N
group NN N
significantly RB N
improved VBN N
in IN N
measures NNS o
of IN o
foot NN o
ulcer JJ o
surface NN o
area NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.024 CD N
) ) N
. . N

VCT NNP o
enhances VBZ N
diabetic JJ o
foot NN o
ulcer NN o
healing VBG o
when WRB N
combined VBN N
with IN N
appropriate JJ N
wound NN N
care NN N
. . N

-DOCSTART- -X- O O

Computer-navigated JJ i
versus NN i
conventional JJ i
total JJ i
knee NN i
arthroplasty IN i
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
literature NN N
lacks VBZ N
studies NNS N
that IN N
confirm VBP N
whether IN N
the DT N
improved JJ N
radiographic JJ N
alignment NN N
that WDT N
can MD N
be VB N
achieved VBN N
with IN N
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
improves VBZ N
patients? JJ N
activities NNS N
of IN N
daily JJ N
living NN N
or CC N
the DT N
durability NN N
of IN N
total JJ N
knee NN N
prostheses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN i
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
improves VBZ i
the DT N
clinical JJ N
function NN N
, , N
alignment NN N
, , N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
. . N

METHODS NNP N
We PRP N
prospectively RB N
compared VBN N
the DT N
results NNS N
of IN N
520 CD p
patients NNS p
with IN p
osteoarthritis NN p
who WP p
underwent VBD i
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
for IN i
one CD i
knee NN i
and CC i
conventional JJ i
total JJ i
knee NN i
arthroplasty NN i
for IN i
the DT i
other JJ i
. . i

The DT N
assignment NN N
of IN N
the DT N
knee NN N
to TO N
navigation NN N
or CC N
not RB N
was VBD N
done VBN N
randomly RB N
. . N

There EX N
were VBD p
452 CD p
women NNS p
( ( p
904 CD p
knees NNS p
) ) p
and CC p
sixty-eight JJ p
men NNS p
( ( p
136 CD p
knees NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
sixty-eight JJ p
years NNS p
( ( p
range NN p
, , p
forty-nine JJ p
to TO p
eighty-eight JJ p
years NNS p
) ) p
at IN p
the DT p
time NN p
of IN p
the DT p
index NN p
arthroplasty NN p
. . p

The DT N
mean JJ N
follow-up JJ N
period NN N
was VBD N
10.8 CD N
years NNS N
( ( N
range NN N
, , N
ten VB N
to TO N
twelve VB N
years NNS N
) ) N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
clinically RB N
and CC N
radiographically RB N
with IN N
the DT o
rating NN o
system NN o
of IN o
the DT o
Knee NNP o
Society NNP o
and CC o
with IN N
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
score NN o
at IN o
three CD N
months NNS N
, , N
one CD N
year NN N
, , N
and CC N
annually RB N
thereafter RB N
. . N

RESULTS NNP o
Total JJ o
knee NN o
scores NNS o
, , o
knee NN o
function NN o
scores NNS o
, , o
pain NN o
scores NNS o
, , o
WOMAC NNP o
scores VBZ o
, , o
knee VB o
motion NN o
, , o
and CC o
activity NN o
scores NNS o
did VBD o
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
preoperatively RB N
or CC N
at IN N
the DT N
time NN N
of IN N
the DT N
final JJ N
follow-up NN N
. . N

Alignment NNP N
and CC N
the DT N
survivorship NN N
of IN N
the DT N
components NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT o
Kaplan-Meier NNP o
survivorship NN o
with IN o
revision NN o
as IN o
the DT N
end NN N
point NN N
at IN N
10.8 CD N
years NNS N
was VBD N
98.8 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT i
computernavigated JJ i
total JJ i
knee NN i
arthroplasty NN i
group NN i
and CC N
99.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
1.00 CD N
) ) N
in IN N
the DT i
conventional JJ i
total JJ i
knee NN i
arthroplasty NN i
group NN i
. . N

CONCLUSIONS NNP N
Our PRP$ N
data NNS N
demonstrated VBD N
no DT N
difference NN N
in IN N
clinical JJ N
function NN N
or CC N
alignment NN N
and CC N
survivorship NN N
of IN N
the DT N
components NNS N
between IN N
the DT p
knees NNS p
that WDT p
underwent VBD i
computer-navigated JJ i
total JJ i
knee NN i
arthroplasty NN i
and CC i
those DT p
that WDT p
underwent JJ i
conventional JJ i
total JJ i
knee NN i
arthroplasty NN i
. . i

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
live JJ N
and CC N
videotape JJ N
ratings NNS N
: : N
clomipramine NN i
and CC i
haloperidol NN i
in IN p
autism NN p
. . p

This DT N
study NN N
compared VBN N
live JJ N
ratings NNS N
with IN N
ratings NNS N
of IN N
videotapes NNS N
and CC N
compared VBN N
response NN N
to TO N
clomipramine VB i
with IN N
response NN N
to TO N
haloperidol VB i
in IN N
8 CD p
subjects NNS p
, , p
mean JJ p
age NN p
5.62 CD p
years NNS p
, , p
who WP p
met VBD p
criteria NNS p
for IN p
autism NN p
. . p

They PRP N
were VBD N
consecutive JJ N
admissions NNS N
to TO N
a DT N
pilot NN N
study NN N
of IN N
clomipramine NN i
( ( N
n JJ N
= NNP N
4 CD N
) ) N
or CC N
a DT N
double-blind JJ N
, , N
placebo NN i
controlled VBD N
study NN N
of IN N
haloperidol NN i
( ( N
n JJ N
= NNP N
4 CD N
) ) N
. . N

Live JJ N
ratings NNS N
were VBD N
performed VBN N
by IN N
two CD N
raters NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
pre-treatment JJ N
placebo NN i
baseline NN N
period NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
drug NN N
treatment NN N
period NN N
on IN N
the DT N
CPRS NNP N
and CC N
the DT N
CGI NNP N
and CC N
were VBD N
videotaped VBN N
. . N

Employing VBG N
the DT N
same JJ N
instruments NNS N
, , N
these DT N
videotapes NNS N
were VBD N
rated VBN N
by IN N
two CD N
raters NNS N
who WP N
did VBD N
not RB N
know VB N
the DT N
subjects NNS N
and CC N
were VBD N
blind NNS N
to TO N
study VB N
design NN N
, , N
treatment NN N
, , N
and CC N
study NN N
phase NN N
. . N

Ratings NNS o
of IN o
videotapes NNS o
significantly RB N
differed VBN N
from IN N
live JJ o
ratings NNS o
. . o

A DT N
treatment NN N
effect NN N
for IN N
haloperidol NN N
was VBD N
detected VBN N
only RB N
on IN N
live JJ o
ratings NNS o
and CC N
not RB N
on IN N
ratings NNS o
of IN o
videotapes NNS o
. . o

No DT N
treatment NN N
effect NN N
was VBD N
detected VBN N
for IN N
clomipramine NN i
in IN N
either CC N
live JJ o
or CC o
videotape JJ o
ratings NNS o
. . o

-DOCSTART- -X- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
investigating VBG N
the DT N
effect NN N
of IN N
porcine NN i
secretin NN i
in IN N
children NNS p
with IN p
autism NN p
. . p

OBJECTIVES CC N
A DT N
recent JJ N
patient NN N
series NN N
reported VBD N
the DT N
incidental JJ N
findings NNS N
of IN N
improved VBN N
social JJ N
and CC N
language NN N
skills NNS N
in IN N
3 CD p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
after IN p
the DT p
administration NN p
of IN p
secretin NN i
, , p
a DT p
peptide NN p
hormone NN p
. . p

However RB N
, , N
a DT N
subsequent JJ N
study NN N
did VBD N
not RB N
find VB N
evidence NN N
for IN N
a DT N
drug NN N
effect NN N
. . N

Parents NNS N
are VBP N
seeking VBG N
treatment NN N
with IN N
secretin JJ i
despite IN N
the DT N
absence NN N
of IN N
empirical JJ N
investigations NNS N
demonstrating VBG N
amelioration NN N
in IN N
autism NN N
symptomology NN N
. . N

In IN N
order NN N
to TO N
more RBR N
precisely RB N
measure VB N
the DT N
effects NNS N
of IN N
secretin NN i
, , N
this DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
intravenous JJ i
dose NN i
of IN i
porcine NN i
secretin NN i
on IN N
12 CD p
autistic JJ p
children NNS p
through IN N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

Children NNP N
were VBD N
assessed VBN N
on IN N
objective JJ o
language NN o
and CC o
on IN o
social JJ o
, , o
neuropsychological JJ o
, , o
and CC o
gastrointestinal JJ o
measures NNS o
to TO N
evaluate VB N
drug NN N
effects NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
over IN N
a DT N
16-week JJ N
trial NN N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
significant JJ N
differences NNS N
were VBD N
not RB N
observed VBN N
on IN N
the DT N
majority NN N
of IN N
the DT N
dependent JJ N
variables NNS N
. . N

Statistically NNP N
significant JJ N
differences NNS N
were VBD N
observed VBN N
on IN N
measures NNS o
of IN o
positive JJ o
affect NN o
and CC o
activity NN o
level NN o
following VBG N
secretin JJ i
infusion NN N
. . N

In IN N
general JJ N
, , N
the DT N
autistic JJ p
children NNS p
did VBD N
not RB N
demonstrate VB N
the DT N
improvements NNS N
described VBN N
in IN N
the DT N
initial JJ N
retrospective JJ N
report NN N
. . N

-DOCSTART- -X- O O

Cost-effectiveness NN o
of IN N
cognitive-behavioral JJ i
group NN i
therapy NN i
for IN N
dysfunctional JJ N
fear NN N
of IN N
progression NN N
in IN N
cancer NN p
patients NNS p
. . p

Anxiety NNP o
and CC o
fear NN o
are VBP N
often RB N
associated VBN N
with IN N
chronic JJ N
conditions NNS N
such JJ N
as IN N
cancer NN N
. . N

This DT N
paper NN N
targets VBZ N
the DT N
cost-effectiveness JJ o
analysis NN o
of IN N
a DT N
cognitive-behavioral JJ i
group NN i
therapy NN i
( ( i
CBT NNP i
) ) i
in IN N
comparison NN N
to TO N
a DT N
client-centered JJ i
, , i
supportive-experiential JJ i
group NN i
therapy NN i
( ( i
SET NNP i
) ) i
in IN N
cancer NN p
patients NNS p
with IN p
dysfunctional JJ p
fear NN p
of IN p
progression NN p
. . p

An DT N
incremental JJ N
cost-effectiveness JJ o
analysis NN o
was VBD N
performed VBN N
using VBG N
data NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
among IN N
cancer NN p
patients NNS p
receiving VBG p
inpatient JJ p
rehabilitation NN p
. . p

The DT N
means NNPS o
, , o
95 CD o
% NN o
confidence NN o
intervals NNS o
[ VBP o
95 CD o
% NN o
CI NNP o
] NNP o
, , o
incremental JJ o
cost-effectiveness JJ o
graphic NN o
and CC o
acceptability NN o
curve NN o
were VBD N
obtained VBN N
from IN N
1,000 CD N
bootstrap NN N
replications NNS N
. . N

A DT p
total NN p
of IN p
174 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
economic JJ p
evaluation NN p
. . p

The DT N
estimated JJ o
means VBZ o
[ JJ N
95 CD N
% NN N
CI NNP N
] NNP N
of IN o
direct JJ o
costs NNS o
and CC o
reduction NN o
of IN o
fear NN o
of IN o
progression NN o
were VBD N
< JJ N
euro JJ N
> NN N
9,045.03 CD N
[ JJ N
6,359.07 CD N
; : N
12,091.87 CD N
] NN N
and CC N
1.41 CD N
[ JJ N
0.93 CD N
; : N
1.92 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
SET NNP N
and CC N
< NNP N
euro VBP N
> $ N
6,682.78 CD N
[ JJ N
4,998.09 CD N
; : N
8,440.95 CD N
] NN N
and CC N
1.44 CD N
[ JJ N
1.02 CD N
; : N
1.09 CD N
] NN N
for IN N
patients NNS N
in IN N
the DT N
CBT NNP i
. . i

The DT N
incremental JJ o
cost-effectiveness JJ o
ratio NN o
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
amounts NNS N
to TO N
minus NNS N
< NNP N
euro VBP N
> $ N
78,741.66 CD N
[ NNP N
-154,987.20 NNP N
; : N
110,486.32 CD N
] NN N
for IN N
an DT N
additional JJ N
unit NN N
of IN N
effect NN N
. . N

Given VBN N
the DT N
acceptability NN o
curve NN o
, , N
there EX N
is VBZ N
a DT N
92.4 CD N
% NN N
chance NN N
that IN N
the DT N
CBT NNP i
, , N
compared VBN N
with IN N
the DT N
SET NNP i
, , N
is VBZ N
cost-effective JJ o
without IN N
the DT N
need NN N
of IN N
additional JJ N
costs NNS N
to TO N
payers NNS N
. . N

Our PRP$ N
main JJ N
result NN N
is VBZ N
the DT N
superior JJ N
cost-effectiveness NN o
of IN N
the DT N
cognitive-behavioral JJ i
intervention NN i
program NN N
in IN N
comparison NN N
to TO N
the DT N
non-directive JJ N
encounter NN N
group NN N
for IN N
our PRP$ N
sample NN N
of IN N
cancer NN p
patients NNS p
with IN p
high JJ p
levels NNS p
of IN p
anxiety NN o
. . o

-DOCSTART- -X- O O

[ JJ o
Effect NNP o
analysis NN o
on IN N
non-and-low JJ N
response NN N
infants NNS p
after IN p
revaccinated VBN p
hepatitis NN i
B NNP i
vaccine NN i
] NN i
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
booster NN o
immunization NN o
effect NN o
to TO N
non-and-low JJ N
response NN N
children NNS N
after IN N
3 CD N
doses NNS N
HepB NNP N
immunization NN N
. . N

METHODS NNP N
Non-and-low JJ p
response NN p
infants NNS p
born VBN p
in IN p
2004 CD p
2005 CD p
administered VBD p
3 CD i
doses NNS i
of IN i
HepB NNP i
at IN i
0 CD i
, , i
1 CD i
, , i
6 CD i
months NNS i
in IN i
Guangzhou NNP i
, , i
Beijing NNP i
and CC i
Zhejiang NNP i
were VBD i
divided VBN i
into IN i
4 CD i
groups NNS i
randomly RB i
, , i
and CC i
boosted VBD i
3 CD i
dose NN i
of IN i
4 CD i
different JJ i
types NNS i
of IN i
HepB NNP i
at IN i
0 CD i
, , i
1 CD i
, , i
6 CD i
months NNS i
. . i

RESULTS VB N
The DT N
GMC NNP N
of IN N
non-and-low JJ p
response NN p
children NNS p
in IN N
group NN N
A NNP N
( ( N
before IN N
booster NN N
) ) N
, , N
group NN N
B NNP N
( ( N
after IN N
1 CD N
dose JJ N
booster NN N
) ) N
and CC N
group NN N
C NNP N
( ( N
after IN N
3 CD N
dose JJ N
booster NN N
) ) N
were VBD N
18.66 CD N
mIUml NN N
, , N
88.82 CD N
mIU/ml NN N
, , N
178.24 CD N
mIU/ml NN N
respectively RB N
; : N
the DT N
proportion NN N
of IN N
non-responders NNS N
in IN N
three CD N
groups NNS N
were VBD N
20.4 CD N
% NN N
, , N
9.1 CD N
% NN N
, , N
1.9 CD N
% NN N
respectively RB N
. . N

In IN N
103 CD p
non-and-low JJ p
response NN p
children NNS p
, , N
proportion NN o
of IN o
titers NNS o
of IN N
more JJR N
than IN N
100 CD N
mIU/ml NN N
of IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
were VBD N
61.2 CD N
% NN N
and CC N
84.5 CD N
% NN N
, , N
and CC N
there RB N
was VBD N
statistical JJ N
significant JJ N
difference NN N
( ( N
chi2 JJ N
= NN N
14.13 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
GMC NNP N
after IN N
3 CD N
doses NNS N
revaccination NN i
with IN N
four CD N
kinds NNS N
of IN N
HepB NNP N
, , N
included VBD N
5 CD N
microg NN N
HepB-Y NNP i
, , N
10 CD N
microg NN N
HepB-Y NNP i
, , N
l0 JJ N
microg NN N
HepB-CHO NNP i
, , N
10 CD N
microg JJ N
HepB-HY NNP i
were VBD N
168.8 CD N
mJU/ml NN N
, , N
174.7 CD N
mIU/ml NN N
, , N
184.9 CD N
mIU/ml NN N
, , N
182.9 CD N
mIU/ml NN N
respectively RB N
. . N

Proportion NN o
of IN o
titers NNS o
of IN N
more JJR N
than IN N
100 CD N
mIU/ml NNS N
for IN N
four CD N
kinds NNS N
HepB NNP N
were VBD N
79.0 CD N
% NN N
, , N
85.7 CD N
% NN N
, , N
88.2 CD N
% NN N
and CC N
84.6 CD N
% NN N
respectively RB N
, , N
and CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
chi2 JJ N
= NN N
0.75 CD N
, , N
0.05 CD N
) ) N
. . N

CONCLUSION NN N
There EX N
were VBD N
no DT N
different JJ N
of IN N
seroconversion NN o
rate NN o
between IN N
study NN N
population NN N
received VBD N
1 CD N
dose NN N
and CC N
3 CD N
dose JJ N
booster NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
but CC N
high JJ N
titer NN N
was VBD N
observed VBN N
after IN N
3 CD N
dose JJ N
booster NN N
. . N

The DT N
four CD N
kinds NNS N
of IN N
HepB NNP N
, , N
including VBG N
5 CD N
microg JJ N
HepB-Y,10 NNP N
microg NN N
HepB-Y NNP N
, , N
10 CD N
microg NN N
HepB-CHO NNP N
, , N
10 CD N
microg NN N
HepB-HY NNP N
had VBD N
the DT N
same JJ N
immunization NN N
effect NN N
after IN N
3 CD N
doses NNS N
revaccination NN N
at IN N
0 CD N
, , N
1 CD N
, , N
6 CD N
months NNS N
to TO N
non-and-low JJ N
response NN N
children NNS N
. . N

-DOCSTART- -X- O O

Pharmacokinetic JJ N
properties NNS N
of IN N
YM17E NNP i
, , i
an DT i
inhibitor NN i
of IN i
acyl NN i
coenzyme NN i
A DT N
: : N
cholesterol NN N
acyl NN N
transferase NN N
, , N
and CC N
serum VB o
cholesterol NN o
levels NNS o
in IN N
healthy JJ p
volunteers NNS p
. . p

We PRP N
conducted VBD N
a DT N
single JJ N
and CC N
repeat JJ N
oral JJ N
dose NN i
study NN i
of IN i
YM17E NNP i
, , N
a DT N
novel JJ N
inhibitor NN N
of IN N
acyl NN N
coenzyme NN N
A NNP N
( ( N
CoA NNP N
) ) N
: : N
cholesterol NN N
acyltransferase NN N
, , N
in IN N
healthy JJ p
male NN p
volunteers NNS p
to TO N
evaluate VB N
the DT N
pharmacokinetic JJ o
profile NN o
, , o
tolerability NN o
and CC o
effect NN o
of IN o
the DT o
drug NN o
on IN o
serum NN o
cholesterol NN o
. . o

In IN N
the DT N
single JJ N
administration NN N
study NN N
, , N
YM17E NNP i
was VBD i
administered VBN i
after IN i
a DT i
meal NN i
to TO i
two CD i
groups NNS i
of IN i
subjects NNS i
( ( i
each DT i
containing VBG i
six CD i
subjects NNS i
taking VBG i
the DT i
drug NN i
and CC i
three CD i
taking VBG i
placebo NN i
) ) i
receiving VBG i
3 CD i
, , i
60 CD i
and CC i
300 CD i
mg NN i
or CC i
15 CD i
, , i
60 CD i
and CC i
450 CD i
mg NN i
YM17E NNP i
, , i
respectively RB i
. . i

Plasma NNP o
concentrations NNS o
of IN N
unchanged JJ N
drug NN N
following VBG N
single JJ N
oral JJ N
administration NN N
at IN N
3-300 JJ N
mg NN N
after IN N
a DT N
meal NN N
increased VBN N
with IN N
increasing VBG N
dose NN N
. . N

In IN N
contrast NN N
, , N
plasma NN o
concentrations NNS o
after IN N
administration NN N
of IN N
450 CD N
mg NNS N
were VBD N
almost RB N
the DT N
same JJ N
as IN N
after IN N
300 CD N
mg NN N
. . N

Unchanged VBD N
YM17E NNP i
was VBD N
not RB N
detected VBN N
in IN N
urine NN N
after IN N
single JJ N
administration NN N
, , N
suggesting VBG N
that IN N
it PRP N
was VBD N
excreted VBN N
via IN N
the DT N
bile NN N
or CC N
urine NN N
after IN N
metabolism NN N
. . N

Five CD N
active JJ N
metabolites NNS N
( ( N
M1 NNP N
, , N
M2-a NNP N
, , N
M2-b NNP N
, , N
M3 NNP N
and CC N
M4 NNP N
) ) N
were VBD N
observed VBN N
in IN N
plasma NN N
at IN N
concentrations NNS N
comparable JJ N
to TO N
those DT N
of IN N
unchanged JJ N
YM17E NNP i
. . i

Their PRP$ N
plasma JJ o
concentrations NNS o
increased VBD N
in IN N
a DT N
slightly RB N
greater JJR N
than IN N
dose-dependent JJ N
manner NN N
from IN N
3 CD N
to TO N
300 CD N
mg NN N
. . N

The DT N
effect NN N
of IN N
food NN N
was VBD N
studied VBN N
in IN N
an DT N
open JJ N
crossover NN N
design NN N
with IN N
a DT N
1-week JJ N
washout NN N
period NN N
. . N

Twelve NNP N
subjects VBZ N
received VBD N
150 CD i
mg NNS i
YM17E VBN i
in IN N
both DT N
the DT N
fasted VBN N
and CC N
post-prandial JJ N
states NNS N
. . N

The DT N
AUC NNP o
and CC o
Cmax NNP o
after IN N
fasting VBG N
were VBD N
closely RB N
similar JJ N
to TO N
those DT N
after IN N
a DT N
meal NN N
, , N
showing VBG N
that IN N
bioavailability NN N
was VBD N
not RB N
affected VBN N
by IN N
food NN N
intake NN N
. . N

In IN N
the DT N
repeated JJ N
oral JJ N
dose NN N
study NN N
, , N
the DT N
subjects NNS N
received VBD N
test JJ i
drug NN i
at IN i
150 CD i
mg NN i
or CC i
300 CD i
mg NN i
( ( N
n JJ N
= RB N
6 CD N
each DT N
) ) N
or CC N
placebo NN i
( ( i
n JJ i
= NNP i
3 CD i
) ) i
twice RB i
a DT i
day NN i
( ( N
after IN N
breakfast NN N
and CC N
after IN N
dinner NN N
) ) N
for IN N
7 CD N
days NNS N
. . N

On IN N
days NNS N
1 CD N
and CC N
7 CD N
, , N
the DT N
subjects NNS N
received VBD N
YM17E NNP i
once RB i
a DT i
day NN i
( ( N
after IN N
breakfast NN N
) ) N
for IN N
evaluation NN N
of IN N
pharmacokinetic JJ N
properties NNS N
. . N

After IN N
repeated VBN N
oral JJ N
administration NN N
of IN N
150 CD N
mg NN N
b.d. NN N
, , N
plasma JJ o
concentrations NNS o
reached VBD N
steady JJ N
state NN N
by IN N
day NN N
5 CD N
( ( N
mean JJ N
Cmin NNP N
48.6 CD N
ng.ml-1 NN N
) ) N
. . N

After IN N
repeated JJ N
administration NN N
of IN N
300 CD N
mg NN N
b.d. NN N
, , N
plasma JJ o
concentrations NNS o
prior RB N
to TO N
each DT N
daily JJ N
morning NN N
dose NN N
increased VBD N
up RB N
to TO N
the DT N
5th JJ N
day NN N
( ( N
mean JJ N
Cmin NNP N
166.6 CD N
ng.ml-1 NN N
) ) N
and CC N
then RB N
tended VBD N
to TO N
decrease VB N
until IN N
the DT N
7th JJ N
day NN N
. . N

No DT N
significant JJ o
signs NNS o
, , o
symptoms NNS o
or CC o
changes NNS o
in IN o
serum NN o
cholesterol NN o
levels NNS o
were VBD N
observed VBN N
during IN N
the DT N
single JJ N
and CC N
repeated JJ N
oral JJ N
dose NN N
studies NNS N
at IN N
150 CD N
mg NN N
b.d NN N
. . N

Although IN N
statistical JJ N
analysis NN N
was VBD N
not RB N
conducted VBN N
because IN N
of IN N
the DT N
small JJ p
number NN p
of IN p
subjects NNS p
, , N
all DT N
subjects NNS N
receiving VBG N
repeated VBD N
oral JJ N
administration NN N
of IN N
300 CD N
mg JJ N
twice RB N
daily RB N
showed VBD N
a DT N
25 CD N
% NN N
decrease NN N
in IN N
serum NN o
cholesterol NN o
level NN N
on IN N
day NN N
7 CD N
, , N
but CC N
also RB N
the DT N
simultaneous JJ N
occurrence NN N
of IN N
diarrhoea NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
micronutrient NN i
supplement NN i
on IN N
health NN o
and CC o
nutritional JJ o
status NN o
of IN N
schoolchildren NNS p
: : p
study NN N
design NN N
. . N

OBJECTIVE IN N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
supplementation NN i
with IN i
a DT i
micronutrient-fortified JJ i
beverage NN i
improves VBZ N
micronutrient JJ N
status NN N
and CC N
physical JJ N
and CC N
mental JJ N
development NN N
in IN N
apparently RB N
healthy JJ N
schoolchildren NNS N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
middle-income JJ p
students NNS p
in IN N
two CD N
residential JJ N
schools NNS N
that WDT N
catered VBD N
to TO N
children NNS p
from IN p
a DT p
semi-urban JJ p
population NN p
near IN p
Hyderabad NNP p
, , p
India NNP p
. . p

Included NNP p
were VBD p
869 CD p
children NNS p
who WP p
were VBD p
6 CD p
to TO p
16 CD p
y NN p
of IN p
age NN p
in IN p
grades NNS p
1 CD p
to TO p
10 CD p
. . p

Because IN N
children NNS N
at IN N
each DT N
grade NN N
were VBD N
distributed VBN N
across IN N
two CD N
classrooms NNS N
( ( N
clusters NNS N
) ) N
and CC N
were VBD N
homogeneous JJ N
, , N
each DT N
grade NN N
was VBD N
considered VBN N
to TO N
consist VB N
of IN N
a DT N
matched JJ N
pair NN N
. . N

There EX N
were VBD N
thus RB N
10 CD N
pairs NNS N
available JJ N
for IN N
the DT N
study NN N
. . N

Classes NNS N
in IN N
each DT N
grade NN N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
micronutrient-enriched JJ i
beverage NN i
or CC i
a DT i
placebo NN i
without IN i
added JJ i
micronutrients NNS i
. . i

The DT N
study NN N
was VBD N
double RB N
blinded VBN N
and CC N
the DT N
duration NN N
was VBD N
14 CD N
mo NN N
, , N
with IN N
supervised JJ N
feeding NN N
of IN N
the DT N
micronutrient-enriched JJ i
beverage NN i
. . i

The DT N
effect NN N
of IN N
the DT N
micronutrients NNS i
on IN N
the DT N
outcome NN o
variables NNS o
growth NN o
, , o
biochemical JJ o
status NN o
, , o
mental JJ o
function NN o
, , o
and CC o
bone NN o
health NN o
were VBD N
assessed VBN N
. . N

RESULTS VB N
The DT N
number NN N
of IN N
matched JJ N
pairs NNS N
varied VBD N
between IN N
seven CD N
and CC N
eight CD N
, , N
and CC N
the DT N
required JJ N
number NN p
of IN p
children NNS p
per IN p
treatment NN p
group NN p
ranged VBD p
from IN p
32 CD p
in IN p
the DT p
case NN p
of IN p
bone NN p
heath NN p
to TO p
177 CD p
for IN p
body NN p
weight NN p
. . p

The DT N
power NN N
of IN N
the DT N
outcome NN N
variables NNS N
ranged VBD N
from IN N
74 CD N
% NN N
to TO N
100 CD N
% NN N
and CC N
was VBD N
adequate NN N
for IN N
successful JJ N
pairing NN N
. . N

The DT N
effect NN N
assessed VBD N
at IN N
the DT N
end NN N
of IN N
supplementation NN i
showed VBD N
that IN N
the DT N
intervention NN N
was VBD N
beneficial JJ o
. . o

CONCLUSIONS NNP N
Designing VBG N
an DT N
intervention NN N
, , N
choosing VBG N
outcome NN N
variables NNS N
, , N
and CC N
implementing VBG N
the DT N
protocol NN N
in IN N
a DT N
typical JJ N
Indian JJ N
school NN N
setting VBG N
were VBD N
achieved VBN N
. . N

-DOCSTART- -X- O O

Laparoscopically RB i
assisted VBN i
vaginal JJ i
hysterectomy NN i
versus IN N
abdominal JJ i
hysterectomy NN i
in IN N
stage NN p
I PRP p
endometrial JJ p
cancer NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
laparoscopic JJ i
treatment NN i
for IN N
stage NN p
I PRP p
endometrial JJ p
cancer NN p
with IN N
the DT N
traditional JJ i
transabdominal JJ i
approach NN i
. . N

From IN N
July NNP N
1996 CD N
to TO N
July NNP N
1998 CD N
, , N
61 CD p
patients NNS p
with IN p
clinical JJ p
stage NN p
I PRP p
endometrial JJ p
cancer NN p
were VBD N
treated VBN N
at IN N
the DT N
Gynaecology NNP p
Oncology NNP p
Unit NNP p
at IN p
the DT p
Royal NNP p
North NNP p
Shore NNP p
of IN p
Sydney NNP p
, , p
Australia NNP p
. . p

Twenty-nine JJ p
patients NNS p
were VBD p
treated VBN p
with IN p
laparoscopic NN i
assisted VBN i
vaginal JJ i
hysterectomy NN i
( ( i
LAVH NNP i
) ) i
and CC i
bilateral JJ i
salpingo-oophrectomy NN i
( ( i
BSO NNP i
) ) i
plus CC i
minus CC i
laparoscopic JJ i
pelvic JJ i
lymphadenectomy NN i
( ( i
LPLA NNP i
) ) i
, , p
while IN p
32 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
the DT p
traditional JJ p
laparotomy NN i
and CC p
underwent JJ p
total JJ i
abdominal JJ i
hysterectomy NN i
( ( i
TAH NNP i
) ) i
and CC p
BSO NNP p
plus CC p
minus CC p
pelvic JJ i
lymphadenectomy NN i
( ( p
PLA NNP p
) ) p
. . p

The DT N
main JJ N
outcomes NNS N
studied VBN N
were VBD N
operative JJ o
time NN o
, , o
blood NN o
loss NN o
, , o
blood NN o
transfusion NN o
, , o
intraoperative JJ o
complications NNS o
, , o
postoperative JJ o
complications NNS o
, , o
duration NN o
of IN o
hospital NN o
stay NN o
, , o
and CC o
number NN o
of IN o
lymph JJ o
nodes NNS o
obtained VBN N
. . N

In IN N
conclusion NN N
, , N
laparoscopic JJ i
treatment NN i
of IN N
endometrial JJ N
cancer NN N
is VBZ N
safe JJ o
in IN N
the DT N
hands NNS N
of IN N
experienced JJ N
operators NNS N
with IN N
minimal JJ N
intraoperative JJ N
and CC N
postoperative JJ N
complications NNS N
. . N

This DT N
procedure NN N
is VBZ N
associated VBN N
with IN N
significantly RB N
less JJR N
blood JJ o
loss NN o
and CC N
shorter JJR N
hospitalization NN o
; : o
however RB N
, , N
it PRP N
is VBZ N
associated VBN N
with IN N
significantly RB N
longer RBR N
operating VBG o
time NN o
. . o

Proper NNP N
selection NN N
of IN N
patients NNS N
for IN N
the DT N
laparoscopic JJ i
procedure NN i
is VBZ N
the DT N
vital JJ N
step NN N
in IN N
achieving VBG N
the DT N
major JJ N
goals NNS N
of IN N
this DT N
approach NN N
. . N

-DOCSTART- -X- O O

Acute NNP i
intravenous JJ i
L-arginine JJ i
infusion NN i
decreases VBZ N
endothelin-1 JJ o
levels NNS o
and CC N
improves VBZ N
endothelial JJ o
function NN o
in IN N
patients NNS p
with IN p
angina JJ p
pectoris NN p
and CC p
normal JJ p
coronary JJ p
arteriograms NNS p
: : p
correlation NN N
with IN N
asymmetric JJ N
dimethylarginine NN o
levels NNS o
. . o

BACKGROUND NNP N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
asymmetric JJ o
dimethylarginine NN o
( ( o
ADMA NNP o
) ) o
levels NNS o
could MD N
be VB N
elevated VBN N
and CC N
influence VB N
endothelin-1 JJ o
and CC i
nitric JJ o
oxide NN o
release NN o
and CC o
action NN o
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome NN p
X NNP p
( ( p
CSX NNP p
) ) p
. . p

In IN N
addition NN N
, , N
we PRP N
evaluated VBD N
whether IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
L-arginine NNP i
would MD N
improve VB N
endothelial JJ o
function NN o
in IN N
these DT N
subjects NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Nine NNP p
patients NNS p
with IN p
CSX NNP p
and CC p
14 CD p
control NN p
subjects NNS p
underwent VBD p
a DT p
continuous JJ p
infusion NN p
of IN p
L-arginine NNP i
( ( i
0.125 CD i
g/min NN i
) ) i
or CC i
saline NN i
for IN p
120 CD p
minutes NNS p
. . p

Sixty NNP N
minutes NNS N
after IN N
L-arginine NNP i
or CC i
saline JJ i
infusions NNS i
, , N
an DT N
intravenous JJ N
insulin NN i
bolus NN N
( ( N
0.1 CD N
U/kg NNP N
) ) N
combined VBD N
with IN N
a DT N
euglycemic JJ i
clamp NN i
was VBD N
performed VBN N
. . N

Basal NNP o
ADMA NNP o
and CC o
endothelin-1 JJ o
levels NNS o
were VBD N
higher JJR N
in IN N
patients NNS p
with IN p
CSX NNP p
than IN N
in IN N
controls NNS p
. . p

At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
hour NN N
of IN N
infusion NN N
, , N
compared VBN N
with IN N
saline NN i
, , i
L-arginine JJ i
infusion NN N
increased VBD N
basal JJ o
forearm NN o
blood NN o
flow NN o
, , o
nitrite JJ o
and CC o
nitrate JJ o
( ( o
NOx NNP o
) ) o
, , o
and CC o
forearm NN o
cGMP NN o
release NN o
and CC N
decreased VBD N
endothelin-1 NN o
. . o

After IN N
insulin NN N
bolus NN N
, , N
during IN N
saline NN N
, , N
insulin-induced JJ o
NOx NNP o
, , o
endothelin-1 JJ o
, , o
and CC o
forearm NN o
cGMP NN o
release NN o
was VBD N
almost RB N
abolished VBN N
. . N

Conversely RB N
, , N
L-arginine NNP N
restored VBD N
a DT N
physiological JJ N
profile NN N
of IN N
all DT N
endothelial JJ o
variables NNS o
compared VBN N
with IN N
control NN N
subjects NNS N
. . N

In IN N
control NN N
subjects NNS N
, , N
compared VBN N
with IN N
saline JJ i
infusion NN i
, , i
L-arginine JJ i
infusion NN i
did VBD N
not RB N
modify VB N
any DT N
parameter NN N
. . N

ADMA NNP o
levels NNS o
were VBD N
positively RB N
correlated VBN N
with IN N
basal JJ N
endothelin-1 JJ o
levels NNS o
and CC N
negatively RB N
correlated VBN N
with IN N
insulin-induced JJ o
incremental JJ o
levels NNS o
of IN o
NOx NNP o
and CC o
forearm NN o
cGMP NN o
release NN o
. . o

CONCLUSIONS NNP N
Plasma NNP o
ADMA NNP o
levels NNS o
are VBP N
increased VBN N
in IN N
patients NNS p
with IN p
CSX NNP p
, , N
and CC N
they PRP N
are VBP N
correlated VBN N
with IN N
increases NNS N
in IN N
endothelin-1 JJ o
and CC N
reductions NNS N
in IN N
insulin-induced JJ N
increments NNS N
in IN N
plasma NN o
NOx NNP o
and CC o
cGMP NN o
, , N
effects NNS N
that WDT N
are VBP N
reversed VBN N
by IN N
intravenous JJ N
L-arginine NNP N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
increased VBD N
ADMA NNP o
levels NNS o
play VBP N
a DT N
role NN N
in IN N
the DT N
abnormal JJ N
vascular JJ N
reactivity NN N
that WDT N
is VBZ N
observed VBN N
in IN N
patients NNS N
with IN N
CSX NNP p
. . p

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
ulinastatin NN i
on IN N
inflammatory JJ o
responses NNS o
induced VBN p
by IN p
oesophagectomy JJ p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effect NN N
of IN N
ulinastatin NN i
( ( N
UTI NNP N
) ) N
on IN N
the DT N
inflammatory JJ o
responses NNS o
induced VBN p
by IN p
oesophagectomy NN p
. . p

METHODS NNP N
Forty NNP p
patients NNS p
with IN p
esophageal JJ p
cancer NN p
( ( p
without IN p
serious JJ p
hypertension NN p
, , p
heart NN p
disease NN p
, , p
or CC p
respiratory JJ p
function NN p
impairment NN p
, , p
including VBG p
34 CD p
men NNS p
and CC p
6 CD p
women NNS p
aged VBD p
46 CD p
to TO p
70 CD p
years NNS p
) ) p
scheduled VBD p
for IN p
oesophagectomy JJ i
via IN i
left JJ i
thoracotomy NN i
were VBD p
randomly RB p
divided VBN p
into IN p
control NN p
group NN p
( ( p
n=20 CC p
) ) p
and CC p
UTI NNP p
group NN p
( ( p
n=20 RB p
) ) p
. . p

Anesthesia NNP i
induction NN i
and CC N
perioperative JJ N
management NN N
followed VBD N
the DT N
same JJ N
protocols NNS N
in IN N
the DT N
two CD N
groups NNS N
, , N
and CC N
in IN N
UTI NNP N
group NN N
, , N
patients NNS N
received VBD i
5000 CD i
U/kg NNP i
UTI NNP i
while IN N
those DT N
in IN N
the DT N
control NN N
group NN N
were VBD N
given VBN N
the DT N
same JJ N
volume NN N
of IN N
saline NN N
. . N

Before IN N
operation NN N
( ( N
T NNP N
( ( N
1 CD N
) ) N
) ) N
, , N
10 CD N
min NN N
after IN N
recovery NN N
of IN N
two-lung JJ N
ventilation NN N
( ( N
T NNP N
( ( N
2 CD N
) ) N
) ) N
, , N
and CC N
24 CD N
h NN N
( ( N
T NNP N
( ( N
3 CD N
) ) N
) ) N
and CC N
48 CD N
h NN N
( ( N
T NNP N
( ( N
4 CD N
) ) N
) ) N
after IN N
operation NN N
, , N
the DT N
venous JJ o
blood NN o
sample NN o
was VBD N
taken VBN N
from IN N
the DT N
internal JJ N
jugular NN N
vein NN N
and CC N
the DT N
plasma NN N
was VBD N
separated VBN N
and CC N
stored VBN N
at IN N
-70 NNP N
degrees NNS N
C NNP N
for IN N
later JJR N
analysis NN N
of IN N
IL-6 NNP N
and CC N
IL-8 NNP N
with IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

The DT N
bronchoalveoar NN o
lavage NN o
fluid NN o
( ( o
BAFL NNP o
) ) o
was VBD N
also RB N
collected VBN N
at IN N
T NNP N
( ( N
1 CD N
) ) N
and CC N
T NNP N
( ( N
2 CD N
) ) N
for IN N
IL-6 NNP N
and CC N
IL-8 NNP N
detection NN N
. . N

RESULTS NNP N
IL-6 JJ o
, , o
IL-8 JJ o
levels NNS o
in IN o
the DT o
plasma NN o
and CC o
BALF NNP o
collected VBD N
at IN N
T NNP N
( ( N
2 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
increased VBD o
significantly RB o
as IN N
compared VBN N
with IN N
those DT N
in IN N
samples NNS N
collected VBN N
at IN N
T NNP N
( ( N
1 CD N
) ) N
, , N
and CC N
their PRP$ N
peak JJ o
concentration NN o
inplasma NN o
and CC o
BALF NNP o
samples NNS N
were VBD N
similar JJ N
. . N

IL-6 JJ o
and CC o
IL-8 JJ o
levels NNS o
in IN N
the DT N
UTI NNP N
group NN N
were VBD N
significantly RB o
lower JJR o
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
during IN N
the DT N
time NN N
points NNS N
of IN N
T NNP N
( ( N
2 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
. . N

CONCLUSION NNP N
Inflammatory NNP N
responses VBZ N
occur VBP N
during IN N
and CC N
after IN N
oesophagectomy NN N
, , N
which WDT N
can MD N
be VB N
inhibited VBN N
with IN N
UTI NNP N
. . N

-DOCSTART- -X- O O

A DT N
psychological JJ i
intervention NN i
reduces NNS N
inflammatory JJ o
markers NNS o
by IN N
alleviating VBG N
depressive JJ o
symptoms NNS o
: : o
secondary JJ N
analysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
test VB N
experimentally RB N
whether IN N
a DT N
psychological JJ i
intervention NN i
reduces NNS N
depression-related JJ N
symptoms NNS N
and CC N
markers NNS N
of IN N
inflammation NN N
among IN N
cancer NN p
patients NNS p
and CC N
to TO N
test VB N
one CD N
mechanism NN N
for IN N
the DT N
intervention NN N
effects NNS N
. . N

Depression NNP N
and CC N
inflammation NN N
are VBP N
common JJ N
among IN N
cancer NN p
patients NNS p
. . p

Data NNP N
suggest NN N
that IN N
inflammation NN N
can MD N
contribute VB N
to TO N
depressive VB o
symptoms NNS o
, , N
although IN N
the DT N
converse NN N
remains VBZ N
untested JJ N
. . N

METHODS NNP N
As IN N
part NN N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
newly RB p
diagnosed VBN p
breast NN p
cancer NN p
patients NNS p
( ( p
n JJ p
= NNP p
45 CD p
) ) p
with IN p
clinically RB p
significant JJ p
depressive JJ p
symptoms NNS p
were VBD N
evaluated VBN N
and CC N
randomized VBN N
to TO N
psychological JJ i
intervention NN i
with IN i
assessment NN i
or CC i
assessment NN i
only RB i
study VBD i
arms NNS N
. . N

The DT N
intervention NN N
spanned VBD N
12 CD N
months NNS N
, , N
with IN N
assessments NNS N
at IN N
baseline NN N
, , N
4 CD N
, , N
8 CD N
, , N
and CC N
12 CD N
months NNS N
. . N

Mixed-effects NNS N
modeling VBG N
tested VBD N
the DT N
hypothesis NN N
that IN N
the DT N
intervention NN N
reduced VBD N
self-reported JJ o
depressive NN o
symptoms NNS o
( ( N
Center NNP N
for IN N
Epidemiological NNP N
Studies NNPS N
Depression NNP N
scale NN N
, , N
Profile NNP N
of IN N
Mood NNP N
States NNPS N
Depression NNP N
and CC N
Fatigue NNP N
subscales NNS N
, , N
and CC N
Medical NNP N
Outcomes NNP N
Study-Short NNP N
Form NNP N
36 CD N
Bodily NNP N
Pain NNP N
subscale NN N
) ) N
and CC N
immune JJ o
cell NN o
numbers NNS o
that WDT N
are VBP N
elevated VBN N
in IN N
the DT N
presence NN N
of IN N
inflammation NN N
( ( N
white JJ N
blood NN N
cell NN N
count NN N
, , N
neutrophil JJ N
count NN N
, , N
and CC N
helper/suppressor VB N
ratio NN N
) ) N
. . N

Mediation NN N
analyses NNS N
tested VBD N
whether IN N
change NN o
in IN o
depressive JJ o
symptoms NNS o
, , o
pain NN o
, , o
or CC o
fatigue NN o
predicted VBN o
change NN o
in IN o
white JJ o
blood NN o
cell NN o
count NN o
, , o
neutrophil JJ o
count NN o
, , o
or CC o
the DT o
helper/suppressor NN o
ratio NN o
. . o

RESULTS VB N
The DT N
intervention NN N
reduced VBD N
significantly RB N
depressive JJ o
symptoms NNS o
, , o
pain NN o
, , o
fatigue NN o
, , o
and CC o
inflammation NN o
markers NNS o
. . o

Moreover RB N
, , N
the DT N
intervention NN N
effect NN N
on IN N
inflammation NN o
was VBD N
mediated VBN N
by IN N
its PRP$ N
effect NN N
on IN N
depressive NN N
symptoms NNS N
. . N

CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
experiment NN N
to TO N
test VB N
whether IN N
psychological JJ N
treatment NN N
effective JJ N
in IN N
reducing VBG N
depressive JJ o
symptoms NNS o
would MD N
also RB N
reduce VB N
indicators NNS N
of IN N
inflammation NN N
. . N

Data NNP N
show NN N
that IN N
the DT N
intervention NN N
reduced VBD N
directly RB N
depressive JJ o
symptoms NNS o
and CC N
reduced VBN N
indirectly RB N
inflammation NN o
. . o

Psychological JJ N
treatment NN N
may MD N
treat VB N
effectively RB N
depressive JJ o
symptoms NNS o
, , o
pain NN o
, , o
and CC o
fatigue NN o
among IN N
cancer NN p
patients NNS p
. . p

-DOCSTART- -X- O O

Therapy NNP o
effect NN o
of IN N
either CC N
paclitaxel NN i
or CC i
cyclophosphamide JJ i
combination NN i
treatment NN i
in IN N
patients NNS p
with IN p
epithelial JJ p
ovarian JJ p
cancer NN p
and CC p
relation NN p
to TO p
TP53 NNP p
gene NN p
status NN p
. . p

Cell NNP N
death NN N
after IN N
treatment NN N
with IN N
chemotherapy NN i
is VBZ N
exerted VBN N
by IN N
activation NN N
of IN N
apoptosis NN N
, , N
and CC N
the DT N
p53 NN N
protein NN N
has VBZ N
been VBN N
shown VBN N
to TO N
actively RB N
participate VB N
in IN N
this DT N
process NN N
. . N

This DT N
recent JJ N
focus NN N
on IN N
TP53 NNP o
status NN o
as IN N
a DT N
possible JJ N
determinant NN N
of IN N
cancer NN N
therapy NN N
response NN N
has VBZ N
raised VBN N
the DT N
question NN N
of IN N
whether IN N
or CC N
not RB N
mutations NNS N
in IN N
the DT N
TP53 NNP N
gene NN N
have VBP N
an DT N
influence NN N
on IN N
paclitaxel NN i
therapy NN i
. . i

The DT N
TP53 NNP o
status NN o
has VBZ N
been VBN N
analysed VBN N
at IN N
the DT N
DNA NNP N
level NN N
in IN N
tumours NNS N
from IN N
45 CD p
ovarian JJ p
cancer NN p
patients NNS p
randomized VBN p
to TO p
treatment NN p
with IN N
paclitaxel NN i
and CC i
cisplatin NN i
or CC i
cyclophosphamide NN i
and CC i
cisplatin NN i
. . i

Therapy NNP o
response NN o
was VBD N
obtained VBN N
for IN N
38 CD p
patients NNS p
with IN p
clinically RB p
evaluable JJ p
disease NN p
after IN p
initial JJ p
surgery NN p
. . p

The DT N
positive JJ o
response NN o
rate NN o
to TO N
the DT N
paclitaxel/cisplatin NN i
therapy NN i
was VBD N
85 CD N
% NN N
vs JJ N
61 CD N
% NN N
for IN N
the DT N
patients NNS N
who WP N
received VBD N
the DT N
cyclophosphamide/cisplatin JJ i
regimen NNS N
. . N

A DT N
significant JJ N
difference NN N
in IN N
relapse-free JJ o
survival NN o
in IN N
favour NN N
of IN N
paclitaxel/cisplatin NN i
chemotherapy NN i
was VBD N
found VBN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

A DT N
total NN N
of IN N
33 CD N
tumour NN N
samples NNS N
( ( N
73 CD N
% NN N
) ) N
had VBD N
detectable JJ N
sequence NN o
alterations NNS o
in IN o
the DT o
TP53 NNP o
gene NN o
. . o

When WRB N
relapse-free JJ o
survival NN o
was VBD N
estimated VBN N
for IN N
all DT N
patients NNS N
with IN N
TP53 NNP o
alterations NNS o
in IN N
their PRP$ N
tumours NNS N
, , N
a DT N
significant JJ N
better RBR N
outcome NN N
for IN N
the DT N
paclitaxel/cisplatin NN i
group NN N
was VBD N
found VBN N
compared VBN N
with IN N
the DT N
patient NN N
group NN N
receiving VBG N
cyclophosphamide NN i
and CC N
cisplatin NN i
therapy NN i
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

We PRP N
did VBD N
not RB N
observe VB N
an DT N
association NN N
between IN N
TP53 NNP o
tumour NN o
status NN o
and CC N
prognosis NN o
for IN N
patients NNS N
who WP N
received VBD N
paclitaxel/cisplatin JJ i
combination NN N
treatment NN N
, , N
indicating VBG N
that IN N
the DT N
effect NN N
of IN N
this DT N
therapy NN N
is VBZ N
not RB N
influenced VBN N
by IN N
this DT N
parameter NN N
. . N

-DOCSTART- -X- O O

Prognostic JJ N
value NN N
of IN N
postoperative JJ i
CEA NNP i
clearance NN i
in IN N
rectal JJ o
cancer NN o
patients NNS p
with IN p
high JJ p
preoperative JJ p
CEA NNP p
levels NNS p
. . p

PURPOSE NNP N
We PRP N
determined VBD N
the DT N
prognostic JJ N
value NN N
of IN N
carcinoembryonic JJ N
antigen NN N
( ( N
CEA NNP N
) ) N
clearance NN N
after IN N
tumor NN i
resection NN i
with IN N
serial JJ N
evaluation NN N
of IN N
postoperative JJ N
CEA NNP N
levels NNS N
in IN N
rectal JJ p
cancer NN p
. . p

METHODS NNP N
Between NNP p
1994 CD p
and CC p
2004 CD p
, , p
we PRP p
retrospectively RB p
reviewed VBD p
122 CD p
patients NNS p
with IN p
rectal JJ p
cancer NN p
whose WP$ p
serum JJ o
CEA NNP o
levels NNS o
were VBD p
measured VBN p
on IN p
the DT p
preoperative JJ p
day NN p
and CC p
postoperative JJ p
days NNS p
7 CD p
and CC p
30 CD p
. . p

Patients NNS p
with IN p
preoperative JJ p
CEA NNP p
levels NNS p
< VBP p
5.0 CD p
ng/ml NNS p
were VBD p
excluded VBN p
. . p

An DT N
exponential JJ N
trend NN N
line NN N
was VBD N
drawn VBN N
using VBG N
the DT N
three CD N
CEA NNP N
values NNS N
. . N

Patients NNS p
were VBD p
categorized VBN p
into IN p
three CD p
groups NNS p
based VBN p
on IN p
R NNP p
( ( p
2 CD p
) ) p
values NNS p
calculated VBN N
through IN N
trend NN N
line NN N
, , N
which WDT N
indicates VBZ N
the DT N
correlation NN N
coefficient NN N
between IN N
exponential JJ N
graph NN N
and CC N
measured VBD N
CEA NNP o
values NNS o
: : o
exponential JJ p
decrease NN p
group NN p
( ( N
group NN N
1 CD N
: : N
0.9 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
1.0 CD N
) ) N
, , N
nearly RB p
exponential JJ p
decrease NN p
group NN p
( ( N
group NN N
2 CD N
: : N
0.5 CD N
< NN N
R NNP N
( ( N
2 CD N
) ) N
< NN N
or CC N
= VB N
0.9 CD N
) ) N
, , N
and CC N
randomized JJ p
clearance NN p
group NN p
( ( N
group NN N
3 CD N
: : N
0.5 CD N
< NN N
or CC N
= VB N
R NNP N
( ( N
2 CD N
) ) N
) ) N
. . N

We PRP N
then RB N
analyzed VBD N
the DT N
CEA NNP N
clearance NN N
pattern NN N
as IN N
a DT N
prognostic JJ N
indicator NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
57 CD N
months NNS N
, , N
the DT N
5-year JJ o
overall JJ o
survival NN o
was VBD N
62.3 CD N
% NN N
vs. FW N
48.1 CD N
% NN N
vs. FW N
25 CD N
% NN N
and CC N
the DT N
5-year JJ o
disease-free JJ o
survival NN o
was VBD N
58.6 CD N
% NN N
vs. FW N
52.7 CD N
% NN N
vs. FW N
25 CD N
% NN N
among IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
( ( N
P NNP N
= NNP N
0.014 CD N
, , N
P NNP N
= NNP N
0.027 CD N
, , N
respectively RB N
) ) N
in IN N
patients NNS p
with IN p
stage NN p
III NNP p
rectal JJ p
cancer NN p
. . p

For IN N
those DT N
with IN N
stage NN N
II NNP N
rectal NN N
cancer NN N
, , N
the DT N
5-year JJ o
overall JJ o
survival NN o
rate NN o
of IN N
group NN N
1 CD N
was VBD N
significantly RB N
better JJR N
than IN N
groups NNS N
2 CD N
and CC N
3 CD N
( ( N
88.8 CD N
% NN N
vs. FW N
74.1 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
0.021 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
postoperative JJ i
pattern NN i
of IN i
CEA NNP i
clearance NN i
is VBZ N
a DT N
useful JJ N
prognostic JJ N
determinant NN N
in IN N
patients NNS p
with IN p
rectal JJ p
cancer NN p
. . p

Patients NNS p
with IN p
a DT p
randomized JJ p
pattern NN p
of IN o
CEA NNP o
clearance NN o
after IN N
tumor NN N
resection NN N
should MD N
be VB N
regarded VBN N
as IN N
having VBG N
the DT N
possibility NN N
of IN N
a DT N
persistent JJ N
CEA NNP N
source NN N
and CC N
may MD N
require VB N
consideration NN N
of IN N
intensive JJ N
follow-up NN N
or CC N
adjuvant JJ N
therapy NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
patient JJ i
education NN i
and CC i
supervised VBD i
exercise NN i
vs NN N
patient JJ i
education NN i
alone RB i
in IN N
patients NNS p
with IN p
hip JJ p
osteoarthritis NN p
: : p
a DT N
single JJ N
blind NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
patient JJ i
education NN i
and CC i
supervised VBD i
exercise NN i
with IN N
that DT N
of IN N
patient JJ i
education NN i
alone RB i
for IN N
the DT N
management NN o
of IN o
pain NN o
in IN N
patients NNS p
with IN p
hip NN p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
. . p

DESIGN NNP N
Single NNP N
blind IN N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Recruitment NNP N
of IN N
patients NNS p
from IN p
hospitals NNS p
, , p
primary JJ p
health NN p
care NN p
and CC p
advertisement NN p
, , p
Oslo NNP p
, , p
Norway NNP p
. . p

PARTICIPANTS NNP N
109 CD p
patients NNS p
with IN p
radiographic JJ p
and CC p
symptomatic JJ p
hip NN p
OA NNP p
with IN p
mild NN p
to TO p
moderate VB p
symptoms NNS p
. . p

INTERVENTIONS NNP N
Patient NNP i
education NN i
( ( i
PE NNP i
) ) i
. . i

Patient JJ i
education NN i
and CC i
supervised VBN i
exercise NN i
( ( i
PE+SE NNP i
) ) i
. . i

PRIMARY NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
pain NN o
subscale NN o
of IN o
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
pain NN o
) ) o
. . o

RESULTS NNP N
No NNP N
significant JJ N
between IN N
group NN N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP o
pain NN o
over IN N
the DT N
16-month JJ N
follow-up NN N
. . N

Significant JJ N
improvements NNS N
were VBD N
found VBN N
for IN N
the DT N
secondary JJ N
outcome NN N
WOMAC NNP o
physical JJ o
function NN o
( ( N
P=0.011 NNP N
) ) N
in IN N
the DT N
group NN N
receiving VBG N
PE+SE NNP i
compared VBN N
to TO N
the DT N
group NN N
receiving VBG N
PE NNP i
only RB N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
WOMAC NNP o
stiffness NN o
, , N
the DT N
SF-36 JJ N
subscales NNS N
or CC N
the DT N
activity NN N
scale NN N
. . N

The DT N
effect NN N
sizes VBZ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
for IN N
WOMAC NNP o
pain NN o
were VBD N
-0.26 NNP N
( ( N
0.11 CD N
, , N
-0.64 NN N
) ) N
, , N
-0.35 NNP N
( ( N
0.07 CD N
, , N
-0.77 NN N
) ) N
, , N
and CC N
-0.30 NNP N
( ( N
0.15 CD N
, , N
-0.75 NN N
) ) N
, , N
and CC N
for IN N
WOMAC NNP o
physical JJ o
function NN o
-0.29 NNP N
( ( N
0.09 CD N
, , N
-0.67 NN N
) ) N
, , N
-0.48 NNP N
( ( N
-0.06 NNP N
, , N
-0.91 NNP N
) ) N
, , N
and CC N
-0.47 NNP N
( ( N
-0.02 NNP N
, , N
-0.93 NNP N
) ) N
at IN N
4 CD N
, , N
10 CD N
and CC N
16 CD N
months NNS N
, , N
respectively RB N
, , N
in IN N
favor NN N
of IN N
the DT N
group NN N
receiving VBG N
both DT N
PE NNP i
and CC i
SE NNP i
. . i

All DT N
patients NNS N
attended VBD N
the DT N
three-session JJ N
PE NNP i
program NN i
, , N
and CC N
75 CD N
% NN N
performed VBN N
?16 JJ N
sessions NNS N
of IN N
the DT N
12-week JJ i
SE NNP i
program NN i
. . N

CONCLUSION NNP N
The DT N
study NN N
could MD N
not RB N
demonstrate VB N
a DT N
significant JJ N
difference NN N
in IN N
pain NN o
reduction NN o
over IN o
time NN N
between IN i
PE+SE NNP i
vs NNP i
PE NNP i
alone RB i
. . i

Adding VBG i
SE NNP i
to TO i
PE NNP i
may MD i
improve VB o
physical JJ o
function NN o
, , o
but CC N
the DT N
magnitude NN N
of IN N
possible JJ N
benefit NN N
is VBZ N
unknown JJ N
as IN N
the DT N
95 CD N
% NN N
confidence NN N
intervals NNS N
around IN N
the DT N
mean JJ N
difference NN N
were VBD N
wide JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials NNP N
NCT00319423 NNP N
. . N

-DOCSTART- -X- O O

Moclobemide NNP i
, , i
imipramine NN i
and CC i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
major JJ p
depression NN o
. . o

Moclobemide NNP i
was VBD N
compared VBN N
with IN N
imipramine NN i
and CC N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
major JJ N
depressive JJ N
episodes NNS N
in IN N
75 CD p
outpatients NNS p
. . p

The DT N
dosage NN N
of IN N
moclobemide NN i
( ( i
25 CD i
patients NNS i
) ) i
was VBD i
300 CD i
mg JJ i
daily RB i
for IN i
the DT i
first JJ i
5 CD i
days NNS i
, , i
after IN i
which WDT i
it PRP i
could MD i
be VB i
increased VBN i
to TO i
600 CD i
mg. NNS i
Imipramine NNP i
( ( i
25 CD i
patients NNS i
) ) i
was VBD i
given VBN i
in IN i
a DT i
dosage NN i
starting VBG i
with IN i
33 CD i
mg NNS i
and CC i
gradually RB i
increased VBD i
to TO i
100 CD i
mg/day NN i
in IN i
the DT i
first JJ i
5 CD i
days NNS i
, , N
after IN N
which WDT N
it PRP N
could MD N
be VB N
further RB N
increased VBN N
; : N
25 CD p
patients NNS p
received VBD N
placebo NN i
. . i

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
as IN N
measured VBN N
by IN N
the DT N
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
, , N
the DT N
overall JJ o
assessment NN o
of IN o
efficacy NN o
and CC N
the DT N
Zung NNP o
Self-rating NNP o
Scale NNP o
, , N
and CC N
clearly RB N
superior JJ N
to TO N
placebo VB N
; : N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
active JJ N
drugs NNS N
. . N

Moclobemide NNP i
was VBD N
better RBR o
tolerated VBN o
than IN N
imipramine NN i
, , N
and CC N
was VBD N
almost RB N
comparable JJ N
to TO N
placebo VB N
in IN N
this DT N
respect NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
comparing VBG N
induction NN i
chemotherapy NN i
versus NN N
induction NN i
chemotherapy NN i
followed VBN i
by IN i
maintenance NN i
chemotherapy NN i
in IN N
small-cell JJ p
lung NN p
cancer NN p
. . p

European JJ N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
. . N

PURPOSE NNP N
AND CC N
METHODS NNP N
The DT N
European NNP N
Lung NNP N
Cancer NNP N
Working NNP N
Party NNP N
( ( N
ELCWP NNP N
) ) N
performed VBD N
a DT N
randomized JJ N
trial NN N
with IN N
the DT N
primary JJ N
end NN N
point NN N
to TO N
determine VB N
if IN N
maintenance NN N
chemotherapy NN N
with IN N
12 CD N
courses NNS N
of IN N
etoposide NN i
( ( N
120 CD N
mg/m2 NN N
on IN N
days NNS N
1 CD N
and CC N
3 CD N
) ) N
and CC N
vindesine NN i
( ( N
3 CD N
mg/m2 NN N
on IN N
day NN N
3 CD N
) ) N
could MD N
improve VB N
progression-free JJ o
survival NN o
in IN N
small-cell JJ p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
patients NNS p
who WP p
responded VBD p
to TO p
six CD p
courses NNS p
of IN p
induction NN i
chemotherapy NN i
with IN i
ifosfamide NN i
, , i
etoposide RB i
, , i
and CC i
an DT i
anthracycline NN i
( ( i
doxorubicin NN i
or CC i
epirubicin NN i
) ) i
. . i

RESULTS NNP N
Among IN p
235 CD p
eligible JJ p
patients NNS p
initially RB p
registered VBD p
, , p
91 CD p
were VBD p
randomized VBN p
to TO p
receive VB p
maintenance NN p
therapy NN p
, , p
including VBG p
seven CD p
patients NNS p
who WP p
were VBD p
no RB p
longer RBR p
responding VBG p
. . p

Among IN N
84 CD N
randomized JJ N
responders NNS N
, , N
progression-free JJ o
survival NN o
was VBD N
significantly RB N
improved VBN N
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
by IN N
maintenance NN N
therapy NN N
, , N
with IN N
median JJ N
durations NNS N
( ( N
maintenance NN N
v IN N
follow-up JJ N
) ) N
of IN N
25 CD N
versus NNS N
12 CD N
weeks NNS N
after IN N
the DT N
second JJ N
randomization NN N
, , N
but CC N
survival NN o
was VBD N
not RB N
significantly RB N
increased VBN N
( ( N
P NNP N
= NNP N
.10 NNP N
) ) N
, , N
with IN N
median JJ N
durations NNS N
of IN N
48 CD N
and CC N
38 CD N
weeks NNS N
. . N

However RB N
, , N
in IN N
a DT N
multi-variate JJ N
analysis NN N
that WDT N
took VBD N
into IN N
account NN o
disease NN o
extent NN o
, , o
maintenance NN o
therapy NN o
, , o
Karnofsky NNP o
performance NN o
status NN o
( ( o
PS NNP o
) ) o
, , o
and CC o
absolute JJ o
dose-intensity NN o
( ( o
ADI NNP o
) ) o
of IN o
anthracycline NN o
given VBN N
during IN N
induction NN N
, , N
limited JJ o
disease NN o
( ( o
LD NNP o
) ) o
and CC o
maintenance NN o
were VBD N
found VBN N
to TO N
be VB N
independent JJ N
positive JJ N
predictors NNS N
of IN N
survival NN o
. . o

CONCLUSION NNP N
We PRP N
conclude VBP N
that DT N
maintenance NN N
chemotherapy NN N
in IN N
responding VBG N
patients NNS N
is VBZ N
beneficial JJ N
in IN N
SCLC NNP N
. . N

-DOCSTART- -X- O O

[ JJ N
Clinical NNP N
application NN N
of IN N
irradiated JJ N
drug-containing JJ i
porcine-cornea NN i
to TO N
patients NNS p
with IN p
ocular JJ p
burns NNS p
] FW p
. . N

OBJECTIVE UH N
To TO N
explore VB N
a DT N
new JJ N
method NN N
for IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
ocular JJ p
burns NNS p
. . p

METHODS NNP N
Fifty-five JJ p
cases NNS p
of IN p
patients NNS p
with IN p
ocular JJ p
burns NNS p
( ( p
in IN p
88 CD p
eyes NNS p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

Thirty NNP N
cases NNS N
in IN N
treatment NN N
group NN N
with IN N
49 CD p
eyes NNS p
were VBD p
transplanted VBN p
with IN N
irradiated JJ i
drug-containing NN i
( ( i
ofloxacin UH i
, , i
acetyl JJ i
cysteine NN i
and CC i
reduced JJ i
glutathione NN i
) ) i
porcine-cornea NN i
. . i

25 CD N
cases NNS N
in IN N
control NN N
group NN N
with IN N
39 CD N
eyes NNS N
were VBD N
treated VBN N
with IN N
routine JJ N
program NN N
. . N

RESULTS NNP N
Thirty-two JJ N
eyes NNS o
were VBD o
rescued VBN o
in IN N
treatment NN N
group NN N
with IN N
the DT N
cure NN N
rate NN N
of IN N
65.3 CD N
% NN N
. . N

But CC N
only RB N
17 CD N
eyes NNS o
were VBD o
saved VBN o
in IN N
control NN N
group NN N
with IN N
the DT N
cure NN N
rate NN N
of IN N
43.59 CD N
% NN N
, , N
indicating VBG N
significant JJ N
difference NN N
of IN N
the DT N
cure NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Irradiated VBD N
drug-containing JJ N
porcine-cornea NN i
might MD N
well RB N
be VB N
an DT N
ideal JJ N
therapeutic JJ N
material NN N
for IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
ocular JJ p
burns NNS p
. . p

-DOCSTART- -X- O O

[ RB i
Dexmedetomidine NNP i
use NN N
for IN N
postoperative JJ o
adrenergic JJ o
analgesia NN o
and CC o
sedation NN o
in IN N
abdominal JJ N
surgery NN N
] NN N
. . N

Comparative NNP N
study NN N
of IN N
postoperative JJ o
analgesia NN o
and CC o
sedation NN o
with IN i
trimeperidine NN i
and CC i
dexmedetomidine NN i
and CC N
their PRP$ N
effects NNS N
on IN N
haemodynamics NNS N
and CC N
vegetative VBP N
nervous JJ N
system NN N
was VBD N
performed VBN N
. . N

Assessment NNP N
of IN N
analgesia NN N
and CC N
sedation NN i
during IN N
vagotonia NN N
( ( N
first JJ N
part NN N
of IN N
the DT N
study NN N
) ) N
and CC N
hypokinetic JJ i
type NN i
of IN i
haemodynamics NNS i
( ( N
second JJ N
part NN N
of IN N
the DT N
study NN N
) ) N
was VBD N
carried VBN N
out RP N
with IN N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
and CC o
Richmond NNP o
scale NN o
. . o

Results NNS N
of IN N
the DT N
study NN N
showed VBD N
that IN N
dexmedetomidine NN i
is VBZ N
more RBR N
effective JJ o
and CC o
safer JJR o
than IN N
trimeperidine NN i
for IN N
analgesia NN o
and CC o
sedation NN o
in IN N
patients NNS p
with IN p
spontaneous JJ p
breathing NN p
after IN p
abdominal JJ p
surgery NN p
. . p

Dexmedetomidine NNP i
use NN N
allows VBZ N
keeping VBG N
optimal JJ N
type NN N
of IN N
haemodynamics NNS N
and CC N
vegetative VBP N
nervous JJ N
system NN N
parameters NNS N
on IN N
first JJ N
day NN N
of IN N
postoperative JJ N
period NN N
. . N

-DOCSTART- -X- O O

Butorphanol NNP i
and CC i
meperidine NN i
compared VBN N
in IN N
patients NNS p
with IN p
acute JJ p
ureteral JJ p
colic NN p
. . p

Pain NNP N
relief NN N
was VBD N
evaluated VBN N
in IN N
81 CD p
patients NNS p
with IN p
acute JJ p
ureteral JJ p
colic NN p
and CC p
the DT p
confirmed JJ p
presence NN p
of IN p
a DT p
calculus NN p
. . p

A DT N
randomized JJ p
double-blind JJ p
comparison NN p
of IN p
intramuscular JJ p
2 CD p
and CC p
4 CD p
mg. NN p
butorphanol NN i
and CC i
80 CD p
mg. NNS p
meperidine NN i
was VBD p
used VBN p
. . p

Pain NNP o
intensity NN o
and CC N
pain NN o
relief NN o
were VBD N
evaluated VBN N
at IN N
half JJ N
hour NN N
and CC N
hourly JJ N
intervals NNS N
for IN N
4 CD N
hours NNS N
. . N

A DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN i
was VBD N
found VBN N
to TO N
be VB N
analgesically RB N
equivalent JJ N
to TO N
80 CD N
mg. NNS N
meperidine NN i
, , N
while IN N
a DT N
4 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN i
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
80 CD N
mg. JJ N
meperidine NN i
and CC N
2 CD N
mg. NN N
butorphanol NN i
. . i

Each DT N
patient NN N
received VBD N
up RB N
to TO N
2 CD N
doses NNS N
of IN N
analgesic JJ N
medication NN N
when WRB N
necessary JJ N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN o
of IN o
side JJ o
effects NNS o
among IN N
treatments NNS N
. . N

One CD N
patient NN N
had VBD N
visual JJ o
hallucinations NNS o
after IN N
a DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN i
, , N
possibly RB N
owing VBG N
to TO N
its PRP$ N
antagonistic JJ N
activity NN N
to TO N
significant JJ N
narcotic JJ N
experience NN N
given VBN N
previously RB N
at IN N
another DT N
hospital NN N
. . N

There EX N
was VBD N
no DT N
other JJ N
evidence NN N
of IN N
toxicity NN o
with IN N
butorphanol NN i
. . i

It PRP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ o
, , o
effective JJ o
and CC o
wall RB o
tolerated JJ o
drug NN N
for IN N
the DT N
treatment NN N
of IN N
ureteral JJ N
colic NN N
and CC N
is VBZ N
recommended VBN N
in IN N
place NN N
of IN N
narcotics NNS N
. . N

-DOCSTART- -X- O O

Long-term JJ N
use NN N
of IN N
Viozan NNP i
( ( i
sibenadet JJ i
HCl NNP i
) ) i
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
: : p
results NNS N
of IN N
a DT N
1-year JJ N
study NN N
. . N

Viozan NNP i
( ( i
sibenadet JJ i
HCl NNP i
, , i
AR-C68397AA NNP i
) ) i
is VBZ N
a DT N
novel JJ N
dual JJ N
D2 NNP N
dopamine NN N
receptor NN N
, , N
beta2-adrenoceptor JJ N
agonist NN N
that WDT N
has VBZ N
been VBN N
investigated VBN N
for IN N
efficacy NN N
in IN N
alleviating VBG N
the DT N
symptoms NNS N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
. . N

The DT N
slowly RB N
progressive JJ N
nature NN N
of IN N
this DT N
disease NN N
means VBZ N
that IN N
patients NNS N
will MD N
require VB N
ongoing JJ N
therapeutic JJ N
management NN N
for IN N
many JJ N
years NNS N
, , N
or CC N
even RB N
decades NNS N
. . N

With IN N
such JJ N
long-term JJ N
treatment NN N
, , N
the DT N
safety NN N
profile NN N
of IN N
new JJ N
agents NNS N
will MD N
be VB N
of IN N
paramount JJ N
importance NN N
. . N

As IN N
part NN N
of IN N
the DT N
large-scale JJ N
assessment NN N
of IN N
sibenadet NN i
, , N
a DT N
12-month JJ N
safety NN N
study NN N
has VBZ N
been VBN N
conducted VBN N
. . N

Following VBG N
completion NN N
of IN N
a DT N
2-week JJ N
baseline NN N
period NN N
, , N
435 CD p
adults NNS p
with IN p
stable JJ p
, , p
symptomatic JJ p
, , p
smoking-related JJ p
COPD NNP p
were VBD p
randomized VBN p
to TO N
receive VB N
either RB N
500 CD i
microg NN i
sibenadet NN i
or CC i
placebo NN i
delivered VBN N
via IN N
pressurized VBN N
metered VBD N
dose JJ N
inhaler NN N
( ( N
pMDI NN N
) ) N
, , N
three CD N
times NNS N
daily RB N
for IN N
52 CD N
weeks NNS N
. . N

Sibenadet NNP i
therapy NN i
was VBD N
generally RB N
well RB o
tolerated VBN o
, , N
with IN N
the DT N
only JJ N
notable JJ o
differences NNS o
seen VBN N
in IN N
the DT N
incidence NN o
of IN o
tremor NN o
and CC o
taste NN o
of IN o
treatment NN o
( ( N
16.9 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
and CC N
14.5 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
in IN N
the DT N
sibenadet NN N
and CC N
placebo NN i
groups NNS N
respectively RB N
) ) N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
79 CD p
patients NNS p
with IN p
serious JJ o
adverse JJ o
events NNS o
( ( p
SAEs NNP p
) ) p
, , p
43 CD p
( ( p
14.8 CD p
% NN p
) ) p
in IN p
the DT p
sibenadet NN p
pMDI NN p
group NN p
and CC p
36 CD p
( ( p
24.8 CD p
% NN p
) ) p
in IN p
the DT p
placebo NN i
group NN i
. . i

No DT N
clinically RB o
significant JJ o
abnormal JJ o
laboratory NN o
values NNS o
or CC N
overall JJ o
differences NNS o
between IN N
treatment NN N
groups NNS N
were VBD N
noted VBN N
. . N

Similarly RB N
, , N
there EX N
were VBD N
no DT o
clinically RB o
significant JJ o
differences NNS o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
cardiac JJ o
variables NNS o
, , o
or CC o
in IN o
vital JJ o
signs NNS o
. . o

The DT N
secondary JJ o
variables NNS o
showed VBD N
no DT o
notable JJ o
differences NNS o
with IN N
respect NN N
to TO N
lung NN o
function NN o
, , o
exacerbations NNS o
or CC o
health-related JJ o
quality NN o
of IN o
life NN o
. . o

Due NNP N
to TO N
the DT N
effective JJ N
beta2-agonist NN N
properties NNS N
, , N
patients NNS N
in IN N
the DT N
sibenadet NN N
group NN N
did VBD N
, , N
however RB N
, , N
report NN N
reduced VBD o
rescue JJ o
medication NN o
usage NN o
at IN o
all DT o
timepoints NNS o
. . o

While IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
, , N
overall JJ N
, , N
sibenadet JJ N
therapy NN N
was VBD N
well RB o
tolerated VBN o
, , N
the DT N
lack NN o
of IN o
sustained JJ o
benefit NN o
reported VBD N
in IN N
large-scale JJ o
clinical JJ o
efficacy NN o
studies NNS o
means VBZ N
that IN N
sibenadet NN N
development NN N
will MD N
not RB N
be VB N
continued VBN N
. . N

-DOCSTART- -X- O O

The DT N
relationship NN N
of IN N
alexithymia NN N
to TO N
emotional JJ N
dysregulation NN N
within IN N
an DT N
alcohol NN p
dependent JJ p
treatment NN p
sample NN p
. . p

Difficulties NNS N
regulating VBG N
emotions NNS N
have VBP N
implications NNS N
for IN N
the DT N
development NN N
, , N
maintenance NN N
, , N
and CC N
recovery NN N
from IN N
alcohol NN p
problems NNS p
. . p

One CD N
construct NN N
thought NN N
to TO N
impede VB N
the DT N
regulation NN N
of IN N
emotion NN N
is VBZ N
alexithymia JJ N
. . N

Alexithymia NNP N
is VBZ N
characterized VBN N
by IN N
difficulties NNS N
identifying VBG N
, , N
differentiating VBG N
and CC N
expressing VBG N
feelings NNS N
, , N
a DT N
limited JJ N
imagination NN N
and CC N
fantasy JJ N
life NN N
, , N
and CC N
an DT N
externally-oriented JJ N
thinking NN N
style NN N
( ( N
e.g. UH N
, , N
prefer VBP N
talking VBG N
about IN N
daily JJ N
activities NNS N
rather RB N
than IN N
feelings NNS N
) ) N
. . N

Given VBN N
that IN N
poor JJ N
emotion NN N
regulation NN N
skills NNS N
have VBP N
been VBN N
found VBN N
to TO N
predict VB N
posttreatment NN p
levels NNS p
of IN p
alcohol NN p
use NN p
, , N
and CC N
that IN N
several JJ N
defining VBG N
characteristics NNS N
of IN N
alexithymia JJ N
bear JJ N
similarity NN N
to TO N
deficits NNS N
in IN N
emotion NN N
regulation NN N
skills NNS N
, , N
it PRP N
is VBZ N
possible JJ N
that IN N
alexithymia NN N
may MD N
predict VB N
poorer JJR N
alcohol NN N
treatment NN N
outcomes NNS N
. . N

Thus RB N
, , N
the DT N
present JJ N
study NN N
first RB N
examined VBD N
the DT N
relationship NN N
of IN N
alexithymia NN i
to TO N
several JJ N
other JJ N
emotion NN o
regulation NN o
measures NNS o
and CC N
then RB N
investigated VBD N
the DT N
impact NN N
of IN N
alexithymia NN i
on IN N
attrition NN N
and CC N
alcohol NN N
treatment NN N
outcomes NNS N
in IN N
men NNS p
and CC p
women NNS p
( ( p
N=77 NNP p
) ) p
enrolled VBD p
in IN p
a DT p
12-week JJ i
cognitive-behavioral JJ i
intervention NN i
for IN i
alcohol NN i
dependence NN i
. . i

At IN N
baseline NN N
, , N
higher JJR N
scores NNS N
on IN N
alexithymia NN N
were VBD N
associated VBN N
poorer JJR o
emotion NN o
regulation NN o
skills NNS o
, , o
fewer JJR o
percent NN o
days NNS o
abstinent NN o
, , o
greater JJR o
alcohol NN o
dependence NN o
severity NN o
, , o
and CC o
several JJ o
high-risk JJ o
drinking NN o
situations NNS o
. . o

Alexithymia NNP N
was VBD N
unrelated JJ N
to TO N
attrition NN N
and CC N
to TO N
level NN N
of IN N
alcohol NN N
consumption NN N
at IN N
posttreatment NN N
. . N

Overall UH N
, , N
the DT N
construct NN N
of IN N
alexithymia NN N
is VBZ N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
several JJ N
theoretically-related JJ N
constructs NNS N
( ( N
e.g. NN N
, , N
emotion NN N
regulation NN N
, , N
mindfulness NN N
) ) N
but CC N
demonstrated VBD N
a DT N
limited JJ N
relationship NN N
to TO N
drinking VBG N
outcomes NNS N
in IN N
those DT p
seeking VBG p
treatment NN p
for IN p
alcohol NN p
dependence NN p
. . p

-DOCSTART- -X- O O

Short-term JJ N
fluoxetine NN i
monotherapy NN i
for IN N
bipolar JJ p
type NN p
II NNP p
or CC p
bipolar JJ p
NOS NNP p
major JJ p
depression NN p
- : p
low JJ p
manic JJ p
switch NN p
rate NN p
. . p

OBJECTIVES CC N
Current NNP N
guidelines NNS N
for IN N
the DT N
initial JJ N
treatment NN N
of IN N
bipolar JJ p
type NN p
II NNP p
( ( p
BP NNP p
II NNP p
) ) p
major JJ p
depressive JJ p
episode NN p
( ( p
MDE NNP p
) ) p
recommend VBP N
using VBG N
either CC N
a DT N
mood NN N
stabilizer NN N
alone RB N
or CC N
a DT N
combination NN N
of IN N
a DT N
mood NN N
stabilizer NN N
plus CC N
a DT N
selective JJ N
serotonin NN N
re-uptake NN N
inhibitor NN N
( ( N
SSRI NNP N
) ) N
. . N

This DT N
recommendation NN N
is VBZ N
the DT N
result NN N
of IN N
concern NN N
over IN N
antidepressant-induced JJ N
manic JJ N
switch NN N
episodes NNS N
. . N

However RB N
, , N
recent JJ N
evidence NN N
suggests VBZ N
that IN N
the DT N
manic JJ N
switch NN N
rate NN N
may MD N
be VB N
low JJ N
in IN N
BP NNP N
II NNP N
MDE NNP N
during IN N
SSRI NNP N
therapy NN N
. . N

METHODS NNP N
As IN p
part NN p
of IN p
a DT p
randomized JJ p
, , p
double-blind JJ p
, , p
placebo-controlled JJ i
relapse-prevention NN p
study NN p
of IN p
fluoxetine JJ i
monotherapy NN i
in IN p
BP NNP p
II NNP p
MDE NNP p
, , p
37 CD p
patients NNS p
received VBD N
open-label JJ i
fluoxetine NN i
20 CD i
mg NN i
every DT i
day NN i
for IN i
up IN i
to TO i
8 CD i
weeks NNS i
. . i

Outcome NNP N
measures NNS N
included VBD N
the DT N
Hamilton NNP N
Depression NNP N
Rating NNP N
( ( N
HAM-D NNP N
17 CD N
) ) N
rating NN N
and CC N
the DT N
Young NNP N
Mania NNP N
Rating NNP N
( ( N
YMR NNP N
) ) N
scale NN N
. . N

RESULTS NNP N
Eleven NNP N
of IN N
23 CD N
patients NNS N
( ( N
48 CD N
% NN N
) ) N
who WP N
completed VBD N
8 CD N
weeks NNS N
of IN N
fluoxetine NN i
treatment NN N
showed VBD N
a DT N
HAM-D JJ o
17 CD o
reduction NN o
of IN N
> NN N
or CC N
=50 CD N
% NN N
, , N
while IN N
14 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
all DT N
treated JJ N
patients NNS N
had VBD N
> VBN N
or CC N
=50 CD N
% NN N
reduction NN N
in IN N
baseline JJ N
HAM-D JJ N
17 CD N
score NN N
. . N

Using VBG N
a DT N
conservative JJ N
YMR NNP o
score NN o
of IN o
> NN o
or CC o
=8 VB o
to TO N
identify VB N
hypomanic JJ N
symptoms NNS N
, , N
the DT N
frequency NN N
of IN N
patients NNS N
with IN N
YMR NNP N
score NN N
> NN N
or CC N
=8 NN N
during IN N
fluoxetine NN N
did VBD N
not RB N
differ VB N
from IN N
that DT N
seen VBN N
during IN N
the DT N
screen NN N
and CC N
baseline JJ N
period NN N
. . N

Only RB N
three CD N
patients NNS N
( ( N
7.3 CD N
% NN N
) ) N
had VBD N
symptoms NNS N
suggestive JJ N
of IN N
hypomania NN o
, , N
and CC N
only RB N
one CD N
patient NN N
stopped VBD N
treatment NN N
because IN N
of IN N
a DT N
rapid JJ o
mood NN o
swing VBG o
into IN o
depression NN o
. . o

LIMITATIONS NNP N
Fluoxetine NNP i
was VBD N
given VBN N
at IN N
a DT N
fixed JJ N
dose NN N
of IN N
20 CD N
mg NNS N
everyday JJ N
. . N

Fluoxetine NNP i
was VBD N
prescribed VBN N
in IN N
an DT N
open-label JJ N
manner NN N
, , N
and CC N
the DT N
sample NN N
size NN N
was VBD N
limited VBN N
. . N

CONCLUSIONS NNP N
These DT N
observations NNS N
support VBP N
the DT N
findings NNS N
of IN N
a DT N
low JJ N
manic JJ N
switch NN N
rate NN N
during IN N
SSRI NNP N
monotherapy NN N
of IN N
BP NNP N
II NNP N
MDE NNP N
, , N
and CC N
suggest VBP N
that IN N
fluoxetine JJ i
monotherapy NN i
may MD N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
initial JJ N
treatment NN N
of IN N
BP NNP p
II NNP p
MDE NNP p
. . p

-DOCSTART- -X- O O

Seven-star NNP i
needle JJ i
stimulation NN i
improves VBZ N
language NN o
and CC o
social JJ o
interaction NN o
of IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

This DT N
is VBZ N
a DT N
randomized JJ N
controlled VBN N
trial NN N
that WDT N
aimed VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
Seven-star NNP i
Needle NNP i
Stimulation NNP i
treatment NN N
on IN N
children NNS p
with IN p
Autistic NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Thirty-two JJ p
children NNS p
with IN p
ASD NNP p
were VBD N
assigned VBN N
randomly RB N
into IN N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

Children NNP N
in IN N
the DT N
treatment NN p
group NN p
underwent VBD N
30 CD N
sessions NNS N
of IN N
stimulation NN N
over IN N
6 CD N
weeks NNS N
, , N
while IN N
children NNS N
in IN N
the DT N
control NN p
group NN p
were VBD N
on IN N
a DT N
waiting VBG N
list NN N
and CC N
did VBD N
not RB N
receive VB N
treatment NN N
during IN N
this DT N
period NN N
of IN N
time NN N
. . N

Intervention NNP N
consisted VBD N
of IN N
a DT N
treatment NN N
regime NN N
comprising NN N
of IN N
30 CD i
sessions NNS i
of IN i
Seven-star NNP i
Needle NNP i
Stimulation NNP i
, , N
delivered VBD N
over IN N
6 CD N
weeks NNS N
. . N

Each DT N
session NN N
lasted VBD N
5 CD N
to TO N
10 CD N
min NN N
, , N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
stimulated VBN N
at IN N
the DT N
front NN N
and CC N
back RB N
sides NNS N
of IN N
their PRP$ N
body NN N
and CC N
the DT N
head NN N
by IN N
using VBG N
Seven-star JJ i
Needles NNP i
. . i

The DT N
change NN N
in IN N
the DT N
children NNS o
's POS o
behavior NN o
was VBD N
evaluated VBN N
using VBG N
parents NNS N
' POS N
report NN N
and CC N
neurophysiological JJ N
changes NNS N
were VBD N
measured VBN N
by IN N
quantitative JJ N
EEG NNP N
( ( N
qEEG NN N
) ) N
. . N

Results CC N
showed VBD N
that IN N
the DT N
treatment NN N
group NN N
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
language NN o
and CC o
social JJ o
interaction NN o
, , N
but CC N
not RB N
in IN N
stereotyped JJ o
behavior NN o
or CC o
motor NN o
function NN o
, , N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

qEEG JJ o
spectral JJ o
amplitudes NNS o
in IN N
the DT N
treatment NN N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
, , N
were VBD N
also RB N
reduced VBN N
significantly RB N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
Seven-star NNP i
Needle NNP i
Stimulation NNP i
might MD N
be VB N
an DT N
effective JJ N
intervention NN N
to TO N
improve VB N
language NN o
and CC o
social JJ o
functioning NN o
of IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Feedlot NNP N
performance NN N
and CC N
carcass NN N
characteristics NNS N
of IN N
Holstein NNP p
steers NNS p
as IN N
affected VBN N
by IN N
source NN N
of IN N
dietary JJ N
protein NN N
and CC N
level NN N
of IN N
ruminally RB N
protected VBN N
lysine NN N
and CC N
methionine NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS o
of IN N
source NN N
of IN N
dietary JJ N
CP NNP N
and CC N
level NN N
of IN N
ruminally RB N
protected VBN N
lysine NN N
and CC N
methionine NN N
( ( N
RPLM NNP N
) ) N
on IN N
feedlot NN o
performance NN o
and CC o
carcass NN o
characteristics NNS o
of IN N
Holstein NNP p
steers NNS p
during IN N
a DT N
growing-finishing JJ N
trial NN N
( ( N
266 CD N
d NN N
) ) N
. . N

A DT N
total NN N
of IN N
168 CD p
Holstein NNP p
steers NNS p
( ( p
182.7 CD p
+/- JJ p
27.5 CD p
kg NN p
) ) p
were VBD N
used VBN N
in IN N
a DT N
completely RB N
randomized JJ N
design NN N
experiment NN N
( ( N
eight CD N
treatments NNS N
; : N
three CD N
pens NNS N
of IN N
seven CD N
steers/treatment NN N
) ) N
. . N

Steers NNPS N
were VBD N
given VBN N
ad NN i
libitum NN i
access NN i
to TO i
high-concentrate JJ i
diets NNS i
( ( i
13 CD i
% NN i
CP NNP i
) ) i
containing VBG i
71 CD i
% NN i
whole JJ i
shelled VBN i
corn NN i
, , i
10 CD i
% NN i
corn NN i
silage NN i
, , i
4 CD i
% NN i
condensed JJ i
distillers NNS i
solubles NNS i
, , i
and CC i
15 CD i
% NN i
protein NN i
supplements NNS i
( ( i
DM NNP i
basis NN i
) ) i
. . i

Treatments NNS N
were VBD N
arranged VBN N
as IN N
a DT N
2 CD N
x NN N
4 CD N
factorial JJ N
. . N

The DT N
main JJ N
factors NNS N
were VBD N
two CD N
sources NNS N
of IN N
dietary JJ N
CP NNP N
and CC N
four CD N
levels NNS N
of IN N
RPLM NNP N
. . N

The DT N
sources NNS N
of IN N
dietary JJ o
CP NNP o
were VBD N
soybean JJ N
meal NN N
( ( N
SBM NNP N
) ) N
or CC N
SBM NNP N
and CC N
urea JJ N
( ( N
SBM-U NNP N
) ) N
. . N

Urea-N NNP o
replaced VBD N
50 CD N
% NN N
of IN N
SBM-N NNP N
in IN N
the DT N
SBM-U NNP N
diet NN N
. . N

The DT N
levels NNS N
of IN N
RPLM NNP N
were VBD N
0 CD N
, , N
5 CD N
, , N
10 CD N
, , N
and CC N
15 CD N
g NN N
per IN N
steer NN N
daily RB N
. . N

No UH N
interactions NNS N
( ( N
P NNP N
> NNP N
.10 NNP N
) ) N
between IN N
source NN N
of IN N
dietary JJ o
CP NNP o
and CC o
level NN o
of IN o
RPLM NNP o
were VBD N
observed VBN N
for IN N
feedlot NN N
performance NN N
or CC N
carcass NN o
characteristics NNS o
. . o

Feedlot NNP o
performance NN o
showed VBD N
an DT N
advantage NN N
( ( N
P NNP N
< NNP N
.10 NNP N
) ) N
to TO N
feeding VBG N
SMB NNP N
during IN N
the DT N
first JJ N
84 CD N
d NN N
of IN N
the DT N
trial NN N
and CC N
an DT N
advantage NN N
to TO N
feeding VBG N
SBM-U NNP N
during IN N
the DT N
last JJ N
98 CD N
d NN N
of IN N
the DT N
trial NN N
. . N

However RB N
, , N
feedlot JJ o
performance NN o
for IN N
the DT N
whole JJ N
trial NN N
and CC N
carcass NN N
characteristics NNS N
( ( N
except IN N
for IN N
fat JJ o
thickness NN o
) ) o
were VBD N
not RB N
affected VBN N
( ( N
P NNP N
> NNP N
.10 NNP N
) ) N
by IN N
the DT N
source NN N
of IN N
dietary JJ N
CP NNP N
. . N

Steers NNP N
fed VBD N
diets NNS N
containing VBG N
SBM-U NNP N
had VBD N
12 CD N
% NN N
less JJR N
( ( N
P NNP N
< NNP N
.10 NNP N
) ) N
fat VBZ o
thickness JJ o
than IN N
those DT N
fed JJ N
diets NNS N
containing VBG N
SBM NNP N
. . N

Supplementation NN N
of IN N
diets NNS N
with IN N
increasing VBG N
levels NNS N
of IN N
RPLM NNP o
did VBD N
not RB N
affect VB N
( ( N
P NNP N
> NNP N
.10 NNP N
) ) N
ADG NNP N
or CC N
carcass NN N
characteristics NNS N
. . N

However RB N
, , N
DMI NNP N
and CC N
gain NN N
: : N
feed NN N
showed VBD N
cubic JJ o
( ( o
P NNP o
< NNP o
.10 NNP o
) ) o
responses VBZ o
to TO N
increasing VBG N
dietary JJ N
level NN N
of IN N
RPLM NNP N
. . N

Supplementation NN N
of IN N
RPLM NNP N
at IN N
the DT N
10 CD N
g/d NNS N
level NN N
improved VBD N
gain NN o
: : o
feed VBN o
by IN N
12 CD N
% NN N
during IN N
the DT N
last JJ N
98 CD N
d NN N
of IN N
the DT N
trial NN N
, , N
and CC N
this DT N
was VBD N
a DT N
direct JJ N
response NN N
to TO N
the DT N
cubic JJ N
effects NNS N
of IN N
RPLM NNP N
on IN N
DMI NNP N
. . N

Results NNP N
suggest VBP N
a DT N
cost NN N
advantage NN N
for IN N
replacing VBG N
50 CD N
% NN N
of IN N
SBM-N NNP N
with IN N
that DT N
from IN N
urea JJ N
in IN N
high-corn JJ N
diets NNS N
without IN N
negative JJ N
effects NNS N
on IN N
feedlot NN N
performance NN N
or CC N
carcass NN N
characteristics NNS N
of IN N
growing-finishing JJ p
Holstein NNP p
steers NNS p
with IN p
extended JJ p
feeding NN p
periods NNS p
( ( p
266 CD p
d NN p
) ) p
. . p

These DT N
types NNS N
of IN N
diets NNS N
seem VBP N
to TO N
meet VB N
the DT N
amino NN N
acid NN N
requirements NNS N
and CC N
are VBP N
not RB N
limiting VBG N
in IN N
lysine NN N
and CC N
methionine NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
, , N
controlled VBN N
study NN N
on IN N
the DT N
influence NN N
of IN N
acetaminophen NN i
, , i
diclofenac NN i
, , i
or CC i
naproxen RB i
on IN i
aspirin-induced JJ i
inhibition NN N
of IN N
platelet NN o
aggregation NN o
. . o

Nonsteroidal NNP i
anti-inflammatory JJ i
drugs NNS i
( ( i
NSAID NNP i
) ) i
may MD N
interfere VB N
with IN N
aspirin NN i
( ( i
acetylsalicylic JJ i
acid NN i
) ) i
and CC N
increase VB N
the DT N
risk NN N
for IN N
cardiovascular JJ o
events NNS o
. . o

The DT N
clinical JJ N
relevance NN N
is VBZ N
uncertain JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
analyse VB N
the DT N
influence NN N
of IN N
a DT N
co-administration NN N
of IN N
aspirin NN i
and CC N
NSAID NNP i
on IN N
platelet NN o
aggregation NN o
. . o

In IN N
a DT N
randomized JJ N
, , N
placebo NN N
controlled VBD N
trial NN N
, , N
eleven RB p
healthy JJ p
volunteers NNS p
were VBD N
studied VBN N
during IN N
4 CD N
separate JJ N
study NN N
periods NNS N
of IN N
4 CD N
days NNS N
each DT N
. . N

Individuals NNS N
were VBD N
treated VBN N
on IN N
each DT N
occasion NN N
with IN N
100 CD N
mg NNS N
aspirin JJ i
daily RB N
in IN N
combination NN N
with IN N
either DT N
3 CD i
x VBD i
1 CD i
g NN i
acetaminophen NN i
, , i
3 CD i
x NN i
50 CD i
mg NN i
diclofenac NN i
, , i
3 CD i
x NN i
250 CD i
mg NN i
naproxen NN i
, , i
or CC i
3 CD i
x JJ i
1 CD i
placebo NN i
. . i

Primary JJ o
hemostasis NN o
was VBD N
assessed VBN N
with IN N
a DT N
platelet NN N
function NN N
analyser NN N
( ( N
PFA-100 NNP N
) ) N
, , N
which WDT N
measures VBZ N
the DT o
closure NN o
time NN o
( ( o
CT NNP o
) ) o
of IN o
a DT o
collagen- JJ o
and CC o
epinephrine-coated JJ o
pore NN o
by IN o
aggregating VBG o
platelets NNS o
in IN o
flowing VBG o
blood NN o
. . o

Naproxen NNP i
enhanced VBD N
the DT N
anti-aggregatory JJ o
action NN o
of IN N
aspirin NN i
after IN N
24 CD N
h NN N
( ( o
CT NNP o
rising VBG N
from IN N
104+/-16 JJ N
s NN N
at IN N
baseline NN N
to TO N
212+/-69 JJ N
s NN N
at IN N
24 CD N
h NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
which WDT N
was VBD N
not RB N
seen VBN N
with IN N
any DT N
other JJ N
drug NN N
combination NN N
. . N

Diclofenac NNP i
reduced VBD N
the DT N
anti-aggregatory JJ o
action NN o
of IN N
aspirin NN i
in IN N
the DT N
first JJ N
two CD N
days NNS N
, , N
since IN N
the DT N
CT NNP o
did VBD N
not RB N
rise VB N
significantly RB N
( ( N
109+/-19 JJ N
s NN N
, , N
148+/-56 JJ N
s NN N
, , N
and CC N
168+/-66 JJ N
s NN N
at IN N
0 CD N
h NN N
, , N
24 CD N
h NN N
, , N
48 CD N
h NN N
, , N
respectively RB N
, , N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Acetaminophen NNP i
had VBD N
no DT N
effect NN N
compared VBN N
with IN N
placebo NN i
. . i

After IN N
4 CD N
days NNS N
of IN N
treatment NN N
platelet NN o
aggregation NN o
was VBD N
similarly RB N
inhibited VBN N
by IN N
all DT N
combinations NNS N
. . N

We PRP N
conclude VBP N
that IN N
a DT N
co-administration NN N
of IN N
NSAID NNP i
and CC N
aspirin NN i
may MD N
interfere VB N
with IN N
platelet NN o
inhibition NN o
at IN N
the DT N
beginning NN N
of IN N
a DT N
treatment NN N
with IN N
an DT N
increase NN N
of IN N
naproxen JJ i
and CC N
a DT N
decrease NN N
of IN N
diclofenac NN i
. . i

This DT N
effect NN N
is VBZ N
lost VBN N
after IN N
4 CD N
days NNS N
, , N
suggesting VBG N
that IN N
a DT N
regular JJ N
daily JJ N
co-administration NN N
of IN N
NSAID NNP i
does VBZ N
not RB N
have VB N
an DT N
influence NN N
on IN N
platelet NN o
inhibition NN o
by IN N
aspirin NN i
. . i

-DOCSTART- -X- O O

Effect NN N
of IN N
adhesive JJ N
system NN N
type NN N
and CC N
tooth DT N
region NN N
on IN N
the DT N
bond NN N
strength NN N
to TO N
dentin VB N
. . N

PURPOSE VB N
This DT N
study NN N
evaluated VBD N
the DT N
bond NN N
strength NN N
of IN N
two CD N
etch-and-rinse JJ i
adhesive JJ i
systems NNS i
( ( N
two- JJ N
and CC N
three-step NN N
) ) N
and CC i
a DT i
self-etching JJ i
system NN i
to TO N
coronal VB o
and CC o
root VB o
canal JJ o
dentin NN o
. . o

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT p
root NN p
canals NNS p
of IN p
30 CD p
human JJ p
incisors NNS p
and CC p
canines NNS p
were VBD N
instrumented VBN N
and CC N
prepared VBN N
with IN N
burs NNS N
. . N

The DT N
posts NNS i
used VBD i
for IN i
luting VBG i
were VBD i
duplicated VBN i
with IN i
dual JJ i
resin NN i
cement NN i
( ( i
Duo-link NNP i
) ) i
inside IN i
Aestheti NNP i
Plus NNP i
# # i
2 CD i
molds NNS i
. . i

Thus RB N
, , N
three CD N
groups NNS N
were VBD N
formed VBN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
according VBG N
to TO N
the DT N
adhesive JJ N
system NN N
employed VBN N
: : N
All-Bond JJ i
2 CD i
( ( i
TE3 NNP i
) ) i
+ VBP i
resin JJ i
cement NN i
post NN i
( ( i
rcp NN i
) ) i
+ VBZ i
Duo-link NNP i
( ( i
Dl NNP i
) ) i
; : i
One-Step JJ i
Plus NNP i
( ( i
TE2 NNP i
) ) i
+ VBP i
rcp JJ i
+ NNP i
Dl NNP i
; : i
Tyrian/One-Step JJ i
Plus NNP i
( ( i
SE NNP i
) ) i
+ VBP i
rcp JJ i
+ NNP i
Dl NNP i
. . i

Afterwards NNP N
, , N
8 CD N
transverse NN N
sections NNS N
( ( N
1.5 CD N
mm NN N
) ) N
were VBD N
cut VBN N
from IN N
4 CD N
mm NNS N
above IN N
the DT N
CEJ NNP N
up RB N
to TO N
4 CD N
mm NNS N
short JJ N
of IN N
the DT N
root NN N
canal JJ N
apex NN N
, , N
comprising VBG N
coronal JJ N
and CC N
root JJ N
canal JJ N
dentin NN N
. . N

The DT N
sections NNS N
were VBD N
submitted VBN N
to TO N
push-out JJ N
testing NN N
in IN N
a DT N
universal JJ N
testing VBG N
machine NN N
EMIC NNP N
( ( N
1 CD N
mm/min NN N
) ) N
. . N

Bond NNP o
strength NN o
data NNS o
were VBD o
analyzed VBN o
with IN o
two-way JJ o
repeated JJ o
measures NNS o
ANOVA NNP o
and CC o
Tukey NNP o
's POS o
test NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
relationship NN o
between IN o
the DT o
adhesives NNS o
was VBD N
not RB N
the DT N
same JJ N
in IN N
the DT N
different JJ N
regions NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Comparison NNP N
of IN N
the DT N
means NNS N
achieved VBN N
with IN N
the DT N
adhesives NNS N
in IN N
each DT N
region NN N
( ( N
Tukey NNP N
; : N
p VBZ N
< $ N
0.05 CD N
) ) N
revealed VBD N
that IN N
TE3 NNP N
( ( N
mean JJ N
+/- JJ N
standard NN N
deviation NN N
: : N
5.22 CD N
+/- JJ N
1.70 CD N
) ) N
was VBD N
higher JJR N
than IN N
TE2 NNP N
( ( N
2.60 CD N
+/- JJ N
1.74 CD N
) ) N
and CC N
SE NNP N
( ( N
1.68 CD N
+/- JJ N
1.85 CD N
) ) N
. . N

CONCLUSION NNP N
Under IN N
the DT N
experimental JJ N
conditions NNS N
, , N
better JJR N
bonding VBG N
to TO N
dentin VB N
was VBD N
achieved VBN N
using VBG N
the DT N
three-step JJ N
etch-and-rinse JJ N
system NN N
, , N
especially RB N
in IN N
the DT N
coronal JJ N
region NN N
. . N

Therefore RB N
, , N
the DT N
traditional JJ N
etch-and-rinse JJ N
three-step NN N
adhesive JJ N
system NN N
seems VBZ N
to TO N
be VB N
the DT N
best JJS N
choice NN N
for IN N
teeth NN N
needing VBG N
adhesive JJ N
endodontic JJ N
restorations NNS N
. . N

-DOCSTART- -X- O O

Amphotericin NNP i
B NNP i
in IN p
children NNS p
with IN p
malignant JJ p
disease NN p
: : p
a DT N
comparison NN N
of IN N
the DT N
toxicities NNS N
and CC N
pharmacokinetics NNS N
of IN N
amphotericin NN i
B NNP i
administered VBN i
in IN i
dextrose JJ i
versus NN i
lipid JJ i
emulsion NN i
. . i

In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
toxicity NN N
of IN N
1 CD N
mg NN N
of IN N
amphotericin NN i
B NNP i
( ( i
AmB NNP i
) ) i
per IN N
kg NN N
of IN N
body NN N
weight JJ N
per IN N
day NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
AmB NNP i
infused VBD i
in IN i
lipid JJ i
emulsion NN i
in IN N
children NNS p
with IN p
malignant JJ p
disease NN p
. . p

In IN N
an DT N
analysis NN N
of IN N
82 CD p
children NNS p
who WP p
received VBD p
a DT p
full JJ p
course NN p
of IN p
6 CD p
days NNS p
or CC p
more JJR p
of IN p
AmB NNP i
( ( p
117 CD p
courses NNS p
) ) p
, , N
it PRP N
was VBD N
shown VBN N
that IN N
there EX N
were VBD N
significant JJ N
increases NNS N
in IN N
plasma JJ N
urea JJ N
and CC N
creatinine JJ N
concentrations NNS N
and CC N
in IN N
potassium NN N
requirement NN N
after IN N
6 CD N
days NNS N
of IN N
therapy NN N
with IN N
both DT N
AmB NNP i
infused VBN N
in IN N
dextrose NN i
and CC N
AmB NNP i
infused VBD N
in IN N
lipid JJ i
emulsion NN i
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
of IN N
AmB NNP i
administration NN N
. . N

An DT N
intent-to-treat JJ N
comparison NN N
of IN N
the DT N
numbers NNS N
of IN N
courses NNS N
affected VBN N
by IN N
acute JJ N
toxicity NN N
( ( N
fever NN N
, , N
rigors NNS N
) ) N
and CC N
chronic JJ N
toxicity NN N
( ( N
nephrotoxicity NN N
) ) N
also RB N
indicated VBD N
that IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
AmB NNP i
infused VBD i
in IN i
dextrose NN i
( ( N
78 CD N
courses NNS N
) ) N
and CC N
AmB NNP i
infused VBD i
in IN i
lipid JJ i
emulsion NN i
( ( N
84 CD N
courses NNS N
) ) N
. . N

The DT N
pharmacokinetics NNS o
of IN o
AmB NNP o
were VBD N
investigated VBN N
in IN N
20 CD N
children NNS N
who WP N
received VBD N
AmB NNP i
in IN i
dextrose NN i
and CC N
15 CD N
children NNS N
who WP N
received VBD N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
. . i

Blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
24 CD N
h NN N
after IN N
administration NN N
of IN N
the DT N
first JJ N
dose NN N
, , N
and CC N
the DT N
concentration NN o
of IN o
AmB NNP o
in IN o
plasma NN o
was VBD N
analyzed VBN N
by IN N
a DT N
high-performance NN N
liquid NN N
chromatography NN N
assay NN N
. . N

The DT N
clearance NN o
( ( o
CL NNP o
) ) o
of IN o
AmB NNP o
in IN o
dextrose NN o
( ( N
0.039 CD N
+/- JJ N
0.016 CD N
liter NN N
. . N

h-1 NN N
. . N

kg-1 NN N
) ) N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
the DT N
CL NNP N
of IN N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
( ( N
0.062 CD N
+/- JJ N
0 CD N
. . N

024 CD N
liter NN N
. . N

h-1 NN N
. . N

kg-1 NN N
) ) N
. . N

The DT N
steady-state JJ o
volume NN o
of IN o
distribution NN o
for IN o
AmB NNP o
in IN N
dextrose NN N
( ( N
0.83 CD N
+/- JJ N
0.33 CD N
liter NN N
. . N

kg-1 NN N
) ) N
was VBD N
also RB N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
that DT N
for IN N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
( ( N
1.47 CD N
+/- JJ N
0.77 CD N
liter NN N
. . N

kg-1 NN N
) ) N
. . N

Although IN N
AmB NNP o
in IN o
lipid JJ o
emulsion NN o
is VBZ N
apparently RB N
cleared VBN N
faster RBR N
and CC N
distributes VBZ N
more RBR N
widely RB N
than IN N
AmB NNP o
in IN o
dextrose NN o
, , N
this DT N
study NN N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
advantage NN N
with IN N
respect NN N
to TO N
safety NN o
and CC o
tolerance NN o
in IN N
the DT N
administration NN N
of IN N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
compared VBN N
to TO N
its PRP$ N
administration NN N
in IN N
dextrose NN i
in IN N
children NNS p
with IN p
malignant JJ p
disease NN p
. . p

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
of IN N
methylphenidate NN i
for IN N
attention-deficit/hyperactivity NN N
disorder NN N
symptoms NNS N
in IN p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
efficacy NN o
and CC N
safety NN N
of IN N
methylphenidate NN i
( ( i
MPH NNP i
) ) i
to TO N
treat VB N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
symptoms NNS N
in IN N
an DT N
understudied JJ p
population NN p
of IN p
preschoolers NNS p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
( ( p
PDD NNP p
) ) p
or CC p
intellectual JJ p
disability NN p
( ( p
ID NNP p
) ) p
. . p

METHODS NNP N
Fourteen NNP p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
( ( p
DD NNP p
, , p
n JJ p
= VBP p
14 CD p
; : p
PDD NNP p
, , p
n JJ p
= VBP p
12 CD p
; : p
ID NNP p
, , p
n JJ p
= NNP p
2 CD p
) ) p
underwent NN N
MPH NNP i
titration NN i
in IN N
a DT N
single-blind JJ N
manner NN N
followed VBN N
by IN N
a DT N
4-week JJ N
double-blind NN N
crossover NN N
phase NN N
. . N

Each DT N
child NN N
was VBD N
administered VBN N
placebo NN i
for IN N
2 CD N
weeks NNS N
and CC N
optimal JJ i
dose NN i
for IN N
2 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Diagnostic NNP o
and CC o
Statistical NNP o
Manual NNP o
of IN o
Mental NNP o
Disorders NNP o
, , o
4 CD o
( ( o
th NN o
) ) o
edition NN o
( ( o
DSM-IV NNP o
) ) o
ADHD NNP o
subscale NN o
of IN o
the DT o
Conners NNP o
' POS o
Parent NN o
Rating VBG o
Scale-Revised JJ o
( ( N
CPRS-R-DSM-IV-ADHD NNP N
) ) N
. . N

RESULTS NNP N
MPH NNP i
improved VBD N
parent-rated JJ o
ADHD NNP o
symptoms NNS o
of IN N
the DT N
preschoolers NNS N
; : N
50 CD N
% NN N
were VBD N
rated VBN N
as IN N
responders NNS N
. . N

The DT N
CPRS-R-DSM-IV-ADHD JJ o
subscale NN o
was VBD N
significant JJ N
for IN N
the DT N
PDD NNP p
subgroup NN p
( ( N
p JJ N
= NN N
0.005 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.97 CD N
) ) N
and CC N
marginally RB N
significant JJ N
for IN N
the DT N
entire JJ N
DD NNP N
sample NN N
( ( N
p JJ N
= NN N
0.08 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.50 CD N
) ) N
. . N

Half NN N
of IN N
the DT N
preschoolers NNS p
experienced VBD N
side JJ o
effects NNS o
with IN N
MPH NNP i
, , N
including VBG N
reports NNS N
of IN N
increased VBN N
stereotypic NN o
behavior NN o
, , o
upset JJ o
stomach NN o
, , o
sleep-related JJ o
difficulties NNS o
, , o
and CC o
emotional JJ o
lability NN o
. . o

One CD N
child NN N
discontinued VBN N
during IN N
titration NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

CONCLUSION VB N
The DT N
predominant JJ N
direction NN N
of IN N
response NN N
in IN N
these DT N
preschoolers NNS p
with IN p
both DT p
ADHD NNP p
and CC p
PDD/ID NNP p
favored VBD N
MPH NNP i
, , N
even RB N
though IN N
the DT N
response NN N
was VBD N
more RBR N
subtle JJ N
and CC N
variable JJ N
than IN N
in IN N
older JJR N
and CC N
typically RB N
developing VBG N
children NNS N
. . N

Due NNP N
to TO N
high JJ N
rates NNS N
of IN N
adverse JJ N
effects NNS N
, , N
preschoolers NNS N
should MD N
be VB N
monitored VBN N
closely RB N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
intravenous JJ i
fructose-1,6-diphosphate NN i
on IN N
myocardial JJ o
contractility NN o
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
dysfunction NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
fructose-1,6-diphosphate NN i
on IN N
myocardial JJ o
performance NN o
using VBG N
nuclear JJ N
scintigraphy NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
single-blind JJ N
, , N
parallel JJ N
study NN N
. . N

SETTING NNP N
Urban NNP p
teaching VBG p
hospital JJ p
clinical JJ p
research NN p
center NN p
. . p

PATIENTS JJ N
Individuals NNS p
with IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
functional JJ p
class NN p
II-III NNP p
heart NN p
failure NN p
( ( p
mild JJ p
to TO p
moderate VB p
) ) p
. . p

INTERVENTIONS JJ N
Subjects NNPS N
received VBD N
either DT N
intravenous JJ i
fructose-1,6-diphosphate JJ i
125 CD i
mg/kg NN i
or CC i
normal JJ i
saline JJ i
1.3 CD N
ml/kg NN N
every DT N
12 CD N
hours NNS N
over IN N
10 CD N
minutes NNS N
for IN N
four CD N
consecutive JJ N
doses NNS N
. . N

Left NNP N
ventricular JJ N
performance NN N
was VBD N
assessed VBN N
by IN N
radionuclide NN i
ventriculography NN i
at IN N
baseline NN N
and CC N
within IN N
60 CD N
minutes NNS N
after IN N
the DT N
fourth JJ N
infusion NN N
. . N

Vital JJ N
signs NNS N
were VBD N
monitored VBN N
throughout IN N
the DT N
study NN N
period NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Fructose-1,6-diphosphate NNP i
resulted VBD N
in IN N
a DT N
modest JJ N
7 CD N
% NN N
increase NN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Peak JJ o
ejection NN o
rate NN o
and CC o
peak VB o
diastolic JJ o
filling VBG o
rate NN o
did VBD N
not RB N
change VB N
significantly RB N
. . N

There EX N
were VBD N
no DT N
changes NNS N
in IN N
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
with IN N
either DT N
fructose-1,6-diphosphate JJ i
or CC N
placebo NN i
. . i

CONCLUSIONS NNP N
Fructose-1,6-diphosphate NNP i
produces VBZ N
a DT N
modest JJ N
but CC N
significant JJ N
increase NN N
in IN N
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
in IN N
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
heart NN p
failure NN p
. . p

-DOCSTART- -X- O O

Preschool NNP N
based VBN N
JASPER NNP i
intervention NN i
in IN N
minimally RB p
verbal JJ p
children NNS p
with IN p
autism NN p
: : p
pilot NN N
RCT NNP N
. . N

In IN N
this DT N
pilot NN N
study NN N
, , N
we PRP N
tested VBD N
the DT N
effects NNS N
of IN N
a DT N
novel JJ N
intervention NN N
( ( i
JASPER NNP i
, , i
Joint NNP i
Attention NNP i
Symbolic NNP i
Play NNP i
Engagement NNP i
and CC i
Regulation NNP i
) ) i
on IN N
3 CD p
to TO p
5 CD p
year NN p
old JJ p
, , p
minimally RB p
verbal JJ p
children NNS p
with IN p
autism NN p
who WP p
were VBD p
attending VBG p
a DT p
non-public JJ p
preschool NN p
. . p

Participants NNS N
were VBD i
randomized VBN i
to TO i
a DT i
control NN i
group NN i
( ( i
treatment NN i
as IN i
usual JJ i
, , i
30 CD i
h NN i
of IN i
ABA-based JJ i
therapy NN i
per IN i
week NN i
) ) i
or CC i
a DT i
treatment NN i
group NN i
( ( i
substitution NN i
of IN i
30 CD i
min NN i
of IN i
JASPER NNP i
treatment NN i
, , i
twice RB i
weekly RB i
during IN i
their PRP$ i
regular JJ i
program NN i
) ) i
. . i

A DT i
baseline NN N
of IN N
12 CD N
weeks NNS N
in IN N
which WDT N
no DT N
changes NNS N
were VBD N
noted VBN N
in IN N
core NN o
deficits NNS o
was VBD o
followed VBN N
by IN N
12 CD N
weeks NNS N
of IN N
intervention NN N
for IN N
children NNS N
randomized VBN N
to TO N
the DT N
JASPER NNP i
treatment NN i
. . N

Participants NNS N
in IN N
the DT N
treatment NN N
group NN N
demonstrated VBD N
greater JJR o
play NN o
diversity NN o
on IN o
a DT o
standardized JJ o
assessment NN o
. . o

Effects NNS o
also RB N
generalized VBD N
to TO N
the DT N
classroom NN N
, , N
where WRB N
participants NNS N
in IN N
the DT N
treatment NN N
group NN N
initiated VBD N
more JJR N
gestures NNS o
and CC o
spent VB o
less JJR o
time NN o
unengaged JJ o
. . o

These DT o
results NNS N
provide VBP N
further JJ N
support NN N
that WDT N
even RB N
brief VBP N
, , N
targeted JJ N
interventions NNS N
on IN N
joint JJ N
attention NN N
and CC N
play NN N
can MD N
improve VB o
core NN o
deficits NNS o
in IN o
minimally RB p
verbal JJ p
children NNS p
with IN p
ASD NNP p
. . N

-DOCSTART- -X- O O

Serum NNP N
selenium NN i
concentration NN N
and CC N
antioxidant JJ N
activity NN N
in IN N
cervical JJ p
cancer NN p
patients NNS p
before IN p
and CC p
after IN p
treatment NN p
. . p

AIM NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
the DT N
effect NN N
of IN N
chemo NN N
and CC N
radio NN N
therapies NNS N
on IN N
serum NN N
trace NN N
elements NNS N
content NN N
and CC N
antioxidant JJ o
activity NN o
in IN N
blood NN N
serum NN N
of IN N
cervical JJ p
cancer NN p
patients NNS p
was VBD N
evaluated VBN N
. . N

METHODS NNP N
Among IN N
104 CD p
cervical JJ p
cancer NN p
patients NNS p
selected VBN p
for IN p
the DT p
present JJ p
study NN p
, , p
54 CD p
and CC p
50 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
chemo- JJ i
and CC i
radiotherapy NN i
respectively RB p
. . p

Plasma NNP N
Se NNP N
, , N
Zn NNP N
, , N
Cu NNP N
and CC N
some DT N
enzymatic JJ N
antioxidants NNS N
activities NNS N
were VBD N
estimated VBN N
in IN N
serum NN N
before IN N
and CC N
after IN N
the DT N
treatment NN N
. . N

RESULTS VB N
The DT N
decreased JJ N
levels NNS N
of IN N
serum NN o
trace NN o
elements NNS o
, , o
glutathione NN o
peroxidase NN o
activity NN o
and CC o
total JJ o
antioxidant JJ o
capacity NN o
, , o
and CC o
increased VBD o
malondialdehyde NN o
, , o
glutathion NN o
reductase NN o
was VBD N
observed VBN N
in IN N
cervical JJ p
cancer NN p
patients NNS p
when WRB N
compared VBN N
to TO N
healthy JJ N
controls NNS N
. . N

The DT N
increased JJ N
concentration NN o
of IN o
serum NN o
Se NNP o
, , o
Zn NNP o
was VBD N
observed VBN N
in IN N
patients NNS p
treated VBN p
with IN p
chemotherapy NN i
. . i

Simultaneously RB N
there EX N
was VBD N
a DT N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
increase NN N
in IN N
glutathione JJ o
peroxidase NN o
and CC o
total JJ o
antioxidant JJ o
capacity NN o
, , N
and CC N
significant JJ N
decrease NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
malondialdehyde NN o
and CC o
glutathion NN o
reductase NN o
levels NNS o
in IN N
the DT N
serum NN N
of IN N
patients NNS N
treated VBN N
with IN N
chemotherapy NN i
compared VBN N
to TO N
the DT N
patients NNS N
treated VBN N
with IN N
radiotherapy NN i
. . i

CONCLUSION VB N
The DT N
results NNS N
demonstrated VBD N
that IN N
chemotherapy NN i
but CC N
not RB N
radiotherapy JJ i
results NNS N
in IN N
significant JJ N
increase NN N
in IN N
the DT N
trace NN o
elements NNS o
levels NNS o
and CC o
antioxidant JJ o
activities NNS o
in IN N
blood NN N
serum NN N
of IN N
cervical JJ p
cancer NN p
patients NNS p
. . p

-DOCSTART- -X- O O

Impact NN N
of IN N
angiotensin-converting JJ N
enzyme JJ N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ o
responses NNS o
to TO N
high- JJ N
versus NN N
low-dose JJ N
enalapril NN N
in IN N
advanced JJ p
heart NN p
failure NN p
. . p

BACKGROUND CC N
The DT N
impact NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
gene NN N
polymorphism NN N
on IN N
neurohormonal JJ N
dose JJ N
response NN N
to TO N
ACE NNP i
inhibitor NN N
therapy NN N
is VBZ N
unclear JJ N
. . N

METHODS NNP N
ACE NNP N
Insertion NNP N
( ( N
I PRP N
) ) N
or CC N
Deletion NNP N
( ( N
D NNP N
) ) N
genotype NN N
was VBD N
determined VBN N
in IN N
74 CD p
patients NNS p
with IN p
chronic JJ p
heart NN p
failure NN p
who WP N
were VBD N
randomly RB i
assigned VBN i
to TO i
receive VB i
either DT i
high-dose JJ i
or CC i
low-dose JJ i
enalapril NN i
over IN i
a DT i
period NN i
of IN i
6 CD i
months NNS i
. . i

Monthly JJ i
pre-enalapril JJ o
and CC o
post-enalapril JJ o
neurohormone NN o
levels NNS o
( ( o
serum JJ o
ACE NNP o
activity NN o
( ( o
sACE NN o
) ) o
, , o
plasma JJ o
angiotensin NN o
II NNP o
( ( o
A-II NNP o
) ) o
, , o
plasma JJ o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
, , o
and CC o
serum VB o
aldosterone NN o
( ( o
ALDO NNP o
) ) o
were VBD N
compared VBN N
between IN N
genotype NN N
subgroups NNS N
and CC N
between IN N
patients NNS N
who WP N
received VBD N
high- JJ N
or CC N
low-dose JJ N
enalapril NN i
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
predose/postdose JJ o
sACE NN o
and CC o
postdose JJ o
PRA NNP o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
DD NNP p
genotype NN p
. . p

At IN N
6-month JJ N
follow-up NN N
, , N
postdose JJ o
sACE NN o
was VBD N
reduced VBN N
in IN N
a DT N
dose-dependent JJ N
fashion NN N
in IN N
all DT N
three CD N
genotypes NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

However RB N
, , N
predose JJ o
and CC o
postdose JJ o
ALDO NNP o
and CC o
A-II NNP o
levels NNS o
did VBD N
not RB N
differ VB N
between IN N
each DT N
genotype NN N
subgroup NN N
at IN N
baseline NN N
or CC N
by IN N
enalapril JJ N
dose NN N
within IN N
each DT N
genotype NN N
subgroup NN N
. . N

ALDO NNP o
escape NN o
and CC o
A-II JJ o
reactivation NN o
were VBD N
not RB N
affected VBN N
by IN N
ACE NNP p
genotype NN p
or CC N
enalapril JJ N
dosage NN N
. . N

CONCLUSIONS NNP N
Predose NNP o
sACE NN o
were VBD N
consistently RB N
higher JJR N
in IN N
the DT N
DD NNP N
genotype NN N
when WRB N
compared VBN N
with IN N
ID NNP p
or CC p
II NNP p
subgroups NNS p
. . p

Despite IN N
a DT N
dose-dependent JJ N
suppression NN o
of IN o
sACE NN o
, , N
there EX N
were VBD N
no DT N
observed VBN N
statistically RB N
significant JJ N
differences NNS N
in IN N
ALDO NNP o
and CC o
A-II NNP o
suppression NN o
or CC N
escape NN N
with IN N
escalating VBG N
doses NNS N
of IN N
enalapril NN N
within IN N
each DT N
subgroup NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
Ezetimibe NNP i
on IN N
LDL-C NNP o
Lowering NNP o
and CC N
Atherogenic NNP o
Lipoprotein NNP o
Profiles NNP o
in IN N
Type NNP p
2 CD p
Diabetic NNP p
Patients NNPS p
Poorly NNP p
Controlled VBN p
by IN p
Statins NNP p
. . p

BACKGROUND NNP N
There EX N
exists VBZ N
a DT N
subpopulation NN N
of IN N
T2DM NNP N
in IN N
whom WP N
first-line JJ N
doses NNS N
of IN N
statin NN N
are VBP N
insufficient JJ N
for IN N
optimally RB N
reducing VBG N
LDL-C NNP o
, , N
representing VBG N
a DT N
major JJ N
risk NN N
of IN N
CVD NNP N
. . N

The DT N
RESEARCH NNP N
study NN N
focuses VBZ N
on IN N
LDL-C NNP o
reduction NN N
in IN N
this DT N
population NN N
along IN N
with IN N
modifications NNS N
of IN N
the DT N
lipid JJ N
profiles NNS N
leading VBG N
to TO N
residual JJ N
risks NNS N
. . N

METHODS NNP N
Lipid NNP o
changes NNS o
were VBD N
assessed VBN N
in IN N
a DT N
randomized JJ N
, , N
multicenter NN N
, , N
12-week JJ N
, , N
open-label JJ N
study NN N
comparing VBG N
a DT N
high-potency NN i
statin NN i
( ( i
10mg CD i
of IN i
atorvastatin NN i
or CC i
1mg CD i
of IN i
pitavastatin NN i
) ) i
plus CC i
ezetimibe JJ i
( ( N
EAT JJ N
: : N
n JJ N
= NNP N
53 CD N
) ) N
with IN N
a DT N
double JJ N
dose NN N
of IN N
statin NN i
( ( N
20mg CD N
of IN N
atorvastatin NN i
or CC N
2mg CD N
of IN N
pitavastatin NN i
) ) i
( ( N
DST NNP N
: : N
n JJ N
= NNP N
56 CD N
) ) N
in IN N
DM NNP p
subjects NNS p
who WP p
had VBD p
failed VBN p
to TO p
achieve VB p
the DT p
optimal JJ p
LDL-C NNP p
targets NNS p
. . p

Lipid JJ o
variables NNS o
were VBD N
compared VBN N
with IN N
a DT N
primary JJ N
focus NN N
on IN N
LDL-C NNP o
and CC N
with IN N
secondary JJ N
focuses NNS N
on IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
reached VBD N
the DT N
LDL-C NNP o
targets NNS N
and CC N
changes NNS N
in IN N
the DT N
levels NNS o
of IN o
RLP-C NNP o
( ( N
remnant VBP N
like IN N
particle NN N
cholesterol NN N
) ) N
and CC N
sd-LDL-C JJ o
, , N
two CD N
characteristic JJ N
atherogenic JJ N
risks NNS N
of IN N
DM NNP N
. . N

RESULTS VB N
The DT N
reduction NN o
of IN o
LDL-C NNP o
( ( N
% NN N
) ) N
, , N
the DT N
primary JJ N
endpoint NN N
, , N
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
( ( N
-24.6 NN N
in IN N
EAT NNP N
vs. FW N
-10.9 NNP N
in IN N
DST NNP N
) ) N
. . N

In IN N
the DT N
analyses NNS N
of IN N
the DT N
secondary JJ N
endpoints NNS N
, , N
EAT NNP N
treatment NN N
brought VBD N
about RB N
significantly RB N
larger JJR N
reductions NNS N
in IN N
sd-LDL-C NN o
( ( N
-20.5 JJ N
vs. FW N
-3.7 NN N
) ) N
and CC N
RLP-C NNP o
( ( N
-19.7 NNP N
vs. IN N
+5.5 NNP N
) ) N
. . N

In IN N
total JJ N
, , N
89.4 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
EAT NNP N
reached VBD N
the DT N
optimized JJ N
treatment NN N
goal NN N
compared VBN N
to TO N
51.0 CD N
% NN N
of IN N
the DT N
patients NNS N
receiving VBG N
DST NNP i
. . i

The DT N
changes NNS N
in IN N
TC NNP o
( ( N
-16.3 NNP N
vs. IN N
-6.3 NNP N
) ) N
and CC N
non-HDL-C JJ o
( ( N
-20.7 JJ N
vs. FW N
-8.3 NN N
) ) N
differed VBD N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Ezetimibe NNP i
added VBD N
to TO N
high-potency NN N
statin NN i
( ( N
10 CD N
mg NN N
of IN N
atorvastatin NN i
or CC N
1 CD N
mg NN N
of IN N
pitavastatin NN i
) ) i
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
intensified-dose JJ N
statin NN i
( ( N
20 CD N
mg NN N
of IN N
atorvastatin NN i
or CC N
2 CD N
mg NN N
of IN N
pitavastatin NN i
) ) i
treatment NN N
not RB N
only RB N
in IN N
helping VBG N
T2DM NNP N
patients NNS N
attain VBP N
more JJR N
LDL-C JJ o
reduction NN o
, , N
but CC N
also RB N
in IN N
improving VBG N
their PRP$ N
atherogenic JJ o
lipid JJ o
profiles NNS o
, , N
including VBG N
their PRP$ N
levels NNS N
of IN N
sd-LDL-C JJ o
and CC o
RLP-C. JJ o
We PRP N
thus RB N
recommend VBP N
the DT N
addition NN N
of IN N
ezetimibe NN N
to TO N
high-potency NN N
statin NN N
as IN N
a DT N
first JJ N
line NN N
strategy NN N
for IN N
T2DM NNP p
patients NNS p
with IN p
insufficient JJ p
statin NN p
response NN p
. . p

TRIAL NNP N
REGISTRATION NNP N
The DT N
UMIN NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
UMIN000002593 NNP N
. . N

-DOCSTART- -X- O O

Low JJ N
body NN N
mass NN N
index NN N
and CC N
dyslipidemia NN N
in IN N
dialysis NN i
patients NNS p
linked VBN N
to TO N
elevated VBN N
plasma NN N
fibroblast NN N
growth NN N
factor NN N
23 CD N
. . N

BACKGROUND NNP N
Fibroblast NNP N
growth NN N
factor NN N
23 CD N
( ( N
FGF23 NNP N
) ) N
has VBZ N
been VBN N
associated VBN N
with IN N
death NN N
in IN N
dialysis NN i
patients NNS p
. . p

Since IN N
FGF23 NNP N
shares NNS N
structural JJ N
features NNS N
with IN N
FGF19 NNP N
subfamily RB N
members NNS N
that IN N
exert JJ N
hormonal JJ N
control NN N
of IN N
fat JJ N
mass NN N
, , N
we PRP N
hypothesized VBD N
that DT N
high JJ N
circulating NN N
FGF23 NNP N
concentrations NNS N
would MD N
be VB N
associated VBN N
with IN N
the DT N
development NN N
of IN N
a DT N
uremic JJ N
lipid NN N
profile NN N
and CC N
lower JJR N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
conducted VBN N
among IN N
654 CD p
patients NNS p
receiving VBG p
chronic JJ p
hemodialysis NN i
. . i

C-terminal JJ o
FGF23 NNP o
concentrations NNS o
were VBD i
measured VBN i
in IN i
stored JJ i
plasma NN i
samples NNS i
. . i

Linear JJ i
regression NN i
was VBD i
used VBN i
to TO i
examine VB i
the DT i
cross-sectional JJ i
associations NNS i
of IN i
plasma NN o
FGF23 NNP o
concentrations NNS o
with IN o
BMI NNP o
, , o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , o
low-density JJ o
lipoprotein-cholesterol NN o
( ( o
LDL-C NNP o
) ) o
, , o
high-density JJ o
lipoprotein-cholesterol NN o
( ( o
HDL-C NNP o
) ) o
and CC o
triglycerides NNS o
. . o

Cox NNP N
proportional JJ N
hazard NN N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
association NN N
between IN N
FGF23 NNP N
concentrations NNS N
and CC N
all-cause JJ N
mortality NN N
. . N

RESULTS JJ N
Participants NNS p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
60 CD p
? . p
11 CD p
years NNS p
and CC p
a DT p
median JJ p
( ( p
IQR NNP p
) ) p
FGF23 NNP p
concentration NN p
of IN p
4,212 CD p
( ( p
1,411-13,816 JJ p
) ) p
RU/ml NNP p
. . p

An DT N
increase NN N
per IN N
SD NNP N
in IN N
log10 JJ N
FGF23 NNP N
was VBD N
associated VBN N
with IN N
lower JJR N
BMI NNP N
( ( N
? . N
= NNP N
-1.11 NNP N
; : N
p VBZ N
= $ N
0.008 CD N
) ) N
, , N
TC NNP N
( ( N
? . N
= NNP N
-6.46 NNP N
; : N
p VBZ N
= $ N
0.02 CD N
) ) N
, , N
LDL-C NNP N
( ( N
? . N
= NNP N
-4.73 NNP N
; : N
p VBZ N
= $ N
0.04 CD N
) ) N
and CC N
HDL-C NNP N
( ( N
? . N
= NNP N
-2.14 NNP N
; : N
p VBZ N
= $ N
0.03 CD N
) ) N
; : N
after IN N
adjusting VBG N
for IN N
age NN N
, , N
gender NN N
, , N
race NN N
, , N
cardiovascular JJ N
risk NN N
factors NNS N
, , N
serum NN N
albumin NN N
, , N
markers NNS N
of IN N
mineral JJ N
metabolism NN N
, , N
and CC N
use NN N
of IN N
lipid-lowering JJ N
drugs NNS N
. . N

The DT N
association NN N
of IN N
FGF23 NNP N
with IN N
death NN N
was VBD N
attenuated VBN N
after IN N
adjustment NN N
for IN N
HDL-C NNP N
( ( N
HR NNP N
of IN N
highest JJS N
quartile NN N
1.53 CD N
, , N
95 CD N
% NN N
CI NNP N
1.06-2.20 CD N
compared VBN N
to TO N
lowest VB N
quartile NN N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
indicate VBP N
that IN N
higher JJR N
plasma NN N
FGF23 NNP N
levels NNS N
are VBP N
associated VBN N
with IN N
lower JJR N
BMI NNP N
and CC N
dyslipidemia NN i
in IN i
dialysis NN i
patients NNS i
. . p

The DT p
association NN N
between IN N
FGF23 NNP N
and CC N
death NN N
may MD N
be VB N
mediated VBN N
through IN N
unexplored JJ N
metabolic JJ N
risk NN N
factors NNS N
unrelated VBD N
to TO N
mineral JJ N
metabolism NN N
. . N

-DOCSTART- -X- O O

Cognitive JJ i
behavioral JJ i
therapy NN i
for IN N
anxiety NN o
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Children NNP p
with IN p
autism NN p
spectrum NN p
disorders NNS p
often RB N
present JJ N
with IN N
comorbid NN p
anxiety NN p
disorders NNS p
that WDT p
cause VBP p
significant JJ p
functional JJ o
impairment NN o
. . o

This DT N
study NN N
tested VBD N
a DT N
modular JJ i
cognitive JJ i
behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
program NN N
for IN N
children NNS N
with IN N
this DT N
profile NN N
. . N

A DT N
standard JJ N
CBT NNP i
program NN N
was VBD N
augmented VBN N
with IN N
multiple JJ N
treatment NN N
components NNS N
designed VBN N
to TO N
accommodate VB N
or CC N
remediate VB N
the DT N
social JJ N
and CC N
adaptive JJ N
skill NN N
deficits NNS N
of IN N
children NNS p
with IN p
ASD NNP p
that WDT N
could MD N
pose VB N
barriers NNS N
to TO N
anxiety VB o
reduction NN o
. . o

METHOD NNP N
Forty NNP p
children NNS p
( ( p
7-11 CD p
years NNS p
old JJ p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP i
or CC N
a DT N
3-month JJ i
waitlist NN i
( ( N
36 CD N
completed VBN N
treatment NN N
or CC N
waitlist NN N
) ) N
. . N

Therapists NNS N
worked VBD N
with IN N
individual JJ N
families NNS N
. . N

The DT N
CBT NNP i
model NN N
emphasized VBD N
behavioral JJ N
experimentation NN N
, , N
parent-training NN N
, , N
and CC N
school NN N
consultation NN N
. . N

Independent JJ N
evaluators NNS N
blind VBP N
to TO N
treatment NN N
condition NN N
conducted VBN N
structured JJ N
diagnostic JJ N
interviews NNS N
and CC N
parents NNS N
and CC N
children NNS N
completed VBN N
anxiety NN o
symptom NN o
checklists NNS o
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
. . N

RESULTS NNP N
In IN N
intent-to-treat JJ N
analyses NNS N
, , N
78.5 CD N
% NN N
of IN N
the DT N
CBT NNP i
group NN N
met VBD N
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
criteria NNS o
for IN N
positive JJ N
treatment NN N
response NN N
at IN N
posttreatment NN N
, , N
as IN N
compared VBN N
to TO N
only RB N
8.7 CD N
% NN N
of IN N
the DT N
waitlist NN i
group NN N
. . N

CBT NNP i
also RB N
outperformed VBD N
the DT N
waitlist NN i
on IN N
diagnostic JJ N
outcomes NNS N
and CC N
parent NN o
reports NNS o
of IN o
child NN o
anxiety NN o
, , N
but CC N
not RB N
children NNS N
's POS N
self-reports NNS N
. . N

Treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
CBT NNP i
manual JJ N
employed VBN N
in IN N
this DT N
study NN N
is VBZ N
one CD N
of IN N
the DT N
first JJ N
adaptations NNS N
of IN N
an DT N
evidence-based JJ N
treatment NN N
for IN N
children NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Remission NN N
of IN N
anxiety NN o
disorders NNS o
appears VBZ N
to TO N
be VB N
an DT N
achievable JJ N
goal NN N
among IN N
high-functioning JJ N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

Reversal NNP N
of IN N
skeletal JJ N
effects NNS o
of IN N
endocrine NN i
treatments NNS i
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
. . N

The DT N
adjuvant JJ N
use NN N
of IN N
aromatase NN i
inhibitors NNS i
in IN N
breast NN N
cancer NN N
is VBZ N
associated VBN N
with IN N
adverse JJ N
effects NNS N
on IN N
bone NN N
health NN N
. . N

We PRP N
previously RB N
reported VBD N
a DT N
decline NN N
in IN N
bone JJ N
mineral JJ N
density NN N
( ( N
BMD NNP N
) ) N
following VBG N
the DT N
switch NN N
from IN N
tamoxifen NN i
to TO N
exemestane VB i
in IN N
the DT N
Intergroup NNP N
Exemestane NNP N
Study NNP N
( ( N
IES NNP N
) ) N
. . N

Here RB N
we PRP N
report VBP N
effects NNS N
of IN N
endocrine JJ i
treatment NN i
withdrawal NN N
on IN N
BMD NNP N
, , N
bone NN N
turnover NN N
markers NNS N
( ( N
BTM NNP N
) ) N
and CC N
fracture JJ N
rates NNS N
. . N

4,724 CD p
patients NNS p
took VBD p
part NN p
in IN p
IES NNP p
, , p
and CC p
206 CD p
patients NNS p
were VBD p
included VBN p
in IN p
a DT p
bone NN p
sub-study NN p
. . p

BMD NNP N
and CC N
BTM NNP N
were VBD N
assessed VBN N
pre-randomization NN N
, , N
during IN N
and CC N
after IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
EOT NNP N
) ) N
. . N

To TO N
evaluate VB N
treatment NN N
withdrawal NN N
effects NNS N
, , N
12- JJ N
and CC N
24-month JJ N
post NN N
EOT NNP N
BMD NNP N
results NNS N
are VBP N
available JJ N
for IN N
122 CD N
and CC N
126 CD N
patients NNS N
, , N
respectively RB N
. . N

Similar JJ N
patient NN N
numbers NNS N
had VBD N
BTM NNP N
measured VBD N
post NN N
EOT NNP N
. . N

Following VBG N
treatment NN N
withdrawal NN N
, , N
the DT N
differences NNS N
in IN N
BMD NNP N
observed VBD N
between IN N
the DT N
two CD N
endocrine NN N
strategies NNS N
were VBD N
partially RB N
reversed VBN N
. . N

At IN N
24 CD N
months NNS N
from IN N
EOT NNP N
, , N
spine JJ o
BMD NNP o
increased VBN o
by IN N
1.53 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
0.63-2.43 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
after IN N
stopping VBG N
exemestane NN N
and CC N
fell VBD N
by IN N
1.93 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-2.91 NNP N
to TO N
0.95 CD N
; : N
p NN N
= VBZ N
0.0002 CD N
) ) N
following VBG N
tamoxifen NN i
withdrawal NN N
. . N

A DT N
similar JJ N
pattern NN N
of IN N
changes NNS N
was VBD N
observed VBN N
at IN N
the DT N
hip NN N
. . N

At IN N
2 CD N
years NNS N
post RB N
EOT NNP N
, , N
BMD NNP o
changes NNS o
from IN o
baseline NN o
were VBD N
similar JJ N
with IN N
both DT N
treatment NN N
strategies NNS N
. . N

Corresponding VBG N
inverse JJ o
changes NNS o
in IN o
BTM NNP o
were VBD N
seen VBN N
, , N
with IN N
an DT N
increase NN N
following VBG N
tamoxifen JJ N
withdrawal NN N
and CC N
a DT N
reduction NN N
after IN N
exemestane NN N
. . N

A DT N
higher JJR N
number NN o
of IN o
fractures NNS o
occurred VBD o
during IN N
exemestane NN i
treatment NN N
, , N
but CC N
fracture NN o
rates NNS o
were VBD N
similar JJ N
after IN N
treatment NN N
withdrawal NN N
. . N

With IN N
the DT N
switch NN N
strategy NN N
used VBN N
in IN N
IES NNP N
, , N
the DT N
on IN N
treatment NN N
adverse JJ o
bone NN o
effects NNS o
of IN N
exemestane NN i
are VBP N
reversed VBN N
. . N

Ongoing VBG N
monitoring NN N
of IN N
BMD NNP N
is VBZ N
therefore RB N
not RB N
routinely RB N
required VBN N
. . N

-DOCSTART- -X- O O

Osteopontin NNP i
is VBZ N
a DT N
prognostic JJ N
factor NN N
for IN N
survival NN o
of IN N
acute JJ p
myeloid JJ p
leukemia NN p
patients NNS p
. . p

Osteopontin NNP o
( ( o
OPN NNP o
) ) o
is VBZ N
a DT N
glycoprotein NN N
that WDT N
is VBZ N
secreted VBN N
by IN N
osteoblasts NNS N
and CC N
hematopoietic JJ N
cells NNS N
. . N

OPN NNP i
suppresses VBZ N
the DT N
proliferation NN N
of IN N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
vitro NN N
and CC N
may MD N
regulate VB N
the DT N
hematopoietic JJ N
stem NN N
cell NN N
pool NN N
. . N

Increased VBN N
serum NN N
OPN NNP N
concentrations NNS N
occur VBP N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
, , N
multiple JJ N
myeloma NN N
, , N
and CC N
acute JJ N
myeloid NN N
leukemia NN N
( ( N
AML NNP N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN o
and CC o
relevance NN o
of IN o
OPN NNP o
in IN N
newly RB p
diagnosed VBN p
AML NNP p
patients NNS p
from IN p
2 CD p
large JJ p
study NN p
groups NNS p
( ( p
the DT p
German JJ p
AML NNP p
Cooperative NNP p
Group NNP p
and CC p
the DT p
Dutch-Belgian JJ p
Hematology NNP p
Oncology NNP p
Cooperative NNP p
group NN p
) ) p
. . p

IHC NNP o
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
ELISAs NNP o
of IN o
blood/BM NN o
sera NN o
( ( N
n JJ N
= NNP N
41 CD N
) ) N
, , N
and CC N
microarray NN o
data NNS o
for IN o
mRNA NN o
levels NNS o
( ( N
n JJ N
= NNP N
261 CD N
) ) N
were VBD N
performed VBN N
. . N

Expression NN o
of IN o
OPN NNP o
protein NN o
was VBD N
increased VBN N
in IN N
AML NNP N
patients NNS N
both DT N
in IN N
BM NNP N
blasts NNS N
( ( i
IHC NNP i
) ) i
and CC N
in IN N
BM NNP N
serum NN N
( ( i
ELISA NNP i
) ) i
compared VBN N
with IN N
healthy JJ N
controls NNS N
. . N

Patients NNS N
expressing VBG N
high JJ N
levels NNS o
of IN o
OPN NNP o
within IN o
the DT o
BM NNP o
( ( N
IHC NNP N
) ) N
experienced VBD N
shortened VBN N
overall JJ o
survival NN o
( ( N
OS NNP N
; : N
P NNP N
= NNP N
.025 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
identified VBD N
karyotype NN o
, , o
blast JJ o
clearance NN o
( ( N
day NN N
16 CD N
) ) N
, , N
and CC N
the DT N
level NN o
of IN o
OPN NNP o
expression NN o
as IN N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
OS NNP o
. . o

This DT N
prompted VBD N
us PRP N
to TO N
analyze VB N
microarray NN N
data NNS N
from IN N
261 CD p
patients NNS p
from IN p
a DT p
third JJ p
cohort NN p
. . p

The DT N
analysis NN N
confirmed VBD N
OPN NNP N
as IN N
a DT N
prognostic JJ N
marker NN N
. . N

In IN N
summary JJ N
, , N
high JJ N
OPN NNP o
mRNA NN o
expression NN o
indicated VBD N
decreased JJ N
event-free JJ o
survival NN o
( ( N
P NNP N
= NNP N
.0002 NNP N
) ) N
and CC N
OS NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

The DT N
prognostic JJ N
role NN N
of IN N
OPN NNP i
was VBD N
most RBS N
prominent JJ N
in IN N
intermediate-risk JJ N
AML NNP N
. . N

These DT N
data NNS N
provide VBP N
evidence NN N
that IN N
OPN NNP o
expression NN o
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
AML NNP N
. . N

-DOCSTART- -X- O O

Pazopanib NNP i
in IN N
locally RB p
advanced JJ p
or CC p
metastatic JJ p
renal NN p
cell NN p
carcinoma NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
Pazopanib NNP i
is VBZ N
an DT N
oral JJ i
angiogenesis NN i
inhibitor NN i
targeting VBG N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor NN N
, , N
platelet-derived JJ N
growth NN N
factor NN N
receptor NN N
, , N
and CC N
c-Kit NN N
. . N

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
phase NN N
III NNP N
study NN N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
pazopanib JJ i
monotherapy NN i
in IN N
treatment-naive JJ p
and CC p
cytokine-pretreated JJ i
patients NNS p
with IN p
advanced JJ p
renal JJ p
cell NN p
carcinoma NN p
( ( p
RCC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Adult NNP p
patients NNS p
with IN p
measurable JJ p
, , p
locally RB p
advanced JJ p
, , p
and/or JJ p
metastatic JJ p
RCC NNP p
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB i
oral JJ i
pazopanib NN i
or CC i
placebo NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

Secondary JJ N
end NN N
points NNS N
included VBD N
overall JJ o
survival NN o
, , o
tumor NN o
response NN o
rate NN o
( ( o
Response NNP o
Evaluation NNP o
Criteria NNP o
in IN o
Solid NNP o
Tumors NNP o
) ) o
, , o
and CC o
safety NN o
. . o

Radiographic JJ N
assessments NNS N
of IN N
tumors NNS N
were VBD N
independently RB N
reviewed VBN N
. . N

Results NNS N
Of IN p
435 CD p
patients NNS p
enrolled VBD p
, , p
233 CD p
were VBD p
treatment NN p
naive JJ p
( ( p
54 CD p
% NN p
) ) p
and CC p
202 CD p
were VBD p
cytokine NN p
pretreated VBN p
( ( p
46 CD p
% NN p
) ) p
. . p

PFS NNP o
was VBD N
significantly RB N
prolonged VBN N
with IN N
pazopanib NNS i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
overall JJ N
study NN N
population NN N
( ( N
median JJ N
, , N
PFS NNP N
9.2 CD N
v NN N
4.2 CD N
months NNS N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
the DT N
treatment-naive JJ i
subpopulation NN N
( ( N
median JJ N
PFS NNP N
11.1 CD N
v NN N
2.8 CD N
months NNS N
; : N
HR NNP N
, , N
0.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.60 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
and CC N
the DT N
cytokine-pretreated JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
, , N
7.4 CD N
v NN N
4.2 CD N
months NNS N
; : N
HR NNP N
, , N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.35 CD N
to TO N
0.84 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
objective JJ o
response NN o
rate NN o
was VBD N
30 CD N
% NN N
with IN N
pazopanib NN i
compared VBN N
with IN N
3 CD N
% NN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
response NN o
was VBD N
longer JJR N
than IN N
1 CD N
year NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
diarrhea RB o
, , o
hypertension NN o
, , o
hair NN o
color NN o
changes NNS o
, , o
nausea NN o
, , o
anorexia NN o
, , o
and CC o
vomiting VBG o
. . o

There EX N
was VBD N
no DT N
evidence NN N
of IN N
clinically RB N
important JJ N
differences NNS N
in IN N
quality NN N
of IN N
life NN N
for IN N
pazopanib JJ i
versus NN i
placebo NN i
. . i

CONCLUSION NNP N
Pazopanib NNP i
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
PFS NNP N
and CC N
tumor NN N
response NN N
compared VBN N
with IN N
placebo NN i
in IN N
treatment-naive JJ p
and CC p
cytokine-pretreated JJ i
patients NNS p
with IN p
advanced JJ p
and/or NNS p
metastatic JJ p
RCC NNP p
. . p

-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
: : N
Multimodal NNP i
Anxiety NNP i
and CC i
Social NNP i
Skill NNP i
Intervention NNP i
for IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Anxiety NN p
is VBZ p
common JJ p
among IN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC N
may MD N
amplify VB N
the DT N
core NN N
social JJ N
disability NN N
, , N
thus RB N
necessitating VBG N
combined VBN N
treatment NN N
approaches NNS N
. . N

This DT N
pilot NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
evaluated VBD N
the DT N
feasibility NN o
and CC N
preliminary JJ o
outcomes NNS o
of IN N
the DT N
Multimodal NNP i
Anxiety NNP i
and CC i
Social NNP i
Skills NNP i
Intervention NNP i
( ( i
MASSI NNP i
) ) i
program NN i
in IN p
a DT p
sample NN p
of IN p
30 CD p
adolescents NNS p
with IN p
ASD NNP p
and CC p
anxiety NN p
symptoms NNS p
of IN p
moderate JJ p
or CC p
greater JJR p
severity NN p
. . p

The DT N
treatment NN N
was VBD N
acceptable JJ N
to TO N
families NNS N
, , N
subject JJ o
adherence NN o
was VBD N
high JJ N
, , N
and CC N
therapist JJ o
fidelity NN o
was VBD N
high JJ N
. . N

A DT N
16 CD N
% NN N
improvement NN N
in IN N
ASD NNP o
social JJ o
impairment NN o
( ( N
within-group JJ N
effect NN N
size NN N
= NNP N
1.18 CD N
) ) N
was VBD N
observed VBN N
on IN N
a DT N
parent-reported JJ N
scale NN N
. . N

Although IN N
anxiety NN o
symptoms NNS o
declined VBD N
by IN N
26 CD N
% NN N
, , N
the DT N
change NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

These DT N
findings NNS N
suggest VBP N
MASSI NNP i
is VBZ N
a DT N
feasible JJ o
treatment NN N
program NN N
and CC N
further JJ N
evaluation NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
an DT N
intervention NN N
to TO N
change VB N
benzodiazepine-prescribing JJ i
behavior NN N
in IN N
a DT N
prepaid NN N
group NN N
practice NN N
setting VBG N
. . N

To TO N
determine VB N
the DT N
effect NN N
of IN N
two CD N
levels NNS N
of IN N
educational JJ i
intervention NN i
on IN i
benzodiazepine-prescribing JJ i
behavior NN i
in IN N
an DT N
elderly JJ p
population NN p
in IN N
a DT N
controlled JJ N
prepaid NN N
group NN N
practice NN N
( ( N
PPGP NNP N
) ) N
setting NN N
, , N
we PRP N
designed VBD N
a DT N
prospective JJ N
controlled VBN N
trial NN N
, , N
with IN N
six-month JJ N
follow-up NN N
. . N

Our PRP$ N
setting NN p
was VBD p
a DT p
270,000 CD p
member NN p
group-model JJ p
PPGP NNP p
in IN p
Colorado NNP p
, , p
from IN p
1990 CD p
to TO p
1991 CD p
. . p

Participants NNS p
included VBD p
91 CD p
physicians NNS p
, , p
62 CD p
men NNS p
and CC p
29 CD p
women NNS p
; : p
median JJ p
age NN p
was VBD p
38.7 CD p
years NNS p
. . p

Group NNP N
1 CD N
received VBD N
a DT N
one-on-one JJ i
educational JJ i
presentation NN i
by IN i
a DT i
clinical JJ i
pharmacist NN i
, , i
written VBN i
educational JJ i
materials NNS i
, , i
a DT i
brief JJ i
follow-up JJ i
visit NN i
, , i
and CC i
feedback NN i
with IN i
recommendations NNS i
. . i

Group NNP N
2 CD N
received VBD N
only RB N
a DT N
face-to-face JJ i
presentation NN i
, , i
given VBN i
to TO i
departmental VB i
groups NNS i
, , i
as RB i
well RB i
as IN i
the DT i
same JJ i
written VBN i
educational JJ i
materials NNS i
used VBN i
in IN i
group NN i
1 CD i
. . i

Controls NNP N
received VBD N
no DT i
intervention NN i
. . i

Our PRP$ N
primary JJ N
outcome JJ N
measure NN N
was VBD N
the DT N
benzodiazepine NN o
on/off NN o
status NN o
of IN o
the DT o
elderly JJ o
PPGP NNP o
members NNS o
. . o

The DT N
secondary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
median JJ o
change NN o
( ( o
preintervention NN o
minus IN o
postintervention NN o
) ) o
in IN o
a DT o
standardized JJ o
amount NN o
of IN o
benzodiazepines NNS o
prescribed VBN o
per IN o
physician NN o
. . o

Logistic JJ N
regression NN N
analysis NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
effect NN N
on IN N
postintervention NN N
benzodiazepine NN o
on/off NN o
status NN o
between IN N
study NN N
groups NNS N
, , N
when WRB N
controlling VBG N
for IN N
preintervention NN N
on/off NN N
status NN N
, , N
PPGP-member NNP N
age NN N
, , N
PPGP-member NNP N
gender NN N
, , N
and CC N
all DT N
possible JJ N
interactions NNS N
. . N

Analysis NN N
of IN N
variance NN N
failed VBD N
to TO N
demonstrate VB N
an DT N
effect NN N
of IN N
either DT N
intervention NN N
on IN N
the DT N
median JJ o
change NN o
in IN o
standardized JJ o
amount NN o
of IN o
benzodiazepines NNS o
prescribed VBN N
per IN N
physician NN N
, , N
with IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
controls NNS N
yielding VBG N
values NNS N
of IN N
-278 NN N
( ( N
range NN N
: : N
-4,137 NN N
, , N
2,844 CD N
) ) N
, , N
-330 NNP N
( ( N
-1,531 NNP N
, , N
1,358 CD N
) ) N
, , N
and CC N
-541 NNP N
( ( N
range NN N
: : N
-3,716 NN N
, , N
2,185 CD N
) ) N
, , N
respectively RB N
. . N

We PRP N
conclude VBP N
that IN N
strategies NNS N
effective JJ N
in IN N
changing VBG N
physician JJ N
prescribing VBG N
behavior NN N
in IN N
other JJ N
settings NNS N
may MD N
not RB N
be VB N
effective JJ N
in IN N
a DT N
PPGP NNP N
setting VBG N
with IN N
benzodiazepines NNS i
in IN N
the DT N
elderly JJ N
as IN N
the DT N
target NN N
for IN N
change NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
bepotastine NN i
besilate NN i
ophthalmic JJ i
solution NN i
1.5 CD N
% NN N
for IN N
seasonal JJ o
allergic JJ o
conjunctivitis NN o
: : o
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
, , N
clinical JJ N
trial NN N
. . N

Allergic NNP N
conjunctivitis NN N
( ( N
AC NNP N
) ) N
affects VBZ N
an DT N
estimated JJ N
20 CD N
% NN N
of IN N
the DT N
population NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
with IN N
a DT N
large JJ N
fraction NN N
suffering VBG N
due JJ N
to TO N
seasonal JJ N
or CC N
perennial JJ N
allergen NN N
exposures NNS N
. . N

Bepotastine NNP i
besilate NN i
ophthalmic JJ i
solution NN i
( ( i
BBOS NNP i
) ) i
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ i
histamine NN i
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
BBOS NNP N
1.5 CD N
% NN N
for IN N
reducing VBG N
ocular JJ p
itching NN p
associated VBN p
with IN p
AC NNP p
in IN p
subjects NNS p
enrolled VBN p
in IN p
a DT p
natural JJ p
exposure NN p
trial NN p
. . p

Eligible JJ p
subjects NNS p
in IN N
a DT N
multicenter NN N
, , N
double-masked JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP i
1.5 CD N
% NN N
or CC i
placebo NN i
eyedrops NNS i
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
instantaneous JJ N
and CC N
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ N
severity NN N
of IN N
instantaneous JJ N
and CC N
reflective JJ N
itching NN N
. . N

Subject-reported JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
also RB N
recorded VBN N
for IN N
safety NN N
. . N

Treatment NN N
with IN N
BBOS NNP N
1.5 CD N
% NN N
significantly RB N
reduced VBN N
instantaneous JJ o
and CC o
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN N
over IN N
the DT N
2-week JJ N
study NN N
period NN N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.005 CD N
, , N
respectively RB N
) ) N
. . N

BBOS $ N
1.5 CD N
% NN N
was VBD N
well RB N
tolerated VBN o
, , o
and CC o
AEs NNP o
were VBD N
generally RB N
transient JJ N
and CC N
mild JJ N
. . N

This DT N
clinical JJ N
study NN N
indicates VBZ N
BBOS NNP N
1.5 CD N
% NN N
effectively RB o
and CC o
safely RB o
treated VBD o
ocular JJ o
itching NN o
in IN N
a DT N
natural JJ N
exposure NN N
allergy NN N
study NN N
and CC N
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
for IN N
the DT N
management NN N
of IN N
ocular JJ N
itching NN N
associated VBN N
with IN N
AC NNP N
. . N

( ( N
ClinicalTrials.gov NNP N
identifier VBZ N
number NN N
: : N
NCT01174823 NNP N
. . N

) ) N
-DOCSTART- -X- O O

Poylmerized VBN i
whole JJ i
ragweed NN i
: : i
an DT N
improved JJ N
method NN N
of IN N
immunotherapy NN N
. . N

A DT N
single-blind JJ N
study NN N
compared VBN N
the DT N
effectiveness NN N
of IN N
glutaraldehyde-treated JJ i
polymerized NNS i
ragweed VBP i
with IN N
nonpolymerized JJ i
monomeric JJ i
ragweed NN i
. . i

These DT N
studies NNS N
are VBP N
an DT N
extension NN N
of IN N
those DT N
previously RB N
reported VBN N
for IN N
polymerized JJ N
AgE NNP N
using VBG N
a DT N
readily RB N
available JJ N
ragweed NN N
preparation NN N
containing VBG N
all DT N
ragweed NN i
antigens NNS N
. . N

Nineteen JJ p
ragweed-sensitive JJ p
patients NNS p
were VBD p
randomized VBN p
into IN p
2 CD p
groups NNS p
; : p
10 CD p
received VBD p
the DT p
polymerized JJ i
form NN i
and CC p
9 CD p
received VBD p
the DT p
monomeric JJ i
form NN i
. . i

Four CD N
parameters NNS N
were VBD N
followed VBN N
: : N
serum-specific JJ i
IgE NNP i
against IN N
antigen NN N
E NNP N
, , N
total JJ N
blocking VBG N
antibody NN N
against IN N
antigen NN N
E NNP N
, , N
local JJ N
and CC N
systemic JJ N
reactions NNS N
to TO N
injection NN N
therapy NN N
, , N
and CC N
symptom NN N
score NN N
indices NNS N
. . N

Pretreatment NNP N
levels NNS N
of IN N
antigen NN N
E NNP N
-- : N
specific JJ N
IgE NNP N
and CC N
blocking VBG N
antibody NN N
activity NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

After IN N
a DT N
total NN N
of IN N
15,000 CD N
protein NNS N
nitrogen JJ N
units NNS N
( ( N
PNU NNP N
) ) N
had VBD N
been VBN N
given VBN N
, , N
blocking VBG o
antibody NN o
activity NN o
in IN N
the DT N
monomer NN N
group NN N
rose VBD N
from IN N
a DT N
mean NN N
of IN N
170 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
a DT N
mean NN N
of IN N
2,813 CD N
. . N

The DT N
rise NN o
in IN o
blocking VBG o
antibody NN o
activity NN o
in IN N
the DT N
polymer NN N
group NN N
was VBD N
from IN N
a DT N
mean NN N
of IN N
181 CD N
ng JJ N
AgE NNP N
bound NN N
per IN N
ml NN N
to TO N
1,574 CD N
. . N

At IN N
15,000 CD N
PNU NNP N
, , N
blocking VBG o
antibody NN o
activity NN o
levels NNS o
were VBD N
not RB N
statistically RB N
different JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

After IN N
1 CD N
year NN N
of IN N
treatment NN N
, , N
no DT N
consistent JJ N
decrease NN N
in IN N
postseasonal JJ o
specific JJ o
IgE NNP o
rise NN o
could MD N
be VB N
shown VBN N
in IN N
either DT N
group NN N
. . N

Forty NNP N
times NNS N
less RBR N
erythema JJ o
and CC N
15 CD N
times NNS N
less JJR N
induration NN o
were VBD N
found VBN N
with IN N
polymerized JJ i
ragweed NN i
. . i

There EX N
were VBD N
7 CD N
systemic JJ o
reactions NNS o
with IN N
the DT N
monomer NN N
and CC N
none NN N
with IN N
the DT N
polymer NN N
. . N

Both DT N
groups NNS N
experienced VBD N
symptomatic JJ o
improvement NN o
with IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
with IN N
buspirone NN i
in IN N
a DT N
patient NN p
with IN p
autism NN p
. . p

This DT N
study NN N
evaluates VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
buspirone NN i
hydrochloride NN i
for IN N
the DT N
treatment NN N
of IN N
a DT N
patient NN p
with IN p
autism NN p
and CC p
hyperactivity NN p
disorder NN p
and CC N
determines VBZ N
the DT N
effect NN N
of IN N
buspirone NN i
on IN N
the DT N
number NN N
of IN N
performance NN N
tasks NNS N
completed VBN N
by IN N
the DT N
patient NN N
at IN N
school NN N
. . N

A DT N
3-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
was VBD N
performed VBN N
in IN p
a DT p
private JJ p
physician NN p
, , p
office-based JJ p
practice NN p
. . p

A DT p
child NN p
with IN p
autism NN p
, , p
which WDT p
was VBD p
diagnosed VBN p
by IN p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Third NNP p
Edition NNP p
, , p
Revised VBN p
, , p
criteria NNS p
, , p
was VBD p
studied VBN p
. . p

The DT N
child NN N
received VBD N
placebo NN i
for IN i
3 CD i
weeks NNS i
and CC i
buspirone NN i
for IN N
3 CD N
weeks NNS N
; : N
there EX N
was VBD N
a DT N
1-week JJ N
interval NN N
between IN N
the DT N
2 CD N
treatments NNS N
. . N

The DT N
outcome NN N
was VBD N
measured VBN N
by IN N
using VBG N
Conners NNS o
abbreviated VBD o
parent NN o
and CC o
teacher NN o
questionnaires NNS o
and CC N
by IN N
determining VBG N
the DT N
number NN N
of IN N
daily JJ N
performance NN N
tasks NNS N
completed VBN N
by IN N
the DT N
child NN N
at IN N
school NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
by IN N
linear JJ N
models NNS N
and CC N
standard JJ N
F NNP N
tests NNS N
. . N

Buspirone NNP i
was VBD N
found VBN N
to TO N
be VB N
safe JJ o
and CC o
efficacious JJ o
, , o
without IN o
side JJ o
effects NNS o
, , N
for IN N
decreasing VBG N
hyperactivity NN o
and CC N
increasing VBG N
completed VBN o
performance NN o
tasks NNS o
. . o

The DT N
beneficial JJ N
effects NNS N
of IN N
buspirone NN i
in IN N
helping VBG N
this DT N
patient NN N
with IN N
autism NN p
in IN N
his PRP$ N
natural JJ N
daily JJ N
settings NNS N
suggest VBP N
that IN N
buspirone NN N
may MD N
be VB N
an DT N
alternative JJ N
to TO N
neuroleptic JJ N
agents NNS N
in IN N
the DT N
medical JJ N
therapy NN N
of IN N
autism NN N
; : N
further JJ N
study NN N
in IN N
other JJ N
patients NNS N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

Most RBS N
effective JJ o
regimen NNS o
of IN o
tranexamic JJ o
acid NN o
in IN N
knee NN p
arthroplasty NN p
: : p
a DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
in IN N
240 CD p
patients NNS p
. . p

BACKGROUND NNP N
The DT N
antifibrinolytic JJ i
tranexamic JJ i
acid NN i
reduces NNS N
surgical JJ N
blood NN N
loss NN N
, , N
but CC N
studies NNS N
have VBP N
not RB N
identified VBN N
an DT N
optimal JJ N
regimen NNS N
. . N

QUESTIONS/PURPOSES NNP N
We PRP N
studied VBD N
different JJ N
dosages NNS N
, , N
timings NNS N
, , N
and CC N
modes NNS N
of IN N
administration NN N
to TO N
identify VB N
the DT N
most RBS N
effective JJ N
regimen NNS N
of IN N
tranexamic JJ i
acid NN i
in IN N
achieving VBG N
maximum JJ N
reduction NN N
of IN N
blood NN N
loss NN N
in IN N
TKA NNP N
. . N

METHODS NNP N
We PRP N
prospectively RB N
studied VBD N
five CD p
regimens NNS p
( ( p
four CD p
intravenous NN i
, , p
one CD p
local JJ i
; : i
40 CD p
patients NNS p
each DT p
) ) p
with IN p
a DT p
control NN p
group NN p
( ( N
no DT N
tranexamic JJ i
acid NN i
) ) i
. . N

The DT N
four CD N
intravenous JJ i
( ( N
10-mg/kg JJ N
dose NN N
) ) N
regimens VBZ N
included VBN N
( ( N
1 CD N
) ) N
intraoperative NN i
dose NN i
( ( i
IO NNP i
) ) i
given VBN i
before IN i
tourniquet JJ i
deflation NN i
, , i
( ( i
2 CD i
) ) i
additional JJ i
preoperative NN i
dose NN i
( ( i
POIO NNP i
) ) i
, , i
( ( i
3 CD i
) ) i
additional JJ i
postoperative NN i
dose NN i
( ( i
IOPO NNP i
) ) i
, , i
and CC i
( ( i
4 CD i
) ) i
all DT i
three CD i
doses NNS i
( ( i
POIOPO NNP i
) ) i
. . N

The DT N
fifth JJ N
regimen NN N
was VBD N
a DT N
single JJ N
local JJ i
application NN i
( ( N
LA NNP N
) ) N
. . N

Two CD N
independent JJ N
parameters NNS N
of IN N
drain NN o
loss NN o
and CC o
total JJ o
blood NN o
loss NN o
, , o
calculated VBN o
by IN o
the DT o
hemoglobin NN o
balance NN o
method NN o
, , N
were VBD N
evaluated VBN N
statistically RB N
. . N

RESULTS NNP N
Both NNP N
parameters NNS N
were VBD N
reduced VBN N
in IN N
all DT N
five CD N
regimens NNS N
as IN N
against IN N
the DT N
control NN N
. . N

A DT N
significant JJ N
reduction NN N
in IN N
drain NN o
loss NN o
was VBD N
seen VBN N
in IN N
the DT N
POIO NNP N
, , N
IOPO NNP N
, , N
and CC N
POIOPO NNP N
groups NNS N
whereas VBP N
total JJ N
blood NN o
loss NN o
was VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
POIO NNP N
, , N
POIOPO NNP N
, , N
and CC N
LA NNP N
groups NNS N
. . N

The DT N
POIOPO NNP N
group NN N
had VBD N
the DT N
least JJS N
drain JJ o
loss NN o
( ( N
303 CD N
mL NN N
) ) N
and CC N
least JJS N
total JJ N
blood NN o
loss NN o
( ( N
688 CD N
mL NN N
) ) N
. . N

The DT N
IO NNP N
group NN N
had VBD N
the DT N
greatest JJS N
drain NN o
loss NN o
and CC N
the DT N
IOPO NNP N
group NN N
the DT N
greatest JJS N
total JJ o
blood NN o
loss NN o
. . o

CONCLUSIONS NNP N
Single-dose JJ N
tranexamic JJ i
acid NN i
did VBD N
not RB N
give VB N
effective JJ N
results NNS N
. . N

The DT N
two-dose JJ N
regimen NNS N
of IN N
POIO NNP N
was VBD N
the DT N
least JJS N
amount NN N
necessary JJ N
for IN N
effective JJ N
results NNS N
. . N

When WRB N
compared VBN N
against IN N
the DT N
control NN N
, , N
this DT N
regimen NNS N
produced VBD N
reduction NN o
of IN o
drain NN o
loss NN o
and CC o
total JJ o
blood NN o
loss NN o
, , N
whereas IN N
the DT N
IOPO NNP N
regimen NNS N
did VBD N
not RB N
. . N

The DT N
three-dose JJ N
regimen NNS N
of IN N
POIOPO NNP N
produced VBD N
maximum JJ N
effective JJ N
reduction NN N
of IN N
drain NN o
loss NN o
and CC o
total JJ o
blood NN o
loss NN o
. . o

-DOCSTART- -X- O O

Osteoporosis NN i
and CC N
gait NN N
and CC N
balance NN N
disturbances NNS N
in IN N
older JJR p
sarcopenic JJ p
obese JJ p
New NNP p
Zealanders NNP p
. . p

UNLABELLED NNP N
Bone NNP N
, , N
muscle NN N
, , N
and CC N
fat NN N
may MD N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR p
adults NNS p
. . p

Osteoporosis NN p
was VBD p
prevalent JJ p
in IN p
low JJ p
muscle NN p
mass NN p
participants NNS p
and CC p
related VBN p
to TO p
gait VB p
and CC p
balance VB p
deficits NNS p
. . p

Low JJ N
muscle NN N
combined VBN N
with IN N
high JJ N
fat JJ N
mass NN N
had VBD N
more RBR N
functional JJ N
deficits NNS N
and CC N
poorer JJR N
bone NN N
health NN N
, , N
which WDT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
and CC N
fractures NNS N
. . N

INTRODUCTION NNP N
Decreasing VBG N
bone NN N
density NN N
and CC N
muscle NN N
mass NN N
and CC N
increasing VBG N
fat JJ N
mass NN N
may MD N
act VB N
synergistically RB N
to TO N
affect VB N
gait NN N
and CC N
balance NN N
in IN N
older JJR N
adults NNS N
. . N

METHODS NNP N
One CD p
hundred VBD p
eighty-three JJ p
older NN p
adults NNS p
( ( p
age NN p
72.7 CD p
+/- JJ p
6 CD p
years NNS p
, , p
range VBP p
56-93 JJ p
; : p
body NN p
mass NN p
index NN p
28.2 CD p
+/- JJ p
4.9 CD p
, , p
range VBP p
16.6-46.0 JJ p
) ) p
were VBD p
recruited VBN p
from IN p
a DT p
New NNP p
Zealand NNP p
falls VBZ p
prevention NN p
intervention NN p
trial NN p
. . p

Total JJ o
and CC o
appendicular JJ o
skeletal JJ o
muscle NN o
mass NN o
( ( o
ASM NNP o
) ) o
, , o
percent JJ o
fat NN o
, , o
and CC o
bone NN o
mineralization NN o
were VBD p
assessed VBN p
by IN p
dual JJ i
energy NN i
X-ray JJ i
absorptiometry NN i
and CC p
used VBD p
to TO p
characterize VB p
normal JJ p
lean JJ p
( ( p
NL NNP p
, , p
n JJ p
= NNP p
51 CD p
) ) p
, , p
sarcopenic JJ p
( ( p
SS NNP p
, , p
n JJ p
= NNP p
18 CD p
) ) p
, , p
sarcopenic JJ p
obese NN p
( ( p
SO NNP p
, , p
n JJ p
= NNP p
29 CD p
) ) p
, , p
and CC p
obese JJ p
( ( p
OO NNP p
, , p
n JJ p
= NNP p
85 CD p
) ) p
phenotypes NNS p
. . p

Functional JJ N
performance NN N
was VBD N
assessed VBN N
using VBG N
timed VBN i
up RP i
and CC i
go VB i
, , i
chair NN i
stand NN i
, , i
single JJ i
leg NN i
stand NN i
, , N
and CC N
step VB i
test NN i
. . i

Regression NN N
models NNS N
were VBD N
adjusted VBN N
for IN N
age NN N
, , N
sex NN N
, , N
medications NNS N
, , N
and CC N
physical JJ N
activity NN N
. . N

RESULTS NNP N
Femoral NNP o
neck NN o
osteoporosis NN o
was VBD N
present JJ N
in IN N
22 CD N
% NN N
SS NNP N
, , N
17 CD N
% NN N
SO NNP N
, , N
12 CD N
% NN N
NL NNP N
, , N
and CC N
7 CD N
% NN N
OO NNP N
. . N

Femoral NNP N
neck NN N
osteoporosis NN N
with IN N
low JJ N
ASM NNP o
predicted VBD N
poor JJ N
chair NN o
stand VBP o
performance NN o
( ( N
beta JJ N
-3.3 NNP N
, , N
standard JJ N
error NN N
1.6 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

SO RB N
scored JJ N
lowest NN N
on IN N
the DT N
chair NN N
stand NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
step JJ N
test NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

Higher JJR o
ASM NNP o
predicted VBD N
faster RBR N
timed VBN N
up RP N
and CC N
go VB N
performance NN N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Osteoporosis NNP N
was VBD N
prevalent VBN N
in IN N
low JJ p
ASM NNP p
groups NNS p
( ( N
SS NNP N
and CC N
SO NNP N
) ) N
and CC N
related VBN N
to TO N
gait VB N
and CC N
balance VB N
deficits NNS N
, , N
particularly RB N
in IN N
the DT N
SO NNP N
. . N

This DT N
has VBZ N
implications NNS N
for IN N
falls NNS N
risk NN N
, , N
fractures NNS N
, , N
and CC N
interventions NNS N
. . N

-DOCSTART- -X- O O

A DT N
web-based JJ i
patient NN i
activation NN i
intervention NN i
to TO N
improve VB N
hypertension NN N
care NN N
: : N
study NN N
design NN N
and CC N
baseline NN N
characteristics NNS N
in IN N
the DT N
web NN N
hypertension NN N
study NN N
. . N

BACKGROUND NNP N
Despite IN N
the DT N
known JJ N
health NN N
risks NNS N
of IN N
hypertension NN N
, , N
many JJ N
hypertensive JJ p
patients NNS p
still RB N
have VBP N
uncontrolled VBN N
blood NN N
pressure NN N
. . N

Clinical JJ N
inertia NN N
, , N
the DT N
tendency NN N
of IN N
physicians NNS N
not RB N
to TO N
intensify VB N
treatment NN N
, , N
is VBZ N
a DT N
common JJ N
barrier NN N
in IN N
controlling VBG N
chronic JJ N
diseases NNS N
. . N

This DT N
trial NN N
is VBZ N
aimed VBN N
at IN N
determining VBG N
the DT N
impact NN N
of IN N
activating VBG N
patients NNS N
to TO N
ask VB N
providers NNS N
to TO N
make VB N
changes NNS N
to TO N
their PRP$ N
care NN N
through IN N
tailored VBN N
feedback NN N
. . N

METHODS NNP N
Diagnosed VBD p
hypertensive JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
RCT NNP N
and CC N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
: : N
( ( N
1 CD N
) ) N
the DT i
intervention NN i
condition NN i
-- : i
Web-based JJ i
hypertension NN i
feedback NN i
, , i
based VBN i
on IN i
the DT i
individual JJ i
patient NN i
's POS i
self-report NN i
of IN i
health NN i
variables NNS i
and CC i
previous JJ i
BP NNP i
measurements NNS i
, , i
to TO i
prompt VB i
them PRP i
to TO i
ask VB i
questions NNS i
during IN i
their PRP$ i
next JJ i
physician NN i
's POS i
visit NN i
about IN i
hypertension NN i
care NN i
( ( N
2 CD N
) ) N
the DT i
control NN i
condition NN i
-- : i
Web-based JJ i
preventive JJ i
health NN i
feedback NN i
, , i
based VBN i
on IN i
the DT i
individual NN i
's POS i
self-report NN i
of IN i
receiving VBG i
preventive JJ i
care NN i
( ( i
e.g. UH i
, , N
pap JJ i
testing VBG i
) ) i
, , i
to TO i
prompt VB i
them PRP i
to TO i
ask VB i
questions NNS i
during IN i
their PRP$ i
next JJ i
physician NN i
's POS i
visit NN i
about IN i
preventive JJ i
care NN i
. . i

The DT N
primary JJ N
outcome NN N
of IN N
the DT N
study NN N
is VBZ N
change VBN o
in IN o
blood NN o
pressure NN o
and CC o
change NN o
in IN o
the DT o
percentage NN o
of IN o
patients NNS o
in IN o
each DT o
group NN o
with IN o
controlled VBN o
blood NN o
pressure NN o
. . o

CONCLUSION NNP N
Five CD p
hundred VBD p
participants NNS p
were VBD p
enrolled VBN p
and CC p
baseline JJ p
characteristics NNS p
include VBP p
a DT p
mean JJ p
age NN p
of IN p
60.0 CD p
years NNS p
; : p
57.6 CD p
% NN p
female NN p
; : p
and CC p
77.6 CD p
% NN p
white JJ p
. . p

Overall JJ N
37.7 CD p
% NN p
participants NNS p
had VBD p
uncontrolled VBN p
blood NN p
pressure NN p
; : p
the DT p
mean NN p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
was VBD p
in IN p
the DT p
obese JJ p
range NN p
( ( p
32.4 CD p
) ) p
and CC p
21.8 CD p
% NN p
had VBD p
diabetes NNS p
. . p

By IN N
activating VBG N
patients NNS N
to TO N
become VB N
involved VBN N
in IN N
their PRP$ N
own JJ N
care NN N
, , N
we PRP N
believe VBP N
the DT N
addition NN N
of IN N
the DT N
web-based JJ N
intervention NN N
will MD N
improve VB N
blood NN o
pressure NN o
control NN o
compared VBN N
to TO N
a DT N
control NN N
group NN N
who WP N
receive VBP N
web-based JJ N
preventive JJ N
messages NNS N
unrelated VBN N
to TO N
hypertension NN N
. . N

-DOCSTART- -X- O O

Sialyl NNP i
Lewisa NNP i
expression NN i
as IN N
a DT N
predictor NN N
of IN N
the DT N
prognosis NN N
of IN N
colon NN p
carcinoma NN p
patients NNS p
in IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
metastatic JJ N
potential NN N
of IN N
tumors NNS N
is VBZ N
dependent JJ N
on IN N
the DT N
cell NN N
to TO N
cell VB N
adhesion NN N
by IN N
cell NN N
surface NN N
carbohydrate NN N
antigens NNS N
. . N

Thus RB N
, , N
expression NN N
of IN N
sialyl NN N
Lewis NNP N
( ( N
a DT N
) ) N
, , N
which WDT N
is VBZ N
one CD N
of IN N
the DT N
important JJ N
molecules NNS N
of IN N
cell NN N
surface NN N
carbohydrates NNS N
, , N
may MD N
serve VB N
as IN N
a DT N
prognostic JJ N
marker NN N
of IN N
aggressive JJ N
and CC N
metastasizing VBG N
tumor NN N
growth NN N
. . N

However RB N
, , N
the DT N
prognostic JJ N
value NN N
of IN N
sialyl JJ N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
in IN N
colon NN N
cancer NN N
is VBZ N
still RB N
controversial JJ N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
expression NN i
of IN i
sialyl NN i
Lewis NNP i
( ( i
a DT i
) ) i
antigen NN i
in IN N
233 CD p
colon NN i
cancer NN i
specimens NNS i
from IN p
patients NNS p
who WP p
were VBD p
registered VBN p
in IN p
a DT p
prospective JJ p
adjuvant NN i
immunochemotherapy NN i
clinical JJ p
trial NN p
. . p

The DT N
clinical JJ N
course NN N
and CC N
the DT N
prognosis NN N
of IN N
the DT N
patients NNS N
were VBD N
evaluated VBN N
after IN N
all PDT N
the DT N
immunohistochemical JJ N
analyses NNS N
had VBD N
been VBN N
performed VBN N
. . N

RESULTS NNP N
Sialyl NNP N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
levels NNS N
were VBD N
correlated VBN N
with IN N
both DT N
overall JJ o
survival NN o
( ( N
P NNP N
= NNP N
0.0006 CD N
) ) N
and CC N
disease-free JJ o
survival NN o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
all DT N
patients NNS N
with IN N
the DT N
log-rank JJ N
test NN N
. . N

This DT N
result NN N
could MD N
be VB N
assumed VBN N
to TO N
have VB N
been VBN N
influenced VBN N
by IN N
the DT N
difference NN N
in IN N
the DT N
metastatic JJ N
preponderance NN N
in IN N
a DT N
high JJ N
versus NN N
low JJ N
sialyl NN N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
in IN N
the DT N
tumor NN N
cells NNS N
. . N

CONCLUSION VB N
This DT N
prospective JJ N
study NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
suggests VBZ N
that IN N
sialyl NN N
Lewis NNP N
( ( N
a DT N
) ) N
expression NN N
levels NNS N
may MD N
serve VB N
as IN N
an DT N
indicator NN N
of IN N
the DT N
metastatic JJ N
potential NN N
of IN N
colon NN N
cancer NN N
cells NNS N
, , N
which WDT N
would MD N
strongly RB N
predict VB N
the DT N
prognosis NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
nitric JJ i
oxide JJ i
synthase NN i
inhibition NN i
on IN N
cutaneous JJ o
vasodilation NN o
in IN N
response NN N
to TO N
acupuncture VB i
stimulation NN N
in IN N
humans NNS p
. . p

OBJECTIVES IN N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
elucidate VB N
the DT N
mechanism NN N
of IN N
cutaneous JJ N
vasodilation NN N
following VBG N
acupuncture NN N
stimulation NN N
by IN N
investigating VBG N
the DT N
roles NNS N
of IN N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
and CC N
axon $ N
reflex JJ N
vasodilation NN N
. . N

METHODS NNP N
The DT N
subjects NNS N
were VBD N
17 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

The DT N
role NN N
of IN N
NO NNP N
was VBD N
investigated VBN N
by IN N
administering VBG N
N NNP i
( ( i
G NNP i
) ) i
-nitro-l-arginine VBP i
methyl JJ i
ester NN i
hydrochloride NN i
( ( i
L-NAME NNP i
, , N
20 CD N
mM NN N
) ) N
, , N
an DT N
NO NNP i
synthase NN i
inhibitor NN i
or CC N
Ringer NNP i
's POS i
solution NN i
( ( N
control VB N
site NN N
) ) N
, , N
via IN N
intradermal JJ N
microdialysis NN N
( ( N
protocol JJ N
1 CD N
; : N
n=7 NN N
) ) N
. . N

The DT N
role NN N
of IN N
axon JJ N
reflex JJ N
vasodilation NN N
by IN N
local JJ N
sensory NN N
neurones NNS N
was VBD N
investigated VBN N
by IN N
comparing VBG N
vasodilation NN N
at IN N
sites NNS N
treated VBN N
with IN N
'eutectic JJ i
mixture NN i
of IN i
local JJ i
anaesthetics NNS i
' POS i
( ( i
EMLA NNP i
) ) i
cream NN N
( ( N
2.5 CD N
% NN N
lidocaine NN i
and CC N
2.5 CD N
% NN N
prilocaine NN i
) ) i
with IN N
untreated JJ N
sites NNS N
( ( N
control VB N
site NN N
) ) N
( ( N
protocol JJ N
2 CD N
; : N
n=10 NN N
) ) N
. . N

After IN N
5 CD N
min NN N
of IN N
baseline NN N
recording NN N
, , N
acupuncture NN i
was VBD N
applied VBN N
to TO N
PC4 NNP N
and CC N
a DT N
control NN N
site NN N
in IN N
proximity NN N
to TO N
PC4 NNP N
for IN N
10 CD N
min NNS N
and CC N
scanning NN N
was VBD N
performed VBN N
for IN N
60 CD N
min NN N
after IN N
acupuncture JJ N
stimulation NN N
. . N

Skin NNP o
blood NN o
flow NN o
( ( o
SkBF NNP o
) ) o
was VBD N
evaluated VBN N
by IN N
laser NN N
Doppler NNP o
perfusion NN o
imaging VBG o
. . o

Cutaneous JJ o
vascular JJ o
conductance NN o
( ( o
CVC NNP o
) ) o
was VBD N
calculated VBN N
from IN N
the DT N
ratio NN N
of IN N
SkBF NNP N
to TO N
mean VB N
arterial JJ N
blood NN N
pressure NN N
. . N

RESULTS NNP N
In IN N
the DT N
first JJ N
protocol NN N
, , N
sites NNS N
administered VBD N
L-NAME NNP N
showed VBD N
significant JJ N
reductions NNS N
in IN N
CVC NNP o
responses NNS o
following VBG N
acupuncture NN N
stimulation NN N
compared VBN N
to TO N
control VB N
sites NNS N
( ( N
administered VBN N
Ringer NNP i
's POS i
solution NN N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
second JJ N
protocol NN N
, , N
changes NNS o
in IN o
CVC NNP o
responses NNS o
after IN N
acupuncture JJ N
stimulation NN N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
treated VBN N
sites NNS N
with IN N
EMLA NNP i
cream NN N
and CC N
untreated JJ N
sites NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
cutaneous JJ N
vasodilation NN N
in IN N
response NN N
to TO N
acupuncture VB N
stimulation NN N
may MD N
not RB N
occur VB N
through IN N
an DT N
axon JJ N
reflex NN N
as IN N
previously RB N
reported VBN N
. . N

Rather NNP N
, , N
NO NNP N
mechanisms NN N
appear VBP N
to TO N
contribute VB N
to TO N
the DT N
vasodilator NN N
response NN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
an DT N
interactive JJ N
multi-media NN N
device NN N
for IN N
delivering VBG N
information NN N
on IN N
Le NNP N
Fort NNP N
I PRP N
osteotomy VBP N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out RP N
on IN N
volunteers NNS p
to TO N
evaluate VB N
a DT N
newly RB N
developed VBN N
interactive JJ N
software NN N
package NN N
aimed VBN N
at IN N
informing VBG N
prospective JJ p
Le NNP p
Fort NNP p
I PRP p
osteotomy VBP p
patients NNS p
regarding VBG N
the DT N
surgical JJ N
technique NN N
and CC N
possible JJ N
complications NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
two CD N
methods NNS N
of IN N
information NN N
delivery NN N
; : N
a DT i
multi-media JJ i
tablet NN i
device NN i
delivering VBG i
both DT i
graphic JJ i
and CC i
verbal JJ i
information NN i
, , i
and CC i
an DT i
audio JJ i
device NN i
delivering VBG i
essentially RB i
the DT i
same JJ i
information NN i
in IN i
verbal JJ i
form NN i
only RB i
. . i

The DT N
null JJ N
hypothesis NN N
was VBD N
that IN N
there EX N
would MD N
be VB N
no DT N
difference NN N
between IN N
the DT N
efficiencies NNS o
of IN N
the DT N
two CD N
methods NNS N
. . N

The DT N
subjects NNS N
' POS N
ability NN o
to TO o
recall VB o
the DT o
information NN o
delivered VBN N
by IN N
both DT N
devices NNS N
was VBD N
assessed VBN N
using VBG N
a DT N
questionnaire NN N
. . N

The DT N
tablet NN N
device NN N
participants NNS N
scored VBD N
an DT N
average NN N
of IN N
15.48 CD N
points NNS N
, , N
while IN N
the DT N
audio JJ N
device NN N
participants NNS N
scored VBD N
an DT N
average NN N
of IN N
268 CD N
points NNS N
. . N

The DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
suggesting VBG N
that IN N
the DT N
multi-media JJ N
tablet NN N
device NN N
was VBD N
more RBR N
effective JJ N
method NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
fenoterol NN i
on IN N
inspiratory JJ N
effort NN N
sensation NN N
and CC N
fatigue NN N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
fenoterol NN i
on IN N
the DT N
relationship NN N
between IN N
inspiratory NN N
effort NN N
sensation NN N
( ( N
IES NNP N
) ) N
and CC N
inspiratory JJ N
muscle NN N
fatigue NN N
induced VBN N
by IN N
inspiratory NN N
threshold NN N
loading NN N
in IN N
healthy JJ p
subjects NNS p
. . p

The DT N
magnitude NN N
of IN N
the DT N
threshold NN N
was VBD N
60 CD N
% NN N
of IN N
maximal JJ N
static JJ N
inspiratory NN N
mouth NN N
pressure NN N
( ( N
PI NNP N
, , N
mmax NN N
) ) N
at IN N
functional JJ N
residual JJ N
capacity NN N
, , N
and CC N
the DT N
duty NN N
cycle NN N
was VBD N
0.5 CD N
. . N

Subjects NNS p
continued VBD N
the DT N
threshold NN N
loaded VBD N
breathing NN N
until IN N
the DT N
target NN N
mouth NN N
pressure NN N
could MD N
no RB N
longer RB N
be VB N
maintained VBN N
( ( N
endurance JJ N
time NN N
) ) N
. . N

The DT N
intensity NN N
of IN N
the DT N
IES NNP N
was VBD N
scored VBN N
with IN N
a DT N
modified JJ N
Borg NNP N
scale NN N
. . N

Either CC N
fenoterol NN i
( ( i
5 CD i
mg NN i
) ) i
or CC i
a DT i
placebo NN i
was VBD N
given VBN N
orally RB N
2 CD N
h NN N
before IN N
loading VBG N
in IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
protocol NN N
. . N

The DT N
endurance NN o
time NN o
with IN N
fenoterol NN N
( ( N
34.4 CD N
+/- JJ N
8.6 CD N
min NN N
) ) N
was VBD N
longer JJR N
than IN N
that DT N
with IN N
the DT N
placebo NN N
( ( N
22.2 CD N
+/- JJ N
7.1 CD N
min NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN o
of IN o
high- JJ o
to TO o
low-frequency JJ o
power NN o
of IN o
the DT o
diaphragmatic JJ o
electromyogram NN o
( ( o
EMGdi NNP o
) ) o
decreased VBD N
during IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
less RBR N
with IN N
fenoterol NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
EMGdi NNP o
also RB N
decreased VBD N
with IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
greater JJR N
on IN N
fenoterol NN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
PI NNP o
, , o
mmax NN o
and CC o
maximal JJ o
transdiaphragmatic JJ o
pressure NN o
( ( o
Pdi NNP o
) ) o
were VBD N
similarly RB N
decreased VBN N
after IN N
loading VBG N
on IN N
either DT N
treatment NN N
. . N

The DT N
intensity NN o
of IN o
the DT o
IES NNP o
rose VBD o
with IN o
time NN o
during IN N
loading VBG N
in IN N
both DT N
groups NNS N
but CC N
was VBD N
lower JJR N
with IN N
fenoterol NN i
than IN N
with IN N
the DT N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN o
of IN o
Pdi NNP o
to TO N
integrated JJ N
activity NN N
of IN N
the DT N
EMGdi NNP N
increased VBD N
with IN N
fenoterol NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Fenoterol NNP N
treatment NN N
increased VBD N
both DT N
superimposed VBN o
Pdi NNP o
twitch NN o
and CC o
Pdi NNP o
twitch NN o
of IN o
relaxed JJ o
diaphragm NN o
and CC N
decreased VBD N
the DT N
value NN o
of IN o
( ( o
1-superimposed JJ o
Pdi NNP o
twitch/Pdi NN o
twitch NN o
of IN o
relaxed JJ o
diaphragm NN o
) ) o
. . o

Thus IN N
we PRP N
conclude VBP N
that IN N
in IN N
normal JJ p
subjects NNS p
fenoterol JJ N
reduces NNS N
diaphragmatic JJ N
fatigue NN N
and CC N
decreases VBZ N
the DT N
motor NN N
command NN N
to TO N
the DT N
diaphragm NN N
, , N
resulting VBG N
in IN N
a DT N
decrease NN N
in IN N
IES NNP N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
and CC N
a DT N
prolongation NN N
of IN N
endurance NN N
. . N

-DOCSTART- -X- O O

A DT N
search NN N
for IN N
serologic JJ N
correlates NNS N
of IN N
immunity NN N
to TO N
Bordetella NNP N
pertussis NN N
cough NN N
illnesses NNS N
. . N

In IN N
a DT N
pertussis NN p
vaccine NN p
efficacy NN p
trial NN p
in IN p
Germany NNP p
we PRP N
collected VBD N
sera NN N
from IN N
vaccinees NNS i
( ( i
DTaP NNP i
or CC i
DTP NNP i
) ) i
after IN N
the DT N
third JJ N
and CC N
fourth JJ N
doses NNS N
of IN N
vaccine NN N
or CC N
at IN N
comparable JJ N
time NN N
periods NNS N
in IN N
DT NNP p
vaccine NN p
recipients NNS p
. . p

In IN N
addition NN N
, , N
sera NN N
were VBD N
collected VBN N
from IN N
a DT N
randomized JJ N
sample NN N
of IN N
subjects NNS p
in IN p
each DT p
vaccine NN p
group NN p
at IN p
approximately RB p
3-month JJ p
intervals NNS p
from IN N
which WDT N
antibody NN N
kinetic JJ N
curves NNS N
were VBD N
constructed VBN N
, , N
which WDT N
allowed VBD N
us PRP N
to TO N
estimate VB N
specific JJ N
antibody NN N
values NNS N
to TO N
pertussis VB i
toxin NN N
( ( N
PT NNP N
) ) N
, , N
filamentous JJ N
hemagglutinin NN N
( ( N
FHA NNP N
) ) N
, , N
pertactin JJ N
and CC N
fimbriae-2 JJ N
at IN N
the DT N
time NN N
of IN N
exposure NN N
in IN N
the DT N
household NN N
setting NN N
. . N

The DT N
imputed JJ N
geometric JJ N
mean NN N
antibody NN N
values NNS N
to TO N
PT NNP N
, , N
pertactin NN N
and CC N
fimbriae-2 NN N
at IN N
the DT N
time NN N
of IN N
household NN N
exposure NN N
to TO N
Bordetella NNP N
pertussis NN N
infection NN N
were VBD N
higher JJR N
( ( N
p JJ N
< VBP N
0.07 CD N
or CC N
lower JJR N
) ) N
in IN N
non-cases NNS N
compared VBN N
with IN N
cases NNS N
. . N

A DT N
multivariate NN N
( ( N
classification NN N
tree NN N
) ) N
analysis NN N
found VBD N
that IN N
only RB N
pertactin NN N
and CC N
PT NNP N
were VBD N
significant JJ N
in IN N
protection NN N
. . N

Subjects NNS N
with IN N
an DT N
imputed JJ N
pertactin NN N
value NN N
of IN N
< $ N
7 CD N
EU NNP N
ml-1 NN N
had VBD N
a DT N
67 CD N
% NN N
( ( N
18/27 CD N
) ) N
chance NN N
of IN N
infection NN N
regardless NN N
of IN N
the DT N
PT NNP N
value NN N
. . N

If IN N
the DT N
pertactin NN N
value NN N
was VBD N
> JJ N
or CC N
= JJ N
7 CD N
EU NNP N
ml-1 NN N
and CC N
the DT N
PT NNP N
value NN N
> NN N
or CC N
= $ N
66 CD N
EU NNP N
ml-1 CD N
all DT N
subjects NNS N
were VBD N
non-cases NNS N
. . N

If IN N
the DT N
pertactin NN N
value NN N
was VBD N
> JJ N
or CC N
= JJ N
7 CD N
and CC N
the DT N
PT NNP N
value NN N
was VBD N
< JJ N
66 CD N
EU NNP N
ml-1 CD N
the DT N
predicted JJ N
probability NN N
of IN N
being VBG N
a DT N
case NN N
was VBD N
31 CD N
% NN N
( ( N
15/49 CD N
) ) N
. . N

Logistic JJ o
regression NN o
analysis NN o
also RB N
found VBD N
that IN N
high JJ N
versus NN N
low JJ N
pertactin NN N
values NNS N
were VBD N
associated VBN N
with IN N
illness JJ N
prevention NN N
following VBG N
household NN N
exposure NN N
. . N

In IN N
the DT N
presence NN N
of IN N
antibody NN N
to TO N
pertactin VB N
, , N
PT NNP N
and CC N
fimbriae-2 JJ N
, , N
the DT N
additional JJ N
presence NN N
of IN N
antibody NN N
to TO N
FHA NNP N
did VBD N
not RB N
contribute VB N
to TO N
protection NN N
. . N

Our PRP$ N
data NNS N
support NN N
historical JJ N
data NNS N
indicating VBG N
that IN N
agglutinating VBG N
antibodies NNS N
are VBP N
associated VBN N
with IN N
protection NN N
and CC N
also RB N
recent JJ N
serologic JJ N
correlates NNS N
data NNS N
and CC N
clinical JJ N
efficacy NN N
data NNS N
which WDT N
indicate VBP N
that IN N
multicomponent NN i
vaccines NNS i
containing VBG i
pertactin NN i
and CC i
fimbriae NN i
have VBP N
better JJR N
efficacy NN N
than IN N
PT NNP N
or CC N
PT/FHA NNP N
vaccines NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
intranasal NN N
beclomethasone NN i
dipropionate NN i
after IN N
polypectomy NN N
. . N

Beneficial JJ N
effects NNS N
of IN N
intranasal NN i
beclomethasone NN i
dipropionate NN i
( ( i
Bdp NNP i
) ) i
in IN N
patients NNS p
with IN p
nasal JJ p
polyposis NN p
have VBP N
been VBN N
reported VBN N
earlier RBR N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
investigate VB N
whether IN N
long-term JJ N
treatment NN N
with IN N
Bdp NNP i
after IN N
polypectomy NN N
could MD N
prevent VB N
formation NN N
of IN N
new JJ N
polyps NNS N
and CC N
reduce VB N
the DT N
number NN N
of IN N
surgical JJ N
removals NNS N
. . N

Forty NNP p
consecutive JJ p
patients NNS p
without IN p
laboratory NN p
or CC p
other JJ p
clinical JJ p
signs NNS p
of IN p
allergy NN p
but CC p
with IN p
severe JJ p
nasal JJ p
polyposis NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Twenty CD p
patients NNS p
were VBD p
treated VBN p
with IN p
intranasal JJ i
Bdp NNP i
and CC p
twenty JJ p
patients NNS p
received VBD p
no DT p
treatment NN p
after IN p
polypectomy NN i
. . i

All DT N
patients NNS p
were VBD p
followed VBN p
for IN p
at IN p
least JJS p
2.5 CD p
years NNS p
. . p

The DT N
size NN o
of IN o
the DT o
polyps NNS o
that WDT o
recurred VBD o
was VBD N
estimated VBN N
at IN N
different JJ N
time-intervals NNS N
by IN N
the DT N
examining VBG N
doctor NN N
. . N

After IN N
six CD N
months NNS N
there RB N
was VBD N
already RB N
a DT N
significant JJ o
difference NN o
in IN N
favour NN N
of IN N
the DT N
group NN N
treated VBD N
with IN N
intranasal JJ N
Bdp NNP i
. . i

Further NNP N
results NNS N
of IN N
the DT N
study NN N
and CC N
the DT N
clinical JJ N
implications NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Intervention NN i
for IN i
ineffective JJ o
airway JJ o
clearance NN o
in IN i
asthmatic JJ i
children NNS i
: : i
a DT N
controlled VBN N
and CC N
randomized VBN N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
analyse VB N
the DT N
effectiveness NN N
of IN N
an DT N
intervention NN N
for IN N
the DT N
nursing NN N
diagnosis NN N
of IN N
ineffective JJ o
airway JJ o
clearance NN o
in IN N
asthmatic JJ p
children NNS p
. . p

A DT N
blinded JJ N
, , N
randomized VBN N
and CC N
controlled VBN N
clinical JJ N
trial NN N
was VBD N
developed VBN N
in IN N
a DT N
paediatric JJ p
hospital NN p
located VBN p
on IN p
northeast NN p
of IN p
Brazil NNP p
with IN p
42 CD p
asthmatic JJ p
children NNS p
aged VBN p
? . p
36 CD p
months NNS p
. . p

The DT p
children NNS p
were VBD p
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
intervention NN N
and CC i
control NN i
) ) i
by IN i
means NNS N
of IN N
a DT N
simple JJ N
drawing NN N
. . N

The DT N
applied JJ N
intervention NN N
included VBD N
actions NNS N
related VBN N
to TO N
change VB i
of IN i
positioning NN i
and CC i
stimulation NN i
of IN i
cough NN i
. . i

The DT N
main JJ N
findings NNS N
of IN N
this DT N
study NN N
show VBP N
that IN N
before IN N
the DT N
intervention NN N
, , N
no DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
in IN N
the DT o
health NN o
status NN o
of IN o
the DT N
children NNS N
. . N

After IN N
the DT N
intervention NN N
, , N
the DT N
indicators NNS N
of IN N
choking VBG o
( ( o
16.83 CD N
vs. FW N
26.17 CD N
, , N
P NNP N
= NNP N
0.007 CD N
) ) N
and CC o
adventitious JJ o
breath NN o
sounds NNS o
( ( o
16.4 CD N
vs. FW N
26.6 CD N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
were VBD N
higher JJR N
, , N
on IN N
average NN N
, , N
in IN N
the DT N
intervention NN N
group NN N
. . N

It PRP N
was VBD N
observed VBN N
an DT N
improvement NN N
in IN N
obstructive JJ o
symptoms NNS o
in IN o
children NNS p
who WP p
received VBD p
the DT p
intervention NN p
proposed VBN p
. . N

-DOCSTART- -X- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
trial NN N
of IN N
risperidone NN i
plus CC i
amantadine NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
10-week JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
adding VBG N
amantadine NN i
to TO i
risperidone VB i
for IN N
treatment NN N
of IN N
autism NN N
. . N

METHODS NNP N
Forty NNP p
outpatients NNS p
aged VBD p
4 CD p
to12 NN p
years NNS p
, , p
who WP p
were VBD p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
based VBN p
on IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
, , p
Text NNP p
Revision NNP p
criteria NNS p
, , N
were VBD N
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

The DT N
subjects NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ i
plus CC i
amantadine JJ i
, , i
and CC i
the DT i
other JJ i
group NN i
received VBD i
risperidone JJ i
plus CC i
placebo NN i
. . i

The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
amantadine NN i
was VBD N
100 CD N
or CC N
150 CD N
mg/d NNS N
for IN N
patients NNS N
less JJR N
than IN N
30 CD N
kg NN N
or CC N
more JJR N
than IN N
30 CD N
kg NNS N
, , N
respectively RB N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP o
Behavioral NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
and CC o
adverse JJ o
effects NNS o
checklist NN o
as RB N
well RB N
as IN N
clinical JJ o
global JJ o
impression-improvement NN o
( ( o
CGI-I NNP o
) ) o
at2 VBZ N
checkpoints NNS N
of IN N
5-week JJ N
intervals NNS N
after IN N
the DT N
baseline NN N
. . N

Informed NNP N
consentwas NN N
obtained VBN N
from IN N
the DT N
parents NNS N
of IN N
each DT N
participant NN N
. . N

RESULTS NNP N
Among IN N
ABC-C NNP o
subscales NNS o
, , o
Hyperactivity NNP o
and CC o
Irritability NNP o
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
adverse JJ o
effects NNS o
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
CGI-I JJ o
scores NNS o
show VBP N
significant JJ N
improvement NN N
in IN N
the DT N
amantadine NN i
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS VB N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
amantadine NN i
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -X- O O

[ JJ o
Efficacy NNP o
and CC o
immune JJ o
memory NN o
of IN N
plasma-derived JJ i
hepatitis NN i
B NNP i
vaccine NN i
11 CD p
years NNS p
after IN p
primary JJ p
immunization NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
long-term JJ o
efficacy NN o
of IN N
hepatitis NN i
B NNP i
vaccine NN i
10 CD p
years NNS p
after IN p
primary JJ p
immunization NN p
to TO N
provide VB N
scientific JJ N
basis NN N
for IN N
the DT N
time NN N
of IN N
revaccination NN N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
strictly RB N
designed VBN N
with IN N
randomization NN N
, , N
double-blinding NN N
, , N
and CC N
placebo-controlled JJ i
method NN N
to TO N
observe VB N
the DT p
efficacy NN o
and CC o
immune JJ o
memory NN o
11 CD p
years NNS p
following VBG p
hepatitis NN i
B NNP i
vaccination NN i
. . i

RESULTS NNP N
Immunogenicity NNP o
and CC o
protective JJ o
rate NN o
of IN o
vaccine NN o
were VBD N
still RB N
kept VBN N
well RB N
11 CD N
years NNS N
after IN N
immunization NN N
with IN N
a DT N
protective JJ o
rate NN o
against IN N
HBV NNP N
infection NN o
of IN N
73.5 CD N
% NN N
. . N

But CC N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
HBV NNP o
infection NN o
rates NNS o
between IN N
vaccine NN p
group NN p
and CC p
placebo-controlled JJ p
group NN p
( ( N
7.89 CD N
% NN N
vs. FW N
13.25 CD N
% NN N
, , N
P NNP N
> NNP N
0.1 CD N
) ) N
nine CD N
to TO N
11 CD N
years NNS N
following VBG N
immunization NN N
. . N

There EX N
still RB N
existed VBD N
immune JJ o
memory NN o
11 CD N
years NNS N
after IN N
immunization NN N
, , N
but CC N
it PRP N
was VBD N
significantly RB N
weaker JJR N
than IN N
that DT N
within IN N
the DT N
first JJ N
10 CD N
years NNS N
after IN N
immunization NN N
. . N

CONCLUSION VB N
The DT N
efficacy NN o
of IN N
the DT N
vaccine NN o
had VBD N
begun VBN N
to TO N
drop VB N
11 CD N
years NNS N
after IN N
immunization NN N
, , N
which WDT N
should MD N
be VB N
followed VBN N
up RP N
further RBR N
to TO N
reach VB N
a DT N
clear JJ N
conclusion NN N
. . N

-DOCSTART- -X- O O

The DT N
neural JJ N
correlates NNS N
of IN N
semantic JJ N
richness NN N
: : N
evidence NN N
from IN N
an DT N
fMRI NN N
study NN N
of IN N
word NN N
learning NN N
. . N

We PRP N
investigated VBD N
the DT N
neural JJ N
correlates NNS N
of IN N
concrete JJ N
nouns NNS N
with IN N
either DT N
many JJ N
or CC N
few JJ N
semantic JJ N
features NNS N
. . N

A DT N
group NN p
of IN p
21 CD p
participants NNS p
underwent JJ p
two CD p
days NNS p
of IN p
training NN i
and CC p
were VBD p
then RB p
asked VBN p
to TO p
categorize VB p
40 CD p
newly RB p
learned VBN p
words NNS p
and CC p
a DT p
set NN p
of IN p
matched NNS i
familiar JJ i
words NNS i
as IN i
living NN i
or CC i
nonliving NN i
in IN i
an DT i
MRI NNP i
scanner NN i
. . i

Our PRP$ N
results NNS N
showed VBD N
that IN N
the DT N
most RBS o
reliable JJ o
effects NNS o
of IN o
semantic JJ o
richness NN o
were VBD N
located VBN o
in IN o
the DT o
left NN o
angular JJ o
gyrus NN o
( ( o
AG NNP o
) ) o
and CC o
middle JJ o
temporal JJ o
gyrus NN o
( ( o
MTG NNP o
) ) o
, , N
where WRB N
activation NN o
was VBD N
higher JJR N
for IN N
semantically RB N
rich JJ N
than IN N
poor JJ N
words NNS N
. . N

Other JJ N
areas NNS N
showing VBG N
the DT N
same JJ N
pattern NN N
included VBD N
bilateral JJ N
precuneus NN N
and CC N
posterior JJ N
cingulate NN N
gyrus NN N
. . N

Our PRP$ N
findings NNS N
support VBP N
the DT N
view NN N
that IN N
AG NNP N
and CC N
anterior JJ N
MTG NNP N
, , N
as IN N
part NN N
of IN N
the DT N
multimodal NN N
network NN N
, , N
play VB N
a DT N
significant JJ N
role NN N
in IN N
representing VBG N
and CC N
integrating VBG o
semantic JJ o
features NNS o
from IN N
different JJ N
input NN N
modalities NNS N
. . N

We PRP N
propose VBP N
that DT N
activation NN N
in IN N
bilateral JJ N
precuneus NN N
and CC N
posterior JJ N
cingulate NN N
gyrus NN N
reflects VBZ N
interplay NN N
between IN N
AG NNP N
and CC N
episodic JJ N
memory NN N
systems NNS N
during IN N
semantic JJ N
retrieval NN N
. . N

-DOCSTART- -X- O O

Antibiotic JJ i
prophylaxis NN i
in IN N
high-risk JJ p
head NN p
and CC p
neck NN p
surgery NN p
: : p
one-day JJ i
vs. IN N
five-day JJ i
therapy NN i
. . i

Patients NNS p
who WP p
undergo VBP p
major JJ p
contaminated VBN p
surgery NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
benefit NN N
from IN N
perioperative JJ N
antibiotic JJ i
prophylaxis NN i
. . i

This DT N
study NN N
was VBD N
developed VBN N
to TO N
determine VB N
if IN N
5 CD N
days NNS N
of IN N
antibiotic JJ o
administration NN o
would MD N
be VB N
more RBR N
effective JJ N
than IN N
1 CD N
day NN N
. . N

A DT N
multi-institutional JJ N
prospective JJ N
randomized VBN N
double-blind NN N
study NN N
was VBD N
designed VBN N
. . N

Patients NNS p
who WP p
were VBD p
identified VBN p
as IN p
requiring VBG p
pedicled VBD p
flap JJ p
reconstruction NN p
were VBD p
potential JJ p
candidates NNS p
for IN p
the DT p
study NN p
. . p

Later NNP N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
cefoperazone NN i
sodium NN i
for IN N
either DT N
24 CD i
hours NNS i
or CC i
120 CD i
hours NNS i
. . i

In IN N
each DT N
case NN N
, , N
the DT N
drug NN N
was VBD N
administered VBN N
intravenously RB N
, , N
beginning VBG N
1 CD N
to TO N
2 CD N
hours NNS N
preoperatively RB N
and CC N
continued VBD N
for IN N
the DT N
prescribed JJ N
period NN N
. . N

One CD p
hundred VBD p
nine CD p
patients NNS p
were VBD p
evaluable JJ p
. . p

Fifty-three JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
day NN N
of IN N
perioperative JJ N
prophylaxis NN N
. . N

Wound NNP o
infection NN o
developed VBD N
in IN N
ten JJ N
patients NNS N
( ( N
18.9 CD N
% NN N
) ) N
. . N

Fifty-six JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
5 CD N
days NNS N
of IN N
perioperative JJ i
antibiotic JJ i
prophylaxis NN i
. . i

Wound NNP o
infection NN o
developed VBD N
in IN N
14 CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
these DT N
patients NNS N
( ( N
P NNP N
greater JJR N
than IN N
.05 NN N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
no DT N
beneficial JJ N
effect NN N
from IN N
administration NN N
of IN N
antibiotics NNS i
for IN N
longer JJR N
than IN N
24 CD N
hours NNS N
postoperatively RB N
can MD N
be VB N
achieved VBN N
in IN N
patients NNS N
who WP N
undergo VBP N
myocutaneous JJ N
flap JJ N
reconstruction NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Supplementary NNP N
treatment NN N
with IN N
Esberitox NNP i
of IN N
female JJ p
patients NNS p
undergoing VBG p
curative JJ i
adjuvant JJ i
irradiation NN i
following VBG p
breast NN p
cancer NN p
] NNP p
. . N

1 CD N
. . N

The DT N
study NN N
was VBD N
supposed VBN N
to TO N
investigate VB N
a DT N
possible JJ N
prevention NN o
or CC o
reduction NN o
of IN o
the DT o
toxicity NN o
of IN N
radiotherapy NN i
by IN N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP i
. . i

This DT N
question NN N
arose VBD N
when WRB N
performing VBG N
an DT N
investigation NN N
about IN N
the DT N
effect NN N
of IN N
Esberitox NNP i
in IN N
a DT N
combined JJ N
chemo-radiotherapy NN N
. . N

Whereas IN N
the DT N
latter JJ N
induces NNS N
above IN N
all PDT N
a DT N
systemic JJ N
damage NN N
to TO N
the DT N
hemopoietic JJ N
system NN N
, , N
radiotherapy NN N
is VBZ N
a DT N
regional JJ N
noxa NN N
. . N

2 CD N
. . N

The DT N
present JJ N
prospective JJ N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
with IN N
50 CD p
patients NNS p
submitted VBN p
to TO p
curative VB i
adjuvant JJ i
irradiation NN i
following VBG p
surgery NN p
for IN p
mammary JJ p
carcinoma NN p
. . p

The DT N
radiotherapy NN i
was VBD N
performed VBN N
in IN N
the DT N
same JJ N
way NN N
in IN N
all DT N
patients NNS p
with IN p
irradiations NNS p
of IN p
the DT p
thoracic NN p
wall NN p
and CC p
the DT p
regional JJ p
lymph NN p
nodes NNS p
. . p

Two CD N
groups NNS N
were VBD N
built VBN N
by IN N
randomization NN N
. . N

The DT N
study NN N
group NN N
received VBD N
an DT N
additional JJ N
treatment NN N
with IN N
Esberitox NNP i
, , N
the DT N
control NN i
group NN i
did VBD i
not RB i
receive VB i
an DT i
additional JJ i
treatment NN i
. . i

3 CD N
. . N

As IN N
a DT N
result NN N
, , N
no DT N
protective JJ N
influence NN N
of IN N
Esberitox NNP N
could MD N
be VB N
demonstrated VBN N
. . N

The DT N
parameters NNS N
investigated VBN N
were VBD N
the DT N
peripheral JJ o
blood NN o
count NN o
( ( o
leucocytes NNS o
, , o
granulocytes NNS o
, , o
lymphocytes NNS o
, , o
monocytes NNS o
, , o
thrombocytes NNS o
, , o
hemoglobin NN o
, , o
hematocrit NN o
) ) o
and CC o
the DT o
incidence NN o
of IN o
infections NNS o
. . o

4 CD N
. . N

This DT N
result NN N
diverging VBG N
from IN N
literature NN N
is VBZ N
discussed VBN N
. . N

It PRP N
is VBZ N
probably RB N
affected VBN N
by IN N
volume NN N
and CC N
extension NN N
of IN N
the DT N
injury NN N
induced VBN N
by IN N
a DT N
hematotoxic NN N
noxa NN N
and CC N
furthermore NN N
by IN N
the DT N
ability NN N
of IN N
regeneration NN N
. . N

If IN N
this DT N
ability NN N
is VBZ N
exhausted VBN N
, , N
the DT N
protective JJ N
effect NN N
of IN N
Esberitox NNP N
can MD N
act VB N
no DT N
longer JJR N
. . N

Therefore VB N
the DT N
essential JJ N
factor NN N
seems VBZ N
to TO N
be VB N
the DT N
duration NN N
of IN N
exposure NN N
to TO N
the DT N
noxa NN N
. . N

Esberitox NNP N
was VBD N
effective JJ N
in IN N
case NN N
of IN N
a DT N
short JJ N
toxicity NN N
, , N
it PRP N
was VBD N
ineffective JJ N
in IN N
case NN N
of IN N
prolonged JJ N
toxicity NN N
, , N
if IN N
the DT N
treatment NN N
continuity NN N
( ( N
noxa JJ N
) ) N
was VBD N
not RB N
broken VBN N
up RP N
by IN N
some DT N
regeneration NN N
intervals NNS N
. . N

The DT N
radiotherapy NN i
studied VBN N
in IN N
this DT N
trial NN N
had VBD N
a DT N
duration NN N
of IN N
50 CD N
days NNS N
, , N
and CC N
its PRP$ N
effect NN N
was VBD N
that IN N
of IN N
a DT N
longterm JJ N
injury NN N
. . N

-DOCSTART- -X- O O

Visit-to-visit NNP N
blood NN o
pressure NN o
variability NN o
in IN N
the DT N
European NNP N
Lacidipine NNP N
Study NNP N
on IN N
Atherosclerosis NNP N
: : N
methodological JJ N
aspects NNS N
and CC N
effects NNS N
of IN N
antihypertensive JJ i
treatment NN i
. . i

BACKGROUND NNP N
Recent NNP N
studies NNS N
have VBP N
reported VBN N
that IN N
in IN N
patients NNS p
under IN p
antihypertensive JJ p
treatment NN p
visit-to-visit NN p
( ( p
or CC p
long-term JJ p
) ) p
variability NN o
of IN o
clinic JJ o
BP NNP o
within IN N
a DT N
given VBN N
patient NN N
has VBZ N
an DT N
independent JJ N
prognostic JJ N
significance NN N
. . N

Partly RB N
based VBN N
on IN N
between-patient JJ N
dispersion NN N
of IN N
BP NNP N
values NNS N
during IN N
treatment NN N
( ( N
interindividual JJ N
variability NN N
) ) N
it PRP N
has VBZ N
also RB N
been VBN N
reported VBN N
that IN N
long-term JJ o
clinic JJ o
BP NNP o
variability NN o
is VBZ N
greater JJR N
for IN N
?-blocker JJR i
than IN N
for IN i
calcium NN i
antagonist NN i
and CC N
other JJ N
types NNS N
of IN N
treatment NN N
. . N

GOALS NNP N
To TO N
measure VB o
visit-to-visit JJ o
intraindividual JJ o
variations NNS o
of IN N
both DT N
clinic JJ N
and CC N
24-h JJ N
mean NN N
BP NNP N
in IN N
the DT p
hypertensive JJ p
patients NNS p
of IN p
the DT p
European NNP p
Lacidipine NNP p
Study NNP p
on IN p
Atherosclerosis NNP p
( ( p
ELSA NNP p
) ) p
trial NN p
treated VBD p
for IN p
4 CD p
years NNS p
with IN p
either DT i
atenolol NN i
or CC i
lacidipine NN i
, , i
and CC N
to TO N
check VB N
whether IN N
interindividual JJ N
clinic NN N
and CC N
24-h JJ o
BP NNP o
variabilities NNS o
during IN N
treatment NN N
can MD N
really RB N
be VB N
considered VBN N
a DT N
surrogate NN N
of IN N
intraindividual JJ N
variabilities NNS N
in IN N
exploring VBG N
differences NNS N
between IN i
?-blocker NN i
and CC i
calcium NN i
antagonist NN i
treatments NNS i
. . i

METHODS NNP o
Long-term JJ o
intraindividual JJ o
BP NNP o
variability NN o
was VBD o
defined VBN N
as IN N
the DT o
coefficient NN o
of IN o
variation NN o
of IN o
the DT o
average JJ o
systolic JJ o
or CC o
diastolic JJ o
values NNS o
of IN o
clinic JJ o
and CC o
24-h JJ o
BP NNP o
measured VBD o
at IN N
each DT N
visit NN N
throughout IN N
the DT N
treatment NN N
period NN p
. . p

Patients NNS p
in IN p
whom WP p
at IN p
least JJS p
seven CD p
clinic JJ p
( ( p
6-month JJ p
intervals NNS p
) ) p
or CC p
at IN p
least JJS p
three CD p
( ( p
yearly JJ p
intervals NNS p
) ) p
24-h JJ p
values NNS p
were VBD p
available JJ p
from IN p
the DT p
end NN p
of IN p
the DT p
drug NN p
titration NN p
phase NN p
to TO p
the DT p
end NN p
of IN p
the DT p
study NN p
were VBD p
considered VBN p
. . p

RESULTS JJ o
Visit-to-visit JJ o
24-h JJ o
SBP/DBP NNP o
variabilities NNS o
were VBD o
20-25 CD N
% NN N
smaller JJR N
than IN N
, , N
and CC N
loosely RB N
correlated VBN N
with IN o
clinic JJ o
BP NNP o
variability NN o
( ( o
r NN N
( ( N
2 CD N
) ) N
< FW N
0.022 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
very RB N
limited JJ N
relationship NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
< FW o
0.026 CD o
) ) o
between IN o
visit-to-visit NN o
and CC o
within IN o
24-h JJ o
ambulatory NN o
BP NNP o
variabilities NNS o
, , o
the DT o
latter JJ o
being VBG N
two CD N
to TO N
three CD N
times NNS N
greater JJR N
than IN N
the DT N
former JJ N
. . o

Visit-to-visit JJ o
intraindividual JJ o
clinic NN o
SBP NNP o
variability NN o
was VBD o
only RB o
slightly RB N
lower JJR N
on IN N
calcium NN N
antagonist NN N
than IN N
on IN N
?-blocker JJ N
treatment NN N
but CC N
little JJ N
or CC N
no DT N
between-treatment JJ N
difference NN N
was VBD N
found VBN N
for IN o
visit-to-visit NN o
clinic NN o
DBP NNP o
and CC o
ambulatory JJ o
SBP/DBP NNP o
particularly RB o
in IN N
patients NNS N
under IN N
monotherapy NN N
throughout IN N
the DT N
study NN N
. . N

Interindividual NNP o
BP NNP o
variability NN o
was VBD o
markedly RB o
greater JJR N
than IN N
the DT N
intra-individiual JJ N
one CD N
of IN N
which WDT N
it PRP N
did VBD N
not RB N
precisely RB N
reflect VB N
the DT N
treatment-induced JJ N
changes NNS N
. . N

CONCLUSION NN N
In IN p
mild-to-moderate JJ p
hypertensive JJ o
patients NNS o
, , o
visit-to-visit JJ o
BP NNP o
variability NN o
does VBZ o
not RB o
differ VB o
substantially RB i
between IN i
?-blocker NN i
and CC i
calcium NN i
antagonist NN i
treatment NN i
. . i

Major JJ N
discrepancies NNS N
exist VBP N
between IN N
visit-to-visit NN N
BP NNP N
variability NN N
as IN N
quantified VBN N
by IN N
24-h JJ N
vs. FW N
clinic JJ N
BP NNP N
, , N
making VBG N
investigation NN N
of IN N
which WDT N
of IN N
these DT N
indices NNS N
is VBZ N
clinically RB N
more RBR N
relevant JJ N
important JJ N
. . N

Interindividual JJ o
BP NNP o
variability NN o
during IN N
treatment NN N
shows NNS N
marked VBD N
quantitative JJ N
differences NNS N
with IN N
intraindividual JJ N
BP NNP N
variability NN N
questioning VBG N
whether IN N
its PRP$ N
use NN N
can MD N
accurately RB N
reflect VB N
individual JJ N
BP NNP N
variations NNS N
from IN N
one CD N
visit NN N
to TO N
another DT N
. . N

-DOCSTART- -X- O O

Azelnidipine NNP i
and CC N
amlodipine VB i
anti-coronary JJ N
atherosclerosis NN N
trial NN N
in IN N
hypertensive JJ p
patients NNS p
undergoing VBG p
coronary JJ p
intervention NN p
by IN p
serial JJ p
volumetric JJ p
intravascular NN p
ultrasound NN p
analysis NN p
in IN p
Juntendo NNP p
university NN p
( ( p
ALPS-J NNP p
) ) p
. . N

PURPOSE NNP N
Many JJ N
trials NNS N
have VBP N
shown VBN N
that IN N
calcium NN N
channel NN N
blockers NNS N
( ( N
CCBs NNP N
) ) N
can MD N
reduce VB N
the DT N
cardiovascular NN o
( ( o
CV NNP o
) ) o
events NNS o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

The DT N
mechanisms NN N
of IN N
this DT N
effect NN N
could MD N
be VB N
associated VBN N
with IN N
plaque JJ N
regression NN N
due JJ N
to TO N
the DT N
anti-atherosclerotic JJ N
properties NNS N
of IN N
CCBs NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
CCB NNP N
on IN N
volumetric JJ N
quantitative JJ N
changes NNS N
of IN N
coronary JJ N
plaques NNS N
accessed VBN N
by IN N
intravascular JJ N
ultrasound NN N
( ( N
IVUS NNP N
) ) N
. . N

To TO N
confirm VB N
this DT N
hypothesis NN N
, , N
a DT N
multicenter NN N
randomized VBN N
trial NN N
of IN N
CCBs NNP N
treatment NN N
with IN N
azelnidipine NN i
or CC N
amlodipine NN i
will MD N
be VB N
conducted VBN N
in IN N
hypertensive JJ p
CAD NNP p
patients NNS p
undergoing VBG p
elective JJ p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNPS p
who WP p
have VBP p
hypertension NN p
and CC p
are VBP p
scheduled VBN p
for IN p
PCI NNP p
will MD p
be VB p
enrolled VBN p
. . p

Subjects NNS N
will MD N
be VB N
randomized VBN N
to TO N
azelnidipine VB i
or CC N
amlodipine VB i
and CC N
observed VB N
for IN N
48 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoint NN N
will MD N
be VB N
the DT N
percent NN o
change NN o
of IN o
coronary JJ o
plaque NN o
volume NN o
. . o

The DT N
secondary JJ N
endpoint NN N
will MD N
include VB N
inflammatory JJ o
markers NNS o
, , o
antioxidant JJ o
activity NN o
, , o
and CC o
incidence NN o
of IN o
composite JJ o
cardiovascular JJ o
events NNS o
. . o

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
will MD N
investigate VB N
the DT N
improvement NN N
of IN N
coronary JJ o
plaque NN o
with IN N
IVUS NNP N
by IN N
treatment NN N
with IN N
two CD N
dihydropyridine NN N
CCBs NNP N
in IN N
hypertensive JJ p
patients NNS p
undergoing VBG p
elective JJ p
PCI NNP p
. . p

This DT N
result NN N
will MD N
lead VB N
to TO N
the DT N
discovery NN N
of IN N
more RBR N
effective JJ N
drug NN N
therapy NN N
for IN N
inhibition NN N
of IN N
coronary JJ o
events NNS o
. . o

-DOCSTART- -X- O O

[ NNP p
Medical NNP p
safety NN p
and CC p
staff NN p
mental JJ p
health NN p
] NNP p
. . N

Improvement NNP N
in IN N
patient JJ N
safety NN N
is VBZ N
a DT N
high-priority JJ N
issue NN N
of IN N
great JJ N
social JJ N
import NN N
. . N

Several JJ N
studies NNS N
have VBP N
reported VBN N
that IN N
most JJS N
adverse JJ N
events NNS N
are VBP N
due JJ N
to TO N
errors NNS N
of IN N
hospital JJ N
staff NN N
, , N
and CC N
emphasized VBD N
the DT N
necessity NN N
of IN N
promoting VBG N
countermeasures NNS N
against IN N
medical JJ N
errors NNS N
. . N

Root NNP N
cause NN N
analysis NN N
( ( N
RCA NNP N
) ) N
has VBZ N
been VBN N
implemented VBN N
to TO N
prevent VB N
such JJ N
errors NNS N
. . N

However RB N
, , N
the DT N
retrospective NN N
and CC N
qualitative JJ N
nature NN N
of IN N
RCA NNP N
is VBZ N
a DT N
limitation NN N
in IN N
scientific JJ N
analyses NNS N
examining VBG N
causal JJ N
relationships NNS N
. . N

We PRP N
showed VBD N
that IN N
prospective JJ N
design NN N
path NN N
analysis NN N
using VBG N
structural JJ i
equation NN i
modeling NN i
( ( i
SEM NNP i
) ) i
model NN N
for IN N
both DT N
direct JJ N
and CC N
indirect JJ N
effects NNS N
enabled VBD N
statistical JJ N
exploration NN N
of IN N
root NN N
causes NNS N
and CC N
estimation NN N
of IN N
their PRP$ N
impact NN N
on IN N
the DT N
outcome NN N
. . N

Our PRP$ N
findings NNS N
suggested VBD N
such JJ N
analysis NN N
to TO N
be VB N
useful JJ N
in IN N
devising VBG N
countermeasures NNS N
against IN N
medical JJ N
errors NNS N
. . N

The DT N
SEM NNP N
model NN N
constructed VBN N
in IN N
this DT N
study NN N
suggested VBD N
that IN N
one CD N
of IN N
the DT N
potential JJ N
root NN N
causes NNS N
was VBD N
sleep JJ o
disturbance NN o
. . o

We PRP N
conducted VBD N
a DT N
randomized VBN N
crossover NN N
study NN N
whether IN N
or CC N
not RB N
brief JJ N
bright JJ N
light NN N
( ( i
BL NNP i
) ) i
exposure NN N
on IN N
workday JJ N
mornings NNS N
can MD N
improve VB N
health NN N
, , N
performance NN N
and CC N
safety NN N
in IN N
nurses NNS p
with IN p
rapidly RB p
rotating VBG p
shifts NNS p
. . p

Significant JJ N
improvements NNS N
were VBD N
noted VBN N
in IN N
the DT N
BL NNP N
periods NNS N
compared VBN N
with IN N
the DT N
non-BL JJ N
periods NNS N
for IN N
self-assessed JJ o
sleepiness NN o
at IN N
10 CD N
: : N
00 CD N
on IN N
day-shift JJ N
days NNS N
, , N
self-assessment NN o
of IN o
night NN o
sleep NN o
for IN o
day-shift JJ o
days NNS o
and CC o
for IN o
fatigue NN o
. . o

Mean NNP o
response NN o
time NN o
evaluated VBN N
using VBG N
the DT N
psychomotor NN N
vigilance NN N
task NN N
test NN N
( ( N
PVT NNP N
) ) N
showed VBD N
significant JJ N
improvement NN N
in IN N
the DT N
BL NNP N
periods NNS N
compared VBN N
with IN N
the DT N
non-BL JJ N
periods NNS N
. . N

The DT N
frequency NN o
of IN o
perceived JJ o
adverse JJ o
events NNS o
and CC o
near JJ o
misses NNS o
was VBD N
also RB N
lower JJR N
in IN N
the DT N
BL NNP N
than IN N
in IN N
the DT N
non-BL JJ N
periods NNS N
, , N
but CC N
not RB N
significantly RB N
so RB N
, , N
possibly RB N
indicating VBG N
that IN N
the DT N
one-month JJ N
observation NN N
period NN N
was VBD N
too RB N
short JJ N
to TO N
achieve VB N
any DT N
significant JJ N
success NN N
. . N

Despite IN N
our PRP$ N
study NN N
's POS N
limitations NNS N
, , N
we PRP N
have VBP N
effectively RB N
demonstrated VBN N
the DT N
potential NN N
for IN N
preventing VBG N
medical JJ N
error NN N
risk NN N
among IN N
night-shift JJ p
workers NNS p
. . p

-DOCSTART- -X- O O

Factors NNS N
that WDT N
influence NN N
cancer NN p
patients NNS p
' POS p
anxiety NN o
following VBG p
a DT p
medical JJ p
consultation NN p
: : p
impact NN N
of IN N
a DT N
communication NN i
skills VBZ i
training VBG i
programme NN i
for IN N
physicians NNS N
. . N

BACKGROUND NNP N
No NNP N
study NN N
has VBZ N
yet RB N
assessed VBN N
the DT N
impact NN N
of IN N
physicians NNS N
' POS N
skills NNS N
acquisition NN N
after IN N
a DT N
communication NN i
skills VBZ i
training VBG i
programme NN i
on IN N
the DT N
evolution NN N
of IN N
patients NNS p
' POS p
anxiety NN N
following VBG N
a DT N
medical JJ N
consultation NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
impact NN N
, , N
on IN N
patients NNS N
' POS N
anxiety NN N
, , N
of IN N
a DT N
basic JJ i
communication NN i
skills NNS i
training VBG i
programme NN i
( ( i
BT NNP i
) ) i
and CC N
the DT N
same JJ N
programme NN N
consolidated VBN N
by IN N
consolidation NN i
workshops NNS i
( ( N
CW NNP N
) ) N
, , N
and CC N
to TO N
investigate VB N
physicians NNS N
' POS N
communication NN N
variables NNS N
associated VBN N
with IN N
patients NNS N
' POS N
anxiety NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Physicians NNP p
, , p
after IN p
attending VBG p
the DT p
BT NNP i
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
CW NNP i
or CC N
to TO N
a DT N
waiting VBG i
list NN i
. . i

The DT N
control NN N
group NN N
was VBD N
not RB N
a DT N
non-intervention JJ N
group NN N
. . N

Consultations NNS N
with IN N
a DT N
cancer NN N
patient NN N
were VBD N
recorded VBN N
. . N

Patients NNS N
' POS N
anxiety NN o
was VBD N
assessed VBN N
with IN N
the DT N
State NNP o
Trait NNP o
Anxiety NNP o
Inventory NNP o
before IN N
and CC N
after IN N
a DT N
consultation NN N
. . N

Communication NNP o
skills NNS o
were VBD N
analysed VBN N
according VBG N
to TO N
the DT N
Cancer NNP N
Research NNP N
Campaign NNP N
Workshop NNP N
Evaluation NNP N
Manual NNP N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
change NN N
over IN N
time NN o
and CC N
between IN N
groups NNS N
was VBD N
observed VBN N
. . N

Mixed-effects NNS N
modelling VBG N
showed VBD N
that IN N
a DT N
decrease NN N
in IN N
patients NNS o
' POS o
anxiety NN o
was VBD N
linked VBN N
with IN N
screening JJ N
questions NNS N
( ( N
P NNP N
= NNP N
0.045 CD N
) ) N
, , N
physicians NNS o
' POS o
satisfaction NN o
about IN N
support NN N
given VBN N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
and CC N
with IN N
patients NNS N
' POS N
distress NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

An DT N
increase NN N
in IN N
anxiety NN o
was VBD N
linked VBN N
with IN N
breaking VBG N
bad JJ N
news NN N
( ( N
P NNP N
= NNP N
0.050 CD N
) ) N
and CC N
with IN N
supportive JJ N
skills NNS N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

No DT N
impact NN N
of IN N
the DT N
training NN N
programme NN N
was VBD N
observed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
the DT N
influence NN N
of IN N
some DT N
communication NN N
skills NNS N
on IN N
the DT N
evolution NN N
of IN N
patients NNS o
' POS o
anxiety NN o
. . o

Physicians NNS p
should MD N
be VB N
aware JJ N
of IN N
these DT N
influences NNS N
. . N

-DOCSTART- -X- O O

Heart NNP o
rate NN o
variability NN o
and CC N
QT NNP o
dispersion NN o
in IN N
patients NNS p
with IN p
subclinical JJ p
hypothyroidism NN p
. . p

UNLABELLED IN N
The DT N
effect NN N
of IN N
subclinical JJ p
hypothyroidism NN p
( ( p
SH NNP p
) ) p
on IN N
cardiovascular JJ N
autonomic JJ N
function NN N
and CC N
ventricular JJ N
repolarization NN N
has VBZ N
not RB N
been VBN N
yet RB N
elucidated VBN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
dispersion NN N
of IN N
QT NNP N
interval NN N
, , N
i.e NN N
. . N

an DT N
index NN N
of IN N
inhomogeneity NN N
of IN N
repolarization NN N
, , N
and CC N
heart NN N
rate NN N
variability NN N
( ( N
HRV NNP N
) ) N
, , N
i.e RB N
. . N

a DT N
measure NN N
of IN N
cardiac JJ N
autonomic JJ N
modulation NN N
, , N
in IN N
SH NNP p
patients NNS p
. . p

METHODS NNP N
The DT N
study NN N
included VBD N
42 CD p
patients NNS p
( ( p
29 CD p
women NNS p
and CC p
13 CD p
men NNS p
; : p
mean JJ p
age NN p
53.2+/-14.2 JJ p
years NNS p
; : p
body NN p
surface JJ p
area NN p
1.76+/-0.14 JJ p
m2 NN p
) ) p
with IN p
SH NNP p
, , p
as IN p
judged VBN p
by IN p
elevated JJ p
serum NN p
TSH NNP p
levels NNS p
( ( p
> $ p
3.6 CD p
mIU/l NN p
; : p
range NN p
, , p
3.8-12.0 JJ p
) ) p
and CC p
normal JJ p
free JJ p
thyroid NN p
hormones NNS p
( ( p
FT4 NNP p
and CC p
FT3 NNP p
) ) p
and CC p
30 CD p
euthyroid JJ p
volunteer NN p
. . p

Subjects NNS p
with IN p
cardiac JJ p
, , p
metabolic JJ p
, , p
neurological JJ p
disease NN p
or CC p
any DT p
other JJ p
systemic JJ p
disease NN p
that WDT p
could MD p
affect VB p
autonomic JJ p
activity NN p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
. . p

Patients NNS p
with IN p
SH NNP p
and CC N
control VB N
subjects NNS N
underwent VB N
a DT N
full JJ N
history NN N
, , N
physical JJ N
examination NN N
, , N
standard JJ N
12-lead JJ i
ECG NNP i
, , i
and CC i
24-h JJ i
ambulatory NN i
ECG NNP i
monitoring NN i
. . i

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
treatment NN N
with IN N
L-thyroxine NNP i
on IN N
QT NNP N
dispersion NN N
and CC N
HRV NNP N
, , N
15 CD N
patients NNS N
with IN N
SH NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
therapy NN N
with IN N
L-thyroxine NNP i
. . i

All PDT N
the DT N
subjects NNS N
were VBD N
evaluated VBN N
at IN N
enrolment NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Patients NNPS p
with IN p
SH NNP p
showed VBD N
higher JJR N
QT NNP o
dispersion NN o
and CC N
lower JJR o
HRV NNP o
measures NNS o
than IN N
healthy JJ N
controls NNS N
( ( N
P NNP N
< VBZ N
0.01 CD N
for IN N
all DT N
) ) N
. . N

In IN N
SH NNP N
patients NNS N
, , N
the DT N
standard JJ o
deviation NN o
of IN o
N-Ns NNP o
( ( o
SDNN NNP o
) ) o
was VBD N
negatively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=-0.42 JJ N
, , N
P=0.006 NNP N
) ) N
, , N
while IN N
low JJ o
frequency NN o
( ( o
LF NNP o
) ) o
/high VBP o
frequency NN o
( ( o
HF NNP o
) ) o
ratio NN o
was VBD N
positively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=0.42 NN N
, , N
P=0.006 NNP N
) ) N
. . N

Moreover RB N
, , N
in IN N
SH NNP p
patients NNS p
both DT N
QT NNP o
dispersion NN o
and CC o
QTc NNP o
dispersion NN o
were VBD N
positively RB N
related VBN N
to TO N
TSH NNP N
( ( N
r=0.64 NN N
and CC N
r=0.63 NN N
, , N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
L-tiroxine NNP i
exhibited VBD N
a DT N
reduction NN N
of IN N
QT NNP o
dispersion NN o
and CC N
an DT N
increase NN N
of IN N
HRV NNP o
parameters NNS o
. . o

CONCLUSION VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
demonstrated VBD N
that IN N
SH NNP N
can MD N
alter VB N
autonomic JJ N
modulation NN N
of IN N
heart NN o
rate NN o
and CC N
cause NN N
increased VBD N
inhomogeneity NN N
of IN N
ventricular JJ N
recovery NN N
times NNS N
. . N

Accordingly RB N
, , N
early JJ N
L-thyroxine JJ i
treatment NN N
may MD N
be VB N
advised VBN N
not RB N
only RB N
to TO N
prevent VB N
progression NN N
to TO N
overt VB N
hypothyroidism NN N
but CC N
also RB N
to TO N
improve VB N
abnormal JJ N
cardiac JJ N
autonomic JJ N
function NN N
and CC N
ventricular JJ N
repolarization NN N
inhomogeneity NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ p
cough NN o
during IN p
general JJ p
anesthesia JJ p
induction NN p
: : p
a DT N
double-blinded JJ N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
suppressive JJ N
effect NN N
of IN N
intravenous JJ N
dezocine NN i
on IN N
fentanyl-induced JJ N
cough NN o
during IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
A NNP N
total NN p
of IN p
120 CD p
patients NNS p
, , p
American NNP p
Society NNP p
of IN p
Anesthesiologists NNP p
( ( p
ASA NNP p
) ) p
physical JJ p
status NN p
I-II NNP p
, , p
were VBD p
randomized VBN p
into IN p
two CD p
equally RB p
sized JJ p
groups NNS p
( ( p
n JJ p
= NNP p
60 CD p
) ) p
. . p

These DT N
two CD N
groups NNS N
were VBD N
given VBN N
either RB N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
or CC i
a DT i
matching JJ i
placebo NN i
( ( N
equal JJ N
volume NN N
of IN N
0.9 CD N
% NN N
saline NN N
) ) N
10 CD N
min NN N
before IN N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
. . N

Patients NNS N
were VBD N
induced VBN N
with IN N
midazolam JJ i
0.1 CD i
mg/kg NN i
, , i
fentanyl VBP i
5 CD i
?g/kg NN i
, , i
propofol JJ i
1-1.5 JJ i
mg/kg NN i
, , i
and CC i
suxamethonium NN i
1.5 CD N
mg/kg NN N
. . N

The DT N
injection NN N
time NN N
of IN N
fentanyl NN N
was VBD N
less JJR N
than IN N
2 CD N
s NNS N
in IN N
all DT N
patients NNS N
. . N

The DT N
occurrence NN N
of IN o
cough NN o
was VBD N
recorded VBN N
2 CD N
min NN N
after IN N
fentanyl JJ N
bolus NN N
. . N

RESULTS NNP p
No NNP p
patient NN p
in IN p
the DT p
dezocine NN p
group NN p
had VBD o
cough VBN o
, , o
and CC p
42 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
had VBD o
cough NN o
. . o

This DT N
difference NN N
was VBD N
statistically RB N
different JJ N
between IN N
these DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

CONCLUSION NNP N
These DT N
results NNS N
demonstrate VBP N
that IN N
intravenous JJ i
dezocine NN i
0.1 CD N
mg/kg NN N
10 CD N
min NN N
prior RB N
to TO N
induction NN N
was VBD N
effective JJ N
in IN N
suppressing VBG p
fentanyl-induced JJ o
cough NN o
in IN p
our PRP$ p
patients NNS p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
inhaled JJ N
heparin NN i
on IN N
adenosine-induced JJ p
bronchial JJ p
hyperreactivity NN p
. . p

Glycosaminoglycan JJ i
heparin NN i
possesses VBZ N
multiple JJ N
noncoagulant JJ N
properties NNS N
including VBG N
antiinflammatory JJ N
actions NNS N
. . N

We PRP N
have VBP N
previously RB N
shown VBN N
that IN N
heparin NN i
attenuates VBZ N
the DT N
methacholine-induced JJ N
bronchoconstriction NN N
in IN N
humans NNS p
. . p

In IN N
contrast NN N
to TO N
methacholine VB N
, , N
a DT N
stimulus NN N
that WDT N
induces VBZ N
airway RP N
constriction NN N
mainly RB N
by IN N
direct JJ N
stimulation NN N
of IN N
airway JJ N
smooth JJ N
muscle NN N
cells NNS N
, , N
adenosine JJ N
airway RB N
responsiveness JJ N
reflects VBZ N
indirectly RB N
induced VBN N
airway RP N
narrowing VBG N
via IN N
inflammatory JJ N
mediators NNS N
or CC N
neural JJ N
reflex JJ N
mechanisms NNS N
. . N

Whether NNP N
heparin NN i
modulates VBZ N
bronchial JJ N
hyperreactivity NN N
induced VBN N
by IN N
adenosine NN N
, , N
is VBZ N
not RB N
well RB N
known VBN N
. . N

We PRP N
investigated VBD N
the DT N
effect NN N
of IN N
inhaled JJ i
heparin NN i
on IN N
adenosine-induced JJ N
bronchoconstriction NN N
and CC N
compared VBN N
the DT N
inhibitory JJ N
role NN N
of IN N
heparin NN i
on IN N
the DT N
adenosine NN N
challenge NN N
test NN N
with IN N
that DT N
on IN N
the DT N
methacholine NN N
challenge NN N
test NN N
. . N

Fifteen JJ p
subjects NNS p
( ( p
7 CD p
males NNS p
, , p
8 CD p
females NNS p
) ) p
with IN p
mild JJ p
asthma NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Bronchial JJ N
provocation NN N
tests NNS N
were VBD N
performed VBN N
in IN N
a DT N
single-blind NN N
, , N
crossover NN N
, , N
randomized VBN N
order NN N
, , N
and CC N
repeated VBD N
45 CD N
minutes NNS N
after IN N
placebo NN i
or CC N
aerosolized VBN i
heparin JJ i
inhalation NN i
( ( N
1,000 CD N
U/kg NNP N
) ) N
. . N

The DT N
heparin NN i
increased VBD N
the DT N
geometric JJ o
mean NN o
log NN o
methacholine NN o
PD20 NNP o
value NN o
from IN N
0.47 CD N
+/- JJ N
0.16 CD N
( ( N
2.95 CD N
mg/ml NN N
) ) N
to TO N
0.96 CD N
+/- JJ N
0.10 CD N
( ( N
8.91 CD N
mg/ml NN N
) ) N
, , N
( ( N
P NNP N
< NNP N
0.0009 CD N
) ) N
in IN N
15 CD N
patients NNS N
and CC N
the DT N
geometric JJ o
mean NN o
log NN o
adenosine NN o
PD20 NNP o
values VBZ o
from IN N
1.59 CD N
+/- JJ N
0.23 CD N
( ( N
38.9 CD N
mg/ml NN N
) ) N
to TO N
1.98 CD N
+/- JJ N
0.14 CD N
( ( N
97.7 CD N
mg/ml NN N
) ) N
( ( N
NS NNP N
) ) N
in IN N
7 CD N
patients NNS N
whose WP$ N
baseline JJ N
adenosine NN N
PD20 NNP N
levels NNS N
were VBD N
less JJR N
than IN N
200 CD N
mg/ml NN N
. . N

The DT N
degree NN o
of IN o
protection NN o
by IN N
heparin NN i
against IN N
adenosine-induced JJ N
bronchoconstriction NN N
was VBD N
not RB N
correlated VBN N
with IN N
that DT N
against IN N
methacholine-induced JJ N
bronchoconstriction NN N
( ( N
r JJ N
= NN N
0.60 CD N
, , N
NS NNP N
) ) N
. . N

The DT N
data NN N
suggest NN N
that WDT N
inhaled VBD N
heparin NN i
may MD N
have VB N
an DT N
inhibitory JJ N
effect NN N
on IN N
the DT N
methacholine NN N
bronchial JJ N
challenge NN N
, , N
and CC N
thus RB N
, , N
most JJS N
likely JJ N
directs VBZ N
its PRP$ N
effect NN N
against IN N
smooth JJ N
muscle NN N
. . N

Heparin NNP i
caused VBD N
less JJR N
attenuation NN N
of IN N
a DT N
challenge NN N
with IN N
adenosine NN N
and CC N
probably RB N
does VBZ N
not RB N
affect VB N
mast NN N
cell NN N
degranulation NN N
. . N

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
six CD N
epoetin JJ i
alfa NN i
dosing VBG N
regimens NNS N
in IN N
anemic JJ p
critically RB p
ill JJ p
patients NNS p
without IN p
acute JJ p
blood NN p
loss NN p
. . p

OBJECTIVE UH N
To TO N
describe VB N
the DT N
pharmacokinetic JJ N
profiles NNS N
of IN N
six CD N
different JJ N
dosing VBG N
regimens NNS N
for IN N
epoetin NN i
alfa NN i
, , N
and CC N
whether IN N
more JJR N
rapid JJ N
and CC N
robust JJ N
reticulocytosis NN N
can MD N
be VB N
elicited VBN N
with IN N
more RBR N
frequent JJ N
administration NN N
of IN N
epoetin JJ i
alfa NN i
in IN N
anemic JJ p
critically RB p
ill JJ p
patients NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
open-label NN N
, , N
multicenter NN N
, , N
28-day JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Ten CD p
centers NNS p
in IN p
the DT p
United NNP p
States NNPS p
. . p

PATIENTS VB N
Adult NNP p
( ( p
age NN p
> VBN p
or=18 CD p
years NNS p
) ) p
critically RB p
ill JJ p
patients NNS p
with IN p
hemoglobin JJ p
< NNP p
or=12 NN p
g/dL NN p
, , p
expected VBN p
hospitalization NN p
of IN p
> NNP p
or=7 NNP p
days NNS p
, , p
with IN p
no DT p
ongoing VBG p
acute RB p
blood NN p
loss NN p
. . p

INTERVENTIONS NNP N
One CD N
of IN N
six CD i
dosing VBG i
epoetin NN i
alfa NN i
regimens VBZ i
for IN N
15 CD N
days NNS N
, , N
as IN N
follows VBZ N
: : N
40,000 CD i
IU NNP i
once RB i
weekly RB i
, , N
subcutaneously RB N
( ( N
group NN N
A NNP N
) ) N
or CC N
intravenously RB N
( ( N
IV NNP N
) ) N
( ( N
group NN N
B NNP N
) ) N
; : N
15,000 CD i
IU NNP i
every DT i
other JJ i
day NN i
, , i
subcutaneously RB i
( ( N
group NN N
C NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
D NNP N
) ) N
; : N
or CC N
40,000 CD i
IU NNP i
day NN i
1 CD N
and CC N
3 CD N
, , N
subcutaneously RB i
( ( N
group NN N
E NNP N
) ) N
or CC N
IV NNP N
( ( N
group NN N
F NNP N
) ) N
, , N
followed VBN N
by IN N
15,000 CD N
IU NNP N
once RB N
every DT N
other JJ N
day NN N
on IN N
[ NN N
corrected VBN N
] JJ N
days NNS N
5-15 JJ N
[ NNP N
corrected VBD N
] NN N
MEASUREMENTS NNP N
Serum NNP o
erythropoietin NN o
concentration NN o
, , o
absolute JJ o
reticulocyte NN o
count NN o
, , o
and CC o
adverse JJ o
events NNS o
. . o

MAIN NNP N
RESULTS NNP N
Of IN N
the DT N
60 CD N
patients NNS N
who WP N
were VBD N
enrolled VBN N
( ( N
60 CD N
% NN N
men NNS N
, , N
mean JJ N
age NN N
53 CD N
years NNS N
, , N
mean VBP N
Acute NNP N
Physiology NNP N
and CC N
Chronic NNP N
Health NNP N
Evaluation NNP N
II NNP N
score NN N
, , N
19.5 CD N
) ) N
, , N
30 CD N
were VBD N
evaluable JJ N
for IN N
both DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
( ( N
50 CD N
% NN N
) ) N
. . N

Erythropoietin NNP o
exposure NN o
was VBD N
approximately RB N
ten JJ N
times NNS N
greater JJR N
for IN N
IV NNP N
dosing VBG N
than IN N
for IN N
subcutaneous JJ i
dosing NN i
. . i

Mean NNP o
absolute JJ o
reticulocyte NN o
count NN o
peaked VBD N
at IN N
day NN N
11 CD N
or CC N
15 CD N
in IN N
each DT N
group NN N
and CC N
appeared VBD N
to TO N
be VB N
greater JJR N
for IN N
subcutaneous JJ N
dosing NN i
( ( N
mean JJ N
peak NN N
response NN N
149-169 JJ N
x NN N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
compared VBN N
with IN N
IV NNP N
dosing VBG i
( ( N
mean JJ N
peak NN N
response NN N
138-147 JJ N
x NN N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
at IN N
most JJS N
visits NNS N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
adverse JJ o
events NNS o
were VBD N
pyrexia NNS o
( ( N
18 CD N
% NN N
) ) N
, , N
hypokalemia NN o
( ( N
15 CD N
% NN N
) ) N
, , N
and CC N
hypophosphatemia NN o
( ( N
15 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
of IN N
anemic JJ N
critically NN N
ill JJ N
patients NNS N
treated VBN N
with IN N
epoetin JJ i
alfa NN i
, , N
all DT N
dosing VBG N
regimens NNS N
were VBD N
well RB N
tolerated VBN o
and CC N
appeared VBN N
to TO N
effect NN N
reticulocytosis NN o
, , N
with IN N
a DT N
peak NN N
at IN N
day NN N
11 CD N
or CC N
15 CD N
in IN N
most JJS N
patients NNS N
. . N

The DT N
pharmacokinetics NNS N
of IN N
epoetin JJ i
alfa NN i
did VBD N
not RB N
predict VB N
pharmacodynamic JJ o
response NN o
in IN N
anemic JJ N
critically RB N
ill JJ N
patients NNS N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
web-based JJ i
tailored JJ i
smoking NN i
cessation NN i
advice NN p
reports NNS p
( ( N
iQuit NN N
) ) N
: : N
a DT N
randomized JJ N
trial NN N
. . N

AIMS NNP N
To TO N
determine VB N
whether IN N
web-based JJ N
tailored JJ N
cessation NN N
advice NN N
, , N
based VBN N
on IN N
social JJ N
cognitive JJ N
theory NN N
and CC N
the DT N
perspectives NNS N
on IN N
change NN N
model NN N
, , N
was VBD N
more RBR N
effective JJ N
in IN N
aiding VBG N
a DT N
quit NN N
attempt NN N
than IN N
broadly RB N
similar JJ N
web-based JJ N
advice NN N
that WDT N
was VBD N
not RB N
tailored VBN N
. . N

DESIGN JJ N
Participants NNS p
were VBD p
allocated VBN p
randomly RB p
to TO p
one CD p
of IN p
two CD p
groups NNS p
, , N
to TO i
receive VB i
either CC i
a DT i
cessation NN i
advice NN i
report NN i
and CC i
progress JJ i
report NN i
that WDT i
were VBD i
tailored VBN i
to TO i
individual-level JJ i
characteristics NNS i
or CC i
a DT i
cessation NN i
advice NN i
report NN i
that WDT i
presented VBD i
standardized JJ i
( ( i
non-tailored JJ i
) ) i
content NN i
. . i

Tailoring NNP N
was VBD N
based VBN N
on IN N
smoking-related JJ N
beliefs NN N
, , N
personal JJ N
characteristics NNS N
and CC N
smoking NN N
patterns NNS N
, , N
self-efficacy NN N
and CC N
outcome JJ N
expectations NNS N
. . N

SETTING NN N
Participant JJ N
enrolment NN N
and CC N
baseline NN i
assessments NNS i
were VBD N
conducted VBN N
remotely RB N
online JJ N
via IN N
the DT N
study NN N
website NN N
, , N
with IN N
the DT N
advice NN N
reports NNS N
presented VBN N
by IN N
the DT N
same JJ N
website NN N
. . N

PARTICIPANTS JJ N
Participants NNS p
( ( p
n IN p
= NNP p
1758 CD p
) ) p
were VBD p
visitors NNS p
to TO p
the DT p
QUIT NNP p
website NN p
who WP p
were VBD p
based VBN p
in IN p
the DT p
United NNP p
Kingdom NNP p
, , p
aged VBD p
18 CD p
years NNS p
or CC p
over RB p
and CC p
who WP p
smoked VBD p
cigarettes NNS p
or CC p
hand-rolled JJ p
tobacco NN p
. . p

MEASUREMENTS NNP p
Follow-up JJ N
assessments NNS N
were VBD N
made VBN N
at IN N
6 CD N
months NNS N
by IN N
telephone NN N
interview NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
self-reported JJ o
3 CD o
months NNS o
prolonged VBN o
abstinence NN o
, , o
and CC o
secondary JJ N
outcomes NNS N
were VBD N
1 CD o
month NN o
prolonged VBD o
abstinence NN o
, , o
7-day JJ o
and CC o
24-hour JJ o
point NN o
prevalence NN o
abstinence NN o
. . o

FINDINGS IN o
The DT N
intervention NN p
group NN p
did VBD p
not RB N
differ VB N
from IN N
the DT N
control NN p
group NN p
on IN p
the DT N
primary JJ o
outcome NN o
( ( o
9.1 CD o
% NN N
versus IN N
9.3 CD N
% NN N
; : N
odds NNS N
ratio VBP N
= $ N
1.02 CD N
95 CD N
% NN N
confidence NN N
interval JJ N
0.73-1.42 NN N
) ) N
or CC N
on IN N
any DT N
of IN N
the DT o
secondary JJ o
outcomes NNS o
. . o

Intervention NN o
participants NNS p
gave VBD p
more RBR p
positive JJ N
evaluations NNS N
of IN N
the DT N
materials NNS p
than IN p
control NN p
participants NNS p
. . p

CONCLUSIONS VB p
A DT N
web-based JJ N
intervention NN N
that WDT N
tailored VBD N
content JJ N
according VBG N
to TO N
smoking-related JJ N
beliefs NN N
, , N
personal JJ N
characteristics NNS N
and CC N
smoking NN N
patterns NNS N
, , N
self-efficacy NN N
and CC N
outcome NN N
expectations NNS N
, , N
was VBD N
not RB N
more RBR N
effective JJ N
than IN N
web-based JJ N
materials NNS N
presenting VBG N
broadly RB N
similar JJ N
non-tailored JJ N
information NN N
. . N

-DOCSTART- -X- O O

On IN N
the DT N
search NN N
for IN N
the DT N
neurophysiological JJ p
manifestation NN p
of IN p
recollective JJ p
experience NN p
. . p

M.E NNP p
. . p

Smith NNP p
( ( p
1993 CD p
) ) p
obtained VBD p
event-related JJ p
brain NN p
potentials NNS p
( ( p
ERPs NNP p
) ) p
from IN N
subjects NNS p
performing VBG p
a DT p
recognition NN i
memory NN i
task NN i
using VBG p
remember NN p
( ( p
R NNP p
) ) p
and CC p
know $ p
( ( p
K NNP p
) ) p
judgments NNS p
, , N
and CC N
reported VBD N
observing VBG N
in IN N
the DT N
ERP NNP N
a DT N
neurophysiological JJ N
manifestation NN N
of IN N
recollective JJ N
experience NN N
as IN N
a DT N
difference NN N
between IN N
the DT N
positive JJ N
waveforms NNS N
elicited VBN N
by IN N
stimuli NNS N
that WDT N
yielded VBD N
R NNP N
and CC N
K NNP N
judgments NNS N
. . N

We PRP N
replicated VBD N
his PRP$ N
experiment NN N
and CC N
examined VBD N
the DT N
componential JJ N
structure NN N
of IN N
the DT N
R NNP N
> NNP N
K NNP N
effect NN N
in IN N
two CD N
ways NNS N
. . N

First NNP N
, , N
we PRP N
found VBD N
that IN N
correction NN N
for IN N
P300 NNP o
latency NN o
jitter NN o
eliminated VBD N
the DT N
effect NN N
reported VBN N
by IN N
Smith NNP N
. . N

Second NNP N
, , N
the DT N
application NN N
of IN N
principal JJ N
component JJ N
analysis NN N
indicated VBD N
that IN N
the DT N
positive JJ o
waveform NN o
elicited VBN N
by IN N
the DT N
words NNS N
in IN N
the DT N
test NN N
list NN N
was VBD N
a DT N
P300 NNP N
. . N

These DT N
analyses NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that IN N
there EX N
is VBZ N
a DT N
new JJ N
component NN N
( ( N
the DT N
memory-evoked JJ o
shift NN o
) ) o
that WDT N
is VBZ N
a DT N
specific JJ N
manifestation NN N
of IN N
recollection NN N
. . N

-DOCSTART- -X- O O

Why WRB N
are VBP N
there RB N
sometimes RB N
concreteness JJ o
effects NNS o
in IN o
memory NN o
for IN N
prose NN N
? . N
Four CD p
experiments NNS p
explored VBD N
on-line JJ N
encoding NN N
strategies NNS N
and CC N
memory NN p
for IN p
high JJ p
imagery NN p
and CC p
low JJ p
imagery NN p
texts NN p
. . p

Results NNP N
consistently RB N
indicated VBD N
that IN N
concreteness NN o
effects NNS o
in IN o
memory NN o
for IN o
text JJ o
depend NN N
on IN N
how WRB N
materials NNS N
are VBP N
presented VBN N
in IN N
several JJ N
different JJ N
respects NNS N
. . N

Most JJS N
importantly RB N
, , N
the DT N
experiments NNS N
clarified VBD N
apparently RB N
contradictory JJ N
results NNS N
of IN N
previous JJ N
studies NNS N
by IN N
indicating VBG N
that IN N
concreteness NN o
effects NNS o
generally RB N
do VBP N
not RB N
occur VB N
in IN N
memory NN N
for IN N
prose NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
between-subjects NNS p
, , N
and CC N
that IN N
their PRP$ N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
occurrence NN N
when WRB N
imageability NN N
is VBZ N
manipulated VBN N
within-subjects NNS N
depends NNS N
on IN N
the DT N
order NN N
of IN N
presentation NN N
. . N

In IN N
addition NN N
, , N
moving VBG N
window JJ N
analyses NNS N
of IN N
text JJ i
processing NN i
strategies NNS i
indicated VBD N
that IN N
differential JJ N
strategies NNS N
observed VBN N
in IN N
previous JJ N
studies NNS N
when WRB N
subjects NNS p
listened VBD N
to TO N
high JJ N
vs NN N
low JJ N
imagery NN N
text NN N
do VBP N
not RB N
generalize VB N
to TO N
reading NN N
of IN N
the DT N
same JJ N
materials NNS N
. . N

Potential JJ N
explanations NNS N
for IN N
the DT N
pattern NN N
of IN N
results NNS N
are VBP N
evaluated VBN N
, , N
and CC N
implications NNS N
for IN N
theories NNS N
of IN N
mental JJ N
imagery NN N
and CC N
memory NN N
are VBP N
considered VBN N
. . N

-DOCSTART- -X- O O

Double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
aprindine NN i
and CC i
digoxin NN i
for IN N
the DT N
prevention NN o
of IN o
symptomatic JJ o
atrial JJ o
fibrillation NN o
. . o

A DT N
multicenter NN N
, , N
placebo-controlled JJ i
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
compared VBN N
the DT N
preventive JJ o
effect NN o
of IN N
aprindine NN i
and CC i
digoxin NN i
on IN N
the DT N
recurrence NN o
of IN o
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
with IN N
placebo NN i
, , N
and CC N
also RB N
compare VBP N
the DT N
effectiveness NN o
of IN N
these DT N
2 CD N
drugs NNS N
in IN N
the DT N
prevention NN o
of IN o
AF NNP o
. . o

Patients NNS p
with IN p
symptomatic JJ p
paroxysmal NN p
or CC p
persistent JJ p
AF NNP p
who WP p
had VBD p
converted VBN p
to TO p
sinus VB p
rhythm NN p
( ( p
SR NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
aprindine NN i
( ( N
40 CD N
mg/day NN N
) ) N
, , N
digoxin NN i
( ( N
0.25 CD N
mg/day NN N
) ) N
or CC i
placebo NN i
and CC N
followed VBD N
up RP N
on IN N
an DT N
outpatient JJ N
basis NN N
every DT N
2 CD N
weeks NNS N
for IN N
6 CD N
months NNS N
. . N

Of IN p
the DT p
141 CD p
patients NNS p
from IN p
36 CD p
participating VBG p
centers NNS p
, , p
47 CD p
were VBD p
given VBN p
aprindine NN i
, , p
47 CD p
digoxin NN i
, , p
and CC p
47 CD p
were VBD p
on IN p
placebo NN i
. . i

After IN N
the DT N
6-month JJ N
follow-up NN N
, , N
the DT N
Kaplan-Meier NNP o
estimates NNS N
of IN N
the DT N
percentage NN N
of IN N
patients NNS N
remaining VBG N
free JJ N
of IN N
recurrent JJ o
symptomatic JJ o
AF NNP o
on IN N
aprindine NN i
, , i
digoxin NN i
and CC N
placebo NN i
were VBD N
33.3 CD N
% NN N
, , N
29.2 CD N
% NN N
and CC N
21.5 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
patients NNS N
remaining VBG N
in IN N
SR NNP N
for IN N
15 CD N
days NNS N
after IN N
from IN N
the DT N
start NN N
of IN N
follow-up NN N
, , N
freedom NN o
from IN o
recurrence NN o
was VBD N
significantly RB N
more RBR N
prevalent JJ o
in IN N
the DT N
aprindine NN N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
p=0.0414 NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ o
difference NN o
between IN N
the DT N
digoxin NN N
and CC N
placebo NN N
groups NNS N
. . N

The DT N
rate NN o
of IN o
adverse JJ o
events NNS o
was VBD N
similar JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
neither CC N
aprindine JJ N
nor CC N
digoxin NN i
had VBD N
a DT N
significant JJ o
effect NN o
on IN N
preventing VBG o
relapse NN o
of IN o
symptomatic JJ o
AF NNP o
; : o
however RB N
, , N
recurrence NN o
of IN o
AF NNP o
occurred VBD N
later RBR o
with IN N
aprindine NN i
than IN N
with IN N
placebo NN i
or CC N
digoxin NN i
. . i

-DOCSTART- -X- O O

Effects NNS N
of IN N
two CD N
different JJ N
short-term JJ i
training NN i
programs NNS i
on IN N
the DT N
physical JJ N
and CC N
technical JJ N
abilities NNS N
of IN N
adolescent JJ p
basketball NN p
players NNS p
. . p

This DT N
study NN N
evaluated VBD N
and CC N
compared VBN N
the DT N
effectiveness NN N
of IN N
two CD N
different JJ N
off-season JJ i
, , i
short-term JJ i
basketball NN i
training NN i
programs NNS i
on IN N
physical JJ N
and CC N
technical JJ N
abilities NNS N
of IN N
young JJ p
basketball NN p
players NNS p
. . p

Twenty-seven JJ p
adolescent JJ p
basketball NN p
players NNS p
( ( p
14.7+/-0.5 CD p
years NNS p
; : p
Tanner NNP p
stage NN p
: : p
3.5+/-0.5 JJ p
) ) p
were VBD N
randomly RB N
divided VBN N
into IN N
a DT N
specialized JJ i
basketball NN i
training NN i
group NN i
( ( N
SP NNP N
, , N
n=10 NN N
) ) N
, , N
a DT i
mixed JJ i
basketball NN i
plus CC i
conditioning VBG i
training NN i
group NN i
( ( N
MX NNP N
, , N
n=10 NN N
) ) N
and CC i
a DT i
control NN i
group NN i
( ( N
n=7 RB N
) ) N
. . N

Training VBG i
included VBD N
five CD N
sessions NNS N
per IN N
week NN N
( ( N
100-120 JJ N
min NNS N
each DT N
) ) N
and CC N
was VBD N
performed VBN N
for IN N
4 CD N
weeks NNS N
. . N

Maximal NNP o
oxygen NN o
uptake NN o
was VBD N
similarly RB N
improved VBN N
after IN N
SP NNP N
( ( N
4.9+/-1.8 CD N
% NN N
) ) N
and CC N
MX NNP N
( ( N
4.9+/-1.4 CD N
% NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
effect NN N
on IN N
ventilatory NN o
threshold NN o
. . o

Peak NNP o
and CC o
mean JJ o
power NN o
output NN o
measured VBD N
during IN N
the DT N
Wingate NNP N
test NN N
were VBD N
also RB N
improved VBN N
by IN N
a DT N
similar JJ N
magnitude NN N
after IN N
SP NNP N
( ( N
21+/-5 CD N
% NN N
) ) N
and CC N
MX NNP N
( ( N
15+/-6 CD N
% NN N
) ) N
. . N

Trunk NNP o
muscle NN o
endurance NN o
was VBD N
equally RB N
increased VBN N
( ( N
SP JJ N
: : N
23+/-4 JJ N
% NN N
, , N
MX NNP N
: : N
25+/-5 CD N
% NN N
) ) N
, , N
but CC N
arms NNS o
endurance NN o
was VBD N
improved VBN N
significantly RB N
more RBR N
after IN N
MX NNP N
( ( N
50+/-11 CD N
% NN N
) ) N
compared VBN N
to TO N
SP NNP N
( ( N
11+/-14 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

Performance NN o
in IN N
four CD N
basketball NN o
technical JJ o
skills NNS o
was VBD N
similarly RB N
increased VBN N
( ( N
by IN N
17-27 CD N
% NN N
) ) N
in IN N
both DT N
groups NNS N
, , N
with IN N
a DT N
tendency NN N
for IN N
greater JJR N
improvement NN N
of IN N
the DT N
SP NNP N
groups NNS N
in IN N
the DT N
technical JJ N
skills NNS N
of IN N
shooting NN o
and CC o
passing NN o
. . o

These DT N
results NNS N
indicate VBP N
that IN N
a DT N
SP NNP N
basketball NN N
training NN N
program NN N
, , N
performed VBD N
exclusively RB N
on-court NN N
was VBD N
as RB N
effective JJ N
as IN N
a DT N
MX NNP N
training NN N
program NN N
in IN N
terms NNS N
of IN N
aerobic NN N
and CC N
anaerobic JJ N
fitness NN N
improvement NN N
. . N

Furthermore RB N
, , N
the DT N
decrease NN N
of IN N
the DT N
total JJ N
on-court JJ N
training NN N
time NN N
in IN N
the DT N
MX NNP N
group NN N
resulted VBD N
in IN N
a DT N
tendency NN N
for IN N
a DT N
smaller JJR N
improvement NN N
of IN N
basketball NN N
technical JJ N
skills NNS N
. . N

In IN N
conclusion NN N
, , N
both DT N
SP NNP N
and CC N
MX NNP N
training NN N
are VBP N
equally RB N
effective JJ N
in IN N
order NN N
to TO N
limit VB N
and/or JJ N
reverse VB N
the DT N
detraining NN N
effects NNS N
that WDT N
occur VBP N
during IN N
the DT N
off-season NN N
in IN N
basketball NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
open-label JJ N
non-comparative JJ N
multicenter NN N
phase NN N
II NNP N
trial NN N
of IN N
sequential JJ N
erlotinib NN i
and CC i
docetaxel NN i
versus NN i
docetaxel NN i
alone RB i
in IN N
patients NNS p
with IN p
non-small-cell JJ p
lung NN p
cancer NN p
after IN p
failure NN p
of IN p
first-line JJ p
chemotherapy NN p
: : p
GFPC NNP N
10.02 CD N
study NN N
. . N

BACKGROUND NNP N
Concomitant NNP i
administration NN i
of IN i
erlotinib NN i
with IN i
standard JJ i
chemotherapy NN i
does VBZ N
not RB N
appear VB N
to TO N
improve VB N
survival NN o
among IN N
patients NNS p
with IN p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
, , N
but CC N
preliminary JJ N
studies NNS N
suggest VBP N
that IN N
sequential JJ N
administration NN N
might MD N
be VB N
effective JJ N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
second-line JJ N
sequential JJ N
administration NN N
of IN N
erlotinib NN i
and CC i
docetaxel NN i
in IN N
advanced JJ N
NSCLC NNP N
. . N

METHODS NNP N
In IN N
an DT N
open-label JJ N
phase NN N
II NNP N
trial NN N
, , N
patients NNS p
with IN p
advanced JJ p
NSCLC NNP p
, , p
EGFR NNP p
wild-type NN p
or CC p
unknown JJ p
, , p
PS NNP p
0-2 CD p
, , p
in IN p
whom WP p
initial JJ p
cisplatin-based JJ p
chemotherapy NN p
had VBD p
failed VBN p
were VBD N
randomized VBN N
to TO N
sequential JJ i
erlotinib NN i
150 CD i
mg/d NN i
( ( i
day NN i
2-16 CD i
) ) i
+docetaxel NN i
( ( i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
d1 NN i
) ) i
( ( i
arm JJ i
ED NNP i
) ) i
or CC i
docetaxel NN i
( ( i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
d1 NN i
) ) i
alone RB i
( ( N
arm JJ N
D NNP N
) ) N
( ( N
21-day JJ N
cycle NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
progression-free JJ o
survival NN o
rate NN o
at IN N
15 CD N
weeks NNS N
( ( N
PFS NNP N
15 CD N
) ) N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
PFS NNP o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
the DT o
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
and CC o
tolerability NN o
. . o

Based VBN N
on IN N
a DT N
Simon NNP N
optimal JJ N
two-stage NN N
design NN N
, , N
the DT N
ED NNP i
strategy NN N
was VBD N
rejected VBN N
if IN N
the DT N
primary JJ N
endpoint NN N
was VBD N
below IN N
33/66 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
two CD N
Simon NNP N
stages NNS N
. . N

RESULTS VB N
147 CD p
patients NNS p
were VBD p
randomized VBN p
( ( p
median JJ p
age NN p
: : p
60?8 CD p
years NNS p
, , p
PS NNP p
0/1/2 CD p
: : p
44/83/20 CD p
patients NNS p
; : p
males NNS p
: : p
78 CD p
% NN p
) ) p
. . p

The DT i
ED NNP i
strategy NN N
was VBD N
rejected VBN N
, , N
with IN N
only RB N
18 CD N
of IN N
73 CD N
patients NNS N
achieving VBG o
PFS15 NNP o
in IN o
arm NN o
ED NN o
at IN N
the DT N
end NN N
of IN N
stage NN N
2 CD N
and CC N
17 CD N
of IN N
74 CD N
patients NNS N
in IN N
arm JJ N
D. NNP N
In IN N
arms NNS i
ED NNP i
and CC i
D NNP i
, , i
respectively RB N
, , N
median JJ o
PFS NNP o
was VBD N
2.2 CD N
and CC N
2.5 CD N
months NNS N
and CC o
median JJ o
OS NNP o
was VBD N
6.5 CD N
and CC N
8.3 CD N
months NNS N
. . N

CONCLUSION NNP i
Sequential NNP i
erlotinib NN i
and CC i
docetaxel NN i
was VBD N
not RB N
more RBR o
effective JJ o
than IN i
docetaxel RB i
alone JJ i
as IN N
second-line JJ N
treatment NN N
for IN N
advanced JJ N
NSCLC NNP N
with IN N
wild-type JJ N
or CC N
unknown JJ o
EGFR NNP o
status NN o
. . o

-DOCSTART- -X- O O

Results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
hepatic JJ i
artery NN i
infusion NN i
with IN i
5-fluorouracil JJ i
versus NN i
intravenous JJ i
5-fluorouracil JJ i
in IN N
patients NNS p
with IN p
hepatic JJ p
metastases NNS p
from IN p
colorectal JJ p
cancer NN p
: : p
A DT N
Central NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
a DT N
controlled VBN N
, , N
prospectively RB N
randomized VBN N
trial NN N
, , N
74 CD p
patients NNS p
with IN p
hepatic JJ p
metastases NNS p
from IN p
colorectal JJ p
cancer NN p
were VBD p
randomized VBN p
to TO p
either DT p
intra-arterial JJ i
hepatic JJ i
artery NN i
infusion NN i
with IN i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
or CC i
systemic JJ i
chemotherapy NN i
with IN i
5-FU JJ i
. . i

In IN N
61 CD N
acceptable JJ N
patients NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
response NN o
rate NN o
, , o
time NN o
to TO o
progression NN o
, , o
duration NN o
of IN o
the DT o
response NN o
, , o
and CC o
survival JJ o
rate NN o
. . o

Though IN N
the DT N
response NN o
rate NN o
for IN N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
slightly RB N
higher JJR N
than IN N
for IN N
the DT N
systemic JJ N
arm NN N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
, , N
and CC N
the DT N
intra-arterial JJ N
infusion NN N
arm NN N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
incidence NN N
of IN N
nausea NN o
, , o
vomiting VBG o
, , o
diarrhea NN o
, , o
in IN o
addition NN o
to TO o
complications NNS o
of IN o
femoral-arterial JJ o
thrombosis NN o
, , o
bleeding NN o
, , o
and CC o
infection NN o
at IN o
the DT o
catheter NN o
site NN o
not RB N
seen VBN N
in IN N
patients NNS N
treated VBN N
by IN N
systemic JJ i
chemotherapy NN i
. . i

Patients NNS N
with IN N
an DT N
objective JJ N
response NN N
to TO N
chemotherapy VB N
on IN N
either DT N
treatment NN N
arm NN N
survived VBD o
twice RB N
as RB N
long RB N
as IN N
the DT N
nonresponders NNS N
. . N

Long-term JJ o
survival NN o
in IN N
one CD N
patient NN N
, , N
77 CD N
months NNS N
, , N
can MD N
occasionally RB N
be VB N
achieved VBN N
in IN N
patients NNS p
with IN p
hepatic JJ p
metastases NNS p
. . p

-DOCSTART- -X- O O

Immunologic NNP N
profiles NNS N
of IN N
persons NNS N
recruited VBN N
for IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
of IN N
hookworm NN p
infection NN p
. . p

Data NNS N
from IN N
epidemiologic JJ N
studies NNS N
suggest VBP N
that IN N
hookworm NN N
infections NNS N
, , N
in IN N
establishing VBG N
an DT N
immunologic JJ N
phenotype NN N
conducive NN N
to TO N
parasite VB N
survival NN N
, , N
may MD N
protect VB N
against IN N
the DT N
development NN N
of IN N
allergic JJ N
disease NN N
. . N

We PRP N
describe VBP N
immunologic JJ N
findings NNS N
from IN N
a DT N
clinical JJ N
study NN N
designed VBN N
to TO N
investigate VB N
the DT N
safety NN N
of IN N
iatrogenic JJ i
hookworm NN i
infection NN i
in IN N
participants NNS p
with IN p
allergic JJ p
rhinitis NN p
. . p

The DT N
low JJ N
, , N
relatively RB N
safe JJ N
level NN N
of IN N
hookworm NN i
infection NN i
used VBN N
in IN N
this DT N
study NN N
was VBD N
immunogenic JJ N
, , N
inducing VBG N
eosinophilia NNS o
and CC N
a DT N
significant JJ N
specific JJ o
IgG NNP o
response NN o
. . o

Importantly RB N
, , N
no DT N
potentiation NN N
of IN N
IgE NNP o
responses NNS o
to TO o
the DT o
environmental JJ o
allergens NNS o
to TO o
which WDT o
the DT o
participants NNS o
were VBD o
sensitized VBN o
was VBD N
seen VBN N
. . N

However RB N
, , N
no DT N
evidence NN N
of IN N
systemic JJ o
immune JJ o
regulation NN o
was VBD N
seen VBN N
in IN N
infected JJ N
participants NNS N
. . N

This DT N
finding NN N
may MD N
indicate VB N
that IN N
the DT N
level NN o
of IN o
infection NN o
or CC N
the DT N
frequency NN o
of IN o
infection NN o
may MD N
have VB N
to TO N
be VB N
altered VBN N
in IN N
future JJ N
trials NNS N
to TO N
induce VB N
a DT N
therapeutically RB N
conducive JJ N
immunologic NN N
phenotype NN N
. . N

-DOCSTART- -X- O O

The DT N
A-V NNP i
Impulse NNP i
System NNP i
reduces VBZ N
deep-vein JJ p
thrombosis NN p
and CC p
swelling NN p
after IN p
hemiarthroplasty NN p
for IN p
hip NN p
fracture NN p
. . p

We PRP N
performed VBD N
a DT N
prospective JJ N
randomised VBN N
controlled JJ N
trial NN N
of IN N
the DT N
A-V NNP i
Impulse NNP i
System NNP i
in IN N
82 CD p
patients NNS p
treated VBN p
by IN p
hemiarthroplasty NN p
for IN p
subcapital JJ p
fracture NN p
of IN p
the DT p
femoral JJ p
neck NN p
. . p

The DT N
incidence NN N
of IN N
proximal JJ N
deep-vein JJ N
thrombosis NN N
as IN N
assessed VBN N
by IN N
Doppler NNP i
ultrasonography NN i
was VBD N
23 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
and CC N
0 CD N
% NN N
in IN N
those DT N
using VBG N
the DT N
device NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Calf NNP N
and CC N
thigh JJ N
circumferences NNS N
were VBD N
measured VBN N
in IN N
both DT N
groups NNS N
at IN N
seven CD N
to TO N
ten VB N
days NNS N
after IN N
operation NN N
. . N

In IN N
the DT N
treatment NN N
group NN N
there EX N
was VBD N
a DT N
mean JJ o
relative JJ o
reduction NN o
of IN o
postoperative JJ o
swelling NN o
of IN o
the DT o
thigh NN o
by IN N
3.27 CD N
cm NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
of IN N
the DT N
calf NN N
by IN N
1.55 CD N
cm NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
A-V NNP N
Impulse NNP N
System NNP N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ o
and CC N
effective JJ N
method NN N
of IN N
reducing VBG N
the DT N
incidence NN o
of IN o
proximal JJ o
deep-vein JJ o
thrombosis NN o
, , o
and CC o
of IN o
postoperative JJ o
swelling NN o
. . o

-DOCSTART- -X- O O

Combining VBG N
weight-loss JJ N
counseling NN N
with IN N
the DT N
weight NN N
watchers NNS N
plan VBP N
for IN N
obese JJ p
breast NN p
cancer NN p
survivors NNS p
. . p

OBJECTIVE IN N
The DT N
objective NN N
was VBD N
to TO N
develop VB N
effective JJ N
weight-loss JJ N
methods NNS N
for IN N
women NNS p
who WP p
have VBP p
had VBN p
breast VBN p
cancer NN p
, , N
because IN N
obesity NN N
may MD N
result VB N
in IN N
an DT N
adverse JJ N
prognosis NN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
This DT N
randomized VBN N
pilot NN N
study NN N
tested VBD N
an DT N
individualized JJ N
approach NN N
toward IN N
weight JJ o
loss NN o
in IN N
obese JJ p
women NNS p
who WP p
have VBP p
had VBD p
a DT p
diagnosis NN p
of IN p
breast NN p
cancer NN p
. . p

An DT N
individualized JJ N
approach NN N
was VBD N
applied VBN N
either CC N
alone RB i
or CC i
combined VBN i
with IN i
the DT i
commercial JJ i
Weight NNP i
Watchers NNP i
program NN i
. . i

Forty-eight JJ p
women NNS p
( ( p
body NN p
mass NN p
index NN p
of IN p
30 CD p
to TO p
44 CD p
kg/m NNS p
( ( p
2 CD p
) ) p
) ) p
were VBD p
enrolled VBN p
. . p

RESULTS NNP N
Weight NNP o
change NN o
after IN N
12 CD N
months NNS N
of IN N
intervention NN N
was VBD N
as IN N
follows VBZ N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
: : N
0.85 CD N
+/- JJ N
6.0 CD N
kg NN N
in IN N
the DT N
control NN i
group NN i
, , N
-2.6 VBZ N
+/- JJ N
5.9 CD N
kg NN N
in IN N
the DT N
Weight NNP i
Watchers NNP i
group NN i
, , N
-8.0 VBZ N
+/- JJ N
5.5 CD N
kg NN N
in IN N
the DT N
individualized JJ N
group NN N
, , N
and CC N
-9.4 VBD N
+/- JJ N
8.6 CD N
kg NN N
in IN N
the DT N
comprehensive JJ i
group NN i
that WDT i
used VBD i
both DT i
individualized JJ i
counseling NN i
and CC i
Weight NNP i
Watchers NNP i
. . i

Weight NNP o
loss NN o
relative NN N
to TO N
control VB N
was VBD N
statistically RB N
significant JJ N
in IN N
the DT N
comprehensive JJ N
group NN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
randomization NN N
, , N
whereas JJ N
weight NN o
loss NN o
in IN N
the DT N
individualized JJ N
group NN N
was VBD N
significant JJ N
only RB N
at IN N
12 CD N
months NNS N
. . N

Weight NNP o
loss NN o
of IN N
10 CD N
% NN N
or CC N
more JJR N
of IN N
initial JJ N
body NN N
weight NN N
was VBD N
observed VBN N
in IN N
6 CD N
of IN N
10 CD N
women NNS N
in IN N
the DT N
comprehensive JJ N
group NN N
at IN N
12 CD N
months NNS N
. . N

In IN N
the DT N
comprehensive JJ N
and CC N
Weight NNP N
Watchers-only NNP N
groups NNS N
, , N
weight JJ o
loss NN o
was VBD N
significantly RB N
related VBN N
to TO N
frequency NN N
of IN N
attendance NN N
at IN N
Weight NNP N
Watchers NNP N
meetings NNS N
, , N
and CC N
attendance NN N
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
comprehensive JJ N
group NN N
. . N

DISCUSSION NNP N
These DT N
data NNS N
indicate VBP N
that IN N
the DT N
most RBS N
weight JJ o
loss NN o
was VBD N
achieved VBN N
when WRB N
the DT N
counseling NN N
approach NN N
combined VBD N
both DT N
Weight NNP N
Watchers NNPS N
and CC N
individualized JJ N
contacts NNS N
. . N

This DT N
was VBD N
effective JJ N
even RB N
though IN N
most JJS N
of IN N
the DT N
individualized JJ N
contacts NNS N
were VBD N
by IN N
telephone NN N
. . N

-DOCSTART- -X- O O

Zinc NNP o
and CC o
copper NN o
balances NNS o
in IN N
preterm JJ p
infants NNS p
. . p

Preterm NNP p
infants NNS p
are VBP N
at IN N
risk NN N
for IN N
copper NN N
and CC N
zinc NN N
depletion NN N
if IN N
sufficient JJ N
quantities NNS N
of IN N
these DT N
nutrients NNS N
are VBP N
not RB N
provided VBN N
in IN N
a DT N
bioavailable JJ N
form NN N
in IN N
postnatal JJ N
life NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
a DT N
whey-predominant JJ i
, , i
50 CD i
% NN i
medium NN i
chain NN i
triglyceride IN i
formula NN i
with IN i
relatively RB i
high JJ i
concentrations NNS i
of IN i
zinc NN i
and CC i
copper NN i
would MD N
promote VB N
the DT N
achievement NN N
of IN N
the DT N
in IN o
utero JJ o
accretion NN o
rate NN o
for IN o
zinc NN o
and CC o
copper NN o
in IN N
the DT N
preterm NN p
infant NN p
. . p

Two CD p
groups NNS p
of IN p
five CD p
preterm JJ p
infants NNS p
were VBD N
fed VBN N
a DT N
diet JJ N
containing VBG N
12.5 CD i
mg/L NN i
of IN i
zinc NN i
and CC N
either DT N
0.9 CD i
mg/L NN i
or CC i
2.1 CD i
mg/L NN i
of IN i
copper NN i
. . i

Seventy-two-hour JJ N
metabolic JJ N
balance NN N
studies NNS N
were VBD N
performed VBN N
at IN N
an DT N
average JJ N
postconceptual JJ N
age NN N
of IN N
34 CD N
weeks NNS N
and CC N
an DT N
average JJ N
weight NN N
of IN N
1,549 CD N
g. NN N
All DT N
infants NNS N
were VBD N
in IN N
positive JJ o
zinc NN o
balance NN o
and CC N
nine CD N
of IN N
ten NNS N
achieved VBN N
the DT N
in IN o
utero JJ o
accretion NN o
rate NN o
for IN o
zinc NN o
for IN N
a DT N
34-week JJ N
gestation NN N
fetus NN N
( ( N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
0.432 CD N
mg/d NN N
) ) N
. . N

Three CD N
infants NNS N
receiving VBG N
the DT N
high JJ N
copper NN N
formula NN N
and CC N
two CD N
receiving VBG N
the DT N
lower JJR N
copper NN N
formula NN N
were VBD N
in IN N
positive JJ o
copper NN o
balance NN o
. . o

Two CD N
infants NNS N
from IN N
each DT N
group NN N
achieved VBD N
the DT N
in IN o
utero JJ o
accretion NN o
rate NN o
for IN o
copper NN o
for IN N
a DT N
34-week JJ N
gestation NN N
fetus NN N
( ( N
0.088 CD N
mg/d NN N
) ) N
. . N

A DT N
formula NN N
that WDT N
provides VBZ N
12.5 CD N
mg/L NN N
of IN N
zinc NN N
permits NNS N
positive JJ o
zinc NN o
balance NN o
and CC o
zinc NN o
retention NN o
similar JJ N
to TO N
in IN N
utero JJ N
rates NNS N
. . N

A DT N
formula NN N
that WDT N
provides VBZ N
as RB N
much JJ N
as IN N
2.1 CD N
mg/L NN N
of IN N
copper NN N
, , N
however RB N
, , N
may MD N
not RB N
always RB N
permit VBP N
positive JJ N
copper NN o
balance NN o
. . o

-DOCSTART- -X- O O

Association NNP N
of IN N
severity NN N
of IN N
coexisting VBG N
patellofemoral JJ N
disease NN N
with IN N
increased JJ N
impairments NNS N
and CC N
functional JJ N
limitations NNS N
in IN N
patients NNS p
with IN p
knee JJ p
osteoarthritis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
association NN N
between IN N
severity NN N
of IN N
coexisting VBG N
patellofemoral JJ N
( ( N
PF NNP N
) ) N
disease NN N
with IN N
lower JJR N
extremity NN N
impairments NNS N
and CC N
functional JJ N
limitations NNS N
in IN N
patients NNS p
with IN p
tibiofemoral JJ p
( ( p
TF NNP p
) ) p
osteoarthritis NN p
( ( p
OA NNP p
) ) p
. . p

METHODS NNP N
Radiographic NNP i
views NNS i
of IN i
the DT i
TF NNP i
and CC i
PF NNP i
compartments NNS i
, , i
knee VB i
extension NN i
strength NN i
, , i
and CC i
knee VB i
range NN i
of IN i
motion NN i
were VBD N
obtained VBN N
for IN N
167 CD p
patients NNS p
with IN p
knee JJ p
OA NNP p
. . p

Additionally RB N
, , N
knee-specific JJ o
symptoms NNS o
and CC N
functional JJ o
limitations NNS o
were VBD N
assessed VBN N
using VBG N
the DT N
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
and CC o
the DT o
Activities NNS o
of IN o
Daily NNP o
Living NNP o
Scale NNP o
( ( o
ADLS NNP o
) ) o
. . o

RESULTS NNP N
Moderate/severe NNP N
PFOA NNP N
was VBD N
associated VBN N
with IN N
lower JJR N
knee NN o
extension NN o
strength NN o
( ( N
mean VB N
? . N
SD NNP N
1.4 CD N
? . N
0.5 CD N
Nm/body NN N
weight VBD N
[ NNP N
BW NNP N
] NNP N
) ) N
compared VBN N
to TO N
no DT N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
1.8 CD N
? . N
0.5 CD N
Nm/BW NNP N
) ) N
. . N

Additionally RB o
, , o
total JJ o
knee NN o
range NN o
of IN o
motion NN o
was VBD o
significantly RB N
lower JJR N
for IN N
patients NNS N
with IN N
moderate/severe JJ N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
120.8? CD N
? . N
14.4? CD N
) ) N
compared VBN N
to TO N
no DT N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
133.5? CD N
? . N
10.7? CD N
) ) N
and CC N
mild JJ N
PFOA NNP N
( ( N
mean VB N
? . N
SD NNP N
125.8? CD N
? . N
13.0? CD N
) ) N
. . N

Moderate/severe NNP N
PFOA NNP N
and CC N
mild JJ N
PFOA NNP N
were VBD N
also RB N
associated VBN N
with IN N
less JJR o
pain NN o
while IN o
standing VBG o
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.2 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
0.1-0.7 JJ N
and CC N
OR NNP N
0.2 CD N
, , N
95 CD N
% NN N
CI NNP N
0.1-0.6 CD N
, , N
respectively RB N
) ) N
on IN N
the DT N
WOMAC NNP N
, , N
and CC N
moderate/severe RB N
PFOA NNP N
was VBD N
associated VBN N
with IN N
greater JJR o
difficulty NN o
with IN o
going VBG o
downstairs NNS o
( ( o
OR NNP o
2.9 CD N
, , N
95 CD N
% NN N
CI NNP N
1.0-8.1 CD N
) ) N
on IN N
the DT N
ADLS NNP N
. . N

CONCLUSION VB N
It PRP N
appears VBZ N
that IN N
knees NNS N
with IN N
more RBR N
severe JJ N
coexisting VBG N
PF NNP N
disease NN N
demonstrate NN N
features NNS N
distinct VBP N
from IN N
those DT N
observed VBN N
in IN N
TFOA NNP N
in IN N
isolation NN N
or CC N
in IN N
combination NN N
with IN N
mild JJ N
PF NNP N
disease NN N
. . N

Treatment NNP i
strategies VBZ i
targeting VBG i
the DT i
PF NNP i
joint NN i
may MD i
be VB N
warranted VBN N
to TO N
mitigate VB N
the DT N
specific JJ N
lower JJR N
extremity NN N
impairments NNS N
and CC N
functional JJ N
problems NNS N
present JJ N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
with IN N
the DT N
dipeptidyl JJ i
peptidase-4 JJ i
inhibitor NN i
vildagliptin NN i
improves VBZ N
fasting VBG N
islet-cell JJ N
function NN N
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

CONTEXT NNP N
Dipeptidyl NNP i
peptidase NN i
4 CD i
( ( i
DPP-4 NNP i
) ) i
inhibitors NNS i
are VBP N
proposed VBN N
to TO N
lower VB N
blood NN N
glucose NN N
in IN N
type NN p
2 CD p
diabetes NNS p
mellitus FW p
( ( p
T2DM NNP p
) ) p
by IN N
prolonging VBG N
the DT N
activity NN N
of IN N
the DT N
circulating NN N
incretins NNS N
, , N
glucose-dependent JJ N
insulinotropic NN N
polypeptide NN N
( ( N
GIP NNP N
) ) N
and CC N
glucagon-like JJ N
peptide NN N
1 CD N
( ( N
GLP-1 NNP N
) ) N
. . N

Consistent JJ N
with IN N
this DT N
mechanism NN N
of IN N
action NN N
, , N
DPP-4 NNP i
inhibitors NNS i
improve VBP N
glucose JJ N
tolerance NN N
after IN N
meals NNS N
by IN N
increasing VBG N
insulin NN N
and CC N
reducing VBG N
glucagon NN N
levels NNS N
in IN N
the DT N
plasma NN N
. . N

However RB N
, , N
DPP-4 NNP i
inhibitors NNS i
also RB N
reduce VB N
fasting VBG N
blood NN N
glucose NN N
, , N
an DT N
unexpected JJ N
effect NN N
because IN N
circulating VBG N
levels NNS N
of IN N
active JJ N
GIP NNP N
and CC N
GLP-1 NNP N
are VBP N
low JJ N
in IN N
the DT N
postabsorptive JJ N
state NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS o
of IN o
DPP-4 NNP o
inhibition NN o
on IN o
fasting VBG o
islet NN o
function NN o
. . o

DESIGN NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

SETTING VB N
The DT N
study NN N
was VBD N
performed VBN N
in IN N
General NNP p
Clinical NNP p
Research NNP p
Centers NNPS p
at IN p
two CD p
University NNP p
Hospitals NNP p
. . p

SUBJECTS NNP N
Forty-one JJ p
subjects NNS p
with IN p
T2DM NNP p
were VBD N
treated VBN N
with IN N
metformin NN i
or CC N
diet NN i
, , N
having VBG N
good JJ N
glycemic NNS N
control NN N
with IN N
glycosylated JJ N
hemoglobin NN N
values NNS N
of IN N
6.2-7.5 JJ N
% NN N
. . N

INTERVENTION JJ N
Subjects NNPS N
were VBD N
treated VBN N
with IN N
vildagliptin NN i
( ( N
50 CD N
mg NN N
twice RB N
daily RB N
) ) N
or CC N
placebo NN i
for IN N
3 CD N
months NNS N
, , N
followed VBN N
by IN N
a DT N
2-wk JJ N
washout NN N
. . N

Major JJ N
Outcome JJ N
Measure NN N
: : N
We PRP N
measured VBD N
insulin JJ o
secretion NN o
in IN o
response NN o
to TO o
iv VB o
glucose JJ o
and CC o
arginine JJ o
before NN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
drug NN N
washout NN N
. . N

RESULTS CC N
There EX N
were VBD N
small JJ N
and CC N
comparable JJ N
reductions NNS N
in IN N
glycosylated JJ o
hemoglobin NN o
in IN N
both DT N
groups NNS N
over IN N
3 CD N
months NNS N
. . N

Vildagliptin NNP N
increased VBD N
fasting VBG N
GLP-1 NNP o
levels NNS N
in IN N
subjects NNS N
taking VBG N
metformin NN i
, , N
but CC N
not RB N
those DT N
managed VBN N
with IN N
diet JJ i
, , N
and CC N
raised VBD N
active JJ N
GIP NNP N
levels NNS N
slightly RB N
. . N

DPP-4 JJ i
inhibitor NN i
treatment NN N
improved VBD N
the DT N
acute JJ o
insulin NN o
and CC o
C-peptide JJ o
responses NNS o
to TO N
glucose VB N
( ( N
50 CD N
and CC N
100 CD N
% NN N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
increased VBD N
the DT N
slope NN N
of IN N
the DT N
C-peptide NNP o
response NN o
to TO N
glucose VB N
( ( N
33 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

CONCLUSION NNP N
Vildagliptin NNP i
improves VBZ N
islet JJ N
function NN N
in IN N
T2DM NNP N
under IN N
fasting VBG N
conditions NNS N
. . N

This DT N
suggests VBZ N
that IN N
DPP-4 NNP N
inhibition NN N
has VBZ N
metabolic JJ N
benefits NNS N
in IN N
addition NN N
to TO N
enhancing VBG N
meal-induced JJ N
GLP-1 NNP N
and CC N
GIP NNP N
activity NN N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
acceptability NN N
of IN N
cellulose JJ i
sulfate NN i
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN N
HIV-infected JJ p
women NNS p
. . p

OBJECTIVES NNP N
Few JJ N
studies NNS N
of IN N
topical JJ N
microbicides NNS N
have VBP N
assessed VBN N
their PRP$ N
safety NN o
in IN o
HIV-infected JJ o
women NNS o
. . o

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
acceptability NN o
of IN N
6 CD N
% NN N
cellulose JJ i
sulfate NN i
( ( i
CS NNP i
) ) i
gel NN N
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN p
sexually RB p
abstinent JJ p
and CC p
active JJ p
HIV-infected JJ p
women NNS p
. . p

METHODS NNP N
Fifty-nine JJ p
HIV-infected JJ p
women NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
comparing VBG N
6 CD N
% NN N
CS NNP i
to TO i
placebo VB i
gel NNS i
used VBN N
for IN N
14 CD N
days NNS N
. . N

Sexually NNP p
abstinent JJ p
women NNS p
applied VBD N
gel JJ N
once RB N
or CC N
twice JJ N
daily JJ N
and CC N
sexually RB N
active JJ N
women NNS N
used VBN N
gel JJ N
once RB N
daily JJ N
. . N

RESULTS NNP N
CS NNP N
gel NN N
was VBD N
safe JJ N
with IN N
no DT N
reported VBN N
severe RB o
or CC o
life-threatening JJ o
adverse JJ o
events NNS o
( ( o
AE NNP o
) ) o
. . o

Thirty-nine NNP N
( ( N
66 CD N
% NN N
) ) N
of IN N
the DT N
participants NNS N
experienced VBD N
urogenital JJ o
AE NNP o
judged VBD N
as IN N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
. . N

The DT N
majority NN N
( ( N
51 CD N
% NN N
) ) N
of IN N
these DT N
participants NNS N
reported VBD N
only RB N
mild JJ o
events NNS o
. . o

Fewer JJR N
women NNS N
( ( N
62 CD N
% NN N
) ) N
who WP N
used VBD N
CS NNP N
experienced VBD N
urogenital JJ o
AE NNP o
than IN N
those DT N
assigned VBN N
to TO N
placebo VB i
gel NN N
( ( N
70 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.59 CD N
) ) N
. . N

Eleven NNP N
( ( N
19 CD N
% NN N
) ) N
women NNS N
experienced VBD N
intermenstrual JJ o
bleeding NN o
judged VBD N
to TO N
be VB N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
use NN N
( ( N
four CD N
in IN N
the DT N
CS NNP N
and CC N
seven CD N
in IN N
the DT N
placebo NN N
gel NN N
group NN N
) ) N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
AE NNP o
by IN N
frequency NN N
of IN N
gel NN N
use NN N
or CC N
sexual JJ N
activity NN N
with IN N
the DT N
exception NN N
of IN N
abdominal/pelvic NN o
pain NN o
which WDT N
was VBD N
noted VBN N
more RBR N
frequently RB N
with IN N
twice RB N
daily JJ N
use NN N
among IN N
sexually RB N
abstinent JJ N
women NNS N
. . N

Women NNS N
and CC N
men NNS N
found VBD N
the DT N
gel NN N
highly RB N
acceptable JJ N
. . N

CONCLUSIONS VB N
This DT N
Phase NNP N
I PRP N
study VBP N
demonstrated VBD N
that IN N
CS NNP i
vaginal JJ i
gel NN i
was VBD N
safe JJ o
, , o
well RB o
tolerated VBN o
and CC o
acceptable JJ o
by IN N
HIV-infected JJ p
women NNS p
and CC p
their PRP$ p
male JJ p
partners NNS p
. . p

Thus RB N
, , N
further JJ N
development NN N
of IN N
CS NNP N
is VBZ N
warranted VBN N
as IN N
a DT N
potential JJ N
method NN N
to TO N
prevent VB N
HIV NNP o
transmission NN o
and CC o
acquisition NN o
. . o

-DOCSTART- -X- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
cutting VBG i
balloon NN i
angioplasty JJ i
versus NN N
high-pressure NN i
balloon NN i
angioplasty NN i
in IN N
hemodialysis NN p
arteriovenous JJ p
fistula NN p
stenoses VBZ p
resistant JJ p
to TO p
conventional JJ p
balloon NN p
angioplasty NN p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
cutting VBG i
balloon NN i
angioplasty NN i
( ( i
CBA NNP i
) ) i
versus IN i
high-pressure NN i
balloon NN i
angioplasty NN i
( ( i
HPBA NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
hemodialysis NN p
autogenous JJ p
fistula NN p
stenoses VBZ p
resistant JJ p
to TO p
conventional JJ p
percutaneous JJ p
transluminal JJ p
angioplasty NN p
( ( p
PTA NNP p
) ) p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
involving VBG N
patients NNS p
with IN p
dysfunctional JJ p
, , p
stenotic JJ p
hemodialysis NN p
arteriovenous JJ p
fistulas NNS p
( ( p
AVFs NNP p
) ) p
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
CBA NNP i
or CC N
HPBA NNP i
if IN N
conventional JJ N
PTA NNP N
had VBD N
suboptimal JJ N
results NNS N
( ( N
ie JJ N
, , N
residual JJ N
stenosis NN N
> VBD N
30 CD N
% NN N
) ) N
. . N

A DT N
total NN p
of IN p
516 CD p
patients NNS p
consented VBN p
to TO p
participate VB p
in IN p
the DT p
study NN p
from IN p
October NNP p
2008 CD p
to TO p
September NNP p
2011 CD p
, , p
85 CD p
% NN p
of IN p
whom WP p
( ( p
n JJ p
= NNP p
439 CD p
) ) p
had VBD p
technically RB p
successful JJ p
conventional JJ p
PTA NNP p
. . p

The DT N
remaining VBG N
71 CD p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
60 CD p
y NN p
; : p
49 CD p
men NNS p
) ) p
with IN p
suboptimal JJ p
PTA NNP p
results NNS p
were VBD N
eventually RB N
randomized VBN N
: : N
36 CD N
to TO N
the DT N
CBA NNP i
arm NN N
and CC N
35 CD N
to TO N
the DT N
HPBA NNP N
arm NN N
. . N

Primary JJ N
and CC N
secondary JJ N
target NN N
lesion NN N
patencies NNS N
were VBD N
determined VBN N
by IN N
Kaplan-Meier NNP N
analysis NN N
. . N

RESULTS NNP N
Clinical JJ o
success NN o
rates NNS o
were VBD N
100 CD N
% NN N
in IN N
both DT N
arms NNS N
. . N

Primary JJ o
target NN o
lesion NN o
patency NN o
rates NNS o
at IN N
6 CD N
months NNS N
were VBD N
66.4 CD N
% NN N
and CC N
39.9 CD N
% NN N
for IN N
CBA NNP i
and CC N
HPBA NNP i
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Secondary JJ o
target NN o
lesion NN o
patency NN o
rates NNS o
at IN N
6 CD N
months NNS N
were VBD N
96.5 CD N
% NN N
for IN N
CBA NNP i
and CC N
80.0 CD N
% NN N
for IN N
HPBA NNP i
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

There EX N
was VBD N
a DT N
single JJ N
major JJ o
complication NN o
of IN N
venous JJ o
perforation NN o
following VBG N
CBA NNP i
. . i

The DT N
30-day JJ o
mortality NN o
rate NN o
was VBD N
1.4 CD N
% NN N
, , N
with IN N
one CD N
non-procedure-related JJ N
death NN N
in IN N
the DT N
HPBA NNP i
group NN N
. . N

CONCLUSIONS NNP N
Primary NNP N
and CC N
secondary JJ N
target NN N
lesion NN N
patency NN N
rates NNS N
of IN N
CBA NNP i
were VBD N
statistically RB N
superior JJ N
to TO N
those DT N
of IN N
HPBA NNP i
following VBG N
suboptimal JJ N
conventional JJ N
PTA NNP N
. . N

For IN N
AVF NNP N
stenoses VBZ N
resistant JJ N
to TO N
conventional JJ N
PTA NNP N
, , N
CBA NNP i
may MD N
be VB N
a DT N
better JJR N
second-line JJ N
treatment NN N
given VBN N
its PRP$ N
superior JJ N
patency NN N
rates NNS N
. . N

-DOCSTART- -X- O O

Dexamethasone NNP i
therapy NN i
and CC N
cortisol JJ N
excretion NN N
in IN N
severe JJ p
pediatric JJ p
head NN p
injury NN p
. . p

Glucocorticoids NNS i
are VBP N
used VBN N
in IN N
an DT N
attempt NN N
to TO N
reduce VB N
brain NN N
edema NN N
secondary JJ N
to TO N
head VB N
injury NN N
. . N

Nevertheless RB N
, , N
their PRP$ N
usefulness JJ N
remains NNS N
uncertain JJ N
and CC N
contradictory NN N
. . N

In IN N
a DT N
randomized JJ N
study NN N
of IN N
24 CD p
children NNS p
with IN p
severe JJ p
head NN p
injury NN p
, , p
urinary JJ p
free JJ p
cortisol NN p
was VBD N
measured VBN N
by IN N
radioimmunoassay NN i
. . i

Twelve CD p
patients NNS p
( ( N
group NN N
1 CD N
) ) N
received VBD N
dexamethasone NN i
and CC N
12 CD p
( ( p
group NN p
2 CD p
) ) p
did VBD N
not RB N
. . N

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
a DT N
standardized JJ N
regimen NN N
. . N

In IN N
group NN N
1 CD N
there EX N
was VBD N
complete JJ N
suppression NN o
of IN o
endogenous JJ o
cortisol NN o
production NN o
. . o

In IN N
group NN N
2 CD N
free JJ N
cortisol NN N
was VBD N
up RB N
to TO N
20-fold CD N
higher JJR N
than IN N
under IN N
basal JJ N
conditions NNS N
and CC N
reached VBN N
maximum JJ N
values NNS N
on IN N
days NNS N
1-3 RB N
. . N

Since IN N
the DT N
excretion NN o
of IN o
cortisol NN o
in IN o
urine JJ o
reflects VBZ N
the DT N
production NN N
rate NN N
closely RB N
and CC N
is VBZ N
not RB N
influenced VBN N
by IN N
liver NN N
function NN N
and CC N
barbiturates NNS N
, , N
the DT N
results NNS N
in IN N
group NN N
2 CD N
show NN N
that IN N
the DT N
endogenous JJ N
production NN N
of IN N
steroids NNS N
is VBZ N
an DT N
adequate JJ N
reaction NN N
to TO N
severe VB N
head JJ N
injury NN N
. . N

Exogenous JJ N
glucocorticoids NNS i
are VBP N
thus RB N
unlikely JJ N
to TO N
have VB N
any DT N
more JJR N
beneficial JJ N
effects NNS N
than IN N
endogenous JJ N
cortisol NN i
. . i

-DOCSTART- -X- O O

The DT N
accuracy NN o
of IN N
clinical JJ o
neurosensory NN o
testing VBG o
for IN N
nerve JJ N
injury NN N
diagnosis NN N
. . N

PURPOSE VB N
The DT N
accuracy NN N
of IN N
the DT N
clinical JJ i
neurosensory JJ i
test NN i
to TO N
diagnose VB N
trigeminal JJ N
nerve NN N
injuries NNS N
has VBZ N
never RB N
been VBN N
statistically RB N
evaluated VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
statistical JJ o
efficacy NN o
of IN o
the DT o
clinical JJ o
neurosensory JJ o
test NN o
using VBG N
surgical JJ N
findings NNS N
as IN N
the DT N
gold JJ N
standard NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
a DT N
correlation NN N
existed VBN N
between IN N
the DT N
sensory JJ N
impairment NN N
score NN N
obtained VBN N
by IN N
preoperative JJ N
testing NN N
and CC N
the DT N
degree NN N
of IN N
nerve NN N
injury NN N
found VBD N
at IN N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
multisite NN N
, , N
randomized VBN N
, , N
prospective JJ N
, , N
blinded VBD N
, , N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
on IN N
130 CD p
patients NNS p
with IN p
inferior JJ p
alveolar JJ p
nerve NN p
( ( p
IAN NNP p
) ) p
and CC p
lingual JJ p
nerve NN p
( ( p
LN NNP p
) ) p
injuries NNS p
. . p

Preoperatively RB N
, , N
patients NNS i
were VBD i
provided VBN i
a DT i
sensory JJ i
impairment NN i
score NN i
using VBG i
a DT i
three-level JJ i
drop-out JJ i
clinical JJ i
neurosensory NN i
test NN i
( ( i
NST NNP i
) ) i
, , i
and CC i
blind IN i
comparisons NNS i
were VBD i
made VBN i
with IN i
the DT i
surgical JJ i
findings NNS i
postoperatively RB i
. . i

RESULTS VB N
The DT N
positive JJ o
predictive NN o
and CC o
negative JJ o
predictive NN o
values NNS o
for IN N
LN-injured JJ N
patients NNS N
were VBD N
95 CD N
% NN N
and CC N
100 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
positive JJ N
predictive NN N
and CC N
negative JJ N
predictive NN N
values NNS N
for IN N
IAN NNP p
patients NNS p
were VBD N
77 CD N
% NN N
and CC N
60 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
distribution NN N
of IN N
age NN N
, , N
duration NN N
of IN N
injury NN N
, , N
cause NN N
of IN N
injury NN N
, , N
presence NN N
of IN N
neuropathic JJ N
pain NN N
, , N
presence NN N
of IN N
trigger NN N
pain NN N
, , N
and CC N
degree NN N
of IN N
injury NN N
between IN N
the DT p
IAN NNP p
and CC p
LN NNP p
patient JJ p
populations NNS p
. . p

There EX N
was VBD N
a DT N
statistically RB o
significant JJ o
positive JJ o
relationship NN o
found VBD o
between IN o
the DT o
sensory JJ o
impairment NN o
score NN o
and CC o
the DT o
degree NN o
of IN o
nerve NN o
injury NN o
. . o

CONCLUSIONS VB N
The DT N
NST NNP i
is VBZ N
a DT N
clinically RB N
useful JJ N
method NN N
to TO N
diagnose VB N
IAN NNP N
and CC N
LN NNP N
injuries NNS N
. . N

However RB N
, , N
the DT N
NST NNP i
results NNS N
are VBP N
less RBR o
efficient JJ o
for IN N
IAN NNP N
injuries NNS N
than IN N
LN NNP N
injuries NNS N
, , N
and CC N
have VBP N
a DT N
high JJ o
incidence NN o
of IN o
false-positive JJ o
( ( N
23 CD N
% NN N
) ) N
and CC N
false-negative JJ o
( ( N
40 CD N
% NN N
) ) N
results NNS N
when WRB N
testing VBG N
patients NNS p
with IN p
IAN NNP p
injuries NNS p
. . p

The DT N
different JJ N
rates NNS N
of IN N
statistical JJ o
efficiency NN o
between IN N
the DT N
two CD N
groups NNS N
of IN N
patients NNS N
may MD N
be VB N
attributable JJ N
to TO N
differences NNS N
in IN N
prevalence NN N
and CC N
biologic NN N
covariates NNS N
. . N

-DOCSTART- -X- O O

Placebo-controlled JJ i
trial NN N
evaluating VBG N
safety NN N
with IN N
12-months JJ N
continuous JJ N
use NN N
of IN N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
. . i

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
over IN N
12 CD N
months NNS N
. . N

METHODS NNP N
80 CD p
adults NNS p
were VBD p
randomly RB p
assigned VBN p
equally RB N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
6 CD i
% NN i
hydrogen NN i
peroxide JJ i
strips NNS i
or CC i
placebo VB i
strips NNS i
. . i

Strips NNS N
were VBD N
worn JJ N
5 CD N
min JJ N
daily RB N
for IN N
12 CD N
months NNS N
. . N

Safety NNP N
and CC N
tolerability NN N
were VBD N
assessed VBN N
via IN N
oral JJ N
status NN N
interviews NNS N
and CC N
oral JJ N
examinations NNS N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
of IN N
use NN N
. . N

RESULTS NNP N
Tooth NNP N
sensitivity NN N
and CC N
oral JJ N
irritation NN N
were VBD N
the DT N
two CD N
most JJS N
common JJ N
adverse JJ N
events NNS N
. . N

After IN N
12 CD N
months NNS N
use RB N
, , N
tooth DT N
sensitivity NN N
was VBD N
reported VBN N
by IN N
10 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
6 CD i
% NN i
strip NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
( ( N
2.8 CD N
% NN N
, , N
23.7 CD N
% NN N
) ) N
and CC N
5 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
placebo NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.6 CD N
% NN N
, , N
16.9 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
reported VBN N
oral JJ N
irritation NN N
was VBD N
0 CD N
% NN N
in IN N
the DT N
6 CD i
% NN i
strip NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0 CD N
% NN N
, , N
8.8 CD N
% NN N
) ) N
and CC N
2.5 CD N
% NN N
in IN N
the DT N
placebo NN i
strip NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.1 CD N
% NN N
, , N
13.2 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
observed JJ N
oral JJ N
irritation NN N
was VBD N
also RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.67 CD N
) ) N
for IN N
the DT N
percent NN N
of IN N
subjects NNS N
with IN N
each DT N
type NN N
of IN N
adverse JJ N
event NN N
. . N

In IN N
the DT N
6 CD i
% NN i
strip NN i
group NN N
, , N
two CD N
subjects NNS N
discontinued VBN N
product NN N
use NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
( ( N
tooth JJ N
sensitivity NN N
) ) N
compared VBN N
to TO N
no DT N
subjects NNS N
in IN N
the DT N
placebo NN i
group NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.49 CD N
) ) N
with IN N
respect NN N
to TO N
this DT N
outcome NN N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
over IN N
12 CD N
months NNS N
resulted VBN N
in IN N
a DT N
safety NN N
profile NN N
similar JJ N
to TO N
that DT N
seen VBN N
with IN N
placebo JJ i
strips NNS i
. . i

-DOCSTART- -X- O O

Prevention NN N
of IN N
coronary JJ p
spasm NN p
by IN N
nicorandil NNS i
: : i
comparison NN N
with IN N
nifedipine NN i
. . i

The DT N
efficacy NN N
of IN N
nicorandil NN i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
nifedipine NN i
in IN N
13 CD p
patients NNS p
with IN p
vasospastic JJ p
angina NNS p
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

All DT p
patients NNS p
had VBD p
a DT p
coronary JJ p
spasm NN p
during IN p
coronary JJ p
arteriography NN p
, , p
either CC p
spontaneously RB p
or CC p
ergometrine-induced JJ p
. . p

During IN N
two CD N
consecutive JJ N
periods NNS N
of IN N
2 CD N
days NNS N
, , N
patients NNS N
received VBD N
active JJ i
drugs NNS i
or CC N
placebo NN i
in IN N
a DT N
randomized JJ N
order NN N
. . N

Each DT N
patient NN N
received VBD N
single JJ N
oral JJ N
doses NNS N
of IN N
30 CD N
mg NN N
nicorandil NN i
, , N
10 CD N
mg NN N
nifedipine NN i
, , N
and CC N
, , N
on IN N
2 CD N
days NNS N
, , N
a DT N
placebo NN i
. . i

One CD N
hour NN N
after IN N
drug NN N
intake NN N
, , N
patients NNS N
underwent VBD N
an DT N
ergometrine JJ N
test NN N
with IN N
increasing VBG N
doses NNS N
of IN N
Methergin NNP i
( ( i
ergometrine NN i
) ) i
( ( N
0.05 CD N
, , N
0.10 CD N
, , N
0.20 CD N
, , N
and CC N
0.40 CD N
mg NN N
every DT N
5 CD N
min NN N
) ) N
. . N

After IN N
placebo NN i
, , N
the DT N
tests NNS N
always RB N
were VBD N
positive JJ N
, , N
and CC N
the DT N
ECG NNP o
changes NNS o
occurred VBD N
at IN N
the DT N
same JJ N
+/- JJ N
1 CD N
dose NN N
of IN N
ergometrine NN i
in IN N
10 CD N
cases NNS N
, , N
showing VBG N
good JJ o
reproducibility NN o
. . o

After IN N
nicorandil NN i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
nine CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
lower JJR N
dose NN N
of IN N
ergometrine NN i
in IN N
three CD N
and CC N
one CD N
patient NN N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0034 CD N
vs. FW N
placebo NN i
) ) i
. . N

After IN N
nifedipine NN i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
five CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
the DT N
same JJ N
dose NN N
of IN N
ergometrine NN i
in IN N
four CD N
and CC N
four CD N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0039 CD N
vs. FW N
placebo NN i
) ) i
. . N

Nifedipine NNP i
( ( N
10 CD N
mg NN N
) ) N
and CC N
nicorandil $ N
( ( N
30 CD N
mg NN N
) ) N
were VBD N
equally RB N
effective JJ N
in IN N
eight CD N
patients NNS N
; : N
in IN N
the DT N
remaining VBG N
five CD N
patients NNS N
, , N
nicorandil NNS i
had VBD N
better JJR N
results NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Nicorandil NNP i
( ( N
30 CD N
mg NN N
) ) N
prevents VBZ N
ergometrine-induced JJ o
coronary JJ o
spasm NN o
. . o

This DT N
compound NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS p
with IN p
vasospastic JJ o
angina NN o
. . o

-DOCSTART- -X- O O

Financial JJ i
and CC i
quality-of-life JJ i
burden NN i
of IN N
dysfunctional JJ p
uterine JJ p
bleeding NN p
among IN p
women NNS p
agreeing VBG p
to TO p
obtain VB p
surgical JJ p
treatment NN p
. . p

PURPOSE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
sought VBD N
to TO N
1 CD N
) ) N
describe NN N
elements NNS N
of IN N
the DT N
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
of IN N
dysfunctional JJ p
uterine JJ p
bleeding NN p
( ( p
DUB NNP p
) ) p
from IN N
the DT N
perspective NN N
of IN p
women NNS p
who WP p
agreed VBD p
to TO p
obtain VB p
surgical JJ p
treatment NN p
; : p
2 CD N
) ) N
explore NN N
associations NNS N
between IN N
DUB NNP N
symptom NN N
characteristics NNS N
and CC N
the DT N
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
; : i
3 CD N
) ) N
estimate VBP N
the DT N
annual JJ N
dollar NN N
value NN N
of IN N
the DT N
financial JJ N
burden NN N
; : N
and CC N
4 CD N
) ) N
estimate VBP N
the DT N
most RBS N
that DT N
could MD N
be VB N
spent VBN N
on IN N
surgery NN N
to TO N
eliminate VB N
DUB NNP N
symptoms NNS N
for IN N
which WDT N
medical JJ N
treatment NN N
has VBZ N
been VBN N
unsuccessful JJ N
that WDT N
would MD N
result VB N
in IN N
a DT N
$ $ N
50,000/quality-adjusted JJ N
life-year JJ N
incremental JJ N
cost-effectiveness NN N
ratio NN N
. . N

METHODS NNP N
We PRP p
collected VBD p
baseline NN i
data NNS i
on IN i
DUB NNP i
symptoms NNS i
and CC i
aspects NNS i
of IN i
the DT i
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
for IN p
237 CD p
women NNS p
agreeing VBG p
to TO p
surgery VB p
for IN p
DUB NNP p
in IN p
a DT p
randomized JJ p
trial NN p
comparing VBG p
hysterectomy NN p
with IN p
endometrial JJ p
ablation NN p
. . p

Measures NNS N
included VBD N
out-of-pocket JJ o
pharmaceutical JJ o
expenditures NNS o
, , o
excess JJ o
expenditures NNS o
on IN o
pads NNS o
or CC o
tampons NNS o
, , o
the DT o
value NN o
of IN o
time NN o
missed VBN o
from IN o
paid VBN o
work NN o
and CC o
home NN o
management NN o
activities NNS o
, , o
and CC o
health NN o
utility NN o
. . o

We PRP N
used VBD N
chi2 NN N
and CC N
t NN N
tests NNS N
to TO N
assess VB N
the DT N
statistical JJ N
significance NN N
of IN N
associations NNS N
between IN N
DUB NNP N
characteristics NNS N
and CC N
the DT N
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
. . i

The DT N
annual JJ N
financial JJ N
burden NN N
was VBD N
estimated VBN N
. . N

RESULTS NNP N
Pelvic NNP o
pain NN o
and CC o
cramps NNS o
were VBD o
associated VBN o
with IN o
activity NN o
limitations NNS o
and CC N
tiredness NN o
was VBD o
associated VBN o
with IN o
a DT o
lower JJR o
health NN o
utility NN o
. . o

Excess NNP o
pharmaceutical JJ o
and CC o
pad NN o
and CC o
tampon NN o
costs NNS o
were VBD N
$ $ N
333 CD N
per IN N
patient NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
$ $ N
263- JJ N
$ $ N
403 CD N
) ) N
. . N

Excess NNP N
paid VBD o
work NN o
and CC o
home NN o
management NN o
loss NN o
costs NNS o
were VBD N
$ $ N
2,291 CD N
per IN N
patient NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
1847- JJ N
$ $ N
2752 CD N
) ) N
. . N

Effective JJ o
surgical JJ o
treatment NN o
costing VBG N
$ $ N
40,000 CD N
would MD N
be VB N
cost-effective JJ o
compared VBN N
with IN N
unsuccessful JJ N
medical JJ N
treatment NN N
. . N

CONCLUSION NNP N
The DT N
financial JJ i
and CC i
quality-of-life JJ i
effects NNS i
of IN N
DUB NNP N
represent VBP N
a DT N
substantial JJ N
burden NN N
. . N

-DOCSTART- -X- O O

A DT N
short-term JJ i
cognitive JJ i
group NN i
treatment NN i
program NN i
gives VBZ N
substantial JJ N
weight NN o
reduction NN o
up RB N
to TO N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

A DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
describe VB N
and CC N
evaluate VB N
long-term JJ N
efficacy NN N
( ( N
18 CD N
months NNS N
from IN N
the DT N
end NN N
of IN N
treatment NN N
) ) N
of IN N
a DT N
new JJ N
cognitive JJ i
short-term JJ i
weight NN i
reducing VBG i
treatment NN i
program NN i
for IN N
obese JJ p
patients NNS p
. . p

SUBJECTS NNP N
One CD p
hundred CD p
and CC p
five CD p
obese JJ p
[ NN p
Body NNP p
Mass NNP p
Index NNP p
( ( p
BMI NNP p
) ) p
> VBD p
or CC p
= $ p
30 CD p
] JJ p
patients NNS p
participated VBN p
in IN p
the DT p
study NN p
. . p

Of IN N
these DT N
, , N
62 CD p
took VBD p
part NN p
in IN p
the DT p
treatment NN p
program NN p
and CC p
43 CD p
served VBD p
as IN p
controls NNS p
. . p

METHOD NNP N
From IN N
an DT N
obesity NN p
unit NN p
's POS p
waiting VBG p
list NN p
, , N
the DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
group NN N
or CC N
remained VBN N
in IN N
the DT N
waiting VBG N
list NN N
to TO N
serve VB N
as IN N
a DT N
control NN i
group NN N
. . N

The DT N
treatment NN N
group NN N
participated VBD N
in IN N
a DT N
10-week JJ i
( ( i
30 CD i
hours NNS i
) ) i
cognitive VBP i
group NN i
treatment NN i
program NN i
. . i

All DT N
participants NNS N
were VBD N
weighed VBN N
at IN N
the DT N
outset NN N
of IN N
the DT N
study NN N
, , N
directly RB N
after IN N
treatment NN N
and CC N
at IN N
a DT N
6- JJ N
, , N
12- JJ N
and CC N
18-month JJ N
post-treatment JJ i
follow-up NN N
without IN N
any DT N
booster NN N
treatment NN i
after IN N
the DT N
10-week JJ N
program NN N
. . N

RESULTS NNP N
Fifty-seven NNP p
( ( p
92 CD p
% NN p
) ) p
patients NNS p
completed VBN p
treatment NN i
. . i

For IN N
the DT N
34 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
who WP N
participated VBD N
in IN N
the DT N
study NN N
18 CD N
months NNS N
after IN N
treatment NN N
was VBD N
terminated VBN N
, , N
the DT N
mean JJ o
weight NN o
loss NN o
at IN N
treatment NN N
's POS N
end NN N
was VBD N
8.5 CD N
kg NN N
( ( N
SD=16.1 NNP N
) ) N
. . N

Eighteen JJ N
months NNS N
later RB N
their PRP$ N
mean JJ o
weight NN o
loss NN o
was VBD N
10.4 CD N
kg NN N
( ( N
SD=10.8 NNP N
) ) N
. . N

The DT N
control NN N
patients NNS N
( ( N
n=31.72 JJ N
% NN N
) ) N
that WDT N
participated VBD N
in IN N
the DT N
study NN N
during IN N
the DT N
same JJ N
period NN N
increased VBD N
in IN N
weight NN o
by IN N
2.3 CD N
kg NNS N
( ( N
SD=7.0 NNP N
) ) N
. . N

The DT N
weight NN o
difference NN o
between IN N
the DT N
treatment NN N
and CC N
control NN N
group NN N
at IN N
the DT N
18-month JJ N
follow-up NN N
was VBD N
highly RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
cognitive JJ i
group NN i
treatment NN i
program NN i
was VBD N
highly RB N
acceptable JJ N
among IN N
the DT N
participants NNS N
and CC N
was VBD N
completed VBN N
by IN N
nearly RB N
all PDT N
the DT N
patients NNS N
. . N

The DT N
10-week JJ N
treatment NN N
program NN N
resulted VBD N
in IN N
satisfactory JJ N
weight JJ o
loss NN o
. . o

The DT N
weight NN N
difference NN N
between IN N
the DT N
treatment NN i
group NN N
and CC N
controls NNS i
was VBD N
nearly RB N
the DT N
same JJ N
at IN N
18 CD N
months NNS N
after IN N
end NN N
of IN N
treatment NN N
as IN N
at IN N
six CD N
months NNS N
. . N

The DT N
study NN N
, , N
therefore RB N
, , N
does VBZ N
not RB N
provide VB N
support NN N
for IN N
the DT N
contention NN N
that IN N
a DT N
lengthy JJ N
therapy NN N
for IN N
obesity NN N
is VBZ N
necessary JJ N
if IN N
treatment NN N
results NNS N
are VBP N
lasting VBG N
. . N

-DOCSTART- -X- O O

Dose-response JJ o
effect NN o
of IN N
flecainide NN i
in IN N
patients NNS p
with IN p
symptomatic JJ p
paroxysmal JJ p
atrial JJ p
fibrillation NN p
and/or NN p
flutter NN p
monitored VBD p
with IN p
trans-telephonic JJ p
electrocardiography NN p
: : p
a DT N
multicenter NN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
trial NN N
. . N

BACKGROUND VB N
A DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS p
with IN p
paroxysmal JJ p
atrial JJ p
fibrillation NN p
or CC p
flutter NN p
( ( p
PAF/PAFL NNP p
) ) p
experiencing VBG p
2 CD p
or CC p
more JJR p
episodes NNS p
of IN p
symptomatic JJ p
PAF/PAFL NNP p
during IN p
a DT p
28-day JJ p
observation NN p
period NN p
to TO p
determine VB p
the DT p
dose-response JJ p
effect NN o
and CC o
safety NN o
of IN p
flecainide NN i
. . i

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
total NN N
of IN N
143 CD p
patients NNS p
at IN p
30 CD p
centers NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
25 CD N
, , N
50 CD N
, , N
or CC N
100 CD N
mg NN N
of IN N
flecainide NN i
or CC i
placebo VB i
twice JJ N
daily JJ N
( ( N
BID NNP N
) ) N
. . N

In IN N
123 CD p
patients NNS p
( ( N
per IN N
protocol NN N
set NN N
) ) N
, , N
those DT N
remaining VBG N
free JJ N
from IN N
PAF/PAFL NNP o
after IN N
the DT N
treatment NN N
were VBD N
3.1 CD N
% NN N
on IN N
placebo NN i
, , N
7.7 CD N
% NN N
on IN N
25 CD N
mg/BID NN N
, , N
9.4 CD N
% NN N
on IN N
50 CD N
mg/BID NN N
, , N
and CC N
39.4 CD N
% NN N
on IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN i
. . i

As IN N
a DT N
whole JJ N
group NN N
, , N
a DT N
significant JJ o
linear JJ o
dose-response NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
was VBD N
observed VBN N
and CC N
a DT N
significant JJ N
difference NN N
between IN N
placebo NN N
and CC N
100 CD N
mg/BID NN N
was VBD N
observed VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
similar JJ N
dose-response NN o
between IN N
the DT N
present JJ N
study NN N
and CC N
Caucasian NNP N
study NN N
was VBD N
demonstrated VBN N
. . N

Although IN N
there EX N
were VBD N
5 CD N
patients NNS N
who WP N
needed VBD N
cardioversion NN o
or CC o
ablation NN o
because IN N
of IN N
frequent JJ N
episodes NNS N
of IN N
PAF/PAFL NNP N
( ( N
2 CD N
in IN N
25 CD N
mg/BID NN N
, , N
1 CD N
in IN N
50 CD N
mg/BID NN N
, , N
and CC N
2 CD N
in IN N
100 CD N
mg/BID NN N
of IN N
flecainide NN i
) ) i
, , N
neither CC N
death NN o
nor CC o
ventricular JJ o
proarrhythmic JJ o
event NN o
was VBD N
reported VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicated VBD N
that IN N
flecainide NN i
exerted VBD N
a DT N
significant JJ N
dose-dependent JJ N
effect NN N
on IN N
the DT N
prevention NN N
of IN N
symptomatic JJ N
PAF/PAFL NNP N
recurrence NN N
and CC N
showed VBD N
that IN N
there EX N
was VBD N
no DT N
inter-ethnic JJ N
difference NN N
in IN N
the DT N
clinical JJ N
effect NN N
of IN N
flecainide NN i
in IN N
patients NNS p
with IN p
PAF/PAFL NNP p
. . p

-DOCSTART- -X- O O

Human NNP i
papillomavirus NN i
and CC N
Papanicolaou NNP i
tests NNS i
to TO N
screen VB N
for IN N
cervical JJ N
cancer NN N
. . N

BACKGROUND NNP N
Screening NNP N
for IN N
cervical JJ N
cancer NN N
based VBN N
on IN N
testing VBG N
for IN N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
increases VBZ N
the DT N
sensitivity NN N
of IN N
detection NN N
of IN N
high-grade NN N
( ( N
grade JJ N
2 CD N
or CC N
3 CD N
) ) N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
, , N
but CC N
whether IN N
this DT N
gain NN N
represents VBZ N
overdiagnosis NN N
or CC N
protection NN N
against IN N
future JJ N
high-grade JJ N
cervical JJ N
epithelial JJ N
neoplasia NN N
or CC N
cervical JJ N
cancer NN N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
In IN p
a DT p
population-based JJ p
screening NN p
program NN p
in IN p
Sweden NNP p
, , p
12,527 CD p
women NNS p
32 CD p
to TO p
38 CD p
years NNS p
of IN p
age NN p
were VBD p
randomly RB p
assigned VBN p
at IN N
a DT N
1:1 CD N
ratio NN N
to TO N
have VB N
an DT N
HPV NNP i
test NN i
plus CC i
a DT i
Papanicolaou NNP i
( ( i
Pap NNP i
) ) i
test NN i
( ( i
intervention NN i
group NN i
) ) i
or CC N
a DT i
Pap JJ i
test NN i
alone RB i
( ( i
control VB i
group NN i
) ) i
. . i

Women NNS N
with IN N
a DT N
positive JJ N
HPV NNP i
test NN i
and CC N
a DT N
normal JJ N
Pap NNP i
test NN i
result NN N
were VBD N
offered VBN N
a DT N
second JJ N
HPV NNP i
test NN i
at IN N
least JJS N
1 CD N
year NN N
later RB N
, , N
and CC N
those DT N
who WP N
were VBD N
found VBN N
to TO N
be VB N
persistently RB N
infected VBN N
with IN N
the DT N
same JJ N
high-risk JJ N
type NN N
of IN N
HPV NNP N
were VBD N
then RB N
offered VBN N
colposcopy NN N
with IN N
cervical JJ N
biopsy NN N
. . N

A DT N
similar JJ N
number NN N
of IN N
double-blinded JJ o
Pap NNP o
smears NNS o
and CC o
colposcopies NNS o
with IN o
biopsy NN o
were VBD N
performed VBN N
in IN N
randomly RB N
selected VBN N
women NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Comprehensive JJ N
registry NN N
data NNS N
were VBD N
used VBN N
to TO N
follow VB N
the DT N
women NNS N
for IN N
a DT N
mean NN N
of IN N
4.1 CD N
years NNS N
. . N

The DT N
relative JJ N
rates NNS o
of IN o
grade JJ o
2 CD o
or CC o
3 CD o
cervical JJ o
intraepithelial JJ o
neoplasia NN o
or CC o
cancer NN o
detected VBN o
at IN N
enrollment NN N
and CC N
at IN N
subsequent JJ N
screening VBG N
examinations NNS N
were VBD N
calculated VBN N
. . N

RESULTS NNP N
At IN N
enrollment NN N
, , N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
intervention NN i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
lesions NNS o
of IN o
grade NN o
2 CD o
or CC o
3 CD o
cervical JJ o
intraepithelial JJ o
neoplasia NN o
or CC o
cancer NN o
was VBD N
51 CD N
% NN N
greater JJR N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
13 CD N
to TO N
102 CD N
) ) N
than IN N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
control NN i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
such JJ N
lesions NNS N
. . N

At IN N
subsequent JJ N
screening VBG N
examinations NNS N
, , N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
intervention NN i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
grade VBN N
2 CD o
or CC o
3 CD o
lesions NNS o
or CC o
cancer NN o
was VBD N
42 CD N
% NN N
less JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
4 CD N
to TO N
64 CD N
) ) N
and CC N
the DT N
proportion NN N
with IN N
grade JJ N
3 CD N
lesions NNS N
or CC N
cancer NN N
was VBD N
47 CD N
% NN N
less JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
2 CD N
to TO N
71 CD N
) ) N
than IN N
the DT N
proportions NNS N
of IN N
control NN i
women NNS N
who WP N
were VBD N
found VBN N
to TO N
have VB N
such JJ N
lesions NNS N
. . N

Women NNS N
with IN N
persistent JJ N
HPV NNP N
infection NN N
remained VBD N
at IN N
high JJ N
risk NN N
for IN N
grade JJ N
2 CD N
or CC N
3 CD N
lesions NNS N
or CC N
cancer NN N
after IN N
referral JJ N
for IN N
colposcopy NN N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
an DT N
HPV NNP i
test NN i
to TO N
the DT N
Pap NNP i
test NN i
to TO N
screen JJ N
women NNS p
in IN p
their PRP$ p
mid-30s NN p
for IN N
cervical JJ N
cancer NN N
reduces VBZ N
the DT N
incidence NN N
of IN N
grade NN N
2 CD N
or CC N
3 CD N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
or CC N
cancer NN N
detected VBN N
by IN N
subsequent JJ N
screening NN N
examinations NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00479375 NNP N
[ NNP N
ClinicalTrials.gov NNP N
] NNP N
. . N

) ) N
. . N

-DOCSTART- -X- O O

Midazolam NNP i
vs NN i
ondansetron NN i
for IN N
preventing VBG N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
: : o
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

We PRP N
compared VBN N
the DT N
prophylactic JJ N
anti-emetic JJ N
efficacy NN N
of IN N
midazolam NN i
and CC N
ondansetron NN i
in IN N
90 CD p
patients NNS p
scheduled VBN p
for IN p
minor JJ p
gynaecological JJ p
( ( p
hysteroscopy NN p
) ) p
or CC p
urological JJ p
( ( p
ureteroscopy JJ p
) ) p
procedures NNS p
planned VBN p
to TO p
last JJ p
1-2 JJ p
h NN p
under IN p
sevoflurane NN p
anaesthesia NN p
with IN p
spontaneous JJ p
ventilation NN p
of IN p
the DT p
lungs NNS p
via IN p
a DT p
laryngeal JJ p
mask NN p
airway NN p
. . p

Midazolam NNP i
2 CD i
mg NN i
or CC i
ondansetron $ i
4 CD i
mg NN i
were VBD N
administered VBN N
intravenously RB N
30 CD N
min NN N
before IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

The DT N
proportions NNS N
of IN N
patients NNS p
who WP p
experienced VBD p
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
in IN p
the DT p
first JJ p
24 CD p
h NN p
( ( p
30 CD p
% NN p
and CC p
27 CD p
% NN p
for IN p
the DT p
midazolam NN i
and CC p
ondansetron NN i
groups NNS p
, , p
respectively RB p
) ) p
were VBD p
similar JJ o
in IN p
the DT p
two CD p
groups NNS p
. . p

The DT N
incidence NN N
of IN N
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
was VBD N
significantly RB N
smaller JJR o
in IN N
both DT N
groups NNS N
than IN N
predicted VBN N
according VBG N
to TO N
the DT N
patients NNS p
' POS p
underlying JJ p
risks NNS p
( ( i
midazolam JJ i
group NN p
: : p
p NN p
= VBZ p
0.018 CD p
; : p
ondansetron VBN i
group NN p
: : p
p NN p
= VBZ p
0.017 CD p
) ) p
. . p

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
in IN N
average JJ o
sedation NN o
scores NNS o
or CC o
pain NN o
scores NNS o
. . o

Treatment NNP N
using VBG N
ondansetron NN i
for IN N
anti-emetic JJ N
prophylaxis NN N
did VBD N
not RB N
provide VB N
a DT N
superior JJ N
benefit NN N
compared VBN N
to TO N
midazolam VB i
in IN N
the DT N
present JJ N
study NN N
. . N

-DOCSTART- -X- O O

Resistance NNP i
training NN i
increases NNS N
basal VBP N
limb JJ N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
in IN N
aging VBG p
humans NNS p
. . p

Age-related JJ N
reductions NNS N
in IN N
basal NN N
limb NN N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
are VBP N
associated VBN N
with IN N
the DT N
metabolic JJ N
syndrome NN N
, , N
functional JJ N
impairments NNS N
, , N
and CC N
osteoporosis NN N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
a DT N
strength NN i
training NN i
program NN i
would MD N
increase VB N
basal JJ o
femoral JJ o
blood NN o
flow NN o
in IN N
aging VBG p
adults NNS p
. . p

Twenty-six JJ p
sedentary JJ p
but CC p
healthy JJ p
middle-aged JJ p
and CC p
older JJR p
subjects NNS p
were VBD N
randomly RB i
assigned VBN i
to TO i
either CC i
a DT i
whole JJ i
body NN i
strength NN i
training VBG i
intervention NN i
group NN i
( ( i
52 CD i
+/- JJ i
2 CD i
yr NN i
, , i
3 CD i
men NNS i
, , i
10 CD i
women NNS i
) ) i
who WP i
underwent VBD i
three CD i
supervised VBN i
resistance NN i
training NN i
sessions NNS i
per IN i
week NN i
for IN i
13 CD i
wk NN i
or CC i
a DT i
control NN i
group NN i
( ( i
53 CD i
+/- JJ i
2 CD i
yr NN i
, , i
4 CD i
men NNS i
, , i
9 CD i
women NNS i
) ) i
who WP i
participated VBD i
in IN i
a DT i
supervised JJ i
stretching NN i
program NN i
. . i

At IN p
baseline NN p
, , p
there EX p
were VBD p
no DT p
significant JJ p
differences NNS p
in IN p
blood NN o
pressure NN o
, , o
cardiac JJ o
output NN o
, , o
basal JJ o
femoral JJ o
blood NN o
flow NN o
( ( o
via IN o
Doppler NNP o
ultrasound NN o
) ) o
, , o
vascular JJ o
conductance NN o
, , o
and CC o
vascular JJ o
resistance NN o
between IN p
the DT p
two CD p
groups NNS p
. . p

The DT N
strength NN i
training VBG i
group NN i
increased VBD N
maximal JJ o
strength NN o
in IN N
all PDT N
the DT N
major JJ N
muscle NN N
groups NNS N
tested VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Whole JJ o
body NN o
lean JJ o
body NN o
mass NN o
increased VBD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
with IN N
strength NN N
training NN N
, , N
but CC N
leg VBZ o
fat-free JJ o
mass NN o
did VBD N
not RB N
. . N

Basal NNP o
femoral JJ o
blood NN o
flow NN o
and CC o
vascular JJ o
conductance NN o
increased VBN N
by IN N
55-60 CD N
% NN N
after IN N
strength NN i
training NN i
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
such JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
both DT N
groups NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
brachial JJ o
blood NN o
pressure NN o
, , o
plasma JJ o
endothelin-1 NN o
and CC o
angiotensin NN o
II NNP o
concentrations NNS o
, , o
femoral JJ o
artery NN o
wall NN o
thickness NN o
, , o
cardiac JJ o
output NN o
, , o
and CC o
systemic JJ o
vascular JJ o
resistance NN o
. . o

Our PRP$ N
results NNS N
indicate VBP N
that IN N
short-term JJ i
strength NN i
training NN i
increases NNS N
basal VBP N
femoral JJ N
blood NN N
flow NN N
and CC N
vascular JJ N
conductance NN N
in IN N
healthy JJ p
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

-DOCSTART- -X- O O

Determinants NNS N
of IN N
serum JJ N
creatinine NN N
trajectory NN N
in IN N
acute JJ p
contrast NN p
nephropathy NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
describe VB N
the DT N
trajectory NN N
of IN N
creatinine NN o
( ( o
Cr NNP o
) ) o
rise NN o
and CC N
its PRP$ N
determinants NNS N
after IN p
exposure NN p
to TO p
radiocontrast VB p
media NNS p
. . p

Included VBN N
were VBD N
98 CD p
subjects NNS p
who WP p
underwent VBP p
cardiac JJ p
catheterization NN p
and CC N
were VBD N
randomized VBN N
to TO N
forced VBN N
diuresis NN i
with IN i
i.v NN i
. . i

crystalloid NN i
, , i
furosemide RB i
, , i
mannitol NN i
( ( i
if IN i
pulmonary JJ i
capillary JJ i
wedge NN i
pressure NN i
was VBD i
< JJ i
20 CD i
mmHg NN i
) ) i
, , i
and CC i
low JJ i
dose JJ i
dopamine NN i
versus NN i
intravenous JJ i
crystalloid NN i
and CC i
matching VBG i
placebos NNS i
. . i

Baseline NNP N
and CC N
postcatheterization NN N
serum NN o
Cr NNP o
levels NNS o
were VBD N
analyzed VBN N
in IN N
a DT N
longitudinal JJ N
fashion NN N
, , N
allowing VBG N
for IN N
differences NNS N
in IN N
the DT N
time NN N
between IN N
blood NN N
draws NNS N
, , N
to TO N
determine VB N
the DT N
different JJ N
critical JJ N
trajectories NNS N
of IN N
serum NN N
Cr NNP N
. . N

The DT p
mean JJ o
age NN o
, , o
baseline NN o
serum NN o
Cr NNP o
, , o
and CC o
Cr NNP o
clearance NN o
( ( o
CrCl NNP o
) ) o
were VBD p
69.3 CD p
+/- JJ p
10.8 CD p
years NNS p
, , p
2.5 CD p
+/- JJ p
0.9 CD p
mg/dL NN p
, , p
and CC p
31.4 CD p
+/- JJ p
12.1 CD p
mL/min NN p
, , p
respectively RB p
. . p

The DT N
clinically RB o
driven JJ o
postprocedural JJ o
observation NN o
time NN o
was VBD N
5.5 CD N
+/- JJ N
5.1 CD N
days NNS N
( ( N
range VB N
19 CD N
hours NNS N
and CC N
one CD N
Cr NNP N
value NN N
to TO N
25.7 CD N
days NNS N
and CC N
18 CD N
values NNS N
) ) N
. . N

The DT N
mean JJ o
maximum NN o
Cr NNP o
was VBD N
3.3 CD N
+/- JJ N
1.4 CD N
, , N
range NN N
1.7-8.7 JJ N
mg/dL NN N
) ) N
. . N

Longitudinal JJ N
models NNS N
support VBP N
baseline JJ N
Cr NNP o
clearance NN o
predictions NNS N
for IN N
the DT N
change NN N
in IN N
Cr NNP N
at IN N
24 CD N
hours NNS N
, , N
time NN N
as IN N
the DT N
determinant NN N
of IN N
Cr NNP N
trajectory NN N
, , N
and CC N
requisite JJ N
monitoring NN N
. . N

For IN N
any DT N
given VBN N
individual NN N
, , N
a DT N
rise NN N
in IN N
Cr NNP o
of IN N
< NNP N
or CC N
= $ N
0.5 CD N
mg/dL NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
after IN N
contrast NN N
exposure NN N
predicted VBD N
a DT N
favorable JJ N
outcome NN N
. . N

Baseline NNP o
renal JJ o
function NN o
is VBZ N
the DT N
major JJ N
determinant NN N
of IN N
the DT N
rate NN N
of IN N
rise NN N
, , N
height NN N
, , N
and CC N
duration NN N
of IN N
Cr NNP N
trajectory NN N
after IN N
contrast NN N
exposure NN N
. . N

Length NNP N
of IN N
observation NN N
and CC N
frequency NN N
of IN N
laboratory NN N
measures NNS N
can MD N
be VB N
anticipated VBN N
from IN N
these DT N
models NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Effect NNP N
of IN N
dopexamine NN i
in IN N
splanchnic JJ N
perfusion NN N
during IN N
surgery NN p
of IN p
the DT p
abdominal JJ p
aorta NN p
] NNP p
. . N

Abdominal NNP N
aortic JJ N
surgery NN N
has VBZ N
significant JJ N
effects NNS N
on IN N
cardiac NN N
and CC N
splanchnic JJ N
perfusion NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
dopexamine NN N
, , N
an DT N
inodilator JJ N
drug NN N
, , N
on IN N
hemodynamic JJ N
and CC N
splanchnic JJ N
perfusion NN N
with IN N
measurement NN N
of IN N
gastric JJ N
intramucosal NN N
pH NN N
, , N
by IN N
the DT N
method NN N
of IN N
gastric JJ N
tonometry NN N
, , N
during IN N
abdominal JJ N
aneurysm JJ N
resection NN N
. . N

Twenty-five JJ p
patients NNS p
undergoing VBG p
excision NN p
of IN p
an DT p
aortic JJ p
abdominal JJ p
aneurysm NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
Group NNP N
II NNP N
patients NNS N
received VBD N
dopexamine JJ i
infusion NN N
, , N
at IN N
a DT N
dose NN N
of IN N
1 CD N
microgram/kg/m NN N
, , N
and CC N
at IN N
a DT N
dose NN N
of IN N
0.5 CD N
micrograms/kg/m NN N
from IN N
declamping VBG N
to TO N
the DT N
end NN N
of IN N
the DT N
surgery NN N
. . N

Whereas NNP N
Group NNP N
I PRP N
patients NNS N
did VBD i
not RB i
receive VB i
a DT i
dopexamine JJ i
infusion NN i
. . i

During IN N
aortic JJ N
cross-clamping VBG N
the DT N
intramucosal NN o
pH VBZ o
value NN o
decreased VBN N
in IN N
Group NNP N
I PRP N
patients NNS N
, , N
but CC N
did VBD N
not RB N
change VB N
in IN N
Group NNP N
II NNP N
patients NNS N
. . N

Heart NNP o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
mixed JJ o
venous JJ o
oxygen NN o
saturation NN o
increased VBD N
significantly RB N
during IN N
dopexamine JJ N
infusion NN N
, , N
whereas JJ N
systemic JJ o
vascular NN o
resistance NN o
was VBD N
reduced VBN N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
dopexamine NN i
was VBD N
a DT N
useful JJ N
agent NN N
in IN N
improving VBG N
splanchnic JJ o
blood NN o
flow NN o
, , o
cardiac JJ o
index NN o
venous JJ o
saturation NN o
. . o

Also RB N
, , N
since IN N
the DT N
drug NN N
produces VBZ N
dose RB N
related JJ N
hemodynamic JJ N
changes NNS N
of IN N
rapid JJ N
onset NN N
and CC N
reversibility NN N
, , N
it PRP N
is VBZ N
possible JJ N
to TO N
interrupt VB N
the DT N
infusion NN N
before IN N
aortic JJ N
declamping NN N
to TO N
avoid VB N
the DT N
decrease NN N
in IN N
the DT N
intramucosal NN N
pH VBZ N
value NN N
. . N

-DOCSTART- -X- O O

Effect NN p
of IN p
resistance NN i
exercise NN i
contraction NN i
mode NN i
and CC p
protein JJ i
supplementation NN i
on IN p
members NNS p
of IN p
the DT p
STARS NNP p
signalling VBG p
pathway RB p
. . p

The DT N
striated JJ N
muscle NN N
activator NN N
of IN N
Rho NNP N
signalling VBG N
( ( N
STARS NNP N
) ) N
pathway NN N
is VBZ N
suggested VBN N
to TO N
provide VB N
a DT N
link NN N
between IN N
external JJ N
stress NN N
responses NNS N
and CC N
transcriptional JJ N
regulation NN N
in IN N
muscle NN N
. . N

However RB N
, , N
the DT N
sensitivity NN N
of IN N
STARS NNP N
signalling VBG N
to TO N
different JJ N
mechanical JJ N
stresses NNS N
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

In IN N
a DT N
comparative JJ N
study NN N
, , N
we PRP N
examined VBD N
the DT N
regulation NN N
of IN N
the DT N
STARS NNP N
signalling VBG N
pathway RB N
in IN N
response NN N
to TO N
unilateral JJ N
resistance NN i
exercise NN i
performed VBN N
as IN N
either DT N
eccentric JJ i
( ( i
ECC NNP i
) ) i
or CC i
concentric JJ i
( ( i
CONC NNP i
) ) i
contractions NNS i
as RB N
well RB N
as IN N
prolonged JJ i
training NN i
; : i
with IN p
and CC p
without IN p
whey JJ i
protein NN i
supplementation NN i
. . i

Skeletal JJ N
muscle NN N
STARS NNP N
, , N
myocardian-related JJ N
transcription NN N
factor-A NN N
( ( N
MRTF-A NNP N
) ) N
and CC N
serum JJ N
response NN N
factor NN N
( ( N
SRF NNP N
) ) N
mRNA NN N
and CC N
protein NN N
, , N
as RB N
well RB N
as IN N
muscle NN N
cross-sectional JJ N
area NN N
and CC N
maximal JJ N
voluntary JJ N
contraction NN N
, , N
were VBD N
measured VBN N
. . N

A DT N
single-bout NN N
of IN N
exercise NN i
produced VBN N
increases NNS N
in IN N
STARS NNP o
and CC o
SRF NNP o
mRNA NN o
and CC o
decreases NNS o
in IN o
MRTF-A NNP o
mRNA NN o
with IN o
both DT o
ECC NNP o
and CC o
CONC NNP o
exercise NN o
, , N
but CC N
with IN N
an DT N
enhanced JJ N
response NN N
occurring VBG N
following VBG N
ECC NNP i
exercise NN i
. . i

A DT N
31 CD N
% NN N
increase NN N
in IN N
STARS NNP o
protein NN o
was VBD N
observed VBN N
exclusively RB N
after IN N
CONC NNP i
exercise NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
pSRF JJ o
protein NN N
levels NNS N
increased VBD N
similarly RB N
by IN N
48 CD N
% NN N
with IN N
both DT N
CONC NNP N
and CC N
ECC NNP N
exercise NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Prolonged VBN N
ECC NNP N
and CC N
CONC NNP N
training VBG N
equally RB N
stimulated VBN N
muscle NN N
hypertrophy NN N
and CC N
produced VBD N
increases NNS N
in IN N
MRTF-A NNP o
protein NN o
of IN N
125 CD N
% NN N
and CC N
99 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No UH N
changes NNS N
occurred VBD N
for IN N
total JJ o
SRF NNP o
protein NN o
. . o

There EX N
was VBD N
no DT N
effect NN N
of IN N
whey NN o
protein NN o
supplementation NN o
. . o

These DT N
results NNS N
show VBP N
that IN N
resistance NN N
exercise NN N
provides VBZ N
an DT N
acute JJ o
stimulation NN o
of IN o
the DT o
STARS NNP o
pathway NN o
that WDT N
is VBZ N
contraction JJ N
mode NN N
dependent NN N
. . N

The DT N
responses NNS N
to TO N
acute VB i
exercise NN i
were VBD N
more RBR N
pronounced JJ N
than IN N
responses NNS N
to TO N
accumulated JJ i
training NN i
, , N
suggesting VBG N
that IN N
STARS NNP N
signalling VBG N
is VBZ N
primarily RB N
involved VBN N
in IN N
the DT N
initial JJ N
phase NN N
of IN N
exercise-induced JJ N
muscle NN N
adaptations NNS N
. . N

-DOCSTART- -X- O O

A DT N
phase NN N
III NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
on IN N
the DT N
efficacy NN N
of IN N
recombinant JJ i
human JJ i
antithrombin NN i
in IN N
heparin-resistant JJ p
patients NNS p
scheduled VBN p
to TO p
undergo VB p
cardiac JJ p
surgery NN p
necessitating VBG p
cardiopulmonary JJ p
bypass NN p
. . p

BACKGROUND IN N
The DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
recombinant JJ i
human JJ i
antithrombin NN i
( ( i
rhAT NN i
) ) i
for IN N
restoring VBG N
heparin NN o
responsiveness NN o
in IN N
heparin NN p
resistant JJ p
patients NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
in IN N
heparin-resistant JJ p
patients NNS p
undergoing VBG p
cardiac JJ p
surgery NN p
with IN p
cardiopulmonary JJ p
bypass NN p
. . p

Heparin NNP i
resistance NN p
was VBD p
diagnosed VBN p
when WRB p
the DT p
activated VBN p
clotting NN p
time NN p
was VBD p
less JJR p
than IN p
480 CD p
s NNS p
after IN p
400 CD p
U/kg NNP p
heparin NN i
. . i

Fifty-four JJ p
heparin-resistant JJ p
patients NNS p
were VBD p
randomized VBN p
. . p

One CD N
cohort NN N
received VBD i
75 CD i
U/kg NNP i
rhAT NN i
, , i
and CC i
the DT i
other JJ i
received VBD i
normal JJ i
saline NN i
. . i

If IN N
the DT N
activated JJ N
clotting NN N
time NN N
remained VBD N
less JJR N
than IN N
480 CD N
s NN N
, , N
this DT N
was VBD N
considered VBN N
treatment NN N
failure NN N
, , N
and CC N
2 CD N
units NNS N
fresh JJ N
frozen JJ N
plasma NN N
was VBD N
transfused VBN N
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ N
events NNS N
. . N

RESULTS NNP N
Only RB N
19 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
rhAT NN i
group NN N
received VBD N
fresh JJ o
frozen JJ o
plasma NN o
, , N
compared VBN N
with IN N
81 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

During IN N
their PRP$ N
hospitalization NN N
, , N
48 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
rhAT NN i
group NN N
received VBD N
fresh JJ o
frozen JJ o
plasma NN o
, , N
compared VBN N
with IN N
85 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

Patients NNS N
in IN N
the DT N
placebo NN N
group NN N
required VBD N
higher JJR N
heparin NN i
doses NNS N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
for IN N
anticoagulation NN N
. . N

There EX N
was VBD N
no DT o
increase NN o
in IN o
serious JJ o
adverse JJ o
events NNS o
associated VBN N
with IN N
rhAT NN i
. . i

There EX N
was VBD N
increased VBN o
blood NN o
loss NN o
12 CD N
h NN N
postoperatively RB N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
with IN N
a DT N
trend NN N
toward IN N
increased VBN N
24-h JJ o
bleeding NN o
in IN N
the DT N
rhAT NN i
group NN N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
blood NN N
and CC N
platelet NN N
transfusions NNS N
. . N

CONCLUSION NNP N
Treatment NNP N
with IN N
75 CD N
U/kg NNP N
rhAT NN i
is VBZ N
effective JJ o
in IN o
restoring VBG o
heparin NN o
responsiveness NN o
and CC N
promoting VBG N
therapeutic JJ o
anticoagulation NN o
in IN N
the DT N
majority NN N
of IN N
heparin-resistant JJ p
patients NNS p
. . p

Treating VBG N
heparin-resistant JJ p
patients NNS p
with IN N
rhAT NN i
may MD N
decrease VB o
the DT o
requirement NN o
for IN o
heparin NN o
and CC N
fresh JJ N
frozen JJ N
plasma NN N
. . N

-DOCSTART- -X- O O

Proposed VBN N
synergistic JJ N
effect NN N
of IN N
calcium NN i
channel NN i
blockers NNS i
with IN N
lipid-lowering JJ i
therapy NN i
in IN N
retarding VBG p
progression NN o
of IN o
coronary JJ o
atherosclerosis NN o
. . o

Lipid-lowering JJ i
therapy NN i
now RB N
has VBZ N
undoubtedly RB N
proven VBN N
to TO N
be VB N
an DT N
effective JJ N
therapeutic JJ N
modality NN N
to TO N
retard VB N
the DT N
progression NN N
of IN N
coronary JJ N
atherosclerosis NN o
. . o

An DT N
additional JJ N
approach NN N
for IN N
prevention NN N
of IN N
the DT N
progression NN o
of IN o
atherosclerosis NN o
is VBZ N
calcium JJ i
channel NN i
blocker NN i
( ( i
CCB NNP i
) ) i
treatment NN N
. . N

Evidence NN N
indicating VBG N
that IN N
CCBs NNP i
inhibit NN N
atherosclerosis NN N
is VBZ N
less RBR N
unequivocal JJ N
than IN N
the DT N
clear JJ N
evidence NN N
for IN N
lipid-lowering JJ i
therapy NN i
. . i

Many JJ N
investigations NNS N
support VBP N
the DT N
view NN N
that IN N
a DT N
number NN N
of IN N
key JJ N
processes NNS N
in IN N
atherosclerosis NN N
may MD N
be VB N
influenced VBN N
by IN N
CCBs NNP i
. . N

From IN N
the DT N
negative JJ N
and CC N
positive JJ N
studies NNS N
with IN N
CCBs NNP i
performed VBD N
in IN N
animals NNS p
and CC p
humans NNS p
we PRP N
must MD N
conclude VB N
that DT N
apparently RB N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
types NNS N
or CC N
stages NNS N
of IN N
the DT N
atherosclerotic JJ N
process NN N
are VBP N
inhibited VBN N
by IN N
CCBs NNP i
. . N

To TO N
assess VB N
whether IN N
lipid-lowering JJ i
therapy NN i
and CC N
CCB NNP i
treatment NN N
may MD N
have VB N
an DT N
additive JJ N
or CC N
synergistic JJ N
beneficial JJ N
effect NN N
on IN N
human JJ N
atherosclerosis NN o
, , N
which WDT N
is VBZ N
conceivable JJ N
because IN N
their PRP$ N
anti-atherosclerotic JJ N
properties NNS N
differ VBP N
, , N
data NNS p
from IN p
the DT p
angiographic JJ p
lipid-lowering JJ p
trial NN p
REGRESS NNP p
( ( i
pravastatin NN i
vs. FW p
placebo NN i
) ) i
were VBD N
reviewed VBN N
. . N

In IN N
REGRESS NNP N
, , N
patients NNS N
in IN N
the DT N
pravastatin NN i
group NN N
had VBD N
significantly RB N
less JJR N
progression NN o
if IN N
cotreated VBN N
with IN N
CCBs NNP i
as IN N
compared VBN N
with IN N
those DT N
with IN N
no DT N
CCB NNP i
cotreatment NN N
, , N
whereas NNS N
in IN N
the DT N
placebo NN i
( ( i
no DT i
pravastatin NN i
) ) i
group NN N
no DT N
effect NN N
of IN N
CCB NNP i
treatment NN N
was VBD N
observed VBN N
. . N

With IN N
respect NN N
to TO N
angiographic VB o
new JJ o
lesion NN o
formation NN o
, , N
in IN N
the DT N
pravastatin NN i
group NN N
there EX N
were VBD N
50 CD N
% NN N
less JJR N
patients NNS N
with IN N
new JJ N
angiographic JJ o
lesions NNS o
if IN N
cotreated VBN N
with IN N
CCBs NNP i
as IN N
compared VBN N
with IN N
no DT N
CCB NNP i
cotreatment NN N
, , N
whereas NNS N
in IN N
the DT N
placebo NN i
( ( i
no DT i
pravastatin NN i
) ) i
group NN N
, , N
again RB N
, , N
no DT N
significant JJ N
effect NN N
of IN N
CCB NNP i
treatment NN N
was VBD N
observed VBN N
. . N

No DT N
beneficial JJ N
effects NNS N
of IN N
CCB NNP i
treatment NN N
on IN N
clinical JJ o
events NNS o
were VBD N
observed VBN N
during IN N
the DT N
2-year JJ N
study NN N
follow-up NN N
. . N

In IN N
view NN N
of IN N
the DT N
correlation NN N
between IN N
angiographic JJ o
progression NN o
and CC N
subsequent JJ N
clinical JJ o
events NNS o
as IN N
demonstrated VBN N
in IN N
several JJ N
large JJ N
trials NNS N
, , N
it PRP N
is VBZ N
not RB N
unrealistic JJ N
to TO N
also RB N
anticipate VB N
in IN N
this DT N
population NN N
, , N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
events NNS N
with IN N
longer JJR N
follow-up NN N
. . N

Although IN N
the DT N
REGRESS NNP N
trial NN N
was VBD N
not RB N
designed VBN N
to TO N
evaluate VB N
combination NN N
therapy NN N
, , N
the DT N
results NNS N
suggest VBP N
that IN N
addition NN N
of IN N
CCBs NNP i
to TO N
HMG-CoA NNP N
reductase NN N
inhibitor NN N
therapy NN N
( ( i
pravastatin NN i
) ) i
acts VBZ N
synergistically RB N
in IN N
retarding VBG N
the DT N
progression NN o
of IN o
established VBN o
coronary JJ o
atherosclerosis NN o
. . o

These DT N
results NNS N
appear VBP N
to TO N
warrant VB N
prospective JJ N
randomized VBN N
trials NNS N
to TO N
determine VB N
in IN N
a DT N
more RBR N
definitive JJ N
manner NN N
the DT N
merits NNS N
of IN N
this DT N
combination NN N
in IN N
the DT N
prevention NN N
of IN N
progression NN o
of IN o
coronary JJ o
atherosclerosis NN o
. . o

Currently RB N
a DT N
number NN N
of IN N
studies NNS N
in IN N
these DT N
fields NNS N
are VBP N
being VBG N
designed VBN N
or CC N
are VBP N
already RB N
underway RB N
. . N

-DOCSTART- -X- O O

Topical JJ i
fibronectin NN i
therapy NN i
for IN N
treatment NN N
of IN N
a DT N
patient NN p
with IN p
chronic JJ o
stasis NN o
ulcers NNS o
. . o

-DOCSTART- -X- O O

Autism-Spectrum JJ i
Quotient-Japanese JJ i
version NN N
and CC N
its PRP$ N
short JJ N
forms NNS N
for IN N
screening VBG p
normally RB p
intelligent JJ p
persons NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

A DT N
Japanese JJ i
version NN i
of IN i
the DT i
Autism NNP i
Spectrum NNP i
Quotient NNP i
( ( i
AQ NNP i
) ) i
, , i
AQ-J NNP i
was VBD N
administered VBN N
to TO N
25 CD p
normally RB p
intelligent JJ p
high-functioning JJ p
pervasive JJ p
developmental NN p
disorder NN p
( ( p
HPDD NNP p
) ) p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
24.2 CD p
years NNS p
; : p
24 CD p
male NN p
, , p
one CD p
female NN p
) ) p
and CC p
215 CD p
controls NNS p
( ( p
mean JJ p
age NN p
, , p
30.4 CD p
years NNS p
; : p
86 CD p
male NN p
, , p
129 CD p
female NN p
) ) p
randomly RB p
selected VBN p
from IN p
the DT p
general JJ p
population NN p
. . p

The DT N
AQ-J NNP i
had VBD N
satisfactory JJ o
internal JJ o
consistency NN o
reliability NN o
( ( N
Cronbach NNP N
's POS N
alpha NN N
> VBD N
0.70 CD N
in IN N
the DT N
two CD N
groups NNS N
) ) N
, , N
test-retest JJ o
reliability NN o
, , o
and CC o
discriminant JJ o
validity NN o
[ NNP N
i.e NN N
. . N

the DT N
AQ-J NNP N
score NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
HPDD NNP N
( ( N
mean NN N
, , N
29.6 CD N
) ) N
than IN N
controls NNS N
( ( N
mean NN N
, , N
22.2 CD N
) ) N
] NN N
. . N

At IN N
a DT N
cut-off NN N
of IN N
26 CD N
, , N
the DT N
AQ-J NNP o
had VBD N
satisfactory JJ o
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
negative JJ o
predictive JJ o
value NN o
, , N
but CC N
it PRP N
had VBD N
low JJ o
positive JJ o
predictive NN o
value NN o
( ( N
0.24 CD N
) ) N
possibly RB N
due JJ N
to TO N
the DT N
facts NNS N
that IN N
the DT N
25 CD N
mild JJ N
HPDD NNP N
patients NNS N
scored VBD N
lower JJR N
and CC N
the DT N
controls NNS N
scored VBD N
higher JJR N
on IN N
the DT N
AQ-J NNP i
than IN N
British NNP N
counterparts NNS N
on IN N
the DT N
AQ NNP N
. . N

The DT N
AQ-J-21 NNP o
( ( o
consisting VBG o
of IN o
21 CD o
items NNS o
significantly RB o
associated VBN o
with IN o
HPDD NNP o
diagnosis NN o
) ) o
and CC N
the DT N
AQ-J-10 NNP o
( ( o
consisting VBG o
of IN o
10 CD o
of IN o
the DT o
21 CD o
items NNS o
with IN o
an DT o
effect NN o
size NN o
> NNP o
0.17 CD o
) ) o
had VBD N
higher JJR o
, , N
although IN N
not RB o
satisfactory JJ o
, , o
positive JJ o
predictive JJ o
values NNS o
of IN N
0.35 CD N
and CC N
0.46 CD N
at IN N
cut-offs NNS N
of IN N
12 CD N
and CC N
7 CD N
, , N
respectively RB N
, , N
than IN N
the DT N
AQ-J NNP i
. . i

The DT N
AQ-J JJ i
and CC N
two CD N
short JJ N
forms NNS N
are VBP N
useful JJ N
not RB N
to TO N
predict VB N
but CC N
to TO N
rule VB N
out RP N
mild NN o
HPDD NNP o
, , N
the DT N
most RBS N
difficult JJ N
part NN N
of IN N
HPDD NNP N
to TO N
be VB N
distinguished VBN N
from IN N
non-PDD JJ N
conditions NNS N
, , N
in IN N
persons NNS N
scoring VBG N
under IN N
the DT N
cut-offs NNS N
and CC N
to TO N
consider VB N
professionals NNS N
' POS N
examination NN N
of IN N
HPDD NNP N
in IN N
persons NNS N
scoring VBG N
over IN N
them PRP N
, , N
because IN N
their PRP$ N
negative JJ N
predictive JJ N
values NNS N
were VBD N
satisfactory JJ N
. . N

-DOCSTART- -X- O O

[ JJ i
Carticaine NNP i
in IN N
the DT N
therapie NN N
of IN N
pain NN o
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
a DT N
24-h JJ N
psychological JJ i
training NN i
program NN i
on IN N
attitudes NNS o
, , o
communication NN o
skills NNS o
and CC o
occupational JJ o
stress NN o
in IN N
oncology NN N
: : N
a DT N
randomised JJ N
study NN N
. . N

The DT N
usefulness NN N
of IN N
psychological JJ i
training NN i
programs NNS i
( ( i
P.T.P NNP i
. . i

) ) i
in IN N
health NN N
care NN N
settings NNS N
devoted VBN N
to TO N
cancer NN N
care NN N
is VBZ N
beginning VBG N
to TO N
be VB N
recognised VBN N
but CC N
their PRP$ N
content NN N
, , N
form NN N
and CC N
effectiveness VB N
need NN N
further JJ N
investigation NN N
. . N

Seventy-two JJ p
oncology NN p
nurses NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
24-h JJ i
P.T.P NNP i
. . i

or CC i
to TO i
a DT i
waiting VBG i
list NN i
period NN i
. . i

Attitudes NNS o
were VBD N
assessed VBN i
by IN i
a DT i
semantic JJ o
differential NN o
questionnaire NN o
, , o
occupational JJ o
stress NN o
was VBD i
assessed VBN i
by IN i
the DT o
Nursing NNP o
Stress NNP o
Scale NNP o
and CC i
communication NN o
skills NNS o
were VBD i
assessed VBN i
by IN i
standardised JJ o
videotaped VBD o
role-playing NN o
exercises NNS o
. . o

These DT N
were VBD N
used VBN N
to TO N
compare VB N
trained JJ N
( ( N
T.S NNP N
. . N

) ) N
and CC N
control NN N
subjects NNS N
( ( N
C.S. NNP N
) ) N
. . N

The DT N
results NNS N
show VBP N
a DT N
significant JJ N
training NN N
effect NN N
on IN N
attitudes NNS o
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
especially RB N
on IN N
those DT N
related VBN N
to TO N
self VB o
concept NN o
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
and CC N
on IN N
the DT N
level NN o
of IN o
occupational JJ o
stress NN o
related VBN N
to TO N
inadequate VB N
preparation NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Limited VBN N
changes NNS N
were VBD N
found VBN N
regarding VBG N
post-training JJ N
communication NN N
skills NNS N
. . N

T.S NNP N
. . N

were VBD N
significantly RB N
more RBR N
in IN N
control NN N
of IN N
the DT N
interview NN N
than IN N
C.S NNP N
. . N

( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
24-h JJ N
P.T.P NNP i
. . i

assessed VBN N
here RB N
are VBP N
effective JJ N
. . N

The DT N
data NN N
also RB N
demonstrate VBP N
the DT N
need NN N
to TO N
consolidate VB N
the DT N
skills NNS N
acquired VBN N
by IN N
regular JJ N
post-training JJ N
sessions NNS N
. . N

-DOCSTART- -X- O O

Association NNP N
of IN N
PML-RAR NNP N
alpha JJ N
fusion NN N
mRNA NN N
type NN N
with IN N
pretreatment JJ N
hematologic JJ o
characteristics NNS o
but CC N
not RB N
treatment NN N
outcome NN N
in IN N
acute JJ p
promyelocytic JJ p
leukemia NN p
: : p
an DT N
intergroup NN N
molecular NN N
study NN N
. . N

In IN N
each DT N
case NN N
of IN N
acute JJ p
promyelocytic JJ p
leukemia NN p
( ( p
APL NNP p
) ) p
one CD N
of IN N
three CD N
PML-RAR JJ N
alpha NN N
mRNA NN N
types NNS N
is VBZ N
produced VBN N
, , N
depending VBG N
on IN N
the DT N
break/fusion NN N
site NN N
in IN N
the DT N
PML NNP N
gene NN N
that WDT N
is VBZ N
linked VBN N
to TO N
a DT N
common JJ N
RAR NNP N
alpha JJ N
gene NN N
segment NN N
: : N
a DT N
short JJ N
( ( N
S NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
3 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
a DT N
long JJ N
( ( N
L NNP N
) ) N
-form NN N
type NN N
, , N
PML NNP N
exon VBZ N
6 CD N
RAR NNP N
alpha NN N
exon VBZ N
3 CD N
; : N
or CC N
a DT N
variable JJ N
( ( N
V NNP N
) ) N
-form NN N
type NN N
, , N
variably RB N
deleted VBD N
PML NNP N
exon VBD N
6 CD N
RAR NNP N
alpha NN N
exon VBD N
3 CD N
. . N

We PRP N
evaluated VBD N
whether IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
type NN N
is VBZ N
associated VBN N
with IN N
distinct JJ N
pretreatment JJ N
clinical JJ N
characteristics NNS N
and CC N
therapeutic JJ N
outcome NN N
in IN N
previously RB p
untreated VBN p
adult NN p
APL NNP p
patients NNS p
registered VBD p
to TO p
protocol VB p
INT NNP p
0129 CD p
by IN p
the DT p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
, , p
the DT p
Southwest NNP p
Oncology NNP p
Group NNP p
, , p
and CC p
the DT p
Cancer NNP p
and CC p
Leukemia NNP p
Group NNP p
B NNP p
. . p

Of IN p
279 CD p
clinically RB p
eligible JJ p
cases NNS p
, , p
230 CD p
were VBD p
molecularly RB i
evaluable JJ i
, , N
and CC N
of IN N
these DT N
, , N
111 CD N
were VBD N
randomized VBN N
to TO N
receive VB i
remission NN i
induction NN i
therapy NN i
with IN i
all-trans NNS i
retinoic JJ i
acid NN i
( ( i
ATRA NNP i
) ) i
and CC N
119 CD N
with IN N
conventional JJ i
chemotherapy NN i
. . i

Nine NNP N
cases NNS N
not RB N
excluded VBN N
by IN N
central JJ N
pathology NN N
review NN N
were VBD N
PML-RAR NNP o
alpha JJ o
negative JJ o
, , N
and CC N
notably RB N
, , N
none NN N
of IN N
five CD N
of IN N
these DT N
cases NNS N
treated VBD N
with IN N
ATRA NNP N
achieved VBD N
complete JJ o
remission NN o
( ( N
CR NNP N
) ) N
. . N

Among IN N
221 CD N
PML-RAR JJ N
alpha-positive JJ N
cases NNS N
, , N
there EX N
were VBD N
82 CD N
S-form JJ N
cases NNS N
( ( N
37 CD N
% NN N
) ) N
, , N
121 CD N
L-form JJ N
cases NNS N
( ( N
55 CD N
% NN N
) ) N
, , N
and CC N
18 CD N
V-form JJ N
cases NNS N
( ( N
8 CD N
% NN N
) ) N
. . N

Before IN N
any DT N
antileukemic JJ N
therapy NN N
, , N
the DT N
S-form NNP N
type NN N
, , N
compared VBN N
with IN N
the DT N
L-form NNP N
type NN N
, , N
was VBD N
associated VBN N
with IN N
higher JJR N
values NNS N
for IN N
the DT N
white JJ o
blood NN o
cell NN o
( ( o
WBC NNP o
) ) o
count NN o
( ( N
median JJ N
2,500/microL CD N
v NN N
1,600/microL CD N
; : N
P NNP N
= NNP N
.009 NNP N
) ) N
, , N
the DT N
percentage NN N
of IN N
blood NN o
blasts NNS o
plus CC o
promyelocytes NNS o
( ( N
median JJ N
29 CD N
% NN N
v JJ N
8.5 CD N
% NN N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
and CC N
the DT N
absolute JJ o
blood NN o
blasts NNS o
plus CC o
promyelocytes NNS o
( ( N
884/microL CD N
v RB N
126/microL CD N
; : N
P NNP N
= NNP N
.019 NNP N
) ) N
. . N

Also RB N
, , N
an DT N
increased JJ N
percentage NN N
of IN N
S-form NNP N
versus IN N
L-form NNP N
cases NNS N
had VBD N
the DT N
M3 NNP o
variant NN o
phenotype NN o
, , N
24 CD N
% NN N
v JJ N
12 CD N
% NN N
( ( N
P NNP N
= NNP N
.036 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
S-form NNP N
and CC N
L-form NNP N
cases NNS N
in IN N
either DT N
CR NNP o
rate NN o
( ( N
79 CD N
% NN N
v JJ N
69 CD N
% NN N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
or CC N
disease JJ o
free JJ o
survival NN o
distribution NN o
( ( N
multivariate JJ N
analysis NN N
adjusting VBG N
for IN N
the DT N
association NN N
of IN N
S-form NNP N
type NN N
and CC N
higher JJR N
WBC NNP N
count NN N
; : N
P NNP N
= NNP N
.40 NNP N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
S-form NNP N
type NN N
is VBZ N
associated VBN N
with IN N
previously-identified JJ N
adverse JJ N
risk NN N
WBC NNP N
parameters NNS N
but CC N
that IN N
the DT N
identification NN N
of IN N
the DT N
S-form NNP N
or CC N
L-form NNP N
type NN N
of IN N
PML-RAR NNP N
alpha NN N
mRNA NN N
, , N
per IN N
se FW N
, , N
does VBZ N
not RB N
predict VB N
clinical JJ N
outcome NN N
or CC N
add VB N
to TO N
the DT N
value NN N
of IN N
an DT N
increased VBN N
WBC NNP N
count NN N
as IN N
a DT N
negative JJ N
prognostic JJ N
indicator NN N
in IN N
APL NNP p
patients NNS p
. . p

-DOCSTART- -X- O O

PROCLAIM NN N
: : N
pilot NN N
study NN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
clopidogrel NN i
on IN N
inflammatory JJ N
markers NNS N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome JJ p
receiving VBG p
low-dose JJ p
aspirin NN i
. . i

Metabolic NNP N
syndrome NN N
is VBZ N
associated VBN N
with IN N
intravascular JJ N
inflammation NN N
, , N
as IN N
determined VBN N
by IN N
increased JJ N
levels NNS N
of IN N
inflammatory NN N
biomarkers NNS N
and CC N
an DT N
increased VBN N
risk NN N
of IN N
ischemic JJ N
atherothrombotic JJ N
events NNS N
. . N

Evidence NN N
suggests VBZ N
that IN N
atherothrombosis NN N
and CC N
intravascular JJ N
inflammation NN N
share NN N
predictive JJ N
biomarkers NNS N
, , N
including VBG N
high-sensitivity JJ N
C-reactive JJ N
protein NN N
, , N
CD40 NNP N
ligand NN N
, , N
P-selectin NNP N
, , N
and CC N
N-terminal JJ N
pro-brain JJ N
natriuretic JJ N
peptide NN N
. . N

Patients NNS p
who WP p
had VBD p
metabolic JJ p
syndrome NN p
were VBD N
randomized VBN N
to TO N
receive VB N
clopidogrel NN i
75 CD i
mg/day JJ i
plus CC i
aspirin JJ i
81 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
89 CD i
) ) i
or CC i
placebo JJ i
plus CC i
aspirin JJ i
81 CD i
mg/day NN i
( ( i
n JJ i
= NNP i
92 CD i
) ) i
for IN i
9 CD i
weeks NNS i
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
each DT N
treatment NN N
in IN N
suppression NN N
of IN N
inflammatory JJ N
markers NNS N
. . N

Change NN N
from IN N
baseline NN N
in IN N
the DT N
levels NNS N
of IN N
high-sensitivity NN o
C-reactive JJ o
protein NN o
, , o
CD40 NNP o
ligand NN o
, , o
P-selectin NNP o
, , o
and CC o
N-terminal JJ o
pro-brain JJ o
natriuretic JJ o
peptide NN o
at IN N
6 CD N
weeks NNS N
was VBD N
assessed VBN N
to TO N
evaluate VB N
each DT N
treatment NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
at IN N
Week JJ N
6 CD N
in IN N
model-adjusted JJ o
CD40-ligand NNP o
levels NNS o
in IN N
favor NN N
of IN N
clopidogrel NN i
plus CC i
aspirin JJ i
compared VBN N
with IN N
placebo NN i
plus CC i
aspirin NN i
in IN N
both DT N
the DT N
intent-to-treat JJ N
population NN N
( ( N
difference NN N
between IN N
least-squares NNS N
means NNS N
= VBP N
-186.5 NNP N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-342.3 NN N
to TO N
-30.8 VB N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
the DT N
per-protocol JJ N
population NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
treatment NN N
arms NNS N
for IN N
high-sensitivity JJ o
C-reactive JJ o
protein NN o
, , o
P-selectin NNP o
, , o
and CC o
N-terminal JJ o
pro-brain JJ o
natriuretic JJ o
peptide NN o
. . o

There EX N
were VBD N
no DT N
deaths NNS o
or CC o
serious JJ o
adverse JJ o
events NNS o
in IN N
either DT N
treatment NN N
arm NN N
. . N

Data NNS N
from IN N
this DT N
study NN N
suggest VBP N
that IN N
clopidogrel NN i
can MD N
decrease VB N
the DT N
expression NN o
of IN o
the DT o
CD40-ligand NNP o
biomarker NN o
. . o

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
disposition NN N
of IN N
carvedilol NN i
in IN p
humans NNS p
. . p

Pharmacokinetics NNS o
of IN N
carvedilol NN i
( ( N
C NNP N
) ) N
have VBP N
been VBN N
studied VBN N
in IN N
healthy JJ p
volunteers NNS p
after IN p
a DT p
single JJ p
i.v NN p
. . p

and CC p
oral JJ p
administration NN p
, , N
and CC N
the DT N
metabolic JJ N
disposition NN N
after IN N
oral JJ N
administration NN N
of IN N
14C-labeled JJ i
drug NN i
. . i

C NNP N
demonstrates VBZ N
dose-linear JJ N
behavior NN N
. . N

The DT N
absolute JJ N
bioavailability NN N
reaches VBZ N
24 CD N
% NN N
probably RB N
due JJ N
to TO N
a DT N
first-pass JJ N
effect NN N
. . N

After IN N
a DT N
50 CD N
mg JJ N
oral JJ N
dose NN N
, , N
maximum JJ N
concentrations NNS N
of IN N
66 CD N
micrograms/l NNS N
are VBP N
achieved VBN N
within IN N
1.2 CD N
h. JJ N
C NNP N
is VBZ N
extensively RB N
distributed VBN N
to TO N
the DT N
tissues NNS N
( ( N
Vz NNP N
= VBZ N
132 CD N
l NN N
) ) N
and CC N
eliminated VBN N
primarily RB N
by IN N
hepatic JJ N
metabolism NN N
( ( N
total JJ N
clearance NN N
590 CD N
ml/min NN N
, , N
renal JJ N
clearance NN N
4 CD N
ml/min NN N
) ) N
. . N

Because IN N
of IN N
the DT N
longer RBR N
half-life NN N
of IN N
6.4 CD N
h NN N
after IN N
oral JJ N
administration NN N
in IN N
contrast NN N
to TO N
2.4 CD N
h NN N
after IN N
i.v NN N
. . N

administration NN N
, , N
C NNP N
is VBZ N
assumed VBN N
to TO N
be VB N
absorption JJ N
dependent JJ N
since IN N
no DT N
sustained-release JJ N
formulation NN N
was VBD N
used VBN N
. . N

The DT N
half-life NN o
of IN N
radioactivity NN N
in IN N
plasma NN N
is VBZ N
39 CD N
h NN N
; : N
16 CD N
% NN N
of IN N
C NNP N
is VBZ N
excreted VBN N
in IN N
urine NN N
in IN N
the DT N
form NN N
of IN N
metabolites NNS N
and CC N
only RB N
0.3 CD N
% NN N
unchanged JJ N
. . N

The DT N
urinary JJ N
metabolites NNS N
consist VBP N
of IN N
carvedilol NN N
glucuronide NN N
( ( N
5.2 CD N
% NN N
of IN N
the DT N
dose NN N
) ) N
, , N
cleavage JJ N
products NNS N
of IN N
the DT N
beta-blocking JJ N
side NN N
chain NN N
( ( N
2.1 CD N
% NN N
) ) N
, , N
and CC N
ring-hydroxylated JJ N
forms NNS N
( ( N
2.9 CD N
% NN N
) ) N
. . N

Sixty NNP N
percent NN N
of IN N
the DT N
dose NN N
is VBZ N
recovered VBN N
in IN N
the DT N
feces NNS N
. . N

A DT N
demethylated JJ N
product NN N
of IN N
C NNP N
exhibits VBZ N
only RB N
minor JJ N
beta-blocking JJ o
activity NN o
. . o

This DT N
metabolite NN o
is VBZ N
detected VBN N
in IN N
plasma NN N
in IN N
concentrations NNS N
ten VBP N
times NNS N
lower JJR N
than IN N
the DT N
parent NN N
compound NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
antihypertensive JJ o
effect NN o
of IN N
metipranolol NN i
, , i
butizide NN i
and CC i
torrat NN i
in IN N
Kenyan NNP p
Africans NNPS p
. . p

-DOCSTART- -X- O O

Baseline NNP N
factors NNS N
predicting VBG N
placebo NN i
response NN N
to TO N
treatment NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
multisite JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE VBZ N
The DT N
finding NN N
of IN N
factors NNS N
that WDT N
differentially RB N
predict VBP N
the DT N
likelihood NN N
of IN N
response NN N
to TO N
placebo VB N
over IN N
that DT N
of IN N
an DT N
active JJ N
drug NN N
could MD N
have VB N
a DT N
significant JJ N
impact NN N
on IN N
study NN N
design NN N
in IN N
this DT N
population NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
possible JJ N
nonspecific NN N
, , N
baseline JJ N
predictors NNS N
of IN N
response NN o
to TO o
intervention NN o
in IN N
a DT N
large JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
clinical JJ N
trial NN N
of IN N
citalopram NN i
hydrobromide NN i
for IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
prominent JJ p
repetitive JJ p
behavior NN p
. . p

Baseline NNP N
data NN N
at IN N
study NN N
entry NN N
were VBD N
examined VBN N
with IN N
respect NN N
to TO N
final JJ N
outcome NN N
to TO N
determine VB N
if IN N
response NN N
predictors NNS N
could MD N
be VB N
identified VBN N
. . N

A DT N
total NN N
of IN N
149 CD p
children NNS p
and CC p
adolescents NNS p
5 CD p
to TO p
17 CD p
years NNS p
of IN p
age NN p
( ( p
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
, , p
9.4 CD p
[ NN p
3.1 CD p
] CD p
years NNS p
) ) p
from IN p
6 CD p
academic JJ p
centers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
citalopram VB i
( ( N
n JJ N
= NNP N
73 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Participants NNS p
had VBD p
autistic JJ p
disorder NN p
, , p
Asperger NNP p
syndrome NN p
, , p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
, , p
not RB p
otherwise RB p
specified VBN p
; : p
had VBD p
illness JJ p
severity NN p
ratings NNS p
that WDT p
were VBD p
moderate JJ p
or CC p
more JJR p
than IN p
moderate VB p
on IN p
the DT p
Clinical JJ p
Global NNP p
Impression-Severity NNP p
scale NN p
; : p
and CC p
scored VBD p
moderate JJ p
or CC p
more JJR p
than IN p
moderate VB p
on IN p
compulsive JJ p
behaviors NNS p
measured VBN p
with IN p
the DT p
modified JJ p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive-Compulsive JJ p
Scale NNP p
. . p

INTERVENTIONS NNP N
Twelve NNP N
weeks NNS N
of IN N
treatment NN N
with IN N
citalopram NN i
( ( N
10 CD N
mg/5 RB N
mL NN N
) ) N
or CC N
placebo NN i
. . i

The DT N
mean NN N
( ( N
SD NNP N
) ) N
maximum VBD N
dose NN N
of IN N
citalopram NN N
was VBD N
16.5 CD N
( ( N
6.5 CD N
) ) N
mg NN N
by IN N
mouth JJ N
daily JJ N
( ( N
maximum JJ N
dose NN N
, , N
20 CD N
mg/d NN N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
A NNP N
positive JJ N
response NN N
was VBD N
defined VBN N
as IN N
having VBG N
a DT N
score NN N
of IN N
at IN N
least JJS N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
scale NN o
at IN N
week NN N
12 CD N
. . N

Baseline NNP N
measures VBZ N
included VBN N
demographic JJ N
( ( N
sex NN N
, , N
age NN N
, , N
weight NN N
, , N
and CC N
pubertal JJ N
status NN N
) ) N
, , N
clinical JJ N
, , N
and CC N
family NN N
measures NNS N
. . N

Clinical JJ N
variables NNS N
included VBD N
baseline NN N
illness NN N
severity NN N
ratings NNS N
( ( o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
the DT o
Child NNP o
and CC o
Adolescent NNP o
Symptom NNP o
Inventory NNP o
, , o
the DT o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
Scales NNP o
, , o
the DT o
Repetitive JJ o
Behavior NNP o
Scale-Revised JJ o
, , o
and CC o
the DT o
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive-Compulsive JJ o
Scale NNP o
) ) o
. . N

Family JJ N
measures NNS N
included VBD N
the DT N
Caregiver NNP o
Strain NNP o
Questionnaire NNP o
. . o

RESULTS NNP N
Several JJ N
baseline JJ N
predictors NNS N
of IN N
response NN N
were VBD N
identified VBN N
, , N
and CC N
a DT N
principal JJ N
component NN N
analysis NN N
yielded VBD N
3 CD N
composite JJ N
measures NNS N
( ( o
disruptive JJ o
behavior NN o
, , o
autism/mood NN o
, , o
and CC o
caregiver RB o
strain NN o
) ) o
that WDT N
significantly RB N
predicted VBD N
response NN N
at IN N
week NN N
12 CD N
. . N

Specifically RB N
, , N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
participants NNS N
in IN N
the DT N
citalopram NN N
group NN N
to TO N
respond VB N
at IN N
week NN N
12 CD N
if IN N
they PRP N
entered VBD N
the DT N
study NN N
more RBR N
symptomatic JJ N
on IN N
each DT N
of IN N
the DT N
3 CD N
composite JJ N
measures NNS N
, , N
and CC N
they PRP N
were VBD N
at IN N
least JJS N
2 CD N
times NNS N
less RBR N
likely JJ N
to TO N
be VB N
responders NNS N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
This DT N
analysis NN N
suggests VBZ N
strategies NNS N
that WDT N
may MD N
be VB N
useful JJ N
in IN N
anticipating VBG N
and CC N
potentially RB N
mitigating VBG N
the DT N
nonspecific JJ N
response NN N
in IN N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00086645 NN N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
sequential JJ N
annual JJ N
vaccination NN i
and CC i
of IN i
DHEA NNP i
administration NN i
on IN N
the DT N
efficacy NN N
of IN N
the DT N
immune JJ N
response NN N
to TO N
influenza VB p
vaccine NN p
in IN p
the DT p
elderly JJ p
. . p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
repeated VBN N
vaccination NN i
and CC N
of IN N
dehydroepiandrosterone NN i
( ( i
DHEA NNP i
) ) i
treatment NN N
on IN N
the DT N
immune JJ N
response NN N
to TO N
influenza VB i
vaccine NN i
in IN p
elderly JJ p
subjects NNS p
. . p

Seventy-one CD p
elderly JJ p
volunteers NNS p
, , p
aged VBN p
61-89 CD p
years NNS p
, , N
enrolled VBD N
in IN N
a DT N
prospective JJ N
randomized VBN N
, , N
double-blind JJ N
study NN N
to TO N
receive VB N
either DT N
DHEA NNP i
( ( N
50 CD N
mg NN N
qd NN N
p.o NN N
. . N

for IN N
4 CD N
consecutive JJ N
days NNS N
starting VBG N
2 CD N
days NNS N
before IN N
immunization NN N
) ) N
or CC N
placebo NN i
. . i

Antibody NNP N
response NN N
against IN N
the DT N
three CD N
strains NNS N
of IN N
vaccine NN N
was VBD N
measured VBN N
before IN N
and CC N
28 CD N
days NNS N
after IN N
vaccination NN N
, , N
and CC N
compared VBN N
between IN N
previously RB N
vaccinated VBN N
and CC N
non-vaccinated JJ N
subjects NNS N
. . N

DHEA NNP i
treatment NN i
did VBD N
not RB N
enhance VB N
established VBN o
immunity NN o
. . o

A DT N
significant JJ N
decrease NN N
in IN N
attainment NN N
of IN N
protective JJ o
antibody NN o
titer NN o
( ( N
titer NN N
of IN N
1:40 CD N
or CC N
greater JJR N
) ) N
against IN N
A/Texas NNP N
in IN N
subjects NNS N
with IN N
non-protective JJ N
baseline NN N
antibody NN N
titer NN N
was VBD N
recorded VBN N
following VBG N
DHEA NNP i
treatment NN i
compared VBN N
to TO N
placebo VB N
( ( N
52 CD N
vs. FW N
84 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Post-immunization NN o
titers NNS o
against IN N
influenza VBP N
A DT N
strains NNS N
were VBD N
significantly RB N
higher JJR N
in IN N
those DT N
subjects NNS N
who WP N
were VBD N
never RB N
immunized VBN N
before RB N
. . N

Additionally RB N
, , N
post-vaccination JJ o
protective JJ o
titers NNS o
against IN N
the DT N
A/Johannesburg NNP N
strain NN N
were VBD N
more RBR N
prevalent JJ N
in IN N
those DT N
subjects NNS N
who WP N
were VBD N
never RB N
vaccinated VBN N
before RB N
. . N

The DT N
results NNS N
were VBD N
not RB N
the DT N
same JJ N
for IN N
anti-B/Harbin JJ N
antibodies-repeated JJ N
vaccination NN N
caused VBD N
a DT N
non-significant JJ N
increase NN N
in IN N
HI NNP N
titer NN N
in IN N
previously RB N
vaccinated VBN N
subjects NNS N
. . N

-DOCSTART- -X- O O

[ JJ o
Metastatic NNP o
breast NN o
cancer NN o
: : o
a DT N
comparative JJ N
study NN N
of IN N
the DT N
efficacy NN N
of IN N
tamoxifen NN i
and CC N
the DT N
sequential JJ N
administration NN N
of IN N
tamoxifen NN i
and CC i
medroxyprogesterone NN i
acetate NN i
] NNP i
. . i

Seventy-nine JJ p
patients NNS p
with IN p
an DT p
histologically RB p
proven RB p
disseminated VBN p
breast NN p
cancer NN p
, , p
never RB p
treated VBN p
before IN p
with IN p
additive JJ p
hormonal JJ p
therapy NN p
, , p
entered VBD p
into IN p
a DT p
randomized JJ p
trial NN p
between IN p
june NN p
1981 CD p
and CC p
december VB p
1982 CD p
. . p

In IN N
the DT N
first JJ N
group NN N
44 CD N
patients NNS N
were VBD N
given VBN N
continually RB N
a DT N
daily JJ N
dose NN N
of IN N
tamoxifen NN i
( ( i
TAM NNP i
) ) i
of IN N
20 CD N
mg/m2 NN N
. . N

In IN N
the DT N
2nd CD N
group NN N
35 CD N
patients NNS N
were VBD N
given VBN N
a DT N
daily JJ N
dose NN N
of IN N
TAM NNP i
of IN N
20 CD N
mg/m2 NN N
for IN N
15 CD N
days NNS N
and CC N
then RB N
an DT N
oral JJ N
daily JJ N
dose NN N
of IN N
medroxyprogesterone NN i
acetate NN i
of IN N
350 CD N
mg/m2 NN N
for IN N
the DT N
next JJ N
15 CD N
days NNS N
. . N

In IN N
both DT N
groups NNS N
I PRP N
and CC N
II NNP N
, , N
the DT N
treatment NN N
was VBD N
stopped VBN N
at IN N
the DT N
first JJ N
manifestation NN N
of IN N
progression NN N
of IN N
the DT N
disease NN N
. . N

The DT N
hormonal JJ N
receptor NN N
status NN N
was VBD N
determined VBN N
in IN N
30 CD N
patients NNS N
of IN N
the DT N
group NN N
I PRP N
and CC N
23 CD N
patients NNS N
of IN N
the DT N
group NN N
II NNP N
. . N

An DT N
objective JJ N
response NN N
to TO N
treatment NN N
was VBD N
observed VBN N
in IN N
48 CD N
per IN N
cent NN N
of IN N
the DT N
patients NNS N
of IN N
the DT N
group NN N
I PRP N
and CC N
60 CD N
per IN N
cent NN N
of IN N
the DT N
group NN N
II NNP N
. . N

This DT N
difference NN N
is VBZ N
not RB N
significant JJ N
( ( N
X2 NNP N
= NNP N
1,05 CD N
) ) N
. . N

However RB N
, , N
the DT N
mean JJ o
duration NN o
of IN o
therapeutic JJ o
response NN o
is VBZ N
significantly RB N
higher RBR N
in IN N
the DT N
group NN N
II NNP N
( ( N
p JJ N
= NNP N
0,01 CD N
) ) N
. . N

-DOCSTART- -X- O O

[ RB N
Comparative NNP N
study NN N
between IN N
5 CD i
% NN i
prilocaine NN i
and CC N
2 CD i
% NN i
mepivacaine NN i
by IN N
the DT N
subarachnoid JJ N
route NN N
in IN N
transurethral JJ p
resections NNS p
] VBP p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
duration NN o
of IN N
spinal JJ N
block NN N
with IN N
5 CD i
% NN i
prilocaine NN i
and CC i
2 CD i
% NN i
mepivacaine NN i
in IN N
short JJ p
procedures NNS p
for IN p
transurethral JJ p
resection NN p
and CC N
to TO N
assess VB o
possible JJ o
complications NNS o
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifty-seven NNP p
patients NNS p
scheduled VBN p
for IN p
transurethral JJ p
resection NN p
of IN p
the DT p
prostate NN p
or CC p
a DT p
vesical JJ p
tumor NN p
. . p

Patients NNS p
were VBD p
ASA NNP p
I-III NNP p
, , p
over IN p
55 CD p
years NNS p
of IN p
age NN p
and CC N
randomly RB N
assigned VBN N
to TO N
two CD i
groups NNS i
to TO i
receive VB i
5 CD i
% NN i
prilocaine NN i
( ( i
1 CD i
mg/kg NN i
, , i
n JJ i
= NNP i
27 CD i
) ) i
or CC i
2 CD i
% NN i
mepivacaine NN i
( ( i
0.8 CD i
mg/kg NN i
, , i
n JJ i
= NNP i
30 CD i
) ) i
. . N

We PRP i
collected VBD i
data NNS i
on IN i
anesthetic JJ o
technique NN o
, , o
levels NNS o
of IN o
extension NN o
of IN o
motor NN o
and CC o
sensory JJ o
blockades NNS o
, , o
duration NN o
of IN o
blockades NNS o
and CC o
complications NNS o
within IN o
the DT o
first JJ o
24 CD o
hours NNS o
after IN i
surgery NN i
. . i

RESULTS NNP N
Demographic NNP N
data NNS N
, , N
ASA NNP N
classification NN N
and CC N
duration NN N
of IN N
surgery NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

We PRP N
found VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
duration NN o
of IN o
sensory JJ o
blockade NN o
( ( N
120.92 CD N
+/- JJ N
36.21 CD N
min NN N
with IN N
prilocaine NN i
and CC N
145.83 CD N
+/- JJ N
35.81 CD N
min NN N
with IN N
mepivacaine NN i
) ) i
and CC N
in IN N
motor NN o
blockade NN o
( ( N
106.29 CD N
+/- JJ N
38.16 CD N
min NN N
with IN N
prilocaine NN N
and CC N
133.16 CD N
+/- JJ N
42.21 CD N
min NN N
with IN N
mepivacaine NN N
) ) N
. . N

Five JJ N
cases NNS N
of IN N
hypotension NN o
and CC N
4 CD N
of IN N
bradycardia NN o
occurred VBN N
in IN N
each DT N
group NN N
and CC N
one CD N
patient NN N
in IN N
the DT N
mepivacaine NN N
group NN N
suffered VBD N
slight JJ N
postoperative JJ N
cephalea NN N
. . N

CONCLUSIONS NNP N
Both NNP N
local JJ N
anesthetics NNS N
offer VBP N
good JJ N
surgical JJ o
conditions NNS o
with IN N
hemodynamic JJ N
stability NN N
and CC N
few JJ N
complications NNS o
. . o

The DT N
duration NN N
of IN N
sensory NN o
and CC o
motor NN o
blockade NN o
is VBZ N
shorter JJR N
with IN N
prilocaine NN N
than IN N
with IN N
mepivacaine NN N
, , N
making VBG N
prilocaine NN N
more JJR N
appropriate JJ N
for IN N
short JJ N
interventions NNS N
. . N

-DOCSTART- -X- O O

Granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
as IN N
immunomodulating VBG N
factor NN N
together RB N
with IN N
influenza JJ i
vaccination NN i
in IN N
stem NN p
cell NN p
transplant NN p
patients NNS p
. . p

The DT N
effect NN N
of IN N
granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
GM-CSF NNP i
) ) i
on IN N
the DT N
serological JJ o
response NN o
at IN N
influenza JJ i
vaccination NN i
was VBD N
studied VBN N
in IN N
117 CD p
patients NNS p
who WP p
had VBD p
undergone JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
SCT NNP p
) ) p
. . p

The DT N
vaccine NN o
response NN o
was VBD N
evaluated VBN N
as IN N
significant JJ N
increases NNS N
in IN N
levels NNS o
of IN o
influenza JJ o
hemagglutination-inhibition NN o
( ( o
HAI NNP o
) ) o
antibodies NNS o
and CC N
of IN N
IgG NNP o
antibodies NNS o
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
ELISA NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
antibody NN o
response NN o
to TO N
either DT N
influenza VB N
A NNP N
or CC N
B NNP N
in IN N
64 CD N
patients NNS N
who WP N
received VBD N
GM-CSF NNP i
at IN N
vaccination NN N
, , N
compared VBN N
with IN N
the DT N
53 NNS N
who WP N
did VBD N
not RB N
. . N

In IN N
the DT N
subgroup NN p
of IN p
allogeneic JJ p
SCT NNP p
patients NNS p
, , N
HAI NNP N
showed VBD N
that IN N
the DT N
response NN o
rate NN o
to TO N
the DT N
influenza NN o
B NNP o
vaccine NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

ELISA NN o
showed VBD N
that IN N
autologous JJ p
SCT NNP p
patients NNS p
with IN p
breast JJ p
cancer NN p
who WP N
received VBD N
GM-CSF NNP N
had VBD N
a DT N
better JJR N
response NN o
to TO N
influenza VB o
A NNP o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
B NNP o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

At IN N
early JJ N
vaccination NN N
, , N
4-12 JJ N
months NNS N
after IN N
stem NN N
cell NN N
transplantation NN N
, , N
these DT N
responses NNS N
were VBD N
more RBR N
pronounced JJ N
. . N

GM-CSF JJ i
appears VBZ N
to TO N
improve VB N
the DT N
response NN o
to TO o
influenza VB o
vaccination NN o
in IN N
some DT N
groups NNS N
of IN N
SCT NNP p
patients NNS p
, , N
but CC N
only RB N
to TO N
a DT N
limited JJ N
extent NN N
. . N

-DOCSTART- -X- O O

Engagement NN i
with IN i
electronic JJ i
screen JJ i
media NNS i
among IN N
students NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
four CD N
types NNS N
of IN N
electronic JJ i
screen JJ i
media NNS i
( ( i
ESM NNP i
) ) i
: : i
animated VBN i
video NN i
, , i
video NN i
of IN i
self NN i
, , i
video NN i
of IN i
a DT i
familiar JJ i
person NN i
engaged VBD i
with IN i
an DT i
immersive JJ i
virtual JJ i
reality NN i
( ( i
VR NNP i
) ) i
game NN i
, , i
and CC i
immersion NN i
of IN i
self NN i
in IN i
the DT i
VR NNP i
game NN i
. . i

Forty-two JJ p
students NNS p
with IN p
autism NN p
, , p
varying VBG p
in IN p
age NN p
and CC p
expressive JJ p
communication NN p
ability NN p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
experimental JJ p
conditions NNS p
. . p

Gaze NNP o
duration NN o
and CC o
vocalization NN o
served VBD N
as IN N
dependent JJ N
measures NNS N
of IN N
engagement NN N
. . N

The DT N
results NNS N
reveal VBP N
differential JJ N
responding NN N
across IN N
ESM NNP o
, , N
with IN N
some DT N
variation NN N
related VBN N
to TO N
the DT N
engagement NN N
metric JJ N
employed VBN N
. . N

Preferences NNS N
for IN N
seeing VBG o
themselves PRP o
on IN o
the DT o
screen NN o
, , o
as RB o
well RB o
as IN o
for IN o
viewing VBG o
the DT o
VR NNP o
scenarios NNS o
, , N
emerged VBD N
from IN N
the DT N
data NNS N
. . N

While IN N
the DT N
study NN N
did VBD N
not RB N
yield VB N
definitive JJ N
data NNS N
about IN N
the DT N
relative JJ N
engagement JJ N
potential NN N
of IN N
ESM NNP i
alternatives NNS N
, , N
it PRP N
does VBZ N
provide VB N
a DT N
foundation NN N
for IN N
future JJ N
research NN N
, , N
including VBG N
guidance NN N
related VBN N
to TO N
participant JJ N
profiles NNS N
, , N
stimulus NN N
characteristics NNS N
, , N
and CC N
data NNS N
coding NN N
challenges NNS N
. . N

-DOCSTART- -X- O O

Long-stay JJ i
versus NN N
short-stay JJ i
hospital NN i
treatment NN i
of IN N
children NNS p
suffering VBG p
from IN p
severe JJ p
protein-energy JJ p
malnutrition NN p
. . p

OBJECTIVE UH N
To TO N
contrast VB N
early JJ i
discharge NN i
versus NN N
attempted VBD i
full JJ i
nutritional JJ i
rehabilitation NN i
in IN N
hospital NN p
of IN p
children NNS p
suffering VBG p
from IN p
severe JJ p
protein-energy JJ p
malnutrition NN p
( ( p
PEM NNP p
) ) p
. . p

DESIGN NNP N
Field NNP N
experiment NN N
, , N
two-way JJ N
analysis NN N
of IN N
variance NN N
with IN N
one CD N
between IN N
group NN p
( ( i
short- JJ i
versus IN i
long-stay NN i
) ) i
and CC p
one CD p
repeated VBN p
measures NNS p
factor NN p
( ( p
admission NN p
, , p
then RB p
12 CD p
, , p
18 CD p
, , p
24 CD p
, , p
30 CD p
and CC p
36 CD p
months NNS p
post-admission NN p
) ) p
. . N

Covariates NNPS N
introduced VBD N
. . N

SETTING NNP p
Primary NNP p
health NN p
care NN p
, , p
Kingston NNP p
, , p
Jamaica NNP p
. . p

SUBJECTS NNP p
n JJ p
= NNP p
81 CD p
; : p
mean JJ p
age NN p
11 CD p
months NNS p
; : p
79 CD p
contribute VBP p
longitudinal JJ p
data NNS p
; : p
44 CD p
every DT p
measurement NN p
. . p

INTERVENTIONS NNP N
When WRB N
concurrent NN N
illnesses NNS N
had VBD N
been VBN N
treated VBN N
and CC N
normal JJ N
feeding VBG N
re-established JJ N
( ( N
weight JJ N
gain NN N
5 CD N
g/kg.day-1 NN N
) ) N
, , N
subjects NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
short-stay NN i
( ( i
SS NNP i
) ) i
or CC i
long-stay JJ i
( ( i
LS NNP i
) ) i
group NN i
. . i

LS NNP i
retained VBD i
in IN i
hospital NN i
for IN i
full JJ i
nutritional JJ i
rehabilitation NN i
mean VB N
40 CD N
days NNS N
) ) N
. . N

SS NNP i
discharged VBD i
immediately RB i
( ( N
mean JJ N
18 CD N
days NNS N
) ) N
for IN i
standard JJ i
Health NNP i
Service NNP i
care NN i
at IN i
home NN i
for IN N
6 CD N
months NNS N
plus CC i
high-energy JJ i
supplement NN i
( ( N
3.31 CD N
MJ NNP N
with IN N
20.6 CD N
g NNS N
protein JJ N
daily JJ N
) ) N
for IN N
first JJ N
3 CD N
months NNS N
. . N

After IN N
discharge NN N
LS NNP i
received VBD N
6 CD N
months NNS N
home NN N
care NN N
, , N
but CC N
without IN N
supplementation NN N
. . N

RESULTS NNP N
Significant NNP N
advantages VBZ N
for IN N
LS NNP N
group NN N
on IN N
NCHS NNP o
weight NN o
& CC o
length NN o
for IN o
age NN o
at IN o
discharge NN o
, , N
and CC N
at IN N
12 CD N
, , N
18 CD N
, , N
24 CD N
and CC N
for IN N
length NN N
also RB N
30 CD N
months NNS N
( ( N
P NNP N
< VBZ N
0.05 CD N
to TO N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Weight NNP o
advantage NN o
peaked VBD N
at IN N
12 CD N
and CC N
18 CD N
months NNS N
, , N
length NN N
later RB N
at IN N
18 CD N
and CC N
24 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Contrary NNP N
to TO N
earlier VB N
reports NNS N
, , N
full JJ N
nutritional JJ N
rehabilitation NN N
can MD N
be VB N
achieved VBN N
in IN N
hospital NN N
for IN N
children NNS N
suffering VBG N
from IN N
PEM NNP N
. . N

Although IN N
in IN N
the DT N
long-term JJ N
both DT N
groups NNS N
move VBP N
towards NNS N
expected VBN N
levels NNS N
in IN N
their PRP$ N
home NN N
community NN N
, , N
a DT N
significant JJ N
advantage NN N
maintained VBD N
for IN N
approximately RB N
2 CD N
years NNS N
is VBZ N
developmentally RB N
advantageous JJ N
during IN N
the DT N
critical JJ N
time NN N
after IN N
weaning VBG N
. . N

-DOCSTART- -X- O O

Ganciclovir NNP i
use NN N
during IN N
mild JJ p
renal JJ o
failure NN o
in IN p
heart NN i
transplantation NN i
. . i

-DOCSTART- -X- O O

Prevention NN N
of IN N
postoperative JJ N
hypocalcemia NN N
with IN N
routine JJ N
oral JJ N
calcium NN i
and CC N
vitamin NN i
D NNP i
supplements NNS i
in IN N
patients NNS p
with IN p
differentiated JJ p
papillary JJ p
thyroid NN p
carcinoma NN p
undergoing JJ p
total JJ p
thyroidectomy NN p
plus CC p
central JJ p
neck NN p
dissection NN p
. . p

BACKGROUND NNP N
Routine NNP N
oral JJ i
calcium NN i
and CC i
vitamin NN i
D NNP i
supplementation NN i
may MD N
prevent VB N
hypocalcemic JJ N
crisis NN N
, , N
but CC N
its PRP$ N
efficacy NN N
has VBZ N
not RB N
been VBN N
studied VBN N
in IN N
patients NNS p
undergoing VBG p
thyroidectomy JJ p
plus JJ p
central JJ p
neck NN p
dissection NN p
( ( p
CND NNP p
) ) p
. . p

The DT N
authors NNS N
therefore VBP N
prospectively RB N
evaluated VBN N
the DT N
clinical JJ N
usefulness NN N
of IN N
routine JJ N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
supplementation NN N
for IN N
prevention NN N
of IN N
hypocalcemia NN N
after IN N
total JJ N
thyroidectomy NN N
and CC N
CND NNP N
. . N

METHODS NNP N
Of IN N
197 CD p
patients NNS p
with IN p
differentiated JJ p
papillary JJ p
thyroid NN p
carcinoma NN p
, , N
49 CD N
underwent JJ N
total JJ N
thyroidectomy NN N
alone RB N
, , N
and CC N
148 CD N
underwent JJ N
total JJ i
thyroidectomy NN i
plus CC i
CND NNP i
. . i

The DT N
latter JJ N
were VBD N
randomized VBN N
to TO N
oral JJ i
calcium NN i
( ( N
3 CD N
g/day NN N
) ) N
plus CC N
vitamin JJ i
D NNP i
( ( N
1 CD N
mg/day NN N
) ) N
( ( N
Group NNP N
A NNP N
, , N
n=49 NN N
) ) N
, , N
calcium NN i
alone RB i
( ( N
Group NNP N
B NNP N
, , N
n=49 NN N
) ) N
, , N
or CC N
no DT i
supplements NNS i
( ( N
Group NNP N
C NNP N
, , N
n=50 RB N
) ) N
. . N

Hypocalcemic NNP o
symptoms NNS o
, , o
serum JJ o
calcium NN o
, , o
and CC o
parathyroid VB o
hormone NN o
( ( o
PTH NNP o
) ) o
levels NNS o
were VBD N
compared VBN N
among IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
Group NNP N
C NNP N
had VBD N
significantly RB N
higher JJR N
incidences NNS N
of IN N
symptomatic JJ N
( ( N
26.0 CD N
% NN N
vs JJ N
6.1 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
and CC N
laboratory NN N
( ( N
44.0 CD N
% NN N
vs JJ N
14.3 CD N
% NN N
; : N
P NNP N
< NNP N
.015 NNP N
) ) N
hypocalcemia NN o
than IN N
the DT N
group NN N
without IN N
CND NNP N
. . N

The DT N
incidences NNS N
of IN N
symptomatic JJ o
and CC o
laboratory JJ o
hypocalcemia NN o
were VBD N
significantly RB N
decreased VBN N
in IN N
Groups NNP N
A NNP N
( ( N
2.0 CD N
% NN N
and CC N
8.2 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
B NNP N
( ( N
12.2 CD N
% NN N
and CC N
24.5 CD N
% NN N
, , N
respectively RB N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Serum NNP o
calcium NN o
levels NNS o
decreased VBN N
in IN N
most JJS N
patients NNS N
after IN N
surgery NN N
, , N
but CC N
recovered VBD N
earliest JJS N
in IN N
Group NNP N
A. NNP N
Hypercalcemia NNP N
and CC N
PTH NNP N
inhibition NN N
did VBD N
not RB N
occur VB N
in IN N
gs NN N
A NNP N
and CC N
B NNP N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
total JJ N
thyroidectomy NN N
alone RB N
, , N
CND NNP N
significantly RB N
increases VBZ N
the DT N
rate NN N
of IN N
postoperative JJ o
hypocalcemia NN o
, , N
which WDT N
can MD N
be VB N
prevented VBN N
by IN N
routine JJ N
postoperative JJ N
supplementation NN N
with IN N
oral JJ N
calcium NN N
and CC N
vitamin NN N
D NNP N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
remifentanil NN i
with IN N
fentanyl NN i
for IN N
deep JJ o
sedation NN o
in IN N
oral JJ N
surgery NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
recovery NN N
for IN N
oral JJ p
surgery NN p
patients NNS p
given VBN N
a DT N
deep JJ N
sedation NN N
regimen NNS N
of IN N
midazolam NN i
, , i
propofol NN i
, , N
and CC N
remifentanil NN i
with IN N
a DT N
standard JJ N
control NN N
of IN N
fentanyl NN N
in IN N
place NN N
of IN N
remifentanil NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized NN N
, , N
prospective JJ N
, , N
single-blinded JJ N
controlled VBD N
study NN N
. . N

Group NNP N
1 CD N
, , N
the DT N
control NN N
, , N
received VBD N
midazolam JJ i
0.03 CD i
mg/kg NN i
, , i
fentanyl VBP i
1 CD i
microg/kg NN i
, , i
and CC i
propofol VB i
initially RB i
at IN i
140 CD i
microg/kg/min NN i
. . i

Group NNP N
2 CD N
received VBD N
midazolam RB i
0.03 CD i
mg/kg NN i
, , i
remifentanil NN i
: : i
propofol NN i
( ( i
1:500 CD i
) ) i
given VBN i
at IN i
an DT i
initial JJ i
propofol JJ i
infusion NN i
rate NN i
of IN i
40 CD i
microg/kg/min NN i
. . i

Outcome NNP N
measures NNS N
included VBD N
time NN o
to TO o
response NN o
to TO o
verbal JJ o
command NN o
, , o
Aldrete NNP o
score VBD o
= JJ o
9 CD o
, , o
Postanesthesia NNP o
Discharge NNP o
Scoring NNP o
System NNP o
= VBD o
7 CD o
, , o
and CC o
assessment NN o
by IN o
the DT o
Digit NNP o
Symbol NNP o
Substitution NNP o
Test NNP o
. . o

RESULTS NNP N
Forty-seven JJ p
subjects NNS p
were VBD p
entered VBN p
in IN p
the DT p
study NN p
. . p

Baseline NNP N
findings NNS N
were VBD N
homogenous JJ N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Subjects NNS N
in IN N
group NN N
2 CD N
recovered VBN N
earlier JJR N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
and CC N
required VBN N
less JJR N
propofol NN i
for IN N
both DT N
the DT N
induction NN o
( ( N
0.8 CD N
+/- JJ N
0.4 CD N
versus NN N
1.2 CD N
+/- JJ N
0.6 CD N
mg/kg NN N
; : N
mean JJ N
+/- JJ N
SD NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
maintenance NN o
of IN o
deep JJ o
sedation NN o
( ( N
46 CD N
+/- JJ N
9 CD N
versus NN N
131 CD N
+/- JJ N
17 CD N
microg/kg/min NN N
; : N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

There EX N
were VBD N
minor JJ N
differences NNS N
in IN N
vital JJ N
signs NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
demonstrated VBD N
that IN N
this DT N
remifentanil JJ N
regimen NNS N
provided VBD N
significantly RB N
more RBR N
rapid JJ o
recovery NN o
and CC N
used VBD N
significantly RB N
less JJR N
propofol JJ i
compared VBN N
with IN N
the DT N
fentanyl JJ i
regimen NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Treatment NNP N
of IN N
autism NN p
children NNS p
: : p
observation NN N
on IN N
efficacy NN o
of IN N
behavior JJ o
training NN o
with IN N
retention NN i
of IN i
needles NNS i
on IN i
head NN i
] NN i
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effect NN N
difference NN N
of IN N
behavior JJ i
training NN i
with IN i
head NN i
needling VBG i
retention NN i
and CC i
behavior NN i
training NN i
after IN i
acupuncture NN i
for IN N
autism NN p
children NNS p
. . p

METHODS NNP N
Sixty NNP p
qualified VBD p
autism NN p
children NNS p
were VBD N
divided VBN N
randomly RB N
into IN N
simultaneous JJ N
head NN i
needling VBG i
retention NN i
and CC i
behavior JJ i
training NN i
group NN i
( ( N
trial NN N
group NN N
) ) N
and CC N
behavior JJ i
training NN i
after IN i
acupuncture NN i
treatment NN i
group NN i
( ( N
control VB N
group NN N
) ) N
with IN N
30 CD N
case NN N
in IN N
each DT N
group NN N
. . N

Retention NNP i
needles NNS i
on IN N
the DT N
head NN N
with IN N
simultaneous JJ N
behavior NN N
training NN N
was VBD N
applied VBN N
for IN N
the DT N
trial NN N
group NN N
. . N

The DT N
main JJ N
acupoints NNS N
included VBD N
Sishen NNP N
Xue NNP N
, , N
Dingshen NNP N
Sanxue NNP N
( ( N
3 CD N
points NNS N
for IN N
mental JJ N
tranquilization NN N
) ) N
, , N
Nao NNP N
Sanxue NNP N
( ( N
3 CD N
points NNS N
for IN N
the DT N
function NN N
of IN N
brain NN N
) ) N
, , N
Shou NNP N
Zhisanxue NNP N
( ( N
3 CD N
points NNS N
for IN N
mental JJ N
activities NNS N
on IN N
hand NN N
) ) N
and CC N
Zozhi NNP N
Sonxue NNP N
( ( N
3 CD N
points NNS N
for IN N
mental JJ N
activities NNS N
on IN N
foot NN N
) ) N
. . N

Other JJ N
points NNS N
were VBD N
combined VBN N
according VBG N
to TO N
conditions NNS N
of IN N
patients NNS N
. . N

Needles NNS N
on IN N
the DT N
4 CD N
extremities NNS N
were VBD N
withdrawn VBN N
first RB N
after IN N
30 CD N
minutes NNS N
, , N
needles NNS N
on IN N
head NN N
were VBD N
remained VBN N
during IN N
behavior JJ i
training NN i
. . i

While IN N
behavior JJ i
training NN i
was VBD N
applied VBN N
to TO N
the DT N
control NN N
group NN N
when WRB N
acupuncture NN N
treatment NN N
was VBD N
completely RB N
accomplished VBN N
. . N

Treatments NNS N
were VBD N
applied VBN N
once RB N
a DT N
day NN N
to TO N
both DT N
groups NNS N
. . N

And CC N
3 CD N
months NNS N
was VBD N
taken VBN N
as IN N
one CD N
observation NN N
cycle NN N
. . N

Estimation NN N
was VBD N
made VBN N
on IN N
therapeutic JJ o
effect NN o
and CC N
developing VBG o
level NN o
of IN o
autism NN o
children NNS o
with IN o
CARS NNP o
and CC o
PEP NNP o
. . o

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
of IN N
the DT N
trial NN N
group NN N
was VBD N
83.3 CD N
% NN N
( ( N
25/30 CD N
) ) N
, , N
better JJR N
than IN N
66.7 CD N
% NN N
( ( N
20/30 CD N
) ) N
of IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
CARS NNPS o
scores NNS o
of IN N
both DT N
groups NNS N
declined VBD N
after IN N
the DT N
treatment NN N
. . N

And CC N
the DT N
score NN N
of IN N
trail NN N
group NN N
was VBD N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

While IN N
the DT N
PEP NNP o
scores NNS o
of IN N
both DT N
groups NNS N
increased VBD N
, , N
and CC N
the DT N
score NN N
of IN N
trail NN N
group NN N
was VBD N
higher JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
increasing VBG N
level NN N
of IN N
scores NNS o
of IN o
cognitive JJ o
understanding NN o
and CC o
cognitive JJ o
expression NN o
were VBD N
all DT N
better JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
effect NN N
of IN N
behavior JJ i
training NN i
with IN N
head NN N
needle JJ N
retention NN N
on IN N
autism NN p
children NNS p
is VBZ N
better JJR N
than IN N
behavior JJ i
training NN i
after IN i
acupuncture NN i
treatment NN N
, , N
especially RB N
in IN N
enhancing VBG o
cognition NN o
understanding NN o
and CC o
cognition NN o
expression NN o
. . o

-DOCSTART- -X- O O

Noradrenergic NNP N
moderation NN o
of IN N
working VBG N
memory NN N
impairments NNS N
in IN N
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

In IN N
addition NN N
to TO N
having VBG N
difficulties NNS N
with IN N
social JJ N
communications NNS N
, , N
individuals NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
often RB N
also RB N
experience JJ N
impairment NN o
in IN o
higher-order NN o
, , o
executive NN o
skills NNS o
. . o

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
pharmacological JJ N
modulation NN N
of IN N
the DT N
norepinephrine NN N
system NN N
on IN N
the DT N
severity NN N
of IN N
such JJ N
impairments NNS N
. . N

A DT N
sample NN N
of IN N
14 CD p
high-functioning JJ p
adults NNS p
with IN p
ASD NNP p
and CC p
a DT p
demographically-matched JJ p
comparison NN p
group NN p
of IN p
13 CD p
typically RB p
developing VBG p
individuals NNS p
participated VBN p
. . p

An DT N
AX NNP o
continuous JJ o
performance NN o
test NN o
( ( o
AX-CPT NNP o
) ) o
was VBD N
used VBN N
to TO N
evaluate VB N
working VBG N
memory NN N
and CC N
inhibitory NN N
control NN N
. . N

AX-CPT JJ o
performance NN o
was VBD N
assessed VBN N
following VBG N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
propranolol NN i
( ( i
a DT i
beta NN i
adrenergic JJ i
antagonist NN i
) ) i
and CC i
following VBG i
placebo NN i
( ( N
sugar NN N
pill NN N
) ) N
administration NN N
. . N

Individuals NNS p
with IN p
ASD NNP p
performed VBD o
more RBR N
poorly RB N
than IN N
non-ASD JJ N
individuals NNS N
in IN N
the DT N
working JJ N
memory NN N
condition NN N
( ( N
BX NNP N
trials NNS N
) ) N
. . N

Importantly RB N
, , N
administration NN N
of IN N
propranolol NN i
attenuated VBN o
this DT o
impairment NN o
, , N
with IN N
the DT N
ASD NNP N
group NN N
performing VBG o
significantly RB N
better RBR N
in IN N
the DT N
propranolol NN N
condition NN N
than IN N
the DT N
placebo JJ N
condition NN N
. . N

Working VBG o
memory NN o
performance NN o
of IN N
the DT N
non-ASD JJ N
group NN N
was VBD N
unaffected VBN N
by IN N
propranolol/placebo JJ N
administration NN N
. . N

No DT N
group NN N
or CC N
medication NN N
effects NNS o
were VBD N
observed VBN N
for IN N
the DT N
inhibition NN o
condition NN o
( ( N
AY NNP N
trials NNS N
) ) N
. . N

The DT N
present JJ N
findings NNS N
suggest VBP N
that IN N
norepinephrine NN N
may MD N
play VB N
a DT N
role NN N
in IN N
some DT N
, , N
but CC N
not RB N
necessarily RB N
all RB N
, , N
cognitive JJ o
impairments NNS o
associated VBN N
with IN N
ASD NNP N
. . N

Additional NNP N
research NN N
is VBZ N
needed VBN N
to TO N
fully RB N
understand VB N
whether IN N
this DT N
role NN N
is VBZ N
primarily RB N
causal JJ N
or CC N
compensatory NN N
in IN N
nature NN N
. . N

-DOCSTART- -X- O O

BNP-guided JJ N
vs NN N
symptom-guided JJ N
heart NN N
failure NN N
therapy NN N
: : N
the DT N
Trial NNP N
of IN N
Intensified NNP i
vs FW i
Standard NNP i
Medical NNP i
Therapy NNP i
in IN p
Elderly JJ p
Patients NNS p
With IN p
Congestive NNP p
Heart NNP p
Failure NNP p
( ( p
TIME-CHF NNP p
) ) p
randomized VBD N
trial NN N
. . N

CONTEXT VB N
It PRP N
is VBZ N
uncertain JJ N
whether IN N
intensified JJ N
heart NN N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
brain NN N
natriuretic JJ N
peptide NN N
( ( N
BNP NNP N
) ) N
is VBZ N
superior JJ N
to TO N
symptom-guided JJ N
therapy NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
18-month JJ N
outcomes NNS N
of IN N
N-terminal JJ N
BNP-guided JJ N
vs NN N
symptom-guided JJ N
heart NN N
failure NN N
therapy NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
Randomized NNP N
controlled VBD N
multicenter RBR N
Trial NNP N
of IN N
Intensified NNP N
vs FW N
Standard NNP N
Medical NNP N
Therapy NNP N
in IN N
Elderly JJ p
Patients NNS p
With IN p
Congestive NNP p
Heart NNP p
Failure NNP p
( ( p
TIME-CHF NNP p
) ) p
of IN p
499 CD p
patients NNS p
aged VBN p
60 CD p
years NNS p
or CC p
older JJR p
with IN p
systolic JJ p
heart NN p
failure NN p
( ( p
ejection NN p
fraction NN p
< NN p
or CC p
= VB p
45 CD p
% NN p
) ) p
, , p
New NNP p
York NNP p
Heart NNP p
Association NNP p
( ( p
NYHA NNP p
) ) p
class NN p
of IN p
II NNP p
or CC p
greater JJR p
, , p
prior JJ p
hospitalization NN p
for IN p
heart NN p
failure NN p
within IN p
1 CD p
year NN p
, , p
and CC p
N-terminal JJ p
BNP NNP p
level NN p
of IN p
2 CD p
or CC p
more JJR p
times NNS p
the DT p
upper JJ p
limit NN p
of IN p
normal JJ p
. . p

The DT N
study NN N
had VBD N
an DT N
18-month JJ N
follow-up NN N
and CC N
it PRP N
was VBD N
conducted VBN N
at IN N
15 CD p
outpatient NN p
centers NNS p
in IN p
Switzerland NNP p
and CC p
Germany NNP p
between IN p
January NNP p
2003 CD p
and CC p
June NNP p
2008 CD p
. . p

INTERVENTION NNP N
Uptitration NNP i
of IN i
guideline-based JJ i
treatments NNS i
to TO i
reduce VB i
symptoms NNS i
to TO i
NYHA NNP i
class NN i
of IN i
II NNP i
or CC i
less JJR i
( ( i
symptom-guided JJ i
therapy NN i
) ) i
and CC i
BNP NNP i
level NN i
of IN i
2 CD i
times NNS i
or CC i
less JJR i
the DT i
upper JJ i
limit NN i
of IN i
normal JJ i
and CC i
symptoms NNS i
to TO i
NYHA NNP i
class NN i
of IN i
II NNP i
or CC i
less JJR i
( ( i
BNP-guided JJ i
therapy NN i
) ) i
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
18-month JJ o
survival JJ o
free JJ o
of IN o
all-cause JJ o
hospitalizations NNS o
and CC o
quality NN o
of IN o
life NN o
as IN o
assessed VBN o
by IN o
structured JJ o
validated JJ o
questionnaires NNS o
. . o

RESULTS NNP N
Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
and CC N
symptom-guided JJ N
therapy NN N
resulted VBD N
in IN N
similar JJ N
rates NNS N
of IN N
survival JJ o
free JJ o
of IN o
all-cause JJ o
hospitalizations NNS o
( ( N
41 CD N
% NN N
vs JJ N
40 CD N
% NN N
, , N
respectively RB N
; : N
hazard PRP N
ratio VBP N
[ JJ N
HR NNP N
] NNP N
, , N
0.91 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
0.72-1.14 JJ N
] NN N
; : N
P NNP N
= NNP N
.39 NNP N
) ) N
. . N

Patients NNS o
' POS o
quality-of-life JJ o
metrics NNS o
improved VBN N
over IN N
18 CD N
months NNS N
of IN N
follow-up JJ N
but CC N
these DT N
improvements NNS N
were VBD N
similar JJ N
in IN N
both DT N
the DT N
N-terminal JJ N
BNP-guided JJ N
and CC N
symptom-guided JJ N
strategies NNS N
. . N

Compared VBN N
with IN N
the DT N
symptom-guided JJ N
group NN N
, , N
survival JJ o
free JJ o
of IN o
hospitalization NN o
for IN o
heart NN o
failure NN o
, , N
a DT N
secondary JJ N
end NN N
point NN N
, , N
was VBD N
higher JJR N
among IN N
those DT N
in IN N
the DT N
N-terminal JJ N
BNP-guided NNP N
group NN N
( ( N
72 CD N
% NN N
vs JJ N
62 CD N
% NN N
, , N
respectively RB N
; : N
HR NNP N
, , N
0.68 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
, , N
0.50-0.92 JJ N
] NN N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal NNP N
BNP NNP N
improved VBD N
outcomes NNS N
in IN N
patients NNS p
aged VBD p
60 CD p
to TO p
75 CD p
years NNS p
but CC N
not RB N
in IN N
those DT p
aged VBN p
75 CD p
years NNS p
or CC p
older JJR p
( ( N
P NNP N
< NNP N
.02 NNP N
for IN N
interaction NN N
) ) N
CONCLUSION NNP N
Heart NNP N
failure NN N
therapy NN N
guided VBN N
by IN N
N-terminal JJ N
BNP NNP N
did VBD N
not RB N
improve VB N
overall JJ N
clinical JJ N
outcomes NNS o
or CC N
quality NN o
of IN o
life NN o
compared VBN N
with IN N
symptom-guided JJ N
treatment NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
isrctn.org NN N
Identifier NNP N
: : N
ISRCTN43596477 NNP N
. . N

-DOCSTART- -X- O O

Skin NNP o
manifestations NNS o
of IN o
inhaled JJ o
corticosteroids NNS o
in IN N
COPD NNP p
patients NNS p
: : p
results NNS N
from IN N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
. . N

OBJECTIVE NNP N
To TO N
define VB N
the DT N
relationship NN N
between IN N
skin NN o
bruising NN o
( ( o
as RB o
well RB o
as IN o
other JJ o
cutaneous JJ o
manifestations NNS o
) ) o
and CC N
inhaled VBN N
corticosteroid NN i
( ( i
ICS NNP i
) ) i
therapy NN N
vs NN N
placebo NN N
in IN N
subjects NNS p
with IN p
COPD NNP p
who WP N
were VBD N
participating VBG N
in IN N
a DT N
clinical JJ N
trial NN N
. . N

To TO N
explore VB N
the DT N
relationship NN N
between IN N
easy JJ o
skin NN o
bruising NN o
and CC o
other JJ o
systemic JJ o
effects NNS o
of IN o
ICS NNP o
therapy NN o
, , N
including VBG N
adrenal JJ o
suppression NN o
and CC o
loss NN o
of IN o
bone JJ o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
. . o

DESIGN NNP N
Double-blind NNP N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
triamcinolone NN i
acetonide NN i
( ( N
1200 CD N
microg FW N
daily RB N
) ) N
vs NN N
placebo NN i
in IN N
participants NNS p
with IN p
mild-to-moderate JJ p
COPD NNP p
. . p

SETTING NNP N
Lung NNP N
Health NNP N
Study NNP N
II NNP N
, , N
a DT N
clinical JJ N
trial NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
ICS NNP i
compared VBN N
to TO N
placebo VB i
in IN N
1,116 CD p
participants NNS p
in IN p
10 CD p
centers NNS p
over IN p
> $ p
3.5 CD p
to TO p
4.5 CD p
years NNS p
. . p

PARTICIPANTS VB N
A DT p
total NN p
of IN p
1,116 CD p
smokers NNS p
or CC p
recent JJ p
ex-smokers NNS p
with IN p
mild-to-moderate JJ p
COPD NNP p
( ( p
age NN p
range NN p
, , p
40 CD p
to TO p
69 CD p
years NNS p
; : p
mean JJ p
age NN p
, , p
56.3 CD p
years NNS p
; : p
37.2 CD p
% NN p
female NN p
) ) p
. . p

MEASUREMENTS NNP N
AND CC N
RESULTS NNP N
Every NNP N
6 CD N
months NNS N
, , N
a DT N
structured JJ N
questionnaire NN N
was VBD N
administered VBN N
to TO N
elicit VB N
reports NNS N
of IN N
any DT N
bruising NN o
and/or NN o
skin NN o
rashes NNS o
, , o
slow JJ o
healing NN o
of IN o
cuts NNS o
or CC o
sores NNS o
, , o
or CC o
other JJ o
skin JJ o
changes NNS o
. . o

Compliance NN N
with IN N
inhaler NN N
use NN N
was VBD N
assessed VBN N
by IN N
canister NN N
weighing VBG N
. . N

A DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
ICS NNP i
than IN N
placebo NN i
participants NNS N
who WP N
complied VBD N
with IN N
using VBG N
their PRP$ N
inhaler NN N
reported VBD N
easy JJ o
bruising NN o
( ( N
11.2 CD N
% NN N
vs JJ N
3.5 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
the DT N
slow JJ o
healing NN o
of IN o
skin NN o
cuts NNS o
or CC o
sores NNS o
( ( N
2.4 CD N
% NN N
vs JJ N
0.5 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

Older JJR p
men NNS p
in IN N
the DT N
ICS NNP i
group NN N
with IN N
good JJ N
inhaler NN N
compliance NN N
appeared VBD N
to TO N
be VB N
at IN N
the DT N
greatest JJS N
risk NN o
of IN o
bruising VBG o
. . o

In IN N
those DT N
participants NNS N
undergoing VBG N
serial JJ N
measurements NNS N
of IN N
adrenal JJ N
function NN N
and CC N
BMD NNP N
, , N
no DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ o
bruising NN o
and CC N
either CC N
the DT N
suppression NN o
of IN o
adrenal JJ o
function NN o
or CC o
the DT o
loss NN o
of IN o
BMD NNP o
as IN N
systemic JJ N
complications NNS N
of IN N
ICS NNP N
use NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
moderate-to-high JJ N
doses NNS N
of IN N
ICSs NNP N
result NN N
in IN N
an DT N
increased JJ N
incidence NN N
of IN N
easy JJ o
bruising NN o
and CC o
impairment NN o
in IN o
skin NN o
healing NN o
in IN N
middle-aged JJ p
to TO p
elderly JJ p
persons NNS p
with IN p
COPD NNP p
. . p

No DT N
association NN N
was VBD N
noted VBN N
between IN N
skin JJ o
bruising NN o
and CC N
other JJ N
markers NNS N
of IN N
systemic JJ o
toxicity NN o
from IN N
the DT N
use NN N
of IN N
ICSs NNP i
. . N

-DOCSTART- -X- O O

Plasmakinetic JJ i
prostate NN i
resection NN i
in IN N
the DT N
treatment NN N
of IN N
benign JJ N
prostate JJ N
hyperplasia NN N
: : N
results NNS N
of IN N
1-year JJ N
follow VBP N
up RP N
. . N

AIM NNP N
In IN N
our PRP$ N
randomized JJ N
prospective JJ N
study NN N
, , N
we PRP N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficiency NN N
of IN N
plasmakinetic JJ i
resection NN i
of IN i
prostate NN i
( ( i
PKRP NNP i
) ) i
by IN N
comparing VBG N
the DT N
preoperative NN N
and CC N
postoperative JJ N
results NNS N
of IN N
the DT N
transurethral JJ i
resection NN i
of IN i
prostate NN i
( ( N
TURP NNP N
) ) N
and CC N
PKRP NNP N
techniques NNS N
which WDT N
we PRP N
administered VBD N
in IN N
patients NNS p
with IN p
benign JJ p
prostate NN p
hyperplasia NN p
( ( p
BPH NNP p
) ) p
in IN p
our PRP$ p
clinic NN p
. . p

METHODS NNP N
Of IN N
57 CD p
patients NNS p
for IN p
whom WP p
we PRP p
thought VBD p
an DT p
operative JJ p
intervention NN p
was VBD p
necessary JJ p
, , N
30 CD N
cases NNS N
in IN N
the DT N
first JJ N
group NN N
had VBD N
a DT N
TURP NNP i
and CC N
24 CD N
cases NNS N
in IN N
the DT N
second JJ N
group NN N
had VBD N
a DT N
PKRP NNP i
. . i

International NNP o
prostate JJ o
symptom NN o
scores NNS o
( ( o
I-PSS NNP o
) ) o
, , o
uroflowmetry UH o
, , o
measurement NN o
of IN o
residual JJ o
urine JJ o
amount NN o
and CC o
ultrasonography NN o
were VBD N
performed VBN N
for IN N
each DT N
patient NN N
both DT N
preoperatively RB N
and CC N
postoperatively RB N
( ( N
first JJ N
month NN N
and CC N
first JJ N
year NN N
) ) N
. . N

Operation NNP o
times NNS o
, , o
urethral JJ o
catheterization NN o
times NNS o
, , o
preoperative JJ o
and CC o
postoperative JJ o
Hb NNP o
, , o
Htc NNP o
and CC o
serum VB o
Na NNP o
values NNS o
of IN N
the DT N
patients NNS N
were VBD N
compared VBN N
and CC N
the DT N
complications NNS N
of IN N
the DT N
groups NNS N
were VBD N
also RB N
compared VBN N
. . N

RESULTS VB N
On IN N
first JJ N
month NN N
and CC N
first JJ N
year NN N
follow VBP N
up RP N
between IN N
the DT N
groups NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
statistical JJ o
difference NN o
in IN N
I-PSS NNP o
, , o
maximum JJ o
flow NN o
rate NN o
, , o
average NN o
flow NN o
, , o
residual JJ o
urine NN o
and CC o
size NN o
of IN o
the DT o
prostate NN o
. . o

The DT N
decrease NN N
in IN N
serum NN o
Na NNP o
level NN o
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
TURP NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
operation NN o
times NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

While IN N
the DT N
postoperative JJ o
catheterization NN o
time NN o
was VBD N
75.7 CD N
h NN N
in IN N
TURP NNP N
group NN N
, , N
it PRP N
was VBD N
found VBN N
to TO N
be VB N
42 CD N
h NN N
in IN N
PKRP NNP N
group NN N
and CC N
it PRP N
was VBD N
clear JJ N
that IN N
catheterization NN o
time NN o
was VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0001 CD N
) ) N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
obvious JJ N
that IN N
PKRP NNP i
is VBZ N
as RB N
efficient JJ N
as IN N
TURP NNP N
and CC N
it PRP N
has VBZ N
a DT N
similar JJ N
morbidity NN N
. . N

In IN N
our PRP$ N
opinion NN N
, , N
PKRP NNP i
makes VBZ N
a DT N
promising JJ N
treatment NN N
for IN N
BPH NNP N
with IN N
its PRP$ N
advantages NNS N
, , N
such JJ N
as IN N
early JJ N
removal NN N
of IN N
postoperative JJ N
urethral JJ N
catheter NN N
, , N
a DT N
shorter JJR N
hospital NN N
stay NN N
and CC N
the DT N
absence NN N
of IN N
TUR NNP N
syndrome NN N
risk NN N
. . N

-DOCSTART- -X- O O

Vaginal JJ i
electrical JJ i
stimulation NN i
of IN i
the DT i
pelvic JJ i
floor NN i
: : i
a DT N
randomized JJ N
feasibility NN N
study NN N
in IN N
urinary JJ p
incontinent NN p
elderly JJ p
women NNS p
. . p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
intravaginal JJ i
electrical JJ i
stimulation NN i
( ( i
ES NNP i
) ) i
of IN N
the DT N
pelvic JJ N
floor NN N
for IN N
urinary JJ N
incontinence NN N
in IN N
elderly JJ p
women NNS p
, , N
and CC N
to TO N
determine VB N
whether IN N
ES NNP i
of IN i
the DT i
pelvic JJ i
floor NN i
is VBZ N
a DT N
preferable JJ N
treatment NN N
for IN N
urinary JJ p
incontinence NN p
in IN p
elderly JJ p
women NNS p
. . p

METHODS NNP N
Postmenopausal NNP p
women NNS p
( ( p
age NN p
65 CD p
years NNS p
or CC p
older JJR p
) ) p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
and CC N
underwent JJ N
every-other-day JJ N
ES NNP i
of IN i
the DT i
pelvic JJ i
floor NN i
, , i
or CC i
a DT i
daily JJ i
Kegel NNP i
exercise NN i
( ( i
KE NNP i
) ) i
program NN i
. . i

Objective NNP N
outcome NN N
variables NNS N
were VBD N
: : N
( ( o
1 CD o
) ) o
Urinary JJ o
leakage NN o
( ( o
during IN o
a DT o
standardized JJ o
PAD NNP o
test NN o
) ) o
, , o
( ( o
2 CD o
) ) o
pelvic NN o
muscle NN o
strength NN o
( ( o
measured VBN o
by IN o
a DT o
perineometer NN o
) ) o
, , o
and CC o
( ( o
3 CD o
) ) o
detrusor NN o
instability NN o
( ( o
on IN o
ambulant NN o
urodynamic JJ o
registration NN o
) ) o
. . o

Subjective JJ N
outcome NN N
variables NNS N
were VBD N
women NNS o
's POS o
subjective JJ o
assessment NN o
of IN o
change NN o
in IN o
urinary JJ o
symptoms NNS o
based VBN o
on IN o
the DT o
PRAFAB NNP o
score NN o
. . o

Twenty-four JJ p
women NNS p
treated VBN p
with IN p
ES NNP i
and CC p
11 CD p
women NNS p
treated VBN p
with IN p
Kegel NNP i
exercises NNS i
completed VBD N
the DT N
8-week JJ N
study NN N
program NN N
. . N

The DT N
Chi-square JJ N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
improvement NN N
in IN N
objective JJ N
outcome NN N
variables NNS N
was VBD N
observed VBN N
in IN N
the DT N
population NN N
treated VBD N
with IN N
ES NNP i
compared VBN N
with IN N
the DT N
population NN N
treated VBD N
with IN N
KE NNP i
( ( N
with IN N
29.2 CD N
% NN N
vs. FW N
36.4 CD N
% NN N
of IN N
the DT N
women NNS N
showing VBG N
objective JJ N
improvement NN N
in IN N
measured JJ o
urinary JJ o
leakage NN o
) ) o
. . N

Neither CC N
was VBD N
subjective JJ N
improvement NN N
significant JJ N
, , N
with IN N
29.2 CD N
% NN N
vs. FW N
27.3 CD N
% NN N
of IN N
the DT N
women NNS N
reporting VBG N
improvement NN N
in IN N
the DT N
amount NN o
of IN o
urinary JJ o
leakage NN o
. . o

CONCLUSIONS NNP N
Although IN N
the DT N
number NN N
of IN N
enrolled JJ N
women NNS N
was VBD N
very RB N
small JJ N
this DT N
study NN N
shows VBZ N
that IN N
: : N
1 CD N
. . N

Treating VBG N
elderly JJ p
women NNS p
with IN N
vaginal JJ N
ES NNP N
of IN N
the DT N
pelvic JJ N
floor NN N
has VBZ N
a DT N
high JJ N
physical JJ N
and CC N
emotional JJ N
cost NN N
for IN N
the DT N
individual NN N
. . N

2 CD N
. . N

The DT N
effectiveness NN o
of IN N
ES NNP i
of IN N
the DT N
pelvic JJ N
floor NN N
in IN N
urinary JJ N
incontinent NN N
elderly JJ N
women NNS N
is VBZ N
low JJ N
. . N

3 CD N
. . N

There EX N
is VBZ N
no DT N
great JJ N
discrepancy NN N
between IN N
objective JJ N
amelioration NN N
( ( N
PAD NNP N
test NN N
) ) N
and CC N
subjective JJ N
amelioration NN N
( ( N
PRAFAB NNP N
score/quantity NN N
of IN N
urinary JJ N
leakage NN N
) ) N
, , N
if IN N
the DT N
objective JJ N
improvement NN N
is VBZ N
adequately RB N
defined VBN N
. . N

4 CD N
. . N

It PRP N
is VBZ N
not RB N
reasonable JJ N
to TO N
advise VB N
elderly JJ N
women NNS N
with IN N
urinary JJ N
incontinence NN N
to TO N
undertake VB N
this DT N
treatment NN N
procedure NN N
. . N

The DT N
effectiveness NN N
of IN N
treatment NN N
does VBZ N
not RB N
compensate VB N
for IN N
the DT N
long-lasting JJ N
and CC N
intense JJ N
treatment NN N
protocol NN N
. . N

5 CD N
. . N

We PRP N
terminated VBD N
this DT N
study NN N
because IN N
of IN N
the DT N
negative JJ N
outcome NN N
with IN N
ES NNP i
. . i

-DOCSTART- -X- O O

Effects NNS N
of IN N
supervised JJ i
exercise NN i
therapy NN i
in IN N
patients NNS p
receiving VBG p
radiotherapy NN i
for IN p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
Postoperative NNP p
radiotherapy NN i
for IN p
breast NN p
cancer NN p
has VBZ N
a DT N
number NN N
of IN N
associated JJ N
complications NNS N
. . N

This DT N
study NN N
examined VBD N
whether IN N
supervised VBN N
moderate-intensity NN i
exercise NN i
could MD N
mitigate VB N
the DT N
complications NNS N
that WDT N
occur VBP N
during IN N
radiotherapy NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty NNP p
women NNS p
were VBD p
randomized VBN p
before IN p
radiotherapy NN i
after IN N
various JJ N
operations NNS N
for IN N
breast NN N
cancer NN N
. . N

Seventeen JJ p
patients NNS p
who WP N
were VBD N
assigned VBN N
to TO N
the DT N
exercise NN i
group NN i
performed VBD N
supervised VBN i
moderate-intensity NN i
exercise NN i
therapy NN i
for IN N
50 CD N
min NN N
3 CD N
times NNS N
per IN N
week NN N
for IN N
5 CD N
weeks NNS N
. . N

Twenty-three JJ p
patients NNS p
in IN N
the DT N
control NN i
group NN i
were VBD N
asked VBN N
to TO N
perform VB i
self-shoulder JJ i
stretching VBG i
exercise NN i
. . i

The DT N
World NNP o
Health NNP o
Organization NNP o
Quality NNP o
of IN o
Life-BREF NNP o
( ( o
WHOQOL-BREF NNP o
) ) o
, , o
brief JJ o
fatigue JJ o
inventory NN o
( ( o
BFI NNP o
) ) o
, , o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
of IN o
the DT o
shoulder NN o
, , o
and CC o
pain NN o
score NN o
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
radiotherapy NN i
. . i

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
noted VBD N
at IN N
baseline NN N
between IN N
groups NNS N
. . N

In IN N
the DT N
exercise NN p
group NN p
, , N
there EX N
was VBD N
an DT N
increase NN N
in IN N
the DT N
WHOQOL-BREF NNP o
and CC o
shoulder NN o
ROM NNP o
and CC N
decrease NN o
in IN o
BFI NNP o
and CC o
pain NN o
score NN o
after IN N
radiotherapy NN i
. . i

On IN N
the DT N
other JJ N
hand NN N
, , N
patients NNS p
in IN N
the DT N
control NN i
group NN p
showed VBD N
decrease NN N
in IN N
the DT N
WHOQOL-BREF NNP o
and CC o
shoulder NN o
ROM NNP o
and CC N
increase VB o
in IN o
BFI NNP o
and CC o
pain NN o
score NN o
after IN N
radiotherapy NN i
. . i

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
changes NNS N
in IN N
the DT N
WHOQOL NNP o
, , o
BFI NNP o
, , o
shoulder NN o
ROM NNP o
, , o
and CC o
pain VB o
score NN o
between IN N
the DT N
groups NNS p
. . p

CONCLUSION NNP N
Patients NNPS p
receiving VBG p
radiotherapy NN i
for IN p
breast NN p
cancer NN p
may MD N
benefit VB N
in IN N
physical JJ N
and CC N
psychological JJ N
aspects NNS N
from IN N
supervised VBN i
moderate-intensity NN i
exercise NN i
therapy NN i
. . i

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
chloroquine NN i
, , i
amodiaquine NN i
and CC N
chloroquine NN i
plus CC i
chlorpheniramine NN i
on IN N
the DT N
disposition NN p
kinetics NNS o
of IN p
the DT p
hepatomegaly NN p
associated VBN p
with IN p
acute NN p
, , p
uncomplicated JJ p
, , p
Plasmodium NNP p
falciparum NN p
malaria NN p
in IN p
children NNS p
. . p

The DT N
effects NNS N
of IN N
chloroquine NN i
( ( i
CQ NNP i
) ) i
, , i
amodiaquine NN i
( ( i
AQ NNP i
) ) i
and CC N
CQ NNP i
plus CC i
chlorpheniramine NN i
( ( N
a DT N
histamine NN N
H NNP N
( ( N
1 CD N
) ) N
antagonist NN N
that IN N
reverses VBZ N
CQ NNP N
resistance NN N
in IN N
vitro NN N
and CC N
in IN N
vivo NN N
) ) N
on IN N
the DT N
disposition NN N
of IN N
the DT N
enlarged JJ p
liver NN p
associated VBN p
with IN p
acute NN p
, , p
symptomatic JJ p
, , p
uncomplicated JJ p
, , p
Plasmodium NNP p
falciparum NN p
malaria NNS p
were VBD N
evaluated VBN N
. . N

The DT p
subjects NNS p
, , p
131 CD p
children NNS p
aged VBN p
0.6-12 CD p
years NNS p
who WP p
lived VBD p
in IN p
an DT p
endemic JJ p
area NN p
of IN p
Nigeria NNP p
, , N
were VBD N
randomly RB N
allotted VBN N
to TO N
the DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
cumulative JJ N
proportions NNS N
of IN N
the DT N
children NNS N
with IN N
complete JJ o
resolution NN o
of IN o
their PRP$ o
enlarged JJ o
livers NNS o
at IN N
48 CD N
, , N
96 CD N
, , N
168 CD N
or CC N
336 CD N
and CC N
504 CD N
h NN N
after IN N
commencement NN N
of IN N
treatment NN N
were VBD N
significantly RB N
higher JJR N
in IN N
those DT N
treated VBN N
with IN N
CQ NNP i
plus CC i
chlorpheniramine NN i
( ( i
CQCP NNP i
) ) i
than IN N
in IN N
the DT N
other JJ N
two CD N
treatment NN N
groups NNS N
( ( N
with IN N
P-values NNP N
of IN N
0.02 CD N
, , N
0.001 CD N
, , N
0.00000 CD N
and CC N
0.00002 CD N
, , N
respectively RB N
) ) N
. . N

Among IN N
those DT N
with IN N
complete JJ N
resolution NN N
, , N
however RB N
, , N
the DT N
times NNS N
to TO N
resolution NN N
of IN N
50 CD N
% NN N
( ( N
HR50 NNP N
) ) N
or CC N
90 CD N
% NN N
( ( N
HR90 NNP N
) ) N
of IN N
the DT N
liver NN N
enlargement NN N
were VBD N
similar JJ N
in IN N
all PDT N
the DT N
treatment NN N
groups NNS N
. . N

Complete JJ o
resolution NN o
of IN o
the DT o
enlarged JJ o
liver NN o
within IN N
168 CD N
h NN N
was VBD N
associated VBN N
with IN N
a DT N
sensitive JJ N
response NN N
to TO N
each DT N
treatment NN N
. . N

Overall JJ N
, , N
in IN N
children NNS N
with IN N
complete JJ o
or CC o
partial JJ o
resolution NN o
of IN N
their PRP$ N
enlarged JJ N
livers NNS N
, , N
the DT N
area NN o
produced VBN o
by IN o
plotting VBG o
liver JJ o
size NN o
against IN o
time NN o
( ( N
i.e NN N
. . N

the DT N
area NN N
under IN N
the DT N
curve NN N
of IN N
hepatomegaly NN N
v. NN N
time NN N
, , N
or CC N
AUC NNP N
( ( N
hp NN N
) ) N
) ) N
and CC N
the DT N
half-life NN o
of IN o
the DT o
hepatomegaly NN o
( ( N
t NN N
( ( N
1/2hp CD N
) ) N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
CQCP NNP i
group NN N
than IN N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
. . N

The DT N
volume NN o
of IN o
blood NN o
completely RB o
cleared VBD o
of IN o
the DT o
'hepatic JJ o
pathological JJ o
processes NNS o
' POS o
which WDT N
led VBD N
to TO N
the DT N
hepatomegaly NN N
( ( N
CL NNP N
( ( N
Bhp NNP N
) ) N
) ) N
and CC N
the DT N
fractional JJ o
reduction NN o
of IN o
AUC NNP o
( ( o
hp NN o
) ) o
at IN N
48 CD N
and CC N
96 CD N
h NN N
( ( N
i.e JJ N
. . N

AUC NNP N
( ( N
hpFr148 NN N
) ) N
and CC N
AUC NNP N
( ( N
hpFr96 NN N
) ) N
) ) N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
CQCP NNP i
group NN N
than IN N
in IN N
the DT N
other JJ N
treatment NN N
groups NNS N
. . N

When WRB N
the DT N
children NNS N
with IN N
complete JJ N
resolution NN N
of IN N
their PRP$ N
liver NN N
enlargement NN N
were VBD N
considered VBN N
separately RB N
, , N
t NN N
( ( N
1/2hp CD N
) ) N
( ( N
P=0.0008 NNP N
) ) N
but CC N
not RB N
AUC NNP o
( ( o
hp NN o
) ) o
was VBD N
found VBN N
to TO N
be VB N
significantly RB N
lower JJR N
, , N
and CC N
AUC NNP o
( ( o
hpFr196 NN o
) ) o
( ( N
P=0.01 NNP N
) ) N
and CC N
CL NNP o
( ( o
Bhl NNP o
) ) o
( ( N
P=0.002 NNP N
) ) N
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
CQCP NNP i
group NN N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Among IN N
the DT N
children NNS N
with IN N
only RB N
partial JJ o
resolution NN o
of IN o
their PRP$ o
enlarged JJ o
livers NNS o
, , N
the DT N
indices NNS o
of IN o
resolution NN o
and CC o
the DT o
kinetic JJ o
parameters NNS o
of IN o
disposition NN o
were VBD N
similar JJ N
in IN N
all DT N
three CD N
groups NNS N
. . N

The DT N
data NN N
indicate NN N
that IN N
the DT N
addition NN N
of IN N
chlorpheniramine NN i
to TO N
chloroquine VB i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
both CC N
the DT N
early JJ p
and CC p
late JJ p
stages NNS p
of IN p
the DT p
resolution NN o
of IN o
the DT o
liver NN o
enlargement NN o
associated VBN p
with IN p
acute NN p
, , p
symptomatic JJ p
, , p
uncomplicated JJ p
, , p
P. NNP p
falciparum NN p
malaria NN p
. . p

-DOCSTART- -X- O O

[ JJ N
Effectiveness NNP N
of IN N
adjuvant JJ i
hormone NN i
therapy NN i
in IN N
breast NN N
cancer NN N
] NNP N
. . N

A NNP N
third JJ N
series NN N
of IN N
randomized JJ N
tests NNS N
was VBD N
undertaken VBN N
to TO N
evaluate VB o
the DT N
efficacy NN o
of IN N
postoperative JJ N
adjuvant JJ i
hormone NN i
therapy NN i
( ( i
tamoxifen NN i
, , i
diethylstilbestrol NN i
, , i
orimethen VBP i
amino JJ i
glutethymide NN i
) ) i
in IN N
breast NN p
cancer NN p
patients NNS p
. . p

Tamoxifen NNP i
was VBD N
studied VBN N
in IN N
176 CD p
patients NNS p
with IN p
T1-2N0M0 NNP p
tumors NNS p
. . p

Five-year JJ o
recurrence-free JJ o
survival NN o
was VBD N
registered VBN N
in IN N
85.2 CD N
% NN N
of IN N
menopausal NN N
patients NNS N
treated VBN N
with IN N
tamoxifen JJ i
versus NN N
71.1 CD N
% NN N
in IN N
control NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Five-year JJ o
recurrence-free JJ o
survival NN o
in IN N
menopausal NN N
females NNS N
with IN N
breast NN N
tumors NNS N
, , N
stage NN N
IIb NNP N
, , N
was VBD N
71.1 CD N
% NN N
among IN N
those DT N
treated VBN N
with IN N
diethylstilbestrol NN N
and CC N
as RB N
low JJ N
as IN N
57.4 CD N
% NN N
in IN N
the DT N
tamoxifen NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Untoward NNP o
side-effect JJ o
incidence NN o
was VBD N
much JJ o
higher JJR o
in IN N
the DT N
diethylstilbestrol NN N
group NN N
( ( N
30.4 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
tamoxifen NN i
( ( N
3.5 CD N
% NN N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
for IN N
the DT N
relationship NN N
between IN N
orimethen NN i
and CC N
tamoxifen JJ i
treatment NN N
with IN N
respect NN N
to TO N
5-year JJ o
survival NN o
and CC o
recurrence-free JJ o
survival NN o
. . o

-DOCSTART- -X- O O

Reducing VBG N
cancer NN o
screening VBG o
disparities NNS N
in IN N
medicare NN N
beneficiaries NNS N
through IN N
cancer NN i
patient JJ i
navigation NN i
. . i

Significant NNP N
racial JJ N
disparities NNS N
in IN N
cancer NN o
mortality NN o
are VBP N
seen VBN N
between IN N
Medicare NNP p
beneficiaries NNS p
. . p

A DT N
randomized JJ N
controlled VBN N
trial NN N
tested VBD N
the DT N
use NN N
of IN N
lay NN i
navigators NNS i
( ( i
care NN i
managers NNS i
) ) i
to TO i
increase VB i
cancer NN o
screening NN o
of IN p
Asian JJ p
and CC p
Pacific NNP p
Islander NNP p
Medicare NNP p
beneficiaries NNS p
. . p

The DT p
study NN p
setting NN p
was VBD p
Moloka'i NNP p
General NNP p
Hospital NNP p
on IN p
the DT p
island NN p
of IN p
Moloka'i NNP p
, , p
Hawai'i NNP p
, , p
which WDT p
was VBD p
one CD p
of IN p
six CD p
sites NNS p
participating VBG p
in IN p
the DT p
Cancer NNP p
Prevention NNP p
and CC p
Treatment NNP p
Demonstration NNP p
sponsored VBN p
by IN p
the DT p
Centers NNPS p
for IN p
Medicare NNP p
and CC p
Medicaid NNP p
Services NNPS p
. . p

Between JJ p
2006 CD p
and CC p
2009 CD p
, , p
488 CD p
Medicare NNP p
beneficiaries NNS p
( ( p
45 CD p
% NN p
Hawaiian JJ p
, , p
35 CD p
% NN p
Filipino NNP p
, , p
11 CD p
% NN p
Japanese JJ p
, , p
8 CD p
% NN p
other JJ p
) ) p
were VBD N
randomized VBN N
to TO N
have VB N
a DT N
navigator NN i
help NN i
them PRP i
access NN i
cancer NN i
screening NN i
services NNS i
( ( i
experimental JJ i
condition NN i
, , N
n JJ N
= NNP N
242 CD N
) ) N
or CC i
cancer NN i
education NN i
( ( i
control JJ i
condition NN i
, , N
n JJ N
= NNP N
246 CD N
) ) N
. . N

Self-reported JJ o
data NNS o
on IN o
screening VBG o
participation NN o
were VBD N
collected VBN N
at IN N
baseline NN i
and CC N
exit NN N
from IN N
the DT N
study NN N
, , N
and CC N
differences NNS N
were VBD N
tested VBN N
using VBG N
chi-square NN N
. . N

Groups NNP N
were VBD N
similar JJ N
in IN N
demographic JJ o
characteristics NNS o
and CC o
baseline NN o
screening VBG o
prevalence NN o
of IN o
breast NN o
, , o
cervical JJ o
, , o
prostate NN o
, , o
and CC o
colorectal JJ o
cancers NNS o
. . o

At IN N
study NN N
exit NN N
, , N
57.0 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
Papanicolaou NNP o
test NN o
in IN o
the DT o
past JJ o
24 CD o
months NNS o
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
, , N
61.7 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
42.4 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
mammogram NN o
in IN o
the DT o
past JJ o
12 CD o
months NNS o
( ( N
P NNP N
= NNP N
.003 NNP N
) ) N
, , N
54.4 CD N
% NN N
of IN N
men NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
36.0 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
prostate-specific JJ o
antigen NN o
test NN o
in IN o
the DT o
past JJ o
12 CD o
months NNS o
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
, , N
and CC N
43.0 CD N
% NN N
of IN N
both DT N
sexes NNS N
in IN N
the DT N
experimental JJ N
arm NN N
and CC N
27.2 CD N
% NN N
of IN N
controls NNS N
had VBD N
had VBN N
a DT N
flexible JJ o
sigmoidoscopy NN o
or CC o
colonoscopy NN o
in IN o
the DT o
past JJ o
5 CD o
years NNS o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Findings NNS N
suggest VBP N
that IN N
navigation NN i
services NNS i
can MD N
increase VB N
cancer NN o
screening VBG o
in IN N
Medicare NNP N
beneficiaries NNS N
in IN N
groups NNS N
with IN N
significant JJ N
disparities NNS N
. . N

-DOCSTART- -X- O O

Tomato NNP i
paste NN i
rich JJ i
in IN i
lycopene JJ i
protects NNS N
against IN N
cutaneous JJ o
photodamage NN o
in IN N
humans NNS p
in IN p
vivo NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous NNP N
epidemiological JJ N
, , N
animal JJ N
and CC N
human JJ N
data NNS N
report NN N
that IN N
lycopene NN N
has VBZ N
a DT N
protective JJ N
effect NN N
against IN N
ultraviolet NN o
radiation NN o
( ( o
UVR NNP o
) ) o
-induced VBD o
erythema NN o
. . o

OBJECTIVES IN N
We PRP N
examined VBD N
whether IN N
tomato NN i
paste NN i
-- : i
rich JJ i
in IN i
lycopene NN i
, , N
a DT N
powerful JJ N
antioxidant NN N
-- : N
can MD N
protect VB N
human JJ N
skin NN N
against IN N
UVR-induced JJ N
effects NNS N
partially RB N
mediated VBN N
by IN N
oxidative JJ N
stress NN N
, , N
i.e NN N
. . N

erythema NN N
, , N
matrix NN N
changes NNS N
and CC N
mitochondrial JJ N
DNA NNP N
( ( N
mtDNA NN N
) ) N
damage NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
study NN N
, , N
20 CD p
healthy JJ p
women NNS p
( ( p
median JJ p
age NN p
33 CD p
years NNS p
, , p
range VBP p
21-47 JJ p
; : p
phototype JJ p
I/II NNP p
) ) p
ingested VBD N
55 CD i
g NN i
tomato NN i
paste NN i
( ( i
16 CD i
mg RB i
lycopene NN i
) ) i
in IN i
olive JJ i
oil NN i
, , i
or CC i
olive JJ i
oil NN i
alone RB i
, , i
daily JJ i
for IN i
12 CD i
weeks NNS i
. . i

Pre- NNP N
and CC N
postsupplementation NN N
, , N
UVR NNP N
erythemal JJ o
sensitivity NN o
was VBD N
assessed VBN N
visually RB N
as IN N
the DT N
minimal JJ N
erythema NN N
dose NN N
( ( N
MED NNP N
) ) N
and CC N
quantified VBN N
with IN N
a DT N
reflectance NN N
instrument NN N
. . N

Biopsies NNS N
were VBD N
taken VBN N
from IN N
unexposed JJ N
and CC N
UVR-exposed JJ N
( ( N
3 CD N
? . N
MED NNP N
24 CD N
h NN N
earlier RBR N
) ) N
buttock NN N
skin JJ N
pre- NN N
and CC N
postsupplementation NN N
, , N
and CC N
analysed VBD N
immunohistochemically RB N
for IN N
procollagen NN N
( ( N
pC NN N
) ) N
I PRP N
, , N
fibrillin-1 JJ N
and CC N
matrix JJ N
metalloproteinase NN N
( ( N
MMP NNP N
) ) N
-1 NN N
, , N
and CC N
by IN N
quantitative JJ N
polymerase NN N
chain NN N
reaction NN N
for IN N
mtDNA JJ N
3895-bp JJ N
deletion NN N
. . N

RESULTS VB o
Mean NNP o
? . o
SD NNP o
erythemal JJ o
D NNP o
( ( o
30 CD o
) ) o
was VBD o
significantly RB N
higher JJR N
following VBG N
tomato JJ N
paste NN N
vs. FW N
control NN N
( ( N
baseline NN N
, , N
26?5 CD N
? . N
7?5 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
control NN N
, , N
23 CD N
? . N
6?6 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
tomato CC N
paste NN N
, , N
36?6 CD N
? . N
14?7 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
P NNP N
= NNP N
0?03 CD N
) ) N
, , N
while IN N
the DT N
MED NNP N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
groups NNS N
( ( N
baseline NN N
, , N
35?1 CD N
? . N
9?9 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
control NN N
, , N
32?6 CD N
? . N
9?6 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
; : N
tomato CC N
paste NN N
, , N
42?2 CD N
? . N
11?3 CD N
mJ NN N
cm NN N
( ( N
-2 NNP N
) ) N
) ) N
. . N

Presupplementation NN N
, , N
UVR NNP N
induced VBD N
an DT N
increase NN N
in IN o
MMP-1 NNP o
( ( o
P NNP N
= NNP N
0?01 CD N
) ) N
and CC N
a DT N
reduction NN o
in IN o
fibrillin-1 NN o
( ( o
P NNP o
= NNP o
0?03 CD N
) ) N
. . N

Postsupplementation NN N
, , N
UVR-induced JJ o
MMP-1 NNP o
was VBD o
reduced VBN N
in IN N
the DT N
tomato NN N
paste NN N
vs. FW N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0?04 CD N
) ) N
, , N
while IN N
the DT N
UVR-induced JJ N
reduction NN N
in IN o
fibrillin-1 NN o
was VBD o
similarly RB o
abrogated VBN N
in IN N
both DT N
groups NNS N
, , N
and CC N
an DT N
increase NN N
in IN N
pCI JJ N
deposition NN N
was VBD N
seen VBN N
following VBG N
tomato JJ N
paste NN N
( ( N
P NNP N
= NNP N
0?05 CD N
) ) N
. . o

mtDNA JJ o
3895-bp JJ o
deletion NN N
following VBG N
3 CD N
? . N
MED NNP N
UVR NNP N
was VBD N
significantly RB N
reduced VBN N
postsupplementation NN N
with IN N
tomato JJ i
paste NN i
( ( i
P NNP i
= NNP i
0?01 CD i
) ) N
. . N

CONCLUSIONS NNP i
Tomato NNP i
paste NN i
containing VBG N
lycopene NNP N
provides VBZ o
protection NN o
against IN o
acute NN o
and CC o
potentially RB o
longer-term JJ o
aspects NNS o
of IN o
photodamage NN o
. . o

-DOCSTART- -X- O O

Administration NN N
of IN N
subcutaneous JJ N
buffered VBN N
lidocaine JJ i
prior RB N
to TO N
breast VB p
lymphoscintigraphy NN p
reduces NNS N
pain VBP o
without IN N
decreasing VBG N
lymph NN N
node DT N
visualization NN N
. . N

UNLABELLED NNP N
Breast NNP N
lymphoscintigraphy NN N
using VBG N
( ( N
99m CD N
) ) N
Tc-sulfur CD N
colloid NN N
( ( N
( ( N
99m CD N
) ) N
Tc-SC NN N
) ) N
is VBZ N
well RB N
established VBN N
in IN N
clinical JJ N
practice NN N
for IN N
staging VBG N
patients NNS p
with IN p
breast JJ p
carcinoma NN p
. . p

Nearly RB N
all DT N
patients NNS N
report VBP N
having VBG N
pain NN o
during IN N
the DT N
procedure NN N
. . N

However RB N
, , N
techniques NNS N
used VBN N
to TO N
minimize VB N
pain NN o
during IN N
breast NN p
lymphoscintigraphy NN i
are VBP N
highly RB N
variable JJ N
across IN N
institutions NNS N
. . N

Our PRP$ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
anesthetizing VBG N
the DT N
skin NN N
with IN N
sodium JJ i
bicarbonatehether-buffered JJ i
lidocaine NN i
before IN N
performing VBG N
breast NN N
lymphoscintigraphy NN N
reduced VBD N
the DT N
pain NN o
experienced VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
second JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
anesthetizing VBG N
the DT N
skin NN N
with IN N
buffered JJ N
lidocaine NN N
changed VBN N
visualization NN o
of IN o
lymph NN o
nodes NNS o
. . o

METHODS NNP N
This DT N
prospective JJ N
, , N
patient-masked JJ N
and CC N
randomized JJ N
study NN N
involved VBN N
performing VBG N
breast NN i
lymphoscintigraphy NN i
in IN N
a DT N
control NN p
group NN p
and CC p
experimental JJ p
group NN p
of IN p
female JJ p
breast NN p
cancer NN p
patients NNS p
. . p

The DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
skin NN N
anesthetic JJ N
before IN N
( ( N
99m CD N
) ) N
Tc-SC CD N
injections NNS N
, , N
whereas IN N
the DT N
experimental JJ N
group NN N
first JJ N
underwent JJ N
skin NN N
anesthesia NN N
with IN N
an DT N
injection NN N
of IN N
2 CD i
% NN i
sodium JJ i
bicarbonate-buffered JJ i
lidocaine NN i
. . i

All DT N
patients NNS N
were VBD N
asked VBN N
to TO N
rate NN o
their PRP$ o
pain NN o
levels NNS o
, , o
using VBG o
the DT o
National NNP o
Institutes NNPS o
of IN o
Health NNP o
pain NN o
scale NN o
, , N
before IN N
the DT N
procedure NN N
and CC N
immediately RB N
after IN N
the DT N
injections NNS N
. . N

The DT N
change NN o
in IN o
pain NN o
from IN o
baseline NN o
was VBD N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

After IN N
the DT N
injections NNS N
, , N
scintigraphic JJ N
imaging NN N
of IN N
the DT N
axilla NN N
was VBD N
performed VBN N
, , N
and CC N
the DT N
number NN o
of IN o
axillary JJ o
lymph NN o
nodes NNS o
visualized VBN o
was VBD N
recorded VBN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
preprocedural JJ N
baseline NN o
pain NN o
from IN N
the DT N
control NN N
group NN N
, , N
compared VBN N
with IN N
the DT N
experimental JJ N
group NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
increase NN o
in IN o
pain NN o
experienced VBD N
during IN N
the DT N
procedure NN N
between IN N
the DT N
control NN N
group NN N
and CC N
the DT N
experimental JJ N
group NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
detection NN o
of IN o
lymph NN o
nodes NNS o
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.56 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
from IN N
our PRP$ N
study NN N
indicate VBP N
that IN N
injecting VBG N
subcutaneous JJ N
buffered VBN N
lidocaine NN i
before IN N
intradermal JJ N
injection NN N
of IN N
( ( N
99m CD N
) ) N
Tc-SC NN N
for IN N
breast NN N
lymphoscintigraphy NN N
significantly RB N
decreases VBZ N
patient JJ o
pain NN o
without IN N
interfering VBG N
with IN N
lymph JJ o
node JJ o
visualization NN o
. . o

-DOCSTART- -X- O O

Aerobic NNP i
exercise NN i
improves VBZ N
self-reported JJ o
sleep NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
older JJR p
adults NNS p
with IN p
insomnia NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN o
of IN N
moderate JJ i
aerobic JJ i
physical JJ i
activity NN i
with IN N
sleep JJ N
hygiene NN N
education NN N
to TO N
improve VB o
sleep NN o
, , o
mood NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
older JJR N
adults NNS N
with IN N
chronic JJ N
insomnia NN N
. . N

METHODS NNP N
Seventeen NNP p
sedentary JJ p
adults NNS p
aged VBN p
> JJ p
or=55 CD p
years NNS p
with IN p
insomnia NN p
( ( p
mean JJ p
age NN p
61.6 CD p
[ NN p
SD?4.3 NNP p
] NNP p
years NNS p
; : p
16 CD p
female NN p
) ) p
participated VBD p
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
comparing VBG i
16 CD i
weeks NNS i
of IN i
aerobic JJ i
physical JJ i
activity NN i
plus CC i
sleep JJ i
hygiene NN i
to TO i
non-physical JJ i
activity NN i
plus CC i
sleep JJ i
hygiene NN i
. . i

Eligibility NNP N
included VBD p
primary JJ p
insomnia NN p
for IN p
at IN p
least JJS p
3 CD p
months NNS p
, , p
habitual JJ p
sleep NN p
duration NN p
< POS p
6.5h CD p
and CC p
a DT p
Pittsburgh NNP p
Sleep NNP p
Quality NNP p
Index NNP p
( ( p
PSQI NNP p
) ) p
score VBD p
> JJ p
5 CD p
. . p

Outcomes NNS o
included VBD o
sleep JJ o
quality NN o
, , o
mood NN o
and CC o
quality NN o
of IN o
life NN o
questionnaires NNS o
( ( o
PSQI NNP o
, , o
Epworth NNP o
Sleepiness NNP o
Scale NNP o
[ NNP o
ESS NNP o
] NNP o
, , o
Short-form NNP o
36 CD o
[ NNP o
SF-36 NNP o
] NNP o
, , o
Center NNP o
for IN o
Epidemiological NNP o
Studies NNPS o
Depression NNP o
Scale NNP o
[ NNP o
CES-D NNP o
] NNP o
) ) o
. . o

RESULTS VB N
The DT N
physical JJ N
activity NN N
group NN N
improved VBD N
in IN o
sleep JJ o
quality NN o
on IN o
the DT o
global JJ o
PSQI NNP o
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
, , N
sleep JJ o
latency NN o
( ( N
p=.049 NN N
) ) N
, , N
sleep JJ o
duration NN o
( ( N
p=.04 NN N
) ) N
, , N
daytime JJ o
dysfunction NN o
( ( N
p=.027 NN N
) ) N
, , N
and CC o
sleep JJ o
efficiency NN o
( ( N
p=.036 NN N
) ) N
PSQI NNP N
sub-scores NNS N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

The DT N
physical JJ N
activity NN N
group NN N
also RB N
had VBD N
reductions NNS N
in IN o
depressive JJ o
symptoms NNS o
( ( N
p=.044 NN N
) ) N
, , N
daytime JJ o
sleepiness NN o
( ( N
p=.02 NN N
) ) N
and CC o
improvements NNS o
in IN o
vitality NN o
( ( N
p=.017 NN N
) ) N
compared VBN N
to TO N
baseline VB N
scores NNS N
. . N

CONCLUSION NNP N
Aerobic NNP N
physical JJ N
activity NN N
with IN N
sleep JJ N
hygiene NN N
education NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
approach NN N
to TO N
improve VB o
sleep JJ o
quality NN o
, , o
mood NN o
and CC o
quality NN o
of IN o
life NN o
in IN p
older JJR p
adults NNS p
with IN p
chronic JJ p
insomnia NN p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
indicators NNS N
for IN N
a DT N
primary JJ N
care NN N
medical JJ N
home NN N
between IN N
children NNS p
with IN p
autism NN p
or CC p
asthma NN p
and CC p
other JJ p
special JJ p
health NN p
care NN p
needs NNS p
: : p
National NNP N
Survey NNP N
of IN N
Children NNP N
's POS N
Health NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS i
of IN i
children NNS i
with IN i
autism NN i
compared VBN i
with IN i
parents NNS i
of IN i
children NNS i
with IN i
asthma NN i
or CC i
other JJ i
special JJ i
health NN i
care NN i
needs VBZ i
report NN N
receiving VBG N
primary JJ N
care NN N
for IN N
their PRP$ N
child NN N
consistent NN N
with IN N
the DT N
American JJ N
Academy NNP N
of IN N
Pediatrics NNP N
medical JJ N
home NN N
model NN N
. . N

DESIGN NNP N
Population-based JJ N
cross-sectional JJ N
study NN N
. . N

SETTING NNP N
National NNP i
Survey NNP i
for IN i
Children NNP i
's POS i
Health NNP i
2003-2004 CD i
telephone NN i
interview NN i
. . i

PARTICIPANTS NNP N
Parents NNPS p
of IN p
495 CD p
children NNS p
with IN p
autism NN p
, , p
parents NNS p
of IN p
6716 CD p
children NNS p
with IN p
asthma NN p
, , p
and CC p
parents NNS p
of IN p
11,403 CD p
children NNS p
with IN p
other JJ p
special JJ p
health NN p
care NN p
needs VBZ p
without IN p
asthma NN p
. . p

Main NNP N
Exposures NNPS N
Autism NNP N
and CC N
other JJ N
special JJ N
health NN N
care NN N
needs VBZ N
including VBG N
asthma NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Medical NNP N
home NN N
score NN N
and CC N
components NNS N
of IN N
care NN N
, , N
as IN N
follows VBZ N
: : N
personal JJ N
provider NN N
and CC N
preventive NN N
; : N
family-centered JJ N
, , N
compassionate NN N
, , N
and CC N
culturally RB N
appropriate JJ N
; : N
accessible JJ N
; : N
comprehensive JJ N
; : N
and CC N
coordinated VBD N
. . N

RESULTS VB N
The DT N
odds NNS o
of IN o
parents NNS o
reporting VBG o
care NN o
consistent JJ o
with IN o
that DT o
in IN o
a DT o
medical JJ o
home NN o
were VBD N
less RBR o
likely JJ o
for IN o
children NNS o
with IN o
autism NN o
( ( N
odds NNS N
ratio NN N
, , N
0.45 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.30-0.66 JJ N
) ) N
and CC N
more RBR N
likely JJ N
for IN N
children NNS N
with IN N
asthma NN N
( ( N
odds NNS N
ratio NN N
, , N
1.17 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.06-1.30 JJ N
) ) N
compared VBN N
with IN N
children NNS N
with IN N
other JJ N
special JJ N
health NN N
care NN N
needs NNS N
( ( N
1 CD N
[ NN N
reference NN N
] NN N
) ) N
. . N

These DT N
differences NNS N
persisted VBD N
even RB N
after IN N
controlling VBG N
for IN N
condition NN N
severity NN N
, , N
personal JJ N
characteristics NNS N
, , N
and CC N
insurance NN N
status NN N
. . N

Specific JJ N
components NNS N
of IN N
a DT N
medical JJ N
home NN N
less RBR N
prevalent JJ N
among IN N
children NNS N
with IN N
autism NN N
than IN N
among IN N
children NNS N
with IN N
other JJ N
special JJ N
health NN N
care NN N
needs VBZ N
included VBN N
family-centered JJ N
, , N
comprehensive JJ N
, , N
and CC N
coordinated VBD N
care NN N
. . N

CONCLUSION NNP N
Although IN N
we PRP N
could MD N
not RB N
evaluate VB N
the DT N
reasons NNS N
why WRB N
, , N
a DT N
large JJ N
percentage NN N
of IN N
children NNS N
with IN N
autism NN N
do VBP N
not RB N
receive VB N
primary JJ o
care NN o
consistent JJ o
with IN o
that DT o
in IN o
a DT o
medical JJ o
home NN o
. . o

-DOCSTART- -X- O O

Trace NNP i
element NN i
supplementation NN i
after IN N
major JJ p
burns NNS p
modulates VBZ N
antioxidant JJ N
status NN N
and CC N
clinical JJ N
course NN N
by IN N
way NN N
of IN N
increased JJ N
tissue NN o
trace NN o
element NN o
concentrations NNS o
. . o

BACKGROUND NNP N
After IN N
major JJ p
burns NNS p
, , p
patients NNS p
can MD N
develop VB N
nutritional JJ p
deficiencies NNS p
including VBG p
trace NN o
element NN o
( ( o
TE NNP o
) ) o
deficiencies NNS p
. . p

Various JJ N
complications NNS N
, , N
such JJ N
as IN N
infections NNS N
and CC N
delayed VBN N
wound NN N
healing NN N
, , N
influence VB N
the DT N
clinical JJ N
course NN N
of IN N
such JJ N
patients NNS N
. . N

OBJECTIVES IN N
We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
large JJ N
, , N
intravenous JJ N
doses NNS N
of IN N
TE NNP i
supplements NNS i
on IN N
circulating NN N
and CC N
cutaneous JJ N
TE NNP N
tissue NN N
concentrations NNS N
, , N
on IN N
antioxidant JJ o
status NN o
, , N
and CC N
on IN N
clinical JJ o
outcome NN o
after IN N
major JJ p
burns NNS p
. . p

DESIGN NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
in IN N
21 CD p
patients NNS p
aged VBD p
35 CD p
+/- JJ p
11 CD p
y NN p
( ( p
x JJ p
+/- NNP p
SD NNP p
) ) p
with IN p
burns NNS p
on IN p
45 CD p
+/- JJ p
21 CD p
% NN p
of IN p
their PRP$ p
body NN p
surface NN p
area NN p
. . p

Intravenous JJ i
copper NN i
, , i
selenium NN i
, , i
and CC i
zinc NN i
( ( i
TE NNP i
group NN i
) ) i
or CC i
vehicle NN i
( ( N
V NNP N
group NN N
) ) N
was VBD N
given VBN N
with IN N
a DT N
saline JJ N
solution NN N
for IN N
14-21 JJ N
d. NN N
Blood NNP N
and CC N
urine JJ N
samples NNS N
were VBD N
collected VBN N
until IN N
day NN N
20 CD N
, , N
and CC N
skin FW N
biopsy NN N
specimens NNS N
were VBD N
collected VBN N
on IN N
days NNS N
3 CD N
, , N
10 CD N
, , N
and CC N
20 CD N
. . N

RESULTS VB N
The DT N
age NN N
of IN N
the DT N
patients NNS N
and CC N
the DT N
severity NN N
of IN N
their PRP$ N
burns NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
. . N

Plasma NNP o
TE NNP o
concentrations NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
TE NNP N
group NN N
. . N

In IN N
burned JJ N
areas NNS N
, , N
skin JJ o
contents NNS o
of IN o
both DT o
selenium NN o
( ( N
P=0.05 NNP N
) ) N
and CC N
zinc NN o
( ( N
P=0.04 NNP N
) ) N
increased VBD N
significantly RB N
by IN N
day NN N
20 CD N
. . N

Plasma NNP o
and CC o
tissue NN o
antioxidant NN o
status NN o
was VBD N
improved VBN N
by IN N
supplementation NN N
. . N

The DT N
number NN o
of IN o
infections NNS o
in IN N
the DT N
first JJ N
30 CD N
d NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
TE NNP N
group NN N
( ( N
P=0.015 NNP N
) ) N
, , N
with IN N
a DT N
median JJ N
number NN N
of IN N
2 CD N
versus NN N
4 CD N
infections NNS N
per IN N
patient NN N
in IN N
the DT N
TE NNP N
and CC N
V NNP N
groups NNS N
, , N
respectively RB N
, , N
as IN N
a DT N
result NN N
of IN N
a DT N
reduction NN N
in IN N
pulmonary JJ o
infections NNS N
( ( N
P=0.03 NNP N
) ) N
. . N

Wound IN o
healing NN o
was VBD N
improved VBN N
in IN N
the DT N
TE NNP N
group NN N
, , N
with IN N
lower JJR N
requirements NNS o
for IN o
regrafting VBG o
( ( N
P=0.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
TE NNP i
supplementation NN N
was VBD N
associated VBN N
with IN N
higher JJR N
circulating NN o
plasma NN o
and CC o
skin JJ o
tissue NN o
contents NNS o
of IN o
selenium NN o
and CC o
zinc NN o
and CC N
improved VBN N
antioxidant JJ o
status NN o
. . o

These DT N
changes NNS N
were VBD N
associated VBN N
with IN N
improved JJ N
clinical JJ o
outcome NN o
, , o
including VBG o
fewer JJR o
pulmonary JJ o
infections NNS o
and CC o
better JJR o
wound NN o
healing NN o
. . o

-DOCSTART- -X- O O

A DT N
double JJ N
blind NN N
randomized VBD N
study NN N
of IN N
oral JJ N
clodronate NN i
in IN N
the DT N
treatment NN N
of IN N
bone NN p
metastases NNS p
from IN p
tumors NNS p
poorly RB p
responsive VBP p
to TO p
chemotherapy VB p
. . p

Bisphosphonates NNS i
are VBP N
used VBN N
in IN N
oncology NN N
as IN N
a DT N
means NN N
of IN N
decreasing VBG N
complications NNS N
due JJ N
to TO N
bone VB p
metastases NNS p
, , N
in IN N
association NN N
with IN N
anticancer NN N
treatment NN N
, , N
especially RB N
in IN N
patients NNS N
with IN N
breast NN N
cancer NN N
, , N
prostate NN N
cancer NN N
and CC N
myeloma NN N
. . N

Little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
bisphosphonates NNS i
on IN N
bone NN N
metastases NNS N
from IN N
other JJ N
tumors NNS N
and CC N
in IN N
particular JJ N
from IN N
tumors NNS N
for IN N
which WDT N
no DT N
effective JJ N
treatment NN N
is VBZ N
available JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
oral JJ i
clodronate NN i
in IN N
patients NNS p
with IN p
bone NN p
metastases NNS p
from IN p
tumors NNS p
poorly RB p
responsive VBP p
to TO p
chemotherapy VB p
, , N
with IN N
the DT N
aims NNS N
of IN N
evaluating VBG N
the DT N
effects NNS o
of IN o
this DT o
drug NN o
on IN o
symptoms NNS o
control NN o
and CC o
bone NN o
metastases NNS o
evolution NN o
. . o

Sixty-six JJ p
patients NNS p
with IN p
poorly JJ p
responsive JJ p
tumors NNS p
such JJ p
as IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
, , p
bladder NN p
cancer NN p
, , p
gastrointestinal JJ p
cancers NNS p
, , p
kidney NN p
cancer NN p
, , p
melanoma NN p
and CC p
metastatic JJ p
carcinoma NN p
of IN p
unknown JJ p
origin NN p
entered VBD p
the DT p
study NN p
. . p

Patients NNS p
were VBD p
randomized VBN p
to TO p
receive VB i
either DT i
clodronate NN i
1,600 CD i
mg/day NN i
for IN i
one CD i
year NN i
or CC i
identical JJ i
placebo-containing JJ i
tablets NNS i
. . i

Various JJ i
parameters NNS i
such JJ i
as IN i
Karnofsky NNP o
performance NN o
status NN o
, , o
pain NN o
score NN o
( ( o
measured VBN o
by IN o
a DT o
visual-analogue JJ o
scale NN o
) ) o
and CC o
analgesic JJ o
requirement NN o
were VBD i
recorded VBN i
at IN i
monthly JJ i
intervals NNS i
. . i

Of IN p
the DT p
66 CD p
patients NNS p
enrolled VBD p
, , p
9 CD p
were VBD p
observed VBN p
for IN p
one CD p
month NN p
or CC p
less JJR p
; : p
7 CD p
were VBD p
followed VBN p
for IN p
two CD p
months NNS p
; : p
only RB p
50 CD p
patients NNS p
were VBD p
followed VBN p
for IN p
more JJR p
than IN p
2 CD p
months NNS p
and CC p
could MD p
be VB p
adequately RB p
evaluated VBN p
. . p

At IN N
3 CD N
months NNS N
both DT N
clodronate NN i
and CC N
placebo-treated JJ i
patients NNS N
had VBD N
a DT N
decrease NN o
in IN o
Karnofsky NNP o
performance NN o
status NN o
, , N
with IN N
the DT N
decrease NN N
being VBG N
more RBR N
evident JJ N
in IN N
the DT N
placebo NN N
group NN N
. . N

Mean NNP o
pain NN o
scores NNS o
showed VBD N
an DT N
increase NN o
of IN o
pain NN o
in IN N
patients NNS N
receiving VBG N
placebo NN i
and CC N
a DT N
decrease NN N
of IN N
pain NN N
in IN N
patients NNS N
receiving VBG N
clodronate NN i
, , N
although IN N
the DT N
difference NN N
failed VBD N
to TO N
be VB N
statistically RB N
significant JJ N
. . N

Analgesics NNPS o
requirement NN o
increased VBN N
in IN N
both DT N
groups NNS N
, , N
but CC N
significantly RB N
more RBR N
in IN N
patients NNS N
receiving VBG N
placebo NN i
( ( N
p JJ N
= NNP N
0.042 CD N
) ) N
, , N
in IN N
whom WP N
increase NN N
in IN N
opioid JJ N
requirements NNS N
was VBD N
particularly RB N
evident JJ N
. . N

Toxicity NNP o
was VBD o
low JJ o
, , N
with IN N
occasional JJ o
gastroenteric JJ o
discomfort NN o
in IN N
both DT N
groups NNS N
. . N

The DT N
main JJ N
problem NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
difficulty NN N
in IN N
recruiting VBG N
an DT N
adequate JJ N
number NN N
of IN N
patients NNS N
and CC N
following VBG N
them PRP N
for IN N
a DT N
sufficient JJ N
period NN N
of IN N
time NN N
: : N
general JJ N
conditions NNS N
rapidly RB N
deteriorated VBD N
in IN N
many JJ N
patients NNS N
, , N
and CC N
approximately RB N
25 CD N
% NN N
of IN N
the DT N
66 CD N
enrolled NNS N
were VBD N
not RB N
considered VBN N
evaluable JJ N
; : N
few JJ N
patients NNS N
survived VBD N
for IN N
the DT N
length NN N
of IN N
the DT N
study NN N
, , N
one CD N
year NN N
. . N

This DT N
might MD N
partly RB N
account VB N
for IN N
the DT N
lack NN N
of IN N
significance NN N
of IN N
some DT N
of IN N
the DT N
parameters NNS N
under IN N
study NN N
. . N

With IN N
these DT N
limits NNS N
, , N
oral JJ N
clodronate NN N
demonstrated VBD N
some DT N
efficacy NN N
in IN N
symptom NN N
control NN N
and CC N
in IN N
reducing VBG N
the DT N
need NN N
for IN N
analgesics NNS N
. . N

-DOCSTART- -X- O O

Echocardiographic JJ N
evaluation NN N
of IN N
children NNS p
with IN p
systemic JJ p
ventricular JJ p
dysfunction NN p
treated VBN p
with IN p
carvedilol NN i
. . i

Echocardiography NN i
is VBZ N
used VBN N
to TO N
measure VB N
the DT N
therapeutic JJ N
effectiveness NN N
of IN N
heart NN N
failure NN N
therapy NN N
in IN N
adults NNS p
and CC p
children NNS p
. . p

The DT N
purposes NNS N
of IN N
this DT N
study NN N
were VBD N
( ( N
1 CD N
) ) N
to TO N
assess VB N
baseline JJ N
echocardiographic JJ N
predictors NNS N
of IN N
clinical JJ N
outcome NN N
, , N
( ( N
2 CD N
) ) N
to TO N
investigate VB N
changes NNS N
in IN N
echocardiographic JJ N
parameters NNS N
, , N
and CC N
( ( N
3 CD N
) ) N
to TO N
compare VB N
these DT N
echocardiographic JJ N
changes NNS N
with IN N
changes NNS N
in IN N
plasma NN N
levels NNS N
of IN N
b-type JJ N
natriuretic JJ i
peptide NN i
( ( N
BNP NNP N
) ) N
in IN p
a DT p
population NN p
of IN p
children NNS p
with IN p
systemic JJ p
ventricular JJ p
dysfunction NN p
and CC p
symptomatic JJ p
heart NN p
failure NN p
treated VBN p
with IN p
carvedilol NN i
or CC i
placebo NN i
. . i

All DT N
available JJ N
baseline NN N
and CC N
6-month JJ N
echocardiograms NNS N
from IN N
Pediatric NNP p
Carvedilol NNP p
Trial NNP p
( ( p
PCT NNP p
) ) p
participants NNS p
( ( i
carvedilol JJ i
n RB p
= JJ p
161 CD p
; : p
placebo NN i
n IN p
= $ p
55 CD p
) ) p
were VBD N
reviewed VBN N
. . N

Systolic NNP o
and CC N
diastolic JJ o
sphericity NN o
index NN o
( ( N
SI NNP N
; : N
n CC N
= VB N
110 CD N
) ) N
, , N
TEI NNP N
index NN N
( ( N
n JJ N
= NNP N
145 CD N
) ) N
, , N
and CC N
systemic JJ N
ventricular NN N
dP/dt NN N
( ( N
n JJ N
= NNP N
70 CD N
) ) N
were VBD N
measured VBN N
. . N

The DT N
PCT NNP N
composite JJ N
definition NN N
of IN N
clinical JJ N
outcome NN N
( ( N
i.e. FW N
, , N
worsened VBD N
, , N
improved VBN N
, , N
or CC N
unchanged JJ N
) ) N
was VBD N
used VBN N
. . N

For IN N
all DT N
patients NNS N
, , N
baseline VBP N
TEI NNP N
index NN N
was VBD N
a DT N
predictor NN N
of IN N
worsened JJ o
outcome NN o
. . o

Only RB N
children NNS p
treated VBD p
with IN p
carvedilol NN i
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
systolic JJ o
SI NNP o
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
diastolic JJ o
SI NNP o
( ( N
P NNP N
B NNP N
0.0001 CD N
) ) N
, , N
and CC N
TEI NNP o
index NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

An DT N
inverse JJ N
correlation NN N
between IN N
changes NNS o
in IN o
BNP NNP o
and CC N
changes NNS o
in IN o
dP/dt NN o
( ( N
r JJ N
= NNP N
-0.45 NNP N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
was VBD N
found VBN N
only RB N
in IN N
the DT N
carvedilol NN i
group NN p
. . p

In IN N
conclusion NN N
, , N
TEI NNP N
index NN N
predicted VBD N
outcome NN N
in IN N
children NNS p
with IN N
systemic JJ o
ventricular JJ o
dysfunction NN o
and CC o
heart NN o
failure NN o
. . o

Carvedilol NN i
may MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
reversal NN N
of IN N
left JJ N
ventricular JJ N
remodeling NN N
and CC N
global JJ N
ventricular NN N
function NN N
in IN N
pediatric JJ N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
diltiazem NN i
on IN N
symptomatic JJ p
and CC p
asymptomatic JJ p
episodes NNS p
of IN p
ST NNP o
segment NN o
depression NN o
occurring VBG p
during IN p
daily JJ p
life NN p
and CC p
during IN p
exercise NN p
. . p

BACKGROUND NNP N
Silent NNP N
myocardial JJ N
ischemia NN N
is VBZ N
an DT N
adverse JJ N
prognostic JJ N
marker NN N
in IN N
patients NNS p
with IN p
coronary JJ p
disease NN p
; : p
however RB N
, , N
controlled VBN N
data NNS N
on IN N
the DT N
effect NN N
of IN N
treatment NN N
are VBP N
sparse JJ N
and CC N
contradictory NN N
, , N
and CC N
the DT N
relations NNS N
among IN N
the DT N
occurrence NN N
of IN N
ST NNP o
segment NN o
depression NN o
, , N
drug NN N
efficacy NN N
, , N
and CC N
heart NN N
rate NN N
are VBP N
unclear JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Sixty NNP p
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
, , p
a DT p
positive JJ p
treadmill NN p
exercise NN p
test NN p
and CC p
asymptomatic JJ p
ST NNP p
segment NN p
depression NN p
on IN p
ambulatory JJ p
electrocardiographic JJ p
recording VBG p
were VBD p
assessed VBN p
in IN p
a DT p
multicenter NN p
, , p
double-blind JJ p
, , p
placebo-controlled JJ i
, , p
cross-over JJ p
trial NN p
. . p

Treadmill NNP o
exercise NN o
tests NNS o
and CC N
72-hour JJ o
electrocardiographic JJ o
recordings NNS o
were VBD N
obtained VBN N
at IN N
the DT N
end NN N
of IN N
two CD N
2-week JJ N
treatment NN N
periods NNS N
with IN N
sustained-release JJ i
diltiazem NN i
180 CD N
mg NN N
b.i.d NN N
. . N

or CC N
equivalent JJ N
placebo NN i
. . i

Episodes NNS o
of IN o
asymptomatic JJ o
ST NNP o
depression NN o
decreased VBN N
by IN N
50 CD N
% NN N
or CC N
more JJR N
in IN N
70 CD N
% NN N
of IN N
the DT N
patients NNS N
from IN N
a DT N
median JJ N
number NN N
of IN N
4.5 CD N
( ( N
range NN N
, , N
0-19 NN N
) ) N
to TO N
1.5 CD N
( ( N
range NN N
, , N
0-13 NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
; : N
their PRP$ N
cumulative JJ o
duration NN o
also RB N
decreased VBD N
from IN N
78.5 CD N
( ( N
range NN N
, , N
0-60 NN N
) ) N
to TO N
24.5 CD N
( ( N
range NN N
, , N
0-411 NN N
) ) N
minutes NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

No DT N
circadian JJ o
variation NN o
was VBD N
found VBN N
in IN N
the DT N
efficacy NN N
of IN N
diltiazem NN i
. . i

The DT N
occurrence NN N
of IN N
ischemic JJ o
type NN o
ST NNP o
segment NN o
depression NN o
was VBD N
modulated VBN N
by IN N
changes NNS o
in IN o
heart NN o
rate NN o
rather RB N
than IN N
by IN N
absolute JJ N
heart NN N
rate NN N
. . N

Diltiazem NNP i
also RB N
improved VBD N
exercise NN o
test NN o
end NN o
points NNS o
but CC N
to TO N
a DT N
lesser JJR N
extent NN N
. . N

Time NN o
to TO o
ST NNP o
segment NN o
depression NN o
increased VBD N
to TO N
341 CD N
+/- JJ N
148 CD N
from IN N
296 CD N
+/- JJ N
154 CD N
seconds NNS N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
. . N

Although IN N
less JJR N
frequent JJ N
with IN N
diltiazem JJ i
administration NN N
( ( N
45 CD N
versus NN N
54 CD N
patients NNS N
, , N
p RB N
less JJR N
than IN N
0.03 CD N
) ) N
, , N
exercise-induced JJ o
ST NNP o
depression NN o
was VBD N
more RBR N
often RB N
asymptomatic JJ N
( ( N
98 CD N
% NN N
versus IN N
72 CD N
% NN N
of IN N
patients NNS N
, , N
p RB N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Diltiazem NNP i
reduces VBZ N
the DT N
frequency NN N
and CC N
severity NN N
of IN N
ischemic JJ o
type NN o
ST NNP o
depression NN o
in IN N
patients NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
. . p

-DOCSTART- -X- O O

Transthoracic NNP i
versus NN i
transesophageal NN i
cardioversion NN i
of IN i
atrial JJ i
fibrillation NN i
under IN i
light JJ i
sedation NN i
: : i
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Electrical JJ p
cardioversion NN p
( ( p
ECV NNP p
) ) p
of IN p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
is VBZ N
limited VBN N
by IN N
a DT N
5-10 JJ N
% NN N
failure NN N
rate NN N
and CC N
by IN N
the DT N
expense NN N
arising VBG N
from IN N
a DT N
perceived JJ N
need NN N
for IN N
general JJ N
anesthesia NN N
. . N

A DT N
transesophageal JJ N
approach NN N
using VBG N
light JJ N
sedation NN N
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
means NN N
of IN N
augmenting VBG N
the DT N
success NN N
rate NN N
and CC N
avoiding VBG N
the DT N
need NN N
for IN N
general JJ N
anesthesia NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
high JJ N
rate NN N
of IN N
success NN N
and CC N
the DT N
lower JJR N
energy NN N
requirement NN N
associated VBN N
with IN N
biphasic JJ N
cardioversion NN N
might MD N
eliminate VB N
any DT N
advantage NN N
of IN N
the DT N
transesophageal JJ N
approach NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
60 CD p
patients NNS p
attending VBG p
for IN p
ECV NNP i
of IN i
persistent JJ i
AF NNP i
to TO i
a DT i
transesophageal NN i
or CC i
a DT i
transthoracic JJ i
approach NN i
. . i

Sedation NN N
of IN N
moderate JJ N
depth NN N
was VBD N
achieved VBN N
with IN N
intravenous JJ i
midazolam NNS i
. . i

The DT N
dose NN N
of IN N
midazolam NN N
was VBD N
titrated VBN N
in IN N
the DT N
same JJ N
manner NN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
Sinus NNP o
rhythm NN o
was VBD N
restored VBN N
in IN N
29/30 CD N
patients NNS N
( ( N
97 CD N
% NN N
) ) N
in IN N
each DT N
group NN N
using VBG N
a DT N
similar JJ N
number NN N
of IN N
shocks NNS N
for IN N
both DT N
groups NNS N
( ( N
1.3 CD N
+/- JJ N
0.6 CD N
transesophageal NN N
vs NN N
1.4 CD N
+/- JJ N
0.7 CD N
transthoracic NN N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
with IN N
a DT N
similar JJ N
procedure NN N
duration NN N
( ( N
14.1 CD N
+/- JJ N
8.2 CD N
minutes NNS N
vs JJ N
13.8 CD N
+/- JJ N
7.5 CD N
minutes NNS N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

Both DT N
groups NNS N
received VBD N
similar JJ N
doses NNS N
of IN N
midazolam NN N
( ( N
4.2 CD N
+/- JJ N
2.7 CD N
mg NN N
vs NN N
4.4 CD N
+/- JJ N
2.8 CD N
mg NN N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
and CC N
both DT N
reported VBD N
a DT N
similar JJ N
discomfort NN o
score NN o
in IN N
( ( N
0.9 CD N
+/- JJ N
1.3 CD N
vs JJ N
1.1 CD N
+/- JJ N
1.8 CD N
, , N
P NNP N
= NNP N
NS NNP N
) ) N
. . N

No DT N
complication NN o
occurred VBD N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
AF NNP N
may MD N
be VB N
cardioverted VBN N
safely RB o
and CC o
effectively RB o
by IN N
either CC N
a DT N
transthoracic NN N
or CC N
a DT N
transesophageal JJ N
approach NN N
. . N

The DT N
use NN N
of IN N
sedation NN N
of IN N
moderate JJ N
depth NN N
renders NNS N
cardioversion NN N
by IN N
either DT N
approach NN N
acceptable JJ N
. . N

As IN N
transesophageal NN N
ECV NNP N
shows VBZ N
no DT N
clear JJ N
advantage NN N
, , N
transthoracic JJ N
cardioversion NN N
should MD N
remain VB N
the DT N
approach NN N
of IN N
first JJ N
choice NN N
. . N

-DOCSTART- -X- O O

Pembrolizumab NNP i
versus NN N
docetaxel NN i
for IN N
previously RB p
treated VBN p
, , p
PD-L1-positive JJ p
, , p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
( ( N
KEYNOTE-010 NNP N
) ) N
: : N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Despite IN N
recent JJ N
advances NNS N
in IN N
the DT N
treatment NN N
of IN N
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
, , N
there EX N
remains VBZ N
a DT N
need NN N
for IN N
effective JJ N
treatments NNS N
for IN N
progressive JJ N
disease NN N
. . N

We PRP N
assessed VBD N
the DT N
efficacy NN N
of IN N
pembrolizumab NN i
for IN N
patients NNS N
with IN N
previously RB p
treated VBN p
, , p
PD-L1-positive JJ p
, , p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

METHODS NNP N
We PRP N
did VBD N
this DT N
randomised VBN N
, , N
open-label JJ N
, , N
phase VB N
2/3 CD N
study NN N
at IN N
202 CD p
academic JJ p
medical JJ p
centres NNS p
in IN p
24 CD p
countries NNS p
. . p

Patients NNS p
with IN p
previously RB p
treated VBN p
non-small-cell JJ p
lung NN p
cancer NN p
with IN p
PD-L1 NNP p
expression NN p
on IN p
at IN p
least JJS p
1 CD p
% NN p
of IN p
tumour JJ p
cells NNS p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1:1 CD N
) ) N
in IN N
blocks NNS N
of IN N
six CD N
per IN N
stratum NN N
with IN N
an DT N
interactive JJ N
voice-response NN N
system NN N
to TO N
receive VB N
pembrolizumab NN i
2 CD i
mg/kg NN i
, , i
pembrolizumab VBP i
10 CD i
mg/kg NN i
, , i
or CC i
docetaxel VB i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
weeks NNS N
. . N

The DT N
primary JJ N
endpoints NNS N
were VBD N
overall JJ N
survival NN o
and CC o
progression-free JJ o
survival NN o
both DT N
in IN N
the DT N
total JJ N
population NN N
and CC N
in IN N
patients NNS N
with IN N
PD-L1 NNP N
expression NN N
on IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
. . N

We PRP N
used VBD N
a DT N
threshold NN N
for IN N
significance NN N
of IN N
p NN N
< NN N
0.00825 CD N
( ( N
one-sided JJ N
) ) N
for IN N
the DT N
analysis NN N
of IN N
overall JJ N
survival NN N
and CC N
a DT N
threshold NN N
of IN N
p NN N
< $ N
0.001 CD N
for IN N
progression-free JJ N
survival NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01905657 NNP N
. . N

FINDINGS NNP N
Between NNP p
Aug NNP p
28 CD p
, , p
2013 CD p
, , p
and CC p
Feb NNP p
27 CD p
, , p
2015 CD p
, , p
we PRP p
enrolled VBD p
1034 CD p
patients NNS p
: : p
345 CD N
allocated VBD N
to TO N
pembrolizumab VB i
2 CD N
mg/kg NN N
, , N
346 CD N
allocated VBD N
to TO N
pembrolizumab VB N
10 CD N
mg/kg NN N
, , N
and CC N
343 CD N
allocated VBN N
to TO N
docetaxel VB i
. . i

By IN N
Sept NNP N
30 CD N
, , N
2015 CD N
, , N
521 CD N
patients NNS N
had VBD N
died VBN N
. . N

In IN N
the DT N
total JJ N
population NN N
, , N
median JJ o
overall JJ o
survival NN o
was VBD N
10.4 CD N
months NNS N
with IN N
pembrolizumab JJ i
2 CD N
mg/kg NN N
, , N
12.7 CD N
months NNS N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
, , N
and CC N
8.5 CD N
months NNS N
with IN N
docetaxel NN N
. . N

Overall JJ o
survival NN o
was VBD N
significantly RB N
longer JJR N
for IN N
pembrolizumab NN i
2 CD N
mg/kg NN N
versus NN N
docetaxel NN i
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
0.71 CD N
, , N
95 CD N
% NN N
CI NNP N
0.58-0.88 CD N
; : N
p=0.0008 NN N
) ) N
and CC N
for IN N
pembrolizumab JJ i
10 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
0.61 CD N
, , N
0.49-0.75 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Median JJ o
progression-free JJ o
survival NN o
was VBD N
3.9 CD N
months NNS N
with IN N
pembrolizumab JJ N
2 CD N
mg/kg NN N
, , N
4.0 CD N
months NNS N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
, , N
and CC N
4.0 CD N
months NNS N
with IN N
docetaxel NN N
, , N
with IN N
no DT N
significant JJ N
difference NN N
for IN N
pembrolizumab NN N
2 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
0.88 CD N
, , N
0.74-1.05 CD N
; : N
p=0.07 NN N
) ) N
or CC N
for IN N
pembrolizumab JJ i
10 CD N
mg/kg NN N
versus NN N
docetaxel NN N
( ( N
HR NNP N
0.79 CD N
, , N
95 CD N
% NN N
CI NNP N
0.66-0.94 CD N
; : N
p=0.004 NN N
) ) N
. . N

Among IN N
patients NNS N
with IN N
at IN N
least JJS N
50 CD N
% NN N
of IN N
tumour JJ N
cells NNS N
expressing VBG N
PD-L1 NNP N
, , N
overall JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
with IN N
pembrolizumab JJ i
2 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
median JJ N
14.9 CD N
months NNS N
vs RB N
8.2 CD N
months NNS N
; : N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.38-0.77 CD N
; : N
p=0.0002 NN N
) ) N
and CC N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
17.3 CD N
months NNS N
vs RB N
8.2 CD N
months NNS N
; : N
0.50 CD N
, , N
0.36-0.70 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Likewise NNP N
, , N
for IN N
this DT N
patient JJ N
population NN N
, , N
progression-free JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
with IN N
pembrolizumab JJ i
2 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN i
( ( N
median JJ N
5.0 CD N
months NNS N
vs RB N
4.1 CD N
months NNS N
; : N
HR NNP N
0.59 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.78 CD N
; : N
p=0.0001 NN N
) ) N
and CC N
with IN N
pembrolizumab JJ N
10 CD N
mg/kg NN N
than IN N
with IN N
docetaxel NN N
( ( N
5.2 CD N
months NNS N
vs RB N
4.1 CD N
months NNS N
; : N
0.59 CD N
, , N
0.45-0.78 CD N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

Grade VBN o
3-5 JJ o
treatment-related JJ o
adverse JJ o
events NNS o
were VBD N
less JJR N
common JJ N
with IN N
pembrolizumab NN i
than IN N
with IN N
docetaxel NN N
( ( N
43 CD N
[ RB N
13 CD N
% NN N
] NN N
of IN N
339 CD N
patients NNS N
given VBN N
2 CD N
mg/kg NNS N
, , N
55 CD N
[ JJ N
16 CD N
% NN N
] NN N
of IN N
343 CD N
given VBN N
10 CD N
mg/kg NN N
, , N
and CC N
109 CD N
[ JJ N
35 CD N
% NN N
] NN N
of IN N
309 CD N
given VBN N
docetaxel NN i
) ) i
. . N

INTERPRETATION NNP N
Pembrolizumab NNP i
prolongs NNS N
overall JJ o
survival NN o
and CC N
has VBZ N
a DT N
favourable JJ N
benefit-to-risk JJ N
profile NN N
in IN N
patients NNS p
with IN p
previously RB p
treated VBN p
, , p
PD-L1-positive JJ p
, , p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

These DT N
data NNS N
establish VB N
pembrolizumab NN i
as IN N
a DT N
new JJ N
treatment NN N
option NN N
for IN N
this DT N
population NN N
and CC N
validate VB N
the DT N
use NN N
of IN N
PD-L1 NNP N
selection NN N
. . N

FUNDING NNP N
Merck NNP N
& CC N
Co NNP N
. . N

-DOCSTART- -X- O O

36-month JJ N
treatment NN N
experience NN N
of IN N
two CD N
doses NNS N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
for IN N
children NNS p
with IN p
central JJ p
precocious JJ p
puberty NN p
. . p

CONTEXT NNP N
We PRP N
have VBP N
recently RB N
demonstrated VBN N
short-term JJ N
( ( N
6-month JJ N
) ) N
efficacy NN N
and CC N
safety NN N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS p
with IN p
central JJ p
precocious JJ p
puberty NN p
( ( p
CPP NNP p
) ) p
. . p

OBJECTIVE UH N
To TO N
assess VB N
long-term JJ o
( ( N
36-month JJ N
) ) N
hypothalamic-pituitary-gonadal JJ o
axis JJ o
suppression NN o
and CC o
safety NN o
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS p
with IN p
CPP NNP p
. . p

DESIGN NNP N
Open-label NNP N
, , N
36-month JJ N
extension NN N
. . N

SETTING NNP N
Twenty NNP p
pediatric JJ p
endocrine NN p
centers NNS p
. . p

PATIENTS VB N
Seventy-two JJ p
children NNS p
( ( p
mean JJ p
age NN p
, , p
8.5 CD p
? . p
1.6 CD p
y NN p
; : p
65 CD p
females NNS p
) ) p
with IN p
CPP NNP p
completed VBD p
and CC p
showed VBD o
maintenance NN o
of IN o
LH NNP o
suppression NN o
after IN p
a DT p
6-month JJ p
lead-in NN p
study NN p
. . p

INTERVENTION NNP i
Leuprolide NNP i
acetate NN i
depot NN i
( ( N
11.25 CD N
or CC N
30 CD N
mg NN N
) ) N
administered VBD N
im JJ N
every DT N
3 CD N
months NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP o
Peak-stimulated NNP o
LH NNP o
, , o
estradiol NN o
, , o
T NNP o
, , o
growth NN o
rate NN o
, , o
pubertal JJ o
progression NN o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

RESULTS JJ N
Twenty-nine NNP N
of IN N
34 CD N
subjects NNS N
in IN N
the DT N
11.25-mg JJ N
group NN N
and CC N
36 CD N
of IN N
38 CD N
subjects NNS N
in IN N
the DT N
30-mg JJ N
group NN N
had VBD o
LH NNP o
values NNS o
< VBP N
4 CD N
mIU/mL NNS N
after IN N
day NN N
1 CD N
at IN N
all DT N
time NN N
points NNS N
. . N

All DT N
seven CD N
subjects NNS N
who WP N
escaped VBD o
LH NNP o
suppression NN o
at IN N
any DT N
time NN N
still RB N
maintained VBD o
sex NN o
steroid NN o
concentrations NNS o
at IN N
prepubertal JJ N
levels NNS N
and CC N
showed VBD N
no DT N
signs NNS N
of IN o
pubertal JJ o
progression NN o
. . o

AEs NNP o
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
with IN o
injection NN o
site NN o
pain NN o
being VBG N
the DT N
most RBS N
common JJ N
( ( N
26.4 CD N
% NN N
overall JJ N
) ) N
. . N

No DT o
AE NNP o
led VBD N
to TO N
discontinuation NN N
of IN N
study JJ N
drug NN N
. . N

The DT o
safety NN o
profile NN o
over IN N
36 CD N
months NNS N
was VBD N
comparable JJ N
to TO N
that DT N
observed VBD N
during IN N
the DT N
6-month JJ N
pivotal NN N
study NN N
. . N

CONCLUSIONS VB N
The DT N
two CD N
doses NNS N
of IN i
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN N
were VBD N
associated VBN N
with IN N
an DT o
acceptable JJ o
safety NN o
profile NN o
and CC N
provided VBD o
maintenance NN o
of IN o
LH NNP o
suppression NN o
in IN N
the DT N
majority NN N
of IN N
children NNS N
with IN N
CPP NNP N
during IN N
the DT N
36 CD N
months NNS N
of IN N
the DT N
study NN N
or CC N
until IN N
readiness NN N
for IN N
puberty NN N
. . N

-DOCSTART- -X- O O

Five-year JJ N
outcome NN N
of IN N
surgical JJ N
treatment NN N
of IN N
migraine NN o
headaches NNS o
. . o

BACKGROUND NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
assess VB N
the DT N
long-term JJ N
efficacy NN N
of IN N
surgical JJ N
deactivation NN N
of IN N
migraine NN o
headache NN o
trigger NN N
sites NNS N
. . N

METHODS NNP N
One CD p
hundred VBD p
twenty-five JJ p
volunteers NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
treatment NN p
( ( p
n JJ p
= NNP p
100 CD p
) ) p
or CC p
control VB p
group NN p
( ( p
n JJ p
= NNP p
25 CD p
) ) p
after IN p
examination NN p
by IN p
the DT p
team NN p
neurologist NN p
to TO p
ensure VB p
a DT p
diagnosis NN p
of IN p
migraine NN o
headache NN o
. . o

Patients NNS N
were VBD N
asked VBN N
to TO N
complete VB N
the DT N
Medical NNP o
Outcomes NNP o
Study NNP o
36-Item JJ o
Short NNP o
Form NNP o
Health NNP o
Survey NNP o
, , o
Migraine-Specific NNP o
Quality NNP o
of IN o
Life NNP o
, , o
and CC o
Migraine NNP o
Disability NNP o
Assessment NNP o
questionnaires VBZ o
before IN N
treatment NN N
and CC N
at IN N
12- JJ N
and CC N
60-month JJ N
postoperative JJ N
follow-up NN N
. . N

The DT N
treatment NN N
group NN N
received VBD N
botulinum RB i
toxin NN i
to TO N
confirm VB N
the DT N
trigger NN N
sites VBZ N
; : N
controls NNS N
received VBD N
saline JJ i
injections NNS i
. . i

Treated VBN N
patients NNS N
underwent JJ N
surgical JJ i
deactivation NN i
of IN N
trigger NN N
site NN N
( ( N
s JJ N
) ) N
. . N

Results NNS N
were VBD N
analyzed VBN N
at IN N
1 CD N
year NN N
( ( N
previously RB N
published VBN N
) ) N
and CC N
5 CD N
years NNS N
postoperatively RB N
( ( N
the DT N
subject NN N
of IN N
this DT N
report NN N
) ) N
. . N

RESULTS JJ N
Eighty-nine NNP N
of IN N
100 CD p
patients NNS p
in IN p
the DT p
treatment NN p
group NN p
underwent JJ N
surgery NN N
, , N
and CC N
79 CD N
were VBD N
followed VBN N
for IN N
5 CD N
years NNS N
. . N

Ten CD N
patients NNS N
underwent JJ N
deactivation NN i
of IN N
additional JJ N
( ( N
different JJ N
) ) N
trigger NN N
sites NNS N
during IN N
the DT N
follow-up JJ N
period NN N
and CC N
were VBD N
not RB N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

The DT N
final JJ N
outcome NN N
with IN N
or CC N
without IN N
inclusion NN N
of IN N
these DT N
10 CD N
patients NNS N
was VBD N
not RB N
statistically RB N
different JJ N
. . N

Sixty-one NN N
( ( N
88 CD N
percent NN N
) ) N
of IN N
69 CD N
patients NNS N
have VBP N
experienced VBN N
a DT N
positive JJ o
response NN o
to TO N
the DT N
surgery NN N
after IN N
5 CD N
years NNS N
. . N

Twenty NNP N
( ( N
29 CD N
percent NN N
) ) N
reported VBD N
complete JJ o
elimination NN o
of IN o
migraine NN o
headache NN o
, , N
41 CD N
( ( N
59 CD N
percent NN N
) ) N
noticed VBD N
a DT N
significant JJ N
decrease NN N
, , N
and CC N
eight CD N
( ( N
12 CD N
percent NN N
) ) N
experienced VBD N
no DT N
significant JJ N
change NN N
. . N

When WRB N
compared VBN N
with IN N
the DT N
baseline NN N
values NNS N
, , N
all DT N
measured VBD N
variables NNS N
at IN N
60 CD N
months NNS N
improved VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION NNP N
Based VBD N
on IN N
the DT N
5-year JJ N
follow-up JJ N
data NNS N
, , N
there EX N
is VBZ N
strong JJ N
evidence NN N
that IN N
surgical JJ N
manipulation NN N
of IN N
one CD N
or CC N
more JJR N
migraine JJ N
trigger NN N
sites NNS N
can MD N
successfully RB N
eliminate VB o
or CC o
reduce VB o
the DT o
frequency NN o
, , o
duration NN o
, , o
and CC o
intensity NN o
of IN o
migraine NN o
headache NN o
in IN N
a DT N
lasting JJ N
manner NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
inhaled JJ i
albuterol NN i
powder NN i
and CC i
aerosol NN i
in IN N
asthma NN p
. . p

In IN N
this DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
aerosolized JJ i
albuterol NN i
with IN i
the DT i
dry JJ i
powder NN i
formulation NN i
, , N
231 CD p
patients NNS p
with IN p
chronic JJ p
reversible JJ p
obstructive JJ p
airway NN p
disease NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
placebo NN i
albuterol NN i
aerosol NN i
followed VBD N
immediately RB N
by IN N
active JJ i
albuterol NN i
powder NN i
( ( N
200 CD N
micrograms NNS N
) ) N
or CC N
active JJ i
albuterol NN i
aerosol NN i
( ( N
two CD N
puffs NNS N
, , N
180 CD N
micrograms NNS N
) ) N
followed VBD N
immediately RB N
by IN N
placebo NN i
lactose JJ i
powder NN i
four CD N
times NNS N
a DT N
day NN N
for IN N
a DT N
period NN N
of IN N
12 CD N
weeks NNS N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
powder NN i
and CC N
aerosol JJ i
formulations NNS N
with IN N
respect NN N
to TO N
pulmonary JJ o
function NN o
, , o
length NN o
of IN o
time NN o
mean JJ o
FEV1 NNP o
remained VBD N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
15 CD N
% NN N
above IN N
baseline NN N
, , N
physicians NNS o
' POS o
assessments NNS o
of IN o
patients NNS o
' POS o
clinical JJ o
response NN o
, , N
or CC N
patients NNS o
' POS o
subjective JJ o
symptom NN o
scores NNS o
. . o

There EX N
were VBD N
also RB N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
cardiovascular JJ o
effects NNS o
, , o
laboratory NN o
values NNS o
, , o
or CC o
adverse JJ o
events NNS o
. . o

Among IN N
patients NNS N
who WP N
expressed VBD N
a DT N
preference NN o
for IN o
one CD o
of IN o
the DT o
delivery NN o
systems NNS o
, , N
half NN p
preferred VBD p
using VBG p
the DT p
powder NN p
. . p

Results NNS N
of IN N
this DT N
study NN N
demonstrate NN N
that IN N
200 CD N
micrograms NNS N
of IN N
albuterol NN i
powder NN i
is VBZ N
as IN N
safe JJ N
and CC N
effective JJ N
as IN N
180 CD N
micrograms NNS N
of IN N
albuterol NN i
aerosol NN i
. . i

-DOCSTART- -X- O O

Teaching VBG N
picture-to-object JJ N
relations NNS N
in IN N
picture-based JJ N
requesting NN N
by IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
comparison NN o
between IN N
error NN i
prevention NN i
and CC N
error NN i
correction NN i
teaching NN i
procedures NNS i
. . i

BACKGROUND NNP N
Children NNP p
who WP p
have VBP p
a DT p
combination NN p
of IN p
language NN p
and CC p
developmental JJ p
disabilities NNS p
with IN p
autism NN p
often RB N
experience JJ N
major JJ N
difficulties NNS N
in IN N
learning VBG N
relations NNS N
between IN N
objects NNS N
and CC N
their PRP$ N
graphic JJ N
representations NNS N
. . N

Therefore RB N
, , N
they PRP N
would MD N
benefit VB N
from IN N
teaching VBG i
procedures NNS i
that WDT N
minimize VBP N
their PRP$ N
difficulties NNS N
in IN N
acquiring VBG N
these DT N
relations NNS N
. . N

This DT N
study NN N
compared VBN N
two CD N
teaching NN i
procedures NNS i
, , i
an DT i
error NN i
prevention NN i
procedure NN i
and CC i
an DT i
error NN i
correction NN i
procedure NN i
, , i
for IN i
teaching VBG i
relations NNS i
between IN i
objects NNS i
and CC i
pictures NNS i
. . i

METHOD JJ N
Participants NNS p
were VBD p
two CD p
groups NNS p
of IN p
children NNS p
with IN p
autism NN p
, , p
aged VBD p
between IN p
3 CD p
and CC p
7 CD p
years NNS p
. . p

In IN N
the DT N
context NN N
of IN N
picture-to-object JJ N
requesting NN N
, , N
one CD N
group NN N
was VBD N
taught VBN N
using VBG N
an DT i
error NN i
correction NN i
method NN i
and CC N
the DT N
other JJ N
group NN N
with IN N
an DT i
error NN i
prevention NN i
method NN i
. . i

The DT N
measures NNS N
for IN N
each DT N
child NN N
were VBD N
accuracy NN o
of IN o
correspondences NNS o
between IN o
taught JJ o
picture NN o
and CC o
object JJ o
pairs NNS o
and CC o
accuracy NN o
of IN o
delayed JJ o
correspondences NNS o
in IN o
learning VBG o
outcome JJ o
tests NNS o
with IN o
all DT o
combinations NNS o
of IN o
object NN o
and CC o
picture NN o
pairs NNS o
presented VBN o
to TO N
them PRP N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
The DT N
group NN N
receiving VBG N
the DT N
error NN N
prevention-based JJ i
teaching NN i
made VBN N
significantly RB N
fewer JJR N
errors NNS o
during IN N
the DT N
teaching NN N
phases NNS N
and CC N
in IN N
their PRP$ N
learning NN N
outcome NN N
test NN N
for IN N
correspondences NNS N
between IN N
all DT N
combinations NNS N
of IN N
pictures NNS N
and CC N
objects NNS N
. . N

CONCLUSIONS VB N
The DT N
error NN N
prevention NN i
teaching NN i
procedure NN i
would MD N
seem VB N
to TO N
provide VB N
a DT N
more RBR N
efficient JJ N
and CC N
ecologically RB N
valid JJ N
method NN N
than IN N
the DT N
error NN N
correction NN N
procedure NN N
for IN N
teaching VBG N
relations NNS N
between IN N
objects NNS N
and CC N
their PRP$ N
graphic-based JJ N
referents NNS N
. . N

Improvements NNS N
in IN N
the DT N
methodology NN N
were VBD N
suggested VBN N
for IN N
providing VBG N
a DT N
stronger JJR N
basis NN N
for IN N
comparison NN N
between IN N
error NN N
correction NN N
and CC N
error NN N
prevention NN N
teaching VBG N
methods NNS N
. . N

-DOCSTART- -X- O O

Laparoscopic NNP i
vs NN N
open JJ i
appendectomy NN i
in IN N
overweight JJ p
patients NNS p
. . p

BACKGROUND NNP N
Laparoscopic NNP i
appendectomy NN i
( ( i
LA NNP i
) ) i
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
faster JJ N
recovery NN N
and CC N
less RBR N
postoperative JJ N
pain NN N
than IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
few JJ N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
clinical JJ N
outcome NN N
of IN N
LA NNP i
in IN N
overweight JJ p
patients NNS p
. . p

METHODS NNP N
A NNP p
group NN p
of IN p
106 CD p
patients NNS p
with IN p
a DT p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
> VBD p
26.4 CD p
, , p
representing VBG p
the DT p
upper JJ p
quintile NN p
of IN p
500 CD p
prospectively RB p
randomized JJ p
patients NNS p
, , N
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

They PRP N
were VBD N
randomized VBN N
to TO N
undergo VB N
either DT N
laparoscopic NN i
or CC i
open JJ i
appendectomy NN i
( ( i
OA NNP i
) ) i
. . i

Operating NN o
and CC o
anesthesia NN o
times NNS o
, , o
postoperative JJ o
pain NN o
, , o
complications NNS o
, , o
hospital NN o
stay NN o
, , o
functional JJ o
index NN o
( ( N
1 CD N
week NN N
postoperatively RB N
) ) N
, , N
sick JJ o
leave VBP o
, , o
and CC o
time NN o
to TO o
full JJ o
recovery NN o
were VBD N
documented VBN N
. . N

RESULTS NNP N
In IN N
OA NNP i
, , N
the DT N
operating NN o
time NN o
for IN N
overweight JJ o
patients NNS p
was VBD N
significantly RB N
longer JJR N
than IN N
that DT N
for IN N
patients NNS N
in IN N
the DT N
normal JJ N
weight NN N
range NN N
( ( N
40 CD N
vs RB N
35 CD N
min NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
LA NNP i
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
operating NN o
time NN o
between IN N
the DT N
normal JJ N
and CC N
overweight JJ N
patients NNS N
. . N

Overweight JJ N
patients NNS N
who WP N
underwent JJ N
LA NNP i
had VBD N
longer RBR N
operating NN o
and CC o
anesthesia NN o
times NNS o
than IN N
their PRP$ N
OA NNP i
counterparts NNS N
( ( N
55 CD N
vs RB N
40 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
; : N
and CC N
125 CD N
vs NN N
100 CD N
min NN N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

Postoperative JJ o
pain NN o
was VBD N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP i
than IN N
in IN N
those DT N
treated VBN N
with IN N
the DT N
laparoscopic NN i
technique NN i
. . i

Postoperative JJ o
pain NN o
was VBD N
also RB N
significantly RB N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP i
than IN N
in IN N
patients NNS N
of IN N
normal JJ N
weight NN N
after IN N
4 CD N
weeks NNS N
; : N
the DT N
clinical JJ N
significance NN N
may MD N
, , N
however RB N
, , N
be VB N
of IN N
less JJR N
importance NN N
since IN N
the DT N
values NNS N
are VBP N
low JJ N
( ( N
0.26 CD N
vs NN N
0.09 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
operating VBG N
techniques NNS N
in IN N
terms NNS N
of IN N
complications NNS N
. . N

Hospital NNP o
stay NN o
was VBD N
longer JJR N
for IN N
overweight NN N
patients NNS N
than IN N
for IN N
normal-weight JJ N
patients NNS N
undergoing VBG N
OA NNP i
( ( N
3.0 CD N
vs NN N
2.0 CD N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
functional JJ N
index NN N
did VBD N
not RB N
differ VB N
between IN N
any DT N
group NN N
of IN N
patients NNS N
. . N

Sick NNP o
leave NN o
was VBD N
longer JJR N
for IN N
overweight JJ N
patients NNS N
who WP N
underwent VBP N
OA NNP i
than IN N
for IN N
normal-weight JJ N
patients NNS N
treated VBN N
with IN N
the DT N
same JJ N
technique NN N
( ( N
17 CD N
vs RB N
13 CD N
days NNS N
, , N
p VBP N
< RB N
0.01 CD N
) ) N
. . N

In IN N
the DT N
laparoscopic NN i
group NN N
, , N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
overweight NN p
and CC p
normal-weight JJ p
patients NNS p
. . p

Time NN o
to TO o
full JJ o
recovery NN o
was VBD N
greater JJR N
in IN N
overweight JJ N
patients NNS N
subjected VBN N
to TO N
OA NNP i
than IN N
in IN N
the DT N
overweight JJ N
patients NNS N
in IN N
the DT N
LA NNP i
group NN N
( ( N
22 CD N
vs RB N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
. . N

CONCLUSION NN N
In IN N
this DT N
study NN N
, , N
overweight JJ N
patients NNS N
who WP N
were VBD N
submitted VBN N
to TO N
LA NNP i
had VBD N
less RBR N
postoperative JJ o
pain NN o
and CC N
a DT N
faster RBR N
postoperative JJ o
recovery NN o
than IN N
overweight JJ N
patients NNS N
who WP N
had VBD N
OA NNP i
. . i

LA NNP i
also RB N
abolished VBD N
some DT N
of IN N
the DT N
negative JJ N
effects NNS N
that WDT N
overweight VBD N
had VBD N
on IN N
operating NN o
time NN o
, , o
hospital NN o
stay NN o
, , o
and CC o
sick JJ o
leave NN o
with IN N
the DT N
open JJ N
technique NN N
. . N

However RB N
, , N
anesthesia NN N
and CC N
operating NN N
times NNS N
were VBD N
significantly RB N
longer RBR N
in IN N
LA NNP i
for IN N
both DT N
overweight JJ N
patients NNS N
and CC N
those DT N
with IN N
a DT N
normal JJ N
BMI NNP N
. . N

-DOCSTART- -X- O O

Two CD N
large JJ N
preoperative JJ N
doses NNS N
of IN N
erythropoietin NN i
do VBP N
not RB N
reduce VB N
the DT N
systemic JJ p
inflammatory NN p
response NN p
to TO p
cardiac VB p
surgery NN p
. . p

OBJECTIVES NNP N
Cardiac NNP N
surgery NN N
and CC N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
induce VBP N
an DT N
inflammatory JJ N
reaction NN N
that WDT N
may MD N
lead VB N
to TO N
tissue VB N
injury NN N
. . N

Experimental JJ N
studies NNS N
suggest VBP N
that IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
EPO NNP i
) ) i
independent JJ N
of IN N
its PRP$ N
erythropoietic JJ N
effect NN N
may MD N
be VB N
used VBN N
clinically RB N
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that IN N
2 CD N
large JJ N
doses NNS N
of IN N
EPO NNP i
administered VBD N
shortly RB N
before IN N
CPB NNP N
ameliorate VBP N
the DT N
systemic JJ N
inflammatory NN N
response NN N
to TO N
CPB NNP N
. . N

DESIGN NNP N
AND NNP N
SETTING NNP N
A NNP N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
and CC N
randomized JJ N
study NN N
at IN N
a DT N
single JJ N
tertiary NN N
care NN N
hospital NN N
. . N

PARTICIPANTS CC N
Patients NNS p
scheduled VBN p
for IN p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
with IN p
CPB NNP p
. . p

INTERVENTIONS NNP N
EPO NNP i
( ( i
epoetin JJ i
alfa NN i
, , N
500 CD N
IU/kg NNP N
intravenously RB N
, , N
n JJ p
= NNP p
22 CD p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
21 CD p
) ) p
was VBD N
administered VBN N
12 CD N
to TO N
18 CD N
hours NNS N
preoperatively RB N
and CC N
again RB N
at IN N
the DT N
induction NN N
of IN N
anesthesia NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
CPB NNP N
in IN N
both DT N
groups NNS N
greatly RB N
increased VBD N
plasma JJ o
concentrations NNS o
of IN o
tumor NN o
necrosis NN o
factor NN o
alpha NN o
( ( o
TNF-alpha NNP o
) ) o
, , o
interleukin FW o
( ( o
IL NNP o
) ) o
-1beta NN o
, , o
IL-1beta NNP o
receptor NN o
antagonist NN o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
N-terminal JJ o
probrain NN o
natriuretic JJ o
peptide NN o
( ( o
NT-proBNP NNP o
) ) o
. . o

Compared VBN N
with IN N
placebo NN i
, , i
EPO NNP i
at IN N
day NN N
3 CD N
after IN N
CPB NNP N
augmented VBD N
the DT N
TNF-alpha JJ o
response NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
2 CD N
hours NNS N
after IN N
CPB NNP N
increased VBD N
NT-proBNP NNP o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
EPO NNP i
tended VBD N
to TO N
enhance VB N
the DT N
CPB-induced JJ N
increase NN N
in IN N
IL-1beta NNP o
receptor NN o
antagonist NN o
( ( N
p JJ N
= NNP N
0.057 CD N
) ) N
. . N

Otherwise UH N
, , N
EPO NNP i
had VBD N
no DT N
effect NN N
on IN N
pro- NN o
and CC o
antiinflammatory NN o
mediators NNS o
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSIONS NNP N
Two CD N
large JJ N
doses NNS N
of IN N
EPO NNP i
given VBN N
shortly RB N
before IN N
CPB NNP N
do VBP N
not RB N
reduce VB N
perioperative JJ o
release NN o
of IN o
inflammatory JJ o
cytokines NNS o
. . o

In IN N
contrast NN N
, , N
EPO NNP i
may MD N
augment VB N
the DT N
TNF-alpha NNP N
and CC N
NT-proBNP NNP N
response NN N
. . N

Although IN N
the DT N
long-term JJ N
clinical JJ N
impact NN N
remains VBZ N
unknown JJ N
, , N
the DT N
findings NNS N
do VBP N
not RB N
support VB N
use NN N
of IN N
EPO NNP i
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
. . p

-DOCSTART- -X- O O

Music NNP i
or CC i
guided VBN i
imagery NN i
for IN N
women NNS p
undergoing VBG p
colposcopy NN i
: : i
a DT N
randomized NN N
controlled VBN N
study NN N
of IN N
effects NNS N
on IN N
anxiety NN o
, , o
perceived VBD o
pain NN o
, , o
and CC o
patient JJ o
satisfaction NN o
. . o

OBJECTIVE IN N
It PRP N
was VBD N
hypothesized VBN N
that IN N
music NN i
or CC i
guided VBN i
imagery NN i
versus NN i
usual JJ i
care NN i
would MD N
result VB N
in IN N
less JJR N
anxiety NN o
and CC N
perceived VBD o
pain NN o
for IN N
colposcopy NN p
patients NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
music NN i
, , i
guided VBD i
imagery NN i
, , i
or CC i
usual JJ i
care NN i
after IN N
completing VBG N
a DT N
baseline NN i
questionnaire NN i
. . i

All DT N
patients NNS N
completed VBD N
a DT N
postprocedure NN i
questionnaire NN i
. . i

RESULTS NNP N
Study NNP p
participants NNS p
( ( p
N=170 NNP p
) ) p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
28.4 CD p
years NNS p
( ( p
SD=9.6 NNP p
; : p
range VB p
18-60 JJ p
) ) p
and CC p
formed VBD p
a DT p
racially RB p
diverse JJ p
group NN p
. . p

Education/income NNP p
levels NNS p
were VBD p
low JJ p
. . p

No DT N
between-group JJ N
differences NNS N
were VBD N
found VBN N
for IN N
postprocedure NN o
anxiety NN o
or CC o
pain NN o
rating NN o
. . o

CONCLUSIONS NNP N
Mind-body JJ i
interventions NNS i
had VBD N
no DT N
statistically RB N
significant JJ N
impact NN N
on IN N
reported VBN N
anxiety NN o
, , o
perceived VBD o
pain NN o
, , o
or CC o
satisfaction NN o
with IN o
care NN o
, , N
even RB N
for IN N
those DT N
who WP N
anticipated VBD N
the DT N
most RBS N
pain NN N
or CC N
started VBN N
with IN N
high JJ N
anxiety NN N
. . N

-DOCSTART- -X- O O

Capsular JJ N
contracture NN N
around IN N
saline-filled JJ i
fine NN i
textured VBN i
and CC i
smooth JJ i
mammary JJ i
implants NNS i
: : i
a DT N
prospective JJ N
7.5-year JJ N
follow-up NN N
. . N

In IN N
a DT N
previous JJ N
prospective JJ N
randomized VBN N
clinical JJ N
study NN N
comparing VBG N
in IN N
the DT N
same JJ N
patient NN N
textured VBD N
and CC N
smooth JJ N
saline-filled JJ i
mammary JJ i
implants NNS i
( ( i
Biocell NNP i
) ) i
with IN N
large JJ N
pore NN N
size NN N
( ( N
300 CD N
to TO N
600 CD N
microm NN N
) ) N
, , N
we PRP N
saw VBD N
no DT N
difference NN N
in IN N
capsular JJ N
contracture NN N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
in IN N
a DT N
similar JJ N
way NN N
to TO N
compare VB N
capsular JJ N
contracture NN N
around IN N
smooth JJ N
and CC N
textured VBD N
saline-filled JJ i
prostheses NNS i
with IN N
pores NNS N
of IN N
small JJ N
size NN N
. . N

During IN p
a DT p
period NN p
of IN p
7.5 CD p
years NNS p
, , N
the DT N
breast NN N
hardness NN N
was VBD N
followed VBN N
up RP N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
patient JJ N
satisfaction NN N
was VBD N
evaluated VBN N
. . N

Twenty NNP p
healthy JJ p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
30 CD p
years NNS p
were VBD p
operated VBN p
on IN p
for IN p
breast NN p
augmentation NN p
. . p

Two CD N
surgeons NNS N
performed VBD N
all DT N
operations NNS N
in IN N
a DT N
standardized JJ N
way NN N
. . N

Each DT N
patient NN N
received VBD N
subglandularly RB i
a DT i
Siltex NNP i
textured VBD i
saline-filled JJ i
prosthesis NN i
with IN N
a DT N
pore NN N
size NN N
of IN N
30 CD N
to TO N
70 CD N
microm NN N
in IN N
one CD N
breast NN N
, , N
and CC N
a DT N
smooth JJ i
saline-filled JJ i
prosthesis NN i
in IN i
the DT i
other JJ i
. . i

The DT o
hardness NN o
of IN o
the DT o
breasts NNS o
was VBD N
evaluated VBN N
after IN N
0.5 CD N
, , N
1 CD N
, , N
and CC N
7.5 CD N
years NNS N
using VBG N
Baker NNP o
grading NN o
and CC o
applanation NN o
tonometry NN o
. . o

Eighteen JJ p
patients NNS p
completed VBN p
1-year JJ p
and CC p
7.5-year JJ p
follow-up NN p
. . p

Two CD N
breasts NNS N
with IN N
smooth JJ N
prostheses NNS N
were VBD N
contracted VBN N
after IN N
6 CD N
months NNS N
( ( N
Baker NNP N
III NNP N
or CC N
IV NNP N
) ) N
. . N

After IN N
1 CD N
year NN N
, , N
four CD N
patients NNS N
with IN N
smooth JJ N
prostheses NNS N
and CC N
one CD N
with IN N
a DT N
textured JJ N
prosthesis NN N
had VBD N
capsular JJ o
contracture NN o
( ( N
p JJ N
= NNP N
0.34 CD N
) ) N
. . N

Seven CD N
and CC N
one-half JJ N
years NNS N
after IN N
surgery NN N
, , N
six CD N
patents NNS N
with IN N
smooth DT N
and CC N
four CD N
with IN N
textured JJ N
implants NNS i
had VBD N
contracture NN o
( ( N
p JJ N
= NNP N
0.66 CD N
) ) N
. . N

On IN N
two CD N
patients NNS N
with IN N
smooth JJ N
prostheses NNS N
and CC N
one CD N
patient NN N
with IN N
a DT N
textured JJ N
prosthesis NN N
, , N
the DT N
capsule NN o
around IN o
the DT o
implant NN o
hardened VBD o
between IN N
6 CD N
and CC N
12 CD N
months NNS N
. . N

Between NNP N
1 CD N
year NN N
and CC N
7.5 CD N
years NNS N
, , N
three CD N
breasts NNS N
with IN N
smooth JJ o
and CC o
textured JJ o
implants NNS o
contracted VBD o
and CC o
one CD o
with IN o
a DT o
textured JJ o
implant NN o
softened.The NN o
patients NNS N
reported VBN N
on IN N
a DT N
Visual NNP o
Analogue NNP o
Scale NNP o
( ( N
1 CD N
to TO N
10 CD N
) ) N
the DT N
impact NN N
of IN N
the DT N
augmentation NN N
on IN N
their PRP$ N
quality NN o
of IN o
life NN o
to TO N
be VB N
9 CD N
+/- JJ N
1 CD N
. . N

Four CD N
patients NNS N
preferred VBD N
the DT N
breast NN N
with IN N
the DT N
smooth JJ N
prosthesis NN N
, , N
three CD N
preferred VBD N
the DT N
breast NN N
with IN N
the DT N
textured JJ N
prosthesis NN N
, , N
and CC N
the DT N
others NNS N
found VBD N
both DT N
breasts NNS N
equal VBP N
. . N

This DT N
study NN N
showed VBD N
no DT N
significant JJ o
difference NN o
of IN N
contracture NN o
with IN N
smooth JJ N
versus FW N
fine JJ N
textured VBN N
implants NNS N
. . N

The DT N
majority NN N
of IN N
the DT N
patients NNS N
preferred VBD o
the DT o
smooth JJ o
implants NNS o
. . o

The DT N
patients NNS N
reported VBD N
that IN N
the DT N
breast NN N
augmentation NN N
had VBD N
had VBN N
an DT N
extremely RB o
high JJ o
impact NN o
on IN o
their PRP$ o
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -X- O O

Blood NNP o
pressure NN o
biofeedback NN i
treatment NN i
of IN N
white-coat JJ N
hypertension NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
biofeedback NN i
treatment NN i
( ( i
BF NNP i
) ) i
effects NNS N
between IN N
white-coat JJ N
hypertension NN N
and CC N
essential JJ N
hypertension NN N
. . N

METHODS NNP N
Fifteen NNP p
white-coat JJ p
hypertensive JJ p
out-patients NNS p
and CC p
23 CD p
essential JJ p
hypertensive JJ p
out-patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
groups NNS N
A NNP N
or CC N
B NNP N
. . N

Subjects NNS N
in IN N
group NN N
A NNP N
underwent NN N
BF NNP i
once RB N
a DT N
week NN N
for IN N
a DT N
total NN N
of IN N
four CD N
sessions NNS N
. . N

Those DT N
in IN N
group NN i
B NNP i
visited VBD i
the DT i
clinic NN i
only RB i
to TO N
measure VB N
BP NNP o
and CC N
later RB N
underwent VBD N
the DT N
same JJ N
BF NNP i
. . i

RESULTS NNP N
In IN N
group NN N
A NNP N
, , N
BPs NNP o
of IN o
white-coat JJ o
hypertensives NNS o
and CC o
essential JJ o
hypertensives NNS o
were VBD N
significantly RB N
reduced VBN N
by IN N
22/11 CD N
and CC N
14/8 CD N
mmHg NN N
, , N
respectively RB N
. . N

In IN N
group NN N
B NNP N
, , N
they PRP N
were VBD N
unchanged JJ N
during IN N
the DT N
same JJ N
period NN N
but CC N
later RB N
suppressed VBN N
by IN N
BF NNP i
. . i

Under IN N
BF NNP i
, , N
pulse NN o
and CC o
respiratory NN o
rates NNS o
were VBD N
significantly RB N
higher JJR N
, , N
and CC N
elevation NN o
of IN o
diastolic JJ o
BP NNP o
due JJ o
to TO o
mental JJ o
stress NN o
testing NN o
was VBD N
better RBR N
suppressed VBN N
in IN N
white-coat NN N
hypertensives NNS N
than IN N
in IN N
essential JJ N
hypertensives NNS N
. . N

CONCLUSION VB N
This DT N
treatment NN N
was VBD N
effective JJ N
in IN N
both DT N
types NNS N
of IN N
hypertension NN N
, , N
and CC N
pressor NN N
response NN N
to TO N
stress VB o
seems VBZ N
to TO N
be VB N
important JJ N
in IN N
the DT N
differentiated JJ N
BF NNP i
effect NN N
. . N

-DOCSTART- -X- O O

Measurement NN N
of IN N
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
multiple JJ p
myeloma NN p
. . p

Nordic NNP N
Myeloma NNP N
Study NNP N
Group NNP N
. . N

When WRB N
a DT N
randomized VBN N
trial NN N
( ( N
NMSG NNP N
4/90 CD N
) ) N
comparing VBG N
treatment NN N
with IN N
melphalan/prednisone NN i
to TO N
melphalan/ VB i
prednisone NN i
+ NNP i
interferon VBZ i
alpha-2b NN i
in IN N
newly RB p
diagnosed VBN p
multiple JJ p
myeloma NN p
was VBD N
initiated VBN N
in IN N
1990 CD N
, , N
a DT N
quality-of-life JJ o
assessment NN o
was VBD N
integrated VBN N
into IN N
the DT N
study NN N
. . N

We PRP N
used VBD N
the DT N
questionnaire NN N
( ( N
QLQ-C30 NNP N
) ) N
developed VBN N
by IN N
the DT N
European JJ N
Organization NNP N
of IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
Study NNP N
Group NNP N
on IN N
Quality NNP o
of IN o
Life NNP o
. . o

The DT N
QLQ-C30 JJ N
incorporates NNS N
five CD N
functional JJ N
scales NNS N
, , N
three CD N
symptom NN N
scales NNS N
, , N
a DT N
global JJ N
health NN N
and CC N
quality-of JJ o
life NN o
scale NN o
and CC N
some DT N
single JJ N
symptom NN N
measures NNS N
. . N

The DT N
questionnaire NN N
was VBD N
completed VBN N
prior JJ N
to TO N
treatment NN N
and CC N
after IN N
1 CD N
, , N
6 CD N
, , N
12 CD N
, , N
24 CD N
, , N
36 CD N
and CC N
48 CD N
months NNS N
. . N

524 CD p
( ( p
90.2 CD p
% NN p
) ) p
of IN p
581 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
NMSG NNP p
4/90 CD p
completed VBD p
the DT p
first JJ p
questionnaire NN p
, , p
and CC p
484 CD p
( ( p
83.3 CD p
% NN p
) ) p
completed VBD p
all DT p
questionnaires NNS p
given VBN p
to TO p
them PRP p
. . p

All DT N
but CC N
one CD N
of IN N
the DT N
scales NNS N
met VBD N
the DT N
minimum JJ N
criteria NNS N
of IN N
reliability NN N
( ( N
Cronbach NNP N
's POS N
alpha NN N
> NNP N
/ NNP N
0.70 CD N
) ) N
. . N

Validity NNP N
was VBD N
shown VBN N
by IN N
( ( N
1 CD N
) ) N
the DT N
ability NN N
of IN N
the DT N
scales NNS N
to TO N
discriminate VB N
clearly RB N
between IN N
patients NNS N
differing VBG N
in IN N
clinical JJ N
status NN N
as IN N
defined VBN N
by IN N
pretreatment NN N
W.H.O NNP N
. . N

performance NN N
index NN N
and CC N
Durie NNP N
& CC N
Salmon NNP N
stage NN N
, , N
and CC N
( ( N
2 CD N
) ) N
the DT N
sensitivity NN N
to TO N
changes NNS N
in IN N
objective JJ N
disease NN N
status NN N
( ( N
response NN N
and CC N
relapse NN N
) ) N
. . N

This DT N
is VBZ N
the DT N
first JJ N
report NN N
of IN N
the DT N
measurement NN N
of IN N
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
a DT N
prospective JJ N
clinical JJ N
trial NN N
in IN N
multiple JJ N
myeloma NN N
. . N

The DT o
results NNS o
demonstrate VBP o
that IN o
the DT o
QLQ-C30 NNP o
is VBZ o
a DT o
reliable JJ o
and CC o
valid JJ o
instrument NN o
for IN o
the DT o
measurement NN o
of IN o
quality NN o
of IN o
life NN o
in IN o
these DT o
patients NNS o
. . o

The DT N
data NN N
will MD N
be VB N
used VBN N
for IN N
a DT N
cost-utility JJ N
analysis NN N
of IN N
the DT N
results NNS N
of IN N
the DT N
NMSG NNP N
4/90 CD N
trial NN N
. . N

-DOCSTART- -X- O O

Early JJ N
treatment NN N
of IN N
cold JJ N
sores NNS N
with IN N
topical JJ N
ME-609 NNP i
decreases VBZ N
the DT N
frequency NN o
of IN o
ulcerative JJ o
lesions NNS o
: : o
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
patient-initiated JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Prior NNP N
pilot NN N
studies NNS N
support VBP N
the DT N
use NN N
of IN N
antiviral JJ N
medications NNS N
with IN N
topical JJ N
corticosteroids NNS N
for IN N
herpes NNS p
simplex JJ p
labialis NN p
( ( p
HSL NNP p
) ) p
. . p

ME-609 NNP i
( ( i
Xerese JJ i
, , i
Xerclear NNP i
) ) i
is VBZ N
a DT N
combination NN N
of IN N
5 CD N
% NN N
acyclovir NN i
and CC N
1 CD N
% NN N
hydrocortisone NN i
developed VBD N
for IN N
the DT N
topical JJ N
treatment NN N
of IN N
HSL NNP N
. . N

OBJECTIVES NNP N
The DT N
primary NN N
study VBD N
end JJ N
point NN N
was VBD N
the DT N
prevention NN N
of IN N
ulcerative JJ o
HSL NNP o
lesions NNS o
. . o

METHODS NNP N
In IN N
all DT N
, , N
2437 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
HSL NNP p
were VBD N
randomized VBN i
to TO i
self-initiate JJ i
treatment NN i
with IN i
ME-609 NNP i
, , i
5 CD i
% NN i
acyclovir NN i
in IN i
ME-609 NNP i
vehicle NN i
, , i
or CC i
ME-609 JJ i
vehicle NN i
( ( i
placebo NN i
) ) i
at IN i
the DT i
earliest JJS i
sign NN i
of IN i
a DT i
cold JJ i
sore NN i
recurrence NN i
. . i

Cream NNP i
was VBD i
applied VBN i
5 CD i
times/d NN i
for IN i
5 CD i
days NNS i
. . i

A DT N
total NN N
of IN N
1443 CD p
patients NNS p
experienced VBD p
a DT o
recurrence NN o
and CC N
initiated JJ N
treatment NN N
with IN N
ME-609 NNP i
( ( N
n JJ N
= NNP N
601 CD N
) ) N
, , N
acyclovir FW i
( ( N
n JJ N
= NNP N
610 CD N
) ) N
, , N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
232 CD N
) ) N
. . N

RESULTS NNP N
Of IN N
patients NNS N
receiving VBG N
ME-609 NNP N
, , N
42 CD N
% NN N
did VBD N
not RB N
develop VB N
an DT N
ulcerative JJ o
lesion NN o
compared VBN N
with IN N
35 CD p
% NN p
of IN p
patients NNS p
receiving VBG N
acyclovir NN i
in IN i
ME-609 NNP i
vehicle NN i
( ( N
P NNP N
= NNP N
.014 NNP N
) ) N
and CC N
26 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
placebo NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

In IN N
patients NNS N
with IN N
ulcerative JJ N
lesions NNS N
, , N
healing VBG o
times NNS o
were VBD N
reduced VBN N
in IN N
the DT N
ME-609 NNP N
and CC N
acyclovir NN N
groups NNS N
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
both DT N
) ) N
. . N

The DT N
cumulative JJ o
lesion NN o
area NN o
for IN N
all DT N
lesions NNS N
was VBD N
reduced VBN N
50 CD N
% NN N
in IN N
patients NNS N
receiving VBG N
ME-609 NNP N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
among IN N
groups NNS N
in IN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
positive JJ N
herpes NNS N
simplex JJ N
virus NN N
cultures NNS N
. . N

The DT N
side-effect JJ o
profile NN o
was VBD N
similar JJ N
among IN N
treatments NNS N
. . N

LIMITATIONS VB N
The DT N
study NN N
did VBD N
not RB N
contain VB N
a DT N
group NN N
treated VBD N
with IN N
a DT N
topical JJ N
corticosteroid NN N
alone RB N
. . N

CONCLUSIONS NNP N
ME-609 NNP N
prevented VBD N
progression NN N
of IN o
cold JJ o
sores NNS o
to TO o
ulcerative JJ o
lesions NNS o
and CC N
significantly RB N
reduced VBD N
the DT N
cumulative JJ o
lesion NN o
area NN o
compared VBN N
with IN N
acyclovir NN N
and CC N
placebo NN N
. . N

ME-609 NNP N
treatment NN N
offers NNS N
additional JJ N
therapeutic JJ N
benefit NN N
compared VBN N
with IN N
therapy NN N
with IN N
topical JJ N
acyclovir NN N
alone RB N
. . N

-DOCSTART- -X- O O

Prevalence NN N
and CC N
treatment NN N
outcome NN N
of IN N
cervicitis NN o
of IN p
unknown JJ p
etiology NN p
. . p

BACKGROUND NNP N
Mucopurulent NNP N
cervicitis NN N
( ( N
MPC NNP N
) ) N
is VBZ N
a DT N
clinical JJ N
syndrome NN N
characterized VBN N
by IN N
mucopurulent JJ N
discharge NN N
from IN N
the DT N
cervix NN N
and CC N
other JJ N
signs NNS N
of IN N
inflammation NN N
. . N

This DT N
was VBD N
a DT N
phase NN N
III NNP N
, , N
multicenter NN N
study NN N
designed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
placebo NN i
versus NN N
empiric JJ i
antibiotic JJ i
treatment NN i
for IN N
clinical JJ N
cure NN N
of IN N
MPC NNP o
of IN N
unknown JJ N
etiology NN N
at IN N
2-month JJ N
follow-up NN N
. . N

Unfortunately RB N
, , N
enrollment NN N
was VBD N
terminated VBN N
because IN N
of IN N
low JJ N
accrual NNS N
of IN N
women NNS p
with IN p
cervicitis NN p
of IN p
unknown JJ p
etiology NN p
, , N
but CC N
important JJ N
prevalence NN N
and CC N
outcome NN N
data NNS N
were VBD N
obtained VBN N
. . N

METHODS NNP N
Five CD p
hundred VBD p
seventy-seven JJ p
women NNS p
were VBD p
screened VBN p
for IN p
MPC NNP p
. . p

Women NNP p
with IN p
MPC NNP p
were VBD N
randomized VBN N
to TO N
the DT N
treatment NN N
or CC N
placebo NN i
arm NN N
of IN N
the DT N
study NN N
, , N
and CC N
the DT N
2 CD N
arms NNS N
were VBD N
evaluated VBN N
based VBN N
on IN N
the DT N
etiology NN o
, , o
clinical JJ o
cure NN o
rates NNS o
, , o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
, , o
and CC o
rates NNS o
of IN o
pelvic JJ o
inflammatory JJ o
disease NN o
. . o

RESULTS NNP N
One CD p
hundred VBD p
thirty-one NN p
( ( p
23 CD p
% NN p
[ CC p
131/577 CD p
] NN p
) ) p
screened VBD p
women NNS p
were VBD N
found VBN N
to TO N
have VB N
MPC NNP N
. . N

Eighty-seven NNP p
were VBD p
enrolled VBN p
and CC N
randomized VBN N
. . N

After IN N
excluding VBG N
women NNS N
with IN N
sexually RB N
transmitted VBN N
infections NNS N
and CC N
other JJ N
exclusions NNS N
, , N
61 CD N
% NN N
( ( N
53/87 CD N
) ) N
had VBD N
cervicitis NN o
of IN N
unknown JJ N
etiology NN N
. . N

The DT N
overall JJ o
clinical JJ o
failure NN o
rate NN o
was VBD N
30 CD N
% NN N
( ( N
10/33 CD N
) ) N
, , N
and CC N
the DT N
clinical JJ o
cure NN o
rate NN o
was VBD N
only RB N
24 CD N
% NN N
( ( N
8/33 CD N
) ) N
. . N

Rates NNS N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
arms NNS N
. . N

There EX N
were VBD N
24 CD N
gastrointestinal JJ o
AEs NNP o
in IN N
the DT N
treatment NN N
arm NN N
compared VBN N
with IN N
1 CD N
AE NNP N
in IN N
the DT N
placebo NN i
arm NN N
. . N

CONCLUSIONS NNP N
More JJR N
than IN N
half NN N
of IN N
the DT N
cases NNS N
of IN N
MPC NNP N
were VBD N
of IN N
unknown JJ N
etiology NN N
. . N

Clinical JJ o
cure NN o
rates NNS o
for IN N
the DT N
placebo NN i
and CC N
treatment NN N
arms NNS N
were VBD N
extremely RB N
low JJ N
, , N
with IN N
most JJS N
women NNS N
concluding VBG N
the DT N
study NN N
with IN N
a DT N
partial JJ N
response NN N
. . N

Gastrointestinal JJ o
AEs NNP o
were VBD N
higher JJR N
in IN N
the DT N
treatment NN N
arm NN N
. . N

-DOCSTART- -X- O O

Oral JJ N
bioavailability NN N
of IN N
moxifloxacin NN i
after IN p
Roux-en-Y NNP i
gastric JJ i
bypass NN i
surgery NN i
. . i

OBJECTIVES CC N
Roux-en-Y JJ i
gastric JJ i
bypass NN i
surgery NN i
is VBZ N
the DT N
most RBS N
commonly RB N
performed JJ N
procedure NN N
for IN N
the DT N
treatment NN N
of IN N
morbid NN N
obesity NN N
. . N

This DT N
anatomical JJ N
alteration NN N
may MD N
affect VB N
the DT N
absorption NN N
and CC N
consequently RB N
the DT N
bioavailability NN N
of IN N
oral JJ N
drugs NNS N
. . N

This DT N
study NN N
aims VBZ N
to TO N
investigate VB N
the DT N
oral JJ o
bioavailability NN o
of IN N
moxifloxacin NN i
in IN N
12 CD p
healthy JJ p
volunteers NNS p
who WP p
underwent VBP p
gastric JJ i
bypass NN i
surgery NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
crossover NN N
study NN N
, , N
each DT N
subject NN N
received VBD N
two CD N
single JJ N
standard NN N
doses NNS N
of IN N
400 CD i
mg NN i
of IN i
moxifloxacin NN i
orally RB i
or CC i
intravenously RB i
administered VBN N
on IN N
two CD N
occasions NNS N
separated VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
1 CD N
week NN N
. . N

Serial JJ N
venous JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
up RB N
to TO N
72 CD N
h NN N
after IN N
dosing VBG N
and CC N
moxifloxacin JJ o
plasma NN o
levels NNS o
were VBD N
measured VBN N
by IN N
a DT N
validated JJ N
HPLC NNP N
method NN N
with IN N
fluorescence NN N
detection NN N
. . N

[ CC N
clinicaltrials.gov JJ N
database NN N
( ( N
identifier NN N
: : N
NCT01130922 NNP N
) ) N
. . N

] JJ N
RESULTS NNP N
After IN N
oral JJ N
dosing NN N
, , N
moxifloxacin FW o
plasma NN o
concentrations NNS o
reached VBD N
a DT N
maximum JJ N
( ( N
C NNP N
( ( N
max NN N
) ) N
) ) N
of IN N
3.38 CD N
? . N
1.41 CD N
mg/L NN N
after IN N
1.75 CD N
h NN N
( ( N
0.75-4.00 JJ N
) ) N
. . N

After IN N
intravenous JJ N
dosing NN N
, , N
C NNP N
( ( o
max NN o
) ) o
and CC o
T NNP o
( ( o
max NN o
) ) o
were VBD N
4.53 CD N
? . N
1.43 CD N
mg/L NN N
and CC N
1.03 CD N
h NN N
( ( N
0.75-2.50 JJ N
) ) N
, , N
respectively RB N
. . N

The DT o
mean JJ o
areas NNS o
under IN o
the DT o
plasma JJ o
concentration NN o
time NN o
curve NN o
extrapolated VBD o
to TO N
infinity NN N
( ( N
AUC NNP N
( ( N
? . N
) ) N
) ) N
were VBD N
46.2 CD N
? . N
1.4 CD N
mg NN N
? . N
h/L NN N
after IN N
oral JJ N
dosing NN N
and CC N
52.3 CD N
? . N
1.3 CD N
mg NN N
? . N
h/L NN N
after IN N
intravenous JJ N
dosing NN N
, , N
resulting VBG N
in IN N
a DT N
mean JJ o
oral JJ o
bioavailability NN o
of IN N
88.32 CD N
% NN N
[ JJ N
90 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
85.64 CD N
% NN N
-91.08 CD N
% NN N
] NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
confirms VBZ N
that IN N
exposure NN N
to TO N
moxifloxacin VB i
is VBZ N
equivalent JJ N
for IN N
oral JJ N
and CC N
intravenous JJ N
administration NN N
of IN N
400 CD N
mg NN N
dosages NNS N
in IN p
healthy JJ p
volunteers NNS p
who WP p
underwent VBP p
gastric JJ p
bypass NN p
surgery NN p
. . p

But CC N
these DT N
exposures NNS N
were VBD N
more JJR N
than IN N
50 CD N
% NN N
higher JJR N
than IN N
those DT N
described VBN N
for IN N
subjects NNS N
without IN N
gastric JJ N
bypass NN N
. . N

This DT N
may MD N
suggest VB N
a DT N
higher JJR N
enterohepatic JJ N
recirculation NN N
of IN N
moxifloxacin NN i
after IN p
gastric JJ p
bypass NN p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
on IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
: : p
a DT N
randomised JJ N
clinical JJ N
trial NN N
. . N

Fatigue NNP N
is VBZ N
a DT N
common JJ N
symptom NN N
of IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
, , N
and CC N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
daily JJ N
activity NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
patients NNS N
with IN N
the DT N
disease NN N
. . N

The DT N
authors NNS N
aimed VBN N
to TO N
identify VB N
the DT N
effect NN N
of IN N
home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
on IN N
fatigue NN N
, , N
activities NNS N
of IN N
daily JJ N
living NN N
( ( N
ADL NNP N
) ) N
and CC N
quality NN N
of IN N
life NN N
( ( N
QOL NNP N
) ) N
in IN N
patients NNS p
with IN p
COPD NNP p
. . p

A NNP N
block NN N
randomisation NN N
method NN N
was VBD N
used VBN N
to TO N
randomise VB N
participants NNS N
into IN N
case NN i
and CC N
control NN i
groups NNS N
. . N

Fatigue NNP o
, , o
ADL NNP o
and CC o
QOL NNP o
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
both DT N
groups NNS N
. . N

Independent NNP N
and CC N
paired VBD N
t-tests NNS N
, , N
chi-squared JJ N
tests NNS N
and CC N
covariance NN N
analysis NN N
were VBD N
used VBN N
to TO N
analysing VBG N
data NNS N
. . N

Findings NNS N
showed VBD N
the DT N
significant JJ N
decrease NN N
in IN N
the DT N
mean JJ o
scores NNS o
of IN o
fatigue NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
significant JJ N
improvement NN N
in IN N
mean JJ o
scores NNS o
of IN o
ADL NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
QOL NNP o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
after IN N
home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
in IN N
the DT N
case NN N
group NN N
. . N

Home-based JJ i
nursing NN i
pulmonary JJ i
rehabilitation NN i
can MD N
be VB N
an DT N
effective JJ o
, , o
inexpensive JJ o
and CC o
accessible JJ o
programme NN N
for IN N
decreasing VBG o
fatigue NN o
and CC o
improving VBG o
ADL NNP o
and CC o
QOL NNP o
for IN N
patients NNS p
with IN p
COPD NNP p
. . p

-DOCSTART- -X- O O

Arterial NNP N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
venous JJ p
thrombosis NN p
: : p
results NNS N
from IN N
a DT N
population-based JJ N
, , N
prospective JJ N
study NN N
( ( N
the DT N
HUNT NNP N
2 CD N
) ) N
. . N

BACKGROUND NNP N
An DT N
explanation NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
myocardial JJ N
infarction NN N
and CC N
stroke NN N
in IN N
patients NNS p
with IN p
venous JJ p
thrombosis NN p
is VBZ N
lacking VBG N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
risk NN N
factors NNS N
for IN N
arterial JJ N
cardiovascular JJ N
disease NN N
also RB N
increase VBZ N
the DT N
risk NN N
of IN N
venous JJ N
thrombosis NN N
. . N

DESIGN NNP N
AND CC N
METHODS NNP N
Cases NNP p
who WP p
had VBD p
a DT p
first JJ p
venous JJ p
thrombosis NN p
( ( p
n=515 JJ p
) ) p
and CC p
matched VBN p
controls NNS p
( ( p
n=1,505 NN p
) ) p
were VBD p
identified VBN p
from IN p
a DT p
population-based JJ p
, , p
nested JJ p
, , p
case-cohort JJ p
study NN p
( ( p
the DT p
HUNT NNP p
2 CD p
study NN p
) ) p
comprising VBG p
71 CD p
% NN p
( ( p
n=66,140 JJ p
) ) p
of IN p
the DT p
adult NN p
residents NNS p
of IN p
Nord-Tr?ndelag NNP p
County NNP p
in IN p
Norway NNP p
. . p

RESULTS VB N
The DT N
age- JJ N
and CC N
sex-adjusted JJ N
odds NNS N
ratio NN N
of IN o
venous JJ o
thrombosis NN o
for IN p
subjects NNS p
with IN p
concentrations NNS p
of IN p
C-reactive JJ p
protein NN p
in IN p
the DT p
highest JJS p
quintile NN p
was VBD N
1.6 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.2-2.2 JJ N
) ) N
compared VBN N
to TO N
subjects NNS N
with IN o
C-reactive JJ o
protein NN o
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

This DT N
association NN N
was VBD N
strongest VBN N
in IN p
subjects NNS p
who WP p
experienced VBD p
venous JJ p
thrombosis NN p
within IN p
a DT p
year NN p
after IN p
blood NN p
sampling VBG p
with IN N
a DT N
three-fold JJ N
increased JJ N
risk NN N
of IN N
participants NNS N
in IN N
the DT N
highest JJS N
versus NN N
the DT N
lowest JJS N
quintile NN N
. . N

Having VBG N
first JJ N
degree JJ N
relatives NNS N
who WP N
had VBD N
a DT N
myocardial JJ N
infarction NN N
before IN N
the DT N
age NN N
of IN N
60 CD N
years NNS N
was VBD N
positively RB N
associated VBN N
with IN o
venous JJ o
thrombosis NN o
compared VBN N
to TO N
not RB N
having VBG N
a DT N
positive JJ N
family NN N
history NN N
[ NNP N
odds VBZ N
ratio NN N
1.3 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
1.1-1.6 JJ N
) ) N
] NN N
. . N

Subjects NNS N
with IN o
blood NN o
pressure NN o
in IN N
the DT N
highest JJS N
quintile NN N
had VBD N
half PDT N
the DT N
risk NN N
of IN N
developing VBG o
venous JJ o
thrombosis NN o
compared VBN N
to TO N
subjects NNS N
whose WP$ N
blood NN N
pressure NN N
was VBD N
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

There EX N
were VBD N
no DT N
associations NNS N
between IN N
the DT o
risk NN o
of IN o
venous JJ o
thrombosis NN o
and CC o
total JJ o
cholesterol NN o
, , o
low JJ o
density NN o
lipoprotein-cholesterol NN o
, , o
high JJ o
density NN o
lipoprotein-cholesterol NN o
, , o
triglycerides NNS o
, , o
glucose NN o
or CC o
smoking NN o
. . o

We PRP N
confirmed VBD N
the DT N
positive JJ N
association NN N
between IN o
obesity NN o
and CC o
venous JJ o
thrombosis NN o
. . o

CONCLUSIONS NNP N
C-reactive JJ N
protein NN N
and CC N
a DT N
family NN N
history NN N
of IN N
myocardial JJ N
infarction NN N
were VBD N
positively RB N
associated VBN N
with IN N
subsequent JJ o
venous JJ o
thrombosis NN o
. . o

Blood NNP o
pressure NN o
was VBD N
inversely RB N
correlated VBN N
to TO p
venous JJ p
thrombosis NN p
. . p

These DT N
findings NNS N
should MD N
be VB N
confirmed VBN N
by IN N
further JJ N
investigations NNS N
. . N

-DOCSTART- -X- O O

A DT N
phase NN N
II NNP N
randomized VBD N
trial NN N
comparing VBG N
radiotherapy NN i
with IN N
concurrent JJ N
weekly JJ N
cisplatin NN i
or CC N
weekly JJ N
paclitaxel NN i
in IN N
patients NNS p
with IN p
advanced JJ p
cervical JJ p
cancer NN p
. . p

PURPOSE/OBJECTIVE VB N
This DT N
is VBZ N
a DT N
prospective JJ N
comparison NN N
of IN N
weekly JJ N
cisplatin NN i
to TO N
weekly VB N
paclitaxel NN i
as IN N
concurrent JJ N
chemotherapy NN N
with IN N
standard JJ i
radiotherapy NN i
for IN N
locally RB N
advanced JJ p
cervical JJ p
carcinoma NN p
. . p

MATERIALS/METHODS NNP N
Between NNP p
May NNP p
2000 CD p
and CC p
May NNP p
2004 CD p
, , p
31 CD p
women NNS p
with IN p
FIGO NNP p
stage NN p
IB2-IVA NNP p
cervical JJ p
cancer NN p
or CC p
with IN p
postsurgical JJ p
pelvic JJ p
recurrence NN p
were VBD p
enrolled VBN p
into IN p
this DT p
phase NN p
II NNP p
study NN p
and CC N
randomized VBN N
to TO N
receive VB N
on IN N
a DT N
weekly JJ N
basis NN N
either CC N
40 CD i
mg/m? NN i
Cisplatin NNP i
( ( i
group NN i
I PRP i
; : i
16 CD i
patients NNS i
) ) i
or CC i
50 CD i
mg/m? NNS i
paclitaxel NN i
( ( i
group NN i
II NNP i
; : i
15 CD i
patients NNS i
) ) i
concurrently RB i
with IN i
radiotherapy NN i
. . i

Median JJ N
total NN N
dose NN N
to TO N
point VB N
A NNP N
was VBD N
74 CD N
Gy NNP N
( ( N
range NN N
: : N
66-92 JJ N
Gy NNP N
) ) N
for IN N
group NN N
I PRP N
and CC N
66 CD N
Gy NNP N
( ( N
range NN N
: : N
40-98 JJ N
Gy NNP N
) ) N
for IN N
group NN N
II NNP N
. . N

Median JJ N
follow-up JJ N
time NN N
was VBD N
46 CD N
months NNS N
. . N

RESULTS NNP p
Patient NNP p
and CC p
tumor NN p
characteristics NNS p
were VBD p
similar JJ N
in IN N
both DT N
groups NNS N
. . N

The DT o
mean JJ o
number NN o
of IN o
chemotherapy NN o
cycles NNS o
was VBD o
also RB N
comparable JJ N
with IN N
87 CD N
% NN N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
at IN N
least JJS N
4 CD N
doses NNS N
in IN N
groups NNS N
I PRP N
and CC N
II NNP N
, , N
respectively RB N
. . N

Seven JJ N
patients NNS N
( ( N
44 CD N
% NN N
) ) N
of IN N
group NN N
I PRP N
and CC N
8 CD N
patients NNS N
( ( N
53 CD N
% NN N
) ) N
of IN N
group NN N
II NNP N
developed VBD o
tumor NN o
recurrence NN o
. . o

The DT o
Median JJ o
Survival NNP o
time NN o
was VBD o
not RB N
reached VBN N
for IN N
Group NNP N
I PRP N
and CC N
53 CD N
months NNS N
for IN N
group NN N
II NNP N
. . N

The DT o
proportion NN o
of IN o
patients NNS o
surviving VBG o
at IN o
2 CD N
and CC N
5 CD N
years NNS N
was VBD N
78 CD N
% NN N
and CC N
54 CD N
% NN N
for IN N
group NN N
I PRP N
and CC N
73 CD N
% NN N
and CC N
43 CD N
% NN N
for IN N
group NN N
II NNP N
respectively RB N
. . N

CONCLUSIONS VB N
This DT N
small JJ N
prospective JJ N
study NN N
shows NNS N
that WDT N
weekly VBP i
paclitaxel NN i
does VBZ i
not RB N
provide VB N
any DT o
clinical JJ o
advantage NN o
over IN o
weekly JJ i
cisplatin NN i
for IN i
concurrent JJ i
chemoradiation NN i
for IN i
advanced JJ p
carcinoma NN p
of IN p
the DT p
cervix NN p
. . p

-DOCSTART- -X- O O

Hysteroscopic NNP i
transcervical JJ i
endometrial JJ i
resection NN i
versus IN N
thermal JJ i
destruction NN i
for IN N
menorrhagia NN N
: : N
a DT N
prospective JJ N
randomized VBN N
trial NN N
on IN N
satisfaction NN N
rate NN N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
satisfaction NN o
rate NN o
and CC o
the DT o
effectiveness NN o
of IN N
transcervical JJ i
hysteroscopic NN i
endometrial JJ i
resection NN i
and CC N
thermal JJ i
destruction NN i
of IN N
the DT N
endometrium NN N
in IN N
the DT N
treatment NN N
of IN N
menorrhagia NN p
. . p

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
randomized VBN N
trial NN N
with IN N
2 CD N
years NNS N
of IN N
follow-up NN N
was VBD N
carried VBN N
out RP N
in IN N
the DT N
Department NNP p
of IN p
Gynecology NNP p
of IN p
the DT p
University NNP p
of IN p
Naples NNP p
. . p

Eighty-two JJ p
patients NNS p
who WP p
were VBD p
affected VBN p
by IN p
menorrhagia NN p
that WDT p
was VBD p
unresponsive JJ p
to TO p
medical JJ p
treatment NN p
were VBD N
respectively RB N
randomized VBN N
to TO N
transcervical JJ i
hysteroscopic NN i
endometrial JJ i
resection NN i
or CC i
to TO i
thermal JJ i
destruction NN i
of IN i
the DT i
endometrium NN i
. . i

Satisfaction NN o
rate NN o
, , o
operative JJ o
time NN o
, , o
discharge NN o
time NN o
, , o
complication NN o
rate NN o
, , o
reintervention NN o
rate NN o
, , o
and CC o
resumption NN o
of IN o
normal JJ o
activity NN o
were VBD N
evaluated VBN N
in IN N
each DT N
group NN N
. . N

RESULTS VB N
The DT N
satisfaction NN o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
thermal JJ i
destruction NN i
group NN N
. . N

Operative JJ o
time NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
thermal JJ N
destruction NN N
group NN N
( ( N
24 CD N
+/- JJ N
4 CD N
minutes NNS N
vs JJ N
37 CD N
+/- JJ N
6 CD N
minutes NNS N
) ) N
. . N

Intraoperative JJ o
blood NN o
loss NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
thermal JJ N
destruction NN N
group NN N
( ( N
7.2 CD N
+/- JJ N
2.8 CD N
mL NN N
vs NN N
89 CD N
+/- JJ N
38 CD N
mL NN N
) ) N
. . N

Reintervention NN o
rates NNS o
were VBD N
higher JJR N
in IN N
the DT N
transcervical JJ i
hysteroscopic NN i
endometrial JJ i
resection NN i
group NN N
, , N
although IN N
postoperative JJ N
pain NN N
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

Discharge NNP o
time NN o
, , o
complication NN o
rate NN o
, , o
and CC o
resumption NN o
of IN o
normal JJ o
activity NN o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Thermal NNP i
destruction NN i
of IN i
the DT i
endometrium NN i
for IN N
the DT N
treatment NN N
of IN N
menorrhagia NN p
should MD N
be VB N
considered VBN N
an DT N
effective JJ N
therapeutic JJ N
option NN N
because IN N
of IN N
its PRP$ N
acceptability NN o
among IN N
patients NNS N
, , N
shorter RB o
operative JJ o
time NN o
, , o
and CC o
lower JJR o
blood NN o
loss NN o
. . o

-DOCSTART- -X- O O

Validation NN N
of IN N
a DT N
novel JJ N
satisfaction NN i
questionnaire NN i
for IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
receiving VBG p
outpatient JJ p
clinical JJ p
nurse NN p
specialist NN p
care NN p
, , p
inpatient NN p
care NN p
, , p
or CC p
day NN p
patient JJ p
team NN p
care NN p
. . p

OBJECTIVES NNP N
To TO N
develop VB N
and CC N
validate VB N
a DT N
questionnaire NN N
for IN N
measuring VBG N
satisfaction NN o
with IN N
different JJ N
forms NNS N
of IN N
complex JJ N
multidisciplinary JJ N
care NN N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

METHODS PDT N
The DT N
satisfaction NN o
questionnaire NN o
( ( N
score JJ N
range NN N
0-100 NN N
) ) N
comprised VBD N
28 CD N
items NNS N
covering VBG N
11 CD N
domains NNS N
. . N

Together RB N
with IN N
a DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
, , o
range VB o
0-100 NNP o
) ) o
on IN o
overall JJ o
satisfaction NN o
, , N
the DT N
questionnaire NN i
was VBD N
applied VBN N
in IN N
210 CD p
RA NNP p
patients NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
comparing VBG N
3 CD N
types NNS N
of IN N
multidisciplinary JJ N
care NN N
. . N

RESULTS VB N
The DT p
questionnaire NN p
was VBD p
returned VBN p
by IN p
174 CD p
patients NNS p
( ( p
83 CD p
% NN p
) ) p
. . p

The DT N
questionnaire NN o
and CC o
VAS NNP o
scores NNS o
in IN N
the DT N
total JJ N
group NN N
were VBD N
75 CD N
( ( N
SD NNP N
12 CD N
) ) N
and CC N
83 CD N
( ( N
SD NNP N
20 CD N
) ) N
, , N
respectively RB N
. . N

Reliability NNP N
analysis NN N
showed VBD N
Cronbach NNP N
's POS N
alpha NN N
of IN N
the DT o
questionnaire NN o
was VBD N
0.91 CD N
. . N

Spearman NNP N
's POS N
correlation NN N
coefficient NN N
between IN N
the DT N
satisfaction NN o
questionnaire NN o
score NN o
and CC o
VAS NNP o
score NN o
was VBD N
0.58 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Mean JJ o
total JJ o
satisfaction NN o
questionnaire NN o
scores NNS o
were VBD N
72 CD N
( ( N
SD NNP N
9 CD N
) ) N
, , N
76 CD N
( ( N
SD NNP N
14 CD N
) ) N
, , N
and CC N
78 CD N
( ( N
SD NNP N
11 CD N
) ) N
, , N
in IN N
the DT N
nurse JJ N
specialist NN N
, , N
inpatient JJ N
and CC N
day NN N
patient NN N
groups NNS N
, , N
respectively RB N
( ( N
nurse JJ N
specialist NN N
versus IN N
day NN N
patient NN N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

Significant JJ N
differences NNS N
between IN N
nurse JJ N
specialist NN N
and CC N
day NN N
patients NNS N
were VBD N
seen VBN N
in IN N
the DT N
following JJ N
domains NNS N
: : N
waiting VBG o
time NN o
during IN o
the DT o
treatment NN o
, , o
autonomy NN o
, , o
coordination NN o
, , o
non-financial JJ o
access NN o
, , o
and CC o
quality NN o
of IN o
general JJ o
information NN o
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
patients NNS N
were VBD N
highly RB N
satisfied VBN N
with IN N
the DT N
multidisciplinary JJ N
care NN N
they PRP N
received VBD N
. . N

Major JJ N
differences NNS N
regarding VBG N
the DT N
organization NN N
of IN N
care NN N
were VBD N
reflected VBN N
in IN N
the DT N
results NNS N
of IN N
the DT N
questionnaire NN N
scores NNS N
. . N

The DT N
satisfaction NN o
questionnaire NN o
appears VBZ N
to TO N
be VB N
a DT N
useful JJ N
instrument NN N
for IN N
measuring VBG N
satisfaction NN o
with IN N
complex JJ N
multidisciplinary NN N
care NN N
in IN N
RA NNP p
patients NNS p
. . p

-DOCSTART- -X- O O

High JJ p
general JJ p
anger NN o
: : o
correlates NNS i
and CC N
treatment NN i
. . i

-DOCSTART- -X- O O

[ JJ N
Hemostatic NNP N
balance NN N
during IN N
treatment NN N
with IN N
the DT N
newest JJS N
contraceptives NNS N
] RB N
. . N

Thirty-four CD p
healthy JJ p
young JJ p
women NNS p
were VBD N
allocated VBN i
to TO i
12 CD i
consecutive JJ i
cycles NNS i
of IN i
treatment NN i
with IN i
monophasic JJ i
combinations NNS i
of IN i
: : i
20 CD i
micrograms NNS i
ethinyl VBP i
estradiol NN i
and CC i
150 CD i
micrograms NNS i
desogestrel NN i
( ( i
n JJ i
= NNP i
15 CD i
) ) i
or CC i
30 CD i
micrograms NNS i
ethinyl VBP i
estradiol NN i
and CC i
75 CD i
micrograms NNS i
gestodene NN i
( ( i
n JJ i
= NNP i
19 CD i
) ) i
. . N

In IN N
both DT N
groups NNS N
plasma VBP o
levels NNS o
of IN o
fibrinogen NN o
and CC o
factor NN o
VII NNP o
increased VBD N
while IN N
the DT N
capacity NN N
of IN N
coagulation NN N
inhibition NN N
was VBD N
affected VBN N
by IN N
increased JJ o
protein NN o
C NNP o
and CC o
decreased VBN o
protein NN o
S NNP o
levels NNS o
. . o

Increased VBN N
fibrinolytic JJ o
capacity NN o
was VBD N
indicated VBN N
by IN N
elevated JJ N
activity NN N
and CC N
reduced JJ N
antigen NN o
levels NNS o
of IN o
tissue NN o
plasminogen NN o
activator NN o
and CC N
reduced JJ N
activity NN N
and CC N
concentration NN o
of IN o
tissue NN o
plasminogen NN o
activator NN o
inhibitor NN o
. . o

The DT N
ratio NN o
between IN o
thrombin-antithrombin-III-complexes NNS o
and CC o
fibrin JJ o
degradation NN o
products NNS o
were VBD o
unchanged JJ o
signifying VBG N
no DT N
effect NN N
of IN N
hormonal JJ N
intake NN N
on IN N
the DT N
balance NN N
between IN N
thrombin JJ N
formation NN N
and CC N
fibrin JJ N
resolution NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
dynamic JJ N
balance NN N
between IN N
generation NN N
and CC N
resolution NN N
of IN N
fibrin NN N
was VBD N
undisturbed JJ N
during IN N
treatment NN N
with IN N
both DT N
hormonal JJ N
compounds NNS N
and CC N
our PRP$ N
findings NNS N
do VBP N
not RB N
provide VB N
evidence NN N
for IN N
increased VBN N
risk NN N
of IN N
thrombosis NN N
in IN N
normal JJ p
women NNS p
. . p

-DOCSTART- -X- O O

Mediterranean NNP i
diet NN i
and CC i
high JJ i
dietary JJ i
acid NN i
load NN i
associated VBN N
with IN N
mixed JJ i
nuts NNS i
: : i
effect NN o
on IN N
bone NN o
metabolism NN o
in IN N
elderly JJ p
subjects NNS p
. . p

OBJECTIVES NNP N
To TO N
analyze VB N
the DT N
effect NN N
of IN N
differing VBG N
diet NN N
on IN N
the DT N
acid JJ N
load NN N
content NN N
on IN N
bone NN o
metabolism NN o
. . o

DESIGN NNP N
Multicentric NNP N
, , N
randomized VBD N
, , N
single-blind JJ N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient JJ p
clinics NNS p
. . p

PARTICIPANTS VB N
Two CD p
hundred CD p
thirty-eight JJ p
elderly JJ p
men NNS p
and CC p
women NNS p
aged VBD p
60 CD p
to TO p
80 CD p
at IN p
high JJ p
risk NN p
for IN p
cardiovascular JJ p
disease NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
interventional JJ N
groups NNS N
: : N
a DT N
recommended JJ i
low-fat JJ i
diet NN i
( ( i
control VB i
diet JJ i
group NN i
) ) i
, , i
a DT i
Mediterranean NNP i
diet NN i
supplemented VBD i
with IN i
virgin JJ i
olive JJ i
oil NN i
, , i
or CC i
a DT i
Mediterranean NNP i
diet NN i
supplemented VBD i
with IN i
mixed JJ i
nuts NNS i
. . i

MEASUREMENTS NNP N
Main NNP N
outcomes NNS N
were VBD N
12-month JJ N
changes NNS N
from IN N
baseline NN N
in IN N
bone NN o
formation NN o
and CC o
resorption NN o
markers NNS o
and CC o
bone NN o
mass NN o
measured VBD o
according VBG N
to TO N
quantitative JJ N
ultrasound JJ N
scanning NN N
. . N

RESULTS VB N
The DT N
baseline NN N
data NNS N
on IN N
the DT N
anthropometric NN o
, , o
bone NN o
densitometry NN o
, , o
and CC o
biochemical JJ o
variables NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
three CD p
groups NNS p
. . p

Dietary NNP o
potential JJ o
renal JJ o
acid NN o
load NN o
( ( o
PRAL NNP o
) ) o
and CC o
daily JJ o
net NN o
endogenous JJ o
acid NN o
production NN o
( ( o
NEAP NNP o
) ) o
at IN N
baseline NN N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

After IN N
intervention NN N
, , N
subjects NNS p
allocated VBD N
to TO N
the DT N
Mediterranean NNP i
diet NN i
with IN i
mixed JJ i
nuts NNS i
had VBD N
a DT N
significant JJ N
increase NN N
of IN N
PRAL NNP o
and CC o
NEAP NNP o
. . o

In IN N
comparison NN N
, , N
subjects NNS N
in IN N
the DT N
Mediterranean NNP i
diet NN i
with IN i
nuts NNS i
group NN p
had VBD N
higher JJR N
parathyroid NN o
hormone NN o
( ( o
PTH NNP o
) ) o
levels NNS o
( ( N
2.63 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
=-1.01-6.35 NN N
, , N
P=.02 NNP N
) ) N
and CC N
a DT N
nonsignificantly RB N
higher JJR N
( ( N
0.31 CD N
, , N
95 CD N
% NN N
CI=-0.13-0.74 NNP N
, , N
P=.14 NNP N
) ) N
urine VBP o
free JJ o
deoxypyridoxine NN o
: : o
creatinine NN o
ratio NN o
, , N
a DT N
marker NN N
of IN N
bone NN N
resorption NN N
, , N
than IN N
the DT N
control NN N
group NN p
and CC N
the DT N
Mediterranean NNP N
diet NN N
with IN N
virgin JJ N
olive JJ N
oil NN N
group NN p
. . p

CONCLUSION VB N
A DT N
Mediterranean NNP i
dietary JJ i
pattern NN i
associated VBN N
with IN N
a DT N
high JJ N
dietary JJ N
acid NN N
load NN N
derived VBN N
from IN N
consumption NN N
of IN N
mixed JJ N
nuts NNS N
does VBZ N
not RB N
seem VB N
to TO N
have VB N
a DT N
much RB N
greater JJR N
effect NN N
on IN N
bone NN o
metabolism NN o
biomarkers NNS o
, , N
with IN N
the DT N
exception NN N
of IN N
PTH NNP o
levels NNS o
, , N
than IN N
a DT N
Mediterranean NNP i
diet NN i
without IN i
mixed JJ i
nuts NNS i
or CC i
a DT i
control NN i
diet NN i
in IN N
elderly JJ p
subjects NNS p
. . p

-DOCSTART- -X- O O

Angiotensin NNP N
converting VBG N
enzyme JJ N
inhibition NN N
does VBZ N
not RB N
affect VB N
the DT N
response NN N
to TO N
exogenous JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ p
forearm NN p
. . p

Suppression NN N
of IN N
endogenous JJ N
levels NNS N
of IN N
angiotensin NN N
II NNP N
by IN N
angiotensin NN N
converting VBG N
enzyme JJ N
inhibition NN N
, , N
may MD N
result VB N
in IN N
up-regulation NN N
of IN N
vascular JJ N
AT1 NNP N
receptors NNS N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
effects NNS N
of IN N
orally RB N
administered VBN N
enalapril NN i
on IN N
angiotensin NN N
II NNP N
induced VBD N
vasoconstriction NN N
in IN N
the DT N
human JJ p
forearm NN p
. . p

Subjects VBZ p
received VBN N
in IN N
random JJ N
order NN N
, , N
enalapril NN i
( ( N
20 CD N
mg NN N
) ) N
or CC i
matched VBN i
placebo JJ i
daily JJ N
for IN N
2 CD N
weeks NNS N
. . N

Forearm NNP o
blood NN o
flow NN o
response NN N
to TO N
increasing VBG N
doses NNS N
of IN N
angiotensin NN N
II NNP N
was VBD N
measured VBN N
using VBG N
venous JJ N
occlusion NN N
plethysmography NN N
at IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
end NN N
of IN N
each DT N
2 CD N
week NN N
treatment NN N
period NN N
. . N

Treatment NN N
with IN N
enalapril NN N
significantly RB N
reduced VBN N
plasma NN o
angiotensin NN o
II NNP o
levels NNS o
and CC o
supine VB o
blood NN o
pressure NN o
compared VBN N
with IN N
placebo NN N
. . N

The DT N
percentage NN N
reductions NNS o
in IN o
forearm NN o
blood NN o
flow NN o
in IN N
the DT N
infused JJ N
arm NN N
, , N
in IN N
response NN N
to TO N
the DT N
maximum JJ N
dose NN N
of IN N
angiotensin NN N
II NNP N
( ( N
50,000 CD N
fmol RB N
min-1 NN N
) ) N
were VBD N
48.1 CD N
+/- JJ N
3.6 CD N
% NN N
at IN N
baseline NN N
, , N
57.5 CD N
+/- JJ N
3.6 CD N
% NN N
on IN N
placebo NN N
and CC N
54.5 CD N
+/- JJ N
4.2 CD N
% NN N
on IN N
enalapril NN N
. . N

The DT N
differences NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

This DT N
demonstrates VBZ N
that IN N
suppression NN N
of IN N
plasma NN N
angiotensin NN N
II NNP N
for IN N
a DT N
14 CD N
day NN N
period NN N
does VBZ N
not RB N
enhance VB N
the DT N
response NN N
to TO N
exogenous JJ N
intra-arterial JJ N
angiotensin NN N
II NNP N
in IN N
the DT N
human JJ p
forearm NN p
of IN p
healthy JJ p
salt NN p
replete JJ p
subjects NNS p
. . p

-DOCSTART- -X- O O

A DT N
randomized VBN N
, , N
phase VB N
II NNP N
study NN N
of IN N
afatinib JJ N
versus NN N
cetuximab NN N
in IN N
metastatic JJ p
or CC p
recurrent JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

BACKGROUND NNP N
Afatinib NNP N
is VBZ N
an DT N
oral JJ N
, , N
irreversible JJ N
ErbB NNP N
family NN N
blocker NN N
that WDT N
has VBZ N
shown VBN N
activity NN N
in IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
( ( N
EGFR NNP N
) ) N
-mutated VBD N
lung NN N
cancer NN N
. . N

We PRP N
hypothesized VBD N
that IN N
the DT N
agent NN N
would MD N
have VB N
greater JJR N
antitumor NN o
activity NN o
compared VBN N
with IN N
cetuximab NN N
in IN N
recurrent NN p
or CC p
metastatic JJ p
( ( p
R/M NNP p
) ) p
head NN p
and CC p
neck NN p
squamous JJ p
cell NN p
carcinoma NN p
( ( p
HNSCC NNP p
) ) p
patients NNS p
, , p
whose WP$ p
disease NN p
has VBZ p
progressed VBN p
after IN p
platinum-containing JJ p
therapy NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
An DT N
open-label JJ N
, , N
randomized VBN N
, , N
phase VB N
II NNP N
trial NN N
was VBD N
conducted VBN N
in IN N
43 CD p
centers NNS p
; : p
124 CD p
patients NNS p
were VBD N
randomized VBN i
( ( i
1 CD i
: : i
1 CD i
) ) i
to TO i
either DT i
afatinib NN i
( ( i
50 CD i
mg/day NN i
) ) i
or CC i
cetuximab NN i
( ( i
250 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/week NN i
) ) i
until IN i
disease JJ i
progression NN i
or CC i
intolerable JJ i
adverse JJ i
events NNS i
( ( i
AEs NNP i
) ) i
( ( i
stage NN i
I PRP i
) ) i
, , i
with IN i
optional JJ i
crossover NN i
( ( i
stage JJ i
II NNP i
) ) i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
tumor JJ o
shrinkage NN o
before IN o
crossover NN o
assessed VBN o
by IN o
investigator NN o
( ( o
IR NNP o
) ) o
and CC o
independent JJ o
central JJ o
review NN o
( ( o
ICR NNP o
) ) o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
121 CD p
patients NNS p
were VBD p
treated VBN p
( ( p
61 CD p
afatinib NN p
, , p
60 CD p
cetuximab NN p
) ) p
and CC p
68 CD p
crossed VBN p
over IN p
to TO p
stage VB p
II NNP p
( ( p
32 CD p
and CC p
36 CD p
respectively RB p
) ) p
. . p

In IN N
stage NN N
I PRP N
, , N
mean JJ o
tumor NN o
shrinkage NN o
by IN o
IR/ICR NNP o
was VBD N
10.4 CD N
% NN N
/16.6 CD N
% NN N
with IN N
afatinib NN N
and CC N
5.4 CD N
% NN N
/10.1 CD N
% NN N
with IN N
cetuximab NN N
( ( N
P NNP N
= NNP N
0.46/0.30 CD N
) ) N
. . N

Objective JJ o
response NN o
rate NN o
was VBD N
16.1 CD N
% NN N
/8.1 CD N
% NN N
with IN N
afatinib NN N
and CC N
6.5 CD N
% NN N
/9.7 CD N
% NN N
with IN N
cetuximab NN N
( ( N
IR/ICR NNP N
) ) N
. . N

Comparable JJ o
disease NN o
control NN o
rates NNS o
were VBD N
observed VBN N
with IN N
afatinib NN N
( ( N
50 CD N
% NN N
) ) N
and CC N
cetuximab NN N
( ( N
56.5 CD N
% NN N
) ) N
by IN N
IR NNP N
; : N
similar JJ N
results NNS N
were VBD N
seen VBN N
by IN N
ICR NNP N
. . N

Most JJS N
common JJ N
grade NN N
?3 JJ o
drug-related JJ o
AEs NNP o
( ( o
DRAEs NNP N
) ) N
were VBD o
rash/acne VBN o
( ( o
18 CD N
% NN N
versus IN N
8.3 CD o
% NN o
) ) o
, , o
diarrhea NN o
( ( o
14.8 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
, , N
and CC o
stomatitis/mucositis NN o
( ( o
11.5 CD N
% NN N
versus IN N
0 CD N
% NN N
) ) N
with IN N
afatinib NN N
and CC N
cetuximab NN N
, , N
respectively RB N
. . N

Patients NNS N
with IN o
DRAEs NNP o
leading VBG o
to TO o
treatment NN o
discontinuation NN o
were VBD o
23 CD N
% NN N
with IN N
afatinib NN N
and CC N
5 CD N
% NN N
with IN N
cetuximab NN N
. . N

In IN N
stage NN N
II NNP N
, , o
disease VB o
control NN o
rate NN o
( ( o
IR/ICR NNP o
) ) o
was VBD o
38.9 CD N
% NN N
/33.3 CD N
% NN N
with IN N
afatinib NN N
and CC N
18.8 CD N
% NN N
/18.8 CD N
% NN N
with IN N
cetuximab NN N
. . N

CONCLUSION NNP N
Afatinib NNP N
showed VBD o
antitumor JJ o
activity NN o
comparable JJ o
to TO N
cetuximab VB N
in IN N
R/M NNP p
HNSCC NNP p
in IN p
this DT N
exploratory JJ N
phase NN N
II NNP N
trial NN N
, , N
although IN N
more JJR N
patients NNS N
on IN N
afatinib JJ N
discontinued VBN N
treatment NN N
due JJ N
to TO N
AEs NNP N
. . N

Sequential NNP N
EGFR/ErbB NNP N
treatment NN N
with IN N
afatinib NN N
and CC N
cetuximab NN N
provided VBD N
sustained JJ o
clinical JJ o
benefit NN o
in IN o
patients NNS N
after IN N
crossover NN N
, , N
suggesting VBG N
a DT N
lack NN N
of IN N
cross-resistance NN N
. . N

-DOCSTART- -X- O O

Improving VBG N
emotion NN o
regulation NN o
with IN N
CBT NNP i
in IN N
young JJ p
children NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
This DT N
pilot NN N
study NN N
tested VBD N
the DT N
efficacy NN N
of IN N
a DT N
developmentally RB N
modified VBN N
CBT NNP i
for IN N
young JJ p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
to TO N
teach VB N
emotion NN o
regulation NN o
strategies NNS N
for IN N
reducing VBG N
anger NN o
and CC o
anxiety NN o
, , N
commonly RB N
noted VBD N
problems NNS N
in IN N
this DT N
population NN N
. . N

METHOD NNP N
Eleven NNP p
5-7 JJ p
year-old JJ p
children NNS p
participated VBN p
in IN N
a DT N
CBT-group NNP i
while IN N
parents NNS N
participated VBN i
in IN i
psychoeducation NN i
. . i

Children NNP i
were VBD i
randomly RB i
assigned VBN i
to TO i
an DT i
experimental JJ i
or CC i
delayed-treatment JJ i
control NN i
group NN i
. . i

RESULTS CC N
From IN N
pre- JJ N
to TO N
post-treatment JJ N
, , N
all DT N
children NNS N
had VBD N
less RBR N
parent NN p
reported VBD p
negativity/lability NN o
, , N
better JJR N
parent NN N
reported VBD N
emotion NN o
regulation NN o
, , o
and CC o
shorter JJR o
outbursts NNS o
, , N
and CC N
also RB N
generated VBD o
more RBR o
coping JJ o
strategies NNS o
in IN N
response NN N
to TO N
vignettes NNS N
. . N

Parents NNS N
also RB N
reported VBD N
increases NNS N
in IN N
their PRP$ N
own JJ N
confidence NN o
and CC N
their PRP$ N
child NN N
's POS N
ability NN o
to TO o
deal VB o
with IN o
anger NN o
and CC o
anxiety NN o
. . o

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
young JJ p
children NNS p
with IN p
high JJ p
functioning VBG p
ASD NNP p
may MD N
benefit VB N
from IN N
CBT NNP i
to TO N
improve VB N
regulation NN o
of IN o
anger NN o
and CC o
anxiety NN o
, , N
and CC N
parent NN N
training NN N
may MD N
improve VB N
parental JJ o
self-efficacy NN o
. . o

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
make VB N
conclusions NNS N
about IN N
its PRP$ N
efficacy NN N
. . N

-DOCSTART- -X- O O

Performance NN N
of IN N
a DT N
modified VBN i
starch NN i
hydrophilic NN i
matrix NN i
for IN i
the DT i
sustained JJ i
release NN i
of IN i
theophylline NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

Two CD N
experimental JJ N
formulations NNS N
of IN N
theophylline NN i
with IN i
a DT i
hydrophilic JJ i
starch NN i
matrix NN i
were VBD N
evaluated VBN N
for IN N
their PRP$ N
sustained-release JJ N
characteristics NNS N
after IN N
single JJ N
administration NN N
in IN N
healthy JJ p
human JJ p
volunteers NNS p
. . p

Theo-dur NN i
was VBD N
chosen VBN N
as IN N
a DT N
reference NN N
sustained-release JJ N
formulation NN N
. . N

In IN N
a DT N
first JJ N
study NN N
, , N
the DT N
extent NN N
of IN N
absorption NN N
was VBD N
similar JJ N
for IN N
a DT N
syrup NN N
, , N
for IN N
Theo-dur NNP i
, , N
and CC N
for IN N
the DT N
experimental JJ N
formulation NN N
of IN N
theophylline NN i
with IN i
70 CD i
% NN i
drum-dried JJ i
corn NN i
starch NN i
as IN i
the DT i
sustained-release JJ i
agent NN i
( ( i
DDCS-70 NNP i
) ) i
. . N

The DT N
maximal JJ o
plasma NN o
concentration NN o
( ( o
Cmax NNP o
) ) o
was VBD N
significantly RB N
lower JJR N
, , N
and CC N
the DT N
time NN o
to TO o
reach VB o
Cmax NNP o
as RB N
well RB N
as IN N
the DT N
time NN N
span NN N
during IN N
which WDT N
the DT N
plasma NN o
concentration NN o
was VBD N
at IN N
least JJS N
75 CD N
% NN N
of IN N
the DT N
Cmax NNP N
were VBD N
significantly RB N
higher JJR N
for IN N
Theo-dur NNP N
than IN N
for IN N
the DT N
DDCS-70 NNP N
formulation NN N
. . N

A DT N
sustained-release JJ N
profile NN N
, , N
as IN N
for IN N
Theo-dur NNP i
, , N
was VBD N
not RB N
reached VBN N
for IN N
DDCS-70 NNP N
. . N

In IN N
a DT N
second JJ N
study NN N
the DT N
influence NN N
of IN N
the DT N
starch NN N
: : N
drug NN N
ratio NN N
on IN N
the DT N
bioavailability NN N
was VBD N
investigated VBN N
. . N

The DT N
decrease NN N
in IN N
starch NN N
content NN N
from IN N
70 CD N
to TO N
50 CD N
% NN N
of IN N
the DT N
formulation NN N
did VBD N
not RB N
improve VB N
the DT N
plasma NN o
concentration-time JJ o
profile NN N
towards NNS N
a DT N
sustained-release JJ N
profile NN N
. . N

-DOCSTART- -X- O O

Sleep NNP o
patterns NNS o
in IN N
autistic JJ p
children NNS p
. . p

Sleep JJ o
disturbances NNS o
are VBP N
regarded VBN N
as IN N
a DT N
common JJ N
clinical JJ N
feature NN N
in IN N
autistic JJ p
children NNS p
. . p

This DT N
concept NN N
is VBZ N
based VBN N
primarily RB N
on IN N
informal JJ N
observations NNS N
or CC N
studies NNS N
conducted VBN N
with IN N
questionnaires NNS i
. . i

In IN N
this DT N
study NN N
we PRP N
compared VBN N
data NNS N
obtained VBN N
by IN N
questionnaires NNS i
to TO N
that DT N
obtained VBN N
with IN N
actigraphy NN i
. . i

Among IN N
22 CD p
autistic JJ p
children NNS p
, , p
12 CD p
were VBD p
reported VBN p
as IN p
having VBG p
sleep JJ p
problems NNS p
and CC N
8 CD p
patients NNS p
completed VBD p
72 CD i
hours NNS i
actigraphy RB i
. . i

While IN N
the DT N
employment NN N
of IN N
questionnaires NNS i
disclosed VBN N
that IN N
autistic JJ N
children NNS N
had VBD N
an DT N
earlier JJR o
morning NN o
awakening NN o
time NN o
and CC o
multiple NN o
and CC o
early JJ o
night NN o
arousals NNS o
, , N
actigraphic JJ i
monitoring NN N
showed VBD N
that IN N
with IN N
the DT N
exception NN N
of IN N
an DT N
earlier JJR o
morning NN o
arousal NN o
time NN o
( ( N
p JJ N
= NNP N
.045 NNP N
) ) N
, , N
sleep JJ o
patterns NNS o
of IN N
autistic JJ p
children NNS p
were VBD N
similar JJ N
to TO N
that DT N
of IN N
normal JJ N
children NNS N
. . N

Parental JJ N
oversensitivity NN N
to TO N
sleep VB o
disturbances NNS o
of IN N
the DT N
autistic JJ p
children NNS p
may MD N
explain VB N
this DT N
phenomenon NN N
. . N

-DOCSTART- -X- O O

The DT N
injured JJ p
colon NN p
: : p
therapeutic JJ N
considerations NNS N
. . N

A DT N
prospective JJ N
randomized NN N
study NN p
was VBD p
carried VBN p
out RP p
at IN p
the DT p
Detroit NNP p
General NNP p
Hospital NNP p
over IN p
a DT p
two CD p
year NN p
period NN p
to TO p
evaluate VB p
methods NNS p
of IN p
management NN p
in IN p
165 CD p
patients NNS p
with IN p
colonic JJ i
injuries NNS i
. . i

Results NNS N
of IN N
the DT N
study NN N
show NN N
that IN N
primary JJ i
closure NN i
is VBZ N
a DT N
safe JJ o
and CC N
reiable JJ o
method NN N
of IN N
management NN N
when WRB N
rigid JJ N
criteria NNS N
are VBP N
incorporated VBN N
in IN N
an DT N
ongoing JJ N
protocol NN N
. . N

Moreover RB N
, , N
the DT N
technic NN N
of IN N
exteriorization NN i
is VBZ N
a DT N
safe JJ o
adjunct NN N
to TO N
management NN N
and CC N
is VBZ N
recommended VBN N
in IN N
any DT p
patient NN p
with IN p
a DT p
colonic JJ p
injury NN p
above IN p
18 CD p
cm NN p
in IN N
which WDT N
one CD N
suture NN N
line NN N
is VBZ N
required VBN N
and CC N
in IN N
which WDT N
the DT N
additional JJ N
operating NN N
time NN N
of IN N
twenty NN N
minutes NNS N
will MD N
not RB N
compromise VB N
the DT N
management NN N
of IN N
secondary JJ N
injuries NNS N
. . N

Patients NNS N
not RB N
fulfilling VBG N
these DT N
criteria NNS N
should MD N
have VB N
primary JJ o
colostomy NN o
. . o

These DT N
principles NNS N
make VBP N
it PRP N
possible JJ N
to TO N
reduce VB N
the DT N
need NN N
for IN N
primary JJ o
colostomy NN o
to TO N
approximately RB N
50 CD N
per IN N
cent NN N
in IN N
a DT N
large JJ N
ongoing VBG N
group NN N
of IN N
patients NNS p
with IN p
colonic JJ p
injury NN p
. . p

-DOCSTART- -X- O O

A DT N
randomized JJ N
prospective NN N
controlled VBN N
trial NN N
of IN N
oral JJ N
ganciclovir NN i
versus IN N
oral JJ N
valacyclovir NN i
for IN N
prophylaxis NN N
of IN N
cytomegalovirus NN o
disease NN o
after IN N
renal JJ p
transplantation NN p
. . p

Oral NNP N
ganciclovir NN i
and CC i
valacyclovir NN i
reduce VB N
the DT N
incidence NN N
of IN N
cytomegalovirus NN o
( ( o
CMV NNP o
) ) o
disease NN o
after IN p
renal JJ p
transplantation NN p
( ( p
RTx NNP p
) ) p
. . p

Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN o
, , o
costs NNS o
, , o
and CC o
safety NN o
of IN N
oral JJ N
ganciclovir NN i
and CC i
valacyclovir NN i
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
over IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
RTx NNP N
. . N

A NNP N
total NN p
of IN p
38 CD p
patients NNS p
was VBD p
randomized VBN p
to TO p
3-month JJ p
treatment NN p
with IN p
either DT p
oral JJ i
ganciclovir NN i
( ( p
1 CD p
g NN p
t.i.d. NN p
, , N
n=14 RB p
, , p
GAN NNP p
group NN p
) ) p
or CC p
oral JJ i
valacyclovir NN i
( ( p
2 CD p
g NN p
q.i.d. NN p
, , N
n=12 RB p
, , p
VAL NNP p
group NN p
) ) p
. . N

A DT N
third JJ N
group NN N
( ( N
C NNP N
, , N
n=12 NN N
) ) N
received VBD N
no DT i
prophylaxis NN i
. . i

The DT N
patients NNS N
were VBD N
monitored VBN N
by IN N
CMV-nested JJ N
PCR NNP N
in IN N
whole JJ N
blood NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
in IN N
their PRP$ N
demographic JJ N
characteristics NNS N
, , N
immunosuppressive JJ N
protocols NNS N
, , N
or CC N
donor NN N
and CC N
recipient NN N
CMV NNP N
serology NN N
. . N

Thirty-six CD N
out IN N
of IN N
38 CD N
( ( N
94.7 CD N
% NN N
) ) N
recipients NNS N
were VBD N
CMV-seropositive JJ o
. . o

Over IN N
the DT N
6-month JJ N
post-RTx JJ N
period NN N
, , N
there EX N
were VBD N
13 CD N
episodes NNS N
of IN N
CMV NNP o
disease NN N
in IN N
eight CD N
( ( N
66.7 CD N
% NN N
) ) N
patients NNS N
of IN N
the DT N
C NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
GAN NNP N
and CC N
VAL NNP N
groups NNS N
( ( N
P=0.0005 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
CMV NNP o
viremia NN o
was VBD N
30.8 CD N
% NN N
, , N
50.0 CD N
% NN N
, , N
and CC N
91.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.004 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.07 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
. . N

Treatment JJ o
failure NN o
( ( o
death NN o
, , o
graft NN o
loss NN o
, , o
CMV NNP o
disease NN o
, , o
or CC o
withdrawal NN o
from IN o
study NN o
) ) o
occurred VBD N
in IN N
14.3 CD N
% NN N
, , N
0 CD N
% NN N
and CC N
66.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.014 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
. . N

The DT N
average JJ o
CMV-associated JJ o
costs NNS o
per IN o
patient NN o
( ( N
in IN N
2001 CD N
euros NN N
) ) N
were VBD N
2,449+/-1,178 JJ N
, , N
2,485+/-581 JJ N
, , N
and CC N
4,259+/-4,616 JJ N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
. . N

Ganciclovir NNP N
and CC N
valacyclovir NN N
were VBD N
well RB o
tolerated VBN o
, , N
with IN N
ganciclovir JJ N
having VBG N
had VBD N
to TO N
be VB N
withdrawn VBN N
shortly RB N
in IN N
one CD N
patient NN N
only RB N
because IN N
of IN N
thrombocytopenia NN N
. . N

In IN N
conclusion NN N
, , N
oral JJ N
ganciclovir NN N
and CC N
valacyclovir NN N
are VBP N
equally RB o
safe JJ o
and CC o
effective JJ o
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
after IN N
RTx NNP N
. . N

Both DT N
are VBP N
cost-effective JJ o
and CC N
help VB N
reduce VB N
CMV-associated JJ o
costs NNS o
by IN N
some DT N
40 CD N
% NN N
compared VBN N
with IN N
patients NNS N
without IN N
prophylaxis NN N
. . N

-DOCSTART- -X- O O

Disparities NNS N
in IN N
transition NN i
planning NN i
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

OBJECTIVE NNP N
Little NNP N
is VBZ N
known VBN N
about IN N
accessibility NN N
to TO N
health NN i
care NN i
transition NN i
( ( i
HCT NNP i
) ) i
services NNS N
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

This DT N
study NN N
expands VBZ N
our PRP$ N
understanding JJ N
by IN N
examining VBG N
the DT N
receipt NN N
of IN N
HCT NNP N
services NNS N
in IN N
youth NN p
with IN p
ASD NNP p
compared VBN p
with IN p
youth NN p
with IN p
other JJ p
special JJ p
health NN p
care NN p
needs NNS p
( ( p
OSHCN NNP p
) ) p
. . p

METHODS NNP N
We PRP p
used VBD p
the DT p
2005-2006 JJ p
National NNP p
Survey NNP p
of IN p
Children NNP p
with IN p
Special NNP p
Health NNP p
Care NNP p
Needs NNP p
to TO p
examine VB p
receipt NN p
of IN p
HCT NNP i
services NNS i
for IN p
youth NN p
( ( p
aged VBN p
12-17 CD p
years NNS p
) ) p
with IN p
ASD NNP p
and CC p
youth NN p
with IN p
OSHCN NNP p
. . p

Logistic JJ N
regression NN N
analyses NNS N
explored VBD N
whether IN N
individual JJ N
, , N
family NN N
, , N
or CC N
health NN N
system NN N
factors NNS N
were VBD N
associated VBN N
with IN N
receipt NN N
of IN N
HCT NNP N
services NNS N
for IN N
youth NN N
with IN N
ASD NNP N
. . N

RESULTS NNP N
Whereas NNP N
half NN N
of IN N
youth NN N
with IN N
OSHCN NNP N
received VBD N
HCT NNP o
services NNS o
, , N
less JJR N
than IN N
a DT N
quarter NN N
of IN N
youth NN N
with IN N
ASD NNP N
did VBD N
. . N

Only RB N
14 CD N
% NN N
of IN N
youth NN N
with IN N
ASD NNP N
had VBD N
a DT N
discussion NN N
with IN N
their PRP$ N
pediatrician JJ N
about IN N
transitioning VBG N
to TO N
an DT N
adult NN N
provider NN N
, , N
less JJR N
than IN N
a DT N
quarter NN N
had VBD N
a DT N
discussion NN N
about IN N
health NN o
insurance NN o
retention NN o
, , N
and CC N
just RB N
under IN N
half NN N
discussed VBN N
adult NN o
health NN o
care NN o
needs NNS o
or CC o
were VBD o
encouraged VBN o
to TO o
take VB o
on IN o
appropriate JJ o
responsibility NN o
. . o

Logistic JJ N
regression NN N
analyses NNS N
indicated VBD N
that IN N
having VBG N
a DT N
developmental JJ N
disability NN N
or CC N
multiple JJ N
health NN N
conditions NNS N
in IN N
addition NN N
to TO N
ASD NNP N
and CC N
quality NN N
of IN N
health NN N
care NN N
were VBD N
strong JJ N
predictors NNS N
of IN N
HCT NNP o
, , N
whereas JJ N
demographic JJ N
and CC N
family NN N
variables NNS N
accounted VBD N
for IN N
little JJ N
variance NN N
. . N

CONCLUSIONS NNP N
Youth NNP p
with IN p
ASD NNP p
experience NN N
disparities NNS N
in IN N
access NN N
to TO N
HCT NNP i
services NNS N
. . N

Youth NN p
with IN p
comorbid JJ p
conditions NNS p
are VBP N
at IN N
greatest JJS N
risk NN N
for IN N
poor JJ N
access NN N
to TO N
HCT NNP i
services NNS N
and CC N
increased JJ N
quality NN N
of IN N
care NN N
has VBZ N
a DT N
positive JJ N
effect NN N
. . N

Research NNP N
is VBZ N
needed VBN N
to TO N
understand VB N
barriers NNS N
to TO N
care VB N
and CC N
develop VB N
policy NN N
and CC N
practice NN N
guidelines NNS N
tailored VBD N
for IN N
youth NN p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

A DT N
controlled VBN N
comparison NN N
between IN N
single JJ N
doses NNS N
of IN N
intravenous JJ i
and CC i
intramuscular JJ i
morphine NN i
with IN N
respect NN N
to TO N
analgesic JJ o
effects NNS o
and CC o
patient JJ o
safety NN o
. . o

UNLABELLED VBN N
BACKGROUND NNP N
AND NNP N
AIM NNP N
OF NNP N
INVESTIGATION NNP N
: : N
Intramuscular NNP N
( ( N
IM NNP N
) ) N
administration NN N
has VBZ N
been VBN N
considered VBN N
to TO N
be VB N
safer JJR N
than IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
for IN N
opioids NNS i
on IN N
wards NNS N
, , N
but CC N
a DT N
comparative JJ N
knowledge NN N
of IN N
patient JJ o
safety NN o
and CC o
analgesic JJ o
potency NN o
following VBG N
a DT N
single JJ N
dose NN N
of IN N
IV NNP N
and CC N
IM NNP N
administration NN N
is VBZ N
lacking VBG N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
compare VB N
patient JJ o
safety NN o
and CC o
analgesic JJ o
efficacy NN o
of IN N
a DT N
single JJ N
and CC N
high JJ N
dose NN N
of IN N
morphine NN i
given VBN i
IM NNP i
or CC i
IV NNP i
for IN N
post-operative JJ p
pain NN p
management NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Thirty-eight NNP p
patients NNS p
with IN p
post-operative JJ p
pain NN p
following VBG p
hip NN i
replacement NN i
surgery NN i
were VBD N
given VBN N
IM NNP i
or CC i
IV NNP i
morphine VBP i
10 CD N
mg NN N
at IN N
a DT N
specified JJ N
pain NN N
level NN N
. . N

The DT N
study NN N
was VBD N
randomized VBN N
and CC N
double JJ N
blinded VBN N
. . N

Time NN o
to TO o
onset VB o
of IN o
analgesic JJ o
effect NN o
( ( o
11-point JJ o
numeric NN o
rating NN o
scale NN o
) ) o
, , o
respiratory JJ o
function NN o
( ( o
p NN o
( ( o
a DT o
) ) o
CO2 NNP o
, , o
p NN o
( ( o
a DT o
) ) o
O2 NNP o
, , o
and CC o
respiratory JJ o
rate NN o
) ) o
, , o
level NN o
of IN o
sedation NN o
( ( o
5-point JJ o
verbal NN o
rating NN o
scale NN o
) ) o
, , o
and CC o
hemodynamic JJ o
function NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
In IN N
the DT N
IV NNP N
group NN N
there EX N
was VBD N
a DT N
slight JJ N
but CC N
significant JJ N
increase NN N
in IN N
p NN o
( ( o
a DT o
) ) o
CO2 NNP o
after IN N
5 CD N
, , N
10 CD N
, , N
and CC N
15 CD N
min NNS N
compared VBN N
with IN N
the DT N
IM NNP N
group NN N
( ( N
5.2 CD N
vs. FW N
4.8 CD N
, , N
5.4 CD N
, , N
vs. FW N
5.0 CD N
and CC N
5.5 CD N
vs. FW N
5.1 CD N
kPa NN N
, , N
respectively RB N
) ) N
. . N

The DT N
IV NNP N
group NN N
had VBD N
a DT N
significantly RB N
faster RBR N
onset NN o
of IN o
analgesic JJ o
effect NN o
than IN N
the DT N
IM NNP N
group NN N
( ( N
5 CD N
vs. FW N
20 CD N
min NN N
) ) N
. . N

Between $ N
5 CD N
and CC N
25 CD N
min NN N
after IN N
morphine JJ i
administration NN N
, , N
pain NN o
status NN o
in IN N
the DT N
IV NNP N
group NN N
was VBD N
significantly RB N
improved VBN N
compared VBN N
with IN N
the DT N
IM NNP N
group NN N
. . N

Patients NNS N
in IN N
the DT N
IV NNP N
group NN N
were VBD N
slightly RB N
more RBR N
sedated JJ o
than IN N
the DT N
IM NNP N
group NN N
5 CD N
and CC N
10 CD N
min NN N
after IN N
morphine NN N
. . N

CONCLUSION VB N
A DT N
10 CD N
mg NN N
bolus NN N
dose NN N
of IN N
IV NNP N
morphine NN N
given VBN N
to TO N
patients NNS N
with IN N
moderate JJ N
pain NN N
after IN N
surgery NN i
does VBZ N
not RB N
cause VB N
severe JJ o
respiratory NN o
depression NN o
, , N
but CC N
provides VBZ N
more RBR N
rapid JJ N
and CC N
better RBR N
initial JJ o
analgesia NN o
than IN N
10 CD N
mg NNS N
given VBN N
IM NNP N
. . N

IV NNP N
morphine VBD i
even RB N
at IN N
a DT N
dose NN N
as RB N
high JJ N
as IN N
10 CD N
mg NN N
IV NNP N
is VBZ N
well RB N
tolerated VBN o
if IN N
there EX N
is VBZ N
a DT N
certain JJ N
level NN N
of IN N
pain NN N
at IN N
its PRP$ N
administration NN N
. . N

The DT N
safety NN N
of IN N
IV NNP N
morphine NN i
on IN N
the DT N
general JJ N
ward NN N
needs VBZ N
to TO N
be VB N
further RB N
explored VBN N
in IN N
adequately RB N
controlled JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

Postoperative JJ o
pain NN o
control NN o
for IN N
outpatient JJ p
oral JJ p
surgery NN p
. . p

16 CD p
healthy JJ p
patients NNS p
requiring VBG p
removal NN p
of IN p
bilateral JJ p
symmetrically-impacted JJ p
mandibular JJ p
third JJ p
molars NNS p
participated VBD N
in IN N
a DT N
double-blind NN N
randomised VBN N
crossover RB N
trial NN N
to TO N
test VB N
the DT N
effectiveness NN o
of IN o
postoperative JJ o
pain NN o
control NN o
using VBG N
a DT N
long-acting JJ N
anti-inflammatory JJ N
agent NN N
( ( i
diflunisal NN i
) ) i
in IN N
combination NN N
with IN N
a DT N
long-acting JJ N
local JJ N
anaesthetic JJ N
agent NN N
( ( i
bupivacaine NN i
) ) i
. . N

Results NNS N
were VBD N
compared VBN N
to TO N
the DT N
more RBR N
traditional JJ N
method NN N
of IN N
using VBG N
an DT N
oral JJ N
analgesic NN N
with IN N
shorter JJR N
duration NN N
of IN N
action NN N
( ( i
paracetamol NN i
with IN i
codeine NN i
) ) i
with IN N
lignocaine NN i
as IN N
the DT N
local JJ N
anaesthetic NN N
. . N

Using VBG N
a DT N
visual JJ o
analogue NN o
pain NN o
scale NN o
, , N
patients NNS N
reported VBD N
that IN N
significantly RB N
reduced VBN N
pain NN o
was VBD N
experienced VBN N
over IN N
the DT N
first JJ N
4 CD N
days NNS N
postoperatively RB N
with IN N
the DT N
diflunisal/bupivacaine NN i
treatment NN i
and CC N
patient JJ o
preference NN o
for IN N
this DT N
treatment NN N
was VBD N
highly RB N
significant JJ N
. . N

This DT N
report NN N
represents VBZ N
the DT N
first JJ N
such JJ N
study NN N
of IN N
diflunisal NN i
used VBN N
for IN N
an DT N
extended JJ N
course NN N
in IN N
oral JJ N
surgery NN N
with IN N
pain NN o
assessment NN N
over IN N
the DT N
same JJ N
period NN N
. . N

No DT N
significant JJ N
side-effects NNS o
or CC o
adverse JJ o
reactions NNS o
were VBD N
encountered VBN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN i
carbasalate NN i
plus CC i
metoclopramide JJ i
versus NN i
ergotamine NN i
tartrate NN i
plus CC i
caffeine NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
migraine NN p
attacks NNS p
. . p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
multicenter NN p
, , N
parallel-group JJ N
study NN N
aimed VBN N
at IN N
comparing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
calcium NN i
carbasalate NN i
( ( i
equivalent JJ i
to TO i
900 CD i
mg NNS i
aspirin RB i
) ) i
plus CC i
metoclopramide $ i
10 CD i
mg NN i
( ( i
CM NNP i
) ) i
with IN i
ergotamine JJ i
tartrate NN i
1 CD i
mg NN i
plus CC i
caffeine JJ i
100 CD i
mg NN i
( ( i
EC NNP i
) ) i
administered VBN N
in IN N
the DT N
treatment NN N
of IN N
2 CD N
acute JJ N
migraine NN N
attacks NNS N
. . N

A DT N
total NN N
of IN N
296 CD p
patients NNS p
fulfilling VBG p
the DT p
International NNP p
Headache NNP p
Society NNP p
diagnostic JJ p
criteria NNS p
for IN p
migraine NN p
were VBD p
enrolled VBN p
. . p

In IN N
total JJ N
, , N
one CD N
or CC N
two CD N
migraine NN N
attacks NNS N
were VBD N
treated VBN N
in IN N
268 CD N
and CC N
235 CD N
patients NNS N
, , N
respectively RB N
. . N

The DT N
primary JJ N
endpoint NN N
for IN N
the DT N
first JJ N
treated VBD N
attack NN N
was VBD N
headache NN N
relief NN N
, , N
with IN N
intensity NN N
decreasing VBG N
from IN N
moderate JJ N
or CC N
severe JJ N
to TO N
mild VB N
or CC N
absent VB N
2 CD N
h NN N
after IN N
drug NN N
intake NN N
. . N

Usual JJ N
secondary JJ N
efficacy NN N
endpoints NNS N
were VBD N
assessed VBN N
. . N

A DT N
superiority NN N
of IN N
CM NNP i
over IN N
EC NNP i
was VBD N
observed VBN N
for IN N
both DT N
treated JJ N
attacks NNS N
for IN N
the DT N
main JJ N
endpoint NN N
: : N
success NN N
in IN N
54 CD N
versus NN N
36 CD N
% NN N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
the DT N
first JJ N
attack NN N
and CC N
60 CD N
versus NN N
44 CD N
% NN N
, , N
p NN N
= VBD N
0.02 CD N
for IN N
the DT N
second JJ N
attack NN N
. . N

CM NNP o
was VBD o
also RB o
significantly RB o
superior JJ o
to TO o
EC NNP o
during IN o
the DT o
first JJ o
attack NN o
for IN o
complete JJ o
headache NN o
relief NN o
( ( o
20 CD o
vs. FW o
8 CD o
% NN o
, , o
p NN o
= NNP o
0.006 CD o
) ) o
, , o
nausea NN o
( ( o
42 CD o
vs. FW o
63 CD o
% NN o
, , o
p NN o
= VBD o
0 CD o
. . o

007 CD o
) ) o
and CC o
willingness NN o
to TO o
take VB o
the DT o
drug NN o
again RB o
( ( o
90 CD o
vs. FW o
80 CD o
% NN o
, , o
p NN o
= NNP o
0.043 CD o
) ) o
. . o

The DT o
global JJ o
efficacy NN o
evaluation NN o
, , o
rated VBN o
by IN o
the DT o
investigators NNS o
, , o
was VBD o
significantly RB o
more RBR o
favorable JJ o
to TO o
CM NNP o
for IN o
both DT o
attacks NNS o
( ( o
p VB o
= $ o
0.001 CD o
for IN o
the DT o
first JJ o
attack NN o
and CC o
p NN o
= VBP o
0.02 CD o
for IN o
the DT o
second JJ o
) ) o
. . o

The DT o
patients NNS o
' POS o
evaluation NN o
was VBD o
significant JJ o
for IN o
the DT o
first JJ o
attack NN o
( ( o
p JJ o
= NNP o
0.002 CD o
) ) o
. . o

The DT o
global JJ o
incidence NN o
of IN o
adverse JJ o
events NNS o
was VBD o
45 CD o
% NN o
higher JJR o
with IN o
EC NNP o
, , o
though IN o
not RB o
significant JJ o
( ( o
32 CD o
vs. FW o
22 CD o
% NN o
, , o
p NN o
= NNP o
0.075 CD o
) ) o
. . o

They PRP o
were VBD o
most RBS o
often RB o
unspecific JJ o
and CC o
mild JJ o
to TO o
moderate VB o
in IN o
intensity NN o
. . o

Gastrointestinal JJ o
side NN o
effects NNS o
were VBD o
significantly RB o
less RBR o
frequent JJ o
with IN o
CM NNP o
than IN o
EC NNP o
( ( o
7 CD o
vs. FW o
21 CD o
% NN o
, , o
p NN o
= NNP o
0.001 CD o
) ) o
. . o

Thus RB o
, , o
CM NNP o
is VBZ o
more RBR o
effective JJ o
and CC o
has VBZ o
a DT o
better JJR o
gastrointestinal JJ o
safety NN o
than IN o
EC NNP o
in IN o
the DT o
acute JJ o
treatment NN o
of IN o
migraine NN o
attacks NNS o
. . o

-DOCSTART- -X- O O

Ropivacaine-clonidine JJ i
combination NN i
for IN N
caudal NN p
blockade NN p
in IN p
children NNS p
. . p

BACKGROUND NNP N
Adding NNP N
clonidine NN i
to TO N
weak JJ i
ropivacaine JJ i
solutions NNS i
( ( N
< VB N
0.2 CD N
% NN N
) ) N
could MD N
potentially RB N
enhance VB o
analgesia NN o
as RB N
well RB N
as IN N
further JJ N
reduce VB o
the DT o
risk NN o
for IN o
unwanted JJ o
motor NN o
blockade NN o
. . o

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
postoperative JJ N
pain-relieving JJ o
quality NN o
of IN N
a DT N
ropivacaine JJ i
0.1 CD i
% NN i
-clonidine JJ i
mixture NN i
to TO N
that DT N
of IN N
plain NN i
ropivacaine VBP i
0.2 CD N
% NN N
following VBG N
caudal JJ p
administration NN p
in IN p
children NNS p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
observer-blinded JJ N
fashion NN N
, , N
40 CD p
ASA NNP p
1 CD p
paediatric JJ p
patients NNS p
undergoing VBG p
subumbilical JJ p
surgery NN p
were VBD N
randomly RB i
allocated VBN i
to TO i
receive VB i
a DT i
caudal JJ i
injection NN i
of IN i
either DT i
plain NN i
ropivacaine VBP i
0.2 CD i
% NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.2 NNP i
) ) i
or CC i
a DT i
mixture NN i
of IN i
ropivacaine JJ i
0.1 CD i
% NN i
with IN i
clonidine JJ i
2 CD i
microg/kg NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.1C NNP i
) ) i
. . N

Objective JJ o
pain NN o
scale NN o
score NN o
and CC o
need NN o
for IN o
supplemental JJ o
analgesia NN o
were VBD i
used VBN i
to TO i
evaluate VB i
analgesia NN i
during IN i
the DT i
first JJ i
24 CD i
h NN i
postoperatively RB i
. . i

Residual JJ o
postoperative JJ o
sedation NN o
was VBD i
also RB i
assessed VBN i
. . i

RESULTS VB N
A DT N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
in IN N
the DT N
R0.1C NNP N
group NN N
( ( N
18/20 CD N
) ) N
could MD N
be VB N
managed VBN N
without IN N
supplemental JJ o
analgesia NN o
during IN N
the DT N
first JJ N
24 CD N
h NN N
postoperatively RB N
compared VBN N
to TO N
the DT N
R0.2 NNP N
group NN N
( ( N
11/20 CD N
) ) N
( ( N
P=0.034 NNP N
) ) N
. . N

Both CC N
the DT N
degree NN o
and CC o
the DT o
duration NN o
of IN o
postoperative JJ o
sedation NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
signs NNS N
of IN N
postoperative JJ o
motor NN o
blockade NN o
were VBD N
observed VBN N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
clonidine NN i
( ( i
2 CD i
microg/kg NN i
) ) i
and CC i
ropivacaine VB i
0.1 CD i
% NN i
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ o
quality NN o
of IN o
postoperative JJ o
analgesia NN o
compared VBN N
to TO N
plain VB i
0.2 CD i
% NN i
ropivacaine NN i
. . i

The DT N
improved JJ o
analgesic JJ o
quality NN o
of IN N
the DT N
clonidine-ropivacaine JJ N
mixture NN N
is VBZ N
achieved VBN N
without IN N
causing VBG N
any DT N
significant JJ N
degree NN N
of IN N
postoperative JJ N
sedation NN N
. . N

-DOCSTART- -X- O O

Peripheral JJ N
arterial JJ N
disease NN N
: : N
therapeutic JJ N
confidence NN N
of IN N
CT NNP i
versus NNP i
digital JJ i
subtraction NN i
angiography NN i
and CC N
effects NNS N
on IN N
additional JJ N
imaging NN N
recommendations NNS N
. . N

PURPOSE NNP N
To TO N
compare VB N
multi-detector JJ i
row NN i
computed VBN i
tomographic JJ i
( ( i
CT NNP i
) ) i
angiography NN i
and CC i
digital JJ i
subtraction NN i
angiography NN i
( ( i
DSA NNP i
) ) i
prior RB N
to TO N
revascularization NN i
in IN N
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
arterial JJ p
disease NN p
for IN N
the DT N
purpose NN N
of IN N
assessing VBG N
recommendations NNS N
for IN N
additional JJ N
imaging NN N
and CC N
physician JJ N
confidence NN N
ratings NNS N
for IN N
chosen NN N
therapy NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
73 CD p
patients NNS p
were VBD p
assigned VBN p
to TO p
CT NNP i
angiography NN i
, , p
and CC p
72 CD p
were VBD p
assigned VBN p
to TO p
DSA NNP i
. . i

Physician JJ o
confidence NN o
in IN o
the DT o
treatment NN o
decision NN o
was VBD N
measured VBN N
as IN N
a DT N
continuous JJ N
outcome NN N
on IN N
a DT N
scale NN N
of IN N
0-10 NNP N
( ( N
uncertain JJ N
to TO N
certain JJ N
) ) N
and CC N
as IN N
a DT N
dichotomous JJ o
outcome NN o
( ( N
further JJ N
imaging NN N
recommended VBD N
, , N
yes UH N
or CC N
no DT N
) ) N
. . N

Mean JJ o
confidence NN o
scores NNS o
and CC N
additional JJ o
imaging NN o
recommendations NNS o
were VBD N
compared VBN N
between IN N
CT NNP i
and CC i
DSA NNP i
groups NNS N
in IN N
an DT N
intention-to-diagnose-and-treat JJ N
analysis NN N
. . N

To TO N
detect VB N
trends NNS N
in IN N
confidence NN N
, , N
confidence NN N
scores NNS N
were VBD N
plotted VBN N
over IN N
time NN N
, , N
and CC N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
was VBD N
performed VBN N
. . N

To TO N
detect VB N
trends NNS N
in IN N
additional JJ o
imaging NN o
recommendations NNS o
, , N
logistic JJ N
regression NN N
analysis NN N
was VBD N
used VBN N
. . N

Data NNS N
from IN N
eligible JJ N
nonrandomized JJ N
patients NNS N
were VBD N
analyzed VBN N
separately RB N
. . N

RESULTS NNP N
No NNP o
statistically RB o
significant JJ o
difference NN o
in IN N
baseline NN N
characteristics NNS N
between IN N
randomized VBN N
groups NNS N
was VBD N
found VBN N
. . N

CT NNP i
had VBD N
a DT N
lower JJR o
confidence NN o
score JJR o
than IN N
did VBD N
DSA NNP i
( ( N
7.2 CD N
vs NN N
8.2 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Further JJ N
imaging NN N
was VBD N
recommended VBN N
more RBR N
often RB N
after IN N
CT NNP i
( ( N
25 CD N
of IN N
71 CD N
patients NNS N
, , N
35 CD N
% NN N
) ) N
than IN N
after IN N
DSA NNP i
( ( N
nine CD N
of IN N
66 CD N
patients NNS N
, , N
14 CD N
% NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Analysis NN N
of IN N
trends NNS N
demonstrated VBN N
increasing VBG N
( ( N
but CC N
not RB N
statistically RB N
significant JJ N
) ) N
confidence NN o
in IN N
CT NNP i
and CC N
stable JJ N
confidence NN o
in IN N
DSA NNP i
. . i

No NNP o
significant JJ o
difference NN o
was VBD N
found VBN N
in IN N
baseline NN N
characteristics NNS N
between IN N
randomized VBN N
and CC N
nonrandomized JJ N
patients NNS N
. . N

Among IN N
nonrandomized JJ N
patients NNS N
, , N
no DT N
significant JJ N
difference NN N
in IN N
mean JJ o
confidence NN o
score NN o
( ( N
8.2 CD N
vs NN N
8.3 CD N
, , N
P NNP N
= NNP N
.26 NNP N
) ) N
was VBD N
found VBN N
between IN N
CT NNP i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
and CC N
DSA NNP i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
. . N

CONCLUSION NN N
With IN N
CT NNP i
angiography NN i
, , N
physician JJ N
confidence NN N
decreases NNS N
with IN N
an DT N
associated JJ N
increase NN N
in IN N
additional JJ N
imaging NN N
prior RB N
to TO N
revascularization NN N
in IN N
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
arterial JJ p
disease NN p
. . p

Given VBN N
that IN N
CT NNP i
is VBZ N
less RBR N
invasive JJ N
than IN N
DSA NNP i
, , N
results NNS N
suggest VBP N
that IN N
CT NNP i
may MD N
replace VB N
DSA NNP i
in IN N
selected VBN N
cases NNS N
. . N

-DOCSTART- -X- O O

Afatinib NNP i
versus NN N
cisplatin-based JJ i
chemotherapy NN i
for IN p
EGFR NNP p
mutation-positive JJ p
lung NN p
adenocarcinoma NN p
( ( p
LUX-Lung JJ p
3 CD p
and CC p
LUX-Lung NNP p
6 CD p
) ) p
: : p
analysis NN N
of IN N
overall JJ o
survival NN o
data NNS N
from IN N
two CD N
randomised VBD N
, , N
phase NN N
3 CD N
trials NNS N
. . N

BACKGROUND IN N
We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
afatinib NN i
on IN N
overall JJ o
survival NN o
of IN N
patients NNS p
with IN p
EGFR NNP p
mutation-positive JJ p
lung NN p
adenocarcinoma NN p
through IN N
an DT N
analysis NN N
of IN N
data NNS N
from IN N
two CD N
open-label JJ N
, , N
randomised VBN N
, , N
phase VB N
3 CD N
trials NNS N
. . N

METHODS NNP N
Previously RB p
untreated VBD p
patients NNS p
with IN p
EGFR NNP p
mutation-positive JJ p
stage NN p
IIIB NNP p
or CC p
IV NNP p
lung NN p
adenocarcinoma NN p
were VBD p
enrolled VBN p
in IN p
LUX-Lung NNP i
3 CD i
( ( p
n=345 NN p
) ) p
and CC p
LUX-Lung JJ i
6 CD i
( ( p
n=364 NN p
) ) p
. . p

These DT N
patients NNS N
were VBD N
randomly RB i
assigned VBN i
in IN i
a DT i
2:1 CD i
ratio NN i
to TO i
receive VB i
afatinib NN i
or CC i
chemotherapy NN i
( ( i
pemetrexed-cisplatin JJ i
[ NNP i
LUX-Lung NNP i
3 CD i
] NN i
or CC i
gemcitabine-cisplatin JJ i
[ JJ i
LUX-Lung NNP i
6 CD i
] NN i
) ) i
, , i
stratified VBN i
by IN i
EGFR NNP i
mutation NN i
( ( i
exon JJ i
19 CD i
deletion NN i
[ NNP i
del19 NN i
] NNP i
, , i
Leu858Arg NNP i
, , i
or CC i
other JJ i
) ) i
and CC i
ethnic JJ i
origin NN i
( ( i
LUX-Lung NNP i
3 CD i
only RB i
) ) i
. . i

We PRP N
planned VBD N
analyses NNS N
of IN N
mature NN N
overall JJ N
survival NN N
data NNS N
in IN N
the DT N
intention-to-treat JJ N
population NN p
after IN N
209 CD N
( ( N
LUX-Lung NNP N
3 CD N
) ) N
and CC N
237 CD N
( ( N
LUX-Lung NNP N
6 CD N
) ) N
deaths NNS N
. . N

These DT N
ongoing JJ N
studies NNS N
are VBP N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
numbers NNS N
NCT00949650 NNP N
and CC N
NCT01121393 NNP N
. . N

FINDINGS NNP N
Median JJ N
follow-up NN N
in IN N
LUX-Lung NNP N
3 CD N
was VBD N
41 CD N
months NNS N
( ( N
IQR NNP N
35-44 NNP N
) ) N
; : N
213 CD N
( ( N
62 CD N
% NN N
) ) N
of IN N
345 CD p
patients NNS p
had VBD N
died VBN N
. . N

Median JJ N
follow-up NN N
in IN N
LUX-Lung NNP N
6 CD N
was VBD N
33 CD N
months NNS N
( ( N
IQR NNP N
31-37 NNP N
) ) N
; : N
246 CD N
( ( N
68 CD N
% NN N
) ) N
of IN N
364 CD N
patients NNS N
had VBD N
died VBN N
. . N

In IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
28.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.6-33.6 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
and CC N
28.2 CD N
months NNS N
( ( N
20.7-33.2 JJ N
) ) N
in IN N
the DT N
pemetrexed-cisplatin JJ N
group NN N
( ( N
HR NNP N
0.88 CD N
, , N
95 CD N
% NN N
CI NNP N
0.66-1.17 CD N
, , N
p=0.39 NN N
) ) N
. . N

In IN N
LUX-Lung NNP N
6 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
23.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
20.4-27.3 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
and CC N
23.5 CD N
months NNS N
( ( N
18.0-25.6 JJ N
) ) N
in IN N
the DT N
gemcitabine-cisplatin JJ N
group NN N
( ( N
HR NNP N
0.93 CD N
, , N
95 CD N
% NN N
CI NNP N
0.72-1.22 CD N
, , N
p=0.61 NN N
) ) N
. . N

However RB N
, , N
in IN N
preplanned JJ N
analyses NNS N
, , N
overall JJ o
survival NN o
was VBD N
significantly RB N
longer JJR N
for IN N
patients NNS N
with IN N
del19-positive JJ N
tumours NNS N
in IN N
the DT N
afatinib NN N
group NN N
than IN N
in IN N
the DT N
chemotherapy NN N
group NN N
in IN N
both DT N
trials NNS N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
33.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
26.8-41.5 CD N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
21.1 CD N
months NNS N
( ( N
16.3-30.7 JJ N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
0.36-0.79 CD N
, , N
p=0.0015 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
31.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
24.2-35.3 CD N
) ) N
versus NN N
18.4 CD N
months NNS N
( ( N
14.6-25.6 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
0.64 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.94 CD N
, , N
p=0.023 NN N
) ) N
. . N

By IN N
contrast NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
by IN N
treatment NN N
group NN N
for IN N
patients NNS p
with IN p
EGFR NNP p
Leu858Arg-positive JJ N
tumours NNS N
in IN N
either DT N
trial NN N
: : N
in IN N
LUX-Lung NNP N
3 CD N
, , N
median JJ N
overall JJ o
survival NN o
was VBD N
27.6 CD N
months NNS N
( ( N
19.8-41.7 JJ N
) ) N
in IN N
the DT N
afatinib NN N
group NN N
versus VBD N
40.3 CD N
months NNS N
( ( N
24.3-not JJ N
estimable NN N
) ) N
in IN N
the DT N
chemotherapy NN N
group NN N
( ( N
HR NNP N
1.30 CD N
, , N
95 CD N
% NN N
CI NNP N
0.80-2.11 CD N
, , N
p=0.29 NN N
) ) N
; : N
in IN N
LUX-Lung NNP N
6 CD N
, , N
it PRP N
was VBD N
19.6 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
17.0-22.1 CD N
) ) N
versus NN N
24.3 CD N
months NNS N
( ( N
19.0-27.0 JJ N
) ) N
, , N
respectively RB N
( ( N
HR NNP N
1.22 CD N
, , N
95 CD N
% NN N
CI NNP N
0.81-1.83 CD N
, , N
p=0.34 NN N
) ) N
. . N

In IN N
both DT N
trials NNS N
, , N
the DT N
most RBS N
common JJ N
afatinib-related JJ N
grade JJ o
3-4 JJ o
adverse JJ o
events NNS o
were VBD N
rash JJ o
or CC o
acne NN o
( ( N
37 CD N
[ RB N
16 CD N
% NN N
] NN N
of IN N
229 CD p
patients NNS p
in IN p
LUX-Lung NNP p
3 CD p
and CC N
35 CD N
[ JJ N
15 CD N
% NN N
] NN N
of IN N
239 CD p
patients NNS p
in IN p
LUX-Lung NNP p
6 CD N
) ) N
, , N
diarrhoea NN o
( ( N
33 CD N
[ RB N
14 CD N
% NN N
] NN N
and CC N
13 CD N
[ JJ N
5 CD N
% NN N
] NN N
) ) N
, , N
paronychia FW o
( ( N
26 CD N
[ RB N
11 CD N
% NN N
] NN N
in IN N
LUX-Lung NNP N
3 CD N
only RB N
) ) N
, , N
and CC N
stomatitis NN o
or CC o
mucositis NN o
( ( N
13 CD N
[ RB N
5 CD N
% NN N
] NN N
in IN N
LUX-Lung NNP N
6 CD N
only RB N
) ) N
. . N

In IN N
LUX-Lung NNP N
3 CD N
, , N
neutropenia NN o
( ( N
20 CD N
[ RB N
18 CD N
% NN N
] NN N
of IN N
111 CD N
patients NNS N
) ) N
, , N
fatigue NN o
( ( N
14 CD N
[ RB N
13 CD N
% NN N
] NN N
) ) N
and CC N
leucopenia $ o
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
were VBD N
the DT N
most RBS N
common JJ N
chemotherapy-related JJ N
grade JJ N
3-4 JJ N
adverse JJ N
events NNS N
, , N
while IN N
in IN N
LUX-Lung NNP N
6 CD N
, , N
the DT N
most RBS N
common JJ N
chemotherapy-related JJ N
grade JJ o
3-4 JJ o
adverse JJ o
events NNS o
were VBD N
neutropenia RB o
( ( N
30 CD N
[ RB N
27 CD N
% NN N
] NN N
of IN N
113 CD N
patients NNS N
) ) N
, , N
vomiting VBG o
( ( N
22 CD N
[ RB N
19 CD N
% NN N
] NN N
) ) N
, , N
and CC N
leucopenia NN o
( ( N
17 CD N
[ RB N
15 CD N
% NN N
] NN N
) ) N
. . N

INTERPRETATION NNP N
Although IN N
afatinib NN N
did VBD N
not RB N
improve VB N
overall JJ N
survival NN N
in IN N
the DT N
whole JJ N
population NN N
of IN N
either DT N
trial NN N
, , N
overall JJ N
survival NN N
was VBD N
improved VBN N
with IN N
the DT N
drug NN N
for IN N
patients NNS p
with IN p
del19 JJ p
EGFR NNP p
mutations NNS p
. . p

The DT N
absence NN N
of IN N
an DT N
effect NN N
in IN N
patients NNS p
with IN p
Leu858Arg NNP p
EGFR NNP p
mutations NNS p
suggests VBZ N
that IN N
EGFR NNP N
del19-positive JJ N
disease NN N
might MD N
be VB N
distinct JJ N
from IN N
Leu858Arg-positive JJ N
disease NN N
and CC N
that IN N
these DT N
subgroups NNS N
should MD N
be VB N
analysed VBN N
separately RB N
in IN N
future JJ N
trials NNS N
. . N

FUNDING NN N
Boehringer NNP N
Ingelheim NNP N
. . N

-DOCSTART- -X- O O

[ JJ i
Prognostic NNP i
experiences NNS i
in IN N
the DT N
long-term JJ i
differential JJ i
therapy NN i
of IN N
chronic JJ p
aggressive JJ p
hepatitides NNS p
] VBP p
. . N

-DOCSTART- -X- O O

Adult NNP p
height NN p
in IN p
short JJ p
children NNS p
born VBN p
SGA NNP p
treated VBD p
with IN p
growth NN i
hormone NN i
and CC i
gonadotropin NN i
releasing VBG i
hormone NN i
analog NN i
: : i
results NNS N
of IN N
a DT N
randomized JJ N
, , N
dose-response JJ N
GH NNP i
trial NN N
. . N

CONTEXT NNP N
GH NNP i
treatment NN i
is VBZ N
effective JJ N
in IN N
improving VBG N
height NN N
in IN N
short JJ p
children NNS p
born VBP p
small JJ p
for IN p
gestational JJ p
age NN p
( ( p
SGA NNP p
) ) p
. . p

GH NNP i
is VBZ N
thought VBN N
to TO N
have VB N
limited VBN N
effect NN N
when WRB N
started VBD N
during IN N
adolescence NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
GH NNP i
treatment NN i
efficacy NN o
in IN N
short JJ N
SGA NNP N
children NNS N
when WRB N
treatment NN N
was VBD N
started VBN N
during IN N
adolescence NN N
; : N
to TO N
assess VB N
whether IN N
GH NNP i
2 CD i
mg/m NN i
( ( i
2 CD i
) ) i
? . N
d NN N
during IN N
puberty JJ N
improves NNS o
adult VBP o
height NN o
( ( o
AH NNP o
) ) o
compared VBN N
with IN N
1 CD N
mg/m NNS N
( ( N
2 CD N
) ) N
? . N
d NN N
; : N
and CC N
to TO N
assess VB N
whether IN N
an DT N
additional JJ N
2-yr JJ N
postponement NN N
of IN N
puberty NN N
by IN N
GnRH NNP i
analog NN i
( ( i
GnRHa NNP i
) ) i
improves VBZ i
AH NNP N
in IN N
children NNS N
who WP N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
( ( N
< JJ N
140 CD N
cm NN N
) ) N
, , N
with IN N
a DT N
poor JJ N
AH NNP N
expectation NN p
. . p

PATIENTS NNP N
AND CC N
DESIGN NNP N
In IN N
this DT N
longitudinal JJ N
, , N
randomized VBN N
, , N
dose-response JJ N
GH NNP N
trial NN N
, , N
we PRP N
included VBD p
121 CD p
short JJ p
SGA NNP p
children NNS p
( ( p
60 CD p
boys NNS p
) ) p
at IN p
least JJS p
8 CD p
yr NN p
of IN p
age NN p
. . p

We PRP N
performed VBD p
intention-to-treat JJ p
analyses NNS p
on IN p
all DT p
children NNS p
and CC p
uncensored JJ p
case NN p
analyses VBZ p
on IN p
84 CD p
children NNS p
who WP p
reached VBD p
AH NNP p
. . p

Besides NNP N
, , N
we PRP N
evaluated VBD o
growth NN o
during IN o
2 CD N
yr NNS N
of IN N
combined JJ i
GH/GnRHa NNP i
and CC i
subsequent JJ i
GH NNP i
treatment NN i
until IN i
AH NNP N
in IN N
a DT N
subgroup NN N
of IN N
40 CD N
pubertal JJ N
children NNS N
with IN N
a DT N
height NN N
of IN N
less JJR N
than IN N
140 CD N
cm NN N
at IN N
the DT N
start NN N
. . N

RESULTS NNP p
Short NNP p
SGA NNP p
children NNS p
started VBD p
treatment NN N
at IN N
a DT N
median JJ N
age NN N
of IN N
11.2 CD N
yr NNS N
, , N
when WRB N
46 CD N
% NN N
had VBD N
already RB N
started VBN N
puberty NN o
. . o

Median JJ o
height NN o
increased VBD o
from IN N
-2.9 NN N
at IN N
start NN N
to TO N
-1.7 VB N
sd NN N
score NN N
( ( N
SDS NNP N
) ) N
at IN N
AH NNP N
( ( N
P NNP N
< NNP N
0.001 CD i
) ) i
. . i

Treatment NN i
with IN i
GH NNP i
2 CD i
vs. FW N
1 CD N
mg/m NN N
( ( N
2 CD N
) ) N
? . N
d NN N
during IN N
puberty NN N
resulted VBD N
in IN N
significantly RB N
better JJR o
AH NNP o
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
also RB N
after IN N
correction NN N
for IN N
gender NN N
, , N
age NN N
at IN N
start NN N
, , N
height VBD N
SDS NNP N
at IN N
start NN N
, , N
treatment NN N
years NNS N
before IN N
puberty NN N
, , N
and CC N
target VB N
height JJ N
SDS NNP N
. . o

AH NNP o
was VBD N
similar JJ N
in IN N
children NNS N
who WP N
started VBD N
puberty NN N
at IN N
less JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD i
GH/GnRHa NNP i
, , i
compared VBN i
with IN N
children NNS N
who WP N
started VBD N
puberty NN N
greater JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD i
GH NNP i
only RB i
( ( i
P NNP i
= NNP N
0.795 CD N
) ) N
. . N

CONCLUSION NN N
When WRB N
started VBN N
in IN N
adolescence NN i
, , i
GH NNP i
treatment NN i
significantly RB i
improves VBZ o
AH NNP o
in IN N
short JJ p
SGA NNP p
children NNS p
, , p
particularly RB p
with IN i
GH NNP i
2 CD p
mg/m NN p
( ( p
2 CD p
) ) p
? . p
d NN p
during IN p
puberty NN p
. . p

When WRB p
SGA NNP N
children NNS N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
, , N
they PRP N
can MD N
benefit VB N
from IN N
combined JJ i
GH/GnRHa NNP i
treatment NN i
. . i

-DOCSTART- -X- O O

The DT N
11-beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
inhibitor NN N
INCB13739 NNP i
improves VBZ N
hyperglycemia NN o
in IN p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
inadequately RB p
controlled VBN p
by IN p
metformin NN p
monotherapy NN p
. . p

OBJECTIVE CC N
11-Beta-hydroxysteroid JJ N
dehydrogenase NN N
type NN N
1 CD N
( ( N
11betaHSD1 CD N
) ) N
converts NNS N
inactive JJ N
cortisone NN N
into IN N
active JJ N
cortisol NN N
, , N
thereby RB N
amplifying VBG N
intracellular JJ N
glucocorticoid JJ N
action NN N
. . N

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
the DT N
11betaHSD1 CD N
inhibitor NN N
INCB13739 NNP N
were VBD N
assessed VBN N
when WRB N
added VBN N
to TO N
ongoing VBG N
metformin NN N
monotherapy NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
exhibiting VBG p
inadequate JJ p
glycemic NNS p
control NN p
( ( p
A1C NNP p
7-11 CD p
% NN p
) ) p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
double-blind JJ N
placebo-controlled JJ i
paralleled VBN N
study NN N
randomized VBD N
302 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
( ( p
mean JJ p
A1C NNP p
8.3 CD p
% NN p
) ) p
on IN p
metformin NN i
monotherapy NN i
( ( p
mean JJ p
1.5 CD p
g/day NN p
) ) p
to TO N
receive VB N
one CD N
of IN N
five CD N
INCB13739 NNP i
doses NNS i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
change NN o
in IN o
A1C NNP o
at IN o
study JJ o
end NN o
. . o

Other JJ N
end NN N
points NNS N
included VBD N
changes NNS o
in IN o
fasting VBG o
glucose NN o
, , o
lipids NNS o
, , o
weight NN o
, , o
adverse JJ o
events NNS o
, , o
and CC o
safety NN o
. . o

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
, , N
200 CD N
mg NN N
of IN N
INCB13739 NNP N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
A1C NNP o
( ( N
-0.6 NNP N
% NN N
) ) N
, , N
fasting VBG o
plasma NN o
glucose NN o
( ( N
-24 NNP N
mg/dl NN N
) ) N
, , N
and CC N
homeostasis NN o
model NN o
assessment-insulin JJ o
resistance NN o
( ( N
HOMA-IR NNP N
) ) N
( ( N
-24 CD N
% NN N
) ) N
compared VBN N
with IN N
placebo NN N
. . N

Total JJ o
cholesterol NN o
, , o
LDL NNP o
cholesterol NN o
, , o
and CC o
triglycerides NNS o
were VBD N
all DT N
significantly RB N
decreased VBN N
in IN N
hyperlipidemic JJ N
patients NNS N
. . N

Body NNP o
weight VBD o
decreased JJ N
relative NN N
to TO N
placebo VB N
after IN N
INCB13739 NNP N
therapy NN N
. . N

A DT N
reversible JJ N
dose-dependent JJ N
elevation NN N
in IN N
adrenocorticotrophic JJ o
hormone NN o
, , N
generally RB N
within IN N
the DT N
normal JJ N
reference NN N
range NN N
, , N
was VBD N
observed VBN N
. . N

Basal NNP o
cortisol JJ o
homeostasis NN o
, , o
testosterone NN o
in IN o
men NNS o
, , o
and CC o
free JJ o
androgen NN o
index NN o
in IN o
women NNS o
were VBD N
unchanged JJ N
by IN N
INCB13739 NNP N
. . N

Adverse JJ N
events NNS N
were VBD N
similar JJ N
across IN N
all DT N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
INCB13739 NNP N
added VBD N
to TO N
ongoing VBG N
metformin NN N
therapy NN N
was VBD N
efficacious JJ o
and CC N
well RB N
tolerated VBN o
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
who WP p
had VBD p
inadequate JJ p
glycemic NNS p
control NN p
with IN p
metformin NN p
alone RB p
. . p

11BetaHSD1 CD N
inhibition NN N
offers NNS N
a DT N
new JJ N
potential JJ N
approach NN N
to TO N
control VB N
glucose JJ o
and CC o
cardiovascular JJ o
risk NN o
factors NNS o
in IN N
type NN p
2 CD p
diabetes NNS p
. . p

-DOCSTART- -X- O O

Long-term JJ N
follow-up NN N
of IN N
a DT N
phase NN N
I/II NNP N
randomized VBD N
, , N
placebo-controlled JJ i
trial NN N
of IN N
palifermin NN i
to TO N
prevent VB N
graft-versus-host JJ p
disease NN p
( ( p
GVHD NNP p
) ) p
after IN p
related VBN p
donor NN p
allogeneic NN p
hematopoietic JJ p
cell NN p
transplantation NN p
( ( p
HCT NNP p
) ) p
. . p

We PRP N
previously RB N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN p
conducted VBN p
from IN p
2000 CD p
to TO p
2003 CD p
of IN p
palifermin NN i
, , p
a DT p
recombinant JJ p
human JJ p
keratinocyte NN p
growth NN p
factor NN p
, , p
dosed VBN p
from IN p
240 CD p
microg/kg NNS p
to TO p
720 CD p
microg/kg NN p
, , p
in IN p
100 CD p
allogeneic JJ p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
HCT NNP p
) ) p
recipients NNS p
. . p

Treatment NN N
with IN N
palifermin NN i
showed VBD N
beneficial JJ N
effects NNS o
on IN N
mucositis NN o
, , o
but CC o
no DT o
significant JJ o
effect NN o
on IN o
engraftment NN o
, , o
acute JJ o
graft-versus-host JJ o
disease NN o
( ( o
GVHD NNP o
) ) o
, , o
or CC o
early JJ o
survival NN o
. . o

In IN N
addition NN N
to TO N
the DT N
effect NN N
of IN N
palifermin NN i
on IN N
mucosa NN o
, , o
other JJ o
pleotrophic JJ o
effects NNS o
, , o
including VBG o
more RBR o
rapid JJ o
immune JJ o
reconstitution NN o
, , N
have VBP N
been VBN N
seen VBN N
in IN N
experimental JJ N
transplant NN N
models NNS N
. . N

Therefore RB N
, , N
we PRP N
investigated VBD N
whether IN N
with IN N
longer JJR N
follow-up NN N
we PRP N
could MD N
detect VB N
additional JJ o
differences NNS o
between IN N
the DT N
palifermin-treated JJ i
and CC N
placebo JJ i
cohorts NNS N
. . N

We PRP N
found VBD N
no DT N
differences NNS N
in IN N
CMV NNP o
or CC o
invasive JJ o
fungal JJ o
infections NNS o
, , o
chronic JJ o
GVHD NNP o
, , o
or CC o
long-term JJ o
survival NN o
between IN N
cohorts NNS N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
benefits NNS N
of IN N
palifermin NN i
appear VBP N
primarily RB N
to TO N
be VB N
limited VBN N
to TO N
ameliorating VBG N
mucotoxicity NN o
when WRB N
given VBN N
to TO N
allogeneic VB p
HCT NNP p
recipients NNS p
. . p

-DOCSTART- -X- O O

Early RB N
versus NN N
late JJ N
hCG NN i
administration NN i
to TO N
trigger VB N
ovulation NN N
in IN N
mild NN N
stimulated VBN N
IUI NNP N
cycles NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
verify VB N
non-inferiority NN N
of IN N
the DT N
clinical JJ N
pregnancy NN N
rate NN N
of IN N
Early NNP i
hCG NN i
administration NN i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
16.0-16.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
compared VBN N
to TO N
Late NNP i
hCG NN i
administration NN i
( ( N
leading VBG N
follicle NN N
sizes NNS N
within IN N
18.0-18.9 JJ N
mm NN N
in IN N
diameter NN N
) ) N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
randomized VBD N
trial NN N
. . N

Six CD p
hundred CD p
and CC p
twelve VB p
infertile JJ p
women NNS p
candidates NNS p
for IN p
intrauterine JJ p
insemination NN p
( ( p
IUI NNP p
) ) p
received VBD N
HP-hMG JJ i
75 CD N
IU/day NNP N
SC NNP N
from IN N
cycle NN N
days NNS N
4 CD N
to TO N
8 CD N
and CC N
then RB N
as IN N
per IN N
ovarian JJ N
response NN N
. . N

Ovulation NN N
was VBD N
randomly RB N
triggered VBN N
( ( N
hCG JJ N
5000 CD N
IU NNP N
, , N
IM NNP N
) ) N
when WRB N
the DT N
leading VBG N
follicle NN N
diameter NN N
ranged VBD N
between IN N
either CC N
16.0 CD N
and CC N
16.9 CD N
mm NN N
( ( N
Early JJ N
hCG NN i
group NN N
, , N
n=227 RB N
) ) N
or CC N
18.0 CD N
and CC N
18.9 CD N
mm NNS N
( ( N
Late JJ N
hCG NN N
group NN N
, , N
n=207 NN N
) ) N
and CC N
IUI NNP N
was VBD N
performed VBN N
approximately RB N
36 CD N
h NN N
later RB N
. . N

RESULTS NNP N
Whereas NNP N
population NN o
and CC o
sperm JJ o
characteristics NNS o
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
, , N
the DT N
number NN o
of IN o
follicles NNS o
? . N
14 CD N
mm NN N
in IN N
diameter NN N
( ( N
P NNP N
< NNP N
0.007 CD N
) ) N
and CC o
serum JJ o
estradiol NN o
levels NNS o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
on IN N
the DT N
day NN N
of IN N
hCG NN i
were VBD i
lower JJR N
in IN N
the DT N
Early JJ N
versus NN N
the DT N
Late NNP i
hCG NN i
groups NNS i
. . N

Clinical NNP N
( ( N
11.9 CD N
% NN N
versus IN N
12.1 CD N
% NN N
) ) N
and CC N
ongoing VBG N
( ( N
11.0 CD N
% NN N
versus IN N
8.6 CD o
% NN o
) ) o
pregnancy NN o
rates NNS o
per IN o
randomized VBN p
women NNS p
were VBD p
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
and CC N
statistical JJ N
non-inferiority NN N
of IN N
clinical JJ o
and CC o
ongoing JJ o
pregnancy NN o
rates NNS o
was VBD N
demonstrated VBN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN i
hCG NN i
administered VBD i
when WRB N
the DT N
largest JJS N
follicle NN N
size NN N
reaches VBZ N
16.0-16.9 JJ N
mm NN N
leads VBZ N
to TO N
similar JJ N
clinical JJ N
and CC N
ongoing JJ N
pregnancy NN N
rates NNS N
as IN N
when WRB N
it PRP N
reaches VBZ N
18.0-18.9 JJ N
mm NN N
in IN N
IUI NNP N
cycles NNS N
. . N

-DOCSTART- -X- O O

Avatar NNP N
assistant NN N
: : N
improving VBG N
social JJ o
skills NNS o
in IN N
students NNS p
with IN p
an DT p
ASD NNP p
through IN N
a DT N
computer-based JJ i
intervention NN i
. . i

This DT N
study NN N
assessed VBD N
the DT N
efficacy NN o
of IN N
FaceSay NNP i
, , i
a DT i
computer-based JJ i
social JJ o
skills NNS o
training VBG i
program NN i
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

This DT N
randomized VBD N
controlled VBN N
study NN p
( ( p
N NNP p
= NNP p
49 CD p
) ) p
indicates VBZ p
that IN N
providing VBG p
children NNS p
with IN p
low-functioning JJ p
autism NN p
( ( p
LFA NNP p
) ) p
and CC p
high JJ p
functioning NN p
autism NN p
( ( p
HFA NNP p
) ) p
opportunities VBZ p
to TO N
practice NN N
attending VBG N
to TO N
eye NN N
gaze NN N
, , N
discriminating VBG N
facial JJ N
expressions NNS N
and CC N
recognizing VBG N
faces VBZ N
and CC N
emotions NNS N
in IN N
FaceSay NNP N
's POS N
structured JJ N
environment NN N
with IN N
interactive JJ N
, , N
realistic JJ N
avatar NN N
assistants NNS N
improved VBD N
their PRP$ o
social JJ o
skills NNS o
abilities NNS o
. . o

The DT N
children NNS N
with IN N
LFA NNP N
demonstrated VBD N
improvements NNS N
in IN N
two CD N
areas NNS N
of IN N
the DT N
intervention NN o
: : o
emotion NN o
recognition NN o
and CC o
social JJ o
interactions NNS o
. . o

The DT N
children NNS N
with IN N
HFA NNP N
demonstrated VBD N
improvements NNS N
in IN N
all DT N
three CD N
areas NNS o
: : o
facial JJ o
recognition NN o
, , o
emotion NN o
recognition NN o
, , o
and CC o
social JJ o
interactions NNS o
. . o

These DT N
findings NNS N
, , N
particularly RB N
the DT N
measured JJ N
improvements NNS N
to TO N
social JJ o
interactions NNS o
in IN o
a DT N
natural JJ N
environment NN N
, , N
are VBP N
encouraging VBG N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
physical JJ i
and CC i
emotional JJ i
status NN i
on IN N
adherence NN N
to TO N
a DT N
low-fat JJ i
dietary JJ i
pattern NN i
in IN N
the DT N
Women NNP N
's POS N
Health NNP N
Initiative NNP N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
whether IN N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
adherance NN N
to TO N
a DT N
low-fat JJ i
( ( i
20 CD i
% NN i
energy NN i
) ) i
dietary JJ i
pattern NN i
are VBP N
mediated VBN N
by IN N
participation NN N
in IN N
an DT N
intervention NN i
program NN i
( ( i
attending VBG i
sessions NNS i
and CC i
self-monitoring NN i
) ) i
. . i

DESIGN VB N
The DT N
Baron NNP N
and CC N
Kenny NNP N
mediator NN N
model NN N
, , N
a DT N
series NN N
of IN N
4 CD N
regression NN N
analyses NNS N
, , N
was VBD N
used VBN N
to TO N
evaluate VB N
whether IN N
: : N
a DT N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
predicted VBD N
program NN N
participation NN N
, , N
b NN N
) ) N
program NN N
participation NN N
predicted VBD N
dietary JJ N
adherence NN N
, , N
c NN N
) ) N
physical JJ N
and CC N
emotional JJ N
status NN N
factors NNS N
predicted VBD N
dietary JJ i
adherence NN i
, , N
and CC N
, , N
ultimately RB N
d NN N
) ) N
the DT N
effects NNS N
of IN N
physical JJ N
and CC N
emotional JJ N
status NN N
on IN N
dietary JJ N
adherence NN N
were VBD N
mediated VBN N
by IN N
program NN N
participation NN N
. . N

SUBJECTS/SETTING NNP N
Data NNP p
from IN p
13,277 CD p
postmenopausal JJ p
women NNS p
randomly RB p
assigned VBN p
to TO p
the DT p
low-fat JJ i
intervention NN i
arm NN p
of IN p
the DT p
Women NNP p
's POS p
Health NNP p
Initiative NNP p
Dietary NNP p
Modification NNP p
Trial NNP p
. . p

INTERVENTION NNP N
The DT N
nutrition NN N
goals NNS N
for IN N
women NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
low-fat JJ i
intervention NN i
were VBD N
to TO N
reduce VB i
total JJ i
fat JJ i
intake NN i
to TO i
20 CD i
% NN i
or CC i
less JJR i
of IN i
energy NN i
from IN i
fat JJ i
and CC i
to TO i
consume VB i
5 CD i
or CC i
more JJR i
fruit/vegetable JJ i
servings NNS i
daily RB i
and CC i
6 CD i
or CC i
more JJR i
grain JJ i
servings NNS i
daily RB i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Year NNP o
1 CD o
program NN o
participation NN o
( ( o
degree NN o
of IN o
attending VBG o
group NN o
sessions NNS o
and CC o
submitting VBG o
fat JJ o
scores NNS o
) ) o
and CC p
adherence NN o
to TO o
the DT o
low-fat JJ o
dietary JJ o
pattern NN o
( ( o
percent JJ o
energy NN o
from IN o
fat NN o
) ) o
as IN N
predicted VBN N
by IN N
baseline JJ N
physical JJ N
and CC N
emotional JJ N
status NN N
( ( N
eight CD N
SF-36 NNP N
Health NNP N
Survey NNP N
subscales VBZ N
) ) N
. . N

RESULTS NNP N
Participating VBG N
in IN N
the DT N
dietary JJ i
intervention NN i
program NN i
reduced VBN N
( ( N
mediated VBN N
) ) N
the DT N
negative JJ N
effect NN o
of IN o
poorer JJR o
mental JJ o
health NN o
on IN N
dietary JJ o
adherence NN o
by IN N
15 CD N
% NN N
. . N

Additional JJ N
findings NNS N
included VBD N
that IN N
a DT N
10 CD N
% NN N
increase NN N
in IN N
physical JJ o
functioning NN o
increased VBD N
session NN o
attendance NN o
by IN N
0.4 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
a DT N
10 CD N
% NN N
increase NN N
in IN N
mental JJ o
health NN o
predicted VBD N
a DT N
decrease NN N
in IN N
percent NN N
energy NN o
from IN o
fat NN o
of IN N
0.3 CD N
% NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Program NNP N
participation NN N
had VBD N
a DT N
marked JJ N
effect NN N
on IN N
dietary JJ o
adherence NN o
: : o
a DT N
10 CD N
% NN N
increase NN N
in IN N
session NN o
attendance NN o
predicted VBD N
a DT N
1.2 CD N
% NN N
decrease NN N
in IN N
percent NN o
energy NN o
from IN o
fat JJ o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

APPLICATIONS/CONCLUSIONS NNP N
Understanding NNP N
and CC N
using VBG N
instruments NNS N
to TO N
assess VB N
the DT N
physical JJ N
and CC N
emotional JJ N
status NN N
of IN N
a DT N
target NN N
population NN N
will MD N
help VB N
dietetic JJ N
professionals NNS N
promote VBP N
healthful JJ N
dietary JJ N
change NN N
and CC N
maintenance NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
creatine JJ i
supplementation NN i
on IN N
repetitive JJ N
sprint NN N
performance NN N
and CC N
body NN N
composition NN N
in IN N
competitive JJ p
swimmers NNS p
. . p

In IN N
a DT N
double-blind NN N
and CC N
randomized JJ N
manner NN N
, , N
18 CD p
male NN p
and CC p
female JJ p
junior JJ p
competitive JJ p
swimmers NNS p
supplemented VBD N
their PRP$ N
diets NNS N
with IN N
21 CD N
g.day-1 NN N
of IN N
creatine NN i
monohydrate NN i
( ( i
Cr NNP i
) ) i
or CC N
a DT N
maltodextrin JJ i
placebo NN i
( ( i
P NNP i
) ) i
for IN N
9 CD p
days NNS p
during IN p
training NN p
. . p

Prior NNP N
to TO N
and CC N
following VBG N
supplementation NN N
, , N
subjects NNS N
performed VBD N
three CD N
100-m JJ N
freestyle JJ N
sprint NN N
swims NNS N
( ( N
long JJ N
course NN N
) ) N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
heats NNS N
. . N

In IN N
addition NN N
, , N
subjects NNS N
performed VBD N
three CD N
20-s JJ N
arm NN N
ergometer NN N
maximal-effort JJ N
sprint NN N
tests NNS N
in IN N
the DT N
prone NN N
position NN N
with IN N
60 CD N
s JJ N
rest/recovery NN N
between IN N
sprint NN N
tests NNS N
. . N

Significant JJ N
differences NNS N
were VBD N
observed VBN N
among IN N
swim JJ o
times NNS o
, , N
with IN N
Cr NNP N
subjects NNS N
swimming VBG N
significantly RB N
faster RBR N
than IN N
P NNP N
subjects NNS N
following VBG N
supplementation NN N
in IN N
Heat NNP N
1 CD N
and CC N
significantly RB N
decreasing VBG N
swim JJ o
time NN o
in IN N
the DT N
second JJ N
100-m JJ N
sprint NN N
. . N

There EX N
was VBD N
also RB N
some DT N
evidence NN N
that IN N
cumulative JJ o
time NN o
to TO o
perform VB o
the DT o
three CD o
100-m JJ o
swims NNS o
was VBD N
decreased VBN N
in IN N
the DT N
Cr NNP N
group NN N
. . N

Results NNP N
indicate VBP N
that IN N
9 CD N
days NNS N
of IN N
Cr NNP i
supplementation NN N
during IN N
swim JJ N
training NN N
may MD N
provide VB N
some DT N
ergogenic JJ N
value NN N
to TO N
competitive JJ N
junior JJ N
swimmers NNS N
during IN N
repetitive JJ N
sprint NN N
performance NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Myocardial NNP N
ischemia NN N
with IN N
stable JJ N
angina JJ N
pectoris NN N
: : N
clinico-ergometric JJ N
evaluation NN N
after IN N
the DT N
use NN N
of IN N
diltiazem NN i
] NN i
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
diltiazem JJ i
versus NN N
placebo NN i
in IN N
patients NNS p
with IN p
stable JJ p
angina NN p
. . p

METHODS NNP N
Eight-seven JJ p
angina NNS p
pectoris JJ p
patients NNS p
, , p
mean JJ p
age NN p
of IN p
57 CD p
+/- JJ p
9 CD p
, , p
82 CD p
white JJ p
and CC p
79 CD p
male NN p
were VBD N
evaluated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
of IN N
two CD N
groups NNS N
of IN N
patients NNS N
diltiazem JJ i
and CC i
placebo NN i
, , N
3 CD N
to TO N
4 CD N
tablets NNS N
a DT N
day NN N
( ( i
diltiazem JJ i
180 CD N
to TO N
240 CD N
mg NNS N
daily RB N
) ) N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
after IN N
laboratory NN N
tests NNS N
and CC N
clinical-ergometric JJ N
examinations NNS N
. . N

A DT N
coronary JJ N
arteriography NN N
was VBD N
performed VBN N
on IN N
study NN N
entry NN N
. . N

RESULTS VB N
The DT N
average NN o
of IN o
anginal JJ o
attacks NNS o
, , o
number NN o
of IN o
weekly JJ o
sublingual JJ o
nitrate NN o
, , o
heart NN o
rate NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
pressure NN o
at IN o
rest NN o
and CC o
at IN o
the DT o
end NN o
of IN o
diltiazem JJ o
period NN o
were VBD N
significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
regarding VBG N
same JJ N
periods NNS N
on IN N
placebo NN i
. . i

The DT N
percentage NN N
of IN N
depression NN o
for IN o
ST-segment NNP o
was VBD N
lower JJR N
for IN N
diltiazem NN i
when WRB N
compared VBN N
with IN N
placebo NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
the DT N
percentage NN N
of IN N
patients NNS N
that WDT N
reach VBP N
higher JJR N
stages NNS N
in IN N
the DT N
ergometric JJ N
test NN N
was VBD N
significantly RB N
better JJR N
for IN N
diltiazem NN i
. . i

Heart NNP o
rate NN o
and CC o
systolic JJ o
plus CC o
diastolic JJ o
pressures NNS o
after IN N
exercise NN N
did VBD N
not RB N
differ VB N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Diltiazem NNP i
reduced VBD N
the DT N
clinical JJ N
and CC N
electrocardiographical JJ N
aspects NNS N
and CC N
raises VBZ N
the DT N
effort NN N
tolerance NN N
during IN N
the DT N
ergometric JJ N
test NN N
in IN N
patients NNS p
with IN p
stable JJ p
angina NN p
. . p

-DOCSTART- -X- O O

Direct JJ i
trocar NN i
insertion NN i
vs. FW i
Verres NNP i
needle FW i
use NN i
for IN N
laparoscopic JJ p
sterilization NN p
. . p

A DT N
randomized JJ p
, , p
prospective JJ p
trial NN p
was VBD p
designed VBN p
to TO p
compare VB p
direct JJ i
trocar NN i
insertion NN i
with IN i
prior JJ i
peritoneal JJ i
insufflation NN i
with IN i
a DT i
Verres NNP i
needle NN i
for IN i
laparoscopic NN i
tubal JJ i
sterilization NN i
. . i

Direct JJ i
trocar NN i
insertion NN i
resulted VBD N
in IN N
fewer JJR N
instrument NN o
insertions NNS o
( ( N
21.8 CD N
% NN N
vs. FW N
7.8 CD N
% NN N
) ) N
and CC N
use NN N
of IN N
smaller JJR o
volumes NNS o
of IN o
CO2 NNP o
( ( N
2.67 CD N
vs. FW N
2.32 CD N
L NNP N
) ) N
. . N

Direct JJ i
trocar NN i
use NN N
resulted VBD N
in IN N
a DT N
decrease NN N
in IN N
operating NN o
time NN o
from IN N
9 CD N
minutes NNS N
, , N
40 CD N
seconds NNS N
in IN N
the DT N
needle JJ p
group NN p
to TO N
7 CD N
minutes NNS N
, , N
30 CD N
seconds NNS N
in IN N
the DT N
trocar NN p
group NN p
. . p

Minor NNP o
omental JJ o
injuries NNS o
occurred VBD N
in IN N
a DT N
small JJ N
percentage NN N
of IN N
each DT N
group NN N
, , N
while IN N
serious JJ N
complications NNS N
occurred VBD N
once RB N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
nitinol JJ i
tipless NN i
stone NN i
baskets NNS i
in IN N
an DT N
in IN N
vitro JJ o
caliceal NN N
model NN N
. . N

PURPOSE NNP N
Tipless NNP i
stone NN i
baskets NNS i
facilitate VBP N
caliceal JJ p
calculi JJ p
extraction NN p
during IN p
flexible JJ p
ureteroscopy NN p
. . p

We PRP N
evaluated VBD N
the DT N
stone NN p
capture NN p
rate NN p
of IN p
9 CD p
commercially RB p
available JJ p
tipless NN i
stone NN i
baskets NNS i
in IN p
an DT p
in IN p
vitro NN p
model NN p
using VBG N
novice NN N
and CC N
expert NN N
operators NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
Microvasive NNP i
Zerotip NNP i
( ( i
2.4Fr CD i
, , i
3.0Fr CD i
) ) i
, , i
Cook NNP i
N-Circle NNP i
( ( i
2.2Fr CD i
, , i
3.0Fr CD i
, , i
3.2Fr CD i
) ) i
, , i
Bard NNP i
Dimension NNP i
( ( i
3.0Fr CD i
, , i
Sacred NNP i
Heart NNP i
Medical NNP i
Halo NNP i
( ( i
1.9Fr CD i
) ) i
, , i
Vantage NNP i
( ( i
1.9Fr CD i
) ) i
and CC i
Circon-ACMI JJ i
Sur-Catch-NT NNP i
( ( i
3.0Fr CD i
) ) i
were VBD N
tested VBN N
by IN N
3 CD p
novice NNS p
and CC p
3 CD p
experienced VBD p
basket NN p
operators NNS p
. . p

Each DT p
operator NN p
performed VBD p
stone JJ i
extraction NN i
of IN p
2 CD p
, , p
5 CD p
and CC p
8 CD p
mm NN p
calculi NN p
( ( N
size NN N
determined VBN N
by IN N
digital JJ N
caliper NN N
with IN N
3 CD N
repetitions NNS N
of IN N
each DT N
basket NN N
. . N

The DT N
time NN N
to TO N
extraction NN N
of IN N
the DT N
calculus NN N
from IN N
a DT N
convex NN N
based VBN N
test NN N
tube NN N
caliceal NN N
model NN N
was VBD N
recorded VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
repeated JJ N
measures NNS N
ANOVA NNP N
and CC N
Fisher NNP N
's POS N
pairwise NN N
comparisons NNS N
. . N

RESULTS NNP N
After IN N
a DT N
learning JJ N
curve NN N
of IN N
27 CD N
basket NN N
retrievals NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
stone NN o
capture NN o
times NNS o
between IN N
novice NN p
( ( N
38 CD N
+/- JJ N
54 CD N
seconds NNS N
) ) N
and CC N
expert JJ p
operators NNS p
( ( N
32 CD N
+/- JJ N
49 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.174 CD N
) ) N
. . N

For IN N
total JJ N
stone NN N
capture NN N
( ( N
all DT N
sizes NNS N
) ) N
the DT N
Sacred NNP N
Heart NNP N
Halo NNP N
resulted VBD N
in IN N
the DT N
most RBS N
rapid JJ o
stone NN o
extraction NN o
( ( N
17 CD N
+/- JJ N
14 CD N
seconds NNS N
) ) N
by IN N
novices NNS N
and CC N
experts NNS N
, , N
while IN N
the DT N
Sur-Catch NNP N
NT NNP N
resulted VBD N
in IN N
the DT N
slowest JJS N
stone NN N
extraction NN N
( ( N
78 CD N
+/- JJ N
90 CD N
, , N
seconds NNS N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
Halo NNP N
( ( N
14 CD N
+/- JJ N
9 CD N
seconds NNS N
) ) N
and CC N
Vantage NNP N
( ( N
19 CD N
+/- JJ N
12 CD N
seconds NNS N
) ) N
baskets NNS N
were VBD N
significantly RB N
faster JJR N
for IN N
2 CD N
mm NNS N
calculi NN N
than IN N
the DT N
N-Circle NNP N
( ( N
73 CD N
+/- JJ N
60 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.006 CD N
) ) N
, , N
Sur-Catch NNP N
( ( N
169 CD N
+/- JJ N
85 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.0005 CD N
) ) N
and CC N
Dimension NNP N
( ( N
73 CD N
+/- JJ N
70 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
. . N

The DT N
Zerotip NNP N
functioned VBD N
well RB N
for IN N
2 CD N
mm NNS N
calculi NN N
in IN N
the DT N
hands NNS N
of IN N
expert NN N
operators NNS N
( ( N
15 CD N
+/- JJ N
9 CD N
seconds NNS N
) ) N
but CC N
not RB N
novice JJ N
operators NNS N
( ( N
94 CD N
+/- JJ N
95 CD N
seconds NNS N
) ) N
. . N

The DT N
Sur-Catch JJ N
NT NNP N
was VBD N
significantly RB N
slower JJR N
for IN N
2 CD N
mm NNS N
calculi NN N
than IN N
the DT N
N-Circle NNP N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
Dimension NNP N
( ( N
p JJ N
=.03 NN N
) ) N
, , N
Halo NNP N
( ( N
p JJ N
=.0005 NN N
) ) N
, , N
Vantage NNP N
( ( N
p JJ N
=.001 NN N
) ) N
and CC N
Zerotip NNP N
( ( N
p JJ N
=.002 NN N
) ) N
. . N

For IN N
5 CD N
mm NNS N
calculi VBP N
the DT N
Halo NNP N
was VBD N
superior JJ N
( ( N
12 CD N
+/- JJ N
8 CD N
seconds NNS N
) ) N
, , N
while IN N
the DT N
Zerotip NNP N
were VBD N
superior JJ N
for IN N
8 CD N
mm NNS N
calculi NN N
( ( N
8 CD N
+/- JJ N
3 CD N
seconds NNS N
) ) N
compared VBN N
to TO N
the DT N
N-Circle NNP N
( ( N
23 CD N
+/- JJ N
28 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.026 CD N
) ) N
, , N
Halo NNP N
( ( N
26 CD N
+/- JJ N
18 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.021 CD N
) ) N
and CC N
Vantage NNP N
( ( N
23 CD N
+/- JJ N
15 CD N
seconds NNS N
, , N
p NN N
= NNP N
0.006 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
Sacred NNP N
Heart NNP N
Halo NNP N
and CC N
Vantage NNP N
baskets NNS N
resulted VBD N
in IN N
the DT N
most RBS o
expeditious JJ o
stone NN o
extraction NN o
, , N
especially RB N
for IN N
2 CD N
to TO N
5 CD N
mm NNS N
calculi VBP N
while IN N
the DT N
Microvasive NNP N
Zerotip NNP N
was VBD N
optimal JJ N
for IN N
8 CD N
mm NN N
calculi NN N
. . N

The DT N
Sur-Catch JJ N
NT NNP N
had VBD N
the DT N
slowest JJS o
stone JJ o
capture NN o
rate NN o
for IN N
all DT N
stone NN N
sizes VBZ N
. . N

Caliceal NNP N
models NNS N
of IN N
stone NN i
basketing NN i
may MD N
be VB N
useful JJ N
to TO N
train VB N
novice JJ N
urology NN p
residents NNS p
and CC p
nursing NN p
assistants NNS p
. . p

-DOCSTART- -X- O O

Toxicity NN o
and CC o
efficacy NN o
of IN N
6-thioguanine JJ i
versus NN i
6-mercaptopurine JJ i
in IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
6-mercaptopurine JJ i
has VBZ N
been VBN N
a DT N
standard JJ N
component NN N
of IN N
long-term JJ N
continuing VBG N
treatment NN N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
, , N
whereas JJ N
6-thioguanine NN i
has VBZ N
been VBN N
mainly RB N
used VBN N
for IN N
intensification NN N
courses NNS N
. . N

Since IN N
preliminary JJ N
data NNS N
have VBP N
shown VBN N
that IN N
6-thioguanine JJ i
is VBZ N
more RBR N
effective JJ N
than IN N
6-mercaptopurine JJ i
, , N
we PRP N
compared VBN N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
the DT N
two CD N
drugs NNS N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
. . p

METHODS NNP N
Consecutive JJ p
children NNS p
with IN p
lymphoblastic JJ p
leukaemia NN p
diagnosed VBN p
in IN p
the DT p
UK NNP p
and CC p
Ireland NNP p
between IN p
April NNP p
, , p
1997 CD p
, , p
and CC p
June NNP p
, , p
2002 CD p
, , N
were VBD N
randomly RB N
assigned VBN N
either CC N
6-thioguanine JJ i
( ( i
750 CD i
patients NNS N
) ) N
or CC N
6-mercaptopurine JJ i
( ( N
748 CD N
patients NNS N
) ) N
during IN N
interim JJ N
maintenance NN N
and CC N
continuing VBG N
therapy NN N
. . N

All DT N
patients NNS N
received VBD N
6-thioguanine JJ i
during IN N
intensification NN N
courses NNS N
. . N

We PRP N
analysed VBD N
event-free JJ o
and CC o
overall JJ o
survival NN o
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

We PRP N
obtained VBD N
toxicity NN o
data NNS N
using VBG N
an DT N
adverse-event JJ N
reporting NN N
system NN N
, , N
with IN N
follow-up JJ N
questionnaires NNS N
to TO N
seek VB N
detailed JJ N
information NN N
for IN N
specific JJ N
toxicities NNS N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Number NNP N
26727615 CD N
with IN N
the DT N
name NN N
ALL97 NNP N
. . N

FINDINGS NNP N
After IN N
a DT N
median JJ N
follow NN N
up IN N
of IN N
6 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
event-free JJ o
or CC o
overall JJ o
survival NN o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Although IN N
6-thioguanine JJ i
conferred VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
of IN N
isolated JJ N
CNS NNP o
relapse NN o
than IN N
did VBD N
6-mercaptopurine JJ i
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
0.30-0.92 CD N
, , N
p=0.02 NN N
) ) N
, , N
the DT N
benefit NN N
was VBD N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN o
of IN o
death NN o
in IN N
remission NN N
( ( N
2.22 CD N
, , N
1.20-4.14 CD N
, , N
p=0.01 NN N
) ) N
, , N
mainly RB N
due JJ N
to TO N
infections NNS N
during IN N
continuing VBG N
therapy NN N
. . N

Additionally RB N
, , N
95 CD N
patients NNS N
developed VBD N
veno-occlusive JJ o
disease NN o
of IN o
the DT o
liver NN o
. . o

Of IN N
these DT N
, , N
82 CD N
were VBD N
randomly RB N
assigned VBN N
6-thioguanine JJ i
, , N
representing VBG N
11 CD N
% NN N
of IN N
all DT N
6-thioguanine JJ i
recipients NNS N
. . N

On IN N
long-term JJ N
follow-up NN N
, , N
about RB N
5 CD N
% NN N
of IN N
6-thioguanine JJ i
recipients NNS N
have VBP N
evidence NN N
of IN N
non-cirrhotic JJ o
portal JJ o
hypertension NN o
due JJ N
to TO N
periportal JJ N
liver JJ N
fibrosis NN N
or CC N
nodular JJ N
regenerative JJ N
hyperplasia NN N
. . N

INTERPRETATION NNP N
Compared VBD N
with IN N
6-mercaptopurine JJ i
, , i
6-thioguanine JJ i
causes NNS N
excess JJ N
toxicity NN o
without IN N
an DT N
overall JJ o
benefit NN o
. . o

6-mercaptopurine JJ i
should MD N
remain VB N
the DT N
thiopurine NN N
of IN N
choice NN N
for IN N
continuing VBG N
therapy NN N
of IN N
childhood NN N
lymphoblastic JJ N
leukaemia NN N
. . N

-DOCSTART- -X- O O

Physicians NNS p
' POS p
management NN i
of IN i
hypertension NN i
: : i
a DT N
randomized VBN N
controlled VBN N
CME NNP N
trial NN N
. . N

-DOCSTART- -X- O O

Heparin-coated JJ i
cardiopulmonary JJ i
bypass NN i
circuits NNS i
reduce VB N
circulating VBG N
complement JJ N
factors NNS N
and CC N
interleukin-6 NN N
in IN N
paediatric JJ p
heart NN p
surgery NN p
. . p

Children NNP p
are VBP N
sensitive JJ N
to TO N
the DT N
inflammatory JJ N
side NN N
effects NNS N
of IN N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
. . N

Our PRP$ N
intention NN N
was VBD N
to TO N
investigate VB N
if IN N
the DT N
biocompatibility NN N
benefits NNS N
of IN N
heparin-coated JJ i
CPB NNP i
circuits NNS i
apply VBP N
to TO N
children NNS p
. . p

In IN N
20 CD N
operations NNS N
, , N
19 CD p
children NNS p
were VBD p
randomized VBN p
to TO p
heparin-coated JJ i
( ( i
group NN i
HC NNP i
, , i
n JJ i
= NNP i
10 CD i
) ) i
or CC i
standard JJ i
( ( i
group NN i
C NNP i
, , i
n JJ i
= NNP i
10 CD i
) ) i
bypass NN i
circuits NNS i
. . i

Plasma NNP o
levels NNS o
of IN o
acute JJ o
phase NN o
reactants NNS o
, , o
interleukins NNS o
, , o
granulocytic JJ o
proteins NNS o
and CC o
complement JJ o
factors NNS o
were VBD N
measured VBN N
. . N

All DT N
were VBD N
significantly RB N
elevated VBN N
after IN N
CPB NNP N
. . N

Levels NNP o
of IN o
complement NN o
factor NN o
C3a NNP o
( ( N
851 CD N
( ( N
791-959 CD N
) ) N
ng/ml FW N
[ JJ N
median NN N
with IN N
quartiles NNS N
] VBP N
in IN N
group NN N
C NNP N
, , N
497 CD N
( ( N
476-573 JJ N
) ) N
ng/ml NN N
in IN N
group NN N
HC NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
Terminal NNP o
Complement NNP o
Complex NNP o
( ( N
114 CD N
( ( N
71-130 CD N
) ) N
AU/ml NNP N
in IN N
group NN N
C NNP N
, , N
35.5 CD N
( ( N
28.9-51.4 JJ N
) ) N
AU/ml NNP N
in IN N
group NN N
HC NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
interleukin-6 NN o
( ( N
570 CD N
( ( N
203-743 JJ N
) ) N
pg/ml NN N
in IN N
group NN N
C NNP N
, , N
168 CD N
( ( N
111-206 CD N
) ) N
pg/ml NN N
in IN N
group NN N
HC NNP N
, , N
p NN N
= NNP N
0.005 CD N
) ) N
, , N
were VBD N
significantly RB N
reduced VBN N
in IN N
group NN N
HC NNP N
. . N

Heparin-coated JJ i
CPB NNP i
circuits NNS i
improve VBP N
the DT N
biocompatibility NN N
of IN N
CPB NNP N
during IN N
heart NN N
surgery NN N
in IN N
the DT N
paediatric JJ p
patient NN p
population NN N
, , N
as IN N
reflected VBN N
by IN N
significantly RB N
reduced VBN N
levels NNS N
of IN N
circulating VBG N
complement JJ N
factors NNS N
and CC N
interleukin-6 NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
gravity NN N
on IN N
robot-assisted JJ i
motor NN i
training NN i
after IN p
chronic JJ o
stroke NN o
: : o
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
2 CD N
distinct JJ N
6-week JJ N
robot-assisted JJ i
reaching NN i
programs NNS i
compared VBN N
with IN N
an DT N
intensive JJ N
conventional JJ i
arm NN i
exercise NN i
program NN i
( ( N
ICAE NNP N
) ) N
for IN N
chronic NN o
, , o
stroke-related JJ o
upper-extremity NN o
( ( o
UE NNP o
) ) o
impairment NN N
. . N

To TO N
examine VB N
whether IN N
the DT N
addition NN N
of IN N
robot-assisted JJ i
training VBG i
out IN p
of IN p
the DT p
horizontal JJ p
plane NN p
leads VBZ N
to TO N
improved VBN N
outcomes NNS N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
, , N
single-blinded JJ N
, , N
with IN N
12-week JJ N
follow-up NN N
. . N

SETTING NNP N
Research NNP N
setting VBG N
in IN N
a DT N
large JJ N
medical JJ N
center NN N
. . N

PARTICIPANTS NNP N
Adults NNP p
( ( p
N=62 NNP p
) ) p
with IN p
chronic JJ p
, , p
stroke-related JJ p
arm NN p
weakness NN p
stratified VBN p
by IN p
impairment JJ p
severity NN p
using VBG p
baseline JJ p
UE NNP p
motor NN p
assessments NNS p
. . p

INTERVENTIONS NNP N
Sixty NNP N
minutes NNS N
, , N
3 CD N
times NNS N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
of IN N
robot-assisted JJ i
planar NN i
reaching NN i
( ( i
gravity NN i
compensated VBN i
) ) i
, , i
combined VBN i
planar NN i
with IN i
vertical JJ i
robot-assisted JJ i
reaching NN i
, , N
or CC N
intensive JJ i
conventional JJ i
arm NN i
exercise NN i
program NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
UE NNP o
Fugl-Meyer NNP o
Assessment NNP o
( ( o
FMA NNP o
) ) o
mean VBP o
change NN o
from IN N
baseline NN N
to TO N
final JJ N
training NN N
. . N

RESULTS NNP N
All DT N
groups NNS N
showed VBD N
modest JJ o
gains NNS o
in IN o
the DT o
FMA NNP o
from IN N
baseline NN N
to TO N
final JJ N
with IN N
no DT N
significant JJ N
between IN N
group NN N
differences NNS N
. . N

Most JJS N
change NN N
occurred VBD N
in IN N
the DT N
planar NN N
robot NN N
group NN N
( ( N
mean JJ N
change NN N
? . N
SD NNP N
, , N
2.94 CD N
? . N
0.77 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.40-4.47 JJ p
) ) p
. . p

Participants NNS p
with IN p
greater JJR o
motor NN o
impairment NN o
( ( o
n=41 JJ p
) ) p
demonstrated VBD p
a DT N
larger JJR N
difference NN N
in IN N
response NN o
( ( o
mean JJ N
change NN N
? . N
SD NNP N
, , N
2.29 CD N
? . N
0.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.85-3.72 NNP N
) ) N
for IN N
planar JJ N
robot-assisted JJ N
exercise NN N
compared VBN N
with IN N
the DT N
intensive JJ N
conventional JJ N
arm NN N
exercise NN N
program NN N
( ( N
mean JJ N
change NN N
? . N
SD NNP N
, , N
0.43 CD N
? . N
0.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.00 NNP N
to TO N
1.86 CD N
) ) N
. . N

CONCLUSIONS NNP o
Chronic NNP o
UE NNP o
deficits NNS o
because IN N
of IN N
stroke NN N
are VBP o
responsive JJ o
to TO N
intensive JJ N
motor NN N
task NN N
training NN N
. . N

However RB N
, , N
training VBG N
outside IN N
the DT N
horizontal JJ N
plane NN N
in IN N
a DT N
gravity NN N
present JJ N
environment NN N
using VBG N
a DT N
combination NN N
of IN N
vertical JJ N
with IN N
planar JJ N
robots NNS N
was VBD o
not RB o
superior JJ o
to TO o
training VBG o
with IN N
the DT N
planar NN N
robot NN N
alone RB N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
of IN N
5-fluorouracil JJ i
, , N
with IN N
or CC N
without IN N
human JJ i
interferon-beta NN i
, , N
for IN N
advanced JJ p
colorectal JJ p
cancer NN p
. . p

This DT N
study NN N
compared VBN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
monotherapy NN i
to TO N
that DT N
of IN N
5-FU JJ i
combined VBN i
with IN i
natural JJ i
human JJ i
interferon-beta NN i
( ( i
IFN-beta NNP i
) ) i
in IN N
patients NNS p
with IN p
unresectable JJ p
, , p
advanced JJ p
colorectal JJ p
carcinoma NN p
. . p

Forty-nine JJ p
chemotherapy-naive JJ p
patients NNS p
were VBD p
randomized VBN p
to TO N
5-FU JJ N
alone RB N
or CC N
to TO N
the DT N
combination NN N
. . N

All DT N
patients NNS N
received VBD N
750 CD N
mg NNS N
m NN N
( ( N
-2 JJ N
) ) N
day NN N
( ( N
-1 JJ N
) ) N
5-FU NN N
for IN N
5 CD N
days NNS N
by IN N
continuous JJ N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
infusion NN N
, , N
followed VBD N
after IN N
day NN N
15 CD N
by IN N
a DT N
weekly JJ N
i.v NN N
. . N

bolus NN N
of IN N
750 CD N
mg NNS N
m NN N
( ( N
-2 NNP N
) ) N
. . N

IFN-beta NNP i
was VBD N
injected VBN N
intramuscularly RB N
three CD N
times NNS N
weekly RB N
at IN N
9 CD N
M NNP N
IU NNP N
. . N

Treatment NNP N
continued VBD N
for IN N
52 CD N
weeks NNS N
, , N
or CC N
until IN N
disease JJ o
progression NN o
or CC N
intolerable JJ o
toxicity NN o
. . o

Clinical JJ N
endpoints NNS N
were VBD N
tumor JJ o
response NN o
, , o
time NN o
to TO o
progression NN o
, , o
survival NN o
and CC o
toxicity NN o
. . o

The DT N
addition NN N
of IN N
IFN-3 NNP i
to TO i
5-FU CD i
significantly RB N
improved VBN o
response NN o
rate NN o
( ( N
33.3 CD N
% NN N
vs JJ N
4.5 CD N
% NN N
for IN N
evaluable JJ N
patients NNS N
; : N
P NNP N
= NNP N
0.021 CD N
) ) N
, , N
time NN o
to TO o
progression NN o
( ( N
median JJ N
7.2 CD N
vs JJ N
4.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.0435 CD N
) ) N
, , N
and CC N
survival JJ o
time NN o
( ( N
median JJ N
15.9 CD N
vs JJ N
7.2 CD N
months NNS N
; : N
P NNP N
= NNP N
0.038 CD N
) ) N
without IN N
significantly RB N
increasing VBG N
toxicity NN o
compared VBN N
to TO N
5-FU JJ N
alone RB N
. . N

Cumulative JJ o
5-FU JJ o
dose NN o
was VBD N
higher JJR N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
: : N
more JJR N
patients NNS N
receiving VBG N
monotherapy JJ N
discontinued VBN N
treatment NN N
because IN N
of IN N
disease NN o
progression NN o
. . o

Fever NNP o
was VBD N
more RBR N
frequent JJ N
with IN N
combined JJ N
therapy NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
; : N
there EX N
were VBD N
no DT N
other JJ N
differences NNS N
in IN N
toxicity NN o
. . o

The DT N
only JJ N
grade NN o
IV NNP o
toxicity NN o
observed VBD N
was VBD N
neutropenia JJ N
( ( N
two CD N
patients NNS N
per IN N
group NN N
) ) N
. . N

A DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
has VBZ N
been VBN N
initiated VBN N
to TO N
confirm VB N
the DT N
synergy NN N
between IN N
5-FU JJ i
and CC N
IFN-beta NNP i
. . i

-DOCSTART- -X- O O

Cryotherapy NN N
does VBZ N
not RB N
affect VB N
peroneal JJ N
reaction NN N
following VBG N
sudden JJ N
inversion NN N
. . N

CONTEXT NNP N
If IN N
ankle JJ N
joint NN N
cryotherapy NN N
impairs VBZ N
the DT N
ability NN N
of IN N
the DT N
ankle JJ N
musculature NN N
to TO N
counteract VB N
potentially RB N
injurious JJ N
forces NNS N
, , N
the DT N
ankle NN N
is VBZ N
left VBN N
vulnerable JJ N
to TO N
injury VB N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
peroneal JJ N
reaction NN N
to TO N
sudden JJ N
inversion NN N
following VBG N
ankle JJ N
joint JJ N
cryotherapy NN N
. . N

DESIGN NNP N
Repeated VBD N
measures NNS N
design NN N
with IN N
independent JJ N
variables NNS N
, , N
treatment NN N
( ( i
cryotherapy NN i
and CC i
control NN i
) ) i
, , N
and CC N
time NN N
( ( N
baseline NN N
, , N
immediately RB N
post NN N
treatment NN N
, , N
15 CD N
minutes NNS N
post RB N
treatment NN N
, , N
and CC N
30 CD N
minutes NNS N
post RB N
treatment NN N
) ) N
. . N

SETTING NNP N
University NNP p
research NN p
laboratory NN p
. . p

PATIENTS CC N
OR CC N
OTHER NNP N
PARTICIPANTS NNP N
Twenty-seven NNP p
healthy JJ p
volunteers NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
An DT N
ice NN N
bag NN N
was VBD N
secured VBN N
to TO N
the DT N
lateral JJ N
ankle NN N
joint NN N
for IN N
20 CD N
minutes NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
onset NN o
and CC o
average JJ o
root NN o
mean JJ o
square JJ o
amplitude NN o
of IN o
EMG NNP o
activity NN o
in IN o
the DT o
peroneal NN o
muscles NNS o
was VBD o
calculated VBN o
following VBG o
the DT o
release NN o
of IN o
a DT o
trap NN o
door NN o
mechanism NN o
causing VBG o
inversion NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
change NN N
from IN N
baseline NN N
for IN N
peroneal JJ o
reaction NN o
time NN o
or CC o
average JJ o
peroneal JJ o
muscle NN o
activity NN o
at IN N
any DT N
post NN N
treatment NN N
time NN N
. . N

CONCLUSIONS NNP N
Cryotherapy NNP N
does VBZ N
not RB N
affect VB N
peroneal JJ N
muscle NN N
reaction NN N
following VBG N
sudden JJ N
inversion NN N
perturbation NN N
. . N

-DOCSTART- -X- O O

A DT N
controlled JJ N
trial NN N
of IN N
extended JJ i
radical JJ i
versus NN N
radical JJ i
mastectomy NN i
. . i

Ten-year JJ N
results NNS N
. . N

In IN N
view NN N
of IN N
increasing VBG N
debate NN N
over IN N
possible JJ N
benefit NN N
of IN N
more JJR N
complete JJ N
surgery NN N
compared VBN N
to TO N
conservative JJ N
procedures NNS N
, , N
a DT N
randomized VBN N
controlled VBN N
trial NN N
contrasting VBG N
the DT N
then RB N
standard NN i
Halsted NNP i
radical NN i
( ( i
RDL NNP i
) ) i
operation NN i
with IN N
the DT N
more RBR N
complete JJ i
extended JJ i
radical NN i
( ( i
EXT NNP i
) ) i
mastectomy NN i
was VBD N
initiated VBN N
in IN N
1973 CD N
. . N

Between IN p
November NNP p
1973 CD p
and CC p
July NNP p
1982 CD p
, , p
123 CD p
women NNS p
younger JJR p
than IN p
70 CD p
years NNS p
of IN p
age NN p
and CC p
at IN p
clinical JJ p
Stages NNP p
I PRP p
and CC p
II NNP p
were VBD p
enrolled VBN p
. . p

Of IN N
the DT N
total JJ N
series NN N
, , N
112 CD p
were VBD p
treated VBN p
by IN p
the DT p
same JJ p
surgeon NN p
and CC p
confirmed VBD p
pathologically RB p
as IN p
having VBG p
invasive JJ p
mammary JJ p
carcinoma NN p
. . p

In IN N
this DT N
more RBR N
homogeneous JJ N
subgroup NN N
, , N
the DT N
10-year JJ o
survival NN o
rates NNS o
( ( N
and CC N
standard JJ N
errors NNS N
) ) N
were VBD N
for IN N
RDL NNP N
, , N
60 CD N
% NN N
( ( N
+/- JJ N
7 CD N
% NN N
) ) N
and CC N
for IN N
EXT NNP N
, , N
74 CD N
% NN N
( ( N
+/- JJ N
6 CD N
% NN N
) ) N
( ( N
P NNP N
value NN N
for IN N
comparison NN N
of IN N
survival JJ N
curves NNS N
= VBP N
0.13 CD N
) ) N
. . N

In IN N
patients NNS N
from IN N
this DT N
subgroup NN N
with IN N
central-medial JJ N
tumors NNS N
, , N
comprising VBG N
62 CD N
% NN N
of IN N
the DT N
total NN N
, , N
survival NN o
after IN N
RDL NNP N
at IN N
10 CD N
years NNS N
was VBD N
60 CD N
% NN N
( ( N
+/- JJ N
8 CD N
% NN N
) ) N
, , N
and CC N
after IN N
EXT NNP N
86 CD N
% NN N
( ( N
+/- JJ N
6 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

In IN N
the DT N
remaining VBG N
patients NNS p
with IN p
lateral JJ p
tumors NNS p
, , N
survival JJ o
rates NNS o
were VBD N
unaffected VBN N
by IN N
treatment NN N
: : N
58 CD N
% NN N
( ( N
+/- JJ N
13 CD N
% NN N
) ) N
and CC N
56 CD N
% NN N
( ( N
+/- JJ N
11 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.62 CD N
) ) N
. . N

Comparison NNP N
of IN N
a DT N
nonrandomized JJ N
series NN N
of IN N
266 CD N
RDL NNP N
and CC N
124 CD N
EXT NNP N
patients NNS p
treated VBD p
between IN p
1960 CD p
and CC p
1978 CD p
found VBD N
differences NNS N
consistent JJ N
with IN N
those DT N
of IN N
the DT N
randomized VBN N
study NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -X- O O

A DT N
sensory JJ i
integration NN i
therapy NN i
program NN i
on IN N
sensory JJ p
problems NNS p
for IN p
children NNS p
with IN p
autism NN p
. . p

The DT N
study NN N
was VBD N
planned VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
a DT N
sensory JJ i
integration NN i
therapy NN i
program NN i
on IN N
sensory JJ o
problems NNS o
of IN N
children NNS p
with IN p
autism NN p
. . p

This DT N
study NN N
was VBD N
conducted VBN N
at IN N
the DT N
Trakya NNP p
University NNP p
Training NNP p
and CC p
Research NNP p
Center NNP p
for IN p
Mentally NNP p
and CC p
Physically NNP p
Handicapped NNP p
Children NNP p
in IN p
Turkey NNP p
. . p

The DT N
children NNS N
were VBD N
separated VBN N
into IN N
two CD N
groups NNS N
, , N
each DT N
comprising VBG p
15 CD p
children NNS p
between IN p
7 CD p
and CC p
11 CD p
years NNS p
of IN p
age NN p
with IN p
autism NN p
, , p
according VBG p
to TO p
DSM-IV NNP p
criteria NNS p
. . p

The DT N
children NNS N
in IN N
each DT N
group NN N
were VBD N
assessed VBN N
initially RB N
on IN N
a DT N
checklist NN N
, , N
Sensory NNP N
Evaluation NNP N
Form NNP N
for IN N
Children NNP N
with IN N
Autism NNP N
, , N
developed VBD N
to TO N
evaluate VB N
sensory JJ o
characteristics NNS o
of IN N
children NNS N
with IN N
autism NN N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
participants NNS N
were VBD N
assessed VBN N
again RB N
on IN N
the DT N
checklist NN N
. . N

Statistically NNP N
significant JJ N
differences NNS N
between IN N
groups NNS N
indicated VBD N
that IN N
the DT N
sensory JJ i
integration NN i
therapy NN i
program NN i
positively RB N
affected VBD N
treated JJ N
children NNS N
. . N

-DOCSTART- -X- O O

The DT N
therapeutic JJ o
efficacy NN o
and CC o
cost-effectiveness NN o
of IN N
aggressive JJ N
tocolysis NN N
for IN N
premature JJ p
labor NN p
associated VBN p
with IN p
premature JJ p
rupture NN p
of IN p
the DT p
membranes NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
bed VBD i
rest NN i
with IN i
tocolysis NN i
to TO N
determine VB N
the DT N
therapeutic JJ o
efficacy NN o
, , o
safety NN o
, , o
and CC o
cost-effectiveness NN o
of IN N
tocolysis NN i
for IN N
the DT N
treatment NN N
of IN N
preterm JJ p
labor NN p
after IN p
membrane JJ p
rupture NN p
. . p

One CD p
hundred VBD p
nine CD p
women NNS p
participated VBD p
over IN p
a DT p
26-month JJ p
interval NN p
. . p

Treatment NNP N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
terms NNS N
of IN N
gestational JJ o
age NN o
at IN o
membrane NN o
rupture NN o
, , o
gestational JJ o
age NN o
at IN o
delivery NN o
, , o
birth NN o
weight NN o
, , o
maternal JJ o
or CC o
fetal JJ o
infectious JJ o
morbidity NN o
, , o
respiratory JJ o
distress NN o
syndrome NN o
, , o
necrotizing VBG o
enterocolitis NN o
, , o
or CC o
perinatal JJ o
mortality NN o
. . o

Prolongation NN N
of IN N
intrauterine JJ N
time NN N
after IN N
the DT N
onset NN N
of IN N
uterine JJ N
contractions NNS N
was VBD N
seen VBN N
in IN N
women NNS N
receiving VBG N
tocolysis NN i
( ( N
105.2 CD N
+/- JJ N
157 CD N
hours NNS N
versus JJ N
62.1 CD N
+/- JJ N
77 CD N
hours NNS N
, , N
p VBP N
= RB N
0.06 CD N
) ) N
. . N

This DT N
prolongation NN N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
total JJ o
cost NN o
per IN N
surviving VBG N
infant NN N
( ( N
tocolysis NN N
, , N
$ $ N
38,593 CD N
+/- JJ N
$ $ N
40,887 CD N
versus NN N
bed NN N
rest NN N
, , N
$ $ N
43,158 CD N
+/- JJ N
$ $ N
37,116 CD N
; : N
p NN N
= VBZ N
0.445 CD N
) ) N
. . N

The DT N
cost NN o
difference NN o
was VBD N
artifactual JJ N
. . N

The DT N
number NN N
of IN N
very RB o
premature JJ o
infants NNS o
born VBN o
( ( N
less JJR N
than IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
) ) N
was VBD N
unequal JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
12 CD N
in IN N
the DT N
bed NN N
rest NN N
group NN N
and CC N
5 CD N
in IN N
the DT N
tocolysis NN N
group NN N
) ) N
and CC N
skewed VBD N
the DT N
results NNS N
. . N

Before IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
tocolysis NN N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN o
in IN o
intrauterine JJ o
time NN o
after IN N
the DT N
onset NN N
of IN N
regular JJ o
contractions NNS o
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
identifiable JJ N
perinatal JJ N
benefit NN N
garnered VBD N
from IN N
the DT N
additional JJ N
5 CD N
days NNS N
. . N

After IN N
28 CD N
weeks NNS N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
in IN N
terms NNS N
of IN N
intrauterine NN o
time NN o
after IN N
the DT N
onset NN N
of IN N
regular JJ o
contractions NNS o
and CC N
total JJ o
cost NN o
per IN N
surviving VBG N
infant NN N
. . N

Because IN N
tocolysis NN i
does VBZ N
not RB N
improve VB N
perinatal JJ N
outcome NN N
and CC N
can MD N
itself PRP N
be VB N
associated VBN N
with IN N
major JJ N
maternal JJ N
morbidity NN N
, , N
it PRP N
should MD N
be VB N
avoided VBN N
after IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Before IN N
28 CD N
weeks NNS N
' POS N
gestation NN N
tocolysis NN i
may MD N
greatly RB N
increase VB N
intrauterine JJ N
time NN N
, , N
but CC N
the DT N
benefit NN N
of IN N
this DT N
prolongation NN N
is VBZ N
not RB N
clear JJ N
. . N

-DOCSTART- -X- O O

Comparison NNP N
between IN N
intermittent JJ i
mandatory JJ i
ventilation NN i
and CC N
synchronized JJ i
intermittent NN i
mandatory JJ i
ventilation NN i
with IN N
pressure NN i
support NN i
in IN p
children NNS p
. . p

OBJECTIVE NN N
To TO N
compare VB N
intermittent JJ i
mandatory JJ i
ventilation NN i
( ( i
IMV NNP i
) ) i
with IN N
synchronized JJ i
intermittent JJ i
mandatory NN i
ventilation NN i
plus CC i
pressure NN i
support NN i
( ( i
SIMV+PS NNP i
) ) i
in IN N
terms NNS N
of IN N
time NN o
on IN o
mechanical JJ o
ventilation NN o
, , o
duration NN o
of IN o
weaning VBG o
and CC o
length NN o
of IN o
stay NN o
in IN o
a DT o
pediatric JJ o
intensive JJ o
care NN o
unit NN o
( ( p
PICU NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
that WDT N
enrolled VBD p
children NNS p
aged VBN p
28 CD p
days NNS p
to TO p
4 CD p
years NNS p
who WP p
were VBD p
admitted VBN p
to TO p
a DT p
PICU NNP p
between IN p
October NNP p
of IN p
2005 CD p
and CC p
June NNP p
of IN p
2007 CD p
and CC p
put VB p
on IN p
mechanical JJ i
ventilation NN i
( ( i
MV NNP i
) ) i
for IN p
more JJR p
than IN p
48 CD p
hours NNS p
. . p

These DT N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
by IN N
drawing VBG N
lots NNS N
: : N
IMV NNP i
group NN N
( ( i
IMVG NNP i
; : i
n CC N
= VB N
35 CD N
) ) N
and CC N
SIMV+PS NNP i
group NN N
( ( i
SIMVG NNP i
; : i
n CC N
= VB N
35 CD N
) ) N
. . N

Children NNP p
were VBD p
excluded VBN p
if IN p
they PRP p
had VBD p
undergone JJ p
tracheotomy NN p
or CC p
had VBD p
chronic JJ p
respiratory NN p
diseases NNS p
. . p

Data NNS N
on IN N
oxygenation NN o
and CC o
ventilation NN o
were VBD N
recorded VBN N
at IN N
admission NN N
and CC N
at IN N
the DT N
start NN N
of IN N
weaning VBG N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
age NN o
, , o
sex NN o
, , o
indication NN o
for IN o
MV NNP o
, , o
PRISM NNP o
score NN o
, , o
Comfort NNP o
scale NN o
, , o
use NN o
of IN o
sedatives NNS o
or CC o
ventilation NN o
and CC o
oxygenation NN o
parameters NNS o
. . o

The DT N
median JJ o
time NN o
on IN o
MV NNP o
was VBD N
5 CD N
days NNS N
for IN N
both DT N
groups NNS N
( ( N
p JJ N
= NNP N
0.120 CD N
) ) N
. . N

There EX N
were VBD N
also RB N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
for IN N
duration NN o
of IN o
weaning VBG o
[ JJ i
IMVG NNP i
: : i
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
vs. FW N
SIMVG NNP i
: : i
1 CD N
day NN N
( ( N
1-6 JJ N
) ) N
; : N
p CC N
= $ N
0.262 CD N
] NN N
or CC N
length NN o
of IN o
hospital NN o
stay NN o
[ JJ i
IMVG NNP i
: : i
8 CD N
days NNS N
( ( N
2-22 JJ N
) ) N
vs. FW N
SIMVG NNP i
: : i
6 CD N
days NNS N
( ( N
3-20 JJ N
) ) N
; : N
p CC N
= $ N
0.113 CD N
] NNP N
. . N

CONCLUSION NNP N
Among IN N
the DT N
children NNS p
studied VBN p
here RB p
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
IMV NNP i
and CC N
SIMV+PS NNP i
in IN N
terms NNS N
of IN N
time NN N
on IN N
MV NNP o
, , o
duration NN o
of IN o
weaning VBG o
or CC o
time NN o
spent VBN o
in IN o
the DT o
PICU NNP o
. . o

ClinicalTrials.govID NN N
: : N
NCT00549809 NNP N
. . N

-DOCSTART- -X- O O

Predictive JJ N
validity NN N
of IN N
a DT N
medication NN N
adherence NN N
measure NN N
in IN N
an DT N
outpatient JJ p
setting NN p
. . p

This DT N
study NN N
examines VBZ N
the DT N
psychometric JJ N
properties NNS N
and CC N
tests VBZ N
the DT N
concurrent NN N
and CC N
predictive JJ N
validity NN N
of IN N
a DT N
structured JJ i
, , i
self-reported JJ i
medication NN i
adherence NN i
measure NN i
in IN N
patients NNS p
with IN p
hypertension NN p
. . p

The DT N
authors NNS N
also RB N
assessed VBD N
various JJ N
psychosocial JJ o
determinants NNS o
of IN o
adherence NN o
, , N
such JJ N
as IN N
knowledge NN o
, , o
social JJ o
support NN o
, , o
satisfaction NN o
with IN o
care NN o
, , N
and CC N
complexity NN o
of IN o
the DT o
medical JJ o
regimen NNS o
. . o

A DT p
total NN p
of IN p
1367 CD p
patients NNS p
participated VBN p
in IN p
the DT p
study NN p
; : p
mean JJ p
age NN p
was VBD p
52.5 CD p
years NNS p
, , p
40.8 CD p
% NN p
were VBD p
male JJ p
, , p
76.5 CD p
% NN p
were VBD p
black JJ p
, , p
50.8 CD p
% NN p
graduated VBN p
from IN p
high JJ p
school NN p
, , p
26 CD p
% NN p
were VBD p
married VBN p
, , p
and CC p
54.1 CD p
% NN p
had VBD p
income NN p
< NNP p
$ $ p
5,000 CD p
. . p

The DT N
8-item JJ N
medication NN i
adherence NN i
scale NN N
was VBD N
reliable JJ N
( ( N
alpha=.83 NN N
) ) N
and CC N
significantly RB N
associated VBN N
with IN N
blood NN o
pressure NN o
control NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Using VBG N
a DT N
cutpoint NN N
of IN N
< $ N
6 CD N
, , N
the DT N
sensitivity NN N
of IN N
the DT N
measure NN N
to TO N
identify VB N
patients NNS N
with IN N
poor JJ N
blood NN o
pressure NN o
control NN o
was VBD N
estimated VBN N
to TO N
be VB N
93 CD N
% NN N
, , N
and CC N
the DT N
specificity NN N
was VBD N
53 CD N
% NN N
. . N

The DT N
medication NN N
adherence NN N
measure NN N
proved VBD N
to TO N
be VB N
reliable JJ N
, , N
with IN N
good JJ N
concurrent NN N
and CC N
predictive JJ N
validity NN N
in IN N
primarily RB p
low-income JJ p
, , p
minority NN p
patients NNS p
with IN p
hypertension NN p
and CC N
might MD N
function VB N
as IN N
a DT N
screening VBG N
tool NN N
in IN N
outpatient JJ p
settings NNS p
with IN N
other JJ N
patient NN p
groups NNS p
. . p

-DOCSTART- -X- O O

Double-blind NNP N
, , N
placebo-controlled JJ N
trial NN N
of IN N
risperidone NN i
plus CC i
topiramate NN i
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

BACKGROUND NNP N
Autism NNP N
is VBZ N
a DT N
complex JJ N
neurodevelopmental JJ N
disorder NN N
that WDT N
forms VBZ N
part NN N
of IN N
a DT N
spectrum NN N
of IN N
related JJ N
disorders NNS N
referred VBD N
to TO N
as IN N
Autism NNP N
Spectrum NNP N
Disorders NNP N
. . N

The DT N
present JJ N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
topiramate NN i
plus CC i
risperidone NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
. . p

METHOD NNP N
Forty NNP p
children NNS p
between IN p
the DT p
ages NNS p
of IN p
4 CD p
and CC p
12 CD p
years NNS p
with IN p
a DT p
DSM NNP p
IV NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
who WP p
were VBD p
outpatients NNS p
from IN p
a DT p
specialty NN p
clinic NN p
for IN p
children NNS p
were VBD p
recruited VBN p
. . p

The DT N
children NNS p
presented VBN N
with IN N
a DT N
chief JJ N
complaint NN N
of IN N
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
topiramate+risperidone VB i
( ( i
Group NNP i
A NNP i
) ) i
or CC i
placebo+risperidone NN i
( ( i
Group NNP i
B NNP i
) ) i
for IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
up RB N
to TO N
2 CD N
mg/day NN N
for IN N
children NNS N
between IN N
10 CD N
and CC N
40 CD N
kg NN N
and CC N
3 CD N
mg/day NN N
for IN N
children NNS N
weighting VBG N
above IN N
40 CD N
kg NN N
. . N

The DT N
dose NN N
of IN N
topiramate NN i
was VBD N
titrated VBN N
up RB N
to TO N
200 CD N
mg/day NN N
depending VBG N
on IN N
weight NN N
( ( N
100 CD N
mg/day NN N
for IN N
< $ N
30 CD N
kg NN N
and CC N
200 CD N
mg/day NN N
for IN N
> $ N
30 CD N
kg NN N
) ) N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
after IN N
starting VBG N
medication NN N
. . N

Measure NN N
of IN N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Rating VBG o
Scale NNP o
. . o

RESULTS NNP N
Difference NNP N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
the DT N
group NN N
that WDT N
received VBD N
topiramate NN i
had VBD N
a DT N
greater JJR N
reduction NN o
in IN o
ABC-C NNP o
subscale NN o
scores NNS o
for IN o
irritability NN o
, , o
stereotypic JJ o
behavior NN o
and CC o
hyperactivity/noncompliance NN o
. . o

CONCLUSION VB N
The DT N
results NNS N
suggest VBP N
that IN N
the DT N
combination NN N
of IN N
topiramate NN i
with IN N
risperidone NN N
may MD N
be VB N
superior JJ N
to TO N
risperidone VB N
monotherapy NN N
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

However RB N
the DT N
results NNS N
need VBP N
to TO N
be VB N
further RB N
confirmed VBN N
by IN N
a DT N
larger JJR N
randomized VBN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -X- O O

In-season JJ N
effect NN N
of IN N
short-term JJ i
sprint NN i
and CC i
power NN i
training NN i
programs NNS i
on IN N
elite JJ p
junior JJ p
soccer NN p
players NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
2 CD N
in-season JJ N
short-term JJ i
sprint NN i
and CC i
power NN i
training NN i
protocols NNS i
on IN N
vertical JJ N
countermovement NN N
jump NN N
height NN N
( ( N
with IN N
or CC N
without IN N
arms NNS N
) ) N
, , N
sprint NN N
( ( N
Sprint-15m NNP N
) ) N
speed NN N
, , N
and CC N
agility NN N
( ( N
Agility-15m NNP N
) ) N
speed NN N
in IN N
male JJ p
elite JJ p
junior JJ p
soccer NN p
players NNS p
. . p

Twenty NNP p
highly RB p
trained VBD p
soccer NN p
players NNS p
( ( p
age NN p
18.3 CD p
+/- JJ p
0.6 CD p
years NNS p
, , p
height VBD p
177 CD p
+/- JJ p
4 CD p
cm NN p
, , p
body NN p
mass VBD p
71.4 CD p
+/- JJ p
6.9 CD p
kg NN p
, , p
sum NN p
skinfolds NNS p
48.1 CD p
+/- JJ p
11.4 CD p
mm NN p
) ) p
, , p
members NNS p
of IN p
a DT p
professional JJ p
soccer NN p
academy NN p
, , N
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
CONTRAST NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
or CC N
SPRINT NNP N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
group NN N
. . N

The DT i
training NN i
intervention NN i
consisted VBD N
of IN N
6 CD i
supervised JJ i
training NN i
sessions NNS i
over IN N
7 CD N
weeks NNS N
, , N
targeting VBG N
the DT N
improvement NN N
of IN N
the DT N
players NNS N
' POS N
speed NN o
and CC o
power NN o
. . o

CONTRAST NNP N
protocol NN N
consisted VBD N
of IN N
alternating VBG N
heavy-light JJ N
resistance NN N
( ( N
15-50 CD N
% NN N
body NN N
mass NN N
) ) N
with IN N
soccer-specific JJ N
drills NNS N
( ( N
small-sided JJ N
games NNS N
or CC N
technical JJ N
skills NNS N
) ) N
. . N

SPRINT NNP i
training NN i
protocol NN i
used VBN N
line NN N
30-m JJ N
sprints NNS N
( ( N
2-4 JJ N
sets NNS N
of IN N
4 CD N
x JJ N
30 CD N
m NN N
with IN N
180 CD N
and CC N
90 CD N
seconds NNS N
of IN N
recovery NN N
, , N
respectively RB N
) ) N
. . N

At IN N
baseline JJ N
no DT N
difference NN N
between IN N
physical JJ o
test NN o
performance NN o
was VBD N
evident JJ N
between IN N
the DT N
2 CD N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

No DT N
time NN N
x VBZ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
any DT N
of IN N
the DT N
vertical JJ o
jump NN o
and CC o
Agility-15m JJ o
variables NNS o
( ( o
p JJ o
> NNP N
0.05 CD N
) ) N
. . N

A DT N
time NN N
x JJ N
training VBG N
group NN N
effect NN N
was VBD N
found VBN N
for IN N
Sprint-15m JJ N
performance NN N
with IN N
the DT N
CONTRAST NNP N
group NN N
showing VBG N
significantly RB N
better JJR N
scores NNS N
than IN N
the DT N
SPRINT NNP N
group NN N
( ( N
7.23 CD N
+/- JJ N
0.18 CD N
vs. FW N
7.09 CD N
+/- JJ N
0.20 CD N
m.s NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
light NN N
of IN N
these DT N
findings NNS N
CONTRAST NNP i
training NN i
should MD N
be VB N
preferred VBN N
to TO N
line NN N
sprint NN N
training NN N
in IN N
the DT N
short JJ N
term NN N
in IN N
young JJ p
elite JJ p
soccer NN p
players NNS p
when WRB N
the DT N
aim NN N
is VBZ N
to TO N
improve VB N
soccer-specific JJ o
sprint NN o
performance NN o
( ( o
15 CD o
m NN o
) ) o
during IN N
the DT N
competitive JJ N
season NN N
. . N

-DOCSTART- -X- O O

A DT N
program NN N
of IN N
screening VBG N
and CC N
prompting VBG N
improves NNS N
short-term JJ N
physician JJ N
counseling NN N
of IN N
dependent NN p
and CC p
nondependent JJ p
harmful JJ p
drinkers NNS p
. . p

BACKGROUND NNP N
Physicians NNPS N
in IN N
the DT N
general JJ N
medical JJ N
setting VBG N
commonly RB N
encounter RB N
but CC N
rarely RB N
counsel NN N
patients NNS p
with IN p
dependent JJ p
or CC p
harmful JJ p
drinking NN p
behaviors NNS p
. . p

We PRP N
tested VBD N
whether IN N
providing VBG N
physicians NNS N
with IN N
their PRP$ N
patients NNS N
' POS N
results NNS N
on IN N
the DT N
alcohol NN N
module NN N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
would MD N
prompt VB N
them PRP N
to TO N
counsel NN N
these DT N
patients NNS N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBN N
83 CD p
first- JJ p
, , p
second- JJ p
, , p
and CC p
third-year JJ p
medical JJ p
residents NNS p
to TO p
receive VB i
or CC i
not RB i
to TO i
receive VB i
diagnostic JJ i
information NN i
and CC i
counseling VBG i
directives NNS i
on IN i
214 CD p
patients NNS p
who WP p
reported VBD p
at IN p
least JJS p
one CD p
symptom NN p
of IN p
alcohol NN p
impairment NN p
as IN p
defined VBN p
in IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Third NNP p
Edition NNP p
. . p

Using VBG N
binary JJ i
logistic JJ i
regression NN i
, , N
we PRP N
examined VBD N
the DT N
effect NN N
of IN N
specific JJ N
covariables NNS N
on IN N
rates NNS N
of IN N
physician JJ N
counseling NN N
. . N

These DT N
variables NNS N
included VBD N
physician JJ N
information NN N
status NN N
, , N
patient JJ N
gender NN N
, , N
and CC N
drinking VBG N
disorder NN N
severity NN N
and CC N
recency NN N
. . N

We PRP N
also RB N
examined VBD N
the DT N
effect NN N
of IN N
physician JJ N
prompting VBG N
on IN N
counseling NN N
of IN N
female JJ p
patients NNS p
, , p
patients NNS p
with IN p
inactive JJ p
disorders NNS p
, , p
and CC p
nondependent NN p
but CC p
harmful JJ p
drinkers NNS p
. . p

We PRP N
determined VBD N
counseling VBG N
by IN N
post-visit JJ N
patient JJ N
interviews NNS N
. . N

RESULTS NNP N
Physician JJ o
prompting NN o
, , o
dependent JJ o
drinking NN o
, , o
and CC o
recent JJ o
disorder NN o
activity NN o
were VBD N
significant JJ N
correlates NNS N
of IN N
physician JJ N
counseling NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
, , N
while IN N
male JJ N
gender NN N
was VBD N
a DT N
marginally RB N
significant JJ N
correlate NN N
( ( N
P NNP N
= NNP N
.08 NNP N
) ) N
. . N

Informed VBN N
physicians NNS N
counseled VBD N
female JJ N
patients NNS N
, , N
harmful JJ N
but CC N
nondependent JJ N
drinkers NNS N
, , N
and CC N
patients NNS N
with IN N
inactive JJ N
disorders NNS N
more RBR N
often RB N
than IN N
their PRP$ N
uninformed JJ N
colleagues NNS N
, , N
although IN N
only RB N
the DT N
last JJ N
variable JJ N
achieved VBD N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Providing VBG N
physicians NNS N
with IN N
the DT N
results NNS N
of IN N
the DT N
Diagnostic NNP N
Interview NNP N
Schedule NNP N
and CC N
counseling VBG N
directives NNS N
resulted VBD N
in IN N
short-term JJ N
improvement NN N
in IN N
their PRP$ N
rates NNS N
of IN N
counseling VBG N
patients NNS N
with IN N
a DT N
history NN N
of IN N
dependent NN N
or CC N
nondependent NN N
but CC N
harmful JJ N
drinking NN N
. . N

Further NNP N
research NN N
is VBZ N
necessary JJ N
to TO N
determine VB N
long-term JJ N
gains NNS N
in IN N
rates NNS N
of IN N
physician JJ i
counseling NN i
and CC i
improvements NNS i
in IN N
the DT N
course NN N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Antihistamines NNS i
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ N
serum NN N
in IN N
resistant JJ N
chronic JJ N
idiopathic JJ N
urticaria NN N
. . N

Some DT N
patients NNS p
with IN p
chronic JJ p
idiopathic JJ p
urticaria NN p
( ( p
CIU NNP p
) ) p
are VBP N
resistant JJ N
to TO N
conventional JJ N
doses NNS N
of IN N
antihistamines NNS i
( ( i
AHs NNP i
) ) i
. . i

This DT N
study NN N
was VBD N
designed VBN N
to TO N
check VB N
whether IN N
the DT N
skin JJ o
wheal NN o
and CC o
flare JJ o
reaction NN o
produced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
autologous JJ i
serum NN i
( ( i
AS IN i
) ) i
and CC N
by IN N
histamine NN i
differs NNS N
in IN N
AH-resistant NNP p
and CC p
AH NNP p
responder VBP p
CIU NNP p
patients NNS p
. . p

CIU NNP p
patients NNS p
with IN p
treatment NN p
failure NN p
under IN p
fexofenadine NN i
at IN p
180 CD p
mg NN p
q.d NN p
. . p

increased VBD i
their PRP$ i
daily JJ i
dose NN i
of IN N
AH NNP N
to TO N
4 CD N
tablets NNS N
daily RB N
. . N

Those DT p
with IN p
significant JJ p
improvement NN p
of IN p
urticaria JJ p
activity NN p
score NN p
under IN p
fexofenadine NN i
at IN p
180 CD p
mg NNS p
were VBD N
included VBN N
in IN N
the DT N
CIU NNP N
group NN N
. . N

Subjects VBZ N
with IN N
treatment NN N
failure NN N
despite IN N
a DT N
full JJ N
8-week JJ N
fourfold JJ N
fexofenadine NN i
treatment NN N
were VBD N
included VBN N
in IN N
the DT N
resistant JJ N
CIU NNP N
( ( N
R-CIU NNP N
group NN N
) ) N
. . N

The DT p
control NN p
group NN p
consisted VBD p
of IN p
sex- JJ p
and CC p
age-matched JJ p
patents NNS p
with IN p
allergic JJ p
rhinitis NN p
. . p

The DT N
AS NNP N
skin JJ N
test NN N
and CC N
intradermal JJ N
histamine-induced JJ i
wheal NN N
and CC N
flare JJ N
reaction NN N
were VBD N
performed VBN N
at IN N
baseline NN N
( ( N
without IN N
AH NNP N
) ) N
, , N
after IN N
8 CD N
and CC N
16 CD N
weeks NNS N
( ( N
under IN N
AH NNP N
treatment NN N
) ) N
. . N

Forty-six JJ p
subjects NNS p
were VBD p
included VBN p
in IN p
the DT p
CIU NNP p
group NN p
, , p
21 CD p
were VBD p
in IN p
the DT p
R-CIU NNP p
group NN p
, , p
and CC p
44 CD p
were VBD p
in IN p
the DT p
control NN p
group NN p
. . p

Under IN N
AH NNP N
therapy NN N
, , N
the DT N
skin JJ o
reaction NN o
to TO o
intradermal VB o
histamine JJ o
injection NN o
was VBD N
significantly RB N
diminished VBN N
in IN N
all DT N
study NN N
groups NNS N
. . N

In IN N
the DT N
R-CIU NNP N
group NN N
, , N
fexofenadine NN i
at IN N
180 CD N
mg NNS N
did VBD N
not RB N
suppress VB N
AS-induced NNP o
wheal JJ o
reaction NN o
( ( N
5.96 CD N
? . N
2.25 CD N
mm NN N
; : N
p CC N
= VB N
0.85 CD N
) ) N
, , N
and CC N
with IN N
a DT N
fourfold JJ i
AH NNP i
dose VB N
some DT o
reduction NN o
of IN o
AS-induced NNP o
wheal NN o
( ( N
3.79 CD N
? . N
1.74 CD N
mm NN N
; : N
p CC N
= VB N
0.008 CD N
) ) N
was VBD N
observed VBN N
but CC N
remained VBD N
larger JJR N
than IN N
in IN N
the DT N
CIU NNP N
( ( N
2.31 CD N
? . N
1.12 CD N
; : N
p NN N
= VBZ N
0.006 CD N
) ) N
and CC N
control NN N
groups NNS N
( ( N
2.52 CD N
? . N
1.36 CD N
; : N
p NN N
= VBZ N
0.037 CD i
) ) i
. . i

AHs NNP i
do VBP N
not RB N
inhibit VB N
the DT N
wheal NN N
induced VBN N
by IN N
the DT N
intradermal JJ N
injection NN N
of IN N
AS NNP N
in IN N
R-CIU NNP N
. . N

-DOCSTART- -X- O O

Plasma NNP N
pH NN N
does VBZ N
not RB N
influence VB N
the DT N
cerebral JJ p
metabolic JJ p
ratio NN p
during IN p
maximal JJ p
whole JJ p
body NN p
exercise NN p
. . p

Exercise NN N
lowers VBZ N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
of IN N
O2 NNP N
to TO N
carbohydrate VB N
( ( N
glucose+1/2 JJ N
lactate NN N
) ) N
and CC N
metabolic JJ N
acidosis NN N
appears VBZ N
to TO N
promote VB o
cerebral JJ o
lactate JJ o
uptake NN o
. . o

However RB N
, , N
the DT N
influence NN N
of IN N
pH NN N
on IN N
cerebral JJ N
lactate JJ N
uptake NN N
and CC N
, , N
in IN N
turn NN N
, , N
on IN N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
exercise NN N
is VBZ N
not RB N
known VBN N
. . N

Sodium NN i
bicarbonate NN i
( ( i
Bicarb NNP i
, , i
1 CD i
M NNP i
; : i
350-500 CD i
ml NN i
) ) i
or CC i
an DT i
equal JJ i
volume NN i
of IN i
normal JJ i
saline NN i
( ( i
Sal NNP i
) ) i
was VBD i
infused VBN i
intravenously RB i
at IN i
a DT i
constant JJ i
rate NN i
during IN i
a DT i
'2000 CD i
m NN i
' '' i
maximal JJ i
ergometer NN i
row NN i
in IN N
six CD p
male JJ p
oarsmen NNS p
( ( p
23?2 CD p
years NNS p
; : p
mean?S.D. NN p
) ) p
. . p

During IN N
the DT N
Sal NNP N
trial NN o
, , o
pH NN o
decreased VBD o
from IN N
7.41?0.01 CD N
at IN N
rest NN N
to TO N
7.02?0.02 CD N
but CC N
only RB N
to TO N
7.36?0.02 CD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
Bicarb NNP N
trial NN N
. . o

Arterial JJ o
lactate NN o
increased VBD o
to TO N
21.4?0.8 CD N
and CC N
32.7?2.3 CD N
mM NN N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
the DT o
arterial-jugular JJ o
venous JJ o
lactate NN o
difference NN o
increased VBD N
from-0.03?0.01 JJ N
mM NN N
at IN N
rest NN N
to TO N
3.2?0.9 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
3.4?1.4 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
following VBG N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
. . N

Accordingly RB o
, , o
the DT o
cerebral JJ o
metabolic NN o
ratio NN o
decreased VBD o
equally RB N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
: : N
from IN N
5.8?0.6 CD N
at IN N
rest NN N
to TO N
1.7?0.1 CD N
and CC N
1.8?0.2 CD N
, , N
respectively RB N
. . N

The DT o
enlarged JJ o
blood-buffering NN o
capacity NN o
after IN o
infusion NN i
of IN i
Bicarb NNP i
eliminated VBD o
metabolic JJ o
acidosis NN o
during IN o
maximal JJ N
exercise NN N
but CC N
that DT N
did VBD N
not RB N
affect VB N
the DT o
cerebral JJ o
lactate NN o
uptake NN o
and CC o
, , o
therefore RB N
, , N
the DT N
decrease NN N
in IN N
the DT o
cerebral JJ o
metabolic NN o
ratio NN o
. . o

-DOCSTART- -X- O O

Incidence NN N
and CC N
clinical JJ N
significance NN N
of IN N
false-negative JJ p
sextant JJ p
prostate NN p
biopsies NNS p
. . p

PURPOSE NNP N
Since IN N
most JJS N
patients NNS N
do VBP N
not RB N
undergo VB N
repeat NN N
sextant JJ N
prostate NN N
biopsies NNS N
after IN N
a DT N
biopsy NN N
is VBZ N
positive JJ N
for IN N
prostate NN N
cancer NN N
, , N
the DT N
true JJ N
incidence NN N
of IN N
false-negative JJ N
biopsies NNS N
is VBZ N
not RB N
well RB N
defined VBN N
. . N

We PRP N
assess VBP N
the DT N
incidence NN N
and CC N
clinical JJ N
significance NN N
of IN N
false-negative JJ p
sextant JJ p
prostate NN p
biopsies NNS p
in IN p
patients NNS p
undergoing VBG p
radical JJ i
prostatectomy NN i
. . i

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
118 CD p
patients NNS p
with IN p
biopsy NN p
proved VBN p
prostate JJ p
cancer NN p
underwent JJ N
repeat NN i
sextant JJ i
prostate NN i
biopsy NN i
before IN N
enrollment NN N
in IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
radical JJ i
prostatectomy NN i
with IN i
or CC i
without IN i
neoadjuvant JJ i
hormonal JJ i
therapy NN i
. . i

Clinical JJ N
parameters NNS N
were VBD N
assessed VBN N
to TO N
determine VB N
potential JJ N
sources NNS N
of IN N
bias NN N
. . N

Pathological JJ N
parameters NNS N
and CC N
prostate NN o
specific JJ o
antigen NN o
relapse-free JJ o
survival NN o
rates NNS o
were VBD N
compared VBN N
to TO N
determine VB N
the DT N
clinical JJ N
significance NN N
of IN N
false-negative JJ N
biopsies NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
118 CD p
patients NNS p
27 CD N
( ( N
23 CD N
% NN N
) ) N
had VBD N
a DT N
negative JJ N
repeat NN N
sextant JJ N
biopsy NN N
. . N

Except IN N
for IN N
initial JJ N
clinical JJ N
stage NN N
, , N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
the DT N
clinical JJ o
or CC o
pathological JJ o
parameters NNS o
, , N
or CC N
prostate VB o
specific JJ o
antigen NN o
relapse NN o
rates NNS o
in IN N
patients NNS N
with IN N
negative JJ N
versus NN N
positive JJ N
repeat NN N
biopsies NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
this DT N
23 CD N
% NN N
incidence NN N
of IN N
false-negative JJ N
biopsies NNS N
represents VBZ N
significant JJ N
cancer NN N
. . N

This DT N
relatively RB N
high JJ N
incidence NN N
is VBZ N
important JJ N
to TO N
consider VB N
in IN N
treatment NN N
modalities NNS N
in IN N
which WDT N
prostate VBP N
biopsy NN N
may MD N
be VB N
performed VBN N
to TO N
determine VB N
response NN N
to TO N
therapy NN N
. . N

-DOCSTART- -X- O O

[ JJ i
Diabetic NNP i
retinopathy NN i
candesartan NN i
trial NN N
] NN N
. . N

-DOCSTART- -X- O O

Lamivudine NNP i
300 CD N
mg NN N
QD NNP N
versus NN N
continued VBD N
lamivudine JJ i
150 CD N
mg NNS N
BID NNP N
with IN N
stavudine NN i
and CC N
a DT N
protease NN i
inhibitor NN i
in IN N
suppressed JJ p
patients NNS p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
( ( N
sustained VBN N
virologic IN N
suppression NN N
) ) N
and CC N
safety/tolerability NN N
of IN N
a DT N
switch NN N
to TO N
lamivudine VB i
300 CD N
mg NNS N
once RB N
daily JJ N
( ( N
QD NNP N
) ) N
versus NN N
continued VBD N
lamivudine JJ i
150 CD N
mg JJ N
twice RB N
daily RB N
( ( N
BID NNP N
) ) N
in IN N
virologically RB p
suppressed VBN p
patients NNS p
( ( p
HIV-1 NNP p
RNA NNP p
< NNP p
400 CD p
copies/mL NN p
for IN p
> NN p
or CC p
=3 JJ p
months NNS p
) ) p
on IN p
stable JJ p
( ( p
> JJ p
or CC p
=6 JJ p
months NNS p
) ) p
therapy NN p
with IN p
lamivudine JJ i
150 CD i
mg NN i
BID NNP i
plus CC i
stavudine NN i
and CC i
either DT i
indinavir NN i
or CC i
nelfinavir NN i
. . i

METHOD NNP N
Eighty-nine NNP p
suppressed VBD p
patients NNS p
> CD p
or CC p
=18 CD p
years NNS p
old JJ p
with IN p
CD4 NNP p
counts VBZ p
> JJ p
50 CD p
cells/mm NN p
( ( p
3 CD p
) ) p
were VBD N
enrolled VBN N
in IN N
this DT N
phase NN N
II NNP N
, , N
open-label NN N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
stratified VBN N
( ( N
by IN N
pretrial JJ i
protease NN i
inhibitor NN i
[ NNP N
PI NNP N
] NNP N
) ) N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
. . N

Eighty-one JJ p
patients NNS p
received VBD N
either RB N
lamivudine JJ i
300 CD N
mg NN N
QD NNP N
( ( N
n JJ N
= NNP N
39 CD N
) ) N
or CC N
150 CD N
mg NNS N
BID NNP N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
with IN N
their PRP$ N
pretrial JJ i
stavudine/PI NN i
regimens NNS i
for IN N
24 CD N
weeks NNS N
. . N

RESULTS VB N
A DT N
high JJ N
rate NN o
of IN o
virologic JJ o
suppression NN o
was VBD N
sustained VBN N
with IN N
both DT N
regimens NNS N
throughout IN N
the DT N
trial NN N
. . N

At IN N
week NN N
24 CD N
, , N
intent-to-treat NN N
: : N
exposed VBN N
( ( N
missing VBG N
= NNP N
failure NN N
) ) N
analyses VBZ N
showed VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
percentage NN o
of IN o
patients NNS o
with IN o
HIV-1 NNP o
RNA NNP o
< NNP N
400 CD N
copies/mL NN N
( ( N
95 CD N
% NN N
[ JJ N
QD NNP N
] NNP N
vs. IN N
90 CD N
% NN N
[ JJ N
BID NNP N
] NNP N
) ) N
or CC N
< $ N
50 CD N
copies/mL NN N
( ( N
82 CD N
% NN N
[ JJ N
QD NNP N
] NNP N
vs. IN N
81 CD N
% NN N
[ JJ N
BID NNP N
] NNP N
) ) N
or CC N
in IN N
the DT N
median JJ o
change NN o
from IN o
baseline NN o
in IN N
CD4 NNP o
counts NNS o
( ( N
+42 JJ N
cells/mm NN N
( ( N
3 CD N
) ) N
[ NN N
QD NNP N
] NNP N
vs. FW N
+22 NNP N
cells/mm NN N
( ( N
3 CD N
) ) N
[ FW N
BID NNP N
] NNP N
) ) N
. . N

Both DT N
regimens NNS N
were VBD N
well RB N
tolerated VBN N
. . N

No DT N
patient NN N
experienced VBD N
virologic JJ o
failure NN o
, , o
clinical JJ o
disease NN o
progression NN o
, , o
or CC o
a DT o
drug-related JJ o
serious JJ o
adverse JJ o
event NN o
during IN N
the DT N
trial NN N
. . N

Self-reported JJ o
medication NN o
adherence NN o
was VBD N
high JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Patients NNPS p
who WP p
experience VBP p
virologic JJ o
suppression NN o
with IN p
a DT p
regimen NNS p
of IN p
lamivudine JJ i
150 CD p
mg NN p
BID NNP p
in IN p
combination NN i
with IN i
stavudine/PI NN i
can MD N
maintain VB N
that DT N
suppression NN o
by IN N
continuing VBG N
their PRP$ N
regimen NNS N
or CC N
switching VBG N
to TO N
lamivudine VB i
300 CD N
mg NN N
QD NNP N
and CC N
continuing VBG N
the DT N
other JJ N
components NNS N
. . N

Adverse JJ N
event NN N
profiles NNS N
were VBD N
comparable JJ N
among IN N
treatment NN N
regimens NNS N
, , N
and CC N
no DT N
new JJ N
safety NN N
concerns NNS N
were VBD N
raised VBN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
chlorhexidine NN i
gluconate NN i
use NN N
in IN N
the DT N
prevention NN N
of IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

The DT N
frequency NN N
of IN N
rectal JJ o
infections NNS o
is VBZ N
increased VBN N
in IN N
patients NNS p
with IN p
acute JJ p
leukemia NN p
. . p

Complications NNS N
associated VBN N
with IN N
rectal JJ N
lesions NNS N
may MD N
be VB N
severe JJ N
enough RB N
to TO N
cause VB N
life-threatening JJ N
septicemia NN N
. . N

Clinical JJ N
research NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
preventive JJ N
perirectal NN N
skin NN N
care NN N
is VBZ N
scarce JJ N
. . N

This DT N
study NN N
's POS N
purpose NN N
was VBD N
to TO N
determine VB N
whether IN N
using VBG N
chlorhexidine JJ i
gluconate NN i
( ( i
CHG NNP i
) ) i
in IN N
a DT N
prophylactic JJ N
perirectal JJ N
skin-care JJ N
regimen NNS N
decreases VBZ N
perirectal JJ N
infections NNS N
and CC N
whether IN N
it PRP N
produces VBZ N
more JJR N
skin JJ N
irritation NN N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

The DT N
sample NN p
consisted VBD p
of IN p
40 CD p
patients NNS p
, , N
16 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
chlorhexidine NN i
and CC N
24 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
use VB N
nonmedicated JJ i
skin NN i
cleanser NN i
. . i

Chi-square JJ N
and CC N
t-tests NNS N
were VBD N
used VBN N
to TO N
analyze VB N
the DT N
incidence NN N
of IN N
skin JJ o
breakdown NN o
and CC N
rectal JJ o
infections NNS o
; : o
the DT N
correlation NN N
between IN N
the DT N
two CD N
factors NNS N
; : N
a DT N
positive JJ N
history NN N
of IN N
rectal JJ N
infections NNS N
, , N
fissures NNS N
, , N
or CC N
hemorrhoids NNS N
; : N
presence NN N
of IN N
hemorrhoids NNS N
; : N
severity NN N
of IN N
diarrhea NN N
; : N
and CC N
duration NN N
and CC N
severity NN N
of IN N
granulocytopenia NN N
. . N

A DT N
positive JJ N
relationship NN N
was VBD N
found VBN N
between IN N
the DT N
severity NN o
of IN o
granulocytopenia NN o
and CC N
the DT N
incidence NN o
of IN o
rectal JJ o
infections NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
in IN N
the DT N
occurrence NN o
of IN o
perirectal JJ o
infections NNS o
( ( N
p JJ N
= NNP N
0.35 CD N
) ) N
or CC N
skin JJ o
breakdown NN o
( ( N
p JJ N
= NNP N
0.18 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
data NN N
suggest NN N
that IN N
CHG NNP N
does VBZ N
not RB N
offer VB N
increased JJ N
protection NN N
against IN N
perirectal JJ N
infections NNS N
in IN N
patients NNS N
undergoing VBG N
intensive JJ N
chemotherapy NN N
, , N
nor CC N
is VBZ N
it PRP N
more RBR N
irritating JJ N
than IN N
a DT N
nonmedicated JJ N
skin NN N
cleanser NN N
. . N

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
hygienic JJ N
measures NNS N
such JJ N
as IN N
using VBG N
skin JJ N
disinfectants NNS N
to TO N
prevent VB N
infections NNS N
in IN N
patients NNS N
who WP N
are VBP N
immunocompromised VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
comparing VBG N
intravesical JJ i
instillations NNS i
of IN N
mitoxantrone NN i
and CC i
doxorubicin NN i
in IN N
patients NNS p
with IN p
superficial JJ p
bladder NN p
cancer NN p
. . p

BACKGROUND NNP N
This DT N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN o
and CC N
side JJ o
effects NNS o
of IN N
intravesical JJ i
mitoxantrone NN i
instillation NN i
with IN N
those DT N
of IN N
doxorubicin NN i
in IN N
superficial JJ p
bladder NN p
cancer NN p
following VBG p
transurethral JJ p
resection NN p
. . p

METHODS NNP N
Sixty-three JJ p
patients NNS p
were VBD p
randomized VBN p
into IN N
mitoxantrone NN i
and CC i
doxorubicin NN i
groups NNS N
. . N

Most JJS N
of IN N
the DT N
patients NNS p
enrolled VBN p
were VBD p
elderly JJ p
people NNS p
( ( p
mean JJ p
age NN p
, , p
71 CD p
years NNS p
) ) p
. . p

The DT N
instilled JJ N
doses NNS N
of IN N
doxorubicin NN i
and CC i
mitoxantrone NN i
were VBD N
30 CD N
and CC N
14 CD N
mg NN N
, , N
respectively RB N
. . N

Disease NNP o
recurrence NN o
and CC o
side NN o
effects NNS o
were VBD N
compared VBN N
using VBG N
Fisher NNP N
's POS N
exact JJ N
test NN N
. . N

The DT N
interval NN o
to TO o
recurrence NN o
was VBD N
shown VBN N
by IN N
Kaplan-Meier NNP N
survivorship NN N
curves NNS N
, , N
and CC N
the DT N
log-rank JJ N
test NN N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
time NN o
to TO o
recurrence VB o
. . o

RESULTS VB N
The DT N
median JJ N
follow-up JJ N
period NN N
was VBD N
36 CD N
months NNS N
. . N

Thirty-three JJ N
patients NNS N
received VBD N
mitoxantrone NN i
, , N
whereas JJ N
30 CD N
patients NNS N
used VBN N
doxorubicin NN i
. . i

The DT N
recurrence NN o
rate NN o
in IN N
the DT N
doxorubicin NN i
group NN N
was VBD N
30 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
19.8 CD N
% NN N
-38.8 NNP N
% NN N
) ) N
, , N
while IN N
it PRP N
was VBD N
27.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
17.5 CD N
% NN N
-36.8 NNP N
% NN N
) ) N
in IN N
the DT N
mitoxantrone NN i
group NN N
. . N

The DT N
median JJ o
recurrence-free JJ o
survival NN o
in IN N
the DT N
mitoxantrone NN i
group NN N
and CC N
in IN N
the DT N
doxorubicin NN i
group NN N
was VBD N
22 CD N
and CC N
20 CD N
months NNS N
, , N
respectively RB N
( ( N
p=0.580 NN N
) ) N
. . N

Higher JJR N
recurrence NN o
rates NNS o
were VBD N
found VBN N
for IN N
Grade NNP N
III NNP N
and CC N
multiple JJ N
primary JJ N
tumors NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
response NN o
rates NNS o
( ( N
p=0.784 NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
side NN o
effects NNS o
was VBD N
20 CD N
% NN N
in IN N
the DT N
doxorubicin NN i
group NN N
and CC N
21.2 CD N
% NN N
in IN N
the DT N
mitoxantrone NN i
group NN N
. . N

However RB N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
( ( N
p JJ N
> NNP N
0.99 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
revealed VBD N
that IN N
the DT N
efficacy NN o
and CC o
side JJ o
effects NNS o
of IN N
mitoxantrone NN i
were VBD N
similar JJ N
to TO N
those DT N
of IN N
doxorubicin NN i
. . i

Especially RB N
for IN N
patients NNS p
with IN p
pulmonary JJ p
tuberculosis NN p
or CC p
aged VBN p
patients NNS p
with IN p
primary JJ p
bladder NN p
tumors NNS p
, , N
mitoxantrone NN i
and CC N
doxorubicin NN i
may MD N
be VB N
the DT N
tolerable JJ N
and CC N
effective JJ N
intravesical JJ N
agents NNS N
. . N

-DOCSTART- -X- O O

Different NNP N
therapeutic JJ N
modalities NNS N
for IN N
treatment NN N
of IN N
melasma NN o
. . o

BACKGROUND NNP N
Chemical NNP i
peels NNS i
and CC N
topical JJ i
depigmenting NN i
agents NNS i
have VBP N
become VBN N
a DT N
popular JJ N
modality NN N
in IN N
the DT N
treatment NN N
of IN N
melasma NN o
. . o

AIMS NNP N
To TO N
compare VB N
the DT N
clinical JJ o
efficacy NN o
of IN N
trichloroacetic JJ i
acid NN i
peel VB i
20 CD i
% NN i
vs NN i
. . N

Jessner NNP i
's POS i
solution NN i
peel NN i
vs. IN i
the DT i
topical JJ i
mixture NN i
of IN i
hydroquinone NN i
2 CD i
% NN i
and CC i
kojic NN i
acid NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty NNP p
five CD p
patients NNS p
with IN p
melasma NNS p
were VBD p
randomly RB p
assigned VBN p
into IN p
three CD p
groups NNS p
of IN p
fifteen JJ p
patients NNS p
each DT p
. . p

Group NNP N
A NNP N
received VBD N
Jessner NNP i
's POS i
solution NN i
peel NN i
, , N
group NN N
B NNP N
received VBD N
trichloroacetic JJ i
acid NN i
peel VB i
20 CD i
% NN i
, , N
and CC N
group NN N
C NNP N
received VBD N
topical JJ i
hydroquinone NN i
2 CD i
% NN i
and CC i
kojic NN i
acid NN i
. . i

All DT N
patients NNS N
were VBD N
seen VBN N
in IN N
follow-up JJ N
period NN N
after IN N
16 CD N
weeks NNS N
; : N
clinical JJ N
evaluation NN N
using VBG N
Melasma NNP o
Area NNP o
and CC o
Severity NNP o
Index NNP o
( ( o
MASI NNP o
) ) o
score NN o
and CC o
photography NN o
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
and CC N
after IN N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
decrease NN N
in IN N
MASI NNP o
score NN o
in IN N
all DT N
three CD N
groups NNS N
after IN N
treatment NN N
and CC N
after IN N
follow-up JJ N
period NN N
but CC N
after IN N
treatment NN N
MASI NNP o
score NN o
was VBD N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
and CC N
it PRP N
was VBD N
also RB N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
but CC N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
. . N

After IN N
the DT N
follow-up JJ N
period NN N
, , N
MASI NNP o
score NN o
was VBD N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
A NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
C NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
statistically RB N
significantly RB N
lower JJR N
in IN N
group NN N
B NNP N
than IN N
group NN N
A NNP N
( ( N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

The DT N
statistical JJ N
analysis NN N
was VBD N
done VBN N
through IN N
one-way JJ N
anova NN N
followed VBN N
by IN N
least JJS N
significant JJ N
difference NN N
( ( N
LSD NNP N
) ) N
. . N

CONCLUSION NNP N
Trichloroacetic NNP i
acid VBD i
20 CD i
% NN i
showed VBD N
better JJR N
results NNS N
than IN N
Jessner NNP i
's POS i
solution NN i
as IN N
peeling NN N
agent NN N
and CC N
hydroquinone VB i
2 CD i
% NN i
with IN i
kojic JJ i
acid NN i
as IN N
a DT N
topical JJ N
agent NN N
in IN N
the DT N
treatment NN o
of IN o
melasma NN o
. . o

-DOCSTART- -X- O O

Pharmacokinetics NNS N
and CC N
follicular JJ N
dynamics NNS N
of IN N
corifollitropin NN i
alfa NN i
versus NN i
recombinant JJ i
FSH NNP i
during IN N
ovarian JJ p
stimulation NN p
for IN p
IVF NNP p
. . p

A NNP N
single JJ N
injection NN N
of IN N
corifollitropin NN i
alfa NN i
can MD N
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN N
recombinant JJ i
FSH NNP i
( ( i
rFSH NN i
) ) i
using VBG N
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB p
to TO p
IVF NNP p
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

This DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
assessed VBD N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
150?g CD i
corifollitropin NN i
alfa NN i
versus IN i
daily JJ i
200IU CD i
rFSH NN i
in IN p
1509 CD p
patients NNS p
. . p

Comparative JJ N
analyses NNS N
were VBD N
performed VBN N
on IN o
serum JJ o
concentrations NNS o
of IN o
FSH NNP o
immunoreactivity NN o
( ( N
pharmacokinetics NNS N
) ) N
, , N
and CC N
the DT o
number NN o
and CC o
size NN o
of IN o
growing VBG o
follicles NNS o
, , o
and CC o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
as IN N
biomarkers NNS N
of IN N
ovarian JJ N
response NN N
( ( N
pharmacodynamics NNS N
) ) N
. . N

The DT o
rate NN o
of IN o
follicular JJ o
development NN o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

By IN N
stimulation NN N
day NN N
8 CD N
, , N
33 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
corifollitropin NN N
alfa NN N
reached VBD N
the DT N
criterion NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
( ( N
HCG NNP N
) ) N
injection NN N
. . N

The DT o
number NN o
of IN o
follicles NNS o
?11mm NNP o
was VBD o
slightly RB N
higher JJR N
after IN i
corifollitropin NN i
alfa NN i
compared VBN i
with IN N
daily JJ N
rFSH NN N
at IN N
stimulation NN N
day NN N
8 CD N
( ( N
difference NN N
, , N
1.2 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.5-1.8 NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
on IN N
the DT N
day NN N
of IN N
HCG NNP N
injection NN N
( ( N
difference NN N
, , N
2.1 CD N
; : N
95 CD N
% NN N
CI NNP N
1.4-2.8 CD N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
rise NN o
of IN o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
was VBD o
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

Although IN N
the DT N
pharmacokinetics NNS N
of IN N
corifollitropin NN i
alfa NN i
and CC i
rFSH NN i
are VBP i
quite RB N
different JJ N
their PRP$ N
pharmacodynamic JJ N
profiles NNS N
at IN N
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

A DT N
single JJ N
injection NN N
of IN N
corifollitropin NN i
alfa NN i
can MD i
replace VB N
seven CD N
daily JJ N
injections NNS N
of IN N
recombinant JJ i
FSH NNP i
( ( i
rFSH NN i
) ) i
using VBG i
a DT N
gonadotrophin-releasing JJ N
hormone NN N
antagonist NN N
protocol NN N
in IN N
ovarian JJ N
stimulation NN N
prior RB N
to TO N
IVF NNP N
or CC N
intracytoplasmic JJ N
sperm JJ N
injection NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
corifollitropin NN i
alfa JJ i
versus JJ i
daily JJ i
rFSH NN i
. . i

A DT i
total NN N
of IN N
1509 CD p
patients NNS p
were VBD p
randomized VBN N
in IN N
a DT N
double-blind NN N
, , N
controlled VBN N
trial NN N
to TO N
either VB N
a DT N
single JJ N
injection NN N
of IN N
150?g CD i
corifollitropin NN i
alfa NN i
or CC i
to TO N
daily JJ N
injections NNS N
of IN N
200IU CD i
rFSH NN i
for IN i
the DT N
first JJ N
7 CD N
days NNS N
of IN N
ovarian JJ N
stimulation NN o
. . o

Serum NNP o
levels NNS o
of IN o
FSH NNP o
immunoreactivity NN o
were VBD o
analysed VBN N
( ( N
pharmacokinetic JJ N
analysis NN N
) ) N
, , N
together RB N
with IN N
the DT N
number NN o
and CC o
size NN o
of IN o
growing VBG o
follicles NNS o
and CC o
serum NN o
inhibin NN o
B NNP o
and CC o
oestradiol JJ o
concentrations NNS o
as IN o
biomarkers NNS N
of IN N
the DT N
ovarian JJ N
response NN N
( ( N
pharmacodynamic JJ N
analysis NN o
) ) o
. . o

Serum NNP o
FSH NNP o
immunoreactivity NN o
levels NNS o
were VBD o
higher JJR N
up RB N
to TO N
stimulation VB N
day NN N
5 CD N
for IN N
corifollitropin NN i
alfa NN i
compared VBN i
with IN N
the DT N
daily JJ i
rFSH NN i
regimen NNS i
but CC N
were VBD N
similar JJ N
from IN N
day NN N
8 CD N
onwards NNS N
, , N
when WRB N
patients NNS N
started VBD N
rFSH RB N
if IN N
the DT N
criteria NN N
for IN N
human JJ N
chorionic NN N
gonadotrophin NN N
were VBD N
not RB N
yet RB N
reached VBN i
. . i

Corifollitropin NNP i
alfa JJ i
treatment NN i
resulted VBD N
in IN N
a DT N
similar JJ o
growth NN o
rate NN o
of IN o
follicles NNS o
though IN o
a DT N
slightly RB o
higher JJR o
number NN o
of IN o
follicles NNS o
were VBD o
recruited VBN N
compared VBN N
with IN N
daily JJ N
rFSH NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
pharmacokinetics NNS i
of IN i
corifollitropin NN i
alfa NN i
and CC i
rFSH NN i
are VBP i
quite RB N
different JJ N
but CC N
their PRP$ N
induced JJ o
pharmacodynamic JJ o
effects NNS o
at IN o
the DT N
dosages NNS N
used VBN N
are VBP N
similar JJ N
. . N

-DOCSTART- -X- O O

Use NNP o
and CC o
limitations NNS o
of IN N
Holter NNP i
electrocardiography NN i
in IN N
assessing VBG N
drug NN p
therapy NN p
of IN p
myocardial JJ p
ischemia NN p
during IN p
the DT p
peri-PTCA JJ p
period NN p
. . p

Incidence NN N
and CC N
pattern NN N
of IN N
myocardial JJ N
ischemia NN N
during IN N
the DT N
peri-PTCA JJ p
( ( p
percutaneous JJ p
transluminal JJ p
coronary JJ p
angioplasty NN p
) ) p
period NN N
and CC N
the DT N
possible JJ N
role NN N
of IN N
continuous JJ i
intravenous JJ i
isosorbide NN i
dinitrate NN i
in IN N
its PRP$ N
prevention NN N
were VBD N
examined VBN N
prospectively RB N
in IN N
30 CD p
patients NNS p
. . p

Holter NNP o
electrocardiographic JJ o
monitoring NN o
was VBD N
performed VBN N
for IN N
21 CD N
+/- JJ N
3 CD N
h NN N
before IN N
PTCA NNP N
and CC N
continued VBN N
during IN N
and CC N
for IN N
41 CD N
+/- JJ N
8 CD N
h NN N
after IN N
the DT N
procedure NN N
. . N

Before IN N
PTCA NNP N
, , N
19 CD N
ischemic JJ N
episodes NNS N
were VBD N
present JJ N
in IN N
10 CD N
( ( N
33 CD N
% NN N
) ) N
of IN N
30 CD p
patients NNS p
. . p

PTCA NNP N
produced VBD N
an DT N
abrupt JJ N
decrease NN N
in IN N
number NN N
( ( N
p JJ N
= NNP N
0.015 CD N
) ) N
and CC N
duration NN N
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
of IN N
spontaneous JJ o
ischemic JJ o
episodes NNS o
. . o

The DT N
rarity NN N
of IN N
recurrent JJ o
myocardial JJ o
ischemic JJ o
events NNS o
by IN N
Holter NNP i
monitoring NN i
after IN N
PTCA NNP N
negated VBD N
any DT N
attempt NN N
at IN N
assessing VBG N
the DT N
efficacy NN N
of IN N
intravenous JJ N
isosorbide JJ i
dinitrate NN i
in IN N
their PRP$ N
prevention NN N
. . N

Holter NNP i
monitoring NN i
could MD N
not RB N
be VB N
used VBN N
as IN N
an DT N
early JJ N
predictor NN N
of IN N
late JJ N
coronary JJ N
restenosis NN N
. . N

-DOCSTART- -X- O O

14 CD N
day NN N
endoscopy NN N
study NN N
comparing VBG N
risedronate NN i
and CC N
alendronate NN i
in IN N
postmenopausal JJ p
women NNS p
stratified VBN p
by IN p
Helicobacter NNP p
pylori NN p
status NN p
. . p

OBJECTIVE NNP N
Bisphosphonates NNPS i
are VBP N
effective JJ N
treatment NN N
for IN N
osteoporosis NN N
but CC N
have VBP N
been VBN N
associated VBN N
with IN N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
mucosal NN N
injury NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
incidence NN N
of IN N
gastric JJ N
ulcers NNS N
after IN N
treatment NN N
with IN N
risedronate NN i
, , i
a DT i
pyridinyl NN i
bisphosphonate NN i
, , i
or CC i
alendronate NN i
, , i
a DT i
primary JJ i
amino NN i
bisphosphonate NN i
, , N
in IN N
healthy JJ p
postmenopausal NN p
women NNS p
stratified VBN p
by IN p
Helicobacter NNP p
pylori NN p
status NN p
. . p

METHODS NNP N
Subjects NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
risedronate NN i
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
318 CD N
) ) N
or CC N
alendronate $ i
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
317 CD N
) ) N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Endoscopy NNP i
and CC N
evaluator-blind JJ N
assessments NNS N
of IN N
the DT N
esophageal NN N
, , N
gastric NN N
, , N
and CC N
duodenal JJ N
mucosa NN N
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
on IN N
Days NNP N
8 CD N
and CC N
15 CD N
. . N

RESULTS NNP N
Overall NNP N
, , N
gastric JJ o
ulcers NNS o
> VBP N
or CC N
= VBP N
3 CD N
mm NNS N
were VBD N
observed VBN N
in IN N
18 CD N
( ( N
6.0 CD N
% NN N
) ) N
of IN N
300 CD N
evaluable JJ N
subjects NNS N
in IN N
the DT N
risedronate NN i
group NN N
and CC N
36 CD N
( ( N
12.1 CD N
% NN N
) ) N
of IN N
297 CD N
in IN N
the DT N
alendronate NN N
group NN N
during IN N
treatment NN N
( ( N
p JJ N
= NNP N
0.013 CD N
) ) N
. . N

On IN N
Day NNP N
8 CD N
, , N
the DT N
incidences NNS o
of IN o
gastric JJ o
ulcers NNS o
in IN N
the DT N
risedronate NN i
and CC N
alendronate NN i
groups NNS N
were VBD N
3.6 CD N
% NN N
and CC N
6.6 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.133 CD N
) ) N
, , N
and CC N
on IN N
Day NNP N
15 CD N
, , N
they PRP N
were VBD N
3.3 CD N
% NN N
and CC N
8.7 CD N
% NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
gastric JJ o
ulcers NNS o
was VBD N
not RB N
affected VBN N
by IN N
H. NNP N
pylori NN N
status NN N
. . N

Mean NNP o
gastric JJ o
endoscopy NN o
scores NNS o
at IN N
Days NNP N
8 CD N
and CC N
15 CD N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
risedronate NN i
group NN N
than IN N
in IN N
the DT N
alendronate NN i
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Mean JJ o
esophageal NN o
and CC o
duodenal JJ o
endoscopy NN o
scores NNS o
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
at IN N
Days NNP N
8 CD N
and CC N
15 CD N
. . N

When WRB N
the DT N
treatment NN N
groups NNS N
were VBD N
combined VBN N
, , N
gastric JJ o
endoscopy NN o
scores NNS o
were VBD N
significantly RB N
higher JJR N
among IN N
H. NNP N
pylori FW N
negative JJ N
than IN N
H. NNP N
pylori FW N
positive JJ N
subjects NNS N
at IN N
Days NNP N
8 CD N
and CC N
15 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
. . N

Upper NNP o
GI NNP o
adverse JJ o
events NNS o
were VBD N
reported VBN N
by IN N
18 CD N
( ( N
5.7 CD N
% NN N
) ) N
subjects VBZ N
in IN N
the DT N
risedronate NN i
group NN N
( ( N
19 CD N
events NNS N
) ) N
and CC N
28 CD N
( ( N
8.8 CD N
% NN N
) ) N
subjects VBZ N
in IN N
the DT N
alendronate NN i
group NN N
( ( N
32 CD N
events NNS N
) ) N
. . N

Symptoms NNS N
did VBD N
not RB N
predict VB N
the DT N
presence NN N
of IN N
mucosal JJ N
damage NN N
. . N

CONCLUSION NNP N
Risedronate NNP i
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
lower JJR N
incidence NN N
of IN N
gastric JJ N
ulcers NNS N
than IN N
alendronate NN i
. . i

H. NNP N
pylori JJ N
infection NN N
did VBD N
not RB N
increase VB N
the DT N
incidence NN N
of IN N
bisphosphonate NN N
related VBN N
gastric JJ N
ulcers NNS N
. . N

The DT N
findings NNS N
from IN N
this DT N
14 CD N
day NN N
study NN N
in IN N
healthy JJ N
volunteers NNS N
support VBP N
the DT N
hypothesis NN N
that WDT N
bisphosphonates VBZ N
may MD N
differ VB N
from IN N
one CD N
another DT N
in IN N
their PRP$ N
potential JJ N
to TO N
produce VB N
upper JJ N
GI NNP N
mucosal NN N
damage NN N
. . N

-DOCSTART- -X- O O

Prophylactic JJ i
lidocaine NN i
in IN N
the DT N
early JJ N
phase NN N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . N

Four CD p
hundred VBD p
two CD p
patients NNS p
with IN p
suspected JJ p
myocardial JJ p
infarction NN p
seen VBN p
within IN p
6 CD p
hours NNS p
of IN p
the DT p
onset NN p
of IN p
symptoms NNS p
entered VBD N
a DT N
double-blind JJ N
randomized JJ N
trial NN N
of IN N
lidocaine NN i
vs NN i
placebo NN i
. . i

During IN N
the DT N
1 CD N
hour NN N
after IN N
administration NN N
of IN N
the DT N
drug NN N
the DT N
incidence NN o
of IN o
ventricular JJ o
fibrillation NN o
or CC o
sustained VBN o
ventricular JJ o
tachycardia NN o
among IN N
the DT N
204 CD p
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
was VBD N
low JJ N
, , N
1.5 CD N
% NN N
. . N

Lidocaine NNP i
, , N
given VBN N
in IN N
a DT N
300 CD N
mg NN N
dose VBD N
intramuscularly RB N
followed VBN N
by IN N
100 CD N
mg NN N
intravenously RB N
, , N
did VBD N
not RB N
prevent VB N
sustained JJ o
ventricular JJ o
tachycardia NN o
, , N
although IN N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
of IN o
patients NNS o
with IN o
warning VBG o
arrhythmias NNS o
between IN N
15 CD N
and CC N
45 CD N
minutes NNS N
after IN N
the DT N
administration NN N
of IN N
lidocaine NN i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
average JJ o
plasma JJ o
lidocaine JJ o
level NN o
10 CD N
minutes NNS o
after IN o
administration NN N
for IN N
patients NNS N
without IN N
a DT N
myocardial JJ N
infarction NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
for IN N
patients NNS N
with IN N
an DT N
acute JJ N
infarction NN N
. . N

The DT N
mean JJ o
plasma NN o
lidocaine JJ o
level NN o
of IN N
patients NNS N
on IN N
beta-blocking JJ N
agents NNS N
was VBD N
no DT N
different JJ N
from IN N
that DT N
in IN N
patients NNS N
not RB N
on IN N
beta NN N
blocking VBG N
agents NNS N
. . N

During IN N
the DT N
1-hour JJ N
study NN N
period NN N
, , N
the DT N
incidence NN o
of IN o
central JJ o
nervous JJ o
system NN o
side NN o
effects NNS o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
lidocaine NN N
group NN N
, , N
hypotension NN o
occurred VBD N
in IN N
11 CD N
patients NNS N
, , N
nine CD N
of IN N
whom WP N
had VBD N
received VBN N
lidocaine NN N
, , N
and CC N
four CD p
patients NNS p
died VBD o
from IN N
asystole NN N
, , N
three CD N
of IN N
whom WP N
had VBD N
had VBN N
lidocaine NN i
. . i

We PRP N
can MD N
not RB N
advocate VB N
the DT N
administration NN N
of IN N
lidocaine JJ i
prophylactically RB N
in IN N
the DT N
early JJ N
hours NNS N
of IN N
suspected JJ N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

Intravenous JJ N
platelet NN N
blockade NN N
with IN N
cangrelor NN i
during IN N
PCI NNP p
. . p

BACKGROUND NNP N
Intravenous NNP N
cangrelor NN i
, , N
a DT N
rapid-acting NN N
, , N
reversible JJ N
adenosine NN N
diphosphate NN N
( ( N
ADP NNP N
) ) N
receptor NN N
antagonist NN N
, , N
might MD N
reduce VB N
ischemic JJ N
events NNS N
during IN N
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned JJ N
5362 CD p
patients NNS p
who WP p
had VBD p
not RB p
been VBN p
treated VBN p
with IN p
clopidogrel NN p
to TO p
receive VB p
either DT p
cangrelor NN i
or CC i
placebo NN i
at IN p
the DT p
time NN p
of IN p
PCI NNP p
, , p
followed VBN p
by IN p
600 CD i
mg NNS i
of IN i
clopidogrel NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
a DT N
composite JJ o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
ischemia-driven JJ o
revascularization NN o
at IN o
48 CD o
hours NNS o
. . o

Enrollment NN N
was VBD N
stopped VBN N
when WRB N
an DT N
interim JJ N
analysis NN N
concluded VBD N
that IN N
the DT N
trial NN N
would MD N
be VB N
unlikely JJ N
to TO N
show VB N
superiority NN N
for IN N
the DT N
primary JJ N
end NN N
point NN N
. . N

RESULTS VB N
The DT N
primary JJ o
end NN o
point NN o
occurred VBD p
in IN p
185 CD p
of IN p
2654 CD p
patients NNS p
receiving VBG p
cangrelor NN i
( ( p
7.0 CD p
% NN p
) ) p
and CC p
in IN p
210 CD p
of IN p
2641 CD p
patients NNS p
receiving VBG p
placebo NN i
( ( p
8.0 CD p
% NN p
) ) p
( ( N
odds NNS N
ratio NN N
in IN N
the DT N
cangrelor NN N
group NN N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.71 CD N
to TO N
1.07 CD N
; : N
P=0.17 NNP N
) ) N
( ( N
modified VBN N
intention-to-treat NN N
population NN N
adjusted VBN N
for IN N
missing VBG N
data NNS N
) ) N
. . N

In IN N
the DT N
cangrelor NN i
group NN N
, , N
as IN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
, , N
two CD N
prespecified VBD N
secondary JJ N
end NN N
points NNS N
were VBD N
significantly RB N
reduced VBN N
at IN N
48 CD N
hours NNS N
: : N
the DT N
rate NN o
of IN o
stent JJ o
thrombosis NN o
, , N
from IN N
0.6 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.31 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.11 CD N
to TO N
0.85 CD N
; : N
P=0.02 NNP N
) ) N
, , N
and CC N
the DT N
rate NN o
of IN o
death NN o
from IN o
any DT o
cause NN o
, , N
from IN N
0.7 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.13 CD N
to TO N
0.83 CD N
; : N
P=0.02 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
blood NN o
transfusion NN o
( ( N
1.0 CD N
% NN N
in IN N
the DT N
cangrelor NN i
group NN N
and CC N
0.6 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
P=0.13 NNP N
) ) N
, , N
though IN N
major JJ o
bleeding VBG o
on IN N
one CD N
scale NN N
was VBD N
increased VBN N
in IN N
the DT N
cangrelor NN N
group NN N
, , N
from IN N
3.5 CD N
% NN N
to TO N
5.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
because IN N
of IN N
more JJR N
groin JJ o
hematomas NN o
. . o

CONCLUSIONS VB N
The DT N
use NN N
of IN N
periprocedural JJ N
cangrelor NN i
during IN N
PCI NNP N
was VBD N
not RB N
superior JJ N
to TO N
placebo VB N
in IN N
reducing VBG N
the DT N
primary JJ N
end NN N
point NN N
. . N

The DT N
prespecified JJ N
secondary JJ N
end NN N
points NNS N
of IN N
stent JJ N
thrombosis NN N
and CC N
death NN N
were VBD N
lower JJR N
in IN N
the DT N
cangrelor NN i
group NN N
, , N
with IN N
no DT N
significant JJ N
increase NN N
in IN N
the DT N
rate NN N
of IN N
transfusion NN N
. . N

Further NNP N
study NN N
of IN N
intravenous JJ N
ADP NNP i
blockade NN i
with IN i
cangrelor NN i
may MD N
be VB N
warranted VBN N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00385138 NNP N
. . N

) ) N
-DOCSTART- -X- O O

Which JJ N
women NNS N
default NN N
from IN N
follow-up JJ N
cervical JJ N
cytology NN N
tests NNS N
? . N
A DT N
cohort NN N
study NN N
within IN N
the DT N
TOMBOLA NNP N
trial NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
factors NNS N
associated VBN N
with IN N
default NN N
from IN N
follow-up JJ o
cervical JJ o
cytology NN o
tests NNS o
. . o

METHODS NNP N
A NNP N
cohort NN N
study NN N
was VBD N
conducted VBN N
involving VBG N
2166 CD p
women NNS p
, , p
aged VBD p
20-59 JJ p
, , p
with IN p
recent JJ p
low-grade JJ p
cervical JJ p
cytology NN p
taken VBN p
within IN p
the DT p
NHS NNP i
Cervical NNP i
Screening NNP i
Programmes NNP i
in IN p
Scotland NNP p
and CC p
England NNP p
, , p
and CC p
managed VBN p
by IN p
6-monthly JJ p
cytology NN p
in IN p
primary JJ p
care NN p
. . p

For IN N
the DT N
first JJ N
( ( N
6-month JJ N
) ) N
and CC N
second JJ N
( ( N
12-month JJ N
) ) N
surveillance NN N
cytology NN N
tests NNS N
separately RB N
, , N
women NNS N
were VBD N
categorized VBN N
as IN N
'on-time JJ i
attendees NNS i
' POS i
( ( i
attended JJ i
?6 NNP i
months NNS i
of IN i
test NN i
being VBG i
due JJ i
) ) i
, , i
'late '' i
attendees NNS i
' POS i
( ( i
attended VBD i
greater JJR i
than IN i
6 CD i
months NNS i
after IN i
test NN i
was VBD i
due JJ i
) ) i
or CC i
'non-attendees NNS i
' POS i
( ( i
failed VBN i
to TO i
attend VB o
) ) o
. . o

Multivariate NNP o
odds JJ o
ratios NNS o
( ( o
ORs NNP N
) ) N
were VBD N
computed VBN N
for IN N
factors NNS N
associated VBN N
with IN o
late JJ o
and CC o
non-attendance JJ o
. . o

RESULTS NNP N
For IN N
the DT N
first JJ N
surveillance NN N
test NN o
, , o
risk NN o
of IN o
non-attendance NN o
was VBD o
significantly RB N
higher JJR N
in IN N
younger JJR p
women NNS p
, , p
those DT p
without IN p
post-secondary JJ p
education NN p
, , p
and CC p
non-users NNS p
of IN p
prescribed JJ p
contraception NN p
. . p

Factors NNS N
significantly RB N
associated VBN N
with IN o
late JJ o
attendance NN o
for IN o
the DT N
first JJ N
test NN N
were VBD N
the DT N
same JJ N
as IN N
for IN N
non-attendance NN N
, , N
plus CC N
current JJ N
smoking NN N
and CC N
having VBG N
children NNS N
. . N

The DT N
most RBS N
important JJ N
predictor NN N
of IN N
non-attendance NN o
for IN o
the DT N
second JJ N
surveillance NN N
test NN N
was VBD N
late JJ N
attendance NN N
for IN N
the DT N
first JJ N
test NN N
( ( N
OR NNP N
= VBZ N
9.65 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
6.60-16.62 JJ o
) ) o
. . o

Non-attendance NN o
for IN o
the DT N
second JJ N
test NN N
was VBD N
also RB N
significantly RB N
higher JJR N
among IN p
women NNS p
who WP p
were VBD p
younger JJR p
, , p
smokers NNS p
and CC p
had VBD p
negative JJ p
cytology NN p
on IN p
the DT N
first JJ N
surveillance NN N
test NN o
. . o

Late JJ o
attendance NN o
for IN o
the DT N
second JJ N
surveillance NN N
test NN N
was VBD N
higher RBR N
in IN N
women NNS p
who WP p
were VBD p
younger JJR p
, , p
smokers NNS p
, , p
had VBD p
children NNS p
and CC p
attended VBD p
late RB p
for IN p
the DT N
first JJ N
test NN N
. . N

CONCLUSIONS NNP N
Women NNP N
at IN N
highest JJS N
risk NN N
of IN N
default NN N
from IN N
follow-up JJ N
cytology NN N
tend NN N
to TO N
be VB N
young JJ p
, , p
smoke NN p
, , p
lack NN p
post-secondary JJ p
education NN p
, , p
and CC p
have VBP p
defaulted VBN p
from IN p
a DT p
previous JJ p
surveillance NN p
appointment NN p
. . p

Tackling VBG N
default NN N
will MD N
require VB N
development NN N
of IN N
targeted JJ N
strategies NNS N
to TO N
encourage VB N
attendance NN N
and CC N
research NN N
to TO N
better JJR N
understand VB N
the DT N
reasons NNS N
underpinning VBG N
default NN N
. . N

-DOCSTART- -X- O O

Comparative JJ N
efficacy NN N
of IN N
oral JJ i
erythromycin FW i
versus FW i
oral JJ i
tetracycline NN i
in IN N
the DT N
treatment NN N
of IN N
acne JJ o
vulgaris NN o
. . o

A DT N
double-blind JJ N
study NN N
. . N

The DT N
efficacy NN o
of IN N
erythromycin JJ o
base NN o
( ( o
E-Mycin JJ o
tablets NNS o
, , o
333 CD o
mg NN o
) ) o
and CC N
the DT N
efficacy NN o
of IN N
tetracycline JJ o
hydrochloride NN o
( ( N
Panmycin NNP N
tablets NNS N
) ) N
were VBD N
compared VBN N
in IN N
this DT N
double-blind NN N
, , N
randomized VBN N
study NN N
. . N

Two CD p
hundred VBD p
patients NNS p
with IN p
moderate JJ p
to TO p
moderately RB p
severe JJ p
acne NNS p
vulgaris NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
study NN N
. . N

One CD N
hundred VBD N
patients NNS N
received VBD N
1 CD i
gm NN i
of IN i
erythromycin JJ i
base NN i
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
333 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN i
for IN i
tetracycline NN i
. . i

The DT N
second JJ N
group NN N
of IN N
patients NNS N
received VBD N
1 CD N
gm NN N
of IN N
tetracycline NN i
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
500 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN i
for IN i
erythromycin NN i
. . i

Both DT N
drugs NNS N
reduced VBD N
acne JJ o
severity NN o
to TO N
the DT N
same JJ N
extent NN N
. . N

Pustules NNP o
, , o
papules NNS o
, , o
and CC o
open JJ o
comedo NN o
counts NNS o
decreased VBN N
significantly RB N
over IN N
the DT N
12-week JJ N
period NN N
. . N

Seventy-seven JJ N
percent NN N
of IN N
the DT N
erythromycin-treated JJ N
patients NNS N
and CC N
89 CD N
% NN N
of IN N
the DT N
tetracycline-treated JJ N
patients NNS N
stated VBD N
that IN N
their PRP$ N
acne NN o
was VBD N
markedly RB N
improved VBN N
or CC N
improved VBN N
by IN N
week NN N
12 CD N
. . N

Most JJS N
of IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
erythromycin NNS N
were VBD N
gastrointestinal JJ o
symptoms NNS o
. . o

Among IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
tetracycline NN N
were VBD N
Candida NNP o
vaginitis NN o
in IN N
one CD N
patient NN N
and CC N
pseudotumor NN o
cerebri NN o
in IN N
one CD N
patient NN N
. . N

-DOCSTART- -X- O O

Randomized NNP N
comparison NN N
of IN N
two CD i
communication NN i
interventions NNS i
for IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
randomized JJ N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD i
communication NN i
interventions NNS i
( ( i
Responsive JJ i
Education NN i
and CC i
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
[ NNP i
RPMT NNP i
] NNP i
and CC i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
[ NNP i
PECS NNP i
] NNP i
) ) i
in IN N
36 CD p
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Each DT N
treatment NN N
was VBD N
delivered VBN N
3 CD N
times NNS N
per IN N
week NN N
, , N
in IN N
20-min JJ N
sessions NNS N
, , N
for IN N
6 CD N
months NNS N
. . N

The DT N
results NNS N
revealed VBD N
that IN N
the DT N
RPMT NNP i
facilitated VBD N
the DT N
frequency NN o
of IN o
generalized JJ o
turn NN o
taking VBG o
and CC o
generalized VBN o
initiating NN o
joint JJ o
attention NN o
more RBR N
than IN N
did VBD N
the DT N
PECS NNP N
. . N

The DT N
latter JJ N
effect NN N
occurred VBD N
only RB N
for IN N
children NNS N
who WP N
began VBD N
treatment NN N
with IN N
at IN N
least JJS N
some DT N
initiating VBG o
joint JJ o
attention NN o
. . o

In IN N
contrast NN N
, , N
the DT N
PECS NNP i
facilitated VBD N
generalized JJ o
requests NNS o
more RBR N
than IN N
the DT N
RPMT NNP N
in IN N
children NNS N
with IN N
very RB N
little JJ N
initiating VBG o
joint JJ o
attention NN o
prior RB N
to TO N
treatment NN N
. . N

These DT N
effect NN o
sizes NNS o
were VBD N
large JJ o
. . o

-DOCSTART- -X- O O

Remifentanil NNP N
with IN N
morphine JJ N
transitional JJ N
analgesia NN N
shortens VBZ N
neurological JJ o
recovery NN o
compared VBN N
to TO N
fentanyl VB N
for IN N
supratentorial JJ N
craniotomy NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
recovery NN o
profiles NNS o
, , o
efficacy NN o
and CC o
safety NN o
of IN N
remifentanil NN N
and CC N
morphine NN N
for IN N
transitional JJ N
analgesia NN N
with IN N
fentanyl NN N
in IN N
patients NNS p
undergoing VBG p
elective JJ p
craniotomy NN p
for IN p
supratentorial JJ p
mass NN p
lesions NNS p
. . p

METHODS NNP N
Ninety-one JJ p
patients NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
multicentre FW N
study NN N
. . N

Anesthesia NNP i
was VBD i
induced VBN i
with IN i
thiopental JJ i
and CC i
remifentanil NN i
( ( i
1.0 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
and CC i
a DT i
1 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
infusion NN i
) ) i
or CC i
fentanyl NN i
( ( i
1 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
and CC i
a DT i
1.0 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
infusion NN i
) ) i
. . i

The DT i
opioid JJ i
infusion NN i
continued VBD i
until IN i
the DT i
level NN i
of IN i
anesthesia NN i
was VBD i
deemed VBN i
appropriate JJ i
for IN i
intubation NN i
. . i

Anesthesia NNP i
was VBD i
maintained VBN i
with IN i
N NNP i
( ( i
2 CD i
) ) i
O/O NNP i
( ( i
2 CD i
) ) i
, , i
isoflurane $ i
0.5 CD i
MAC NNP i
and CC i
remifentanil VB i
0.2 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 JJ i
) ) i
or CC i
fentanyl $ i
0.04 CD i
micro NN i
g NN i
x NNP i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
. . i

At IN i
bone NN i
flap NN i
replacement NN i
, , i
either DT i
morphine NN i
0.08 CD i
mg NN i
x NN i
kg NN i
( ( i
-1 NN i
) ) i
( ( i
remifentanil JJ i
group NN i
) ) i
or CC i
saline NN i
( ( i
fentanyl JJ i
group NN i
) ) i
was VBD i
given VBN i
. . i

RESULTS NNP N
Systolic NNP o
blood NN o
pressure NN o
was VBD N
greater JJR N
in IN N
those DT N
receiving VBG N
fentanyl NN N
during IN N
induction NN N
( ( N
145.6 CD N
+/-17.5 JJ N
mmHg NN N
vs NN N
128.8 CD N
+/-18.3 JJ N
mmHg NN N
; : N
P NNP N
= NNP N
0.006 CD N
) ) N
and CC N
intubation NN N
( ( N
126.9 CD N
+/-17.1 JJ N
vs NN N
110.9 CD N
+/-16.5 JJ N
mmHg NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Median JJ o
time NN o
to TO o
tracheal VB o
extubation NN o
was VBD N
similar JJ N
but CC N
less RBR N
variable JJ N
in IN N
the DT N
remifentanil NN N
group NN N
( ( N
remifentanil JJ N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
2-44 JJ N
min NN N
; : N
fentanyl CC N
= $ N
8 CD N
min NN N
: : N
range NN N
= VBZ N
1-732 JJ N
min NN N
) ) N
. . N

The DT N
fentanyl JJ N
patients NNS N
required VBD N
a DT N
longer JJR N
time NN o
to TO o
achieve VB o
the DT o
first JJ o
normal JJ o
neurological JJ o
score NN o
( ( N
fentanyl JJ N
= $ N
38.0 CD N
min NN N
; : N
remifentanil CC N
= $ N
26.0 CD N
min NN N
; : N
P NNP N
= NNP N
0.035 CD N
) ) N
. . N

Both CC N
the DT N
anesthesiologists NNS N
and CC N
the DT N
recovery NN N
room NN N
nurses NNS N
rated VBD N
remifentanil JJ N
better RBR N
with IN N
respect NN N
to TO N
level NN o
of IN o
consciousness NN o
. . o

Analgesics NNS o
were VBD N
required VBN N
earlier RBR N
in IN N
patients NNS N
receiving VBG N
remifentanil NN N
; : N
median JJ N
time NN N
0.5 CD N
vs NN N
1.08 CD N
hr NN N
, , N
P NNP N
< VBZ N
0.001 CD N
. . N

CONCLUSIONS NNP N
Remifentanil NNP N
is VBZ N
a DT N
suitable JJ N
alternative NN N
to TO N
fentanyl VB N
in IN N
supratentorial JJ N
craniotomy NN N
. . N

Time NN o
to TO o
preoperative VB o
neurological JJ o
recovery NN o
is VBZ N
faster RBR N
and CC N
morphine VB N
provides VBZ N
some DT N
transitional JJ o
analgesia NN o
without IN N
compromising VBG N
the DT N
quality NN o
of IN o
recovery NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
delayed JJ i
cord NN i
clamping VBG i
on IN N
iron NN o
stores NNS o
in IN N
infants NNS p
born VBN p
to TO p
anemic JJ p
mothers NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effects NNS N
of IN N
cord NN N
clamping VBG N
on IN N
iron NN N
stores NNS N
of IN N
infants NNS p
born VBN p
to TO p
anemic VB p
mothers NNS p
at IN p
3 CD p
months NNS p
of IN p
age NN p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Teaching NNP p
hospital NN p
. . p

METHODS NNP N
Infants NNPS p
born VBN p
to TO p
mothers NNS p
with IN p
hemoglobin NN p
( ( p
Hb NNP p
) ) p
< VBD p
100 CD p
g/L NNS p
were VBD N
randomized VBN N
at IN N
delivery NN N
to TO N
either DT N
immediate JJ i
cord NN i
clamping NN i
( ( N
early JJ N
group NN N
) ) N
or CC N
cord NN i
clamping VBG i
delayed VBN i
till JJ i
descent NN i
of IN i
placenta NN i
into IN i
vagina NN i
( ( N
delayed VBN N
group NN N
) ) N
. . N

The DT N
outcome NN N
measures NNS N
were VBD N
infant NN o
's POS o
hemoglobin NN o
and CC o
serum NN o
ferritin VBP o
3 CD o
months NNS o
after IN o
delivery NN o
. . o

RESULTS CC N
There EX N
were VBD N
102 CD p
neonates NNS p
randomized VBN N
to TO N
early JJ N
( ( N
n JJ N
= NNP N
43 CD N
) ) N
or CC N
delayed VBN N
cord NN N
clamping NN N
( ( N
n JJ N
= NNP N
59 CD N
) ) N
. . N

The DT N
groups NNS N
were VBD N
comparable JJ N
for IN N
maternal JJ N
age NN N
, , N
parity NN N
, , N
weight NN N
and CC N
supplemental JJ N
iron NN N
intake NN N
, , N
infant JJ N
s NN N
birth NN N
weight NN N
, , N
gestation NN N
and CC N
sex NN N
. . N

The DT N
mean JJ o
infant NN o
ferritin NN o
and CC o
Hb NNP o
at IN o
3 CD o
months NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
delayed JJ i
clamping NN i
group NN N
( ( N
118.4 CD N
microg/L NN N
and CC N
99 CD N
g/L NN N
) ) N
than IN N
in IN N
the DT N
early JJ i
clamping NN i
group NN N
( ( N
73 CD N
microg/L NN N
and CC N
88 CD N
g/L NN N
) ) N
. . N

The DT N
mean JJ N
decrease NN N
in IN N
Hb NNP o
( ( N
g/L NN N
) ) N
at IN N
3 CD N
months NNS N
adjusted VBN N
for IN N
co-variates NNS N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
delayed JJ i
clamping NN i
group NN N
compared VBN N
to TO N
the DT N
early JJ i
clamping NN i
group NN N
( ( N
-1.09 NNP N
, , N
95 CD N
% NN N
CI-1.58 NNP N
to TO N
-0.62 VB N
, , N
p VB N
> NNP N
0.001 CD N
) ) N
. . N

The DT N
odds NNS N
for IN N
anemia NN o
( ( N
< JJ N
100 CD N
g/L NN N
) ) N
at IN N
3 CD N
months NNS N
was VBD N
7.7 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.84-34.9 CD N
) ) N
times NNS N
higher RBR N
in IN N
the DT N
early JJ N
compared VBN N
to TO N
the DT N
delayed JJ i
clamping NN i
group NN N
. . N

CONCLUSION NNP N
Iron NNP o
stores NNS o
and CC o
Hb NNP o
in IN N
infancy NN N
can MD N
be VB N
improved VBN N
in IN N
neonates NNS p
born VBN p
to TO p
anemic VB p
mothers NNS p
by IN N
delaying VBG i
cord NN i
clamping NN i
at IN N
birth NN N
. . N

-DOCSTART- -X- O O

Calcitriol NNP i
for IN N
bone NN N
disease NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
. . p

BACKGROUND NNP N
Osteoporosis NNP N
is VBZ N
associated VBN N
with IN N
cirrhosis NN N
of IN N
the DT N
liver NN N
, , N
but CC N
the DT N
effects NNS N
of IN N
therapy NN N
for IN N
osteoporosis NN o
associated VBN N
with IN N
cirrhosis NN N
are VBP N
still RB N
controversial JJ N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
the DT N
effects NNS o
of IN N
calcitriol NN i
( ( i
1alpha,25-dihydroxyvitamin JJ i
D3 NNP i
) ) i
on IN N
bone NN o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
in IN N
76 CD p
patients NNS p
( ( p
26 CD p
men NNS p
and CC p
50 CD p
women NNS p
) ) p
with IN p
cirrhosis NN p
who WP N
were VBD N
assigned VBN N
randomly RB i
to TO i
receive VB i
calcitriol NN i
( ( i
0.5 CD i
mg NN i
twice RB i
per IN i
day NN i
) ) i
or CC i
not RB i
. . i

The DT N
BMD NNP o
of IN o
the DT o
lumbar NN o
vertebrae NN o
was VBD N
measured VBN i
by IN i
dual-energy JJ o
X-ray JJ o
absorptiometry NN o
at IN i
least JJS i
twice RB i
, , i
12-57 JJ i
months NNS i
apart RB i
. . i

RESULTS VB N
For IN p
men NNS p
, , p
the DT p
mean JJ p
annual JJ p
change NN o
in IN o
BMD NNP o
was VBD p
1.1 CD p
% NN p
in IN p
the DT p
treated JJ p
group NN p
and CC p
-0.4 CD p
% NN p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
median JJ N
( ( N
25th CD N
and CC N
75th CD N
percentiles NNS N
) ) N
annual JJ o
change NN o
in IN o
BMD NNP o
was VBD N
0.6 CD N
( ( N
-0.1 NN N
, , N
2.1 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-1.4 NNP N
( ( N
-1.9 NNP N
, , N
1.6 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
difference NN N
in IN N
the DT N
median JJ N
annual JJ N
change NN N
between IN N
the DT N
two CD p
groups NNS p
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

For IN p
women NNS p
, , p
the DT p
mean JJ p
annual JJ p
change NN o
in IN o
BMD NNP o
was VBD p
-0.5 JJ p
% NN p
in IN p
the DT p
treated JJ p
group NN p
and CC p
-2.3 CD p
% NN p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
median JJ N
( ( N
25th CD N
and CC N
75th CD N
percentiles NNS N
) ) N
annual JJ N
change NN N
in IN N
BMD NNP o
was VBD N
-0.5 NNP N
( ( N
-1.8 NNP N
, , N
1.3 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
group NN N
and CC N
-1.5 NNP N
( ( N
-3.8 NNP N
, , N
-0.7 NNP N
% NN N
) ) N
in IN N
the DT N
control NN p
group NN p
. . p

This DT N
difference NN N
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.011 CD N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
calcitriol NN N
can MD N
prevent VB N
bone JJ o
loss NN o
and CC N
, , N
therefore RB N
, , N
may MD N
be VB N
useful JJ N
for IN N
the DT N
treatment NN N
of IN N
bone NN N
disease NN N
in IN N
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
yoga NNP i
versus NN i
stretching VBG i
for IN N
chronic JJ o
low JJ o
back RB o
pain NN o
: : o
protocol NN N
for IN N
the DT N
Yoga NNP N
Exercise NNP N
Self-care NNP N
( ( N
YES NNP N
) ) N
trial NN N
. . N

BACKGROUND NNP N
Back NNP o
pain NN o
, , N
one CD N
of IN N
the DT N
most RBS N
prevalent JJ N
conditions NNS N
afflicting VBG N
American JJ N
adults NNS N
, , N
is VBZ N
the DT N
leading VBG N
reason NN N
for IN N
using VBG N
complementary JJ i
and CC i
alternative JJ i
medicine NN i
( ( i
CAM NNP i
) ) i
therapies NNS i
. . i

Yoga NNP i
is VBZ N
an DT N
increasingly RB N
popular JJ N
mind-body NN N
CAM NNP N
therapy NN N
often RB N
used VBN N
for IN N
relieving VBG o
back RB o
pain NN o
and CC N
several JJ N
small JJ N
studies NNS N
have VBP N
found VBN N
yoga RB N
effective JJ N
for IN N
this DT N
condition NN N
. . N

This DT N
study NN N
will MD N
assess VB N
whether IN N
yoga NN i
is VBZ N
effective JJ N
for IN N
treating VBG N
chronic JJ o
low JJ o
back RB o
pain NN o
compared VBN N
with IN N
self PRP i
care NN i
and CC i
exercise NN i
and CC N
will MD N
explore VB N
the DT N
mechanisms NNS N
responsible JJ N
for IN N
any DT N
observed JJ N
benefits NNS N
. . N

METHODS/DESIGN NNP N
A NNP p
total NN p
of IN p
210 CD p
participants NNS p
with IN p
low JJ p
back RB p
pain NN p
lasting NN p
at IN p
least JJS p
3 CD p
months NNS p
will MD p
be VB p
recruited VBN p
from IN p
primary JJ p
care NN p
clinics NNS p
of IN p
a DT p
large JJ p
healthcare NN p
system NN p
based VBN p
in IN p
Seattle NNP p
. . p

They PRP N
will MD N
be VB N
randomized VBN N
in IN N
a DT N
2:2:1 CD N
ratio NN N
to TO N
receive VB N
12 CD i
weekly JJ i
yoga NN i
classes NNS i
, , i
12 CD i
weekly JJ i
conventional JJ i
therapeutic JJ i
exercise NN i
classes NNS i
of IN i
comparable JJ i
physical JJ i
exertion NN i
, , i
or CC i
a DT i
self-care JJ i
book NN i
. . i

Interviewers NNS N
masked VBD N
to TO N
participants NNS N
' POS N
treatment NN N
group NN N
will MD N
assess VB N
outcomes NNS N
at IN N
baseline NN N
and CC N
6 CD N
, , N
12 CD N
and CC N
26 CD N
weeks NNS N
after IN N
randomization NN N
. . N

Primary JJ N
outcomes NNS N
will MD N
be VB N
back-related JJ o
dysfunction NN o
and CC o
symptom NN o
bothersomeness NN o
. . o

In IN N
addition NN N
, , N
data NNS N
will MD N
be VB N
collected VBN N
on IN N
physical JJ o
measurements NNS o
( ( o
e.g. NN o
, , N
flexion NN o
) ) o
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
and CC N
saliva NN N
samples NNS N
will MD N
be VB N
obtained VBN N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
weeks NNS N
. . N

Information NN N
will MD N
be VB N
collected VBN N
on IN N
specific JJ N
physical JJ N
, , N
psychological JJ N
, , N
and CC N
physiological JJ N
factors NNS N
to TO N
allow VB N
exploration NN N
of IN N
possible JJ N
mechanisms NNS N
of IN N
action NN N
through IN N
which WDT N
yoga NN i
could MD N
relieve VB o
back RB o
pain NN o
and CC o
dysfunction NN o
. . o

The DT N
effectiveness NN N
of IN N
yoga NN i
will MD N
be VB N
assessed VBN N
using VBG N
analysis NN N
of IN N
covariance NN N
( ( N
using VBG N
general JJ N
estimating VBG N
equations NNS N
- : N
GEE NNP N
) ) N
within IN N
an DT N
intention-to-treat JJ N
context NN N
. . N

If IN N
yoga NN i
is VBZ N
found VBN N
effective JJ N
, , N
further JJ N
analyses NNS N
will MD N
explore VB N
whether IN N
yoga NN N
's POS N
benefits NNS N
are VBP N
attributable JJ N
to TO N
physical JJ N
, , N
psychological JJ N
and/or NN N
physiological JJ N
factors NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
will MD N
provide VB N
the DT N
clearest JJS N
evidence NN N
to TO N
date NN N
about IN N
the DT N
value NN N
of IN N
yoga NN i
as IN N
a DT N
therapeutic JJ N
option NN N
for IN N
treating VBG N
chronic JJ o
back RB o
pain NN o
, , N
and CC N
if IN N
the DT N
results NNS N
are VBP N
positive JJ N
, , N
will MD N
help VB N
focus VB N
future JJ N
, , N
more RBR N
in-depth JJ N
, , N
research NN N
on IN N
the DT N
most RBS N
promising JJ N
potential JJ N
mechanisms NN N
of IN N
action NN N
identified VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -X- O O

Clinical JJ N
pathway NN N
for IN N
fractured JJ p
neck NN p
of IN p
femur NN p
: : p
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
outcomes NNS N
of IN N
using VBG N
a DT N
clinical JJ N
pathway NN N
for IN N
managing VBG N
patients NNS p
with IN p
fractured JJ p
neck NN p
of IN p
femur NN p
. . p

DESIGN NNP N
Prospective NNP N
, , N
pseudorandomised VBD N
, , N
controlled VBD N
trial NN N
. . N

SETTING NN N
St NNP p
Vincent NNP p
's POS p
Hospital NNP p
, , p
Melbourne NNP p
, , p
Victoria NNP p
( ( p
a DT p
tertiary JJ p
referral NN p
, , p
university NN p
teaching VBG p
hospital NN p
) ) p
, , p
1 CD p
October NNP p
1997 CD p
to TO p
30 CD p
November NNP p
1998 CD p
. . p

PARTICIPANTS VB N
111 CD p
patients NNS p
( ( p
80 CD p
women NNS p
and CC p
31 CD p
men NNS p
; : p
mean JJ p
age NN p
, , p
81 CD p
years NNS p
) ) p
admitted VBD p
via IN p
the DT p
emergency NN p
department NN p
with IN p
a DT p
primary JJ p
diagnosis NN p
of IN p
fractured JJ p
neck NN p
of IN p
femur NN p
. . p

INTERVENTIONS NNP N
Management NNP i
guided VBN i
by IN i
a DT i
clinical JJ i
pathway NN i
( ( i
55 CD i
patients NNS i
) ) i
or CC i
established VBN i
standard NN i
of IN i
care NN i
( ( N
control NN N
group NN N
, , N
56 CD N
patients NNS N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Timing NNP o
of IN o
referrals NNS o
and CC o
discharge NN o
planning NN o
; : o
total JJ o
length NN o
of IN o
stay NN o
; : o
and CC o
complication NN o
and CC o
readmission NN o
rates NNS o
within IN o
28 CD o
days NNS o
of IN o
discharge NN o
. . o

RESULTS JJ N
Patients NNS N
managed VBD N
according VBG N
to TO N
the DT N
clinical JJ N
pathway NN N
had VBD N
a DT N
shorter NN N
total JJ o
stay NN o
( ( N
6.6 CD N
versus NN N
8.0 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
even RB N
if IN N
assessment NN N
for IN N
placement NN N
by IN N
the DT N
Aged NNP N
Care NNP N
Assessment NNP N
Service NNP N
was VBD N
required VBN N
( ( N
9.5 CD N
versus NN N
13.6 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
complication NN o
and CC o
readmission NN o
rates NNS o
between IN N
pathway NN N
and CC N
control NN p
patients NNS p
( ( N
complication NN N
rates NNS N
, , N
24 CD N
% NN N
versus IN N
36 CD N
% NN N
; : N
P NNP N
= VBZ N
0.40 CD N
; : N
readmission NN N
rates NNS N
, , N
4 CD N
% NN N
versus IN N
11 CD N
% NN N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
. . N

CONCLUSION NNP N
Coordinated VBD N
multidisciplinary JJ N
care NN N
of IN N
patients NNS p
with IN p
fractured JJ p
neck NN p
of IN p
femur NN p
reduces NNS N
length NN o
of IN o
stay NN o
without IN N
increasing VBG N
complications NNS N
. . N

-DOCSTART- -X- O O

In IN N
high JJ p
risk NN p
hypertensive JJ p
subjects NNS p
with IN p
incidental JJ p
and CC p
unilateral JJ p
renal JJ p
artery NN p
stenosis NN p
percutaneous JJ p
revascularization NN p
with IN N
stent JJ N
improves NNS N
blood NN o
pressure NN o
control NN o
but CC N
not RB N
glomerular JJ o
filtration NN o
rate NN o
. . o

AIM NNP N
In IN N
high-risk JJ p
hypertensive JJ p
subjects NNS p
( ( p
HTs NNP p
) ) p
with IN p
incidental JJ p
unilateral JJ p
renal JJ p
artery NN p
stenosis NN p
( ( p
RAS NNP p
) ) p
, , N
the DT N
effectiveness NN N
of IN N
percutaneous JJ i
revascularization NN i
with IN i
stent NN i
( ( i
PR-STENT NNP i
) ) i
on IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
and CC N
glomerular JJ o
filtration NN o
rate NN o
( ( o
GFR NNP o
) ) o
is VBZ N
not RB N
established VBN N
. . N

METHODS NNP N
Eighteen NNP p
HTs NNP p
aged VBD p
65.7 CD p
? . p
9.2 CD p
years NNS p
with IN p
angiographically RB p
diagnosed VBN p
unilateral JJ p
RAS NNP p
( ( p
? . p
60 CD p
% NN p
) ) p
were VBD p
randomized VBN N
to TO N
receive VB N
PR-STENT NNP N
( ( N
N=9 NNP N
) ) N
or CC N
to TO N
NO-STENT NNP i
( ( i
N=9 NNP i
) ) N
. . N

BP NNP N
( ( N
mercury NN N
sphygmomanometer NN N
) ) N
and CC N
GFR NNP N
( ( N
99mTc-DTPA JJ N
clearances NNS N
during IN N
renal JJ N
scintigraphy NN N
) ) N
were VBD N
evaluated VBN N
yearly RB N
for IN N
three CD N
years NNS N
. . N

Echo-Doppler NN N
of IN N
renal JJ N
arteries NNS N
was VBD N
performed VBN N
to TO N
verify VB N
the DT N
anatomic JJ N
patency NN N
and CC N
flow JJ N
velocities NNS N
of IN N
the DT N
reperfused JJ N
artery NN N
. . N

Analysis NN N
of IN N
variance NN N
compared VBN N
BP NNP N
and CC N
GFR NNP N
values NNS N
changes NNS N
from IN N
baseline NN N
to TO N
the DT N
follow-up NN N
; : N
differences NNS N
for IN N
continuous JJ N
variables NNS N
were VBD N
evaluated VBN N
between IN N
groups NNS N
with IN N
the DT N
Tukey NNP N
's POS N
post NN N
hoc NN N
test NN N
after IN N
adjustment NN N
for IN N
age NN N
, , N
change NN N
of IN N
BP NNP N
between IN N
baseline NN N
and CC N
at IN N
the DT N
follow-up NN N
, , N
GFR NNP N
and CC N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
. . N

RESULTS NNP o
Baseline NNP o
systolic JJ o
BP NNP o
and CC o
GFR NNP o
values NNS o
were VBD o
not RB N
different JJ N
between IN N
groups NNS N
. . N

The DT N
significantly RB N
greater JJR o
GFR NNP o
increase NN o
observed VBD o
in IN N
PR-STENT NNP N
than IN N
in IN N
NO-STENT NNP N
at IN N
univariate JJ N
analysis NN N
at IN N
the DT N
end NN N
of IN N
follow-up NN N
( ( N
62.5 CD N
? . N
19.2 CD N
vs. IN N
42.24 CD N
? . N
17.6 CD N
, , N
P NNP N
< NNP N
0.02 CD N
) ) N
disappeared VBD N
after IN N
adjustment NN N
for IN N
confounding VBG N
factors NNS N
. . N

However RB o
, , o
systolic JJ o
BP NNP o
remained VBD o
significantly RB N
lower JJR N
in IN N
PR-STENT NNP N
than IN N
in IN N
NO-STENT NNP N
( ( N
140.1 CD N
? . N
4.6 CD N
vs. IN N
170.0 CD N
? . N
8.3 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
also RB N
after IN N
adjustment NN N
for IN N
age NN N
, , N
GFR NNP N
and CC N
BMI NNP N
. . N

CONCLUSION NNP N
PR-STENT NNP N
reduces VBZ N
systolic JJ o
BP NNP o
without IN o
improving VBG o
GFR NNP o
. . o

Due NNP o
to TO N
the DT N
strong JJ N
association NN N
between IN N
high JJ N
BP NNP N
and CC N
renal JJ N
damage NN N
, , N
this DT N
study NN N
raises VBZ N
the DT N
question NN N
on IN N
whether IN N
PR-STENT NNP N
should MD N
be VB N
performed VBN N
in IN N
all DT N
HTs NNP p
with IN p
unilateral JJ p
and CC p
incidental JJ p
RAS NNP p
. . p

-DOCSTART- -X- O O

Efficacy NN o
of IN N
dose-intensified JJ N
MEC NNP i
( ( i
methotrexate NN i
, , i
epirubicin NN i
and CC i
cisplatin NN i
) ) i
chemotherapy NN N
for IN N
advanced JJ p
urothelial JJ p
carcinoma NN p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
MEC NNP i
and CC N
M-VAC NNP i
( ( i
methotrexate NN i
, , i
vinblastine NN i
, , i
doxorubicin NN i
and CC i
cisplatin NN i
) ) i
. . N

Japanese JJ p
Urothelial JJ p
Cancer NNP p
Research NNP p
Group NNP p
. . p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
antitumor NN o
activity NN o
in IN N
patients NNS p
with IN p
T3b NNP p
, , p
T4 NNP p
or CC p
metastatic JJ p
urothelial JJ p
carcinoma NN p
treated VBN p
with IN p
MEC NNP i
or CC p
M-VAC NNP i
chemotherapy NN p
, , N
by IN N
performing VBG N
a DT N
multi-center JJ N
randomized JJ N
prospective JJ N
study NN N
. . N

METHODS NNP N
From IN p
1991 CD p
to TO p
1995 CD p
, , p
89 CD p
patients NNS p
with IN p
T3b NNP p
, , p
T4 NNP p
or CC p
metastatic JJ p
urothelial JJ p
carcinoma NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
methotrexate NN i
, , i
epirubicin NN i
and CC i
cisplatin NN i
chemotherapy NN i
group NN i
( ( i
arm JJ i
1 CD i
: : i
S-MEC JJ i
therapy NN i
; : i
n CC i
= VB i
29 CD i
) ) i
, , i
a DT i
dose-intensified JJ i
MEC NNP i
therapy NN i
combined VBN i
with IN i
G-CSF NNP i
group NN i
( ( i
arm JJ i
2 CD i
: : i
I-MEC JJ i
therapy NN i
; : i
n CC i
= VB i
30 CD i
) ) i
or CC i
a DT i
methotrexate NN i
, , i
vinblastine NN i
, , i
doxorubicin NN i
and CC i
cisplatin NN i
chemotherapy NN i
( ( i
arm JJ i
3 CD i
: : i
M-VAC JJ i
therapy NN i
; : i
n CC i
= VB i
30 CD i
) ) i
. . i

At IN N
the DT N
registration NN N
center NN N
, , N
the DT N
patients NNS N
were VBD N
stratified VBN N
into IN N
previously RB N
untreated JJ N
patients NNS N
and CC N
patients NNS N
with IN N
recurrence NN N
after IN N
radical JJ N
operation NN N
and CC N
then RB N
randomly RB N
allocated VBN N
to TO N
the DT N
treatment NN N
groups NNS N
. . N

In IN N
each DT N
arm NN N
, , N
two CD N
or CC N
more JJR N
courses NNS N
of IN N
chemotherapy NN N
( ( N
4-week JJ N
cycles NNS N
) ) N
were VBD N
performed VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
88 CD N
eligible JJ N
patients NNS N
, , N
four CD N
treated VBN N
with IN N
S-MEC NNP i
therapy NN i
and CC N
two CD N
treated VBN N
with IN N
I-MEC NNP i
therapy NN N
showed VBD N
CR NNP N
. . N

The DT N
response NN o
rates NNS o
( ( o
CR NNP o
+ NNP o
PR NNP o
) ) o
were VBD N
52 CD N
% NN N
( ( N
15/29 CD N
) ) N
with IN N
S-MEC NNP i
therapy NN i
, , N
76 CD N
% NN N
( ( N
22/29 CD N
) ) N
with IN N
I-MEC NNP i
therapy NN N
and CC N
47 CD N
% NN N
( ( N
14/30 CD N
) ) N
with IN N
M-VAC NNP i
therapy NN N
. . N

The DT N
response NN o
rate NN o
with IN o
I-MEC NNP o
therapy NN o
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
with IN N
M-VAC NNP i
therapy NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Although IN N
the DT N
incidence NN N
of IN N
leukopenia NN N
was VBD N
low JJ N
with IN N
I-MEC NNP o
therapy NN o
, , N
the DT N
incidence NN N
of IN N
thrombocytopenia NN o
was VBD N
high JJ N
with IN N
this DT N
therapy NN N
. . N

CONCLUSION NNP N
MEC NNP i
therapy NN i
used VBN N
in IN N
this DT N
study NN N
is VBZ N
promising VBG N
in IN N
terms NNS N
of IN N
the DT N
antitumor NN o
effects NNS o
. . o

-DOCSTART- -X- O O

Milk NNP N
protein NN N
quantity NN N
and CC N
quality NN N
in IN N
low-birth-weight JJ p
infants NNS p
. . p

IV NNP N
. . N

Effects NNS N
on IN N
tyrosine NN o
and CC N
phenylalanine NN o
in IN o
plasma NN o
and CC o
urine NN o
. . o

Well UH N
, , N
appropriate-for-gestational JJ p
age NN p
, , p
low-birth-weight JJ p
infants NNS p
were VBD N
divided VBN N
into IN N
three CD N
gestational JJ N
age NN N
groups NNS N
and CC N
assigned VBD N
randomly RB N
within IN N
each DT N
age NN N
group NN N
to TO N
one CD N
of IN N
five CD N
feeding VBG N
regimens NNS N
: : N
pooled VBN i
human JJ i
milk NN i
( ( i
BM NNP i
) ) i
; : i
formula $ i
1 CD i
( ( i
F1 NNP i
) ) i
= VBD i
1.5 CD i
gm/dl NN i
protein NN i
, , i
60 CD i
parts NNS i
bovine NN i
whey NN i
proteins NNS i
: : i
40 CD i
parts NNS i
bovine NN i
caseins NNS i
; : i
F2 NNP i
= VBD i
3.0 CD i
gm/dl NN i
, , i
60:40 CD i
; : i
F3 NNP i
= VBD i
1.5 CD i
gm/dl NN i
, , i
18:82 CD i
; : i
F4 NNP i
= VBD i
3.0 CD i
gm/dl NN i
, , N
18:82 CD N
. . N

Plasma NNP o
and CC o
urine JJ o
concentrations NNS o
of IN o
tyrosine NN o
and CC o
phenylalanine NN o
were VBD N
far RB N
higher JJR o
in IN N
the DT N
infants NNS N
fed VBP N
F1 NNP N
to TO N
F4 NNP N
, , N
especially RB N
F2 NNP N
and CC N
F4 NNP N
, , N
than IN N
in IN N
the DT N
infants NNS N
fed VBN N
BM NNP N
. . N

These DT N
findings NNS N
offer VBP N
further JJ N
evidence NN N
for IN N
the DT N
limited JJ N
capacity NN N
of IN N
the DT N
low-birth-weight JJ N
infant NN N
to TO N
catabolize VB o
tyrosine NN o
. . o

Infants NNS N
fed VBD N
F3 NNP N
had VBD N
significantly RB o
higher JJR o
plasma JJ o
tyrosine NN o
concentrations NNS o
than IN N
infants NNS N
fed VBN N
F1 NNP N
, , N
and CC N
those DT N
fed VBN N
F4 NNP N
had VBD N
higher JJR N
concentrations NNS N
than IN N
those DT N
fed JJ N
F2 NNP N
. . N

Thus NNP N
, , N
increased VBD o
plasma JJ o
tyrosine NN o
concentrations NNS o
in IN N
low-birth-weight JJ N
infants NNS N
are VBP N
related VBN N
directly RB N
both DT N
to TO N
the DT N
quantity NN N
and CC N
to TO N
the DT N
quality NN N
of IN N
the DT N
protein NN N
in IN N
their PRP$ N
diets NNS N
. . N

-DOCSTART- -X- O O

High-pressure NN i
, , i
rapid-inflation NN i
pneumatic JJ i
compression NN i
improves VBZ N
venous JJ N
hemodynamics NNS N
in IN N
healthy JJ p
volunteers NNS p
and CC p
patients NNS p
who WP p
are VBP p
post-thrombotic JJ p
. . p

PURPOSE NNP N
Deep NNP p
vein NN p
thrombosis NN p
( ( p
DVT NNP p
) ) p
is VBZ N
a DT N
preventable JJ N
cause NN N
of IN N
morbidity NN p
and CC p
mortality NN p
in IN p
patients NNS p
who WP p
are VBP p
hospitalized VBN p
. . p

An DT N
important JJ N
part NN N
of IN N
the DT N
mechanism NN N
of IN N
DVT NNP N
prophylaxis NN N
with IN N
intermittent JJ N
pneumatic JJ N
compression NN N
( ( N
IPC NNP N
) ) N
is VBZ N
reduced VBN N
venous JJ N
stasis NN N
with IN N
increased JJ N
velocity NN N
of IN N
venous JJ N
return NN N
. . N

The DT N
conventional JJ N
methods NNS N
of IN N
IPC NNP N
use NN N
low JJ N
pressure NN N
and CC N
slow JJ N
inflation NN N
of IN N
the DT N
air NN N
bladder NN N
on IN N
the DT N
leg NN N
to TO N
augment VB N
venous JJ N
return NN N
. . N

Recently RB N
, , N
compression NN N
devices NNS N
have VBP N
been VBN N
designed VBN N
that IN N
produce VBP N
high JJ N
pressure NN N
and CC N
rapid JJ N
inflation NN N
of IN N
air NN N
cuffs NNS N
on IN N
the DT N
plantar NN N
plexus NN N
of IN N
the DT N
foot NN N
and CC N
the DT N
calf NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
venous JJ N
velocity NN N
response NN N
to TO N
high-pressure NN N
, , N
rapid-inflation NN N
compression NN N
devices NNS N
versus VBP N
standard JJ N
, , N
low-pressure JJ N
, , N
slow-inflation JJ N
compression NN N
devices NNS N
in IN N
healthy JJ p
volunteers NNS p
and CC p
patients NNS p
with IN p
severe JJ p
post-thrombotic JJ p
venous JJ p
disease NN p
. . p

METHOD NNP N
Twenty-two NNP p
lower JJR p
extremities NNS p
from IN p
healthy JJ p
volunteers NNS p
and CC p
11 CD p
lower JJR p
extremities NNS p
from IN p
patients NNS p
with IN p
class NN p
4 CD p
to TO p
class NN p
6 CD p
post-thrombotic JJ p
chronic JJ p
venous JJ p
insufficiency NN p
were VBD p
studied VBN p
. . p

With IN N
duplex JJ i
ultrasound NN i
scanning NN i
( ( N
ATL-Ultramark NNP N
9 CD N
, , N
Advanced NNP N
Tech NNP N
Laboratory NNP N
, , N
Bothell NNP N
, , N
Wash NNP N
) ) N
, , N
acute JJ N
DVT NNP N
was VBD N
excluded VBN N
before IN N
subject JJ N
evaluation NN N
. . N

Venous JJ N
velocities NNS N
were VBD N
monitored VBN N
after IN N
the DT N
application NN N
of IN N
each DT N
of IN N
five CD N
IPC NNP N
devices NNS N
, , N
with IN N
all PDT N
the DT N
patients NNS N
in IN N
the DT N
supine JJ N
position NN N
. . N

Three CD i
high-pressure NN i
, , i
rapid-compression NN i
devices NNS i
and CC i
two CD i
standard NN i
, , i
low-pressure JJ i
, , i
slow-inflation JJ i
compression NN i
devices NNS i
were VBD N
applied VBN N
in IN N
a DT N
random JJ N
sequence NN N
. . N

Maximal NNP N
venous JJ N
velocities NNS N
were VBD N
obtained VBN N
at IN N
the DT N
common JJ N
femoral JJ N
vein NN N
and CC N
the DT N
popliteal NN N
vein NN N
for IN N
all PDT N
the DT N
devices NNS N
and CC N
were VBD N
recorded VBN N
as IN N
the DT N
mean JJ N
peak JJ N
velocity NN N
of IN N
three CD N
compression NN N
cycles NNS N
and CC N
compared VBN N
with IN N
baseline NN N
velocities NNS N
. . N

RESULTS VB N
The DT N
baseline NN N
venous JJ N
velocities NNS N
were VBD N
higher JJR N
in IN N
the DT N
femoral JJ N
veins NNS N
than IN N
in IN N
the DT N
popliteal NN N
veins NNS N
in IN N
both DT N
the DT N
volunteers NNS N
and CC N
the DT N
post-thrombotic JJ N
subjects NNS N
. . N

Standard NNP o
and CC o
high-pressure NN o
, , o
rapid-inflation NN o
compression NN o
significantly RB N
increased VBD N
the DT N
popliteal NN o
and CC o
femoral JJ o
vein NN o
velocities NNS o
in IN N
healthy JJ N
and CC N
post-thrombotic JJ N
subjects NNS N
. . N

High-pressure NN N
, , N
rapid-inflation NN N
compression NN N
produced VBD N
significantly RB N
higher JJR N
maximal JJ o
venous JJ o
velocities NNS o
in IN o
the DT o
popliteal NN o
and CC o
femoral JJ o
veins NNS o
in IN N
both DT N
healthy JJ N
volunteers NNS N
and CC N
patients NNS N
who WP N
were VBD N
post-thrombotic JJ N
as IN N
compared VBN N
with IN N
standard JJ N
compression NN N
. . N

Compared VBN N
with IN N
the DT N
healthy JJ N
volunteers NNS N
, , N
the DT N
patients NNS N
who WP N
were VBD N
post-thrombotic JJ N
had VBD N
a DT N
significantly RB N
attenuated VBN N
velocity NN o
response NN o
at IN N
both DT N
the DT N
popliteal NN N
and CC N
the DT N
femoral JJ N
vein NN N
levels NNS N
. . N

CONCLUSION NNP N
High-pressure NNP N
, , N
rapid-inflation NN N
pneumatic JJ N
compression NN N
increases NNS N
popliteal NN o
and CC o
femoral JJ o
vein NN o
velocity NN o
as IN N
compared VBN N
with IN N
standard JJ N
, , N
low-pressure JJ N
, , N
slow-inflation JJ N
pneumatic JJ N
compression NN N
. . N

Patients NNS p
with IN p
post-thrombotic JJ p
venous JJ p
disease NN p
have VBP N
a DT N
compromised JJ N
hemodynamic JJ N
response NN N
to TO N
all DT N
IPC NNP N
devices NNS N
. . N

However RB N
, , N
an DT N
increased VBN N
velocity NN N
response NN N
to TO N
the DT N
high-pressure NN N
, , N
rapid-inflation NN N
compression NN N
device NN N
is VBZ N
preserved VBN N
. . N

High-pressure NN N
, , N
rapid-inflation NN N
pneumatic JJ N
compression NN N
may MD N
offer VB N
additional JJ N
protection NN N
from IN N
thrombotic JJ N
complications NNS N
on IN N
the DT N
basis NN N
of IN N
an DT N
improved JJ N
hemodynamic JJ o
response NN o
, , N
both DT N
in IN N
healthy JJ p
volunteers NNS p
and CC p
in IN p
patients NNS p
who WP p
were VBD p
post-thrombotic JJ p
. . p

-DOCSTART- -X- O O

Acute JJ N
effects NNS N
of IN N
caffeine JJ i
ingestion NN i
on IN N
signal-averaged JJ o
electrocardiograms NNS o
. . o

BACKGROUND NNP N
Although IN N
moderate JJ N
caffeine NN N
ingestion NN N
has VBZ N
not RB N
been VBN N
shown VBN N
to TO N
be VB N
arrhythmogenic JJ N
, , N
caffeine JJ N
toxicity NN N
can MD N
cause VB N
severe JJ N
cardiac JJ N
arrhythmias NN N
, , N
including VBG N
atrial JJ N
fibrillation NN N
and CC N
ventricular JJ N
tachycardia NN N
. . N

Atrial JJ N
fibrillation NN N
and CC N
ventricular JJ N
tachycardia NN N
have VBP N
been VBN N
associated VBN N
with IN N
prolongation NN o
of IN o
P-wave NNP o
and CC o
QRS NNP o
complex JJ o
durations NNS o
on IN o
signal-averaged JJ o
electrocardiograms NNS o
. . o

This DT N
study NN N
investigated VBD N
acute JJ N
effects NNS N
of IN N
caffeine JJ N
ingestion NN N
on IN N
signal-averaged JJ o
P-wave NNP o
and CC o
QRS NNP o
complexes NNS o
. . o

METHODS NNP N
AND CC N
RESULTS NNP N
Signal-averaged JJ o
electrocardiograms NNS o
were VBD N
obtained VBN N
from IN N
12 CD p
normal JJ p
subjects NNS p
( ( p
6 CD p
men NNS p
, , p
6 CD p
women NNS p
; : p
ages VBZ p
21 CD p
to TO p
26 CD p
years NNS p
) ) p
before IN p
and CC p
after IN p
ingestion NN p
of IN p
caffeine NN i
( ( N
5 CD N
mg/kg NN N
body NN N
weight NN N
) ) N
or CC N
placebo NN i
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover JJ N
fashion NN N
. . N

Electrocardiograms NNP N
for IN N
signal JJ N
averaging NN N
were VBD N
recorded VBN N
from IN N
electrodes NNS N
left VBN N
in IN N
a DT N
constant JJ N
location NN N
. . N

After IN N
bandpass NN N
filtering NN N
( ( N
30 CD N
to TO N
300 CD N
Hz NNP N
) ) N
and CC N
amplification NN N
, , N
signals NNS N
were VBD N
sampled VBN N
over IN N
7.2 CD N
minutes NNS N
at IN N
2000 CD N
Hz NNP N
. . N

Signal-averaged JJ o
P-wave NNP o
and CC o
QRS NNP o
complex JJ o
durations NNS o
did VBD N
not RB N
significantly RB N
change VBP N
after IN N
placebo NN N
ingestion NN N
. . N

After IN N
caffeine JJ N
ingestion NN N
QRS NNP o
duration NN o
prolonged VBD N
in IN N
9 CD N
of IN N
11 CD N
subjects NNS N
at IN N
90 CD N
minutes NNS N
( ( N
mean JJ N
+/- JJ N
SEM NNP N
= NNP N
0.8+/-0.3 JJ N
ms NN N
, , N
P NNP N
< NNP N
.02 NNP N
) ) N
and CC N
in IN N
8 CD N
of IN N
9 CD N
after IN N
3 CD N
hours NNS N
( ( N
1.1+/-0.2 JJ N
ms NN N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

No DT N
significant JJ N
change NN N
in IN N
P-wave NNP o
duration NN o
or CC o
heart NN o
rate NN o
was VBD N
found VBN N
after IN N
caffeine JJ N
ingestion NN N
at IN N
any DT N
test NN N
interval NN N
. . N

Average JJ o
caffeine JJ o
level NN o
in IN o
saliva JJ o
90 CD N
minutes NNS N
after IN N
ingestion NN N
was VBD N
6.6+/-1.6 JJ N
( ( N
SD NNP N
) ) N
microg/dL NN N
. . N

CONCLUSIONS NNP N
Although IN N
probably RB N
not RB N
arrhythmogenic JJ N
in IN N
normal JJ p
subjects NNS p
, , N
moderate JJ N
caffeine NN N
ingestion NN N
does VBZ N
produce VB N
a DT N
small JJ N
but CC N
statistically RB N
significant JJ N
prolongation NN N
of IN N
signal-averaged JJ o
QRS NNP o
complexes NNS o
. . o

Further JJ N
prolongation NN N
caused VBN N
by IN N
excessive JJ N
caffeine NNS N
intake VBP N
may MD N
be VB N
a DT N
factor NN N
in IN N
the DT N
genesis NN N
of IN N
arrhythmias NNS N
associated VBN N
with IN N
caffeine JJ N
toxicity NN N
. . N

-DOCSTART- -X- O O

Working VBG N
well RB N
with IN N
a DT N
disability NN p
: : p
health NN i
promotion NN i
as IN N
a DT N
means NN N
to TO N
employment NN N
. . N

PURPOSE/OBJECTIVE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
utility NN N
of IN N
the DT N
Working NNP i
Well NNP i
with IN i
a DT i
Disability NNP i
health-promotion NN i
program NN i
with IN N
vocational JJ i
rehabilitation NN i
( ( p
VR NNP p
) ) p
clients NNS p
. . p

Health-promotion NN i
interventions NNS i
have VBP N
been VBN N
shown VBN N
to TO N
reduce VB N
limitation NN N
from IN N
secondary JJ N
conditions NNS N
, , N
which WDT N
can MD N
be VB N
a DT N
significant JJ N
barrier NN N
to TO N
labor NN N
force NN N
participation NN N
among IN N
people NNS p
with IN p
disabilities NNS p
. . p

The DT N
state NN N
and CC N
federal JJ N
VR NNP N
system NN N
represents VBZ N
a DT N
potential JJ N
access NN N
point NN N
for IN N
delivery NN N
of IN N
health-promotion NN N
activities NNS N
. . N

RESEARCH NNP N
METHOD/DESIGN NNP N
A NNP p
total NN p
of IN p
297 CD p
VR NNP p
clients NNS p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
of IN N
the DT N
Working NNP i
Well NNP i
health NN i
promotion NN i
program NN i
. . i

Control NNP N
and CC N
intervention NN N
participants NNS N
provided VBD N
baseline NN N
and CC N
four CD N
waves NNS N
of IN N
quarterly JJ N
follow-up JJ N
data NNS N
. . N

Data NNS N
were VBD N
analyzed VBN N
with IN N
repeated-measures NNS N
ANOVA NNP N
. . N

RESULTS NNP N
Intervention-group JJ i
participants NNS N
who WP N
attended VBD N
over IN N
half NN N
of IN N
the DT N
Working NNP i
Well NNP i
sessions NNS N
reported VBD N
significantly RB N
lower JJR N
rates NNS o
of IN o
limitation NN o
from IN o
secondary JJ o
conditions NNS o
over IN N
the DT N
1-year JJ N
study NN N
span NN N
, , N
F NNP N
( ( N
1 CD N
, , N
124 CD N
) ) N
= NN N
4.11 CD N
, , N
p NN N
= NNP N
.004 NNP N
. . N

Control-group NN i
participants NNS N
also RB N
experienced VBD N
significantly RB N
lower JJR o
rates NNS o
of IN o
limitation NN o
, , N
but CC N
pre- JJ o
to TO o
postdifferences NNS o
were VBD N
less RBR N
dramatic JJ N
, , N
F NNP N
( ( N
1 CD N
, , N
308 CD N
) ) N
= NN N
4.19 CD N
, , N
p NN N
= NNP N
.006 NNP N
. . N

CONCLUSIONS/IMPLICATIONS NNP N
Overall NNP N
, , N
health NN N
data NNS N
indicated VBD N
that IN N
the DT N
Working NNP i
Well NNP i
program NN i
may MD N
be VB N
particularly RB N
helpful JJ o
to TO N
VR NNP p
clients NNS p
with IN p
higher JJR p
rates NNS p
of IN p
secondary JJ p
health NN p
conditions NNS p
and CC N
may MD N
represent VB N
one CD N
strategy NN N
for IN N
overcoming VBG o
barriers NNS o
to TO o
employment NN o
. . o

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
metronidazole NN i
on IN N
the DT N
incidence NN o
of IN o
postoperative JJ o
wound NN o
infection NN o
in IN p
elective JJ p
colon NN p
surgery NN p
. . p

A DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
assessing VBG N
the DT N
relative JJ N
effectiveness NN N
of IN N
erythromycin-neomycin JJ i
and CC i
metronidazole-neomycin JJ i
as IN N
a DT N
preoperative JJ N
bowel NN N
preparation NN N
was VBD N
carried VBN N
out RP N
. . N

Bacteriologic NNP N
studies NNS N
of IN N
feces NNS N
and CC N
colon NN N
content NN N
revealed VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
reduction NN o
of IN o
aerobic JJ o
bacteria NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significantly RB N
greater JJR N
reduction NN o
in IN N
anaerobic JJ o
bacteria NNS o
in IN N
the DT N
feces NNS N
and CC N
colon NN N
contents NNS N
of IN N
patients NNS N
receiving VBG N
metronidazole NN N
. . N

Wound IN o
infection NN o
rate NN o
was VBD N
25 CD N
% NN N
in IN N
the DT N
erythromycin NN N
group NN N
, , N
and CC N
organisms NNS N
recovered VBN N
from IN N
the DT N
wound NN N
in IN N
all DT N
cases NNS N
were VBD N
fecal JJ N
in IN N
nature NN N
. . N

Two CD N
wound IN o
infections NNS o
occurred VBD N
in IN N
the DT N
metronidazole NN N
group NN N
( ( N
5 CD N
% NN N
) ) N
and CC N
in IN N
both DT N
cases NNS N
the DT N
organisms NNS N
recovered VBN N
were VBD N
staphylococci NNS o
of IN o
presumed JJ o
skin JJ o
origin NN o
. . o

These DT N
studies NNS N
suggest VBP N
that IN N
anaerobic JJ N
bacteria NNS N
are VBP N
the DT N
major JJ N
contributors NNS N
to TO N
wound VB o
infection NN o
after IN N
colon NN N
surgery NN N
and CC N
that IN N
their PRP$ N
specific JJ N
reduction NN N
is VBZ N
associated VBN N
with IN N
a DT N
lower JJR N
incidence NN N
of IN N
wound JJ o
infection NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
chelation NN i
therapy NN i
on IN N
progressive JJ N
diabetic JJ N
nephropathy NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
and CC p
high-normal JJ p
body NN p
lead JJ p
burdens NNS p
. . p

BACKGROUND VB N
A DT N
previous JJ N
study NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN N
high-normal JJ N
body NN N
lead NN N
burdens VBZ N
showed VBD N
that IN N
EDTA NNP i
chelation NN i
therapy NN i
for IN N
3 CD N
months NNS N
slows VBZ N
progressive JJ N
diabetic JJ N
nephropathy NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
a DT N
longer JJR N
course NN N
of IN N
therapy NN N
on IN N
kidney NN N
function NN N
decrease NN N
over IN N
a DT N
longer JJR N
follow-up NN N
is VBZ N
not RB N
known VBN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
12-month JJ N
run-in JJ N
phase NN N
, , N
then RB N
a DT N
randomized VBN N
single-blind NN N
study NN N
with IN N
a DT N
27-month JJ N
intervention NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
University NNP p
medical JJ p
center NN p
; : p
50 CD p
patients NNS p
( ( p
serum JJ p
creatinine NN p
, , p
1.5-3.9 JJ p
mg/dL NN p
) ) p
with IN p
high-normal JJ p
body NN p
lead JJ p
burden NN p
( ( p
?80- JJ p
< NN p
600 CD p
?g NN p
) ) p
were VBD p
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN i
and CC i
control NN i
groups NNS i
. . i

INTERVENTION NNP i
The DT N
treatment NN N
group NN N
received VBD N
weekly JJ i
chelation NN i
therapy NN i
for IN i
3 CD N
months NNS N
to TO N
reduce VB N
their PRP$ N
body NN N
lead JJ N
burden NN N
to TO N
< VB N
60 CD N
?g NNS N
and CC N
then RB N
as IN N
needed VBN N
for IN N
24 CD N
months NNS N
to TO N
maintain VB N
this DT N
level NN N
. . N

The DT N
control NN N
group NN N
received VBD i
placebo NN i
for IN i
3 CD N
months NNS N
and CC N
then RB N
weekly VB N
for IN N
5 CD N
weeks NNS N
at IN N
6-month JJ N
intervals NNS N
for IN N
24 CD N
months NNS N
. . N

OUTCOMES IN o
The DT o
primary JJ o
end NN o
point NN o
was VBD o
change NN o
in IN o
estimated VBN o
glomerular JJ o
filtration NN o
rate NN o
( ( o
eGFR NN o
) ) o
over IN o
time NN o
. . o

A DT o
secondary JJ N
end NN N
point NN N
was VBD N
a DT o
2-fold JJ o
increase NN o
in IN o
baseline JJ o
serum NN o
creatinine NN o
level NN o
or CC o
the DT o
requirement NN o
for IN o
renal JJ o
replacement NN o
therapy NN o
. . o

MEASUREMENTS NNP o
Body NNP N
lead JJ N
burdens NNS N
were VBD N
assessed VBN N
by IN N
EDTA NNP N
mobilization NN N
tests NNS N
and CC N
eGFR NN N
was VBD N
calculated VBN N
using VBG N
the DT N
equation NN N
for IN N
Chinese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

RESULTS NNP o
Mean NNP o
baseline NN o
eGFRs NN o
in IN o
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
were VBD N
similar JJ N
. . N

After IN N
3 CD N
months NNS N
of IN N
chelation NN N
therapy NN N
, , N
the DT N
change NN o
in IN o
eGFR NN o
in IN o
the DT N
treatment NN N
group NN N
( ( N
+1.0 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
) ) N
differed VBN N
significantly RB N
from IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
-1.5 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

In IN N
the DT N
subsequent JJ N
24-month JJ N
intervention NN N
, , N
the DT N
yearly JJ N
rate NN o
of IN o
decrease NN o
in IN o
eGFR NN o
( ( N
5.6 CD N
? . N
5.0 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slower JJR N
than IN N
that DT N
( ( N
9.2 CD N
? . N
3.6 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
control NN N
group NN p
. . p

17 CD p
( ( p
68 CD p
% NN p
) ) N
control-group NN p
patients NNS p
and CC p
9 CD p
( ( p
36 CD p
% NN p
) ) p
treatment-group NN p
patients NNS p
achieved VBD p
the DT N
secondary JJ N
end NN N
point NN N
. . N

LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
, , N
not RB N
double JJ N
blind NN N
. . N

CONCLUSIONS VB N
A DT N
27-month JJ N
course NN N
of IN N
EDTA NNP N
chelation NN N
therapy NN N
retards VBZ N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN p
in IN p
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
high-normal JJ p
body NN p
lead JJ p
burdens NNS p
. . N

-DOCSTART- -X- O O

Egg NNP i
intake NN i
during IN N
carbohydrate JJ N
restriction NN N
alters NNS N
peripheral JJ N
blood NN N
mononuclear NN N
cell NN N
inflammation NN N
and CC N
cholesterol NN N
homeostasis NN N
in IN N
metabolic JJ N
syndrome NN N
. . N

Egg NNP N
yolk NN N
contains NNS N
bioactive JJ N
components NNS N
that WDT N
improve VBP N
plasma NN N
inflammatory NN N
markers NNS N
and CC N
HDL NNP N
profiles NNS N
in IN N
metabolic JJ N
syndrome NN N
( ( N
MetS NNP N
) ) N
under IN N
carbohydrate NN N
restriction NN N
. . N

We PRP N
further RB N
sought VBD N
to TO N
determine VB N
whether IN N
egg NN i
yolk NNS i
intake VBP i
affects NNS N
peripheral JJ o
blood NN o
mononuclear NN o
cell NN o
( ( o
PBMC NNP o
) ) o
inflammation NN o
and CC N
cholesterol NN N
homeostasis NN N
in IN N
MetS NNP N
, , N
as IN N
HDL NNP N
and CC N
its PRP$ N
associated JJ N
lipid JJ N
transporter NN N
ATP-binding NNP N
cassette NN N
transporter NN N
A1 NNP N
( ( N
ABCA1 NNP N
) ) N
reduce VB N
the DT N
inflammatory JJ N
potential NN N
of IN N
leukocytes NNS N
through IN N
modulation NN N
of IN N
cellular JJ N
cholesterol NN N
content NN N
and CC N
distribution NN N
. . N

Thirty-seven JJ p
men NNS p
and CC p
women NNS p
classified VBN p
with IN p
MetS NNP p
consumed VBD N
a DT N
moderate JJ i
carbohydrate-restricted JJ i
diet NN i
( ( N
25 CD N
% NN N
-30 CD N
% NN N
of IN N
energy NN N
) ) N
for IN N
12 CD N
weeks NNS N
, , N
in IN N
addition NN N
to TO N
consuming VBG N
either DT i
three CD i
whole JJ i
eggs NNS i
per IN i
day NN i
( ( i
EGG NNP i
) ) i
or CC i
the DT i
equivalent JJ i
amount NN i
of IN i
yolk-free JJ i
egg NN i
substitute NN i
( ( i
SUB NNP i
) ) i
. . N

Interestingly RB N
, , N
lipopolysaccharide-induced JJ o
PBMC NNP o
IL-1? NNP o
and CC o
TNF? NNP o
secretion NN o
increased VBD o
from IN o
baseline NN N
to TO N
week NN N
12 CD N
in IN N
the DT N
SUB NNP N
group NN N
only RB N
, , N
despite IN N
increases NNS N
in IN N
PBMC NNP o
toll-like JJ o
receptor NN o
4 CD o
( ( o
TLR4 NNP o
) ) o
mRNA NN o
expression NN o
in IN o
the DT N
EGG NNP N
group NN N
. . N

Compared VBN N
to TO N
baseline VB o
, , o
ABCA1 NNP o
and CC o
3-hydroxy-3-methyl-glutaryl NNP o
( ( o
HMG NNP o
) ) o
-CoA VBP o
reductase NN o
mRNA JJ o
expression NN o
increased VBN o
by IN o
week NN N
12 CD N
in IN N
the DT N
EGG NNP N
group NN N
only RB N
, , N
whereas NNS N
changes NNS N
in IN N
PBMC NNP o
total JJ o
cholesterol NN o
positively RB o
correlated VBN N
with IN N
changes NNS N
in IN N
lipid JJ N
raft NN N
content NN N
. . N

Together RB N
, , N
these DT N
findings NNS N
suggest VBP N
that IN N
intake NN N
of IN N
whole JJ N
eggs NNS N
during IN N
carbohydrate JJ N
restriction NN N
alters NNS o
PBMC NNP o
inflammation NN o
and CC o
cholesterol NN o
homeostasis NN o
in IN o
MetS NNP N
. . N

-DOCSTART- -X- O O

Prognostic JJ N
factor NN N
analysis NN N
in IN N
patients NNS p
with IN p
advanced JJ p
prostate NN p
cancer NN p
treated VBN p
by IN p
castration NN i
plus CC i
anandron NN i
or CC i
placebo NN i
: : i
a DT N
final JJ N
update NN N
. . N

PURPOSE NNP N
Different NNP N
outcome NN N
results NNS N
have VBP N
been VBN N
published VBN N
in IN N
trials NNS N
comparing VBG N
maximal JJ N
androgen NN N
blockade NN N
( ( N
MAB NNP N
) ) N
with IN N
chemical NN i
or CC i
surgical JJ i
castration NN i
alone RB i
. . i

The DT N
conflicting NN N
results NNS N
could MD N
be VB N
explained VBN N
by IN N
the DT N
fact NN N
that IN N
patients NNS N
were VBD N
included VBN N
with IN N
different JJ N
prognostic JJ N
factors NNS N
. . N

In IN N
this DT N
new JJ N
analysis NN N
of IN N
the DT N
Anandron NNP N
European NNP N
Study NNP N
, , N
independent JJ N
prognostic JJ N
factors NNS N
have VBP N
been VBN N
evaluated VBN N
in IN N
order NN N
to TO N
identify VB N
those DT N
which WDT N
could MD N
influence VB N
the DT N
study NN N
outcome NN N
and CC N
the DT N
impact NN N
of IN N
the DT N
treatment NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
399 CD p
out IN p
of IN p
457 CD p
patients NNS p
recruited VBN p
in IN p
this DT p
study NN p
were VBD p
divided VBN p
in IN p
a DT p
good JJ p
or CC p
poor JJ p
prognostic JJ p
group NN p
depending VBG p
on IN p
the DT p
presence NN p
of IN p
two CD p
or CC p
more JJR p
poor JJ p
prognostic JJ p
factors NNS p
, , p
these DT p
were VBD p
pain NN p
requiring VBG p
treatment NN p
, , p
> VBZ p
5 CD p
bone NN p
metastases NNS p
, , p
hydronephrosis NN p
, , p
and CC p
alkaline JJ p
phosphatase NN p
> VBD p
2 CD p
ULN NNP p
. . p

RESULTS NNP N
When WRB N
expressed VBN N
as IN N
a DT N
percentage NN N
, , N
the DT N
improvement NN o
in IN o
time NN o
to TO o
progression NN o
, , o
overall JJ o
and CC o
cancer NN o
specific JJ o
survival NN o
in IN N
the DT N
Anandron NNP i
treated VBD N
patients NNS N
was VBD N
identical JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
absolute JJ N
terms NNS N
this DT N
improvement NN N
, , N
however RB N
, , N
was VBD N
greater JJR N
in IN N
the DT N
good JJ N
prognostic JJ N
group NN N
. . N

CONCLUSION NNP N
In IN N
comparison NN N
with IN N
surgical JJ i
castration NN i
MAB NNP i
using VBG i
Anandron NNP i
, , N
in IN N
patients NNS p
with IN p
metastatic JJ p
prostate NN p
cancer NN p
improves VBZ N
the DT N
time NN N
to TO N
objective VB o
progression NN o
, , o
overall JJ o
and CC o
cancer NN o
specific JJ o
survival NN o
, , N
irrespective NN N
of IN N
certain JJ N
poor JJ N
prognostic JJ N
factors NNS N
. . N

-DOCSTART- -X- O O

Secondary JJ N
analysis NN N
of IN N
RTOG NNP N
9508 CD N
, , N
a DT N
phase NN N
3 CD N
randomized JJ N
trial NN N
of IN N
whole-brain JJ i
radiation NN i
therapy NN i
versus NN i
WBRT NNP i
plus CC i
stereotactic JJ i
radiosurgery NN i
in IN N
patients NNS p
with IN p
1-3 JJ p
brain NN p
metastases NNS p
; : p
poststratified VBN p
by IN p
the DT p
graded JJ p
prognostic JJ p
assessment NN p
( ( p
GPA NNP p
) ) p
. . p

PURPOSE NNP N
Radiation NNP i
Therapy NNP i
Oncology NNP i
Group NNP i
( ( i
RTOG NNP i
) ) i
9508 CD i
showed VBD N
a DT N
survival JJ N
advantage NN N
for IN N
patients NNS p
with IN p
1 CD p
but CC p
not RB p
2 CD p
or CC p
3 CD p
brain NN p
metastasis NN p
( ( p
BM NNP p
) ) p
treated VBD N
with IN N
whole-brain JJ i
radiation NN i
therapy NN i
( ( i
WBRT NNP i
) ) i
and CC i
stereotactic JJ i
radiosurgery NN i
( ( i
SRS NNP i
) ) i
versus NN i
WBRT NNP i
alone RB i
. . i

An DT N
improved JJ N
prognostic JJ N
index NN N
, , N
the DT N
graded JJ N
prognostic JJ N
assessment NN N
( ( N
GPA NNP N
) ) N
has VBZ N
been VBN N
developed VBN N
. . N

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
if IN N
the DT N
data NN N
from IN N
RTOG JJ i
9508 CD i
were VBD N
poststratified VBN N
by IN N
the DT N
GPA NNP N
, , N
the DT N
conclusions NNS N
may MD N
vary VB N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
In IN N
this DT N
analysis NN N
, , N
252 CD p
of IN p
the DT p
331 CD p
patients NNS p
were VBD p
evaluable JJ p
by IN p
GPA NNP p
. . p

Of IN p
those DT p
, , p
211 CD p
had VBD p
lung NN p
cancer NN p
. . p

Breast NNP p
cancer NN p
patients NNS p
were VBD p
excluded VBN p
because IN N
the DT N
components NNS N
of IN N
the DT N
breast NN N
GPA NNP N
are VBP N
not RB N
in IN N
the DT N
RTOG NNP N
database NN N
. . N

Multiple NNP N
Cox NNP N
regression NN N
was VBD N
used VBN N
to TO N
compare VB N
survival NN N
between IN N
treatment NN p
groups NNS p
, , N
adjusting VBG N
for IN N
GPA NNP N
. . N

Treatment NNP N
comparisons NNS N
within IN N
subgroups NNS N
were VBD N
performed VBN N
with IN N
the DT N
log-rank JJ N
test NN N
. . N

A DT N
free JJ N
online NN N
tool NN N
( ( N
brainmetgpa.com NN N
) ) N
simplified VBD N
GPA NNP N
use NN N
. . N

RESULTS VB N
The DT N
fundamental JJ N
conclusions NNS N
of IN N
the DT N
primary JJ N
analysis NN N
were VBD N
confirmed VBN N
in IN N
that DT N
there EX N
was VBD N
no DT N
survival JJ o
benefit NN o
overall JJ N
for IN N
patients NNS N
with IN N
1 CD N
to TO N
3 CD N
metastases NNS N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
benefit NN N
for IN N
the DT N
subset NN N
of IN N
patients NNS N
with IN N
GPA NNP N
3.5 CD N
to TO N
4.0 CD N
( ( N
median JJ N
survival NN N
time NN N
[ NNP N
MST NNP N
] NNP N
for IN N
WBRT NNP i
+ NNP i
SRS NNP i
vs FW N
WBRT NNP N
alone RB N
was VBD N
21.0 CD N
versus NN N
10.3 CD N
months NNS N
, , N
P=.05 NNP N
) ) N
regardless NN N
of IN N
the DT N
number NN N
of IN N
metastases NNS N
. . N

Among IN N
patients NNS N
with IN N
GPA NNP N
3.5 CD N
to TO N
4.0 CD N
treated VBN N
with IN N
WBRT NNP i
and CC i
SRS NNP i
, , N
the DT N
MST NNP o
for IN N
patients NNS N
with IN N
1 CD N
versus NN N
2 CD N
to TO N
3 CD N
metastases NNS N
was VBD N
21 CD N
and CC N
14.1 CD N
months NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
This DT N
secondary JJ N
analysis NN N
of IN N
predominantly RB N
lung JJ p
cancer NN p
patients NNS p
, , N
consistent JJ N
with IN N
the DT N
original JJ N
analysis NN N
, , N
shows VBZ N
no DT N
survival JJ o
advantage NN o
for IN N
the DT N
group NN N
overall JJ N
when WRB N
treated VBN N
with IN N
WBRT NNP N
and CC N
SRS NNP N
; : N
however RB N
, , N
in IN N
patients NNS p
with IN p
high JJ p
GPA NNP p
( ( N
3.5-4 JJ N
) ) N
, , N
there EX N
is VBZ N
a DT N
survival JJ N
advantage NN N
regardless NN N
of IN N
whether IN N
they PRP N
have VBP N
1 CD N
, , N
2 CD N
, , N
or CC N
3 CD N
BM NNPS N
. . N

This DT N
benefit NN N
did VBD N
not RB N
extend VB N
to TO N
patients NNS N
with IN N
lower JJR N
GPA NNP N
. . N

Prospective JJ N
validation NN N
of IN N
this DT N
survival JJ N
benefit NN N
for IN N
patients NNS p
with IN p
multiple JJ p
BM NNP p
and CC p
high JJ p
GPA NNP p
when WRB p
treated VBN p
with IN p
WBRT NNP i
and CC i
SRS NNP i
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

Trials NNS o
and CC N
tribulations NNS o
in IN N
speech NN i
therapy NN i
. . i

-DOCSTART- -X- O O

The DT N
Finnish JJ p
Diabetes NNP p
Prevention NNP N
Study NNP N
. . N

The DT N
aim NN N
of IN N
the DT N
Finnish NNP p
Diabetes NNP p
Prevention NNP N
Study NNP N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
an DT N
intensive JJ i
diet-exercise NN i
programme NN i
in IN N
preventing VBG N
or CC N
delaying VBG N
type JJ o
2 CD o
diabetes NNS o
in IN p
individuals NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
( ( p
IGT NNP p
) ) p
and CC N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
programme NN N
on IN N
the DT N
risk NN N
factors NNS N
of IN N
atherosclerotic JJ N
vascular NN N
diseases NNS N
and CC N
the DT N
incidence NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

In IN N
this DT N
ongoing JJ N
study NN N
, , N
a DT p
total NN p
of IN p
523 CD p
overweight JJ p
subjects NNS p
with IN p
IGT NNP p
based VBN p
on IN p
two CD p
oral JJ p
glucose JJ p
tolerance NN p
tests NNS p
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
intervention NN p
group NN p
or CC N
a DT N
control NN p
group NN p
. . p

The DT N
main JJ N
measure NN N
in IN N
the DT N
intervention NN N
group NN N
is VBZ N
individual JJ o
dietary JJ o
advice NN o
aimed VBN N
at IN N
reducing VBG i
weight NN i
and CC i
intake NN i
of IN i
saturated JJ i
fat NN i
and CC i
increasing VBG i
intake NN i
of IN i
dietary JJ i
fibre NN i
. . i

The DT N
intervention NN N
subjects NNS N
are VBP N
individually RB N
guided VBN N
to TO N
increase VB o
their PRP$ o
level NN o
of IN o
physical JJ o
activity NN o
. . o

The DT N
control NN i
group NN i
receives VBZ i
general JJ i
information NN i
about IN i
the DT i
benefits NNS i
of IN i
weight NN i
reduction NN i
, , i
physical JJ i
activity NN i
and CC i
healthy JJ i
diet NN i
in IN i
the DT i
prevention NN i
of IN i
diabetes NNS i
. . i

A DT N
pilot NN N
study NN N
began VBD N
in IN N
1993 CD N
, , N
and CC N
recruitment NN N
ended VBN N
in IN N
1998 CD N
. . N

By IN N
the DT N
end NN N
of IN N
April NNP N
1999 CD N
there EX N
were VBD N
65 CD N
new JJ N
cases NNS N
of IN N
diabetes NNS N
, , N
34 CD N
drop-outs NNS N
and CC N
one CD N
death NN o
. . o

The DT N
weight NN o
reduction NN o
was VBD N
greater JJR N
( ( N
-4.6 NNP N
kg NN N
) ) N
at IN N
1 CD N
year NN N
in IN N
the DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
152 CD N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NN N
143 CD N
, , N
-0.9 NNP N
kg NNP N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
this DT N
difference NN N
was VBD N
sustained VBN N
in IN N
the DT N
second JJ N
year NN N
of IN N
follow-up NN N
. . N

At IN N
1 CD N
year NN N
43.4 CD N
% NN N
and CC N
at IN N
2 CD N
years NNS N
41.8 CD N
% NN N
of IN N
the DT N
intervention NN N
subjects NNS N
had VBD N
achieved VBN N
a DT N
weight JJ o
reduction NN o
of IN N
at IN N
least JJS N
5 CD N
kg NNS N
, , N
while IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
control NN N
subjects VBZ N
were VBD N
14.0 CD N
and CC N
12.0 CD N
% NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
between IN N
the DT N
groups NNS N
) ) N
. . N

At IN N
1 CD N
year NN N
the DT N
intervention NN N
group NN N
showed VBD N
significantly RB N
greater JJR o
reductions NNS o
in IN N
2 CD o
h NN o
glucose NN o
, , o
fasting VBG o
and CC o
2 CD o
h NN o
insulin NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
and CC o
serum NN o
triglycerides NNS o
. . o

Most JJS N
of IN N
the DT N
beneficial JJ N
changes NNS N
in IN N
cardiovascular JJ o
risk NN o
factors NNS o
were VBD N
sustained VBN N
for IN N
2 CD N
years NNS N
. . N

These DT N
interim JJ N
results NNS N
of IN N
the DT N
ongoing JJ N
Finnish JJ N
Diabetes NNP N
Prevention NNP N
Study NNP N
demonstrate VB N
the DT N
efficacy NN o
and CC o
feasibility NN o
of IN N
the DT N
lifestyle JJ N
intervention NN N
programme NN N
. . N

-DOCSTART- -X- O O

Instant JJ i
Recess? NNP i
: : i
a DT N
practical JJ N
tool NN N
for IN N
increasing VBG o
physical JJ o
activity NN o
during IN N
the DT N
school NN N
day NN N
. . N

BACKGROUND NNP N
An DT N
increased JJ N
prevalence NN N
of IN p
overweight/obesity NN p
among IN p
children NNS p
has VBZ N
led VBN N
to TO N
school NN N
district NN N
level NN N
policies NNS N
to TO N
increase VB o
physical JJ o
activity NN o
( ( o
PA NNP o
) ) o
among IN p
elementary JJ p
school NN p
students NNS p
. . p

Interventions NNS N
are VBP N
needed VBN N
that IN N
increase NN N
activity NN N
levels NNS N
without IN N
sacrificing VBG N
time NN N
spent VBN N
in IN N
academics NNS N
. . N

OBJECTIVES IN N
We PRP N
evaluated VBD N
a DT N
policy NN i
implementation NN i
intervention NN i
for IN N
to TO N
increase VB N
in-school JJ i
PA NNP i
in IN p
elementary JJ p
schools NNS p
in IN p
Forsyth NNP p
County NNP p
, , p
North NNP p
Carolina NNP p
, , p
in IN N
a DT N
randomized JJ N
study NN N
with IN N
a DT N
delayed JJ N
intervention NN N
control NN N
group NN N
. . N

METHODS NNP p
The DT p
study NN p
included VBD p
third- JJ p
through IN p
fifth-grade JJ p
classrooms NNS p
in IN p
eight CD p
elementary JJ p
schools NNS p
. . p

Instant NNP i
Recess? NNP i
was VBD i
used VBN N
to TO N
introduce VB N
10-minute JJ i
PA NNP i
breaks NNS i
in IN i
classrooms NNS N
on IN N
schedules NNS N
determined VBN N
by IN N
teachers NNS N
. . N

Direct JJ N
observation NN N
was VBD N
used VBN N
to TO N
measure VB o
activity NN o
levels NNS o
, , o
other JJ o
student NN o
behaviors NNS o
, , o
and CC o
teacher NN o
behaviors NNS o
related VBN o
to TO N
PA NNP N
in IN N
the DT N
classrooms NNS N
. . N

RESULTS NNP N
Twenty-eight JJ N
visits NNS N
to TO N
schools NNS N
were VBD N
made VBN N
during IN N
the DT N
spring NN N
and CC N
fall NN N
semesters NNS N
of IN N
2009 CD N
. . N

At IN N
baseline JJ N
11 CD N
% NN N
to TO N
44 CD N
% NN N
of IN N
intervention NN N
and CC N
control NN N
schools NNS N
were VBD N
engaged VBN N
in IN N
classroom-based JJ i
PA. NNP o
PA NNP o
increased VBD o
from IN N
baseline NN N
to TO N
spring VB N
follow-up NN N
in IN N
intervention NN N
schools NNS N
and CC N
was VBD N
maintained VBN N
the DT N
following VBG N
fall NN N
. . N

Control NNP N
schools NNS N
decreased VBD o
PA NNP o
from IN o
baseline NN N
to TO N
spring NN N
and CC N
increased VBD o
PA NNP o
once RB o
they PRP N
began VBD N
the DT N
intervention NN N
. . N

Students NNS N
in IN N
classrooms NNS N
engaged VBN N
in IN N
Instant NNP N
Recess NNP N
exhibited VBD o
statistically RB o
significant JJ o
increases NNS o
in IN o
light NN o
( ( o
51 CD o
% NN o
) ) o
and CC o
moderate-intensity NN o
( ( o
16 CD o
% NN o
) ) o
PA NNP o
and CC o
increases NNS o
in IN o
time NN o
spent VBN o
in IN o
on-task JJ o
behavior NN o
( ( o
11 CD N
% NN N
) ) N
. . N

Control NNP N
schools NNS N
experienced VBD N
similar JJ N
benefits NNS N
after IN N
they PRP N
began VBD N
implementing VBG N
Instant NNP N
Recess NNP N
. . N

CONCLUSIONS NNP N
Instant NNP N
Recess NNP N
is VBZ N
useful JJ N
for IN o
increasing VBG o
PA NNP o
and CC o
improving VBG o
behavior NN o
among IN o
elementary JJ p
school NN p
children NNS p
. . p

Additional NNP N
research NN N
may MD N
be VB N
needed VBN N
to TO N
understand VB N
how WRB N
to TO N
create VB N
policies NNS N
supporting VBG N
classroom NN N
activity NN N
breaks NNS N
and CC N
how WRB N
to TO N
assess VB N
policy NN N
adherence NN N
. . N

-DOCSTART- -X- O O

Do NNP N
heavier JJR p
women NNS p
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
leuprolide JJ i
acetate NN i
for IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
? . N
OBJECTIVE UH N
To TO N
determine VB N
if IN N
heavier JJR p
women NNS p
benefit VBP N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
the DT N
gonadotropin-releasing JJ i
hormone NN i
analogue NN i
leuprolide NN i
acetate NN i
( ( i
LA NNP i
) ) i
depot NN N
in IN N
terms NNS N
of IN N
suppression NN N
of IN N
serum NN N
estradiol NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
retrospective JJ N
analysis NN N
of IN N
the DT N
effect NN N
of IN N
LA NNP i
depot FW i
3.75 CD N
mg NN N
and CC N
7.5 CD N
mg NN N
on IN N
serum NN i
estradiol NN i
from IN N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
, , N
12-week JJ N
study NN N
of IN N
women NNS p
with IN p
anemia NN p
due JJ p
to TO p
bleeding VBG p
from IN p
uterine JJ p
leiomyomata NN p
. . p

Serum NNP o
estradiol NN o
levels NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
week NN N
12 CD N
. . N

Patients NNS p
were VBD p
divided VBN p
into IN p
weight NN p
quartiles NNS p
according VBG p
to TO p
their PRP$ p
baseline NN p
weight NN p
in IN p
kilograms NNS p
: : p
46- JJ p
< NN p
64 CD p
, , p
64- JJ p
< NN p
72 CD p
, , p
72- JJ p
< NN p
89 CD p
, , p
89-159 JJ p
( ( p
pounds-102- JJ p
< NN p
140 CD p
, , p
140- JJ p
< NN p
159 CD p
, , p
159- JJ p
< NN p
196 CD p
, , p
196-350 JJ p
) ) p
. . p

RESULTS VBN N
At IN N
baseline NN N
there EX N
was VBD N
no DT o
statistically RB o
significant JJ o
difference NN o
in IN N
estradiol JJ o
level NN o
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
weight JJ N
quartiles NNS N
. . N

Within IN N
each DT N
group NN N
there EX N
was VBD N
no DT N
relationship NN N
between IN N
weight NN N
and CC N
baseline NN N
estradiol NN N
. . N

At IN N
week NN N
12 CD N
, , N
whereas NNS N
estradiol VBP o
levels NNS o
were VBD N
significantly RB o
greater JJR o
in IN N
the DT N
heavier JJR N
patients NNS N
in IN N
each DT N
of IN N
the DT N
groups NNS N
( ( N
LA NNP N
3.75 CD N
mg NN N
, , N
p NN N
= VBD N
0.044 CD N
; : N
LA NNP N
7.5 CD N
mg NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
there EX N
was VBD N
no DT o
significant JJ o
difference NN o
in IN o
estradiol NN o
between IN N
groups NNS N
as IN N
a DT N
whole NN N
or CC N
within IN N
any DT N
of IN N
the DT N
weight NN N
quartiles NNS N
. . N

Moreover RB N
, , N
at IN N
week NN N
12 CD N
there EX N
was VBD N
no DT o
significant JJ o
difference NN o
between IN N
groups NNS N
in IN N
the DT N
percentage NN o
of IN o
patients NNS o
with IN o
estradiol NNS o
suppressed VBN o
to TO o
the DT o
menopausal NN o
range NN o
. . o

CONCLUSION NNP N
Heavier NNP p
women NNS p
do VBP N
not RB N
benefit VB N
from IN N
a DT N
higher JJR N
dose NN N
of IN N
LA NNP i
depot NNP N
( ( N
7.5 CD N
vs. FW N
3.75 CD N
mg NN N
) ) N
for IN N
suppression NN N
of IN N
serum NN N
levels NNS N
of IN N
estradiol NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
haloperidol NN i
on IN N
discrimination NN o
learning NN o
and CC o
behavioral JJ o
symptoms NNS o
in IN N
autistic JJ p
children NNS p
. . p

This DT N
double-blind JJ N
and CC N
placebo-controlled JJ i
clinical JJ N
trial NN N
in IN N
autistic JJ p
children NNS p
had VBD N
three CD N
objectives NNS N
: : N
( ( N
a DT N
) ) N
to TO N
replicate VB N
earlier JJR N
findings NNS N
that IN N
haloperidol JJ i
administration NN N
is VBZ N
associated VBN N
with IN N
a DT N
significant JJ N
reduction NN N
of IN N
behavioral JJ o
symptoms NNS o
; : o
( ( N
b NN N
) ) N
to TO N
further JJ N
assess NN N
its PRP$ N
safety NN o
when WRB N
given VBN N
on IN N
a DT N
short-term JJ N
basis NN N
; : N
and CC N
( ( N
c NN N
) ) N
to TO N
assess VB N
whether IN N
it PRP N
has VBZ N
an DT N
effect NN o
on IN o
discrimination NN o
learning NN o
. . o

Forty-five JJ p
children NNS p
, , p
2.02 CD p
to TO p
7.58 CD p
years NNS p
old JJ p
( ( p
M NNP p
= NNP p
4.49 CD p
) ) p
, , N
completed VBD N
this DT N
crossover NN N
design NN N
, , N
with IN N
random JJ N
assignment NN N
to TO N
treatment NN N
sequences NNS N
. . N

Haloperidol NNP i
was VBD N
shown VBN N
to TO N
be VB N
a DT N
powerful JJ N
therapeutic JJ N
agent NN N
when WRB N
administered VBN N
for IN N
4 CD N
weeks NNS N
and CC N
free JJ N
of IN N
side JJ o
effects NNS o
; : o
at IN N
doses NNS N
ranging VBG N
from IN N
0.25 CD N
to TO N
4.0 CD N
mg/day NN N
( ( N
M NNP N
= NNP N
0.844 CD N
) ) N
, , N
there EX N
was VBD N
a DT N
clinically RB N
and CC N
statistically RB N
significant JJ N
reduction NN N
of IN N
a DT N
variety NN o
of IN o
symptoms NNS o
. . o

Under IN N
the DT N
given VBN N
conditions NNS N
, , N
the DT N
children NNS N
failed VBD N
to TO N
learn VB N
on IN N
either DT N
haloperidol NN i
or CC N
placebo NN i
. . i

-DOCSTART- -X- O O

A DT N
controlled JJ N
trial NN N
of IN N
trimethoprim-sulfamethoxazole JJ i
or CC i
aerosolized JJ i
pentamidine NN i
for IN N
secondary JJ N
prophylaxis NN N
of IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
in IN N
patients NNS p
with IN p
the DT p
acquired JJ p
immunodeficiency NN p
syndrome NN p
. . p

AIDS NNP N
Clinical JJ N
Trials NNP N
Group NNP N
Protocol NNP N
021 CD N
. . N

BACKGROUND NNP N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
( ( N
PCP NNP N
) ) N
continues VBZ N
to TO N
be VB N
the DT N
most RBS N
common JJ N
index NN N
diagnosis NN N
in IN N
the DT N
acquired JJ N
immunodeficiency NN N
syndrome NN N
( ( N
AIDS NNP N
) ) N
, , N
but CC N
it PRP N
is VBZ N
not RB N
clear JJ N
which WDT N
of IN N
several JJ N
available JJ N
agents NNS N
is VBZ N
the DT N
most RBS N
effective JJ N
in IN N
preventing VBG o
a DT o
recurrence NN o
of IN o
PCP NNP o
. . o

METHODS NNP N
We PRP N
conducted VBD N
a DT N
comparative JJ N
, , N
open-label JJ N
trial NN N
in IN N
310 CD p
adults NNS p
with IN p
AIDS NNP p
who WP p
had VBD p
recently RB p
recovered VBN p
from IN p
an DT p
initial JJ p
episode NN p
of IN p
PCP NNP p
and CC p
had VBD p
no DT p
treatment-limiting JJ p
toxic NN p
effects NNS p
of IN p
trimethoprim-sulfamethoxazole JJ i
or CC i
pentamidine NN i
. . i

All PDT N
the DT N
patients NNS N
were VBD N
treated VBN i
with IN i
zidovudine NN i
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB i
either RB i
800 CD i
mg NN i
of IN i
sulfamethoxazole NN i
and CC i
160 CD i
mg NN i
of IN i
trimethoprim JJ i
once JJ i
daily JJ i
or CC i
300 CD i
mg NN i
of IN i
aerosolized JJ i
pentamidine NN i
administered VBN i
every DT i
four CD i
weeks NNS i
by IN i
jet NN i
nebulizer NN i
. . i

The DT N
participants NNS N
were VBD N
followed VBN N
for IN N
a DT N
median NN N
of IN N
17.4 CD N
months NNS N
. . N

RESULTS NNP N
In IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
group NN N
( ( N
n JJ N
= NNP N
154 CD N
) ) N
there EX N
were VBD N
14 CD N
recurrences NNS o
of IN o
PCP NNP o
, , N
as IN N
compared VBN N
with IN N
36 CD N
recurrences NNS N
( ( N
including VBG N
1 CD N
extrapulmonary JJ N
recurrence NN N
) ) N
in IN N
the DT N
aerosolized-pentamidine JJ N
group NN N
( ( N
n JJ N
= NNP N
156 CD N
) ) N
. . N

The DT N
estimated JJ N
recurrence NN o
rates NNS o
at IN N
18 CD N
months NNS N
were VBD N
11.4 CD N
percent NN N
with IN N
trimethoprim-sulfamethoxazole JJ i
and CC N
27.6 CD N
percent NN N
with IN N
pentamidine NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
risk NN N
of IN N
a DT N
recurrence NN o
( ( N
adjusted VBN N
for IN N
initial JJ N
CD4 NNP N
cell NN N
count NN N
) ) N
was VBD N
3.25 CD N
times NNS N
higher RBR N
in IN N
the DT N
pentamidine NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
1.72 CD N
to TO N
6.16 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
in IN N
survival NN o
or CC o
in IN o
hematologic JJ o
or CC o
hepatic JJ o
toxicity NN o
. . o

Crossovers NNS N
from IN N
trimethoprim-sulfamethoxazole JJ i
to TO N
aerosolized JJ N
pentamidine NN i
were VBD N
more JJR N
common JJ N
than IN N
the DT N
reverse NN N
( ( N
27 CD N
vs. FW N
4 CD N
percent NN N
) ) N
, , N
partly RB N
because IN N
of IN N
the DT N
study NN N
protocols NNS N
for IN N
the DT N
management NN N
of IN N
leukopenia NN N
. . N

There EX N
were VBD N
19 CD N
serious JJ N
bacterial JJ o
infections NNS o
in IN N
the DT N
trimethoprim-sulfamethoxazole JJ N
group NN N
and CC N
38 CD N
in IN N
the DT N
pentamidine NN N
group NN N
. . N

The DT N
time NN o
to TO o
a DT o
first JJ o
bacterial JJ o
infection NN o
was VBD N
significantly RB N
greater JJR N
for IN N
those DT N
assigned VBN N
to TO N
trimethoprim-sulfamethoxazole JJ N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
AIDS NNP p
who WP p
are VBP p
receiving VBG p
zidovudine NN i
, , i
trimethoprim-sulfamethoxazole JJ i
is VBZ N
more RBR N
effective JJ N
than IN N
aerosolized JJ i
pentamidine NN i
in IN N
conventional JJ N
doses NNS N
for IN N
the DT N
prevention NN o
of IN o
recurrent NN o
pneumocystis NN o
infection NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
large JJ N
doses NNS N
of IN N
arachidonic JJ i
acid NN i
added VBD N
to TO N
docosahexaenoic VB i
acid NN i
on IN N
social JJ p
impairment NN p
in IN p
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
trial NN N
. . N

Autism NNP N
spectrum NN N
disorders NNS N
are VBP N
a DT N
neurodevelopmental JJ N
disorders NNS N
with IN N
reduced JJ N
cortical JJ N
functional JJ N
connectivity NN N
relating VBG N
to TO N
social JJ N
cognition NN N
. . N

Polyunsaturated VBN i
fatty JJ i
acids NNS i
arachidonic JJ i
acid NN i
( ( i
ARA NNP i
) ) i
and CC N
docosahexaenoic JJ i
acid NN i
( ( i
DHA NNP i
) ) i
may MD N
have VB N
key JJ N
role NN N
in IN N
brain NN N
network NN N
maturation NN N
. . N

In IN N
particularly RB N
, , N
ARA NNP i
is VBZ N
important JJ N
in IN N
signal JJ N
transduction NN N
related VBN N
to TO N
neuronal JJ N
maturation NN N
. . N

Supplementation NN N
with IN N
larger JJR N
ARA NNP i
doses VBZ i
added VBN i
to TO i
DHA NNP i
may MD N
therefore VB N
mitigate VB N
social JJ N
impairment NN N
. . N

In IN N
a DT N
16-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
, , N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
supplementation NN N
with IN N
large JJ N
doses NNS N
of IN N
ARA NNP i
added VBD i
to TO i
DHA NNP i
( ( i
n JJ i
= NNP i
7 CD i
) ) i
or CC p
placebo NN i
( ( i
n JJ i
= NNP i
6 CD i
) ) i
in IN p
13 CD p
participants NNS p
( ( p
mean JJ p
age NN p
, , p
14.6 CD p
[ NN p
SD NNP p
, , p
5.9 CD p
] CD p
years NNS p
) ) p
. . p

To TO N
examine VB N
underlying JJ N
mechanisms NNS N
underlying VBG N
the DT N
effect NN N
of IN N
our PRP$ N
supplementation NN N
regimen NNS N
, , N
we PRP N
examined VBD N
plasma JJ o
levels NNS o
of IN o
antioxidants NNS o
transferrin JJ o
and CC o
superoxide JJ o
dismutase NN o
, , N
which WDT N
are VBP N
useful JJ N
markers NNS N
of IN N
signal JJ N
transduction NN N
. . N

The DT N
outcome NN N
measures NNS N
were VBD N
the DT N
Social NNP o
Responsiveness NNP o
Scale NNP o
and CC o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
. . o

Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
revealed VBD N
that IN N
our PRP$ N
supplementation NN N
regimen NNS N
significantly RB N
improved VBN N
Aberrant NNP o
Behavior NNP o
Checklist-Community-measured NNP o
social JJ o
withdrawal NN o
and CC N
Social NNP o
Responsiveness NNP o
Scale-measured JJ o
communication NN o
. . o

Treatment NNP N
effect NN N
sizes NNS N
were VBD N
more RBR N
favorable JJ N
for IN N
the DT N
treatment NN N
group NN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
communication NN N
: : N
treatment NN N
groups NNS N
, , N
0.87 CD N
vs NN N
, , N
placebo NN i
, , N
0.44 CD N
; : N
social JJ N
withdrawal NN N
: : N
treatment NN N
groups NNS N
, , N
0.88 CD N
, , N
vs NN N
placebo NN i
, , N
0.54 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN o
in IN o
plasma NN o
transferrin NN o
levels NNS o
and CC N
a DT N
trend NN N
toward IN N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN N
in IN N
plasma JJ o
superoxide JJ o
dismutase NN o
levels NNS o
between IN N
the DT N
2 CD N
groups NNS N
. . N

This DT N
preliminary JJ N
study NN N
suggests VBZ N
that IN N
supplementation NN N
with IN N
larger JJR N
ARA NNP i
doses VBZ i
added VBN i
to TO i
DHA NNP i
improves NNS N
impaired VBD N
social JJ o
interaction NN o
in IN N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
by IN N
up-regulating JJ N
signal JJ N
transduction NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
clinical JJ i
pharmacy NN i
services NNS i
on IN N
the DT N
blood NN o
pressure NN o
of IN N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
. . p

OBJECTIVE IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
who WP N
received VBD N
direct JJ N
patient NN N
care NN N
from IN N
a DT N
clinical JJ i
pharmacist NN i
had VBD N
better RBR N
blood NN o
pressure NN o
control NN o
compared VBN N
to TO N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
who WP p
did VBD p
not RB p
have VB p
clinical JJ p
pharmacy NN p
services NNS p
. . p

METHODS NNP N
Renal NNP p
transplant NN p
patients NNS p
were VBD N
prospectively RB N
randomized VBN N
into IN N
an DT N
intervention NN N
group NN N
or CC N
a DT N
control NN N
group NN N
. . N

Patients NNS N
in IN N
the DT N
intervention NN N
group NN N
received VBD i
clinical JJ i
pharmacy NN i
services NNS i
that WDT i
included VBD i
a DT i
clinical JJ i
pharmacist NN i
performing VBG i
patient JJ i
medication NN i
reviews NNS i
, , i
with IN i
emphasis NN i
on IN i
preventing VBG i
or CC i
resolving VBG i
medication-related JJ i
problems NNS i
and CC i
providing VBG i
medication NN i
recommendations NNS i
. . i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
received VBD i
routine JJ i
clinic NN i
services NNS i
, , i
but CC i
had VBD i
no DT i
clinical JJ i
pharmacist NN i
interaction NN i
. . i

Analysis NN N
was VBD N
performed VBN N
to TO N
detect VB N
differences NNS N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
in IN N
baseline NN o
and CC o
quarterly JJ o
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
for IN N
one CD N
year NN N
post-study NN N
enrollment NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
intervention NN N
( ( p
N NNP p
= NNP p
13 CD p
) ) p
and CC N
control NN N
( ( p
N NNP p
= NNP p
10 CD p
) ) p
groups NNS N
in IN N
baseline NN N
blood NN o
pressures NNS o
or CC N
in IN N
the DT N
percentage NN N
of IN N
hypertensive JJ N
patients NNS N
. . N

Significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
SBP NNP o
and CC o
DBP NNP o
from IN N
baseline NN N
between IN N
the DT N
intervention NN N
and CC N
control NN N
groups NNS N
were VBD N
observed VBN N
at IN N
the DT N
second JJ N
, , N
third JJ N
, , N
and CC N
fourth JJ N
quarters NNS N
of IN N
the DT N
study NN N
, , N
favoring VBG N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Mean NNP o
SBP NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
at IN N
the DT N
second JJ N
( ( N
137.8 CD N
+/- JJ N
15.0 CD N
vs JJ N
168.9 CD N
+/- JJ N
15.3 CD N
) ) N
, , N
third JJ N
( ( N
135.9 CD N
+/- JJ N
11.7 CD N
vs JJ N
164.6 CD N
+/- JJ N
20.1 CD N
) ) N
, , N
and CC N
fourth JJ N
( ( N
145.3 CD N
+/- JJ N
16.8 CD N
vs JJ N
175.8 CD N
+/- JJ N
33.9 CD N
) ) N
quarters NNS N
of IN N
the DT N
study NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Mean NNP o
DBP NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
at IN N
the DT N
second JJ N
( ( N
76.0 CD N
+/- JJ N
11.8 CD N
vs JJ N
84.9 CD N
+/- JJ N
6.1 CD N
) ) N
and CC N
fourth JJ N
( ( N
77.0 CD N
+/- JJ N
10.2 CD N
vs JJ N
91.8 CD N
+/- JJ N
12.0 CD N
) ) N
quarters NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
Direct NNP N
patient NN N
care NN N
services NNS N
provided VBN N
by IN N
a DT N
clinical JJ N
pharmacist NN N
, , N
in IN N
addition NN N
to TO N
routine VB N
clinical JJ N
services NNS N
, , N
have VBP N
a DT N
positive JJ N
effect NN N
on IN N
the DT N
blood NN o
pressure NN o
of IN N
African-American JJ p
renal JJ p
transplant NN p
patients NNS p
. . p

A DT N
multidisciplinary JJ N
team NN N
that WDT N
includes VBZ N
a DT N
clinical JJ N
pharmacist NN N
is VBZ N
beneficial JJ N
to TO N
patient VB N
care NN N
. . N

-DOCSTART- -X- O O

Granulocyte-colony JJ i
stimulating NN i
factor NN i
for IN N
mobilizing VBG N
bone NN N
marrow NN N
stem NN N
cells NNS N
in IN N
subacute JJ N
stroke NN N
: : N
the DT N
stem NN i
cell VBP i
trial NN N
of IN N
recovery NN p
enhancement NN p
after IN p
stroke VBD p
2 CD p
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Granulocyte-colony NNP i
stimulating VBG i
factor NN i
( ( i
G-CSF NNP i
) ) i
is VBZ N
neuroprotective JJ N
in IN N
experimental JJ N
stroke NN N
and CC N
mobilizes VBZ N
CD34 NNP N
( ( N
+ NNP N
) ) N
peripheral JJ N
blood NN N
stem NN N
cells NNS N
into IN N
the DT N
circulation NN N
. . N

We PRP N
assessed VBD N
the DT N
safety NN N
of IN N
G-CSF NNP i
in IN N
recent JJ N
stroke NN N
in IN N
a DT N
phase NN N
IIb NNP N
single-center NN N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

METHODS NNP N
G-CSF NNP i
( ( i
10 CD i
?g/kg NN i
) ) i
or CC i
placebo NN i
( ( N
ratio VB N
2:1 CD N
) ) N
was VBD N
given VBN i
SC NNP i
for IN N
5 CD N
days NNS N
to TO p
60 CD p
patients NNS p
3 CD p
to TO p
30 CD p
days NNS p
after IN p
ischemic JJ p
or CC p
hemorrhagic JJ p
stroke NN p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
the DT o
frequency NN o
of IN o
serious JJ o
adverse JJ o
events NNS o
. . o

Peripheral NNP o
blood NN o
counts NNS o
, , o
CD34 NNP o
( ( o
+ NNP o
) ) o
count NN o
, , o
and CC o
functional JJ o
outcome NN o
were VBD N
measured VBN N
. . N

MRI NNP N
assessed VBD o
lesion NN o
volume NN o
, , o
atrophy NN o
, , o
and CC o
the DT o
presence NN o
of IN o
iron-labeled JJ o
CD34 NNP o
( ( o
+ NNP o
) ) o
cells NNS o
reinjected VBN N
on IN N
day NN N
6 CD N
. . N

RESULTS NNP p
Sixty NNP p
patients NNS p
were VBD p
recruited VBN p
at IN o
mean NN o
of IN o
8 CD o
days NNS o
( ( p
SD NNP p
? . p
5 CD p
) ) p
post NN p
ictus NN p
, , p
with IN p
mean JJ p
age NN p
71 CD p
years NNS p
( ( p
? . p
12 CD p
years NNS p
) ) p
and CC p
53 CD p
% NN p
men NNS p
. . p

The DT p
groups NNS N
were VBD N
well RB N
matched VBN N
for IN N
baseline JJ N
minimization/prognostic JJ N
factors NNS N
. . N

There EX N
were VBD p
no DT p
significant JJ p
differences NNS p
between IN p
groups NNS p
in IN p
the DT N
number NN N
of IN N
participants NNS N
with IN o
serious JJ o
adverse JJ o
events NNS o
: : o
G-CSF JJ o
15 CD o
( ( N
37.5 CD N
% NN N
) ) N
of IN N
40 CD N
versus NN i
placebo NN i
7 CD i
( ( N
35 CD N
% NN N
) ) N
of IN N
20 CD N
, , N
death NN o
or CC o
dependency NN o
( ( o
modified JJ o
Rankin NNP N
Score NN N
: : N
G-CSF JJ N
3.3 CD N
? . N
1.3 CD N
, , N
placebo NN i
3.0 CD i
? . N
1.3 CD N
) ) N
at IN N
90 CD N
days NNS N
, , N
or CC N
the DT o
number NN o
of IN o
injections NNS o
received VBN o
. . o

G-CSF NNP o
increased VBD o
CD34 NNP o
( ( o
+ NNP o
) ) o
and CC o
total JJ o
white JJ o
cell NN o
counts NNS o
of IN o
9.5- CD o
and CC N
4.2-fold JJ N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
reduction NN o
in IN o
MRI NNP o
ischemic JJ o
lesion NN o
volume NN o
with IN o
respect NN N
to TO N
change VB N
from IN N
baseline NN i
in IN i
G-CSF-treated JJ i
patients NNS i
( ( p
P=0.06 NNP p
) ) N
. . N

In IN N
1 CD N
participant NN N
, , N
there EX N
was VBD N
suggestion NN N
that IN N
labeled VBD o
CD34 NNP o
( ( o
+ NNP o
) ) o
cells NNS o
had VBD o
migrated VBN N
to TO N
the DT N
ischemic JJ N
lesion NN N
. . N

CONCLUSIONS VB N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
suggests VBZ N
that IN N
G-CSF NNP i
is VBZ i
safe JJ i
when WRB N
administered VBN N
subacutely RB N
. . N

It PRP N
is VBZ N
feasible JJ N
to TO N
label VB N
and CC N
readminister VB N
iron-labeled JJ N
CD34 NNP N
( ( N
+ NNP N
) ) N
cells NNS N
in IN p
patients NNS p
with IN p
ischemic JJ p
stroke NN p
. . p

CLINICAL NNP p
TRIAL NNP N
REGISTRATION NNP N
URL NNP N
: : N
www.controlled-trials.com NN N
. . N

Unique NNP N
identifier NN N
: : N
ISRCTN63336619 NNP N
. . N

-DOCSTART- -X- O O

Polymorphisms NNP p
of IN p
ADORA2A NNP p
modulate NNP p
psychomotor NN p
vigilance NN p
and CC p
the DT p
effects NNS p
of IN p
caffeine NN p
on IN p
neurobehavioural JJ o
performance NN o
and CC o
sleep JJ o
EEG NNP o
after IN p
sleep JJ p
deprivation NN p
. . p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Prolonged NNP N
wakefulness NN N
impairs NNS N
sustained VBD N
vigilant JJ o
attention NN o
, , N
measured VBN N
with IN N
the DT N
psychomotor NN o
vigilance NN o
task NN o
( ( o
PVT NNP o
) ) o
, , N
and CC N
induces VBZ N
a DT N
compensatory JJ N
increase NN N
in IN N
sleep JJ N
intensity NN N
in IN N
recovery NN N
sleep NN N
, , N
quantified VBN N
by IN N
slow-wave JJ o
activity NN o
( ( o
SWA NNP o
) ) o
in IN N
the DT N
sleep JJ o
electroencephalogram NN o
( ( o
EEG NNP o
) ) o
. . N

These DT N
effects NNS N
of IN N
sleep JJ N
deprivation NN N
are VBP N
counteracted VBN N
by IN N
the DT N
adenosine NN N
receptor NN N
antagonist JJ N
caffeine NN N
, , N
implying VBG N
involvement NN N
of IN N
the DT N
adenosine NN N
neuromodulator/receptor NN N
system NN N
. . N

To TO N
examine VB N
a DT N
role NN N
for IN N
adenosine NN N
A NNP N
( ( N
2A CD N
) ) N
receptors NNS N
, , N
we PRP N
investigated VBD N
whether IN N
variation NN N
of IN N
the DT N
A NNP N
( ( N
2A CD N
) ) N
receptor NN N
gene NN N
( ( N
ADORA2A NNP N
) ) N
modified VBD N
effects NNS N
of IN N
caffeine NN i
on IN N
PVT NNP o
and CC N
SWA NNP o
after IN N
sleep JJ i
deprivation NN i
. . i

EXPERIMENTAL NNP N
APPROACH NNP N
A NNP p
haplotype JJ p
analysis NN p
of IN p
eight CD p
single-nucleotide JJ p
polymorphisms NNS p
of IN p
ADORA2A NNP p
was VBD p
performed VBN p
in IN p
82 CD p
volunteers NNS p
. . p

In IN p
45 CD p
young JJ p
men NNS p
carrying VBG p
five CD p
different JJ p
allele NN p
combinations NNS p
, , p
we PRP p
investigated VBD p
the DT p
effects NNS p
of IN p
prolonged JJ i
waking NN i
and CC i
2 CD i
? . i
200 CD i
mg JJ i
caffeine NN i
or CC i
2 CD i
? . i
100 CD i
mg NN i
modafinil NN i
on IN i
psychomotor NN i
vigilance NN i
, , i
sleepiness NN i
, , i
and CC i
the DT i
waking NN i
and CC o
sleep JJ o
EEG NNP o
. . o

KEY NNP N
RESULTS NNP N
Throughout NNP N
extended VBD N
wakefulness NN N
, , N
the DT N
carriers NNS N
of IN N
haplotype NN N
HT4 NNP N
performed VBD N
faster RBR N
on IN N
the DT o
PVT NNP o
than IN o
carriers NNS N
of IN N
non-HT4 JJ N
haplotype NN N
alleles NNS N
. . N

In IN N
haplotype JJ N
HT4 NNP N
, , N
caffeine NN N
failed VBD N
to TO N
counteract VB N
the DT N
waking-induced JJ N
impairment NN N
of IN N
PVT NNP o
performance NN o
and CC o
the DT N
rebound NN N
of IN N
SWA NNP o
in IN o
recovery NN N
sleep NN N
. . N

However RB i
, , i
caffeine NN i
was VBD i
effective JJ N
in IN N
non-HT4 JJ N
allele NN N
carriers NNS N
, , N
and CC N
modafinil NN N
reduced VBD N
the DT N
consequences NNS N
of IN N
prolonged JJ N
waking NN N
, , N
independently RB N
of IN N
ADORA2A NNP N
haplotype NN N
. . N

CONCLUSIONS NNP N
AND CC N
IMPLICATIONS NNP N
Common NNP N
genetic JJ N
variation NN N
of IN N
ADORA2A NNP N
is VBZ N
an DT N
important JJ N
determinant NN N
of IN N
psychomotor NN o
vigilance NN o
in IN o
rested JJ N
and CC N
sleep-deprived JJ N
state NN N
. . N

It PRP N
also RB N
modulates VBZ N
individual JJ N
responses NNS N
to TO N
caffeine VB i
after IN i
sleep JJ N
deprivation NN N
. . N

These DT N
findings NNS N
demonstrate VBP N
a DT N
role NN N
for IN N
adenosine NN N
A NNP N
( ( N
2A CD N
) ) N
receptors NNS N
in IN N
the DT N
effects NNS N
of IN N
prolonged JJ o
wakefulness NN o
on IN o
vigilant JJ o
attention NN o
and CC o
the DT o
sleep JJ o
EEG NNP o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
device-guided JJ i
breathing NN i
exercises NNS i
on IN N
blood NN o
pressure NN o
in IN N
patients NNS p
with IN p
hypertension NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NNP N
Hypertension NNP N
is VBZ N
a DT N
chronic JJ N
disorder NN N
with IN N
a DT N
high JJ N
prevalence NN N
worldwide NN N
. . N

Despite IN N
considerable JJ N
efforts NNS N
, , N
it PRP N
is VBZ N
sometimes RB N
hard JJ N
to TO N
reach VB N
treatment NN N
goals NNS N
for IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
with IN N
classical JJ N
treatment NN N
options NNS N
. . N

Reducing VBG N
breathing VBG N
frequency NN N
has VBZ N
been VBN N
advocated VBN N
as IN N
a DT N
method NN N
to TO N
reduce VB N
BP NNP o
. . o

METHODS NNP N
A NNP N
randomized JJ N
, , N
single-blind JJ N
, , N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
in IN N
30 CD p
non-diabetic JJ p
patients NNS p
with IN p
hypertension NN p
over IN N
a DT N
period NN N
of IN N
9 CD N
weeks NNS N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
device NN i
that WDT i
helps VBZ i
to TO i
slow VB o
breathing NN o
( ( i
Resperate NNP i
) ) i
on IN N
BP NNP o
and CC o
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
. . o

The DT N
control NN N
group NN N
listened VBD i
to TO i
music NN i
and CC i
used VBN i
no DT i
other JJ i
therapeutic JJ i
device NN i
. . i

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
change NN N
in IN N
BP NNP o
between IN N
intervention NN N
and CC N
control NN N
; : N
BP NNP o
-4.2 NNP N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-12.4 NNP N
to TO N
3.9 CD N
) ) N
/-2.6 NN N
mmHg NN N
( ( N
95 CD N
% NN N
CI NNP N
-8.4 NNP N
to TO N
3.3 CD N
) ) N
. . N

This DT N
result NN N
did VBD N
not RB N
alter VB N
in IN N
post NN N
hoc NN N
analyses NNS N
, , N
when WRB N
patients NNS N
not RB N
achieving VBG N
target NN o
breathing NN o
frequency NN o
( ( N
< JJ N
10 CD N
breaths/min NN N
) ) N
or CC N
non-compliant JJ N
patients NNS N
were VBD N
excluded VBN N
. . N

QoL NNP o
did VBD N
not RB N
change VB N
over IN N
time NN N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
no DT N
effect NN N
of IN N
the DT N
Resperate NNP N
on IN N
BP NNP o
or CC N
QoL NNP o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
, , N
at IN N
this DT N
moment NN N
, , N
this DT N
device NN N
has VBZ N
no DT N
added VBN N
value NN N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -X- O O

Management NN N
of IN N
unstable JJ p
angina NN p
at IN p
rest NN p
by IN N
verapamil NN i
. . i

A DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
coronary JJ N
care NN N
unit NN N
. . N

A NNP N
therapeutic JJ N
trial NN N
with IN N
verapamil NN i
, , N
a DT N
calcium-antagonist JJ i
drug NN i
, , N
was VBD N
performed VBN N
in IN N
12 CD p
patients NNS p
admitted VBN p
to TO p
our PRP$ p
coronary JJ p
care NN p
unit NN p
because IN p
of IN p
frequent JJ p
daily JJ p
attacks NNS p
of IN p
angina NN p
at IN p
rest NN p
attributed VBN p
to TO p
coronary JJ p
vasospasm NN p
. . p

After IN N
a DT N
48-hour JJ N
run-in JJ N
period NN N
, , N
oral JJ i
verapamil NN i
480 CD i
mg/day NN i
and CC i
placebo NN i
were VBD N
administered VBN N
alternately RB N
during IN N
4 CD N
randomised VBD N
48-hour CD N
periods NNS N
. . N

Transient NNP o
ischaemic JJ o
attacks NNS o
with IN o
ST NNP o
segment NN o
elevation NN o
or CC o
depression NN o
, , o
with IN o
or CC o
without IN o
pain NN o
, , N
were VBD N
documented VBN N
by IN N
continuous JJ o
electrocardiographic JJ o
monitoring NN o
. . o

The DT N
number NN o
of IN o
attacks NNS o
during IN N
the DT N
run-in JJ N
and CC N
2 CD N
placebo NN i
periods NNS N
were VBD N
128 CD N
, , N
123 CD N
, , N
and CC N
130 CD N
, , N
respectively RB N
, , N
and CC N
31 CD N
and CC N
23 CD N
during IN N
the DT N
2 CD N
treatment NN N
periods NNS N
( ( N
P NNP N
less JJR N
than IN N
0.006 CD N
and CC N
P NNP N
less JJR N
than IN N
0.003 CD N
) ) N
. . N

This DT N
drug NN N
therefore RB N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
the DT N
management NN N
of IN N
patients NNS p
with IN p
frequent JJ p
attacks NNS o
of IN o
angina NN o
at IN o
rest NN o
. . o

-DOCSTART- -X- O O

Rate-modulated JJ N
cardiac NN N
pacing NN N
based VBN N
on IN N
transthoracic JJ N
impedance NN N
measurements NNS N
of IN N
minute JJ N
ventilation NN N
: : N
correlation NN N
with IN N
exercise NN N
gas NN N
exchange NN N
. . N

The DT N
relation NN N
of IN N
pacing VBG N
rate NN N
to TO N
physiologic VB N
variables NNS N
of IN N
metabolic JJ N
demand NN N
was VBD N
examined VBN N
in IN N
10 CD p
consecutive JJ p
patients NNS p
with IN p
a DT p
minute NN p
ventilation-sensing NN p
, , p
rate-modulating JJ p
ventricular JJ p
pacemaker NN p
implanted VBN p
for IN p
complete JJ p
heart NN p
block NN p
. . p

All DT p
patients NNS p
had VBD p
paroxysmal JJ p
( ( p
seven CD p
patients NNS p
) ) p
or CC p
chronic JJ p
( ( p
three CD p
patients NNS p
) ) p
atrial JJ p
fibrillation NN p
and CC p
were VBD p
referred VBN p
for IN p
catheter JJR i
ablation NN i
of IN i
the DT i
atrioventricular JJ i
junction NN i
. . i

Treadmill NNP i
exercise NN i
testing VBG i
with IN N
measurement NN N
of IN N
expired NNP o
gas NN o
exchange NN o
and CC o
respiratory NN o
flow NN o
was VBD N
performed VBN N
before IN N
ablation NN N
and CC N
4 CD N
weeks NNS N
after IN N
pacemaker NN N
implantation NN N
, , N
with IN N
the DT N
pacemaker NN N
programmed VBD N
to TO N
both DT N
the DT N
fixed-rate JJ N
VVI NNP N
and CC N
rate-modulating JJ N
minute NN N
ventilation NN N
VVIR NNP N
pacing VBG N
modes NNS N
in IN N
random JJ N
sequence NN N
. . N

The DT N
relation NN o
of IN o
pacing VBG o
rate NN o
to TO o
oxygen VB o
consumption NN o
( ( o
VO2 NNP o
) ) o
, , o
expired VBD o
carbon NN o
dioxide NN o
concentration NN o
( ( o
VCO2 NNP o
) ) o
, , o
respiratory JJ o
quotient NN o
, , o
tidal JJ o
volume NN o
, , o
respiratory NN o
rate NN o
and CC o
minute NN o
ventilation NN o
was VBD N
determined VBN N
during IN N
exercise NN N
in IN N
the DT N
rate-modulating JJ N
minute NN N
ventilation NN N
pacing VBG N
mode NN N
. . N

Pacing VBG o
rate NN o
was VBD N
highly RB N
correlated VBN N
with IN N
minute JJ o
ventilation NN o
( ( N
r JJ N
= NNP N
0.89 CD N
) ) N
, , N
respiratory JJ o
quotient NN o
( ( N
r JJ N
= NNP N
0.89 CD N
) ) N
, , N
VCO2 NNP o
( ( N
r VB N
= RB N
0.87 CD N
) ) N
, , N
tidal JJ o
volume NN o
( ( N
r JJ N
= NNP N
0.87 CD N
) ) N
, , N
VO2 NNP o
( ( N
r VB N
= RB N
0.84 CD N
) ) N
and CC N
respiratory JJ o
rate NN o
( ( N
r NN N
= RB N
0.84 CD N
) ) N
. . N

The DT N
mean JJ o
exercise NN o
duration NN o
increased VBD N
from IN N
8.3 CD N
+/- JJ N
2.8 CD N
min NN N
in IN N
the DT N
fixed JJ N
rate NN N
pacing VBG N
mode NN N
to TO N
10.2 CD N
+/- JJ N
3.4 CD N
min NN N
in IN N
the DT N
rate-modulating NN N
, , N
minute NN N
ventilation NN N
mode NN N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
. . N

The DT N
maximal JJ o
VO2 NNP o
increased VBD N
from IN N
13.4 CD N
+/- JJ N
3.4 CD N
to TO N
16.3 CD N
+/- JJ N
4.1 CD N
cc/kg NN N
per IN N
min NN N
( ( N
p JJ N
= NNP N
0.0004 CD N
) ) N
. . N

The DT N
maximal JJ N
heart NN N
rate NN N
achieved VBN N
in IN N
the DT N
minute NN N
ventilation NN N
pacing VBG N
mode NN N
was VBD N
136 CD N
+/- JJ N
9.7 CD N
beats/min NN N
, , N
similar JJ N
to TO N
that DT N
observed VBN N
in IN N
the DT N
patient NN N
's POS N
intrinsic JJ N
cardiac JJ N
rhythm NN N
before IN N
ablation NN N
( ( N
134.9 CD N
+/- JJ N
30.1 CD N
beats/min NN N
, , N
p NN N
= NNP N
NS NNP N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Supporting VBG N
families NNS p
in IN p
challenging VBG p
contexts NN p
: : p
the DT N
CAPEDP NNP N
project NN N
. . N

Although IN N
France NNP p
has VBZ N
one CD N
of IN N
the DT N
most RBS N
generous JJ N
health NN N
and CC N
social JJ N
care NN N
systems NNS N
for IN N
infant NN N
and CC N
maternal JJ N
well-being NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
professionals NNS N
have VBP N
been VBN N
increasingly RB N
concerned VBN N
by IN N
the DT N
rising VBG N
number NN N
of IN N
children NNS p
being VBG p
referred VBN p
for IN p
mental JJ p
health NN p
problems NNS p
. . p

The DT N
present JJ N
article NN N
describes VBZ N
the DT N
first JJ N
home-visiting JJ i
program NN i
in IN N
France NNP N
to TO N
specifically RB N
target VB N
mental JJ N
health NN N
questions NNS N
in IN N
families NNS p
living VBG p
in IN p
vulnerable JJ p
contexts NN p
. . p

The DT N
CAPEDP NNP N
project NN N
, , N
involving VBG N
440 CD p
women NNS p
and CC p
their PRP$ p
families NNS p
, , p
took VBD p
place NN p
in IN p
Paris NNP p
and CC p
its PRP$ p
inner JJ p
suburbs NNS p
from IN p
2006 CD p
to TO p
2011 CD p
. . p

To TO p
be VB p
eligible JJ p
for IN p
inclusion NN p
, , p
women NNS p
had VBD p
to TO p
be VB p
( ( p
i NN p
) ) p
under IN p
26 CD p
years NNS p
old JJ p
, , p
( ( p
ii NN p
) ) p
less JJR p
that IN p
27 CD p
weeks NNS p
pregnant JJ p
, , p
( ( p
iii NN p
) ) p
sufficiently RB p
fluent VBN p
in IN p
French JJ p
to TO p
give VB p
truly NN p
informed JJ p
consent NN p
to TO p
participate VB p
in IN p
the DT p
study NN p
and CC p
benefit NN p
from IN p
the DT p
intervention NN p
and CC p
( ( p
iv NN p
) ) p
presenting VBG p
with IN p
one CD p
or CC p
more JJR p
of IN p
the DT p
following JJ p
social JJ p
vulnerability NN p
factors NNS p
: : p
low JJ p
income NN p
, , p
low JJ p
educational JJ p
level NN p
, , p
and/or RB p
intending VBG p
to TO p
bring VB p
up RP p
the DT p
child NN p
without IN p
the DT p
child NN p
's POS p
father NN p
. . p

The DT i
intervention NN i
consisted VBD i
of IN i
44 CD i
home NN i
visits NNS i
from IN i
the DT i
third JJ i
trimester NN i
of IN i
pregnancy NN i
through IN i
to TO i
the DT i
child NN i
's POS i
second JJ i
birthday NN i
. . i

The DT N
aim NN N
of IN N
the DT N
intervention NN N
was VBD N
to TO N
promote VB N
infant JJ o
mental JJ o
health NN o
and CC N
reduce VB N
the DT N
incidence NN o
of IN o
infant JJ o
mental JJ o
health NN o
problems NNS o
at IN N
the DT N
age NN N
of IN N
two CD N
years NNS N
. . N

The DT N
intervention NN N
paid VBD N
particular JJ N
attention NN N
to TO N
postnatal JJ N
maternal JJ N
depression NN N
and CC N
promoting VBG N
parenting VBG N
skills NNS N
and CC N
attachment JJ N
security NN N
, , N
particularly RB N
through IN N
the DT N
use NN i
of IN i
video NN i
during IN i
home-visits NNS i
. . i

A DT N
major JJ N
issue NN N
was VBD N
that IN N
of IN N
adapting VBG N
international JJ N
best JJS N
practice NN N
recommendations NNS N
with IN N
regard NN N
to TO N
home-visiting JJ N
programs NNS N
to TO N
the DT N
particularities NNS N
of IN N
the DT N
existing VBG N
French JJ N
social JJ N
and CC N
health NN N
care NN N
system NN N
. . N

An DT N
original JJ N
aspect NN N
of IN N
the DT N
intervention NN N
was VBD N
to TO N
use VB N
trained JJ N
clinical JJ N
psychologists NNS N
to TO N
conduct VB N
all DT N
home NN N
visits NNS N
. . N

-DOCSTART- -X- O O

The DT N
Social NNP i
Communication NNP i
Assessment NNP i
for IN i
Toddlers NNP i
with IN i
Autism NNP i
( ( i
SCATA NNP i
) ) i
: : i
an DT N
instrument NN N
to TO N
measure VB N
the DT N
frequency NN o
, , N
form NN N
and CC N
function NN o
of IN o
communication NN o
in IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
Social NNP i
Communication NNP i
Assessment NNP i
for IN i
Toddlers NNP i
with IN i
Autism NNP i
( ( i
SCATA NNP i
) ) i
was VBD N
designed VBN N
to TO N
measure VB N
non-verbal JJ o
communication NN o
, , o
including VBG o
early JJ o
and CC o
atypical JJ o
communication NN o
, , N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Each DT N
communicative JJ N
act NN N
is VBZ N
scored VBN N
according VBG N
to TO N
its PRP$ N
form NN N
, , N
function NN N
, , N
role NN N
and CC N
complexity NN N
. . N

The DT N
SCATA NNP i
was VBD N
used VBN N
to TO N
measure VB N
communicative JJ N
ability NN N
longitudinally RB N
in IN N
two CD N
samples NNS N
of IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Overall JJ o
frequency NN o
of IN o
non-verbal JJ o
communicative JJ o
acts NNS o
did VBD N
not RB N
change NN N
between IN N
the DT N
two CD N
assessments NNS N
. . N

However RB N
, , N
the DT N
form NN o
and CC o
complexity NN o
, , o
the DT o
function NN o
and CC o
the DT o
role NN o
the DT N
child NN N
took VBD N
in IN N
the DT N
interaction NN N
did VBD N
change VB N
with IN N
time NN N
. . N

Both DT N
frequency NN o
and CC o
function NN o
of IN o
communicative JJ o
acts NNS o
in IN N
toddlerhood NN N
were VBD N
positively RB N
associated VBN N
with IN N
later JJ o
language NN o
ability NN o
: : o
social JJ o
acts NNS o
, , o
comments NNS o
and CC o
initiations NNS o
showed VBD N
greater JJR N
predictive JJ N
association NN N
than IN N
requests NNS N
and CC N
responses NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Comparative NNP N
effects NNS N
of IN N
nebivolol NN i
and CC i
valsartan NN i
on IN N
atrial JJ o
electromechanical JJ o
coupling NN o
in IN N
newly RB p
diagnosed VBN p
stage NN p
1 CD p
hypertensive JJ p
patients NNS p
] VBP p
. . N

OBJECTIVES NNP N
Hypertension NNP N
is VBZ N
an DT N
important JJ N
cardiovascular NN N
risk NN N
factor NN N
for IN N
the DT N
development NN N
of IN N
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
. . o

Increased VBN N
atrial JJ N
electromechanical JJ N
coupling NN N
time NN N
interval NN N
measured VBN N
by IN N
tissue NN N
Doppler NNP N
is VBZ N
accepted VBN N
as IN N
an DT N
important JJ N
factor NN N
for IN N
prediction NN N
of IN N
AF NNP o
development NN o
in IN N
hypertensive JJ p
patients NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
valsartan NN i
, , N
an DT N
angiotensin NN N
receptor NN N
blocker NN N
, , N
and CC N
nebivolol RB i
, , N
a DT N
beta-blocker NN N
, , N
on IN N
atrial JJ N
electromechanical JJ N
coupling NN N
in IN N
newly RB p
diagnosed VBN p
stage NN p
1 CD p
hypertensive JJ p
patients NNS p
. . p

STUDY NNP N
DESIGN NNP N
The DT N
study NN N
included VBD N
60 CD p
newly RB p
diagnosed VBN p
stage NN p
1 CD p
hypertensive JJ p
patients NNS p
with IN p
no DT p
other JJ p
systemic JJ p
disease NN p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
nebivolol JJ i
5 CD i
mg NN i
( ( N
30 CD N
patients NNS N
; : N
21 CD N
women NNS N
, , N
9 CD N
men NNS N
; : N
mean JJ N
age NN N
48.4 CD N
? . N
11.4 CD N
years NNS N
) ) N
and CC i
valsartan $ i
160 CD i
mg NN i
( ( N
30 CD N
patients NNS N
; : N
21 CD N
women NNS N
, , N
9 CD N
men NNS N
; : N
mean JJ N
age NN N
49.8 CD N
? . N
11.3 CD N
years NNS N
) ) N
. . N

All PDT N
the DT N
patients NNS N
underwent JJ N
tissue NN N
Doppler NNP N
echocardiographic JJ N
examination NN N
before IN N
and CC N
three CD N
months NNS N
after IN N
treatment NN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
two CD N
drugs NNS N
on IN N
atrial JJ o
electromechanical JJ o
coupling NN o
. . o

RESULTS NNP o
Baseline NNP o
blood NN o
pressures NNS o
, , o
electrocardiographic JJ o
and CC o
echocardiographic JJ o
findings NNS o
, , o
and CC o
atrial JJ o
electromechanical JJ o
coupling NN o
were VBD o
similar JJ N
in IN N
both DT N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Both DT N
drugs NNS N
significantly RB N
reduced VBD o
blood NN o
pressure NN o
after IN o
treatment NN N
, , N
with IN N
similar JJ N
efficacy NN N
( ( N
p JJ N
> NNP o
0.05 CD o
) ) o
. . o

Atrial JJ o
electromechanical JJ o
coupling NN o
time NN o
intervals NNS o
showed VBD o
significant JJ N
decreases NNS N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP o
Prolonged VBD o
interatrial JJ o
electromechanical JJ o
time NN o
intervals NNS o
in IN o
hypertensives NNS N
are VBP N
improved VBN N
with IN N
antihypertensive JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Beta-carotene NNP i
in IN N
HIV NNP p
infection NN p
. . p

beta-Carotene NN i
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
an DT N
immunostimulatory JJ N
effect NN N
. . N

Recent JJ N
studies NNS N
suggest VBP N
that IN N
beta-carotene JJ i
supplementation NN i
can MD N
increase VB N
CD4 NNP o
counts NNS o
in IN N
HIV-infected JJ p
patients NNS p
. . p

Our PRP$ N
double-blind JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
beta-carotene NN i
in IN N
raising VBG N
CD4 NNP N
counts NNS N
in IN N
HIV-infected JJ p
patients NNS p
. . p

Twenty-one CD p
HIV-seropositive JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
beta-carotene NN i
, , i
180 CD i
mg/day NN i
or CC i
placebo NN i
for IN N
4 CD N
weeks NNS N
, , N
and CC N
then RB N
crossed VBD N
over IN N
to TO N
receive VB N
the DT N
alternative JJ N
treatment NN N
for IN N
the DT N
following JJ N
4 CD N
weeks NNS N
. . N

beta-Carotene NN N
resulted VBD N
in IN N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
total JJ o
WBC NNP o
count NN o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
% NN o
change NN o
in IN o
CD4 NNP o
count NN o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
% NN o
change NN o
in IN o
CD4/CD8 NNP o
ratios NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
absolute JJ o
CD4 NNP o
count NN o
, , o
absolute JJ o
CD4/CD8 NNP o
ratio NN o
, , o
and CC o
total JJ o
and CC o
B-lymphocytes NNP o
all DT N
increased VBN N
on IN N
carotene NN N
and CC N
fell VBD N
during IN N
placebo NN N
, , N
but CC N
these DT N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

No DT N
toxicity NN o
was VBD N
observed VBN N
on IN N
either DT N
treatment NN N
. . N

beta-Carotene JJ N
appears VBZ N
to TO N
have VB N
an DT N
immunostimulatory JJ o
effect NN o
in IN N
HIV-infected JJ p
patients NNS p
. . p

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
demonstrate VB N
whether IN N
beta-carotene NN N
has VBZ N
a DT N
role NN N
as IN N
adjunct JJ N
therapy NN N
in IN N
treatment NN N
of IN N
HIV-infected JJ o
patients NNS o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
vitamin/mineral JJ i
supplement NN i
on IN N
children NNS p
and CC p
adults NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
Vitamin/mineral NNP i
supplements NNS i
are VBP N
among IN N
the DT N
most RBS N
commonly RB N
used JJ N
treatments NNS N
for IN N
autism NN N
, , N
but CC N
the DT N
research NN N
on IN N
their PRP$ N
use NN N
for IN N
treating VBG N
autism NN N
has VBZ N
been VBN N
limited VBN N
. . N

METHOD NNP N
This DT N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
three CD N
month NN N
vitamin/mineral JJ i
treatment NN i
study NN i
. . i

The DT N
study NN N
involved VBD N
141 CD p
children NNS p
and CC p
adults NNS p
with IN p
autism NN p
, , p
and CC p
pre NN p
and CC p
post NN p
symptoms NNS p
of IN p
autism NN p
were VBD N
assessed VBN N
. . N

None NN p
of IN p
the DT p
participants NNS p
had VBD p
taken VBN p
a DT p
vitamin/mineral JJ i
supplement NN i
in IN p
the DT p
two CD p
months NNS p
prior RB p
to TO p
the DT p
start NN p
of IN p
the DT p
study NN p
. . p

For IN p
a DT p
subset NN p
of IN p
the DT p
participants NNS p
( ( p
53 CD p
children NNS p
ages VBZ p
5-16 JJ p
) ) p
pre NN N
and CC N
post NN N
measurements NNS N
of IN N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
were VBD N
also RB N
conducted VBN N
. . N

RESULTS VB N
The DT N
vitamin/mineral JJ i
supplement NN i
was VBD N
generally RB N
well-tolerated JJ o
, , N
and CC N
individually RB N
titrated VBN N
to TO N
optimum JJ N
benefit NN N
. . N

Levels NNP o
of IN o
many JJ o
vitamins NNS o
, , o
minerals NNS o
, , o
and CC o
biomarkers NNS o
improved/increased VBD N
showing VBG N
good JJ N
compliance NN o
and CC o
absorption NN o
. . o

Statistically NNP N
significant JJ N
improvements NNS N
in IN N
metabolic JJ N
status NN N
were VBD N
many JJ N
including VBG N
: : N
total JJ o
sulfate NN o
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
, , N
S-adenosylmethionine NNP o
( ( N
SAM NNP N
; : N
+6 CD N
% NN N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
, , N
reduced VBD N
glutathione NN o
( ( N
+17 CD N
% NN N
, , N
p NN N
= NNP N
0.0008 CD N
) ) N
, , N
ratio NN o
of IN o
oxidized JJ o
glutathione NN o
to TO o
reduced VB o
glutathione NN o
( ( N
GSSG NNP N
: : N
GSH NNP N
; : N
-27 CD N
% NN N
, , N
p NN N
= NNP N
0.002 CD N
) ) N
, , N
nitrotyrosine JJ o
( ( N
-29 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
, , N
ATP NNP o
( ( N
+25 CD N
% NN N
, , N
p NN N
= NNP N
0.000001 CD N
) ) N
, , N
NADH NNP o
( ( N
+28 CD N
% NN N
, , N
p NN N
= NNP N
0.0002 CD N
) ) N
, , N
and CC N
NADPH NNP o
( ( N
+30 CD N
% NN N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
. . N

Most JJS N
of IN N
these DT N
metabolic JJ N
biomarkers NNS N
improved VBN N
to TO N
normal JJ N
or CC N
near-normal JJ N
levels.The JJ N
supplement NN i
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
the DT N
placebo NN i
group NN N
on IN N
the DT N
Parental NNP o
Global NNP o
Impressions-Revised JJ o
( ( N
PGI-R NNP N
, , N
Average NNP N
Change NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
and CC N
on IN N
the DT N
subscores NNS N
for IN N
Hyperactivity NNP o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
, , N
Tantrumming NNP o
( ( N
p JJ N
= NNP N
0.009 CD N
) ) N
, , N
Overall NNP o
( ( N
p NN N
= RB N
0.02 CD N
) ) N
, , N
and CC N
Receptive JJ o
Language NNP o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
. . N

For IN N
the DT N
other JJ N
three CD N
assessment NN N
tools VBZ N
the DT N
difference NN N
between IN N
treatment NN N
group NN N
and CC N
placebo NN N
group NN N
was VBD N
not RB N
statistically RB N
significant.Regression JJ N
analysis NN N
revealed VBD N
that IN N
the DT N
degree NN N
of IN N
improvement NN N
on IN N
the DT N
Average JJ o
Change NN o
of IN o
the DT o
PGI-R NNP o
was VBD N
strongly RB N
associated VBN N
with IN N
several JJ N
biomarkers NNS N
( ( N
adj NN N
. . N

R2 NNP N
= VBD N
0.61 CD N
, , N
p NN N
< NNP N
0.0005 CD N
) ) N
with IN N
the DT N
initial JJ N
levels NNS N
of IN N
biotin NN N
and CC N
vitamin NN N
K NNP N
being VBG N
the DT N
most RBS N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
both DT N
biotin NN N
and CC N
vitamin NN N
K NNP N
are VBP N
made VBN N
by IN N
beneficial JJ N
intestinal JJ N
flora NN N
. . N

CONCLUSIONS NNP N
Oral NNP N
vitamin/mineral JJ i
supplementation NN i
is VBZ N
beneficial JJ N
in IN N
improving VBG N
the DT N
nutritional JJ N
and CC N
metabolic JJ N
status NN N
of IN N
children NNS p
with IN p
autism NN p
, , N
including VBG N
improvements NNS N
in IN N
methylation NN N
, , N
glutathione NN N
, , N
oxidative JJ N
stress NN N
, , N
sulfation NN N
, , N
ATP NNP N
, , N
NADH NNP N
, , N
and CC N
NADPH NNP N
. . N

The DT N
supplement NN i
group NN N
had VBD N
significantly RB N
greater JJR N
improvements NNS N
than IN N
did VBD N
the DT N
placebo NN i
group NN N
on IN N
the DT N
PGI-R JJ N
Average JJ N
Change NN N
. . N

This DT N
suggests VBZ N
that IN N
a DT N
vitamin/mineral JJ i
supplement NN i
is VBZ N
a DT N
reasonable JJ N
adjunct JJ N
therapy NN N
to TO N
consider VB N
for IN N
most JJS p
children NNS p
and CC p
adults NNS p
with IN p
autism NN p
. . p

TRIAL NNP N
REGISTRATION NNP N
CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
NCT01225198 NNP N
. . N

-DOCSTART- -X- O O

Randomized NNP N
comparison NN N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
zotarolimus-eluting JJ i
stents NNS i
vs. IN N
sirolimus-eluting JJ i
stents NNS i
for IN N
percutaneous JJ p
coronary JJ p
intervention NN p
in IN p
chronic JJ p
total JJ p
occlusion NN p
-- : p
CAtholic NNP p
Total NNP p
Occlusion NNP p
Study NNP p
( ( p
CATOS NNP p
) ) p
trial NN p
. . p

BACKGROUND NNP N
Limited NNP N
data NNS N
are VBP N
available JJ N
regarding VBG N
the DT N
direct JJ N
comparison NN N
of IN N
angiographic JJ N
and CC N
clinical JJ N
outcomes NNS N
after IN N
percutaneous JJ N
coronary JJ N
intervention NN N
( ( N
PCI NNP N
) ) N
with IN N
drug-eluting JJ i
stents NNS i
( ( N
DESs NNP N
) ) N
for IN N
chronic JJ p
total JJ p
occlusion NN p
( ( p
CTO NNP p
) ) p
. . p

METHODS NNP N
AND NNP N
RESULTS NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
, , N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
non-inferiority NN N
of IN N
a DT N
zotarolimus-eluting JJ i
stent NN i
( ( i
ZES NNP i
; : i
Endeavor NNP i
Sprint? NNP i
, , i
n=80 RB N
) ) N
to TO N
a DT N
sirolimus-eluting JJ i
stent NN i
( ( i
SES NNP i
; : i
Cypher? NNP i
, , i
n=80 NN N
) ) N
in IN N
patients NNS p
with IN p
CTO NNP p
lesion NN p
with IN p
a DT p
reference NN p
vessel NN p
diameter NN p
? . p
2.5mm CD p
. . p

The DT p
primary JJ N
endpoint NN N
was VBD N
in-segment JJ o
binary JJ o
restenosis NN o
rate NN o
at IN o
9-month JJ N
angiographic JJ N
follow-up NN N
. . N

Key NNP N
secondary JJ N
endpoints NNS N
included VBD o
target NN o
vessel NN o
failure NN o
( ( o
TVF NNP o
; : o
including VBG o
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
and CC o
target VB o
vessel JJ o
revascularization NN o
) ) o
and CC o
Academic NNP o
Research NNP o
Consortium-defined NNP o
definite/probable JJ o
stent NN o
thrombosis NN o
( ( o
ST NNP o
) ) o
within IN o
12 CD N
months NNS N
. . N

The DT N
ZES NNP N
was VBD N
non-inferior JJ N
to TO N
the DT N
SES NNP N
with IN N
respect NN N
to TO N
the DT N
primary JJ N
endpoint NN o
, , o
which WDT o
occurred VBD N
in IN N
14.1 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
6.0-22.2 JJ N
) ) N
and CC N
in IN N
13.7 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
5.8-21.6 JJ N
) ) N
of IN N
patients NNS N
, , N
respectively RB N
( ( N
non-inferiority JJ N
margin NN N
, , N
15.0 CD N
% NN N
; : N
P NNP N
for IN N
non-inferiority JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
between-group JJ N
differences NNS N
in IN N
the DT N
rate NN o
of IN o
TVF NNP o
( ( N
10.0 CD N
% NN N
vs. FW N
17.5 CD N
% NN N
; : N
P=0.168 NNP N
) ) N
nor CC N
in IN N
the DT N
rate NN N
of IN N
ST NNP N
( ( N
0.0 CD N
% NN N
vs. FW N
1.3 CD N
% NN N
; : N
P=0.316 NNP N
) ) N
during IN N
the DT N
12-month JJ N
clinical JJ N
follow-up NN N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
and CC N
safety NN N
of IN N
ZES NNP N
are VBP N
similar JJ N
to TO N
those DT N
of IN N
SES NNP N
and CC N
therefore VB N
it PRP N
is VBZ N
a DT N
good JJ N
treatment NN N
option NN p
in IN p
patients NNS p
undergoing VBG p
PCI NNP p
for IN p
CTO NNP p
with IN p
DESs NNP p
. . p

-DOCSTART- -X- O O

Improved VBN N
fibrinolysis NN N
after IN N
1-year JJ N
treatment NN N
with IN N
HMG NNP i
CoA NNP i
reductase NN i
inhibitors NNS i
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
. . p

The DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
statins NNS i
on IN N
the DT N
levels NNS N
of IN N
haemostatic JJ N
variables NNS N
reflecting VBG N
procoagulant NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
, , N
with IN N
the DT N
hypothesis NN N
that WDT N
statins VBZ i
might MD N
beneficially RB N
modify VB N
these DT N
levels NNS N
. . N

Fifty-eight JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
atorvastatin NN i
( ( N
n=28 JJ N
) ) N
or CC N
simvastatin NN i
( ( N
n=30 JJ N
) ) N
for IN N
1 CD N
year NN N
. . N

The DT N
starting VBG N
dose NN N
in IN N
both DT N
groups NNS N
was VBD N
20 CD N
mg/day NN N
. . N

Fasting VBG o
blood NN o
samples NNS o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
12-month JJ N
treatment NN N
for IN N
determinations NNS N
of IN N
fibrinogen NN o
, , o
prothrombin JJ o
fragment NN o
1+2 CD o
( ( o
F1+2 NNP o
) ) o
, , o
plasma JJ o
D-dimer NNP o
, , o
soluble JJ o
tissue NN o
factor NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
( ( o
tPA NN o
) ) o
antigen NN o
, , o
tPA NN o
activity NN o
, , o
plasminogen NN o
activator NN o
inhibitor JJ o
type-1 JJ o
activity NN o
( ( o
PAI-1 NNP o
activity NN o
) ) o
and CC o
serum JJ o
D-dimer NNP o
as IN o
a DT o
global JJ o
test NN o
of IN o
fibrinolytic JJ o
activity NN o
. . o

In IN N
the DT N
total JJ N
population NN N
, , N
improved VBN o
fibrinolytic JJ o
activity NN o
was VBD N
observed VBN N
after IN N
1 CD N
year NN N
with IN N
increased JJ o
levels NNS o
of IN N
serum NN o
D-dimer NNP o
( ( N
P=.001 NNP N
) ) N
and CC N
tPA JJ o
activity NN o
( ( N
P=.024 NNP N
) ) N
and CC N
a DT N
reduction NN o
in IN o
tPA NN o
antigen NN o
( ( N
P=.048 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
measured JJ N
coagulation NN N
variables NNS N
. . N

Separately RB N
examined VBD N
, , N
an DT N
improved JJ N
fibrinolytic JJ N
profile NN N
was VBD N
seen VBN N
in IN N
the DT N
atorvastatin NN i
group NN N
with IN N
a DT N
significant JJ o
increase NN o
in IN o
serum JJ o
D-dimer NNP o
( ( N
P=.005 NNP N
) ) N
, , N
a DT N
borderline JJ o
increase NN o
in IN o
tPA JJ o
activity NN o
( ( N
P=.083 NNP N
) ) N
and CC N
a DT N
borderline NN o
reduction NN o
in IN o
tPA NN o
antigen NN o
( ( N
P=.069 NNP N
) ) N
. . N

Within IN N
the DT N
simvastatin NN i
group NN N
, , N
a DT N
reduction NN o
in IN o
prothrombin NN o
F1+2 NNP o
was VBD N
observed VBN N
( ( N
P=.038 NNP N
) ) N
. . N

The DT N
differences NNS N
in IN N
changes NNS N
between IN N
the DT N
groups NNS N
were VBD N
statistically RB N
significant JJ N
only RB N
for IN N
global JJ o
fibrinolysis NN o
( ( N
serum JJ N
D-dimer NNP N
, , N
P=.046 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
an DT N
improved JJ N
fibrinolytic JJ o
profile NN o
was VBD N
observed VBN N
after IN N
statin NN i
treatment NN N
, , N
most RBS N
pronounced JJ N
with IN N
atorvastatin NN i
. . i

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
drugs NNS N
promote VBP N
a DT N
profibrinolytic JJ N
profile NN N
, , N
and CC N
may MD N
in IN N
part NN N
explain VBP N
the DT N
benefit NN N
of IN N
statin NN i
treatment NN N
rendered VBN N
in IN N
the DT N
prevention NN N
of IN N
CHD NNP N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
recruited JJ N
melanoma NN p
families NNS p
into IN N
a DT N
behavioral JJ i
intervention NN i
project NN i
. . i

BACKGROUND NNP N
Examination NNP N
of IN N
families NNS p
represents VBZ N
an DT N
important JJ N
priority NN N
in IN N
health NN N
research NN N
. . N

In IN N
this DT N
paper NN N
we PRP N
report VBP o
on IN N
individual JJ o
and CC o
family-level JJ o
factors NNS o
associated VBN N
with IN N
enrollment NN N
in IN N
a DT N
cancer NN N
prevention NN N
research NN N
project NN N
. . N

We PRP N
approached VBD N
families NNS p
affected VBN p
by IN p
melanoma NN p
for IN N
possible JJ N
participation NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
a DT N
web-based JJ i
communication NN i
and CC i
support NN i
intervention NN i
. . i

METHODS NNP N
We PRP N
recruited VBD N
three CD p
family NN p
members NNS p
per IN p
family NN p
for IN p
assessment NN p
- : p
the DT p
melanoma NN p
case NN p
, , p
a DT p
first-degree JJ p
relative NN p
( ( p
FDR NNP p
) ) p
, , p
and CC p
a DT p
relative NN p
who WP p
is VBZ p
a DT p
parent NN p
of IN p
a DT p
child JJ p
age NN p
18 CD p
or CC p
younger JJR p
. . p

Recruitment NNP N
involved VBD N
three CD N
steps NNS N
: : N
requesting VBG N
the DT N
physician NN N
's POS N
consent NN N
to TO N
approach VB N
the DT N
melanoma NN N
case NN N
, , N
approaching VBG N
the DT N
case NN N
to TO N
request VB N
their PRP$ N
participation NN N
and CC N
family NN N
contact NN N
information NN N
, , N
and CC N
they PRP N
approaching VBG N
the DT N
FDRs NNP N
and CC N
parents NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
1380 CD p
families NNS p
approached VBD p
, , p
313 CD p
were VBD p
enrolled VBN p
, , p
263 CD p
were VBD p
excluded VBN p
because IN p
we PRP p
could MD p
not RB p
find VB p
or CC p
contact VB p
a DT p
family NN p
member NN p
( ( p
FDR CD p
or CC p
parent NN p
) ) p
, , p
331 CD p
did VBD p
not RB p
have VB p
eligible JJ p
family NN p
members NNS p
, , p
and CC p
473 CD p
refused VBD p
. . p

The DT N
most RBS N
frequently RB o
noted VBD N
reason NN N
for IN N
refusal NN o
was VBD N
being VBG N
too RB N
busy JJ N
or CC N
having VBG N
no DT N
time NN N
. . N

The DT N
primary JJ N
predictors NNS N
of IN N
participation NN o
for IN N
cases NNS N
( ( N
OR=1.6 NNP N
; : N
CI=1.01-2.51 NNP N
) ) N
and CC N
FDRs NNP N
( ( N
OR=2.15 NNP N
; : N
CI=1.11-4.13 NNP N
) ) N
included VBD N
higher JJR o
educational JJ o
attainment NN o
. . o

FDRs NNP N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB o
if IN N
they PRP N
were VBD N
female JJ o
( ( N
OR=1.77 NNP N
; : N
CI=1.1-.85 NNP N
) ) N
and CC N
parents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB o
if IN N
the DT N
case NN N
had VBD N
been VBN N
diagnosed VBN o
more RBR o
recently RB o
( ( N
OR=3.3 NNP N
; : N
CI=1.9-5.93 NNP N
) ) N
, , N
if IN N
the DT N
parent NN o
was VBD o
partnered VBN o
( ( N
OR=4.37 NNP N
; : N
CI=1.86-10.26 NNP N
) ) N
, , N
and CC N
if IN N
the DT N
parent NN o
lived VBD o
in IN o
the DT o
same JJ o
city NN o
as IN o
the DT o
case NN o
( ( N
OR=2.88 NNP N
; : N
CI=1.08-7.68 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
can MD N
provide VB N
information NN N
on IN N
potential JJ N
directions NNS N
for IN N
future JJ N
family NN N
recruitment NN N
. . N

-DOCSTART- -X- O O

Suppression NN N
of IN N
immediate JJ N
and CC N
late JJ N
anti-IgE-induced JJ o
skin NN o
reactions NNS o
by IN N
topically RB N
applied VBN N
alcohol/onion NN i
extract NN i
. . i

In IN N
a DT N
double JJ N
blind NN N
study NN N
, , N
alcohol/onion NN i
extract NN i
( ( i
5 CD i
% NN i
ethanol NN i
) ) i
was VBD N
injected VBN N
simultaneously RB N
with IN N
20 CD i
IU NNP i
and CC i
200 CD i
IU NNP i
rabbit NN i
anti-human-IgE JJ i
intradermally RB i
in IN N
12 CD p
adult NN p
volunteers NNS p
( ( p
6 CD p
atopics NNS p
, , p
6 CD p
non-atopics NNS p
) ) p
. . p

Diameters NNS N
of IN N
wheals NNS N
and CC N
flares NNS N
were VBD N
measured VBN N
10 CD N
min NN N
after IN N
and CC N
compared VBN N
with IN N
control NN N
sites NNS N
challenged VBD N
with IN N
20 CD N
IU NNP N
and CC N
200 CD N
IU NNP N
anti-IgE NN i
in IN i
a DT i
5 CD i
% NN i
ethanol JJ i
solution NN N
. . N

The DT N
skin NN N
sites NNS N
were VBD N
then RB N
treated VBN N
epidermally RB N
with IN N
45 CD i
% NN i
alcohol/onion NN i
extract NN i
and CC N
45 CD i
% NN i
ethanol NN i
under IN N
occlusion NN N
. . N

Diameters NNS N
of IN N
late JJ N
cutaneous JJ N
reactions NNS N
were VBD N
measured VBN N
hourly RB N
. . N

Oedema NNP N
formation NN N
was VBD N
clinically RB N
estimated VBN N
according VBG N
to TO N
an DT N
arbitrary JJ N
scale NN N
and CC N
skin NN N
thickness NN N
measured VBN N
with IN N
a DT N
calliper NN N
. . N

In IN N
the DT N
onion-treated JJ i
skin NN N
sites VBZ N
the DT N
wheal JJ o
areas NNS o
were VBD N
significantly RB o
reduced VBN o
( ( N
20 CD N
IU NNP N
: : N
control NN N
: : N
108 CD N
+/- JJ N
53 CD N
mm2 NN N
; : N
onion NN N
69 CD N
+/- JJ N
42 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.05 CD N
; : N
200 CD N
IU NNP N
anti-IgE JJ N
: : N
control NN N
: : N
152 CD N
+/- JJ N
25 CD N
mm2 NN N
, , N
onion NN N
: : N
138 CD N
+/- JJ N
26 CD N
mm2 NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

The DT N
oedema JJ o
formation NN o
during IN N
the DT N
late JJ N
phase NN N
skin JJ N
reaction NN N
was VBD N
markedly RB N
depressed JJ N
( ( N
P NNP N
less JJR N
than IN N
0.005 CD N
at IN N
2 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
at IN N
4 CD N
and CC N
6 CD N
h NN N
, , N
P NNP N
less JJR N
than IN N
0.02 CD N
at IN N
8 CD N
h NN N
) ) N
. . N

The DT N
extent NN N
of IN N
late JJ N
skin NN o
reactions NNS o
was VBD N
slightly RB N
, , N
but CC N
not RB N
significantly RB N
reduced VBN N
. . N

Obviously RB N
, , N
onions NNS i
contain VBP N
pharmacologically RB N
active JJ N
substances NNS N
with IN N
anti-inflammatory JJ N
and/or NN N
allergic NN N
properties NNS N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
a DT N
multi-component JJ N
higher-functioning JJ p
autism NN p
anti-stigma JJ N
program NN N
on IN N
adolescent JJ p
boys NNS p
. . p

A DT N
six-session JJ N
higher-functioning JJ p
autism NN p
anti-stigma JJ N
program NN N
incorporating NN N
descriptive NN N
, , N
explanatory NN N
and CC N
directive JJ N
information NN N
was VBD N
delivered VBN N
to TO N
adolescent VB p
boys NNS p
and CC N
the DT N
impact NN N
upon IN N
knowledge NN o
, , o
attitudes NNS o
and CC o
behavioural JJ o
intentions NNS o
towards NNS N
peers NNS N
with IN N
autism NN N
was VBD N
evaluated VBN N
. . N

Participants NNS p
were VBD p
seventh- JJ p
, , p
eighth- JJ p
and CC p
ninth-grade JJ p
students NNS p
( ( p
N NNP p
= NNP p
395 CD p
) ) p
from IN p
regular JJ p
classes NNS p
in IN p
a DT p
mainstream JJ p
school NN p
. . p

Two-eighth-grade JJ p
classes NNS p
were VBD i
randomly RB i
allocated VBN i
to TO i
the DT i
intervention NN i
condition NN i
and CC i
all DT i
remaining VBG i
students NNS i
were VBD i
either RB i
allocated VBN i
to TO i
the DT i
no-intervention JJ i
peer NN i
or CC i
no-intervention JJ i
non-peer JJ i
condition NN i
. . i

The DT N
anti-stigma JJ N
program NN N
improved VBD N
the DT o
knowledge NN o
and CC o
attitudes NNS o
, , o
but CC N
not RB N
the DT o
behavioural JJ o
intentions NNS o
of IN o
participants NNS N
towards VBP N
their PRP$ N
peers NNS N
with IN N
autism NN o
. . o

Knowledge NNP o
and CC o
attitudinal JJ o
changes NNS o
were VBD o
maintained VBN N
at IN N
follow-up NN N
. . N

There EX N
were VBD N
no DT N
spill-over JJ o
effects NNS o
of IN o
the DT N
program NN N
to TO N
non-targeted JJ N
students NNS N
. . N

These DT N
results NNS N
provide VBP N
some DT N
preliminary JJ N
evidence NN N
for IN N
the DT N
effectiveness NN N
of IN N
multi-session NN N
anti-stigma JJ N
programs NNS N
incorporating VBG N
combined VBN N
information NN N
for IN p
adolescent NN p
students NNS p
in IN p
inclusive JJ p
educational JJ p
environments NNS p
. . p

-DOCSTART- -X- O O

Take VB N
a DT N
walk NN N
in IN N
the DT N
park NN N
? . N
A DT N
cross-over NN N
pilot NN N
trial NN N
comparing VBG N
brisk JJ i
walking VBG i
in IN i
two CD i
different JJ i
environments NNS i
: : i
park NN N
and CC N
urban JJ N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
differences NNS N
exist VBP N
between IN N
a DT N
30 CD i
minute NN i
brisk NN i
walk VBP i
taken VBN N
in IN N
two CD N
different JJ N
environments NNS N
in IN N
order NN N
to TO N
determine VB N
which WDT N
environment NN N
best JJS N
facilitates NNS N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
: : N
park NN N
or CC N
urban JJ N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
cross-over NN N
pilot NN N
study NN N
, , N
participants NNS p
performed VBD p
a DT p
self-timed JJ i
30 CD i
minute NN i
brisk NN i
walk VBP i
in IN i
two CD i
different JJ i
environments NNS i
, , i
park NN i
and CC i
urban JJ i
, , N
in IN N
Glasgow NNP N
, , N
Scotland NNP N
( ( N
October NNP N
2009 CD N
to TO N
January NNP N
2010 CD N
) ) N
. . N

Cadence NN o
, , N
recorded VBD N
using VBG N
the DT N
activPAL? NN N
activity NN N
monitor NN N
, , N
was VBD N
used VBN N
to TO N
measure VB N
intensity NN N
. . N

Outcome CC N
measures NNS N
were VBD o
: : o
mean JJ o
cadence NN o
; : o
moderate-to-vigorous JJ o
physical JJ o
activity NN o
time NN o
accumulated VBN o
in IN o
bouts NNS o
lasting VBG o
? . o
10 CD o
min NN o
; : o
number NN o
of IN o
walking VBG o
breaks NNS o
; : o
and CC o
duration NN o
. . o

RESULTS VB o
A DT N
convenience NN N
sample NN p
of IN p
40 CD p
healthy JJ p
adults NNS p
was VBD p
recruited VBN p
: : p
16 CD p
males NNS p
, , p
24 CD p
females NNS p
, , p
mean JJ p
age NN p
22.9 CD p
( ( p
5.5 CD p
) ) p
years NNS p
. . p

The DT p
mean JJ o
cadence NN o
for IN o
the DT o
whole JJ o
walk NN o
was VBD o
higher RBR N
in IN N
the DT N
park NN N
: : N
119.3 CD N
( ( N
8.3 CD N
) ) N
vs. FW N
110.9 CD N
( ( N
8.9 CD N
) ) N
steps/min NN p
. . p

Participants NNS p
accumulated VBD p
more RBR N
moderate-to-vigorous JJ o
physical JJ o
activity NN o
in IN o
? . o
10 CD o
minute NN o
bouts NNS o
during IN N
park JJ N
walks NNS N
: : N
25.5 CD N
( ( N
9.6 CD N
) ) N
[ NN N
median JJ N
( ( N
interquartile JJ N
range NN N
) ) N
] VBZ N
vs. FW N
14.0 CD N
( ( N
20.3 CD N
) ) N
min NN N
. . N

There EX N
was VBD N
no DT N
difference NN o
in IN o
self-timed JJ o
duration NN o
between IN o
locations NNS N
. . N

CONCLUSION NNP N
Participants NNPS N
accumulated VBD o
more RBR o
moderate-to-vigorous JJ o
physical JJ o
activity NN o
in IN o
bouts NNS o
? . N
10 CD N
min NN N
in IN N
duration NN N
on IN N
park NN N
walks NNS N
due JJ N
to TO N
the DT N
lack NN N
of IN N
interruptions NNS N
in IN N
walking VBG N
. . N

Hence NNP N
the DT N
park NN N
environment NN N
better RBR N
facilitated VBD N
the DT N
achievement NN N
of IN N
current JJ N
physical JJ N
activity NN N
guidelines NNS N
. . N

Further JJ N
research NN N
involving VBG N
a DT N
larger JJR N
, , N
more RBR N
heterogeneous JJ N
sample NN N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -X- O O

Predicting VBG N
completion NN N
of IN N
treatment NN N
among IN N
foreign-born JJ p
adolescents NNS p
treated VBN p
for IN p
latent JJ p
tuberculosis NN p
infection NN p
in IN p
Los NNP p
Angeles NNP p
. . p

SETTING NNP N
Two CD p
health NN p
clinics NNS p
in IN p
Los NNP p
Angeles NNP p
County NNP p
, , p
California NNP p
. . p

OBJECTIVE NNP N
To TO N
identify VB N
factors NNS N
associated VBN N
with IN N
completion NN N
of IN N
care NN N
among IN N
foreign-born JJ p
adolescents NNS p
treated VBN p
for IN p
latent JJ p
tuberculosis NN p
infection NN p
( ( p
LTBI NNP p
) ) p
. . p

DESIGN VB N
A DT p
total NN p
of IN p
766 CD p
low-income JJ p
adolescents NNS p
( ( p
79 CD p
% NN p
participation NN p
rate NN p
) ) p
, , p
including VBG p
610 CD p
foreign-born JJ p
, , p
were VBD p
recruited VBN p
. . p

In IN N
prospective JJ N
face-to-face NN i
interviews NNS i
, , N
data NNS N
were VBD N
obtained VBN N
on IN N
socio-demographic JJ N
and CC N
lifestyle JJ N
characteristics NNS N
, , N
psychosocial JJ N
factors NNS N
and CC N
clinic-related JJ N
variables NNS N
. . N

Medical JJ i
chart NN i
data NNS i
were VBD i
abstracted VBN i
regarding VBG N
clinic JJ N
appointment NN N
keeping VBG N
and CC N
completion NN N
of IN N
treatment NN N
. . N

Univariate NNP i
and CC i
multivariate VB i
logistic JJ i
regression NN i
analyses NNS i
were VBD N
performed VBN N
to TO N
identify VB N
factors NNS N
associated VBN N
with IN N
completion NN N
of IN N
care NN N
. . N

RESULTS NNP N
Foreign-born JJ p
adolescents NNS p
were VBD N
more RBR N
likely JJ N
to TO N
complete VB o
care NN o
than IN N
US-born JJ N
adolescents NNS N
, , N
with IN N
82 CD N
% NN N
completion NN N
of IN N
care NN N
rate NN N
. . N

In IN N
logistic JJ N
regression NN N
analyses NNS N
after IN N
controlling VBG N
for IN N
age NN N
, , N
medication NN o
taking VBG o
behavior NN o
( ( N
OR CC N
1.26 CD N
, , N
95 CD N
% NN N
CI NNP N
1.15-1.39 CD N
) ) N
, , N
living VBG o
with IN o
both DT o
parents NNS o
( ( N
OR NNP N
1.74 CD N
, , N
95 CD N
% NN N
CI NNP N
1.02-2.97 CD N
) ) N
, , N
sexual JJ o
intercourse NN o
( ( N
OR CC N
0.66 CD N
, , N
95 CD N
% NN N
CI NNP N
0.36-1.19 NN N
) ) N
and CC N
speaking VBG o
mostly RB o
or CC o
only RB o
English JJ o
with IN o
parents NNS o
( ( N
OR NNP N
0.39 CD N
, , N
95 CD N
% NN N
CI NNP N
0.15-1.03 NN N
) ) N
were VBD N
independently RB N
associated VBN N
with IN N
completion NN N
of IN N
care NN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
contribute VBP N
to TO N
our PRP$ N
understanding NN N
of IN N
the DT N
factors NNS N
that WDT N
may MD N
explain VB N
why WRB N
some DT N
adolescents NNS N
complete JJ N
care NN N
whereas IN N
others NNS N
do VBP N
not RB N
. . N

They PRP N
provide VBP N
supportive JJ N
evidence NN N
that WDT N
tailored VBD N
intervention NN N
programs NNS N
should MD N
be VB N
developed VBN N
to TO N
support VB N
the DT N
screening NN N
and CC N
completion NN N
of IN N
treatment NN N
of IN N
foreign-born JJ p
adolescents NNS p
. . p

-DOCSTART- -X- O O

Brief JJ N
report NN N
: : N
a DT N
controlled JJ N
evaluation NN N
of IN N
facilitated JJ p
communication NN p
using VBG p
open-ended JJ i
and CC i
fill-in JJ i
questions NNS i
. . i

-DOCSTART- -X- O O

Accumulated VBN i
brisk JJ i
walking NN i
reduces NNS N
arterial JJ N
stiffness NN N
in IN p
overweight JJ p
adults NNS p
: : p
evidence NN N
from IN N
a DT N
randomized VBN N
control NN N
trial NN N
. . N

Arterial JJ N
stiffness NN N
is VBZ N
a DT N
major JJ N
contributor NN N
to TO N
the DT N
development NN N
of IN N
atherosclerosis NN N
and CC N
consequently RB N
cardiovascular JJ N
disease NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
examine VB N
whether IN N
6 CD N
months NNS N
of IN N
accumulated VBN N
( ( N
3 CD N
? . N
10 CD N
minutes NNS N
, , N
5 CD N
days/week NN i
) ) i
brisk NN i
walking NN i
was VBD N
sufficient JJ N
to TO N
reduce VB N
arterial JJ N
stiffness NN p
in IN p
sedentary JJ p
, , p
overweight JJ p
individuals NNS p
. . p

Seventy-seven JJ p
individuals NNS p
( ( p
19 CD p
men NNS p
, , p
58 CD p
women NNS p
; : p
age NN p
, , p
30-55 CD p
years NNS p
) ) p
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS p
; : p
two CD p
groups NNS p
completed VBD i
30 CD i
minutes NNS i
of IN i
accumulated JJ i
walking VBG i
with IN i
either DT i
monthly JJ i
or CC i
weekly JJ i
telephone NN i
support NN i
; : i
the DT p
third JJ i
group NN i
( ( i
control NN i
) ) i
performed VBD i
stretching VBG i
exercises NNS i
. . i

The DT p
walking VBG p
groups NNS p
were VBD N
combined VBN N
and CC N
telephone NN N
support NN N
included VBD N
as IN N
a DT N
covariate NN N
. . N

Anthropometry NNP o
, , o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
blood NN o
lipids NNS o
, , o
pulse RB o
wave VBP o
velocity NN o
( ( o
PWV NNP o
) ) o
, , o
and CC o
NOx NNP o
( ( o
surrogate JJ o
marker NN o
for IN o
nitric JJ o
oxide NN o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
4 CD N
months NNS N
post-intervention NN N
. . N

No CC N
changes NNS N
were VBD N
observed VBN N
for IN o
anthropometry NN o
, , o
BP NNP o
, , o
or CC o
lipids NNS o
. . o

However RB N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
, , N
there EX N
was VBD N
a DT N
decrease NN N
in IN o
PWV NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
accompanied VBN N
by IN N
an DT N
increase NN N
in IN o
NOx NNP o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
with IN N
changes NNS N
maintained VBD N
4 CD N
months NNS N
post-intervention NN N
. . N

A NNP N
strong JJ N
negative JJ N
correlation NN N
between IN o
PWV NNP o
and CC o
NOx NNP o
was VBD N
also RB N
observed VBN N
( ( N
P NNP N
< NNP N
.001 NNP N
; : N
r NN N
= NNP N
-0.65 NNP N
) ) N
. . N

A DT N
lifestyle JJ N
approach NN N
to TO N
meeting VBG N
current JJ i
physical JJ i
activity NN i
guidelines NNS N
results NNS N
in IN N
favorable JJ N
alterations NNS N
in IN N
arterial JJ N
function NN N
in IN p
overweight JJ p
individuals NNS p
. . p

-DOCSTART- -X- O O

Households NNS p
with IN p
young JJ p
children NNS p
and CC p
use NN p
of IN p
freely RB p
distributed VBN p
bednets NNS i
in IN p
rural JJ p
Madagascar NNP p
. . p

BACKGROUND NNP N
Malaria NNP N
infections NNS N
are VBP N
the DT N
leading VBG N
cause NN N
of IN N
death NN N
for IN N
children NNS p
in IN p
Madagascar NNP p
. . p

Insecticide-treated JJ i
bednets NNS i
offer VBP N
effective JJ N
prevention NN N
, , N
but CC N
it PRP N
is VBZ N
unclear JJ N
how WRB N
well RB N
free JJ i
bednet NN i
distribution NN i
programs NNS i
reach VBP N
young JJ p
children NNS p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
secondary JJ N
analysis NN N
of IN N
a DT N
free JJ i
bednet NN i
distribution NN i
program NN i
in IN p
Madagascar NNP p
from IN p
2007-2008 JJ p
. . p

Interviews NNS i
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

Principal JJ N
components NNS N
analysis NN N
was VBD N
used VBN N
to TO N
construct VB N
a DT N
wealth NN N
and CC N
malaria NNS N
knowledge VBP N
index NN N
. . N

Coverage NNP N
efficiency NN N
was VBD N
calculated VBN N
as IN N
coverage NN i
of IN i
children NNS i
per IN i
bednet NN i
owned VBN i
. . i

Univariable JJ N
and CC N
multivariable JJ N
regressions NNS N
were VBD N
used VBN N
to TO N
determine VB N
predictors NNS N
of IN N
bednet NN i
use NN N
. . N

RESULTS NNP N
Bednet NNP o
use NN o
, , N
among IN N
the DT N
560 CD p
households NNS p
in IN p
the DT p
study NN p
, , N
increased VBD N
from IN N
6 CD N
to TO N
91 CD N
% NN N
after IN N
6 CD N
months NNS N
. . N

Coverage NNP o
efficiency NN o
increased VBD N
from IN N
1.29 CD N
to TO N
1.56 CD N
children NNS N
covered VBN N
per IN N
bednet NN N
owned VBN N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
having VBG N
a DT N
child NN p
under IN p
5 CD p
years NNS p
of IN p
age NN p
was VBD N
the DT N
only JJ N
variable NN N
associated VBN N
with IN N
bednet NN N
use NN N
( ( N
OR CC N
9.10 CD N
; : N
p=0.001 NN N
) ) N
, , N
yielding VBG N
a DT N
99 CD N
% NN N
likelihood NN N
of IN N
using VBG N
a DT N
bednet NN N
( ( N
95 CD N
% NN N
CI NNP N
96.4 CD N
to TO N
99.9 CD N
% NN N
) ) N
versus VBZ N
82 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
72.2 CD N
to TO N
88.4 CD N
% NN N
) ) N
in IN N
households NNS N
without IN N
young JJ N
children NNS N
. . N

CONCLUSION VB N
This DT N
free JJ i
bednet NN i
distribution NN i
program NN i
achieved VBN N
high JJ N
levels NNS N
of IN N
adherence NN N
after IN N
6 CD N
months NNS N
. . N

Household NNP N
presence NN N
of IN N
children NNS p
was VBD N
associated VBN N
with IN N
bednet NN N
use NN N
, , N
but CC N
not RB N
household JJ N
income NN N
or CC N
education NN N
, , N
suggesting VBG N
that IN N
distribution NN N
to TO N
priority NN N
groups NNS N
may MD N
help VB N
overcome VB N
traditional JJ N
barriers NNS N
to TO N
adoption NN N
in IN N
some DT N
settings NNS N
. . N

-DOCSTART- -X- O O

Intranasal NNP N
nicotine NN i
for IN N
postoperative JJ p
pain NN p
treatment NN p
. . p

BACKGROUND NNP N
Despite IN N
pharmacological JJ N
treatment NN N
, , N
70-80 CD N
% NN N
of IN N
patients NNS N
report NN N
moderate VBP N
to TO N
severe VB N
pain NN N
after IN N
surgery NN N
. . N

Because IN N
nicotine NN N
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
analgesic JJ N
properties NNS N
in IN N
animal NN N
and CC N
human JJ N
volunteer NN N
studies NNS N
, , N
the DT N
authors NNS N
assessed VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
a DT N
single JJ N
3 CD N
mg NN N
dose NN N
of IN N
nicotine JJ i
nasal NN N
spray NN N
administered VBD N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
trial NN N
of IN N
20 CD p
healthy JJ p
women NNS p
( ( p
mean JJ p
age NN p
45 CD p
( ( p
SD NNP p
8 CD p
) ) p
yr NN p
) ) p
who WP p
were VBD p
to TO p
undergo VB p
uterine JJ i
surgery NN i
through IN p
a DT p
low JJ i
transverse NN i
incision NN i
. . i

After IN N
the DT N
conclusion NN N
of IN N
surgery NN N
but CC N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
, , N
the DT N
anesthesiologist NN N
administered VBD N
either CC N
nicotine JJ i
nasal NN i
spray NN i
or CC i
a DT i
placebo NN i
. . i

Numerical JJ N
analog NN N
pain NN N
score NN N
and CC N
morphine JJ N
utilization NN N
and CC N
hemodynamic JJ N
values NNS N
were VBD N
measured VBN N
for IN N
24 CD N
h. NN N
RESULTS NNP N
The DT N
patients NNS N
treated VBN N
with IN N
nicotine NN N
reported VBN N
lower JJR o
pain NN o
scores NNS o
during IN N
the DT N
first JJ N
hour NN N
after IN N
surgery NN N
( ( N
peak JJ N
numerical JJ N
analog NN N
score NN N
, , N
7.6 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
versus NN N
5.3 CD N
( ( N
SD NNP N
1.6 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
used VBN N
half PDT N
the DT N
amount NN o
of IN o
morphine NN o
as IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
( ( N
SD NNP N
6 CD N
) ) N
versus NN N
6 CD N
( ( N
SD NNP N
5 CD N
) ) N
mg NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
nicotine NN N
still RB N
reported VBD o
less RBR o
pain NN o
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
24 CD N
h NN N
after IN N
surgery NN N
( ( N
1.5 CD N
( ( N
SD NNP N
0.5 CD N
) ) N
versus NN N
4.9 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Systolic JJ o
blood NN o
pressure NN o
was VBD o
lower JJR o
in IN N
the DT N
group NN N
that WDT N
received VBD N
nicotine JJ N
( ( N
105 CD N
( ( N
SD NNP N
3 CD N
) ) N
versus NN N
122 CD N
( ( N
SD NNP N
3 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT o
difference NN o
in IN o
diastolic JJ o
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
. . o

CONCLUSIONS NNP N
Treatment NNP N
with IN N
a DT N
single JJ N
dose NN N
of IN N
nicotine JJ N
immediately RB N
before IN N
emergence NN N
from IN N
anesthesia NN N
was VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
reported VBD N
pain JJ o
scores NNS o
during IN N
the DT N
first JJ N
day NN N
after IN N
surgery NN N
. . N

The DT N
decreased JJ N
pain NN o
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
morphine JJ N
utilization NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
nicotine NN N
was VBD N
not RB N
associated VBN N
with IN N
hypertension NN N
or CC N
tachycardia NN N
. . N

-DOCSTART- -X- O O

Safety NN o
and CC N
efficacy NN o
of IN N
a DT N
low JJ N
molecular JJ N
weight NN N
heparin NN N
( ( N
Logiparin NNP N
) ) N
versus NN N
dextran NN N
as IN N
prophylaxis NN N
against IN N
thrombosis NN o
after IN N
total JJ p
hip NN p
replacement NN p
. . p

In IN N
order NN N
to TO N
study VB N
the DT N
plasma NN N
levels NNS N
of IN N
factor NN N
XaI NNP N
and CC N
IIaI NNP N
activity NN N
an DT N
enzymatically RB i
depolymerized VBN i
low JJ i
molecular JJ i
weight NN i
heparin NN i
( ( i
LMW-heparin NNP i
; : i
Logiparin NNP i
) ) i
was VBD N
given VBN N
s.c. NN N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
for IN N
7 CD N
days NNS N
to TO N
10 CD p
patients NNS p
undergoing JJ p
total JJ p
hip NN p
replacement NN p
( ( p
THR NNP p
) ) p
in IN N
a DT N
pilot NN N
study NN N
. . N

The DT N
XaI NN N
activity NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.24 CD N
XaI NNP N
units/ml NN N
and CC N
the DT N
IIaI NNP N
activity NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.043 CD N
IIaI NNP N
mu/ml NN N
. . N

No DT N
accumulation NN N
of IN N
the DT N
activities NNS N
were VBD N
seen VBN N
. . N

No DT N
phlebographically RB o
verified VBN o
thrombi NN o
or CC N
any DT N
bleeding JJ o
complications NNS o
were VBD N
registered VBN N
. . N

From IN N
this DT N
study NN N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
given VBN N
dose NN N
of IN N
Logiparin NNP N
was VBD N
safe JJ N
with IN N
regard NN N
to TO N
bleeding VBG N
complications NNS N
. . N

Based VBN N
on IN N
these DT N
data NNS N
, , N
an DT N
open JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
was VBD N
started VBN N
. . N

In IN N
this DT N
main JJ N
study NN N
the DT N
thromboprophylactic JJ o
effect NN o
of IN N
the DT N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
in IN N
a DT N
dose NN N
of IN N
35 CD N
XaI NNP N
mu/kg NN N
b.w NN N
. . N

once RB N
daily JJ N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
dextran NN N
70 CD N
in IN N
patients NNS p
undergoing JJ p
THR NNP p
. . p

100 CD p
patients NNS p
were VBD p
randomized VBN p
. . p

The DT N
over-all JJ o
thrombosis NN o
rate NN o
was VBD N
28 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
LMW-heparin NNP N
and CC N
39 CD N
% NN N
in IN N
those DT N
given VBN N
dextran NN N
, , N
a DT N
non-significant JJ N
difference NN N
. . N

No UH N
bleeding VBG o
complications NNS o
, , o
deaths NNS o
or CC o
pulmonary JJ o
embolism NN o
were VBD N
recorded VBN N
in IN N
either DT N
group NN N
. . N

Peroperative JJ o
blood NN o
loss NN o
and CC o
transfusion NN o
requirements NNS o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
the DT N
investigated JJ N
LMW-heparin NNP N
( ( N
Logiparin NNP N
) ) N
is VBZ N
safe JJ N
and CC N
effective JJ N
in IN N
preventing VBG N
postoperative JJ N
thromboembolism NN N
in IN N
patients NNS p
undergoing JJ p
total JJ p
hip NN p
replacement NN p
, , N
but CC N
the DT N
dosage NN N
can MD N
probably RB N
be VB N
optimized VBN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
and CC o
safety NN o
of IN N
sildenafil NN i
in IN N
Asian JJ p
males NNS p
with IN p
erectile JJ p
dysfunction NN p
and CC p
cardiovascular JJ p
risk NN p
. . p

OBJECTIVE NNP N
Assess NNP N
the DT N
effectiveness NN N
of IN N
sildenafil NN i
in IN N
Asian JJ p
males NNS p
with IN p
erectile JJ p
dysfunction NN p
( ( p
ED NNP p
) ) p
and CC p
one CD p
or CC p
more JJR p
of IN p
the DT p
co-morbidities NNS p
, , p
mild-to-moderate JJ p
hypertension NN p
, , p
dyslipidemia NN p
, , p
and CC p
diabetes NNS p
. . p

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
six-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP N
, , N
Malaysia NNP N
and CC N
Singapore NNP N
. . N

One CD p
hundred CD p
and CC p
fifty VB p
five CD p
male JJ p
subjects NNS p
were VBD N
randomized VBN N
( ( N
2:1 CD N
) ) N
to TO N
sildenafil VB i
( ( N
n JJ N
= NNP N
104 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
51 CD N
) ) N
. . N

Sildenafil NNP i
was VBD N
started VBN N
at IN N
50 CD N
mg NN N
and CC N
increased VBD N
( ( N
100 CD N
mg NN N
) ) N
or CC N
decreased VBN N
( ( N
25 CD N
mg NN N
) ) N
at IN N
week NN N
2 CD N
if IN N
necessary JJ N
. . N

RESULTS VB N
On IN N
the DT N
primary JJ N
efficacy NN N
endpoint NN N
, , N
sildenafil-treated JJ i
subjects NNS N
had VBD N
significantly RB N
better JJR N
scores NNS o
on IN N
the DT N
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function NNP o
( ( o
IIEF NNP o
) ) o
questions NNS o
3 CD o
and CC o
4 CD o
than IN N
placebo NN N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
both DT N
questions NNS N
) ) N
. . N

When WRB N
accumulated VBN N
into IN N
IIEF NNP N
domains NNS N
, , N
all DT N
five CD N
domains NNS N
were VBD N
significant JJ N
in IN N
favor NN N
of IN N
sildenafil NN N
. . N

In IN N
addition NN N
, , N
sildenafil-treated JJ i
subjects NNS N
were VBD N
more RBR N
satisfied JJ o
with IN N
treatment NN N
and CC N
had VBD N
a DT N
higher JJR N
intercourse JJ o
success NN o
rate NN o
. . o

The DT N
majority NN N
of IN N
adverse JJ N
events NNS N
were VBD N
mild VBN N
in IN N
severity NN o
; : o
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
events NNS N
were VBD N
dizziness NN o
( ( N
7.7 CD N
% NN N
) ) N
and CC N
tinnitus NN o
( ( N
2.9 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Sildenafil NNP N
( ( N
25 CD N
, , N
50 CD N
, , N
and CC N
100 CD N
mg NN N
) ) N
was VBD N
found VBN N
to TO N
be VB N
an DT N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
ED NNP N
in IN N
the DT N
present JJ N
study NN N
population NN N
of IN N
Thai NNP N
, , N
Malaysian NNP N
, , N
and CC N
Singaporean NNP N
males NNS N
who WP N
also RB N
had VBD N
increased VBN N
cardiovascular JJ N
risk NN N
-DOCSTART- -X- O O

T NNP N
lymphocyte JJ N
subsets NNS N
and CC N
NK NNP N
cell VBP N
cytotoxicity NN N
in IN N
chronic JJ p
hemodialysis NN p
patients NNS p
. . p

The DT N
effect NN N
of IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
rHu-EPO JJ i
) ) i
treatment NN i
. . i

We PRP N
investigated VBD N
subpopulations NNS N
of IN N
T NNP o
lymphocytes NNS o
, , o
NK NNP o
cell NN o
number NN o
and CC o
cytotoxic JJ o
activity NN o
in IN N
14 CD p
chronic JJ p
uremic JJ p
patients NNS p
on IN p
regular JJ i
hemodialysis NN i
treatment NN i
. . i

We PRP N
observed VBD N
a DT N
significantly RB N
decreased VBN N
absolute NN o
lymphocyte NN o
number NN o
and CC o
percentage NN o
of IN o
CD3 NNP o
cells NNS o
. . o

Relative JJ N
numbers NNS N
of IN N
CD16 NNP o
cells NNS o
were VBD N
significantly RB N
elevated VBN N
, , N
but CC N
NK NNP o
cell VBP o
cytotoxic JJ o
activity NN o
was VBD N
within IN N
a DT N
normal JJ N
range NN N
. . N

Nine JJ p
patients NNS p
with IN p
chronic JJ p
renal JJ p
anemia NN p
on IN p
maintenance NN p
hemodialysis NN p
were VBD N
enrolled VBN N
in IN N
rHu-EPO JJ i
treatment NN N
trial NN N
. . N

The DT N
treatment NN N
was VBD N
continued VBN N
till IN N
the DT N
hematocrit NN o
level NN o
reached VBD N
30 CD N
% NN N
. . N

Each DT N
of IN N
the DT N
patients NNS p
had VBD p
corrected VBN N
anemia NN o
and CC N
well-being NN N
. . N

After IN N
12 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
we PRP N
observed VBD N
in IN N
these DT N
patients NNS N
decreases NNS N
in IN N
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
and CC o
CD16 NNP o
cell NN o
numbers NNS o
and CC N
elevation NN N
of IN N
CD4/CD8 NNP o
ratio NN o
. . o

Cytotoxic NNP o
activity NN o
of IN o
NK NNP o
cells NNS o
did VBD N
not RB N
change VB N
significantly RB N
. . N

Presented VBN N
results NNS N
indicate VBP N
that IN N
chronic JJ p
hemodialysis NN p
patients NNS p
have VBP N
significantly RB N
diminished VBN N
lymphocyte JJ o
number NN o
. . o

rHu JJ i
EPO NNP i
treatment NN N
affects VBZ N
the DT N
T NNP N
lymphocyte NN N
subsets NNS N
inducing VBG N
a DT N
deep JJ N
decrease NN N
of IN N
CD8 NNP o
and CC o
CD16 NNP o
cell NN o
percentage NN o
leading VBG N
to TO N
normalisation NN N
of IN N
the DT N
CD4/CD8 NNP o
ratio NN o
. . o

-DOCSTART- -X- O O

Initial JJ o
abstinence NN o
status NN o
and CC o
contingency NN o
management NN o
treatment NN o
outcomes NNS N
: : N
does VBZ N
race NN N
matter NN N
? . N
OBJECTIVE NNP N
Limited NNP N
research NN N
has VBZ N
evaluated VBN N
African JJ p
American JJ p
substance NN p
users NNS p
' POS p
response NN N
to TO N
evidence-based JJ N
treatments NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
contingency NN o
management NN o
( ( o
CM NNP o
) ) o
in IN N
African JJ p
American NNP p
and CC p
White NNP p
cocaine NN p
users NNS p
. . p

METHOD VB N
A DT N
secondary JJ N
analysis NN N
evaluated VBD N
effects NNS N
of IN N
race NN N
, , N
treatment NN N
condition NN N
, , N
and CC N
baseline NN N
cocaine NN N
urine JJ N
sample NN N
results NNS N
on IN N
treatment NN N
outcomes NNS N
of IN N
African JJ p
American NNP p
( ( p
n JJ p
= NNP p
444 CD p
) ) p
and CC p
White NNP p
( ( p
n JJ p
= NNP p
403 CD p
) ) p
cocaine NN p
abusers NNS p
participating VBG p
in IN p
one CD p
of IN p
six CD p
randomized JJ p
clinical JJ p
trials NNS p
comparing VBG p
CM NNP i
to TO p
standard VB i
care NN i
. . i

RESULTS JJ N
African JJ p
American JJ p
and CC p
White NNP p
patients NNS p
who WP p
initiated VBD p
treatment NN p
with IN p
a DT p
cocaine-negative JJ p
urine JJ p
sample NN p
remained VBD N
in IN N
treatment NN N
for IN N
similar JJ N
durations NNS N
and CC N
submitted VBD N
a DT N
comparable JJ N
proportion NN N
of IN N
negative JJ N
samples NNS N
during IN N
treatment NN N
regardless NN N
of IN N
treatment NN N
type NN N
; : N
CM NNP i
was VBD N
efficacious JJ N
in IN N
both DT N
races NNS N
in IN N
terms NNS N
of IN N
engendering VBG N
longer JJR N
durations NNS N
of IN N
abstinence NN N
in IN N
patients NNS N
who WP N
began VBD N
treatment NN N
abstinent NN N
. . N

Whites NNS p
who WP p
began VBD p
treatment NN p
with IN p
a DT p
cocaine NN p
positive JJ p
sample NN p
remained VBD N
in IN N
treatment NN N
longer NN N
and CC N
submitted VBD N
a DT N
higher JJR N
proportion NN N
of IN N
negative JJ N
samples NNS N
when WRB N
assigned VBN N
to TO N
CM NNP i
than IN N
standard JJ i
care NN i
. . i

African JJ p
Americans NNPS p
who WP p
initiated VBD p
treatment NN p
with IN p
a DT p
cocaine NN p
positive JJ p
sample NN p
, , N
however RB N
, , N
did VBD N
not RB N
remain VB N
in IN N
treatment NN N
longer NN N
with IN N
CM NNP i
compared VBN N
with IN N
standard JJ i
care NN i
, , N
and CC N
gains NNS o
in IN o
terms NNS o
of IN o
drug NN o
use NN o
outcomes NNS o
were VBD N
muted VBN N
in IN N
nature NN N
relative NN N
to TO N
Whites NNP N
. . N

This DT N
interaction NN N
effect NN N
persisted VBN N
through IN N
the DT N
9-month JJ N
follow-up JJ N
period NN N
. . N

CONCLUSIONS NNP N
CM NNP i
is VBZ N
not RB N
equally RB N
effective JJ N
in IN N
reducing VBG N
drug NN N
use NN N
among IN N
all DT N
subgroups NNS N
, , N
specifically RB N
African JJ p
American JJ p
patients NNS p
who WP p
are VBP p
using VBG p
cocaine JJ p
upon IN p
treatment NN p
entry NN p
. . p

Future NNP N
research NN N
on IN N
improving VBG N
treatment NN N
outcomes NNS N
in IN N
this DT N
population NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

Mechanical JJ o
efficiency NN o
and CC o
propulsion NN o
technique NN o
after IN N
7 CD N
weeks NNS N
of IN N
low-intensity JJ N
wheelchair NN N
training NN N
. . N

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
7-week JJ N
low-intensity NN N
hand NN N
rim VBZ N
wheelchair JJ N
training VBG N
on IN N
the DT N
submaximal JJ N
metabolic NN N
cost NN N
, , N
mechanical JJ o
efficiency NN o
and CC N
propulsion NN N
technique NN N
in IN N
able-bodied JJ p
participants NNS p
. . p

METHODS JJ N
Participants NNS p
were VBD N
randomly RB N
divided VBN N
over RP N
an DT N
experimental JJ N
group NN N
( ( p
n=14 CC p
) ) p
and CC p
a DT p
control NN p
group NN p
( ( p
n=7 RB p
) ) p
. . p

The DT N
experimental JJ N
group NN N
received VBD i
7 CD i
weeks NNS i
wheelchair JJ i
training NN i
( ( i
3 CD i
week NN i
( ( i
-1 NN i
) ) i
, , i
70 CD i
min NN i
) ) i
at IN i
a DT i
low JJ i
intensity NN i
( ( i
30 CD i
% NN i
of IN i
the DT i
heart NN i
rate NN i
reserve NN i
) ) i
, , i
whereas IN i
the DT i
control NN i
group NN i
did VBD i
not RB i
receive VB i
training NN i
. . i

During IN i
pre- JJ i
and CC i
post-tests NNS i
, , i
submaximal JJ i
exercise NN i
was VBD i
performed VBN i
on IN i
a DT i
stationary JJ i
wheelchair NN i
ergometer NN i
at IN i
fixed JJ i
levels NNS i
of IN i
power NN i
output NN i
. . i

Mechanical JJ o
efficiency NN o
, , o
oxygen NN o
uptake NN o
, , o
heart NN o
rate NN o
, , o
timing VBG o
parameters NNS o
and CC o
stroke NN o
angles NNS o
were VBD i
measured VBN i
. . i

Video NNP N
recordings NNS N
were VBD N
made VBN N
to TO N
determine VB N
the DT N
stroke NN o
pattern NN o
. . o

FINDINGS NNP N
Mechanical NNP o
efficiency NN o
increased VBD o
and CC o
metabolic JJ o
cost NN o
decreased VBN o
significantly RB N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Push NNP o
time NN o
increased VBD N
and CC N
cycle NN o
frequency NN o
decreased VBD N
as IN N
a DT N
result NN N
of IN N
training NN N
. . N

The DT N
stroke NN o
angle NN o
increased VBD N
in IN N
the DT N
experimental JJ N
group NN N
during IN N
the DT N
training NN N
period NN N
. . N

The DT N
experimental JJ N
group NN N
preferred VBD N
double-looping NN N
over IN N
propulsion NN N
, , N
while IN N
the DT N
control NN N
group NN N
mainly RB N
used VBD N
single-looping NN o
over IN o
propulsion NN o
patterns NNS N
during IN N
the DT N
post-test JJ N
. . N

INTERPRETATION VB N
A DT N
low-intensity NN N
, , N
7-week JJ N
training NN N
protocol NN N
has VBZ N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
mechanical JJ o
efficiency NN o
and CC o
metabolic JJ o
cost NN o
of IN N
wheelchair NN N
propulsion NN N
in IN N
able-bodied JJ p
participants NNS p
. . p

The DT N
improved JJ N
mechanical JJ N
efficiency NN N
seems VBZ N
to TO N
be VB N
the DT N
result NN N
of IN N
changes NNS N
in IN N
propulsion NN N
technique NN N
that WDT N
were VBD N
found VBN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
daily JJ N
versus FW N
weekly JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ i
in IN N
patients NNS p
with IN p
hairy JJ p
cell NN p
leukemia NN p
: : p
a DT p
multicenter NN p
phase NN p
III NNP p
trial NN p
( ( p
SAKK NNP p
32/98 CD p
) ) p
. . p

Daily JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ i
( ( i
Cladribine NNP i
, , i
CDA NNP i
) ) i
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
hairy NN N
cell NN N
leukemia NN N
, , N
but CC N
may MD N
cause VB N
severe JJ N
neutropenia NN o
and CC o
neutropenic JJ o
fever NN o
. . o

This DT N
trial NN N
compared VBN N
toxicity NN N
and CC N
efficacy NN N
of IN N
weekly JJ N
versus NN N
daily RB N
CDA NNP i
administration NN N
. . N

One CD p
hundred VBD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
standard NN N
( ( i
CDA NNP i
0.14 CD N
mg/kg/day JJ N
day NN N
1-5 JJ N
[ NNP N
Arm NNP N
A NNP N
] NN N
) ) N
or CC N
experimental JJ N
treatment NN N
( ( i
CDA NNP i
0.14 CD N
mg/kg/day NN N
once RB N
weekly JJ N
for IN N
5 CD N
weeks NNS N
[ JJ N
Arm NNP N
B NNP N
] NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
average JJ o
leukocyte JJ o
count NN o
within IN N
6 CD N
weeks NNS N
from IN N
randomization NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
response NN o
rates NNS o
, , o
other JJ o
acute JJ o
hematotoxicity NN o
, , o
acute JJ o
infection NN o
rate NN o
, , o
hospital NN o
admission NN o
, , o
remission NN o
duration NN o
, , o
event-free JJ o
, , o
and CC o
overall JJ o
survival NN o
. . o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
average JJ o
leukocyte JJ o
count NN o
. . o

Response JJ o
rate NN o
( ( N
complete JJ N
+ NNP N
partial JJ N
remission NN N
) ) N
at IN N
week NN N
10 CD N
was VBD N
78 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
64-88 CD N
% NN N
) ) N
in IN N
Arm NNP N
A NNP N
and CC N
68 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
54-80 CD N
% NN N
) ) N
in IN N
Arm NNP N
B NNP N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
. . N

Best JJS N
response NN o
rates NNS o
during IN N
follow-up JJ N
were VBD N
identical JJ N
( ( N
86 CD N
% NN N
) ) N
in IN N
both DT N
arms NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
rate NN N
of IN N
grade NN o
3+4 CD o
leukocytopenia NN o
( ( N
94 CD N
% NN N
vs NN N
. . N

84 CD N
% NN N
) ) N
, , N
grade VBD o
3+4 CD o
neutropenia NN o
( ( N
90 CD N
% NN N
vs NN N
. . N

80 CD N
% NN N
) ) N
, , N
acute JJ o
infection NN o
( ( N
44 CD N
% NN N
vs NN N
. . N

40 CD N
% NN N
) ) N
, , N
hospitalization NN o
( ( N
38 CD N
% NN N
vs NN N
. . N

34 CD N
% NN N
) ) N
, , N
and CC N
erythrocyte JJ o
support NN o
( ( N
22 CD N
% NN N
vs NN N
. . N

30 CD N
% NN N
) ) N
within IN N
10 CD N
weeks NNS N
. . N

Overall JJ N
, , N
these DT N
findings NNS N
indicate VBP N
that IN N
there EX N
are VBP N
no DT N
apparent JJ N
advantages NNS N
in IN N
toxicity NN o
and CC o
efficacy NN o
by IN N
giving VBG N
CDA NNP i
weekly RB N
rather RB N
than IN N
daily RB N
. . N

-DOCSTART- -X- O O

Immunologic NNP N
and CC N
hemodynamic JJ N
effects NNS N
of IN N
low-dose JJ i
hydrocortisone NN i
in IN N
septic JJ p
shock NN p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

Within IN N
the DT N
last JJ N
few JJ N
years NNS N
, , N
increasing VBG N
evidence NN N
of IN N
relative JJ N
adrenal JJ p
insufficiency NN p
in IN p
septic JJ p
shock NN p
evoked VBD N
a DT N
reassessment NN N
of IN N
hydrocortisone NN i
therapy NN i
. . i

To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
hydrocortisone NN i
on IN N
the DT N
balance NN N
between IN N
proinflammatory NN N
and CC N
antiinflammation NN N
, , N
40 CD p
patients NNS p
with IN p
septic JJ p
shock NN p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
to TO N
receive VB N
either CC N
the DT N
first JJ N
100 CD N
mg NN N
of IN N
hydrocortisone NN i
as IN N
a DT N
loading NN N
dose NN N
and CC N
10 CD N
mg NNS N
per IN N
hour NN N
until IN N
Day NNP N
3 CD N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
, , N
followed VBN N
by IN N
the DT N
opposite JJ N
medication NN N
until IN N
Day NNP N
6 CD N
. . N

Hydrocortisone CD i
infusion NN N
induced VBD N
an DT N
increase NN N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
systemic JJ o
vascular NN o
resistance NN o
, , N
and CC N
a DT N
decline NN N
of IN N
heart NN o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
norepinephrine JJ o
requirement NN o
. . o

A DT N
reduction NN N
of IN N
plasma NN o
nitrite/nitrate NN o
indicated VBD N
inhibition NN N
of IN N
nitric JJ o
oxide JJ o
formation NN o
and CC N
correlated VBN N
with IN N
a DT N
reduction NN o
of IN o
vasopressor NN o
support NN o
. . o

The DT N
inflammatory JJ o
response NN o
( ( o
interleukin-6 JJ o
and CC o
interleukin-8 JJ o
) ) o
, , o
endothelial JJ o
( ( o
soluble JJ o
E-selectin NN o
) ) o
and CC o
neutrophil JJ o
activation NN o
( ( o
expression NN o
of IN o
CD11b NNP o
, , o
CD64 NNP o
) ) o
, , o
and CC o
antiinflammatory JJ o
response NN o
( ( o
soluble JJ o
tumor NN o
necrosis NN o
factor NN o
receptors NNS o
I PRP o
and CC o
II NNP o
and CC o
interleukin-10 JJ o
) ) o
were VBD N
attenuated VBN N
. . N

In IN N
peripheral JJ N
blood NN N
monocytes NNS N
, , N
human JJ o
leukocyte VBD o
antigen-DR JJ o
expression NN o
was VBD N
only RB N
slightly RB N
depressed VBN N
, , N
whereas NNS N
in IN o
vitro JJ o
phagocytosis NN o
and CC o
the DT o
monocyte-activating JJ o
cytokine JJ o
interleukin-12 NN o
increased VBD N
. . N

Hydrocortisone NNP i
withdrawal NN N
induced VBD N
hemodynamic JJ o
and CC o
immunologic JJ o
rebound NN o
effects NNS o
. . o

In IN N
conclusion NN N
, , N
hydrocortisone NN i
therapy NN i
restored VBD N
hemodynamic JJ o
stability NN o
and CC N
differentially RB N
modulated VBD N
the DT N
immunologic JJ o
response NN o
to TO o
stress VB o
in IN N
a DT N
way NN N
of IN N
antiinflammation NN N
rather RB N
than IN N
immunosuppression NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
Dader NNP i
Method NNP i
for IN N
pharmaceutical JJ N
care NN N
on IN N
control NN o
of IN o
blood NN o
pressure NN o
and CC o
total JJ o
cholesterol NN o
in IN N
outpatients NNS p
with IN p
cardiovascular JJ p
disease NN p
or CC p
cardiovascular JJ p
risk NN p
: : p
EMDADER-CV JJ N
randomized NNS N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
some DT N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
pharmacist JJ i
intervention NN i
can MD N
improve VB N
drug NN N
therapy NN N
among IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
( ( p
CVD NNP p
) ) p
, , N
more JJR N
evidence NN N
derived VBN N
from IN N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCTs NNP N
) ) N
is VBZ N
needed VBN N
, , N
including VBG N
assessment NN N
of IN N
the DT N
effect NN N
of IN N
community NN i
pharmacist NN i
interventions NNS i
in IN N
patients NNS p
with IN p
CVD NNP p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
the DT N
Dader NNP i
Method NNP i
for IN i
pharmaceutical JJ i
care NN i
on IN N
achieving VBG N
therapeutic JJ N
goals NNS N
for IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
total JJ o
cholesterol NN o
( ( o
TC NNP o
) ) o
, , N
and CC N
both DT o
BP NNP o
and CC o
TC NNP o
( ( o
BP/TC NNP o
) ) o
in IN N
patients NNS p
with IN p
CVD NNP p
and/or VBP p
high JJ p
or CC p
intermediate JJ p
cardiovascular NN p
( ( p
CV NNP p
) ) p
risk NN p
attending VBG p
community NN p
pharmacies NNS p
in IN p
Spain NNP p
. . p

METHODS NNP N
Patients NNPS p
aged VBD p
25 CD p
to TO p
74 CD p
years NNS p
attending VBG p
community NN p
pharmacies NNS p
with IN p
a DT p
prescription NN p
for IN p
at IN p
least JJS p
1 CD p
drug NN p
indicated VBN p
for IN p
CVD NNP p
or CC p
CV NNP p
risk NN p
factors NNS p
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
: : N
an DT N
intervention NN i
group NN i
that WDT i
received VBD i
pharmaceutical JJ i
care NN i
, , i
which WDT i
was VBD i
provided VBN i
by IN i
specially RB i
trained JJ i
pharmacists NNS i
working VBG i
in IN i
collaboration NN i
with IN i
physicians NNS i
, , N
and CC N
a DT N
control NN i
group NN i
that WDT i
received VBD i
usual JJ i
care NN i
( ( i
routine JJ i
dispensing VBG i
counseling NN i
) ) i
and CC i
verbal JJ i
and CC i
written VBN i
counseling VBG i
regarding VBG i
CVD NNP i
prevention NN i
. . i

Patients NNS p
were VBD p
recruited VBN p
from IN p
December NNP p
2005 CD p
to TO p
September NNP p
2006 CD p
, , N
and CC N
both DT N
groups NNS N
were VBD N
followed VBN N
for IN N
8 CD N
months NNS N
. . N

Study NNP N
outcomes NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
at IN N
16 CD N
and CC N
32 CD N
weeks NNS N
after IN N
randomization NN N
. . N

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
proportions NNS o
of IN o
patients NNS o
achieving VBG o
BP NNP o
, , o
TC NNP o
, , o
and CC o
BP/TC NNP o
therapeutic JJ o
goals NNS o
( ( N
BP NNP N
lower JJR N
than IN N
140/90 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
uncomplicated JJ N
hypertension NN N
and CC N
lower JJR N
than IN N
130/80 CD N
mm NNS N
Hg NNP N
for IN N
patients NNS N
with IN N
diabetes NNS N
, , N
chronic JJ N
kidney NN N
disease NN N
, , N
or CC N
history NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
stroke NN N
; : N
TC NNP N
lower JJR N
than IN N
200 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
without IN N
CVD NNP N
and CC N
lower JJR N
than IN N
175 CD N
mg NNS N
per IN N
dL NN N
for IN N
patients NNS N
with IN N
CVD NNP N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
mean JJ o
BP NNP o
and CC o
TC NNP o
values NNS o
. . o

BP NNP o
was VBD o
assessed VBN o
manually RB o
by IN N
the DT N
pharmacist NN N
after IN N
a DT N
10-minute JJ N
rest NN N
in IN N
the DT N
supine JJ N
position NN N
. . N

This DT N
measurement NN N
was VBD N
performed VBN N
twice RB N
for IN N
every DT N
participant NN N
, , N
and CC N
the DT N
average NN N
of IN N
the DT N
2 CD N
measurements NNS N
was VBD N
calculated VBN N
. . N

TC NNP o
was VBD N
measured VBN N
by IN N
the DT N
pharmacist NN N
during IN N
the DT N
study NN N
visit NN N
using VBG N
the DT N
enzymatic JJ o
dry JJ o
method NN o
. . o

Statistical JJ N
analyses NNS N
were VBD N
performed VBN N
using VBG N
2-tailed JJ N
McNemar NNP N
tests NNS N
, , N
Pearson NNP N
chi-square NN N
tests NNS N
, , N
and CC N
Student NNP N
's POS N
t-tests NNS N
; : N
P NNP N
< VBD N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
714 CD p
patients NNS p
were VBD N
included VBN N
in IN N
the DT N
study NN N
( ( N
356 CD N
intervention NN i
, , N
358 CD N
control NN i
) ) i
, , N
and CC N
the DT N
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
was VBD p
62.8 CD p
[ JJ p
8.1 CD p
] JJ p
years NNS p
. . p

The DT N
2 CD N
groups NNS N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
clinical JJ N
and CC N
demographic JJ N
characteristics NNS N
, , N
including VBG N
the DT N
proportion NN N
of IN N
patients NNS N
at IN N
therapeutic JJ N
goals NNS o
for IN o
BP NNP o
, , o
TC NNP o
, , o
and CC o
BP/TC NNP o
. . o

After IN N
8 CD N
months NNS N
of IN N
follow-up NN N
, , N
there EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
favor NN N
of IN N
pharmaceutical JJ N
care NN N
in IN N
the DT N
proportions NNS N
of IN N
patients NNS N
who WP N
achieved VBD N
therapeutic JJ N
goals NNS o
for IN o
BP NNP o
( ( N
52.5 CD N
% NN N
vs. FW N
43.0 CD N
% NN N
, , N
P=0.017 NNP N
) ) N
, , N
TC NNP o
( ( N
56.5 CD N
% NN N
vs. FW N
44.1 CD N
% NN N
, , N
P=0.001 NNP N
) ) N
, , N
and CC N
BP/TC NNP o
( ( N
37.1 CD N
% NN N
vs. FW N
21.8 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
usual JJ i
care NN i
plus CC i
written VBN i
education NN i
, , i
pharmaceutical JJ i
care NN i
focused VBN i
on IN i
patient JJ i
evaluation NN i
and CC i
follow-up NN i
in IN i
collaboration NN i
with IN i
physicians NNS i
improved VBN N
the DT N
achievement NN N
of IN N
BP NNP o
, , o
TC NNP o
, , o
and CC o
BP/TC NNP o
treatment NN N
goals NNS N
in IN N
patients NNS p
with IN p
CVD NNP p
and/or VBP p
high JJ p
or CC p
intermediate JJ p
CV NNP p
risk NN p
attending VBG p
community NN p
pharmacies NNS p
in IN p
Spain NNP p
. . p

-DOCSTART- -X- O O

Argatroban NNP i
for IN N
elective JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
: : N
the DT N
ARG-E04 NNP N
multi-center NN N
study NN N
. . N

UNLABELLED IN N
The DT N
synthetic JJ N
arginine-derived JJ N
direct JJ N
thrombin NN N
inhibitor NN N
argatroban NN i
is VBZ N
an DT N
attractive JJ N
anticoagulant NN N
for IN N
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
, , N
because IN N
of IN N
its PRP$ N
rapid JJ N
onset NN N
and CC N
offset NN N
, , N
and CC N
its PRP$ N
hepatic JJ N
elimination NN N
. . N

Argatroban NNP i
was VBD N
approved VBN N
for IN N
PCI NNP N
in IN N
patients NNS p
with IN p
heparin-induced JJ p
thrombocytopenia NN p
( ( p
HIT NNP p
) ) p
. . p

However RB N
, , N
there EX N
are VBP N
limited VBN N
data NNS N
about IN N
argatroban NN i
in IN N
non-HIT JJ N
patients NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
open-label JJ N
, , N
multiple-dose JJ N
, , N
controlled VBD N
study NN N
was VBD N
to TO N
examine VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
argatroban NN i
in IN N
patients NNS p
undergoing VBG p
elective JJ p
PCI NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Of IN N
140 CD p
patients NNS p
randomized VBN N
to TO N
three CD N
argatroban NNS i
dose JJ N
groups NNS N
( ( i
ARG250 NNP i
, , i
ARG300 NNP i
, , N
and CC N
ARG350 NNP i
with IN N
250 CD N
, , N
300 CD N
, , N
or CC N
350 CD N
?g/kg JJ N
bolus NN N
, , N
followed VBN N
by IN N
15 CD N
, , N
20 CD N
, , N
or CC N
25 CD N
?g/kg/min JJ N
infusion NN N
) ) N
and CC N
one CD i
unfractionated JJ i
heparin NN i
( ( i
UFH NNP i
) ) i
group NN i
( ( N
70-100 JJ N
IU/kg NNP N
bolus NN p
) ) p
, , p
138 CD p
patients NNS p
were VBD p
analyzed VBN i
. . i

Argatroban NNP i
dose-dependently RB i
prolonged VBD o
activated VBN o
clotting NN o
time NN o
( ( o
ACT NNP o
) ) o
with IN o
more JJR N
patients NNS N
reaching VBG N
the DT N
minimum NN N
target NN o
ACT NNP o
after IN o
the DT N
initial JJ N
bolus NN N
injection NN i
( ( i
ARG250 NNP i
: : i
86.1 CD i
% NN i
, , i
ARG300 NNP i
: : i
89.5 CD i
% NN N
, , N
and CC i
ARG350 NNP i
: : i
96.8 CD i
% NN N
) ) N
compared VBN N
to TO N
45.5 CD N
% NN N
in IN N
UFH NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
patient JJ o
proportion NN o
who WP o
did VBD o
not RB o
require VB o
additional JJ o
bolus NN o
injections NNS o
to TO o
start VB N
PCI NNP N
was VBD N
significantly RB N
higher JJR N
in IN N
argatroban NN i
than IN i
in IN N
UFH NNP i
( ( i
p VB N
? . N
0.002 CD N
) ) N
. . N

Consequently RB o
, , o
the DT o
time NN o
to TO o
start VB o
of IN o
PCI NNP o
was VBD N
shortened VBN i
in IN i
argatroban JJ i
groups NNS i
. . N

Composite NNP o
incidences NNS o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
and CC o
urgent JJ o
revascularization NN o
until IN o
day NN N
30 CD N
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS i
( ( i
ARG250 NNP i
: : i
2.8 CD i
% NN i
, , i
ARG300 NNP i
: : i
0.0 CD i
% NN i
, , i
ARG350 NNP i
: : i
3.2 CD i
% NN N
vs. FW N
UFH NNP i
: : N
3.0 CD N
% NN N
) ) o
. . o

Major JJ o
bleeding NN o
was VBD o
observed VBN N
only RB N
in IN i
UFH NNP i
( ( N
3.0 CD N
% NN N
) ) N
, , N
while IN o
minor JJ o
bleeding NN o
occurred VBD o
in IN i
ARG350 NNP i
( ( i
3.2 CD i
% NN N
) ) N
and CC N
UFH NNP i
( ( N
6.1 CD N
% NN N
, , N
n.s. NN N
) ) N
. . N

CONCLUSION NNP i
Argatroban NNP i
dose-dependently JJ i
increases NNS o
coagulation NN o
parameters NNS o
and CC o
, , N
compared VBN i
to TO i
UFH NNP i
, , N
demonstrates VBZ N
a DT N
superior JJ N
predictable JJ o
anticoagulant JJ o
effect NN o
in IN o
patients NNS p
undergoing VBG i
elective JJ i
PCI NNP i
. . p

-DOCSTART- -X- O O

Environmental JJ i
enrichment NN i
as IN N
a DT N
therapy NN N
for IN N
autism NN p
: : p
A DT N
clinical JJ N
trial NN N
replication NN N
and CC N
extension NN N
. . N

Based VBN N
on IN N
work NN N
done VBN N
in IN N
animal NN N
models NNS N
showing VBG N
that IN N
autism-like JJ N
symptoms NNS N
are VBP N
ameliorated VBN N
following JJ N
exposure NN N
to TO N
an DT N
enriched JJ i
sensorimotor NN i
environment NN i
, , N
we PRP N
attempted VBD N
to TO N
develop VB N
a DT N
comparable JJ N
therapy NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

In IN N
an DT N
initial JJ N
randomized NN N
controlled VBD N
trial NN N
, , N
children NNS p
with IN p
autism NN p
who WP p
received VBD p
sensorimotor NN i
enrichment NN i
at IN i
home NN i
for IN p
6 CD p
months NNS p
had VBD p
significant JJ p
improvements NNS p
in IN p
both DT p
their PRP$ p
cognitive NN p
ability NN p
and CC p
the DT p
severity NN p
of IN p
their PRP$ p
autism NN p
symptoms NNS p
( ( N
Woo NNP N
& CC N
Leon NNP N
, , N
2013 CD N
) ) N
. . N

We PRP N
now RB N
report VBP N
the DT N
outcomes NNS N
of IN N
a DT N
similar JJ N
randomized NN N
controlled VBD N
trial NN N
in IN N
which WDT N
children NNS p
with IN p
autism NN p
, , p
3 CD p
to TO p
6 CD p
years NNS p
old JJ p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO N
groups NNS i
that WDT i
received VBD i
either DT i
daily JJ i
sensorimotor NN i
enrichment NN i
, , i
administered VBN i
by IN i
their PRP$ i
parents NNS i
, , i
along IN i
with IN i
standard JJ i
care NN i
, , i
or CC i
they PRP i
received VBD i
standard JJ i
care NN i
alone RB i
. . i

After IN N
6 CD N
months NNS N
, , N
enriched VBD N
children NNS N
showed VBD N
statistically RB N
significant JJ N
gains NNS N
in IN N
their PRP$ N
IQ NNP o
scores NNS o
, , N
a DT N
decline NN N
in IN N
their PRP$ N
atypical JJ o
sensory NN o
responses NNS o
, , N
and CC N
an DT N
improvement NN N
in IN N
their PRP$ N
receptive JJ o
language NN o
performance NN o
, , N
compared VBN N
to TO N
controls NNS N
. . N

Furthermore NNP N
, , N
after IN N
6 CD N
months NNS N
of IN N
enrichment JJ N
therapy NN N
, , N
21 CD N
% NN N
of IN N
the DT N
children NNS N
who WP N
initially RB N
had VBD N
been VBN N
given VBN N
an DT N
autism NN N
classification NN N
, , N
using VBG N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
improved VBN N
to TO N
the DT N
point NN N
that IN N
, , N
although IN N
they PRP N
remained VBD N
on IN N
the DT N
autism NN N
spectrum NN N
, , N
they PRP N
no RB N
longer RBR N
met VBD N
the DT N
criteria NNS N
for IN N
classic JJ N
autism NN N
. . N

None NN N
of IN N
the DT N
standard NN N
care NN N
controls VBZ N
reached VBD N
an DT N
equivalent JJ N
level NN N
of IN N
improvement NN N
. . N

Finally RB N
, , N
the DT N
outcome NN o
measures NNS o
for IN N
children NNS N
who WP N
received VBD N
only RB N
a DT N
subset NN N
of IN N
sensory JJ N
stimuli NNS N
were VBD N
similar JJ N
to TO N
those DT N
receiving VBG N
the DT N
full JJ N
complement NN N
of IN N
enrichment NN N
exercises NNS N
. . N

Sensorimotor NNP N
enrichment JJ N
therapy NN N
therefore RB N
appears VBZ N
to TO N
be VB N
a DT N
cost-effective JJ o
means NNS N
of IN N
treating VBG N
a DT N
range NN N
of IN N
symptoms NNS N
for IN N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

The DT N
lunar JJ i
stent NN i
characteristics NNS N
and CC N
clinical JJ N
results NNS N
. . N

One CD N
of IN N
the DT N
frequent JJ N
long-term JJ N
complications NNS N
after IN N
stent JJ i
implantation NN i
is VBZ N
restenosis JJ N
due JJ N
to TO N
the DT N
building NN N
up IN N
of IN N
a DT N
neointima NN N
within IN N
the DT N
artery NN N
, , N
as RB N
well RB N
as IN N
endovascular JJ N
hyperplasia NN N
( ( N
tissue VB N
growth NN N
) ) N
. . N

The DT N
interesting JJ N
feature NN N
of IN N
the DT N
Lunar NNP i
stent NN i
from IN i
Inflow NNP i
Dynamics NNP i
is VBZ N
that IN N
it PRP N
is VBZ N
coated VBN N
with IN N
a DT N
layer NN N
of IN N
iridium NN N
oxide NN N
. . N

The DT N
iridium NN i
oxide IN i
coating NN N
is VBZ N
believed VBN N
to TO N
reduce VB N
restenosis NN o
by IN N
decreasing VBG N
the DT N
inflammatory JJ o
response NN o
to TO N
the DT N
stent NN N
via IN N
its PRP$ N
antioxidant JJ N
action NN N
. . N

The DT N
MOONLIGHT NNP p
( ( p
Multicenter NNP p
Objective NNP p
ObservatioNal NNP p
Lunar NNP i
Iridiumoxide NNP i
intimal JJ p
GrowtH NNP p
Trial NNP p
) ) p
study NN p
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
immediate JJ N
outcome NN N
and CC N
long-term JJ N
angiographic JJ N
success NN N
after IN N
implantation NN i
of IN i
Lunar NNP i
stents NNS i
. . i

Between IN p
March NNP p
2001 CD p
and CC p
November NNP p
2001 CD p
, , p
87 CD p
patients NNS p
with IN p
99 CD p
lesions NNS p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
and CC N
were VBD N
treated VBN N
with IN N
12 CD N
and CC N
16 CD N
mm NNS N
long JJ N
iridium-oxide JJ i
coated VBN i
Lunar NNP i
stents NNS i
. . i

Delivery NN N
of IN N
the DT N
Lunar NNP i
stent NN i
was VBD N
successful JJ N
in IN N
most JJS N
lesions NNS N
and CC N
the DT N
optimal JJ N
radiopacity NN N
facilitated VBN N
optimal JJ N
stent NN o
positioning VBG o
with IN N
optimal JJ N
immediate JJ N
clinical JJ N
and CC N
angiographic JJ N
results NNS N
is VBZ N
an DT N
unselected JJ N
patient NN N
and CC N
lesion NN N
population NN N
. . N

Preliminary JJ N
clinical JJ N
and CC N
angiographic JJ N
follow-up JJ N
show NN N
a DT N
low JJ N
rate NN o
of IN o
cardiac JJ o
events NNS o
at IN N
6 CD N
months NNS N
( ( N
16.1 CD N
% NN N
MACE NNP N
) ) N
and CC N
a DT N
moderate JJ N
hyperplastic JJ o
response NN o
. . o

-DOCSTART- -X- O O

Probiotics NNS i
prevent VBP N
IgE-associated JJ N
allergy NN N
until IN N
age NN N
5 CD N
years NNS N
in IN p
cesarean-delivered JJ p
children NNS p
but CC N
not RB N
in IN N
the DT N
total JJ N
cohort NN N
. . N

BACKGROUND NNP N
Less NNP N
microbial JJ N
exposure NN N
in IN N
early JJ N
childhood NN N
is VBZ N
associated VBN N
with IN N
more RBR N
allergic JJ N
disease NN N
later RB N
. . N

Allergic NNP p
children NNS p
have VBP N
a DT N
different JJ N
fecal JJ N
microflora NN N
, , N
with IN N
less JJR N
lactobacilli NN N
and CC N
bifidobacteria NN N
. . N

Beneficial JJ N
effects NNS N
regarding VBG N
the DT N
development NN N
of IN N
allergy NNS N
have VBP N
been VBN N
suggested VBN N
to TO N
come VB N
through IN N
probiotic JJ N
supplementation NN N
. . N

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
study VB N
the DT N
effect NN N
of IN N
probiotic JJ i
and CC i
prebiotic JJ i
supplementation NN i
in IN N
preventing VBG N
allergies NNS N
. . N

METHODS NNP N
In IN N
a DT N
double-blinded JJ N
, , N
placebo-controlled JJ i
study NN N
we PRP N
randomized VBD N
1223 CD p
mothers NNS p
with IN p
infants NNS p
at IN p
high JJ p
risk NN p
for IN p
allergy NN p
to TO N
receive VB N
a DT N
probiotic JJ i
mixture NN i
( ( i
2 CD i
lactobacilli NN i
, , i
bifidobacteria NN i
, , i
and CC i
propionibacteria NN i
) ) i
or CC i
placebo NN i
during IN N
the DT N
last JJ p
month NN p
of IN p
pregnancy NN p
and CC p
their PRP$ p
infants NNS p
to TO p
receive VB p
it PRP p
from IN p
birth NN p
until IN p
age NN p
6 CD p
months NNS p
. . p

Infants NNS N
also RB N
received VBD N
a DT N
prebiotic JJ i
galacto-oligosaccharide NN i
or CC i
placebo NN i
. . i

At IN N
5 CD N
years NNS N
, , N
we PRP N
evaluated VBD N
the DT N
cumulative JJ N
incidence NN N
of IN N
allergic JJ o
diseases NNS o
( ( o
eczema NN o
, , o
food NN o
allergy NN o
, , o
allergic JJ o
rhinitis NN o
, , o
and CC o
asthma NN o
) ) o
and CC o
IgE NNP o
sensitization NN o
. . o

RESULTS NNP N
Of IN p
the DT p
1018 CD p
intent-to-treat NN p
infants NNS p
, , p
891 CD p
( ( p
88 CD p
% NN p
) ) p
attended VBD p
the DT p
5-year JJ p
visit NN p
. . p

Frequencies NNS o
of IN o
allergic JJ o
and CC o
IgE-associated JJ o
allergic JJ o
disease NN o
and CC N
sensitization NN o
in IN N
the DT N
probiotic JJ i
and CC N
placebo JJ i
groups NNS N
were VBD N
similar JJ N
: : N
52.6 CD N
% NN N
versus IN N
54.9 CD N
% NN N
and CC N
29.5 CD N
% NN N
versus IN N
26.6 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
41.3 CD N
% NN N
in IN N
both DT N
. . N

No DT N
significant JJ N
difference NN N
appeared VBD N
in IN N
frequencies NNS o
of IN o
eczema NN o
( ( N
39.3 CD N
% NN N
vs JJ N
43.3 CD N
% NN N
) ) N
, , N
atopic JJ o
eczema NN o
( ( N
24.0 CD N
% NN N
vs JJ N
25.1 CD N
% NN N
) ) N
, , N
allergic JJ o
rhinitis NN o
( ( N
20.7 CD N
% NN N
vs JJ N
19.1 CD N
% NN N
) ) N
, , N
or CC N
asthma NN o
( ( N
13.0 CD N
% NN N
vs JJ N
14.1 CD N
% NN N
) ) N
between IN N
groups NNS N
. . N

However RB N
, , N
less JJR N
IgE-associated JJ o
allergic JJ o
disease NN o
occurred VBD N
in IN N
cesarean-delivered JJ N
children NNS N
receiving VBG N
probiotics NNS i
( ( N
24.3 CD N
% NN N
vs JJ N
40.5 CD N
% NN N
; : N
odds NNS N
ratio VBP N
, , N
0.47 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.23 CD N
% NN N
to TO N
0.96 CD N
% NN N
; : N
P NNP N
= NNP N
.035 NNP N
) ) N
. . N

CONCLUSIONS NNP N
No NNP N
allergy-preventive JJ N
effect NN N
that WDT N
extended VBD N
to TO N
age NN N
5 CD N
years NNS N
was VBD N
achieved VBN N
with IN N
perinatal JJ N
supplementation NN N
of IN N
probiotic JJ i
bacteria NNS i
to TO N
high-risk JJ p
mothers NNS p
and CC p
children NNS p
. . p

It PRP N
conferred VBD N
protection NN N
only RB N
to TO N
cesarean-delivered JJ N
children NNS N
. . N

-DOCSTART- -X- O O

Assessment NN N
of IN N
global JJ o
functioning NN o
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
utility NN N
of IN N
the DT N
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
. . o

Assessment NN N
of IN N
global JJ o
functioning NN o
is VBZ N
an DT N
important JJ N
consideration NN N
in IN N
treatment NN N
outcome NN N
research NN N
; : N
yet RB N
, , N
there EX N
is VBZ N
little JJ N
guidance NN N
on IN N
its PRP$ N
evidence-based JJ N
assessment NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
utility NN N
and CC N
validity NN N
of IN N
clinician-rated JJ N
global JJ o
functioning NN o
using VBG N
the DT N
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
in IN N
a DT N
sample NN p
of IN p
higher JJR p
functioning NN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
comorbid NN p
anxiety NN p
disorders NNS p
enrolled VBD p
in IN p
a DT p
randomized NN p
controlled VBN i
trial NN p
( ( p
n JJ p
= NNP p
30 CD p
) ) p
. . p

Pretreatment JJ N
Developmental JJ o
Disability-Child JJ o
Global NNP o
Assessment NNP o
Scale NNP o
scores NNS N
correlated VBD N
with IN N
severity NN N
of IN N
autism NN N
spectrum NN N
disorders NNS N
core VBP N
symptoms NNS N
( ( N
r VB N
= NNP N
-.388 NNP N
, , N
p NN N
= NNP N
.034 NNP N
) ) N
, , N
pragmatic JJ N
communication NN N
( ( N
r JJ N
= NNP N
.407 NNP N
, , N
p NN N
= NNP N
.032 NNP N
) ) N
, , N
and CC N
verbal JJ N
ability NN N
( ( N
r JJ N
= NNP N
.449 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
and CC N
did VBD N
not RB N
correlate VB N
with IN N
severity NN N
of IN N
anxiety NN o
symptoms NNS o
or CC N
with IN N
parent-reported JJ N
adaptive JJ N
behavior NN N
. . N

Change NN o
in IN o
Developmental NNP o
Disability-Child NNP o
Global NNP o
Assessment NNP o
Scale NNP o
scores VBZ o
during IN N
treatment NN N
was VBD N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
symptomatic JJ o
improvement NN o
( ( N
r JJ N
= NNP N
.414 NNP N
, , N
p NN N
= NNP N
.040 NNP N
) ) N
and CC N
with IN N
improved JJ N
general JJ o
communication NN o
( ( N
r JJ N
= NNP N
.499 NNP N
, , N
p NN N
= NNP N
.013 NNP N
) ) N
. . N

Results JJ N
support NN N
the DT N
importance NN N
of IN N
assessing VBG N
global JJ o
functioning NN o
in IN N
addition NN N
to TO N
symptom VB o
change NN o
and CC N
treatment NN o
response NN o
in IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

Enhancing VBG N
the DT N
self-esteem NN o
of IN N
inpatient JJ p
alcoholics NNS p
. . p

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
pairing VBG N
inpatient JJ p
alcoholics NNS p
with IN p
nursing NN i
home NN i
residents NNS i
( ( i
NHRs NNP i
) ) i
on IN N
the DT N
alcoholics NNS o
' POS o
self-esteem NN o
. . o

In IN N
this DT N
PALS NNP N
program NN N
, , N
the DT N
alcoholic JJ N
inpatients NNS N
assumed VBD N
a DT N
helping-companion NN N
relationship NN N
with IN N
the DT N
NHRs NNP N
for IN N
2 CD N
hr NNS N
per IN N
day NN N
during IN N
their PRP$ N
last JJ N
2 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Fifty NNP p
alcoholic JJ p
inpatients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
the DT p
PALS NNP i
program NN i
( ( p
n JJ p
= NNP p
25 CD p
) ) p
or CC p
to TO p
the DT p
library NN i
for IN i
free JJ i
reading NN i
time NN i
( ( p
n JJ p
= NNP p
25 CD p
) ) p
. . p

The DT N
Tennessee NNP o
Self-Concept NNP o
Scale NNP o
( ( o
TSCS NNP o
) ) o
was VBD N
administered VBN N
to TO N
all DT N
subjects NNS N
in IN N
both DT N
groups NNS N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Of IN N
the DT N
nine CD N
TSCS NNP o
scales NNS o
, , N
the DT N
improvement NN N
on IN N
the DT N
Moral-Ethical JJ o
scale NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
PALS NNP N
group NN N
. . N

Because IN N
the DT N
alcoholic JJ N
inpatients NNS N
in IN N
the DT N
PALS NNP N
group NN N
engaged VBD N
in IN N
altruistic JJ o
( ( o
moral JJ o
) ) o
behavior NN o
, , N
this DT N
study NN N
provides VBZ N
a DT N
logical JJ N
link NN N
between IN N
the DT N
intervention NN N
and CC N
the DT N
outcome NN N
, , N
which WDT N
has VBZ N
been VBN N
a DT N
prevalent JJ N
weakness NN N
in IN N
previous JJ N
studies NNS N
of IN N
self-esteem NN N
in IN N
alcoholics NNS N
. . N

-DOCSTART- -X- O O

Clinical JJ N
Study NNP N
to TO N
Assess VB N
the DT N
Stain NNP o
Removal NNP o
Effectiveness NNP o
of IN N
a DT N
Tooth NNP i
Whitening NNP i
Regimen NNP i
with IN i
Added NNP i
Whitening NNP i
Booster NNP i
. . i

OBJECTIVE NNP N
This DT N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
extrinsic JJ o
stain NN o
reduction NN o
achieved VBN N
by IN N
brushing VBG N
with IN N
a DT N
whitening NN N
dentifrice NN N
and CC N
powered VBD N
toothbrush NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
a DT N
whitening NN N
booster NN N
paste NN N
to TO N
this DT N
regimen NNS N
would MD N
enhance VB N
its PRP$ N
stain NN o
reducing VBG o
effectiveness NN o
. . o

METHODS NNP N
Sixty NNP p
qualifying VBG p
subjects NNS p
were VBD p
randomly RB p
assigned VBN p
either RB N
to TO N
Regimen NNP N
One NNP N
, , N
a DT i
whitening NN i
dentifrice NN i
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
toothpaste NN N
] NN N
and CC N
powered VBD i
toothbrush NN i
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
Extra NNP N
Whitening NNP N
Spinbrush NNP N
) ) N
; : N
Regimen NNP N
Two CD N
, , N
the DT i
dentifrice NN i
and CC i
powered VBD i
toothbrush NN i
with IN i
the DT i
addition NN i
of IN i
a DT i
whitening JJ i
booster NN i
; : i
or CC N
Regimen NNP N
Three NNP N
, , N
a DT N
negative JJ i
control NN i
( ( i
Colgate NNP i
Cavity NNP i
Protection NNP i
toothpaste NN i
and CC i
an DT i
ADA NNP i
standard NN i
manual JJ i
brush NN i
) ) i
. . N

They PRP N
were VBD N
instructed VBN N
in IN N
the DT N
use NN N
of IN N
their PRP$ N
assigned VBN N
products NNS N
and CC N
then RB N
brushed VBD N
unsupervised JJ N
at IN N
home NN N
for IN N
two CD N
minutes NNS N
, , N
twice RB N
daily RB N
, , N
for IN N
14 CD N
days NNS N
. . N

Extrinsic JJ o
tooth NN o
stain NN N
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
and CC N
14 CD N
days NNS N
using VBG N
a DT N
Modified NNP o
Lobene NNP o
Stain NNP o
Index NNP o
( ( o
MLSI NNP o
) ) o
with IN N
Lobene NNP N
inclusion NN N
criteria NNS N
of IN N
? . N
1.5 CD N
. . N

RESULTS VB N
All DT N
three CD N
treatment NN N
groups NNS N
had VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.0001 CD o
) ) o
mean NN o
total JJ o
MLSI NNP o
reductions NNS o
from IN o
baseline NN N
at IN N
each DT N
time NN N
point NN N
, , N
in IN N
a DT N
time-dependent JJ N
manner NN N
. . N

Day NNP N
14 CD N
reductions NNS N
were VBD N
22.2 CD N
% NN N
for IN N
Colgate NNP N
Cavity NNP N
Protection NNP N
, , N
29.1 CD N
% NN N
for IN N
Regimen NNP N
One NNP N
, , N
and CC N
34.4 CD N
% NN N
for IN N
Regimen NNP N
Two CD o
. . o

Reductions NNS o
for IN o
Regimen NNP N
One CD N
and CC N
Regimen NNP N
Two CD N
were VBD N
significantly RB N
greater JJR N
compared VBN N
to TO N
Regimen NNP N
Three NNP N
, , N
the DT N
negative JJ N
control NN N
, , N
at IN N
each DT N
time NN N
period NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
those DT N
for IN N
Regimen NNP N
Two CD N
were VBD N
significantly RB N
greater JJR N
compared VBN N
to TO N
Regimen NNP N
One NNP N
on IN N
days NNS N
2 CD N
and CC N
14 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
and CC N
directionally RB N
more RBR N
effective JJ N
on IN N
day NN N
5 CD N
( ( N
p NN N
= RB N
0.0673 CD N
) ) N
. . N

CONCLUSION VB N
The DT i
combination NN i
of IN i
Truly NNP i
Radiant NNP i
toothpaste NN i
and CC i
Truly NNP i
Radiant NNP i
Spinbrush NNP i
provides VBZ o
safe JJ o
and CC o
effective JJ o
stain NN o
removal NN o
that WDT o
can MD N
be VB N
further RB N
enhanced VBN N
by IN N
the DT N
addition NN N
of IN N
the DT N
whitening NN N
booster NN N
. . N

-DOCSTART- -X- O O

Is VBZ N
periprostatic JJ N
local JJ N
anesthesia NN i
for IN N
transrectal JJ p
ultrasound NN p
guided VBD p
prostate NN p
biopsy NN p
associated VBN N
with IN N
increased JJ N
infectious JJ o
or CC o
hemorrhagic JJ o
complications NNS o
? . N
A DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

PURPOSE NNP N
Periprostatic NNP N
local JJ N
anesthesia NN N
for IN N
prostate NN N
biopsy NN N
requires VBZ N
2 CD N
or CC N
more JJR N
extra JJ N
needle JJ N
punctures NNS N
and CC N
injection NN N
of IN N
the DT N
local JJ N
anesthetic NN N
through IN N
the DT N
highly RB N
colonized JJ N
rectum NN N
. . N

To TO N
our PRP$ N
knowledge NN N
we PRP N
report VBP N
the DT N
first JJ N
prospective JJ N
randomized VBN N
trial NN N
to TO N
assess VB N
the DT N
infectious JJ o
or CC o
hemorrhagic JJ o
complications NNS o
associated VBN N
with IN N
this DT N
method NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP N
total NN N
of IN N
100 CD p
consecutive JJ p
patients NNS p
with IN p
sterile JJ p
urine JJ p
cultures NNS p
underwent JJ p
transrectal JJ i
ultrasound NN i
guided VBD i
prostate NN i
biopsy NN i
. . i

They PRP N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
periprostatic JJ i
nerve NN i
block NN i
or CC i
no DT i
anesthesia NN i
. . i

Patients NNS i
were VBD i
evaluated VBN i
for IN i
the DT i
amount NN o
of IN o
rectal NN o
and CC o
urethral JJ o
bleeding NN o
, , i
and CC i
symptoms NNS i
and CC i
signs NNS i
of IN i
infection NN o
after IN o
biopsy NN o
. . o

RESULTS VB N
The DT N
amount NN o
of IN o
urethral JJ o
bleeding NN o
was VBD N
slight JJ N
and CC N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
. . N

Rectal JJ o
bleeding NN o
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
patients NNS N
who WP N
received VBD N
anesthesia NN N
. . N

High JJ o
fever NN o
( ( N
greater JJR N
than IN N
37.8C CD N
) ) N
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
nerve NN N
block NN N
group NN N
and CC N
2 CD N
patients NNS N
in IN N
this DT N
group NN N
required VBD N
rehospitalization NN N
. . N

Bacteriuria NNP o
in IN o
post-biopsy JJ o
urine JJ o
cultures NNS o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
periprostatic JJ N
local JJ N
anesthesia NN i
for IN N
prostate JJ N
biopsy NN N
does VBZ N
not RB N
increase VB N
the DT N
risk NN N
of IN N
urethral JJ o
bleeding NN o
. . o

It PRP N
is VBZ N
associated VBN N
with IN N
a DT N
decreased JJ N
incidence NN N
of IN N
rectal JJ o
bleeding NN o
, , N
presumably RB N
due JJ N
to TO N
decreased JJ N
patient NN N
discomfort NN N
. . N

The DT N
incidence NN N
of IN N
bacteriuria NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
anesthesia NN N
group NN N
. . N

High NNP o
fever NN o
and CC o
hospitalization NN o
due JJ N
to TO N
infectious JJ N
complications NNS N
were VBD N
also RB N
more RBR N
common JJ N
in IN N
the DT N
local JJ N
anesthesia NN N
group NN N
, , N
although IN N
not RB N
statistically RB N
significant JJ N
. . N

Prospective JJ N
randomized JJ N
trials NNS N
seem VBP N
warranted VBN N
to TO N
determine VB N
the DT N
optimum JJ N
antibiotic JJ N
prophylaxis NN N
regimen NNS N
in IN N
patients NNS N
undergoing VBG N
biopsy NN N
with IN N
a DT N
periprostatic JJ N
nerve NN N
block NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
single-dose JJ N
cefixime NN i
with IN N
ceftriaxone NN i
as IN N
treatment NN N
for IN N
uncomplicated JJ o
gonorrhea NN o
. . o

The DT N
Gonorrhea NNP N
Treatment NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
Because IN N
of IN N
the DT N
widespread JJ N
existence NN N
of IN N
Neisseria NNP N
gonorrhoeae NN N
resistant NN N
to TO N
penicillin VB N
or CC N
tetracycline VB N
, , N
ceftriaxone NN N
is VBZ N
now RB N
recommended VBN N
for IN N
the DT N
treatment NN N
of IN N
gonorrhea NN o
. . o

There EX N
is VBZ N
, , N
however RB N
, , N
a DT N
need NN N
for IN N
effective JJ N
antibiotics NNS N
that WDT N
can MD N
be VB N
administered VBN N
orally RB N
as IN N
an DT N
alternative NN N
to TO N
ceftriaxone NN i
, , N
which WDT N
requires VBZ N
intramuscular JJ N
administration NN N
. . N

Cefixime NNP N
is VBZ N
an DT N
orally RB N
absorbed JJ N
cephalosporin NN N
that WDT N
is VBZ N
active JJ N
against IN N
resistant JJ N
gonococci NN N
and CC N
has VBZ N
pharmacokinetic JJ N
activity NN N
suitable JJ N
for IN N
single-dose JJ N
administration NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
a DT N
randomized JJ N
, , N
unblinded JJ p
multicenter NN p
study NN p
of IN p
209 CD p
men NNS p
and CC p
124 CD p
women NNS p
with IN p
uncomplicated JJ p
gonorrhea NN p
, , N
we PRP N
compared VBN N
three CD N
single-dose JJ N
treatment NN N
regimens NNS N
: : N
400 CD i
mg NN i
or CC i
800 CD i
mg NN i
of IN i
cefixime NN i
, , i
administered VBN i
orally RB i
, , i
and CC i
250 CD i
mg NN i
of IN i
ceftriaxone NN i
administered VBN N
intramuscularly RB N
. . N

The DT N
overall JJ o
cure NN o
rates NNS o
were VBD N
96 CD N
percent NN N
for IN N
the DT N
400-mg JJ N
dose NN N
of IN N
cefixime NN i
( ( N
89 CD N
of IN N
93 CD N
patients NNS N
) ) N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
93.5 CD N
percent NN N
to TO N
97.8 CD N
percent NN N
) ) N
; : N
98 CD N
percent NN N
for IN N
the DT N
800-mg JJ N
dose NN N
of IN N
cefixime NN i
( ( N
86 CD N
of IN N
88 CD N
patients NNS N
) ) N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
94.6 CD N
percent NN N
to TO N
100 CD N
percent NN N
) ) N
; : N
and CC N
98 CD N
percent NN N
for IN N
ceftriaxone NN i
( ( N
92 CD N
of IN N
94 CD N
patients NNS N
) ) N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
94.9 CD N
to TO N
100 CD N
percent NN N
) ) N
. . N

The DT N
cure NN o
rates NNS o
were VBD N
similar JJ N
in IN N
men NNS N
and CC N
women NNS N
, , N
and CC N
pharyngeal JJ o
infection NN o
was VBD N
eradicated VBN N
in IN N
20 CD N
of IN N
22 CD N
patients NNS N
( ( N
91 CD N
percent NN N
) ) N
. . N

Thirty-nine JJ N
percent NN N
of IN N
303 CD N
pretreatment JJ N
gonococcal JJ N
isolates NNS N
had VBD N
one CD N
or CC N
more JJR N
types NNS N
of IN N
antimicrobial JJ N
resistance NN N
; : N
the DT N
efficacy NN o
of IN N
all DT N
three CD N
regimens NNS N
was VBD N
independent JJ N
of IN N
the DT N
resistance NN N
pattern NN N
. . N

Chlamydia NNP o
trachomatis NN o
infection NN o
persisted VBN N
in IN N
at IN N
least JJS N
half PDT N
the DT N
patients NNS N
infected VBN N
in IN N
each DT N
treatment NN N
group NN N
. . N

All DT N
three CD N
regimens NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSIONS NNP N
In IN N
the DT N
treatment NN N
of IN N
uncomplicated JJ o
gonorrhea NN o
, , N
a DT N
single JJ N
dose NN N
of IN N
cefixime NN i
( ( N
400 CD N
or CC N
800 CD N
mg NN N
) ) N
given VBN N
orally RB N
appears VBZ N
to TO N
be VB N
as RB N
effective JJ o
as IN N
the DT N
currently RB N
recommended VBN N
regimen NNS N
of IN N
ceftriaxone NN i
( ( N
250 CD N
mg NN N
given VBN N
intramuscularly RB N
) ) N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Shenmen NNP i
point NN i
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ p
section NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
transcutaneous JJ N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNP N
point NN N
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
and CC N
patient-controlled JJ N
epidural JJ N
analgesia NN N
in IN N
cesarean JJ N
section NN N
. . N

METHODS NNP N
After IN N
IRB NNP N
approval NN N
and CC N
informed JJ N
consent NN N
, , N
one CD p
hundred CD p
and CC p
eighty VB p
singleton NN p
primiparas IN p
undergoing VBG p
elective JJ p
cesarean JJ p
section NN p
, , p
in IN p
Qingdao NNP p
Municipal NNP p
Hospital NNP p
, , p
and CC p
Qingdao NNP p
Hiser NNP p
Medical NNP p
Center NNP p
, , p
from IN p
November NNP p
2011 CD p
to TO p
March NNP p
2012 CD p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO N
three CD N
groups NNS N
: : N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Shenmen NNP i
point NN i
group NN i
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
, , N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN i
auricular JJ i
Eye NNP i
point NN i
group NN i
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
and CC N
control NN i
group NN i
( ( N
group NN N
C NNP N
, , N
n JJ N
= NNP N
60 CD N
) ) N
. . N

Women NNP N
of IN N
group NN N
A NNP N
received VBD N
transcutaneous JJ i
electrical JJ i
stimulation NN i
of IN N
auricular JJ N
Shenmen NNP N
point NN N
( ( N
frequency NN N
1.5 CD N
HZ NNP N
) ) N
at IN N
the DT N
time NN N
of IN N
preoperation NN N
, , N
4 CD N
, , N
10 CD N
and CC N
22 CD N
hours NNS N
of IN N
postoperation NN N
for IN N
30 CD N
minutes NNS N
. . N

The DT N
strength NN N
was VBD N
controlled VBN N
by IN N
themselves PRP N
. . N

Women NNP N
of IN N
group NN N
B NNP N
received VBD N
stimulation NN N
of IN N
auricular JJ N
Eye NNP N
point NN N
as IN N
group NN N
A NNP N
. . N

Women NNP N
of IN N
group NN N
C NNP N
received VBD N
pressurization NN i
and CC i
connected VBN i
line NN i
were VBD i
the DT i
same JJ i
with IN i
group NN i
A NNP i
, , i
but CC i
without IN i
electrical JJ i
stimulation NN i
. . i

The DT N
following JJ N
indexes NNS N
was VBD N
observed VBN N
: : N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
for IN N
48 CD N
hours NNS N
; : N
the DT N
rate NN N
of IN N
metoclopramide NN N
; : N
the DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
score NN o
of IN o
rest NN o
pain NN o
, , o
uterine JJ o
contration NN o
pain NN o
and CC o
dynamic JJ o
pain NN o
at IN o
the DT o
time NN o
of IN o
postoperation NN o
for IN o
6 CD o
, , o
12 CD o
, , o
24 CD o
and CC o
48 CD o
hours NNS o
( ( o
T NNP o
( ( o
1 CD o
) ) o
-T NN o
( ( o
4 CD o
) ) o
) ) o
; : o
the DT o
total JJ o
number NN o
and CC o
effective JJ o
compressions NNS o
number NN o
of IN o
patient-controlled JJ o
epidural JJ o
analgesia NN o
( ( o
PCEA NNP o
) ) o
; : o
the DT o
dose NN o
of IN o
analgesia JJ o
mixture NN o
; : o
the DT o
anal JJ o
exhaust JJ o
time NN o
; : o
the DT o
volume NN o
of IN o
postoperative JJ o
bleeding NN o
for IN o
6 CD o
hours NNS o
of IN o
postoperation NN o
and CC o
the DT o
other JJ o
side NN o
effects NNS o
. . o

RESULTS NNP N
Compared NNP N
with IN N
group NN N
B NNP N
and CC N
group NN N
C NNP N
, , N
the DT N
incidence NN o
of IN o
PONV NNP o
, , o
the DT o
rate NN o
of IN o
metoclopramide NN o
, , o
the DT o
VAS NNP o
score NN o
at IN N
the DT N
time NN N
T NNP N
( ( N
1 CD N
) ) N
-T NN N
( ( N
4 CD N
) ) N
, , N
the DT N
total JJ o
number NN o
and CC o
effective JJ o
compressions NNS o
number NN o
of IN o
PCEA NNP o
, , o
the DT o
ratio NN o
of IN o
the DT o
total JJ o
number NN o
with IN o
effective JJ o
compressions NNS o
number NN o
and CC o
the DT o
dose NN o
of IN o
analgesia JJ o
mixture NN o
were VBD N
decreased VBN N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
no DT N
difference NN N
compared VBN N
group NN N
B NNP N
with IN N
group NN N
C NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
anal JJ o
exhaust NN o
time NN o
and CC o
the DT o
volume NN o
of IN o
postoperative JJ o
bleeding NN o
for IN N
6 CD N
hours NNS N
of IN N
postoperation NN N
were VBD N
no DT N
difference NN N
in IN N
the DT N
three CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

No UH N
other JJ N
side NN o
effects NNS o
were VBD N
observed VBN N
. . N

CONCLUSION NNP N
Transcutaneous NNP N
electrical JJ N
stimulation NN N
of IN N
auricular JJ N
Shenmen NNS N
point NN N
can MD N
reduce VB N
the DT N
incidence NN o
of IN o
PONV NNP o
and CC o
improves VBZ o
analgesia JJ o
effect NN o
of IN o
PCEA NNP o
in IN o
postoperation NN o
of IN o
cesarean JJ o
section NN o
. . o

-DOCSTART- -X- O O

Randomized VBN N
controlled VBD N
trial NN N
to TO N
compare VB N
the DT N
dose NN N
of IN N
adjuvant JJ i
chemotherapy NN i
after IN N
curative JJ i
resection NN i
of IN N
hepatocellular JJ p
carcinoma NN p
. . p

BACKGROUND NNP N
AND NNP N
AIM NNP N
Adjuvant NNP i
locoregional JJ i
chemotherapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
useful JJ N
to TO N
prevent VB N
recurrence NN N
after IN N
curative JJ N
resection NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
in IN N
some DT N
retrospective JJ N
studies NNS N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
dose JJ N
effect NN N
in IN N
the DT N
prevention NN N
of IN N
tumor NN N
recurrence NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS p
with IN p
curative JJ p
resection NN p
of IN p
HCC NNP p
; : p
they PRP N
were VBD N
given VBN N
either DT N
one CD N
intra-arterial JJ N
dose NN N
of IN N
cisplatin/lipiodol NN i
, , N
or CC N
received VBD N
four CD N
doses NNS N
, , N
once RB N
every DT N
3 CD N
months NNS N
. . N

The DT N
rates NNS o
of IN o
recurrence NN o
, , o
disease-free JJ o
and CC o
overall JJ o
survival NN o
were VBD N
compared VBN N
. . N

RESULTS NNP N
During IN N
a DT N
median JJ N
follow NN N
up IN N
of IN N
818 CD p
days NNS p
, , p
21 CD p
patients NNS p
received VBD p
one CD p
dose NN p
and CC p
19 CD p
received VBD p
four CD p
doses NNS p
, , p
with IN p
10 CD p
( ( p
47.6 CD p
% NN p
) ) p
and CC p
eight CD p
( ( p
42.1 CD p
% NN p
) ) p
recurrences NNS p
, , p
respectively RB p
. . p

The DT N
1-year JJ o
, , o
2-year JJ o
and CC o
3-year JJ o
disease-free JJ o
survival NN o
rates NNS o
were VBD N
71 CD N
% NN N
, , N
54 CD N
% NN N
and CC N
44 CD N
% NN N
for IN N
the DT N
one-dose JJ N
group NN N
and CC N
74 CD N
% NN N
, , N
60 CD N
% NN N
and CC N
40 CD N
% NN N
for IN N
the DT N
four-dose JJ N
group NN N
( ( N
P NNP N
= NNP N
0.78 CD N
) ) N
. . N

The DT N
respective JJ o
overall JJ o
survival NN o
rates NNS o
were VBD N
85 CD N
% NN N
, , N
74 CD N
% NN N
, , N
55 CD N
% NN N
and CC N
84 CD N
% NN N
, , N
71 CD N
% NN N
, , N
40 CD N
% NN N
( ( N
P NNP N
= NNP N
0.64 CD N
) ) N
. . N

The DT N
only JJ N
prognostic JJ N
factor NN N
was VBD N
presence NN o
of IN o
vascular JJ o
permeation NN o
. . o

The DT N
side-effects NNS o
were VBD N
mild JJ o
and CC o
tolerable JJ o
. . o

CONCLUSIONS NNP N
There EX N
is VBZ N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
survival NN o
rates NNS o
between IN N
the DT N
two CD p
groups NNS p
. . p

Adjuvant NNP i
chemotherapy NN i
may MD N
not RB N
be VB N
useful JJ N
. . N

-DOCSTART- -X- O O

The DT N
efficacy NN N
of IN N
audiotapes NNS i
in IN N
promoting VBG o
psychological JJ o
well-being NN o
in IN N
cancer NN p
patients NNS p
: : p
a DT N
randomised JJ N
, , N
controlled JJ N
trial NN N
. . N

Open VB N
or CC N
uncontrolled JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
providing VBG N
cancer NN p
patients NNS p
with IN N
audiotapes NNS i
of IN N
their PRP$ N
clinical JJ N
interviews NNS N
can MD N
improve VB N
information NN o
recall NN o
and CC N
reduce VB N
psychological JJ o
distress NN o
. . o

We PRP N
tested VBD N
these DT N
hypotheses NNS N
in IN N
a DT N
'clinician-blind JJ N
' '' N
, , N
prospective JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
. . N

A DT p
total NN p
of IN p
117 CD p
patients NNS p
newly RB p
referred VBN p
to TO p
a DT p
medical JJ p
oncology NN p
clinic NN p
who WP p
were VBD p
to TO p
be VB p
given VBN p
'bad CD p
news NN p
' POS p
had VBD N
their PRP$ N
consultations NNS N
audiotaped VBN i
. . i

Blind NNP N
to TO N
the DT N
clinician JJ N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
a DT N
copy NN i
of IN i
the DT i
tape NN i
to TO i
play VB i
at IN i
home NN i
or CC i
not RB i
( ( i
control VB i
group NN i
) ) i
. . i

At IN N
6 CD N
months NNS N
follow-up JJ N
, , N
tape NN N
group NN N
patients NNS N
reported VBD N
positive JJ o
attitudes NNS o
to TO N
the DT N
audiotape NN i
and CC N
were VBD N
shown VBN N
to TO N
recall VB o
significantly RB o
more JJR o
information NN o
about IN o
their PRP$ o
illness NN o
than IN N
did VBD N
controls NNS N
. . N

Overall JJ N
improvement NN N
in IN N
psychological JJ o
distress NN o
at IN N
1 CD N
and CC N
6 CD N
months NNS N
follow-up RB N
, , N
as IN N
measured VBN N
with IN N
the DT N
30-item JJ o
General NNP o
Health NNP o
Questionnaire NNP o
and CC o
the DT o
Hospital NNP o
Anxiety NNP o
and CC o
Depression NNP o
Scale NNP o
was VBD N
no DT N
different JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

However RB N
, , N
a DT N
second-order JJ N
interaction NN N
suggested VBD N
that IN N
poor-prognosis NN N
patients NNS N
were VBD N
disadvantaged VBN N
specifically RB N
by IN N
access NN N
to TO N
the DT N
audiotape NN N
, , N
with IN N
less JJR N
improvement NN N
in IN N
psychological JJ o
distress NN o
at IN N
6 CD N
months NNS N
follow-up JJ N
than IN N
non-tape JJ N
controls NNS N
. . N

Patient JJ N
access NN N
to TO N
audiotapes NNS i
of IN N
clinical JJ N
interviews NNS N
promotes VBZ N
factual JJ o
retention NN o
but CC N
does VBZ N
not RB N
reliably RB N
reduce VB N
psychological JJ o
distress NN o
and CC N
may MD N
be VB N
actively RB N
unhelpful JJ N
in IN N
some DT N
subgroups NNS N
of IN N
patients NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomised JJ N
comparison NN N
of IN N
three CD N
drainage NN N
systems NNS N
following VBG p
cholecystectomy NN p
. . p

The DT N
efficacy NN o
of IN N
low JJ i
pressure NN i
, , i
high JJ i
pressure NN i
and CC i
passive JJ i
drainage NN i
systems NNS i
have VBP N
been VBN N
compared VBN N
after IN p
cholecystectomy NN p
. . p

Symptoms NNS o
of IN o
pain NN o
, , o
discomfort NN o
and CC o
nausea NN o
were VBD N
compared VBN N
using VBG N
linear JJ N
analogue NN N
scales NNS N
and CC N
spirometry NN N
was VBD N
used VBN N
to TO N
examine VB N
pre-operative JJ N
and CC N
postoperative JJ N
respiratory NN o
function NN o
. . o

The DT N
low JJ i
pressure NN i
suction NN i
drain NN i
removed VBD N
an DT N
intraperitoneal NN o
marker NN o
, , o
gentamicin NN o
, , N
more RBR N
effectively RB N
than IN N
the DT N
high JJ i
pressure NN i
suction NN i
drain NN i
, , N
but CC N
not RB N
more RBR N
effectively RB N
than IN N
the DT N
passive JJ i
drain NN i
. . i

There EX N
were VBD N
no DT N
differences NNS N
in IN N
postoperative JJ o
respiratory NN o
function NN o
nor CC N
in IN N
the DT N
amount NN o
of IN o
pain NN o
or CC o
discomfort NN o
between IN N
the DT N
groups NNS N
. . N

The DT N
passive JJ N
drain NN N
group NN N
reported VBD N
less JJR N
nausea NN o
than IN N
the DT N
suction NN N
drain NN N
groups NNS N
. . N

If IN N
a DT N
negative JJ N
pressure NN N
drainage NN N
system NN N
is VBZ N
to TO N
be VB N
used VBN N
, , N
a DT N
low JJ N
pressure NN N
suction NN N
drain NN N
should MD N
be VB N
used VBN N
in IN N
preference NN N
to TO N
a DT N
high JJ N
pressure NN N
system NN N
. . N

-DOCSTART- -X- O O

The DT N
cost-effectiveness NN o
of IN N
parasitologic JJ N
diagnosis NN N
for IN N
malaria-suspected JJ p
patients NNS p
in IN N
an DT N
era NN N
of IN N
combination NN N
therapy NN N
. . N

The DT N
introduction NN N
of IN N
artemisinin-based JJ i
combination NN i
therapy NN i
in IN N
sub-Saharan NN p
Africa NNP p
has VBZ N
prompted VBN N
calls NNS N
for IN N
increased VBN N
use NN N
of IN N
parasitologic JJ N
diagnosis NN N
for IN N
malaria NN N
. . N

We PRP N
evaluated VBD N
the DT N
cost-effectiveness NN o
of IN N
rapid JJ i
diagnostic JJ i
tests NNS i
( ( i
RDTs NNP i
) ) i
in IN N
comparison NN N
to TO N
microscopy VB i
in IN N
guiding VBG N
treatment NN N
of IN N
non-severe JJ N
febrile JJ N
illness NN N
at IN N
varying VBG N
levels NNS N
of IN N
malaria NN N
endemicity NN N
using VBG N
data NNS N
on IN N
test NN N
accuracy NN N
and CC N
costs NNS o
collected VBN N
as IN N
part NN N
of IN N
a DT N
Tanzanian JJ p
trial NN p
. . p

If IN N
prescribers NNS N
complied VBD N
with IN N
current JJ N
guidelines NNS N
, , N
microscopy NN N
would MD N
give VB N
rise NN N
to TO N
lower JJR N
average NN N
costs NNS o
per IN N
patient NN N
correctly RB N
treated VBD N
than IN N
RDTs NNP i
in IN N
areas NNS N
of IN N
both DT N
high JJ N
and CC N
low JJ N
transmission NN N
. . N

RDT NNP N
introduction NN N
would MD N
result VB N
in IN N
an DT N
additional JJ N
2.3 CD N
% NN N
and CC N
9.4 CD o
% NN o
of IN o
patients NNS o
correctly RB o
treated VBN o
, , N
at IN N
an DT N
incremental JJ o
cost NN o
of IN N
$ $ N
25 CD N
and CC N
$ $ N
7 CD N
in IN N
the DT N
low JJ N
and CC N
high JJ N
transmission NN N
settings NNS N
, , N
respectively RB N
. . N

Cost-effectiveness NNP o
would MD N
be VB N
worse JJR N
if IN N
prescribers NNS N
do VBP N
not RB N
comply VB N
with IN N
test NN N
results NNS N
. . N

The DT N
cost NN N
of IN N
this DT N
additional JJ N
benefit NN N
may MD N
be VB N
higher JJR N
than IN N
many JJ N
countries NNS N
can MD N
afford VB N
without IN N
external JJ N
assistance NN N
or CC N
lower JJR N
RDT NNP N
prices NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
hydraulic JJ N
circuit NN N
training NN N
on IN N
cardiovascular JJ p
function NN p
. . p

The DT N
effect NN N
of IN N
hydraulic JJ N
circuit NN N
training NN N
( ( N
HCT NNP N
) ) N
on IN N
cardiovascular NN o
( ( o
CV NNP o
) ) o
function NN o
was VBD N
assessed VBN N
in IN N
32 CD p
healthy JJ p
middle-aged JJ p
males NNS p
( ( p
X JJ p
age NN p
= VBD p
42.2 CD p
+/- JJ p
2.1 CD p
yr NN p
) ) p
. . p

Maximal NNP o
aerobic JJ o
power NN o
( ( o
VO2max NNP o
) ) o
, , o
with IN o
simultaneous JJ o
measurement NN o
of IN o
stroke NN o
volume NN o
( ( o
SV NNP o
) ) o
and CC o
cardiac JJ o
output NN o
( ( o
CO NNP o
) ) o
, , o
by IN o
impedance NN o
cardiography NN o
, , N
was VBD N
assessed VBN N
pre- JJ N
and CC N
post-training JJ N
. . N

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
nonexercising JJ i
control NN i
group NN i
, , i
a DT i
cycle NN i
training NN i
group NN i
( ( i
cycle NN i
) ) i
, , i
or CC i
one CD i
of IN i
the DT i
two CD i
HCT NNP i
groups NNS i
. . i

Training VBG i
groups NNS i
participated VBN i
in IN i
a DT i
9 CD i
wk NN i
program NN i
, , i
3 CD i
d.wk-1 NN i
. . i

Subjects NNS i
assigned VBD i
to TO i
HCT NNP i
exercised VBN i
on IN i
a DT i
9 CD i
station NN i
circuit NN i
, , i
completing VBG i
3 CD i
circuits.d-1 JJ i
. . i

Each DT N
circuit NN N
consisted VBD N
of IN N
three CD N
20 CD N
s JJ N
work NN N
intervals NNS N
at IN N
each DT N
station NN N
with IN N
a DT N
1:1 CD N
work NN N
: : N
rest NN N
ratio NN N
. . N

One CD N
HCT NNP N
group NN N
( ( N
HCTmax NNP N
) ) N
completed VBD N
the DT N
maximal JJ N
repetitions NNS N
possible JJ N
( ( N
RM NNP N
) ) N
during IN N
each DT N
work NN N
interval NN N
. . N

The DT N
other JJ N
HCT NNP N
group NN N
( ( N
HCTsub NNP N
) ) N
exercised VBD N
at IN N
70-85 CD N
% NN N
of IN N
RM NNP N
. . N

Following VBG N
training NN N
VO2max NNP o
( ( o
ml.kg-1 JJ o
min-1 NN o
) ) o
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
training NN N
groups NNS N
( ( N
18.0 CD N
, , N
12.5 CD N
, , N
and CC N
11.3 CD N
% NN N
for IN N
cycle NN N
, , N
HCTsub NNP N
, , N
and CC N
HCTmax NNP o
groups NNS o
, , N
respectively RB N
; : N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
increase NN N
in IN N
VO2max NNP o
observed VBD N
in IN N
the DT N
cycle NN N
group NN N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
recorded VBN N
by IN N
the DT N
two CD N
HCT NNP N
groups NNS N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

For IN N
all DT N
three CD N
training VBG N
groups NNS N
, , N
the DT N
increase NN N
in IN N
VO2max NNP o
was VBD N
associated VBN N
with IN N
increases NNS N
in IN N
SVmax NNP o
and CC o
COmax NNP o
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
for IN N
both DT N
) ) N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
both DT N
maximal JJ N
and CC N
submaximal JJ N
HCT NNP N
programs NNS N
can MD N
elicit VB N
improvements NNS N
in IN N
cardiovascular JJ o
fitness NN o
. . o

-DOCSTART- -X- O O

Randomized VBN N
, , N
controlled VBD N
study NN N
of IN N
various JJ N
agents NNS N
for IN N
endoscopic NN N
injection NN N
sclerotherapy NN N
of IN N
bleeding VBG N
canine NN N
gastric JJ N
varices NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
relative JJ o
efficacy NN o
and CC o
technical JJ o
ease NN o
of IN o
use NN o
of IN N
eight CD N
different JJ N
agents NNS N
for IN N
endoscopic JJ N
hemostasis NN N
and CC N
obliteration NN N
of IN N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
a DT N
canine NN N
model NN N
, , N
as IN N
no DT N
comparative JJ N
data NNS N
are VBP N
available JJ N
on IN N
gastric JJ N
variceal NN N
sclerotherapy NN N
. . N

Large JJ N
bleeding VBG N
gastric JJ N
varices NNS N
in IN N
20 CD p
heparinized JJ p
dogs NNS p
were VBD N
randomized VBN i
to TO i
endoscopic VB i
injection NN i
treatment NN i
with IN i
one CD i
of IN i
the DT i
following JJ i
agents NNS i
: : i
cyanoacrylate NN i
; : i
a DT i
1:1:1 CD i
mixture NN i
of IN i
sodium NN i
tetradecyl NN i
sulfate VBP i
3 CD i
% NN i
, , i
ethanol RB i
98 CD i
% NN i
, , i
and CC i
normal JJ i
saline JJ i
solution NN i
; : i
ethanolamine VB i
oleate VBP i
5 CD i
% NN i
; : i
sodium NN i
morrhuate VBP i
5 CD i
% NN i
; : i
sodium NN i
tetradecyl NN i
sulfate VBP i
1.5 CD i
% NN i
; : i
polidocanol CC i
1 CD i
% NN i
; : i
normal JJ i
saline JJ i
solution NN i
with IN i
epinephrine JJ i
1:10,000 CD i
; : i
or CC i
normal JJ i
saline JJ i
solution NN i
( ( i
control NN i
) ) i
. . i

The DT N
number NN N
and CC N
volume NN N
of IN N
injections NNS N
and CC N
the DT N
time NN N
required VBN N
to TO N
achieve VB N
complete JJ N
hemostasis NN N
were VBD N
evaluated VBN N
; : N
follow-up JJ N
endoscopy NN N
was VBD N
performed VBN N
at IN N
1 CD N
month NN N
to TO N
assess VB N
gastric JJ N
variceal NN N
obliteration NN N
. . N

Cyanoacrylate NNP N
was VBD N
the DT N
best JJS N
agent NN N
overall JJ N
in IN N
terms NNS N
of IN N
immediate JJ o
efficacy NN o
, , o
low JJ o
volume NN o
requirement NN o
, , o
time NN o
required VBN o
for IN o
initial JJ o
hemostasis NN o
, , o
and CC o
reduction NN o
of IN o
gastric JJ o
variceal NN o
size NN o
. . o

Cyanoacrylate NNP o
, , o
tetradecyl NN o
sulfate NN o
, , o
and CC o
polidocanol NN o
were VBD N
the DT N
most RBS N
effective JJ N
agents NNS N
for IN N
reducing VBG N
gastric JJ N
variceal NN N
size NN N
. . N

Epinephrine NNP N
was VBD N
effective JJ N
for IN N
controlling VBG N
induced JJ o
or CC o
secondary JJ o
bleeding NN o
caused VBN N
by IN N
puncture NN N
of IN N
the DT N
gastric JJ N
varices NNS N
with IN N
the DT N
sclerotherapy NN N
needle NN N
during IN N
intravariceal JJ N
injections NNS N
. . N

Ongoing VBG N
studies NNS N
are VBP N
evaluating VBG N
combinations NNS N
of IN N
agents NNS N
with IN N
different JJ N
mechanisms NNS N
of IN N
action NN N
, , N
such JJ N
as IN N
epinephrine NN N
( ( N
for IN N
vasoconstriction NN N
to TO N
minimize VB N
secondary JJ N
bleeding NN N
) ) N
plus CC N
alcohol NN N
, , N
and/or JJ N
tetradecyl NN N
sulfate NN N
( ( N
for IN N
variceal NN N
thrombosis NN N
and CC N
sclerosis NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Midazolam NNP i
as IN N
a DT N
main JJ N
anesthesia NN N
induction NN N
agent NN N
-- : N
a DT N
comparison NN N
with IN N
thiopental JJ i
and CC i
diazepam NN i
. . i

A DT N
clinical JJ N
randomized JJ N
investigation NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
value NN o
of IN N
midazolam NN i
as IN N
a DT N
narcotic JJ N
adjuvant NN N
for IN N
anesthetic JJ N
induction NN N
. . N

Thirty NNP p
ASA NNP p
I-II NNP p
adult NN p
patients NNS p
undergoing VBG p
selective JJ p
surgery NN p
were VBD N
allocated VBN N
randomly RB N
into IN N
two CD N
groups NNS N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
agents NNS N
: : N
midazolam NN i
0.3 CD i
mg/kg NN i
, , i
thiopental JJ i
5 CD i
mg/kg NN i
, , i
or CC i
diazepam VB i
0.4 CD i
mg/kg NN i
. . i

The DT N
induction NN o
time NN o
as IN o
measured VBN o
from IN o
the DT o
onset NN o
of IN o
injection NN o
to TO o
loss NN o
of IN o
the DT o
eyelash NN o
reflex NN o
was VBD N
shortest VBN N
in IN N
the DT N
case NN N
of IN N
thiopental NN N
; : N
while IN N
a DT N
lower JJR o
frequency NN o
of IN o
apnea NN o
, , o
lesser JJR o
suppression NN o
of IN o
circulation NN o
, , N
and CC N
lack NN o
of IN o
venous JJ o
irritation NN o
were VBD N
points NNS N
favoring VBG N
midazolam NN N
. . N

However RB N
, , N
further JJ N
study NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
the DT N
moderate JJ o
cardiovascular JJ o
response NN o
seen VBN N
during IN N
intubation NN N
in IN N
some DT N
cases NNS N
as RB N
well RB N
as IN N
to TO N
elucidate VB N
any DT N
patient JJ N
population NN N
differences NNS N
. . N

-DOCSTART- -X- O O

Sodium NN i
bicarbonate NN i
, , i
N-acetylcysteine NNP i
, , i
and CC i
saline NN i
for IN N
prevention NN N
of IN N
radiocontrast-induced JJ o
nephropathy NN o
. . o

A DT N
comparison NN N
of IN N
3 CD N
regimens NNS N
for IN N
protecting VBG N
contrast-induced JJ N
nephropathy JJ N
in IN N
patients NNS p
undergoing VBG p
coronary JJ i
procedures NNS i
. . i

A DT N
single-center JJ p
prospective NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Several NNP N
protective JJ N
therapies NNS N
have VBP N
been VBN N
developed VBN N
to TO N
prevent VB N
contrast-induced JJ o
nephropathy JJ o
( ( o
CIN NNP o
) ) o
. . o

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
sodium NN i
bicarbonate NN i
by IN N
comparing VBG N
2 CD N
other JJ N
regimens NNS N
, , N
including VBG N
combination NN i
of IN i
N-acetylcysteine NNP i
( ( i
NAC NNP i
) ) i
plus CC i
sodium JJ i
chloride NN i
and CC i
sodium NN i
chloride NN i
alone RB i
, , N
to TO N
prevent VB N
CIN NNP N
in IN N
patients NNS p
undergoing VBG p
cardiovascular JJ p
procedures NNS p
. . p

METHODS NNP N
We PRP p
prospectively RB p
enrolled VBD p
264 CD p
patients NNS p
who WP p
were VBD p
scheduled VBN p
for IN p
cardiovascular JJ p
procedures NNS p
and CC p
had VBD p
a DT p
baseline JJ p
creatinine NN p
level NN p
> VBD p
1.2 CD p
mg/dL NN p
. . p

The DT N
patients NNS N
were VBD N
assigned VBN N
1 CD N
of IN N
3 CD N
prophylactic JJ N
regimens NNS N
: : N
infusion NN i
of IN i
sodium NN i
bicarbonate NN i
, , i
sodium NN i
chloride NN i
, , i
sodium NN i
chloride NN i
plus CC i
oral JJ i
NAC NNP i
( ( N
600 CD N
mg RB N
bid NN N
) ) N
. . N

Contrast-induced JJ o
nephropathy NN o
was VBD N
defined VBN N
as IN N
an DT N
increase NN o
in IN o
serum JJ o
creatinine NN o
level NN o
> VBD o
25 CD o
% NN o
or CC N
0.5 CD N
mg/dL NNS N
after IN N
48 CD N
hours NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
groups NNS N
regarding VBG N
baseline NN N
demographic JJ o
properties NNS o
and CC N
nephropathy JJ o
risk NN o
factors NNS o
. . o

The DT N
change NN o
in IN o
creatinine JJ o
clearance NN o
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
sodium NN i
bicarbonate NN i
group NN N
than IN N
other JJ N
2 CD N
groups NNS N
( ( N
P NNP N
= NNP N
.007 NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
CIN NNP o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sodium NN i
bicarbonate NN i
group NN N
( ( N
4.5 CD N
% NN N
) ) N
compared VBN N
with IN N
sodium JJ i
chloride NN i
alone RB i
( ( N
13.6 CD N
% NN N
, , N
P NNP N
= NNP N
.036 NNP N
) ) N
and CC N
tended VBD N
to TO N
be VB N
lower JJR N
than IN N
in IN N
the DT N
combination NN i
group NN N
( ( N
12.5 CD N
% NN N
, , N
P NNP N
= NNP N
.059 NNP N
) ) N
. . N

After IN N
adjusting VBG N
the DT N
Mehran NNP o
nephropathy NN o
risk NN o
score NN o
, , N
the DT N
risk NN o
of IN o
CIN NNP o
significantly RB N
reduced VBD N
with IN N
sodium NN i
bicarbonate NN i
compared VBN N
with IN N
sodium JJ i
chloride NN i
alone RB N
( ( N
adjusted VBN N
risk NN N
ratio NN N
0.29 CD N
, , N
P NNP N
= NNP N
.043 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Hydration NNP N
with IN N
sodium JJ i
bicarbonate NN i
provides VBZ N
better JJR N
protection NN o
against IN N
CIN NNP o
than IN N
the DT N
sodium NN i
chloride JJ i
infusion NN i
does VBZ N
alone RB N
. . N

Combination NNP i
therapy NN i
of IN i
NAC NNP i
plus CC i
sodium JJ i
chloride NN i
did VBD N
not RB N
offer VB N
additional JJ N
benefit NN N
over IN N
hydration NN N
with IN N
sodium JJ i
chloride NN i
alone RB i
. . i

-DOCSTART- -X- O O

Histamine NNP p
intolerance-like NN p
symptoms NNS p
in IN p
healthy JJ p
volunteers NNS p
after IN N
oral JJ N
provocation NN N
with IN N
liquid JJ N
histamine NN N
. . N

Histamine NNP N
in IN N
food NN N
at IN N
non-toxic JJ N
doses NNS N
has VBZ N
been VBN N
proposed VBN N
to TO N
be VB N
a DT N
major JJ N
cause NN N
of IN N
food NN N
intolerance NN N
causing NN N
symptoms NNS N
like IN N
diarrhea NN N
, , N
hypotension NN N
, , N
headache NN N
, , N
pruritus NN N
and CC N
flush NN N
( ( N
histamine JJ N
intolerance NN N
) ) N
. . N

Histamine-rich JJ N
foods NNS N
such JJ N
as IN N
cheese NN N
, , N
sausages NNS N
, , N
sauerkraut NN N
, , N
tuna NN N
, , N
tomatoes NNS N
, , N
and CC N
alcoholic JJ N
beverages NNS N
may MD N
contain VB N
histamine VB N
up IN N
to TO N
500 CD N
mg/kg NNS N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
in IN N
10 CD p
healthy JJ p
females NNS p
( ( p
age NN p
range NN p
22-36 CD p
years NNS p
, , p
mean JJ p
29.1 CD p
+/- JJ p
5.4 CD p
) ) p
who WP p
were VBD p
hospitalized VBN p
and CC p
challenged VBN p
on IN p
two CD p
consecutive JJ p
days NNS p
with IN p
placebo NN i
( ( i
peppermint JJ i
tea NN i
) ) i
or CC i
75 CD i
mg NN i
of IN i
pure JJ i
histamine NN i
( ( p
equaling VBG p
124 CD p
mg JJ p
histamine NN p
dihydrochloride NN p
, , p
dissolved VBN p
in IN p
peppermint NN p
tea NN p
) ) p
. . p

Objective JJ N
parameters NNS N
( ( N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
skin JJ N
temperature NN N
, , N
peak VB N
flow NN N
) ) N
as RB N
well RB N
as IN N
a DT N
total JJ N
clinical JJ N
symptom NN N
score NN N
using VBG N
a DT N
standardized VBN N
protocol NN N
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
80 CD N
minutes NNS N
, , N
and CC N
24 CD N
hours NNS N
. . N

The DT N
subjects NNS N
received VBD N
a DT N
histamine-free JJ i
diet NN i
also RB N
low JJ N
in IN N
allergen NN N
24 CD N
hours NNS N
before IN N
hospitalization NN N
and CC N
over IN N
the DT N
whole JJ N
observation NN N
period NN N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
at IN N
baseline NN N
, , N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
and CC N
80 CD N
minutes NNS N
, , N
and CC N
histamine NN N
and CC N
the DT N
histamine-degrading JJ N
enzyme NN N
diamine NN N
oxidase NN N
( ( N
DAO NNP N
) ) N
were VBD N
determined VBN N
. . N

After IN N
histamine JJ N
challenge NN N
, , N
5 CD N
of IN N
10 CD N
subjects NNS N
showed VBD N
no DT o
reaction NN o
. . o

One CD N
individual NN N
experienced VBD N
tachycardia NN o
, , o
mild JJ o
hypotension NN o
after IN o
20 CD o
minutes NNS o
, , o
sneezing VBG o
, , o
itching NN o
of IN o
the DT o
nose NN o
, , o
and CC o
rhinorrhea NN o
after IN o
60 CD o
minutes NNS o
. . o

Four CD N
subjects NNS N
experienced VBD N
delayed JJ N
symptoms NNS N
like IN N
diarrhea NN o
( ( o
4x CD o
) ) o
, , o
flatulence NN o
( ( o
3x CD o
) ) o
, , o
headache NN o
( ( o
3x CD o
) ) o
, , o
pruritus NN o
( ( o
2x CD o
) ) o
and CC o
ocular JJ o
symptoms NNS o
( ( N
1x CD N
) ) N
starting VBG N
3 CD N
to TO N
24 CD N
hours NNS N
after IN N
provocation NN N
. . N

No DT N
subject NN N
reacted VBD N
to TO N
placebo VB N
. . N

No DT N
changes NNS N
were VBD N
observed VBN N
in IN N
histamine NN o
and CC o
DAO NNP o
levels NNS o
within IN N
the DT N
first JJ N
80 CD N
minutes NNS N
in IN N
non-reactors NNS N
as RB N
well RB N
as IN N
reactors NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
challenge NN N
with IN N
histamine JJ N
versus NN N
challenge NN N
with IN N
placebo NN N
. . N

We PRP N
conclude VBP N
that IN N
75 CD N
mg NN N
of IN N
pure NN N
liquid JJ N
oral JJ N
histamine NN N
-- : N
a DT N
dose JJ N
found VBN N
in IN N
normal JJ N
meals NNS N
-- : N
can MD N
provoke VB N
immediate JJ N
as RB N
well RB N
as IN N
delayed VBN N
symptoms NNS N
in IN N
50 CD N
% NN N
of IN N
healthy JJ p
females NNS p
without IN p
a DT p
history NN p
of IN p
food NN p
intolerance NN p
. . p

-DOCSTART- -X- O O

The DT N
NORwegian JJ N
study NN N
on IN N
DIstrict NNP N
treatment NN N
of IN N
ST-elevation NNP p
myocardial JJ p
infarction NN p
( ( N
NORDISTEMI NNP N
) ) N
. . N

OBJECTIVES NNP N
Thrombolysis NNP N
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
patients NNS p
with IN p
ST-elevation NNP p
myocardial JJ p
infarction NN p
( ( p
STEMI NNP p
) ) p
living NN p
in IN p
rural JJ p
areas NNS p
with IN p
long JJ p
transfer NN p
delays NNS p
to TO p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

This DT N
trial NN N
compares VBZ N
two CD N
different JJ N
strategies NNS N
following VBG N
thrombolysis NN N
: : N
to TO N
transfer VB N
all DT N
patients NNS N
for IN N
immediate JJ N
coronary JJ N
angiography NN N
and CC N
intervention NN N
, , N
or CC N
to TO N
manage VB N
the DT N
patients NNS N
more RBR N
conservatively RB N
. . N

DESIGN VB N
The DT p
NORwegian JJ p
study NN p
on IN p
DIstrict NNP p
treatment NN p
of IN p
STEMI NNP p
( ( p
NORDISTEMI NNP p
) ) p
is VBZ N
an DT N
open JJ N
, , N
prospective JJ N
, , N
randomized VBD i
controlled VBN i
trial NN i
in IN i
patients NNS i
with IN i
STEMI NNP i
of IN i
less JJR i
than IN i
6 CD i
hours NNS i
of IN i
duration NN i
and CC i
more JJR i
than IN i
90 CD i
minutes NNS i
expected VBD i
time NN i
delay NN i
to TO i
PCI NNP i
. . i

A NNP p
total NN p
of IN p
266 CD p
patients NNS p
will MD N
receive VB i
full-dose JJ i
thrombolysis NN i
, , i
preferably RB i
pre-hospital JJ i
, , i
and CC i
then RB i
be VB i
randomized VBN i
to TO i
either DT i
strategy NN i
. . i

Our PRP$ N
primary JJ N
endpoint NN N
is VBZ N
the DT N
one CD N
year NN N
combined VBN o
incidence NN o
of IN o
death NN o
, , o
reinfarction NN o
, , o
stroke VBD o
or CC o
new JJ o
myocardial JJ o
ischaemia NN o
. . o

The DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00161005 NNP N
. . N

RESULTS VBN N
By IN N
April NNP p
2006 CD p
, , p
109 CD p
patients NNS p
have VBP N
been VBN N
randomized VBN N
. . N

Thrombolysis NN N
has VBZ N
been VBN N
given VBN N
pre-hospital JJ N
to TO N
52 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
median JJ N
transport NN N
distance NN N
from IN N
first JJ N
medical JJ N
contact NN N
to TO N
catheterization NN N
laboratory NN N
was VBD N
155 CD N
km NN N
( ( N
range JJ N
90-396 CD N
km NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
study NN N
are VBP N
expected VBN N
in IN N
2008 CD N
. . N

-DOCSTART- -X- O O

Bradykinin-induced JJ N
cough NN N
reflex NN N
markedly RB N
increases VBZ N
in IN N
patients NNS p
with IN p
cough NN p
associated VBN p
with IN p
captopril NN p
and CC p
enalapril NN p
. . p

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
angiotensin NN i
converting VBG i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
on IN N
cough NN o
responses NNS o
to TO i
bradykinin VB i
( ( i
BK NNP i
) ) i
, , i
substance NN i
P NNP i
( ( i
SP NNP i
) ) i
and CC i
citric JJ i
acid NN i
in IN N
a DT N
double JJ N
blind NN N
, , N
random NN N
study NN N
on IN N
10 CD p
hypertensive JJ p
patients NNS p
receiving VBG p
ACE NNP i
inhibitors NNS i
. . i

Of IN p
these DT p
patients NNS p
, , p
five CD p
had VBD p
reported VBN p
cough NN p
with IN p
ACE NNP i
inhibitors NNS i
. . i

Cough NNP N
responses VBZ N
to TO N
citric VB N
acid NN N
were VBD N
similar JJ N
between IN N
patients NNS N
with IN N
and CC N
without IN N
cough NN N
, , N
and CC N
SP NNP N
up RB N
to TO N
10 CD N
( ( N
-5 NN N
) ) N
M NNP N
did VBD N
not RB N
cause VB N
cough NN N
in IN N
any DT N
of IN N
the DT N
subjects NNS N
. . N

BK NNP i
caused VBD p
cough NN o
at IN p
13.4 CD p
+/- JJ p
1.2 CD p
( ( p
-log NNP p
M NNP p
) ) p
in IN p
5 CD p
patients NNS p
with IN p
cough NN p
associated VBN p
with IN p
ACE NNP i
inhibitors NNS i
, , p
but CC p
it PRP p
did VBD p
not RB p
cause VB p
cough NN o
at IN p
concentrations NNS p
up RB p
to TO p
10 CD p
( ( p
-5 NN p
) ) p
M NNP p
in IN p
other JJ p
5 CD p
patients NNS p
. . p

One CD N
month NN N
after IN N
the DT N
withdrawal NN N
of IN N
ACE NNP N
inhibitors NNS N
, , N
5 CD p
patients NNS p
were VBD p
free JJ p
from IN p
cough NN o
symptoms NNS o
, , p
and CC p
BK NNP p
did VBD p
not RB p
cause VB p
cough NN o
up RB p
to TO p
10 CD p
( ( p
-5 NN p
) ) p
M NNP p
in IN p
these DT p
patients NNS p
, , p
except IN p
for IN p
one CD p
who WP p
coughed VBD p
at IN p
10 CD p
( ( p
-9 NN p
) ) p
M NNP p
, , N
without IN N
changes NNS N
in IN N
responses NNS N
to TO N
citric VB N
acid NN N
. . N

BK NNP N
caused VBD N
cough NN o
at IN N
14.3 CD N
+/- JJ N
0.7 CD N
( ( N
-log NNP N
M NNP N
) ) N
although IN N
BK1-7 NNP N
, , N
a DT N
major JJ N
metabolite NN N
of IN N
BK NNP N
by IN N
ACE NNP N
, , N
caused VBD N
cough NN o
at IN N
5.7 CD N
+/- JJ N
0.7 CD N
( ( N
-log NNP N
M NNP N
) ) N
in IN N
another DT N
3 CD N
patients NNS N
with IN N
cough NN N
associated VBN N
with IN N
ACE NNP N
inhibitor NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
impaired JJ N
metabolism NN N
of IN N
BK NNP N
induced VBN N
by IN N
ACE NNP N
inhibitors NNS N
may MD N
relate VB N
to TO N
the DT N
manifestation NN N
of IN N
cough NN N
in IN N
hypertensive JJ p
patients NNS p
receiving VBG p
ACE NNP p
inhibitors NNS p
. . p

-DOCSTART- -X- O O

Open JJ i
flap NN i
debridement NN i
with IN i
or CC i
without IN i
intentional JJ i
cementum NN i
removal NN i
: : i
a DT N
4-month JJ N
follow-up NN N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
cementum NN i
removal NN i
on IN i
periodontal JJ i
repair NN i
. . i

MATERIAL NNP N
AND NNP N
METHODS NNP N
Forty NNP p
subjects NNS p
with IN p
chronic JJ p
periodontitis NN p
and CC p
presenting NN p
, , p
at IN p
least JJS p
, , p
two CD p
proximal JJ p
sites NNS p
in IN p
anterior JJ p
teeth NNS p
( ( p
upper JJ p
or CC p
lower JJR p
) ) p
with IN p
probing VBG p
depth JJ p
> NN p
or CC p
=5 JJ p
mm NNS p
were VBD p
selected VBN p
. . p

After IN N
oral JJ N
hygiene NN N
instructions NNS N
and CC N
ultrasonic JJ N
supragingival NN N
instrumentation NN N
, , N
the DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
for IN N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
CIC NNP i
, , i
scaled VBD i
with IN i
Gracey NNP i
curettes NNS i
; : i
CIUS NNP i
, , i
scaled VBD i
with IN i
ultrasonic JJ i
device NN i
; : i
CDC NNP i
, , i
calculus JJ i
deattachment NN i
with IN i
Gracey NNP i
curettes NNS i
and CC i
brushing VBG i
with IN i
saline JJ i
solution NN i
; : i
and CC i
CDUS NNP i
, , i
calculus JJ i
deattachment NN i
with IN i
ultrasonic JJ i
device NN i
and CC i
brushing VBG i
with IN i
saline JJ i
solution NN i
. . i

Full-thickness JJ N
flaps NNS N
were VBD N
reflected VBN N
and CC N
the DT N
instrumentation NN N
was VBD N
performed VBN N
with IN N
a DT N
clinical JJ N
microscope NN N
. . N

Probing VBG o
depth NN o
( ( o
PD NNP o
) ) o
, , o
relative JJ o
gingival NN o
margin NN o
level NN o
( ( o
RGML NNP o
) ) o
and CC o
relative JJ o
attachment NN o
level NN o
( ( o
RAL NNP o
) ) o
were VBD N
registered VBN N
at IN N
five CD N
experimental JJ N
periods NNS N
: : N
baseline NN N
and CC N
30 CD N
, , N
60 CD N
, , N
90 CD N
and CC N
120 CD N
days NNS N
postoperative JJ N
. . N

RESULTS VB N
All PDT N
the DT N
approaches NNS N
were VBD N
able JJ N
to TO N
markedly RB N
reduce VB N
the DT N
PD NNP N
values NNS N
from IN N
the DT N
baseline NN N
to TO N
the DT N
other JJ N
evaluation NN N
periods NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
increase NN N
in IN N
RGML NNP o
values NNS o
was VBD N
statistically RB N
significant JJ N
only RB N
for IN N
the DT N
CDUS NNP i
group NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
baseline NN N
and CC N
postoperative JJ N
values NNS N
in IN N
all DT N
groups NNS N
for IN N
the DT N
RAL NNP o
changes NNS o
. . o

The DT N
changes NNS N
in IN N
RAL NNP o
were VBD N
statistically RB N
significant JJ N
only RB N
among IN N
the DT N
groups NNS N
CDC NNP i
and CC N
CDUS NNP i
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
conventional JJ i
scaling NN i
and CC i
root NN i
planing NN i
and CC i
the DT i
calculus JJ i
deattachment NN i
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
probing VBG N
depth NN N
values NNS N
, , N
regardless RB N
of IN N
the DT N
instrumentation NN N
method NN N
. . N

-DOCSTART- -X- O O

Impacts NNS N
of IN N
a DT N
disease JJ i
management NN i
program NN i
for IN N
dually RB p
eligible JJ p
beneficiaries NNS p
. . p

The DT N
LifeMasters NNPS i
Supported NNP i
SelfCare NNP i
demonstration NN i
program NN i
provides VBZ N
disease JJ i
management NN i
( ( i
DM NNP i
) ) i
services NNS i
to TO N
Florida NNP p
Medicare NNP p
beneficiaries NNS p
who WP p
are VBP p
also RB p
enrolled VBN p
in IN p
Medicaid NNP p
and CC p
have VBP p
congestive JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
, , p
diabetes VBZ p
, , p
or CC p
coronary JJ p
artery NN p
disease NN p
( ( p
CAD NNP p
) ) p
. . p

The DT N
population-based JJ N
program NN N
provides VBZ N
primarily RB i
telephonic JJ i
patient JJ i
education NN i
and CC i
monitoring NN i
services NNS i
. . i

Findings NNS N
from IN N
the DT N
randomized VBN N
, , N
intent-to-treat JJ N
design NN N
over IN N
the DT N
first JJ N
18 CD N
months NNS N
of IN N
operations NNS N
show VBP N
virtually RB N
no DT N
overall JJ N
impacts NNS o
on IN o
hospital NN o
or CC o
emergency NN o
room NN o
( ( o
ER NNP o
) ) o
use NN o
, , o
Medicare NNP o
expenditures VBZ o
, , o
quality NN o
of IN o
care NN o
, , o
or CC o
prescription NN o
drug NN o
use NN o
for IN N
the DT N
33,000 CD p
enrollees NNS p
. . p

However RB N
, , N
for IN N
beneficiaries NNS p
with IN p
CHF NNP p
who WP p
resided VBD p
in IN p
high-cost NN p
South NNP p
Florida NNP p
counties NNS p
, , N
the DT N
program NN N
reduced VBN N
Medicare NNP o
expenditures NNS o
by IN N
9.6 CD N
percent NN N
. . N

-DOCSTART- -X- O O

See VB N
what WP N
I PRP N
see VBP N
, , N
do VBP N
as IN N
I PRP N
do VBP N
: : N
promoting NN i
joint JJ i
attention NN i
and CC i
imitation NN i
in IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Since IN N
imitation NN N
and CC N
joint JJ N
attention NN N
are VBP N
both DT N
important JJ N
abilities NNS N
for IN N
young JJ N
children NNS N
and CC N
since IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
show VBP N
a DT N
range NN N
of IN N
problems NNS N
in IN N
these DT N
domains NNS N
, , N
imitation NN i
and CC N
joint JJ i
attention NN i
are VBP N
important JJ N
targets NNS N
for IN N
intervention NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
the DT N
possibility NN N
of IN N
promoting VBG N
imitation NN i
and CC N
joint JJ i
attention NN i
by IN N
means NNS N
of IN N
a DT N
training NN i
programme NN i
specifically RB i
designed VBN i
for IN i
low-intensity NN i
, , i
non-residential JJ i
treatment NN i
. . i

Two CD p
matched VBD p
groups NNS p
of IN p
18 CD p
children NNS p
each DT p
participated VBN p
in IN p
the DT p
study NN p
. . p

The DT N
experimental JJ N
group NN N
, , N
receiving VBG o
the DT o
training NN o
programme NN o
, , N
improved VBN N
significantly RB N
more RBR N
on IN N
joint JJ o
attention NN o
than IN N
the DT N
group NN N
receiving VBG o
only RB o
treatment NN o
as IN o
usual JJ o
. . o

Only RB N
the DT N
experimental JJ N
group NN N
obtained VBD N
a DT N
significantly RB N
higher JJR o
imitation NN o
score RBR o
during IN N
the DT N
post-test JJ o
compared VBN N
to TO N
the DT N
pre-test NN o
. . o

This DT N
study NN N
shows VBZ N
that IN N
it PRP N
is VBZ N
possible JJ N
to TO N
promote VB o
joint JJ o
attention NN o
with IN N
a DT N
low-intensity JJ o
treatment NN o
programme NN o
. . o

The DT N
results NNS N
concerning VBG N
imitation NN o
are VBP o
more RBR o
modest JJ o
. . o

Future JJ N
replications NNS N
should MD N
involve VB N
measures NNS N
of IN N
stability NN o
and CC o
generalization NN o
. . o

-DOCSTART- -X- O O

Improved VBN o
intraoperative JJ o
management NN o
of IN N
anastomotic JJ o
bleeding NN o
during IN p
aortic JJ p
reconstruction NN p
: : p
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
the DT N
effectiveness NN o
of IN N
a DT N
polymeric JJ i
surgical JJ i
sealant NN i
( ( i
CoSeal NNP i
) ) i
was VBD N
compared VBN i
to TO i
Gelfoam/thrombin NNP i
for IN i
managing VBG i
anastomotic JJ o
bleeding NN o
after IN i
implantation NN i
of IN i
Dacron NNP i
grafts NNS i
during IN i
aortic JJ i
reconstruction NN i
for IN i
nonruptured JJ i
aneurysms NNS i
. . i

Each DT i
treatment NN i
was VBD i
directly RB i
applied VBN i
to TO i
the DT i
suture NN i
line NN i
after IN i
confirmation NN i
of IN i
anastomotic JJ i
bleeding NN i
. . i

The DT N
proportion NN N
of IN N
suture NN N
line NN N
sites VBZ N
that IN N
achieved VBD N
immediate JJ o
sealing NN o
and CC N
the DT N
proportion NN N
sealed VBD N
within IN N
5 CD N
minutes NNS N
were VBD N
determined VBN N
among IN N
37 CD p
experimental JJ p
( ( p
59 CD p
sites NNS p
) ) p
and CC p
17 CD p
control NN p
subjects NNS p
( ( p
27 CD p
sites NNS p
) ) p
. . p

A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
bleeding VBG N
suture NN N
line NN N
sites NNS N
treated VBD N
with IN N
the DT N
polymeric JJ i
sealant NN i
achieved VBN N
immediate JJ o
sealing NN o
following VBG N
reestablishment NN N
of IN N
blood NN N
flow NN N
compared VBN N
with IN N
control-treated JJ N
sites NNS N
[ VBP N
48 CD N
of IN N
59 CD N
( ( N
81 CD N
% NN N
) ) N
vs VBZ N
10 CD N
of IN N
27 CD N
( ( N
37 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.002 CD N
] NN N
. . N

The DT N
difference NN N
between IN N
treatment NN N
groups NNS N
was VBD N
maintained VBN N
after IN N
5 CD N
minutes NNS N
with IN N
approximately RB N
85 CD N
per IN N
cent NN N
( ( N
50 CD N
of IN N
59 CD N
) ) N
of IN N
CoSeal NNP i
sites NNS N
compared VBN N
to TO N
just RB N
over IN N
one-half JJ N
( ( N
14 CD N
of IN N
27 CD N
) ) N
of IN N
control NN N
sites VBZ N
demonstrating VBG N
ultimate JJ o
sealing NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
adverse JJ N
events NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
the DT N
polymeric JJ i
sealant NN i
in IN N
this DT N
study NN N
. . N

These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
this DT N
novel JJ N
sealant NN N
for IN N
the DT N
intraoperative JJ p
management NN p
of IN p
anastomotic JJ p
bleeding NN p
during IN p
aortic JJ p
reconstruction NN p
procedures NNS p
. . p

-DOCSTART- -X- O O

Exposure NN i
to TO i
the DT i
self-face NN i
facilitates VBZ i
identification NN o
of IN o
dynamic JJ o
facial JJ o
expressions NNS o
: : o
influences NNS N
on IN N
individual JJ N
differences NNS N
. . N

A DT N
growing VBG N
literature NN N
suggests VBZ N
that IN N
the DT N
self-face NN i
is VBZ N
involved VBN N
in IN N
processing VBG o
the DT o
facial JJ o
expressions NNS o
of IN N
others NNS N
. . N

The DT N
authors NNS N
experimentally RB N
activated VBD N
self-face JJ i
representations NNS i
to TO N
assess VB N
its PRP$ N
effects NNS N
on IN N
the DT N
recognition NN o
of IN o
dynamically RB o
emerging VBG o
facial JJ o
expressions NNS o
of IN o
others NNS o
. . o

They PRP N
exposed VBD N
participants NNS p
to TO N
videos NNS N
of IN N
either DT N
their PRP$ N
own JJ N
faces VBZ N
( ( i
self-face JJ i
prime NN i
) ) i
or CC i
faces VBZ i
of IN i
others NNS i
( ( i
nonself-face JJ i
prime NN i
) ) i
prior RB N
to TO N
a DT N
facial JJ N
expression NN N
judgment NN N
task NN N
. . N

Their PRP$ N
results NNS N
show VBP N
that IN N
experimentally RB N
activating VBG N
self-face JJ N
representations NNS N
results NNS N
in IN N
earlier JJR N
recognition NN o
of IN o
dynamically RB o
emerging VBG o
facial JJ o
expression NN o
. . o

As IN N
a DT N
group NN N
, , N
participants NNS p
in IN p
the DT p
self-face JJ p
prime JJ p
condition NN p
recognized VBD o
expressions NNS o
earlier RBR N
( ( N
when WRB N
less RBR N
affective JJ N
perceptual JJ N
information NN N
was VBD N
available JJ N
) ) N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
nonself-face JJ N
prime JJ N
condition NN N
. . N

There EX N
were VBD N
individual JJ N
differences NNS N
in IN N
performance NN N
, , N
such JJ N
that IN N
poorer JJR N
expression NN o
identification NN o
was VBD N
associated VBN N
with IN N
higher JJR p
autism NN p
traits NNS p
( ( N
in IN N
this DT N
neurocognitively RB p
healthy JJ p
sample NN p
) ) p
. . N

However RB N
, , N
when WRB N
randomized VBN N
into IN N
the DT N
self-face JJ N
prime JJ N
condition NN N
, , N
participants NNS p
with IN p
high JJ p
autism NN p
traits NNS p
performed VBN p
as RB p
well RB p
as IN p
those DT p
with IN p
low JJ p
autism NN p
traits NNS p
. . p

Taken VB N
together RB N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
the DT N
ability NN o
to TO o
recognize VB o
facial JJ o
expressions NNS o
in IN N
others NNS N
is VBZ N
linked VBN N
with IN N
the DT N
internal JJ N
representations NNS N
of IN N
our PRP$ N
own JJ N
faces VBZ N
. . N

-DOCSTART- -X- O O

Successful JJ N
treatment NN N
of IN N
blepharitis NN p
with IN N
bibrocathol NN i
( ( i
Posiformin? NNP i
2 CD i
% NN i
) ) i
. . i

BACKGROUND NNP i
Bibrocathol NNP i
is VBZ N
a DT N
well-established JJ i
antiseptic JJ i
drug NN i
for IN N
the DT N
treatment NN N
of IN p
acute NN p
eyelid JJ p
diseases NNS p
like IN p
blepharitis NN p
. . p

Despite IN N
its PRP$ N
frequent JJ N
use NN N
in IN N
clinical JJ N
practice NN N
, , N
no DT N
controlled JJ N
clinical JJ N
trial NN N
on IN N
the DT o
efficacy NN o
of IN i
bibrocathol $ i
2 CD i
% NN i
eye NN N
ointment NN N
has VBZ N
been VBN N
performed VBN N
until IN N
now RB N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB o
efficacy NN o
, , o
safety NN o
and CC o
tolerability NN o
of IN i
bibrocathol NN i
( ( i
Posiformin? NNP i
2 CD i
% NN N
) ) N
eye NN N
ointment NN N
in IN N
patients NNS p
diagnosed VBN p
with IN p
blepharitis NN p
. . p

METHODS NNP p
In IN N
this DT p
multi-center NN p
, , p
randomized VBN p
, , N
double-masked JJ i
, , i
placebo-controlled JJ i
parallel-group NN i
comparison NN N
, , N
the DT N
change NN N
of IN N
signs NNS N
and CC N
symptoms NNS N
( ( N
sum VB N
score NN N
) ) N
of IN N
blepharitis NN N
in IN N
197 CD p
patients NNS p
( ( p
ITT NNP p
( ( p
intention-to-treat-group JJ p
) ) p
; : p
mean JJ p
age NN p
56 CD p
? . p
18 CD p
years NNS p
, , p
56 CD p
% NN p
female NN p
, , p
active JJ p
drug NN p
: : p
vehicle NN p
= IN p
97:100 CD p
) ) p
over IN p
2 CD p
weeks NNS p
treatment NN N
with IN N
bibrocathol JJ i
2 CD i
% NN i
eye NN i
ointment NN i
was VBD i
evaluated VBN N
. . N

RESULTS JJ N
Patients NNPS N
receiving VBG i
bibrocathol RB i
2 CD i
% NN i
showed VBD o
greater JJR o
improvement NN o
in IN o
the DT o
sum NN o
score NN o
than IN N
the DT i
placebo NN i
patients NNS N
( ( N
p JJ N
< NN N
0.0001 CD N
, , N
Cohen NNP N
's POS N
effect NN N
size NN N
d NN N
= NNP N
0.73 CD N
) ) N
. . N

Also RB N
, , N
the DT N
results NNS N
from IN N
further JJ N
efficacy NN o
assessments NNS o
improvement NN N
of IN o
single JJ o
symptoms NNS o
and CC o
ocular JJ o
discomfort NN o
measured VBN o
by IN N
a DT N
VAS NNP o
( ( o
visual JJ o
analogue NN o
scale NN o
) ) o
supported VBD N
treatment NN N
with IN N
bibrocathol NN i
. . i

Patients NNS i
and CC N
investigators NNS N
provided VBD o
favorable JJ o
tolerability NN o
ratings NNS o
preferring VBG o
bibrocathol NN i
over IN i
placebo NN i
. . N

No DT o
safety NN o
issues NNS o
were VBD o
observed VBN o
with IN N
regard NN N
to TO o
intraocular JJ o
pressure NN o
, , o
visual JJ o
acuity NN o
, , o
or CC o
occurrence NN o
of IN o
adverse JJ o
events NNS o
. . o

CONCLUSIONS NNP o
Blepharitis NNP N
therapy NN N
with IN N
the DT i
antiseptic JJ i
bibrocathol NN i
2 CD i
% NN i
in IN i
this DT i
trial NN N
was VBD N
highly RB N
efficacious JJ N
and CC N
safe JJ N
. . N

-DOCSTART- -X- O O

Mediation NN N
analysis NN N
demonstrates VBZ N
that IN N
trans-eQTLs NN o
are VBP N
often RB N
explained VBN N
by IN N
cis-mediation NN N
: : N
a DT N
genome-wide JJ N
analysis NN N
among IN N
1,800 CD p
South NNP p
Asians NNPS p
. . p

A DT N
large JJ N
fraction NN N
of IN N
human JJ N
genes NNS N
are VBP N
regulated VBN N
by IN N
genetic JJ N
variation NN N
near IN N
the DT N
transcribed JJ N
sequence NN N
( ( N
cis-eQTL JJ N
, , N
expression JJ N
quantitative JJ N
trait NN N
locus NN N
) ) N
, , N
and CC N
many JJ N
cis-eQTLs NNS N
have VBP N
implications NNS N
for IN N
human JJ N
disease NN N
. . N

Less NNP N
is VBZ N
known VBN N
regarding VBG N
the DT N
effects NNS N
of IN N
genetic JJ N
variation NN N
on IN N
expression NN o
of IN o
distant JJ o
genes NNS o
( ( o
trans-eQTLs NN o
) ) o
and CC N
their PRP$ N
biological JJ N
mechanisms NNS N
. . N

In IN N
this DT N
work NN N
, , N
we PRP N
use VBP N
genome-wide JJ i
data NNS i
on IN i
SNPs NNP i
and CC N
array-based JJ i
expression NN i
measures NNS i
from IN N
mononuclear JJ N
cells NNS N
obtained VBN N
from IN N
a DT N
population-based JJ N
cohort NN N
of IN N
1,799 CD p
Bangladeshi NNP p
individuals NNS p
to TO N
characterize VB N
cis- JJ o
and CC o
trans-eQTLs JJ o
and CC N
determine VB N
if IN N
observed VBN N
trans-eQTL JJ o
associations NNS o
are VBP N
mediated VBN N
by IN N
expression NN N
of IN N
transcripts NNS N
in IN N
cis NN N
with IN N
the DT N
SNPs NNP N
showing VBG N
trans-association NN N
, , N
using VBG N
Sobel NNP o
tests NNS o
of IN o
mediation NN o
. . o

We PRP N
observed VBD N
434 CD p
independent JJ p
trans-eQTL JJ o
associations NNS o
at IN N
a DT N
false-discovery JJ N
rate NN N
of IN N
0.05 CD N
, , N
and CC N
189 CD N
of IN N
these DT N
trans-eQTLs NNS o
were VBD N
also RB N
cis-eQTLs JJ N
( ( N
enrichment JJ N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Among IN N
these DT N
189 CD p
trans-eQTL NN o
associations NNS o
, , p
39 CD p
were VBD p
significantly RB p
attenuated VBN p
after IN N
adjusting VBG N
for IN N
a DT N
cis-mediator NN N
based VBN N
on IN N
Sobel NNP N
P NNP N
< NNP N
10-5 JJ N
. . N

We PRP N
attempted VBD N
to TO N
replicate VB N
21 CD N
of IN N
these DT N
mediation NN N
signals NNS N
in IN N
two CD N
European JJ N
cohorts NNS N
, , N
and CC N
while IN N
only RB N
7 CD N
trans-eQTL JJ o
associations NNS o
were VBD N
present JJ N
in IN N
one CD N
or CC N
both DT N
cohorts NNS N
, , N
6 CD N
showed VBD N
evidence NN N
of IN N
cis-mediation NN N
. . N

Analyses NNS N
of IN N
simulated JJ N
data NNS N
show VBP N
that IN N
complete JJ N
mediation NN N
will MD N
be VB N
observed VBN N
as IN N
partial JJ N
mediation NN N
in IN N
the DT N
presence NN N
of IN N
mediator NN N
measurement NN N
error NN N
or CC N
imperfect JJ N
LD NNP N
between IN N
measured VBN N
and CC N
causal JJ N
variants NNS N
. . N

Our PRP$ N
data NNS N
demonstrates VBZ N
that IN N
trans-associations NNS N
can MD N
become VB N
significantly RB N
stronger JJR N
or CC N
switch VB N
directions NNS N
after IN N
adjusting VBG N
for IN N
a DT N
potential JJ N
mediator NN N
. . N

Using VBG N
simulated JJ N
data NNS N
, , N
we PRP N
demonstrate VBP N
that IN N
this DT N
phenomenon NN N
is VBZ N
expected VBN N
in IN N
the DT N
presence NN N
of IN N
strong JJ N
cis-trans NNS N
confounding NN N
and CC N
when WRB N
the DT N
measured VBN N
cis-transcript NN N
is VBZ N
correlated VBN N
with IN N
the DT N
true JJ N
( ( N
unmeasured JJ N
) ) N
mediator NN N
. . N

In IN N
conclusion NN N
, , N
by IN N
applying VBG N
mediation NN N
analysis NN N
to TO N
eQTL VB N
data NNS N
, , N
we PRP N
show VBP N
that IN N
a DT N
substantial JJ N
fraction NN N
of IN N
observed JJ N
trans-eQTL JJ o
associations NNS o
can MD N
be VB N
explained VBN N
by IN N
cis-mediation NN N
. . N

Future JJ N
studies NNS N
should MD N
focus VB N
on IN N
understanding VBG N
the DT N
mechanisms JJ N
underlying JJ N
widespread JJ N
cis-mediation NN N
and CC N
their PRP$ N
relevance NN N
to TO N
disease VB N
biology NN N
, , N
as RB N
well RB N
as IN N
using VBG N
mediation NN N
analysis NN N
to TO N
improve VB N
eQTL NN N
discovery NN N
. . N

-DOCSTART- -X- O O

Conjugated VBN N
equine JJ N
estrogen NN N
influence NN N
on IN N
mammographic JJ o
density NN o
in IN N
postmenopausal JJ p
women NNS p
in IN p
a DT p
substudy NN p
of IN p
the DT p
women NNS p
's POS p
health NN p
initiative NN p
randomized VBN p
trial NN p
. . p

PURPOSE NNP N
Increased VBD N
mammographic JJ o
density NN o
is VBZ N
associated VBN N
with IN N
increased JJ N
breast NN N
cancer NN N
risk NN N
and CC N
reduced JJ N
sensitivity NN N
of IN N
screening VBG N
mammography NN N
and CC N
is VBZ N
related VBN N
to TO N
hormone VB N
exposure NN N
. . N

However RB N
, , N
the DT N
effects NNS N
of IN N
conjugated JJ i
equine NN i
estrogens NNS i
( ( i
CEEs NNP i
) ) i
alone RB N
on IN N
mammographic JJ o
density NN o
in IN N
diverse JJ p
racial/ethnic JJ p
populations NNS p
are VBP N
not RB N
established VBN N
. . N

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
CEE NNP N
alone RB N
on IN N
mammographic JJ o
density NN o
in IN N
a DT N
subsample NN p
of IN p
the DT p
Women NNP p
's POS p
Health NNP p
Initiative NNP p
( ( p
WHI NNP p
) ) p
clinical JJ p
trial NN p
participants NNS p
. . p

PATIENTS NNS N
AND CC N
METHODS NNP N
In IN N
the DT N
WHI NNP N
trial NN N
, , N
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
daily VB i
CEE NNP i
0.625 CD i
mg NN i
or CC i
placebo NN i
. . i

The DT N
effect NN N
of IN N
CEE NNP N
on IN N
mammographic JJ o
percent NN o
density NN o
was VBD N
determined VBN N
over IN N
1 CD N
and CC N
2 CD N
years NNS N
in IN N
a DT N
stratified JJ N
random JJ p
sample NN p
of IN p
435 CD p
racially RB p
and CC p
ethnically RB p
diverse JJ p
participants NNS p
from IN p
15 CD p
of IN p
40 CD p
WHI NNP p
clinics NNS p
. . p

RESULTS NNP N
Use NNP N
of IN N
CEE NNP N
resulted VBD N
in IN N
mean JJ N
increase NN N
in IN N
mammographic JJ o
percent NN o
density NN o
of IN N
1.6 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.8 CD N
to TO N
2.4 CD N
) ) N
at IN N
year NN N
1 CD N
compared VBN N
with IN N
a DT N
mean JJ N
decrease NN N
of IN N
1.0 CD N
percentage NN N
point NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-1.7 NNP N
to TO N
-0.4 VB N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
effect NN N
persisted VBD N
for IN N
2 CD N
years NNS N
, , N
with IN N
a DT N
mean JJ N
increase NN N
of IN N
1.7 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.7 CD N
to TO N
2.7 CD N
) ) N
versus NN N
a DT N
mean JJ N
decrease NN N
of IN N
1.2 CD N
percentage NN N
points NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
to TO N
-0.5 VB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
in IN N
the DT N
hormone NN N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

These DT N
effects NNS N
were VBD N
greater JJR N
in IN N
women NNS p
age NN p
60 CD p
to TO p
79 CD p
years NNS p
( ( N
P NNP N
= NNP N
.03 NNP N
for IN N
interaction NN N
across IN N
age NN N
) ) N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
CEE NNP N
results NNS N
in IN N
a DT N
modest JJ N
but CC N
statistically RB N
significant JJ N
increase NN N
in IN N
mammographic JJ o
density NN o
that WDT N
is VBZ N
sustained VBN N
over IN N
at IN N
least JJS N
a DT N
2-year JJ N
period NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
the DT N
CEE NNP N
effect NN N
on IN N
mammographic JJ o
density NN o
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -X- O O

Azathioprine NNP i
and CC N
the DT N
treatment NN N
of IN N
chronic JJ p
inflammatory NN p
bowel NN p
disease NN p
. . p

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
to TO N
assess VB N
5 CD N
% NN N
imiquimod JJ i
cream NN i
for IN N
the DT N
treatment NN N
of IN p
multiple JJ o
actinic JJ o
keratoses NNS o
. . o

BACKGROUND NNP N
Actinic NNP o
keratoses NNS o
( ( o
AKs NNP o
) ) o
are VBP N
precancerous JJ N
epidermal JJ N
lesions NNS N
found VBD N
most JJS N
frequently RB N
on IN N
areas NNS N
of IN N
the DT N
skin NN N
exposed VBD N
to TO N
the DT N
sun NN N
. . N

Several JJ N
case NN N
studies NNS N
published VBN N
recently RB N
have VBP N
indicated VBN N
that IN N
5 CD N
% NN N
imiquimod JJ i
cream NN N
, , N
currently RB N
licensed VBN N
for IN N
the DT N
treatment NN N
of IN N
genital JJ N
warts NNS N
, , N
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
AK NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
imiquimod NN N
for IN N
the DT N
treatment NN N
of IN N
AK NNP o
. . o

DESIGN NNP N
Patients NNPS N
in IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
applied VBD N
5 CD i
% NN i
imiquimod JJ i
cream NN i
or CC i
vehicle NN i
to TO i
AK NNP o
lesions NNS o
3 CD i
times NNS i
per IN i
week NN i
for IN i
a DT i
maximum NN i
of IN i
12 CD i
weeks NNS i
or CC i
until IN i
lesions NNS i
had VBD i
resolved VBN i
. . i

In IN N
the DT N
event NN N
of IN N
an DT N
adverse JJ N
reaction NN N
, , N
application NN N
of IN N
imiquimod NN i
was VBD N
reduced VBN N
to TO N
1 CD N
or CC N
2 CD N
times NNS N
per IN N
week NN N
. . N

Rest JJS N
periods NNS N
were VBD N
also RB N
allowed VBN N
if IN N
necessary JJ N
. . N

SETTING VB N
A DT p
specialized JJ p
outpatient NN p
dermatology NN p
clinic NN p
within IN p
a DT p
state-funded JJ p
hospital NN p
in IN p
Germany NNP p
. . p

PATIENTS VB p
The DT p
study NN p
population NN p
was VBD p
aged VBN p
45 CD p
to TO p
85 CD p
years NNS p
. . p

Of IN p
52 CD p
patients NNS p
screened VBD p
, , p
36 CD p
men NNS p
and CC p
women NNS p
with IN p
AK NNP p
confirmed VBN p
by IN p
histological JJ p
diagnosis NN p
were VBD p
enrolled VBN p
. . p

Patients NNS p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
if IN p
they PRP p
did VBD p
not RB p
have VB p
a DT p
histological JJ p
diagnosis NN p
for IN p
AK NNP p
, , p
if IN p
they PRP p
were VBD p
older JJR p
than IN p
85 CD p
years NNS p
, , p
or CC p
if IN p
they PRP p
did VBD p
not RB p
comply VB p
with IN p
the DT p
protocol NN p
. . p

All DT p
patients NNS p
had VBD p
responded VBN p
to TO p
a DT p
notice NN p
asking VBG p
for IN p
volunteers NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN o
and CC o
appearance NN o
of IN o
lesions NNS o
were VBD N
evaluated VBN N
before RB N
, , N
during IN N
, , N
and CC N
after IN N
treatment NN N
. . N

All DT N
adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Lesions NNP N
treated VBD N
with IN N
5 CD N
% NN N
imiquimod JJ i
cream NN i
were VBD N
clinically RB o
cleared VBN o
in IN N
21 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
25 CD N
patients NNS N
and CC N
partially RB o
cleared VBN o
in IN N
2 CD N
( ( N
8 CD N
% NN N
) ) N
. . N

Clearance NN o
was VBD N
histologically RB N
confirmed VBN N
2 CD N
weeks NNS N
after IN N
the DT N
last JJ N
application NN N
of IN N
imiquimod NN i
in IN N
all DT N
patients NNS N
clinically RB N
diagnosed VBN N
as IN N
lesion NN N
free NN N
. . N

Only RB N
10 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
imiquimod NN i
were VBD N
clinically RB N
diagnosed VBN N
with IN N
recurrence NN N
1 CD N
year NN N
after IN N
treatment NN N
. . N

No DT N
reduction NN o
in IN o
the DT o
size NN o
or CC o
number NN o
of IN o
AK NNP o
lesions NNS o
was VBD N
observed VBN N
in IN N
vehicle-treated JJ N
patients NNS N
. . N

Adverse JJ N
effects NNS N
reported VBN N
by IN p
patients NNS p
treated VBN p
with IN p
imiquimod NN i
included VBD N
erythema NN o
, , o
edema NN o
, , o
induration NN o
, , o
vesicles NNS o
, , o
erosion NN o
, , o
ulceration NN o
, , o
excoriation NN o
, , o
and CC o
scabbing VBG o
. . o

However RB N
, , N
imiquimod NN i
was VBD N
well RB N
tolerated VBN o
since IN N
all DT N
patients NNS N
completed VBD N
the DT N
12-week JJ N
treatment NN N
. . N

Only RB N
a DT N
few JJ N
, , N
mild JJ N
adverse JJ N
reactions NNS N
to TO N
the DT N
vehicle NN N
cream NN N
were VBD N
reported VBN N
. . N

CONCLUSION NNP N
Application NNP N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN i
for IN N
12 CD N
weeks NNS N
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
AK NNP o
. . o

-DOCSTART- -X- O O

Analysis NN N
of IN N
face NN i
gaze NN i
in IN N
autism NN p
using VBG N
Bubbles NNP N
. . N

One CD N
of IN N
the DT N
components NNS N
of IN N
abnormal JJ N
social JJ N
functioning NN N
in IN N
autism NN p
is VBZ N
an DT N
impaired JJ N
ability NN N
to TO N
direct VB N
eye NN N
gaze NN N
onto IN N
other JJ N
people NNS N
's POS N
faces VBZ N
in IN N
social JJ N
situations NNS N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
gaze NN o
onto IN o
the DT o
eye NN o
and CC o
mouth JJ o
regions NNS o
of IN o
faces VBZ o
, , N
and CC N
the DT N
visual JJ N
information NN N
that WDT N
was VBD N
present JJ N
within IN N
those DT N
regions NNS N
. . N

We PRP N
used VBD N
the DT N
Bubbles NNP i
method NN i
to TO N
vary VB N
the DT N
facial JJ N
information NN N
available JJ N
on IN N
any DT N
given VBN N
trial NN N
by IN N
revealing VBG N
only RB N
small JJ N
parts NNS N
of IN N
the DT N
face NN N
, , N
and CC N
measured VBD N
the DT N
eye NN o
movements NNS o
made VBN N
as IN N
participants NNS N
viewed IN N
these DT N
stimuli NNS N
. . N

Compared VBN p
to TO p
ten VB p
IQ- NNP p
and CC p
age-matched JJ p
healthy JJ p
controls NNS p
, , p
eight CD p
participants NNS p
with IN p
autism NN p
showed VBD N
less JJR N
fixation JJ o
specificity NN o
to TO N
the DT N
eyes NNS N
and CC N
mouth NN N
, , N
a DT N
greater JJR N
tendency NN N
to TO N
saccade VB N
away RB N
from IN N
the DT N
eyes NNS N
when WRB N
information NN N
was VBD N
present JJ N
in IN N
those DT N
regions NNS N
, , N
and CC N
abnormal JJ N
directionality NN N
of IN N
saccades NNS N
. . N

The DT N
findings NNS N
provide VBP N
novel JJ N
detail NN N
to TO N
the DT N
abnormal JJ N
way NN N
in IN N
which WDT N
people NNS N
with IN N
autism NN N
look NN N
at IN N
faces VBZ N
, , N
an DT N
impairment NN N
that WDT N
likely JJ N
influences VBZ N
all DT N
subsequent JJ N
face NN N
processing NN N
. . N

-DOCSTART- -X- O O

Exploratory JJ N
Subset NNP N
Analysis NNP N
of IN N
African JJ p
Americans NNPS p
From IN p
the DT p
PointBreak NNP p
Study NNP p
: : p
Pemetrexed-Carboplatin-Bevacizumab JJ i
Followed NNP i
by IN i
Maintenance NNP i
Pemetrexed-Bevacizumab NNP i
Versus NNP N
Paclitaxel-Carboplatin-Bevacizumab NNP i
Followed NNP i
by IN i
Maintenance NNP i
Bevacizumab NNP i
in IN p
Patients NNP p
With IN p
Stage NNP p
IIIB/IV NNP p
Nonsquamous NNP p
Non-Small-Cell NNP p
Lung NNP p
Cancer NNP p
. . p

INTRODUCTION NNP p
African JJ p
Americans NNPS p
have VBP p
a DT p
greater JJR p
incidence NN p
of IN p
lung NN p
cancer NN p
than IN p
whites NNS p
and CC N
have VBP N
been VBN N
underrepresented VBN N
in IN N
clinical JJ N
trials NNS N
. . N

In IN N
the DT N
PointBreak NNP N
trial NN N
( ( N
pemetrexed-carboplatin-bevacizumab JJ i
and CC i
maintenance JJ i
pemetrexed-bevacizumab JJ i
[ NN i
PemCBev NNP i
] NNP i
vs. IN N
paclitaxel-carboplatin-bevacizumab NN i
and CC i
maintenance NN i
bevacizumab NN i
[ NNP i
PacCBev NNP i
] NNP i
) ) i
, , i
10 CD p
% NN p
of IN p
the DT p
patients NNS p
were VBD p
African JJ p
American NNP p
. . p

PointBreak NNP N
had VBD N
negative JJ N
findings NNS N
; : N
PemCBev NNP N
did VBD N
not RB N
demonstrate VB o
superior JJ o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
. . o

MATERIALS NNP N
AND CC N
METHODS NNP N
PointBreak NNP N
subgroup NN o
efficacy NN o
and CC o
safety NN o
data NNS N
were VBD N
retrospectively RB N
analyzed VBN p
: : p
African JJ p
Americans NNPS p
versus VBP p
whites NNS p
for IN i
PemCBev NNP i
; : i
PemCBev NNP p
versus NN i
PacCBev NNP i
in IN p
African NNP p
Americans NNPS p
; : p
and CC p
academic JJ p
versus NN p
community NN p
settings NNS p
for IN p
African JJ p
Americans NNPS p
. . p

Hazard NNP o
ratios NNS o
( ( o
HRs NNP o
) ) o
and CC o
P NNP o
values NNS o
were VBD N
derived VBN N
from IN N
a DT N
multivariate NN o
Cox NNP o
proportional JJ N
hazards NNS N
model NN N
after IN N
adjusting VBG N
for IN N
covariates NNS N
. . N

RESULTS NNP p
Of IN p
939 CD p
intent-to-treat NN p
( ( p
ITT NNP p
) ) p
patients NNS p
, , p
94 CD p
were VBD p
African JJ p
American NNP p
and CC p
805 CD p
were VBD p
white JJ p
. . p

African-American JJ p
enrollment NN N
was VBD N
uniform JJ N
across IN N
the DT N
study NN N
sites NNS N
( ( N
median JJ N
, , N
1 CD N
African JJ N
American NNP N
per IN N
site NN N
) ) N
. . N

In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
OS NNP N
( ( N
HR NNP N
, , N
1.125 CD N
; : N
P NNP N
= NNP N
.525 NNP o
) ) o
, , o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
( ( o
HR NNP N
, , N
1.229 CD N
; : N
P NNP N
= NNP N
.251 NNP o
) ) o
, , o
response NN o
( ( o
P NNP o
= NNP N
.607 NNP N
) ) N
, , N
and CC N
toxicity NN o
profiles NNS o
were VBD o
similar JJ N
in IN N
African JJ N
Americans NNPS N
versus NN N
whites NNS N
. . N

For IN N
African JJ N
Americans NNPS o
, , o
OS NNP o
( ( N
HR NNP N
, , N
1.375 CD N
; : N
P NNP N
= NNP N
.209 NNP N
) ) N
, , o
PFS NNP o
( ( N
HR NNP N
, , N
0.902 CD N
; : N
P NNP N
= NNP N
.670 NNP N
) ) N
, , N
response NN N
( ( N
P NNP N
= NNP N
1.000 CD N
) ) N
, , N
and CC o
toxicity NN o
profiles NNS o
were VBD o
similar JJ o
in IN N
the DT N
PemCBev NNP N
versus NN N
PacCBev NNP N
arm NN N
. . N

For IN N
African JJ N
Americans NNPS N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
OS NNP o
( ( N
HR NNP N
, , N
0.661 CD N
; : N
P NNP N
= NNP N
.191 NNP N
) ) N
or CC N
PFS NNP o
( ( N
HR NNP N
, , N
0.969 CD N
; : N
P NNP N
= NNP N
.915 NNP N
) ) N
in IN N
academic JJ N
versus NN N
community NN N
practice NN N
settings NNS N
. . N

CONCLUSION NNP N
In IN N
the DT N
PemCBev NNP N
arm NN N
, , N
this DT N
exploratory NN N
analysis NN N
showed VBD N
no DT N
significant JJ N
differences NNS p
between IN p
African JJ p
Americans NNPS p
and CC p
whites NNS p
for IN o
the DT o
efficacy NN o
outcomes VBZ o
or CC o
toxicity NN o
profiles NNS o
. . N

Consistent JJ N
with IN N
the DT N
ITT NNP N
population NN N
negative JJ N
trial NN N
result NN N
, , N
for IN p
African JJ p
Americans NNPS p
, , p
the DT p
median JJ p
OS NNP N
was VBD N
not RB N
superior JJ N
for IN N
either DT N
arm NN N
. . N

For IN N
African JJ p
Americans NNPS p
, , p
PFS NNP p
and CC p
OS NNP N
were VBD N
similar JJ N
in IN N
the DT N
academic JJ N
and CC N
community NN N
settings NNS N
. . N

Additional JJ N
outcomes NNS N
data NNS p
for IN p
African JJ p
Americans NNPS p
should MD N
be VB N
collected VBN N
in IN N
lung NN N
cancer NN N
studies NNS N
. . N

-DOCSTART- -X- O O

A DT N
multicenter NN N
, , N
open-label JJ N
study NN N
of IN N
vernakalant NN N
for IN N
the DT N
conversion NN N
of IN N
atrial JJ p
fibrillation NN p
to TO N
sinus VB N
rhythm NN N
. . N

BACKGROUND IN N
The DT N
efficacy NN o
and CC o
safety NN o
of IN N
vernakalant NN N
, , N
a DT N
relatively RB N
atrial-selective JJ N
antiarrhythmic JJ N
agent NN N
, , N
in IN N
converting VBG N
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
to TO N
sinus VB o
rhythm NN o
( ( o
SR NNP o
) ) o
were VBD N
evaluated VBN N
in IN N
this DT N
multicenter NN p
, , p
open-label JJ p
study NN p
of IN p
patients NNS p
with IN p
AF NNP p
lasting VBG p
> RB p
3 CD p
hours NNS p
and CC p
< NNP p
or CC p
=45 JJ p
days NNS p
( ( N
RCT NNP N
no DT N
. . N

NCT00281554 NNP N
) ) N
. . N

METHODS NNP N
Adult NNP p
patients NNS p
with IN p
AF NNP p
and CC p
an DT p
indication NN p
for IN p
conversion NN p
to TO p
SR NNP o
received VBD i
a DT i
10-minute JJ i
intravenous JJ i
infusion NN i
of IN i
vernakalant NN i
( ( i
3 CD i
mg/kg NN i
) ) i
. . i

If IN i
after IN i
a DT i
15-minute JJ i
observation NN i
period NN i
AF NNP i
was VBD i
present JJ i
, , i
a DT i
second JJ i
10-minute JJ i
infusion NN i
of IN i
intravenous JJ i
vernakalant NN i
( ( i
2 CD i
mg/kg NN i
) ) i
was VBD i
given VBN i
. . i

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
was VBD N
the DT N
proportion NN N
of IN N
patients NNS i
with IN i
recent-onset JJ i
AF NNP o
( ( i
AF NNP i
lasting VBG i
> RB i
3 CD i
hours NNS i
to TO i
< VB i
or CC i
=7 VB i
days NNS i
) ) i
who WP i
converted VBD i
to TO i
SR NNP i
within IN i
90 CD i
minutes NNS i
of IN i
the DT i
start NN i
of IN i
the DT i
first JJ i
infusion NN i
. . i

Safety NNP i
evaluations NNS i
included VBD i
vital JJ o
signs NNS o
, , o
telemetry NN o
and CC o
Holter NNP o
monitoring NN o
, , o
12-lead JJ o
electrocardiography NN o
, , o
clinical JJ o
laboratory NN o
tests NNS o
, , o
physical JJ o
examinations NNS o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
236 CD p
hemodynamically RB p
stable JJ p
patients NNS p
with IN p
AF NNP p
received VBD N
intravenous JJ N
vernakalant NN N
. . N

Among IN N
them PRP N
, , N
167 CD p
( ( p
71 CD p
% NN p
) ) p
had VBD p
recent-onset VBN o
AF NNP o
and CC N
were VBD N
eligible JJ N
for IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
. . N

Vernakalant NNP N
rapidly RB N
converted VBD N
recent-onset JJ o
AF NNP o
to TO o
SR NNP o
in IN N
50.9 CD N
% NN N
of IN N
patients NNS N
, , N
with IN N
a DT N
median JJ N
time NN N
to TO N
conversion NN N
of IN N
14 CD N
minutes NNS N
among IN N
responders NNS N
. . N

The DT N
most RBS N
common JJ N
AEs NNP N
were VBD N
dysgeusia NNS o
, , o
sneezing VBG o
, , o
and CC o
paresthesia NN o
. . o

These DT N
occurred VBD N
at IN N
the DT N
time NN N
of IN N
vernakalant JJ N
infusion NN N
, , N
were VBD N
transient JJ N
, , N
and CC N
resolved VBD N
spontaneously RB N
. . N

Ten CD N
patients NNS N
( ( N
4.2 CD N
% NN N
) ) N
discontinued VBN N
vernakalant JJ N
treatment NN N
because IN N
of IN N
AEs NNP N
, , N
most JJS N
commonly RB N
( ( N
in IN N
4 CD N
of IN N
10 CD N
) ) N
hypotension NN o
. . o

There EX N
were VBD N
no DT N
episodes NNS N
of IN N
torsades NNS o
de FW o
pointes NNS o
, , o
ventricular JJ o
fibrillation NN o
, , o
or CC o
sustained VBD o
ventricular JJ o
tachycardia NN o
. . o

CONCLUSIONS NNP N
Vernakalant NNP N
rapidly RB N
converted VBD N
recent-onset JJ N
AF NNP N
to TO N
SR NNP N
, , N
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
may MD N
be VB N
a DT N
valuable JJ N
therapeutic JJ N
alternative NN N
for IN N
reestablishing VBG N
SR NNP N
in IN N
patients NNS p
with IN p
recent-onset JJ p
AF NNP p
. . p

-DOCSTART- -X- O O

Oral JJ i
sildenafil NN i
to TO N
control VB N
pulmonary JJ o
hypertension NN o
after IN p
congenital JJ p
heart NN p
surgery NN p
. . p

This DT N
study NN N
investigates VBZ N
the DT N
role NN N
of IN N
oral JJ N
sildenafil NN i
in IN N
decreasing VBG N
pulmonary JJ o
pressure NN o
after IN p
congenital JJ i
heart NN i
surgery NN i
. . i

Between NNP p
September NNP p
2002 CD p
and CC p
September NNP p
2004 CD p
, , p
among IN p
a DT p
group NN p
of IN p
postoperative JJ p
children NNS p
with IN p
large JJ p
septal JJ p
defects NNS p
, , p
moderate VBP p
to TO p
severe VB p
pulmonary JJ p
hypertension NN p
[ NNP p
pulmonary JJ p
artery NN p
( ( p
PA NNP p
) ) p
to TO p
aortic JJ p
( ( p
Ao NNP p
) ) p
pressure NN p
ratio NN p
of IN p
0.76 CD p
+/- JJ p
0.17 CD p
] NN p
and CC p
systemic JJ p
desaturation NN p
( ( p
Ao NNP p
Sat NNP p
= VBD p
0.89 CD p
+/- JJ p
0.11 CD p
) ) p
, , p
oral JJ i
sildenafil NN i
( ( p
0.3 CD p
mg NN p
x NN p
kg NN p
( ( p
-1 NNP p
) ) p
, , p
every DT p
3 CD p
hours NNS p
) ) p
was VBD p
administered VBN p
for IN p
a DT p
period NN p
of IN p
24-48 JJ p
hours NNS p
( ( i
sildenafil JJ i
group NN p
) ) p
. . p

These DT N
patients NNS p
were VBD N
compared VBN N
to TO N
a DT N
group NN N
of IN N
22 CD p
children NNS p
with IN p
similar JJ p
pathologies NNS p
who WP p
did VBD p
not RB p
receive VB p
sildenafil NN i
( ( i
control VB i
group NN p
) ) p
. . p

Postoperative JJ o
PA NNP o
pressure NN o
( ( N
28.61 CD N
+/- JJ N
7.80 CD N
vs JJ N
39.40 CD N
+/- JJ N
10.80 CD N
mm NN N
Hg NNP N
) ) N
and CC N
PA/Ao NNP o
pressure NN o
( ( N
0.28 CD N
+/- JJ N
0.08 CD N
vs JJ N
0.41 CD N
+/- JJ N
0.11 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sildenafil NN i
group NN N
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
0.001 CD N
respectively RB N
) ) N
. . N

Pulmonary JJ o
hypertensive JJ o
crisis NN o
was VBD N
detected VBN N
in IN N
4 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
none NN N
in IN N
the DT N
sildenafil NN i
group NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
rise NN N
in IN N
PA NNP o
pressure NN o
following VBG N
discontinuation NN N
of IN N
the DT N
drug NN N
( ( N
26.30 CD N
+/- JJ N
6.66 CD N
vs JJ N
28.49 CD N
+/- JJ N
10.93 CD N
mm NN N
Hg NNP N
, , N
p NN N
= NNP N
0.366 CD N
) ) N
. . N

No DT N
significant JJ o
complications NNS o
were VBD N
noticed VBN N
regarding VBG N
sildenafil NN i
use NN N
. . N

Low JJ N
doses NNS N
of IN N
oral JJ N
sildenafil NN i
appear VBP N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
to TO N
control VB N
postoperative JJ N
PA NNP N
pressure NN N
in IN N
children NNS N
. . N

Absence NN N
of IN N
rebound NN N
pulmonary JJ o
hypertension NN o
, , N
availability NN N
, , N
and CC N
low JJ N
cost NN N
of IN N
the DT N
drug NN N
are VBP N
considered VBN N
as IN N
its PRP$ N
major JJ N
advantages NNS N
. . N

-DOCSTART- -X- O O

Bioequivalence NNP N
evaluation NN N
of IN N
a DT N
fixed VBN i
dose JJ i
combination NN i
lamivudine NN i
+ NNP i
stavudine NN i
tablet NN N
with IN N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ i
tablet NN N
and CC N
stavudine NN i
capsule NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

The DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rate NN o
and CC o
extent NN o
of IN o
absorption NN o
of IN N
a DT N
fixed VBN N
dose JJ N
combination NN N
tablet NN N
of IN N
lamivudine NN i
( ( i
CAS NNP i
134678-17-4 CD i
) ) i
and CC i
stavudine NN i
( ( i
CAS NNP i
3056-17-5 CD i
) ) i
with IN N
the DT N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ i
tablet NN i
and CC i
stavudine NN i
capsule NN i
in IN N
24 CD p
healthy JJ p
volunteers NNS p
under IN p
fasting VBG p
conditions NNS p
. . p

The DT N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
test NN N
or CC N
reference NN N
treatment NN N
, , N
with IN N
the DT N
two CD N
treatment NN N
periods NNS N
separated VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
7 CD N
days NNS N
. . N

Plasma NNP o
samples NNS o
were VBD N
analyzed VBN N
for IN N
both DT N
analytes NNS N
lamivudine VBP i
and CC N
stavudine VBP i
by IN N
a DT N
validated JJ N
analytical JJ N
method NN N
. . N

Since IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
test/reference NN o
mean JJ N
ratio NN N
of IN N
the DT N
In-transformed NNP N
pharmacokinetic JJ N
variables NNS N
C NNP o
( ( o
max NN o
) ) o
AUC NNP o
( ( o
0-t JJ o
) ) o
and CC o
AUC NNP o
( ( o
0-infinity NN o
) ) o
were VBD N
clearly RB N
within IN N
the DT N
conventional JJ N
bioequivalence NN N
range NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
, , N
the DT N
two CD N
treatments NNS N
were VBD N
considered VBN N
bioequivalent NN N
. . N

The DT N
safety NN o
profiles NNS o
of IN N
both DT N
the DT N
test NN N
and CC N
reference NN N
formulations NNS N
were VBD N
comparable JJ N
. . N

-DOCSTART- -X- O O

High-dose JJ N
vitamin NN i
D3 NNP i
supplementation NN i
in IN N
children NNS p
and CC p
young JJ p
adults NNS p
with IN p
HIV NNP o
: : o
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
trial NN i
. . i

BACKGROUND NNP N
Suboptimal NNP N
vitamin NNP N
D NNP N
status NN N
is VBZ N
prevalent JJ N
in IN N
HIV-infected JJ p
patients NNS p
and CC N
associated VBN N
with IN N
increased JJ N
risk NN o
of IN o
disease NN o
severity NN o
and CC o
morbidity NN o
. . o

We PRP N
aimed VBD N
to TO N
determine VB N
12-month JJ N
safety NN o
and CC o
efficacy NN o
of IN N
daily JJ N
7000 CD i
IU NNP i
vitamin FW i
D3 NNP i
( ( N
vitD3 NN N
) ) N
versus NN N
placebo NN i
to TO N
sustain VB N
increased JJ o
serum NN o
25-hydroxyvitamin JJ o
D NNP o
( ( o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
) ) o
and CC o
improve VB o
immune NN o
status NN o
in IN N
HIV-infected JJ p
subjects NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
trial NN N
of IN N
perinatally RB p
acquired VBN p
HIV NNP p
( ( p
PHIV NNP p
) ) p
-infected VBD p
subjects NNS p
or CC p
behaviorally RB p
acquired VBN p
HIV NNP p
( ( p
BHIV NNP p
) ) p
-infected VBD p
subjects NNS p
( ( p
5.0-24.9 CD p
years NNS p
) ) p
. . p

Safety NNP o
, , o
25 CD o
( ( o
OH NNP o
) ) o
D-related NNP o
parameters NNS o
and CC o
immune JJ o
status NN o
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
. . N

RESULTS NNP N
Fifty-eight JJ p
subjects NNS p
enrolled VBN p
( ( p
67 CD p
% NN p
male NN p
, , p
85 CD p
% NN p
African JJ p
American NNP p
and CC p
64 CD p
% NN p
BHIV NNP p
) ) p
and CC p
50 CD p
completed VBN p
with IN p
no DT p
safety NN o
concerns NNS o
. . o

In IN N
unadjusted JJ N
analyses NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
randomization NN N
groups NNS N
at IN N
baseline NN N
; : N
at IN N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
, , N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
was VBD N
higher RBR N
with IN N
supplementation NN N
than IN N
baseline NN N
and CC N
higher JJR N
than IN N
with IN N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
adjusted JJ N
mixed JJ N
models NNS N
, , N
in IN N
the DT N
supplementation NN N
group NN N
, , N
the DT N
fixed JJ N
effect NN N
of IN N
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
was VBD N
higher JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Percentage NN o
of IN o
naive JJ o
T-helper NNP o
cells NNS o
( ( o
Th NNP o
naive CD o
% NN o
) ) o
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
T-helper NNP o
cells NNS o
( ( o
CD4 NNP o
% NN o
) ) o
marginally RB N
( ( N
P NNP N
< NNP N
0.10 CD N
) ) N
increased VBN N
with IN N
supplementation NN N
in IN N
those DT N
taking VBG N
highly RB N
active JJ N
antiretroviral JJ N
therapy NN N
( ( N
HAART NNP N
) ) N
, , N
and CC N
RNA NNP o
viral JJ o
load NN o
was VBD N
reduced VBN N
( ( N
P NNP N
? . N
0.05 CD N
) ) N
. . N

In IN N
exploratory JJ N
linear JJ N
models NNS N
, , N
change NN N
in IN N
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
predicted VBD o
RNA NNP o
viral JJ o
load NN o
at IN o
3 CD N
and CC N
12 CD N
months NNS N
and CC o
CD4 NNP o
% NN o
at IN o
3 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Daily JJ N
7000 CD N
IU NNP N
vitD3 NN N
for IN N
12 CD N
months NNS N
was VBD N
safe JJ N
in IN N
HIV-infected JJ N
subjects NNS N
and CC N
effective JJ N
in IN N
increasing VBG o
25 CD o
( ( o
OH NNP o
) ) o
D. NNP o
Supplementation NNP N
improved VBD N
some DT o
clinically RB o
important JJ o
HIV NNP o
immune NN o
markers NNS o
in IN o
subjects NNS N
on IN N
HAART NNP N
. . N

Adjunct NNP N
therapy NN N
with IN N
high-dose JJ N
, , N
daily JJ i
vitD3 NN i
for IN i
HIV-infected JJ N
subjects NNS N
and CC N
for IN N
those DT N
on/off JJ N
HAART NNP N
requires VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -X- O O

Brief JJ N
acceptance-based JJ i
intervention NN i
for IN N
increasing VBG N
intake JJ o
attendance NN o
at IN p
a DT p
community NN p
mental JJ p
health NN p
center NN p
. . p

Intake VB N
no-show JJ N
rates NNS N
for IN N
psychotherapy NN N
vary NN N
from IN N
20 CD N
% NN N
to TO N
57 CD N
% NN N
( ( N
Swenson NNP N
& CC N
Pekarik NNP N
, , N
1988 CD N
) ) N
, , N
and CC N
experiential JJ N
avoidance NN N
may MD N
be VB N
related VBN N
to TO N
failure NN N
to TO N
attend VB N
intake JJ N
sessions NNS N
. . N

This DT N
pilot NN N
study NN N
attempted VBD N
to TO N
increase VB N
intake VB N
attendance NN N
at IN p
a DT p
community NN p
mental JJ p
health NN p
center NN p
by IN N
employing VBG N
a DT N
brief JJ N
experiential JJ N
acceptance-based JJ N
intervention NN N
. . N

Those DT p
who WP p
scheduled VBD p
intakes NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
orientation NN i
letter NN i
or CC i
acceptance-enhanced JJ i
orientation NN i
letter NN i
; : i
rates NNS N
from IN N
these DT N
conditions NNS N
were VBD N
compared VBN N
with IN N
a DT N
retrospective JJ N
comparison NN N
control NN N
group NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
by IN N
way NN N
of IN N
an DT N
online JJ N
random NN N
number NN N
generator NN N
. . N

Persons NNS N
assigned VBD N
to TO N
the DT N
orientation NN N
group NN N
did VBD N
not RB N
have VB N
a DT N
higher JJR N
show NN o
rate NN o
than IN N
persons NNS N
within IN N
the DT N
control NN i
group NN N
( ( N
?48 CD N
% NN N
compared VBN N
with IN N
?52 NNP N
% NN N
) ) N
. . N

Persons NNS N
assigned VBD N
to TO N
the DT N
acceptance NN i
group NN i
did VBD N
have VB N
higher JJR o
show NN o
rates NNS o
than IN o
persons NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
?67 CD N
% NN N
compared VBN N
with IN N
?48 NNP N
% NN N
and CC N
?52 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
however RB N
this DT N
difference NN N
was VBD N
nonsignificant JJ N
. . N

Results VB N
suggest JJS N
that DT N
brief JJ N
acceptance-based JJ N
interventions NNS N
should MD N
be VB N
further JJ N
studied VBN N
for IN N
their PRP$ N
potential JJ N
value NN N
in IN N
maximizing VBG N
client NN N
attendance NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
initiating VBG N
treatment NN N
with IN N
valsartan/hydrochlorothiazide NN i
in IN N
patients NNS p
with IN p
stage-1 JJ p
or CC p
stage-2 JJ p
hypertension NN p
. . p

This DT N
prospective JJ N
, , N
6-week JJ N
, , N
multicenter NN N
, , N
double-blind NN N
study NN N
examined VBD N
the DT N
benefits NNS N
of IN N
initiating VBG N
treatment NN N
with IN N
combination NN N
valsartan/hydrochlorothiazide NN i
( ( i
HCTZ NNP i
) ) i
compared VBN N
with IN N
initial JJ N
valsartan NNS N
monotherapy NN N
for IN N
648 CD p
patients NNS p
with IN p
stage-1 JJ p
or CC p
stage-2 JJ p
hypertension NN p
( ( p
age=52.6+/-10 JJ p
years NNS p
; : p
54 CD p
% NN p
male NN p
; : p
baseline VB p
blood NN p
pressure NN p
( ( p
BP NNP p
) ) p
=161/98 VBP p
mm JJ p
Hg NNP p
, , p
32 CD p
% NN p
stage NN p
1 CD p
) ) p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
valsartan VB i
80 CD i
mg NN i
( ( i
V-low NNP i
) ) i
, , i
valsartan $ i
160 CD i
mg NN i
( ( i
V-high NNP i
) ) i
or CC i
valsartan/HCTZ $ i
160/12.5 CD i
mg NN i
( ( i
V/HCTZ NNP i
) ) i
, , i
and CC i
electively RB i
titrated VBN i
after IN i
weeks NNS i
2 CD i
and CC i
4 CD i
to TO i
the DT i
next JJ i
dosage NN i
level NN i
( ( i
maximum JJ i
dose NN i
valsartan/HCTZ NN i
160/25 CD i
mg NN i
) ) i
if IN i
BP NNP i
remained VBD i
> JJ i
140/90 CD i
mm NN i
Hg NNP i
. . i

At IN N
end NN N
of IN N
the DT N
study NN N
, , N
patients NNS N
initiated VBN N
with IN N
V/HCTZ NNP i
required VBD N
less JJR o
titration JJ o
steps NNS o
compared VBN N
with IN N
the DT N
initial JJ N
valsartan NN N
monotherapy NN N
groups NNS N
( ( N
63 CD N
vs RB N
86 CD N
% NN N
required VBN N
titration NN N
by IN N
study JJ N
end NN N
, , N
respectively RB N
) ) N
and CC N
reached VBD N
the DT N
target NN N
BP NNP o
goal NN o
of IN N
< $ N
140/90 CD N
mm NN N
Hg NNP N
in IN N
a DT N
shorter JJ N
period NN N
of IN N
time NN N
( ( N
2.8 CD N
weeks NNS N
) ) N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
vs NN N
V-low NNP N
( ( N
4.3 CD N
weeks NNS N
) ) N
and CC N
V-high NNP N
( ( N
3.9 CD N
weeks NNS N
) ) N
. . N

Initial JJ N
combination NN N
therapy NN N
was VBD N
also RB N
associated VBN N
with IN N
higher JJR N
BP NNP o
control NN o
rates NNS o
and CC N
greater JJR N
reductions NNS o
in IN o
both DT o
systolic JJ o
and CC o
diastolic JJ o
BP NNP o
from IN N
baseline NN N
( ( N
63 CD N
% NN N
, , N
-27.7+/-13/-15.1+/-8 NNP N
mm NNP N
Hg NNP N
) ) N
compared VBN N
with IN N
V-low NNP N
( ( N
46 CD N
% NN N
, , N
-21.2+/-13/-11.4+/-8 NNP N
mm NNP N
Hg NNP N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
or CC N
V-high NNP N
( ( N
51 CD N
% NN N
, , N
-24.0+/-13/-12.0+/-10 NNP N
mm NNP N
Hg NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Overall JJ N
and CC N
drug-related JJ o
AEs NNP o
were VBD N
mild JJ N
to TO N
moderate VB N
and CC N
were VBD N
similar JJ N
between IN N
V/HCTZ NNP i
( ( N
53.1 CD N
and CC N
14.1 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
the DT N
two CD N
monotherapy NN N
groups NNS N
, , N
V-low NNP N
( ( N
50.5 CD N
and CC N
13.8 CD N
% NN N
) ) N
and CC N
V-high NNP N
( ( N
50.7 CD N
and CC N
11.8 CD N
% NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
initiating VBG N
therapy NN N
with IN N
a DT N
combination NN N
of IN N
valsartan NN i
and CC N
low-dose JJ N
HCTZ NNP i
results NNS N
in IN N
early JJ o
, , o
improved JJ o
BP NNP o
efficacy NN o
with IN N
similar JJ N
tolerability NN o
as IN N
compared VBN N
with IN N
starting VBG N
treatment NN N
with IN N
a DT N
low JJ N
or CC N
higher JJR N
dose NN N
of IN N
valsartan NN i
for IN N
patients NNS p
with IN p
stage-1 JJ p
and CC p
stage-2 JJ p
hypertension NN p
. . p

-DOCSTART- -X- O O

Impact NN N
of IN N
vitamin NN i
D NNP i
supplementation NN i
on IN N
inflammatory JJ o
markers NNS o
in IN N
African JJ p
Americans NNPS p
: : p
results NNS N
of IN N
a DT N
four-arm JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
trial NN N
. . N

African JJ p
Americans NNPS p
have VBP p
a DT p
disproportionate JJ p
burden NN p
of IN p
inflammation-associated JJ p
chronic JJ p
diseases NNS p
such JJ N
as IN N
cancer NN N
and CC N
lower JJR N
circulating NN N
levels NNS N
of IN N
25-hydroxyvitamin JJ N
D NNP N
[ NN N
25 CD N
( ( N
OH NNP N
) ) N
D NNP N
] NNP N
. . N

The DT N
effect NN N
of IN N
vitamin NN i
D3 NNP i
( ( i
cholecalciferol NN i
) ) i
supplementation NN i
on IN N
inflammatory JJ o
markers NNS o
is VBZ N
uncertain JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
supplemental JJ i
oral JJ i
vitamin NN i
D NNP i
( ( i
placebo NN i
, , N
1,000 CD N
, , N
2,000 CD N
, , N
or CC N
4,000 CD N
IU/day NN N
of IN N
vitamin NN N
D3 NNP N
orally RB N
for IN N
3 CD N
months NNS N
) ) N
in IN N
328 CD p
African JJ p
Americans NNPS p
( ( p
median JJ p
age NN p
, , p
51 CD p
years NNS p
) ) p
of IN p
public JJ p
housing NN p
communities NNS p
in IN p
Boston NNP p
, , p
MA NNP p
, , p
who WP p
were VBD p
enrolled VBN p
over RP p
three CD p
consecutive JJ p
winter NN p
periods NNS p
( ( p
2007-2010 JJ p
) ) p
. . p

Change NN N
from IN N
0 CD N
to TO N
3 CD N
months NNS N
of IN N
plasma NN o
levels NNS o
of IN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
, , o
high-sensitivity JJ o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
interleukin FW o
( ( o
IL NNP o
) ) o
-6 NN o
, , o
IL-10 NNP o
, , o
and CC o
soluble JJ o
TNF-? NNP o
receptor NN o
type NN o
2 CD o
( ( o
sTNF-R2 NN o
) ) o
in IN N
292 CD N
( ( N
89 CD N
% NN N
) ) N
participants NNS N
were VBD N
measured VBN N
. . N

Overall NNP N
, , N
no DT N
statistically RB N
significant JJ N
changes NNS N
in IN o
CRP NNP o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
sTNF-R2 NNS o
were VBD N
observed VBN N
after IN N
the DT N
vitamin NN N
D NNP N
supplementation NN N
period NN N
. . N

Baseline NNP o
CRP NNP o
was VBD N
significantly RB N
inversely RB N
associated VBN N
with IN N
the DT o
baseline NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
level NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
unadjusted JJ N
and CC N
adjusted JJ N
models NNS N
. . N

An DT N
interaction NN N
between IN N
baseline NN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
and CC o
vitamin NNP o
D NNP o
supplementation NN o
was VBD N
observed VBN N
for IN N
outcome JJ N
change NN N
in IN o
log NN o
CRP NNP o
( ( N
month NN N
3-month RB N
0 CD N
; : N
P NNP N
for IN N
interaction NN N
= NNP N
0.04 CD N
) ) N
. . N

Within IN N
an DT N
unselected JJ N
population NN N
of IN N
African JJ N
Americans NNPS N
, , N
short-term JJ i
exposure NN i
to TO i
vitamin VB i
D NNP i
supplementation NN i
produced VBD N
no DT N
change NN N
in IN o
circulating VBG o
inflammatory JJ o
markers NNS o
. . o

This DT N
study NN N
confirms VBZ N
the DT N
strong JJ N
independent JJ N
association NN N
of IN o
CRP NNP o
with IN o
25 CD o
( ( o
OH NNP o
) ) o
D NNP o
status NN N
even RB N
after IN N
adjusting VBG N
for IN N
body NN N
mass NN N
index NN N
. . N

Future JJ N
studies NNS N
of IN N
longer JJR N
supplemental JJ N
vitamin NN N
D3 NNP N
duration NN N
are VBP N
necessary JJ N
to TO N
examine VB N
the DT N
complex JJ N
influence NN N
of IN N
vitamin NN N
D3 NNP N
on IN N
CRP NNP N
and CC N
other JJ N
chronic JJ N
inflammatory NN N
cytokines NNS N
for IN N
possible JJ N
reduction NN N
of IN p
cancer NN p
health NN p
disparities NNS p
in IN p
African JJ p
Americans NNPS p
. . p

-DOCSTART- -X- O O

Mouth NNP N
closing NN N
device NN N
( ( N
chinstrap NN N
) ) N
reduces VBZ N
mouth JJ o
leak NN o
during IN N
nasal JJ p
CPAP NNP p
. . p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Mouth NNP N
leak VBP N
occasionally RB N
complicates VBZ N
continuous JJ N
positive JJ N
airway NN N
pressure NN N
( ( p
CPAP NNP p
) ) p
therapy NN p
, , N
which WDT N
leads VBZ N
to TO N
discomfort VB N
. . N

While IN N
a DT N
chinstrap NN N
prevents VBZ N
the DT N
mouth NN N
from IN N
opening VBG N
during IN N
sleep NN N
, , N
its PRP$ N
efficacy NN N
in IN N
diminishing VBG N
mouth NN N
leak NN N
has VBZ N
not RB N
been VBN N
studied VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Fifteen NNP p
patients NNS p
with IN p
mouth JJ p
leak JJ p
complaining NN p
of IN p
mouth NN p
dryness NN p
and CC p
nasal JJ p
obstruction NN p
underwent JJ N
two CD i
consecutive JJ i
overnight JJ i
polysomnographies NNS i
, , i
one CD i
with IN i
a DT i
chinstrap NN i
, , i
in IN i
random JJ i
order NN i
. . i

Cephalometry NN o
with IN i
and CC i
without IN i
a DT i
chinstrap NN i
was VBD N
randomly RB N
performed VBN N
on IN N
six CD p
patients NNS p
. . p

RESULTS NNP N
With IN N
the DT N
chinstrap NN N
, , N
both DT N
mouth FW o
leak NN o
and CC o
the DT o
arousal NN o
index NN o
decreased VBD N
significantly RB N
, , N
from IN N
( ( N
mean+/-SD JJ N
) ) N
42.9+/-23.5 CD N
to TO N
23.8+/-13.3 CD N
% NN N
of IN N
total JJ o
sleep JJ o
time NN o
( ( N
TST NNP N
) ) N
, , N
and CC N
from IN N
33.4+/-18.6 JJ N
to TO N
23.6+/-9.3/sleep JJ N
hour NN N
, , N
respectively RB N
. . N

However RB N
, , N
snoring VBG o
time NN o
showed VBD N
a DT N
concomitant JJ N
increase NN N
from IN N
6.7+/-14.3 JJ N
to TO N
24.0+/-13.2 CD N
% NN N
of IN N
TST NNP N
. . N

The DT N
arousal JJ o
index NN o
was VBD N
significantly RB N
higher JJR N
during IN N
leak JJR N
periods NNS N
, , N
and CC N
its PRP$ N
changes NNS N
correlated VBN N
positively RB N
with IN N
changes NNS N
in IN N
mouth NN o
leak NN o
. . o

Cephalometric JJ o
measures NNS o
showed VBD N
a DT N
significant JJ N
decrease NN N
in IN N
anterior JJ o
lower JJR o
facial JJ o
height NN o
. . o

CONCLUSIONS VB N
The DT N
chinstrap NN N
, , N
by IN N
closing VBG N
the DT N
mouth NN N
during IN N
CPAP NNP N
, , N
reduces VBZ N
mouth JJ N
leak NN N
and CC N
therefore RB N
the DT N
arousal NN N
index NN N
in IN N
most JJS N
patients NNS N
. . N

Nevertheless NNP N
, , N
the DT N
indices NNS N
remained VBD N
unacceptably RB N
high JJ N
. . N

The DT N
chinstrap NN N
may MD N
also RB N
increase VB N
snoring NN N
and CC N
, , N
in IN N
rare JJ N
cases NNS N
, , N
can MD N
worsen VB N
the DT N
respiratory NN N
disturbance NN N
index NN N
. . N

Consideration NN N
of IN N
these DT N
potential JJ N
effects NNS N
is VBZ N
important JJ N
before IN N
instituting VBG N
regular JJ N
home NN N
use NN N
of IN N
the DT N
chinstrap NN N
. . N

-DOCSTART- -X- O O

Stepping VBG i
Stones NNP i
Triple NNP i
P NNP i
: : i
an DT N
RCT NNP N
of IN N
a DT N
parenting VBG i
program NN i
with IN N
parents NNS p
of IN p
a DT p
child NN p
diagnosed VBN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
. . p

Whilst IN N
the DT N
Triple NNP i
P NNP i
Positive NNP i
Parenting NNP i
Program NNP i
has VBZ N
a DT N
large JJ N
evidence NN N
base NN N
( ( N
Sanders NNP N
, , N
Clinical NNP N
Child NNP N
and CC N
Family NNP N
Psychology NNP N
Review NNP N
2:71-90 CD N
, , N
1999 CD N
; : N
Sanders NNP N
, , N
Journal NNP N
of IN N
Consulting NNP N
and CC N
Clinical NNP N
Psychology NNP N
68:624-640 CD N
, , N
2000 CD N
) ) N
and CC N
preliminary JJ N
evidence NN N
indicates VBZ N
that IN N
Stepping VBG i
Stones NNP i
Triple NNP i
P NNP i
is VBZ N
also RB N
efficacious JJ N
( ( N
Roberts NNP N
, , N
Journal NNP N
of IN N
Clinical NNP N
Child NNP N
and CC N
Adolescent NNP N
Psychology NNP N
, , N
35 CD N
( ( N
2 CD N
) ) N
:180-193 NN N
, , N
2006 CD N
) ) N
, , N
to TO N
date NN N
Stepping NNP i
Stones NNP i
has VBZ N
not RB N
been VBN N
evaluated VBN N
with IN N
the DT N
ASD NNP N
population NN N
. . N

Fifty-nine JJ p
families NNS p
with IN p
a DT p
child NN p
with IN p
ASD NNP p
aged VBD p
between IN p
2 CD p
and CC p
9 CD p
participated VBN p
in IN N
this DT N
randomized VBN N
controlled VBD N
trial NN N
. . N

The DT N
results NNS N
demonstrate VBP N
significant JJ N
improvements NNS N
in IN N
parental JJ o
reports NNS o
of IN o
child JJ o
behaviour NN o
and CC o
parenting NN o
styles NNS o
with IN o
the DT o
treatment NN o
effects NNS o
for IN o
child NN o
behaviour NN o
, , o
parental NN o
over IN o
reactivity NN o
and CC o
parental JJ o
verbosity NN o
being VBG N
maintained VBN N
at IN N
follow-up JJ N
6 CD N
months NNS N
later RB N
. . N

Further RBR N
, , N
the DT N
results NNS N
suggest VBP N
significant JJ N
improvements NNS N
in IN N
parental JJ o
satisfaction NN o
and CC o
conflict NN o
about RB o
parenting VBG o
as RB N
well RB N
as IN N
a DT N
sleeper JJ o
effect NN o
for IN o
parental JJ o
efficacy NN o
. . o

The DT N
results NNS N
indicate VBP N
that IN N
Stepping VBG i
Stones NNP i
Triple NNP i
P NNP i
is VBZ N
a DT N
promising JJ N
intervention NN N
for IN N
parents NNS p
of IN p
children NNS p
with IN p
ASD NNP p
. . p

Limitations NNS N
and CC N
future JJ N
research NN N
are VBP N
also RB N
addressed VBN N
. . N

-DOCSTART- -X- O O

Different NNP i
aprotinin NN i
applications NNS i
influencing VBG N
hemostatic JJ N
changes NNS N
in IN N
orthotopic NN p
liver NN p
transplantation NN p
. . p

The DT N
effect NN N
of IN N
different JJ N
aprotinin NN i
applications NNS i
on IN N
hemostatic JJ N
changes NNS N
and CC N
blood NN N
product NN N
requirements NNS N
in IN N
orthotopic JJ p
liver NN p
transplantation NN p
was VBD N
investigated VBN N
in IN N
a DT N
prospective JJ N
, , N
open JJ N
, , N
and CC N
randomized VBD N
study NN N
. . N

From IN p
November NNP p
1989 CD p
to TO p
June NNP p
1990 CD p
, , p
13 CD p
patients NNS p
received VBD N
aprotinin RB i
as IN N
a DT N
bolus NN i
of IN i
0.5 CD i
Mill NNP i
. . i

Kallikrein NNP N
inactivator JJ N
units NNS N
( ( N
KIU NNP N
) ) N
on IN N
three CD N
occasions NNS N
in IN N
the DT N
course NN N
of IN N
an DT N
OLT NNP N
, , N
whereas RB N
10 CD N
other JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
continuous JJ i
aprotinin JJ i
infusion NN i
of IN i
0.1-0.4 JJ i
Mill NNP i
. . i

KIU/hr NNP N
. . N

Before IN N
and CC N
after IN N
reperfusion NN N
of IN N
the DT N
graft NN o
liver NN o
, , o
signs NNS o
of IN o
hyperfibrinolysis NN o
, , N
measured VBN N
by IN N
thrombelastography NN N
, , N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
infusion NN N
group NN N
. . N

Tissue-type JJ o
plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
activity NN o
increased VBD N
during IN N
the DT N
anhepatic JJ N
phase NN N
but CC N
to TO N
a DT N
significantly RB N
lesser JJR N
extent NN N
in IN N
the DT N
infusion NN N
group NN N
. . N

Blood NNP o
product NN o
requirements NNS o
during IN N
OLT NNP N
were VBD N
tendentiously RB N
higher JJR N
in IN N
the DT N
bolus NN N
group NN N
but CC N
not RB N
significantly RB N
so RB N
. . N

However RB N
, , N
the DT N
use NN N
of IN N
packed JJ o
red JJ o
blood NN o
cells NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
postoperative JJ N
period NN N
, , N
whereas IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
fresh JJ N
frozen NN N
plasma NN o
requirements NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

All DT N
23 CD p
patients NNS p
have VBP N
survived VBN o
, , N
and CC N
only RB N
one CD N
woman NN N
of IN N
each DT N
group NN N
required VBN N
retransplantation NN o
due JJ N
to TO N
severe VB N
host-versus-graft JJ o
reactions NNS o
. . o

Furthermore RB N
, , N
we PRP N
investigated VBD N
the DT N
perfusate NN N
of IN N
the DT N
graft NN N
liver NN N
in IN N
both DT N
groups NNS N
and CC N
detected JJ N
signs NNS N
of IN N
a DT N
decreased JJ N
t-PA JJ o
release NN o
in IN N
the DT N
infusion NN N
group NN N
. . N

Our PRP$ N
results NNS N
demonstrate VBP N
an DT N
advantage NN N
of IN N
aprotinin NN i
given VBN N
as IN N
continuous JJ N
infusion NN N
over IN N
bolus JJ N
application NN N
in IN N
OLT NNP N
. . N

-DOCSTART- -X- O O

Making VBG N
the DT N
connection NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
social JJ N
skills NNS N
at IN N
school NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
This DT N
study NN N
compared VBN N
two CD N
interventions NNS N
for IN N
improving VBG N
the DT N
social JJ o
skills NNS o
of IN N
high JJ p
functioning VBG p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
in IN p
general JJ p
education NN p
classrooms NNS p
. . p

One CD N
intervention NN N
involved VBN N
a DT N
peer-mediated JJ i
approach NN i
( ( i
PEER NNP i
) ) i
and CC N
the DT N
other JJ N
involved VBD N
a DT N
child-assisted JJ i
approach NN i
( ( i
CHILD NNP i
) ) i
. . i

METHOD PDT N
The DT N
two CD N
interventions NNS N
were VBD N
crossed VBN N
in IN N
a DT N
2 CD N
? . N
2 CD N
factorial JJ N
design NN N
yielding VBG N
control NN i
, , i
PEER NNP i
, , i
CHILD NNP i
, , i
and CC i
both DT N
PEER NNP i
and CC i
CHILD NNP i
conditions NNS i
. . p

Sixty NNP p
children NNS p
participated VBD p
from IN p
56 CD p
classrooms NNS p
in IN p
30 CD p
schools NNS p
. . p

Interventions NNS p
involved VBD N
12 CD N
sessions NNS N
over IN N
6 CD N
weeks NNS N
, , N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

Outcome NNP N
measures NNS N
included VBD o
self NN o
, , o
peer NN o
and CC o
teacher JJR o
reports NNS o
of IN o
social JJ o
skills NNS o
and CC o
independent JJ o
weekly JJ o
observations NNS o
of IN o
children NNS o
on IN o
their PRP$ o
school NN o
playground NN o
over IN o
the DT o
course NN o
of IN o
the DT o
intervention NN o
. . o

RESULTS NNP o
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN o
social JJ o
network NN o
salience NN o
, , o
number NN o
of IN o
friendship JJ o
nominations NNS o
, , o
teacher JJ o
report NN o
of IN o
social JJ o
skills NNS o
in IN o
the DT o
classroom NN o
, , o
and CC o
decreased JJ o
isolation NN o
on IN o
the DT o
playground NN o
for IN o
children NNS N
who WP N
received VBD i
PEER NNP i
interventions NNS N
. . N

Changes NNS N
obtained VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
persisted VBD N
to TO N
the DT N
3-month JJ N
follow-up NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
significant JJ N
improvements NNS N
can MD N
be VB N
made VBN N
in IN o
peer JJ o
social JJ o
connections NNS o
for IN o
children NNS N
with IN N
autism NN p
spectrum NN p
disorders NNS p
in IN p
general JJ p
education NN N
classrooms NNS N
with IN N
a DT N
brief JJ N
intervention NN N
, , N
and CC N
that IN N
these DT N
gains NNS N
persist VBP N
over IN N
time NN N
. . N

-DOCSTART- -X- O O

The DT N
peroxisome JJ N
proliferator-activated JJ N
receptor-gamma JJ N
agonist NN N
pioglitazone NN i
increases VBZ N
number NN o
and CC o
function NN o
of IN o
endothelial JJ o
progenitor NN o
cells NNS o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
and CC p
normal JJ p
glucose JJ p
tolerance NN p
. . p

OBJECTIVE CC N
Peroxisome JJ N
proliferator-activated JJ N
receptor-gamma NN N
( ( N
PPAR NNP N
gamma NN N
) ) N
agonists VBZ N
( ( i
thiazolidinediones NNS i
[ NNP i
TZDs NNP i
] NNP i
) ) i
are VBP N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
diabetes NNS N
. . N

Bone CD N
marrow-derived JJ N
endothelial JJ N
progenitor NN N
cells NNS N
( ( N
EPCs NNP N
) ) N
improve VB N
vascular JJ o
function NN o
and CC N
predict NN N
cardiovascular NN o
risk NN o
. . o

The DT N
effect NN N
of IN N
pioglitazone NN i
therapy NN N
on IN N
EPCs NNP N
was VBD N
examined VBN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
AND NNP N
RESULTS NNP N
We PRP N
performed VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
on IN N
patients NNS p
with IN p
documented JJ p
stable JJ p
coronary JJ p
artery NN p
disease NN p
and CC p
normal JJ p
glucose JJ p
tolerance NN p
. . p

Of IN N
54 CD p
patients NNS p
with IN p
normal JJ p
fasting VBG p
glucose JJ p
levels NNS p
, , p
18 CD p
showed VBD p
impaired JJ p
glucose JJ p
tolerance NN p
and CC p
36 CD p
patients NNS p
with IN p
normal JJ p
glucose JJ p
tolerance NN p
were VBD p
randomized VBN p
to TO N
30-day JJ N
treatment NN N
with IN N
pioglitazone NN i
( ( N
45 CD N
mg NN N
) ) N
or CC i
placebo NN i
in IN i
addition NN i
to TO i
optimal VB i
medical JJ i
therapy NN i
. . i

All DT N
patients NNS N
in IN N
the DT N
TZD NNP i
group NN N
showed VBD N
an DT N
increase NN N
of IN N
adiponectin JJ o
levels NNS o
as IN N
an DT N
indicator NN N
of IN N
compliance NN N
( ( N
11.4 CD N
+/- JJ N
1.1 CD N
to TO N
36.8 CD N
+/- JJ N
2.1 CD N
microg/ml NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

TZD NNP i
, , N
but CC N
not RB N
placebo VB i
, , N
decreased VBN N
mean JJ o
high-sensitivity NN o
C-reactive JJ o
protein NN o
to TO N
43 CD N
+/- JJ N
19 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Pioglitazone NN N
increased VBD N
CD34 NNP o
( ( o
+ NNP o
) ) o
/kinase NN o
insert JJ o
domain NN o
receptor NN o
( ( o
+ NNP o
) ) o
EPCs NNP o
to TO N
142 CD N
+/- JJ N
9 CD N
% NN N
and CC N
cultured VBD o
1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine-labeled JJ o
acetylated JJ o
LDL NNP o
( ( o
+ NNP o
) ) o
/lectin NN o
( ( o
+ NNP o
) ) o
EPCs NNP o
to TO N
180 CD N
+/- JJ N
3 CD N
% NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

EPC JJ o
numbers NNS o
were VBD N
not RB N
changed VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

TZD NNP N
increased VBD N
the DT N
SDF-1-induced NNP o
migratory NN o
capacity NN o
to TO N
146 CD N
+/- JJ N
9 CD N
% NN N
per IN N
EPC NNP N
number NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
upregulated VBD N
the DT N
clonogenic JJ o
potential NN o
of IN o
EPCs NNP o
, , N
increasing VBG N
the DT o
colony-forming JJ o
units NNS o
to TO N
172 CD N
+/- JJ N
12 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
cultured JJ N
human JJ N
EPCs NNP N
, , N
TZD NNP i
increased VBD N
EPC NNP o
numbers NNS o
and CC o
migration NN o
and CC o
reduced JJ o
NADPH-oxidase NNP o
activity NN o
. . o

The DT N
TZD NNP i
effect NN N
was VBD N
reversed VBN N
by IN N
the DT N
PPAR NNP N
gamma NN N
antagonist NN N
GW9662 NNP N
and CC N
mimicked VBN N
by IN N
treatment NN N
with IN N
adiponectin NN N
. . N

CONCLUSIONS VB N
The DT N
PPAR NNP N
gamma NN N
agonist NN N
pioglitazone NN i
increases VBZ N
the DT N
number NN o
and CC o
function NN o
of IN o
EPCs NNP o
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

The DT N
effect NN N
represents VBZ N
a DT N
potential JJ N
regenerative NN N
mechanism NN N
in IN N
atherosclerosis NN N
and CC N
is VBZ N
observed VBN N
in IN N
normoglycemic JJ p
individuals NNS p
with IN p
stable JJ p
coronary JJ p
artery NN p
disease NN p
. . p

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
Naftidrofuryl NNP i
on IN N
ethanol-induced JJ N
liver NN N
damage NN N
in IN N
chronic JJ p
alcoholic JJ p
patients NNS p
. . p

A DT N
prospective JJ N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
intramuscular JJ N
Naftidrofuryl NNP i
was VBD N
carried VBN N
out RP N
on IN N
32 CD p
randomly RB p
selected VBN p
hospitalized VBN p
male JJ p
alcoholic JJ p
patients NNS p
with IN p
clinical JJ p
, , p
biochemical JJ p
and CC p
histological JJ p
evidence NN p
of IN p
hepatic JJ p
damage NN p
. . p

Seventeen JJ N
patients NNS N
received VBD N
the DT N
drug NN N
( ( N
40 CD N
mg NN N
in IN N
5 CD N
ml NN N
i.m NN N
. . N

three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
) ) N
and CC N
15 CD N
patients NNS N
received VBD N
a DT N
placebo NN i
( ( N
5 CD N
ml NN N
in IN N
normal JJ N
saline JJ N
i.m NN N
. . N

three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
) ) N
. . N

The DT N
drug NN N
was VBD N
well RB N
tolerated VBN N
and CC N
there EX N
were VBD N
no DT N
adverse JJ o
side-effects NNS o
. . o

Naftidrofuryl NNP i
significantly RB N
improved VBD N
the DT N
physiological JJ o
function NN o
of IN o
the DT o
liver NN o
cells NNS o
as IN o
reflected VBN o
by IN o
indocyanine NN o
green NN o
( ( o
ICG NNP o
) ) o
clearance NN o
by IN N
the DT N
liver NN N
( ( N
t JJ N
= VBZ N
2.61 CD N
; : N
p NN N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
0.02 CD N
) ) N
and CC N
also RB N
caused VBD N
a DT N
larger JJR N
fall NN N
in IN N
raised VBN N
serum NN o
levels NNS o
of IN o
gamma NN o
glutamyl NN o
transpeptidase NN o
( ( o
GGT NNP o
) ) o
than IN N
did VBD N
the DT N
placebo NN i
injections NNS N
. . N

Overall JJ N
clinical JJ o
improvement NN o
( ( o
e.g NN o
. . o

appetite NN o
, , o
body NN o
weight NN o
, , o
reduced VBD o
liver JJ o
size NN o
, , o
general JJ o
sense NN o
of IN o
well-being NN o
) ) o
was VBD N
more RBR N
clearly RB N
evident JJ N
in IN N
patients NNS N
of IN N
the DT N
treated VBN N
group NN N
than IN N
in IN N
those DT N
of IN N
the DT N
placebo NN i
group NN N
. . N

Naftidrofuryl NNP i
, , N
therefore RB N
, , N
appears VBZ N
to TO N
be VB N
of IN N
benefit NN N
in IN N
ethanol-induced JJ p
liver NN p
damage NN p
and CC N
more RBR N
extensive JJ N
long-term JJ N
trials NNS N
are VBP N
suggested VBN N
in IN N
patients NNS p
with IN p
alcoholic JJ p
liver NN p
disease NN p
( ( p
ALD NNP p
) ) p
. . p

-DOCSTART- -X- O O

Quantitative JJ N
measurements NNS N
of IN N
HER2 NNP N
and CC N
phospho-HER2 JJ N
expression NN N
: : N
correlation NN N
with IN N
pathologic JJ N
response NN N
to TO N
neoadjuvant JJ i
chemotherapy NN i
and CC i
trastuzumab NN i
. . i

BACKGROUND NNP N
Preoperative NNP i
therapy NN i
with IN i
chemotherapy NN i
and CC N
the DT N
HER2-targeted JJ i
monoclonal JJ i
antibody NN i
trastuzumab NN i
is VBZ N
valuable JJ N
for IN N
patients NNS p
with IN p
large JJ p
or CC p
locally RB p
advanced JJ p
HER2-positive NNP p
( ( p
HER2+ NNP p
) ) p
breast NN p
cancers NNS p
but CC N
traditional JJ N
methods NNS N
of IN N
measuring VBG N
HER2 NNP N
expression NN N
do VBP N
not RB N
accurately RB N
stratify JJ N
patients NNS N
for IN N
likelihood NN N
of IN N
response NN N
. . N

Quantitative JJ N
immunofluorescent NN N
approaches NNS N
have VBP N
the DT N
potential JJ N
to TO N
provide VB N
a DT N
mathematically RB N
continuous JJ N
measure NN N
of IN N
HER2 NNP N
. . N

Here RB N
we PRP N
seek VBP N
to TO N
determine VB N
whether IN N
quantitative JJ N
measurement NN N
of IN N
HER2 NNP N
or CC N
phospho-HER2 JJ N
correlates NNS N
with IN N
likelihood NN N
of IN N
response NN N
to TO N
trastuzumab- JJ N
containing NN N
neoadjuvant JJ N
therapy NN N
. . N

METHODS NNP N
We PRP N
evaluated VBD N
core NN p
biopsy NN p
samples NNS p
from IN p
27 CD p
HER2+ NNP p
breast NN p
cancer NN p
patients NNS p
enrolled VBN p
in IN p
a DT p
preoperative JJ p
clinical JJ p
trial NN p
using VBG p
trastuzumab NN i
, , i
nab-paclitaxel JJ i
and CC i
carboplatin JJ i
combination NN i
therapy NN i
( ( p
BrUOG NNP p
BR-211B NNP p
( ( p
NCT00617942 NNP p
) ) p
) ) p
. . p

Tumor NNP N
core NN N
biopsies NNS N
were VBD N
taken VBN N
before IN N
initiation NN N
of IN N
treatment NN N
and CC N
9-13 CD N
days NNS N
after IN N
patients NNS N
received VBD N
run-in JJ N
doses NNS N
of IN N
either DT N
single JJ N
agent NN N
trastuzumab NN i
or CC N
nab-paclitaxel NN i
. . i

The DT N
AQUA NNP N
method NN N
of IN N
quantitative JJ N
immunofluorescence NN N
was VBD N
used VBN N
for IN N
analysis NN N
of IN N
in IN N
situ NN N
protein NN N
expression NN N
. . N

Patients NNS N
then RB N
received VBD N
18 CD p
weeks NNS p
of IN p
treatment NN p
, , p
followed VBN N
by IN N
surgery NN N
to TO N
assess VB o
pathologic JJ o
response NN o
to TO N
the DT N
neoadjuvant JJ N
regimen NNS N
. . N

RESULTS VB N
A DT N
HER2 NNP N
score NN N
of IN N
2111 CD N
by IN N
AQUA NNP N
analysis NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
equivalent JJ N
to TO N
HER2 NNP N
3+ CD N
by IN N
immunohistochemical JJ N
staining NN N
in IN N
previous JJ N
studies NNS N
. . N

Of IN N
20 CD N
evaluable JJ N
patients NNS N
, , N
10 CD N
cases NNS N
who WP N
achieved VBD N
a DT N
pathologic JJ o
complete JJ o
response NN o
( ( o
pathCR NN o
) ) o
with IN N
neoadjuvant JJ N
treatment NN N
had VBD N
a DT N
mean JJ N
HER2 NNP N
level NN N
of IN N
10251 CD N
compared VBN N
with IN N
4766 CD N
in IN N
the DT N
patients NNS N
without IN N
pathCR NN N
( ( N
p JJ N
= NNP N
0.0021 CD N
) ) N
. . N

Measurement NN o
of IN o
phospho-HER2 NN o
showed VBD o
no DT N
difference NN N
in IN N
pathCR JJ N
vs JJ N
non-pathCR JJ N
groups NNS N
. . N

In IN N
9 CD N
patients NNS N
who WP N
had VBD N
HER2 NNP N
levels NNS N
repeated VBN N
after IN N
a DT N
single JJ N
treatment NN N
with IN N
trastuzumab NN N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
reduction NN N
in IN N
the DT o
HER2 NNP o
or CC o
phospho-HER2 JJ o
levels NNS o
following VBG o
that IN N
exposure NN N
. . N

CONCLUSIONS NNP N
High NNP N
levels NNS o
of IN o
HER2 NNP o
are VBP N
associated VBN N
with IN N
achievement NN N
of IN N
a DT N
pathCR NN N
in IN N
the DT N
preoperative JJ N
setting NN N
, , N
while IN N
levels NNS o
of IN o
Phospho-HER2 NNP o
were VBD o
not RB N
predictive JJ N
of IN N
response NN N
. . N

This DT N
data NN N
suggests VBZ N
that IN N
accurate JJ N
measurement NN N
of IN N
HER2 NNP N
may MD N
help VB N
determine VB N
the DT N
likelihood NN N
of IN N
response NN N
in IN N
the DT N
pre-surgical JJ N
setting NN N
. . N

Further JJ N
validation NN N
in IN N
larger JJR N
cohorts NNS N
is VBZ N
required VBN N
, , N
but CC N
this DT N
pilot NN N
data NN N
shows VBZ N
the DT N
feasibility NN N
of IN N
this DT N
approach NN N
. . N

-DOCSTART- -X- O O

?-Blockers NNS N
in IN p
patients NNS p
with IN p
intermittent JJ p
claudication NN p
and CC p
arterial JJ p
hypertension NN p
: : p
results NNS N
from IN N
the DT N
nebivolol NN N
or CC N
metoprolol NN N
in IN N
arterial JJ N
occlusive JJ N
disease NN N
trial NN N
. . N

The DT N
use NN N
of IN N
?-receptor NN N
blockers NNS N
in IN N
peripheral JJ N
arterial JJ N
disease NN N
is VBZ N
controversial JJ N
for IN N
their PRP$ N
impact NN N
on IN N
vasomotor NN N
tone NN N
. . N

The DT N
?-blocker NN N
nebivolol NN N
possesses VBZ N
vasodilating VBG N
, , N
endothelium-dependent JJ N
, , N
NO-releasing JJ N
properties NNS N
that WDT N
might MD N
be VB N
beneficial JJ N
in IN N
peripheral JJ N
arterial JJ N
disease NN N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS o
and CC o
tolerability NN o
of IN o
nebivolol NN i
in IN i
comparison NN N
with IN i
metoprolol NN i
in IN i
these DT N
patients NNS p
. . p

A DT p
total NN p
of IN p
128 CD p
patients NNS p
with IN p
intermittent JJ p
claudication NN p
and CC p
essential JJ p
hypertension NN p
were VBD p
included VBN N
and CC N
double-blind JJ N
randomized VBN N
to TO N
receive VB i
5 CD i
mg NN i
of IN i
nebivolol NN i
( ( i
N=65 NNP i
) ) N
or CC N
95 CD i
mg NN i
of IN i
metoprolol NN i
( ( i
N=63 NNP i
) ) N
once RB N
daily JJ N
. . N

End NN N
points NNS N
were VBD N
changes NNS N
in IN N
ankle-brachial JJ o
index NN o
, , o
initial JJ o
and CC o
absolute JJ o
claudication NN o
distance NN o
, , o
endothelial JJ o
function NN o
assessed VBN o
by IN o
flow-mediated JJ o
dilatation NN o
of IN o
the DT o
brachial JJ o
artery NN o
, , o
blood NN o
pressure NN o
, , o
and CC o
quality NN o
of IN o
life NN o
using VBG o
the DT o
claudication NN o
scale NN o
questionnaire NN o
. . o

End NN o
point NN N
analysis NN N
was VBD N
possible JJ N
in IN N
109 CD N
patients NNS N
( ( N
85.2 CD N
% NN N
) ) N
. . N

After IN N
the DT N
48-week JJ N
treatment NN N
period NN o
, , o
ankle-brachial JJ o
index NN o
and CC o
absolute JJ o
claudication NN o
distance NN o
improved VBD o
significantly RB N
in IN N
both DT N
patient JJ N
groups NNS N
( ( N
P NNP N
< VBZ N
0.05 CD N
for IN N
both DT N
) ) N
, , N
with IN N
no DT N
difference NN N
across IN N
treatments NNS N
. . N

A DT N
significant JJ N
increase NN N
of IN N
initial JJ o
claudication NN o
distance NN o
was VBD o
found VBN N
in IN N
the DT N
nebivolol JJ N
group NN N
. . N

Adjusted VBN N
mean JJ N
change NN N
of IN N
initial JJ o
claudication NN o
distance NN o
was VBD o
33.9 CD N
% NN N
after IN N
nebivolol NN N
( ( N
P=0.003 NNP N
) ) N
and CC N
16.6 CD N
% NN N
after IN N
metoprolol NN N
( ( N
P=0.12 NNP N
) ) N
treatment NN o
. . o

Quality NN o
of IN o
life NN o
was VBD o
not RB N
influenced VBN N
by IN N
either DT N
treatment NN N
, , N
and CC N
there EX N
was VBD N
no DT N
relevant JJ N
change NN N
in IN N
flow-mediated JJ o
dilatation NN o
in IN o
patients NNS N
treated VBN N
with IN N
nebivolol NN N
or CC N
metoprolol NN N
( ( N
P=0.16 NNP N
) ) N
. . N

Both DT N
drugs NNS N
were VBD N
equally RB N
effective JJ N
in IN N
lowering VBG o
blood NN o
pressure NN o
. . o

In IN o
conclusion NN N
, , N
?-blocker JJ N
therapy NN N
was VBD N
well RB N
tolerated VBN p
in IN p
patients NNS p
with IN p
intermittent JJ p
claudication NN p
and CC p
arterial JJ p
hypertension NN p
during IN p
a DT N
treatment NN N
period NN N
of IN N
?1 JJ N
year NN N
. . N

In IN N
the DT N
direct JJ N
comparison NN N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
nebivolol NNS N
and CC N
metoprolol NN N
. . N

-DOCSTART- -X- O O

Practice NNP N
makes VBZ N
improvement NN N
: : N
how WRB N
adults NNS p
with IN p
autism NN p
out-perform JJ N
others NNS N
in IN N
a DT N
naturalistic JJ N
visual JJ N
search NN N
task NN N
. . N

People NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
often RB N
exhibit JJ N
superior JJ N
performance NN N
in IN N
visual JJ N
search NN N
compared VBN N
to TO N
others NNS N
. . N

However RB N
, , N
most JJS N
studies NNS N
demonstrating VBG N
this DT N
advantage NN N
have VBP N
employed VBN N
simple JJ N
, , N
uncluttered JJ N
images NNS N
with IN N
fully RB N
visible JJ N
targets NNS N
. . N

We PRP N
compare VBP N
the DT N
performance NN N
of IN N
high-functioning JJ p
adults NNS p
with IN p
ASD NNP p
and CC N
matched VBN p
controls NNS p
on IN N
a DT N
naturalistic JJ i
luggage NN i
screening VBG i
task NN i
. . i

Although IN N
the DT N
two CD N
groups NNS N
were VBD N
equally RB N
accurate JJ N
in IN N
detecting VBG N
targets NNS N
, , N
the DT N
ASD NNP p
adults NNS p
improve VBP N
in IN N
their PRP$ N
correct JJ o
elimination NN o
of IN o
target-absent NN o
bags NNS N
faster RBR N
than IN N
controls NNS N
. . N

This DT N
feature NN N
of IN N
their PRP$ N
behavior NN N
is VBZ N
extremely RB N
important JJ N
for IN N
many JJ N
real-world JJ N
monitoring NN N
tasks NNS N
that WDT N
require VBP N
sustained JJ N
attention NN N
for IN N
long JJ N
time NN N
periods NNS N
. . N

Further JJ N
analyses NNS N
suggest VBP N
that IN N
this DT N
improvement NN N
is VBZ N
attributable JJ N
neither RB N
to TO N
the DT N
motor NN N
speed NN N
nor CC N
to TO N
the DT N
level NN N
of IN N
intelligence NN N
of IN N
the DT N
adults NNS p
with IN p
ASD NNP p
. . p

These DT N
findings NNS N
may MD N
have VB N
possible JJ N
implications NNS N
for IN N
employment NN N
opportunities NNS N
of IN N
adult NN p
individuals NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -X- O O

Rationale NNP N
and CC N
study VB N
design NN N
of IN N
the DT N
increase NN N
of IN N
vagal JJ N
tone NN N
in IN N
heart NN p
failure NN p
study NN N
: : N
INOVATE-HF NNP N
. . N

BACKGROUND NNP N
Imbalance NNP N
between IN N
the DT N
parasympathetic JJ N
and CC N
sympathetic JJ N
nervous JJ N
systems NNS N
is VBZ N
a DT N
recognized VBN N
contributor NN N
to TO N
progression NN N
of IN N
chronic JJ p
heart NN p
failure NN p
. . p

Current JJ N
therapy NN N
with IN N
beta NN N
adrenergic JJ N
antagonists NNS N
is VBZ N
designed VBN N
to TO N
moderate VB N
the DT N
up-regulation NN N
of IN N
norepinephrine NN N
and CC N
sympathetic JJ N
effects NNS N
; : N
however RB N
, , N
to TO N
date NN N
, , N
there EX N
are VBP N
no DT N
therapies NNS N
that WDT N
specifically RB N
address VBP N
the DT N
withdrawal NN N
of IN N
parasympathetic JJ N
influences NNS N
on IN N
cardiac JJ N
function NN N
and CC N
structure NN N
. . N

METHODS/RESULTS NNP N
In IN N
order NN N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
vagus NN N
nerve NN N
stimulation NN N
, , N
an DT N
international JJ N
multi-center NN N
randomized VBD N
clinical JJ N
trial NN N
( ( N
INOVATE-HF NNP N
) ) N
has VBZ N
been VBN N
designed VBN N
to TO N
assess VB N
safety NN o
and CC o
efficacy NN o
of IN N
vagus NN N
nerve NN N
stimulation NN N
in IN N
symptomatic JJ p
patients NNS p
with IN p
heart NN p
failure NN p
on IN p
optimal JJ p
medical JJ p
therapy NN p
using VBG N
the DT N
CardioFit NNP i
System NNP i
( ( N
BioControl NNP N
Medical NNP N
, , N
Yehud NNP N
, , N
Israel NNP N
) ) N
. . N

Up UH p
to TO p
650 CD p
patients NNS p
from IN p
80 CD p
sites NNS p
will MD p
be VB p
recruited VBN p
and CC N
randomized VBN N
in IN N
a DT N
3:2 CD N
ratio NN N
to TO N
receive VB N
active JJ N
treatment NN N
or CC N
standard NN i
optimal JJ i
medical JJ i
therapy NN i
. . i

Inclusion NNP p
criteria NNS p
include VBP p
left JJ p
ventricular JJ p
systolic JJ p
dysfunction NN p
, , p
the DT p
presence NN p
of IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
Class NNP p
III NNP p
symptoms NNS p
, , p
sinus NN p
rhythm NN p
, , p
and CC p
QRS NNP p
width VBD p
less JJR p
than IN p
120 CD p
milliseconds NNS p
. . p

The DT N
study NN N
is VBZ N
powered VBN N
to TO N
detect VB N
differences NNS N
in IN N
the DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
of IN N
all-cause JJ o
mortality NN o
and CC o
heart NN o
failure NN o
hospitalization NN o
and CC o
2 CD o
safety NN o
end NN o
points NNS o
. . o

CONCLUSION NNP N
Vagal NNP N
nerve NN N
stimulation NN N
with IN N
CardioFit NNP i
as IN N
a DT N
treatment NN N
for IN N
symptomatic JJ N
heart NN N
failure NN N
is VBZ N
under IN N
active JJ N
investigation NN N
as IN N
a DT N
novel JJ N
approach NN N
to TO N
restore VB N
balance NN N
between IN N
the DT N
sympathetic JJ N
and CC N
parasympathetic JJ N
nervous JJ N
systems NNS N
. . N

If IN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
decreasing VBG N
heart NN o
failure NN o
events NNS o
and CC o
mortality NN o
, , N
this DT N
novel JJ N
approach NN N
will MD N
impact VB N
the DT N
treatment NN N
paradigm NN N
for IN N
heart NN N
failure NN N
. . N

-DOCSTART- -X- O O

Preliminary JJ N
findings NNS N
of IN N
the DT N
minimally-invasive JJ i
surgery NN i
plus CC i
rtPA NN i
for IN N
intracerebral JJ o
hemorrhage NN o
evacuation NN o
( ( p
MISTIE NNP p
) ) p
clinical JJ N
trial NN N
. . N

INTRODUCTION NNP N
Compared VBD N
to TO N
ischemic VB N
stroke NN N
, , N
intracerebral JJ N
hemorrhage NN N
( ( N
ICH NNP N
) ) N
is VBZ N
easily RB N
and CC N
rapidly RB N
identified VBN N
, , N
occurs VBZ N
in IN N
younger JJR p
patients NNS p
, , p
and CC p
produces VBZ p
relatively RB p
small JJ p
initial JJ p
injury NN p
to TO p
cerebral JJ p
tissues NNS p
-- : p
all DT p
factors NNS p
suggesting VBG p
that IN p
interventional JJ p
amelioration NN p
is VBZ p
possible JJ p
. . p

Investigations NNS N
from IN N
the DT N
last JJ N
decade NN N
established VBD N
that IN N
extent NN N
of IN N
ICH-mediated NNP N
brain NN N
injury NN N
relates VBZ N
directly RB N
to TO N
blood VB N
clot NN N
volume NN N
and CC N
duration NN N
of IN N
blood NN N
exposure NN N
to TO N
brain NN N
tissue NN N
. . N

Using VBG N
minimally-invasive JJ i
surgery NN i
plus CC i
recombinant JJ i
tissue NN i
plasminogen NN i
activator NN i
( ( i
rtPA NN i
) ) i
, , N
MISTIE NNP N
investigators NNS N
explored VBD N
aggressive JJ N
avenues NNS N
to TO N
treat VB N
ICH NNP N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
difference NN N
between IN N
surgical JJ i
intervention NN i
plus CC i
rtPA NN i
and CC i
standard JJ i
medical JJ i
management NN i
for IN i
ICH NNP N
. . N

Subjects NNS p
in IN p
both DT p
groups NNS p
were VBD N
medically RB p
managed VBN p
according VBG p
to TO p
standard JJ p
ICU NNP p
protocols NNS p
. . p

Subjects NNS N
randomized VBD N
to TO N
surgery VB N
underwent JJ N
stereotactic JJ i
catheter NN i
placement NN i
and CC i
clot NN i
aspiration NN i
. . i

Injections NNS i
of IN i
rtPA NN i
were VBD N
then RB N
given VBN N
through IN N
hematoma NN N
catheter NN N
every DT N
8 CD N
h NN N
, , N
up RB N
to TO N
9 CD N
doses NNS N
, , N
or CC N
until IN N
a DT N
clot-reduction JJ N
endpoint NN N
. . N

After IN N
each DT N
injection NN N
the DT N
system NN N
was VBD N
flushed VBN N
with IN N
sterile JJ i
saline NN i
and CC N
closed VBD N
for IN N
60 CD N
min NN N
before IN N
opening VBG N
to TO N
spontaneous JJ N
drainage NN N
. . N

RESULTS JJ N
Average JJ o
aspiration NN o
of IN o
clots NNS o
for IN N
all DT N
patients NNS N
randomized VBN N
to TO N
surgery VB N
plus CC N
rtPA VB N
was VBD N
20 CD N
% NN N
of IN N
mean JJ N
initial JJ N
clot NN N
size NN N
. . N

After IN N
acute JJ N
treatment NN N
phase NN N
( ( N
aspiration NN N
plus CC N
rtPA NN N
) ) N
, , N
clot NN o
was VBD o
reduced VBN o
an DT N
average NN N
of IN N
46 CD N
% NN N
. . N

Recorded VBN N
adverse JJ N
events NNS N
were VBD N
within IN N
safety NN N
limits NNS N
, , N
including VBG N
30-day JJ o
mortality NN o
, , N
8 CD N
% NN N
; : N
symptomatic JJ o
re-bleeding NN o
, , N
8 CD N
% NN N
; : N
and CC N
bacterial JJ o
ventriculitis NN o
, , N
0 CD N
% NN N
. . N

Patients NNS N
randomized VBD N
to TO N
medical JJ N
management NN N
showed VBD N
4 CD N
% NN N
clot NN o
resolution NN o
in IN N
a DT N
similar JJ N
time NN N
window NN N
. . N

Preliminary JJ N
analysis NN N
indicates VBZ N
that IN N
clot NN o
resolution NN o
rates NNS o
are VBP N
greatly RB N
dependent JJ N
on IN N
catheter NN N
placement NN N
. . N

Location NN N
of IN N
ICH NNP N
also RB N
affects VBZ N
efficacy NN N
of IN N
aggressive JJ N
treatment NN N
of IN N
ICH NNP N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
tentative JJ N
indication NN N
that IN N
minimally-invasive JJ N
surgery NN N
plus CC N
rtPA NN N
shows NNS N
greater JJR o
clot NN o
resolution NN o
than IN N
traditional JJ N
medical JJ N
management NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
and CC o
safety NN o
of IN N
bexarotene NN i
combined VBN i
with IN i
psoralen-ultraviolet NN i
A NNP i
( ( i
PUVA NNP i
) ) i
compared VBN i
with IN i
PUVA NNP i
treatment NN i
alone RB i
in IN N
stage JJ N
IB-IIA JJ N
mycosis NN N
fungoides NNS N
: : N
final JJ N
results NNS N
from IN N
the DT N
EORTC NNP N
Cutaneous NNP p
Lymphoma NNP p
Task NNP p
Force NNP p
phase NN p
III NNP p
randomized VBD p
clinical JJ p
trial NN p
( ( N
NCT00056056 NNP N
) ) N
. . N

BACKGROUND NNP N
Psoralen NNP i
plus CC i
ultraviolet VB i
A NNP i
( ( i
PUVA NNP i
) ) i
is VBZ N
the DT N
standard JJ N
treatment NN N
for IN N
early JJ p
stages NNS p
of IN p
mycosis NN p
fungoides NNS p
. . p

There EX N
have VBP N
been VBN N
no DT N
adequate JJ N
randomized VBN N
controlled JJ N
trials NNS N
with IN N
sufficient JJ N
power NN N
comparing VBG N
this DT N
modality NN N
with IN N
other JJ N
therapies NNS N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
disease NN o
response NN o
and CC N
to TO N
compare VB N
the DT N
response NN o
rates NNS o
of IN N
patients NNS p
treated VBN p
with IN p
PUVA NNP i
alone RB i
or CC p
PUVA NNP i
and CC i
bexarotene NN i
. . i

METHODS NNP N
EORTC NNP N
21011 CD N
( ( N
NCT NNP N
00056056 CD N
) ) N
was VBD N
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
comparing VBG N
combined VBN i
bexarotene NN i
( ( i
Targretin NNP i
( ( i
? . i
) ) i
) ) i
and CC i
PUVA NNP i
vs. FW i
PUVA NNP i
alone RB i
in IN p
patients NNS p
with IN p
stage NN p
IB NNP p
and CC p
IIA NNP p
mycosis NN p
fungoides NNS p
( ( p
MF NNP p
) ) p
. . p

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT o
overall JJ o
response NN o
rate NN o
[ NNP o
complete JJ o
clinical JJ o
response NN o
( ( o
CCR NNP o
) ) o
plus CC o
partial JJ o
response NN o
( ( o
PR NNP o
) ) o
] NN o
. . o

RESULTS VB N
The DT N
study NN N
was VBD N
prematurely RB N
closed VBN N
due JJ N
to TO N
low JJ N
accrual JJ N
after IN p
93 CD p
of IN p
145 CD p
required JJ p
patients NNS p
( ( N
65 CD N
% NN N
) ) N
were VBD N
randomized VBN N
. . N

Of IN N
the DT p
93 CD p
randomized JJ p
patients NNS p
, , p
87 CD p
started VBD p
treatment NN p
, , p
41 CD p
received VBD i
PUVA NNP i
and CC p
46 CD p
received VBD i
PUVA NNP i
+ NNP i
bexarotene NN i
. . i

Total JJ o
UVA NNP o
doses NNS o
received VBD N
were VBD N
107 CD N
J NNP N
cm NN N
( ( N
-2 NN N
) ) N
( ( N
range VB N
1?4-489?9 CD N
) ) N
in IN N
the DT N
PUVA NNP i
arm NN i
vs. FW N
101?7 CD N
J NNP N
cm NN N
( ( N
-2 NN N
) ) N
( ( N
0?2-529?9 JJ N
) ) N
in IN N
the DT N
combination NN N
arm NN N
. . N

The DT o
safety NN o
profile NN o
was VBD o
acceptable JJ o
with IN N
few JJ o
grade JJ o
3-4 JJ o
toxicities NNS o
observed VBN o
in IN N
either DT N
arm NN N
. . N

More JJR N
drop-outs NNS o
due JJ o
to TO o
toxicity NN o
were VBD o
observed VBN N
in IN N
the DT N
combination NN N
arm NN N
compared VBN N
with IN N
the DT i
PUVA-alone JJ i
arm NN i
. . i

The DT N
best JJS o
overall JJ o
response NN o
( ( o
CCR NNP o
+ NNP o
PR NNP o
) ) o
rate NN o
was VBD N
71 CD N
% NN N
for IN i
PUVA NNP i
alone RB i
and CC N
77 CD N
% NN N
for IN N
the DT N
combination NN N
arm NN N
( ( N
P NNP N
= NNP N
0?57 CD N
) ) N
. . N

The DT o
median JJ o
duration NN o
of IN o
response NN o
was VBD o
9?7 CD o
months NNS N
for IN i
PUVA NNP i
vs. FW i
5?8 CD N
months NNS N
for IN N
the DT N
combination NN N
arm NN N
( ( N
P NNP N
= NNP N
0?33 CD N
) ) N
. . N

CCR NNP o
was VBD o
seen VBN N
in IN N
25 CD N
patients NNS N
of IN N
whom WP N
10 CD N
received VBD i
PUVA NNP i
alone RB i
( ( o
CCR NNP o
22 CD o
% NN o
) ) o
and CC N
15 CD N
received VBN i
combination NN o
therapy NN o
( ( o
CCR NNP o
31 CD o
% NN o
) ) o
( ( N
P NNP N
= NNP N
0?45 CD N
) ) N
. . o

CCR NNP o
was VBD o
sustained VBN o
in IN N
25 CD N
% NN N
of IN N
patients NNS N
regardless RB N
of IN N
therapy NN N
. . N

There EX N
was VBD N
a DT N
trend NN N
towards VBZ N
fewer JJR i
PUVA NNP i
sessions NNS o
needed VBD o
to TO o
achieve VB o
CCR NNP o
in IN o
the DT o
combination NN N
arm NN N
( ( N
median JJ N
22 CD N
) ) N
compared VBN N
with IN i
the DT i
PUVA NNP i
arm NN i
( ( N
median JJ N
27?5 CD N
) ) N
( ( N
P NNP N
= NNP N
0?11 CD N
) ) N
. . N

Similarly RB N
, , N
a DT N
trend NN N
towards NNS N
lower JJR N
UVA NNP i
dose NN o
required VBN o
to TO o
achieve VB o
CCR NNP o
in IN N
the DT N
combination NN N
arm NN N
( ( N
median JJ N
55?8 CD N
J NNP N
cm NN N
( ( N
-2 NNP N
) ) N
) ) N
compared VBN N
with IN N
the DT i
PUVA NNP i
arm NN N
alone RB N
( ( N
median JJ N
117?5 CD N
J NNP N
cm NN N
( ( N
-2 NNP N
) ) N
) ) N
( ( N
P NNP N
= NNP N
0?5 CD N
) ) N
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
No NNP N
significant JJ N
difference NN o
in IN o
response NN o
rate NN o
or CC o
response NN o
duration NN o
was VBD o
observed VBN o
in IN N
this DT N
study NN N
. . N

However RB N
, , N
there EX N
was VBD N
a DT N
trend NN N
towards VBZ N
fewer JJR o
PUVA NNP o
sessions NNS o
and CC o
lower JJR o
UVA NNP o
dose NN o
required VBN o
to TO o
achieve VB o
CCR NNP o
in IN N
the DT N
combination NN N
arm NN N
( ( i
PUVA NNP i
+ NNP i
bexarotene NN i
) ) i
but CC i
this DT N
did VBD N
not RB N
achieve VB N
statistical JJ N
significance NN N
due JJ N
to TO N
insufficient JJ N
power NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
random JJ i
modulation NN i
of IN i
functional JJ i
electrical JJ i
stimulation NN i
parameters NNS i
on IN N
muscle NN p
fatigue NN p
. . p

Muscle NNP N
contractions NNS N
induced VBN N
by IN N
functional JJ i
electrical JJ i
stimulation NN i
( ( N
FES NNP N
) ) N
tend VBP N
to TO N
result VB N
in IN N
rapid JJ o
muscle NN o
fatigue NN o
, , N
which WDT N
greatly RB N
limits VBZ N
activities NNS N
such JJ N
as IN N
FES-assisted JJ N
standing NN N
and CC N
walking NN N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
muscle NN o
fatigue NN o
caused VBN N
by IN N
FES NNP N
could MD N
be VB N
reduced VBN N
by IN N
randomly RB N
modulating VBG N
parameters NNS N
of IN N
the DT N
electrical JJ N
stimulus NN N
. . N

Seven NNP p
paraplegic JJ p
subjects NNS p
participated VBN p
in IN N
this DT N
study NN N
. . N

While IN N
subjects NNS N
were VBD N
seated VBN N
, , N
FES NNP N
was VBD N
applied VBN N
to TO N
quadriceps NNS N
and CC N
tibialis JJ N
anterior JJ N
muscles NNS N
bilaterally RB N
using VBG N
surface NN N
electrodes NNS N
. . N

The DT N
isometric JJ o
force NN o
was VBD N
measured VBN N
, , N
and CC N
the DT N
time NN N
for IN N
the DT N
force NN N
to TO N
drop VB N
by IN N
3 CD N
dB NN N
( ( N
fatigue JJ N
time NN N
) ) N
and CC N
the DT N
normalized JJ N
force-time JJ o
integral JJ o
( ( o
FTI NNP o
) ) o
were VBD N
determined VBN N
. . N

Four CD N
different JJ N
modes NNS N
of IN N
FES NNP N
were VBD N
applied VBN N
in IN N
random JJ N
order NN N
: : N
constant JJ N
stimulation NN N
, , N
randomized VBN N
frequency NN N
( ( N
mean JJ N
40 CD N
Hz NNP N
) ) N
, , N
randomized VBN N
current JJ N
amplitude NN N
, , N
and CC N
randomized VBD N
pulsewidth NN N
( ( N
mean JJ N
250 CD N
micros NN N
) ) N
. . N

In IN N
randomized JJ N
trials NNS N
, , N
stimulation NN N
parameters NNS N
were VBD N
stochastically RB N
modulated VBN N
every DT N
100 CD N
ms NN N
in IN N
a DT N
range NN N
of IN N
+/-15 NNP N
% NN N
using VBG N
a DT N
uniform JJ N
probability NN N
distribution NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
fatigue NN o
time NN o
measurements NNS o
for IN N
the DT N
four CD N
modes NNS N
of IN N
stimulation NN N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
FTI NNP o
measurements NNS o
. . o

Therefore RB N
, , N
our PRP$ N
particular JJ N
method NN N
of IN N
stochastic JJ N
modulation NN N
of IN N
the DT N
stimulation NN N
parameters NNS N
, , N
which WDT N
involved VBD N
moderate JJ N
( ( N
15 CD N
% NN N
) ) N
variations NNS N
updated VBN N
every DT N
100 CD N
ms NN N
and CC N
centered VBD N
around IN N
40 CD N
Hz NNP N
, , N
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
muscle NN o
fatigue NN o
. . o

There EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
maximum JJ N
force NN N
measurements NNS N
and CC N
stimulation NN N
order NN N
, , N
which WDT N
was VBD N
not RB N
apparent JJ N
in IN N
the DT N
fatigue JJ o
time NN o
or CC o
FTI NNP o
measurements NNS o
. . o

It PRP N
was VBD N
concluded VBN N
that IN N
a DT N
10-min JJ N
rest NN N
period NN N
between IN N
stimulation NN N
trials NNS N
was VBD N
insufficient JJ N
to TO N
allow VB N
full JJ N
recovery NN o
of IN o
muscle NN o
strength NN o
. . o

-DOCSTART- -X- O O

Covariation NN N
of IN N
adolescent JJ o
physical JJ o
activity NN o
and CC i
dietary JJ o
behaviors NNS o
over IN N
12 CD N
months NNS N
. . N

PURPOSE VB N
This DT N
study NN N
examined VBD N
covariation NN N
among IN N
changes NNS i
in IN i
dietary JJ i
, , i
physical JJ i
activity NN i
, , i
and CC i
sedentary JJ i
behaviors NNS i
over IN N
12 CD N
months NNS N
among IN N
adolescents NNS p
participating VBG p
in IN p
a DT p
health NN p
behavior NN p
intervention NN p
. . p

Evidence NN N
of IN N
covariation NN N
among IN N
behaviors NNS N
would MD N
suggest VB N
multi-behavior JJ N
interventions NNS N
could MD N
have VB N
synergistic JJ N
effects NNS N
. . N

METHODS NNP N
Prospective JJ N
analyses NNS N
were VBD N
conducted VBN N
with IN N
baseline NN N
and CC N
12-month JJ N
assessments NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
promote VB N
improved JJ N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
sedentary JJ o
behaviors NNS o
( ( i
experimental JJ i
condition NN i
) ) i
or CC i
SUN NNP o
protection NN o
behaviors NNS o
( ( N
comparison JJ N
condition NN N
) ) N
. . N

Participants NNS p
were VBD p
adolescent JJ p
girls NNS p
and CC p
boys NNS p
( ( p
N NNP p
= NNP p
878 CD p
) ) p
aged VBN p
11-15 CD p
years NNS p
on IN p
entry NN p
. . p

The DT N
main JJ N
outcomes NNS N
were VBD N
: : N
diet NN o
, , N
based VBN N
on IN N
multiple JJ N
24-hour JJ N
recalls NNS N
( ( N
total JJ N
fat NN N
, , N
grams NNS N
of IN N
fiber NN N
, , N
servings NNS N
of IN N
fruit NN N
and CC N
vegetables NNS N
, , N
total JJ N
calories NNS N
) ) N
; : N
average JJ o
daily JJ o
energy NN o
expenditure NN o
( ( N
kcals/kg NN N
) ) N
based VBN N
on IN N
7-day JJ N
physical JJ N
activity NN N
recall VBP N
interviews NNS N
; : N
daily JJ o
minutes NNS o
of IN o
moderate-vigorous JJ o
physical JJ o
activity NN o
minutes NNS N
from IN N
accelerometery NN N
; : N
and CC N
self-reported JJ o
daily JJ o
hours NNS o
of IN o
sedentary JJ o
behavior NN o
. . o

RESULTS NNP N
Covariation NNP N
was VBD N
found VBN N
between IN N
fat NN o
and CC o
calories NNS o
( ( N
r NN N
= NNP N
.16 NNP N
) ) N
, , N
fiber NN o
and CC o
calories NNS o
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
fiber NN o
and CC o
fruit/vegetables NNS o
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
calories NNS o
and CC o
fruit/vegetables NNS o
( ( N
r NN N
= NNP N
.34 NNP N
) ) N
, , N
and CC N
fruit NN o
and CC o
vegetables NNS o
and CC o
sedentary JJ o
behavior NN o
( ( N
r JJ N
= NNP N
-.12 NNP N
) ) N
for IN N
the DT N
total JJ N
sample NN N
( ( N
all DT N
p NN N
values NNS N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
pattern NN N
of IN N
findings NNS N
was VBD N
similar JJ N
for IN N
most JJS N
subgroups NNS N
defined VBN N
by IN N
gender NN N
and CC N
study NN N
condition NN N
. . N

CONCLUSIONS VB N
The DT N
strongest JJS N
covariation NN N
was VBD N
observed VBN N
for IN N
diet JJ o
variables NNS o
that WDT N
are VBP N
inherently RB N
related VBN N
( ( N
calories NNS N
and CC N
fat NN N
, , N
fiber NN N
, , N
and CC N
fruit/vegetables NNS N
) ) N
. . N

Little JJ N
covariation NN N
was VBD N
detected VBN N
within IN N
or CC N
between IN N
other JJ N
diet JJ o
, , o
physical JJ o
activity NN o
and CC o
sedentary JJ o
behavior NN o
domains NNS N
suggesting VBG N
that IN N
interventions NNS N
to TO N
improve VB N
these DT N
behaviors NNS N
in IN N
adolescents NNS p
need VBP N
to TO N
include VB N
specific JJ N
program NN N
components NNS N
for IN N
each DT N
target NN N
behavior NN N
of IN N
interest NN N
. . N

-DOCSTART- -X- O O

The DT N
evaluation NN N
of IN N
pulmonary JJ N
hypertension NN N
using VBG N
right JJ i
ventricular JJ i
myocardial JJ i
isovolumic JJ i
relaxation NN i
time NN i
. . i

Right JJ N
ventricular NN N
( ( N
RV NNP N
) ) N
blood VBD N
pool-derived JJ N
isovolumic JJ N
relaxation NN N
time NN N
( ( N
IVRT NNP N
) ) N
correlates VBZ N
well RB N
with IN N
systolic JJ N
pulmonary JJ N
arterial JJ N
pressure NN N
( ( N
PAP NNP N
) ) N
. . N

However RB N
, , N
because IN N
of IN N
complex JJ N
parameter NN N
derivation NN N
, , N
the DT N
method NN N
is VBZ N
rarely RB N
used VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
validate VB N
the DT N
measurement NN N
of IN N
myocardial JJ N
velocity NN N
imaging-derived JJ N
RV NNP i
IVRT NNP i
( ( i
IVRT NNP i
' POS i
) ) i
against IN N
invasively RB i
measured VBN i
PAP NNP i
. . i

Transthoracic NNP i
echocardiography NN i
with IN i
myocardial JJ i
velocity NN i
imaging NN i
and CC i
right JJ i
heart NN i
catheterization NN i
were VBD N
performed VBN N
in IN N
33 CD p
patients NNS p
with IN p
pulmonary JJ p
hypertension NN p
. . p

Blood NNP o
pool NN o
IVRT NNP o
and CC o
myocardial JJ o
IVRTs NNP o
for IN o
the DT o
tricuspid JJ o
valve NN o
annulus NN o
ring NN o
, , o
basal NN o
and CC o
apical JJ o
RV NNP o
free JJ o
wall NN o
segments NNS o
were VBD N
measured VBN N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
33 CD p
age- JJ p
and CC p
sex-matched JJ p
control NN p
subjects NNS p
. . p

Measured VBN o
IVRTs NNP o
were VBD N
significantly RB o
longer RBR o
in IN N
patients NNS N
with IN N
pulmonary JJ N
hypertension NN N
than IN N
in IN N
control NN N
subjects NNS N
. . N

The DT N
strongest JJS N
correlation NN N
( ( N
R NNP N
= NNP N
0.74 CD N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
was VBD N
found VBN N
between IN N
systolic JJ o
PAP NNP o
and CC o
the DT o
heart NN o
rate-corrected JJ o
IVRT NNP o
' POS o
derived VBN N
from IN N
the DT N
basal NN N
RV NNP N
free JJ N
wall NN N
segment NN N
. . N

The DT N
basal NN o
segment NN o
IVRT NNP o
' POS o
corrected VBN N
for IN N
heart NN o
rate NN o
correlates NNS N
well RB N
with IN N
the DT N
invasive JJ N
PAP NNP N
measurement NN N
and CC N
, , N
therefore RB N
, , N
can MD N
be VB N
used VBN N
to TO N
predict VB N
systolic JJ o
PAP NNP o
. . o

It PRP N
can MD N
even RB N
be VB N
considered VBN N
as IN N
an DT N
alternative NN N
to TO N
tricuspid VB N
regurgitation-derived JJ N
PAP NNP N
systolic NN N
when WRB N
tricuspid JJ N
regurgitation NN N
is VBZ N
nonrecordable JJ N
. . N

A DT N
proposed VBN N
method NN N
to TO N
derive VB N
systolic JJ N
PAP NNP N
should MD N
be VB N
used VBN N
while IN N
screening VBG N
the DT N
patients NNS N
at IN N
risk NN N
for IN N
pulmonary JJ N
hypertension NN N
, , N
monitoring VBG N
the DT N
disease NN N
progression NN N
and CC N
the DT N
effect NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Prospective JJ N
study NN N
of IN N
Clostridium NNP o
difficile JJ o
intestinal JJ N
colonization NN N
and CC N
disease NN N
following VBG N
single-dose JJ i
antibiotic JJ i
prophylaxis NN i
in IN N
surgery NN N
. . N

A DT N
total NN N
of IN N
108 CD p
volunteers NNS p
undergoing VBG p
an DT p
elective JJ p
surgical JJ p
procedure NN p
were VBD N
randomly RB N
given VBN N
a DT N
single JJ N
2-g JJ N
intravenous JJ i
prophylactic JJ i
dose NN i
of IN i
either CC i
a DT i
cephalosporin NN i
or CC i
mezlocillin NN i
. . i

Stool NNP N
samples NNS N
were VBD N
cultured VBN N
for IN N
Clostridium NNP N
difficile VBP N
the DT N
day NN N
before IN N
the DT N
operation NN N
and CC N
later RB N
on IN N
postoperative JJ N
days NNS N
4 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
. . N

C. NNP o
difficile NN o
was VBD N
detected VBN N
in IN N
23.0 CD N
% NN N
of IN N
patients NNS p
who WP N
received VBD N
a DT N
cephalosporin NN i
( ( i
cefoxitin NN i
, , i
8.3 CD i
% NN i
; : i
cefazolin NN i
, , i
14.3 CD i
% NN i
; : i
cefotetan NN i
, , i
20.0 CD i
% NN i
; : i
ceftriaxone NN i
, , i
25.0 CD i
% NN i
; : i
cefoperazone NN i
, , i
43.7 CD i
% NN i
) ) i
, , N
in IN N
3.3 CD N
% NN N
of IN N
patients NNS p
given VBN N
mezlocillin NNS i
, , N
and CC N
in IN N
none NN N
of IN N
15 CD p
control NN p
volunteers NNS p
given VBN N
no DT i
antimicrobial JJ i
agent NN i
. . i

No DT N
patient NN N
experienced VBD N
diarrhea NN o
. . o

-DOCSTART- -X- O O

Treatment NN N
of IN N
vasculogenic JJ p
sexual JJ p
dysfunction NN p
with IN N
pentoxifylline NN i
. . i

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
use NN N
of IN N
pentoxifylline NN i
to TO N
treat VB N
impotence NN N
in IN N
men NNS p
with IN p
mild NN p
to TO p
moderate VB p
penile IN p
vascular JJ p
insufficiency NN p
. . p

DESIGN NNP N
Double-blind NNP N
randomized VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Sexual JJ p
Dysfunction NNP p
Clinic NNP p
at IN p
VA NNP p
Medical NNP p
Center NNP p
, , p
Sepulveda NNP p
, , p
CA NNP p
. . p

PARTICIPANTS NNP N
Convenience NNP p
sample NN p
of IN p
couples NNS p
. . p

INTERVENTION NNP N
Twelve NNP N
weeks NNS N
of IN N
treatment NN N
with IN N
placebo NN i
or CC i
400 CD i
mg JJ i
tid NN i
of IN i
pentoxifylline NN i
. . i

MEASUREMENTS NNP N
( ( N
1 CD N
) ) N
Report NN o
of IN o
patient JJ o
verified VBN o
by IN o
partner NN o
as IN o
to TO o
number NN o
of IN o
coital JJ o
episodes NNS o
per IN o
month NN o
; : o
( ( N
2 CD N
) ) N
penile-brachial JJ o
pressure NN o
index NN o
determinations NNS o
. . o

RESULTS NNP N
Pentoxifylline NNP i
therapy VBZ i
regularly RB N
increased VBN N
the DT N
PBPI NNP o
in IN N
impotent JJ p
men NNS p
in IN N
comparison NN N
with IN N
the DT N
placebo NN N
, , N
frequently RB N
into IN N
the DT N
normal JJ N
range NN N
. . N

Pentoxifylline NNP N
therapy NN N
was VBD N
particularly RB N
useful JJ N
in IN N
restoring VBG o
the DT o
PBPI NNP o
in IN N
men NNS p
with IN p
the DT p
pelvic JJ p
steal JJ p
syndrome NN p
; : p
six CD N
of IN N
seven CD N
such JJ N
subjects NNS N
improved VBN N
into IN N
the DT N
normal JJ N
range NN N
. . N

During IN N
the DT N
pentoxifylline JJ N
treatment NN N
period NN N
, , N
in IN N
contrast NN N
with IN N
the DT N
control NN N
period NN N
, , N
nine CD N
men NNS N
were VBD N
able JJ N
to TO N
reestablish VB o
coital JJ o
function NN o
and CC N
three CD N
had VBD N
no DT N
improvement NN N
. . N

Six NNP N
couples NNS N
did VBD N
not RB N
attempt VB o
intercourse JJ o
despite IN N
a DT N
professed JJ N
interest NN N
in IN N
sexual JJ o
activity NN o
; : o
however RB N
five CD N
out IN N
of IN N
the DT N
six CD N
men NNS N
experienced VBD N
erections NNS o
during IN o
episodes NNS o
of IN o
fantasy NN o
or CC o
attempts NNS o
at IN o
masturbation NN o
during IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
complications NNS o
of IN N
therapy NN N
. . N

CONCLUSIONS NNP N
These DT N
promising VBG N
preliminary JJ N
results NNS N
suggest VBP N
a DT N
well RB N
tolerated JJ N
alternative JJ N
therapy NN N
for IN N
erectile JJ p
dysfunction NN p
in IN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
penile IN p
vascular JJ p
disease NN p
. . p

-DOCSTART- -X- O O

Removal NN N
of IN N
inflammatory JJ N
cytokines NNS N
and CC N
endotoxin NN N
by IN N
veno-venous JJ i
continuous JJ i
renal JJ i
replacement NN i
therapy NN i
for IN N
burned JJ p
patients NNS p
with IN p
sepsis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
veno-venous JJ i
continuous JJ i
renal JJ i
replacement NN i
therapy NN i
( ( i
CRRT NNP i
) ) i
on IN N
the DT N
plasma NN N
levels NNS N
of IN N
endotoxin NN N
and CC N
cytokines NNS N
in IN N
severely RB p
burned VBN p
patients NNS p
with IN p
sepsis NN p
. . p

METHODS NNP N
Twenty NNP p
adult NN p
severely RB p
burned VBD p
patients NNS p
with IN p
sepsis NN p
were VBD p
studied VBN p
. . p

For IN N
the DT N
diagnosis NN N
of IN N
sepsis NN N
, , N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
CRRT NNP i
( ( N
n=10 NN N
) ) N
and CC N
Control NNP i
( ( N
n=10 RB N
) ) N
. . N

Both DT N
groups NNS N
received VBD N
conventional JJ i
therapy NN i
after IN N
admission NN N
. . N

Veno-venous JJ i
CRRT NNP i
was VBD N
administered VBN N
to TO N
10 CD N
patients NNS N
in IN N
the DT N
CRRT NNP N
group NN N
whenever WDT N
patients NNS N
were VBD N
determined VBN N
to TO N
be VB N
septic JJ N
. . N

The DT N
plasma JJ N
level NN N
of IN N
endotoxin NN N
, , N
TNF-alpha NNP N
, , N
IL-1 NNP N
beta NN N
, , N
IL-6 NNP N
and CC N
IL-8 NNP N
were VBD N
measured VBN N
at IN N
0 CD N
, , N
1 CD N
, , N
2 CD N
, , N
6 CD N
, , N
12 CD N
, , N
36 CD N
and CC N
60 CD N
h NN N
after IN N
CRRT NNP N
initiation NN N
, , N
and CC N
at IN N
0 CD N
, , N
12 CD N
, , N
36 CD N
and CC N
60 CD N
h NN N
after IN N
the DT N
patients NNS N
were VBD N
diagnosed VBN N
as IN N
having VBG N
sepsis NN N
in IN N
the DT N
Control NNP N
group NN N
. . N

MAIN NNP N
RESULTS NNP N
Plasma NNP o
level NN o
of IN o
endotoxin NN o
and CC o
all PDT o
the DT o
cytokines NNS o
after IN o
CRRT NNP o
initiation NN o
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
before IN N
the DT N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
serial JJ o
change NN o
of IN o
endotoxin NN o
, , o
IL-1 NNP o
beta NN o
, , o
IL-6 NNP o
and CC o
IL-8 NNP o
was VBD N
significantly RB N
lower JJR N
at IN N
12 CD N
, , N
36 CD N
and CC N
60 CD N
h NN N
after IN N
treatment NN N
compared VBN N
with IN N
Control NNP N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
plasma JJ o
TNF-alpha JJ o
levels NNS o
was VBD N
seen VBN N
at IN N
36 CD N
and CC N
60 CD N
h NN N
after IN N
treatment NN N
compared VBN N
with IN N
Control NNP N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Plasma NNP N
endotoxin NN N
and CC N
cytokines NNS N
( ( N
TNF-alpha NNP N
, , N
IL-1 NNP N
beta NN N
, , N
IL-6 NNP N
and CC N
IL-8 NNP N
) ) N
can MD N
be VB N
removed VBN N
effectively RB N
with IN N
CRRT NNP i
in IN N
severely RB N
burned VBN N
patients NNS N
with IN N
sepsis NN N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
survival NN N
and CC N
eradication NN N
of IN N
Mycobacterium NNP N
avium NN N
complex NN N
bacteremia NN N
( ( N
MAC NNP N
) ) N
in IN p
AIDS NNP p
patients NNS p
in IN p
the DT p
Canadian NNP p
randomized VBD p
MAC NNP p
treatment NN p
trial NN p
. . p

Canadian JJ N
HIV NNP N
Trials NNP N
Network NNP N
Protocol NNP N
010 CD N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
importance NN N
of IN N
baseline NN N
characteristics NNS N
including VBG N
medical JJ o
history NN o
, , o
indicators NNS o
of IN o
current JJ o
disease NN o
status NN o
, , o
therapeutic JJ o
drug NN o
use NN o
, , o
in IN o
vitro JJ o
drug NN o
susceptibility NN o
, , o
immune JJ o
status NN o
and CC o
mycobacterial JJ o
load NN o
on IN o
bacteriologic JJ o
response NN o
and CC N
survival NN o
in IN N
HIV-positive JJ p
patients NNS p
with IN p
Mycobacterium NNP p
avium NN p
complex NN p
( ( p
MAC NNP p
) ) p
bacteremia NN p
. . p

DESIGN NNP N
An DT N
observational JJ N
substudy NN N
of IN N
an DT N
open-label JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
two CD i
alternative JJ i
therapeutic JJ i
regimens NNS i
for IN i
MAC NNP i
. . i

SETTING NNP N
Twenty-four JJ p
hospital-based JJ p
HIV NNP p
clinics NNS p
in IN p
16 CD p
Canadian JJ p
cities NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
main JJ N
outcome NN N
measures NNS N
were VBD N
survival JJ o
and CC o
bacteriologic JJ o
response NN o
, , o
defined VBN o
by IN o
consecutive JJ o
negative JJ o
blood NN o
cultures NNS o
for IN o
MAC NNP o
at IN N
least JJS N
2 CD N
weeks NNS N
apart RB N
within IN N
16 CD N
weeks NNS N
of IN N
study NN N
entry NN N
. . N

RESULTS NNP N
Prior NNP N
AIDS NNP N
diagnosis NN N
, , N
low JJ N
Karnofsky NNP N
score NN N
, , N
active JJ N
unstable JJ N
AIDS-related JJ N
conditions NNS N
, , N
absence NN N
of IN N
antiretroviral JJ N
therapy NN N
and CC N
absence NN N
of IN N
Pneumocystis NNP N
carinii NN N
pneumonia NN N
prophylaxis NN N
were VBD N
associated VBN N
with IN N
shorter JJR N
survival NN o
by IN N
univariate JJ N
regression NN N
using VBG N
the DT N
proportional JJ N
hazards NNS N
model NN N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
antiretroviral JJ N
therapy NN N
was VBD N
not RB N
an DT N
independent JJ N
predictor NN N
of IN N
mortality NN o
, , N
and CC N
previous JJ N
rifabutin NN N
prophylaxis NN N
was VBD N
independently RB N
associated VBN N
with IN N
poor JJ N
survival NN N
outcomes NNS N
, , N
a DT N
result NN N
consistent JJ N
across IN N
study NN N
treatment NN N
. . N

Using VBG N
a DT N
logistic JJ N
regression NN N
model NN N
, , N
baseline JJ o
quantitative JJ o
mycobacterial JJ o
load NN o
[ NNP N
relative JJ N
odds NNS N
of IN N
clearing NN N
, , N
1.97 CD N
for IN N
a DT N
decrease NN N
of IN N
1 CD N
log10 JJ N
colony NN N
forming VBG N
count NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.36-2.87 JJ N
; : N
P NNP N
< VBD N
0.001 CD N
] NN N
and CC N
Karnofsky NNP o
score NN o
were VBD N
the DT N
only JJ N
statistically RB N
significant JJ N
univariate JJ N
predictors NNS N
of IN N
clearance NN N
, , N
although IN N
previous JJ N
prophylaxis NN N
with IN N
rifabutin NN N
was VBD N
also RB N
a DT N
significant JJ N
predictor NN N
in IN N
a DT N
multivariate NN o
model NN o
( ( N
relative JJ N
odds NNS N
of IN N
clearing NN N
, , N
0.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.17-0.88 NNP N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicates VBZ N
that IN N
although IN N
the DT N
level NN N
of IN N
MAC NNP N
bacteremia NN N
is VBZ N
an DT N
important JJ N
predictor NN N
of IN N
clearance NN N
, , N
it PRP N
is VBZ N
not RB N
associated VBN N
with IN N
survival NN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
the DT N
PostureJac NNP i
on IN N
deep JJ o
cervical JJ o
flexor NN o
endurance NN o
: : o
implications NNS N
in IN N
the DT N
management NN N
of IN N
cervicogenic JJ o
headache NN o
and CC N
mechanical JJ o
neck NN o
pain NN o
. . o

The DT N
convergence NN N
of IN N
cervical JJ N
and CC N
trigeminal JJ N
afferents NNS N
on IN N
second-order JJ N
neurons NNS N
in IN N
the DT N
trigeminocervical JJ N
nucleus NN N
may MD N
refer VB N
pain NN N
from IN N
the DT N
upper JJ N
cervical JJ N
spine NN N
into IN N
the DT N
head NN N
and CC N
face NN N
. . N

Furthermore RB N
, , N
bi-directional JJ N
interactions NNS N
between IN N
trigeminal JJ N
and CC N
upper JJ N
cervical JJ N
afferents NNS N
may MD N
also RB N
explain VB N
neck NN N
symptoms NNS N
of IN N
trigeminal JJ N
origin NN N
( ( N
e.g. JJ N
, , N
migraine NN N
) ) N
. . N

It PRP N
is VBZ N
known VBN N
that IN N
cervicogenic JJ N
headache NN N
sufferers NNS N
present JJ N
with IN N
several JJ N
musculoskeletal JJ N
changes NNS N
including VBG N
poor JJ N
endurance NN N
of IN N
the DT N
deep JJ N
cervical JJ N
flexor NN N
muscles NNS N
. . N

These DT N
intrinsic JJ N
muscles NNS N
of IN N
the DT N
neck NN N
contribute NN N
to TO N
stabilization NN N
and CC N
protection NN N
of IN N
the DT N
cervical JJ N
spine NN N
and CC N
are VBP N
critical JJ N
for IN N
the DT N
control NN N
of IN N
both DT N
intervertebral JJ N
motion NN N
and CC N
the DT N
cervical JJ N
lordosis NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
use NN N
of IN N
the DT N
PostureJac NNP i
( ( N
SomatoCentric NNP N
Systems NNP N
, , N
Inc. NNP N
, , N
Toronto NNP N
, , N
Ontario NNP N
, , N
Canada NNP N
) ) N
, , N
a DT N
posture NN N
support NN N
and CC N
exercise NN N
jacket NN N
, , N
was VBD N
effective JJ N
in IN N
enhancing VBG N
deep JJ o
cervical JJ o
muscle NN o
endurance NN o
. . o

Forty-five JJ p
( ( p
45 CD p
) ) p
female NN p
subjects NNS p
, , p
between IN p
the DT p
ages NNS p
of IN p
18 CD p
and CC p
40 CD p
years NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
consisting VBG N
of IN N
the DT N
no-treatment JJ i
control NN i
, , p
the DT p
treatment-control NN i
( ( i
table JJ i
stabilization NN i
) ) i
, , i
and CC i
the DT i
experimental JJ i
( ( i
PostureJac NNP i
) ) i
group NN i
. . i

The DT N
outcome JJ N
measure NN N
of IN N
deep JJ o
cervical JJ o
flexor NN o
muscle NN o
endurance NN o
was VBD N
based VBN N
on IN N
the DT N
Flexor NNP o
Endurance NNP o
Test NNP o
and CC N
was VBD N
recorded VBN N
in IN N
seconds NNS N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
the DT N
PostureJac NNP i
group NN p
was VBD N
superior JJ N
to TO N
the DT N
no-treatment JJ p
control NN p
( ( p
p=.001 NN p
) ) p
and CC p
the DT p
treatment-control NN p
( ( p
p=.004 NN p
) ) p
groups NNS p
in IN N
terms NNS N
of IN N
increasing VBG N
endurance NN o
of IN o
the DT o
deep JJ o
cervical JJ o
flexors NNS o
. . o

Consequently RB N
, , N
the DT N
PostureJac NNP i
may MD N
be VB N
a DT N
useful JJ N
therapeutic JJ N
tool NN N
in IN N
the DT N
management NN N
of IN N
cervicogenic JJ o
headache NN o
and CC o
mechanical JJ o
neck NN o
pain NN o
. . o

-DOCSTART- -X- O O

The DT N
effect NN o
of IN N
quality NN N
and CC N
amount NN N
of IN N
dietary JJ N
fat NN N
on IN N
the DT N
susceptibility NN o
of IN o
low JJ o
density NN o
lipoprotein NN o
to TO o
oxidation NN o
in IN p
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
. . p

OBJECTIVES IN N
We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
a DT N
high JJ i
fat NN i
diet JJ i
rich JJ i
in IN i
monounsaturated JJ i
fat NN i
( ( i
MUFA-diet NNP i
) ) i
and CC N
a DT N
moderate JJ i
fat NN i
diet JJ i
rich JJ i
in IN i
polyunsaturated JJ i
fat NN i
( ( i
PUFA-diet NNP i
) ) i
on IN N
the DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation NN o
. . o

SUBJECTS NNP N
29 CD p
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
. . p

METHODS NNP N
After IN N
consuming VBG N
a DT N
run-in JJ N
diet JJ N
[ FW N
37 CD N
% NN N
of IN N
energy NN N
( ( N
E NNP N
% NN N
) ) N
fat NN N
, , N
18 CD N
E NNP N
% NN N
saturated VBD N
fat JJ N
] NN N
for IN N
three CD N
weeks NNS N
, , N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
a DT N
MUFA-diet JJ N
( ( N
40 CD N
E NNP N
% NN N
fat NN N
, , N
19 CD N
E NNP N
% NN N
monounsaturated VBD N
fatty JJ N
acids NNS N
) ) N
or CC N
a DT N
PUFA-diet JJ N
( ( N
34 CD N
E NNP N
% NN N
fat NN N
, , N
10 CD N
E NNP N
% NN N
polyunsaturated VBD N
fat NN N
) ) N
for IN N
eight CD N
weeks NNS N
. . N

The DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation NN o
was VBD N
measured VBN N
by IN N
challenging VBG N
LDL NNP N
with IN N
hemin NN N
and CC N
H2O2 NNP N
and CC N
measuring VBG N
the DT N
time NN o
for IN o
the DT o
reaction NN o
to TO o
reach VB o
maximum JJ o
velocity NN o
. . o

Results NNS N
are VBP N
expressed VBN N
as IN N
lag NN o
time NN o
to TO o
oxidation NN o
in IN N
minutes NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PUFA-diet JJ N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
lag NN o
time NN o
tended VBD N
to TO N
decrease VB N
during IN N
the DT N
experimental JJ N
diet NN N
( ( N
97 CD N
+/- JJ N
28 CD N
vs JJ N
90 CD N
+/- JJ N
25 CD N
min NN N
, , N
mean JJ N
+/- JJ N
s.d. NN N
, , N
P NNP N
= NNP N
0.073 CD N
) ) N
, , N
whereas RB N
in IN N
the DT N
MUFA-diet JJ N
group NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
there EX N
was VBD N
no DT N
significant JJ N
change NN N
( ( N
lag JJ N
time NN N
96 CD N
+/- JJ N
24 CD N
vs JJ N
100 CD N
+/- JJ N
16 CD N
min NN N
, , N
P NNP N
= NNP N
0.408 CD N
) ) N
. . N

The DT N
mean JJ o
change NN o
in IN o
lag NN o
time NN o
was VBD N
-7 JJ N
+/- JJ N
14 CD N
min NN N
( ( N
-7.2 CD N
% NN N
) ) N
in IN N
the DT N
PUFA-diet JJ N
group NN N
and CC N
+4 VBZ N
+/- JJ N
16 CD N
min NN N
( ( N
+4.0 CD N
% NN N
) ) N
in IN N
the DT N
MUFA-diet JJ N
group NN N
( ( N
P NNP N
= NNP N
0.029 CD N
, , N
PUFA-diet JJ N
group NN N
vs VBD N
MUFA-diet NNP N
group NN N
) ) N
. . N

The DT N
alpha-tocopherol JJ o
concentration NN o
in IN o
LDL NNP o
increased VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
both DT N
diet JJ N
groups NNS N
relative VBP N
to TO N
the DT N
run-in JJ N
diet JJ N
period NN N
, , N
but CC N
LDL NNP o
particle VBD o
score RB o
did VBD N
not RB N
change VB N
in IN N
either DT N
of IN N
the DT N
diet JJ N
groups NNS N
during IN N
the DT N
dietary JJ N
intervention NN N
. . N

In IN N
subjects NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
a DT N
PUFA-rich JJ i
diet NN N
with IN N
a DT N
moderate JJ N
amount NN N
of IN N
fat NN N
tended VBN N
to TO N
increase VB N
the DT N
susceptibility NN o
of IN o
LDL NNP o
to TO o
oxidation NN o
as IN N
compared VBN N
to TO N
a DT N
higher JJR N
fat JJ N
diet JJ N
rich NN N
in IN N
MUFA NNP i
. . i

Furthermore NNP N
, , N
the DT N
negative JJ N
mean NN N
change NN N
in IN N
lag NN o
time NN o
to TO o
oxidation NN o
found VBN N
in IN N
the DT N
PUFA-diet JJ N
group NN N
differed VBD N
significantly RB N
from IN N
the DT N
slightly RB N
positive JJ N
mean NN N
change NN N
found VBD N
in IN N
the DT N
MUFA-diet JJ N
group NN N
. . N

-DOCSTART- -X- O O

Nordic NNP i
walking NN i
and CC N
chronic JJ N
low JJ N
back RB N
pain NN N
: : N
design NN N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Low NNP N
Back NNP N
Pain NNP N
is VBZ N
a DT N
major JJ N
public JJ N
health NN N
problem NN N
all DT N
over IN N
the DT N
western JJ N
world NN N
. . N

Active JJ N
approaches NNS N
including VBG N
exercise NN N
in IN N
the DT N
treatment NN N
of IN N
low JJ N
back RB N
pain NN N
results NNS N
in IN N
better JJR N
outcomes NNS N
for IN N
patients NNS N
, , N
but CC N
it PRP N
is VBZ N
not RB N
known VBN N
exactly RB N
which WDT N
types NNS N
of IN N
back NN N
exercises NNS N
are VBP N
most RBS N
beneficial JJ N
or CC N
whether IN N
general JJ N
physical JJ N
activity NN N
provide VBP N
similar JJ N
benefits NNS N
. . N

Nordic NNP i
Walking NNP i
is VBZ N
a DT N
popular JJ N
and CC N
fast JJ N
growing VBG N
type NN N
of IN N
exercise NN N
in IN N
Northern NNP N
Europe NNP N
. . N

Initial NNP N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
persons NNS N
performing VBG N
Nordic NNP i
Walking NNP i
are VBP N
able JJ N
to TO N
exercise VB N
longer JJR N
and CC N
harder RBR N
compared VBN N
to TO N
normal JJ N
walking VBG N
thereby RB N
increasing VBG N
their PRP$ N
cardiovascular JJ N
metabolism NN N
. . N

Until IN N
now RB N
no DT N
studies NNS N
have VBP N
been VBN N
performed VBN N
to TO N
investigate VB N
whether IN N
Nordic NNP i
Walking NNP i
has VBZ N
beneficial JJ N
effects NNS o
in IN N
relation NN N
to TO N
low VB N
back RB N
pain NN N
. . N

The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
whether IN N
supervised JJ i
Nordic NNP i
Walking NNP i
can MD N
reduce VB o
pain NN o
and CC N
improve VB o
function NN o
in IN p
a DT p
population NN p
of IN p
chronic JJ p
low JJ p
back RB p
pain NN p
patients NNS p
when WRB N
compared VBN N
to TO N
unsupervised JJ i
Nordic NNP i
Walking NNP i
and CC i
advice NN i
to TO i
stay VB i
active JJ i
. . i

In IN N
addition NN N
we PRP N
investigate VBP N
whether IN N
there EX N
is VBZ N
an DT N
increase NN N
in IN N
the DT N
cardiovascular JJ N
metabolism NN N
in IN N
persons NNS p
performing VBG p
supervised VBD i
Nordic NNP i
Walking NNP i
compared VBN N
to TO N
persons NNS p
who WP p
are VBP p
advised VBN i
to TO i
stay VB i
active JJ i
. . i

Finally RB N
, , N
we PRP N
investigate VBP N
whether IN N
there EX N
is VBZ N
a DT N
difference NN N
in IN N
compliance NN o
between IN N
persons NNS p
receiving VBG p
supervised VBD i
Nordic NNP i
Walking NNP i
and CC N
persons NNS p
doing VBG p
unsupervised JJ i
Nordic NNP i
Walking NNP i
. . i

METHODS NNP N
One CD p
hundred CD p
and CC p
fifty JJ p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
for IN p
at IN p
least JJS p
eight CD p
weeks NNS p
and CC p
referred VBD p
to TO p
a DT p
specialized JJ p
secondary JJ p
sector NN p
outpatient NN p
back RB p
pain NN p
clinic NN p
are VBP p
included VBN p
in IN p
the DT p
study NN p
. . p

After IN N
completion NN N
of IN N
the DT N
standard NN i
back RB i
centre JJ i
treatment NN i
patients NNS N
are VBP N
randomized VBN N
into IN N
one CD N
of IN N
three CD p
groups NNS p
: : p
A DT p
) ) p
Nordic NNP i
Walking NNP i
twice RB i
a DT i
week NN i
for IN i
eight CD i
weeks NNS i
under IN i
supervision NN i
of IN i
a DT i
specially RB i
trained JJ i
instructor NN i
; : i
B NNP p
) ) p
Unsupervised VBD i
Nordic NNP i
Walking NNP i
for IN i
eight CD i
weeks NNS i
after IN i
one CD i
training NN i
session NN i
with IN i
an DT i
instructor NN i
; : i
C NNP p
) ) p
A DT i
one CD i
hour NN i
motivational JJ i
talk NN i
including VBG i
advice NN i
to TO i
stay VB i
active JJ i
. . i

Outcome NN N
measures NNS N
are VBP N
pain NN o
, , o
function NN o
, , o
overall JJ o
health NN o
, , o
cardiovascular JJ o
ability NN o
and CC o
activity NN o
level NN o
. . o

RESULTS NNP N
No NNP N
results NNS N
available JJ N
at IN N
this DT N
point NN N
. . N

DISCUSSION NNP N
This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
Nordic NNP i
Walking VBG i
on IN N
pain NN N
and CC N
function NN N
in IN N
a DT N
population NN p
of IN p
people NNS p
with IN p
chronic JJ p
LBP NNP p
. . p

-DOCSTART- -X- O O

Calcium NNP i
channel NN i
blocker NN i
inhibition NN i
of IN i
AGE NNP i
and CC i
RAGE NNP i
axis VBP N
limits NNS N
renal JJ o
injury NN o
in IN N
nondiabetic JJ p
patients NNS p
with IN p
stage NN p
I PRP p
or CC p
II NNP p
chronic JJ p
kidney NN p
disease NN p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
growing VBG N
body NN N
of IN N
evidence NN N
that IN N
advanced VBD N
glycation JJ N
end NN N
products NNS N
( ( N
AGE NNP N
) ) N
and CC N
their PRP$ N
receptor NN N
( ( N
RAGE NNP N
) ) N
system NN N
are VBP N
implicated VBN N
in IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
. . N

We PRP N
have VBP N
previously RB N
found VBN N
that IN N
a DT N
long-acting JJ N
calcium NN i
channel NN i
blocker NN i
, , i
azelnidipine NN i
, , i
but CC i
not RB i
amlodipine VB i
, , N
improves VBZ N
renal JJ o
injury NN o
in IN N
CKD NNP N
patients NNS N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effect NN N
of IN N
azelnidipine NN i
on IN N
the DT N
AGE-RAGE NNP o
axis NN o
in IN N
humans NNS N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
whether IN N
azelnidipine JJ i
addition NN N
could MD N
have VB N
renoprotective JJ o
properties NNS o
in IN N
hypertensive JJ N
CKD NNP N
patients NNS N
by IN N
reducing VBG N
serum NN o
levels NNS o
of IN o
AGE NNP o
and CC o
soluble JJ o
form NN o
of IN o
RAGE NNP o
( ( o
sRAGE NN o
) ) o
. . o

Thirty NNP p
nondiabetic JJ p
stage NN p
I PRP p
or CC p
II NNP p
CKD NNP p
patients NNS p
who WP p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN p
II NNP p
receptor NN p
blockers NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

HYPOTHESIS NNP N
We PRP N
hypothesized VBD N
that IN N
azelnidipine NN i
treatment NN N
could MD N
limit VB N
renal JJ N
injury NN N
partly RB N
by IN N
blocking VBG N
the DT N
AGE-RAGE NNP o
axis NN o
. . o

METHODS JJ N
Patients NNPS p
were VBD N
randomly RB N
divided VBN N
into IN N
2 CD p
groups NNS p
; : p
one CD N
group NN N
was VBD N
treated VBN N
with IN N
16 CD N
mg NNS N
azelnidipine NN i
and CC N
the DT N
other JJ N
with IN N
5 CD N
mg NNS N
amlodipine JJ i
once RB N
daily JJ N
. . N

They PRP N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
Proteinuria NNP o
was VBD N
positively RB N
correlated VBN N
with IN N
circulating VBG o
AGE NNP o
and CC o
sRAGE NN o
levels NNS o
in IN N
our PRP$ N
subjects NNS N
. . N

Both DT N
drugs NNS N
exhibited VBN N
comparable JJ N
and CC N
significant JJ N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
-lowering VBG o
effects NNS o
. . o

Although IN N
neither DT N
of IN N
them PRP N
affected VBD N
glucose NN o
, , o
glycated VBD o
hemoglobin NN o
, , o
lipid JJ o
levels NNS o
, , o
and CC o
estimated VBD o
glomerular JJ o
filtration NN o
rate NN o
, , o
treatment NN o
with IN o
azelnidipine NN o
, , N
but CC N
not RB N
amlodipine VB i
, , N
decreased VBN N
circulating NN o
AGE NNP o
, , o
sRAGE NN o
, , o
proteinuria NN o
, , o
and CC o
urinary JJ o
levels NNS o
of IN o
liver-type JJ o
fatty JJ o
acid NN o
binding VBG o
protein NN o
, , N
a DT N
marker NN N
of IN N
tubular JJ N
injury NN N
, , N
in IN N
a DT N
BP-lowering-independent JJ N
manner NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
present JJ N
results NNS N
suggest VBP N
that IN N
azelnidipine NN i
may MD N
exert VB N
renoprotective JJ o
properties NNS o
in IN N
nondiabetic JJ p
hypertensive JJ p
CKD NNP p
patients NNS p
via IN N
its PRP$ N
unique JJ N
inhibitory JJ N
effects NNS N
on IN N
the DT N
AGE-RAGE NNP N
axis NN N
. . N

-DOCSTART- -X- O O

Quantification NN N
of IN N
cyproheptadine NN i
in IN p
human JJ p
plasma NN p
by IN N
high-performance NN N
liquid NN N
chromatography NN N
coupled VBD N
to TO N
electrospray VB N
tandem JJ N
mass NN N
spectrometry NN N
in IN N
a DT N
bioequivalence NN N
study NN N
. . N

A DT N
rapid JJ N
, , N
sensitive JJ N
and CC N
specific JJ N
method NN N
to TO N
quantify VB N
cyproheptadine NN i
in IN N
human JJ N
plasma NN N
using VBG N
amitriptyline NN N
as IN N
the DT N
internal JJ N
standard NN N
( ( N
IS NNP N
) ) N
is VBZ N
described VBN N
. . N

The DT N
analyte NN p
and CC p
the DT p
IS NNP p
were VBD N
extracted VBN N
from IN N
plasma NN N
by IN N
liquid-liquid JJ N
extraction NN N
using VBG N
a DT N
diethyl-ether/dichloromethane NN N
( ( N
70/30 CD N
; : N
v/v NN N
) ) N
solvent NN N
. . N

After IN N
removing VBG N
and CC N
drying VBG N
the DT N
organic JJ p
phase NN p
, , N
the DT N
extracts NNS N
were VBD N
reconstituted VBN N
with IN N
a DT N
fixed JJ N
volume NN N
of IN N
acetonitrile/water NN N
( ( N
50/50 CD N
v/v NN N
) ) N
+0.1 CD N
% NN N
of IN N
acetic JJ N
acid NN N
. . N

The DT N
extracts NNS N
were VBD N
analyzed VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
coupled VBD N
to TO N
electrospray VB N
tandem JJ N
mass NN N
spectrometry NN N
( ( N
LC-MS/MS NNP N
) ) N
. . N

Chromatography NNP i
was VBD N
performed VBN N
isocratically RB N
using VBG N
an DT N
Alltech NNP N
Prevail NNP N
C18 NNP N
5 CD N
?m NNP N
analytical JJ N
column NN N
, , N
( ( N
150 CD N
mm NN N
x VBD N
4.6 CD N
mm NNS N
I.D. NNP N
) ) N
. . N

The DT N
method NN N
had VBD N
a DT N
chromatographic JJ N
run NN N
time NN N
of IN N
4 CD N
min NNS N
and CC N
a DT N
linear JJ N
calibration NN N
curve NN N
ranging VBG N
from IN N
0.05 CD N
to TO N
10 CD N
ng/mL NNS N
( ( N
r2 VB N
> RB N
0.99 CD N
) ) N
. . N

The DT N
limit NN N
of IN N
quantification NN N
was VBD N
0.05 CD N
ng/mL RB N
. . N

This DT N
HPLC/MS/MS NNP N
procedure NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
bioequivalence NN N
of IN N
cyproheptadine NN N
in IN N
two CD N
cyproheptadine NN N
+ NNS N
cobamamide VBP N
( ( N
4 CD N
mg NN N
+ VBD N
1 CD N
mg NN N
) ) N
tablet NN N
formulations NNS N
( ( N
Cobactin? NNP N
[ NNP N
cyproheptadine NN N
+ NNP N
cobamamide NN N
] NNP N
test NN N
formulation NN N
supplied VBN N
from IN N
Zambon NNP N
Laborat?rios NNP N
Farmac?uticos NNP N
Ltda NNP N
. . N

and CC N
Cobavital? NNP N
from IN N
Solvay NNP N
Farma NNP N
( ( N
standard JJ N
reference NN N
formulation NN N
) ) N
) ) N
. . N

A DT N
single JJ N
4 CD N
mg NN N
+ VBD N
1 CD N
mg NN N
[ NNP N
cyproheptadine NN N
+ NNP N
cobamamide NN N
] NNP N
dose NN N
of IN N
each DT N
formulation NN N
was VBD N
administered VBN N
to TO p
healthy JJ p
volunteers NNS p
. . p

The DT p
study NN p
was VBD N
conducted VBN N
using VBG N
an DT N
open JJ N
, , N
randomized VBN N
, , N
two-period JJ N
crossover NN N
design NN N
with IN N
a DT N
1-week JJ N
washout NN N
interval NN N
. . N

Since IN N
the DT o
90 CD o
% NN o
CI NNP o
for IN o
Cmax NNP o
and CC o
AUCs NNP o
ratios NNS o
were VBD N
all DT N
within IN N
the DT N
80-125 JJ N
% NN N
bioequivalence NN N
limit NN N
proposed VBN N
by IN N
the DT N
US NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
cyproheptadine JJ N
test NN N
formulation NN N
( ( N
Cobactin? NNP N
) ) N
is VBZ N
bioequivalent JJ N
to TO N
the DT N
Cobavital? NNP N
formulation NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
the DT N
extent NN N
of IN N
absorption NN N
of IN i
cyproheptadine NN i
. . i

-DOCSTART- -X- O O

A DT N
clinical JJ N
evaluation NN N
of IN N
a DT N
blood NN i
conservation NN i
device NN i
in IN N
medical JJ p
intensive JJ p
care NN p
unit NN p
patients NNS p
. . p

OBJECTIVES NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
a DT N
) ) N
document NN N
the DT N
efficacy NN N
of IN N
a DT N
device NN N
intended VBN N
to TO N
conserve VB N
blood NN N
in IN N
critically RB p
ill JJ p
patients NNS p
; : p
b NN N
) ) N
determine VBZ N
the DT N
effect NN N
of IN N
this DT N
blood NN N
conservation NN N
on IN N
hemoglobin JJ o
concentration NN o
and CC N
the DT N
need NN o
for IN o
blood NN o
transfusions NNS o
; : o
c NNS N
) ) N
determine VBP N
if IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
interference NN N
with IN N
arterial JJ N
pressure NN N
waveforms NNS N
; : N
d NN N
) ) N
determine NN N
if IN N
use NN N
of IN N
the DT N
blood NN N
conservation NN N
device NN N
resulted VBD N
in IN N
a DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
accidental JJ N
needle JJ N
punctures NNS N
suffered VBN N
by IN N
healthcare JJ N
workers NNS N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
trial NN N
. . N

A DT N
clinical JJ N
trial NN N
using VBG N
prospective JJ N
, , N
random JJ N
allocation NN N
of IN N
consecutive JJ N
eligible JJ N
patients NNS N
. . N

SETTING VBG N
The DT p
medical JJ p
intensive JJ p
care NN p
unit NN p
( ( p
ICU NNP p
) ) p
of IN p
a DT p
university NN p
hospital NN p
located VBN p
in IN p
a DT p
large JJ p
metropolitan JJ p
area NN p
. . p

PATIENTS VB N
A DT p
total NN p
of IN p
100 CD p
patients NNS p
who WP p
were VBD p
admitted VBN p
to TO p
the DT p
medical JJ p
ICU NNP p
, , p
required VBD p
arterial JJ p
line NN p
monitoring NN p
for IN p
clinical JJ p
purposes NNS p
, , p
and CC p
were VBD p
managed VBN p
by IN p
the DT p
ICU NNP p
medical JJ p
service NN p
. . p

Exclusion NNP p
criteria NNS p
included VBD p
active JJ p
bleeding NN p
or CC p
chronic JJ p
renal JJ p
failure NN p
at IN p
the DT p
time NN p
of IN p
ICU NNP p
admission NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
in IN N
the DT N
experimental JJ N
group NN N
had VBD N
a DT N
blood NN i
conservation NN i
device NN i
incorporated VBN i
into IN i
the DT i
arterial JJ i
pressure NN i
monitoring NN i
system NN i
, , N
while IN N
patients NNS N
in IN N
the DT N
control NN i
group NN i
received VBD i
a DT i
conventional JJ i
arterial JJ i
pressure NN i
monitoring NN i
system NN i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Data NNP N
gathered VBD N
included VBN N
: : N
age NN N
; : N
gender NN N
; : N
ICU NNP N
discharge NN N
status NN N
; : N
the DT N
duration NN o
of IN o
ICU NNP o
stay NN o
; : o
time NN o
in IN o
the DT o
study NN o
; : o
volume NN o
of IN o
all DT o
blood NN o
drawn NN o
, , o
discarded VBD o
, , o
or CC o
lost VBN o
due JJ o
to TO o
leakage VB o
; : o
hemoglobin JJ o
concentrations NNS o
; : o
blood NN o
transfusions NNS o
; : o
and CC o
accidental JJ o
needle JJ o
injuries NNS o
. . o

Arterial JJ o
pressure NN o
waveforms NNS o
were VBD N
recorded VBN N
and CC N
inspected VBN N
for IN N
dampening VBG N
or CC N
other JJ N
deformation NN N
. . N

Mean NNP o
hemoglobin JJ o
concentrations NNS o
were VBD N
compared VBN N
on IN N
ICU NNP N
admission NN N
and CC N
at IN N
12-hr JJ N
intervals NNS N
. . N

Demographic NNP N
and CC N
clinical JJ N
characteristics NNS N
of IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
volume NN o
of IN o
blood NN o
drawn NN o
and CC o
discarded VBD o
from IN o
arterial JJ o
catheters NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
( ( N
blood NN N
conservation NN N
device NN N
: : N
5.7 CD N
+/- JJ N
7.5 CD N
mL NN N
; : N
control NN N
: : N
96.4 CD N
+/- JJ N
88.5 CD N
mL NN N
; : N
p CC N
< NNP N
.0001 NNP N
) ) N
, , N
as IN N
was VBD N
the DT N
total JJ o
volume NN o
of IN o
blood NN o
discarded VBN o
( ( N
blood NN N
conservation NN N
device NN N
: : N
19.4 CD N
+/- JJ N
47.4 CD N
mL NN N
; : N
control NN N
: : N
103.5 CD N
+/- JJ N
99.9 CD N
mL NN N
; : N
p CC N
< NNP N
.0001 NNP N
) ) N
. . N

Mean NNP o
hemoglobin JJ o
concentration NN o
on IN N
admission NN N
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
blood NN N
conservation NN N
device NN N
group NN N
: : N
11.8 CD N
+/- JJ N
2.5 CD N
g/dL NN N
; : N
control NN N
group NN N
: : N
12.6 CD N
+/- JJ N
2.3 CD N
g/dL NN N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
mean JJ o
hemoglobin NN o
concentration NN o
declined VBD N
most JJS N
rapidly RB N
in IN N
the DT N
first JJ N
24 CD N
hrs NN N
of IN N
ICU NNP N
care NN N
and CC N
, , N
thereafter RB N
, , N
declined VBD N
more RBR N
slowly RB N
. . N

Although IN N
the DT N
mean JJ o
hemoglobin NN o
concentration NN o
was VBD N
higher RBR N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
after IN N
6 CD N
days NNS N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
until IN N
9.5 CD N
days NNS N
of IN N
ICU NNP N
care NN N
. . N

The DT N
mean JJ o
change NN o
in IN o
hemoglobin JJ o
concentration NN o
( ( N
overall JJ N
: : N
1.2 CD N
+/- JJ N
2.2 CD N
g/dL NN N
) ) N
during IN N
the DT N
study NN N
represents VBZ N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
.0001 NNP N
) ) N
decrease NN N
of IN N
9.7 CD N
% NN N
. . N

Hemoglobin NNP o
concentration NN o
during IN N
the DT N
study NN N
decreased VBN N
by IN N
1.4 CD N
+/- JJ N
2.2 CD N
g/dL NN N
in IN N
the DT N
control NN N
group NN N
and CC N
1.0 CD N
+/- JJ N
2.3 CD N
g/dL NN N
in IN N
the DT N
blood NN N
conservation NN N
group NN N
( ( N
p JJ N
= NNP N
nonsignificant NN N
) ) N
. . N

Univariate NNP o
and CC o
multiple JJ o
regression NN o
analysis NN o
demonstrated VBD N
discarded JJ N
blood NN o
volume NN o
to TO N
be VB N
a DT N
significant JJ N
and CC N
independent JJ N
predictor NN N
of IN N
the DT N
decline NN N
in IN N
hemoglobin JJ N
concentration NN N
. . N

Transfusion NN o
requirements NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

The DT N
blood NN i
conservation NN i
system NN i
did VBD N
not RB N
alter VB N
or CC N
interfere VB N
with IN N
pressure NN o
waveforms NNS o
. . o

There EX N
were VBD N
no DT N
accidental JJ o
needle JJ o
injuries NNS o
noted VBD N
. . N

CONCLUSIONS VB N
The DT N
conservation NN N
of IN N
blood NN N
in IN N
critically RB p
ill JJ p
patients NNS p
must MD N
be VB N
a DT N
high-priority JJ N
concern NN N
of IN N
all DT N
healthcare JJ N
workers NNS N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
blood NN N
conservation NN N
system NN N
eliminates VBZ N
a DT N
significant JJ N
factor NN N
in IN N
the DT N
decline NN N
in IN N
hemoglobin JJ o
concentration NN o
. . o

With IN N
devices NNS N
as IN N
described NN N
here RB N
, , N
there EX N
is VBZ N
no DT N
reason NN N
to TO N
continue VB N
the DT N
practice NN N
of IN N
wasting VBG N
the DT N
blood NN N
of IN N
critically RB p
ill JJ p
patients NNS p
in IN N
order NN N
to TO N
prevent VB N
preanalytic JJ N
error NN N
. . N

-DOCSTART- -X- O O

Omega-3/omega-6 NNP i
fatty JJ i
acids NNS i
for IN N
attention NN o
deficit NN o
hyperactivity NN o
disorder NN o
: : o
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
in IN N
children NNS p
and CC p
adolescents NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
omega JJ i
3/6 CD i
fatty JJ i
acids NNS i
( ( N
eye NN N
q NN N
) ) N
in IN N
attention NN o
deficit NN o
hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
. . o

METHOD PDT N
The DT N
study NN N
included VBD N
a DT N
randomized VBN N
, , N
3-month JJ N
, , N
omega JJ i
3/6 CD i
placebo-controlled JJ i
, , N
one-way JJ N
crossover NN N
trial NN N
with IN N
75 CD p
children NNS p
and CC p
adolescents NNS p
( ( p
8-18 CD p
years NNS p
) ) p
, , N
followed VBN i
by IN i
3 CD i
months NNS i
with IN i
omega JJ i
3/6 CD i
for IN i
all DT i
. . i

Investigator-rated JJ o
ADHD NNP o
Rating NNP o
Scale-IV NNP o
and CC o
Clinical NNP o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
scale NN o
were VBD N
outcome JJ N
measures NNS N
. . N

RESULTS VB N
A DT N
majority NN N
did VBD N
not RB N
respond VB N
to TO N
omega VB N
3/6 CD N
treatment NN N
. . N

However RB N
, , N
a DT N
subgroup NN N
of IN N
26 CD N
% NN N
responded VBD N
with IN N
more JJR N
than IN N
25 CD N
% NN N
reduction NN o
of IN o
ADHD NNP o
symptoms NNS o
and CC N
a DT N
drop NN o
of IN o
CGI NNP o
scores NNS o
to TO N
the DT N
near-normal JJ N
range NN N
. . N

After IN N
6 CD N
months NNS N
, , N
47 CD N
% NN N
of IN N
all DT N
showed VBD N
such JJ N
improvement NN N
. . N

Responders NNS p
tended VBD p
to TO p
have VB p
ADHD NNP o
inattentive JJ p
subtype NN p
and CC p
comorbid NN p
neurodevelopmental JJ p
disorders NNS p
. . p

CONCLUSION VB N
A DT p
subgroup NN p
of IN p
children NNS p
and CC p
adolescents NNS p
with IN p
ADHD NNP o
, , N
characterized VBN N
by IN N
inattention NN N
and CC N
associated VBN N
neurodevelopmental JJ N
disorders NNS N
, , N
treated VBN N
with IN N
omega JJ i
3/6 CD i
fatty JJ i
acids NNS i
for IN N
6 CD N
months NNS N
responded VBN N
with IN N
meaningful JJ N
reduction NN o
of IN o
ADHD NNP o
symptoms NNS o
. . o

-DOCSTART- -X- O O

Mandibular JJ i
advancement NN i
splint NN i
improves VBZ N
indices NNS N
of IN N
obstructive JJ p
sleep NN p
apnoea NN p
and CC p
snoring VBG p
but CC N
side JJ N
effects NNS N
are VBP N
common JJ N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
mandibular JJ i
advancement NN i
splint NN i
( ( i
MAS NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
obstructive JJ o
sleep JJ o
apnoea NN o
syndrome NN o
( ( o
OSAS NNP o
) ) o
. . o

METHODS NNP N
Nineteen NNP p
patients NNS p
using VBG p
a DT p
MAS NNP i
for IN p
symptomatic JJ p
OSAS NNP p
underwent NN p
polysomnography NN i
, , p
with IN p
MAS NNP i
use NN p
randomised VBD p
to TO p
one CD p
half NN p
of IN p
the DT p
night NN p
. . p

Indices NNS o
of IN o
snoring VBG o
and CC o
OSAS NNP o
were VBD N
compared VBN N
. . N

Side NNP o
effects NNS o
, , o
compliance NN o
and CC o
treatment NN o
response NN o
were VBD N
evaluated VBN N
by IN N
questionnaire NN N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP i
improved VBD N
total JJ o
respiratory NN o
disturbance NN o
index NN o
( ( o
RDI NNP o
) ) o
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS o
per IN o
hour NN o
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ o
RDI NNP o
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ o
index NN o
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG o
intensity NN o
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ o
snore NN o
frequency NN o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Using VBG N
polysomnographic JJ N
criteria NNS N
, , N
MAS NNP i
treatment NN N
was VBD N
completely RB o
successful JJ o
in IN N
four CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
, , N
partially RB o
successful JJ o
in IN N
ten NN N
( ( N
52.6 CD N
% NN N
) ) N
and CC N
a DT N
failure NN o
in IN N
five CD N
( ( N
26.3 CD N
% NN N
) ) N
. . N

Treatment NN N
over IN N
a DT N
median NN N
of IN N
6.5 CD N
weeks NNS N
( ( N
range VB N
2-48 CD N
) ) N
was VBD N
perceived VBN N
as IN N
beneficial JJ N
by IN N
ten NN N
of IN N
eleven JJ N
partners NNS N
. . N

Fifteen JJ p
patients NNS p
( ( p
79 CD p
% NN p
) ) p
reported VBD N
side JJ o
effects NNS o
, , N
9 CD N
( ( N
46 CD N
% NN N
) ) N
did VBD N
not RB N
use VB N
the DT N
device NN N
every DT N
night NN N
and CC N
four CD N
( ( N
21 CD N
% NN N
) ) N
used VBD N
the DT N
device NN N
less JJR N
than IN N
three CD N
nights NNS N
per IN N
week NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
the DT N
MAS NNP i
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
indices NNS N
of IN N
OSAS NNP o
and CC o
snoring VBG o
. . o

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
patients NNS N
had VBD N
difficulty NN N
tolerating NN N
and CC N
regularly RB N
using VBG N
the DT N
device NN N
. . N

-DOCSTART- -X- O O

Metabolic JJ N
responses NNS N
to TO N
oral JJ i
surgery NN i
under IN N
local JJ i
anesthesia NN i
and CC N
sedation NN N
with IN N
intravenous JJ N
midazolam NNS i
: : i
the DT N
effects NNS N
of IN N
two CD N
different JJ N
local JJ i
anesthetics NNS i
. . i

The DT N
effects NNS N
of IN N
epinephrine-free JJ i
and CC i
epinephrine-containing JJ i
local JJ i
anesthetic JJ i
solutions NNS N
on IN N
plasma NN o
potassium NN o
and CC o
blood NN o
glucose JJ o
concentrations NNS o
were VBD N
investigated VBN N
in IN N
20 CD p
patients NNS p
undergoing JJ p
oral JJ p
surgery NN p
with IN p
intravenous JJ p
midazolam NNS i
sedation NN p
. . p

Ten CD N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
4.4 CD i
mL NN i
of IN i
2 CD i
% NN i
lidocaine NN i
with IN i
1:80,000 CD i
epinephrine NN i
as IN i
a DT i
local JJ i
anesthetic NN i
and CC i
10 CD i
were VBD i
given VBN i
4.4 CD i
mL NN i
of IN i
3 CD i
% NN i
prilocaine NN i
with IN i
0.03 CD i
IU/mL NNP i
felypressin NN i
. . i

There EX N
were VBD N
significant JJ N
changes NNS N
from IN N
baseline NN N
potassium NN o
and CC o
glucose JJ o
concentrations NNS o
both DT N
within IN N
and CC N
between IN N
treatments NNS N
in IN N
the DT N
early JJ N
postinjection NN N
period NN N
. . N

The DT N
epinephrine-containing JJ N
local JJ N
anesthetic NN N
significantly RB N
reduced VBD N
the DT N
plasma NN o
potassium NN o
concentration NN o
10 CD o
min NN o
after IN o
injection NN o
, , N
by IN N
0.16 CD N
+/- JJ N
0.20 CD N
mmol/L NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
and CC N
increased VBD N
the DT N
blood NN o
glucose JJ o
concentration NN o
at IN N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
min NN N
( ( N
by IN N
0.46 CD N
+/- JJ N
0.37 CD N
, , N
0.63 CD N
+/- JJ N
0.45 CD N
, , N
and CC N
0.56 CD N
+/- JJ N
0.28 CD N
mmol/L NN N
, , N
respectively RB N
) ) N
. . N

Conversely RB N
, , N
plasma JJ o
potassium NN o
increased VBD N
and CC N
blood NN o
glucose NN o
decreased VBD N
10 CD N
, , N
20 CD N
, , N
and CC N
30 CD N
min NN N
following VBG N
the DT N
administration NN N
of IN N
the DT N
epinephrine-free JJ i
solution NN i
. . i

At IN N
30 CD o
min NN o
potassium NN o
was VBD N
increased VBN N
by IN N
0.24 CD N
+/- JJ N
0.16 CD N
mmol/L NN N
, , N
and CC N
glucose NN o
was VBD N
decreased VBN N
by IN N
0.23 CD N
+/- JJ N
0.16 CD N
mmol/L NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
epinephrine-free JJ i
and CC N
epinephrine-containing JJ i
local JJ i
anesthetics NNS i
differ VBP N
in IN N
their PRP$ N
metabolic JJ N
effects NNS N
during IN N
oral JJ N
surgery NN N
with IN N
midazolam JJ i
sedation NN i
. . i

-DOCSTART- -X- O O

Chocolate NNP i
frogs NNS i
do VBP N
not RB N
increase VB N
completion NN N
of IN N
parent NN N
survey NN N
: : N
randomised VBN N
study NN N
. . N

Four CD N
months NNS N
into IN N
a DT N
year-long JJ N
, , N
national JJ N
survey NN N
assessing VBG N
parents NNS N
' POS N
experiences NNS N
of IN N
a DT N
child NN N
's POS N
diagnosis NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
, , N
our PRP$ N
response NN N
fraction NN N
was VBD N
only RB N
23 CD N
% NN N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
whether IN N
including VBG N
a DT N
chocolate NN i
incentive NN i
in IN N
the DT N
postal JJ N
survey NN N
would MD N
increase VB o
the DT o
response NN o
fraction NN o
. . o

Families NNS p
enrolled VBD p
between IN p
15 CD p
March NNP p
and CC p
25 CD p
May NNP p
2012 CD p
were VBD N
randomised VBN N
to TO N
receive VB N
a DT N
chocolate NN i
frog NN i
versus IN i
no DT i
chocolate NN i
frog NN i
. . i

Both DT p
groups NNS p
received VBD N
a DT N
written VBN i
reminder NN i
and CC N
replacement NN N
survey NN N
2 CD N
weeks NNS N
after IN N
the DT N
survey NN N
was VBD N
posted VBN N
and CC N
up RB N
to TO N
two CD N
telephone NN N
reminders NNS N
thereafter RB N
. . N

We PRP N
analysed VBD N
the DT N
effect NN o
of IN N
the DT N
incentive NN N
using VBG N
? . o
( ( o
2 CD o
) ) o
tests NNS o
for IN N
the DT N
categorical JJ N
response NN N
variable JJ N
and CC o
t-tests NNS o
for IN N
the DT N
continuous JJ N
reminder NN N
and CC N
length NN N
of IN N
response NN N
variables NNS N
at IN N
the DT N
end NN N
of IN N
( ( N
i NN N
) ) N
randomisation NN N
and CC N
( ( N
ii NN N
) ) N
the DT N
study NN N
( ( N
1 CD N
November NNP N
2012 CD p
) ) p
. . p

A DT p
total NN p
of IN p
137 CD p
families NNS p
were VBD p
randomised VBN N
in IN N
the DT N
6-week JJ N
period NN p
. . p

Parents NNS p
who WP p
received VBD p
an DT p
incentive NN p
were VBD p
more RBR p
likely JJ p
to TO p
return VB p
a DT p
completed VBN p
survey NN p
in IN p
the DT p
6 CD p
weeks NNS p
than IN p
those DT p
who WP p
did VBD p
not RB p
( ( p
21 CD p
% NN p
vs. FW p
6 CD p
% NN p
, , N
P NNP p
= NNP p
0.009 CD o
) ) o
. . o

This DT o
effect NN o
faded VBN N
by IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
53 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
P NNP N
= NNP N
0.4 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
groups NNS N
at IN N
either DT N
follow-up NN N
in IN N
the DT N
number NN N
of IN N
reminders NNS N
that WDT N
parents NNS N
received VBD N
or CC N
the DT o
number NN o
of IN o
days NNS o
it PRP o
took VBD N
parents NNS N
to TO N
return VB N
the DT N
survey NN N
. . N

Including VBG N
a DT N
chocolate-based JJ i
incentive NN i
does VBZ N
not RB N
significantly RB o
increase VB o
response NN o
rate NN o
in IN o
a DT o
postal JJ N
survey NN N
over IN N
and CC N
above JJ N
standard NN N
reminder NN N
techniques NNS N
like IN N
posting VBG N
follow-up JJ N
survey NN N
packs NNS N
or CC N
phoning VBG N
families NNS N
. . N

-DOCSTART- -X- O O

Active JJ o
warming NN o
, , o
not RB o
passive JJ o
heat NN o
retention NN o
, , N
maintains VBZ N
normothermia JJ o
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
for IN N
hip NN p
and CC p
knee NN p
arthroplasty NN p
. . p

STUDY NNP N
OBJECTIVE NNP N
to TO N
compare VB N
passive JJ N
heat NN N
retention NN N
by IN N
low-flow JJ N
anesthesia NN N
, , N
alone RB N
and CC N
with IN N
additional JJ N
thermal JJ N
insulation NN N
by IN N
reflective JJ N
blankets NNS N
, , N
with IN N
forced-air JJ N
warming VBG N
preventing VBG N
intraoperative JJ N
hypothermia NN N
during IN N
combined JJ N
epidural-general JJ N
anesthesia NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
study NN N
. . N

SETTING NNP N
Inpatient NNP p
anesthesia NN p
at IN p
a DT p
university NN p
department NN p
of IN p
orthopedic JJ p
surgery NN p
. . p

PATIENTS CC p
30 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
and CC p
II NNP p
patients NNS p
, , p
who WP p
were VBD p
scheduled VBN p
for IN p
elective JJ p
hip NN p
or CC p
knee VB p
arthroplasty JJ p
and CC p
were VBD p
free JJ p
from IN p
systemic JJ p
disease NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
received VBD N
epidural JJ N
block NN N
up RB N
to TO N
T10 NNP N
by IN N
alkalinized JJ i
lidocaine JJ i
2 CD i
% NN i
, , N
and CC N
then RB N
were VBD N
administered VBN N
standard JJ i
general JJ i
anesthesia NN i
by IN i
means NNS i
of IN i
low-flow JJ i
rebreathing NN i
system NN i
( ( N
fresh JJ N
gas NN N
flow NN N
= VBD N
1 CD N
L/min NNP N
) ) N
. . N

All DT N
procedures NNS N
started VBD N
between IN N
8 CD N
and CC N
10 CD N
AM NNP N
, , N
and CC N
operating NN N
room NN N
( ( N
OR NNP N
) ) N
temperature NN N
was VBD N
maintained VBN N
between IN N
21 CD N
degrees NNS N
and CC N
23 CD N
degrees NNS N
C NNP N
, , N
with IN N
relative JJ N
humidity NN N
ranging VBG N
between IN N
40 CD N
% NN N
and CC N
45 CD N
% NN N
. . N

For IN N
heat NN N
retention NN N
or CC N
warming VBG N
therapy NN N
, , N
patients NNS N
received VBD N
either RB N
low-flow JJ i
anesthesia NN i
only RB i
( ( N
control NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
low-flow JJ i
anesthesia NN i
with IN i
additional JJ i
reflective JJ i
blankets NNS i
( ( N
blanket NN N
, , N
n JJ N
= NNP N
10 CD N
) ) N
, , N
or CC N
low-flow JJ i
anesthesia NN i
with IN i
active JJ i
forced-air JJ i
warming NN i
( ( N
forced-air JJ N
, , N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Tympanic JJ o
temperature NN o
was VBD N
measured VBN N
at IN N
OR NNP N
arrival NN N
( ( N
baseline NN N
) ) N
; : N
immediately RB N
following VBG N
general JJ N
anesthesia JJ N
induction NN N
; : N
30 CD N
, , N
60 CD N
, , N
90 CD N
, , N
and CC N
120 CD N
minutes NNS N
from IN N
general JJ N
anesthesia NN N
induction NN N
; : N
and CC N
at IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Duration NNP o
of IN o
anesthesia NN o
, , o
invasiveness NN o
of IN o
surgery NN o
, , o
and CC o
baseline NN o
core NN o
temperature NN o
were VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
. . N

Core NNP o
temperature NN o
decreased VBN N
in IN N
all PDT N
the DT N
three CD N
groups NNS N
30 CD N
minutes NNS N
after IN N
general JJ N
anesthesia NN N
induction NN N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
; : N
afterwards NNS N
, , N
it PRP N
progressively RB N
decreased VBD N
in IN N
the DT N
control NN N
and CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
, , N
with IN N
a DT N
reduction NN o
from IN o
baseline NN o
values NNS o
measured VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
of IN N
2.0 CD N
degrees NNS N
C NNP N
and CC N
1.6 CD N
degrees NNS N
C NNP N
, , N
respectively RB N
. . N

In IN N
the DT N
forced-air JJ N
group NN N
, , N
after IN N
the DT N
initial JJ N
significant JJ N
decrease NN N
( ( N
p JJ N
= $ N
0.01 CD N
vs. FW N
baseline NN N
) ) N
, , N
core JJ o
temperature NN o
progressively RB N
increased VBD N
to TO N
35.8 CD N
+/- JJ N
0.6 CD N
degrees NNS N
C NNP N
, , N
which WDT N
was VBD N
similar JJ N
to TO N
preoperative VB N
values NNS N
and CC N
significantly RB N
higher JJR N
than IN N
either CC N
the DT N
control NN N
or CC N
blankets NNS N
groups NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

CONCLUSIONS NNP N
During IN N
combined VBN N
epidural-general JJ N
anesthesia NN N
for IN N
elective JJ p
hip NN p
and CC p
knee NN p
arthroplasty NN p
, , N
passive JJ N
heat NN N
retention NN N
by IN N
means NNS N
of IN N
low-flow JJ i
anesthesia NN i
alone RB i
and CC i
in IN i
combination NN i
with IN i
reflective JJ i
blankets NNS i
is VBZ N
ineffective JJ N
in IN N
maintaining VBG o
intraoperative JJ o
normothermia NN o
and CC N
definitely RB N
inferior JJ N
to TO N
active JJ N
forced-air JJ N
warning NN N
. . N

-DOCSTART- -X- O O

[ JJ o
Acute NNP o
cardiovascular NN o
and CC o
metabolic JJ o
changes NNS o
in IN N
interval NN N
and CC N
endurance NN i
training NN i
in IN N
selected VBN p
patients NNS p
following VBG p
aortocoronary JJ p
bypass NN p
operation NN p
] NNP p
. . N

UNLABELLED VB N
This DT N
study NN N
compared VBN N
the DT N
acute NN o
changes NNS o
of IN o
cardiovascular NN o
and CC o
metabolic JJ o
reactions NNS o
during IN N
interval NN i
and CC i
continuous JJ i
training NN i
after IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

Two CD p
groups NNS p
of IN p
9 CD p
male JJ p
patients NNS p
( ( p
age NN p
: : p
59 CD p
+/- JJ p
4 CD p
and CC p
56 CD p
+/- JJ p
6 CD p
years NNS p
, , p
resp NN p
. . p

) ) p
each DT i
trained VBN i
on IN i
bicycle NN i
ergometer JJ i
start NN i
on IN i
post-operative JJ i
days NNS i
24 CD i
and CC i
26 CD i
, , i
resp NN i
. . i

In IN N
both DT N
training NN N
groups NNS N
training VBG o
heart NN o
rate NN o
was VBD N
set VBN N
at IN N
86 CD N
% NN N
of IN N
individual JJ N
maximum JJ N
heart NN N
rate NN N
. . N

In IN i
the DT i
last JJ i
week NN i
of IN i
training VBG i
the DT i
exercise NN i
intensity NN i
in IN i
the DT i
group NN i
of IN i
patients NNS i
who WP i
were VBD i
trained VBN i
by IN i
the DT i
continuous JJ i
method NN i
was VBD i
at IN i
83 CD i
watts NN i
, , i
and CC i
at IN i
20:121 CD i
watts NN i
in IN i
the DT i
group NN i
of IN i
patients NNS i
who WP i
were VBD i
trained VBN i
by IN i
interval JJ i
method NN i
( ( i
rest NN i
: : i
work NN i
each DT i
1:1 CD i
min NN i
) ) i
. . i

At IN N
this DT N
exercise NN N
training NN N
that WDT N
lasted VBD N
for IN N
20 CD N
min PDT N
the DT N
acute JJ o
response NN o
of IN o
heart NN o
rate NN o
, , o
blood NN o
pressure NN o
, , o
rate-pressure JJ o
product NN o
, , o
glucose JJ o
, , o
lactate JJ o
and CC o
catecholamines NNS o
was VBD N
measured VBN N
. . N

RESULTS NNP N
In IN N
both DT N
methods NNS N
there EX N
were VBD N
no DT o
significant JJ o
differences NNS o
in IN o
systolic JJ o
and CC o
diastolic JJ o
pressure NN o
, , o
rate-pressure JJ o
product NN o
, , o
in IN o
glucose NN o
or CC o
catecholamine NN o
levels NNS o
. . o

However RB N
, , N
there EX N
was VBD N
a DT N
significantly RB N
higher JJR N
rate NN o
of IN o
lactate NN o
in IN N
the DT N
second JJ N
10 CD N
min NN N
of IN N
the DT N
interval JJ N
training NN N
. . N

And CC N
, , N
in IN N
spite NN N
of IN N
higher JJR N
peripheral JJ N
exercise NN N
intensity NN N
by IN N
interval JJ N
training NN N
, , N
there EX N
was VBD N
no DT N
higher JJR N
cardiac NN o
work NN o
than IN N
by IN N
the DT N
continuous JJ N
training NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
interval JJ N
training NN N
strains VBZ N
the DT N
oxidative JJ N
capacity NN N
of IN N
the DT N
trained JJ N
muscles NNS N
in IN N
a DT N
more RBR N
intensive JJ N
and CC N
direct JJ N
way NN N
than IN N
does VBZ N
continuous JJ N
training NN N
. . N

-DOCSTART- -X- O O

Children NNP N
's POS N
Yale-Brown JJ N
Obsessive NNP N
Compulsive NNP N
Scale NNP N
modified VBD N
for IN N
pervasive JJ N
developmental NN N
disorders NNS N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
psychometric JJ N
properties NNS N
of IN N
the DT N
Children NNP i
's POS i
Yale-Brown JJ i
Obsessive NNP i
Compulsive NNP i
Scales NNP i
( ( i
CYBOCS NNP i
) ) i
modified VBD i
for IN i
pervasive JJ i
developmental NN i
disorders NNS i
( ( i
PDDs NNP i
) ) i
. . i

METHOD NNP N
Raters NNPS N
from IN N
five CD N
Research NNP N
Units NNS N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
) ) N
Autism NNP N
Network NNP N
were VBD N
trained VBN N
to TO N
reliability NN N
. . N

The DT N
modified JJ N
scale NN N
( ( i
CYBOCS-PDD NNP i
) ) i
, , N
which WDT N
contains VBZ N
only RB N
the DT N
five CD i
Compulsion NNP i
severity NN i
items NNS i
( ( N
range VB N
0-20 NN N
) ) N
, , N
was VBD N
administered VBN p
to TO p
172 CD p
medication-free JJ p
children NNS p
( ( p
mean JJ p
8.2 CD p
+/- JJ p
2.6 CD p
years NNS p
) ) p
with IN p
PDD NNP p
( ( p
autistic JJ p
disorder NN p
, , p
n JJ p
= VBP p
152 CD p
; : p
Asperger NNP p
's POS p
disorder NN p
, , p
n JJ p
= VBP p
6 CD p
; : p
PDD NNP p
not RB p
otherwise RB p
specified VBN p
, , p
n JJ p
= NNP p
14 CD p
) ) p
participating NN p
in IN p
RUPP NNP p
clinical JJ p
trials NNS p
. . p

Reliability NNP o
was VBD N
assessed VBN N
by IN N
intraclass NN N
correlation NN N
coefficient NN N
( ( N
ICC NNP N
) ) N
and CC N
internal JJ N
consistency NN N
by IN N
Cronbach NNP N
's POS N
alpha JJ N
coefficient NN N
. . N

Correlations NNS N
with IN N
ratings NNS N
of IN N
repetitive JJ N
behavior NN N
and CC N
disruptive JJ N
behavior NN N
were VBD N
examined VBN N
for IN N
validity NN N
. . N

RESULTS NNP N
Eleven NNP N
raters NNS N
showed VBD N
excellent JJ N
reliability NN o
( ( N
ICC NNP N
= NNP N
0.97 CD N
) ) N
. . N

The DT N
mean JJ o
CYBOCS NNP o
score NN o
was VBD N
14.4 CD N
( ( N
+/- JJ N
3.86 CD N
) ) N
with IN N
excellent JJ N
internal JJ o
consistency NN o
( ( N
alpha JJ N
= NNP N
.85 NNP N
) ) N
. . N

Correlations NNS N
with IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
ranged VBD N
from IN N
r NN N
= $ N
0.11 CD N
to TO N
r VB N
= JJ N
0.28 CD N
and CC N
were VBD N
similar JJ N
to TO N
correlations NNS N
with IN N
measures NNS o
of IN o
irritability NN o
( ( N
r JJ N
= NNP N
0.24 CD N
) ) N
and CC N
hyperactivity NN o
( ( N
r JJ N
= NNP N
0.25 CD N
) ) N
. . N

Children NNP p
with IN p
higher JJR p
scores NNS p
on IN N
the DT N
CYBOCS-PDD NNP N
had VBD N
higher JJR N
levels NNS N
of IN N
maladaptive JJ o
behaviors NNS o
and CC o
lower JJR o
adaptive JJ o
functioning NN o
. . o

CONCLUSIONS VB N
The DT N
five-item JJ N
CYBOCS-PDD NNP N
is VBZ N
reliable JJ N
, , N
distinct JJ N
from IN N
other JJ N
measures NNS N
of IN N
repetitive JJ N
behavior NN N
, , N
and CC N
sensitive JJ N
to TO N
change VB N
. . N

-DOCSTART- -X- O O

Response NN N
of IN N
pre-core NN p
mutant NN p
chronic JJ p
hepatitis NN p
B NNP p
infection NN p
to TO N
lamivudine VB i
. . i

The DT N
proportion NN N
of IN N
chronic JJ N
liver NN N
disease NN N
associated VBN N
with IN N
the DT N
pre-core JJ p
mutant NN p
of IN p
hepatitis NN p
B NNP p
virus NN p
( ( p
HBV NNP p
) ) p
infection NN p
is VBZ N
increasing VBG N
, , N
particularly RB N
in IN N
Mediterranean NNP p
Europe NNP p
and CC p
in IN p
Asia NNP p
. . p

The DT N
pre-core JJ p
mutant NN p
HBV NNP p
is VBZ N
unable JJ N
to TO N
produce VB N
hepatitis NN N
B NNP N
e NN N
antigen NN N
( ( N
HBeAg NNP N
) ) N
, , N
so RB N
that IN N
patients NNS p
with IN p
this DT p
variant NN p
do VBP N
not RB N
present VB N
with IN N
HBV NNP N
characterised VBN N
by IN N
HBeAg NNP o
in IN o
the DT o
serum NN o
. . o

Pre-core NN N
mutant JJ N
chronic JJ N
hepatitis NN N
B NNP N
infection NN N
usually RB N
proceeds VBZ N
to TO N
serious JJ N
liver JJ N
disease NN N
. . N

Wild-type JJ N
HBV NNP N
infection NN N
may MD N
be VB N
mild JJ N
and CC N
respond NN N
relatively RB N
well RB N
to TO N
interferon VB N
( ( N
IFN NNP N
) ) N
alpha NN N
therapy NN N
, , N
but CC N
IFN NNP N
alpha NN N
is VBZ N
not RB N
an DT N
effective JJ N
therapeutic JJ N
option NN N
in IN N
pre-core NN N
mutant NN N
hepatitis NN N
B NNP N
infection NN N
and CC N
new JJ N
therapeutic JJ N
options NNS N
are VBP N
needed VBN N
. . N

Clinical JJ N
data NNS N
show VBP N
that IN N
lamivudine NN i
is VBZ N
an DT N
effective JJ o
treatment NN N
for IN N
patients NNS p
with IN p
pre-core JJ p
mutant NN p
hepatitis NN p
B NNP p
. . p

There EX N
is VBZ N
profound JJ N
suppression NN N
of IN N
HBV NNP o
replication NN o
and CC N
improvement NN N
in IN N
indicators NNS o
of IN o
liver JJ o
disease NN o
in IN N
most JJS N
patients NNS N
. . N

In IN N
conclusion NN N
, , N
lamivudine NN i
is VBZ N
suitable JJ N
for IN N
treatment NN N
of IN N
a DT N
wide JJ N
range NN N
of IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
B NNP p
, , p
including VBG p
those DT p
with IN p
pre-core JJ p
mutant JJ p
HBV NNP p
infection NN p
. . p

-DOCSTART- -X- O O

Evolution NN N
of IN N
coronary JJ N
stenoses NNS N
is VBZ N
related VBN N
to TO N
baseline VB N
severity NN N
-- : N
a DT N
prospective JJ N
quantitative JJ N
angiographic JJ N
analysis NN N
in IN N
patients NNS p
with IN p
moderate JJ p
coronary JJ p
disease NN p
. . p

INTACT JJ N
Investigators NNPS N
. . N

International NNP N
Nifedipine NNP N
Trial NNP N
on IN N
Antiatherosclerotic NNP N
Therapy NNP N
. . N

A DT N
correlation NN N
of IN N
the DT N
angiographic JJ N
evolution NN N
of IN N
coronary JJ N
stenoses NNS N
( ( N
stenosis NN N
diameter NN N
> NN N
or CC N
= VB N
20 CD N
% NN N
) ) N
with IN N
morphological JJ N
stenosis NN N
parameters NNS N
at IN N
baseline NN N
could MD N
help VB N
to TO N
identify VB o
the DT o
risk NN o
of IN o
progressive JJ o
stenoses NNS o
. . o

Therefore RB N
, , N
the DT N
data NN N
of IN N
the DT N
prospective JJ N
INTACT NNP N
study NN N
( ( N
International NNP N
Nifedipine NNP N
Trial NNP N
on IN N
Antiatherosclerotic NNP N
Therapy NNP N
) ) N
were VBD N
reviewed VBN N
. . N

In IN N
348 CD p
patients NNS p
with IN p
moderate JJ p
coronary JJ p
artery NN p
disease NN p
, , p
standardized VBD i
coronary JJ i
angiograms NNS i
were VBD p
taken VBN p
3 CD p
years NNS p
apart RB p
and CC N
were VBD N
quantitatively RB N
analysed VBN N
. . N

Changes NNS N
in IN N
the DT N
minimal JJ o
diameter NN o
of IN N
the DT N
1063 CD N
preexisting VBG N
coronary JJ N
stenoses NNS N
compared VBN N
between IN N
both DT N
angiograms NNS N
were VBD N
set VBN N
in IN N
relation NN N
to TO N
a DT N
number NN o
of IN o
conventional JJ o
stenosis NN o
parameters NNS o
at IN N
baseline NN N
. . N

Regression NNP N
analysis NN N
demonstrated VBD N
a DT N
significant JJ N
correlation NN o
of IN N
the DT N
changes NNS o
in IN o
minimal JJ o
diameter NN o
with IN N
baseline NN o
% NN o
diameter NN o
stenosis NN o
( ( N
r JJ N
= VBZ N
0.30 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
minimal JJ o
diameter NN o
( ( N
r JJ N
= NNP N
-0.28 NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
reference NN o
diameter NN o
of IN o
stenoses NNS o
( ( N
r NN N
= NNP N
-0.14 NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
changes NNS o
were VBD o
not RB o
correlated VBN o
with IN N
stenosis NN o
length NN o
and CC o
plaque JJ o
area NN o
. . o

The DT N
baseline NN N
parameters NNS N
of IN N
22 CD N
preexisting VBG N
stenoses NNS N
progressing VBG o
to TO o
occlusions NNS o
differed VBN N
from IN N
those DT N
remaining VBG o
patent NN o
only RB N
with IN N
regard NN N
to TO N
the DT N
% NN o
diameter NN o
stenosis NN o
( ( N
43 CD N
+/- JJ N
9 CD N
% NN N
vs JJ N
39 CD N
+/- JJ N
11 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Additional JJ N
progression NN o
of IN o
coronary JJ o
disease NN o
became VBD N
manifest JJS N
through IN N
development NN N
of IN N
228 CD N
stenoses NNS o
and CC N
19 CD N
occlusions NNS o
at IN N
arterial JJ N
sites NNS N
free VBP N
from IN N
definitive JJ N
stenoses NNS N
in IN N
the DT N
baseline NN N
angiograms NN N
. . N

Thus RB N
, , N
progression NN o
of IN o
atherosclerosis NN o
predominantly RB o
occurred VBD o
in IN N
mild NN N
preexisting VBG N
coronary JJ N
stenoses NNS N
and CC N
developed VBN N
at IN N
previously RB N
angiographically RB N
normal JJ N
sites NNS N
. . N

Since IN N
the DT N
conventional JJ N
angiographic JJ N
parameters NNS N
analysed VBN N
in IN N
this DT N
study NN N
failed VBD N
to TO N
identify VB N
individual JJ N
arterial JJ N
sites NNS N
with IN N
an DT N
increased VBN N
risk NN N
for IN N
progression NN N
, , N
definition NN N
of IN N
new JJ N
angiographic JJ N
parameters NNS N
or CC N
application NN N
of IN N
new JJ N
techniques NNS N
seem VBP N
mandatory JJ N
to TO N
this DT N
end NN N
. . N

-DOCSTART- -X- O O

Uvulopalatopharyngoplasty NNP i
versus NN N
laser NN i
assisted VBD i
uvulopalatoplasty JJ i
for IN N
the DT N
treatment NN N
of IN N
snoring NN p
: : p
an DT N
objective NN N
randomised VBD N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
objectively RB N
the DT N
clinical JJ N
effectiveness NN N
of IN N
surgery NN N
for IN N
snoring VBG N
and CC N
to TO N
compare VB N
the DT N
results NNS N
of IN N
conventional JJ i
uvulopalatopharyngoplasty JJ i
( ( i
UPPP NNP i
) ) i
and CC N
laser $ i
assisted VBN i
uvulopalatoplasty JJ i
( ( i
LAUP NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
snoring VBG N
. . N

Patients NNS p
who WP p
had VBD p
been VBN p
referred VBN p
for IN p
investigation NN p
and CC p
treatment NN p
of IN p
their PRP$ p
snoring NN p
were VBD p
randomly RB p
allocated VBN p
to TO p
receive VB p
either DT p
UPPP NNP i
or CC i
LAUP NNP i
. . i

Forty-seven JJ p
patients NNS p
with IN p
confirmed JJ p
palatal JJ p
flutter NN p
had VBD p
surgery NN p
and CC p
all DT p
of IN p
them PRP p
had VBD p
a DT p
preoperative JJ p
and CC p
postoperative JJ p
objective JJ p
assessment NN p
of IN p
their PRP$ p
snoring NN o
loudness NN o
and CC o
duration NN o
in IN o
the DT o
home NN o
. . o

The DT N
recording NN N
device NN N
( ( N
Snore NNP N
Box NNP N
) ) N
is VBZ N
simple JJ N
for IN N
the DT N
patient NN N
to TO N
operate VB N
, , N
portable JJ N
with IN N
a DT N
built VBN N
in IN N
microphone NN N
, , N
and CC N
able JJ N
to TO N
produce VB N
objective JJ N
results NNS N
, , N
which WDT N
can MD N
be VB N
automatically RB N
analysed VBN N
. . N

Of IN N
the DT N
38 CD N
patients NNS N
, , N
who WP N
had VBD N
technically RB N
valid JJ N
recordings NNS N
, , N
22 CD N
underwent JJ N
LAUP NNP i
and CC N
16 CD N
UPPP NNP i
. . i

Overall VB N
the DT N
mean NN o
postoperative NN o
Snore NNP o
Index NNP o
( ( o
SI NNP o
) ) o
was VBD N
less JJR N
than IN N
the DT N
preoperative JJ N
SI NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
the DT N
average JJ N
difference NN N
being VBG N
78.2 CD N
snores/h NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
LAUP NNP i
and CC N
UPPP NNP i
regarding VBG N
the DT N
fall NN o
in IN o
the DT o
SI NNP o
. . o

This DT N
study NN N
is VBZ N
the DT N
first JJ N
objective JJ N
comparative NN N
study NN N
to TO N
demonstrate VB N
the DT N
effectiveness NN o
of IN o
snoring VBG o
surgery NN o
. . o

-DOCSTART- -X- O O

Efficacy NN N
of IN N
a DT N
family NN i
practice-based JJ i
lifestyle JJ i
intervention NN i
program NN i
to TO N
increase VB N
physical JJ o
activity NN o
and CC N
reduce VB N
clinical JJ N
and CC N
physiological JJ N
markers NNS N
of IN N
vascular JJ N
health NN N
in IN N
patients NNS p
with IN p
high JJ p
normal JJ p
blood NN p
pressure NN p
and/or RB p
high JJ p
normal JJ p
blood NN p
glucose NN p
( ( p
SNAC NNP p
) ) p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Previous JJ N
interventions NNS N
to TO N
increase VB N
physical JJ o
activity NN o
and CC N
reduce VB N
cardiovascular JJ N
risk NN N
factors NNS N
have VBP N
been VBN N
targeted VBN N
at IN N
individuals NNS N
with IN N
established VBN N
disease NN N
; : N
less CC N
attention NN N
has VBZ N
been VBN N
given VBN N
to TO N
intervention VB N
among IN N
individuals NNS p
with IN p
high JJ p
risk NN p
for IN p
disease NN p
nor CC N
has VBZ N
there RB N
been VBN N
determination NN N
of IN N
the DT N
influence NN N
of IN N
setting VBG N
in IN N
which WDT N
the DT N
intervention NN N
is VBZ N
provided VBN N
. . N

In IN N
particular JJ N
, , N
family NN N
practice NN N
represents VBZ N
an DT N
ideal JJ N
setting NN N
for IN N
the DT N
provision NN N
and CC N
long-term JJ N
maintenance NN N
of IN N
lifestyle JJ N
interventions NNS N
for IN N
patients NNS p
at IN p
risk NN p
( ( p
ie JJ p
high-normal JJ p
blood NN p
pressure NN p
or CC p
impaired JJ p
glucose JJ p
tolerance NN p
) ) p
. . p

METHODS/DESIGN PDT N
The DT N
Staged NNP p
Nutrition NNP p
and CC p
Activity NNP p
Counseling NNP p
( ( p
SNAC NNP p
) ) p
study NN p
is VBZ N
a DT N
randomized JJ N
clustered JJ N
design NN N
clinical JJ N
trial NN N
that WDT N
will MD N
investigate VB N
the DT N
effectiveness NN N
and CC N
efficacy NN N
of IN N
a DT N
multi-component JJ i
lifestyle JJ i
intervention NN i
on IN N
cardiovascular JJ p
disease NN p
risk NN p
factors NNS p
and CC p
vascular JJ p
function NN p
in IN p
patients NNS p
at IN p
risk NN p
in IN p
primary JJ p
care NN p
. . p

Patients NNS N
will MD N
be VB N
randomized VBN N
by IN N
practice NN N
to TO N
either VB N
a DT N
standard NN i
of IN i
care NN i
lifestyle JJ i
intervention NN i
or CC N
a DT N
behaviourally-based JJ i
, , i
matched VBD i
prescriptive JJ i
physical JJ i
activity NN i
and CC i
diet JJ i
change NN i
program NN i
. . i

The DT N
primary JJ N
goal NN N
is VBZ N
to TO N
increase VB N
physical JJ o
activity NN o
and CC N
improve VB N
dietary JJ o
intake NN o
according VBG N
to TO N
Canada NNP o
's POS o
Guides NNP o
to TO o
Physical NNP o
Activity NNP o
Healthy NNP o
Eating NNP o
over IN N
24 CD N
months NNS N
. . N

The DT N
primary JJ N
intention NN N
to TO N
treat VB N
analysis NN N
will MD N
compare VB N
behavioral JJ N
, , N
physiological JJ N
and CC N
metabolic JJ N
outcomes NNS N
at IN N
6 CD N
, , N
12 CD N
and CC N
24 CD N
months NNS N
post-randomization JJ N
including VBG N
estimation NN N
of IN N
incident JJ N
hypertension NN o
and/or NN N
diabetes VBZ o
. . o

DISCUSSION VB N
The DT N
design NN N
features NNS N
of IN N
our PRP$ N
trial NN N
, , N
and CC N
the DT N
practical JJ N
problems NNS N
( ( N
and CC N
solutions NNS N
) ) N
associated VBN N
with IN N
implementing VBG N
these DT N
design NN N
features NNS N
, , N
particularly RB N
those DT N
that IN N
result NN N
in IN N
potential JJ N
delay NN N
between IN N
recruitment NN N
, , N
baseline NN N
data NNS N
collection NN N
, , N
randomization NN N
, , N
intervention NN N
, , N
and CC N
assessment NN N
will MD N
be VB N
discussed VBN N
. . N

Results NNS N
of IN N
the DT N
SNAC NNP N
trial NN N
will MD N
provide VB N
scientific JJ N
rationale NN N
for IN N
the DT N
implementation NN N
of IN N
this DT N
lifestyle JJ N
intervention NN N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN NNP N
: : N
ISRCTN:42921300 NNP N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
to TO N
improve VB N
venipuncture NN o
compliance NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

OBJECTIVE NNP N
Medical NNP N
procedures NNS N
, , N
particularly RB N
venipuncture NN N
( ( N
the DT N
puncture NN N
of IN N
a DT N
vein NN N
especially RB N
for IN N
the DT N
withdrawal NN N
of IN N
blood NN N
) ) N
, , N
can MD N
cause VB N
serious JJ o
distress NN o
and CC N
behavior JJ o
disturbance NN o
for IN N
many JJ N
children NNS N
. . N

Noncompliance NN N
to TO N
blood VB N
draws NNS N
can MD N
have VB N
significant JJ N
ramifications NNS N
in IN N
both DT N
research NN N
and CC N
clinical JJ N
settings NNS N
. . N

The DT N
negative JJ o
reactions NNS o
may MD N
be VB N
exacerbated VBN N
in IN N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Even RB N
so RB N
, , N
there EX N
has VBZ N
been VBN N
little JJ N
research NN N
into IN N
the DT N
prevalence NN N
of IN N
the DT N
problem NN N
or CC N
effective JJ N
intervention NN N
procedures NNS N
. . N

In IN N
response NN N
to TO N
these DT N
concerns NNS N
, , N
we PRP N
developed VBD N
and CC N
evaluated VBD N
the DT N
Blood NNP i
Draw NNP i
Intervention NNP i
Program NNP i
. . i

The DT N
program NN N
was VBD N
designed VBN N
to TO N
be VB N
easy JJ N
to TO N
use VB N
, , N
require VB N
little JJ N
provider NN N
or CC N
family NN N
time NN N
, , N
effectively RB N
reduce VB N
negative JJ o
behaviors NNS o
, , N
and CC N
increase VB o
blood NN o
draw JJ o
compliance NN o
. . o

METHOD NNP N
In IN N
a DT N
quasi-randomized JJ N
trial NN N
over IN N
the DT N
course NN N
of IN N
? . N
18 CD N
months NNS p
, , p
58 CD p
of IN p
210 CD p
families NNS p
with IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
participating VBG p
in IN p
a DT p
larger JJR p
study NN p
of IN p
phenotypic NN p
and CC p
genotypic NN p
factors NNS p
reported VBD p
significant JJ p
concerns NNS p
about IN p
blood NN p
draws NNS p
and CC p
elected VBN p
to TO p
use VB p
the DT p
Blood NNP p
Draw NNP p
Intervention NNP p
Program NNP p
. . p

RESULTS NNP N
Completion NNP N
of IN N
the DT N
program NN N
increased VBD o
blood NN o
draw NN o
compliance NN o
rates NNS o
from IN o
85.4 CD N
% NN N
to TO N
96.6 CD N
% NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
4.80 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
1.12 CD N
, , N
20.59 CD N
; : N
p NN N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSION NNP N
Results NNP N
indicate VBP N
the DT N
efficacy NN N
of IN N
the DT N
program NN N
in IN N
a DT N
research NN N
setting NN N
and CC N
suggest VB N
a DT N
potential JJ N
clinical JJ N
application NN N
. . N

The DT N
current JJ N
intervention NN N
, , N
unlike IN N
many JJ N
others NNS N
for IN N
the DT N
same JJ N
or CC N
similar JJ N
difficulties NNS N
proposed VBN N
in IN N
the DT N
past NN N
, , N
was VBD N
successful JJ N
without IN N
requiring VBG N
extensive JJ N
time NN N
, , N
training NN N
, , N
or CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
providers NNS N
and CC N
parents NNS N
or CC N
their PRP$ N
children NNS N
, , N
nor CC N
did VBD N
it PRP N
require VB N
large-scale JJ N
institutional JJ N
changes NNS N
. . N

-DOCSTART- -X- O O

Short-term JJ N
studies NNS N
on IN N
the DT N
use NN N
of IN N
glycerol NN i
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ p
ambulatory JJ p
peritoneal JJ p
dialysis NN p
( ( p
CAPD NNP p
) ) p
. . p

The DT N
use NN N
of IN N
glycerol NN i
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
two CD N
different JJ N
concentrations NNS N
( ( N
92 CD N
mmol/l NN N
and CC N
272 CD N
mmol/l NN N
) ) N
in IN N
peritoneal JJ N
dialysis NN N
fluid NN N
was VBD N
investigated VBN N
over IN N
3 CD N
days NNS N
in IN p
six CD p
patients NNS p
on IN p
continuous JJ p
ambulatory JJ p
peritoneal JJ p
dialysis NN p
and CC N
compared VBN N
with IN N
two CD N
concentrations NNS N
of IN N
glucose NN i
( ( N
76 CD N
mmol/l NN N
and CC N
215 CD N
mmol/l NN N
) ) N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
calorific JJ o
value NN o
of IN N
the DT N
absorbed JJ N
osmotic JJ N
agent NN N
was VBD N
lower JJR N
, , N
by IN N
19 CD N
% NN N
with IN N
isotonic JJ N
and CC N
22 CD N
% NN N
with IN N
hypertonic JJ N
solutions NNS N
, , N
when WRB N
glycerol NN i
was VBD N
used VBN N
in IN N
place NN N
of IN N
glucose NN i
. . i

However RB N
, , N
glycerol NN N
provided VBD N
significantly RB N
lower JJR N
total JJ o
ultrafiltration NN o
than IN N
glucose NN N
at IN N
each DT N
concentration NN N
, , N
despite IN N
a DT N
higher JJR N
initial JJ N
osmotic JJ N
pressure NN N
of IN N
the DT N
glycerol-based JJ N
solutions NNS N
. . N

Thus RB N
, , N
the DT N
higher JJR N
concentration NN N
of IN N
glycerol NN N
required VBN N
to TO N
provide VB N
equal JJ o
ultrafiltration NN o
may MD N
offset VB N
any DT N
calorific JJ N
advantage NN N
. . N

Equilibration NN o
of IN o
creatinine NN o
and CC o
urea NN o
was VBD N
slower JJR N
and CC N
creatinine JJ o
clearance NN o
lower RBR N
with IN N
glycerol NN i
. . i

Solutions NNS N
containing VBG N
glycerol NN i
were VBD N
initially RB N
less JJR N
acid JJ N
( ( N
pH JJ N
6.5 CD N
) ) N
than IN N
those DT N
containing VBG N
glucose NN N
( ( N
pH JJ N
5.1 CD N
) ) N
. . N

Blood NNP o
glycerol NN o
levels NNS o
, , N
which WDT N
were VBD N
in IN N
the DT N
physiological JJ N
range NN N
with IN N
glucose NN N
as IN N
the DT N
osmotic JJ N
agent NN N
, , N
reached VBD N
a DT N
peak JJ N
80-fold JJ N
greater JJR N
at IN N
4.3 CD N
+/- JJ N
0.8 CD N
mmol/l NN N
during IN N
dialysis NN N
with IN N
fluid NN N
containing VBG N
glycerol NN i
at IN N
272 CD N
mmol/l NN N
and CC N
eightfold VB N
higher JJR N
at IN N
0.42 CD N
+/- JJ N
0.09 CD N
mmol/l NN N
with IN N
glycerol NN i
at IN N
92 CD N
mmol/l NN N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
haemolysis NN o
or CC N
other JJ N
toxic JJ o
effect NN o
despite IN N
these DT N
levels NNS N
. . N

The DT N
rise NN N
in IN N
blood NN o
glucose NN o
and CC o
insulin NN o
noted VBD N
during IN N
the DT N
use NN N
of IN N
glucose-based JJ N
solutions NNS N
was VBD N
not RB N
found VBN N
with IN N
glycerol NN i
. . i

Circulating NNP o
levels NNS o
of IN o
lactate NN o
, , o
pyruvate NN o
, , o
alanine NN o
, , o
non-esterified JJ o
fatty JJ o
acids NNS o
and CC o
the DT o
ketone NN o
bodies NNS o
were VBD N
similar JJ N
with IN N
the DT N
two CD N
agents NNS N
. . N

Although IN N
these DT N
short-term JJ N
studies NNS N
have VBP N
shown VBN N
no DT N
conclusive JJ N
advantage NN N
of IN N
glycerol NN i
over IN N
glucose JJ i
, , N
long-term JJ N
effects NNS N
of IN N
glycerol NN i
, , N
particularly RB N
on IN N
circulating VBG o
lipid JJ o
levels NNS o
, , N
will MD N
determine VB N
its PRP$ N
future JJ N
role NN N
as IN N
an DT N
osmotic JJ N
agent NN N
in IN N
continuous JJ N
ambulatory JJ p
peritoneal JJ p
dialysis NN p
. . p

-DOCSTART- -X- O O

Twice-a-day JJ N
versus NN N
four-times-a-day JJ N
ofloxacin JJ N
treatment NN N
of IN N
external JJ N
ocular JJ N
infection NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS o
of IN N
0.3 CD N
% NN N
ofloxacin JJ N
eyedrops NNS N
, , N
when WRB N
given VBN N
twice-a-day JJ N
( ( N
BID NNP N
) ) N
versus IN N
four-times-a-day JJ N
( ( N
QID NNP N
) ) N
, , N
for IN N
the DT N
treatment NN N
of IN N
external JJ N
ocular JJ N
disease NN N
. . N

METHOD NNP N
Fifty NNP p
patients NNS p
with IN p
blepharitis NN p
, , p
conjuctivitis NN p
, , p
or CC p
blepharoconjunctivitis NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
with IN i
0.3 CD i
% NN i
ofloxacin JJ i
eyedrops NNS i
, , i
BID NNP i
or CC i
QID NNP i
, , i
for IN i
10 CD i
days NNS i
. . i

Signs NNP N
, , N
symptoms NNS N
, , N
and CC N
cultures NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
was VBD N
virtually RB N
identical JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
clinical JJ o
scores NNS o
in IN N
the DT N
BID NNP N
and CC N
QID NNP N
groups NNS N
by IN N
days NNS N
3 CD N
to TO N
5 CD N
( ( N
2.6-3.0 JJ N
points NNS N
) ) N
and CC N
a DT N
further JJ N
decrease NN N
by IN N
day NN N
11 CD N
( ( N
4.3-5.0 JJ N
points NNS N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
any DT N
time NN N
interval NN N
. . N

Microbiologic NNP N
studies NNS N
showed VBD N
a DT N
reduction NN N
in IN N
colony-forming JJ o
units NNS o
in IN N
87 CD N
% NN N
of IN N
the DT N
BID NNP N
group NN N
and CC N
in IN N
80 CD N
% NN N
of IN N
the DT N
QID NNP N
group NN N
. . N

CONCLUSION NNP N
The DT N
treatment NN N
of IN N
external JJ o
ocular JJ o
disease NN o
with IN N
0.3 CD N
% NN N
ofloxacin JJ o
eyedrops NN o
was VBD o
equally RB o
effective JJ o
when WRB o
given VBN o
BID NNP o
or CC o
QID NNP o
. . o

-DOCSTART- -X- O O

An DT N
open JJ N
multicenter NN N
efficacy NN o
and CC o
safety NN o
evaluation NN o
of IN N
amlodipine NN i
in IN N
the DT N
treatment NN N
of IN N
symptomatic JJ p
myocardial JJ p
ischemia NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
amlodipine NN i
( ( N
5-10 JJ N
mg NN N
) ) N
once RB N
daily JJ N
were VBD N
studied VBN N
in IN N
an DT p
open JJ p
study NN p
in IN p
patients NNS p
with IN p
symptomatic JJ p
myocardial JJ p
ischemia NN p
. . p

The DT N
study NN N
is VBZ N
ongoing VBG N
and CC N
this DT N
report NN N
is VBZ N
based VBN N
on IN N
an DT N
interim JJ N
analysis NN N
of IN N
data NNS p
from IN p
78 CD p
patients NNS p
. . p

A DT N
2-week JJ N
baseline NN N
period NN N
in IN N
which WDT N
patients NNS N
maintained VBD N
their PRP$ N
current JJ i
antianginal JJ i
therapy NN i
was VBD N
followed VBN N
by IN N
a DT N
10-week JJ N
treatment NN N
period NN N
with IN N
5-10 JJ N
mg NN N
of IN N
amlodipine/day NN i
. . N

Both CC N
the DT N
median JJ o
number NN o
of IN o
angina JJ o
attacks NNS o
per IN o
week NN o
and CC o
the DT o
median JJ o
number NN o
of IN o
nitroglycerin NN o
( ( o
NTG NNP o
) ) o
tablets NNS o
consumed/week VBP o
were VBD N
significantly RB N
reduced VBN N
after IN N
amlodipine NN i
( ( N
mean JJ N
daily RB N
dose NN N
of IN N
8.6 CD N
mg NNS N
) ) N
when WRB N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
total NN N
of IN N
98.4 CD N
% NN N
of IN N
patients NNS N
( ( N
63/64 CD N
) ) N
experienced VBD N
a DT N
reduction NN N
in IN N
the DT N
frequency NN o
of IN o
angina JJ o
attacks/week NN o
and CC N
91 CD N
% NN N
of IN N
patients NNS N
( ( N
58/64 CD N
) ) N
had VBD N
angina VBN o
attacks NNS o
reduced VBD N
to TO N
< VB N
or CC N
= VB N
2/week CD N
. . N

In IN N
self-assessments NNS o
, , N
95 CD N
% NN N
of IN N
patients NNS N
( ( N
55/58 CD N
) ) N
reported VBD N
improved JJ N
angina NNS o
control NN o
and CC N
91 CD N
% NN N
( ( N
53/58 CD N
) ) N
felt VBD N
their PRP$ N
ability NN o
to TO o
perform VB o
usual JJ o
activities NNS o
had VBD N
improved VBN N
. . N

Twenty-seven JJ N
patients NNS N
experienced JJ N
adverse JJ o
events NNS o
reported VBN N
as IN N
drug NN N
related VBN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
event NN o
noted VBD N
was VBD N
edema RB o
. . o

Amlodipine NNP i
once RB N
daily RB N
significantly RB N
reduced VBN N
the DT N
incidence NN o
of IN o
angina NN o
attacks NNS o
and CC N
the DT N
concomitant JJ N
need NN o
of IN o
nitroglycerin NN o
for IN N
relief NN N
of IN N
symptoms NNS N
and CC N
thus RB N
improved VBN N
the DT N
patients NNS N
' POS N
ability NN N
to TO N
perform VB N
daily JJ N
activities NNS N
. . N

Most JJS N
adverse JJ N
events NNS N
reported VBN N
were VBD N
mild JJ N
or CC N
moderate JJ N
and CC N
the DT N
incidence NN N
is VBZ N
as RB N
would MD N
be VB N
expected VBN N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
imidapril NN i
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
. . p

This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
early JJ N
treatment NN N
with IN N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
is VBZ N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ o
function NN o
, , N
as RB N
well RB N
as IN N
left VBN o
ventricular JJ o
function NN o
. . o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN o
plasminogen NN o
activator NN o
inhibitor NN o
( ( o
PAI NNP o
) ) o
activity NN o
and CC N
serum JJ o
ACE NNP o
activity NN o
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD p
patients NNS p
with IN p
AMI NNP p
within IN p
12 CD p
hours NNS p
after IN p
the DT p
onset NN p
of IN p
the DT p
symptom NN p
and CC p
who WP p
randomly VBP p
received VBN p
early JJ p
treatment NN p
with IN p
either CC p
the DT p
ACE NNP i
inhibitor NN i
imidapril NN i
or CC i
a DT i
placebo NN i
( ( p
20 CD p
patients NNS p
in IN p
the DT p
imidapril NN p
group NN p
and CC p
20 CD p
in IN p
the DT p
placebo NN p
group NN p
) ) p
. . p

The DT N
levels NNS o
of IN o
serum JJ o
ACE NNP o
activity NN o
in IN N
the DT N
imidapril NN i
group NN N
decreased VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
8 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN i
, , N
and CC N
the DT N
levels NNS N
24 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
3.6 CD N
+/- JJ N
0.6 CD N
IU/L NNP N
vs VBD N
7.4 CD N
+/- JJ N
0.8 CD N
IU/L NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
. . N

The DT N
plasma JJ o
PAI NNP o
activity NN o
increased VBD N
gradually RB N
to TO N
peak VB N
levels NNS N
16 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
and CC N
placebo NN N
. . N

The DT N
levels NNS N
in IN N
the DT N
placebo NN N
group NN N
decreased VBD N
gradually RB N
but CC N
remained VBD N
high JJ N
during IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS o
of IN o
PAI NNP o
activity NN o
in IN N
the DT N
imidapril NN i
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

The DT N
levels NNS o
of IN o
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
imidapril NN i
, , N
an DT N
ACE NNP N
inhibitor NN N
, , N
might MD N
be VB N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ o
function NN o
and CC N
left VBD o
ventricular JJ o
function NN o
in IN N
the DT N
acute JJ N
phase NN N
of IN N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -X- O O

Gonadotropin-releasing VBG i
hormone NN i
agonist NN N
in IN N
the DT N
treatment NN N
of IN N
premenstrual JJ N
symptoms NNS N
with IN N
and CC N
without IN N
ongoing VBG N
dysphoria NN N
: : N
a DT N
controlled VBN N
study NN N
. . N

Gonadotropin-releasing VBG i
hormone NN i
( ( i
GnRH NNP i
) ) i
agonists NNS i
have VBP N
been VBN N
shown VBN N
to TO N
reduce VB N
symptoms NNS o
of IN o
premenstrual JJ o
syndrome NN o
( ( o
PMS NNP o
) ) o
. . o

This DT N
randomized JJ N
, , N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
efficacy NN N
of IN N
the DT N
GnRH NNP i
agonist NN i
, , N
leuprolide JJ N
acetate NN N
depot NN N
, , N
in IN N
a DT N
clearly RB p
defined VBN p
PMS NNP p
sample JJ p
versus NNS p
women NNS p
with IN p
premenstrual JJ p
symptoms NNS p
in IN p
combination NN p
with IN p
dysphoric NN p
symptoms NNS p
throughout IN p
the DT p
cycle NN p
, , p
termed VBD p
the DT p
premenstrual JJ p
exacerbation NN p
( ( p
PME NNP p
) ) p
group NN p
. . p

Evaluation NN N
included VBD N
the DT N
Structured NNP o
Clinical NNP o
Interview NNP o
for IN o
DSM-III-R NNP o
, , N
administered VBN N
in IN N
the DT N
follicular JJ N
phase NN N
, , N
and CC N
the DT N
subject NN o
Penn NNP o
Dally NNP o
Symptoms NNP o
Report NNP o
( ( o
DSR NNP o
) ) o
maintained VBD N
throughout IN N
the DT N
study NN N
. . N

Thirty-three NNP p
eligible JJ p
women NNS p
were VBD N
randomized VBN N
to TO N
double-blind VB N
treatment NN N
and CC N
administered VBD N
3.75 CD i
mg NN i
of IN i
depot NN i
leuprolide NN i
or CC i
a DT i
placebo NN i
once RB N
a DT N
month NN N
for IN N
3 CD N
months NNS N
. . N

The DT N
subjects NNS N
were VBD N
seen VBN N
for IN N
efficacy NN o
evaluations NNS N
at IN N
the DT N
end NN N
of IN N
each DT N
cycle NN N
. . N

Outcome CC N
measures NNS N
were VBD N
the DT N
DSRs NNP o
and CC o
the DT o
17-item JJ o
Hamilton NNP o
Depression NNP o
Rating NNP o
Scale NNP o
( ( o
HAM-D17 NNP o
) ) o
. . o

The DT N
PMS NNP N
leuprolide JJ i
subjects NNS N
improved VBN N
significantly RB N
compared VBN N
with IN N
the DT N
PMS NNP N
placebo NN N
and CC N
PME NNP N
leuprolide RB N
groups NNS N
. . N

The DT N
PME NNP N
leuprolide NN i
group NN N
, , N
who WP N
had VBD N
dysphoric NN o
symptoms NNS o
throughout IN N
the DT N
cycle NN N
, , N
did VBD N
not RB N
improve VB N
. . N

Depression NNP o
symptoms NNS o
were VBD N
at IN N
clinical JJ N
levels NNS N
premenstrually RB N
in IN N
the DT N
PMS NNP N
and CC N
PME NNP N
groups NNS N
; : N
following VBG N
treatment NN N
they PRP N
remitted VBD N
in IN N
the DT N
PMS NNP N
group NN N
but CC N
not RB N
in IN N
the DT N
PME NNP N
leuprolide JJ i
subjects NNS N
. . N

Efficacy NN N
did VBD N
not RB N
occur VB N
until IN N
after IN N
several JJ N
months NNS N
of IN N
leuprolide JJ i
treatment NN N
, , N
but CC N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
PMS NNP o
symptoms NNS o
worsened VBD N
with IN N
the DT N
onset NN N
of IN N
treatment NN N
. . N

These DT N
results NNS N
replicate VBP N
the DT N
findings NNS N
in IN N
our PRP$ N
preliminary JJ N
open-label NN N
study NN N
. . N

Leuprolide NNP i
reduced VBD N
PMS NNP o
symptoms NNS o
to TO N
minimal JJ N
levels NNS N
where WRB N
symptoms NNS N
were VBD N
limited VBN N
to TO N
the DT N
luteal JJ N
phase NN N
. . N

Leuprolide NNP i
was VBD N
not RB N
effective JJ N
for IN N
women NNS N
with IN N
ongoing VBG N
dysphoric NN N
symptoms NNS N
, , N
suggesting VBG N
that IN N
premenstrual JJ N
depression NN N
may MD N
have VB N
mechanisms NNS N
different JJ N
from IN N
those DT N
of IN N
other JJ N
dysphoric JJ N
mood NN N
disorders NNS N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
special-effect JJ i
contact NN i
lenses NNS i
( ( i
Crazy NNP i
Lenses NNP i
) ) i
on IN N
visual JJ o
function NN o
. . o

PURPOSE NNP N
Special-effect JJ i
contact NN i
lenses NNS i
( ( N
opaque NN N
, , N
tinted VBD N
soft JJ N
contact NN N
lenses VBZ N
that IN N
incorporate JJ N
decorative JJ N
images NNS N
such JJ N
as IN N
cateyes NNS N
, , N
stars NNS N
, , N
or CC N
hearts NNS N
to TO N
alter VB N
eye NN N
color NN N
and CC N
structure NN N
) ) N
have VBP N
become VBN N
increasingly RB N
popular JJ N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
such JJ N
lenses NNS N
impair VBP N
visual JJ o
function NN o
. . o

METHODS NNP N
A DT i
clear JJ i
soft JJ i
contact NN i
lens NNS i
and CC i
a DT i
special-effect JJ i
soft JJ i
contact NN i
lens NNS i
( ( i
Crazy NNP i
lens VBZ i
, , i
) ) i
were VBD N
fit JJ N
in IN N
changing VBG N
sequence NN N
in IN N
nine CD p
healthy JJ p
subjects NNS p
. . p

The DT N
parameters NNS N
studied VBD N
included VBN N
: : N
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
, , o
visual JJ o
field NN o
, , o
and CC o
mesopic NN o
vision NN o
( ( o
with IN o
and CC o
without IN o
glare NN o
) ) o
. . o

RESULTS VB N
The DT N
following JJ N
parameters NNS N
displayed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Visual JJ o
acuity NN o
was VBD N
decreased VBN N
to TO N
0.9 CD N
+/- JJ N
0.23 CD N
in IN N
the DT N
Crazy NNP N
lens VBZ N
group NN N
as IN N
compared VBN N
with IN N
1.2 CD N
+/- JJ N
0.13 CD N
in IN N
the DT N
clear JJ i
lens NNS i
group NN N
. . N

Goldmann NNP o
visual JJ o
field NN o
displayed VBD N
a DT N
significant JJ N
constriction NN o
of IN o
the DT o
isopters NNS o
: : o
III/4 NNP N
, , N
I/4 NNP N
, , N
and CC N
I/3 NNP N
. . N

Mesopic NNP o
vision NN o
without IN o
glare NN o
was VBD N
reduced VBN N
from IN N
1:2.5 CD N
to TO N
1:7.4 CD N
. . N

Contrast NNP o
sensitivity NN o
was VBD N
significantly RB N
reduced VBN N
in IN N
a DT N
photopic JJ N
condition NN N
with IN N
and CC N
without IN N
glare NN N
and CC N
in IN N
a DT N
scotopic JJ N
condition NN N
without IN N
glare NN N
. . N

Furthermore RB N
, , N
the DT N
special-effect JJ i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
lens NNS o
wearing VBG o
comfort NN o
. . o

CONCLUSIONS NNP N
Special-effect JJ i
contact NN i
lenses NNS i
were VBD N
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
many JJ N
visual JJ o
functions NNS o
, , N
including VBG N
visual JJ o
acuity NN o
and CC o
contrast NN o
sensitivity NN o
. . o

For IN N
some DT N
wearers NNS p
this DT N
may MD N
interfere VB N
with IN N
activities NNS N
where WRB N
excellent JJ N
vision NN N
is VBZ N
crucial JJ N
, , N
such JJ N
as IN N
driving VBG N
a DT N
car NN N
. . N

-DOCSTART- -X- O O

Response NNP N
prediction NN N
in IN N
metastasised JJ N
colorectal NN N
cancer NN N
using VBG N
intratumoural JJ N
thymidylate JJ N
synthase NN N
: : N
results NNS N
of IN N
a DT N
randomised JJ N
multicentre NN N
trial NN N
. . N

BACKGROUND NNP N
Molecular NNP N
markers NNS N
to TO N
predict VB N
response NN N
to TO N
5-fluorouracil JJ i
( ( i
FU NNP i
) ) i
-based VBD i
treatment NN N
of IN N
recurrent NN p
or CC p
metastasised VBN p
colorectal JJ p
cancer NN p
( ( p
mCRC NN p
) ) p
are VBP N
not RB N
established VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
value NN N
of IN N
thymidylate JJ N
synthase NN N
( ( N
TS NNP N
) ) N
, , N
a DT N
key JJ N
enzyme NN N
of IN N
DNA NNP N
synthesis NN N
and CC N
target NN N
of IN N
5-FU JJ N
, , N
to TO N
predict VB o
response NN o
to TO N
chemotherapy NN N
of IN N
mCRC NN N
. . N

METHODS NNP N
Tumour NNP p
tissue NN p
was VBD p
obtained VBN p
from IN p
168 CD p
patients NNS p
with IN p
mCRC NN p
for IN p
relative JJ p
thymidylate NN o
synthase NN o
( ( o
TS NNP o
) ) o
mRNA NN p
quantitation NN p
. . p

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
5-FU/folinic JJ i
acid NN i
( ( i
FA NNP i
, , i
FUFA NNP i
) ) i
alone RB i
or CC i
in IN i
combination NN i
with IN i
irinotecan JJ i
5-fluorouracil/folinic JJ i
acid NN i
and CC i
irinotecan JJ i
( ( i
FOLFIRI NNP i
) ) i
stratified VBN i
by IN i
TS NNP i
( ( i
low JJ i
versus RB i
high JJ i
) ) i
. . N

Primary JJ N
end-point NN N
was VBD N
overall JJ o
response NN o
to TO o
first-line JJ o
treatment NN o
among IN N
TS NNP N
high JJ N
patients NNS N
. . N

All DT N
parties NNS N
, , N
except IN N
for IN N
the DT N
randomisation NN N
centre NN N
, , N
were VBD N
blinded VBN N
for IN N
TS NNP N
status NN N
. . N

RESULTS NNP N
Biopsies NNP N
( ( N
n=168 RB N
) ) N
were VBD N
taken VBN N
without IN N
complications NNS N
. . N

TS NN o
levels NNS o
were VBD N
available JJ N
for IN N
147 CD N
patients NNS N
( ( N
87.5 CD N
% NN N
) ) N
. . N

Analysing VBG N
response NN o
to TO o
FUFA NNP o
and CC o
FOLFIRI NNP o
in IN N
the DT N
per NN N
protocol NN N
set VBN N
( ( N
n=119 NN N
) ) N
after IN N
un-blinding JJ N
TS NNP N
in IN N
the DT N
data NN N
base NN N
revealed VBD N
a DT N
trend NN N
to TO N
better JJR N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
( ( N
9/19 CD N
, , N
47 CD N
% NN N
) ) N
in IN N
TS NNP N
high JJ N
compared VBN N
to TO N
FUFA NNP N
( ( N
5/23 CD N
, , N
22 CD N
% NN N
, , N
p=0.077 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
biopsies NNS N
taken VBN N
from IN N
liver JJ N
lesions NNS N
( ( N
n=91 NN N
) ) N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
in IN N
TS NNP N
high NN N
was VBD N
53 CD N
% NN N
( ( N
9/17 CD N
) ) N
and CC N
18 CD N
% NN N
( ( N
3/17 CD N
) ) N
, , N
respectively RB N
( ( N
p=0.035 NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
low JJ N
TS NNP N
, , N
no DT N
remarkable JJ N
difference NN N
in IN N
overall JJ N
response NN N
to TO N
FOLFIRI NNP N
and CC N
FUFA NNP N
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Taking VBG N
a DT N
pre-treatment JJ N
biopsy NN N
is VBZ N
a DT N
safe JJ N
and CC N
feasible JJ N
procedure NN N
in IN N
mCRC NN N
. . N

After IN N
validation NN N
of IN N
our PRP$ N
data NNS N
in IN N
a DT N
larger JJR N
group NN N
TS NNP N
determination NN N
may MD N
have VB N
the DT N
potential NN N
to TO N
better JJR N
help NN N
direct VB N
systemic JJ N
treatment NN N
in IN N
patients NNS p
with IN p
primarily RB p
non-resectable JJ p
mCRC NN p
. . p

-DOCSTART- -X- O O

[ JJ i
Intra-arterial JJ i
( ( i
5-FU/FA JJ i
and CC i
FUDR NNP i
) ) i
versus VBP i
systemic JJ i
chemotherapy NN i
( ( i
5-FU/FA JJ i
) ) i
of IN N
non-resectable JJ o
colorectal JJ o
liver NN o
metastases NNS o
] VBP o
. . N

The DT N
relative JJ o
efficacy NN o
of IN N
HAI NNP i
FUDR NNP i
, , i
HAI NNP i
5-FU/FA CD i
, , i
and CC i
i.v NN i
. . i

5-FU/FA JJ i
chemotherapy NN i
for IN N
the DT N
treatment NN N
of IN N
unresectable JJ p
colorectal JJ p
liver NN p
metastases NNS p
was VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

The DT N
response NN o
rate NN o
after IN N
HAI NNP i
treatment NN N
was VBD N
significantly RB N
higher JJR N
as IN N
compared VBN N
to TO N
i.v VB N
. . N

treatment NN N
with IN N
no DT N
statistical JJ N
benefit NN N
regarding VBG N
survival NN o
and CC o
time NN o
to TO o
progression NN o
. . o

HAI NNP i
FUDR NNP i
treatment NN N
was VBD N
inferior JJ o
as IN N
compared VBN N
to TO N
HAI NNP i
or CC N
i.v NN N
. . N

5-FU/FA JJ i
. . i

i.v NN N
. . N

5-FU/FA-therapy NN i
is VBZ N
therefore IN N
the DT N
method NN N
of IN N
choice NN N
outside IN N
clinical JJ N
trials NNS N
. . N

-DOCSTART- -X- O O

Use NNP N
of IN N
high-dose JJ N
cytarabine NN i
to TO N
enhance VB N
cisplatin JJ i
cytotoxicity-effects NNS o
on IN N
the DT N
response NN N
and CC N
overall JJ N
survival NN o
rates NNS o
of IN N
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

UNLABELLED IN N
It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
cytarabine NN i
, , N
acting VBG N
by IN N
at IN N
least JJS N
two CD N
different JJ N
mechanisms NNS N
, , N
enhances VBZ N
the DT N
cytotoxic JJ N
effect NN N
of IN N
cisplatin NN i
in IN N
in IN N
vitro JJ N
systems NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
open JJ N
, , N
prospective JJ N
, , N
randomised VBD N
study NN N
was VBD N
to TO N
estimate VB N
the DT N
eventual JJ N
benefits NNS N
from IN N
the DT N
inclusion NN N
of IN N
high-dose JJ N
cytarabine NN i
in IN N
the DT N
cisplatin-5-fluorouracil NN i
( ( i
5-FU JJ i
) ) i
regimen NNS N
as IN N
first-line JJ p
treatment NN p
of IN p
patients NNS p
with IN p
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
. . p

The DT N
study NN N
recruited VBD N
successive JJ p
patients NNS p
with IN p
unresectable JJ p
grade NN p
I/II NNP p
head NN p
and CC p
neck NN p
cancer NN p
who WP p
were VBD p
not RB p
suitable JJ p
for IN p
irradiation NN i
treatment NN i
( ( p
T NNP p
any DT p
N3 NNP p
or CC p
T4 NNP p
N2C NNP p
) ) p
, , p
metastatic JJ p
or CC p
previously RB p
irradiated VBN p
. . p

All DT N
patients NNS N
gave VBD N
their PRP$ N
informed JJ N
consent NN N
. . N

A DT N
joint JJ N
ear NN N
, , N
nose JJ N
and CC N
throat NN N
( ( N
ENT NNP N
) ) N
oncological JJ N
committee NN N
performed VBD N
the DT N
selection NN N
. . N

A DT p
total NN p
of IN p
170 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
randomised VBD N
to TO N
arm VB N
A NNP N
were VBD N
given VBN N
1000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
cytarabine NN i
on IN N
day NN N
1 CD N
preceding NN N
for IN N
6 CD N
h NN N
cisplatin NN i
infusion NN i
, , N
30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h NN N
cisplatin NN i
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
bolus JJ N
days NNS N
1-4 CD N
and CC N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h JJ N
5-FU JJ N
in IN N
a DT N
4-h JJ N
infusion NN N
on IN N
days NNS N
1-4 JJ N
. . N

Patients NNS N
in IN N
arm NN N
B NNP N
were VBD N
given VBN N
cisplatin NNS i
and CC i
5-FU JJ i
in IN N
the DT N
same JJ N
dosage NN N
and CC N
schedule NN N
as IN N
in IN N
arm NN N
A NNP N
. . N

Additional NNP N
irradiation+/-surgery NN i
was VBD N
performed VBN N
if IN N
and CC N
when WRB N
feasible JJ N
. . N

Patients NNS N
in IN N
both DT N
arms NNS N
were VBD N
well RB N
balanced VBN N
with IN N
regard NN N
to TO N
clinical JJ N
variables NNS N
. . N

The DT N
following JJ N
results NNS N
were VBD N
obtained VBN N
: : N
Arm NN N
A NN N
: : N
84 CD N
patients NNS N
were VBD N
included VBN N
, , N
74 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
8 CD N
( ( N
11 CD N
% NN N
) ) N
, , N
partial JJ o
response NN o
( ( o
PR NNP o
) ) o
40 CD N
( ( N
54 CD N
% NN N
) ) N
, , N
stable JJ o
disease NN o
( ( o
SD NNP o
) ) o
11 CD N
( ( N
15 CD N
% NN N
) ) N
, , N
progressive JJ o
disease NN o
( ( N
PD NNP N
) ) N
15 CD N
( ( N
20 CD N
% NN N
) ) N
. . N

The DT N
overall JJ o
response NN o
rate NN o
( ( o
RR NNP o
) ) o
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
48/74 CD N
( ( N
65 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
54-75 CD N
% NN N
) ) N
; : N
The DT N
RR NNP o
based VBN o
on IN o
an DT o
intent-to-treat JJ o
analysis NN o
was VBD N
57 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
47-67 CD N
% NN N
; : N
Median JJ o
survival NN o
was VBD N
13 CD N
months NNS N
; : N
There EX N
were VBD N
50 CD N
episodes NNS N
of IN N
granulocytopenia NN o
grade NN o
IV NNP o
and CC N
15 CD N
of IN N
febrile JJ o
neutropenia NNS o
per IN N
316 CD N
cycles NNS N
. . N

Arm NN N
B NN N
: : N
86 CD N
patients NNS N
were VBD N
included VBN N
, , N
80 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
CR NNP o
7 CD N
( ( N
9 CD N
% NN N
) ) N
, , N
PR NNP o
29 CD N
( ( N
36 CD N
% NN N
) ) N
, , N
SD NNP o
10 CD N
( ( N
12.5 CD N
% NN N
) ) N
, , N
PD NNP o
34 CD N
( ( N
42.5 CD N
% NN N
) ) N
; : N
The DT N
overall JJ o
RR NNP o
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
36/80 CD N
( ( N
45 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
35-56 CD N
% NN N
) ) N
; : N
The DT N
RR NNP o
based VBN o
on IN o
an DT o
intent-to-treat JJ o
analysis NN o
was VBD N
42 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
32-52 CD N
% NN N
; : N
Median JJ o
survival NN o
was VBD N
8 CD N
months NNS N
; : N
There EX N
were VBD N
14 CD N
episodes NNS N
of IN N
granulocytopenia NN N
grade NN N
IV NNP N
and CC N
7 CD N
febrile NN N
neutropenias NNS N
per IN N
324 CD N
cycles NNS N
. . N

The DT N
RR NNP o
was VBD o
significantly RB o
higher JJR o
in IN N
arm NN N
A NNP N
( ( N
P=0.013 NNP N
) ) N
, , N
power NN N
( ( N
one-sided JJ N
) ) N
80 CD N
% NN N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
from IN N
the DT N
appropriate JJ N
subset NN N
who WP N
achieved VBD N
a DT N
clinical JJ o
response NN o
making VBG o
additional JJ o
treatment NN o
feasible NN o
was VBD N
higher RBR o
in IN N
arm NN N
A NNP N
( ( N
P=0.00015 NNP N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
a DT o
performance NN o
status NN o
2+3 CD o
achieving VBG o
a DT o
response NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Using VBG N
the DT N
Log-rank JJ N
test NN N
, , N
patients NNS N
from IN N
arm NN N
A NNP N
achieved VBD N
a DT N
significantly RB o
longer RBR o
survival JJ o
( ( N
P=0.009 NNP N
) ) N
, , N
with IN N
the DT N
probability NN N
of IN N
survival NN o
at IN o
12 CD o
months NNS o
of IN N
0.58 CD N
for IN N
patients NNS N
in IN N
arm NN N
A NN N
and CC N
0.28 CD N
for IN N
patients NNS N
in IN N
arm NN N
B. NNP N
Grade NNP o
IV NNP o
granulocytopenia NN o
and CC o
thrombocytopenia NN o
were VBD N
more RBR o
frequent JJ o
in IN N
arm NN N
A NN N
. . N

Due JJ N
to TO N
its PRP$ N
haematological JJ o
side-effects NNS o
, , N
cytarabine NN i
might MD N
not RB N
be VB N
the DT N
ideal JJ N
drug NN N
to TO N
modulate VB N
the DT N
cytotoxicity NN o
of IN N
cisplatin NN i
. . i

However RB N
, , N
other JJ N
modulators NNS N
of IN N
its PRP$ N
activity NN N
could MD N
be VB N
of IN N
interest NN N
for IN N
further JJ N
studies NNS N
in IN N
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

-DOCSTART- -X- O O

Eberconazole JJ i
1 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ o
and CC o
safe JJ o
alternative NN N
for IN N
dermatophytosis NN N
treatment NN N
: : N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
comparative JJ N
trial NN N
with IN N
miconazole JJ i
2 CD N
% NN N
cream NN N
. . N

BACKGROUND NNP N
Eberconazole NNP i
is VBZ N
a DT N
topical JJ N
, , N
broad-spectrum JJ N
imidazole NN N
derivative NN N
, , N
effective JJ N
in IN N
dermatophytoses NNS N
, , N
candidiasis NN N
, , N
and CC N
pityriasis NN N
treatment NN N
. . N

In IN N
previous JJ N
trials NNS N
, , N
it PRP N
showed VBD N
a DT N
higher JJR N
efficacy NN N
than IN N
clotrimazole NN N
in IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
eberconazole JJ i
1 CD N
% NN N
cream NN N
compared VBN N
with IN N
miconazole JJ i
2 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

METHODS NNP N
A NNP N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
trial NN N
was VBD N
performed VBN N
in IN N
653 CD p
patients NNS p
with IN p
dermatophytoses NNS p
, , N
randomized VBN N
to TO N
eberconazole VB i
1 CD N
% NN N
cream NN N
every DT N
12 CD N
h NN N
or CC N
miconazole VB i
2 CD N
% NN N
cream NN N
every DT N
12 CD N
h NN N
for IN N
4 CD N
weeks NNS N
. . N

Treatment NNP o
efficacy NN o
was VBD N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
the DT N
percentage NN N
of IN N
effective JJ N
response NN N
after IN N
4 CD N
weeks NNS N
through IN N
mycologic NN N
and CC N
clinical JJ N
assessment NN N
. . N

RESULTS NNP N
Of IN N
the DT N
653 CD p
patients NNS p
included VBN p
in IN p
the DT p
trial NN p
, , N
360 CD N
produced VBD N
positive JJ N
baseline NN N
mycologic NN N
cultures NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
efficacy NN N
assessment NN N
. . N

Clinical JJ N
efficacy NN N
was VBD N
shown VBN N
in IN N
76.1 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
eberconazole JJ N
and CC N
in IN N
75.0 CD N
% NN N
of IN N
patients NNS N
receiving VBG N
miconazole NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
related VBN N
to TO N
treatment NN N
was VBD N
0.91 CD N
% NN N
for IN N
eberconazole NN N
and CC N
0.92 CD N
% NN N
for IN N
miconazole NN N
, , N
none NN N
being VBG N
serious JJ N
, , N
and CC N
all DT N
being VBG N
local JJ N
and CC N
transient NN N
. . N

CONCLUSIONS NNP N
Eberconazole NNP N
1 CD N
% NN N
cream NN N
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
fungal JJ N
infections NNS N
produced VBN N
by IN N
dermatophytes NNS N
, , N
with IN N
a DT N
good JJ N
safety NN o
and CC o
tolerability NN o
profile NN N
, , N
and CC N
can MD N
be VB N
considered VBN N
a DT N
good JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
dermatophytoses NNS N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
Thai NNP N
traditional JJ N
massage NN N
on IN N
autistic JJ p
children NNS p
's POS p
behavior NN p
. . p

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
access NN N
whether IN N
there EX N
were VBD N
any DT N
therapeutic JJ N
effects NNS N
of IN N
Thai NNP i
Traditional NNP i
Massage NNP i
( ( i
TTM NNP i
) ) i
on IN N
major JJ N
behavioral JJ p
and CC p
emotional JJ p
disturbances NNS p
in IN p
Thai NNP p
autistic JJ p
children NNS p
. . p

DESIGN NN N
This DT N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
study NN N
. . N

SETTINGS/LOCATION NNP N
The DT p
study NN p
was VBD p
conducted VBN p
at IN p
the DT p
Rehabilitation NNP p
Centre NNP p
of IN p
the DT p
Thai NNP p
Red NNP p
Cross NNP p
Society NNP p
. . p

SUBJECTS NNP N
A NNP p
total NN p
of IN p
60 CD p
autistic JJ p
children NNS p
between IN p
the DT p
ages NNS p
of IN p
3 CD p
and CC p
10 CD p
completed VBD p
this DT p
study NN p
. . p

INTERVENTIONS NNP N
Standard NNP i
sensory JJ i
integration NN i
therapy NN i
( ( i
SI NNP i
) ) i
was VBD N
compared VBN N
to TO N
the DT N
SI NNP N
with IN N
TTM NNP i
treatments NNS N
. . N

OUTCOME NNP N
MEASURES NNP N
Parents NNP N
and CC N
teachers NNS N
assessed VBD N
major JJ o
behavior NN o
disturbances NNS o
using VBG N
the DT N
Conners NNPS o
' POS o
Rating VBG o
Scales NNS o
at IN N
0 CD N
and CC N
8 CD N
weeks NNS N
. . N

Sleep JJ o
Diary NNP o
( ( o
SD NNP o
) ) o
, , N
recorded VBN N
by IN N
the DT N
parents NNS N
, , N
assessed VBD N
the DT N
patient NN N
's POS N
sleeping NN N
patterns NNS N
every DT N
week NN N
. . N

RESULTS NNP N
Sixty NNP p
( ( p
60 CD p
) ) p
autistic JJ p
children NNS p
, , p
mean JJ p
age NN p
4.67 CD p
+/- JJ p
1.82 CD p
, , p
were VBD p
recruited VBN p
. . p

No DT N
statistical JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
demographic JJ N
and CC N
baseline JJ N
data NN N
among IN N
both DT N
groups NNS N
. . N

From IN N
both CC N
the DT N
Conners NNPS o
' POS o
Teacher NNP o
Questionnaire NNP o
and CC o
SD NNP o
, , N
statistical JJ N
improvement NN N
was VBD N
detected VBN N
for IN N
conduct NN o
problem NN o
, , o
hyperactivity NN o
, , o
inattention-passivity NN o
, , o
hyperactivity NN o
index NN o
, , o
and CC o
sleeping VBG o
behavior NN o
. . o

However RB N
, , N
results NNS N
from IN N
the DT N
Conners NNP o
' POS o
Parent NNP o
Questionnaire NNP o
revealed VBD N
an DT N
improvement NN N
only RB N
for IN N
anxiety NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
massage NN N
group NN N
, , N
whereas IN N
when WRB N
both DT N
groups NNS N
were VBD N
compared VBN N
, , N
a DT N
significant JJ N
improvement NN N
in IN N
conduct NN o
problem NN o
( ( N
p JJ N
= NNP N
0.03 CD N
) ) N
and CC N
anxiety NN o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
was VBD N
found VBN N
. . N

Results NNS N
indicated VBD N
that IN N
TTM NNP N
may MD N
have VB N
a DT N
positive JJ N
effect NN N
in IN N
improving VBG N
stereotypical JJ o
behaviors NNS o
in IN N
autistic JJ N
children NNS N
. . N

CONCLUSIONS NNP N
Over IN N
a DT N
period NN N
of IN N
8 CD N
weeks NNS N
, , N
our PRP$ N
findings NNS N
suggested VBD N
that IN N
TTM NNP N
could MD N
be VB N
used VBN N
as IN N
a DT N
complementary JJ N
therapy NN N
for IN N
autistic JJ N
children NNS N
in IN N
Thailand NNP p
. . p

-DOCSTART- -X- O O

Effects NNS N
of IN N
exposure NN N
to TO N
thin-ideal JJ N
media NNS N
images NNS N
on IN N
body NN o
dissatisfaction NN o
: : o
testing VBG N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN i
versus NN i
warning VBG i
label NN i
. . i

The DT N
current JJ N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
whether IN N
the DT N
inclusion NN N
of IN N
a DT N
disclaimer NN N
( ( N
i.e. FW N
, , N
Retouched NNP N
photograph NN N
aimed VBN N
at IN N
changing VBG N
a DT N
person NN N
's POS N
physical JJ N
appearance NN N
. . N

) ) N
or CC N
warning VBG N
( ( N
i.e. FW N
, , N
Warning VBG N
: : N
Trying NN N
to TO N
look VB N
as RB N
thin JJ N
as IN N
this DT N
model NN N
may MD N
be VB N
dangerous JJ N
to TO N
your PRP$ N
health NN N
. . N

) ) N
added VBD N
to TO N
images NNS N
of IN N
thin/attractive JJ N
models NNS N
would MD N
affect VB N
body NN o
dissatisfaction NN o
and CC N
intent NN N
to TO N
diet VB N
in IN N
female JJ p
undergraduate JJ p
students NNS p
( ( p
n=342 NN p
) ) p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
four CD N
groups NNS i
: : i
( ( i
a DT i
) ) i
disclaimer NN i
, , i
( ( i
b NN i
) ) i
warning NN i
, , i
( ( i
c NN i
) ) i
model NN i
control NN i
, , i
or CC i
( ( i
d NN i
) ) i
car NN i
control NN i
. . i

Results NNP N
revealed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
group NN N
and CC N
time NN N
, , N
whereby WRB N
only RB N
the DT N
car NN N
control NN N
group NN N
reported VBD N
a DT N
significant JJ N
change NN N
( ( N
i.e. FW N
, , N
decrease NN N
) ) N
in IN N
body NN o
dissatisfaction NN o
over IN N
time NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
on IN N
intent NN N
to TO N
diet VB o
measured VBN N
at IN N
post-exposure NN N
. . N

The DT N
results NNS N
largely RB N
replicate VBP N
other JJ N
findings NNS N
in IN N
this DT N
area NN N
and CC N
call VB N
into IN N
question NN N
advocacy NN N
efforts NNS N
to TO N
label VB N
media NNS N
images NNS N
as IN N
a DT N
strategy NN N
to TO N
decrease VB N
women NNS p
's POS p
identification NN N
with IN N
the DT N
stimuli NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
an DT N
intensive JJ i
therapy NN i
program NN i
for IN N
behaviorally RB p
disordered VBN p
mentally RB p
handicapped JJ p
patients NNS p
on IN p
staff NN p
personnel NNS p
in IN p
residential JJ p
care NN p
] NNP p
. . N

This DT N
study NN N
evaluates VBZ N
the DT N
effects NNS N
of IN N
an DT N
intensive JJ i
therapy NN i
program NN i
designed VBN N
for IN N
mentally RB p
handicapped JJ p
persons NNS p
with IN p
severely RB p
disturbed VBN p
or CC p
autistic JJ p
behavior NN p
on IN p
their PRP$ p
staff NN p
personal JJ p
which WDT p
had VBD p
an DT p
active JJ p
role NN p
in IN p
the DT p
program NN p
. . p

The DT N
staff NN N
members NNS N
rated VBD N
their PRP$ N
professional JJ N
competence NN N
, , N
quality NN N
of IN N
interaction NN N
with IN N
the DT N
client NN N
, , N
team JJ N
culture NN N
and CC N
work NN N
satisfaction NN N
before IN N
and CC N
after IN N
being VBG N
engaged VBN N
in IN N
the DT N
program NN N
, , N
with IN N
additional JJ N
ratings NNS N
of IN N
their PRP$ N
personal JJ N
aims NNS N
at IN N
the DT N
beginning NN N
of IN N
the DT N
program NN N
. . N

Three NNP N
sets NNS N
of IN N
data NNS N
were VBD N
obtained VBN N
with IN N
the DT N
program NN N
being VBG N
conducted VBN N
three CD N
times NNS N
in IN N
a DT N
row NN N
. . N

The DT N
testings NNS N
of IN N
the DT N
related VBN N
as RB N
well RB N
as IN N
the DT N
independent JJ N
samples NNS N
show VBP N
differentiated JJ N
program NN N
effects NNS N
. . N

The DT N
main JJ N
effect NN N
is VBZ N
an DT N
increase NN N
of IN N
the DT N
professional JJ o
competence NN o
and CC o
quality NN o
of IN o
interaction NN o
, , N
especially RB N
by IN N
the DT N
qualified JJ N
staff NN N
members NNS N
. . N

Trainees NNP N
put VBD N
emphasis NN N
on IN N
the DT N
development NN N
of IN N
their PRP$ N
personal JJ N
relationship NN N
with IN N
the DT N
client NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
impact NN N
of IN N
learning VBG N
processes NNS N
specific JJ N
to TO N
the DT N
roles NNS N
of IN N
the DT N
staff NN N
members NNS N
and CC N
motivational JJ N
factors NNS N
on IN N
learning NN N
and CC N
therapy NN N
outcome NN N
, , N
along IN N
with IN N
institutional JJ N
conditions NNS N
influencing VBG N
successful JJ N
learning NN N
. . N

Thus VB N
the DT N
program NN N
facilitates VBZ N
the DT N
professional JJ N
and CC N
interpersonal JJ N
learning NN N
process NN N
of IN N
staff NN N
members NNS N
in IN N
a DT N
specific JJ N
way NN N
with IN N
success NN N
as RB N
well RB N
as IN N
with IN N
limitations NNS N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
a DT N
brief JJ N
cognitive-behavioural JJ i
therapy NN i
intervention NN i
in IN N
the DT N
treatment NN N
of IN N
schizophrenia NN o
. . o

BACKGROUND NNP N
Little NNP N
evidence NN N
exists VBZ N
to TO N
indicate VB N
whether IN N
community NN N
psychiatric JJ N
nurses NNS N
can MD N
achieve VB N
the DT N
results NNS N
reported VBN N
by IN N
expert JJ N
cognitive-behavioural JJ i
therapists NNS i
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

AIMS NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
a DT N
brief JJ N
cognitive-behavioural JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
intervention NN i
in IN N
a DT N
representative JJ p
community NN p
sample NN p
of IN p
patients NNS p
with IN p
schizophrenia NN p
in IN p
secondary JJ p
care NN p
settings NNS p
. . p

METHOD NNP N
A NNP N
pragmatic JJ N
randomised VBD N
trial NN N
was VBD N
performed VBN N
involving VBG N
422 CD p
patients NNS p
and CC p
carers NNS p
to TO p
compare VB p
a DT p
brief JJ p
CBT NNP i
intervention NN i
against IN p
treatment NN p
as IN p
usual JJ p
. . p

RESULTS JJ N
Patients NNPS N
who WP N
received VBD N
CBT NNP i
( ( i
n=257 NN i
) ) i
improved VBN N
in IN N
overall JJ o
symptomatology NN o
( ( N
P=0.015 NNP N
; : N
number NN o
needed VBN o
to TO o
treat VB o
[ JJ N
NNT NNP N
] NNP N
=13 NNP N
) ) N
, , N
insight JJ o
( ( N
P NNP N
< NNP N
0.001 CD N
; : N
NNT=10 NNP N
) ) N
and CC N
depression NN o
( ( N
P=0.003 NNP N
; : N
NNT=9 NNP N
) ) N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
n=165 RB N
) ) N
. . N

Insight NNP o
was VBD N
clinically RB N
significantly RB N
improved VBN N
( ( N
risk NN N
ratio=1.15 NN N
, , N
95 CD N
% NN N
CI NNP N
1.01-1.31 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
suicidal JJ o
ideation NN o
. . o

CONCLUSIONS NNP N
Community NNP N
psychiatric JJ N
nurses NNS N
can MD N
safely RB o
and CC o
effectively RB o
deliver VB N
a DT N
brief JJ N
CBT NNP i
intervention NN i
to TO N
patients NNS N
with IN N
schizophrenia NN N
and CC N
their PRP$ N
carers NNS N
. . N

-DOCSTART- -X- O O

Cost-effectiveness NN N
of IN N
combined JJ i
manipulation NN i
, , i
stabilizing VBG i
exercises NNS i
, , i
and CC i
physician JJ i
consultation NN i
compared VBN N
to TO N
physician JJ i
consultation NN i
alone RB i
for IN N
chronic JJ p
low JJ p
back RB p
pain NN p
: : p
a DT N
prospective JJ N
randomized VBN N
trial NN N
with IN N
2-year JJ N
follow-up NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
prospective JJ N
, , N
randomized VBD N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
long-term JJ N
effects NNS N
and CC N
costs NNS N
of IN N
combined JJ i
manipulative JJ i
treatment NN i
, , i
stabilizing VBG i
exercises NNS i
, , i
and CC i
physician JJ i
consultation NN i
compared VBN i
with IN i
physician JJ i
consultation NN i
alone RB i
for IN N
chronic JJ p
low JJ p
back RB p
pain NN p
( ( p
cLBP NN p
) ) p
. . p

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
An DT N
obvious JJ N
gap NN N
exists NNS N
in IN N
knowledge NN N
concerning VBG N
long-term JJ N
efficacy NN N
and CC N
cost-effectiveness NN N
of IN N
manipulative JJ N
treatment NN N
methods NNS N
. . N

METHODS NNP N
Of IN N
204 CD p
patients NNS p
with IN p
cLBP NNS p
whose WP$ p
Oswestry NNP p
Disability NNP p
Index NNP p
( ( p
ODI NNP p
) ) p
was VBD p
at IN p
least JJS p
16 CD p
% NN p
, , p
102 CD p
were VBD p
randomized VBN p
into IN p
a DT p
combined JJ i
manipulative JJ i
treatment NN i
, , i
exercise NN i
, , i
and CC i
physician JJ i
consultation NN i
group NN i
( ( p
i.e. FW p
, , N
a DT p
combination NN p
group NN p
) ) p
, , p
and CC p
102 CD p
to TO p
a DT p
consultation NN i
alone RB i
group NN p
. . p

All DT N
patients NNS N
were VBD N
clinically RB N
examined VBN N
, , N
informed VBN N
about IN N
their PRP$ N
back NN N
pain NN N
, , N
and CC N
encouraged VBD N
to TO N
stay VB N
active JJ N
and CC N
exercise NN N
according VBG N
to TO N
specific JJ N
instructions NNS N
based VBN N
on IN N
clinical JJ N
evaluation NN N
. . N

Treatment NNP N
included VBD N
4 CD N
sessions NNS N
of IN N
manual JJ i
therapy NN i
and CC i
stabilizing NN i
exercises NNS i
aimed VBN N
at IN N
correcting VBG N
the DT N
lumbopelvic JJ N
rhythm NN N
. . N

Questionnaires VBZ N
inquired VBN N
about IN N
pain NN o
( ( o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
) ) o
, , o
disability NN o
( ( o
ODI NNP o
) ) o
, , o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
15D CD o
Quality NN o
of IN o
Life NNP o
Instrument NNP o
) ) o
, , o
satisfaction NN o
with IN o
care NN o
, , o
and CC o
costs NNS o
. . o

RESULTS NNP N
Significant NNP N
improvement NN N
occurred VBD N
in IN N
both DT N
groups NNS N
on IN N
every DT N
self-rated JJ o
outcome NN o
measurement NN N
. . N

Within IN N
2 CD N
years NNS N
, , N
the DT N
combination NN N
group NN N
showed VBD N
only RB N
a DT N
slightly RB N
more RBR N
significant JJ N
reduction NN N
in IN N
VAS NNP o
( ( N
P NNP N
= NNP N
0.01 CD N
, , N
analysis NN N
of IN N
variance NN N
) ) N
but CC N
clearly RB N
higher JJR N
patient JJ o
satisfaction NN o
( ( N
P NNP N
= NNP N
0.001 CD N
, , N
Pearson NNP N
chi2 NN N
) ) N
as IN N
compared VBN N
to TO N
the DT N
consultation NN N
group NN N
. . N

Incremental JJ N
analysis NN N
showed VBD N
that IN N
for IN N
combined JJ N
group NN N
compared VBN N
to TO N
consultation NN N
group NN N
, , N
a DT N
one-point JJ N
change NN N
in IN N
VAS NNP o
scale NN o
cost NN o
$ $ N
512 CD N
. . N

CONCLUSIONS NNP N
Physician JJ i
consultation NN i
alone RB i
was VBD N
more RBR N
cost-effective JJ o
for IN N
both DT N
health NN N
care NN N
use NN N
and CC N
work NN N
absenteeism NN N
, , N
and CC N
led VBD N
to TO N
equal JJ N
improvement NN N
in IN N
disability NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
. . N

It PRP N
seems VBZ N
obvious JJ N
that IN N
encouraging VBG N
information NN N
and CC N
advice NN N
are VBP N
major JJ N
elements NNS N
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
cLBP NN p
. . p

-DOCSTART- -X- O O

The DT N
effects NNS o
of IN N
chewing VBG i
versus NN i
caffeine NN i
on IN N
alertness NN N
, , N
cognitive JJ N
performance NN N
and CC N
cardiac JJ N
autonomic JJ N
activity NN N
during IN N
sleep JJ p
deprivation NN p
. . p

Chewing NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
alleviate VB N
feelings NNS N
of IN N
sleepiness NN N
and CC N
improve VB N
cognitive JJ N
performance NN N
during IN N
the DT N
day NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
effect NN o
of IN N
chewing VBG i
on IN N
alertness NN N
and CC N
cognitive JJ N
performance NN N
across IN N
one CD N
night NN N
without IN N
sleep NN N
as RB N
well RB N
as IN N
the DT N
possible JJ N
mediating JJ N
role NN N
of IN N
cardiac JJ N
autonomic JJ N
activity NN N
. . N

Fourteen NNP p
adults NNS p
participated VBD p
in IN N
a DT N
randomized JJ N
, , N
counterbalanced VBD N
protocol NN N
employing VBG N
a DT N
chewing NN i
, , i
placebo NN i
and CC i
caffeine JJ i
condition NN N
. . N

Participants NNS N
completed VBD N
tasks NNS N
assessing VBG N
psychomotor NN o
vigilance NN o
, , o
tracking VBG o
, , o
grammatical JJ o
reasoning NN o
, , o
alertness NN o
and CC o
sleepiness JJ o
each DT N
hour NN N
across IN N
the DT N
night NN N
. . N

All DT N
participants NNS N
received VBD N
either CC N
placebo NN i
or CC i
caffeine NN i
( ( N
200 CD N
mg NN N
) ) N
, , N
while IN N
the DT N
chewing VBG i
condition NN N
also RB N
chewed VBD i
on IN i
a DT i
tasteless NN i
and CC i
odorless JJ i
substance NN i
for IN N
15 CD N
min NNS N
each DT N
hour NN N
. . N

Heart NNP o
rate NN o
( ( o
HR NNP o
) ) o
, , o
root JJ o
mean JJ o
square NN o
of IN o
the DT o
successive JJ o
differences NNS o
in IN o
R-R NNP o
intervals NNS o
on IN o
the DT o
ECG NNP o
( ( o
RMSSD NNP o
) ) o
, , o
and CC o
preejection NN o
period NN o
( ( o
PEP NNP o
) ) o
were VBD N
simultaneously RB N
recorded VBN N
. . N

Alertness NNP o
and CC o
cognitive JJ o
performance NN o
amongst VBD N
the DT N
chewing VBG N
condition NN N
did VBD N
not RB o
differ VB o
or CC o
were VBD o
in IN o
fact NN o
worse NN o
when WRB N
compared VBN N
with IN N
placebo NN i
. . i

Similarly RB N
, , N
measures NNS N
of IN N
HR NNP o
and CC o
RMSSD NNP o
remained VBD N
the DT N
same JJ o
between IN N
these DT N
two CD N
conditions NNS N
; : N
however RB N
, , N
PEP NNP o
was VBD N
reduced VBN N
in IN N
the DT N
later JJ N
part NN N
of IN N
the DT N
night NN N
in IN N
the DT N
chewing VBG i
condition NN N
compared VBN N
with IN N
a DT N
relative JJ N
increase NN N
for IN N
placebo NN i
. . i

Caffeine NNP i
led VBD N
to TO N
improved VBN o
speed NN o
and CC o
accuracy NN o
on IN o
cognitive JJ o
tasks NNS o
and CC o
increased VBD o
alertness NN o
when WRB N
compared VBN N
with IN N
chewing VBG i
. . i

Relative JJ o
increases NNS o
in IN o
RMSSD NNP o
and CC N
reductions NNS o
in IN o
HR NNP o
were VBD N
demonstrated VBN N
following VBG N
caffeine NN N
; : N
however RB N
, , N
no DT o
change NN o
in IN o
PEP NNP o
was VBD N
seen VBN N
. . N

Strong JJ N
associations NNS N
between IN N
cardiac JJ N
parasympathetic JJ N
activity NN N
and CC N
complex JJ N
cognitive NN N
tasks NNS N
, , N
as RB N
well RB N
as IN N
between IN N
subjective JJ N
alertness NN o
and CC N
simpler NN o
cognitive JJ o
tasks NNS o
, , N
suggest VBP N
a DT N
differential JJ N
process NN N
mediating VBG N
complex JJ N
versus NN N
simple JJ N
cognitive JJ N
performance NN N
during IN N
sleep JJ N
deprivation NN N
. . N

-DOCSTART- -X- O O

Relaxation NN i
and CC i
imagery NN i
and CC i
cognitive-behavioral JJ i
training NN i
reduce VB N
pain NN o
during IN N
cancer NN N
treatment NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

Few NNP N
controlled VBD N
clinical JJ N
trials NNS N
of IN N
psychological JJ N
interventions NNS N
for IN N
cancer NN o
pain NN o
relief NN o
exist NN N
in IN N
spite NN N
of IN N
frequent JJ N
support NN N
for IN N
their PRP$ N
importance NN N
as IN N
adjuncts NNS N
to TO N
medical JJ N
treatment NN N
. . N

This DT N
study NN N
compared VBN N
oral JJ N
mucositis NN N
pain NN N
levels NNS N
in IN N
4 CD p
groups NNS p
of IN p
cancer NN p
patients NNS p
receiving VBG p
bone NN p
marrow NN p
transplants NNS p
( ( p
BMT NNP p
) ) p
: : p
( ( p
1 CD p
) ) p
treatment NN i
as IN i
usual JJ i
control NN i
, , i
( ( i
2 CD i
) ) i
therapist NN i
support NN i
, , i
( ( i
3 CD i
) ) i
relaxation NN i
and CC i
imagery NN i
training NN i
, , i
and CC i
( ( i
4 CD i
) ) i
training NN i
in IN i
a DT i
package NN i
of IN i
cognitive-behavioral JJ i
coping NN i
skills NNS i
which WDT i
included VBD i
relaxation NN i
and CC i
imagery NN i
. . i

A DT N
total NN N
of IN N
94 CD p
patients NNS p
completed VBD p
the DT p
study NN p
which WDT p
involved VBD p
two CD p
training NN p
sessions NNS p
prior RB p
to TO p
treatment NN p
and CC p
twice RB p
a DT p
week NN p
'booster POS p
' POS p
sessions NNS p
during IN p
the DT p
first JJ p
5 CD p
weeks NNS p
of IN p
treatment NN p
. . p

Results NNS N
confirmed VBD N
our PRP$ N
hypothesis NN N
that IN N
patients NNS N
who WP N
received VBD N
either DT N
relaxation NN N
and CC N
imagery VB N
alone RB N
or CC N
patients NNS N
who WP N
received VBD N
the DT N
package NN N
of IN N
cognitive-behavioral JJ N
coping NN N
skills NNS N
would MD N
report VB N
less JJR N
pain NN o
than IN N
patients NNS N
in IN N
the DT N
other JJ N
2 CD N
groups NNS N
. . N

The DT N
hypothesis NN N
that IN N
the DT N
cognitive-behavioral JJ N
skills NNS N
package NN N
would MD N
have VB N
an DT N
additive JJ N
effect NN N
beyond IN N
relaxation NN N
and CC N
imagery NN N
alone RB N
was VBD N
not RB N
confirmed VBN N
. . N

Average JJ o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
report NN o
of IN o
pain NN o
within IN N
the DT N
therapist JJ N
support NN N
group NN N
was VBD N
not RB N
significantly RB N
lower JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.103 CD N
) ) N
nor CC N
significantly RB N
higher JJR N
than IN N
the DT N
training NN N
groups NNS N
. . N

Patient JJ N
reports NNS N
of IN N
relative JJ N
helpfulness NN N
of IN N
the DT N
interventions NNS N
for IN N
managing VBG N
pain NN o
and CC o
nausea NN o
matched VBD N
the DT N
results NNS N
of IN N
VAS NNP N
reports NNS N
. . N

From IN N
these DT N
results NNS N
, , N
we PRP N
conclude VBP N
that DT N
relaxation NN N
and CC N
imagery NN N
training NN N
reduces NNS N
cancer NN o
treatment-related JJ o
pain NN o
; : o
adding VBG N
cognitive-behavioral JJ N
skills NNS N
to TO N
the DT N
relaxation NN N
with IN N
imagery NN N
does VBZ N
not RB N
, , N
on IN N
average NN N
, , N
further JJ N
improve VB N
pain NN o
relief NN o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
inguinal JJ i
approach NN i
, , i
scrotal JJ i
sclerotherapy NN i
and CC N
subinguinal JJ i
antegrade NN i
sclerotherapy NN i
in IN N
varicocele JJ p
treatment NN N
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

We PRP N
compared VBN N
outcome NN N
and CC N
complications NNS N
of IN N
three CD N
simple JJ N
varicocelectomy NN N
techniques NNS N
. . N

Groups NNP p
were VBD p
divided VBN p
according VBG p
to TO p
whether IN p
they PRP p
would MD p
receive VB p
the DT p
Ivanissevich NNP i
technique NN i
( ( p
n JJ p
= NNP p
55 CD p
) ) p
, , p
Tauber NNP i
's POS i
technique NN i
( ( p
n JJ p
= NNP p
51 CD p
) ) p
or CC p
subinguinal JJ i
sclerotherapy NN i
( ( p
n JJ p
= NNP p
49 CD p
) ) p
. . p

Selection NN p
criteria NNS p
were VBD p
: : p
infertility NN p
> VBZ p
1 CD p
year NN p
, , p
subnormal JJ p
semen NNS p
, , p
sonographic JJ p
diameter NN p
of IN p
veins NNS p
> VBP p
3 CD p
mm NN p
and CC p
time NN p
of IN p
regurge NN p
> $ p
2 CD p
s. NN p
Patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
groups NNS N
of IN N
treatment NN N
, , N
with IN N
follow-up JJ N
every DT N
3 CD N
months NNS N
for IN N
1 CD N
year NN N
. . N

Improvement NNP N
was VBD N
only RB N
in IN N
sperm JJ o
count NN o
and CC o
total JJ o
motility NN o
for IN N
all DT N
groups NNS N
. . N

Pregnancy NN o
rates NNS o
were VBD N
20 CD N
, , N
13.73 CD N
and CC N
12.24 CD N
% NN N
, , N
respectively RB N
, , N
with IN N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

Hydrocele NNP o
occurred VBD N
only RB N
in IN N
the DT N
group NN N
which WDT N
received VBD N
the DT N
Ivanissevich NNP N
technique NN N
( ( N
5.5 CD N
% NN N
) ) N
. . N

Tauber NNP N
's POS N
technique NN N
is VBZ N
simple JJ N
; : N
however RB N
, , N
it PRP N
has VBZ N
the DT N
disadvantage NN N
of IN N
multiple JJ o
branching NN o
of IN o
small JJ o
veins NNS o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
chemotherapy NN i
with IN i
chemohormonal JJ i
therapy NN i
as IN N
first-line JJ N
therapy NN N
for IN N
metastatic JJ p
, , p
hormone-sensitive JJ p
breast NN p
cancer NN p
: : p
An DT p
Eastern JJ p
Cooperative NNP p
Oncology NNP p
Group NNP p
study NN p
. . p

PURPOSE NNP N
Although IN N
hormonal JJ N
therapy NN N
represents VBZ N
standard JJ N
therapy NN N
for IN N
metastatic JJ N
hormone-sensitive JJ N
disease NN N
, , N
many JJ N
patients NNS N
receive VBP N
initial JJ N
chemotherapy NN i
because IN N
of IN N
the DT N
location NN N
, , N
bulk NN N
, , N
or CC N
aggressiveness NN N
of IN N
their PRP$ N
disease NN N
. . N

It PRP N
is VBZ N
uncertain JJ N
whether IN N
simultaneous JJ i
hormonal JJ i
therapy NN i
provides VBZ N
additional JJ N
benefit NN N
compared VBN N
with IN N
chemotherapy NN N
alone RB N
. . N

Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
trial NN N
E3186 NNP N
was VBD N
initiated VBN N
to TO N
explore VB N
this DT N
question NN N
. . N

PATIENTS NN N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1988 CD p
and CC p
December NNP p
1992 CD p
, , p
231 CD p
patients NNS p
with IN p
estrogen JJ p
receptor NN p
( ( p
ER NNP p
) ) p
-positive CD p
or CC p
ER-unknown JJ p
metastatic JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil RB i
?CAF NNP i
) ) i
or CC i
chemohormonal JJ i
therapy NN i
( ( i
CAF NNP i
plus CC i
tamoxifen NN i
and CC i
Halotestin NNP i
?fluoxymesterone NN i
; : i
Pharmacia-Upjohn NNP i
, , i
Kalamazoo NNP i
, , i
MI NNP i
?CAFTH NNP i
) ) i
as IN i
front-line JJ i
therapy NN i
for IN i
metastatic JJ N
breast NN N
cancer NN N
. . N

Patients NNS N
who WP N
experienced VBD N
a DT N
complete JJ N
response NN N
to TO N
induction NN N
therapy NN N
either CC N
received VBD N
or CC N
did VBD N
not RB N
receive JJ N
maintenance NN N
cyclophosphamide NN N
, , N
methotrexate NN N
, , N
fluorouracil NN N
, , N
prednisone NN N
, , N
and CC N
TH NNP N
as IN N
a DT N
secondary JJ N
randomization NN N
. . N

RESULTS VB N
The DT N
response NN o
rates NNS o
( ( o
complete JJ o
response NN o
and CC o
partial JJ o
response NN o
) ) o
of IN o
patients NNS N
who WP N
received VBD N
CAF NNP N
and CC N
CAFTH NNP N
were VBD N
similar JJ N
( ( N
69.2 CD N
% NN N
v JJ N
68.9 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
=.99 NNP o
) ) o
. . o

Time NN o
to TO o
treatment NN o
failure NN o
( ( o
TTF NNP o
) ) o
was VBD o
slightly RB N
longer JJR N
for IN N
patients NNS N
who WP N
received VBD N
chemohormonal JJ N
therapy NN N
compared VBN N
with IN N
chemotherapy NN N
alone RB N
patients NNS N
( ( N
13.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.087 NNP N
) ) N
, , N
and CC N
TTF NNP o
was VBD o
significantly RB N
longer RBR N
in IN N
ER-positive JJ N
compared VBN N
with IN N
ER-negative JJ N
patients NNS N
( ( N
17.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.048 NNP N
) ) N
. . N

However RB N
, , N
ER NNP N
status NN N
had VBD N
no DT N
effect NN N
on IN N
overall JJ o
survival NN o
( ( o
30.0 CD o
months NNS N
for IN N
CAF NNP N
v FW N
29.3 CD N
months NNS N
for IN N
CAFTH NNP N
) ) N
. . N

CONCLUSION NNP N
In IN N
patients NNS N
with IN N
potentially RB N
hormone-sensitive JJ N
metastatic JJ N
breast NN N
cancer NN i
, , i
chemohormonal JJ i
therapy NN i
prolongs NNS i
TTF NNP N
for IN N
ER-positive JJ N
patients NNS N
without IN N
improving VBG N
overall JJ N
survival NN N
. . N

-DOCSTART- -X- O O

Digestive JJ i
enzyme NN i
supplementation NN i
for IN N
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

To TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
digestive JJ i
enzyme NN i
supplement NN i
in IN N
improving VBG N
expressive JJ o
language NN o
, , o
behaviour NN o
and CC o
other JJ o
symptoms NNS o
in IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

Randomized VBN N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
using VBG N
crossover NN N
design NN N
over IN N
6 CD N
months NNS N
for IN N
43 CD p
children NNS p
, , p
aged VBN p
3-8 CD p
years NNS p
. . p

Outcome NNP N
measurement NN N
tools NNS N
included VBD N
monthly JJ N
Global NNP o
Behaviour NNP o
Rating NNP o
Scales NNP o
, , o
Additional NNP o
Rating NNP o
Scales NNP o
of IN o
other JJ o
symptoms NNS o
by IN o
parents NNS o
and CC o
therapists NNS o
, , N
and CC N
monthly JJ o
completion NN o
of IN o
the DT o
Rescorla NNP o
Language NNP o
Development NNP o
Survey NNP o
. . o

Compared VBN N
with IN N
placebo NN i
, , N
treatment NN N
with IN N
enzyme NN i
was VBD N
not RB N
associated VBN N
with IN N
clinically RB N
significant JJ o
improvement NN o
in IN o
behaviour NN o
, , o
food NN o
variety NN o
, , o
gastrointestinal JJ o
symptoms NNS o
, , o
sleep JJ o
quality NN o
, , o
engagement NN o
with IN o
therapist NN o
, , o
or CC o
the DT o
Language NNP o
Development NNP o
Survey NNP o
Vocabulary NNP o
or CC o
Sentence NNP o
Complexity NNP o
Scores NNP o
. . o

A NNP N
small JJ N
statistically RB N
significant JJ o
improvement NN o
on IN N
enzyme NN N
therapy NN N
was VBD N
seen VBN N
for IN N
the DT N
food NN N
variety NN N
scores NNS N
. . N

No DT N
clinically RB N
significant JJ N
effect NN N
improvement NN N
of IN N
autism NN o
symptoms NNS o
with IN N
enzyme NN N
use NN N
was VBD N
shown VBN N
with IN N
this DT N
trial NN N
, , N
however RB N
, , N
possible JJ N
effects NNS N
on IN N
improvement NN o
in IN o
food NN o
variety NN o
warrants NNS N
further RBR N
detailed JJ N
investigation NN N
. . N

-DOCSTART- -X- O O

The DT N
adrenocorticotrophic JJ i
hormone NN i
( ( i
4-9 JJ i
) ) i
analog NN i
ORG IN i
2766 CD i
benefits NNS N
autistic JJ p
children NNS p
: : p
report NN N
on IN N
a DT N
second JJ N
controlled JJ N
clinical JJ N
trial NN N
. . N

In IN N
a DT N
second JJ N
controlled VBN N
crossover NN N
trial NN N
, , N
20 CD p
autistic JJ p
children NNS p
received VBD p
40 CD i
mg/day NN i
of IN i
the DT i
neuropeptide NN i
ORG NNP i
2766 CD i
, , i
a DT i
synthetic JJ i
analog NN i
of IN i
ACTH NNP i
( ( i
4-9 JJ i
) ) i
, , p
for IN p
8 CD p
weeks NNS p
. . p

Parents NNS o
' POS o
checklist NN o
ratings NNS o
( ( o
ABC NNP o
) ) o
as RB N
well RB N
as IN N
clinicians NNS o
' POS o
ratings NNS o
( ( o
CGI NNP o
) ) o
pointed VBD N
to TO N
significant JJ N
improvements NNS N
after IN N
the DT N
course NN N
of IN N
treatment NN N
; : N
improvements NNS N
were VBD N
clearest VBN N
on IN N
the DT N
ABC NNP o
social JJ o
withdrawal NN o
subscale NN o
. . o

The DT N
analysis NN N
of IN N
individual JJ N
target NN N
symptoms NNS N
and CC N
the DT N
parents NNS N
' POS N
treatment NN N
preferences NNS N
substantiated VBD N
the DT N
beneficial JJ N
effects NNS N
of IN N
ORG NNP i
2766 CD i
. . i

In IN N
an DT N
ethologically RB N
analyzed JJ N
playroom NN N
session NN N
, , N
ORG NNP N
2766 CD N
treatment NN N
was VBD N
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
the DT N
children NNS o
's POS o
play NN o
behavior NN o
and CC N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
social JJ o
interaction NN o
between IN o
child NN o
and CC o
experimenter NN o
. . o

Gaze NNP o
coordination NN o
between IN N
child NN N
and CC N
experimenter NN N
also RB N
was VBD N
improved VBN N
. . N

-DOCSTART- -X- O O

Disopyramide-pyridostigmine JJ i
interaction NN N
: : N
selective JJ N
reversal NN N
of IN N
anticholinergic NN N
symptoms NNS N
with IN N
preservation NN N
of IN N
antiarrhythmic JJ N
effect NN N
. . N

This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo FW i
crossover NN N
study NN N
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
cholinesterase NN i
inhibitor NN i
-- : i
slow-release JJ i
pyridostigmine NN i
( ( N
180 CD N
mg NNS N
orally RB N
every DT N
12 CD N
hours NNS N
) ) N
-- : N
on IN N
the DT N
anticholinergic NN o
and CC o
antiarrhythmic JJ o
properties NNS o
of IN N
disopyramide NN i
. . i

Quantitative JJ N
side NN N
effects NNS N
questionnaire VBP N
scores NNS N
were VBD N
used VBN N
to TO N
guide VB N
disopyramide JJ i
administration NN N
in IN N
20 CD p
men NNS p
with IN p
ventricular JJ p
tachycardia NN p
. . p

Disopyramide NNP i
was VBD N
given VBN N
to TO N
each DT N
patient NN p
both DT p
with IN p
placebo NN i
and CC p
with IN p
active JJ p
pyridostigmine NN i
. . i

The DT N
maximal JJ N
administered VBD N
dose NN N
for IN N
each DT N
regimen NN N
was VBD N
used VBN N
in IN N
conjunction NN N
with IN N
corresponding JJ N
questionnaire NN N
scores NNS N
to TO N
calculate VB N
an DT N
index NN N
or CC N
estimate NN N
of IN N
the DT N
maximal JJ o
tolerable JJ o
dose NN o
of IN N
disopyramide NN i
. . i

Additional JJ N
evaluations NNS N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
each DT N
maximal NN N
administered VBD N
dose JJ N
regimen NNS N
included VBD N
tear JJ o
and CC o
saliva JJ o
quantitation NN o
, , o
24 CD o
hour NN o
electrocardiogram NN o
( ( o
ECG NNP o
) ) o
, , o
exercise VBP o
testing VBG o
and CC o
programmed VBD o
ventricular JJ o
stimulation NN o
. . o

Results NNS N
showed VBD N
that IN N
the DT N
maximal NN N
administered VBD N
dose NN N
of IN N
disopyramide NN i
was VBD N
greater JJR N
with IN N
active JJ N
pyridostigmine NN i
than IN N
with IN N
placebo NN N
: : N
295 CD N
+/- JJ N
75 CD N
versus NN N
245 CD N
+/- JJ N
100 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

The DT N
calculated JJ N
maximal NN o
tolerable JJ o
dose NN o
was VBD N
substantially RB N
greater JJR N
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN i
: : i
355 CD N
+/- JJ N
90 CD N
versus NN N
260 CD N
+/- JJ N
115 CD N
mg NN N
every DT N
6 CD N
hours NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Maximal JJ o
side NN o
effects NNS o
questionnaire NN o
scores NNS o
also RB N
reflected VBD N
decreased JJ N
anticholinergic JJ o
activity NN o
in IN N
the DT N
presence NN N
of IN N
pyridostigmine NN i
compared VBN N
with IN N
placebo NN i
: : i
101.9 CD N
+/- JJ N
2.2 CD N
versus NN N
104.6 CD N
+/- JJ N
2.8 CD N
, , N
respectively RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
. . N

Baseline NNP N
tear NN N
and CC N
saliva JJ N
production NN N
was VBD N
significantly RB N
reduced VBN N
during IN N
disopyramide JJ N
therapy NN N
, , N
but CC N
was VBD N
restored VBN N
toward IN N
normal JJ N
by IN N
the DT N
addition NN N
of IN N
pyridostigmine NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

MF101 NNP i
, , i
a DT i
selective JJ i
estrogen NN i
receptor NN i
beta NN N
modulator NN N
for IN N
the DT N
treatment NN N
of IN N
menopausal NN N
hot JJ N
flushes NNS N
: : N
a DT N
phase NN N
II NNP N
clinical JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
optimal JJ N
dose NN N
, , N
safety NN N
, , N
and CC N
efficacy NN N
of IN N
an DT N
estrogen NN i
receptor NN i
beta NN i
selective JJ i
Chinese NNP i
herbal NN i
extract NN i
, , i
menopausal JJ i
formula NN i
101 CD i
( ( N
MF101 NNP N
) ) N
, , N
for IN N
treating VBG N
hot JJ N
flushes NNS N
. . N

METHODS NNP N
A NNP N
randomized NN p
, , p
blinded VBD p
trial NN p
in IN p
217 CD p
postmenopausal JJ p
women NNS p
with IN p
hot JJ p
flushes NNS p
randomized VBD p
to TO p
5 CD p
or CC p
10 CD p
g/day NN p
of IN p
MF101 NNP i
or CC i
placebo NN i
for IN p
12 CD p
weeks NNS p
. . p

RESULTS VB N
The DT N
effects NNS N
of IN N
5 CD N
g/day NN N
of IN N
MF101 NNP N
did VBD N
not RB N
differ VB N
from IN N
those DT N
of IN N
placebo NN i
. . i

After IN N
12 CD N
weeks NNS N
, , N
the DT N
mean JJ o
percent NN o
decrease NN o
in IN o
frequency NN o
of IN o
hot JJ o
flushes NNS o
in IN N
the DT N
10 CD N
g/day NN N
group NN N
was VBD N
12.9 CD N
% NN N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
, , N
the DT N
median JJ N
percent NN N
decrease NN N
was VBD N
11.7 CD N
% NN N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
and CC N
the DT N
proportion NN o
of IN o
women NNS o
with IN o
at IN o
least JJS o
a DT o
50 CD o
% NN o
reduction NN o
in IN o
hot JJ o
flushes NNS o
was VBD N
16.2 CD N
% NN N
greater JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
10 CD N
g/day NN N
of IN N
MF101 NNP i
reduces VBZ N
the DT N
frequency NN N
of IN N
hot JJ N
flushes NNS N
. . N

Trials NNS N
with IN N
higher JJR N
doses NNS N
are VBP N
planned VBN N
. . N

-DOCSTART- -X- O O

Maintenance NN N
of IN N
response NN N
following VBG N
stabilization NN N
of IN N
mixed JJ N
index NN N
episodes NNS N
with IN N
olanzapine JJ i
monotherapy NN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
bipolar JJ p
1 CD p
disorder NN p
. . p

BACKGROUND NNP N
In IN N
a DT N
population NN N
of IN N
patients NNS p
with IN p
manic JJ p
and CC p
mixed JJ p
mood NN p
episodes NNS p
, , N
olanzapine NN i
has VBZ N
proven VBN N
effective JJ N
in IN N
maintaining VBG N
response NN N
, , N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

Whether IN N
this DT N
is VBZ N
true JJ N
for IN N
the DT N
subpopulation NN N
of IN N
patients NNS N
with IN N
a DT N
mixed JJ N
index NN N
episode NN N
is VBZ N
not RB N
known VBN N
. . N

METHODS NNP N
Post-hoc JJ N
analyses NNS N
were VBD N
conducted VBN N
on IN N
data NNS N
from IN N
patients NNS p
presenting VBG p
with IN p
a DT p
mixed JJ p
index NN p
episode NN p
who WP p
were VBD p
enrolled VBN p
in IN p
a DT p
larger JJR p
double-blind NN p
, , p
placebo-controlled JJ i
trial NN p
. . p

Patients NNS p
who WP p
met VBD p
remission NN p
criteria NNS p
at IN p
2 CD p
consecutive JJ p
weekly JJ p
visits NNS p
during IN p
6 CD p
to TO p
12 CD p
weeks NNS p
of IN p
open-label JJ p
olanzapine JJ i
treatment NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
olanzapine VB i
or CC N
placebo VB i
treatment NN N
for IN N
48 CD N
weeks NNS N
. . N

The DT N
incidence NN N
of IN N
and CC N
time NN N
to TO N
symptomatic JJ o
relapse NN o
were VBD N
calculated VBN N
for IN N
any DT N
mood NN N
episode NN N
, , N
and CC N
for IN N
depressive JJ N
, , N
manic JJ N
, , N
hypo-manic JJ N
, , N
and CC N
mixed JJ N
mood NN N
episodes NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
121 CD p
of IN p
304 CD p
patients NNS p
( ( N
39.8 CD N
% NN N
) ) N
met VBD N
criteria NNS N
for IN N
symptomatic JJ o
remission NN o
in IN N
the DT N
open-label JJ N
treatment NN N
phase NN N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
olanzapine VB i
( ( N
n=76 NN N
) ) N
or CC N
placebo NN N
( ( N
n=45 JJ N
) ) N
. . N

Compared VBN N
to TO N
the DT N
placebo NN i
group NN N
, , N
the DT N
olanzapine NN i
group NN N
had VBD N
a DT N
lower JJR N
incidence NN N
of IN N
( ( N
59.2 CD N
% NN N
versus IN N
91.1 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
longer JJR N
time NN N
to TO N
( ( N
46 CD N
versus NN N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
symptomatic JJ o
relapse NN o
of IN N
any DT N
kind NN N
. . N

Olanzapine-treated JJ i
patients NNS N
also RB N
experienced VBD N
longer JJR N
time NN o
to TO o
depressive VB o
symptomatic JJ o
relapse NN o
( ( N
85 CD N
versus NN N
22 CD N
days NNS N
, , N
p=0.001 NN N
) ) N
and CC N
manic JJ o
symptomatic JJ o
relapse NN o
( ( N
too RB N
few JJ N
relapses NNS N
to TO N
calculate VB N
versus NN N
42 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
than IN N
did VBD N
placebo-treated JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
placebo NN i
, , i
olanzapine JJ i
treatment NN N
was VBD N
associated VBN N
with IN N
longer JJR N
maintenance NN o
of IN o
response NN o
in IN N
patients NNS p
presenting VBG p
with IN p
a DT p
mixed JJ p
index NN p
episode NN p
of IN p
bipolar NN p
I PRP p
disorder VBP p
. . p

-DOCSTART- -X- O O

Mapping VBG N
from IN N
disease-specific JJ N
measures NNS N
to TO N
health-state JJ N
utility NN N
values NNS N
in IN N
individuals NNS p
with IN p
migraine NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
empirical JJ N
algorithms NN N
that WDT N
estimate VBP N
health-state JJ N
utility NN N
values NNS N
from IN N
disease-specific JJ N
quality-of-life JJ N
scores NNS N
in IN N
individuals NNS p
with IN p
migraine NN p
. . p

METHODS NNP N
Data NNP N
from IN N
a DT N
cross-sectional JJ N
, , N
multicountry NN N
study NN N
were VBD N
used VBN N
. . N

Individuals NNS p
with IN p
episodic NN p
and CC p
chronic JJ p
migraine NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
training NN N
or CC N
validation NN N
samples NNS N
. . N

Spearman NNP o
's POS o
correlation NN o
coefficients NNS o
between IN N
paired VBN N
EuroQol NNP i
five-dimensional JJ i
( ( i
EQ-5D NNP i
) ) i
questionnaire NN i
utility NN N
values NNS N
and CC N
both DT N
Headache NNP o
Impact NNP o
Test NNP o
( ( o
HIT-6 NNP o
) ) o
scores NNS N
and CC N
Migraine-Specific NNP o
Quality-of-Life NNP o
Questionnaire NNP o
version NN o
2.1 CD o
( ( o
MSQ NNP o
) ) o
domain NN o
scores NNS o
( ( N
role NN N
restrictive NN N
, , N
role NN N
preventive NN N
, , N
and CC N
emotional JJ N
function NN N
) ) N
were VBD N
examined VBN N
. . N

Regression NN N
models NNS N
were VBD N
constructed VBN N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
from IN N
the DT N
HIT-6 NNP N
score NN N
or CC N
the DT N
MSQ NNP N
domain NN N
scores NNS N
. . N

Preferred VBN N
algorithms NNS N
were VBD N
confirmed VBN N
in IN N
the DT N
validation NN N
samples NNS N
. . N

RESULTS NNP N
In IN N
episodic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP i
and CC N
MSQ NNP i
algorithms VBP i
explained VBD N
22 CD N
% NN N
and CC N
25 CD N
% NN N
of IN N
the DT N
variance NN N
( ( N
R NNP N
( ( N
2 CD N
) ) N
) ) N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
of IN N
0.30 CD N
) ) N
. . N

In IN N
chronic JJ N
migraine NN N
, , N
the DT N
preferred JJ N
HIT-6 NNP i
and CC i
MSQ NNP i
algorithms VBP i
explained VBD N
36 CD N
% NN N
and CC N
45 CD N
% NN N
of IN N
the DT N
variance NN N
in IN N
the DT N
training NN N
samples NNS N
, , N
respectively RB N
, , N
and CC N
had VBD N
similar JJ N
prediction NN N
errors NNS N
( ( N
root JJ N
mean NN N
square JJ N
errors NNS N
0.31 CD N
and CC N
0.29 CD N
) ) N
. . N

In IN N
episodic JJ N
and CC N
chronic JJ N
migraine NN N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
the DT N
mean NN o
observed VBD o
and CC o
the DT o
mean NN o
estimated VBD o
EQ-5D NNP o
questionnaire NN o
utility NN o
values NNS o
for IN N
the DT N
preferred JJ N
HIT-6 NNP i
and CC N
MSQ NNP i
algorithms NN N
in IN N
the DT N
validation NN N
samples NNS N
. . N

CONCLUSIONS VB N
The DT N
relationship NN N
between IN N
the DT N
EQ-5D NNP N
questionnaire NN N
and CC N
the DT N
HIT-6 NNP N
or CC N
the DT N
MSQ NNP N
is VBZ N
adequate JJ N
to TO N
use VB N
regression NN N
equations NNS N
to TO N
estimate VB N
EQ-5D NNP N
questionnaire NN N
utility NN N
values NNS N
. . N

The DT N
preferred JJ N
HIT-6 NNP i
and CC i
MSQ NNP i
algorithms NN N
will MD N
be VB N
useful JJ N
in IN N
estimating VBG N
health-state JJ N
utilities NNS N
in IN N
migraine NN N
trials NNS N
in IN N
which WDT N
no DT N
preference-based JJ N
measure NN N
is VBZ N
present JJ N
. . N

-DOCSTART- -X- O O

Sustained VBN N
oral JJ o
health NN o
improvement NN o
and CC N
use NN N
of IN N
toothbrushes NNS i
and CC i
dentifrice NN i
by IN N
previous JJ p
users NNS p
of IN p
traditional JJ p
materials NNS p
in IN p
a DT p
rural JJ p
population NN p
in IN p
Andhra NNP p
Pradesh NNP p
, , p
India NNP p
. . p

AIM NNP N
To TO N
follow-up NN N
, , N
one CD N
year NN N
later RB N
, , N
a DT N
double-blind NN N
, , N
randomised VBN N
study NN N
, , N
which WDT N
investigated VBD N
the DT N
effect NN o
of IN N
regular JJ i
brushing NN i
with IN i
dentifrices NNS i
on IN N
the DT N
oral JJ p
health NN p
of IN p
an DT p
economically RB p
disadvantaged JJ p
rural JJ p
population NN p
in IN p
Andhra NNP p
Pradesh NNP p
, , p
India NNP p
who WP p
were VBD p
primarily RB p
users NNS p
of IN p
traditional JJ p
materials NNS p
. . p

SUBJECTS NNP N
150 CD p
of IN p
the DT p
original JJ p
study NN p
population NN p
. . p

METHOD NNP N
Examination NNP N
to TO N
determine VB N
whether IN N
the DT N
improvements NNS o
in IN o
oral JJ o
health NN o
status NN o
and CC o
oral JJ o
health NN o
behaviour NN o
( ( N
use NN N
of IN N
toothbrush NN i
and CC i
dentifrice NN i
) ) i
, , N
being VBG N
unsupported JJ N
, , N
had VBD N
been VBN N
sustained VBN N
since IN N
completion NN N
of IN N
the DT N
original JJ N
study NN N
. . N

RESULTS NNP N
Data NNP N
analysis NN N
showed VBD N
sustained VBN N
, , N
statistically RB o
significant JJ o
improvements NNS o
in IN o
gingival JJ o
health NN o
as IN o
measured VBN o
by IN o
gingival NN o
bleeding NN o
and CC o
plaque NN o
indices NNS o
( ( o
GBI NNP o
and CC o
PI NNP o
) ) o
comparing VBG N
users NNS N
and CC N
non-users NNS N
of IN N
toothbrushes NNS N
and CC N
dentifrice NN N
in IN N
the DT N
original JJ N
study NN N
( ( N
PI NNP N
: : N
p NN N
= VBZ N
0.04 CD N
; : N
GBI NNP N
: : N
p NN N
= VBZ N
0.03 CD N
) ) N
and CC N
sustained VBN o
use NN o
of IN o
toothbrushes NNS o
and CC o
dentifrice NN o
by IN N
60 CD N
% NN N
of IN N
the DT N
subjects NNS N
at IN N
follow-up JJ N
one CD N
year NN N
later RB N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
a DT N
beneficial JJ o
effect NN o
on IN o
oral JJ o
hygiene NN o
indices NNS N
following VBG N
the DT N
introduction NN i
of IN i
toothbrushes NNS i
and CC i
dentifrices NNS i
to TO N
a DT N
community NN N
using VBG N
traditional JJ N
oral JJ N
hygiene NN N
materials NNS N
and CC N
sustainability NN N
of IN N
use NN N
of IN N
these DT N
materials NNS N
with IN N
motivation NN N
and CC N
support NN N
. . N

It PRP N
may MD N
therefore RB N
be VB N
concluded VBN N
that IN N
it PRP N
is VBZ N
feasible JJ N
to TO N
achieve VB N
significant JJ N
use NN N
of IN N
conventional JJ N
toothbrushes NNS N
and CC N
toothpastes NNS N
, , N
with IN N
consequent JJ N
major JJ N
and CC N
sustained JJ N
improvements NNS N
in IN N
plaque NN N
control NN N
and CC N
gingival JJ N
health NN N
in IN N
a DT N
disadvantaged JJ N
population NN N
hitherto NN N
often RB N
considered VBN N
as IN N
not RB N
amenable JJ N
to TO N
conventional JJ N
oral JJ N
hygiene NN N
for IN N
cultural JJ N
or CC N
economic JJ N
reasons NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
systemic JJ N
nitric JJ i
oxide IN i
synthase JJ i
inhibition NN N
on IN N
postexercise NN p
hypotension NN p
in IN p
humans NNS p
. . p

An DT N
acute JJ N
bout NN N
of IN N
aerobic JJ N
exercise NN N
results NNS N
in IN N
a DT N
reduced JJ N
blood NN o
pressure NN o
that WDT N
lasts VBZ N
several JJ N
hours NNS N
. . N

Animal NNP N
studies NNS N
suggest VBP N
this DT N
response NN N
is VBZ N
mediated VBN N
by IN N
increased JJ N
production NN N
of IN N
nitric JJ N
oxide NN N
. . N

We PRP N
tested VBD N
the DT N
extent NN N
to TO N
which WDT N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
[ NNP N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-L-arginine NN N
( ( N
L-NMMA NNP N
) ) N
] NN N
can MD N
reverse VB N
the DT N
drop NN N
in IN N
blood NN o
pressure NN o
that WDT p
occurs VBZ p
after IN p
exercise NN p
in IN p
humans NNS p
. . p

Eight NNP p
healthy JJ p
subjects NNS p
underwent JJ N
parallel JJ N
experiments NNS N
on IN N
2 CD N
separate JJ N
days NNS N
. . N

The DT N
order NN N
of IN N
the DT N
experiments NNS N
was VBD N
randomized VBN N
between IN N
sham NN N
( ( i
60 CD i
min NN i
of IN i
seated JJ i
upright JJ i
rest NN i
) ) i
and CC N
exercise NN N
( ( i
60 CD i
min NN i
of IN i
upright JJ i
cycling NN i
at IN i
60 CD i
% NN i
peak NN i
aerobic JJ i
capacity NN i
) ) i
. . N

After IN N
both DT N
sham NN N
and CC N
exercise NN N
, , N
subjects VBZ N
received VBN N
, , N
in IN N
sequence NN N
, , N
systemic JJ N
alpha-adrenergic JJ N
blockade NN N
( ( N
phentolamine NN N
) ) N
and CC N
L-NMMA NNP N
. . N

Phentolamine NNP N
was VBD N
given VBN N
first RB N
to TO N
isolate VB N
the DT N
contribution NN N
of IN N
nitric JJ N
oxide NN N
to TO N
postexercise VB N
hypotension NN N
by IN N
preventing VBG N
reflex JJ N
changes NNS N
in IN N
sympathetic JJ N
tone NN N
that WDT N
result NN N
from IN N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
and CC N
to TO N
control VB N
for IN N
alterations NNS N
in IN N
resting VBG N
sympathetic JJ N
activity NN N
after IN N
exercise NN N
. . N

During IN N
each DT N
condition NN N
, , N
systemic JJ o
and CC o
regional JJ o
hemodynamics NNS o
were VBD N
measured VBN N
. . N

Throughout IN N
the DT N
study NN N
, , N
arterial JJ o
pressure NN o
and CC o
vascular JJ o
resistances NNS o
remained VBD N
lower JJR N
postexercise NN N
vs. FW N
postsham NN N
despite IN N
nitric JJ o
oxide JJ o
synthase NN o
inhibition NN N
( ( N
e.g. JJ N
, , N
mean JJ o
arterial JJ o
pressure NN o
after IN o
L-NMMA NNP o
was VBD N
108.0+/-2.4 JJ N
mmHg NN N
postsham NN N
vs. FW N
102.1+/-3.3 JJ N
mmHg NN N
postexercise NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Thus VB N
it PRP N
does VBZ N
not RB N
appear VB N
that IN N
postexercise NN o
hypotension NN o
is VBZ N
dependent JJ N
on IN N
increased JJ N
production NN o
of IN o
nitric JJ o
oxide NN o
in IN N
humans NNS p
. . p

-DOCSTART- -X- O O

Biomarkers NNS N
of IN N
dietary JJ i
exposure NN i
are VBP N
associated VBN N
with IN N
lower JJR N
risk NN N
of IN N
breast NN p
fibroadenomas NN p
in IN p
Chinese JJ p
women NNS p
. . p

Fibroadenomas NNP N
are VBP N
the DT N
most RBS N
common JJ N
benign NN N
breast JJ N
condition NN N
among IN N
women NNS N
and CC N
account NN N
for IN N
up IN N
to TO N
50 CD N
% NN N
of IN N
all DT N
breast NN N
biopsies NNS N
being VBG N
performed VBN N
. . N

Although IN N
considered VBN N
a DT N
benign JJ N
condition NN N
, , N
fibroadenomas JJ N
utilize VBP N
substantial JJ N
resources NNS N
for IN N
management NN N
and CC N
treatment NN N
to TO N
rule VB N
out RP N
potential JJ N
malignancies NNS N
. . N

Dietary JJ i
factors NNS i
may MD N
influence VB N
benign JJ N
fibrocystic JJ N
breast NN N
conditions NNS N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
of IN N
their PRP$ N
association NN N
with IN N
fibroadenomas NN N
. . N

We PRP N
examined VBD N
possible JJ N
associations NNS N
between IN N
a DT N
broad JJ N
spectrum NN N
of IN N
circulating VBG N
biomarkers NNS o
of IN o
dietary JJ o
intake NN o
and CC N
risk NN N
of IN N
fibroadenomas NN N
. . N

Participants NNS p
were VBD p
women NNS p
in IN p
a DT p
breast NN i
self-examination NN i
trial NN p
in IN p
Shanghai NNP p
, , p
China NNP p
who WP p
were VBD p
diagnosed VBN p
with IN p
fibroadenomas NN p
( ( p
n JJ p
= NNP p
258 CD p
) ) p
and CC p
1035 CD p
controls NNS p
. . p

Conditional NNP o
logistic JJ o
regression NN o
was VBD N
used VBN N
to TO N
estimate VB o
adjusted VBN o
odds NNS o
ratios NNS o
( ( o
OR NNP o
) ) o
and CC N
95 CD o
% NN o
CI NNP o
. . o

Isoflavone NNP o
concentrations NNS o
were VBD N
inversely RB N
associated VBN N
with IN N
risk NN o
of IN o
fibroadenomas NN o
. . o

Adjusted VBN o
OR NNP o
( ( o
95 CD o
% NN o
CI NNP o
) ) o
for IN N
the DT N
highest JJS N
versus NN N
the DT N
lowest JJS N
quartile NN N
of IN N
plasma JJ N
concentration NN N
were VBD N
0.36 CD N
( ( N
0.16-0.79 CD N
; : N
P-trend NNP N
< NNP N
0.001 CD N
) ) N
for IN N
daidzein NN i
and CC N
0.39 CD N
( ( N
0.19-0.84 CD N
; : N
P-trend NNP N
= NNP N
0.010 CD N
) ) N
for IN N
genistein NN i
. . i

We PRP N
also RB N
observed VBD N
inverse JJ o
associations NNS o
between IN N
higher JJR N
percentages NNS o
of IN o
the DT o
RBC NNP o
( ( o
n-3 JJ o
) ) o
fatty JJ o
acids NNS o
, , o
eicosapentaenoic JJ o
acid NN o
( ( o
EPA NNP o
) ) o
( ( N
[ $ N
0.38 CD N
( ( N
0.19-0.77 JJ N
) ) N
; : N
P-trend JJ N
= NN N
0.007 CD N
] NN N
and CC N
docosapentaenoic NN o
acid NN o
( ( o
DPA NNP o
) ) o
[ VBZ N
0.32 CD N
( ( N
0.15-0.70 JJ N
) ) N
; : N
P-trend JJ N
= NN N
0.024 CD N
] NN N
, , N
and CC N
fibroadenoma NN N
risk NN N
. . N

Circulating VBG N
concentrations NNS N
of IN N
carotenoids NNS o
, , o
vitamin FW o
C NNP o
, , o
retinol NN o
, , o
and CC o
ferritin NNS o
were VBD N
not RB N
associated VBN N
with IN N
fibroadenoma NN N
risk NN N
. . N

The DT N
inverse JJ o
associations NNS o
between IN N
plasma NN o
isoflavone NN o
concentrations NNS o
and CC N
RBC NNP o
EPA NNP o
and CC o
DPA NNP o
and CC N
fibroadenoma NN o
risk NN o
suggest VBP N
that IN N
higher JJR N
intakes NNS N
of IN N
soy JJ i
foods NNS i
and CC i
fatty JJ i
fish NN i
may MD N
lower VB N
the DT N
risk NN o
of IN o
fibroadenomas NN o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
effectiveness NN o
of IN N
oral JJ N
diazepam NN i
and CC i
midazolam NN i
for IN N
the DT N
sedation NN o
of IN p
autistic JJ p
patients NNS p
during IN p
dental JJ p
treatment NN p
. . p

PURPOSE VB N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effectiveness NN o
of IN N
oral JJ N
diazepam NN i
and CC i
midazolam NN i
in IN N
sedating VBG p
autistic JJ p
patients NNS p
during IN p
dental JJ p
treatment NN p
. . p

METHODS NNP N
The DT N
treatment NN N
regimen NNS N
consisted VBD N
of IN N
nitrous JJ i
oxide/oxygen NN i
inhalation NN i
in IN N
conjunction NN N
with IN N
oral JJ i
administration NN i
of IN i
either DT i
diazepam NN i
0.3 CD i
mg/kg NN i
or CC i
midazolam VB i
0.5 CD i
mg/kg NN i
in IN N
a DT N
cross-over JJ N
design NN N
study NN N
of IN N
13 CD p
subjects NNS p
aged VBD p
5.8 CD p
to TO p
14.7 CD p
years NNS p
. . p

A DT N
drug NN N
was VBD N
classified VBN N
as IN N
being VBG N
effective JJ o
when WRB N
over RB N
70 CD N
% NN N
of IN N
the DT N
patients NNS N
taking VBG N
the DT N
drug NN N
were VBD N
judged VBN N
as IN N
success NN N
in IN N
all DT N
3 CD N
behavioral JJ N
criteria NNS N
: : N
( ( N
1 CD N
) ) N
sleeping NN N
; : N
( ( N
2 CD N
) ) N
body NN N
movement NN N
; : N
and CC N
( ( N
3 CD N
) ) N
crying NN N
behaviors NNS N
. . N

The DT N
study NN N
was VBD N
observed VBN N
by IN N
an DT N
independent JJ N
clinician NN N
with IN N
an DT N
intraexaminer NN N
reliability NN N
of IN N
88 CD N
% NN N
. . N

RESULTS NNP N
For IN N
sleeping VBG o
behavior NN o
, , N
midazolam NN N
was VBD N
found VBN N
to TO N
be VB N
significantly RB o
more RBR o
effective JJ o
than IN N
diazepam RB N
as IN N
the DT N
duration NN N
of IN N
stimulation NN N
increased VBN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
the DT N
movement NN o
and CC o
crying NN o
behaviors NNS o
, , N
midazolam NN N
also RB N
proved VBD N
to TO N
be VB N
significantly RB o
more RBR o
effective JJ o
from IN N
the DT N
start NN N
of IN N
treatment NN N
through IN N
the DT N
35- JJ N
and CC N
40-min JJ N
markers NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
the DT N
remainder NN o
of IN o
treatment NN o
, , N
however RB N
, , N
there EX N
was VBD N
no DT o
statistically RB o
significant JJ o
difference NN o
in IN N
these DT N
behaviors NNS N
between IN N
the DT N
trials NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

Diazepam NNP N
and CC N
midazolam NNS N
were VBD N
rated VBN N
as IN N
77 CD N
% NN N
and CC N
100 CD N
% NN N
successful JJ o
, , N
according VBG N
to TO N
the DT N
overall JJ N
behavior NN o
evaluation NN o
criteria NNS N
( ( N
P=.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Both NNP N
diazepam NN N
and CC N
midazolam NN N
were VBD N
shown VBN N
to TO N
be VB N
effective JJ o
sedative JJ N
agents NNS N
, , N
successfully RB N
and CC N
safely RB N
used VBN N
to TO N
sedate VB N
autistic JJ p
patients NNS p
for IN N
dental JJ N
treatment NN N
. . N

Midazolam NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
diazepam NN N
in IN N
those DT N
portions NNS N
of IN N
the DT N
procedure NN N
with IN N
increased JJ N
stimulation NN N
. . N

-DOCSTART- -X- O O

[ RB N
Clinical NNP N
study NN N
on IN N
dan NN i
shao NN i
tang NN i
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
of IN N
deficiency NN N
of IN N
yin NN N
with IN N
damp-heat JJ N
symptom NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
effect NN N
of IN N
Dan NNP i
Shao NNP i
Tang NNP i
( ( i
DST NNP i
) ) i
in IN N
treating VBG N
IgA NNP N
nephropathy NN N
( ( N
IgAN NNP N
) ) N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

METHODS NNP N
90 CD p
patients NNS p
with IN p
IgAN NNP p
of IN p
deficiency NN p
of IN p
Yin NNP p
with IN p
damp-heat JJ p
symptom NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

50 CD N
patients NNS N
in IN N
treatment NN N
group NN N
were VBD N
treated VBN N
with IN N
DST NNP i
and CC i
western JJ i
medicine NN i
and CC N
40 CD N
patients NNS N
in IN N
control NN N
group NN N
were VBD N
treated VBN N
only RB i
with IN i
western JJ i
medicine NN i
. . i

The DT N
effects NNS N
and CC N
changes NNS N
of IN N
the DT N
indexes NNS N
including VBG N
renal JJ o
function NN o
, , o
hematuria NN o
, , o
proteinuria NN o
, , o
blood NN o
IgA NNP o
before IN N
and CC N
after IN N
treatment NN N
were VBD N
observed VBN N
. . N

RESULTS NNP N
After IN N
six CD N
months NNS N
treatment NN N
, , N
the DT N
general JJ o
effective JJ o
rate NN o
in IN N
treatment NN N
group NN N
was VBD N
70.00 CD N
% NN N
, , N
which WDT N
was VBD N
markedly RB N
higher JJR N
than IN N
that DT N
in IN N
control NN N
group NN N
( ( N
37.50 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Treatment NNP N
group NN N
is VBZ N
obviously RB N
better JJR N
than IN N
control NN N
group NN N
on IN N
decreasing VBG o
hematuria NN o
, , o
proteinuria NN o
, , o
blood NN o
IgA NNP o
and CC o
improving VBG o
renal JJ o
function NN o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
DST NNP i
is VBZ N
effective JJ N
on IN N
IgAN NNP N
of IN N
deficiency NN N
of IN N
Yin NNP N
with IN N
damp-heat JJ N
symptom NN N
. . N

-DOCSTART- -X- O O

Fentanyl NNP i
supplementation NN N
to TO N
inhalation NN p
anaesthesia NN p
. . p

In IN N
eight CD p
out IN p
of IN p
15 CD p
healthy JJ p
patients NNS p
undergoing VBG p
body NN p
surface NN p
surgery NN p
, , N
the DT N
effect NN N
of IN N
a DT N
fentanyl JJ i
infusion NN i
on IN N
a DT N
conventional JJ N
thiopentone NN i
, , i
nitrous JJ i
oxide NN i
, , i
oxygen NN i
and CC N
halothane NN i
anaesthetic NN i
was VBD N
studied VBN N
. . N

The DT N
fentanyl JJ i
infusion NN i
( ( N
2 CD N
micrograms/kg/hour NN N
) ) N
reduced VBD N
the DT N
induction NN o
dose NN o
of IN o
thiopentone NN o
and CC N
caused VBD N
marked JJ o
respiratory JJ o
depression NN o
with IN N
a DT N
reduction NN N
in IN N
the DT N
patients NNS N
' POS N
response NN N
to TO N
surgery NN N
. . N

The DT N
mean JJ o
arterial JJ o
pressures NNS o
and CC o
pulse JJ o
rates NNS o
were VBD N
not RB N
significantly RB N
different JJ N
in IN N
each DT N
group NN N
throughout IN N
the DT N
course NN N
of IN N
the DT N
operation NN N
. . N

The DT N
fentanyl NN i
made VBD N
no DT N
difference NN N
to TO N
the DT N
patients NNS N
' POS N
postoperative JJ N
analgesic JJ N
requirements NNS N
or CC N
to TO N
their PRP$ N
recovery NN N
in IN N
the DT N
first JJ N
24 CD N
hours NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
direct JJ i
current JJ i
pulse NN i
stimulating VBG i
acupoints NNS i
of IN i
JiaJi NNP i
( ( N
T10-13 NNP N
) ) N
and CC N
Ciliao NNP N
( ( N
BL NNP N
32 CD N
) ) N
with IN N
Han NNP i
's POS i
Acupoint NNP i
Nerve NNP i
Stimulator NNP i
on IN N
labour NN o
pain NN o
in IN p
women NNS p
: : p
a DT N
randomized NN N
controlled VBD N
clinical JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
clinical JJ N
effect NN N
and CC N
safety NN N
of IN N
direct JJ i
current JJ i
( ( i
DC NNP i
) ) i
pulse NN i
produced VBN i
by IN i
Han NNP i
's POS i
Acupoint NNP i
Nerve NNP i
Stimulator NNP i
in IN N
reduction NN N
( ( N
HANS NNP N
) ) N
of IN N
labor NN o
pain NN o
. . o

METHODS NNP N
Totally RB N
120 CD p
participants NNS p
were VBD N
enrolled VBN N
in IN N
this DT N
clinical JJ N
trial NN N
, , N
and CC N
were VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
groups NNS N
including VBG N
: : N
HANS NNP i
group NN i
, , i
patient NN i
controlled VBD i
intravenous JJ i
analgesia NN i
( ( i
PCIA NNP i
) ) i
group NN i
, , i
patient-controlled JJ i
epidural JJ i
analgesia NN i
( ( i
PCEA NNP i
) ) i
group NN N
and CC N
control NN N
group NN N
. . N

The DT N
HANS NNP i
group NN N
was VBD N
treated VBN N
by IN N
stimulating VBG N
the DT N
acupoints NNS i
of IN i
JiaJi NNP i
( ( N
T10-L3 NNP N
) ) N
and CC N
Ciliao NNP i
( ( N
BL NNP N
32 CD N
) ) N
with IN N
DC NNP i
pulse NN i
of IN N
100 CD N
Hz NNP N
and CC N
15-30 JJ N
mA NN N
produced VBN N
by IN N
a DT N
portable JJ i
battery-powered JJ i
Han NNP i
's POS i
Acupoint NNP i
Nerve NNP i
Stimulator NNP i
for IN N
30 CD N
min NN N
. . N

The DT N
PCIA NNP i
group NN N
was VBD N
intravenously RB N
infused VBN N
Ondansetron NNP i
( ( N
8 CD N
mg NN N
) ) N
for IN N
5 CD N
min NNS N
, , N
then RB N
tramadol VB i
injection NN i
( ( N
1.5 CD N
mg/kg NN N
) ) N
was VBD N
slowly RB N
dripped VBN N
by IN N
using VBG N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
with IN N
50 CD N
mL NNS N
tramadol NN i
( ( N
0.70 CD N
% NN N
) ) N
+ NN N
ondansetron NN i
( ( N
8 CD N
mg NN N
) ) N
, , N
background JJ N
infusion NN N
2 CD N
mL/h NN N
, , N
PCA NNP N
dose NN N
of IN N
2 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
. . N

In IN N
PCEA NNP i
group NN N
, , N
women NNS N
received VBD N
intrathecal JJ N
injection NN i
ropivacaine NN i
( ( N
3 CD N
mg NN N
) ) N
in IN N
L2-3 NNP N
, , N
and CC N
epidural JJ N
catheter NN N
was VBD N
connected VBN N
to TO N
BaxterAP NNP N
II NNP N
electronic JJ N
pump NN N
, , N
with IN N
100 CD N
mL NNS N
Ropivacaine NNP i
( ( N
0.1 CD N
% NN N
) ) N
and CC N
Sufentanil NNP i
( ( N
50 CD N
ug NN N
) ) N
, , N
background JJ N
infusion NN N
5 CD N
mL NN N
, , N
Patient NNP i
controlled VBD i
analgesia NN i
( ( i
PCA NNP i
) ) i
dose NN N
of IN N
5 CD N
mL NNS N
, , N
lockout IN N
interval NN N
of IN N
10 CD N
min NN N
. . N

The DT N
control NN N
group NN N
was VBD N
not RB N
received VBN N
analgesia NN N
. . N

The DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
, , o
stage NN o
and CC o
manner NN o
of IN o
labor NN o
, , o
Apgar NNP o
score NN o
of IN o
newborn JJ o
, , o
neonatal JJ o
weights NNS o
, , o
oxytocin JJ o
dosage NN o
, , o
postpartum NN o
hemorrhage NN o
and CC o
side NN o
effects NNS o
were VBD N
monitored VBN N
in IN N
all DT N
groups NNS N
. . N

RESULTS VB N
The DT N
vital JJ N
signs NNS N
were VBD N
all DT N
stable JJ N
in IN N
the DT N
four CD N
analgesic JJ N
groups NNS N
. . N

After IN N
analgesia NN N
, , N
there EX N
was VBD N
statistical JJ N
difference NN N
in IN N
VAS NNP o
score NN o
between IN N
HANS NNP i
group NN N
and CC N
control NN i
group NN N
, , N
between IN N
PCEA NNP i
group NN N
and CC N
the DT N
control NN i
group NN N
, , N
between IN N
PCIA NNP i
group NN N
and CC N
control NN i
group NN N
. . N

The DT N
analgesic JJ o
effect NN o
in IN N
the DT N
PCEA NNP i
group NN N
was VBD N
significantly RB N
better JJR N
than IN N
that DT N
of IN N
other JJ N
two CD N
groups NNS N
. . N

The DT N
second JJ N
stage NN N
of IN N
labor NN N
in IN N
the DT N
PCEA NNP i
group NN N
was VBD N
longer JJR N
than IN N
the DT N
other JJ N
three CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
Apgar NNP N
score NN N
of IN N
newborn JJ N
1 CD N
min NN N
after IN N
birth NN N
in IN N
the DT N
PCIA NNP i
group NN N
was VBD N
slightly RB N
lower JJR N
than IN N
that DT N
of IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
showing VBG N
significant JJ N
difference NN N
between IN N
them PRP N
. . N

The DT N
neonatal JJ o
weights NNS o
between IN N
four CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

The DT N
rate NN o
of IN o
cesarean JJ o
section NN o
in IN N
the DT N
control NN N
group NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
of IN N
the DT N
labor NN N
analgesia NN N
group NN N
, , N
there EX N
was VBD N
statistically RB N
difference NN N
in IN N
four CD N
groups NNS N
. . N

The DT N
number NN N
of IN N
PCIA NNP i
group NN N
that WDT N
used VBD o
oxytocin NN o
was VBD N
lower JJR N
than IN N
that DT N
of IN N
other JJ N
three CD N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
postpartum JJ o
hemorrhage NN o
between IN N
four CD N
groups NNS N
. . N

The DT N
side NN N
effects NNS N
of IN N
the DT N
PCEA NNP i
group NN N
were VBD N
itching VBG o
, , o
uroschesis NN o
and CC o
neonatal JJ o
asphyxia NN o
and CC N
PCIA NNP i
group NN N
were VBD N
nausea RB o
and CC o
vomiting VBG o
and CC o
neonatal JJ o
asphyxia NN o
. . o

However RB N
, , N
fewer JJR N
side-effects NNS o
were VBD N
observed VBN N
in IN N
the DT N
HANS NNP i
group NN N
. . N

CONCLUSION NNP N
The DT N
DC NNP N
pulse NN N
produced VBN N
by IN N
HANS NNP i
may MD N
be VB N
a DT N
non-pharmacological JJ N
alternative NN N
to TO N
labor NN N
pain NN N
with IN N
fewer JJR N
side NN N
effects NNS N
. . N

-DOCSTART- -X- O O

International NNP p
Czech NNP i
and CC i
Slovak NNP i
cooperation NN i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
paper NN N
is VBZ N
to TO N
present VB N
our PRP$ N
experience NN N
concerning VBG N
cooperation NN N
in IN N
the DT N
treatment NN N
of IN N
Slovak NNP p
patients NNS p
with IN p
differentiated JJ p
thyroid NN p
cancer NN p
in IN p
Slovak NNP p
and CC p
Czech NNP p
hospitals NNS p
. . p

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
demonstrate VB N
the DT N
means NNS o
of IN o
this DT o
cooperation NN o
and CC N
the DT N
results NNS o
of IN N
therapy NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
From NNP p
September NNP p
1991 CD p
to TO p
October NNP p
2005 CD p
in IN p
the DT p
Department NNP p
of IN p
Nuclear NNP p
Medicine NNP p
in IN p
Ostrava NNP p
357 CD p
patients NNS p
from IN p
the DT p
Slovak NNP p
Republic NNP p
with IN p
differentiated VBN p
thyroid NN p
cancers NNS p
( ( p
follicular JJ p
and CC p
papillary JJ p
) ) p
underwent NN p
complex JJ i
therapy NN i
. . i

They PRP p
were VBD p
diagnosed VBN p
and CC p
operated VBN p
due JJ p
to TO p
the DT p
cancer NN p
( ( p
near-total JJ p
thyroidectomy NN p
and CC p
removal NN p
of IN p
lymph JJ p
node JJ p
metastases NNS p
) ) p
in IN p
Slovak NNP p
hospitals NNS p
. . p

Then RB p
they PRP p
were VBD p
sent VBN p
to TO p
the DT p
Department NNP p
of IN p
Nuclear NNP p
Medicine NNP p
in IN p
Ostrava NNP p
in IN p
the DT p
Czech NNP p
Republic NNP p
. . p

In IN N
this DT N
department NN N
a DT N
radioiodine JJ i
ablation NN N
of IN N
thyroid JJ N
remnants NNS N
, , N
by IN N
means NNS N
of IN N
the DT N
treatment NN i
amount NN N
of IN N
radioiodine NN i
of IN N
a DT N
standard JJ N
activity NN N
of IN N
3.7 CD N
GBq NNP N
, , N
was VBD N
performed VBN N
, , N
and CC N
then RB N
a DT N
suppression NN N
and CC N
substitution NN i
therapy NN i
of IN N
thyroid JJ N
hormones NNS N
was VBD N
started VBN N
. . N

After IN N
3-6 JJ N
months NNS N
some DT N
patients NNS N
were VBD N
examined VBN N
by IN N
means NNS N
of IN N
diagnostic JJ o
whole JJ o
body NN o
scintigraphy NN o
after IN N
application NN N
of IN N
300 CD N
MBq NNP N
131I CD N
. . N

Some DT N
patients NNS N
were VBD N
treated VBN N
by IN N
means NNS N
of IN N
a DT N
standard JJ N
activity NN N
of IN N
7.4 CD N
GBq NNP N
131I CD N
and CC N
after IN N
5 CD N
days NNS N
whole JJ N
body NN N
scintigraphy NN N
( ( N
WBS NNP N
) ) N
was VBD N
performed VBN N
. . N

In IN N
both DT N
of IN N
these DT N
groups NNS N
of IN N
patients NNS N
the DT N
diagnostic JJ N
or CC N
therapeutic JJ N
radioiodine NN i
application NN N
was VBD N
done VBN N
after IN N
withdrawal NN N
of IN N
thyroid JJ N
hormone NN N
treatment NN N
. . N

If IN N
thyroglobulin JJ o
levels NNS o
were VBD N
low JJ N
and CC N
WBSs NNP o
were VBD N
negative JJ N
, , N
patients NNS N
were VBD N
followed VBN N
up RP N
in IN N
the DT N
Department NNP N
of IN N
Nuclear NNP N
Medicine NNP N
in IN N
Martin NNP N
. . N

Patients NNS N
with IN N
radioiodine NN N
accumulated VBN N
metastases NNS N
were VBD N
again RB N
treated VBN N
with IN N
radioiodine NN i
in IN N
Ostrava NNP N
. . N

If IN N
indicated VBN N
, , N
external JJ N
radiation NN i
therapy NN i
targeted VBN N
on IN N
the DT N
neck NN N
and CC N
upper JJ N
mediastinum NN N
was VBD N
performed VBN N
in IN N
the DT N
Slovak NNP p
Republic NNP p
, , p
in IN p
the DT p
University NNP p
Hospital NNP p
in IN p
Martin NNP p
. . p

Newly RB N
formed VBN N
lymph JJ N
node NN N
metastases NNS N
were VBD N
surgically RB N
treated VBN N
in IN N
Slovakia NNP N
, , N
too RB N
. . N

Generally RB N
we PRP N
have VBP N
very RB N
good JJ o
treatment NN o
results NNS o
. . o

Also RB N
, , N
economically RB N
our PRP$ N
partnership NN N
is VBZ N
cost VBN o
effective JJ o
. . o

Our PRP$ N
collaboration NN N
also RB N
successfully RB N
continues VBZ N
after IN N
entrance NN N
of IN N
the DT N
Slovak NNP N
Republic NNP N
and CC N
the DT N
Czech NNP N
Republic NNP N
to TO N
the DT N
European NNP N
Union NNP N
in IN N
2004 CD N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
multi-centre JJ N
study NN N
show NN N
that IN N
international JJ N
Czech NNP N
and CC N
Slovak NNP N
cooperation NN i
in IN N
the DT N
complex JJ N
therapy NN N
of IN N
patients NNS N
with IN N
differentiated JJ N
thyroid NN N
cancers NNS N
is VBZ N
successful JJ N
, , N
with IN N
high JJ N
efficacy NN N
. . N

The DT N
treatment NN N
results NNS N
were VBD N
very RB N
similar JJ N
to TO N
therapeutic JJ N
results NNS N
in IN N
our PRP$ N
patients NNS N
from IN N
the DT N
Czech NNP N
Republic NNP N
. . N

-DOCSTART- -X- O O

Mometasone NNP i
furoate NN i
nasal NN i
spray NN i
improves VBZ N
olfactory JJ o
performance NN o
in IN o
seasonal JJ o
allergic JJ o
rhinitis NN o
. . o

-DOCSTART- -X- O O

Quantitative JJ N
angiographic JJ N
methods NNS N
for IN N
appropriate JJ N
end-point JJ o
analysis NN o
, , o
edge-effect JJ o
evaluation NN o
, , N
and CC N
prediction NN o
of IN o
recurrent NN o
restenosis NN o
after IN N
coronary JJ i
brachytherapy NN i
with IN p
gamma JJ p
irradiation NN p
. . p

OBJECTIVES CC N
The DT N
study NN N
was VBD N
done VBN N
to TO N
investigate VB N
the DT N
relationship NN N
between IN N
clinical JJ N
restenosis NN N
and CC N
the DT N
relative JJ N
angiographic JJ N
location NN N
of IN N
the DT N
recurrent NN N
restenotic JJ N
lesion NN N
, , N
after IN N
treatment NN N
of IN N
in-stent JJ p
restenosis NN p
with IN N
vascular JJ i
brachytherapy NN i
in IN N
the DT N
Washington NNP p
Radiation NNP p
for IN p
In-Stent NNP p
Restenosis NNP p
Trial NNP p
( ( p
WRIST NNP p
) ) p
. . p

BACKGROUND NNP N
Intracoronary NNP i
radiation NN i
therapy NN i
reduces VBZ N
recurrence NN N
of IN N
in-stent JJ N
restenosis NN N
. . N

We PRP N
investigated VBD N
the DT N
above JJ N
objective NN N
in IN N
patients NNS p
enrolled VBN p
in IN p
WRIST NNP p
. . p

METHODS NNP N
The DT N
WRIST NNP N
study NN N
randomized VBD p
130 CD p
patients NNS p
to TO p
double-blinded JJ i
therapy NN i
with IN i
gamma JJ i
irradiation NN i
( ( i
iridium-192 JJ i
[ NNP i
( ( i
192 CD i
) ) i
Ir NNP i
] NNP i
) ) i
versus NN i
placebo NN i
after IN p
interventional JJ i
treatment NN i
of IN i
diffuse NN i
in-stent JJ i
restenosis NN i
. . i

After IN N
the DT N
intervention NN N
and CC N
at IN N
follow-up NN N
, , N
three CD N
vessel NN N
segments NNS N
were VBD N
individually RB N
analyzed VBN N
with IN N
quantitative JJ N
coronary JJ N
angiography NN N
: : N
1 CD N
) ) N
the DT N
stent NN N
, , N
2 CD N
) ) N
the DT N
radiation NN N
ribbon NN N
, , N
and CC N
3 CD N
) ) N
the DT N
ribbon+margin NN N
segment NN N
( ( N
including VBG N
5 CD N
mm NN N
on IN N
either DT N
end NN N
of IN N
the DT N
injured JJ N
or CC N
radiation-ribbon JJ N
segment NN N
) ) N
. . N

Receiver NNP N
operator NN N
curves NNS N
( ( N
ROC NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
follow-up JJ N
percent NN N
diameter NN N
stenosis NN N
( ( N
DS NNP N
) ) N
for IN N
each DT N
of IN N
the DT N
three CD N
analyzed VBD N
segments NNS N
in IN N
predicting VBG N
target NN N
vessel NN N
revascularization NN N
( ( N
TVR NNP N
) ) N
. . N

RESULTS NNP N
( ( N
192 CD N
) ) N
Ir NNP N
reduced VBD N
recurrent JJ o
restenosis NN o
( ( N
23.7 CD N
% NN N
vs. FW N
60.7 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
length NN o
of IN o
recurrent JJ o
restenosis NN o
( ( N
8.99 CD N
+/- JJ N
4.34 CD N
mm NN N
vs. FW N
17.54 CD N
+/- JJ N
10.48 CD N
mm NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
at IN N
follow-up JJ N
compared VBN N
to TO N
placebo VB N
. . N

Isolated NNP o
stent NN o
edge NN o
( ( N
3.4 CD N
% NN N
) ) N
and CC N
ribbon NN o
edge NN o
( ( N
1.7 CD N
% NN N
) ) N
restenoses VBZ o
were VBD N
infrequent NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
best JJS N
angiographic JJ N
surrogate NN N
of IN N
TVR NNP N
was VBD N
the DT N
50 CD N
% NN N
follow-up JJ N
DS NNP N
obtained VBD N
from IN N
the DT N
ribbon+margin NN N
analysis NN N
( ( N
ROC NNP N
area NN N
0.806 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
WRIST NNP N
, , N
not RB N
only RB N
was VBD N
( ( i
192 CD i
) ) i
Ir NNP i
therapy NN i
effective JJ N
in IN N
reducing VBG N
restenosis NN N
, , N
but CC N
it PRP N
also RB N
reduced VBD N
the DT N
lesion NN N
length NN N
of IN N
treatment NN N
failures NNS N
by IN N
50 CD N
% NN N
, , N
and CC N
it PRP N
was VBD N
not RB N
associated VBN N
with IN N
edge NN N
proliferation NN N
. . N

The DT N
restenosis NN N
rate NN N
obtained VBN N
from IN N
the DT N
vessel NN N
segment NN N
inclusive NN N
of IN N
the DT N
dose JJ N
fall-off JJ N
zones NNS N
was VBD N
the DT N
best JJS N
correlate NN N
of IN N
TVR NNP N
and CC N
should MD N
become VB N
a DT N
standard JJ N
analysis NN N
site NN N
in IN N
all DT N
vascular JJ N
brachytherapy NN N
trials NNS N
. . N

-DOCSTART- -X- O O

[ JJ N
Carbohydrate NNP N
substitutes NNS N
: : N
comparative JJ N
study NN N
of IN N
intestinal JJ p
absorption NN p
of IN p
fructose NN i
, , i
sorbitol NN i
and CC i
xylitol NNP i
] NNP i
. . N

BACKGROUND NNP N
The DT N
carbohydrate NN N
substitutes NNS N
fructose VBP i
, , i
sorbitol JJ i
and CC i
xylitol NNS i
are VBP N
gaining VBG N
more JJR N
and CC N
more JJR N
importance NN N
in IN N
the DT N
production NN N
of IN N
dietary JJ N
food NN N
. . N

But CC N
they PRP N
can MD N
provoke VB N
gastrointestinal JJ N
side-effects NNS N
. . N

In IN N
a DT N
randomized JJ N
double JJ N
blind NN N
study VBD N
the DT N
rate NN N
of IN N
malabsorption NN N
of IN N
these DT N
sugars NNS N
was VBD N
compared VBN N
and CC N
the DT N
concomitant NN N
symptoms NNS N
were VBD N
recorded VBN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
25 CD p
healthy JJ p
controls NNS p
received VBD N
25 CD i
g NN i
of IN i
each DT i
sugar NN i
within IN N
3 CD N
consecutive JJ N
days NNS N
. . N

The DT N
intestinal JJ o
absorption NN o
was VBD o
determined VBN o
by IN o
H2-exhalation NNP o
tests NNS o
and CC N
the DT N
clinical JJ o
symptoms NNS o
were VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
rate NN o
of IN o
malabsorption NN o
was VBD N
84 CD N
% NN N
for IN N
sorbitol NN i
, , N
36 CD N
% NN N
for IN N
fructose JJ i
and CC N
12 CD N
% NN N
for IN N
xylitol NNP i
( ( N
p JJ N
< VBP N
0.01 CD N
for IN N
sorbitol NN i
versus NN i
fructose NN i
and CC i
xylitol NN i
) ) i
. . N

57 CD N
% NN N
of IN N
the DT N
participants NNS N
with IN N
pathological JJ N
H2-test NNP N
after IN N
sorbitol NN i
and CC N
56 CD N
% NN N
after IN N
fructose JJ i
reported VBD N
symptoms NNS N
, , N
while IN N
all DT N
of IN N
the DT N
3 CD N
malabsorbers NNS N
of IN N
xylitol NN i
were VBD N
symptomatic JJ N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
an DT N
advantage NN N
to TO N
administering VBG N
xylitol NN i
and CC N
fructose JJ i
with IN N
regard NN N
to TO N
the DT N
intestinal JJ o
absorption NN o
and CC N
concomitant NN N
symptoms NNS N
as IN N
compared VBN N
with IN N
sorbitol NN i
. . i

H2-exhalation NN N
tests NNS N
appear VBP N
to TO N
be VB N
a DT N
reliable JJ N
diagnostic JJ N
tool NN N
to TO N
detect VB N
carbohydrate JJ o
malabsorption NN o
and CC N
should MD N
find VB N
broader JJR N
application NN N
in IN N
patients NNS N
suffering VBG N
from IN N
non-specific JJ N
abdominal JJ N
complaints NNS N
. . N

-DOCSTART- -X- O O

Dietary NNP N
patterns NNS N
differ VBP N
between IN N
urban JJ p
and CC p
rural JJ p
older JJR p
, , p
long-term JJ p
survivors NNS p
of IN p
breast NN p
, , p
prostate NN p
, , p
and CC p
colorectal JJ p
cancer NN p
and CC N
are VBP N
associated VBN N
with IN N
body NN N
mass NN N
index NN N
. . N

BACKGROUND NNP N
Older NNP p
adult NN p
cancer NN p
survivors NNS p
are VBP N
at IN N
greater JJR N
risk NN N
of IN N
cancer NN o
recurrence NN o
and CC N
other JJ N
comorbidities NNS o
that WDT N
can MD N
be VB N
prevented VBN N
through IN N
improved VBN N
diet JJ N
and CC N
weight JJ N
management NN N
. . N

The DT N
tertiary JJ N
prevention NN N
needs NNS N
of IN N
rural-dwelling JJ N
survivors NNS N
can MD N
be VB N
even RB N
greater JJR N
, , N
yet RB N
little JJ N
is VBZ N
known VBN N
about IN N
rural JJ N
and CC N
urban JJ N
differences NNS N
in IN N
lifestyle JJ N
factors NNS N
among IN N
this DT N
high-risk JJ N
population NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB i
dietary JJ i
patterns NNS i
of IN N
urban JJ p
and CC p
rural JJ p
cancer NN p
survivors NNS p
and CC N
to TO N
examine VB N
associations NNS N
of IN N
dietary JJ o
patterns NNS o
with IN N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
. . o

DESIGN VB N
A DT N
secondary JJ N
analysis NN N
was VBD N
performed VBN N
of IN N
baseline NN N
data NNS N
from IN N
the DT N
Reach NNP o
Out NNP o
to TO o
Enhance VB o
Wellness NNP o
( ( N
RENEW NNP N
) ) N
trial NN N
, , N
a DT N
diet JJ i
and CC i
exercise JJ i
intervention NN i
among IN N
overweight JJ N
, , N
long-term JJ N
( ( N
?5 CD N
years NNS N
) ) N
, , N
older JJR N
survivors NNS N
of IN N
colorectal NN N
, , N
breast NN N
, , N
and CC N
prostate NN N
cancer NN p
. . p

Survivors NNS p
in IN p
the DT p
present JJ p
analysis NN p
( ( p
n=729 JJ p
) ) p
underwent JJ i
two CD i
45- JJ i
to TO i
60-minute JJ i
telephone NN i
surveys NNS i
, , i
which WDT i
included VBD i
two CD i
24-hour JJ i
dietary JJ i
recalls NNS i
. . i

Principal JJ i
components NNS i
analysis NN i
and CC i
multivariable JJ i
general JJ i
linear JJ i
models NNS i
were VBD i
used VBN N
to TO N
derive VB o
dietary JJ o
patterns NNS o
and CC o
to TO N
evaluate VB N
associations NNS N
between IN o
dietary JJ o
patterns NNS o
and CC o
BMI NNP o
, , o
respectively RB N
. . N

RESULTS VB N
Principal JJ N
components NNS N
analysis NN N
identified VBD N
three CD o
primary JJ o
dietary JJ o
patterns NNS o
among IN o
rural JJ N
dwellers NNS N
( ( N
high JJ N
sweets NNS N
and CC N
starches NNS N
, , N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
, , N
and CC N
mixed JJ N
) ) N
and CC N
three CD N
among IN N
urban JJ N
dwellers NNS N
( ( N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
, , N
high JJ N
meat NN N
and CC N
refined VBD N
grains NNS N
, , N
and CC N
high JJ N
sugar-sweetened JJ N
beverages NNS N
) ) N
. . N

Among IN p
rural JJ p
survivors NNS p
, , p
greater JJR N
adherence NN N
to TO N
the DT N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
pattern NN N
was VBD N
positively RB N
associated VBN N
with IN N
lower JJR o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
, , N
whereas IN N
higher JJR N
scores NNS N
on IN N
the DT N
mixed JJ N
pattern NN N
was VBD N
associated VBN N
with IN N
greater JJR o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

Greater NNP N
adherence NN N
to TO N
the DT N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
pattern VBP N
among IN N
urban JJ N
survivors NNS N
was VBD N
inversely RB N
associated VBN N
with IN o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Urban NNP N
and CC N
rural JJ N
differences NNS N
in IN N
dietary JJ N
intake NN N
behavior NN N
should MD N
be VB N
considered VBN N
in IN N
designing VBG N
public JJ N
health NN N
interventions NNS N
among IN N
the DT o
increasing VBG o
population NN o
of IN o
older JJR N
cancer NN N
survivors NNS N
. . N

In IN N
addition NN N
, , N
targeting VBG N
overall JJ N
dietary JJ N
patterns NNS N
might MD N
be VB N
one CD N
approach NN N
to TO N
help VB N
reduce VB N
the DT N
burden NN N
of IN N
obesity NN N
among IN N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Cardiovascular JJ N
effects NNS N
of IN N
tamoxifen NN i
in IN N
women NNS p
with IN p
and CC p
without IN p
heart NN p
disease NN p
: : p
breast NN N
cancer NN N
prevention NN N
trial NN N
. . N

National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
Investigators NNP N
. . N

BACKGROUND NNP N
The DT N
overall JJ N
effect NN N
of IN N
prophylactic JJ N
tamoxifen NN N
in IN N
women NNS N
depends NNS N
on IN N
the DT N
balance NN N
between IN N
the DT N
effects NNS N
of IN N
the DT N
drug NN N
, , N
which WDT N
include VBP N
preventing VBG o
breast NN o
cancer NN o
and CC N
altering VBG N
cardiovascular JJ o
risk NN o
. . o

In IN N
a DT N
recent JJ N
clinical JJ N
trial NN N
, , N
postmenopausal JJ N
estrogen-progestin JJ N
therapy NN N
was VBD N
shown VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
early JJ o
cardiovascular JJ o
events NNS o
among IN N
women NNS p
with IN p
a DT p
history NN p
of IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
. . p

The DT N
cardiovascular JJ o
effects NNS o
of IN N
tamoxifen NN N
in IN N
women NNS p
with IN p
and CC p
without IN p
CHD NNP p
are VBP N
not RB N
known VBN N
. . N

The DT N
National NNP N
Surgical NNP N
Adjuvant NNP N
Breast NNP N
and CC N
Bowel NNP N
Project NNP N
Breast NNP N
Cancer NNP N
Prevention NNP N
Trial NNP N
( ( N
BCPT NNP N
) ) N
is VBZ N
the DT N
only JJ N
clinical JJ N
trial NN N
that WDT N
provides VBZ N
data NNS N
to TO N
assess VB N
the DT N
cardiovascular JJ o
effects NNS o
of IN N
tamoxifen NN N
in IN N
women NNS N
with IN N
and CC N
without IN N
CHD NNP N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
13 CD p
388 CD p
women NNS p
at IN p
increased VBN p
risk NN p
for IN p
breast NN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
in IN N
the DT N
BCPT NNP N
to TO N
receive VB N
either DT N
tamoxifen NN i
( ( i
20 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
. . i

Cardiovascular JJ p
follow-up NN p
was VBD p
available JJ p
for IN p
13 CD p
194 CD p
women NNS p
, , p
1048 CD p
of IN p
whom WP p
had VBD p
prior RB p
clinical JJ p
CHD NNP p
. . p

Fatal NNP o
and CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
unstable JJ o
angina NN o
, , o
and CC o
severe JJ o
angina NN o
were VBD N
tabulated VBN N
( ( N
mean JJ N
follow-up NN N
: : N
49 CD N
months NNS N
) ) N
. . N

All DT N
statistical JJ N
tests NNS N
were VBD N
two-sided JJ N
. . N

RESULTS NNP N
Cardiovascular JJ o
event NN o
rates NNS o
were VBD N
not RB N
statistically RB N
significantly RB N
different JJ N
between IN N
women NNS N
assigned VBN N
to TO N
receive VB N
tamoxifen NN N
and CC N
those DT N
assigned VBN N
to TO N
receive VB N
placebo NN N
, , N
independent JJ N
of IN N
pre-existing JJ N
CHD NNP N
. . N

Among IN N
women NNS N
without IN N
CHD NNP N
( ( N
6074 CD N
on IN N
tamoxifen NN N
versus NN N
6072 CD N
on IN N
placebo NN N
) ) N
, , N
risk JJ N
ratios NNS N
( ( N
95 CD N
% NN N
confidence NN N
intervals NNS N
[ VBP N
CIs NNP N
] NNP N
) ) N
for IN N
tamoxifen NN N
users NNS N
were VBD N
1.75 CD N
( ( N
0.44 CD N
to TO N
8.13 CD N
) ) N
for IN N
fatal JJ o
myocardial JJ o
infarction NN o
, , N
1.11 CD N
( ( N
0.55 CD N
to TO N
2.28 CD N
) ) N
for IN N
nonfatal JJ o
myocardial JJ o
infarction NN o
, , N
0.69 CD N
( ( N
0.29 CD N
to TO N
1.57 CD N
) ) N
for IN N
unstable JJ o
angina NN o
, , N
and CC N
0.83 CD N
( ( N
0.32 CD N
to TO N
2.10 CD N
) ) N
for IN N
severe JJ o
angina NN o
. . o

In IN N
women NNS N
with IN N
CHD NNP N
( ( N
516 CD N
on IN N
tamoxifen NNS N
versus $ N
532 CD N
on IN N
placebo NN N
) ) N
, , N
risk JJ o
ratios NNS o
( ( N
95 CD N
% NN N
CIs NNP N
) ) N
for IN N
tamoxifen NN N
users NNS N
were VBD N
0.00 CD N
( ( N
0 CD N
to TO N
1.58 CD N
) ) N
for IN N
fatal JJ o
myocardial JJ o
infarction NN o
, , N
1.25 CD N
( ( N
0.32 CD N
to TO N
5.18 CD N
) ) N
for IN N
nonfatal JJ o
myocardial JJ o
infarction NN o
, , N
2.26 CD N
( ( N
0.87 CD N
to TO N
6.55 CD N
) ) N
for IN N
unstable JJ o
angina NN o
, , N
and CC N
1.39 CD N
( ( N
0.23 CD N
to TO N
9.47 CD N
) ) N
for IN N
severe JJ o
angina NN o
. . o

There EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
lack NN N
of IN N
association NN N
between IN N
tamoxifen NN N
and CC N
cardiovascular JJ o
events NNS o
was VBD N
related VBN N
to TO N
an DT N
early JJ N
increase NN o
in IN o
risk NN o
that WDT N
may MD N
have VB N
been VBN N
offset VBN N
by IN N
a DT N
late JJ N
decrease NN N
in IN N
risk NN N
. . N

CONCLUSION NN N
When WRB N
used VBN N
for IN N
breast NN N
cancer NN N
prevention NN N
in IN N
women NNS p
with IN p
or CC p
without IN p
heart NN p
disease NN p
, , N
tamoxifen NN N
is VBZ N
not RB N
associated VBN N
with IN N
beneficial JJ N
or CC N
adverse JJ N
cardiovascular JJ o
effects NNS o
. . o

-DOCSTART- -X- O O

Dental NNP i
prophylaxis NN i
decreases VBZ p
the DT p
risk NN p
of IN p
esophageal JJ o
cancer NN o
in IN p
males NNS p
; : p
a DT p
nationwide JJ p
population-based JJ p
study NN p
in IN p
Taiwan NNP p
. . p

BACKGROUND NNP N
Periodontal NNP N
disease NN N
( ( N
PD NNP N
) ) N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
chronic JJ N
inflammatory NN N
diseases NNS N
. . N

Esophageal NN o
cancer NN o
( ( o
EC NNP o
) ) o
is VBZ p
also RB p
a DT p
common JJ p
cause NN p
of IN p
death NN p
due JJ p
to TO p
cancer NN p
among IN p
males NNS p
. . p

Systemic NNP N
inflammatory NN N
processes NNS N
have VBP N
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
cancer NN o
. . o

We PRP N
conducted VBD N
a DT N
retrospective JJ N
cohort NN N
study NN N
to TO N
investigate VB N
the DT N
association NN N
between IN N
PD NNP o
and CC o
EC NNP o
. . o

METHODS NNP N
A NNP N
total NN N
of IN N
718,409 CD p
subjects NNS p
were VBD p
recruited VBN p
from IN p
the DT p
Taiwan NNP p
National NNP p
Health NNP p
Insurance NNP p
Research NNP p
Database NNP p
( ( p
NHIRD NNP p
) ) p
and CC N
followed VBN N
from IN N
January NNP N
1 CD N
, , N
2000 CD N
to TO N
December NNP N
31 CD N
, , N
2010 CD N
. . N

Of IN N
these DT N
, , N
519,831 CD p
subjects NNS p
were VBD p
diagnosed VBN p
with IN p
PD NNP p
and CC N
were VBD N
grouped VBN N
according VBG N
to TO N
the DT N
most RBS N
advanced JJ N
treatment NN N
they PRP N
received VBD N
: : N
dental JJ i
prophylaxis NN i
, , i
intensive JJ i
treatment NN i
, , i
or CC i
no DT i
treatment NN i
. . i

The DT N
IRs NNP o
of IN o
EC NNP o
were VBD N
compared VBN N
among IN N
groups NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
682 CD p
patients NNS p
developed VBD p
EC NNP o
, , N
resulting VBG N
in IN N
an DT N
overall JJ o
IR NNP o
of IN N
0.11 CD N
case-number JJ N
per IN N
1000 CD N
person-years NNS N
( ( p
?/y NN p
) ) p
. . p

The DT p
dental JJ p
prophylaxis NN p
group NN p
had VBD p
a DT N
significantly RB N
lower JJR o
IR NNP o
of IN o
EC NNP o
( ( o
0.06?/y CD N
) ) N
than IN N
other JJ N
groups NNS N
( ( N
p JJ N
< NNP N
0.001 CD o
) ) o
. . o

Multivariable JJ o
Cox NNP o
regression NN o
analysis NN o
further RBR o
revealed VBD N
that IN N
male JJ p
subjects NNS p
[ JJ p
hazard NN p
ratio NN N
( ( N
HR NNP N
) ) N
= VBD N
10.04 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
= VBD N
7.58-13.30 JJ N
] NN N
, , N
as RB N
well RB N
as IN N
a DT N
history NN N
of IN N
esophageal JJ N
ulcers NNS N
( ( N
HR NNP N
= NNP N
7.10 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
5.03-10.01 JJ N
) ) N
, , N
alcohol NN N
abuse NN N
( ( N
HR NNP N
= NNP N
5.46 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
2.26-13.18 JJ N
) ) N
, , N
or CC N
esophageal VB N
reflux NN N
( ( N
HR NNP N
= NNP N
1.86 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
1.02-3.52 JJ N
) ) N
, , N
were VBD N
factors NNS N
associated VBN N
with IN N
a DT N
higher JJR N
risk NN N
of IN N
EC NNP N
. . N

And CC p
the DT p
dental JJ p
prophylaxis NN p
group NN p
showed VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
for IN o
EC NNP o
( ( o
HR NNP N
= NNP N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
0.44-0.65 NN N
) ) N
. . N

Further NNP N
subgroup NN N
analysis NN p
showed VBD p
that IN p
the DT p
dental JJ p
prophylaxis NN p
group NN p
among IN p
males NNS p
had VBD p
a DT p
significant JJ p
lower JJR p
risk NN p
( ( p
HR NNP p
= NNP N
0.54 CD N
, , N
95 CD N
% NN N
CI NNP N
= NNP N
0.44-0.66 NN N
) ) N
for IN o
EC NNP o
, , N
while IN N
that DT N
of IN N
the DT N
females NNS N
did VBD N
not RB N
has VBZ N
statistically RB N
significant JJ N
difference NN N
. . N

CONCLUSION NN N
For IN N
this DT N
cohort NN N
, , N
subjects VBZ N
received VBN N
dental JJ N
prophylaxis NN N
reduced VBD N
the DT o
risk NN o
of IN o
EC NNP o
compared VBN N
to TO N
all DT N
PD NNP N
and CC N
no DT N
PD NNP N
groups NNS N
among IN N
males NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
amiodarone NN i
and CC i
disopyramide NN i
in IN N
the DT N
control NN o
of IN o
paroxysmal JJ o
atrial JJ o
fibrillation NN o
and CC o
atrial JJ o
flutter NN o
( ( N
interim JJ N
report NN N
) ) N
. . N

-DOCSTART- -X- O O

Low-dose JJ N
, , N
vaginally RB N
administered VBN N
estrogens NNS i
may MD N
enhance VB N
local JJ N
benefits NNS N
of IN N
systemic JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
urogenital JJ p
atrophy NN p
in IN p
postmenopausal JJ p
women NNS p
on IN p
hormone NN p
therapy NN p
. . p

BACKGROUND NNP N
When WRB N
genital JJ N
atrophy NN N
exists NNS N
, , N
systemic JJ i
hormone NN i
therapy NN i
( ( i
HT NNP i
) ) i
has VBZ N
a DT N
timing NN N
until IN N
to TO N
induce VB N
vaginal JJ N
proliferation NN N
and CC N
symptomatic JJ N
relieve NN N
. . N

Thus RB N
, , N
in IN N
order NN N
to TO N
obtain VB N
a DT N
prompt JJ N
improvement NN N
, , N
the DT N
association NN N
of IN N
local JJ N
therapy NN N
acting VBG N
on IN N
the DT N
genital JJ N
epithelium NN N
to TO N
the DT N
systemic JJ N
treatment NN N
should MD N
be VB N
considered VBN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
combined JJ N
therapy NN N
consisting NN N
of IN N
vaginal JJ N
estriol NN N
with IN N
transdermal JJ N
17-beta-estradiol JJ N
( ( N
50 CD N
microg/day NN N
) ) N
plus CC N
medroxyprogesterone JJ N
acetate NN N
( ( N
5 CD N
mg/day NN N
) ) N
per IN N
os NN N
in IN N
shortening VBG N
the DT N
period NN N
of IN N
uro-genital JJ N
symptoms NNS N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double JJ N
blind NN N
, , N
controlled VBN N
with IN N
placebo NN i
study NN N
, , N
27 CD p
women NNS p
with IN p
climacteric JJ p
symptoms NNS p
and CC p
atrophic JJ p
vaginitis NN p
were VBD N
treated VBN N
for IN N
4 CD N
months NNS N
with IN N
HT NNP i
plus CC i
vaginal JJ i
estriol NN i
0.5 CD i
mg/day NN i
( ( N
group NN N
E NNP N
) ) N
or CC N
placebo NN i
( ( N
group NN N
P NNP N
) ) N
. . N

Patients NNS N
use VBP N
the DT N
local JJ N
medication NN N
daily RB N
for IN N
the DT N
first JJ N
3 CD N
weeks NNS N
and CC N
twice-weekly JJ N
thereafter NN N
. . N

Before IN N
entering VBG N
in IN N
the DT N
study NN N
, , N
patients NNS N
were VBD N
asked VBN N
about IN N
HT NNP N
and CC N
selected VBN N
for IN N
inclusion NN N
. . N

In IN N
the DT N
first JJ N
visit NN N
, , N
electible JJ N
patients NNS N
after IN N
written VBN N
informed JJ N
consent NN N
were VBD N
randomized VBN N
to TO N
receive VB p
HT NNP i
plus CC i
local JJ i
estriol NN i
or CC p
placebo NN i
. . i

All PDT N
the DT N
subjects NNS N
had VBD N
baseline NN N
studies NNS N
, , N
including VBG N
medical JJ N
history NN N
, , N
physical JJ N
examination NN N
, , N
blood NN N
and CC N
urine JJ N
analysis NN N
. . N

In IN N
order NN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
local JJ N
treatment NN N
on IN N
urinary JJ N
and CC N
genital JJ N
symptoms NNS N
, , N
a DT N
score NN N
for IN N
genital NN N
, , N
urinary JJ N
and CC N
colposcopic JJ N
complaints NNS N
( ( N
0 CD N
minimum-100 JJ N
maximum NN N
) ) N
was VBD N
developed VBN N
. . N

This DT N
score NN N
and CC N
Blatt-Kuperman NNP N
were VBD N
recorded VBN N
and CC N
performed VBN N
in IN N
every DT N
control NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT o
differences NNS o
on IN o
climacteric NN o
symptoms NNS o
relief NN o
between IN o
the DT o
two CD o
groups NNS o
. . o

Additionally RB N
, , N
the DT N
improvement NN o
in IN o
urinary JJ o
symptoms NNS o
at IN o
the DT o
end NN o
of IN o
the DT o
study NN o
was VBD o
similar JJ o
for IN o
both DT o
groups NNS o
( ( N
from IN N
16.5 CD N
+/- JJ N
6.1 CD N
to TO N
8.5 CD N
+/- JJ N
2.4 CD N
for IN N
E NNP N
group NN N
and CC N
from IN N
15.8 CD N
+/- JJ N
7.8 CD N
to TO N
8.8 CD N
+/- JJ N
2.7 CD N
for IN N
P NNP N
group NN N
; : N
P NNP N
< VBD N
0.01 CD N
versus NN N
basal NN N
) ) N
; : N
however RB N
, , N
those DT N
women NNS o
in IN o
group NN o
E NNP o
reached VBD o
significant JJ o
improvement NN o
on IN o
urinary JJ o
complaints NNS o
since IN o
the DT o
first JJ o
month NN o
of IN o
treatment NN o
. . o

Additionally RB N
, , N
a DT N
significant JJ o
difference NN o
between IN o
E NNP o
and CC o
P NNP o
was VBD o
observed VBN o
at IN o
months NNS o
2 CD o
and CC o
3 CD o
, , o
although IN o
no DT o
differences NNS o
were VBD o
detected VBN o
at IN o
the DT o
end NN o
of IN o
the DT o
study NN o
. . o

Papanicolaou NNP o
smear JJ o
showed VBD o
reactive JJ o
or CC o
reparative JJ o
changes NNS o
and CC o
karyopyknotic JJ o
index NN o
exhibited VBD o
a DT o
significant JJ o
increase NN o
in IN o
superficial JJ o
cells NNS o
in IN o
both DT o
groups NNS o
and CC o
at IN o
the DT o
end NN o
of IN o
the DT o
study NN o
. . o

CONCLUSIONS NNP N
Adding NNP N
vaginal JJ N
estriol NN N
to TO N
HRT NNP N
may MD N
shorten VB N
the DT N
latency NN N
period NN N
for IN N
urinary JJ N
symptoms NNS N
. . N

-DOCSTART- -X- O O

Timing NN o
of IN o
death NN o
and CC o
myocardial JJ o
infarction NN o
in IN p
patients NNS p
with IN p
non-ST JJ p
elevation NN p
acute NN p
coronary JJ p
syndromes NNS p
: : p
insights NNS N
from IN N
randomized VBN N
clinical JJ N
trials NNS N
. . N

BACKGROUND NNP N
Adverse NNP N
events NNS N
occur VBP N
following VBG N
non-ST JJ p
elevation NN p
acute NN p
coronary JJ p
syndromes NNS p
( ( p
NSTE NNP p
ACS NNP p
) ) p
. . p

However RB N
, , N
the DT N
timing NN N
of IN N
these DT N
events NNS N
in IN N
relation NN N
to TO N
index NN N
event NN N
is VBZ N
less RBR N
clear JJ N
. . N

METHODS NNP N
Accordingly RB N
, , N
we PRP p
evaluated VBD p
26,466 CD p
NSTE NNP p
ACS NNP p
patients NNS p
from IN p
the DT p
Global NNP p
Use NNP p
of IN p
Strategies NNPS p
to TO p
Open VB p
Occluded NNP p
Arteries NNPS p
in IN p
Acute NNP p
Coronary NNP p
Syndromes NNP p
( ( p
GUSTO-IIb NNP p
) ) p
, , p
Platelet NNP i
Glycoprotein NNP i
IIb/IIIa NNP i
in IN p
Unstable JJ p
Angina NNP p
: : p
Receptor NNP i
Suppression NNP i
Using NNP i
Integrilin NNP i
Therapy NNP i
( ( N
PURSUIT NNP N
) ) N
, , N
and CC N
Platelet NNP i
IIb/IIIa NNP i
Antagonism NNP i
for IN N
the DT N
Reduction NNP N
of IN N
Acute NNP N
Coronary NNP N
Syndrome NNP N
Events NNP N
in IN N
a DT N
Global NNP N
Organization NNP N
Network NNP N
( ( N
PARAGON NNP N
) ) N
A NNP N
and CC N
B NNP N
trials NNS N
to TO N
ascertain VB N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
. . N

Outcomes NNS N
of IN N
interest NN N
were VBD N
death NN o
, , o
myocardial JJ o
infarction NN o
( ( o
MI NNP o
) ) o
, , o
and CC o
death NN o
or CC o
MI NNP o
at IN o
180 CD o
days NNS o
. . o

Logistic JJ i
regression NN i
modeling VBG i
for IN N
death NN N
was VBD N
used VBN N
to TO N
categorize VB N
patients NNS N
into IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-risk JJ N
groups NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
6.2 CD N
% NN N
of IN N
patients NNS N
died VBD o
, , N
12.1 CD N
% NN N
had VBD N
MI NNP o
, , N
and CC N
15.7 CD N
% NN N
suffered VBD N
death NN o
or CC o
MI NNP o
. . o

From IN N
15 CD N
% NN N
to TO N
40 CD N
% NN N
of IN N
these DT N
events NNS N
occurred VBD N
beyond IN N
30 CD N
days NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
3 CD N
% NN N
, , N
4 CD N
% NN N
, , N
and CC N
13 CD N
% NN N
of IN N
patients NNS N
died VBN N
in IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-risk JJ N
groups NNS N
, , N
respectively RB N
. . N

However RB N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
dying VBG o
beyond IN N
30 CD N
days NNS N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
( ( N
44 CD N
% NN N
, , N
43 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
of IN N
death NN N
, , N
respectively RB N
) ) N
. . N

Similarly RB N
, , N
whereas JJ N
death NN o
or CC o
MI NNP o
increased VBD N
with IN N
higher JJR N
risk NN N
( ( N
11 CD N
% NN N
, , N
14 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN N
this DT N
event NN N
beyond IN N
30 CD N
days NNS N
did VBD N
not RB N
differ VB N
in IN N
the DT N
three CD N
strata NNS N
( ( N
22 CD N
% NN N
, , N
20 CD N
% NN N
, , N
and CC N
25 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
provides VBZ N
important JJ N
insights NNS N
into IN N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
and CC N
suggests VBZ N
that IN N
the DT N
substantial JJ N
proportion NN N
of IN N
patients NNS N
suffer VBP N
subsequent JJ N
adverse JJ N
events NNS N
after IN N
their PRP$ N
index NN N
NSTE NNP N
ACS NNP N
. . N

Thus RB N
, , N
these DT N
data NNS N
call NN N
for IN N
continuous JJ N
surveillance NN N
for IN N
these DT N
events NNS N
and CC N
efforts NNS N
beyond IN N
the DT N
acute JJ N
phase NN N
at IN N
increasing VBG N
adherence NN N
to TO N
evidence-based JJ N
therapies NNS N
to TO N
improve VB N
the DT N
outcomes NNS N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -X- O O

Blind NNP i
versus NN i
open JJ i
approach NN i
to TO i
laparoscopic VB i
cholecystectomy NN i
: : i
a DT N
randomized JJ N
study NN N
. . N

Intraabdominal NNP N
structures NNS N
may MD N
be VB N
damaged VBN N
during IN N
blind JJ N
introduction NN N
of IN N
the DT N
first JJ N
trocar NN N
for IN N
laparoscopic JJ i
operations NNS N
. . N

In IN N
this DT N
study NN N
, , N
150 CD p
patients NNS p
with IN p
gallbladder JJ p
lithiasis NN p
who WP p
underwent JJ p
laparoscopy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
, , N
a DT N
blind NN N
( ( N
V NNP N
group NN N
) ) N
or CC N
an DT N
open JJ N
( ( N
H NNP N
group NN N
) ) N
, , N
in IN N
order NN N
to TO N
compare VB N
the DT N
results NNS N
and CC N
the DT N
rate NN o
of IN o
complications NNS o
. . o

No DT N
mortality NN o
was VBD N
observed VBN N
. . N

Major JJ o
complications NNS o
occurred VBD N
in IN N
3/75 CD N
( ( N
4 CD N
% NN N
) ) N
patients NNS N
of IN N
the DT N
V NNP N
group NN N
and CC N
in IN N
1/75 CD N
( ( N
1.3 CD N
% NN N
) ) N
patient NN N
of IN N
the DT N
H NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Minor JJ o
complications NNS o
occurred VBD N
in IN N
5/75 CD N
( ( N
6.7 CD N
% NN N
) ) N
patients NNS N
of IN N
either DT N
group NN N
. . N

The DT N
achievement NN o
of IN o
pneumoperitoneum NN o
required VBN N
4.5+/-0.4 JJ N
min NN N
in IN N
the DT N
V NNP N
group NN N
and CC N
3.2+/-0.2 JJ N
min NN N
in IN N
the DT N
H NNP N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
open JJ i
laparoscopic NN i
technique NN i
is VBZ N
safer JJR N
and CC N
faster RBR N
than IN N
the DT N
blind JJ i
approach NN i
; : i
therefore RB N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
this DT N
approach NN N
be VB N
routinely RB N
used VBN N
in IN N
all DT N
laparoscopic NN N
procedures NNS N
. . N

-DOCSTART- -X- O O

The DT N
use NN N
of IN N
transvaginal JJ i
synthetic JJ i
mesh NN i
for IN N
anterior JJ p
vaginal JJ p
wall NN p
prolapse NN p
repair NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

INTRODUCTION NNP N
AND CC N
HYPOTHESIS NNP N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
transvaginal JJ i
trocar-guided JJ i
polypropylene NN i
mesh JJ i
insertion NN i
with IN i
traditional JJ i
colporrhaphy NN i
for IN N
treatment NN N
of IN N
anterior JJ p
vaginal JJ p
wall NN p
prolapse NN p
. . p

METHODS NNP N
This DT N
is VBZ N
a DT N
randomized JJ N
controlled JJ N
trial NN N
in IN N
which WDT N
women NNS p
with IN p
advanced JJ p
anterior JJ p
vaginal NN p
wall NN p
prolapse NN p
, , p
at IN p
least JJS p
stage NN p
II NNP p
with IN p
Ba NNP p
? . p
+1 NN p
cm NN p
according VBG p
to TO p
the DT p
Pelvic NNP p
Organ NNP p
Prolapse NNP p
Quantification NNP p
( ( p
POP-Q NNP p
) ) p
classification NN p
, , p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
either DT i
anterior JJ i
colporrhaphy NN i
( ( i
n JJ N
= NNP N
39 CD N
) ) N
or CC N
repair NN i
using VBG i
trocar-guided JJ i
transvaginal JJ i
mesh NN i
( ( i
n JJ N
= NNP N
40 CD N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD o
objective JJ o
cure NN o
rate NN o
of IN o
the DT o
anterior JJ o
compartment NN o
( ( o
point NN o
Ba NNP o
) ) o
assessed VBD o
at IN N
the DT N
12-month JJ N
follow-up JJ N
visit NN N
, , N
with IN N
stages NNS N
0 CD N
and CC N
I PRP N
defined VBD N
as IN N
anatomical JJ N
success NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD o
quantification NN o
of IN o
other JJ o
vaginal JJ o
compartments NNS o
( ( o
POP-Q NNP o
points NNS o
) ) o
, , o
comparison NN o
of IN o
quality NN o
of IN o
life NN o
by IN o
the DT o
prolapse NN o
quality NN o
of IN o
life NN o
( ( o
P-QOL NNP o
) ) o
questionnaire NN o
, , o
and CC o
complication NN o
rate NN o
between IN o
the DT N
groups NNS N
after IN N
1 CD N
year NN N
. . N

Study NNP N
power NN N
was VBD N
fixed VBN N
as IN N
80 CD N
% NN N
with IN N
5 CD N
% NN N
cutoff NN N
point NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
statistical JJ N
significance NN N
. . N

RESULTS VB N
The DT N
groups NNS N
were VBD N
similar JJ N
regarding VBG N
demographic JJ N
and CC N
clinical JJ N
preoperative NN N
parameters NNS o
. . o

Anatomical JJ o
success NN o
rates NNS o
for IN o
colporrhaphy NN o
and CC o
repair NN o
with IN o
mesh JJ i
placement NN i
groups NNS i
were VBD N
56.4 CD N
vs JJ N
82.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval JJ N
0.068-0.54 NN N
) ) N
, , N
respectively RB N
, , N
and CC N
the DT N
difference NN N
between IN N
the DT N
groups NNS N
was VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.018 CD N
) ) N
. . N

Similar JJ o
total JJ o
complication NN o
rates NNS o
were VBD o
observed VBN N
in IN N
both DT N
groups NNS N
, , N
with IN N
tape NN N
exposure NN N
observed VBN N
in IN N
5 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
all DT o
P-QOL NNP o
domains NNS o
as IN o
a DT N
result NN N
of IN N
both DT N
procedures NNS N
( ( N
p VB N
< RB N
0.001 CD N
) ) N
, , N
but CC N
they PRP N
were VBD N
not RB N
distinct JJ N
between IN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP i
Trocar-guided JJ i
transvaginal JJ i
synthetic JJ i
mesh NN i
for IN i
advanced JJ N
anterior JJ N
POP NNP N
repair NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR o
anatomical JJ o
success NN o
rate NN o
for IN o
the DT N
anterior JJ N
compartment NN N
compared VBN N
with IN N
traditional JJ i
colporrhaphy NN o
. . o

Quality NN o
of IN o
life NN o
equally RB o
improved VBN o
after IN N
both DT N
techniques NNS N
. . N

However RB N
, , N
the DT N
trial NN N
failed VBD N
to TO N
detect VB N
differences NNS N
in IN N
P-QOL NNP o
scores NNS o
and CC o
complication NN o
rates NNS o
between IN o
the DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Timing VBG N
for IN N
delivering VBG N
individualized JJ i
patient JJ i
education NN i
intervention NN i
to TO N
Coronary NNP p
Artery NNP p
Bypass NNP p
Graft NNP p
patients NNS p
: : p
An DT N
RCT NNP N
. . N

BACKGROUND NNP N
The DT N
primary JJ N
focus NN N
of IN N
this DT N
study NN N
is VBZ N
on IN N
the DT N
timing NN N
of IN N
the DT N
delivery NN N
of IN N
education NN N
to TO N
patients NNS p
who WP p
had VBD p
CABG NNP i
surgery NN i
. . i

AIM NNP N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
an DT N
individualized JJ i
telephone NN i
patient JJ i
education NN i
intervention NN i
, , N
delivered VBN N
at IN N
two CD N
different JJ N
points NNS N
in IN N
time NN N
( ( N
1-2 JJ N
days NNS N
pre-discharge JJ N
versus JJ N
1-2 JJ N
days NNS N
post-discharge NN N
) ) N
in IN N
enhancing VBG N
the DT N
CABG NNP p
patient NN p
's POS p
knowledge NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
performance NN N
of IN N
self-care JJ N
behaviours NNS N
, , N
and CC N
symptom JJ N
frequency NN N
. . N

METHOD NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
that WDT N
included VBD N
a DT N
convenience NN p
sample NN p
of IN p
first JJ p
time NN p
CABG NNP p
patients NNS p
. . p

Individuals NNS N
who WP N
received VBD N
education NN i
pre-discharge NN i
were VBD N
compared VBN N
to TO N
individuals NNS p
who WP p
received VBD p
education NN p
post-discharge NN p
on IN p
the DT p
outcomes NNS p
. . p

RESULTS NNP N
Results NNP N
indicated VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
outcomes NNS o
between IN o
the DT o
two CD o
time NN o
points NNS o
. . o

As NNP N
well RB N
, , N
anxiety NN o
levels NNS o
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
higher JJR N
in IN N
the DT N
pre-discharge NN N
group NN N
than IN N
the DT N
post-discharge JJ N
group NN N
. . N

CONCLUSIONS VB N
The DT N
individualized JJ N
nature NN N
of IN N
the DT N
educational JJ i
intervention NN i
may MD N
have VB N
accounted VBN N
for IN N
non-significant JJ N
findings NNS N
reported VBN N
in IN N
outcomes NNS N
between IN N
the DT N
two CD N
time NN N
points NNS N
. . N

PRACTICE NNP N
IMPLICATIONS NNP N
Nurses NNP N
may MD N
consider VB N
assessing VBG N
anxiety NN o
levels NNS o
prior RB N
to TO N
delivery NN N
of IN N
educational JJ N
interventions NNS N
, , N
implement JJ N
interventions NNS N
aimed VBN N
at IN N
reducing VBG N
anxiety NN N
levels NNS N
, , N
and CC N
provide VB N
individualized JJ N
teaching NN N
. . N

-DOCSTART- -X- O O

Efficacy NN N
of IN N
artemisinin-based JJ i
combination NN i
treatments NNS i
of IN N
uncomplicated JJ N
falciparum NN N
malaria NNS N
in IN N
under-five-year-old JJ p
Nigerian JJ p
children NNS p
. . p

The DT N
efficacy NN N
of IN N
3-day JJ i
regimens NNS i
of IN i
artemether-lumefantrine JJ i
and CC i
artesunate-amodiaquine JJ i
were VBD N
evaluated VBN N
in IN N
747 CD p
children NNS p
< JJ p
5 CD p
years NNS p
of IN p
age NN p
with IN p
uncomplicated JJ p
malaria NNS p
from IN p
six CD p
geographical JJ p
areas NNS p
of IN p
Nigeria NNP p
. . p

Fever NNP N
clearance NN o
was VBD N
significantly RB N
faster RBR N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
and CC N
the DT N
proportion NN N
of IN N
children NNS N
with IN N
parasitemia NN N
1 CD N
day NN N
after IN N
treatment NN N
began VBD N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
= NNP N
0.016 CD N
) ) N
in IN N
artesunate-amodiaquine-compared JJ N
with IN N
artemether-lumefantrine-treated JJ i
children NNS N
. . N

Parasite NNP o
clearance NN o
times NNS N
were VBD N
similar JJ N
with IN N
both DT N
treatments NNS N
. . N

Overall JJ N
efficacy NN N
was VBD N
96.3 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
94.5-97.6 CD N
% NN N
) ) N
, , N
and CC N
was VBD N
similar JJ N
for IN N
both DT N
regimens NNS N
. . N

Polymerase NNP o
chain NN o
reaction-corrected JJ o
parasitologic JJ o
cure NN o
rates NNS o
on IN N
Day NNP N
28 CD N
were VBD N
96.9 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
93.9-98.2 CD N
% NN N
) ) N
and CC N
98.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
96.1-99.3 CD N
% NN N
) ) N
for IN N
artemether-lumefantrine JJ i
and CC i
artesunate-amodiaquine JJ i
, , N
respectively RB N
. . N

Gametocyte NNP o
carriage NN o
post NN o
treatment NN o
was VBD N
significantly RB N
lower JJR N
than IN N
pretreatment NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
anemic JJ p
children NNS p
, , N
mean JJ o
time NN o
to TO o
recovery NN o
from IN o
anemia NN o
was VBD N
10 CD N
days NNS N
( ( N
95 CD N
% NN N
CI NNP N
9.04-10.9 CD N
) ) N
and CC N
was VBD N
similar JJ N
for IN N
both DT N
regimens NNS N
. . N

Both DT N
treatments NNS N
were VBD N
well RB o
tolerated VBN o
and CC o
are VBP o
safe JJ o
and CC o
efficacious JJ o
treatments NNS o
of IN N
uncomplicated JJ N
falciparum NN N
malaria NN N
in IN N
young JJ p
Nigerian JJ p
children NNS p
. . p

-DOCSTART- -X- O O

Control NN N
of IN N
perioperative JJ N
hypertension NN o
during IN N
coronary JJ i
artery NN i
surgery NN i
. . i

A DT N
randomised JJ N
double-blind NN N
study NN N
comparing VBG N
isosorbide JJ i
dinitrate NN i
and CC i
nitroglycerin NN i
. . i

A DT N
reduction NN N
in IN N
the DT N
causes NNS N
of IN N
myocardial JJ o
ischaemia NN o
remains VBZ N
of IN N
prime JJ N
importance NN N
during IN N
coronary JJ N
artery NN N
surgery NN N
. . N

Hypertension NN o
with IN N
the DT N
ensuing VBG N
increase NN N
in IN N
myocardial JJ o
oxygen NN o
demand NN o
is VBZ N
a DT N
major JJ N
factor NN N
in IN N
the DT N
aetiology NN N
of IN N
perioperative JJ N
myocardial JJ o
ischaemia NN o
. . o

Nitroglycerin NNP i
( ( i
NTG NNP i
) ) i
has VBZ N
long RB N
been VBN N
used VBN N
beneficially RB N
to TO N
reduce VB N
myocardial JJ o
oxygen NN o
demand NN o
by IN N
its PRP$ N
effects NNS N
on IN N
the DT N
systemic JJ N
and CC N
peripheral JJ N
vascular JJ N
resistances NNS N
. . N

An DT N
alternative JJ N
nitrate NN i
, , i
isosorbide JJ i
dinitrate NN i
( ( i
ISDN NNP i
) ) i
is VBZ N
now RB N
available JJ N
as IN N
an DT N
intravenous JJ N
preparation NN N
, , N
and CC N
may MD N
offer VB N
technical JJ N
advantages NNS N
, , N
both DT N
due JJ N
to TO N
its PRP$ N
stability NN N
in IN N
solution NN N
and CC N
also RB N
its PRP$ N
longer NN N
in IN N
vivo JJ N
half-life NN N
. . N

We PRP N
designed VBD N
and CC N
carried VBD N
out RP N
a DT N
multi-centre JJ N
study NN N
to TO N
compare VB N
and CC N
evaluate VB N
the DT N
efficacy NN o
of IN o
ISDN NNP o
and CC o
NTG NNP o
in IN N
the DT N
management NN N
of IN N
perioperative JJ N
hypertension NN N
in IN N
85 CD p
patients NNS p
undergoing JJ p
elective JJ i
coronary JJ i
artery NN i
surgery NN i
. . i

A DT p
total NN p
of IN p
288 CD p
events NNS p
in IN p
which WDT p
the DT p
systolic NN o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
exceeded VBD p
a DT p
predetermined JJ p
trigger NN p
value NN p
were VBD p
observed VBN p
. . p

ISDN NNP i
was VBD N
successful JJ o
in IN N
treating VBG N
hypertension NN o
in IN N
63 CD N
% NN N
of IN N
the DT N
events NNS N
, , N
whereas NNS N
NTG NNP i
had VBD N
an DT N
83 CD N
% NN N
success NN N
. . N

The DT N
SBP NNP o
was VBD N
significantly RB N
lowered VBN N
after IN N
treatment NN N
with IN N
either DT N
ISDN NNP i
, , N
155 CD N
mmHg NN N
to TO N
138 CD N
mmHg NN N
, , N
or CC N
NTG NNP N
, , N
160 CD N
mmHg NN N
to TO N
130 CD N
mmHg NN N
. . N

The DT N
mean JJ o
successful JJ o
dose NN o
rate NN o
for IN N
ISDN NNP i
was VBD N
6.5 CD N
micrograms JJ N
kg-1 JJ N
min-1 NN N
, , N
whereas NNS N
for IN N
NTG NNP i
this DT N
was VBD N
3.8 CD N
micrograms JJ N
kg-1 JJ N
min-1 NN N
. . N

In IN N
the DT N
ISDN NNP i
group NN N
less JJR N
events NNS o
took VBD N
place NN N
possibly RB N
due JJ N
to TO N
the DT N
longer JJR N
duration NN N
of IN N
this DT N
drug NN N
. . N

In IN N
many JJ N
previous JJ N
studies NNS N
NTG NNP i
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
controlling VBG N
hypertension NN o
; : o
ISDN NNP i
offers NNS N
and CC N
alternative JJ N
approach NN N
in IN N
reducing VBG o
hypertension NN o
. . o

-DOCSTART- -X- O O

Use NNP N
of IN N
an DT N
inspiratory JJ i
impedance NN i
threshold JJ i
device NN i
on IN i
a DT i
facemask NN i
and CC i
endotracheal VB i
tube NN i
to TO N
reduce VB N
intrathoracic JJ o
pressures NNS o
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ p
compression-decompression NN o
cardiopulmonary JJ o
resuscitation NN o
. . o

INTRODUCTION NNP N
Use NNP N
of IN N
an DT N
inspiratory JJ i
impedance NN i
threshold NN i
device NN i
( ( i
ITD NNP i
) ) i
significantly RB N
increases VBZ N
coronary JJ N
perfusion NN N
pressures NNS N
and CC N
survival NN N
in IN N
patients NNS p
ventilated VBN p
with IN p
an DT p
endotracheal JJ i
tube NN i
( ( i
ETT NNP i
) ) i
during IN p
active JJ i
compression-decompression NN i
cardiopulmonary JJ i
resuscitation NN i
. . i

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
the DT N
ITD NNP i
could MD N
lower VB N
intratracheal NN N
pressures NNS N
when WRB N
attached VBN N
to TO N
either VB N
a DT N
facemask NN i
or CC i
ETT NNP i
. . i

METHODS NNP N
An DT i
active JJ i
and CC i
sham JJ i
ITD NNP i
were VBD N
randomly RB N
applied VBN N
first RB N
to TO N
a DT N
facemask NN i
and CC N
then RB N
to TO N
an DT N
ETT NNP i
during IN N
active JJ i
compression-decompression NN i
cardiopulmonary JJ i
resuscitation NN i
in IN p
13 CD p
out-of-hospital JJ p
cardiac JJ p
arrest NN p
patients NNS p
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
prospective JJ N
clinical JJ N
trial NN N
. . N

The DT N
compression-to-bag-valve JJ N
ventilation NN N
ratio NN N
was VBD N
15:2 CD N
. . N

Airway NN N
pressures NNS N
( ( N
surrogate NN N
for IN N
intrathoracic JJ N
pressure NN N
) ) N
were VBD N
measured VBN N
with IN N
a DT N
pressure NN N
transducer NN N
. . N

A DT i
sham NN i
and CC i
an DT i
active JJ i
ITD NNP i
were VBD N
used VBN N
for IN N
1 CD N
min NNS N
each DT N
in IN N
a DT N
randomized JJ N
order NN N
, , N
first RB N
on IN N
a DT N
facemask NN i
and CC N
then RB N
on IN N
an DT N
ETT NNP i
. . i

Statistical JJ N
analyses NNS N
were VBD N
made VBN N
using VBG N
Friedman NNP N
's POS N
and CC N
Wilcoxon NNP N
's POS N
rank-sum JJ N
tests NNS N
. . N

RESULTS NNP N
For IN N
the DT N
primary JJ N
end NN N
point NN N
, , N
mean JJ o
+/- JJ o
sd NN o
maximum JJ o
negative JJ o
intrathoracic NN o
pressures NNS o
( ( N
mm VB N
Hg NNP N
) ) N
during IN N
the DT N
decompression NN o
phase NN o
of IN o
cardiopulmonary JJ o
resuscitation NN o
were VBD N
-1.0 JJ N
+/- JJ N
0.73 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN i
vs. FW N
-4.6 NNP N
+/- JJ N
3.7 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ i
ITD NN i
on IN N
the DT N
facemask NN N
( ( N
p JJ N
= NNP N
.003 NNP N
) ) N
and CC N
-1.3 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
with IN N
a DT N
sham NN N
ITD NNP N
vs. IN N
-7.3 NNP N
+/- JJ N
4.5 CD N
mm NN N
Hg NNP N
with IN N
an DT N
active JJ N
ITD NNP N
on IN N
an DT N
ETT NNP N
( ( N
p JJ N
= NNP N
.0009 NNP N
) ) N
. . N

Decompression NNP o
phase NN o
airway NN o
pressures NNS o
with IN N
the DT N
facemask NN i
and CC i
ETT NNP i
were VBD N
not RB N
statistically RB N
different JJ N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
an DT N
active JJ i
ITD NNP i
attached VBD i
to TO i
a DT i
facemask NN i
or CC i
an DT i
ETT NNP i
resulted VBD N
in IN N
a DT N
significantly RB N
lower JJR N
negative JJ o
intratracheal JJ o
pressure NN o
during IN N
the DT N
decompression NN N
phase NN N
of IN N
active JJ N
compression-decompression NN N
cardiopulmonary JJ N
resuscitation NN N
when WRB N
compared VBN N
with IN N
controls NNS N
. . N

Airway NNP N
pressures VBZ N
with IN N
an DT N
ITD NNP i
on IN N
either CC N
a DT i
facemask NN i
or CC N
ETT NNP i
were VBD N
similar JJ N
. . N

The DT N
ITD-facemask JJ i
combination NN i
was VBD N
practical JJ N
and CC N
enables VBZ N
rapid JJ N
deployment NN N
of IN N
this DT N
life-saving JJ N
technology NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
the DT N
effect NN N
of IN N
dried JJ i
purple JJ i
carrot NN i
on IN N
body NN N
mass NN N
, , N
lipids NNS N
, , N
blood NN N
pressure NN N
, , N
body NN N
composition NN N
, , N
and CC N
inflammatory JJ N
markers NNS N
in IN N
overweight NN p
and CC p
obese JJ p
adults NNS p
: : p
the DT N
QUENCH NNP N
trial NN N
. . N

Obesity NNP N
is VBZ N
a DT N
significant JJ N
health NN N
issue NN N
worldwide NN N
and CC N
is VBZ N
associated VBN N
with IN N
chronic JJ N
, , N
low-grade JJ N
inflammation NN N
predisposing VBG N
the DT N
individual NN N
to TO N
cardiovascular VB N
disease NN N
and CC N
impaired JJ N
blood NN N
glucose JJ N
homeostasis NN N
. . N

Anthocyanins NNS i
and CC i
phenolic JJ i
acids NNS i
from IN i
purple JJ i
carrots NNS i
are VBP N
effective JJ N
at IN N
reversing VBG N
inflammation NN N
and CC N
metabolic JJ N
alterations NNS N
in IN N
animal NN N
models NNS N
, , N
potentially RB N
through IN N
inhibition NN N
of IN N
inflammatory JJ N
pathways NNS N
. . N

The DT N
effects NNS N
of IN N
dried JJ i
purple JJ i
carrot NN i
on IN N
body NN o
mass NN o
, , o
body NN o
composition NN o
, , o
blood NN o
pressure NN o
, , o
lipids NNS o
, , o
inflammatory JJ o
markers NNS o
, , o
liver JJ o
function NN o
tests NNS o
, , o
and CC o
appetite RB o
were VBD N
investigated VBN N
in IN N
16 CD p
males NNS p
( ( p
aged VBN p
53.1 CD p
? . p
7.6 CD p
years NNS p
and CC p
with IN p
a DT p
mean JJ p
BMI NNP p
of IN p
32.8 CD p
? . p
4.6 CD p
kg/m NN p
( ( p
2 CD p
) ) p
) ) p
with IN p
normal JJ p
lipid JJ p
and CC p
inflammatory JJ p
markers NNS p
. . p

There EX N
was VBD N
no DT N
evidence NN N
that IN N
118.5 CD N
mg/day NN N
of IN N
anthocyanins NNS i
and CC i
259.2 CD N
mg/day NN N
of IN N
phenolic JJ i
acids NNS i
for IN i
4 CD N
weeks NNS N
resulted VBD N
in IN N
statistically RB N
significant JJ N
changes NNS N
in IN N
body NN o
mass NN o
, , o
body NN o
composition NN o
, , o
appetite RB o
, , o
dietary JJ o
intake NN o
, , o
low JJ o
density NN o
lipoprotein NN o
, , o
total JJ o
cholesterol NN o
, , o
blood NN o
pressure NN o
, , o
or CC o
C-reactive JJ o
protein NN o
in IN o
these DT N
obese JJ N
participants NNS N
at IN N
the DT N
dose NN N
and CC N
length NN N
of IN N
intervention NN N
used VBN N
in IN N
this DT N
trial NN o
. . o

High JJ o
density NN o
lipoprotein VBP o
cholesterol NN o
was VBD o
lower JJR N
in IN N
the DT N
intervention NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD o
) ) o
. . o

Aspartate NNP o
amino NN o
transferase NN o
and CC o
alanine NN o
amino NN o
transferase NN o
did VBD o
not RB N
change NN N
, , N
indicating VBG N
that IN N
the DT N
intervention NN N
was VBD N
safe JJ N
. . N

More JJR N
studies NNS N
are VBP N
required VBN N
to TO N
establish VB N
the DT o
bioavailability NN o
and CC o
pharmacokinetic JJ o
effects NNS o
of IN o
purple JJ i
carrot NN i
anthocyanins NNS i
and CC i
phenolic JJ i
acids NNS i
prior RB i
to TO N
further JJ N
trials NNS N
of IN N
efficacy NN N
with IN N
respect NN N
to TO N
treating VBG o
inflammation NN o
and CC o
metabolic JJ o
alterations NNS o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
m-chlorophenylpiperazine NN i
on IN N
plasma NN o
homovanillic JJ o
acid NN o
concentrations NNS o
in IN N
healthy JJ p
subjects NNS p
. . p

In IN N
view NN N
of IN N
the DT N
abundant JJ N
anatomical JJ N
and CC N
functional JJ N
interactions NNS N
between IN N
serotonin NN N
and CC N
dopamine NN N
systems NNS N
, , N
this DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
the DT N
serotonin JJ N
agonist NN N
, , N
m-chlorophenylpiperazine NN i
( ( i
mCPP NN i
) ) i
on IN N
plasma NN o
concentrations NNS o
of IN o
the DT o
dopamine NN o
metabolite NN o
, , o
homovanillic JJ o
acid NN o
. . o

Plasma NNP N
prolactin NN N
levels NNS N
, , N
body NN N
temperature NN N
, , N
and CC N
mCPP RB o
blood NN N
level NN N
were VBD N
also RB N
measured VBN N
. . N

mCPP NN i
( ( N
0.35 CD N
mg/kg NN N
) ) N
and CC N
placebo $ i
were VBD N
administered VBN N
orally RB N
to TO N
10 CD p
healthy JJ p
men NNS p
in IN N
a DT N
randomized JJ N
double-blind NN N
design NN N
. . N

Variables NNS N
were VBD N
measured VBN N
for IN N
210 CD N
min NNS N
after IN N
administration NN N
of IN N
capsules NNS N
. . N

mCPP NNS o
raised VBD o
prolactin NN o
and CC o
temperature NN o
as IN o
compared VBN o
to TO o
placebo VB o
, , N
but CC N
did VBD N
not RB N
affect VB N
plasma NN o
homovanillic JJ o
acid JJ o
concentrations NNS o
. . o

Results VB N
suggest JJS N
that IN N
mCPP NN o
does VBZ o
not RB o
alter VB o
dopamine NN o
function NN o
. . o

-DOCSTART- -X- O O

A DT N
double-blind JJ N
placebo NN i
controlled VBD N
trial NN N
of IN N
piracetam NN i
added VBN N
to TO N
risperidone VB i
in IN N
patients NNS p
with IN p
autistic JJ p
disorder NN p
. . p

It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
autism NN N
is VBZ N
a DT N
hypoglutamatergic JJ N
disorder NN N
. . N

Therefore RB N
, , N
it PRP N
was VBD N
of IN N
interest NN N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
piracetam NN i
, , N
a DT N
positive JJ N
modulator NN N
of IN N
AMPA-sensitive JJ N
glutamate NN N
receptors NNS N
in IN N
autistic JJ N
disorder NN N
. . N

About IN p
40 CD p
children NNS p
between IN p
the DT p
ages NNS p
three CD p
and CC p
11 CD p
years NNS p
( ( p
inclusive JJ p
) ) p
with IN p
a DT p
DSM NNP p
IV NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
and CC p
who WP p
were VBD p
outpatients NNS p
from IN p
a DT p
specialty NN p
clinic NN p
for IN p
children NNS p
were VBD p
recruited VBN p
. . p

The DT N
children NNS p
presented VBN p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
piracetam VB i
+ NNP i
risperidone NN i
( ( i
Group NNP i
A NNP i
) ) i
or CC i
placebo JJ i
+ NN i
risperidone NN i
( ( N
Group NNP N
B NNP N
) ) N
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
up RB N
to TO N
2 CD N
mg/day NN N
for IN N
children NNS N
between IN N
10 CD N
and CC N
40 CD N
kg NN N
and CC N
3 CD N
mg/day NN N
for IN N
children NNS N
weighting VBG N
above IN N
40 CD N
kg NN N
. . N

The DT N
dose NN N
of IN N
piracetam NN i
was VBD N
titrated VBN N
up RB N
to TO N
800 CD N
mg/day NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Rating VBG o
Scale NNP o
( ( o
total JJ o
score NN o
) ) o
. . o

The DT N
ABC-C JJ o
Rating NNP o
Scale NNP o
scores VBZ o
improved VBN N
with IN N
piracetam NN N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
the DT N
between IN N
subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
5.85 CD N
, , N
d.f NN N
. . N

= CC N
1 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
changes NNS N
at IN N
the DT N
endpoint NN N
compared VBN N
with IN N
baseline NN N
were VBD N
: : N
-11.90 JJ N
+/- JJ N
3.79 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
and CC N
-5.15 JJ N
+/- JJ N
3.04 CD N
for IN N
group NN N
A NNP N
and CC N
B NNP N
respectively RB N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
on IN N
the DT N
change NN N
in IN N
scores NNS o
in IN o
the DT o
ABC-C NNP o
Rating NNP o
Scale NNP o
in IN N
week NN N
10 CD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
t JJ N
= NN N
6.017 CD N
, , N
d.f NN N
. . N

= CC N
38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
combination NN N
of IN N
atypical JJ N
antipsychotic JJ N
medications NNS N
and CC N
a DT N
glutamate JJ N
agent NN N
such JJ N
as IN N
piracetam NNS N
, , N
might MD N
have VB N
increase VBN N
synergistic JJ N
effects NNS N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
specific JJ N
preparation NN N
of IN N
Chinese JJ i
herbs NNS i
( ( N
clear JJ N
the DT N
way NN N
) ) N
on IN N
duration NN o
and CC o
severity NN o
of IN o
the DT o
common JJ o
cold NN o
. . o

-DOCSTART- -X- O O

A DT N
further JJ N
investigation NN N
of IN N
goal-directed JJ o
intention NN o
understanding NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Findings NNS N
from IN N
research NN N
investigating VBG N
goal-directed JJ o
intention NN o
understanding NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
have VBP N
been VBN N
equivocal JJ N
, , N
in IN N
part NN N
because IN N
of IN N
the DT N
varying NN N
methodologies NNS N
used VBN N
across IN N
studies NNS N
. . N

This DT N
study NN N
compares VBZ N
both DT N
object-oriented JJ i
and CC i
social-communicatively JJ i
cued VBN i
goal-directed JJ i
intention NN i
understanding NN i
in IN N
children NNS p
with IN p
ASD NNP p
and CC p
typically-developing JJ p
children NNS p
. . p

Relative JJ N
to TO N
matched VB N
controls NNS N
, , N
children NNS N
with IN N
ASD NNP N
did VBD N
not RB N
exhibit VB N
deficits NNS N
in IN N
object-oriented JJ o
intention NN o
understanding NN o
. . o

While IN N
children NNS p
with IN p
ASD NNP p
also RB N
demonstrated VBD N
the DT N
ability NN N
to TO N
understand VB N
intention NN N
when WRB N
cued VBN N
by IN N
social-communication NN N
indicators NNS N
, , N
typically-developing JJ N
children NNS N
differentiated VBD N
between IN N
intentional JJ N
and CC N
unintentional JJ N
acts NNS N
at IN N
a DT N
significantly RB N
greater JJR N
level NN N
. . N

Group NNP N
differences VBZ N
in IN N
performance NN N
were VBD N
eliminated VBN N
if IN N
only JJ N
trials NNS N
in IN N
which WDT N
children NNS N
attended VBD N
to TO N
the DT N
experimenter NN N
's POS N
face NN N
were VBD N
considered VBN N
. . N

Results VB N
suggest JJS N
that IN N
children NNS p
with IN p
ASD NNP p
have VBP N
intact JJ N
object-oriented JJ o
intention NN o
understanding VBG o
abilities NNS N
, , N
and CC N
are VBP N
able JJ N
to TO N
use VB N
social-communicative JJ N
cues NNS N
to TO N
understand VB N
intention NN N
. . N

However RB N
, , N
their PRP$ N
ability NN N
to TO N
demonstrate VB N
social-communicatively JJ o
cued VBN o
intention NN o
understanding NN i
is VBZ N
limited VBN N
by IN N
a DT N
lack NN N
of IN N
attention NN N
to TO N
relevant VB N
social-communicative JJ N
information NN N
. . N

-DOCSTART- -X- O O

Cimetidine NNP i
is VBZ N
not RB N
more RBR N
effective JJ o
than IN N
placebo NN i
in IN N
acute JJ p
infectious JJ p
mononucleosis NN p
. . p

-DOCSTART- -X- O O

Iobitridol NNP i
300 CD i
compared VBN N
to TO N
iopromide VB i
300 CD i
-- : i
a DT i
double-blind JJ N
randomized JJ N
phase-III NN N
study NN N
of IN N
clinical JJ N
tolerance NN N
in IN N
total JJ p
body NN p
CT. NNP p
UNLABELLED NNP N
PURPOSE NNP N
, , N
MATERIAL NNP N
AND NNP N
METHODS NNP N
: : N
The DT N
clinical JJ N
safety NN N
of IN N
iobitriodol JJ i
300 CD i
mg NN i
I/ml NNP i
and CC i
iopromide RB i
300 CD i
mg NNS i
I/ml NNP i
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
double JJ N
blind IN N
phase-III JJ N
study NN N
conducted VBD N
on IN N
60 CD p
patients NNS p
undergoing JJ p
abdominal JJ p
CT NNP p
for IN p
a DT p
variety NN p
of IN p
indications NNS p
. . p

Each DT N
examination NN N
was VBD N
rated VBN N
as IN N
diagnostic JJ N
or CC N
nondiagnostic JJ N
and CC N
the DT N
image NN N
quality NN N
was VBD N
noted VBN N
. . N

Nature NN N
, , N
onset NN o
, , N
intensity NN N
as RB N
well RB N
as IN N
outcome NN N
of IN N
each DT N
adverse JJ o
reaction NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
imaging VBG o
quality NN o
and CC o
side NN o
effects NNS o
between IN N
the DT N
contrast NN N
media NNS N
. . N

In IN N
this DT N
study NN N
, , N
both DT N
iobitridol NNS i
and CC N
iopromide NN i
provided VBD N
excellent JJ o
image NN o
quality NN o
and CC N
a DT N
low JJ o
rate NN o
of IN o
side NN o
effects NNS o
. . o

CONCLUSION NNP N
Iobitridol NNP i
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
nonionic JJ o
contrast NN o
agent NN o
for IN N
contrast-enhanced JJ N
body NN N
CT NNP N
. . N

-DOCSTART- -X- O O

The DT N
double-blind JJ N
sham-controlled JJ N
study NN N
of IN N
high-frequency NN i
rTMS NN i
( ( N
20 CD N
Hz NNP N
) ) N
for IN N
negative JJ N
symptoms NNS N
in IN N
schizophrenia NN p
: : p
negative JJ N
results NNS N
. . N

The DT N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
HF-rTMS NNP i
) ) i
over IN N
the DT N
prefrontal JJ N
cortex NN N
is VBZ N
a DT N
promising JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
negative JJ N
symptoms NNS N
of IN N
schizophrenia NN p
. . p

Using VBG N
double-blind JJ N
sham-controlled JJ N
parallel NN N
design NN N
, , N
we PRP N
evaluated VBD N
the DT N
effect NN N
of IN N
HF-rTMS NNP i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
( ( N
DLPFC NNP N
) ) N
on IN N
negative JJ N
symptoms NNS N
in IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

Sixteen NNP p
schizophrenia NN p
patients NNS p
with IN p
predominantly RB p
negative JJ p
symptoms NNS p
on IN p
stable JJ p
antipsychotic JJ p
medication NN p
were VBD N
treated VBN N
with IN N
20 CD i
Hz NNP i
rTMS NN i
( ( N
90 CD N
% NN N
of IN N
motor NN N
threshold NN N
, , N
2000 CD N
stimuli NN N
per IN N
session NN N
) ) N
over IN N
ten JJ N
days NNS N
within IN N
2 CD N
weeks NNS N
with IN N
six CD N
weeks NNS N
follow-up RB N
. . N

The DT N
effect NN N
was VBD N
assessed VBN N
using VBG N
PANSS NNP o
, , o
CGI NNP o
, , o
MADRS NNP o
and CC o
neuropsychological JJ o
tests NNS o
. . o

We PRP N
failed VBD N
to TO N
find VB N
any DT N
significant JJ N
effect NN N
of IN N
active JJ o
rTMS NN o
. . o

Sham NNP o
rTMS NN o
showed VBD N
a DT N
trend NN N
for IN N
improvement NN o
over IN o
time NN o
on IN N
positive JJ o
and CC o
negative JJ o
subscales NNS o
of IN o
PANSS NNP o
and CC o
MADRS NNP o
. . o

Between-group NNP N
comparisons NNS N
failed VBD N
to TO N
reveal VB N
any DT N
significant JJ N
differences NNS N
on IN N
any DT N
rating NN o
scales NNS o
except IN N
a DT N
positive JJ o
subscale NN o
of IN o
PANSS NNP o
after IN N
8 CD N
weeks NNS N
. . N

Results NNS N
from IN N
our PRP$ N
study NN N
did VBD N
not RB N
confirm VB N
that IN N
HF-rTMS NNP o
over IN N
the DT N
left JJ N
DLPCF NNP o
affects VBZ o
the DT o
negative JJ o
symptoms NNS o
of IN o
schizophrenia NN o
and CC N
alternative JJ N
rTMS NN N
approaches NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
comparison NN N
of IN N
parecoxib/valdecoxib NN i
and CC N
placebo NN i
for IN N
the DT N
prevention NN N
of IN N
cystoid JJ N
macular NN N
edema NN N
after IN N
scleral JJ p
buckling NN p
surgery NN p
. . p

AIMS NNP N
To TO N
assess VB N
the DT N
impact NN N
of IN N
valdecoxib NN i
on IN N
the DT N
incidence NN N
of IN N
macular JJ N
edema NN N
, , N
after IN N
scleral JJ N
buckling NN N
surgery NN N
. . N

METHODS NNP N
Prospective NNP N
randomized VBD N
double JJ N
masked JJ N
placebo NN i
controlled VBD N
study NN N
. . N

Patients NNS p
undergoing VBG p
scleral JJ p
buckle NN p
surgery NN p
over IN p
18 CD p
months NNS p
were VBD N
recruited VBN N
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
valdecoxib NN i
or CC i
placebo NN i
. . i

Patients NNS N
also RB N
received VBD N
two CD N
doses NNS N
of IN N
either DT N
parecoxib NN i
( ( i
pro-drug JJ i
of IN i
valdecoxib NN i
) ) i
intravenously RB i
40 CD N
mg NNS N
6 CD N
hourly RB N
day NN N
one CD N
postoperative NN N
or CC N
identical JJ i
placebo NN i
injection NN i
Patients NNP N
underwent JJ N
retinal JJ N
examination NN N
, , N
optical JJ N
coherence NN N
tomography NN N
and CC N
retinal JJ N
thickness NN N
analyzer NN N
scan NN N
of IN N
the DT N
macula NN N
preoperatively RB N
, , N
and CC N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postoperatively RB N
. . N

Outcome NNP N
measures NNS N
were VBD N
the DT N
incidence NN N
of IN N
macular JJ o
edema NN o
, , o
retinal JJ o
thickness NN o
, , o
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
and CC o
presence NN o
of IN o
persistent JJ o
subretinal JJ o
fluid NN o
. . o

RESULTS NNP N
Interim NNP N
analysis NN N
was VBD N
performed VBN N
with IN N
116 CD p
patients NNS p
were VBD p
recruited VBN p
, , p
58 CD p
to TO p
each DT p
treatment NN p
arm NN p
. . p

The DT N
incidence NN o
of IN o
macular JJ o
edema NN o
in IN N
all DT N
patients NNS N
was VBD N
5 CD N
% NN N
at IN N
visit NN N
1 CD N
and CC N
2.2 CD N
% NN N
at IN N
visit NN N
2 CD N
postoperatively RB N
. . N

This DT N
incidence NN N
was VBD N
much RB o
lower JJR o
than IN N
the DT N
expected JJ N
incidence NN N
used VBN N
in IN N
the DT N
power NN N
calculation NN N
to TO N
determine VB N
study NN N
size NN N
. . N

It PRP N
was VBD N
therefore RB N
apparent JJ N
that IN N
a DT N
much RB N
larger JJR N
study NN N
population NN N
would MD N
be VB N
required VBN N
to TO N
test VB N
for IN N
an DT N
effect NN N
and CC N
that IN N
this DT N
was VBD N
not RB N
achievable JJ N
within IN N
the DT N
study NN N
time NN N
period NN N
. . N

The DT N
study NN N
was VBD N
therefore RB N
terminated VBN N
early RB N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
difference NN N
between IN N
COX NNP N
2 CD N
inhibitor NN N
and CC N
placebo NN N
groups NNS N
in IN N
the DT N
incidence NN o
of IN o
edema NN o
, , o
retinal JJ o
thickness NN o
or CC o
visual JJ o
outcome NN o
. . o

The DT N
presence NN o
of IN o
residual JJ o
subretinal JJ o
fluid NN o
at IN o
the DT o
macula NN o
was VBD N
significantly RB N
reduced VBN N
by IN N
COX NNP N
2 CD N
inhibitor NN N
treatment NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN N
of IN N
cystoid NN N
macular NN N
edema NN N
after IN N
scleral JJ N
buckling NN N
surgery NN N
is VBZ N
low JJ N
and CC N
is VBZ N
not RB N
influenced VBN N
by IN N
prophylactic JJ N
use NN N
of IN N
valdecoxib NN i
. . i

The DT N
rate NN N
of IN N
residual JJ N
subretinal JJ N
fluid NN N
was VBD N
reduced VBN N
by IN N
COX NNP N
2 CD N
inhibitor NN N
treatment NN N
. . N

Enhanced NNP N
antiinflammatory NN N
therapy NN N
has VBZ N
the DT N
potential NN N
to TO N
improve VB N
outcomes NNS N
in IN N
scleral JJ N
buckling NN N
surgery NN N
. . N

-DOCSTART- -X- O O

Simulating VBG N
a DT N
memory NN N
impairment NN N
: : N
can MD N
amnesics VB p
implicitly RB N
outperform JJ N
simulators NNS N
? . N
OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effectiveness NN o
of IN N
a DT N
variety NN N
of IN N
tests NNS N
in IN N
differentiating VBG N
simulating VBG o
test NN o
performances NNS o
from IN N
genuine JJ N
memory-impaired JJ o
and CC N
normal JJ N
( ( N
control NN N
) ) N
test NN N
performances NNS N
. . N

DESIGN VB N
A DT i
simulation NN i
design NN i
was VBD N
implemented VBN N
, , N
based VBN N
on IN N
an DT N
analogue NN N
design NN N
in IN N
which WDT N
normal JJ N
participants NNS N
were VBD N
given VBN N
experimental JJ N
instructions NNS N
to TO N
feign VB N
a DT N
mental JJ N
impairment NN N
and CC N
are VBP N
compared VBN N
to TO N
( ( N
a DT N
) ) N
other JJ N
normal JJ N
participants NNS N
with IN N
instructions NNS N
to TO N
perform VB N
honestly RB N
, , N
and CC N
( ( N
b NN N
) ) N
a DT N
comparison NN N
group NN N
, , N
for IN N
example NN N
, , N
acquired VBD p
brain-injured JJ p
persons NNS p
, , N
with IN N
similar JJ N
instructions NNS N
. . N

METHOD NNP N
Forty NNP p
individuals NNS p
comprised VBD p
the DT p
simulating NN p
and CC p
control NN p
group NN p
and CC N
all DT N
participants NNS N
were VBD N
randomly RB i
assigned VBN i
to TO i
the DT i
simulating NN i
and CC i
control NN i
groups NNS i
. . i

Twenty CD p
memory-impaired JJ p
patients NNS p
, , p
all DT p
of IN p
whom WP p
had VBD p
been VBN p
diagnosed VBN p
as IN p
suffering VBG p
from IN p
a DT p
memory NN p
impairment NN p
following VBG p
acquired VBD p
brain NN p
damage NN p
, , p
participated VBD p
as IN p
the DT p
memory-impaired JJ p
control NN p
group NN p
. . p

The DT i
simulation NN i
group NN i
was VBD i
directed VBN i
to TO i
imitate VB i
a DT i
person NN i
with IN i
a DT i
memory NN i
impairment NN i
. . i

The DT N
primary JJ o
outcome JJ o
measure NN o
involved VBN N
identifying VBG o
those DT o
tests NNS o
, , o
if IN o
any DT o
, , o
where WRB o
simulators NNS o
were VBD o
significantly RB o
different JJ o
from IN o
normal JJ o
and CC o
memory-impaired JJ o
participants NNS o
. . o

RESULTS VB N
On IN N
5 CD N
of IN N
the DT N
15 CD N
tasks NNS N
administered VBN N
, , N
simulators NNS o
performed VBD o
significantly RB o
differently RB o
from IN o
normal JJ o
and CC o
memory-impaired JJ o
participants NNS o
. . o

Of IN N
these DT N
5 CD N
tasks NNS N
, , N
the DT N
coin-in-the-hand NN N
, , N
when WRB N
administered VBN N
in IN N
conjunction NN N
with IN N
the DT N
autobiographical JJ N
interview NN N
, , N
identified VBD N
95 CD N
per IN N
cent NN N
of IN N
the DT N
simulators NNS N
without IN N
misclassifying VBG N
any DT N
of IN N
the DT N
memory-impaired JJ N
or CC N
normal JJ N
participants NNS N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
suggested VBN N
that IN N
these DT N
two CD N
tests NNS N
, , N
when WRB N
administered VBN N
jointly RB N
, , N
might MD N
be VB N
of IN N
use NN N
in IN N
clinical JJ N
settings NNS N
to TO N
assist VB N
in IN N
the DT N
detection NN N
of IN N
malingerers NNS N
. . N

-DOCSTART- -X- O O

Tofacitinib NN i
with IN i
methotrexate NN i
in IN N
third-line JJ N
treatment NN N
of IN N
patients NNS p
with IN p
active JJ p
rheumatoid NN p
arthritis NN p
: : p
patient-reported JJ N
outcomes NNS N
from IN N
a DT N
phase NN N
III NNP N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
patient-reported JJ N
outcomes NNS N
( ( N
PROs NNP N
) ) N
for IN N
tofacitinib NN N
, , N
an DT N
oral JJ N
JAK NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
, , N
in IN N
a DT N
6-month JJ N
, , N
phase JJ N
III NNP N
, , N
randomized VBD N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Patients NNPS p
ages VBZ p
?18 CD p
years NNS p
with IN p
active JJ p
RA NNP p
with IN p
an DT p
inadequate JJ p
response NN p
to TO p
?1 VB p
tumor NN p
necrosis NN p
factor NN p
inhibitor NN p
( ( p
TNFi NNP p
) ) p
and CC p
receiving VBG p
stable JJ p
background NN p
methotrexate NN p
were VBD p
randomized VBN p
2:2:1:1 CD i
to TO i
tofacitinib VB i
5 CD i
mg NN i
or CC i
10 CD i
mg JJ i
twice RB i
daily RB i
, , i
or CC i
placebo NN i
advanced VBD i
to TO i
tofacitinib VB i
5 CD i
mg NN i
or CC i
10 CD i
mg JJ i
twice RB i
daily RB i
at IN i
month NN i
3 CD i
. . i

PROs NNS N
measured VBD N
at IN N
month NN N
3 CD N
included VBD o
patient NN o
global JJ o
assessment NN o
of IN o
disease NN o
activity NN o
( ( o
PtGA NNP o
) ) o
, , o
pain VBP o
, , o
Health NNP o
Assessment NNP o
Questionnaire NNP o
( ( o
HAQ NNP o
) ) o
disability NN o
index NN o
( ( o
DI NNP o
) ) o
, , o
Medical NNP o
Outcomes NNP o
Study NNP o
( ( o
MOS NNP o
) ) o
Short NNP o
Form NNP o
36 CD o
Health NNP o
Survey NNP o
version NN o
2 CD o
( ( o
SF-36v2 NNP o
; : o
acute NN o
) ) o
, , o
Functional NNP o
Assessment NNP o
of IN o
Chronic NNP o
Illness NNP o
Therapy-Fatigue NNP o
( ( o
FACIT-F NNP o
) ) o
, , o
and CC o
MOS NNP o
Sleep NNP o
Scale NNP o
. . o

RESULTS NNP o
Patients NNPS N
received VBD N
tofacitinib JJ N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
133 CD N
) ) N
or CC N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
134 CD N
) ) N
or CC N
placebo NN N
advanced VBD N
to TO N
tofacitinib VB N
5 CD N
mg NN N
( ( N
n JJ N
= NNP N
66 CD N
) ) N
or CC N
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
66 CD N
) ) N
. . N

HAQ NNP o
DI NNP o
( ( o
reported VBD o
previously RB o
) ) o
, , o
PtGA NNP o
( ( o
P NNP o
< NNP o
0.0001 CD o
) ) o
, , o
and CC o
SF-36v2 NNP o
physical JJ o
and CC o
mental JJ o
component NN o
summary NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
scores NNS o
were VBD o
improved VBN o
for IN o
both DT N
tofacitinib JJ N
doses NNS N
versus VBP N
placebo NN N
. . N

Furthermore NNP N
, , N
improvements NNS N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
the DT N
minimum NN N
clinically RB N
important JJ N
difference NN N
were VBD N
more RBR N
frequently RB N
reported VBN N
by IN N
tofacitinib-treated JJ N
patients NNS N
versus VBP N
placebo NN N
for IN N
PtGA NNP o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) o
, , o
pain NN o
( ( o
P NNP o
< NNP N
0.0001 CD o
) ) o
, , o
HAQ NNP o
DI NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) o
, , o
SF-36v2 NNP o
physical JJ o
and CC o
mental JJ o
component NN o
summary JJ o
scores NNS o
( ( o
P NNP o
< NNP N
0.05 CD N
) ) N
, , N
and CC N
FACIT-F NNP o
( ( o
P NNP o
< VBZ N
0.001 CD N
for IN N
5 CD N
mg JJ N
twice RB N
daily RB o
) ) o
. . o

No DT o
statistical JJ o
differences NNS o
were VBD o
observed VBN N
in IN N
the DT N
MOS NNP o
Sleep NNP o
Scale NNP o
. . o

CONCLUSION NNP o
Tofacitinib NNP N
treatment NN N
resulted VBD N
in IN N
significant JJ N
, , N
clinically RB N
meaningful JJ N
improvements NNS N
in IN N
multiple JJ N
PROs NNP N
versus NN N
placebo NN N
over IN N
3 CD N
months NNS N
of IN N
treatment NN p
in IN p
patients NNS p
with IN p
active JJ p
RA NNP p
and CC p
a DT p
previous JJ p
inadequate JJ p
response NN p
to TO p
TNFi NNP p
. . p

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
tailored JJ N
skin NN N
cancer NN N
prevention NN N
messages NNS N
for IN N
adults NNS p
: : p
Project NN N
SCAPE NNP N
. . N

OBJECTIVES NNP N
We PRP N
evaluated VBD N
the DT N
impact NN N
of IN N
a DT N
mailed VBN i
, , i
tailored VBN i
intervention NN i
on IN N
skin JJ o
cancer NN o
prevention NN N
and CC N
skin JJ o
self-examination NN o
behaviors NNS o
of IN N
adults NNS p
at IN p
moderate JJ p
and CC p
high JJ p
risk NN p
for IN p
skin JJ p
cancer NN p
. . p

METHODS NNP N
Adults NNP p
at IN p
moderate NNP p
and CC p
high JJ p
risk NN p
for IN p
skin JJ p
cancer NN p
were VBD p
recruited VBN p
in IN p
primary JJ p
health NN p
care NN p
settings NNS p
in IN p
Honolulu NNP p
, , p
HI NNP p
, , p
and CC p
Long NNP p
Island NNP p
, , p
NY NNP p
. . p

After IN N
completing VBG N
a DT N
baseline NN N
survey NN N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
2 CD N
groups NNS N
. . N

The DT N
treatment NN N
group NN N
received VBD N
tailored JJ i
materials NNS i
, , i
including VBG i
personalized VBN i
risk NN i
feedback NN i
, , N
and CC N
the DT N
control NN i
group NN N
received VBD N
general JJ i
educational JJ i
materials NNS i
. . i

Multivariate NNP N
analyses NNS N
compared VBN N
sun JJ o
protection NN o
and CC N
skin VB o
self-examination NN o
between IN N
groups NNS N
, , N
controlling VBG N
for IN N
location NN N
, , N
risk NN N
level NN N
, , N
gender NN N
, , N
and CC N
age NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
596 CD p
adults NNS p
completed VBD p
the DT p
trial NN p
. . p

The DT N
tailored JJ N
materials NNS N
had VBD N
a DT N
significant JJ N
effect NN N
on IN N
overall JJ o
sun-protection NN o
habits NNS o
, , o
the DT o
use NN o
of IN o
hats NNS o
, , o
the DT o
use NN o
of IN o
sunglasses NNS o
, , o
and CC o
the DT o
recency NN o
of IN o
skin JJ o
self-examination NN o
. . o

Some DT N
effects NNS N
were VBD N
moderated VBN N
by IN N
location NN N
and CC N
risk NN N
level NN N
. . N

CONCLUSIONS NNP N
Tailored NNP i
communications NNS i
including VBG N
personalized VBN N
risk NN N
feedback NN N
can MD N
improve VB N
sun-protection NN o
behaviors NNS o
and CC o
skin JJ o
self-examination NN o
among IN N
adults NNS p
at IN p
increased VBN p
risk NN p
for IN p
skin JJ p
cancer NN p
. . p

These DT N
convenient NN N
, , N
low-cost JJ N
interventions NNS N
can MD N
be VB N
implemented VBN N
in IN N
a DT N
variety NN N
of IN N
settings NNS N
and CC N
should MD N
be VB N
tested VBN N
further JJ N
to TO N
assess VB N
their PRP$ N
long-term JJ N
effectiveness NN N
. . N

-DOCSTART- -X- O O

Chemoradiation NN N
comparing VBG N
cisplatin JJ i
versus NN N
carboplatin NN i
in IN N
locally RB p
advanced JJ p
nasopharyngeal JJ p
cancer NN p
: : p
randomised VBN N
, , N
non-inferiority NN N
, , N
open JJ N
trial NN N
. . N

PURPOSE VB N
This DT N
single JJ p
centre NN p
, , N
open JJ N
labelled VBD N
, , N
randomised VBD N
non-inferiority JJ N
trial NN N
compared VBN N
concurrent JJ N
chemoradiotherapy NN i
with IN i
carboplatin JJ i
versus JJ N
standard NN i
concurrent NN i
chemoradiotherapy NN i
with IN i
cisplatin NN i
in IN N
patients NNS p
with IN p
locoregionally RB p
advanced JJ p
nasopharyngeal JJ p
cancer NN p
( ( N
NPC NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP p
August NNP p
1999 CD p
to TO p
December NNP p
2004 CD p
, , p
206 CD p
patients NNS p
with IN p
locally RB p
advanced JJ p
NPC NNP p
were VBD p
randomised VBN p
with IN p
101 CD i
to TO i
cisplatin VB i
arm NN i
and CC i
105 CD i
to TO i
carboplatin VB i
arm NN p
. . p

Planned VBD i
radiotherapy NN i
was VBD N
the DT N
same JJ N
in IN N
both DT N
groups NNS N
. . N

All PDT N
the DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
toxicity NN o
and CC o
survival NN o
according VBG N
to TO N
the DT N
as-treated JJ N
principle NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
26.3 CD N
months NNS N
( ( N
range VB N
3-74.6 JJ N
months NNS N
) ) N
, , N
59 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
cisplatin NN N
arm NN N
completed VBD N
the DT N
planned VBN N
concurrent NN N
chemoradiation NN N
treatment NN N
, , N
compared VBN N
to TO N
73 CD N
% NN N
in IN N
the DT N
carboplatin NN N
arm NN N
. . N

Forty-two JJ N
percent NN N
of IN N
cisplatin NN N
patients NNS N
completed VBD N
the DT N
3 CD o
cycles NNS o
of IN o
adjuvant JJ o
therapy NN o
compared VBN N
to TO N
70 CD N
% NN N
in IN N
the DT N
carboplatin NN N
group NN N
. . N

There EX N
were VBD N
more JJR N
renal JJ o
toxicity NN o
, , o
leucopenia NN o
, , o
and CC o
anaemia NN o
in IN N
the DT N
cisplatin NN N
group NN N
, , N
and CC N
more JJR N
thrombocytopenia NN o
in IN N
the DT N
carboplatin NN N
arm NN N
. . N

The DT N
3 CD o
year NN o
disease NN o
free JJ o
survival NN o
rates NNS o
were VBD N
63.4 CD N
% NN N
for IN N
the DT N
cisplatin NN N
group NN N
and CC N
60.9 CD N
% NN N
for IN N
the DT N
carboplatin NN N
group NN N
( ( N
p=0.9613 NN N
) ) N
( ( N
HR $ N
0.70 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
0.50-0.98 JJ N
) ) N
. . N

The DT N
3 CD o
year NN o
overall JJ o
survival NN o
rates NNS o
were VBD N
77.7 CD N
% NN N
and CC N
79.2 CD N
% NN N
for IN N
cisplatin NN N
and CC N
carboplatin NN N
groups NNS N
, , N
respectively RB N
( ( N
p=0.9884 NN N
) ) N
( ( N
HR $ N
0.83 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.63-1.010 NN N
) ) N
. . N

CONCLUSION NNP N
We PRP N
concluded VBD N
that IN N
the DT N
tolerability NN o
of IN o
carboplatin NN o
based VBN o
regimen NNS o
is VBZ N
better JJR N
than IN N
that DT N
of IN N
the DT N
cisplatin NN i
regimen NN N
. . N

Moreover RB N
, , N
the DT N
treatment NN N
efficacy NN N
of IN N
carboplatin NN N
arm NN N
is VBZ N
not RB N
different JJ N
from IN N
the DT N
standard JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
locoregional JJ p
advanced JJ p
stage NN p
NPC NNP p
. . p

-DOCSTART- -X- O O

Measuring VBG N
the DT N
plasticity NN N
of IN N
social JJ N
approach NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
the DT N
effects NNS N
of IN N
the DT N
PEERS NNP i
intervention NN i
on IN N
EEG NNP i
asymmetry NN i
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
examined VBD N
whether IN N
the DT N
Program NNP i
for IN i
the DT i
Education NNP i
and CC i
Enrichment NNP i
of IN i
Relational NNP i
Skills NNP i
( ( i
PEERS NNS i
: : i
Social NNP N
skills NNS N
for IN N
teenagers NNS p
with IN p
developmental JJ p
and CC p
autism NN p
spectrum NN p
disorders NNS p
: : p
The DT N
PEERS NNP i
treatment NN N
manual NN N
, , N
Routledge NNP N
, , N
New NNP N
York NNP N
, , N
2010a CD N
) ) N
affected VBD N
neural JJ o
function NN o
, , o
via IN o
EEG NNP o
asymmetry NN o
, , N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
adolescents NNS p
with IN p
Autism NNP p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC p
a DT p
group NN p
of IN p
typically RB p
developing VBG p
adolescents NNS p
. . p

Adolescents NNS p
with IN p
ASD NNP p
in IN p
PEERS NNP i
shifted VBD N
from IN N
right-hemisphere JJ o
gamma-band NN o
EEG NNP o
asymmetry NN o
before IN N
PEERS NNS N
to TO N
left-hemisphere JJ o
EEG NNP o
asymmetry NN o
after IN N
PEERS NNP N
, , N
versus VBZ N
a DT N
waitlist JJ N
ASD NNP N
group NN N
. . N

Left-hemisphere JJ N
EEG NNP o
asymmetry NN o
was VBD N
associated VBN N
with IN N
more RBR N
social JJ o
contacts NNS o
and CC o
knowledge NN o
, , N
and CC N
fewer JJR N
symptoms NNS o
of IN o
autism NN o
. . o

Adolescents NNS p
with IN p
ASD NNP p
in IN p
PEERS NNP i
no RB N
longer RB N
differed VBN N
from IN N
typically RB N
developing VBG N
adolescents NNS N
in IN N
left-dominant JJ o
EEG NNP o
asymmetry NN o
at IN N
post-test NN N
. . N

These DT N
findings NNS N
are VBP N
discussed VBN N
via IN N
the DT N
Modifier NNP N
Model NNP N
of IN N
Autism NNP N
( ( N
Mundy NNP N
et RB N
al RB N
. . N

in IN N
Res NNP N
Pract NNP N
Persons NNP N
Severe NNP N
Disabl NNP N
32 CD N
( ( N
2 CD N
) ) N
:124 NN N
, , N
2007 CD N
) ) N
, , N
with IN N
emphasis NN N
on IN N
remediating VBG N
isolation/withdrawal NN N
in IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
body NN o
weight NN o
and CC o
blood NN o
pressure NN o
: : o
paradoxical JJ N
outcome NN N
events NNS N
in IN N
overweight NN p
and CC p
obese JJ p
subjects NNS p
with IN p
cardiovascular JJ p
disease NN p
. . p

BACKGROUND/OBJECTIVES IN N
The DT N
Sibutramine NNP N
Cardiovascular NNP N
OUTcomes NNP N
( ( N
SCOUT NNP N
) ) N
trial NN N
showed VBD N
a DT N
significantly RB N
increased VBN N
relative JJ N
risk NN N
of IN N
nonfatal JJ o
cardiovascular JJ o
events NNS o
, , N
but CC N
not RB N
mortality NN o
, , N
in IN N
overweight JJ p
and CC p
obese JJ p
subjects NNS p
receiving VBG p
long-term JJ i
sibutramine NN i
treatment NN i
with IN i
diet JJ i
and CC i
exercise NN i
. . i

We PRP N
examined VBD N
the DT N
relationship NN N
between IN N
early JJ N
changes NNS N
( ( N
both DT N
increases NNS N
and CC N
decreases NNS N
) ) N
in IN N
body NN o
weight NN o
and CC N
blood NN o
pressure NN o
, , N
and CC N
the DT N
impact NN N
of IN N
these DT N
changes NNS N
on IN N
subsequent JJ N
cardiovascular JJ o
outcome NN o
events NNS o
. . o

SUBJECTS/METHODS VB N
A DT p
total NN p
of IN p
9804 CD p
male NN p
and CC p
female JJ p
subjects NNS p
, , p
aged VBD p
55 CD p
years NNS p
or CC p
older JJR p
, , p
with IN p
a DT p
body NN p
mass NN p
index NN p
of IN p
27-45 JJ p
kg NNS p
m NN p
( ( p
-2 NN p
) ) p
were VBD p
included VBN p
in IN p
this DT p
current JJ p
subanalysis NN p
of IN p
the DT N
SCOUT NNP N
trial NN N
. . N

Subjects NNS N
were VBD N
required VBN p
to TO p
have VB p
a DT p
history NN p
of IN p
cardiovascular JJ p
disease NN p
and/or VBD p
type JJ p
2 CD p
diabetes NNS p
mellitus VBP p
with IN p
at IN p
least JJS p
one CD p
cardiovascular NN p
risk NN p
factor NN p
( ( p
hypertension NN p
, , p
dyslipidemia NN p
, , p
current JJ p
smoking NN p
or CC p
diabetic JJ p
nephropathy NN p
) ) p
to TO p
assess VB N
cardiovascular JJ N
outcomes NNS N
. . N

Post NNP N
hoc NN N
subgroup NN N
analyses NNS o
of IN o
weight NN o
change NN o
( ( o
categories NNS o
) ) N
and CC N
blood NN o
pressure NN o
were VBD o
performed VBN N
overall JJ N
and CC N
by IN N
treatment NN N
group NN N
( ( N
6-week JJ i
sibutramine NN i
followed VBN i
by IN N
randomized JJ i
placebo NN i
or CC i
continued JJ i
sibutramine NN i
) ) i
. . i

The DT i
primary JJ o
outcome NN o
event NN o
( ( o
POE NNP o
) ) o
was VBD o
a DT o
composite NN o
of IN o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
nonfatal JJ o
stroke NN o
, , o
resuscitated VBD o
cardiac JJ o
arrest NN o
or CC o
cardiovascular JJ o
death NN o
. . o

Time-to-event JJ o
analyses NNS N
of IN N
the DT N
POE NNP N
were VBD N
performed VBN N
using VBG N
Cox NNP N
regression NN N
models NNS N
with IN N
factors NNS N
for IN N
treatment NN N
, , N
subgroups NNS N
and CC N
interactions NNS N
. . N

RESULTS NNP N
During IN N
the DT N
initial JJ N
6-week JJ i
sibutramine NN i
treatment NN i
period NN o
, , o
systolic JJ o
blood NN o
pressure NN o
decreased VBD o
progressively RB N
with IN N
increasing VBG o
weight JJ o
loss NN o
in IN o
hypertensive JJ N
subjects NNS N
( ( N
-8.1?10.5 JJ N
mm NN N
Hg NNP N
with IN N
< NNP N
5 CD N
kg NN N
weight NN N
loss NN N
to TO N
-10.8?11.0 VB N
mm JJ N
Hg NNP N
with IN N
?5 NNP N
kg FW N
weight JJ N
loss NN N
) ) N
. . N

The DT N
highest JJS o
POE JJ o
incidence NN o
occurred VBD o
mainly RB N
in IN N
groups NNS N
with IN N
increases NNS N
in IN N
both DT o
weight NN o
and CC o
blood NN o
pressure NN o
. . o

However RB N
, , N
with IN N
long-term JJ i
sibutramine NN i
treatment NN i
, , N
a DT N
markedly RB o
lower JJR o
blood NN o
pressure NN o
tended VBD o
to TO N
increase VB o
POEs NNP o
. . o

CONCLUSION NNP o
Modest NNP o
weight VBD o
loss NN o
and CC N
modest JJ N
lower JJR o
blood NN o
pressure NN o
each DT o
reduced VBD N
the DT N
incidence NN N
of IN N
cardiovascular JJ N
events NNS N
, , N
as IN N
expected VBN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
early JJ N
marked JJ o
weight NN o
loss NN o
and CC N
rapid JJ o
blood NN o
pressure NN o
reduction NN o
seems VBZ N
to TO N
be VB N
harmful JJ N
in IN N
this DT p
obese JJ p
elderly JJ p
cardiovascular NN p
diseased VBD p
population NN p
. . N

-DOCSTART- -X- O O

[ NNS p
Localised VBN p
prostate JJ p
cancer NN p
: : p
the DT N
PREFERE NNP N
trial NN N
] NNP N
. . N

Prostate NNP N
cancer NN N
is VBZ N
the DT N
most RBS N
common JJ N
carcinoma NN p
of IN p
the DT p
elderly JJ p
man NN p
and CC N
holds VBZ N
the DT N
third JJ N
place NN N
in IN N
the DT N
ranking NN N
of IN N
cancer-specific JJ o
mortality NN o
. . o

However RB N
, , N
mortality NN o
rates NNS o
of IN N
3 CD N
% NN N
are VBP N
low JJ N
, , N
and CC N
half NN N
of IN N
the DT N
patients NNS N
will MD N
die VB N
from IN N
intercurrent JJ N
disease NN N
. . N

Due NNP N
to TO N
the DT N
significantly RB N
improved VBN N
diagnostic JJ N
methods NNS N
and CC N
the DT N
increasing VBG N
use NN N
of IN N
PSA NNP N
screening NN N
, , N
there EX N
has VBZ N
been VBN N
a DT N
stage NN N
migration NN N
towards NNS N
early RB N
tumour VBP N
stages NNS N
that WDT N
are VBP N
prognostically RB N
heterogeneous JJ N
and CC N
require NN N
differentiated VBN N
treatment NN N
. . N

Based VBN N
on IN N
the DT N
discussions NNS N
of IN N
the DT N
Joint NNP N
Federal NNP N
Committee NNP N
( ( N
G-BA NNP N
) ) N
and CC N
the DT N
conceptual JJ N
work NN N
of IN N
the DT N
MDS NNP N
, , N
the DT N
Competence NNP N
Centre NNP N
Oncology NNP N
of IN N
the DT N
MDK NNP N
, , N
the DT N
IQWIG NNP N
and CC N
the DT N
National NNP N
Association NNP N
of IN N
Statutory NNP N
Health NNP N
Insurance NNP N
Funds NNP N
( ( N
GKV-Spitzenverband NNP N
) ) N
, , N
a DT N
prospective JJ N
randomised VBN N
multicentre JJ N
trial NN N
was VBD N
developed VBN N
comparing VBG N
the DT N
four CD N
treatments NNS N
actually RB N
recommended VBN N
by IN N
the DT N
German JJ N
and CC N
European JJ N
guidelines NNS N
for IN N
localised JJ N
prostate NN N
cancer NN N
( ( o
radical JJ o
prostatectomy NN o
, , o
percutaneous JJ o
radiotherapy NN o
and CC o
permanent JJ o
seed NN o
implantation NN o
and CC o
active JJ o
surveillance NN o
) ) o
allowing VBG N
a DT N
rejection NN N
of IN N
one CD N
or CC N
two CD N
treatment NN N
options NNS N
. . N

The DT N
trial NN N
is VBZ N
expected VBN N
to TO N
start VB N
at IN N
the DT N
beginning NN N
of IN N
next JJ N
year NN N
. . N

-DOCSTART- -X- O O

MRI-detected JJ N
skull-base JJ N
invasion NN N
: : N
prognostic JJ N
value NN N
and CC N
therapeutic JJ N
implication NN N
in IN N
intensity-modulated JJ N
radiotherapy NN N
treatment NN N
for IN N
nasopharyngeal JJ p
carcinoma NN p
. . p

PURPOSE NNP N
With IN N
advances NNS N
in IN N
imaging VBG N
and CC N
radiotherapy NN N
, , N
the DT N
prognostic JJ N
value NN N
of IN N
skull-base JJ N
invasion NN N
in IN N
nasopharyngeal JJ N
carcinoma NN N
( ( N
NPC NNP N
) ) N
needs VBZ N
to TO N
be VB N
reassessed VBN N
. . N

We PRP N
aimed VBD N
to TO N
define VB N
a DT N
classification NN N
system NN N
and CC N
evaluate VB N
the DT N
prognostic JJ N
value NN N
of IN N
the DT N
classification NN N
of IN N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
-detected VBD N
skull-base JJ N
invasion NN N
in IN N
NPC NNP N
treated VBD N
with IN N
intensity-modulated JJ i
radiotherapy NN i
( ( N
IMRT NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
MATERIALS NNP N
We PRP N
retrospectively RB p
reviewed VBD p
749 CD p
patients NNS p
who WP p
underwent VBP p
MRI NNP i
and CC i
were VBD i
subsequently RB i
histologically RB i
diagnosed VBN i
with IN i
nondisseminated JJ i
NPC NNP i
and CC i
treated VBN i
with IN i
IMRT NNP i
. . i

RESULTS NNP N
MRI-detected JJ N
skull-base JJ N
invasion NN N
was VBD N
not RB N
found VBN N
to TO N
be VB N
an DT N
independent JJ N
prognostic JJ N
factor NN N
for IN N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
distant JJ o
metastasis-free JJ o
survival NN o
( ( o
DMFS NNP o
) ) o
, , o
local JJ o
relapse-free JJ o
survival NN o
( ( o
LRFS NNP o
) ) o
, , o
or CC o
disease-free JJ o
survival NN o
( ( o
DFS NNP o
; : o
p VBZ N
> $ N
0.05 CD N
for IN N
all DT N
) ) N
. . N

Skull-base JJ N
invasion NN N
was VBD N
classified VBN N
according VBG N
to TO N
the DT N
incidence NN N
of IN N
each DT N
site NN N
( ( N
type JJ N
I PRP N
sites NNS N
inside IN N
pharyngobasilar JJ N
fascia NN N
and CC N
clivus NN N
vs. FW N
type NN N
II NNP N
sites VBZ N
outside IN N
pharyngobasilar JJ N
fascia NN N
) ) N
. . N

The DT N
5-year JJ o
OS NNP o
, , o
DMFS NNP o
, , o
LRFS NNP o
, , o
and CC o
DFS NNP o
rates NNS o
in IN o
the DT N
classification NN N
of IN N
skull-base JJ N
invasion NN N
in IN N
NPC NNP N
were VBD N
83 CD N
vs. FW N
67 CD N
% NN N
, , N
85 CD N
vs.75 NN N
% NN N
, , N
95 CD N
vs. FW N
88 CD N
% NN N
, , N
and CC N
76 CD N
vs. FW N
62 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
< VBP N
0.05 CD N
for IN N
all DT N
) ) N
. . N

Multivariate NNP N
analysis NN N
indicated VBD N
the DT N
classification NN N
of IN N
skull-base JJ N
invasion NN N
was VBD N
an DT N
independent JJ N
prognostic JJ N
factor NN N
. . N

CONCLUSION NNP N
MRI-detected JJ N
skull-base JJ N
invasion NN N
is VBZ N
not RB N
an DT N
independent JJ N
prognostic JJ N
factor NN p
in IN p
patients NNS p
with IN p
NPC NNP p
treated VBD p
with IN N
IMRT NNP N
. . N

However RB N
, , N
classification NN N
according VBG N
to TO N
the DT N
site NN N
of IN N
invasion NN N
has VBZ N
prognostic JJ N
value NN N
. . N

Therefore NNP N
, , p
patients NNS p
with IN p
various JJ p
subclassifications NNS p
of IN p
stage NN p
T3 NNP p
disease NN p
may MD N
receive VB N
treatment NN N
with IN N
different JJ N
intensities NNS N
; : N
however RB N
, , N
further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
prove VB N
this DT N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
combination NN N
chemotherapy NN i
in IN N
hormone-resistant JJ p
metastatic JJ p
prostate NN p
carcinoma NN p
. . p

A DT N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
in IN N
51 CD p
patients NNS p
with IN p
stage JJ p
D NNP p
hormone-resistant JJ p
prostatic JJ p
carcinoma NN p
, , N
comparing VBG N
a DT N
combination NN N
of IN N
doxorubicin NN i
and CC i
lomustine NN i
( ( N
DC NNP N
) ) N
with IN N
cyclophosphamide NN i
and CC i
5-FU JJ i
( ( i
CF NNP i
) ) i
. . i

Patients NNS N
were VBD N
assessed VBN N
objectively RB N
( ( N
employing VBG N
National NNP N
Prostate NNP N
Cancer NNP N
Project NNP N
criteria NNS N
) ) N
and CC N
subjectively RB N
( ( N
using VBG N
a DT N
numerical JJ N
scoring NN N
scheme NN N
) ) N
. . N

Each DT N
regimen NN N
was VBD N
well RB N
tolerated VBN o
with IN N
acceptable JJ N
levels NNS o
of IN o
myelosuppression NN o
. . o

The DT N
objective JJ o
partial JJ o
response NN o
rate NN o
was VBD N
57 CD N
% NN N
for IN N
DC NNP N
and CC N
8 CD N
% NN N
for IN N
CF NNP N
. . N

Objective NNP o
stabilization NN o
occurred VBD N
, , N
respectively RB N
, , N
in IN N
14 CD N
% NN N
and CC N
44 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Similarly RB N
, , N
DC NNP N
demonstrated VBD N
a DT N
significantly RB N
superior JJ N
subjective JJ o
response NN o
rate NN o
( ( o
partial JJ o
plus CC o
complete JJ o
) ) o
of IN N
82 CD N
% NN N
, , N
compared VBN N
to TO N
48 CD N
% NN N
for IN N
CF NNP i
. . i

Patients NNS N
with IN N
poor JJ p
initial JJ p
performance NN p
status NN p
or CC p
liver VB p
involvement NN p
had VBD N
significantly RB N
lower JJR N
response NN o
rates NNS o
and CC N
reduced JJ N
survival NN o
. . o

Overall JJ N
, , N
there EX o
was VBD o
no DT o
significant JJ o
difference NN o
in IN o
survival NN o
between IN o
the DT o
two CD o
arms NNS o
, , o
reflecting VBG o
the DT o
similarity NN o
between IN o
DC NNP o
and CC o
CF NNP o
in IN o
total JJ o
objective JJ o
response NN o
rate NN o
( ( o
partial JJ o
response NN o
plus CC o
stable JJ o
disease NN o
) ) o
. . o

DC NNP i
provided VBD N
superior JJ N
palliation NN o
and CC N
was VBD N
well RB N
tolerated VBN o
by IN N
an DT N
essentially RB p
geriatric JJ p
population NN p
. . p

-DOCSTART- -X- O O

Improved VBN N
frontoparietal JJ o
white JJ o
matter NN o
integrity NN o
in IN N
overweight JJ p
children NNS p
is VBZ N
associated VBN N
with IN N
attendance NN N
at IN N
an DT N
after-school JJ i
exercise NN i
program NN i
. . i

Aerobic NNP N
fitness NN N
is VBZ N
associated VBN N
with IN N
white JJ o
matter NN o
integrity NN o
( ( o
WMI NNP o
) ) o
in IN N
adults NNS N
as IN N
measured VBN N
by IN N
diffusion NN o
tensor NN o
imaging NN o
( ( o
DTI NNP o
) ) o
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
an DT N
8-month JJ N
exercise NN i
intervention NN i
on IN N
WMI NNP o
in IN N
children NNS p
. . p

Participants NNS N
were VBD N
18 CD p
sedentary JJ p
, , p
overweight JJ p
( ( p
BMI?85th NNP p
percentile NN p
) ) p
8- CD p
to TO p
11-year-old JJ p
children NNS p
( ( p
94 CD p
% NN p
Black NNP p
) ) p
, , p
randomly RB N
assigned VBN N
to TO N
either DT N
an DT N
aerobic JJ N
exercise NN N
( ( N
n=10 JJ N
) ) N
or CC N
sedentary JJ N
attention NN N
control NN N
group NN N
( ( N
n=8 RB N
) ) N
. . N

Each DT N
group NN N
was VBD N
offered VBN N
an DT N
instructor-led JJ i
after-school JJ i
program NN i
every DT i
school NN N
day NN N
for IN N
approximately RB N
8 CD N
months NNS N
. . N

Before IN N
and CC N
after IN N
the DT N
program NN N
, , N
all DT N
subjects NNS N
participated VBN N
in IN N
DTI NNP o
scans NNS o
. . o

Tractography NN i
was VBD i
conducted VBN N
to TO N
isolate VB N
the DT N
superior JJ N
longitudinal JJ N
fasciculus NN N
and CC N
investigate VB N
whether IN N
the DT N
exercise NN N
intervention NN N
affected VBD o
WMI NNP o
in IN o
this DT N
region NN N
. . N

There EX N
was VBD N
no DT N
group NN N
by IN N
time NN o
interaction NN o
for IN o
WMI NNP o
in IN o
the DT N
superior JJ N
longitudinal JJ N
fasciculus NN N
. . N

There EX N
was VBD N
a DT N
group NN o
by IN o
time NN o
by IN o
attendance NN o
interaction NN o
, , o
however RB N
, , N
such JJ N
that IN N
higher JJR o
attendance NN o
at IN o
the DT i
exercise NN i
intervention NN i
, , i
but CC N
not RB N
the DT i
control NN i
intervention NN i
, , i
was VBD N
associated VBN N
with IN o
increased JJ o
WMI NNP o
. . o

Heart NNP o
rate NN o
and CC o
the DT o
total JJ o
dose NN o
of IN o
exercise NN o
correlated VBN o
with IN o
WMI NNP o
changes NNS o
in IN o
the DT N
exercise NN N
group NN N
. . N

In IN N
the DT N
overall JJ N
sample NN N
, , N
increased VBD o
WMI NNP o
was VBD o
associated VBN N
with IN o
improved JJ o
scores NNS o
on IN o
a DT o
measure NN o
of IN o
attention NN o
and CC o
improved VBN o
teacher JJ o
ratings NNS o
of IN o
executive NN o
function NN o
. . o

This DT N
study NN N
indicates VBZ N
that IN N
participating VBG N
in IN N
an DT N
exercise NN i
intervention NN o
improves VBZ o
WMI NNP o
in IN o
children NNS N
as IN N
compared VBN N
to TO N
a DT N
sedentary JJ N
after-school JJ N
program NN N
. . N

-DOCSTART- -X- O O

Caregiver-mediated JJ N
intervention NN i
for IN N
low-resourced JJ p
preschoolers NNS p
with IN p
autism NN p
: : p
an DT N
RCT NNP N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
2 CD N
short-term JJ N
, , N
community NN i
caregiver RB i
training NN i
interventions NNS i
for IN N
preschool-aged JJ p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
who WP p
had VBD p
low JJ p
resources NNS p
. . p

Low NNP N
resource NN N
was VBD N
defined VBN N
by IN N
the DT N
US NNP N
Department NNP N
of IN N
Housing NNP N
and CC N
Urban NNP N
Development NNP N
low-income JJ N
index NN N
or CC N
1 CD N
indicator NN o
, , N
( ( N
e.g. UH N
, , N
Medicaid NNP N
eligibility NN N
) ) N
. . N

Child NNP N
outcomes NNS N
focused VBD N
on IN N
joint JJ N
engagement NN o
, , N
joint JJ N
attention NN N
, , N
and CC N
play NN N
. . N

METHODS NNP N
Participants NNP p
included VBD p
112 CD p
families NNS p
of IN p
a DT p
child NN p
who WP p
had VBD p
Autism NNP p
Spectrum NNP p
Disorder NNP p
who WP p
met VBD p
criteria NNS p
for IN p
being VBG p
low-resourced JJ p
and CC p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
1 CD p
of IN p
2 CD i
3-month JJ i
interventions NNS i
, , i
group NN i
caregiver NN o
education NN i
or CC i
individualized VBN i
caregiver-mediated JJ i
intervention NN i
( ( i
CMM NNP i
) ) i
. . i

Children NNP N
were VBD N
assessed VBN N
for IN N
social JJ N
communication NN N
skills NNS N
pre- JJ o
and CC o
post-treatment JJ o
, , N
and CC N
followed VBD N
up RB N
at IN N
3 CD N
months NNS N
. . N

RESULTS NNP N
All NNP N
children NNS N
improved VBN N
in IN N
joint JJ o
engagement NN o
and CC o
initiating VBG o
joint JJ o
attention NN o
, , N
with IN N
significantly RB N
greater JJR N
improvement NN N
by IN N
the DT N
CMM NNP i
group NN N
. . N

Outcomes CC N
on IN N
play NN o
skills NNS o
were VBD N
mixed JJ N
, , N
with IN N
improvement NN N
of IN N
symbolic JJ o
play NN o
for IN N
the DT N
CMM NNP N
group NN N
and CC N
no DT N
change NN N
in IN N
functional JJ o
play NN o
skills NNS o
. . o

Joint JJ N
engagement NN N
maintained VBD N
over IN N
time NN N
for IN N
the DT N
CMM NNP i
group NN N
, , N
and CC N
initiating VBG N
joint JJ N
attention NN N
maintained VBD N
for IN N
both DT N
groups NNS N
over IN N
time NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
is VBZ N
among IN N
the DT N
first JJ N
randomized JJ N
trials NNS N
comparing VBG N
2 CD N
active JJ N
interventions NNS N
with IN N
a DT N
large JJ N
sample NN N
of IN N
low-resourced JJ p
families NNS p
. . p

Results NNP N
suggest JJ N
improvements NNS N
in IN N
core NN N
autism NN N
deficits NNS N
of IN N
joint JJ N
engagement NN N
, , N
joint JJ o
attention NN o
, , N
and CC N
symbolic JJ N
play NN N
with IN N
relatively RB N
brief JJ N
, , N
caregiver-mediated JJ o
interventions NNS N
, , N
but CC N
additional JJ N
support NN N
is VBZ N
necessary JJ N
to TO N
maintain VB N
and CC N
generalize VB N
these DT N
gains NNS N
over IN N
time NN N
. . N

-DOCSTART- -X- O O

Physical JJ N
activity NN N
for IN N
patients NNS p
undergoing VBG p
an DT p
allogeneic JJ p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
: : p
benefits NNS N
of IN N
a DT N
moderate JJ i
exercise NN i
intervention NN i
. . i

UNLABELLED IN N
An DT N
allogeneic JJ i
hematopoietic JJ i
stem NN i
cell NN i
transplantation NN i
( ( N
HSCT NNP N
) ) N
can MD N
have VB N
profound VBN N
and CC N
lasting JJ N
adverse JJ N
effects NNS N
on IN N
a DT N
patient NN N
's POS N
physical JJ N
and CC N
psychological JJ N
well-being NN N
. . N

So RB N
far RB N
, , N
only RB N
few JJ N
studies NNS N
have VBP N
investigated VBN N
the DT N
effectiveness NN o
of IN N
physical JJ N
activity NN N
over IN N
the DT N
entire JJ N
inpatient NN N
phase NN N
of IN N
an DT N
allogeneic JJ N
HSCT NNP N
. . N

PURPOSE NNP N
We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
to TO N
examine VB N
the DT N
influence NN N
of IN N
a DT N
controlled JJ N
moderate JJ i
exercise NN i
program NN i
starting VBG N
parallel JJ N
to TO N
chemotherapeutic JJ N
conditioning NN N
and CC N
total JJ N
body NN N
irradiation NN N
on IN N
the DT N
patient NN N
's POS N
physical JJ N
and CC N
psychological JJ N
constitution NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-seven NNP p
patients NNS p
undergoing VBG p
an DT p
allogeneic JJ p
HSCT NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
exercise NN i
group NN i
( ( i
EG NNP i
) ) i
or CC N
a DT N
control NN i
group NN i
( ( i
CG NNP i
) ) i
. . N

While IN N
the DT N
EG NNP N
took VBD N
part NN N
in IN N
an DT N
endurance NN N
and CC N
activity NN N
of IN N
daily JJ N
living-training JJ N
twice NN N
a DT N
day NN N
, , N
the DT N
CG NNP N
received VBD N
the DT N
clinic NN N
's POS N
standard JJ N
physiotherapy NN N
program NN N
once RB N
a DT N
day NN N
. . N

RESULTS NNP N
Significant NNP o
differences VBZ o
and/or JJ N
trends NNS N
in IN N
favor NN N
of IN N
the DT N
EG NNP N
were VBD N
observed VBN N
regarding VBG N
the DT N
primary JJ N
endpoint NN N
endurance NN o
performance NN o
( ( N
P=0.002 NNP N
) ) N
, , N
muscular JJ o
strength NN o
( ( N
P=0.022 NNP N
) ) N
, , N
fatigue NN o
( ( N
P=0.046 NNP N
) ) N
, , N
and CC N
emotional JJ o
state NN o
( ( N
P=0.028 NNP N
) ) N
without IN N
posing VBG N
an DT N
additional JJ N
risk NN N
for IN N
the DT N
individual NN N
. . N

CONCLUSION VB N
The DT N
results NNS N
show VBP N
that IN N
the DT N
training NN N
program NN N
is VBZ N
feasible JJ N
and CC N
seems VBZ N
to TO N
have VB N
positive JJ N
influences NNS N
on IN N
physical JJ o
performance NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
patients NNS p
undergoing VBG p
an DT p
allogeneic JJ p
HSCT NNP p
. . p

However RB N
, , N
further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
confirm VB N
these DT N
results NNS N
. . N

-DOCSTART- -X- O O

Assessment NN N
of IN N
therapeutic JJ o
response NN N
of IN N
Plasmodium NNP N
falciparum NN N
to TO N
chloroquine VB i
and CC N
sulfadoxine-pyrimethamine VB i
in IN N
an DT N
area NN p
of IN p
low JJ p
malaria NNS p
transmission NN p
in IN p
Colombia NNP p
. . p

Although IN N
chloroquine NN i
( ( N
CQ NNP N
) ) N
resistance NN N
was VBD N
first RB N
reported VBN N
in IN N
Colombia NNP N
in IN N
1961 CD N
and CC N
sulfadoxine-pyrimethamine JJ i
( ( N
SP NNP N
) ) N
resistance NN N
in IN N
1981 CD N
, , N
the DT N
frequency NN N
of IN N
treatment NN N
failures NNS N
to TO N
these DT N
drugs NNS N
in IN N
Colombia NNP N
is VBZ N
unclear JJ N
. . N

A DT N
modified JJ N
World NNP N
Health NNP N
Organization NNP N
14-day JJ N
in IN N
vivo JJ N
drug NN N
efficacy NN N
test NN N
for IN N
uncomplicated JJ N
Plasmodium NNP N
falciparum NN N
malaria NN N
in IN N
areas NNS N
with IN N
intense JJ N
malaria NNS N
transmission NN N
was VBD N
adapted VBN N
to TO N
reflect VB N
the DT N
clinical JJ N
and CC N
epidemiologic JJ N
features NNS N
of IN N
a DT N
low-intensity JJ N
malaria NN N
transmission NN N
area NN N
in IN N
the DT N
Pacific NNP N
Coast NNP N
Region NNP N
of IN N
Colombia NNP N
. . N

Patients NNPS p
> JJ p
or CC p
=1 JJ p
year NN p
of IN p
age NN p
with IN p
a DT p
parasite JJ p
density NN p
> NN p
or CC p
=1,000 CD p
asexual JJ p
parasites NNS p
per IN p
microliter NN p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
. . p

Forty-four CD p
percent NN p
( ( p
24 CD p
of IN p
54 CD p
) ) p
of IN p
the DT p
CQ-treated JJ i
patients NNS p
were VBD p
therapeutic JJ o
failures NNS o
, , p
including VBG p
7 CD p
early JJ o
treatment NN o
failures NNS o
( ( o
ETFs NNP o
) ) o
and CC p
17 CD p
late JJ o
treatment NN o
failures NNS o
( ( o
LTFs NNP o
) ) o
. . o

Four CD p
( ( p
6 CD p
% NN p
) ) p
of IN p
67 CD p
SP-treated JJ N
patients NNS N
were VBD N
therapeutic JJ o
failures NNS o
( ( N
2 CD N
ETFs NNP N
and CC N
2 CD N
LTFs NNP N
) ) N
. . N

Therapeutic JJ o
failure NN o
in IN N
the DT N
CQ-treated JJ i
group NN N
was VBD N
associated VBN N
with IN N
an DT N
age NN N
< VBD N
15 CD N
years NNS N
old JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
was VBD N
not RB N
associated VBN N
with IN N
initial JJ N
parasite JJ N
density NN N
, , N
the DT N
presence NN N
of IN N
CQ NNP i
or CC N
sulfa-containing JJ N
drugs NNS N
in IN N
urine NN N
, , N
or CC N
a DT N
history NN N
of IN N
malaria NN N
. . N

The DT N
high JJ N
level NN N
of IN N
therapeutic JJ o
failures NNS o
to TO N
CQ NNP i
detected VBN N
in IN N
this DT N
study NN N
underscores VBZ N
the DT N
need NN N
and CC N
importance NN N
of IN N
drug NN N
efficacy NN o
evaluation NN N
in IN N
the DT N
development NN N
of IN N
a DT N
rational JJ N
national JJ N
antimalarial JJ N
drug NN N
policy NN N
. . N

The DT N
relatively RB N
low JJ N
level NN N
of IN N
therapeutic JJ o
failures NNS o
to TO N
SP NNP N
compared VBN N
with IN N
other JJ N
South JJ N
American JJ N
countries NNS N
raises VBZ N
further JJ N
questions NNS N
regarding VBG N
factors NNS N
that WDT N
might MD N
have VB N
prevented VBN N
the DT N
rapid JJ N
development NN N
of IN N
in IN N
vivo NN N
resistance NN N
to TO N
this DT N
drug NN N
combination NN N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN i
group NN i
therapy NN i
for IN N
functional JJ p
memory NN p
disorder NN p
. . p

-DOCSTART- -X- O O

Prospective JJ N
randomised VBD N
trial NN N
of IN N
amifostine JJ i
cytoprotection NN i
in IN N
myeloma NN p
patients NNS p
undergoing VBG p
high-dose JJ i
melphalan NN i
conditioned VBN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
. . p

In IN N
this DT N
prospective JJ N
multicentre NN N
trial NN N
, , N
90 CD p
patients NNS p
undergoing VBG p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
ASCT NNP p
) ) p
were VBD p
randomised VBN p
to TO N
receive VB N
( ( N
n=43 NN N
) ) N
or CC N
not RB N
receive JJ N
( ( N
n=47 JJ N
) ) N
amifostine VBP i
910 CD i
mg/m NN i
( ( i
2 CD i
) ) i
prior RB i
to TO i
melphalan VB i
200 CD i
mg/m NN i
( ( i
2 CD i
) ) i
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
regimen-related JJ o
toxicity NN o
, , o
engraftment NN o
, , o
supportive JJ o
care NN o
, , o
response NN o
and CC o
survival NN o
. . o

Both DT p
groups NNS p
underwent VBD N
ASCT NNP i
at IN N
a DT N
median NN N
of IN N
8 CD N
months NNS N
from IN N
diagnosis NN N
and CC N
were VBD N
matched VBN N
for IN N
disease NN N
characteristics NNS N
, , N
prior JJ N
therapy NN N
and CC N
pre-ASCT JJ N
disease NN N
responsiveness NN N
. . N

Amifostine NNP i
infusional JJ N
side-effects NNS N
were VBD N
frequent JJ N
, , N
occurring VBG N
in IN N
65 CD N
% NN N
of IN N
patients NNS N
, , N
but CC N
of IN N
mild JJ N
severity NN N
. . N

Amifostine NNP i
use NN N
was VBD N
associated VBN N
with IN N
a DT N
reduction NN o
in IN N
the DT N
median JJ o
grade NN o
of IN o
oral JJ o
mucositis NN o
( ( N
1 CD N
vs NN N
2 CD N
, , N
P=0.01 NNP N
) ) N
and CC N
the DT N
frequency NN o
of IN o
severe JJ o
( ( o
WHO NNP o
grades VBZ o
3 CD o
or CC o
4 CD o
) ) o
mucositis NN o
( ( N
12 CD N
vs RB N
33 CD N
% NN N
, , N
P=0.02 NNP N
) ) N
, , N
but CC N
no DT N
reduction NN N
in IN N
the DT N
requirement NN N
for IN N
parenteral JJ N
nutrition NN N
or CC N
analgesic JJ N
use NN N
. . N

Conversion NN N
to TO N
complete VB N
remission NN N
post-ASCT NN o
occurred VBD N
in IN N
30 CD N
and CC N
14 CD N
% NN N
of IN N
the DT N
amifostine NN i
and CC N
control NN N
groups NNS N
, , N
respectively RB N
( ( N
P=0.09 NNP N
) ) N
. . N

With IN N
a DT N
median JJ N
follow-up NN N
of IN N
35 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
median JJ o
progression-free NN o
or CC o
overall JJ o
survival NN o
times NNS o
for IN N
the DT N
two CD N
groups NNS N
. . N

We PRP N
conclude VBP N
that IN N
amifostine NN i
can MD N
be VB N
safely RB N
administered VBN N
prior RB N
to TO N
high-dose JJ N
melphalan NN N
and CC N
significantly RB N
reduces VBZ N
the DT N
frequency NN o
and CC o
severity NN o
of IN o
therapy-induced JJ o
oral JJ o
mucositis NN o
. . o

-DOCSTART- -X- O O

Treatment NN N
of IN N
acute JJ N
asthma NN N
. . N

Lack NNP N
of IN N
therapeutic JJ o
benefit NN o
and CC o
increase NN o
of IN o
the DT o
toxicity NN o
from IN N
aminophylline JJ i
given VBN N
in IN N
addition NN N
to TO N
high JJ N
doses NNS N
of IN N
salbutamol NN i
delivered VBN N
by IN N
metered-dose JJ N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
to TO N
determine VB N
if IN N
intravenous JJ N
aminophylline NN i
adds VBZ N
any DT N
benefit NN o
to TO N
high JJ N
doses NNS N
of IN N
inhaled JJ N
salbutamol NN i
in IN N
patients NNS p
who WP p
presented VBD p
for IN p
treatment NN p
of IN p
acute JJ p
asthma NN p
. . p

We PRP N
studied VBD N
94 CD p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
35.6 CD p
+/- JJ p
11.2 CD p
years NNS p
) ) p
with IN p
moderate JJ p
to TO p
severe VB p
acute JJ p
asthma NN p
. . p

All DT N
patients NNS N
received VBD N
therapy NN N
with IN N
salbutamol NN i
delivered VBN N
with IN N
metered-dose JJ i
inhaler NN i
( ( i
MDI NNP i
) ) i
into IN i
a DT i
spacer NN i
device NN i
( ( N
Volumatic NNP N
) ) N
in IN N
four CD N
puffs NNS N
( ( N
400 CD N
micrograms NNS N
) ) N
at IN N
10-min JJ N
interval NN N
, , N
and CC N
intravenous JJ i
hydrocortisone NN i
( ( N
500 CD N
mg NN N
) ) N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
loading NN N
dose NN N
of IN N
intravenous JJ N
aminophylline NN i
followed VBN N
by IN N
a DT N
routine JJ N
infusion NN N
( ( N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
an DT N
equal JJ N
volume NN N
of IN N
placebo NN i
as IN N
a DT N
loading NN N
dose NN N
and CC N
infusion NN N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
showed VBD N
no DT N
differences NNS N
in IN N
measurements NNS N
of IN N
peak JJ o
expiratory NN o
flow NN o
, , o
FEV1 NNP o
, , o
and CC o
FVC NNP o
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

However RB N
, , N
the DT N
patients NNS N
treated VBN N
with IN N
aminophylline NN i
had VBD N
significantly RB N
more RBR N
adverse JJ o
effects NNS o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
final JJ N
mean NN N
dose NN N
of IN N
salbutamol NN N
( ( N
6.3 CD N
+/- JJ N
44.5 CD N
mg NN N
for IN N
the DT N
placebo NN i
group NN N
and CC N
5.8 CD N
+/- JJ N
4.2 CD N
mg NN N
for IN N
the DT N
aminophylline NN N
group NN N
) ) N
, , N
hospital JJ N
admission NN N
rate NN N
( ( N
10.2 CD N
percent NN N
for IN N
the DT N
placebo NN N
group NN N
and CC N
9.0 CD N
percent NN N
for IN N
the DT N
aminophylline NN i
group NN N
) ) N
, , N
and CC N
mean JJ N
duration NN N
of IN N
Emergency NNP N
Department NNP N
treatment NN N
( ( N
2.5 CD N
+/- JJ N
1.83 CD N
h NN N
for IN N
the DT N
placebo NN i
group NN N
and CC N
2.37 CD N
+/- JJ N
1.75 CD N
h NN N
for IN N
the DT N
aminophylline NN i
group NN N
) ) N
. . N

The DT N
results NNS N
were VBD N
similar JJ N
when WRB N
the DT N
patients NNS N
were VBD N
divided VBN N
in IN N
accord NN N
with IN N
the DT N
degree NN N
of IN N
respiratory NN o
obstruction NN o
( ( N
baseline JJ N
FEV1 NNP N
< NNP N
30 CD N
percent NN N
of IN N
predicted VBN N
) ) N
and CC N
theophylline JJ o
level NN o
at IN N
30 CD N
min NN N
of IN N
treatment NN N
( ( N
placebo JJ N
group NN N
patients NNS N
with IN N
theophylline JJ i
level NN N
< VBD N
10 CD N
mg/L NN N
vs NN N
aminophylline NN i
group NN N
patients NNS N
with IN N
theophylline JJ N
level NN N
> NN N
or CC N
= $ N
10 CD N
mg/L NN N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
intravenous JJ N
aminophylline NN N
adds VBZ N
to TO N
the DT N
toxicity NN o
but CC N
not RB N
the DT N
efficacy NN o
of IN N
inhaled JJ N
salbutamol NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
exacerbations NNS N
of IN N
asthma NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
extended JJ N
release NN N
methylphenidate NN i
treatment NN i
on IN N
ratings NNS o
of IN o
attention-deficit/hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
and CC o
associated VBN o
behavior NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
ADHD NNP p
symptoms NNS p
. . p

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
behavioral JJ o
effects NNS o
of IN N
four CD N
doses NNS N
of IN N
psychostimulant JJ i
medication NN i
, , i
combining VBG i
extended-release JJ i
methylphenidate NN i
( ( i
MPH NNP i
) ) i
in IN i
the DT i
morning NN i
with IN i
immediate-release JJ i
MPH NNP i
in IN i
the DT i
afternoon NN i
. . i

METHOD NNP N
The DT N
sample NN N
comprised VBD N
24 CD p
children NNS p
( ( p
19 CD p
boys NNS p
; : p
5 CD p
girls NNS p
) ) p
who WP p
met VBD p
American NNP p
Psychiatric NNP p
Association NNP p
, , p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
4th CD p
ed NN p
. . p

( ( N
DSM-IV-TR NNP N
) ) N
criteria NN N
for IN N
an DT N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
on IN N
the DT N
Autism NNP N
Diagnostic NNP N
Interview-Revised JJ N
( ( N
ADI-R NNP N
) ) N
and CC N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
, , N
and CC N
had VBD N
significant JJ N
symptoms NNS N
of IN N
attention-deficit/hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
. . N

This DT N
sample NN N
consisted VBD N
of IN N
elementary JJ p
school-age NN p
, , p
community-based JJ p
children NNS p
( ( p
mean JJ p
chronological JJ p
age=8.8 NN p
years NNS p
, , p
SD=1.7 NNP p
; : p
mean JJ p
intelligence NN p
quotient NN p
[ NNP p
IQ NNP p
] NNP p
=85 NNP p
; : p
SD=16.8 NNP p
) ) p
. . p

Effects NNS N
of IN N
four CD N
dose NN N
levels NNS N
of IN N
MPH NNP i
on IN N
parent NN o
and CC o
teacher RB o
behavioral JJ o
ratings NNS o
were VBD N
investigated VBN N
using VBG N
a DT N
within-subject JJ N
, , N
crossover NN N
, , N
placebo-controlled JJ N
design NN N
. . N

RESULTS NNP N
MPH NNP i
treatment NN N
was VBD N
associated VBN N
with IN N
significant JJ N
declines NNS N
in IN N
hyperactive JJ o
and CC o
impulsive JJ o
behavior NN o
at IN o
both DT o
home NN o
and CC o
school NN o
. . o

Parents NNS N
noted VBD N
significant JJ N
declines NNS N
in IN N
inattentive JJ o
and CC o
oppositional JJ o
behavior NN o
, , N
and CC N
improvements NNS N
in IN N
social JJ o
skills NNS o
. . o

No DT N
exacerbation NN o
of IN o
stereotypies NNS o
was VBD N
noted VBN N
, , N
and CC N
side JJ o
effects NNS o
were VBD N
similar JJ N
to TO N
those DT N
seen VBN N
in IN N
typically RB N
developing VBG N
children NNS N
with IN N
ADHD NNP N
. . N

Dose NNP N
response NN N
was VBD N
primarily RB N
linear JJ N
in IN N
the DT N
dose JJ N
range NN N
studied VBN N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
MPH NNP N
formulations NNS N
are VBP N
efficacious JJ o
and CC o
well-tolerated JJ o
for IN N
children NNS p
with IN p
ASD NNP p
and CC p
significant JJ p
ADHD NNP p
symptoms NNS p
. . p

-DOCSTART- -X- O O

[ JJ N
Therapeutic NNP N
efficacy NN N
of IN N
compound NN i
Xuanju NNP i
capsule NN N
on IN N
type NN p
III NNP p
prostatitis NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
therapeutic JJ N
effect NN N
of IN N
Compound NNP i
Xuanju NNP i
Capsule NNP N
on IN N
type NN N
III NNP N
prostatitis NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
242 CD p
patients NNS p
with IN p
type JJ p
III NNP p
prostatitis NN p
diagnosed VBN p
by IN p
the DT p
NIH NNP p
criteria NNS p
were VBD N
randomly RB i
divided VBN i
into IN i
an DT i
experimental JJ i
and CC i
a DT i
control NN i
group NN i
of IN i
equal JJ i
number NN i
, , i
the DT i
former JJ i
treated VBN i
with IN i
Compound NNP i
Xuanju NNP i
Capsule NNP i
+ NNP i
Tamsulosin NNP i
Hydrochloride NNP i
, , i
and CC i
the DT i
latter NN i
with IN i
Quinolinone NNP i
antibiotics NNS i
+ VBP i
Tamsulosin NNP i
and CC i
Hydrochloride NNP i
, , i
both DT i
for IN i
6 CD i
months NNS i
. . i

After IN N
treatment NN N
, , N
we PRP N
assessed VBD N
the DT N
therapeutic JJ o
effects NNS o
based VBN o
on IN o
the DT o
NIH-CPSI JJ o
scores NNS o
and CC o
the DT o
improvement NN o
of IN o
relevant JJ o
complications NNS o
. . o

RESULTS NNP N
All PDT p
the DT p
242 CD p
patients NNS p
completed VBD p
the DT p
treatment NN p
. . p

The DT N
total JJ o
effectiveness NN o
rate NN o
was VBD N
77.69 CD N
% NN N
( ( N
94/121 CD N
) ) N
in IN N
the DT N
experimental JJ N
group NN N
, , N
71.56 CD N
% NN N
( ( N
78/109 CD N
) ) N
in IN N
those DT N
with IN N
complications NNS N
. . N

In IN N
comparison NN N
, , N
it PRP N
was VBD N
only RB N
47.10 CD N
% NN N
( ( N
57/121 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
, , N
31.78 CD N
% NN N
( ( N
34/107 CD N
) ) N
in IN N
those DT N
with IN N
complications NNS N
. . N

Both DT N
the DT N
NIH-CPSI NNP o
scores NNS o
and CC o
the DT o
improvement NN o
of IN o
complications NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
experimental JJ N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Compound NNP i
Xuanju NNP i
Capsule NNP N
has VBZ N
a DT N
good JJ N
therapeutic JJ N
effect NN N
on IN N
type NN N
III NNP N
prostatitis NN N
. . N

-DOCSTART- -X- O O

Randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
treatment NN N
of IN N
plantar NN p
fasciitis NN p
with IN N
an DT N
extracoporeal NN i
shockwave NN i
therapy NN i
( ( i
ESWT NNP i
) ) i
device NN i
: : i
a DT N
North JJ p
American JJ p
confirmatory NN p
study NN p
. . p

Despite IN N
numerous JJ N
publications NNS N
and CC N
clinical JJ N
trials NNS N
, , N
the DT N
results NNS N
of IN N
treatment NN N
of IN N
recalcitrant JJ p
chronic JJ p
plantar NN p
fasciitis NN p
with IN N
extracorporeal JJ i
shockwave JJ i
therapy NN i
( ( i
ESWT NNP i
) ) i
still RB N
remain VBP N
equivocal JJ N
as IN N
to TO N
whether IN N
or CC N
not RB N
this DT N
treatment NN N
provides VBZ N
relief NN o
from IN N
the DT o
pain NN o
associated VBN N
with IN N
this DT N
condition NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
extracorporeal NN N
shock NN N
wave VBP N
therapy NN N
can MD N
safely RB o
and CC o
effectively RB o
relieve VB o
the DT o
pain NN o
associated VBN N
with IN N
chronic JJ N
plantar NN N
fasciitis NN N
compared VBN N
to TO N
placebo VB N
treatment NN N
, , N
as IN N
demonstrated VBN N
by IN N
pain NN N
with IN N
walking NN N
in IN N
the DT N
morning NN N
. . N

This DT N
was VBD N
set VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
confirmatory JJ N
clinical JJ N
study NN N
undertaken VBN N
in IN N
four CD p
outpatient NN p
orthopedic NN p
clinics NNS p
. . p

The DT p
patients NNS p
, , p
114 CD p
adult NN p
subjects NNS p
with IN p
chronic JJ p
plantar NN p
fasciitis NN p
, , p
recalcitrant JJ p
to TO p
conservative JJ p
therapies NNS p
for IN p
at IN p
least JJS p
6 CD p
months NNS p
, , N
were VBD N
randomized VBN N
to TO N
two CD N
groups NNS N
. . N

Treatment NNP N
consisted VBD N
of IN N
approximately RB N
3,800 CD i
total JJ i
shock NN i
waves NNS i
( ( N
+/-10 JJ N
) ) N
reaching VBG N
an DT N
approximated JJ N
total NN N
energy NN N
delivery NN N
of IN N
1,300 CD N
mJ/mm NN N
( ( N
2 CD N
) ) N
( ( N
ED+ NNP N
) ) N
in IN N
a DT N
single JJ N
session NN N
versus IN N
placebo NN i
treatment NN i
. . i

This DT N
study NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
in IN N
the DT N
primary JJ N
efficacy NN N
outcome NN N
of IN N
pain NN o
during IN N
the DT o
first JJ o
few JJ o
minutes NNS o
of IN o
walking VBG o
measured VBN N
by IN N
a DT N
visual JJ o
analog NN o
scale NN o
. . o

There EX N
was VBD N
also RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatments NNS N
in IN N
the DT N
number NN N
of IN N
participants NNS N
whose WP$ N
changes NNS N
in IN N
Visual NNP o
Analog NNP o
Scale NNP o
scores VBZ o
met VBD N
the DT N
study NN N
definition NN N
of IN N
success NN N
at IN N
both DT N
6 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
posttreatment NN N
; : N
and CC N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
posttreatment NN N
in IN N
the DT N
Roles NNP o
and CC o
Maudsley NNP o
Score NNP o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
confirm VBP N
that IN N
ESWT NNP i
administered VBD N
with IN N
the DT N
Dornier NNP N
Epos NNP N
Ultra NNP N
is VBZ N
a DT N
safe JJ o
and CC N
effective JJ o
treatment NN N
for IN N
recalcitrant JJ N
plantar NN N
fasciitis NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
total JJ i
androgen NN i
ablation NN i
on IN N
pathologic JJ o
stage NN o
and CC o
resection NN o
limit NN o
status NN o
of IN o
prostate NN o
cancer NN o
. . o

Initial JJ N
results NNS N
of IN N
the DT N
Italian JJ p
PROSIT NNP p
study NN p
. . p

The DT N
likelihood NN N
of IN N
finding VBG N
organ-confined JJ N
untreated JJ N
prostate NN N
cancer NN N
( ( N
PCa NNP N
) ) N
by IN N
pathological JJ N
examination NN N
at IN N
the DT N
time NN N
of IN N
radical JJ i
prostatectomy NN i
( ( i
RP NNP i
) ) i
is VBZ N
only RB N
50 CD N
% NN N
in IN N
patients NNS N
with IN N
clinically RB N
organ-confined JJ N
disease NN N
. . N

In IN N
addition NN N
, , N
tumour NN N
is VBZ N
present JJ N
at IN N
the DT N
resection NN N
margin NN N
in IN N
approximately RB N
30 CD N
% NN N
of IN N
clinical JJ N
T2 NNP N
( ( N
clinical JJ N
stage NN N
B NNP N
) ) N
cases NNS N
. . N

The DT N
issue NN N
of IN N
clinical JJ N
understaging NN N
and CC N
of IN N
resection NN N
limit NN N
positivity NN N
have VBP N
led VBN N
to TO N
the DT N
development NN N
of IN N
novel JJ N
management NN N
practices NNS N
, , N
including VBG N
neoadjuvant JJ i
hormonal JJ i
therapy NN i
( ( i
NHT NNP i
) ) i
. . i

The DT N
optimal JJ N
duration NN N
of IN N
NHT NNP N
is VBZ N
unknown JJ N
. . N

We PRP N
undertook VBD N
the DT N
present JJ N
analysis NN N
to TO N
evaluate VB N
the DT N
effect NN o
of IN o
NHT NNP o
on IN o
pathologic JJ o
stage NN o
of IN o
PCa NNP o
and CC o
resection NN o
limit NN o
status NN o
in IN N
patients NNS p
with IN p
prostate JJ p
cancer NN p
and CC p
treated VBN p
with IN p
total JJ i
androgen NN i
ablation NN i
either DT p
for IN p
three CD p
or CC p
six CD p
months NNS p
before IN p
RP NNP p
. . p

Between NNP p
January NNP p
1996 CD p
and CC p
February NNP p
1998 CD p
, , p
259 CD p
men NNS p
with IN p
prostate NN p
cancer NN p
underwent JJ p
radical JJ i
retropubic NN i
prostatectomy NN i
and CC i
bilateral JJ i
pelvic JJ i
node NN i
dissection NN i
in IN p
the DT p
26 CD p
centres NNS p
participating VBG p
in IN p
the DT p
Italian JJ p
randomised VBD p
prospective JJ p
PROSIT NNP p
study NN p
. . p

Whole NNP N
mount NN N
sectioning NN N
of IN N
the DT N
complete JJ N
RP NNP N
specimens NNS N
was VBD N
adopted VBN N
in IN N
each DT N
centre NN N
for IN N
accurately RB N
evaluating VBG N
the DT N
pathologic JJ o
stage NN o
and CC o
resection NN o
limit NN o
status NN o
. . o

By IN N
February NNP N
1998 CD N
, , N
haematoxylin NN N
and CC N
eosin NN N
stained VBD N
sections NNS N
from IN N
155 CD N
RP NNP N
specimens NNS N
had VBD N
been VBN N
received VBN N
and CC N
evaluated VBN N
by IN N
the DT N
reviewing VBG N
pathologist NN N
( ( N
RM NNP N
) ) N
. . N

64 CD N
cases NNS N
had VBD N
not RB N
been VBN N
treated VBN N
with IN N
total JJ i
androgen NN i
ablation NN i
( ( N
e.g JJ N
. . N

NHT NNP i
) ) i
before IN N
RP NNP N
was VBD N
performed VBN N
, , N
whereas JJ N
58 CD N
and CC N
33 CD N
had VBD N
been VBN N
treated VBN N
for IN N
three CD N
and CC N
six CD N
months NNS N
, , N
respectively RB N
. . N

114 CD p
patients NNS p
were VBD N
clinical JJ N
stage NN N
B NNP N
whereas IN N
41 CD N
were VBD N
clinical JJ N
stage NN N
C. NNP N
After IN N
three CD N
months NNS N
of IN N
total JJ i
androgen NN i
ablation NN i
, , N
pathological JJ o
stage NN o
B NNP o
was VBD N
more RBR N
prevalent JJ N
among IN N
patients NNS N
with IN N
clinical JJ N
B NNP N
tumours NN N
, , N
compared VBN N
with IN N
untreated JJ N
patients NNS N
( ( N
57 CD N
% NN N
in IN N
treated JJ N
patients NNS N
vs. FW N
36 CD N
% NN N
in IN N
untreated JJ N
) ) N
. . N

The DT N
percentage NN o
of IN o
cancers NNS o
with IN o
negative JJ o
margins NNS o
was VBD N
statistically RB N
significantly RB N
greater JJR N
in IN N
patients NNS N
treated VBN N
with IN N
neoadjuvant JJ i
therapy NN i
than IN N
those DT N
treated VBN N
with IN N
immediate JJ i
surgery NN i
alone RB i
( ( N
69 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

After IN N
six CD N
months NNS N
of IN N
NHT NNP N
therapy VBP N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
pathological JJ o
stage NN o
B NNP o
( ( N
67 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
negative JJ o
margins NNS o
was VBD N
greater JJR N
than IN N
after IN N
3 CD N
months NNS N
( ( N
92 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

For IN N
clinical JJ N
C NNP N
tumours NN N
, , N
the DT N
prevalence NN N
of IN N
pathological JJ o
stage NN o
B NNP o
and CC o
negative JJ o
margins NNS o
in IN N
the DT N
patients NNS N
treated VBD N
for IN N
either DT N
3 CD N
or CC N
6 CD N
months NNS N
was VBD N
not RB N
as RB N
high JJ N
as IN N
in IN N
the DT N
clinical JJ N
B NNP N
tumours NN N
, , N
when WRB N
compared VBN N
with IN N
the DT N
untreated JJ N
group NN N
( ( N
pathological JJ N
stage NN N
B NNP N
: : N
31 CD N
% NN N
and CC N
33 CD N
% NN N
vs. FW N
6 CD N
% NN N
in IN N
the DT N
clinical JJ N
C NNP N
cases NNS N
, , N
respectively RB N
. . N

Negative JJ N
margins NNS N
: : N
56 CD N
% NN N
and CC N
67 CD N
% NN N
vs. FW N
31 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

The DT N
initial JJ N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
total JJ i
androgen NN i
ablation NN i
before IN i
RP NNP i
is VBZ N
beneficial JJ N
in IN N
men NNS N
with IN N
clinical JJ N
stage NN N
B NNP N
because IN N
of IN N
the DT N
significant JJ N
pathological JJ o
downstaging NN o
and CC N
decrease NN N
in IN N
the DT N
number NN N
of IN N
positive JJ o
margins NNS o
in IN o
the DT o
RP NNP o
specimens NNS o
. . o

These DT N
two CD N
effects NNS N
are VBP N
more RBR N
pronounced JJ N
after IN N
six CD N
months NNS N
of IN N
NHT NNP i
than IN N
after IN N
three CD N
months NNS N
of IN N
therapy NN N
. . N

The DT N
same JJ N
degree NN N
of IN N
beneficial JJ o
effects NNS o
are VBP N
not RB N
observed VBN N
in IN N
clinical JJ N
C NNP N
tumours NN N
. . N

-DOCSTART- -X- O O

Serum NNP o
bactericidal NN o
activities NNS o
and CC o
comparative JJ o
pharmacokinetics NNS o
of IN N
meropenem NN N
and CC N
imipenem-cilastatin NN N
. . N

The DT N
pharmacokinetics NNS o
and CC o
serum NN o
bactericidal NN o
activities NNS o
( ( o
SBAs NNP o
) ) o
of IN N
imipenem NN i
and CC N
meropenem NN i
were VBD N
investigated VBN N
in IN N
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

Twelve NNP p
healthy JJ p
male NN p
volunteers NNS p
received VBD N
a DT N
constant JJ i
30-min JJ i
infusion NN i
of IN i
either CC i
1 CD i
g NN i
of IN i
imipenem JJ i
plus CC i
1 CD i
g NN i
of IN i
cilastatin NN i
or CC i
1 CD i
g NN i
of IN i
meropenem NN i
. . i

The DT N
concentrations NNS o
of IN o
the DT o
drugs NNS o
in IN o
serum NN o
and CC o
urine NN o
were VBD N
determined VBN i
by IN i
bioassay NN o
and CC o
high-pressure NN o
liquid NN o
chromatography NN o
. . o

Pharmacokinetic JJ N
parameters NNS N
were VBD N
based VBN N
on IN N
an DT N
open JJ N
two-compartment JJ i
model NN i
and CC i
a DT i
noncompartmental JJ i
technique NN i
. . i

At IN N
the DT N
end NN N
of IN N
infusion NN N
, , N
the DT N
mean JJ o
concentrations NNS o
of IN o
imipenem NN o
and CC o
meropenem NN o
measured VBN o
in IN o
serum NN o
were VBD N
61.2 CD N
+/- JJ N
9.8 CD N
and CC N
51.6 CD N
+/- JJ N
6.5 CD N
mg/liter NN N
, , N
respectively RB N
; : N
urinary JJ o
recoveries NNS o
were VBD N
48.6 CD N
% NN N
+/- JJ N
8.2 CD N
% NN N
and CC N
60.0 CD N
% NN N
+/- JJ N
6.5 CD N
% NN N
of IN N
the DT N
dose NN N
in IN N
12 CD N
h NN N
, , N
respectively RB N
; : N
and CC N
the DT N
areas NNS o
under IN o
the DT o
concentration-time JJ o
curve NN o
from IN N
time NN N
zero CD N
to TO N
infinity NN N
were VBD N
96.1 CD N
+/- JJ N
14.4 CD N
and CC N
70.5 CD N
+/- JJ N
10.3 CD N
mg.h/liter NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
or CC N
= VB N
0.02 CD N
) ) N
. . N

Imipenem NNP N
had VBD N
a DT N
mean JJ N
half-life NN N
of IN N
66.7 CD N
+/- JJ N
10.4 CD N
min NN N
; : N
that IN N
of IN N
meropenem NN N
was VBD N
64.4 CD N
+/- JJ N
6.9 CD N
min NN N
. . N

The DT N
volumes NNS N
of IN N
distribution NN N
at IN N
steady JJ N
state NN N
of IN N
imipenem NN N
and CC N
meropenem NN N
were VBD N
15.3 CD N
+/- JJ N
3.3 CD N
and CC N
18.6 CD N
+/- JJ N
3.0 CD N
liters/70 NN N
kg NN N
, , N
respectively RB N
, , N
and CC N
the DT N
mean JJ N
renal JJ N
clearances NNS N
per IN N
1.73 CD N
m2 NNS N
were VBD N
85.6 CD N
+/- JJ N
17.6 CD N
and CC N
144.6 CD N
+/- JJ N
26.0 CD N
ml/min NN N
, , N
respectively RB N
. . N

Both DT p
antibiotics NNS p
were VBD p
well RB p
tolerated VBN p
in IN p
this DT p
single-dose JJ p
administration NN p
study NN p
. . p

The DT N
SBAs NNP o
were VBD N
measured VBN N
by IN N
the DT N
microdilution NN o
method NN o
of IN o
Reller NNP o
and CC o
Stratton NNP o
( ( N
L. NNP N
B. NNP N
Reller NNP N
and CC N
C. NNP N
W. NNP N
Stratton NNP N
, , N
J. NNP N
Infect NNP N
. . N

Dis NNP N
. . N

136:196-204 CD N
, , N
1977 CD N
) ) N
against IN N
40 CD N
clinically RB N
isolated JJ N
strains NNS N
. . N

Mean NNP o
reciprocal JJ o
bactericidal NN o
titers NNS o
were VBD N
measured VBN N
1 CD N
and CC N
6 CD N
h NN N
after IN N
administration NN N
. . N

After IN N
1 CD N
and CC N
6 CD N
h NN N
the DT N
median JJ N
SBAs NNP o
for IN N
imipenem NN N
and CC N
meropenem NN N
, , N
were VBD N
409 CD N
and CC N
34.9 CD N
and CC N
97.9 CD N
and CC N
5.8 CD N
, , N
respectively RB N
, , N
against IN N
Staphylococcus NNP N
aureus NN N
, , N
19.9 CD N
and CC N
4.4 CD N
and CC N
19.4 CD N
and CC N
4.8 CD N
, , N
respectively RB N
, , N
against IN N
Pseudomonas NNP N
aeruginosa NN N
, , N
34.3 CD N
and CC N
2.2 CD N
and CC N
232 CD N
and CC N
15.5 CD N
, , N
respectively RB N
, , N
against IN N
Enterobacter NNP N
cloacae NN N
, , N
and CC N
13.4 CD N
and CC N
2.25 CD N
and CC N
90.7 CD N
and CC N
7.9 CD N
, , N
respectively RB N
, , N
against IN N
Proteus NNP N
mirabilis NN N
. . N

Both DT p
drugs NNS p
had VBD p
rather RB p
short JJ p
biological JJ p
elimination NN p
half-lives NNS o
and CC p
a DT p
predominantly RB p
renal JJ p
route NN p
of IN p
elimination NN p
. . p

Both DT N
carbapenems NNS N
revealed VBD N
high JJ N
SBAs NNP o
against IN o
clinically RB o
important JJ o
pathogens NNS o
at IN N
1 CD N
h NN N
; : N
meropenem NN N
had VBD N
a DT N
higher JJR N
SBA NNP o
against IN N
E. NNP N
cloacae NN N
and CC N
P. NNP N
mirabilis NN N
, , N
and CC N
the DT N
SBA NNP o
of IN N
imipenem NN N
against IN N
S. NNP N
aureus NN N
was VBD N
greater JJR N
than IN N
the DT N
SBA NNP N
of IN N
meropenem NN N
. . N

-DOCSTART- -X- O O

Study NNP N
protocol NN N
: : N
Phase NNP N
III NNP N
single-blinded JJ N
fast-track JJ N
pragmatic NN N
randomised VBD N
controlled JJ N
trial NN N
of IN N
a DT N
complex JJ N
intervention NN N
for IN N
breathlessness NN o
in IN o
advanced JJ o
disease NN o
. . o

BACKGROUND NNP N
Breathlessness NNP N
in IN N
advanced JJ N
disease NN N
causes VBZ N
significant JJ N
distress NN o
to TO o
patients NNS o
and CC N
carers NNS N
and CC N
presents NNS N
management NN o
challenges VBZ o
to TO o
health NN o
care NN o
professionals NNS o
. . o

The DT N
Breathlessness NNP i
Intervention NNP i
Service NNP i
( ( i
BIS NNP i
) ) i
seeks VBZ N
to TO N
improve VB N
the DT N
care NN o
of IN o
breathless NN o
patients NNS o
with IN p
advanced JJ p
disease NN p
( ( p
regardless NN p
of IN p
cause NN p
) ) p
through IN N
the DT N
use NN N
of IN N
evidence-based JJ N
practice NN N
and CC N
working VBG N
with IN N
other JJ N
healthcare NN N
providers NNS N
. . N

BIS NNP i
delivers VBZ N
a DT i
complex JJ i
intervention NN i
( ( i
of IN i
non-pharmacological JJ i
and CC i
pharmacological JJ i
treatments NNS i
) ) i
via IN N
a DT N
multi-professional JJ N
team NN N
. . N

BIS NNP i
is VBZ N
being VBG N
continuously RB N
developed VBN N
and CC N
its PRP$ N
impact NN N
evaluated VBN N
using VBG N
the DT N
MRC NNP N
's POS N
framework NN N
for IN N
complex JJ N
interventions NNS N
( ( N
PreClinical NNP N
, , N
Phase NNP N
I PRP N
and CC N
Phase NNP N
II NNP N
completed VBD N
) ) N
. . N

This DT N
paper NN N
presents VBZ N
the DT N
protocol NN N
for IN N
Phase NNP N
III NNP N
. . N

METHODS/DESIGN NNP N
Phase NNP N
III NNP N
comprises VBZ N
a DT N
pragmatic JJ N
, , N
fast-track JJ N
, , N
single-blind JJ N
randomised VBD N
controlled JJ N
trial NN N
of IN N
BIS NNP i
versus FW N
standard NN i
care NN i
. . i

Due NNP N
to TO N
differing VBG N
disease NN N
trajectories NNS N
, , N
the DT N
service NN N
uses VBZ N
two CD i
broad JJ i
service NN i
models NNS i
: : i
one CD N
for IN N
patients NNS p
with IN p
malignant JJ p
disease NN p
( ( p
intervention NN p
delivered VBN p
over IN p
two CD p
weeks NNS p
) ) p
and CC p
one CD p
for IN p
patients NNS p
with IN p
non-malignant JJ p
disease NN p
( ( p
intervention NN p
delivered VBN p
over IN p
four CD p
weeks NNS p
) ) p
. . p

The DT N
Phase NNP N
III NNP N
trial NN N
therefore NN N
consists VBZ N
of IN N
two CD N
sub-protocols NNS N
: : N
one CD N
for IN N
patients NNS p
with IN p
malignant JJ p
conditions NNS p
( ( p
four CD p
week NN p
protocol NN p
) ) p
and CC p
one CD p
for IN p
patients NNS p
with IN p
non-malignant JJ p
conditions NNS p
( ( N
eight CD N
week NN N
protocol NN N
) ) N
. . N

Mixed JJ i
method NN i
interviews NNS i
are VBP N
conducted VBN N
with IN N
patients NNS N
and CC N
their PRP$ N
lay NN N
carers NNS N
at IN N
three CD N
to TO N
five CD N
measurement NN N
points NNS N
depending VBG N
on IN N
randomisation NN N
and CC N
sub-protocol NN N
. . N

Qualitative JJ N
interviews NNS N
are VBP N
conducted VBN N
with IN N
referring VBG N
and CC N
non-referring JJ N
health NN N
care NN N
professionals NNS N
( ( N
malignant JJ N
disease NN N
protocol NN N
only RB N
) ) N
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
'patient JJ o
distress NN o
due JJ o
to TO o
breathlessness VB o
' '' o
measured VBN o
on IN o
a DT o
numerical JJ o
rating NN o
scale NN o
( ( o
0-10 JJ o
) ) o
. . o

The DT N
trial NN N
includes VBZ N
economic JJ o
evaluation NN o
. . o

Analysis NN N
will MD N
be VB N
on IN N
an DT N
intention NN N
to TO N
treat VB N
basis NN N
. . N

DISCUSSION NNP N
This DT N
is VBZ N
the DT N
first JJ N
evaluation NN N
of IN N
a DT N
breathlessness NN N
intervention NN N
for IN N
advanced JJ N
disease NN N
to TO N
have VB N
followed VBN N
the DT N
MRC NNP N
framework NN N
and CC N
one CD N
of IN N
the DT N
first JJ N
palliative JJ N
care NN N
trials NNS N
to TO N
use VB N
fast JJ N
track NN N
methodology NN N
and CC N
single-blinding NN N
. . N

The DT N
results NNS N
will MD N
provide VB N
evidence NN N
of IN N
the DT N
clinical JJ o
and CC o
cost-effectiveness NN o
of IN o
the DT o
service NN o
, , N
informing VBG N
its PRP$ N
longer JJR N
term NN N
development NN N
and CC N
implementation NN N
of IN N
the DT N
model NN N
in IN N
other JJ N
centres NNS N
nationally RB N
and CC N
internationally RB N
. . N

It PRP N
adds VBZ N
to TO N
methodological JJ N
developments NNS N
in IN N
palliative JJ i
care NN i
research NN N
where WRB N
complex JJ N
interventions NNS N
are VBP N
common JJ N
but CC N
evidence NN N
sparse NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00678405ISRCTN NN N
: : N
ISRCTN04119516 NNP N
. . N

-DOCSTART- -X- O O

Carotid NNP N
sinus CC N
syndrome NN N
: : N
a DT N
modifiable JJ N
risk NN N
factor NN N
for IN N
nonaccidental JJ o
falls NNS o
in IN p
older JJR p
adults NNS p
( ( N
SAFE NNP N
PACE NNP N
) ) N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
cardiac JJ i
pacing NN i
reduces NNS N
falls VBZ o
in IN N
older JJR p
adults NNS p
with IN p
cardioinhibitory JJ p
carotid NNS p
sinus VBP p
hypersensitivity NN p
( ( p
CSH NNP p
) ) p
. . p

BACKGROUND NNP N
Cardioinhibitory NNP N
carotid NN N
sinus NN N
syndrome JJ N
causes NNS N
syncope NN p
, , N
and CC N
symptoms NNS N
respond NN N
to TO N
cardiac VB i
pacing NN i
. . i

There EX N
is VBZ N
circumstantial JJ N
evidence NN N
for IN N
an DT N
association NN N
between IN N
falls NNS o
and CC N
the DT N
syndrome NN N
. . N

METHODS NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
done VBN N
of IN N
consecutive JJ p
older JJR p
patients NNS p
( ( p
> JJ p
50 CD p
years NNS p
) ) p
attending VBG p
an DT p
accident NN p
and CC p
emergency NN p
facility NN p
because IN p
of IN p
a DT p
non-accidental JJ o
fall NN o
. . o

Patients NNS N
were VBD N
randomized VBN N
to TO N
dual-chamber VB i
pacemaker NN i
implant NN i
( ( i
paced JJ i
patients NNS i
) ) i
or CC N
standard JJ i
treatment NN i
( ( i
controls NNS i
) ) i
. . i

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
number NN o
of IN o
falls NNS o
during IN o
one CD o
year NN o
of IN o
follow-up NN o
. . o

RESULTS NNP N
One CD p
hundred VBD p
seventy-five JJ p
eligible JJ p
patients NNS p
( ( p
mean JJ p
age NN p
73 CD p
+/- JJ p
10 CD p
years NNS p
; : p
60 CD p
% NN p
women NNS p
) ) p
were VBD p
randomized VBN p
to TO p
the DT p
trial NN p
: : p
pacemaker NN i
87 CD p
; : p
controls NNS i
88 CD p
. . p

Falls NNP o
( ( o
without IN o
loss NN o
of IN o
consciousness NN o
) ) o
were VBD N
reduced VBN N
by IN N
two-thirds NNS N
: : N
controls NNS N
reported VBD N
669 CD N
falls NNS N
( ( N
mean JJ N
9.3 CD N
; : N
range NN N
0 CD N
to TO N
89 CD N
) ) N
, , N
and CC N
paced VBD N
patients NNS N
216 CD N
falls NNS N
( ( N
mean JJ N
4.1 CD N
; : N
range NN N
0 CD N
to TO N
29 CD N
) ) N
. . N

Thus RB N
, , N
paced VBD N
patients NNS N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
fall VB o
( ( N
odds NNS N
ratio VBP N
0.42 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
0.23 CD N
, , N
0.75 CD N
) ) N
than IN N
were VBD N
controls NNS N
. . N

Syncopal JJ o
events NNS o
were VBD N
also RB N
reduced VBN N
during IN N
the DT N
follow-up JJ N
period NN N
, , N
but CC N
there EX N
were VBD N
much RB N
fewer JJR N
syncopal JJ o
events NNS o
than IN N
falls-28 JJ o
episodes NNS N
in IN N
paced JJ N
patients NNS N
and CC N
47 CD N
in IN N
controls NNS N
. . N

Injurious JJ o
events NNS o
were VBD N
reduced VBN N
by IN N
70 CD N
% NN N
( ( N
202 CD N
in IN N
controls NNS N
compared VBN N
to TO N
61 CD N
in IN N
paced JJ N
patients NNS N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
is VBZ N
a DT N
strong JJ N
association NN N
between IN N
non-accidental JJ o
falls NNS N
and CC N
cardioinhibitory NN N
CSH NNP N
. . N

These DT N
patients NNS N
would MD N
not RB N
usually RB N
be VB N
referred VBN N
for IN N
cardiovascular JJ N
assessment NN N
. . N

Carotid NNP N
sinus JJ N
hypersensitivity NN N
should MD N
be VB N
considered VBN N
in IN N
all DT N
older JJR p
adults NNS p
who WP p
have VBP p
non-accidental JJ p
falls NNS p
. . p

-DOCSTART- -X- O O

The DT N
Beyond NNP N
Ageing NNP N
Project NNP N
Phase NNP N
2 CD N
-- : N
a DT N
double-blind JJ N
, , N
selective JJ N
prevention NN N
, , N
randomised VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
omega-3 JJ i
fatty JJ i
acids NNS i
and CC i
sertraline NN i
in IN N
an DT p
older JJR p
age NN p
cohort NN p
at IN p
risk NN p
for IN p
depression NN p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Late-life JJ p
depression NN p
is VBZ N
associated VBN N
with IN N
high JJ o
rates NNS o
of IN o
morbidity NN o
, , o
premature NN o
mortality NN o
, , o
disability NN o
, , o
functional JJ o
decline NN o
, , o
caregiver NN o
burden NN o
and CC o
increased VBD o
health NN o
care NN o
costs NNS o
. . o

While IN N
clinical JJ N
and CC N
public JJ N
health NN N
approaches NNS N
are VBP N
focused VBN N
on IN N
prevention NN N
or CC N
early JJ N
intervention NN N
strategies NNS N
, , N
the DT N
ideal JJ N
method NN N
of IN N
intervention NN N
remains VBZ N
unclear JJ N
. . N

No DT N
study NN N
has VBZ N
set VBN N
out RP N
to TO N
evaluate VB N
the DT N
role NN N
of IN N
neurobiological JJ N
agents NNS N
in IN N
preventing VBG N
depressive JJ N
symptoms NNS N
in IN N
older JJR N
populations NNS N
at IN N
risk NN N
of IN N
depression NN N
. . N

METHODS/DESIGN NNP N
Subjects VBZ p
with IN p
previously RB p
reported VBN p
sub-threshold JJ p
depressive NN p
symptoms NNS p
, , p
aged VBD p
60 CD p
to TO p
74 CD p
years NNS p
, , N
will MD N
be VB N
screened VBN N
to TO N
participate VB N
in IN N
a DT N
single-centre JJ N
, , N
double-blind JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN i
three CD i
parallel JJ i
groups NNS i
involving VBG i
omega-3 JJ i
fatty JJ i
acid JJ i
supplementation NN i
or CC i
sertraline NN i
hydrochloride NN i
, , i
compared VBN i
with IN i
matching VBG i
placebo NN i
. . i

Subjects NNS p
will MD p
be VB p
excluded VBN p
if IN p
they PRP p
have VBP p
current JJ p
depression NN p
or CC p
suicide JJ p
ideation NN p
; : p
are VBP p
taking VBG p
antidepressants NNS p
or CC p
any DT p
supplement JJ p
containing VBG p
omega-3 JJ p
fatty JJ p
acid NN p
; : p
or CC p
have VBP p
a DT p
prior JJ p
history NN p
of IN p
stroke NN p
or CC p
other JJ p
serious JJ p
cerebrovascular NN p
or CC p
cardiovascular JJ p
disease NN p
, , p
neurological JJ p
disease NN p
, , p
significant JJ p
psychiatric JJ p
disease NN p
( ( p
other JJ p
than IN p
depression NN p
) ) p
or CC p
neurodegenerative JJ p
disease NN p
. . p

The DT N
trial NN N
will MD N
consist VB N
of IN N
a DT N
12 CD N
month NN N
treatment NN N
phase NN N
with IN N
follow-up NN N
at IN N
three CD N
months NNS N
and CC N
12 CD N
months NNS N
to TO N
assess VB N
outcome JJ N
events NNS N
. . N

At IN i
three CD i
months NNS i
, , i
subjects NNS i
will MD i
undergo VB i
structural JJ o
neuroimaging VBG o
to TO i
assess VB i
whether IN i
treatment NN i
effects NNS i
on IN i
depressive JJ i
symptoms NNS i
correlate VBP i
with IN i
brain NN i
changes NNS i
. . i

Additionally RB N
, , N
proton NN o
spectroscopy NN o
techniques NNS N
will MD N
be VB N
used VBN N
to TO N
capture VB N
brain-imaging JJ o
markers NNS o
of IN N
the DT N
biological JJ N
effects NNS N
of IN N
the DT N
interventions NNS N
. . N

The DT N
trial NN N
will MD N
be VB N
conducted VBN N
in IN N
urban JJ p
New NNP p
South NNP p
Wales NNP p
, , p
Australia NNP p
, , N
and CC N
will MD N
recruit VB N
a DT N
community-based JJ p
sample NN p
of IN p
450 CD p
adults NNS p
. . p

Using VBG N
intention-to-treat JJ N
methods NNS N
, , N
the DT N
primary JJ N
endpoint NN N
is VBZ N
an DT N
absence NN N
of IN N
clinically RB N
relevant JJ N
depression NN N
scores NNS N
at IN N
12 CD N
months NNS N
between IN N
the DT N
omega-3 JJ N
fatty JJ N
acid NN N
and CC N
sertraline JJ N
interventions NNS N
and CC N
the DT N
placebo NN N
condition NN N
. . N

DISCUSSION VB N
The DT N
current JJ N
health NN o
, , o
social JJ o
and CC o
economic JJ o
costs NNS o
of IN N
late-life JJ N
depression NN N
make VBP N
prevention NN N
imperative NN N
from IN N
a DT N
public JJ N
health NN N
perspective NN N
. . N

This DT N
innovative JJ N
trial NN N
aims NNS N
to TO N
address VB N
the DT N
long-neglected JJ N
area NN N
of IN N
prevention NN N
of IN N
depression NN N
in IN N
older JJR N
adults NNS N
. . N

The DT N
interventions NNS N
are VBP N
targeted VBN N
to TO N
the DT N
pathophysiology NN N
of IN N
disease NN N
, , N
and CC N
regardless RB N
of IN N
the DT N
effect NN N
size NN N
of IN N
treatment NN N
, , N
the DT N
outcomes NNS N
will MD N
offer VB N
major JJ N
scientific JJ N
advances NNS N
regarding VBG N
the DT N
neurobiological JJ N
action NN N
of IN N
these DT N
agents NNS N
. . N

The DT N
main JJ N
results NNS N
are VBP N
expected VBN N
to TO N
be VB N
available JJ N
in IN N
2017 CD N
. . N

TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
and CC N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
ACTRN12610000032055 NNP N
( ( N
12 CD N
January NNP N
2010 CD N
) ) N
. . N

-DOCSTART- -X- O O

Effectiveness NN o
of IN N
the DT N
school NN i
dental JJ i
screening VBG i
programme NN i
in IN N
stimulating VBG o
dental JJ o
attendance NN o
for IN N
children NNS p
in IN p
need NN p
of IN p
treatment NN p
in IN p
Northern NNP p
Ireland NNP p
. . p

UNLABELLED IN N
The DT N
school NN i
dental JJ i
screening NN i
programme NN i
has VBZ N
been VBN N
in IN N
existence NN N
from IN N
the DT N
beginning NN N
of IN N
the DT N
20th JJ N
century NN N
yet RB N
its PRP$ N
value NN N
in IN N
encouraging JJ N
attendance NN N
among IN N
children NNS p
with IN p
a DT p
dental JJ p
health NN p
need NN p
is VBZ N
not RB N
fully RB N
established VBN N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
school NN i
dental JJ i
screening NN i
in IN N
promoting VBG N
dental JJ o
attendance NN o
among IN N
children NNS p
with IN p
a DT p
treatment NN p
need NN p
and CC N
to TO N
examine VB N
the DT N
relative JJ N
importance NN N
of IN N
screening NN N
, , N
social JJ N
class NN N
and CC N
other JJ N
factors NNS N
in IN N
dental JJ o
attendance NN o
. . o

METHODS NNP N
Sixty-four JJ p
participating NN p
schools NNS p
were VBD N
assigned VBN N
to TO N
study VB N
and CC N
control VB N
groups NNS N
using VBG N
a DT N
stratified JJ N
, , N
blocked JJ N
randomisation NN N
technique NN N
. . N

The DT N
study NN N
group NN N
children NNS N
received VBD N
the DT N
standard JJ i
school NN i
dental JJ i
screening NN i
and CC N
the DT N
dental JJ o
attendance NN o
of IN N
those DT N
with IN N
a DT N
positive JJ N
screening NN o
result NN o
was VBD N
assessed VBN N
after IN N
2 CD N
months NNS N
by IN N
means NNS N
of IN N
a DT N
questionnaire NN N
issued VBN N
to TO N
the DT N
children NNS N
's POS N
parents NNS N
. . N

The DT N
control NN N
group NN i
children NNS i
were VBD i
not RB i
, , i
at IN i
this DT i
stage NN i
, , i
screened VBD i
, , N
yet CC N
their PRP$ N
parents NNS N
received VBD N
the DT N
same JJ i
questionnaire NN i
assessing VBG i
dental JJ o
attendance NN o
over IN i
the DT i
2-month JJ i
period NN i
. . i

However RB N
, , N
only RB N
questionnaires VBZ N
from IN N
control NN i
group NN N
children NNS N
who WP N
had VBD N
a DT N
positive JJ N
result NN N
at IN N
a DT N
subsequent JJ N
screening NN N
were VBD N
retained VBN N
for IN N
analysis NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
2,321 CD p
children NNS p
were VBD p
screened VBN p
, , p
with IN p
980 CD p
having VBG p
a DT p
positive JJ p
result NN p
. . p

The DT N
mean JJ N
dmft NN N
of IN N
those DT N
screening VBG N
positive JJ N
was VBD N
4.85 CD N
. . N

In IN N
all DT N
, , N
664 CD p
completed VBN p
questionnaires NNS p
were VBD N
returned VBN N
, , N
giving VBG N
a DT N
response NN N
rate NN N
of IN N
67.8 CD N
% NN N
. . N

Dental JJ o
attendance NN o
was VBD N
reported VBN N
among IN N
45.5 CD N
% NN N
of IN N
the DT N
study NN N
group NN N
( ( N
n=352 NN N
) ) N
in IN N
the DT N
2 CD N
months NNS N
following VBG N
screening NN N
. . N

In IN N
the DT N
same JJ N
period NN N
, , N
27.6 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
n=312 RB N
) ) N
claimed VBD N
attendance NN N
. . N

The DT N
effect NN N
was VBD N
found VBN N
to TO N
be VB N
significant JJ N
among IN N
the DT N
high JJ N
employed VBN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
the DT N
unemployed JJ N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
School NNP N
dental JJ N
screening NN N
was VBD N
capable JJ N
of IN N
stimulating VBG N
dental JJ o
attendance NN o
. . o

The DT N
strong JJ N
effect NN N
among IN N
the DT N
lowest JJS N
socio-economic JJ N
group NN N
shows VBZ N
that IN N
school NN N
dental JJ N
screening NN N
may MD N
be VB N
used VBN N
to TO N
decrease VB N
dental JJ o
health NN o
inequalities NNS o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
Chinese NNP i
herbal JJ i
medicine NN i
on IN N
vascular JJ o
functions NNS o
during IN N
60-day JJ N
head-down JJ N
bed NN N
rest NN N
. . N

PURPOSE NNP N
Chinese JJ i
herbal JJ i
medicine NN i
is VBZ N
a DT N
promising JJ N
countermeasure NN N
against IN N
cardiovascular JJ o
dysfunction NN o
associated VBN p
with IN p
a DT p
sedentary JJ p
lifestyle NN p
. . p

We PRP N
examined VBD N
the DT N
impact NN N
of IN N
the DT N
Chinese JJ i
herb NN i
, , i
Taikong NNP i
Yangxin NNP i
, , N
on IN N
the DT N
micro- JJ o
and CC o
macrovascular JJ o
dysfunction NN o
associated VBN N
with IN N
a DT N
60-day JJ p
bed NN p
rest NN p
. . p

METHODS NNP N
Fourteen NNP p
healthy JJ p
men NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
those DT N
given VBN N
herbal JJ i
supplement NN i
, , N
and CC N
the DT N
control NN N
group NN N
; : N
the DT N
two CD N
groups NNS N
underwent VBD N
a DT N
60-day JJ i
bed NN i
rest NN i
. . i

The DT N
macrovasculature NN o
was VBD N
assessed VBN N
by IN N
sonography NN N
. . N

Skin NNP o
microvascular JJ o
functions NNS o
were VBD N
assessed VBN N
with IN N
laser NN N
Doppler NNP N
. . N

The DT N
plasma JJ o
level NN o
of IN o
endothelial JJ o
microparticles NNS o
( ( o
EMPs NNP o
) ) o
, , N
markers NNS N
of IN N
endothelial JJ o
injury NN o
, , N
was VBD N
determined VBN N
. . N

RESULTS NNP N
Bed NNP N
rest NN N
induced VBD N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
the DT N
femoral JJ o
artery NN o
diameter NN o
and CC N
compliance NN o
whereas NNS N
carotid VBP o
wall NN o
thickness NN o
, , o
diameter NN o
, , o
and CC o
compliance NN o
remained VBD N
unchanged JJ N
. . N

The DT N
early JJ o
phase NN o
of IN o
endothelium-dependent JJ o
vasodilation NN o
to TO o
ACh NNP o
was VBD N
unmodified VBN N
by IN N
bed NN N
rest NN N
, , N
while IN N
the DT N
late JJ o
phase NN o
was VBD N
reduced VBN N
by IN N
30 CD N
% NN N
along IN N
with IN N
a DT N
twofold JJ N
increase NN N
in IN N
EMPs NNP o
. . o

In IN N
those DT N
given VBN N
Taikong NNP i
Yangxin NNP i
, , N
the DT N
early JJ o
phase NN o
was VBD N
amplified VBN N
by IN N
2.5-fold JJ N
, , N
and CC N
the DT N
effects NNS o
of IN o
bed NN o
rest NN o
on IN N
the DT N
late JJ o
phase NN o
were VBD N
prevented VBN N
. . N

CONCLUSION NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
Taikong NNP N
Yangxin NNP N
ameliorates VBZ N
endothelium-dependent JJ o
vasodilation NN o
, , N
likely RB N
by IN N
improving VBG N
the DT N
NO NNP N
pathway NN N
. . N

The DT N
study NN N
suggests VBZ N
Taikong NNP N
Yangxin NNP N
as IN N
a DT N
new JJ N
countermeasure NN N
to TO N
prevent VB N
the DT N
changes NNS N
in IN N
microvascular JJ o
function NN o
induced VBN N
by IN N
physical JJ N
inactivity NN N
. . N

-DOCSTART- -X- O O

[ NN N
Study NNP N
on IN N
safety NN N
and CC N
immunogenicity NN N
of IN N
oral JJ i
poliomyelitis NN i
attenuated VBD i
live JJ i
vaccine NN i
( ( N
human JJ N
diploid NN N
cell NN N
) ) N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN o
and CC N
Immunogenicity NNP o
of IN N
the DT N
Poliomyelitis NNP i
vaccine NN i
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB p
month-old JJ p
children NNS p
. . p

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD p
healthy JJ p
children NNS p
of IN p
2-5 JJ p
months NNS p
old JJ p
in IN p
Jiangsu NNP p
province NN p
were VBD p
administered VBN p
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
and CC i
control NN i
vaccines NNS i
. . i

The DT N
antibody NN N
was VBD N
tested VBN N
by IN N
neutralization NN N
test NN N
. . N

RESULTS NNP N
After IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
, , N
the DT N
systemic JJ o
reactions NNS o
were VBD N
mild JJ N
. . N

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
, , N
the DT N
immune JJ o
success NN o
rates NNS o
of IN o
I PRP o
, , o
II NNP o
, , o
III NNP o
type NN o
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP o
of IN o
I PRP o
, , o
II NNP o
, , o
III NNP o
type NN o
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
was VBD N
safe JJ N
and CC N
immunogenicity NN N
for IN N
the DT p
children NNS p
> VBP p
or CC p
=2 JJ p
months NNS p
old JJ p
. . p

-DOCSTART- -X- O O

Brief JJ N
Report NNP N
: : N
Cobicistat NNP i
Compared NNP N
With IN N
Ritonavir NNP i
as IN N
a DT N
Pharmacoenhancer NNP N
for IN N
Atazanavir NNP i
in IN N
Combination NNP i
With IN i
Emtricitabine/Tenofovir NNP i
Disoproxil NNP i
Fumarate NNP i
: : i
Week JJ N
144 CD N
Results NNPS N
. . N

BACKGROUND NNP N
Cobicistat NNP i
( ( N
COBI NNP N
) ) N
is VBZ N
a DT N
pharmacoenhancer NN N
with IN N
no DT N
antiretroviral JJ N
activity NN N
. . N

METHODS NNP N
International NNP N
, , N
randomized VBD N
double-blind JJ N
active-controlled JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
COBI NNP i
vs FW i
ritonavir NN i
( ( i
RTV NNP i
) ) i
as IN N
a DT N
pharmacoenhancer NN N
of IN N
atazanavir NN i
in IN i
combination NN i
with IN i
emtricitabine/tenofovir JJ i
disoproxil NN i
fumarate NN i
in IN N
HIV NNP p
treatment-naive JJ p
patients NNS p
followed VBD N
through IN N
week NN N
144 CD N
. . N

RESULTS NN N
At IN N
Week NNP N
144 CD N
, , N
virologic JJ o
suppression NN o
was VBD N
achieved VBN N
in IN N
72 CD N
% NN N
( ( i
COBI NNP i
) ) i
and CC N
74 CD N
% NN N
( ( i
RTV NNP i
) ) i
of IN N
patients NNS N
. . N

Adverse JJ o
events NNS o
leading VBG N
to TO N
study VB N
drug NN N
discontinuation NN N
occurred VBD N
in IN N
11 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
group NN N
. . N

Median JJ N
changes NNS o
in IN o
serum NN o
creatinine NN o
( ( N
mg/dL NN N
) ) N
were VBD N
+0.13 NNP N
( ( N
COBI NNP N
) ) N
and CC N
+0.07 NNP N
( ( N
RTV NNP N
) ) N
and CC N
were VBD N
unchanged JJ N
from IN N
week NN N
48 CD N
. . N

CONCLUSIONS VB N
Once-daily JJ N
COBI NNP i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pharmacoenhancer NN o
of IN N
the DT N
protease NN N
inhibitor NN N
atazanavir NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
L-type NNP N
calcium NN N
channel NN N
blocker NN N
( ( i
amlodipine NN i
) ) i
on IN N
myocardial JJ o
iron NN o
deposition NN o
in IN N
patients NNS p
with IN p
thalassaemia NN p
with IN p
moderate-to-severe JJ p
myocardial JJ o
iron NN o
deposition NN o
: : o
protocol NN N
for IN N
a DT N
randomised JJ N
, , N
controlled JJ N
trial NN N
. . N

INTRODUCTION NNP N
Sideroblastic NNP N
cardiomyopathy NN N
secondary JJ N
to TO N
repeated VB o
blood NN o
transfusions NNS o
is VBZ N
a DT N
feared JJ N
complication NN N
in IN N
thalassaemia NN N
. . N

Control NNP N
of IN N
myocardial JJ o
iron NN o
is VBZ N
thus RB N
becoming VBG N
the DT N
cornerstone NN N
of IN N
thalassaemia JJ N
management NN N
. . N

Recent JJ N
evidence NN N
suggests VBZ N
a DT N
role NN N
for IN N
L-type NNP N
Ca NNP N
( ( N
2+ CD N
) ) N
channels NNS N
in IN N
mediating VBG N
iron NN N
uptake NN N
by IN N
the DT N
heart NN N
. . N

Blocking VBG N
the DT N
cellular JJ N
iron NN N
uptake VBP N
through IN N
these DT N
channels NNS N
may MD N
add VB N
to TO N
the DT N
benefit NN N
of IN N
therapy NN N
to TO N
standard VB N
chelation NN N
in IN N
reducing VBG N
myocardial JJ o
iron NN o
. . o

We PRP N
aim VBP N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
amlodipine NN i
( ( N
a DT N
calcium NN N
channel NN N
blocker NN N
) ) N
as IN N
an DT N
adjunct NN N
to TO N
standard VB N
aggressive JJ N
chelation NN N
in IN N
retarding VBG N
myocardial JJ o
iron NN o
deposition NN o
in IN N
thalassaemics NNS N
with IN N
or CC N
without IN N
cardiomyopathy JJ N
. . N

OUTCOMES IN N
The DT N
primary JJ N
outcome NN N
is VBZ N
to TO N
compare VB o
the DT o
efficacy NN o
of IN o
amlodipine+chelation NN o
( ( o
intervention NN o
) ) o
versus FW o
standard JJ o
chelation NN o
( ( o
control NN o
) ) o
in IN o
retarding VBG o
myocardial JJ o
iron NN o
deposition NN o
. . o

Secondary JJ N
outcomes NNS N
include VBP N
the DT N
effect NN o
of IN o
amlodipine NN o
therapy NN o
on IN o
systolic JJ o
and CC o
diastolic JJ o
function NN o
, , o
strain NN o
and CC o
strain NN o
rate NN o
and CC o
liver NN o
iron NN o
content NN o
. . o

METHODS NNP N
AND CC N
ANALYSIS NNP N
This DT N
is VBZ N
a DT N
single-centre JJ N
, , N
parallel-group JJ N
, , N
prospective JJ N
randomised VBN N
control NN N
trial NN N
. . N

Twenty CD p
patients NNS p
will MD N
be VB N
randomised VBN N
in IN N
a DT N
1:1 CD N
allocation NN N
ratio NN N
into IN N
the DT N
intervention NN N
and CC N
control NN N
arms NNS N
. . N

In IN N
addition NN N
to TO N
conventional JJ N
echocardiography NN N
, , N
MRI NNP N
T2* NNP N
values NNS N
for IN N
assessment NN N
of IN N
cardiac NN o
and CC o
liver NN o
iron NN o
load NN o
will MD N
be VB N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
. . N

Cardiac NNP N
T2* NNP N
will MD N
be VB N
reported VBN N
as IN N
the DT N
geometric JJ N
mean NN N
and CC N
per IN N
cent NN N
coefficient NN N
of IN N
variation NN N
, , N
and CC N
an DT N
increase NN N
in IN N
cardiac JJ N
T2* NNP N
values NNS N
from IN N
baseline NN N
will MD N
be VB N
used VBN N
as IN N
an DT N
end NN N
point NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
therapy NN N
. . N

A DT N
p JJ N
Value NNP N
of IN N
< NNP N
0.05 CD N
will MD N
be VB N
considered VBN N
significant JJ N
. . N

STUDY NNP N
SETTING NNP N
Department NNP p
of IN p
Pediatric NNP p
and CC p
Child NNP p
Health NNP p
, , p
Aga NNP p
Khan NNP p
University NNP p
Hospital NNP p
, , p
Karachi NNP p
, , p
Pakistan NNP p
. . p

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
This DT N
study NN N
has VBZ N
been VBN N
approved VBN N
by IN N
the DT N
Ethics NNP N
Review NNP N
Committee NNP N
and CC N
Clinical NNP N
Trials NNP N
Unit NNP N
at IN N
The DT p
Aga NNP p
Khan NNP p
University NNP p
with IN N
respect NN N
to TO N
scientific JJ N
content NN N
and CC N
compliance NN N
with IN N
applicable JJ N
research NN N
and CC N
human JJ N
subjects NNS N
regulations NNS N
. . N

Findings NNS N
will MD N
be VB N
reported VBN N
through IN N
scientific JJ N
publications NNS N
and CC N
research NN N
conferences NNS N
and CC N
project NN N
summary JJ N
papers NNS N
for IN N
participants NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ClinicalTrials.Gov NNP N
. . N

Registration NNP N
no DT N
: : N
NCT02065492 NN N
. . N

-DOCSTART- -X- O O

Inflammatory JJ N
response NN N
in IN N
humans NNS p
exposed VBN p
to TO p
2.0 CD p
ppm NNS p
nitrogen JJ i
dioxide NN i
. . i

Nitrogen NNP i
dioxide NN i
( ( i
NO2 NNP i
) ) i
is VBZ N
a DT N
common JJ N
indoor NN N
air NN N
pollutant NN N
, , N
especially RB N
in IN N
homes NNS N
with IN N
unvented JJ N
combustion NN N
appliances NNS N
. . N

Epidemiological JJ N
studies NNS N
suggest VBP N
that IN N
children NNS N
living VBG N
in IN N
homes NNS N
with IN N
unvented JJ N
heating NN N
sources NNS N
are VBP N
more JJR N
prone NN N
to TO N
respiratory NN N
infections NNS N
than IN N
children NNS N
living VBG N
in IN N
homes NNS N
with IN N
lower JJR N
levels NNS N
of IN N
NO2 NNP i
. . i

However RB N
, , N
experimental JJ N
studies NNS N
in IN N
which WDT N
human JJ N
volunteers NNS N
were VBD N
exposed VBN N
acutely RB N
to TO N
moderate JJ N
levels NNS N
of IN N
NO2 NNP i
( ( N
0.5-2.0 JJ N
ppm NN N
) ) N
have VBP N
shown VBN N
little JJ N
evidence NN N
of IN N
lung NN N
inflammation NN N
or CC N
decreased VBN N
host NN N
resistance NN N
capacity NN N
. . N

In IN N
the DT N
study NN N
reported VBD N
here RB N
, , N
8 CD p
healthy JJ p
volunteers NNS p
were VBD p
exposed VBN p
to TO p
2.0 CD p
ppm NN p
NO2 NNP i
and CC p
to TO p
filtered VB i
air NN i
for IN p
4 CD p
h NNS p
while IN p
undergoing VBG i
intermittent JJ i
moderate JJ i
exercise NN i
. . i

Bronchoalveolar JJ i
lavage NN i
was VBD N
performed VBN N
the DT N
following JJ N
morning NN N
. . N

The DT N
lavage NN N
was VBD N
divided VBN N
into IN N
a DT N
predominantly RB N
bronchial JJ N
washing NN N
( ( N
first JJ N
20 CD N
ml NN N
of IN N
lavage NN N
; : N
BL NNP N
) ) N
and CC N
a DT N
predominantly RB N
alveolar JJ N
washing NN N
( ( N
BAL NNP N
) ) N
. . N

In IN N
the DT N
BL NNP N
, , N
NO2 NNP o
exposure NN o
caused VBD N
increases NNS N
in IN N
polymorphonuclear JJ o
neutrophils NNS o
( ( o
PMNs NNP o
) ) o
, , o
interleukin JJ o
6 CD o
( ( o
IL-6 NNP o
) ) o
, , o
IL-8 NNP o
, , o
alpha1-antitrypsin NN o
, , o
and CC o
tissue NN o
plasminogen NN o
activator NN o
, , N
and CC N
decreases NNS N
in IN N
epithelial JJ o
cells NNS o
. . o

In IN N
the DT N
BAL NNP N
, , N
there EX N
were VBD N
no DT N
NO2-induced JJ N
changes NNS N
in IN N
either DT N
cell NN o
numbers NNS o
or CC o
soluble JJ o
mediators NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
alveolar JJ N
macrophages NNS N
from IN N
BAL NNP N
showed VBD N
a DT N
decrease NN N
in IN N
the DT N
ability NN N
to TO N
phagocytose VB o
unopsonized JJ o
Candida NNP o
albicans NNS o
and CC N
a DT N
decrease NN N
in IN N
superoxide JJ o
production NN o
. . o

No DT N
difference NN N
in IN N
susceptibility NN o
to TO o
virus VB o
infection NN o
was VBD N
found VBN N
between IN N
the DT N
NO2- NNP i
and CC N
air-exposed JJ N
macrophages NNS N
. . N

No DT N
changes NNS N
in IN N
lung NN N
function NN N
were VBD N
observed VBN N
, , N
but CC N
the DT N
aerosol JJ N
bolus JJ N
recovery NN N
technique NN N
revealed VBD N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
decrease NN N
in IN N
the DT N
fraction NN N
of IN N
aerosol NN N
recovered VBD N
following VBG N
nitrogen NN i
dioxide NN i
exposure NN N
, , N
which WDT N
is VBZ N
suggestive JJ N
of IN N
small JJ N
obstructive JJ N
changes NNS N
induced VBN N
by IN N
NO2 NNP i
. . i

-DOCSTART- -X- O O

Indicators NNS N
for IN N
Cervical JJ N
Length NNP N
in IN N
Twin NNP p
Pregnancies NNP p
. . p

OBJECTIVE NNP N
Cervical NNP o
length NN o
( ( o
CL NNP o
) ) o
is VBZ N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
preterm JJ N
birth NN N
( ( N
PTB NNP N
) ) N
in IN N
multiple JJ N
pregnancies NNS N
. . N

However RB N
, , N
the DT N
position NN N
of IN N
CL NNP N
within IN N
the DT N
pathophysiological JJ N
pathway NN N
of IN N
PTB NNP N
is VBZ N
unclear JJ N
, , N
and CC N
it PRP N
is VBZ N
unknown JJ N
which WDT N
factors NNS N
are VBP N
predictive JJ N
for IN N
CL NNP o
. . o

This DT N
study NN N
aims VBZ N
to TO N
investigate VB N
whether IN N
in IN N
twin JJ N
pregnancies NNS N
baseline VBP N
maternal JJ N
and CC N
obstetrical JJ N
characteristics NNS N
are VBP N
potential JJ N
indicators NNS N
for IN N
CL NNP o
, , N
to TO N
improve VB N
insight NN N
in IN N
the DT N
pathophysiological JJ N
pathway NN N
of IN N
PTB NNP N
. . N

STUDY NNP N
DESIGN NNP N
Secondary NNP N
analysis NN o
of IN o
data NNS o
on IN o
twin NN o
pregnancies NNS o
and CC p
CL NNP o
measurement NN o
between IN p
16 CD p
and CC p
22 CD p
weeks NNS p
. . p

A DT N
set NN N
of IN N
10 CD N
potential JJ N
indicators NNS N
, , N
known VBN N
to TO N
be VB N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
PTB NNP N
and/or NN N
which WDT N
have VBP N
a DT N
plausible JJ N
mechanism NN N
resulting VBG N
in IN N
a DT o
change NN o
of IN o
CL NNP o
were VBD N
selected VBN N
. . N

We PRP N
used VBD N
multivariable JJ N
linear JJ N
regression NN N
with IN N
backward JJ N
selection NN N
to TO N
identify VB N
independent JJ N
indicators NNS o
for IN o
CL NNP o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
1,447 CD p
women NNS p
with IN p
twin JJ p
pregnancies NNS p
were VBD p
included VBN p
. . p

Mean NNP o
CL NNP o
was VBD N
43.7 CD N
( ( N
?8.9 NN N
) ) N
mm NN N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
age NN N
( ( N
0.27 CD N
mm/y NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] VBD N
0.16 CD N
to TO N
0.39 CD N
) ) N
, , N
use NN N
of IN N
assisted JJ N
reproductive JJ N
technologies NNS N
( ( N
ART NNP N
) ) N
( ( N
-1.42 JJ N
mm NN N
, , N
95 CD N
% NN N
CI NNP N
-2.6 NNP N
to TO N
-0.25 VB N
) ) N
, , N
and CC N
having VBG N
delivered VBN N
at IN N
term NN N
in IN N
a DT N
previous JJ N
pregnancy NN N
( ( N
1.32 CD N
mm NN N
, , N
95 CD N
% NN N
CI NNP N
0.25 CD N
to TO N
2.39 CD N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
CL NNP o
. . o

CONCLUSION NNP N
This DT N
study NN N
shows VBZ N
that IN N
in IN p
twin NN p
pregnancies NNS p
, , p
age NN p
, , N
use NN N
of IN N
ART NNP N
and CC N
having VBG N
delivered VBN N
term NN N
in IN N
a DT N
previous JJ N
pregnancy NN N
has VBZ N
an DT N
association NN N
with IN N
CL NNP o
. . o

-DOCSTART- -X- O O

Magnetic JJ i
resonance NN i
imaging NN i
in IN N
the DT N
evaluation NN N
of IN N
clinical JJ N
treatment NN N
of IN N
otospongiosis NN p
: : p
a DT N
pilot NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
applicability NN N
of IN N
magnetic JJ i
resonance NN i
imaging NN i
( ( i
MRI NNP i
) ) i
as IN N
a DT N
method NN N
for IN N
monitoring VBG N
the DT N
activity NN N
of IN N
otospongiotic JJ N
lesions NNS N
before IN N
and CC N
after IN N
clinical JJ N
treatment NN N
. . N

STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
, , N
double-blind NN N
study NN N
. . N

SETTING CC N
One CD p
single JJ p
tertiary NN p
care NN p
institution NN p
in IN p
a DT p
large JJ p
, , p
cosmopolitan JJ p
city NN p
. . p

METHODS NNP N
Twenty-six JJ p
patients NNS p
( ( p
n JJ p
= $ p
42 CD p
ears NNS p
) ) p
with IN p
clinical JJ p
, , p
audiometric JJ p
, , p
and CC p
tomographic JJ p
diagnosis NN p
of IN p
otosclerosis NN p
were VBD p
enrolled VBN p
. . p

If IN N
computed VBN i
tomography NN i
( ( N
CT NNP N
) ) N
demonstrated VBD N
active JJ N
lesions NNS N
, , N
these DT N
patients NNS N
underwent VBD i
MRI NNP i
to TO N
detect VB N
otospongiotic JJ N
foci NN N
, , N
seen VBN N
as IN N
areas NNS N
of IN N
gadolinium NN N
enhancement NN N
. . N

Patients NNS N
were VBD N
divided VBN N
into IN N
3 CD N
groups NNS N
and CC N
received VBN N
treatment NN N
with IN N
placebo NN i
, , i
sodium NN i
alendronate NN i
, , i
or CC i
sodium NN i
fluoride NN i
for IN N
6 CD N
months NNS N
. . N

After IN N
this DT N
period NN N
, , N
clinical JJ N
and CC N
audiometric JJ N
evaluations NNS N
and CC N
a DT N
second JJ N
MRI NNP i
were VBD N
performed VBN N
. . N

Each DT N
MRI NNP i
was VBD N
evaluated VBN N
by IN N
both DT N
a DT N
neuroradiologist NN N
and CC N
an DT N
otolaryngologist NN N
in IN N
a DT N
subjective JJ N
( ( N
visual JJ N
) ) N
and CC N
objective JJ N
( ( N
using VBG N
specific JJ N
eFilm JJ N
Workstation NNP N
software NN N
) ) N
manner NN N
. . N

RESULTS NNP N
Otospongiosis NNP N
was VBD N
most JJS N
predominantly RB N
identified VBN N
in IN N
the DT N
region NN N
anterior RB N
to TO N
the DT N
oval NN N
window NN N
, , N
and CC N
this DT N
site NN N
was VBD N
reliable JJ N
for IN N
comparing VBG N
pre- JJ N
and CC N
posttreatment JJ N
scans NNS N
. . N

The DT N
patients NNS N
in IN N
the DT N
alendronate NN N
and CC N
sodium NN N
fluoride NN N
groups NNS N
had VBD N
MRI NNP i
findings NNS N
that WDT N
suggested VBD N
a DT N
decrease NN N
in IN N
activity NN N
of IN N
otospongiotic JJ N
lesions NNS N
, , N
more RBR N
relevant JJ N
in IN N
the DT N
alendronate NN N
group NN N
. . N

These DT N
findings NNS N
were VBD N
statistically RB N
significant JJ N
for IN N
both DT N
subjective JJ N
and CC N
objective JJ N
MRI NNP i
evaluations NNS N
. . N

CONCLUSIONS NNP N
MRI NNP N
shows VBZ N
higher JJR N
sensitivity NN N
than IN N
clinical JJ N
or CC N
audiometric JJ N
assessment NN N
for IN N
detecting VBG N
reduction NN N
in IN N
activity NN N
of IN N
otospongiosis NN N
. . N

The DT N
objective JJ N
MRI NNP i
evaluation NN N
based VBN N
on IN N
software NN N
analysis NN N
was VBD N
the DT N
most RBS N
accurate JJ N
method NN N
of IN N
monitoring VBG N
clinical JJ N
treatment NN N
response NN N
in IN N
otospongiosis NN N
. . N

-DOCSTART- -X- O O

Use NNP i
of IN i
an DT i
Internet NNP i
portal NN i
to TO N
improve VB N
community-based JJ p
pediatric JJ p
ADHD NNP p
care NN p
: : p
a DT N
cluster NN N
randomized VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
quality NN i
improvement NN i
program NN i
to TO N
improve VB N
pediatricians NNS p
' POS p
adherence NN N
to TO N
existing VBG N
, , N
evidence-based JJ N
, , N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
practice NN N
guidelines NNS N
. . N

METHODS NNP N
Forty-nine JJ p
community-based JJ p
pediatricians NNS p
at IN p
8 CD p
practices NNS p
participated VBN p
in IN p
a DT p
cluster-randomized JJ p
trial NN p
. . p

Practices NNS N
were VBD N
matched VBN N
according VBG N
to TO N
the DT N
numbers NNS p
of IN p
pediatricians NNS p
and CC p
the DT p
proportions NNS p
of IN p
patients NNS p
receiving VBG p
Medicaid NNP p
. . p

The DT N
medical JJ N
charts NNS N
for IN N
a DT N
random JJ N
sample NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
for IN N
each DT N
of IN N
the DT N
participating VBG N
pediatricians NNS N
were VBD N
examined VBN N
at IN N
baseline NN N
and CC N
6 CD N
months NNS N
. . N

All DT N
practices NNS N
participated VBN N
in IN N
4 CD N
sessions NNS N
of IN N
training NN i
, , i
including VBG i
didactic JJ i
lectures NNS i
and CC i
office NN i
flow NN i
modification NN i
workshops NNS i
. . i

Practices NNS N
were VBD N
then RB N
given VBN N
access NN N
to TO N
an DT N
ADHD NNP i
Internet NNP i
portal NN i
that WDT N
allowed VBD N
parents NNS N
, , N
teachers NNS N
, , N
and CC N
pediatricians NNS N
to TO N
input VB N
information NN N
( ( N
eg NN N
, , N
rating NN N
scales NNS N
) ) N
about IN N
patients NNS N
, , N
after IN N
which WDT N
information NN N
was VBD N
scored VBN N
, , N
interpreted VBN N
, , N
and CC N
formatted VBN N
in IN N
a DT N
report NN N
style NN N
that WDT N
was VBD N
helpful JJ N
for IN N
assessment NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
ADHD NNP N
. . N

Physicians NNPS N
evaluated VBD N
their PRP$ N
practice NN o
behaviors NNS o
quarterly RB N
and CC N
addressed VBD N
underperforming JJ o
areas NNS o
. . o

RESULTS NNP N
Pediatricians NNPS N
in IN N
the DT N
intervention NN N
group NN N
, , N
compared VBN N
with IN N
those DT N
in IN N
the DT N
control NN i
group NN N
, , N
demonstrated VBD N
significantly RB N
higher JJR N
rates NNS N
of IN N
many JJ N
American JJ N
Academy NNP N
of IN N
Pediatrics-recommended NNP N
ADHD NNP N
care NN N
practices NNS N
, , N
including VBG N
collection NN o
of IN o
parent NN o
( ( N
Cohen NNP N
's POS N
d NN N
= VBZ N
0.69 CD N
) ) N
and CC N
teacher $ o
( ( N
d JJ N
= NNP N
0.68 CD N
) ) N
rating NN o
scales NNS o
for IN N
assessment NN N
of IN N
children NNS N
with IN N
ADHD NNP N
, , N
use NN N
of IN N
Diagnostic NNP N
and CC N
Statistical NNP o
Manual NNP o
of IN o
Mental NNP o
Disorders NNP o
, , N
Fourth NNP N
Edition NNP N
, , N
criteria NNS N
( ( N
d VB N
= RB N
0.85 CD N
) ) N
, , N
and CC N
use NN N
of IN N
teacher NN o
rating NN o
scales NNS o
to TO N
monitor VB N
treatment NN N
responses NNS N
( ( N
d VB N
= RB N
1.01 CD N
) ) N
. . N

CONCLUSION VB N
A DT i
quality NN i
improvement NN i
intervention NN i
that WDT N
can MD N
be VB N
widely RB N
disseminated VBN N
by IN N
using VBG N
Internet-based JJ i
information NN i
technology NN i
significantly RB N
improved VBD N
the DT N
quality NN N
of IN N
ADHD NNP N
care NN N
in IN N
community-based JJ p
pediatric JJ p
settings NNS p
. . p

-DOCSTART- -X- O O

Lack NN N
of IN N
effect NN N
of IN N
warfarin NN i
on IN N
the DT N
restenosis NN o
rate NN o
or CC N
on IN p
clinical JJ p
outcome NN p
after IN p
balloon NN p
coronary JJ p
angioplasty NN p
. . p

Between NNP p
September NNP p
1985 CD p
and CC p
April NNP p
1987 CD p
, , p
110 CD p
consecutive JJ p
patients NNS p
who WP p
had VBD p
successful JJ p
coronary JJ p
angioplasty NN p
were VBD N
included VBN N
in IN N
a DT N
randomised JJ N
prospective NN N
controlled VBN N
evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
warfarin NN i
on IN N
restenosis NN N
. . N

The DT N
warfarin NN i
( ( N
n JJ N
= NNP N
56 CD N
) ) N
and CC N
the DT N
control NN i
( ( N
n JJ N
= NNP N
54 CD N
) ) N
groups NNS N
were VBD N
not RB N
different JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
sex NN N
, , N
previous JJ N
coronary JJ N
bypass NN N
surgery NN N
or CC N
coronary JJ N
balloon NN N
angioplasty NN N
, , N
severity NN N
of IN N
symptoms NNS N
, , N
and CC N
frequency NN N
of IN N
multivessel JJ N
disease NN N
or CC N
of IN N
total JJ N
coronary JJ N
occlusions NNS N
. . N

Warfarin NNP i
was VBD N
started VBN N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
the DT N
dosage NN N
was VBD N
adjusted VBN N
to TO N
maintain VB N
the DT N
thromboplastin JJ N
international JJ N
normalised VBN N
ratio NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
2.5 CD N
. . N

One CD N
hundred CD N
and CC N
five CD N
( ( N
96 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
were VBD N
given VBN N
verapamil NNS i
and CC N
other JJ i
antianginal JJ i
drugs NNS i
were VBD N
prescribed VBN N
as IN N
needed VBN N
. . N

Low JJ i
molecular JJ i
weight NN i
dextran NN i
and CC i
heparin NN i
were VBD N
given VBN N
during IN N
the DT N
procedure NN N
and CC N
heparin NN i
was VBD N
continued VBN N
for IN N
24 CD N
hours NNS N
in IN N
all DT N
patients NNS N
. . N

One CD p
hundred CD p
and CC p
eight CD p
( ( p
98 CD p
% NN p
) ) p
of IN p
patients NNS p
were VBD p
followed VBN p
up RP p
clinically RB p
after IN p
a DT p
median NN p
of IN p
five CD p
months NNS p
( ( p
range VB p
1-20 CD p
) ) p
. . p

Eighty NNP p
five CD p
( ( p
77 CD p
% NN p
) ) p
had VBD p
follow VBN p
up RP p
angiography NN p
at IN p
five CD p
months NNS p
. . p

In IN N
the DT N
warfarin NN i
group NN N
symptoms NNS o
improved VBN o
in IN N
46 CD N
( ( N
85 CD N
% NN N
) ) N
patients NNS N
by IN N
at IN N
least JJS N
1 CD N
angina JJ N
class NN N
and CC N
31 CD N
( ( N
57 CD N
% NN N
) ) N
were VBD N
symptom JJ o
free JJ o
; : o
the DT N
exercise NN N
test NN N
remained VBD N
positive JJ N
in IN N
20 CD N
( ( N
36 CD N
% NN N
) ) N
patients NNS N
and CC N
the DT N
angiographic JJ o
restenosis NN o
rate NN o
was VBD N
25 CD N
% NN N
per IN N
lesion NN N
and CC N
29 CD N
% NN N
per IN N
patient NN N
. . N

There EX N
were VBD N
no DT N
major JJ o
bleeding NN o
complications NNS o
. . o

In IN N
the DT N
control NN i
group NN N
46 CD N
( ( N
85 CD N
% NN N
) ) N
patients NNS N
were VBD N
improved VBN N
by IN N
at IN N
least JJS N
1 CD N
angina JJ N
class NN N
and CC N
31 CD N
( ( N
57 CD N
% NN N
) ) N
were VBD N
symptom JJ N
free JJ N
; : N
the DT N
exercise NN o
test NN o
was VBD N
positive JJ N
in IN N
11 CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
and CC N
the DT N
angiographic JJ o
restenosis NN o
rate NN o
was VBD N
33 CD N
% NN N
per IN N
lesion NN N
and CC N
37 CD N
% NN N
per IN N
patient NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
angiographic JJ N
restenosis NN N
tended VBD N
to TO N
be VB N
lower JJR N
with IN N
warfarin NN i
, , N
none NN N
of IN N
these DT N
differences NNS N
was VBD N
significant JJ N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
combination NN N
of IN N
verapamil NN i
and CC N
warfarin NN i
, , N
in IN N
the DT N
absence NN N
of IN N
aspirin NN i
, , N
is VBZ N
not RB N
significantly RB N
better JJR N
than IN N
verapamil NN N
alone RB N
in IN N
preventing VBG N
symptom JJ N
recurrence NN N
or CC N
angiographic JJ o
restenosis NN o
after IN N
coronary JJ N
angioplasty NN N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
a DT N
new JJ i
computer NN i
intervention NN i
to TO N
teach VB N
people NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome VBP p
to TO N
recognize VB N
and CC N
predict VB N
emotions NNS N
in IN N
others NNS N
. . N

This DT N
randomized VBD N
controlled JJ N
trial NN N
looked VBD N
at IN N
the DT N
effect NN N
of IN N
a DT N
new JJ i
computer NN i
program NN i
designed VBN N
to TO N
teach VB N
people NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
to TO N
better JJR N
recognize VB N
and CC N
predict VBP N
emotional JJ N
responses NNS N
in IN N
others NNS N
. . N

Two CD p
groups NNS p
of IN p
11 CD p
children NNS p
( ( p
age NN p
12-18 CD p
) ) p
with IN p
autism NN p
or CC p
Asperger NNP p
syndrome VBP p
at IN p
two CD p
special JJ p
schools NNS p
participated VBD p
: : p
one CD i
group NN i
used VBD i
the DT i
computer NN i
program NN i
for IN i
10 CD i
half-hour JJ i
sessions NNS i
over IN i
2 CD i
weeks NNS i
. . i

Within-program NNP N
data NN N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
errors NNS N
made VBN N
from IN N
first JJ N
to TO N
last JJ N
use NN N
. . N

Students NNS N
were VBD N
assessed VBN N
pre- JJ N
and CC N
post-intervention NN N
using VBG N
facial JJ o
expression NN o
photographs NN o
, , o
cartoons NNS o
depicting VBG o
emotion-laden JJ o
situations NNS o
, , o
and CC o
non-literal JJ o
stories NNS o
. . o

Scores NNS N
were VBD N
not RB N
related VBN N
to TO N
age NN N
or CC N
verbal JJ N
ability NN N
. . N

The DT N
experimental JJ N
group NN N
made VBD N
gains NNS N
relative JJ N
to TO N
the DT N
control NN N
group NN N
on IN N
all DT N
three CD N
measures NNS N
. . N

Gains NNP N
correlated VBD N
significantly RB N
with IN N
the DT N
number NN N
of IN N
times NNS N
the DT N
computer NN i
program NN i
was VBD N
used VBN N
and CC N
results NNS N
suggest VBP N
positive JJ N
effects NNS N
. . N

Further NNP N
research NN N
could MD N
assess VB N
whether IN N
these DT N
gains NNS N
generalized VBD N
into IN N
real JJ N
life NN N
or CC N
improved VBN N
performance NN N
on IN N
theory NN N
of IN N
mind NN N
measures NNS N
. . N

-DOCSTART- -X- O O

Evaluation NN N
of IN N
AMSA NNP i
in IN N
children NNS p
with IN p
acute JJ p
leukemia NN p
. . p

A DT N
Pediatric NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

One CD p
hundred VBD p
four CD p
children NNS p
with IN p
advanced JJ p
leukemia NN p
in IN p
relapse NN p
( ( p
74 CD p
with IN p
acute JJ p
lymphocytic JJ p
leukemia NN p
[ NNP p
ALL NNP p
] NNP p
and CC p
30 CD p
with IN p
acute JJ p
nonlymphocytic JJ p
leukemia NN p
[ NNP p
ANLL NNP p
] NNP p
) ) p
received VBD N
AMSA NNP i
( ( i
4'- JJ i
( ( i
9-Acridinylamino CD i
) ) i
methanesulfon FW i
-m-anisidide NN i
) ) i
at IN N
a DT N
dose NN N
of IN N
120 CD N
mg/m2/day NN N
for IN N
5 CD N
days NNS N
( ( N
Regimen NNP N
I PRP N
) ) N
or CC N
60 CD N
mg/m2/day NN N
for IN N
10 CD N
days NNS N
( ( N
Regimen NNP N
II NNP N
) ) N
. . N

Children NNP p
with IN p
ALL NNP p
were VBD N
randomized VBN N
between IN N
Regimens NNP N
I PRP N
and CC N
II NNP N
( ( N
31 CD N
and CC N
36 CD N
evaluable JJ N
patients NNS N
, , N
respectively RB N
) ) N
. . N

All DT N
29 CD p
evaluable JJ p
patients NNS p
with IN p
ANLL NNP p
were VBD N
treated VBN N
on IN N
Regimen NNP N
I. NNP N
Eighty-eight NNP N
percent NN N
of IN N
evaluable JJ N
patients NNS N
experienced VBD N
severe JJ o
or CC o
life-threatening JJ o
toxicity NN o
, , N
with IN N
no DT N
statistical JJ N
differences NNS N
between IN N
Regimens NNP N
I PRP N
and CC N
II NNP N
. . N

Bacterial NNP o
or CC o
fungal JJ o
infections NNS o
( ( N
considered VBN N
life-threatening NN N
or CC N
fatal NN N
) ) N
occurred VBD N
in IN N
17 CD p
children NNS p
with IN p
ALL DT p
and CC p
in IN p
7 CD p
with IN p
ANLL NNP p
. . p

Fatal NNP o
cardiac JJ o
toxicity NN o
occurred VBD p
in IN p
one CD p
patient NN p
. . p

Complete NNP o
or CC o
partial JJ o
response NN o
occurred VBD N
in IN N
25.0 CD N
% NN N
( ( N
SE NNP N
= RB N
8.8 CD N
% NN N
) ) N
, , N
28.1 CD N
% NN N
( ( N
SE NNP N
= RB N
8.0 CD N
% NN N
) ) N
, , N
and CC N
25.9 CD N
% NN N
( ( N
SE NNP N
= RB N
8.4 CD N
% NN N
) ) N
of IN N
evaluable JJ N
patients NNS N
on IN N
ALL NNP N
Regimen NNP N
I PRP N
, , N
ALL DT N
Regimen NNP N
II NNP N
, , N
and CC N
ANLL NNP N
, , N
respectively RB N
. . N

However RB N
, , N
responses NNS o
were VBD N
of IN N
short JJ N
duration NN N
( ( N
16-91 JJ N
days NNS N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
duration NN o
of IN o
survival NN o
from IN N
treatment NN N
start NN N
for IN N
the DT N
two CD N
ALL DT N
regimens NNS N
( ( N
P NNP N
= NNP N
0.46 CD N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
survival NN o
for IN N
ANLL NNP N
patients NNS N
was VBD N
significantly RB N
longer JJR N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
than IN N
that DT N
of IN N
ALL NNP N
patients NNS N
treated VBD N
on IN N
Regimens NNP N
I PRP N
and CC N
II NNP N
combined VBD N
. . N

Eighty-two JJ N
percent NN N
of IN N
the DT N
complete JJ o
or CC o
partial JJ o
responses NNS o
( ( N
18 CD N
of IN N
22 CD N
) ) N
occurred VBD N
after IN N
the DT N
first JJ N
course NN N
of IN N
AMSA NNP i
. . i

At IN N
the DT N
dose JJ N
schedules NNS N
investigated VBN N
, , N
and CC N
in IN N
a DT N
heavily RB p
pretreated VBN p
patient JJ p
population NN p
, , N
AMSA NNP N
had VBD N
activity NN o
in IN o
childhood NN o
leukemia NN o
. . o

However RB N
, , N
the DT N
high JJ N
incidence NN o
of IN o
severe JJ o
, , o
life-threatening JJ o
, , o
or CC o
fatal JJ o
infections NNS o
meant VBP N
that IN N
the DT N
quality NN o
and CC o
quantity NN o
of IN o
responses NNS o
and CC o
survival NN o
was VBD N
not RB N
commensurate JJ N
with IN N
the DT N
toxicity NN o
, , N
and CC N
that IN N
it PRP N
would MD N
be VB N
difficult JJ N
to TO N
incorporate VB N
this DT N
drug NN N
into IN N
combination NN N
chemotherapy NN N
with IN N
other JJ N
myelosuppressive JJ N
agents NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
an DT N
inference NN i
generation NN i
strategy NN i
intervention NN i
for IN N
adults NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorder NN p
. . p

PURPOSE VB N
The DT N
present JJ N
intervention NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
the DT N
ACT NNP i
& CC i
Check NNP i
Strategy NNP i
intervention NN i
to TO N
improve VB N
inference NN o
generation NN o
when WRB o
reading NN o
, , o
metacognitive JJ o
ability NN o
, , o
general JJ o
reading NN o
comprehension NN o
, , o
and CC o
social JJ o
inference NN o
ability NN o
in IN N
adults NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorder NN p
( ( p
HF-ASD NNP p
) ) p
. . p

METHOD NNP N
Twenty-five JJ p
adults NNS p
with IN p
HF-ASD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
treatment NN N
or CC N
a DT N
control NN i
group NN i
. . i

Treatment JJ N
sessions NNS N
were VBD N
conducted VBN N
in IN N
1-hr JJ N
sessions NNS N
, , N
twice RB N
a DT N
week NN N
, , N
for IN N
a DT N
total NN N
of IN N
6 CD N
weeks NNS N
. . N

Treatment NNP N
focused VBD N
on IN N
explicit JJ i
instruction NN i
of IN i
components NNS i
of IN i
inference NN i
generation NN i
, , i
categories NNS i
of IN i
inferences NNS i
, , i
and CC i
increasingly RB i
independent JJ i
strategy NN i
use NN i
. . i

RESULTS VB N
The DT N
treatment NN N
group NN N
demonstrated VBD N
significantly RB N
superior JJ o
performance NN o
on IN o
1 CD o
of IN o
2 CD o
measures NNS o
of IN o
inference NN o
generation NN o
in IN o
reading NN o
and CC o
1 CD o
measure NN o
of IN o
metacognitive JJ o
ability NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Significant JJ N
differences NNS N
between IN N
groups NNS N
were VBD N
not RB N
found VBN N
on IN N
measures NNS o
of IN o
reading VBG o
comprehension NN o
or CC o
social JJ o
inference NN o
ability NN o
. . o

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
ACT NNP i
& CC i
Check NNP i
Strategy NNP i
was VBD N
effective JJ N
in IN N
improving VBG N
participants NNS o
' POS o
ability NN o
to TO o
generate VB o
inferences NNS o
in IN o
reading NN o
and CC o
certain JJ o
metacognitive JJ o
abilities NNS o
, , N
but CC N
the DT N
skills NNS N
do VBP N
not RB N
appear VB N
to TO N
generalize VB N
to TO N
other JJ N
social JJ N
communication NN N
contexts NNS N
, , N
such JJ N
as IN N
social JJ o
inference NN o
generation NN o
. . o

This DT N
research NN N
provides VBZ N
a DT N
measure NN N
of IN N
support NN N
for IN N
explicitly RB N
teaching VBG N
inference NN N
generation NN N
to TO N
address VB N
a DT N
reading NN o
inference NN o
deficit NN o
in IN N
adults NNS p
with IN p
HF-ASD NNP p
. . p

-DOCSTART- -X- O O

Perceptual JJ o
wind-up NN o
in IN N
the DT N
human JJ p
oesophagus NN p
is VBZ N
enhanced VBN N
by IN N
central JJ N
sensitisation NN N
. . N

BACKGROUND NNP N
Oesophageal NNP N
acid JJ N
infusion NN N
induces NNS N
enhanced VBD N
pain NN N
hypersensitivity NN N
in IN N
non-acid JJ N
exposed JJ N
upper JJ N
oesophagus NN N
( ( N
secondary JJ N
hyperalgesia NN N
) ) N
in IN N
patients NNS N
with IN N
non-cardiac JJ N
chest NN N
pain NN N
, , N
thus RB N
suggesting VBG N
central JJ N
sensitisation NN N
contributes NNS N
to TO N
visceral JJ N
pain NN N
hypersensitivity NN N
in IN N
functional JJ N
gut NN N
disorders NNS N
( ( N
FGD NNP N
) ) N
. . N

Perceptual JJ N
wind-up JJ N
( ( N
increased JJ N
pain NN N
perception NN N
to TO N
constant JJ N
intensity NN N
sensory NN N
stimuli NN N
at IN N
frequencies NNS N
> VBP N
or=0.3 JJ N
Hz NNP N
) ) N
is VBZ N
used VBN N
as IN N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
to TO N
investigate VB N
pain NN N
syndromes NNS N
where WRB N
pain NN N
hypersensitivity NN N
is VBZ N
important JJ N
( ( N
for IN N
example NN N
, , N
fibromyalgia NN N
) ) N
. . N

AIMS $ N
Wind-up JJ N
in IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

We PRP N
hypothesised VBD N
that IN N
if IN N
wind-up NN N
is VBZ N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
, , N
then RB N
oesophageal JJ N
wind-up NN N
should MD N
be VB N
enhanced VBN N
by IN N
secondary JJ N
hyperalgesia NN N
. . N

METHODS NNP N
In IN N
eight CD p
healthy JJ p
volunteers NNS p
( ( p
seven CD p
males NNS p
; : p
mean JJ p
age NN p
32 CD p
years NNS p
) ) p
, , N
perception NN N
at IN N
pain NN N
threshold NN N
to TO N
a DT N
train NN N
of IN N
20 CD N
electrical JJ i
stimuli NNS i
applied VBN N
to TO N
the DT N
hand NN N
and CC N
upper JJ N
oesophagus NN N
( ( N
UO NNP N
) ) N
at IN N
either DT N
0.1 CD i
Hz NNP i
( ( N
control NN N
) ) N
or CC N
2 CD i
Hz NNP i
was VBD N
determined VBN N
before IN N
and CC N
one CD N
hour NN N
after IN N
a DT N
30 CD N
minute NN N
lower JJR N
oesophageal NN N
acid JJ N
infusion NN N
. . N

RESULTS NNP N
Wind-up JJ o
occurred VBD N
only RB N
with IN N
the DT N
2 CD i
Hz NNP i
train NN N
in IN N
the DT N
UO NNP N
and CC N
hand NN N
( ( N
both DT N
p=0.01 NN N
) ) N
. . N

Following VBG N
acid JJ N
infusion NN N
, , N
pain VBP o
threshold JJ o
decreased VBN o
( ( N
17 CD N
( ( N
4 CD N
) ) N
% NN N
; : N
p=0.01 NN N
) ) N
in IN N
the DT N
UO NNP N
, , N
suggesting VBG N
the DT N
presence NN N
of IN N
secondary JJ N
hyperalgesia NN N
. . N

Wind-up UH o
to TO o
the DT o
2 CD o
Hz NNP o
train NN o
increased VBD N
in IN N
the DT N
UO NNP o
( ( N
wind-up JJ N
ratio NN N
1.4 CD N
( ( N
0.1 CD N
) ) N
to TO N
1.6 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.03 NN N
) ) N
but CC N
not RB N
in IN N
the DT N
hand NN N
( ( N
wind-up JJ N
ratio NN N
1.3 CD N
( ( N
0.1 CD N
) ) N
and CC N
1.3 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.3 NN N
) ) N
CONCLUSION NNP N
Enhanced NNP N
wind-up NN N
after IN N
secondary JJ N
oesophageal NN N
hyperalgesia NN N
suggests VBZ N
that IN N
visceral JJ N
pain NN N
hypersensitivity NN N
induced VBN N
by IN N
central JJ N
sensitisation NN N
results NNS N
from IN N
increased JJ N
central JJ N
neuronal JJ N
excitability NN N
. . N

Wind-up JJ N
may MD N
offer VB N
new JJ N
opportunities NNS N
to TO N
investigate VB N
the DT N
contribution NN N
of IN N
central JJ N
neuronal JJ N
changes NNS N
to TO N
symptoms NNS N
in IN N
FGD NNP N
. . N

-DOCSTART- -X- O O

Vaginal NNP o
pH NN o
and CC o
microflora NN o
related VBN N
to TO N
yeast VB p
infections NNS p
and CC p
treatment NN p
. . p

The DT N
relationship NN N
between IN N
vaginal JJ o
pH NN o
, , o
microflora NN o
, , N
and CC N
yeast JJS p
infection NN p
was VBD p
investigated VBN p
in IN p
93 CD p
women NNS p
randomly RB p
treated VBN p
with IN p
either DT p
nystatin NN i
or CC i
miconazole JJ i
pessaries NNS i
and CC i
cream NN i
for IN p
two CD p
weeks NNS p
. . p

The DT N
vaginal JJ o
pH NN o
was VBD N
measured VBN N
in IN N
a DT N
control NN p
group NN p
of IN p
48 CD p
women NNS p
. . p

In IN N
the DT N
study NN N
group NN N
, , N
37 CD N
patients NNS N
defaulted VBD N
, , N
39 CD N
were VBD N
cured VBN N
, , N
and CC N
17 CD N
required JJ N
treatment NN N
during IN N
the DT N
six-month JJ N
follow-up JJ N
period NN N
. . N

In IN N
both DT N
study NN N
and CC N
control NN N
groups NNS N
before IN N
and CC N
after IN N
treatment NN N
the DT N
mean JJ o
vaginal JJ o
pH NN o
was VBD N
in IN N
the DT N
range NN N
of IN N
4.3-4.6 JJ N
. . N

Lactobacilli NNP o
were VBD N
plentiful JJ N
in IN N
78 CD N
( ( N
91 CD N
% NN N
) ) N
out IN N
of IN N
86 CD N
patients NNS N
and CC N
shows VBZ N
that IN N
lactobacilli NN N
and CC N
yeasts NNS N
commonly RB N
coexist VBP N
. . N

The DT N
influence NN N
of IN N
other JJ N
organisms NNS N
appeared VBD N
to TO N
be VB N
negligible JJ N
. . N

The DT N
trial NN N
showed VBD N
that IN N
nystatin NN N
and CC N
micromazole NN N
were VBD N
equallly RB N
effective JJ o
in IN N
the DT N
treatment NN N
of IN N
vaginal JJ p
yeast NN p
infection NN p
and CC N
that IN N
the DT N
broad-spectrum JJ N
activity NN N
of IN N
micronazole NN i
offered VBN N
no DT N
advantage NN N
in IN N
this DT N
condition NN N
. . N

-DOCSTART- -X- O O

Assessment NN N
of IN N
bone NN i
marrow-derived JJ i
Cellular NNP i
Therapy NNP i
in IN N
progressive JJ p
Multiple JJ p
Sclerosis NNP p
( ( N
ACTiMuS NNP N
) ) N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
We PRP N
have VBP N
recently RB N
completed VBN N
an DT N
evaluation NN N
of IN N
the DT N
safety NN o
and CC N
feasibility NN o
of IN N
intravenous JJ N
delivery NN i
of IN i
autologous JJ i
bone NN i
marrow NN i
in IN N
patients NNS p
with IN p
progressive JJ p
multiple JJ p
sclerosis NN p
( ( p
MS NNP p
) ) p
. . p

The DT N
possibility NN N
of IN N
repair NN N
was VBD N
suggested VBN N
by IN N
improvement NN N
in IN N
the DT N
neurophysiological JJ N
secondary JJ N
outcome NN N
measure NN N
seen VBN N
in IN N
all DT N
participants NNS N
. . N

The DT N
current JJ N
study NN N
will MD N
examine VB N
the DT N
efficacy NN o
of IN N
intravenous JJ i
delivery NN i
of IN i
autologous JJ i
marrow NN i
in IN N
progressive JJ N
MS NNP N
. . N

Laboratory NNP N
studies NNS N
performed VBN N
in IN N
parallel NN N
with IN N
the DT N
clinical JJ N
trial NN N
will MD N
further RBR N
investigate VB N
the DT N
biology NN N
of IN N
bone NN i
marrow-derived JJ i
stem NN i
cell NN i
infusion NN i
in IN N
MS NNP N
, , N
including VBG N
mechanisms NNS N
underlying VBG N
repair NN N
. . N

METHODS/DESIGN CC N
A DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
stepped VBD N
wedge NN N
design NN N
will MD N
be VB N
employed VBN N
at IN N
a DT p
single JJ p
centre NN p
( ( p
Bristol NNP p
, , p
UK NNP p
) ) p
. . p

Eighty JJ p
patients NNS p
with IN p
progressive JJ p
MS NNP p
will MD p
be VB p
recruited VBN p
; : p
60 CD p
will MD p
have VB p
secondary JJ p
progressive JJ p
disease NN p
( ( p
SPMS NNP p
) ) p
but CC p
a DT p
subset NN p
( ( p
n JJ p
= NNP p
20 CD p
) ) p
will MD p
have VB p
primary JJ p
progressive JJ p
disease NN p
( ( p
PPMS NNP p
) ) p
. . p

Participants NNS N
will MD N
be VB N
randomised VBN N
to TO N
either DT N
early JJ N
or CC N
late JJ N
( ( N
1 CD N
year NN N
) ) N
intravenous JJ i
infusion NN i
of IN i
autologous JJ i
, , i
unfractionated JJ i
bone NN i
marrow NN i
. . i

The DT N
placebo NN i
intervention NN i
is VBZ N
infusion NN i
of IN i
autologous JJ i
blood NN i
. . i

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
global JJ o
evoked JJ o
potential JJ o
derived VBN o
from IN o
multimodal NN o
evoked VBN o
potentials NNS o
. . o

Secondary JJ N
outcome NN N
measures NNS N
include VBP N
adverse JJ o
event NN o
reporting NN o
, , o
clinical JJ o
( ( o
EDSS NNP o
and CC o
MSFC NNP o
) ) o
and CC o
self-assessment JJ o
( ( o
MSIS-29 NNP o
) ) o
rating NN o
scales NNS o
, , o
optical JJ o
coherence NN o
tomography NN o
( ( o
OCT NNP o
) ) o
as RB o
well RB o
as IN o
brain NN o
and CC o
spine JJ o
MRI NNP o
. . o

Participants NNS N
will MD N
be VB N
followed VBN N
up RP N
for IN N
a DT N
further JJ N
year NN N
following VBG N
the DT N
final JJ N
intervention NN N
. . N

Outcomes CC N
will MD N
be VB N
analysed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

DISCUSSION NNP N
Assessment NNP N
of IN N
bone NN i
marrow-derived JJ i
Cellular NNP i
Therapy NNP i
in IN N
progressive JJ N
Multiple JJ N
Sclerosis NNP N
( ( N
ACTiMuS NNP N
) ) N
is VBZ N
the DT N
first JJ N
randomised VBN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
non-myeloablative JJ i
autologous JJ i
bone NN i
marrow-derived JJ i
stem NN i
cell NN i
therapy NN i
in IN N
MS NNP N
. . N

It PRP N
will MD N
determine VB N
whether IN N
bone NN i
marrow NN i
cell NN i
therapy NN i
can MD N
, , N
as IN N
was VBD N
suggested VBN N
by IN N
the DT N
phase NN N
I PRP N
safety NN N
study NN N
, , N
improve VB N
conduction NN N
in IN N
multiple JJ N
central JJ N
nervous JJ N
system NN N
pathways NNS N
affected VBN N
in IN N
progressive JJ p
MS NNP p
. . p

Furthermore NNP N
, , N
laboratory NN N
studies NNS N
performed VBN N
in IN N
parallel NN N
with IN N
the DT N
clinical JJ N
trial NN N
will MD N
inform VB N
our PRP$ N
understanding NN N
of IN N
the DT N
cellular JJ N
pharmacodynamics NNS N
of IN N
bone NN N
marrow NN N
infusion NN N
in IN N
MS NNP p
patients NNS p
and CC N
the DT N
mechanisms NNS N
underlying VBG N
cell NN i
therapy NN i
. . i

TRIAL NNP N
REGISTRATION NNP N
ISRCTN27232902 NNP N
Registration NNP N
date NN N
11/09/2012 CD N
. . N

NCT01815632 NNP N
Registration NNP N
date NN N
19/03/2013 CD N
. . N

-DOCSTART- -X- O O

Humoral NNP o
immune JJ o
response NN o
to TO N
tetanus-diphtheria JJ i
vaccine NN i
given VBN N
during IN N
extended VBN N
use NN N
of IN N
chloroquine NN i
or CC i
primaquine NN i
malaria NNS i
chemoprophylaxis NN i
. . i

Immune NNP o
suppression NN o
resulting VBG N
from IN N
prolonged VBN N
chemoprophylaxis NN N
and CC N
potential JJ N
drug-vaccine JJ N
interaction NN N
were VBD N
investigated VBN N
within IN N
the DT N
context NN N
of IN N
a DT N
randomized JJ N
placebo-controlled JJ i
trial NN N
that WDT N
compared VBN N
daily RB N
primaquine NN i
or CC N
weekly JJ N
chloroquine NN i
administration NN N
for IN N
malaria JJ N
prevention NN N
. . N

After IN N
11 CD N
months NNS N
of IN N
prophylaxis NN N
, , N
adult VB p
male JJ p
subjects NNS p
received VBD N
a DT N
tetanus-diphtheria NN i
( ( i
Td NNP i
) ) i
vaccination NN i
. . i

Prophylaxis NNP N
continued VBD N
4 CD N
weeks NNS N
longer RBR N
. . N

Anti-tetanus JJ o
and CC o
anti-diphtheria JJ o
antibody NN o
levels NNS o
were VBD o
measured VBN o
by IN o
ELISA NNP o
at IN N
baseline NN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
months NNS N
after IN N
Td NNP N
vaccination NN N
. . N

All DT N
groups NNS N
were VBD N
comparable JJ N
at IN N
baseline NN N
. . N

Immunization NN N
triggered VBD N
significant JJ N
increases NNS N
in IN N
anti-tetanus JJ o
and CC o
anti-diphtheria JJ o
IgG NNP o
levels NNS o
over IN N
each DT N
group NN N
's POS N
pre-Td JJ N
baseline NN N
levels NNS N
and CC N
those DT N
of IN N
an DT N
unvaccinated JJ N
control NN N
group NN N
. . N

Geometric JJ o
mean JJ o
anti-tetanus JJ o
titers NNS o
( ( o
GMTs NNP o
) ) o
in IN N
the DT N
primaquine NN N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
placebo NN i
group NN N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
14 CD N
months NNS N
. . N

Anti-tetanus NNP o
GMTs NNP o
in IN N
placebo NN i
and CC N
chloroquine NN i
groups NNS N
declined VBD N
over IN N
14 CD N
months NNS N
to TO N
levels NNS N
comparable JJ N
to TO N
those DT N
of IN N
unvaccinated JJ N
controls NNS N
, , N
but CC N
levels NNS N
in IN N
the DT N
primaquine NN N
group NN N
remained VBD N
significantly RB N
higher JJR N
than IN N
in IN N
controls NNS N
. . N

-DOCSTART- -X- O O

A DT N
six-month JJ N
crossover NN N
chemoprevention NN N
clinical JJ N
trial NN N
of IN N
tea NN i
in IN N
smokers NNS o
and CC o
non-smokers NNS o
: : o
methodological JJ N
issues NNS N
in IN N
a DT N
feasibility NN N
study NN N
. . N

BACKGROUND NNP N
Chemoprevention NNP N
crossover NN N
trials NNS N
of IN N
tea NN N
can MD N
be VB N
more RBR N
efficient JJ N
than IN N
parallel JJ N
designs NNS N
but CC N
the DT N
attrition NN N
and CC N
compliance NN N
rates NNS N
with IN N
such JJ N
trials NNS N
are VBP N
unknown JJ N
. . N

METHODS NNP N
Attrition NNP N
( ( N
dropouts NNS N
) ) N
and CC N
compliance NN N
with IN N
treatment NN N
were VBD N
assessed VBN N
in IN N
a DT N
25-week JJ N
randomized NN N
, , N
placebo NN N
controlled VBD N
, , N
crossover NN N
, , N
feasibility NN N
clinical JJ N
trial NN N
of IN N
four CD i
tea NN i
treatments NNS i
to TO i
investigate VB i
the DT i
effect NN i
of IN i
tea NN i
on IN i
oral JJ i
cancer NN i
biomarkers NNS i
. . i

Each DT N
treatment NN N
lasted VBD N
4 CD N
weeks NNS N
with IN N
2 CD N
weeks NNS N
of IN N
washout NN N
in IN N
between IN N
. . N

Participants NNS N
were VBD N
32 CD p
smokers NNS p
and CC p
33 CD p
non-smokers NNS p
without IN p
any DT p
evidence NN p
of IN p
premalignant JJ p
oral JJ p
lesions NNS p
. . p

The DT p
interventions NNS N
consisted VBD N
of IN N
packets NNS i
of IN i
green JJ i
tea NN i
, , i
black JJ i
tea NN i
, , i
caffeinated JJ i
water NN i
, , i
or CC i
placebo NN i
. . i

Participants NNS i
were VBD N
assigned VBN N
to TO N
each DT N
treatment NN N
for IN N
four CD N
weeks NNS N
, , N
and CC N
were VBD N
instructed VBN N
to TO N
drink VB N
five CD N
packets NNS N
per IN N
day NN N
while IN N
on IN N
the DT N
treatment NN o
. . o

Dropout IN o
from IN o
the DT o
trial NN o
and CC o
compliance NN o
( ( o
consumption NN o
of IN N
?85 NNP N
% NN N
of IN N
the DT N
prescribed JJ N
treatment NN N
packets NNS N
) ) N
are VBP N
the DT N
main JJ N
outcome NN N
measures NNS N
reported VBN N
. . N

RESULTS NNP N
There EX N
was VBD o
a DT o
high JJ o
rate NN o
of IN o
dropout NN o
( ( N
51 CD N
% NN N
) ) N
from IN N
the DT N
study NN N
, , N
and CC N
the DT N
rates NNS N
were VBD N
significantly RB N
higher JJR N
among IN N
smokers NNS N
( ( N
64 CD N
% NN N
) ) N
than IN N
non-smokers NNS N
( ( N
36 CD N
% NN N
) ) N
. . N

Among IN N
participants NNS N
who WP N
completed VBD N
the DT N
study NN N
the DT N
rate NN N
of IN N
compliance NN N
was VBD N
72 CD N
% NN N
. . N

The DT N
highest JJS N
rates NNS o
of IN o
dropouts NNS o
occurred VBD o
between IN N
the DT N
first JJ N
and CC N
second JJ N
treatment NN N
visits NNS N
in IN N
both DT N
smokers NNS N
( ( N
38 CD N
% NN N
dropout NN N
) ) N
and CC N
non-smokers NNS N
( ( N
18 CD N
% NN N
dropout NN N
) ) N
. . N

Throughout IN N
the DT N
study NN o
smokers NNS o
were VBD N
more RBR N
likely JJ N
to TO o
dropout VB o
than IN N
non-smokers NNS N
. . N

Black NNP N
tea NN N
treatment NN N
was VBD N
associated VBN N
with IN N
the DT N
highest JJS o
rates NNS o
of IN o
dropout NN o
among IN N
smokers NNS N
( ( N
37 CD N
% NN N
) ) N
, , N
but CC N
was VBD N
associated VBN N
with IN N
the DT N
lowest JJS o
rate NN o
of IN o
dropout NN o
among IN N
non-smokers NNS N
( ( N
4 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
a DT N
study NN N
conducted VBN N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
a DT N
four-treatment JJ N
crossover NN N
tea NN N
trial NN N
, , N
a DT N
high JJ N
rate NN N
of IN N
dropout NN N
among IN N
smokers NNS N
and CC N
non-smokers NNS N
was VBD N
observed VBN N
. . N

Multi-arm JJ N
crossover NN N
tea NN N
trials NNS N
might MD N
pose VB N
a DT N
higher JJR N
burden NN N
on IN N
participants NNS N
and CC N
research NN N
is VBZ N
needed VBN N
to TO N
improve VB N
adherence NN N
and CC N
treatment NN N
compliance NN N
in IN N
such JJ N
trials NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN70410203 NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
lowering VBG N
LDL NNP N
cholesterol NN N
on IN N
vascular JJ N
access NN N
patency NN N
: : N
post NN N
hoc NN N
analysis NN N
of IN N
the DT N
Study NNP N
of IN N
Heart NNP N
and CC N
Renal NNP N
Protection NNP N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Reducing NNP N
LDL NNP N
cholesterol NN N
( ( N
LDL-C NNP N
) ) N
with IN N
statin-based JJ i
therapy NN i
reduces VBZ N
the DT N
risk NN N
of IN N
major JJ N
atherosclerotic JJ N
events NNS N
among IN N
patients NNS p
with IN p
CKD NNP p
, , p
including VBG p
dialysis NN p
patients NNS p
, , N
but CC N
the DT N
effect NN N
of IN N
lowering VBG N
LDL-C NNP N
on IN N
vascular JJ N
access NN N
patency NN N
is VBZ N
unclear JJ N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
The DT N
Study NNP N
of IN N
Heart NNP N
and CC N
Renal NNP N
Protection NNP N
( ( N
SHARP NNP N
) ) N
randomized VBD N
patients NNS p
with IN p
CKD NNP p
to TO p
20 CD i
mg NN i
simvastatin NN i
plus CC i
10 CD i
mg NNS i
ezetimibe JJ i
daily JJ i
versus NN i
matching VBG i
placebo NN i
. . i

This DT N
study NN N
aimed VBD N
to TO N
explore VB N
the DT N
effects NNS N
of IN N
treatment NN N
on IN N
vascular JJ N
access NN N
occlusive JJ N
events NNS N
, , N
defined VBN N
as IN N
any DT o
access NN o
revision NN o
procedure NN o
, , o
access NN o
thrombosis NN o
, , o
removal NN o
of IN o
an DT o
old JJ o
dialysis NN o
access NN o
, , o
or CC o
formation NN o
of IN o
new JJ o
permanent JJ o
dialysis NN o
access NN o
. . o

RESULTS NNP N
Among IN N
2353 CD p
SHARP NNP p
participants NNS p
who WP p
had VBD p
functioning VBG p
vascular JJ p
access NN p
at IN N
randomization NN N
, , N
allocation NN N
to TO N
simvastatin VB N
plus JJ N
ezetimibe NN N
resulted VBD N
in IN N
a DT N
13 CD N
% NN N
proportional JJ N
reduction NN o
in IN o
vascular JJ o
access NN o
occlusive JJ o
events NNS o
( ( N
355 CD N
[ RB N
29.7 CD N
% NN N
] NN N
for IN N
simvastatin/ezetimibe JJ i
versus NN N
388 CD N
[ JJ N
33.5 CD N
% NN N
] NN N
for IN N
placebo NN i
; : i
risk NN N
ratio VBP N
[ NNP N
RR NNP N
] NNP N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ VBD N
95 CD N
% NN N
CI NNP N
] NNP N
, , N
0.75 CD N
to TO N
1.00 CD N
; : N
P=0.05 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
that IN N
the DT N
effects NNS N
of IN N
treatment NN N
differed VBN N
for IN N
any DT N
of IN N
the DT N
separate JJ N
components NNS N
of IN N
this DT N
outcome NN N
. . N

To TO N
test VB N
the DT N
hypothesis NN N
raised VBN N
by IN N
SHARP NNP N
, , N
comparable JJ N
analyses NNS N
were VBD N
performed VBN N
using VBG N
the DT N
AURORA NNP N
( ( N
A NNP N
Study NNP N
to TO N
Evaluate VB N
the DT N
Use NNP N
of IN N
Rosuvastatin NNP N
in IN N
Subjects NNP N
on IN N
Regular JJ N
Hemodialysis NN N
: : N
An DT N
Assessment NN N
of IN N
Survival NNP N
and CC N
Cardiovascular NNP N
Events NNP N
) ) N
trial NN N
cohort NN N
. . N

AURORA NNP N
did VBD N
not RB N
provide VB N
independent JJ N
confirmation NN N
( ( N
vascular JJ N
access NN N
occlusive JJ N
events NNS N
: : N
352 CD N
[ $ N
28.9 CD N
% NN N
] NN N
for IN N
rosuvastatin NN N
versus NN N
337 CD N
[ JJ N
27.6 CD N
% NN N
] NN N
for IN N
placebo NN N
; : N
RR NNP N
, , N
1.06 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
0.91 CD N
to TO N
1.23 CD N
; : N
P=0.44 NNP N
) ) N
. . N

After IN N
combining VBG N
the DT N
two CD N
trials NNS N
, , N
the DT N
overall JJ N
effect NN N
of IN N
reducing VBG N
LDL-C NNP o
with IN N
a DT N
statin-based JJ N
regimen NN N
on IN N
vascular JJ N
access NN N
occlusive JJ N
events NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
707 CD N
[ RB N
29.3 CD N
% NN N
] NN N
with IN N
any DT N
LDL-C-lowering JJ N
therapy NN N
versus NN N
725 CD N
[ JJ N
30.5 CD N
% NN N
] NN N
with IN N
placebo NN N
; : N
RR NNP N
, , N
0.95 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
0.85 CD N
to TO N
1.05 CD N
; : N
P=0.29 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Exploratory NNP N
analyses VBZ N
from IN N
SHARP NNP N
suggest VBP N
that IN N
lowering VBG N
LDL-C JJ N
with IN N
statin-based JJ i
therapy NN i
may MD N
improve VB N
vascular JJ N
access NN N
patency NN N
, , N
but CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
benefit NN N
in IN N
AURORA NNP N
. . N

Taken NNP N
together RB N
, , N
the DT N
available JJ N
evidence NN N
suggests VBZ N
that IN N
any DT N
benefits NNS N
of IN N
lowering VBG N
LDL-C NNP N
on IN N
vascular JJ N
access NN N
patency NN N
are VBP N
likely JJ N
to TO N
be VB N
modest JJ N
. . N

-DOCSTART- -X- O O

Risperidone NN i
in IN N
the DT N
treatment NN N
of IN N
negative JJ o
symptoms NNS o
of IN N
schizophrenia NN p
: : p
a DT N
meta-analysis NN N
. . N

Risperidone NN i
has VBZ N
antiserotonergic VBN N
and CC N
antidopaminergic JJ N
properties NNS N
that WDT N
may MD N
make VB N
it PRP N
more RBR N
effective JJ N
than IN N
conventional JJ N
antipsychotic JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
the DT N
negative JJ o
symptoms NNS o
of IN N
schizophrenia NN p
. . p

Clinical JJ N
trials NNS N
in IN N
chronic JJ p
schizophrenic JJ p
patients NNS p
have VBP N
shown VBN N
trends NNS N
in IN N
favor NN N
of IN N
risperidone NN i
in IN N
the DT N
control NN N
of IN N
negative JJ o
symptoms NNS o
compared VBN N
with IN N
haloperidol NN i
, , i
perphenazine NN i
or CC i
zuclopenthixol NN i
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
consistently RB N
statistically RB N
significant JJ N
. . N

A DT N
meta-analysis NN N
of IN N
the DT N
pooled JJ N
results NNS N
from IN N
six CD p
double-blind JJ p
trials NNS p
showed VBD N
that IN N
risperidone NN i
at IN N
doses NNS N
ranging VBG N
from IN N
4 CD N
to TO N
8 CD N
mg/day NN N
had VBD N
a DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
higher JJR N
negative JJ o
symptom JJ o
response NN o
rate NN o
, , N
defined VBN N
as IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
a DT N
20 CD N
% NN N
or CC N
more JJR o
reduction NN o
in IN o
scores NNS o
on IN o
the DT o
negative JJ o
subscale NN o
of IN o
the DT o
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
, , N
than IN N
patients NNS N
receiving VBG N
active JJ N
controls NNS N
. . N

The DT N
combined JJ p
patient JJ p
population NN p
treated VBN N
with IN N
4-8 JJ N
mg/day NN N
of IN N
risperidone NN i
was VBD N
1.43 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
had VBN N
a DT N
clinical JJ o
response NN o
on IN o
the DT o
negative JJ o
symptom NN o
subscale NN o
than IN N
the DT N
combined JJ N
population NN N
treated VBN N
with IN N
haloperidol NN i
, , i
perphenazine NN i
or CC i
zuclopenthixol NN i
. . i

-DOCSTART- -X- O O

Temozolomide NNP i
and CC i
cisplatin VB i
versus NN i
temozolomide NN i
in IN N
patients NNS p
with IN p
advanced JJ p
melanoma NN p
: : p
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
of IN N
the DT N
Hellenic NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
. . N

PURPOSE NNP N
Temozolomide NNP i
( ( i
TMZ NNP i
) ) i
is VBZ N
an DT N
oral JJ N
alkylating NN N
agent NN N
that WDT N
produces VBZ N
methyl JJ N
adducts NNS N
at IN N
the DT N
0.6 CD N
position NN N
of IN N
guanine NN N
. . N

The DT N
methyl NN N
adducts NNS N
are VBP N
removed VBN N
by IN N
the DT N
DNA NNP N
repair NN N
enzyme JJ N
AGAT NNP N
. . N

As IN N
demonstrated VBN N
by IN N
in IN N
vitro NN N
studies NNS N
, , N
cisplatin NN i
( ( i
CDDP NNP i
) ) i
is VBZ N
able JJ N
to TO N
down-regulate VB N
the DT N
AGAT NNP N
activity NN N
, , N
suggesting VBG N
that IN N
CDDP NNP i
could MD N
enhance VB N
the DT N
antitumor NN o
activity NN o
of IN o
TMZ NNP o
. . o

We PRP N
designed VBD N
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
to TO N
evaluate VB N
and CC N
compare VB N
the DT N
activity NN N
and CC N
safety NN N
profile NN N
of IN N
the DT N
combination NN i
versus IN i
single-agent JJ i
TMZ NNP i
in IN N
patients NNS p
with IN p
advanced JJ p
melanoma NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP p
January NNP p
2000 CD p
to TO p
April NNP p
2002 CD p
, , p
132 CD p
patients NNS p
were VBD p
enrolled VBN p
on IN p
the DT p
study NN p
. . p

Patient NNP p
and CC p
tumor NN p
characteristics NNS p
were VBD N
well RB N
balanced VBN N
between IN N
the DT N
two CD N
arms NNS N
. . N

Patients NNS p
with IN p
cerebral JJ p
metastases NNS p
were VBD p
included VBN p
. . p

Patients NNS N
received VBD N
TMZ NNP i
200 CD i
mg/m NN i
( ( i
2 CD i
) ) i
/day NN i
orally RB i
for IN N
five CD N
consecutive JJ N
days NNS N
every DT N
4 CD N
weeks NNS N
or CC N
TMZ NNP i
+ NNP i
CDDP NNP i
200 CD N
mg/m NN N
( ( N
2 CD N
) ) N
daily RB N
on IN N
days NNS N
1-5 CD N
and CC N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
of IN N
CDDP NNP i
on IN N
day NN N
1 CD N
. . N

RESULTS NNP N
Tumor NNP o
responses VBZ o
( ( N
complete JJ N
and CC N
partial JJ N
responses NNS N
) ) N
were VBD N
seen VBN N
in IN N
16 CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
in IN N
arm NN N
A NN N
and CC N
19 CD N
patients NNS N
( ( N
29 CD N
% NN N
) ) N
in IN N
arm NN N
B NNP N
. . N

The DT N
median JJ o
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
was VBD N
3.8 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
5.8 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

The DT N
median JJ o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
was VBD N
11.5 CD N
months NNS N
in IN N
arm NN N
A NN N
and CC N
12 CD N
months NNS N
in IN N
arm NN N
B NNP N
. . N

The DT N
difference NN N
between IN N
treatment NN N
arms NNS N
regarding VBG N
objective JJ o
response NN o
rates NNS o
, , o
TTP NNP o
and CC o
OS NNP o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Toxicity NN N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
arms NNS N
for IN N
anemia NN o
, , o
leukopenia NN o
, , o
neutropenia NN o
, , o
thrombocytopenia NN o
, , o
fatigue NN o
, , o
constipation NN o
and CC o
arthralgias/myalgias NN o
. . o

There EX N
was VBD N
significantly RB N
more JJR N
grade JJ o
3 CD o
and CC o
4 CD o
emesis NN o
in IN N
the DT N
combination NN N
arm NN N
. . N

CONCLUSIONS NNP N
No NNP o
clear JJ o
benefit NN o
in IN N
terms NNS N
of IN N
response NN o
rates NNS o
, , o
median JJ o
TTP NNP o
or CC N
OS NNP N
was VBD N
shown VBN N
with IN N
the DT N
combination NN N
of IN N
TMZ NNP i
+ NNP i
CDDP NNP i
. . i

Additionally RB N
, , N
the DT N
combination NN N
was VBD N
associated VBN N
with IN N
higher JJR N
incidence NN N
of IN N
grade NN o
3 CD o
and CC o
4 CD o
emesis NN o
. . o

-DOCSTART- -X- O O

Delayed VBN p
perceptual JJ p
awareness NN p
in IN N
rapid JJ p
perceptual JJ p
decisions NNS p
. . p

The DT N
flourishing NN N
of IN N
studies NNS N
on IN N
the DT N
neural JJ N
correlates NNS N
of IN N
decision-making JJ N
calls NNS N
for IN N
an DT N
appraisal NN N
of IN N
the DT N
relation NN N
between IN N
perceptual JJ N
decisions NNS N
and CC N
conscious JJ N
perception NN N
. . N

By IN N
exploiting VBG N
the DT N
long JJ i
integration NN i
time NN i
of IN i
noisy JJ i
motion NN i
stimuli NN i
, , i
and CC i
by IN i
forcing VBG i
human JJ i
observers NNS i
to TO i
make VB i
difficult JJ i
speeded VBN i
decisions NNS i
-- : i
sometimes RB i
a DT i
blind JJ i
guess NN i
-- : i
about IN i
stimulus JJ i
direction NN i
, , N
we PRP N
traced VBD N
the DT N
temporal JJ N
buildup NN N
of IN N
motion NN N
discrimination NN N
capability NN N
and CC N
perceptual JJ N
awareness NN N
, , N
as IN N
assessed VBN N
trial NN N
by IN N
trial NN N
through IN N
direct JJ N
rating NN N
. . N

We PRP N
found VBD N
that IN N
both DT N
increased VBN N
gradually RB N
with IN N
motion NN o
coherence NN o
and CC o
viewing NN o
time NN o
, , N
but CC N
discrimination NN o
was VBD o
systematically RB o
leading JJ o
awareness NN o
, , o
reaching VBG o
a DT o
plateau NN o
much RB o
earlier RBR o
. . o

Sensitivity NNP o
and CC o
criterion NN o
changes NNS o
contributed VBD N
jointly RB N
to TO N
the DT N
slow JJ o
buildup NN o
of IN o
perceptual JJ o
awareness NN o
. . o

It PRP N
made VBD N
no DT o
difference NN o
whether IN N
motion NN o
discrimination NN o
was VBD N
accomplished VBN N
by IN N
saccades NNS o
or CC o
verbal JJ o
responses NNS o
. . o

These DT N
findings NNS N
suggest VBP N
that IN N
perceptual JJ o
awareness NN o
emerges VBZ o
on IN o
the DT o
top NN o
of IN o
a DT o
developing NN o
or CC o
even RB o
mature VBP o
perceptual JJ o
decision NN o
. . o

We PRP N
argue VBP N
that IN N
the DT N
middle JJ N
temporal JJ N
( ( N
MT NNP N
) ) N
cortical JJ N
region NN N
does VBZ N
not RB N
confer VB N
us PRP N
the DT N
full JJ o
phenomenic JJ o
depth NN o
of IN o
motion NN o
perception NN o
, , N
although IN N
it PRP N
may MD N
represent VB N
a DT N
precursor NN o
stage NN o
in IN o
building VBG o
our PRP$ o
subjective JJ o
sense NN o
of IN o
visual JJ o
motion NN o
. . o

-DOCSTART- -X- O O

A DT N
randomized JJ N
trial NN N
of IN N
a DT N
brief JJ i
alcohol NN i
intervention NN i
for IN N
needle JJ p
exchangers NNS p
( ( N
BRAINE NNP N
) ) N
. . N

AIMS UH N
To TO N
test VB N
motivational JJ i
interviewing NN i
( ( i
MI NNP i
) ) i
as IN N
a DT N
brief JJ N
intervention NN N
for IN N
reducing VBG N
alcohol NN o
use NN o
among IN N
needle JJ p
exchange NN p
clients NNS p
. . p

DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

SETTING NNP N
Needle NNP N
exchange NN N
program-Providence NN N
, , N
Rhode NNP p
Island NNP p
, , p
USA NNP p
. . p

PARTICIPANTS NNP N
Between NNP p
2/98 CD p
and CC p
10/99 CD p
, , p
we PRP p
recruited VBD p
187 CD p
AUDIT-positive JJ p
( ( p
> JJ p
8 CD p
) ) p
active JJ p
injection NN p
drug NN p
users NNS p
. . p

INTERVENTION NNP N
Those DT N
assigned VBN N
to TO N
a DT N
brief JJ i
motivational JJ i
intervention NN i
( ( i
MI NNP i
) ) i
condition NN N
received VBD N
two CD i
1-hour JJ i
therapist JJ i
sessions NNS i
following VBG i
assessment NN i
visits NNS i
, , N
1 CD N
month NN N
apart RB N
, , N
focusing VBG N
on IN N
alcohol NN N
use NN N
and CC N
HIV NNP N
risk-taking NN N
. . N

MEASUREMENTS NNP N
Control NNP i
and CC N
MI NNP i
subjects NNS N
received VBD N
identical JJ N
research NN N
assessments NNS N
at IN N
baseline NN N
, , N
1 CD N
and CC N
6 CD N
months NNS N
following VBG N
study NN N
enrollment NN N
. . N

At IN N
6 CD N
months NNS N
, , N
study NN N
outcomes NNS N
included VBD N
days NNS o
of IN o
alcohol NN o
use NN o
measured VBD N
using VBG N
the DT N
time-line JJ N
follow-back JJ N
method NN N
. . N

FINDINGS NNP N
Study NNP o
retention NN o
was VBD N
96.8 CD N
% NN N
at IN N
6 CD N
months NNS N
. . N

Participants NNS N
reported VBD N
an DT N
average NN N
of IN N
12.0 CD N
drinking NN o
days NNS o
at IN N
baseline NN N
and CC N
8.3 CD N
at IN N
6 CD N
months NNS N
. . N

Significant JJ N
reductions NNS N
in IN N
drinking NN o
days NNS o
were VBD N
observed VBN N
in IN N
both DT N
treatment NN N
conditions NNS N
. . N

We PRP N
found VBD N
significant JJ N
treatment NN N
x NNP N
baseline NN o
drinking VBG o
day NN o
interaction NN o
effects NNS o
. . o

Tests NNS N
for IN N
simple JJ N
main JJ N
effects NNS N
were VBD N
significant JJ N
for IN N
subjects NNS N
with IN N
above JJ N
median NN o
( ( o
> JJ o
9 CD o
) ) o
baseline NN o
drinking VBG o
day NN o
frequency NN o
, , N
but CC N
not RB N
for IN N
those DT N
with IN N
below JJ N
median JJ N
baseline NN o
drinking NN o
frequency NN o
. . o

Comparisons NNS N
on IN N
dichotomous JJ N
outcomes NNS N
provided VBD N
supporting VBG N
evidence NN N
of IN N
treatment NN o
efficacy NN o
; : o
those DT N
in IN N
MI NNP N
were VBD N
over RB N
two CD N
times NNS N
more RBR N
likely JJ N
than IN N
controls NNS N
to TO N
report VB N
reductions NNS o
of IN o
7 CD o
days NNS o
or CC o
more JJR o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
provides VBZ N
the DT N
first JJ N
direct JJ N
evidence NN N
that IN N
brief JJ i
MI NNP i
can MD N
decrease VB N
alcohol NN o
use NN o
among IN N
active JJ N
injection NN p
drug NN p
users NNS p
with IN p
drinking NN p
problems NNS p
. . p

Heavier JJR N
drinkers NNS N
seem VBP N
best RB N
suited VBN N
for IN N
this DT N
intervention NN N
, , N
but CC N
the DT N
optimal JJ N
intensity NN N
of IN N
treatments NNS N
and CC N
which WDT N
components NNS N
of IN N
brief JJ N
intervention NN N
are VBP N
most RBS N
effective JJ N
deserve NN N
further RB N
study NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
HIV NNP N
infection NN N
on IN N
tolerability NN o
and CC o
bacteriologic JJ o
outcomes NNS o
of IN N
tuberculosis NN N
treatment NN N
. . N

SETTING NN N
Two CD N
international JJ N
, , N
multicenter JJ N
Phase NNP N
2 CD N
clinical JJ N
trials NNS N
examining VBG N
fluoroquinolone-containing JJ i
regimens NNS i
in IN N
adults NNS p
with IN p
smear-positive JJ p
pulmonary JJ p
tuberculosis NN p
( ( p
TB NNP p
) ) p
, , N
conducted VBN N
from IN N
July NNP N
2003 CD N
to TO N
March NNP N
2007 CD N
. . N

Both DT N
trials NNS N
enrolled VBD N
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
infected VBD p
participants NNS p
who WP p
were VBD p
not RB p
receiving VBG p
antiretroviral JJ p
therapy NN p
( ( p
ART NNP p
) ) p
at IN p
TB NNP p
treatment NN p
initiation NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
impact NN N
of IN N
HIV NNP N
infection NN N
on IN N
TB NNP N
treatment NN N
outcomes NNS N
in IN N
Phase NNP N
2 CD N
clinical JJ N
trials NNS N
. . N

DESIGN NNP N
Cross-protocol JJ i
analysis NN i
comparing VBG i
the DT i
safety NN o
, , o
tolerability NN o
and CC o
outcomes NNS o
of IN i
anti-tuberculosis NN i
treatment NN i
by IN i
HIV NNP i
status NN i
. . i

RESULTS NNP N
Of IN p
750 CD p
participants NNS p
who WP p
received VBD p
at IN p
least JJS p
one CD p
dose NN p
of IN p
study NN p
treatment NN p
, , p
123 CD p
( ( p
16 CD p
% NN p
) ) p
were VBD p
HIV-infected JJ p
. . p

Treatment JJ o
completion NN o
rates NNS o
were VBD N
similar JJ N
by IN N
HIV NNP N
status NN N
( ( N
81 CD N
% NN N
infected VBN N
vs. IN N
85 CD N
% NN N
non-infected JJ N
) ) N
, , N
as IN N
were VBD N
rates NNS N
of IN N
week NN N
8 CD N
culture NN N
conversion NN N
( ( N
66 CD N
% NN N
infected VBN N
vs. IN N
63 CD N
% NN N
non-infected JJ N
) ) N
, , N
and CC N
treatment NN N
failure NN N
( ( N
5 CD N
% NN N
infected VBN N
vs. IN N
3 CD N
% NN N
non-infected JJ N
) ) N
. . N

Among IN N
HIV-infected JJ p
participants NNS p
, , N
treatment NN o
failure NN o
detected VBD N
using VBG N
liquid JJ N
media NNS N
was VBD N
more RBR N
frequent JJ N
in IN N
those DT N
treated JJ N
thrice JJ N
weekly JJ N
( ( N
14 CD N
% NN N
thrice JJ N
weekly JJ N
vs. FW N
2 CD N
% NN N
daily RB N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

HIV-infected JJ p
participants NNS p
more RBR N
frequently RB N
experienced VBD N
an DT N
adverse JJ o
event NN o
during IN N
the DT N
intensive JJ N
phase NN N
treatment NN N
than IN N
non-HIV-infected JJ N
participants NNS N
( ( N
30 CD N
% NN N
vs. FW N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
HIV-infected JJ p
persons NNS p
not RB N
receiving VBG N
ART NNP N
had VBD N
more RBR N
adverse JJ N
events NNS N
during IN N
the DT N
intensive JJ N
phase NN N
of IN N
anti-tuberculosis NN N
treatment NN N
, , N
but CC N
tolerated VBD o
treatment NN o
well RB o
. . o

Failure NN N
rates NNS N
were VBD N
higher JJR N
among IN N
HIV-infected JJ p
persons NNS p
treated VBN N
with IN N
thrice-weekly JJ N
intensive JJ N
phase NN N
therapy NN N
. . N

-DOCSTART- -X- O O

The DT N
clinician NN N
's POS N
decision NN N
of IN N
whether IN N
CHOP NNP i
chemotherapy NN i
should MD N
be VB N
standard JJ N
therapy NN N
for IN N
treatment NN o
of IN o
patients NNS o
with IN o
diffuse NN o
histiocytic JJ o
lymphoma NN o
. . o

-DOCSTART- -X- O O

Efficacy NN o
of IN N
a DT N
barrier NN i
cream NN i
and CC i
its PRP$ i
vehicle NN i
as IN N
protective JJ N
measures NNS N
against IN N
occupational JJ o
irritant JJ o
contact NN o
dermatitis NN o
. . o

The DT N
actual JJ N
advantage NN N
of IN N
barrier NN i
creams NNS i
over IN N
bland NN N
emollients NNS N
for IN N
skin NN N
protection NN N
is VBZ N
still RB N
hotly RB N
debated VBN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
study NN N
, , N
a DT N
newly-introduced JJ N
barrier NN i
cream NN i
and CC N
its PRP$ N
moisturizing NN i
vehicle NN i
were VBD N
compared VBN N
regarding VBG N
their PRP$ N
skin NN o
compatibility NN o
, , o
efficacy NN o
and CC o
resulting VBG o
acceptance NN o
. . o

Thus NNP N
, , N
2 CD p
panels NNS p
of IN p
25 CD p
hospital NN p
nurses NNS p
with IN p
mild JJ p
signs NNS p
of IN p
skin JJ p
irritation NN p
were VBD N
asked VBN N
to TO N
use VB N
1 CD N
of IN N
the DT N
test NN N
products NNS N
provided VBN N
( ( i
verum NN i
or CC i
vehicle NN i
) ) i
over IN i
a DT i
period NN i
of IN i
4 CD i
weeks NNS i
. . i

Effects NNS N
of IN N
both DT N
types NNS N
of IN N
preparations NNS N
were VBD N
studied VBN N
weekly JJ N
by IN N
clinical JJ N
examination NN N
and CC N
the DT N
instrumental JJ N
assessment NN N
of IN N
bioengineering VBG N
parameters NNS N
. . N

Results NNS N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
barrier NN i
cream NN i
and CC N
vehicle NN i
. . i

In IN N
both DT N
groups NNS N
, , N
clinical JJ o
skin NN o
status NN o
improved VBN N
and CC N
stratum JJ o
corneum NN o
hydration NN o
increased VBD N
significantly RB N
during IN N
the DT N
study NN N
period NN N
. . N

Both DT N
preparations NNS N
were VBD N
tolerated VBN o
and CC o
accepted VBN o
well RB o
, , N
thus RB N
showing VBG N
both DT N
skin JJ o
protection NN o
and CC o
skin NN o
care NN o
. . o

These DT N
results NNS N
contribute VBP N
to TO N
the DT N
debate NN N
as IN N
to TO N
whether IN N
a DT N
strict JJ N
distinction NN N
between IN N
skin NN N
care NN N
and CC N
skin NN N
protection NN N
products NNS N
is VBZ N
justified JJ N
. . N

The DT N
vehicle NN i
alone RB N
is VBZ N
capable JJ N
of IN N
positively RB N
influencing VBG N
skin NN N
status NN N
. . N

Emphasis NN N
must MD N
be VB N
laid VBN N
on IN N
regular JJ N
, , N
frequent JJ N
, , N
and CC N
correct JJ N
application NN N
of IN N
a DT N
product NN N
for IN N
it PRP N
to TO N
be VB N
effective JJ N
. . N

-DOCSTART- -X- O O

Is VBZ N
the DT N
effect NN N
of IN N
mobile JJ i
phone NN i
radiofrequency NN i
waves NNS i
on IN N
human JJ N
skin JJ N
perfusion NN N
non-thermal JJ N
? . N
OBJECTIVE UH N
To TO N
establish VB N
whether IN N
SkBF NNP o
can MD N
be VB N
modified VBN N
by IN N
exposure NN N
to TO N
the DT N
radiofrequency NN i
waves NNS i
emitted VBN i
by IN i
a DT i
mobile JJ i
phone NN i
when WRB N
the DT N
latter NN N
is VBZ N
held VBN N
against IN N
the DT N
jaw NN N
and CC N
ear NN N
. . N

METHODS NNP N
Variations NNP o
in IN o
SkBF NNP o
and CC N
Tsk NNP N
in IN N
adult NN p
volunteers NNS p
were VBD N
simultaneously RB N
recorded VBN i
with IN i
a DT i
thermostatic JJ i
laser NN i
Doppler NNP i
system NN i
during IN i
a DT i
20-minute JJ i
radiofrequency NN i
exposure NN i
session NN i
and CC i
a DT i
20-minute JJ i
sham NN i
session NN i
. . i

The DT N
skin JJ N
microvessels NNS N
' POS N
vasodilatory NN N
reserve NN N
was VBD N
assessed VBN N
with IN N
a DT N
heat NN N
challenge NN N
at IN N
the DT N
end NN N
of IN N
the DT N
protocol NN N
. . N

RESULTS NNP N
During IN N
the DT N
radiofrequency NN i
exposure NN i
session NN i
, , N
SkBF NNP o
increased VBD N
( ( N
vs. FW N
baseline NN N
) ) N
more JJR N
than IN N
during IN N
the DT N
sham JJ i
exposure NN i
session NN i
. . i

The DT N
sessions NNS N
did VBD N
not RB N
differ VB N
significant JJ N
in IN N
terms NNS N
of IN N
the DT N
Tsk NNP o
time-course JJ o
response NN o
. . o

The DT N
skin JJ o
microvessels NNS o
' POS o
vasodilatory NN o
ability NN o
was VBD N
found VBN N
to TO N
be VB N
greater JJR N
during IN N
radiofrequency NN N
exposure NN N
than IN N
during IN N
sham JJ N
exposure NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
reveal VBP N
the DT N
existence NN N
of IN N
a DT N
specific JJ N
vasodilatory JJ o
effect NN N
of IN N
mobile JJ i
phone NN i
radiofrequency NN i
emission NN i
on IN N
skin JJ N
perfusion NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
controlled JJ N
release NN N
melatonin NN i
treatment NN i
of IN N
delayed JJ p
sleep JJ p
phase NN p
syndrome NN p
and CC N
impaired JJ p
sleep JJ p
maintenance NN p
in IN N
children NNS p
with IN p
neurodevelopmental JJ p
disabilities NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
efficacy NN o
of IN N
controlled-release NN N
( ( N
CR NNP N
) ) N
melatonin NN i
in IN N
the DT N
treatment NN N
of IN N
delayed JJ p
sleep JJ p
phase NN p
syndrome NN p
and CC N
impaired JJ p
sleep JJ p
maintenance NN p
of IN N
children NNS p
with IN p
neurodevelopmental JJ p
disabilities NNS p
including VBG p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
crossover NN N
trial NN N
of IN N
CR NNP i
melatonin NN i
( ( N
5 CD N
mg NN N
) ) N
followed VBN N
by IN N
a DT N
3-month JJ N
open-label NN N
study NN N
was VBD N
conducted VBN N
during IN N
which WDT N
the DT N
dose NN N
was VBD N
gradually RB N
increased VBN N
until IN N
the DT N
therapy NN N
showed VBD N
optimal JJ N
beneficial JJ N
effects NNS N
. . N

Sleep JJ o
characteristics NNS o
were VBD N
measured VBN N
by IN N
caregiver NN N
who WP N
completed VBD N
somnologs NNS N
and CC N
wrist JJ N
actigraphs NN N
. . N

Clinician JJ o
rating NN o
of IN N
severity NN N
of IN N
the DT N
sleep JJ N
disorder NN N
and CC N
improvement NN N
from IN N
baseline NN N
, , N
along IN N
with IN N
caregiver JJ o
ratings NNS o
of IN N
global JJ N
functioning NN N
and CC N
family NN N
stress NN N
were VBD N
also RB N
obtained VBN N
. . N

Fifty-one CD p
children NNS p
( ( p
age NN p
range NN p
2-18 CD p
years NNS p
) ) p
who WP p
did VBD p
not RB p
respond VB p
to TO p
sleep VB p
hygiene NN p
intervention NN p
were VBD N
enrolled VBN N
. . N

Fifty JJ N
patients NNS N
completed VBD N
the DT N
crossover NN N
trial NN N
and CC N
47 CD N
completed VBD N
the DT N
open-label JJ N
phase NN N
. . N

Recordings NNS N
of IN N
total JJ o
night-time JJ o
sleep NN o
and CC N
sleep JJ o
latency NN o
showed VBD N
significant JJ N
improvement NN N
of IN N
approximately RB N
30 CD N
min NNS N
. . N

Similarly RB N
, , N
significant JJ o
improvement NN o
was VBD N
observed VBN N
in IN N
clinician JJ o
and CC o
parent JJ o
ratings NNS o
. . o

There EX N
was VBD N
additional JJ N
improvement NN o
in IN N
the DT N
open-label JJ o
somnolog NN o
measures NNS o
of IN N
sleep JJ o
efficiency NN o
and CC N
the DT o
longest JJS o
sleep JJ o
episode NN o
in IN N
the DT N
open-label JJ N
phase NN N
. . N

Overall UH N
, , N
the DT N
therapy NN N
improved VBD o
the DT o
sleep NN o
of IN N
47 CD N
children NNS N
and CC N
was VBD N
effective JJ o
in IN o
reducing VBG o
family NN o
stress NN o
. . o

Children NNP p
with IN p
neurodevelopmental JJ p
disabilities NNS p
, , N
who WP N
had VBD p
treatment NN o
resistant JJ o
chronic JJ o
delayed VBN o
sleep JJ o
phase NN o
syndrome NN o
and CC p
impaired JJ o
sleep JJ o
maintenance NN o
, , N
showed VBD N
improvement NN N
in IN N
melatonin NN i
therapy NN i
. . i

-DOCSTART- -X- O O

[ JJ N
Comparison NNP N
between IN N
anterior JJ i
rhinomanometry NN i
and CC N
impulse-oscillometric JJ i
rhinometry NN i
found VBD N
within IN N
nasal JJ o
allergen JJ o
provocation NN o
] NNP o
. . N

UNLABELLED NNP N
Besides IN N
the DT N
standard JJ N
method NN N
of IN N
anterior JJ i
rhinomanometry NN i
( ( i
aR NN i
) ) i
, , i
the DT i
impulse-oscillometric JJ i
rhinometry NN i
( ( i
IOS NNP i
) ) i
is VBZ N
available JJ N
for IN N
measurements NNS N
of IN N
the DT N
nasal JJ o
resistance NN o
. . o

The DT N
aR NN N
is VBZ N
a DT N
procedure NN N
dependent NN N
on IN N
the DT N
cooperation NN N
of IN N
the DT N
patient NN N
, , N
whereas JJ N
IOS NNP N
is VBZ N
measured VBN N
regardless RB N
from IN N
the DT N
breathing NN N
activities NNS N
of IN N
the DT N
patient NN N
. . N

We PRP N
examined VBD N
weather RP N
the DT N
resistance-measurement NN N
by IN N
means NNS N
of IN N
IOS NNP N
in IN N
comparison NN N
to TO N
the DT N
aR NN N
is VBZ N
a DT N
more RBR N
suitable JJ N
method NN N
for IN N
nasal JJ o
allergic JJ o
provocation NN o
. . o

METHOD NNP N
17 CD p
patients NNS p
with IN p
anamnestic JJ p
known VBN p
rhinokonjunktivitis NN p
( ( p
6 CD p
f NN p
, , p
11 CD p
m NN p
) ) p
had VBD p
a DT p
pricktest NN i
and CC p
then RB p
a DT p
nasal JJ i
provocation NN i
testing VBG i
with IN p
an DT p
allergen NN p
which WDT p
provoked VBD p
a DT p
reaction NN p
on IN p
the DT p
skin NN p
. . p

The DT N
complete JJ N
resistance NN o
of IN N
the DT N
nose NN N
was VBD N
measured VBN N
in IN N
a DT N
randomized JJ N
order NN N
by IN N
means NNS N
of IN N
aR NN i
and CC i
IOS NNP i
. . i

RESULTS VB N
The DT N
complete JJ o
resistance NN o
showed VBD N
neither CC N
in IN N
the DT N
basic JJ N
measurement NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
kPa/l/s NN N
; : N
IOS NNP N
0,38 CD N
+/- JJ N
0,11 CD N
kPa/l/s NN N
) ) N
nor CC N
in IN N
the DT N
control NN N
solution NN N
( ( N
aR JJ N
0,38 CD N
+/- JJ N
0,14 CD N
; : N
IOS NNP N
0,39 CD N
+/- JJ N
0,14 CD N
) ) N
nor CC N
after IN N
application NN N
of IN N
the DT N
allergenic JJ N
solution NN N
( ( N
15 CD N
min NN N
: : N
aR JJ N
0,69 CD N
+/- JJ N
0,27 CD N
; : N
IOS NNP N
0,77 CD N
+/- JJ N
0,42 CD N
; : N
30 CD N
min NN N
: : N
aR JJ N
0,65 CD N
+/- JJ N
0,29 CD N
; : N
IOS NNP N
0,6 CD N
+/- JJ N
0,38 CD N
) ) N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
. . N

The DT N
results NNS N
of IN N
the DT N
measurement NN o
of IN o
aR NN o
and CC o
IOS NNP o
after IN N
the DT N
allergenic JJ N
solution NN N
showed VBD N
a DT N
positive JJ N
correlation NN o
( ( N
15 CD N
min NN N
: : N
r NN N
= VBZ N
0,63 CD N
, , N
p NN N
< VBD N
0,01 CD N
; : N
30 CD N
min NN N
: : N
r NN N
= VBZ N
0,67 CD N
, , N
p NN N
< NNP N
0,01 CD N
) ) N
. . N

We PRP N
found VBD N
by IN N
means NNS N
of IN N
clinic NN N
and CC N
measurement NN N
methods NNS N
in IN N
the DT N
aR NN N
of IN N
7 CD p
patients NNS p
a DT p
positive JJ p
reaction NN o
, , p
within IN p
7 CD p
patient NN p
a DT p
negative JJ p
reaction NN o
, , p
3 CD p
patients NNS p
had VBD p
a DT p
unspecific JJ o
nasal NN o
hyperreactivity NN o
. . o

There EX N
was VBD N
a DT N
correspondence NN N
in IN N
6 CD p
of IN p
the DT p
7 CD p
patients NNS p
with IN p
positive JJ p
reaction NN o
in IN p
aR NN p
between IN N
both DT N
methods NNS N
. . N

4 CD N
of IN p
the DT p
7 CD p
results NNS p
with IN p
negative JJ p
reaction NN o
in IN N
the DT N
aR NN N
would MD N
have VB N
been VBN N
positive JJ N
then RB N
underlying VBG N
the DT N
same JJ N
criteria NNS N
in IN N
the DT N
IOS NNP N
without IN N
announcing VBG N
the DT N
symptomscore NN o
a DT N
relevant JJ N
clinical JJ N
symptomatic NN N
while IN N
testing VBG N
. . N

CONCLUSION NNP N
IOS NNP i
is VBZ N
a DT N
suitable JJ N
procedure NN N
for IN N
nasal JJ N
provocation NN N
testing VBG N
and CC N
provides VBZ N
results NNS N
similar JJ N
to TO N
the DT N
aR NN N
. . N

In IN N
comparison NN N
to TO N
aR VB N
IOS NNP N
is VBZ N
not RB N
dependent JJ N
on IN N
the DT N
patients NNS N
cooperation NN N
. . N

Due NNP N
to TO N
its PRP$ N
higher JJR N
sensitivity NN N
the DT N
valid JJ N
limits NNS N
of IN N
the DT N
aR NN N
at IN N
provocation NN N
testings NNS N
can MD N
not RB N
be VB N
transferred VBN N
to TO N
IOS NNP N
to TO N
avoid VB N
a DT N
false JJ o
positive JJ o
reaction NN o
. . o

-DOCSTART- -X- O O

Results NNS N
of IN N
a DT N
phase NN N
I/II NNP N
trial NN N
of IN N
recombinant JJ i
human JJ i
granulocyte-macrophage NN i
colony-stimulating NN i
factor NN i
in IN N
very RB p
low JJ p
birthweight NN p
neonates NNS p
: : p
significant JJ N
induction NN N
of IN N
circulatory NN N
neutrophils NNS N
, , N
monocytes NNS N
, , N
platelets NNS N
, , N
and CC N
bone NN N
marrow NN N
neutrophils NNS N
. . N

Neonates NNS N
, , N
especially RB N
those DT p
of IN p
very RB p
low JJ p
birthweight NN p
( ( p
VLBW NNP p
) ) p
, , N
have VBP N
an DT N
increased VBN N
risk NN N
of IN N
nosocomial JJ N
infections NNS N
secondary JJ N
to TO N
deficiencies NNS N
in IN N
development NN N
. . N

We PRP N
previously RB N
demonstrated VBD N
that IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
production NN N
and CC N
mRNA JJ N
expression NN N
from IN N
stimulated VBN N
neonatal JJ N
mononuclear JJ N
cells NNS N
are VBP N
significantly RB N
less JJR N
than IN N
that DT N
from IN N
adult NN N
cells NNS N
. . N

Recombinant JJ i
murine JJ i
GM-CSF NNP i
administration NN i
to TO N
neonatal JJ N
rats NNS N
has VBZ N
resulted VBN N
in IN N
neutrophilia JJ N
, , N
increased JJ N
neutrophil NN N
production NN N
, , N
and CC N
increased VBD N
survival NN N
of IN N
pups NNS N
during IN N
experimental JJ N
Staphylococcus NNP N
aureus NN N
sepsis NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
biologic JJ N
response NN N
of IN N
recombinant JJ i
human JJ i
( ( i
rhu NN i
) ) i
GM-CSF NNP i
in IN N
VLBW NNP N
neonates NNS N
. . N

Twenty NNP p
VLBW NNP p
neonates NNS p
( ( p
500 CD p
to TO p
1,500 CD p
g NN p
) ) p
, , p
aged VBD p
< JJ p
72 CD p
hours NNS p
, , p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
placebo NN i
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
rhuGM-CSF NN i
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
or CC N
10 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
given VBN N
via IN N
2-hour JJ N
intravenous JJ N
infusion NN N
for IN N
7 CD N
days NNS N
. . N

Complete JJ N
blood NN N
counts NNS N
, , N
differential NN N
, , N
and CC N
platelet NN N
counts NNS N
were VBD N
obtained VBN N
, , N
and CC N
tibial JJ N
bone NN N
marrow NN N
aspirate NN N
was VBD N
performed VBN N
on IN N
day NN N
8 CD N
. . N

Neutrophil NNP N
C3bi NNP N
receptor NN N
expression NN N
was VBD N
measured VBN N
at IN N
0 CD N
and CC N
24 CD N
hours NNS N
. . N

GM-CSF JJ o
levels NNS o
were VBD N
measured VBN N
by IN N
a DT N
sandwich JJ N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN i
. . i

At IN N
all DT N
doses NNS N
, , N
rhuGM-CSF NN i
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
grade NN o
III NNP o
or CC o
IV NNP o
toxicity NN o
. . o

Within IN N
48 CD N
hours NNS N
of IN N
administration NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
circulating VBG o
absolute JJ o
neutrophil NN o
count NN o
( ( o
ANC NNP o
) ) o
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
, , N
which WDT N
continued VBD N
for IN N
at IN N
least JJS N
24 CD N
hours NNS N
after IN N
discontinuation NN N
of IN N
rhuGM-CSF NN i
. . i

When WRB N
the DT N
ANC NNP N
was VBD N
normalized VBN N
for IN N
each DT N
patient NN N
's POS N
first JJ N
ANC NNP N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
ANC NNP o
on IN N
days NNS N
6 CD N
and CC N
7 CD N
at IN N
each DT N
dose JJ N
level NN N
. . N

By IN N
day NN N
7 CD N
, , N
all DT N
tested JJ N
doses NNS N
of IN N
rhuGM-CSF NN i
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
the DT N
absolute NN o
monocyte NN o
count NN o
( ( o
AMC NNP o
) ) o
compared VBN N
with IN N
placebo-treated JJ N
neonates NNS N
. . N

In IN N
those DT N
receiving VBG N
rhuGM-CSF JJ i
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
, , N
there EX N
was VBD N
additionally RB N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
day NN o
7 CD o
and CC o
8 CD o
platelet NN o
count NN o
. . o

Tibial NNP N
bone NN N
marrow NN N
aspirates VBZ N
demonstrated VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
bone NN o
marrow NN o
neutrophil JJ o
storage NN o
pool NN o
( ( o
BM NNP o
NSP NNP o
) ) o
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

Neutrophil NNP o
C3bi NNP o
receptor NN o
expression NN o
was VBD N
significantly RB N
increased VBN N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN i
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

The DT N
elimination NN N
half-life NN N
( ( N
T1/2 NNP N
) ) N
of IN N
rhuGM-CSF NN N
was VBD N
1.4 CD N
+/- JJ N
0.8 CD N
to TO N
3.9 CD N
+/- JJ N
2.8 CD N
hours NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Immunogenicity NN o
and CC N
reactogenicity NN o
of IN N
a DT N
group NN N
C NNP N
meningococcal JJ N
conjugate NN N
vaccine NN N
compared VBN N
with IN N
a DT N
group NN N
A+C NNP N
meningococcal JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS p
in IN N
a DT N
randomised JJ N
observer-blind NN N
controlled VBN N
trial NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
immunogenicity NN o
and CC N
reactogenicity NN o
of IN N
a DT N
group NN i
C NNP i
meningococcal JJ i
conjugate NN i
vaccine NN i
( ( i
MenC NNP i
) ) i
compared VBN i
with IN i
a DT i
group NN i
A+C NNP i
meningococcal JJ i
polysaccharide NN i
vaccine NN i
( ( i
MenPS NNP i
) ) i
in IN N
healthy JJ p
adolescents NNS p
. . p

Subjects NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
MenC NNP i
( ( N
n=92 NN N
) ) N
or CC N
MenPS NNP i
( ( N
n=90 NN N
) ) N
. . N

Group NNP N
C NNP N
meningococcal JJ o
IgG NNP o
antibody NN o
concentrations NNS o
and CC o
bactericidal JJ o
titres NNS o
were VBD N
higher JJR N
in IN N
the DT N
MenC NNP N
group NN N
than IN N
the DT N
MenPS NNP N
group NN N
at IN N
1 CD N
month NN N
( ( N
22.8 CD N
U/ml NNP N
vs NN N
4.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
87 CD N
vs NN N
20 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
and CC N
12 CD N
months NNS N
( ( N
6.1 CD N
U/ml NNP N
vs NN N
3.0 CD N
U/ml NNP N
, , N
p NN N
< VBD N
0.001 CD N
, , N
and CC N
81.3 CD N
vs NN N
20.2 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

No DT N
differences NNS N
in IN N
post NN o
immunisation NN o
reaction NN o
rates NNS o
were VBD N
noted VBN N
between IN N
the DT N
two CD N
vaccinated VBD N
groups NNS N
. . N

This DT N
study NN N
demonstrated VBD N
the DT N
safety NN N
and CC N
enhanced JJ N
immunogenicity NN o
of IN N
the DT N
candidate NN N
meningococcal JJ N
conjugate NN N
vaccine NN N
as IN N
compared VBN N
with IN N
the DT N
licensed JJ N
polysaccharide NN N
vaccine NN N
in IN N
adolescents NNS p
. . p

-DOCSTART- -X- O O

New NNP N
hope NN N
for IN N
children NNS p
with IN p
Kawasaki NNP p
disease NN p
. . p

Kawasaki NNP N
disease NN N
is VBZ N
now RB N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
acquired VBN p
heart NN p
disease NN p
in IN p
America NNP p
's POS p
children NNS p
. . p

It PRP N
is VBZ N
an DT N
acute JJ N
febrile NN N
illness NN N
that WDT N
may MD N
cause VB N
coronary JJ N
artery NN N
aneurysm NN N
formation NN N
in IN N
infected JJ p
children NNS p
. . p

The DT N
results NNS N
of IN N
a DT N
multicenter NN N
, , N
randomized VBN N
trial NN N
on IN N
the DT N
effect NN N
of IN N
intravenous JJ i
administration NN i
of IN i
gamma JJ i
globulin NN i
( ( i
IVGG NNP i
) ) i
plus CC i
aspirin JJ i
versus NN i
aspirin NN i
alone RB i
upon IN N
coronary JJ N
aneurysm NN N
formation NN N
show VBP N
a DT N
decrease NN N
in IN N
coronary JJ o
aneurysm NN o
formation NN o
from IN N
the DT N
usual JJ N
20 CD N
% NN N
-30 NN N
% NN N
to TO N
3 CD N
% NN N
. . N

Administration NNP N
of IN N
IVGG NNP i
presents VBZ N
some DT N
unique JJ N
challenges NNS N
for IN N
nurses NNS N
. . N

Also RB N
, , N
the DT N
pediatric JJ N
nurse NN N
must MD N
educate VB N
parents NNS N
and CC N
children NNS p
about IN N
this DT N
disease NN N
to TO N
prepare VB N
them PRP N
for IN N
discharge NN N
and CC N
long-term JJ N
follow-up JJ N
care NN N
. . N

-DOCSTART- -X- O O

Cardiovascular JJ N
effects NNS N
of IN N
non-depolarizing JJ i
neuromuscular JJ i
blockers NNS i
in IN N
patients NNS p
with IN p
aortic JJ p
valve NN p
disease NN p
. . p

To TO N
compare VB N
haemodynamic JJ N
responses NNS N
associated VBN N
with IN N
equipotent JJ N
doses NNS N
of IN N
neuromuscular JJ i
blockers NNS i
and CC N
high-dose JJ N
fentanyl NN i
( ( N
50 CD N
micrograms.kg-1 NN N
) ) N
, , N
40 CD p
patients NNS p
with IN p
aortic JJ p
valve NNS p
stenosis NN p
( ( p
AS IN p
) ) p
and CC p
20 CD p
patients NNS p
with IN p
aortic JJ p
insufficiency NN p
( ( p
AI NNP p
) ) p
were VBD N
randomized VBN N
to TO N
four CD N
study NN N
groups NNS N
to TO N
receive VB N
the DT N
following NN N
: : N
( ( N
1 CD N
) ) N
pancuronium NN i
0.12 CD i
mg.kg-1 NN i
, , i
( ( i
2 CD i
) ) i
vecuronium NN i
0.12 CD i
mg.kg-1 NN i
, , i
( ( i
3 CD i
) ) i
atracurium NN i
0.4 CD i
mg.kg-1 NN i
, , i
or CC i
( ( i
4 CD i
) ) i
pancuronium-metocurine NN i
mixture NN i
( ( N
0.4 CD N
mg NN N
+ VBD N
1.6 CD N
mg/ml NN N
) ) N
: : N
1 CD N
ml/10 NNS N
kg NN N
) ) N
. . N

Neuromuscular JJ i
blockers NNS i
were VBD N
injected VBN N
at IN N
the DT N
same JJ N
time NN N
with IN N
the DT N
fentanyl NN i
; : i
haemodynamics NNS N
were VBD N
recorded VBN N
with IN N
the DT N
patients NNS N
awake VBP N
( ( N
baseline NN N
) ) N
, , N
at IN N
two CD N
minutes NNS N
post-induction NN N
, , N
and CC N
at IN N
two CD N
and CC N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

In IN N
patients NNS N
with IN N
AS NNP N
, , N
pancuronium NN i
increased VBD N
heart NN o
rate NN o
more JJR N
than IN N
vecuronium NN i
or CC N
atracurium NN i
; : i
heart NN o
rates NNS o
were VBD N
also RB N
higher JJR o
with IN N
the DT N
pancuronium-metocurine JJ i
mixture NN i
than IN N
with IN N
vecuronium NN i
. . i

Although IN N
there EX N
were VBD N
no DT N
ECG NNP o
signs NNS o
of IN o
ischaemia NN o
, , N
one CD N
patient NN N
given VBN N
pancuronium NN N
developed VBD N
severe JJ o
hypotension NN o
associated VBN o
with IN o
tachycardia NN o
. . o

Reductions NNS N
in IN N
SVR NNP o
after IN N
atracurium NN N
allowed VBD N
small JJ N
but CC N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
decreases NNS N
in IN N
MAP NNP o
which WDT N
were VBD N
well RB o
tolerated VBN o
; : o
one CD N
patient NN N
, , N
however RB N
, , N
did VBD N
develop VB N
severe JJ o
hypotension NN o
. . o

Intubation NNP N
resulted VBD N
in IN N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
increases NNS N
in IN N
MAP NNP o
in IN N
the DT N
pancuronium-metocurine JJ i
mixture NN N
group NN N
. . N

Vecuronium NNP i
permitted VBD N
the DT N
most RBS N
stable JJ N
overall JJ o
haemodynamic JJ o
course NN o
at IN N
all DT N
measurement JJ N
times NNS N
. . N

In IN N
contrast NN N
, , N
patients NNS N
with IN N
AI NNP N
showed VBD N
stable JJ o
haemodynamics NNS o
after IN N
vecuronium NN i
, , i
pancuronium NN i
and CC N
the DT N
pancuronium-metocurine JJ i
mixture NN i
; : i
one CD N
patient NN N
became VBD N
tachycardic JJ o
following VBG N
vecuronium NN i
. . i

Atracurium NNP i
caused VBD N
unexplained JJ N
elevations NNS o
in IN o
diastolic JJ o
and CC o
mean JJ o
arterial NN o
pressures NNS o
which WDT N
were VBD N
significant JJ N
when WRB N
compared VBN N
to TO N
vecuronium VB i
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
results NNS N
in IN N
increases NNS N
in IN N
PCWP NNP o
; : o
mean JJ o
PA NNP o
pressures NNS o
and CC o
CVP NNP o
were VBD N
also RB N
increased VBN o
. . o

These DT N
effects NNS N
of IN N
atracurium NN i
inpatients NNS N
with IN N
Al NNP N
need VBP N
further JJ N
evaluation NN N
. . N

-DOCSTART- -X- O O

Monotherapy NNP N
of IN N
mild JJ p
hypertension NN o
with IN N
nifedipine NN i
. . i

The DT N
effectiveness NN o
of IN N
nifedipine JJ i
as IN N
first-line JJ N
monotherapy NN N
for IN N
mild JJ p
diastolic JJ o
hypertension NN o
( ( p
range NN p
: : p
95 CD p
to TO p
105 CD p
mm NNS p
Hg NNP p
) ) p
was VBD N
tested VBN N
in IN N
this DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
. . N

Fifty-six JJ p
patients NNS p
were VBD p
enrolled VBN p
and CC N
, , N
after IN N
titration NN N
of IN N
the DT N
placebo NN i
or CC N
active JJ i
drug NN i
, , N
they PRP N
were VBD N
followed VBN N
for IN N
12 CD N
weeks NNS N
. . N

Significant JJ N
declines NNS N
in IN N
the DT N
sitting VBG N
systolic JJ o
and CC o
diastolic JJ o
pressures NNS o
of IN N
-19 JJ N
+/- JJ N
4 CD N
mm NN N
Hg NNP N
( ( N
standard JJ N
error NN N
) ) N
and CC N
-13 $ N
+/- JJ N
2 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
, , N
were VBD N
observed VBN N
during IN N
this DT N
follow-up JJ N
period NN N
. . N

Overall JJ N
, , N
75 CD N
percent NN N
of IN N
patients NNS N
receiving VBG N
active JJ i
drug NN i
had VBD N
diastolic JJ o
pressures NNS o
less RBR N
than IN N
or CC N
equal JJ N
to TO N
90 CD N
mm NNS N
Hg NNP N
at IN N
the DT N
last JJ N
treatment NN N
visit NN N
. . N

Heart NNP o
rate NN o
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
the DT N
sitting VBG N
position NN N
during IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
the DT N
majority NN N
of IN N
patients NNS N
( ( N
75 CD N
percent NN N
) ) N
showed VBD N
a DT N
response NN N
to TO N
nifedipine JJ i
doses NNS N
of IN N
10 CD N
or CC N
20 CD N
mg NNS N
orally RB N
three CD N
times NNS N
daily RB N
in IN N
the DT N
capsule NN N
form NN N
. . N

The DT N
levels NNS N
of IN N
the DT N
systolic NN o
and CC o
diastolic JJ o
pressures NNS o
at IN N
entry NN N
were VBD N
not RB N
predictive JJ N
of IN N
the DT N
dose NN N
of IN N
nifedipine NN i
required VBN N
for IN N
effective JJ o
blood NN o
pressure NN o
control NN N
. . N

-DOCSTART- -X- O O

Unstable JJ p
angina NN p
. . p

Quality NN o
of IN o
life NN o
. . o

-DOCSTART- -X- O O

Couple-responsible JJ i
therapy NN i
process NN i
: : i
positive JJ o
proximal JJ o
outcomes NNS o
. . o

Therapist-couple JJ N
struggle NN N
vs. FW N
cooperation NN N
is VBZ N
linked VBN N
to TO N
clinical JJ N
outcome NN N
. . N

This DT N
research NN N
conceptualizes NN N
and CC N
investigates VBZ N
treatment NN N
process NN N
as IN N
it PRP N
relates VBZ N
to TO N
the DT N
occurrence NN N
of IN N
struggle NN N
versus NN N
cooperation NN N
. . N

Models NNS N
of IN N
couple-responsible JJ i
and CC i
therapist-responsible JJ i
process NN i
in IN N
couple NN i
therapy NN i
were VBD N
developed VBN N
. . N

Couple-responsible JJ i
process NN i
consists VBZ i
of IN i
enactments NNS i
, , i
accommodation NN i
, , i
and CC i
inductive JJ i
process NN i
. . i

Therapist-responsible JJ i
process NN i
consists VBZ i
of IN i
primary JJ i
therapist-couple JJ i
interaction NN i
, , i
therapist JJ i
interpretation NN i
, , i
and CC i
direct JJ i
instruction NN i
. . i

In IN N
counterbalanced JJ N
order NN N
, , N
25 CD p
couples NNS p
were VBD N
exposed VBN N
to TO N
couple-responsible JJ i
and CC i
therapist-responsible JJ i
episodes NNS i
during IN N
one CD N
therapy NN N
session NN N
. . N

Couples NNP N
reviewed VBD N
videotapes NNS N
of IN N
the DT N
episodes NNS N
and CC N
completed VBD N
measures NNS N
of IN N
responsibility NN N
, , N
struggle NN N
, , N
and CC N
cooperation NN N
. . N

Perceived NNP o
responsibility NN o
was VBD N
higher JJR N
and CC N
struggle NN o
was VBD N
lower JJR N
during IN N
couple-responsible JJ i
episodes NNS i
. . i

No DT N
difference NN N
in IN N
cooperation NN o
was VBD N
found VBN N
. . N

Presence NN N
or CC N
absence NN N
of IN N
a DT N
contrast NN N
condition NN N
, , N
where WRB N
couples NNS N
reported VBD N
on IN N
one CD N
therapist NN i
process NN i
after IN N
already RB N
experiencing VBG N
its PRP$ N
opposite NN N
, , N
led VBN N
to TO N
main JJ N
effects NNS N
for IN N
responsibility NN N
and CC N
struggle NN N
, , N
and CC N
mediated VBD N
effects NNS N
of IN N
struggle NN N
and CC N
cooperation NN N
. . N

Generally NNP N
speaking NN N
, , N
responsibility NN o
was VBD N
even RB N
higher JJR N
during IN N
couple-responsible JJ i
episodes NNS i
and CC N
even RB N
lower JJR N
during IN N
therapist-responsible JJ i
episodes NNS i
when WRB N
contrast NN N
was VBD N
present JJ N
. . N

Similarly RB N
, , N
struggle NN o
was VBD N
even RB N
lower JJR N
during IN N
couple-responsible JJ i
episodes NNS i
and CC N
even RB N
higher JJR N
during IN N
therapist-responsible JJ i
episodes NNS i
when WRB N
contrast NN N
was VBD N
present JJ N
. . N

For IN N
both DT N
couple-responsible JJ N
and CC N
therapist-responsible JJ N
episodes NNS N
, , N
cooperation NN o
was VBD N
negatively RB N
affected VBN N
by IN N
a DT N
shift NN N
from IN N
the DT N
prior JJ N
, , N
opposite JJ N
therapist NN N
process NN N
. . N

Significant JJ N
proportions NNS N
of IN N
the DT N
variance NN N
in IN N
responsibility NN o
, , o
struggle NN o
, , o
and CC o
cooperation NN o
, , N
however RB N
, , N
were VBD N
not RB N
accounted VBN N
for IN N
by IN N
therapist JJ N
process NN N
alone RB N
. . N

-DOCSTART- -X- O O

Addition NN N
of IN N
fexofenadine NN i
to TO N
inhaled VB i
corticosteroid JJ i
therapy NN i
to TO N
reduce VB N
inflammatory JJ o
biomarkers NNS o
in IN p
atopic NN p
asthma NN p
. . p

BACKGROUND IN N
We PRP N
previously RB N
showed VBD N
that IN N
H1-antihistamines NNP N
may MD N
shift VB N
the DT N
PC20 NNP N
( ( N
provocation NN N
concentration NN N
that WDT N
caused VBD N
a DT N
decrease NN N
in IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second NN N
of IN N
20 CD N
% NN N
) ) N
threshold NN N
to TO N
adenosine VB N
monophosphate NN N
( ( N
AMP NNP N
) ) N
challenge NN N
but CC N
may MD N
paradoxically RB N
prolong VB N
recovery NN N
. . N

OBJECTIVES UH N
To TO N
measure VB N
AMP NNP N
recovery NN N
using VBG N
a DT N
constant JJ N
predetermined VBN N
AMP NNP N
PC20 NNP N
and CC N
to TO N
evaluate VB N
whether IN N
fexofenadine NN i
use NN N
confers NNS N
add-on JJ N
effects NNS N
to TO N
treatment NN N
with IN N
either DT N
fluticasone NN i
propionate NN i
alone RB N
or CC N
combined VBN i
fluticasone CD i
propionate-salmeterol NN i
. . i

METHODS NNP N
Fourteen NNP p
atopic NN p
patients NNS p
with IN p
mild-to-moderate JJ p
asthma NN p
( ( p
forced JJ p
expiratory NN p
volume NN p
in IN p
1 CD p
second NN p
of IN p
76 CD p
% NN p
) ) p
completed VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
consisting VBG N
of IN N
3-week JJ N
treatment NN N
blocks NNS N
of IN N
either DT N
fluticasone JJ i
propionate-salmeterol NN i
, , N
250 CD N
microg NN N
twice RB N
daily RB N
, , N
or CC N
fluticasone JJ i
propionate NN i
alone RB i
, , N
250 CD N
microg NN N
twice RB N
daily RB N
, , N
in IN N
conjunction NN N
with IN N
either DT N
fexofenadine NN i
, , N
180 CD N
mg NN N
once RB N
daily JJ N
, , N
or CC N
matched VBD N
placebo NN i
. . i

Recovery NN o
after IN N
a DT N
predetermined JJ o
AMP NNP o
PC20 NNP o
challenge NN o
was VBD N
measured VBN N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
along IN N
with IN N
exhaled JJ o
nitric JJ o
oxide NN o
levels NNS o
, , o
plasma NN o
eosinophil NN o
cationic JJ o
protein NN o
levels NNS o
, , o
peripheral JJ o
eosinophil NN o
counts NNS o
, , o
pulmonary JJ o
function NN o
, , o
diary JJ o
card NN o
outcomes NNS o
, , o
and CC o
quality NN o
of IN o
life NN o
( ( N
all DT N
secondary JJ N
outcomes NNS N
) ) N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
any DT N
of IN N
the DT N
primary JJ N
or CC N
secondary JJ N
outcomes NNS N
when WRB N
fexofenadine NN i
was VBD N
added VBN N
to TO N
treatment NN N
with IN N
either DT N
fluticasone JJ i
propionate-salmeterol NN i
or CC i
fluticasone NN i
propionate NN i
alone RB N
. . N

The DT N
mean NN N
AMP NNP N
recovery NN N
time NN N
was VBD N
25.0 CD N
vs NN N
23.4 CD N
minutes NNS N
for IN N
fexofenadine NN i
and CC N
placebo NN i
, , N
respectively RB N
, , N
as IN N
add-on JJ N
to TO N
fluticasone-salmeterol NN i
and CC N
22.5 CD N
vs NN N
23.9 CD N
minutes NNS N
, , N
respectively RB N
, , N
as IN N
add-on JJ N
to TO N
fluticasone VB i
alone RB N
. . N

CONCLUSION NNP N
Fexofenadine NNP i
did VBD N
not RB N
affect VB N
recovery NN N
to TO N
a DT N
fixed VBN N
dose NN N
of IN N
AMP NNP N
challenge NN N
or CC N
any DT N
other JJ N
surrogate JJ N
inflammatory NN N
markers NNS N
when WRB N
given VBN N
as IN N
add-on JJ N
therapy NN N
to TO N
corticosteroid-treatedatopic JJ p
asthmatic JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

Fusidic NNP N
acid VBZ N
prophylaxis NN N
before IN p
cataract JJ p
surgery NN p
: : p
patient JJ p
self-administration NN p
. . p

In IN N
a DT N
placebo-controlled JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
the DT N
authors NNS N
evaluated VBD N
the DT N
efficacy NN N
of IN N
patient-administered JJ N
1 CD N
% NN N
fusidic JJ i
acid RB i
viscous JJ i
eye NN i
drops NNS i
in IN N
clearing VBG N
the DT N
commonest JJS N
organisms JJ N
causing VBG N
pseudophakic NN N
endophthalmitis NN N
( ( N
Staphylococcus NNP N
epidermidis RB N
and CC N
aureus RB N
) ) N
from IN N
the DT N
lids NNS N
and CC N
conjunctivae NN N
of IN N
79 CD p
patients NNS p
before IN p
cataract JJ p
surgery NN p
. . p

The DT N
treatment NN N
group NN N
self-administered JJ N
fusidic JJ i
acid NN i
viscous JJ N
eye NN N
drops VBZ N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
; : N
the DT N
placebo NN N
group NN N
received VBD N
inert JJ i
ophthalmic JJ i
drops NNS i
. . i

Fellow NNP N
eyes NNS N
of IN N
both DT N
groups NNS N
remained VBD N
untreated JJ N
as IN N
a DT N
natural JJ N
control NN N
. . N

Lower JJR N
fornix NN N
and CC N
lid JJ N
margin NN N
cultures NNS N
were VBD N
taken VBN N
from IN N
both DT N
eyes NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

Before IN N
treatment NN N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
organism NN o
counts NNS o
between IN N
the DT N
groups NNS N
. . N

After IN N
treatment NN N
, , N
eyes NNS N
receiving VBG N
fusidic JJ i
acid NNS i
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
free JJ N
of IN N
clinically RB N
relevant JJ N
Staphylococcus NNP N
spp NN N
. . N

than IN N
all DT N
pre-treatment JJ N
eyes NNS N
( ( N
for IN N
lids NNS N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
conjunctivae NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

A DT N
highly RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
number NN o
of IN o
lid JJ o
margins NNS o
were VBD N
rendered VBN N
'clinically RB N
clean JJ N
' '' N
( ( N
i.e. FW N
, , N
0-49 JJ N
organisms/swab NN N
) ) N
by IN N
fusidic JJ N
acid NN N
when WRB N
compared VBN N
with IN N
untreated JJ N
eyes NNS N
. . N

Treatment NNP N
also RB N
effectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
reduced VBD N
the DT N
numbers NNS o
of IN o
bacteria NNS o
isolated VBN o
from IN o
conjunctivae NN o
. . o

This DT N
study NN N
indicates VBZ N
that IN N
there EX N
is VBZ N
a DT N
highly RB N
significant JJ N
reduction NN N
of IN N
Staphylococcus NNP N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
non-Staphylococcus JJ N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
attainment NN N
of IN N
sterile JJ N
eyes NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
operation NN N
gained VBN N
by IN N
patient JJ N
self-administration NN N
of IN N
1 CD N
% NN N
fusidic JJ N
acid RB N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
whiplash NN N
associated VBN N
neck RB N
pain VBP N
[ RB N
corrected VBN N
] NN N
with IN N
botulinum JJ i
toxin-A NN i
: : i
a DT N
pilot NN N
study NN N
. . N

OBJECTIVE NNP N
Up NNP N
to TO N
87 CD N
% NN N
of IN N
patients NNS N
with IN N
whiplash NN N
associated VBN N
disorder NN N
( ( N
WAD NNP N
) ) N
have VBP N
some DT N
degree NN N
of IN N
muscle NN N
spasm NN N
that WDT N
is VBZ N
contributory JJ N
to TO N
both DT N
pain NN N
and CC N
dysfunction NN N
. . N

Botulinum NNP i
toxin NN i
A NNP i
( ( i
BTX-A NNP i
) ) i
produces VBZ N
prolonged JJ N
muscle NN N
relaxation NN N
that WDT N
is VBZ N
dose-dependent JJ N
and CC N
can MD N
be VB N
easily RB N
targeted VBN N
to TO N
affected JJ N
muscles NNS N
. . N

BTX-A NNP N
therapy NN N
may MD N
be VB N
an DT N
effective JJ N
form NN N
of IN N
therapy NN N
offering VBG N
an DT N
alternative NN N
or CC N
adjunct NN N
to TO N
conventional JJ N
modalities NNS N
. . N

We PRP N
investigated VBD N
BTX-A NNP i
as IN N
therapy NN N
in IN N
patients NNS p
with IN p
WAD NNP p
. . p

METHODS NNP N
This DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
study NN N
compares VBZ N
outcome JJ N
measures NNS N
in IN N
26 CD p
patients NNS p
with IN p
chronic JJ p
neck NN p
pain NN p
( ( p
WAD-II NNP p
chronic NN p
) ) p
subsequent NN p
to TO p
a DT p
motor NN p
vehicle NN p
accident NN p
. . p

One-half NN N
of IN N
the DT N
patients NNS N
received VBD N
100 CD i
units NNS i
BTX-A NNP i
, , i
diluted VBD i
in IN i
1 CD i
ml NNS i
saline NN i
, , i
while IN i
the DT i
other JJ i
half NN i
received VBD i
just RB i
saline NN i
( ( N
1 CD N
ml NN N
) ) N
. . N

Five CD N
trigger NN N
points NNS N
received VBD N
0.2 CD N
ml NNS N
each DT N
of IN N
injectant JJ N
via IN N
a DT N
30 CD N
gauge NN N
needle NN N
. . N

Outcome NNP N
measures NNS N
included VBD N
total JJ o
subjective JJ o
neck NN o
, , o
shoulder NN o
, , o
and CC o
head NN o
pain NN o
based VBN o
on IN o
visual JJ o
analog NN o
scales NNS o
; : o
objective JJ o
total JJ o
range NN o
of IN o
neck NN o
motion NN o
( ( o
ROM NNP o
) ) o
, , o
and CC o
the DT o
Vernon-Mior NNP o
subjective JJ o
function NN o
index NN o
. . o

Followup CD N
assessments NNS N
were VBD N
carried VBN N
out RP N
at IN N
2 CD N
and CC N
4 CD N
weeks NNS N
post-treatment JJ N
. . N

RESULTS NNP N
Fourteen NNP p
subjects VBZ p
receiving VBG p
BTX-A NNP i
and CC p
12 CD p
receiving NN p
saline NN p
completed VBD p
the DT p
study NN p
. . p

The DT N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN o
toward IN o
improvement NN o
in IN o
ROM NNP o
and CC o
reduction NN o
in IN o
pain NN o
at IN N
2 CD N
weeks NNS N
post-injection NN N
. . N

At IN N
4 CD N
weeks NNS N
post-injection NN N
the DT N
treatment NN N
group NN N
was VBD N
significantly RB N
improved VBN N
from IN N
preinjection NN N
levels NNS N
( ( N
p VB N
< RB N
0.01 CD N
) ) N
. . N

The DT N
placebo NN N
group NN N
showed VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
at IN N
any DT N
post-treatment JJ N
time NN N
. . N

The DT N
Vernon-Mior JJ o
scale NN o
revealed VBD N
a DT N
trend NN N
to TO N
improvement NN o
for IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
BTX-A NNP i
treatment NN N
of IN N
subjects NNS N
with IN N
chronic JJ N
WAD NNP N
II NNP N
neck NN N
pain NN N
resulted VBD N
in IN N
a DT N
significant JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
improvement NN N
in IN N
ROM NNP o
and CC N
subjective JJ o
pain NN o
compared VBN N
to TO N
a DT N
placebo NN N
group NN N
, , N
but CC N
only RB N
a DT N
trend NN N
to TO N
improvement NN N
in IN N
subjective JJ o
functioning NN o
. . o

-DOCSTART- -X- O O

Comparison NNP N
of IN N
0.25 CD N
% NN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine VBP N
with IN N
0.25 CD N
% NN N
RS-bupivacaine NNP N
for IN N
epidural JJ N
analgesia NN o
in IN p
labour NN p
. . p

We PRP N
have VBP N
compared VBN N
the DT N
efficacy NN N
of IN N
0.25 CD N
% NN N
S NNP i
( ( i
- : i
) ) i
-bupivacaine VBP i
with IN N
0.25 CD N
% NN N
RS-bupivacaine NNP i
in IN N
providing VBG N
epidural JJ o
analgesia NN o
for IN N
labour NN N
in IN N
a DT N
randomized JJ N
, , N
multicentre JJ N
, , N
double-blind JJ N
study NN N
. . N

Analgesia NNP i
was VBD i
initiated VBN i
with IN i
10 CD i
ml NN i
of IN i
the DT i
study NN i
solution NN i
and CC i
maintained VBN i
with IN i
10-ml JJ i
top-ups NNS i
. . i

We PRP N
studied VBD N
137 CD p
women NNS p
and CC N
treatments NNS N
were VBD N
found VBN N
to TO N
be VB N
equivalent JJ N
for IN N
onset NN N
, , N
duration NN N
and CC N
quality NN N
of IN N
block NN N
. . N

Median JJ o
onset NN o
of IN o
pain NN o
relief NN o
was VBD N
12 CD N
min NN N
for IN N
both DT N
drugs NNS N
and CC N
median JJ N
duration NN N
was VBD N
49 CD N
( ( N
range VB N
3-129 NNP N
) ) N
min NN N
and CC N
51 CD N
( ( N
7-157 CD N
) ) N
min NN N
for IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
RS NNP N
bupivacaine NN N
, , N
respectively RB N
. . N

The DT N
estimated JJ N
treatment NN N
difference NN N
for IN N
duration NN o
of IN o
pain NN o
relief NN o
was VBD N
-4 NNP N
( ( N
90 CD N
% NN N
CI NNP N
-13 NNP N
, , N
6 CD N
) ) N
min NN N
. . N

Thirty NNP N
patients NNS N
failed VBD N
to TO N
achieve VB o
pain NN o
relief NN o
after IN N
the DT N
first JJ N
injection NN N
( ( N
20 CD N
patients NNS N
after IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
10 CD N
after IN N
RS-bupivacaine NNP N
; : N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

However RB N
, , N
median JJ o
duration NN o
of IN o
pain NN o
relief NN o
from IN N
the DT N
first JJ N
top-up NN N
was VBD N
82 CD N
( ( N
range VB N
3-164 NNP N
) ) N
min NN N
for IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
76 CD N
( ( N
22-221 JJ N
) ) N
min NN N
for IN N
RS-bupivacaine NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
quality NN o
of IN o
analgesia NN o
, , N
as IN N
assessed VBN N
by IN N
the DT N
investigators NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
extent NN N
of IN N
sensory JJ o
block NN o
, , o
percentage NN o
of IN o
patients NNS o
with IN o
motor NN o
block NN o
or CC o
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

-DOCSTART- -X- O O

Detection NN N
of IN N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
using VBG N
the DT N
saline JJ i
solution NN i
load NN i
test NN i
. . i

BACKGROUND IN N
The DT N
saline JJ i
solution NN i
load NN i
test NN i
helps VBZ N
to TO N
determine VB N
if IN N
a DT N
wound NN N
extends VBZ N
into IN N
the DT N
knee NN N
joint NN N
. . N

Little JJ N
is VBZ N
known VBN N
about IN N
the DT N
volume NN N
of IN N
injected JJ N
intra-articular JJ N
saline NN i
solution NN i
that WDT N
is VBZ N
needed VBN N
to TO N
effectively RB N
rule VB N
in IN N
or CC N
rule VB N
out IN N
a DT N
traumatic JJ N
arthrotomy NN N
of IN N
the DT N
knee NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
appropriate JJ o
volume NN o
and CC N
needle JJ o
location NN o
for IN N
the DT N
diagnosis NN N
of IN N
a DT N
traumatic JJ N
knee NN N
arthrotomy NN N
and CC N
to TO N
assess VB N
the DT N
effect NN o
of IN N
associated JJ o
variables NNS o
, , N
including VBG N
knee NN o
circumference NN o
, , o
body NN o
mass NN o
index NN o
, , o
and CC o
sex NN o
. . o

METHODS NNP N
Fifty-six NNP p
consecutive JJ p
patients NNS p
scheduled VBN p
for IN p
knee NN p
arthroscopy NN p
were VBD N
enrolled VBN N
. . N

A DT i
standard JJ i
inferolateral JJ i
arthroscopic NN i
portal NN i
was VBD i
made VBN i
with IN i
a DT i
single JJ i
stab NN i
incision NN i
with IN i
use NN i
of IN i
a DT i
number-11 JJ i
blade NN i
. . i

Injection NN N
sites NNS N
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
superomedial NN N
or CC N
inferomedial JJ N
location NN N
. . N

The DT N
injection NN i
of IN i
normal JJ i
saline JJ i
solution NN i
at IN i
a DT i
rate NN i
of IN i
5 CD i
mL/sec NNS i
through IN i
an DT i
18-gauge JJ i
needle NN i
was VBD N
continued VBN N
while IN N
the DT N
knee NN N
was VBD N
moved VBN N
through IN N
a DT N
range NN N
of IN N
motion NN N
until IN N
fluid NNS N
extravasated VBN N
from IN N
the DT N
iatrogenic JJ N
laceration NN N
. . N

The DT N
volume NN N
of IN N
injected JJ N
fluid NN N
was VBD N
recorded VBN N
. . N

RESULTS VB N
The DT N
study NN N
group NN N
included VBD N
thirty-one JJ p
female NN p
patients NNS p
and CC p
twenty-five JJ p
male NN p
patients NNS p
with IN p
a DT p
combined JJ p
average JJ p
age NN p
of IN p
fifty JJ p
years NNS p
and CC p
an DT p
average JJ o
body NN o
mass NN o
index NN o
of IN p
30.9 CD p
. . p

In IN N
order NN N
to TO N
effectively RB N
diagnose VB o
50 CD o
% NN o
of IN o
the DT o
arthrotomies NNS o
, , N
75 CD N
mL NN N
of IN N
injected JJ N
fluid NN N
was VBD N
needed VBN N
; : N
the DT N
volumes NNS o
that WDT o
were VBD o
needed VBN o
in IN o
order NN o
to TO o
effectively RB o
diagnose VB o
75 CD o
% NN o
, , N
90 CD N
% NN N
, , N
95 CD N
% NN N
, , N
and CC N
99 CD N
% NN N
of IN N
the DT N
arthrotomies NNS o
were VBD N
110 CD N
, , N
145 CD N
, , N
155 CD N
, , N
and CC N
175 CD N
mL NN N
, , N
respectively RB N
. . N

The DT N
mean JJ o
volumes NNS o
of IN o
injected JJ o
fluid NN o
needed VBN o
for IN o
a DT o
positive JJ o
result NN o
at IN o
the DT o
inferomedial JJ o
and CC o
superomedial JJ o
needle JJ o
locations NNS o
were VBD N
64.0 CD N
and CC N
95.2 CD N
mL NN N
, , N
respectively RB N
; : N
this DT N
difference NN N
was VBD N
significant JJ N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT o
correlation NN o
between IN o
necessary JJ o
injection NN o
volume NN o
and CC o
sex NN o
, , o
body NN o
mass NN o
index NN o
, , o
or CC o
knee VB o
circumference NN o
. . o

CONCLUSIONS NNP N
In IN N
order NN N
to TO N
detect VB N
95 CD N
% NN N
of IN N
1-cm JJ N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
with IN N
use NN N
of IN N
the DT N
saline JJ N
solution NN N
load NN N
test NN N
, , N
155 CD N
mL NN N
must MD N
be VB N
injected VBN N
. . N

An DT N
inferomedial JJ o
injection NN o
location NN o
requires VBZ N
significantly RB o
less JJR o
fluid NN o
than IN N
a DT N
superomedial JJ o
injection NN o
location NN o
does VBZ N
for IN N
the DT N
diagnosis NN N
of IN N
inferolateral JJ N
arthrotomies NNS N
of IN N
the DT N
knee NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
latanoprost NN i
when WRB N
stored VBN N
at IN N
room NN N
temperature NN N
. . N

We PRP N
compared VBN N
the DT N
ocular JJ N
hypotensive JJ N
effect NN o
for IN N
24 CD N
hours NNS N
and CC N
the DT N
tolerability NN N
of IN N
latanoprost NN i
stored VBN N
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C. NNP N
Seventeen NNP p
healthy JJ p
volunteers NNS p
were VBD p
included VBN p
in IN p
this DT p
crossover NN p
trial NN p
. . p

Latanoprost VB i
0.005 CD N
% NN N
( ( i
Xalatan NNP i
) ) i
was VBD N
stored VBN N
at IN N
4 CD N
degrees NNS N
C NNP N
or CC N
30 CD N
degrees NNS N
C NNP N
for IN N
4 CD N
weeks NNS N
in IN N
the DT N
dark NN N
. . N

The DT N
subjects NNS N
enrolled VBD N
to TO N
the DT N
study NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
latanoprost NN i
stored VBD N
at IN N
4 CD N
degrees NNS N
C NNP N
or CC N
that IN N
stored VBN N
at IN N
30 CD N
degrees NNS N
C. NNP N
The DT N
eye NN N
drop NN N
was VBD N
applied VBN N
to TO N
the DT N
right JJ N
eye NN N
of IN N
each DT N
subject NN N
for IN N
3 CD N
days NNS N
. . N

The DT N
left NN N
eye NN N
served VBD N
as IN N
a DT N
control NN N
without IN N
administration NN N
. . N

Slit-lamp JJ i
biomicroscopy NN i
and CC N
circadian JJ i
intra NN i
ocular JJ i
pressure NN i
( ( i
IOP NNP i
) ) i
curve NN i
was VBD N
performed VBN N
at IN N
Day NNP N
3 CD N
, , N
every DT N
3 CD N
hours NNS N
from IN N
6 CD N
pm NN N
. . N

This DT N
procedure NN N
was VBD N
repeated VBN N
7 CD N
days NNS N
after IN N
changing VBG N
the DT N
drug NN N
from IN N
4 CD N
degrees NNS N
C NNP N
to TO N
30 CD N
degrees NNS N
C NNP N
or CC N
vice NN N
versa NN N
, , N
and CC N
application NN N
to TO N
the DT N
left NN N
eye NN N
for IN N
3 CD N
days NNS N
. . N

Eyes NNS N
treated VBD N
with IN N
latanoprost NN N
, , N
stored VBD N
both DT N
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C NNP N
, , N
achieved VBD N
statistically RB o
significantly RB o
lower JJR o
mean NN o
IOPs NNP o
than IN N
untreated JJ N
eyes NNS N
at IN N
all DT N
time NN N
points NNS N
, , N
except IN N
at IN N
21 CD N
hours NNS N
treated VBN N
by IN N
the DT N
drug NN N
stored VBD N
at IN N
30 CD N
degrees NNS N
C. NNP N
We PRP N
subtracted VBD N
the DT N
IOP NNP N
of IN N
eyes NNS N
receiving VBG N
latanoprost NN N
from IN N
the DT N
IOP NNP N
of IN N
untreated JJ N
eyes NNS N
for IN N
each DT N
time NN N
point NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
the DT N
eye NN N
drops NNS N
( ( N
delta JJ N
IOP NNP N
) ) N
. . N

There EX N
were VBD N
no DT o
statistically RB o
significant JJ o
differences NNS o
between IN o
the DT o
delta NN o
IOPs NNP o
with IN o
the DT o
drug NN o
stored VBD o
at IN N
4 CD N
degrees NNS N
C NNP N
and CC N
30 CD N
degrees NNS N
C. NNP N
During IN N
the DT N
study NN N
, , N
no DT o
subject NN o
developed VBD o
a DT o
serious JJ o
adverse JJ o
event NN o
. . o

These DT N
results NNS N
suggest VBP N
that IN N
latanoprost NN N
stored VBN N
at IN N
30 CD N
degrees NNS N
C NNP N
for IN N
4 CD o
weeks NNS o
after IN o
opening VBG o
the DT o
bottle NN o
remains VBZ o
as IN o
effective JJ o
and CC o
safe JJ o
as IN N
latanoprost NN N
stored VBN N
under IN N
cold JJ N
conditions NNS N
. . N

-DOCSTART- -X- O O

Single NNP i
negative JJ i
colposcopy NN i
: : i
is VBZ N
it PRP N
enough RB N
to TO N
rule VB N
out IN N
high-grade JJ N
disease NN N
? . N
It PRP N
has VBZ N
been VBN N
proposed VBN N
that IN N
women NNS p
who WP p
have VBP p
a DT p
negative JJ p
colposcopic NN p
examination NN p
or CC p
who WP p
have VBP p
no DT p
cervical JJ p
intraepithelial JJ p
neoplasia NN p
( ( p
CIN NNP p
) ) p
on IN p
colposcopic NN i
biopsy NN i
can MD N
be VB N
safely RB N
returned VBN N
to TO N
routine VB N
screening VBG N
with IN N
the DT N
next JJ N
visit NN N
being VBG N
three CD N
or CC N
five CD N
years NNS N
later RB N
. . N

We PRP N
present JJ N
data NNS N
regarding VBG N
551 CD p
women NNS p
who WP p
had VBD p
colposcopy NN i
in IN p
Wales NNP p
for IN p
a DT p
low-grade JJ p
cytological JJ p
abnormality NN p
and CC p
who WP p
were VBD p
followed VBN p
through IN p
Cervical NNP p
Screening NNP p
Wales NNP p
for IN p
subsequent JJ p
CIN NNP p
. . p

Of IN N
436 CD N
women NNS N
declared VBD N
CIN NNP o
free JJ o
initially RB N
, , N
26 CD N
( ( N
6.0 CD N
% NN N
) ) N
had VBD N
high-grade JJ o
CIN NNP o
diagnosed VBD N
on IN N
follow-up NN N
. . N

We PRP N
suggest VBP N
that IN N
additional JJ N
screening NN N
at IN N
an DT N
interval NN N
of IN N
less JJR N
than IN N
three CD N
years NNS N
should MD N
be VB N
offered VBN N
to TO N
women NNS p
with IN p
a DT p
negative JJ p
colposcopy NN p
or CC p
a DT p
biopsy NN p
without IN p
CIN NNP p
. . p

-DOCSTART- -X- O O

Bronchodilator NNP N
response NN N
to TO N
salbutamol VB i
after IN N
spontaneous JJ N
recovery NN N
from IN N
nonspecific JJ N
bronchial JJ N
provocation NN N
tests NNS N
in IN N
asthma NN p
. . p

Assessment NN N
of IN N
airway NN N
responsiveness NN N
by IN N
bronchoprovocation NN N
and CC N
bronchodilatation NN N
tests NNS N
is VBZ N
important JJ N
in IN N
the DT N
diagnostic JJ N
work-up JJ N
protocol NN N
of IN N
bronchial JJ p
asthma NN p
and CC N
it PRP N
would MD N
be VB N
convenient JJ N
to TO N
undertake VB N
both DT N
tests NNS N
on IN N
the DT N
same JJ N
occasion NN N
. . N

However RB N
, , N
it PRP N
is VBZ N
not RB N
known VBN N
whether IN N
this DT N
can MD N
be VB N
done VBN N
accurately RB N
. . N

Therefore RB N
, , N
this DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
a DT N
prior JJ N
bronchial JJ N
provocation NN N
test NN N
on IN N
the DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB i
after IN N
spontaneous JJ N
recovery NN N
of IN N
the DT N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( o
FEV1 NNP o
) ) o
in IN N
a DT p
group NN p
of IN p
asthmatic JJ p
subjects NNS p
. . p

On IN N
two CD N
separate JJ N
occasions NNS N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
, , N
concentration-response JJ N
studies NNS N
with IN N
inhaled JJ N
histamine NN i
or CC i
methacholine NN i
, , i
or CC i
a DT i
sham JJ i
challenge NN i
with IN i
normal JJ i
saline NN i
were VBD N
carried VBN N
out RP N
in IN N
a DT N
blinded JJ N
, , N
randomized JJ N
manner NN N
. . N

Changes NNS N
in IN N
airway NN N
calibre NN N
were VBD N
followed VBN N
as IN N
FEV1 NNP o
and CC N
agonist JJ N
responsiveness NN N
expressed VBN N
as IN N
the DT N
provocative JJ N
concentration NN N
causing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP o
( ( N
PC20 NNP N
) ) N
. . N

After IN N
either DT N
spontaneous JJ N
recovery NN N
or CC N
a DT N
fixed-duration JJ N
wait NN N
of IN N
45 CD N
min NNS N
( ( N
when WRB N
appropriate NN N
) ) N
, , N
the DT N
subjects NNS N
received VBD N
2x100 CD N
microg NN N
of IN N
salbutamol NN i
from IN N
a DT N
metered VBN N
dose NN N
inhaler NN N
with IN N
a DT N
spacer NN N
. . N

The DT N
bronchodilator NN N
response NN N
to TO N
salbutamol VB N
was VBD N
expressed VBN N
as IN N
a DT N
percentage NN N
of IN N
initial JJ o
FEV1 NNP o
( ( N
deltaFEV1 CD N
% NN N
init NN N
) ) N
. . N

Bronchial JJ N
challenge NN N
with IN N
both DT N
agonists NNS N
failed VBD N
to TO N
alter VB N
significantly RB N
the DT N
airway NN o
response NN o
to TO N
salbutamol VB N
, , N
with IN N
the DT N
deltaFEV1 NN o
% NN o
init JJ o
mean JJ o
value NN o
( ( N
range NN N
) ) N
being VBG N
16.9 CD N
% NN N
( ( N
9.0-31.9 CD N
) ) N
and CC N
17.5 CD N
% NN N
( ( N
11.6-31.2 JJ N
) ) N
on IN N
the DT N
sham NN N
and CC N
histamine/methacholine JJ N
challenge NN N
day NN N
respectively RB N
. . N

It PRP N
was VBD N
shown VBN N
that IN N
the DT N
degree NN N
of IN N
bronchodilatation NN N
achieved VBN N
after IN N
salbutamol JJ N
200 CD N
microg NN N
is VBZ N
not RB N
affected VBN N
by IN N
prior JJ N
bronchoprovocation NN N
testing VBG N
when WRB N
enough JJ N
time NN N
is VBZ N
allowed VBN N
for IN N
the DT N
airways NNS N
to TO N
recover VB N
spontaneously RB N
to TO N
baseline VB N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
. . N

Thus NNP N
evaluation NN N
of IN N
airway NN N
responsiveness NN N
by IN N
both DT N
bronchial JJ N
provocation NN N
tests NNS N
and CC N
bronchodilator NN N
testing NN N
can MD N
be VB N
assessed VBN N
reliably RB N
within IN N
a DT N
few JJ N
hours NNS N
in IN N
asthmatic JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

Are NNP N
oral JJ N
cathartics NNS N
of IN N
value NN N
in IN N
optimizing VBG N
the DT N
gallium NN N
scan JJ N
? . N
Concise NNP N
communication NN N
. . N

The DT N
normal JJ N
intestinal JJ N
secretion NN N
of IN N
9-15 CD N
% NN N
of IN N
an DT N
administered VBN N
dose NN N
of IN N
gallium-67 NN i
may MD N
prevent VB N
early JJ N
detection NN N
of IN N
intra-abdominal JJ N
disease NN N
. . N

We PRP p
randomized VBD p
50 CD p
patients NNS p
to TO N
receive VB N
either DT N
no DT i
bowel NN i
preparation NN i
or CC i
30 CD i
cc NN i
of IN i
milk NN i
of IN i
magnesia JJ i
plus CC i
5 CD i
cc NN i
of IN i
cascara NN i
. . i

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
frequency NN o
with IN o
which WDT o
gallium NN o
interfered VBD o
with IN o
readings NNS o
or CC o
time NN o
to TO o
complete VB o
the DT o
study NN o
. . o

-DOCSTART- -X- O O

Brief JJ N
report NN N
: : N
case NN N
reports NNS N
on IN N
naltrexone NN i
use NN N
in IN N
children NNS p
with IN p
autism NN p
: : p
controlled VBN N
observations NNS N
regarding VBG N
benefits NNS o
and CC N
practical JJ o
issues NNS o
of IN N
medication NN N
management NN N
. . N

-DOCSTART- -X- O O

Design NN N
and CC N
methods NNS N
of IN N
a DT N
double JJ N
blind NN N
randomized VBD N
placebo-controlled JJ i
trial NN N
of IN N
extended-release JJ i
naltrexone NN i
for IN N
alcohol NN p
dependent NN p
and CC p
hazardous JJ p
drinking NN p
prisoners NNS p
with IN p
HIV NNP p
who WP p
are VBP p
transitioning VBG p
to TO p
the DT p
community NN p
. . p

BACKGROUND NNP N
HIV-infected JJ p
prisoners NNS p
have VBP p
a DT p
high JJ p
prevalence NN p
of IN p
alcohol NN p
use NN p
disorders NNS p
and CC p
commonly RB p
relapse NN o
to TO o
alcohol VB o
soon RB p
after IN p
release NN p
to TO p
the DT p
community NN p
which WDT p
is VBZ p
linked VBN p
to TO p
high JJ p
morbidity NN p
, , p
poor JJ p
antiretroviral JJ p
therapy NN p
( ( p
ART NNP p
) ) p
adherence NN p
and CC p
increased VBD p
sexual JJ p
risk-taking JJ p
behaviors NNS p
. . p

Extended-release NNP i
naltrexone NN i
( ( i
XR-NTX JJ i
) ) i
effectively RB N
reduces VBZ N
relapse NN o
to TO o
alcohol VB o
in IN N
alcohol NN N
dependent JJ N
persons NNS N
, , N
yet CC N
it PRP N
remains VBZ N
unexamined JJ N
among IN N
criminal JJ N
justice NN N
system NN N
( ( N
CJS NNP N
) ) N
populations NNS N
transitioning VBG N
to TO N
the DT N
community NN N
. . N

METHODS VB N
A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
XR-NTX NN i
to TO N
improve VB N
HIV NNP N
treatment NN N
outcomes NNS N
via IN N
reducing VBG N
relapse NN o
to TO o
alcohol VB o
use NN N
after IN N
prison NN N
release NN N
for IN N
HIV-infected NNP N
hazardous JJ N
drinking NN N
and CC N
alcohol NN p
dependent NN p
prisoners NNS p
is VBZ N
discussed VBN N
. . N

RESULTS NNP N
Acceptability NNP o
of IN N
study NN N
participation NN N
is VBZ N
high JJ N
with IN N
86 CD N
% NN N
of IN N
those DT N
referred VBN N
who WP N
met VBD N
eligibility NN N
criteria NNS N
and CC N
85 CD N
% NN N
of IN N
those DT N
who WP N
were VBD N
able JJ N
to TO N
receive VB N
injections NNS N
prior RB N
to TO N
release VB N
accepted JJ N
injections NNS N
, , N
yet RB N
important JJ N
implementation NN N
issues NNS N
are VBP N
identified VBN N
and CC N
addressed VBN N
during IN N
the DT N
study NN N
and CC N
are VBP N
discussed VBN N
in IN N
this DT N
paper NN N
. . N

CONCLUSION NNP N
Medication-assisted JJ N
therapies NNS N
for IN N
prevention NN N
of IN N
relapse NN N
to TO N
alcohol VB N
use NN N
for IN N
CJS NNP N
populations NNS N
transitioning VBG N
to TO N
the DT N
community NN N
, , N
especially RB N
for IN N
HIV-infected JJ p
patients NNS p
, , N
are VBP N
urgently RB N
needed VBN N
in IN N
order NN N
to TO N
reduce VB N
alcohol NN o
relapse NN o
after IN N
release NN N
and CC N
improve VB N
HIV NNP o
treatment NN o
outcomes NNS o
and CC N
contribute NN N
to TO N
improved VBN N
individual JJ o
and CC o
public JJ o
health NN o
. . o

-DOCSTART- -X- O O

Expectancies NNS N
, , N
not RB N
aroma RB N
, , N
explain JJ N
impact NN N
of IN N
lavender NN i
aromatherapy NN i
on IN N
psychophysiological JJ N
indices NNS N
of IN N
relaxation NN N
in IN N
young JJ p
healthy JJ p
women NNS p
. . p

OBJECTIVES NNP N
In IN N
aromatherapy NN i
, , i
lavender JJR i
aroma NN i
is VBZ N
reputed VBN N
to TO N
assist VB N
with IN N
relaxation NN N
. . N

However RB N
, , N
while IN N
there EX N
is VBZ N
much JJ N
anecdotal JJ N
evidence NN N
to TO N
that DT N
effect NN N
, , N
the DT N
empirical JJ N
literature NN N
is VBZ N
very RB N
inconsistent JJ N
. . N

Failure NN N
to TO N
employ VB N
adequate JJ N
placebos NNS i
, , N
proper JJ N
blinding NN N
, , N
objective JJ N
measures NNS N
, , N
or CC N
screening NN N
of IN N
prior JJ N
beliefs NNS N
about IN N
aromatherapy NN N
means NNS N
that IN N
many JJ N
previous JJ N
findings NNS N
could MD N
have VB N
been VBN N
influenced VBN N
by IN N
expectancy NN N
biases NNS N
. . N

The DT N
present JJ N
study NN N
sought VBD N
to TO N
establish VB N
whether IN N
lavender NN i
aroma NN i
and/or JJ N
expectancies NNS N
affect VBP N
post-stress JJ N
relaxation NN N
. . N

DESIGN VB N
A DT N
double-blind NN N
, , N
3 CD N
( ( N
aroma NN N
) ) N
x VBZ N
3 CD N
( ( N
instruction NN N
) ) N
x VBZ N
10 CD N
( ( N
time NN N
in IN N
minutes NNS N
) ) N
mixed-factorial JJ i
placebo-controlled JJ i
trial NN N
. . N

METHOD NNP N
In IN N
a DT N
laboratory NN N
, , N
96 CD p
healthy JJ p
undergraduate JJ p
women NNS p
were VBD N
exposed VBN i
to TO i
lavender VB i
, , i
placebo NN i
, , i
or CC i
no DT i
aroma NN i
during IN N
physiologically RB N
assessed VBN N
relaxation NN N
after IN N
an DT N
arousing VBG N
cognitive JJ i
task NN i
. . i

Where WRB N
an DT N
aroma NN N
was VBD N
presented VBN N
, , N
an DT N
instructional JJ N
priming NN N
procedure NN N
was VBD N
used VBN N
to TO N
manipulate VB N
participants NNS N
' POS N
expectancies NNS N
about IN N
the DT N
aroma NN N
's POS N
likely JJ N
impact NN N
on IN N
their PRP$ N
ability NN N
to TO N
relax VB N
. . N

RESULTS NNP N
Results NNP N
showed VBD N
no DT N
effect NN N
of IN N
aroma NN o
on IN o
galvanic JJ o
skin NN o
response NN o
during IN N
relaxation NN N
. . N

However RB N
, , N
the DT N
nature NN N
of IN N
instructional JJ N
prime NN N
was VBD N
associated VBN N
with IN N
relaxation NN o
patterns NNS o
: : o
when WRB N
expecting VBG N
the DT N
aroma NN N
to TO N
inhibit VB N
them PRP N
, , N
participants NNS N
relaxed VBD o
more RBR N
; : N
when WRB N
expecting VBG N
facilitation NN N
, , N
participants NNS N
relaxed VBD o
less RBR N
. . N

The DT N
effect NN N
was VBD N
not RB N
seen VBN N
with IN N
regard NN N
to TO N
self-reported JJ o
relaxation NN o
( ( N
as IN N
represented VBN N
by IN N
changes NNS N
in IN N
state NN N
anxiety NN N
) ) N
and CC N
was VBD N
independent JJ N
of IN N
ratings NNS N
of IN N
attitudes NNS o
towards NNS N
aromatherapy NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
imply VBP N
that IN N
the DT N
previous JJ N
associations NNS N
of IN N
lavender NN i
aroma NN i
with IN N
assisted JJ N
relaxation NN N
may MD N
have VB N
been VBN N
influenced VBN N
by IN N
expectancy NN N
biases NNS N
, , N
and CC N
that IN N
the DT N
relevant JJ N
expectancies NNS N
are VBP N
easily RB N
manipulable JJ N
. . N

-DOCSTART- -X- O O

Safety NN N
and CC N
possible JJ N
effects NNS N
of IN N
low-intensity NN i
resistance NN i
training NN i
associated VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
in IN N
polymyositis NN p
and CC p
dermatomyositis NN p
. . p

INTRODUCTION NNP N
Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
a DT N
low-intensity JJ i
resistance NN i
training NN i
program NN i
combined VBN N
with IN N
partial JJ N
blow NN N
flow NN N
restriction NN N
( ( N
BFR NNP N
training NN N
) ) N
in IN N
a DT N
cohort NN N
of IN N
patients NNS p
with IN p
polymyositis NN p
( ( p
PM NNP p
) ) p
and CC p
dermatomyositis NN p
( ( p
DM NNP p
) ) p
. . p

METHODS NNP N
In IN N
total JJ N
, , N
13 CD p
patients NNS p
with IN p
PM NNP p
and CC p
DM NNP p
completed VBD p
a DT N
12-week JJ N
twice NN N
a DT N
week NN N
low-intensity NN i
( ( i
that WDT i
is VBZ i
, , i
30 CD i
% NN i
one-repetition-maximum JJ i
( ( i
1RM CD i
) ) i
) ) i
resistance NN i
exercise NN i
training NN i
program NN i
combined VBN i
with IN i
partial JJ i
blood NN i
flow NN i
restriction NN i
( ( i
BFR NNP i
) ) i
. . i

Assessments NNS N
of IN N
muscle NN N
strength NN N
, , N
physical JJ N
function NN N
, , N
quadriceps NNS N
cross VBP N
sectional JJ N
( ( N
CSA NNP N
) ) N
area NN N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
clinical JJ N
and CC N
laboratory JJ N
parameters NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
the DT N
intervention NN N
. . N

RESULTS VB N
The DT N
BFR NNP i
training NN N
program NN N
was VBD N
effective JJ N
in IN N
increasing VBG N
the DT N
maximal JJ o
dynamic JJ o
strength NN o
in IN N
both DT N
the DT N
leg-press NN i
( ( N
19.6 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
knee-extension NN o
exercises NNS o
( ( N
25.2 CD N
% NN N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
as RB N
well RB N
as IN N
in IN N
the DT N
timed-stands NNS o
( ( N
15.1 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
timed-up-and-go JJ o
test NN o
( ( N
-4.5 CD N
% NN N
, , N
P NNP N
=0.002 NNP N
) ) N
. . N

Quadriceps NNP o
CSA NNP o
was VBD N
also RB N
significantly RB N
increased VBN N
after IN N
the DT N
intervention NN N
( ( N
4.57 CD N
% NN N
, , N
P NNP N
=0.01 NNP N
) ) N
. . N

Similarly RB N
, , N
all DT N
of IN N
the DT N
components NNS N
of IN N
the DT N
Short NNP o
Form-36 NNP o
Health NNP o
Survey NNP o
, , o
the DT o
Health NNP o
Assessment NNP o
Questionnaire NNP o
scores NNS o
, , o
and CC o
the DT o
patient- JJ o
and CC o
physician JJ o
reported VBD o
Visual NNP o
Analogue NNP o
Scale NNP o
were VBD N
significantly RB N
improved VBN N
after IN N
training NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Importantly RB N
, , N
no DT N
clinical JJ N
evidence NN N
or CC N
any DT N
other JJ N
self-reported JJ o
adverse JJ o
event NN N
were VBD N
found VBN N
. . N

Laboratory JJ o
parameters NNS o
( ( o
creatine JJ o
kinase NN o
and CC o
aldolase NN o
) ) o
were VBD N
also RB N
unchanged JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
after IN N
the DT N
intervention NN N
. . N

CONCLUSIONS NNP N
We PRP N
demonstrated VBD N
that IN N
a DT N
12-week JJ N
supervised JJ N
low-intensity NN i
resistance NN i
training NN i
program NN i
associated VBN N
with IN N
partial JJ N
blood NN N
flow NN N
restriction NN N
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
improving VBG N
muscle NN N
strength NN N
and CC N
function NN N
as RB N
well RB N
as IN N
muscle NN N
mass NN N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
in IN N
patients NNS p
with IN p
PM NNP p
and CC p
DM NNP p
. . p

TRIAL NNP N
REGISTRATION NNP N
Clinicaltrials.gov NNP N
NCT01501019 NNP N
. . N

Registered NNP N
November NNP N
29 CD N
, , N
2011 CD N
. . N

-DOCSTART- -X- O O

Primary JJ i
stenting NN i
of IN N
occluded JJ N
native JJ N
coronary JJ N
arteries NNS N
: : N
final JJ N
results NNS N
of IN N
the DT N
Primary NNP N
Stenting NNP N
of IN N
Occluded NNP p
Native NNP p
Coronary NNP p
Arteries NNP p
( ( p
PRISON NNP p
) ) p
study NN N
. . N

BACKGROUND NNP N
Primary NNP i
intracoronary JJ i
stent NN i
placement NN i
after IN N
successfully RB N
crossing VBG N
chronic JJ N
total JJ p
coronary JJ p
occlusions NNS p
may MD N
decrease VB N
the DT N
high JJ N
restenosis NN o
rate NN o
at IN N
long-term JJ N
follow-up JJ N
compared VBN N
with IN N
conventional JJ i
balloon NN i
angioplasty NN i
. . i

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
, , N
balloon NN i
angioplasty NN i
was VBD N
compared VBN N
with IN N
stent JJ i
implantation NN i
for IN N
the DT N
treatment NN N
of IN N
chronic JJ p
total JJ p
occlusions NNS p
. . p

Patients NNS N
were VBD N
followed VBN N
for IN N
12 CD N
months NNS N
with IN N
angiographic JJ N
follow-up NN N
at IN N
6 CD N
months NNS N
. . N

Quantitative JJ N
coronary JJ N
analysis NN N
was VBD N
performed VBN N
by IN N
an DT N
independent JJ N
core NN N
lab NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
200 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

Baseline JJ N
characteristics NNS N
were VBD N
evenly RB N
distributed VBN N
. . N

After IN N
the DT N
procedure NN N
the DT N
mean NN o
minimal JJ o
luminal JJ o
diameter NN o
in IN N
the DT N
conventional JJ i
group NN N
was VBD N
2.34 CD N
+/- JJ N
0.46 CD N
mm NN N
versus NN N
2.90 CD N
+/- JJ N
0.41 CD N
mm NN N
in IN N
the DT N
stented VBN i
group NN N
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
6-month JJ N
angiographic JJ N
follow-up NN N
showed VBD N
a DT N
mean JJ o
minimal JJ o
luminal JJ o
diameter NN o
of IN N
1.57 CD N
+/- JJ N
0.74 CD N
mm NN N
in IN N
the DT N
conventional JJ N
group NN N
versus VBD N
1.93 CD N
+/- JJ N
0.85 CD N
mm NN N
in IN N
the DT N
stented VBN N
group NN N
( ( N
P NNP N
=.009 NNP N
) ) N
and CC N
a DT N
mean JJ o
diameter NN o
stenosis NN o
of IN N
44.7 CD N
% NN N
+/- JJ N
25.0 CD N
% NN N
versus IN N
35.5 CD N
% NN N
+/- JJ N
26.5 CD N
% NN N
( ( N
P NNP N
=.036 NNP N
) ) N
. . N

Binary JJ o
angiographic JJ o
restenosis NN o
( ( N
> JJ N
50 CD N
% NN N
diameter JJ N
stenosis NN N
) ) N
was VBD N
seen VBN N
in IN N
33 CD N
% NN N
in IN N
the DT N
conventional JJ N
group NN N
versus VBD N
22 CD N
% NN N
in IN N
the DT N
stented VBN i
group NN N
( ( N
P NNP N
=.137 NNP N
) ) N
. . N

The DT N
reocclusion NN o
rates NNS o
were VBD N
7.3 CD N
% NN N
and CC N
8.2 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
1.00 CD N
) ) N
. . N

At IN N
12 CD N
month NN N
follow-up NN N
, , N
the DT N
rate NN o
of IN o
target NN o
lesion NN o
revascularization NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
conventional JJ i
group NN N
( ( N
29 CD N
% NN N
versus IN N
13 CD N
% NN N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

CONCLUSION NNP N
These DT N
data NNS N
demonstrate NN N
that IN N
stenting VBG i
of IN N
chronic JJ p
total JJ p
occlusions NNS p
is VBZ N
superior JJ N
to TO N
balloon VB i
angioplasty JJ i
alone RB i
with IN N
a DT N
statistically RB N
significant JJ N
reduction NN N
in IN N
the DT N
need NN N
for IN N
target NN o
lesion NN o
revascularization NN o
and CC N
a DT N
lower JJR N
, , N
but CC N
not RB N
significant JJ N
, , N
restenosis NN o
rate NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
aspirin NN i
and CC N
clopidogrel NN i
in IN N
healthy JJ p
men NNS p
measured VBN N
by IN N
platelet NN N
aggregation NN N
and CC N
PFA-100 NNP N
. . N

There EX N
are VBP N
no DT N
generally RB N
accepted VBN N
definitions NNS N
for IN N
low-response NN N
( ( N
frequently RB N
called VBN N
resistance NN N
) ) N
to TO N
the DT N
platelet NN N
inhibitors NNS N
, , N
aspirin NN i
and CC N
clopidogrel NN i
. . i

Low-response NN N
may MD N
increase VB N
the DT N
risk NN N
of IN N
cardiovascular JJ N
events NNS N
in IN N
atherosclerotic JJ p
patients NNS p
. . p

We PRP N
aimed VBD N
to TO N
define VB N
the DT N
normal JJ N
drug NN N
responses NNS N
in IN N
healthy JJ p
men NNS p
. . p

Platelet NNP N
function NN N
was VBD N
measured VBN N
in IN N
20 CD p
healthy JJ p
men NNS p
during IN N
11 CD N
days NNS N
of IN N
aspirin NN i
or CC i
clopidogrel NN i
intake NN N
, , N
using VBG N
light JJ N
transmission NN N
aggregometry NN N
( ( N
LTA NNP N
) ) N
and CC N
the DT N
Platelet NNP N
Function NNP N
Analyzer NNP N
100 CD N
( ( N
PFA-100 NNP N
) ) N
. . N

The DT N
lower JJR N
limits NNS N
for IN N
LTA NNP N
at IN N
baseline NN N
were VBD N
64 CD N
% NN N
and CC N
61 CD N
% NN N
, , N
using VBG N
arachidonic JJ N
acid NN N
and CC N
ADP NNP N
as IN N
agonists NNS N
, , N
respectively RB N
. . N

During IN N
aspirin JJ i
intake VBP N
the DT N
LTA NNP o
results NNS o
were VBD N
stable JJ N
from IN N
day NN N
to TO N
day NN N
, , N
and CC N
an DT N
upper JJ N
limit NN N
of IN N
9 CD N
% NN N
arachidonic JJ o
acid NN o
stimulated VBD o
aggregation NN o
was VBD N
found VBN N
. . N

Clopidogrel NNP o
intake NN o
was VBD N
best RBS N
shown VBN N
by IN N
ADP NNP N
induced JJ N
aggregation NN N
. . N

However RB N
, , N
two CD N
out IN N
of IN N
20 CD N
individuals NNS N
exhibited VBD N
low-response NN o
to TO o
clopidogrel VB o
. . o

In IN N
the DT N
remaining VBG N
18 CD N
volunteers NNS N
an DT N
upper JJ N
limit NN N
of IN N
48 CD N
% NN N
aggregation NN N
was VBD N
found VBN N
. . N

We PRP N
found VBD N
an DT N
upper JJ N
limit NN N
for IN N
collagen-epinephrine JJ o
stimulated JJ o
PFA-100 JJ o
results NNS o
of IN N
166 CD N
s NNS N
at IN N
baseline NN N
. . N

During IN N
aspirin JJ i
intake NN N
, , N
these DT N
results NNS N
varied VBD N
considerably RB N
from IN N
day NN N
to TO N
day NN N
in IN N
nine CD N
out IN N
of IN N
20 CD p
men NNS p
, , N
resulting VBG N
in IN N
an DT N
overlap NN N
between IN N
the DT N
reference NN N
ranges VBZ N
at IN N
baseline NN N
and CC N
during IN N
therapy NN N
. . N

In IN N
conclusion NN N
, , N
platelet NN o
inhibition NN o
by IN o
aspirin NN o
and CC o
clopidogrel NN o
assessed VBN o
by IN o
aggregometry NN o
was VBD N
stable JJ N
during IN N
11 CD N
days NNS N
of IN N
treatment NN N
and CC N
reference NN N
ranges NNS N
were VBD N
established VBN N
. . N

The DT N
PFA-100 JJ N
results NNS N
varied VBD N
greatly RB N
and CC N
low-response NN N
was VBD N
not RB N
precisely RB N
defined VBN N
by IN N
this DT N
method NN N
. . N

-DOCSTART- -X- O O

A DT N
multifactorial JJ N
strategy NN N
of IN N
pain NN N
management NN N
is VBZ N
associated VBN N
with IN N
less JJR N
pain NN N
in IN N
scheduled JJ p
vaccination NN p
of IN N
children NNS p
. . p

A DT N
study NN N
realized VBN N
by IN N
family NN N
practitioners NNS N
in IN p
239 CD p
children NNS p
aged VBN p
4-12 CD p
years NNS p
old JJ p
. . p

BACKGROUND NNP N
AND CC N
AIMS NNP N
The DT N
multiplicity NN N
of IN N
vaccine JJ N
injections NNS N
during IN N
childhood NN N
leads NNS N
to TO N
iterative VB N
painful JJ N
and CC N
stressful JJ N
experiences NNS N
which WDT N
may MD N
lead VB N
in IN N
turn NN N
to TO N
anticipated VBN N
pain NN N
and CC N
then RB N
possibly RB N
to TO N
a DT N
true JJ N
needle JJ N
phobia NN N
. . N

We PRP N
aimed VBD N
at IN N
evaluating VBG N
a DT N
multifactorial JJ N
strategy NN N
of IN N
pain NN N
management NN N
combining VBG N
pharmacological JJ N
and CC N
non-pharmacological JJ N
approaches NNS N
during IN N
vaccination NN N
, , N
as IN N
compared VBN N
to TO N
usual JJ N
care NN N
, , N
in IN p
4- JJ p
to TO p
12-year-old JJ p
children NNS p
. . p

METHODS NNP N
In IN N
all DT N
, , N
239 CD p
children NNS p
were VBD p
enrolled VBN p
by IN p
25 CD p
family NN p
practitioners NNS p
in IN N
an DT N
open-label JJ N
study NN N
. . N

After IN N
a DT N
pseudo-randomization NN N
, , N
usual JJ i
pain NN i
management NN i
( ( i
n JJ i
= NNP i
132 CD i
) ) i
was VBD i
compared VBN i
to TO i
a DT i
multifactorial JJ i
strategy NN i
( ( i
n JJ i
= NNP i
107 CD i
) ) i
associating VBG i
preliminary JJ i
application NN i
of IN i
an DT i
anesthesic JJ i
patch NN i
, , i
preferential JJ i
use NN i
of IN i
specified JJ i
vaccines NNS i
, , i
child JJ i
education NN i
by IN i
the DT i
parents NNS i
and CC i
the DT i
doctor NN i
, , i
parental JJ i
accompaniment NN i
and CC i
child JJ i
distraction NN i
with IN i
soap NN i
bubbles NNS i
during IN i
the DT i
procedure NN i
. . i

The DT N
primary JJ N
outcome NN N
( ( N
i.e JJ N
. . N

child VB o
pain NN o
) ) o
was VBD N
assessed VBN N
with IN N
a DT N
self-report JJ o
scale NN o
named VBN o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
of IN o
pain NN o
. . o

RESULTS VB N
A DT N
significant JJ N
decrease NN N
in IN N
pain NN o
was VBD N
obtained VBN N
using VBG N
the DT N
multifactorial JJ N
strategy NN N
, , N
as IN N
assessed VBN N
by IN N
self-reported JJ N
VAS NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

This DT N
was VBD N
confirmed VBN N
by IN N
another DT N
self-report JJ N
scale NN N
( ( N
the DT N
facial NN o
pain NN o
scale NN o
revised VBN N
: : N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
as RB N
well RB N
as IN N
with IN N
hetero-evaluations NNS N
by IN N
GPs NNP N
and CC N
parents NNS N
[ VBP o
Children NNP o
's POS o
Hospital NNP o
of IN o
Eastern NNP o
Ontario NNP o
Pain NNP o
Scale NNP o
: : o
P NNP N
= VBZ N
0.0007 CD N
; : N
GPs NNP N
VAS NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
parents NNS o
VAS NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
] NN N
, , N
which WDT N
were VBD N
secondary JJ N
outcome NN N
criteria NNS N
. . N

CONCLUSIONS VB N
This DT N
multifactorial JJ N
method NN N
significantly RB N
decreases VBZ N
vaccination NN N
pain NN o
in IN N
4- JJ p
to TO p
12-year-old JJ p
children NNS p
. . p

This DT N
strategy NN N
could MD N
make VB N
vaccines NNS N
more RBR N
acceptable JJ N
to TO N
children NNS p
and CC N
may MD N
improve VB N
child-doctor NN N
relationships NNS N
and CC N
contribute NN N
to TO N
a DT N
decrease NN N
in IN N
child JJ N
fear VBP N
about IN N
health NN N
care NN N
. . N

-DOCSTART- -X- O O

Anthropometric JJ N
indices NNS N
of IN N
Gambian JJ p
children NNS p
after IN N
one CD N
or CC N
three CD N
annual JJ N
rounds NNS N
of IN N
mass JJ i
drug NN i
administration NN i
with IN N
azithromycin NN i
for IN N
trachoma NN p
control NN N
. . N

BACKGROUND NNP N
Mass NNP N
drug NN N
administration NN N
( ( N
MDA NNP N
) ) N
with IN N
azithromycin NN i
, , N
carried VBD N
out RP N
for IN N
the DT N
control NN N
of IN N
blinding VBG N
trachoma NN N
, , N
has VBZ N
been VBN N
linked VBN N
to TO N
reduced VBN N
mortality NN N
in IN N
children NNS p
. . p

While IN N
the DT N
mechanism NN N
behind IN N
this DT N
reduction NN N
is VBZ N
unclear JJ N
, , N
it PRP N
may MD N
be VB N
due JJ N
, , N
in IN N
part NN N
, , N
to TO N
improved VBN N
nutritional JJ N
status NN N
via IN N
a DT N
potential JJ N
reduction NN N
in IN N
the DT N
community NN N
burden NN N
of IN N
infectious JJ N
disease NN N
. . N

To TO N
determine VB N
whether IN N
MDA NNP i
with IN i
azithromycin JJ i
improves NNS N
anthropometric JJ N
indices NNS N
at IN N
the DT N
community NN N
level NN N
, , N
we PRP N
measured VBD N
the DT N
heights NNS o
and CC o
weights NNS o
of IN N
children NNS p
aged VBN p
1 CD p
to TO p
4 CD p
years NNS p
in IN p
communities NNS p
where WRB p
one CD p
( ( p
single JJ p
MDA NNP p
arm NN p
) ) p
or CC p
three CD p
annual JJ p
rounds NNS p
( ( p
annual JJ p
MDA NNP p
arm NN p
) ) p
of IN p
azithromycin NN i
had VBD N
been VBN N
distributed VBN N
. . N

METHODS NNP N
Data NNP N
collection NN N
took VBD N
place NN N
three CD N
years NNS N
after IN N
treatment NN N
in IN N
the DT N
single JJ N
MDA NNP N
arm NN N
and CC N
one CD N
year NN N
after IN N
the DT N
final JJ N
round NN N
of IN N
treatment NN N
in IN N
the DT N
annual JJ N
MDA NNP N
arm NN N
. . N

Mean JJ o
height-for-age NN o
, , o
weight-for-age NN o
and CC o
weight-for-height JJ o
z NN o
scores NNS o
were VBD N
compared VBN N
between IN N
treatment NN N
arms NNS N
. . N

RESULTS NNP N
No NNP N
significant JJ o
differences NNS o
in IN N
mean JJ o
height-for-age NN o
, , o
weight-for-age NN o
or CC o
weight-for-height JJ o
z NN o
scores NNS o
were VBD N
found VBN N
between IN N
the DT N
annual JJ N
MDA NNP N
and CC N
single JJ N
MDA NNP N
arms NNS N
, , N
nor CC N
was VBD N
there EX N
a DT N
significant JJ o
reduction NN o
in IN N
prevalence NN o
of IN o
stunting NN o
, , o
wasting VBG o
or CC o
underweight JJ o
between IN N
arms NNS N
. . N

CONCLUSIONS VB N
Our PRP$ N
data NNS N
do VBP N
not RB N
provide VB N
evidence NN N
that IN N
community NN N
MDA NNP i
with IN i
azithromycin NN i
improved VBN N
anthropometric JJ o
outcomes NNS o
of IN N
children NNS p
in IN p
The DT p
Gambia NNP p
. . p

This DT N
may MD N
suggest VB N
reductions NNS N
in IN N
mortality NN N
associated VBN N
with IN N
azithromycin JJ i
MDA NNP i
are VBP N
due JJ N
to TO N
a DT N
mechanism NN N
other JJ N
than IN N
improved JJ N
nutritional JJ N
status NN N
. . N

-DOCSTART- -X- O O

Propranolol NNP i
vs NN i
acetazolamide NN i
. . i

A DT p
long-term JJ p
double-masked JJ p
study NN p
of IN p
the DT p
effect NN p
on IN p
intraocular JJ o
pressure NN o
and CC o
blood NN o
pressure NN o
. . o

-DOCSTART- -X- O O

An DT N
empirical JJ N
comparison NN N
of IN N
the DT N
St NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
and CC N
the DT N
Chronic NNP N
Respiratory NNP N
Disease NNP N
Questionnaire NNP N
( ( N
CRQ NNP N
) ) N
in IN N
a DT N
clinical JJ N
trial NN N
setting NN N
. . N

BACKGROUND IN N
The DT N
Chronic NNP N
Respiratory NNP N
Questionnaire NNP N
( ( N
CRQ NNP N
) ) N
and CC N
the DT N
St NNP N
George NNP N
's POS N
Respiratory NNP N
Questionnaire NNP N
( ( N
SGRQ NNP N
) ) N
are VBP N
the DT N
two CD N
most JJS N
widely RB N
used VBN N
quality NN N
of IN N
life NN N
questionnaires NNS N
in IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( p
COPD NNP p
) ) p
. . p

A DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
directly RB N
the DT N
self-administered JJ N
version NN N
of IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
with IN N
respect NN N
to TO N
feasibility NN N
, , N
internal JJ N
consistency NN N
, , N
validity NN N
, , N
and CC N
sensitivity NN N
to TO N
changes NNS N
resulting VBG N
from IN N
bronchodilator NN N
therapy NN N
. . N

METHODS NNP N
One CD p
hundred CD p
and CC p
forty VB p
four CD p
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
COPD NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
three CD N
months NNS N
of IN N
treatment NN N
with IN N
either DT N
salmeterol NN i
, , i
salmeterol NN i
+ NNP i
ipratropium NN i
bromide NN i
, , i
or CC i
placebo NN i
. . i

Quality NN o
of IN o
life NN o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS VB N
The DT N
proportions NNS o
of IN o
missing VBG o
values NNS o
per IN N
patient NN N
were VBD N
low JJ N
for IN N
both DT N
questionnaires NNS N
( ( N
0.54 CD N
% NN N
for IN N
the DT N
CRQ NNP N
and CC N
2 CD N
% NN N
for IN N
the DT N
SGRQ NNP N
) ) N
. . N

The DT N
internal JJ o
consistency NN o
was VBD N
good JJ N
for IN N
both DT N
questionnaires NNS N
( ( N
Cronbach NNP N
's POS N
alpha NN N
coefficients NNS N
> VBP N
/= $ N
0.84 CD N
for IN N
the DT N
CRQ NNP N
and CC N
> NNP N
/= NNP N
0.76 CD N
for IN N
the DT N
SGRQ NNP N
) ) N
. . N

Factor NNP N
analysis NN N
confirmed VBD N
the DT N
original JJ N
domain NN N
structure NN N
of IN N
the DT N
CRQ NNP N
but CC N
not RB N
of IN N
the DT N
SGRQ NNP N
. . N

Correlations NNS N
with IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
one CD N
second NN N
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
% NN o
predicted VBN N
and CC N
peak JJ o
expiratory NN o
flow NN o
rate NN o
( ( o
PEFR NNP o
) ) o
were VBD N
low JJ N
for IN N
both DT N
questionnaires NNS N
but CC N
better JJR N
for IN N
the DT N
SGRQ NNP N
than IN N
for IN N
the DT N
CRQ NNP N
. . N

The DT N
ability NN N
to TO N
discriminate VB N
between IN N
subjects NNS N
with IN N
different JJ N
levels NNS N
of IN N
FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
somewhat RB N
better JJR N
for IN N
the DT N
SGRQ NNP N
. . N

The DT N
correlations NNS N
with IN N
symptom JJ N
scores NNS N
were VBD N
comparable JJ N
for IN N
both DT N
questionnaires NNS N
. . N

Cross NNP N
sectionally RB N
, , N
the DT N
scores NNS N
of IN N
the DT N
two CD N
questionnaires NNS N
were VBD N
moderately RB N
to TO N
highly RB N
correlated VBN N
( ( N
coefficients NNS N
ranged VBD N
from IN N
0.35 CD N
to TO N
0.72 CD N
) ) N
. . N

Longitudinally RB N
, , N
these DT N
correlations NNS N
were VBD N
lower JJR N
( ( N
coefficients NNS N
ranged VBD N
from IN N
0.17 CD N
to TO N
0.54 CD N
) ) N
but CC N
were VBD N
still RB N
significant JJ N
. . N

The DT N
CRQ NNP o
total NN o
and CC o
emotions NNS o
score NN o
and CC o
the DT o
SGRQ NNP o
symptoms NNS o
score NN o
were VBD N
the DT N
most RBS N
responsive JJ N
to TO N
change VB N
. . N

The DT N
SGRQ NNP o
symptoms NNS o
domain NN o
was VBD N
the DT N
only JJ N
domain NN N
where WRB N
the DT N
improvement NN N
in IN N
patients NNS p
receiving VBG p
combination NN p
treatment NN p
crossed VBD N
the DT N
threshold NN N
for IN N
clinical JJ N
relevance NN N
. . N

CONCLUSIONS NNP N
Since IN N
this DT N
analysis NN N
of IN N
reliability NN N
, , N
validity NN N
, , N
and CC N
responsiveness NN N
to TO N
change VB N
did VBD N
not RB N
clearly RB N
favour VBP N
one CD N
instrument NN N
above IN N
the DT N
other JJ N
, , N
the DT N
choice NN N
between IN N
the DT N
CRQ NNP N
and CC N
the DT N
SGRQ NNP N
can MD N
be VB N
based VBN N
on IN N
other JJ N
considerations NNS N
such JJ N
as IN N
the DT N
required JJ N
sample NN N
size NN N
or CC N
the DT N
availability NN N
of IN N
reference NN N
values NNS N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
infusion NN p
time NN p
on IN N
the DT N
acute JJ o
toxicity NN o
of IN o
amphotericin NN o
B NNP o
: : o
results NNS N
of IN N
a DT N
randomized JJ N
double-blind NN N
study NN N
. . N

-DOCSTART- -X- O O

Levels NNS N
of IN N
recombinant JJ o
human JJ o
granulocyte NN o
colony-stimulating NN o
factor NN o
in IN N
serum NN N
are VBP N
inversely RB N
correlated VBN N
with IN N
circulating VBG N
neutrophil JJ N
counts NNS N
. . N

Recombinant NNP i
human JJ i
granulocyte NN i
colony-stimulating NN i
factor NN i
( ( i
rhG-CSF NN i
) ) i
is VBZ N
effective JJ N
in IN N
countering VBG N
chemotherapy-induced JJ N
neutropenia NN N
. . N

However RB N
, , N
serum JJ o
rhG-CSF NN o
levels NNS o
can MD N
not RB N
be VB N
maintained VBN N
throughout IN N
the DT N
course NN N
of IN N
rhG-CSF JJ i
therapy NN i
. . i

The DT N
drop NN N
in IN N
serum JJ o
rhG-CSF JJ o
levels NNS o
may MD N
vary VB N
with IN N
the DT N
duration NN N
of IN N
rhG-CSF JJ i
administration NN N
or CC N
with IN N
the DT N
circulating VBG N
neutrophil JJ N
counts NNS N
. . N

We PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
serum JJ o
G-CSF NNP o
levels NNS o
and CC N
circulating VBG o
neutrophil JJ o
counts NNS o
and CC N
the DT N
pharmacokinetics NNS N
of IN N
rhG-CSF NN N
for IN N
patients NNS p
with IN p
lung NN p
cancer NN p
who WP p
had VBD p
been VBN p
treated VBN p
with IN p
myelosuppressive JJ p
chemotherapy NN p
and CC p
then RB p
with IN p
subcutaneous JJ p
rhG-CSF NN i
( ( p
lenograstim NN p
, , p
2 CD p
micrograms NNS p
per IN p
kg NN p
of IN p
body NN p
weight JJ p
per IN p
day NN p
) ) p
. . p

Twelve CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
four CD N
groups NNS N
with IN N
different JJ N
rhG-CSF JJ i
therapy NN i
schedules NNS i
. . i

Serum NNP o
G-CSF JJ o
levels NNS o
were VBD N
measured VBN N
by IN N
an DT N
enzyme JJ N
immunoassay NN N
method NN N
. . N

Serum NNP o
G-CSF NNP o
levels NNS o
during IN N
the DT N
rhG-CSF JJ i
therapy NN i
greatly RB N
exceeded VBD N
endogenous JJ o
G-CSF NNP o
levels NNS o
and CC N
were VBD N
mainly RB N
due JJ N
to TO N
the DT N
presence NN N
of IN N
exogenous JJ N
rhG-CSF NN i
rather RB N
than IN N
increased VBN N
levels NNS N
of IN N
endogenous JJ N
G-CSF NNP N
. . N

Despite IN N
the DT N
duration NN N
of IN N
rhG-CSF JJ i
administration NN N
, , N
serum JJ o
G-CSF NNP o
levels NNS o
during IN N
rhG-CSF JJ i
therapy NN i
were VBD N
inversely RB N
correlated VBN N
with IN N
circulating VBG N
neutrophil JJ N
counts NNS N
( ( N
r2 VB N
= RB N
0.73 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
value NN N
for IN N
the DT N
area NN N
under IN N
the DT N
concentration-time JJ o
curve NN o
of IN N
rhG-CSF NN o
on IN N
the DT N
day NN N
of IN N
neutrophilia NN N
was VBD N
lower JJR N
than IN N
that DT N
on IN N
the DT N
day NN N
of IN N
neutropenia NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
the DT N
fall NN N
in IN N
serum JJ o
G-CSF NNP o
levels NNS o
during IN N
rhG-CSF JJ i
therapy NN i
may MD N
result VB N
from IN N
increased VBN N
clearance NN N
and/or NN N
decreased VBD N
absorption NN N
of IN N
rhG-CSF NN i
, , N
two CD N
processes NNS N
related VBN N
to TO N
circulating VBG N
neutrophil JJ N
counts NNS N
. . N

-DOCSTART- -X- O O

Measuring VBG p
the DT p
impact NN p
of IN p
patient JJ i
counseling NN i
in IN p
the DT p
outpatient JJ p
pharmacy NN p
setting NN p
: : p
the DT p
research NN p
design NN p
of IN p
the DT p
Kaiser NNP p
Permanente/USC NNP p
patient NN p
consultation NN p
study NN p
. . p

This DT N
article NN N
describes VBZ N
the DT N
research NN N
method NN N
used VBN N
to TO N
measure VB N
the DT N
impact NN N
of IN N
three CD N
alternative JJ N
models NNS N
of IN N
patient JJ i
counseling NN i
in IN N
the DT N
outpatient JJ p
pharmacy NN p
setting VBG p
. . p

The DT p
study NN p
was VBD p
conducted VBN p
in IN p
pharmacies NNS p
operated VBN p
by IN p
the DT p
Southern NNP p
California NNP p
region NN p
Kaiser NNP p
Permanente NNP p
Medical NNP p
Care NNP p
Program NNP p
. . p

Both DT N
random JJ N
assignment NN N
and CC N
large-scale JJ N
geographic JJ N
area NN N
research NN N
designs NNS N
were VBD N
used VBN N
. . N

The DT N
presentation NN N
of IN N
the DT N
research NN N
design NN N
includes VBZ N
discussions NNS N
of IN N
data NNS N
collection NN N
and CC N
patient JJ N
sampling VBG N
methods NNS N
; : N
the DT N
measurement NN N
of IN N
patient JJ o
outcomes NNS o
, , N
including VBG N
measures NNS o
of IN o
health NN o
care NN o
costs NNS o
and CC o
utilization NN o
, , o
patient JJ o
functional JJ o
status NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

Demographic NNP N
data NNS N
are VBP N
presented VBN N
for IN N
the DT N
study NN N
population NN N
, , N
including VBG N
an DT N
analysis NN N
of IN N
potential JJ N
biased JJ N
selection NN N
of IN N
patients NNS N
electing VBG N
to TO N
participate VB N
in IN N
random JJ N
assignment NN N
. . N

Data NNS N
are VBP N
also RB N
presented VBN N
documenting VBG N
potential JJ N
selection NN N
bias NN N
across IN N
geographically RB N
determined VBN N
treatment NN N
groups NNS N
in IN N
the DT N
geographic JJ N
area NN N
design NN N
arm NN N
. . N

Finally RB N
, , N
the DT N
article NN N
presents VBZ N
the DT N
analysis NN N
plan NN N
for IN N
the DT N
study NN N
and CC N
discusses NNS N
study VBP N
limitations NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
a DT N
carbohydrate-protein JJ i
supplement NN i
on IN N
endurance NN o
performance NN o
during IN N
exercise NN N
of IN N
varying VBG N
intensity NN N
. . N

Increasing VBG N
the DT N
plasma NN N
glucose NN N
and CC N
insulin NN N
concentrations NNS N
during IN N
prolonged JJ N
variable JJ N
intensity NN N
exercise NN N
by IN N
supplementing VBG N
with IN N
carbohydrate NN N
has VBZ N
been VBN N
found VBN N
to TO N
spare VB N
muscle NN N
glycogen NN N
and CC N
increase VB N
aerobic JJ o
endurance NN o
. . o

Furthermore RB N
, , N
the DT N
addition NN N
of IN N
protein NN i
to TO i
a DT i
carbohydrate NN i
supplement NN i
will MD N
enhance VB N
the DT N
insulin NN N
response NN N
of IN N
a DT N
carbohydrate JJ N
supplement NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
carbohydrate NN i
and CC N
a DT N
carbohydrate-protein JJ i
supplement NN i
on IN N
aerobic JJ o
endurance NN o
performance NN o
. . o

Nine NNP p
trained JJ p
cyclists NNS p
exercised VBD N
on IN N
3 CD N
separate JJ N
occasions NNS N
at IN N
intensities NNS N
that WDT N
varied VBD N
between IN N
45 CD N
% NN N
and CC N
75 CD N
% NN N
VO2max NNP N
for IN N
3 CD N
h NN N
and CC N
then RB N
at IN N
85 CD N
% NN N
VO2max NNP N
until IN N
fatigued VBN N
. . N

Supplements NNS i
( ( i
200 CD i
ml NN i
) ) i
were VBD i
provided VBN i
every DT i
20 CD i
min NN i
and CC i
consisted VBN i
of IN i
placebo NN i
, , i
a DT i
7.75 CD i
% NN i
carbohydrate JJ i
solution NN i
, , i
and CC i
a DT i
7.75 CD i
% NN i
carbohydrate/1.94 NN i
% NN i
protein JJ i
solution NN i
. . i

Treatments NNS N
were VBD N
administered VBN N
using VBG N
a DT N
double-blind JJ N
randomized JJ N
design NN N
. . N

Carbohydrate NNP N
supplementation NN N
significantly RB N
increased VBD N
time NN o
to TO o
exhaustion NN o
( ( N
carbohydrate JJ N
19.7 CD N
+/- JJ N
4.6 CD N
min NN N
vs. FW N
placebo NN N
12.7 CD N
+/- JJ N
3.1 CD N
min NN N
) ) N
, , N
while IN N
the DT N
addition NN N
of IN N
protein NN N
enhanced VBD N
the DT N
effect NN N
of IN N
the DT N
carbohydrate NN N
supplement NN N
( ( N
carbohydrate-protein JJ N
26.9 CD N
+/- JJ N
4.5 CD N
min NN N
, , N
p NN N
< NNP N
.05 NNP N
) ) N
. . N

Blood NNP o
glucose NN o
and CC o
plasma JJ o
insulin NN o
levels NNS o
were VBD N
elevated VBN N
above IN N
placebo NN N
during IN N
carbohydrate NN i
and CC N
carbohydrate-protein JJ i
supplementation NN i
, , N
but CC N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
carbohydrate NN N
and CC N
carbohydrate-protein JJ i
treatments NNS N
. . N

In IN N
summary JJ N
, , N
we PRP N
found VBD N
that IN N
the DT N
addition NN N
of IN N
protein NN N
to TO N
a DT N
carbohydrate NN i
supplement NN i
enhanced VBD N
aerobic JJ o
endurance NN o
performance NN o
above IN N
that DT N
which WDT N
occurred VBD N
with IN N
carbohydrate NN N
alone RB N
, , N
but CC N
the DT N
reason NN N
for IN N
this DT N
improvement NN N
in IN N
performance NN N
was VBD N
not RB N
evident JJ N
. . N

-DOCSTART- -X- O O

Detection NN p
and CC p
quantification NN p
of IN p
the DT p
solid JJ p
component NN p
in IN p
pulmonary JJ p
subsolid JJ p
nodules NNS p
by IN p
semiautomatic JJ i
segmentation NN i
. . i

OBJECTIVE UH N
To TO N
determine VB N
whether IN N
semiautomatic JJ i
volumetric NNS i
software NN i
can MD N
differentiate VB N
part-solid JJ N
from IN N
nonsolid JJ N
pulmonary JJ N
nodules NNS N
and CC N
aid JJ N
quantification NN N
of IN N
the DT N
solid JJ N
component NN N
. . N

METHODS NNP N
As IN N
per IN N
reference NN N
standard NN N
, , N
115 CD p
nodules NNS p
were VBD N
differentiated VBN N
into IN N
nonsolid JJ N
and CC N
part-solid JJ N
by IN N
two CD N
radiologists NNS N
; : N
disagreements NNS N
were VBD N
adjudicated VBN N
by IN N
a DT N
third JJ N
radiologist NN N
. . N

The DT N
diameters NNS N
of IN N
solid JJ N
components NNS N
were VBD N
measured VBN N
manually RB N
. . N

Semiautomatic JJ N
volumetric JJ N
measurements NNS N
were VBD N
used VBN N
to TO N
identify VB N
and CC N
quantify VB N
a DT N
possible JJ N
solid JJ N
component NN N
, , N
using VBG N
different JJ N
Hounsfield NNP N
unit NN N
( ( N
HU NNP N
) ) N
thresholds NNS N
. . N

The DT N
measurements NNS N
were VBD N
compared VBN N
with IN N
the DT N
reference NN N
standard NN N
and CC N
manual JJ N
measurements NNS N
. . N

RESULTS VB N
The DT N
reference NN N
standard NN N
detected VBD N
a DT N
solid JJ N
component NN N
in IN N
86 CD N
nodules NNS N
. . N

Diagnosis NN N
of IN N
a DT N
solid JJ N
component NN N
by IN N
semiautomatic JJ N
software NN N
depended VBN N
on IN N
the DT N
threshold JJ N
chosen NN N
. . N

A DT N
threshold NN N
of IN N
-300 NNP N
HU NNP N
resulted VBD N
in IN N
the DT N
detection NN o
of IN o
a DT o
solid JJ o
component NN o
in IN N
75 CD N
nodules NNS N
with IN N
good JJ N
sensitivity NN N
( ( N
90 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
88 CD N
% NN N
) ) N
. . N

At IN N
a DT N
threshold NN N
of IN N
-130 NNP N
HU NNP N
, , N
semiautomatic JJ N
measurements NNS N
of IN N
the DT N
diameter NN N
of IN N
the DT N
solid JJ o
component NN o
( ( N
mean JJ N
2.4 CD N
mm NN N
, , N
SD NNP N
2.7 CD N
mm NN N
) ) N
were VBD N
comparable JJ N
to TO N
manual JJ N
measurements NNS N
at IN N
the DT N
mediastinal JJ N
window NN N
setting NN N
( ( N
mean JJ N
2.3 CD N
mm NN N
, , N
SD NNP N
2.5 CD N
mm NN N
[ NNP N
p NN N
= VBD N
0.63 CD N
] NN N
) ) N
. . N

CONCLUSION NNP N
Semiautomatic NNP N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
could MD N
diagnose VB N
part-solid JJ N
nodules NNS N
and CC N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
human JJ N
observers NNS N
. . N

Performance NNP N
depends VBZ N
on IN N
the DT N
attenuation NN N
segmentation NN N
thresholds NNS N
. . N

This DT N
method NN N
may MD N
prove VB N
useful JJ N
in IN N
managing VBG N
subsolid JJ N
nodules NNS N
. . N

KEY NNP N
POINTS NNP N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
accurately RB N
differentiate VB N
nonsolid JJ N
from IN N
part-solid JJ N
pulmonary JJ N
nodules NNS N
? . N
Semiautomatic JJ N
segmentation NN N
can MD N
quantify VB N
the DT N
solid JJ N
component NN N
similar JJ N
to TO N
manual JJ N
measurements NNS N
? . N
Semiautomatic JJ N
segmentation NN N
may MD N
aid VB N
management NN N
of IN N
subsolid JJ N
nodules NNS N
following VBG N
Fleischner NNP N
Society NNP N
recommendations NNS N
? . N
Performance NN N
for IN N
the DT N
segmentation NN N
of IN N
subsolid JJ N
nodules NNS N
depends VBZ N
on IN N
the DT N
chosen VBN N
attenuation NN N
thresholds NNS N
. . N

-DOCSTART- -X- O O

Scales NNS N
for IN N
the DT N
assessment NN N
of IN N
neuroleptic JJ o
response NN o
in IN N
schizophrenic JJ p
children NNS p
: : p
specific JJ N
measures NNS N
derived VBN N
from IN N
the DT N
CPRS NNP N
. . N

This DT N
article NN N
reports VBZ N
the DT N
psychometric JJ N
properties NNS N
of IN N
two CD N
scales NNS N
for IN N
rating NN N
positive JJ N
and CC N
negative JJ N
schizophrenic JJ N
signs NNS N
and CC N
symptoms NNS N
. . N

These DT N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scales NNP o
consist NN N
of IN N
items NNS N
selected VBN N
from IN N
the DT N
Children NNP N
's POS N
Psychiatric NNP N
Rating NNP N
Scale NNP N
( ( N
CPRS NNP N
) ) N
, , N
which WDT N
contains VBZ N
items NNS N
covering VBG N
a DT N
wide JJ N
range NN N
of IN N
childhood NN N
psychopathology NN N
. . N

CPRS NNP N
rating NN N
data NNS N
were VBD N
analyzed VBN N
for IN N
19 CD p
schizophrenic JJ p
children NNS p
, , p
16 CD p
males NNS p
and CC p
3 CD p
females NNS p
, , p
mean JJ p
age NN p
8.9 CD p
years NNS p
( ( p
range VB p
5.5-11.7 NNP p
) ) p
, , N
evaluated VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
of IN N
haloperidol NN i
. . i

We PRP N
describe VBP N
the DT N
item NN N
composition NN N
and CC N
coherence NN N
of IN N
each DT N
scale NN N
, , N
the DT N
interrater NN N
reliabilities NNS N
of IN N
clinicians NNS N
using VBG N
the DT N
scales NNS N
, , N
and CC N
the DT N
sensitivity NN N
of IN N
the DT N
scales NNS N
for IN N
resolving VBG N
treatment NN N
response NN N
. . N

Schizophrenic JJ p
children NNS p
showed VBD N
both DT N
positive JJ o
and CC o
negative JJ o
signs NNS o
and CC o
symptoms NNS o
, , N
and CC N
both DT N
improved VBN N
with IN N
neuroleptic JJ o
treatment NN o
. . o

-DOCSTART- -X- O O

Failure NN N
of IN N
lithium NN i
to TO N
reduce VB N
period NN N
of IN N
neutropenia NN N
during IN N
induction NN i
therapy NN i
of IN N
acute JJ p
myeloid NN p
leukemia NN p
. . p

Fifty-four CD p
patients NNS p
treated VBN p
with IN p
daunorubicin NN i
, , i
cytosine JJ i
arabinoside NN i
and CC i
thioquanine NN i
for IN p
acute JJ p
myeloid NN p
leukemia NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
oral JJ i
lithium NN i
carbonate NN i
1200 CD i
mg JJ i
daily JJ i
or CC i
no DT i
lithium NN i
. . i

The DT N
duration NN o
of IN o
neutropenia NN o
( ( N
less JJR N
than IN N
0.5 CD N
x JJ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
) ) N
was VBD N
similar JJ N
between IN N
controls NNS N
( ( N
median JJ N
22.5 CD N
days NNS N
) ) N
and CC N
patients NNS N
treated VBN N
with IN N
lithium NN i
( ( N
median JJ N
24 CD N
days NNS N
) ) N
. . N

The DT N
number NN o
of IN o
remissions NNS o
, , o
relapse-free JJ o
survival NN o
and CC o
survival NN o
were VBD N
similar JJ o
for IN N
the DT N
lithium NN i
treated VBD N
and CC N
control VB N
groups NNS N
of IN N
patients NNS N
. . N

There EX N
was VBD N
no DT N
apparent JJ N
clinical JJ o
efficacy NN o
in IN N
the DT N
use NN N
of IN N
lithium NN i
to TO N
reduce VB N
the DT N
period NN N
of IN N
neutropenia NN N
in IN N
patients NNS p
undergoing JJ p
remission NN p
induction NN i
therapy NN i
for IN p
acute JJ p
myeloid NN p
leukemia NN p
. . p

-DOCSTART- -X- O O

The DT N
Coping NNP N
Cat NNP N
program NN N
for IN N
children NNS p
with IN p
anxiety NN p
and CC p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
a DT N
modified JJ i
version NN i
of IN i
the DT i
Coping NNP i
Cat NNP i
program NN i
could MD N
be VB N
effective JJ N
in IN N
reducing VBG N
anxiety NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

Twenty-two JJ p
children NNS p
( ( p
ages VBZ p
8-14 NN p
; : p
IQ NNP p
? . p
70 CD p
) ) p
with IN p
ASD NNP p
and CC p
clinically RB p
significant JJ p
anxiety NN p
were VBD p
randomly RB N
assigned VBN i
to TO i
16 CD i
sessions NNS i
of IN i
the DT i
Coping NNP i
Cat NNP i
program NN i
( ( i
cognitive-behavioral JJ i
therapy NN i
; : i
CBT NNP i
) ) i
or CC i
a DT N
16-week JJ i
waitlist NN i
. . i

Children NNP i
in IN N
the DT N
CBT NNP N
condition NN N
evidenced VBD N
significantly RB N
larger JJR N
reductions NNS o
in IN o
anxiety NN o
than IN o
those DT N
in IN N
the DT N
waitlist NN N
. . N

Treatment NN N
gains NNS N
were VBD N
largely RB N
maintained VBN N
at IN N
two-month JJ N
follow-up NN N
. . N

Results NNP N
provide VBP N
preliminary JJ N
evidence NN N
that IN N
a DT N
modified JJ N
version NN N
of IN N
the DT N
Coping NNP i
Cat NNP i
program NN i
may MD i
be VB N
a DT N
feasible JJ N
and CC N
effective JJ N
program NN N
for IN N
reducing VBG N
clinically RB N
significant JJ N
levels NNS o
of IN o
anxiety NN o
in IN o
children NNS p
with IN p
high-functioning JJ p
ASD NNP p
. . N

-DOCSTART- -X- O O

Supplementation NN i
with IN i
iron NN i
and CC i
riboflavin NN i
enhances NNS N
dark JJ N
adaptation NN N
response NN N
to TO N
vitamin VB i
A-fortified NNP i
rice NN i
in IN N
iron-deficient JJ p
, , p
pregnant JJ p
, , p
nightblind JJ p
Nepali NNP p
women NNS p
. . p

BACKGROUND NNP N
Nightblindness NNP N
affects VBZ N
16-52 CD N
% NN N
of IN N
pregnant JJ N
women NNS N
in IN N
areas NNS N
of IN N
Nepal NNP N
and CC N
in IN N
some DT N
cases NNS N
persists NNS N
after IN N
vitamin VBG i
A DT i
treatment NN N
. . N

Iron NNP i
and CC i
riboflavin VB i
affect JJ N
vitamin NN N
A DT N
utilization NN N
and CC N
photoreceptor NN N
function NN N
, , N
respectively RB N
, , N
and CC N
pilot NN N
data NNS N
in IN N
the DT N
study NN N
population NN N
showed VBD N
a DT N
high JJ N
prevalence NN N
of IN N
iron NN N
and CC N
riboflavin NN N
deficiencies NNS N
. . N

OBJECTIVE IN N
The DT N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
supplemental JJ i
iron NN i
and CC i
riboflavin NN i
on IN N
pupillary JJ N
threshold NN N
( ( N
PT NNP N
) ) N
and CC N
plasma JJ N
retinol NN N
in IN N
nightblind NN N
, , N
pregnant JJ p
Nepali NNP p
women NNS p
given VBN p
vitamin JJ p
A-fortified JJ p
rice NN p
. . p

DESIGN NNP N
Nightblind NNP p
pregnant JJ p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
, , N
6 CD N
d/wk NN N
under IN N
supervision NN N
for IN N
6 CD N
wk NN N
, , N
a DT N
vitamin JJ i
A-fortified JJ i
rice NN i
curry NN i
dish JJ i
providing VBG N
850 CD N
microg JJ N
retinal JJ N
activity NN N
equivalents/d NN N
with IN N
either DT N
a DT N
30-mg JJ i
Fe NNP i
and CC i
6-mg JJ i
riboflavin NN i
( ( N
FeR NNP N
+ NNP N
VA NNP N
) ) N
capsule NN N
or CC N
a DT N
placebo NN i
control NN i
( ( N
VA NNP N
only RB N
) ) N
capsule NN N
. . N

Hemoglobin NNP o
, , o
erythrocyte NN o
riboflavin NN o
, , o
and CC o
plasma NN o
ferritin NN o
and CC o
retinol NN o
were VBD N
measured VBN N
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Dark NNP N
adaptation NN N
was VBD N
assessed VBN N
by IN N
PT NNP N
score NN N
. . N

RESULTS NNP N
Women NNP N
who WP N
were VBD N
iron JJ N
deficient NN N
at IN N
baseline NN N
( ( N
n=38 JJ N
) ) N
had VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
PT NNP o
score NN o
with IN o
iron NN o
and CC o
riboflavin NN o
supplementation NN o
than IN N
without IN N
( ( N
P=0.05 NNP N
) ) N
. . N

Iron NNP N
and CC N
riboflavin JJ N
supplements NNS N
significantly RB N
reduced VBD N
the DT N
prevalences NNS N
of IN N
riboflavin JJ o
deficiency NN o
( ( N
from IN N
60 CD N
% NN N
to TO N
6 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
iron JJ o
deficiency NN o
anemia NN o
( ( N
from IN N
35 CD N
% NN N
to TO N
15 CD N
% NN N
; : N
P NNP N
< NNP N
0.007 CD N
) ) N
, , N
and CC N
abnormal JJ o
PT NNP o
( ( N
from IN N
87 CD N
% NN N
to TO N
30 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
from IN N
baseline NN N
. . N

Mean JJ N
increases NNS N
in IN N
erythrocyte JJ o
riboflavin NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
plasma JJ o
ferritin NN o
( ( N
P=0.01 NNP N
) ) N
were VBD N
greater JJR N
in IN N
the DT N
FeR NNP N
+ NNP N
VA NNP N
group NN N
than IN N
in IN N
the DT N
VA NNP N
only RB N
group NN N
. . N

CONCLUSIONS NNP N
Iron NNP N
deficiency NN N
may MD N
limit VB N
the DT N
efficacy NN N
of IN N
vitamin NN i
A DT i
to TO N
normalize VB N
dark JJ N
adaptation NN N
in IN N
pregnant JJ p
Nepali NNP p
women NNS p
. . p

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
simultaneous JJ N
delivery NN N
of IN N
iron NN N
and CC N
vitamin VB N
A NNP N
for IN N
the DT N
treatment NN N
of IN N
nightblindness NN N
. . N

-DOCSTART- -X- O O

Ongoing VBG i
Telmisartan NNP i
Alone NNP i
and CC i
in IN i
Combination NNP i
With IN i
Ramipril NNP i
Global NNP i
Endpoint NNP i
Trial NNP i
( ( i
ONTARGET NNP i
) ) i
: : i
implications NNS N
for IN N
reduced JJ N
cardiovascular JJ o
risk NN o
. . o

The DT N
recently RB N
published VBN N
Ongoing NNP i
Telmisartan NNP i
Alone NNP i
and CC i
in IN i
Combination NNP i
With IN i
Ramipril NNP i
Global NNP i
Endpoint NNP i
Trial NNP i
( ( i
ONTARGET NNP i
) ) i
in IN N
patients NNS p
with IN p
vascular JJ p
disease NN p
or CC p
high-risk JJ p
diabetes NNS p
, , N
as IN N
the DT N
largest JJS N
published VBN N
comparative JJ N
trial NN N
of IN N
these DT N
agent NN N
classes NNS N
, , N
provides VBZ N
further JJ N
evidence NN N
concerning VBG N
the DT N
comparison NN N
between IN N
the DT N
angiotensin-receptor NN i
blockers NNS i
( ( i
ARBs NNP i
) ) i
and CC N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitors NNS i
( ( i
ACEIs NNP i
) ) i
. . i

In IN N
this DT N
trial NN N
, , N
telmisartan NN i
( ( i
an DT i
ARB NNP i
) ) i
was VBD N
non-inferior JJ N
to TO N
ramipril VB i
( ( i
an DT i
ACEI NNP i
) ) i
in IN N
reducing VBG N
fatal JJ o
and CC o
nonfatal JJ o
cardiovascular JJ o
events NNS o
. . o

Moreover RB N
, , N
ONTARGET NNP i
is VBZ N
an DT N
example NN N
of IN N
a DT N
high-quality JJ N
noninferiority NN N
trial NN N
. . N

However RB N
, , N
the DT N
combination NN N
of IN N
the DT N
2 CD N
agents NNS N
was VBD N
associated VBN N
with IN N
more JJR N
adverse JJ o
effects NNS o
without IN N
an DT N
increase NN N
in IN N
benefit NN N
. . N

The DT N
study NN N
differed VBD N
from IN N
several JJ N
other JJ N
comparative JJ N
studies NNS N
in IN N
which WDT N
the DT N
dose NN N
and CC N
choice NN N
of IN N
ACEI NNP i
was VBD N
left VBN N
to TO N
individual JJ N
physicians NNS N
. . N

Further NNP N
, , N
in IN N
ONTARGET NNP i
, , N
the DT N
ACEI NNP i
was VBD N
not RB N
titrated VBN N
to TO N
the DT N
maximum JJ N
dose NN N
and CC N
patients NNS N
with IN N
heart NN N
failure NN N
were VBD N
excluded VBN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
dietary JJ i
zinc NN i
oxide NN i
on IN N
jejunal JJ N
morphological JJ N
and CC N
immunological JJ N
characteristics NNS N
in IN N
weaned JJ p
piglets NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
age-related JJ N
changes NNS N
and CC N
the DT N
effect NN N
of IN N
dietary JJ N
Zn NNP N
concentration NN N
on IN N
morphological JJ N
and CC N
immunological JJ N
characteristics NNS N
in IN N
the DT N
gastrointestinal JJ p
tract NN p
of IN p
piglets NNS p
. . p

A DT p
total NN p
of IN p
96 CD p
purebred JJ p
Landrace NNP p
piglets NNS p
were VBD p
weaned VBN p
at IN p
the DT p
age NN p
of IN p
26 CD p
? . p
1 CD p
d NN p
, , p
and CC N
randomly RB N
allocated VBD N
into IN N
3 CD N
treatment NN N
groups NNS N
fed VBP N
with IN i
low JJ i
( ( i
57 CD i
mg RB i
Zn/kg NNP i
) ) i
, , i
medium NN i
( ( i
164 CD i
mg RB i
Zn/kg NNP i
) ) i
, , i
and CC i
high JJ i
( ( i
2425 CD i
mg NN i
Zn/kg NNP i
) ) i
dietary JJ i
Zn NNP i
( ( i
ZnO NNP i
) ) i
. . i

Piglets NNS p
( ( p
4 CD p
males NNS p
and CC p
4 CD p
females NNS p
per IN p
treatment NN p
group NN p
) ) p
were VBD N
killed VBN N
at IN N
33 CD N
? . N
1 CD N
, , N
40 CD N
? . N
1 CD N
, , N
47 CD N
? . N
1 CD N
, , N
and CC N
54 CD N
? . N
1 CD N
d NN N
of IN N
age NN N
. . N

In IN N
the DT N
jejunum NN N
, , N
villus JJ N
height NN N
, , N
crypt NN N
depth NN N
, , N
and CC N
the DT N
number NN N
of IN N
goblet NN N
cells NNS N
producing VBG N
neutral JJ N
, , N
acidic JJ N
, , N
sulfated VBN N
, , N
and CC N
sialylated VBD N
mucins NNS N
were VBD N
measured VBN N
. . N

Intraepithelial JJ N
lymphocytes NNS N
were VBD N
characterized VBN N
by IN N
flow JJ N
cytometry NN N
and CC N
the DT N
gene NN N
expression NN N
of IN N
mucin NN N
2 CD N
( ( N
MUC2 NNP N
) ) N
, , N
mucin $ N
20 CD N
( ( N
MUC20 NNP N
) ) N
, , N
?-defensin JJ N
3 CD N
, , N
and CC N
trefoil NN N
factor NN N
3 CD N
( ( N
TFF3 NNP N
) ) N
was VBD N
determined VBN N
by IN N
reverse JJ N
transcription NN N
quantitative JJ N
PCR NNP N
. . N

Villus CC N
height JJ N
and CC N
crypt JJ N
depth NN N
in IN N
the DT N
jejunum NN N
showed VBD N
age NN N
related VBN N
differences NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
the DT N
dietary JJ N
concentrations NNS N
of IN N
Zn NNP N
had VBD N
no DT N
effect NN N
. . N

The DT N
mucin NN N
types NNS N
were VBD N
modified VBN N
mainly RB N
by IN N
age NN N
, , N
and CC N
dietary JJ N
Zn NNP N
had VBD N
no DT N
effect NN N
in IN N
the DT N
proximal JJ N
jejunum NN N
. . N

In IN N
the DT N
distal JJ N
jejunum NN N
, , N
age NN N
and CC N
Zn NNP N
had VBD N
effects NNS N
on IN N
the DT N
mucin NN N
types NNS N
. . N

The DT N
abundance NN o
of IN o
sulfomucins NNS o
decreased VBN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC o
sialomucins NNS o
increased VBD o
with IN N
age NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
high JJ N
dietary JJ N
ZnO NNP N
reduced VBD N
the DT N
sulfomucins NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
increased VBD N
the DT N
sialomucins NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
crypts NNS N
. . N

The DT N
phenotypes NNS N
of IN N
lymphocytes NNS N
in IN N
the DT N
epithelium NN N
of IN N
the DT N
proximal JJ N
jejunum NN N
showed VBD N
relatively RB N
constant JJ o
percentages NNS o
of IN o
T-cells NNP o
, , o
as RB o
well RB o
as IN N
natural JJ N
killer NN N
cells NNS N
. . N

High NNP o
dietary JJ o
Zn NNP o
treatment NN o
led VBD o
to TO o
a DT N
reduced JJ N
abundance NN o
of IN o
CD8 NNP o
( ( o
+ NNP o
) ) o
?? VBZ o
T-cells NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
apportionment NN N
of IN N
different JJ o
cytotoxic JJ o
T-cell NNP o
was VBD N
age NN N
dependent NN N
. . N

Although IN N
the DT N
percentage NN o
of IN o
CD4 NNP o
( ( o
- : o
) ) o
CD8? NNP o
( ( o
+ NNP o
) ) o
increased VBD o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
the DT o
relative JJ o
amount NN o
of IN o
CD4 NNP o
( ( o
+ NNP o
) ) o
CD8? NNP o
( ( o
+ NNP o
) ) o
decreased VBD o
with IN N
age NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
expression NN N
of IN N
MUC2 NNP N
and CC N
MUC20 NNP N
was VBD N
not RB N
influenced VBN N
by IN N
age NN N
or CC N
dietary JJ N
Zn NNP N
concentration NN i
. . i

High JJ i
Zn NNP i
intakes NNS N
resulted VBD N
in IN N
a DT N
reduced JJ N
gene NN N
expression NN N
of IN o
?-defensin JJ o
3 CD o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
the DT N
expression NN N
of IN N
TFF3 NNP N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
Zn NNP N
in IN N
the DT N
form NN N
of IN N
ZnO NNP N
appears VBZ N
to TO N
have VB N
specific JJ N
effects NNS N
on IN N
the DT N
innate NN N
and CC N
adaptive JJ N
gut NN N
associated VBN N
immune JJ N
system NN p
of IN p
piglets NNS p
. . N

These DT N
might MD N
contribute VB N
to TO N
the DT N
positive JJ N
effects NNS N
of IN N
Zn NNP N
on IN N
the DT N
prevention NN N
of IN N
postweaning VBG N
diarrhea NN N
. . N

-DOCSTART- -X- O O

Event-related JJ N
potentials NNS N
and CC N
monoamines NNS N
in IN N
autistic JJ p
children NNS p
on IN N
a DT N
clinical JJ N
trial NN N
of IN N
fenfluramine NN i
. . i

In IN N
a DT N
double JJ N
blind NN N
, , N
crossover NN N
study NN N
of IN N
the DT N
response NN N
of IN N
autistic JJ p
subjects NNS p
to TO N
fenfluramine VB i
, , i
event-related JJ i
potentials NNS i
( ( i
ERPs NNP i
) ) i
were VBD N
recorded VBN N
from IN N
7 CD p
subjects NNS p
on IN N
an DT N
attention-demanding JJ N
auditory NN N
choice NN N
reaction NN N
time NN N
task NN N
( ( N
ACRT NNP N
) ) N
. . N

ACRT NNP N
, , N
IQ NNP N
and CC N
biochemical JJ N
measures NNS N
were VBD N
taken VBN N
after IN N
5 CD N
months NNS N
placebo NN i
and CC N
5 CD N
months NNS N
fenfluramine JJ i
treatment NN i
. . i

After IN N
fenfluramine JJ N
treatment NN N
blood NN N
serotonin NN N
levels NNS N
fell VBD N
, , N
urinary JJ N
catecholamine NN N
levels NNS N
fell VBD N
and CC N
the DT N
HVA/DA NNP N
ratio NN N
rose VBD N
. . N

IQ NNP o
and CC o
ACRT NNP o
performance NN o
improved VBD N
. . N

On IN N
the DT N
ACRT NNP o
subjects NNS N
were VBD N
asked VBN N
to TO N
press VB N
a DT N
button NN N
to TO N
a DT N
rare JJ N
target NN N
( ( N
500 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
to TO N
ignore VB N
higher JJR N
pitched VBN N
rare JJ N
( ( N
2,000 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
frequent JJ N
non-targets NNS N
( ( N
1,000 CD N
Hz NNP N
) ) N
. . N

After IN N
fenfluramine JJ i
treatment NN N
N1 NNP o
latencies NNS o
increased VBD N
. . N

The DT N
scalp JJ o
distribution NN o
of IN o
ERP NNP o
maxima NNP N
changes NNS N
slightly RB N
with IN N
treatment NN N
. . N

P3 NNP o
maxima NN o
elicited VBN N
by IN N
rare JJ N
non-targets NNS N
were VBD N
recorded VBN N
more RBR N
rostrally RB N
after IN N
fenfluramine JJ i
treatment NN N
. . N

After IN N
rare JJ N
non-targets NNS N
N1 NNP o
amplitudes NNS o
at IN o
Fz NNP o
decreased VBD N
but CC N
P3 NNP o
amplitudes NNS o
at IN o
Pz NNP o
increased VBD N
. . N

Early JJ N
negativity NN N
after IN N
the DT N
rare JJ N
non-target JJ N
( ( N
particularly RB N
on IN N
the DT N
right JJ N
side NN N
) ) N
was VBD N
negatively RB N
correlated VBN N
with IN N
the DT N
HVA/DA NNP N
ratio NN N
. . N

Subtraction NN N
of IN N
the DT N
P3 NNP N
component NN N
elicited VBN N
in IN N
a DT N
passive JJ N
condition NN N
where WRB N
no DT N
response NN N
was VBD N
required VBN N
from IN N
the DT N
active JJ N
condition NN N
showed VBD N
that IN N
P3 NNP o
positivity NN o
to TO N
targets NNS N
was VBD N
halved VBN N
with IN N
treatment NN N
. . N

( ( N
In IN N
contrast NN N
Nd NNP N
increased VBD N
on IN N
fenfluramine JJ N
treatment NN N
) ) N
. . N

Overall JJ N
, , N
N1 NNP N
and CC N
P3 NNP N
components NNS N
showed VBD N
greatest JJS N
responsiveness NN N
to TO N
rare VB N
non-targets NNS N
on IN N
fenfluramine NN N
. . N

N1 NNP N
but CC N
not RB N
P3 NNP N
changes NNS N
may MD N
represent VB N
slight JJ N
improvement NN N
of IN N
attention-related JJ N
function NN N
with IN N
treatment NN N
. . N

Small JJ N
changes NNS N
in IN N
ERP NNP o
latency NN o
and CC o
distribution NN o
, , N
associated VBN N
with IN N
the DT N
neuroleptic JJ N
action NN N
of IN N
fenfluramine NN i
may MD N
be VB N
partly RB N
responsible JJ N
for IN N
a DT N
mild JJ N
improvement NN N
of IN N
IQ NNP N
and CC N
ACRT NNP N
performance NN N
on IN N
medication NN N
. . N

-DOCSTART- -X- O O

Parent NN p
and CC p
family NN p
outcomes NNS p
of IN p
PEERS NNS i
: : i
a DT p
social JJ i
skills NNS i
intervention NN i
for IN p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Raising VBG N
a DT N
child NN p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
is VBZ N
associated VBN N
with IN N
increased VBN N
family NN p
chaos NN N
and CC N
parent NN p
distress NN N
. . N

Successful JJ N
long-term JJ N
treatment NN N
outcomes NNS N
are VBP N
dependent JJ N
on IN N
healthy JJ N
systemic JJ N
functioning NN N
, , N
but CC N
the DT N
family NN o
impact NN o
of IN o
treatment NN o
is VBZ N
rarely RB N
evaluated VBN N
. . N

The DT i
Program NNP i
for IN i
the DT i
Education NNP i
and CC i
Enrichment NNP i
of IN i
Relational NNP i
Skills NNP i
( ( i
PEERS NNP i
) ) i
is VBZ N
a DT N
social JJ N
skills NNS N
intervention NN N
designed VBN N
for IN N
adolescents NNS p
with IN p
high-functioning JJ p
ASD NNP p
. . p

This DT N
study NN N
assessed VBD N
the DT N
impact NN N
of IN N
PEERS NNS o
on IN N
family NN o
chaos NN o
, , o
parenting VBG o
stress NN o
, , o
and CC o
parenting VBG o
self-efficacy NN o
via IN N
a DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Results NNP N
suggested VBD N
beneficial JJ N
effects NNS N
for IN N
the DT N
experimental JJ N
group NN N
in IN N
the DT N
domain NN N
of IN N
family NN o
chaos NN o
compared VBN N
to TO N
the DT N
waitlist NN N
control NN N
, , N
while IN N
parents NNS p
in IN p
the DT p
PEERS NNP i
experimental JJ p
group NN p
also RB N
demonstrated VBD N
increased JJ N
parenting VBG o
self-efficacy NN o
. . o

These DT N
findings NNS N
highlight VBD N
adjunctive JJ N
family NN N
system NN N
benefits NNS N
of IN N
PEERS NNP i
intervention NN i
and CC N
suggest VBP N
the DT N
need NN N
for IN N
overall JJ N
better JJR N
understanding NN N
of IN N
parent NN N
and CC N
family NN N
outcomes NNS N
of IN N
ASD NNP N
interventions NNS N
. . N

-DOCSTART- -X- O O

Single NNP N
and CC N
short-term JJ N
dosing NN N
effects NNS N
of IN N
levocetirizine NN i
on IN N
adenosine JJ N
monophosphate NN N
bronchoprovocation NN N
in IN N
atopic NN N
asthma NN N
. . N

AIMS NNP N
Adenosine NNP N
monophosphate NN N
( ( N
AMP NNP N
) ) N
acts VBZ N
indirectly RB N
via IN N
primed VBN N
airway RB N
mast JJ N
cells NNS N
to TO N
induce VB N
bronchial JJ N
hyper-responsiveness NN N
, , N
which WDT N
in IN N
turn NN N
correlates NNS N
with IN N
eosinophilic JJ o
asthmatic JJ o
inflammation NN o
and CC o
atopic JJ o
disease NN o
expression NN o
. . o

We PRP N
evaluated VBD N
single JJ N
and CC N
short-term JJ N
dosing NN N
effects NNS N
of IN N
a DT N
modern JJ N
histamine NN N
H1-receptor NNP N
antagonist NN N
, , N
levocetirizine NN i
, , N
given VBN N
at IN N
the DT N
usual JJ N
clinically RB N
recommended VBD N
dose NN N
, , N
on IN N
the DT N
primary JJ N
outcome NN N
of IN N
AMP NNP N
bronchoprovocation NN N
. . N

METHODS NNP N
Fifteen NNP p
atopic NN p
asthmatics NNS p
were VBD p
randomized VBN p
in IN p
double-blind NN p
, , p
cross-over JJ p
fashion NN p
to TO p
receive VB p
for IN p
1 CD p
week NN p
either CC p
levocetirizine JJ i
5 CD i
mg NN i
or CC i
placebo NN i
. . i

There EX N
was VBD N
a DT N
1-week JJ N
washout NN N
period NN N
prior RB N
to TO N
each DT N
randomized VBN N
treatment NN N
. . N

The DT N
provocative JJ N
concentration NN N
of IN N
AMP NNP N
producing VBG N
a DT N
20 CD N
% NN N
fall NN N
in IN N
FEV1 NNP N
( ( N
PC20 NNP N
) ) N
was VBD N
measured VBN N
after IN N
each DT N
washout NN N
at IN N
baseline NN N
and CC N
at IN N
4-6 JJ N
h NN N
following VBG N
the DT N
first JJ N
and CC N
last JJ N
doses NNS N
of IN N
each DT N
randomized VBN N
treatment NN N
. . N

RESULTS NNP N
Baseline NNP N
mean JJ o
+/- JJ o
SEM NNP o
values NNS o
after IN N
washout NN N
prior RB N
to TO N
each DT N
randomized VBN N
treatment NN N
comparing VBG N
levocetirizine JJ i
vs NN N
placebo NN i
were VBD N
not RB N
significantly RB N
different JJ N
for IN N
prechallenge NN N
FEV1 NNP o
( ( N
% NN N
predicted VBN N
) ) N
83 CD N
+/- JJ N
4 CD N
vs JJ N
82 CD N
+/- JJ N
4 CD N
, , N
or CC N
AMP NNP o
PC20 NNP o
( ( N
mg JJ N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
45 CD N
+/- JJ N
24 CD N
vs JJ N
45 CD N
+/- JJ N
22 CD N
, , N
respectively RB N
. . N

Airway NNP o
calibre NN o
as IN o
prechallenge NN o
FEV1 NNP o
for IN N
levocetirizine JJ i
vs NN N
placebo NN i
was VBD N
not RB N
significantly RB N
different JJ N
following VBG N
the DT N
first JJ N
dose JJ N
86 CD N
+/- JJ N
4 CD N
vs JJ N
82 CD N
+/- JJ N
4 CD N
, , N
or CC N
the DT N
last JJ N
dose JJ N
85 CD N
+/- JJ N
4 CD N
vs JJ N
83 CD N
+/- JJ N
4 CD N
, , N
respectively RB N
. . N

There EX N
were VBD N
significant JJ N
improvements NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
AMP NNP o
PC20 NNP o
comparing VBG N
levocetirizine JJ N
vs NN N
placebo NN N
following VBG N
the DT N
first JJ N
dose JJ N
123 CD N
+/- JJ N
73 CD N
vs JJ N
48 CD N
+/- JJ N
24 CD N
, , N
a DT N
1.4 CD N
doubling VBG N
dilution NN N
difference NN N
( ( N
95 CD N
% NN N
CI NNP N
0.8 CD N
, , N
1.9 CD N
) ) N
, , N
and CC N
the DT N
last JJ N
dose JJ N
127 CD N
+/- JJ N
74 CD N
vs JJ N
53 CD N
+/- JJ N
29 CD N
, , N
a DT N
1.2 CD N
doubling VBG N
dilution NN N
difference NN N
( ( N
95 CD N
% NN N
CI NNP N
0.5 CD N
, , N
2.0 CD N
) ) N
. . N

AMP NNP o
PC20 NNP o
was VBD N
also RB N
improved VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
by IN N
the DT N
first JJ N
and CC N
last JJ N
doses NNS N
of IN N
levocetirizine NN N
but CC N
not RB N
placebo VB N
, , N
vs FW N
respective JJ N
baseline NN N
values NNS N
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
in IN N
the DT N
degree NN N
of IN N
protection NN N
between IN N
first JJ N
and CC N
last JJ N
doses NNS N
. . N

CONCLUSIONS NNP N
Single NNP N
and CC N
short-term JJ N
dosing NN N
with IN N
levocetirizine NN i
conferred VBN N
similar JJ N
improvements NNS N
in IN N
bronchial JJ o
hyper-responsiveness NN o
to TO o
AMP NNP o
challenge NN N
, , N
which WDT N
was VBD N
unrelated JJ N
to TO N
prechallenge VB N
airway RB N
calibre NN N
. . N

Further JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
the DT N
longer-term JJ N
effects NNS N
of IN N
levocetirizine NN i
on IN N
asthma JJ o
exacerbations NNS o
. . o

-DOCSTART- -X- O O

Brief JJ N
report NN N
: : N
effects NNS N
of IN N
cognitive JJ i
behavioral JJ i
therapy NN i
on IN N
parent-reported JJ o
autism NN o
symptoms NNS o
in IN p
school-age JJ p
children NNS p
with IN p
high-functioning JJ p
autism NN p
. . p

This DT N
pilot NN N
study NN N
tested VBD N
the DT N
effect NN N
of IN N
cognitive JJ i
behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
on IN N
parent-reported JJ p
autism NN p
symptoms NNS p
. . p

Nineteen JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
an DT p
anxiety NN p
disorder NN p
( ( p
7-11 CD p
years NNS p
old JJ p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO N
16 CD N
sessions NNS N
of IN N
CBT NNP i
or CC N
a DT N
waitlist JJ i
condition NN i
. . i

The DT N
CBT NNP i
program NN N
emphasized VBN N
in IN N
vivo NN N
exposure NN N
supported VBN N
by IN N
parent NN N
training NN N
and CC N
school NN N
consultation NN N
to TO N
promote VB N
social JJ N
communication NN N
and CC N
emotion NN N
regulation NN N
skills NNS N
. . N

Parents NNS N
completed VBD N
a DT N
standardized JJ o
autism NN o
symptom JJ o
checklist NN o
at IN N
baseline NN N
and CC N
posttreatment/postwaitlist NN N
and CC N
3-month JJ N
follow-up JJ N
assessments NNS N
. . N

CBT NNP i
outperformed VBD N
the DT N
waitlist JJ N
condition NN N
at IN N
posttreatment/postwaitlist NN N
on IN N
total JJ o
parent-reported JJ o
autism NN o
symptoms NNS o
( ( N
Cohen NNP N
's POS N
d JJ N
effect NN N
size NN N
= NNP N
.77 NNP N
) ) N
. . N

Treatment NN N
gains NNS N
were VBD N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
. . N

Further JJ N
investigation NN N
of IN N
this DT N
intervention NN N
modality NN N
with IN N
larger JJR N
samples NNS N
and CC N
broader JJR N
outcome NN N
measures NNS N
appears VBZ N
to TO N
be VB N
indicated VBN N
. . N

-DOCSTART- -X- O O

[ JJ N
GISSI-2 NNP N
; : N
the DT N
beginning NN N
of IN N
the DT N
end NN N
or CC N
the DT N
end NN N
of IN N
the DT N
beginning NN N
for IN N
tissue NN i
plasminogen NN i
activator NN N
in IN N
acute JJ o
myocardial JJ o
infarct NN o
? . N
] NN N
. . N

-DOCSTART- -X- O O

Allogeneic NNP i
marrow NN i
transplantation NN i
in IN N
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
the DT p
chronic JJ p
phase NN p
: : p
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
irradiation NN N
regimens NNS N
. . N

A DT N
randomized JJ N
trial NN N
was VBD N
performed VBN N
to TO N
compare VB N
two CD N
regimens NNS N
of IN N
total JJ i
body NN i
irradiation NN i
in IN N
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
treated VBN p
by IN p
allogeneic JJ i
marrow NN i
transplantation NN i
while IN p
in IN p
the DT p
chronic JJ p
phase NN p
. . p

All DT N
patients NNS N
received VBD N
cyclophosphamide JJ i
120 CD N
mg/kg NN N
followed VBN N
by IN N
total JJ i
body NN i
irradiation NN i
and CC i
marrow NN i
from IN i
HLA-identical JJ i
siblings NNS i
. . i

Cyclosporine NNP i
and CC i
methotrexate NN i
were VBD N
used VBN N
for IN N
prophylaxis NN N
against IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Fifty-seven JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
2.0 CD N
Gy NNP N
fractions NNS N
of IN N
irradiation NN i
daily NN N
for IN N
6 CD N
days NNS N
and CC N
59 CD N
were VBD N
randomized VBN N
to TO N
receive VB N
2.25 CD N
Gy NNP N
fractions NNS N
daily RB N
for IN N
7 CD N
days NNS N
. . N

The DT N
probabilities NNS o
of IN o
relapse NN o
at IN N
4 CD N
years NNS N
were VBD N
0.25 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

The DT N
actuarial JJ o
probabilities NNS o
of IN o
survival NN o
and CC o
relapse-free JJ o
survival NN o
at IN N
4 CD N
years NNS N
were VBD N
0.60 CD N
and CC N
0.58 CD N
among IN N
the DT N
patients NNS N
who WP N
received VBD N
12.0 CD N
Gy NNP N
compared VBN N
with IN N
0.66 CD N
and CC N
0.66 CD N
for IN N
those DT N
who WP N
received VBD N
15.75 CD N
Gy NNP N
. . N

The DT N
4-year JJ o
probabilities NNS o
of IN o
transplant-related JJ o
mortality NN o
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN o
of IN o
moderate JJ o
to TO o
severe VB o
acute JJ o
graft-versus-host JJ o
disease NN o
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

The DT N
lower JJR N
relapse NN o
probability NN o
in IN N
the DT N
patients NNS p
receiving VBG p
the DT p
higher JJR p
dose NN p
of IN p
total JJ i
body NN i
irradiation NN i
did VBD N
not RB N
result VB N
in IN N
improved JJ o
survival NN o
because IN N
mortality NN N
from IN N
causes VBZ N
other JJ N
than IN N
relapse NN N
was VBD N
increased VBN N
. . N

-DOCSTART- -X- O O

Randomised VBN N
trial NN N
of IN N
laparoscopic NN i
versus NN i
open JJ i
cholecystectomy NN i
for IN N
acute NN p
and CC p
gangrenous JJ p
cholecystitis NN p
. . p

BACKGROUND NNP N
Laparoscopic NNP i
cholecystectomy NN i
( ( i
LC NNP i
) ) i
has VBZ N
become VBN N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
elective JJ i
cholecystectomy NN i
, , N
but CC N
controversy NN N
persists NNS N
over IN N
use NN N
of IN N
this DT N
approach NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
cholecystitis NN p
. . p

We PRP N
undertook VBD N
a DT N
randomised JJ N
comparison NN N
of IN N
the DT N
safety NN N
and CC N
outcome NN N
of IN N
LC NNP i
and CC N
open JJ i
cholecystectomy NN i
( ( i
OC NNP i
) ) i
in IN N
patients NNS p
with IN p
acute JJ p
cholecystitis NN p
. . p

METHODS NNP N
63 CD p
of IN p
68 CD p
consecutive JJ p
patients NNS p
who WP p
met VBD p
criteria NNS p
for IN p
acute JJ p
cholecystitis NN p
were VBD p
randomly RB p
assigned VBN p
OC NNP i
( ( p
31 CD p
patients NNS p
) ) p
or CC p
LC NNP i
( ( p
32 CD p
patients NNS p
) ) p
. . p

The DT N
primary JJ N
endpoints NNS N
were VBD N
hospital JJ o
mortality NN o
and CC o
morbidity NN o
, , o
length NN o
of IN o
hospital NN o
stay NN o
, , o
and CC o
length NN o
of IN o
sick JJ o
leave VBP o
from IN o
work NN o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

Suspected VBN o
bile-duct NN o
stones NNS o
were VBD N
investigated VBN N
by IN N
preoperative JJ N
endoscopic NN N
retrograde NN N
cholangiography NN N
( ( i
LC NNP i
group NN N
) ) N
or CC N
intraoperative JJ i
cholangiography NN i
( ( i
OC NNP i
group NN N
) ) N
. . N

FINDINGS PDT N
The DT N
two CD N
randomised VBD N
groups NNS N
were VBD N
similar JJ N
in IN N
demographic JJ N
, , N
physical JJ N
, , N
and CC N
clinical JJ N
characteristics NNS N
. . N

48 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
OC NNP i
group NN N
and CC N
59 CD N
% NN N
in IN N
the DT N
LC NNP i
group NN N
were VBD N
older JJR N
than IN N
60 CD N
years NNS N
. . N

13 CD N
patients NNS N
in IN N
each DT N
group NN N
had VBD N
gangrene NN o
or CC o
empyema NN o
, , N
and CC N
one CD N
in IN N
each DT N
group NN N
had VBD N
perforation NN o
of IN o
the DT o
gallbladder NN o
causing NN o
diffuse NN o
peritonitis NN o
. . o

Five CD N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
LC NNP i
group NN N
required VBD N
conversion NN N
to TO N
OC NNP i
, , N
in IN N
most JJS N
because IN N
severe JJ o
inflammation NN o
distorted VBD N
the DT N
anatomy NN N
of IN N
Calot NNP N
's POS N
triangle NN N
. . N

There EX N
were VBD N
no DT N
deaths NNS o
or CC o
bile-duct NN o
lesions NNS o
in IN N
either DT N
group NN N
, , N
but CC N
the DT N
postoperative JJ o
complication NN o
rate NN N
was VBD N
significantly RB N
( ( N
p=0.0048 NN N
) ) N
higher JJR N
in IN N
the DT N
OC NNP i
than IN N
in IN N
the DT N
LC NNP i
group NN N
: : N
seven CD N
( ( N
23 CD N
% NN N
) ) N
patients NNS N
had VBD N
major JJ N
and CC N
six CD N
( ( N
19 CD N
% NN N
) ) N
minor NN o
complications NNS o
after IN N
OC NNP i
, , N
whereas IN N
only RB N
one CD N
( ( N
3 CD N
% NN N
) ) N
minor JJ N
complication NN N
occurred VBD N
after IN N
LC NNP i
. . i

The DT N
postoperative JJ o
hospital NN o
stay NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
LC NNP i
than IN N
the DT N
OC NNP i
group NN N
( ( N
median JJ N
4 CD N
[ JJ N
IQR NNP N
2-5 JJ N
] NNP N
vs NN N
6 CD N
[ JJ N
5-8 JJ N
] NNP N
days NNS N
; : N
p=0.0063 NN N
) ) N
. . N

Mean JJ o
length NN o
of IN o
sick JJ o
leave NN o
was VBD N
shorter RBR N
in IN N
the DT N
LC NNP i
group NN N
( ( N
13.9 CD N
vs RB N
30.1 CD N
days NNS N
; : N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
10.9-21.7 CD N
) ) N
. . N

INTERPRETATION NNP N
Even RB N
though IN N
LC NNP i
for IN N
acute NN N
and CC N
gangrenous JJ N
cholecystitis NN N
is VBZ N
technically RB N
demanding VBG N
, , N
in IN N
experienced JJ N
hands NNS N
it PRP N
is VBZ N
safe JJ o
and CC N
effective JJ o
. . o

It PRP N
does VBZ N
not RB N
increase VB N
the DT N
mortality NN o
rate NN o
, , N
and CC N
the DT N
morbidity NN o
rate NN o
seems VBZ N
to TO N
be VB N
even RB N
lower JJR N
than IN N
that DT N
in IN N
OC NNP i
. . i

However RB N
, , N
a DT N
moderately RB N
high JJ N
conversion NN N
rate NN N
must MD N
be VB N
accepted VBN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
nebulized JJ i
flunisolide NN i
combined VBN i
with IN i
salbutamol NN i
and CC i
ipratropium NN i
bromide NN i
in IN N
stable JJ p
patients NNS p
with IN p
moderate-to-severe JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

BACKGROUND IN N
The DT N
efficacy NN o
of IN N
nebulized JJ N
corticosteroids NNS i
in IN N
the DT N
prevention NN N
of IN N
exacerbation NN N
of IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
has VBZ N
been VBN N
poorly RB N
studied VBN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
nebulized JJ i
flunisolide NN i
( ( N
1 CD N
mg NN N
) ) N
+ VBZ i
salbutamol/ipratropium JJ i
bromide NN i
( ( N
1,875/375 CD N
microg NN N
) ) N
b.i.d NN N
. . N

in IN N
comparison NN N
with IN N
placebo NN i
+ NNP i
salbutamol/ipratropium NN i
bromide NN i
. . i

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
study NN N
on IN N
114 CD p
patients NNS p
with IN p
COPD NNP p
of IN p
moderate-to-severe JJ p
degree NN p
. . p

The DT N
main JJ N
outcome NN N
was VBD N
the DT N
frequency NN o
of IN o
severe JJ o
exacerbations NNS o
over IN N
a DT N
6-month JJ N
period NN N
. . N

Before IN N
and CC N
after IN N
treatment NN N
, , N
respiratory NN o
symptoms NNS o
, , o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
s NN o
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
, , o
shuttle JJ o
walking VBG o
test NN o
distance NN o
and CC o
St. NNP o
George NNP o
's POS o
Respiratory NNP o
Questionnaire NNP o
scores NNS o
were VBD N
evaluated VBN N
. . N

RESULTS VB N
The DT N
total JJ o
number NN o
of IN o
exacerbations NNS o
was VBD N
slightly RB N
lower JJR N
in IN N
the DT N
flunisolide NN i
group NN N
compared VBN N
to TO N
the DT N
placebo NN i
group NN N
( ( N
19 CD N
vs. FW N
34 CD N
, , N
p NN N
= NNP N
0.054 CD N
) ) N
; : N
the DT N
number NN o
of IN o
patients NNS o
experiencing VBG o
at IN o
least JJS o
one CD o
exacerbation NN o
during IN o
the DT o
study NN o
was VBD N
also RB N
decreased VBN N
( ( N
16 CD N
vs. FW N
26 CD N
, , N
p NN N
= NNP N
0.059 CD N
) ) N
. . N

In IN N
particular JJ N
, , N
type JJ o
3 CD o
Anthonisens NNP o
's POS o
exacerbations NNS o
were VBD N
significantly RB N
reduced VBN N
by IN N
flunisolide NN i
( ( N
p JJ N
= NNP N
0.044 CD N
) ) N
. . N

In IN N
the DT N
placebo NN i
group NN N
, , N
scores NNS N
were VBD N
higher JJR N
than IN N
in IN N
the DT N
flunisolide JJ i
group NN N
but CC N
nonsignificant NN N
for IN N
dyspnea NN o
, , o
cough NN o
, , o
sputum NN o
amount NN o
and CC o
purulence NN o
. . o

FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
significantly RB N
increased VBN N
compared VBN N
to TO N
baseline VB N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
area NN o
under IN o
the DT o
FEV NNP o
( ( o
1 CD o
) ) o
-time NN o
curve NN o
during IN o
the DT o
6-month JJ o
period NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
flunisolide NN i
group NN N
( ( N
5.2 CD N
+/- JJ N
10.6 CD N
vs. FW N
2.1 CD N
+/- JJ N
5.0 CD N
, , N
flunisolide RB i
vs. FW N
placebo NN i
, , N
respectively RB N
; : N
p VB N
= $ N
0.047 CD N
) ) N
. . N

For IN N
shuttle JJ o
walking VBG o
test NN o
distance NN o
and CC o
scores NNS o
of IN o
the DT o
St. NNP o
George NNP o
's POS o
Respiratory NNP o
Questionnaire NNP o
, , N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
baseline NN N
evaluation NN N
and CC N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Nebulized NNP i
flunisolide NN i
is VBZ N
a DT N
good JJ N
alternative NN N
to TO N
other JJ N
inhaled JJ N
corticosteroids NNS N
when WRB N
added VBN N
to TO N
nebulized JJ i
salbutamol/ipratropium NN i
bromide NN i
in IN N
the DT N
long-term JJ N
treatment NN N
of IN N
moderate-to-severe JJ p
COPD NNP p
patients NNS p
. . p

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
magnesium NN i
added VBN N
to TO N
levobupivacaine VB i
for IN N
femoral JJ N
nerve NN N
block NN N
on IN N
postoperative JJ N
analgesia NN N
in IN N
patients NNS p
undergoing VBG p
ACL NNP p
reconstruction NN p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
randomised VBD N
double-blind NN N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
magnesium NN i
added VBN N
to TO N
local JJ N
anaesthetics NNS N
on IN N
postoperative JJ N
VAS NNP N
scores NNS N
, , N
total JJ N
opioid JJ N
consumption NN N
, , N
time NN N
to TO N
first JJ N
mobilisation NN N
, , N
patient JJ N
satisfaction NN N
and CC N
rescue NN N
analgesic JJ N
requirements NNS N
in IN N
arthroscopic JJ N
ACL NNP N
reconstruction NN N
surgery NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
107 CD p
American JJ p
Society NNP p
of IN p
Anaesthesiologists NNP p
physical JJ p
status NN p
grade NN p
I PRP p
and CC p
II NNP p
patients NNS p
between IN p
18 CD p
and CC p
65 CD p
years NNS p
of IN p
age NN p
who WP p
were VBD p
scheduled VBN p
to TO p
undergo VB p
elective JJ p
anterior JJ p
crucial JJ p
ligament NN p
( ( p
ACL NNP p
) ) p
reconstruction NN p
with IN p
hamstring VBG p
autografts NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
Groups NNP N
L NNP N
( ( N
n JJ N
= NNP N
51 CD N
) ) N
and CC N
LM NNP N
( ( N
n JJ N
= NNP N
56 CD N
) ) N
using VBG N
the DT N
closed-envelope NN N
method NN N
. . N

Group NNP N
LM NNP N
was VBD N
administered VBN N
19 CD N
ml NN N
of IN N
0.25 CD i
% NN i
levobupivacaine NN i
and CC i
1 CD i
ml NN i
of IN i
15 CD i
% NN i
magnesium NN i
sulphate NN i
, , N
while IN N
Group NNP i
L NNP i
was VBD i
administered VBN i
20 CD i
ml NN i
of IN i
0.25 CD i
% NN i
levobupivacaine NN i
for IN N
femoral JJ N
blockade NN N
. . N

General NNP N
anaesthesia NN N
was VBD N
administered VBN N
using VBG N
laryngeal JJ N
airway RB N
masks NNS N
following VBG N
neural JJ N
blockade NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
for IN N
heart NN o
rate NN o
and CC o
mean VB o
arterial JJ o
pressure NN o
, , o
oxygen NN o
saturation NN o
, , o
visual JJ o
analogue NN o
score NN o
( ( o
VAS NNP o
) ) o
, , o
verbal JJ o
rating NN o
scale NN o
( ( o
VRS NNP o
) ) o
, , o
rescue NN o
analgesic JJ o
requirements NNS o
, , o
total JJ o
opioid JJ o
consumption NN o
, , N
side NN N
effects NNS N
and CC N
time NN N
to TO N
first JJ N
mobilisation NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
4th CD N
, , N
6th CD N
, , N
12th CD N
and CC N
24th CD N
hours NNS N
postoperatively RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
demographic JJ o
data NNS o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
heart NN o
rate NN o
or CC o
oxygen NN o
saturation NN o
between IN N
groups NNS N
. . N

The DT N
area NN o
under IN o
the DT o
curve NN o
VAS NNP o
and CC o
VRS NNP o
scores NNS o
were VBD N
lower JJR N
at IN N
4 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NN N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.001 CD N
, , N
p NN N
= VBD N
0.016 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
rescue NN o
analgesic JJ o
requirement NN o
and CC o
the DT o
total JJ o
opioid JJ o
consumption NN o
were VBD N
significantly RB N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.015 CD N
, , N
p NN N
= VBD N
0.019 CD N
, , N
respectively RB N
) ) N
. . N

The DT N
time NN o
to TO o
first JJ o
mobilisation NN o
and CC o
the DT o
Likert NNP o
score NN o
( ( N
completely RB N
comfortable JJ N
; : N
quite RB N
comfortable JJ N
; : N
slight JJ N
discomfort NN N
; : N
painful JJ N
; : N
very RB N
painful JJ N
) ) N
were VBD N
higher JJR N
, , N
and CC N
the DT N
block NN o
onset VBD o
time NN o
was VBD N
lower JJR N
in IN N
Group NNP N
LM NNP N
( ( N
p JJ N
= NN N
0.014 CD N
and CC N
p VB N
= JJ N
0.012 CD N
, , N
respectively RB N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
magnesium NN i
to TO N
levobupivacaine VB N
prolongs NNS N
the DT N
sensory NN N
and CC N
motor NN N
block NN N
duration NN N
without IN N
increasing VBG N
side NN N
effects NNS N
, , N
enhances VBZ N
the DT N
quality NN N
of IN N
postoperative JJ N
analgesia NN N
and CC N
increases VBZ N
patient JJ N
satisfaction NN N
; : N
however RB N
, , N
the DT N
addition NN N
of IN N
magnesium NN N
delays VBZ N
the DT N
time NN N
to TO N
first JJ N
mobilisation NN N
and CC N
decreases VBZ N
rescue NN N
analgesic JJ N
requirements NNS N
. . N

-DOCSTART- -X- O O

Abacavir NNP i
once RB N
or CC N
twice RB N
daily RB N
combined VBN N
with IN N
once-daily JJ N
lamivudine NN i
and CC i
efavirenz NN i
for IN N
the DT N
treatment NN N
of IN N
antiretroviral-naive JJ o
HIV-infected JJ p
adults NNS p
: : p
results NNS N
of IN N
the DT N
Ziagen NNP i
Once NNP N
Daily NNP N
in IN N
Antiretroviral NNP N
Combination NNP N
Study NNP N
. . N

The DT N
long JJ N
intracellular JJ N
half-life NN N
of IN N
abacavir NN i
( ( i
ABC NNP i
) ) i
supports VBZ N
its PRP$ N
once-daily JJ N
use NN N
, , N
and CC N
this DT N
would MD N
be VB N
expected VBN N
to TO N
simplify VB N
treatment NN N
if IN N
ABC NNP i
could MD N
be VB N
given VBN N
as IN N
part NN N
of IN N
a DT N
complete JJ N
once-daily JJ N
regimen NNS N
. . N

A DT N
randomized JJ N
double-blind JJ N
clinical JJ N
trial NN N
compared VBN N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
600 CD N
mg NN N
of IN N
ABC NNP i
administered VBD N
once RB N
daily JJ N
( ( N
n JJ N
= NNP N
384 CD N
) ) N
versus NN N
300 CD N
mg NN N
of IN N
ABC NNP i
administered VBD N
twice RB N
daily JJ N
( ( N
n JJ N
= NNP N
386 CD N
) ) N
in IN N
combination NN N
with IN N
300 CD N
mg NNS N
of IN N
lamivudine NN i
( ( i
3TC CD i
) ) i
and CC N
600 CD N
mg NN N
of IN N
efavirenz NN i
( ( i
EFV NNP i
) ) i
administered VBD N
once RB N
daily JJ N
in IN N
antiretroviral-naive JJ p
patients NNS p
over IN p
48 CD p
weeks NNS p
. . p

The DT N
baseline NN o
median JJ o
plasma NN o
HIV-1 NNP o
RNA NNP o
level NN o
was VBD N
4.89 CD N
log10 JJ N
copies/mL NN N
( ( N
44 CD N
% NN N
with IN N
viral JJ N
load NN N
> VBD N
100,000 CD N
copies/mL NN N
) ) N
, , N
and CC N
the DT N
median JJ N
CD4 NNP N
cell NN N
count NN N
was VBD N
262 CD N
cells/mm NN N
. . N

ABC NNP i
administered VBD N
once RB N
daily JJ N
was VBD N
non-inferior JJ N
to TO N
the DT N
twice-daily JJ N
regimen NNS N
, , N
with IN N
66 CD N
% NN N
and CC N
68 CD N
% NN N
of IN N
patients NNS N
in IN N
these DT N
respective JJ N
treatment NN N
arms NNS N
achieving VBG N
a DT N
confirmed JJ N
plasma NN o
HIV-1 NNP o
RNA NNP o
level NN o
< VBD N
50 CD N
copies/mL NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
-8.4 CD N
% NN N
, , N
4.9 CD N
% NN N
) ) N
. . N

The DT N
ABC NNP i
once-daily JJ N
and CC N
twice-daily JJ N
regimens NNS N
were VBD N
similar JJ N
with IN N
respect NN N
to TO N
infrequency NN o
of IN o
virologic JJ o
failure NN o
( ( N
10 CD N
% NN N
vs. FW N
8 CD N
% NN N
) ) N
, , N
emergence NN o
of IN o
resistance NN o
mutations NNS o
, , o
CD4 NNP o
cell NN o
increases NNS o
from IN o
baseline NN o
( ( N
median JJ N
, , N
188 CD N
vs. FW N
200 CD N
cells/mm NN N
) ) N
, , N
safety NN o
profile NN o
, , o
and CC o
incidence NN o
of IN o
ABC-related NNP o
hypersensitivity NN o
reactions NNS o
( ( N
9 CD N
% NN N
vs. FW N
7 CD N
% NN N
) ) N
. . N

ABC NNP i
administered VBD N
once RB N
daily JJ N
in IN N
combination NN N
with IN N
3TC CD i
and CC N
EFV NNP i
administered VBD N
once RB N
daily JJ N
was VBD N
non-inferior JJ N
to TO N
the DT N
ABC NNP i
twice-daily JJ N
dosing NN N
schedule NN N
when WRB N
combined VBN N
with IN N
3TC CD i
and CC N
EFV NNP i
over IN N
48 CD N
weeks NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
study NN N
comparing VBG N
levofloxacin NN i
, , i
omeprazole NN i
, , i
nitazoxanide RB i
, , N
and CC N
doxycycline VB i
versus NN N
triple JJ i
therapy NN i
for IN N
the DT N
eradication NN N
of IN N
Helicobacter NNP o
pylori NN o
. . o

OBJECTIVES NNP N
Resistance NNP N
to TO N
standard VB N
Helicobacter NNP p
pylori NN p
( ( p
HP NNP p
) ) p
treatment NN N
regimens VBZ N
has VBZ N
led VBN N
to TO N
unsatisfactory JJ N
cure NN N
rates NNS N
in IN N
HP-infected JJ p
patients NNS p
. . p

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
a DT N
novel JJ N
four-drug JJ i
regimen NNS i
( ( N
three CD N
antibiotics NNS N
and CC N
a DT N
proton NN N
pump NN N
inhibitor NN N
( ( N
PPI NNP N
) ) N
) ) N
for IN N
eradication NN N
of IN N
HP NNP N
infection NN N
in IN N
treatment-naive JJ p
patients NNS p
. . p

METHODS NNP N
Patients NNPS p
with IN p
a DT p
diagnosis NN p
of IN p
HP NNP p
gastritis NN p
or CC p
peptic JJ p
ulcer JJ p
disease NN p
confirmed VBD p
using VBG p
endoscopy NN p
and CC p
stool NN p
antigen NN p
testing VBG p
were VBD p
eligible JJ p
for IN p
inclusion NN p
in IN p
this DT p
study NN p
. . p

All DT N
patients NNS p
underwent VBD N
a DT N
washout JJ N
period NN N
of IN N
6 CD N
weeks NNS N
from IN N
any DT N
prior JJ N
antibiotic JJ N
or CC N
PPI JJ N
usage NN N
. . N

Patients NNS p
were VBD N
then RB N
randomized VBN N
to TO N
either DT N
levofloxacin NN i
, , i
omeprazole NN i
, , i
nitazoxanide RB i
, , i
and CC i
doxycycline NN i
( ( i
LOAD NNP i
) ) i
therapy NN N
for IN N
7 CD N
days NNS N
( ( N
LOAD-7 NNP N
) ) N
or CC N
10 CD N
days NNS N
( ( N
LOAD-10 NNP N
) ) N
, , N
including VBG N
levofloxacin JJ i
250 CD i
mg NN i
with IN i
breakfast NN i
, , i
omeprazole JJ i
40 CD i
mg NN i
before IN i
breakfast NN i
, , i
nitazoxanide RB i
( ( i
Alina NNP i
) ) i
500 CD i
mg JJ i
twice RB i
daily RB i
with IN i
meals NNS i
and CC i
doxycycline VB i
100 CD i
mg NN i
at IN i
dinner NN i
, , i
or CC i
lansoprozole NN i
, , i
amoxicillin NN i
, , i
and CC i
clarithromycin NN i
( ( i
LAC NNP i
) ) i
therapy NN i
for IN N
10 CD N
days NNS N
, , N
which WDT N
included VBD N
lansoprozole JJ i
30 CD i
mg NN i
, , i
amoxicillin VBZ i
1 CD i
g NN i
with IN i
breakfast NN i
and CC i
dinner NN i
, , i
and CC i
clarithromycin VBZ i
500 CD i
mg NN i
with IN i
breakfast NN i
and CC i
dinner NN i
. . i

HP NNP N
eradication NN N
was VBD N
confirmed VBN N
by IN N
stool NN o
antigen NN o
testing VBG o
at IN N
least JJS N
4 CD N
weeks NNS N
after IN N
cessation NN N
of IN N
therapy NN N
. . N

RESULTS NNP N
Intention-to-treat JJ o
analysis NN o
revealed VBD N
significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
respective JJ N
eradication NN o
rates NNS o
of IN o
the DT o
LOAD NNP o
therapies NNS o
( ( N
88.9 CD N
% NN N
( ( N
80/90 CD N
) ) N
LOAD-10 NNP N
, , N
90 CD N
% NN N
( ( N
81/90 CD N
) ) N
LOAD-7 NNP N
, , N
89.4 CD N
% NN N
( ( N
161/180 CD N
) ) N
for IN N
combined VBN N
LOAD NNP N
) ) N
compared VBN N
with IN N
those DT N
receiving VBG N
LAC NNP o
, , N
73.3 CD N
% NN N
( ( N
66/90 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
adverse JJ o
effects NNS o
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
This DT N
open-label JJ N
, , N
prospective JJ N
trial NN N
demonstrates VBZ N
that IN N
LOAD NNP o
is VBZ N
a DT N
highly RB N
active JJ N
regimen NNS N
for IN N
the DT N
treatment NN N
of IN N
HP NNP p
in IN p
treatment-naive JJ p
patients NNS p
. . p

A DT N
large JJ N
randomized VBN N
controlled JJ N
trial NN N
is VBZ N
warranted VBN N
to TO N
further RBR N
evaluate VB N
the DT N
efficacy NN N
of IN N
this DT N
regimen NNS N
. . N

-DOCSTART- -X- O O

A DT N
two-part JJ N
phase NN N
II NNP N
study NN N
of IN N
cediranib NN i
in IN N
patients NNS p
with IN p
advanced JJ p
solid JJ p
tumours NN p
: : p
the DT N
effect NN N
of IN N
food NN N
on IN N
single-dose JJ N
pharmacokinetics NNS N
and CC N
an DT N
evaluation NN N
of IN N
safety NN o
, , o
efficacy NN o
and CC o
imaging VBG o
pharmacodynamics NNS o
. . o

BACKGROUND NNP N
Cediranib NNP i
( ( i
RECENTIN? NNP i
) ) i
is VBZ i
an DT N
oral JJ N
, , N
highly RB N
potent JJ i
VEGF NNP i
inhibitor NN i
. . i

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
food NN N
on IN N
the DT N
pharmacokinetics NNS N
of IN N
cediranib NN i
and CC i
compared VBN N
the DT N
administration NN N
of IN N
continual JJ i
cediranib NN i
via IN i
two CD N
dosing VBG N
strategies NNS N
using VBG N
this DT N
as IN N
a DT N
platform NN N
to TO N
investigate VB N
pharmacodynamic JJ N
imaging NN N
biomarkers NNS N
. . N

METHODS NNP p
Sixty NNP p
patients NNS p
were VBD p
randomised VBN N
to TO N
receive VB N
two CD N
single JJ N
doses NNS N
of IN N
cediranib NN i
in IN i
either CC i
fed/fasted VBD i
or CC i
fasted/fed JJ i
state NN i
( ( i
Part NNP N
A NNP N
) ) N
. . N

In IN N
continual JJ N
dosage NN N
phase NN N
( ( N
Part NNP N
B NNP N
) ) N
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
a DT N
fixed-dose JJ N
or CC N
dose-escalation JJ N
arm NN o
. . o

Exploratory JJ o
pharmacodynamic JJ o
assessments NNS o
were VBD o
performed VBN N
using VBG i
DCE-MRI NNP i
and CC i
CT NNP i
enhancing VBG i
fraction NN i
( ( i
EnF NNP N
) ) N
. . N

RESULTS VBN N
In IN N
part NN N
A NNP N
, , N
plasma NN o
AUC NNP o
and CC o
C NNP o
( ( o
max NN o
) ) o
of IN o
cediranib NN o
were VBD o
lower JJR N
in IN N
the DT N
presence NN N
of IN N
food NN N
by IN N
a DT N
mean NN N
of IN N
24 CD N
and CC N
33 CD N
% NN N
, , N
respectively RB N
( ( N
94 CD N
% NN N
CI NNP N
: : N
AUC NNP N
, , N
12-34 CD N
% NN N
and CC N
C NNP N
( ( N
max NN N
) ) N
, , N
20-43 JJ N
% NN N
) ) N
, , N
indicating VBG N
food NN N
reduces NNS o
cediranib VBP o
plasma JJ o
exposure NN o
. . o

In IN N
part NN N
B NNP N
, , N
cediranib VBZ i
30 CD i
mg/day NN N
appeared VBD N
to TO N
be VB N
the DT N
most RBS N
sustainable JJ N
for IN N
chronic JJ N
dosing NN i
. . i

Continuous JJ i
cediranib NN i
therapy NN i
was VBD i
associated VBN N
with IN o
sustained JJ o
antivascular JJ o
effects NNS o
up RB o
to TO N
16 CD N
weeks NNS N
, , N
with IN N
significant JJ N
reductions NNS o
in IN o
DCE-MRI NNP o
parameters NNS o
and CC o
CT NNP o
EnF NNP o
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
recommended VBN N
that IN N
cediranib NN i
be VB i
administered VBN N
at IN N
least JJS N
1 CD N
h NN N
before IN N
or CC N
2 CD N
h NN N
after IN N
food NN N
. . N

Evidence NN o
of IN o
antitumour JJ o
activity NN o
was VBD o
observed VBN o
, , N
with IN N
significant JJ N
sustained JJ N
effects NNS o
upon IN o
imaging VBG o
vascular JJ o
parameters NNS o
. . o

-DOCSTART- -X- O O

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
an DT N
intervention NN i
for IN N
toddlers NNS p
with IN p
autism NN p
: : p
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
. . N

OBJECTIVE NNP N
To TO N
conduct VB N
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
the DT N
Early JJ i
Start NNP i
Denver NNP i
Model NNP i
( ( i
ESDM NNP i
) ) i
, , N
a DT N
comprehensive JJ N
developmental JJ N
behavioral JJ N
intervention NN N
, , N
for IN N
improving VBG N
outcomes NNS N
of IN N
toddlers NNS p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
Forty-eight JJ p
children NNS p
diagnosed VBN p
with IN p
ASD NNP p
between IN p
18 CD p
and CC p
30 CD p
months NNS p
of IN p
age NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
ESDM NNP i
intervention NN i
, , N
which WDT N
is VBZ N
based VBN N
on IN N
developmental JJ N
and CC N
applied JJ N
behavioral JJ N
analytic JJ N
principles NNS N
and CC N
delivered VBN N
by IN N
trained JJ N
therapists NNS N
and CC N
parents NNS N
for IN N
2 CD N
years NNS N
; : N
or CC N
( ( N
2 CD N
) ) N
referral NN i
to TO i
community NN i
providers NNS i
for IN i
intervention NN i
commonly RB i
available JJ i
in IN i
the DT i
community NN i
. . i

RESULTS NNP N
Compared VBD N
with IN N
children NNS N
who WP N
received VBD N
community-intervention NN N
, , N
children NNS N
who WP N
received VBD N
ESDM NNP N
showed VBD N
significant JJ N
improvements NNS N
in IN N
IQ NNP o
, , o
adaptive JJ o
behavior NN o
, , o
and CC o
autism NN o
diagnosis NN o
. . o

Two CD N
years NNS N
after IN N
entering VBG N
intervention NN N
, , N
the DT N
ESDM NNP N
group NN N
on IN N
average NN N
improved VBD N
17.6 CD N
standard NN N
score NN N
points NNS N
( ( N
1 CD N
SD NNP N
: : N
15 CD N
points NNS N
) ) N
compared VBN N
with IN N
7.0 CD N
points NNS N
in IN N
the DT N
comparison NN N
group NN N
relative VBP N
to TO N
baseline VB N
scores NNS N
. . N

The DT N
ESDM NNP N
group NN N
maintained VBD N
its PRP$ N
rate NN o
of IN o
growth NN o
in IN o
adaptive JJ o
behavior NN o
compared VBN N
with IN N
a DT N
normative JJ N
sample NN N
of IN N
typically RB N
developing VBG N
children NNS N
. . N

In IN N
contrast NN N
, , N
over IN N
the DT N
2-year JJ N
span NN N
, , N
the DT N
comparison NN N
group NN N
showed VBD N
greater JJR N
delays NNS N
in IN N
adaptive JJ o
behavior NN o
. . o

Children NNP N
who WP N
received VBD N
ESDM NNP i
also RB N
were VBD N
more RBR N
likely JJ N
to TO N
experience VB N
a DT N
change NN o
in IN o
diagnosis NN o
from IN N
autism NN N
to TO N
pervasive VB N
developmental JJ N
disorder NN N
, , N
not RB N
otherwise RB N
specified VBN N
, , N
than IN N
the DT N
comparison NN N
group NN N
. . N

CONCLUSIONS NNP N
This DT N
is VBZ N
the DT N
first JJ N
randomized VBN N
, , N
controlled VBN N
trial NN N
to TO N
demonstrate VB N
the DT N
efficacy NN N
of IN N
a DT N
comprehensive JJ N
developmental JJ N
behavioral JJ N
intervention NN N
for IN N
toddlers NNS p
with IN p
ASD NNP p
for IN N
improving VBG N
cognitive JJ o
and CC o
adaptive JJ o
behavior NN o
and CC N
reducing VBG N
severity NN o
of IN o
ASD NNP o
diagnosis NN o
. . o

Results NNS N
of IN N
this DT N
study NN N
underscore VBD N
the DT N
importance NN N
of IN N
early JJ N
detection NN N
of IN N
and CC N
intervention NN N
in IN N
autism NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
L-carnitine NNP i
on IN N
myocardial JJ N
metabolism NN N
: : N
results NNS N
of IN N
a DT N
balanced JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
study NN N
in IN N
patients NNS p
undergoing VBG p
open JJ p
heart NN p
surgery NN p
. . p

The DT N
effects NNS N
of IN N
L-carnitine NNP i
on IN N
cardiac JJ N
performance NN N
after IN N
open JJ N
heart NN N
surgery NN N
were VBD N
evaluated VBN N
in IN N
a DT N
balanced JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
study NN N
in IN N
38 CD p
patients NNS p
. . p

Preoperative JJ N
haemodynamic JJ N
status NN N
was VBD N
good JJ N
in IN N
all DT N
of IN N
them PRP N
. . N

Seventeen JJ p
subjects NNS p
underwent JJ p
mitral JJ i
valve NN i
replacement NN i
and CC p
19 CD p
patients NNS p
coronary JJ i
artery JJ i
bypass NN i
grafting NN i
. . i

Five CD N
grams NNS N
L-carnitine JJ i
were VBD N
given VBN N
intravenously RB N
over IN N
2 CD N
h NNS N
, , N
twice RB N
daily RB N
for IN N
5 CD N
consecutive JJ N
days NNS N
; : N
moreover RB N
, , N
10 CD N
g JJ N
L-carnitine NNP i
in IN i
1500 CD i
ml NN i
cardioplegia NN i
were VBD N
administered VBN N
through IN N
the DT N
aortic JJ N
root NN N
after IN N
aortic JJ i
cross-clamping NN i
. . i

Surgery NN N
was VBD N
always RB N
planned VBN N
on IN N
treatment NN N
day NN N
3 CD N
. . N

The DT N
post-ischaemic JJ N
functional JJ N
recovery NN N
of IN N
the DT N
heart NN N
was VBD N
assessed VBN N
by IN N
clinical JJ N
parameters NNS N
, , N
as RB N
well RB N
as IN N
by IN N
biochemical JJ N
and CC N
ultrastructure JJ N
evaluations NNS N
on IN N
biopsy NN N
specimens NNS N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
control NN N
and CC N
the DT N
treatment NN N
group NN N
with IN N
respect NN N
to TO N
all DT N
clinical JJ N
parameters NNS N
of IN N
cardiac JJ N
performance NN N
after IN N
cardiopulmonary JJ N
bypass NN N
. . N

At IN N
anaesthesia JJ N
induction NN N
, , N
serum JJ o
carnitine NN o
was VBD N
significantly RB N
increased VBN N
in IN N
treated JJ N
patients NNS N
, , N
but CC N
carnitine JJ o
concentrations NNS o
in IN N
the DT N
right JJ N
atrial JJ N
biopsy NN N
obtained VBN N
just RB N
before RB N
aortic JJ N
declamping NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
patients NNS N
with IN N
mitral JJ N
valve FW N
replacement NN N
, , N
L-carnitine JJ i
therapy NN i
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
concentrations NNS N
of IN N
pyruvate NN o
, , o
ATP NNP o
and CC o
creatine JJ o
phosphate NN o
in IN N
papillary JJ N
muscle NN N
. . N

Glycogen NN o
levels NNS o
were VBD N
also RB N
higher JJR N
in IN N
the DT N
treated JJ N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Myocardial JJ N
ultrastructure NN N
on IN N
septal JJ N
biopsies NNS N
, , N
obtained VBD N
within IN N
5 CD N
min NN N
from IN N
weaning VBG N
from IN N
extracorporeal JJ N
circulation NN N
, , N
showed VBD N
better JJR N
preservation NN N
scores NNS N
for IN N
all DT N
considered VBN N
parameters NNS N
( ( o
nucleus NN o
, , o
sarcoplasmic JJ o
reticulum NN o
, , o
mitochondria NN o
and CC o
cellular JJ o
oedema NN o
) ) o
in IN N
the DT N
treated JJ N
subjects NNS N
, , N
although IN N
the DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
only RB N
for IN N
nuclei NN N
. . N

When WRB N
biochemical JJ N
and CC N
ultrastructural JJ N
data NNS N
are VBP N
considered VBN N
, , N
these DT N
findings NNS N
suggest VBP N
that IN N
L-carnitine NNP i
improves VBZ N
myocardial JJ o
metabolism NN o
. . o

However RB N
, , N
it PRP N
can MD N
not RB N
be VB N
concluded VBN N
that IN N
L-carnitine NNP N
provides VBZ N
an DT N
advantageous JJ o
support NN o
therapy NN o
for IN N
well-compensated JJ N
patients NNS p
requiring VBG p
cardiac JJ p
surgery NN p
. . p

In IN N
contrast NN N
, , N
the DT N
positive JJ N
effects NNS N
of IN N
L-carnitine NNP N
on IN N
cardiac JJ o
recovery NN o
after IN N
bypass NN N
might MD N
become VB N
clinically RB N
relevant JJ N
in IN N
the DT N
surgical JJ N
setting NN N
for IN N
haemodynamically RB p
compromised JJ p
patients NNS p
, , N
in IN N
which WDT N
further JJ N
investigations NNS N
are VBP N
required VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
standardized JJ i
pamphlet NN i
on IN N
insomnia NN o
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

OBJECTIVE NNP N
Sleep NNP o
difficulties NNS o
are VBP N
common JJ N
reasons NNS N
why WRB p
parents NNS p
seek VBP p
medical JJ p
intervention NN p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
. . p

We PRP N
determined VBD N
whether IN N
a DT N
pamphlet NN i
alone RB N
could MD N
be VB N
used VBN N
by IN N
parents NNS N
to TO N
help VB N
their PRP$ N
child NN N
's POS N
insomnia NN o
. . o

METHODS NNP N
Thirty-six JJ p
children NNS p
with IN p
ASD NNP p
, , p
ages VBZ p
2 CD p
to TO p
10 CD p
years NNS p
, , p
were VBD p
enrolled VBN p
. . p

All DT p
had VBD p
prolonged VBN p
sleep JJ o
latency NN o
confirmed VBN p
by IN p
actigraphy NN p
showing VBG p
a DT p
mean JJ p
sleep JJ o
latency NN o
of IN p
30 CD p
minutes NNS p
or CC p
more JJR p
. . p

Parents NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
the DT p
sleep JJ i
education NN i
pamphlet NN i
or CC i
no DT i
intervention NN i
. . i

Children NNP N
wore VBD N
an DT N
actigraphy NN i
device NN i
to TO N
record VB N
baseline NN N
sleep JJ o
parameters NNS o
, , N
with IN N
the DT N
primary JJ N
outcome NN N
variable JJ N
being VBG N
change NN o
in IN o
sleep JJ o
latency NN o
. . o

Actigraphy NNP N
data NNS N
were VBD N
collected VBN N
a DT N
second JJ N
time NN N
2 CD N
weeks NNS N
after IN N
the DT N
parent NN N
received VBD N
the DT N
randomization NN N
assignment NN N
and CC N
analyzed VBN N
by IN N
using VBG N
Student NNP N
's POS N
t JJ N
test NN N
. . N

Parents NNS N
were VBD N
also RB N
asked VBN N
a DT N
series NN N
of IN N
questions NNS N
to TO N
gather VB N
information NN N
about IN N
the DT N
pamphlet NN i
and CC N
its PRP$ N
usefulness NN N
. . N

RESULTS NNP N
Although IN N
participants NNS N
randomized VBN N
to TO N
the DT N
2 CD N
arms NNS N
did VBD N
not RB N
differ VB N
statistically RB N
in IN N
age NN o
, , o
gender NN o
, , o
socioeconomic JJ o
status NN o
, , o
total JJ o
Children NNP o
's POS o
Sleep NNP o
Habits NNP o
Questionnaire NNP o
score NN o
, , o
or CC o
actigraphy NN o
parameters NNS o
, , N
some DT N
differences NNS N
may MD N
be VB N
large JJ N
enough RB N
to TO N
affect VB N
results NNS N
. . N

Mean JJ o
change NN o
in IN o
sleep-onset JJ o
latency NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
randomized VBN N
groups NNS N
( ( i
pamphlet VB i
versus NN i
no DT i
pamphlet NN i
) ) i
. . i

Parents NNS N
commented VBD N
that IN N
the DT N
pamphlet NN i
contained VBD N
good JJ N
information NN o
, , N
but CC N
indicated VBD N
that IN N
it PRP N
would MD N
have VB N
been VBN N
more RBR N
useful JJ N
to TO N
be VB N
given VBN N
specific JJ N
examples NNS N
of IN N
how WRB N
to TO N
take VB N
the DT N
information NN N
and CC N
put VB N
it PRP N
into IN N
practice NN N
. . N

CONCLUSIONS VB N
A DT N
sleep JJ i
education NN i
pamphlet NN i
did VBD N
not RB N
appear VB N
to TO N
improve VB N
sleep JJ o
latency NN o
in IN p
children NNS p
with IN p
ASDs NNP p
. . p

-DOCSTART- -X- O O

Health NNP N
promotion NN N
and CC N
disease NN N
prevention NN N
for IN N
older JJR p
adults NNS p
: : p
opportunity NN N
for IN N
change NN N
or CC N
preaching NN N
to TO N
the DT N
converted VBN N
? . N
Health NNP N
promotion NN N
and CC N
disease NN N
prevention NN N
for IN N
the DT p
elderly JJ p
offer NN N
the DT N
potential NN N
for IN N
improving VBG N
the DT N
quality NN N
of IN N
life NN N
for IN N
the DT N
growing VBG N
population NN N
of IN N
older JJR p
adults NNS p
, , N
while IN N
reducing VBG N
the DT N
economic JJ N
burden NN N
on IN N
the DT N
health NN N
system NN N
. . N

Whether CC N
this DT N
potential JJ N
can MD N
be VB N
realized VBN N
depends NNS N
, , N
in IN N
part NN N
, , N
on IN N
whether IN N
those DT N
older JJR p
adults NNS p
whose WP$ p
health NN p
behaviors NNS p
put VBD p
them PRP p
at IN p
risk NN p
actually RB N
use VBP N
preventive JJ i
services NNS i
when WRB N
offered VBD N
the DT N
opportunity NN N
. . N

In IN N
1988 CD p
the DT p
Health NNP p
Care NNP p
Financing NNP p
Administration NNP p
began VBD N
a DT N
series NN N
of IN N
health NN i
promotion NN i
demonstrations NNS i
to TO N
address VB N
health NN N
issues NNS N
related VBN N
to TO N
older JJR p
adults NNS p
. . p

This DT N
article NN N
reports VBZ N
on IN N
program NN N
participation NN N
at IN N
one CD p
of IN p
the DT p
five CD p
demonstration NN p
sites NNS p
. . p

Over IN p
1,900 CD p
community-dwelling JJ p
Medicare NNP p
beneficiaries NNS p
who WP p
receive VBP p
their PRP$ p
health NN p
care NN p
through IN p
fee-for-service JJ p
providers NNS p
were VBD p
enrolled VBN p
in IN p
the DT p
demonstration NN p
. . p

These DT N
enrollees NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
control VB i
and CC N
experimental JJ N
groups NNS N
, , N
with IN N
the DT N
latter JJ N
offered VBN N
health NN i
screening NN i
and CC i
promotion NN i
services NNS i
. . i

Nine NNP p
hundred-seventy-three NN p
of IN p
the DT p
experimental JJ p
subjects NNS p
and CC p
938 CD p
of IN p
the DT p
control NN p
subjects VBZ p
completed VBN p
a DT p
lengthy JJ p
telephone NN p
interview NN p
, , p
which WDT p
determined VBD p
each DT p
person NN p
's POS p
use NN p
of IN p
preventive JJ p
services NNS p
and CC p
practices NNS p
. . p

Although IN p
all DT p
973 CD p
experimental JJ p
subjects NNS p
were VBD p
invited VBN p
by IN p
letter NN p
and CC p
follow-up JJ p
telephone NN p
calls VBZ p
to TO p
attend VB p
these DT p
free-of-charge JJ p
, , p
Medicare-provided JJ p
sessions NNS p
, , p
not RB p
everyone NN p
attended VBD p
. . N

We PRP N
analyzed VBD N
17 CD N
health NN N
behaviors NNS N
of IN N
those DT N
who WP N
attended VBD N
the DT N
first JJ N
session NN N
and CC N
those DT N
who WP N
did VBD N
not RB N
. . N

Those DT N
engaging VBG N
in IN N
these DT N
preventive JJ N
behaviors NNS N
were VBD N
neither RB N
more JJR N
nor CC N
less RBR N
likely JJ N
to TO N
attend VB N
the DT N
screening NN N
services NNS N
. . N

Thus RB N
, , N
we PRP N
found VBD N
neither CC N
favorable JJ N
nor CC N
unfavorable JJ N
selection NN N
bias NN N
in IN N
the DT N
use NN N
of IN N
these DT N
preventive JJ N
services NNS N
. . N

-DOCSTART- -X- O O

Development NNP N
of IN N
the DT N
Therapist NNP p
Empathy NNP N
Scale NNP N
. . N

BACKGROUND NNP N
Few JJ N
measures NNS N
exist VBP N
to TO N
examine VB N
therapist NN p
empathy NN N
as IN N
it PRP N
occurs VBZ N
in IN N
session NN N
. . N

AIMS VB N
A DT N
9-item JJ N
observer NN N
rating NN N
scale NN N
, , N
called VBD N
the DT N
Therapist NNP i
Empathy NNP i
Scale NNP i
( ( N
TES NNP N
) ) N
, , N
was VBD N
developed VBN N
based VBN N
on IN N
Watson NNP N
's POS N
( ( N
1999 CD N
) ) N
work NN N
to TO N
assess VB N
affective JJ N
, , N
cognitive JJ N
, , N
attitudinal JJ N
, , N
and CC N
attunement JJ N
aspects NNS N
of IN N
therapist NN N
empathy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
inter-rater JJ N
reliability NN N
, , N
internal JJ N
consistency NN N
, , N
and CC N
construct NN N
and CC N
criterion NN N
validity NN N
of IN N
the DT N
TES NNP N
. . N

METHOD NNP N
Raters NNPS N
evaluated VBD N
therapist JJ p
empathy NN N
in IN N
315 CD p
client NN i
sessions NNS i
conducted VBN p
by IN p
91 CD p
therapists NNS p
, , p
using VBG p
data NNS p
from IN p
a DT p
multi-site JJ p
therapist NN p
training NN p
trial NN p
( ( p
Martino NNP p
et RB p
al. RB p
, , N
2010 CD p
) ) p
in IN p
Motivational NNP i
Interviewing NNP i
( ( i
MI NNP i
) ) i
. . i

RESULTS JJ N
Inter-rater JJ o
reliability NN o
( ( N
ICC NNP N
= NNP N
.87 NNP N
to TO N
.91 VB N
) ) N
and CC N
internal JJ o
consistency NN o
( ( N
Cronbach NNP N
's POS N
alpha NN N
= NNP N
.94 NNP N
) ) N
were VBD N
high JJ N
. . N

Confirmatory NNP N
factor NN o
analyses NNS o
indicated VBD N
some DT N
support NN N
for IN N
single-factor JJ N
fit NN N
. . N

Convergent NNP o
validity NN o
was VBD N
supported VBN N
by IN N
correlations NNS N
between IN N
TES NNP o
scores NNS o
and CC o
MI NNP o
fundamental JJ o
adherence NN o
( ( N
r JJ N
range NN N
.50 NN N
to TO N
.67 VB N
) ) N
and CC N
competence NN o
scores NNS o
( ( N
r NN N
range NN N
.56 NN N
to TO N
.69 VB N
) ) N
. . N

Discriminant JJ o
validity NN o
was VBD N
indicated VBN N
by IN N
negative JJ N
or CC N
nonsignificant JJ N
correlations NNS N
between IN N
TES NNP N
and CC N
MI-inconsistent NNP N
behavior NN N
( ( N
r JJ N
range NN N
.05 NN N
to TO N
-.33 VB N
) ) N
. . N

CONCLUSIONS VB N
The DT N
TES NNP N
demonstrates VBZ N
excellent JJ N
inter-rater JJ N
reliability NN N
and CC N
internal JJ N
consistency NN N
. . N

RESULTS NNP N
indicate VBP N
some DT N
support NN N
for IN N
a DT N
single-factor JJ N
solution NN N
and CC N
convergent NN N
and CC N
discriminant JJ N
validity NN N
. . N

Future JJ N
studies NNS N
should MD N
examine VB N
the DT N
use NN N
of IN N
the DT N
TES NNP N
to TO N
evaluate VB N
therapist NN p
empathy NN N
in IN N
different JJ N
psychotherapy NN N
approaches NNS N
and CC N
to TO N
determine VB N
the DT N
impact NN N
of IN N
therapist NN N
empathy NN N
on IN N
client NN N
outcome NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN o
of IN N
norgestimate NN i
and CC N
ethinyl NN i
estradiol NN i
in IN N
treating VBG N
moderate JJ p
acne NN p
vulgaris NN p
. . p

BACKGROUND NNP N
An DT N
excess NN N
of IN N
androgen NN N
is VBZ N
believed VBN N
to TO N
contribute VB N
to TO N
development NN N
of IN N
acne NN N
in IN N
some DT N
patients NNS N
. . N

Because IN N
oral JJ i
contraceptives NNS i
( ( N
OCs NNP N
) ) N
may MD N
reduce VB N
the DT N
active JJ o
androgen NN o
level NN o
, , N
hormonal JJ N
therapy NN N
with IN N
OCs NNP N
has VBZ N
been VBN N
used VBN N
successfully RB N
to TO N
treat VB N
patients NNS p
with IN p
acne NN p
, , N
although IN N
this DT N
treatment NN N
has VBZ N
previously RB N
not RB N
been VBN N
studied VBN N
in IN N
placebo-controlled JJ N
trials NNS N
. . N

OBJECTIVE CC N
Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
a DT N
triphasic JJ i
, , i
combination NN i
OC NNP i
( ( i
ORTHO NNP i
TRI-CYCLEN NNP i
[ NNP i
Ortho-McNeil NNP i
Pharmaceutical NNP i
, , i
Raritan NNP i
, , i
N.J. NNP i
] NNP i
, , i
norgestimate/ethinyl RB i
estradiol NN i
) ) i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
moderate JJ N
acne NN N
vulgaris NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
fifty-seven RB p
healthy JJ p
female NN p
subjects NNS p
, , p
15 CD p
to TO p
49 CD p
years NNS p
of IN p
age NN p
with IN p
moderate JJ p
acne NNS p
vulgaris NN p
, , N
were VBD N
enrolled VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Each DT N
month NN N
for IN N
6 CD N
months NNS N
, , N
subjects VBZ N
received VBN N
either RB N
3 CD N
consecutive JJ N
weeks NNS N
of IN N
the DT N
OC NNP i
( ( N
i.e. FW N
, , N
tablets NNS N
containing VBG N
a DT N
fixed VBN N
dose NN N
of IN N
ethinyl JJ i
estradiol NN i
[ VBD i
0.035 CD i
mg NN i
] NN i
and CC i
increasing VBG i
doses NNS i
of IN i
norgestimate JJ i
[ NNS N
0.180 CD N
mg NNS N
, , N
0.215 CD N
mg NN N
, , N
0.250 CD N
mg NN N
] NN N
) ) N
followed VBN N
by IN N
7 CD N
days NNS N
of IN N
inactive JJ i
drug NN i
or CC i
placebo NN i
( ( N
color-matched JJ N
tablets NNS N
) ) N
. . N

Efficacy NN o
was VBD N
assessed VBN N
by IN N
facial JJ o
acne JJ o
lesion NN o
counts NNS o
, , N
an DT N
investigator NN N
's POS N
global JJ o
assessment NN o
, , N
a DT N
subject NN o
's POS o
self-assessment NN o
, , N
and CC N
an DT N
analysis NN N
of IN N
within-cycle JJ o
variation NN o
( ( o
cycle NN o
6 CD o
) ) o
in IN o
lesion NN o
counts NNS o
. . o

RESULTS NNP N
Of IN N
the DT N
160 CD p
subjects NNS p
in IN N
whom WP N
efficacy NN N
could MD N
be VB N
evaluated VBN N
, , N
the DT N
OC NNP N
group NN N
showed VBD N
a DT N
statistically RB N
significantly RB N
greater JJR N
improvement NN o
than IN N
the DT N
placebo NN p
group NN p
for IN N
all DT N
primary JJ N
efficacy NN N
measures NNS N
. . N

The DT N
mean JJ o
decrease NN o
in IN o
inflammatory JJ o
lesion NN o
count NN o
from IN N
baseline NN N
to TO N
cycle NN N
6 CD N
was VBD N
11.8 CD N
( ( N
62.0 CD N
% NN N
) ) N
versus NN N
7.6 CD N
( ( N
38.6 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
, , N
and CC N
the DT N
mean JJ o
decrease NN o
in IN o
total JJ o
lesion NN o
count NN o
was VBD N
29.1 CD N
( ( N
53.1 CD N
% NN N
) ) N
versus NN N
14.1 CD N
( ( N
26.8 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.0001 CD N
) ) N
in IN N
the DT N
OC NNP N
and CC N
placebo NN N
groups NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
investigator NN o
's POS o
global JJ o
assessment NN o
, , N
93.7 CD N
% NN N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
versus VBD N
65.4 CD N
% NN N
of IN N
the DT N
placebo NN N
group NN N
were VBD N
rated VBN N
as IN N
improved VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Six CD N
of IN N
the DT N
seven CD N
secondary JJ o
efficacy NN o
measures NNS o
( ( o
total JJ o
comedones NNS o
, , o
open JJ o
comedones NNS o
, , o
closed VBD o
comedones NNS o
, , o
papules NNS o
, , o
pustules NNS o
, , o
and CC o
the DT o
subject NN o
's POS o
self-assessment NN o
of IN o
study NN o
treatment NN o
) ) o
were VBD N
also RB N
significantly RB N
more RBR N
favorable JJ N
in IN N
the DT N
OC NNP N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
. . N

CONCLUSION NNP N
An DT N
OC NNP N
containing VBG N
0.035 CD N
mg NN N
of IN N
ethinyl JJ i
estradiol NN i
combined VBN N
with IN N
the DT N
triphasic JJ N
regimen NNS N
of IN N
norgestimate NN N
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
treatment NN o
of IN o
moderate JJ o
acne NNS o
vulgaris VBP o
in IN p
women NNS p
with IN p
no DT p
known VBN p
contraindication NN p
to TO p
OC NNP p
therapy NN p
. . p

-DOCSTART- -X- O O

Parents NNS p
' POS p
state NN N
and CC N
trait NN N
anxiety NN N
: : N
relationships NNS N
with IN N
anxiety NN o
severity NN o
and CC N
treatment NN N
response NN N
in IN N
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Comorbid NNP N
anxiety NN N
is VBZ N
common JJ N
among IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
, , p
and CC p
parents NNS p
of IN p
children NNS p
with IN p
ASD NNP p
are VBP p
more RBR p
likely JJ p
to TO p
have VB p
anxiety NN p
disorders NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
relationship NN N
between IN N
parents NNS i
' POS i
state NN o
and CC o
trait NN o
anxiety NN o
and CC p
parent-reported JJ i
internalizing NN i
and CC i
externalizing VBG i
symptoms NNS i
among IN i
adolescents NNS i
( ( p
n JJ p
= NNP p
30 CD p
) ) p
with IN p
ASD NNP p
, , p
as RB p
well RB p
as IN p
the DT p
relationship NN p
of IN p
parents NNS o
' POS o
anxiety NN o
symptoms NNS o
and CC o
adolescent JJ o
treatment NN o
response NN o
in IN o
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN o
. . o

Parental JJ o
state NN o
anxiety NN o
correlated VBD o
with IN o
severity NN o
of IN o
adolescent JJ o
anxiety NN o
, , o
and CC o
trait NN o
anxiety NN o
in IN o
parents NNS N
correlated VBN N
with IN o
parent-reported JJ o
adolescent NN o
internalizing NN o
and CC o
externalizing NN o
symptoms NNS o
. . o

Also RB N
, , N
parents NNS N
of IN N
adolescent JJ N
treatment NN N
responders NNS N
experienced VBD N
a DT N
decrease NN o
in IN o
their PRP$ o
own JJ o
trait NN o
anxiety NN o
. . o

Findings NNS N
highlight VBD N
the DT N
importance NN N
of IN N
considering VBG o
parental JJ o
anxiety NN o
when WRB o
targeting VBG o
anxiety NN o
among IN o
youth NN N
with IN N
ASD NNP N
. . N

-DOCSTART- -X- O O

Chemotherapy NN N
of IN N
large JJ p
bowel NN p
carcinoma NN i
-- : i
fluorouracil NN i
( ( i
FU NNP i
) ) i
+ VBP i
hydroxyurea NN i
( ( i
HU NNP i
) ) i
vs. FW i
methyl-CCNU NN i
, , i
oncovin NN i
, , i
fluorouracil NN i
, , i
and CC i
streptozotocin NN i
( ( i
MOF-Strep NNP i
) ) i
. . i

An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
of IN N
initial JJ N
chemotherapy NN N
for IN N
advanced JJ p
measurable JJ p
metastatic JJ p
large JJ p
bowel NN o
carcinoma NN o
, , N
the DT N
response NN o
rate NN o
was VBD N
6/32 CD p
( ( p
19 CD p
% NN p
) ) p
for IN p
FU NNP p
+ NNP p
HU NNP p
and CC p
5/32 CD p
( ( p
16 CD p
% NN p
) ) p
for IN p
MOF-Strep NNP p
; : p
the DT N
estimated JJ N
median JJ o
survival NN o
is VBZ N
43 CD N
weeks NNS N
for IN N
both DT N
treatments NNS N
. . N

Patients NNS N
who WP N
received VBD N
MOF-Strep NNP N
experienced VBD N
substantially RB N
greater JJR N
vomiting VBG o
and CC o
hematologic JJ o
toxicity NN o
than IN N
patients NNS p
who WP p
received VBD p
FU NNP N
+ NNP N
HU NNP N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -X- O O

Specific JJ i
immunoglobulin NN i
for IN N
treatment NN N
of IN N
whooping JJ p
cough NN p
. . p

Immunoglobulin NNP i
treatment NN N
for IN N
whooping JJ N
cough NN N
( ( N
pertussis NN N
) ) N
is VBZ N
widely RB N
believed VBN N
to TO N
be VB N
ineffective JJ o
although IN N
there EX N
are VBP N
sound JJ N
reasons NNS N
for IN N
regarding VBG N
the DT N
condition NN N
as IN N
a DT N
toxin-induced JJ N
disease NN N
. . N

We PRP N
wondered VBD N
whether IN N
the DT N
lack NN o
of IN o
success NN o
with IN N
pertussis NN N
immunoglobulins NNS i
might MD N
be VB N
attributable JJ N
to TO N
inadequate VB N
dose NN N
, , N
so IN N
we PRP N
designed VBD N
a DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
two CD N
immunoglobulin JJ N
preparations NNS N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
at IN N
three CD p
Swedish JJ p
hospitals NNS p
. . p

We PRP N
enrolled VBD N
73 CD p
children NNS p
aged VBD p
less JJR p
than IN p
36 CD p
months NNS p
who WP p
were VBD p
admitted VBN p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
whooping JJ p
cough NN p
. . p

On IN N
admission NN N
they PRP N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
: : N
( ( N
a DT N
) ) N
monocomponent NN i
pertussis NN i
toxoid JJ i
vaccine NN i
; : i
( ( i
b NN i
) ) i
two-component NN i
acellular JJ i
vaccine NN i
also RB i
containing VBG i
filamentous JJ i
haemagglutinin NN i
; : i
or CC i
( ( i
c NN i
) ) i
20 CD i
% NN i
albumin JJ i
solution NN i
( ( i
placebo NN i
) ) i
. . i

The DT N
immunoglobulins NNS i
had VBD N
a DT N
high JJ N
antitoxin NN N
content NN N
and CC N
had VBD N
been VBN N
raised VBN N
with IN N
acellular JJ N
pertussis NN N
vaccines NNS N
. . N

Diagnosis NN N
of IN N
pertussis NN N
was VBD N
confirmed VBN N
by IN N
laboratory NN N
tests NNS N
and CC N
the DT N
follow-up NN N
was VBD N
completed VBN N
in IN N
67 CD N
children NNS N
. . N

The DT N
main JJ N
study NN N
group NN N
consisted VBD N
of IN N
47 CD p
children NNS p
with IN p
less JJR p
than IN p
or CC p
equal JJ p
to TO p
14 CD p
days NNS p
of IN p
disease NN p
before IN p
therapy NN p
. . p

Duration NN o
of IN o
whoops JJ o
post-treatment NN o
was VBD N
8.7 CD N
days NNS N
( ( N
95 CD N
% NN N
Cl NNP N
4.8 CD N
, , N
12.6 CD N
) ) N
in IN N
the DT N
33 CD N
children NNS N
receiving VBG N
immunoglobulin NN i
vs NN N
20.6 CD N
( ( N
95 CD N
% NN N
Cl NNP N
11.9 CD N
, , N
29.3 CD N
) ) N
in IN N
the DT N
14 CD N
receiving NN N
placebo NN i
( ( N
p JJ N
= NNP N
0.0041 CD N
) ) N
. . N

Mean JJ o
number NN o
of IN o
whoops NNS o
during IN N
the DT N
first JJ N
week NN N
of IN N
follow-up NN N
was VBD N
also RB N
significantly RB N
reduced VBN N
( ( N
p JJ N
= NNP N
0.0196 CD N
) ) N
. . N

We PRP N
found VBD N
that IN N
early JJ N
treatment NN N
was VBD N
important JJ N
, , N
since IN N
the DT N
effect NN N
on IN N
duration NN o
of IN o
whoops NNS o
was VBD N
most RBS N
pronounced JJ N
when WRB N
disease NN N
duration NN N
before IN N
treatment NN N
was VBD N
less JJR N
than IN N
or CC N
equal JJ N
to TO N
7 CD N
days NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS o
between IN N
the DT N
two CD N
immunoglobulin NN N
preparations NNS N
. . N

High-dose JJ N
specific JJ N
pertussis NN N
immunoglobulin NN i
with IN N
a DT N
high JJ N
antitoxin NN N
concentration NN N
has VBZ N
a DT N
beneficial JJ o
effect NN o
in IN N
the DT N
treatment NN N
of IN N
whooping JJ N
cough NN N
. . N

-DOCSTART- -X- O O

Behavioral JJ i
parent NN i
training NN i
to TO N
address VB N
sleep JJ o
disturbances NNS o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
pilot NN N
trial NN N
. . N

OBJECTIVES CC N
A DT N
large JJ N
percentage NN N
of IN N
children NNS N
with IN N
autism NN N
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
have VBP N
bedtime VBN o
and CC N
sleep JJ o
disturbances NNS o
. . o

However RB N
, , N
the DT N
treatment NN N
of IN N
these DT N
disturbances NNS o
has VBZ N
been VBN N
understudied VBN N
. . N

The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
develop VB N
a DT N
manualized JJ i
behavioral JJ i
parent NN i
training NN i
( ( N
BPT NNP N
) ) N
program NN N
for IN N
parents NNS p
of IN p
young JJ p
children NNS p
with IN p
ASD NNP p
and CC N
sleep JJ o
disturbances NNS o
and CC N
to TO N
test VB N
the DT N
feasibility NN o
, , o
fidelity NN o
, , o
and CC o
initial JJ o
efficacy NN o
of IN N
the DT N
treatment NN N
in IN N
a DT N
small JJ N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

PARTICIPANTS NNP N
AND CC N
METHODS NNP N
Parents NNP p
of IN p
a DT p
sample NN p
of IN p
40 CD p
young JJ p
children NNS p
diagnosed VBN p
with IN p
ASD NNP p
with IN p
an DT p
average JJ p
age NN p
of IN p
3.5years CD p
were VBD p
enrolled VBN p
in IN p
our PRP$ p
study NN p
. . p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
BPT NNP i
program NN i
group NN i
or CC i
a DT i
comparison NN i
group NN i
who WP i
were VBD i
given VBN i
nonsleep-related JJ i
parent NN i
education NN i
. . i

Each DT N
participant NN N
was VBD N
individually RB N
administered VBN N
a DT N
5-session JJ N
program NN N
delivered VBN N
over IN N
the DT N
8-week JJ N
study NN N
. . N

Outcome NNP N
measures NNS N
of IN N
feasibility NN o
, , o
fidelity NN o
, , o
and CC o
efficacy NN o
were VBD o
collected VBN N
at IN N
weeks NNS N
4 CD N
and CC N
8 CD N
after IN N
the DT N
baseline NN N
time NN N
point NN N
. . N

Children NNP N
's POS N
sleep NN o
was VBD N
assessed VBN N
by IN N
parent NN N
report NN N
and CC N
objectively RB N
by IN N
actigraphy NN N
. . N

RESULTS NNP N
Of IN N
the DT N
20 CD p
participants NNS p
in IN p
each DT p
group NN p
, , p
data NNS p
were VBD p
available JJ p
for IN p
15 CD p
participants NNS p
randomized VBN p
to TO p
BPT NNP p
and CC p
18 CD p
participants NNS p
randomized VBN p
to TO p
the DT p
comparison NN p
condition NN p
. . p

Results NNP N
supported VBD N
the DT N
feasibility NN o
of IN N
the DT N
manualized JJ N
parent NN N
training NN N
program NN N
and CC N
the DT N
comparison NN N
program NN N
. . N

Treatment NNP N
fidelity NN o
was VBD N
high JJ N
for IN N
both DT N
groups NNS N
. . N

The DT N
BPT NNP N
program NN N
group NN N
significantly RB N
improved VBD N
more JJR N
than IN N
the DT N
comparison NN N
group NN N
based VBN N
on IN N
the DT N
primary JJ o
sleep JJ o
outcome NN o
of IN N
parent NN N
report NN N
. . N

There EX N
were VBD N
no DT N
objective JJ N
changes NNS o
in IN o
sleep NN o
detected VBN N
by IN N
actigraphy NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
is VBZ N
one CD N
of IN N
few JJ N
RCTs NNP N
of IN N
a DT N
BPT NNP N
program NN N
to TO N
specifically RB N
target VB N
sleep JJ o
disturbances NNS o
in IN N
a DT N
well-characterized JJ N
sample NN N
of IN N
young JJ N
children NNS N
with IN N
ASD NNP N
and CC N
to TO N
demonstrate VB N
the DT N
feasibility NN o
of IN N
the DT N
approach NN N
. . N

Initial JJ o
efficacy NN o
favored VBD N
the DT N
BPT NNP N
program NN N
over IN N
the DT N
comparison NN N
group NN N
and CC N
suggested VBD N
that IN N
this DT N
manualized JJ N
parent NN N
training NN N
approach NN N
is VBZ N
worthy JJ N
of IN N
further JJ N
examination NN N
of IN N
the DT N
efficacy NN N
within IN N
a DT N
larger JJR N
RCT NNP N
. . N

-DOCSTART- -X- O O

The DT N
Social NNP N
Communication NNP N
Intervention NNP N
Project NNP N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
the DT N
effectiveness NN N
of IN N
speech NN N
and CC N
language NN N
therapy NN N
for IN N
school-age JJ p
children NNS p
who WP p
have VBP p
pragmatic JJ p
and CC p
social JJ p
communication NN p
problems NNS p
with IN p
or CC p
without IN p
autism NN p
spectrum NN p
disorder NN p
. . p

BACKGROUND NNP N
Children NNPS p
who WP p
show VBP p
disproportionate JJ p
difficulty NN p
with IN p
the DT p
pragmatic JJ p
as IN p
compared VBN p
with IN p
the DT p
structural JJ p
aspects NNS p
of IN p
language NN p
are VBP p
described VBN p
as IN p
having VBG p
pragmatic JJ p
language NN p
impairment NN p
( ( p
PLI NNP p
) ) p
or CC p
social JJ p
communication NN p
disorder NN p
( ( p
SCD NNP p
) ) p
. . p

Some DT N
children NNS N
who WP N
have VBP N
PLI NNP N
also RB N
show VBP N
mild JJ N
social JJ N
impairments NNS N
associated VBN N
with IN N
high-functioning JJ N
autism NN N
or CC N
autism NN N
spectrum JJ N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

There EX N
is VBZ N
little JJ N
robust JJ N
evidence NN N
of IN N
effectiveness NN N
of IN N
speech-language NN N
interventions NNS N
which WDT N
target VBP N
the DT N
language NN N
, , N
pragmatic JJ N
or CC N
social JJ N
communication NN N
needs NNS N
of IN N
these DT N
children NNS N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
an DT N
intensive JJ i
manualized VBN i
social JJ i
communication NN i
intervention NN i
( ( i
SCIP NNP i
) ) i
for IN N
children NNS p
who WP p
have VBP p
PLI VBN p
with IN p
or CC p
without IN p
features NNS p
of IN p
ASD NNP p
. . p

METHODS NNP N
& CC N
PROCEDURES NNP N
In IN N
a DT N
single-blind JJ N
RCT NNP N
design NN N
, , N
88 CD p
children NNS p
with IN p
pragmatic JJ p
and CC p
social JJ p
communication NN p
needs NNS p
aged VBD p
5 CD p
; : p
11-10 JJ p
; : p
8 CD p
, , p
recruited VBN p
from IN p
UK NNP p
speech NN p
and CC p
language NN p
therapy NN p
services NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
2:1 CD N
ratio NN N
to TO N
SCIP NNP i
or CC N
to TO N
treatment-as-usual JJ i
. . i

Children NNP p
in IN p
the DT p
SCIP NNP i
condition NN p
received VBD N
up RB N
to TO N
20 CD i
sessions NNS i
of IN i
direct JJ i
intervention NN i
from IN i
a DT i
specialist JJ i
research NN i
speech NN i
and CC i
language NN i
therapist NN i
working VBG i
with IN i
supervised JJ i
assistants NNS i
. . i

All DT N
therapy NN N
content NN N
and CC N
methodology NN N
was VBD N
derived VBN N
from IN N
an DT N
intervention NN N
manual NN N
. . N

A DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ o
language NN o
and CC N
secondary JJ N
outcome NN N
measures NNS N
of IN N
narrative JJ o
, , o
parent-reported JJ o
pragmatic JJ o
functioning NN o
and CC o
social JJ o
communication NN o
, , o
blind-rated JJ o
perceptions NNS o
of IN o
conversational JJ o
competence NN o
and CC o
teacher-reported JJ o
ratings NNS o
of IN o
classroom NN o
learning VBG o
skills NNS o
were VBD N
taken VBN N
pre-intervention NN N
, , N
immediately RB N
post-intervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

OUTCOMES NNP N
& CC N
RESULTS NNP N
No NNP N
significant JJ N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ o
language NN o
ability NN o
or CC o
for IN o
a DT o
measure NN o
of IN o
narrative JJ o
ability NN o
. . o

Significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
blind-rated JJ o
perceptions NNS o
of IN o
conversational JJ o
competence NN o
, , o
for IN o
parent-reported JJ o
measures NNS o
of IN o
pragmatic JJ o
functioning NN o
and CC o
social JJ o
communication NN o
, , o
and CC o
for IN o
teacher-reported JJ o
ratings NNS o
of IN o
classroom NN o
learning NN o
skills NNS o
. . o

CONCLUSIONS NNP N
& CC N
IMPLICATIONS NNP N
There EX N
is VBZ N
some DT N
evidence NN N
of IN N
an DT N
intervention NN N
effect NN N
on IN N
blind NN N
and CC N
parent/teacher-reported JJ N
communication NN N
outcomes NNS N
, , N
but CC N
not RB N
standardized JJ N
language NN N
assessment NN N
outcomes NNS N
, , N
for IN N
6-11-year-old JJ p
children NNS p
who WP p
have VBP p
pragmatic JJ p
and CC p
social JJ p
communication NN p
needs NNS p
. . p

These DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
the DT N
context NN N
of IN N
the DT N
increasingly RB N
central JJ N
role NN N
of IN N
service NN N
user NN N
outcomes NNS N
in IN N
providing VBG N
evidence NN N
for IN N
an DT N
intervention NN N
. . N

The DT N
substantial JJ N
overlap NN N
between IN N
the DT N
presence NN N
of IN N
PLI NNP N
and CC N
ASD NNP N
( ( N
75 CD N
% NN N
) ) N
across IN N
the DT N
whole JJ N
cohort NN N
suggests VBZ N
that IN N
the DT N
intervention NN N
may MD N
also RB N
be VB N
applicable JJ N
to TO N
some DT N
verbally RB N
able JJ N
children NNS N
with IN N
ASD NNP N
who WP N
have VBP N
pragmatic JJ N
communication NN N
needs NNS N
. . N

-DOCSTART- -X- O O

A DT N
1.5-year JJ N
follow-up NN N
of IN N
an DT N
Internet-based JJ i
intervention NN i
for IN N
complicated JJ N
grief NN N
. . N

Only RB N
recently RB N
have VBP N
psychotherapeutic JJ i
interventions NNS i
for IN N
complicated JJ N
grief NN N
been VBN N
developed VBN N
and CC N
evaluated VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
. . N

These DT N
trials NNS N
have VBP N
reported VBN N
significant JJ N
reductions NNS N
in IN N
complicated JJ N
grief NN N
and CC N
related JJ N
symptoms NNS N
in IN N
response NN N
to TO N
treatment NN N
relative JJ N
to TO N
control VB i
groups NNS i
. . i

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
long-term JJ N
outcomes NNS N
of IN N
these DT N
treatments NNS N
. . N

The DT N
authors NNS N
present VBP N
an DT N
evaluation NN N
of IN N
a DT N
1.5-year JJ N
follow-up NN N
of IN N
an DT N
Internet-based JJ i
cognitive-behavioral JJ i
intervention NN i
for IN p
complicated JJ p
grief NN p
. . p

Treatment NNP p
group NN p
patients NNS p
( ( p
n JJ p
= NNP p
22 CD p
) ) p
were VBD p
administered VBN p
various JJ p
assessments NNS p
of IN p
complicated JJ p
grief NN p
indicators NNS p
, , N
including VBG N
the DT N
Impact NN o
of IN o
Event NNP o
Scale NNP o
, , N
the DT N
anxiety NN o
and CC o
depression NN o
subscales NNS o
of IN o
the DT o
Brief NNP o
Symptom NNP o
Inventory NNP o
, , o
and CC o
the DT o
SF-12 NNP o
. . o

Results NNP N
indicate VBP N
that IN N
the DT N
reduction NN N
in IN N
symptoms NNS o
of IN o
complicated JJ o
grief NN o
observed VBN N
at IN N
posttreatment NN N
was VBD N
maintained VBN N
at IN N
1.5-year JJ N
follow-up NN N
. . N

-DOCSTART- -X- O O

[ NN N
It PRP N
is VBZ N
difficult JJ N
to TO N
predict VB N
the DT N
effect NN N
of IN N
minoxidil NN i
liniment NN i
on IN N
hair NN o
loss NN o
in IN p
men NNS p
] VBP p
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
performing VBG N
eye-hand JJ N
integration NN N
tasks NNS N
: : N
four CD N
preliminary JJ N
studies NNS N
with IN N
children NNS p
showing VBG p
low-functioning JJ p
autism NN p
. . p

This DT N
report NN N
, , N
based VBN N
on IN N
four CD N
studies NNS N
with IN N
children NNS p
with IN p
low-functioning JJ p
autism NN p
, , N
aimed VBN N
at IN N
evaluating VBG N
the DT N
effects NNS N
of IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
delivered VBN N
on IN N
the DT N
left NN N
and CC N
right JJ N
premotor NN N
cortices NNS N
on IN N
eye-hand JJ N
integration NN N
tasks NNS N
; : N
defining VBG N
the DT N
long-lasting JJ N
effects NNS N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
; : i
and CC N
investigating VBG N
the DT N
real JJ N
efficacy NN N
of IN N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
by IN N
comparing VBG N
three CD N
kinds NNS N
of IN N
treatments NNS N
( ( N
high-frequency JJ N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
, , N
a DT N
traditional JJ N
eye-hand JJ N
integration NN N
training NN N
, , N
and CC N
both DT N
treatments NNS N
combined VBN N
) ) N
. . N

Results $ N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
eye-hand JJ o
performances NNS o
only RB N
when WRB N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
was VBD N
delivered VBN N
on IN N
the DT N
left JJ N
premotor NN N
cortex NN N
; : N
a DT N
persistent NN N
improvement NN N
up IN N
to TO N
1 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
the DT N
stimulation NN N
; : N
better JJR N
outcomes NNS N
in IN N
the DT N
treatment NN N
combining VBG N
high-frequency NN N
repetitive JJ N
transcranial JJ N
magnetic JJ N
stimulation NN N
and CC N
eye-hand JJ N
integration NN N
training NN N
. . N

Based VBN N
on IN N
these DT N
preliminary JJ N
findings NNS N
, , N
further JJ N
evaluations NNS N
on IN N
the DT N
usefulness NN N
of IN N
high-frequency NN i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
rehabilitation NN N
of IN N
children NNS o
with IN o
autism NN o
are VBP N
strongly RB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Partial-area JJ p
method NN p
in IN p
bioequivalence NN p
assessment NN N
: : N
naproxen NN i
. . i

Regulatory NNP N
authorities NNS N
require VBP N
demonstration NN N
of IN N
bioequivalence NN p
through IN N
comparisons NNS N
of IN N
different JJ N
pharmacokinetic JJ N
parameters NNS N
, , N
the DT N
area NN o
under IN o
the DT o
plasma JJ o
concentration-time JJ o
curve NN o
( ( o
AUC NNP o
) ) o
, , o
the DT o
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
, , N
and CC N
the DT o
time NN o
to TO o
reach VB o
peak JJ o
concentration NN o
( ( o
Tmax NNP o
) ) o
. . o

The DT N
applicability NN N
and CC N
validity NN N
of IN N
regulatory JJ N
requirements NNS N
have VBP N
been VBN N
widely RB N
criticized VBN N
on IN N
statistical JJ N
and CC N
clinical JJ N
relevance NN N
grounds NNS N
. . N

For IN N
most JJS N
noncomplicated JJ N
absorption NN N
models NNS N
, , N
the DT N
AUC NNP o
correlates VBZ N
well RB N
with IN N
the DT N
extent NN N
of IN N
absorption NN N
. . N

However RB N
, , N
in IN N
nonlinear JJ N
models NNS N
of IN N
absorption NN N
, , N
in IN N
mechanisms NN N
involving VBG N
recycling NN N
of IN N
drugs NNS N
, , N
and CC N
for IN N
drugs NNS N
with IN N
long JJ N
half-life NN N
, , N
the DT N
use NN N
of IN N
total JJ N
AUC NNP o
( ( N
from IN N
zero CD N
to TO N
infinity NN N
) ) N
can MD N
give VB N
erroneous JJ N
and CC N
clinically RB N
irrelevant JJ N
results NNS N
since IN N
the DT N
area NN N
is VBZ N
mostly RB N
determined VBN N
by IN N
elimination NN N
phase NN N
or CC N
by IN N
recycling VBG N
. . N

The DT N
calculation NN N
of IN N
total JJ N
AUC NNP o
also RB N
involves VBZ N
prolonged JJ N
sampling NN N
, , N
adding VBG N
to TO N
the DT N
cost NN N
and CC N
risks NNS N
associated VBN N
with IN N
bioequivalence NN N
studies NNS N
. . N

The DT N
use NN N
of IN N
Cmax NNP o
or CC o
Tmax NNP o
as IN N
a DT N
measure NN N
of IN N
rate NN N
of IN N
absorption NN N
, , N
to TO N
correlate VB N
with IN N
clinical JJ N
relevance NN N
, , N
is VBZ N
widely RB N
criticized VBN N
on IN N
logical JJ N
, , N
technical JJ N
, , N
and CC N
statistical JJ N
grounds NNS N
. . N

For IN N
drugs NNS N
used VBN N
on IN N
a DT N
multiple-dose JJ N
basis NN N
, , N
Cmax NNP o
and CC N
Tmax NNP o
evaluations NNS N
become VBP N
redundant JJ N
since IN N
the DT N
average JJ N
plateau NN o
concentration NN o
is VBZ N
not RB N
affected VBN N
by IN N
these DT N
parameters NNS N
. . N

To TO N
resolve VB N
the DT N
drawbacks NNS N
in IN N
the DT N
traditional JJ N
methodology NN N
of IN N
bioequivalence NN N
evaluation NN N
, , N
the DT N
use NN N
of IN N
partial JJ N
areas NNS N
in IN N
lieu NN N
of IN N
total JJ N
AUC NNP o
, , o
Tmax NNP o
, , o
and CC o
Cmax NNP o
is VBZ N
suggested VBN N
. . N

This DT N
study NN N
investigates VBZ N
the DT N
logic NN N
and CC N
robustness NN N
of IN N
the DT N
partial-area JJ p
method NN p
in IN p
establishing VBG p
bioequivalence NN p
. . p

We PRP N
conclude VBP N
that IN N
the DT N
5h CD o
AUC NNP o
is VBZ N
a DT N
more RBR N
relevant JJ N
parameter NN N
to TO N
establish VB N
naproxen NNS i
bioequivalence NN N
than IN N
AUCinf NNP o
. . o

We PRP N
recommend VBP N
against IN N
using VBG N
symmetrical JJ N
confidence NN N
intervals NNS N
and CC N
report NN N
excellent JJ N
agreement NN N
among IN N
several JJ N
methods NNS N
of IN N
calculating VBG N
confidence NN o
intervals NNS o
, , o
probability NN o
values NNS o
, , o
and CC o
nonparametric JJ o
tests NNS o
. . o

We PRP N
suggest VBP N
that IN N
a DT N
single-point JJ o
short-term JJ o
AUC NNP o
is VBZ N
a DT N
better JJR N
indicator NN N
of IN N
the DT N
bioequivalence NN N
of IN N
generic JJ N
products NNS N
than IN N
the DT N
total JJ N
AUC NNP o
, , o
Cmax NNP o
, , o
and CC o
Tmax NNP o
as IN N
required VBN N
currently RB N
by IN N
the DT N
regulatory JJ N
authorities NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN o
and CC o
cost-effectiveness NN o
of IN N
an DT N
experimental JJ N
short-term JJ N
inpatient JJ i
Dialectical NNP i
Behavior NNP i
Therapy NNP i
( ( i
DBT NNP i
) ) i
program NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Borderline NNP p
Personality NNP p
Disorder NNP p
( ( p
BPD NNP p
) ) p
is VBZ N
a DT N
serious JJ N
psychiatric JJ N
condition NN N
associated VBN N
with IN N
substantial JJ N
mortality NN N
, , N
burden NN N
and CC N
public JJ N
health NN N
costs NNS N
. . N

DBT NNP N
is VBZ N
the DT N
treatment NN N
model NN N
with IN N
the DT N
largest JJS N
number NN N
of IN N
published VBN N
research NN N
articles VBZ N
showing VBG N
effectiveness NN N
. . N

However RB N
, , N
some DT N
patients NNS N
are VBP N
not RB N
sufficiently RB N
engaged VBN N
in IN N
outpatient JJ N
treatment NN N
while IN N
presenting VBG N
severe JJ N
parasuicidal JJ N
behavior NN N
, , N
making VBG N
hospitalization NN N
necessary JJ N
. . N

The DT N
Center NNP N
for IN N
Personality NNP N
Disorders NNP N
Jelgersma NNP N
developed VBD N
an DT N
intensive JJ N
12-week JJ N
inpatient NN N
DBT NNP N
program NN N
that IN N
( ( N
i NN N
) ) N
rapidly RB N
reduces VBZ N
core NN N
borderline NN N
symptoms NNS N
like IN N
suicidal JJ N
behavior NN N
, , N
( ( N
ii NN N
) ) N
minimizes VBZ N
the DT N
negative JJ N
effects NNS N
of IN N
an DT N
inpatient NN N
setting NN N
, , N
and CC N
( ( N
iii NN N
) ) N
enhances VBZ N
compliance NN N
with IN N
outpatient JJ N
treatment NN N
. . N

We PRP N
evaluate VBP N
the DT N
( ( o
cost- NN o
) ) o
effectiveness NN o
of IN N
this DT N
experimental JJ N
program NN N
. . N

METHODS/DESIGN NNP N
Seventy NNP p
patients NNS p
, , p
aged VBD p
18 CD p
to TO p
45 CD p
years NNS p
with IN p
a DT p
primary JJ p
diagnosis NN p
of IN p
BPD NNP p
, , p
showing VBG p
a DT p
chronic JJ p
pattern NN p
of IN p
parasuicidal JJ p
gestures NNS p
and/or IN p
reporting VBG p
high JJ p
degrees NNS p
of IN p
severity NN p
of IN p
other JJ p
borderline NN p
symptoms NNS p
, , p
are VBP p
randomly RB p
allocated VBN p
to TO p
the DT p
control NN p
and CC p
intervention NN p
groups NNS p
. . p

Subjects NNS p
in IN p
the DT p
control NN p
group NN p
receive VBP p
standard JJ i
outpatient NN i
DBT NNP i
, , i
provided VBD p
in IN p
one CD p
of IN p
three CD p
regular JJ p
mental JJ p
health NN p
settings NNS p
in IN p
GGZ NNP p
Rivierduinen NNP p
. . p

Subjects NNS p
in IN p
the DT p
intervention NN p
group NN p
receive VBP i
12 CD i
weeks NNS i
of IN i
intensified JJ i
inpatient NN i
DBT NNP i
plus CC i
six CD i
months NNS i
of IN i
standard JJ i
DBT NNP i
, , i
provided VBN p
in IN p
the DT p
Center NNP p
for IN p
Personality NNP p
Disorders NNP p
Jelgersma NNP p
. . p

The DT N
primary JJ N
outcome NN N
is VBZ N
the DT o
number NN o
of IN o
suicide JJ o
attempts/self-harming JJ o
acts NNS o
. . o

Secondary JJ N
outcomes NNS N
are VBP o
severity NN o
of IN o
other JJ o
borderline NN o
complaints NNS o
, , o
quality NN o
of IN o
life NN o
, , o
general JJ o
psychopathological NN o
symptoms NNS o
and CC o
health NN o
care NN o
utilization NN o
and CC o
productivity NN o
costs NNS o
. . o

Data NNS N
are VBP N
gathered VBN N
using VBG N
a DT N
prospective JJ N
, , N
two CD N
( ( N
group NN N
: : N
intervention NN N
and CC N
control NN N
) ) N
by IN N
five CD N
( ( N
time NN N
of IN N
measurement NN N
) ) N
repeated VBD N
measures NNS N
factorial JJ N
design.Participants NNS N
will MD N
complete VB N
three-monthly JJ N
outcome NN N
assessments NNS N
in IN N
the DT N
course NN N
of IN N
therapy NN N
: : N
at IN N
baseline NN N
, , N
and CC N
12 CD N
, , N
24 CD N
, , N
36 CD N
and CC N
52 CD N
weeks NNS N
after IN N
the DT N
start NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
period NN N
of IN N
recruitment NN N
started VBN N
in IN N
March NNP N
2012 CD N
and CC N
the DT N
study NN N
will MD N
end VB N
in IN N
December NNP N
2014 CD N
. . N

DISCUSSION NNP p
Highly NNP p
suicidal JJ p
outpatient NN p
patients NNS p
can MD p
pose VB N
a DT N
dilemma NN N
for IN N
mental JJ N
health NN N
care NN N
professionals NNS N
. . N

Although IN N
hospitalization NN N
seems VBZ N
inevitable JJ N
under IN N
some DT N
circumstances NNS N
, , N
it PRP N
has VBZ N
proven VBN N
to TO N
be VB N
harmful JJ N
in IN N
its PRP$ N
own JJ N
right NN N
. . N

This DT N
paper NN N
outlines VBZ N
the DT N
background NN N
and CC N
methods NNS N
of IN N
a DT N
randomized JJ N
trial NN N
evaluating VBG N
the DT N
possible JJ N
surplus NN N
value NN N
of IN N
a DT N
short-term JJ N
inpatient NN N
DBT NNP N
program NN N
. . N

-DOCSTART- -X- O O

Modulation NN i
of IN i
oxidant JJ i
stress NN i
in IN i
vivo NN i
in IN N
chronic JJ p
cigarette NN p
smokers NNS p
. . p

BACKGROUND NNP N
Free JJ N
radical-induced JJ N
oxidative JJ N
damage NN N
is VBZ N
thought VBN N
to TO N
be VB N
involved VBN N
in IN N
the DT N
pathogenesis NN N
of IN N
diseases NNS N
associated VBN N
with IN N
cigarette NN N
smoking NN N
. . N

We PRP N
examined VBD N
the DT N
production NN N
of IN N
8-epi-prostaglandin JJ i
( ( i
PG NNP i
) ) i
F2 NNP i
alpha NN i
, , i
a DT i
stable JJ i
product NN i
of IN i
lipid JJ i
peroxidation NN i
in IN i
vivo NN i
, , N
and CC N
its PRP$ N
modulation NN i
by IN i
aspirin NN i
and CC i
antioxidant JJ i
vitamins NNS i
in IN N
chronic JJ p
cigarette NN p
smokers NNS p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
performed VBD N
the DT N
following JJ N
studies NNS N
: : N
( ( N
1 CD N
) ) N
a DT p
cross-sectional JJ p
comparison NN p
of IN p
smokers NNS p
and CC p
control NN p
subjects NNS p
, , N
( ( N
2 CD N
) ) N
an DT N
examination NN N
of IN N
the DT N
dose-response JJ N
relationship NN N
, , N
( ( N
3 CD N
) ) N
an DT N
exploration NN N
of IN N
the DT N
effect NN N
of IN N
smoking VBG i
cessation NN i
( ( i
3 CD i
weeks NNS i
) ) i
and CC i
nicotine JJ i
patch NN i
supplementation NN i
, , N
( ( N
4 CD N
) ) N
the DT N
effect NN N
of IN N
aspirin NN i
consumption NN i
, , N
and CC N
( ( N
5 CD N
) ) N
the DT N
effects NNS N
of IN N
5 CD N
days NNS N
' POS N
dosing VBG N
with IN N
vitamin NN i
E NNP i
( ( N
100 CD N
and CC N
800 CD N
U NNP N
) ) N
, , N
vitamin FW i
C NNP i
( ( i
2 CD i
g NN i
) ) i
, , N
and CC N
their PRP$ N
combination NN N
. . N

8-epi-PGF2 JJ o
alpha JJ o
excretion NN o
( ( N
in IN N
pmol/mmol NN N
, , N
mean JJ N
+/- JJ N
SEM NNP N
) ) N
was VBD N
176.5+/-30.6 JJ N
in IN N
heavy JJ p
smokers NNS p
, , N
92.7+/-4.8 CD N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
in IN N
moderate JJ p
smokers NNS p
, , N
and CC N
54.1+/-2.7 JJ N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
in IN N
nonsmokers NNS p
. . p

Urinary JJ o
levels NNS o
fell VBD o
from IN N
145.5+/-24.9 CD N
to TO N
114.6+/-27.1 CD N
( ( N
week NN N
2 CD N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
112.6+/-24.9 JJ N
( ( N
week NN N
3 CD N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
on IN N
cessation NN N
of IN N
smoking NN N
. . N

Aspirin NNP i
treatment NN i
failed VBD N
to TO N
suppress VB N
urinary JJ o
levels NNS o
of IN o
8-epi-PGF2 JJ o
alpha NN o
despite IN N
a DT N
significant JJ N
reduction NN N
in IN N
urinary JJ o
11-dehydro-TxB2 JJ o
production NN o
and CC N
suppression NN o
of IN o
8-epi-PGF2 JJ o
alpha NN o
and CC o
TxB2 NNP o
in IN o
serum NN o
. . o

Vitamin NNP i
C NNP i
( ( N
pre NN N
, , N
194.6+/-40.9 JJ N
; : N
post NN N
, , N
137.2+/-34.1 JJ N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
and CC N
a DT N
combination NN i
of IN i
vitamin JJ i
C NNP i
and CC i
E NNP i
( ( N
pre NN N
, , N
171.0+/-39.8 JJ N
; : N
post NN N
, , N
133.5+/-29.6 JJ N
P NNP N
< NNP N
.05 NNP N
) ) N
suppressed VBD N
urinary JJ o
8-epi-PGF2 JJ o
alpha NN o
, , N
whereas IN N
vitamin JJ i
E NNP i
alone RB N
had VBD N
no DT N
effect NN N
. . N

CONCLUSIONS NNP N
Urinary NNP o
8-epi-PGF2 JJ o
alpha NN o
may MD N
represent VB N
a DT N
noninvasive JJ N
, , N
quantitative JJ N
index NN N
of IN N
oxidant JJ N
stress NN N
in IN N
vivo NN N
. . N

Elevated JJ o
levels NNS o
of IN o
8-epi-PGF2 JJ o
alpha NN o
in IN o
smokers NNS o
may MD N
be VB N
modulated VBN N
by IN N
quitting VBG i
cigarettes NNS i
and CC i
switching VBG i
to TO i
nicotine VB i
patches NNS i
or CC N
by IN N
antioxidant JJ i
vitamin NN i
therapy NN i
. . i

-DOCSTART- -X- O O

Risperidone NN i
in IN N
children NNS p
with IN p
autism NN p
and CC p
serious JJ p
behavioral JJ p
problems NNS p
. . p

BACKGROUND NNP N
Atypical NNP N
antipsychotic JJ N
agents NNS N
, , N
which WDT N
block VBP N
postsynaptic JJ N
dopamine NN N
and CC N
serotonin NN N
receptors NNS N
, , N
have VBP N
advantages NNS N
over IN N
traditional JJ N
antipsychotic JJ N
medications NNS N
in IN N
the DT N
treatment NN N
of IN N
adults NNS N
with IN N
schizophrenia NN N
and CC N
may MD N
be VB N
beneficial JJ N
in IN N
children NNS N
with IN N
autistic JJ N
disorder NN N
who WP N
have VBP N
serious JJ N
behavioral JJ N
disturbances NNS N
. . N

However RB N
, , N
data NNS N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
atypical JJ i
antipsychotic JJ i
agents NNS N
in IN N
children NNS N
are VBP N
limited VBN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
multisite NN N
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
of IN N
risperidone NN i
as IN N
compared VBN N
with IN N
placebo NN i
for IN N
the DT N
treatment NN p
of IN p
autistic JJ p
disorder NN p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
in IN p
children NNS p
5 CD p
to TO p
17 CD p
years NNS p
old JJ p
. . p

The DT N
primary JJ N
outcome NN N
measures NNS N
were VBD N
the DT N
score NN N
on IN N
the DT N
Irritability NNP N
subscale NN N
of IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
and CC N
the DT N
rating NN N
on IN N
the DT N
Clinical NNP N
Global NNP N
Impressions NNP N
- : N
Improvement NN N
( ( N
CGI-I NNP N
) ) N
scale NN N
at IN N
eight CD N
weeks NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
101 CD p
children NNS p
( ( p
82 CD p
boys NNS p
and CC p
19 CD p
girls NNS p
; : p
mean VB p
[ IN p
+/-SD JJ p
] NNP p
age NN p
, , p
8.8+/-2.7 CD p
years NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
risperidone NN i
( ( p
49 CD p
children NNS p
) ) p
or CC p
placebo NN i
( ( p
52 CD p
) ) p
. . N

Treatment NN N
with IN N
risperidone NN i
for IN N
eight CD N
weeks NNS N
( ( N
dose JJ N
range NN N
, , N
0.5 CD N
to TO N
3.5 CD N
mg NNS N
per IN N
day NN N
) ) N
resulted VBD N
in IN N
a DT N
56.9 CD N
percent NN N
reduction NN N
in IN N
the DT N
Irritability NNP o
score NN o
, , N
as IN N
compared VBN N
with IN N
a DT N
14.1 CD N
percent NN N
decrease NN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
rate NN N
of IN N
a DT N
positive JJ N
response NN N
, , N
defined VBD N
as IN N
at IN N
least JJS N
a DT N
25 CD N
percent NN N
decrease NN N
in IN N
the DT N
Irritability NNP o
score NN o
and CC N
a DT N
rating NN N
of IN N
much JJ N
improved VBN N
or CC N
very RB N
much JJ N
improved VBN N
on IN N
the DT N
CGI-I NNP o
scale NN o
, , N
was VBD N
69 CD N
percent NN N
in IN N
the DT N
risperidone NN i
group NN N
( ( N
34 CD N
of IN N
49 CD N
children NNS N
had VBD N
a DT N
positive JJ N
response NN N
) ) N
and CC N
12 CD N
percent NN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
6 CD N
of IN N
52 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Risperidone NNP i
therapy NN N
was VBD N
associated VBN N
with IN N
an DT N
average JJ o
weight JJ o
gain NN o
of IN N
2.7+/-2.9 JJ N
kg NN N
, , N
as IN N
compared VBN N
with IN N
0.8+/-2.2 JJ N
kg NN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Increased VBN N
appetite RB o
, , o
fatigue NN o
, , o
drowsiness NN o
, , o
dizziness NN o
, , o
and CC o
drooling VBG o
were VBD N
more JJR N
common JJ N
in IN N
the DT N
risperidone NN i
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< VBZ N
0.05 CD N
for IN N
each DT N
comparison NN N
) ) N
. . N

In IN N
two CD N
thirds NNS N
of IN N
the DT N
children NNS N
with IN N
a DT N
positive JJ N
response NN N
to TO N
risperidone VB N
at IN N
eight CD N
weeks NNS N
( ( N
23 CD N
of IN N
34 CD N
) ) N
, , N
the DT N
benefit NN N
was VBD N
maintained VBN N
at IN N
six CD N
months NNS N
. . N

CONCLUSIONS NNP N
Risperidone NNP i
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
the DT N
treatment NN N
of IN N
tantrums NNS N
, , N
aggression NN N
, , N
or CC N
self-injurious JJ N
behavior NN N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

The DT N
short JJ N
period NN N
of IN N
this DT N
trial NN N
limits VBZ N
inferences NNS N
about IN N
adverse JJ N
effects NNS N
such JJ N
as IN N
tardive JJ N
dyskinesia NN N
. . N

-DOCSTART- -X- O O

Gastrointestinal NNP o
safety NN o
of IN N
NO-aspirin NNP i
( ( i
NCX-4016 NNP i
) ) i
in IN N
healthy JJ p
human JJ p
volunteers NNS p
: : p
a DT N
proof NN N
of IN N
concept NN N
endoscopic NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
NCX-4016 NNP i
is VBZ N
a DT N
nitric JJ N
oxide-releasing JJ N
derivative NN N
of IN N
aspirin NN N
with IN N
antiplatelet NN o
activity NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
NCX-4016 NNP i
on IN N
gastrointestinal JJ N
mucosa NN N
and CC N
platelet NN o
functions NNS o
in IN N
healthy JJ p
human JJ p
volunteers NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Forty NNP p
healthy JJ p
subjects NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
7 CD N
days NNS N
of IN N
treatment NN N
with IN N
NCX-4016 NNP i
( ( i
400 CD i
and CC i
800 CD i
mg NN i
twice RB i
daily RB i
) ) i
, , i
equimolar JJ i
doses NNS i
of IN i
aspirin NN i
( ( i
200 CD i
and CC i
420 CD i
mg NN i
twice RB i
daily RB i
) ) i
, , i
or CC i
placebo NN i
. . i

Upper IN N
endoscopies NNS N
were VBD N
performed VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
gastroduodenal JJ o
lesions NNS o
were VBD N
graded VBN N
using VBG N
a DT N
predefined VBN o
scoring NN o
system NN o
. . o

Basal NNP o
and CC o
posttreatment JJ o
platelet NN o
aggregation NN o
in IN N
response NN N
to TO N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
and CC N
serum JJ N
thromboxane NN N
( ( N
TX NNP N
) ) N
B NNP N
( ( N
2 CD N
) ) N
and CC N
AA-stimulated JJ N
platelet NN N
TXB NNP N
( ( N
2 CD N
) ) N
production NN N
were VBD N
investigated VBN N
. . N

RESULTS NNP N
Mucosal NNP o
endoscopic JJ o
injury NN o
score NN o
on IN N
day NN N
7 CD N
was VBD N
0.63 CD N
+/- JJ N
0.16 CD N
in IN N
the DT N
placebo NN N
group NN N
and CC N
11.0 CD N
+/- JJ N
3.0 CD N
and CC N
16.1 CD N
+/- JJ N
1.6 CD N
in IN N
healthy JJ p
volunteers NNS p
treated VBD N
with IN N
200 CD N
and CC N
420 CD N
mg NN N
aspirin JJ N
twice RB N
daily RB N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN N
) ) N
. . N

NCX-4016 NN N
was VBD N
virtually RB N
devoid JJ N
of IN N
gastric JJ o
and CC o
duodenal JJ o
toxicity NN o
, , N
resulting VBG N
in IN N
a DT N
total JJ o
gastric NN o
and CC o
duodenal JJ o
endoscopic NN o
score NN o
of IN N
1.38 CD N
+/- JJ N
0.3 CD N
and CC N
1.25 CD N
+/- JJ N
0.5 CD N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. NN N
aspirin NN N
, , N
not RB N
significant JJ N
vs. FW N
placebo NN N
) ) N
. . N

NCX-4016 JJ N
inhibited JJ N
AA-induced JJ o
platelet NN o
aggregation NN o
as RB N
well RB N
as IN N
serum NN o
TXB NNP o
( ( o
2 CD o
) ) o
and CC N
platelet NN o
TXB NNP o
( ( o
2 CD o
) ) o
generation NN o
induced VBN N
by IN N
AA NNP N
to TO N
the DT N
same JJ N
extent NN N
as IN N
aspirin NN i
( ( N
not RB N
significant JJ N
vs. FW N
aspirin NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
have VBP N
proven VBN N
the DT N
concept NN N
that IN N
addition NN N
of IN N
an DT N
NO-donating JJ N
moiety NN N
to TO N
aspirin VB N
results NNS N
in IN N
a DT N
new JJ N
chemical NN N
entity NN N
that WDT N
maintains VBZ N
cyclooxygenase-1 NN N
and CC N
platelet VB N
inhibitory JJ N
activity NN N
while IN N
nearly RB N
avoiding VBG N
gastrointestinal JJ o
damage NN o
. . o

-DOCSTART- -X- O O

Sucralfate NNP i
overcomes VBZ N
adverse JJ N
effect NN N
of IN N
cigarette NN N
smoking NN N
on IN N
duodenal JJ p
ulcer NN o
healing NN o
and CC N
prolongs NNS N
subsequent JJ N
remission NN N
. . N

A DT N
unicenter JJ N
, , N
single-blind JJ N
, , N
randomized VBD N
study NN N
was VBD N
conducted VBN N
on IN N
283 CD p
patients NNS p
with IN p
active JJ p
duodenal JJ p
ulcer NN p
to TO p
compare VB p
possible JJ p
factors NNS p
that WDT p
may MD p
affect VB p
healing NN p
and CC p
relapse NN p
in IN p
patients NNS p
treated VBN p
with IN p
a DT p
potent JJ p
antisecretory NN i
agent NN i
, , i
cimetidine NN i
, , p
or CC p
a DT p
site-protective JJ p
and CC p
cytoprotective JJ p
agent NN p
, , p
sucralfate NN i
. . i

The DT N
endoscopic NN o
healing VBG o
rates NNS o
at IN N
4 CD N
wk NNS N
were VBD N
76 CD N
% NN N
and CC N
79 CD N
% NN N
, , N
respectively RB N
, , N
and CC N
cross-over JJ N
treatment NN N
of IN N
the DT N
failures NNS N
for IN N
a DT N
further JJ N
4 CD N
wk NN N
resulted VBD N
in IN N
68 CD N
% NN N
healing VBG N
with IN N
cimetidine NN i
and CC N
69 CD N
% NN N
healing VBG N
with IN N
sucralfate NN i
, , N
both DT N
differences NNS N
being VBG N
not RB N
statistically RB N
different JJ N
. . N

Unlike IN N
cimetidine NN i
, , N
healing VBG N
by IN N
sucralfate NN i
was VBD N
unaffected VBN N
by IN N
cigarette NN N
smoking NN N
, , N
reluctance NN N
to TO N
give VB N
up RP N
smoking NN N
, , N
habitual JJ N
use NN N
of IN N
alcohol NN N
, , N
high JJ N
maximal JJ N
acid NN N
output NN N
, , N
and CC N
large JJ N
ulcer JJ N
diameter NN N
. . N

In IN N
particular JJ N
, , N
the DT N
healing VBG o
rate NN o
of IN N
smokers NNS N
treated VBN N
with IN N
sucralfate NN i
( ( N
82 CD N
% NN N
) ) N
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
of IN N
smokers NNS N
treated VBN N
with IN N
cimetidine NN i
( ( N
63 CD N
% NN N
) ) N
. . N

Duodenal NNP N
bulb NN N
deformity NN N
significantly RB N
affected VBD N
healing NN N
in IN N
both DT p
groups NNS p
, , N
and CC N
was VBD N
the DT N
only JJ N
offsetting VBG N
factor NN N
identifiable JJ N
for IN N
sucralfate NN i
out IN N
of IN N
46 CD N
factors NNS N
examined VBD N
. . N

Of IN N
the DT N
patients NNS p
with IN p
healed JJ p
ulcers NNS p
, , p
238 CD p
participated VBN p
in IN N
a DT N
24-mo JJ N
follow-up NN N
study NN N
consisting VBG N
of IN N
interviews NNS N
at IN N
2-mo JJ N
intervals NNS N
and CC N
endoscopy NN N
at IN N
4-mo JJ N
intervals NNS N
or CC N
whenever WRB N
symptoms NNS N
recurred VBD N
. . N

The DT N
cumulative JJ o
relapse NN o
rate NN o
was VBD N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.007 CD N
) ) N
greater JJR N
in IN N
patients NNS p
healed VBN N
with IN N
cimetidine NN i
than IN N
with IN N
sucralfate NN i
, , N
50 CD N
% NN N
relapse NN N
occurring VBG N
at IN N
6 CD N
and CC N
12 CD N
mo NN N
, , N
respectively RB N
. . N

In IN N
both DT N
, , N
the DT N
cumulative JJ o
relapse NN o
rate NN o
was VBD N
significantly RB N
greater JJR N
in IN N
cigarette NN N
smokers NNS N
than IN N
in IN N
nonsmokers NNS N
, , N
but CC N
smokers NNS N
and CC N
nonsmokers NNS N
treated VBN N
with IN N
cimetidine NN i
relapsed VBN o
( ( N
50 CD N
% NN N
at IN N
4 CD N
and CC N
8 CD N
mo NN N
, , N
respectively RB N
) ) N
faster RBR N
than IN N
the DT N
corresponding JJ N
smokers NNS N
and CC N
nonsmokers NNS N
treated VBN N
with IN N
sucralfate NN i
( ( N
50 CD N
% NN N
at IN N
8 CD N
and CC N
18 CD N
mo NN N
, , N
respectively RB N
) ) N
. . N

Furthermore UH N
, , N
in IN N
cimetidine- NN i
but CC N
not RB N
sucralfate-healed JJ i
patients NNS N
, , N
early JJ N
ulcer NN N
relapse NN N
( ( N
within IN N
6 CD N
mo NN N
) ) N
was VBD N
associated VBN N
with IN N
short JJ N
duration NN o
of IN o
illness NN o
, , N
short JJ N
remission NN o
period NN o
, , o
long JJ o
symptomatic JJ o
spell NN o
, , o
and CC o
reluctance NN o
to TO o
give VB o
up RP o
smoking VBG o
. . o

We PRP N
conclude VBP N
that IN N
smoking VBG N
adversely RB N
affects VBZ N
duodenal JJ N
ulcer NN N
healing NN N
by IN N
cimetidine NN i
and CC N
hastens VBZ N
subsequent JJ N
relapse NN N
, , N
and CC N
that IN N
sucralfate NN i
overcomes VBZ N
the DT N
adverse JJ N
effect NN N
of IN N
smoking VBG N
on IN N
healing NN N
as IN N
encountered VBN N
with IN N
cimetidine NN i
, , N
and CC N
results NNS N
in IN N
a DT N
subsequent JJ N
remission NN N
period NN N
double JJ N
that IN N
of IN N
cimetidine NN i
. . i

-DOCSTART- -X- O O

Effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole JJ i
20 CD N
mg NN N
and CC N
esomeprazole JJ i
40 CD N
mg NN N
on IN N
24-h JJ o
intragastric JJ o
pH NN o
in IN p
healthy JJ p
subjects NNS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
antisecretory JJ N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
rabeprazole NN i
and CC N
esomeprazole NN i
. . i

METHODS NNP N
Open NNP N
, , N
randomised VBD N
, , N
2-way JJ N
crossover NN N
, , N
clinical JJ N
pharmacology NN N
study NN N
. . N

24 CD p
healthy JJ p
subjects NNS p
( ( p
10 CD p
men NNS p
; : p
mean JJ p
age NN p
26.2 CD p
y NN p
) ) p
received VBD N
a DT N
single JJ N
dose NN N
of IN N
rabeprazole JJ i
20 CD i
mg NN i
or CC i
esomeprazole JJ i
40 CD i
mg NN i
, , N
with IN N
a DT N
14-day JJ N
'washout NN N
' POS N
. . N

Intragastric NNP o
pH NN o
was VBD N
recorded VBN N
continuously RB N
from IN N
24 CD N
h NN N
before IN N
to TO N
24 CD N
h NN N
after IN N
dosing VBG N
. . N

RESULTS JJ N
Mean NNP o
intragastric JJ o
pH NN o
was VBD N
higher JJR N
after IN N
esomeprazole JJR i
than IN N
rabeprazole NN i
during IN N
0-5 JJ N
h NN N
after IN N
dosing VBG N
( ( N
P=0.0001 NNP N
) ) N
; : N
the DT N
reverse NN N
was VBD N
true JJ N
from IN N
14-24 JJ N
h NN N
( ( N
P=0.0002 NNP N
) ) N
. . N

Mean VB o
% NN o
time NN o
pH JJ o
> $ o
3 CD o
and CC o
> $ o
4 CD o
was VBD N
greater JJR N
after IN N
esomeprazole JJR i
than IN N
rabeprazole NN i
during IN N
0-14 JJ N
h NN N
( ( N
P=0.041 NNP N
and CC N
0.044 CD N
) ) N
, , N
but CC N
the DT N
reverse NN N
was VBD N
true JJ N
during IN N
14-24 JJ N
h NN N
( ( N
P=0.0005 NNP N
and CC N
0.001 CD N
) ) N
. . N

In IN N
the DT N
0-24 JJ N
h NN N
interval NN N
as IN N
a DT N
whole NN N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
treatments NNS N
in IN N
mean JJ o
pH NN o
or CC o
% NN o
time NN o
pH JJ o
> JJ o
3 CD o
or CC o
> $ o
4 CD o
. . o

CONCLUSION NNP N
Single-dose JJ N
rabeprazole NN i
20 CD N
mg NN N
was VBD N
as RB N
effective JJ N
as IN N
esomeprazole JJ i
40 CD N
mg NN N
in IN N
increasing VBG N
intragastric JJ o
pH NN o
and CC N
maintaining VBG N
pH NN o
> $ o
3 CD o
and CC o
> $ o
4 CD o
, , N
despite IN N
the DT N
2-fold JJ N
difference NN N
in IN N
dose NN N
. . N

-DOCSTART- -X- O O

Parent NNP i
management NN i
training NN i
and CC p
Asperger NNP p
syndrome NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
evaluate VB N
a DT N
parent NN o
based VBN o
intervention NN o
. . o

This DT N
controlled JJ N
trial NN N
of IN N
a DT N
parent NN i
management NN i
intervention NN i
aimed VBN N
to TO N
increase VB N
parental JJ N
competence NN N
in IN N
management NN N
of IN N
problem NN N
behaviours NNS N
associated VBN N
with IN N
Asperger NNP p
syndrome NN p
. . p

The DT N
intervention NN N
compared VBN N
two CD N
formats NNS N
, , N
a DT N
1 CD i
day NN i
workshop NN i
and CC i
six CD i
individual JJ i
sessions NNS i
. . i

Measures NNS N
were VBD N
taken VBN N
on IN N
three CD N
occasions NNS N
: : N
pre-intervention NN N
, , N
at IN N
4 CD N
weeks NNS N
, , N
and CC N
at IN N
3 CD N
month NN N
follow-up NN N
. . N

Variables NNS N
of IN N
interest NN N
were VBD N
number NN o
and CC o
intensity NN o
of IN o
problem NN o
behaviours NN o
, , o
and CC o
parent JJ o
evaluation NN o
of IN o
social JJ o
interaction NN o
skills NNS o
. . o

Results NNS N
showed VBD N
parents NNS N
reporting VBG N
fewer JJR N
and CC N
lower JJR N
intensity NN o
of IN o
problem NN o
behaviours NNS o
and CC N
increased VBD o
social JJ o
interactions NNS o
at IN N
4 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
. . N

Results NNS N
held VBD N
across IN N
formats NNS N
and CC N
suggest VBP N
that IN N
parent NN N
management NN N
training NN N
can MD N
provide VB N
an DT N
effective JJ o
intervention NN o
for IN o
parents NNS o
of IN o
a DT o
child NN o
with IN o
Asperger NNP o
syndrome NN o
. . o

Group NNP N
differences VBZ N
on IN N
outcome NN N
measures NNS N
and CC N
in IN N
the DT N
use NN N
of IN N
strategies NNS N
are VBP N
discussed VBN N
along IN N
with IN N
limitations NNS N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Improving VBG N
the DT N
transition NN p
from IN p
residential JJ i
to TO i
outpatient JJ i
addiction NN i
treatment NN i
: : i
gender NN N
differences NNS N
in IN N
response NN N
to TO N
supportive VB N
telephone NN N
calls NNS N
. . N

Substance NN N
use NN N
relapse NN N
rates NNS N
are VBP N
often RB N
high JJ N
in IN N
the DT N
first JJ N
months NNS N
after IN N
discharge NN N
from IN N
inpatient JJ i
substance NN i
abuse NN i
treatment NN i
, , N
and CC N
patient JJ o
adherence NN o
to TO o
aftercare VB o
plans NNS N
is VBZ N
often RB N
low JJ N
. . N

Four CD p
residential JJ p
addiction NN p
treatment NN p
centers NNS p
participated VBD N
in IN N
a DT N
feasibility NN N
study NN N
designed VBN N
to TO N
estimate VB N
the DT N
efficacy NN o
of IN N
a DT N
post-discharge JJ i
telephone NN i
intervention NN i
intended VBN i
to TO i
encourage VB i
compliance NN i
with IN i
aftercare NN i
. . i

A DT p
total NN p
of IN p
282 CD p
participants NNS p
( ( p
100 CD p
women NNS p
, , p
182 CD p
men NNS p
) ) p
with IN p
substance NN p
use NN p
disorders NNS p
were VBD p
included VBN p
in IN p
this DT p
secondary JJ p
analysis NN p
. . p

The DT N
findings NNS N
revealed VBD N
that IN N
women NNS N
were VBD N
more RBR N
likely JJ N
than IN N
men NNS N
to TO N
attend VB o
aftercare NN o
. . o

This DT N
gender NN N
effect NN N
persisted VBN N
after IN N
adjustment NN N
for IN N
a DT N
number NN N
of IN N
potential JJ N
mediators NNS N
. . N

-DOCSTART- -X- O O

Intra-operative JJ N
antibiotic JJ i
prophylaxis NN N
in IN N
neurosurgery NN p
. . p

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
controlled VBN N
study NN N
on IN N
cefotiam NN i
. . i

In IN N
this DT N
prospective JJ N
, , N
randomized VBN N
and CC N
controlled VBN N
study VB N
the DT N
effect NN N
of IN N
cefotiam NN i
for IN N
the DT N
prevention NN N
of IN N
wound JJ N
infections NNS N
following VBG N
trepanations NNS p
was VBD N
investigated VBN N
. . N

The DT N
main JJ N
interest NN N
was VBD N
centered VBN N
on IN N
the DT N
rate NN N
of IN N
post-operative JJ N
bone NN N
flap NN N
infections NNS N
requiring VBG N
operative JJ N
revision NN N
. . N

Administration NNP N
of IN N
cefotiam NN i
was VBD N
randomized VBN N
for IN N
patients NNS p
undergoing VBG p
major JJ p
craniotomies NNS p
. . p

The DT N
antibiotic NN i
was VBD N
administered VBN N
intravenously RB N
in IN N
a DT N
single JJ N
dose NN N
of IN N
2 CD N
g NN N
with IN N
induction NN N
of IN N
anaesthesia NN i
. . i

Only JJ p
clean JJ p
or CC p
clean JJ p
contaminated VBN p
cases NNS p
were VBD p
included VBN p
. . p

Excluded VBN p
were VBD p
contaminated VBN p
cases NNS p
, , p
operations NNS p
with IN p
a DT p
transnasal-transsphenoidal JJ p
approach NN p
, , p
shunt-operations NNS p
and CC p
patients NNS p
with IN p
any DT p
other JJ p
preoperative JJ p
infection NN p
or CC p
antibiotic JJ i
therapy NN i
. . i

Outpatients NNS p
were VBD p
excluded VBN p
due JJ p
to TO p
difficulties NNS p
in IN p
obtaining VBG p
sufficient JJ p
clinical JJ p
information NN p
. . p

From NNP p
originally RB p
918 CD p
consecutive JJ p
patients NNS p
operated VBN p
on IN p
711 CD p
fulfilled VBD p
the DT p
entry NN p
criteria NNS p
. . p

With IN p
regard NN p
to TO p
age NN p
, , p
sex NN p
, , p
diagnosis NN p
and CC p
the DT p
site NN p
of IN p
te JJ p
trepanation NN p
, , p
control NN i
patients NNS i
( ( p
n JJ p
= NNP p
355 CD p
) ) p
and CC p
cefotiam $ p
treated VBN p
patients NNS p
( ( p
n JJ p
= NNP p
356 CD p
) ) p
were VBD p
shown VBN p
to TO p
be VB p
comparable JJ p
. . p

In IN N
the DT N
various JJ N
subgroups NNS N
formed VBN N
for IN N
different JJ p
primary JJ p
diagnoses NNS p
, , p
concomitant JJ i
steroidal NN i
therapy NN i
and CC N
concomitant NN p
severe JJ p
internal JJ p
medical JJ p
diseases NNS p
cefotiam VBP N
treated VBN N
patients NNS N
and CC N
controls NNS N
were VBD N
comparable JJ N
as RB N
well RB N
. . N

A DT N
highly RB N
significant JJ N
difference NN N
for IN N
bone NN o
flap NN o
infection NN o
could MD N
be VB N
shown VBN N
with IN N
0.3 CD N
% NN N
in IN N
the DT N
cefotiam NN N
group NN N
versus VBD N
5.1 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
p VBZ N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
overall JJ o
rate NN o
of IN o
post-operative JJ o
deep JJ o
wound NN o
infections NNS o
including VBG o
meningitis NN o
and CC o
abscesses NNS o
was VBD N
also RB N
significantly RB N
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
different JJ o
with IN N
3.1 CD N
% NN N
in IN N
the DT N
cefotiam NN i
versus IN N
9.0 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

Thus VB N
it PRP N
was VBD N
concluded VBN N
that IN N
a DT N
single JJ N
dose NN N
of IN N
cefotiam NN N
significantly RB N
reduces VBZ N
post-operative JJ o
deep JJ o
wound NN o
infection NN o
. . o

-DOCSTART- -X- O O

Interferon NNP i
alfa NN i
in IN N
acute JJ p
posttransfusion NN p
hepatitis NN p
C NNP p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

-DOCSTART- -X- O O

Predictors NNS N
of IN N
smoking VBG p
cessation NN p
among IN p
cancer NN p
patients NNS p
enrolled VBN p
in IN p
a DT p
smoking NN i
cessation NN i
program NN p
. . p

UNLABELLED NNP N
Many JJ N
cancer NN p
patients NNS p
continue VBP N
to TO N
smoke VB N
postdiagnosis NN N
, , N
which WDT N
is VBZ N
associated VBN N
with IN N
poorer JJR N
clinical JJ N
outcomes NNS N
. . N

Identifying VBG N
prospective JJ N
predictors NNS N
of IN N
smoking VBG N
cessation NN N
among IN N
patients NNS N
currently RB N
receiving VBG N
smoking VBG i
cessation NN i
treatment NN N
can MD N
help VB N
guide VB N
the DT N
development NN N
and CC N
implementation NN N
of IN N
smoking VBG i
cessation NN i
programs NNS i
with IN N
this DT N
population NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
Data NNP p
from IN p
246 CD p
cancer NN p
patients NNS p
participating VBG p
in IN p
a DT p
randomized JJ p
placebo-controlled JJ i
smoking NN p
cessation NN p
clinical JJ p
trial NN p
were VBD N
used VBN N
to TO N
examine VB N
baseline JJ N
predictors NNS N
of IN N
end-of-treatment JJ N
and CC N
six-month JJ N
postbaseline NN N
smoking NN i
cessation NN i
outcomes RB N
. . N

Baseline NNP N
demographic JJ N
, , N
smoking-related JJ N
, , N
disease-related JJ N
, , N
and CC N
psychological JJ N
variables NNS N
were VBD N
examined VBN N
as IN N
predictors NNS N
of IN N
biochemically-confirmed JJ N
point-prevalence NN N
abstinence NN N
. . N

RESULTS NNP N
Multivariate NNP o
analysis NN N
indicated VBD N
that IN N
, , N
for IN N
end-of-treatment JJ o
abstinence NN o
, , N
patients NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
have VB N
quit NN o
smoking VBG o
if IN N
they PRP N
were VBD N
older JJR N
( ( N
OR NNP N
= VBZ N
1.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.03-1.10 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
were VBD N
diagnosed VBN N
with IN N
a DT N
non-tobacco JJ N
related JJ N
cancer NN N
( ( N
OR NNP N
= VBZ N
2.54 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.24-5.20 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Likewise NNP N
, , N
for IN N
six-month JJ o
abstinence NN o
, , N
patients NNS N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
have VB N
quit NN o
smoking VBG o
if IN N
they PRP N
were VBD N
older JJR N
( ( N
OR NNP N
= VBZ N
1.04 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.08 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
have VB N
quit NN N
smoking VBG N
if IN N
they PRP N
were VBD N
female JJ N
( ( N
OR NNP N
= VBZ N
0.47 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.22-0.97 JJ N
, , N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNS p
with IN p
tobacco-related JJ p
cancers NNS p
and CC p
female JJ p
patients NNS p
reported VBD N
significantly RB N
higher JJR N
levels NNS o
of IN o
depression NN o
symptoms NNS o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
which WDT N
proved VBD N
predictive NN o
of IN o
smoking VBG o
relapse NN o
. . o

CONCLUSIONS NNP N
Patient NNP N
age NN N
, , N
gender NN N
, , N
and CC N
cancer-type NN N
may MD N
be VB N
important JJ N
factors NNS N
to TO N
consider VB N
when WRB N
developing VBG N
and CC N
implementing VBG N
smoking VBG i
cessation NN i
interventions NNS i
for IN N
cancer NN p
patients NNS p
. . p

-DOCSTART- -X- O O

Endurance NN N
training NN N
has VBZ N
little JJ N
effect NN N
on IN N
active JJ N
muscle NN N
free JJ o
fatty NN o
acid NN o
, , o
lipoprotein FW o
cholesterol NN o
, , o
or CC o
triglyceride JJ o
net JJ N
balances NNS N
. . N

We PRP N
evaluated VBD N
the DT N
hypothesis NN N
that WDT N
net JJ o
leg NN o
total JJ o
FFA NNP o
, , o
LDL-C NNP o
, , o
and CC o
TG NNP o
uptake JJ o
and CC o
HDL-C JJ o
release NN o
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
would MD N
be VB N
increased VBN N
following VBG N
endurance NN N
training NN N
. . N

Eight NNP p
sedentary JJ p
men NNS p
( ( p
26 CD p
+/- JJ p
1 CD p
yr NN p
, , p
77.4 CD p
+/- JJ p
3.7 CD p
kg NN p
) ) p
were VBD p
studied VBN p
in IN N
the DT N
postprandial JJ N
state NN N
during IN N
90 CD i
min NNS i
of IN i
rest NN i
and CC i
60 CD i
min NN i
of IN i
exercise NN i
twice NN i
before IN N
( ( N
45 CD N
% NN N
and CC N
65 CD N
% NN N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
and CC N
twice RB N
after IN N
9 CD i
wk NN i
of IN i
endurance NN i
training NN i
( ( N
55 CD N
% NN N
and CC N
65 CD N
% NN N
posttraining VBG N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
. . N

Measurements NNS N
across IN N
an DT N
exercising VBG N
leg NN N
were VBD N
taken VBN N
to TO N
be VB N
a DT N
surrogate NN N
for IN N
active JJ N
skeletal JJ N
muscle NN N
. . N

To TO N
determine VB N
limb NN o
lipid JJ o
exchange NN o
, , N
femoral JJ N
arterial NN N
and CC N
venous JJ N
blood NN N
samples NNS N
drawn VBP N
simultaneously RB N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
were VBD N
analyzed VBN N
for IN N
total JJ N
and CC N
individual JJ N
FFA NNP N
( ( N
e.g. NN N
, , N
palmitate NN N
, , N
oleate NN N
) ) N
, , N
LDL-C NNP o
, , o
HDL-C NNP o
, , o
and CC o
TG NNP o
concentrations NNS o
, , o
and CC o
limb NN o
blood NN o
flow NN o
was VBD N
determined VBN N
by IN N
thermodilution NN N
. . N

The DT N
transition NN N
from IN N
rest NN N
to TO N
exercise VB N
resulted VBN N
in IN N
a DT N
shift NN N
from IN N
net JJ N
leg NN N
total JJ o
FFA NNP o
release NN o
( ( N
-44 JJ N
+/- JJ N
16 CD N
micromol/min NN N
) ) N
to TO N
uptake VB N
( ( N
193 CD N
+/- JJ N
49 CD N
micromol/min NN N
) ) N
that WDT N
was VBD N
unaffected VBN N
by IN N
either DT N
exercise NN N
intensity NN N
or CC N
endurance NN N
training NN N
. . N

The DT N
relative JJ N
net NN N
leg NN N
release NN N
and CC N
uptake NN N
of IN N
individual JJ N
FFA NNP N
closely RB N
resembled VBD N
their PRP$ N
relative JJ N
abundances NNS N
in IN N
the DT N
plasma NN N
with IN N
approximately RB N
21 CD N
and CC N
41 CD N
% NN N
of IN N
net JJ N
leg NN N
total JJ N
FFA NNP N
uptake NN N
during IN N
exercise NN N
accounted VBN N
for IN N
by IN N
palmitate NN N
and CC N
oleate NN N
, , N
respectively RB N
. . N

Endurance NNP i
training NN i
resulted VBD N
in IN N
significant JJ N
changes NNS N
in IN N
arterial JJ o
concentrations NNS o
of IN o
HDL-C NNP o
( ( N
49 CD N
+/- JJ N
5 CD N
vs. FW N
52 CD N
+/- JJ N
5 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
and CC N
LDL-C NNP o
( ( N
82 CD N
+/- JJ N
9 CD N
vs. FW N
76 CD N
+/- JJ N
9 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
net JJ o
TG NN o
or CC o
LDL-C JJ o
uptake NN o
or CC o
HDL-C JJ o
release NN o
across IN N
the DT N
resting NN N
or CC N
active JJ N
leg NN N
before IN N
or CC N
after IN N
endurance JJ N
training NN N
. . N

In IN N
conclusion NN N
, , N
endurance NN N
training NN N
favorably RB N
affects VBZ N
blood NN o
lipoprotein NN o
profiles NNS o
, , N
even RB N
in IN p
young JJ p
, , p
healthy JJ p
normolipidemic JJ p
men NNS p
, , N
but CC N
muscle NN N
contractions NNS N
per IN N
se NN N
have VBP N
little JJ N
effect NN N
on IN N
net JJ N
leg NN o
LDL-C NNP o
, , o
or CC o
TG NNP o
uptake VBP o
or CC o
HDL-C JJ o
release NN o
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
favorable JJ N
effects NNS N
of IN N
physical JJ N
activity NN N
on IN N
the DT N
lipid JJ N
profiles NNS N
of IN N
young JJ p
, , p
healthy JJ p
normolipidemic JJ p
men NNS p
in IN p
the DT p
postprandial JJ p
state NN p
are VBP N
not RB N
attributable JJ N
to TO N
changes NNS N
in IN N
HDL-C NNP o
or CC o
LDL-C NNP o
exchange NN N
across IN N
active JJ N
skeletal JJ N
muscle NN N
. . N

-DOCSTART- -X- O O

Dexamethasone NN i
phosphate NN i
in IN i
antibiotic JJ i
ear NN i
drops NNS i
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
bacterial JJ p
otitis NN p
externa NN p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
polymyxin NN i
sulfate NN i
7500 CD i
IU/neomycin NNP i
sulfate NN i
3500 CD i
IU/dexamethasone NNP i
phosphate VB i
0.1 CD i
% NN i
( ( i
PN+Dx NNP i
) ) i
otic JJ i
solution NN i
with IN i
polymyxin NN i
sulfate NN i
7500 CD i
IU/neomycin NNP i
sulfate NN i
3500 CD i
IU NNP i
( ( i
PN-Dx NNP i
) ) i
in IN N
patients NNS p
with IN p
acute JJ p
bacterial JJ p
otitis NN p
externa NN p
( ( p
AOE NNP p
) ) p
, , N
in IN N
order NN N
to TO N
determine VB N
the DT N
possible JJ N
benefit NN N
of IN N
the DT N
addition NN N
of IN N
dexamethasone NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Active NNP N
controlled VBD N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
, , N
multi-center JJ p
clinical JJ p
trial NN p
in IN p
ear NN p
, , p
nose RB p
, , p
and CC p
throat NN p
( ( p
ENT NNP p
) ) p
specialist NN p
practices NNS p
with IN N
a DT N
planned VBN N
interim NN N
analysis NN N
for IN N
sample JJ N
size NN N
adaptation NN N
. . N

In IN N
total JJ N
, , N
338 CD p
patients NNS p
aged VBN p
18-76 NNS p
who WP p
had VBD p
a DT p
previous JJ p
episode NN p
of IN p
otitis NN p
externa NN p
within IN p
the DT p
last JJ p
year NN p
were VBD N
randomized VBN N
to TO N
receive VB N
10 CD N
+/- JJ N
2 CD N
days NNS N
of IN N
treatment NN N
with IN N
two CD i
drops NNS i
, , i
three CD i
times NNS i
daily RB i
, , i
of IN i
either DT i
PN+Dx NNP i
or CC i
PN-Dx NNP i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP o
in IN o
the DT o
clinical JJ o
symptom NN o
score NN o
( ( o
consisting VBG o
of IN o
the DT o
subscores NNS o
redness NN o
, , o
swelling VBG o
, , o
pain NN o
, , o
and CC o
secretion NN o
) ) o
and CC N
of IN N
the DT N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
rating NN o
for IN o
pain NN o
from IN N
Visit NNP N
1 CD N
( ( N
Day NNP N
1 CD N
) ) N
to TO N
Visit VB N
2 CD N
( ( N
Day NNP N
4 CD N
+/- JJ N
1 CD N
) ) N
, , N
patient NN o
's POS o
assessment NN o
of IN o
efficacy NN o
at IN N
Visit NNP N
3 CD N
( ( N
Day NNP N
10 CD N
+/- JJ N
2 CD N
) ) N
, , N
and CC N
the DT N
frequency NN o
and CC o
type NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
of IN N
swelling VBG o
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
with IN N
PN+Dx NNP N
, , N
and CC N
more JJR N
patients NNS N
rated VBD N
the DT N
efficacy NN o
of IN N
PN+Dx NNP N
as IN N
'very RB N
good JJ N
' '' N
or CC N
'good POS N
' '' N
at IN N
Visit NNP N
3 CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
clinical JJ o
symptom NN o
score NN o
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
in IN N
the DT N
PN+Dx NNP N
group NN N
in IN N
patients NNS N
who WP N
had VBD N
at IN N
least JJS N
a DT N
moderately RB N
severe JJ o
symptom NN o
score NN o
with IN N
more JJR N
than IN N
seven CD N
points NNS N
at IN N
Visit NNP N
1 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
and CC N
in IN N
patients NNS N
suffering VBG N
from IN N
their PRP$ N
current JJ N
episode NN N
of IN N
otitis NN N
externa NN N
for IN N
more JJR N
than IN N
2 CD N
days NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

In IN N
total JJ N
, , N
14 CD N
adverse JJ N
events NNS N
were VBD N
reported VBN N
during IN N
the DT N
study NN N
period NN N
with IN N
no DT N
related JJ N
adverse JJ o
drug NN o
reactions NNS o
for IN N
PN+Dx NNP N
. . N

CONCLUSIONS NNP N
The DT N
addition NN i
of IN i
dexamethasone NN i
phosphate NN i
to TO i
polymyxin VB i
B/neomycin NNP i
significantly RB N
reduces VBZ N
swelling VBG N
in IN N
patients NNS p
with IN p
AOE NNP p
and CC N
leads VBZ N
to TO N
significantly RB N
higher JJR N
patient NN N
's POS N
ratings NNS N
of IN N
treatment NN N
efficacy NN N
. . N

It PRP N
especially RB N
leads VBZ N
to TO N
an DT N
overall JJ N
reduction NN N
of IN N
symptoms NNS N
in IN N
cases NNS N
of IN N
moderately RB N
or CC N
more JJR N
severe JJ N
otitis NN N
externa NN N
and CC N
cases NNS N
lasting VBG N
for IN N
more JJR N
than IN N
2 CD N
days NNS N
. . N

-DOCSTART- -X- O O

Effectiveness NN N
of IN N
a DT N
clinical JJ i
intervention NN i
in IN N
improving VBG N
pain NN N
control NN N
in IN N
outpatients NNS p
with IN p
cancer NN p
treated VBN p
by IN p
radiation NN i
therapy NN i
. . i

PURPOSE NNP N
To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
a DT N
multicomponent JJ i
clinical JJ i
intervention NN i
to TO N
reduce VB N
pain NN N
in IN N
outpatients NNS p
with IN p
cancer NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
Sixty-four JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either CC N
a DT N
clinical JJ i
intervention NN i
including VBG N
an DT N
information NN i
session NN i
, , N
the DT N
use NN N
of IN N
a DT N
pain NN i
diary JJ i
, , N
and CC N
the DT N
possibility NN N
to TO N
contact VB i
a DT i
physician NN i
to TO N
adjust VB N
the DT N
pain NN N
medication NN N
, , N
or CC i
the DT i
usual JJ i
treatment NN i
of IN i
pain NN i
by IN i
the DT i
staff NN i
radiation NN i
oncologist NN i
. . i

All DT N
patients NNS N
reported VBD N
their PRP$ N
average NN N
and CC N
worst JJS N
pain NN o
levels NNS o
at IN N
baseline NN N
and CC N
2 CD N
and CC N
3 CD N
weeks NNS N
after IN N
the DT N
start NN N
of IN N
the DT N
intervention NN N
. . N

RESULTS VB N
The DT N
study NN N
groups NNS N
were VBD N
similar JJ N
with IN N
respect NN N
to TO N
their PRP$ N
baseline NN N
characteristics NNS N
and CC N
pain NN N
levels NNS N
at IN N
randomization NN N
. . N

After IN N
3 CD N
weeks NNS N
, , N
the DT N
average NN N
and CC N
worst JJS N
pain NN N
experienced VBN N
by IN N
patients NNS N
randomized VBN N
to TO N
the DT N
clinical JJ i
intervention NN i
group NN i
was VBD N
significantly RB N
inferior JJ N
to TO N
the DT N
average NN N
pain NN N
experienced VBN N
by IN N
patients NNS N
in IN N
the DT N
control NN i
group NN N
( ( N
2.9/10 CD N
vs. FW N
4.4/10 CD N
and CC N
4.2/10 CD N
vs. FW N
5.5/10 CD N
, , N
respectively RB N
) ) N
. . N

Results CC N
showed VBD N
that IN N
the DT N
experimental JJ N
group NN N
patients NNS N
decreased VBD N
their PRP$ N
pain NN N
levels NNS N
more RBR N
than IN N
the DT N
control NN N
group NN N
patients NNS N
did VBD N
over IN N
time NN N
. . N

CONCLUSION NNP N
An DT o
intervention NN o
including VBG o
patient JJ o
education NN o
, , o
a DT o
pain NN o
diary JJ o
, , o
and CC o
defining VBG o
a DT o
procedure NN o
for IN o
therapeutic JJ o
adjustments NNS o
can MD o
be VB o
effective JJ o
to TO o
improve VB o
pain NN o
relief NN o
in IN o
outpatients NNS o
with IN o
cancer NN o
. . o

-DOCSTART- -X- O O

Virtual JJ i
patients NNS i
design NN i
and CC N
its PRP$ N
effect NN N
on IN N
clinical JJ o
reasoning NN o
and CC N
student NN o
experience NN o
: : o
a DT N
protocol NN N
for IN N
a DT N
randomised JJ N
factorial JJ N
multi-centre NN N
study NN N
. . N

BACKGROUND NNP N
Virtual JJ i
Patients NNP i
( ( i
VPs NNP i
) ) i
are VBP N
web-based JJ N
representations NNS N
of IN N
realistic JJ N
clinical JJ N
cases NNS N
. . N

They PRP N
are VBP N
proposed VBN N
as IN N
being VBG N
an DT N
optimal JJ N
method NN N
for IN N
teaching VBG N
clinical JJ N
reasoning NN N
skills NNS N
. . N

International NNP N
standards NNS N
exist VBP N
which WDT N
define VBP N
precisely RB N
what WP N
constitutes VBZ N
a DT N
VP NNP i
. . i

There EX N
are VBP N
multiple JJ N
design NN N
possibilities NNS N
for IN N
VPs NNP N
, , N
however RB N
there EX N
is VBZ N
little JJ N
formal JJ N
evidence NN N
to TO N
support VB N
individual JJ N
design NN N
features NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
trial NN N
is VBZ N
to TO N
explore VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
potentially RB N
important JJ N
design NN N
features NNS N
on IN N
clinical JJ o
reasoning NN o
skills NNS o
and CC o
the DT o
student NN o
experience NN o
. . o

These DT N
are VBP N
the DT N
branching VBG N
case NN N
pathways NNS N
( ( N
present JJ N
or CC N
absent NN N
) ) N
and CC N
structured JJ N
clinical JJ N
reasoning VBG N
feedback NN N
( ( N
present JJ N
or CC N
absent NN N
) ) N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
a DT N
multi-centre JJ N
randomised JJ N
2 CD N
x JJ N
2 CD N
factorial JJ N
design NN N
study NN N
evaluating VBG N
two CD N
independent JJ N
variables NNS N
of IN N
VP NNP i
design NN i
, , i
branching NN i
( ( i
present JJ i
or CC i
absent NN i
) ) i
, , N
and CC N
structured VBD i
clinical JJ i
reasoning NN i
feedback NN i
( ( i
present JJ i
or CC i
absent NN i
) ) i
.The NN i
study NN N
will MD N
be VB N
carried VBN N
out RP N
in IN N
medical JJ p
student NN p
volunteers NNS p
in IN p
one CD p
year NN p
group NN p
from IN p
three CD p
university NN p
medical JJ p
schools NNS p
in IN p
the DT p
United NNP p
Kingdom NNP p
, , p
Warwick NNP p
, , p
Keele NNP p
and CC p
Birmingham NNP p
. . p

There EX N
are VBP N
four CD N
core NN N
musculoskeletal NN N
topics NNS N
. . N

Each DT N
case NN N
can MD N
be VB N
designed VBN N
in IN N
four CD N
different JJ N
ways NNS N
, , N
equating VBG N
to TO N
16 CD N
VPs NNP N
required VBN N
for IN N
the DT N
research NN N
. . N

Students NNS p
will MD N
be VB N
randomised VBN N
to TO N
four CD N
groups NNS N
, , N
completing VBG N
the DT N
four CD N
VP NNP i
topics NNS N
in IN N
the DT N
same JJ N
order NN N
, , N
but CC N
with IN N
each DT N
group NN N
exposed VBD N
to TO N
a DT N
different JJ N
VP NNP i
design NN N
sequentially RB N
. . N

All DT N
students NNS p
will MD N
be VB N
exposed VBN N
to TO N
the DT N
four CD N
designs NNS N
. . N

Primary JJ N
outcomes NNS N
are VBP N
performance NN o
for IN o
each DT o
case NN o
design NN o
in IN o
a DT o
standardized JJ o
fifteen JJ o
item NN o
clinical JJ o
reasoning NN o
assessment NN o
, , o
integrated VBN o
into IN o
each DT o
VP NNP o
, , o
which WDT o
is VBZ o
identical JJ o
for IN o
each DT o
topic NN o
. . o

Additionally RB N
a DT N
15-item JJ o
self-reported JJ o
evaluation NN o
is VBZ N
completed VBN N
for IN N
each DT N
VP NNP i
, , N
based VBN N
on IN N
a DT N
widely RB N
used VBN N
EViP NNP N
tool NN N
. . N

Student NN p
patterns NNS N
of IN N
use NN N
of IN N
the DT N
VPs NNP N
will MD N
be VB N
recorded.In JJ N
one CD N
centre NN N
, , N
formative JJ N
clinical JJ N
and CC N
examination NN N
performance NN N
will MD N
be VB N
recorded VBN N
, , N
along IN N
with IN N
a DT N
self NN N
reported VBN N
pre JJ N
and CC N
post-intervention NN N
reasoning NN N
score NN N
, , N
the DT N
DTI NNP N
. . N

Our PRP$ N
power NN N
calculations NNS N
indicate VBP N
a DT p
sample JJ p
size NN p
of IN p
112 CD p
is VBZ p
required VBN p
for IN N
both DT N
primary JJ N
outcomes NNS N
. . N

DISCUSSION NNP N
This DT N
trial NN N
will MD N
provide VB N
robust JJ N
evidence NN N
to TO N
support VB N
the DT N
effectiveness NN N
of IN N
different JJ N
designs NNS N
of IN N
virtual JJ N
patients NNS N
, , N
based VBN N
on IN N
student NN o
performance NN o
and CC o
evaluation NN o
. . o

The DT N
cases NNS N
and CC N
all DT N
learning JJ N
materials NNS N
will MD N
be VB N
open JJ N
access NN N
and CC N
available JJ N
on IN N
a DT N
Creative JJ N
Commons NNP N
Attribution-Share-Alike NNP N
license NN N
. . N

-DOCSTART- -X- O O

Cytokine NN o
levels NNS o
and CC o
systemic JJ o
toxicity NN o
in IN N
patients NNS p
undergoing VBG p
isolated JJ i
limb NN i
perfusion NN i
with IN i
high-dose JJ i
tumor NN i
necrosis NN i
factor NN i
, , i
interferon NN i
gamma NN i
, , i
and CC i
melphalan NN i
. . i

PURPOSE NNP N
Isolated NNP i
limb NN i
perfusion NN i
( ( i
ILP NNP i
) ) i
with IN i
tumor NN i
necrosis NN i
factor NN i
( ( i
TNF NNP i
) ) i
, , i
interferon JJ i
gamma NN i
, , i
and CC i
melphalan NN i
( ( i
M NNP i
) ) i
has VBZ N
been VBN N
reported VBN N
to TO N
result VB N
in IN N
high JJ N
response NN o
rates NNS o
for IN N
extremity NN N
melanoma NN N
and CC N
sarcoma NN N
. . N

We PRP N
have VBP N
evaluated VBN N
the DT N
relationship NN N
of IN N
systemic JJ N
TNF NNP N
exposure NN N
to TO N
induction NN N
of IN N
several JJ N
secondary JJ o
mediators NNS o
and CC N
incidence NN N
of IN N
systemic JJ o
toxicity NN o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
Nineteen NNP p
patients NNS p
with IN p
extremity NN p
melanoma NN p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
or CC p
sarcoma NN p
( ( p
n JJ p
= NNP p
3 CD p
) ) p
, , N
underwent JJ N
90-minute JJ N
ILP NNP i
with IN i
TNF-alpha NNP i
, , i
interferon NN i
gamma NN i
( ( N
0.2 CD N
mg NN N
) ) N
, , N
and CC i
M NNP i
( ( N
10 CD N
to TO N
13 CD N
mg/L NN N
of IN N
limb NN N
volume NN N
) ) N
( ( i
TNF/IFN/M NNP i
) ) i
( ( N
n JJ N
= NNP N
12 CD N
) ) N
, , N
or CC i
M NNP i
alone RB i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
. . N

Continuous JJ N
intraoperative JJ N
monitoring NN N
( ( N
CIM NNP N
) ) N
for IN N
systemic JJ N
leak NN N
from IN N
the DT N
perfusion NN N
circuit NN N
was VBD N
performed VBN N
using VBG N
radioactive JJ N
iodine-131 JJ i
albumin NN i
. . i

Cytokine NN N
levels NNS N
in IN N
the DT N
perfusate NN N
and CC N
systemic JJ N
circulation NN N
during IN N
and CC N
after IN N
ILP NNP N
were VBD N
measured VBN N
by IN N
enzyme-linked JJ i
immunosorbent NN i
assay NN i
. . i

RESULTS NNP N
Systemic NNP o
leaks VBZ o
> CD o
or CC o
= VB o
1 CD o
% NN o
from IN N
the DT N
perfusion NN o
circuit NN o
occurred VBD N
in IN N
six CD N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
and CC N
in IN N
four CD N
who WP N
received VBD N
M NNP N
alone RB N
. . N

Hypotension NNP o
that IN o
required VBD o
vasopressor NN o
support NN o
occurred VBD N
in IN N
six CD N
of IN N
six CD N
patients NNS N
with IN N
evidence NN N
of IN N
a DT N
leak NN N
( ( N
> CD N
or CC N
= VB N
1 CD N
% NN N
) ) N
and CC N
zero CD N
of IN N
six CD N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
< JJ N
1 CD N
% NN N
) ) N
. . N

These DT N
six CD N
patients NNS N
had VBD N
significantly RB N
higher JJR N
peak JJ o
systemic JJ o
TNF NNP o
levels NNS o
during IN N
and CC N
after IN N
perfusion NN N
than IN N
patients NNS N
without IN N
a DT N
leak NN N
( ( N
2.8 CD N
and CC N
8.2 CD N
ng/mL JJ N
v NN N
0.7 CD N
and CC N
2.0 CD N
ng/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

All PDT N
patients NNS N
who WP N
received VBD N
TNF/IFN/M NNP N
had VBD N
significantly RB N
greater JJR N
increases NNS N
in IN N
systemic JJ o
interleukin-6 JJ o
( ( o
IL-6 NNP o
) ) o
levels NNS o
than IN N
in IN N
patients NNS N
with IN N
M NNP N
alone RB N
( ( N
12,395 CD N
+/- JJ N
10,374 CD N
pg/mL NN N
v NN N
79.4 CD N
+/- JJ N
7.2 CD N
pg/mL NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Intracellular JJ o
adhesion NN o
molecule NN o
( ( o
ICAM NNP o
) ) o
, , o
IL-8 NNP o
, , o
and CC o
TNF-R JJ o
levels NNS o
were VBD N
also RB N
increased VBN N
after IN N
ILP NNP N
with IN N
TNF/IFN/M NNP N
. . N

CONCLUSION NNP N
ILP NNP N
with IN N
TNF/IFN/M NNP N
can MD N
be VB N
safely RB N
performed VBN N
, , N
as IN N
I131 NNP N
albumin VBP N
provides VBZ N
a DT N
sensitive JJ N
measure NN N
of IN N
systemic JJ N
leakage NN N
from IN N
the DT N
perfusion NN N
circuit NN N
. . N

Patients NNS N
with IN N
a DT N
measured JJ N
leak NN N
of IN N
> NN N
or CC N
= VB N
1 CD N
% NN N
develop NN N
mild NN N
and CC N
transient JJ N
postoperative JJ N
hypotension NN N
with IN N
significantly RB N
higher JJR N
systemic JJ N
TNF NNP N
levels NNS N
and CC N
lower JJR N
perfusate NN N
TNF NNP N
levels NNS N
than IN N
in IN N
patients NNS N
without IN N
leaks NNS N
. . N

-DOCSTART- -X- O O

Paromomycin NNP i
for IN N
cryptosporidiosis NN N
in IN N
AIDS NNP p
: : p
a DT N
prospective JJ N
, , N
double-blind JJ N
trial NN N
. . N

To TO N
test VB N
the DT N
effects NNS N
of IN N
paromomycin NN i
, , N
10 CD p
patients NNS p
with IN p
AIDS NNP p
and CC p
cryptosporidiosis NN p
were VBD N
randomized VBN N
to TO N
paromomycin VB i
or CC i
placebo VB i
in IN N
a DT N
double-blind JJ N
trial NN N
. . N

After IN N
14 CD N
days NNS N
, , N
patients NNS N
were VBD N
switched VBN N
to TO N
the DT N
other JJ N
treatment NN N
for IN N
14 CD N
additional JJ N
days NNS N
. . N

Measures NNS N
included VBD N
the DT N
number NN o
and CC o
character NN o
of IN o
each DT o
stool NN o
and CC N
weekly JJ N
24-h JJ N
stool NN o
specimens NNS o
for IN o
weight NN o
and CC o
oocyst NN o
excretion NN o
. . o

During IN N
the DT N
paromomycin NN i
treatment NN N
phase NN N
, , N
oocyst JJ o
excretion NN o
decreased VBD N
from IN N
314 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
to TO N
109 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
24 CD N
h NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Oocyst NNP o
excretion NN o
increased VBD N
for IN N
the DT N
4 CD N
patients NNS N
initially RB N
on IN N
placebo NNS i
compared VBN N
to TO N
a DT N
median JJ N
decrease NN N
of IN N
128 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/24 NN N
h NN N
for IN N
the DT N
6 CD N
initially RB N
treated VBN N
with IN N
drug NN N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Stool NNP o
frequency NN o
also RB N
decreased VBD N
more RBR N
in IN N
those DT N
treated VBN N
with IN N
drug NN i
( ( N
3.6 CD N
fewer JJR N
vs. NN N
1.25 CD N
fewer/24 NN N
h NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Trends NNS N
favored JJ N
drug NN N
over IN N
placebo NN i
for IN N
stool NN o
weight NN o
, , o
stool JJ o
character NN o
, , o
and CC o
Karnofsky NNP o
score NN o
. . o

Paromomycin NNP i
treatment NN N
resulted VBD N
in IN N
improvement NN N
in IN N
both DT N
clinical JJ N
and CC N
parasitologic JJ N
parameters NNS N
in IN N
cryptosporidiosis NN N
in IN N
AIDS NNP N
. . N

-DOCSTART- -X- O O

Anemia NNP N
and CC N
associated VBN N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
due JJ p
to TO p
reduced VB p
left JJ p
ventricular JJ p
systolic JJ p
function NN p
. . p

BACKGROUND NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
decreased JJ N
functional JJ N
capacity NN N
, , N
reduced VBD N
quality NN N
of IN N
life NN N
, , N
and CC N
worsened VBD N
outcomes NNS N
among IN N
patients NNS p
with IN p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
due JJ p
to TO p
reduced VB p
left JJ p
ventricular JJ p
ejection NN p
fraction NN p
( ( p
HFREF NNP p
) ) p
. . p

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
independent JJ N
effect NN N
of IN N
anemia NN N
on IN N
clinical JJ N
outcomes NNS N
among IN N
those DT p
with IN p
HFREF NNP p
. . p

HYPOTHESIS NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ N
events NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

METHODS PDT N
The DT N
HF-ACTION NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
exercise NN i
therapy NN i
vs NN i
usual JJ i
care NN i
in IN N
2331 CD p
patients NNS p
with IN p
HFREF NNP p
. . p

Patients NNS p
with IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II NNP p
to TO p
IV NNP p
HF NNP p
and CC p
left VBD p
ventricular JJ p
ejection NN p
fractions NNS p
of IN p
? . p
35 CD p
% NN p
were VBD p
recruited VBN o
. . o

Hemoglobin NNP o
( ( o
Hb NNP o
) ) o
was VBD o
measured VBN N
up RB N
to TO N
1 CD N
year NN N
prior RB N
to TO N
entry NN N
and CC N
was VBD N
stratified VBN N
by IN N
quintile NN o
. . o

Anemia NNP o
was VBD o
defined VBN N
as IN N
baseline NN p
Hb NNP p
< VBZ p
13 CD p
g/dL NN p
and CC p
< $ p
12 CD p
g/dL NN p
in IN p
men NNS p
and CC p
women NNS p
, , p
respectively RB o
. . o

Hemoglobin NNP o
was VBD o
assessed VBN N
in IN N
2 CD N
models NNS N
: : N
a DT N
global JJ N
prediction NN N
model NN N
that WDT N
had VBD N
been VBN N
previously RB N
developed VBN N
, , N
and CC N
a DT N
modified JJ N
model NN N
including VBG N
variables NNS N
associated VBN N
with IN N
anemia NN N
and CC N
the DT N
studied JJ N
outcomes NNS N
. . N

RESULTS NNP o
Hemoglobin NNP o
was VBD o
available JJ N
at IN N
baseline NN N
in IN N
1763 CD p
subjects NNS p
( ( p
76 CD p
% NN p
of IN p
total JJ p
study NN p
population NN p
) ) p
; : p
their PRP$ p
median JJ p
age NN p
was VBD p
59.0 CD p
years NNS p
, , p
73 CD p
% NN p
were VBD p
male JJ p
, , p
and CC p
62 CD p
% NN p
were VBD p
Caucasian JJ p
. . p

The DT N
prevalence NN N
of IN N
anemia NN N
was VBD N
515/1763 CD N
( ( N
29 CD N
% NN N
) ) N
. . N

Older JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
African JJ N
American NNP N
race NN N
, , N
diabetes VBZ N
, , N
hypertension NN N
, , N
and CC N
lower JJR N
estimated VBN N
glomerular JJ N
filtration NN N
rates NNS N
were VBD N
all DT N
more RBR N
frequent JJ N
in IN N
lower JJR N
Hb NNP N
quintiles NNS N
. . N

Over IN N
a DT N
median JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ o
mortality NN o
or CC o
all-cause JJ o
hospitalization NN o
occurred VBD o
in IN N
78 CD N
% NN N
of IN N
those DT N
with IN N
anemia NN N
and CC N
64 CD N
% NN N
in IN N
those DT N
without IN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
secondary JJ N
outcomes NNS N
of IN N
all-cause JJ o
mortality NN o
alone RB o
, , o
cardiovascular JJ o
( ( o
CV NNP o
) ) o
mortality NN o
or CC o
CV NNP o
hospitalization NN o
, , o
and CC o
CV NNP o
mortality NN o
or CC o
HF NNP o
hospitalization NN o
occurred VBD o
in IN N
23 CD N
% NN N
vs JJ N
15 CD N
% NN N
, , N
67 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
and CC N
44 CD N
vs NNS N
29 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD o
) ) o
. . o

Heart NNP o
failure NN o
hospitalizations NNS o
occurred VBD o
in IN N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
, , N
and CC o
urgent JJ o
outpatient NN o
visits NNS o
for IN o
HF NNP o
exacerbations NNS o
occurred VBD o
in IN N
67 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
the DT N
global JJ N
model NN N
, , N
there EX N
was VBD N
an DT N
association NN N
observed VBD N
for IN N
anemia NN N
and CC o
all-cause JJ o
mortality NN o
or CC o
hospitalization NN o
( ( o
adjusted VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NN N
: : N
1.15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.01-1.32 JJ N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
but CC N
other JJ N
outcomes NNS N
were VBD N
not RB N
significant JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

In IN N
the DT N
modified JJ N
model NN N
, , N
the DT N
adjusted JJ o
HR NNP o
for IN o
anemia NN N
and CC N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ N
mortality NN N
or CC N
all-cause JJ N
hospitalization NN N
was VBD N
1.25 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.10-1.42 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
independent JJ N
associations NNS N
between IN o
anemia NN o
and CC o
all-cause JJ o
death NN o
( ( o
HR NNP N
: : N
1.11 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.87-1.42 JJ N
, , N
P NNP N
= NNP N
0.38 CD o
) ) o
, , o
CV NNP o
death NN o
or CC o
CV NNP o
hospitalization NN o
( ( o
HR NNP N
: : N
1.16 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.33 JJ N
, , N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
and CC N
CV NNP N
death NN N
and CC o
HF NNP o
hospitalization NN o
( ( o
HR NNP N
: : N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.06-1.51 JJ N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Anemia NNP N
modestly RB N
is VBZ N
associated VBN N
with IN N
increased JJ N
rates NNS N
of IN N
death NN N
, , N
hospitalization NN N
, , N
and CC N
HF NNP N
exacerbation NN N
in IN N
patients NNS p
with IN p
chronic JJ p
HFREF NNP p
. . p

After IN N
adjusting VBG N
for IN N
other JJ N
important JJ N
covariates NNS N
, , N
anemia NN N
is VBZ N
independently RB N
associated VBN N
with IN N
an DT N
excess JJ N
hazard NN N
for IN N
all-cause JJ N
mortality NN N
and CC N
all-cause JJ N
hospitalization NN N
. . N

Anemia NNP N
is VBZ N
also RB N
associated VBN N
with IN N
combinations NNS N
of IN N
CV NNP N
death NN N
and CC N
CV/HF NNP N
hospitalizations NNS N
as IN N
composite JJ N
endpoints NNS N
. . N

-DOCSTART- -X- O O

Myocardial JJ N
extracellular JJ N
volume NN N
by IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
in IN N
patients NNS p
treated VBN p
with IN p
anthracycline-based JJ p
chemotherapy NN p
. . p

We PRP N
aimed VBD N
to TO N
determine VB N
whether IN N
the DT N
myocardial JJ o
extracellular JJ o
volume NN o
( ( o
ECV NNP o
) ) o
, , N
measured VBN N
using VBG N
T1 NNP o
measurements NNS o
obtained VBD N
during IN N
cardiac JJ N
magnetic JJ N
resonance NN N
imaging NN N
were VBD N
increased VBN N
in IN N
patients NNS i
treated VBN i
with IN i
anthracyclines NNS i
. . i

We PRP N
performed VBD N
cardiac JJ i
magnetic JJ i
resonance NN i
imaging NN i
and CC i
echocardiography NN i
and CC i
measured VBD i
the DT i
ECV NNP o
in IN N
42 CD p
patients NNS p
treated VBN p
with IN p
anthracyclines NNS i
. . i

The DT N
data NN N
from IN N
the DT N
cardiac JJ N
magnetic JJ N
resonance NN N
study NN N
were VBD N
compared VBN N
to TO N
those DT N
from IN N
healthy JJ p
volunteers NNS p
. . p

The DT N
anthracycline-treated JJ N
cohort NN N
consisted VBD N
of IN N
21 CD p
men NNS p
and CC p
21 CD p
women NNS p
with IN p
a DT p
mean JJ p
age NN p
of IN p
55 CD p
? . p
17 CD p
years NNS p
, , p
who WP p
presented VBD p
a DT p
median NN p
of IN p
84 CD p
months NNS p
after IN p
chemotherapy NN p
with IN p
a DT p
cumulative JJ p
anthracycline NN p
exposure NN p
of IN p
282 CD p
? . p
65 CD p
mg/m NN p
( ( p
2 CD p
) ) p
and CC p
a DT p
mean NN o
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
of IN o
52 CD p
? . p
12 CD p
% NN p
. . p

The DT p
ECV NNP o
was VBD o
elevated VBN N
in IN N
the DT N
anthracycline-treated JJ N
patients NNS N
compared VBN N
to TO N
the DT N
age- JJ N
and CC N
gender-matched JJ N
controls NNS N
( ( N
0.36 CD N
? . N
0.03 CD N
vs NN N
0.28 CD N
? . N
0.02 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

A NNP N
positive JJ N
association NN N
was VBD N
found VBN N
between IN o
the DT o
ECV NNP o
and CC N
left VBD N
atrial JJ N
volume NN o
( ( o
ECV NNP o
vs RB o
indexed VBD o
left JJ o
atrial JJ o
volume NN o
, , o
r NN o
= VBD o
0.65 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
negative JJ N
association NN N
was VBD N
found VBN N
between IN N
the DT N
ECV NNP N
and CC o
diastolic JJ o
function NN o
( ( o
E NNP o
' POS o
lateral NN N
, , N
r NN N
= NNP N
-0.64 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
myocardial JJ o
ECV NNP o
is VBZ N
elevated VBN p
in IN p
patients NNS p
with IN p
previous JJ p
anthracycline NN p
treatment NN p
and CC p
is VBZ N
associated VBN N
with IN N
the DT N
diastolic JJ N
function NN N
and CC N
increased VBD N
atrial JJ N
volumes NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
food NN i
on IN N
the DT N
antiviral JJ o
activity NN o
of IN N
didanosine JJ i
enteric-coated JJ i
capsules NNS i
: : i
a DT N
pilot NN N
comparative NN N
study NN N
. . N

OBJECTIVES NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
food NN i
on IN N
the DT N
antiviral JJ N
activity NN N
of IN N
enteric-coated JJ i
( ( i
EC NNP i
) ) i
capsules NNS i
of IN i
didanosine NN i
( ( i
ddI NN i
) ) i
. . i

METHODS NNP N
We PRP N
conducted VBD N
a DT N
pilot NN N
, , N
randomized VBN N
, , N
open-label JJ N
study NN N
of IN N
28-day JJ N
ddI-EC JJ i
capsules NNS i
monotherapy-administered VBN i
in IN N
a DT N
fasted JJ i
state NN i
( ( p
group NN p
1 CD p
, , p
n=11 NN p
) ) p
or CC p
with IN i
food NN i
( ( p
group NN p
2 CD p
, , p
n=10 RB p
) ) p
to TO p
treatment-na?ve JJ p
chronically RB p
HIV-1-infected JJ p
individuals NNS p
. . p

To TO N
assess VB N
the DT o
antiviral JJ o
efficacy NN o
, , o
HIV-1 NNP o
RNA NNP o
was VBD N
determined VBN N
at IN N
baseline NN N
, , N
day NN N
3 CD N
, , N
day NN N
7 CD N
and CC N
weekly JJ N
thereafter NN N
. . N

The DT N
area NN N
under IN N
the DT N
HIV-1 NNP N
RNA NNP N
curve NN N
minus NN N
baseline NN N
weighted VBN N
by IN N
time NN o
( ( o
AUCMB/day NNP o
) ) o
was VBD N
calculated VBN N
. . N

RESULTS JJ o
Mean JJ o
baseline JJ o
HIV-1 NNP o
RNA NNP o
was VBD N
4.2 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
1 CD N
and CC N
3.8 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
in IN N
group NN N
2 CD N
. . N

After IN N
28 CD N
days NNS N
, , N
the DT o
mean JJ o
HIV-1 NNP o
RNA NNP o
reduction NN o
was VBD N
0.99 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
[ $ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.45-1.53 CD N
] NN N
for IN N
group NN N
1 CD N
and CC N
0.89 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.38-1.40 NN N
) ) N
for IN N
group NN N
2 CD N
. . N

AUCMB/day JJ o
values NNS o
were VBD N
0.775 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.33-1.22 NN N
) ) N
and CC N
0.774 CD N
log NN N
( ( N
10 CD N
) ) N
copies/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
0.48-1.07 NN N
) ) N
, , N
respectively RB N
, , N
showing VBG N
no DT N
difference NN N
in IN N
the DT N
rate NN N
of IN N
decrease NN N
of IN o
HIV-1 NNP o
RNA NNP o
( ( N
P=0.995 NNP N
) ) N
. . N

Mean NNP o
ddI JJ o
plasma NN o
levels NNS o
at IN N
day NN N
28 CD N
were VBD N
0.0234 CD N
mg/L NN N
for IN N
group NN N
1 CD N
and CC N
0.0227 CD N
mg/L NN N
for IN N
group NN N
2 CD N
( ( N
P=0.96 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
pilot NN N
study NN N
, , N
the DT N
administration NN N
of IN i
food NN i
did VBD N
not RB N
have VB N
any DT N
significant JJ N
effect NN N
on IN N
the DT o
antiviral JJ o
activity NN o
of IN o
ddI-EC JJ o
capsules NNS o
. . o

-DOCSTART- -X- O O

Contrast NNP N
, , N
motion NN N
, , N
perceptual JJ N
integration NN N
, , N
and CC N
neurocognition NN N
in IN N
schizophrenia NN N
: : N
the DT N
role NN N
of IN N
fragile-X JJ N
related JJ N
mechanisms NN N
. . N

Recent JJ N
studies NNS N
demonstrated VBD N
a DT N
reduced JJ N
expression NN N
of IN N
Fragile NNP N
X NNP N
Mental NNP N
Retardation NNP N
Protein NNP N
( ( N
FMRP NNP N
) ) N
, , N
an DT N
RNA NNP N
binding NN N
protein NN N
and CC N
translation NN N
regulator NN N
, , N
in IN N
the DT N
brain NN N
and CC N
peripheral JJ N
lymphocytes NNS N
of IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

Low JJ N
FMRP NNP N
levels NNS N
may MD N
be VB N
related VBN N
to TO N
impaired JJ N
neurodevelopmental JJ N
processes NNS N
and CC N
synaptic JJ N
plasticity NN N
. . N

Here RB N
, , N
we PRP N
studied VBD N
the DT N
relationship NN N
between IN N
peripheral JJ N
FMRP NNP N
level NN N
, , N
visual JJ o
perception NN o
( ( o
contrast JJ o
sensitivity NN o
, , o
perceptual JJ o
integration NN o
, , o
motion/form VB o
perception NN o
) ) o
, , o
and CC o
neuropsychological JJ o
functions NNS o
in IN N
schizophrenia NN N
as IN N
measured VBN i
with IN i
the DT i
Repeatable JJ i
Battery NN i
for IN i
the DT i
Assessment NNP i
of IN i
Neuropsychological NNP i
Status NNP i
( ( i
RBANS NNP i
) ) i
. . N

Results NNP N
revealed VBD N
that IN N
patients NNS p
with IN p
schizophrenia JJ p
displayed NNS p
lower JJR p
FMRP NNP o
levels NNS o
in IN p
peripheral JJ p
lymphocytes NNS p
as IN N
compared VBN N
to TO N
control VB p
individuals NNS p
. . p

We PRP N
found VBD N
significant JJ N
correlations NNS N
between IN N
FMRP NNP o
levels NNS o
and CC N
contrast NN N
sensitivity NN N
at IN N
low JJ N
spatial NN N
and CC N
high JJ N
temporal JJ N
frequencies NNS N
, , N
perceptual JJ N
integration NN N
, , N
and CC N
motion NN N
perception NN N
. . N

The DT N
relationship NN N
between IN N
FMRP NNP o
level NN o
and CC o
neuropsychological JJ o
functions NNS o
was VBD N
less RBR N
pronounced JJ N
than IN N
that DT N
seen VBN N
in IN N
the DT N
case NN N
of IN N
visual JJ N
perception NN N
, , N
with IN N
the DT N
greatest JJS N
effect NN N
for IN N
RBANS NNP N
attention NN N
. . N

FMRP NNP o
level NN o
was VBD N
not RB N
related VBN N
to TO N
contrast VB N
sensitivity NN N
at IN N
high JJ N
spatial JJ N
and CC N
low JJ N
temporal JJ N
frequencies NNS N
and CC N
form JJ N
perception NN N
. . N

This DT N
pattern NN N
of IN N
data NNS N
is VBZ N
reminiscent JJ N
to TO N
that DT N
observed VBN N
in IN N
patients NNS p
with IN N
Fragile NNP N
X NNP N
Syndrome NNP N
( ( N
FXS NNP N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
FMRP NNP N
may MD N
be VB N
implicated VBN N
in IN N
the DT N
pathogenesis NN N
of IN N
schizophrenia NN N
, , N
possibly RB N
via IN N
the DT N
regulation NN N
of IN N
neurodevelopment NN o
, , o
plasticity NN o
, , o
GABA-ergic NNP o
, , o
and CC o
glutamatergic JJ o
neurotransmission NN o
. . o

-DOCSTART- -X- O O

Enhanced NNP o
bioavailability NN o
of IN o
zeaxanthin NN o
in IN N
a DT N
milk-based JJ N
formulation NN N
of IN N
wolfberry NN N
( ( N
Gou NNP N
Qi NNP N
Zi NNP N
; : N
Fructus NNP N
barbarum IN N
L. NNP N
) ) N
. . N

The DT N
carotenoid NN N
zeaxanthin NN i
is VBZ N
concentrated VBN N
within IN N
the DT N
macula NN N
. . N

Increased VBD N
macular JJ N
zeaxanthin NN i
is VBZ N
suggested VBN N
to TO N
lower VB N
the DT N
risk NN o
of IN o
age-related JJ o
macular JJ o
degeneration NN o
. . o

The DT N
small JJ N
red JJ N
berry NN N
, , N
wolfberry NN N
( ( N
Fructus NNP N
barbarum VBZ N
L. NNP N
; : N
Gou NNP N
Qi NNP N
Zi NNP N
and CC N
Kei NNP N
Tze NNP N
) ) N
, , N
is VBZ N
one CD N
of IN N
the DT N
richest JJS N
natural JJ N
sources NNS N
of IN N
zeaxanthin NN i
. . i

However RB N
, , N
carotenoid JJ o
bioavailability NN o
is VBZ N
low JJ N
, , N
and CC N
food-based JJ N
products NNS N
with IN N
enhanced JJ N
bioavailability NN o
are VBP N
of IN N
interest NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
zeaxanthin JJ o
bioavailability NN o
from IN N
three CD N
wolfberry NN N
formulations NNS N
. . N

Berries NNS N
were VBD N
homogenised VBN N
in IN N
hot JJ N
( ( N
80 CD N
degrees NNS N
C NNP N
) ) N
water NN N
, , N
warm NN N
( ( N
40 CD N
degrees NNS N
C NNP N
) ) N
skimmed VBD N
milk NN N
and CC N
hot JJ N
( ( N
80 CD N
degrees NNS N
C NNP N
) ) N
skimmed VBD N
milk NN N
, , N
with IN N
freeze JJ N
drying NN N
of IN N
each DT N
preparation NN N
into IN N
a DT N
powdered JJ N
form NN N
. . N

A DT N
zeaxanthin-standardised JJ i
dose NN i
( ( N
15 CD N
mg NN N
) ) N
of IN N
each DT N
was VBD N
consumed VBN N
, , N
in IN N
randomised JJ N
order NN N
, , N
together RB N
with IN N
a DT N
standardised VBN N
breakfast NN N
by IN N
twelve NN p
healthy JJ p
, , p
consenting VBG p
subjects NNS p
in IN N
a DT N
cross-over JJ N
trial NN N
, , N
with IN N
a DT N
3-5-week JJ N
washout NN N
period NN N
between IN N
treatments NNS N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
via IN N
a DT N
venous JJ N
cannula NN N
immediately RB N
before IN N
( ( N
fasting VBG N
) ) N
and CC N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
7 CD N
, , N
8 CD N
and CC N
10 CD N
h JJ N
post-ingestion NN N
. . N

Zeaxanthin NNP o
concentration NN o
in IN N
the DT N
triacylglycerol-rich JJ N
lipoprotein JJ N
fraction NN N
of IN N
plasma NN N
was VBD N
measured VBN N
by IN N
HPLC NNP o
. . o

Results NNP N
showed VBD N
that IN N
triacylglycerol-rich JJ o
lipoprotein NN o
zeaxanthin NN o
peaked VBD o
at IN N
6 CD N
h JJ N
post-ingestion NN N
for IN N
all DT N
formulations NNS N
. . N

Zeaxanthin NNP o
bioavailability NN o
from IN N
the DT N
hot JJ N
milk NN N
formulation NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
than IN N
from IN N
the DT N
others NNS N
. . N

Mean JJ o
area NN o
under IN o
the DT o
curve NN o
( ( N
n JJ N
12 CD N
) ) N
results NNS N
were VBD N
9.73 CD N
( ( N
sem VB N
2.45 CD N
) ) N
, , N
3.24 CD N
( ( N
sem VB N
0.72 CD N
) ) N
and CC N
3.14 CD N
( ( N
sem VB N
1.09 CD N
) ) N
nmol NN N
x NNP N
h/l NN N
for IN N
the DT N
hot JJ N
milk NN N
, , N
warm JJ N
milk NN N
and CC N
hot JJ N
water NN N
formulations NNS N
, , N
respectively RB N
. . N

Results NNS N
showed VBD N
clearly RB N
that DT N
homogenisation NN N
of IN N
wolfberry NN N
in IN N
hot JJ N
skimmed VBN N
milk NN N
results NNS N
in IN N
a DT N
formulation NN N
that WDT N
has VBZ N
a DT N
3-fold JJ o
enhanced JJ o
bioavailability NN o
of IN o
zeaxanthin NN o
compared VBN N
with IN N
both DT N
the DT N
'classical JJ N
' POS N
hot JJ N
water NN N
and CC N
warm NN N
skimmed VBD N
milk JJ N
treatment NN N
of IN N
the DT N
berries NNS N
. . N

-DOCSTART- -X- O O

Reduced VBN N
albuminuria NNS N
with IN N
sarpogrelate NN i
is VBZ N
accompanied VBN N
by IN N
a DT N
decrease NN N
in IN N
monocyte JJ N
chemoattractant JJ N
protein-1 NN N
levels NNS N
in IN N
type NN p
2 CD p
diabetes NNS p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Sarpogrelate NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
albuminuria NNS N
in IN N
diabetic JJ N
nephropathy NN N
. . N

For IN N
examination NN N
of IN N
whether IN N
this DT N
is VBZ N
based VBN N
on IN N
the DT N
same JJ N
mechanisms NN N
as IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
or CC N
thiazolidinedione NN i
, , N
effects NNS N
of IN N
sarpogrelate NN i
on IN N
atherosclerotic JJ N
inflammatory NN N
molecules NNS N
and CC N
their PRP$ N
relations NNS N
to TO N
albuminuria NNS N
in IN N
patients NNS p
who WP p
had VBD p
diabetes NNS p
and CC p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN i
II NNP i
receptor NN i
blockers NNS i
and CC p
with IN p
or CC p
without IN p
thiazolidinedione NN i
were VBD N
examined VBN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Forty NNP p
patients NNS p
who WP p
had VBD p
diabetes NNS p
with IN p
nephropathy JJ p
and CC p
arteriosclerosis NN p
obliterans NNS p
and CC p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN i
II NNP i
receptor NN i
blocker NN i
( ( p
n JJ p
= NNP p
40 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
sarpogrelate VB i
( ( N
300 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
or CC N
aspirin JJ i
group NN i
( ( N
100 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
. . N

Plasma NNP o
monocyte JJ o
chemoattractant JJ o
protein-1 NN o
and CC o
urinary JJ o
albumin-to-creatinine JJ o
ratio NN o
and CC o
monocyte NN o
chemoattractant JJ o
protein-1 NN o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
16 CD N
wk NN N
after IN N
administration NN N
. . N

RESULTS NNP N
Only RB N
the DT N
sarpogrelate NN i
group NN N
showed VBD N
increases NNS N
in IN N
plasma NN o
adiponectin NN o
and CC N
decreases NNS N
in IN N
both DT N
plasma NN o
and CC o
urinary JJ o
monocyte NN o
chemoattractant JJ o
protein-1 JJ o
and CC o
albumin-to-creatinine JJ o
ratio NN o
levels NNS o
. . o

Moreover RB N
, , N
percentage NN o
change NN o
of IN o
monocyte NN o
chemoattractant JJ o
protein-1 JJ o
level NN o
correlated VBD N
positively RB N
to TO N
that DT N
of IN N
albumin-to-creatinine JJ N
ratio NN N
. . N

Even RB N
when WRB N
the DT N
sarpogrelate NN i
group NN N
was VBD N
further RB N
divided VBN N
into IN N
two CD N
groups NNS N
with IN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
without IN N
thiazolidinedione NN i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
changes NNS N
in IN N
monocyte NN o
chemoattractant JJ o
protein-1 JJ o
or CC o
albumin-to-creatinine JJ o
ratio NN o
did VBD N
not RB N
differ VB N
. . N

CONCLUSIONS NNP N
Sarpogrelate NNP i
can MD N
reduce VB N
albuminuria NNS N
and CC N
plasma NN N
and CC N
urinary JJ N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
levels NNS N
while IN N
increasing VBG N
plasma NN N
adiponectin NN N
in IN N
diabetic JJ N
nephropathy NN N
. . N

These DT N
effects NNS N
seem VBP N
to TO N
be VB N
mediated VBN N
via IN N
mechanisms NNS N
that WDT N
are VBP N
different JJ N
from IN N
those DT N
of IN N
angiotensin JJ i
II NNP i
receptor NN i
blocker NN i
or CC N
thiazolidinedione NN i
. . i

-DOCSTART- -X- O O

B-type JJ i
natriuretic JJ i
peptide NN i
for IN N
acute JJ N
dyspnea NN N
in IN N
patients NNS p
with IN p
kidney JJ p
disease NN p
: : p
insights NNS N
from IN N
a DT N
randomized JJ N
comparison NN N
. . N

BACKGROUND NNP N
B-type NNP o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
levels NNS o
are VBP N
reliably RB N
elevated VBN N
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
and CC N
therefore RB N
helpful JJ N
in IN N
its PRP$ N
diagnosis NN N
. . N

However RB N
, , N
kidney FW N
disease NN N
results NNS N
in IN N
elevated JJ N
BNP NNP N
levels NNS N
independently RB N
of IN N
CHF NNP N
. . N

Accordingly RB N
, , N
the DT N
impact NN N
of IN N
kidney NN N
disease NN N
on IN N
the DT N
benefit NN N
of IN N
BNP NNP i
testing VBG N
needs NNS N
to TO N
be VB N
scrutinized VBN N
. . N

METHODS NNP N
This DT N
study NN N
evaluated VBD N
patients NNS p
with IN p
and CC p
without IN p
kidney NN p
disease NN p
[ NNP p
glomerular JJ p
filtration NN p
rate NN p
( ( p
GFR NNP p
) ) p
less JJR p
than IN p
60 CD p
mL/min/1.73 JJ p
m NN p
( ( p
2 CD p
) ) p
) ) p
presenting VBG p
with IN p
acute JJ p
dyspnea NN p
. . p

A DT N
total NN N
of IN N
452 CD p
consecutive JJ p
patients NNS p
( ( p
240 CD p
with IN p
kidney NN p
disease NN p
and CC p
212 CD p
without IN p
kidney NN p
disease NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
diagnostic JJ i
strategy NN i
with IN i
( ( i
BNP NNP i
group NN i
) ) i
or CC i
without IN i
( ( i
control NN i
group NN i
) ) i
the DT i
use NN i
of IN i
BNP NNP i
levels NNS i
provided VBN i
by IN i
a DT i
rapid JJ i
bedside NN i
assay NN i
. . i

RESULTS JJ N
Patients NNS p
with IN p
kidney JJ p
disease NN p
were VBD p
older JJR p
, , p
more RBR p
often RB p
had VBD p
CHF NNP o
as IN o
the DT o
cause NN o
of IN o
acute JJ o
dyspnea NN o
, , p
and CC p
more RBR p
often RB p
died JJ p
in-hospital JJ p
or CC p
within IN p
30 CD p
days NNS p
as RB p
compared VBN p
to TO p
patients NNS p
without IN p
kidney NN p
disease NN p
. . N

In IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
BNP NNP i
testing VBG i
significantly RB N
reduced VBN N
median JJ o
time NN o
to TO o
discharge VB o
( ( N
from IN N
9.5 CD N
days NNS N
to TO N
2.5 CD N
days NNS N
) ) N
( ( N
P= NNP N
0.003 CD N
) ) N
and CC N
total JJ o
cost NN o
of IN o
treatment NN o
( ( N
from IN N
7184 CD N
dollars NNS N
to TO N
4151 CD N
dollars NNS N
) ) N
( ( N
P= NNP N
0.004 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
in IN N
patients NNS N
with IN N
kidney NN N
disease NN N
, , N
time NN N
to TO N
discharge VB N
and CC N
total JJ N
cost NN N
of IN N
treatment NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
When WRB N
applying VBG N
BNP NNP i
cut-off NN N
values NNS N
without IN N
adjustment NN N
for IN N
the DT N
presence NN N
of IN N
kidney NN N
disease NN N
, , N
the DT N
use NN N
of IN N
BNP NNP o
levels NNS o
does VBZ N
significantly RB N
improve VB N
the DT N
management NN N
of IN N
patients NNS N
without IN N
kidney NN N
disease NN N
, , N
but CC N
not RB N
of IN N
those DT N
with IN N
kidney JJ N
disease NN N
. . N

-DOCSTART- -X- O O

Perispinal JJ N
analgesia NN N
for IN N
labour NN p
followed VBN N
by IN N
patient-controlled JJ N
infusion NN N
with IN N
bupivacaine NN i
and CC N
sufentanil NN i
: : i
combined VBN i
spinal-epidural JJ i
vs. FW i
epidural JJ i
analgesia NN N
alone RB N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Combined NNP N
spinal-epidural JJ N
is VBZ N
an DT N
alternative JJ N
technique NN N
to TO N
epidural JJ N
analgesia NN N
for IN N
labour NN N
, , N
but CC N
its PRP$ N
benefits NNS N
are VBP N
not RB N
clearly RB N
identified VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
, , N
blinded VBD N
, , N
randomized VBD N
study NN N
was VBD N
undertaken JJ N
involving VBG N
113 CD p
women NNS p
attending VBG p
a DT p
university NN p
hospital NN p
obstetric JJ p
department NN p
. . p

Analgesia NNP N
was VBD N
initiated VBN i
with IN i
intrathecal JJ i
bupivacaine NN i
0.25 CD i
% NN i
1 CD i
mL NN i
+ NNP i
sufentanil VBD i
5 CD i
microg NN i
in IN i
the DT i
combined JJ i
spinal-epidural JJ i
group NN i
( ( i
n JJ i
= NNP i
54 CD i
) ) i
, , i
and CC i
with IN i
bupivacaine JJ i
0.125 CD i
% NN i
+ JJ i
epinephrine NN i
2.5 CD i
microg NN i
mL NN i
( ( i
-1 NNP i
) ) i
+ VBD i
sufentanil $ i
7.5 CD i
microg NN i
in IN i
the DT i
epidural JJ i
group NN i
( ( i
n JJ i
= NNP i
59 CD i
) ) i
. . i

In IN i
both DT i
cases NNS i
this DT i
was VBD i
followed VBN i
by IN i
patient-controlled JJ i
epidural JJ i
analgesia NN i
with IN i
bupivacaine JJ i
0.125 CD i
% NN i
( ( i
+ JJ i
sufentanil NN i
0.25 CD i
microg NN i
mL NN i
( ( i
-1 NNP i
) ) i
) ) i
. . i

Duration NN N
of IN N
labour NN N
, , N
quality NN o
of IN o
analgesia NN o
and CC o
side-effects NNS o
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
the DT N
onset NN o
of IN o
analgesia NN o
was VBD o
faster RBR o
( ( N
5 CD N
vs. FW N
15 CD N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
the DT N
consumption NN o
of IN o
bupivacaine NN o
was VBD o
lower JJR o
( ( N
7.5 CD N
vs. FW N
11.3 CD N
mg NN N
h NN N
( ( N
-1 NNP N
) ) N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
and CC N
there EX N
was VBD N
less JJR o
unilateral JJ o
analgesia NN o
( ( N
14.8 CD N
% NN N
vs. FW N
40.7 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
than IN N
in IN N
the DT N
epidural JJ N
group NN N
. . N

The DT p
characteristics NNS o
of IN o
labour NN o
were VBD p
similar JJ p
in IN p
both DT p
groups NNS p
. . p

However RB N
, , N
in IN N
the DT N
combined JJ N
spinal-epidural JJ N
group NN N
, , N
there EX N
was VBD N
a DT N
higher JJR o
incidence NN o
of IN o
posterior JJ o
presentation NN o
( ( N
25.9 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
pruritus NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
hypotension NN o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
somnolence NN o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
nausea NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
and CC N
one CD N
case NN N
of IN N
meningitis NN o
. . o

CONCLUSIONS VB N
The DT N
combined JJ N
spinal-epidural JJ N
technique NN N
provided VBD N
more RBR N
effective JJ N
analgesia NN N
during IN p
labour JJR p
than IN N
epidural JJ N
analgesia NN N
alone RB N
but CC N
offered VBN N
no DT N
other JJ N
advantage NN N
. . N

It PRP N
induced VBD N
more RBR N
adverse JJ N
effects NNS N
and CC N
this DT N
should MD N
be VB N
considered VBN N
before IN N
routinely RB N
using VBG N
the DT N
combined JJ N
spinal-epidural JJ N
technique NN N
. . N

-DOCSTART- -X- O O

Laser NNP N
treatment NN N
of IN N
childhood NN N
haemangioma NN N
: : N
progress NN N
or CC N
not RB N
? . N
-DOCSTART- -X- O O

Activator NNP i
protein-1 NN i
( ( i
AP-1 NNP i
) ) i
signalling VBG N
in IN N
human JJ p
atherosclerosis NN p
: : p
results NNS N
of IN N
a DT N
systematic JJ N
evaluation NN N
and CC N
intervention NN N
study NN N
. . N

Animal NNP N
studies NNS N
implicate VBP N
the DT N
AP-1 NNP i
( ( i
activator IN i
protein-1 NN i
) ) i
pro-inflammatory NN N
pathway NN N
as IN N
a DT N
promising NN N
target NN N
in IN N
the DT N
treatment NN N
of IN N
atherosclerotic JJ p
disease NN p
. . p

It PRP N
is VBZ N
, , N
however RB N
, , N
unclear JJ N
whether IN N
these DT N
observations NNS N
apply VBP N
to TO N
human JJ p
atherosclerosis NN p
. . p

Therefore IN N
we PRP N
evaluated VBD N
the DT N
profile NN N
of IN N
AP-1 NNP i
activation NN i
through IN N
histological JJ N
analysis NN N
and CC N
tested VBD N
the DT N
potential JJ N
benefit NN N
of IN N
AP-1 NNP i
inhibition NN i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

AP-1 JJ i
activation NN i
was VBD N
quantified VBN N
by IN N
phospho-c-Jun JJ N
nuclear JJ N
translocation NN N
( ( N
immunohistochemistry NN N
) ) N
on IN N
a DT N
biobank NN p
of IN p
aortic JJ p
wall NN p
samples NNS p
from IN p
organ JJ p
donors NNS p
. . p

The DT N
effect NN N
of IN N
AP-1 NNP o
inhibition NN o
on IN N
vascular JJ N
parameters NNS N
was VBD N
tested VBN N
through IN N
a DT N
double JJ N
blind JJ N
placebo-controlled JJ N
cross-over NN N
study NN N
of IN N
28 CD i
days NNS i
doxycycline NN i
or CC i
placebo NN i
in IN p
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
artery NN p
disease NN p
. . p

Vascular JJ o
function NN o
was VBD N
assessed VBN N
by IN N
brachial JJ N
dilation NN N
as RB N
well RB N
as IN N
by IN N
plasma NN N
samples NNS N
analysed VBN N
for IN N
hs-CRP NN N
( ( N
high-sensitivity JJ N
C-reactive NNP N
protein NN N
) ) N
, , N
IL-6 NNP N
( ( N
interleukin-6 NN N
) ) N
, , N
IL-8 NNP N
, , N
ICAM-1 NNP N
( ( N
intercellular JJ N
adhesion NN N
molecule-1 NN N
) ) N
, , N
vWF FW N
( ( N
von FW N
Willebrand NNP N
factor NN N
) ) N
, , N
MCP-1 NNP N
( ( N
monocyte JJ N
chemoattractant NN N
protein-1 NN N
) ) N
, , N
PAI-1 NNP N
( ( N
plasminogen JJ N
activator NN N
inhibitor-1 NN N
) ) N
and CC N
fibrinogen NN N
. . N

Histological JJ N
evaluation NN N
of IN N
human JJ o
atherosclerosis NN o
showed VBD N
minimal JJ o
AP-1 NNP o
activation NN o
in IN N
non-diseased JJ N
arterial JJ N
wall NN N
( ( N
i.e JJ N
. . N

vessel NN N
wall NN N
without IN N
any DT N
signs NNS N
of IN N
atherosclerotic JJ N
disease NN N
) ) N
. . N

A DT N
gradual JJ N
increase NN N
of IN o
AP-1 NNP o
activation NN o
was VBD N
found VBN N
in IN N
non-progressive JJ N
and CC N
progressive JJ N
phases NNS N
of IN N
atherosclerosis NN N
respectively RB N
( ( N
P NNP N
< NNP N
0.044 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
progressive JJ N
and CC o
vulnerable JJ o
lesions NNS N
. . N

The DT o
expression NN o
of IN o
phospho-c-Jun JJ o
diminished VBN N
as IN N
the DT N
lesion NN N
stabilized VBN N
( ( N
P NNP N
< NNP N
0.016 CD N
) ) N
and CC N
does VBZ N
not RB N
significantly RB N
differ VBP N
from IN N
the DT N
normal JJ N
aortic JJ N
wall NN N
( ( N
P NNP N
< NNP N
0.33 CD N
) ) N
. . N

Evaluation NN N
of IN N
the DT i
doxycycline NN i
intervention NN i
only RB N
revealed VBD N
a DT N
borderline-significant JJ N
reduction NN N
of IN o
circulating VBG o
hs-CRP JJ o
levels NNS o
( ( N
-0.51 NNP N
?g/ml NNP N
, , N
P=0.05 NNP N
) ) N
and CC N
did VBD N
not RB N
affect VB N
any DT N
of IN N
the DT N
other JJ o
markers NNS o
of IN o
systemic JJ o
inflammation NN o
and CC o
vascular JJ o
function NN o
. . o

Our PRP$ N
studies NNS N
do VBP N
not RB N
characterize VB i
AP-1 NNP i
as IN i
a DT N
therapeutic JJ N
target NN N
for IN p
progressive JJ p
human JJ p
atherosclerotic JJ p
disease NN p
. . p

-DOCSTART- -X- O O

The DT N
additive JJ N
analgesic JJ N
efficacy NN N
of IN N
acetaminophen NN i
, , N
1000 CD N
mg NN N
, , N
and CC N
codeine NN i
, , N
60 CD N
mg NN N
, , N
in IN N
dental JJ p
pain NN p
. . p

In IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
single-dose JJ N
trial NN N
the DT N
analgesic JJ N
contribution NN N
of IN N
acetaminophen NN i
, , i
1000 CD i
mg NN i
, , i
and CC i
codeine NN i
, , i
60 CD i
mg NN i
, , N
was VBD N
determined VBN N
. . N

The DT N
study NN N
was VBD N
a DT N
2 CD N
X NN N
2 CD N
factorial JJ N
experiment NN N
in IN N
which WDT N
120 CD p
patients NNS p
suffering VBG p
from IN p
pain NN p
as IN p
a DT p
result NN p
of IN p
oral JJ p
surgery NN p
rated VBD N
their PRP$ N
pain NN o
intensity NN o
and CC o
pain NN o
relief NN o
for IN N
up IN N
to TO N
5 CD N
hours NNS N
after IN N
a DT N
single JJ N
dose NN N
of IN N
one CD N
of IN N
: : N
1000 CD N
mg NN N
acetaminophen NN i
, , N
60 CD N
mg NN N
codeine NN i
, , N
1000 CD N
mg NN N
acetaminophen NN i
plus CC i
60 CD i
mg NN i
codeine NN i
, , N
or CC N
placebo NN i
. . i

The DT N
factorial JJ N
analysis NN N
showed VBD N
that IN N
both DT N
1000 CD N
mg NN N
acetaminophen NN i
and CC N
60 CD N
mg NN N
codeine NN i
made VBD N
a DT N
statistically RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
contribution NN N
to TO N
the DT N
analgesic JJ o
effectiveness NN o
of IN o
the DT o
combination NN o
on IN o
all DT o
measures NNS o
of IN o
efficacy NN o
( ( o
sum NN o
of IN o
pain NN o
intensity NN o
differences NNS o
, , o
largest JJS o
pain NN o
intensity NN o
difference NN o
, , o
total JJ o
pain NN o
relief NN o
, , o
largest JJS o
pain NN o
relief NN o
, , o
and CC o
time NN o
to TO o
remedication NN o
) ) o
. . o

The DT N
incidence NN o
of IN o
adverse JJ o
effects NNS o
did VBD N
not RB N
appear VB N
to TO N
differ VB N
among IN N
the DT N
treatments NNS N
, , N
including VBG N
placebo NN i
. . i

-DOCSTART- -X- O O

MSLT NNP i
in IN N
primary JJ N
insomnia NN o
: : o
stability NN N
and CC N
relation NN N
to TO N
nocturnal JJ o
sleep NN o
. . o

STUDY NNP N
OBJECTIVES NNP N
To TO N
assess VB N
the DT N
stability NN N
of IN N
the DT N
multiple JJ i
sleep JJ i
latency NN i
test NN i
( ( i
MSLT NNP i
) ) i
in IN N
primary JJ o
insomnia NN o
and CC N
its PRP$ N
relation NN N
to TO N
total JJ o
sleep JJ o
time NN o
. . o

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo NN N
controlled VBD N
, , N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient NN N
with IN N
sleep JJ N
laboratory NN N
assessments NNS N
in IN N
months NNS N
1 CD N
and CC N
8 CD N
of IN N
treatment NN N
. . N

PARTICIPANTS VB N
Ninety-five JJ p
primary JJ p
insomniacs NN p
, , p
32-64 CD p
years NNS p
old JJ p
and CC p
55 CD p
age- JJ p
and CC p
sex-matched JJ p
general JJ p
population-based JJ p
, , p
representative JJ p
controls NNS p
. . p

INTERVENTIONS NNP N
After IN N
a DT N
screening JJ N
nocturnal JJ i
polysomnograms NNS i
( ( i
NPSG NNP i
) ) i
and CC N
MSLT NNP i
the DT N
following JJ N
day NN N
, , N
participants NNS p
with IN p
primary JJ p
insomnia NNS p
were VBD N
randomized VBN N
to TO N
take VB N
zolpidem NN i
10 CD N
mg NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
45 CD N
) ) N
nightly RB N
for IN N
12 CD N
months NNS N
. . N

During IN N
months NNS N
1 CD N
and CC N
8 CD N
, , N
while IN N
taking VBG N
their PRP$ N
prescribed JJ N
treatments NNS N
, , N
NPSGs NNP N
and CC N
MSLTs NNP i
the DT N
following JJ N
day NN N
were VBD N
conducted VBN N
. . N

A DT N
population-based JJ N
sample NN N
served VBD N
as IN N
controls NNS N
and CC N
received VBD N
a DT N
single JJ N
NPSG NNP N
followed VBN N
by IN N
MSLT NNP i
. . i

RESULTS NNP N
Mean NNP o
daily JJ o
sleep NN o
latency NN o
on IN o
the DT o
screening VBG o
MSLT NNP o
of IN o
insomniacs NN o
was VBD N
normally RB N
distributed VBN N
across IN N
the DT N
full JJ N
range NN N
of IN N
MSLT NNP i
scores NNS N
and CC N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
a DT N
population-based JJ N
representative NN N
control NN N
sample NN N
( ( N
P NNP N
< NNP N
0.006 CD N
) ) N
. . N

The DT N
insomniacs NN N
with IN N
the DT N
highest JJS N
screening NN o
MSLTs NNP o
had VBD N
the DT N
shortest JJS N
screening NN o
total JJ o
sleep JJ o
times NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
MSLTs NNP i
of IN N
insomniacs NN N
during IN N
treatment NN N
in IN N
study JJ N
month NN N
1 CD N
were VBD N
correlated VBN N
( ( N
r VB N
= RB N
0.44 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
with IN N
their PRP$ N
month NN N
8 CD N
MSLT NNP N
. . N

The DT N
mean JJ o
MSLT NNP o
score NN o
of IN N
the DT N
zolpidem NNP N
group NN N
did VBD N
not RB N
differ VB N
from IN N
that DT N
of IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
the DT N
stability NN N
within IN N
treatment NN N
groups NNS N
also RB N
did VBD N
not RB N
differ VB N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
support NN N
the DT N
hypothesis NN N
that IN N
some DT N
insomniacs NN p
show VBP N
a DT N
reliable JJ N
disorder NN N
of IN N
hyperarousal NN o
with IN N
increased JJ N
wake NN o
drive NN o
both DT N
at IN N
night NN N
and CC N
during IN N
the DT N
day NN N
. . N

-DOCSTART- -X- O O

Can MD N
simvastatin VB i
improve VB N
erectile JJ o
function NN o
and CC N
health-related JJ o
quality NN o
of IN o
life NN o
in IN N
men NNS p
aged VBN p
?40 CD p
years NNS p
with IN p
erectile JJ p
dysfunction NN p
? . p
Results NNS N
of IN N
the DT N
Erectile NNP N
Dysfunction NNP N
and CC N
Statins NNP N
Trial NNP N
[ NNP N
ISRCTN66772971 NNP N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT o
effectiveness NN o
and CC o
cost-effectiveness NN o
of IN o
simvastatin NN i
on IN i
erectile JJ o
function NN o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
in IN o
men NNS p
aged VBN p
?40 CD p
years NNS p
with IN p
erectile JJ p
dysfunction NN p
( ( p
ED NNP p
) ) p
. . p

PATIENTS NNP p
AND CC N
METHODS NNP N
ED NNP N
is VBZ N
common JJ N
in IN N
men NNS N
aged VBN N
?40 CD N
years NNS N
and CC N
impacts NNS N
upon VBP N
their PRP$ N
overall JJ N
health-related JJ N
quality NN N
of IN N
life NN N
and CC N
that IN N
of IN N
their PRP$ N
partners NNS p
. . p

Men NNP p
aged VBD p
?40 CD p
years NNS p
who WP p
were VBD p
not RB p
receiving VBG p
lipid JJ p
lowering NN p
or CC p
anti-hypertensive JJ p
medication NN p
and CC p
not RB p
at IN p
high JJ p
cardiovascular JJ p
risk NN p
were VBD p
recruited VBN p
from IN p
10 CD p
general JJ p
practices NNS p
in IN p
the DT p
East NNP p
of IN p
England NNP p
. . N

In IN N
total JJ N
, , p
173 CD p
eligible JJ p
men NNS p
with IN p
untreated JJ p
ED NNP p
were VBD p
randomized VBN p
to TO p
double-blind VB p
treatment NN i
with IN i
40 CD i
mg NNS i
of IN i
simvastatin NN i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Data NNS N
were VBD N
collected VBN N
at IN N
three CD N
points NNS N
over IN N
30 CD N
weeks NNS N
. . N

The DT N
main JJ N
outcome NN N
was VBD o
erectile JJ o
function NN o
( ( o
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function-5 NNP o
score NN o
) ) o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
male JJ o
ED-specific JJ o
quality NN o
of IN o
life NN o
( ( o
MED-QoL NNP o
) ) o
, , o
quality-adjusted JJ o
life NN o
years NNS o
( ( o
QALYs NNP o
) ) o
using VBG o
the DT o
generic JJ o
Euroqol NNP o
measure NN o
( ( o
EQ-5D NNP o
) ) o
, , o
endothelial JJ o
function NN o
, , o
cardiovascular JJ o
risk NN o
, , o
cholesterol NN o
and CC o
health NN o
service NN o
costs NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
erectile JJ o
function NN o
between IN o
the DT i
simvastatin NN i
and CC i
placebo NN i
groups NNS N
( ( N
mean JJ N
change NN N
, , N
1.28 CD N
vs NN N
0.07 CD N
, , N
z NN N
= VBD N
1.1 CD N
, , N
p NN N
= NNP N
0.27 CD N
) ) N
, , N
although IN N
a DT N
significant JJ N
improvement NN o
in IN o
MED-QoL NNP o
was VBD N
observed VBN N
( ( N
5 CD N
% NN N
vs JJ N
2 CD N
% NN N
, , N
z NN N
= VBD N
2.09 CD N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Both DT o
10-year JJ o
cardiovascular NN o
risk NN o
and CC o
low-density NN o
lipoprotein NN o
were VBD o
reduced VBN o
( ( N
cardiovascular JJ N
risk NN N
, , N
z NN N
= NNP N
-3.67 NNP N
, , N
p NN N
< VBD N
0.001 CD N
; : N
low-density JJ N
lipoprotein NN N
, , N
z NN N
= NNP N
-5.46 NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
with IN N
no DT N
consistent JJ N
change NN N
in IN o
endothelial JJ o
function NN o
. . o

The DT o
frequency NN o
of IN o
sexual JJ o
encounters NNS o
is VBZ o
correlated VBN o
with IN o
improved JJ o
erectile JJ o
function NN o
. . o

The DT o
joint JJ o
distribution NN o
of IN o
costs NNS o
and CC o
QALY NNP o
benefits NNS o
indicates VBZ o
that IN N
the DT N
probability NN N
of IN N
simvastatin NN o
being VBG o
cost-effective JJ o
for IN o
willingness-to-pay JJ o
thresholds NNS N
of IN N
?20,000 NN N
and CC N
?30,000 NN N
is VBZ N
86 CD N
% NN N
and CC N
83 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Identifying VBG p
men NNS p
with IN p
ED NNP p
provides VBZ p
an DT N
opportunity NN N
to TO N
modify VB N
future JJ N
cardiovascular JJ N
risk NN N
and CC N
to TO N
improve VB N
MED-QoL NNP N
by IN N
treating VBG N
them PRP N
with IN N
40 CD N
mg NNS N
of IN i
simvastatin NN i
. . i

The DT i
joint JJ i
analysis NN N
of IN o
costs NNS o
and CC N
QALY NNP o
benefits NNS o
suggests VBZ N
that IN N
there EX N
is VBZ N
high JJ N
probability NN N
that IN N
simvastatin NN N
is VBZ N
a DT N
cost-effective JJ N
strategy NN N
in IN N
men NNS N
with IN N
ED NNP N
. . N

The DT N
findings NNS N
could MD N
influence VB N
urological JJ N
and CC N
primary JJ N
care NN N
practice NN N
by IN N
including VBG N
questions NNS N
on IN N
ED NNP N
during IN N
routine JJ N
consultations NNS N
and CC N
relevant JJ N
clinical JJ N
protocols NNS N
. . N

This DT N
provides VBZ N
an DT N
opportunity NN N
to TO N
impart VB N
lifestyle JJ N
advice NN N
. . N

-DOCSTART- -X- O O

[ RB i
Accelerated NNP i
postoperative JJ i
radiotherapy NN i
in IN N
patients NNS p
with IN p
advanced JJ p
larynx NN p
cancer NN p
] NNP p
. . N

AIM NNP N
The DT N
aim NN N
of IN N
study NN N
was VBD N
test JJ N
efficacy NN o
of IN N
accelerated JJ i
postoperative JJ i
radiotherapy NN i
-- : i
concomitant JJ i
boost NN i
in IN N
patients NNS p
with IN p
advanced JJ p
larynx NN p
cancer NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
The DT N
prospective JJ N
study NN N
included VBD N
112 CD p
patients NNS p
with IN p
advanced JJ p
larynx NN p
cancer NN p
after IN p
radical JJ i
surgical JJ i
treatment NN i
. . i

Patients NNS N
had VBD N
postoperative JJ i
radiation NN i
therapy NN i
, , i
conventional JJ i
( ( i
C NNP i
) ) i
or CC i
accelerated VBN i
( ( i
CB NNP i
) ) i
. . i

RESULTS VB N
The DT N
3-year JJ o
overall JJ o
survival NN o
in IN N
CB NNP i
was VBD N
59 CD N
% NN N
, , N
in IN N
C NNP N
-- : N
58 CD N
% NN N
( ( N
p JJ N
= NNP N
0.2 CD N
) ) N
, , N
3-year JJ o
locoregional JJ o
control NN o
in IN N
CB NNP i
-- : i
83 CD i
% NN i
, , N
in IN N
C NNP N
-- : N
75 CD N
% NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
the DT N
3-year JJ o
disease NN o
free JJ o
survival NN o
was VBD N
in IN N
CB NNP i
-- : i
72 CD i
% NN i
, , N
C NNP N
-- : N
66 CD N
% NN N
( ( N
p JJ N
= NNP N
0.1 CD N
) ) N
. . N

CONCLUSION NNP N
Concomitant NNP i
boost VBD i
postoperative JJ i
radiation NN i
therapy NN i
did VBD N
not RB N
improve VB N
overall JJ o
survival NN o
, , o
loco-regional JJ o
control NN o
, , o
disease NN o
free JJ o
survival NN o
. . o

Patients NNS p
with IN p
close JJ p
surgical JJ p
margins NNS p
, , N
longer JJR N
interval NN N
between IN N
surgery NN N
and CC N
radiation NN N
, , N
high JJ N
level NN N
of IN N
hemoglobin NN N
, , N
T4 NNP N
had VBD N
benefit VBN N
from IN N
accelerated VBN i
radiotherapy NN i
. . i

-DOCSTART- -X- O O

Safety NN o
and CC o
effectiveness NN o
of IN N
bevacizumab-containing JJ i
treatment NN N
for IN N
non-small-cell JJ N
lung NN N
cancer NN N
: : N
final JJ N
results NNS N
of IN N
the DT N
ARIES NNP N
observational JJ N
cohort NN N
study NN N
. . N

INTRODUCTION NNP N
Bevacizumab NNP i
, , N
a DT N
recombinant JJ N
humanized JJ N
monoclonal JJ N
antibody NN N
against IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
, , N
was VBD N
approved VBN N
by IN N
the DT N
US NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
for IN N
the DT N
treatment NN N
of IN N
advanced JJ N
non-small-cell JJ N
lung NN N
cancer NN N
( ( N
NSCLC NNP N
) ) N
in IN N
combination NN N
with IN N
carboplatin NN i
and CC N
paclitaxel NN i
. . i

ARIES NNP N
( ( N
Avastin NNP N
Regimens NNP N
: : N
Investigation NN N
of IN N
Effectiveness NNP N
and CC N
Safety NNP N
) ) N
, , N
a DT N
prospective JJ N
observational JJ N
cohort NN N
study NN N
, , N
evaluated VBN N
outcomes NNS N
in IN N
a DT N
large JJ N
, , N
community-based JJ N
population NN N
of IN N
patients NNS p
with IN p
first-line JJ p
NSCLC NNP p
. . p

METHODS NNP N
From IN N
2006 CD N
to TO N
2009 CD N
, , N
ARIES NNP p
enrolled VBD p
patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
NSCLC NNP p
who WP p
were VBD p
eligible JJ p
for IN p
bevacizumab NN i
, , p
excluding VBG p
those DT p
with IN p
predominantly RB p
squamous JJ p
histology NN p
. . p

Patients NNS p
were VBD p
required VBN p
to TO p
provide VB p
informed JJ p
consent NN p
and CC p
to TO p
have VB p
initiated VBN p
bevacizumab NN i
with IN i
chemotherapy NN i
within IN p
4 CD p
months NNS p
before IN p
enrollment NN p
. . N

There EX N
were VBD N
no DT N
protocol-defined JJ N
treatments NNS N
or CC N
assessments NNS N
. . N

The DT N
dosing NN N
of IN N
bevacizumab NN i
and CC i
chemotherapy NN i
, , N
and CC N
the DT N
choice NN N
of IN N
chemotherapy NN N
regimen NNS N
, , N
was VBD N
at IN N
the DT N
discretion NN N
of IN N
the DT N
treating NN N
physician NN N
. . N

RESULTS NNP N
ARIES NNP N
enrolled VBD N
1967 CD p
patients NNS p
with IN p
first-line JJ p
NSCLC NNP p
. . p

At IN N
study NN N
closure NN N
, , N
median JJ o
follow-up NN o
was VBD N
12.5 CD N
months NNS N
( ( N
range NN N
, , N
0.2-65.5 JJ N
) ) N
. . N

Median JJ p
age NN p
was VBD p
65 CD p
years NNS p
( ( p
range NN p
, , p
31-93 JJ p
) ) p
, , p
and CC p
252 CD p
patients NNS p
( ( p
12.8 CD p
% NN p
) ) p
identified VBN p
as IN p
never RB p
smokers NNS p
. . p

Median JJ o
progression-free JJ o
survival NN o
was VBD N
6.6 CD N
months NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
6.3-6.9 JJ N
) ) N
, , N
and CC N
median JJ o
overall JJ o
survival NN o
was VBD N
13.0 CD N
months NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
12.2-13.8 JJ N
) ) N
with IN N
first-line JJ N
bevacizumab NN i
plus CC i
chemotherapy NN i
. . i

Incidences NNS o
of IN o
bevacizumab-associated JJ o
adverse JJ o
events NNS o
( ( N
19.7 CD N
% NN N
overall JJ N
) ) N
were VBD N
consistent JJ N
with IN N
those DT N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
bevacizumab NN i
in IN N
NSCLC NNP N
. . N

CONCLUSION NNP N
Results NNP N
from IN N
ARIES NNP N
demonstrate VBP N
similar JJ N
outcomes NNS N
to TO N
randomized VB N
controlled JJ N
trials NNS N
of IN N
bevacizumab NN i
when WRB N
added VBD N
to TO N
standard VB N
chemotherapy NN N
in IN N
a DT N
real-world JJ p
patient NN p
population NN p
with IN p
advanced JJ p
NSCLC NNP p
. . p

-DOCSTART- -X- O O

Rehabilitation NN i
of IN N
therapy-related JJ N
cognitive JJ N
deficits NNS N
in IN N
patients NNS p
after IN p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
. . p

Neuropsychological JJ N
deficits NNS N
are VBP N
potential JJ N
side NN N
effects NNS N
of IN N
hematopoietic JJ i
stem NN i
cell NN i
therapy NN i
( ( i
HSCT NNP i
) ) i
. . i

Systematic JJ N
data NNS N
on IN N
the DT N
long-term JJ N
course NN N
of IN N
and CC N
therapeutic JJ N
options NNS N
for IN N
these DT N
consequences NNS N
are VBP N
limited VBN N
. . N

One CD p
hundred VBD p
fifty-seven JJ p
patients NNS p
were VBD p
screened VBN p
for IN p
cognitive JJ p
deficits NNS p
following VBG p
HSCT NNP i
for IN p
malignant JJ p
diseases NNS p
at IN p
an DT p
in-patient JJ p
oncologic NN p
rehabilitation NN p
clinic NN p
. . p

Patients NNS p
showing VBG p
evidence NN p
of IN p
impairment NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
training VBG p
groups NNS p
: : p
individualized VBN i
PC-supported JJ i
training NN i
or CC i
neuropsychological JJ i
group NN i
therapy NN i
. . i

The DT p
control NN p
group NN p
consisted VBD p
of IN p
patients NNS p
who WP p
received VBD p
no DT i
specific JJ i
training NN i
. . i

During IN N
in-patient JJ N
rehabilitation NN N
, , N
the DT N
results NNS o
of IN o
a DT o
comprehensive JJ o
neuropsychological JJ o
test NN o
battery NN o
improved VBD N
significantly RB N
in IN N
all DT N
three CD N
groups NNS N
, , N
and CC N
no DT N
specific JJ N
intervention NN N
effects NNS N
were VBD N
identified VBN N
. . N

Neuropsychological JJ o
deficits NNS o
were VBD N
still RB N
evident JJ N
in IN N
a DT N
subgroup NN N
of IN N
patients NNS N
6 CD N
months NNS N
later RB N
. . N

Correlation NN o
between IN o
neuropsychological JJ o
testing NN o
and CC o
patients NNS o
' POS o
self-evaluation NN o
of IN o
cognitive JJ o
functioning NN o
in IN o
daily JJ o
life NN o
was VBD N
generally RB N
low JJ N
. . N

Sustained VBN o
attention NN o
and CC o
verbal-semantic JJ o
memory NN o
played VBD N
the DT N
main JJ N
role NN N
for IN N
self-appraisal JJ N
and CC N
in IN N
the DT N
designation NN N
as IN N
'neuropsychologically RB N
impaired VBN N
' '' N
. . N

In IN N
conclusion NN N
, , N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS N
revealed JJ N
evidence NN N
of IN N
cognitive JJ N
deficits NNS N
a DT N
long JJ N
time NN N
after IN N
HSCT NNP i
. . i

There EX N
is VBZ N
a DT N
need NN N
for IN N
more JJR N
studies NNS N
and CC N
for IN N
the DT N
development NN N
of IN N
differentiated JJ N
rehabilitative JJ N
measures NNS N
for IN N
such JJ N
therapeutic JJ N
consequences NNS N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
two CD N
monophasic JJ i
oral JJ i
contraceptives NNS i
containing VBG i
gestodene NN i
or CC i
desogestrel NN i
on IN N
serum NN N
lipoprotein NN N
lipid JJ N
levels NNS N
. . N

Forty-nine NNP p
healthy JJ p
women NNS p
aged VBN p
20-35 JJ p
years NNS p
who WP p
had VBD p
not RB p
been VBN p
pregnant JJ p
or CC p
using VBG p
an DT p
oral JJ i
contraceptive NN i
( ( i
OC NNP i
) ) i
for IN p
the DT p
previous JJ p
3 CD p
months NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
, , N
one CD N
group NN N
taking VBG N
an DT N
OC NNP i
containing VBG N
75 CD N
micrograms NNS N
gestodene NN i
( ( i
GTD NNP i
) ) i
and CC N
30 CD N
micrograms NNS N
ethinyl VBP i
estradiol NN i
( ( i
EE NNP i
) ) i
, , N
and CC N
the DT N
other JJ N
group NN N
using VBG N
an DT N
OC NNP i
with IN N
150 CD N
micrograms NNS N
desogestrel NN i
( ( i
DSG NNP i
) ) i
and CC N
30 CD N
micrograms NNS N
EE NNP i
. . i

Fasting VBG o
blood NN o
samples NNS o
were VBD N
taken VBN N
before RB N
treatment NN N
, , N
and CC N
after IN N
cycles NNS N
3 CD N
and CC N
6 CD N
, , N
between IN N
the DT N
18th CD N
and CC N
the DT N
22nd CD N
day NN N
of IN N
the DT N
cycle NN N
. . N

Blood NNP o
lipoprotein JJ o
lipid JJ o
levels NNS o
were VBD N
measured VBN N
. . N

Serum NNP o
total JJ o
cholesterol NN o
did VBD o
not RB o
change VB o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
in IN N
the DT N
first JJ N
three CD N
cycles NNS N
, , N
serum JJ o
triglyceride NN o
increased VBN o
by IN N
46 CD N
% NN N
and CC N
40 CD N
% NN N
and CC N
HDL-cholesterol NNP o
by IN o
14 CD o
% NN o
and CC N
8 CD o
% NN o
in IN o
the DT o
GTD NNP o
and CC o
DSG NNP o
groups NNS N
, , N
respectively RB N
. . N

The DT N
serum NN o
LDL NNP o
level NN o
decreased VBN o
by IN N
6.2 CD N
% NN N
and CC N
11.8 CD N
% NN N
, , N
respectively RB N
. . N

Between VB N
the DT N
third JJ N
and CC N
sixth JJ N
cycle NN N
, , N
no DT o
further JJ o
significant JJ o
changes NNS o
were VBD N
observed VBN N
, , N
nor CC N
did VBD N
these DT N
changes NNS N
differ VBP N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
both DT N
OC NNP i
preparations NNS N
exerted VBD N
small JJ o
and CC o
probably RB o
favorable JJ o
effects NNS o
on IN o
serum NN o
lipoprotein NN o
lipid JJ o
levels NNS o
. . o

-DOCSTART- -X- O O

Clozapine NNP i
versus NN i
placebo NN i
in IN N
Huntington NNP p
's POS p
disease NN p
: : p
a DT N
double JJ N
blind NN N
randomised VBD N
comparative JJ N
study NN N
. . N

OBJECTIVES NNP N
To TO N
establish VB N
the DT N
effect NN N
of IN N
the DT N
atypical JJ N
neuroleptic JJ N
clozapine NN i
on IN N
chorea NN N
, , N
voluntary JJ N
motor NN N
performance NN N
, , N
and CC N
functional JJ N
disability NN N
in IN N
patients NNS p
with IN p
Huntington NNP p
's POS p
disease NN p
. . p

METHODS NNP N
Thirty NNP p
three CD p
patients NNS p
with IN p
Huntington NNP p
's POS p
disease NN p
participated VBD p
in IN N
a DT N
double JJ N
blind NN N
randomised VBD N
trial NN N
. . N

A DT N
maximum NN N
of IN N
150 CD N
mg/day JJ N
clozapine NN i
or CC i
placebo NN i
equivalent NN N
was VBD N
given VBN N
for IN N
a DT N
period NN N
of IN N
31 CD N
days NNS N
. . N

Assessments NNS N
were VBD N
performed VBN N
in IN N
the DT N
week NN N
before IN N
and CC N
at IN N
the DT N
last JJ N
day NN N
of IN N
the DT N
trial NN N
. . N

Chorea NNP N
was VBD N
scored VBN N
using VBG N
the DT N
abnormal JJ N
involuntary JJ N
movement NN N
scale NN N
( ( N
AIMS NNP N
) ) N
, , N
the DT N
chorea NN N
score NN N
of IN N
the DT N
unified JJ N
Huntington NNP N
's POS N
disease NN N
rating NN N
scale NN N
( ( N
UHDRS NNP N
) ) N
, , N
and CC N
judgement NN N
of IN N
video JJ N
recordings NNS N
. . N

Voluntary JJ N
motor NN N
performance NN N
was VBD N
assessed VBN N
using VBG N
the DT N
UHDRS NNP N
motor NN N
scale NN N
. . N

Patients NNS p
and CC p
their PRP$ p
partners NNS p
completed VBD N
a DT N
questionnaire NN N
regarding VBG N
functional JJ N
disability NN N
. . N

Twelve CD N
patients NNS N
already RB N
used VBD N
other JJ N
neuroleptic JJ N
medication NN N
, , N
which WDT N
was VBD N
kept FW N
unchanged JJ N
during IN N
the DT N
trial NN N
period NN N
. . N

Results NNS N
of IN N
neuroleptic JJ N
naive JJ N
and CC N
neuroleptic JJ N
treated JJ N
patients NNS N
were VBD N
analysed VBN N
separately RB N
. . N

RESULTS NNP N
Clozapine NNP i
tended VBD N
to TO N
reduce VB N
chorea NN o
in IN N
neuroleptic JJ N
naive JJ N
patients NNS N
only RB N
( ( N
AIMS NNP N
) ) N
; : N
improvement NN N
seemed VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS N
receiving VBG N
higher JJR N
doses NNS N
of IN N
clozapine NN N
. . N

Other JJ N
measures NNS o
of IN o
chorea NN o
( ( o
UHDRS NNP o
chorea NN o
score NN o
, , o
video JJ o
ratings NNS o
) ) o
showed VBD N
no DT N
improvement NN N
. . N

Clozapine NNP i
had VBD N
no DT N
beneficial JJ N
effect NN N
on IN N
chorea NN o
in IN N
patients NNS N
already RB N
receiving VBG N
neuroleptic JJ N
medication NN N
. . N

Voluntary JJ o
motor NN o
performance NN o
did VBD N
not RB N
improve VB N
with IN N
clozapine NN N
. . N

Neuroleptic JJ N
naive JJ N
patients NNS N
reported VBN N
aggravation NN N
of IN N
functional JJ o
disability NN o
, , N
possibly RB N
reflecting VBG N
the DT N
frequent JJ N
occurrence NN N
of IN N
side NN N
effects NNS N
. . N

Adverse JJ N
reactions NNS N
forced VBD N
trial NN N
termination NN N
in IN N
six CD N
patients NNS N
and CC N
dose JJ N
reduction NN N
in IN N
another DT N
eight CD N
, , N
and CC N
consisted VBD N
mainly RB N
of IN N
drowsiness NN o
, , o
fatigue NN o
, , o
anticholinergic NN o
symptoms NNS o
, , o
and CC o
walking VBG o
difficulties NNS o
. . o

CONCLUSIONS NNP N
Clozapine NNP i
has VBZ N
little JJ N
beneficial JJ N
effect NN N
in IN N
patients NNS p
with IN p
Huntington NNP p
's POS p
disease NN p
, , N
although IN N
individual JJ N
patients NNS N
may MD N
tolerate VB N
doses NNS N
high JJ N
enough RB N
to TO N
reduce VB N
chorea NN N
. . N

Because IN N
adverse JJ N
reactions NNS N
are VBP N
often RB N
encountered VBN N
, , N
clozapine NN i
should MD N
be VB N
used VBN N
with IN N
restraint NN N
in IN N
this DT N
patient NN N
group NN N
. . N

-DOCSTART- -X- O O

Lipoprotein NNP N
( ( N
a DT N
) ) N
serum NN N
levels NNS N
in IN N
post-menopausal JJ p
women NNS p
treated VBN p
with IN p
oral JJ i
estrogens NNS i
administered VBN p
at IN p
different JJ p
times NNS p
. . p

The DT N
different JJ N
effects NNS o
on IN N
serum NN N
lipoprotein NN N
( ( N
a DT N
) ) N
[ NN N
Lp NNP N
( ( N
a DT N
) ) N
] NN N
levels NNS N
by IN N
administering VBG N
estrogens NNS i
at IN i
different JJ i
times NNS i
of IN i
the DT i
day NN i
( ( N
8 CD N
a.m. RB N
and CC N
8 CD N
p.m. NN N
) ) N
were VBD N
evaluated VBN N
in IN N
twenty-four JJ p
post-menopausal JJ p
women NNS p
. . p

Patients NNS N
were VBD N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
treatment NN N
groups NNS N
by IN N
random JJ N
sampling VBG N
numbers NNS N
. . N

Patients NNS N
of IN N
both DT N
groups NNS N
received VBD N
0.625 CD N
mg NNS N
conjugated VBN i
equine JJ i
estrogens NNS i
daily JJ N
per IN N
os NN N
for IN N
21 CD N
days NNS N
. . N

Group NNP N
A NNP N
patients NNS N
( ( N
n JJ N
: : N
9 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
a.m. NN N
, , N
and CC N
group NN N
B NNP N
patients NNS N
( ( N
n JJ N
: : N
12 CD N
) ) N
received VBD N
the DT N
pill NN N
at IN N
8 CD N
p.m NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
as IN N
regards NNS N
the DT N
anthropometric JJ o
characteristics NNS o
, , o
the DT o
basal NN o
values NNS o
of IN o
the DT o
Lp NNP o
( ( o
a DT o
) ) o
, , o
the DT o
sex NN o
steroid NN o
and CC o
pituitary JJ o
hormone NN o
levels NNS o
. . o

Administration NN N
of IN N
conjugated JJ i
equine NN i
estrogens NNS i
resulted VBD N
in IN N
decreased JJ N
levels NNS o
of IN o
Lp NNP o
( ( o
a DT o
) ) o
only RB N
in IN N
group NN N
B NNP N
after IN N
treatment NN N
. . N

The DT N
different JJ N
Lp NNP N
( ( N
a DT N
) ) N
behaviour NN N
in IN N
the DT N
two CD N
groups NNS N
and CC N
in IN N
the DT N
presence NN N
of IN N
the DT N
same JJ N
serum JJ N
hormonal NN N
levels NNS N
, , N
seems VBZ N
to TO N
be VB N
dependent JJ N
on IN N
the DT N
existence NN N
of IN N
a DT N
circadian JJ N
rhythm NN N
of IN N
the DT N
hepatic JJ N
responsiveness NN N
to TO N
estrogens VB N
, , N
whose WP$ N
expression NN N
is VBZ N
higher JJR N
during IN N
evening NN N
hours NNS N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
the DT N
effects NNS N
of IN N
terazosin NN i
and CC N
enalapril NN i
on IN N
laboratory NN N
stress NN N
testing VBG N
blood NN N
pressure NN N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

It PRP N
is VBZ N
the DT N
current JJ N
opinion NN N
that IN N
an DT N
ideal JJ N
antihypertensive JJ i
drug NN i
should MD N
reduce VB N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
not RB N
only RB N
at IN N
rest NN N
but CC N
also RB N
during IN N
stressful JJ N
situations NNS N
. . N

The DT N
current JJ N
study NN N
was VBD N
aimed VBN N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
selective JJ i
alpha NN i
1-adrenergic JJ i
blocker NN i
terazosin NN i
( ( N
5 CD N
mg NN N
once RB N
daily JJ N
) ) N
and CC N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
enalapril NN i
( ( N
20 CD N
mg NN N
once RB N
daily RB N
) ) N
on IN N
cardiovascular JJ N
response NN N
to TO N
a DT N
set NN N
of IN N
standardized JJ N
laboratory NN N
stressors NNS N
, , N
such JJ N
as IN N
mental JJ N
arithmetic JJ N
, , N
handgrip JJ N
test NN N
and CC N
cycle NN N
ergometry NN N
, , N
in IN N
a DT N
group NN p
of IN p
16 CD p
essential JJ p
hypertensive JJ p
patients NNS p
. . p

The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
cross-over JJ N
trial NN N
preceded VBN N
by IN N
a DT N
placebo JJ i
run-in JJ N
period NN N
. . N

Terazosin NNP i
and CC i
enalapril VB i
had VBD N
a DT N
comparable JJ N
effect NN N
on IN N
resting VBG o
BP NNP o
, , o
reducing VBG o
systolic JJ o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
( ( o
DBP NNP o
) ) o
blood NN o
pressure NN o
from IN N
159.5 CD N
+/- JJ N
13.9/101.6 CD N
+/- JJ N
8.8 CD N
mm NN N
Hg NNP N
during IN N
placebo NN N
by IN N
7.8 CD N
% NN N
/6.7 CC N
% NN N
and CC N
by IN N
11.3 CD N
% NN N
/10.2 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
response NN o
rate NN o
to TO N
the DT N
two CD N
treatments NNS N
was VBD N
approximately RB N
the DT N
same JJ N
, , N
being VBG N
69 CD N
% NN N
and CC N
75 CD N
% NN N
after IN N
terazosin NN i
and CC N
enalapril NN i
, , N
respectively RB N
. . N

During IN N
mental JJ N
arithmetic JJ N
, , N
from IN N
an DT N
average NN N
of IN N
181.6 CD N
+/- JJ N
17.8/118.6 CD N
+/- JJ N
11.5 CD N
mm NN N
Hg NNP N
during IN N
placebo NN i
, , N
BP NNP o
was VBD N
reduced VBN N
by IN N
11.5 CD N
% NN N
/7.9 CD N
% NN N
after IN N
terazosin NN i
and CC N
by IN N
13.6 CD N
% NN N
/8.5 CD N
% NN N
after IN N
enalapril NN i
; : i
during IN N
handgrip NN N
test NN N
, , N
BP NNP o
decreased VBD N
from IN N
207.2 CD N
+/- JJ N
22.2/142.2 CD N
+/- JJ N
13.6 CD N
mm NN N
Hg NNP N
by IN N
7.3 CD N
% NN N
/8.4 CD N
% NN N
after IN N
terazosin NN i
and CC N
by IN N
7.7 CD N
% NN N
/7.1 CD N
% NN N
after IN N
enalapril NN i
; : i
finally RB N
, , N
during IN N
cycle NN N
ergometry NN N
, , N
terazosin NN N
and CC N
enalapril NN N
lowered VBN N
BP NNP o
by IN N
5.4 CD N
% NN N
/6.7 CC N
% NN N
and CC N
7 CD N
% NN N
/3.1 CD N
% NN N
, , N
respectively RB N
, , N
from IN N
a DT N
placebo NN i
value NN N
of IN N
215.5 CD N
+/- JJ N
17.3/127.6 CD N
+/- JJ N
11.2 CD N
. . N

No DT N
significant JJ N
difference NN N
in IN N
antihypertensive JJ N
efficacy NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
drugs NNS N
, , N
either RB N
at IN N
rest NN N
and CC N
during IN N
stress JJ N
testing VBG N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Ciprofloxacin NNP i
, , i
lomefloxacin NN i
, , i
or CC i
levofloxacin CC i
as IN N
treatment NN N
for IN N
chronic JJ o
osteomyelitis NN o
. . o

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
three CD N
oral JJ i
fluoroquinolones NNS i
( ( i
lomefloxacin NN i
, , i
levofloxacin NN i
, , i
and CC i
ciprofloxacin NN i
) ) i
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
osteomyelitis NN N
were VBD N
analyzed VBN N
. . N

Twenty-seven JJ p
patients NNS p
had VBD p
documented VBN p
infections NNS p
with IN p
quinolone-sensitive JJ p
organisms NNS p
and CC N
received VBD N
either DT i
lomefloxacin NN i
, , i
levofloxacin NN i
, , i
or CC i
ciprofloxacin NN i
. . i

Levofloxacin NNP N
was VBD N
effective JJ N
therapy NN N
for IN N
9 CD N
of IN N
15 CD N
( ( N
60 CD N
% NN N
) ) N
patients NNS N
. . N

Lomefloxacin NNP N
was VBD N
effective JJ N
therapy NN N
for IN N
five CD N
of IN N
seven CD N
( ( N
71 CD N
% NN N
) ) N
patients NNS N
, , N
and CC N
ciprofloxacin NN N
was VBD N
effective JJ N
therapy NN N
for IN N
two CD N
of IN N
five CD N
patients NNS N
( ( N
40 CD N
% NN N
) ) N
. . N

Average JJ N
follow-up NN N
was VBD N
11.8 CD N
months NNS N
for IN N
patients NNS N
who WP N
completed VBD N
the DT N
course NN N
of IN N
therapy NN N
, , N
and CC N
the DT N
average JJ N
duration NN o
of IN o
therapy NN o
was VBD N
60.6 CD N
days NNS N
. . N

Gram-positive JJ o
bacteria NNS o
were VBD N
isolated VBN N
from IN N
18 CD N
patients NNS N
, , N
and CC N
11 CD N
patients NNS N
were VBD N
cured VBN o
. . o

Oral JJ N
fluoroquinolones NNS N
can MD N
be VB N
safe JJ o
, , o
effective JJ o
therapy NN N
if IN N
they PRP N
are VBP N
given VBN N
for IN N
a DT N
prolonged JJ N
course NN N
as IN N
treatment NN N
for IN N
infections NNS N
caused VBN N
by IN N
susceptible JJ N
gram-positive JJ N
as RB N
well RB N
as IN N
gram-negative JJ N
organisms NNS N
and CC N
in IN N
combination NN N
with IN N
adequate JJ N
surgical JJ N
debridement NN N
. . N

-DOCSTART- -X- O O

Analysis NN o
of IN o
treatment NN o
in IN N
childhood NN p
leukaemia NN p
. . p

I. NNP N
Predisposition NNP N
to TO N
methotrexate-induced JJ N
neutropenia NN N
after IN p
craniospinal JJ p
irradiation NN p
. . p

Report NNP N
to TO N
the DT N
Medical NNP N
Research NNP N
Council NNP N
of IN N
the DT N
Working NNP N
Party NNP N
on IN N
Leukaemia NNP p
in IN p
Childhood NNP p
. . p

The DT N
degree NN N
of IN N
drug-induced JJ N
neutropenia NNS o
resulting VBG N
from IN N
a DT N
controlled VBN N
trial NN N
( ( N
UKALL NNP N
I PRP N
) ) N
of IN N
treatment NN N
in IN N
acute JJ p
lymphoblastic JJ p
leukaemia NN p
was VBD N
analysed VBN N
. . N

The DT N
main JJ N
agent NN N
associated VBN N
with IN N
severe JJ o
neutropenia NN o
was VBD N
methotrexate NN i
, , N
and CC N
methotrexate-induced JJ o
neutropenia NN o
was VBD N
significantly RB N
greater JJR N
in IN N
patients NNS p
who WP p
had VBD p
received VBN p
craniospinal JJ p
irradiation NN p
. . p

The DT N
synergistic JJ o
toxic NN o
effect NN o
of IN o
irradiation NN o
followed VBN N
by IN N
methotrexate NN N
treatment NN N
seems VBZ N
to TO N
have VB N
contributed VBN N
to TO N
three CD N
of IN N
the DT N
five CD N
deaths NNS o
which WDT N
occurred VBD N
in IN N
complete JJ N
remission NN o
in IN N
this DT N
trial NN N
; : N
all DT N
deaths NNS N
in IN N
remission NN N
occurred VBD N
in IN N
patients NNS N
who WP N
had VBD N
received VBN N
central JJ N
nervous JJ N
system NN N
prophylaxis NN N
. . N

Analysis NN N
of IN N
patients NNS N
who WP N
subsequently RB N
relapsed VBD N
compared VBN N
with IN N
those DT N
still RB N
in IN N
remission NN N
after IN N
18 CD N
months NNS N
of IN N
treatment NN N
indicated VBD N
that IN N
the DT N
former JJ N
, , N
on IN N
average NN N
, , N
had VBD N
slightly RB N
lower JJR N
neutrophil NN o
counts NNS o
. . o

This DT N
suggests VBZ N
that IN N
the DT N
children NNS p
who WP N
relapsed VBD N
did VBD N
not RB N
receive VB N
any DT N
less RBR N
aggressive JJ N
treatment NN N
than IN N
those DT N
who WP N
remained VBD N
in IN N
remission NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
succinylcholine NN i
with IN N
two CD N
doses NNS N
of IN N
rocuronium NN i
using VBG N
a DT N
new JJ N
method NN N
of IN N
monitoring VBG N
neuromuscular JJ o
block NN o
at IN p
the DT p
laryngeal NN p
muscles NNS p
by IN N
surface NN p
laryngeal NN p
electromyography NN p
. . N

We PRP N
compared VBN N
the DT N
onset NN o
of IN o
neuromuscular JJ o
block NN o
with IN N
succinylcholine NN i
( ( i
1 CD i
mg RB i
kg-1 NN i
) ) i
and CC i
two CD i
doses NNS i
of IN i
rocuronium NN i
( ( i
0.6 CD i
and CC i
0.9 CD i
mg JJ i
kg-1 NN i
) ) i
at IN N
the DT N
adductor NN N
pollicis NN N
muscle NN N
using VBG N
electromyography NN i
( ( i
EMG NNP i
) ) i
and CC i
acceleromyography NN i
( ( N
AMG NNP N
) ) N
, , N
and CC N
at IN N
the DT N
adductor NN N
laryngeal NN N
muscles NNS N
with IN N
a DT N
new JJ N
electromyographic JJ i
method NN i
using VBG N
a DT N
disposable JJ N
surface NN N
electrode NN N
attached VBN N
to TO N
the DT N
cuff NN N
of IN N
a DT N
tracheal JJ N
tube NN N
. . N

At IN N
the DT N
larynx NN N
, , N
the DT N
mean NN o
( ( o
+/- JJ o
SD NNP o
) ) o
time NN o
to TO o
90 CD o
% NN o
block NN o
and CC o
the DT o
onset JJ o
time NN o
of IN N
succinylcholine NN o
( ( N
38 CD N
+/- JJ N
15 CD N
and CC N
47 CD N
+/- JJ N
19 CD N
s NN N
, , N
respectively RB N
) ) N
were VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
for IN N
rocuronium NN i
0.6 CD N
mg NN N
kg-1 NN N
( ( N
92 CD N
+/- JJ N
42 CD N
and CC N
106 CD N
+/- JJ N
38 CD N
s NN N
) ) N
and CC N
rocuronium $ i
0.9 CD N
mg JJ N
kg-1 NN N
( ( N
52 CD N
+/- JJ N
31 CD N
and CC N
64 CD N
+/- JJ N
30 CD N
s NN N
) ) N
. . N

We PRP N
found VBD N
that IN N
, , N
with IN N
comparable JJ N
degrees NNS N
of IN N
neuromuscular JJ o
block NN o
, , N
the DT N
onset JJ o
time NN o
of IN o
succinylcholine NN o
at IN o
the DT o
adductor NN o
pollicis NN o
was VBD N
significantly RB N
shorter JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
than IN N
for IN N
rocuronium NN i
0.6 CD N
mg NN N
kg-1 NN N
and CC N
0.9 CD N
mg NNS N
kg-1 JJ N
( ( N
EMG NNP N
, , N
80 CD N
+/- JJ N
39 CD N
vs JJ N
145 CD N
+/- JJ N
48 CD N
s NN N
and CC N
99 CD N
+/- JJ N
31 CD N
s NN N
; : N
AMG NNP N
, , N
90 CD N
+/- JJ N
39 CD N
vs JJ N
124 CD N
+/- JJ N
53 CD N
s NN N
and CC N
106 CD N
+/- JJ N
38 CD N
s NN N
) ) N
. . N

Clinical JJ o
duration NN o
at IN o
the DT o
adductor NN o
pollicis NN o
( ( o
AMG NNP o
) ) o
was VBD N
significantly RB N
longer JJR N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
for IN N
both DT N
rocuronium NN i
groups NNS N
than IN N
for IN N
succinylcholine NN i
( ( N
T4 NNP N
: : N
T1 NNP N
= VBZ N
0.7 CD N
, , N
54 CD N
+/- JJ N
18 CD N
and CC N
77 CD N
+/- JJ N
21 CD N
vs JJ N
8 CD N
+/- JJ N
6 CD N
min NN N
) ) N
. . N

The DT N
surface NN N
laryngeal JJ N
electrode NN N
proved VBD N
non-invasive JJ N
, , N
easy JJ N
to TO N
use VB N
and CC N
reliable VB N
in IN N
measuring VBG N
onset NN o
of IN o
the DT o
neuromuscular JJ o
block NN o
at IN p
the DT p
larynx NN p
. . p

-DOCSTART- -X- O O

Preoperative JJ N
irradiation NN N
versus IN N
the DT N
use NN N
of IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drugs NNS N
for IN N
prevention NN N
of IN N
heterotopic JJ o
ossification NN o
following VBG p
total JJ p
hip JJ p
replacement NN p
: : p
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

PURPOSE NNP N
Previous JJ N
studies NNS N
showed VBD N
the DT N
effectiveness NN N
of IN N
early JJ N
preoperative NN N
( ( N
4 CD N
h NN N
before IN N
operation NN N
) ) N
irradiation NN N
for IN N
prevention NN N
of IN N
heterotopic NN o
ossification NN o
( ( o
HO NNP o
) ) o
after IN N
total JJ N
hip NN N
replacement NN N
. . N

This DT N
procedure NN N
can MD N
result VB N
in IN N
logistic JJ N
problems NNS N
, , N
if IN N
there EX N
is VBZ N
a DT N
great JJ N
distance NN N
between IN N
the DT N
department NN N
of IN N
radiotherapy NN N
and CC N
the DT N
orthopedic JJ N
clinic NN N
. . N

To TO N
avoid VB N
these DT N
organizational JJ N
problems NNS N
a DT N
prospective JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
analyze VB N
the DT N
effectiveness NN o
of IN o
preoperative JJ o
irradiation NN o
on IN N
the DT N
day NN N
preceding VBG N
surgery NN N
( ( N
16-20 JJ N
h NN N
before IN N
operation NN N
) ) N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP p
1995 CD p
and CC p
1996 CD p
, , p
100 CD p
patients NNS p
were VBD p
randomized VBN i
to TO p
receive VB p
a DT p
prophylactic JJ p
therapy NN p
for IN p
prevention NN p
of IN p
heterotopic NN p
ossification NN p
. . p

Forty-six JJ N
patients NNS N
were VBD N
irradiated VBN i
with IN i
7 CD i
Gy NNP i
single JJ i
dose NN i
within IN i
16-20 JJ i
h NN i
before IN i
operation NN i
. . i

Fifty-four CD N
patients NNS N
were VBD N
treated VBN i
with IN i
nonsteroidal JJ i
anti-inflammatory JJ i
drugs NNS i
( ( i
NSAID NNP i
) ) i
( ( i
Voltaren NNP i
resinat VBZ i
2 CD i
x NN i
75 CD i
mg/day NN i
for IN i
2 CD i
weeks NNS i
) ) i
. . i

Heterotopic NNP o
ossification NN o
was VBD o
scored VBN o
according VBG o
to TO o
the DT o
Brooker NNP o
Grading NNP o
system NN o
. . o

One CD p
hundred VBD p
patients NNS p
receiving VBG p
no DT p
prophylactic JJ p
therapy NN p
after IN p
total JJ p
hip NN p
arthroplasty NN p
between IN p
1988 CD p
and CC p
1992 CD p
were VBD p
analyzed VBN p
and CC p
defined VBN p
as IN p
the DT p
historical JJ p
control NN p
group NN p
. . p

RESULTS NNP N
Incidence NNP N
of IN N
heterotopic NN o
ossification NN o
was VBD N
47.8 CD N
% NN N
in IN N
the DT N
7 CD N
Gy NNP N
preoperative JJ N
group NN N
( ( o
Brooker NNP o
Score NNP o
I PRP o
: : o
36.9 CD N
% NN N
; : N
II NNP N
: : N
8.7 CD N
% NN N
; : N
III NNP N
: : N
2.2 CD N
% NN N
; : N
IV NNP N
: : N
0 CD N
% NN N
) ) N
and CC N
11.1 CD N
% NN N
in IN N
the DT N
NSAID NNP N
group NN N
( ( o
Brooker NNP o
Score NNP o
I PRP o
: : o
9.3 CD N
% NN N
; : N
II NNP N
: : N
1.8 CD N
% NN N
; : N
III NNP N
: : N
0 CD N
% NN N
; : N
IV NNP N
: : N
0 CD N
% NN N
) ) N
. . N

Regarding VBG N
overall JJ N
heterotopic NN o
ossification NN o
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
NSAID NNP N
group NN N
and CC N
the DT N
7 CD N
Gy NNP N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Analyzing VBG N
the DT N
clinically RB N
significant JJ N
heterotopic NN o
ossification NN o
( ( o
Brooker NNP o
Score NNP o
III NNP o
and CC o
IV NNP o
) ) o
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
untreated JJ N
historical JJ N
control NN N
group NN N
the DT N
incidence NN N
of IN N
heterotopic NN o
ossification NN o
was VBD N
65 CD N
% NN N
( ( o
Brooker NNP o
Score NNP o
I PRP N
: : N
26 CD N
% NN N
; : N
II NNP N
: : N
15 CD N
% NN N
; : N
III NNP N
: : N
19 CD N
% NN N
; : N
IV NNP N
: : N
5 CD N
% NN N
) ) N
. . N

Referring VBG N
to TO N
overall JJ N
and CC N
to TO N
clinically RB N
relevant JJ N
heterotopic NN o
ossification NN o
the DT N
incidence NN N
of IN N
HO NNP o
was VBD N
greater JJR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
prophylactically RB N
treated VBN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Irradiation NNP N
within IN N
16-20 JJ N
h NN N
before IN N
operation NN N
and CC N
use NN N
of IN N
NSAID NNP N
( ( N
Voltaren NNP N
resinat NN N
) ) N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
relevant JJ N
heterotopic NN o
ossification NN o
after IN N
total JJ N
hip NN N
replacement NN N
. . N

-DOCSTART- -X- O O

Onset/offset NNP o
characteristics NNS o
and CC o
intubating VBG o
conditions NNS o
of IN N
rapacuronium NN N
: : N
a DT N
comparison NN N
with IN N
rocuronium NN N
. . N

We PRP N
compared VBN N
onset PRP o
and CC o
offset VB o
of IN o
action NN o
and CC o
tracheal JJ o
intubating NN o
conditions NNS o
after IN N
rapacuronium NN i
and CC i
rocuronium NN i
in IN N
60 CD p
patients NNS p
in IN N
a DT N
randomized JJ N
, , N
assessor-blinded JJ N
study NN N
. . N

Following VBG N
induction NN N
of IN N
anaesthesia NN i
with IN i
propofol JJ i
2.5 CD i
mg JJ i
kg-1 NN i
, , i
either CC i
rapacuronium NN i
1.5 CD i
mg NN i
kg-1 NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
or CC i
rocuronium $ i
0.6 CD i
mg JJ i
kg-1 NN i
( ( i
n JJ i
= NNP i
30 CD i
) ) i
was VBD i
administered VBN i
to TO i
facilitate VB i
tracheal JJ i
intubation NN i
. . i

Anaesthesia NNP i
was VBD i
maintained VBN i
with IN i
either CC i
a DT i
propofol JJ i
infusion NN i
( ( i
100 CD i
micrograms NNS i
kg-1 JJ i
min-1 JJ i
) ) i
or CC i
sevoflurane NN i
( ( i
1 CD i
% NN i
end-tidal JJ i
) ) i
with IN i
66 CD i
% NN i
nitrous JJ i
oxide NN i
( ( i
N2O NNP i
) ) i
, , i
n JJ i
= VBP i
15 CD i
in IN i
each DT i
subgroup NN i
. . i

Neuromuscular JJ o
monitoring NN o
was VBD i
performed VBN i
using VBG i
an DT i
electromyographic JJ i
( ( i
EMG NNP i
) ) i
device NN i
( ( i
Datex NNP i
Relaxograph NNP i
) ) i
. . i

The DT N
lag NN o
times NNS o
( ( N
mean JJ N
42 CD N
( ( N
SD NNP N
11 CD N
) ) N
s NN N
and CC N
44 CD N
( ( N
16 CD N
) ) N
s NN N
) ) N
, , N
maximum JJ o
block NN o
( ( N
99 CD N
( ( N
2 CD N
) ) N
% NN N
and CC N
98 CD N
( ( N
3 CD N
) ) N
% NN N
) ) N
and CC N
intubating JJ o
conditions NNS o
at IN o
60 CD o
s NN o
( ( N
good-to-excellent JJ N
in IN N
86 CD N
% NN N
and CC N
84 CD N
% NN N
of IN N
patients NNS N
) ) N
were VBD N
similar JJ N
for IN N
rapacuronium NN N
and CC N
rocuronium NN N
, , N
respectively RB N
. . N

The DT N
onset JJ o
time NN o
of IN N
rapacuronium NN N
was VBD N
shorter JJR N
than IN N
rocuronium NN N
( ( N
87 CD N
( ( N
20 CD N
) ) N
vs NN N
141 CD N
( ( N
65 CD N
) ) N
s NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
degree NN o
of IN o
block NN o
at IN o
60 CD o
s NN o
was VBD N
greater JJR N
( ( N
69 CD N
( ( N
26 CD N
) ) N
vs NN N
50 CD N
( ( N
27 CD N
) ) N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Twenty-five JJ N
per IN N
cent NN N
recovery NN o
was VBD N
shorter JJR N
with IN N
rapacuronium NN N
than IN N
rocuronium NN N
during IN N
propofol NN N
( ( N
15.0 CD N
( ( N
3.2 CD N
) ) N
vs NN N
39.1 CD N
( ( N
14.2 CD N
) ) N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
sevoflurane NN N
( ( N
15.1 CD N
( ( N
4.2 CD N
) ) N
vs NN N
47.8 CD N
( ( N
19.0 CD N
) ) N
min NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
anaesthesia NN N
. . N

We PRP N
conclude VBP N
that IN N
rapacuronium NN N
1.5 CD N
mg NN N
kg-1 NN N
had VBD N
a DT N
more RBR N
rapid JJ N
onset NN o
, , N
similar JJ N
intubating NN o
conditions NNS o
, , N
and CC N
shorter JJR N
recovery NN o
times NNS o
than IN N
rocuronium NN N
0.6 CD N
mg JJ N
kg-1 NN N
. . N

-DOCSTART- -X- O O

Absence NN N
of IN N
analgesic JJ N
effect NN N
of IN N
intravenous JJ N
melatonin JJ i
administration NN N
during IN N
daytime NN N
after IN N
laparoscopic JJ N
cholecystectomy NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
whether IN N
melatonin NN i
administered VBN N
intraoperatively RB N
reduced VBN N
pain NN o
following VBG p
laparoscopic JJ p
cholecystectomy NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
placebo-controlled JJ N
, , N
double-blinded JJ N
study NN N
. . N

SETTING CD N
Two CD p
surgical JJ p
departments NNS p
in IN p
Copenhagen NNP p
. . p

PATIENTS NNP N
44 CD p
women NNS p
between IN p
18 CD p
and CC p
70 CD p
years NNS p
of IN p
age NN p
, , p
who WP p
were VBD p
surgical JJ p
candidates NNS p
for IN p
laparoscopic JJ p
cholecystectomy NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
anesthetized VBN i
by IN i
a DT i
standard JJ i
protocol NN i
and CC i
received VBD i
a DT i
standard JJ i
multimodal NN i
postoperative JJ i
analgesic JJ i
regimen NNS i
. . i

Patients NNS p
undergoing VBG p
surgery NN p
were VBD p
admitted VBN p
on IN p
the DT p
day NN p
of IN p
surgery NN p
and CC p
were VBD p
discharged VBN p
the DT p
day NN p
after IN p
surgery NN p
. . p

Ten CD i
mg NN i
of IN i
intravenous JJ i
( ( i
IV NNP i
) ) i
melatonin NN i
or CC i
placebo NN i
were VBD N
administered VBN N
at IN N
the DT N
time NN N
of IN N
surgical JJ N
incision NN N
. . N

MEASUREMENTS NNP N
Pain NNP o
was VBD N
assessed VBN N
by IN N
a DT N
set NN N
of IN N
questionnaires NNS N
documenting VBG N
pain NN N
at IN N
rest NN N
using VBG N
a DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
. . N

The DT N
use NN N
of IN N
rescue NN N
medication NN N
was VBD N
recorded VBN N
. . N

Sleep JJ o
quality NN o
and CC o
general JJ o
well-being NN o
were VBD N
measured VBN N
on IN N
separate JJ N
VAS NNP o
scales NNS o
. . o

Sleepiness NNP o
was VBD N
assessed VBN N
by IN N
the DT N
Karolinska NNP N
Sleepiness NNP N
Scale NNP N
. . N

MAIN NNP N
RESULTS NNP N
Forty-four JJ p
patients NNS p
were VBD p
included VBN p
and CC p
randomized VBN p
to TO p
the DT p
study NN p
. . p

Three CD p
patients NNS p
did VBD p
not RB p
complete VB p
the DT p
study NN p
. . p

No DT N
differences NNS N
in IN N
VAS NNP o
pain NN o
scores NNS o
, , o
sleep VBP o
quality NN o
, , o
general JJ o
well-being NN o
, , o
or CC o
sleepiness NN o
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
postoperative JJ N
period NN N
. . N

The DT N
use NN N
of IN N
postoperative JJ N
rescue NN N
medication NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
use NN N
of IN N
10mg CD N
of IN N
IV NNP N
melatonin NN i
administered VBD N
during IN N
laparoscopic JJ N
cholecystectomy NN N
did VBD N
not RB N
affect VB N
postoperative JJ o
pain NN o
or CC o
use NN o
of IN o
analgesic JJ o
medication NN o
. . o

-DOCSTART- -X- O O

Rett NNP p
syndrome NN p
: : p
randomized VBN N
controlled VBD N
trial NN N
of IN N
L-carnitine NNP i
. . i

Rett NNP N
syndrome NN N
is VBZ N
a DT N
severe JJ N
neurodevelopmental JJ N
disorder NN N
of IN N
unknown JJ N
etiology NN N
, , N
occurring VBG N
almost RB N
exclusively RB N
in IN N
female JJ p
patients NNS p
. . p

The DT N
etiology NN N
and CC N
functional JJ N
significance NN N
of IN N
plasma JJ N
carnitine NN N
deficiency NN N
seen VBN N
in IN N
some DT N
patients NNS N
with IN N
Rett NNP N
syndrome NN N
is VBZ N
unknown JJ N
. . N

To TO N
investigate VB N
whether IN N
L-carnitine JJ i
might MD N
be VB N
of IN N
benefit NN N
in IN N
Rett NNP N
syndrome NN N
, , N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
crossover NN N
trial NN N
of IN N
L-carnitine NNP i
has VBZ N
been VBN N
completed VBN N
in IN N
35 CD p
subjects NNS p
. . p

Eight-week JJ N
treatment NN N
phases NNS N
were VBD N
completed VBN N
for IN N
both DT N
a DT N
placebo NN i
and CC i
L-carnitine NNP i
. . i

Outcome NNP N
was VBD N
measured VBN N
by IN N
parents/caregivers NNS N
and CC N
at IN N
medical JJ N
follow-up NN N
using VBG N
three CD N
established VBN N
tools NNS N
: : N
the DT o
Rett NNP o
Syndrome NNP o
Motor NNP o
Behavioral NNP o
Assessment NNP o
, , o
the DT o
Hand NNP o
Apraxia NNP o
Scale NNP o
, , o
and CC o
the DT o
Patient NNP o
Well-Being NNP o
Index NNP o
. . o

Analysis NNP N
comparing VBG N
change NN N
between IN N
baseline NN N
and CC N
week NN N
8 CD N
of IN N
treatment NN N
for IN N
L-carnitine NNP i
and CC N
the DT N
placebo NN i
showed VBD N
that IN N
both DT N
parents/caregivers NNS N
and CC N
medical JJ N
follow-up NN N
detected JJ N
improvements NNS N
in IN N
the DT N
subjects NNS N
' POS N
well-being NN o
. . o

In IN N
addition NN N
, , N
medical JJ N
review NN N
showed VBD N
an DT N
improvement NN N
on IN N
the DT N
Hand NNP o
Apraxia NNP o
Scale NNP o
for IN N
a DT N
higher JJR N
proportion NN N
of IN N
girls NNS N
on IN N
L-carnitine NNP N
. . N

Identification NN N
of IN N
predictors NNS N
of IN N
clinical JJ N
improvement NN N
has VBZ N
been VBN N
limited VBN N
by IN N
the DT N
power NN N
of IN N
the DT N
study NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
L-carnitine NNP i
is VBZ N
of IN N
benefit NN N
in IN N
some DT N
patients NNS p
with IN p
Rett NNP p
syndrome NN p
. . p

While IN N
L-carnitine NNP i
did VBD N
not RB N
lead VB N
to TO N
major JJ N
functional JJ N
changes NNS N
in IN N
ability NN N
, , N
the DT N
type NN N
of IN N
changes NNS N
reported VBN N
could MD N
still RB N
have VB N
a DT N
substantial JJ N
impact NN N
on IN N
the DT N
girls NNS N
and CC N
their PRP$ N
families NNS N
. . N

Information NN N
is VBZ N
still RB N
needed VBN N
, , N
however RB N
, , N
to TO N
determine VB N
if IN N
only RB N
subgroups NNS N
of IN N
girls NNS N
with IN N
the DT N
disorder NN N
are VBP N
responsive JJ N
to TO N
L-carnitine NNP i
and CC N
the DT N
appropriate JJ N
duration NN N
of IN N
therapy NN N
. . N

-DOCSTART- -X- O O

Memory NN o
monitoring NN N
by IN N
animals NNS p
and CC p
humans NNS p
. . p

The DT N
authors NNS N
asked VBD N
whether IN N
animals NNS p
and CC p
humans NNS p
would MD N
use VB N
similarly RB N
an DT N
uncertain JJ N
response NN o
to TO N
escape VB N
indeterminate JJ N
memories NNS N
. . N

Monkeys NNS p
and CC p
humans NNS p
performed VBD p
serial JJ i
probe NN i
recognition NN i
tasks NNS i
that WDT N
produced VBD N
differential JJ N
memory NN N
difficulty NN N
across IN N
serial JJ N
positions NNS N
( ( N
e.g. NN N
, , N
primacy NN N
and CC N
recency NN N
effects NNS N
) ) N
. . N

Participants NNS p
were VBD N
given VBN N
an DT N
escape NN N
option NN N
that WDT N
let VBD N
them PRP N
avoid VB N
any DT N
trials NNS N
they PRP N
wished VBD N
and CC N
receive VB N
a DT N
hint NN N
to TO N
the DT N
trial NN N
's POS N
answer NN N
. . N

Across IN N
species NNS N
, , N
across IN N
tasks NNS N
, , N
and CC N
even RB N
across IN N
conspecifics NNS N
with IN N
sharper NN N
or CC N
duller NN N
memories NNS N
, , N
monkeys NNS p
and CC p
humans NNS p
used VBD o
the DT o
escape NN o
option NN o
selectively RB N
when WRB N
more RBR N
indeterminate JJ N
memory NN N
traces NNS N
were VBD N
probed VBN N
. . N

Their PRP$ N
pattern NN N
of IN N
escaping VBG N
always RB N
mirrored VBN N
the DT N
pattern NN N
of IN N
their PRP$ N
primary JJ N
memory NN N
performance NN N
across IN N
serial JJ N
positions NNS N
. . N

Signal-detection NN o
analyses NNS o
confirm VBP N
the DT N
similarity NN N
of IN N
the DT N
animals NNS N
' POS N
and CC N
humans NNS N
' POS N
performances NNS N
. . N

Optimality NNP o
analyses VBZ o
assess VB N
their PRP$ N
efficiency NN o
. . o

Several JJ N
aspects NNS N
of IN N
monkeys NNS N
' POS N
performance NN N
suggest VBP N
the DT N
cognitive JJ N
sophistication NN N
of IN N
their PRP$ N
decisions NNS N
to TO N
escape VB N
. . N

-DOCSTART- -X- O O

FDA NNP N
review NN N
of IN N
a DT N
panitumumab NN i
( ( i
Vectibix NNP i
) ) i
clinical JJ N
trial NN N
for IN N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

On IN N
September NNP N
27 CD N
, , N
2006 CD N
, , N
the DT N
U.S. NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
granted VBD N
accelerated VBD N
approval NN N
to TO N
panitumumab VB i
( ( i
Vectibix NNP i
; : i
Amgen NNP N
, , N
Inc. NNP N
, , N
Thousand NNP N
Oaks NNP N
, , N
CA NNP N
) ) N
for IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
epidermal JJ p
growth NN p
factor NN p
receptor-expressing NN p
, , p
metastatic JJ p
colorectal NN p
carcinoma NN p
with IN p
disease JJ p
progression NN p
on IN p
or CC p
following VBG p
fluoropyrimidine- JJ i
, , i
oxaliplatin- JJ i
, , i
and CC i
irinotecan-containing JJ i
chemotherapy NN i
regimens NNS i
. . i

Accelerated NNP N
approval NN N
was VBD N
based VBN N
on IN N
demonstration NN N
of IN N
a DT N
beneficial JJ N
effect NN N
on IN N
progression-free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
. . N

The DT N
present JJ N
submission NN N
summarizes VBZ N
a DT N
second JJ N
clinical JJ N
trial NN N
, , N
to TO N
be VB N
included VBN N
in IN N
the DT N
panitumumab JJ i
package NN N
insert NN N
in IN N
June NNP N
2008 CD N
, , N
of IN N
chemotherapy NN i
and CC i
bevacizumab NN i
with IN i
and CC i
without IN i
panitumumab NN i
in IN N
the DT N
first-line JJ N
treatment NN N
of IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

The DT N
study NN N
was VBD N
closed VBN N
when WRB N
inferior JJ N
PFS NNP N
and CC N
greater JJR N
toxicity NN N
were VBD N
demonstrated VBN N
at IN N
the DT N
time NN N
of IN N
the DT N
planned VBN N
interim NN N
efficacy NN N
analysis NN N
. . N

Patients NNS p
receiving VBG p
panitumumab NN i
in IN N
combination NN N
with IN N
bevacizumab NN i
and CC i
chemotherapy NN i
experienced VBD N
a DT N
higher JJR N
incidence NN N
of IN N
death NN o
( ( N
9 CD N
% NN N
versus IN N
4 CD N
% NN N
) ) N
and CC N
a DT N
higher JJR N
risk NN N
for IN N
grade NN o
3 CD o
and CC o
4 CD o
toxicities NNS o
than IN N
patients NNS p
receiving VBG p
bevacizumab NN i
and CC i
chemotherapy NN i
alone RB i
. . i

The DT N
incidences NNS o
of IN o
any DT o
Common NNP o
Terminology NNP o
Criteria NNP o
for IN o
Adverse NNP o
Events NNP o
grade VBD o
3 CD o
and CC o
4 CD o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
87 CD N
% NN N
and CC N
72 CD N
% NN N
in IN N
the DT N
panitumumab NN i
and CC N
control NN N
groups NNS N
, , N
respectively RB N
. . N

Grade VB o
3 CD o
and CC o
4 CD o
AEs NNP o
occurring VBG N
more JJR N
commonly RB N
in IN N
panitumumab-treated JJ i
patients NNS N
included VBD N
rash/acneiform NN o
dermatitis NN o
, , o
diarrhea NN o
, , o
dehydration NN o
, , o
primarily RB o
resulting VBG o
from IN o
diarrhea NN o
, , o
hypokalemia NN o
, , o
stomatitis/mucositis NN o
, , o
and CC o
pulmonary JJ o
embolism NN o
. . o

The DT N
addition NN N
of IN N
panitumumab NN i
to TO i
bevacizumab VB i
and CC i
chemotherapy VB i
for IN N
the DT N
first-line JJ N
treatment NN N
of IN N
metastatic JJ p
colorectal NN p
cancer NN p
was VBD N
harmful JJ N
when WRB N
compared VBN N
with IN N
bevacizumab NN i
and CC i
chemotherapy NN i
alone RB i
. . i

The DT N
use NN N
of IN N
panitumumab NN i
in IN N
this DT N
setting NN N
can MD N
not RB N
be VB N
recommended VBN N
. . N

-DOCSTART- -X- O O

Pathological JJ N
features NNS N
and CC N
inhaled JJ N
corticosteroid NN N
response NN N
of IN N
eosinophilic JJ p
and CC p
non-eosinophilic JJ p
asthma NN p
. . p

BACKGROUND NNP N
Non-eosinophilic JJ N
asthma NN N
is VBZ N
a DT N
potentially RB N
important JJ N
clinicopathological JJ N
phenotype NN N
since IN N
there EX N
is VBZ N
evidence NN N
that IN N
it PRP N
responds VBZ N
poorly RB N
to TO N
inhaled VB N
corticosteroid JJ N
therapy NN N
. . N

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
underlying JJ N
airway NN N
immunopathology NN N
and CC N
there EX N
are VBP N
no DT N
data NNS N
from IN N
placebo-controlled JJ N
studies NNS N
examining VBG N
the DT N
effect NN N
of IN N
inhaled JJ N
corticosteroids NNS N
. . N

METHODS NNP N
Airway NNP N
immunopathology NN N
was VBD N
investigated VBN N
using VBG N
induced JJ o
sputum NN o
, , o
bronchial JJ o
biopsies NNS o
, , o
bronchial JJ o
wash NN o
and CC N
bronchoalveolar JJ o
lavage NN o
in IN N
12 CD p
patients NNS p
with IN p
symptomatic JJ p
eosinophilic JJ p
asthma NN p
, , p
11 CD p
patients NNS p
with IN p
non-eosinophilic JJ p
asthma NN p
and CC p
10 CD p
healthy JJ p
controls NNS p
. . p

The DT N
patients NNS p
with IN p
non-eosinophilic JJ p
asthma NN p
and CC p
6 CD p
different JJ p
patients NNS p
with IN p
eosinophilic JJ p
asthma NN p
entered VBD N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
inhaled JJ i
mometasone NN i
400 CD i
microg NN i
once RB N
daily JJ N
for IN N
8 CD N
weeks NNS N
on IN N
airway NN o
responsiveness NN o
and CC N
asthma JJ o
quality NN o
of IN o
life NN o
were VBD N
investigated VBN N
. . N

RESULTS JJ N
Patients NNS p
with IN p
non-eosinophilic JJ p
asthma NN p
had VBD N
absence NN o
of IN o
eosinophils NNS o
in IN o
the DT o
mucosa NN o
( ( N
median JJ N
4.4 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
vs NN N
23 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
0 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
in IN N
normal JJ N
controls NNS N
; : N
p VB N
= $ N
0.03 CD N
) ) N
and CC N
normal JJ N
subepithelial JJ o
layer NN o
thickness NN o
( ( N
5.8 CD N
microm NN N
vs NN N
10.3 CD N
microm NN N
in IN N
eosinophilic JJ N
asthma NN N
and CC N
5.1 CD N
microm NN N
in IN N
controls NNS N
, , N
p VBP N
= RB N
0.002 CD N
) ) N
. . N

Non-eosinophilic JJ p
and CC p
eosinophilic JJ p
asthma NN p
groups NNS p
had VBD N
increased VBN N
mast RB o
cell NN o
numbers NNS o
in IN N
the DT N
airway NN N
smooth JJ N
muscle NN N
compared VBN N
with IN N
normal JJ N
controls NNS N
( ( N
9 CD N
vs RB N
8 CD N
vs NNS N
0 CD N
cells/mm NN N
( ( N
2 CD N
) ) N
, , N
p JJ N
= NNP N
0.016 CD N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
8 CD N
weeks NNS N
of IN N
treatment NN N
with IN N
inhaled JJ N
mometasone NN N
led VBD N
to TO N
less RBR N
improvement NN o
in IN N
methacholine JJ o
PC NN o
( ( o
20 CD o
) ) o
( ( N
0.5 CD N
vs RB N
5.5 CD N
doubling VBG N
concentrations NNS N
, , N
95 CD N
% NN N
CI NNP N
of IN N
difference NN N
1.1 CD N
to TO N
9.1 CD N
; : N
p NN N
= VBZ N
0.018 CD N
) ) N
and CC N
asthma JJ o
quality NN o
of IN o
life NN o
( ( N
0.2 CD N
vs RB N
1.0 CD N
points NNS N
, , N
95 CD N
% NN N
CI NNP N
of IN N
difference NN N
0.27 CD N
to TO N
1.43 CD N
; : N
p NN N
= VBZ N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Non-eosinophilic JJ N
asthma NN N
represents VBZ N
a DT N
pathologically RB N
distinct JJ N
disease NN N
phenotype NN N
which WDT N
is VBZ N
characterised VBN N
by IN N
the DT N
absence NN N
of IN N
airway NN o
eosinophilia NNS o
, , N
normal JJ N
subepithelial JJ o
layer NN o
thickness NN o
and CC N
a DT N
poor JJ N
short-term JJ o
response NN o
to TO o
treatment NN o
with IN N
inhaled JJ N
corticosteroids NNS N
. . N

-DOCSTART- -X- O O

Gamma-hydroxybutyric JJ i
acid NN i
versus NN N
clomethiazole NN i
for IN N
the DT N
treatment NN N
of IN N
alcohol NN o
withdrawal NN o
syndrome NN o
in IN p
a DT p
medical JJ p
intensive JJ p
care NN p
unit NN p
: : p
an DT N
open JJ N
, , N
single-center JJ N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Clomethiazole NNP i
( ( i
CLO NNP i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
treating VBG o
alcohol NN o
withdrawal NN o
syndrome NN o
( ( o
AWS NNP o
) ) o
. . o

Gamma-Hydroxybutyric JJ i
acid NN i
( ( i
GHB NNP i
) ) i
has VBZ N
also RB N
been VBN N
introduced VBN N
in IN N
the DT N
treatment NN N
of IN N
alcoholic JJ N
patients NNS N
and CC N
is VBZ N
effective JJ N
in IN N
surgical JJ N
intensive JJ N
care NN N
unit NN N
( ( N
ICU NNP N
) ) N
patients NNS N
in IN N
preventing VBG N
and CC N
treating VBG N
AWS NNP o
. . o

There EX N
are VBP N
no DT N
comparative JJ N
studies NNS N
between IN N
CLO NNP i
and CC N
GHB NNP i
in IN N
a DT N
medical JJ N
ICU NNP N
setting NN N
. . N

METHODS NNP N
Twenty-six NNP p
alcoholic JJ p
patients NNS p
with IN p
severe JJ p
AWS NNP o
and CC p
concomitant JJ p
medical JJ o
diseases NNS o
were VBD p
randomally RB p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

CLO NNP i
was VBD N
given VBN N
orally RB N
to TO N
12 CD N
patients NNS N
in IN N
a DT N
dosage NN N
of IN N
250 CD N
mg NN N
every DT N
4 CD N
hours NNS N
as IN N
a DT N
liquid NN N
; : N
GHB NNP i
( ( N
initially RB N
30 CD N
mg/kg NNS N
body NN N
weight NN N
( ( N
BW NNP N
) ) N
followed VBN N
by IN N
15 CD N
mg/kg NNS N
BW NNP N
) ) N
was VBD N
administered VBN N
intravenously RB N
to TO N
14 CD N
patients NNS N
. . N

Four CD N
major JJ N
AWS NNP o
symptoms NNS o
( ( o
tremor NN o
, , o
sweating VBG o
, , o
nausea NN o
, , o
restlessness NN o
) ) o
were VBD N
scored VBN N
, , N
and CC N
the DT N
administration NN N
of IN N
additional JJ o
medication NN o
was VBD N
registered VBN N
. . N

RESULTS NNP N
GHB NNP i
was VBD N
more RBR N
effective JJ N
in IN N
treating VBG N
AWS NNP N
symptoms NNS N
. . N

In IN N
the DT N
GHB NNP i
group NN N
, , N
AWS NNP o
score NN o
dropped VBD N
from IN N
6.6 CD N
+/- JJ N
2.6 CD N
to TO N
1.8 CD N
+/- JJ N
2.1 CD N
( ( N
p JJ N
< NNP N
.01 NNP N
) ) N
, , N
while IN N
in IN N
the DT N
CLO NNP i
group NN N
, , N
the DT N
score NN N
dropped VBD N
from IN N
6 CD N
+/- JJ N
2.5 CD N
to TO N
4.1 CD N
+/- JJ N
2.4 CD N
( ( N
n. JJ N
s. NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
significant JJ N
( ( N
p JJ N
=.021 NN N
, , N
two-way JJ N
ANOVA NNP N
) ) N
. . N

The DT N
treatment NN N
did VBD N
not RB N
alter VB N
outcome NN o
or CC N
the DT N
duration NN o
of IN o
ICU NNP o
stay NN o
. . o

No DT o
serious JJ o
side NN o
effects NNS o
were VBD N
detected VBN N
. . N

CONCLUSION NNP N
GHB NNP i
effectively RB N
controls VBZ o
AWS NNP o
symptoms NNS o
in IN N
medical JJ N
ICU NNP N
patients NNS N
. . N

The DT N
rapid JJ N
initial JJ N
treatment NN N
response NN N
of IN N
GHB NNP N
in IN N
contrast NN N
to TO N
CLO NNP i
has VBZ N
no DT N
influence NN N
on IN N
duration NN o
of IN o
patient NN o
withdrawal NN o
. . o

-DOCSTART- -X- O O

The DT N
impact NN N
of IN N
schizophrenic JJ p
patient NN p
functionality NN N
on IN N
service NN o
utilization NN o
and CC o
cost NN o
. . o

Based VBN N
on IN N
a DT N
presentation NN N
by IN N
Sandra NNP N
L. NNP N
Tunis NNP N
, , N
PhD NNP N
. . N

With IN N
the DT N
advent NN N
of IN N
atypical JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
schizophrenia NN N
, , N
physicians NNS N
and CC N
policy NN N
makers NNS N
must MD N
consider VB N
the DT N
costs NNS N
that WDT N
may MD N
accompany VB N
greater JJR N
clinical JJ N
efficacy NN N
. . N

Analyses VBZ N
reveal NN N
that WDT N
olanzapine NN i
shows VBZ N
a DT N
greater JJR N
clinical JJ o
cost NN o
effectiveness NN o
, , N
as RB N
well RB N
as IN N
a DT N
greater JJR N
functional JJ o
cost NN o
effectiveness NN o
, , N
than IN N
haloperidol NN i
, , N
and CC N
that IN N
functional JJ o
outcomes NNS o
, , N
in IN N
particular JJ N
, , N
show VBP N
promise NN N
as IN N
important JJ N
measures NNS N
of IN N
effectiveness NN N
. . N

Functional JJ N
outcomes NNS N
can MD N
help VB N
differentiate VB N
medications NNS N
and CC N
can MD N
be VB N
used VBN N
to TO N
help VB N
demonstrate VB N
the DT N
cost NN o
effectiveness NN o
of IN N
atypical JJ N
agents NNS N
. . N

Mental NNP o
health NN o
and CC o
physical JJ o
health NN o
functioning NN o
, , o
as RB o
well RB o
as IN o
work NN o
status NN o
, , N
are VBP N
all DT N
measures NNS N
of IN N
functioning VBG N
that WDT N
have VBP N
been VBN N
used VBN N
to TO N
evaluate VB N
treatment NN N
strategies NNS N
. . N

When WRB N
comparing VBG N
olanzapine NN i
with IN N
haloperidol NN i
, , N
cost NN o
savings NNS o
are VBP N
seen VBN N
throughout IN N
the DT N
treatment NN N
period NN N
( ( N
1 CD N
year NN N
) ) N
, , N
with IN N
physical JJ o
functioning VBG o
most JJS N
highly RB N
affected VBN N
over IN N
time NN N
. . N

Functional JJ o
outcomes NNS o
can MD N
therefore VB N
serve VB N
2 CD N
purposes NNS N
: : N
to TO N
enhance VB N
compliance NN N
by IN N
improving VBG N
health-related JJ o
quality NN o
of IN o
life NN o
and CC N
to TO N
assist VB N
in IN N
making VBG N
both DT N
treatment NN N
and CC N
formulary JJ N
decisions NNS N
. . N

-DOCSTART- -X- O O

Junctional NNP o
ectopic NN o
tachycardia NN o
after IN N
congenital JJ N
heart NN N
surgery NN N
in IN N
the DT N
current JJ N
surgical JJ N
era NN N
. . N

To TO N
determine VB N
the DT N
incidence NN N
of IN N
postoperative JJ o
junctional JJ o
ectopic NN o
tachycardia NN o
( ( o
JET NNP o
) ) o
in IN N
a DT N
modern JJ p
cohort NN p
of IN p
pediatric JJ p
patients NNS p
, , N
evaluate VBP N
possible JJ N
risk NN o
factors NNS o
for IN o
JET NNP o
, , N
and CC N
examine VB N
the DT N
effects NNS o
of IN o
JET NNP o
on IN N
postoperative JJ o
morbidity NN o
and CC o
mortality NN o
. . o

JET NN N
is VBZ N
common JJ N
after IN N
congenital JJ N
heart NN N
surgery NN N
. . N

JET-related JJ N
mortality NN N
has VBZ N
been VBN N
a DT N
rare JJ N
event NN N
at IN N
our PRP$ N
center NN N
, , N
which WDT N
is VBZ N
different JJ N
from IN N
previous JJ N
reports NNS N
. . N

We PRP N
reviewed VBD N
records NNS N
for IN N
pediatric JJ p
patients NNS p
who WP p
had VBD p
postoperative JJ p
arrhythmias NN p
between IN p
January NNP p
2006 CD p
and CC p
June NNP p
2010 CD p
at IN p
a DT p
large JJ p
tertiary-care JJ p
children NNS p
's POS p
hospital NN p
. . p

We PRP N
performed VBD N
a DT N
matched VBN N
case-control NN N
study NN N
to TO N
identify VB N
risk NN N
factors NNS N
for IN N
JET NNP N
and CC N
a DT N
matched-cohort NN N
study NN N
to TO N
compare VB N
outcomes NNS N
between IN N
patients NNS N
and CC N
controls NNS N
. . N

Whenever NNP N
possible JJ N
, , N
each DT N
JET NNP N
case NN N
was VBD N
randomly RB N
matched VBN N
to TO N
two CD N
controls NNS N
on IN N
the DT N
basis NN N
of IN N
lesion NN N
, , N
repair NN N
, , N
and CC N
surgical JJ N
period NN N
. . N

We PRP N
identified VBD N
54 CD p
patients NNS p
with IN p
JET NNP p
( ( N
incidence NN N
= RB N
1.4 CD N
% NN N
) ) N
. . N

After IN N
multivariate JJ N
logistic JJ N
regression NN N
analysis NN N
, , N
low JJ o
operative JJ o
weight NN o
, , o
cardiopulmonary JJ o
bypass NN o
( ( o
CPB NNP o
) ) o
duration NN o
> $ N
100 CD N
min NN N
, , N
and CC N
immediate JJ o
postoperative JJ o
serum NN o
lactic JJ o
acid NN o
level NN o
> VBD N
20 CD N
mg/dl NNS N
were VBD N
associated VBN N
with IN N
increased JJ N
odds NNS N
of IN N
developing VBG N
JET NNP N
. . N

Patients NNS p
with IN p
JET NNP i
had VBD N
longer RBR N
mechanical JJ o
ventilation NN o
time NN o
, , o
cardiac JJ o
intensive JJ o
care NN o
unit NN o
( ( o
CICU NNP o
) ) o
stay NN o
, , o
and CC o
hospital NN o
stay NN o
. . o

There EX N
was VBD N
only RB N
one CD N
death NN o
in IN N
JET NNP N
group NN N
( ( N
1.8 CD N
% NN N
) ) N
with IN N
no DT N
significant JJ N
difference NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

JET NNP N
remains VBZ N
a DT N
relatively RB N
common JJ N
postoperative JJ o
arrhythmia NN o
, , N
but CC N
it PRP N
is VBZ N
less RBR N
frequent JJ N
than IN N
previously RB N
reported VBN N
. . N

JET NNP N
occurs VBZ N
more JJR N
commonly RB N
in IN N
smaller JJR p
patients NNS p
with IN p
longer JJR p
CPB NNP p
runs NNS N
and CC N
significant JJ N
postoperative JJ o
lactic JJ o
acidosis NN o
levels NNS o
. . o

Mortality NNP o
associated VBD N
with IN N
JET NNP N
is VBZ N
lower JJR N
than IN N
historically RB N
reported VBN N
, , N
but CC N
morbidity NN o
remains VBZ N
high JJ N
. . N

-DOCSTART- -X- O O

Eye NNP N
movements NNS N
affirm NN N
: : N
automatic JJ o
overt NN o
gaze NN o
and CC o
arrow NN o
cueing NN o
for IN N
typical JJ p
adults NNS p
and CC p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

People NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
show NN N
reduced VBN N
interest NN o
towards NNS N
social JJ o
aspects NNS o
of IN o
the DT o
environment NN o
and CC N
a DT N
lesser JJR N
tendency NN o
to TO N
follow VB o
other JJ o
people NNS o
's POS o
gaze NN o
in IN N
the DT N
real JJ N
world NN N
. . N

However RB N
, , N
most JJS N
studies NNS N
have VBP N
shown VBN N
that IN N
people NNS p
with IN p
ASD NNP p
do VBP N
respond VB N
to TO N
eye-gaze JJ N
cues NNS N
in IN N
experimental JJ N
paradigms NN N
, , N
though IN N
it PRP N
is VBZ N
possible JJ N
that IN N
this DT N
behaviour NN N
is VBZ N
based VBN N
on IN N
an DT N
atypical JJ N
strategy NN N
. . N

We PRP N
tested VBD N
this DT N
possibility NN N
in IN N
adults NNS p
with IN p
ASD NNP p
using VBG N
a DT N
cueing NN i
task NN i
combined VBN i
with IN i
eye-movement JJ i
recording NN i
. . i

Both DT N
eye NN N
gaze NN N
and CC N
arrow VB N
pointing VBG N
distractors NNS N
resulted VBD N
in IN N
overt JJ o
cueing NN o
effects NNS o
, , N
both DT N
in IN N
terms NNS N
of IN N
increased VBN o
saccadic JJ o
reaction NN o
times NNS o
, , N
and CC N
in IN N
proportions NNS o
of IN o
saccades NNS o
executed VBN o
to TO o
the DT o
cued VBN o
direction NN o
instead RB o
of IN o
to TO o
the DT o
target NN o
, , N
for IN N
both DT N
participant JJ N
groups NNS N
. . N

Our PRP$ N
results NNS N
confirm VBP N
previous JJ N
reports NNS N
that IN N
eye NN N
gaze NN N
cues NNS N
as RB N
well RB N
as IN N
arrow NN N
cues NNS N
result VBP N
in IN N
automatic JJ o
orienting NN o
of IN o
overt JJ o
attention NN o
. . o

Moreover RB N
, , N
since IN N
there EX N
were VBD N
no DT N
group NN N
differences VBZ N
between IN N
arrow NN N
and CC N
eye NN N
gaze NN N
cues NNS N
, , N
we PRP N
conclude VBP N
that IN N
overt JJ o
attentional JJ o
orienting NN o
in IN N
ASD NNP N
, , N
at IN N
least JJS N
in IN N
response NN N
to TO N
centrally RB N
presented VBN N
schematic JJ N
directional JJ N
distractors NNS N
, , N
is VBZ N
typical JJ N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
venous JJ N
thromboembolism NN N
after IN N
knee NN p
arthroplasty NN p
. . p

A DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
comparing VBG N
enoxaparin NN i
with IN N
warfarin NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
fixed-dose JJ i
enoxaparin NN i
and CC N
adjusted VBD i
dose JJ i
warfarin NN i
in IN N
preventing VBG N
venous JJ N
thromboembolism NN N
after IN p
knee NN p
arthroplasty NN p
. . p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
8 CD p
university NN p
hospitals NNS p
. . p

PATIENTS VB N
670 CD p
consecutive JJ p
patients NNS p
who WP p
had VBD p
knee VBN p
arthroplasty RB p
. . p

INTERVENTION NN N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
enoxaparin NN i
( ( i
30 CD i
mg NN i
subcutaneously RB i
every DT i
12 CD i
hours NNS i
) ) i
or CC i
adjusted-dose JJ i
warfarin NN i
( ( i
international JJ i
normalized VBN i
ratio NN i
, , i
2.0 CD i
to TO i
3.0 CD i
) ) i
. . N

Both DT N
regimens NNS N
were VBD N
started VBN N
after IN N
surgery NN N
. . N

MEASUREMENTS PDT N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
incidence NN o
of IN o
deep JJ o
venous JJ o
thrombosis NN o
in IN N
patients NNS p
with IN p
adequate JJ p
bilateral JJ p
venograms NNS p
; : p
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
hemorrhage NN o
. . o

RESULTS NNP N
Among IN N
the DT N
417 CD p
patients NNS p
with IN p
adequate JJ p
venograms NNS p
, , N
109 CD N
of IN N
211 CD N
warfarin NN i
recipients NNS N
( ( N
51.7 CD N
% NN N
) ) N
had VBD N
deep JJ o
venous JJ o
thrombosis NN o
compared VBN N
with IN N
76 CD N
of IN N
206 CD N
enoxaparin NN i
recipients NNS N
( ( N
36.9 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
14.8 CD N
% NN N
in IN N
favor NN N
of IN N
enoxaparin NN i
( ( N
95 CD N
% NN N
Cl NNP N
, , N
5.3 CD N
% NN N
to TO N
24.1 CD N
% NN N
) ) N
Twenty-two NNP N
warfarin NN i
recipients NNS N
( ( N
10.4 CD N
% NN N
) ) N
and CC N
24 CD N
enoxaparin NN i
recipients NNS N
( ( N
11.7 CD N
% NN N
) ) N
had VBD N
proximal JJ N
venous JJ N
thrombosis NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
1.2 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN i
( ( N
Cl NNP N
, , N
-7.2 NNP N
% NN N
to TO N
4.8 CD N
% NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
major JJ o
bleeding NN o
was VBD N
1.8 CD N
% NN N
( ( N
6 CD N
of IN N
334 CD N
patients NNS N
) ) N
in IN N
the DT N
warfarin NN N
group NN N
and CC N
2.1 CD N
% NN N
( ( N
7 CD N
of IN N
336 CD N
patients NNS N
) ) N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
0.3 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN N
( ( N
Cl NNP N
, , N
-2.4 NNP N
% NN N
to TO N
1.8 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
A DT N
postoperative JJ N
, , N
fixed-dose JJ N
enoxaparin NN i
regimen NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
adjusted-dose JJ N
warfarin NN i
in IN N
preventing VBG N
deep JJ N
venous JJ N
thrombosis NN N
after IN p
knee NN p
arthroplasty NN p
. . p

No DT N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
incidence NN N
of IN N
proximal JJ N
venous JJ N
thrombosis NN N
or CC N
clinically RB N
overt JJ N
hemorrhage NN N
. . N

-DOCSTART- -X- O O

Long-term JJ N
follow-up NN N
of IN N
cytostatic JJ i
intravesical JJ i
instillation NN i
in IN N
patients NNS p
with IN p
superficial JJ p
bladder NN p
carcinoma NN p
. . p

Is VBZ N
short-term JJ N
, , N
intensive JJ N
instillation NN N
better RBR N
than IN N
maintenance NN N
therapy NN N
? . N
OBJECTIVES NNP N
Comparisons NNPS N
of IN N
two CD N
3-year JJ N
protocols NNS N
, , N
one CD N
20-week JJ N
protocol NN N
of IN N
mitomycin NN i
C NNP i
instillation NN i
and CC N
one CD N
3-year JJ N
protocol NN N
of IN N
doxorubicin JJ i
instillation NN i
for IN N
the DT N
prevention NN N
of IN N
recurrent NN o
tumors NNS o
and CC N
progression NN o
in IN N
patients NNS p
whose WP$ p
superficial JJ p
bladder NN p
tumors NNS p
had VBD p
been VBN p
removed VBN p
by IN p
transurethral JJ p
resection NN p
. . p

METHODS NNP N
A NNP N
prospective JJ N
, , N
randomized JJ N
parallel NN N
group NN N
multicenter RBR N
trial NN N
was VBD N
conducted VBN N
. . N

419 CD p
patients NNS p
were VBD p
evaluated VBN p
after IN p
a DT p
median JJ p
follow-up NN p
of IN p
57 CD p
months NNS p
. . p

Cox NNP N
proportional JJ N
hazards NNS N
analysis NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
An DT N
overall JJ o
recurrence NN o
rate NN o
of IN N
22.7 CD N
% NN N
and CC N
an DT N
overall JJ o
progression NN o
rate NN o
of IN N
9.8 CD N
% NN N
was VBD N
found VBN N
. . N

For IN N
time NN N
to TO N
progression VB N
a DT N
significant JJ N
overall JJ o
treatment NN o
effect NN o
was VBD N
detected VBN N
dependent NN N
on IN N
the DT N
recurrence NN N
status NN N
before IN N
entry NN N
into IN N
the DT N
study NN N
( ( N
p JJ N
= NNP N
0.0059 CD N
) ) N
. . N

Pairwise VB N
comparisons NNS N
showed VBD N
the DT N
mitomycin NN N
protocol NN N
with IN N
short-term JJ N
intensive JJ N
( ( N
weekly JJ N
) ) N
combined VBN N
with IN N
long-term JJ N
maintenance NN N
instillation NN N
to TO N
have VB N
a DT N
highly RB N
beneficial JJ o
effect NN o
compared VBN N
to TO N
long-term JJ N
maintenance NN N
instillation NN N
only RB N
especially RB N
for IN N
patients NNS N
entering VBG N
the DT N
study NN N
with IN N
recurrent JJ N
tumors NNS N
( ( N
RR NNP N
= NNP N
0.06 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
[ NN N
0.008 CD N
, , N
0.506 CD N
] NN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
show VBP N
that IN N
intensive JJ o
therapeutic JJ o
instillation NN o
may MD N
have VB N
an DT N
advantage NN N
over IN N
less JJR N
intensive JJ N
, , N
prophylactic JJ N
regimens NNS N
. . N

-DOCSTART- -X- O O

Satisfactory JJ N
sampling NN N
in IN N
cytological JJ p
cervical JJ p
diagnosis NN p
: : p
comparison NN N
between IN N
a DT N
conventional JJ i
and CC i
a DT i
new JJ i
sampling NN i
device NN i
. . i

AIM NNP N
Inadequate NNP N
cervical JJ N
sampling NN N
is VBZ N
the DT N
most RBS N
frequent JJ N
cause NN N
of IN N
misdiagnosis NN N
in IN N
cervical JJ p
cancer NN p
screening NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
ability NN N
of IN N
PapCone? NNP i
versus IN i
the DT i
conventional JJ i
sampling NN i
method NN i
( ( i
Ayre NNP i
's POS i
spatula NN i
plus CC i
cytobrush NN i
) ) i
to TO N
collect VB N
ectocervical JJ N
and CC N
glandular JJ N
cells NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN p
18 CD p
healthy JJ p
women NNS p
, , p
two CD p
ecto-endocervical JJ p
samples NNS p
, , p
obtained VBN p
by IN p
two CD p
different JJ p
methods NNS p
, , p
were VBD p
obtained VBN p
at IN p
a DT p
three-month JJ p
interval NN p
. . p

Qualitative JJ N
and CC N
quantitative JJ N
parameters NNS N
were VBD N
evaluated VBN N
. . N

Ultrastructure NN o
features NNS o
of IN o
sampling VBG o
devices NNS o
were VBD N
analyzed VBN N
by IN N
scanning VBG N
electron NN N
microscopy NN N
( ( N
SEM NNP N
) ) N
before IN N
and CC N
after IN N
sampling VBG N
. . N

RESULTS VB N
The DT N
? . N
( ( N
2 CD N
) ) N
test NN N
revealed VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
: : N
PapCone? NNP N
caused VBD N
less JJR o
cell NN o
overlap NN o
and CC o
sampled VBD N
less JJR o
white JJ o
blood NN o
cells NNS o
( ( o
p JJ o
< NNP N
0.05 CD N
) ) N
and CC N
more RBR o
metaplastic JJ o
cells NNS o
( ( o
p JJ o
< NNP N
0.01 CD N
) ) N
. . N

SEM NNP N
evaluation NN o
highlighted VBD o
the DT N
porous JJ N
and CC N
spongy JJ N
structure NN N
of IN N
PapCone? NNP N
that WDT N
was VBD N
responsible JJ N
for IN N
the DT N
large JJ N
number NN N
of IN N
glandular JJ N
cells NNS N
on IN N
its PRP$ N
surface NN N
. . N

CONCLUSION NNP N
Cervical NNP N
smears NNS N
performed VBN N
by IN N
PapCone? NNP N
were VBD N
adequate JJ N
and CC N
generally RB N
easier JJR N
to TO N
screen VB N
than IN N
conventionally RB N
performed VBN N
ones NNS N
. . N

-DOCSTART- -X- O O

Analgesic JJ o
efficacy NN o
of IN N
piroxicam NN i
in IN N
the DT N
treatment NN N
of IN N
postoperative JJ o
pain NN o
. . o

Two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
single-dose JJ N
studies NNS N
were VBD N
conducted VBN N
to TO N
assess VB N
the DT N
analgesic JJ o
efficacy NN o
and CC o
safety NN o
of IN N
piroxicam NN i
for IN N
the DT N
treatment NN N
of IN N
moderate JJ o
or CC o
severe JJ o
postoperative JJ o
pain NN o
. . o

Study NNP N
1 CD N
evaluated VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
piroxicam NN i
20 CD N
mg NN N
compared VBN N
with IN N
that DT N
of IN N
codeine NN i
sulfate NN i
60 CD N
mg NN N
and CC i
placebo NN i
. . i

A DT p
final JJ p
patient NN p
population NN p
of IN p
149 CD p
subjects NNS p
rated VBN N
pain JJ o
intensity NN o
and CC o
pain NN o
relief NN o
at IN N
one CD N
half NN N
hour NN N
and CC N
one CD N
hour NN N
following VBG N
treatment NN N
and CC N
then RB N
hourly RB N
for IN N
six CD N
hours NNS N
, , N
with IN N
a DT N
global JJ N
assessment NN N
made VBN N
at IN N
the DT N
completion NN N
of IN N
24 CD N
hours NNS N
. . N

Piroxicam NNP i
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
efficacious JJ o
than IN N
placebo NN i
for IN N
all DT N
analgesic JJ N
variables NNS N
, , N
including VBG N
the DT N
sum NN o
of IN o
the DT o
pain NN o
intensity NN o
differences NNS o
( ( o
SPID NNP o
) ) o
, , o
total JJ o
pain NN o
relief NN o
( ( o
TOTAL NNP o
) ) o
, , o
percent JJ o
SPID NNP o
, , o
duration NN o
of IN o
effect NN o
, , o
and CC o
time NN o
to TO o
remedication NN o
. . o

Codeine VB i
60 CD N
mg NN N
was VBD N
significantly RB N
superior JJ N
to TO N
placebo VB i
for IN N
percent NN o
SPID NNP o
and CC N
some DT N
hourly JJ N
measures NNS N
. . N

Piroxicam NNP i
20 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
codeine VBP i
60 CD N
mg NN N
for IN N
percent NN o
SPID NNP o
and CC N
a DT N
few JJ N
hourly JJ N
measures NNS N
including VBG N
time NN N
to TO N
remedication NN N
. . N

Study NNP N
2 CD N
assessed VBD N
the DT N
efficacy NN o
of IN N
piroxicam NN i
20 CD N
mg NN N
or CC N
40 CD N
mg NNS N
compared VBN N
with IN N
aspirin JJ i
648 CD N
mg NN N
and CC N
placebo NN i
. . i

Sixty CD p
patients NNS p
rated VBN N
their PRP$ N
pain NN o
intensity NN o
and CC o
relief NN o
hourly RB N
for IN N
12 CD N
hours NNS N
and CC N
at IN N
24 CD N
hours NNS N
after IN N
administration NN N
of IN N
study JJ N
medication NN N
. . N

Both DT N
doses NNS N
of IN N
piroxicam NN i
were VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
placebo NN N
from IN N
Hours $ N
2 CD N
to TO N
12 CD N
for IN N
pain NN o
intensity NN o
difference NN o
( ( o
PID NNP o
) ) o
and CC o
relief NN o
scores NNS o
, , o
as RB o
well RB o
as IN o
for IN o
SPID NNP o
and CC o
TOTAL NNP o
. . o

Aspirin NNP N
was VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
placebo NN i
from IN N
Hours $ N
2 CD N
to TO N
8 CD N
for IN N
relief NN o
and CC N
Hours $ N
2 CD N
to TO N
10 CD N
for IN N
PID NNP o
as RB o
well RB o
as IN o
SPID NNP o
and CC o
TOTAL NNP o
. . o

Piroxicam NNP i
40 CD N
mg NN N
was VBD N
significantly RB N
more RBR N
effective JJ o
than IN N
aspirin RB i
648 CD N
mg NN N
for IN N
SPID NNP o
, , o
TOTAL NNP o
, , o
and CC o
hourly RB o
measures NNS o
beginning VBG N
with IN N
Hour NNP N
6 CD N
through IN N
Hour NNP N
12 CD N
. . N

Piroxicam VB i
20 CD N
mg NN N
was VBD N
significantly RB N
better JJR N
than IN N
aspirin NN i
for IN N
a DT N
few JJ N
hourly JJ N
measures NNS N
: : N
Hours $ N
7 CD N
to TO N
9 CD N
for IN N
relief NN N
and CC N
Hour $ N
7 CD N
for IN N
PID NNP o
. . o

In IN N
addition NN N
, , N
effects NNS N
of IN N
piroxicam NN N
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR o
duration NN o
than IN N
aspirin NN N
. . N

Similarly RB N
, , N
piroxicam VBD i
20 CD N
mg NN N
had VBD N
a DT N
significantly RB N
longer JJR o
time NN o
to TO o
remedication VB o
compared VBN N
with IN N
aspirin NN i
and CC N
placebo NN i
. . N

The DT N
results NNS N
of IN N
these DT N
studies NNS N
provide VBP N
evidence NN N
in IN N
support NN N
of IN N
the DT N
longer JJR N
duration NN o
of IN o
analgesic JJ o
efficacy NN o
of IN N
piroxicam NNS i
compared VBN N
with IN N
codeine NN i
or CC i
aspirin NN i
in IN N
patients NNS p
with IN p
postoperative JJ o
pain NN o
. . o

-DOCSTART- -X- O O

Treatment NN N
of IN N
posterior JJ p
uveitis NN p
with IN N
a DT N
fluocinolone NN i
acetonide NN i
implant NN i
: : i
three-year JJ N
clinical JJ N
trial NN N
results NNS N
. . N

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
0.59-mg JJ N
and CC N
2.1-mg JJ N
fluocinolone NN i
acetonide NN i
( ( N
FA NNP N
) ) N
intravitreous JJ N
implants NNS N
in IN N
noninfectious JJ p
posterior JJ p
uveitis NN p
. . p

DESIGN VB N
A DT N
3-year JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
historically RB N
controlled VBN N
trial NN N
of IN N
the DT N
0.59-mg JJ i
FA NNP i
intravitreous JJ i
implant NN i
in IN p
110 CD p
patients NNS p
and CC p
the DT p
2.1-mg JJ p
FA NNP p
intravitreous JJ p
implant NN p
in IN p
168 CD p
patients NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Recurrence NNP o
rate NN o
, , o
vision NN o
, , o
and CC o
complications NNS o
. . o

RESULTS NNP N
Uveitis NNP o
recurrence NN o
was VBD o
reduced VBN o
in IN N
implanted JJ N
eyes NNS N
from IN N
62 CD N
% NN N
( ( N
during IN N
the DT N
1-year JJ N
preimplantation NN N
period NN N
) ) N
to TO N
4 CD N
% NN N
, , N
10 CD N
% NN N
, , N
and CC N
20 CD N
% NN N
during IN N
the DT N
1- JJ N
, , N
2- JJ N
, , N
and CC N
3-year JJ N
postimplantation NN N
periods NNS N
, , N
respectively RB N
, , N
for IN N
the DT N
0.59-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
from IN N
58 CD N
% NN N
to TO N
7 CD N
% NN N
, , N
17 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
the DT N
2.1-mg JJ N
dose NN N
group NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

More RBR N
implanted JJ N
eyes NNS N
than IN N
nonimplanted JJ N
eyes NNS N
had VBD N
improved VBN o
visual JJ o
acuity NN o
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Implanted VBN o
eyes NNS o
had VBD o
higher JJR o
incidences NNS o
of IN o
intraocular JJ o
pressure NN o
elevation NN o
( ( N
> CD N
or CC N
= VB N
10 CD N
mm NNS N
Hg NNP N
) ) N
than IN N
nonimplanted VBN N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
and CC N
glaucoma NN o
surgery NN o
was VBD N
required VBN N
in IN N
40 CD N
% NN N
of IN N
implanted JJ N
eyes NNS N
vs VBP N
2 CD N
% NN N
of IN N
nonimplanted JJ N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Cataracts NNPS o
were VBD N
extracted VBN N
in IN N
93 CD N
% NN N
of IN N
phakic NN N
implanted VBN N
eyes NNS N
vs VBP N
20 CD N
% NN N
of IN N
phakic NN N
nonimplanted VBN N
eyes NNS N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
FA NNP N
implant NN N
significantly RB N
reduced VBN o
uveitis JJ o
recurrence NN o
and CC o
improved VBD o
or CC o
stabilized VBN o
visual JJ o
acuity NN o
in IN N
subjects NNS p
with IN p
noninfectious JJ p
posterior JJ p
uveitis NN p
. . p

Most JJS N
subjects NNS N
required VBN N
cataract JJ o
extraction NN o
, , N
and CC N
a DT N
significant JJ N
proportion NN N
required VBN N
intraocular JJ o
pressure-lowering JJ o
surgery NN o
. . o

APPLICATION NNP N
TO NNP N
CLINICAL NNP N
PRACTICE NNP N
The DT N
FA NNP N
implant NN N
provides VBZ N
an DT N
alternative JJ N
therapy NN N
for IN N
prolonged JJ N
control NN N
of IN N
inflammation NN N
in IN N
noninfectious JJ N
posterior JJ N
uveitis NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00407082 NN N
. . N

-DOCSTART- -X- O O

Chemotherapy NN i
with IN i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
and CC i
prednisone VB i
alone RB i
or CC i
with IN i
levamisole JJ i
or CC i
with IN i
levamisole JJ i
plus CC i
BCG NNP i
for IN i
malignant JJ N
lymphoma NN N
: : N
a DT N
Southwest NNP N
Oncology NNP N
Group NNP N
Study NNP N
. . N

Between NNP N
1977 CD N
and CC N
1983 CD N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
( ( N
SWOG NNP N
) ) N
evaluated VBD N
chemotherapy NN i
alone RB i
( ( i
cyclophosphamide JJ i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
prednisone NN i
; : i
CHOP NNP i
) ) i
or CC N
chemoimmunotherapy NN i
( ( i
CHOP-levamisole JJ i
or CC i
CHOP-levamisole-BCG JJ i
) ) i
in IN N
a DT N
randomized JJ N
prospective JJ N
clinical JJ N
trial NN N
involving VBG N
715 CD p
eligible JJ p
patients NNS p
with IN p
all DT p
types NNS p
of IN p
malignant JJ p
lymphoma NN p
( ( p
ML NNP p
) ) p
. . p

Of IN N
281 CD p
evaluable JJ p
patients NNS p
with IN p
favorable JJ p
histologic JJ p
types NNS p
of IN p
ML NNP p
, , N
171 CD N
( ( N
61 CD N
% NN N
) ) N
achieved VBD N
complete JJ o
remission NN o
( ( o
CR NNP o
) ) o
and CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
CR NNP o
rate NN o
, , o
CR NNP o
duration NN o
, , o
or CC o
survival NN o
according VBG N
to TO N
the DT N
type NN N
of IN N
initial JJ N
treatment NN N
. . N

Of IN N
388 CD p
evaluable JJ p
patients NNS p
with IN p
unfavorable JJ p
histologic JJ p
types NNS p
of IN p
ML NNP p
, , N
194 CD N
( ( N
50 CD N
% NN N
) ) N
achieved VBD N
CR NNP o
. . o

Levamisole NNP i
appeared VBD N
to TO N
adversely RB N
affect VB N
CR NNP o
rates NNS o
in IN N
nodular JJ N
mixed JJ N
and CC N
nodular JJ N
large-cell NN N
lymphoma NN N
and CC N
CR NNP o
duration NN o
in IN N
patients NNS N
with IN N
unfavorable JJ N
histology NN N
ML NNP N
. . N

Chemoimmunotherapy NNP i
with IN i
levamisole JJ i
or CC i
levamisole-BCG JJ i
offers NNS N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
CR NNP o
rates NNS o
, , o
CR NNP o
duration NN o
, , o
or CC o
survival NN o
compared VBN N
to TO N
CHOP NNP i
chemotherapy NN i
alone RB N
, , N
and CC N
levamisole NN i
may MD N
have VB N
had VBD N
an DT N
adverse JJ N
impact NN N
on IN N
outcome NN N
in IN N
certain JJ N
subtypes NNS N
of IN N
ML NNP N
. . N

-DOCSTART- -X- O O

Greater NNP N
knowledge NN o
gain NN o
with IN N
structured VBN i
than IN N
student-directed JJ i
learning NN i
in IN N
Child NNP p
Health NNP p
: : p
cluster NN N
randomized VBD N
trial NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
detect VB N
a DT N
difference NN N
in IN N
knowledge NN o
gain NN o
between IN N
students NNS p
receiving VBG p
structured JJ i
versus NN i
student-directed JJ i
learning NN i
for IN p
the DT p
two-week JJ p
Child NNP p
Health NNP p
outpatient NN p
module NN p
. . p

A DT p
total NN p
of IN p
138 CD p
phase NN p
3 CD p
( ( p
year NN p
4 CD p
) ) p
medical JJ p
students NNS p
in IN p
10 CD p
two-week JJ p
paediatric JJ p
outpatient NN p
blocks NNS p
at IN p
the DT p
Department NNP p
of IN p
Child NNP p
Health NNP p
, , p
University NNP p
of IN p
Dundee NNP p
, , p
Scotland NNP p
, , N
were VBD N
randomized VBN N
to TO N
student-directed JJ i
or CC i
structured VBN i
learning NN i
between IN N
January NNP N
and CC N
December NNP N
2002 CD N
. . N

Pre- JJ o
and CC o
post-course JJ o
tests NNS o
were VBD N
administered VBN N
at IN N
the DT N
start NN N
and CC N
the DT N
end NN N
of IN N
the DT N
attachment NN N
; : N
129 CD p
students NNS p
sat VBD p
both DT p
tests NNS p
. . p

Results NNS N
are VBP N
presented VBN N
as IN N
mean JJ N
scores NNS N
with IN N
standard JJ N
deviations NNS N
or CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CI NNP N
) ) N
in IN N
parentheses NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
gain NN o
in IN o
knowledge NN o
of IN N
the DT N
Child NNP N
Health NNP N
core NN N
curriculum NN N
that WDT N
is VBZ N
covered VBN N
in IN N
the DT N
outpatient JJ N
setting NN N
. . N

Although IN N
pre-course JJ o
scores NNS o
were VBD N
similar JJ N
( ( N
student-directed JJ N
25.3 CD N
( ( N
7.3 CD N
) ) N
; : N
structured VBN N
24.8 CD N
( ( N
7.5 CD N
) ) N
) ) N
the DT N
structured JJ N
approach NN N
resulted VBD N
in IN N
higher JJR N
post-course NN o
scores NNS o
in IN N
comparison NN N
with IN N
the DT N
student-directed JJ N
approach NN N
( ( N
student-directed JJ N
41.8 CD N
( ( N
9.4 CD N
) ) N
; : N
structured VBN N
53.8 CD N
( ( N
8.8 CD N
) ) N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

Knowledge NNP o
gain NN o
showed VBD N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
learning NN N
approaches NNS N
( ( N
student-directed JJ N
16.5 CD N
( ( N
3.7 CD N
) ) N
; : N
structured VBN N
29.1 CD N
( ( N
3.8 CD N
) ) N
, , N
difference NN N
= VBD N
12.6 CD N
( ( N
95 CD N
% NN N
CI NNP N
11.3 CD N
to TO N
13.9 CD N
) ) N
) ) N
. . N

Low JJ N
pre-course JJ o
scores NNS o
or CC N
gender VB N
did VBD N
not RB N
affect VB N
knowledge NN o
gain NN o
. . o

In IN N
the DT N
Child NNP N
Health NNP N
outpatient NN N
setting NN N
, , N
the DT N
'traditional NNP N
' POS N
structured JJ N
approach NN N
led VBD N
to TO N
significantly RB N
greater JJR N
knowledge NN o
gain NN o
in IN N
comparison NN N
with IN N
the DT N
'novel NNP N
' POS N
student-directed JJ N
approach NN N
. . N

The DT N
findings NNS N
emphasize VBP N
the DT N
importance NN N
of IN N
careful JJ N
evaluation NN N
of IN N
novel JJ N
medical JJ N
education NN N
strategies NNS N
before IN N
their PRP$ N
implementation NN N
in IN N
medical JJ N
schools NNS N
, , N
and CC N
the DT N
need NN N
for IN N
further JJ N
research NN N
to TO N
define VB N
the DT N
effective JJ N
methods NNS N
for IN N
delivering VBG N
medical JJ N
education NN N
in IN N
Child NNP N
Health NNP N
. . N

-DOCSTART- -X- O O

Randomized VBN N
Phase NNP N
II NNP N
trial NN N
assessing VBG N
estramustine NN i
and CC i
vinblastine JJ i
combination NN i
chemotherapy NN i
vs JJ i
estramustine NN i
alone RB i
in IN N
patients NNS p
with IN p
progressive JJ p
hormone-escaped JJ p
metastatic JJ p
prostate NN p
cancer NN p
. . p

Based VBN N
on IN N
the DT N
results NNS N
of IN N
combined JJ N
data NNS N
from IN N
three CD N
North JJ N
American JJ N
Phase NNP N
II NNP N
studies NNS N
, , N
a DT N
randomised JJ N
Phase NNP N
II NNP N
study NN N
in IN N
the DT N
same JJ N
patient JJ N
population NN N
was VBD N
performed VBN N
, , N
using VBG N
combination NN N
chemotherapy NN i
with IN i
estramustine JJ i
phosphate NN i
( ( i
EMP NNP i
) ) i
and CC i
vinblastine NN i
( ( i
VBL NNP i
) ) i
in IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
patients NNS N
. . N

In IN N
all DT N
, , N
92 CD p
patients NNS p
were VBD p
randomised VBN p
into IN p
a DT p
Phase NNP p
II NNP p
study NN p
of IN N
oral JJ i
EMP NNP i
( ( i
10 CD i
mg NNS i
kg JJ i
day NN i
continuously RB i
) ) i
or CC i
oral JJ i
EMP NNP i
in IN i
combination NN i
with IN i
intravenous JJ i
VBL NNP i
( ( N
4 CD N
mg NN N
m NN N
( ( N
2 CD N
) ) N
week NN N
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
2 CD N
weeks NNS N
rest NN N
) ) N
. . N

The DT N
end NN N
points NNS N
were VBD N
toxicity NN o
and CC o
PSA NNP o
response NN o
in IN N
both DT N
groups NNS N
, , N
with IN N
the DT N
option NN N
to TO N
continue VB N
the DT N
trial NN N
as IN N
a DT N
Phase NNP N
III NNP N
study NN N
with IN N
time NN o
to TO o
progression NN o
and CC N
survival NN o
as IN N
end NN N
points NNS N
, , N
if IN N
sufficient JJ N
responses NNS N
were VBD N
observed VBN N
. . N

Toxicity NNP o
was VBD N
unexpectedly RB N
high JJ N
in IN N
both DT N
treatment NN N
arms NNS N
and CC N
led VBD N
to TO N
treatment NN N
withdrawal NN N
or CC N
refusal NN N
in IN N
49 CD N
% NN N
of IN N
all DT N
patients NNS N
, , N
predominantly RB N
already RB N
during IN N
the DT N
first JJ N
treatment NN N
cycle NN N
. . N

The DT N
mean JJ o
treatment NN o
duration NN o
was VBD N
10 CD N
and CC N
14 CD N
weeks NNS N
, , N
median JJ o
time NN o
to TO o
PSA NNP o
progression NN o
was VBD N
27.2 CD N
and CC N
30.8 CD N
weeks NNS N
, , N
median JJ o
survival NN o
time NN o
was VBD N
44 CD N
and CC N
50.9 CD N
weeks NNS N
, , N
and CC N
PSA NNP o
response NN o
rate NN o
was VBD N
only RB N
24.6 CD N
and CC N
28.9 CD N
% NN N
in IN N
the DT N
EMP/VBL NNP i
and CC N
EMP NNP i
arms NNS N
, , N
respectively RB N
. . N

There EX N
was VBD N
no DT N
correlation NN N
between IN N
PSA NNP o
response NN o
and CC o
survival NN o
. . o

While IN N
the DT N
PSA NNP o
response NN o
in IN N
the DT N
patients NNS N
tested VBD N
was VBD N
less JJR N
than IN N
half NN N
that WDT N
recorded VBD N
in IN N
the DT N
North JJ N
American JJ N
studies NNS N
, , N
the DT N
toxicity NN o
of IN o
EMP NNP o
monotherapy NN o
or CC N
in IN N
combination NN N
with IN N
VBL NNP i
was VBD N
much RB N
higher JJR N
than IN N
expected VBN N
. . N

Further NNP N
research NN N
on IN N
more RBR N
effective JJ o
and CC N
less RBR N
toxic JJ o
treatment NN N
strategies NNS N
for IN N
hormone NN N
refractory NN N
prostate NN N
cancer NN N
is VBZ N
mandatory JJ N
. . N

-DOCSTART- -X- O O

[ IN N
The DT N
prognostic JJ N
value NN N
of IN N
gastric JJ N
metaplasia NN N
in IN N
the DT N
duodenal JJ N
mucosa NN N
in IN N
patients NNS p
with IN p
Helicobacter NNP p
pylori VBP p
positive JJ p
duodenal JJ p
bulb NN p
ulcer NN p
] NNP p
. . N

The DT N
predictive JJ N
value NN N
of IN N
gastric JJ N
metaplasia NN N
in IN N
the DT N
duodenal JJ N
mucosa NN N
in IN N
patients NNS p
Helicobacter NNP p
pylori-positive JJ p
patients NNS p
with IN p
duodenal JJ p
bulb NN p
ulcer NN p
( ( p
DBU NNP p
) ) p
was VBD N
investigated VBN N
. . N

One CD p
hundred CD p
and CC p
twenty VB p
four CD p
randomly RB p
selected VBN p
patients NNS p
with IN p
DBU NNP p
were VBD N
included VBN N
in IN N
this DT N
prospective JJ N
study NN N
. . N

The DT i
detection NN i
of IN i
Helicobacter NNP i
pylori FW i
( ( i
HP NNP i
) ) i
in IN i
the DT i
stomach NN i
and CC i
duodenum NN i
was VBD i
carried VBN i
out RP i
with IN i
Giemsa NNP i
( ( i
using VBG i
standard JJ i
visual JJ i
analogue NN i
scale NN i
) ) i
, , i
rapid JJ i
urease JJ i
test NN i
( ( i
standard JJ i
Jatrox-HP NNP i
test NN i
, , i
Rohm NNP i
Pharma NNP i
, , i
Germany NNP i
) ) i
, , i
and CC i
polymerase NN i
chain NN i
reaction NN i
( ( i
PCR NNP i
) ) i
to TO i
detect VB i
the DT i
specific JJ i
fragment NN i
of IN i
ureC JJ i
HP NNP i
gene NN i
( ( i
Helicopol NNP i
II NNP i
, , i
Lytech NNP i
, , i
Russia NNP i
) ) i
. . N

Regions NNS N
of IN N
gastric JJ N
metaplasia NN N
of IN N
the DT N
duodenum NN N
were VBD N
confirmed VBN N
by IN N
periodic JJ N
acid-Schiff JJ N
and CC N
alcian JJ N
blue NN N
( ( N
Serva NNP N
) ) N
staining NN N
( ( N
pH JJ N
1.0 CD N
; : N
2.5 CD N
) ) N
Duodenal NNP N
ulcer NN N
( ( N
DU NNP N
) ) N
complications NNS N
were VBD N
registered VBN N
within IN N
8 CD N
to TO N
10 CD N
years NNS N
. . N

Estimation NN N
of IN N
the DT N
predictive JJ N
factor NN N
( ( o
gastric JJ o
metaplasia NN o
in IN o
the DT o
duodenum NN o
) ) o
was VBD N
carried VBN N
out RP N
in IN N
patients NNS N
with IN N
non-complicated JJ N
DU NNP N
( ( N
Group NNP N
1 CD N
; : N
n CC N
= VB N
73 CD N
) ) N
, , N
and CC N
with IN N
such JJ N
complications NNS N
as IN N
bleeding NN N
, , N
perforation NN N
, , N
penetration NN N
, , N
pyloroduodenal JJ N
stenosis NN N
( ( N
Group NNP N
2 CD N
; : N
n CC N
= VB N
51 CD N
) ) N
which WDT N
were VBD N
revealed VBN N
within IN N
the DT N
8 CD N
to TO N
10 CD N
years NNS N
of IN N
observation NN N
. . N

Gastric NNP o
metaplasia NN o
in IN o
the DT o
duodenum NN o
was VBD N
found VBN N
in IN N
64 CD N
or CC N
87.7 CD N
% NN N
of IN N
the DT N
73 CD N
patients NNS N
with IN N
non-complicated JJ N
DU NNP N
and CC N
in IN N
5 CD N
or CC N
9.8 CD N
% NN N
of IN N
the DT N
51 CD N
patients NNS N
with IN N
complicated JJ N
DU NNP N
within IN N
8 CD N
to TO N
10 CD N
years NNS N
of IN N
observation NN N
. . N

The DT N
following JJ N
facts NNS N
about IN N
the DT N
predictive JJ N
factor NN N
for IN N
the DT N
prognosis NN N
of IN N
DU NNP N
complication NN N
were VBD N
found VBN N
: : N
the DT N
sensitivity NN o
of IN N
83.6 CD N
% NN N
, , N
the DT N
specificity NN o
of IN N
92.8 CD N
% NN N
, , N
the DT N
predictive JJ o
accuracy NN o
of IN N
88.7 CD N
% NN N
, , N
the DT N
relative JJ o
risk NN o
of IN o
the DT o
predicted JJ o
outcome NN o
of IN N
7.5 CD N
, , N
the DT N
relative JJ N
risk NN N
of IN N
a DT N
different JJ N
outcome NN N
of IN N
0.11 CD N
, , N
the DT N
odds NNS N
ration NN N
of IN N
65.4 CD N
. . N

The DT N
study NN N
revealed VBD N
a DT N
high JJ N
and CC N
significant JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
predictive JJ N
value NN N
of IN N
gastric JJ o
metaplasia NN o
in IN N
the DT N
duodenum NN N
as IN N
a DT N
marker NN N
of IN N
non-complicated JJ N
clinical JJ N
course NN N
of IN N
DU NNP N
in IN N
HP-positive JJ p
patients NNS p
within IN N
an DT N
8 CD N
to TO N
10-year JJ N
period NN N
. . N

-DOCSTART- -X- O O

Does NNP N
temporary JJ i
clamping NN i
of IN i
drains NNS i
following VBG N
knee NN N
arthroplasty JJ N
reduce VB N
blood NN N
loss NN N
? . N
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomised JJ N
, , N
blinded VBD N
study NN N
76 CD p
patients NNS p
undergoing JJ p
primary JJ p
total JJ p
knee NN p
arthroplasty NN p
were VBD p
assigned VBN p
to TO N
either DT N
immediate JJ i
drain NN i
opening NN i
( ( i
n JJ i
= NNP i
45 CD i
) ) i
or CC i
drains NNS i
opened VBN i
at IN i
2 CD i
h NN i
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
for IN N
the DT N
volume NN o
of IN o
drained JJ o
blood NN o
, , o
transfusion NN o
requirements NNS o
, , o
knee JJ o
motion NN o
or CC o
wound NN o
status NN o
. . o

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
practice NN N
of IN N
clamping VBG i
drains NNS i
has VBZ N
no DT N
benefit NN N
in IN N
routine JJ N
knee NN N
arthroplasty NN N
. . N

However RB N
, , N
when WRB N
faced VBN N
with IN N
immediate JJ N
brisk JJ N
blood NN o
loss NN o
, , N
the DT N
results NNS N
suggest VBP N
that IN N
drains NNS i
can MD N
be VB N
clamped VBN N
without IN N
any DT N
excess JJ N
morbidity NN o
. . o

-DOCSTART- -X- O O

Efficiency NN o
of IN i
adjuvant JJ i
immunochemotherapy NN i
following VBG N
curative JJ N
resection NN N
in IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
gastric JJ p
cancer NN p
. . p

BACKGROUND NNP N
Despite IN N
curative JJ N
resection NN N
, , N
50 CD N
% NN N
-90 CD N
% NN N
of IN N
gastric JJ p
cancer NN p
patients NNS p
die VBP N
of IN N
disease NN o
relapse NN o
. . o

Although IN N
some DT N
clinical JJ N
trials NNS N
have VBP N
indicated VBN N
that IN N
chemotherapy NN N
and CC N
immunochemotherapy NN N
may MD N
be VB N
effective JJ N
modalities NNS N
, , N
more RBR N
recent JJ N
studies NNS N
have VBP N
not RB N
been VBN N
able JJ N
to TO N
define VB N
the DT N
standard JJ N
treatment NN N
for IN N
advanced JJ p
gastric JJ p
cancer NN p
. . p

The DT N
present JJ N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
adjuvant JJ i
immunochemotherapy NN i
with IN i
the DT i
use NN i
of IN i
BCG NNP i
( ( i
bacille IN i
Calmette-Guerin NNP i
) ) i
and CC i
FAM NNP i
( ( i
5-fluorouracil JJ i
, , i
adriamycin JJ i
, , i
mitomycin JJ i
C NNP i
) ) i
chemotherapy NN i
on IN N
the DT N
survival NN o
of IN o
patients NNS o
with IN p
locally RB p
advanced VBN p
resectable JJ p
gastric JJ p
cancer NN p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
156 CD p
patients NNS p
with IN p
stage NN p
III NNP p
or CC p
IV NNP p
gastric JJ p
cancer NN p
who WP p
had VBD p
undergone JJ p
curative JJ p
resection NN p
were VBD N
randomly RB i
assigned VBN i
to TO i
three CD i
treatment NN i
groups NNS i
: : i
BCG NNP i
+ NNP i
FAM NNP i
( ( i
immunochemotherapy NN i
) ) i
, , i
FAM NNP i
( ( i
chemotherapy NN i
) ) i
, , i
and CC i
control NN i
( ( i
surgery NN i
only RB i
) ) i
. . i

Treatment NN i
was VBD i
continued VBN i
for IN i
2 CD i
years NNS i
or CC i
until IN i
death NN i
. . i

Further NNP i
postsurgical JJ i
follow VBP i
up RP i
was VBD i
carried VBN i
on IN i
for IN i
up IN i
to TO i
10 CD i
years NNS i
. . i

RESULTS VB N
Overall JJ N
10-year JJ o
survival NN o
was VBD N
47.1 CD N
% NN N
for IN N
the DT N
immunochemotherapy NN N
group NN N
( ( N
P NNP N
< VBZ N
0.037 CD N
vs NN N
FAM NNP i
and CC N
P NNP N
< NNP N
0.0006 CD N
vs NNS N
control NN N
) ) N
, , N
30 CD N
% NN N
for IN N
the DT N
chemotherapy NN i
group NN N
( ( N
vs FW N
control NN N
, , N
NS NNP N
) ) N
, , N
and CC N
15.2 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
. . N

In IN N
patients NNS p
with IN p
pT2/T3 JJ p
primary JJ p
tumors NNS p
, , N
10-year JJ o
survival NN o
was VBD N
55.3 CD N
% NN N
for IN N
BCG NNP i
+ NNP i
FAM NNP i
vs VBD N
28.2 CD N
% NN N
for IN N
FAM NNP N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
14.6 CD N
% NN N
for IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.00018 CD N
) ) N
. . N

BCG NNP i
+ NNP i
FAM NNP i
significantly RB N
improved VBD N
the DT N
survival NN o
of IN o
patients NNS o
with IN p
intestinal-type JJ p
but CC p
not RB p
diffuse-type JJ p
cancer NN p
. . p

Immunochemotherapy NNP i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION VB N
This DT N
study NN N
, , N
based VBN N
on IN N
a DT N
limited JJ p
number NN p
of IN p
patients NNS p
, , N
indicates VBZ N
that IN N
adjuvant JJ N
immunochemotherapy NN N
( ( N
BCG NNP N
+ NNP N
FAM NNP N
) ) N
may MD N
prolong VB N
the DT N
survival NN o
of IN N
gastric JJ p
cancer NN p
patients NNS p
after IN p
curative JJ p
gastrectomy NN p
; : p
in IN p
particular JJ p
, , p
in IN p
patients NNS p
with IN p
pT2/T3 JJ p
tumors NNS p
and CC p
intestinal-type JJ p
primary JJ p
tumors NNS p
. . p

There EX N
was VBD N
no DT N
survival JJ o
benefit NN o
from IN N
FAM NNP i
adjuvant JJ i
chemotherapy NN i
. . i

-DOCSTART- -X- O O

Prenatal JJ N
depression NN N
predicts VBZ N
postpartum JJ N
maternal JJ N
attachment NN N
in IN N
low-income JJ p
Latina NNP p
mothers NNS p
with IN p
infants NNS p
. . p

Although IN N
maternal JJ N
attachment NN N
is VBZ N
an DT N
important JJ N
predictor NN N
of IN N
infant JJ N
attachment JJ N
security NN N
and CC N
other JJ N
developmental JJ N
outcomes NNS N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
formation NN N
of IN N
maternal JJ N
attachment NN N
in IN N
the DT N
first JJ N
few JJ N
months NNS N
of IN N
the DT N
infant NN N
's POS N
life NN N
, , N
particularly RB N
among IN N
ethnic JJ N
minority NN N
mothers NNS N
. . N

The DT N
current JJ N
study NN N
examined VBD N
the DT N
predictors NNS N
of IN N
postpartum JJ N
maternal JJ N
attachment NN N
in IN N
a DT N
sample NN N
of IN N
217 CD p
Latina NNP p
women NNS p
enrolled VBD p
in IN p
a DT p
perinatal JJ p
depression NN p
prevention NN p
trial NN p
. . p

Mothers NNS N
' POS N
attachment NN i
to TO N
their PRP$ N
infants NNS N
was VBD N
measured VBN N
at IN N
6-8 JJ i
weeks NNS i
postpartum NN i
using VBG i
the DT i
Maternal NNP o
Postnatal NNP o
Attachment NNP o
Scale NNP o
. . o

A NNP N
variety NN N
of IN N
predictors NNS N
of IN N
early JJ N
attachment NN N
were VBD N
explored VBN N
including VBG N
: : N
depressive JJ o
symptoms NNS o
during IN o
pregnancy NN o
, , o
pregnancy NN o
intention NN o
, , o
feelings NNS o
about IN o
the DT o
pregnancy NN o
, , o
and CC o
the DT o
quality NN o
of IN o
the DT o
partner NN o
relationship NN o
. . o

The DT N
strongest JJS N
predictor NN N
of IN N
lower JJR o
maternal JJ o
attachment NN o
was VBD N
depressive JJ o
symptoms NNS o
late RB N
in IN N
pregnancy NN N
; : N
pregnancy NN N
intention NN N
was VBD N
marginally RB N
predictive JJ N
of IN N
attachment NN o
, , N
with IN N
lower JJR N
scores NNS N
being VBG N
associated VBN N
with IN N
unwanted JJ N
pregnancies NNS N
. . N

The DT N
study NN N
fills VBZ N
a DT N
critical JJ N
gap NN N
in IN N
our PRP$ N
understanding NN N
of IN N
the DT N
role NN N
of IN N
depressive JJ N
symptoms NNS N
during IN N
pregnancy NN N
in IN N
shaping VBG N
mothers NNS N
' POS N
early JJ N
attachment NN N
to TO N
their PRP$ N
infants NNS N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
a DT N
stage-of-change NN i
oriented VBN i
smoking VBG i
cessation NN i
intervention NN i
in IN N
infertile NN p
and CC p
pregnant JJ p
women NNS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
a DT N
stage-of-change NN i
oriented VBN i
smoking VBG i
cessation NN i
intervention NN i
for IN N
infertile NN p
and CC p
pregnant JJ p
women NNS p
, , N
compared VBN N
with IN N
standard NN N
of IN N
care NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Three CD p
university NN p
teaching VBG p
hospitals NNS p
in IN p
Hamilton NNP p
, , p
Ontario NNP p
, , p
Canada NNP p
. . p

PATIENT NNP N
( ( N
S NNP N
) ) N
Infertile NNP p
women NNS p
at IN p
their PRP$ p
first JJ p
visit NN p
to TO p
a DT p
tertiary JJ p
referral JJ p
infertility NN p
clinic NN p
( ( p
n JJ p
= NNP p
94 CD p
) ) p
and CC p
new JJ p
patients NNS p
seeking VBG p
pre-natal JJ p
care NN p
( ( p
n JJ p
= NNP p
110 CD p
) ) p
who WP p
had VBD p
smoked VBN p
> NNP p
/= $ p
3 CD p
cigarettes NNS p
in IN p
the DT p
past JJ p
six CD p
months NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
A NNP N
three CD i
to TO i
five CD i
minute NN i
scripted VBN i
intervention NN i
and CC i
booklet NN i
specific NN i
to TO i
the DT i
woman NN i
's POS i
stage-of-change NN i
in IN i
the DT i
smoking NN i
continuum NN i
, , i
versus JJ i
standard NN i
of IN i
care NN i
. . i

Exhaled VBN i
carbon-monoxide NN i
( ( i
CO NNP i
) ) i
monitoring NN i
was VBD N
used VBN N
to TO N
validate VB N
exposure NN N
in IN N
both DT N
groups NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Delta NNP o
stage-of-change NN o
and CC o
rate NN o
of IN o
maintained VBN o
cessation NN o
at IN N
12 CD N
months NNS N
post VBN N
follow-up JJ N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Intervention NNP N
and CC N
control NN N
were VBD N
similarly RB N
effective JJ N
for IN N
infertile JJ N
women NNS N
: : N
the DT N
rate NN o
of IN o
maintained VBN o
cessation NN o
rose VBD N
significantly RB N
from IN N
4 CD N
% NN N
to TO N
24 CD N
% NN N
over IN N
twelve JJ N
months NNS N
, , N
with IN N
a DT N
mean JJ o
delta NN o
stage-of-change NN o
0.28 CD N
. . N

In IN N
prenatal JJ N
women NNS N
, , N
neither CC N
approach NN N
was VBD N
effective JJ N
. . N

Maintained VBN o
cessation NN o
did VBD N
not RB N
significantly RB N
change VBP N
from IN N
0 CD N
to TO N
12 CD N
months NNS N
( ( N
19 CD N
% NN N
to TO N
18 CD N
% NN N
) ) N
. . N

Mean JJ o
delta JJ o
stage-of-change NN o
declined VBN N
by IN N
-0.62 NNP N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
For IN N
infertile JJ N
women NNS N
, , N
basic JJ N
information NN N
describing VBG N
the DT N
impact NN N
of IN N
smoking VBG N
on IN N
fertility NN N
, , N
along IN N
with IN N
exhaled JJ N
CO NNP N
monitoring NN N
and CC N
a DT N
more RBR N
intensive JJ N
intervention NN N
were VBD N
both DT N
highly RB N
effective JJ N
. . N

In IN N
pregnant JJ N
women NNS N
neither CC N
approach NN N
was VBD N
beneficial JJ N
, , N
with IN N
some DT N
evidence NN N
of IN N
post-partum JJ N
relapse NN N
. . N

-DOCSTART- -X- O O

An DT N
evaluation NN N
of IN N
an DT N
adaptive JJ i
automation NN i
system NN i
using VBG N
a DT N
cognitive JJ i
vigilance NN i
task NN i
. . i

The DT N
performance NN N
of IN N
an DT N
adaptive JJ i
automation NN i
system NN i
was VBD N
evaluated VBN N
using VBG N
a DT N
cognitive JJ N
vigilance NN N
task NN N
. . N

Participants NNS p
responded VBD N
to TO N
the DT N
presence NN N
of IN N
a DT N
green JJ i
K NNP i
in IN i
an DT i
array NN i
of IN i
two CD i
, , i
five CD i
, , i
or CC i
nine CD i
distractor NN i
stimuli NNS i
during IN i
a DT i
40-min JJ i
vigil NN i
. . i

The DT N
array NN N
with IN N
the DT N
target NN N
stimulus NN N
was VBD N
presented VBN N
once RB N
each DT N
minute NN N
. . N

Participants NNS p
EEG NNP i
was VBD N
recorded VBN N
and CC N
an DT N
engagement JJ o
index NN o
( ( N
EI NNP N
= VBZ N
20 CD N
x NN N
beta/ NN N
( ( N
alpha JJ N
+ NNP N
theta NN N
) ) N
) ) N
was VBD N
derived VBN N
. . N

In IN N
the DT N
negative JJ N
feedback NN N
condition NN N
, , N
increases VBZ N
in IN N
the DT N
EI NNP o
caused VBD o
the DT o
number NN o
of IN o
stimuli NNS o
in IN o
the DT o
array NN o
to TO o
decrease VB o
while IN N
decreases NNS o
in IN o
the DT o
EI NNP o
caused VBD o
the DT o
number NN o
of IN o
stimuli NNS o
to TO o
increase VB o
. . o

For IN N
the DT N
positive JJ N
feedback NN N
condition NN N
, , N
increases VBZ o
in IN o
the DT o
index NN o
caused VBD o
an DT o
increase NN o
in IN o
the DT o
array NN o
size NN o
( ( o
AS IN o
) ) o
while IN N
decreases NNS o
caused VBD o
a DT o
decrease NN o
in IN o
the DT o
array NN o
size NN o
. . o

Each DT N
experimental JJ N
participant NN p
had VBD p
a DT p
yoked VBN p
control NN p
partner NN p
who WP N
received VBD N
the DT N
same JJ N
pattern NN N
of IN N
changes NNS N
in IN N
array JJ N
irrespective NN N
of IN N
their PRP$ N
engagement JJ N
index NN N
. . N

A DT N
vigilance NN N
decrement NN N
was VBD N
seen VBN N
only RB N
for IN N
the DT N
positive JJ N
feedback NN N
, , N
experimental JJ p
group NN p
. . p

-DOCSTART- -X- O O

Chemoprevention NN N
of IN N
gastric JJ N
dysplasia NN N
: : N
randomized JJ N
trial NN N
of IN N
antioxidant JJ i
supplements NNS i
and CC i
anti-helicobacter JJ i
pylori NN i
therapy NN i
. . i

BACKGROUND NNP N
Previous NNP N
research NN N
has VBZ N
identified VBN N
a DT N
high JJ N
risk NN N
of IN N
gastric JJ N
carcinoma NN N
as RB N
well RB N
as IN N
a DT N
high JJ N
prevalence NN N
of IN N
cancer NN N
precursor NN N
lesions NNS N
in IN N
rural JJ p
populations NNS p
living VBG p
in IN p
the DT p
province NN p
of IN p
Nari?o NNP p
, , p
Colombia NNP p
, , p
in IN p
the DT p
Andes NNP p
Mountains NNP p
. . p

METHODS NNP N
A NNP N
randomized NN N
, , N
controlled VBN N
chemoprevention NN N
trial NN N
was VBD N
conducted VBN N
in IN p
subjects NNS p
with IN p
confirmed JJ p
histologic JJ p
diagnoses NNS p
of IN p
multifocal JJ p
nonmetaplastic JJ p
atrophy NN p
and/or IN p
intestinal JJ p
metaplasia NN p
, , p
two CD p
precancerous JJ p
lesions NNS p
. . p

Individuals NNS N
were VBD N
assigned VBN N
to TO i
receive VB i
anti-Helicobacter JJ i
pylori NN i
triple JJ i
therapy NN i
and/or NN i
dietary JJ i
supplementation NN i
with IN i
ascorbic JJ i
acid NN i
, , i
beta-carotene JJ i
, , i
or CC i
their PRP$ i
corresponding JJ i
placebos NN i
. . i

Gastric NNP o
biopsy NN o
specimens VBZ o
taken VBN i
at IN i
baseline NN i
were VBD i
compared VBN i
with IN i
those DT i
taken VBN i
at IN i
72 CD i
months NNS i
. . i

Relative JJ N
risks NNS N
of IN o
progression NN o
, , o
no DT o
change NN o
, , o
and CC o
regression NN o
from IN N
multifocal JJ N
nonmetaplastic JJ N
atrophy NN N
and CC N
intestinal JJ N
metaplasia NN N
were VBD N
analyzed VBN N
with IN N
multivariate NN N
polytomous JJ N
logistic JJ N
regression NN N
models NNS N
to TO N
estimate VB N
treatment NN N
effects NNS N
. . N

All DT N
statistical JJ N
tests NNS N
were VBD N
two-sided JJ N
. . N

RESULTS VB N
All DT N
three CD N
basic JJ N
interventions NNS N
resulted VBD N
in IN N
statistically RB N
significant JJ N
increases NNS N
in IN N
the DT o
rates NNS o
of IN o
regression NN o
: : o
Relative JJ N
risks NNS N
were VBD N
4.8 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.6-14.2 JJ N
) ) N
for IN N
anti-H. JJ N
pylori NN N
treatment NN N
, , N
5 CD N
. . N

1 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.7-15.0 JJ N
) ) N
for IN i
beta-carotene JJ i
treatment NN N
, , N
and CC N
5.0 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.7-14.4 JJ N
) ) N
for IN i
ascorbic JJ i
acid JJ i
treatment NN N
in IN N
subjects NNS N
with IN N
atrophy NN N
. . N

Corresponding VBG N
relative JJ o
risks NNS o
of IN o
regression NN o
in IN N
subjects NNS N
with IN N
intestinal JJ N
metaplasia NNS N
were VBD N
3.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.0-9.3 JJ N
) ) N
, , N
3.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.1-9.8 JJ N
) ) N
, , N
and CC N
3.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.1-9.5 JJ N
) ) N
. . N

Combinations NNS N
of IN N
treatments NNS N
did VBD N
not RB N
statistically RB N
significantly RB N
increase VB N
the DT o
regression NN o
rates NNS o
. . o

Curing VBG N
the DT N
H. NNP N
pylori NN N
infection NN N
( ( N
which WDT N
occurred VBD N
in IN N
74 CD N
% NN N
of IN N
the DT N
treated JJ N
subjects NNS N
) ) N
produced VBD N
a DT N
marked JJ N
and CC N
statistically RB N
significant JJ N
increase NN N
in IN N
the DT o
rate NN o
of IN o
regression NN o
of IN N
the DT N
precursor NN N
lesions NNS N
( ( N
relative JJ N
risks NNS N
= VBP N
8.7 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
= NNP N
2.7-28.2 JJ N
] NN N
for IN p
subjects NNS p
with IN p
atrophy NN p
and CC N
5.4 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
= NNP N
1.7-17.6 JJ N
] NN N
for IN p
subjects NNS p
with IN p
intestinal JJ p
metaplasia NN p
) ) p
. . p

CONCLUSIONS NNP N
In IN N
the DT p
very RB p
high-risk JJ p
population NN p
studied VBN N
, , N
effective JJ N
anti-H. JJ N
pylori NN N
treatment NN N
and CC N
dietary JJ N
supplementation NN N
with IN N
antioxidant JJ N
micronutrients NNS N
may MD N
interfere VB N
with IN N
the DT N
precancerous JJ N
process NN N
, , N
mostly RB N
by IN N
increasing VBG N
the DT N
rate NN N
of IN o
regression NN o
of IN N
cancer NN N
precursor NN N
lesions NNS N
, , N
and CC N
may MD N
be VB N
an DT N
effective JJ N
strategy NN N
to TO N
prevent VB N
gastric JJ N
carcinoma NN N
. . N

-DOCSTART- -X- O O

Sulforaphane NNP i
treatment NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

Autism NNP N
spectrum JJ N
disorder NN N
( ( N
ASD NNP N
) ) N
, , N
characterized VBN N
by IN N
both DT N
impaired JJ N
communication NN N
and CC N
social JJ N
interaction NN N
, , N
and CC N
by IN N
stereotypic JJ N
behavior NN N
, , N
affects VBZ N
about IN N
1 CD N
in IN N
68 CD N
, , N
predominantly RB p
males NNS p
. . p

The DT N
medico-economic JJ N
burdens NNS N
of IN N
ASD NNP N
are VBP N
enormous JJ N
, , N
and CC N
no DT N
recognized VBN N
treatment NN N
targets VBZ N
the DT N
core NN N
features NNS N
of IN N
ASD NNP N
. . N

In IN N
a DT N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
trial NN N
, , N
young JJ p
men NNS p
( ( p
aged VBN p
13-27 NNS p
) ) p
with IN p
moderate JJ p
to TO p
severe VB p
ASD NNP p
received VBD N
the DT N
phytochemical JJ i
sulforaphane NN i
( ( i
n JJ i
= NNP i
29 CD i
) ) i
-- : i
derived VBN i
from IN i
broccoli NN i
sprout NN i
extracts NNS i
-- : i
or CC i
indistinguishable JJ i
placebo NN i
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

The DT N
effects NNS N
on IN N
behavior NN N
of IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
sulforaphane NN i
( ( N
50-150 JJ N
?mol NN N
) ) N
for IN N
18 CD N
wk NN N
, , N
followed VBN N
by IN N
4 CD N
wk NNS N
without IN N
treatment NN N
, , N
were VBD N
quantified VBN N
by IN N
three CD N
widely RB N
accepted VBD N
behavioral JJ N
measures NNS N
completed VBN N
by IN N
parents/caregivers NNS N
and CC N
physicians NNS o
: : o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , o
Social NNP o
Responsiveness NNP o
Scale NNP o
( ( o
SRS NNP o
) ) o
, , o
and CC o
Clinical NNP o
Global NNP o
Impression NNP o
Improvement NNP o
Scale NNP o
( ( o
CGI-I NNP o
) ) o
. . o

Initial JJ o
scores NNS o
for IN o
ABC NNP o
and CC o
SRS NNP o
were VBD N
closely RB N
matched VBN N
for IN N
participants NNS N
assigned VBN N
to TO i
placebo VB i
and CC i
sulforaphane VB i
. . i

After IN N
18 CD N
wk NN N
, , N
participants NNS N
receiving VBG i
placebo NN i
experienced VBD N
minimal JJ N
change NN N
( ( N
< JJ N
3.3 CD N
% NN N
) ) N
, , N
whereas VBP N
those DT N
receiving VBG i
sulforaphane NN i
showed VBD N
substantial JJ N
declines NNS N
( ( N
improvement NN N
of IN N
behavior NN N
) ) N
: : N
34 CD N
% NN N
for IN o
ABC NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
comparing VBG N
treatments NNS N
) ) N
and CC N
17 CD N
% NN N
for IN o
SRS NNP o
scores NNS N
( ( N
P NNP N
= NNP N
0.017 CD N
) ) N
. . N

On IN o
CGI-I NNP o
, , o
a DT N
significantly RB N
greater JJR N
number NN N
of IN p
participants NNS p
receiving VBG i
sulforaphane NN i
had VBD N
improvement NN N
in IN o
social JJ o
interaction NN o
, , o
abnormal JJ o
behavior NN o
, , o
and CC o
verbal JJ o
communication NN o
( ( N
P NNP N
= NNP N
0.015-0.007 NN N
) ) N
. . N

Upon IN N
discontinuation NN N
of IN i
sulforaphane NN i
, , i
total JJ N
scores NNS N
on IN N
all DT N
scales NNS N
rose VBD N
toward IN N
pretreatment JJ N
levels NNS N
. . N

Dietary NNP i
sulforaphane NN i
, , i
of IN N
recognized VBN N
low JJ N
toxicity NN N
, , N
was VBD N
selected VBN N
for IN N
its PRP$ N
capacity NN N
to TO N
reverse VB N
abnormalities NNS N
that WDT N
have VBP N
been VBN N
associated VBN N
with IN N
ASD NNP N
, , N
including VBG o
oxidative JJ o
stress NN o
and CC o
lower JJR o
antioxidant NN o
capacity NN o
, , o
depressed VBD o
glutathione NN o
synthesis NN o
, , o
reduced VBN o
mitochondrial JJ o
function NN o
and CC o
oxidative JJ o
phosphorylation NN o
, , o
increased VBD o
lipid JJ o
peroxidation NN o
, , o
and CC o
neuroinflammmation NN o
. . o

-DOCSTART- -X- O O

Double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
secretin NN i
: : i
effects NNS N
on IN N
aberrant JJ o
behavior NN o
in IN o
children NNS o
with IN o
autism NN o
. . o

Secretin NNP i
has VBZ N
been VBN N
proposed VBN N
as IN N
a DT N
treatment NN N
alternative NN N
for IN N
autistic JJ o
spectrum NN o
disorders NNS o
, , N
but CC N
empirical JJ N
support NN N
is VBZ N
lacking VBG N
. . N

A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
synthetic JJ i
human JJ i
secretin NN i
on IN N
aberrant JJ o
behavior NN o
. . o

Parent NN p
and CC p
teacher NN p
data NNS p
from IN p
the DT p
Aberrant NNP o
Behavior NNP o
Checklist NNP o
for IN N
eight CD p
male JJ p
children NNS p
were VBD N
analyzed VBN N
for IN N
reliable JJ N
change NN N
in IN N
a DT N
clinical JJ N
replication NN N
series NN N
. . N

By IN N
parent NN N
and CC N
teacher NN N
report NN N
, , N
the DT N
majority NN N
of IN N
change NN N
occurred VBD N
either CC N
on IN N
the DT N
placebo NN i
trial NN N
or CC N
reflected VBN N
deterioration NN N
subsequent NN N
to TO N
secretin VB i
infusion NN N
. . N

Repeated-measures JJ N
multivariate JJ N
analysis NN N
of IN N
variance NN N
results NNS N
were VBD N
similar JJ N
. . N

Results NNS N
are VBP N
consistent JJ N
with IN N
other JJ N
studies NNS N
, , N
suggesting VBG N
that IN N
secretin NN i
may MD N
not RB N
be VB N
an DT N
effective JJ N
treatment NN N
option NN N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
porcine NN i
secretin NN i
in IN N
children NNS p
with IN p
autism NN p
and CC p
pervasive JJ p
developmental JJ p
disorder NN p
. . p

Secretin NNP i
, , N
a DT N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
hormone NN N
, , N
was VBD N
reported VBN N
in IN N
a DT N
preliminary JJ N
study NN N
to TO N
improve VB N
language NN o
and CC o
behavior NN o
in IN N
children NNS p
with IN p
autism/pervasive JJ p
developmental JJ p
disorder NN p
( ( p
PDD NNP p
) ) p
and CC p
chronic JJ p
diarrhea NN p
. . p

To TO N
determine VB N
the DT N
efficacy NN N
of IN N
secretin NN i
, , N
we PRP N
completed VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
( ( N
3 CD N
weeks NNS N
) ) N
study NN N
in IN N
children NNS p
with IN p
autism/PDD NN p
and CC p
various JJ p
GI NNP p
conditions NNS p
using VBG N
a DT N
single JJ N
dose NN N
of IN N
intravenous JJ i
porcine NN i
secretin NN i
. . i

Children NNP p
with IN p
chronic NN p
, , p
active JJ p
diarrhea NN p
showed VBD N
a DT N
reduction NN N
in IN N
aberrant JJ o
behaviors NNS o
when WRB N
treated VBN N
with IN N
the DT N
secretin NN i
but CC N
not RB N
when WRB N
treated VBN N
with IN N
the DT N
placebo NN i
. . i

Children NNP p
with IN p
no DT p
GI NNP p
problems NNS p
are VBP N
unaffected VBN N
by IN N
either DT N
secretin NN i
or CC i
placebo NN i
. . i

The DT N
improvement NN N
seen VBN N
with IN N
secretin NN i
in IN N
children NNS p
with IN p
autism/PDD NN p
and CC p
chronic JJ p
diarrhea NN p
suggests VBZ N
that IN N
there EX N
may MD N
be VB N
a DT N
subtype NN N
of IN N
children NNS N
with IN N
autism/PDD NN N
who WP N
respond VBZ N
to TO N
secretin VB i
. . i

-DOCSTART- -X- O O

Amphotericin NNP i
versus NN N
pentamidine NN i
in IN N
antimony-unresponsive JJ p
kala-azar NN p
. . p

We PRP N
compared VBN N
the DT N
efficacy NN N
of IN N
amphotericin NN i
B NNP i
and CC N
pentamidine JJ i
isethionate NN i
in IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
in IN N
120 CD p
uncomplicated JJ p
and CC p
parasitologically RB p
confirmed VBN p
cases NNS p
of IN p
antimony-unresponsive JJ p
kala-azar NN p
. . p

Doses NNS N
were VBD N
twenty JJ N
intramuscular JJ N
injections NNS N
of IN N
pentamidine NN i
4 CD N
mg/kg NN N
on IN N
alternate JJ N
days NNS N
or CC N
fourteen JJ N
definitive JJ N
doses NNS N
of IN N
amphotericin JJ i
0.5 CD N
mg/kg NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN N
on IN N
alternate JJ N
days NNS N
. . N

48 CD N
( ( N
80 CD N
% NN N
) ) N
patients NNS N
given VBN N
pentamidine VBP i
showed VBN N
initial JJ o
cure NN o
and CC N
46 CD N
( ( N
77 CD N
% NN N
) ) N
showed VBD N
definitive JJ o
cure NN o
compared VBN N
with IN N
60 CD N
( ( N
100 CD N
% NN N
) ) N
and CC N
59 CD N
( ( N
98 CD N
% NN N
) ) N
cases NNS N
, , N
respectively RB N
, , N
on IN N
amphotericin NN i
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Amphotericin NNP i
also RB N
brought VBD N
about RB N
quicker JJR N
abatement NN o
of IN o
fever NN o
and CC N
more JJR N
complete JJ o
spleen JJ o
regression NN o
. . o

-DOCSTART- -X- O O

Arthroscopic NNP i
rotator NN i
cuff NN i
repair NN i
with IN i
and CC i
without IN i
acromioplasty NN i
in IN N
the DT N
treatment NN N
of IN N
full-thickness JJ p
rotator NN p
cuff NN p
tears NNS p
: : p
a DT N
multicenter NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
to TO N
compare VB N
functional JJ o
and CC o
quality-of-life JJ o
indices NNS o
and CC N
rates NNS o
of IN o
revision NN o
surgery NN o
in IN N
arthroscopic NN i
rotator NN i
cuff NN i
repair NN i
with IN i
and CC i
without IN i
acromioplasty JJ i
. . i

METHODS NNP N
Eighty-six JJ p
patients NNS p
consented VBN N
and CC N
were VBD N
randomly RB N
assigned VBN N
intraoperatively RB N
to TO N
one CD N
of IN N
two CD N
study NN N
groups NNS N
, , N
and CC N
sixty-eight NN p
of IN p
them PRP p
completed VBD p
the DT p
study NN p
. . p

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
Western JJ o
Ontario NNP o
Rotator NNP o
Cuff NNP o
( ( o
WORC NNP o
) ) o
index NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
the DT N
American JJ o
Shoulder NNP o
and CC o
Elbow NNP o
Surgeons NNP o
( ( o
ASES NNP o
) ) o
shoulder NN o
assessment JJ o
form NN o
and CC o
a DT o
count NN o
of IN o
revisions NNS o
required VBN N
in IN N
each DT N
group NN N
. . N

Outcome NNP N
measures NNS N
were VBD N
completed VBN N
preoperatively RB N
and CC N
at IN N
three CD N
, , N
six CD N
, , N
twelve NN N
, , N
eighteen NN N
, , N
and CC N
twenty-four JJ N
months NNS N
after IN N
surgery NN N
. . N

RESULTS NNP N
WORC NNP o
and CC o
ASES NNP o
scores VBZ o
improved VBN N
significantly RB N
in IN N
each DT N
group NN N
over IN N
time NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
WORC NNP o
or CC o
ASES NNP o
scores NNS o
between IN N
the DT N
groups NNS N
that WDT N
had VBD N
arthroscopic VBN i
cuff JJ i
repair NN i
with IN i
or CC i
without IN i
acromioplasty JJ i
at IN N
any DT N
time NN N
point NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
scores NNS N
on IN N
the DT N
basis NN N
of IN N
acromion NN N
type NN N
, , N
nor CC N
were VBD N
any DT N
interaction NN N
effects NNS N
identified VBN N
between IN N
group NN N
and CC N
acromion NN N
type NN N
. . N

Four CD p
participants NNS p
( ( p
9 CD p
% NN p
) ) p
in IN p
the DT p
group NN p
that WDT p
had VBD p
arthroscopic VBN i
cuff JJ i
repair NN o
alone RB p
, , p
one CD p
with IN p
a DT p
Type-2 JJ p
and CC p
three CD p
with IN p
a DT p
Type-3 JJ p
acromion NN p
, , p
required VBN p
additional JJ o
surgery NN o
by IN N
the DT N
twenty-four-month JJ N
time NN N
point NN N
. . N

The DT N
number NN o
of IN o
patients NNS o
who WP o
required VBD o
additional JJ o
surgery NN o
was VBD N
greater JJR N
( ( N
p JJ N
= NNP N
0.05 CD N
) ) N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
alone RB N
than IN N
in IN N
the DT N
group NN N
that WDT N
had VBD N
arthroscopic VBN N
cuff JJ N
repair NN N
and CC N
acromioplasty NN N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
reports NNS N
in IN N
which WDT N
there EX N
was VBD N
no DT N
difference NN N
in IN N
functional JJ o
and CC o
quality-of-life JJ o
indices NNS o
for IN N
patients NNS p
who WP p
had VBD p
rotator NN p
cuff NN p
repair NN p
with IN p
or CC p
without IN p
acromioplasty JJ p
. . p

The DT N
higher JJR o
reoperation NN o
rate NN o
was VBD N
found VBN N
in IN N
the DT N
group NN p
without IN N
acromioplasty NN N
. . N

Further CC N
study NN N
that WDT N
includes VBZ N
follow-up JJ N
imaging NN N
and CC N
patient-reported JJ N
outcomes NNS N
over IN N
a DT N
greater JJR N
follow-up JJ N
period NN N
is VBZ N
needed VBN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
combination NN N
of IN N
evening VBG i
primrose JJ i
oil NN i
( ( i
gamma NN i
linolenic RB i
acid NN i
) ) i
and CC i
fish JJ i
oil NN i
( ( i
eicosapentaenoic JJ i
+ NNP i
docahexaenoic NN i
acid NN i
) ) i
versus NN i
magnesium NN i
, , i
and CC i
versus NN i
placebo NN i
in IN N
preventing VBG N
pre-eclampsia NN o
. . o

In IN N
a DT N
placebo NN i
controlled VBN N
, , N
partially RB N
double-blinded JJ N
, , N
clinical JJ N
trial NN N
, , N
a DT N
combination NN i
of IN i
evening VBG i
primrose JJ i
oil NN i
and CC i
fish JJ i
oil NN i
was VBD i
compared VBN i
to TO i
Magnesium NNP i
Oxide NNP i
, , i
and CC i
to TO i
a DT i
Placebo NNP i
in IN N
preventing VBG N
Pre-Eclampsia NNP o
of IN o
Pregnancy NNP o
. . o

All DT N
were VBD N
given VBN N
as IN N
nutritional JJ N
supplements NNS N
for IN N
six CD N
months NNS N
to TO N
a DT N
group NN p
of IN p
primiparous JJ p
and CC p
multiparous JJ p
pregnant JJ p
women NNS p
. . p

Some DT p
of IN p
these DT p
women NNS p
had VBD p
personal JJ p
or CC p
family NN p
histories NNS p
of IN p
hypertension NN p
( ( p
21 CD p
% NN p
) ) p
. . p

Only RB p
those DT p
patients NNS p
who WP p
received VBD p
prenatal JJ p
care NN p
at IN p
the DT p
Central NNP p
Maternity NNP p
Hospital NNP p
for IN p
Luanda NNP p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Compared VBN N
to TO N
the DT N
Placebo NNP i
group NN N
( ( N
29 CD N
% NN N
) ) N
, , N
the DT N
group NN N
receiving VBG N
the DT N
mixture NN N
of IN N
evening VBG i
primrose JJ i
oil NN i
and CC N
fish JJ i
oil NN i
containing VBG N
Gamma-linolenic JJ i
acid NN i
( ( i
GLA NNP i
) ) i
, , i
Eicosapentaenoic NNP i
acid NN i
( ( i
EPA NNP i
) ) i
, , N
and CC N
Docosahexaenoic NNP i
acid NN i
( ( i
DHA NNP i
) ) i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
edema NN o
( ( N
13 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
group NN N
receiving VBG N
Magnesium NNP i
Oxide NNP i
had VBD N
statistically RB N
significant JJ N
fewer JJR N
subjects NNS N
who WP N
developed VBD N
hypertension NN o
of IN o
pregnancy NN o
. . o

There EX N
were VBD N
3 CD N
cases NNS N
of IN N
eclampsia NN o
, , N
all DT N
in IN N
the DT N
Placebo NNP i
group NN N
. . N

-DOCSTART- -X- O O

Successful JJ N
new JJ N
method NN N
of IN N
extracorporeal JJ i
percutaneous JJ i
endoscopic NN i
gastrostomy NN i
( ( i
E-PEG NNP i
) ) i
. . i

BACKGROUND NNP N
Although IN N
percutaneous JJ i
endoscopic NNS i
gastrostomy NN i
( ( i
PEG NNP i
) ) i
has VBZ N
become VBN N
popular JJ N
for IN N
patients NNS p
with IN p
swallowing VBG p
disorders NNS p
as IN p
a DT p
nutrition NN p
support NN p
or CC p
a DT p
decompressant NN p
of IN p
gastrointestine NN p
, , p
perioperative JJ p
complications NNS p
associated VBN p
with IN p
PEG NNP i
have VBP p
not RB p
decreased VBN p
, , p
especially RB p
peristomal JJ p
infections NNS p
. . p

To TO N
reduce VB N
peristomal JJ N
infections NNS N
, , N
we PRP N
designed VBD N
a DT N
new JJ N
method NN N
of IN N
gastrostomy NN N
by IN N
extracorporeal JJ N
approach NN N
under IN N
endoscopic JJ N
observation NN N
, , N
named VBN N
as IN N
extra-corporeal JJ i
PEG NNP i
( ( i
E-PEG NNP i
) ) i
. . i

METHODS NNP N
Experimental NNP N
studies NNS N
for IN N
E-PEG NNP i
were VBD N
performed VBN N
repeatedly RB N
using VBG N
pigs NNS p
under IN p
general JJ p
anesthesia NN i
to TO N
confirm VB N
the DT N
safety NN N
of IN N
its PRP$ N
procedure NN N
for IN N
human JJ N
use NN N
. . N

After IN N
approval NN N
of IN N
institutional JJ N
ethics NNS N
review VBP N
board NN N
in IN N
our PRP$ N
university NN N
, , N
thirty JJ p
patients NNS p
with IN p
prior JJ p
consent NN p
participated VBN N
in IN N
this DT N
study NN N
. . N

The DT N
operation NN o
time NN o
, , N
the DT N
incidence NN o
rate NN o
of IN o
complications NNS o
and CC o
the DT o
hospital NN o
stay NN o
were VBD N
compared VBN N
between IN N
E-PEG NNP i
and CC i
ordinary JJ i
pull-method JJ i
PEG NNP i
groups NNS i
. . N

RESULTS NNP N
Two CD N
patients NNS N
( ( N
6.7 CD N
% NN N
) ) N
in IN N
E-PEG NNP i
group NN N
had VBD N
postoperative JJ o
complications NNS o
, , N
i.e. FW N
, , N
aspiration NN o
pneumonia NN o
and CC o
surgical JJ o
site NN o
infection NN o
. . o

The DT N
operation NN o
time NN o
of IN N
E-PEG NNP i
group NN N
was VBD N
5-16 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
10.3 CD N
+/- JJ N
2.96 CD N
) ) N
min NN N
as IN N
compared VBN N
to TO N
14-37 JJ N
( ( N
mean JJ N
+/- JJ N
SD NN N
: : N
26.9 CD N
+/- JJ N
8.39 CD N
) ) N
min NN N
with IN N
pull-method JJ N
PEG NNP i
. . i

The DT N
postoperative JJ o
hospital NN o
day NN o
of IN N
E-PEG NNP i
was VBD N
within IN N
two CD N
days NNS N
except IN N
for IN N
the DT N
two CD N
complicated VBD N
cases NNS N
. . N

Significance NNP N
differences NNS N
of IN N
operation NN o
time NN o
, , o
complication NN o
rate NN o
and CC o
postoperative JJ o
hospital NN o
stay NN o
between IN N
those DT N
groups NNS N
observed VBD N
statistically RB N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
that IN N
E-PEG NNP i
was VBD N
safe JJ o
, , o
tolerable JJ o
and CC N
speedy NN N
when WRB N
compared VBN N
ordinary JJ N
pull-method JJ N
PEG NNP i
. . i

-DOCSTART- -X- O O

Sustained JJ N
effect NN N
of IN N
SQ-standardized NNP N
grass NN N
allergy NN N
immunotherapy NN i
tablet NN i
on IN N
rhinoconjunctivitis NN N
quality NN N
of IN N
life NN N
. . N

BACKGROUND IN N
The DT N
prevalence NN N
of IN N
allergic JJ N
rhinoconjunctivitis NN N
has VBZ N
increased VBN N
significantly RB N
over IN N
the DT N
past JJ N
decades NNS N
with IN N
grass NN N
pollen NN N
being VBG N
a DT N
common JJ N
trigger NN N
. . N

The DT N
impact NN N
of IN N
allergy NN N
on IN N
patient NN N
's POS N
quality NN N
of IN N
life NN N
is VBZ N
substantial JJ N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
sustained JJ N
effect NN N
on IN N
quality NN N
of IN N
life NN N
during IN N
the DT N
grass NN N
pollen NN N
season NN N
1 CD N
year NN N
after IN N
3 CD N
years NNS N
of IN N
treatment NN N
with IN N
the DT N
SQ-standardized JJ N
grass NN i
allergy NN i
immunotherapy NN i
tablet NN i
( ( i
AIT NNP i
) ) i
, , N
Graza NNP N
( ( N
Phleum NNP N
pratense VBZ N
75,000 CD N
SQ-T/2800 JJ N
BAU NNP N
; : N
ALK NNP N
, , N
Denmark NNP N
) ) N
. . N

METHODS PDT N
The DT N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
in IN N
adult NN p
subjects NNS p
with IN p
a DT p
history NN p
of IN p
moderate-severe JJ p
grass NN p
pollen NN p
induced VBD p
rhinoconjunctivitis NN p
inadequately RB p
controlled VBN p
by IN p
symptomatic JJ p
medications NNS p
. . p

Subjects NNS p
received VBD N
3 CD N
years NNS N
of IN N
grass NN i
AIT NNP i
( ( N
n JJ N
= NNP N
157 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
126 CD N
) ) N
, , N
followed VBN N
by IN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

Quality NN o
of IN o
life NN o
assessments NNS N
were VBD N
based VBN N
on IN N
the DT N
standardized JJ o
rhinoconjunctivitis NN o
quality NN o
of IN o
life NN o
questionnaire NN o
( ( o
RQLQ NNP o
( ( o
S NNP o
) ) o
) ) o
; : o
completed VBN N
weekly JJ N
during IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
. . N

RESULTS NNP N
During IN N
follow-up JJ N
, , N
the DT N
overall JJ N
RQLQ NNP o
( ( o
S NNP o
) ) o
score NN o
for IN N
the DT N
entire JJ N
grass NN N
pollen NN N
season NN N
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
active JJ N
group NN N
( ( N
relative JJ N
difference NN N
to TO N
placebo VB i
: : i
23 CD N
% NN N
, , N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
improvement NN N
was VBD N
higher JJR N
during IN N
the DT N
peak NN N
pollen NN N
season NN N
( ( N
28 CD N
% NN N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
treatment NN N
effect NN N
of IN N
grass NN N
AIT NNP N
during IN N
the DT N
follow-up JJ N
year NN N
and CC N
the DT N
previous JJ N
three CD N
treatment NN N
years NNS N
was VBD N
similar JJ N
. . N

Improvements NNS N
were VBD N
found VBN N
in IN N
all DT N
seven CD N
RQLQ NNP o
( ( o
S NNP o
) ) o
domains VBZ o
. . o

The DT N
RQLQ NNP o
( ( o
S NNP o
) ) o
as IN N
a DT N
function NN N
of IN N
the DT N
weekly JJ N
average NN N
pollen NN N
counts VBZ N
showed VBD N
a DT N
clear JJ N
separation NN N
between IN N
the DT N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
In IN N
subjects NNS N
inadequately RB N
controlled VBN N
by IN N
symptomatic JJ N
medications NNS N
, , N
grass NN N
AIT NNP i
provided VBD N
sustained VBN N
and CC N
clinically RB N
relevant JJ N
improvements NNS N
in IN N
rhinoconjunctivitis NN o
quality NN o
of IN o
life NN o
compared VBN N
to TO N
placebo VB i
. . i

The DT N
effect NN N
increased VBD o
with IN N
increasing VBG N
grass NN N
pollen NN N
exposure NN N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
ventricular JJ N
fibrillation NN N
duration NN N
on IN N
defibrillation NN o
efficacy NN o
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
. . N

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
prospectively RB N
investigate VB N
the DT N
influence NN N
of IN N
ventricular JJ N
fibrillation NN N
( ( N
VF NNP N
) ) N
durations NNS N
of IN N
5 CD N
, , N
10 CD N
and CC N
20 CD N
s NN N
on IN N
the DT N
defibrillation NN o
threshold NN o
( ( o
DFT NNP o
) ) o
during IN N
implantable JJ N
cardioverter-defibrillator NN N
( ( N
ICD NNP N
) ) N
implantation NN N
. . N

BACKGROUND NNP N
Although IN N
the DT N
DFT NNP o
using VBG o
monophasic JJ o
waveforms NNS o
has VBZ N
been VBN N
shown VBN N
to TO N
increase VB N
with IN N
VF NNP N
duration NN N
in IN N
humans NNS N
, , N
the DT N
effect NN N
of IN N
VF NNP N
duration NN N
on IN N
defibrillation NN N
efficacy NN N
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
is VBZ N
not RB N
known VBN N
. . N

METHODS NNP N
Thirty NNP p
patients NNS p
undergoing VBG p
primary JJ p
ICD NNP p
implantation NN p
or CC p
pulse JJ p
generator NN p
replacement NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
have VB N
the DT N
DFT NNP i
determined VBD i
using VBG i
biphasic JJ i
shocks NNS i
at IN N
two CD N
durations NNS N
of IN N
VF NNP i
each DT N
( ( N
5 CD N
and CC N
10 CD N
s NN N
, , N
10 CD N
and CC N
20 CD N
s NN N
or CC N
5 CD N
and CC N
20 CD N
s NN N
) ) N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
mean JJ o
DFT NNP o
comparing VBG N
VF NNP N
durations NNS N
of IN N
5 CD N
s NNS N
( ( N
9.5+/-6.0 CD N
J NNP N
) ) N
and CC N
10 CD N
s NN N
( ( N
10.8+/-7.0 JJ N
J NNP N
) ) N
( ( N
p=0.4 NN N
) ) N
. . N

The DT N
mean JJ o
DFT NNP o
significantly RB N
increased VBD N
from IN N
10.9+/-6.1 JJ N
J NNP N
at IN N
10 CD N
s NN N
of IN N
VF NNP N
to TO N
12.6+/-5.6 JJ N
J NNP N
( ( N
p=0.03 NN N
) ) N
at IN N
20 CD N
s NN N
of IN N
VF NNP N
, , N
and CC N
from IN N
7.0+/-3.5 JJ N
J NNP N
at IN N
5 CD N
s NN N
of IN N
VF NNP N
to TO N
10.5+/-6.3 JJ N
J NNP N
( ( N
p=0.04 NN N
) ) N
at IN N
20 CD N
s NN N
of IN N
VF NNP N
. . N

An DT N
increase NN N
in IN N
the DT N
DFT NNP o
was VBD N
observed VBN N
in IN N
14 CD p
patients NNS p
as IN N
VF NNP N
duration NN N
increased VBD N
. . N

There EX N
were VBD N
no DT N
clinical JJ N
characteristics NNS N
that WDT N
differentiated VBD N
patients NNS N
with IN N
and CC N
without IN N
an DT N
increase NN N
in IN N
the DT N
DFT NNP o
. . o

CONCLUSIONS NNP N
Defibrillation NNP o
efficacy NN o
decreases VBZ N
with IN N
increasing VBG N
VF NNP N
duration NN N
using VBG N
biphasic JJ N
waveforms NNS N
in IN N
humans NNS N
. . N

Ventricular JJ N
fibrillation NN N
durations NNS N
greater JJR N
than IN N
10 CD N
s NN N
may MD N
negatively RB N
affect VB N
the DT N
effectiveness NN o
of IN o
ICD NNP o
therapy NN o
. . o

-DOCSTART- -X- O O

Intermittent NNP i
recombinant JJ i
growth NN i
hormone NN i
treatment NN i
in IN N
short JJ p
children NNS p
born VBP p
small JJ p
for IN p
gestational JJ p
age NN p
: : p
four-year JJ N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
different JJ N
treatment NN N
regimens NNS N
. . N

BACKGROUND NNP N
Treatment NNP N
of IN N
short JJ p
children NNS p
born VBP p
small JJ p
for IN p
gestational JJ p
age NN p
SGA NNP p
with IN N
recombinant JJ i
human JJ i
growth NN i
hormone VBD i
r-hGH JJ i
increases NNS N
growth NN o
velocity NN o
during IN N
childhood NN N
. . N

As IN N
in IN N
other JJ N
indications NNS N
, , N
the DT N
growth NN o
velocity NN o
in IN N
these DT N
patients NNS N
is VBZ N
more JJR N
marked JJ N
during IN N
the DT N
first JJ N
year NN N
of IN N
treatment NN N
and CC N
then RB N
decreases VBZ N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
different JJ N
r-hGH JJ i
treatment NN i
schedules NNS N
( ( N
67 CD N
microg/kg/day NN N
in IN N
a DT N
discontinuous JJ N
or CC N
continuous JJ N
regimen NNS N
) ) N
during IN N
the DT N
second JJ N
year NN N
of IN N
r-hGH JJ N
treatment NN N
by IN N
comparing VBG N
height JJ o
velocity NN o
changes NNS N
and CC N
total JJ o
gain NN o
of IN o
height NN o
over IN N
a DT N
4-year JJ N
period NN N
. . N

METHODS $ N
58 CD p
growth-retarded JJ p
SGA NNP p
children NNS p
aged VBN p
2-5 CD p
years NNS p
were VBD p
randomized VBN p
to TO N
a DT N
TOTO NNP i
regimen NN i
( ( N
4 CD N
years NNS N
alternating VBG N
treatment NN N
( ( N
T NNP N
) ) N
and CC N
observation NN N
( ( N
O NNP N
) ) N
, , N
n JJ N
= NNP N
30 CD N
) ) N
or CC N
a DT N
TTOO JJ N
regimen NN N
( ( N
2 CD N
years NNS N
' POS N
treatment NN N
, , N
followed VBN N
by IN N
2 CD N
years NNS N
' POS N
observation NN N
, , N
n JJ N
= NNP N
28 CD N
) ) N
. . N

Height NNP o
velocity NN o
HV NNP o
and CC o
total JJ o
height NN o
gain NN o
were VBD N
assessed VBN N
during IN N
the DT N
4-year JJ N
study NN N
. . N

RESULTS NNP N
In IN N
both DT N
groups NNS N
, , N
HV NNP o
and CC o
HV NNP o
standard JJ o
deviation NN o
score VBD o
HV-SDSCA NNP o
increased VBD N
during IN N
treatment NN N
and CC N
decreased VBD N
during IN N
observation NN N
periods NNS N
. . N

Interruption NN N
of IN N
treatment NN N
in IN N
the DT N
TOTO NNP N
group NN N
did VBD N
not RB N
result VB N
in IN N
a DT N
better JJR N
gain NN o
in IN o
height JJ o
standard NN o
deviation NN o
score VBD o
H-SDSCA NNP o
when WRB N
compared VBN N
with IN N
the DT N
TTOO NNP N
group NN N
. . N

After IN N
4 CD N
years NNS N
of IN N
study NN N
, , N
the DT N
gain NN o
in IN o
H-SDSCA NNP o
was VBD N
1.4 CD N
+ NN N
or CC N
- : N
01 CD N
in IN N
the DT N
TOTO NNP N
group NN N
and CC N
1.6 CD N
+ NN N
or CC N
- : N
0.2 CD N
in IN N
the DT N
TTOO NNP N
group NN N
leading VBG N
to TO N
a DT N
mean JJ N
height NN o
of IN N
-2.0 NNP N
+ NNP N
or CC N
- : N
1.0 CD N
SDS NNP N
and CC N
-2.0 NNP N
+ NNP N
or CC N
- : N
0.8 CD N
SDS NNP N
, , N
respectively RB N
. . N

The DT N
rate NN o
of IN o
bone NN o
maturation NN o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
short JJ N
SGA NNP N
children NNS N
, , N
TOTO NNP i
and CC N
TTOO NNP i
regimens NNS N
produced VBD N
significant JJ N
improvements NNS N
in IN N
growth NN o
during IN N
r-hGH JJ i
treatment NN i
. . N

However RB N
, , N
treatment NN N
interruption NN N
after IN N
1 CD N
year NN N
did VBD N
not RB N
influence VB N
the DT N
overall JJ o
gain NN o
in IN o
height NN o
SDS NNP o
when WRB N
compared VBN N
with IN N
2 CD N
years NNS N
' POS N
continuous JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Humour-related JJ N
interventions NNS N
for IN N
people NNS p
with IN p
mental JJ p
illness NN p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

This DT N
study NN N
explored VBD N
the DT N
feasibility NN N
and CC N
effects NNS N
of IN N
humour-related JJ i
interventions NNS N
for IN N
mentally RB p
ill JJ p
adults NNS p
. . p

Twelve NNP p
, , p
randomly RB p
assigned VBN p
, , p
participated VBN p
in IN N
each DT N
of IN N
3 CD N
arms NNS i
-- : i
stand VBP i
up RP i
comedy NN i
training NN i
( ( i
the DT i
experimental NN i
arm NN i
) ) i
, , i
discussing VBG i
comedy NN i
videos NNS i
( ( i
the DT i
active JJ i
control NN i
arm NN i
) ) i
, , i
and CC i
no DT i
humour-related JJ i
intervention NN i
( ( N
the DT N
passive NN N
control NN N
arm NN N
) ) N
. . N

Quantitative JJ o
and CC o
qualitative JJ o
data NNS o
were VBD N
collected VBN N
at IN N
baseline NN N
, , N
end NN N
of IN N
interventions NNS N
( ( N
3 CD N
months NNS N
) ) N
and CC N
follow VB N
up RP N
( ( N
after IN N
another DT N
3 CD N
months NNS N
) ) N
. . N

Scale JJ o
comparisons NNS o
were VBD N
largely RB N
negative JJ N
, , N
although IN N
self-esteem JJ o
marginally RB N
increased VBN N
in IN N
the DT N
experimental JJ N
arm NN N
. . N

Interview NNP N
responses VBZ N
indicated JJ N
benefits NNS N
for IN N
the DT N
interventions NNS N
, , N
including VBG N
improved VBN o
self-esteem NN o
in IN N
the DT N
experimental JJ N
arm NN N
. . N

These DT N
results NNS N
, , N
though IN N
mixed JJ N
, , N
justify VB N
further JJ N
study NN N
. . N

-DOCSTART- -X- O O

Enhancing VBG N
implementation NN N
of IN N
tobacco NN i
use NN i
prevention NN i
and CC i
cessation NN i
counselling VBG i
guideline NN i
among IN p
dental JJ p
providers NNS p
: : p
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Tobacco NNP N
use NN N
adversely RB N
affects VBZ N
oral JJ N
health NN N
. . N

Tobacco NNP i
use NN i
prevention NN i
and CC i
cessation NN i
( ( i
TUPAC NNP i
) ) i
counselling VBG i
guidelines NNS i
recommend VBP N
that IN N
healthcare NN p
providers NNS p
ask VBP N
about IN N
each DT N
patient NN p
's POS p
tobacco NN N
use NN N
, , N
assess IN N
the DT N
patient NN N
's POS N
readiness NN N
and CC N
willingness NN N
to TO N
stop VB N
, , N
document NN N
tobacco NN p
use NN p
habits NNS p
, , N
advise VBP N
the DT N
patient NN N
to TO N
stop VB N
, , N
assist NN N
and CC N
help NN N
in IN N
quitting NN N
, , N
and CC N
arrange JJ N
monitoring NN N
of IN N
progress NN N
at IN N
follow-up JJ N
appointments NNS N
. . N

Adherence NN N
to TO N
such JJ N
guidelines NNS N
, , N
especially RB N
among IN N
dental JJ p
providers NNS p
, , N
is VBZ N
poor JJ N
. . N

To TO N
improve VB N
guideline NN N
implementation NN N
, , N
it PRP N
is VBZ N
essential JJ N
to TO N
understand VB N
factors NNS N
influencing VBG N
it PRP N
and CC N
find VB N
effective JJ N
ways NNS N
to TO N
influence VB N
those DT N
factors NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
protocol NN N
is VBZ N
to TO N
introduce VB N
a DT N
theory-based JJ i
approach NN i
to TO i
diagnose VB i
implementation NN i
difficulties NNS i
of IN i
TUPAC NNP i
counselling VBG i
guidelines NNS i
among IN i
dental JJ i
providers NNS i
. . i

METHODS NNP N
Theories NNPS o
of IN o
behaviour NN o
change NN o
have VBP N
been VBN N
used VBN N
to TO N
identify VB N
key JJ N
theoretical JJ N
domains NNS N
relevant VBP N
to TO N
the DT N
behaviours NN N
of IN N
healthcare JJ p
providers NNS p
involved VBN N
in IN N
implementing VBG N
clinical JJ N
guidelines NNS N
. . N

These DT N
theoretical JJ N
domains NNS N
will MD N
inform VB N
the DT N
development NN N
of IN N
a DT N
questionnaire NN o
aimed VBN N
at IN N
assessing VBG N
the DT N
implementation NN N
of IN N
the DT N
TUPAC NNP i
counselling VBG i
guidelines NNS i
among IN N
Finnish JJ p
municipal JJ p
dental JJ p
providers NNS p
. . p

Specific JJ N
items NNS N
will MD N
be VB N
drawn VBN N
from IN N
the DT N
guidelines NNS N
and CC N
the DT N
literature NN N
on IN N
TUPAC NNP i
studies NNS N
. . N

After IN N
identifying VBG N
potential JJ N
implementation NN N
difficulties NNS N
, , N
we PRP N
will MD N
design VB N
two CD N
interventions NNS N
using VBG N
theories NNS i
of IN i
behaviour JJ i
change NN i
to TO N
link VB N
them PRP N
with IN N
relevant JJ N
behaviour NN N
change NN N
techniques NNS N
aiming VBG N
to TO N
improve VB N
guideline NN i
adherence NN i
. . i

For IN N
assessing VBG N
the DT N
implementation NN N
of IN N
TUPAC NNP i
guidelines NNS i
, , N
the DT N
electronic JJ o
dental NN o
record NN o
audit NN o
and CC N
self-reported JJ o
questionnaires NNS o
will MD N
be VB N
used VBN N
. . N

DISCUSSION NNP N
To TO N
improve VB N
guideline NN N
adherence NN N
, , N
the DT N
theoretical-domains NNS N
approach NN N
could MD N
provide VB N
a DT N
comprehensive JJ N
basis NN N
for IN N
assessing VBG N
implementation NN N
difficulties NNS N
, , N
as RB N
well RB N
as IN N
designing VBG N
and CC N
evaluating VBG N
interventions NNS N
. . N

After IN N
having VBG N
identified VBN N
implementation NN N
difficulties NNS N
, , N
we PRP N
will MD N
design VB N
and CC N
test VB N
two CD N
interventions NNS N
to TO N
enhance VB N
TUPAC NNP i
guideline JJ i
adherence NN N
. . N

Using VBG N
the DT N
cluster NN N
randomised VBD N
controlled JJ N
design NN N
, , N
we PRP N
aim VBP N
to TO N
provide VB N
further JJ N
evidence NN N
on IN N
intervention NN N
effects NNS N
, , N
as RB N
well RB N
as IN N
on IN N
the DT N
validity NN N
and CC N
feasibility NN N
of IN N
the DT N
theoretical-domain JJ N
approach NN N
. . N

The DT N
empirical JJ N
data NNS N
collected VBN N
within IN N
this DT N
trial NN N
will MD N
be VB N
useful JJ N
in IN N
testing VBG N
whether IN N
this DT N
theoretical-domain JJ i
approach NN i
can MD N
improve VB N
our PRP$ N
understanding NN N
of IN N
the DT N
implementation NN N
of IN N
TUPAC NNP i
guidelines NNS i
among IN N
dental JJ p
providers NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN15427433 NNP N
. . N

-DOCSTART- -X- O O

Impact NN N
of IN N
prior JJ N
pharmacotherapy NN i
on IN N
remission NN o
of IN o
psychotic JJ o
depression NN o
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Having VBG N
failed VBN N
to TO N
respond VB N
to TO N
an DT N
adequate JJ N
antidepressant JJ N
treatment NN N
course NN N
predicts VBZ N
poorer JJR N
treatment NN o
outcomes NNS o
in IN N
patients NNS p
with IN p
major JJ p
depression NN p
. . p

However RB N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
impact NN N
of IN N
prior JJ N
treatment NN N
on IN N
the DT N
outcome NN o
of IN N
major JJ p
depression NN p
with IN p
psychotic JJ p
features NNS p
( ( p
MDpsy NNP p
) ) p
. . p

We PRP N
examined VBD N
the DT N
effect NN N
of IN N
prior JJ N
treatment NN N
history NN N
on IN N
the DT N
outcome NN o
of IN o
pharmacotherapy NN o
of IN N
MDpsy NNP p
in IN p
patients NNS p
who WP p
participated VBD p
in IN p
the DT p
STOPD-PD NNP p
study NN p
, , p
a DT p
randomized VBN p
, , p
double-blind JJ p
, , p
clinical JJ p
trial NN p
comparing VBG p
a DT p
combination NN N
of IN N
olanzapine JJ i
plus CC i
sertraline JJ i
vs. FW i
olanzapine JJ i
plus CC i
placebo NN i
. . i

The DT N
strength NN N
of IN N
treatment NN N
courses NNS N
received VBD N
prior RB N
to TO N
randomization NN N
was VBD N
classified VBN N
using VBG N
a DT N
validated JJ N
method NN N
. . N

A DT N
hierarchy NN N
of IN N
outcomes NNS o
was VBD N
hypothesized VBN N
based VBN N
on IN N
treatments NNS N
received VBN N
prior RB N
to TO N
randomization NN N
and CC N
randomized JJ N
treatment NN N
. . N

A DT N
high JJ o
remission NN o
rate NN o
was VBD N
observed VBN N
in IN N
subjects NNS p
with IN p
a DT p
history NN p
of IN p
no DT p
prior JJ p
treatment NN p
or CC p
inadequate JJ p
treatment NN p
who WP p
were VBD p
treated VBN p
with IN p
a DT p
combination NN p
of IN p
olanzapine NN i
and CC p
sertraline NN i
. . i

A DT N
low JJ o
remission NN o
rate NN o
was VBD N
observed VBN N
in IN N
subjects NNS p
who WP p
had VBD p
previously RB p
failed VBN p
to TO p
respond VB p
to TO p
an DT p
antidepressant JJ p
alone NN p
and CC p
who WP p
were VBD p
treated VBN p
with IN p
olanzapine JJ i
monotherapy NN p
. . p

A DT N
low JJ o
remission NN o
rate NN o
was VBD N
also RB N
observed VBN N
in IN N
subjects NNS p
who WP p
had VBD p
previously RB p
failed VBN p
to TO p
respond VB p
to TO p
a DT p
combination NN p
of IN p
an DT p
antipsychotic JJ p
and CC p
an DT p
antidepressant NN p
. . p

Similar JJ N
to TO N
patients NNS N
with IN N
major JJ N
depression NN N
, , N
these DT N
results NNS N
emphasize VBP N
the DT N
impact NN o
of IN o
prior JJ o
pharmacotherapy NN o
on IN N
treatment NN o
outcomes NNS o
in IN N
patients NNS p
with IN p
MDpsy NNP p
. . p

-DOCSTART- -X- O O

The DT N
role NN N
of IN N
adjunctive JJ i
exenatide NN i
therapy NN i
in IN N
pediatric JJ p
type NN p
1 CD p
diabetes NNS p
. . p

OBJECTIVE NNP N
Exenatide NNP i
improves VBZ N
postprandial JJ N
glycemic JJ o
excursions NNS o
in IN N
type NN N
2 CD N
diabetes NNS N
. . N

Exenatide NNP i
could MD N
benefit VB N
type JJ N
1 CD N
diabetes NNS N
as RB N
well RB N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
an DT N
effective JJ N
and CC N
safe JJ N
glucose-lowering NN o
adjuvant JJ N
exenatide NN N
dose NN N
in IN N
adolescents NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Eight NNP p
subjects NNS p
completed VBD N
a DT N
three-part JJ N
double-blinded JJ N
randomized VBN N
controlled VBN N
study NN N
of IN N
premeal JJ N
exenatide NN i
. . i

Two CD i
doses NNS i
of IN i
exenatide NN i
( ( i
1.25 CD i
and CC i
2.5 CD i
microg NN i
) ) i
were VBD i
compared VBN i
with IN i
insulin NN i
monotherapy NN i
. . i

Prandial JJ N
insulin NN i
dose NN N
was VBD N
reduced VBN N
by IN N
20 CD N
% NN N
. . N

Gastric NNP N
emptying VBG N
and CC N
hormones NNS N
were VBD N
analyzed VBN N
for IN N
300 CD N
min JJ N
postmeal NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
both DT N
doses NNS N
of IN N
exenatide JJ i
versus NN N
insulin NN i
monotherapy NN i
significantly RB N
reduced VBD o
glucose JJ o
excursions NNS o
over IN N
300 CD N
min NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Exenatide NNP i
administration NN N
failed VBD o
to TO o
suppress VB o
glucagon NN o
but CC o
delayed VBD o
gastric JJ o
emptying NN o
( ( N
P NNP N
< NNP N
0.004 CD N
) ) N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
exenatide NN i
therapy NN N
reduces VBZ o
postprandial JJ o
hyperglycemia NN o
in IN N
adolescents NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

This DT N
reduction NN N
in IN N
glucose JJ o
excursion NN o
occurs VBZ N
despite IN N
reduction NN N
in IN N
insulin NN N
dose NN N
. . N

We PRP N
suggest VBP N
that DT N
exenatide NN i
has VBZ N
therapeutic JJ N
potential NN N
as IN N
adjunctive JJ N
therapy NN N
in IN N
type NN N
1 CD N
diabetes NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
parallel NN N
study NN N
to TO N
assess VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
two CD N
different JJ N
dosing VBG N
regimens NNS N
of IN N
5 CD N
% NN N
imiquimod NN i
in IN N
the DT N
treatment NN N
of IN N
superficial JJ p
basal NN p
cell NN p
carcinoma NN p
. . p

OBJECTIVES CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
two CD N
cycled VBD N
dosing VBG N
regimens NNS N
of IN N
imiquimod JJ i
5 CD N
% NN N
cream NN N
for IN N
treatment NN N
of IN N
superficial JJ p
basal NN p
cell NN p
carcinoma NN p
( ( p
sBCC NN p
) ) p
. . p

METHODS JJ N
Patients NNPS p
( ( p
n JJ p
= NNP p
32 CD p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
two CD N
treatment NN N
regimens NNS N
: : N
8 CD i
weeks NNS i
of IN i
treatment NN i
with IN i
once-daily JJ i
dosing VBG i
for IN i
alternate JJ i
weeks NNS i
( ( i
R1 NNP i
) ) i
and CC i
5 CD i
weeks NNS i
of IN i
once-daily JJ i
dosing NN i
with IN i
a DT i
1-week JJ i
interval NN i
in IN i
the DT i
middle NN i
of IN i
the DT i
course NN i
( ( N
R2 NNP N
) ) N
. . N

Efficacy NN N
measures NNS N
were VBD N
tumour JJ o
clearance NN o
at IN N
weeks NNS N
19 CD N
and CC N
52 CD N
and CC N
measures NNS o
of IN o
patients NNS o
' POS o
acceptability NN o
. . o

RESULTS NNP N
Data NNP N
from IN N
30 CD p
patients NNS p
( ( p
13 CD p
females NNS p
) ) p
, , p
14 CD p
on IN p
R1 NNP p
and CC p
16 CD p
on IN p
R2 NNP p
, , N
were VBD N
analysed VBN N
. . N

The DT N
results NNS N
revealed VBD N
an DT N
initial JJ N
clearance NN o
rate NN o
of IN N
64 CD N
% NN N
at IN N
week NN N
19 CD N
for IN N
R1 NNP N
and CC N
81 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
-14 NN N
% NN N
to TO N
45 CD N
% NN N
, , N
p NN N
= NNP N
0.21 CD N
) ) N
. . N

However RB N
, , N
clearance NN o
rates NNS o
at IN N
week NN N
52 CD N
were VBD N
significantly RB N
different JJ N
: : N
43 CD N
% NN N
for IN N
R1 NNP N
and CC N
88 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
11 CD N
% NN N
to TO N
68 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
acceptability NN o
of IN o
treatment NN o
as IN N
measured VBN N
by IN N
composite JJ N
median JJ N
visual JJ N
analogue NN N
scores NNS N
at IN N
week NN N
8 CD N
. . N

CONCLUSION NNP N
Five NNP N
weeks NNS N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN N
once RB N
daily JJ N
with IN N
a DT N
1-week JJ N
interval NN N
was VBD N
more RBR N
effective JJ o
but CC N
as RB N
well RB o
tolerated VBN o
as IN N
the DT N
8-week JJ N
alternate NN N
week NN N
regimen NNS N
for IN N
sBCC NN p
. . p

-DOCSTART- -X- O O

Utilization NN N
patterns NNS N
of IN N
conventional JJ i
and CC i
complementary/alternative JJ i
treatments NNS i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
developmental JJ p
disabilities NNS p
in IN p
a DT p
population-based JJ p
study NN p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
utilization NN N
of IN N
conventional JJ i
treatments NNS i
and CC i
utilization NN i
of IN i
complementary JJ i
and CC i
alternative JJ i
medicine NN i
in IN N
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
and CC p
other JJ p
developmental JJ p
disabilities NNS p
( ( p
DD NNP p
) ) p
. . p

METHODS JJ N
Participants NNS p
were VBD p
578 CD p
children NNS p
who WP p
were VBD p
part NN p
of IN p
an DT p
ongoing JJ p
population-based JJ p
, , p
case-control JJ p
study NN p
of IN p
2- JJ p
to TO p
5-year JJ p
olds NNS p
with IN p
ASD NNP p
, , p
DD NNP p
, , p
and CC p
the DT p
general JJ p
population NN p
. . p

Parents NNS N
completed VBD N
an DT N
interview NN N
on IN N
past JJ N
and CC N
current JJ N
services NNS N
. . N

RESULTS NNP N
Four CD p
hundred VBD p
fifty-three JJ p
children NNS p
with IN p
ASD NNP p
and CC p
125 CD p
DD NNP p
children NNS p
were VBD p
included VBN p
. . p

ASD NNP N
families NNS N
received VBD N
more RBR N
hours NNS N
of IN N
conventional JJ o
services NNS o
compared VBN N
with IN N
DD NNP N
families NNS N
( ( N
17.8 CD N
vs RB N
11 CD N
; : N
p NN N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
use NN N
of IN N
psychotropic NN N
medications NNS N
was VBD N
low JJ N
in IN N
both DT N
groups NNS N
( ( N
approximately RB N
3 CD N
% NN N
) ) N
. . N

Overall JJ N
, , N
complementary JJ o
and CC o
alternative JJ o
medicine NN o
( ( o
CAM NNP o
) ) o
use NN N
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
ASD NNP N
( ( N
39 CD N
% NN N
) ) N
versus NN N
DD NNP N
( ( N
30 CD N
% NN N
) ) N
. . N

Hispanic JJ p
families NNS p
in IN N
both DT N
groups NNS N
used VBD N
CAM NNP o
less RBR N
often RB N
than IN N
non-Hispanic JJ p
families NNS p
. . p

Variables NNS N
such JJ N
as IN N
level NN o
of IN o
function NN o
, , o
immunization NN o
status NN o
, , o
and CC o
the DT o
presence NN o
of IN o
an DT o
identified VBN o
neurogenetic JJ o
disorder NN o
were VBD N
not RB N
predictive JJ N
of IN N
CAM NNP i
use NN N
. . N

A DT N
higher JJR N
level NN o
of IN o
parental JJ o
education NN o
was VBD N
associated VBN N
with IN N
an DT N
increased VBN N
CAM NNP o
use NN N
in IN N
ASD NNP N
and CC N
DD NNP N
. . N

Families NNS p
who WP N
used VBD N
> $ N
20 CD N
hours NNS N
per IN N
week NN N
of IN N
conventional JJ i
services NNS i
were VBD N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP i
, , N
including VBG N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP i
. . i

Underimmunized VBN p
children NNS p
were VBD N
marginally RB N
more RBR N
likely JJ N
to TO N
use VB N
CAM NNP i
but CC N
not RB N
more RBR N
likely JJ N
to TO N
have VB N
received VBN N
potentially RB N
unsafe JJ N
or CC N
disproven JJ N
CAM NNP i
. . i

CONCLUSION NNP N
Use NNP N
of IN N
CAM NNP i
is VBZ N
common JJ N
in IN N
families NNS p
of IN p
young JJ p
children NNS p
with IN p
neurodevelopmental JJ p
disorders NNS p
, , N
and CC N
it PRP N
is VBZ N
predicted VBN N
by IN N
higher JJR N
parental JJ N
education NN N
and CC N
non-Hispanic JJ N
ethnicity NN N
but CC N
not RB N
developmental JJ N
characteristics NNS N
. . N

Further NNP N
research NN N
should MD N
address VB N
how WRB N
health NN N
care NN N
providers NNS N
can MD N
support VB N
families NNS N
in IN N
making VBG N
decisions NNS N
about IN N
CAM NNP i
use NN N
. . N

-DOCSTART- -X- O O

Long-term JJ o
outcome NN o
of IN N
migraine JJ i
therapy NN i
: : i
predictive JJ N
value NN N
of IN N
the DT N
frontotemporal JJ i
nitroglycerin JJ i
test NN i
. . i

We PRP N
evaluated VBD N
whether IN N
type NN N
of IN N
response NN N
to TO N
the DT N
migraine-induction JJ N
test NN N
with IN N
a DT N
nitroglycerin JJ i
ointment NN i
applied VBN N
to TO N
the DT N
frontotemporal JJ N
head NN N
region NN N
could MD N
predict VB o
the DT o
efficacy NN o
of IN o
antimigraine JJ o
therapy NN o
. . o

Forty-two JJ p
patients NNS p
with IN p
migraine NN p
without IN p
aura JJ p
underwent NN p
the DT p
test NN p
before IN p
and CC p
2 CD p
months NNS p
after IN p
antimigraine JJ i
therapy NN i
. . i

Two CD N
and CC N
4 CD N
months NNS N
after IN N
treatment NN N
withdrawal NN N
, , N
most RBS N
subjects NNS N
with IN N
a DT N
negative JJ N
response NN N
to TO N
the DT N
post-treatment JJ N
test NN N
maintained VBD o
treatment NN o
benefit NN o
, , N
whereas JJ N
benefit NN o
was VBD N
lost VBN N
in IN N
patients NNS N
with IN N
an DT N
early JJ o
onset NN o
migraine NN o
response NN o
. . o

-DOCSTART- -X- O O

A DT N
simplified JJ N
4-site JJ N
economical JJ N
intradermal JJ N
post-exposure NN N
rabies NNS i
vaccine VBP i
regimen NNS p
: : p
a DT N
randomised JJ N
controlled VBN N
comparison NN N
with IN N
standard JJ N
methods NNS N
. . N

BACKGROUND IN N
The DT N
need NN N
for IN N
economical JJ N
rabies NNS p
post-exposure JJ p
prophylaxis NN p
( ( p
PEP NNP p
) ) p
is VBZ N
increasing VBG N
in IN N
developing VBG N
countries NNS N
. . N

Implementation NN N
of IN N
the DT N
two CD N
currently RB N
approved VBN N
economical JJ N
intradermal NN N
( ( N
ID NNP N
) ) N
vaccine NN N
regimens VBZ N
is VBZ N
restricted VBN N
due JJ N
to TO N
confusion NN N
over IN N
different JJ N
vaccines NNS N
, , N
regimens NNS N
and CC N
dosages NNS N
, , N
lack NN N
of IN N
confidence NN N
in IN N
intradermal JJ N
technique NN N
, , N
and CC N
pharmaceutical JJ N
regulations NNS N
. . N

We PRP N
therefore RB N
compared VBN N
a DT N
simplified JJ N
4-site JJ N
economical JJ N
PEP NNP N
regimen NNS N
with IN N
standard JJ N
methods NNS N
. . N

METHODS NNP N
Two CD p
hundred VBD p
and CC p
fifty-four JJ p
volunteers NNS p
were VBD p
randomly RB p
allocated VBN p
to TO N
a DT N
single JJ N
blind NN N
controlled VBD N
trial NN N
. . N

Each DT N
received VBD N
purified JJ i
vero NN i
cell NN i
rabies NNS i
vaccine VBP i
by IN N
one CD N
of IN N
four CD N
PEP NNP N
regimens NNS N
: : N
the DT N
currently RB N
accepted VBN N
2-site JJ N
ID NNP N
; : N
the DT N
8-site JJ N
regimen NNS N
using VBG N
0.05 CD N
ml JJ N
per IN N
ID NNP N
site NN N
; : N
a DT N
new JJ N
4-site JJ N
ID NNP N
regimen NNS N
( ( N
on IN N
day NN N
0 CD N
, , N
approximately RB N
0.1 CD N
ml NNS N
at IN N
4 CD N
ID NNP N
sites NNS N
, , N
using VBG N
the DT N
whole JJ N
0.5 CD N
ml JJ N
ampoule NN N
of IN N
vaccine NN N
; : N
on IN N
day NN N
7 CD N
, , N
0.1 CD N
ml NN N
ID NNP N
at IN N
2 CD N
sites NNS N
and CC N
at IN N
one CD N
site NN N
on IN N
days NNS N
28 CD N
and CC N
90 CD N
) ) N
; : N
or CC N
the DT N
standard JJ i
5-dose JJ i
intramuscular JJ N
regimen NNS N
. . N

All DT N
ID NNP N
regimens NNS N
required VBD N
the DT N
same JJ N
total JJ N
amount NN N
of IN N
vaccine NN N
, , N
60 CD N
% NN N
less JJR N
than IN N
the DT N
intramuscular JJ N
method NN N
. . N

Neutralising VBG N
antibody NN N
responses NNS N
were VBD N
measured VBN N
five CD N
times NNS N
over IN N
a DT N
year NN N
in IN N
229 CD N
people NNS N
, , N
for IN N
whom WP N
complete JJ N
data NNS N
were VBD N
available JJ N
. . N

FINDINGS NNP N
All NNP N
ID NNP N
regimens VBZ N
showed VBD N
similar JJ N
immunogenicity NN o
. . o

The DT N
intramuscular JJ N
regimen NNS N
gave VBD N
the DT N
lowest JJS N
geometric JJ o
mean NN o
antibody NN o
titres NNS o
. . o

Using VBG N
the DT N
rapid JJ N
fluorescent JJ N
focus NN N
inhibition NN N
test NN N
, , N
some DT N
sera NN N
had VBD N
unexpectedly RB N
high JJ o
antibody NN o
levels NNS o
that WDT N
were VBD N
not RB N
attributable JJ N
to TO N
previous JJ N
vaccination NN N
. . N

The DT N
results NNS N
were VBD N
confirmed VBN N
using VBG N
the DT N
fluorescent NN N
antibody NN N
virus JJ N
neutralisation NN N
method NN N
. . N

CONCLUSIONS VB N
This DT N
4-site JJ N
PEP NNP N
regimen NNS N
proved VBD N
as RB N
immunogenic JJ o
as IN N
current JJ N
regimens NNS N
, , N
and CC N
has VBZ N
the DT N
advantages NNS N
of IN N
requiring VBG N
fewer JJR N
clinic JJ N
visits NNS N
, , N
being VBG N
more RBR N
practicable JJ N
, , N
and CC N
having VBG N
a DT N
wider JJR N
margin NN N
of IN N
safety NN N
, , N
especially RB N
in IN N
inexperienced JJ N
hands NNS N
, , N
than IN N
the DT N
2-site JJ N
regimen NNS N
. . N

It PRP N
is VBZ N
more RBR N
convenient JJ N
than IN N
the DT N
8-site JJ N
method NN N
, , N
and CC N
can MD N
be VB N
used VBN N
economically RB N
with IN N
vaccines NNS N
formulated VBN N
in IN N
1.0 CD N
or CC N
0.5 CD N
ml NN N
ampoules NNS N
. . N

The DT N
4-site JJ N
regimen NNS N
now RB N
meets VBZ N
all DT N
requirements NNS N
of IN N
immunogenicity NN o
for IN o
PEP NNP o
and CC N
can MD N
be VB N
introduced VBN N
without IN N
further JJ N
studies NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN NNP N
30087513 CD N
. . N

-DOCSTART- -X- O O

Preliminary JJ N
findings NNS N
from IN N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
two CD N
palatal JJ i
operations NNS i
for IN N
sleep-disordered JJ N
breathing NN N
. . N

OBJECTIVES IN N
We PRP N
compared VBN N
the DT N
efficacy NN o
of IN N
2 CD i
palatal JJ i
surgical JJ i
procedures NNS i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
mild JJ p
sleep-disordered JJ p
breathing NN p
( ( p
SDB NNP p
) ) p
. . p

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
crossover RB N
surgical JJ N
trial NN N
at IN N
a DT N
university NN N
hospital NN N
. . N

METHODS NNP N
Twenty NNP p
patients NNS p
with IN p
mild JJ p
SDB NNP p
for IN p
whom WP p
conservative JJ p
treatment NN p
failed VBD p
were VBD N
identified VBN N
and CC N
consecutively RB N
enrolled VBD N
into IN N
an DT N
institutional JJ N
review NN N
board-approved JJ N
surgical JJ N
protocol NN N
. . N

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
either DT N
radiofrequency NN i
ablation NN i
of IN i
the DT i
palate NN i
( ( i
RFAP NNP i
) ) i
for IN i
a DT i
planned JJ i
3-stage JJ i
treatment NN i
or CC i
laser-assisted JJ i
uvulopalatoplasty JJ i
( ( i
LAUP NNP i
) ) i
, , i
also RB i
for IN i
3 CD i
stages NNS i
of IN i
treatment NN i
, , i
using VBG i
a DT i
CO NNP i
( ( i
2 CD i
) ) i
laser NN i
. . i

Parameters NNS N
assessed VBD N
included JJ N
severity NN o
of IN o
SDB NNP o
( ( o
polysomnography NN o
) ) o
, , o
subjective JJ o
and CC o
objective JJ o
loudness NN o
of IN o
snoring VBG o
( ( o
visual JJ o
analog NN o
scale NN o
and CC o
SNAP NNP o
recording NN o
) ) o
, , o
sleepiness NN o
( ( o
Epworth NNP o
Sleepiness NNP o
Scale NNP o
) ) o
, , N
and CC N
anatomic JJ o
changes NNS o
( ( o
upper JJ o
airway RB o
endoscopy NN o
) ) o
, , N
as RB N
well RB N
as IN N
demographic JJ N
factors NNS N
. . N

Patients NNS N
not RB N
achieving VBG N
satisfactory JJ N
improvement NN N
in IN N
their PRP$ N
condition NN N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
alternative JJ i
surgical JJ i
therapy NN i
for IN i
attempted JJ i
salvage NN i
. . i

RESULTS NNP N
Seventeen NNP N
of IN N
the DT N
enrolled JJ N
patients NNS N
have VBP N
completed VBN N
the DT N
protocol NN N
. . N

Ten CD N
of IN N
these DT N
were VBD N
randomized VBN N
to TO N
the DT N
RFAP NNP i
group NN N
, , N
and CC N
7 CD N
to TO N
the DT N
LAUP NNP i
group NN N
. . N

Six CD N
of IN N
the DT N
RFAP NNP i
patients NNS N
( ( N
60 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN o
, , N
and CC N
4 CD N
failed VBD N
and CC N
were VBD N
salvaged VBN N
with IN N
LAUP NNP i
. . i

Six NNP N
of IN N
the DT N
LAUP NNP i
patients NNS N
( ( N
86 CD N
% NN N
) ) N
achieved VBD N
a DT N
satisfactory JJ N
resolution NN N
of IN N
their PRP$ N
snoring NN o
, , N
and CC N
1 CD N
patient NN N
failed VBD N
and CC N
was VBD N
salvaged VBN N
with IN N
nasal JJ i
surgery NN i
. . i

One CD N
patient NN N
who WP N
was VBD N
initially RB N
cured VBN N
had VBD N
a DT N
relapse NN N
after IN N
9 CD N
months NNS N
and CC N
was VBD N
successfully RB N
salvaged VBN N
with IN N
RFA NNP i
. . i

CONCLUSION NNP N
Prospective NNP N
, , N
randomized VBD N
trials NNS N
of IN N
surgery NN N
for IN N
SDB NNP N
are VBP N
possible JJ N
. . N

Preliminary JJ N
findings NNS N
from IN N
the DT N
current JJ N
protocol NN N
reveal NN N
a DT N
slight JJ N
advantage NN N
of IN N
LAUP NNP i
over IN N
RFAP NNP i
but CC N
with IN N
a DT N
greater JJR N
degree NN N
of IN N
discomfort NN N
postoperatively RB N
. . N

-DOCSTART- -X- O O

Monitoring VBG N
tumour NN N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
of IN N
small JJ p
cell NN p
lung NN p
cancer NN p
patients NNS p
. . p

BACKGROUND NNP N
Flow NNP i
cytometry NN i
was VBD N
used VBN N
to TO N
enumerate VB N
tumour JJ N
cells NNS N
in IN N
longitudinal JJ N
studies NNS N
of IN N
peripheral JJ N
blood NN N
from IN N
small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
SCLC NNP p
) ) p
patients NNS p
, , N
together RB N
with IN N
magnetic JJ N
bead NN N
selection NN N
to TO N
isolate VB N
and CC N
identify VB N
these DT N
cells NNS N
. . N

As IN N
part NN N
of IN N
a DT N
trial NN N
, , N
11 CD p
patients NNS p
received VBD p
either RB p
standard JJ p
( ( p
four CD p
weekly RB p
) ) p
chemotherapy NN i
with IN i
ifosfamide NN i
, , i
carboplatin NN i
, , i
and CC i
etoposide RB i
( ( i
ICE NNP i
) ) i
or CC i
accelerated VBN i
( ( i
two CD i
weekly RB i
) ) i
ICE NNP i
with IN i
filgrastim NN i
( ( i
granulocyte JJ i
colony-stimulating NN i
factor NN i
[ IN i
G-CSF NNP i
] NNP i
) ) i
and CC i
autologous JJ i
stem NN i
cell NN i
support NN i
. . i

METHODS NNP N
Fresh NNP N
venous JJ N
blood NN N
was VBD N
taken VBN N
throughout IN N
treatment NN N
and CC N
follow-up NN N
. . N

Aliquots NNS N
were VBD N
stained VBN N
with IN N
a DT N
tumour-specific JJ N
antibody NN N
against IN N
epithelial JJ N
tissue NN N
( ( N
Ber NNP N
EP4 NNP N
) ) N
, , N
verified VBD N
as IN N
a DT N
good JJ N
marker NN N
of IN N
SCLC NNP N
cells NNS N
by IN N
immunohistochemistry NN N
. . N

Matched NNP N
samples NNS N
labelled VBD N
with IN N
Ber NNP N
EP4 NNP N
were VBD N
separated VBN N
magnetically RB N
by IN N
adding VBG N
a DT N
secondary JJ N
bead-antibody NN N
conjugate NN N
for IN N
confirmation NN N
of IN N
tumour NN N
cell NN N
identity NN N
. . N

RESULTS NNP N
Circulating NNP o
tumour JJ o
cells NNS o
were VBD N
detected VBN N
and CC N
monitored VBN N
throughout IN N
treatment NN N
periods NNS N
. . N

An DT N
initial JJ o
rise NN o
in IN o
circulating VBG o
cells NNS o
after IN o
the DT o
first JJ o
cycle NN o
was VBD N
followed VBN N
by IN N
a DT N
fall NN N
in IN N
both DT N
treatment NN N
arms NNS N
to TO N
baseline NN N
levels NNS N
set VBN N
by IN N
normal JJ N
controls NNS N
. . N

This DT N
was VBD N
achieved VBN N
by IN N
week NN N
12 CD N
in IN N
the DT N
accelerated JJ N
treatment NN N
arm NN N
and CC N
by IN N
week NN N
24 CD N
in IN N
the DT N
standard JJ N
arm NN N
. . N

CONCLUSIONS NNP N
Flow NNP N
cytometry NN N
and CC N
magnetic JJ N
bead NN N
isolation NN N
can MD N
be VB N
used VBN N
to TO N
identify VB N
changes NNS N
in IN N
numbers NNS N
of IN N
circulating VBG N
tumour JJ N
cells NNS N
in IN N
patients NNS N
undergoing JJ N
chemotherapy NN i
for IN N
SCLC NNP N
and CC N
thereafter RB N
during IN N
follow-up JJ N
periods NNS N
. . N

Absence NN N
of IN N
tumour JJ N
cells NNS N
may MD N
indicate VB N
a DT N
more RBR N
favourable JJ N
patient NN N
group NN N
who WP N
would MD N
benefit VB N
from IN N
a DT N
more RBR N
intense JJ N
course NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
a DT N
spiritually RB i
based VBN i
and CC i
non-spiritually RB i
based VBN i
educational JJ i
intervention NN i
for IN N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN N
church-attending JJ p
African-American JJ p
men NNS p
. . p

INTRODUCTION NNP N
Health NNP i
communication NN i
interventions NNS i
have VBP N
been VBN N
modestly RB N
effective JJ N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
for IN N
prostate NN N
cancer NN N
screening VBG N
among IN p
African-American JJ p
men NNS p
; : p
however RB N
, , N
knowledge NN N
and CC N
informed JJ N
decision NN N
making NN N
is VBZ N
still RB N
questionable JJ N
even RB N
with IN N
screening VBG N
. . N

Church-based JJ N
programs NNS N
may MD N
be VB N
more RBR N
effective JJ N
if IN N
they PRP N
are VBP N
spiritually RB N
based VBN N
in IN N
nature NN N
. . N

OBJECTIVE CC N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were VBD N
to TO N
implement VB N
and CC N
provide VB N
an DT N
initial JJ N
evaluation NN N
of IN N
a DT N
spiritually RB N
based VBN N
prostate NN N
cancer NN N
screening VBG N
informed JJ N
decision NN N
making VBG N
intervention NN N
for IN N
African-American JJ p
men NNS p
who WP p
attend VBP p
church NN p
, , N
and CC N
determine VB N
its PRP$ N
efficacy NN N
for IN N
increasing VBG N
informed JJ N
decision NN N
making NN N
. . N

DESIGN NNP N
AND CC N
METHOD NNP N
Churches NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
the DT N
spiritually RB i
based VBN i
or CC i
the DT i
non-spiritual JJ i
intervention NN i
. . i

Trained NNP N
community NN N
health NN N
advisors NNS N
, , N
who WP N
were VBD N
African-American JJ N
male JJ N
church NN N
members NNS N
, , N
led VBD N
an DT N
educational JJ i
session NN i
and CC N
distributed VBD i
educational JJ i
print NN i
materials NNS i
. . i

Participants NNS N
completed VBD N
baseline NN N
and CC N
immediate JJ N
follow-up JJ N
surveys NNS N
to TO N
assess VB N
the DT N
intervention NN N
impact NN N
on IN N
study NN N
outcomes NNS N
. . N

RESULTS VB N
The DT N
spiritually RB N
based VBN N
intervention NN N
appeared VBD N
to TO N
be VB N
more RBR N
effective JJ N
in IN N
areas NNS N
such JJ N
as IN N
knowledge NN N
, , N
and CC N
men NNS N
read VBP N
more JJR N
of IN N
their PRP$ N
materials NNS o
in IN N
the DT N
spiritually RB N
based VBN N
group NN N
than IN N
in IN N
the DT N
non-spiritual JJ N
group NN N
. . N

CONCLUSIONS NNP N
Further NNP N
examination NN N
of IN N
the DT N
efficacy NN o
of IN N
the DT N
spiritually RB N
based VBN N
approach NN N
to TO N
health NN N
communication NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
comparison NN N
of IN N
the DT N
Endeavor NNP i
zotarolimus-eluting JJ i
stent NN i
versus IN i
the DT i
TAXUS NNP i
paclitaxel-eluting JJ i
stent NN i
in IN N
de FW N
novo FW N
native JJ N
coronary JJ N
lesions NNS N
12-month JJ N
outcomes NNS N
from IN N
the DT N
ENDEAVOR NNP N
IV NNP N
trial NN N
. . N

OBJECTIVES CC N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP i
and CC N
Paclitaxel-Eluting NNP i
Stents NNP i
in IN N
Patients NNP N
with IN N
Coronary NNP N
Artery NNP N
Disease NNP N
) ) N
trial NN N
evaluated VBD N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
the DT N
zotarolimus-eluting JJ i
stent NN i
( ( i
ZES NNP i
) ) i
compared VBN i
with IN i
the DT i
paclitaxel-eluting JJ i
stent NN i
( ( i
PES NNP i
) ) i
. . N

BACKGROUND NNP N
First-generation NNP N
drug-eluting NN N
stents NNS N
have VBP N
reduced VBN N
angiographic JJ N
and CC N
clinical JJ N
restenosis NN N
, , N
but CC N
long-term JJ N
safety NN N
remains VBZ N
controversial JJ N
. . N

A DT N
second-generation JJ i
drug-eluting JJ i
stent NN i
, , N
which WDT N
delivers VBZ N
zotarolimus NN i
, , N
a DT N
potent JJ N
antiproliferative JJ N
agent NN N
, , N
via IN N
a DT N
biocompatible JJ N
phosphorylcholine NN N
polymer NN N
on IN N
a DT N
cobalt JJ N
alloy NN N
thin-strut JJ N
stent NN N
has VBZ N
shown VBN N
promising JJ N
experimental JJ N
and CC N
early JJ N
clinical JJ N
results NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
( ( N
1:1 CD N
) ) N
, , N
single-blind JJ N
, , N
controlled JJ N
trial NN N
comparing VBG N
outcomes NNS N
of IN N
patients NNS p
with IN p
single JJ p
de FW p
novo FW p
coronary JJ p
lesions NNS p
treated VBN p
with IN p
ZES NNP p
or CC p
PES NNP p
. . p

The DT N
primary JJ o
end NN o
point NN o
was VBD o
noninferiority NN o
of IN o
9-month JJ o
target NN o
vessel JJ o
failure NN o
defined VBD o
as IN o
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
target VB o
vessel JJ o
revascularization NN o
. . o

RESULTS NNP N
Among IN N
a DT N
total NN N
of IN N
1,548 CD p
patients NNS p
assigned VBN p
to TO p
ZES NNP i
( ( p
n JJ p
= NNP p
773 CD p
) ) p
or CC p
PES NNP p
( ( N
n JJ N
= NNP N
775 CD N
) ) N
, , N
at IN N
9 CD N
months NNS N
, , N
ZES NNP N
was VBD N
noninferior JJ N
to TO N
PES VB N
with IN N
rates NNS N
of IN N
target NN o
vessel JJ o
failure NN o
6.6 CD N
% NN N
versus IN N
7.1 CD N
% NN N
, , N
respectively RB N
( ( N
p NN N
( ( N
noninferiority NN N
) ) N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ o
myocardial JJ o
infarctions NNS o
with IN N
ZES NNP i
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS N
of IN N
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
target NN o
vessel NN o
revascularization NN o
, , o
or CC o
stent JJ o
thrombosis NN o
. . o

Although IN N
incidence NN N
of IN N
8-month JJ N
binary JJ o
angiographic JJ o
in-segment JJ o
restenosis NN o
was VBD N
higher RBR N
in IN N
patients NNS N
treated VBN N
with IN N
ZES NNP i
versus NN N
PES NNP N
( ( N
15.3 CD N
% NN N
vs. FW N
10.4 CD N
% NN N
; : N
p CC N
= VB N
0.284 CD N
) ) N
, , N
rates NNS N
of IN N
12-month JJ N
target NN o
lesion NN o
revascularization NN o
were VBD N
similar JJ N
( ( N
4.5 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.228 CD N
) ) N
, , N
especially RB N
in IN N
patients NNS N
without IN N
planned JJ N
angiographic JJ N
follow-up NN N
( ( N
3.6 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.756 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP i
has VBZ N
similar JJ N
clinical JJ N
safety NN N
and CC N
efficacy NN N
compared VBN N
with IN N
PES NNP i
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

( ( N
ENDEAVOR NNP N
IV NNP N
Clinical NNP N
Trial NNP N
; : N
NCT00217269 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Does NNP N
privatisation NN N
of IN N
vocational JJ N
rehabilitation NN N
improve VB N
labour NN N
market NN N
opportunities NNS N
? . N
Evidence NN N
from IN N
a DT N
field NN p
experiment NN p
in IN p
Sweden NNP p
. . p

This DT N
paper NN N
analyses VBZ N
if IN N
privatisation NN i
of IN i
vocational JJ i
rehabilitation NN i
can MD N
improve VB N
labour JJ N
market NN N
opportunities NNS N
for IN N
individuals NNS p
on IN p
long-term JJ p
sickness NN p
absence NN p
. . p

We PRP N
use VBP N
a DT N
field NN N
experiment NN N
performed VBN N
by IN p
the DT p
Public NNP p
Employment NNP p
Service NNP p
and CC p
the DT p
Social NNP p
Insurance NNP p
Agency NNP p
in IN p
Sweden NNP p
during IN p
2008-2010 JJ p
, , p
in IN p
which WDT p
over IN p
4000 CD p
participants NNS p
were VBD p
randomly RB p
offered VBN p
private JJ i
and CC i
public JJ i
rehabilitation NN i
. . i

We PRP N
find VBP N
no DT N
differences NNS N
in IN N
employment NN o
rates NNS o
following VBG N
rehabilitation NN i
between IN N
individuals NNS p
who WP N
received VBD N
rehabilitation NN N
by IN N
private JJ N
and CC N
public JJ N
providers NNS N
. . N

Also RB N
the DT N
average JJ o
cost NN o
of IN o
rehabilitation NN o
was VBD N
essentially RB N
equal JJ N
for IN N
the DT N
two CD N
types NNS N
of IN N
providers NNS N
. . N

This DT N
suggests VBZ N
that IN N
there EX N
are VBP N
no DT N
large JJ N
efficiency NN o
gains NNS o
from IN N
privatising VBG N
vocational JJ N
rehabilitation NN N
. . N

-DOCSTART- -X- O O

Ranibizumab NNP i
plus CC i
verteporfin JJ i
photodynamic JJ N
therapy NN N
in IN N
neovascular JJ N
age-related JJ N
macular JJ N
degeneration NN N
: : N
12 CD N
months NNS N
of IN N
retreatment NN N
and CC N
vision NN N
outcomes NNS N
from IN N
a DT N
randomized VBN N
study NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
injection NN N
frequency NN N
and CC N
visual JJ N
acuity NN N
( ( N
VA NNP N
) ) N
outcomes VBZ N
with IN N
combination NN N
therapy NN N
( ( i
ranibizumab JJ i
plus CC i
verteporfin JJ i
photodynamic JJ i
therapy NN i
, , i
PDT NNP i
) ) i
versus NN N
monotherapy NN N
( ( i
ranibizumab NN i
) ) i
. . N

METHODS CC N
A DT N
total NN N
of IN N
40 CD p
patients NNS p
with IN p
exudative JJ p
age-related JJ p
macular JJ p
degeneration NN p
were VBD p
randomized VBN p
1:1 CD N
to TO N
ranibizumab VB i
0.3 CD i
mg JJ i
plus CC i
single JJ i
standard NN i
verteporfin NN i
PDT NNP i
or CC i
ranibizumab VB i
0.3 CD i
mg JJ i
plus CC i
sham JJ i
PDT NNP i
. . i

Ranibizumab NNP i
was VBD N
administered VBN N
3 CD N
times NNS N
monthly JJ N
followed VBN N
by IN N
'as NNP N
needed VBD N
' '' N
to TO N
month NN N
12 CD N
based VBN N
on IN N
predetermined JJ N
vision/anatomical JJ N
criteria NNS N
. . N

Retreatment NN o
rates NNS o
, , o
VA NNP o
outcomes NNS o
and CC o
safety NN o
were VBD N
assessed VBN N
. . N

RESULTS NNP N
During IN N
months NNS N
3-12 CD N
, , N
combination NN N
therapy NN N
patients NNS N
required VBD N
fewer JJR N
ranibizumab JJ i
injections NNS N
( ( N
mean VB N
1.3 CD N
) ) N
compared VBN N
with IN N
monotherapy NN N
patients NNS N
( ( N
2.8 CD N
) ) N
. . N

Mean NNP o
VA NNP o
improved VBN N
by IN N
9.0 CD N
letters NNS N
with IN N
combination NN N
therapy NN N
versus NN N
7.5 CD N
letters NNS N
in IN N
the DT N
monotherapy NN N
group NN N
at IN N
month NN N
12 CD N
. . N

Both DT N
treatment NN N
regimens NNS N
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSION VB N
The DT N
need NN N
for IN N
ranibizumab JJ i
retreatment NN N
might MD N
be VB N
reduced VBN N
by IN N
administering VBG N
a DT N
single JJ N
verteporfin NN i
PDT NNP i
on IN N
the DT N
same JJ N
day NN N
as IN N
the DT N
first JJ N
ranibizumab NN i
injection NN N
, , N
without IN N
compromising VBG N
VA NNP N
outcomes NNS N
or CC N
safety NN N
. . N

-DOCSTART- -X- O O

Naltrexone NN i
in IN N
young JJ p
autistic JJ p
children NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
naltrexone NN i
, , N
an DT N
opiate NN N
blocker NN N
, , N
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

METHOD NNP N
Thirteen NNP p
children NNS p
with IN p
autistic JJ p
disorder NN p
, , p
aged VBD p
3.4 CD p
to TO p
8.3 CD p
years NNS p
( ( p
mean VB p
5.4 CD p
) ) p
, , p
were VBD p
studied VBN p
in IN p
home NN p
, , p
school NN p
, , p
and CC p
outpatient JJ p
laboratory NN p
. . p

Naltrexone NNP i
, , i
1.0 CD i
mg/kg NN i
, , i
was VBD i
given VBN i
daily RB i
in IN i
a DT i
randomized JJ i
, , i
double-blind JJ i
, , i
placebo-controlled JJ i
crossover NN i
design NN i
. . i

Dependent JJ i
measures NNS i
included VBD i
parent NN i
and CC i
teacher RB i
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
, , o
Conners NNPS o
Rating NNP o
Scales NNP o
, , o
and CC o
Naltrexone NNP o
Side-Effects NNP o
( ( o
SE NNP o
) ) o
Rating NNP o
Scale NNP o
; : o
laboratory NN o
CGI NNP o
, , o
movement NN o
actometer NN o
readings NNS o
, , o
and CC o
a DT o
10-second JJ o
interval NN o
recording VBG o
system NN o
analysis NN o
of IN o
on-task NN o
, , o
communication NN o
initiations NNS o
, , o
disruptive JJ o
behavior NN o
, , o
and CC o
self-stimulation NN o
. . o

RESULTS NNP N
Eight NNP N
of IN N
13 CD N
subjects NNS N
improved VBN N
in IN N
two CD N
or CC N
more JJR N
settings NNS N
. . N

Changes NNS N
in IN N
parent NN o
measures NNS o
( ( o
CGI NNP o
, , o
Conners NNP o
Impulsivity-Hyperactivity NNP o
Factor NNP o
, , o
and CC o
SE-Restlessness NNP o
) ) o
and CC o
Teacher NNP o
CGI NNP o
achieved VBD N
statistical JJ N
significance NN N
. . N

Teacher CC o
SE-Restlessness JJ o
and CC o
initiation NN o
of IN o
communication NN o
in IN N
the DT N
clinic NN N
showed VBD N
a DT N
trend NN N
toward IN N
improvement NN N
. . N

Actometer NNP o
readings NNS o
improved VBN N
in IN N
two CD N
children NNS N
who WP N
were VBD N
very RB N
active JJ N
at IN N
baseline NN N
. . N

Adverse JJ o
side NN o
effects NNS o
were VBD N
behavioral JJ N
, , N
mild JJ N
, , N
and CC N
transient NN N
. . N

Administering VBG N
the DT N
bitter JJ N
tablet NN N
was VBD N
a DT N
challenge NN N
. . N

CONCLUSIONS NNP N
Naltrexone NNP i
offers VBZ N
promise RB N
as IN N
an DT N
agent NN N
for IN N
modest JJ N
improvement NN N
of IN N
behavior NN o
and CC N
social JJ o
communication NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

Parent NN N
and CC N
teacher NN N
measures NNS N
can MD N
be VB N
useful JJ N
in IN N
outpatient JJ N
trials NNS N
to TO N
evaluate VB N
change NN N
. . N

-DOCSTART- -X- O O

Cardiovascular JJ o
safety NN o
and CC o
gastrointestinal JJ o
tolerability NN o
of IN N
etoricoxib JJ i
vs NN i
diclofenac NN i
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
( ( N
The DT N
MEDAL NNP N
study NN N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
cardiovascular JJ o
( ( o
CV NNP o
) ) o
and CC o
other JJ o
safety NN o
and CC o
efficacy NN o
parameters NNS o
of IN N
etoricoxib JJ i
60 CD N
and CC N
90 CD N
mg NN N
, , N
and CC N
diclofenac VBZ i
150 CD N
mg. NN N
METHODS NNP N
This DT N
double-blind NN N
study NN N
randomized VBD N
OA NNP p
patients NNS p
to TO N
etoricoxib VB i
90 CD N
mg NN N
, , N
then RB N
to TO N
60 CD N
mg NNS N
once RB N
daily JJ N
vs NNS N
diclofenac VBP i
75 CD N
mg JJ N
twice RB N
daily RB N
; : N
RA NNP p
patients NNS p
were VBD N
randomized VBN N
to TO N
etoricoxib VB i
90 CD N
mg NNS N
once RB N
daily JJ N
or CC N
diclofenac JJ i
75 CD N
mg JJ N
twice RB N
daily RB N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
non-inferiority NN N
of IN N
etoricoxib JJ i
vs NN N
diclofenac NN i
for IN N
thrombotic JJ N
CV NNP N
events NNS N
( ( N
95 CD N
% NN N
CI NNP N
upper JJ N
bound NN N
of IN N
hazard NN N
ratio NN N
< NNP N
1.30 CD N
) ) N
. . N

Other JJ o
safety NN o
and CC o
efficacy NN o
parameters NNS o
were VBD N
evaluated VBN N
in IN N
cohorts NNS N
of IN N
patients NNS N
based VBN N
on IN N
etoricoxib NN i
dose NN N
and CC N
disease NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
23 CD p
504 CD p
patients NNS p
were VBD N
randomized VBN N
with IN N
mean JJ N
treatment NN N
duration NN N
from IN N
19.4 CD N
to TO N
20.8 CD N
months NNS N
. . N

The DT N
thrombotic JJ o
CV NNP o
risk NN o
hazard NN o
ratio NN o
( ( o
HR NNP o
) ) o
( ( i
etoricoxib UH i
to TO N
diclofenac VB N
) ) N
was VBD N
0.96 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.81 CD N
, , N
1.15 CD N
) ) N
, , N
consistent JJ N
with IN N
non-inferiority NN N
of IN N
etoricoxib NN i
to TO N
diclofenac VB i
. . i

The DT N
cumulative JJ o
gastrointestinal NN o
( ( o
GI NNP o
) ) o
/liver VBP o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
discontinuation NN o
rate NN o
was VBD N
significantly RB N
lower JJR N
for IN N
etoricoxib JJR i
than IN N
diclofenac NN i
in IN N
each DT N
patient NN N
cohort NN N
; : N
HR NNP N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
of IN N
0.46 CD N
( ( N
0.39 CD N
, , N
0.54 CD N
) ) N
, , N
0.52 CD N
( ( N
0.42 CD N
, , N
0.63 CD N
) ) N
and CC N
0.49 CD N
( ( N
0.39 CD N
, , N
0.62 CD N
) ) N
for IN N
the DT N
60 CD N
mg NN N
OA NNP N
, , N
90 CD N
mg NN N
OA NNP N
and CC N
RA NNP N
cohorts NNS N
. . N

The DT N
maximum JJ o
average JJ o
change NN o
in IN o
systolic JJ o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
with IN N
etoricoxib NN i
was VBD N
3.4-3.6 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
1.0-1.5 JJ N
mmHg NN N
) ) N
, , N
while IN N
diclofenac NN N
produced VBD N
a DT N
maximum JJ N
average JJ N
change NN N
of IN N
0.9-1.9 JJ N
mmHg NN N
( ( N
diastolic JJ N
BP NNP N
: : N
0.0-0.5 JJ N
mmHg NN N
) ) N
. . N

Both DT N
agents NNS N
resulted VBD N
in IN N
similar JJ N
efficacy NN o
regardless NN N
of IN N
etoricoxib NN N
dose NN N
. . N

CONCLUSION NNP N
Long-term NNP N
etoricoxib NN i
use NN N
is VBZ N
associated VBN N
with IN N
a DT N
risk NN o
of IN o
thrombotic JJ o
CV NNP o
events NNS o
comparable JJ N
with IN N
that DT N
of IN N
diclofenac NN i
. . i

Compared VBN N
with IN N
diclofenac NN i
, , i
etoricoxib RB i
demonstrated VBD N
a DT N
greater JJR N
risk NN o
of IN o
renovascular JJ o
AEs NNP o
, , N
but CC N
a DT N
more RBR N
favourable JJ N
GI/liver NNP o
tolerability NN o
profile NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
ranolazine NN i
on IN N
A1C NNP N
and CC N
glucose JJ N
levels NNS N
in IN N
hyperglycemic JJ p
patients NNS p
with IN p
non-ST JJ p
elevation NN p
acute NN p
coronary JJ p
syndrome NN p
. . p

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
relationships NNS N
between IN N
glycemia NN N
at IN N
randomization NN N
, , N
concurrent JJ i
antidiabetic JJ i
therapy NN i
, , N
and CC N
change NN N
in IN N
A1C NNP N
and CC N
fasting VBG N
plasma NN N
glucose NN N
( ( N
FPG NNP N
) ) N
in IN N
patients NNS p
with IN p
diabetes NNS p
receiving VBG p
standard JJ p
treatment NN p
for IN p
diabetes NNS p
and CC p
randomized VBN p
to TO p
ranolazine VB i
or CC i
placebo VB i
within IN p
the DT p
MERLIN-TIMI-36 NNP p
( ( p
MERLIN NNP p
) ) p
study NN p
. . p

Ranolazine NNP i
is VBZ N
a DT N
novel JJ N
first-in-class JJ N
drug NN N
approved VBD N
for IN N
treating VBG N
angina JJ N
pectoris NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Randomization NNP N
and CC N
4-month JJ N
glycemic NN i
and CC i
antidiabetes VBZ i
drug NN i
usage NN i
data NNS i
from IN N
MERLIN NNP N
were VBD N
analyzed VBN N
using VBG N
Spotfire NNP N
and CC N
SAS NNP N
version NN N
9.1 CD N
software NN N
. . N

RESULTS NNP N
In IN N
patients NNS p
with IN p
diabetes NNS p
and CC p
A1C NNP p
of IN p
> NNP p
or=8-10 JJ p
% NN p
at IN p
randomization NN p
( ( p
n JJ p
= NNP p
171 CD p
) ) p
, , N
there EX N
was VBD N
an DT N
absolute JJ N
A1C NNP o
reduction NN o
in IN N
the DT N
ranolazine NN i
group NN N
of IN N
1.2 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-1.4 NNP N
to TO N
-1.0 VB N
) ) N
, , N
and CC N
the DT N
placebo-adjusted JJ i
( ( p
n JJ p
= NNP p
182 CD p
) ) p
decrease NN N
in IN N
A1C NNP o
by IN N
ranolazine NN N
was VBD N
0.59 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-0.99 NNP N
to TO N
-0.20 VB N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
patients NNS p
with IN p
FPG NNP p
of IN p
150-400 JJ p
mg/dl NN p
at IN p
randomization NN p
, , p
ranolazine NN i
( ( p
n JJ p
= NNP p
131 CD p
) ) p
compared VBN N
with IN N
placebo NN i
( ( p
n JJ p
= NNP p
147 CD p
) ) p
reduced VBN N
FPG NNP N
by IN N
25.7 CD N
mg/dl NNS N
( ( N
95 CD N
% NN N
CI NNP N
-43.3 NNP N
to TO N
-8.1 VB N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

When WRB N
changes NNS N
in IN N
either DT N
A1C NNP o
or CC o
FPG NNP o
were VBD N
correlated VBN N
to TO N
A1C NNP o
or CC o
FPG NNP o
at IN N
randomization NN N
, , N
the DT N
slopes NNS N
were VBD N
significantly RB N
steeper JJR N
for IN N
ranolazine NN i
than IN N
placebo NN i
( ( N
A1C NNP N
, , N
P NNP N
= NNP N
0.046 CD N
; : N
FPG NNP N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
indicating VBG N
that IN N
lowering VBG N
of IN N
A1C NNP o
and CC o
FPG NNP o
by IN N
ranolazine NN i
is VBZ N
related VBN N
to TO N
hyperglycemia VB N
at IN N
randomization NN N
. . N

Ranolazine NNP N
, , N
compared VBN N
with IN N
placebo NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
serious JJ o
hypoglycemic JJ o
events NNS o
, , N
associated VBN N
with IN N
significant JJ N
changes NNS N
in IN N
concurrent JJ o
antidiabetic JJ o
therapy NN o
, , N
or CC N
dependent NN N
on IN N
a DT N
history NN o
of IN o
angina NN o
. . o

CONCLUSIONS NNP N
Ranolazine NNP i
, , N
when WRB N
added VBN N
to TO N
concurrent VB N
antidiabetes NNS N
treatment NN N
, , N
lowers NNS N
FPG NNP o
and CC o
A1C NNP o
in IN N
patients NNS p
with IN p
cardiovascular JJ p
disease NN p
and CC p
poorly RB p
controlled VBN p
diabetes NNS p
. . p

-DOCSTART- -X- O O

[ JJ N
Biological NNP N
and CC N
clinical JJ N
effects NNS N
of IN N
oral JJ i
magnesium NN i
and CC i
associated VBN i
magnesium-vitamin JJ i
B6 NNP i
administration NN i
on IN N
certain JJ p
disorders NNS p
observed VBN p
in IN p
infantile JJ p
autism NN p
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

-DOCSTART- -X- O O

Treating VBG N
the DT N
substance-abusing JJ p
suicidal JJ p
patient NN p
. . p

Studies NNPS N
concerning VBG N
the DT N
treatment NN N
of IN N
substance-abusing JJ p
suicidal NN p
patients NNS p
are VBP N
scarce JJ N
despite IN N
the DT N
frequent JJ N
presence NN N
of IN N
suicidal JJ N
behavior NN N
among IN N
this DT N
population NN N
. . N

Indeed RB N
, , N
suicidality NN N
( ( N
ideation NN N
or CC N
behavior NN N
) ) N
is VBZ N
generally RB N
an DT N
exclusion NN N
criterion NN N
for IN N
participation NN N
in IN N
treatment NN N
studies NNS N
of IN N
subjects NNS p
with IN p
alcohol NN p
or CC p
drug NN p
abuse NN p
. . p

Consequently RB N
, , N
to TO N
date NN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
optimal JJ N
treatment NN N
of IN N
this DT N
population NN N
. . N

The DT N
first JJ N
study NN N
involving VBG N
substance-abusing JJ p
suicidal JJ p
patients NNS p
was VBD N
an DT N
open-label JJ N
trial NN N
conducted VBN N
in IN N
the DT N
early JJ N
1990s CD N
. . N

This DT N
study NN N
involved VBD N
12 CD p
patients NNS p
, , p
all DT p
of IN p
whom WP p
demonstrated VBD p
recent JJ p
suicidal JJ o
ideations NNS o
and CC p
had VBD p
made VBN p
a DT p
lifetime NN p
suicide NN p
attempt NN p
. . p

The DT N
results NNS N
of IN N
that DT N
open-label JJ i
study NN i
demonstrated VBD N
significant JJ N
within-group JJ N
improvement NN N
in IN N
both DT N
depressive JJ o
symptoms NNS o
( ( o
including VBG o
suicidal JJ o
ideations NNS o
) ) o
and CC o
level NN o
of IN o
drinking NN o
. . o

However RB N
, , N
substantial JJ N
residual JJ N
depressive NN o
symptoms NNS o
and CC o
drinking NN o
persisted VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
. . N

Also RB N
, , N
because IN N
no DT N
placebo NN i
control NN N
group NN N
was VBD N
utilized VBN N
, , N
the DT N
authors NNS N
of IN N
that DT N
study NN N
could MD N
not RB N
rule VB N
out IN N
the DT N
possibility NN N
that IN N
the DT N
apparent JJ N
therapeutic JJ N
effect NN N
from IN N
fluoxetine NN i
was VBD N
the DT N
result NN N
of IN N
the DT N
placebo NN i
effect NN N
. . N

To TO N
date NN N
, , N
only RB N
one CD N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
of IN N
subjects NNS p
with IN p
alcohol NN p
or CC p
substance NN p
abuse NN p
has VBZ N
included VBN N
substantial JJ N
numbers NNS N
of IN N
suicidal JJ N
patients NNS N
. . N

The DT N
study NN N
involved VBD N
51 CD p
subjects NNS p
, , p
of IN p
whom WP p
20 CD p
( ( p
39 CD p
% NN p
) ) p
had VBD p
made VBN p
a DT p
suicide JJ p
attempt NN p
in IN p
the DT p
current JJ p
depressive JJ p
episode NN p
, , p
31 CD p
( ( p
61 CD p
% NN p
) ) p
had VBD p
made VBN p
a DT p
suicide JJ p
attempt NN p
in IN p
their PRP$ p
lifetime NN p
, , p
and CC p
46 CD p
( ( p
90 CD p
% NN p
) ) p
had VBD p
reported VBN p
suicidal JJ p
ideations NNS p
in IN p
the DT p
week NN p
before IN p
hospitalization NN p
. . p

The DT N
results NNS N
of IN N
that DT N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
suggest VBP N
that IN N
fluoxetine NN i
was VBD N
effective JJ N
in IN N
decreasing VBG N
but CC N
not RB N
eliminating VBG N
both CC N
the DT N
depressive NN o
symptoms NNS o
( ( o
including VBG o
suicidal JJ o
ideations NNS o
) ) o
and CC o
the DT o
level NN o
of IN o
alcohol JJ o
consumption NN o
among IN N
a DT N
study NN N
group NN N
of IN N
subjects NNS N
with IN N
comorbid NN N
major JJ N
depressive JJ N
disorder NN N
and CC N
alcohol NN N
dependence NN N
, , N
many JJ N
of IN N
whom WP N
displayed VBD N
suicidal JJ N
ideations NNS N
. . N

A DT N
secondary JJ N
data NN N
analysis NN N
from IN N
that DT N
study NN N
suggested VBD N
that IN N
cigarette NN o
smoking NN o
is VBZ N
also RB N
significantly RB N
decreased VBN N
by IN N
fluoxetine NN i
, , N
but CC N
the DT N
magnitude NN N
of IN N
the DT N
decrease NN N
is VBZ N
limited JJ N
and CC N
few JJ N
of IN N
these DT N
patients NNS N
totally RB N
quit VBP N
smoking VBG N
with IN N
fluoxetine JJ N
treatment NN N
alone RB N
. . N

Another DT N
secondary JJ N
data NN N
analysis NN N
from IN N
that DT N
study NN N
suggested VBD N
that IN N
marijuana NN o
smoking NN o
was VBD N
also RB N
significantly RB N
decreased VBN N
in IN N
a DT N
subgroup NN N
of IN N
subjects NNS N
who WP N
demonstrated VBD N
cannabis NN N
abuse NN N
and CC N
that IN N
the DT N
magnitude NN N
of IN N
this DT N
improvement NN N
was VBD N
robust JJ N
. . N

A DT N
third JJ N
secondary JJ N
data NNS N
analysis NN N
from IN N
that DT N
study NN N
suggested VBD N
that IN N
cocaine NN o
abuse NN o
acts VBZ N
as IN N
a DT N
predictor NN N
of IN N
poor JJ N
outcome NN N
for IN N
both DT N
depressive JJ o
symptoms NNS o
( ( o
including VBG o
suicidality NN o
) ) o
and CC o
level NN o
of IN o
alcohol NN o
use NN o
in IN N
this DT N
population NN N
. . N

The DT N
results NNS N
of IN N
a DT N
1-year JJ N
naturalistic JJ N
follow-up NN N
study NN N
involving VBG N
the DT N
patients NNS N
from IN N
that DT N
study NN N
suggest VBP N
that IN N
the DT N
benefits NNS N
of IN N
fluoxetine NN i
in IN N
decreasing VBG N
depressive JJ o
symptoms NNS o
and CC o
level NN o
of IN o
drinking VBG o
persist NN N
1 CD N
year NN N
after IN N
entering VBG N
the DT N
treatment NN N
program NN N
. . N

To TO N
date NN N
, , N
no DT N
other JJ N
double-blind NN N
, , N
placebo-controlled JJ i
studies NNS N
involving VBG N
substantial JJ N
numbers NNS N
of IN N
substance-abusing JJ p
suicidal NN p
patients NNS p
have VBP N
been VBN N
reported VBN N
to TO N
either DT N
confirm NN N
or CC N
refute VB N
these DT N
findings NNS N
. . N

Further JJ N
studies NNS N
are VBP N
clearly RB N
warranted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
various JJ N
pharmacotherapeutic JJ N
agents NNS N
and CC N
various JJ N
psychotherapies NNS i
in IN N
the DT N
treatment NN N
of IN N
substance-abusing JJ p
suicidal JJ p
patients NNS p
. . p

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
peer NN i
counseling VBG i
on IN N
smoking VBG N
cessation NN o
and CC N
reduction NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
a DT N
peer NN i
counseling VBG i
intervention NN i
for IN N
pregnant JJ p
smokers NNS p
. . p

METHODS NNP N
One CD p
hundred VBD p
forty-two NN p
pregnant NN p
, , p
predominantly RB p
Hispanic JJ p
women NNS p
were VBD N
assigned VBN N
to TO N
a DT N
peer-led JJ i
smoking NN i
cessation NN i
program NN i
or CC i
to TO i
usual JJ i
care NN i
. . i

RESULTS NNP N
Compared VBD N
with IN N
usual JJ i
care NN i
, , i
peer NN i
counseling NN i
reduced VBN N
smoking NN N
( ( N
-9.1 JJ N
versus NN N
-4.5 NNP N
cigarettes VBZ N
daily RB N
, , N
P NNP N
=.03 NNP N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
absolute JJ N
quit NN o
rates NNS o
( ( N
24 CD N
% NN N
versus IN N
21 CD N
% NN N
) ) N
at IN N
36 CD N
weeks NNS N
' POS N
gestation NN N
. . N

Infant NNP o
birth NN o
weight VBD o
negatively RB N
correlated VBN N
with IN N
cigarettes NNS N
smoked VBN N
per IN N
day NN N
( ( N
r VB N
= NNP N
-0.29 NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
expired JJ N
carbon NN N
monoxide NN N
( ( N
r JJ N
= NNP N
-0.39 NN N
, , N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
delivery NN N
. . N

Birth NNP o
weight VBD o
for IN o
infants NNS o
born VBN o
to TO o
women NNS o
who WP o
quit VBP o
smoking VBG o
averaged VBD N
7.2 CD N
lb JJ N
versus NN N
6.8 CD N
and CC N
6.3 CD N
lb NN N
for IN N
mothers NNS N
smoking VBG N
one CD N
to TO N
six CD N
and CC N
more JJR N
than IN N
six CD N
cigarettes NNS N
per IN N
day NN N
at IN N
delivery NN N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

CONCLUSION NNP N
Peer NNP o
counseling NN o
reduced VBD N
the DT N
number NN o
of IN o
cigarettes NNS o
smoked VBN o
daily RB o
but CC N
did VBD N
not RB N
increase VB N
cigarette NN o
abstinence NN o
rates NNS o
. . o

Infant NNP o
birth NN o
weight NN o
increases NNS N
with IN N
both DT N
smoking VBG N
cessation NN N
and CC N
smoking NN N
reduction NN N
, , N
suggesting VBG N
that IN N
peer NN i
counseling VBG i
intervention NN i
programs NNS i
may MD N
improve VB N
newborn JJR o
health NN o
despite IN N
their PRP$ N
failure NN N
to TO N
affect VB N
smoking VBG N
cessation NN N
. . N

-DOCSTART- -X- O O

Roles NNS o
of IN o
adapalene NN o
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

BACKGROUND NNP N
Ketoconazole NNP i
is VBZ N
a DT N
typical JJ N
treatment NN N
available JJ N
for IN N
pityriasis NN p
versicolor NN p
; : p
tretinoin CC i
cream NN i
is VBZ N
effective JJ N
, , N
too RB N
. . N

Adapalene NNP i
gel NN i
is VBZ N
a DT N
tretinoin JJ N
derivative NN N
and CC N
has VBZ N
a DT N
lower JJR N
incidence NN N
of IN N
irritation NN o
compared VBN N
with IN N
other JJ N
topical JJ N
retinoid NN N
products NNS N
. . N

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
on IN N
adapalene NN i
gel NN i
for IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
of IN N
adapalene NN i
gel NN i
comparing VBG N
the DT N
treatment NN N
with IN N
adapalene JJ i
gel NNS i
and CC i
2 CD i
% NN i
ketoconazole JJ i
cream NN i
in IN N
pityriasis NN p
versicolor NN p
. . p

METHODS NNP N
Eighty NNP p
patients NNS p
suffering VBG p
from IN p
pityriasis NN p
versicolor NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
one CD N
group NN N
were VBD N
treated VBN N
with IN N
2 CD i
% NN i
ketoconazole JJ i
cream NN i
topically RB N
twice JJ N
daily RB N
for IN N
2 CD N
weeks NNS N
, , N
adapalene JJ i
gel NN i
was VBD N
used VBN N
for IN N
the DT N
other JJ N
group NN N
in IN N
a DT N
similar JJ N
fashion NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

No DT N
major JJ N
side NN o
effects NNS o
were VBD N
noted VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
either CC N
. . N

CONCLUSION NNP N
Adapalene NNP i
was VBD N
the DT N
favorable JJ N
option NN N
in IN N
the DT N
treatment NN N
of IN N
pityriasis NN p
versicolor NN p
. . p

The DT N
probable JJ N
therapeutic JJ N
mechanism NN N
of IN N
adapalene NN i
is VBZ N
also RB N
discussed VBN N
. . N

-DOCSTART- -X- O O

Beneficial JJ N
effects NNS N
of IN N
a DT N
soy-based JJ i
dietary JJ i
supplement NN i
on IN N
lipid JJ o
levels NNS o
and CC o
cardiovascular JJ o
risk NN o
markers NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
. . p

OBJECTIVE NNP N
Consumption NNP N
of IN N
soy NN N
protein NN N
has VBZ N
recently RB N
been VBN N
shown VBN N
to TO N
improve VB N
the DT N
blood NN o
lipid JJ o
levels NNS o
in IN N
nondiabetic JJ N
subjects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
if IN N
a DT N
dietary JJ N
supplement NN N
of IN N
soy NN i
protein NN i
, , i
isoflavones NNS i
, , i
and CC i
cotyledon VB i
fiber NN i
( ( i
Abalon NNP i
) ) i
affects VBZ N
cardiovascular JJ o
risk NN o
markers NNS o
, , o
blood NN o
glucose NN o
, , o
and CC o
insulin NN o
levels NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Twenty NNP p
type NN p
2 CD p
diabetic JJ p
subjects NNS p
participated VBN p
in IN p
a DT p
crossover NN p
trial NN p
. . p

They PRP N
were VBD N
randomized VBN N
to TO N
double-blind JJ N
supplementation NN N
for IN N
6 CD i
weeks NNS i
with IN i
Abalon NNP i
( ( i
soy JJ i
protein NN i
[ VBD N
50 CD N
g/day JJ N
] NNP N
with IN N
high JJ N
levels NNS N
of IN N
isoflavones NNS i
[ NNP N
minimum VBD N
165 CD N
mg/day NN N
] NNP N
and CC N
cotyledon VB i
fiber NN i
[ $ N
20 CD N
g/day JJ N
] NNPS N
) ) N
or CC N
placebo NN i
( ( N
casein JJ N
[ VBZ N
50 CD N
g/day NN N
] NNP N
and CC N
cellulose VB N
[ JJ N
20 CD N
g/day JJ N
] NNP N
) ) N
, , N
separated VBN N
by IN N
a DT N
3-week JJ N
wash-out JJ N
period NN N
. . N

RESULTS VB N
The DT N
results NNS N
are VBP N
expressed VBN N
as IN N
means NNS N
+/- JJ N
SD NNP N
. . N

The DT N
percentage NN N
mean JJ N
treatment NN N
difference NN N
between IN N
Abalon NNP i
and CC N
placebo NN i
demonstrated VBD N
significantly RB N
lower JJR N
mean NN N
values NNS N
after IN N
Abalon NNP i
for IN N
LDL NNP o
cholesterol NN o
( ( N
10 CD N
+/- JJ N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
LDL/UHDL NNP o
ratio NN o
( ( N
12 CD N
+/- JJ N
18 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
apolipoprotein RB o
( ( N
apo NN N
) ) N
B100 NNP N
( ( N
30 CD N
+/- JJ N
38 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
triglycerides NNS o
( ( N
22 CD N
+/- JJ N
10 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
homocysteine NN o
( ( N
14 CD N
+/- JJ N
21 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas VBD N
the DT N
total JJ o
cholesterol NN o
value NN o
tended VBD N
to TO N
be VB N
less RBR N
significant JJ N
but CC N
still RB N
lower JJR N
( ( N
8 CD N
+/- JJ N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.08 CD N
) ) N
. . N

No UH N
change NN N
occurred VBD N
in IN N
HDL NNP o
cholesterol NN o
, , o
apo JJ o
B100/apo NNP o
A1 NNP o
ratio NN o
, , o
plasminogen NN o
activator NN o
inhibitor NN o
1 CD o
, , o
factor NN o
VIIc NNP o
, , o
von NNP o
Willebrand NNP o
factor NN o
, , o
fibrinogen NN o
, , o
lipoprotein NN o
( ( o
a DT o
) ) o
, , o
glucose JJ o
, , o
HbA1c NNP o
, , o
or CC o
24-h JJ o
blood NN o
pressure NN o
. . o

CONCLUSIONS NNP N
These DT N
results NNS N
indicate VBP N
beneficial JJ N
effects NNS N
of IN N
dietary JJ N
supplementation NN N
with IN N
Abalon NNP i
on IN N
cardiovascular JJ o
risk NN o
markers NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
. . p

This DT N
improvement NN N
is VBZ N
seen VBN N
even RB N
in IN N
individuals NNS N
with IN N
near-normal JJ N
lipid JJ N
values NNS N
. . N

-DOCSTART- -X- O O

Efficacy NN o
of IN N
amantadine NN i
on IN N
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
treated VBD p
with IN p
interferon-alpha JJ i
and CC i
ribavirin NN i
: : i
results NNS N
from IN N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
trial NN N
. . N

AIM VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
amantadine JJ N
reduces NNS N
deterioration NN o
of IN o
quality NN o
of IN o
life NN o
in IN N
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
during IN p
and CC p
after IN p
treatment NN p
with IN p
interferon-alpha JJ p
( ( p
IFN-alpha NNP p
) ) p
and CC p
ribavirin NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized VBN N
, , N
prospective JJ N
, , N
placebo-controlled JJ i
, , N
multicenter JJ N
trial NN N
, , N
previously RB p
untreated JJ p
patients NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
were VBD N
treated VBN N
with IN N
IFN-alpha NNP i
plus CC i
ribavirin JJ i
[ NN i
17 CD i
] NN i
and CC N
randomized VBN N
for IN N
treatment NN N
with IN N
amantadine NN i
( ( N
200 CD N
mg/day NN N
, , N
orally RB N
, , N
n=136 NN N
) ) N
or CC i
placebo NN i
( ( N
n=131 JJ N
) ) N
. . N

Quality NN o
of IN o
life NN o
was VBD N
assessed VBN N
with IN N
the DT N
'Profile NN o
of IN o
Mood NNP o
States NNPS o
' POS o
scale NN o
and CC o
the DT o
'Everyday JJ o
Life NNP o
' POS o
questionnaire NN o
at IN N
baseline NN N
, , N
treatment NN N
week NN N
( ( N
TW NNP N
) ) N
8 CD N
, , N
TW24 NNP N
, , N
TW48 NNP N
, , N
and CC N
at IN N
follow-up JJ N
. . N

RESULTS VB N
Early JJ N
during IN N
treatment NN N
at IN N
TW8 NNP N
, , N
quality NN o
of IN o
life NN o
was VBD N
not RB N
different JJ N
between IN N
patients NNS p
in IN p
the DT p
control NN p
and CC p
the DT p
amantadine NN p
group NN p
. . p

At IN N
TW24 NNP N
, , N
the DT N
control NN N
group NN N
but CC N
not RB N
the DT N
amantadine NN i
group NN N
, , N
however RB N
, , N
showed VBD N
significant JJ N
deterioration NN N
of IN N
the DT N
modalities NNS o
depression NN o
, , o
fatigue NN o
, , o
and CC o
vigor NN o
compared VBN N
with IN N
baseline NN N
. . N

Especially RB N
, , N
nonresponders NNS N
in IN N
the DT N
amantadine NN N
group NN N
showed VBD N
significantly RB N
lower JJR o
deterioration NN o
of IN o
depression NN o
, , o
anger NN o
, , o
mind NN o
function NN o
, , o
everyday JJ o
life NN o
, , o
and CC o
zest JJS o
for IN o
life NN o
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
. . N

After IN N
treatment NN N
, , N
the DT N
beneficial JJ o
effects NNS o
of IN N
amantadine NN N
disappeared VBN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
amantadine NN i
to TO N
IFN-alpha NNP i
plus CC i
ribavirin JJ i
combination NN N
therapy NN N
may MD N
reduce VB N
deterioration NN o
of IN o
depression NN o
, , o
fatigue NN o
, , o
and CC o
vigor NN o
during IN N
treatment NN N
but CC N
does VBZ N
not RB N
affect JJ N
quality NN o
of IN o
life NN o
after IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
a DT N
videotape NN i
information NN i
intervention NN i
at IN N
discharge NN N
on IN N
diet JJ N
and CC N
exercise NN N
compliance NN N
after IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
evaluated VBD N
the DT N
relative JJ N
effects NNS N
on IN N
compliance NN N
with IN N
recommended JJ N
lifestyle JJ N
changes NNS N
of IN N
two CD N
experimental JJ i
videotapes NNS i
that WDT N
involved VBD N
different JJ N
approaches NNS N
for IN N
preparing VBG N
coronary JJ p
artery NN p
bypass NN p
graft NN p
( ( p
CABG NNP p
) ) p
patients NNS p
for IN N
the DT N
posthospital JJ N
recovery NN N
period NN N
. . N

The DT N
tapes NNS N
differed VBN N
in IN N
the DT N
extent NN N
to TO N
which WDT N
they PRP N
portrayed VBD N
the DT N
recovery NN N
period NN N
as IN N
a DT N
steady JJ N
, , N
forward JJ N
progression NN N
versus IN N
a DT N
series NN N
of IN N
ups NNS N
and CC N
downs NNS N
. . N

METHODS NNP N
Two CD p
hundred VBD p
sixteen JJ p
male NN p
and CC p
female JJ p
CABG NNP p
patients NNS p
were VBD N
assigned VBN N
randomly RB N
either DT N
to TO N
view VB N
one CD i
of IN i
the DT i
two CD i
videotapes NNS i
before IN i
discharge NN i
from IN i
the DT i
hospital NN i
or CC i
to TO i
receive VB i
only RB i
the DT i
standard JJ i
discharge NN i
preparation NN i
provided VBN N
by IN N
the DT N
hospital NN N
. . N

All DT N
patients NNS N
completed VBN N
measures NNS o
of IN o
anxiety NN o
and CC o
self-efficacy NN o
at IN N
discharge NN N
, , N
1 CD N
month NN N
and CC N
3 CD N
months NNS N
after IN N
discharge NN N
from IN N
the DT N
hospital NN N
. . N

Patients NNS N
also RB N
completed VBD N
measures NNS N
of IN N
dietary JJ o
fat JJ o
consumption NN o
and CC N
activity NN o
level NN o
1 CD o
and CC o
3 CD o
months NNS N
after IN N
discharge NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
controls NNS N
, , N
patients NNS N
who WP N
viewed VBD N
either DT N
of IN N
the DT N
videotapes NNS i
before IN N
hospital NN N
release NN N
reported VBD N
higher JJR N
self-efficacy NN o
for IN o
adhering VBG o
to TO o
the DT o
recommended VBN o
low-fat NN o
diet JJ o
both DT N
at IN N
discharge NN N
and CC N
1 CD N
month NN N
after IN N
surgery NN N
. . N

Viewing VBG N
either DT N
of IN N
the DT N
videotapes NNS N
also RB N
resulted VBD N
in IN N
significantly RB o
less JJR o
dietary JJ o
fat NN o
intake NN o
1 CD o
month NN o
after IN o
hospital NN o
release NN o
compared VBN N
with IN N
controls NNS N
. . N

Patients NNS N
who WP N
viewed VBD N
the DT N
tape NN N
that WDT N
portrayed VBD N
the DT N
recovery NN N
period NN N
as IN N
consisting NN N
of IN N
ups NNS N
and CC N
downs NNS N
also RB N
reported VBD N
significantly RB N
more RBR N
frequent JJ N
moderate JJ o
exercise NN o
at IN o
1 CD o
month NN o
and CC N
more RBR N
frequent JJ N
strenuous JJ o
exercise NN o
3 CD N
months NNS N
after IN N
discharge NN N
. . N

CONCLUSIONS VB N
The DT N
experimental JJ N
videotapes NNS i
proved VBD N
to TO N
be VB N
an DT N
effective JJ N
method NN N
for IN N
increasing VBG N
dietary JJ o
and CC o
exercise NN o
compliance NN o
during IN N
the DT N
first JJ N
3 CD N
months NNS N
after IN N
CABG NNP N
. . N

-DOCSTART- -X- O O

Determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG o
capacity NN o
among IN N
individuals NNS p
with IN p
chronic JJ p
stroke NN p
following VBG N
a DT N
multi-dimensional JJ i
exercise NN i
program NN i
. . i

OBJECTIVE NNP N
To TO N
identify VB N
the DT N
determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG o
capacity NN o
following VBG N
therapeutic JJ i
exercise NN i
in IN N
chronic JJ p
stroke NN p
survivors NNS p
. . p

DESIGN VB N
A DT N
secondary JJ N
analysis NN N
of IN N
data NNS N
obtained VBN N
from IN N
a DT N
prospective JJ N
, , N
single-blind JJ N
, , N
randomized VBN N
controlled VBN N
intervention NN N
trial NN N
. . N

SUBJECTS JJ N
Sixty-three JJ p
community-dwelling JJ p
individuals NNS p
( ( p
mean JJ p
age NN p
= VBD p
65 CD p
years NNS p
, , p
age NN p
range NN p
= NNP p
50-87 CD p
years NNS p
) ) p
with IN p
a DT p
chronic JJ p
stroke NN p
( ( p
post-stroke JJ p
duration NN p
: : p
mean JJ p
= VBP p
5.5 CD p
years NNS p
, , p
range NN p
= NNP p
1-28 CD p
years NNS p
) ) p
. . p

METHODS JJ N
Subjects NNPS N
were VBD N
randomized VBN N
into IN N
a DT N
leg JJ i
exercise NN i
group NN N
( ( N
n JJ N
= NNP N
32 CD N
) ) N
or CC N
an DT N
arm JJ i
exercise NN i
group NN N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
. . N

Subjects NNS N
in IN N
each DT N
group NN N
underwent VBD N
3 CD N
1-hour JJ N
exercise NN i
sessions NNS i
per IN N
week NN N
for IN N
19 CD N
weeks NNS N
. . N

Walking VBG o
capacity NN o
, , o
cardiorespiratory NN o
fitness NN o
, , o
isometric JJ o
knee NN o
extensor NN o
muscle NN o
strength NN o
, , o
balance NN o
ability NN o
, , o
and CC o
balance NN o
confidence NN o
were VBD N
evaluated VBN N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

Multiple JJ N
regression NN N
analysis NN N
was VBD N
performed VBN N
to TO N
identify VB N
the DT N
determinants NNS N
of IN N
improvement NN N
in IN N
walking VBG N
capacity NN N
. . N

RESULTS VB N
After IN N
controlling VBG N
for IN N
age NN N
, , N
gender NN N
, , N
post-stroke JJ N
duration NN N
, , N
and CC N
baseline NN N
walking NN o
capacity NN o
, , o
gain NN o
in IN o
paretic JJ o
leg NN o
muscle NN o
strength NN o
and CC o
peak NN o
oxygen NN o
consumption NN o
remained VBD o
independently RB o
associated VBN N
with IN N
gain NN o
in IN o
walking VBG o
capacity NN o
( ( N
R2 NNP N
= NNP N
0.229 CD N
) ) N
. . N

CONCLUSION NNP N
Enhancement NNP N
of IN N
cardiorespiratory NN N
fitness NN N
and CC N
paretic JJ N
leg NN N
muscle NN N
strength NN N
are VBP N
both DT N
significant JJ N
determinants NNS N
in IN N
improving VBG N
walking JJ N
capacity NN N
among IN N
chronic JJ N
stroke NN N
survivors NNS N
. . N

However RB N
, , N
the DT N
rather RB N
weak JJ N
relationship NN N
( ( N
R2 NNP N
= NNP N
0.229 CD N
) ) N
indicates VBZ N
that IN N
other JJ N
factors NNS N
not RB N
measured VBN N
in IN N
this DT N
study NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN N
in IN N
walking VBG N
capacity NN N
. . N

-DOCSTART- -X- O O

Nasal NNP N
oxytocin MD i
for IN N
social JJ N
deficits NNS N
in IN N
childhood NN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

The DT N
last JJ N
two CD N
decades NNS N
have VBP N
witnessed VBN N
a DT N
surge NN N
in IN N
research NN N
investigating VBG N
the DT N
application NN N
of IN N
oxytocin NN N
as IN N
a DT N
method NN N
of IN N
enhancing VBG N
social JJ N
behaviour NN N
in IN N
humans NNS N
. . N

Preliminary JJ N
evidence NN N
suggests VBZ N
oxytocin NN N
may MD N
have VB N
potential NN N
as IN N
an DT N
intervention NN N
for IN N
autism NN N
. . N

We PRP N
evaluated VBD N
a DT N
5-day JJ N
'live-in NN N
' POS N
intervention NN N
using VBG N
a DT N
double-blind JJ N
randomized VBN N
control NN N
trial NN N
. . N

38 CD p
male JJ p
youths NNS p
( ( p
7-16 CD p
years NNS p
old JJ p
) ) p
with IN p
autism NN p
spectrum NN p
disorders NNS p
were VBD N
administered VBN N
24 CD i
or CC i
12 CD i
international JJ i
units NNS i
( ( i
depending VBG i
on IN i
weight NN i
) ) i
intranasal NN i
placebo NN i
or CC i
oxytocin JJ i
once RB N
daily RB N
over IN N
four CD N
consecutive JJ N
days NNS N
. . N

The DT N
oxytocin NN N
or CC N
placebo NN N
was VBD N
administered VBN N
during IN N
parent-child JJ N
interaction NN N
training NN N
sessions NNS N
. . N

Parent NN N
and CC N
child NN N
behaviours NNS N
were VBD N
assessed VBN N
using VBG N
parent NN o
reports NNS o
, , o
clinician JJ o
ratings NNS o
, , o
and CC o
independent JJ o
observations NNS o
, , N
at IN N
multiple JJ N
time NN N
points NNS N
to TO N
measure VB o
side-effects NNS o
; : o
social JJ o
interaction NN o
skills NNS o
; : o
repetitive JJ o
behaviours NNS o
; : o
emotion NN o
recognition NN o
and CC o
diagnostic JJ o
status NN o
. . o

Compared VBN N
to TO N
placebo VB N
, , N
intranasal VB N
oxytocin RB N
did VBD N
not RB N
significantly RB N
improve VB N
emotion NN o
recognition NN o
, , o
social JJ o
interaction NN o
skills NNS o
, , o
or CC o
general JJ o
behavioral JJ o
adjustment NN o
in IN N
male JJ N
youths NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
the DT N
benefits NNS N
of IN N
nasal JJ N
oxytocin NN N
for IN N
young JJ p
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
may MD N
be VB N
more JJR N
circumscribed JJ N
than IN N
suggested VBN N
by IN N
previous JJ N
studies NNS N
, , N
and CC N
suggest JJS N
caution NN N
in IN N
recommending VBG N
it PRP N
as IN N
an DT N
intervention NN N
that WDT N
is VBZ N
broadly RB N
effective JJ N
. . N

-DOCSTART- -X- O O

Weight NNP o
and CC o
leptin JJ o
changes NNS o
among IN N
risperidone-treated JJ i
youths NNS p
with IN p
autism NN p
: : p
6-month JJ N
prospective JJ N
data NNS N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
examined VBD N
the DT N
developmental JJ N
impact NN N
and CC N
temporal JJ N
characteristics NNS N
of IN N
risperidone-associated JJ i
weight NN o
change NN o
. . o

METHOD NNP N
Weight NNP o
change NN o
was VBD N
measured VBN N
for IN N
63 CD p
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
treated VBN p
with IN p
risperidone NN i
for IN p
6 CD p
months NNS p
. . p

Change NNP o
in IN o
serum NN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
was VBD N
examined VBN N
as IN N
a DT N
predictor NN N
of IN N
final JJ o
weight NN o
gain NN o
in IN N
mixed JJ N
regression NN N
models NNS N
that WDT N
controlled VBD N
for IN N
site NN N
, , N
gender NN N
, , N
age NN N
, , N
and CC N
risperidone NN i
dose NN N
. . N

RESULTS NNP N
Age- JJ N
and CC N
gender-standardized JJ N
weight NN o
increased VBD o
after IN N
6 CD N
months NNS N
of IN N
treatment NN N
( ( N
gross JJ N
: : N
mean=5.6 NN N
kg NN N
[ NNP N
SD=3.9 NNP N
] NNP N
; : N
standardized VBN N
: : N
mean=0.6 NN N
z NN N
[ NNP N
SD=0.5 NNP N
] NNP N
) ) N
and CC N
was VBD N
positively RB N
correlated VBN N
with IN N
weight NN o
gained VBN o
after IN N
1 CD N
month NN N
. . N

Change NN o
in IN o
leptin NN o
levels NNS o
after IN N
2 CD N
months NNS N
of IN N
treatment NN N
( ( N
mean=-0.3 JJ N
ng/ml NN N
, , N
SD=6.2 NNP N
) ) N
( ( N
N=48 NNP N
) ) N
did VBD N
not RB N
predict JJ N
final JJ o
weight NN o
gain NN o
. . o

CONCLUSIONS NNP N
Chronic NNP N
risperidone NN i
exposure NN N
in IN N
children NNS N
with IN N
autism NN N
causes NNS N
weight VBD o
gain NN o
in IN N
excess NN N
of IN N
developmentally RB N
expected VBN N
norms NNS N
that WDT N
follows VBZ N
a DT N
curvilinear JJ N
trajectory NN N
and CC N
decelerates VBZ N
over IN N
time NN N
. . N

Serum NNP o
leptin JJ o
change NN o
does VBZ N
not RB N
reliably VB N
predict JJ N
risperidone-associated JJ N
weight NN o
gain NN o
. . o

-DOCSTART- -X- O O

Immune NNP o
response NN o
in IN N
healthy JJ p
volunteers NNS p
vaccinated VBD p
with IN p
BCG NNP i
plus CC i
killed VBN p
leishmanial JJ p
promastigotes NNS p
: : p
antibody NN N
responses VBZ N
to TO N
mycobacterial VB N
and CC N
leishmanial JJ N
antigens NNS N
. . N

Antibody NNP o
( ( o
IgG NNP o
) ) o
responses VBZ o
to TO N
mycobacterial VB N
( ( N
BCG NNP N
; : N
PPD NNP N
; : N
Mycobacterium NNP N
leprae VBZ N
soluble JJ N
antigen NN N
, , N
MLSA NNP N
) ) N
and CC N
leishmanial JJ N
( ( N
Leishmania NNP N
mexicana NNP N
LV4 NNP N
) ) N
antigens NNS N
were VBD N
measured VBN N
in IN N
208 CD p
initially RB p
PPD NNP p
and CC p
leishmanin JJ p
skin-test JJ p
negative JJ p
volunteers NNS p
divided VBD N
into IN N
four CD i
vaccine NN i
groups NNS i
as IN i
follows VBZ i
: : i
68 CD i
received VBD i
BCG NNP i
plus CC i
killed VBN i
promastigotes NNS i
( ( i
group NN i
A NNP i
) ) i
, , i
47 CD i
received VBD i
BCG NNP i
alone RB i
( ( i
group NN i
B NNP i
) ) i
, , i
47 CD i
received VBD i
killed VBN i
promastigotes NNS i
alone RB i
( ( i
group NN i
C NNP i
) ) i
, , i
and CC i
46 CD i
formed VBD i
the DT i
diluent NN i
control NN i
( ( i
placebo NN i
, , i
group NN i
D NNP i
) ) i
. . i

Three CD i
vaccine NN i
doses NNS i
were VBD i
administered VBN i
at IN i
8-12 JJ i
week NN i
intervals NNS i
. . i

Vaccinees NNS i
were VBD i
bled VBN i
immediately RB i
prior JJ i
to TO i
each DT i
vaccination NN i
, , i
and CC i
again RB i
at IN i
3- JJ i
and CC i
12-month JJ i
follow-up NN i
. . i

Skin JJ o
tests NNS o
were VBD i
performed VBN i
prevaccination NN i
, , i
and CC i
again RB i
at IN i
the DT i
3- JJ i
and CC i
12-month JJ i
follow-up NN i
. . i

Anti-BCG JJ N
, , N
anti-PPD JJ N
and CC N
anti-MLSA JJ N
IgG NNP N
levels NNS N
increased VBD N
significantly RB N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
receiving VBG N
BCG NNP N
. . N

The DT N
presence NN N
of IN N
leishmanial JJ N
antigen NN N
( ( N
with IN N
BCG NNP N
) ) N
in IN N
the DT N
inoculum NN N
suppressed VBD N
the DT N
IgG NNP N
response NN N
to TO N
Mycobacterium NNP N
tuberculosis/Mycobacterium NN N
bovis-related JJ N
( ( N
PPD NNP N
and CC N
BCG NNP N
) ) N
, , N
but CC N
not RB N
M. NNP N
leprae-related JJ N
( ( N
MLSA NNP N
) ) N
-related VBD N
, , N
antigens NNS N
. . N

A DT N
small JJ N
but CC N
significant JJ N
increase NN N
( ( N
relative JJ N
to TO N
prevaccination VB N
level NN N
) ) N
in IN N
response NN N
to TO N
MLSA NNP N
, , N
but CC N
not RB N
to TO N
BCG NNP N
or CC N
PPD NNP N
was VBD N
observed VBN N
in IN N
the DT N
non-BCG-vaccinated JJ N
groups NNS N
. . N

The DT N
background NN N
level NN N
of IN N
response NN N
to TO N
mycobacterial JJ N
and CC N
leishmanial JJ N
antigens NNS N
was VBD N
higher RBR N
in IN N
the DT N
Venezuelan NNP p
vaccinees NNS p
than IN N
in IN N
non-endemic JJ p
( ( p
British JJ p
) ) p
volunteers NNS p
. . p

Responses NNS N
to TO N
leishmanial JJ o
antigen NN o
were VBD N
not RB N
enhanced VBN N
in IN N
the DT N
two CD N
vaccine NN N
groups NNS N
receiving VBG N
killed VBN N
promastigotes NNS N
( ( N
with/without IN N
BCG NNP N
) ) N
compared VBN N
with IN N
the DT N
BCG NNP N
alone RB N
and CC N
placebo JJ N
groups NNS N
. . N

Instead RB N
, , N
all DT N
vaccine NN N
groups NNS N
showed VBD N
a DT N
pattern NN N
of IN N
response NN N
consistent NN N
with IN N
either DT N
( ( N
i NN N
) ) N
a DT N
response NN N
to TO N
the DT N
skin-test JJ N
antigen NN N
or CC N
, , N
more RBR N
likely JJ N
, , N
( ( N
ii NN N
) ) N
seasonal JJ N
endemic JJ N
exposure NN N
to TO N
leishmanial JJ N
antigen NN N
. . N

Interestingly RB N
, , N
this DT N
endemic JJ N
response NN N
to TO N
leishmanial JJ N
antigen NN N
was VBD N
enhanced VBN N
in IN N
the DT N
vaccine NN N
groups NNS N
receiving VBG N
BCG NNP N
, , N
despite IN N
the DT N
fact NN N
that IN N
group NN N
B NNP N
received VBD N
no DT N
leishmanial JJ N
antigen NN N
in IN N
the DT N
vaccine NN N
inoculum NN N
. . N

When WRB N
prevaccination NN N
IgG NNP N
levels NNS N
( ( N
mean VB N
+ RB N
3 CD N
standard JJ N
deviations NNS N
) ) N
were VBD N
used VBN N
to TO N
determine VB N
a DT N
negative JJ N
cut-off NN N
, , N
a DT N
low JJ N
percentage NN N
( ( N
< JJ N
38 CD N
% NN N
) ) N
of IN N
vaccinees NNS N
converted VBN N
to TO N
responder VB N
status NN N
for IN N
either DT N
anti-mycobacterial JJ N
or CC N
anti-leishmanial JJ N
responses NNS N
, , N
and CC N
those DT N
who WP N
did VBD N
would MD N
be VB N
classified VBN N
as IN N
'low-responder NN N
' '' N
status NN N
compared VBN N
with IN N
titres NNS N
observed VBN N
in IN N
severe JJ N
forms NNS N
of IN N
disease NN N
. . N

Hence NNP N
, , N
although IN N
there EX N
was VBD N
evidence NN N
for IN N
a DT N
background NN N
endemic JJ N
response NN N
to TO N
both DT N
leishmanial JJ N
and CC N
mycobacterial JJ N
antigens NNS N
, , N
there EX N
was VBD N
no DT N
evidence NN N
that IN N
vaccination NN N
per IN N
se NN N
led VBD N
to TO N
a DT N
potentially RB N
disease JJ N
exacerbatory JJ N
level NN N
of IN N
TH2-associated NNP N
antibody NN N
response NN N
especially RB N
with IN N
respect NN N
to TO N
the DT N
anti-leishmanial JJ N
response NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Effectiveness NN N
of IN N
manual JJ i
physical JJ i
therapy NN i
and CC i
exercise NN i
in IN N
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

A DT N
randomized JJ N
, , N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Few JJ N
investigations NNS N
include VBP N
both DT N
subjective JJ N
and CC N
objective JJ N
measurements NNS N
of IN N
the DT N
effectiveness NN N
of IN N
treatments NNS N
for IN N
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

Beneficial JJ N
interventions NNS N
may MD N
decrease VB N
the DT N
disability NN o
associated VBN N
with IN N
osteoarthritis NN N
and CC N
the DT N
need NN N
for IN N
more RBR N
invasive JJ N
treatments NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
physical JJ i
therapy NN i
for IN N
osteoarthritis NN N
of IN N
the DT N
knee NN N
, , N
applied VBN N
by IN N
experienced JJ N
physical JJ N
therapists NNS N
with IN N
formal JJ N
training NN N
in IN N
manual JJ N
therapy NN N
. . N

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient NNP p
physical JJ p
therapy NN p
department NN p
of IN p
a DT p
large JJ p
military JJ p
medical JJ p
center NN p
. . p

PATIENTS CC N
83 CD p
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
treatment NN i
( ( p
n JJ p
= VBZ p
42 CD p
; : p
15 CD p
men NNS p
and CC p
27 CD p
women NNS p
[ JJ p
mean JJ p
age NN p
, , p
60 CD p
+/- JJ p
11 CD p
years NNS p
] RB p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= VBZ p
41 CD p
; : p
19 CD p
men NNS p
and CC p
22 CD p
women NNS p
[ JJ p
mean JJ p
age NN p
, , p
62 CD p
+/- JJ p
10 CD p
years NNS p
] RB p
) ) p
. . p

INTERVENTION NNP N
The DT N
treatment NN p
group NN p
received VBD N
manual JJ i
therapy NN i
, , N
applied VBN N
to TO N
the DT N
knee NN N
as RB N
well RB N
as IN N
to TO N
the DT N
lumbar NN N
spine NN N
, , N
hip NN N
, , N
and CC N
ankle RB N
as IN N
required VBN N
, , N
and CC N
performed VBD N
a DT N
standardized JJ i
knee NN i
exercise NN i
program NN i
in IN N
the DT N
clinic NN N
and CC N
at IN N
home NN N
. . N

The DT N
placebo NN i
group NN p
had VBD N
subtherapeutic JJ i
ultrasound NN i
to TO N
the DT N
knee NN N
at IN N
an DT N
intensity NN N
of IN N
0.1 CD N
W/cm2 NNP N
with IN N
a DT N
10 CD N
% NN N
pulsed JJ N
mode NN N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
at IN N
the DT N
clinic JJ N
twice JJ N
weekly NN N
for IN N
4 CD N
weeks NNS N
. . N

MEASUREMENTS NNP N
Distance NNP o
walked VBD o
in IN o
6 CD o
minutes NNS o
and CC o
sum NN o
of IN o
the DT o
function NN o
, , o
pain NN o
, , o
and CC o
stiffness JJ o
subscores NNS o
of IN o
the DT o
Western NNP o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
Osteoarthritis NNP o
Index NNP o
( ( o
WOMAC NNP o
) ) o
. . o

A DT N
tester NN N
who WP N
was VBD N
blinded VBN N
to TO N
group NN N
assignment NN N
made VBD N
group NN N
comparisons NNS N
at IN N
the DT N
initial JJ N
visit NN N
( ( N
before IN N
initiation NN N
of IN N
treatment NN N
) ) N
, , N
4 CD N
weeks NNS N
, , N
8 CD N
weeks NNS N
, , N
and CC N
1 CD N
year NN N
. . N

RESULTS NNP N
Clinically NNP N
and CC N
statistically RB N
significant JJ N
improvements NNS N
in IN N
6-minute JJ o
walk NN o
distance NN o
and CC o
WOMAC NNP o
score NN o
at IN N
4 CD N
weeks NNS N
and CC N
8 CD N
weeks NNS N
were VBD N
seen VBN N
in IN N
the DT N
treatment NN i
group NN N
but CC N
not RB N
the DT N
placebo NN i
group NN N
. . N

By IN N
8 CD N
weeks NNS N
, , N
average JJ N
6-minute JJ o
walk NN o
distances NNS o
had VBD N
improved VBN N
by IN N
13.1 CD N
% NN N
and CC N
WOMAC NNP o
scores NNS o
had VBD N
improved VBN N
by IN N
55.8 CD N
% NN N
over IN N
baseline NN N
values NNS N
in IN N
the DT N
treatment NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
controlling VBG N
for IN N
potential JJ N
confounding NN N
variables NNS N
, , N
the DT N
average JJ N
distance NN o
walked VBD o
in IN o
6 CD o
minutes NNS o
at IN N
8 CD N
weeks NNS N
among IN N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
was VBD N
170 CD N
m NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
71 CD N
to TO N
270 CD N
m NN N
) ) N
more JJR N
than IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
and CC N
the DT N
average JJ N
WOMAC JJ o
scores NNS o
were VBD N
599 CD N
mm NN N
higher JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
197 CD N
to TO N
1002 CD N
mm NN N
) ) N
. . N

At IN N
1 CD N
year NN N
, , N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
had VBD N
clinically RB N
and CC N
statistically RB N
significant JJ N
gains NNS N
over IN N
baseline JJ o
WOMAC NNP o
scores NNS o
and CC o
walking VBG o
distance NN o
; : o
20 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
and CC N
5 CD N
% NN N
of IN N
patients NNS N
in IN N
the DT N
treatment NN i
group NN N
had VBD N
undergone JJ N
knee NN o
arthroplasty NN o
. . o

CONCLUSIONS VB N
A DT N
combination NN N
of IN N
manual JJ i
physical JJ i
therapy NN i
and CC i
supervised VBD i
exercise NN i
yields NNS N
functional JJ o
benefits NNS o
for IN N
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
and CC N
may MD N
delay VB N
or CC N
prevent VB N
the DT N
need NN N
for IN N
surgical JJ o
intervention NN o
. . o

-DOCSTART- -X- O O

Effect NN N
of IN N
phenylephrine NN i
on IN N
the DT N
haemodynamic JJ o
state NN o
and CC o
cerebral JJ o
oxygen NN o
saturation NN o
during IN N
anaesthesia NN N
in IN N
the DT N
upright JJ N
position NN N
. . N

BACKGROUND IN N
The DT N
upright JJ N
sitting NN N
or CC N
beachchair NN N
position NN N
is VBZ N
associated VBN N
with IN N
hypotension NN o
, , o
risk NN o
of IN o
cerebral JJ o
hypoperfusion NN o
, , o
and CC o
cerebral JJ o
injury NN o
. . o

We PRP N
hypothesized VBD N
that IN N
by IN N
increasing VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine JJ i
administration NN N
, , N
cerebral JJ o
perfusion NN o
, , N
and CC N
postoperative JJ o
recovery NN o
would MD N
be VB N
improved VBN N
. . N

METHODS NNP N
Thirty-four JJ p
patients NNS p
undergoing VBG p
elective JJ p
shoulder NN p
surgery NN p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
saline NN i
or CC i
phenylephrine NN i
infusion NN i
( ( i
PE NNP i
) ) i
5 CD N
min NN N
before IN N
being VBG N
placed VBN N
in IN N
the DT N
upright JJ N
position NN N
. . N

Simultaneous JJ N
measurements NNS N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
cerebral JJ o
oxygen NN o
saturation NN o
, , o
middle JJ o
cerebral JJ o
artery NN o
velocity NN o
, , o
and CC o
cardiac JJ o
function NN o
using VBG o
transthoracic JJ o
echocardiography NN o
were VBD N
made VBN N
. . N

Postoperative JJ N
neurocognitive JJ o
function NN o
was VBD N
assessed VBN N
. . N

RESULTS NNP N
At IN N
the DT N
commencement NN N
of IN N
PE NNP N
, , N
mean NN o
( ( o
SD NNP o
) ) o
cerebral JJ o
oxygen NN o
saturation NN o
significantly RB N
decreased VBN N
from IN N
77 CD N
( ( N
10 CD N
) ) N
to TO N
67 CD N
( ( N
13 CD N
) ) N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
and CC N
further RB N
to TO N
59 CD N
( ( N
11 CD N
) ) N
% NN N
on IN N
upright JJ N
positioning NN N
. . N

The DT N
level NN o
of IN o
cerebral JJ o
saturation NN o
upright NN o
was VBD N
not RB N
significantly RB N
different JJ N
to TO N
patients NNS N
receiving VBG N
saline NN N
( ( N
P=0.07 NNP N
) ) N
, , N
with IN N
values NNS N
remaining VBG N
at IN N
room-air JJ N
levels NNS N
. . N

Middle NNP o
cerebral JJ o
artery RB o
blood NN o
velocity NN o
increased VBN N
by IN N
20 CD N
% NN N
( ( N
P=0.04 NNP N
) ) N
. . N

Phenylephrine NNP N
prevented VBD N
hypotension NN o
in IN N
the DT N
upright JJ N
position NN N
primarily RB N
by IN N
maintaining VBG N
preload NN N
and CC N
increasing VBG N
systemic JJ o
vascular NN o
resistance NN o
( ( N
P=0.01 NNP N
) ) N
, , N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
cardiac JJ o
output NN o
. . o

No DT N
postoperative JJ o
neurocognitive JJ o
dysfunction NN o
was VBD N
identified VBN N
. . N

CONCLUSIONS NNP N
Despite IN N
maintaining VBG N
arterial JJ N
pressure NN N
with IN N
phenylephrine NN i
, , N
cerebral JJ o
desaturation NN o
occurred VBD N
with IN N
upright JJ N
positioning VBG N
. . N

Cerebral NNP o
oxygen IN o
saturation NN o
can MD N
provide VB N
a DT N
valuable JJ N
endpoint NN N
when WRB N
evaluating VBG N
the DT N
effect NN N
of IN N
vasopressor NN N
therapy NN N
on IN N
cerebral JJ N
perfusion NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
skin-to-skin JJ i
contact NN i
on IN N
autonomic JJ o
pain NN o
responses NNS o
in IN N
preterm JJ p
infants NNS p
. . p

UNLABELLED IN N
The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
crossover NN N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
effects NNS N
on IN N
autonomic JJ N
responses NNS N
in IN N
preterm JJ p
infants NNS p
of IN p
longer JJR p
Kangaroo NNP i
Care NNP i
( ( p
30 CD p
minutes NNS p
, , p
KC30 NNP i
) ) i
and CC p
shorter JJR p
KC NNP i
( ( p
15 CD p
minutes NNS p
, , p
KC15 NNP i
) ) i
before IN p
and CC p
throughout IN p
heel NN p
stick NNS p
compared VBN p
with IN p
incubator NN i
care NN i
( ( i
IC NNP i
) ) i
. . p

Beat-to-beat JJ N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
and CC N
spectral JJ N
power NN N
analysis NN N
of IN N
heart NN N
rate NN N
variability NN N
, , N
low JJ N
frequency NN N
power NN N
( ( N
LF NNP N
) ) N
, , N
high JJ N
frequency NN N
power NN N
( ( N
HF NNP N
) ) N
, , N
and CC N
LF/HF NNP N
ratio NN N
were VBD N
measured VBN N
in IN N
26 CD p
infants NNS p
. . p

HR NNP o
changes NNS N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
were VBD N
significantly RB N
less RBR N
in IN N
KC30 NNP N
and CC N
KC15 NNP N
than IN N
in IN N
IC NNP N
, , N
and CC N
more JJR N
infants NNS N
had VBD N
HR NNP o
decrease NN N
in IN N
IC NNP N
than IN N
in IN N
2 CD N
KC NNP N
conditions NNS N
. . N

In IN N
IC NNP N
, , N
LF NNP o
and CC o
HF NNP o
significantly RB N
increased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
dropped VBD N
from IN N
Heel NNP N
Stick NNP N
to TO N
Recovery NNP N
; : N
in IN N
2 CD N
KC NNP N
conditions NNS N
, , N
no DT N
changes NNS N
across IN N
study NN N
phases NNS N
were VBD N
found VBN N
. . N

During IN N
Heel NNP N
Stick NNP N
, , N
LF NNP o
and CC N
HF NNP o
were VBD N
significantly RB N
higher JJR N
in IN N
IC NNP N
than IN N
in IN N
KC30 NNP i
. . i

In IN N
all DT N
3 CD N
conditions NNS N
, , N
LF/HF NNP o
ratio NN o
decreased VBD N
from IN N
Baseline NNP N
to TO N
Heel NNP N
Stick NNP N
and CC N
increased VBD N
to TO N
Recovery NNP N
; : N
no DT N
differences NNS N
were VBD N
found VBN N
between IN N
IC NNP i
and CC N
two CD N
KC NNP i
conditions NNS N
. . N

Both NNP N
longer JJR N
and CC N
shorter JJR N
KC NNP i
before IN N
and CC N
throughout IN N
heel NN N
stick NN N
can MD N
stabilize VB N
HR NNP o
response NN o
in IN N
preterm JJ N
infants NNS N
, , N
and CC N
longer JJR N
KC NNP i
significantly RB N
affected VBD N
infants NNS N
' POS N
sympathetic JJ N
and CC N
parasympathetic JJ N
responses NNS N
during IN N
heel NN N
stick NNS N
compared VBN N
with IN N
incubator NN i
care NN i
. . i

PERSPECTIVE VB N
This DT N
study NN N
showed VBD N
that IN N
KC NNP i
has VBZ N
a DT N
significant JJ N
effect NN N
on IN N
reducing VBG N
autonomic JJ N
pain NN N
responses NNS N
in IN N
preterm JJ p
infants NNS p
. . p

The DT N
findings NNS N
support NN N
that IN N
KC NNP i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
pain NN N
intervention NN N
in IN N
the DT N
neonatal JJ N
intensive JJ N
care NN N
unit NN N
. . N

-DOCSTART- -X- O O

Lung NNP N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
a DT N
1-year JJ N
randomized JJ N
smoking NN N
cessation NN N
trial NN N
of IN N
varenicline NN i
in IN N
COPD NNP p
patients NNS p
. . p

UNLABELLED IN N
There EX N
are VBP N
few JJ N
data NNS N
concerning VBG N
changes NNS N
in IN N
lung NN N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
smokers NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
weeks NNS p
to TO p
months NNS p
after IN p
quitting VBG p
smoking NN p
. . p

We PRP N
examined VBD N
serial JJ N
changes NNS N
in IN N
spirometry NN N
and CC N
Clinical NNP N
COPD NNP N
Questionnaire NNP N
( ( N
CCQ NNP N
) ) N
scores VBZ N
( ( N
measuring VBG N
respiratory NN N
symptoms NNS N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
) ) N
in IN N
COPD NNP p
participants NNS p
by IN p
smoking VBG p
status NN p
during IN N
a DT N
smoking NN N
cessation NN N
trial NN N
. . N

In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
smokers NNS p
with IN p
mild-to-moderate JJ p
COPD NNP p
were VBD N
treated VBN N
with IN N
varenicline JJ i
1 CD i
mg NN i
b.i.d NN i
. . i

or CC i
placebo NN i
for IN N
12 CD N
weeks NNS N
and CC N
followed VBD N
to TO N
Week VB N
52 CD N
. . N

Primary JJ N
endpoints NNS N
of IN N
abstinence NN o
were VBD N
previously RB N
reported VBN N
. . N

Secondary JJ N
endpoints NNS N
were VBD N
mean JJ o
changes NNS o
from IN o
baseline NN o
in IN N
post-bronchodilator NN o
forced VBN o
expired JJ o
volume NN o
in IN o
1 CD o
s NN o
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
and CC o
CCQ NNP o
scores NNS o
. . o

Change NN o
from IN o
baseline NN o
in IN N
post-bronchodilator NN N
FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
significantly RB N
improved VBN N
in IN N
continuous JJ N
abstainers NNS N
( ( N
121.8 CD N
mL NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
37.9 CD N
mL NN N
) ) N
at IN N
Week $ N
12 CD N
( ( N
P NNP N
= NNP N
0.0069 CD N
) ) N
, , N
but CC N
not RB N
at IN N
Weeks NNP N
24 CD N
or CC N
52 CD N
. . N

Mean JJ o
change NN o
from IN o
baseline NN o
at IN o
Week NNP o
12 CD o
in IN o
CCQ NNP o
Total NNP o
Score NNP o
was VBD N
significantly RB N
better RBR N
in IN N
continuous JJ N
abstainers NNS N
( ( N
-1.04 NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
-0.53 NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
: : N
this DT N
improvement NN N
was VBD N
sustained VBN N
at IN N
Weeks NNP N
24 CD N
and CC N
52 CD N
. . N

In IN N
a DT N
1-year JJ N
cessation NN N
trial NN N
of IN N
smokers NNS p
with IN p
COPD NNP p
, , N
continuous JJ o
abstinence NN o
compared VBN N
with IN N
continuous JJ N
smoking VBG N
significantly RB N
improved VBN N
post-bronchodilator NN o
FEV NNP N
( ( N
1 CD N
) ) N
at IN N
Week $ N
12 CD N
( ( N
although IN N
the DT N
difference NN N
narrowed VBD N
subsequently RB N
) ) N
and CC N
CCQ NNP o
Total NNP o
Scores NNP o
at IN N
Week NNP N
12 CD N
, , N
with IN N
sustained JJ N
improvement NN N
thereafter RB N
. . N

( ( N
TRIAL NNP N
REGISTRY NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
; : N
trial NN N
identifier NN N
: : N
NCT00285012 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Determination NN N
of IN N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
DIG NNP N
trial NN N
. . N

The DT N
Digitalis NNP N
Investigation NNP N
Group NNP N
( ( N
DIG NNP N
) ) N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
placebo-controlled JJ i
trial NN N
whose WP$ N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
digoxin NN i
had VBD N
beneficial JJ N
, , N
harmful JJ N
, , N
or CC N
no DT N
effect NN N
on IN N
total JJ N
mortality NN N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
who WP p
were VBD p
in IN p
sinus NN p
rhythm NN p
and CC p
whose WP$ p
ejection NN p
fraction NN p
was VBD p
< JJ p
/=0.45 NNP p
. . p

The DT N
study NN N
was VBD N
designed VBN N
as IN N
a DT N
large JJ N
simple JJ N
trial NN N
with IN N
a DT p
large JJ p
number NN p
of IN p
centers NNS p
( ( p
302 CD p
) ) p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
, , p
many JJ p
of IN p
which WDT p
were VBD p
inexperienced VBN p
in IN p
research NN p
. . p

To TO N
ensure VB N
that IN N
the DT N
results NNS N
of IN N
the DT N
trial NN N
would MD N
be VB N
reported VBN N
accurately RB N
without IN N
possible JJ N
bias NN N
due JJ N
to TO N
missing VBG N
data NNS N
, , N
the DT N
study NN N
leadership NN N
decided VBD N
that IN N
no DT N
outcome NN N
results NNS N
would MD N
be VB N
reported VBN N
until IN N
the DT N
vital JJ N
status NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
known VBN N
for IN N
at IN N
least JJS N
97 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
. . N

Planning VBG N
for IN N
closeout NN N
of IN N
the DT N
study NN N
began VBD N
a DT N
year NN N
prior RB N
to TO N
the DT N
common JJ N
end NN N
date NN N
of IN N
December NNP N
31 CD N
, , N
1995 CD N
and CC N
included VBD N
plans NNS N
for IN N
obtaining VBG N
vital JJ N
status NN N
on IN N
December NNP N
31 CD N
, , N
1995 CD N
. . N

Participants NNS N
were VBD N
given VBN i
postcards NNS i
at IN i
their PRP$ i
final JJ i
study NN i
visit NN i
to TO i
be VB i
completed VBN i
and CC i
mailed VBN i
on IN i
or CC i
after IN i
January NNP i
1 CD i
, , i
1996 CD i
. . i

Of IN p
5602 CD p
postcards NNS p
distributed VBN p
, , p
5070 CD p
( ( p
90.5 CD p
% NN p
) ) p
were VBD p
completed VBN p
and CC p
returned VBN p
. . p

A DT N
contract NN N
search NN N
agency NN N
was VBD N
hired VBN N
to TO N
locate VB N
the DT N
remaining VBG N
participants NNS N
. . N

Of IN p
the DT p
total JJ p
7788 CD p
participants NNS p
entered VBD p
into IN p
the DT p
DIG NNP p
trial NN p
, , p
only RB p
97 CD p
participants NNS p
( ( p
1.2 CD p
% NN p
) ) p
could MD p
not RB p
have VB p
their PRP$ p
vital JJ o
status NN o
as IN p
of IN p
December NNP p
31 CD p
, , p
1995 CD p
determined VBD p
. . p

It PRP N
is VBZ N
recommended VBN N
that IN N
investigators NNS N
having VBG N
an DT N
outcome NN N
measure NN N
with IN N
a DT N
common JJ N
end NN N
date NN N
include VBP N
plans NNS N
in IN N
their PRP$ N
protocols NNS N
for IN N
obtaining VBG N
their PRP$ N
measures NNS N
and CC N
activate VBP N
those DT N
plans NNS N
as RB N
early RB N
as IN N
possible JJ N
during IN N
the DT N
course NN N
of IN N
the DT N
study NN N
. . N

-DOCSTART- -X- O O

Interferential JJ i
therapy NN i
electrode NN i
placement NN i
technique NN i
in IN N
acute NN p
low JJ p
back RB p
pain NN p
: : p
a DT N
preliminary JJ N
investigation NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
interferential JJ i
therapy NN i
( ( i
IFT NNP i
) ) i
electrode VBP i
placement NN i
technique NN i
compared VBN N
with IN N
a DT N
control NN i
treatment NN i
in IN N
subjects NNS p
with IN p
acute NN p
low JJ p
back RB p
pain NN p
( ( p
LBP NNP p
) ) p
. . p

DESIGN NNP N
Single-blind NNP N
, , N
randomized VBD N
, , N
controlled VBD N
trial NN N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

SETTING NN N
Outpatient NNP p
physiotherapy NN p
departments NNS p
in IN p
hospital NN p
and CC p
university NN p
settings NNS p
. . p

PATIENTS VB N
A DT N
random JJ N
sample NN N
of IN N
60 CD p
eligible JJ p
patients NNS p
with IN p
back JJ p
pain NN p
( ( p
28 CD p
men NNS p
, , p
32 CD p
women NNS p
) ) p
were VBD p
recruited VBN p
by IN p
general JJ p
practitioners NNS p
and CC p
self-referral JJ p
for IN N
physiotherapy NN N
treatment NN N
and CC N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
3 CD N
groups NNS N
. . N

INTERVENTIONS NNP N
( ( N
1 CD N
) ) N
IFT NNP i
painful JJ i
area NN i
and CC i
The DT i
Back NNP i
Book NNP i
, , N
( ( N
2 CD N
) ) N
IFT NNP i
spinal JJ i
nerve NN i
and CC i
The DT i
Back NNP i
Book NNP i
, , N
and CC N
( ( N
3 CD N
) ) N
Control NN i
, , i
The DT i
Back NNP i
Book NNP i
only RB N
. . N

Standardized VBN N
IFT NNP i
stimulation NN N
parameters NNS N
were VBD N
used VBN N
: : N
carrier NN N
frequency NN N
3.85 CD N
kHz NN N
; : N
140 CD N
Hz NNP N
constant NN N
; : N
pulse JJ N
duration NN N
130 CD N
micros NN N
; : N
30 CD N
minutes NNS N
' POS N
duration NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Pain NNP o
Rating NNP o
Index NNP o
, , o
Roland-Morris NNP o
Disability NNP o
Questionnaire NNP o
( ( o
RMDQ NNP o
) ) o
, , o
and CC o
EuroQol NNP o
were VBD N
completed VBN N
by IN N
subjects NNS N
pretreatment JJ N
, , N
at IN N
discharge NN N
, , N
and CC N
3-month JJ N
follow-up NN N
. . N

RESULTS NNP N
All NNP N
groups NNS N
had VBD N
significant JJ N
improvements NNS N
in IN N
all DT N
outcomes NNS N
at IN N
follow-up NN N
. . N

Subjects NNS N
managed VBN N
by IN N
IFT NNP N
spinal JJ N
nerve NN N
and CC N
The DT N
Back NNP N
Book NNP N
displayed VBD N
both DT N
a DT N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
.030 NNP N
) ) N
and CC N
clinically RB N
meaningful JJ N
reduction NN o
in IN o
functional JJ o
disability NN o
( ( o
RMDQ NNP o
) ) o
, , N
compared VBN N
with IN N
management NN N
via IN N
IFT NNP N
painful JJ N
area NN N
and CC N
The DT N
Back NNP N
Book NNP N
combined VBD N
or CC N
The DT N
Back JJ N
Book NNP N
alone RB N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
showed VBD N
that IN N
IFT NNP i
electrode FW i
placement NN i
technique NN i
affects VBZ N
LBP-specific JJ N
functional JJ N
disability NN N
, , N
providing VBG N
preliminary JJ N
implications NNS N
for IN N
future JJ N
clinical JJ N
studies NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
short-term JJ N
aromatase NN i
inhibitor NN i
( ( i
letrozole JJ i
) ) i
and CC i
GnRH NNP i
agonist NN i
( ( i
triptorelin NN i
) ) i
versus NN N
case NN N
control NN N
on IN N
pregnancy NN o
rate NN o
and CC o
symptom NN o
and CC o
sign NN o
recurrence NN o
after IN N
laparoscopic JJ N
treatment NN N
of IN N
endometriosis NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
role NN N
of IN N
an DT N
aromatase NN i
inhibitor NN i
( ( i
letrozole JJ i
) ) i
with IN N
a DT N
GnRH NNP i
agonist NN i
( ( i
triptorelin NN i
) ) i
versus NN N
case NN N
control NN N
on IN N
the DT N
pregnancy NN o
rate NN o
and CC o
recurrence NN o
of IN o
symptoms NNS o
and CC o
signs NNS o
in IN N
patients NNS p
with IN p
endometriosis NN p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
, , N
after IN p
treatment NN p
of IN p
144 CD p
infertile JJ p
women NNS p
in IN p
their PRP$ p
reproductive JJ p
age NN p
by IN p
laparoscopy NN i
( ( p
whose WP$ p
endometriosis NN i
was VBD p
confirmed VBN p
by IN p
prior JJ p
laparoscopy NN i
) ) i
, , N
they PRP N
were VBD N
divided VBN N
into IN N
3 CD N
groups NNS N
: : N
group NN N
1 CD N
( ( p
47 CD p
cases NNS p
) ) p
who WP p
received VBD p
letrozole NN i
for IN p
2 CD p
months NNS p
, , p
group NN p
2 CD p
( ( p
40 CD p
patients NNS p
) ) p
who WP p
were VBD p
prescribed VBN p
triptorelin NN i
for IN p
2 CD p
months NNS p
and CC p
group NN p
3 CD p
who WP p
were VBD p
57 CD p
patients NNS p
in IN p
the DT p
control NN i
group NN p
and CC p
did VBD i
not RB i
receive VB i
any DT i
medication NN i
. . i

We PRP N
followed VBD N
up RP N
each DT N
group NN N
at IN N
least JJS N
for IN N
12 CD N
months NNS N
after IN N
their PRP$ N
restoration NN N
of IN N
regular JJ N
cycle NN N
. . N

RESULTS JJ N
Pregnancy NNP o
rate NN o
was VBD N
23.4 CD N
% NN N
in IN N
group NN N
1 CD N
, , N
27.5 CD N
% NN N
in IN N
group NN N
2 CD N
, , N
and CC N
28.1 CD N
% NN N
in IN N
group NN N
3 CD N
. . N

The DT N
results NNS N
did VBD o
not RB o
show VB o
significant JJ o
differences NNS o
among IN N
the DT N
3 CD N
groups NNS N
. . N

Recurrence NNP o
rate NN o
of IN o
endometriosis NN o
was VBD N
6.4 CD N
% NN N
in IN N
group NN N
1 CD N
, , N
5 CD N
% NN N
group NN N
2 CD N
and CC N
5.3 CD N
% NN N
in IN N
group NN N
3 CD N
, , N
which WDT N
was VBD N
not RB o
statistically RB o
significantly RB o
different JJ o
as RB N
well RB N
. . N

CONCLUSION NNP N
Pregnancy NNP o
rate NN o
and CC o
endometriosis NN o
recurrence NN o
rate NN o
are VBP N
comparable JJ N
among IN N
the DT N
3 CD N
groups NNS N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
motor NN N
cortex NN N
excitability NN N
associated VBN N
with IN N
temporal JJ i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
tinnitus NN p
: : p
hints NNS N
for IN N
cross-modal JJ N
plasticity NN N
? . N
BACKGROUND NNP N
Motor NNP N
cortex VBP N
excitability NN N
was VBD N
found VBN N
to TO N
be VB N
changed VBN N
after IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
of IN N
the DT N
temporal JJ N
cortex NN N
highlighting VBG N
the DT N
occurrence NN N
of IN N
cross-modal JJ N
plasticity NN N
in IN N
non-invasive JJ N
brain NN N
stimulation NN N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
temporal JJ i
low-frequency NN i
rTMS NN i
on IN N
motor NN N
cortex NN N
plasticity NN N
in IN N
a DT N
large JJ N
sample NN N
of IN N
tinnitus NN p
patients NNS p
. . p

In IN N
116 CD p
patients NNS p
with IN p
chronic JJ p
tinnitus NN p
different JJ N
parameters NNS N
of IN N
cortical JJ N
excitability NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
ten JJ N
rTMS JJ i
treatment NN N
sessions NNS N
. . N

Patients NNS N
received VBD N
one CD N
of IN N
three CD N
different JJ N
protocols NNS N
all DT N
including VBG N
1 CD i
Hz NNP i
rTMS NN i
over IN i
the DT i
left JJ i
temporal JJ i
cortex NN i
. . i

Treatment NNP N
response NN N
was VBD N
defined VBN N
as IN N
improvement NN N
by IN N
at IN N
least JJS N
five CD N
points NNS N
in IN N
the DT N
tinnitus NN N
questionnaire NN N
( ( N
TQ NNP N
) ) N
. . N

Variables NNS N
of IN N
interest NN N
were VBD N
resting VBG o
motor NN o
threshold NN o
( ( o
RMT NNP o
) ) o
, , o
short-interval JJ o
intra-cortical JJ o
inhibition NN o
( ( o
SICI NNP o
) ) o
, , o
intracortical JJ o
facilitation NN o
( ( o
ICF NNP o
) ) o
, , o
and CC o
cortical JJ o
silent JJ o
period NN o
( ( o
CSP NNP o
) ) o
. . o

RESULTS NNP N
After IN N
rTMS JJ i
treatment NN N
RMT NNP o
was VBD o
decreased VBN o
by IN N
about IN N
1 CD N
% NN N
of IN N
stimulator NN N
output NN N
near-significantly RB N
in IN N
the DT N
whole JJ N
group NN N
of IN N
patients NNS N
. . N

SICI NNP o
was VBD N
associated VBN N
with IN N
significant JJ N
changes NNS N
with IN N
respect NN N
to TO N
treatment NN N
response NN N
. . N

The DT N
group NN N
of IN N
treatment NN N
responders NNS N
showed VBD N
a DT N
decrease NN o
of IN o
SICI NNP o
over IN N
the DT N
course NN N
of IN N
treatment NN N
, , N
the DT N
group NN N
of IN N
non-responders NNS N
the DT N
reverse NN N
pattern NN N
. . N

CONCLUSIONS NNP N
Minor NNP o
RMT NNP o
changes NNS o
during IN N
rTMS NN i
treatment NN N
do VBP N
not RB N
necessarily RB N
suggest VB N
the DT N
need NN N
for IN N
systematic JJ N
re-examination NN N
of IN N
the DT N
RMT NNP N
for IN N
safety NN N
and CC N
efficacy NN N
issues NNS N
. . N

Treatment NNP N
response NN N
to TO N
rTMS VB i
was VBD N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
changes NNS N
in IN N
SICI NNP N
that WDT N
might MD N
reflect VB N
modulation NN N
of IN N
GABAergic NNP N
mechanisms FW N
directly RB N
or CC N
indirectly RB N
related VBN N
to TO N
rTMS VB N
treatment NN N
effects NNS N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
parent-assisted JJ i
Children NNP i
's POS i
Friendship NNP i
Training NNP i
with IN N
children NNS p
having VBG p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
evaluated VBD N
Children NNP i
's POS i
Friendship NNP i
Training NNP i
( ( i
CFT NNP i
) ) i
, , i
a DT i
manualized JJ i
parent-assisted JJ i
intervention NN i
to TO N
improve VB N
social JJ N
skills NNS N
among IN N
second JJ p
to TO p
fifth VB p
grade JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Comparison NNP N
was VBD N
made VBN N
with IN N
a DT N
delayed JJ i
treatment NN i
control NN i
group NN i
( ( i
DTC NNP i
) ) i
. . N

Targeted VBN N
skills NNS N
included VBD N
conversational JJ o
skills NNS o
, , o
peer VBP o
entry NN o
skills NNS o
, , o
developing VBG o
friendship JJ o
networks NNS o
, , o
good JJ o
sportsmanship NN o
, , o
good JJ o
host NN o
behavior NN o
during IN o
play NN o
dates NNS o
, , o
and CC o
handling VBG o
teasing NN o
. . o

At IN N
post-testing NN N
, , N
the DT N
CFT NNP p
group NN p
was VBD N
superior JJ N
to TO N
the DT N
DTC NNP p
group NN p
on IN N
parent NN N
measures NNS N
of IN N
social JJ o
skill NN o
and CC o
play NN o
date NN o
behavior NN o
, , N
and CC N
child JJ N
measures NNS N
of IN N
popularity NN o
and CC o
loneliness NN o
, , N
At IN N
3-month JJ N
follow-up NN N
, , N
parent NN N
measures NNS N
showed VBD N
significant JJ N
improvement NN N
from IN N
baseline NN N
. . N

Post-hoc JJ N
analysis NN N
indicated VBD N
more JJR N
than IN N
87 CD N
% NN N
of IN N
children NNS N
receiving VBG N
CFT NNP i
showed VBD N
reliable JJ N
change NN N
on IN N
at IN N
least JJS N
one CD N
measure NN N
at IN N
post-test NN N
and CC N
66.7 CD N
% NN N
after IN N
3 CD N
months NNS N
follow-up RB N
. . N

-DOCSTART- -X- O O

Benzodiazepine NNP i
and CC N
opioid JJ i
sedation NN i
attenuate IN N
the DT N
sympathetic JJ N
response NN N
to TO N
fiberoptic JJ o
bronchoscopy NN o
. . o

Prophylactic JJ N
labetalol NN N
gave VBD N
no DT N
additional JJ N
benefit NN N
. . N

Results NNS N
of IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

BACKGROUND NNP N
Hypertension NNP N
and CC N
tachycardia NN N
are VBP N
common JJ N
during IN N
fiber-optic JJ i
bronchoscopy NN i
( ( i
FOB NNP i
) ) i
, , N
and CC N
this DT N
may MD N
lead VB N
to TO N
cardiac JJ N
ischemia NN N
. . N

The DT N
prophylactic JJ N
addition NN N
of IN N
a DT N
beta-adrenergic JJ i
anatagonist NN i
might MD N
mask VB N
this DT N
response NN N
and CC N
prevent VB N
the DT N
deleterious JJ N
cardiovascular JJ o
effects NNS o
of IN o
FOB NNP o
. . o

METHODS NNP N
We PRP N
performed VBD N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
labetalol $ i
10mg CD i
iv NN i
given VBN i
with IN i
midazolam-alfentanil JJ i
sedation NN i
. . i

We PRP N
monitored VBD N
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
and CC o
systolic/diastolic JJ o
blood NN o
pressure NN o
( ( o
SBP/DBP NNP o
) ) o
throughout IN N
the DT N
bronchoscopy NN N
and CC N
calculated VBD N
the DT N
rate-pressure JJ N
product NN N
( ( N
RPP= NNP N
( ( N
HRxSBP NNP N
) ) N
/100 NN N
) ) N
. . N

One-hundred JJ p
twenty NN p
patients NNS p
were VBD p
enrolled VBN p
. . p

RESULTS NNP N
In IN N
the DT N
placebo NN N
group NN N
, , N
there EX N
was VBD N
no DT N
rise NN N
in IN N
HR NNP o
, , o
SBP NNP o
, , o
DBP NNP o
or CC o
RPP NNP o
, , N
and CC N
there EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
placebo NN N
and CC N
labetalol NN i
groups NNS N
. . N

Adverse JJ o
events NNS o
during IN o
bronchoscopy NN o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
a DT N
subgroup NN N
of IN N
patients NNS N
undergoing VBG N
interventional JJ N
bronchoscopy NN N
, , N
there EX N
was VBD N
a DT N
trend NN N
towards NNS N
lower JJR N
SBP NNP o
( ( N
p=0.06 NN N
) ) N
. . N

CONCLUSIONS JJ N
Patients NNPS p
undergoing VBG p
FOB NNP p
under IN N
adequate JJ N
midazolam-alfentanil JJ i
sedation NN i
do VBP N
not RB N
develop VB N
excessive JJ N
sympathetic JJ N
drive NN N
that WDT N
may MD N
lead VB N
to TO N
cardiac JJ N
stress NN N
. . N

The DT N
addition NN N
of IN N
labetalol NN i
did VBD N
not RB N
confer VB N
additional JJ N
benefit NN N
or CC N
risk NN N
to TO N
the DT N
patients NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00394537 NNP N
) ) N
. . N

-DOCSTART- -X- O O

Accuracy NN N
and CC N
feasibility NN N
of IN N
contrast NN i
echocardiography NN i
for IN N
detection NN N
of IN N
perfusion NN N
defects NNS N
in IN N
routine JJ N
practice NN N
: : N
comparison NN N
with IN N
wall JJ i
motion NN i
and CC i
technetium-99m JJ i
sestamibi NN i
single-photon JJ i
emission NN i
computed VBD i
tomography NN i
. . i

The DT N
Nycomed NNP N
NC100100 NNP N
Investigators NNP N
. . N

OBJECTIVES NNP N
We PRP N
sought VBD N
to TO N
assess VB N
the DT N
feasibility NN N
and CC N
accuracy NN N
of IN N
myocardial JJ i
contrast NN i
echocardiography NN i
( ( i
MCE NNP i
) ) i
using VBG N
standard JJ N
imaging NN N
approaches NNS N
for IN N
the DT N
detection NN N
of IN N
perfusion NN N
defects NNS N
in IN N
patients NNS p
who WP p
had VBD p
a DT p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
. . p

BACKGROUND NNP N
Myocardial NNP i
contrast NN i
echocardiography NN i
may MD N
be VB N
more JJR N
versatile JJ N
than IN N
perfusion NN i
scintigraphy NN i
for IN N
identifying VBG N
the DT N
presence NN N
and CC N
extent NN N
of IN N
perfusion NN N
defects NNS N
after IN N
MI NNP N
. . N

However RB N
, , N
its PRP$ N
reliability NN N
in IN N
routine JJ N
practice NN N
is VBZ N
unclear JJ N
. . N

METHODS NNP N
Fundamental NNP N
or CC N
harmonic JJ N
MCE NNP N
was VBD N
performed VBN N
with IN N
continuous JJ N
or CC N
triggered JJ N
imaging NN N
in IN N
203 CD p
patients NNS p
with IN p
a DT p
previous JJ p
MI NNP p
using VBG N
bolus JJ N
doses NNS N
of IN N
a DT N
perfluorocarbon-filled JJ i
contrast NN i
agent NN i
( ( i
NC100100 NNP i
) ) i
. . i

All DT N
patients NNS N
underwent JJ N
single-photon JJ i
emission NN i
computed VBN i
tomography NN i
( ( i
SPECT NNP i
) ) i
after IN i
the DT i
injection NN i
of IN i
technetium-99m JJ i
( ( i
Tc-99m NNP i
) ) i
sestamibi NN i
at IN i
rest NN i
. . i

Quantitative NNP i
and CC i
semiquantitative JJ i
SPECT NNP i
, , N
wall NN N
motion NN N
and CC N
digitized JJ N
echocardiographic JJ N
data NNS N
were VBD N
interpreted VBN N
independently RB N
. . N

The DT N
accuracy NN N
of IN N
MCE NNP i
was VBD N
assessed VBN N
for IN N
detection NN N
of IN N
segments NNS N
and CC N
patients NNS N
with IN N
moderate JJ N
and CC N
severe JJ N
sestamibi-SPECT JJ N
defects NNS N
, , N
as RB N
well RB N
as IN N
for IN N
detection NN N
of IN N
patients NNS N
with IN N
extensive JJ N
perfusion NN N
defects NNS N
( ( N
> VB N
12 CD N
% NN N
of IN N
left JJ N
ventricle NN N
) ) N
. . N

RESULTS NNP N
In IN N
segments NNS N
with IN N
diagnostic JJ N
MCE NNP N
, , N
the DT N
segmental JJ o
sensitivity NN o
ranged VBD N
from IN N
14 CD N
% NN N
to TO N
65 CD N
% NN N
, , N
and CC N
the DT N
specificity NN o
varied VBD N
from IN N
78 CD N
% NN N
to TO N
95 CD N
% NN N
, , N
depending VBG N
on IN N
the DT N
dose NN N
of IN N
contrast NN N
agent NN N
. . N

Using VBG N
both DT N
segment- JJ N
and CC N
patient-based JJ N
analysis NN N
, , N
the DT N
greatest JJS N
accuracy NN N
and CC N
proportion NN N
of IN N
interpretable JJ N
images NNS N
were VBD N
obtained VBN N
using VBG N
harmonic JJ N
imaging NN N
in IN N
the DT N
triggered JJ N
mode NN N
. . N

For IN N
the DT N
detection NN N
of IN N
extensive JJ N
defects NNS N
, , N
the DT N
sensitivity NN o
varied VBD N
from IN N
13 CD N
% NN N
to TO N
48 CD N
% NN N
, , N
with IN N
specificity NN N
from IN N
63 CD N
% NN N
to TO N
100 CD N
% NN N
. . N

Harmonic NNP N
imaging NN N
remained VBD N
the DT N
most RBS N
accurate JJ N
approach NN N
. . N

Time NNP o
since IN o
MI NNP o
and CC o
SPECT NNP o
defect VBP o
location NN o
and CC o
intensity NN o
were VBD N
all DT N
determinants NNS N
of IN N
the DT N
MCE NNP N
response NN N
. . N

The DT N
extent NN o
of IN o
defects NNS o
on IN o
MCE NNP o
was VBD N
less JJR N
than IN N
the DT N
extent NN N
of IN N
either DT N
abnormal JJ N
wall NN N
motion NN N
or CC N
SPECT NNP N
abnormalities NNS N
. . N

The DT N
combination NN N
of IN N
wall JJ N
motion NN N
and CC N
MCE NNP N
assessment NN N
gave VBD N
the DT N
best JJS N
balance NN N
of IN N
sensitivity NN N
( ( N
46 CD N
% NN N
to TO N
55 CD N
% NN N
) ) N
and CC N
specificity NN N
( ( N
82 CD N
% NN N
to TO N
83 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
MCE NNP N
is VBZ N
specific JJ N
, , N
it PRP N
has VBZ N
limited VBN N
sensitivity NN N
for IN N
detection NN N
of IN N
moderate JJ o
or CC o
severe JJ o
perfusion NN o
defects NNS o
, , N
and CC N
it PRP N
underestimates VBZ N
the DT N
extent NN N
of IN N
SPECT NNP o
defects NNS o
. . N

The DT N
best JJS N
results NNS N
are VBP N
obtained VBN N
by IN N
integration NN N
with IN N
wall DT N
motion NN N
. . N

More RBR N
sophisticated JJ N
methods NNS N
of IN N
acquisition NN N
and CC N
interpretation NN N
are VBP N
needed VBN N
to TO N
enhance VB N
the DT N
feasibility NN N
of IN N
this DT N
technique NN N
in IN N
routine JJ N
practice NN N
. . N

-DOCSTART- -X- O O

A DT N
placebo-controlled JJ i
, , N
fixed-dose JJ N
study NN N
of IN N
aripiprazole NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
short-term JJ N
efficacy NN o
and CC N
safety NN o
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . p

METHOD NNP N
Two CD p
hundred VBD p
eighteen JJ p
children NNS p
and CC p
adolescents NNS p
( ( p
aged VBN p
6-17 CD p
years NNS p
) ) p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
, , p
and CC p
with IN p
behaviors NNS p
such JJ p
as IN p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
symptoms NNS p
, , N
were VBD N
randomized VBN N
1:1:1:1 CD N
to TO N
aripiprazole VB i
( ( i
5 CD i
, , i
10 CD i
, , i
or CC i
15 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
in IN N
this DT N
8-week JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
. . N

Efficacy NNP o
was VBD N
evaluated VBN N
using VBG N
the DT N
caregiver-rated JJ N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
subscale NN o
( ( o
primary JJ o
efficacy NN o
measure NN o
) ) o
and CC o
the DT o
clinician-rated JJ o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
score NN o
. . o

Safety NNP o
and CC o
tolerability NN o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
At IN N
week NN N
8 CD N
, , N
all DT N
aripiprazole JJ i
doses NNS N
produced VBN N
significantly RB N
greater JJR N
improvement NN o
than IN N
placebo NN N
in IN N
mean JJ N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
subscale NN o
scores NNS o
( ( N
5 CD N
mg/day NN N
, , N
-12.4 NNP N
; : N
10 CD N
mg/day NN N
, , N
-13.2 NNP N
; : N
15 CD N
mg/day NN N
, , N
-14.4 NNP N
; : N
versus NN N
placebo NN N
, , N
-8.4 NNP N
; : N
all DT N
p VBP N
< NNP N
.05 NNP N
) ) N
. . N

All DT N
aripiprazole JJ i
doses NNS N
demonstrated VBN N
significantly RB N
greater JJR N
improvements NNS o
in IN o
mean JJ o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
score NN o
than IN N
placebo NN i
at IN N
week NN N
8 CD N
. . N

Discontinuation NN N
rates NNS N
due JJ N
to TO N
adverse JJ o
events NNS o
were VBD N
as IN N
follows VBZ N
: : N
placebo VB N
7.7 CD N
% NN N
, , N
aripiprazole JJ N
5 CD N
mg/day JJ N
9.4 CD N
% NN N
, , N
10 CD N
mg/day JJ N
13.6 CD N
% NN N
, , N
and CC N
15 CD N
mg/day JJ N
7.4 CD N
% NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
event NN o
leading VBG N
to TO N
discontinuation NN N
was VBD N
sedation NN o
. . o

There EX N
were VBD N
two CD N
serious JJ o
adverse JJ o
events NNS o
: : o
presyncope NN o
( ( N
5 CD N
mg/day NN N
) ) N
and CC N
aggression NN o
( ( N
10 CD N
mg/day NN N
) ) N
. . N

At IN N
week NN N
8 CD N
, , N
mean JJ N
weight NN o
change NN o
( ( N
last JJ N
observation NN N
carried VBD N
forward RB N
) ) N
was VBD N
as IN N
follows VBZ N
: : N
placebo NN N
+0.3 NNP N
kg NN N
, , N
aripiprazole JJ i
5 CD N
mg/day JJ N
+1.3 NNP N
kg NN N
, , N
10 CD N
mg/day NN N
+1.3 NNP N
kg NN N
, , N
and CC N
15 CD N
mg/day NN N
+1.5 NNP N
kg NN N
; : N
all DT N
p VBP N
< JJ N
.05 NNP N
versus NN N
placebo NN i
. . i

CONCLUSIONS NNP N
Aripiprazole NNP i
was VBD N
efficacious JJ o
and CC N
generally RB N
safe JJ o
and CC N
well RB o
tolerated VBN o
in IN N
the DT N
treatment NN N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -X- O O

Comparison NNP N
with IN N
computed JJ i
tomography NN i
of IN N
two CD N
ultrasound JJ N
devices NNS N
for IN N
diagnosis NN N
of IN N
abdominal JJ p
aortic JJ p
aneurysm NN p
. . p

Screening VBG N
for IN N
abdominal JJ p
aortic JJ p
aneurysms NNS p
( ( p
AAAs NNP p
) ) p
in IN p
patients NNS p
at IN p
risk NN p
will MD N
become VB N
more RBR N
cost JJ N
effective JJ N
if IN N
a DT N
simple NN N
, , N
inexpensive JJ N
, , N
and CC N
reliable JJ N
ultrasound JJ N
device NN N
is VBZ N
available JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
2-dimensional JJ N
, , N
handheld JJ i
ultrasound JJ i
device NN i
and CC N
a DT N
newly RB N
developed VBN N
ultrasound JJ i
volume NN i
scanner NN i
( ( N
based VBN N
on IN N
bladder NN N
scan JJ N
technology NN N
) ) N
with IN N
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
for IN N
diagnosing VBG N
AAA NNP N
. . N

A NNP N
total NN N
of IN N
146 CD p
patients NNS p
( ( p
mean JJ p
age NN p
69 CD p
+/- JJ p
10 CD p
years NNS p
; : p
127 CD p
men NNS p
) ) p
were VBD N
screened VBN N
for IN N
the DT N
presence NN N
of IN N
AAAs NNP N
( ( N
diameter NN N
> VBZ N
3 CD N
cm NN N
) ) N
using VBG N
CT. NNP N
All NNP N
patients NNS N
were VBD N
examined VBN N
with IN N
the DT N
handheld NN N
ultrasound JJ N
device NN N
and CC N
the DT N
volume NN N
scanner NN N
. . N

Maximal JJ o
diameters NNS o
and CC o
volumes NNS o
were VBD N
used VBN N
for IN N
the DT N
analyses NNS N
. . N

AAAs NNP N
were VBD N
diagnosed VBN N
by IN N
CT NNP i
in IN N
116 CD N
patients NNS N
( ( N
80 CD N
% NN N
) ) N
. . N

The DT N
absolute JJ o
difference NN o
of IN o
aortic JJ o
diameter NN o
between IN N
ultrasound NN i
and CC N
CT NNP i
was VBD N
< JJ N
5 CD N
mm NN N
in IN N
88 CD N
% NN N
of IN N
patients NNS N
. . N

Limits NNS N
of IN N
agreement NN N
between IN N
ultrasound NN N
and CC N
CT NNP i
( ( N
-6.6 NNP N
to TO N
9.4 CD N
mm NN N
) ) N
exceeded VBD N
the DT N
limits NNS N
of IN N
clinical JJ N
acceptability NN N
( ( N
+/-5 JJ N
mm NN N
) ) N
. . N

An DT N
excellent JJ N
correlation NN o
between IN N
ultrasound NN i
and CC N
CT NNP i
was VBD N
observed VBN N
( ( N
r JJ N
= NNP N
0.98 CD N
) ) N
. . N

The DT N
correlation NN o
coefficient NN o
between IN N
the DT N
volume NN N
scanner NN N
and CC N
CT NNP i
was VBD N
0.86 CD N
, , N
with IN N
agreement NN N
of IN N
90 CD N
% NN N
and CC N
kappa JJ N
value NN N
of IN N
0.73 CD N
. . N

Using VBG N
an DT N
optimal JJ o
cut-off NN o
value NN o
of IN N
> $ N
56 CD N
ml NN N
, , N
defined VBN N
by IN N
receiver-operating JJ o
characteristic JJ o
curve NN o
analysis NN o
, , o
sensitivity NN o
, , o
specificity NN o
, , o
and CC o
the DT o
positive JJ o
and CC o
negative JJ o
predictive JJ o
values NNS o
of IN N
the DT N
volume NN N
scanner NN N
for IN N
detecting VBG N
AAA NNP N
were VBD N
90 CD N
% NN N
, , N
90 CD N
% NN N
, , N
97 CD N
% NN N
, , N
and CC N
71 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
conclusion NN N
, , N
this DT N
study NN N
shows VBZ N
that IN N
a DT N
2-dimensional JJ N
, , N
handheld JJ N
ultrasound JJ N
device NN N
and CC N
a DT N
newly RB N
developed VBN N
ultrasound JJ N
volume NN N
scanner NN N
can MD N
effectively RB N
identify VB N
patients NNS p
with IN p
AAAs NNP p
confirmed VBN p
by IN p
CT NNP p
. . p

-DOCSTART- -X- O O

Bilateral NNP i
transversus NN i
abdominis NN i
plane NN i
block NN i
does VBZ N
not RB N
decrease VB N
postoperative JJ N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ i
anesthetic JJ i
infiltration NN i
of IN i
trocar NN i
insertion NN i
sites NNS i
. . i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Transversus NNP i
abdominis NN i
plane NN i
( ( i
TAP NNP i
) ) i
block NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
pain NN N
and CC N
analgesic JJ N
requirements NNS N
after IN N
abdominal JJ N
surgery NN N
. . N

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
bilateral JJ i
TAP NNP i
blocks NNS i
decrease NN N
pain NN N
after IN N
laparoscopic NN N
cholecystectomy NN N
when WRB N
compared VBN N
with IN N
local JJ i
anesthetic JJ i
infiltration NN i
of IN N
trocar NN N
insertion NN N
sites NNS N
. . N

METHODS NNP N
Eighty NNP p
patients NNS p
undergoing VBG p
laparoscopic JJ p
cholecystectomy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
bilateral JJ i
TAP NNP i
blocks NNS i
or CC i
local JJ i
anesthetic JJ i
infiltration NN i
of IN i
trocar NN i
insertion NN i
sites VBZ i
with IN i
ropivacaine JJ i
0.5 CD i
% NN i
. . i

Postoperative JJ o
pain NN o
scores NNS N
and CC N
analgesic JJ N
use NN N
for IN N
the DT N
first JJ N
24 CD N
hrs NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Eighty NNP p
patients NNS p
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

After IN N
exclusions NNS N
, , N
data NNS N
were VBD N
analyzed VBN N
on IN N
39 CD N
patients NNS N
in IN N
group NN N
T NNP N
( ( N
bilateral JJ N
TAP NNP i
block NN i
) ) i
and CC N
35 CD N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
infiltration NN N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB o
significant JJ o
difference NN o
in IN N
pain NN o
scores NNS o
on IN o
the DT o
numeric JJ o
analog NN o
scale NN o
( ( N
0-10 JJ N
) ) N
between IN N
the DT N
groups NNS N
at IN N
4 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.18 CD N
) ) N
or CC N
during IN N
the DT N
24 CD N
hrs NN N
after IN N
surgery NN N
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

The DT N
time NN o
interval NN o
from IN o
anesthesia JJ o
start NN o
to TO o
surgery VB o
start NN o
was VBD N
greater JJR N
in IN N
group NN N
T NNP N
than IN N
group NN N
I PRP N
( ( N
48 CD N
vs RB N
35 CD N
mins NNS N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ o
difference NN o
found VBD N
in IN N
analgesic JJ o
use NN o
during IN N
the DT N
first JJ N
24 CD N
hrs NN N
after IN N
surgery NN N
. . N

CONCLUSIONS NNP N
Bilateral NNP i
ultrasound-guided JJ i
TAP NNP i
block NN i
is VBZ N
equivalent JJ N
to TO N
local JJ i
anesthetic JJ i
infiltration NN i
of IN N
trocar NN N
insertion NN N
sites VBZ N
for IN N
overall JJ N
postoperative JJ o
pain NN o
in IN N
a DT N
heterogeneous JJ N
group NN N
of IN N
patients NNS N
undergoing VBG N
laparoscopic JJ N
cholecystectomy NN N
. . N

-DOCSTART- -X- O O

Weight NNP o
loss NN o
maintenance NN o
in IN N
overweight JJ p
subjects NNS p
on IN N
ad NN i
libitum NN i
diets NNS i
with IN N
high JJ N
or CC N
low JJ N
protein NN N
content NN N
and CC N
glycemic JJ N
index NN N
: : N
the DT N
DIOGENES NNP N
trial NN N
12-month JJ N
results NNS N
. . N

BACKGROUND NNP N
A NNP i
high JJ i
dietary JJ i
protein NN i
( ( i
P NNP i
) ) i
content NN i
and CC i
low JJ i
glycemic JJ i
index NN i
( ( N
LGI NNP N
) ) N
have VBP N
been VBN N
suggested VBN N
to TO N
be VB N
beneficial JJ N
for IN N
weight JJ N
management NN N
, , N
but CC N
long-term JJ N
studies NNS N
are VBP N
scarce JJ N
. . N

OBJECTIVE IN N
The DT N
DIOGENES NNP N
randomized VBD N
clinical JJ N
trial NN N
investigated VBD N
the DT N
effect NN o
of IN N
P NNP N
and CC N
GI NNP N
on IN N
weight JJ o
loss NN o
maintenance NN o
in IN N
overweight NN p
or CC p
obese JJ p
adults NNS p
in IN p
eight CD p
centers NNS p
across IN p
Europe NNP p
. . p

This DT N
study NN N
reports VBZ N
the DT N
1-year JJ N
results NNS N
in IN N
two CD N
of IN N
the DT N
centers NNS N
that WDT N
extended VBD N
the DT N
intervention NN N
to TO N
1 CD N
year NN N
. . N

METHOD NNP N
After IN N
an DT N
8-week JJ N
low-calorie JJ N
diet NN N
( ( N
LCD NNP N
) ) N
, , N
256 CD p
adults NNS p
( ( p
body NN p
mass NN p
index NN p
> VBD p
27 CD p
kg NNS p
m NN p
( ( p
- : p
) ) p
( ( p
2 CD p
) ) p
) ) p
were VBD p
randomized VBN i
to TO i
five CD i
ad NN i
libitum NN i
diets NNS i
for IN i
12 CD i
months NNS i
: : i
high JJ i
P/LGI NNP i
( ( i
HP/LGI NNP i
) ) i
, , i
HP/high NNP i
GI NNP i
( ( i
HP/HGI NNP i
) ) i
, , i
low JJ i
P/LGI NNP i
( ( i
LP/LGI NNP i
) ) i
, , i
LP/HGI NNP i
and CC i
a DT i
control NN i
diet JJ i
. . i

During IN i
the DT N
first JJ N
6 CD N
months NNS i
, , i
foods NNS i
were VBD i
provided VBN i
for IN i
free JJ i
through IN i
a DT i
shop NN i
system NN i
and CC i
during IN i
the DT i
whole JJ i
12-month JJ i
period NN i
, , i
subjects VBZ i
received VBN i
guidance NN i
by IN i
a DT i
dietician JJ i
. . i

Primary JJ i
outcome NN N
variable NN N
was VBD N
the DT N
change NN o
in IN o
body NN o
weight NN o
over IN o
the DT N
12-month JJ N
intervention NN N
period NN N
. . N

RESULTS NNP N
During IN N
the DT N
LCD NNP N
period NN N
, , N
subjects VBZ N
lost VBN N
11.2 CD N
( ( N
10.8 CD N
, , N
12.0 CD N
) ) N
kg NN N
( ( N
mean JJ N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
) ) N
) ) N
. . N

Average JJ o
weight JJ o
regain NN o
over IN o
the DT N
12-month JJ N
intervention NN N
period NN N
was VBD N
3.9 CD N
( ( N
95 CD N
% NN N
CI NNP N
3.0-4.8 CD N
) ) N
kg NN N
. . N

Subjects NNS N
on IN N
the DT N
HP NNP N
diets NNS N
regained VBD o
less JJR o
weight NN o
than IN o
subjects NNS N
on IN N
the DT N
LP NNP N
diets NNS N
. . N

The DT N
difference NN o
in IN o
weight NN o
regain NN o
after IN o
1 CD N
year NN N
was VBD N
2.0 CD N
( ( N
0.4 CD N
, , N
3.6 CD N
) ) N
kg NN N
( ( N
P=0.017 NNP N
) ) N
( ( N
completers NNS N
analysis NN N
, , N
N=139 NNP N
) ) N
or CC N
2.8 CD N
( ( N
1.4 CD N
, , N
4.1 CD N
) ) N
kg NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
( ( N
intention-to-treat JJ N
analysis NN N
, , N
N=256 NNP N
) ) N
. . N

No DT N
consistent JJ N
effect NN N
of IN N
GI NNP N
on IN o
weight NN o
regain NN o
was VBD o
found VBN N
. . N

There EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
differences NNS N
in IN N
changes NNS N
in IN N
cardiometabolic JJ N
risk NN N
factors NNS N
among IN N
diet JJ N
groups NNS N
. . N

CONCLUSION VB N
A DT N
higher JJR i
protein NN i
content NN i
of IN i
an DT i
ad NN i
libitum NN i
diet JJ i
improves NNS o
weight VBD o
loss NN o
maintenance NN o
in IN p
overweight NN p
and CC p
obese JJ p
adults NNS p
over IN p
12 CD N
months NNS N
. . N

-DOCSTART- -X- O O

Low-intensity NNP i
exercise NN i
and CC N
reduction NN N
of IN N
the DT o
risk NN o
for IN o
falls NNS o
among IN p
at-risk JJ p
elders NNS p
. . p

BACKGROUND NNP N
Among IN N
elderly JJ p
persons NNS p
, , N
falls VBZ o
account NN N
for IN N
87 CD N
% NN N
of IN N
all DT N
fractures NNS N
and CC N
are VBP N
contributing VBG N
factors NNS N
in IN N
many JJ N
nursing NN N
home NN N
admissions NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ i
exercise NN i
program NN i
on IN N
the DT N
incidence NN o
of IN o
falls NNS o
and CC p
the DT p
time NN o
to TO o
first VB o
fall NN o
among IN p
a DT p
clinically RB p
defined JJ p
population NN p
of IN p
elderly JJ p
men NNS p
and CC p
women NNS p
. . p

METHODS VB N
This DT N
community-based JJ N
, , N
randomized JJ N
trial NN N
compared VBN N
the DT N
exercise NN i
intervention NN i
with IN N
a DT N
no-intervention JJ i
control NN i
. . i

The DT p
participants NNS p
were VBD p
294 CD p
men NNS p
and CC p
women NNS p
, , p
aged VBD p
60 CD p
years NNS p
or CC p
older JJR p
, , p
who WP p
had VBD p
either CC p
a DT p
hospital JJ p
admission NN p
or CC p
bed NN p
rest NN p
for IN p
2 CD p
days NNS p
or CC p
more JJR p
within IN p
the DT p
previous JJ p
month NN p
. . p

Exercise NN i
participants NNS N
were VBD N
scheduled VBN N
to TO N
attend VB N
exercise NN i
sessions NNS i
lasting VBG N
45 CD N
minutes NNS N
, , N
including VBG N
warm-up JJ N
and CC N
cool-down JJ N
, , N
3 CD N
times NNS N
a DT N
week NN N
for IN N
8 CD N
weeks NNS N
( ( N
24 CD N
sessions NNS N
) ) N
. . N

Assessments NNS N
included VBD N
gait NN o
and CC o
balance NN o
measures NNS o
, , o
self-reported JJ o
physical JJ o
function NN o
, , N
the DT N
number NN o
of IN o
medications NNS o
being VBG o
taking VBG o
at IN o
baseline NN o
, , N
participant JJ N
age NN N
, , N
sex NN N
, , N
and CC N
history NN o
of IN o
falling VBG o
. . o

Falls NNS o
were VBD N
tracked VBN N
for IN N
1 CD N
year NN N
after IN N
each DT N
participant NN N
's POS N
baseline JJ N
assessment NN N
. . N

RESULTS VB N
29 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
reported VBD N
a DT N
fall NN o
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
effect NN N
of IN N
exercise NN i
in IN N
preventing VBG o
falls NNS o
varied VBN N
significantly RB N
by IN N
baseline JJ N
physical JJ N
function NN N
level NN N
( ( N
p JJ N
< NN N
or CC N
=.002 NN N
) ) N
. . N

The DT N
risk NN o
for IN o
falls NNS o
decreased VBN N
for IN N
exercise NN N
participants NNS N
with IN N
low JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
.51 NN N
) ) N
but CC N
increased VBD N
for IN N
exercise NN N
participants NNS N
with IN N
high JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
3.51 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ i
exercise NN i
program NN i
appears VBZ N
to TO N
reduce VB N
the DT N
risk NN o
for IN o
falls NNS o
among IN p
elderly JJ p
men NNS p
and CC p
women NNS p
recovering VBG p
from IN p
recent JJ p
hospitalizations NNS p
, , p
bed VBD p
rest NN p
, , p
or CC p
both DT p
who WP p
have VBP p
low JJ p
levels NNS p
of IN p
physical JJ p
functioning NN p
. . p

-DOCSTART- -X- O O

[ NN i
Mitoxantrone NNP i
( ( i
MTX NNP i
) ) i
versus NN i
mitomycin NN i
C NNP i
( ( i
MMC NNP i
) ) i
in IN N
the DT N
ablative JJ N
treatment NN N
of IN p
Ta NNP p
, , p
T1 NNP p
superficial JJ p
bladder NN p
tumors NNS p
. . p

Phase NNP N
III NNP N
, , N
randomized VBD N
prospective JJ N
study NN N
] NNP N
. . N

A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
ablation NN o
capacity NN o
of IN N
mitoxantrone NN i
in IN N
Ta-T1 NNP N
superficial JJ N
bladder NN N
tumors NNS N
versus VBP N
mitomycin JJ i
C NNP i
, , N
a DT N
drug NN N
whose WP$ N
intravesical JJ N
ablation NN N
properties NNS N
are VBP N
well-known JJ N
. . N

Fifty-seven JJ p
patients NNS p
comprised VBD N
the DT N
study NN N
. . N

The DT N
tumor NN N
was VBD N
not RB N
completely RB N
resected VBN N
when WRB N
the DT N
patient NN N
underwent JJ N
TUR NNP N
. . N

This DT N
residual JJ N
tumor NN N
was VBD N
used VBN N
as IN N
control NN N
. . N

The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
either DT N
20 CD N
mg NN N
Mitoxantrone NNP i
or CC N
40 CD N
mg NNS N
mitomycin JJ i
C NNP i
weekly NN N
for IN N
8 CD N
weeks NNS N
and CC N
two CD N
other JJ N
instillations NNS N
every DT N
15 CD N
days NNS N
in IN N
50 CD N
ml NNS N
saline JJ N
solution NN N
. . N

Response NNP o
to TO o
therapy NN o
was VBD N
evaluated VBN N
between IN N
the DT N
4th CD N
and CC N
8th CD N
week NN N
and CC N
classified VBD N
as IN N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
, , N
defined VBD N
as IN N
no DT N
gross JJ o
and CC o
microscopic JJ o
evidence NN o
of IN o
residual JJ o
tumor NN o
, , N
or CC N
no DT o
response NN o
( ( o
NR NNP o
) ) o
or CC o
therapeutic JJ o
failure NN o
. . o

CR NNP N
was VBD N
observed VBN N
in IN N
77.7 CD N
% NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
mitomycin JJ i
C NNP i
and CC N
in IN N
50 CD N
% NN N
in IN N
those DT N
that WDT N
had VBD N
been VBN N
treated VBN N
with IN N
Mitoxantrone NNP i
. . i

Treatment NNP N
was VBD N
discontinued VBN N
because IN N
of IN N
side NN o
effects NNS o
in IN N
15 CD N
% NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
mitomycin JJ i
C NNP i
and CC N
in IN N
63.4 CD N
% NN N
of IN N
those DT N
who WP N
received VBD N
Mitoxantrone NNP i
. . i

We PRP N
can MD N
conclude VB N
from IN N
the DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
that IN N
Mitoxantrone NNP i
is VBZ N
a DT N
useful JJ N
agent NN N
for IN N
ablation NN N
therapy NN N
of IN N
superficial JJ p
bladder NN p
tumors NNS p
, , N
although IN N
the DT N
high JJ N
incidence NN N
of IN N
severe JJ N
side NN o
effects NNS o
warrants NNS N
its PRP$ N
limited JJ N
use NN N
and CC N
at IN N
high JJ N
dilutions NNS N
. . N

-DOCSTART- -X- O O

Insular JJ N
and CC N
anterior JJ N
cingulate NN N
circuits NNS N
in IN N
smokers NNS p
with IN p
schizophrenia NN p
. . p

Schizophrenia NNP p
( ( p
SZ NNP p
) ) p
is VBZ N
associated VBN N
with IN N
high JJ N
rates NNS N
of IN N
smoking NN N
. . N

We PRP N
previously RB N
found VBD N
that IN N
resting VBG N
state NN N
functional JJ N
connectivity NN N
( ( N
rsFC NN N
) ) N
between IN N
the DT N
dorsal NN N
anterior JJ N
cingulate NN N
( ( N
dACC NN N
) ) N
and CC N
striatum NN N
is VBZ N
independently RB N
associated VBN N
with IN N
nicotine JJ N
addiction NN N
and CC N
psychiatric JJ N
illness NN N
. . N

Since IN N
the DT N
insula NN N
is VBZ N
implicated VBN N
in IN N
nicotine JJ N
dependence NN N
, , N
we PRP N
hypothesized VBD N
that IN N
SZ NNP N
smokers NNS N
will MD N
have VB N
greater JJR N
dysfunction NN N
in IN N
smoking-related JJ N
insular NN N
and CC N
dACC NN N
circuits NNS N
than IN N
normal JJ p
control NN p
smokers NNS p
( ( p
NC NNP p
) ) p
independent JJ N
of IN N
smoking VBG N
severity NN N
, , N
consistent NN N
with IN N
an DT N
inherent JJ N
disease-related JJ N
weakening NN N
of IN N
smoking-related JJ N
circuits NNS N
. . N

Nicotine NNP N
challenge NN N
was VBD N
used VBN N
to TO N
demonstrate VB N
that DT N
decreased VBD N
rsFC NN N
in IN N
identified JJ N
circuits NNS N
reflects VBZ N
addiction JJ N
trait NN N
and CC N
is VBZ N
not RB N
affected VBN N
by IN N
pharmacological JJ N
state NN N
. . N

Twenty-four CD p
NC NNP p
smokers NNS p
and CC p
20 CD p
smokers NNS p
with IN p
SZ NNP p
matched VBD p
on IN p
nicotine JJ p
addiction NN p
severity NN p
participated VBN N
in IN N
a DT N
resting NN i
state NN i
fMRI NN i
study NN i
and CC i
were VBD i
scanned VBN i
during IN i
two CD i
separate JJ i
sessions NNS i
while IN i
receiving VBG i
a DT i
placebo NN i
or CC i
nicotine JJ i
patch NN i
, , i
in IN i
a DT i
randomized JJ i
, , i
cross-over JJ i
design NN i
. . i

Using VBG N
individualized JJ N
, , N
anatomically RB N
defined VBN N
anterior JJ N
and CC N
posterior JJ N
insula NN N
and CC N
dACC NN N
as IN N
regions NNS N
of IN N
interest NN N
( ( N
ROI NNP N
) ) N
, , N
whole JJ N
brain NN N
rsFC NN N
was VBD N
performed VBN N
using VBG N
each DT N
ROI NNP N
as IN N
a DT N
seed NN N
. . N

Significant NNP N
negative JJ N
correlations NNS N
between IN N
smoking VBG o
severity NN o
and CC o
rsFC NN o
between IN o
insula NN o
, , N
dACC NN N
and CC N
striatum NN N
were VBD N
found VBN N
for IN N
both DT N
groups NNS N
. . N

Furthermore RB N
, , N
smokers NNS p
with IN p
SZ NNP p
demonstrated VBD N
additive JJ N
reductions NNS N
in IN N
circuit NN N
strength NN N
between IN N
the DT N
dACC NN N
and CC N
insula NN N
compared VBN N
to TO N
NC NNP p
smokers NNS p
independent JJ N
of IN N
smoking VBG N
severity NN N
. . N

Nicotine NNP o
challenge NN o
did VBD N
not RB N
significantly RB N
alter VB o
rsFC NN o
in IN o
insula-dACC-striatal JJ o
circuits NNS o
. . o

Reduced VBN N
rsFC JJ o
strength NN o
between IN N
the DT N
insula NN N
, , N
dACC NN N
and CC N
striatum NN N
is VBZ N
associated VBN N
with IN N
nicotine JJ N
addiction NN N
severity NN N
in IN N
both DT N
non-psychiatrically RB N
ill NN N
and CC N
in IN N
SZ NNP N
smokers NNS N
. . N

Decreased VBN N
insula-dACC JJ N
rsFC NN N
may MD N
index NN N
overlapping VBG N
circuitry NN N
associated VBN N
with IN N
smoking NN N
and CC N
SZ NNP N
. . N

-DOCSTART- -X- O O

Relationship NN N
between IN N
endogenous JJ i
estrogen NN i
concentrations NNS i
and CC N
serum NN i
cholesteryl NN i
ester NN i
transfer NN N
protein NN N
concentrations NNS N
in IN p
Chinese JJ p
women NNS p
. . p

BACKGROUND NNP N
CETP NNP N
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
HDL NNP N
metabolism NN N
and CC N
in IN N
the DT N
reverse NN N
cholesterol NN N
transport NN N
pathway NN N
. . N

METHODS NNP N
The DT N
relationship NN N
between IN N
the DT N
changes NNS N
of IN N
endogenous JJ N
estrogen NN N
and CC N
the DT N
concentration NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein NN N
( ( N
CETP NNP N
) ) N
in IN N
the DT N
serum NN N
of IN N
Chinese JJ p
women NNS p
was VBD N
investigated VBN N
. . N

Serum NNP o
concentrations NNS o
of IN o
estradiol NN o
( ( o
E NNP o
( ( o
2 CD o
) ) o
) ) o
, , o
follicle-stimulating JJ o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
CETP NNP o
and CC o
lipid JJ o
profile NN o
were VBD i
determined VBN i
in IN i
196 CD i
Chinese JJ i
women NNS i
( ( i
52 CD i
premenopausal NN i
with IN i
ages NNS i
ranging VBG i
from IN i
18 CD i
to TO i
40 CD i
years NNS i
, , i
57 CD i
perimenopausal NN i
from IN i
41 CD i
to TO i
60 CD i
years NNS i
, , i
and CC i
87 CD i
postmenopausal NN i
from IN i
61 CD i
to TO i
81 CD i
years NNS i
) ) i
. . i

RESULTS NNP N
Serum NNP o
CETP NNP o
concentration NN o
was VBD N
significantly RB N
lower JJR N
in IN N
postmenopausal JJ N
women NNS N
compared VBN N
with IN N
those DT N
in IN N
perimenopausal NN N
and CC N
premenopausal JJ N
women NNS N
( ( N
1.39+/-1.06 JJ N
, , N
2.36+/-1.50 JJ N
and CC N
2.31+/-1.25 JJ N
mg/l NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Even RB N
in IN N
the DT N
women NNS p
around IN p
the DT p
menopausal NN p
, , N
CETP NNP o
concentration NN o
in IN N
postmenopause NN N
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
premenopause NN N
( ( N
1.93+/-1.33 JJ N
vs. IN N
3.42+/-1.35 JJ N
mg/l NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
CETP NNP N
concentration NN N
had VBD N
a DT N
highly RB N
positive JJ N
correlation NN N
with IN N
serum JJ o
concentration NN o
of IN N
E NNP N
( ( N
2 CD N
) ) N
( ( N
r=0.243 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
negative JJ N
correlation NN N
of IN N
CETP NNP o
concentration NN o
with IN N
serum JJ o
concentration NN o
of IN o
FSH NNP o
was VBD N
found VBN N
( ( N
r=-0.273 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Estrogen NNP N
may MD N
affect VB N
the DT N
concentration NN o
of IN o
CETP NNP o
. . o

-DOCSTART- -X- O O

Line-item JJ N
analysis NN N
of IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
: : N
results NNS N
from IN N
two CD p
studies NNS p
of IN p
aripiprazole NN i
in IN p
the DT p
treatment NN p
of IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
discrete JJ N
symptoms NNS N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ N
disorder NN N
, , N
as RB N
well RB N
as IN N
other JJ N
symptoms NNS N
captured VBN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
two CD p
8-week JJ p
, , p
randomized VBN p
, , p
double-blind JJ p
, , p
multicenter JJ p
trials NNS p
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN i
dosed VBN i
flexibly RB i
( ( N
2-15 JJ N
mg/day NN N
, , N
n=47 NN N
) ) N
or CC N
fixed VBN N
( ( N
5 CD N
, , N
10 CD N
, , N
or CC N
15 CD N
mg/day NN N
, , N
n JJ N
= NNP N
166 CD N
) ) N
versus NN N
placebo NN i
( ( N
flexibly RB N
dosed VBN N
, , N
n JJ N
= VBP N
51 CD N
; : N
fixed VBN N
dose NN N
, , N
n JJ N
= NNP N
52 CD N
) ) N
. . N

The DT N
effects NNS N
of IN N
treatment NN N
on IN N
the DT N
58 CD N
ABC NNP N
items NNS N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Statistically NNP N
significantly RB N
greater JJR N
improvement NN N
was VBD N
seen VBN N
with IN N
aripiprazole JJ i
versus NN i
placebo NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
on IN N
the DT N
ABC-Irritability NNP o
total JJ o
subscale NN o
score NN o
and CC o
on IN o
the DT o
following JJ o
individual JJ o
ABC-Irritability NNP o
items NNS o
: : o
Mood NNP o
changes NNS o
quickly RB o
, , o
cries/screams NNS o
inappropriately RB o
, , o
and CC o
stamps JJ o
feet/bangs NNS o
objects NNS o
. . o

Several JJ N
additional JJ N
items NNS N
measuring VBG N
tantrum-like JJ o
behaviors NNS o
improved VBN N
in IN N
the DT N
flexibly RB N
dosed VBN N
trial NN N
and CC N
at IN N
least JJS N
one CD N
arm NN N
of IN N
the DT N
fixed-dose JJ N
trial NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Measures NNS o
of IN o
self-injurious JJ o
behavior NN o
, , N
which WDT N
had VBD N
low JJ N
baseline NN N
values NNS N
, , N
demonstrated VBD N
numerical JJ N
, , N
but CC N
not RB N
statistically RB N
significant JJ N
, , N
improvement NN N
in IN N
both DT N
trials NNS N
. . N

Statistically RB N
significantly RB N
greater JJR N
improvement NN N
in IN N
ABC NNP o
Stereotypic NNP o
Behavior NNP o
and CC o
Hyperactivity NNP o
total JJ o
subscale NN o
scores NNS o
was VBD N
also RB N
consistent JJ N
across IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
. . N

In IN N
particular JJ N
, , N
there EX N
was VBD N
a DT N
cluster NN N
of IN N
items NNS N
related VBN N
to TO N
hyperkinesis VB o
that WDT N
were VBD N
consistently RB N
sensitive JJ N
to TO N
treatment NN N
. . N

CONCLUSIONS NNP N
Aripiprazole NNP i
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
, , N
particularly RB N
with IN N
respect NN N
to TO N
symptoms NNS N
associated VBN N
with IN N
tantrum JJ N
behavior NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized JJ N
comparison NN N
of IN N
tamoxifen NN i
with IN N
surgical JJ i
oophorectomy NN i
in IN N
premenopausal NN p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

We PRP N
randomized VBD N
122 CD p
premenopausal JJ p
women NNS p
to TO N
receive VB N
tamoxifen NN i
or CC N
to TO N
undergo VB i
a DT i
surgical JJ i
oophorectomy NN i
. . i

Of IN N
54 CD p
evaluable JJ p
women NNS p
treated VBN p
with IN p
tamoxifen NN i
, , p
24 CD p
% NN p
had VBD p
an DT p
objective JJ o
response NN o
, , p
as IN p
compared VBN p
with IN p
21 CD p
% NN p
of IN p
53 CD p
women NNS p
having VBG p
an DT p
oophorectomy NN i
. . i

The DT N
median JJ o
duration NN o
of IN o
response NN o
for IN N
tamoxifen NN i
( ( N
20 CD N
months NNS N
) ) N
was VBD N
longer JJR N
than IN N
that DT N
for IN N
surgical JJ i
oophorectomy NN i
( ( N
7 CD N
months NNS N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
achieve VB N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
.056 NNP N
) ) N
. . N

Overall JJ o
median JJ o
survival NN o
was VBD N
15 CD N
months NNS N
for IN N
58 CD p
patients NNS p
receiving VBG N
tamoxifen NN N
and CC N
25 CD N
months NNS N
for IN N
53 CD N
patients NNS N
undergoing JJ N
oophorectomy JJ N
( ( N
P NNP N
= NNP N
.18 NNP N
) ) N
. . N

Toxicity NN o
was VBD N
greater JJR N
in IN N
those DT N
undergoing JJ N
oophorectomy NN N
, , N
though IN N
both DT o
treatments NNS o
were VBD o
well RB o
tolerated VBN o
. . o

In IN N
those DT N
premenopausal JJ p
women NNS p
for IN N
whom WP N
hormonal JJ N
therapy NN N
is VBZ N
indicated VBN N
, , N
tamoxifen EX i
is VBZ N
a DT N
suitable JJ N
alternative NN N
to TO N
surgical JJ i
oophorectomy NN i
. . i

-DOCSTART- -X- O O

Efficacy NN o
and CC o
safety NN o
of IN N
mizolastine JJ i
10 CD N
mg NN N
in IN N
a DT N
placebo-controlled JJ i
comparison NN N
with IN N
loratadine NN i
in IN N
chronic JJ p
idiopathic JJ p
urticaria NNS p
: : p
results NNS N
of IN N
the DT N
MILOR NNP N
Study NNP N
. . N

BACKGROUND NNP N
Mizolastine NNP i
is VBZ N
a DT N
novel JJ N
histamine NN N
H1-antagonist NN N
registered VBD N
in IN N
Europe NNP N
for IN N
the DT N
management NN N
of IN N
allergic JJ N
rhinitis NN N
and CC N
urticaria NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
clinical JJ N
efficacy NN o
and CC o
safety NN o
of IN N
mizolastine NN i
with IN i
loratadine NN i
and CC i
placebo NN i
in IN N
patients NNS p
with IN p
chronic JJ p
idiopathic JJ p
urticaria NN p
( ( p
CIU NNP p
) ) p
. . p

METHODS CC N
A DT N
multicentre NN N
, , N
double-blind NN N
, , N
parallel JJ N
group NN N
study NN N
was VBD N
designed VBN N
in IN N
which WDT N
247 CD p
patients NNS p
with IN p
CIU NNP p
were VBD N
randomised VBN N
after IN N
a DT N
1-week JJ N
placebo NN i
run-in JJ N
period NN N
to TO N
10 CD N
mg NNS N
daily JJ N
mizolastine NN i
( ( N
n JJ N
= NNP N
88 CD N
) ) N
, , N
10 CD N
mg JJ N
daily JJ N
loratadine NN i
( ( N
n JJ N
= NNP N
79 CD N
) ) N
, , N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
80 CD N
) ) N
for IN N
a DT N
4-week JJ N
treatment NN N
period NN N
. . N

RESULTS NNP N
Mizolastine NNP i
and CC N
loratadine VB i
both DT N
relieved JJ o
symptoms NNS o
of IN o
CIU NNP o
. . o

After IN N
2 CD N
weeks NNS N
' POS N
treatment NN N
, , N
the DT N
severity NN o
of IN o
pruritus NN o
( ( o
visual JJ o
analogue NN o
score NN o
( ( o
VAS NNP o
) ) o
assessed VBN o
by IN o
patients NNS o
) ) o
decreased VBD N
significantly RB N
in IN N
both CC N
the DT N
mizolastine NN i
and CC i
loratadine NN i
groups NNS N
compared VBN N
with IN N
placebo NN i
( ( i
mizolastine NN i
: : i
-36.7 NN N
mm NN N
, , N
P NNP N
= NNP N
0.0001 CD N
; : N
loratadine NN i
: : i
-29.8 NN N
, , N
P NNP N
= NNP N
0.0071 CD N
; : N
placebo NN i
: : i
-16.3 NN N
) ) N
; : N
this DT N
improvement NN N
with IN N
both DT N
active JJ N
treatments NNS N
was VBD N
maintained VBN N
throughout IN N
the DT N
treatment NN N
period NN N
, , N
the DT N
difference NN N
being VBG N
significant JJ N
only RB N
for IN N
the DT N
mizolastine NN N
group NN N
( ( N
P NNP N
= NNP N
0.0090 CD N
) ) N
. . N

Both DT N
active JJ N
treatments NNS N
were VBD N
also RB N
associated VBN N
with IN N
reduced JJ N
weekly JJ N
episodes NNS o
of IN o
urticaria NNS o
compared VBN N
with IN N
placebo NN i
, , N
which WDT N
was VBD N
significant JJ N
after IN N
2 CD N
weeks NNS N
' POS N
treatment NN N
( ( i
mizolastine NN i
: : i
7.9 CD N
episodes NNS N
, , N
P NNP N
= NNP N
0.0061 CD N
; : N
loratadine NN i
: : i
8.3 CD N
, , N
P NNP N
= NNP N
0.0221 CD N
; : N
placebo NN i
: : i
13.3 CD N
) ) N
. . N

Angioedema NNP o
was VBD N
improved VBN N
to TO N
a DT N
clinically RB N
significant JJ N
extent NN N
with IN N
mizolastine NN i
, , N
and CC N
loratadine NN i
compared VBN N
with IN N
placebo NN i
in IN N
those DT N
patients NNS p
who WP p
had VBD p
this DT p
symptom NN p
before IN p
treatment NN p
. . p

Overall JJ o
tolerability NN o
of IN N
both DT N
treatments NNS N
was VBD N
similar JJ N
to TO N
placebo VB i
, , N
and CC N
there EX N
were VBD N
no DT N
clinically RB N
relevant JJ N
effects NNS o
on IN o
cardiac JJ o
repolarisation NN o
with IN N
either DT N
mizolastine NN i
or CC i
loratadine NN i
. . i

CONCLUSION NNP N
Mizolastine NNP i
( ( N
10 CD N
mg NNS N
daily RB N
) ) N
is VBZ N
confirmed VBN N
as IN N
an DT N
effective JJ o
and CC o
well RB o
tolerated JJ o
agent NN N
, , N
comparable JJ N
to TO N
loratadine VB N
and CC N
superior VB N
to TO N
placebo VB i
, , N
for IN N
the DT N
management NN N
of IN N
CIU NNP N
. . N

Mizolastine NNP i
acted VBD N
as RB N
rapidly RB N
as IN N
loratadine NN i
in IN N
improving VBG N
urticarial JJ o
symptoms NNS o
from IN N
the DT N
first JJ N
day NN N
of IN N
treatment NN N
. . N

-DOCSTART- -X- O O

Anti-angiogenic JJ N
effect NN N
of IN N
tamoxifen NN i
combined VBN i
with IN i
epirubicin NN i
in IN N
breast NN p
cancer NN p
patients NNS p
. . p

Vascular JJ N
endothelial JJ N
growth NN N
factor NN N
A NNP N
( ( N
VEGF-A NNP N
) ) N
and CC N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
( ( N
VEGFR2 NNP N
) ) N
are VBP N
the DT N
key JJ N
factors NNS N
mediating VBG N
neo-vascularization NN N
. . N

They PRP N
are VBP N
often RB N
coexpressed VBN N
in IN N
breast NN N
cancer NN N
. . N

Sex NNP N
steroids NNS N
may MD N
stimulate VB N
angiogenesis NN N
via IN N
the DT N
estrogen NN N
receptor NN N
( ( N
ER NNP N
) ) N
pathway RB N
. . N

We PRP N
investigated VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
addition NN N
of IN N
tamoxifen NN i
to TO i
epirubicin VB i
versus NN i
epirubicin FW i
alone RB i
on IN N
VEGF NNP N
and CC N
VEGFR2 NNP N
expression NN N
in IN N
breast NN N
cancer NN N
patients NNS N
. . N

The DT N
expression NN N
of IN N
VEGF NNP o
and CC o
VEGFR2 NNP o
was VBD N
assessed VBN N
on IN N
tissue NN N
microarray NN N
by IN N
immunohistochemistry NN N
at IN N
baseline JJ N
conditions NNS N
and CC N
after IN N
treatments NNS N
in IN N
the DT N
case NN N
of IN N
191 CD p
patients NNS p
with IN p
T2-4 NNP p
N0-1 NNP p
breast NN p
cancer NN p
enrolled VBN p
in IN p
a DT p
randomized JJ p
trial NN p
comparing VBG N
four CD N
cycles NNS N
of IN N
single JJ N
agent NN N
epirubicin NN N
versus NN N
epirubicin NN N
plus CC N
tamoxifen NN N
as IN N
primary JJ N
systemic JJ N
treatment NN N
. . N

Epirubicin NNP N
alone RB N
failed VBD N
to TO N
induce VB N
changes NNS o
in IN o
VEGF NNP o
expression NN o
( ( N
P NNP N
= NNP N
0.54 CD N
) ) N
, , N
while IN N
the DT N
addition NN N
of IN N
tamoxifen NN i
to TO i
epirubicin VB i
resulted VBN N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
VEGF NNP o
expression NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

As IN N
a DT N
consequence NN N
, , N
baseline NN o
VEGF NNP o
had VBD N
a DT N
negative JJ N
prognostic JJ N
role NN N
in IN N
patients NNS N
who WP N
received VBD N
epirubicin JJ N
alone RB N
but CC N
not RB N
in IN N
patients NNS N
receiving VBG N
epirubicin JJ i
plus CC i
tamoxifen JJ i
( ( N
interaction JJ N
test NN N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

VEGFR2 NNP o
expression NN o
increased VBD N
at IN N
residual JJ N
tumor NN N
histology NN N
in IN N
both DT N
treatment NN N
arms NNS N
, , N
with IN N
a DT N
lesser JJR N
extent NN N
in IN N
patients NNS N
receiving VBG N
tamoxifen JJ i
plus CC i
epirubicin JJ i
. . i

Decrease NNP N
in IN N
VEGFR2 NNP o
expression NN o
was VBD N
significantly RB N
associated VBN N
with IN N
response NN o
rate NN o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
addition NN i
of IN i
tamoxifen NN i
to TO i
epirubicin VB i
resulted VBN N
in IN N
a DT N
suppression NN o
of IN o
a DT o
key JJ o
angiogenic JJ o
pathway NN o
. . o

These DT N
data NNS N
suggest VBP N
a DT N
potential JJ N
synergism NN N
of IN N
these DT N
two CD N
drugs NNS N
. . N

-DOCSTART- -X- O O

Antibiotic JJ N
therapy NN N
of IN N
acute JJ N
exacerbations NNS N
of IN N
chronic JJ N
bronchitis NN N
. . N

A DT N
controlled VBN N
study NN N
using VBG N
tetracycline NN i
. . i

We PRP N
conducted VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
in IN N
40 CD p
patients NNS p
to TO p
evaluate VB p
the DT p
need NN p
for IN p
antibiotics NNS p
in IN p
acute JJ p
exacerbations NNS p
of IN p
chronic JJ p
bronchitis NN p
. . p

All DT p
patients NNS p
were VBD p
sufficiently RB p
ill VBN p
to TO p
require VB p
hospitalization NN p
although IN p
none NN p
needed VBD p
ventilatory JJ p
support NN p
; : p
the DT p
presence NN p
of IN p
pneumonia NN p
was VBD p
excluded VBN p
. . p

Treatment NNP N
consisted VBD N
of IN N
bronchodilators NNS i
, , i
corticosteroids NNS i
, , N
and CC N
either DT N
tetracycline NN i
, , N
500 CD N
mg NN N
, , N
or CC i
placebo NN i
by IN N
mouth NN N
every DT N
6 CD N
hours NNS N
for IN N
1 CD N
week NN N
. . N

Arterial JJ o
blood NN o
gases NNS o
, , o
spirometric JJ o
tests NNS o
, , o
bacteriologic JJ o
evaluation NN o
of IN o
sputum NN o
, , o
and CC o
patient NN o
and CC o
physician JJ o
evaluation NN o
of IN o
the DT o
severity NN o
of IN o
illness NN o
were VBD N
assessed VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
study NN N
. . N

All DT N
patients NNS N
improved VBN N
both DT N
symptomatically RB N
and CC N
by IN N
objective JJ N
measures NNS N
of IN N
lung NN N
function NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
those DT N
patients NNS N
receiving VBG N
tetracycline NN N
and CC N
those DT N
receiving VBG N
placebo NN i
. . i

We PRP N
conclude VBP N
that IN N
antibiotic JJ N
therapy NN N
is VBZ N
not RB N
needed VBN N
in IN N
moderately RB p
ill JJ p
patients NNS p
with IN p
exacerbations NNS p
of IN p
chronic JJ p
bronchitis NN p
. . p

-DOCSTART- -X- O O

An DT N
interactive JJ i
computer NN i
program NN i
can MD N
effectively RB N
educate VB N
potential JJ p
users NNS p
of IN p
cystic JJ p
fibrosis NN p
carrier NN p
tests NNS p
. . p

The DT N
demand NN N
for IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
carrier NN N
testing VBG N
is VBZ N
steadily RB N
growing VBG N
, , N
not RB N
only RB N
from IN N
individuals NNS p
with IN p
raised VBN p
a DT p
priori FW p
carrier NN p
risk NN p
, , N
but CC N
also RB N
from IN N
the DT N
general JJ N
population NN N
. . N

This DT N
trend NN N
will MD N
likely RB N
exceed VB N
the DT N
availability NN N
of IN N
genetic JJ N
counselors NNS N
, , N
making VBG N
it PRP N
impossible JJ N
to TO N
provide VB N
standard JJ N
face-to-face JJ N
genetic JJ N
counseling NN N
to TO N
all PDT N
those DT N
asking VBG N
for IN N
the DT N
test NN N
. . N

In IN N
order NN N
to TO N
reduce VB N
the DT N
time NN N
needed VBN N
to TO N
educate VB N
individuals NNS N
on IN N
the DT N
basics NNS N
of IN N
the DT N
disease NN N
, , N
its PRP$ N
genetic JJ N
transmission NN N
, , N
and CC N
carrier NN N
testing VBG N
peculiarities NNS N
, , N
we PRP N
developed VBD N
an DT N
educational JJ i
method NN i
based VBN i
on IN i
an DT i
interactive JJ i
computer NN i
program NN i
( ( i
IC NNP i
) ) i
. . i

To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
this DT N
program NN N
and CC N
to TO N
compare VB N
it PRP N
to TO N
a DT N
classical JJ N
genetic JJ N
counseling NN N
session NN N
, , N
we PRP N
conducted VBD N
a DT N
comparative JJ N
trial NN N
. . N

In IN N
a DT N
population NN N
setting NN N
of IN N
people NNS N
undergoing VBG N
assisted JJ N
reproduction NN N
, , N
44 CD p
individuals NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
receiving VBG N
standard JJ i
one-on-one JJ i
genetic JJ i
counseling NN i
or CC i
education NN i
by IN i
the DT i
IC NNP i
program NN i
. . i

We PRP N
measured VBD N
pre- JJ N
and CC N
post-intervention NN N
knowledge NN N
about IN N
CF NNP N
genetic JJ N
transmission NN N
and CC N
carrier NN N
testing NN N
. . N

Starting VBG o
from IN o
an DT o
equivalent JJ o
baseline NN o
of IN o
correct JJ o
answers NNS o
to TO o
a DT o
specially RB o
designed VBN o
multiple-choice NN o
questionnaire NN o
( ( o
47 CD o
% NN o
in IN o
the DT o
counselor NN o
group NN o
and CC o
45 CD o
% NN o
in IN o
the DT o
computer NN o
group NN o
) ) o
both DT o
groups NNS o
showed VBD o
a DT o
highly RB o
significant JJ o
and CC o
similar JJ o
increase NN o
( ( o
reaching VBG o
84 CD o
% NN o
in IN o
the DT o
counselor NN o
group NN o
and CC o
85 CD o
% NN o
in IN o
the DT o
computer NN o
group NN o
) ) o
. . o

The DT N
computer NN N
program NN N
under IN N
evaluation NN N
can MD N
successfully RB N
educate VB N
individuals NNS N
considering VBG N
genetic JJ N
testing NN N
for IN N
CF NNP N
. . N

-DOCSTART- -X- O O

Dentists NNS N
United NNP N
to TO N
Extinguish VB N
Tobacco NNP N
( ( N
DUET NNP N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
cluster NN N
randomized VBN N
, , N
controlled VBN N
trial NN N
for IN N
enhancing VBG N
implementation NN N
of IN N
clinical JJ i
practice NN i
guidelines NNS i
for IN N
treating VBG N
tobacco NN p
dependence NN p
in IN p
dental JJ p
care NN p
settings NNS p
. . p

BACKGROUND NNP N
Although IN N
dental JJ N
care NN N
settings NNS N
provide VBP N
an DT N
exceptional JJ N
opportunity NN N
to TO N
reach VB N
smokers NNS p
and CC N
provide VB N
brief JJ N
cessation NN N
advice NN N
and CC N
treatment NN N
to TO N
reduce VB N
oral JJ N
and CC N
other JJ N
tobacco-related JJ N
health NN N
conditions NNS N
, , N
dental JJ N
care NN N
providers NNS N
demonstrate VBP N
limited JJ N
adherence NN N
to TO N
evidence-based JJ N
guidelines NNS N
for IN N
treatment NN N
of IN N
tobacco NN p
use NN p
and CC p
dependence NN p
. . p

METHODS/DESIGN NNP N
Guided VBN N
by IN N
a DT N
multi-level NN N
, , N
conceptual JJ N
framework NN N
that WDT N
emphasizes VBZ N
changes NNS N
in IN N
provider NN N
beliefs NNS N
and CC N
organizational JJ N
characteristics NNS N
as IN N
drivers NNS N
of IN N
improvement NN N
in IN N
tobacco NN N
treatment NN N
delivery NN N
, , N
the DT N
current JJ N
protocol NN N
will MD N
use VB N
a DT N
cluster NN N
, , N
randomized VBN N
design NN N
and CC N
multiple JJ N
data NNS N
sources NNS N
( ( N
patient JJ N
exit NN N
interviews NNS N
, , N
provider NN N
surveys NNS N
, , N
site NN N
observations NNS N
, , N
chart JJ N
audits NN N
, , N
and CC N
semi-structured JJ N
provider NN N
interviews NNS N
) ) N
to TO N
study VB N
the DT N
process NN N
of IN N
implementing VBG N
clinical JJ N
practice NN N
guidelines NNS N
for IN N
treating VBG N
tobacco NN N
dependence NN N
in IN N
18 CD p
public JJ p
dental NN p
care NN p
clinics NNS p
in IN p
New NNP p
York NNP p
City NNP p
. . p

The DT N
specific JJ N
aims NNS N
of IN N
this DT N
comparative-effectiveness JJ o
research NN N
trial NN N
are VBP N
to TO N
: : N
compare VB N
the DT N
effectiveness NN N
of IN N
three CD N
promising VBG N
strategies NNS N
for IN N
implementation NN N
of IN N
tobacco NN i
use NN i
treatment NN i
guidelines-staff JJ i
training NN i
and CC i
current JJ i
best JJS i
practices NNS i
( ( i
CBP NNP i
) ) i
, , i
CBP NNP i
+ NNP i
provider NN i
performance NN i
feedback NN i
( ( i
PF NNP i
) ) i
, , i
and CC i
CBP NNP i
+ NNP i
PF NNP i
+ NNP i
provider NN i
reimbursement NN i
for IN i
delivery NN i
of IN i
tobacco NN i
cessation NN i
treatment NN i
( ( i
pay-for-performance NN i
, , i
or CC i
P4P NNP i
) ) i
; : i
examine JJ i
potential JJ N
theory-driven JJ N
mechanisms NNS N
hypothesized VBN N
to TO N
explain VB N
the DT N
comparative JJ N
effectiveness NN N
of IN N
three CD N
strategies NNS N
for IN N
implementation NN N
; : N
and CC N
identify VB N
baseline JJ N
organizational JJ N
factors NNS N
that WDT N
influence VBP N
the DT N
implementation NN N
of IN N
evidence-based JJ N
tobacco NN N
use NN N
treatment NN N
practices NNS N
in IN N
dental JJ N
clinics NNS N
. . N

The DT N
primary JJ N
outcome NN o
is VBZ o
change VBN o
in IN o
providers NNS o
' POS o
tobacco NN o
treatment NN o
practices NNS o
and CC o
the DT N
secondary JJ N
outcomes NNS N
are VBP N
cost VBN o
per IN o
quit NN o
, , o
use NN o
of IN o
tobacco NN o
cessation NN o
treatments NNS o
, , o
quit NN o
attempts NNS o
, , o
and CC o
smoking VBG o
abstinence NN o
. . o

DISCUSSION NNP N
We PRP N
hypothesize VBP N
that IN N
the DT N
value NN N
of IN N
these DT N
promising JJ N
implementation NN N
strategies NNS N
is VBZ N
additive JJ N
and CC N
that IN N
incorporating VBG N
all DT N
three CD N
strategies NNS N
( ( N
CBP NNP N
, , N
PF NNP N
, , N
and CC N
P4P NNP N
) ) N
will MD N
be VB N
superior JJ N
to TO N
CBP VB i
alone RB i
and CC i
CBP NNP i
+ NNP i
PF NNP i
in IN i
improving VBG N
delivery NN N
of IN N
cessation NN N
assistance NN N
to TO N
smokers NNS N
. . N

The DT N
findings NNS N
will MD N
improve VB N
knowledge NN N
pertinent NN N
to TO N
the DT N
implementation NN N
, , N
dissemination NN N
, , N
and CC N
sustained VBD N
utilization NN N
of IN N
evidence-based JJ N
tobacco NN N
use NN N
treatment NN N
in IN N
dental JJ N
practices NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT01615237 NNP N
. . N

-DOCSTART- -X- O O

Treatment NN N
of IN N
duodenal JJ p
ulcer NN p
with IN N
low-dose JJ i
antacids NNS i
. . i

The DT N
aim NN N
of IN N
the DT N
present JJ N
investigation NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
a DT N
low-dose JJ i
antacid NN i
( ( i
Maalox NNP i
70 CD i
, , N
280 CD N
mmol/day NN N
) ) N
with IN N
that DT N
of IN N
the DT N
H2-receptor NNP i
antagonist NN i
cimetidine NN i
( ( i
Tagamet NNP i
, , N
200 CD N
mg NN N
three CD N
times NNS N
daily RB N
and CC N
400 CD N
mg/day NN N
) ) N
after IN N
14 CD N
and CC N
28 CD N
days NNS N
in IN N
the DT N
treatment NN N
of IN N
duodenal JJ p
ulcer NN p
. . p

The DT N
prospective JJ N
multicentre NN N
study NN N
included VBD N
171 CD p
patients NNS p
with IN p
endoscopically RB p
confirmed VBN p
duodenal JJ p
ulcers NNS p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
groups NNS N
with IN N
antacid JJ i
containing VBG i
Mg NNP i
and CC i
Al NNP i
hydroxide NN i
( ( i
M NNP i
) ) i
( ( i
4 CD i
X RB N
70 CD N
mmol/day NN N
; : N
n CC N
= VB N
86 CD N
) ) N
or CC N
to TO N
the DT N
group NN N
receiving VBG N
cimetidine NN i
( ( N
T NNP N
) ) N
( ( N
1000 CD N
mg/day NN N
; : N
n CC N
= VB N
85 CD N
) ) N
. . N

The DT N
two CD p
treatment NN p
groups NNS p
were VBD N
matched VBN N
for IN N
age NN N
, , N
sex NN N
, , N
drinking NN N
and CC N
smoking NN N
habits NNS N
, , N
and CC N
drug NN N
use NN N
. . N

Endoscopic JJ N
examinations NNS N
were VBD N
carried VBN N
out RP N
before IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
14 CD N
days NNS N
later RB N
. . N

If IN N
the DT N
ulcer NN N
was VBD N
still RB N
present JJ N
at IN N
this DT N
time NN N
, , N
the DT N
second JJ N
endoscopic NN N
examination NN N
was VBD N
done VBN N
after IN N
a DT N
further JJ N
14 CD N
days NNS N
. . N

Endoscopically RB N
, , N
the DT N
ulcer NN N
had VBD N
healed VBN o
at IN N
14 CD N
days NNS N
in IN N
38.8 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
in IN N
34.9 CD N
% NN N
( ( N
T NNP N
) ) N
and CC N
at IN N
28 CD N
days NNS N
in IN N
80.0 CD N
% NN N
( ( N
M NNP N
) ) N
and CC N
74.7 CD N
% NN N
( ( N
T NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
healing VBG o
rate NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Complaints NNS o
, , N
measured VBN N
as IN N
percentage NN N
of IN N
days NNS N
per IN N
week NN N
with IN N
upper JJ o
abdominal JJ o
pain NN o
, , N
were VBD N
significantly RB N
reduced VBN N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
pain VB o
relief NN o
or CC o
side NN o
effects NNS o
. . o

Treatment NN N
had VBD N
to TO N
be VB N
abandoned VBN N
in IN N
one CD N
patient NN N
receiving VBG N
antacid NN N
because IN N
of IN N
diarrhoea NN N
and CC N
in IN N
one CD N
patient NN N
receiving VBG N
cimetidine NN N
because IN N
of IN N
the DT N
absence NN N
of IN N
any DT N
response NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Effect NN N
of IN N
ischemic JJ o
postconditioning NN o
in IN N
correction NN N
of IN N
tetralogy NN N
of IN N
Fallot NNP N
. . N

Inappropriate NNP N
myocardial JJ N
protection NN N
is VBZ N
considered VBN N
one CD N
of IN N
the DT N
main JJ N
causes NNS N
of IN N
mortality NN N
and CC N
morbidity NN N
in IN N
the DT N
correction NN N
of IN N
tetralogy NN p
of IN p
Fallot NNP p
( ( p
TOF NNP p
) ) p
. . p

Results NNS N
of IN N
previous JJ N
reports NNS N
about IN N
the DT N
effects NNS N
of IN N
ischemic JJ N
postconditioning NN N
on IN N
myocardial JJ o
protection NN o
in IN N
animals NNS N
and CC N
humans NNS N
are VBP N
very RB N
encouraging JJ N
. . N

This DT N
randomized JJ N
and CC N
controlled JJ N
trial NN N
aimed VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
ischemic JJ o
postconditioning VBG o
on IN N
protection NN o
against IN o
myocardial JJ o
ischemia NN o
reperfusion NN N
injury NN N
in IN N
TOF NNP p
patients NNS p
receiving VBG p
cardioplegia NN p
. . p

From IN p
January NNP p
2008 CD p
to TO p
June NNP p
2010 CD p
, , p
80 CD p
consecutive JJ p
children NNS p
undergoing VBG p
correction NN p
of IN p
TOF NNP p
were VBD N
enrolled VBN i
and CC i
randomly RB i
assigned VBN i
to TO i
either VB i
a DT i
postconditioning NN i
group NN i
( ( i
three CD i
cycles NNS i
of IN i
30 CD i
seconds NNS i
of IN i
ischemia NN i
and CC i
30 CD i
seconds NNS i
of IN i
reperfusion NN i
using VBG i
re-clamping JJ i
and CC i
de-clamping JJ i
starting VBG i
30 CD i
seconds NNS i
after IN i
the DT i
initial JJ i
de-clamping NN i
of IN i
the DT i
aorta NN i
, , i
n JJ i
= NNP i
41 CD i
) ) i
or CC i
a DT i
control NN i
group NN i
( ( i
n JJ i
= NNP i
39 CD i
) ) i
. . i

Cardiac NNP o
troponin NN o
I PRP o
( ( i
cTnI NN i
) ) i
was VBD i
assayed VBN i
preoperatively RB i
, , i
and CC i
then RB i
4 CD i
hours NNS i
, , i
8 CD i
hours NNS i
, , i
12 CD i
hours NNS i
, , i
20 CD i
hours NNS i
, , i
and CC i
48 CD i
hours NNS i
after IN i
persistent JJ i
reperfusion NN i
. . i

The DT N
pre- JJ N
, , N
intra- JJ N
and CC N
postoperative JJ N
relevant JJ N
data NNS N
of IN N
all DT N
selected VBN N
patients NNS N
were VBD N
analyzed VBN N
. . N

As IN N
a DT N
result NN N
, , N
ischemic JJ N
postconditioning NN N
reduced VBD N
postoperative JJ o
peak NN o
release NN o
by IN N
45 CD N
% NN N
for IN N
cTnI NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
0.43 CD N
? . N
0.18 CD N
ng/mL JJ N
versus NN N
0.78 CD N
? . N
0.15 CD N
ng/mL NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Ischemic NNP N
postconditioned VBD N
patients NNS N
had VBD N
a DT N
lower JJR o
peak NN o
inotropic NN o
score NN o
during IN o
the DT N
first JJ N
postoperative JJ N
24 CD N
hours NNS N
( ( N
5.6 CD N
? . N
2.2 CD N
?g/kg/minute JJ N
versus NN N
8.6 CD N
? . N
3.6 CD N
?g/kg/minute NN N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) o
, , o
extubation JJ o
time NN o
( ( N
21.5 CD N
? . N
7.3 CD N
hours NNS N
versus IN N
30.2 CD N
? . N
12.4 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0002 CD N
) ) N
and CC o
length NN o
of IN o
ICU NNP o
stay NN o
( ( o
43.4 CD o
? . N
12.6 CD N
hours NNS N
versus IN N
56.3 CD N
? . N
17.8 CD N
hours NNS N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
, , N
while IN N
they PRP N
had VBD N
a DT N
higher JJR o
cardiac JJ o
output NN o
on IN o
the DT N
first JJ N
postoperative JJ N
day NN N
( ( N
1.41 CD N
? . N
0.26 CD N
L/minute NNP N
versus NN N
1.28 CD N
? . N
0.25 CD N
L/minute NNP N
, , N
P NNP N
= NNP N
0.0255 CD N
) ) N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
ischemic JJ N
postconditioning NN N
may MD N
to TO N
some DT N
extent NN N
provide VBP N
myocardial JJ N
protection NN N
in IN p
children NNS p
undergoing VBG p
correction NN p
of IN p
tetralogy NN p
of IN p
Fallot NNP p
. . p

-DOCSTART- -X- O O

The DT N
Randomised JJ N
Intervention NNP N
Treatment NNP N
of IN N
Angina NNP N
( ( N
RITA NNP N
) ) N
Trial NNP N
protocol NN N
: : N
a DT N
long JJ N
term NN N
study NN N
of IN N
coronary JJ i
angioplasty NN i
and CC i
coronary JJ i
artery NN i
bypass NN i
surgery NN i
in IN p
patients NNS p
with IN p
angina NN p
. . p

The DT N
Randomised JJ N
Intervention NNP N
Treatment NNP N
of IN N
Angina NNP N
( ( N
RITA NNP N
) ) N
Trial NNP N
is VBZ N
a DT N
prospective JJ N
, , N
randomised VBD N
study NN N
to TO N
compare VB N
the DT N
short JJ N
term NN N
and CC N
long JJ N
term NN N
effects NNS N
of IN N
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
and CC i
coronary JJ i
artery NN i
bypass NN i
surgery NN i
. . i

During IN N
the DT N
study NN N
a DT N
register NN N
of IN N
patients NNS p
undergoing VBG p
coronary JJ i
arteriography NN i
at IN p
the DT p
fourteen JJ p
participating VBG p
centres NNS p
is VBZ N
being VBG N
maintained VBN N
to TO N
assess VB N
the DT N
overall JJ N
context NN N
of IN N
patient JJ N
recruitment NN N
. . N

Patients NNS p
with IN p
arteriographically RB p
proven JJ p
coronary JJ p
artery NN p
disease NN p
are VBP p
considered VBN p
for IN p
the DT p
trial NN p
if IN N
the DT N
participating VBG N
cardiologist NN N
and CC N
surgeon NN N
agree VBP N
that IN N
equivalent JJ N
revascularisation NN N
could MD N
be VB N
achieved VBN N
by IN N
either DT N
treatment NN N
method NN N
. . N

Patients NNS N
who WP N
satisfy VBP N
the DT N
trial NN N
entry NN N
criteria NNS N
are VBP N
randomised VBN N
to TO N
treatment NN N
by IN N
coronary JJ i
angioplasty NN i
or CC i
coronary JJ i
artery NN i
bypass NN i
surgery NN i
, , N
with IN N
prospective JJ N
stratification NN N
into IN N
groups NNS N
with IN N
one CD N
, , N
two CD N
, , N
or CC N
three CD N
treatment NN N
vessels NNS N
. . N

Randomisation NNP N
implies VBZ N
an DT N
intention NN N
to TO N
treat VB N
the DT N
patient NN N
by IN N
the DT N
assigned JJ N
procedure NN N
and CC N
the DT N
analysis NN N
of IN N
long JJ N
term NN N
results NNS N
will MD N
include VB N
all DT N
randomised JJ N
cases NNS N
. . N

The DT p
trial NN p
will MD p
recruit VB p
at IN p
least JJS p
1000 CD p
patients NNS p
who WP p
will MD p
be VB p
followed VBN p
for IN p
five CD p
years NNS p
. . p

The DT N
major JJ N
trial NN N
end NN N
points NNS N
include VBP N
death NN o
, , o
new JJ o
myocardial JJ o
infarction NN o
, , o
and CC o
new JJ o
coronary JJ o
angioplasty NN o
or CC o
coronary JJ o
artery NN o
bypass NN o
procedures NNS o
. . o

Other JJ N
outcome JJ N
measures NNS N
include VBP N
symptom NN o
and CC o
employment NN o
status NN o
, , o
quality NN o
of IN o
life NN o
, , o
exercise NN o
tolerance NN o
, , o
and CC o
left VBD o
ventricular JJ o
function NN o
. . o

-DOCSTART- -X- O O

Effects NNS N
of IN N
monotherapy NN i
and CC i
combination NN i
therapy NN i
on IN N
blood NN N
pressure NN N
control NN N
and CC N
target NN N
organ JJ N
damage NN N
: : N
a DT N
randomized JJ N
prospective JJ N
intervention NN N
study NN N
in IN N
a DT N
large JJ p
population NN p
of IN p
hypertensive JJ p
patients NNS p
. . p

This DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
evaluated VBD N
the DT N
effect NN N
of IN N
monotherapy NN i
and CC i
different JJ i
combination NN i
therapies NNS i
on IN N
cardiovascular JJ p
target NN p
organ JJ p
damage NN p
and CC p
metabolic JJ p
profile NN p
in IN p
520 CD p
hypertensive JJ p
patients NNS p
. . p

Patients NNS N
were VBD N
allocated VBN N
to TO N
a DT N
single JJ N
agent NN N
: : N
carvedilol NN i
25 CD i
mg NN i
, , i
amlodipine VBP i
10 CD i
mg NN i
, , i
enalapril VBZ i
20 CD i
mg NN i
, , i
or CC i
losartan VBZ i
50 CD i
mg NN i
( ( N
groups NNS N
C NNP N
, , N
A NNP N
, , N
E NNP N
, , N
and CC N
L NNP N
, , N
respectively RB N
) ) N
. . N

After IN N
2 CD N
months NNS N
( ( N
level JJ N
2 CD N
) ) N
, , N
nonresponders NNS N
received VBD N
a DT N
low-dose JJ i
thiazide NN i
diuretic NN i
, , N
and CC N
after IN N
4 CD N
months NNS N
( ( N
level JJ N
3 CD N
) ) N
, , N
amlodipine JJ i
( ( N
groups NNS N
E NNP N
, , N
C NNP N
, , N
and CC N
L NNP N
) ) N
and CC N
carvedilol NN i
( ( N
group NN N
A DT N
) ) N
. . N

Twenty-four-hour JJ o
blood NN o
pressure NN o
was VBD N
significantly RB N
lowered VBN N
in IN N
all DT N
treatment NN N
groups NNS N
. . N

Blood NNP o
pressure NN o
control NN o
was VBD N
more RBR N
pronounced JJ N
in IN N
patients NNS p
receiving VBG N
two CD N
or CC N
three CD N
drugs NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
the DT N
carotid JJ o
intima-media JJ o
thickness NN o
decreased VBN N
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
left VBD o
ventricular JJ o
mass NN o
index NN o
in IN N
groups NNS N
E NNP N
and CC N
L NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
and CC N
P NNP N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
, , N
with IN N
a DT N
concomitant JJ N
reduction NN N
in IN N
cholesterol NN o
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.03 NNP N
) ) N
. . N

Diastolic NNP o
function NN o
improved VBD N
significantly RB N
in IN N
group NN N
L NNP N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

This DT N
study NN N
describes VBZ N
the DT N
need NN N
to TO N
control VB N
blood NN o
pressure NN o
with IN N
two CD N
or CC N
more JJR N
drugs NNS N
in IN N
most JJS N
hypertensive JJ p
patients NNS p
and CC N
illustrates NNS N
good JJ N
clinical JJ N
outcomes NNS N
, , N
independent JJ N
of IN N
blood NN N
pressure NN N
lowering NN N
, , N
using VBG N
combination NN N
therapy NN N
with IN N
losartan JJ i
, , i
low-dose JJ i
thiazide NN i
, , i
and CC i
amlodipine NN i
. . i

-DOCSTART- -X- O O

Pharmacokinetic NNP N
study NN N
of IN N
RU NNP i
486 CD i
and CC N
its PRP$ N
metabolites NNS N
after IN N
oral JJ N
administration NN N
of IN N
single JJ N
doses NNS N
to TO N
pregnant VB p
and CC p
non-pregnant JJ p
women NNS p
. . p

RU NNP i
486 CD i
and CC i
three CD i
of IN i
its PRP$ i
metabolites NNS i
( ( i
RU NNP i
42633-monodemethyl CD i
, , i
RU NNP i
42848-didemethyl CD i
, , i
and CC i
RU NNP i
42698-hydroxymetabolite JJ i
) ) i
were VBD N
determined VBN N
by IN N
HPLC NNP N
in IN N
plasma NN N
from IN N
nine CD p
non-pregnant JJ p
and CC p
36 CD p
pregnant JJ p
women NNS p
. . p

Each DT N
non-pregnant JJ N
subject NN N
took VBD N
an DT N
oral JJ N
dose NN N
of IN N
RU NNP i
486 CD i
( ( N
25 CD N
, , N
100 CD N
, , N
400 CD N
and CC N
600 CD N
mg NNS N
consecutively RB N
) ) N
once RB N
per IN N
menstrual JJ N
cycle NN N
. . N

Six CD N
of IN N
the DT N
nine CD N
women NNS N
also RB N
received VBD N
a DT N
dose NN i
of IN N
200 CD N
mg NN N
. . N

The DT N
36 CD p
pregnant JJ p
women NNS p
were VBD N
randomized VBN N
into IN N
four CD N
groups NNS N
which WDT N
were VBD N
given VBN N
a DT N
single JJ N
dose NN N
of IN N
25 CD N
, , N
100 CD N
, , N
400 CD N
or CC N
600 CD N
mg NNS N
RU NNP N
486 CD N
. . N

Blood NN o
samples NNS o
were VBD N
taken VBN N
up RB N
to TO N
120 CD N
h NN N
after IN N
dosing VBG N
. . N

Peak NNP o
concentrations NNS o
of IN o
RU NNP o
486 CD o
occurred VBD N
on IN N
most JJS N
occasions NNS N
within IN N
2 CD N
h. NN N
Plasma NNP o
concentrations NNS o
at IN N
1 CD N
h NN N
and CC N
at IN N
24 CD N
h NN N
increased VBN N
in IN N
proportion NN N
to TO N
log VB N
dose RB N
. . N

There EX N
was VBD N
a DT N
wide JJ N
variability NN N
( ( N
up IN N
to TO N
ten-fold JJ N
) ) N
in IN N
the DT N
pharmacokinetic JJ N
parameters NNS N
within IN N
each DT N
dose NN N
group NN N
. . N

Plasma NNP o
concentrations NNS o
of IN o
RU NNP o
42633 CD o
were VBD N
similar JJ N
to TO N
those DT N
of IN N
RU NNP N
486 CD N
but CC N
concentrations NNS N
of IN N
RU NNP N
42848 CD N
and CC N
RU NNP N
42698 CD N
were VBD N
much JJ N
lower JJR N
. . N

As IN N
with IN N
RU NNP N
486 CD N
, , N
the DT N
plasma JJ o
concentrations NNS o
of IN o
the DT o
metabolites NNS o
were VBD N
maintained VBN N
at IN N
high JJ N
levels NNS N
for IN N
up IN N
to TO N
48-72 JJ N
h NN N
after IN N
dosing VBG N
. . N

The DT N
findings NNS N
were VBD N
consistent JJ N
with IN N
a DT N
rapid JJ N
metabolism NN N
of IN N
RU NNP o
486 CD o
to TO o
RU NNP o
42633 CD o
; : o
removal NN N
of IN N
the DT N
second JJ N
methyl NN N
group NN N
leading VBG N
to TO N
RU NNP N
42698 CD N
occurred VBD N
much RB N
more RBR N
slowly RB N
and CC N
to TO N
a DT N
much RB N
less RBR N
extent JJ N
than IN N
removal NN N
of IN N
the DT N
first JJ N
. . N

There EX N
appeared VBD N
to TO N
be VB N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
non-pregnant JJ p
and CC p
pregnant JJ p
women NNS p
in IN N
either CC N
the DT N
plasma JJ N
concentrations NNS N
or CC N
pharmacokinetic JJ N
parameters NNS N
of IN N
RU NNP i
486 CD i
and CC N
its PRP$ N
metabolites NNS N
. . N

-DOCSTART- -X- O O

Multicomponent NNP N
interdisciplinary JJ N
group NN N
intervention NN N
for IN N
self-management NN N
of IN N
fibromyalgia NN p
: : p
a DT N
mixed-methods NNS N
randomized VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND VB N
This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN N
of IN N
the DT N
PASSAGE NNP i
Program NNP i
, , N
a DT N
structured JJ N
multicomponent NN i
interdisciplinary JJ i
group NN i
intervention NN i
for IN N
the DT N
self-management NN N
of IN N
FMS NNP p
. . p

METHODS NNP N
A DT N
mixed-methods NNS N
randomized VBN N
controlled VBN N
trial NN N
( ( i
intervention NN i
( ( i
INT NNP i
) ) i
vs. FW i
waitlist NN i
( ( i
WL NNP i
) ) i
) ) i
was VBD N
conducted VBN N
with IN N
patients NNS p
suffering VBG p
from IN p
FMS NNP p
. . p

Data NNP N
were VBD N
collected VBN N
at IN N
baseline NN N
( ( N
T0 NNP N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
T1 NNP N
) ) N
, , N
and CC N
3 CD N
months NNS N
later RB N
( ( N
T2 NNP N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
change NN N
in IN N
pain NN o
intensity NN o
( ( N
0-10 JJ N
) ) N
. . N

Secondary JJ N
outcomes NNS N
were VBD N
fibromyalgia JJ o
severity NN o
, , o
pain NN o
interference NN o
, , o
sleep JJ o
quality NN o
, , o
pain VBP o
coping VBG o
strategies NNS o
, , o
depression NN o
, , o
health-related JJ o
quality NN o
of IN o
life NN o
, , o
patient JJ o
global JJ o
impression NN o
of IN o
change NN o
( ( o
PGIC NNP o
) ) o
, , o
and CC o
perceived VBD o
pain NN o
relief NN o
. . o

Qualitative JJ N
group NN N
interviews NNS N
with IN N
a DT N
subset NN N
of IN N
patients NNS N
were VBD N
also RB N
conducted VBN N
. . N

Complete NNP N
data NN N
from IN N
T0 NNP N
to TO N
T2 NNP N
were VBD N
available JJ N
for IN N
43 CD p
patients NNS p
. . p

RESULTS VB N
The DT N
intervention NN N
had VBD N
a DT N
statistically RB N
significant JJ N
impact NN N
on IN N
the DT N
three CD N
PGIC NNP N
measures NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
PASSAGE NNP N
Program NNP N
, , N
the DT N
percentages NNS N
of IN N
patients NNS N
who WP N
perceived VBD N
overall JJ N
improvement NN N
in IN N
their PRP$ N
pain NN o
levels NNS o
, , o
functioning NN o
and CC o
quality NN o
of IN o
life NN o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
INT NNP N
Group NNP N
( ( N
73 CD N
% NN N
, , N
55 CD N
% NN N
, , N
77 CD N
% NN N
respectively RB N
) ) N
than IN N
in IN N
the DT N
WL NNP N
Group NNP N
( ( N
8 CD N
% NN N
, , N
12 CD N
% NN N
, , N
20 CD N
% NN N
) ) N
. . N

The DT N
same JJ N
differences NNS N
were VBD N
observed JJ N
3 CD N
months NNS N
post-intervention NN N
( ( N
Intervention NNP N
group NN N
: : N
62 CD N
% NN N
, , N
43 CD N
% NN N
, , N
38 CD N
% NN N
vs JJ N
Waitlist NNP N
Group NNP N
: : N
13 CD N
% NN N
, , N
13 CD N
% NN N
, , N
9 CD N
% NN N
) ) N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
who WP N
reported VBD N
? . o
50 CD o
% NN o
pain NN o
relief NN o
was VBD o
also RB N
significantly RB N
higher RBR N
in IN N
the DT N
INT NNP N
Group NNP N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
( ( N
36 CD N
% NN N
vs JJ N
12 CD N
% NN N
) ) N
and CC N
3 CD N
months NNS N
post-intervention NN N
( ( N
33 CD N
% NN N
vs JJ N
4 CD N
% NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
qualitative JJ N
analysis NN N
were VBD N
in IN N
line NN N
with IN N
the DT N
quantitative JJ N
findings NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
the DT N
intervention NN N
. . N

The DT N
improvement NN N
, , N
however RB N
, , N
was VBD N
not RB N
reflected VBN N
in IN N
the DT N
primary JJ N
outcome NN N
and CC N
other JJ N
secondary JJ N
outcome NN N
measures NNS N
. . N

CONCLUSION NNP N
The DT N
PASSAGE NNP N
Program NNP N
was VBD N
effective JJ N
in IN N
helping VBG p
FMS NNP p
patients NNS p
gain VBP p
a DT N
sense NN N
of IN N
control NN N
over IN N
their PRP$ N
symptoms NNS N
. . N

We PRP N
suggest VBP N
including VBG N
PGIC NNP N
in IN N
future JJ N
clinical JJ N
trials NNS N
on IN N
FMS NNP p
as IN p
they PRP N
appear VBP N
to TO N
capture VB N
important JJ N
aspects NNS N
of IN N
the DT N
patients NNS N
' POS N
experience NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
International NNP N
Standard NNP N
Randomized NNP N
Controlled NNP N
Trial NNP N
Number NNP N
Register NNP N
ISRCTN14526380 NNP N
. . N

-DOCSTART- -X- O O

The DT N
influence NN N
of IN N
fidelity NN o
of IN o
implementation NN o
on IN N
teacher-student JJ o
interaction NN o
quality NN o
in IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
the DT N
Responsive NNP i
Classroom NNP i
approach NN i
. . i

This DT N
study NN N
examined VBD N
the DT N
direct JJ o
and CC o
indirect JJ o
effects NNS o
between IN N
training NN N
in IN N
the DT N
Responsive NNP i
Classroom? NNP i
( ( i
RC NNP i
) ) i
approach NN i
, , i
teachers NNS N
' POS N
uptake NN N
of IN N
RC NNP N
practices NNS N
, , N
and CC N
teacher-student JJ N
interaction NN N
quality NN N
, , N
using VBG N
a DT N
structural JJ i
equation NN i
modeling VBG i
framework NN i
. . i

A DT N
total NN p
of IN p
24 CD p
schools NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
experimental VB N
or CC N
control VB N
conditions NNS N
. . N

Third- CD p
and CC p
fourth-grade JJ p
teachers NNS p
in IN p
treatment NN p
schools NNS p
( ( p
n=132 NN p
) ) p
received VBD p
training NN p
in IN p
the DT i
RC NNP i
approach NN i
, , i
whereas JJ p
teachers NNS p
in IN p
control NN p
schools NNS p
( ( p
n=107 NN p
) ) p
continued VBD N
business NN i
as IN i
usual JJ i
. . i

Observers NNS N
rated VBD N
teachers NNS o
' POS o
fidelity NN o
of IN o
implementation NN o
( ( o
FOI NNP o
) ) o
of IN i
RC NNP i
practices NNS N
5 CD N
times NNS N
throughout IN N
the DT N
year NN N
using VBG N
the DT o
Classroom NNP o
Practices NNPS o
Observation NNP o
Measure NNP o
. . o

In IN N
addition NN N
, , N
teachers NNS o
completed VBD o
self-report JJ o
measures NNS o
of IN o
FOI NNP o
, , o
the DT o
Classroom NNP o
Practices NNPS o
Teacher NNP o
Survey NNP o
and CC o
Classroom NNP o
Practices NNP o
Frequency NNP o
Survey NNP o
, , o
at IN N
the DT N
end NN N
of IN N
the DT N
school NN N
year NN N
. . N

Teacher-student JJ o
interactions NNS o
were VBD N
rated VBN N
during IN N
classroom NN N
observations NNS N
using VBG N
the DT o
Classroom NNP o
Assessment NNP o
Scoring NNP o
System NNP o
. . o

Controlling VBG N
for IN N
teachers NNS N
' POS N
grade NN N
level NN N
and CC N
teacher-student JJ N
interaction NN N
quality NN N
at IN N
pretest JJS N
, , N
RC NNP N
training NN N
was VBD N
expected VBN N
to TO N
predict VB N
posttest JJS o
teacher-student JJ o
interaction NN o
quality NN o
directly RB N
and CC N
indirectly RB N
through IN N
FOI NNP N
. . N

Results NNP N
supported VBD N
only RB N
a DT N
significant JJ N
indirect JJ N
effect NN N
, , N
?=0.85 NNP N
, , N
p=.002 NN N
. . N

Specifically RB N
, , N
RC NNP N
teachers NNS N
had VBD N
higher JJR N
levels NNS N
of IN N
FOI NNP o
of IN o
RC NNP o
practices NNS o
, , o
?=1.62 NNP N
, , N
p NN N
< NNP N
.001 NNP N
, , N
R2=.69 NNP N
. . N

In IN N
turn NN N
, , N
FOI NNP N
related VBD N
to TO N
greater JJR N
improvement NN N
in IN N
teacher-student JJ o
interaction NN o
quality NN o
, , o
?=0.52 NNP o
, , N
p=.001 NN N
, , N
R2=.32 NNP N
. . N

Discussion NNP N
highlights NNS N
factors NNS N
contributing VBG N
to TO N
variability NN N
in IN N
FOI NNP N
and CC N
school NN N
administrators NNS N
roles NNS N
in IN N
supporting VBG N
FOI NNP N
. . N

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
a DT N
course NN N
of IN N
intranasal JJ i
oxytocin NN i
on IN N
social JJ N
behaviors NNS N
in IN N
youth NN p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
oxytocin NN i
as IN N
a DT N
therapeutic JJ N
to TO N
treat VB N
social JJ N
deficits NNS N
in IN N
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
a DT N
course NN N
of IN N
oxytocin JJ i
nasal NN i
spray NN i
to TO N
improve VB N
social JJ N
behavior NN N
in IN N
youth NN p
with IN p
ASD NNP p
. . p

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
across IN N
two CD p
Australian JJ p
university NN p
sites NNS p
between IN p
February NNP p
2009 CD p
and CC p
January NNP p
2012 CD p
, , p
50 CD p
male NN p
participants NNS p
aged VBN p
between IN p
12 CD p
and CC p
18 CD p
years NNS p
, , p
with IN p
Autistic NNP p
or CC p
Asperger NNP p
's POS p
Disorder NNP p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oxytocin NN i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
nasal NN i
sprays NNS i
( ( N
either CC N
18 CD N
or CC N
24 CD N
International NNP N
Units NNP N
) ) N
, , N
administered VBN N
twice-daily RB N
for IN N
8 CD N
weeks NNS N
. . N

Participants NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
after IN N
4- JJ N
and CC N
8-weeks CD N
of IN N
treatment NN N
, , N
and CC N
at IN N
3-month JJ N
follow-up NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
change NN N
in IN N
total JJ o
scores NNS o
on IN o
the DT o
caregiver-completed JJ o
Social NNP o
Responsiveness NNP o
Scale NNP o
and CC o
clinician-ratings NNS o
on IN o
the DT o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
. . o

Secondary JJ N
assessments NNS N
included VBD N
caregiver NN o
reports NNS o
of IN o
repetitive JJ o
and CC o
other JJ o
developmental JJ o
behaviors NNS o
and CC o
social JJ o
cognition NN o
. . o

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
www.anzctr.org.au VBD N
ACTRN12609000513213 NNP N
. . N

RESULTS NNP N
Participants NNPS N
who WP N
received VBD N
oxytocin RB N
showed VBN N
no DT N
benefit NN N
following VBG N
treatment NN N
on IN N
primary JJ N
or CC N
secondary JJ N
outcomes NNS N
. . N

However RB N
, , N
caregivers NNS N
who WP N
believed VBD N
their PRP$ N
children NNS N
received VBN N
oxytocin RB i
reported VBN N
greater JJR N
improvements NNS N
compared VBN N
to TO N
caregivers NNS N
who WP N
believed VBD N
their PRP$ N
child NN N
received VBD N
placebo NN i
. . i

Nasal NNP N
sprays NNS N
were VBD N
well RB N
tolerated VBN o
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
increased JJ N
side NN o
effects NNS o
resulting VBG N
from IN N
oxytocin JJ i
administration NN N
. . N

CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
evaluation NN N
of IN N
the DT N
efficacy NN N
for IN N
a DT N
course NN N
of IN N
oxytocin JJ i
treatment NN N
for IN N
youth NN N
with IN N
ASD NNP N
. . N

Although IN N
results NNS N
did VBD N
not RB N
suggest VB N
clinical JJ N
efficacy NN N
, , N
further JJ N
research NN N
is VBZ N
needed VBN N
to TO N
explore VB N
alternative JJ N
delivery NN N
methods NNS N
, , N
earlier JJR N
age NN N
of IN N
intervention NN N
, , N
and CC N
the DT N
influence NN N
of IN N
caregiver NN N
expectation NN N
on IN N
treatment NN N
response NN N
. . N

-DOCSTART- -X- O O

Microbiologic JJ N
yields NNS N
and CC N
complication NN N
rates NNS N
of IN N
vitreous JJ i
needle JJ i
aspiration NN i
versus IN N
mechanized VBN i
vitreous JJ i
biopsy NN i
in IN N
the DT N
Endophthalmitis NNP N
Vitrectomy NNP N
Study NNP N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
microbiologic JJ N
yields NNS N
and CC N
complication NN N
rates NNS N
associated VBN N
with IN N
vitreous JJ i
needle JJ i
tap NN i
and CC N
vitreous JJ i
biopsy NN i
in IN N
the DT N
Endophthalmitis NNP p
Vitrectomy NNP p
Study NNP p
( ( p
EVS NNP p
) ) p
. . p

METHODS NNP N
Of IN N
420 CD p
EVS NNP p
patients NNS p
with IN p
postoperative JJ p
endophthalmitis NN p
, , p
201 CD p
received VBD p
immediate JJ p
vitreous JJ i
tap NN i
or CC i
biopsy NN i
( ( i
without IN i
pars NNS i
plana VBP i
vitrectomy NN i
) ) i
by IN N
random JJ N
assignment NN N
and CC N
193 CD p
completed VBN N
9-12 CD N
months NNS N
of IN N
follow-up NN N
. . N

Vitreous JJ N
specimens NNS N
were VBD N
obtained VBN N
by IN N
biopsy NN N
with IN N
a DT N
20-gauge JJ i
vitrectomy NN i
cutting VBG N
instrument NN N
or CC N
by IN N
needle JJ N
tap NN N
with IN N
a DT N
22-27-gauge JJ N
needle NN N
. . N

If IN N
resistance NN N
to TO N
aspiration NN N
by IN N
needle JJ N
tap NN N
was VBD N
noted VBN N
, , N
a DT N
vitreous JJ N
biopsy NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
Of IN N
201 CD p
patients NNS p
undergoing JJ p
tap NN p
or CC p
biopsy NN p
, , p
70 CD p
( ( p
35 CD p
% NN p
) ) p
had VBD p
needle JJ p
tap NN p
, , p
127 CD p
( ( p
63 CD p
% NN p
) ) p
had VBD p
mechanized VBN p
biopsy NN p
, , p
and CC p
4 CD p
( ( p
2 CD p
% NN p
) ) p
had VBD p
initial JJ p
needle JJ p
tap NN p
that WDT N
was VBD N
aborted VBN N
to TO N
mechanized VBN N
biopsy NN N
( ( N
abort JJ N
eyes NNS N
) ) N
. . N

Intraoperative JJ o
hyphema NN o
occurred VBD N
in IN N
2 CD N
tap JJ N
eyes NNS N
( ( N
3 CD N
% NN N
) ) N
, , N
3 CD N
biopsy NN N
eyes NNS N
( ( N
2 CD N
% NN N
) ) N
, , N
and CC N
0 CD N
( ( N
0 CD N
% NN N
) ) N
abort NN N
eyes NNS N
. . N

Postoperative JJ o
retinal JJ o
detachment NN o
developed VBD N
in IN N
8 CD N
( ( N
11 CD N
% NN N
) ) N
tap NN N
eyes NNS N
, , N
10 CD N
( ( N
8 CD N
% NN N
) ) N
biopsy NN N
eyes NNS N
, , N
and CC N
0 CD N
( ( N
0 CD N
% NN N
) ) N
abort NN N
eyes NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

Respective JJ o
rates NNS o
of IN o
culture NN o
and CC o
gram NN o
stain VBP o
positivity NN o
were VBD N
69 CD N
% NN N
and CC N
42 CD N
% NN N
in IN N
tap JJ N
eyes NNS N
and CC N
66 CD N
% NN N
and CC N
41 CD N
% NN N
in IN N
biopsy JJ N
eyes NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

The DT N
rate NN o
of IN o
severe JJ o
visual JJ o
loss NN o
( ( N
final JJ N
acuity NN N
< NNP N
5/200 CD N
) ) N
was VBD N
significantly RB N
higher JJR N
in IN N
tap JJ N
eyes NNS N
( ( N
16 CD N
eyes NNS N
, , N
24 CD N
% NN N
) ) N
compared VBN N
with IN N
biopsy JJ N
eyes NNS N
( ( N
13 CD N
eyes NNS N
, , N
11 CD N
% NN N
) ) N
and CC N
abort JJ N
eyes NNS N
( ( N
0 CD N
eyes NNS N
, , N
0 CD N
% NN N
; : N
P NNP N
= NNP N
0.043 CD N
) ) N
. . N

The DT N
difference NN N
was VBD N
largely RB N
explained VBN N
by IN N
the DT N
greater JJR N
proportion NN o
of IN o
virulent JJ o
organisms NNS o
in IN o
the DT o
tap JJ o
eyes NNS o
compared VBN N
with IN N
biopsy JJ N
eyes NNS N
. . N

When WRB N
visual JJ o
acuity NN o
outcome NN o
was VBD N
defined VBN N
by IN N
other JJ N
thresholds NNS N
( ( N
20/40 CD N
and CC N
20/100 CD N
) ) N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

CONCLUSIONS VB N
This DT N
study NN N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
mechanized VBN N
vitreous JJ N
biopsy NN N
and CC N
needle JJ N
tap NN N
with IN N
respect NN N
to TO N
microbiologic JJ N
yield NN N
, , N
operative JJ N
complications NNS N
, , N
short-term JJ N
( ( N
9-12 JJ N
months NNS N
) ) N
retinal JJ N
detachment NN N
risk NN N
, , N
or CC N
visual JJ N
outcome NN N
. . N

Choice NNP N
of IN N
vitreous JJ N
sampling VBG N
procedure NN N
must MD N
depend VB N
on IN N
the DT N
clinical JJ N
judgment NN N
of IN N
the DT N
surgeon NN N
. . N

-DOCSTART- -X- O O

A DT N
step-by-step JJ N
introduction NN N
to TO N
vegetables NNS i
at IN N
the DT N
beginning NN N
of IN N
complementary JJ N
feeding NN N
. . N

The DT N
effects NNS N
of IN N
early JJ N
and CC N
repeated JJ N
exposure NN N
. . N

Breastfeeding NNP p
( ( p
BF NNP p
) ) p
is VBZ N
associated VBN N
with IN N
willingness NN N
to TO N
accept VB N
vegetables NNS N
. . N

This DT N
may MD N
be VB N
due JJ N
to TO N
the DT N
variety NN N
of IN N
flavours NNS N
delivered VBN N
via IN N
breast NN N
milk NN N
. . N

Some DT N
mothers NNS p
add VBP N
vegetables NNS N
to TO N
milk VB N
during IN N
complementary JJ N
feeding NN N
( ( N
CF NNP N
) ) N
to TO N
enhance VB N
acceptance NN N
. . N

The DT N
present JJ N
study NN N
tested VBD N
a DT N
step-by-step JJ N
exposure NN N
to TO N
vegetables NNS i
in IN i
milk NN i
then RB i
rice NN i
during IN N
CF NNP N
, , N
on IN N
intake NN N
and CC N
liking NN N
of IN N
vegetables NNS N
. . N

Just NNP N
before IN N
CF NNP N
, , N
enrolled VBD p
mothers NNS p
were VBD p
randomised VBN p
to TO p
an DT p
intervention NN p
( ( p
IG NNP p
, , p
n JJ p
= VBP p
18 CD p
; : p
6 CD p
BF NNP p
) ) p
or CC p
control VB p
group NN p
( ( p
CG NNP p
, , p
n JJ p
= VBP p
18 CD p
; : p
6 CD p
BF NNP p
) ) p
. . p

IG JJ p
infants NNS p
received VBD N
12 CD N
daily JJ N
exposures NNS i
to TO i
vegetable JJ i
puree NN i
added VBD i
to TO i
milk VB i
( ( N
days NNS N
1-12 RB N
) ) N
, , N
then RB N
12 CD N
? . N
2 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ i
puree NN i
added VBD i
to TO i
rice VB i
at IN i
home NN i
( ( N
days NNS N
13-24 RB N
) ) N
. . N

Plain NNP i
milk NN i
and CC i
rice NN i
were VBD i
given VBN N
to TO N
CG NNP N
. . N

Then RB N
both DT N
received VBD N
11 CD N
daily JJ N
exposures NNS N
to TO N
vegetable JJ i
puree NN i
. . i

Intake NNP i
was VBD N
weighed VBN N
and CC N
liking VBG N
rated VBN N
on IN N
days NNS N
25-26 JJ N
and CC N
33-35 JJ N
after IN N
the DT N
start NN N
of IN N
CF NNP N
in IN N
the DT N
laboratory NN N
, , N
supplemented VBN N
by IN N
the DT N
same JJ N
data NN N
recorded VBD N
at IN N
home NN N
. . N

Vegetables NNS N
were VBD N
rotated VBN N
daily RB N
( ( N
carrots NNS N
, , N
green JJ N
beans NNS N
, , N
spinach NN N
, , N
broccoli NN o
) ) o
. . o

Intake NNP o
, , o
liking VBG o
and CC o
pace NN o
of IN o
eating VBG o
were VBD o
greater JJR N
for IN N
IG NNP N
than IN N
CG NNP N
infants NNS o
. . o

Intake NNP o
and CC o
liking NN o
of IN o
carrots NNS o
were VBD o
greater JJR N
than IN N
green JJ N
beans NNS N
. . N

However RB N
, , N
at IN N
6m CD N
then RB N
18m CD N
follow VBP N
up RB N
, , N
vegetable JJ N
( ( N
carrot JJ N
> NN N
green JJ N
beans NNS N
) ) N
but CC N
not RB N
group NN N
differences NNS N
were VBD N
observed VBN p
. . p

Mothers NNS p
reported VBD p
appreciation NN N
of IN N
the DT N
structure NN N
and CC N
guidance NN N
of IN N
this DT N
systematic JJ N
approach NN N
. . N

Early JJ N
exposure NN N
to TO N
vegetables NNS i
in IN i
a DT N
step-by-step JJ N
method NN N
could MD N
be VB N
included VBN N
in IN N
CF NNP N
guidelines NNS N
and CC N
longer JJR N
term NN N
benefits NNS N
assessed VBN N
by IN N
extending VBG N
the DT N
exposure NN N
period NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
between IN N
the DT N
central JJ N
effects NNS N
of IN N
camazepam NN i
and CC i
temazepam NN i
. . i

Computerized JJ N
analysis NN N
of IN N
sleep JJ N
recordings NNS N
. . N

The DT N
effects NNS N
of IN N
acute JJ N
administration NN N
per IN N
os NN N
of IN N
30 CD N
mg NNS N
camazepam NN i
and CC N
the DT N
same JJ N
dose NN N
of IN N
temazepam NN i
, , N
were VBD N
compared VBN N
with IN N
placebo NN i
in IN N
8 CD p
young JJ p
male NN p
volunteers NNS p
, , p
fully RB p
adapted VBN p
to TO p
the DT p
laboratory NN p
environment NN p
by IN p
6 CD p
nights NNS p
of IN p
adaptation NN p
. . p

The DT N
study NN N
was VBD N
double-blind JJ N
, , N
in IN N
a DT N
random NN N
order NN N
, , N
10 CD N
days NNS N
separating VBG N
each DT N
session NN N
. . N

Spectral JJ N
analysis NN N
was VBD N
performed VBN N
on IN N
the DT N
all-night JJ N
records NNS N
( ( N
1-min JJ N
epochs NN N
) ) N
, , N
and CC N
the DT N
relative JJ N
power NN N
of IN N
six CD N
frequency NN N
bands NNS N
calculated VBN N
. . N

Concerning VBG N
sleep JJ o
parameters NNS o
, , N
temazepam NN i
induces NNS N
a DT N
statistically RB N
significant JJ N
reduction NN N
of IN N
: : N
phase NN N
shifts NNS N
; : N
number NN N
of IN N
awakenings NNS N
; : N
percent JJ N
duration NN N
of IN N
sleep JJ N
stages NNS N
I PRP N
and CC N
IV NNP N
. . N

A NNP N
significant JJ N
increase NN N
of IN N
the DT N
percent NN o
duration NN o
of IN o
stage NN o
II NNP o
and CC o
sleep JJ o
efficiency NN o
was VBD N
also RB N
found VBN N
. . N

Camazepam NNP o
shows VBZ o
modification NN o
, , o
with IN o
the DT o
same JJ o
trend NN o
, , o
but CC o
not RB o
reaching VBG o
statistical JJ o
significance NN o
. . N

Concerning VBG N
spectral JJ N
analysis NN N
, , N
temazepam NN o
induces NNS N
a DT N
light JJ N
increase NN N
of IN N
the DT N
relative JJ N
power NN N
of IN N
the DT N
slowest JJS N
frequencies NNS N
, , N
paralleled VBN N
by IN N
an DT N
increase NN N
of IN N
the DT N
fast JJ N
bands NNS N
, , N
while IN N
major JJ N
effects NNS N
are VBP N
found VBN N
on IN N
the DT N
characteristic JJ N
periodicity NN N
of IN N
delta NN N
activities NNS N
, , N
which WDT N
appear VBP N
disrupted VBN N
by IN N
the DT N
drug NN N
. . N

These DT N
effects NNS N
are VBP N
not RB N
evident JJ N
with IN N
camazepam NN i
, , N
which WDT N
does VBZ N
not RB N
seem VB N
to TO N
distort VB N
the DT N
normal JJ N
sleep JJ N
pattern NN N
. . N

-DOCSTART- -X- O O

Poor NNP p
prognosis NN p
patients NNS p
with IN p
inoperable JJ p
locally RB p
advanced JJ p
NSCLC NNP p
and CC p
large JJ p
tumors NNS p
benefit VBP N
from IN N
palliative JJ i
chemoradiotherapy NN i
: : i
a DT N
subset NN N
analysis NN N
from IN N
a DT N
randomized JJ N
clinical JJ N
phase NN N
III NNP N
trial NN N
. . N

INTRODUCTION NNP N
Poor NNP p
prognosis NN p
patients NNS p
with IN p
bulky JJ p
stage NN p
III NNP p
locally RB p
advanced VBD p
non-small-cell JJ p
lung NN p
cancer NN p
may MD N
not RB N
be VB N
offered VBN N
concurrent JJ N
chemoradiotherapy NN N
( ( N
CRT NNP N
) ) N
. . N

Following VBG N
a DT N
phase NN N
III NNP N
trial NN N
concerning VBG N
the DT N
effect NN o
of IN N
palliative JJ N
CRT NNP i
in IN N
inoperable JJ N
poor JJ p
prognosis NN p
patients NNS p
, , N
this DT N
analysis NN N
was VBD N
performed VBN N
to TO N
explore VB N
how WRB N
tumor JJ N
size NN N
influenced VBD N
survival JJ o
and CC o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQOL NNP o
) ) o
. . o

METHODS CC N
A DT p
total NN p
of IN p
188 CD p
poor JJ p
prognosis NN p
patients NNS p
recruited VBN p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
received VBD N
four CD N
courses NNS N
intravenous JJ i
carboplatin NNS i
day NN i
1 CD i
and CC i
oral JJ i
vinorelbine NN i
day NN i
1 CD i
and CC i
8 CD i
, , i
at IN i
3-week JJ i
intervals NNS i
. . i

The DT N
experimental JJ N
arm NN N
( ( N
N NNP N
= NNP N
94 CD N
) ) N
received VBD N
radiotherapy NN i
with IN i
fractionation NN i
42 CD i
Gy/15 NNP i
, , N
starting VBG N
at IN N
the DT N
second JJ N
chemotherapy NN N
course NN N
. . N

This DT N
subset NN N
study NN N
compares VBZ o
outcomes NNS o
in IN o
patients NNS o
with IN o
tumors NNS o
larger JJR o
than IN o
7 CD o
cm NN o
( ( o
N NNP o
= NNP o
108 CD o
) ) o
versus NN o
tumors NNS o
7 CD o
cm NN o
or CC o
smaller JJR o
( ( o
N NNP o
= NNP o
76 CD o
) ) o
. . o

RESULTS NNP N
Among IN N
those DT N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NN N
, , N
the DT N
median JJ o
overall JJ o
survival NN o
in IN N
the DT N
chemotherapy NN i
versus NN N
CRT NNP i
arm NN N
was VBD N
9.7 CD N
and CC N
13.4 CD N
months NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
1-year JJ o
survival NN o
was VBD N
33 CD N
% NN N
and CC N
56 CD N
% NN N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
. . N

Except IN N
for IN N
a DT N
temporary JJ N
decline NN N
during IN N
treatment NN N
, , N
HRQOL NNP o
was VBD N
maintained VBN N
in IN N
the DT N
CRT NNP i
arm NN N
, , N
regardless RB N
of IN N
tumor NN N
size NN N
. . N

Among IN N
those DT N
who WP N
did VBD N
not RB N
receive VB N
CRT NNP i
, , N
patients NNS N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NN N
experienced VBD N
a DT N
gradual JJ N
decline NN N
in IN N
the DT N
HRQOL NNP o
. . o

The DT N
CRT NNP i
group NN N
had VBD N
significantly RB o
more RBR o
esophagitis JJ o
and CC o
hospitalizations NNS o
because IN N
of IN N
side NN o
effects NNS o
regardless RB N
of IN N
tumor NN N
size NN N
. . N

CONCLUSION NNP N
In IN N
patients NNS p
with IN p
poor JJ p
prognosis NN p
and CC p
inoperable JJ p
locally RB p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
, , N
large JJ N
tumor NN N
size NN N
should MD N
not RB N
be VB N
considered VBN N
a DT N
negative JJ N
predictive JJ N
factor NN N
. . N

Except IN N
for IN N
performance NN N
status NN N
2 CD N
, , N
patients NNS N
with IN N
tumors NNS N
larger JJR N
than IN N
7 CD N
cm NNS N
apparently RB N
benefit VBP N
from IN N
CRT NNP i
. . i

-DOCSTART- -X- O O

Infrared NNP i
LED NNP i
irradiation NN i
applied VBD N
during IN N
high-intensity NN N
treadmill NN N
training VBG N
improves NNS N
maximal JJ o
exercise NN o
tolerance NN o
in IN N
postmenopausal JJ p
women NNS p
: : p
a DT N
6-month JJ N
longitudinal JJ N
study NN N
. . N

Reduced NNP N
aerobic JJ N
fitness NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
diseases NNS N
among IN N
the DT N
older JJR p
population NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS o
of IN N
LED NNP i
irradiation NN i
( ( N
850 CD N
nm RB N
) ) N
applied VBD N
during IN N
treadmill JJ N
training VBG N
on IN N
the DT N
maximal JJ o
exercise NN o
tolerance NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

At IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
, , N
45 CD p
postmenopausal JJ p
women NNS p
were VBD N
assigned VBN N
randomly RB N
to TO N
three CD N
groups NNS N
, , N
and CC N
30 CD N
women NNS N
completed VBD N
the DT N
entire JJ N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

The DT N
groups NNS N
were VBD N
: : N
( ( i
1 CD i
) ) i
the DT i
LED NNP i
group NN i
( ( i
treadmill IN i
training VBG i
associated VBN i
with IN i
phototherapy NN i
, , i
n JJ i
= NNP i
10 CD i
) ) i
, , i
( ( i
2 CD i
) ) i
the DT i
exercise NN i
group NN i
( ( i
treadmill IN i
training NN i
, , i
n JJ i
= NNP i
10 CD i
) ) i
, , i
and CC i
( ( i
3 CD i
) ) i
the DT i
sedentary JJ i
group NN i
( ( i
neither DT i
physical JJ i
training NN i
nor CC i
phototherapy NN i
, , i
n JJ i
= NNP i
10 CD i
) ) i
. . i

The DT i
training NN i
was VBD N
performed VBN N
for IN N
45 CD N
min NN N
twice RB N
a DT N
week NN N
for IN N
6 CD N
months NNS N
at IN N
intensities NNS N
between IN N
85 CD N
% NN N
and CC N
90 CD N
% NN N
maximal JJ N
heart NN N
rate NN N
( ( N
HRmax NNP N
) ) N
. . N

The DT N
irradiation NN N
parameters NNS N
were VBD N
39 CD N
mW/cm NN N
( ( N
2 CD N
) ) N
, , N
45 CD N
min NN N
and CC N
108 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
. . N

The DT N
cardiovascular JJ o
parameters NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

As IN N
expected VBN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
sedentary JJ N
group NN N
( ( N
p VB N
? . N
0.05 CD N
) ) N
. . N

The DT o
maximal JJ o
time NN o
of IN o
tolerance NN o
( ( o
Tlim NNP o
) ) o
, , o
metabolic JJ o
equivalents NNS o
( ( o
METs NNP o
) ) o
and CC o
Bruce NNP o
stage NN o
reached VBD o
significantly RB N
higher JJR N
values NNS N
in IN N
the DT i
LED NNP i
group NN N
and CC N
the DT N
exercise NN i
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH o
, , o
the DT o
HR NNP o
, , o
double JJ o
product NN o
and CC o
Borg NNP o
score NN o
at IN o
isotime NN o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
LED NNP N
group NN N
and CC N
in IN N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
the DT o
time NN o
of IN o
recovery NN o
showed VBD o
a DT N
significant JJ N
decrease NN N
only RB N
in IN N
the DT N
LED NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
differences NNS o
between IN o
before IN o
and CC o
after IN o
training NN o
( ( o
delta JJ o
values NNS o
) ) o
for IN N
the DT o
Tlim NNP o
, , o
METs NNP o
and CC o
HR NNP o
at IN o
isotime NN N
were VBD N
greater JJR N
in IN N
the DT N
LED NNP N
group NN N
than IN N
in IN N
the DT N
exercise NN N
group NN N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Therefore RB i
, , i
the DT i
infrared JJ i
LED NNP i
irradiation NN i
during IN N
treadmill JJ N
training NN o
can MD o
improve VB o
maximal JJ o
performance NN o
and CC o
post-exercise JJ o
recovery NN o
in IN o
postmenopausal JJ o
women NNS p
. . p

-DOCSTART- -X- O O

Boosting VBG N
uptake NN o
of IN N
influenza JJ N
immunisation NN N
: : N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
telephone NN i
appointing VBG i
in IN N
general JJ N
practice NN N
. . N

BACKGROUND NNP N
Immunisation NNP N
against IN N
influenza NN N
is VBZ N
an DT N
effective JJ N
intervention NN N
that WDT N
reduces VBZ N
serologically RB N
confirmed VBN N
cases NNS N
by IN N
between IN N
60 CD N
% NN N
and CC N
70 CD N
% NN N
. . N

Almost NNP N
all DT N
influenza JJ N
immunisation NN N
in IN N
the DT N
UK NNP p
is VBZ N
done VBN N
within IN N
general JJ N
practice NN N
. . N

Current JJ N
evidence NN N
on IN N
the DT N
effectiveness NN N
of IN N
patient JJ N
reminders NNS N
for IN N
all DT N
types NNS N
of IN N
immunisation NN N
programmes NNS N
is VBZ N
largely RB N
based VBN N
on IN N
North JJ N
American JJ N
studies NNS N
. . N

AIM NNP N
To TO N
determine VB N
whether IN N
telephone NN i
appointments NNS i
offered VBD N
bygeneral JJ N
practice NN N
receptionists NNS N
increase VBP N
the DT N
uptake NN o
of IN o
irfluenza JJ o
immunisation NN o
among IN N
the DT N
registered JJ p
population NN p
aged VBD p
over IN p
65 CD p
years NNS p
in IN p
east JJ p
London NNP p
practices NNS p
. . p

DESIGN NNP N
OF NNP N
STUDY NNP N
Randomised VBD N
controlled VBN N
trial NN N
. . N

SETTING NNP N
Three NNP N
research NN N
general JJ N
practices NNS N
within IN N
the DT N
East NNP p
London NNP p
and CC p
Essex NNP p
network NN p
of IN p
researchers NNS p
( ( p
ELENoR NNP p
) ) p
. . p

METHOD JJ N
Participants NNS p
were VBD p
1,820 CD p
low-risk JJ p
patients NNS p
aged VBD p
65 CD p
to TO p
74 CD p
years NNS p
who WP p
had VBD p
not RB p
previously RB p
been VBN p
in IN p
a DT p
recall NN p
system NN p
for IN p
influenza JJ p
immunisation NN p
at IN p
their PRP$ p
general JJ p
practice NN p
. . p

The DT N
intervention NN N
, , N
during IN N
October NNP N
2000 CD N
, , N
was VBD N
a DT N
telephone NN i
call NN i
from IN i
the DT i
practice NN i
receptionist NN i
to TO N
intervention NN i
group NN N
households NNS N
, , N
offering VBG N
an DT N
appointment NN N
for IN N
influenza JJ N
immunisation NN N
at IN N
a DT N
nurse-run JJ N
. . N

clinic JJ N
Main NNP N
outcome NN N
measures NNS N
were VBD N
the DT N
numbers NNS o
of IN o
individuals NNS o
in IN o
each DT o
group NN o
receiving VBG o
immunisation NN o
, , o
and CC o
practice NN o
costs NNS o
of IN o
a DT o
telephone-appointing JJ o
programme NN o
. . o

RESULTS NNP N
intention NN N
to TO N
treat VB N
analysis NN N
showed VBD N
an DT N
immunisation NN o
rate NN o
in IN N
the DT N
control NN i
group NN N
of IN N
44 CD N
% NN N
, , N
compared VBN N
with IN N
50 CD N
% NN N
in IN N
the DT N
intervention NN i
group NN i
( ( N
odds NNS N
ratio VBP N
= JJ N
1.29 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
1.03 CD N
to TO N
1.63 CD N
) ) N
. . N

Of IN N
the DT N
patients NNS p
making VBG p
a DT p
telephone NN i
appointment NN i
, , N
88 CD N
% NN N
recieved JJ N
immunisation NN o
, , N
while IN N
22 CD N
% NN N
of IN N
those DT N
not RB N
wanting VBG N
an DT N
appointment NN N
went VBD N
on IN N
to TO N
be VB N
immunised VBN N
. . N

In IN N
the DT N
controlgroup NN i
, , N
income NN o
generated VBD o
was VBD N
11.35 CD N
pounds NNS N
per IN N
immunisation NN N
, , N
for IN N
each DT N
additional JJ N
immunisation NN N
in IN N
the DT N
intervention NN N
group NN N
the DT N
income NN N
was VBD N
5.20 CD N
pounds NNS N
. . N

The DT N
'number NNP o
needed VBD o
to TO o
telephone NN o
' '' o
was VBD N
17 CD N
. . N

CONCLUSION NNP N
Uptake NNP N
of IN N
influenza JJ N
immunisation NN o
among IN N
the DT N
low-risk JJ p
older JJR p
population NN p
in IN p
inner-city JJ p
areas NNS p
can MD N
be VB N
boosted VBN N
by IN N
around IN N
6 CD N
% NN N
using VBG N
a DT N
simple JJ N
intervention NN i
by IN N
receptionists NNS N
. . N

Immunisation NN o
rates NNS o
in IN N
this DT N
low-risk JJ N
group NN N
fell VBD N
well RB N
short RB N
of IN N
the DT N
60 CD N
% NN N
government NN N
target NN N
. . N

Improving VBG N
immunisation NN o
rates NNS o
will MD N
require VB N
a DT N
sustained JJ N
public JJ N
health NN N
campaign NN N
. . N

Retaining VBG N
the DT N
item-of-service JJ N
payments NNS N
to TO N
practices NNS N
should MD N
support VB N
costs NNS N
of IN N
practice-based JJ N
interventions NNS N
. . N

-DOCSTART- -X- O O

Losartan NNP i
vs. FW i
amlodipine NN i
treatment NN N
in IN N
elderly JJ p
oncologic JJ p
hypertensive JJ p
patients NNS p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Elderly JJ p
neoplastic JJ p
patients NNS p
frequently RB N
may MD N
show VB N
hypertension NN p
and CC p
hyperuricemia NN p
, , N
before IN N
and CC N
after IN N
chemotherapeutic JJ N
treatments NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
losartan NN i
which WDT N
is VBZ N
an DT N
antihypertensive JJ i
drug NN i
with IN N
uricosuric JJ i
properties NNS N
vs. FW N
amlodipine NN i
in IN N
hypertensive JJ p
neoplastic JJ p
elderly JJ p
patients NNS p
. . p

This DT N
was VBD N
an DT N
open-labeled JJ N
, , N
randomized VBN N
, , N
comparative JJ N
trial NN N
. . N

The DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
30-day JJ N
study NN N
. . N

Seventy NNP p
patients NNS p
with IN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
losartan NN i
or CC i
amlodipine NN i
. . i

Blood NNP o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
blood VBD o
urea JJ o
nitrogen NN o
( ( o
BUN NNP o
) ) o
levels NNS o
, , o
creatinine NN o
, , o
serum NN o
and CC o
urinary JJ o
uric JJ o
acid NN o
, , o
creatinine NN o
and CC o
uric JJ o
acid JJ o
clearance NN o
were VBD N
determined VBN N
before IN N
and CC N
after IN N
chemotherapy NN i
. . i

One CD N
day NN N
after IN N
chemotherapy NN N
in IN N
losartan JJ i
group NN N
vs. FW N
amlodipine NN i
group NN N
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
urinary JJ o
uric JJ o
acid NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
18 CD N
mg/24 NNS N
h VBD N
vs. FW N
40 CD N
mg/24 NN N
h. NN N
Thirty NNP N
days NNS N
after IN N
chemotherapy NN i
we PRP N
observed VBD N
a DT N
significant JJ N
difference NN N
in IN N
azotemia NN o
of IN N
0.0 CD N
mg/dl NNS N
vs. FW N
3.8 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
serum JJ o
uric JJ o
acid NN o
of IN N
0.05 CD N
mg/dl NNS N
vs. FW N
0.49 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
urinary JJ o
uric JJ o
acid NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
of IN N
23 CD N
mg/24 NNS N
h VBD N
vs. FW N
0.0 CD N
mg/24 NN N
h NN N
, , N
GFR NNP N
of IN N
2 CD N
ml/min/1.73 NNS N
m NN N
( ( N
2 CD N
) ) N
vs. FW N
-8 FW N
ml/min/1.73 FW N
m NN N
( ( N
2 CD N
) ) N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
systolic JJ o
BP NNP o
( ( N
SBP NNP N
) ) N
of IN N
3.6 CD N
mmHg NNS N
vs. FW N
0.8 CD N
mmHg NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
findings NNS N
of IN N
the DT N
present JJ N
study NN N
support VBD N
the DT N
effective JJ N
role NN N
of IN N
losartan JJ i
compared VBN N
to TO N
amlodipine VB i
in IN N
treating VBG N
hypertension NN p
and CC p
hyperuricemia NN p
in IN p
elderly JJ p
patients NNS p
under IN p
chemotherapeutic JJ p
treatment NN p
. . p

-DOCSTART- -X- O O

Evaluating VBG N
the DT N
efficacy NN o
of IN N
thoracoscopy NN i
and CC i
talc JJ i
poudrage NN i
versus NN i
pleurodesis NN i
using VBG i
talc JJ i
slurry NN i
( ( N
TAPPS NNP N
trial NN N
) ) N
: : N
protocol NN N
of IN N
an DT N
open-label NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

INTRODUCTION VB N
The DT N
management NN N
of IN N
recurrent NN N
malignant JJ N
pleural JJ N
effusions NNS N
( ( N
MPE NNP N
) ) N
can MD N
be VB N
challenging VBG N
. . N

Various JJ N
options NNS N
are VBP N
available JJ N
, , N
with IN N
the DT N
most RBS N
efficacious JJ N
and CC N
widely RB N
used VBD N
being VBG N
talc JJ i
pleurodesis NN i
. . i

Talc NNP i
can MD N
either RB N
be VB N
applied VBN N
via IN N
a DT N
chest NN N
drain NN N
in IN N
the DT N
form NN N
of IN N
slurry NN N
, , N
or CC N
at IN N
medical JJ i
thoracoscopy NN i
using VBG i
poudrage NN i
. . i

Current JJ N
evidence NN N
regarding VBG N
which WDT N
method NN N
is VBZ N
most RBS N
effective JJ N
is VBZ N
conflicting VBG N
and CC N
often RB N
methodologically RB N
flawed VBN N
. . N

The DT N
TAPPS NNP N
trial NN N
is VBZ N
a DT N
suitably RB N
powered VBN N
, , N
multicentre FW N
, , N
open-label JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
designed VBN N
to TO N
compare VB N
the DT N
pleurodesis NN N
success NN N
rate NN N
of IN N
medical JJ i
thoracoscopy NN i
and CC i
talc JJ i
poudrage NN i
with IN i
chest NN i
drain NN i
insertion NN i
and CC i
talc NN i
slurry NN i
. . i

METHODS NNP N
AND CC N
ANALYSIS NNP N
330 CD p
patients NNS p
with IN p
a DT p
confirmed JJ p
MPE NNP p
requiring VBG p
intervention NN p
will MD p
be VB p
recruited VBN p
from IN p
UK NNP p
hospitals NNS p
. . p

Patients NNS N
will MD N
be VB N
randomised VBN N
( ( N
1:1 CD N
) ) N
to TO N
undergo VB N
either RB N
small JJ i
bore NN i
( ( i
< JJ i
14 CD i
Fr NNP i
) ) i
Seldinger NNP i
chest JJS i
drain NN i
insertion NN i
followed VBN i
by IN i
instillation NN i
of IN i
sterile JJ i
talc NN i
( ( i
4 CD N
g NN N
) ) N
, , N
or CC N
to TO i
undergo VB i
medical JJ i
thoracoscopy NN i
and CC i
simultaneous JJ i
poudrage NN i
( ( i
4 CD i
g NN N
) ) N
. . N

The DT N
allocated JJ N
procedure NN N
will MD N
be VB N
performed VBN N
as IN N
an DT N
inpatient NN N
within IN N
3 CD N
days NNS N
of IN N
randomisation NN N
taking VBG N
place NN N
. . N

Following VBG N
discharge NN N
, , N
patients NNS N
will MD N
be VB N
followed VBN N
up RP N
at IN N
regular JJ N
intervals NNS N
for IN N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome JJ N
measure NN N
is VBZ N
pleurodesis JJ o
failure NN o
rates NNS o
at IN o
3 CD N
months NNS N
. . N

Pleurodesis NNP o
failure NN o
is VBZ o
defined VBN N
as IN N
the DT N
need NN N
for IN N
further JJ N
pleural JJ N
intervention NN N
for IN N
fluid JJ N
management NN N
on IN N
the DT N
side NN N
of IN N
the DT N
trial NN N
intervention NN N
. . N

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
The DT N
trial NN N
has VBZ N
received VBN N
ethical JJ N
approval NN N
from IN N
the DT N
National NNP N
Research NNP N
Ethics NNP N
Service NNP N
Committee NNP N
North NNP N
West-Preston NNP N
( ( N
12/NW/0467 CD N
) ) N
. . N

There EX N
is VBZ N
a DT N
trial NN N
steering VBG N
committee NN N
which WDT N
includes VBZ N
independent JJ N
members NNS N
and CC N
a DT N
patient NN N
and CC N
public JJ N
representative NN N
. . N

The DT N
trial NN N
results NNS N
will MD N
be VB N
published VBN N
in IN N
a DT N
peer-reviewed JJ N
journal NN N
and CC N
presented VBD N
at IN N
international JJ N
conferences NNS N
, , N
as RB N
well RB N
as IN N
being VBG N
disseminated VBN N
via IN N
local JJ N
and CC N
national JJ N
charities NNS N
and CC N
patient JJ N
groups NNS N
. . N

All DT N
participants NNS N
who WP N
wish VBP N
to TO N
know VB N
the DT N
study NN N
results NNS N
will MD N
also RB N
be VB N
contacted VBN N
directly RB N
on IN N
their PRP$ N
publication NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN47845793 NNP N
. . N

-DOCSTART- -X- O O

Mebendazole NNP i
in IN N
enterobiasis NN o
: : o
a DT N
placebo NN i
-- : i
controlled VBD i
trial NN N
in IN N
a DT N
paediatric JJ p
community NN p
. . p

-DOCSTART- -X- O O

Effect NN N
of IN N
spinal JJ i
versus NN i
general JJ i
anesthesia NN i
on IN N
bladder NN o
compliance NN o
and CC o
intraabdominal JJ o
pressure NN o
during IN N
transurethral JJ p
procedures NNS p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
influence NN N
of IN N
spinal JJ i
versus NN i
general JJ i
anesthesia NN i
on IN N
bladder NN o
compliance NN o
and CC o
intraabdominal JJ o
pressure NN o
in IN N
elderly JJ p
males NNS p
undergoing VBG p
elective JJ i
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
. . i

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
open-label JJ N
study NN N
. . N

SETTING NN N
Teaching NNP p
hospital NN p
. . p

PATIENTS CC N
21 CD p
ASA NNP p
physical JJ p
status NN p
I PRP p
, , p
II NNP p
, , p
and CC p
III NNP p
patients NNS p
at IN p
least JJS p
18 CD p
years NNS p
of IN p
age NN p
, , p
undergoing VBG p
transurethral JJ i
surgery NN i
. . i

INTERVENTIONS NNP N
According VBG N
to TO N
a DT N
computer-generated JJ N
randomization NN N
schedule NN N
, , N
patients NNS N
were VBD N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

In IN N
Group NNP N
Spinal NNP N
( ( N
S NNP N
) ) N
, , N
10 CD N
mg NN N
of IN N
hyperbaric JJ i
tetracaine NN i
was VBD N
administered VBN N
intrathecally RB N
. . N

In IN N
Group NNP N
General NNP i
Anesthesia NNP i
( ( i
GA NNP i
) ) i
, , N
patients NNS N
received VBD N
, , N
fentanyl RB i
intravenous JJ i
( ( N
i.v JJ N
. . N

1 CD N
to TO N
2 CD N
micrograms/kg NNS N
and CC N
propofol NN N
i.v NN N
. . N

1.0 CD N
to TO N
2.0 CD N
mg/kg NN N
for IN N
induction NN N
of IN N
anesthesia NN i
. . i

Thereafter NNP N
, , N
a DT N
laryngeal JJ N
mask NN N
airway NN N
was VBD N
inserted VBN N
and CC N
, , N
with IN N
spontaneous JJ N
ventilation NN N
, , N
anesthesia NN i
was VBD N
maintained VBN N
by IN N
administering VBG N
isoflurane NN i
( ( N
end-tidal JJ N
0.7 CD N
% NN N
to TO N
1.2 CD N
% NN N
) ) N
and CC N
70 CD N
% NN N
nitrous JJ i
oxide NN i
( ( i
N2O NNP i
) ) i
in IN i
oxygen NN i
. . i

Intraabdominal JJ o
pressure NN o
and CC o
bladder NN o
compliance NN o
were VBD N
recorded VBN N
prior RB N
to TO N
the DT N
induction NN N
of IN N
anesthesia NN i
and CC N
immediately RB N
before IN N
the DT N
onset NN N
of IN N
the DT N
surgical JJ N
procedure NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
two CD N
groups NNS N
were VBD N
demographically RB N
comparable JJ N
. . N

In IN N
Group NNP N
S NNP N
, , N
mean JJ N
bladder NN N
compliance NN N
was VBD N
significantly RB N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
higher JJR N
and CC N
mean JJ N
intraabdominal JJ o
pressure NN o
significantly RB N
lower JJR N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
values NNS N
. . N

In IN N
Group NNP N
GA NNP N
, , N
mean JJ o
intraabdominal JJ o
pressure NN o
significantly RB N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
decreased VBD N
when WRB N
compared VBN N
to TO N
baseline VB N
preanesthetic JJ N
recordings NNS N
. . N

Following VBG N
the DT N
induction NN N
of IN N
general JJ N
anesthesia NN N
, , N
a DT N
small JJ N
change NN N
in IN N
bladder NN o
compliance NN o
was VBD N
noted VBN N
. . N

However RB N
, , N
statistical JJ N
significance NN N
was VBD N
not RB N
reached VBN N
. . N

Data NNS N
were VBD N
analyzed VBN N
and CC N
compared VBN N
using VBG N
Student NNP N
's POS N
t-test NN N
( ( N
p JJ N
< NN N
0.05 CD N
was VBD N
considered VBN N
statistically RB N
significant JJ N
) ) N
. . N

CONCLUSION NNP N
Both NNP N
spinal JJ i
and CC i
general JJ i
anesthesia NN i
induced VBD N
a DT N
significant JJ o
decrease NN o
in IN o
intraabdominal JJ o
pressure NN o
. . o

While IN N
both DT N
techniques NNS N
were VBD N
associated VBN N
with IN N
an DT N
increase NN o
in IN o
bladder NN o
compliance NN o
, , N
statistical JJ N
significance NN N
was VBD N
demonstrated VBN N
only RB N
in IN N
the DT N
spinal JJ i
anesthesia NN i
treatment NN N
group NN N
. . N

-DOCSTART- -X- O O

The DT N
effectiveness NN N
of IN N
single-dose JJ N
metronidazole JJ i
therapy NN N
for IN N
patients NNS p
and CC p
their PRP$ p
partners NNS p
with IN p
bacterial JJ p
vaginosis NN p
. . p

A DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
clinical JJ N
trial NN N
was VBD N
performed VBN N
to TO N
test VB N
the DT N
hypothesis NN N
that IN N
a DT N
2-g JJ N
single JJ N
dose NN N
of IN N
metronidazole NN i
for IN N
male JJ p
partners NNS p
of IN p
women NNS p
with IN p
bacterial JJ p
vaginosis NN p
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN N
in IN N
improving VBG N
cure NN N
rate NN N
and CC N
decreasing VBG N
recurrence NN N
rate NN N
. . N

In IN N
addition NN N
, , N
the DT N
effectiveness NN N
of IN N
a DT N
2-g JJ N
single JJ i
dose NN i
of IN i
metronidazole NN i
was VBD N
compared VBN N
with IN N
a DT N
seven-day JJ i
course NN i
of IN i
500 CD i
mg NN i
of IN i
metronidazole JJ i
twice NN N
a DT N
day NN N
in IN N
patients NNS p
with IN p
bacterial JJ p
vaginosis NN p
. . p

Statistically NNP N
significant JJ N
benefits NNS N
of IN N
partner NN N
treatment NN N
were VBD N
noted VBN N
in IN N
the DT N
initial JJ N
cure NN N
rate NN N
by IN N
Gram-stained JJ N
smear JJ N
criteria NNS N
( ( N
P NNP N
less JJR N
than IN N
.01 NN N
) ) N
and CC N
in IN N
percentage NN N
of IN N
women NNS N
with IN N
symptoms NNS N
eight CD N
weeks NNS N
after IN N
initiating VBG N
therapy NN N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
. . N

The DT N
seven-day JJ N
course NN N
of IN N
metronidazole NN N
was VBD N
superior JJ N
to TO N
the DT N
single-dose JJ N
regimen NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
clue JJ N
cells NNS N
and CC N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
a DT N
positive JJ N
sniff NN N
test NN N
at IN N
the DT N
first JJ N
follow-up JJ N
visit NN N
; : N
however RB N
, , N
differences NNS N
in IN N
the DT N
initial JJ o
cure NN o
rate NN o
assessed VBN o
by IN o
clinical JJ o
criteria NNS o
and CC o
Gram-stained JJ o
smear JJ o
criteria NNS o
were VBD N
not RB N
statistically RB N
significant JJ N
between IN N
the DT N
two CD N
patient NN N
treatment NN N
regimens NNS N
. . N

Recurrence NN o
rates NNS o
by IN o
Gram-stained JJ o
smear JJ o
criteria NNS o
between IN N
patient NN N
and CC N
partner NN N
treatment NN N
groups NNS N
at IN N
five CD N
and CC N
eight CD N
weeks NNS N
after IN N
initiation NN N
of IN N
treatment NN N
were VBD N
also RB N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
patient NN N
regimens NNS N
. . N

Single-dose JJ N
metronidazole JJ i
treatment NN N
of IN N
the DT N
sexual JJ p
partner NN p
of IN p
women NNS p
with IN p
bacterial JJ p
vaginosis NN p
improves VBZ N
initial JJ N
bacterial JJ o
vaginosis NN o
cure NN o
rates NNS o
. . o

The DT N
seven-day JJ N
course NN N
of IN N
metronidazole NN N
was VBD N
not RB N
found VBN N
by IN N
statistical JJ N
analysis NN N
to TO N
be VB N
significantly RB N
superior JJ N
to TO N
single-dose JJ N
therapy NN N
when WRB N
considering VBG N
initial JJ N
cure NN N
rates NNS N
by IN N
clinical JJ N
or CC N
Gram-stained JJ N
smear JJ N
criteria NNS N
or CC N
recurrence NN N
rates NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -X- O O

Improved NNP o
responsiveness NN o
of IN N
PCOS NNP p
patients NNS p
to TO N
clomiphene VB i
after IN p
CYP17a NNP i
inhibitor NN i
. . i

PURPOSE NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
CYP17a NNP i
inhibitor NN i
, , i
ketoconazole NN i
, , i
on IN N
clomiphene NN N
responsiveness NN N
in IN N
PCOS NNP p
patients NNS p
. . p

METHODS NNP N
Prospective JJ N
analysis NN N
was VBD N
employed VBN N
with IN N
the DT N
setup NN N
at IN N
Alexandria NNP p
IVF/ICSI NNP p
center NN p
. . p

Ninety-seven JJ p
insulin-resistant JJ p
PCOS NNP p
patients NNS p
undergoing VBG p
ovulation NN p
induction NN p
using VBG p
clomiphene JJ i
citrate NN i
were VBD N
randomly RB N
divided VBN N
, , N
by IN N
random JJ N
number NN N
table NN N
, , N
into IN N
two CD N
groups NNS N
. . N

The DT N
first JJ N
group NN N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
received VBN N
ketoconazole NN i
( ( N
400 CD N
mg NNS N
daily RB N
) ) N
till NN N
correction NN N
of IN N
metabolic JJ N
syndrome NN N
followed VBN N
by IN N
clomiphene NN i
( ( N
100 CD N
mg/day NN N
) ) N
; : N
the DT N
second JJ N
group NN N
( ( N
n JJ N
= NNP N
48 CD N
) ) N
receiving VBG N
clomiphene NN i
without IN i
ketoconazole JJ i
pretreatment NN i
. . i

Main NNP N
outcome JJ N
measures NNS N
were VBD N
incidence NN o
of IN o
clomiphene NN o
resistance NN o
, , o
monofollicular JJ o
response NN o
, , o
fasting VBG o
insulin/glucose JJ o
ratio NN o
, , o
serum NN o
testosterone NN o
, , o
and CC o
pregnancy NN o
rates NNS o
. . o

RESULTS VB N
The DT N
ketoconazole NN i
group NN N
showed VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
incidence NN o
of IN o
monofollicular JJ o
response NN o
( ( N
38 CD N
% NN N
) ) N
, , N
higher JJR o
pregnancy NN o
rates NNS o
, , N
and CC N
significantly RB o
less JJR o
marked JJ o
antiestrogenic NN o
manifestations NNS o
than IN N
did VBD N
the DT N
control NN N
group NN N
. . N

They PRP N
also RB N
had VBD N
significantly RB N
lower JJR N
incidence NN o
of IN o
clomiphene NN o
resistance NN o
( ( N
11.6 CD N
% NN N
) ) N
, , N
lower JJR o
serum NN o
testosterone NN o
levels NNS o
, , N
less JJR N
hyperinsulinaemia NN o
, , N
than IN N
did VBD N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Ketoconazole NNP i
improved VBD N
clomiphene JJ o
responsivenss NN o
in IN o
PCOS NNP o
patients NNS o
and CC N
attenuated VBD N
its PRP$ N
untoward JJ o
biological JJ o
effects NNS o
. . o

-DOCSTART- -X- O O

Laser-aided JJ i
external JJ i
drainage NN i
of IN p
subretinal JJ p
fluid NN p
: : p
prospective JJ N
randomized VBN N
comparison NN N
with IN N
needle JJ N
drainage NN N
. . N

In IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
50 CD p
consecutive JJ p
eyes NNS p
, , N
we PRP N
compared VBN N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
draining VBG N
subretinal JJ i
fluid NN i
transchoroidally RB i
in IN N
primary JJ N
scleral JJ N
buckling NN N
for IN N
rhegmatogenous JJ N
retinal JJ N
detachment NN N
using VBG N
a DT N
needle JJ i
, , N
with IN N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
the DT N
same JJ N
procedure NN N
using VBG N
an DT N
angulated VBN i
endolaser NN i
probe NN i
set VBN N
at IN N
1 CD N
W NNP N
for IN N
0.2 CD N
seconds NNS N
, , N
using VBG N
an DT N
average NN N
of IN N
2.4 CD N
laser NN N
burns NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
complications NNS o
associated VBN N
with IN N
the DT N
laser-aided JJ i
drainage NN i
procedures NNS N
( ( N
25 CD N
eyes NNS N
) ) N
. . N

In IN N
the DT N
transchoroidal NN i
needle JJ i
drainage NN i
procedures NNS N
( ( N
25 CD N
eyes NNS N
) ) N
, , N
subretinal JJ o
hemorrhage NN o
occurred VBD N
in IN N
three CD N
eyes NNS N
and CC N
retinal JJ N
incarceration NN N
in IN N
one CD N
. . N

Thus VB N
, , N
though IN N
our PRP$ N
numbers NNS N
are VBP N
small JJ N
, , N
there EX N
appears VBZ N
to TO N
be VB N
some DT N
advantage NN N
of IN N
laser-assisted JJ N
drainage NN N
in IN N
terms NNS N
of IN N
a DT N
lower JJR N
incidence NN o
of IN o
complications NNS o
. . o

-DOCSTART- -X- O O

Fludarabine NN i
in IN N
chronic JJ p
leukaemia NN p
. . p

-DOCSTART- -X- O O

MSL-109 NNP i
adjuvant JJ i
therapy NN i
for IN N
cytomegalovirus NN p
retinitis NN p
in IN p
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
: : p
the DT N
Monoclonal NNP N
Antibody NNP N
Cytomegalovirus NNP N
Retinitis NNP N
Trial NNP N
. . N

The DT p
Studies NNPS p
of IN p
Ocular JJ p
Complications NNS p
of IN p
AIDS NNP p
Research NNP p
Group NNP p
. . p

AIDS NNP p
Clinical JJ p
Trials NNP p
Group NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
an DT N
intravenous JJ N
human JJ N
monoclonal NN N
antibody NN N
to TO N
cytomegalovirus VB N
( ( N
CMV NNP N
) ) N
, , N
MSL-109 NNP i
, , N
as IN N
adjuvant JJ N
treatment NN N
for IN N
CMV NNP N
retinitis NN N
. . N

METHODS NNP N
Two CD p
hundred VBD p
nine CD p
patients NNS p
with IN p
acquired JJ p
immunodeficiency NN p
syndrome NN p
and CC p
active JJ p
CMV NNP p
retinitis NN p
were VBD p
enrolled VBN p
in IN p
a DT p
multicenter NN p
, , p
phase NN p
2/3 CD p
, , p
randomized VBN p
, , p
placebo-controlled JJ i
clinical JJ p
trial NN p
. . p

Patients NNS N
received VBD N
adjuvant JJ N
treatment NN N
with IN N
MSL-109 NNP i
, , N
60 CD N
mg NN N
intravenously RB N
every DT N
2 CD N
weeks NNS N
, , N
or CC N
placebo NN i
. . i

Randomization NN N
was VBD N
stratified VBN N
on IN N
the DT N
basis NN N
of IN N
whether IN N
patients NNS N
had VBD N
untreated VBN N
or CC N
relapsed VBN N
retinitis NN N
. . N

Primary JJ i
drug NN i
therapy NN i
for IN N
CMV NNP N
retinitis NN N
was VBD N
determined VBN N
by IN N
the DT N
treating NN N
physician NN N
. . N

RESULTS VB N
The DT N
rates NNS o
of IN o
retinitis NN o
progression NN o
, , N
as IN N
evaluated VBN N
in IN N
a DT N
masked JJ N
fashion NN N
, , N
were VBD N
3.04/person-year JJ N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
and CC N
3.05/person-year JJ N
in IN N
the DT N
placebo-treated JJ i
group NN N
( ( N
P=.98 NNP N
; : N
Wald NNP N
test NN N
) ) N
; : N
the DT N
median JJ N
times NNS N
to TO N
progression NN N
were VBD N
67 CD N
days NNS N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
and CC N
65 CD N
days NNS N
in IN N
the DT N
placebo-treated JJ N
group NN N
. . N

No DT N
differences NNS N
between IN N
the DT N
2 CD N
groups NNS N
were VBD N
noted VBN N
in IN N
the DT N
rates NNS o
of IN o
increase NN o
in IN o
retinal JJ o
area NN o
involved VBN o
by IN o
CMV NNP o
, , o
visual JJ o
field NN o
loss NN o
, , o
or CC o
visual JJ o
acuity NN o
outcomes NNS o
. . o

The DT N
mortality NN o
rate NN o
in IN N
the DT N
MSL-109-treated NNP i
group NN N
was VBD N
0.68/person-year JJ N
, , N
and CC N
in IN N
the DT N
placebo-treated JJ i
group NN N
, , N
0.31/person-year JJ N
( ( N
P=.01 NNP N
) ) N
. . N

The DT N
mortality NN o
difference NN N
was VBD N
not RB N
explained VBN N
by IN N
differences NNS N
in IN N
baseline NN N
variables NNS N
or CC N
in IN N
concurrent JJ N
antiretroviral JJ N
therapy NN N
. . N

Among IN p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
retinitis NN p
, , N
mortality NN o
rates NNS o
were VBD N
similar JJ N
( ( N
MSL-109 NNP N
, , N
0.41/person-year JJ N
; : N
placebo NN N
, , N
0.42/person-year JJ N
; : N
P=.95 NNP N
) ) N
, , N
whereas JJ N
among IN N
patients NNS N
with IN N
relapsed JJ N
retinitis NN N
the DT N
MSL-109-treated NNP i
group NN N
had VBD N
a DT N
greater JJR N
mortality NN o
rate NN o
( ( i
MSL-109 NNP i
, , N
0.83/person-year JJ N
; : N
placebo NN i
, , N
0.24/person-year JJ N
; : N
P=.003 NNP N
) ) N
. . N

However RB N
, , N
the DT N
mortality NN o
rate NN o
in IN N
the DT N
placebo-treated JJ i
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
with IN N
newly RB N
diagnosed VBN N
CMV NNP N
retinitis NN N
and CC N
lower JJR N
than IN N
that DT N
in IN N
other JJ N
trials NNS N
of IN N
patients NNS N
with IN N
relapsed JJ N
CMV NNP N
retinitis NN N
. . N

CONCLUSIONS NNP N
Intravenous NNP N
MSL-109 NNP i
, , N
60 CD N
mg NN N
every DT N
2 CD N
weeks NNS N
, , N
appeared VBD N
to TO N
be VB N
ineffective JJ o
adjuvant JJ N
therapy NN N
for IN N
CMV NNP N
retinitis NN N
. . N

The DT N
mortality NN o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
MSL-109-treated NNP i
group NN N
, , N
but CC N
the DT N
reasons NNS N
for IN N
this DT N
difference NN N
remain NN N
uncertain JJ N
. . N

-DOCSTART- -X- O O

Clofibrate NNP o
and CC o
diabetes VBZ o
control NN o
in IN N
patients NNS p
treated VBN p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
. . i

1 CD N
. . N

Twenty-two JJ p
maturity-onset JJ p
type NN p
diabetics NNS p
treated VBD p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
entered VBD N
a DT N
single-blind JJ N
crossover NN N
study NN N
using VBG N
placebo NN i
( ( N
periods VB N
A DT N
and CC N
C NNP N
, , N
2 CD N
months NNS N
each DT N
) ) N
and CC N
clofibrate NN i
( ( N
2 CD N
g/day NN N
; : N
period NN N
B NNP N
; : N
2 CD N
months NNS N
) ) N
. . N

2 CD N
. . N

In IN N
thirteen JJ p
patients NNS p
, , p
under IN p
reasonably RB p
good JJ p
control NN p
, , N
clofibrate NN i
did VBD N
not RB N
reduce VB o
fasting VBG o
or CC o
post-prandial JJ o
blood NN o
glucose NN o
, , N
nor CC N
24 CD o
h NN o
glycosuria NN o
; : o
no DT N
improvement NN N
was VBD N
noted VBN N
in IN N
the DT N
M-value NNP o
, , o
an DT o
index NN o
of IN o
diabetes NNS o
control NN o
. . o

3 CD N
. . N

In IN N
contrast NN N
, , N
in IN N
nine CD N
patients NNS N
, , N
with IN N
poor JJ N
diabetes NNS o
control NN o
, , N
clofibrate NN i
reduced VBD N
24 CD o
h NN o
glycosuria NN o
and CC N
significantly RB N
improved VBD N
the DT N
M-value NNP o
. . o

4 CD N
. . N

In IN N
all DT N
patients NNS N
, , N
clofibrate JJ i
therapy NN i
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
19-23 JJ N
% NN N
reduction NN N
in IN N
plasma NN o
fibrinogen NN o
. . o

5 CD N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
addition NN N
of IN N
clofibrate NN i
may MD N
be VB N
useful JJ N
in IN N
maturity-onset JJ p
diabetics NNS p
not RB p
adequately RB p
controlled VBN p
by IN p
diet NN p
combined VBN p
with IN p
oral JJ i
hypoglycaemic JJ i
agents NNS i
. . i

-DOCSTART- -X- O O

Trachoma NNP N
prevalence NN N
and CC N
associated VBN N
risk NN N
factors NNS N
in IN N
the DT p
gambia NN p
and CC p
Tanzania NNP p
: : p
baseline NN N
results NNS N
of IN N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Blinding NNP N
trachoma NN N
, , N
caused VBN N
by IN N
ocular JJ N
infection NN N
with IN N
Chlamydia NNP N
trachomatis NN N
, , N
is VBZ N
targeted VBN N
for IN N
global JJ N
elimination NN N
by IN N
2020 CD N
. . N

Knowledge NNP N
of IN N
risk NN N
factors NNS N
can MD N
help VB N
target VB N
control JJ N
interventions NNS N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
As IN N
part NN N
of IN N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
, , N
we PRP N
assessed VBD o
the DT o
baseline NN o
prevalence NN o
of IN o
, , o
and CC o
risk NN o
factors NNS o
for IN o
, , N
active JJ N
trachoma NN o
and CC N
ocular JJ o
C. NNP o
trachomatis NN o
infection NN o
in IN N
randomly RB p
selected VBN p
children NNS p
aged VBN p
0-5 CD p
years NNS p
from IN p
48 CD p
Gambian JJ p
and CC p
36 CD p
Tanzanian JJ p
communities NNS p
. . p

Both DT i
children NNS i
's POS i
eyes NNS i
were VBD i
examined VBN i
according VBG N
to TO N
the DT N
World NNP o
Health NNP o
Organization NNP o
( ( o
WHO NNP o
) ) o
simplified VBD o
grading VBG o
system NN o
, , N
and CC N
an DT i
ocular JJ o
swab NN o
was VBD i
taken VBN i
from IN i
each DT i
child NN i
's POS i
right JJ i
eye NN i
and CC i
processed VBN i
by IN i
Amplicor NNP o
polymerase NN o
chain NN o
reaction NN o
to TO i
test VB i
for IN i
the DT i
presence NN i
of IN i
C. NNP i
trachomatis NN i
DNA NNP i
. . i

Prevalence NN N
of IN N
active JJ N
trachoma NN N
was VBD N
6.7 CD N
% NN N
( ( N
335/5033 CD N
) ) N
in IN N
The DT p
Gambia NNP p
and CC N
32.3 CD N
% NN N
( ( N
1008/3122 CD N
) ) N
in IN N
Tanzania NNP p
. . p

The DT N
countries NNS N
' POS N
corresponding VBG N
Amplicor NNP o
positive JJ o
prevalences NNS o
were VBD N
0.8 CD N
% NN N
and CC N
21.9 CD N
% NN N
. . N

After IN N
adjustment NN N
, , N
risk NN N
factors NNS N
for IN N
follicular JJ N
trachoma NN N
( ( N
TF NNP N
) ) N
in IN N
both DT N
countries NNS N
were VBD N
ocular JJ o
or CC o
nasal JJ o
discharge NN o
, , N
a DT N
low JJ o
level NN o
of IN o
household NN o
head NN o
education NN o
, , N
and CC N
being VBG N
aged VBN o
? . o
1 CD o
year NN o
. . o

Additional NNP N
risk NN N
factors NNS N
in IN N
Tanzania NNP p
were VBD o
flies NNS o
on IN o
the DT o
child NN o
's POS o
face NN o
, , o
being VBG o
Amplicor NNP o
positive JJ o
, , o
and CC o
crowding NN o
( ( o
the DT N
number NN N
of IN N
children NNS N
per IN N
household NN N
) ) N
. . N

The DT N
risk NN N
factors NNS N
for IN N
being VBG o
Amplicor NNP o
positive JJ o
in IN o
Tanzania NNP p
were VBD p
similar JJ N
to TO N
those DT N
for IN N
TF NNP N
, , N
with IN N
the DT N
exclusion NN N
of IN N
flies NNS N
and CC N
crowding VBG N
. . N

In IN N
The DT p
Gambia NNP p
, , p
only RB o
ocular JJ o
discharge NN o
was VBD o
associated VBN N
with IN N
being VBG o
Amplicor NNP o
positive JJ o
. . o

CONCLUSIONS/SIGNIFICANCE NNP N
These DT N
results NNS N
indicate VBP N
that IN N
although IN N
the DT N
prevalence NN N
of IN N
active JJ N
trachoma NN N
and CC o
Amplicor NNP o
positives NNS o
were VBD o
very RB N
different JJ N
between IN N
the DT N
two CD N
countries NNS N
, , N
the DT N
risk NN N
factors NNS N
for IN N
active JJ N
trachoma NN N
were VBD N
similar JJ N
but CC N
those DT N
for IN N
being VBG o
Amplicor NNP o
positive JJ o
were VBD o
different JJ N
. . N

The DT N
lack NN N
of IN N
an DT N
association NN N
between IN N
being VBG N
Amplicor NNP N
positive JJ N
and CC N
TF NNP N
in IN N
The DT p
Gambia NNP p
highlights VBZ p
the DT N
poor JJ N
correlation NN N
between IN N
the DT N
presence NN N
of IN N
trachoma JJ o
clinical JJ o
signs NNS o
and CC o
evidence NN o
of IN o
C. NNP o
trachomatis NN o
infection NN o
in IN o
this DT N
setting NN N
. . N

Only RB o
ocular JJ o
discharge NN o
was VBD o
associated VBN N
with IN N
evidence NN N
of IN N
C. NNP N
trachomatis NN N
DNA NN N
in IN N
The DT p
Gambia NNP p
, , p
suggesting VBG N
that IN N
at IN N
this DT N
low JJ N
endemicity NN N
, , N
this DT N
may MD N
be VB N
the DT N
most RBS N
important JJ N
risk NN N
factor NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00792922 NNP N
. . N

-DOCSTART- -X- O O

Learning VBG N
about IN N
the DT N
equal JJ N
sign NN N
: : N
does VBZ N
comparing VBG N
with IN N
inequality NN N
symbols NNS N
help VB N
? . N
This DT i
study NN i
investigated VBD i
whether IN i
instruction NN i
that WDT i
involves VBZ i
comparing VBG i
the DT i
equal JJ i
sign NN i
with IN i
other JJ i
relational JJ i
symbols NNS i
is VBZ i
more RBR i
effective JJ i
at IN i
imparting VBG i
a DT i
relational JJ o
interpretation NN o
of IN o
the DT o
equal JJ o
sign NN o
than IN i
instruction NN i
about IN i
the DT i
equal JJ i
sign NN i
alone RB i
. . i

Third- JJ i
and CC i
fourth-grade JJ i
students NNS i
in IN i
a DT i
comparing NN i
symbols NNS i
group NN i
learned VBD i
about IN i
the DT i
greater JJR i
than IN i
, , i
less JJR i
than IN i
, , i
and CC i
equal JJ i
signs NNS i
and CC i
had VBD i
the DT i
opportunity NN i
to TO i
compare VB i
the DT i
inequality NN i
symbols VBZ i
with IN i
the DT i
equal JJ i
sign NN i
. . i

Students NNS i
in IN i
an DT i
equal JJ i
sign NN i
group NN i
learned VBD i
about IN i
the DT i
equal JJ i
sign NN i
only RB i
. . i

A NNP i
third JJ i
group NN i
of IN i
students NNS i
served VBD i
as IN i
a DT i
control NN i
group NN i
. . i

Three CD N
aspects NNS N
of IN N
students NNS N
' POS N
knowledge NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
lesson NN N
: : N
( ( N
a DT N
) ) N
conceptual JJ o
understanding NN o
of IN o
the DT o
equal JJ o
sign NN o
, , N
( ( N
b NN N
) ) N
equation NN o
encoding NN o
, , N
and CC N
( ( N
c NN N
) ) N
problem NN o
solving VBG o
. . o

Students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
showed VBD N
greater JJR N
gains NNS N
in IN N
conceptual JJ o
understanding NN o
from IN N
pretest NN N
to TO N
posttest VB N
than IN N
students NNS N
in IN N
the DT N
other JJ N
two CD N
groups NNS N
, , N
and CC N
students NNS N
in IN N
the DT N
comparing NN N
symbols NNS N
group NN N
also RB N
scored VBD N
higher JJR N
on IN N
a DT N
posttest NN o
that WDT o
assessed VBD o
knowledge NN o
about IN o
inequality NN o
symbols NNS o
and CC o
inequality NN o
problem NN o
solving VBG o
. . o

Thus RB N
, , N
they PRP N
learned VBD N
about IN N
three CD N
symbols NNS N
in IN N
the DT N
same JJ N
amount NN N
of IN N
time NN N
as IN N
other JJ N
students NNS N
learned VBD N
about IN N
the DT N
equal JJ N
sign NN N
alone RB N
or CC N
not RB N
at IN N
all DT N
. . N

Therefore NNP N
, , N
an DT N
instructional JJ N
approach NN N
involving VBG N
comparison NN N
can MD N
be VB N
an DT N
effective JJ N
tool NN N
for IN N
learning VBG N
about IN N
concepts NNS N
in IN N
mathematics NNS N
. . N

-DOCSTART- -X- O O

[ RB N
Clinical JJ N
trial NN N
of IN N
2 CD N
tobacco NN N
use NN N
cessation NN i
interventions NNS i
in IN N
primary JJ N
care NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
efficacy NN N
of IN N
two CD N
types NNS N
of IN N
intervention NN N
to TO N
stop VB N
tobacco NN o
dependency NN o
. . o

DESIGN NNP N
Randomised VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Primary NNP N
care NN N
centre NN N
. . N

PATIENTS NNP N
AND CC N
OTHER NNP N
PARTICIPANTS NNP N
Smokers NNP p
recruited VBD p
from IN p
among IN p
the DT p
health NN p
centre NN p
users NNS p
through IN p
the DT p
preventive JJ p
activities NNS p
and CC p
health NN p
promotion NN p
programme NN p
. . p

INTERVENTIONS NNP N
INDEPENDENT NNP i
VARIABLE NNP i
type NN i
of IN i
intervention NN i
. . i

General JJ N
variables NNS N
: : N
age NN N
, , N
sex NN N
, , N
marital JJ N
status NN N
, , N
educational JJ N
level NN N
, , N
work NN N
situation NN N
, , N
cohabitation NN N
with IN N
children NNS N
, , N
smokers NNS N
at IN N
home NN N
, , N
number NN N
of IN N
years NNS N
smoking VBG N
, , N
type NN N
of IN N
tobacco NN N
. . N

There EX N
were VBD N
two CD N
types NNS N
of IN N
intervention NN N
: : N
a DT N
) ) N
Minimal NNP i
Intervention NNP i
( ( N
MI NNP N
) ) N
. . N

b NN N
) ) N
Advanced NNP i
Intervention NNP i
( ( N
AI NNP N
) ) N
. . N

54 CD p
patients NNS p
were VBD p
included VBN p
, , p
with IN p
6 CD p
losses NNS p
. . p

21 CD p
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
the DT N
MI NNP i
group NN p
and CC N
27 CD p
to TO N
the DT N
AI NNP i
group NN p
. . p

Progress NNP N
was VBD N
measured VBN N
at IN N
15 CD N
days NNS N
, , N
1 CD N
month NN N
, , N
3 CD N
months NNS N
, , N
6 CD N
months NNS N
and CC N
a DT N
year NN N
. . N

RESULTS NNP N
In IN N
the DT N
MI NNP N
, , N
23.8 CD N
% NN N
were VBD N
abstinent JJ o
at IN N
15 CD N
days NNS N
; : N
the DT N
same JJ N
percentage NN N
at IN N
one CD N
month NN N
and CC N
3 CD N
months NNS N
; : N
19 CD N
% NN N
at IN N
6 CD N
months NNS N
; : N
and CC N
14.3 CD N
% NN N
remained VBD N
abstinent JJ o
after IN o
a DT o
year NN o
. . o

In IN N
the DT N
AI NNP N
, , N
51.9 CD N
% NN N
were VBD N
abstinent JJ o
at IN N
15 CD N
days NNS N
; : N
48.1 CD N
% NN N
at IN N
both DT N
one CD N
and CC N
3 CD N
months NNS N
; : N
25.9 CD N
% NN N
at IN N
6 CD N
months NNS N
; : N
and CC N
22.2 CD N
% NN N
were VBD N
still RB N
not RB o
smoking VBG o
after IN o
a DT o
year NN o
. . o

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
interventions NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
observations NNS N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
do VBP N
not RB N
show VB N
that IN N
one CD N
intervention NN N
is VBZ N
better RBR N
than IN N
the DT N
other JJ N
. . N

With IN N
the DT N
passage NN N
of IN N
time NN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
decreased VBN N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Obesity NN N
and CC N
mortality NN N
in IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
: : p
analysis NN N
of IN N
RTOG NNP N
85-31 JJ N
. . N

BACKGROUND NNP N
Greater NNP N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
is VBZ N
associated VBN N
with IN N
shorter JJR N
time NN N
to TO N
prostate-specific JJ N
antigen NN N
( ( N
PSA NNP N
) ) N
failure NN N
following VBG N
radical JJ i
prostatectomy NN i
and CC N
radiation NN i
therapy NN i
( ( N
RT NNP N
) ) N
. . N

Whether NNP N
BMI NNP N
is VBZ N
associated VBN N
with IN N
prostate JJ N
cancer-specific JJ N
mortality NN N
( ( N
PCSM NNP N
) ) N
was VBD N
investigated VBN N
in IN N
a DT N
large JJ N
randomized JJ N
trial NN N
of IN N
men NNS p
treated VBN p
with IN p
RT NNP i
and CC i
androgen JJ i
deprivation NN i
therapy NN i
( ( i
ADT NNP i
) ) i
for IN i
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

METHODS NNP N
Between NNP p
1987 CD p
and CC p
1992 CD p
, , p
945 CD p
eligible JJ p
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
were VBD p
enrolled VBN p
in IN p
a DT p
phase NN p
3 CD p
trial NN p
( ( p
RTOG NNP p
85-31 CD p
) ) p
and CC N
randomized VBN N
to TO N
RT NNP i
and CC i
immediate JJ i
goserelin NN i
or CC i
RT NNP i
alone RB i
followed VBD i
by IN i
goserelin NN i
at IN i
recurrence NN i
. . i

Height NNP N
and CC N
weight VBN N
data NNS N
were VBD N
available JJ N
at IN N
baseline NN N
for IN p
788 CD p
( ( p
83 CD p
% NN p
) ) p
subjects VBZ p
. . p

Cox NNP i
regression NN i
analyses NNS i
were VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
relations NNS N
between IN N
BMI NNP o
and CC o
all-cause JJ o
mortality NN o
, , o
PCSM NNP o
, , o
and CC o
nonprostate JJ o
cancer NN o
mortality NN o
. . o

Covariates NNS N
included VBD N
age NN N
, , N
race NN N
, , N
treatment NN N
arm NN N
, , N
history NN N
of IN N
prostatectomy NN N
, , N
nodal JJ N
involvement NN N
, , N
Gleason NNP N
score NN N
, , N
clinical JJ N
stage NN N
, , N
and CC N
BMI NNP N
. . N

RESULTS VB N
The DT N
5-year JJ o
PCSM NNP o
rate NN o
for IN N
men NNS N
with IN N
BMI NNP o
< NNP N
25 CD N
kg/m NN N
( ( N
2 CD N
) ) N
was VBD N
6.5 CD N
% NN N
, , N
compared VBN N
with IN N
13.1 CD N
% NN N
and CC N
12.2 CD N
% NN N
in IN N
men NNS N
with IN N
BMI NNP N
> NNP N
or CC N
=25 VB N
to TO N
< VB N
30 CD N
and CC N
BMI NNP N
> NNP N
or CC N
=30 NNP N
, , N
respectively RB N
( ( N
Gray NNP N
's POS N
P NNP N
= NNP N
.005 NNP N
) ) N
. . N

In IN N
multivariate NN N
analyses NNS N
, , N
greater JJR N
BMI NNP N
was VBD N
significantly RB N
associated VBN N
with IN N
higher JJR o
PCSM NNP o
( ( N
for IN N
BMI NNP N
> NNP N
or CC N
=25 VB N
to TO N
< VB N
30 CD N
, , N
hazard RB N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1.52 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-2.27 JJ N
, , N
P NNP N
= NNP N
.04 NNP N
; : N
for IN N
BMI NNP N
> NNP N
or CC N
=30 NNP N
, , N
HR NNP N
1.64 CD N
, , N
95 CD N
% NN N
CI NNP N
, , N
1.01-2.66 JJ N
, , N
P NNP N
= NNP N
.04 NNP N
) ) N
. . N

BMI NNP o
was VBD N
not RB N
associated VBN N
with IN N
nonprostate JJ o
cancer NN o
or CC N
all-cause JJ o
mortality NN o
. . o

CONCLUSIONS NNP N
Greater NNP N
baseline NN o
BMI NNP o
is VBZ N
independently RB N
associated VBN N
with IN N
higher JJR N
PCSM NN o
in IN N
men NNS p
with IN p
locally RB p
advanced JJ p
prostate NN p
cancer NN p
. . p

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
evaluate VB N
the DT N
mechanism NN N
( ( N
s NN N
) ) N
for IN N
increased VBN N
cancer-specific JJ o
mortality NN o
and CC N
to TO N
assess VB N
whether IN N
weight JJ o
loss NN o
after IN N
prostate JJ N
cancer NN N
diagnosis NN N
alters NNS N
disease VBP N
course NN N
. . N

-DOCSTART- -X- O O

Parenteral JJ N
nutrition NN N
and CC N
protein NN N
sparing NN N
after IN N
surgery NN i
: : i
do VBP N
we PRP N
need VB N
glucose RB i
? . N
Although IN N
capable JJ N
of IN N
inducing VBG N
an DT N
anabolic JJ N
state NN N
after IN N
surgery NN N
, , N
parenteral JJ i
nutrition NN i
, , N
including VBG N
glucose NN i
, , N
leads VBZ N
to TO N
hyperglycemia VB N
. . N

Even RB N
moderate JJ N
increases NNS N
in IN N
blood NN N
glucose NN N
are VBP N
associated VBN N
with IN N
poor JJ N
surgical JJ N
outcome NN N
. . N

We PRP N
examined VBD N
the DT N
hypothesis NN N
that WDT N
amino NN i
acids NNS i
, , N
in IN N
the DT N
absence NN N
of IN N
glucose JJ i
supply NN N
, , N
spare JJ N
protein NN N
while IN N
preventing VBG N
hyperglycemia NN N
. . N

In IN N
this DT N
prospective JJ N
study NN N
, , N
14 CD p
patients NNS p
with IN p
colonic JJ p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
a DT N
6-hour JJ N
stable JJ N
isotope NN i
infusion NN i
study NN N
( ( N
3 CD N
hours NNS N
of IN N
fasting VBG i
followed VBN N
by IN N
3-hour JJ N
infusions NNS N
of IN N
amino NN i
acids NNS i
, , i
Travasol NNP i
[ NNP N
Baxter NNP N
, , N
Montreal NNP N
, , N
Canada NNP N
] VBD N
10 CD N
% NN N
at IN N
0.02 CD N
mL.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
, , N
with IN i
or CC i
without IN i
glucose JJ i
at IN N
4 CD N
mg.kg NN N
( ( N
-1 NNP N
) ) N
.min NNP N
( ( N
-1 NNP N
) ) N
) ) N
on IN N
the DT N
second JJ N
day NN N
after IN N
colorectal JJ N
surgery NN N
. . N

Protein NNP o
breakdown NN o
, , o
protein JJ o
oxidation NN o
, , o
protein JJ o
balance NN o
, , o
and CC o
glucose JJ o
production NN o
were VBD N
assessed VBN N
by IN N
stable JJ N
isotope NN N
tracer NN N
kinetics NNS N
using VBG N
l- JJ N
[ JJ N
1- JJ N
( ( N
13 CD N
) ) N
C NNP N
] NNP N
leucine NN N
and CC N
[ JJ N
6,6- JJ N
( ( N
2 CD N
) ) N
H2 NNP N
] NNP N
glucose NN N
. . N

Circulating VBG o
concentrations NNS o
of IN o
glucose NN o
, , o
cortisol NN o
, , o
insulin NN o
, , o
and CC o
glucagon NN o
were VBD N
determined VBN N
. . N

The DT N
administration NN N
of IN N
amino JJ i
acids NNS i
increased VBD N
protein JJ o
balance NN o
from IN N
-16+/-4 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
in IN N
the DT N
fasted JJ N
state NN N
to TO N
16+/-3 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

Combined VBN N
infusion NN N
of IN N
amino JJ i
acids NNS i
and CC i
glucose VB i
increased JJ N
protein NN o
balance NN o
from IN N
-17+/-7 JJ N
to TO N
7+/-5 JJ N
micromol.kg NN N
( ( N
-1 NNP N
) ) N
.h NNP N
( ( N
-1 NNP N
) ) N
. . N

The DT N
increase NN N
in IN N
protein JJ o
balance NN o
during IN N
nutrition NN N
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
P=.07 NNP N
) ) N
. . N

Combined VBN N
administration NN N
of IN N
amino JJ i
acids NNS i
and CC i
glucose VB i
decreased VBN N
endogenous JJ o
glucose JJ o
production NN o
( ( N
P=.001 NNP N
) ) N
and CC N
stimulated VBN N
insulin NN o
secretion NN o
( ( N
P=.001 NNP N
) ) N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
the DT N
administration NN N
of IN N
amino JJ i
acids NNS i
alone RB N
. . N

Hyperglycemia NNP o
( ( N
blood NN N
glucose NN N
, , N
10.1+/-1.9 JJ N
micromol/L NN N
) ) N
occurred VBD N
only RB N
in IN N
the DT N
presence NN N
of IN N
glucose JJ i
infusion NN N
. . N

In IN N
summary JJ N
, , N
excluding VBG N
glucose NN i
from IN N
a DT N
short-term JJ N
feeding NN N
protocol NN N
does VBZ N
not RB N
diminish VB N
the DT N
protein-sparing JJ o
effect NN o
of IN N
amino NN i
acids NNS i
and CC N
avoids NNS N
hyperglycemia NN o
. . o

-DOCSTART- -X- O O

Severe NNP N
enteropathy NN N
among IN N
patients NNS p
with IN p
stage NN p
II/III NNP p
colon NN p
cancer NN p
treated VBN N
on IN N
a DT N
randomized JJ N
trial NN N
of IN N
bolus JJ i
5-fluorouracil/leucovorin JJ i
plus CC i
or CC i
minus CC i
oxaliplatin NN i
: : i
a DT N
prospective JJ N
analysis NN N
. . N

BACKGROUND NNP N
Cases NNP N
of IN N
severe JJ N
gastrointestinal JJ N
toxicity NN N
were VBD N
monitored VBN N
prospectively RB N
during IN N
NSABP NNP N
C-07 NNP N
, , N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
adjuvant JJ N
therapy NN N
for IN N
patients NNS p
with IN p
stage NN p
II/III NNP p
colon NN p
cancer NN p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
treated VBN N
with IN N
weekly JJ N
bolus NN i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
and CC i
leucovorin $ i
( ( N
FL NNP N
; : N
Roswell NNP N
Park NNP N
Regimen NNP N
) ) N
or CC N
the DT N
same JJ i
regimen NNS i
plus CC i
oxaliplatin NN i
( ( i
FLOX NNP i
) ) i
. . i

RESULTS NNP N
Of IN N
1857 CD p
patients NNS p
, , p
79 CD p
( ( p
4.3 CD p
% NN p
) ) p
developed VBD p
a DT p
syndrome NN o
of IN o
bowel NN o
wall NN o
injury NN o
( ( o
BWI NNP o
, , o
small JJ o
or CC o
large JJ o
) ) o
characterized VBN p
by IN p
hospitalization NN p
for IN p
the DT p
management NN p
of IN p
severe JJ o
diarrhea NN o
or CC o
dehydration NN o
and CC o
radiographic JJ o
or CC o
endoscopic JJ o
evidence NN o
of IN o
bowel NN o
wall NN o
thickening NN o
or CC o
ulceration NN o
. . o

Fifty-one CD N
( ( N
64.6 CD N
% NN N
) ) N
of IN N
these DT N
adverse JJ o
events NNS o
occurred VBD N
in IN N
patients NNS N
treated VBN N
with IN N
FLOX NNP i
and CC N
28 CD N
( ( N
35.4 CD N
% NN N
) ) N
in IN N
those DT N
treated VBN N
with IN N
FL NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Enteric JJ o
sepsis NN o
( ( o
ES NNP o
) ) o
, , N
characterized VBN N
by IN N
grade NN o
3 CD o
or CC o
greater JJR o
diarrhea NN o
and CC o
grade VBD o
4 CD o
neutropenia NN o
with IN o
or CC o
without IN o
proven JJ o
bacteremia NN o
occurred VBD N
in IN N
22 CD N
patients NNS N
treated VBN N
with IN N
FLOX NNP i
, , N
versus NN N
8 CD N
in IN N
those DT N
treated VBN N
with IN N
FL NNP i
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Patients NNPS N
> JJ N
60 CD N
years NNS N
were VBD N
at IN N
higher JJR o
risk NN o
for IN o
BWI NNP o
after IN N
treatment NN N
with IN N
FLOX NNP i
( ( N
6.7 CD N
% NN N
) ) N
versus NN N
treatment NN N
with IN N
FL NNP i
( ( N
2.9 CD N
% NN N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Female JJ N
patients NNS N
had VBD N
a DT N
higher JJR o
incidence NN o
of IN o
BWI NNP o
with IN N
FLOX NNP i
( ( N
9.1 CD N
% NN N
) ) N
than IN N
with IN N
FL NNP N
( ( N
3.9 CD N
% NN N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Severe JJ o
gastrointestinal JJ o
toxicity NN o
usually RB N
occurred VBD N
during IN N
the DT N
third JJ N
or CC N
fourth JJ N
week NN N
on IN N
the DT N
first JJ N
cycle NN N
of IN N
therapy NN N
, , N
required VBN N
hospitalization NN N
, , N
and CC N
was VBD N
managed VBN N
with IN N
fluids NNS N
, , N
antidiarrheals NNS N
, , N
and CC N
antibiotics NNS N
. . N

There EX N
were VBD N
5 CD N
deaths NNS o
( ( N
0.3 CD N
% NN N
) ) N
due JJ N
to TO N
enteropathy VB N
, , N
2 CD N
related VBN N
to TO N
ES NNP N
and CC N
3 CD N
related VBN N
to TO N
both DT N
BWI NNP N
and CC N
ES NNP N
. . N

Seventy-one CD N
percent NN N
of IN N
patients NNS N
resumed VBN N
treatment NN N
with IN N
FL NNP i
after IN N
recovery NN N
. . N

CONCLUSIONS NNP N
Patients NNPS N
treated VBD N
with IN N
adjuvant JJ N
FL NNP i
should MD N
be VB N
closely RB N
monitored VBN N
for IN N
diarrhea NN o
and CC N
aggressively RB N
managed VBN N
, , N
especially RB N
if IN N
oxaliplatin VBN N
has VBZ N
been VBN N
added VBN N
to TO N
the DT N
regimen NNS N
. . N

Society NN N
. . N

-DOCSTART- -X- O O

Pre-operative JJ i
radiochemotherapy NN i
for IN N
rectal JJ p
cancer NN p
. . p

A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
pre-operative JJ i
vs. FW i
postoperative JJ i
radiochemotherapy NN i
in IN N
rectal JJ p
cancer NN p
patients NNS p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
find VB N
out RP N
whether IN N
pre-operative JJ i
radiochemotherapy NN i
had VBD N
any DT N
survival JJ o
advantage NN o
over IN N
postoperative JJ i
radiochemotherapy NN i
for IN N
rectal JJ p
carcinoma NN p
patients NNS p
without IN p
distant JJ p
metastasis NN p
or CC p
peritoneal JJ p
carcinomatosis NN p
. . p

MATERIAL NNP N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1998 CD p
and CC p
December NNP p
2003 CD p
, , p
51 CD p
rectal JJ p
carcinoma NN p
patients NNS p
without IN p
distant JJ p
metastasis NN p
or CC p
peritoneal JJ p
carcinomatosis NN p
were VBD N
randomly RB N
divided VBN N
into IN N
pre-operative JJ i
( ( i
PRE NNP i
) ) i
and CC N
postoperative JJ i
( ( i
POST NNP i
) ) i
radiochemotherapy NN i
groups NNS N
. . N

Twenty-six CD N
were VBD N
assigned VBN N
to TO N
the DT N
PRE NNP N
group NN N
and CC N
were VBD N
operated VBN N
on IN N
5 CD N
to TO N
8 CD N
weeks NNS N
after IN N
the DT N
completion NN N
of IN N
radiotherapy NN i
. . i

The DT N
other JJ N
25 CD N
patients NNS N
were VBD N
operated VBN N
on IN N
immediately RB N
and CC N
received VBD N
radiotherapy NN N
postoperatively RB N
2 CD N
to TO N
4 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
between IN N
4 CD N
to TO N
51 CD N
months NNS N
. . N

RESULTS NNP N
In IN N
the DT N
PRE NNP N
group NN N
the DT N
rates NNS o
of IN o
disease-free JJ o
survival NN o
were VBD N
92 CD N
% NN N
, , N
70 CD N
% NN N
, , N
56 CD N
% NN N
and CC N
56 CD N
% NN N
at IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
POST NNP N
group NN N
those DT N
percentages NNS N
were VBD N
83 CD N
% NN N
, , N
68 CD N
% NN N
, , N
51 CD N
% NN N
and CC N
51 CD N
% NN N
at IN N
the DT N
1st CD N
, , N
2nd CD N
, , N
3rd CD N
and CC N
4th CD N
years NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.707 CD N
) ) N
. . N

One-year JJ o
and CC o
4-year JJ o
overall JJ o
survival NN o
rates NNS o
in IN N
the DT N
PRE NNP N
group NN N
were VBD N
100 CD N
% NN N
and CC N
86 CD N
% NN N
respectively RB N
and CC N
100 CD N
% NN N
and CC N
60 CD N
% NN N
in IN N
the DT N
POST NNP N
group NN N
( ( N
p JJ N
= NNP N
0.520 CD N
) ) N
. . N

CONCLUSION NNP N
No NNP N
statistical JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
survival JJ o
rates NNS o
of IN N
the DT N
rectal JJ p
carcinoma NN p
patients NNS p
receiving VBG N
radiotherapy NN N
either CC N
pre-operatively RB N
or CC N
postoperatively RB N
. . N

However RB N
, , N
the DT N
disease-free JJ o
survival NN o
rates NNS o
of IN N
the DT N
PRE NNP i
group NN N
were VBD N
higher JJR N
than IN N
the DT N
POST NNP i
group NN N
's POS N
during IN N
each DT N
year NN N
and CC N
overall JJ o
survival NN o
rates NNS o
were VBD N
higher JJR N
after IN N
the DT N
third JJ N
and CC N
fourth JJ N
years NNS N
. . N

We PRP N
conclude VBP N
that IN N
pre-operative JJ i
radiotherapy NN i
is VBZ N
at IN o
least JJS o
as RB o
effective JJ o
as IN o
postoperative JJ i
radiotherapy NN i
. . i

-DOCSTART- -X- O O

Effect NN N
of IN N
negative JJ i
air NN i
ionization NN i
on IN N
hyperactive JJ p
and CC p
autistic JJ p
children NNS p
. . p

Twenty-one CD p
attention NN p
deficit NN p
disorder NN p
with IN p
hyperactivity NN p
and CC p
seven CD p
autistic JJ p
children NNS p
were VBD N
randomly RB i
exposed VBN i
to TO i
negatively RB i
ionized JJ i
and CC i
ambient JJ i
atmospheres NNS i
under IN i
rigorously RB i
controlled VBN i
experimental JJ i
conditions NNS i
. . i

The DT N
negatively RB i
ionized JJ i
condition NN i
did VBD N
not RB N
significantly RB N
affect JJ N
measurements NNS N
of IN N
activity NN o
level NN o
, , o
impulsivity NN o
, , o
reality NN o
orientation NN o
, , o
destructive/constructiveness NN o
, , o
attention NN o
, , o
or CC o
task NN o
performance NN o
. . o

Significant JJ N
results NNS N
might MD N
be VB N
obtained VBN N
if IN N
subgroups NNS N
of IN N
known JJ p
hyperserotoninemic JJ p
autistic NN p
and CC p
attention NN p
deficit NN p
disorder NN p
children NNS p
were VBD N
exposed VBN N
to TO N
negatively RB i
ionized JJ i
conditions NNS i
. . i

-DOCSTART- -X- O O

Sinemet NNP i
CR NNP i
in IN p
Parkinson NNP p
's POS p
disease NN p
. . p

Sinemet NNP i
CR NNP i
, , N
a DT N
controlled JJ N
release NN N
carbidopa/levodopa NN i
preparation NN i
, , N
was VBD N
compared VBN N
to TO N
conventional JJ N
carbidopa/levodopa NN i
in IN N
a DT N
double JJ N
blind NN N
, , N
placebo-controlled JJ i
trial NN N
. . N

Comparable JJ o
clinical JJ o
benefits NNS o
and CC o
adverse JJ o
effects NNS o
were VBD N
noted VBN N
with IN N
the DT N
two CD N
medications NNS N
. . N

However RB N
significantly RB N
less RBR N
frequent JJ N
dosing NN N
was VBD N
necessary JJ N
with IN N
Sinemet NNP N
CR NNP N
. . N

-DOCSTART- -X- O O

Direct JJ i
renin NN i
inhibition NN i
improves VBZ N
parasympathetic JJ N
function NN N
in IN N
diabetes NNS p
. . p

AIM VB N
The DT N
renin-angiotensin-aldosterone NN N
system NN N
( ( N
RAAS NNP N
) ) N
and CC N
autonomic JJ N
nervous JJ N
system NN N
regulate VB N
the DT N
cardiovascular JJ N
system NN N
. . N

Blockade NN N
of IN N
the DT N
RAAS NNP N
may MD N
slow VB N
the DT N
progression NN N
of IN N
end-organ JJ N
damage NN N
. . N

Direct JJ i
renin NN i
inhibition NN i
offers VBZ N
a DT N
means NN N
for IN N
blocking VBG N
the DT N
RAAS NNP N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
direct JJ i
renin NN i
inhibition NN i
on IN N
cardiovascular JJ N
autonomic JJ N
function NN N
. . N

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
, , N
60 CD p
individuals NNS p
with IN p
diabetes NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
300 CD N
mg NN N
of IN N
aliskiren NN i
or CC i
placebo NN i
once RB N
daily JJ N
for IN N
6 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
a DT N
change NN o
in IN o
tests NNS o
of IN o
cardiovascular JJ o
autonomic JJ o
function NN o
. . o

Autonomic NNP o
function NN o
was VBD N
assessed VBN N
by IN N
power NN N
spectral JJ N
analysis NN N
and CC N
RR-variation NNP N
during IN N
deep JJ N
breathing NN N
[ JJ N
i.e NN N
. . N

mean VB N
circular JJ N
resultant NN N
( ( N
MCR NNP N
) ) N
, , N
expiration/inspiration NN N
( ( N
E/I NNP N
) ) N
ratio NN N
] NN N
. . N

The DT N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
assess NN N
parasympathetic JJ N
function NN N
. . N

Secondary JJ N
measures NNS N
included VBD N
change NN o
in IN o
biochemical JJ o
parameters NNS o
[ VBP o
e.g NN o
. . o

plasma JJ o
renin NN o
activity NN o
, , o
leptin NN o
and CC o
interleukin-6 JJ o
] NN o
. . o

Change NN o
in IN o
cardiovascular JJ o
autonomic JJ o
function NN o
and CC o
blood NN o
analytes NNS o
were VBD N
analysed VBN N
by IN N
a DT N
mixed JJ N
effects NNS N
model NN N
for IN N
repeated JJ N
measures NNS N
. . N

RESULTS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
similar JJ N
between IN N
treatment NN N
groups NNS N
. . N

In IN N
response NN N
to TO N
aliskiren NNS i
compared VBN N
with IN N
placebo NN i
, , N
blood NN o
pressure NN o
was VBD N
reduced VBN N
as RB N
well RB N
as IN N
plasma JJ N
renin NN N
activity NN N
[ VBP N
from IN N
2.4 CD N
? . N
3.8 CD N
( ( N
mean VB N
? . N
standard JJ N
deviation NN N
) ) N
to TO N
0.5 CD N
? . N
0.4 CD N
?g/l/h NN N
, , N
p NN N
< VBD N
0.001 CD N
] NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN i
( ( i
aliskiren VB i
? . i
visit NN i
) ) N
for IN N
MCR NNP N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
E/I NNP N
ratio NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
indicating VBG N
improvement NN N
in IN N
MCR NNP N
and CC N
E/I NNP N
ratio NN N
for IN N
those DT N
on IN i
aliskiren NNS i
. . i

MCR NNP i
means VBZ N
, , N
baseline VB N
vs. IN N
follow-up JJ N
, , N
were VBD N
41.8 CD N
? . N
19.7 CD N
vs. IN N
50.8 CD N
? . N
26.1 CD N
( ( i
aliskiren NN i
) ) i
and CC i
38.2 CD i
? . N
23.6 CD N
vs. IN N
37.5 CD N
? . N
24.1 CD N
( ( N
placebo NN i
) ) N
. . N

CONCLUSIONS NNP N
Parasympathetic NNP N
function NN N
( ( N
i.e JJ N
. . N

MCR NNP N
and CC N
E/I NNP N
ratio NN N
) ) N
was VBD N
enhanced VBN N
by IN N
downregulation NN N
of IN N
the DT N
RAAS NNP N
. . N

-DOCSTART- -X- O O

Cross-modal JJ N
attention-switching NN N
is VBZ N
impaired VBN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

This DT N
investigation NN N
aimed VBN N
to TO N
determine VB N
if IN N
children NNS p
with IN p
ASD NNP p
are VBP N
impaired VBN N
in IN N
their PRP$ N
ability NN N
to TO N
switch VB N
attention NN N
between IN N
different JJ N
tasks NNS N
, , N
and CC N
whether IN N
performance NN N
is VBZ N
further RB N
impaired JJ N
when WRB N
required VBN N
to TO N
switch VB N
across IN N
two CD N
separate JJ N
modalities NNS N
( ( N
visual JJ N
and CC N
auditory NN N
) ) N
. . N

Eighteen JJ p
children NNS p
with IN p
ASD NNP p
( ( p
9-13 CD p
years NNS p
old JJ p
) ) p
were VBD p
compared VBN p
with IN p
18 CD p
typically-developing JJ p
children NNS p
matched VBN p
with IN p
the DT p
ASD NNP p
group NN p
for IN p
mental JJ p
age NN p
, , p
and CC p
also RB p
with IN p
18 CD p
subjects NNS p
with IN p
learning VBG p
difficulties NNS p
matched VBN p
with IN p
the DT p
ASD NNP p
group NN p
for IN p
mental JJ p
and CC p
chronological JJ p
age NN p
. . p

Individuals NNS N
alternated VBD N
between IN N
two CD i
different JJ i
visual JJ i
tasks NNS i
, , i
and CC i
between IN i
a DT i
different JJ i
visual JJ i
task NN i
and CC i
an DT i
auditory JJ i
task NN i
. . i

Children NNP N
with IN N
ASD NNP N
performed VBD o
worse JJR o
than IN N
both DT N
comparison JJ N
groups NNS N
at IN N
both DT N
switching VBG o
tasks NNS o
. . o

Moreover RB N
, , N
children NNS N
with IN N
ASD NNP N
had VBD N
greater JJR o
difficulty NN o
when WRB o
different JJ o
modalities NNS o
were VBD o
required VBN o
than IN o
where WRB o
only RB o
one CD o
modality NN o
was VBD o
required VBN o
in IN o
the DT o
switching NN o
task NN o
in IN N
comparison NN N
with IN N
participants NNS N
matched VBN N
in IN N
terms NNS N
of IN N
mental NN N
and CC N
chronological JJ N
age NN N
. . N

-DOCSTART- -X- O O

Infant NNP N
distress NN N
and CC N
development NN N
of IN N
functional JJ N
gastrointestinal JJ N
disorders NNS N
in IN N
childhood NN N
: : N
is VBZ N
there EX N
a DT N
connection NN N
? . N
-DOCSTART- -X- O O

Effect NN N
of IN N
sulfasalazine NN i
on IN N
inflammation NN o
and CC o
endothelial JJ o
function NN o
in IN N
patients NNS p
with IN p
established VBN p
coronary JJ p
artery NN p
disease NN p
. . p

Inflammation NNP N
is VBZ N
critical JJ N
for IN N
atherosclerosis NN N
development NN N
and CC N
may MD N
be VB N
a DT N
target NN N
for IN N
risk-reduction NN N
therapy NN N
. . N

In IN N
experimental JJ N
studies NNS N
, , N
activation NN N
of IN N
the DT N
inflammatory JJ N
regulator NN N
, , N
nuclear JJ N
factor NN N
kappa NN N
B NNP N
( ( N
NFlB NNP N
) ) N
, , N
contributes VBZ N
to TO N
endothelial JJ N
activation NN N
and CC N
reduced JJ N
nitric JJ N
oxide NN N
production NN N
. . N

We PRP N
treated VBD N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
with IN N
sulfasalazine NN i
, , i
an DT i
inhibitor NN i
of IN i
NF?B NNP i
, , i
and CC i
placebo NN i
in IN i
a DT i
randomized JJ i
, , i
double-blind JJ i
, , i
crossover NN i
study NN i
design NN i
. . i

Brachial JJ o
artery JJ o
flow-mediated JJ o
dilation NN o
( ( o
FMD NNP o
) ) o
and CC o
digital JJ o
vascular JJ o
function NN o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
each DT N
6-week JJ N
treatment NN N
period NN N
. . N

Of IN N
the DT p
53 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
crossover NN p
study NN p
, , p
32 CD p
( ( p
age NN p
60 CD p
? . p
10 CD p
, , p
22 CD p
% NN p
female NN p
) ) p
completed VBD p
all PDT N
the DT N
visits NNS N
, , N
with IN N
a DT N
high JJ N
rate NN N
of IN N
study NN N
withdrawal NN N
due JJ N
to TO N
gastrointestinal JJ N
side NN N
effects NNS N
. . N

In IN N
a DT N
subset NN N
of IN N
10 CD p
participants NNS p
, , p
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
4 CD N
days NNS N
of IN N
sulfasalazine JJ i
treatment NN i
( ( N
n JJ N
= NNP N
5 CD N
) ) N
to TO N
no DT N
treatment NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
on IN N
NF?B-regulated JJ N
gene NN N
expression NN N
in IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS o
. . o

Tumor NNP o
necrosis JJ o
factor NN o
?-stimulated JJ o
expression NN o
of IN o
CD69 NNP o
and CC o
NFlB NNP o
subunit VBD o
p50 NN N
was VBD N
significantly RB N
blunted VBN N
after IN N
4 CD N
days NNS N
of IN N
sulfasalazine JJ N
treatment NN N
but CC N
not RB N
after IN N
no DT N
treatment NN N
. . N

However RB o
, , o
FMD NNP o
and CC o
digital JJ o
vasodilator NN o
response NN o
did VBD o
not RB N
significantly RB N
change VBP N
from IN N
baseline NN N
with IN N
long-term JJ i
sulfasalazine NN i
treatment NN i
. . N

Short-term JJ i
sulfasalazine NN i
inhibited VBN i
NFlB NNP N
activity NN N
; : N
however RB N
, , N
long-term JJ N
treatment NN N
was VBD N
poorly RB N
tolerated VBN N
and CC N
did VBD N
not RB N
improve VB N
endothelial JJ N
function NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
sulfasalazine JJ N
therapy NN N
is VBZ N
not RB N
the DT N
optimal JJ N
anti-inflammatory JJ N
treatment NN N
for IN N
reversing VBG N
endothelial JJ N
dysfunction NN N
in IN N
cardiovascular JJ N
disease NN N
. . N

Further JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
investigate VB N
the DT N
potential NN N
for IN N
NFlB NNP N
inhibition NN N
to TO N
reduce VB N
cardiovascular JJ N
risk NN N
. . N

-DOCSTART- -X- O O

[ JJ i
Radiotherapy NNP i
for IN N
choroidal JJ N
neovascularization NN N
in IN N
age-related JJ N
macular JJ N
degeneration NN N
. . N

A DT N
pilot NN N
study NN N
using VBG N
low- JJ i
versus NN i
high-dose JJ i
photon NN i
bean NN i
radiation NN i
] NN i
. . N

PURPOSE NNP N
Several JJ N
pilot NN N
studies NNS N
have VBP N
indicated VBN N
that IN N
low-dose JJ i
radiation NN i
therapy NN i
might MD N
have VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
course NN N
of IN N
choroidal JJ N
neovascularization NN N
( ( N
CNV NNP N
) ) N
in IN N
age-related JJ p
macular JJ p
degeneration NN p
( ( p
AMD NNP p
) ) p
. . p

This DT N
study NN N
aimed VBD N
to TO N
ascertain VB N
whether IN N
such JJ N
treatment NN N
might MD N
halt VB N
the DT N
progression NN N
of IN N
neovascular JJ N
AMD NNP N
and CC N
whether IN N
a DT N
low JJ N
or CC N
a DT N
high JJ N
radiation NN N
dose NN N
should MD N
be VB N
applied VBN N
. . N

PATIENTS VB N
The DT N
patients NNS p
comprised VBD p
some DT p
randomized VBN p
to TO p
0 CD i
vs NNS i
10 CD i
vs NNS i
36 CD i
Gy NNP i
of IN i
radiation NN i
and CC p
( ( p
after IN p
a DT p
change NN p
of IN p
the DT p
study NN p
protocol NN p
became VBD p
necessary JJ p
) ) p
others NNS p
who WP p
participated VBD p
in IN p
a DT p
prospective JJ p
, , p
controlled VBD p
non-randomized JJ p
pilot NN p
study NN p
. . p

Enclosed VBN N
were VBD N
eyes NNS p
with IN p
visual JJ p
acuity NN p
of IN p
> NN p
or CC p
= VB p
0.1 CD p
and CC p
< NNP p
or CC p
= $ p
0.6 CD p
revealing VBG p
a DT p
juxta-subfoveal JJ p
CNV NNP p
either NN p
of IN p
the DT p
occult NN p
type NN p
( ( p
type JJ p
1 CD p
) ) p
or CC p
the DT p
classic JJ p
type NN p
( ( p
isolated JJ p
or CC p
as IN p
part NN p
of IN p
a DT p
predominantly RB p
occult JJ p
lesion NN p
) ) p
. . p

RESULTS NNP N
Eyes NNP N
treated VBD N
with IN N
10 CD i
Gy NNP i
for IN N
occult NN N
CNV NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
were VBD N
subject JJ N
to TO N
severe JJ o
visual JJ o
loss NN o
in IN N
41.6 CD N
% NN N
of IN N
the DT N
cases NNS N
compared VBN N
to TO N
38.5 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
13 CD N
) ) N
at IN N
12 CD N
months NNS N
of IN N
follow-up NN N
. . N

For IN N
eyes NNS N
treated VBN N
with IN N
10 CD i
Gy NNP i
because IN N
of IN N
classic JJ N
CNV NNP N
, , N
the DT N
corresponding JJ N
figures NNS N
were VBD N
33 CD N
% NN N
( ( N
n JJ N
= NNP N
18 CD N
) ) N
and CC N
57 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
respectively RB N
. . N

At IN N
18 CD N
months NNS N
of IN N
follow-up NN N
, , N
the DT N
percentages NNS N
were VBD N
63 CD N
% NN N
and CC N
75 CD N
% NN N
respectively RB N
. . N

Fluorescein NNP o
angiographic JJ o
growth NN o
of IN o
classic JJ o
and CC o
occult NN o
CNV NNP o
could MD N
not RB N
be VB N
halted VBN N
by IN N
10 CD N
Gy NNP N
, , N
while IN N
a DT N
temporary JJ o
growth NN o
retardation NN o
was VBD N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD i
Gy NNP i
. . i

CONCLUSION NNP N
In IN N
the DT N
study NN N
presented VBD N
, , N
the DT N
natural JJ N
course NN N
of IN N
occult NN N
CNV NNP N
could MD N
not RB N
be VB N
improved VBN N
by IN N
irradiation NN N
with IN N
10 CD i
or CC i
36 CD i
Gy NNP i
. . i

In IN N
cases NNS N
of IN N
classic JJ N
CNV NNP N
, , N
low-dose JJ N
irradiation NN N
with IN N
10 CD i
Gy NNP i
postponed VBD N
severe JJ o
visual JJ o
loss NN o
by IN N
a DT N
maximum NN N
of IN N
18 CD N
months NNS N
. . N

A DT N
positive JJ N
treatment NN N
effect NN N
was VBD N
also RB N
observed VBN N
in IN N
cases NNS N
irradiated VBN N
with IN N
36 CD i
Gy NNP i
; : i
however RB N
, , N
a DT N
25 CD N
% NN N
incidence NN N
of IN N
radiation NN N
retinopathy NN N
seems VBZ N
unacceptable JJ N
. . N

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
liberal JJ i
versus NN i
restrictive JJ i
guidelines NNS i
for IN i
red JJ i
blood NN i
cell NN i
transfusion NN i
in IN N
preterm JJ p
infants NNS p
. . p

OBJECTIVE NNP N
Although IN N
many JJ N
centers NNS N
have VBP N
introduced VBN N
more RBR N
restrictive JJ N
transfusion NN N
policies NNS N
for IN N
preterm JJ p
infants NNS p
in IN N
recent JJ N
years NNS N
, , N
the DT N
benefits NNS N
and CC N
adverse JJ N
consequences NNS N
of IN N
allowing VBG N
lower JJR N
hematocrit NN N
levels NNS N
have VBP N
not RB N
been VBN N
systematically RB N
evaluated VBN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
restrictive JJ i
guidelines NNS i
for IN i
red JJ i
blood NN i
cell NN i
( ( i
RBC NNP i
) ) i
transfusions NNS i
for IN N
preterm JJ N
infants NNS N
can MD N
reduce VB N
the DT N
number NN o
of IN o
transfusions NNS o
without IN N
adverse JJ N
consequences NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
enrolled VBD N
100 CD p
hospitalized JJ p
preterm NN p
infants NNS p
with IN p
birth JJ p
weights NNS p
of IN p
500 CD p
to TO p
1300 CD p
g NN p
into IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
2 CD N
levels NNS N
of IN N
hematocrit NN N
threshold NN N
for IN N
RBC NNP N
transfusion NN N
. . N

INTERVENTION NNP N
The DT N
infants NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
either VB N
the DT N
liberal- NN i
or CC i
the DT i
restrictive-transfusion NN i
group NN N
. . N

For IN N
each DT N
group NN N
, , N
transfusions NNS N
were VBD N
given VBN N
only RB N
when WRB N
the DT N
hematocrit NN N
level NN N
fell VBD N
below IN N
the DT N
assigned JJ N
value NN N
. . N

In IN N
each DT N
group NN N
, , N
the DT N
transfusion NN N
threshold NN N
levels NNS N
decreased VBN N
with IN N
improving VBG N
clinical JJ N
status NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
We PRP N
recorded VBD N
the DT N
number NN o
of IN o
transfusions NNS o
, , o
the DT o
number NN o
of IN o
donor JJ o
exposures NNS o
, , o
and CC o
various JJ o
clinical JJ o
and CC o
physiologic JJ o
outcomes NNS o
. . o

RESULTS JJ N
Infants NNS N
in IN N
the DT N
liberal-transfusion NN N
group NN N
received VBD N
more JJR N
RBC JJ o
transfusions NNS o
( ( N
5.2 CD N
+/- JJ N
4.5 CD N
[ JJ N
mean JJ N
+/- JJ N
SD NNP N
] NNP N
vs VBD N
3.3 CD N
+/- JJ N
2.9 CD N
in IN N
the DT N
restrictive-transfusion NN i
group NN N
) ) N
. . N

However RB N
, , N
the DT N
number NN o
of IN o
donors NNS o
to TO N
whom WP N
the DT N
infants NNS N
were VBD N
exposed VBN N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
2.8 CD N
+/- JJ N
2.5 CD N
vs JJ N
2.2 CD N
+/- JJ N
2.0 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
the DT N
percentage NN o
of IN o
infants NNS o
who WP o
avoided VBD o
transfusions NNS o
altogether RB o
( ( N
12 CD N
% NN N
in IN N
the DT N
liberal-transfusion NN N
group NN N
versus VBD N
10 CD N
% NN N
in IN N
the DT N
restrictive-transfusion NN N
group NN N
) ) N
. . N

Infants NNS N
in IN N
the DT N
restrictive-transfusion NN i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
intraparenchymal JJ o
brain NN o
hemorrhage NN o
or CC o
periventricular JJ o
leukomalacia NN o
, , N
and CC N
they PRP N
had VBD N
more RBR o
frequent JJ o
episodes NNS o
of IN o
apnea NN o
, , N
including VBG N
both DT N
mild JJ o
and CC o
severe JJ o
episodes NNS o
. . o

CONCLUSIONS NNP N
Although IN N
both DT N
transfusion NN i
programs NNS N
were VBD N
well RB N
tolerated VBN N
, , N
our PRP$ N
finding NN N
of IN N
more RBR N
frequent JJ N
major JJ o
adverse JJ o
neurologic NN o
events NNS o
in IN N
the DT N
restrictive JJ i
RBC-transfusion NNP i
group NN N
suggests VBZ N
that IN N
the DT N
practice NN N
of IN N
restrictive JJ i
transfusions NNS i
may MD N
be VB N
harmful JJ N
to TO N
preterm VB N
infants NNS N
. . N

-DOCSTART- -X- O O

Stress NNP i
reduction NN i
prolongs NNS N
life NN N
in IN N
women NNS p
with IN p
coronary JJ p
disease NN p
: : p
the DT N
Stockholm NNP N
Women NNP N
's POS N
Intervention NNP N
Trial NNP N
for IN N
Coronary NNP N
Heart NNP N
Disease NNP N
( ( N
SWITCHD NNP N
) ) N
. . N

BACKGROUND NNP N
Psychosocial NNP N
stress NN N
may MD N
increase VB N
risk NN N
and CC N
worsen JJ N
prognosis NN N
of IN N
coronary JJ p
heart NN p
disease NN p
in IN p
women NNS p
. . p

Interventions NNS N
that IN N
counteract JJ N
women NNS N
's POS N
psychosocial JJ N
stress NN N
have VBP N
not RB N
previously RB N
been VBN N
presented VBN N
. . N

This DT N
study NN N
implemented VBD N
a DT N
stress JJ i
reduction NN i
program NN i
for IN N
women NNS p
and CC N
investigated VBD N
its PRP$ N
ability NN N
to TO N
improve VB N
survival NN o
in IN o
women NNS o
coronary JJ o
patients NNS o
. . o

METHODS NNP N
AND CC N
RESULTS NNP N
Two CD p
hundred VBD p
thirty-seven JJ p
consecutive JJ p
women NNS p
patients NNS p
, , p
aged VBD p
75 CD p
years NNS p
or CC p
younger JJR p
, , p
hospitalized VBN p
for IN p
acute JJ p
myocardial JJ p
infarction NN p
, , p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
, , p
or CC p
percutaneous JJ p
coronary JJ p
intervention NN p
were VBD N
randomized VBN N
to TO N
a DT N
group-based JJ i
psychosocial JJ i
intervention NN i
program NN i
or CC i
usual JJ i
care NN i
. . i

Initiated VBN N
4 CD N
months NNS N
after IN N
hospitalization NN N
, , N
intervention NN N
groups NNS N
of IN N
4 CD N
to TO N
8 CD N
women NNS N
met VBD N
for IN N
a DT N
total NN N
of IN N
20 CD N
sessions NNS N
that WDT N
were VBD N
spread VBN N
over IN N
a DT N
year NN N
. . N

We PRP N
provided VBD N
education NN i
about IN i
risk NN i
factors NNS i
, , i
relaxation NN i
training NN i
techniques NNS i
, , i
methods NNS i
for IN i
self-monitoring NN i
and CC i
cognitive JJ i
restructuring NN i
, , i
with IN i
an DT i
emphasis NN i
on IN i
coping VBG i
with IN i
stress JJ i
exposure NN i
from IN i
family NN i
and CC i
work NN i
, , i
and CC i
self-care NN i
and CC i
compliance NN i
with IN i
clinical JJ i
advice NN i
. . i

From IN N
randomization NN N
until IN N
end NN N
of IN N
follow-up NN N
( ( N
mean JJ N
duration NN N
, , N
7.1 CD N
years NNS N
) ) N
, , N
25 CD N
women NNS N
( ( N
20 CD N
% NN N
) ) N
in IN N
the DT N
usual JJ N
care NN N
and CC N
8 CD N
women NNS N
( ( N
7 CD N
% NN N
) ) N
in IN N
the DT N
stress NN o
reduction NN o
died VBD N
, , N
yielding VBG N
an DT N
almost RB N
3-fold JJ N
protective JJ N
effect NN N
of IN N
the DT N
intervention NN N
( ( N
odds NNS N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.15 CD N
to TO N
0.74 CD N
; : N
P=0.007 NNP N
) ) N
. . N

Introducing VBG N
baseline JJ N
measures NNS N
of IN N
clinical JJ N
prognostic JJ N
factors NNS N
, , N
including VBG N
use NN o
of IN o
aspirin NN o
, , o
beta-blockers NNS o
, , o
angiotensin-converting JJ o
enzyme NN o
inhibitors NNS o
, , o
calcium-channel JJ o
blockers NNS o
, , o
and CC o
statins VBZ o
into IN i
multivariate NN i
models NNS i
confirmed VBD N
the DT N
unadjusted JJ N
results NNS N
( ( N
P=0.009 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Although IN N
mechanisms NN N
remain VBP N
unclear JJ N
, , N
a DT N
group-based JJ i
psychosocial JJ i
intervention NN i
program NN i
for IN N
women NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
may MD N
prolong VB N
lives NNS N
independent JJ N
of IN N
other JJ N
prognostic JJ N
factors NNS N
. . N

-DOCSTART- -X- O O

Opioid-immune JJ N
interactions NNS N
in IN N
autism NN p
: : p
behavioural JJ N
and CC N
immunological JJ N
assessment NN N
during IN N
a DT N
double-blind JJ N
treatment NN N
with IN N
naltrexone NN i
. . i

The DT N
emerging VBG N
concept NN N
of IN N
opioid JJ N
peptides NNS N
as IN N
a DT N
new JJ N
class NN N
of IN N
chemical JJ N
messengers NNS N
of IN N
the DT N
neuroimmune JJ N
axis NN N
and CC N
the DT N
presence NN N
of IN N
a DT N
number NN N
of IN N
immunological JJ N
abnormalities NNS N
in IN N
infantile JJ N
autism NN N
prompted VBD N
us PRP N
to TO N
correlate VB N
biological JJ N
( ( N
hormonal JJ N
and CC N
immunological JJ N
) ) N
determinations NNS N
and CC N
behavioural JJ N
performances NNS N
during IN N
treatment NN N
with IN N
the DT N
potent NN N
opiate JJ N
antagonist NN N
, , N
naltrexone NN i
( ( i
NAL NNP i
) ) i
. . i

Twelve NNP p
autistic JJ p
patients NNS p
ranging VBG p
from IN p
7 CD p
to TO p
15 CD p
years NNS p
, , p
diagnosed VBD p
according VBG p
to TO p
DSM-III-R NNP p
, , N
entered VBD N
a DT N
double-blind JJ i
crossover NN i
study NN i
with IN i
NAL NNP i
at IN i
the DT i
doses NNS i
of IN i
0.5 CD i
, , i
1.0 CD i
and CC i
1.5 CD i
mg/kg NN i
every DT i
48 CD i
hours NNS i
. . i

The DT i
behavioural JJ i
evaluation NN i
was VBD i
conducted VBN i
using VBG i
the DT i
specific JJ i
BSE NNP o
and CC o
CARS NNP o
rating NN o
scales NNS o
NAL NNP i
treatment NN i
produced VBD i
a DT i
significant JJ i
reduction NN i
of IN i
the DT i
autistic JJ o
symptomatology NN o
in IN i
seven CD i
( ( i
responders NNS i
) ) i
out IN i
of IN i
12 CD i
children NNS i
. . i

The DT N
behavioural JJ N
improvement NN N
was VBD N
accompanied VBN N
by IN N
alterations NNS N
in IN N
the DT N
distribution NN N
of IN N
the DT N
major JJ N
lymphocyte NN N
subsets NNS N
, , N
with IN N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
T-helper-inducers NNP o
( ( o
CD4+CD8- NNP o
) ) o
and CC N
a DT N
significant JJ N
reduction NN N
of IN N
the DT N
T-cytotoxic-suppressor NNP o
( ( o
CD4-CD8+ NNP o
) ) o
resulting VBG N
in IN N
a DT N
normalization NN N
of IN N
the DT N
CD4/CD8 NNP o
ratio NN o
. . o

Changes NNS N
in IN N
natural JJ o
killer NN o
cells NNS o
and CC o
activity NN o
were VBD N
inversely RB N
related VBN N
to TO N
plasma VB N
beta-endorphin JJ N
levels NNS N
. . N

It PRP N
is VBZ N
suggested VBN N
that IN N
the DT N
mechanisms NNS N
underlying VBG N
opioid-immune JJ N
interactions NNS N
are VBP N
altered VBN N
in IN N
this DT N
population NN p
of IN p
autistic JJ p
children NNS p
and CC N
that DT N
an DT N
immunological JJ N
screening NN N
may MD N
have VB N
prognostic JJ N
value NN N
for IN N
the DT N
pharmacological JJ i
therapy NN i
with IN i
opiate JJ i
antagonists NNS i
. . i

-DOCSTART- -X- O O

Superior JJ N
survival NN o
with IN N
capecitabine JJ i
plus CC i
docetaxel JJ i
combination NN i
therapy NN i
in IN N
anthracycline-pretreated JJ p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
: : p
phase NN N
III NNP N
trial NN N
results NNS N
. . N

PURPOSE NNP N
Docetaxel NNP i
and CC i
capecitabine NN i
, , N
a DT N
tumor-activated JJ N
oral JJ N
fluoropyrimidine NN N
, , N
show VBP N
high JJ N
single-agent JJ N
efficacy NN N
in IN N
metastatic JJ p
breast NN p
cancer NN p
( ( N
MBC NNP N
) ) N
and CC N
synergy NN N
in IN N
preclinical JJ N
studies NNS N
. . N

This DT N
international JJ N
phase NN N
III NNP N
trial NN N
compared VBN N
efficacy NN o
and CC o
tolerability NN o
of IN N
capecitabine/docetaxel JJ i
therapy NN i
with IN N
single-agent JJ i
docetaxel NN i
in IN N
anthracycline-pretreated JJ p
patients NNS p
with IN p
MBC NNP p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
21-day JJ N
cycles NNS N
of IN N
oral JJ N
capecitabine NN i
1,250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
twice RB N
daily RB N
on IN N
days NNS N
1 CD N
to TO N
14 CD N
plus CC N
docetaxel JJ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
( ( N
n JJ N
= NNP N
255 CD N
) ) N
or CC N
to TO N
docetaxel VB i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
( ( N
n JJ N
= NNP N
256 CD N
) ) N
. . N

RESULTS NNP N
Capecitabine/docetaxel NNP i
resulted VBD N
in IN N
significantly RB N
superior JJ N
efficacy NN o
in IN N
time NN o
to TO o
disease VB o
progression NN o
( ( o
TTP NNP o
) ) o
( ( N
hazard JJ N
ratio NN N
, , N
0.652 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.545 CD N
to TO N
0.780 CD N
; : N
P NNP N
=.0001 NNP N
; : N
median JJ N
, , N
6.1 CD N
v NN N
4.2 CD N
months NNS N
) ) N
, , N
overall JJ o
survival NN o
( ( N
hazard JJ N
ratio NN N
, , N
0.775 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.634 CD N
to TO N
0.947 CD N
; : N
P NNP N
=.0126 NNP N
; : N
median JJ N
, , N
14.5 CD N
v NN N
11.5 CD N
months NNS N
) ) N
, , N
and CC N
objective JJ o
tumor NN o
response NN o
rate NN o
( ( N
42 CD N
% NN N
v JJ N
30 CD N
% NN N
, , N
P NNP N
=.006 NNP N
) ) N
compared VBN N
with IN N
docetaxel NN i
. . i

Gastrointestinal JJ o
side NN o
effects NNS o
and CC o
hand-foot JJ o
syndrome NN o
were VBD N
more JJR N
common JJ N
with IN N
combination NN i
therapy NN i
, , N
whereas JJ N
myalgia NN o
, , o
arthralgia NN o
, , N
and CC N
neutropenic JJ o
fever/sepsis NN o
were VBD N
more JJR N
common JJ N
with IN N
single-agent JJ i
docetaxel NN i
. . i

More JJR N
grade JJ o
3 CD o
adverse JJ o
events NNS o
occurred VBD N
with IN N
combination NN i
therapy NN i
( ( N
71 CD N
% NN N
v JJ N
49 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
whereas JJ N
grade VBP o
4 CD o
events NNS o
were VBD N
slightly RB N
more RBR N
common JJ N
with IN N
docetaxel NN i
( ( N
31 CD N
% NN N
v JJ N
25 CD N
% NN N
with IN N
combination NN N
) ) N
. . N

CONCLUSION VB N
The DT N
significantly RB N
superior JJ N
TTP NNP o
and CC o
survival NN o
achieved VBN N
with IN N
the DT N
addition NN i
of IN i
capecitabine NN i
to TO i
docetaxel VB i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
with IN N
the DT N
manageable JJ N
toxicity NN o
profile NN o
, , N
indicate VBP N
that IN N
this DT N
combination NN i
provides VBZ N
clear JJ N
benefits NNS N
over IN N
single-agent JJ i
docetaxel NN i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

Docetaxel/capecitabine NNP i
therapy NN i
is VBZ N
an DT N
important JJ N
treatment NN N
option NN N
for IN N
women NNS p
with IN p
anthracycline-pretreated JJ p
MBC NNP p
. . p

-DOCSTART- -X- O O

Fake NNP p
bad JJ p
test NN p
response NN p
bias NN p
effects NNS p
on IN N
the DT N
test NN o
of IN o
variables NNS o
of IN o
attention NN o
. . o

This DT N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
faking VBG i
bad JJ i
( ( i
FB NNP i
) ) i
on IN i
the DT i
Test NNP i
of IN i
Variables NNP i
of IN i
Attention NNP i
( ( i
TOVA NNP i
) ) i
using VBG p
subjects NNS p
randomly RB N
placed VBN N
into IN N
two CD N
groups NNS N
. . N

Subjects NNS N
in IN N
Group NNP N
1 CD N
took VBD N
the DT N
TOVA NNP i
under IN i
normal JJ i
conditions NNS i
( ( i
NC NNP i
) ) i
first RB N
; : N
they PRP N
were VBD N
then RB N
requested VBN N
to TO N
subtly RB i
fake VB i
bad JJ i
. . i

Group NNP N
2 CD N
subjects NNS N
took VBD N
the DT N
TOVA NNP i
under IN i
the DT i
same JJ i
fake JJ i
bad JJ i
instructions NNS i
first RB i
, , i
then RB i
took VBD i
the DT i
test NN i
under IN i
normal JJ i
conditions NNS i
the DT i
second JJ i
time NN i
. . i

An DT N
analysis NN N
of IN N
the DT N
effects NNS N
of IN N
test NN N
order NN N
yielded VBN N
non-significant JJ N
differences NNS N
for IN N
basic JJ N
TOVA NNP o
variables NNS o
across IN N
all DT N
four CD N
quarters NNS N
, , N
both DT N
halves NNS N
and CC N
the DT N
total JJ N
score NN N
. . N

An DT N
analysis NN N
for IN N
group NN N
mean NN N
differences NNS N
between IN N
the DT N
NC NNP N
and CC N
the DT N
FB NNP N
instructions NNS N
yielded VBD N
significant JJ N
differences NNS N
across IN N
the DT N
basic JJ o
TOVA NNP o
variables NNS o
across IN N
the DT N
four CD N
quarters NNS N
, , N
two CD N
halves NNS N
and CC N
total JJ N
score NN N
. . N

The DT N
FB NNP N
group NN N
had VBD N
excessive JJ N
amounts NNS o
of IN o
omission NN o
and CC o
commission NN o
errors NNS o
, , N
a DT N
greater JJR N
response NN o
time NN o
mean NN o
( ( N
i.e. FW N
, , N
slower JJR N
to TO N
respond VB N
) ) N
and CC N
had VBD N
greater JJR N
variance NN o
around IN o
their PRP$ o
mean JJ o
response NN o
time NN o
. . o

The DT N
study NN N
affirms VBZ N
that IN N
the DT N
professional JJ N
using VBG N
the DT N
TOVA NNP N
needs VBZ N
to TO N
carefully RB N
eliminate VB N
a DT N
fake JJ N
bad JJ N
test-taking NN N
bias NN N
when WRB N
subjects NNS N
produce VBP N
excessive JJ N
test NN N
results NNS N
. . N

-DOCSTART- -X- O O

Changes NNS N
of IN N
activated JJ N
circulating VBG N
endothelial JJ N
cells NNS N
and CC N
survivin NN N
in IN N
patients NNS p
with IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
after IN p
antiangiogenesis NN i
therapy NN i
. . i

BACKGROUND NNP N
Although IN N
antiangiogenesis NN i
therapy NN i
plays VBZ N
an DT N
important JJ N
role NN N
in IN N
anti-neoplastic JJ i
treatment NN i
with IN N
its PRP$ N
recognized VBN N
efficacy NN N
and CC N
slight JJ N
adverse JJ N
effect NN N
, , N
there EX N
is VBZ N
no DT N
prospective JJ N
clinical JJ N
trial NN N
to TO N
define VB N
ideal JJ N
markers NNS N
for IN N
predicting VBG N
efficacy NN N
of IN N
antiangiogenic JJ i
therapy NN i
. . i

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
investigate VB N
the DT N
changes NNS N
of IN N
activated JJ N
circulating VBG N
endothelial JJ N
cells NNS N
( ( N
aCECs NN N
) ) N
and CC N
survivin JJ N
after IN N
anti-angiogenesis JJ N
therapy NN N
and CC N
their PRP$ N
significance NN N
in IN N
predicting VBG N
the DT N
efficacy NN N
of IN N
the DT N
therapy NN N
. . N

METHODS NNP N
Patients NNPS p
of IN p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
treated VBD p
with IN p
chemotherapy NN i
with IN i
or CC i
without IN i
Endostar NNP i
were VBD N
observed VBN N
. . N

The DT N
amount NN N
of IN N
activated JJ N
CECs NNP N
was VBD N
detected VBN N
by IN N
flow JJ N
cytometry NN N
, , N
and CC N
the DT N
expression NN N
of IN N
survivin NN N
mRNA NN N
was VBD N
determined VBN N
by IN N
real-time JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
PCR NNP N
) ) N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
amount NN N
of IN N
activated JJ o
CECs NNP o
decreased VBD N
significantly RB N
in IN N
clinical JJ N
benefit NN N
cases NNS N
( ( N
P NNP N
= VBZ N
0.021 CD N
in IN N
chemotherapy NN i
alone RB N
, , N
P NNP N
= VBZ N
0.001 CD N
in IN N
chemotherapy NN i
plus CC i
Endostar NNP i
) ) i
, , N
increased VBN N
in IN N
disease NN o
progressive JJ o
cases NNS o
( ( N
P NNP N
= VBZ N
0.015 CD N
in IN N
chemotherapy NN i
alone RB N
, , N
but CC N
P NNP N
= NNP N
0.293 CD N
in IN N
chemotherapy NN i
with IN i
Endotatar NNP i
) ) i
. . N

After IN N
therapy NN N
, , N
the DT N
expression NN o
of IN o
survivin JJ o
mRNA NN o
decreased VBN N
in IN N
clinical JJ N
benefit NN N
cases NNS N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
and CC N
increased VBN N
in IN N
disease NN o
progressive JJ o
cases NNS o
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
activated VBN o
CECs NNP o
and CC N
survivin NN N
in IN N
the DT N
chemotherapy NN i
group NN N
pre- JJ N
and CC N
post-therapy JJ N
( ( N
P NNP N
= NNP N
0.001 CD N
and CC N
0.021 CD N
, , N
respectively RB N
) ) N
, , N
but CC N
only RB N
in IN N
the DT N
chemotherapy NN i
with IN i
Endostar NNP i
group NN N
pre-therapy NN N
( ( N
P NNP N
= NNP N
0.030 CD N
) ) N
rather RB N
than IN N
post-therapy NN N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
decreased VBN N
activated VBN o
CECs NNP o
after IN N
therapy NN N
and CC N
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
( ( N
r JJ N
= NN N
0.322 CD N
, , N
P NNP N
= NNP N
0.012 CD N
) ) N
; : N
a DT N
negative JJ N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
amount NN o
of IN o
survivin NN o
mRNA NN o
in IN o
serum JJ o
post-therapy NN o
and CC o
TTP NNP o
( ( N
r NN N
= NNP N
-0.291 NNP N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

CONCLUSIONS NNP N
Activated NNP N
CECs NNP N
and CC N
survivin NN N
may MD N
be VB N
ideal JJ N
markers NNS N
forecasting VBG N
efficacy NN N
and CC N
prognosis NN N
of IN N
NSCLC NNP N
. . N

The DT N
former JJ N
can MD N
reflect VB N
more RBR N
sensitively RB N
antiangiogenic JJ N
efficacy NN N
and CC N
the DT N
latter NN N
is VBZ N
more RBR N
sensitive JJ N
to TO N
shrinkage VB N
or CC N
swelling VBG N
of IN N
tumors NNS N
. . N

Their PRP$ N
combination NN N
can MD N
evaluate VB N
more RBR N
accurately RB N
the DT N
efficacy NN N
of IN N
antiangiogenic JJ i
therapy NN i
of IN N
NSCLC NNP N
. . N

-DOCSTART- -X- O O

[ JJ i
Local NNP i
therapy NN i
of IN i
grade NN i
1 CD i
and CC i
2 CD i
hemorrhoids NNS i
. . i

Effectiveness NN N
of IN N
a DT N
combination NN i
preparation NN i
with IN i
standardized JJ i
blood NN i
leech NN i
extract NN i
] NNP i
. . N

AIMS NNP N
Testing VBG N
the DT N
effectiveness NN N
of IN N
a DT N
topical JJ i
combination NN i
preparation NN i
containing VBG i
standardized VBN i
leech JJ i
extract NN i
, , i
polidocanol NN i
and CC i
allantoin NN i
. . i

STUDY NNP N
DESIGN NNP N
Placebo-controlled NNP i
, , N
double-blind NN N
study NN N
in IN N
80 CD p
patients NNS p
with IN p
first JJ p
and CC p
second JJ p
degree NN p
hemorrhoids NNS p
; : p
duration NN N
of IN N
treatment NN N
one CD N
week NN N
; : N
examinations NNS N
performed VBD N
on IN N
admission NN N
and CC N
on IN N
days NNS N
3 CD N
, , N
4 CD N
, , N
5 CD N
and CC N
8 CD N
. . N

RESULTS VB N
Both DT N
the DT N
subjective NN o
and CC o
objective JJ o
symptoms NNS o
and CC o
signs NNS o
improved VBN o
during IN N
the DT N
one CD N
week NN N
of IN N
treatment NN N
statistically RB N
significantly RB N
more RBR N
rapidly RB N
under IN N
the DT N
test NN i
preparation NN i
as IN N
compared VBN N
with IN N
placebo NN i
. . i

Histologically NNP o
demonstrable JJ o
signs NNS o
of IN o
inflammation NN o
were VBD N
more JJR N
clearly RB N
improved VBN N
in IN N
the DT N
preparation NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

No DT o
side NN o
effects NNS o
were VBD N
observed VBN N
. . N

CONCLUSIONS VB N
The DT N
good JJ N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
topical JJ i
therapeutic JJ i
preparation NN i
in IN N
first JJ p
and CC p
second JJ p
degree NN p
hemorrhoids NNS p
have VBP N
been VBN N
convincingly RB N
demonstrated VBN N
. . N

-DOCSTART- -X- O O

Changes NNS N
in IN N
spinal JJ N
inhibitory NN N
networks NNS N
induced VBN N
by IN N
furosemide NN i
in IN N
humans NNS N
. . N

During IN N
neural JJ N
development NN N
in IN N
animals NNS N
, , N
GABAergic NNP N
and CC N
glycinergic JJ N
neurons NNS N
are VBP N
first JJ N
excitatory NN N
, , N
and CC N
then RB N
become VB N
inhibitory NN N
in IN N
the DT N
mature NN N
state NN N
. . N

This DT N
developmental JJ N
shift NN N
is VBZ N
due JJ N
mainly RB N
to TO N
strong JJ N
expression NN N
of IN N
the DT N
cation-chloride JJ N
K-Cl NNP N
cotransporter NN N
2 CD N
( ( N
KCC2 NNP N
) ) N
and CC N
down-regulation NN N
of IN N
Na-K-Cl NNP N
cotransporter NN N
1 CD N
( ( N
NKCC1 NNP N
) ) N
during IN N
maturation NN N
. . N

The DT N
down-regulation NN N
of IN N
co-transporter NN N
KCC2 NNP N
after IN N
spinal JJ N
cord NN N
transection NN N
in IN N
animals NNS N
leads NNS N
to TO N
the DT N
depolarising NN N
( ( N
excitatory NN N
) ) N
action NN N
of IN N
GABA NNP N
and CC N
glycine NN N
and CC N
thus RB N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
inhibitory JJ N
synaptic JJ N
efficiency NN N
. . N

Furosemide NNP i
, , N
a DT N
loop NN N
diuretic NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
selectively RB N
and CC N
reversibly RB N
block VB N
inhibitory NN N
postsynaptic JJ N
potentials NNS N
without IN N
affecting VBG N
excitatory JJ N
postsynaptic JJ N
potentials NNS N
in IN N
animal JJ N
spinal JJ N
neurons NNS N
. . N

Moreover RB N
, , N
this DT N
diuretic NN N
has VBZ N
been VBN N
also RB N
demonstrated VBN N
to TO N
block VB N
the DT N
cation-chloride JJ N
co-transporters NNS N
. . N

Here RB N
, , N
we PRP N
used VBD N
furosemide RB i
to TO N
demonstrate VB N
changes NNS p
in IN p
spinal JJ p
inhibitory NN p
networks NNS p
in IN p
healthy JJ p
human JJ p
subjects NNS p
. . p

Non-invasive JJ N
electrophysiological JJ N
techniques NNS N
were VBD N
used VBN N
to TO N
assess VB N
presynaptic JJ N
inhibition NN N
, , N
postsynaptic JJ N
inhibition NN N
and CC N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
in IN N
the DT N
spinal JJ N
cord NN N
. . N

Orally RB i
administered VBN i
furosemide NN i
, , i
at IN i
doses NNS i
commonly RB i
used VBN i
in IN i
the DT i
clinic NN i
( ( i
40 CD i
mg NN i
) ) i
, , N
significantly RB N
reduced VBN N
spinal JJ o
inhibitory JJ o
interneuronal JJ o
activity NN o
for IN N
at IN N
least JJS N
70 CD N
min NN N
from IN N
intake NN N
compared VBN N
to TO N
control VB N
experiments NNS N
in IN N
the DT N
same JJ N
subjects NNS N
while IN N
no DT N
changes NNS N
were VBD N
observed VBN N
in IN N
the DT N
efficacy NN N
of IN N
synaptic JJ N
transmission NN N
between IN N
muscle NN N
afferent NN N
terminals NNS N
and CC N
soleus JJ N
motoneurons NNS N
. . N

The DT N
reduction NN o
of IN o
inhibition NN o
was VBD N
dose-dependent JJ N
. . N

Our PRP$ N
results NNS N
provide VBP N
indirect JJ N
evidence NN N
that IN N
reversible JJ N
changes NNS N
in IN N
the DT N
cation-chloride JJ N
transport NN N
system NN N
induce JJ N
modulations NNS N
of IN N
inhibitory JJ N
neuronal JJ N
activity NN N
at IN N
spinal JJ N
cord NN N
level NN N
in IN N
humans NNS N
. . N

-DOCSTART- -X- O O

A DT N
prospective JJ N
randomised JJ N
comparison NN N
of IN N
the DT N
dynamic JJ i
hip NN i
screw NN i
and CC p
the DT p
gamma NN i
locking VBG i
nail NN i
. . i

We PRP N
made VBD N
a DT N
randomised JJ N
prospective JJ N
comparison NN N
of IN N
the DT N
Dynamic NNP i
Hip NNP i
Screw NNP i
and CC i
the DT i
Gamma NNP i
locking VBG i
nail NN i
for IN N
the DT N
internal JJ N
fixation NN N
of IN N
200 CD p
petrochanteric JJ p
femoral JJ p
fractures NNS p
in IN p
elderly JJ p
patients NNS p
. . p

There EX N
was VBD N
less RBR N
intraoperative JJ o
blood NN o
loss NN o
and CC o
a DT o
lower JJR o
rate NN o
of IN o
wound NN o
complications NNS o
in IN N
the DT N
patients NNS N
treated VBN N
by IN N
the DT N
Gamma NNP i
nail NN i
. . i

They PRP N
had VBD N
, , N
however RB N
, , N
a DT N
high JJ N
incidence NN N
of IN N
femoral JJ o
shaft NN o
fracture NN o
which WDT N
we PRP N
relate VBP N
in IN N
part NN N
to TO N
implant VB N
design NN N
. . N

We PRP N
do VBP N
not RB N
recommend VB N
the DT N
use NN N
of IN N
the DT N
Gamma NNP i
nail NN i
for IN N
these DT N
fractures NNS N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
arm NN i
support NN i
combined VBD i
with IN i
rehabilitation NN i
games NNS i
on IN N
upper-extremity JJ o
function NN o
in IN N
subacute JJ o
stroke NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Use NNP N
of IN N
rehabilitation NN i
technology NN i
, , N
such JJ N
as IN N
( ( i
electro NN i
) ) i
mechanical JJ i
devices NNS i
or CC i
robotics NNS i
, , N
could MD N
partly RB N
relieve VB N
the DT N
increasing VBG N
strain NN N
on IN N
stroke NN N
rehabilitation NN N
caused VBN N
by IN N
an DT N
increasing VBG N
prevalence NN N
of IN N
stroke NN N
. . N

Arm NNP i
support NN i
( ( i
AS IN i
) ) i
training NN i
showed VBD N
improvement NN N
of IN N
unsupported JJ N
arm NN o
function NN o
in IN N
chronic JJ o
stroke NN o
. . o

OBJECTIVE UH N
To TO N
examine VB N
the DT N
effect NN N
of IN N
weight-supported JJ i
arm NN i
training NN i
combined VBN N
with IN N
computerized JJ i
exercises NNS i
on IN N
arm NN o
function NN o
and CC N
capacity NN o
, , N
compared VBN N
with IN N
dose-matched JJ N
conventional JJ i
reach NN i
training NN i
in IN N
subacute JJ p
stroke NN p
patients NNS p
. . p

METHODS NNP N
In IN N
a DT N
single-blind NN N
, , N
multicenter NN N
, , N
randomized VBN N
controlled VBN N
trial NN N
, , N
70 CD p
subacute NN p
stroke NN p
patients NNS p
received VBD N
6 CD N
weeks NNS N
of IN N
training VBG i
with IN N
either DT N
an DT N
AS NNP i
device NN i
combined VBD i
with IN i
computerized JJ i
exercises NNS i
or CC i
dose-matched JJ i
conventional JJ i
training NN i
( ( i
CON NNP i
) ) i
. . i

Arm NNP N
function NN N
was VBD N
evaluated VBN N
pretraining NN N
and CC N
posttraining NN N
by IN N
Fugl-Meyer NNP o
assessment NN o
( ( o
FM NNP o
) ) o
, , o
maximal JJ o
reach NN o
distance NN o
, , o
Stroke NNP o
Upper NNP o
Limb NNP o
Capacity NNP o
Scale NNP o
( ( o
SULCS NNP o
) ) o
, , o
and CC o
arm NN o
pain NN o
via IN o
Visual NNP o
Analogue NNP o
Scale NNP o
, , N
in IN N
addition NN N
to TO N
perceived VBN N
motivation NN N
by IN N
Intrinsic NNP N
Motivation NNP N
Inventory NNP N
posttraining VBG N
. . N

RESULTS NNP N
FM NNP o
and CC o
SULCS NNP o
scores NNS o
and CC o
reach VB o
distance NN o
improved VBN N
significantly RB N
within IN N
both DT N
groups NNS N
. . N

These DT N
improvements NNS N
and CC N
experienced VBD N
pain NN o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

The DT N
AS NNP N
group NN N
reported VBD N
higher JJR o
interest/enjoyment NN o
during IN N
training NN N
than IN N
the DT N
CON NNP N
group NN N
. . N

CONCLUSIONS NNP N
AS IN N
training NN i
with IN i
computerized JJ i
exercises NNS i
is VBZ N
as RB N
effective JJ N
as IN N
conventional JJ N
therapy NN N
dedicated VBN N
to TO N
the DT N
arm NN N
to TO N
improve VB N
arm NN o
function NN o
and CC o
activity NN o
in IN N
subacute NN p
stroke NN p
rehabilitation NN N
, , N
when WRB N
applied VBN N
at IN N
the DT N
same JJ N
dose NN N
. . N

-DOCSTART- -X- O O

Cholesterol-lowering JJ N
effect NN N
of IN N
stanol NN i
ester NN i
in IN N
a DT N
US NNP p
population NN p
of IN p
mildly RB p
hypercholesterolemic JJ p
men NNS p
and CC p
women NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
stanol NN i
esters NNS i
in IN N
lowering VBG N
cholesterol NN N
in IN N
a DT N
US NNP p
population NN p
. . p

SUBJECTS NNP N
AND NNP N
METHODS NNP N
After IN N
a DT N
run-in JJ N
phase NN N
, , N
318 CD p
subjects NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
margarine-like JJ N
spreads NNS N
containing VBG N
stanol JJ i
ester NN i
or CC i
placebo NN i
for IN N
8 CD N
weeks NNS N
: : N
EU NNP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN i
( ( i
ester JJ i
form NN i
) ) i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
European JJ N
formula NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
3 CD N
G NNP N
: : N
1 CD N
g NN N
of IN N
stanol NN i
( ( i
ester JJ i
form NN i
) ) i
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
US PRP N
2 CD N
G NNP N
: : N
0.67 CD N
g NN N
of IN N
stanol NN i
( ( N
ester JJ N
form NN N
) ) N
per IN N
8-g JJ N
serving NN N
of IN N
a DT N
US NNP N
reformulation NN N
3 CD N
times NNS N
a DT N
day NN N
; : N
or CC N
placebo VB i
spread NN N
. . N

RESULTS JJ N
Mean JJ o
+/- JJ o
SD NNP o
baseline NN o
total NN o
cholesterol NN o
( ( o
TC NNP o
) ) o
and CC o
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-C NNP o
) ) o
levels NNS o
were VBD N
233+/-20 JJ N
and CC N
153+21 CD N
mg+/-dL NN N
, , N
respectively RB N
. . N

In IN N
the DT N
US NNP N
3 CD N
G NNP N
group NN N
, , N
3 CD N
g JJ N
daily NN N
of IN N
stanol JJ i
esters NNS i
lowered VBD N
TC NNP o
and CC o
LDL-C NNP o
levels NNS o
by IN N
6.4 CD N
% NN N
and CC N
10.1 CD N
% NN N
, , N
respectively RB N
. . N

There EX N
was VBD N
a DT N
dose-dependent JJ N
response NN N
compared VBN N
with IN N
2 CD N
g NNS N
daily RB N
( ( N
US PRP N
2 CD N
G NNP N
) ) N
. . N

Triglyceride NNP o
and CC o
high-density NN o
lipoprotein NNS o
cholesterol NN o
levels NNS o
were VBD N
unchanged JJ N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
effects NNS o
was VBD N
not RB N
different JJ N
from IN N
placebo NN i
. . i

Serum NNP o
vitamin VBD o
A DT o
and CC o
25-hydroxyvitamin JJ o
D NNP o
levels NNS o
were VBD N
not RB N
affected VBN N
. . N

CONCLUSIONS NNP N
Stanol NNP i
esters NNS i
lowered VBD N
TC NNP o
and CC o
LDL-C NNP o
levels NNS o
in IN N
a DT N
mildly RB p
hypercholesterolemic JJ p
US NNP p
population NN p
without IN N
evidence NN N
of IN N
adverse JJ N
effects NNS N
. . N

It PRP N
may MD N
be VB N
a DT N
useful JJ N
dietary JJ N
adjunct NN N
to TO N
lower VB N
cholesterol NN N
. . N

-DOCSTART- -X- O O

[ JJ o
Rapidity NNP o
of IN o
pain NN o
relief NN o
, , o
medication NN o
requirement NN o
and CC o
patient JJ o
satisfaction NN o
with IN p
reflux JJ p
treatment NN p
in IN N
the DT N
physician NN N
's POS N
office NN N
] NN N
. . N

Treatment NN N
of IN N
gastroesophageal NN o
reflux NN o
disease NN o
( ( o
GERD NNP o
) ) o
with IN N
proton NN o
pump NN o
inhibitors NNS o
was VBD N
investigated VBN N
in IN N
three CD N
controlled VBD N
prospective JJ N
, , N
randomized JJ N
open JJ N
studies NNS N
. . N

Lansoprazole NNP i
, , i
omeprazole JJ i
MUPS NNP i
and CC i
esomeprazole NN i
were VBD N
compared VBN N
under IN N
doctor NN N
's POS N
office NN N
conditions NNS N
. . N

The DT N
outcomes NNS N
of IN N
interest NN N
were VBD N
the DT N
rapidity NN o
of IN o
pain NN o
relief NN o
achieved VBN N
with IN N
a DT N
single JJ o
dose NN o
, , o
effectiveness NN o
and CC o
patient JJ o
satisfaction NN o
with IN N
on IN N
demand NN N
therapy NN N
. . N

In IN N
the DT N
first JJ N
study NN N
, , N
180 CD p
patients NNS p
with IN p
chronic JJ p
and CC p
prolonged JJ p
episodes NNS p
of IN p
reflux NN p
were VBD p
investigated VBN p
. . p

Time NN N
to TO N
pain VB o
relief NN o
following VBG N
a DT N
single JJ N
dose NN N
was VBD N
1.1 CD N
+/- JJ N
0.8 CD N
hours NNS N
with IN N
30 CD N
mg NNS N
lansoprazole JJ i
, , N
3.0 CD N
+/- JJ N
2.5 CD N
hours NNS N
with IN N
20 CD N
mgomeprazole JJ i
MUPS NNP N
and CC N
2.1 CD N
+/- JJ N
1.2 CD N
hours NNS N
with IN N
40 CD N
mg NNS N
esomeprazole JJ i
. . i

Studies NNS N
2 CD N
and CC N
3 CD N
were VBD N
designed VBN N
as IN N
cross-over NN N
studies NNS N
intended VBN N
to TO N
investigate VB N
drug NN o
consumption NN o
. . o

In IN N
study NN N
2 CD N
, , N
the DT N
amount NN o
of IN o
lansoprazole NN o
consumed VBN o
was VBD N
approximately RB N
50 CD N
% NN N
less JJR N
than IN N
that DT N
of IN N
omeprazole NN i
, , N
and CC N
this DT N
translated VBN N
to TO N
81 CD N
% NN N
patient JJ o
satisfaction NN o
with IN N
lansoprazole JJ i
compared VBN N
with IN N
only RB N
9.5 CD N
% NN N
for IN N
omeprazole NN i
. . i

In IN N
study NN N
3 CD N
comparing VBG N
lansoprazole NN N
and CC N
esomeprazole NN i
, , N
consumption NN o
of IN N
the DT N
former JJ N
was VBD N
85 CD N
% NN N
that WDT N
of IN N
the DT N
latter NN N
. . N

58 CD N
% NN N
of IN N
the DT N
patients NNS N
opted VBD N
to TO N
continuetreatment VB o
with IN N
lansoprazole NN i
, , N
compared VBN N
with IN N
only RB N
25 CD N
% NN N
in IN N
the DT N
case NN N
of IN N
esomeprazole NN i
. . N

The DT N
appreciably RB N
greater JJR N
patient JJ o
satisfaction NN o
with IN N
lansoprazole NN i
was VBD N
due JJ N
tothe NN N
faster RBR o
pain NN o
relief NN o
achieved VBN N
with IN N
this DT N
drug NN N
. . N

-DOCSTART- -X- O O

Phase NNP N
III NNP N
trial NN N
comparing VBG N
whole-pelvic JJ N
versus NN N
prostate-only JJ N
radiotherapy NN i
and CC N
neoadjuvant JJ i
versus NN i
adjuvant NN i
combined VBN i
androgen JJ i
suppression NN i
: : i
Radiation NN i
Therapy NNP i
Oncology NNP N
Group NNP N
9413 CD N
. . N

PURPOSE VB N
This DT N
trial NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
combined VBD N
androgen DT i
suppression NN i
( ( i
CAS NNP i
) ) i
and CC i
whole-pelvic JJ i
( ( i
WP NNP i
) ) i
radiotherapy NN i
( ( i
RT NNP i
) ) i
followed VBN N
by IN N
a DT N
boost NN N
to TO N
the DT N
prostate NN N
improves VBZ N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
by IN N
10 CD N
% NN N
compared VBN N
with IN N
CAS NNP N
and CC N
prostate-only RB N
( ( N
PO NNP N
) ) N
RT NNP N
. . N

This DT N
trial NN N
also RB N
tested VBD N
the DT N
hypothesis NN N
that WDT N
neoadjuvant JJ i
and CC i
concurrent JJ i
hormonal JJ i
therapy NN i
( ( i
NCHT NNP i
) ) i
improves VBZ N
PFS NNP N
compared VBN N
with IN N
adjuvant JJ i
hormonal JJ i
therapy NN i
( ( i
AHT NNP i
) ) i
by IN N
10 CD N
% NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Eligibility NNP p
included VBD p
localized JJ p
prostate NN p
cancer NN p
with IN p
an DT p
elevated JJ p
prostate-specific JJ p
antigen NN p
( ( p
PSA NNP p
) ) p
< VBD p
or CC p
= $ p
100 CD p
ng/mL NN p
and CC p
an DT p
estimated VBN p
risk NN p
of IN p
lymph JJ p
node NN p
( ( p
LN NNP p
) ) p
involvement NN p
of IN p
15 CD p
% NN p
. . p

Between NNP p
April NNP p
1 CD p
, , p
1995 CD p
, , p
and CC p
June NNP p
1 CD p
, , p
1999 CD p
, , p
1,323 CD p
patients NNS p
were VBD p
accrued VBN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
WP NNP N
+ NNP N
NCHT NNP N
, , N
PO NNP N
+ NNP N
NCHT NNP N
, , N
WP NNP N
+ NNP N
AHT NNP N
, , N
or CC N
PO NNP N
+ NNP N
AHT NNP N
. . N

Failure NN o
for IN o
PFS NNP o
was VBD N
defined VBN N
as IN N
the DT N
first JJ N
occurrence NN N
of IN N
local JJ o
, , o
regional JJ o
, , o
or CC o
distant JJ o
disease NN o
; : o
PSA NNP o
failure NN o
; : o
or CC N
death NN o
for IN N
any DT N
cause NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
59.5 CD N
months NNS N
, , N
WP NNP N
RT NNP N
was VBD N
associated VBN N
with IN N
a DT N
4-year JJ o
PFS NNP o
of IN N
54 CD N
% NN N
compared VBN N
with IN N
47 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
PO NNP N
RT NNP N
( ( N
P NNP N
=.022 NNP N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
NCHT NNP i
experienced VBD N
a DT N
4-year JJ o
PFS NNP o
of IN N
52 CD N
% NN N
versus IN N
49 CD N
% NN N
for IN N
AHT NNP i
( ( N
P NNP N
=.56 NNP N
) ) N
. . N

When WRB N
comparing VBG N
all DT N
four CD N
arms NNS N
, , N
there EX N
was VBD N
a DT N
progression-free JJ o
difference NN o
among IN N
WP NNP i
RT NNP i
+ NNP i
NCHT NNP i
, , i
PO NNP i
RT NNP i
+ NNP i
NCHT NNP i
, , i
WP NNP i
RT NNP i
+ NNP i
AHT NNP i
, , N
and CC N
PO NNP i
RT NNP i
+ NNP i
AHT NNP i
( ( N
60 CD N
% NN N
v JJ N
44 CD N
% NN N
v JJ N
49 CD N
% NN N
v JJ N
50 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
=.008 NNP N
) ) N
. . N

No UH N
survival JJ o
advantage NN o
has VBZ N
yet RB N
been VBN N
seen VBN N
. . N

CONCLUSION NNP N
WP NNP i
RT NNP i
+ NNP i
NCHT NNP i
improves VBZ N
PFS NNP o
compared VBN N
with IN N
PO NNP i
RT NNP i
and CC N
NCHT NNP i
or CC N
PO NNP i
RT NNP i
and CC N
AHT NNP i
, , N
and CC N
compared VBN N
with IN N
WP NNP i
RT NNP i
+ NNP i
AHT NNP i
in IN N
patients NNS p
with IN p
a DT p
risk NN p
of IN p
LN NNP p
involvement NN p
of IN p
15 CD p
% NN p
. . p

-DOCSTART- -X- O O

Scaling VBG N
clinical JJ N
judgments NNS N
of IN N
symptom JJ N
pathology NN N
by IN N
means NNS N
of IN N
the DT N
psychophysiological JJ N
method NN N
of IN N
magnitude NN N
estimation NN N
. . N

Summing VBG N
scores NNS N
across IN N
heterogeneous JJ N
symptom NN N
items NNS N
without IN N
consideration NN N
of IN N
their PRP$ N
differing JJ N
psychopathological JJ N
significance NN N
has VBZ N
been VBN N
criticized VBN N
as IN N
producing VBG N
an DT N
inadequate JJ N
picture NN N
of IN N
an DT N
individual NN N
's POS N
clinical JJ N
status NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
derive JJ N
symptom JJ N
item NN N
weights NNS N
representing VBG N
clinically RB N
judged VBN N
seriousness NN N
of IN N
each DT N
symptom NN N
through IN N
the DT N
application NN N
of IN N
Steven NNP i
's POS i
psychophysical JJ i
method NN i
of IN i
magnitude NN i
estimation NN i
. . i

A DT N
nationwide JJ N
sample NN N
of IN N
129 CD p
clinicians NNS p
rated VBD N
the DT N
pathological JJ N
significance NN N
of IN N
221 CD N
symptom JJ N
items NNS N
in IN N
a DT N
design NN N
such JJ N
that IN N
every DT N
rater NN N
rated VBD N
121 CD N
items NNS N
, , N
21 CD N
of IN N
which WDT N
were VBD N
rated VBN N
by IN N
all DT N
raters NNS N
and CC N
100 CD N
of IN N
which WDT N
were VBD N
rated VBN N
only RB N
by IN N
the DT N
A NNP N
or CC N
B NNP N
subgroup NN N
to TO N
which WDT N
each DT N
rater NN N
was VBD N
randomly RB N
assigned VBN N
. . N

Each DT N
item NN N
was VBD N
rated VBN N
as IN N
to TO N
the DT N
seriousness NN N
of IN N
the DT N
pathology NN N
it PRP N
would MD N
represent VB N
if IN N
manifested VBN N
by IN N
either CC N
a DT N
boy NN N
child NN N
, , N
girl JJ N
child NN N
, , N
boy JJ N
adolescent NN N
, , N
or CC N
girl JJ N
adolescent NN N
, , N
with IN N
one-fourth NN N
of IN N
the DT N
raters NNS N
assigned VBD N
to TO N
each DT N
condition NN N
. . N

The DT N
results NNS N
of IN N
211 CD N
two-way JJ i
analyses NNS i
of IN i
variance NN i
revealed VBD N
that IN N
age NN N
and CC N
age NN o
and CC o
sex NN o
in IN N
interaction NN N
, , N
but CC N
not RB N
sex VB N
alone RB N
, , N
significantly RB N
influenced VBD N
the DT N
clinical JJ N
ratings NNS N
. . N

The DT N
resulting VBG N
magnitude JJ o
estimation NN o
ratings NNS o
of IN o
symptom JJ o
pathology NN o
ranged VBD N
from IN N
1.0 CD N
to TO N
9.9 CD N
. . N

They PRP N
were VBD N
demonstrated VBN N
to TO N
have VB N
satisfactoy VBN N
reliability NN N
and CC N
convergent NN N
validity NN N
and CC N
to TO N
have VB N
the DT N
psychophysical JJ N
characteristics NNS N
of IN N
a DT N
prothetic JJ N
continuum NN N
. . N

-DOCSTART- -X- O O

Oestrogen NNP o
replacement NN o
after IN p
oophorectomy NN p
: : p
comparison NN N
of IN N
patches NNS i
and CC N
implants NNS i
. . i

-DOCSTART- -X- O O

The DT N
role NN N
of IN N
choice NN N
in IN N
health NN p
education NN p
intervention NN p
trials NNS p
: : p
a DT N
review NN N
and CC N
case NN N
study NN N
. . N

Although IN N
the DT N
randomized VBN N
, , N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
is VBZ N
considered VBN N
the DT N
gold JJ N
standard NN N
in IN N
research NN N
for IN N
determining VBG N
the DT N
efficacy NN N
of IN N
health NN N
education NN N
interventions NNS N
, , N
such JJ N
trials NNS N
may MD N
be VB N
vulnerable JJ N
to TO N
preference VB N
effects NNS N
; : N
that DT N
is VBZ N
, , N
differential JJ N
outcomes NNS N
depending VBG N
on IN N
whether IN N
an DT N
individual NN N
is VBZ N
randomized VBN N
to TO N
his PRP$ N
or CC N
her PRP$ N
preferred JJ N
treatment NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
review VBP N
theoretical JJ N
and CC N
empirical JJ N
literature NN N
regarding VBG N
designs NNS N
that WDT N
account VBP N
for IN N
such JJ N
effects NNS N
in IN N
medical JJ N
research NN N
, , N
and CC N
consider VB N
the DT N
appropriateness NN N
of IN N
these DT N
designs NNS N
to TO N
health NN p
education NN p
research NN p
. . p

To TO N
illustrate VB N
the DT N
application NN N
of IN N
a DT N
preference NN N
design NN N
to TO N
health NN N
education NN N
research NN N
, , N
we PRP N
present VBP N
analyses NNS N
using VBG N
process NN N
data NNS N
from IN N
a DT N
mixed JJ p
RCT/preference NNP p
trial NN p
comparing VBG p
two CD p
formats NNS p
( ( i
Group NNP i
or CC N
Self-Directed NNP i
) ) i
of IN N
the DT N
Women NNP p
take VB p
PRIDE NNP p
heart NN p
disease NN p
management NN p
program NN p
. . p

Results NNP N
indicate VBP N
that IN N
being VBG N
able JJ N
to TO N
choose VB N
one CD N
's POS N
program NN N
format NN N
did VBD N
not RB N
significantly RB N
affect VB N
the DT N
decision NN o
to TO o
participate VB o
in IN N
the DT N
study NN N
. . N

However RB N
, , N
women NNS p
who WP N
chose VBD i
the DT i
Group NNP i
format WDT i
were VBD N
over RB N
4 CD N
times NNS N
as RB N
likely JJ N
to TO N
attend VB N
at IN N
least JJS N
one CD N
class NN N
and CC N
were VBD N
twice RB N
as RB N
likely JJ N
to TO N
attend VB N
a DT N
greater JJR N
number NN N
of IN N
classes NNS N
than IN N
those DT N
who WP N
were VBD N
randomized VBN i
to TO i
the DT i
Group NNP i
format NN i
. . i

Several JJ N
predictors NNS N
of IN N
format JJ N
preference NN N
were VBD N
also RB N
identified VBN N
, , N
with IN N
important JJ N
implications NNS N
for IN N
targeting VBG N
disease-management JJ N
education NN N
to TO N
this DT N
population NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
short-term JJ N
isotonic JJ i
& CC i
isometric JJ i
training NN i
on IN N
cardiovascular JJ o
& CC o
pulmonary JJ o
function NN o
. . o

A DT N
randomised JJ N
control NN N
trial NN N
of IN N
short-term JJ i
exercises NNS i
on IN N
specific JJ N
cardiovascular JJ N
and CC N
respiratory JJ N
parameters NNS N
was VBD N
undertaken VBN N
in IN p
normal JJ p
male JJ p
college NN p
students NNS p
. . p

The DT N
effects NNS N
of IN N
isotonic JJ i
training NN i
( ( i
5BX CD i
programme NN i
) ) i
and CC i
isometric JJ i
training NN i
( ( i
a DT i
programme NN i
of IN i
isometric JJ i
exercises NNS i
working VBG i
all DT i
major JJ i
groups NNS i
of IN i
muscles NNS i
) ) i
were VBD N
compared VBN N
with IN i
a DT i
control NN i
group NN i
with IN N
no DT N
specific JJ N
workout NN N
. . N

Both DT N
isotonic JJ i
and CC i
isometric JJ i
training NN i
resulted VBD N
in IN N
significant JJ o
cardiovascular JJ o
improvement NN o
but CC N
seemed VBD N
inadequate JJ N
to TO N
improve VB N
vital JJ o
capacity NN o
and CC o
flow NN o
rates NNS o
. . o

Isotonic JJ i
training NN i
in IN N
addition NN N
, , N
improved JJ N
ventilatory NN o
efficiency NN o
. . o

It PRP N
is VBZ N
concluded VBN N
that IN N
such JJ N
isotonic JJ i
or CC i
isometric JJ i
training NN i
of IN N
thrice NN N
a DT N
week NN N
for IN N
ten JJ N
weeks NNS N
, , N
requiring VBG N
no DT N
equipment NN N
, , N
less JJR N
time NN N
and CC N
space NN N
can MD N
be VB N
promoted VBN N
to TO N
improve VB N
physical JJ o
fitness NN o
. . o

-DOCSTART- -X- O O

Attenuation NN N
of IN N
hemodynamic JJ N
responses NNS N
to TO N
laryngoscopy VB N
and CC N
tracheal VB N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
: : N
remifentanil NN i
vs. FW N
lidocaine NN i
with IN i
esmolol NN i
. . i

AIM NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
remifentanil NN i
vs. FW N
a DT N
lidocaine-esmolol JJ i
combination NN N
in IN N
blunting VBG N
the DT N
hemodynamic JJ o
response NN o
to TO N
laryngoscopy VB N
and CC N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
using VBG N
thiopental JJ N
and CC N
rocuronium NN N
in IN N
normotensive JJ p
patients NNS p
. . p

METHODS NNP N
Sixty-six JJ p
patients NNS p
with IN p
American JJ p
Society NNP p
of IN p
Anesthesiologists NNP p
( ( p
ASA NNP p
) ) p
physical JJ p
status NN p
class NN p
I PRP p
who WP p
required VBD p
tracheal JJ p
intubation NN p
for IN p
elective JJ p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
R NNP N
received VBD N
0.9 CD i
% NN i
saline NN i
10 CD i
ml NN i
and CC i
remifentanil VB i
1 CD i
microg/kg NN i
. . i

Group NNP N
LE NNP N
received VBD N
lidocaine JJ i
1.5 CD i
mg/kg NN i
and CC i
esmolol $ i
1.0 CD i
mg/kg NN i
. . i

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopental JJ i
sodium NN i
5 CD N
mg/kg NN N
, , N
followed VBN N
by IN N
rocuronium NN i
1.0 CD N
mg/kg NN N
. . N

Mean NNP o
arterial JJ o
pressure NN o
and CC o
heart NN o
rate NN o
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
induction NN N
, , N
immediately RB N
after IN N
intubation NN N
and CC N
every DT N
minute NN N
for IN N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
mean JJ o
arterial JJ o
pressure NN o
over IN o
time NN o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significantly RB N
different JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
maximum JJ o
pressor NN o
response NN o
was VBD N
observed VBN N
immediately RB N
after IN N
intubation NN N
, , N
at IN N
which WDT N
time NN N
the DT N
mean JJ o
arterial JJ o
pressure NN o
change NN o
from IN N
baseline NN N
in IN N
group NN N
LE NNP N
( ( N
29.7 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
116.1 CD N
, , N
121.9 CD N
) ) N
was VBD N
higher JJR N
than IN N
that DT N
in IN N
group NN N
R NNP N
( ( N
4.4 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
CI NNP N
: : N
92.9 CD N
, , N
98.5 CD N
) ) N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Two CD N
patients NNS N
in IN N
group NN N
R NNP N
and CC N
15 CD N
patients NNS N
in IN N
group NN N
LE NNP N
developed VBD N
hypertension NN o
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NN N
: : N
0.064 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Changes NNS N
in IN N
heart NN o
rate NN o
over IN o
time NN o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P=0.465 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
remifentanil VBZ i
1 CD N
mg/kg NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
combination NN N
of IN N
lidocaine JJ i
1.5 CD N
mg/kg NN N
and CC N
esmolol $ i
1 CD N
mg/kg NN N
for IN N
attenuating VBG N
the DT N
hemodynamic JJ o
responses NNS o
to TO N
rapid JJ N
sequence NN N
intubation NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Effects NNS N
of IN N
dujieqing VBG i
oral JJ i
liquid NN i
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
Dujieqing VBG i
Oral NNP i
Liquid NNP i
( ( i
DJQ NNP i
) ) i
on IN N
the DT N
promoter NN N
methylation NN N
of IN N
the DT N
O6-methylguanine-DNA JJ N
methyltransferase NN N
( ( N
MGMT NNP N
) ) N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples NNS N
from IN N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
. . p

METHODS NNP N
Recruited VBD p
60 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
the DT N
treatment NN i
group NN i
( ( i
treated VBN i
by IN i
conventional JJ i
chemotherapy NN i
combined VBN i
DJQ NNP i
, , N
20 CD N
mL NN N
each DT N
time NN N
, , N
three CD N
times NNS N
daily RB N
) ) N
and CC N
the DT N
control NN i
group NN i
( ( i
treated VBN i
by IN i
chemotherapy NN i
alone RB i
) ) i
, , N
30 CD N
in IN N
each DT N
group NN N
. . N

The DT N
therapeutic JJ N
course NN N
was VBD N
8 CD N
weeks NNS N
. . N

The DT N
promoter NN N
methylation NN N
of IN N
the DT N
MGMT NNP N
gene NN N
in IN N
the DT N
plasma NN N
DNA NNP N
samples VBZ N
form VB N
middle-and-late JJ p
stage NN p
tumor NN p
patients NNS p
receiving VBG p
chemotherapy NN p
was VBD N
detected VBN N
before IN N
and CC N
after IN N
treatment NN N
using VBG N
nested JJ N
methylation-specific JJ N
polymerase NN N
chain NN N
reaction NN N
( ( N
MSP NNP N
) ) N
. . N

Meanwhile RB N
, , N
the DT N
peripheral JJ N
hemogram NN N
was VBD N
detected VBN N
. . N

The DT N
clinical JJ o
efficacy NN o
and CC o
toxic/adverse JJ o
reactions NNS o
were VBD N
assessed VBN N
using VBG N
Karnofsky NNP N
performance NN N
scale NN N
( ( N
KPS NNP N
) ) N
. . N

RESULTS JJ N
Results NNP N
of IN N
the DT N
promoter NN N
methylation NN N
of IN N
MGMT NNP N
genes NNS N
showed VBD N
that IN N
methylation NN N
rate NN N
was VBD N
20.00 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
46.67 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
before RB N
treatment NN N
, , N
the DT N
KPS NNP o
was VBD N
significantly RB N
improved VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
, , N
while IN N
it PRP N
significantly RB N
decreased VBD N
in IN N
the DT N
control NN N
group NN N
after IN N
treatment NN N
( ( N
both DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
statistical JJ N
difference NN N
in IN N
the DT N
KPS NNP o
between IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
toxic/adverse JJ o
reactions NNS o
were VBD N
milder VBN N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
DJQ NNP i
showed VBD N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
effects NNS N
, , N
but CC N
with IN N
no DT N
effect NN N
on IN N
the DT N
hematopoietic JJ N
function NN N
of IN N
the DT N
bone NN N
marrow NN N
. . N

MGMT NNP N
gene NN N
was VBD N
indicated VBN N
as IN N
DJQ NNP i
's POS i
target NN N
point NN N
for IN N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing NN N
. . N

The DT N
efficiency NN N
synergism NN N
and CC N
toxicity NN N
reducing VBG N
effects NNS N
were VBD N
achieved VBN N
by IN N
regulating VBG N
the DT N
activities NNS N
of IN N
MGMT NNP N
gene NN N
. . N

-DOCSTART- -X- O O

[ VB N
A DT N
clinical JJ N
trial NN N
of IN N
ultrasound-guided JJ i
facet NNS i
joint JJ i
block NN i
in IN N
the DT N
lumbar NN N
spine NN N
to TO N
treat VB N
facet JJ p
joint NN p
related VBD p
low JJ p
back RB p
pain NN p
] NN p
. . N

OBJECTIVE UH N
To TO N
determine VB N
the DT N
feasibility NN N
and CC N
clinical JJ N
efficacy NN N
of IN N
ultrasound-guided JJ i
facet NNS i
joint JJ i
injection NN i
and CC N
nerve NN i
block NN i
in IN i
lumbar NN i
facet NN i
joint NN i
for IN N
the DT N
treatment NN N
of IN N
facet-joint NN p
related VBN p
low JJ p
back RB p
pain NN p
. . p

METHODS NNP N
20 CD p
patients NNS p
with IN p
facet-joint JJ p
pain NN p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
received VBD N
block RB i
blindly RB i
( ( i
B NNP i
group NN i
) ) i
or CC i
guided VBN i
by IN i
ultrasound NN i
( ( i
US NNP i
group NN i
) ) i
respectively RB i
. . i

The DT N
location NN N
of IN N
needle JJ N
tip NN N
was VBD N
confirmed VBN N
by IN N
CT NNP N
in IN N
both DT N
groups NNS N
, , N
and CC N
the DT N
accuracy NN N
was VBD N
computed VBN N
afterwards NNS N
. . N

VAS NNP o
score NN o
, , o
puncture NN o
time NN o
and CC o
one-time JJ o
puncture NN o
success NN o
rate NN o
( ( N
% NN N
) ) N
were VBD N
recorded VBN N
. . N

VAS NNP o
scores NNS o
and CC o
pain VB o
remission NN o
rates NNS o
in IN N
both DT N
groups NNS N
were VBD N
recorded VBN N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
, , N
6 CD N
weeks NNS N
after IN N
the DT N
block NN N
. . N

RESULTS VB N
The DT N
VAS NNP o
scores NNS o
were VBD N
3.3 CD N
+/- JJ N
0.4 CD N
in IN N
US NNP N
group NN N
and CC N
1.2 CD N
+/- JJ N
0.3 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
puncture NN o
time NN o
was VBD N
( ( N
206 CD N
+/- JJ N
27 CD N
) ) N
s NN N
in IN N
US NNP N
group NN N
while IN N
( ( N
397 CD N
+/- JJ N
31 CD N
) ) N
s NN N
in IN N
B NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
37 CD N
facet JJ i
joint NN i
blocks NNS i
guided VBN i
by IN i
ultrasound NN i
, , N
in IN N
which WDT N
32 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN o
rate NN o
is VBZ N
86.5 CD N
% NN N
. . N

There EX N
were VBD N
35 CD N
facet JJ i
joint NN i
blocks NNS i
blindly RB i
, , N
in IN N
which WDT N
11 CD N
were VBD N
correctly RB N
targeted VBN N
with IN N
the DT N
first JJ N
puncture NN N
. . N

The DT N
success NN o
rate NN o
is VBZ N
31.4 CD N
% NN N
. . N

The DT N
difference NN N
of IN N
one-time JJ o
puncture NN o
success NN o
rate NN o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
significant JJ o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Differences NNS N
of IN N
VAS NNP o
and CC o
pain VB o
remission NN o
rate NN o
at IN N
half PDT N
an DT N
hour NN N
after IN N
facet JJ N
joint JJ N
injection NN N
between IN N
B NNP N
group NN N
and CC N
US NNP N
group NN N
were VBD N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
8 CD N
, , N
9 CD N
, , N
9 CD N
, , N
and CC N
9 CD N
patients NNS N
in IN N
US NNP N
group NN N
obtaining VBG N
a DT N
reduction NN o
in IN N
VAS NNP o
scores NNS o
> VBP N
or CC N
= VBP N
3 CD N
at IN N
30 CD N
min NN N
, , N
1 CD N
d NN N
, , N
2 CD N
d NN N
and CC N
6 CD N
weeks NNS N
after IN N
the DT N
procedure NN N
respectively RB N
, , N
while IN N
the DT N
numbers NNS N
of IN N
such JJ N
patients NNS N
were VBD N
5 CD N
, , N
6 CD N
, , N
5 CD N
, , N
5 CD N
in IN N
B NNP N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

After IN N
6 CD N
weeks NNS N
of IN N
follow-up NN N
, , N
the DT N
overall JJ o
remission NN o
rates NNS o
were VBD N
( ( N
72.3 CD N
+/- JJ N
14.0 CD N
) ) N
% NN N
in IN N
US NNP N
group NN N
, , N
and CC N
( ( N
56.7 CD N
+/- JJ N
11.0 CD N
) ) N
% NN N
in IN N
B NNP N
group NN N
, , N
there EX N
was VBD N
no DT o
significant JJ o
difference NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
ultrasound-guided JJ i
lumbar NN i
facet NN i
joint JJ i
injection NN i
technique NN i
had VBD N
a DT N
high JJ N
feasibility NN N
and CC N
accuracy NN N
, , N
and CC N
had VBD N
better RBR N
clinical JJ N
efficacy NN N
than IN N
block NN i
blindly RB i
. . i

-DOCSTART- -X- O O

Effect NN N
of IN N
cervical JJ i
spine NN i
manipulative JJ i
therapy NN i
on IN N
judo NN p
athletes NNS p
' POS p
grip NN N
strength NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
perform VB N
an DT N
investigation NN N
evaluating VBG N
if IN N
cervical JJ i
spinal JJ i
manipulative JJ i
therapy NN i
( ( i
SMT NNP i
) ) i
can MD N
increase VB N
grip JJ N
strength NN N
on IN N
judo NN p
athletes NNS p
in IN p
a DT p
top JJ p
10 CD p
national-ranked JJ p
team NN p
. . p

METHODS VB N
A DT N
single-blinded JJ N
, , N
prospective JJ N
, , N
comparative JJ N
, , N
pilot NN N
, , N
randomized VBN N
, , N
clinical JJ N
trial NN N
was VBD N
performed VBN N
with IN N
18 CD p
athletes NNS p
of IN p
both DT p
sexes NNS p
from IN p
a DT p
judo NN p
team NN p
currently RB p
competing VBG p
on IN p
a DT p
national JJ p
level NN p
. . p

The DT N
athletes NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
groups NNS N
: : N
chiropractic JJ i
SMT NNP i
and CC i
sham NN i
. . i

Three CD N
interventions NNS N
were VBD N
performed VBN N
on IN N
each DT N
of IN N
the DT N
athletes NNS N
at IN N
different JJ N
time NN N
points NNS N
. . N

Force NN N
measurements NNS N
were VBD N
obtained VBN N
by IN N
a DT N
hydraulic JJ N
dynamometer NN N
immediately RB N
before IN N
and CC N
after IN N
each DT N
intervention NN N
at IN N
the DT N
same JJ N
period NN N
before IN N
training VBG N
up RP N
to TO N
3 CD N
weeks NNS N
with IN N
at IN N
least JJS N
36 CD N
hours NNS N
between IN N
interventions NNS N
. . N

RESULTS NNP N
Analysis NNP N
of IN N
grip NN o
strength NN o
data NNS o
revealed VBD N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
strength NN o
within IN N
the DT N
treatment NN N
group NN N
after IN N
the DT N
first JJ N
intervention NN N
( ( N
6.95 CD N
% NN N
right NN N
, , N
12.61 CD N
% NN N
left NN N
) ) N
as IN N
compared VBN N
with IN N
the DT N
second JJ N
( ( N
11.53 CD N
% NN N
right NN N
, , N
17.02 CD N
% NN N
left NN N
) ) N
and CC N
the DT N
third JJ N
interventions NNS N
( ( N
10.53 CD N
% NN N
right NN N
, , N
16.81 CD N
% NN N
left VBD N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
grip JJ o
strength NN o
comparison NN o
within IN N
the DT N
sham NN N
group NN N
. . N

Overall JJ N
differences NNS o
in IN o
strength NN o
were VBD N
consistently RB N
significant JJ N
between IN N
the DT N
study NN N
groups NNS N
( ( N
P NNP N
= NNP N
.0025 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
the DT N
grip NN N
strength NN N
of IN N
national JJ p
level NN p
judo NN p
athletes NNS p
receiving VBG N
chiropractic JJ i
SMT NNP i
improved VBD N
compared VBN N
to TO N
those DT N
receiving VBG N
sham NN N
. . N

-DOCSTART- -X- O O

Acute NNP N
pressor NN N
and CC N
hormonal JJ N
effects NNS N
of IN N
beta-endorphin NN i
at IN N
high JJ N
doses NNS N
in IN N
healthy JJ p
and CC p
hypertensive JJ p
subjects NNS p
: : p
role NN N
of IN N
opioid JJ N
receptor NN N
agonism NN N
. . N

CONTEXT VB N
The DT N
opioid NN N
system NN N
is VBZ N
involved VBN N
in IN N
blood NN N
pressure NN N
regulation NN N
in IN N
both DT N
normal JJ p
humans NNS p
and CC p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
a DT N
high-dose JJ N
infusion NN N
of IN N
beta-endorphin NN i
, , N
an DT N
opioid JJ N
peptide NN N
, , N
on IN N
blood NN N
pressure NN N
and CC N
on IN N
the DT N
hormonal JJ N
profile NN N
in IN N
healthy JJ p
subjects NNS p
and CC p
in IN p
hypertensive JJ p
patients NNS p
and CC N
the DT N
mediation NN N
played VBN N
by IN N
opioid JJ N
receptor NN N
agonism NN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
According VBG N
to TO N
a DT N
randomized VBN N
double-blind NN N
design NN N
, , N
11 CD p
healthy JJ p
subjects NNS p
( ( p
controls NNS p
) ) p
and CC p
12 CD p
hypertensive JJ p
inpatients NNS p
( ( p
mean JJ p
age NN p
, , p
38.9 CD p
and CC p
40.4 CD p
yr NN p
, , p
respectively RB p
) ) p
received VBD N
1-h JJ i
iv JJ i
infusion NN i
of IN i
beta-endorphin JJ i
( ( i
250 CD i
mug/h NN i
) ) i
and CC i
, , i
on IN i
another DT i
occasion NN i
, , i
the DT i
same JJ i
infusion NN i
protocol NN i
preceded VBN i
by IN i
the DT i
opioid JJ i
antagonist NN i
naloxone NN i
( ( i
8 CD i
mg NN i
) ) i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Hemodynamic NNP o
and CC o
hormonal JJ o
measurements NNS o
were VBD N
performed VBN N
at IN N
established VBN N
times NNS N
during IN N
the DT N
infusion NN N
protocols NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
circulating VBG o
beta-endorphin JJ o
, , o
norepinephrine JJ o
, , o
and CC o
endothelin-1 NN o
in IN N
hypertensive JJ N
patients NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
higher JJR N
than IN N
in IN N
controls NNS N
. . N

In IN N
controls NNS N
, , N
beta-endorphin JJ N
reduced VBD N
blood NN o
pressure NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
circulating VBG o
norepinephrine NN o
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
and CC N
increased VBD N
plasma JJ o
atrial JJ o
natriuretic JJ o
factor NN o
( ( N
P NNP N
< NNP N
0.003 CD N
) ) N
and CC N
GH NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
hypertensive JJ N
patients NNS N
, , N
beta-endorphin JJ i
decreased JJ N
systemic JJ o
vascular NN o
resistance NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
blood NN o
pressure NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
plasma JJ o
norepinephrine NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
endothelin-1 JJ o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
raised VBD N
circulating VBG o
atrial JJ o
natriuretic JJ o
factor NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
GH NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
IGF-I NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

These DT N
hemodynamic JJ o
and CC o
hormonal JJ o
responses NNS o
to TO N
beta-endorphin JJ N
in IN N
hypertensive JJ N
patients NNS N
were VBD N
significantly RB N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
greater JJR N
than IN N
in IN N
controls NNS N
but CC N
were VBD N
annulled VBN N
in IN N
all DT N
individuals NNS N
when WRB N
naloxone NN N
preceded VBD N
beta-endorphin JJ N
infusion NN N
. . N

CONCLUSIONS NNP N
High NNP N
doses NNS N
of IN N
beta-endorphin JJ i
induce NN N
hypotensive NN N
and CC N
beneficial JJ N
hormonal JJ N
effects NNS N
in IN N
humans NNS N
, , N
which WDT N
are VBP N
enhanced VBN N
in IN N
essential JJ N
hypertension NN N
and CC N
are VBP N
mediated VBN N
by IN N
opioid JJ N
receptors NNS N
. . N

-DOCSTART- -X- O O

Ovulation NN N
and CC N
follicular JJ N
development NN N
associated VBN N
with IN N
three CD N
low-dose JJ i
oral JJ i
contraceptives NNS i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
address VB N
the DT N
hypothesis NN N
that WDT N
multiphasic JJ i
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
increase NN N
rather RB N
than IN N
decrease VB N
the DT N
risk NN o
of IN o
functional JJ o
ovarian JJ o
cysts NNS o
. . o

METHODS NNP N
In IN N
this DT N
single-center NN N
, , N
randomized VBN N
controlled VBD N
study NN N
, , N
women NNS p
were VBD N
assigned VBN N
to TO N
a DT N
multiphasic JJ i
pill NN i
, , i
a DT i
lower-dose JJ i
monophasic NN i
pill NN i
, , i
a DT i
higher-dose JJ i
monophasic NN i
pill NN i
, , i
or CC i
nonsteroidal JJ i
contraception NN i
. . i

Forty JJ p
volunteers NNS p
were VBD p
randomized VBN p
( ( p
ten VB p
each DT p
) ) p
to TO p
three CD i
different JJ i
pill NN i
regimens VBZ i
or CC p
to TO p
nonsteroidal DT i
contraception NN i
. . i

During IN N
6 CD N
months NNS N
of IN N
treatment NN N
, , N
follicular JJ o
development NN o
was VBD N
measured VBN N
by IN N
vaginal JJ N
ultrasonography NN N
and CC N
ovulation NN o
was VBD N
indicated VBN N
by IN N
serum NN N
progesterone NN N
levels NNS N
. . N

RESULTS VB N
The DT N
relative JJ o
risk NN o
( ( o
RR NNP o
) ) o
of IN o
developing VBG o
a DT o
follicular JJ o
structure NN o
greater JJR o
than IN o
30 CD o
mm NN o
in IN o
diameter NN o
during IN N
a DT N
cycle NN N
with IN N
the DT N
higher-dose JJ N
monophasic NN i
pill NN i
was VBD N
0.5 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
0.1-1.9 NN N
; : N
P NNP N
= NNP N
.49 NNP N
) ) N
compared VBN N
with IN N
the DT N
multiphasic NN N
pill NN N
. . N

The DT N
risk NN o
with IN o
the DT o
lower-dose JJ o
monophasic NN o
pill NN o
was VBD N
comparable JJ N
to TO N
that DT N
with IN N
the DT N
multiphasic NN i
pill NN i
( ( N
RR NNP N
1.3 CD N
, , N
95 CD N
% NN N
CI NNP N
0.5-3.6 CD N
; : N
P NNP N
= NNP N
.56 NNP N
) ) N
. . N

With IN N
the DT N
multiphasic NN i
pill NN i
, , N
the DT N
maximum JJ o
ovulation NN o
rate NN o
over IN N
60 CD N
cycles NNS N
was VBD N
1.7 CD N
per IN N
100 CD N
cycles NNS N
( ( N
95 CD N
% NN N
CI NNP N
0.0-8.9 NN N
) ) N
. . N

CONCLUSION VB N
This DT N
multiphasic JJ i
pill NN i
more RBR N
closely RB N
resembled VBN N
the DT N
lower-dose JJ N
monophasic NN i
pill NN i
than IN N
the DT N
higher-dose JJ N
monophasic NN i
pill NN i
in IN N
its PRP$ N
suppression NN o
of IN o
follicular JJ o
development NN o
. . o

-DOCSTART- -X- O O

A DT N
good JJ N
response NN N
to TO N
oil NN i
with IN i
medium- NN i
and CC i
long-chain JJ i
fatty JJ i
acids NNS i
in IN N
body NN o
fat JJ o
and CC p
blood NN o
lipid JJ o
profiles NNS o
of IN p
male JJ p
hypertriglyceridemic JJ p
subjects NNS p
. . p

A DT N
double JJ N
blind NN N
clinical JJ N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
clarify VB N
the DT N
effects NNS N
of IN N
oil NN i
with IN i
medium- NN i
and CC i
long-chain JJ i
triglyceride NN i
( ( i
MLCT NNP i
) ) i
on IN N
body NN o
fat JJ o
and CC p
blood NN o
lipid JJ o
profiles NNS o
in IN p
hypertriglyceridemic JJ p
subjects NNS p
. . p

One-hundred-and-twelve JJ p
subjects NNS p
were VBD N
enrolled VBN N
and CC N
divided VBN N
into IN N
two CD N
groups NNS N
; : N
those DT i
that IN i
consumed VBD i
MLCT NNP i
oil NN i
and CC i
those DT i
that WDT i
consumed VBD i
long-chain JJ i
triglyceride NN i
( ( i
LCT NNP i
) ) i
oil NN i
for IN N
8 CD N
weeks NNS N
. . N

All DT N
subjects NNS N
were VBD N
requested VBN N
to TO N
consume VB N
25-30 JJ N
g NN N
of IN N
the DT N
oils NNS N
daily RB N
and CC N
maintain VB N
a DT N
fixed JJ N
level NN N
of IN N
energy NN N
intake NN N
and CC N
exercise NN N
. . N

Anthropometric NNP o
and CC o
blood NN o
biochemical JJ o
parameters NNS o
were VBD N
measured VBN N
when WRB N
the DT N
study NN N
was VBD N
initiated VBN N
and CC N
completed VBN N
. . N

The DT N
LCT NNP i
group NN N
consisted VBD N
of IN N
50 CD p
subjects NNS p
( ( p
34 CD p
men NNS p
and CC p
16 CD p
women NNS p
) ) p
, , p
while IN p
the DT p
MLCT NNP i
group NN p
consisted VBD p
of IN p
51 CD p
subjects NNS p
( ( p
33 CD p
men NNS p
and CC p
18 CD p
women NNS p
) ) p
who WP p
completed VBD p
the DT p
study NN p
. . p

Larger NNP N
decreases VBZ N
in IN N
body NN o
weight NN o
, , o
body NN o
mass NN o
index NN o
, , o
waist NN o
circumference NN o
, , o
body NN o
fat NN o
, , o
total JJ o
fat JJ o
area NN o
and CC o
subcutaneous JJ o
fat JJ o
area NN o
in IN o
the DT o
abdomen NNS o
and CC o
serum NN o
triglycerides NNS o
, , o
low-density NN o
lipoprotein NN o
cholesterol NN o
, , o
apolipoprotein NN o
B NNP o
, , o
C2 NNP o
, , o
C3 NNP o
and CC o
E NNP o
were VBD N
observed VBN N
in IN N
male JJ N
subjects NNS N
in IN N
the DT N
MLCT NNP i
group NN N
than IN N
those DT N
in IN N
the DT N
LCT NNP i
group NN N
. . N

However RB N
, , N
no DT N
significant JJ N
differences NNS N
in IN N
these DT o
parameters NNS o
between IN N
the DT N
female JJ N
subjects NNS N
in IN N
the DT N
two CD N
groups NNS N
were VBD N
observed VBN N
. . N

Data NNS N
from IN N
this DT N
study NN N
indicate VBP N
that IN N
consumption NN N
of IN N
medium-and JJ N
long-chain JJ N
triglycerides NNS N
can MD N
reduce VB N
body NN o
weight NN o
and CC N
body NN o
fat NN o
and CC N
improve VB N
blood NN o
lipid JJ o
profiles NNS o
in IN N
male JJ p
hypertriglyceridemic JJ p
subjects NNS p
. . p

-DOCSTART- -X- O O

The DT N
sequencing NN N
of IN N
chemotherapy NN i
and CC N
radiation NN i
therapy NN i
after IN N
conservative JJ p
surgery NN p
for IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

BACKGROUND NNP N
Patients NNPS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
who WP p
are VBP p
at IN p
substantial JJ p
risk NN p
for IN p
systemic JJ p
metastases NNS p
are VBP N
increasingly RB N
treated VBN N
with IN N
breast-conserving JJ i
therapy NN i
and CC i
adjuvant JJ i
chemotherapy NN i
. . i

However RB N
, , N
the DT N
optimal JJ N
sequencing NN N
of IN N
chemotherapy NN i
and CC i
radiation NN i
therapy NN i
is VBZ N
not RB N
clear JJ N
. . N

METHODS NNP N
Two CD p
hundred VBD p
forty-four JJ p
patients NNS p
with IN p
stage NN p
I PRP p
or CC p
II NNP p
breast NN p
cancer NN p
who WP p
were VBD p
at IN p
substantial JJ p
risk NN p
for IN p
distant JJ p
metastases NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
12-week JJ i
course NN i
of IN i
chemotherapy NN i
either CC i
before IN i
or CC i
after IN i
radiation NN i
therapy NN i
. . i

All DT p
had VBD p
had VBN p
breast-conserving JJ p
surgery NN p
. . p

The DT N
median JJ N
length NN N
of IN N
follow-up NN N
in IN N
surviving VBG N
patients NNS N
was VBD N
58 CD N
months NNS N
( ( N
range NN N
, , N
10 CD N
to TO N
124 CD N
) ) N
. . N

RESULTS VB N
The DT N
five-year JJ o
actuarial JJ o
rates NNS o
of IN o
cancer NN o
recurrence NN o
at IN N
any DT N
site NN N
and CC N
of IN N
distant JJ N
metastases NNS N
in IN N
the DT N
radiotherapy-first JJ i
group NN N
and CC N
the DT N
chemotherapy-first JJ i
group NN N
were VBD N
38 CD N
percent NN N
and CC N
31 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.17 CD N
) ) N
and CC N
36 CD N
percent NN N
and CC N
25 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Overall JJ o
survival NN o
was VBD N
73 CD N
percent NN N
and CC N
81 CD N
percent NN N
( ( N
P NNP N
= NNP N
0.11 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
five-year JJ o
crude NN o
rates NNS o
of IN o
first JJ o
recurrence NN o
according VBG N
to TO N
site NN N
in IN N
the DT N
radiotherapy-first JJ i
and CC i
chemotherapy-first JJ i
groups NNS N
, , N
respectively RB N
, , N
were VBD N
5 CD N
percent NN N
and CC N
14 CD N
percent NN N
for IN N
local JJ N
recurrence NN N
and CC N
32 CD N
percent NN N
and CC N
20 CD N
percent NN N
for IN N
distant NN N
or CC N
regional JJ N
recurrence NN N
or CC N
both DT N
. . N

This DT N
difference NN N
in IN N
the DT N
pattern NN o
of IN o
recurrence NN o
was VBD N
of IN N
borderline JJ N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
for IN N
patients NNS p
ar VBP p
substantial JJ p
risk NN p
for IN p
systemic JJ p
metastases NNS p
, , N
it PRP N
is VBZ N
preferable JJ N
to TO N
give VB N
a DT N
12-week JJ N
course NN N
of IN N
chemotherapy NN i
followed VBN N
by IN N
radiation NN i
therapy NN i
, , N
rather RB N
than IN N
radiation NN i
therapy NN i
followed VBN i
by IN i
chemotherapy NN i
. . i

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
orthotic JJ i
heel NN i
lifts NNS i
on IN N
Achilles NNP o
tendon NNP o
force NN o
and CC o
strain NN o
during IN N
running VBG N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
orthotic JJ i
heel NN i
lifts NNS i
on IN N
Achilles NNP o
tendon NN o
( ( o
AT NNP o
) ) o
force NN o
and CC o
strain NN o
during IN N
running VBG N
. . N

Ten CD p
females NNS p
ran VBD p
barefoot NN p
over IN p
a DT p
force NN p
plate NN p
in IN p
three CD p
conditions NNS p
: : p
no DT i
heel NN i
lifts NNS i
( ( p
NHL NNP p
) ) p
, , p
with IN p
12 CD i
mm NNS i
heel JJ i
lifts NNS i
( ( p
12HL CD p
) ) p
and CC p
with IN p
18 CD i
mm NNS i
heel JJ i
lifts NNS i
( ( p
18HL CD p
) ) p
. . p

Kinematics NNS o
for IN o
the DT o
right JJ o
lower JJR o
limb NN o
were VBD N
collected VBN N
( ( N
200 CD N
Hz NNP N
) ) N
. . N

AT NNP o
force NN o
was VBD N
calculated VBN N
from IN N
inverse JJ N
dynamics NNS N
. . N

AT NNP o
strain NN o
was VBD N
determined VBN N
from IN N
kinematics NNS N
and CC N
ultrasound JJ N
images NNS N
of IN N
medial JJ N
gastrocnemius NN N
( ( N
50 CD N
Hz NNP N
) ) N
. . N

Peak NNP o
AT NNP o
strain NN o
was VBD N
less JJR N
for IN N
18HL CD N
( ( N
5.5 CD N
? . N
4.4 CD N
% NN N
) ) N
than IN N
for IN N
NHL NNP N
( ( N
7.4 CD N
? . N
4.2 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
.029 NNP N
, , N
effect NN N
size NN N
[ NNP N
ES NNP N
] NNP N
= NNP N
0.44 CD N
) ) N
but CC N
not RB N
for IN N
12HL CD N
( ( N
5.8 CD N
? . N
4.8 CD N
% NN N
) ) N
versus NN N
NHL NNP N
( ( N
ES NNP N
= NNP N
0.35 CD o
) ) o
. . o

Peak NNP o
AT NNP o
force NN o
was VBD o
significantly RB N
( ( N
p JJ N
= NNP N
.024 NNP N
, , N
ES NNP N
= NNP N
0.42 CD N
) ) N
less JJR N
for IN N
18HL CD N
( ( N
2382 CD N
? . N
717 CD N
N NNP N
) ) N
than IN N
for IN N
NHL NNP N
( ( N
2710 CD N
? . N
830 CD N
N NNP N
) ) N
but CC N
not RB N
for IN N
12HL CD N
( ( N
2538 CD N
? . N
823 CD N
N NNP N
, , N
ES NNP N
= NNP N
0.21 CD N
) ) N
. . N

The DT N
18HL CD N
reduced VBD o
ankle JJ o
dorsiflexion NN o
but CC o
not RB o
flexion-extension JJ o
ankle NN o
moments NNS o
and CC o
increased VBD o
the DT o
AT NNP o
moment NN o
arm NN o
compared VBN o
with IN N
NHL NNP N
. . N

Thus NNP N
, , N
18HL CD N
reduced VBN o
force NN o
and CC o
strain NN o
on IN o
the DT o
AT NNP N
during IN N
running VBG N
via IN N
a DT N
reduction NN o
in IN o
dorsiflexion NN o
, , o
which WDT o
lengthened VBD o
the DT o
AT NNP o
moment NN o
arm NN o
. . o

Therefore RB i
, , i
heel NN i
lifts NNS i
could MD N
be VB N
used VBN N
to TO N
reduce VB N
AT NNP o
loading NN o
and CC o
strain NN o
during IN o
the DT N
rehabilitation NN N
of IN N
AT NNP N
injuries NNS N
. . N

-DOCSTART- -X- O O

Etanercept NNP i
treatment NN N
in IN N
adults NNS p
with IN p
established VBN p
rheumatoid NN p
arthritis NN p
: : p
7 CD N
years NNS N
of IN N
clinical JJ N
experience NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
safety NN o
and CC o
efficacy NN o
of IN N
longterm JJ N
etanercept FW i
treatment NN N
in IN N
patients NNS p
with IN p
disease NN p
modifying VBG p
antirheumatic JJ p
drug NN p
( ( p
DMARD NNP p
) ) p
refractory NN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

METHODS NNP N
Safety NNP N
results NNS N
are VBP N
reported VBN N
for IN N
714 CD p
patients NNS p
who WP p
received VBD p
etanercept RB i
in IN p
one CD p
of IN p
7 CD p
initial JJ p
trials NNS p
or CC p
a DT p
longterm JJ p
extension NN p
. . p

Efficacy NN N
results NNS N
are VBP N
reported VBN N
for IN N
581 CD p
patients NNS p
who WP p
enrolled VBD p
in IN p
the DT p
extension NN p
. . p

RESULTS NNP N
Of IN N
the DT N
714 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
initial JJ p
trials NNS p
, , p
581 CD p
( ( p
81 CD p
% NN p
) ) p
enrolled VBN p
in IN p
the DT p
extension NN p
, , p
and CC p
388 CD p
( ( p
54 CD p
% NN p
) ) p
patients NNS p
are VBP p
continuing VBG p
to TO p
receive VB p
etanercept JJ i
therapy NN i
. . i

The DT N
longest JJS N
individual JJ N
treatment NN N
was VBD N
8.2 CD N
years NNS N
, , N
with IN N
3139 CD N
total JJ N
patient-years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

Rates NNS o
of IN o
serious JJ o
adverse JJ o
events NNS o
( ( N
overall JJ N
rate=14.8 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
serious JJ o
infections NNS o
( ( N
overall JJ N
rate=4.2 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
cancer NN o
( ( N
overall JJ N
rate=1.0 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
and CC o
deaths NNS o
( ( N
overall JJ N
rate=0.7 NN N
events/100 IN N
patient-yrs NN N
) ) N
were VBD N
stable JJ N
each DT N
year NN N
, , N
through IN N
8 CD N
years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

For IN N
356 CD p
patients NNS p
who WP p
completed VBD p
6 CD p
years NNS p
of IN p
etanercept JJ p
treatment NN p
, , N
response NN o
rates NNS o
were VBD N
ACR20=73 NNP N
% NN N
, , N
ACR50=52 NNP N
% NN N
, , N
ACR70=27 NNP N
% NN N
, , N
DAS28 NNP N
CRP NNP N
good JJ N
response=52 NN N
% NN N
, , N
and CC N
DAS28 NNP N
CRP NNP N
remission=37 VBZ N
% NN N
of IN N
patients NNS N
. . N

Similar JJ N
responses NNS N
occurred VBD N
in IN N
167 CD p
patients NNS p
who WP p
completed VBD p
Year NNP p
7 CD p
. . p

Doses NNS o
of IN N
concomitant JJ N
methotrexate NN N
or CC N
corticosteroids NNS N
were VBD N
reduced VBN N
in IN N
many JJ N
patients NNS N
who WP N
maintained VBD N
clinical JJ N
responses NNS N
. . N

CONCLUSION VB N
The DT N
safety NN o
profile NN o
of IN N
etanercept NN i
was VBD N
consistent JJ N
over IN N
time NN N
, , N
with IN N
rates NNS o
of IN o
adverse JJ o
events NNS o
similar JJ N
to TO N
those DT N
reported VBN N
for IN N
patients NNS p
with IN p
RA NNP p
in IN p
general JJ p
. . p

Durable JJ N
clinical JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
some DT N
patients NNS N
for IN N
7 CD N
years NNS N
or CC N
more JJR N
. . N

The DT N
benefit-to-risk JJ N
ratio NN N
for IN N
longterm JJ N
etanercept JJ i
treatment NN N
remains VBZ N
highly RB N
favorable JJ N
. . N

-DOCSTART- -X- O O

LEGO NNP i
therapy NN i
and CC N
the DT N
social JJ i
use NN i
of IN i
language NN i
programme NN i
: : i
an DT N
evaluation NN N
of IN N
two CD N
social JJ o
skills NNS o
interventions NNS N
for IN N
children NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
and CC p
Asperger NNP p
Syndrome NNP p
. . p

LEGO NNP i
therapy NN i
and CC N
the DT N
Social NNP i
Use NNP i
of IN i
Language NNP i
Programme NNP i
( ( i
SULP NNP i
) ) i
were VBD N
evaluated VBN N
as IN N
social JJ i
skills NNS i
interventions NNS i
for IN p
6-11 JJ p
year NN p
olds NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
and CC p
Asperger NNP p
Syndrome NNP p
. . p

Children NNP p
were VBD N
matched VBN N
on IN N
CA NNP N
, , N
IQ NNP N
, , N
and CC N
autistic JJ N
symptoms NNS N
before IN N
being VBG N
randomly RB N
assigned VBN N
to TO N
LEGO NNP i
or CC N
SULP NNP i
. . i

Therapy NNP N
occurred VBD N
for IN N
1 CD p
h/week NN p
over IN p
18 CD p
weeks NNS p
. . p

A DT N
no-intervention JJ i
control NN i
group NN i
was VBD N
also RB N
assessed VBN N
. . N

Results NNS N
showed VBD N
that IN N
the DT N
LEGO NNP i
therapy NN N
group NN N
improved VBD N
more JJR N
than IN N
the DT N
other JJ p
groups NNS p
on IN p
autism-specific JJ o
social JJ o
interaction NN o
scores NNS o
( ( o
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
) ) o
. . N

Maladaptive JJ o
behaviour NN o
decreased VBD N
significantly RB N
more RBR N
in IN N
the DT N
LEGO NNP i
and CC p
SULP NNP i
groups NNS p
compared VBN p
to TO p
the DT p
control NN p
group NN p
. . p

There EX N
was VBD N
a DT N
non-significant JJ N
trend NN N
for IN N
SULP NNP i
and CC p
LEGO NNP i
groups NNS p
to TO N
improve VB N
more JJR N
than IN N
the DT N
no-intervention JJ i
group NN N
in IN N
communication NN o
and CC o
socialisation NN o
skills NNS o
. . o

-DOCSTART- -X- O O

On IN N
the DT N
possibility NN N
of IN N
incorporating VBG p
patients NNS p
from IN p
non-randomising JJ p
centres NNS p
into IN p
a DT p
randomised JJ p
clinical JJ p
trial NN p
. . p

-DOCSTART- -X- O O

Total JJ N
intravenous JJ N
anesthesia NN N
using VBG N
remifentanil NN i
in IN N
extracorporeal NN i
shock NN i
wave VBP i
lithotripsy NN i
( ( i
ESWL NNP i
) ) i
. . i

Comparison NNP N
of IN N
two CD N
dosages NNS N
: : N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Extracorporeal NNP i
Shock NNP i
Wave NNP i
Lithotripsy NNP i
is VBZ N
usually RB N
performed VBN N
in IN N
day NN N
surgery NN N
setting NN N
, , N
consequently RB N
people NNS N
who WP N
undergo VBP N
to TO N
this DT N
procedure NN N
need VB N
a DT N
safe JJ N
and CC N
fast JJ N
recovery NN N
. . N

Conscious JJ N
sedation NN N
with IN N
remifentanil NN i
can MD N
relieve VB N
from IN N
pain NN N
and CC N
keep VB N
patients NNS N
in IN N
touch JJ N
with IN N
anaesthesiologists NNS N
. . N

Few JJ N
publications NNS N
tell VBP N
about IN N
infusion NN N
rates NNS N
administered VBD N
to TO N
perform VB N
this DT N
procedure7 NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
which WDT N
is VBZ N
the DT N
most RBS N
appropriate JJ N
infusion NN N
rate NN N
. . N

METHODS CC N
Patients NNPS p
were VBD p
randomly RB p
assigned VBN p
to TO p
two CD p
groups NNS p
. . p

Two CD N
different JJ N
infusion NN N
rates NNS N
were VBD N
compared VBN N
: : N
0,05 CD N
mcg/kg/min NN N
, , N
GROUP NNP N
A NNP N
( ( N
N.=114 NNP N
) ) N
, , N
vs. FW N
0.1 CD N
?g/kg/min NNP N
, , N
GROUP NNP N
B NNP N
( ( N
N.=114 NNP N
) ) N
. . N

Patients NNS o
' POS o
vital JJ o
signs NNS o
, , o
additional JJ o
analgesic NN o
requests NNS o
, , o
PONV NNP o
( ( o
postoperative JJ o
nausea NN o
and CC o
vomiting NN o
) ) o
and CC N
other JJ N
side NN N
effects NNS N
were VBD N
registered VBN N
. . N

The DT N
deepness NN N
of IN N
sedation NN N
and CC N
patient NN N
's POS N
satisfaction NN N
were VBD N
evaluated VBN N
referring VBG N
to TO o
Obsever NNP o
's POS o
Assessment NNP o
of IN o
Alertness NNP o
and CC o
Sedation NNP o
scale NN o
( ( N
O/ASS NNP N
) ) N
and CC N
using VBG N
a DT N
Likert NNP N
's POS N
scale NN N
respectively RB N
. . N

Pain NNP o
intensity NN o
was VBD N
assessed VBN N
with IN N
a DT N
11-points NNS N
VAS NNP N
( ( N
visual JJ N
analogue NN N
scale NN N
) ) N
. . N

Differences NNS N
between IN N
groups NNS N
were VBD N
analyzed VBN N
using VBG N
Student NNP N
t JJ N
test NN N
for IN N
independent JJ N
variables NNS N
. . N

The DT N
?2 JJ N
test NN N
was VBD N
used VBN N
to TO N
analyze VB N
categorical JJ N
variables NNS N
. . N

RESULTS VB N
The DT N
study NN N
enrolled VBD p
228 CD p
patients NNS p
and CC p
assigned VBD N
them PRP N
to TO N
two CD N
groups NNS N
( ( N
N.=114 NNP N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
regarding VBG o
Likert NNP o
's POS o
scale NN o
values NNS o
( ( o
P=0.20 NNP N
) ) N
, , N
additional JJ N
analgesic JJ N
request NN N
( ( N
P=0.30 NNP N
) ) N
and CC N
mean JJ o
VAS NNP o
values NNS o
( ( o
P NNP N
> NNP N
0.05 CD N
) ) N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
about IN o
PONV NNP o
, , o
hypotension NN o
, , o
oxygen NN o
desaturation NN o
and CC o
respiratory NN o
depression NN o
was VBD o
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
as IN N
a DT N
matter NN N
of IN N
fact NN N
in IN N
group NN N
A NNP N
these DT N
side NN N
effects NNS N
occurred VBD N
less RBR N
frequently RB N
. . N

The DT o
fifth JJ o
degree NN o
of IN o
O/ASS NNP o
was VBD o
estimated VBN N
in IN N
about RB N
1.61?0.19 CD N
min NNS N
and CC N
2.987?0.20 CD N
min NN N
in IN N
group NN N
A NNP N
and CC N
in IN N
group NN N
B NNP N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
According VBG N
with IN N
previous JJ N
results NNS N
remifentanil VBP N
at IN N
the DT N
infusion NN N
rate NN N
of IN N
0.05 CD N
?g/kg/min NNP N
provides VBZ N
an DT N
effective JJ N
analgesia NN N
, , N
causing VBG N
a DT N
lower JJR N
incidence NN N
of IN N
side NN N
effect NN N
than IN N
0.1 CD N
?g/kg/min NN N
, , N
granting VBG N
a DT N
fast JJ N
and CC N
safe JJ N
recovery NN N
. . N

-DOCSTART- -X- O O

[ JJ N
Comparison NNP N
of IN N
fracture NN o
resistance NN o
of IN N
pulpless NN i
teeth NNS i
restored VBD i
with IN i
fiber NN i
reinforced VBN i
composite JJ i
posts NNS i
and CC N
three CD i
kinds NNS i
of IN i
resin NN i
core NN i
material NN i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
fracture NN o
resistances NNS o
of IN N
pulpless NN N
teeth NNS N
restored VBD N
with IN N
FRC NNP i
( ( i
Fiber NNP i
Reinforced NNP i
Composite NNP i
) ) i
posts NNS i
and CC N
three CD i
kinds NNS i
of IN i
resin NN i
core NN i
material NN i
. . i

METHODS NNP N
A NNP p
total NN p
of IN p
42 CD p
recently RB p
extracted VBN p
upper JJ p
incisors NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
. . p

Group NNP N
A NNP N
was VBD N
restored VBN N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
Artglass NNP i
polymer NN i
core NN i
; : i
group NN N
B NNP N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
Charisma NNP i
composite JJ i
resin NN i
core NN i
; : i
and CC N
group NN N
C NNP N
with IN N
prefabricated JJ i
glass-fiber JJ i
posts NNS i
and CC i
AB NNP i
composite JJ i
resin NN i
core NN i
. . i

In IN N
every DT N
group NN N
, , N
the DT N
core NN N
material NN N
was VBD N
processed VBN N
by IN N
hot-press NN N
and CC N
non JJ N
hot-press NN N
respectively RB N
. . N

The DT N
posts NNS N
size NN N
and CC N
shape NN N
were VBD N
identical JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

All DT p
teeth NNS p
were VBD p
fully RB p
covered VBN p
with IN p
polycarbonate JJ p
resin NN p
crowns NNS p
. . p

Fracture NN o
resistance NN o
was VBD N
measured VBN N
by IN N
applying VBG N
point NN N
force NN N
at IN N
130 CD N
degrees NNS N
to TO N
the DT N
long JJ N
axis NN N
of IN N
the DT N
teeth NN N
on IN N
an DT N
universal JJ N
testing NN N
machine NN N
. . N

RESULTS JJ N
Mean JJ o
fracture NN o
threshold NN o
was VBD N
505.4 CD N
N NNP N
+/- JJ N
42.0 CD N
N NNP N
and CC N
564.1 CD N
N NNP N
+/- JJ N
41.7 CD N
N NNP N
in IN N
group NN N
A NNP N
, , N
411.3 CD N
N NNP N
+/- JJ N
23.3 CD N
N NNP N
and CC N
315.3 CD N
N NNP N
+/- JJ N
19.1 CD N
N NNP N
in IN N
group NN N
B NNP N
and CC N
358.4 CD N
N NNP N
+/- JJ N
36.1 CD N
N NNP N
and CC N
423.4 CD N
N NNP N
+/- JJ N
47.5 CD N
N NNP N
in IN N
group NN N
C. NNP N
In IN N
all DT N
groups NNS N
, , N
there EX N
was VBD N
no DT o
posts NNS o
fracture NN o
and CC o
polycarbonate NN o
resin NN o
crowns NNS o
fragmentation NN o
. . o

CONCLUSION VB N
The DT N
composite JJ N
restoration NN N
of IN N
FRC NNP i
posts NNS i
combined VBD i
with IN i
resin NN i
core NN i
and CC i
resin VB i
crown NN i
can MD N
improve VB N
the DT N
fracture NN o
resistance NN o
of IN N
the DT N
pulpless JJ N
roots NNS N
. . N

The DT N
strength NN N
of IN N
resin NN N
core NN N
material NN N
can MD N
be VB N
increased VBN N
by IN N
hot-press JJ i
methods NNS i
. . i

-DOCSTART- -X- O O

Warfarin NNP i
versus NN N
aspirin NN i
for IN N
prevention NN N
of IN N
thromboembolism NN o
in IN N
atrial JJ N
fibrillation NN N
: : N
Stroke NNP N
Prevention NNP N
in IN N
Atrial NNP N
Fibrillation NNP N
II NNP N
Study NNP N
. . N

Warfarin NNP i
is VBZ N
an DT N
established JJ N
treatment NN N
for IN N
prevention NN N
of IN N
ischaemic JJ N
stroke NN N
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
, , N
but CC N
the DT N
value NN N
of IN N
this DT N
agent JJ N
relative NN N
to TO N
aspirin VB N
in IN N
unclear JJ N
. . N

In IN N
the DT N
first JJ N
Stroke NNP N
Prevention NNP N
in IN N
Atrial NNP N
Fibrillation NNP N
( ( N
SPAF-I NNP N
) ) N
study NN N
, , N
direct JJ N
comparison NN N
of IN N
warfarin NN i
with IN N
aspirin NN i
was VBD N
limited VBN N
by IN N
the DT N
small JJ N
number NN N
of IN N
thromboembolic JJ N
events NNS N
. . N

SPAF-II JJ N
aims NNS N
to TO N
address VB N
this DT N
issue NN N
and CC N
also RB N
to TO N
assess VB N
the DT N
differential JJ N
effects NNS N
of IN N
the DT N
two CD N
treatments NNS N
according VBG N
to TO N
age NN N
. . N

We PRP N
compared VBN N
warfarin NN i
( ( N
prothrombin JJ N
time NN N
ratio JJ N
1.3-1.8 JJ N
, , N
international JJ N
normalised JJ N
ratio NN N
2.0-4.5 JJ N
) ) N
with IN N
aspirin $ i
325 CD i
mg JJ i
daily RB i
for IN N
prevention NN N
of IN N
ischaemic JJ o
stroke NN o
and CC N
systemic JJ o
embolism NN o
( ( N
primary JJ N
events NNS N
) ) N
in IN N
two CD N
parallel NNS N
randomised VBD N
trials NNS N
involving VBG N
715 CD p
patients NNS p
aged VBN p
75 CD p
years NNS p
or CC p
less JJR p
and CC p
385 CD p
patients NNS p
older JJR p
than IN p
75 CD p
; : p
we PRP N
sought VBD N
reductions NNS N
in IN N
the DT N
absolute JJ N
rate NN N
of IN N
primary JJ N
events NNS N
by IN N
warfarin NNS i
compared VBN N
with IN N
aspirin NN i
of IN N
2 CD N
% NN N
per IN N
year NN N
and CC N
4 CD N
% NN N
per IN N
year NN N
, , N
respectively RB N
. . N

In IN N
the DT N
younger JJR N
patients NNS N
, , N
warfarin NNS i
decreased VBD N
the DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
by IN N
0.7 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI-0.4 NNP N
to TO N
1.7 CD N
) ) N
. . N

The DT N
primary JJ o
event NN o
rate NN o
per IN o
year NN o
was VBD N
1.3 CD N
% NN N
with IN N
warfarin NN i
and CC N
1.9 CD N
% NN N
with IN N
aspirin NN i
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
0.67 CD N
, , N
p NN N
= NNP N
0.24 CD N
) ) N
. . N

The DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
in IN N
low-risk JJ N
younger NN N
patients NNS N
( ( N
without IN N
hypertension NN N
, , N
recent JJ N
heart NN N
failure NN N
, , N
or CC N
previous JJ N
thromboembolism NN N
) ) N
on IN N
aspirin NN i
was VBD N
0.5 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI NNP N
0.1 CD N
to TO N
1.9 CD N
) ) N
. . N

Among IN N
older JJR N
patients NNS N
, , N
warfarin NNS i
decreased VBD N
the DT N
absolute JJ o
rate NN o
of IN o
primary JJ o
events NNS o
by IN N
1.2 CD N
% NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI-1.7 NNP N
to TO N
4.1 CD N
) ) N
. . N

The DT N
primary JJ o
event NN o
rate NN o
per IN o
year NN o
was VBD N
3.6 CD N
% NN N
with IN N
warfarin NN i
and CC N
4.8 CD N
% NN N
with IN N
aspirin NN i
( ( N
RR NNP N
0.73 CD N
, , N
p NN N
= NNP N
0.39 CD N
) ) N
. . N

In IN N
this DT N
older JJR N
group NN N
, , N
the DT N
rate NN o
of IN o
all DT o
stroke NN o
with IN o
residual JJ o
deficit NN o
( ( N
ischaemic JJ N
or CC N
haemorrhagic NN N
) ) N
was VBD N
4.3 CD N
% NN N
per IN N
year NN N
with IN N
aspirin NN i
and CC N
4.6 CD N
% NN N
per IN N
year NN N
with IN N
warfarin NN i
( ( N
RR NNP N
1.1 CD N
) ) N
. . N

Warfarin NNP i
may MD N
be VB N
more RBR N
effective JJ N
than IN N
aspirin NN i
for IN N
prevention NN N
of IN N
ischaemic JJ o
stroke NN o
in IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
, , N
but CC N
the DT N
absolute JJ o
reduction NN o
in IN N
stroke NN o
rate NN o
by IN N
warfarin NN i
is VBZ N
small JJ N
. . N

Younger JJR N
patients NNS N
without IN N
risk NN N
factors NNS N
had VBD N
a DT N
low JJ N
rate NN o
of IN o
stroke NN o
when WRB N
treated VBN N
with IN N
aspirin NN i
. . i

In IN N
older JJR N
patients NNS N
the DT N
rate NN o
of IN o
stroke NN o
( ( N
ischaemic JJ N
and CC N
haemorrhagic NN N
) ) N
was VBD N
substantial JJ N
, , N
irrespective NN N
of IN N
which WDT N
agent NN N
was VBD N
given VBN N
. . N

Patient JJ N
age NN N
and CC N
the DT N
inherent JJ N
risk NN N
of IN N
thromboembolism NN N
should MD N
be VB N
considered VBN N
in IN N
the DT N
choice NN N
of IN N
antithrombotic JJ N
prophylaxis NN N
for IN N
patients NNS N
with IN N
atrial JJ N
fibrillation NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
the DT N
Quest NNP i
to TO i
Lava NNP i
Mountain NNP i
Computer NNP i
Game NNP i
on IN N
Dietary NNP o
and CC o
Physical NNP o
Activity NNP o
Behaviors NNP o
of IN N
Elementary NNP p
School NNP p
Children NNP p
: : p
A DT N
Pilot NNP N
Group-Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

BACKGROUND NNP N
Computer-based JJ i
educational JJ i
games NNS i
present VBP N
an DT N
opportunity NN N
for IN N
health NN N
education NN N
in IN N
school NN N
; : N
however RB N
, , N
their PRP$ N
feasibility NN N
in IN N
school NN N
settings NNS N
and CC N
effectiveness NN N
in IN N
changing VBG N
behavior NN N
are VBP N
poorly RB N
understood JJ N
. . N

OBJECTIVE NN N
To TO N
evaluate VB N
the DT N
feasibility NN N
, , N
acceptability NN N
, , N
and CC N
effects NNS N
of IN N
the DT N
Quest NNP i
to TO i
Lava NNP i
Mountain NNP i
( ( i
QTLM NNP i
) ) i
computer NN i
game NN i
on IN N
dietary JJ o
behaviors NNS o
, , o
physical JJ o
activity NN o
behaviors NNS o
, , o
and CC o
psychosocial JJ o
factors NNS o
among IN N
ethnically RB p
diverse JJ p
children NNS p
in IN p
Texas NNP p
. . p

DESIGN NNP N
Quasi-experimental JJ N
group-randomized JJ N
controlled VBN N
trial NN N
conducted VBN N
during IN N
the DT N
2012-2013 JJ p
school NN p
year NN p
. . p

PARTICIPANTS/SETTING CC N
A DT p
total NN p
of IN p
107 CD p
children NNS p
in IN p
fourth JJ p
and CC p
fifth JJ p
grade NN p
consented VBN p
. . p

There EX p
was VBD p
an DT p
attrition NN p
rate NN p
of IN p
8.8 CD p
% NN p
with IN p
a DT p
final JJ p
sample NN p
size NN p
of IN p
44 CD p
children NNS p
in IN p
three CD p
intervention NN p
schools NNS p
, , p
and CC p
a DT p
sample NN p
of IN p
50 CD p
children NNS p
in IN p
three CD p
comparison NN p
schools NNS p
. . p

Dietary NNP N
intake NN N
was VBD N
measured VBN N
using VBG N
two CD N
random JJ N
24-hour JJ N
recalls NNS N
, , N
whereas JJ N
child NN N
self-report JJ N
surveys NNS N
measured VBN N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
psychosocial JJ o
factors NNS o
before IN N
and CC N
after IN N
the DT N
intervention NN N
. . N

Process NNP N
data NN N
on IN N
QTLM NNP i
usability NN N
and CC N
back-end JJ N
server NN N
data NNS N
on IN N
QTLM NNP N
exposure NN N
and CC N
progress NN N
achieved VBN N
were VBD N
collected VBN N
. . N

INTERVENTION NNP N
QTLM NNP i
was VBD N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
in-school NN p
or CC p
afterschool JJ p
program NN p
. . p

Recommended JJ N
game NN N
exposure NN N
duration NN N
was VBD N
90 CD N
min/wk NN N
for IN N
6 CD N
weeks NNS N
. . N

STATISTICAL JJ N
ANALYSIS NNP N
Analysis NNP N
of IN N
covariance NN N
or CC N
logistic JJ N
regression NN N
models NNS N
evaluated VBN N
effects NNS N
of IN N
QTLM NNP i
on IN N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
psychosocial JJ o
factors NNS o
. . o

Post NNP N
hoc JJ N
exploratory NN N
analysis NN N
examined VBD N
the DT N
changes NNS N
before IN N
and CC N
after IN N
the DT N
intervention NN N
in IN N
outcome JJ N
variables NNS N
among IN N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

Significance NN N
was VBD N
set VBN N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

RESULTS NNP N
Children NNP N
played VBD N
an DT N
average NN N
of IN N
274?110 CD N
minutes NNS N
( ( N
approximately RB N
4.6 CD N
hours NNS N
) ) N
of IN i
QTLM NNP i
during IN N
the DT N
6 CD N
weeks NNS N
( ( N
51 CD N
% NN N
of IN N
recommended JJ N
dosage NN N
) ) N
. . N

Compared VBN N
with IN N
the DT N
comparison NN N
group NN N
, , N
children NNS N
in IN N
the DT N
intervention NN N
group NN N
reported VBD o
decreased JJ o
sugar NN o
consumption NN o
( ( N
P=0.021 NNP N
) ) N
and CC o
higher JJR o
nutrition/physical JJ o
activity NN o
attitudes NNS o
( ( N
P=0.041 NNP N
) ) N
pre- NN N
to TO N
postintervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
effects NNS N
of IN N
QTLM NNP N
on IN o
physical JJ o
activity NN o
. . o

However RB N
, , N
post NN N
hoc NN N
analysis NN N
showed VBD N
that IN N
higher JJR i
QTLM NNP i
exposure NN N
and CC N
gaming VBG N
progress NN N
was VBD N
associated VBN N
with IN N
increased JJ o
frequency NN o
of IN o
physical JJ o
activity NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP i
QTLM NNP i
has VBZ N
some DT N
promising JJ N
acceptability NN N
and CC N
initial JJ N
effects NNS N
on IN o
diet JJ o
and CC o
physical JJ o
activity NN o
behaviors NNS o
among IN p
children NNS p
in IN p
elementary JJ p
school NN p
. . p

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
the DT N
serologic JJ N
responses NNS N
to TO N
oral JJ N
and CC N
injectable JJ N
trivalent NN i
poliovirus NN i
vaccines NNS i
. . i

United NNP p
States NNPS p
children NNS p
two CD p
months NNS p
of IN p
age NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
that WDT N
received VBD N
either RB N
the DT N
commercially RB N
available JJ N
oral JJ i
trivalent NN i
poliovirus NN i
vaccine NN i
( ( i
OPV NNP i
) ) i
or CC N
an DT N
injectable JJ i
( ( i
inactivated VBN i
) ) i
trivalent NN i
poliovirus NN i
vaccine NN i
( ( i
IPV NNP i
) ) i
with IN N
a DT N
confirmed JJ N
minimum JJ N
D-antigen NNP N
content NN N
of IN N
27 CD N
, , N
3.5 CD N
, , N
and CC N
29 CD N
units NNS N
for IN N
poliovirus NN N
types NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
. . N

Vaccine NNP N
was VBD N
given VBN N
at IN N
two CD N
, , N
four CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

Sera NN N
obtained VBN N
from IN N
439 CD p
children NNS p
at IN p
two CD p
, , p
four CD p
, , p
and CC p
six CD p
months NNS p
of IN p
age NN p
and CC p
from IN p
85 CD p
children NNS p
at IN p
18 CD p
and CC p
20 CD p
months NNS p
of IN p
age NN p
were VBD N
examined VBN N
for IN N
neutralizing VBG o
antibodies NNS o
. . o

The DT N
percentage NN o
of IN o
children NNS o
with IN o
detectable JJ o
antibodies NNS o
and CC o
the DT o
reciprocal JJ o
geometric JJ o
mean NN o
titers NNS o
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
at IN N
two CD N
months NNS N
of IN N
age NN N
for IN N
antibodies NNS o
to TO o
all DT o
three CD o
poliovirus NN o
types NNS o
. . o

At IN N
20 CD N
months NNS N
of IN N
age NN N
, , N
all DT N
children NNS N
but CC N
one CD N
had VBD N
detectable JJ o
antibodies NNS N
to TO N
all DT N
three CD N
poliovirus NN N
types NNS N
. . N

Significantly RB N
higher JJR N
geometric JJ o
mean NN o
titers NNS o
against IN o
types NNS o
2 CD o
and CC o
3 CD o
were VBD N
noted VBN N
at IN N
20 CD N
months NNS N
of IN N
age NN N
for IN N
the DT N
IPV NNP i
group NN N
. . N

-DOCSTART- -X- O O

Riding VBG N
the DT N
rapids NNS N
: : N
living NN N
with IN N
autism NN N
or CC N
disability NN N
-- : N
an DT N
evaluation NN N
of IN N
a DT N
parenting VBG i
support NN i
intervention NN i
for IN N
parents NNS p
of IN p
disabled JJ p
children NNS p
. . p

Evidence NN N
on IN N
the DT N
effectiveness NN N
of IN N
interventions NNS N
to TO N
support VB N
parents NNS p
of IN p
disabled JJ p
children NNS p
to TO N
manage VB N
their PRP$ N
child NN N
's POS N
behaviour NN N
problems NNS N
is VBZ N
limited VBN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
a DT N
group-delivered JJ i
intervention NN i
( ( i
Riding VBG i
the DT i
Rapids NNP i
) ) i
which WDT N
was VBD N
specifically RB N
developed VBN N
for IN N
parents NNS p
of IN p
a DT p
child NN p
with IN p
a DT p
disability NN p
or CC p
autistic JJ p
spectrum NN p
condition NN p
. . p

This DT N
programme NN N
has VBZ N
been VBN N
routinely RB N
delivered VBN N
by IN N
a DT N
community-based JJ N
mental JJ N
health NN N
team NN N
across IN N
an DT N
urban JJ N
, , N
multi-ethnic JJ N
locality NN N
for IN N
a DT N
number NN N
of IN N
years NNS N
. . N

A DT N
non-randomised JJ N
controlled JJ i
study NN N
design NN N
comprising VBG p
an DT p
intervention NN i
group NN i
( ( p
n=48 CC p
) ) p
and CC p
comparator NN i
( ( i
no DT i
intervention NN i
) ) i
group NN p
( ( p
n=28 RB p
) ) p
was VBD p
used VBN p
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
the DT N
intervention NN N
on IN N
child JJ o
behaviour NN o
( ( o
Eyberg NNP o
Child NNP o
Behaviour NNP o
Inventory NNP o
; : o
parent-set JJ o
goals NNS o
) ) o
and CC N
parenting VBG o
efficacy NN o
and CC o
satisfaction NN o
( ( o
Parents NNP o
Sense NNP o
of IN o
Competence NNP o
Scale NNP o
) ) o
at IN N
post-intervention NN N
and CC N
six-month JJ N
follow-up NN N
. . N

Data NNS N
on IN N
costs NNS N
to TO N
the DT N
service NN N
provider NN N
of IN N
delivering VBG N
the DT N
intervention NN N
were VBD N
also RB N
collected VBN N
. . N

Receipt NNP N
of IN N
the DT N
intervention NN N
was VBD N
associated VBN N
with IN N
significant JJ o
reductions NNS o
in IN N
parent-reported JJ o
behaviour NN o
problems NNS o
and CC N
significant JJ o
improvements NNS o
in IN o
parenting VBG o
efficacy NN o
and CC o
satisfaction NN o
. . o

At IN N
six-month JJ N
follow-up NN N
, , N
progress NN N
towards NNS N
achieving VBG N
parent-set JJ o
child NN o
behaviour NN o
goals NNS o
and CC N
parenting VBG o
satisfaction NN o
had VBD N
been VBN N
maintained VBN N
. . N

Post NNP N
hoc JJ N
analysis NN N
suggests VBZ N
parents NNS p
who WP p
do VBP p
not RB p
have VB p
English NNP p
as IN p
a DT p
first JJ p
language NN p
may MD N
not RB o
benefit VB o
as RB N
much RB N
as IN N
other JJ N
parents NNS N
from IN N
this DT N
intervention NN N
. . N

Findings NNS N
suggest VBP N
this DT N
is VBZ N
a DT N
promising JJ N
intervention NN i
for IN i
parents NNS i
of IN N
a DT N
child NN N
with IN N
a DT N
disability NN N
that WDT N
is VBZ N
likely JJ N
to TO N
be VB N
less JJR N
resource JJ N
intensive NN N
to TO N
service NN N
providers NNS N
than IN N
individually RB N
delivered VBN N
interventions NNS N
. . N

Limitations NNS N
and CC N
implications NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
study NN N
of IN N
L-carnosine NNP i
supplementation NN i
in IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

L-Carnosine NNP i
, , i
a DT i
dipeptide NN i
, , N
can MD N
enhance VB N
frontal JJ N
lobe NN N
function NN N
or CC N
be VB N
neuroprotective JJ N
. . N

It PRP N
can MD N
also RB N
correlate VB N
with IN N
gamma-aminobutyric JJ N
acid NN N
( ( N
GABA NNP N
) ) N
-homocarnosine NN N
interaction NN N
, , N
with IN N
possible JJ N
anticonvulsive JJ N
effects NNS N
. . N

We PRP N
investigated VBD N
31 CD p
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
in IN p
an DT p
8-week JJ p
, , p
double-blinded JJ p
study NN p
to TO N
determine VB N
if IN N
800 CD N
mg JJ N
L-carnosine JJ i
daily NN N
would MD N
result VB N
in IN N
observable JJ N
changes NNS N
versus VBP N
placebo NN i
. . i

Outcome CC N
measures NNS N
were VBD N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , o
the DT o
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , o
the DT o
Expressive NNP o
and CC o
Receptive NNP o
One-Word NNP o
Picture NNP o
Vocabulary NNP o
tests NNS o
, , o
and CC o
Clinical NNP o
Global NNP o
Impressions NNP o
of IN o
Change NNP o
. . o

Children NNP N
on IN N
placebo NN i
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
changes NNS N
. . N

After IN N
8 CD N
weeks NNS N
on IN N
L-carnosine NNP i
, , N
children NNS N
showed VBD N
statistically RB N
significant JJ N
improvements NNS N
on IN N
the DT N
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
total JJ o
score NN o
and CC o
the DT o
Behavior NNP o
, , o
Socialization NNP o
, , o
and CC o
Communication NNP o
subscales NNS o
) ) o
and CC o
the DT o
Receptive JJ o
One-Word NNP o
Picture NNP o
Vocabulary NNP o
test NN o
( ( N
all DT N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Improved VBN N
trends NNS N
were VBD N
noted VBN N
on IN N
other JJ N
outcome JJ N
measures NNS N
. . N

Although IN N
the DT N
mechanism NN N
of IN N
action NN N
of IN N
L-carnosine NNP i
is VBZ N
not RB N
well RB N
understood RB N
, , N
it PRP N
may MD N
enhance VB N
neurologic JJ N
function NN N
, , N
perhaps RB N
in IN N
the DT N
enterorhinal JJ N
or CC N
temporal JJ N
cortex NN N
. . N

-DOCSTART- -X- O O

An DT N
evaluation NN N
of IN N
chemical JJ N
arthrodesis NN N
of IN N
the DT N
proximal JJ p
interphalangeal NN p
joint NN p
in IN p
the DT p
horse NN p
by IN N
using VBG N
monoiodoacetate NN i
. . i

The DT N
use NN N
of IN N
monoiodoacetate NN i
( ( i
MIA NNP i
) ) i
for IN N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
( ( N
PIJ NNP N
) ) N
and CC N
the DT N
effect NN N
of IN N
exercise NN N
on IN N
the DT N
degree NN N
of IN N
fusion NN N
were VBD N
investigated VBN N
. . N

Eight JJ p
horses NNS p
received VBD N
3 CD N
injections NNS N
( ( N
Weeks NNP N
0 CD N
, , N
3 CD N
, , N
6 CD N
) ) N
of IN N
MIA NNP i
( ( N
2 CD N
mL NN N
; : N
60 CD N
mg/mL NN N
) ) N
into IN N
the DT N
right NN N
or CC N
left VBD N
front JJ N
PIJ NNP N
. . N

Peri-operatively RB N
, , N
the DT N
horses NNS N
received VBD N
phenylbutazone NN i
, , i
butorphanol NN i
, , i
and CC i
abaxial JJ i
sesamoidean NN i
nerve NN i
blocks NNS i
to TO N
relieve VB N
pain NN N
. . N

During IN N
the DT N
study NN N
, , N
the DT N
horses NNS N
were VBD N
monitored VBN N
for IN N
general JJ N
health NN N
, , N
lameness NN N
, , N
and CC N
swelling VBG N
around IN N
the DT N
injection NN N
area NN N
. . N

Radiographs NNP N
were VBD N
taken VBN N
biweekly RB N
to TO N
evaluate VB N
bony NN N
fusion NN N
. . N

Horses NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
non-exercised JJ i
and CC N
exercised JJ i
groups NNS N
. . N

Exercise NNP i
consisted VBD N
of IN N
20 CD N
minutes NNS N
of IN N
trotting VBG N
on IN N
a DT N
treadmill NN N
( ( N
4 CD N
m/s NN N
) ) N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
13 CD N
weeks NNS N
. . N

The DT N
horses NNS N
were VBD N
euthanized VBN N
at IN N
24 CD N
weeks NNS N
. . N

Slab NNP N
sections NNS N
of IN N
the DT N
PIJ NNP N
were VBD N
evaluated VBN N
grossly RB N
and CC N
radiographically RB N
for IN N
bony NN N
fusion NN N
. . N

Histologic JJ N
examinations NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
articular JJ N
cartilage NN N
. . N

Three CD N
horses NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
after IN N
developing VBG N
soft JJ N
tissue NN N
necrosis NN N
around IN N
the DT N
injection NN N
site NN N
, , N
septic JJ N
arthritis NN N
, , N
and CC N
necrotic JJ N
tendinitis NN N
. . N

The DT N
remaining VBG N
horses NNS N
remained VBD N
healthy JJ N
, , N
developed VBD N
a DT N
grade NN N
1 CD N
to TO N
4 CD N
lameness NN N
with IN N
minimal JJ N
to TO N
severe VB N
swelling VBG N
in IN N
the DT N
PIJ NNP N
region NN N
. . N

All DT o
5 CD o
horses NNS o
showed VBD o
radiographic JJ o
evidence NN o
of IN o
bony NN o
fusion NN o
, , o
however RB o
, , o
no DT o
fusion NN o
was VBD o
present JJ o
when WRB o
injected JJ o
joints NNS o
were VBD o
examined VBN o
on IN o
postmortem NN o
examination NN o
. . o

Histologic NNP o
examination NN o
revealed VBD o
thinning NN o
of IN o
the DT o
cartilage NN o
, , o
diffuse VBP o
necrosis NN o
of IN o
chondrocytes NNS o
, , o
with IN o
the DT o
calcified JJ o
zone NN o
intact JJ o
. . o

Subjectively RB o
, , o
exercise NN o
did VBD o
not RB o
influence VB o
the DT o
degree NN o
of IN o
cartilage NN o
destruction NN o
. . o

Based VBN o
on IN o
this DT o
study NN o
, , o
chemical JJ o
arthrodesis NN o
can MD o
not RB o
be VB o
advocated VBN o
in IN o
clinical JJ o
cases NNS o
because IN o
of IN o
the DT o
high JJ o
complication NN o
rate NN o
and CC o
lack NN o
of IN o
bony NN o
fusion NN o
. . o

-DOCSTART- -X- O O

Modest NNP N
antihypertensive JJ N
effect NN N
of IN N
epanolol NN i
, , N
a DT N
beta NN N
1-selective JJ N
receptor NN N
blocker NN N
with IN N
beta NN N
1 CD N
agonist NN N
activity NN N
: : N
an DT N
acute NN N
and CC N
long-term JJ N
hemodynamic NN N
study NN N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
and CC N
double JJ N
crossover NN N
comparison NN N
with IN N
atenolol NN N
on IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

Beta-blockers NNS N
with IN N
less JJR N
cardiodepressive JJ N
effect NN N
than IN N
traditional JJ N
nonselective JJ N
beta NN N
( ( N
1+2 CD N
) ) N
-blocking VBG N
agents NNS N
could MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
, , N
provided VBD N
the DT N
reduction NN N
in IN N
blood NN N
pressure NN N
was VBD N
satisfactory JJ N
. . N

Epanolol NNP i
, , N
a DT N
selective JJ N
beta NN N
1-receptor JJ N
blocker NN N
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
, , N
induced VBD N
a DT N
fall NN N
in IN N
intraarterial JJ o
pressure NN o
of IN N
8 CD N
% NN N
at IN N
rest NN N
sitting VBG N
and CC N
11 CD N
% NN N
during IN N
100 CD N
W NNP N
bicycle NN N
exercise NN N
after IN N
the DT N
first JJ N
dose NN N
of IN N
200 CD N
mg NNS N
in IN N
12 CD p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

Heart NNP o
rate NN o
, , o
stroke VBD o
index NN o
, , o
and CC o
cardiac JJ o
index NN o
initially RB N
fell VBD N
by IN N
14 CD N
% NN N
, , N
11 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
total JJ o
peripheral JJ o
resistance NN o
index NN o
increased VBD N
by IN N
21 CD N
% NN N
after IN N
2 CD N
hours NNS N
, , N
and CC N
then RB N
reverted VBD N
towards IN N
the DT N
pretreatment NN N
level NN N
. . N

After IN N
10 CD N
months NNS N
of IN N
epanolol JJ i
treatment NN N
( ( N
mean JJ N
300 CD N
mg/day NN N
) ) N
, , N
the DT N
reduction NN o
in IN N
arterial JJ o
pressure NN o
was VBD N
5 CD N
% NN N
at IN N
rest NN N
and CC N
10 CD N
% NN N
during IN N
exercise NN N
. . N

Cardiac NNP o
index NN o
and CC o
heart NN o
rate NN o
were VBD N
still RB N
reduced VBN N
14-21 CD N
% NN N
, , N
while IN N
total JJ o
peripheral JJ o
resistance NN o
was VBD N
unchanged JJ N
or CC N
slightly RB N
increased VBN N
( ( N
2-10 CD N
% NN N
) ) N
. . N

Twenty-four JJ o
hour NN o
ambulatory NN o
blood NN o
pressure NN o
was VBD N
higher JJR N
on IN N
epanolol NN i
( ( N
300 CD N
mg/day NN N
) ) N
than IN N
on IN N
atenolol NN i
( ( N
150 CD N
mg/day NN N
) ) N
treatment NN N
( ( N
137/97 CD N
vs. FW N
128/91 CD N
mmHg NN N
) ) N
. . N

Thus RB N
, , N
the DT N
achieved VBN o
blood NN o
pressure NN o
reduction NN o
induced VBN N
by IN N
epanolol NN i
was VBD N
moderate JJ N
, , N
while IN N
other JJ N
characteristics NNS N
of IN N
beta-receptor NN N
blockade NN N
, , N
in IN N
particular JJ N
, , N
the DT N
reduction NN o
of IN o
heart NN o
rate NN o
and CC o
cardiac JJ o
output NN o
, , N
were VBD N
maintained VBN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
compound NN N
may MD N
be VB N
useful JJ N
for IN N
other JJ N
cardiovascular JJ p
disorders NNS p
, , N
e.g. NN N
, , N
angina JJ p
pectoris NN p
in IN p
patients NNS p
without IN p
hypertension NN p
or CC p
cardiac JJ p
arrhythmia NN p
. . p

-DOCSTART- -X- O O

Assessment NN N
in IN N
multisite JJ N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
patients NNS p
with IN p
autistic JJ o
disorder NN o
: : o
the DT p
Autism NNP p
RUPP NNP p
Network NNP p
. . p

Research NNP N
Units VBZ N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
. . N

Assessment NNP N
of IN N
autistic JJ o
disorder NN o
( ( o
autism NN o
) ) o
symptoms NNS o
, , o
primary JJ o
and CC o
secondary JJ o
, , N
poses VBZ N
more RBR N
challenging JJ N
problems NNS N
than IN N
ordinarily RB N
found VBN N
in IN N
multisite JJ N
randomized JJ N
clinical JJ N
trial NN N
( ( N
RCT NNP N
) ) N
assessments NNS N
. . N

For IN N
example NN N
, , N
subjects NNS N
may MD N
be VB N
uncommunicative JJ p
and CC p
extremely RB p
heterogeneous JJ p
in IN p
problem NN p
presentation NN p
, , N
and CC N
current JJ N
pharmacological JJ N
treatments NNS N
are VBP N
not RB N
likely JJ N
to TO N
alter VB N
most JJS N
core NN N
features NNS N
of IN N
autism NN N
. . N

The DT N
Autism NNP N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
( ( N
RUPP NNP N
Autism NNP N
Network NNP N
) ) N
resolved VBD N
some DT N
of IN N
these DT N
problems NNS N
during IN N
the DT N
design NN N
of IN N
a DT N
risperidone NN i
RCT NNP i
in IN N
children/adolescents NNS p
. . p

The DT N
inappropriateness NN N
of IN N
the DT N
usual JJ N
anchors NNS N
for IN N
a DT N
Clinical JJ N
Global NNP N
Impression NNP N
of IN N
Severity NNP N
( ( N
CGI-S NNP N
) ) N
was VBD N
resolved VBN N
by IN N
defining VBG N
uncomplicated JJ p
autism NN p
without IN p
secondary JJ p
symptoms NNS p
as IN p
a DT p
CGI-S NNP p
of IN p
3 CD p
, , p
mildly RB p
ill JJ p
. . p

The DT N
communication NN o
problems NNS o
, , N
compromising VBG N
use NN N
of IN N
the DT N
patient NN N
as IN N
an DT N
informant NN N
, , N
were VBD N
addressed VBN N
by IN N
several JJ N
strategies NNS N
, , N
including VBG N
careful JJ o
questioning NN o
of IN o
care NN o
providers NNS o
, , o
rating NN o
scales NNS o
, , o
laboratory NN o
tests NNS o
, , i
and CC i
physical JJ o
exams NN o
. . o

The DT N
broad JJ N
subject JJ N
heterogeneity NN N
requires VBZ N
outcome JJ N
measures NNS N
sensitive JJ N
to TO N
individual JJ N
change NN N
over IN N
a DT N
wide JJ N
spectrum NN N
of IN N
treatment NN N
response NN o
and CC N
side NN o
effects NNS o
. . o

The DT N
problems NNS N
of IN N
neuropsychologically RB N
testing VBG N
nonverbal JJ p
, , p
lower JJR p
functioning NN p
, , p
sometimes RB p
noncompliant JJ p
subjects NNS p
requires VBZ N
careful JJ N
instrument JJ N
selection/adaptation NN N
and CC N
flexible JJ N
administration NN N
techniques NNS N
. . N

The DT N
problems NNS N
of IN N
assessing VBG N
low-end JJ o
IQs NNP o
, , N
neglected VBN N
by IN N
most JJS N
standardized JJ N
test NN N
developers NNS N
, , N
was VBD N
resolved VBN N
by IN N
an DT N
algorithm NN N
of IN N
test NN N
hierarchy NN N
. . N

Scarcity NN N
of IN N
other JJ N
autism-adapted JJ N
cognitive NN N
and CC N
neuropsychological JJ N
tests NNS N
and CC N
lack NN N
of IN N
standardization NN N
required VBN N
development NN N
of IN N
a DT N
new JJ N
, , N
specially RB N
adapted VBN N
battery NN N
. . N

Reliability NN N
on IN N
the DT N
Autism NNP o
Diagnostic NNP o
Interview NNP o
( ( N
currently RB N
the DT N
most RBS N
valid JJ N
diagnostic JJ N
instrument NN N
) ) N
and CC N
other JJ N
clinician JJ N
instruments NNS N
required VBN N
extensive JJ N
cross-site JJ N
training NN N
( ( N
in-person JJ N
, , N
videotape NN N
, , N
and CC N
teleconference NN N
sessions NNS N
) ) N
. . N

Definition NN N
of IN N
a DT N
treatment NN N
responder NN N
required VBN N
focus NN N
on IN N
individually RB N
relevant JJ N
target NN N
symptoms NNS N
, , N
synthesis NN N
of IN N
possible JJ N
modest JJ N
improvements NNS N
in IN N
many JJ N
domains NNS N
, , N
and CC N
acceptance NN N
of IN N
attainable JJ N
though IN N
imperfect JJ N
goals NNS N
. . N

The DT N
assessment NN i
strategy NN i
developed VBD N
is VBZ N
implemented VBN N
in IN N
a DT N
RCT NNP N
of IN N
risperidone NN i
( ( N
McDougle NNP N
et RB N
al. RB N
, , N
2000 CD N
) ) N
for IN N
which WDT N
the DT N
design NN N
and CC N
other JJ N
methodological JJ N
challenges NNS N
are VBP N
described VBN N
elsewhere RB N
( ( N
Scahill NNP N
et VBZ N
al. RB N
, , N
2000 CD N
) ) N
. . N

Some DT N
of IN N
these DT N
problems NNS N
and CC N
solutions NNS N
are VBP N
partially RB N
shared VBN N
with IN N
RCTs NNP N
of IN N
other JJ N
treatments NNS N
and CC N
other JJ N
disorders NNS N
. . N

-DOCSTART- -X- O O

Dietary NNP i
lignan NN i
and CC i
proanthocyanidin NN i
consumption NN i
and CC N
colorectal JJ o
adenoma NN o
recurrence NN o
in IN N
the DT N
Polyp NNP N
Prevention NNP N
Trial NNP N
. . N

Lignans NNPS N
and CC N
proanthocyanidins NNS N
are VBP N
plant NN N
polyphenols NNS i
that WDT N
have VBP N
shown VBN N
protective JJ N
properties NNS N
against IN N
colorectal JJ o
neoplasms NNS o
in IN p
some DT p
human JJ p
studies NNS p
. . p

Using VBG N
logistic JJ N
regression NN N
, , N
we PRP N
estimated VBD N
odds NNS N
ratios NNS N
( ( N
ORs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
to TO N
prospectively RB N
evaluate VB N
the DT N
association NN N
between IN N
lignan NN i
and CC i
proanthocyanidin JJ i
intake NN i
, , N
estimated VBN N
from IN N
databases NNS N
linked VBN N
to TO N
a DT N
food NN N
frequency NN N
questionnaire NN N
, , N
and CC N
adenoma JJ o
recurrence NN o
in IN N
1,859 CD p
participants NNS p
of IN p
the DT p
Polyp NNP p
Prevention NNP p
Trial NNP p
. . p

Overall NNP N
, , N
individual NN N
or CC N
total JJ N
lignans NNS N
or CC N
proanthocyanidins NNS N
were VBD N
not RB N
associated VBN N
with IN N
colorectal JJ o
adenoma NN o
recurrence NN o
. . o

However RB N
, , N
in IN N
sex-specific JJ N
analyses NNS N
, , N
total JJ N
lignan JJ N
intake NN N
was VBD N
positively RB N
associated VBN N
with IN N
any DT N
adenoma JJ o
recurrence NN o
in IN N
women NNS N
( ( N
highest JJS N
vs. NN N
lowest JJS N
lignan JJ N
intake NN N
quartile NN N
OR NNP N
= VBZ N
2.07 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.22-3.52 JJ N
, , N
p JJ N
trend NN N
= VBZ N
0.004 CD N
) ) N
but CC N
not RB N
in IN N
men NNS N
( ( N
p JJ N
interaction NN N
= NNP N
0.04 CD N
) ) N
. . N

To TO N
conclude VB N
, , N
dietary JJ N
lignan NN N
and CC N
proanthocyanidin NN N
consumption NN N
were VBD N
not RB N
generally RB N
related VBN N
to TO N
colorectal JJ o
adenoma JJ o
recurrence NN o
; : o
however RB N
, , N
high JJ N
lignan NNS N
intake VBP N
may MD N
increase VB N
the DT N
risk NN o
of IN o
adenoma JJ o
recurrence NN o
in IN p
women NNS p
. . p

-DOCSTART- -X- O O

Comparison NNP N
of IN N
analgesic JJ N
effect NN N
of IN N
locally RB N
and CC N
systemically RB N
administered VBN N
ketorolac NN i
in IN N
mastectomy JJ p
patients NNS p
. . p

BACKGROUND NNP N
Ketorolac NNP i
is VBZ N
a DT N
parenteral JJ N
nonsteroidal JJ N
antiinflammatory JJ N
drug NN N
( ( N
NSAID NNP N
) ) N
. . N

Two CD N
features NNS N
have VBP N
limited VBN N
its PRP$ N
clinical JJ N
utility NN N
: : N
tendency NN N
to TO N
elicit VB N
kidney NN N
failure NN N
and CC N
inability NN N
to TO N
produce VB N
complete JJ N
analgesia NN N
. . N

Because IN N
most JJS N
NSAIDs NNP i
are VBP N
weak JJ N
acids NNS N
( ( N
pKa IN N
3-5 NNP N
) ) N
and CC N
become VBN N
concentrated JJ N
in IN N
acidic JJ N
tissues NNS N
, , N
such JJ N
as IN N
injured JJ N
and CC N
inflamed JJ N
tissues NNS N
, , N
we PRP N
hypothesized VBD N
that IN N
local JJ N
administration NN N
may MD N
enhance VB N
its PRP$ N
analgesic JJ N
efficacy NN N
while IN N
lowering VBG N
the DT N
potential NN N
for IN N
systemic JJ N
complications NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
of IN N
60 CD p
group NN p
I-II NNP p
( ( p
American JJ p
Society NNP p
of IN p
Anesthesiology NNP p
criteria NNS p
) ) p
mastectomy NN p
patients NNS p
, , p
20 CD p
in IN p
each DT p
group NN p
. . p

Near IN N
the DT N
end NN N
of IN N
surgery NN N
and CC N
every DT N
6 CD N
h NN N
postoperatively RB N
, , N
20 CD N
ml NN N
of IN N
the DT N
study NN N
solution NN N
containing VBG N
normal JJ i
saline NN i
with IN i
or CC i
without IN i
30 CD i
mg NN i
of IN i
ketorolac NN i
were VBD N
administered VBN N
simultaneously RB N
either CC N
via IN N
a DT N
Jackson-Pratt JJ N
drain NN N
or CC N
intravenously RB N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

The DT N
quality NN o
of IN o
pain NN o
control NN o
, , o
the DT o
amount NN o
and CC o
character NN o
of IN o
the DT o
drain NN o
fluid NN o
, , o
incidence NN o
of IN o
nausea NN o
and CC o
vomiting NN o
, , o
length NN o
of IN o
stay NN o
in IN o
the DT o
postoperative JJ o
care NN o
unit NN o
, , o
and CC o
amount NN o
of IN o
morphine NN o
used VBN N
for IN N
treatment NN N
of IN N
break-through JJ N
pain NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Intraoperative NNP N
administration NN N
of IN N
ketorolac NN i
resulted VBD N
in IN N
better JJR N
quality NN o
of IN o
pain NN o
control NN o
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
regardless NN N
of IN N
route NN N
of IN N
administration NN N
. . N

The DT N
incidence NN o
of IN o
nausea NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
placebo NN N
group NN N
, , N
and CC N
drain NN o
output NN o
in IN N
the DT N
ketorolac NN i
groups NNS N
did VBD N
not RB N
exceed VB N
the DT N
output NN N
in IN N
the DT N
placebo NN i
group NN N
. . N

CONCLUSION NNP N
Analgesic NNP N
of IN N
the DT N
locally RB N
administered VBN N
ketorolac NN i
is VBZ N
equally RB N
effective JJ o
to TO N
the DT N
efficacy NN o
of IN N
ketorolac NN i
administered VBN N
intravenously RB N
. . N

-DOCSTART- -X- O O

Double-blind NNP N
comparison NN N
of IN N
ketazolam NN i
, , i
diazepam NN i
and CC i
placebo NN i
in IN N
once-a-day JJ N
vs NN N
t.i.d NN N
. . N

dosing VBG N
. . N

Comparison NNP N
of IN N
ketazolam NNP i
given VBN N
once-a-day JJ N
with IN N
diazepam NN i
given VBN N
three CD N
times NNS N
a DT N
day NN N
and CC i
placebo VB i
given VBN N
either DT N
once RB N
or CC N
3 CD N
times NNS N
a DT N
day NN N
in IN N
101 CD p
anxious JJ p
outpatients NNS p
showed VBD N
ketazolam NNS N
to TO N
be VB N
significantly RB N
better JJR N
than IN N
placebo NN N
in IN N
alleviating VBG N
the DT N
symptoms NNS p
of IN p
anxiety NN p
and CC N
, , N
on IN N
several JJ N
measures NNS N
of IN N
efficacy NN N
, , N
better JJR N
than IN N
diazepam NN N
as IN N
well RB N
. . N

Significantly RB N
fewer JJR N
patients NNS p
on IN p
ketazolam NN i
dropped VBD p
out IN p
of IN p
the DT p
study NN p
due JJ N
to TO N
ineffective JJ N
medication NN N
than IN N
on IN N
the DT N
other JJ N
3 CD N
treatments NNS N
. . N

The DT N
incidence NN o
of IN o
side NN o
effects NNS o
was VBD o
lowest JJS o
in IN N
the DT N
ketazolam NN N
group NN N
. . N

Of IN N
particular JJ N
note NN N
, , N
drowsiness NN o
was VBD N
reported VBN N
twice RB N
as RB N
often RB N
by IN N
diazepam JJ i
patients NNS N
as IN N
by IN N
ketazolam NN i
patients NNS N
. . N

-DOCSTART- -X- O O

Poor NNP N
self-rated JJ N
health NN N
is VBZ N
not RB N
associated VBN N
with IN N
a DT N
high JJ N
total JJ N
allostatic JJ N
load NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
-- : p
but CC p
high JJ N
blood NN N
pressure NN N
is VBZ N
. . N

OBJECTIVE NNP N
Allostatic NNP N
load NN N
has VBZ N
been VBN N
linked VBN N
to TO N
self-rated JJ N
health NN N
( ( N
SRH NNP N
) ) N
, , N
cardiovascular JJ N
disease NN N
and CC N
mortality NN N
in IN N
non-diabetic JJ p
individuals NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
construct VB N
an DT N
allostatic JJ N
load NN N
score NN N
and CC N
to TO N
find VB N
any DT N
correlations NNS N
with IN N
SRH NNP N
. . N

METHODS NNP N
The DT N
subjects NNS p
included VBN p
in IN p
the DT p
study NN p
came VBD p
from IN p
a DT p
randomized VBN p
, , p
controlled VBD p
trial NN p
of IN p
type NN p
2 CD p
diabetes NNS p
. . p

Blood NN N
samples NNS N
were VBD N
drawn VBN N
, , N
urine NN N
was VBD N
collected VBN N
for IN N
24h CD N
, , N
and CC N
questionnaires NNS N
, , N
including VBG N
SRH NNP N
, , N
were VBD N
filled VBN N
out RP N
on IN N
three CD N
occasions NNS N
: : N
at IN N
baseline NN N
; : N
after IN N
the DT N
10-week JJ N
intervention NN N
; : N
and CC N
at IN N
a DT N
follow-up JJ N
3 CD N
months NNS N
after IN N
the DT N
intervention NN N
. . N

Allostatic JJ N
load NN N
was VBD N
estimated VBN N
using VBG N
a DT N
wide JJ N
range NN N
of IN N
variables NNS N
, , N
including VBG N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
pulse JJ o
pressure NN o
, , o
cortisol NN o
, , o
catecholamines NNS o
, , o
HbA NNP o
( ( o
1c CD o
) ) o
, , o
insulin NN o
, , o
plasma VBP o
glucose JJ o
and CC o
waist JJ o
circumference NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
association NN N
between IN N
SRH NNP N
and CC N
allostatic JJ N
load NN N
. . N

However RB N
, , N
three CD N
other JJ N
components NNS N
were VBD N
significantly RB N
correlated VBN N
with IN N
allostatic JJ N
load NN N
at IN N
the DT N
baseline NN N
investigation NN N
and CC N
the DT N
two CD N
follow-up JJ N
investigations NNS N
- : N
namely RB N
, , N
systolic JJ o
blood NN o
pressure NN o
, , o
diastolic JJ o
blood NN o
pressure NN o
and CC o
HbA NNP o
( ( o
1c CD o
) ) o
. . o

CONCLUSION VB N
The DT N
absence NN N
of IN N
an DT N
association NN N
between IN N
allostatic JJ N
load NN N
and CC N
SRH NNP o
in IN N
diabetic JJ p
individuals NNS p
contrasts NNS N
with IN N
previous JJ N
findings NNS N
in IN N
non-diabetic JJ p
women NNS p
, , N
and CC N
shows VBZ N
that IN N
it PRP N
is VBZ N
hazardous JJ N
to TO N
apply VB N
findings NNS N
in IN N
one CD N
population NN N
to TO N
another DT N
, , N
especially RB N
diabetic JJ p
and CC p
non-diabetic JJ p
populations NNS p
. . p

-DOCSTART- -X- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
inhaled JJ N
treprostinil NN i
for IN N
the DT N
treatment NN N
of IN N
pulmonary JJ p
arterial JJ p
hypertension NN p
in IN p
children NNS p
. . p

The DT N
introduction NN N
of IN N
prostanoid NN i
therapy NN i
has VBZ N
revolutionized VBN N
the DT N
treatment NN N
of IN N
pulmonary JJ N
arterial JJ N
hypertension NN N
( ( N
PAH NNP N
) ) N
. . N

However RB N
, , N
continuous JJ N
intravenous JJ N
prostacyclin NN i
infusion NN N
poses VBZ N
significant JJ N
risks NNS N
and CC N
challenges NNS N
, , N
particularly RB N
in IN N
children NNS p
. . p

Inhaled VBN N
treprostinil NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
efficacious JJ N
in IN N
adults NNS N
. . N

This DT N
study NN N
describes VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
inhaled JJ N
treprostinil NN i
in IN N
children NNS p
with IN p
PAH NNP p
. . p

A NNP N
retrospective JJ N
analysis NN N
of IN N
29 CD p
children NNS p
treated VBN p
with IN p
inhaled JJ p
treprostinil NN i
for IN p
?6 JJ p
weeks NNS p
was VBD p
performed VBN p
. . p

Effects NNS N
of IN N
inhaled JJ i
treprostinil NN i
on IN i
exercise NN N
capacity NN N
, , N
functional JJ N
class NN N
, , N
and CC N
echocardiographic JJ N
and CC N
hemodynamic JJ N
data NNS N
were VBD N
evaluated VBN N
. . N

Adverse JJ N
events NNS N
were VBD N
documented VBN N
. . N

Patients NNS N
received VBD N
3 CD N
to TO N
9 CD N
breaths NNS N
( ( N
6 CD N
?g/breath NN N
) ) N
of IN N
inhaled VBN i
treprostinil NN i
4 CD i
times/day NN N
. . N

All DT N
were VBD N
receiving VBG i
background NN i
PAH NNP i
therapy NN i
; : i
12 CD i
had VBD N
previously RB N
received VBN N
parenteral JJ N
prostanoid NN N
. . N

Inhaled VBD i
treprostinil NN i
was VBD i
discontinued VBN N
in IN N
4 CD p
patients NNS p
because IN p
of IN N
symptoms NNS N
including VBG o
cough NN o
and CC o
bronchospasm NN o
( ( o
n JJ o
= NNP N
3 CD N
) ) N
and CC N
progression NN o
of IN o
PAH NNP o
( ( o
n JJ o
= NNP N
1 CD N
) ) N
. . N

Mild JJ o
side JJ o
effects NNS o
including VBG o
cough NN o
( ( o
n JJ o
= NNP N
9 CD N
) ) N
and CC N
sore $ o
throat NN o
( ( o
n JJ o
= NNP N
6 CD N
) ) N
did VBD N
not RB N
require VB N
discontinuation NN N
of IN N
therapy NN o
. . o

World NNP o
Health NNP o
Organization NNP o
functional JJ o
class NN o
improved VBN o
in IN N
19 CD N
and CC N
was VBD N
unchanged JJ N
in IN N
10 CD N
; : N
exercise NN o
capacity NN o
significantly RB o
improved VBN N
with IN N
the DT N
6-minute JJ N
walk NN N
distance NN N
, , N
improving VBG N
on IN N
follow-up NN N
from IN N
455.7 CD N
? . N
71.5 CD N
to TO N
498 CD N
? . N
70 CD N
m NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
and CC o
peak JJ o
oxygen NN o
consumption NN o
increasing VBG o
from IN N
25.5 CD N
? . N
10.2 CD N
to TO N
27.4 CD N
? . N
10 CD N
( ( N
p NN N
= RB N
0.04 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
inhaled VBD N
treprostinil NN N
was VBD N
associated VBN N
with IN N
improvement NN o
in IN o
exercise NN o
capacity NN o
and CC o
World NNP o
Health NNP o
Organization NNP o
functional JJ o
class NN o
when WRB N
added VBD N
to TO N
background VB N
targeted JJ p
PAH NNP p
therapy NN p
in IN p
children NNS p
and CC p
had VBD p
an DT N
acceptable JJ N
safety NN N
profile NN N
. . N

Based VBN N
on IN N
these DT N
early JJ N
data NNS N
, , N
further JJ N
study NN N
of IN N
inhaled JJ N
treprostinil NN i
appears VBZ i
warranted VBN p
in IN p
pediatric JJ p
patients NNS p
with IN p
PAH NNP p
. . p

-DOCSTART- -X- O O

Secretin NNP N
and CC N
autism NN N
: : N
a DT N
two-part JJ N
clinical JJ N
investigation NN N
. . N

Recent JJ N
anecdotal JJ N
reports NNS N
have VBP N
touted VBN N
the DT N
gastrointestinal NN N
( ( N
GI NNP N
) ) N
hormone NN N
secretin NN i
as IN N
a DT N
treatment NN N
modality NN N
for IN N
autism NN N
, , N
though IN N
there EX N
is VBZ N
little JJ N
clinical JJ N
evidence NN N
or CC N
literature NN N
to TO N
support VB N
its PRP$ N
viability NN N
. . N

We PRP N
undertook VBD N
a DT N
two-part JJ N
clinical JJ N
trial NN N
to TO N
investigate VB N
these DT N
claims NNS N
. . N

Fifty-six JJ p
patients NNS p
( ( p
49 CD p
boys NNS p
, , p
7 CD p
girls NNS p
, , p
mean JJ p
age NN p
= VBD p
6.4 CD p
years NNS p
, , p
SD NNP p
= NNP p
2.7 CD p
) ) p
enrolled VBN p
in IN p
an DT p
open-label JJ p
trial NN p
of IN p
secretin NN i
, , p
during IN p
which WDT p
they PRP p
received VBD p
one CD p
injection NN p
of IN p
the DT p
hormone NN p
( ( p
2 CD p
IU/kg NNP p
) ) p
. . p

All DT N
subjects NNS N
were VBD N
evaluated VBN N
by IN N
their PRP$ N
parents NNS N
at IN N
baseline NN N
and CC N
follow-up JJ N
visits NNS N
( ( N
3-6 JJ N
weeks NNS N
later RB N
, , N
M NNP N
= NNP N
3.7 CD N
, , N
SD NNP N
= VBZ N
1.4 CD N
weeks NNS N
) ) N
with IN N
Childhood NNP o
Autism NNP o
Rating NNP o
Scales NNP o
( ( o
CARS NNP o
) ) o
. . N

Thirty-four JJ p
patients NNS p
were VBD p
labeled VBN p
with IN p
Pervasive NNP p
Developmental NNP p
Disorder NNP p
Not RB p
Otherwise NNP p
Specified NNP p
, , p
and CC p
22 CD p
met VBD p
diagnostic JJ p
criteria NNS p
for IN p
Autistic JJ p
Disorder NNP p
. . p

Forty-five JJ p
patients NNS p
were VBD p
concurrently RB p
on IN p
other JJ p
drug NN p
treatments NNS p
. . p

At IN N
follow-up NN N
, , N
some DT N
reported VBD N
minimal JJ N
but CC N
potentially RB N
significant JJ N
improvements NNS N
including VBG N
changes NNS o
in IN o
GI NNP o
symptoms NNS o
, , o
expressive JJ o
and/or NN o
receptive JJ o
language NN o
function NN o
, , o
and CC o
improved JJ o
awareness NN o
and CC o
social JJ o
interactions NNS o
. . o

No DT N
adverse JJ o
effects NNS o
were VBD N
reported VBN N
or CC N
observed VBN N
. . N

Subsequently NNP N
, , N
17 CD N
of IN N
the DT N
most RBS N
responsive JJ N
patients NNS N
from IN N
Study NNP N
1 CD N
began VBD N
a DT N
double-blind JJ N
trial NN N
that WDT N
also RB N
included VBD N
8 CD N
newly RB N
enrolled VBN N
patients NNS N
. . N

Patients NNS N
in IN N
this DT N
second JJ N
study NN N
were VBD N
alternatively RB N
entered VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
and CC N
received VBD N
injections NNS N
of IN N
secretin NN i
or CC i
placebo NN i
with IN N
crossover NN N
at IN N
4 CD N
weeks NNS N
. . N

Patients NNS p
from IN p
Study NNP p
1 CD p
entered VBD p
into IN p
Study NNP p
2 CD p
at IN p
an DT p
average NN p
of IN p
6.5 CD p
( ( p
SD NNP p
= NNP p
0.8 CD p
) ) p
weeks NNS p
after IN p
beginning VBG p
Study NNP p
1 CD p
. . p

Results NNS N
of IN N
both DT N
inquiries NNS N
indicate VBP N
that IN N
although IN N
treatment NN N
with IN N
secretin NN i
was VBD N
reported VBN N
to TO N
cause VB N
transient JJ o
changes NNS o
in IN o
speech NN o
and CC o
behavior NN o
in IN N
some DT N
children NNS N
, , N
overall JJ N
it PRP N
produced VBD N
few JJ N
clinically RB N
meaningful JJ N
changes NNS N
when WRB N
compared VBN N
to TO N
children NNS N
given VBN N
placebo JJ i
injections NNS N
. . N

-DOCSTART- -X- O O

Comments NNS N
on IN N
Secretin NNP o
and CC N
autism NN o
: : o
a DT N
two-part JJ N
clinical JJ N
investigation NN N
by IN N
M.G NNP N
. . N

Chez NNP N
et CC N
al NN N
. . N

-DOCSTART- -X- O O

Risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
a DT p
UK JJ p
population NN p
: : p
a DT N
prospective JJ N
cohort NN i
study NN i
. . i

BACKGROUND NNP N
Common NNP N
clinical JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
older JJR p
women NNS p
have VBP N
been VBN N
identified VBN N
. . N

To TO N
date NN N
, , N
most JJS N
of IN N
these DT N
risk NN N
factors NNS N
have VBP N
not RB N
been VBN N
confirmed VBN N
in IN N
a DT N
UK NNP p
population NN p
. . p

AIM NNP N
To TO N
confirm VB N
the DT N
important JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
in IN p
older JJR p
women NNS p
. . p

DESIGN NNP N
Comprehensive NNP i
cohort NN i
study NN i
( ( i
CCS NNP i
) ) i
with IN N
a DT N
nested JJ N
randomized NN N
controlled VBD i
trial NN i
. . i

METHODS NNP N
The DT N
CCS NNP i
included VBD p
4292 CD p
women NNS p
aged VBD p
> JJ p
70 CD p
years NNS p
. . p

We PRP N
assessed VBD N
potential JJ N
risk NN i
factors NNS i
for IN i
fracture NN i
, , N
and CC N
followed-up JJ N
participants NNS N
for IN N
24 CD N
months NNS N
for IN N
incidence NN N
of IN N
non-vertebral JJ N
fractures NNS N
. . N

RESULTS NNP N
Odds NNP N
ratios NNS N
( ( N
ORs NNP N
) ) N
for IN N
predicting VBG N
any DT N
non-vertebral JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.67 CD N
( ( N
95 CD N
% NN N
CI NNP N
2.10-3.40 CD N
) ) N
; : N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
2.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.63-2.59 CD N
) ) N
; : N
and CC N
age NN o
( ( N
per IN N
year NN N
increase NN N
) ) N
, , N
1.03 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.01-1.05 CD N
) ) N
. . N

ORs NNP N
for IN N
predicting VBG N
hip JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.31 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.31-4.08 CD N
) ) N
; : N
low JJ o
body NN o
weight NN o
( ( N
< JJ N
58 CD N
kg NN N
) ) N
, , N
2.20 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.28-3.77 CD N
) ) N
; : N
maternal JJ o
history NN o
of IN o
hip NN o
fracture NN o
, , N
1.68 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.85-3.31 NN N
) ) N
; : N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
2.92 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.70-5.01 CD N
) ) N
; : N
and CC N
age NN o
( ( N
per IN N
year NN N
increase NN N
) ) N
, , N
1.09 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.04-1.13 CD N
) ) N
. . N

ORs NNP N
for IN N
predicting VBG N
wrist JJ N
fracture NN N
were VBD N
: : N
previous JJ o
fracture NN o
, , N
2.29 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.56-3.34 CD N
) ) N
; : N
and CC N
a DT o
fall NN o
in IN o
the DT o
last JJ o
12 CD o
months NNS o
, , N
1.60 CD N
( ( N
95 CD N
% NN N
CI NNP N
1.10-2.31 CD N
) ) N
. . N

Being VBG N
a DT N
current JJ o
smoker NN o
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
risk NN N
, , N
and CC N
was VBD N
consistent JJ N
across IN N
all DT N
fracture NN N
types NNS N
. . N

DISCUSSION NNP N
Older NNP N
women NNS N
with IN N
the DT N
clinical JJ N
risk NN N
factors NNS N
identified VBN N
in IN N
this DT N
study NN N
should MD N
be VB N
investigated VBN N
for IN N
osteoporosis NN N
or CC N
offered VBN N
preventive JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Using VBG N
the DT N
virtual JJ i
reality-cognitive JJ i
rehabilitation NN i
approach NN N
to TO N
improve VB N
contextual JJ o
processing NN o
in IN o
children NNS p
with IN p
autism NN p
. . p

BACKGROUND NNP N
This DT N
pilot NN N
study NN N
investigated VBD N
the DT N
efficacy NN N
of IN N
a DT N
novel JJ i
virtual JJ i
reality-cognitive JJ i
rehabilitation NN i
( ( i
VR-CR NNP i
) ) i
intervention NN i
to TO N
improve VB N
contextual JJ o
processing NN o
of IN N
objects NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

Previous JJ N
research NN N
supports VBZ N
that IN N
children NNS p
with IN p
autism NN p
show NN N
deficits NNS N
in IN N
contextual JJ o
processing NN o
, , N
as RB N
well RB N
as IN N
deficits NNS N
in IN N
its PRP$ N
elementary JJ N
components NNS N
: : N
abstraction NN o
and CC o
cognitive JJ o
flexibility NN o
. . o

METHODS NNP N
Four CD p
children NNS p
with IN p
autism NN p
participated VBN N
in IN N
a DT N
multiple-baseline JJ N
, , N
single-subject JJ N
study NN N
. . N

The DT N
children NNS p
were VBD N
taught JJ N
how WRB N
to TO N
see VB N
objects NNS N
in IN N
context NN N
by IN N
reinforcing VBG N
attention NN N
to TO N
pivotal JJ N
contextual JJ N
information NN N
. . N

RESULTS NNP N
All NNP N
children NNS p
demonstrated VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
contextual JJ o
processing NN o
and CC o
cognitive JJ o
flexibility NN o
. . o

Mixed JJ N
results NNS N
were VBD N
found VBN N
on IN N
the DT N
control NN N
test NN N
and CC N
changes NNS N
in IN N
context-related JJ o
behaviours NNS o
. . o

CONCLUSIONS NNP N
Larger-scale JJ N
studies NNS N
are VBP N
warranted VBN N
to TO N
determine VB N
the DT N
effectiveness NN N
and CC N
usability NN N
in IN N
comprehensive JJ N
educational JJ N
programs NNS N
. . N

-DOCSTART- -X- O O

Interleukin-6 NNP N
receptor NN N
inhibition NN N
with IN N
tocilizumab NN i
and CC N
attainment NN N
of IN N
disease NN N
remission NN N
in IN N
rheumatoid JJ p
arthritis NN p
: : p
the DT N
role NN N
of IN N
acute-phase JJ N
reactants NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
tocilizumab NN i
on IN N
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
disease NN o
activity NN o
and CC N
remission NN o
assessment NN o
, , N
using VBG N
measures NNS N
that WDT N
do VBP N
or CC N
do VB N
not RB N
comprise VB N
acute-phase JJ N
reactants NNS N
. . N

METHODS NNP N
Simplified NNP o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
SDAI NNP o
) ) o
scores VBZ o
, , o
Clinical JJ o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
CDAI NNP o
) ) o
scores VBZ o
, , o
and CC o
the DT o
Disease NNP o
Activity NNP o
Score NNP o
in IN o
28 CD o
joints NNS o
( ( o
DAS28 NNP o
) ) o
were VBD N
calculated VBN N
using VBG N
data NNS N
from IN N
tocilizumab JJ i
trials NNS N
in IN N
patients NNS p
with IN p
RA NNP p
in IN p
whom WP p
disease NN p
had VBD p
remained VBN p
active JJ p
despite IN p
treatment NN p
with IN p
disease-modifying JJ i
antirheumatic JJ i
drugs NNS i
. . i

The DT N
CDAI NNP N
does VBZ N
not RB N
contain VB N
an DT N
acute-phase JJ N
reactant NN N
component NN N
. . N

Disease NNP o
activity NN o
states NNS o
, , o
including VBG o
remission NN o
, , N
were VBD N
defined VBN N
using VBG N
established VBN N
cut NN N
points NNS N
; : N
for IN N
the DT N
DAS28 NNP N
, , N
an DT N
alternative JJ N
cut NN N
point NN N
of IN N
< $ N
2.4 CD N
was VBD N
also RB N
used VBN N
. . N

RESULTS JJ N
Changes NNS o
in IN o
the DT o
DAS28 NNP o
, , o
the DT o
SDAI NNP o
score NN o
, , o
and CC o
the DT o
CDAI NNP o
score NN o
among IN N
patients NNS N
receiving VBG N
tocilizumab NN i
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
among IN N
patients NNS N
receiving VBG N
placebo NN i
, , N
and CC N
the DT N
magnitude NN N
of IN N
these DT N
changes NNS N
was VBD N
similar JJ N
for IN N
the DT N
SDAI NNP o
and CC N
the DT N
CDAI NNP o
. . o

Among IN N
patients NNS N
who WP N
achieved VBD N
50 CD N
% NN N
improvement NN o
in IN o
disease NN o
activity NN o
according VBG N
to TO N
the DT N
American NNP N
College NNP N
of IN N
Rheumatology NNP N
criteria NNS N
, , N
only RB N
?20 VBZ N
% NN N
required VBN N
a DT N
reduction NN N
in IN N
acute-phase JJ N
reactant NN N
values NNS N
in IN N
order NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
. . N

However RB o
, , o
DAS28 NNP o
remission NN o
rates NNS o
were VBD o
higher JJR N
( ( N
even RB N
when WRB N
using VBG N
the DT N
lower JJR N
cut NN N
point NN N
) ) N
than IN N
the DT o
SDAI NNP o
and CC o
CDAI NNP o
remission NN o
rates NNS o
. . o

Only RB N
a DT N
minority NN N
of IN N
tocilizumab-treated JJ i
patients NNS i
with IN o
DAS28 NNP o
remission NN o
also RB o
had VBD o
disease NN o
remission NN o
according VBG o
to TO N
the DT N
SDAI NNP N
( ( N
26 CD N
% NN N
) ) N
or CC N
CDAI NNP N
( ( N
?21 NNP N
% NN N
) ) N
. . N

With IN N
infliximab JJ i
treatment NN o
, , o
SDAI NNP o
and CC o
CDAI NNP o
remission NN o
rates NNS o
were VBD o
of IN N
the DT N
same JJ N
magnitude NN N
as IN N
those DT N
observed VBN N
with IN N
tocilizumab JJ i
treatment NN i
, , N
and CC N
DAS28 NNP o
remission NN o
rates NNS o
were VBD o
lower JJR i
. . i

Tocilizumab-treated JJ i
patients NNS i
with IN N
DAS28 NNP o
remission NN o
but CC o
without IN o
CDAI NNP o
remission NN o
had VBD o
significantly RB N
higher JJR o
swollen JJ o
joint JJ o
counts NNS o
but CC o
lower JJR o
erythrocyte NN o
sedimentation NN o
rates NNS o
( ( o
ESRs NNP o
) ) o
compared VBN o
with IN N
patients NNS N
with IN N
SDAI NNP N
or CC N
CDAI NNP N
remission NN N
. . N

CONCLUSION NNP o
Disease NNP o
activity NN o
in IN o
RA NNP N
is VBZ N
reduced VBN i
by IN i
tocilizumab NN i
treatment NN i
, , N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
composite JJ N
measure NN N
used VBN N
to TO N
evaluate VB N
disease NN N
activity NN o
. . o

Remission NN o
rates NNS o
were VBD o
much RB N
higher JJR N
using VBG N
the DT N
DAS28 NNP N
compared VBN N
with IN N
the DT N
SDAI NNP N
and CC N
CDAI NNP N
, , N
due JJ N
to TO N
the DT N
high JJ N
weight NN N
of IN N
the DT N
ESR NNP N
in IN N
the DT N
DAS28 NNP N
and CC N
the DT N
effect NN N
of IN N
tocilizumab NN N
on IN N
the DT N
ESR NNP N
. . N

Using VBG N
the DT N
stringent NN N
SDAI NNP N
and CC N
CDAI NNP N
criteria NNS N
, , N
however RB N
, , N
remission NN N
rates NNS N
in IN N
patients NNS N
treated VBN N
with IN N
tocilizumab NNS i
were VBD i
in IN N
the DT N
same JJ N
range NN N
as IN N
those DT N
seen VBN N
in IN N
patients NNS N
treated VBN N
with IN N
tumor NN N
necrosis NN N
factor NN N
inhibitors NNS N
. . N

-DOCSTART- -X- O O

Placebo-controlled JJ N
pilot NN N
trial NN N
of IN N
mecamylamine NN i
for IN N
treatment NN N
of IN N
autism NN o
spectrum NN o
disorders NNS o
. . o

OBJECTIVE NNP N
To TO N
explore VB N
possible JJ N
benefits NNS N
of IN N
a DT N
nicotinic JJ i
acetylcholine NN i
receptor NN i
( ( i
nAChR JJ i
) ) i
agent NN i
for IN N
autistic JJ o
symptoms NNS o
based VBN N
on IN N
postmortem NN N
observation NN N
of IN N
nAChR JJ N
abnormalities NNS N
( ( N
deficient JJ N
?4?2 NN N
nAChRs NN N
, , N
excess JJ N
?7 NNP N
nAChRs NN N
) ) N
in IN N
brains NNS p
of IN p
patients NNS p
with IN p
autism NN p
. . p

METHOD NNP i
Mecamylamine NNP i
, , i
because IN i
of IN N
its PRP$ N
safety NN N
record NN N
in IN N
children NNS N
with IN N
other JJ N
disorders NNS N
, , N
was VBD N
chosen VBN N
for IN N
this DT N
first JJ N
exploration NN p
. . p

Twenty NNP p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
age NN p
4-12 CD p
years NNS p
were VBD p
randomly RB N
assigned VBN N
for IN N
14 CD N
weeks NNS N
to TO N
placebo VB i
( ( i
n=8 NN i
) ) N
or CC N
mecamylamine NN i
( ( i
n=12 JJ i
) ) N
in IN N
ascending VBG N
fixed JJ N
doses NNS N
: : N
0.5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
, , N
2.5 CD N
mg NN N
for IN N
2 CD N
weeks NNS N
, , N
then RB N
5 CD N
mg/day NN N
for IN N
6 CD N
weeks NNS N
. . N

Improvement NNP N
was VBD N
rated VBN N
by IN N
a DT N
blinded JJ N
independent JJ N
evaluator NN N
. . N

Because IN N
of IN N
small JJ N
sample NN N
, , N
data NNS N
analysis NN N
was VBD N
descriptive JJ N
. . N

RESULTS NNP p
Eighteen JJ p
participants NNS p
( ( p
10 CD p
mecamylamine NN i
, , i
8 CD i
placebo NN i
) ) i
completed VBD i
the DT p
study NN p
. . p

All DT p
doses NNS N
were VBD N
well RB o
tolerated VBN o
; : o
the DT o
only JJ N
side NN N
effect NN N
of IN N
note NN N
was VBD N
constipation NN o
( ( o
50 CD o
% NN N
compared VBN N
with IN N
25 CD N
% NN N
of IN N
placebo NN i
group NN i
) ) N
. . N

Three CD N
children NNS N
had VBD N
clinically RB o
nonsignificant JJ o
electrocardiographic JJ o
QT NNP o
prolongation NN o
. . o

Both DT o
groups NNS N
showed VBD N
modest JJ N
to TO N
moderate VB N
improvement NN N
, , N
but CC N
differences NNS N
between IN N
groups NNS N
were VBD N
negligible JJ N
. . N

On IN N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
the DT N
Ohio NNP o
Autism NNP o
Clinical NNP o
Impressions NNP o
Scale NNP o
, , o
90 CD o
% NN N
of IN N
the DT N
active JJ N
treatment NN N
group NN N
showed VBD N
improvement NN N
at IN N
some DT N
point NN N
( ( N
but CC N
only RB N
40 CD N
% NN N
sustained VBD N
it PRP N
) ) N
, , N
compared VBN N
with IN N
62 CD N
% NN N
on IN N
placebo NN i
. . i

Of IN i
the DT N
four CD N
in IN N
active JJ N
treatment NN N
that WDT N
sustained VBD N
improvement NN N
, , N
three CD N
had VBD N
a DT N
maximum JJ N
dose NN N
of IN N
0.13-0.15 JJ N
mg/kg/day NN N
, , N
while IN N
those DT N
who WP N
regressed VBD N
had VBD N
doses NNS N
?0.18 JJ N
mg/kg/day NN N
. . N

Graphed VBN N
means NNS N
suggested VBD N
better RBR N
outcome NN N
with IN N
lower JJR N
mg/kg NN N
and CC N
longer JJR N
medication NN N
duration NN N
. . N

Four CD N
parents NNS N
spontaneously RB N
reported VBD N
reduced JJ o
hyperactivity NN o
and CC o
irritability NN o
and CC o
better JJR o
verbalization NN o
and CC o
continued JJ i
mecamylamine NN i
at IN i
their PRP$ i
own JJ N
expense NN N
. . N

CONCLUSION NNP i
Mecamylamine NNP i
appeared VBD i
to TO N
be VB N
safe JJ N
, , N
but CC N
not RB N
very RB N
effective JJ o
in IN o
autism NN o
. . o

The DT o
suggestion NN N
of IN N
better JJR N
results NNS N
at IN N
lower JJR N
doses NNS N
and CC N
longer JJR N
exposure NN N
warrants NNS N
consideration NN N
for IN N
future JJ N
trials NNS N
. . N

The DT N
next JJ N
step NN N
would MD N
be VB N
exploration NN N
of IN N
a DT N
more RBR N
specific JJ i
?4?2 NNP i
nAChR JJ i
agonist NN i
, , i
such JJ i
as IN i
varenicline NN i
. . i

-DOCSTART- -X- O O

Safety NN o
, , o
pharmacokinetics NNS o
, , o
pharmacogenomics NNS o
and CC o
QT NNP o
concentration-effect JJ o
modelling NN o
of IN N
the DT N
SirT1 NNP i
inhibitor NN i
selisistat NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

AIM NNP N
Selisistat NNP i
( ( i
SEN0014196 NNP i
) ) i
, , i
a DT i
first-in-class JJ i
SirT1 NNP i
inhibitor NN i
, , N
is VBZ N
being VBG N
developed VBN N
as IN N
a DT N
disease-modifying JJ N
therapy NN N
for IN N
Huntington NNP p
's POS p
disease NN p
. . p

This DT N
first-in-human JJ N
study NN N
investigated VBD N
the DT N
safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacogenomics NNS N
of IN N
single JJ N
and CC N
multiple JJ N
doses NNS N
of IN N
selisistat NN i
in IN N
healthy JJ p
male NN p
and CC p
female JJ p
subjects NNS p
. . p

METHOD NNP N
In IN N
this DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
, , N
seven CD p
cohorts NNS p
of IN p
eight CD p
subjects NNS p
received VBD N
a DT N
single JJ N
dose NN N
of IN N
selisistat NN i
at IN N
dose JJ N
levels NNS N
of IN N
5 CD N
, , N
25 CD N
, , N
75 CD N
, , N
150 CD N
, , N
300 CD N
and CC N
600 CD N
mg NNS N
and CC N
four CD p
cohorts NNS p
of IN p
eight CD p
subjects NNS p
were VBD N
administered VBN N
100 CD N
, , N
200 CD N
and CC N
300 CD N
mg NN N
once RB N
daily JJ N
for IN N
7 CD N
days NNS N
. . N

Blood NNP N
sampling NN N
and CC N
safety NN o
assessments NNS o
were VBD N
conducted VBN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Selisistat NNP i
was VBD N
rapidly RB N
absorbed VBN N
and CC N
systemic JJ N
exposure NN N
increased VBN N
in IN N
proportion NN N
to TO N
dose VB N
in IN N
the DT N
5-300 JJ N
mg NN N
range NN N
. . N

Steady-state JJ o
plasma JJ o
concentrations NNS o
were VBD N
achieved VBN N
within IN N
4 CD N
days NNS N
of IN N
repeated JJ N
dosing NN N
. . N

The DT N
incidence NN N
of IN N
drug NN N
related VBN N
adverse JJ o
events NNS o
showed VBD N
no DT N
correlation NN N
with IN N
dose JJ N
level NN N
or CC N
number NN N
of IN N
doses NNS N
received VBN N
and CC N
was VBD N
comparable JJ N
with IN N
the DT N
placebo NN i
group NN N
. . N

No DT N
serious JJ N
adverse JJ o
events NNS o
were VBD N
reported VBN N
and CC N
no DT N
subjects NNS N
were VBD N
withdrawn VBN N
due JJ N
to TO N
adverse JJ N
events NNS N
. . N

There EX N
were VBD N
no DT N
trends NNS N
in IN N
clinical JJ N
laboratory NN N
parameters NNS N
or CC N
vital JJ N
signs NNS N
. . N

No DT N
trends NNS N
in IN N
heart NN o
rate NN o
or CC o
ECG NNP o
parameters NNS o
, , o
including VBG o
the DT o
QTc NNP o
interval NN o
and CC o
T-wave NNP o
morphology NN o
, , N
were VBD N
observed VBN N
. . N

There EX N
were VBD N
no DT N
findings NNS N
in IN N
physical JJ N
or CC N
neurological JJ N
examinations NNS N
or CC N
postural JJ N
control NN N
. . N

Transcriptional JJ N
alteration NN N
was VBD N
observed VBN N
in IN N
peripheral JJ N
blood NN N
. . N

CONCLUSION NNP N
Selisistat NNP i
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
by IN N
healthy JJ p
male NN p
and CC p
female JJ p
subjects NNS p
after IN N
single JJ N
doses VBZ N
up IN N
to TO N
600 CD N
mg NNS N
and CC N
multiple NN N
doses VBZ N
up IN N
to TO N
300 CD N
mg NNS N
day NN N
( ( N
-1 NN N
) ) N
. . N

-DOCSTART- -X- O O

The DT N
role NN N
of IN N
ethnic JJ N
matching VBG N
between IN N
patient NN N
and CC N
provider NN N
on IN N
the DT N
effectiveness NN o
of IN N
brief NN i
alcohol NN i
interventions NNS i
with IN N
Hispanics NNPS p
. . p

BACKGROUND NNP N
Evaluating VBG N
the DT N
effectiveness NN N
of IN N
treatments NNS N
such JJ N
as IN N
brief JJ N
alcohol JJ N
interventions NNS N
among IN N
Hispanics NNPS p
is VBZ N
essential JJ N
to TO N
effectively RB N
addressing VBG N
their PRP$ N
treatment NN N
needs NNS N
. . N

Clinicians NNPS N
of IN N
the DT N
same JJ N
ethnicity NN N
as IN N
the DT N
client NN N
may MD N
be VB N
more RBR N
likely JJ N
to TO N
understand VB N
the DT N
culture-specific JJ N
values NNS N
, , N
norms NNS N
, , N
and CC N
attitudes NNS N
and CC N
, , N
therefore RB N
, , N
the DT N
intervention NN N
may MD N
be VB N
more RBR N
effective JJ N
. . N

Thus RB N
, , N
in IN N
cases NNS N
in IN N
which WDT N
Hispanic JJ p
patients NNS p
were VBD N
provided VBN N
intervention NN N
by IN N
a DT N
Hispanic JJ N
clinician NN N
improved VBD N
drinking NN N
outcomes NNS N
were VBD N
expected VBN N
. . N

METHODS NNP N
Patients NNPS p
were VBD p
recruited VBN p
from IN p
an DT p
urban JJ p
Level NN p
I PRP p
Trauma VBP p
following VBG p
screening NN p
for IN p
an DT p
alcohol-related JJ p
injury NN p
or CC p
alcohol NN p
problems NNS p
. . p

Five CD p
hundred VBD p
thirty-seven JJ p
Hispanics NNPS p
were VBD N
randomly RB N
assigned VBN N
to TO N
brief VB i
intervention NN i
or CC i
treatment NN i
as IN i
usual JJ i
. . i

Hierarchical JJ N
linear JJ N
modeling NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
effects NNS o
of IN o
ethnic JJ o
match NN o
on IN o
drinking NN o
outcomes NNS o
including VBG N
volume NN o
per IN o
week NN o
, , o
maximum JJ o
amount NN o
, , o
and CC o
frequency NN o
of IN o
5 CD o
or CC o
more JJR o
drinks NNS o
per IN o
occasion NN o
. . o

Analyses NNS N
controlled VBD N
for IN N
level NN N
of IN N
acculturation NN N
and CC N
immigration NN N
status NN N
. . N

RESULTS NNP N
For IN N
Hispanics NNPS p
who WP N
received VBD N
brief JJ N
motivational JJ N
intervention NN N
, , N
an DT N
ethnic JJ N
match NN N
between IN N
patient NN N
and CC N
provider NN N
resulted VBD N
in IN N
a DT N
significant JJ o
reduction NN o
in IN o
drinking NN o
outcomes NNS o
at IN N
12-month JJ N
follow-up NN N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
ethnic JJ N
match NN N
to TO N
be VB N
most RBS o
beneficial JJ o
to TO N
foreign-born JJ N
Hispanics NNPS N
and CC N
less RBR o
acculturated JJ N
Hispanics NNPS N
. . N

CONCLUSION NNP N
As IN N
hypothesized VBN N
, , N
an DT N
ethnic JJ N
match NN N
between IN N
patient NN N
and CC N
provider NN N
significantly RB N
enhanced VBD N
the DT N
effectiveness NN o
of IN o
brief JJ o
intervention NN o
among IN N
Hispanics NNPS p
. . p

Ethnic JJ N
concordance NN N
between IN N
patient NN N
and CC N
provider NN N
may MD N
have VB N
impacted VBN N
the DT N
effectiveness NN o
of IN N
the DT N
intervention NN N
through IN N
several JJ N
mechanisms NNS N
including VBG N
cultural JJ N
scripts NNS N
, , N
ethnic-specific JJ N
perceptions NNS N
pertaining VBG N
to TO N
substance NN N
abuse NN N
, , N
and CC N
ethnic-specific JJ N
preferred JJ N
channels NNS N
of IN N
communication NN N
. . N

-DOCSTART- -X- O O

[ VB N
A NNP N
controlled JJ N
study NN N
of IN N
treating VBG N
haemophilia PRP N
A NNP N
on IN N
an DT N
out-patient JJ N
basis NN N
( ( N
author NN N
's POS N
transl NN N
) ) N
] NN N
. . N

For IN N
six CD N
months NNS N
36 CD i
U NNP i
factor NN i
VIII NNP i
concentrates VBZ i
per IN N
kg NN N
bodyweight NN N
and CC N
week NN N
were VBD N
administered VBN N
to TO N
six CD p
out-patients NNS p
with IN p
severe JJ p
haemophilia NN p
A NNP p
. . p

The DT N
injection NN N
regimen NN N
was VBD N
changed VBN N
in IN N
every DT N
patient NN N
every DT N
two CD N
months NNS N
, , N
from IN N
36 CD N
U/kg NNP N
once RB N
to TO N
18 CD N
U/kg NNP N
twice RB N
and CC N
12 CD N
U/kg NNP N
three CD N
times NNS N
, , N
intravenously RB N
. . N

The DT N
six CD N
possible JJ N
combinations NNS N
of IN N
these DT N
three CD N
dosage NN N
schedules NNS N
were VBD N
used VBN N
in IN N
the DT N
patients NNS N
in IN N
a DT N
strictly RB N
randomised JJ N
manner NN N
, , N
and CC N
all DT N
patients NNS N
were VBD N
treated VBN N
during IN N
the DT N
same JJ N
period NN N
. . N

In IN N
the DT N
pre-trial JJ N
period NN N
( ( N
treatment NN N
as IN N
needed VBN N
) ) N
there EX N
were VBD N
an DT N
average NN N
of IN N
35 CD N
bleedings NNS o
per IN N
two CD N
months NNS N
. . N

On IN N
continual JJ N
treatment NN N
there EX N
were VBD N
21 CD N
bleedings NNS o
on IN N
weekly JJ N
injections NNS N
of IN N
36 CD N
U NNP i
factor NN i
VIII NNP i
per IN N
kg NN N
, , N
14 CD N
on IN N
twice JJ N
weekly JJ N
18 CD N
U/kg NNP N
and CC N
none NN N
on IN N
12 CD N
U/kg NNP N
, , N
three CD N
times NNS N
weekly RB N
. . N

The DT N
differences NNS N
are VBP N
statistically RB N
significant JJ N
. . N

The DT N
absence NN o
of IN o
bleeding VBG o
on IN N
the DT N
last JJ N
dosage NN N
schedule NN N
was VBD N
achieved VBN N
during IN N
normal JJ N
working VBG N
. . N

Days NNPS o
lost VBD o
from IN o
work NN o
per IN o
patient JJ o
per IN o
month NN o
was VBD N
zero NN N
on IN N
three CD N
times NNS N
12 CD N
U/kg NNP N
, , N
0.4 CD N
day NN N
on IN N
twice RB N
18 CD N
U/kg NNP N
and CC N
once RB N
36 CD N
U/kg NNP N
, , N
while IN N
it PRP N
had VBD N
been VBN N
five CD N
days NNS N
in IN N
the DT N
pre-trial JJ N
period NN N
. . N

In IN N
addition NN N
to TO N
freedom NN o
from IN o
bleeding VBG o
and CC N
no DT N
lost JJ o
days NNS o
from IN N
work NN N
, , N
there EX N
was VBD N
increased VBN N
mobility NN o
and CC o
physical JJ o
capacity NN o
. . o

-DOCSTART- -X- O O

Symptomatic JJ i
treatment NN i
versus NN N
combination NN i
chemotherapy NN i
for IN N
patients NNS p
with IN p
extensive JJ p
non-small NN p
cell NN p
lung NN p
cancer NN p
. . p

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
87 CD p
patients NNS p
with IN p
inoperable JJ p
, , p
extensive JJ p
non-small NN p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
combination NN i
chemotherapy NN i
( ( i
cisplatin NN i
at IN N
70 CD N
mg/m2 NN N
intravenously RB N
[ NNP N
i.v NN N
. . N

] VB N
on IN N
day NN N
1 CD N
and CC N
etoposide VB i
at IN N
100 CD N
mg/m2 NN N
i.v NN N
. . N

on IN N
day NN N
1 CD N
and CC N
200 CD N
mg/m2 NNS N
orally RB N
on IN N
days NNS N
2 CD N
and CC N
3 CD N
) ) N
or CC N
symptomatic JJ i
treatment NN i
. . i

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival JJ o
time NN o
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
techniques NNS N
. . N

A DT N
major JJ N
problem NN N
in IN N
the DT N
interpretation NN N
of IN N
the DT N
results NNS N
was VBD N
the DT N
use NN N
of IN N
semicurative JJ N
radiation NN N
therapy NN N
( ( N
3000 CD N
to TO N
4200 CD N
cGy NN N
) ) N
to TO N
the DT N
primary JJ N
tumor NN N
and CC N
mediastinum NN N
, , N
which WDT N
was VBD N
given VBN N
with IN N
symptomatic JJ N
intent NN N
. . N

Three CD o
long-term JJ o
survivors NNS o
were VBD o
seen VBN o
in IN o
the DT o
latter JJ o
group NN o
. . o

-DOCSTART- -X- O O

CASTLE NNP i
data NNS i
show VBP p
no DT p
gender NN p
differences NNS p
. . p

-DOCSTART- -X- O O

Women NNP p
's POS p
responses NNS p
to TO p
information NN p
on IN p
mammographic JJ p
breast NN p
density NN p
. . p

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
negative JJ N
and CC N
positive JJ N
outcomes NNS N
of IN N
providing VBG N
mammographic JJ N
breast NN N
density NN N
( ( N
MBD NNP N
) ) N
information NN N
to TO N
participants NNS p
of IN p
a DT p
screening JJ i
program NN i
. . i

A DT N
randomized JJ N
experiment NN N
was VBD N
conducted VBN N
with IN N
a DT N
sample NN p
of IN p
618 CD p
women NNS p
50 CD p
years NNS p
or CC p
older JJR p
with IN p
MBD NNP p
greater JJR p
than IN p
50 CD p
% NN p
of IN p
breast NN p
volume NN p
. . p

The DT N
intervention NN N
consisted VBD N
of IN N
reporting VBG i
the DT i
presence NN i
of IN i
MBD NNP i
in IN i
the DT i
screening NN i
mammography NN i
results NNS i
letter NN i
that WDT i
was VBD i
sent VBN i
along IN i
with IN i
an DT i
information NN i
pamphlet NN i
. . i

Compared VBN N
to TO N
the DT N
controls NNS i
, , N
more JJR N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
described VBD N
the DT N
term NN N
breast NN o
density NN o
correctly RB N
and CC N
recognized VBD N
it PRP N
as IN N
a DT N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
. . N

Although IN N
at IN N
the DT N
4-week JJ N
follow-up NN N
the DT N
intervention NN N
group NN N
indicated VBD N
that IN N
they PRP N
were VBD N
very RB N
likely JJ N
to TO N
have VB N
an DT N
annual JJ i
clinical JJ i
breast NN i
examination NN i
more RBR N
frequently RB N
than IN N
controls NNS N
, , N
no DT N
differences NNS N
were VBD N
detected VBN N
at IN N
6 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
other JJ N
behavioural JJ o
or CC o
psychological JJ o
measures NNS o
, , N
although IN N
at IN N
the DT N
4-week JJ N
follow-up JJ N
the DT N
control NN N
group NN N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
, , N
relative VBP N
to TO N
other JJ N
women NNS N
their PRP$ N
age NN N
, , N
as IN N
a DT N
lot NN N
lower JJR N
than IN N
did VBD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

The DT N
results NNS N
demonstrate VBP N
a DT N
feasible JJ N
and CC N
non-threatening JJ N
way NN N
to TO N
provide VB N
women NNS N
with IN N
important JJ N
personalized VBN N
information NN N
about IN N
breast NN o
cancer NN o
risk NN o
. . o

-DOCSTART- -X- O O

[ RB N
Perioperative NNP N
teicoplanin NN i
prophylaxis NN i
in IN N
patients NNS p
undergoing VBG p
breast JJ p
reconstruction NN p
with IN p
the DT p
abdominal JJ p
wall NN p
. . p

A DT N
case-control NN N
study NN N
] NNP N
. . N

The DT N
authors NNS N
report VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
antibiotic JJ N
prophylaxis NN N
of IN N
postoperative JJ N
infection NN N
following VBG N
breast NN p
reconstruction NN p
by IN p
transposition NN p
of IN p
rectus NN p
abdominis NN p
myocutaneous JJ p
flap NN p
( ( N
TRAMF NNP N
) ) N
. . N

The DT N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
a DT N
short-term JJ N
parenteral JJ i
prophylaxis NN i
with IN i
Teicoplanin NNP i
and CC N
the DT N
end-point NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
evaluation NN N
of IN N
wound NN N
contamination NN N
assessed VBN N
by IN N
means NNS N
of IN N
microbiologic JJ N
culture NN N
of IN N
drainage NN N
fluid NN N
. . N

From IN p
October NNP p
1990 CD p
to TO p
March NNP p
1992 CD p
38 CD p
patients NNS p
were VBD p
recruited VBN p
: : p
20 CD p
patients NNS p
in IN p
the DT p
antibiotic JJ p
prophylaxis NN p
arm NN p
and CC p
18 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
. . p

Analysis NN N
of IN N
drainage NN N
fluids NNS N
showed VBD N
a DT N
higher JJR o
contamination NN o
rate NN o
( ( N
15/18 CD N
= RB N
83 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
as IN N
compared VBN N
to TO N
the DT N
prophylaxis NN N
arm NN N
( ( N
2/20 CD N
= RB N
10 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Moreover RB N
, , N
11 CD N
patients NNS N
in IN N
the DT N
control NN N
arm NN N
suffered VBD N
from IN N
fever NN o
> $ o
37.5 CD o
degrees NNS o
C NNP o
for IN N
at IN N
least JJS N
3 CD N
days NNS N
as RB N
compared VBN N
to TO N
1 CD N
patient NN N
in IN N
the DT N
antibiotic JJ N
prophylaxis NN N
group NN N
; : N
the DT N
postoperative JJ o
stay NN o
was VBD N
13.3 CD N
+/- JJ N
4.3 CD N
and CC N
9.0 CD N
+/- JJ N
1.6 CD N
in IN N
the DT N
control NN N
and CC N
antibiotic JJ N
arm NN N
respectively RB N
. . N

No NNP N
antibiotic JJ o
related JJ o
side NN o
effects NNS o
were VBD N
evidenced VBN N
through IN N
the DT N
study NN N
. . N

These DT N
results NNS N
seem VBP N
to TO N
confirm VB N
the DT N
value NN N
of IN N
parenteral JJ N
short-term JJ N
antibiotic JJ N
prophylaxis NN N
of IN N
postoperative JJ N
infection NN N
in IN N
such JJ N
kind NN N
of IN N
clean JJ N
operative JJ N
procedure NN N
. . N

-DOCSTART- -X- O O

Continuous JJ N
and CC N
cyclical JJ i
clodronate NN i
therapies NNS i
and CC N
bone NN N
density NN N
in IN N
postmenopausal JJ p
bone NN p
loss NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
different JJ N
clodronate NN i
regimens NNS N
in IN N
postmenopausal JJ p
osteoporosis NN p
. . p

METHODS NNP N
In IN N
groups NNS p
of IN p
20 CD p
, , p
60 CD p
women NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
treatments NNS N
: : N
oral JJ i
calcium NN i
, , i
1000 CD i
mg/day NN i
; : i
oral JJ i
calcium NN i
plus CC i
oral JJ i
clodronate NN i
, , i
400 CD i
mg/day NN i
; : i
oral JJ i
calcium NN i
plus CC i
oral JJ i
clodronate NN i
, , i
400 CD i
mg/day NN i
for IN i
30 CD i
days NNS i
, , i
followed VBN i
by IN i
a DT i
60-day JJ i
period NN i
of IN i
calcium JJ i
supplement NN i
alone RB i
. . i

This DT N
last JJ N
regimen NN N
was VBD N
repeated VBN N
four CD N
times NNS N
in IN N
the DT N
12-month JJ N
study NN N
period NN N
. . N

RESULTS JJ N
Patients NNPS p
who WP p
received VBD p
calcium NN i
alone RB i
showed VBD N
a DT N
decline NN N
in IN N
spinal JJ o
bone NN o
mass NN o
, , N
both DT N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.03 NNP N
and CC N
P NNP N
< NNP N
.005 NNP N
, , N
respectively RB N
) ) N
; : N
femoral JJ N
density NN N
in IN N
this DT N
group NN N
also RB N
decreased VBD N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.002 NNP N
and CC N
P NNP N
< NNP N
.05 NNP N
, , N
respectively RB N
) ) N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
both DT N
clodronate-treated JJ i
groups NNS N
had VBD N
increased VBN N
levels NNS N
of IN N
lumbar NN N
bone NN N
mass NN N
compared VBN N
with IN N
controls NNS N
, , N
both DT N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
therapy NN N
. . N

However RB N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
patients NNS N
treated VBD N
with IN N
cyclical JJ i
clodronate NN i
had VBD N
higher JJR N
spinal JJ o
bone NN o
mass NN o
compared VBN N
with IN N
those DT N
treated VBN N
continuously RB N
( ( N
3.32 CD N
+/- JJ N
0.71 CD N
versus NN N
0.43 CD N
+/- JJ N
0.89 CD N
% NN N
, , N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

After IN N
6 CD N
months NNS N
, , N
femoral JJ o
bone NN o
density NN o
was VBD N
significantly RB N
higher JJR N
both DT N
in IN N
subjects NNS N
treated VBN N
with IN N
clodronate NN N
, , N
both DT N
cyclically RB N
and CC N
continuously RB N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
, , N
compared VBN N
with IN N
controls NNS N
. . N

Continuous JJ i
clodronate NN i
treatment NN i
resulted VBD N
in IN N
a DT N
clear JJ N
fall NN N
in IN N
biochemical JJ N
indices NNS N
of IN N
bone NN o
resorption NN o
, , N
together RB N
with IN N
a DT N
consequent JJ N
decrease NN N
in IN N
osteocalcin NN N
at IN N
6 CD N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
and CC N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
and CC N
a DT N
significant JJ N
increase NN N
in IN N
parathyroid JJ o
hormone NN o
after IN N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
of IN N
therapy NN N
. . N

CONCLUSION NNP N
One-year JJ N
treatment NN N
with IN N
clodronate NN i
induces NNS N
a DT N
gain NN N
in IN N
bone NN N
mass NN N
, , N
especially RB N
in IN N
the DT N
spine NN N
. . N

The DT N
continuous JJ N
regimen NN N
does VBZ N
not RB N
result VB N
in IN N
any DT N
further JJ N
benefit NN N
in IN N
lumbar NN N
bone NN N
density NN N
over IN N
the DT N
cyclical JJ N
one CD N
, , N
probably RB N
because IN N
of IN N
a DT N
greater JJR N
suppression NN N
of IN N
bone NN N
turnover NN N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
once RB N
and CC N
twice RB N
daily JJ N
atenolol NN i
for IN N
angina JJ p
pectoris NN p
. . p

We PRP N
have VBP N
studied VBN N
the DT N
effects NNS N
of IN N
four CD N
doses NNS N
of IN N
atenolol NN i
in IN N
11 CD p
patients NNS p
with IN p
stable JJ p
angina NNS p
pectoris VBP p
using VBG N
a DT N
symptom-limited JJ N
exercise NN N
test NN N
and CC N
angina NN N
diaries NNS N
. . N

The DT N
doses NNS N
100 CD N
mg JJ N
twice RB N
daily RB N
and CC N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
and CC N
200 CD N
mg NN N
once RB N
daily JJ N
were VBD N
given VBN N
double-blind NNS N
and CC N
randomised VBD N
within IN N
patients NNS N
following VBG N
run-in NN N
on IN N
placebo NN i
. . i

Measurements NNS N
were VBD N
made VBN N
12 CD N
hours NNS N
after IN N
the DT N
last JJ N
twice JJ N
daily RB N
dose JJ N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
last JJ N
once JJ N
daily JJ N
dose NN N
. . N

Exercise NN o
tolerance NN o
was VBD N
improved VBN N
by IN N
40-74 JJ N
% NN N
and CC N
exercise NN o
duration NN o
before IN o
the DT o
onset NN o
of IN o
angina NN o
by IN N
61-94 JJ N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Maximal JJ o
heart NN o
rate NN o
was VBD N
reduced VBN N
further RB N
by IN N
a DT N
total JJ N
daily JJ N
dose NN N
of IN N
200 CD N
mg NNS N
than IN N
by IN N
lower JJR N
doses NNS N
, , N
but CC N
no DT N
extra JJ N
benefit NN N
was VBD N
derived VBN N
by IN N
giving VBG N
the DT N
drug NN N
twice RB N
daily RB N
. . N

The DT N
largest JJS N
increase NN N
in IN N
exercise NN o
tolerance NN o
was VBD N
obtained VBN N
during IN N
treatment NN N
with IN N
50 CD N
mg NNS N
once RB N
daily RB N
. . N

Atenolol NNP i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ N
anti-anginal JJ N
agent NN N
when WRB N
given VBN N
once RB N
daily JJ N
, , N
and CC N
there EX N
were VBD N
no DT N
major JJ N
differences NNS N
between IN N
the DT N
doses NNS N
studied VBN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
acute NN i
exercise NN i
on IN N
executive NN o
function NN o
in IN N
children NNS p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
. . p

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
acute NN i
aerobic JJ i
exercise NN i
on IN N
executive NN o
function NN o
in IN N
children NNS p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
. . p

Forty NNP p
children NNS p
with IN p
ADHD NNP p
were VBD N
randomly RB N
assigned VBN N
into IN N
exercise NN N
or CC N
control NN N
groups NNS N
. . N

Participants NNS N
in IN N
the DT N
exercise NN N
group NN N
performed VBD N
a DT N
moderate JJ i
intensity NN i
aerobic JJ i
exercise NN i
for IN i
30 CD i
min NN i
, , N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
running/exercise-related JJ i
video NN i
. . i

Neuropsychological JJ o
tasks NNS o
, , o
the DT o
Stroop NNP o
Test NNP o
and CC o
the DT o
Wisconsin NNP o
Card NNP o
Sorting NNP o
Test NNP o
( ( o
WCST NNP o
) ) o
, , N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
acute JJ N
exercise NN N
facilitated VBN N
performance NN N
in IN N
the DT N
Stroop NNP N
Test NNP N
, , N
particularly RB N
in IN N
the DT N
Stroop NNP o
Color-Word NNP o
condition NN o
. . o

Additionally RB N
, , N
children NNS N
in IN N
the DT N
exercise NN N
group NN N
demonstrated VBD N
improvement NN N
in IN N
specific JJ N
WCST NNP o
performances NNS o
in IN N
Non-perseverative JJ o
Errors NNS o
and CC o
Categories NNP o
Completed NNP o
, , N
whereas VBZ N
no DT N
influences NNS N
were VBD N
found VBN N
in IN N
those DT N
performances NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Tentative JJ N
explanations NNS N
for IN N
the DT N
exercise NN N
effect NN N
postulate NN N
that WDT N
exercise NN N
allocates VBZ N
attention NN o
resources NNS N
, , N
influences VBZ N
the DT N
dorsolateral JJ o
prefrontal NN o
cortex NN o
, , N
and CC N
is VBZ N
implicated VBN N
in IN N
exercise-induced JJ o
dopamine NN o
release NN o
. . o

These DT N
findings NNS N
are VBP N
promising VBG N
and CC N
additional JJ N
investigations NNS N
to TO N
explore VB N
the DT N
efficacy NN o
of IN i
exercise NN i
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
ADHD NNP N
are VBP N
encouraged VBN N
. . N

-DOCSTART- -X- O O

Speech NN i
following VBG i
sign JJ i
language NN i
training NN i
in IN N
autistic JJ p
children NNS p
with IN p
minimal JJ p
verbal JJ p
language NN p
. . p

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
test VB N
the DT N
main JJ o
and CC o
interaction JJ o
effects NNS o
of IN N
training VBG N
condition NN N
and CC N
pretreatment-elicited JJ N
verbal JJ N
imitation NN N
ability NN N
when WRB N
predicting VBG N
spoken JJ N
language NN N
use NN N
during IN N
language NN i
training NN i
of IN N
60 CD p
minimally RB p
verbal JJ p
autistic JJ p
children NNS p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
Speech NNP o
Alone NNP o
, , o
Sign NNP o
Alone NNP o
, , o
Simultaneous NNP o
Presentation NNP o
of IN o
Sign NNP o
and CC o
Speech NNP o
, , o
and CC o
Alternating NNP o
Presentation NNP o
of IN o
Sign NNP o
and CC o
Speech NNP o
training NN o
conditions NNS o
. . o

Speech NNP o
Alone RB o
, , o
Simultaneous JJ o
Presentation NNP o
, , o
and CC o
Alternating NNP o
Presentation NNP o
condition NN o
facilitated VBD N
more RBR N
child-initiated JJ N
speech NN N
during IN N
treatment NN N
than IN N
did VBD N
the DT N
Sign NNP i
Alone NNP i
condition NN N
. . N

Regardless NNP N
of IN N
training VBG N
condition NN N
, , N
pretreatment NN N
verbal JJ N
imitation NN N
ability NN N
positively RB N
predicted VBD N
the DT N
size NN o
of IN o
child-initiated JJ o
spoken JJ o
vocabulary JJ o
observed VBD N
during IN N
training NN N
. . N

Exploratory JJ N
analyses NNS N
indicated VBD N
that IN N
, , N
in IN N
addition NN N
to TO N
verbal JJ N
imitation NN N
, , N
pretreatment JJ N
age NN N
and CC N
IQ NNP N
may MD N
also RB N
predict VB N
spoken JJ N
language NN N
developed VBD N
during IN N
training NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
extradural JJ i
analgesia NN i
on IN N
stress NN o
responses NNS o
to TO N
abdominal JJ N
surgery NN N
in IN N
infants NNS p
. . p

We PRP N
studied VBD N
40 CD p
children NNS p
younger JJR p
than IN p
4 CD p
yr NNS p
having VBG p
elective JJ p
abdominal JJ p
surgery NN p
under IN p
general JJ i
anaesthesia NN i
supplemented VBN p
with IN p
either DT p
systemic JJ i
opioids NNS i
or CC i
extradural JJ i
bupivacaine NN i
. . i

Venous JJ o
blood NN o
samples NNS o
were VBD N
obtained VBN N
before IN N
tracheal JJ N
intubation NN N
to TO N
measure VB N
baseline JJ N
concentrations NNS o
of IN o
adrenaline NN o
, , o
noradrenaline NN o
, , o
glucose NN o
, , o
ACTH NNP o
and CC o
cortisol NN o
. . o

Additional JJ N
samples NNS N
were VBD N
obtained VBN N
45 CD N
min NNS N
after IN N
the DT N
start NN N
of IN N
surgery NN N
, , N
at IN N
the DT N
end NN N
of IN N
surgery NN N
, , N
1 CD N
h NN N
and CC N
24 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

Plasma NNP o
concentrations NNS o
of IN o
bupivacaine NN o
were VBD N
measured VBN N
also RB N
in IN N
the DT N
extradural JJ N
group NN N
at IN N
each DT N
sampling VBG N
time NN N
. . N

Both DT N
techniques NNS N
provided VBN N
acceptable JJ N
analgesia NN N
, , N
but CC N
the DT N
perioperative JJ o
increases NNS o
in IN o
adrenaline NN o
, , o
glucose NN o
and CC o
ACTH NNP o
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
opioid JJ N
group NN N
. . N

Noradrenaline NNP o
concentrations NNS o
decreased VBD N
to TO N
less JJR N
than IN N
baseline NN N
values NNS N
in IN N
the DT N
extradural JJ N
group NN N
and CC N
were VBD N
significantly RB N
less JJR N
than IN N
in IN N
the DT N
opioid JJ N
group NN N
. . N

The DT N
perioperative JJ o
increase NN o
in IN o
cortisol NN o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
despite IN N
the DT N
differences NNS N
in IN N
ACTH NNP N
responses NNS N
. . N

Most JJS N
responses NNS N
returned VBN N
to TO N
the DT N
baseline NN N
values NNS N
within IN N
24 CD N
h. NN N
Plasma NNP o
bupivacaine NN o
concentrations NNS o
remained VBD N
within IN N
safe JJ N
limits NNS N
during IN N
the DT N
study NN N
, , N
but CC N
systemic JJ o
concentrations NNS o
increased VBD N
in IN N
some DT N
of IN N
the DT N
patients NNS N
during IN N
postoperative JJ N
infusion NN N
with IN N
0.125 CD N
% NN N
bupivacaine NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
glucagon-like JJ i
peptide-1 JJ i
( ( i
7-36 JJ i
) ) i
amide NN i
on IN N
motility NN o
and CC o
sensation NN o
of IN o
the DT o
proximal JJ o
stomach NN o
in IN p
humans NNS p
. . p

BACKGROUND NNP N
Glucagon-like JJ i
peptide-1 NN i
( ( i
7-36 JJ i
) ) i
amide NN i
( ( i
GLP-1 NNP i
) ) i
retards NNS N
gastric JJ o
emptying NN o
, , o
reduces NNS o
food NN o
intake NN o
, , o
and CC o
inhibits VBZ o
antroduodenal JJ o
and CC o
stimulates VBZ o
pyloric JJ o
motility NN o
. . o

AIMS NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
synthetic JJ i
GLP-1 NNP i
on IN N
fundus NN o
tone NN o
and CC o
volume NN o
waves NNS o
, , o
gastric JJ o
compliance NN o
, , o
and CC o
perception NN o
of IN o
gastric JJ o
distension NN o
. . o

SUBJECTS NNP N
Eleven NNP p
healthy JJ p
male NN p
volunteers NNS p
. . p

METHODS NNP N
Background NNP N
infusions NNS N
were VBD N
saline JJ i
, , i
or CC i
GLP-1 NNP i
at IN N
0.3 CD N
or CC N
0.9 CD N
pmol/ JJ N
kg/min NN N
on IN N
separate JJ N
days NNS N
in IN N
random JJ N
order NN N
. . N

Interdigestive JJ o
fundus NN o
motility NN o
was VBD N
recorded VBN N
by IN N
barostat NN N
( ( N
maximum JJ N
capacity NN N
of IN N
intragastric JJ N
bag NN N
1200 CD N
ml NN N
) ) N
during IN N
basal NN N
and CC N
peptide JJ N
periods NNS N
of IN N
60 CD N
minutes NNS N
each DT N
. . N

Thereafter RB N
stepwise JJ N
isobaric JJ N
distensions NNS N
were VBD N
performed VBN N
with IN N
ongoing JJ N
peptide NN N
infusion NN N
, , N
and CC N
gastric JJ o
sensation NN o
was VBD N
scored VBN N
. . N

RESULTS NNP N
Low NNP N
and CC N
high JJ N
loads NNS N
of IN N
GLP-1 NNP i
induced JJ N
physiological JJ o
and CC o
supraphysiological JJ o
plasma NN o
immunoreactivities NNS o
, , N
respectively RB N
. . N

GLP-1 NNP i
dose NN N
dependently RB N
diminished VBD N
fundus JJ o
tone NN o
( ( N
162.9 CD N
( ( N
15.0 CD N
) ) N
and CC N
259.5 CD N
( ( N
17.2 CD N
) ) N
v NN N
121.1 CD N
( ( N
6.0 CD N
) ) N
ml NN N
with IN N
saline NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

It PRP N
greatly RB N
reduced VBD N
volume NN o
waves NNS o
and CC o
total JJ o
volume NN o
displaced VBN o
by IN N
these DT N
events NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Gastric NNP o
compliance NN o
derived VBD N
from IN N
isobaric JJ N
distension NN N
rose VBD N
in IN N
a DT N
dose NN N
related JJ N
manner NN N
( ( N
42.6 CD N
( ( N
5.5 CD N
) ) N
and CC N
63.6 CD N
( ( N
7.7 CD N
) ) N
v NN N
27.0 CD N
( ( N
3.5 CD N
) ) N
ml/mm NN N
Hg NNP N
; : N
p=0.0004 NN N
) ) N
with IN N
a DT N
concomitant JJ N
reduction NN N
of IN N
the DT N
pressure NN o
at IN N
half JJ N
maximum JJ N
bag NN N
volume NN N
( ( N
6.4 CD N
( ( N
0.4 CD N
) ) N
and CC N
5.5 CD N
( ( N
0.4 CD N
) ) N
v NN N
7.2 CD N
( ( N
0.1 CD N
) ) N
mm NN N
Hg NNP N
; : N
p VBZ N
< $ N
0.0001 CD N
) ) N
. . N

GLP-1 NNP i
did VBD N
not RB N
change VB N
perception NN N
of IN N
isobaric JJ o
distension NN o
but CC N
reduced VBD N
the DT N
perception NN o
score RB o
related VBN N
to TO N
corresponding VBG N
bag NN N
volume NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
GLP-1 NNP i
is VBZ N
a DT N
candidate JJ N
physiological JJ N
inhibitory NN N
regulator NN N
of IN N
fundus JJ o
motility NN o
. . o

It PRP N
allows VBZ N
the DT N
stomach NN N
to TO N
afford VB N
a DT N
larger JJR N
volume NN N
without IN N
increase NN o
in IN o
sensation NN o
. . o

-DOCSTART- -X- O O

Improved VBN N
acidosis NN N
correction NN N
and CC N
recovery NN N
of IN N
mesothelial JJ N
cell NN N
mass NN N
with IN N
neutral-pH JJ i
bicarbonate JJ i
dialysis NN i
solution NN i
among IN N
children NNS p
undergoing VBG p
automated VBN i
peritoneal JJ i
dialysis NN i
. . i

Acid-base JJ N
balance NN N
and CC N
peritoneal JJ N
membrane NN N
longevity NN N
are VBP N
of IN N
utmost JJ N
relevance NN N
for IN N
pediatric JJ p
patients NNS p
undergoing VBG p
peritoneal JJ i
dialysis NN i
( ( i
PD NNP i
) ) i
. . i

PD NNP N
fluids NNS N
with IN N
neutral JJ N
pH NN N
and CC N
reduced VBD N
glucose JJ N
degradation NN N
product NN N
contents NNS N
are VBP N
considered VBN N
more RBR N
biocompatible JJ N
, , N
because IN N
they PRP N
preserve VBP N
peritoneal JJ N
cell NN N
functions NNS N
in IN N
vitro NN N
. . N

To TO N
investigate VB N
the DT N
clinical JJ N
effects NNS o
of IN N
a DT N
novel JJ i
PD NNP i
fluid NN i
buffered VBD i
with IN i
34 CD i
mM NNS i
pure JJ i
bicarbonate NN i
at IN i
neutral JJ i
pH NN i
, , N
a DT N
randomized VBN N
, , N
prospective JJ N
, , N
crossover JJ N
comparison NN N
with IN N
conventional JJ i
, , i
acidic JJ i
, , i
35 CD i
mM NN i
lactate NN i
PD NNP i
fluid NN i
was VBD N
performed VBN N
for IN N
two CD N
consecutive JJ N
12-wk JJ N
periods NNS N
with IN N
28 CD p
children NNS p
( ( p
age NN p
, , p
6 CD p
mo NN p
to TO p
15 CD p
yr NN p
) ) p
undergoing NN p
automated VBN i
PD NNP i
( ( i
APD NNP i
) ) i
. . i

Blood NNP o
bicarbonate NN o
levels NNS o
and CC o
arterial JJ o
pH NN o
were VBD N
significantly RB N
higher JJR o
after IN N
3 CD N
mo NN N
of IN N
bicarbonate NN o
PD NNP o
( ( N
24.6 CD N
+/- JJ N
2.3 CD N
mM NN N
and CC N
7.43 CD N
+/- JJ N
0.06 CD N
, , N
respectively RB N
) ) N
, , N
compared VBN N
with IN N
lactate JJ o
PD NNP o
( ( N
22.8 CD N
+/- JJ N
3.9 CD N
mM NN N
and CC N
7.38 CD N
+/- JJ N
0.05 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
reversible JJ N
among IN N
patients NNS N
who WP N
returned VBD N
from IN N
bicarbonate NN N
to TO N
lactate VB N
fluid NN N
. . N

Low JJ N
initial JJ o
pH NN o
and CC N
young JJ N
patient NN N
age NN N
independently RB N
predicted VBD N
increased VBN N
blood NN o
pH NN o
during IN N
bicarbonate NN o
APD NNP o
. . o

Peritoneal NNP N
equilibration NN N
tests NNS N
revealed VBD N
subtle JJ o
changes NNS o
in IN o
solute NN o
transport NN o
, , N
with IN N
a DT N
less RBR o
steep JJ o
creatinine NN o
equilibration NN o
curve NN o
during IN N
bicarbonate JJ N
dialysis NN N
, , N
suggesting VBG N
reduced VBN N
peritoneal JJ N
vasodilation NN N
. . N

The DT N
peritoneal JJ o
release NN o
of IN o
carcinogen JJ o
antigen-125 NNS o
increased VBD o
twofold NN N
during IN N
bicarbonate NN N
APD NNP N
( ( N
29 CD N
+/- JJ N
15 CD N
versus NN N
15 CD N
+/- JJ N
8 CD N
U/ml NNP N
per IN N
4 CD N
h NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
which WDT N
is VBZ N
consistent JJ N
with IN N
recovery NN N
of IN N
the DT N
mesothelial JJ N
cell NN N
layer NN N
. . N

This DT N
effect NN N
was VBD N
fully RB N
reversed VBN N
when WRB N
the DT N
patients NNS N
returned VBD N
to TO N
lactate VB N
fluid NN N
. . N

Effluent JJ o
carcinogen NN o
antigen-125 JJ o
levels NNS o
were VBD N
inversely RB N
correlated VBN N
with IN N
peritoneal JJ N
glucose JJ N
exposure NN N
during IN N
lactate NN N
but CC N
not RB N
bicarbonate VB N
APD NNP N
, , N
indicating VBG N
improved VBN N
in IN N
vivo JJ N
mesothelial NN N
cell NN N
tolerance NN N
of IN N
high-dose JJ N
glucose NN N
with IN N
the DT N
neutral-pH JJ i
PD NNP i
fluid NN i
with IN i
reduced VBN i
glucose JJ i
degradation NN i
product NN i
content NN i
. . i

Among IN N
children NNS p
undergoing VBG p
APD NNP i
, , i
neutral-pH JJ i
, , i
bicarbonate-buffered JJ i
PD NNP i
fluid NN i
provides VBZ N
more RBR N
effective JJ N
correction NN N
of IN N
metabolic JJ N
acidosis NN N
and CC N
better JJR N
preservation NN N
of IN N
peritoneal NN N
cell NN N
mass NN N
than IN N
do VBP N
conventional JJ i
, , i
acidic JJ i
, , i
lactate-based JJ i
fluids NNS i
. . i

-DOCSTART- -X- O O

Lack NN N
of IN N
interaction NN N
between IN N
pantoprazole NN i
and CC i
digoxin NN i
at IN N
therapeutic JJ N
doses NNS N
in IN p
man NN p
. . p

Substituted JJ i
benzimidazole JJ i
inhibitors NNS i
of IN N
the DT N
gastric JJ N
H+/K+ATPase NNP N
may MD N
interact VB N
with IN N
the DT N
cytochrome NN N
P450 NNP N
enzyme NN N
system NN N
and CC N
alter VB N
the DT N
pharmacokinetics NNS N
of IN N
coadministered JJ N
drugs NNS N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
changes NNS N
in IN N
intragastric JJ N
pH NN N
might MD N
alter VB N
the DT N
absorption NN N
of IN N
other JJ N
drugs NNS N
. . N

The DT N
primary JJ N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
pantoprazole JJ i
modifies NNS N
the DT N
steady-state JJ N
serum NN N
concentrations NNS N
of IN N
orally RB N
administered VBN N
digoxin NN i
. . i

Secondary JJ N
aims NNS N
were VBD N
the DT N
influence NN N
of IN N
digoxin NN i
on IN N
the DT N
pharmacokinetics NNS N
of IN N
pantoprazole NN i
as RB N
well RB N
as IN N
safety NN N
and CC N
tolerability NN N
. . N

Eighteen NNP p
healthy JJ p
volunteers NNS p
received VBD N
a DT N
single JJ N
oral JJ i
dose NN i
of IN i
pantoprazole NN i
( ( i
40 CD i
mg NN i
) ) i
and CC i
serum JJ i
concentrations NNS i
were VBD N
determined VBN N
. . N

Three CD N
to TO N
10 CD N
days NNS N
later RB N
, , N
subjects NNS N
received VBD N
in IN N
a DT N
single-blind NN N
, , N
randomized VBN N
, , N
crossover JJ N
fashion NN N
oral JJ N
beta-acetyldigoxin NN i
( ( N
0.2 CD N
mg NN N
) ) N
twice RB N
daily RB N
and CC N
concomitant JJ i
oral JJ i
pantoprazole NN i
( ( N
40 CD N
mg NN N
) ) N
or CC N
placebo JJ i
once RB N
daily JJ N
for IN N
5 CD N
days NNS N
. . N

Serum NNP N
concentrations NNS N
of IN N
pantoprazole NN i
and CC i
digoxin NN i
were VBD N
determined VBN N
on IN N
day NN N
5 CD N
. . N

Primary JJ N
characteristics NNS N
for IN N
confirmative JJ N
assessment NN N
of IN N
no DT N
interaction NN N
were VBD N
AUC NNP o
and CC o
Cmax NNP o
of IN o
digoxin NN o
. . o

Lack NNP N
of IN N
interaction NN N
in IN N
the DT N
sense NN N
of IN N
equivalence NN N
was VBD N
concluded VBN N
for IN N
both DT N
digoxin NN N
( ( N
with IN N
and CC N
without IN N
pantoprazole NN i
) ) i
and CC N
pantoprazole JJ i
( ( i
with IN i
and CC i
without IN i
digoxin NN i
) ) i
as IN N
the DT N
90 CD N
% NN N
-confidence NN N
intervals NNS N
of IN N
the DT N
respective JJ N
AUC- NNP o
and CC o
Cmax-ratios NNP o
were VBD N
within IN N
the DT N
equivalence NN N
range NN N
of IN N
0.8-1.25 NNP N
. . N

Pantoprazole NNP i
did VBD N
not RB N
influence VB N
the DT N
characteristic JJ N
ECG NNP N
modifications NNS N
( ( N
T-wave NNP N
) ) N
caused VBN N
by IN N
digoxin NN N
. . N

Both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN o
and CC N
no DT N
adverse JJ o
events NNS o
or CC N
clinically RB N
relevant JJ N
alterations NNS N
in IN N
vital JJ N
signs NNS N
or CC N
clinical JJ N
laboratory NN N
parameters NNS N
were VBD N
observed VBN N
during IN N
treatment NN N
. . N

In IN N
conclusion NN N
, , N
pantoprazole NN i
and CC i
digoxin NN i
may MD N
be VB N
administered VBN N
concomitantly RB N
without IN N
the DT N
need NN N
for IN N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -X- O O

Enhanced NNP N
inotropic NN N
state NN N
of IN N
the DT N
failing NN N
left VBD N
ventricle NN N
by IN N
cardiac JJ i
contractility NN i
modulation NN i
electrical JJ i
signals NNS i
is VBZ N
not RB N
associated VBN N
with IN N
increased JJ N
myocardial JJ o
oxygen NN o
consumption NN o
. . o

BACKGROUND NNP N
Previous NNP N
studies NNS N
in IN N
patients NNS p
and CC p
in IN p
dogs NNS p
with IN p
experimentally RB p
induced JJ p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
showed VBD N
that IN N
electrical JJ i
signals NNS i
applied VBN N
to TO N
the DT N
failing VBG N
myocardium NN N
during IN N
the DT N
absolute JJ N
refractory NN N
period NN N
improved VBD N
left JJ o
ventricular NN o
( ( o
LV NNP o
) ) o
function NN o
. . o

We PRP N
examined VBD N
the DT N
effects NNS N
these DT N
same JJ N
cardiac NN i
contractility NN i
modulating NN i
( ( i
CCM NNP i
) ) i
electrical JJ i
signals NNS i
on IN N
myocardial JJ o
oxygen NN o
consumption NN o
( ( o
MVO NNP o
( ( o
2 CD o
) ) o
) ) o
in IN N
both DT p
patients NNS p
and CC p
dogs NNS p
with IN p
chronic JJ p
HF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Six NNP p
dogs NNS p
with IN p
microembolizations-induced JJ i
HF NNP i
and CC p
9 CD p
HF NNP p
patients NNS p
underwent JJ p
CCM NNP i
leads NNS i
and CC i
generator NN i
( ( i
OPTIMIZER NNP i
II NNP i
) ) i
implantation NN i
. . i

After IN N
baseline NN N
measurements NNS N
, , N
CCM NNP i
signals NNS i
were VBD N
delivered VBN N
continuously RB N
for IN N
2 CD N
hours NNS N
in IN N
dogs NNS N
and CC N
for IN N
30 CD N
minutes NNS N
in IN N
patients NNS N
. . N

MVO NNP o
( ( o
2 CD o
) ) o
was VBD N
measured VBN N
before IN N
and CC N
after IN N
CCM NNP i
therapy NN i
. . i

In IN N
dogs NNS N
, , N
CCM NNP i
therapy NN i
increased VBD N
LV NNP o
ejection NN o
fraction NN o
at IN N
2 CD N
hours NNS N
( ( N
26 CD N
+/- JJ N
1 CD N
versus NN N
31 CD N
+/- JJ N
2 CD N
% NN N
, , N
P NNP N
= NNP N
.001 NNP N
) ) N
without IN N
increasing VBG N
MVO NNP o
( ( o
2 CD o
) ) o
( ( N
257 CD N
+/- JJ N
41 CD N
versus NN N
180 CD N
+/- JJ N
34 CD N
micromol/min NN N
) ) N
. . N

In IN N
patients NNS N
, , N
CCM NNP i
therapy NN i
increased VBD N
LV NNP o
peak NN o
+dP/dt NN o
by IN N
10.1 CD N
+/- JJ N
1.5 CD N
% NN N
. . N

As IN N
with IN N
dogs NNS N
, , N
the DT N
increase NN N
in IN N
LV NNP o
function NN o
after IN N
30 CD N
minutes NNS N
of IN N
CCM NNP i
therapy NN i
was VBD N
not RB N
associated VBN N
with IN N
increased VBN N
MVO NNP o
( ( o
2 CD o
) ) o
( ( N
13.6 CD N
+/- JJ N
9.7 CD N
versus NN N
12.5 CD N
+/- JJ N
7.2 CD N
mL NN N
O NNP N
( ( N
2 CD N
) ) N
/min NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
study NN N
results NNS N
suggest VBP N
that IN N
unlike IN N
cAMP-dependent JJ N
positive JJ N
inotropic NN N
drugs NNS N
, , N
the DT N
increase NN N
in IN N
LV NNP o
function NN o
during IN N
CCM NNP i
therapy NN i
is VBZ N
elicited VBN N
without IN N
increasing VBG N
MVO NNP o
( ( o
2 CD o
) ) o
. . o

-DOCSTART- -X- O O

[ JJ N
Dose-reduced NNP N
antihypertensive JJ i
agents NNS i
-- : i
use NN i
in IN N
complex JJ N
nonmedicamentous JJ i
therapy NN N
of IN N
hypertension NN N
] NNP N
. . N

In IN N
order NN N
to TO N
estimate VB N
the DT N
influence NN N
of IN N
a DT N
non-medicamentous JJ i
therapy NN i
( ( i
CNT NNP i
) ) i
on IN N
the DT N
consumption NN N
of IN N
medicaments NNS N
and CC N
coronary JJ N
risk NN N
in IN N
high JJ N
blood NN N
pressure NN N
73 CD p
hypertensives NNS p
of IN p
a DT p
medicamentously RB p
stabilized VBN p
CNT-group NNP p
were VBD N
examined VBN N
in IN N
comparison NN N
to TO N
a DT N
group NN p
of IN p
the DT p
same JJ p
size NN p
of IN p
patients NNS p
with IN p
hypertension NN p
who WP p
were VBD p
managed VBN p
exclusively RB p
medicamentously RB p
for IN N
behaviour NN N
of IN N
blood NN N
pressure NN N
, , N
need NN N
of IN N
antihypertensive JJ i
drugs NNS i
and CC N
changes NNS N
of IN N
hypertension-associated JJ N
risk NN N
factors NNS N
. . N

After IN N
an DT N
exactly RB N
controlled VBN N
6-month JJ N
treatment NN N
hypertensives NNS p
with IN N
additionally RB N
recommended VBN N
far-reaching NN N
CNT NNP N
showed VBD N
an DT N
economization NN N
of IN N
medicaments NNS N
by IN N
scarcely RB N
the DT N
half NN N
in IN N
comparison NN N
to TO N
the DT N
reference NN N
group NN N
. . N

By IN N
means NNS N
of IN N
suitable JJ N
control NN N
methods VBZ N
a DT N
causal JJ N
non-medicamentously RB i
conditioned JJ N
decrease NN N
of IN N
blood NN o
pressure NN o
could MD N
be VB N
excluded VBN N
. . N

A DT N
different JJ N
need NN N
of IN N
antihypertensive JJ i
drugs NNS i
was VBD N
simulated VBN N
by IN N
the DT N
exacter JJ N
intake NN N
of IN N
medicaments NNS N
in IN N
the DT N
index-patients NNS N
. . N

Notwithstanding VBG N
the DT N
metabolic JJ N
effects NNS N
of IN N
the DT N
additional JJ N
therapy NN N
have VBP N
induced VBN N
a DT N
positive JJ N
change NN N
of IN N
atherogenic JJ o
lipids NNS o
. . o

The DT N
examinations NNS N
indicate VBP N
in IN N
general JJ N
the DT N
difficulty NN N
of IN N
the DT N
judgement NN N
of IN N
efficacy NN N
of IN N
non-medicamentous JJ i
therapeutic JJ i
measures NNS N
in IN N
connection NN N
with IN N
a DT N
rational JJ N
dose-reduced JJ N
long-term JJ N
therapy NN N
with IN N
antihypertensive JJ N
drugs NNS N
. . N

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
seven CD p
antiarrhythmic JJ i
drugs NNS i
in IN p
patients NNS p
with IN p
ventricular JJ p
tachyarrhythmias NNS p
. . p

Electrophysiologic NNP N
Study NNP N
versus VBD N
Electrocardiographic NNP N
Monitoring NNP N
Investigators NNP N
. . N

BACKGROUND NNP N
The DT N
relative JJ N
efficacies NNS N
of IN N
various JJ N
antiarrhythmic JJ N
drugs NNS N
in IN N
the DT N
treatment NN N
of IN N
ventricular JJ N
tachyarrhythmias NNS N
are VBP N
not RB N
well RB N
known VBN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
imipramine NN i
, , i
mexiletine NN i
, , i
pirmenol NN i
, , i
procainamide NN i
, , i
propafenone NN i
, , i
quinidine NN i
, , i
and CC i
sotalol NN i
in IN N
patients NNS p
with IN p
ventricular JJ p
tachyarrhythmias NNS p
who WP N
were VBD N
enrolled VBN N
in IN N
the DT N
Electrophysiologic NNP N
Study NNP N
versus VBD N
Electrocardiographic NNP N
Monitoring NNP N
trial NN N
. . N

METHODS JJ N
Patients NNPS p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
serial JJ N
testing NN N
of IN N
the DT N
efficacy NN N
of IN N
the DT N
seven CD N
antiarrhythmic JJ N
drugs NNS N
by IN N
one CD N
of IN N
two CD N
strategies NNS N
: : N
electrophysiologic NN i
study NN i
or CC i
Holter NNP i
monitoring VBG i
together RB i
with IN i
exercise NN i
testing NN i
. . i

The DT N
seven CD N
drugs NNS N
were VBD N
then RB N
tested VBN N
for IN N
efficacy NN N
in IN N
random JJ N
order NN N
in IN N
patients NNS N
who WP N
were VBD N
eligible JJ N
to TO N
receive VB N
them PRP N
. . N

The DT N
frequencies NNS N
of IN N
predictions NNS N
of IN N
drug NN N
efficacy NN N
and CC N
of IN N
adverse JJ N
drug NN N
effects NNS N
during IN N
the DT N
initial JJ N
drug NN N
titration NN N
were VBD N
tabulated VBN N
for IN N
all DT N
486 CD p
randomized VBN p
subjects NNS p
. . p

Patients NNS N
received VBD N
long-term JJ N
treatment NN N
with IN N
the DT N
first JJ N
antiarrhythmic JJ N
drug NN N
that WDT N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ N
on IN N
the DT N
basis NN N
of IN N
drug NN N
testing NN N
. . N

Recurrences NNS N
of IN N
arrhythmia NN N
, , N
deaths NNS N
, , N
and CC N
adverse JJ N
drug NN N
effects NNS N
during IN N
long-term JJ N
follow-up NNS N
were VBD N
recorded VBN N
for IN N
the DT N
296 CD p
patients NNS p
in IN N
whom WP N
an DT N
antiarrhythmic JJ N
drug NN N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ N
. . N

RESULTS NNP N
In IN N
the DT N
electrophysiologic-study JJ N
group NN N
, , N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
had VBD N
predictions NNS N
of IN N
drug NN o
efficacy NN o
was VBD N
higher JJR o
with IN N
sotalol NN N
( ( N
35 CD N
percent NN N
) ) N
than IN N
with IN N
the DT N
other JJ N
drugs NNS N
( ( N
16 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT o
significant JJ o
difference NN o
among IN N
the DT N
drugs NNS N
in IN N
the DT N
Holter-monitoring NNP N
group NN N
. . N

The DT N
percentage NN N
of IN N
patients NNS o
with IN o
adverse JJ o
drug NN o
effects NNS o
was VBD N
lowest JJS o
among IN N
those DT N
receiving VBG N
sotalol NN N
. . N

The DT N
actuarial JJ o
probability NN o
of IN o
a DT o
recurrence NN o
of IN o
arrhythmia NN o
after IN N
a DT N
prediction NN N
of IN N
drug NN N
efficacy NN N
by IN N
either DT N
strategy NN N
was VBD N
significantly RB o
lower JJR o
for IN N
patients NNS N
treated VBN N
with IN N
sotalol NN N
than IN N
for IN N
patients NNS N
treated VBN N
with IN N
the DT N
other JJ N
drugs NNS N
( ( N
risk NN N
ratio NN N
, , N
0.43 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.29 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

With IN N
sotalol NN N
, , N
as IN N
compared VBN N
with IN N
the DT N
other JJ N
drugs NNS N
combined VBN N
, , N
there EX N
were VBD N
lower JJR o
risks NNS o
of IN o
death NN o
from IN N
any DT N
cause NN N
( ( N
risk NN N
ratio NN N
, , N
0.50 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.30 CD N
to TO N
0.80 CD N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
death NN N
from IN N
cardiac JJ N
causes NNS N
, , N
( ( N
0.50 CD N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
death NN o
from IN o
arrhythmia NN o
( ( N
0.50 CD N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
cumulative JJ N
percentage NN N
of IN N
patients NNS N
in IN N
whom WP N
a DT N
drug NN N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ o
and CC N
in IN N
whom WP N
it PRP N
remained VBD N
effective JJ o
and CC o
tolerated VBD o
was VBD N
higher JJR o
for IN N
sotalol JJR N
than IN N
for IN N
the DT N
other JJ N
drugs NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Sotalol NNP N
was VBD N
more RBR N
effective JJ o
than IN N
the DT N
other JJ N
six CD N
antiarrhythmic JJ N
drugs NNS N
in IN N
preventing VBG o
death NN o
and CC o
recurrences NNS o
of IN o
arrhythmia NN o
. . o

In IN N
patients NNS N
similar JJ N
to TO N
those DT N
in IN N
this DT N
study NN N
, , N
if IN N
antiarrhythmic-drug JJ N
therapy NN N
is VBZ N
to TO N
be VB N
used VBN N
to TO N
prevent VB N
recurrences NNS N
of IN N
ventricular JJ N
tachyarrhythmias NNS N
, , N
treatment NN N
with IN N
sotalol NN N
and CC N
assessment NN N
of IN N
its PRP$ N
potential JJ N
efficacy NN N
by IN N
Holter NNP N
monitoring NN N
are VBP N
a DT N
reasonable JJ N
initial JJ N
strategy NN N
. . N

-DOCSTART- -X- O O

Determining VBG N
the DT N
trough-to-peak JJ o
ratio NN o
in IN N
parallel-group JJ N
trials NNS N
. . N

Systolic JJ N
Hypertension NNP N
in IN N
Europe NNP N
( ( N
SYST-EUR NNP N
) ) N
Trial NNP N
Investigators NNP N
. . N

We PRP N
explored VBD N
how WRB N
in IN N
parallel-group JJ N
trials NNS N
interindividual JJ N
variability NN N
, , N
correction NN N
for IN N
placebo NN N
effects NNS N
, , N
and CC N
smoothing NN N
of IN N
blood NN N
pressure NN N
profiles NNS N
can MD N
be VB N
handled VBN N
in IN N
measuring VBG N
the DT N
trough-to-peak JJ o
ratio NN o
in IN N
244 CD p
individuals NNS p
with IN p
isolated JJ p
systolic JJ p
hypertension NN p
( ( p
> CD p
or CC p
= $ p
60 CD p
years NNS p
) ) p
enrolled VBD p
in IN p
the DT p
placebo-controlled JJ p
Systolic NNP p
Hypertension NNP p
in IN p
europe JJ p
Trial NNP p
. . p

Net JJ N
treatment NN N
effects NNS N
were VBD N
computed VBN N
by IN N
subtracting VBG N
the DT N
mean JJ N
changes NNS N
from IN N
baseline NN N
during IN N
placebo NN N
( ( N
n JJ N
= NNP N
133 CD N
) ) N
from IN N
those DT N
during IN N
active JJ N
treatment NN N
( ( N
n JJ N
= NNP N
111 CD N
) ) N
. . N

At IN p
entry NN p
, , p
systolic/diastolic JJ o
pressures NNS o
averaged VBD p
176/86 CD p
mm NN p
Hg NNP p
in IN p
the DT p
clinic NN p
and CC p
149/80 CD p
mm NN p
Hg NNP p
on IN p
24-hour JJ p
ambulatory JJ p
monitoring NN p
. . p

With IN N
corrections NNS N
applied VBN N
for IN N
baseline NN N
and CC N
placebo NN N
, , N
nitrendipine NN i
( ( i
10 CD i
to TO i
40 CD i
mg/d NN i
) ) i
, , i
with IN i
the DT i
possible JJ i
addition NN i
of IN i
enalapril NN i
( ( i
5 CD i
to TO i
20 CD i
mg/d NN i
) ) i
and/or NN i
hydrochlorothiazide NN i
( ( i
12.5 CD i
to TO i
25 CD i
mg/d NN i
) ) i
, , i
reduced VBN i
( ( i
P NNP i
< NNP i
.001 NNP i
) ) i
these DT i
blood NN o
pressure NN o
values NNS o
by IN i
16.6/7.3 CD i
and CC i
9.8/4.7 CD i
mm NN i
Hg NNP i
, , i
respectively RB i
. . i

The DT N
net JJ o
trough-to-peak JJ o
ratios NNS o
were VBD N
first RB N
determined VBN N
from IN N
blood NN o
pressure NN o
profiles NNS o
( ( i
12 CD i
hours NNS i
) ) i
with IN i
1-hour JJ i
precision NN i
, , i
synchronized VBN i
by IN i
the DT i
morning NN i
and CC i
evening NN i
doses NNS i
of IN i
the DT i
double-blind JJ i
medication NN i
. . i

According VBG N
to TO N
the DT N
usual JJ N
approach NN N
, , N
disregarding VBG N
interindividual JJ N
variability NN N
, , N
the DT N
systolic/diastolic JJ o
net JJ o
trough-to-peak JJ o
ratios NNS o
were VBD N
0.46/0.40 CD N
in IN N
the DT N
morning NN N
and CC N
0.77/0.99 CD N
in IN N
the DT N
evening NN N
. . N

In IN N
individual JJ N
subjects NNS N
, , N
the DT N
baseline-adjusted JJ o
trough-to-peak JJ o
ratios NNS o
were VBD N
nonnormally RB N
distributed VBN N
. . N

We PRP N
therefore VBP N
used VBD N
a DT N
nonparametric JJ N
technique NN N
to TO N
calculate VB N
the DT N
net JJ o
trough-to-peak JJ o
ratios NNS o
from IN N
the DT N
results NNS N
in IN N
individual JJ N
subjects NNS N
. . N

In IN N
the DT N
morning NN N
, , N
these DT N
ratios NNS N
averaged VBD N
0.25 CD N
systolic NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.09 CD N
to TO N
0.41 CD N
) ) N
and CC N
0.15 CD N
diastolic NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.00 CD N
to TO N
0.31 CD N
) ) N
and CC N
in IN N
the DT N
evening NN N
, , N
0.19 CD N
and CC N
0.36 CD N
( ( N
95 CD N
% NN N
confidence NN N
intervals NNS N
, , N
0.00 CD N
to TO N
0.38 CD N
and CC N
0.14 CD N
to TO N
0.56 CD N
) ) N
, , N
respectively RB N
. . N

When WRB N
the DT N
blood NN o
pressure NN o
profiles NNS o
were VBD N
smoothed VBN N
by IN N
substituting VBG N
the DT N
1-hour JJ N
averages NNS N
by IN N
moving VBG N
or CC N
fixed VBN N
2-hour JJ N
averages NNS N
or CC N
by IN N
Fourier NNP N
modeling NN N
, , N
the DT N
trough-to-peak JJ o
ratios NNS o
remained VBD N
unchanged JJ N
after IN N
the DT N
morning NN N
dose NN N
( ( N
0.20/0.13 CD N
, , N
0.20/0.14 CD N
, , N
and CC N
0.16/0.21 CD N
, , N
respectively RB N
) ) N
but CC N
tended VBD N
to TO N
increase VB N
in IN N
the DT N
evening NN N
( ( N
0.32/0.38 CD N
, , N
0.28/0.40 CD N
, , N
and CC N
0.48/0.49 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
parallel-group JJ N
analysis NN N
proposed VBN N
makes VBZ N
it PRP N
possible JJ N
for IN N
one CD N
to TO N
correct VB N
the DT N
trough-to-peak JJ o
ratio NN o
for IN N
baseline NN N
as RB N
well RB N
as IN N
placebo NN N
, , N
to TO N
account VB N
for IN N
interindividual JJ N
variability NN N
, , N
and CC N
to TO N
calculate VB N
a DT N
confidence NN N
interval NN N
for IN N
the DT N
net JJ N
trough-to-peak JJ o
ratio NN o
. . o

Accounting NN N
for IN N
interindividual JJ N
variability NN N
reduces VBZ N
the DT N
trough-to-peak JJ o
ratio NN o
. . o

Smoothing VBG N
affects VBZ N
the DT N
individualized JJ N
net JJ N
trough-to-peak JJ o
ratios NNS o
in IN N
an DT N
unpredictable JJ N
way NN N
and CC N
should MD N
therefore RB N
be VB N
avoided VBN N
. . N

-DOCSTART- -X- O O

S-phase JJ i
kinase-associated JJ i
protein NN i
2 CD N
expression NN N
in IN N
laryngeal JJ p
squamous JJ p
cell NN p
carcinomas NN p
and CC N
its PRP$ N
prognostic JJ N
implications NNS N
. . N

The DT N
F-box JJ N
protein JJ N
S-phase JJ i
kinase-associated JJ i
protein NN i
2 CD N
( ( i
Skp2 NNP i
) ) i
positively RB N
regulates VBZ N
the DT N
G1-S JJ N
transition NN N
by IN N
controlling VBG N
the DT N
stability NN N
of IN N
several JJ N
G1 NNP N
regulators NNS N
, , N
such JJ N
as IN N
the DT N
cell NN N
cycle NN N
inhibitor NN N
p27kip1 NN N
. . N

However RB N
, , N
the DT N
clinical JJ N
significance NN N
of IN N
Skp2 NNP i
in IN N
patients NNS p
with IN p
laryngeal JJ p
squamous JJ p
cell NN p
carcinoma NN p
( ( p
LSCC NNP p
) ) p
remains VBZ N
unknown JJ N
. . N

In IN N
this DT N
study NN N
, , N
a DT N
potential JJ N
distribution NN N
of IN N
Skp2 NNP i
in IN N
LSCC NNP N
and CC N
its PRP$ N
clinical JJ N
implications NNS N
was VBD N
investigated VBN N
by IN N
an DT N
immunohistochemical JJ i
study NN i
. . i

Overall NNP N
, , N
Skp2 NNP o
overexpression NN o
was VBD N
observed VBN N
in IN N
36.7 CD p
% NN p
( ( p
37 CD p
of IN p
102 CD p
) ) p
patients NNS p
and CC N
was VBD N
significantly RB N
associated VBN N
with IN N
lymph JJ N
node JJ N
metastasis NN N
( ( N
p=0.002 NN N
) ) N
and CC N
was VBD N
inversely RB N
associated VBN N
with IN N
p27kip1 JJ N
expression NN N
( ( N
p=0.026 NN N
) ) N
. . N

Survival JJ o
analysis NN o
using VBG N
the DT N
Kaplan-Meier NNP N
method NN N
showed VBD N
that IN N
Skp2 NNP i
overexpression NN N
was VBD N
significantly RB N
associated VBN N
with IN N
shorter JJR N
disease-free NN o
and CC o
overall JJ o
survival NN o
( ( N
p=0.0051 NN N
and CC N
p=0.0002 NN N
, , N
respectively RB N
) ) N
. . N

When WRB N
Skp2 NNP o
expression NN o
and CC o
p27kip1 JJ o
expression NN o
were VBD N
combined VBN N
, , N
patients NNS N
with IN N
both DT N
Skp2 NNP i
overexpression NN N
and CC N
reduced JJ N
expression NN o
of IN o
p27kip1 NN o
revealed VBN N
poorest JJS o
disease-free JJ o
and CC N
overall JJ o
survival NN o
as IN N
compared VBN N
to TO N
the DT N
other JJ N
cases NNS N
( ( N
p=0.0017 NN N
and CC N
p NN N
< NN N
0.0001 CD N
, , N
respectively RB N
) ) N
. . N

Additionally RB N
, , N
in IN N
early JJ N
stage NN N
( ( N
I PRP N
, , N
II NNP N
) ) N
cases NNS N
, , N
Skp2 NNP i
expression NN N
was VBD N
also RB N
revealed VBN N
to TO N
possess VB N
a DT N
significant JJ N
prognostic JJ N
factor NN N
in IN N
overall JJ o
survival NN o
( ( o
p=0.0234 NN o
) ) o
, , N
but CC N
not RB N
in IN N
disease-free JJ o
survival NN o
( ( N
p=0.2055 NN N
) ) N
. . N

By IN N
multivariate NN N
analysis NN N
using VBG N
the DT N
Cox NNP o
proportional JJ o
hazards NNS o
model NN o
, , o
tumor NN o
grade NN o
, , o
tumor NN o
size NN o
, , o
clinical JJ o
stage NN o
and CC o
Skp2 NNP o
expression NN o
were VBD N
independent JJ N
prognostic JJ N
factors NNS N
both DT N
in IN N
disease-free JJ o
and CC o
overall JJ o
survival NN o
. . o

These DT N
findings NNS N
indicated VBD N
that IN N
Skp2 NNP o
expression NN o
was VBD N
closely RB N
associated VBN N
with IN N
tumor NN N
progression NN N
and CC N
represented VBD N
an DT N
independent JJ N
marker NN N
for IN N
prognosis NN N
of IN N
LSCC NNP N
. . N

-DOCSTART- -X- O O

Kata NNP i
techniques NNS i
training VBG i
consistently RB N
decreases VBZ N
stereotypy NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
effects NNS N
of IN N
14 CD N
weeks NNS N
of IN N
Kata NNP i
techniques NNS i
training VBG i
on IN N
stereotypic JJ N
behaviors NNS N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
were VBD N
investigated VBN N
. . N

The DT N
study NN N
included VBD N
30 CD p
eligible JJ p
( ( p
diagnosed JJ p
ASD NNP p
, , p
school NN p
age NN p
) ) p
children NNS p
with IN p
ages NNS p
ranging VBG p
from IN p
5 CD p
to TO p
16 CD p
years NNS p
whom WP N
they PRP N
assigned VBD N
to TO N
an DT N
exercise NN N
( ( N
n=15 JJ N
) ) N
or CC N
a DT N
no-exercise JJ i
control NN i
group NN i
( ( N
n=15 RB N
) ) N
. . N

Participants NNS N
of IN N
the DT N
exercise NN N
group NN N
received VBD N
Kata NNP i
techniques NNS i
instruction VBP i
four CD N
times NNS N
per IN N
week NN N
for IN N
14 CD N
weeks NNS N
( ( N
56 CD N
sessions NNS N
) ) N
. . N

Stereotypy NNP i
was VBD N
assessed VBN N
at IN N
baseline NN N
( ( N
pre-intervention NN N
) ) N
, , N
week NN N
14 CD N
( ( N
post-intervention NN N
) ) N
, , N
and CC N
at IN N
one CD N
month NN N
follow VB N
up RP N
in IN N
both DT N
groups NNS N
. . N

Results NNS N
showed VBD N
that IN N
Kata NNP N
techniques NNS N
training VBG N
significantly RB N
reduced VBN o
stereotypy NN o
in IN o
the DT o
exercise NN o
group NN o
. . o

Following VBG N
participation NN N
in IN N
Kata NNP N
techniques NNS N
training NN N
, , N
stereotypy NN o
decreased VBN o
from IN o
baseline NN o
levels NNS o
by IN N
a DT N
M NNP N
of IN N
42.54 CD N
% NN N
across IN N
participants NNS N
. . N

Interestingly NNP N
, , N
after IN N
30 CD N
days NNS N
of IN N
no DT N
practice NN N
, , N
stereotypy NN o
in IN o
the DT o
exercise NN o
group NN o
remained VBD o
significantly RB o
decreased VBN o
compared VBN N
to TO N
pre-intervention NN N
time NN N
. . N

The DT N
participants NNS N
of IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
in IN N
the DT N
stereotypy NN o
. . o

Teaching VBG N
martial JJ N
arts NNS N
techniques NNS N
to TO N
children NNS p
with IN p
ASD NNP p
for IN N
a DT N
long JJ N
period NN N
of IN N
time NN N
consistently RB N
decreased VBN N
their PRP$ N
stereotypic NN N
behaviors NNS N
. . N

-DOCSTART- -X- O O

Acid NNP o
resistance NN o
of IN N
enamel JJ p
subsurface NN p
lesions NNS p
remineralized VBN p
by IN p
a DT p
sugar-free JJ i
chewing NN i
gum NN i
containing VBG p
casein JJ p
phosphopeptide-amorphous JJ p
calcium NN p
phosphate NN p
. . p

The DT N
aim NN N
of IN N
this DT N
clinical JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
acid JJ o
resistance NN o
of IN N
enamel JJ p
lesions NNS p
remineralized VBN p
in IN p
situ NN p
by IN p
a DT p
sugar-free JJ i
chewing NN i
gum NN i
containing VBG p
casein JJ p
phosphopeptide-amorphous JJ p
calcium NN p
phosphate NN p
nanocomplexes NNS p
( ( p
CPP-ACP JJ p
: : p
Recaldent NN p
) ) p
. . p

The DT N
study NN N
utilized VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover VB N
design NN N
with IN N
two CD N
treatments NNS N
: : N
( ( N
i NN N
) ) N
sugar-free JJ i
gum NN i
containing VBG N
18.8 CD N
mg NN N
of IN N
CPP-ACP NNP i
, , N
and CC N
( ( N
ii NN N
) ) N
sugar-free JJ i
gum NN i
not RB i
containing VBG i
CPP-ACP NNP i
as IN N
control NN N
. . N

Subjects NNS p
wore RBR p
removable JJ p
palatal JJ p
appliances NNS p
with IN p
insets NNS p
of IN p
human JJ p
enamel NN p
containing VBG p
demineralized JJ p
subsurface NN p
lesions NNS p
and CC p
chewed VBD p
the DT p
gum NN i
for IN i
20 CD p
min NN p
4 CD p
times NNS p
per IN p
day NN p
for IN p
14 CD p
days NNS p
. . p

After IN N
each DT N
treatment NN N
the DT N
enamel NN N
slabs NN N
were VBD N
removed VBN N
and CC N
half NN N
of IN N
each DT N
lesion NN N
challenged VBD o
with IN o
acid NN o
in IN o
vitro NN o
for IN N
8 CD N
or CC N
16 CD N
h. VBP N
The DT N
level NN o
of IN o
remineralization NN o
was VBD N
determined VBN N
using VBG N
microradiography NN o
. . o

The DT N
gum NN i
containing VBG i
CPP-ACP NNP i
produced VBD N
approximately RB N
twice JJ N
the DT N
level NN o
of IN o
remineralization NN o
as IN N
the DT N
control NN N
sugar-free JJ N
gum NN N
. . N

The DT N
8- JJ N
and CC N
16-hour JJ N
acid NN N
challenge NN N
of IN N
the DT N
lesions NNS o
remineralized VBN o
with IN N
the DT N
control NN i
gum NN i
resulted VBD N
in IN N
65.4 CD N
and CC N
88.0 CD N
% NN N
reductions NNS N
, , N
respectively RB N
, , N
of IN N
deposited JJ N
mineral NN N
, , N
while IN N
for IN N
the DT N
CPP-ACP-remineralized JJ N
lesions NNS N
the DT N
corresponding JJ N
reductions NNS N
were VBD N
30.5 CD N
and CC N
41.8 CD N
% NN N
. . N

The DT N
acid NN N
challenge NN N
after IN N
in IN N
situ JJ N
remineralization NN N
for IN N
both DT N
control NN N
and CC N
CPP-ACP-treated JJ N
lesions NNS N
resulted VBD N
in IN N
demineralization NN o
underneath IN N
the DT N
remineralized JJ N
zone NN N
, , N
indicating VBG N
that IN N
the DT N
remineralized JJ N
mineral NN N
was VBD N
more RBR N
resistant JJ N
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
sugar-free JJ i
gum NN i
containing VBG i
CPP-ACP NNP i
is VBZ N
superior JJ o
to TO N
an DT N
equivalent JJ N
gum NN i
not RB N
containing VBG N
CPP-ACP NNP N
in IN N
remineralization NN N
of IN N
enamel JJ N
subsurface NN N
lesions NNS N
in IN N
situ NN N
with IN N
mineral NN N
that WDT N
is VBZ N
more RBR o
resistant JJ o
to TO N
subsequent JJ N
acid NN N
challenge NN N
. . N

-DOCSTART- -X- O O

The DT N
effectiveness NN N
of IN N
educational JJ i
interventions NNS i
to TO N
enhance VB N
the DT N
adoption NN o
of IN o
fee-based JJ o
arsenic JJ o
testing NN o
in IN p
Bangladesh NNP p
: : p
a DT N
cluster NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

Arsenic NNP N
( ( N
As IN N
) ) N
testing NN N
could MD N
help VB N
22 CD N
million CD N
people NNS N
, , N
using VBG N
drinking NN N
water NN N
sources NNS N
that WDT N
exceed VBP N
the DT N
Bangladesh NNP N
As NNP N
standard NN N
, , N
to TO N
identify VB N
safe JJ N
sources NNS N
. . N

A DT N
cluster NN N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN o
of IN o
household NN o
education NN o
and CC o
local JJ o
media NNS o
in IN N
the DT N
increasing VBG N
demand NN N
for IN N
fee-based JJ N
As IN N
testing VBG N
. . N

Randomly RB p
selected VBN p
households NNS p
( ( p
N NNP p
= NNP p
452 CD p
) ) p
were VBD N
divided VBN N
into IN N
three CD i
interventions NNS i
implemented VBN i
by IN i
community NN i
workers NNS i
: : i
1 CD i
) ) i
fee-based JJ i
As IN i
testing VBG i
with IN i
household NN i
education NN i
( ( i
HE NNP i
) ) i
; : i
2 CD i
) ) i
fee-based JJ i
As IN i
testing VBG i
with IN i
household NN i
education NN i
and CC i
a DT i
local JJ i
media NNS i
campaign NN i
( ( i
HELM NNP i
) ) i
; : i
and CC i
3 CD i
) ) i
fee-based JJ i
As IN i
testing VBG i
alone RB i
( ( i
Control NNP i
) ) i
. . i

The DT N
fee NN N
for IN N
the DT N
As NNP N
test NN N
was VBD N
US NNP N
$ $ N
0.28 CD N
, , N
higher JJR N
than IN N
the DT N
cost NN N
of IN N
the DT N
test NN N
( ( N
US NNP N
$ $ N
0.16 CD N
) ) N
. . N

Of IN N
households NNS N
with IN N
untested JJ N
wells NNS N
, , N
93 CD N
% NN N
in IN N
both DT N
intervention NN N
groups NNS N
HE NNP o
and CC o
HELM NNP o
purchased VBD o
an DT o
As IN o
test NN o
, , N
whereas IN N
only RB N
53 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
fee-based JJ o
As IN o
testing VBG o
with IN i
household NN o
education NN o
is VBZ o
effective JJ o
in IN o
the DT o
increasing VBG o
demand NN o
for IN o
As IN o
testing VBG o
in IN p
rural JJ p
Bangladesh NNP p
. . p

-DOCSTART- -X- O O

GPs NNP N
' POS N
experiences NNS N
with IN N
brief JJ i
intervention NN i
for IN N
medication-overuse JJ N
headache NN N
: : N
a DT N
qualitative JJ N
study NN N
in IN N
general JJ N
practice NN N
. . N

BACKGROUND NNP N
Medication-overuse NNP N
headache NN N
( ( N
MOH NNP N
) ) N
is VBZ N
common JJ N
in IN N
the DT N
general JJ N
population NN N
, , N
and CC N
most JJS N
patients NNS N
are VBP N
managed VBN N
in IN N
primary JJ N
health NN N
care NN N
. . N

Brief JJ i
Intervention NNP i
( ( i
BI NNP i
) ) i
has VBZ N
been VBN N
used VBN N
as IN N
a DT N
motivational JJ N
technique NN N
for IN N
patients NNS p
with IN p
drug NN p
and CC p
alcohol NN p
overuse NN p
, , N
and CC N
may MD N
a DT N
have VB N
role NN N
in IN N
the DT N
treatment NN N
of IN N
MOH NNP N
. . N

AIM NNP N
To TO N
explore VB N
GPs NNP i
' POS i
experiences NNS i
using VBG i
BI NNP i
in IN i
the DT N
management NN p
of IN p
patients NNS p
with IN p
MOH NNP p
. . p

DESIGN NNP N
AND CC N
SETTING NNP N
Qualitative NNP N
study NN N
in IN N
Norwegian JJ p
general JJ p
practice NN p
. . p

METHOD NNP N
Data NNP N
were VBD N
collected VBN N
through IN N
four CD p
focus NN p
group NN p
interviews VBZ p
with IN p
22 CD p
GPs NNP p
who WP p
participated VBD p
in IN p
an DT p
intervention NN p
study NN p
on IN p
BI NNP i
for IN p
MOH NNP p
. . p

Systematic NNP N
text JJ N
condensation NN N
was VBD N
used VBN N
to TO N
analyse VB N
transcripts NNS N
from IN N
the DT N
focus NN p
group NN p
interviews NNS p
. . p

RESULTS VB N
The DT N
GPs NNP i
experienced VBD i
challenges NNS N
when WRB N
trying VBG N
to TO N
convince VB N
patients NNS N
that IN N
the DT N
medication NN N
they PRP N
used VBD N
to TO N
treat VB N
and CC N
prevent VB N
headache NN N
could MD N
cause VB N
headache NN N
, , N
but CC N
labelling VBG N
MOH NNP N
as IN N
a DT N
diagnosis NN N
opened VBD N
up RP N
a DT N
space NN N
for IN N
change NN N
. . N

GPs NNP N
were VBD N
able JJ N
to TO N
use VB N
BI NNP i
within IN N
the DT N
scope NN N
of IN N
a DT N
regular JJ N
consultation NN N
, , N
and CC N
they PRP N
thought VBD N
that IN N
the DT N
structured JJ N
approach NN N
had VBD N
a DT N
potential JJ N
to TO N
change VB N
patients NNS N
' POS N
views NNS N
about IN N
their PRP$ N
condition NN N
and CC N
medication NN N
use NN N
. . N

Being VBG N
diagnosed VBN N
with IN N
medication NN N
overuse NN N
could MD N
bring VB N
about RP N
feelings NNS N
of IN N
guilt NN o
in IN N
patients NNS N
, , N
and CC N
GPs NNP N
emphasised VBD N
that IN N
a DT N
good JJ N
alliance NN N
with IN N
the DT N
patient NN N
was VBD N
necessary JJ N
for IN N
successful JJ N
change NN N
using VBG N
BI NNP N
to TO N
manage VB N
MOH NNP N
. . N

CONCLUSION NNP N
GPs NNP i
experience NN i
BI NNP i
as IN N
a DT N
feasible JJ N
strategy NN N
to TO N
treat VB N
MOH NNP N
, , N
and CC N
the DT N
technique NN N
relies VBZ N
on IN N
a DT N
good JJ N
alliance NN N
between IN N
the DT N
doctor NN N
and CC N
patient NN N
. . N

When WRB N
using VBG N
BI NNP i
, , N
GPs NNP N
must MD N
be VB N
prepared VBN N
to TO N
counter VB N
patients NNS N
' POS N
misconceptions NNS N
about IN N
medication NN N
used VBN N
for IN N
headache NN N
. . N

